Selegiline B-Chemical 0 0.99990475
- O 0 0.02784196
induced O 0 0.007993438
postural B-Disease 0 0.99709487
hypotension I-Disease 2 0.9999784
in O 0 0.005005039
Parkinson B-Disease 0 0.99982053
' I-Disease 0 0.0033519045
s I-Disease 0 0.0018281587
disease I-Disease 0 0.5042771
: O 0 0.0018761121
a O 0 0.0012334824
longitudinal O 0 0.0013895247
study O 0 0.0010646689
on O 0 0.000797997
the O 0 0.0012915761
effects O 0 0.002850659
of O 0 0.0042614243
drug O 0 0.9212049
withdrawal O 0 0.96661043
. O 0 0.010636271

OBJECTIVES O 0 0.029171038
: O 0 0.00926057
The O 0 0.0048465477
United O 0 0.00664564
Kingdom O 0 0.015649136
Parkinson B-Disease 0 0.99878174
' I-Disease 0 0.0035196452
s I-Disease 0 0.0025674463
Disease I-Disease 0 0.33689436
Research O 0 0.022553269
Group O 0 0.051866613
( O 0 0.0016797131
UKPDRG O 0 0.15450047
) O 0 0.0012908591
trial O 0 0.0007270416
found O 0 0.00036699531
an O 0 0.00065909454
increased O 0 0.0007022926
mortality O 0 0.19501442
in O 0 0.00053371926
patients O 0 0.0023541823
with O 0 0.0008709486
Parkinson B-Disease 0 0.9998766
' I-Disease 0 0.0014806263
s I-Disease 0 0.00092018384
disease I-Disease 0 0.76565987
( O 0 0.0039810673
PD B-Disease 2 0.99891496
) O 0 0.0013406313
randomized O 0 0.0004919305
to O 0 0.00030299625
receive O 0 0.00032928013
10 O 0 0.00041636525
mg O 0 0.17501919
selegiline B-Chemical 1 0.9999596
per O 0 0.00036067356
day O 0 0.00054376887
and O 0 0.001137954
L B-Chemical 1 0.96150213
- I-Chemical 1 0.0112890005
dopa I-Chemical 1 0.99988246
compared O 0 0.0007657358
with O 0 0.0012792123
those O 0 0.0023422018
taking O 0 0.01004082
L B-Chemical 1 0.9697277
- I-Chemical 1 0.049876478
dopa I-Chemical 1 0.9997838
alone O 0 0.011551222
. O 0 0.009560095

Recently O 0 0.0121628465
, O 0 0.0068099755
we O 0 0.0029140064
found O 0 0.0022023804
that O 0 0.0017908511
therapy O 0 0.009426004
with O 0 0.0032370016
selegiline B-Chemical 1 0.9999914
and O 0 0.016943626
L B-Chemical 1 0.99559575
- I-Chemical 1 0.04878901
dopa I-Chemical 1 0.99995875
was O 0 0.0010547548
associated O 0 0.00089570606
with O 0 0.00088848826
selective O 0 0.022384593
systolic B-Disease 0 0.9948426
orthostatic I-Disease 2 0.9999664
hypotension I-Disease 2 0.99999607
which O 0 0.004355162
was O 0 0.0016567379
abolished O 0 0.002767992
by O 0 0.0029519852
withdrawal O 0 0.8923565
of O 0 0.021054175
selegiline B-Chemical 1 0.9999522
. O 0 0.01173336

This O 0 0.011896455
unwanted O 0 0.03467051
effect O 0 0.0043419944
on O 0 0.0028626337
postural O 0 0.72615725
blood O 0 0.027670829
pressure O 0 0.06314339
was O 0 0.0018624435
not O 0 0.0015067545
the O 0 0.0016077725
result O 0 0.0019516597
of O 0 0.0032740543
underlying O 0 0.013980955
autonomic O 0 0.9950413
failure O 0 0.9144794
. O 0 0.011875695

The O 0 0.0072540985
aims O 0 0.005965676
of O 0 0.003819054
this O 0 0.0025262511
study O 0 0.0021116745
were O 0 0.0012850385
to O 0 0.00082646107
confirm O 0 0.00049411994
our O 0 0.0005404975
previous O 0 0.00053834164
findings O 0 0.001077578
in O 0 0.00049184257
a O 0 0.0006259686
separate O 0 0.0003816246
cohort O 0 0.000880584
of O 0 0.00051460945
patients O 0 0.0013902104
and O 0 0.00045849598
to O 0 0.00029620974
determine O 0 0.00017758623
the O 0 0.00030766148
time O 0 0.00025117528
course O 0 0.0003889795
of O 0 0.0004761331
the O 0 0.00051712856
cardiovascular O 0 0.99182194
consequences O 0 0.004872705
of O 0 0.00091733487
stopping O 0 0.08642481
selegiline B-Chemical 1 0.999992
in O 0 0.00045792555
the O 0 0.00039755538
expectation O 0 0.00056162436
that O 0 0.00029840218
this O 0 0.00035457374
might O 0 0.00028645093
shed O 0 0.00062637887
light O 0 0.00090839143
on O 0 0.00038694535
the O 0 0.0006073426
mechanisms O 0 0.0011083246
by O 0 0.001065163
which O 0 0.0013683491
the O 0 0.0015267695
drug O 0 0.7766486
causes O 0 0.12211401
orthostatic B-Disease 2 0.9999411
hypotension I-Disease 2 0.9999696
. O 0 0.016477792

METHODS O 0 0.010801942
: O 0 0.0076195695
The O 0 0.004034317
cardiovascular O 0 0.8552004
responses O 0 0.0043831193
to O 0 0.0018299052
standing O 0 0.0035062328
and O 0 0.0017228419
head O 0 0.088901356
- O 0 0.0019785424
up O 0 0.0007591741
tilt O 0 0.009472537
were O 0 0.00065752235
studied O 0 0.00065808406
repeatedly O 0 0.000945397
in O 0 0.0008382329
PD B-Disease 2 0.99684227
patients O 0 0.0057091326
receiving O 0 0.008589172
selegiline B-Chemical 1 0.9999826
and O 0 0.0020326956
as O 0 0.0018066654
the O 0 0.0022514327
drug O 0 0.5413723
was O 0 0.004715898
withdrawn O 0 0.02369108
. O 0 0.007989219

RESULTS O 0 0.033524882
: O 0 0.012000915
Head O 0 0.081558034
- O 0 0.005587243
up O 0 0.002699481
tilt O 0 0.016559264
caused O 0 0.003039768
systolic B-Disease 0 0.9909101
orthostatic I-Disease 2 0.99995255
hypotension I-Disease 2 0.9999963
which O 0 0.0034931556
was O 0 0.00081561273
marked O 0 0.0010093806
in O 0 0.00043513332
six O 0 0.00032611258
of O 0 0.00062242744
20 O 0 0.0007890479
PD B-Disease 2 0.99268323
patients O 0 0.0023158155
on O 0 0.0006155734
selegiline B-Chemical 1 0.999985
, O 0 0.001240703
one O 0 0.00060251716
of O 0 0.00093923486
whom O 0 0.0028335075
lost O 0 0.0019052585
consciousness O 0 0.9077551
with O 0 0.0032575966
unrecordable O 0 0.70291257
blood O 0 0.047774207
pressures O 0 0.05894769
. O 0 0.008544162

A O 0 0.051730134
lesser O 0 0.020142796
degree O 0 0.01365421
of O 0 0.01786555
orthostatic B-Disease 2 0.9996791
hypotension I-Disease 2 0.9999361
occurred O 0 0.022051618
with O 0 0.014553937
standing O 0 0.04270931
. O 0 0.015626961

Orthostatic B-Disease 0 0.99785197
hypotension I-Disease 2 0.999908
was O 0 0.0074484576
ameliorated O 0 0.28581947
4 O 0 0.0017749327
days O 0 0.0010079027
after O 0 0.0007457091
withdrawal O 0 0.4946893
of O 0 0.0025426706
selegiline B-Chemical 1 0.99998856
and O 0 0.0018727116
totally O 0 0.0034006971
abolished O 0 0.0015627206
7 O 0 0.00085489725
days O 0 0.00070315506
after O 0 0.0008273614
discontinuation O 0 0.32198766
of O 0 0.003023402
the O 0 0.00442887
drug O 0 0.7344304
. O 0 0.009392134

Stopping O 0 0.74249
selegiline B-Chemical 1 0.9998473
also O 0 0.0057398877
significantly O 0 0.0037087996
reduced B-Disease 0 0.002207912
the I-Disease 0 0.001590065
supine I-Disease 0 0.003113426
systolic I-Disease 0 0.4926187
and I-Disease 0 0.0013673432
diastolic I-Disease 0 0.79972804
blood I-Disease 0 0.00527526
pressures I-Disease 0 0.0038365107
consistent O 0 0.0008967428
with O 0 0.0011518543
a O 0 0.001730568
previously O 0 0.0017232706
undescribed O 0 0.0034757722
supine O 0 0.013794092
pressor O 0 0.9938911
action O 0 0.068454824
. O 0 0.009452456

CONCLUSION O 0 0.7138196
: O 0 0.009087261
This O 0 0.0050212285
study O 0 0.0029046529
confirms O 0 0.0016687303
our O 0 0.0013467823
previous O 0 0.0012084851
finding O 0 0.0016513583
that O 0 0.0012780811
selegiline B-Chemical 1 0.999984
in O 0 0.0013215118
combination O 0 0.0036747744
with O 0 0.003247925
L B-Chemical 1 0.9932985
- I-Chemical 1 0.053598728
dopa I-Chemical 1 0.9999393
is O 0 0.001988856
associated O 0 0.0023005346
with O 0 0.0033310605
selective O 0 0.19574225
orthostatic B-Disease 2 0.9999155
hypotension I-Disease 2 0.99996376
. O 0 0.01620406

The O 0 0.006788562
possibilities O 0 0.005289341
that O 0 0.0030788074
these O 0 0.0032528406
cardiovascular O 0 0.9735692
findings O 0 0.005167045
might O 0 0.0010959994
be O 0 0.001019229
the O 0 0.00074777426
result O 0 0.00070683553
of O 0 0.00097336894
non O 0 0.006508872
- O 0 0.003118213
selective O 0 0.0061478154
inhibition O 0 0.005607848
of O 0 0.0038226198
monoamine O 0 0.9999732
oxidase O 0 0.99825555
or O 0 0.0018368397
of O 0 0.005019073
amphetamine B-Chemical 1 0.9999851
and O 0 0.01275759
metamphetamine B-Chemical 0 0.99956626
are O 0 0.005493006
discussed O 0 0.005481182
. O 0 0.008212156

Further O 0 0.014173471
studies O 0 0.009988218
on O 0 0.006536019
effects O 0 0.007834845
of O 0 0.007702616
irrigation O 0 0.03565991
solutions O 0 0.040252384
on O 0 0.007116731
rat O 0 0.042370383
bladders O 0 0.7669744
. O 0 0.015642473

Further O 0 0.008689825
studies O 0 0.0054328456
on O 0 0.0029877082
the O 0 0.0025769498
effects O 0 0.0025880174
of O 0 0.002007026
certain O 0 0.002070143
irrigating O 0 0.03392574
fluids O 0 0.024896275
on O 0 0.001024119
the O 0 0.0013518725
rat O 0 0.0057914183
bladder O 0 0.7816647
for O 0 0.0017337705
18 O 0 0.0023049465
hours O 0 0.0021101306
are O 0 0.00391305
reported O 0 0.006776253
. O 0 0.0084862625

The O 0 0.0074395086
results O 0 0.005408495
have O 0 0.003467003
shown O 0 0.0022187985
that O 0 0.0016588918
the O 0 0.001648844
degradation O 0 0.003535525
product O 0 0.0047729705
p B-Chemical 0 0.006627524
- I-Chemical 0 0.00290378
choloroaniline I-Chemical 0 0.0515254
is O 0 0.0008601458
not O 0 0.0007089586
a O 0 0.0010324041
significant O 0 0.0011332035
factor O 0 0.009349059
in O 0 0.0018141054
chlorhexidine B-Chemical 0 0.99630094
- I-Chemical 0 0.03363045
digluconate I-Chemical 0 0.9964922
associated O 0 0.032498762
erosive O 0 0.99969006
cystitis B-Disease 2 0.99996054
. O 0 0.046385117

A O 0 0.026579965
high O 0 0.006303884
percentage O 0 0.0035622518
of O 0 0.004908833
kanamycin B-Chemical 1 0.99121463
- O 0 0.012466425
colistin B-Chemical 0 0.99897206
and O 0 0.0038521178
povidone B-Chemical 0 0.99814105
- I-Chemical 0 0.027484171
iodine I-Chemical 0 0.9996457
irrigations O 0 0.5568612
were O 0 0.00112947
associated O 0 0.001126341
with O 0 0.0014456923
erosive O 0 0.9995407
cystitis B-Disease 2 0.9999895
and O 0 0.0041574817
suggested O 0 0.0013124602
a O 0 0.0018897456
possible O 0 0.0019070866
complication O 0 0.43825802
with O 0 0.0040314742
human O 0 0.0069591217
usage O 0 0.009037546
. O 0 0.008968477

Picloxydine B-Chemical 0 0.67696255
irrigations O 0 0.19976363
appeared O 0 0.004474665
to O 0 0.0026226605
have O 0 0.0017892945
a O 0 0.0019494263
lower O 0 0.0014151535
incidence O 0 0.0061955024
of O 0 0.0022464478
erosive O 0 0.99957734
cystitis B-Disease 2 0.9999925
but O 0 0.0025967848
further O 0 0.0009723892
studies O 0 0.0007730648
would O 0 0.0004424999
have O 0 0.00042912582
to O 0 0.0004613804
be O 0 0.00051212165
performed O 0 0.00043262835
before O 0 0.00036992962
it O 0 0.0006673997
could O 0 0.0005537004
be O 0 0.00083590066
recommended O 0 0.0009752375
for O 0 0.0010219694
use O 0 0.0019435051
in O 0 0.0026861553
urological O 0 0.35712406
procedures O 0 0.0078345705
. O 0 0.008872613

Effects O 0 0.017632881
of O 0 0.010925676
tetrandrine B-Chemical 0 0.9997688
and O 0 0.009406337
fangchinoline B-Chemical 0 0.99652183
on O 0 0.0024318795
experimental O 0 0.00400291
thrombosis B-Disease 2 0.99957067
in O 0 0.0030028182
mice O 0 0.002418461
and O 0 0.004237746
human O 0 0.009012581
platelet B-Disease 2 0.9972217
aggregation I-Disease 2 0.9304781
. O 0 0.014841079

Tetrandrine B-Chemical 0 0.9994956
( O 0 0.034163192
TET B-Chemical 1 0.9948691
) O 0 0.010295402
and O 0 0.005144231
fangchinoline B-Chemical 0 0.9984491
( O 0 0.012865382
FAN B-Chemical 1 0.9965113
) O 0 0.003980532
are O 0 0.0015701582
two O 0 0.0012912723
naturally O 0 0.004110597
occurring O 0 0.004609651
analogues O 0 0.5524821
with O 0 0.004541466
a O 0 0.009583402
bisbenzylisoquinoline B-Chemical 0 0.9972851
structure O 0 0.01543018
. O 0 0.010443653

The O 0 0.0069168033
present O 0 0.00402388
study O 0 0.0037573408
was O 0 0.0023286627
undertaken O 0 0.0013934113
to O 0 0.0010644434
investigate O 0 0.00066029286
the O 0 0.0008783901
effects O 0 0.0016019066
of O 0 0.0019731044
TET B-Chemical 1 0.99842876
and O 0 0.001603541
FAN B-Chemical 1 0.9921497
on O 0 0.00038777696
the O 0 0.0004898338
experimental O 0 0.00085220276
thrombosis B-Disease 2 0.99983203
induced O 0 0.001231163
by O 0 0.0011581752
collagen O 0 0.6569733
plus O 0 0.0022185198
epinephrine B-Chemical 1 0.9999443
( O 0 0.0127317915
EP B-Chemical 0 0.99823403
) O 0 0.0021161141
in O 0 0.00061003363
mice O 0 0.00057898584
, O 0 0.0011672013
and O 0 0.0012852688
platelet B-Disease 2 0.9912723
aggregation I-Disease 2 0.6992838
and O 0 0.0041516274
blood B-Disease 2 0.49222636
coagulation I-Disease 2 0.9952278
in O 0 0.005587026
vitro O 0 0.011735992
. O 0 0.009154322

In O 0 0.0072677466
the O 0 0.005060313
in O 0 0.0035116784
vivo O 0 0.0035280152
study O 0 0.0026246544
, O 0 0.0020179166
the O 0 0.00120126
administration O 0 0.052909683
( O 0 0.0016308725
50 O 0 0.0011769728
mg O 0 0.19866174
/ O 0 0.0018017164
kg O 0 0.004502926
, O 0 0.0008352064
i O 0 0.0016747429
. O 0 0.0004061189
p O 0 0.0006797483
. O 0 0.0004002021
) O 0 0.000815474
of O 0 0.00074361416
TET B-Chemical 1 0.9954157
and O 0 0.0010397944
FAN B-Chemical 1 0.9939023
in O 0 0.00044910412
mice O 0 0.00030958405
showed O 0 0.0003318786
the O 0 0.00040643726
inhibition O 0 0.0011005632
of O 0 0.0008241153
thrombosis B-Disease 2 0.9998312
by O 0 0.00081306207
55 O 0 0.00074304827
% O 0 0.0005004584
and O 0 0.00043061865
35 O 0 0.00048037642
% O 0 0.0005498139
, O 0 0.00062143337
respectively O 0 0.000994316
, O 0 0.0008144493
while O 0 0.0008049177
acetylsalicylic B-Chemical 1 0.99999774
acid I-Chemical 1 0.99873346
( O 0 0.015784584
ASA B-Chemical 1 0.9986072
, O 0 0.0009837057
50 O 0 0.0007824044
mg O 0 0.13785194
/ O 0 0.0013057683
kg O 0 0.0030645065
, O 0 0.00071828294
i O 0 0.0014796638
. O 0 0.00040663144
p O 0 0.0007189743
. O 0 0.0004725316
) O 0 0.001019787
, O 0 0.0006940521
a O 0 0.00067074096
positive O 0 0.00072948245
control O 0 0.000909825
, O 0 0.0013422556
showed O 0 0.0010748422
only O 0 0.001601016
30 O 0 0.0020818333
% O 0 0.004135963
inhibition O 0 0.008555552
. O 0 0.0078561185

In O 0 0.00753608
the O 0 0.005428915
vitro O 0 0.005032044
human O 0 0.004796558
platelet B-Disease 0 0.9895509
aggregations I-Disease 0 0.24079604
induced O 0 0.0029295397
by O 0 0.0019852258
the O 0 0.0014294513
agonists O 0 0.738144
used O 0 0.0010402264
in O 0 0.00094640494
tests O 0 0.003006376
, O 0 0.0024412852
TET B-Chemical 1 0.9918475
and O 0 0.0023648771
FAN B-Chemical 1 0.99066263
showed O 0 0.001777557
the O 0 0.0026862945
inhibitions O 0 0.8655179
dose O 0 0.25959817
dependently O 0 0.97471637
. O 0 0.011698868

In O 0 0.007310235
addition O 0 0.0043089944
, O 0 0.004729987
neither O 0 0.003341425
TET B-Chemical 1 0.98688334
nor O 0 0.0027621172
FAN B-Chemical 1 0.9898074
showed O 0 0.0010508897
any O 0 0.00088948995
anticoagulation O 0 0.70282793
activities O 0 0.0011623855
in O 0 0.00048170894
the O 0 0.0004364097
measurement O 0 0.00034289833
of O 0 0.00053243886
the O 0 0.000511744
activated O 0 0.0007805832
partial O 0 0.0013979545
thromboplastin O 0 0.8623679
time O 0 0.00061202096
( O 0 0.0018940063
APTT O 0 0.99301755
) O 0 0.0018613152
, O 0 0.0010598222
prothrombin O 0 0.85243195
time O 0 0.00057746423
( O 0 0.0011912413
PT O 0 0.039587434
) O 0 0.0012820238
and O 0 0.0009020232
thrombin O 0 0.7481029
time O 0 0.0009904362
( O 0 0.0023028199
TT O 0 0.38326293
) O 0 0.0026803585
using O 0 0.0016460206
human O 0 0.0034022212
- O 0 0.0064031933
citrated O 0 0.28574955
plasma O 0 0.08148929
. O 0 0.00912268

These O 0 0.008703321
results O 0 0.0053351927
suggest O 0 0.0030398765
that O 0 0.0026526104
antithrombosis O 0 0.34915918
of O 0 0.0049814875
TET B-Chemical 1 0.9981255
and O 0 0.0038453082
FAN B-Chemical 1 0.9954797
in O 0 0.0012928094
mice O 0 0.000899884
may O 0 0.00099029
be O 0 0.0010793713
mainly O 0 0.0014620674
related O 0 0.0011010875
to O 0 0.0015601523
the O 0 0.002577814
antiplatelet O 0 0.98034036
aggregation O 0 0.37277728
activities O 0 0.021064743
. O 0 0.009595281

Angioedema B-Disease 0 0.99849796
due O 0 0.014373733
to O 0 0.012987807
ACE B-Chemical 0 0.9988827
inhibitors I-Chemical 0 0.74607396
: O 0 0.0149721205
common O 0 0.010257814
and O 0 0.011171735
inadequately O 0 0.37280306
diagnosed O 0 0.23025313
. O 0 0.015685204

The O 0 0.007488678
estimated O 0 0.00568374
incidence O 0 0.010803961
of O 0 0.007959928
angioedema B-Disease 2 0.9999666
during O 0 0.0066134813
angiotensin B-Chemical 1 0.9999646
- I-Chemical 0 0.061329875
converting I-Chemical 0 0.4194848
enzyme I-Chemical 0 0.55328184
( I-Chemical 0 0.011849954
ACE I-Chemical 0 0.9996866
) I-Chemical 0 0.005151767
inhibitor I-Chemical 0 0.035975564
treatment O 0 0.0017271575
is O 0 0.00089941075
between O 0 0.0007073035
1 O 0 0.0012666881
and O 0 0.001411945
7 O 0 0.0015828122
per O 0 0.0016823699
thousand O 0 0.0038604469
patients O 0 0.009468498
. O 0 0.008002347

This O 0 0.011380815
potentially O 0 0.008988002
serious O 0 0.14678244
adverse O 0 0.9076027
effect O 0 0.003590667
is O 0 0.0022903853
often O 0 0.0026756052
preceded O 0 0.002463676
by O 0 0.0020434503
minor O 0 0.0049116146
manifestations O 0 0.73160654
that O 0 0.0019401708
may O 0 0.0022351216
serve O 0 0.0037380704
as O 0 0.0039359964
a O 0 0.0074373116
warning O 0 0.17528439
. O 0 0.010133157

Cocaine B-Chemical 1 0.9998074
- O 0 0.024376549
induced O 0 0.008728494
mood B-Disease 0 0.99844736
disorder I-Disease 0 0.9953447
: O 0 0.0054836003
prevalence O 0 0.0032686917
rates O 0 0.0020860992
and O 0 0.003096139
psychiatric B-Disease 2 0.99949515
symptoms O 0 0.9874858
in O 0 0.0018345166
an O 0 0.003054021
outpatient O 0 0.013037291
cocaine B-Chemical 1 0.9998522
- O 0 0.008140467
dependent O 0 0.003948461
sample O 0 0.007813404
. O 0 0.008365077

This O 0 0.01075277
paper O 0 0.0067377198
attempts O 0 0.0047951513
to O 0 0.002461791
examine O 0 0.0013719903
and O 0 0.0016247528
compare O 0 0.00080271094
prevalence O 0 0.0017736913
rates O 0 0.0012584866
and O 0 0.0013579011
symptom O 0 0.22319923
patterns O 0 0.000983716
of O 0 0.0019224626
DSM O 0 0.6791768
substance O 0 0.9914278
- O 0 0.0060904226
induced O 0 0.0023472044
and O 0 0.0035216324
other O 0 0.006152811
mood B-Disease 0 0.9989961
disorders I-Disease 0 0.98598796
. O 0 0.012067824

243 O 0 0.10975105
cocaine B-Chemical 1 0.999527
- O 0 0.008771441
dependent O 0 0.0027124262
outpatients O 0 0.038770653
with O 0 0.0030053298
cocaine B-Chemical 1 0.99996126
- O 0 0.01803037
induced O 0 0.0033586717
mood B-Disease 0 0.9997205
disorder I-Disease 0 0.9988714
( O 0 0.021021638
CIMD B-Disease 2 0.99720097
) O 0 0.00318759
, O 0 0.00093332486
other O 0 0.00081259734
mood B-Disease 0 0.99858594
disorders I-Disease 0 0.9566397
, O 0 0.001202347
or O 0 0.00058575196
no O 0 0.00063967315
mood B-Disease 0 0.99797183
disorder I-Disease 0 0.9726313
were O 0 0.001050562
compared O 0 0.00068602595
on O 0 0.00090697437
measures O 0 0.0019386052
of O 0 0.005259712
psychiatric B-Disease 2 0.99948394
symptoms O 0 0.99532074
. O 0 0.011420961

The O 0 0.012331645
prevalence O 0 0.011358169
rate O 0 0.008495446
for O 0 0.007429023
CIMD B-Disease 2 0.9000989
was O 0 0.0066822777
12 O 0 0.0051548304
% O 0 0.00707485
at O 0 0.0063555012
baseline O 0 0.010176832
. O 0 0.0123108765

Introduction O 0 0.011554871
of O 0 0.007038
the O 0 0.005518512
DSM O 0 0.19273353
- O 0 0.0064699636
IV O 0 0.1722231
diagnosis O 0 0.010025092
of O 0 0.003252711
CIMD B-Disease 2 0.98115516
did O 0 0.0012986938
not O 0 0.001098864
substantially O 0 0.0014011038
affect O 0 0.0008998094
rates O 0 0.0015576035
of O 0 0.002249464
the O 0 0.0028731576
other O 0 0.008131291
depressive B-Disease 2 0.99993896
disorders I-Disease 0 0.99160963
. O 0 0.013318674

Patients O 0 0.016974548
with O 0 0.007928401
CIMD B-Disease 2 0.87057984
had O 0 0.0037231622
symptom O 0 0.27760372
severity O 0 0.04696414
levels O 0 0.0016257231
between O 0 0.001011326
those O 0 0.0016707525
of O 0 0.0016677751
patients O 0 0.0040366086
with O 0 0.0019089108
and O 0 0.002535801
without O 0 0.0029491126
a O 0 0.009053501
mood B-Disease 0 0.9987446
disorder I-Disease 0 0.9943936
. O 0 0.012402834

These O 0 0.008927131
findings O 0 0.006964923
suggest O 0 0.0030496712
some O 0 0.002892539
validity O 0 0.0035020886
for O 0 0.0013531322
the O 0 0.0013802816
new O 0 0.0021005624
DSM O 0 0.38257176
- O 0 0.003189759
IV O 0 0.23235174
diagnosis O 0 0.008882297
of O 0 0.0022214043
CIMD B-Disease 2 0.9946801
, O 0 0.001441143
but O 0 0.0006920989
also O 0 0.0006649826
suggest O 0 0.00053376716
that O 0 0.00076375133
it O 0 0.0011974587
requires O 0 0.0009389799
further O 0 0.002210874
specification O 0 0.014562302
and O 0 0.0053464454
replication O 0 0.028339919
. O 0 0.009257703

Effect O 0 0.013952539
of O 0 0.0109052025
fucoidan B-Chemical 0 0.99727553
treatment O 0 0.0144298365
on O 0 0.0047854306
collagenase O 0 0.96179634
- O 0 0.019875012
induced O 0 0.009212547
intracerebral B-Disease 0 0.9994411
hemorrhage I-Disease 2 0.9998518
in O 0 0.009823982
rats O 0 0.034025133
. O 0 0.011997641

Inflammatory O 0 0.61660093
cells O 0 0.012595755
are O 0 0.006123933
postulated O 0 0.0056724357
to O 0 0.0030568761
mediate O 0 0.002496984
some O 0 0.0025678116
of O 0 0.0030158511
the O 0 0.0034625167
brain B-Disease 2 0.80566156
damage I-Disease 2 0.98810685
following O 0 0.03139965
ischemic B-Disease 2 0.9999422
stroke I-Disease 2 0.99986887
. O 0 0.018271329

Intracerebral B-Disease 0 0.99256027
hemorrhage I-Disease 2 0.99957496
is O 0 0.010318077
associated O 0 0.0075376853
with O 0 0.006523955
more O 0 0.008750016
inflammation B-Disease 2 0.99533737
than O 0 0.014209455
ischemic B-Disease 2 0.9998994
stroke I-Disease 2 0.99981564
. O 0 0.021791711

We O 0 0.007832614
tested O 0 0.004563962
the O 0 0.004251404
sulfated O 0 0.7713389
polysaccharide O 0 0.5711839
fucoidan B-Chemical 0 0.9997619
, O 0 0.008815866
which O 0 0.0021993786
has O 0 0.0009681715
been O 0 0.00091987307
reported O 0 0.0008562326
to O 0 0.0006036331
reduce O 0 0.0007092126
inflammatory O 0 0.9709489
brain B-Disease 2 0.9700492
damage I-Disease 2 0.99346703
, O 0 0.0019766819
in O 0 0.0004866101
a O 0 0.00069157744
rat O 0 0.0016844872
model O 0 0.00060621725
of O 0 0.0011333314
intracerebral B-Disease 0 0.9995209
hemorrhage I-Disease 2 0.9999633
induced O 0 0.001402742
by O 0 0.0011098894
injection O 0 0.0023568429
of O 0 0.0013849561
bacterial O 0 0.029597444
collagenase O 0 0.8931791
into O 0 0.0019389559
the O 0 0.0038504114
caudate O 0 0.71094555
nucleus O 0 0.010052282
. O 0 0.0076334057

Rats O 0 0.02260191
were O 0 0.0058957366
treated O 0 0.0040063565
with O 0 0.0025573934
seven O 0 0.0017406539
day O 0 0.0014138145
intravenous O 0 0.13931668
infusion O 0 0.015157945
of O 0 0.002440902
fucoidan B-Chemical 0 0.9996482
( O 0 0.0045988336
30 O 0 0.0011492484
micrograms O 0 0.09837177
h O 0 0.0015995215
- O 0 0.0028761807
1 O 0 0.0023995873
) O 0 0.0039993892
or O 0 0.0039848885
vehicle O 0 0.10698146
. O 0 0.008874941

The O 0 0.016578695
hematoma B-Disease 2 0.9893083
was O 0 0.010269814
assessed O 0 0.0070253876
in O 0 0.0070767133
vivo O 0 0.009444021
by O 0 0.0103962645
magnetic O 0 0.33377284
resonance O 0 0.5994865
imaging O 0 0.04826994
. O 0 0.016665148

Motor O 0 0.8314037
behavior O 0 0.015668435
, O 0 0.006359366
passive O 0 0.0058161975
avoidance O 0 0.017223371
, O 0 0.0035512045
and O 0 0.002394356
skilled O 0 0.0037304068
forelimb O 0 0.20065594
function O 0 0.0018222512
were O 0 0.0016270129
tested O 0 0.0014524935
repeatedly O 0 0.002624697
for O 0 0.002254775
six O 0 0.0030450094
weeks O 0 0.0046010204
. O 0 0.007669695

Fucoidan B-Chemical 0 0.99737334
- O 0 0.013333149
treated O 0 0.0048537673
rats O 0 0.0051885704
exhibited O 0 0.0017646922
evidence O 0 0.0015211288
of O 0 0.0018234304
impaired B-Disease 0 0.0039995126
blood I-Disease 0 0.042944998
clotting I-Disease 0 0.9511407
and O 0 0.0017840822
hemodilution B-Disease 0 0.99778533
, O 0 0.0013455707
had O 0 0.0005835176
larger O 0 0.0007791195
hematomas B-Disease 0 0.99968195
, O 0 0.0011293403
and O 0 0.0006497065
tended O 0 0.00047761455
to O 0 0.00042294714
have O 0 0.0004646413
less O 0 0.0007094253
inflammation B-Disease 2 0.9661532
in O 0 0.00083333906
the O 0 0.00079622254
vicinity O 0 0.0009810457
of O 0 0.0013250678
the O 0 0.0018848754
hematoma B-Disease 2 0.9980375
after O 0 0.0017515501
three O 0 0.0026898177
days O 0 0.00445225
. O 0 0.007249711

They O 0 0.012120294
showed O 0 0.005035569
significantly O 0 0.004081769
more O 0 0.0029399206
rapid O 0 0.003227322
improvement O 0 0.00177617
of O 0 0.0014151373
motor O 0 0.040205833
function O 0 0.0009139864
in O 0 0.0005831395
the O 0 0.0005210628
first O 0 0.0004309874
week O 0 0.00045425442
following O 0 0.00075871346
hemorrhage B-Disease 2 0.9997962
and O 0 0.0012015004
better O 0 0.0011631752
memory O 0 0.06570555
retention O 0 0.0022700084
in O 0 0.0013025897
the O 0 0.0017984314
passive O 0 0.0046940325
avoidance O 0 0.034524705
test O 0 0.008202192
. O 0 0.008595289

Acute O 0 0.96081066
white B-Disease 0 0.13242981
matter I-Disease 0 0.07013681
edema I-Disease 2 0.99979645
and O 0 0.0057988525
eventual O 0 0.1444153
neuronal B-Disease 0 0.9107293
loss I-Disease 0 0.018830672
in O 0 0.0011211344
the O 0 0.0011295711
striatum O 0 0.25245264
adjacent O 0 0.0012145609
to O 0 0.00076440343
the O 0 0.0011017496
hematoma B-Disease 2 0.99845207
did O 0 0.0011265422
not O 0 0.0011488469
differ O 0 0.0014735835
between O 0 0.0014127512
the O 0 0.0025862243
two O 0 0.0035378607
groups O 0 0.007995752
. O 0 0.008714152

Investigation O 0 0.017304692
of O 0 0.007156775
more O 0 0.0050445576
specific O 0 0.0033778162
anti O 0 0.023879124
- O 0 0.007143709
inflammatory O 0 0.89060193
agents O 0 0.59290767
and O 0 0.004023454
hemodiluting O 0 0.5110238
agents O 0 0.3433261
are O 0 0.0029535212
warranted O 0 0.0026409419
in O 0 0.0046412176
intracerebral B-Disease 0 0.9992199
hemorrhage I-Disease 2 0.99979
. O 0 0.013355249

Recurarization O 0 0.08574013
in O 0 0.030929646
the O 0 0.02917925
recovery O 0 0.03750267
room O 0 0.030522736
. O 0 0.035409346

A O 0 0.035452135
case O 0 0.010689541
of O 0 0.009537762
recurarization O 0 0.4518184
in O 0 0.0065480936
the O 0 0.0061014965
recovery O 0 0.009254135
room O 0 0.006027749
is O 0 0.008117634
reported O 0 0.012509628
. O 0 0.013980877

Accumulation O 0 0.015762685
of O 0 0.0068328283
atracurium B-Chemical 0 0.9969483
in O 0 0.003096476
the O 0 0.0022066853
intravenous O 0 0.32333302
line O 0 0.003024388
led O 0 0.0015034545
to O 0 0.0011696172
recurarization O 0 0.5387651
after O 0 0.0009504171
flushing O 0 0.8535016
the O 0 0.0017897035
line O 0 0.0029082983
in O 0 0.002088634
the O 0 0.0029428506
recovery O 0 0.006661206
room O 0 0.005076197
. O 0 0.008022669

A O 0 0.15444474
respiratory B-Disease 0 0.9397357
arrest I-Disease 0 0.9182206
with O 0 0.014600267
severe O 0 0.7343361
desaturation B-Disease 0 0.9977191
and O 0 0.027640823
bradycardia B-Disease 2 0.9991806
occurred O 0 0.01961791
. O 0 0.016744144

Circumstances O 0 0.39447644
leading O 0 0.008393944
to O 0 0.0036626554
this O 0 0.00263815
event O 0 0.006002486
and O 0 0.0017634126
the O 0 0.0011811503
mechanisms O 0 0.0014681455
enabling O 0 0.0012526512
a O 0 0.001646497
neuromuscular B-Disease 0 0.9900152
blockade I-Disease 0 0.80319446
to O 0 0.0007633275
occur O 0 0.0008026524
, O 0 0.0007711974
following O 0 0.00045148944
the O 0 0.00050700916
administration O 0 0.009954702
of O 0 0.0008157619
a O 0 0.0010635251
small O 0 0.0010944017
dose O 0 0.007257533
of O 0 0.002749061
relaxant O 0 0.9944313
, O 0 0.0056091426
are O 0 0.0045403144
discussed O 0 0.005133816
. O 0 0.008080821

The O 0 0.0076335245
haemodynamic O 0 0.394622
effects O 0 0.006023327
of O 0 0.0044399323
propofol B-Chemical 1 0.99932504
in O 0 0.0021121257
combination O 0 0.0031827225
with O 0 0.0023855858
ephedrine B-Chemical 1 0.9999461
in O 0 0.0017704809
elderly O 0 0.56209654
patients O 0 0.012189895
( O 0 0.0036915059
ASA O 1 0.99217755
groups O 0 0.0025592174
3 O 0 0.0022065886
and O 0 0.0030597928
4 O 0 0.003974357
) O 0 0.008087535
. O 0 0.0075684753

The O 0 0.008859347
marked O 0 0.009918675
vasodilator O 0 0.9881793
and O 0 0.005156506
negative O 0 0.0043916213
inotropic O 0 0.99167013
effects O 0 0.0068336437
of O 0 0.0044118953
propofol B-Chemical 1 0.9995983
are O 0 0.0029431651
disadvantages O 0 0.00215086
in O 0 0.0033568142
frail O 0 0.59234196
elderly O 0 0.55232763
patients O 0 0.025300356
. O 0 0.009623785

We O 0 0.007266289
investigated O 0 0.004137971
the O 0 0.003318807
safety O 0 0.0038936166
and O 0 0.002136403
efficacy O 0 0.0025850292
of O 0 0.001467794
adding O 0 0.0015776625
different O 0 0.00089512335
doses O 0 0.019259319
of O 0 0.0020359678
ephedrine B-Chemical 1 0.9999509
to O 0 0.0013875794
propofol B-Chemical 1 0.99931455
in O 0 0.0010819883
order O 0 0.000944485
to O 0 0.0014705908
obtund O 0 0.1487056
the O 0 0.0037832214
hypotensive B-Disease 2 0.9987143
response O 0 0.017438268
. O 0 0.010293464

The O 0 0.0072736638
haemodynamic O 0 0.35817635
effects O 0 0.0051919045
of O 0 0.003118047
adding O 0 0.002997891
15 O 0 0.0014163061
, O 0 0.0013004179
20 O 0 0.000767972
or O 0 0.0005928099
25 O 0 0.00079136674
mg O 0 0.07338661
of O 0 0.00089054654
ephedrine B-Chemical 1 0.99991477
to O 0 0.0005838881
200 O 0 0.0013239236
mg O 0 0.11275144
of O 0 0.00067238614
propofol B-Chemical 1 0.9990289
were O 0 0.0004583496
compared O 0 0.00024553775
to O 0 0.00031304796
control O 0 0.0003667096
in O 0 0.000382486
40 O 0 0.0006090495
ASA O 1 0.97373194
3 O 0 0.0005117274
/ O 0 0.0009175915
4 O 0 0.00041323117
patients O 0 0.00072295824
over O 0 0.00038872496
60 O 0 0.00065565563
years O 0 0.001049465
presenting O 0 0.0047707804
for O 0 0.0015534253
genito O 0 0.12287628
- O 0 0.0076338686
urinary O 0 0.89144
surgery O 0 0.03034264
. O 0 0.009323595

The O 0 0.00656693
addition O 0 0.003735124
of O 0 0.0048124674
ephedrine B-Chemical 1 0.99978393
to O 0 0.0032514913
propofol B-Chemical 1 0.9995639
appears O 0 0.0013400811
to O 0 0.00090780354
be O 0 0.0008215557
an O 0 0.0008888854
effective O 0 0.00074237166
method O 0 0.00087182614
of O 0 0.00090966723
obtunding O 0 0.776402
the O 0 0.00094543706
hypotensive B-Disease 2 0.9989981
response O 0 0.001739804
to O 0 0.000995191
propofol B-Chemical 1 0.99908495
at O 0 0.0007771376
all O 0 0.0010210942
doses O 0 0.0087642
used O 0 0.001839167
in O 0 0.0023925356
this O 0 0.0036066638
study O 0 0.007050022
. O 0 0.00792207

However O 0 0.009282827
, O 0 0.0070790253
marked O 0 0.007475736
tachycardia B-Disease 2 0.999049
associated O 0 0.0030919812
with O 0 0.0016413258
the O 0 0.0011421122
use O 0 0.0010840757
of O 0 0.0015185833
ephedrine B-Chemical 1 0.99994695
in O 0 0.00083863316
combination O 0 0.0014467913
with O 0 0.0009342933
propofol B-Chemical 1 0.99953115
occurred O 0 0.0007338878
in O 0 0.00045631413
the O 0 0.0004434942
majority O 0 0.00056208007
of O 0 0.00078906375
patients O 0 0.0035368172
, O 0 0.0012346985
occasionally O 0 0.0018629204
reaching O 0 0.0015884445
high O 0 0.0015517147
levels O 0 0.0016516548
in O 0 0.0022286132
individual O 0 0.003637951
patients O 0 0.014208078
. O 0 0.008219123

Due O 0 0.008506492
to O 0 0.004964588
the O 0 0.0037902906
risk O 0 0.012286074
of O 0 0.0029564928
this O 0 0.002698929
tachycardia B-Disease 2 0.9998715
inducing O 0 0.054714285
myocardial B-Disease 0 0.99995196
ischemia I-Disease 2 0.99997663
, O 0 0.0022515152
we O 0 0.00042534797
would O 0 0.0003989582
not O 0 0.0003903171
recommend O 0 0.00033125113
the O 0 0.00041736587
use O 0 0.0005413525
in O 0 0.000534417
elderly O 0 0.15463497
patients O 0 0.0014426082
of O 0 0.000706207
any O 0 0.0006364283
of O 0 0.0010878511
the O 0 0.0016528134
ephedrine B-Chemical 1 0.99993753
/ O 0 0.05749886
propofol B-Chemical 1 0.9995382
/ O 0 0.018203247
mixtures O 0 0.023796737
studied O 0 0.008232453
. O 0 0.009203794

Gemcitabine B-Chemical 0 0.9975527
plus O 0 0.008995166
vinorelbine B-Chemical 1 0.99839586
in O 0 0.0048761424
nonsmall B-Disease 0 0.99770266
cell I-Disease 0 0.116439894
lung I-Disease 0 0.9169486
carcinoma I-Disease 2 0.9998628
patients O 0 0.016236387
age O 0 0.0030878303
70 O 0 0.0012174381
years O 0 0.0012767559
or O 0 0.0010120701
older O 0 0.002841446
or O 0 0.0013804439
patients O 0 0.0038162954
who O 0 0.004512161
cannot O 0 0.013700053
receive O 0 0.0067510363
cisplatin B-Chemical 1 0.9992015
. O 0 0.011218326

Oncopaz O 0 0.46421796
Cooperative O 0 0.2796398
Group O 0 0.14510095
. O 0 0.07567824

BACKGROUND O 0 0.543122
: O 0 0.008234454
Although O 0 0.0033976051
the O 0 0.0026618051
prevalence O 0 0.0029533412
of O 0 0.0028580201
nonsmall B-Disease 0 0.9986527
cell I-Disease 0 0.19864967
lung I-Disease 0 0.9774475
carcinoma I-Disease 2 0.99997294
( O 0 0.048176482
NSCLC B-Disease 2 0.99975544
) O 0 0.0037098164
is O 0 0.00060894445
high O 0 0.0006717376
among O 0 0.00080122077
elderly O 0 0.28809473
patients O 0 0.0026489517
, O 0 0.00064772903
few O 0 0.00028257372
data O 0 0.0005126223
are O 0 0.0004197841
available O 0 0.00035059883
regarding O 0 0.00030746328
the O 0 0.00045909977
efficacy O 0 0.0016189635
and O 0 0.0011007383
toxicity B-Disease 2 0.9935482
of O 0 0.001744609
chemotherapy O 0 0.73125464
in O 0 0.0014254709
this O 0 0.0017191783
group O 0 0.002999374
of O 0 0.004678666
patients O 0 0.02771561
. O 0 0.008484207

Recent O 0 0.010605786
reports O 0 0.0060279802
indicate O 0 0.0030676108
that O 0 0.0021707881
single O 0 0.0022632377
agent O 0 0.106754296
therapy O 0 0.029466176
with O 0 0.0025730624
vinorelbine B-Chemical 1 0.9998833
( O 0 0.012881877
VNB B-Chemical 1 0.99846005
) O 0 0.0022741614
or O 0 0.0008738692
gemcitabine B-Chemical 1 0.99947375
( O 0 0.0038467513
GEM B-Chemical 1 0.99780875
) O 0 0.0012510243
may O 0 0.00034621859
obtain O 0 0.00024528106
a O 0 0.00047722543
response O 0 0.00049520354
rate O 0 0.00040213892
of O 0 0.0005758324
20 O 0 0.00063251896
- O 0 0.00072488067
30 O 0 0.00030254707
% O 0 0.00043540262
in O 0 0.00038479414
elderly O 0 0.112208426
patients O 0 0.0021450487
, O 0 0.0008314921
with O 0 0.00063991646
acceptable O 0 0.0010543414
toxicity B-Disease 2 0.98945785
and O 0 0.0012687764
improvement O 0 0.0013886647
in O 0 0.0012775697
symptoms O 0 0.6078353
and O 0 0.0027079734
quality O 0 0.0031006504
of O 0 0.0052962243
life O 0 0.018875232
. O 0 0.009074127

In O 0 0.0069630668
the O 0 0.004781955
current O 0 0.004365533
study O 0 0.002680059
the O 0 0.0017159968
efficacy O 0 0.0031745317
and O 0 0.0018199456
toxicity B-Disease 2 0.99225736
of O 0 0.0013243612
the O 0 0.0007927038
combination O 0 0.0013919682
of O 0 0.0015435391
GEM B-Chemical 1 0.9987012
and O 0 0.0016179597
VNB B-Chemical 1 0.9960562
in O 0 0.0006226641
elderly O 0 0.22484553
patients O 0 0.0020314634
with O 0 0.00077259116
advanced O 0 0.12137022
NSCLC B-Disease 2 0.9993445
or O 0 0.00084189913
those O 0 0.0010228417
with O 0 0.000752334
some O 0 0.0008669386
contraindication O 0 0.0012456272
to O 0 0.0012240362
receiving O 0 0.005856714
cisplatin B-Chemical 1 0.99935466
were O 0 0.004724903
assessed O 0 0.004969356
. O 0 0.007852926

METHODS O 0 0.011675334
: O 0 0.008518631
Forty O 0 0.009144732
- O 0 0.004803304
nine O 0 0.0025204197
patients O 0 0.0032092503
with O 0 0.0018961412
advanced O 0 0.0762785
NSCLC B-Disease 2 0.9989489
were O 0 0.0012104138
included O 0 0.00079800456
, O 0 0.00084314385
38 O 0 0.00073940697
of O 0 0.0005128408
whom O 0 0.001086645
were O 0 0.00053558656
age O 0 0.0013017961
> O 0 0.0010243738
/ O 0 0.0012166984
= O 0 0.0005999585
70 O 0 0.0004053442
years O 0 0.0004729771
and O 0 0.00043618318
11 O 0 0.0005161717
were O 0 0.00041406712
age O 0 0.00082627335
< O 0 0.0005324934
70 O 0 0.0005373273
years O 0 0.000698188
but O 0 0.00060754584
who O 0 0.0011325404
had O 0 0.0008326057
some O 0 0.0012216851
contraindication O 0 0.0020191753
to O 0 0.0023297833
receiving O 0 0.016500028
cisplatin B-Chemical 1 0.9994134
. O 0 0.010429145

All O 0 0.01738415
patients O 0 0.017409263
were O 0 0.012239291
evaluable O 0 0.019315409
for O 0 0.009366804
response O 0 0.013850056
and O 0 0.018935975
toxicity B-Disease 2 0.99653673
. O 0 0.022350727

Treatment O 0 0.024141647
was O 0 0.005806536
comprised O 0 0.0040748296
of O 0 0.0042863186
VNB B-Chemical 1 0.9907973
, O 0 0.0028713208
25 O 0 0.0019237439
mg O 0 0.23245412
/ O 0 0.003252394
m O 0 0.0076814448
( O 0 0.0014276432
2 O 0 0.00082162145
) O 0 0.0011136048
, O 0 0.0007429357
plus O 0 0.00060768833
GEM B-Chemical 1 0.99297076
, O 0 0.0008887148
1000 O 0 0.0010664581
mg O 0 0.13388622
/ O 0 0.0016680921
m O 0 0.004379475
( O 0 0.0009116594
2 O 0 0.0005892057
) O 0 0.00083770155
, O 0 0.0005673663
both O 0 0.00041907703
on O 0 0.0004259534
Days O 0 0.16296601
1 O 0 0.00082221586
, O 0 0.0009483113
8 O 0 0.0008129017
, O 0 0.0010891249
and O 0 0.0011930747
15 O 0 0.0012558869
every O 0 0.00128046
28 O 0 0.002868975
days O 0 0.0035672449
. O 0 0.0065196017

Patients O 0 0.014942256
received O 0 0.006792099
a O 0 0.0058742086
minimum O 0 0.0034382783
of O 0 0.0037455114
three O 0 0.0027947484
courses O 0 0.0048595057
unless O 0 0.005471238
progressive O 0 0.36452207
disease O 0 0.8863658
was O 0 0.007891043
detected O 0 0.007200217
. O 0 0.011074735

RESULTS O 0 0.029371776
: O 0 0.010799982
One O 0 0.0071204985
hundred O 0 0.004981892
sixty O 0 0.0049975207
- O 0 0.0037835268
five O 0 0.0018833588
courses O 0 0.0025906158
were O 0 0.0020161257
administered O 0 0.0025342237
, O 0 0.0024623112
with O 0 0.0021153411
a O 0 0.0030629185
median O 0 0.003074582
of O 0 0.005221349
3 O 0 0.007006366
. O 0 0.008551524

6 O 0 0.035415776
courses O 0 0.03879645
per O 0 0.031211914
patient O 0 0.04588888
. O 0 0.043812506

The O 0 0.007808471
overall O 0 0.0060918084
response O 0 0.0047639003
rate O 0 0.0033236358
was O 0 0.0026904123
26 O 0 0.002778065
% O 0 0.0023593532
( O 0 0.0022220903
95 O 0 0.0023425373
% O 0 0.0017431959
confidence O 0 0.0029059236
interval O 0 0.0020359617
, O 0 0.0023897325
15 O 0 0.00204703
- O 0 0.0035422104
41 O 0 0.0052261655
% O 0 0.005688442
) O 0 0.009311037
. O 0 0.008559726

Two O 0 0.009461488
patients O 0 0.008147731
attained O 0 0.0051706093
a O 0 0.003513955
complete O 0 0.002170492
response O 0 0.0026637132
( O 0 0.0024500357
4 O 0 0.0012161909
% O 0 0.0013960426
) O 0 0.0014908895
and O 0 0.0009913046
11 O 0 0.0011569704
patients O 0 0.0019173905
( O 0 0.0016043016
22 O 0 0.0015394386
% O 0 0.0016756448
) O 0 0.0023056846
achieved O 0 0.0019542917
a O 0 0.0033014335
partial O 0 0.0050625503
response O 0 0.008363154
. O 0 0.0090685375

Eastern O 0 0.18328683
Cooperative O 0 0.076744154
Oncology O 0 0.016957784
Group O 0 0.010703921
performance O 0 0.003305291
status O 0 0.0025090766
improved O 0 0.0020659764
in O 0 0.0010158239
35 O 0 0.001004091
% O 0 0.000812379
of O 0 0.0006548438
those O 0 0.0007673363
patients O 0 0.001233194
with O 0 0.00052060786
an O 0 0.0006276279
initial O 0 0.00047292837
value O 0 0.0005870121
> O 0 0.000929438
0 O 0 0.0006015947
, O 0 0.0004783786
whereas O 0 0.00033381872
relief O 0 0.024566835
of O 0 0.00044757882
at O 0 0.0002729344
least O 0 0.00023770123
1 O 0 0.00042013382
symptom O 0 0.040297944
without O 0 0.0004848736
worsening O 0 0.4270781
of O 0 0.00079864735
other O 0 0.0009334463
symptoms O 0 0.7878511
was O 0 0.00082664035
noted O 0 0.00070444954
in O 0 0.0009223651
27 O 0 0.0019311733
patients O 0 0.003214902
( O 0 0.0031069003
55 O 0 0.003717335
% O 0 0.0048278477
) O 0 0.0082188025
. O 0 0.0075562755

The O 0 0.007272865
median O 0 0.005154427
time O 0 0.0035934641
to O 0 0.003083912
progression O 0 0.051913206
was O 0 0.0020926264
16 O 0 0.001506105
weeks O 0 0.0009194665
and O 0 0.0011962013
the O 0 0.0012273062
1 O 0 0.0015695521
- O 0 0.0019501102
year O 0 0.0014852032
survival O 0 0.010130221
rate O 0 0.0025726464
was O 0 0.0034900215
33 O 0 0.006398832
% O 0 0.0073840604
. O 0 0.008064028

Toxicity B-Disease 2 0.97108823
was O 0 0.0771721
mild O 0 0.6853737
. O 0 0.07052175

Six O 0 0.011490414
patients O 0 0.010516783
( O 0 0.005995293
12 O 0 0.0027994183
% O 0 0.0030111605
) O 0 0.0027004771
had O 0 0.0014666511
World O 0 0.0030504975
Health O 0 0.0019273711
Organization O 0 0.0018506744
Grade O 0 0.68972164
3 O 0 0.0007538157
- O 0 0.00091838086
4 O 0 0.00054069044
neutropenia B-Disease 2 0.99847704
, O 0 0.0009202425
2 O 0 0.0005059948
patients O 0 0.0011537145
( O 0 0.00071608054
4 O 0 0.00041713915
% O 0 0.00055699487
) O 0 0.0007048699
had O 0 0.00046210093
Grade O 0 0.74502563
3 O 0 0.0005742074
- O 0 0.0008298976
4 O 0 0.0005436914
thrombocytopenia B-Disease 2 0.9996637
, O 0 0.0010648232
and O 0 0.00074402895
2 O 0 0.0007037149
patients O 0 0.0016210828
( O 0 0.0012742899
4 O 0 0.0009365184
% O 0 0.0014954311
) O 0 0.0023812389
had O 0 0.0022702236
Grade O 0 0.8848445
3 O 0 0.005704939
neurotoxicity B-Disease 2 0.9993679
. O 0 0.010087215

Three O 0 0.013053887
patients O 0 0.011869121
with O 0 0.007817332
severe O 0 0.42574322
neutropenia B-Disease 2 0.99958116
( O 0 0.010411763
6 O 0 0.0037848281
% O 0 0.0050238594
) O 0 0.0065398193
died O 0 0.012795529
of O 0 0.009917565
sepsis B-Disease 2 0.99824893
. O 0 0.016602376

The O 0 0.006605197
median O 0 0.004667047
age O 0 0.0047468306
of O 0 0.0028429518
those O 0 0.002548184
patients O 0 0.0039806045
developing O 0 0.009640793
Grade O 0 0.94785
3 O 0 0.001265094
- O 0 0.0013477382
4 O 0 0.00064564333
neutropenia B-Disease 2 0.99810684
was O 0 0.0006089427
significantly O 0 0.0006131609
higher O 0 0.00040294434
than O 0 0.00028063927
that O 0 0.0002813452
of O 0 0.00042258605
the O 0 0.00038594846
remaining O 0 0.00043650498
patients O 0 0.0018403552
( O 0 0.00081867597
75 O 0 0.0006937935
years O 0 0.00067759125
vs O 0 0.0009400415
. O 0 0.00049483683
72 O 0 0.0007102874
years O 0 0.001175078
; O 0 0.0018884265
P O 0 0.028078483
= O 0 0.0023335589
0 O 0 0.0025288032
. O 0 0.0025420575
047 O 0 0.15558305
) O 0 0.008090359
. O 0 0.0075162873

CONCLUSIONS O 0 0.4014398
: O 0 0.00836238
The O 0 0.0037349039
combination O 0 0.0038290096
of O 0 0.003718259
GEM B-Chemical 1 0.9954175
and O 0 0.0036552555
VNB B-Chemical 1 0.9949391
is O 0 0.0013015652
moderately O 0 0.0048846873
active O 0 0.0014037263
and O 0 0.0009185375
well O 0 0.000740646
tolerated O 0 0.0070276135
except O 0 0.00067930145
in O 0 0.0009014957
patients O 0 0.0027849623
age O 0 0.0039124778
> O 0 0.003460071
/ O 0 0.0051447577
= O 0 0.0039066784
75 O 0 0.0046728146
years O 0 0.0065040323
. O 0 0.0071451836

This O 0 0.018331049
age O 0 0.014897964
group O 0 0.009925353
had O 0 0.007916237
an O 0 0.009708082
increased O 0 0.010378241
risk O 0 0.1902373
of O 0 0.03255149
myelosuppression B-Disease 2 0.99980575
. O 0 0.025108092

Therefore O 0 0.0066825245
the O 0 0.004916402
prophylactic O 0 0.007097725
use O 0 0.003466822
of O 0 0.0038246126
granulocyte O 0 0.950657
- O 0 0.011274957
colony O 0 0.07588804
stimulating O 0 0.0054517947
factor O 0 0.009058139
should O 0 0.0013426277
be O 0 0.0019233904
considered O 0 0.0019500565
with O 0 0.0031224685
this O 0 0.0043339543
treatment O 0 0.010253875
. O 0 0.009653935

New O 0 0.015520085
chemotherapy O 0 0.14463739
combinations O 0 0.0047245943
with O 0 0.0033330268
higher O 0 0.002372545
activity O 0 0.0024350546
and O 0 0.0021535638
lower O 0 0.0022190223
toxicity B-Disease 2 0.99502844
are O 0 0.0018498254
needed O 0 0.0011370477
for O 0 0.0014535658
elderly O 0 0.30583656
patients O 0 0.007771111
with O 0 0.005010018
advanced O 0 0.5551805
NSCLC B-Disease 2 0.9992924
. O 0 0.012625852

A O 0 0.13549432
selective O 0 0.111982696
dopamine B-Chemical 1 0.9996049
D4 O 0 0.99773586
receptor O 0 0.8070118
antagonist O 0 0.99466926
, O 0 0.020742085
NRA0160 B-Chemical 1 0.9922504
: O 0 0.0061458843
a O 0 0.004992139
preclinical O 0 0.04522536
neuropharmacological O 0 0.98057544
profile O 0 0.0119655505
. O 0 0.011446346

NRA0160 B-Chemical 1 0.9748443
, O 0 0.0111872805
5 B-Chemical 0 0.005522819
- I-Chemical 0 0.005939261
[ I-Chemical 0 0.004992511
2 I-Chemical 0 0.002392631
- I-Chemical 0 0.0027261842
( I-Chemical 0 0.0018439814
4 I-Chemical 0 0.0011182864
- I-Chemical 0 0.0015440418
( I-Chemical 0 0.0011528757
3 I-Chemical 0 0.00077286083
- I-Chemical 0 0.001154358
fluorobenzylidene I-Chemical 0 0.010861007
) I-Chemical 0 0.0023348639
piperidin I-Chemical 0 0.4859255
- I-Chemical 0 0.0026058261
1 I-Chemical 0 0.001011617
- I-Chemical 0 0.0024696116
yl I-Chemical 0 0.9343191
) I-Chemical 0 0.010090744
ethyl I-Chemical 0 0.999173
] I-Chemical 0 0.022044752
- I-Chemical 0 0.001991395
4 I-Chemical 0 0.0006064374
- I-Chemical 0 0.0009781906
( I-Chemical 0 0.0007233859
4 I-Chemical 0 0.0005197541
- I-Chemical 0 0.0011840092
fluorophenyl I-Chemical 0 0.94728386
) I-Chemical 0 0.0032095264
thiazole I-Chemical 0 0.9842427
- I-Chemical 0 0.002832334
2 I-Chemical 0 0.0007104458
- I-Chemical 0 0.001310967
carboxamide I-Chemical 0 0.9415428
, O 0 0.0008420283
has O 0 0.00033743723
a O 0 0.00054999586
high O 0 0.0005537964
affinity O 0 0.0011537952
for O 0 0.00038982995
human O 0 0.0012430092
cloned O 0 0.0050721136
dopamine B-Chemical 1 0.9999398
D4 O 0 0.99582505
. O 0 0.00048815622
2 O 0 0.0005584025
, O 0 0.0008187789
D4 O 0 0.9257528
. O 0 0.00035065378
4 O 0 0.00037085405
and O 0 0.000557845
D4 O 0 0.94039845
. O 0 0.00037901205
7 O 0 0.00043857744
receptors O 0 0.01146485
, O 0 0.00066978723
with O 0 0.0005267057
Ki O 0 0.7219297
values O 0 0.00045785264
of O 0 0.0005377216
0 O 0 0.00070315506
. O 0 0.00034016912
5 O 0 0.00040254815
, O 0 0.0005828498
0 O 0 0.0006226425
. O 0 0.00042556296
9 O 0 0.0006219083
and O 0 0.0007934807
2 O 0 0.0010222158
. O 0 0.0010291085
7 O 0 0.0017991926
nM O 0 0.014785144
, O 0 0.005029984
respectively O 0 0.0080696605
. O 0 0.0076533635

NRA0160 B-Chemical 1 0.93336713
is O 0 0.00655001
over O 0 0.0033396834
20 O 0 0.0032372922
, O 0 0.0029094464
000fold O 0 0.005998186
more O 0 0.0018602978
potent O 0 0.0055079153
at O 0 0.00094241346
the O 0 0.0014686916
dopamine B-Chemical 1 0.99987197
D4 O 0 0.9944647
. O 0 0.00084478594
2 O 0 0.0008846418
receptor O 0 0.005606032
compared O 0 0.0006521792
with O 0 0.0011533546
the O 0 0.0015182551
human O 0 0.0037811801
cloned O 0 0.022496413
dopamine B-Chemical 1 0.9998374
D2L O 0 0.998552
receptor O 0 0.36673105
. O 0 0.010469639

NRA0160 B-Chemical 1 0.94969815
has O 0 0.005891328
negligible O 0 0.0047887038
affinity O 0 0.0045911605
for O 0 0.0017764979
the O 0 0.0017491472
human O 0 0.0030065288
cloned O 0 0.010974794
dopamine B-Chemical 1 0.99994826
D3 O 0 0.99990034
receptor O 0 0.621719
( O 0 0.0048590587
Ki O 0 0.96323925
= O 0 0.0013616235
39 O 0 0.0012829755
nM O 0 0.025402242
) O 0 0.0013106168
, O 0 0.0007764801
rat O 0 0.0061872844
serotonin B-Chemical 1 0.9997043
( O 0 0.0014108716
5 B-Chemical 0 0.00063238334
- I-Chemical 0 0.0016827232
HT I-Chemical 0 0.9935406
) O 0 0.0018376845
2A O 0 0.0013455906
receptors O 0 0.05963611
( O 0 0.0014882747
Ki O 0 0.8874545
= O 0 0.0010347768
180 O 0 0.0010112531
nM O 0 0.008712109
) O 0 0.0011218202
and O 0 0.0008490635
rat O 0 0.007536009
alpha1 O 0 0.9502368
adrenoceptor O 0 0.9998394
( O 0 0.006935747
Ki O 0 0.94502884
= O 0 0.004387012
237 O 0 0.013701116
nM O 0 0.042848844
) O 0 0.009196114
. O 0 0.007584323

NRA0160 B-Chemical 1 0.98495495
and O 0 0.021333763
clozapine B-Chemical 1 0.9999373
antagonized O 0 0.9952171
locomotor O 2 0.99916506
hyperactivity B-Disease 2 0.9999716
induced O 0 0.021423249
by O 0 0.020408962
methamphetamine B-Chemical 1 0.9999747
( O 0 0.03849766
MAP B-Chemical 0 0.9543884
) O 0 0.008668898
in O 0 0.0048391367
mice O 0 0.0059602014
. O 0 0.009434952

NRA0160 B-Chemical 1 0.9851391
and O 0 0.017149279
clozapine B-Chemical 1 0.9999454
antagonized O 0 0.9912934
MAP B-Chemical 0 0.9946801
- O 0 0.0093365135
induced O 0 0.0021186036
stereotyped O 0 0.8177706
behavior O 0 0.007828667
in O 0 0.0007849161
mice O 0 0.0005800602
, O 0 0.0008573822
although O 0 0.00046306284
their O 0 0.0005410046
effects O 0 0.0009000925
did O 0 0.000484646
not O 0 0.00049520633
exceed O 0 0.00052927993
50 O 0 0.00093021244
% O 0 0.0008747772
inhibition O 0 0.0015833917
, O 0 0.0011496647
even O 0 0.00090918754
at O 0 0.000873686
the O 0 0.0013098115
highest O 0 0.002067422
dose O 0 0.011790326
given O 0 0.004302531
. O 0 0.0077258996

NRA0160 B-Chemical 1 0.9828059
and O 0 0.013764467
clozapine B-Chemical 1 0.999912
significantly O 0 0.015259315
induced O 0 0.013171727
catalepsy B-Disease 2 0.9999863
in O 0 0.0022988827
rats O 0 0.009017544
, O 0 0.0013737468
although O 0 0.00064605055
their O 0 0.0006927377
effects O 0 0.0010666999
did O 0 0.0005731603
not O 0 0.00057196536
exceed O 0 0.0005995584
50 O 0 0.0009867483
% O 0 0.00087369804
induction O 0 0.0008101897
even O 0 0.00097300176
at O 0 0.000923236
the O 0 0.001382177
highest O 0 0.0021706694
dose O 0 0.013053387
given O 0 0.0044290028
. O 0 0.007895129

NRA0160 B-Chemical 1 0.98035735
and O 0 0.013662547
clozapine B-Chemical 1 0.999877
significantly O 0 0.007554377
reversed O 0 0.005025788
the O 0 0.0019725855
disruption O 0 0.0021299638
of O 0 0.002502768
prepulse O 0 0.99414885
inhibition O 0 0.023472117
( O 0 0.003752746
PPI O 0 0.38994077
) O 0 0.003080756
in O 0 0.0016521157
rats O 0 0.004375061
produced O 0 0.0034609165
by O 0 0.010458195
apomorphine B-Chemical 1 0.9999199
. O 0 0.0120796375

NRA0160 B-Chemical 1 0.9785363
and O 0 0.01288058
clozapine B-Chemical 1 0.9998734
significantly O 0 0.0074707028
shortened O 0 0.006701708
the O 0 0.0038688618
phencyclidine B-Chemical 0 0.99999785
( O 0 0.070807695
PCP B-Chemical 0 0.99967873
) O 0 0.013593193
- O 0 0.0021022293
induced O 0 0.001042827
prolonged O 0 0.005968612
swimming O 0 0.1562788
latency O 0 0.0039697294
in O 0 0.0012265041
rats O 0 0.00292766
in O 0 0.0017021446
a O 0 0.0033448343
water O 0 0.021442773
maze O 0 0.0572622
task O 0 0.007742705
. O 0 0.008146977

These O 0 0.009158936
findings O 0 0.0073927026
suggest O 0 0.0033616354
that O 0 0.003099737
NRA0160 B-Chemical 1 0.9704772
may O 0 0.0018980345
have O 0 0.0012230538
unique O 0 0.001684144
antipsychotic O 0 0.9991867
activities O 0 0.0017790864
without O 0 0.00082114636
the O 0 0.00089119456
liability O 0 0.3396891
of O 0 0.0014063892
motor O 0 0.12507772
side O 0 0.044921547
effects O 0 0.002847064
typical O 0 0.002548574
of O 0 0.0038879598
classical O 0 0.0627254
antipsychotics O 0 0.99967825
. O 0 0.010332003

Warfarin B-Chemical 1 0.99879885
- O 0 0.021337537
induced O 0 0.010615307
artery B-Disease 2 0.8900171
calcification I-Disease 2 0.99892503
is O 0 0.007379232
accelerated O 0 0.010861795
by O 0 0.0073749516
growth O 0 0.062213343
and O 0 0.02537881
vitamin B-Chemical 1 0.99983263
D I-Chemical 1 0.9973756
. O 0 0.022711718

The O 0 0.007020014
present O 0 0.0040378817
studies O 0 0.0035302928
demonstrate O 0 0.0019349932
that O 0 0.001899625
growth O 0 0.014982496
and O 0 0.0060528987
vitamin B-Chemical 1 0.9999683
D I-Chemical 1 0.9975228
treatment O 0 0.0047838143
enhance O 0 0.00058540155
the O 0 0.0006137341
extent O 0 0.00043094836
of O 0 0.0009823523
artery B-Disease 2 0.9237191
calcification I-Disease 2 0.99967873
in O 0 0.0006393775
rats O 0 0.0013934835
given O 0 0.00027493734
sufficient O 0 0.00027049464
doses O 0 0.010086154
of O 0 0.0014336488
Warfarin B-Chemical 1 0.9999378
to O 0 0.00066332927
inhibit O 0 0.0008367231
gamma O 0 0.8566485
- O 0 0.008576706
carboxylation O 0 0.9468685
of O 0 0.0012840334
matrix O 0 0.19879116
Gla O 0 0.99758327
protein O 0 0.0061983424
, O 0 0.0016164682
a O 0 0.0014737084
calcification B-Disease 2 0.9969338
inhibitor O 0 0.086317904
known O 0 0.001046957
to O 0 0.00055290613
be O 0 0.0005740334
expressed O 0 0.0004277138
by O 0 0.0007007319
smooth O 0 0.0077163717
muscle O 0 0.037524324
cells O 0 0.0020987738
and O 0 0.0016947354
macrophages O 0 0.005086872
in O 0 0.0022161186
the O 0 0.003227845
artery O 0 0.29577017
wall O 0 0.18707006
. O 0 0.009740174

The O 0 0.006827407
first O 0 0.004253036
series O 0 0.004166994
of O 0 0.0027322422
experiments O 0 0.0017757895
examined O 0 0.0011972857
the O 0 0.0011722154
influence O 0 0.00090174784
of O 0 0.0013131065
age O 0 0.0030571262
and O 0 0.0014395295
growth O 0 0.0050420137
status O 0 0.0018719976
on O 0 0.0010792243
artery B-Disease 2 0.90588176
calcification I-Disease 2 0.9996691
in O 0 0.0060327305
Warfarin B-Chemical 1 0.99989235
- O 0 0.010618332
treated O 0 0.0068601803
rats O 0 0.019066973
. O 0 0.0091707185

Treatment O 0 0.022257341
for O 0 0.004797664
2 O 0 0.003487008
weeks O 0 0.0019892298
with O 0 0.0022809957
Warfarin B-Chemical 1 0.9995926
caused O 0 0.0020622457
massive O 0 0.119220935
focal O 0 0.2654949
calcification B-Disease 2 0.99650216
of I-Disease 0 0.0011895632
the I-Disease 0 0.0007582797
artery I-Disease 0 0.119259566
media O 0 0.003771674
in O 0 0.0005653733
20 O 0 0.0006518197
- O 0 0.0007266679
day O 0 0.00042093277
- O 0 0.0006941606
old O 0 0.00054711493
rats O 0 0.0009498575
and O 0 0.00060361065
less O 0 0.0005705579
extensive O 0 0.00088563864
focal O 0 0.09805317
calcification B-Disease 2 0.9948167
in O 0 0.0013871362
42 O 0 0.0024828291
- O 0 0.0023628091
day O 0 0.0018031716
- O 0 0.003795786
old O 0 0.004630111
rats O 0 0.010312086
. O 0 0.008528237

In O 0 0.007782307
contrast O 0 0.005722629
, O 0 0.004624096
no O 0 0.0026962236
artery B-Disease 2 0.68906283
calcification I-Disease 2 0.9987733
could O 0 0.0014766192
be O 0 0.0011721507
detected O 0 0.0006680144
in O 0 0.00077536074
10 O 0 0.0008947648
- O 0 0.0010601646
month O 0 0.00055046944
- O 0 0.0009225818
old O 0 0.00074337685
adult O 0 0.0010305326
rats O 0 0.0014648141
even O 0 0.00089064584
after O 0 0.0007052698
4 O 0 0.0011510707
weeks O 0 0.0012780493
of O 0 0.0036657522
Warfarin B-Chemical 1 0.999608
treatment O 0 0.014222471
. O 0 0.009373647

To O 0 0.006368659
directly O 0 0.004397914
examine O 0 0.0021545577
the O 0 0.0021282902
importance O 0 0.0015440608
of O 0 0.0019532691
growth O 0 0.013208383
to O 0 0.0019589216
Warfarin B-Chemical 1 0.9999516
- O 0 0.0057161986
induced O 0 0.001285968
artery B-Disease 2 0.92073464
calcification I-Disease 2 0.9995602
in O 0 0.0006001467
animals O 0 0.0004249873
of O 0 0.00048811108
the O 0 0.00039775934
same O 0 0.00029386638
age O 0 0.001326837
, O 0 0.0007169651
20 O 0 0.0005292083
- O 0 0.00062906666
day O 0 0.00037040072
- O 0 0.00063190894
old O 0 0.00048853003
rats O 0 0.0008971274
were O 0 0.00042519235
fed O 0 0.00054028473
for O 0 0.00032042316
2 O 0 0.00038724532
weeks O 0 0.0002604885
either O 0 0.00037863504
an O 0 0.00065602944
ad O 0 0.0015419422
libitum O 0 0.0020905302
diet O 0 0.0151768355
or O 0 0.0005923459
a O 0 0.00087285147
6 O 0 0.0005642255
- O 0 0.00094016106
g O 0 0.0011191027
/ O 0 0.0014293867
d O 0 0.00091229944
restricted O 0 0.0006690223
diet O 0 0.010699954
that O 0 0.0011129067
maintains O 0 0.0019137664
weight O 0 0.0085364245
but O 0 0.0034276973
prevents O 0 0.0063097407
growth O 0 0.064286724
. O 0 0.010085549

Concurrent O 0 0.020378957
treatment O 0 0.0065669613
of O 0 0.0041698087
both O 0 0.0028617433
dietary O 0 0.39766252
groups O 0 0.0028997352
with O 0 0.0022983055
Warfarin B-Chemical 1 0.9998559
produced O 0 0.0011432507
massive O 0 0.09557996
focal O 0 0.22607154
calcification B-Disease 2 0.9960743
of I-Disease 0 0.0009996446
the I-Disease 0 0.00067726395
artery I-Disease 0 0.1203684
media O 0 0.003791992
in O 0 0.0005240131
the O 0 0.00057142024
ad O 0 0.0023905865
libitum O 0 0.0054623894
- O 0 0.0011305129
fed O 0 0.00071740325
rats O 0 0.0011118905
but O 0 0.00046105028
no O 0 0.00036946722
detectable O 0 0.0005144565
artery B-Disease 2 0.7459543
calcification I-Disease 2 0.99913174
in O 0 0.0009032681
the O 0 0.0009264611
restricted O 0 0.00088905095
- O 0 0.0028659294
diet O 0 0.10332666
, O 0 0.0038161464
growth O 0 0.025437027
- O 0 0.006653584
inhibited O 0 0.0054472727
group O 0 0.009011545
. O 0 0.009019683

Although O 0 0.0062117064
the O 0 0.004130801
explanation O 0 0.002429715
for O 0 0.0017389262
the O 0 0.0014805419
association O 0 0.0010458954
between O 0 0.0009257615
artery B-Disease 2 0.87154317
calcification I-Disease 2 0.9996519
and O 0 0.0020436067
growth O 0 0.012087077
status O 0 0.0014946922
cannot O 0 0.004345599
be O 0 0.0005556708
determined O 0 0.00032943932
from O 0 0.00039021956
the O 0 0.00036415982
present O 0 0.00029051572
study O 0 0.00058153935
, O 0 0.0005342929
there O 0 0.00024159923
was O 0 0.00032189593
a O 0 0.0003974815
relationship O 0 0.00026230584
between O 0 0.00027031288
higher O 0 0.00054847513
serum O 0 0.3709285
phosphate B-Chemical 1 0.99843687
and O 0 0.0012303429
susceptibility O 0 0.004167305
to O 0 0.0006668468
artery B-Disease 2 0.9241518
calcification I-Disease 2 0.9997956
, O 0 0.0012866969
with O 0 0.00050127006
30 O 0 0.0003343162
% O 0 0.00040501278
higher O 0 0.00029395547
levels O 0 0.0003582986
of O 0 0.00072138844
serum O 0 0.41963235
phosphate B-Chemical 1 0.99843293
in O 0 0.00086183293
young O 0 0.03209142
, O 0 0.0011187595
ad O 0 0.0026064063
libitum O 0 0.005567736
- O 0 0.000984588
fed O 0 0.00057721685
rats O 0 0.0008506581
compared O 0 0.0002485825
with O 0 0.00038083238
either O 0 0.00037524517
of O 0 0.00046192654
the O 0 0.00040715738
groups O 0 0.0005533321
that O 0 0.0003372237
was O 0 0.0004501452
resistant O 0 0.0006475115
to O 0 0.0007152604
Warfarin B-Chemical 1 0.99995327
- O 0 0.0025500606
induced O 0 0.00085808424
artery B-Disease 2 0.93001306
calcification I-Disease 2 0.99978715
, O 0 0.0014793609
ie O 0 0.001757274
, O 0 0.0006603905
the O 0 0.00041698173
10 O 0 0.0005136867
- O 0 0.00065534335
month O 0 0.0003565713
- O 0 0.0006634013
old O 0 0.0005548434
rats O 0 0.001006565
and O 0 0.0006760567
the O 0 0.0006904539
restricted O 0 0.000728446
- O 0 0.0023671933
diet O 0 0.093094334
, O 0 0.0031786691
growth O 0 0.023524886
- O 0 0.005607133
inhibited O 0 0.0044845426
young O 0 0.052080207
rats O 0 0.01950199
. O 0 0.009247054

This O 0 0.009938305
observation O 0 0.0049491925
suggests O 0 0.0028182515
that O 0 0.0024088887
increased O 0 0.0028991837
susceptibility O 0 0.006049314
to O 0 0.0029510816
Warfarin B-Chemical 1 0.9999366
- O 0 0.0081460215
induced O 0 0.0021966456
artery B-Disease 2 0.9421787
calcification I-Disease 2 0.9995819
could O 0 0.0012666216
be O 0 0.0013866058
related O 0 0.0011059527
to O 0 0.0016374765
higher O 0 0.0026447026
serum O 0 0.5722735
phosphate B-Chemical 1 0.99793553
levels O 0 0.01067389
. O 0 0.010312986

The O 0 0.0074660154
second O 0 0.0051573496
set O 0 0.0033108897
of O 0 0.0028951836
experiments O 0 0.0020482363
examined O 0 0.0015123506
the O 0 0.0016807095
possible O 0 0.0018610619
synergy O 0 0.02525308
between O 0 0.0024885682
vitamin B-Chemical 1 0.9999466
D I-Chemical 1 0.9982962
and O 0 0.037086282
Warfarin B-Chemical 1 0.99985445
in O 0 0.007231247
artery B-Disease 2 0.97129166
calcification I-Disease 2 0.9992812
. O 0 0.014111398

High O 0 0.03710307
doses O 0 0.05636398
of O 0 0.0150764445
vitamin B-Chemical 1 0.99988556
D I-Chemical 1 0.9955813
are O 0 0.003683927
known O 0 0.0024666062
to O 0 0.0014867684
cause O 0 0.009547763
calcification B-Disease 2 0.9937442
of I-Disease 0 0.001484448
the I-Disease 0 0.0010454402
artery I-Disease 0 0.11819505
media O 0 0.004007953
in O 0 0.0008663325
as O 0 0.00096270675
little O 0 0.0009671619
as O 0 0.0013943271
3 O 0 0.0016421103
to O 0 0.0019050862
4 O 0 0.0029267583
days O 0 0.0038511192
. O 0 0.006752853

High O 0 0.028121002
doses O 0 0.021228757
of O 0 0.0063835923
the O 0 0.007072962
vitamin B-Chemical 0 0.999946
K I-Chemical 1 0.9999255
antagonist O 0 0.9993476
Warfarin B-Chemical 1 0.9999645
are O 0 0.0016276676
also O 0 0.0009107457
known O 0 0.00094113615
to O 0 0.0006609395
cause O 0 0.006728398
calcification B-Disease 2 0.99470866
of I-Disease 0 0.0009328946
the I-Disease 0 0.0006722468
artery I-Disease 0 0.19578809
media O 0 0.011490875
, O 0 0.000941936
but O 0 0.0004488835
at O 0 0.00030962122
treatment O 0 0.0005357009
times O 0 0.00033157752
of O 0 0.0005743289
2 O 0 0.00059411285
weeks O 0 0.00045160088
or O 0 0.00068350654
longer O 0 0.00069637696
yet O 0 0.0014468429
not O 0 0.0014946486
at O 0 0.0018713714
1 O 0 0.0034252745
week O 0 0.0038976762
. O 0 0.0066237766

In O 0 0.0070733298
the O 0 0.004924256
current O 0 0.0047012963
study O 0 0.0030552621
, O 0 0.0021161262
we O 0 0.0009051812
investigated O 0 0.0008036546
the O 0 0.0008359771
synergy O 0 0.003319948
between O 0 0.00046321357
these O 0 0.00080960774
2 O 0 0.00063767534
treatments O 0 0.0011468824
and O 0 0.00057784084
found O 0 0.00035181103
that O 0 0.00036446872
concurrent O 0 0.0065905494
Warfarin B-Chemical 1 0.99994993
administration O 0 0.13404259
dramatically O 0 0.0014562979
increased O 0 0.00070735614
the O 0 0.00045023486
extent O 0 0.0003563146
of O 0 0.0009688986
calcification B-Disease 2 0.99570686
in O 0 0.0006326483
the O 0 0.0006779122
media O 0 0.011339214
of O 0 0.0064166677
vitamin B-Chemical 1 0.9999846
D I-Chemical 1 0.9991211
- O 0 0.011973959
treated O 0 0.0018824708
rats O 0 0.0032479155
at O 0 0.0011625704
3 O 0 0.0016159519
and O 0 0.0022954163
4 O 0 0.0029387523
days O 0 0.003824752
. O 0 0.006692984

There O 0 0.008742089
was O 0 0.0053433776
a O 0 0.0040965467
close O 0 0.0023299628
parallel O 0 0.0020134728
between O 0 0.0010930414
the O 0 0.0012023791
effect O 0 0.0012359881
of O 0 0.003715065
vitamin B-Chemical 1 0.9999759
D I-Chemical 1 0.9970559
dose O 0 0.081773214
on O 0 0.0006926506
artery B-Disease 2 0.91890335
calcification I-Disease 2 0.99965894
and O 0 0.0010495166
the O 0 0.0005774002
effect O 0 0.0006431735
of O 0 0.0029505754
vitamin B-Chemical 1 0.99998546
D I-Chemical 1 0.9970196
dose O 0 0.048670158
on O 0 0.00040252382
the O 0 0.0006180113
elevation O 0 0.20885582
of O 0 0.0012196074
serum O 0 0.61816084
calcium B-Chemical 1 0.99980325
, O 0 0.0020688784
which O 0 0.00086822413
suggests O 0 0.00043881516
that O 0 0.00096620864
vitamin B-Chemical 1 0.9999746
D I-Chemical 1 0.9970208
may O 0 0.0013731752
induce O 0 0.0011468208
artery B-Disease 2 0.9396684
calcification I-Disease 2 0.9995479
through O 0 0.0016913457
its O 0 0.002982653
effect O 0 0.0023116034
on O 0 0.0026442246
serum O 0 0.6984561
calcium B-Chemical 1 0.99903643
. O 0 0.012783705

Because O 0 0.00900622
Warfarin B-Chemical 1 0.99838555
treatment O 0 0.005589226
had O 0 0.0021066072
no O 0 0.0012606052
effect O 0 0.0011822693
on O 0 0.00078652473
the O 0 0.0010892593
elevation O 0 0.2721457
in O 0 0.0010762397
serum O 0 0.4728916
calcium B-Chemical 1 0.9997062
produced O 0 0.0019575888
by O 0 0.00811219
vitamin B-Chemical 1 0.9999869
D I-Chemical 1 0.9986772
, O 0 0.0025364377
the O 0 0.00065583416
synergy O 0 0.014045813
between O 0 0.00058623793
Warfarin B-Chemical 1 0.99995816
and O 0 0.0074260533
vitamin B-Chemical 1 0.99998677
D I-Chemical 1 0.9976999
is O 0 0.0009461508
probably O 0 0.0010016981
best O 0 0.0005103698
explained O 0 0.0004615977
by O 0 0.00050867605
the O 0 0.0004473681
hypothesis O 0 0.00071612856
that O 0 0.000734638
Warfarin B-Chemical 1 0.9999095
inhibits O 0 0.0008326846
the O 0 0.0007970124
activity O 0 0.0011329236
of O 0 0.0016871642
matrix O 0 0.1937082
Gla O 0 0.99629694
protein O 0 0.006427871
as O 0 0.003684599
a O 0 0.009615527
calcification B-Disease 2 0.998028
inhibitor O 0 0.5642419
. O 0 0.011866762

High O 0 0.02624616
levels O 0 0.0060687
of O 0 0.005903173
matrix O 0 0.11046145
Gla O 0 0.98879063
protein O 0 0.005688867
are O 0 0.0017667052
found O 0 0.000911511
at O 0 0.00066961173
sites O 0 0.0007370867
of O 0 0.0010494465
artery B-Disease 2 0.88466114
calcification I-Disease 2 0.9996402
in O 0 0.000906156
rats O 0 0.0043409327
treated O 0 0.0013842322
with O 0 0.0031793655
vitamin B-Chemical 1 0.9999858
D I-Chemical 1 0.99850357
plus O 0 0.0057688686
Warfarin B-Chemical 1 0.999969
, O 0 0.0014627305
and O 0 0.0006718112
chemical O 0 0.009018022
analysis O 0 0.00074609864
showed O 0 0.00042689504
that O 0 0.0004176405
the O 0 0.0005689806
protein O 0 0.0011089689
that O 0 0.0007319984
accumulated O 0 0.0010491618
was O 0 0.0013244861
indeed O 0 0.0020617829
not O 0 0.0029499985
gamma B-Chemical 0 0.90706426
- I-Chemical 0 0.03491596
carboxylated I-Chemical 0 0.99095905
. O 0 0.011855655

These O 0 0.008404816
observations O 0 0.005673417
indicate O 0 0.0030958108
that O 0 0.0022203785
although O 0 0.0019127569
the O 0 0.002163244
gamma B-Chemical 0 0.937105
- I-Chemical 0 0.01057397
carboxyglutamate I-Chemical 0 0.37103856
residues O 0 0.02645303
of O 0 0.0017797345
matrix O 0 0.19537865
Gla O 0 0.9964132
protein O 0 0.0028336584
are O 0 0.00073838164
apparently O 0 0.001319414
required O 0 0.00026572487
for O 0 0.00032693878
its O 0 0.00071563333
function O 0 0.0005732684
as O 0 0.00059679104
a O 0 0.0015206554
calcification B-Disease 2 0.99774504
inhibitor O 0 0.17349924
, O 0 0.0014157142
they O 0 0.00063534384
are O 0 0.0006605686
not O 0 0.00059798616
required O 0 0.0005080904
for O 0 0.0008532798
its O 0 0.0022982135
accumulation O 0 0.0037520023
at O 0 0.0031330304
calcification B-Disease 2 0.99328315
sites O 0 0.008230741
. O 0 0.008794367

Test O 0 0.04379244
conditions O 0 0.009324498
influence O 0 0.005708074
the O 0 0.0050555635
response O 0 0.005311847
to O 0 0.0041964655
a O 0 0.005961535
drug O 0 0.4881625
challenge O 0 0.0075456947
in O 0 0.007707162
rodents O 0 0.029543485
. O 0 0.012388102

These O 0 0.008840868
studies O 0 0.005607207
were O 0 0.0034673854
conducted O 0 0.002031135
to O 0 0.0014189773
examine O 0 0.00081556727
the O 0 0.0009528687
differential O 0 0.0013525948
response O 0 0.0011819196
to O 0 0.00067496486
a O 0 0.00095514936
drug O 0 0.22641698
challenge O 0 0.00065641914
under O 0 0.00033803322
varied O 0 0.0006028509
experimental O 0 0.00054332026
test O 0 0.00059095514
conditions O 0 0.0005547305
routinely O 0 0.00045944666
employed O 0 0.0005766794
to O 0 0.0004929195
study O 0 0.00089943653
drug O 0 0.5755098
- O 0 0.0022021886
induced O 0 0.0012198171
behavioral O 0 0.061094165
and O 0 0.002153836
neurophysiological O 0 0.11881212
responses O 0 0.005645119
in O 0 0.00436197
rodents O 0 0.020706052
. O 0 0.008288043

Apomorphine B-Chemical 0 0.99983966
, O 0 0.011905594
a O 0 0.007184367
nonselective O 0 0.97636807
dopamine B-Chemical 1 0.9998838
agonist I-Chemical 0 0.98414814
, O 0 0.0026230707
was O 0 0.00081785995
selected O 0 0.00053405727
due O 0 0.00042508412
to O 0 0.00045880812
its O 0 0.0009069839
biphasic O 0 0.058036998
behavioral O 0 0.07664184
effects O 0 0.0024042467
, O 0 0.0009612495
its O 0 0.0008146724
ability O 0 0.0004886754
to O 0 0.00048847456
induce O 0 0.00061446487
hypothermia B-Disease 2 0.99965954
, O 0 0.0013169051
and O 0 0.0006572216
to O 0 0.00047839052
produce O 0 0.00047646728
distinct O 0 0.00073958305
changes O 0 0.0012160254
to O 0 0.0013395941
dopamine B-Chemical 1 0.9996201
turnover O 0 0.00557085
in O 0 0.0019452578
the O 0 0.0027946956
rodent O 0 0.0077602793
brain O 0 0.21155633
. O 0 0.008764356

From O 0 0.007941337
such O 0 0.004268323
experiments O 0 0.0029867764
there O 0 0.0018517773
is O 0 0.0016526254
evidence O 0 0.0012765614
that O 0 0.0009511843
characterization O 0 0.0012096645
and O 0 0.0012403836
detection O 0 0.0012905383
of O 0 0.0034933551
apomorphine B-Chemical 1 0.999995
- O 0 0.010939457
induced O 0 0.0011483382
activity O 0 0.0011782892
in O 0 0.0008030736
rodents O 0 0.0024584844
critically O 0 0.001576518
depends O 0 0.00084806257
upon O 0 0.0011152837
the O 0 0.0018236509
test O 0 0.0030805292
conditions O 0 0.004804399
employed O 0 0.007830071
. O 0 0.0084896

In O 0 0.008540437
rats O 0 0.010318312
, O 0 0.005376754
detection O 0 0.0037348594
of O 0 0.0056635076
apomorphine B-Chemical 1 0.9999852
- O 0 0.03668985
induced O 0 0.005282832
hyperactivity B-Disease 2 0.9999305
was O 0 0.0016823554
facilitated O 0 0.001228621
by O 0 0.0010976814
a O 0 0.0012221949
period O 0 0.00089305366
of O 0 0.0014793002
acclimatization O 0 0.010119349
to O 0 0.0019305483
the O 0 0.0027012017
test O 0 0.0046509053
conditions O 0 0.00768031
. O 0 0.008907419

Moreover O 0 0.0104867155
, O 0 0.0070389723
test O 0 0.004326968
conditions O 0 0.003095019
can O 0 0.0018098957
impact O 0 0.0013108897
upon O 0 0.0010847688
other O 0 0.0012850277
physiological O 0 0.0040222392
responses O 0 0.003537486
to O 0 0.0018976885
apomorphine B-Chemical 1 0.99997866
such O 0 0.0022330214
as O 0 0.0029594752
drug O 0 0.87291086
- O 0 0.012360165
induced O 0 0.009307045
hypothermia B-Disease 2 0.9992636
. O 0 0.011799963

In O 0 0.008028865
mice O 0 0.00551322
, O 0 0.006888927
apomorphine B-Chemical 1 0.99988246
produced O 0 0.002571599
qualitatively O 0 0.0019577632
different O 0 0.0010723583
responses O 0 0.0016167946
under O 0 0.0006287001
novel O 0 0.0011177874
conditions O 0 0.0008804695
when O 0 0.0005010384
compared O 0 0.00046021378
to O 0 0.00067082373
those O 0 0.0012537785
behaviors O 0 0.03526412
elicited O 0 0.0016809801
in O 0 0.0015556767
the O 0 0.002039867
home O 0 0.003292471
test O 0 0.0045586773
cage O 0 0.0104541695
. O 0 0.008048607

Drug O 0 0.9608111
- O 0 0.011434341
induced O 0 0.004324871
gross O 0 0.0065255007
activity O 0 0.0024249142
counts O 0 0.0017609239
were O 0 0.0012355549
increased O 0 0.0011212811
in O 0 0.00075029244
the O 0 0.00070881
novel O 0 0.0011086857
exploratory O 0 0.004451756
box O 0 0.001336407
only O 0 0.0006957239
, O 0 0.00092222105
while O 0 0.00059765397
measures O 0 0.00077744713
of O 0 0.0013263253
stereotypic O 0 0.76341265
behavior O 0 0.005766263
were O 0 0.0020572904
similar O 0 0.0018720021
in O 0 0.0032837538
both O 0 0.0055508884
. O 0 0.008061

By O 0 0.013114753
contrast O 0 0.008422777
, O 0 0.011392307
apomorphine B-Chemical 1 0.99994016
- O 0 0.011939641
induced O 0 0.0036315084
locomotion O 0 0.26100713
was O 0 0.0022300093
more O 0 0.002275614
prominent O 0 0.0044442005
in O 0 0.0022777163
the O 0 0.0028674284
novel O 0 0.0059227003
exploratory O 0 0.032291453
box O 0 0.013424559
. O 0 0.010074476

Dopamine B-Chemical 1 0.9990459
turnover O 0 0.03239368
ratios O 0 0.012095751
( O 0 0.045643706
DOPAC B-Chemical 1 0.99998367
: O 0 0.03813351
DA B-Chemical 1 0.9997305
and O 0 0.014505243
HVA B-Chemical 0 0.99999094
: O 0 0.014798903
DA B-Chemical 1 0.99966097
) O 0 0.0019016583
were O 0 0.00057318155
found O 0 0.00038848032
to O 0 0.00041898154
be O 0 0.0004601192
lower O 0 0.00042647184
in O 0 0.00039722165
those O 0 0.0005946718
animals O 0 0.0004176337
exposed O 0 0.00045301294
to O 0 0.0004711052
the O 0 0.0005773349
exploratory O 0 0.002659564
box O 0 0.0011733879
when O 0 0.00061534136
compared O 0 0.0007137684
to O 0 0.0012145482
their O 0 0.0020488573
home O 0 0.0032567468
cage O 0 0.0065104263
counterparts O 0 0.007277724
. O 0 0.008037798

However O 0 0.011745625
, O 0 0.013910657
apomorphine B-Chemical 1 0.99992955
- O 0 0.014013913
induced O 0 0.003232299
reductions O 0 0.003033318
in O 0 0.0021005594
striatal O 0 0.9902367
dopamine B-Chemical 1 0.99983394
turnover O 0 0.0071583474
were O 0 0.0011841819
detected O 0 0.0008057995
in O 0 0.0010613428
both O 0 0.0013639044
novel O 0 0.002711596
and O 0 0.003095128
home O 0 0.004244305
cage O 0 0.007953116
environments O 0 0.010697774
. O 0 0.008689802

The O 0 0.00759912
implications O 0 0.005710573
of O 0 0.004066409
these O 0 0.0032956018
findings O 0 0.003933626
are O 0 0.0020702938
discussed O 0 0.0012954657
with O 0 0.001283196
particular O 0 0.0009598448
emphasis O 0 0.001888128
upon O 0 0.0011143745
conducting O 0 0.0019739359
psychopharmacological O 0 0.6762692
challenge O 0 0.003308755
tests O 0 0.0065423753
in O 0 0.00465973
rodents O 0 0.019444015
. O 0 0.009104529

Hemolysis B-Disease 0 0.98508793
of O 0 0.009814191
human O 0 0.0076660533
erythrocytes O 0 0.193484
induced O 0 0.005807642
by O 0 0.0061710295
tamoxifen B-Chemical 1 0.99942756
is O 0 0.003177896
related O 0 0.002036801
to O 0 0.002414956
disruption O 0 0.0037090075
of O 0 0.0049080225
membrane O 0 0.042670615
structure O 0 0.011695644
. O 0 0.010360176

Tamoxifen B-Chemical 0 0.9994443
( O 0 0.0527891
TAM B-Chemical 1 0.9995447
) O 0 0.014304258
, O 0 0.0035059832
the O 0 0.0020385494
antiestrogenic O 0 0.99278283
drug O 0 0.6744869
most O 0 0.0017959774
widely O 0 0.0013448903
prescribed O 0 0.007364494
in O 0 0.00055297674
the O 0 0.0006116095
chemotherapy O 0 0.55758077
of O 0 0.0024235973
breast B-Disease 2 0.99968445
cancer I-Disease 2 0.9999373
, O 0 0.005964562
induces O 0 0.00073538185
changes O 0 0.0010362117
in O 0 0.00073834026
normal O 0 0.0019849744
discoid O 0 0.38920125
shape O 0 0.002435767
of O 0 0.002671562
erythrocytes O 0 0.5215691
and O 0 0.029475478
hemolytic B-Disease 2 0.9999511
anemia I-Disease 2 0.9999629
. O 0 0.04084088

This O 0 0.010389109
work O 0 0.0058243754
evaluates O 0 0.003689423
the O 0 0.0025373283
effects O 0 0.003104656
of O 0 0.0033255173
TAM B-Chemical 1 0.99973243
on O 0 0.0009125663
isolated O 0 0.0010799416
human O 0 0.0016255836
erythrocytes O 0 0.25996596
, O 0 0.0012433763
attempting O 0 0.0009892653
to O 0 0.00040120847
identify O 0 0.00033034256
the O 0 0.0004365588
underlying O 0 0.0010195946
mechanisms O 0 0.0012640475
on O 0 0.00071354676
TAM B-Chemical 1 0.9999652
- O 0 0.01557558
induced O 0 0.004461085
hemolytic B-Disease 2 0.99999046
anemia I-Disease 2 0.9999951
and O 0 0.004945397
the O 0 0.0012191533
involvement O 0 0.003491604
of O 0 0.0020471974
biomembranes O 0 0.9737465
in O 0 0.002212705
its O 0 0.0068740174
cytostatic O 0 0.97329867
action O 0 0.09133872
mechanisms O 0 0.012984068
. O 0 0.009599751

TAM B-Chemical 1 0.997891
induces O 0 0.017018374
hemolysis B-Disease 2 0.99862003
of O 0 0.012852882
erythrocytes O 0 0.2678708
as O 0 0.007007295
a O 0 0.007643718
function O 0 0.0069550136
of O 0 0.009304952
concentration O 0 0.02098201
. O 0 0.01393074

The O 0 0.0075065875
extension O 0 0.0062505933
of O 0 0.0054934775
hemolysis B-Disease 2 0.99905545
is O 0 0.0029926621
variable O 0 0.0020588867
with O 0 0.0016643782
erythrocyte O 0 0.35053042
samples O 0 0.0017020085
, O 0 0.0014472738
but O 0 0.0007779807
12 O 0 0.0005706169
. O 0 0.0005319326
5 O 0 0.00077800115
microM O 0 0.63268614
TAM B-Chemical 1 0.99963045
induces O 0 0.0012365202
total O 0 0.0020111746
hemolysis B-Disease 2 0.9995283
of O 0 0.0034447352
all O 0 0.0030343481
tested O 0 0.003717164
suspensions O 0 0.082576
. O 0 0.009681547

Despite O 0 0.0105798235
inducing O 0 0.009106276
extensive O 0 0.0064908857
erythrocyte O 0 0.5423241
lysis O 0 0.60176337
, O 0 0.012161929
TAM B-Chemical 1 0.9995571
does O 0 0.0019866312
not O 0 0.0017102243
shift O 0 0.0024246003
the O 0 0.0020024593
osmotic O 0 0.34936133
fragility O 0 0.6853129
curves O 0 0.008732343
of O 0 0.008643381
erythrocytes O 0 0.638367
. O 0 0.011684294

The O 0 0.009489464
hemolytic B-Disease 0 0.9968754
effect O 0 0.00642528
of O 0 0.008744685
TAM B-Chemical 1 0.9998229
is O 0 0.003247846
prevented O 0 0.005205524
by O 0 0.0015741027
low O 0 0.0014816645
concentrations O 0 0.0036903447
of O 0 0.002676196
alpha B-Chemical 0 0.9781286
- I-Chemical 0 0.08598844
tocopherol I-Chemical 0 0.9999924
( O 0 0.032152086
alpha B-Chemical 0 0.9615277
- I-Chemical 0 0.021388063
T I-Chemical 0 0.9764624
) O 0 0.0029389623
and O 0 0.0012437138
alpha B-Chemical 0 0.93541574
- I-Chemical 0 0.051386725
tocopherol I-Chemical 0 0.9999943
acetate I-Chemical 0 0.9998648
( O 0 0.032250077
alpha B-Chemical 0 0.95546865
- I-Chemical 0 0.019898629
TAc I-Chemical 0 0.9810219
) O 0 0.0034594494
( O 0 0.0009606696
inactivated O 0 0.0006357587
functional O 0 0.0013157794
hydroxyl B-Chemical 0 0.9991379
) O 0 0.004005145
indicating O 0 0.0006089642
that O 0 0.00087255373
TAM B-Chemical 1 0.9999386
- O 0 0.008081554
induced O 0 0.002140404
hemolysis B-Disease 2 0.9998735
is O 0 0.0016091908
not O 0 0.001278613
related O 0 0.001366408
to O 0 0.0025258113
oxidative O 0 0.98403084
membrane O 0 0.33488703
damage O 0 0.9494185
. O 0 0.012335821

This O 0 0.010213864
was O 0 0.0051155
further O 0 0.0035084593
evidenced O 0 0.0037704755
by O 0 0.0023356515
absence O 0 0.0012041
of O 0 0.0021055178
oxygen B-Chemical 1 0.9884058
consumption O 0 0.3578011
and O 0 0.002534137
hemoglobin O 0 0.98308116
oxidation O 0 0.95025814
both O 0 0.0011879938
determined O 0 0.000907072
in O 0 0.0012144347
parallel O 0 0.0020450386
with O 0 0.0039380565
TAM B-Chemical 1 0.9998498
- O 0 0.02678934
induced O 0 0.01267762
hemolysis B-Disease 2 0.99967635
. O 0 0.014610782

Furthermore O 0 0.0099716075
, O 0 0.007157453
it O 0 0.004167585
was O 0 0.0026463454
observed O 0 0.0016264522
that O 0 0.0019530944
TAM B-Chemical 1 0.9997781
inhibits O 0 0.002611502
the O 0 0.002356615
peroxidation O 0 0.99996185
of O 0 0.0027640392
human O 0 0.002871744
erythrocytes O 0 0.4392175
induced O 0 0.002595071
by O 0 0.008594849
AAPH B-Chemical 0 0.9999962
, O 0 0.0035965643
thus O 0 0.0019396261
ruling O 0 0.032799374
out O 0 0.0022170362
TAM B-Chemical 1 0.999863
- O 0 0.008580961
induced O 0 0.003997906
cell O 0 0.20973559
oxidative O 0 0.9965339
stress O 0 0.94600034
. O 0 0.015218856

Hemolysis B-Disease 0 0.99373055
caused O 0 0.010830078
by O 0 0.008437158
TAM B-Chemical 1 0.9994318
was O 0 0.00290433
not O 0 0.0015424796
preceded O 0 0.0017005936
by O 0 0.0012081134
the O 0 0.00096875743
leakage O 0 0.47604054
of O 0 0.0031656977
K B-Chemical 1 0.9995141
( O 0 0.004902976
+ O 0 0.001256253
) O 0 0.0010288998
from O 0 0.00043085433
the O 0 0.00043539185
cells O 0 0.0009808391
, O 0 0.00062166445
also O 0 0.00039867035
excluding O 0 0.00072738604
a O 0 0.0008300862
colloid O 0 0.8847699
- O 0 0.002471259
osmotic O 0 0.15064052
type O 0 0.0007154093
mechanism O 0 0.00086511835
of O 0 0.0018595568
hemolysis B-Disease 2 0.9999211
, O 0 0.0021102764
according O 0 0.0007701134
to O 0 0.0007593637
the O 0 0.00097523467
effects O 0 0.002051015
on O 0 0.0015690918
osmotic O 0 0.5096711
fragility O 0 0.8271502
curves O 0 0.02104402
. O 0 0.009808974

However O 0 0.011746644
, O 0 0.011830216
TAM B-Chemical 1 0.998744
induces O 0 0.004207653
release O 0 0.03730537
of O 0 0.0025548295
peripheral O 0 0.06407018
proteins O 0 0.0028217512
of O 0 0.0021261708
membrane O 0 0.051999636
- O 0 0.004277356
cytoskeleton O 0 0.05273511
and O 0 0.0017273913
cytosol O 0 0.0150198825
proteins O 0 0.0022706199
essentially O 0 0.0017903789
bound O 0 0.0018022655
to O 0 0.002784589
band O 0 0.008974539
3 O 0 0.0057095443
. O 0 0.007265319

Either O 0 0.13740423
alpha B-Chemical 0 0.8353648
- I-Chemical 0 0.018168047
T I-Chemical 0 0.8754945
or O 0 0.005058827
alpha B-Chemical 0 0.87329245
- I-Chemical 0 0.012408413
TAc I-Chemical 0 0.8921667
increases O 0 0.0018391903
membrane O 0 0.00985386
packing O 0 0.04510007
and O 0 0.0028842662
prevents O 0 0.00496387
TAM B-Chemical 1 0.9996984
partition O 0 0.007178544
into O 0 0.0026694008
model O 0 0.0059888335
membranes O 0 0.16508152
. O 0 0.010148895

These O 0 0.0084140515
effects O 0 0.0056843436
suggest O 0 0.0026371314
that O 0 0.0020876226
the O 0 0.0019782016
protection O 0 0.006541465
from O 0 0.0023839294
hemolysis B-Disease 2 0.9998853
by O 0 0.011964412
tocopherols B-Chemical 0 0.9999722
is O 0 0.0012863616
related O 0 0.0005692708
to O 0 0.00060444034
a O 0 0.0011861132
decreased O 0 0.0033641944
TAM B-Chemical 1 0.9999213
incorporation O 0 0.008203868
in O 0 0.00070694136
condensed O 0 0.015345558
membranes O 0 0.021039067
and O 0 0.0008431214
the O 0 0.00073147676
structural O 0 0.0023052567
damage O 0 0.45970923
of O 0 0.0016564281
the O 0 0.0016936846
erythrocyte O 0 0.5576813
membrane O 0 0.033681065
is O 0 0.0035021538
consequently O 0 0.0072792987
avoided O 0 0.0074456376
. O 0 0.008460659

Therefore O 0 0.009296779
, O 0 0.012400381
TAM B-Chemical 1 0.9994375
- O 0 0.012010395
induced O 0 0.0039402586
hemolysis B-Disease 2 0.99958163
results O 0 0.001976168
from O 0 0.001136995
a O 0 0.0011762762
structural O 0 0.0014329999
perturbation O 0 0.0012488116
of O 0 0.000997035
red O 0 0.012292411
cell O 0 0.027575579
membrane O 0 0.030984104
, O 0 0.0011368755
leading O 0 0.0009005728
to O 0 0.00039944152
changes O 0 0.00052528735
in O 0 0.00033988938
the O 0 0.0003603725
framework O 0 0.00043393168
of O 0 0.0005119264
the O 0 0.00053842424
erythrocyte O 0 0.29754174
membrane O 0 0.009250245
and O 0 0.00093236583
its O 0 0.0016521589
cytoskeleton O 0 0.052377537
caused O 0 0.0012763595
by O 0 0.0013671056
its O 0 0.001971069
high O 0 0.0018723774
partition O 0 0.0034325973
in O 0 0.0025979807
the O 0 0.0040716478
membrane O 0 0.029997325
. O 0 0.008859238

These O 0 0.009709422
defects O 0 0.006897531
explain O 0 0.0035178815
the O 0 0.0029158068
abnormal O 0 0.013432412
erythrocyte O 0 0.2836154
shape O 0 0.003130498
and O 0 0.0018411594
decreased O 0 0.0021004777
mechanical O 0 0.070861325
stability O 0 0.0027747063
promoted O 0 0.0054980093
by O 0 0.004924267
TAM B-Chemical 1 0.9998654
, O 0 0.0053149094
resulting O 0 0.004213703
in O 0 0.007340411
hemolytic B-Disease 2 0.9999348
anemia I-Disease 2 0.9999572
. O 0 0.03953573

Additionally O 0 0.009803145
, O 0 0.0066958475
since O 0 0.0031637722
membrane O 0 0.0066913483
leakage O 0 0.37822005
is O 0 0.0018086005
a O 0 0.0016178141
final O 0 0.0012585501
stage O 0 0.0019997004
of O 0 0.0016487074
cytotoxicity O 0 0.9934722
, O 0 0.0014403159
the O 0 0.00054149935
disruption O 0 0.0005747328
of O 0 0.00052056613
the O 0 0.0004532159
structural O 0 0.00092425174
characteristics O 0 0.0006314862
of O 0 0.0011195868
biomembranes O 0 0.98881125
by O 0 0.0037749184
TAM B-Chemical 1 0.9999101
may O 0 0.00082625914
contribute O 0 0.00067642756
to O 0 0.0006802161
the O 0 0.0008444714
multiple O 0 0.0019169087
mechanisms O 0 0.0021280434
of O 0 0.0028665534
its O 0 0.009193111
anticancer O 0 0.9872939
action O 0 0.14044519
. O 0 0.009570729

Changes O 0 0.012074705
of O 0 0.009695932
sodium B-Chemical 1 0.99877125
and O 0 0.008032728
ATP B-Chemical 1 0.99522674
affinities O 0 0.0052333176
of O 0 0.0021932663
the O 0 0.0018337115
cardiac O 0 0.8555958
( O 0 0.013742481
Na B-Chemical 1 0.9998853
, O 0 0.009202711
K B-Chemical 1 0.99894184
) O 0 0.008739847
- O 0 0.0026885285
ATPase O 0 0.034885768
during O 0 0.0008833769
and O 0 0.0017038858
after O 0 0.0016791055
nitric B-Chemical 0 0.9995876
oxide I-Chemical 0 0.9987691
deficient O 0 0.011116356
hypertension B-Disease 2 0.9998149
. O 0 0.013374987

In O 0 0.009086037
the O 0 0.0074788425
cardiovascular O 0 0.96925396
system O 0 0.011764686
, O 0 0.007821438
NO B-Chemical 0 0.9967964
is O 0 0.0027050416
involved O 0 0.0017362598
in O 0 0.0015867264
the O 0 0.0016622237
regulation O 0 0.001622753
of O 0 0.0024691843
a O 0 0.003766698
variety O 0 0.007371326
of O 0 0.0065296288
functions O 0 0.010418732
. O 0 0.010073867

Inhibition O 0 0.04487638
of O 0 0.027154263
NO B-Chemical 0 0.995557
synthesis O 0 0.3460773
induces O 0 0.020429041
sustained O 0 0.35319236
hypertension B-Disease 2 0.9995152
. O 0 0.030899826

In O 0 0.007879994
several O 0 0.005645475
models O 0 0.0053630187
of O 0 0.006596368
hypertension B-Disease 2 0.9998747
, O 0 0.008837408
elevation O 0 0.31361273
of O 0 0.003071304
intracellular O 0 0.06796411
sodium B-Chemical 1 0.99965346
level O 0 0.0018679873
was O 0 0.0022115412
documented O 0 0.0035361936
in O 0 0.0036757467
cardiac O 0 0.70251554
tissue O 0 0.113077305
. O 0 0.010967369

To O 0 0.0059307767
assess O 0 0.0029349
the O 0 0.003006612
molecular O 0 0.00646468
basis O 0 0.0022311418
of O 0 0.0024839798
disturbances O 0 0.67715704
in O 0 0.001377755
transmembraneous O 0 0.09883173
transport O 0 0.008112295
of O 0 0.0030421463
Na B-Chemical 1 0.99993265
+ O 0 0.0015898827
, O 0 0.00073371443
we O 0 0.00029022282
studied O 0 0.00043663874
the O 0 0.00042870507
response O 0 0.00070245244
of O 0 0.0010497915
cardiac O 0 0.923893
( O 0 0.014031946
Na B-Chemical 1 0.9999434
, O 0 0.008166343
K B-Chemical 1 0.9993864
) O 0 0.010323718
- O 0 0.0022659947
ATPase O 0 0.095549256
to O 0 0.00069633784
NO B-Chemical 0 0.9996105
- O 0 0.004427554
deficient O 0 0.0006436038
hypertension B-Disease 2 0.9999528
induced O 0 0.0011348159
in O 0 0.00068902125
rats O 0 0.008142496
by O 0 0.0017651921
NO B-Chemical 0 0.999808
- O 0 0.008173846
synthase O 0 0.6593909
inhibition O 0 0.0020533763
with O 0 0.0005444384
40 O 0 0.0005790565
mg O 0 0.13746122
/ O 0 0.0012762892
kg O 0 0.0027693966
/ O 0 0.0012894375
day O 0 0.0006352
N B-Chemical 0 0.966215
( I-Chemical 0 0.0026835303
G I-Chemical 0 0.8582235
) I-Chemical 0 0.008605876
- I-Chemical 0 0.0060119014
nitro I-Chemical 0 0.9993961
- I-Chemical 0 0.03304192
L I-Chemical 1 0.98804075
- I-Chemical 1 0.038954843
arginine I-Chemical 1 0.9965545
methyl I-Chemical 0 0.99913496
ester I-Chemical 0 0.9992442
( O 0 0.082419254
L B-Chemical 1 0.99234176
- I-Chemical 1 0.048470173
NAME I-Chemical 1 0.99977154
) O 0 0.0042368327
for O 0 0.0016374937
4 O 0 0.0021671103
four O 0 0.0025466199
weeks O 0 0.0038984462
. O 0 0.006772387

After O 0 0.007096271
4 O 0 0.005808686
- O 0 0.005114789
week O 0 0.0024872879
administration O 0 0.011560269
of O 0 0.004191526
L B-Chemical 1 0.98400426
- I-Chemical 1 0.046689406
NAME I-Chemical 1 0.9997757
, O 0 0.0022586337
the O 0 0.0011625045
systolic O 0 0.57979846
blood O 0 0.013830447
pressure O 0 0.102465145
( O 0 0.0032138494
SBP O 0 0.7580757
) O 0 0.003250308
increased O 0 0.0025099588
by O 0 0.0034339565
36 O 0 0.00459846
% O 0 0.006579744
. O 0 0.0074083353

Two O 0 0.010173172
weeks O 0 0.005286592
after O 0 0.003654276
terminating O 0 0.008735928
the O 0 0.0035232557
treatment O 0 0.004600825
, O 0 0.0040753544
the O 0 0.003154359
SBP O 0 0.4639015
recovered O 0 0.0032125618
to O 0 0.00382266
control O 0 0.0052749696
value O 0 0.007785641
. O 0 0.009868862

When O 0 0.008847091
activating O 0 0.009855555
the O 0 0.0062727374
( O 0 0.0113241915
Na B-Chemical 1 0.99965715
, O 0 0.015906204
K B-Chemical 1 0.99886215
) O 0 0.015924614
- O 0 0.0033472418
ATPase O 0 0.051923845
with O 0 0.0009076201
its O 0 0.0018410544
substrate O 0 0.012586821
ATP B-Chemical 1 0.9984773
, O 0 0.0011017245
no O 0 0.00044326743
changes O 0 0.00081905205
in O 0 0.00071514724
Km O 0 0.20521021
and O 0 0.0010469885
Vmax O 0 0.33176082
values O 0 0.00086432067
were O 0 0.0009182408
observed O 0 0.0008851182
in O 0 0.00210553
NO B-Chemical 0 0.9985239
- O 0 0.007440198
deficient O 0 0.0038743822
rats O 0 0.014298242
. O 0 0.008698752

During O 0 0.008440273
activation O 0 0.009711802
with O 0 0.0074215163
Na B-Chemical 1 0.99947256
+ O 0 0.0050253994
, O 0 0.0024991753
the O 0 0.0014501618
Vmax O 0 0.37355632
remained O 0 0.0011313694
unchanged O 0 0.0009270156
, O 0 0.00093930686
however O 0 0.00081701484
the O 0 0.0010256838
K B-Chemical 1 0.99918944
( O 0 0.011871979
Na B-Chemical 1 0.99991095
) O 0 0.0022868728
increased O 0 0.0007310204
by O 0 0.0006430669
50 O 0 0.0008405035
% O 0 0.00060354825
, O 0 0.0005193058
indicating O 0 0.00031394762
a O 0 0.0005691091
profound O 0 0.004920358
decrease O 0 0.00050718454
in O 0 0.0004337989
the O 0 0.00051576685
affinity O 0 0.0012507491
of O 0 0.0010010126
the O 0 0.0016020722
Na B-Chemical 1 0.9999014
+ O 0 0.0026529008
- O 0 0.0020688411
binding O 0 0.0011631089
site O 0 0.0014864116
in O 0 0.0022757547
NO B-Chemical 0 0.9988493
- O 0 0.0079492815
deficient O 0 0.00388856
rats O 0 0.014646103
. O 0 0.008686844

After O 0 0.0065303803
recovery O 0 0.0080271745
from O 0 0.0053138128
hypertension B-Disease 2 0.9996118
, O 0 0.0042604757
the O 0 0.0017718499
activity O 0 0.0017923256
of O 0 0.0023749524
( O 0 0.010295724
Na B-Chemical 1 0.999913
, O 0 0.011519096
K B-Chemical 1 0.9993623
) O 0 0.012718396
- O 0 0.0024469888
ATPase O 0 0.07137127
increased O 0 0.00077873503
, O 0 0.0006926776
due O 0 0.0003184613
to O 0 0.00035880588
higher O 0 0.0004030562
affinity O 0 0.0009975862
of O 0 0.00073514716
the O 0 0.0009686706
ATP B-Chemical 1 0.99909353
- O 0 0.0021528443
binding O 0 0.0006729092
site O 0 0.0006909617
, O 0 0.00086497737
as O 0 0.00064810505
revealed O 0 0.0007723203
from O 0 0.00095925044
the O 0 0.001313747
lowered O 0 0.0076645575
Km O 0 0.32674113
value O 0 0.0032365262
for O 0 0.004252622
ATP B-Chemical 1 0.99490017
. O 0 0.0100992685

The O 0 0.019012844
K B-Chemical 1 0.9916272
( O 0 0.029134369
Na B-Chemical 1 0.9986846
) O 0 0.011107093
value O 0 0.0052170213
for O 0 0.0047143805
Na B-Chemical 1 0.99907047
+ O 0 0.005568142
returned O 0 0.003955971
to O 0 0.0038479848
control O 0 0.005257181
value O 0 0.0077289636
. O 0 0.009825123

Inhibition O 0 0.025238825
of O 0 0.0123167345
NO B-Chemical 0 0.9989159
- O 0 0.0249528
synthase O 0 0.71450984
induced O 0 0.003219799
a O 0 0.00374188
reversible O 0 0.7778759
hypertension B-Disease 2 0.9999666
accompanied O 0 0.032481793
by O 0 0.0047785793
depressed B-Disease 2 0.99369615
Na B-Chemical 1 0.9999616
+ O 0 0.004253335
- O 0 0.0020445737
extrusion O 0 0.099112116
from O 0 0.0006453779
cardiac O 0 0.4228021
cells O 0 0.0011418425
as O 0 0.00054104533
a O 0 0.0006853476
consequence O 0 0.00045413105
of O 0 0.0011794105
deteriorated O 0 0.6875963
Na B-Chemical 1 0.99993527
+ O 0 0.0023697342
- O 0 0.0014475018
binding O 0 0.0006924793
properties O 0 0.001076892
of O 0 0.0013561073
the O 0 0.0018278072
( O 0 0.011738293
Na B-Chemical 1 0.99980885
, O 0 0.014442089
K B-Chemical 1 0.99831724
) O 0 0.020018416
- O 0 0.010876208
ATPase O 0 0.187665
. O 0 0.008477921

After O 0 0.0057868594
recovery O 0 0.006120286
of O 0 0.0037548982
blood O 0 0.00890815
pressure O 0 0.024817932
to O 0 0.0014321437
control O 0 0.0011680663
values O 0 0.0011276471
, O 0 0.001158018
the O 0 0.0007857861
extrusion O 0 0.16709998
of O 0 0.0029181612
Na B-Chemical 1 0.9999262
+ O 0 0.0013323594
from O 0 0.00065901264
cardiac O 0 0.42759112
cells O 0 0.0012359051
was O 0 0.0005056669
normalized O 0 0.000377992
, O 0 0.00062198145
as O 0 0.00046265847
revealed O 0 0.0005403877
by O 0 0.0006847359
restoration O 0 0.00106298
of O 0 0.0010515768
the O 0 0.001479899
( O 0 0.008746578
Na B-Chemical 1 0.99982834
, O 0 0.011680964
K B-Chemical 1 0.99846786
) O 0 0.015169874
- O 0 0.0077092773
ATPase O 0 0.13443936
activity O 0 0.0072658923
. O 0 0.008200587

Effects O 0 0.014735833
of O 0 0.0076045194
long O 0 0.005867324
- O 0 0.0054704626
term O 0 0.002888754
pretreatment O 0 0.18683481
with O 0 0.0043852003
isoproterenol B-Chemical 1 0.9998884
on O 0 0.0031018266
bromocriptine B-Chemical 1 0.9999825
- O 0 0.022227619
induced O 0 0.0054714433
tachycardia B-Disease 2 0.99974364
in O 0 0.004713774
conscious O 0 0.1048697
rats O 0 0.018459387
. O 0 0.009586562

It O 0 0.010776573
has O 0 0.0053969827
been O 0 0.0040800245
shown O 0 0.002370139
that O 0 0.0024122244
bromocriptine B-Chemical 1 0.99997175
- O 0 0.018435841
induced O 0 0.0032543947
tachycardia B-Disease 2 0.9999248
, O 0 0.0019140827
which O 0 0.0008371478
persisted O 0 0.0005839505
after O 0 0.00035302155
adrenalectomy O 0 0.6349655
, O 0 0.0010596275
is O 0 0.00059678225
( O 0 0.0008956501
i O 0 0.0033013206
) O 0 0.001228229
mediated O 0 0.00046057982
by O 0 0.0007166608
central O 0 0.0128607135
dopamine B-Chemical 1 0.9999305
D2 O 0 0.9958645
receptor O 0 0.18186945
activation O 0 0.0026341155
and O 0 0.00085633044
( O 0 0.0009992364
ii O 0 0.0014923427
) O 0 0.0010668229
reduced O 0 0.000447963
by O 0 0.0005305735
5 O 0 0.00042813495
- O 0 0.0006255443
day O 0 0.00040901697
isoproterenol B-Chemical 1 0.9998234
pretreatment O 0 0.2575486
, O 0 0.0008337481
supporting O 0 0.00038905808
therefore O 0 0.00044228105
the O 0 0.00037610022
hypothesis O 0 0.0005166472
that O 0 0.00040012447
this O 0 0.00051078346
effect O 0 0.0006474013
is O 0 0.00070937694
dependent O 0 0.00073494844
on O 0 0.00096262427
sympathetic O 0 0.95241904
outflow O 0 0.9239953
to O 0 0.0026620517
the O 0 0.004151642
heart O 0 0.6848579
. O 0 0.008801918

This O 0 0.010693334
study O 0 0.0059784586
was O 0 0.0035794317
conducted O 0 0.0021552017
to O 0 0.0015601582
examine O 0 0.0009259189
whether O 0 0.0007972878
prolonged O 0 0.00908894
pretreatment O 0 0.38176647
with O 0 0.0039521623
isoproterenol B-Chemical 1 0.9999491
could O 0 0.0015799106
abolish O 0 0.011197756
bromocriptine B-Chemical 1 0.9999871
- O 0 0.016506867
induced O 0 0.0044171386
tachycardia B-Disease 2 0.99977106
in O 0 0.0040235515
conscious O 0 0.09854432
rats O 0 0.017160745
. O 0 0.008882774

Isoproterenol B-Chemical 1 0.99962056
pretreatment O 0 0.278445
for O 0 0.003659325
15 O 0 0.0024826261
days O 0 0.0017564008
caused O 0 0.0024885058
cardiac B-Disease 2 0.96765804
hypertrophy I-Disease 2 0.9996319
without O 0 0.002196233
affecting O 0 0.0026273332
baseline O 0 0.0021489249
blood O 0 0.012377242
pressure O 0 0.060974237
and O 0 0.0042777755
heart O 0 0.5864454
rate O 0 0.00692118
. O 0 0.009059192

In O 0 0.007944547
control O 0 0.0058745653
rats O 0 0.007919301
, O 0 0.004927703
intravenous O 0 0.760287
bromocriptine B-Chemical 1 0.999966
( O 0 0.005422572
150 O 0 0.0028758994
microg O 0 0.0032264013
/ O 0 0.003968444
kg O 0 0.0104571385
) O 0 0.0030620887
induced O 0 0.0023277758
significant O 0 0.005029786
hypotension B-Disease 2 0.9999076
and O 0 0.029725624
tachycardia B-Disease 2 0.9996443
. O 0 0.01230861

Bromocriptine B-Chemical 0 0.99972266
- O 0 0.025860095
induced O 0 0.008244691
hypotension B-Disease 2 0.999908
was O 0 0.0037096946
unaffected O 0 0.0026489266
by O 0 0.0027183932
isoproterenol B-Chemical 1 0.9999367
pretreatment O 0 0.73705375
, O 0 0.002788592
while O 0 0.0010147928
tachycardia B-Disease 2 0.99987364
was O 0 0.0007823552
reversed O 0 0.001058683
to O 0 0.0004612753
significant O 0 0.00092665973
bradycardia B-Disease 2 0.9998442
, O 0 0.00093198754
an O 0 0.00059806136
effect O 0 0.00039891634
that O 0 0.0003423166
was O 0 0.0004500113
partly O 0 0.00068765064
reduced O 0 0.00053186977
by O 0 0.0007017593
i O 0 0.0043721334
. O 0 0.000564254
v O 0 0.033474468
. O 0 0.0008463165
domperidone B-Chemical 0 0.9999863
( O 0 0.002105576
0 O 0 0.0014150658
. O 0 0.0008880976
5 O 0 0.0013447662
mg O 0 0.098326445
/ O 0 0.006216878
kg O 0 0.014721785
) O 0 0.009909295
. O 0 0.008167621

Neither O 0 0.015373372
cardiac O 0 0.36907038
vagal O 0 0.97009957
nor O 0 0.008545858
sympathetic O 0 0.96071315
tone O 0 0.76040316
was O 0 0.006256346
altered O 0 0.007361545
by O 0 0.011304893
isoproterenol B-Chemical 1 0.9997193
pretreatment O 0 0.85802203
. O 0 0.016622428

In O 0 0.007357564
isolated O 0 0.005684888
perfused O 0 0.034675024
heart O 0 0.41533035
preparations O 0 0.008838385
from O 0 0.0032679662
isoproterenol B-Chemical 1 0.9999242
- O 0 0.009651383
pretreated O 0 0.017403936
rats O 0 0.00986877
, O 0 0.0014042177
the O 0 0.0009783623
isoproterenol B-Chemical 1 0.9999447
- O 0 0.002795048
induced O 0 0.000562053
maximal O 0 0.0005144329
increase O 0 0.00031215628
in O 0 0.00035788058
left O 0 0.0014082005
ventricular O 0 0.982627
systolic O 0 0.8080452
pressure O 0 0.033636298
was O 0 0.0003922059
significantly O 0 0.0005343158
reduced O 0 0.0005030833
, O 0 0.0005834886
compared O 0 0.00024599372
with O 0 0.0005268307
saline O 0 0.34751263
- O 0 0.0016622086
pretreated O 0 0.006403545
rats O 0 0.004976803
( O 0 0.00086557184
the O 0 0.000476525
EC50 O 0 0.60485715
of O 0 0.00069471844
the O 0 0.00091492356
isoproterenol B-Chemical 1 0.9999565
- O 0 0.0030664243
induced O 0 0.00061738596
increase O 0 0.00041686883
in O 0 0.00048117843
left O 0 0.0017706326
ventricular O 0 0.97768676
systolic O 0 0.7489807
pressure O 0 0.022514798
was O 0 0.0008486365
enhanced O 0 0.0010114431
approximately O 0 0.0013675021
22 O 0 0.0026828297
- O 0 0.0036701472
fold O 0 0.005871021
) O 0 0.0097256005
. O 0 0.007853321

These O 0 0.008253566
results O 0 0.005088001
show O 0 0.0030518698
that O 0 0.00228607
15 O 0 0.0019886761
- O 0 0.002255715
day O 0 0.0013290643
isoproterenol B-Chemical 1 0.99975544
pretreatment O 0 0.29800272
not O 0 0.00092345855
only O 0 0.00077048264
abolished O 0 0.0020873165
but O 0 0.0010730379
reversed O 0 0.020642824
bromocriptine B-Chemical 1 0.9999949
- O 0 0.014605482
induced O 0 0.0017996099
tachycardia B-Disease 2 0.9999391
to O 0 0.001014183
bradycardia B-Disease 2 0.9998963
, O 0 0.0009167679
an O 0 0.0005499906
effect O 0 0.00035274212
that O 0 0.00029382852
is O 0 0.00035117767
mainly O 0 0.00051977293
related O 0 0.00029638037
to O 0 0.00035736524
further O 0 0.00055499125
cardiac O 0 0.757568
beta O 0 0.8135099
- O 0 0.006841655
adrenoceptor O 0 0.9998367
desensitization O 0 0.23748624
rather O 0 0.00058199844
than O 0 0.00047772063
to O 0 0.00069213787
impairment O 0 0.075429015
of O 0 0.0015889949
autonomic O 0 0.95453435
regulation O 0 0.001661261
of O 0 0.0029175996
the O 0 0.0042776563
heart O 0 0.7698526
. O 0 0.008805921

They O 0 0.0113573605
suggest O 0 0.004325571
that O 0 0.0034099824
, O 0 0.003310405
in O 0 0.0018456745
normal O 0 0.0025744042
conscious O 0 0.018212043
rats O 0 0.0035448
, O 0 0.0012355678
the O 0 0.0007370446
central O 0 0.0034736537
tachycardia B-Disease 2 0.9998005
of O 0 0.0026004727
bromocriptine B-Chemical 1 0.9999852
appears O 0 0.0006592319
to O 0 0.00055338326
predominate O 0 0.0024617244
and O 0 0.000662507
to O 0 0.0004991631
mask O 0 0.0014064836
the O 0 0.0008684723
bradycardia B-Disease 2 0.99942964
of O 0 0.0013061601
this O 0 0.001415361
agonist O 0 0.8428875
at O 0 0.0018204916
peripheral O 0 0.5454115
dopamine B-Chemical 1 0.99985206
D2 O 0 0.9967103
receptors O 0 0.46197844
. O 0 0.010109747

A O 0 0.033814665
developmental O 0 0.009599419
analysis O 0 0.005634263
of O 0 0.005408854
clonidine B-Chemical 1 0.9998858
' O 0 0.004294027
s O 0 0.0022511424
effects O 0 0.002006695
on O 0 0.0011411639
cardiac O 0 0.22816718
rate O 0 0.0016607936
and O 0 0.0023209278
ultrasound O 0 0.04302459
production O 0 0.0041504907
in O 0 0.003886499
infant O 0 0.023309829
rats O 0 0.024224527
. O 0 0.010465817

Under O 0 0.012823278
controlled O 0 0.0059101223
conditions O 0 0.0048626643
, O 0 0.003866246
infant O 0 0.0049644704
rats O 0 0.0037191387
emit O 0 0.0028647576
ultrasonic O 0 0.01778407
vocalizations O 0 0.14636122
during O 0 0.00081523426
extreme O 0 0.0025204509
cold O 0 0.0377967
exposure O 0 0.0024785697
and O 0 0.00085277547
after O 0 0.0004018147
administration O 0 0.015265536
of O 0 0.0009655925
the O 0 0.001096619
alpha O 0 0.39472494
( O 0 0.002861493
2 O 0 0.0017758165
) O 0 0.005685675
adrenoceptor O 0 0.9997825
agonist O 0 0.97306097
, O 0 0.035525933
clonidine B-Chemical 1 0.9998647
. O 0 0.010435529

Previous O 0 0.009097877
investigations O 0 0.006625515
have O 0 0.0033452748
determined O 0 0.0022732918
that O 0 0.001864476
, O 0 0.0021883443
in O 0 0.0012114361
response O 0 0.0016725002
to O 0 0.0014476418
clonidine B-Chemical 1 0.99997807
, O 0 0.0025500488
ultrasound O 0 0.040056143
production O 0 0.0013662212
increases O 0 0.00081824925
through O 0 0.0007526607
the O 0 0.0010043421
2nd O 0 0.008348319
- O 0 0.00215216
week O 0 0.0011882551
postpartum O 0 0.006797744
and O 0 0.0029898067
decreases O 0 0.004188568
thereafter O 0 0.0064687924
. O 0 0.0075660897

Given O 0 0.0063970922
that O 0 0.0045842235
sympathetic O 0 0.75069773
neural O 0 0.021729356
dominance O 0 0.0075518745
exhibits O 0 0.00206957
a O 0 0.0014792875
similar O 0 0.00069993257
developmental O 0 0.0016832334
pattern O 0 0.000733207
, O 0 0.000942903
and O 0 0.0005921662
given O 0 0.00036121174
that O 0 0.00054581376
clonidine B-Chemical 1 0.9999831
induces O 0 0.0008694435
sympathetic O 0 0.98740655
withdrawal O 0 0.9018814
and O 0 0.0016800938
bradycardia B-Disease 2 0.9998648
, O 0 0.00074415695
we O 0 0.00025124117
hypothesized O 0 0.00035874228
that O 0 0.00048061874
clonidine B-Chemical 1 0.99997234
' O 0 0.0010644896
s O 0 0.0006360866
developmental O 0 0.00087729766
effects O 0 0.0008011586
on O 0 0.00043663252
cardiac O 0 0.2503271
rate O 0 0.00084013765
and O 0 0.0012877512
ultrasound O 0 0.029034808
production O 0 0.0023054786
would O 0 0.00181986
mirror O 0 0.0053323465
each O 0 0.0026451855
other O 0 0.005824942
. O 0 0.008233917

Therefore O 0 0.0072326334
, O 0 0.0058537023
in O 0 0.002967424
the O 0 0.0021230276
present O 0 0.0012959439
experiment O 0 0.0011389864
, O 0 0.0013446687
the O 0 0.0007861351
effects O 0 0.0013423635
of O 0 0.0018222391
clonidine B-Chemical 1 0.9999887
administration O 0 0.41338846
( O 0 0.0019209982
0 O 0 0.00082937145
. O 0 0.0003153804
5 O 0 0.00034055137
mg O 0 0.051335804
/ O 0 0.0010756708
kg O 0 0.0026060669
) O 0 0.0007104987
on O 0 0.0002710703
cardiac O 0 0.10089652
rate O 0 0.00043544543
and O 0 0.0005717874
ultrasound O 0 0.018261962
production O 0 0.000787192
were O 0 0.00046350138
examined O 0 0.00033168535
in O 0 0.00051161036
2 O 0 0.0007183939
- O 0 0.0010615522
, O 0 0.00075687194
8 O 0 0.0006091621
- O 0 0.0009114219
, O 0 0.0007620647
15 O 0 0.00059887447
- O 0 0.0010393759
, O 0 0.00093022914
and O 0 0.001000108
20 O 0 0.0012723324
- O 0 0.0019322975
day O 0 0.001650729
- O 0 0.003538052
old O 0 0.0044415724
rats O 0 0.009847085
. O 0 0.008370787

Age O 0 0.44634703
- O 0 0.009774087
related O 0 0.0035979813
changes O 0 0.0033394406
in O 0 0.0021738259
ultrasound O 0 0.022904424
production O 0 0.0022203117
corresponded O 0 0.0010173571
with O 0 0.0010144246
changes O 0 0.0011596445
in O 0 0.0008289855
cardiovascular O 0 0.9832277
variables O 0 0.0036140005
, O 0 0.001123747
including O 0 0.0006888076
baseline O 0 0.0010963001
cardiac O 0 0.25155813
rate O 0 0.0014487174
and O 0 0.003942996
clonidine B-Chemical 1 0.9999639
- O 0 0.018425932
induced O 0 0.0104744015
bradycardia B-Disease 2 0.9995534
. O 0 0.010857893

This O 0 0.009374143
experiment O 0 0.0042855926
is O 0 0.0031827665
discussed O 0 0.0019390159
with O 0 0.0016241913
regard O 0 0.001154511
to O 0 0.0008980771
the O 0 0.00078887644
hypothesis O 0 0.0008710033
that O 0 0.0006141854
ultrasound O 0 0.03601162
production O 0 0.0012280206
is O 0 0.0006004256
the O 0 0.0005371504
acoustic O 0 0.042188328
by O 0 0.0010099481
- O 0 0.0011664551
product O 0 0.00086612743
of O 0 0.000544109
a O 0 0.0007022427
physiological O 0 0.001768999
maneuver O 0 0.14740366
that O 0 0.0004367861
compensates O 0 0.00053105573
for O 0 0.0006626311
clonidine B-Chemical 1 0.9999522
' O 0 0.0017962985
s O 0 0.0014358897
detrimental O 0 0.0025215559
effects O 0 0.0032116338
on O 0 0.0023647894
cardiovascular O 0 0.9948966
function O 0 0.010608704
. O 0 0.009040843

Recurrent O 0 0.19050695
use O 0 0.008585754
of O 0 0.0070499186
newer O 0 0.08164884
oral B-Chemical 1 0.95872086
contraceptives I-Chemical 1 0.9998093
and O 0 0.007184357
the O 0 0.0047235377
risk O 0 0.07986865
of O 0 0.009250765
venous B-Disease 0 0.9822223
thromboembolism I-Disease 0 0.99992275
. O 0 0.019364193

The O 0 0.007382817
epidemiological O 0 0.007114965
studies O 0 0.0036973609
that O 0 0.002097482
assessed O 0 0.0015673535
the O 0 0.0014861942
risk O 0 0.014472676
of O 0 0.0019024006
venous B-Disease 0 0.9632259
thromboembolism I-Disease 0 0.99999523
( O 0 0.043802228
VTE B-Disease 2 0.9999708
) O 0 0.0033718692
associated O 0 0.00083594734
with O 0 0.0007422776
newer O 0 0.09190738
oral B-Chemical 1 0.97581226
contraceptives I-Chemical 1 0.99998677
( O 0 0.03398984
OC B-Chemical 1 0.99975675
) O 0 0.002190832
did O 0 0.0004274299
not O 0 0.00037011513
distinguish O 0 0.00038598044
between O 0 0.00031710614
patterns O 0 0.0004929745
of O 0 0.0011947898
OC B-Chemical 1 0.9991159
use O 0 0.0011695359
, O 0 0.0011683154
namely O 0 0.0011121639
first O 0 0.00088759855
- O 0 0.0018535287
time O 0 0.0010860746
users O 0 0.006560475
, O 0 0.0033146178
repeaters O 0 0.19459964
and O 0 0.0056741107
switchers O 0 0.20713441
. O 0 0.008583424

Data O 0 0.0141108595
from O 0 0.006229334
a O 0 0.00557475
Transnational O 0 0.00797291
case O 0 0.0029595625
- O 0 0.002724328
control O 0 0.0012680931
study O 0 0.0011933425
were O 0 0.0008007437
used O 0 0.0005888239
to O 0 0.0004834929
assess O 0 0.00030649337
the O 0 0.00057784084
risk O 0 0.023447717
of O 0 0.0014083236
VTE B-Disease 2 0.9999281
for O 0 0.0005266736
the O 0 0.0005528087
latter O 0 0.0010550321
patterns O 0 0.00052059
of O 0 0.00084323745
use O 0 0.0010207483
, O 0 0.001209145
while O 0 0.0008664556
accounting O 0 0.0019023048
for O 0 0.0013589542
duration O 0 0.0026990098
of O 0 0.004383369
use O 0 0.007258279
. O 0 0.008441387

Over O 0 0.010778201
the O 0 0.006331615
period O 0 0.0047817663
1993 O 0 0.011822363
- O 0 0.004930379
1996 O 0 0.005620767
, O 0 0.002402772
551 O 0 0.0141330995
cases O 0 0.0018205678
of O 0 0.0018810442
VTE B-Disease 2 0.999838
were O 0 0.0013477639
identified O 0 0.0009690741
in O 0 0.0012235221
Germany O 0 0.010921457
and O 0 0.0015772532
the O 0 0.0017431398
UK O 0 0.016929708
along O 0 0.0022613786
with O 0 0.0036190485
2066 O 0 0.04394952
controls O 0 0.008810918
. O 0 0.008160458

Totals O 0 0.82806975
of O 0 0.008240406
128 O 0 0.009041232
cases O 0 0.0045090714
and O 0 0.0028601126
650 O 0 0.0043597342
controls O 0 0.0020000697
were O 0 0.001137963
analysed O 0 0.00096242345
for O 0 0.0007484458
repeat O 0 0.0012283417
use O 0 0.0010484483
and O 0 0.0012247685
135 O 0 0.0030016645
cases O 0 0.0018192683
and O 0 0.0017591185
622 O 0 0.017817277
controls O 0 0.0026132378
for O 0 0.0020655007
switching O 0 0.0045911693
patterns O 0 0.0052781184
. O 0 0.008149732

The O 0 0.0068982043
adjusted O 0 0.0052016512
rate O 0 0.0033323127
ratio O 0 0.0030427896
of O 0 0.003263219
VTE B-Disease 2 0.99975497
for O 0 0.0013596013
repeat O 0 0.0017570775
users O 0 0.0036410221
of O 0 0.0009162334
third O 0 0.0010595659
generation O 0 0.0016541634
OC B-Chemical 1 0.9991671
was O 0 0.00080357963
0 O 0 0.00084255956
. O 0 0.00036000405
6 O 0 0.00037119552
( O 0 0.00060526846
95 O 0 0.00084771035
% O 0 0.0006812908
CI O 0 0.07044267
: O 0 0.0006736135
0 O 0 0.000558567
. O 0 0.0003053364
3 O 0 0.0004024064
- O 0 0.0006152203
1 O 0 0.0003973004
. O 0 0.000269427
2 O 0 0.00034465894
) O 0 0.00044841244
relative O 0 0.00022601422
to O 0 0.00028707925
repeat O 0 0.00053185
users O 0 0.0015062598
of O 0 0.00042733864
second O 0 0.00046034498
generation O 0 0.0009035549
pills O 0 0.95397496
, O 0 0.00089496694
whereas O 0 0.0004182545
it O 0 0.00049271045
was O 0 0.0004231931
1 O 0 0.0004590632
. O 0 0.00029213275
3 O 0 0.00037999538
( O 0 0.0005632417
95 O 0 0.00078985584
% O 0 0.00063615997
CI O 0 0.064616896
: O 0 0.0006391591
0 O 0 0.0005330009
. O 0 0.00029671084
7 O 0 0.00039803926
- O 0 0.0005861111
2 O 0 0.00037080803
. O 0 0.00027532136
4 O 0 0.00033384832
) O 0 0.0005066744
for O 0 0.000264381
switchers O 0 0.005476168
from O 0 0.00035491327
second O 0 0.00036682378
to O 0 0.00035613374
third O 0 0.0005684104
generation O 0 0.00080823497
pills O 0 0.72877777
relative O 0 0.0005770175
to O 0 0.0007684867
switchers O 0 0.026454957
from O 0 0.001080815
third O 0 0.0014900536
to O 0 0.0015854186
second O 0 0.0026830428
generation O 0 0.0065821153
pills O 0 0.9634746
. O 0 0.010001812

We O 0 0.006835449
conclude O 0 0.004011876
that O 0 0.0027852315
second O 0 0.002400125
and O 0 0.0020175194
third O 0 0.0018582913
generation O 0 0.0018218776
agents O 0 0.14071997
are O 0 0.001120308
associated O 0 0.00096423936
with O 0 0.0007217102
equivalent O 0 0.00066207617
risks O 0 0.017716995
of O 0 0.0014005777
VTE B-Disease 2 0.999943
when O 0 0.0003931091
the O 0 0.00042025477
same O 0 0.0002986857
agent O 0 0.04755861
is O 0 0.00048721582
used O 0 0.0003857693
repeatedly O 0 0.00053225673
after O 0 0.00025880957
interruption O 0 0.0010914672
periods O 0 0.00051764067
or O 0 0.00046639572
when O 0 0.00044284007
users O 0 0.0028988766
are O 0 0.00072396564
switched O 0 0.0010590138
between O 0 0.00066834677
the O 0 0.001184966
two O 0 0.0015655452
generations O 0 0.0034057102
of O 0 0.0055245683
pills O 0 0.9641034
. O 0 0.009880201

These O 0 0.008351947
analyses O 0 0.005622484
suggest O 0 0.0026989845
that O 0 0.0021078598
the O 0 0.0018522639
higher O 0 0.0015076647
risk O 0 0.016651152
observed O 0 0.0007572319
for O 0 0.00067266147
the O 0 0.00083930156
newer O 0 0.085632674
OC B-Chemical 1 0.999052
in O 0 0.00070988754
other O 0 0.00067724456
studies O 0 0.00069956115
may O 0 0.00046514496
be O 0 0.00045971325
the O 0 0.00039505065
result O 0 0.0004261853
of O 0 0.0005784354
inadequate O 0 0.0009932106
comparisons O 0 0.000578388
of O 0 0.0009086542
pill O 0 0.8507772
users O 0 0.0071536754
with O 0 0.0011483644
different O 0 0.0012739609
patterns O 0 0.0017639035
of O 0 0.004130018
pill O 0 0.94558054
use O 0 0.008877239
. O 0 0.009092771

Differential O 0 0.014331331
effects O 0 0.006913277
of O 0 0.0047237375
systemically O 0 0.14684887
administered O 0 0.012212112
ketamine B-Chemical 1 0.9999441
and O 0 0.0037206514
lidocaine B-Chemical 1 0.9998599
on O 0 0.00089554995
dynamic O 0 0.0017404724
and O 0 0.0015282407
static O 0 0.008711607
hyperalgesia B-Disease 2 0.9999057
induced O 0 0.0035755017
by O 0 0.0040608314
intradermal O 0 0.8289866
capsaicin B-Chemical 1 0.999835
in O 0 0.0076844175
humans O 0 0.03923072
. O 0 0.0100997705

We O 0 0.007205481
have O 0 0.004002433
examined O 0 0.002478264
the O 0 0.0021141195
effect O 0 0.0015508219
of O 0 0.0018013255
systemic O 0 0.89972144
administration O 0 0.27852818
of O 0 0.0040760795
ketamine B-Chemical 1 0.99998116
and O 0 0.0029632403
lidocaine B-Chemical 1 0.99994123
on O 0 0.0005991208
brush O 0 0.15571752
- O 0 0.0026662874
evoked O 0 0.16550504
( O 0 0.0011796256
dynamic O 0 0.0013123451
) O 0 0.0024894278
pain B-Disease 2 0.9956014
and O 0 0.0011038776
punctate O 0 0.0018278508
- O 0 0.0023781871
evoked O 0 0.1411909
( O 0 0.0022290496
static O 0 0.004022644
) O 0 0.012108117
hyperalgesia B-Disease 2 0.9998311
induced O 0 0.007407164
by O 0 0.016894942
capsaicin B-Chemical 1 0.99970144
. O 0 0.013475729

In O 0 0.007998378
a O 0 0.0067231576
randomized O 0 0.0046072863
, O 0 0.0037696355
double O 0 0.0027377123
- O 0 0.003215067
blind O 0 0.00722079
, O 0 0.0019897996
placebo O 0 0.13737008
- O 0 0.0017540196
controlled O 0 0.00087005686
, O 0 0.0010726051
crossover O 0 0.0033598356
study O 0 0.0010731432
, O 0 0.0010201359
we O 0 0.00063014287
studied O 0 0.0010409452
12 O 0 0.0010431608
volunteers O 0 0.0027327922
in O 0 0.0020868715
three O 0 0.0027138586
experiments O 0 0.005092126
. O 0 0.008104085

Capsaicin B-Chemical 1 0.9993394
100 O 0 0.011875565
micrograms O 0 0.14409475
was O 0 0.0025525424
injected O 0 0.0016001902
intradermally O 0 0.0022495922
on O 0 0.0008285693
the O 0 0.0008627885
volar O 0 0.0037226176
forearm O 0 0.05575556
followed O 0 0.0005451073
by O 0 0.000658018
an O 0 0.0008145126
i O 0 0.0026726334
. O 0 0.00043604898
v O 0 0.010466685
. O 0 0.00032503708
infusion O 0 0.0017759579
of O 0 0.00074908446
ketamine B-Chemical 1 0.9999696
( O 0 0.0011442313
bolus O 0 0.038444962
0 O 0 0.0006282982
. O 0 0.00026839736
1 O 0 0.00036671365
mg O 0 0.04240253
kg O 0 0.0039441134
- O 0 0.0007219682
1 O 0 0.00032931936
over O 0 0.00019332909
10 O 0 0.00028026817
min O 0 0.00029347718
followed O 0 0.00022500342
by O 0 0.0003363411
infusion O 0 0.0011533129
of O 0 0.0004369577
7 O 0 0.0004149489
micrograms O 0 0.04997654
kg O 0 0.010157267
- O 0 0.0010563455
1 O 0 0.0005200293
min O 0 0.000602921
- O 0 0.00086622156
1 O 0 0.00058372284
) O 0 0.00094078167
, O 0 0.00087041466
lidocaine B-Chemical 1 0.99957377
5 O 0 0.00068398454
mg O 0 0.12117679
kg O 0 0.006793699
- O 0 0.0017153445
1 O 0 0.0011544686
or O 0 0.0013019694
saline O 0 0.037412662
for O 0 0.002202982
50 O 0 0.0048428075
min O 0 0.005802854
. O 0 0.0070679677

Infusion O 0 0.2028166
started O 0 0.013871812
15 O 0 0.009538563
min O 0 0.009664163
after O 0 0.007067036
injection O 0 0.014013886
of O 0 0.018605513
capsaicin B-Chemical 1 0.9992125
. O 0 0.025709545

The O 0 0.006944035
following O 0 0.0046156477
were O 0 0.0034476058
measured O 0 0.0022336354
: O 0 0.0030399098
spontaneous O 0 0.05400822
pain B-Disease 2 0.99906105
, O 0 0.0055255056
pain B-Disease 2 0.9984504
evoked O 0 0.31216747
by O 0 0.0010616508
punctate O 0 0.0010741666
and O 0 0.0008685481
brush O 0 0.043400034
stimuli O 0 0.029975133
( O 0 0.004408855
VAS O 0 0.9700842
) O 0 0.0018340574
, O 0 0.00090129994
and O 0 0.00072754885
areas O 0 0.0013372583
of O 0 0.0010581324
brush O 0 0.07842843
- O 0 0.00319761
evoked O 0 0.102788694
and O 0 0.0024023992
punctate O 0 0.0046066022
- O 0 0.009706964
evoked O 0 0.7150995
hyperalgesia B-Disease 2 0.99976057
. O 0 0.012264393

Ketamine B-Chemical 1 0.99908674
reduced O 0 0.0071728122
both O 0 0.003592189
the O 0 0.0026024997
area O 0 0.002618386
of O 0 0.0021798871
brush O 0 0.12964782
- O 0 0.0036771074
evoked O 0 0.1145149
and O 0 0.0013718446
punctate O 0 0.002169218
- O 0 0.0030498074
evoked O 0 0.44116184
hyperalgesia B-Disease 2 0.99993145
significantly O 0 0.002511079
and O 0 0.0014684957
it O 0 0.0012112892
tended O 0 0.0010325684
to O 0 0.001155674
reduce O 0 0.0016821856
brush O 0 0.17915495
- O 0 0.015115556
evoked O 0 0.7007756
pain B-Disease 2 0.99852943
. O 0 0.011607981

Lidocaine B-Chemical 0 0.9988863
reduced O 0 0.0122813415
the O 0 0.007904938
area O 0 0.008010993
of O 0 0.007027137
punctate O 0 0.010262813
- O 0 0.015138291
evoked O 0 0.75012696
hyperalgesia B-Disease 2 0.9997174
significantly O 0 0.035427034
. O 0 0.01616303

It O 0 0.011523911
tended O 0 0.006264037
to O 0 0.004373113
reduce O 0 0.0037266128
VAS O 0 0.7085178
scores O 0 0.0030787825
of O 0 0.002606582
spontaneous O 0 0.102365024
pain B-Disease 2 0.9981989
but O 0 0.0022500695
had O 0 0.0016619822
no O 0 0.001573103
effect O 0 0.0025303261
on O 0 0.003102502
evoked O 0 0.69032764
pain B-Disease 2 0.99857366
. O 0 0.0126847075

The O 0 0.0063821007
differential O 0 0.0057240343
effects O 0 0.004748464
of O 0 0.0044834362
ketamine B-Chemical 1 0.9999224
and O 0 0.004281405
lidocaine B-Chemical 1 0.9998777
on O 0 0.0008119166
static O 0 0.0017406465
and O 0 0.0009480431
dynamic O 0 0.0019532945
hyperalgesia B-Disease 2 0.9998344
suggest O 0 0.000440571
that O 0 0.00041988838
the O 0 0.00045733008
two O 0 0.0004243509
types O 0 0.0006646617
of O 0 0.0017832026
hyperalgesia B-Disease 2 0.9999486
are O 0 0.0012892595
mediated O 0 0.0008549225
by O 0 0.0010036263
separate O 0 0.00088114553
mechanisms O 0 0.0016364402
and O 0 0.0018292511
have O 0 0.001868863
a O 0 0.0036448576
distinct O 0 0.004963875
pharmacology O 0 0.47037715
. O 0 0.009429269

Development O 0 0.03153162
of O 0 0.013026392
apomorphine B-Chemical 1 0.9999348
- O 0 0.017554494
induced O 0 0.0044738734
aggressive B-Disease 2 0.7171907
behavior I-Disease 2 0.14754862
: O 0 0.0031046472
comparison O 0 0.0013430676
of O 0 0.0019291864
adult O 0 0.003232643
male O 0 0.009448434
and O 0 0.003917722
female O 0 0.026507812
Wistar O 0 0.25520995
rats O 0 0.017013995
. O 0 0.010473581

The O 0 0.007885662
development O 0 0.008180338
of O 0 0.008099743
apomorphine B-Chemical 1 0.9999709
- O 0 0.023301207
induced O 0 0.00300495
( O 0 0.0026716422
1 O 0 0.0011334729
. O 0 0.00059477007
0 O 0 0.00075753435
mg O 0 0.05325803
/ O 0 0.0012275295
kg O 0 0.0021808231
s O 0 0.0007077859
. O 0 0.00039975994
c O 0 0.0021536998
. O 0 0.00031948704
once O 0 0.0003482289
daily O 0 0.00089165545
) O 0 0.000925675
aggressive B-Disease 2 0.20928946
behavior I-Disease 2 0.017013142
of O 0 0.00069269084
adult O 0 0.001138559
male O 0 0.0050178138
and O 0 0.0006973682
female O 0 0.004734218
Wistar O 0 0.046361063
rats O 0 0.0011641696
obtained O 0 0.00058508135
from O 0 0.0006117046
the O 0 0.00064202124
same O 0 0.0006156446
breeder O 0 0.0035315894
was O 0 0.0011677347
studied O 0 0.0015013108
in O 0 0.0017128886
two O 0 0.0022336196
consecutive O 0 0.0042820633
sets O 0 0.0060581965
. O 0 0.007981883

In O 0 0.0073127165
male O 0 0.010456848
animals O 0 0.0038794572
, O 0 0.0034864577
repeated O 0 0.0026098248
apomorphine B-Chemical 1 0.9999608
treatment O 0 0.004288428
induced O 0 0.0013863634
a O 0 0.0013285163
gradual O 0 0.0011111806
development O 0 0.0012727227
of O 0 0.0010430455
aggressive B-Disease 2 0.7352494
behavior I-Disease 2 0.093850404
as O 0 0.00071868213
evidenced O 0 0.0013791386
by O 0 0.0006042039
the O 0 0.00046158803
increased O 0 0.00058708177
intensity O 0 0.00049443165
of O 0 0.00105188
aggressiveness B-Disease 2 0.9887587
and O 0 0.00134706
shortened O 0 0.0017754203
latency O 0 0.0023527145
before O 0 0.000614397
the O 0 0.0010353231
first O 0 0.0013494233
attack O 0 0.26941952
toward O 0 0.003903223
the O 0 0.005288929
opponent O 0 0.49235287
. O 0 0.009485076

In O 0 0.011353389
female O 0 0.01583812
rats O 0 0.011551635
, O 0 0.006681923
only O 0 0.0043201568
a O 0 0.0050799404
weak O 0 0.0069488343
tendency O 0 0.007616699
toward O 0 0.007313806
aggressiveness B-Disease 2 0.98570883
was O 0 0.008993772
found O 0 0.00890464
. O 0 0.012326529

In O 0 0.0068733245
conclusion O 0 0.0043991082
, O 0 0.004047418
the O 0 0.0021838052
present O 0 0.0013126788
study O 0 0.001442427
demonstrates O 0 0.000855026
gender O 0 0.0091199735
differences O 0 0.0005263544
in O 0 0.00055092137
the O 0 0.0005691433
development O 0 0.0010202705
of O 0 0.0008841648
the O 0 0.0013971472
apomorphine B-Chemical 1 0.99999607
- O 0 0.009004021
induced O 0 0.0010340367
aggressive B-Disease 2 0.77059036
behavior I-Disease 2 0.092924885
and O 0 0.00074818265
indicates O 0 0.000385946
that O 0 0.00034176908
the O 0 0.00046070892
female O 0 0.0025795102
rats O 0 0.0013020934
do O 0 0.0004719349
not O 0 0.0005178087
fill O 0 0.0005587384
the O 0 0.0006069546
validation O 0 0.00089650444
criteria O 0 0.0011484617
for O 0 0.0010276234
use O 0 0.0018579272
in O 0 0.002268715
this O 0 0.0035598201
method O 0 0.007657898
. O 0 0.008338175

Intracranial B-Disease 0 0.97637695
aneurysms I-Disease 2 0.9962238
and O 0 0.023188284
cocaine B-Disease 0 0.9998827
abuse I-Disease 2 0.9995053
: O 0 0.015546531
analysis O 0 0.007927547
of O 0 0.008167011
prognostic O 0 0.035334438
indicators O 0 0.01428905
. O 0 0.014101516

OBJECTIVE O 0 0.43763584
: O 0 0.0102731725
The O 0 0.0049463212
outcome O 0 0.006098943
of O 0 0.005906486
subarachnoid B-Disease 0 0.9996234
hemorrhage I-Disease 2 0.9999001
associated O 0 0.008438307
with O 0 0.011434001
cocaine B-Disease 0 0.99997425
abuse I-Disease 2 0.9998068
is O 0 0.011933769
reportedly O 0 0.31394762
poor O 0 0.07544165
. O 0 0.011676478

However O 0 0.0089388285
, O 0 0.0060859565
no O 0 0.0029798935
study O 0 0.0028641652
in O 0 0.0018584649
the O 0 0.0015683427
literature O 0 0.001977661
has O 0 0.0009779223
reported O 0 0.0011015203
the O 0 0.0007954224
use O 0 0.00081500557
of O 0 0.0009074169
a O 0 0.0011239204
statistical O 0 0.0023135473
model O 0 0.0009963216
to O 0 0.00081943296
analyze O 0 0.00076262304
the O 0 0.0013605866
variables O 0 0.0028427648
that O 0 0.0021637978
influence O 0 0.0033513026
outcome O 0 0.019232973
. O 0 0.009105102

METHODS O 0 0.012156741
: O 0 0.00930843
A O 0 0.013020409
review O 0 0.004659416
of O 0 0.002937456
admissions O 0 0.0065430515
during O 0 0.0014385709
a O 0 0.0018095217
6 O 0 0.0011431037
- O 0 0.0014020903
year O 0 0.0008428856
period O 0 0.0007496057
revealed O 0 0.00094664935
14 O 0 0.0012447751
patients O 0 0.0025952316
with O 0 0.002980004
cocaine B-Chemical 1 0.999866
- O 0 0.011476109
related O 0 0.005343768
aneurysms B-Disease 2 0.99429554
. O 0 0.01119566

This O 0 0.010066557
group O 0 0.0056776046
was O 0 0.0034775494
compared O 0 0.0018555112
with O 0 0.0018268521
a O 0 0.001818207
control O 0 0.0012031754
group O 0 0.0012259743
of O 0 0.0012780129
135 O 0 0.0034377899
patients O 0 0.0021794941
with O 0 0.0014987527
ruptured B-Disease 0 0.9551284
aneurysms I-Disease 2 0.99864477
and O 0 0.0021585238
no O 0 0.0015811704
history O 0 0.06006538
of O 0 0.01781293
cocaine B-Disease 0 0.99996436
abuse I-Disease 2 0.9997242
. O 0 0.01826147

Age O 0 0.11878542
at O 0 0.0055239787
presentation O 0 0.007448316
, O 0 0.0035503742
time O 0 0.0017837374
of O 0 0.0019980513
ictus O 0 0.6005084
after O 0 0.0010727129
intoxication O 0 0.9994604
, O 0 0.0038298445
Hunt O 0 0.2702128
and O 0 0.0011690941
Hess O 0 0.7574096
grade O 0 0.26037964
of O 0 0.001656533
subarachnoid B-Disease 0 0.9999052
hemorrhage I-Disease 2 0.9999727
, O 0 0.0013401608
size O 0 0.0006339991
of O 0 0.00056291587
the O 0 0.0006260131
aneurysm B-Disease 2 0.97197175
, O 0 0.0008553438
location O 0 0.000437908
of O 0 0.0006071493
the O 0 0.0007659248
aneurysm B-Disease 2 0.9769676
, O 0 0.001370482
and O 0 0.0009713341
the O 0 0.001101778
Glasgow O 0 0.74565566
Outcome O 0 0.025394218
Scale O 0 0.879061
score O 0 0.0018791014
were O 0 0.0017405958
assessed O 0 0.0019311586
and O 0 0.0036956435
compared O 0 0.0040613296
. O 0 0.007762254

RESULTS O 0 0.023817498
: O 0 0.0075105107
The O 0 0.0035271568
patients O 0 0.00391472
in O 0 0.0019592117
the O 0 0.0015600594
study O 0 0.0014781957
group O 0 0.001285516
were O 0 0.0009333551
significantly O 0 0.0010590154
younger O 0 0.0071153087
than O 0 0.0004691585
the O 0 0.0005671987
patients O 0 0.0012657661
in O 0 0.00057824794
the O 0 0.00066995446
control O 0 0.0008487748
group O 0 0.0015389806
( O 0 0.002507917
P O 0 0.07596432
< O 0 0.0020876455
0 O 0 0.002789202
. O 0 0.00276753
002 O 0 0.1336235
) O 0 0.008095044
. O 0 0.0076724207

In O 0 0.008811783
patients O 0 0.008603696
in O 0 0.004453749
the O 0 0.003525488
study O 0 0.0033094406
group O 0 0.0031037144
, O 0 0.0029979667
all O 0 0.0022726504
aneurysms B-Disease 2 0.96466696
were O 0 0.0025806671
located O 0 0.002391506
in O 0 0.0025679532
the O 0 0.0037532842
anterior O 0 0.016282294
circulation O 0 0.026314717
. O 0 0.009800438

The O 0 0.0065844855
majority O 0 0.0049829176
of O 0 0.0039117774
these O 0 0.0035758144
aneurysms B-Disease 2 0.96723694
were O 0 0.0017087603
smaller O 0 0.0010690632
than O 0 0.0006278875
those O 0 0.00077588693
of O 0 0.0006735939
the O 0 0.0005590226
control O 0 0.0005743557
group O 0 0.0008733373
( O 0 0.0010091632
8 O 0 0.0005779108
+ O 0 0.00066615606
/ O 0 0.0017159062
- O 0 0.00084671366
6 O 0 0.00035962946
. O 0 0.0003419648
08 O 0 0.0027797904
mm O 0 0.00080942037
versus O 0 0.00042338923
11 O 0 0.00069192285
+ O 0 0.000691971
/ O 0 0.0016239054
- O 0 0.0009867591
5 O 0 0.0005289849
. O 0 0.0004966732
4 O 0 0.0006959497
mm O 0 0.002085621
; O 0 0.002108291
P O 0 0.02444124
= O 0 0.0025587596
0 O 0 0.0027899144
. O 0 0.0027902725
05 O 0 0.052324813
) O 0 0.007805506
. O 0 0.0076228795

The O 0 0.008697711
differences O 0 0.0052849595
in O 0 0.005109321
mortality O 0 0.083047606
and O 0 0.0050489698
morbidity O 0 0.3286668
between O 0 0.0023958553
the O 0 0.0027790754
two O 0 0.0026730846
groups O 0 0.004082019
were O 0 0.0042164386
not O 0 0.004680416
significant O 0 0.007777029
. O 0 0.010122109

Hunt O 0 0.12517983
and O 0 0.01058118
Hess O 0 0.65218824
grade O 0 0.47196165
( O 0 0.0062550325
P O 0 0.065735884
< O 0 0.002208395
0 O 0 0.0018415415
. O 0 0.001077055
005 O 0 0.029050102
) O 0 0.0013520925
and O 0 0.00086021225
age O 0 0.0018276995
( O 0 0.0013379366
P O 0 0.042032994
< O 0 0.0007691255
0 O 0 0.00081856595
. O 0 0.00049850164
007 O 0 0.06854389
) O 0 0.0007854365
were O 0 0.0004121128
significant O 0 0.0004249545
predictors O 0 0.00046907444
of O 0 0.00063312816
outcome O 0 0.001497968
for O 0 0.00061190926
the O 0 0.0009189248
patients O 0 0.0036336689
with O 0 0.0030627605
cocaine B-Chemical 1 0.99990475
- O 0 0.011984382
related O 0 0.0048383465
aneurysms B-Disease 2 0.9946532
. O 0 0.010397352

CONCLUSION O 0 0.8815697
: O 0 0.023097804
Cocaine B-Chemical 1 0.99978954
use O 0 0.008265729
predisposed O 0 0.3824851
aneurysmal B-Disease 0 0.9997441
rupture I-Disease 0 0.9990466
at O 0 0.0018765661
a O 0 0.0022091107
significantly O 0 0.0019445114
earlier O 0 0.0017686707
age O 0 0.003414826
and O 0 0.002361583
in O 0 0.002423303
much O 0 0.0030523688
smaller O 0 0.005593815
aneurysms B-Disease 2 0.989432
. O 0 0.011041377

Contrary O 0 0.008613769
to O 0 0.0060292142
the O 0 0.0047794776
published O 0 0.0037363907
literature O 0 0.004366541
, O 0 0.0032462631
this O 0 0.0021434154
group O 0 0.0024295696
did O 0 0.0021340908
reasonably O 0 0.0033931548
well O 0 0.002981254
with O 0 0.0051124482
aggressive O 0 0.40365398
management O 0 0.03128156
. O 0 0.012004295

Effect O 0 0.011936192
of O 0 0.008721668
intravenous O 0 0.79150325
nimodipine B-Chemical 1 0.99994206
on O 0 0.00362034
blood O 0 0.025373586
pressure O 0 0.070738
and O 0 0.004036277
outcome O 0 0.00871379
after O 0 0.00422253
acute B-Disease 0 0.9982274
stroke I-Disease 2 0.9998142
. O 0 0.01805018

BACKGROUND O 0 0.27747297
AND O 0 0.0102806715
PURPOSE O 0 0.015722597
: O 0 0.005509932
The O 0 0.0032827398
Intravenous O 0 0.9842163
Nimodipine B-Chemical 0 0.9999869
West O 0 0.11174811
European O 0 0.013470264
Stroke B-Disease 0 0.9990464
Trial O 0 0.15053059
( O 0 0.0016472765
INWEST O 0 0.31625244
) O 0 0.001099905
found O 0 0.00039827422
a O 0 0.0005880256
correlation O 0 0.00041278984
between O 0 0.00057941757
nimodipine B-Chemical 1 0.9999957
- O 0 0.0058066156
induced O 0 0.00083398726
reduction B-Disease 0 0.0012466462
in I-Disease 0 0.0005744373
blood I-Disease 0 0.01948538
pressure I-Disease 0 0.1549256
( O 0 0.0024012877
BP O 0 0.87327325
) O 0 0.0016411243
and O 0 0.0010476386
an O 0 0.0015607391
unfavorable O 0 0.02103071
outcome O 0 0.008998566
in O 0 0.004582987
acute B-Disease 0 0.99891055
stroke I-Disease 2 0.99986446
. O 0 0.015150302

We O 0 0.007330973
sought O 0 0.00517097
to O 0 0.0028539859
confirm O 0 0.001555322
this O 0 0.001442227
correlation O 0 0.0009887861
with O 0 0.0010798775
and O 0 0.0010155616
without O 0 0.0007464318
adjustment O 0 0.00090670993
for O 0 0.00043152148
prognostic O 0 0.0023093533
variables O 0 0.0012425398
and O 0 0.0006551273
to O 0 0.00046613836
investigate O 0 0.00036762582
outcome O 0 0.0021426375
in O 0 0.00085487694
subgroups O 0 0.0025395018
with O 0 0.0013655176
increasing O 0 0.0020814727
levels O 0 0.002359938
of O 0 0.0061243945
BP B-Disease 0 0.99475205
reduction I-Disease 0 0.052895855
. O 0 0.009027299

METHODS O 0 0.010757411
: O 0 0.0078618005
Patients O 0 0.0060587307
with O 0 0.0027566457
a O 0 0.0025729574
clinical O 0 0.0051008733
diagnosis O 0 0.010792929
of O 0 0.004547331
ischemic B-Disease 2 0.9999801
stroke I-Disease 2 0.9999776
( O 0 0.002951514
within O 0 0.00035800567
24 O 0 0.00036669263
hours O 0 0.00030975294
) O 0 0.0006157477
were O 0 0.00032318127
consecutively O 0 0.00041300082
allocated O 0 0.00026147335
to O 0 0.0002770799
receive O 0 0.00033135788
placebo O 0 0.037473172
( O 0 0.0005857492
n O 0 0.00048635827
= O 0 0.0006245143
100 O 0 0.0008330095
) O 0 0.0007912665
, O 0 0.00052176486
1 O 0 0.00041238745
mg O 0 0.075033695
/ O 0 0.0010902004
h O 0 0.00037919998
( O 0 0.0006289248
low O 0 0.00064407376
- O 0 0.001009777
dose O 0 0.013356103
) O 0 0.005339319
nimodipine B-Chemical 1 0.999992
( O 0 0.0011110642
n O 0 0.00062905584
= O 0 0.0007342302
101 O 0 0.003930948
) O 0 0.00080578483
, O 0 0.0005153114
or O 0 0.000379503
2 O 0 0.00047908982
mg O 0 0.108145095
/ O 0 0.0013847259
h O 0 0.00051267503
( O 0 0.0008592394
high O 0 0.0008903865
- O 0 0.001520667
dose O 0 0.015101239
) O 0 0.009527808
nimodipine B-Chemical 1 0.9999777
( O 0 0.0034793054
n O 0 0.0026789107
= O 0 0.0037541543
94 O 0 0.004713725
) O 0 0.007093049
. O 0 0.006871918

The O 0 0.0068346146
correlation O 0 0.0038969507
between O 0 0.0026125296
average O 0 0.0024482685
BP O 0 0.40242344
change O 0 0.0017276591
during O 0 0.00095098675
the O 0 0.0009282955
first O 0 0.0007719679
2 O 0 0.0008428479
days O 0 0.0006613163
and O 0 0.0009531757
the O 0 0.0009925652
outcome O 0 0.0021726515
at O 0 0.0012375502
day O 0 0.0017051096
21 O 0 0.002889897
was O 0 0.003210033
analyzed O 0 0.005012396
. O 0 0.008124967

RESULTS O 0 0.025284937
: O 0 0.0084475875
Two O 0 0.0047121835
hundred O 0 0.0036625771
sixty O 0 0.0036600619
- O 0 0.00264517
five O 0 0.0011352007
patients O 0 0.0018009645
were O 0 0.0009006878
included O 0 0.0006698229
in O 0 0.0005715188
this O 0 0.00056288484
analysis O 0 0.0008093031
( O 0 0.00081800175
n O 0 0.0006377492
= O 0 0.00072824955
92 O 0 0.0008563321
, O 0 0.0005621669
93 O 0 0.0008107859
, O 0 0.00048344268
and O 0 0.00041028668
80 O 0 0.00047740786
for O 0 0.00033553687
placebo O 0 0.028989213
, O 0 0.0007716207
low O 0 0.0007635826
dose O 0 0.0066413647
, O 0 0.0013345107
and O 0 0.0012223584
high O 0 0.0018151945
dose O 0 0.026839241
, O 0 0.0048410706
respectively O 0 0.00797812
) O 0 0.010606991
. O 0 0.0076530194

Nimodipine B-Chemical 0 0.99981767
treatment O 0 0.011954209
resulted O 0 0.0035774661
in O 0 0.002314928
a O 0 0.0021907238
statistically O 0 0.0013010856
significant O 0 0.0012486421
reduction B-Disease 0 0.0015901332
in I-Disease 0 0.0010330796
systolic I-Disease 0 0.9035727
BP I-Disease 0 0.95215434
( O 0 0.0019858
SBP O 0 0.785632
) O 0 0.001417412
and O 0 0.0008997511
diastolic O 0 0.9604053
BP O 0 0.931962
( O 0 0.0016003776
DBP O 0 0.54143834
) O 0 0.00092876615
from O 0 0.00047120222
baseline O 0 0.000561649
compared O 0 0.00041108084
with O 0 0.0008074344
placebo O 0 0.025408054
during O 0 0.00091536075
the O 0 0.0014245746
first O 0 0.0017496328
few O 0 0.002461913
days O 0 0.004206374
. O 0 0.007150815

In O 0 0.0074013146
multivariate O 0 0.010305182
analysis O 0 0.005070913
, O 0 0.003456748
a O 0 0.0022892687
significant O 0 0.0015163681
correlation O 0 0.0009926269
between O 0 0.00091800065
DBP B-Disease 0 0.9468701
reduction I-Disease 0 0.005615849
and O 0 0.0010128001
worsening O 0 0.5383827
of O 0 0.00085824117
the O 0 0.0007536071
neurological O 0 0.98896337
score O 0 0.001208255
was O 0 0.00046743362
found O 0 0.00031514533
for O 0 0.00030609567
the O 0 0.00042312898
high O 0 0.0007339249
- O 0 0.0010013398
dose O 0 0.003426955
group O 0 0.000945856
( O 0 0.0012760868
beta O 0 0.24394473
= O 0 0.0011111345
0 O 0 0.0008190388
. O 0 0.00052536395
49 O 0 0.0012587492
, O 0 0.0013329757
P O 0 0.022667421
= O 0 0.0021568637
0 O 0 0.0023455292
. O 0 0.0023310669
048 O 0 0.07751426
) O 0 0.007985604
. O 0 0.00739293

Patients O 0 0.015196903
with O 0 0.006354685
a O 0 0.0066950894
DBP B-Disease 0 0.8462068
reduction I-Disease 0 0.006180606
of O 0 0.0023707163
> O 0 0.002379804
or O 0 0.0010655117
= O 0 0.0011965984
20 O 0 0.0006258967
% O 0 0.00059133576
in O 0 0.0003968299
the O 0 0.00044512545
high O 0 0.00072168896
- O 0 0.00092507945
dose O 0 0.0022860952
group O 0 0.000574133
had O 0 0.000395421
a O 0 0.0006125753
significantly O 0 0.0006574829
increased O 0 0.000661536
adjusted O 0 0.0008830008
OR O 0 0.054375995
for O 0 0.00030786812
the O 0 0.0004205317
compound O 0 0.03911127
outcome O 0 0.00234655
variable O 0 0.0010009807
death B-Disease 2 0.99720407
or O 0 0.0006607663
dependency O 0 0.0038574587
( O 0 0.0013447623
Barthel O 0 0.017991897
Index O 0 0.0013583188
< O 0 0.0003836133
60 O 0 0.00036576082
) O 0 0.0005867425
( O 0 0.0004766567
n O 0 0.0004633916
/ O 0 0.0014470194
N O 0 0.8706198
= O 0 0.0007202489
25 O 0 0.0005619028
/ O 0 0.00083459466
26 O 0 0.00058685907
, O 0 0.00054847565
OR O 0 0.010596403
10 O 0 0.00041035138
. O 0 0.0002863663
16 O 0 0.0004055166
, O 0 0.00050418836
95 O 0 0.0007815511
% O 0 0.00064197445
CI O 0 0.06273534
1 O 0 0.000492112
. O 0 0.00033985957
02 O 0 0.0039013904
to O 0 0.00033538594
101 O 0 0.0020513008
. O 0 0.00032183545
74 O 0 0.00080787425
) O 0 0.0007323267
and O 0 0.00060946756
death B-Disease 2 0.98939997
alone O 0 0.0007553898
( O 0 0.0008199438
n O 0 0.00061639317
/ O 0 0.0023907982
N O 0 0.92310613
= O 0 0.00078401424
9 O 0 0.0004575333
/ O 0 0.0007971943
26 O 0 0.0005911393
, O 0 0.0005644213
OR O 0 0.012477349
4 O 0 0.00040418355
. O 0 0.00032739976
336 O 0 0.0049663694
, O 0 0.00056967756
95 O 0 0.0008148794
% O 0 0.00063363515
CI O 0 0.05428659
1 O 0 0.00045630027
. O 0 0.00030471932
131 O 0 0.0011653545
16 O 0 0.00041865857
. O 0 0.0003172942
619 O 0 0.02913025
) O 0 0.0005468381
compared O 0 0.00021687342
with O 0 0.0003317818
all O 0 0.00035299224
placebo O 0 0.026301337
patients O 0 0.0014775953
( O 0 0.0007639894
n O 0 0.00068587135
/ O 0 0.002349036
N O 0 0.8956736
= O 0 0.0010799267
62 O 0 0.0012345844
/ O 0 0.0013042595
92 O 0 0.0012324929
and O 0 0.00095608755
14 O 0 0.0012964736
/ O 0 0.0026304503
92 O 0 0.0033189398
, O 0 0.0033616931
respectively O 0 0.0058083716
) O 0 0.009005888
. O 0 0.007709533

There O 0 0.015954254
was O 0 0.010842816
no O 0 0.0075435597
correlation O 0 0.006847071
between O 0 0.0069442354
SBP O 0 0.51619065
change O 0 0.009592055
and O 0 0.011461918
outcome O 0 0.023854086
. O 0 0.016204536

CONCLUSIONS O 0 0.70559317
: O 0 0.014628964
DBP O 0 0.57618135
, O 0 0.0050483514
but O 0 0.0025804131
not O 0 0.002062511
SBP O 0 0.64103645
, O 0 0.0018737725
reduction O 0 0.0014324669
was O 0 0.0007915202
associated O 0 0.0008613158
with O 0 0.000999287
neurological O 0 0.99421656
worsening O 0 0.7379292
after O 0 0.0003827483
the O 0 0.00055380625
intravenous O 0 0.2588132
administration O 0 0.04846467
of O 0 0.0013332587
high O 0 0.0022228314
- O 0 0.004821332
dose O 0 0.1437585
nimodipine B-Chemical 1 0.9999839
after O 0 0.0036171817
acute B-Disease 0 0.99915123
stroke I-Disease 2 0.9998796
. O 0 0.015256134

For O 0 0.011267645
low O 0 0.01156519
- O 0 0.011385202
dose O 0 0.0976127
nimodipine B-Chemical 1 0.9999399
, O 0 0.008586314
the O 0 0.004362177
results O 0 0.0047193416
were O 0 0.0056389454
not O 0 0.0062885433
conclusive O 0 0.015978634
. O 0 0.011798267

These O 0 0.011945728
results O 0 0.007940224
do O 0 0.0055475277
not O 0 0.004334316
confirm O 0 0.0028818124
or O 0 0.0034397724
exclude O 0 0.0033077786
a O 0 0.006352313
neuroprotective O 0 0.95301396
property O 0 0.10788535
of O 0 0.046438485
nimodipine B-Chemical 1 0.9999474
. O 0 0.018671598

Neonatal O 0 0.72097963
pyridoxine B-Chemical 1 0.9997173
responsive O 0 0.04515121
convulsions B-Disease 2 0.9997869
due O 0 0.012012489
to O 0 0.013672322
isoniazid B-Chemical 1 0.99968624
therapy O 0 0.32123625
. O 0 0.01812068

A O 1 0.11712255
17 O 1 0.012412972
- O 0 0.006337408
day O 0 0.0032031136
- O 0 0.0030986934
old O 0 0.00196815
infant O 0 0.003037061
on O 0 0.0011118026
isoniazid B-Chemical 1 0.9998529
therapy O 0 0.013789281
13 O 0 0.0011791065
mg O 0 0.21436128
/ O 0 0.001536237
kg O 0 0.0020827467
daily O 0 0.0008540518
from O 0 0.0004643491
birth O 0 0.0010853446
because O 0 0.0003910221
of O 0 0.0006963776
maternal O 0 0.004733617
tuberculosis B-Disease 2 0.8153115
was O 0 0.0010508683
admitted O 0 0.002416484
after O 0 0.0007016865
4 O 0 0.0011781764
days O 0 0.0014526899
of O 0 0.004627341
clonic B-Disease 0 0.99989724
fits I-Disease 0 0.561255
. O 0 0.010247561

No O 0 0.018295957
underlying O 0 0.015518858
infective O 0 0.10251105
or O 0 0.010423345
biochemical O 0 0.07501951
cause O 0 0.024322782
could O 0 0.008543713
be O 0 0.010446669
found O 0 0.010555496
. O 0 0.014537821

The O 0 0.007666031
fits B-Disease 0 0.0102750305
ceased O 0 0.0060121724
within O 0 0.0018956113
4 O 0 0.0016127357
hours O 0 0.0010181421
of O 0 0.0013007784
administering O 0 0.017040651
intramuscular O 0 0.9388184
pyridoxine B-Chemical 1 0.99999297
, O 0 0.003753336
suggesting O 0 0.0008869881
an O 0 0.0018467761
aetiology O 0 0.53645104
of O 0 0.024298029
pyridoxine B-Chemical 1 0.99999297
deficiency O 0 0.94592845
secondary O 0 0.0732682
to O 0 0.0068541793
isoniazid B-Chemical 1 0.99991524
medication O 0 0.73136634
. O 0 0.00957222

Ketamine B-Chemical 1 0.99905807
sedation O 0 0.7525982
for O 0 0.0047098114
the O 0 0.0037434266
reduction O 0 0.0037751028
of O 0 0.0031809153
children O 0 0.0054813847
' O 0 0.0039527556
s O 0 0.0041990904
fractures B-Disease 2 0.933807
in O 0 0.003820008
the O 0 0.004974383
emergency O 0 0.048483614
department O 0 0.05241751
. O 0 0.012343679

BACKGROUND O 0 0.59126985
: O 0 0.009418381
There O 0 0.004883841
recently O 0 0.0035731804
has O 0 0.0023240424
been O 0 0.0019800605
a O 0 0.0019562368
resurgence O 0 0.0090747615
in O 0 0.0010009124
the O 0 0.0009071891
utilization O 0 0.0013286808
of O 0 0.0015296099
ketamine B-Chemical 1 0.9999635
, O 0 0.0015349108
a O 0 0.0009778286
unique O 0 0.0009862314
anesthetic O 0 0.39404687
, O 0 0.0015272276
for O 0 0.0008914074
emergency O 0 0.0033185282
- O 0 0.0025897904
department O 0 0.0028762904
procedures O 0 0.0030371188
requiring O 0 0.0048642126
sedation O 0 0.7679684
. O 0 0.008909312

The O 0 0.0065119434
purpose O 0 0.0047727777
of O 0 0.0034924303
the O 0 0.0023413764
present O 0 0.0014286891
study O 0 0.0016387096
was O 0 0.001016247
to O 0 0.0006833903
examine O 0 0.00042831092
the O 0 0.00062140316
safety O 0 0.0013377194
and O 0 0.0006696513
efficacy O 0 0.0015267724
of O 0 0.001104747
ketamine B-Chemical 1 0.99995697
for O 0 0.0005716098
sedation O 0 0.54921114
in O 0 0.0005096926
the O 0 0.00055448123
treatment O 0 0.00091840094
of O 0 0.0010238073
children O 0 0.0031173786
' O 0 0.001891375
s O 0 0.002166501
fractures B-Disease 2 0.9285896
in O 0 0.00238781
the O 0 0.0034864976
emergency O 0 0.044757094
department O 0 0.047630496
. O 0 0.010280434

METHODS O 0 0.01161866
: O 0 0.008077434
One O 0 0.0052047316
hundred O 0 0.0034171927
and O 0 0.0026236037
fourteen O 0 0.002705641
children O 0 0.0028483095
( O 0 0.0015565162
average O 0 0.00077350176
age O 0 0.0018673739
, O 0 0.0010942088
5 O 0 0.0005883835
. O 0 0.00042445183
3 O 0 0.00044478846
years O 0 0.0006699104
; O 0 0.0007238414
range O 0 0.0005831651
, O 0 0.00048898195
twelve O 0 0.00034435184
months O 0 0.00025521245
to O 0 0.0002674795
ten O 0 0.00027215667
years O 0 0.00048430514
and O 0 0.00038266182
ten O 0 0.0003003491
months O 0 0.00033500118
) O 0 0.000624174
who O 0 0.0005733286
underwent O 0 0.00039889503
closed O 0 0.00050310866
reduction O 0 0.0005581955
of O 0 0.00050155405
an O 0 0.00072046305
isolated O 0 0.00070877105
fracture B-Disease 0 0.9113814
or O 0 0.0009531757
dislocation B-Disease 0 0.91612166
in O 0 0.00063447753
the O 0 0.00066842133
emergency O 0 0.0073426557
department O 0 0.0033764339
at O 0 0.0006191836
a O 0 0.0011600709
level O 0 0.0009153408
- O 0 0.0027734109
I O 0 0.024035346
trauma B-Disease 0 0.8697227
center O 0 0.002705493
were O 0 0.0028606304
prospectively O 0 0.0052792444
evaluated O 0 0.0051641874
. O 0 0.008204853

Ketamine B-Chemical 1 0.9997658
hydrochloride I-Chemical 0 0.9993125
was O 0 0.004858593
administered O 0 0.0036557403
intravenously O 0 0.0062763384
( O 0 0.0018037613
at O 0 0.00065848185
a O 0 0.0007766518
dose O 0 0.0014295751
of O 0 0.00052807457
two O 0 0.0003454443
milligrams O 0 0.00076053035
per O 0 0.00027376265
kilogram O 0 0.0008167985
of O 0 0.0005758226
body O 0 0.006374896
weight O 0 0.0144073535
) O 0 0.0013092315
in O 0 0.00043668618
ninety O 0 0.0011217315
- O 0 0.0006636498
nine O 0 0.00033831692
of O 0 0.00041214164
the O 0 0.00040055191
patients O 0 0.001291824
and O 0 0.00060399255
intramuscularly O 0 0.031055324
( O 0 0.0007050439
at O 0 0.00026839762
a O 0 0.0004206247
dose O 0 0.00094583665
of O 0 0.00040235324
four O 0 0.0002955088
milligrams O 0 0.00077211426
per O 0 0.00035442624
kilogram O 0 0.0011354852
of O 0 0.0010070321
body O 0 0.0078003514
weight O 0 0.013871245
) O 0 0.0031209355
in O 0 0.0017847753
the O 0 0.0024876818
other O 0 0.003987575
fifteen O 0 0.0071011297
. O 0 0.008148538

A O 0 0.058143992
board O 0 0.014647913
- O 0 0.007359096
certified O 0 0.004659015
emergency O 0 0.004429823
physician O 0 0.005832648
skilled O 0 0.0028672784
in O 0 0.0011442847
airway O 0 0.07743643
management O 0 0.0028145942
supervised O 0 0.001584652
administration O 0 0.020972349
of O 0 0.0009299678
the O 0 0.00082565704
anesthetic O 0 0.5358279
, O 0 0.0013907176
and O 0 0.0009302993
the O 0 0.0008762443
patients O 0 0.002155265
were O 0 0.0012290692
monitored O 0 0.0010197612
by O 0 0.002137427
a O 0 0.003573861
registered O 0 0.005405577
nurse O 0 0.009971771
. O 0 0.008380845

Any O 0 0.01990638
pain B-Disease 2 0.9787482
during O 0 0.0036738196
the O 0 0.0027318355
reduction O 0 0.0028421378
was O 0 0.0015841895
rated O 0 0.002230163
by O 0 0.0010956215
the O 0 0.0008177404
orthopaedic O 0 0.0024769115
surgeon O 0 0.0014595613
treating O 0 0.0014651532
the O 0 0.00064762007
patient O 0 0.00095427874
according O 0 0.0005622494
to O 0 0.0005526325
the O 0 0.00069537055
Children O 0 0.004317889
' O 0 0.0010473791
s O 0 0.0010768654
Hospital O 0 0.002473529
of O 0 0.0018269018
Eastern O 0 0.23716104
Ontario O 0 0.14613302
Pain B-Disease 2 0.9990212
Scale O 0 0.9875052
( O 0 0.009324983
CHEOPS O 0 0.9694821
) O 0 0.010728162
. O 0 0.008522702

RESULTS O 0 0.021653574
: O 0 0.0067460216
The O 0 0.002962206
average O 0 0.0019503412
time O 0 0.0015163176
from O 0 0.0013677353
intravenous O 0 0.15861061
administration O 0 0.061463088
of O 0 0.0021009264
ketamine B-Chemical 1 0.9999567
to O 0 0.00073151593
manipulation O 0 0.00080956536
of O 0 0.00075236923
the O 0 0.0007447699
fracture B-Disease 0 0.89395314
or O 0 0.0008377618
dislocation B-Disease 0 0.90056777
was O 0 0.00049085077
one O 0 0.0003075741
minute O 0 0.000318389
and O 0 0.0004084574
thirty O 0 0.0004833745
- O 0 0.0005872754
six O 0 0.00024188387
seconds O 0 0.0004109986
( O 0 0.0005111639
range O 0 0.00050027145
, O 0 0.0004107647
twenty O 0 0.0002573939
seconds O 0 0.00028932552
to O 0 0.00024006469
five O 0 0.0002313028
minutes O 0 0.0003198256
) O 0 0.0007084797
, O 0 0.00044552176
and O 0 0.00032745968
the O 0 0.0002705604
average O 0 0.00022693342
time O 0 0.00025276325
from O 0 0.00034669953
intramuscular O 0 0.14925668
administration O 0 0.019572169
to O 0 0.00037190484
manipulation O 0 0.000525891
was O 0 0.0003614863
four O 0 0.00027171773
minutes O 0 0.00032104726
and O 0 0.00048292545
forty O 0 0.0007934724
- O 0 0.00079392205
two O 0 0.00044178215
seconds O 0 0.0006893123
( O 0 0.0009503586
range O 0 0.0010639826
, O 0 0.0011400295
sixty O 0 0.0013684401
seconds O 0 0.0012635466
to O 0 0.001492077
fifteen O 0 0.0026832533
minutes O 0 0.003349987
) O 0 0.008102651
. O 0 0.0075926255

The O 0 0.006770248
average O 0 0.00431843
score O 0 0.0039961087
according O 0 0.0023391163
to O 0 0.0017649434
the O 0 0.0015995475
Children O 0 0.0045918273
' O 0 0.0014409057
s O 0 0.0011522977
Hospital O 0 0.0020291707
of O 0 0.0011979088
Eastern O 0 0.18189459
Ontario O 0 0.086812094
Pain B-Disease 2 0.99909353
Scale O 0 0.96578
was O 0 0.0005610245
6 O 0 0.00036818694
. O 0 0.00029343693
4 O 0 0.00032615053
points O 0 0.00046800383
( O 0 0.000585536
range O 0 0.0006285746
, O 0 0.00058232475
5 O 0 0.00034118767
to O 0 0.0003374514
10 O 0 0.00044669225
points O 0 0.0006543859
) O 0 0.0010312079
, O 0 0.0007441985
reflecting O 0 0.0006814791
minimal O 0 0.00076298474
or O 0 0.0010350868
no O 0 0.001447907
pain B-Disease 2 0.9971866
during O 0 0.0033297844
fracture B-Disease 0 0.9683035
reduction O 0 0.016848058
. O 0 0.009396717

Adequate O 0 0.030094905
fracture B-Disease 0 0.60362554
reduction O 0 0.0118352575
was O 0 0.00717958
obtained O 0 0.006316558
in O 0 0.0062108263
111 O 0 0.0140944505
of O 0 0.007466125
the O 0 0.00861102
children O 0 0.018565662
. O 0 0.013644181

Ninety O 0 0.018772937
- O 0 0.008734771
nine O 0 0.004248442
percent O 0 0.0033441987
( O 0 0.003365779
sixty O 0 0.0028901254
- O 0 0.0021972205
eight O 0 0.0010106219
) O 0 0.0013806234
of O 0 0.0008346634
the O 0 0.00071779336
sixty O 0 0.0011837814
- O 0 0.0009661985
nine O 0 0.00052900636
parents O 0 0.0010756437
present O 0 0.00032647248
during O 0 0.00033406133
the O 0 0.00046290286
reduction O 0 0.00082713633
were O 0 0.00054073654
pleased O 0 0.0035845274
with O 0 0.0004895915
the O 0 0.0005461984
sedation O 0 0.42072278
and O 0 0.0006738702
would O 0 0.00046780315
allow O 0 0.00045802028
it O 0 0.0007211355
to O 0 0.0006796767
be O 0 0.00091756834
used O 0 0.0009832119
again O 0 0.0014402061
in O 0 0.0016617822
a O 0 0.0030585043
similar O 0 0.002991132
situation O 0 0.007642372
. O 0 0.008138808

Patency O 0 0.017241817
of O 0 0.0073970035
the O 0 0.005144167
airway O 0 0.032415368
and O 0 0.004064729
independent O 0 0.0029366475
respiration O 0 0.09668358
were O 0 0.002453318
maintained O 0 0.0018945805
in O 0 0.0021194397
all O 0 0.0025125556
of O 0 0.0039267833
the O 0 0.0052458914
patients O 0 0.017285964
. O 0 0.010244027

Blood O 0 0.07633651
pressure O 0 0.04288402
and O 0 0.020183928
heart O 0 0.2204349
rate O 0 0.01707319
remained O 0 0.018676262
stable O 0 0.021437718
. O 0 0.022244612

Minor O 0 0.5383001
side O 0 0.062935844
effects O 0 0.007885333
included O 0 0.0052661104
nausea B-Disease 2 0.9999827
( O 0 0.005595346
thirteen O 0 0.0028266595
patients O 0 0.006858046
) O 0 0.0035863565
, O 0 0.0022527818
emesis B-Disease 0 0.99996996
( O 0 0.0012840206
eight O 0 0.00039352872
of O 0 0.0005025388
the O 0 0.0004409212
thirteen O 0 0.00078782585
patients O 0 0.0019333591
with O 0 0.0014043032
nausea B-Disease 2 0.99999785
) O 0 0.020157238
, O 0 0.0029916354
clumsiness B-Disease 0 0.9996917
( O 0 0.0011660474
evident O 0 0.0005255563
as O 0 0.0007245232
ataxic B-Disease 0 0.9996909
movements I-Disease 0 0.018070614
in O 0 0.00051687966
ten O 0 0.0005008512
patients O 0 0.0030425668
) O 0 0.002161532
, O 0 0.0014255336
and O 0 0.0018733863
dysphoric B-Disease 0 0.9998097
reaction I-Disease 0 0.20464525
( O 0 0.004291426
one O 0 0.0026376895
patient O 0 0.0059491177
) O 0 0.010294828
. O 0 0.008013214

No O 0 0.013463239
long O 0 0.0087785525
- O 0 0.007623121
term O 0 0.004442724
sequelae O 0 0.42252073
were O 0 0.003243055
noted O 0 0.0022930915
, O 0 0.002710813
and O 0 0.0021549268
no O 0 0.0018752544
patients O 0 0.006436831
had O 0 0.0055317245
hallucinations B-Disease 2 0.9999058
or O 0 0.01531404
nightmares O 0 0.99799997
. O 0 0.01355616

CONCLUSIONS O 0 0.7043111
: O 0 0.01661765
Ketamine B-Chemical 1 0.99945766
reliably O 0 0.005799221
, O 0 0.0033797526
safely O 0 0.003802633
, O 0 0.0018338846
and O 0 0.0011559626
quickly O 0 0.0013057383
provided O 0 0.0006629953
adequate O 0 0.0007328514
sedation O 0 0.30937296
to O 0 0.00053561915
effectively O 0 0.00065431854
facilitate O 0 0.00035797287
the O 0 0.0004894125
reduction O 0 0.00078241853
of O 0 0.0007470933
children O 0 0.0022100306
' O 0 0.001246315
s O 0 0.0013008292
fractures B-Disease 2 0.9127865
in O 0 0.0011120812
the O 0 0.0014174532
emergency O 0 0.010006355
department O 0 0.006655677
at O 0 0.0023812274
our O 0 0.0034218174
institution O 0 0.0073975157
. O 0 0.008257087

Ketamine B-Chemical 1 0.9988747
should O 0 0.004648928
only O 0 0.0033842556
be O 0 0.0024080926
used O 0 0.0015334198
in O 0 0.0012032825
an O 0 0.0013985817
environment O 0 0.0013357735
such O 0 0.0007500716
as O 0 0.000754981
the O 0 0.0007068073
emergency O 0 0.008496661
department O 0 0.0069144974
, O 0 0.0008791026
where O 0 0.0004125123
proper O 0 0.0004204231
one O 0 0.00045969203
- O 0 0.0008144446
on O 0 0.0003203905
- O 0 0.0007216432
one O 0 0.0003066033
monitoring O 0 0.0004495607
is O 0 0.00038327408
used O 0 0.00038458
and O 0 0.0005846549
board O 0 0.001534148
- O 0 0.0009406615
certified O 0 0.00071871607
physicians O 0 0.0010530951
skilled O 0 0.0008485984
in O 0 0.00045265854
airway O 0 0.05068423
management O 0 0.0019226712
are O 0 0.00087722414
directly O 0 0.00087157777
involved O 0 0.00082042447
in O 0 0.0010079319
the O 0 0.0013674357
care O 0 0.0022993663
of O 0 0.0027537355
the O 0 0.003897423
patient O 0 0.008574352
. O 0 0.008400393

Cyclosporine B-Chemical 0 0.99907887
and O 0 0.047154043
tacrolimus B-Chemical 1 0.9997186
- O 0 0.107782505
associated O 0 0.053146545
thrombotic B-Disease 2 0.999801
microangiopathy I-Disease 2 0.99993217
. O 0 0.07085982

The O 0 0.008662266
development O 0 0.009044634
of O 0 0.009306306
thrombotic B-Disease 2 0.99991405
microangiopathy I-Disease 2 0.99999213
( O 0 0.18928377
TMA B-Disease 2 0.9985545
) O 0 0.0053041587
associated O 0 0.0016312995
with O 0 0.0012946319
the O 0 0.0012033186
use O 0 0.0015689371
of O 0 0.0031711296
cyclosporine B-Chemical 1 0.99996567
has O 0 0.0031499863
been O 0 0.0038255556
well O 0 0.004138378
documented O 0 0.010025612
. O 0 0.009383917

Treatments O 0 0.17517924
have O 0 0.0050635547
included O 0 0.0034777874
discontinuation O 0 0.4939375
or O 0 0.0020535695
reduction O 0 0.0023449857
of O 0 0.0021553328
cyclosporine B-Chemical 1 0.99998224
dose O 0 0.08879421
with O 0 0.00095939485
or O 0 0.00063043414
without O 0 0.00057374616
concurrent O 0 0.0026431608
plasma O 0 0.049004767
exchange O 0 0.0021608449
, O 0 0.0010524703
plasma O 0 0.012120775
infusion O 0 0.017201116
, O 0 0.001489377
anticoagulation O 0 0.77957886
, O 0 0.0016760565
and O 0 0.0017851549
intravenous O 0 0.65057945
immunoglobulin O 0 0.9522342
G O 0 0.96806717
infusion O 0 0.24057755
. O 0 0.009585005

However O 0 0.009119521
, O 0 0.0063321665
for O 0 0.0029858337
recipients O 0 0.004111329
of O 0 0.0024758384
organ O 0 0.11615037
transplantation O 0 0.25153235
, O 0 0.001817778
removing O 0 0.0013207286
the O 0 0.00095498725
inciting O 0 0.5759173
agent O 0 0.24626963
is O 0 0.0008478109
not O 0 0.00060498
without O 0 0.0006276333
the O 0 0.0007490837
attendant O 0 0.004052026
risk O 0 0.050481245
of O 0 0.0023408595
precipitating O 0 0.97666913
acute O 0 0.99510586
rejection O 0 0.998428
and O 0 0.011081328
graft O 0 0.23736669
loss O 0 0.023625446
. O 0 0.00992751

The O 0 0.007240265
last O 0 0.004543738
decade O 0 0.0052243746
has O 0 0.0022651558
seen O 0 0.0016758984
the O 0 0.0014082714
emergence O 0 0.0018988675
of O 0 0.0021311478
tacrolimus B-Chemical 1 0.99996567
as O 0 0.0017570507
a O 0 0.0019846268
potent O 0 0.032135256
immunosuppressive O 0 0.9793626
agent O 0 0.44368595
with O 0 0.0012708033
mechanisms O 0 0.0015945331
of O 0 0.0013088413
action O 0 0.005005641
virtually O 0 0.0012102051
identical O 0 0.0009394461
to O 0 0.0015602949
those O 0 0.003425942
of O 0 0.0077354903
cyclosporine B-Chemical 1 0.9999256
. O 0 0.012499884

As O 0 0.0068087056
a O 0 0.0061740545
result O 0 0.0040482734
, O 0 0.0034754947
switching O 0 0.0028796867
to O 0 0.0020801667
tacrolimus B-Chemical 1 0.9999304
has O 0 0.0016550379
been O 0 0.0012905446
reported O 0 0.0010905098
to O 0 0.00070718786
be O 0 0.00072175637
a O 0 0.0008149042
viable O 0 0.0008506293
therapeutic O 0 0.0046467637
option O 0 0.0012721495
in O 0 0.00082562957
the O 0 0.0010042154
setting O 0 0.0015351848
of O 0 0.0040676706
cyclosporine B-Chemical 1 0.9999777
- O 0 0.045010343
induced O 0 0.01191545
TMA B-Disease 2 0.99731284
. O 0 0.011543678

With O 0 0.009111286
the O 0 0.0054205153
more O 0 0.004223366
widespread O 0 0.004603039
application O 0 0.003596899
of O 0 0.0034562636
tacrolimus B-Chemical 1 0.9999424
in O 0 0.0023833073
organ O 0 0.36669865
transplantation O 0 0.59376913
, O 0 0.010485171
tacrolimus B-Chemical 1 0.9999707
- O 0 0.0132274395
associated O 0 0.003687846
TMA B-Disease 2 0.99315417
has O 0 0.002610166
also O 0 0.0037776001
been O 0 0.005225864
recognized O 0 0.008368051
. O 0 0.009597017

However O 0 0.009309248
, O 0 0.00662959
literature O 0 0.0043009273
regarding O 0 0.0022444925
the O 0 0.0019803753
incidence O 0 0.0044167363
of O 0 0.0018099585
the O 0 0.0014776073
recurrence O 0 0.78032196
of O 0 0.002904244
TMA B-Disease 2 0.9952089
in O 0 0.0011791224
patients O 0 0.0027947088
exposed O 0 0.0010651221
sequentially O 0 0.001831158
to O 0 0.0019489932
cyclosporine B-Chemical 1 0.9999684
and O 0 0.013966481
tacrolimus B-Chemical 1 0.999928
is O 0 0.0065627946
limited O 0 0.006534471
. O 0 0.00861666

We O 0 0.007939117
report O 0 0.0071283607
a O 0 0.0042605666
case O 0 0.0026398744
of O 0 0.0022462807
a O 0 0.0022632817
living O 0 0.005924994
donor O 0 0.0025396394
renal O 0 0.9713628
transplant O 0 0.48454714
recipient O 0 0.0041728434
who O 0 0.0027248748
developed O 0 0.0032700994
cyclosporine B-Chemical 1 0.9999938
- O 0 0.012652589
induced O 0 0.0012987121
TMA B-Disease 2 0.9945279
that O 0 0.00047430486
responded O 0 0.00086252094
to O 0 0.00039864343
the O 0 0.0005012825
withdrawal O 0 0.64526314
of O 0 0.0015725115
cyclosporine B-Chemical 1 0.9999881
in O 0 0.0008896018
conjunction O 0 0.0011022965
with O 0 0.0010500307
plasmapheresis O 0 0.69013226
and O 0 0.0018814201
fresh O 0 0.003560377
frozen O 0 0.0068667135
plasma O 0 0.055676155
replacement O 0 0.01592173
therapy O 0 0.081244156
. O 0 0.00934434

Introduction O 0 0.01117193
of O 0 0.0074916882
tacrolimus B-Chemical 1 0.99965715
as O 0 0.0040433626
an O 0 0.0030943307
alternative O 0 0.0021654663
immunosuppressive O 0 0.9555872
agent O 0 0.44840991
resulted O 0 0.0012578927
in O 0 0.0009456488
the O 0 0.0010063915
recurrence O 0 0.75919724
of O 0 0.0024114877
TMA B-Disease 2 0.9946181
and O 0 0.0014905689
the O 0 0.0011474676
subsequent O 0 0.0014845103
loss O 0 0.0026025046
of O 0 0.0027100386
the O 0 0.004060616
renal O 0 0.9946731
allograft O 0 0.9901675
. O 0 0.013464627

Patients O 0 0.014530273
who O 0 0.007908893
are O 0 0.0040908377
switched O 0 0.00400211
from O 0 0.0028671694
cyclosporine B-Chemical 1 0.99994934
to O 0 0.0029422976
tacrolimus B-Chemical 1 0.99996734
or O 0 0.0023987303
vice O 0 0.04088932
versa O 0 0.0011887521
should O 0 0.00046760656
be O 0 0.00058657443
closely O 0 0.00051066274
monitored O 0 0.00041963087
for O 0 0.0005852593
the O 0 0.0009900433
signs O 0 0.13385165
and O 0 0.0027184892
symptoms O 0 0.82942945
of O 0 0.007181504
recurrent O 0 0.9804167
TMA B-Disease 2 0.9980958
. O 0 0.012352482

Analgesic O 0 0.9959557
effect O 0 0.0056721102
of O 0 0.004583692
intravenous O 0 0.8106349
ketamine B-Chemical 1 0.9999536
in O 0 0.0028520445
cancer B-Disease 2 0.9973023
patients O 0 0.0139012085
on O 0 0.0008790775
morphine B-Chemical 1 0.99996173
therapy O 0 0.052577883
: O 0 0.0014993171
a O 0 0.00085367635
randomized O 0 0.0008026501
, O 0 0.00071807834
controlled O 0 0.00055100536
, O 0 0.0007822907
double O 0 0.0007517557
- O 0 0.0013940576
blind O 0 0.00410924
, O 0 0.0013568926
crossover O 0 0.006785939
, O 0 0.002031444
double O 0 0.0020650465
- O 0 0.004059208
dose O 0 0.011693417
study O 0 0.0071669775
. O 0 0.007772122

Pain B-Disease 2 0.9815996
not O 0 0.015425566
responsive O 0 0.012709525
to O 0 0.012573992
morphine B-Chemical 1 0.99950564
is O 0 0.0142378295
often O 0 0.018158942
problematic O 0 0.02114732
. O 0 0.016586145

Animal O 0 0.019539122
and O 0 0.0070840716
clinical O 0 0.008475351
studies O 0 0.0033275164
have O 0 0.001979763
suggested O 0 0.0016766262
that O 0 0.0018152827
N B-Chemical 1 0.99536127
- I-Chemical 1 0.04236697
methyl I-Chemical 1 0.99734217
- I-Chemical 1 0.0870944
D I-Chemical 1 0.9942222
- I-Chemical 1 0.098701
aspartate I-Chemical 1 0.99996483
( O 0 0.0555039
NMDA B-Chemical 1 0.999995
) O 0 0.01580996
antagonists O 0 0.9586285
, O 0 0.0009124246
such O 0 0.00047368862
as O 0 0.00080381247
ketamine B-Chemical 1 0.9999728
, O 0 0.0011444766
may O 0 0.0004323511
be O 0 0.0004493821
effective O 0 0.0005067134
in O 0 0.00044330338
improving O 0 0.0007602529
opioid O 0 0.99925834
analgesia O 0 0.99466234
in O 0 0.0008645868
difficult O 0 0.0011697153
pain B-Disease 2 0.99908257
syndromes O 0 0.95064
, O 0 0.0033928114
such O 0 0.0025400114
as O 0 0.00938057
neuropathic B-Disease 2 0.99997485
pain I-Disease 2 0.99979264
. O 0 0.016601536

A O 0 0.028118094
slow O 0 0.008948453
bolus O 0 0.034793697
of O 0 0.003985082
subhypnotic O 0 0.9992606
doses O 0 0.13067687
of O 0 0.004611329
ketamine B-Chemical 1 0.99997604
( O 0 0.0033554651
0 O 0 0.0011628296
. O 0 0.00043847607
25 O 0 0.00063553423
mg O 0 0.06294371
/ O 0 0.0010789206
kg O 0 0.0016756544
or O 0 0.000460589
0 O 0 0.0006375174
. O 0 0.00030305487
50 O 0 0.0005364459
mg O 0 0.07801346
/ O 0 0.0011852002
kg O 0 0.0033484271
) O 0 0.0007673494
was O 0 0.00032157265
given O 0 0.0002313692
to O 0 0.00032403803
10 O 0 0.00047384162
cancer B-Disease 2 0.97590554
patients O 0 0.0032865112
whose O 0 0.00173837
pain B-Disease 2 0.99913114
was O 0 0.0010041072
unrelieved O 0 0.9823568
by O 0 0.0013921214
morphine B-Chemical 1 0.999956
in O 0 0.00061335205
a O 0 0.0008450271
randomized O 0 0.00079159415
, O 0 0.0007742902
double O 0 0.00072607986
- O 0 0.0013566911
blind O 0 0.0040349388
, O 0 0.0013197715
crossover O 0 0.0066396594
, O 0 0.0019922073
double O 0 0.002032073
- O 0 0.0040130997
dose O 0 0.0115865655
study O 0 0.0071133217
. O 0 0.0077246134

Pain B-Disease 2 0.9678018
intensity O 0 0.0056094592
on O 0 0.0030834735
a O 0 0.0032082363
0 O 0 0.002341217
to O 0 0.0013561028
10 O 0 0.0012047808
numerical O 0 0.00450755
scale O 0 0.0033806618
; O 0 0.0051859324
nausea B-Disease 2 0.9999933
and O 0 0.0052950345
vomiting B-Disease 2 0.9999871
, O 0 0.016854906
drowsiness O 0 0.9999807
, O 0 0.0031770016
confusion B-Disease 2 0.9430314
, O 0 0.0011982664
and O 0 0.000797164
dry B-Disease 2 0.21730581
mouth I-Disease 2 0.75945574
, O 0 0.0009840488
using O 0 0.0003921756
a O 0 0.0005469963
scale O 0 0.00072081527
from O 0 0.00038255096
0 O 0 0.00049429195
to O 0 0.00031603323
3 O 0 0.0003945553
( O 0 0.0004763215
not O 0 0.00029658416
at O 0 0.0002532358
all O 0 0.0003421613
, O 0 0.00055876584
slight O 0 0.0006004548
, O 0 0.00064225163
a O 0 0.0006636315
lot O 0 0.0014810559
, O 0 0.0013287454
awful O 0 0.33028963
) O 0 0.004045337
; O 0 0.0025683308
Mini O 0 0.025945418
- O 0 0.0013555094
Mental O 0 0.03597702
State O 0 0.0017022889
Examination O 0 0.000816017
( O 0 0.00087513437
MMSE O 0 0.9661884
) O 0 0.0009898654
( O 0 0.000718217
0 O 0 0.00067246595
- O 0 0.0006598582
30 O 0 0.0003410218
) O 0 0.00070510246
; O 0 0.00057832187
and O 0 0.0003819322
arterial O 0 0.19004013
pressure O 0 0.0136745805
were O 0 0.00032781047
recorded O 0 0.00032945815
before O 0 0.0001904371
administration O 0 0.00575008
of O 0 0.00064187683
drugs O 0 0.8473708
( O 0 0.0019385113
T0 O 0 0.027369391
) O 0 0.00082291506
and O 0 0.00037457986
after O 0 0.00020972065
30 O 0 0.000252837
minutes O 0 0.00028771028
( O 0 0.0006732104
T30 O 0 0.17371753
) O 0 0.0008872342
, O 0 0.0005129859
60 O 0 0.00034844194
minutes O 0 0.00032465556
( O 0 0.00070888526
T60 O 0 0.054559946
) O 0 0.00095042074
, O 0 0.0006327454
120 O 0 0.0005447151
minutes O 0 0.00047320614
( O 0 0.0010941452
T120 O 0 0.103689276
) O 0 0.0015396463
, O 0 0.0012217702
and O 0 0.0012721972
180 O 0 0.002104843
minutes O 0 0.0017484714
( O 0 0.0041980455
T180 O 0 0.12080767
) O 0 0.0092562605
. O 0 0.007893434

Ketamine B-Chemical 1 0.9994023
, O 0 0.0103226695
but O 0 0.004180042
not O 0 0.0028437546
saline O 0 0.09465445
solution O 0 0.026453653
, O 0 0.0021843163
significantly O 0 0.0014545212
reduced O 0 0.0011516233
the O 0 0.0012260975
pain B-Disease 2 0.99480397
intensity O 0 0.0009935105
in O 0 0.0008710714
almost O 0 0.00087549514
all O 0 0.0010137492
the O 0 0.001338525
patients O 0 0.0033432248
at O 0 0.0020525577
both O 0 0.003652886
doses O 0 0.081092596
. O 0 0.009066019

This O 0 0.013565083
effect O 0 0.007184762
was O 0 0.0057412107
more O 0 0.0048176083
relevant O 0 0.00366975
in O 0 0.0035050518
patients O 0 0.0065511586
treated O 0 0.0053061643
with O 0 0.005724773
higher O 0 0.006952194
doses O 0 0.20342255
. O 0 0.013003208

Hallucinations B-Disease 2 0.99662244
occurred O 0 0.007200534
in O 0 0.003910605
4 O 0 0.0027251057
patients O 0 0.0037203864
, O 0 0.0022374133
and O 0 0.001617845
an O 0 0.0021331385
unpleasant O 0 0.7826109
sensation O 0 0.9820586
( O 0 0.0031308627
" O 0 0.0017072341
empty O 0 0.0016037279
head O 0 0.043881662
" O 0 0.0023036066
) O 0 0.0023413517
was O 0 0.0012644478
also O 0 0.001581372
reported O 0 0.0025675367
by O 0 0.0033709046
2 O 0 0.0043656495
patients O 0 0.010426128
. O 0 0.008298565

These O 0 0.012876965
episodes O 0 0.11920173
reversed O 0 0.008922686
after O 0 0.0035734775
the O 0 0.0039447886
administration O 0 0.05642127
of O 0 0.0089956075
diazepam B-Chemical 1 0.99995625
1 O 0 0.009596854
mg O 0 0.70127535
intravenously O 0 0.030390007
. O 0 0.011049472

Significant O 0 0.010455674
increases O 0 0.005566637
in O 0 0.004597733
drowsiness O 0 0.9997663
were O 0 0.0027915663
reported O 0 0.0019322094
in O 0 0.0011449226
patients O 0 0.002444526
treated O 0 0.0012867164
with O 0 0.0014040404
ketamine B-Chemical 1 0.99995494
in O 0 0.000776522
both O 0 0.0006631302
groups O 0 0.0008758794
and O 0 0.0007337214
were O 0 0.00062358024
more O 0 0.00069629605
marked O 0 0.0012807582
with O 0 0.0013532946
ketamine B-Chemical 1 0.9999188
0 O 0 0.0023169597
. O 0 0.0012843497
50 O 0 0.002864357
mg O 0 0.22813112
/ O 0 0.00910576
kg O 0 0.018299324
. O 0 0.008332113

A O 0 0.027313266
significant O 0 0.006192203
difference O 0 0.0032785484
in O 0 0.0032917918
MMSE O 0 0.906163
was O 0 0.0017704885
observed O 0 0.0010441731
at O 0 0.0010308061
T30 O 0 0.082261615
in O 0 0.00090575585
patients O 0 0.0017011669
who O 0 0.0014898613
received O 0 0.0009636836
0 O 0 0.0013745779
. O 0 0.00089080713
50 O 0 0.0017908018
mg O 0 0.13867825
/ O 0 0.0048010782
kg O 0 0.010179089
of O 0 0.0072214734
ketamine B-Chemical 1 0.9997658
. O 0 0.011294707

Ketamine B-Chemical 1 0.9990043
can O 0 0.0076773963
improve O 0 0.0052403305
morphine B-Chemical 1 0.999806
analgesia O 0 0.9973763
in O 0 0.0033033702
difficult O 0 0.0032152873
pain B-Disease 2 0.99903417
syndromes O 0 0.9668959
, O 0 0.00553252
such O 0 0.003919014
as O 0 0.011882108
neuropathic B-Disease 2 0.99996877
pain I-Disease 2 0.9997743
. O 0 0.0196494

However O 0 0.00898109
, O 0 0.0062542553
the O 0 0.0034555194
occurrence O 0 0.0038373948
of O 0 0.0026008734
central O 0 0.0043379287
adverse O 0 0.85660505
effects O 0 0.0027185548
should O 0 0.0007371885
be O 0 0.0008440265
taken O 0 0.0006205681
into O 0 0.0005924442
account O 0 0.0010296862
, O 0 0.0014434808
especially O 0 0.0015125738
when O 0 0.0014112196
using O 0 0.0023029153
higher O 0 0.0034984928
doses O 0 0.091019034
. O 0 0.008957144

This O 0 0.01381169
observation O 0 0.0075402213
should O 0 0.004678404
be O 0 0.0046192748
tested O 0 0.0033230751
in O 0 0.003569895
studies O 0 0.004203128
of O 0 0.0055624894
prolonged O 0 0.12499945
ketamine B-Chemical 1 0.9998876
administration O 0 0.7471945
. O 0 0.014501249

Paclitaxel B-Chemical 1 0.9989579
, O 0 0.017850092
cisplatin B-Chemical 1 0.99901223
, O 0 0.0062734033
and O 0 0.0034028115
gemcitabine B-Chemical 1 0.9965044
combination O 0 0.0039193076
chemotherapy O 0 0.5956275
within O 0 0.0008426921
a O 0 0.0015616704
multidisciplinary O 0 0.0025162941
therapeutic O 0 0.010070587
approach O 0 0.002273387
in O 0 0.0023891404
metastatic O 0 0.99541473
nonsmall B-Disease 0 0.99959534
cell I-Disease 0 0.53986895
lung I-Disease 0 0.9916986
carcinoma I-Disease 2 0.9997929
. O 0 0.018451128

BACKGROUND O 0 0.81990516
: O 0 0.020589614
Cisplatin B-Chemical 1 0.99956053
- O 0 0.0069338623
based O 0 0.002759544
chemotherapy O 0 0.22751075
combinations O 0 0.0016873499
improve O 0 0.0009409282
quality O 0 0.0010167138
of O 0 0.0012697708
life O 0 0.0030214752
and O 0 0.0014399551
survival O 0 0.052817233
in O 0 0.0014919426
advanced O 0 0.19865169
nonsmall B-Disease 0 0.9995455
cell I-Disease 0 0.3644297
lung I-Disease 0 0.9900359
carcinoma I-Disease 2 0.9999279
( O 0 0.16418165
NSCLC B-Disease 2 0.9993753
) O 0 0.030651594
. O 0 0.009785567

The O 0 0.007523619
emergence O 0 0.0064842966
of O 0 0.0043281927
new O 0 0.003934071
active O 0 0.0038926494
drugs O 0 0.5699332
might O 0 0.0013007981
translate O 0 0.0012029484
into O 0 0.0007168349
more O 0 0.001057569
effective O 0 0.0011870898
regimens O 0 0.0032679355
for O 0 0.0010304939
the O 0 0.0014988754
treatment O 0 0.0028850096
of O 0 0.0037374634
this O 0 0.005369845
disease O 0 0.9020965
. O 0 0.011377049

METHODS O 0 0.010115619
: O 0 0.006773968
The O 0 0.00323772
objective O 0 0.003265636
of O 0 0.0021622826
this O 0 0.0015370739
study O 0 0.0014512946
was O 0 0.0009030785
to O 0 0.00062057725
determine O 0 0.0003703716
the O 0 0.0005747632
feasibility O 0 0.00073048874
, O 0 0.000861668
response O 0 0.000785007
rate O 0 0.00069762673
, O 0 0.00097541464
and O 0 0.00081863767
toxicity B-Disease 2 0.9921029
of O 0 0.0011242342
a O 0 0.0024401904
paclitaxel B-Chemical 1 0.99966276
, O 0 0.0044187536
cisplatin B-Chemical 1 0.99975246
, O 0 0.0019929665
and O 0 0.0016351382
gemcitabine B-Chemical 1 0.9978536
combination O 0 0.0031941317
to O 0 0.0023432975
treat O 0 0.04289658
metastatic O 0 0.99832577
NSCLC B-Disease 2 0.9995283
. O 0 0.012478806

Thirty O 0 0.014625074
- O 0 0.007276315
five O 0 0.0029345374
consecutive O 0 0.002869559
chemotherapy O 0 0.48037437
- O 0 0.0033980152
naive O 0 0.002920149
patients O 0 0.002929923
with O 0 0.0014496386
Stage O 0 0.82310724
IV O 0 0.6951134
NSCLC B-Disease 2 0.9991054
and O 0 0.001370011
an O 0 0.001866999
Eastern O 0 0.22038181
Cooperative O 0 0.08337067
Oncology O 0 0.011046653
Group O 0 0.0050746123
performance O 0 0.0006522829
status O 0 0.0006526162
of O 0 0.0006571509
0 O 0 0.0011677737
- O 0 0.0008676651
2 O 0 0.00038286689
were O 0 0.00032557765
treated O 0 0.00041464999
with O 0 0.00040892768
a O 0 0.0005798534
combination O 0 0.0007756323
of O 0 0.0009978034
paclitaxel B-Chemical 1 0.9996383
( O 0 0.0014549909
135 O 0 0.0036626607
mg O 0 0.23268929
/ O 0 0.001730143
m O 0 0.0047153966
( O 0 0.00069825636
2 O 0 0.0003943763
) O 0 0.00045445343
given O 0 0.00019676788
intravenously O 0 0.0006299362
in O 0 0.0002935382
3 O 0 0.00031147432
hours O 0 0.00024619012
) O 0 0.0005094939
on O 0 0.00023626801
Day O 0 0.0026826744
1 O 0 0.0004699521
, O 0 0.00067513407
cisplatin B-Chemical 1 0.99905246
( O 0 0.000840864
120 O 0 0.0005231134
mg O 0 0.11043398
/ O 0 0.0013796391
m O 0 0.0037411686
( O 0 0.0006795384
2 O 0 0.00039062044
) O 0 0.00045050532
given O 0 0.00019574113
intravenously O 0 0.0006022404
in O 0 0.00028302075
6 O 0 0.000255102
hours O 0 0.00023777329
) O 0 0.00050311635
on O 0 0.00023659148
Day O 0 0.0024706807
1 O 0 0.00043771436
, O 0 0.0005053758
and O 0 0.000558764
gemcitabine B-Chemical 1 0.99785185
( O 0 0.0009361615
800 O 0 0.0019103395
mg O 0 0.14987293
/ O 0 0.0014974244
m O 0 0.003720994
( O 0 0.00071517855
2 O 0 0.0004203846
) O 0 0.0004922794
given O 0 0.00022618665
intravenously O 0 0.00065337116
in O 0 0.00034263264
30 O 0 0.0003269927
minutes O 0 0.00036474998
) O 0 0.00074067846
on O 0 0.00044678035
Days O 0 0.08761441
1 O 0 0.0008765765
and O 0 0.0010206355
8 O 0 0.0011823812
, O 0 0.0016217002
every O 0 0.0013070834
4 O 0 0.0025316903
weeks O 0 0.0033941872
. O 0 0.0062741493

Although O 0 0.006838617
responding O 0 0.0071270647
patients O 0 0.0053019146
were O 0 0.002277624
scheduled O 0 0.0013490905
to O 0 0.0010699639
receive O 0 0.0009731265
consolidation O 0 0.020194748
radiotherapy O 0 0.3964722
and O 0 0.0008711922
24 O 0 0.00044550156
patients O 0 0.00078336307
received O 0 0.0004194155
preplanned O 0 0.0034956743
second O 0 0.0005965591
- O 0 0.0010097544
line O 0 0.0008312929
chemotherapy O 0 0.38836592
after O 0 0.0003754776
disease O 0 0.7879865
progression O 0 0.671582
, O 0 0.0014127103
the O 0 0.00056408864
response O 0 0.0009972431
and O 0 0.001186784
toxicity B-Disease 2 0.9956846
rates O 0 0.0011526452
reported O 0 0.0011666507
refer O 0 0.001307934
only O 0 0.0008545796
to O 0 0.0010513599
the O 0 0.0016907098
chemotherapy O 0 0.60519665
regimen O 0 0.011223125
given O 0 0.0044327765
. O 0 0.0077974037

RESULTS O 0 0.026640648
: O 0 0.009152729
All O 0 0.004934846
the O 0 0.0039479258
patients O 0 0.0046401983
were O 0 0.0027794829
examined O 0 0.0020368225
for O 0 0.0024471649
toxicity B-Disease 2 0.99578506
; O 0 0.0062657506
34 O 0 0.0035682907
were O 0 0.0028629466
examinable O 0 0.006768773
for O 0 0.0038086316
response O 0 0.008754131
. O 0 0.009782928

An O 0 0.012097034
objective O 0 0.007639755
response O 0 0.004669227
was O 0 0.0027544205
observed O 0 0.0015251073
in O 0 0.0014809121
73 O 0 0.0026460458
. O 0 0.00079094194
5 O 0 0.0006407547
% O 0 0.00066718285
of O 0 0.00058053696
the O 0 0.00058081205
patients O 0 0.0018792965
( O 0 0.0010277365
95 O 0 0.001090938
% O 0 0.0006579414
confidence O 0 0.0014808661
interval O 0 0.000945975
[ O 0 0.004140601
CI O 0 0.42880836
] O 0 0.0015105401
, O 0 0.0007122793
55 O 0 0.00062765
. O 0 0.00033055805
6 O 0 0.00035694326
- O 0 0.0006082726
87 O 0 0.00073404104
. O 0 0.00033167363
1 O 0 0.00046240183
% O 0 0.0006064342
) O 0 0.0008489786
, O 0 0.00062410167
including O 0 0.00048974465
4 O 0 0.0005629025
complete O 0 0.00060461514
responses O 0 0.0015767068
( O 0 0.001820475
11 O 0 0.0017046503
. O 0 0.0013841413
7 O 0 0.0022968976
% O 0 0.004176935
) O 0 0.0075897006
. O 0 0.0072787134

According O 0 0.008832056
to O 0 0.0056498637
intention O 0 0.029027652
- O 0 0.005319461
to O 0 0.0024324304
- O 0 0.0030053284
treat O 0 0.0031591181
, O 0 0.0015024021
the O 0 0.0007585652
overall O 0 0.0007823439
response O 0 0.0009031085
rate O 0 0.00068631495
was O 0 0.00064919714
71 O 0 0.0016348687
. O 0 0.00041097737
4 O 0 0.00046308295
% O 0 0.00066389656
( O 0 0.0008087057
95 O 0 0.0010896645
% O 0 0.000942049
CI O 0 0.05633056
, O 0 0.0009555166
53 O 0 0.0013345216
. O 0 0.00067202066
7 O 0 0.00095377624
- O 0 0.0015342582
85 O 0 0.001767516
. O 0 0.0014334316
4 O 0 0.0022822267
% O 0 0.0043102736
) O 0 0.0077338037
. O 0 0.0075171166

After O 0 0.0063618305
154 O 0 0.009928109
courses O 0 0.0044034207
of O 0 0.0029594628
therapy O 0 0.0062587713
, O 0 0.001817335
the O 0 0.00089889765
median O 0 0.00072622136
dose O 0 0.0023680741
intensity O 0 0.00065837364
was O 0 0.0006720251
131 O 0 0.004568414
mg O 0 0.2510351
/ O 0 0.0023240035
m O 0 0.0069206194
( O 0 0.00097514235
2 O 0 0.0005687838
) O 0 0.00076329557
for O 0 0.00039923406
paclitaxel B-Chemical 1 0.99789196
( O 0 0.0009981181
97 O 0 0.00087378215
. O 0 0.00029805477
3 O 0 0.0003519375
% O 0 0.00050713046
) O 0 0.0007162931
, O 0 0.0005394773
117 O 0 0.0014925586
mg O 0 0.11161939
/ O 0 0.0015072697
m O 0 0.0042818277
( O 0 0.0008034452
2 O 0 0.00049822475
) O 0 0.0006956606
for O 0 0.00038727597
cisplatin B-Chemical 1 0.99935967
( O 0 0.0010684126
97 O 0 0.0009111826
. O 0 0.00030913958
3 O 0 0.00037221695
% O 0 0.00054852996
) O 0 0.0007925475
, O 0 0.00059264136
and O 0 0.0005919461
1378 O 0 0.07621203
mg O 0 0.16216046
/ O 0 0.0018864889
m O 0 0.0044294633
( O 0 0.0010639031
2 O 0 0.0007287223
) O 0 0.0010959286
for O 0 0.0007333223
gemcitabine B-Chemical 1 0.9960227
( O 0 0.002172955
86 O 0 0.002570269
. O 0 0.0014600167
2 O 0 0.0024835332
% O 0 0.004333559
) O 0 0.007706196
. O 0 0.0073441574

World O 0 0.018409474
Health O 0 0.010185995
Organization O 0 0.0075988974
Grade O 0 0.6247023
3 O 0 0.002707913
- O 0 0.0026177545
4 O 0 0.0013769678
neutropenia B-Disease 2 0.9982326
and O 0 0.002200562
thrombocytopenia B-Disease 2 0.9998733
occurred O 0 0.001379932
in O 0 0.00078358705
39 O 0 0.0013245491
. O 0 0.000489853
9 O 0 0.00059458584
% O 0 0.00067929784
and O 0 0.0007070026
11 O 0 0.0009290848
. O 0 0.0006538081
4 O 0 0.0008752779
% O 0 0.001369821
of O 0 0.0019035416
patients O 0 0.0062591895
, O 0 0.005725266
respectively O 0 0.009294356
. O 0 0.008200435

There O 0 0.023629604
was O 0 0.018180344
one O 0 0.0152833015
treatment O 0 0.020123625
- O 0 0.02340831
related O 0 0.018588057
death B-Disease 2 0.993932
. O 0 0.02777104

Nonhematologic O 0 0.9943018
toxicities B-Disease 2 0.9965125
were O 0 0.06412652
mild O 0 0.78792924
. O 0 0.051811863

After O 0 0.0061544473
a O 0 0.0056400257
median O 0 0.003591242
follow O 0 0.0026505953
- O 0 0.002743495
up O 0 0.0013896953
of O 0 0.0013006681
22 O 0 0.0012520076
months O 0 0.0006567026
, O 0 0.0007656497
the O 0 0.00052251143
median O 0 0.0005781518
progression O 0 0.056575768
free O 0 0.0011618311
survival O 0 0.02954801
rate O 0 0.00070273574
was O 0 0.000628273
7 O 0 0.00054951827
months O 0 0.00046137866
, O 0 0.0007485517
and O 0 0.0007262553
the O 0 0.000776737
median O 0 0.001037397
survival O 0 0.010533041
time O 0 0.0017140646
was O 0 0.0025113488
16 O 0 0.0036426554
months O 0 0.0041633784
. O 0 0.0068988707

CONCLUSIONS O 0 0.40721825
: O 0 0.00829054
The O 0 0.003687208
combination O 0 0.0038542997
of O 0 0.003875925
paclitaxel B-Chemical 1 0.99942684
, O 0 0.009607728
cisplatin B-Chemical 1 0.99978346
, O 0 0.0028986544
and O 0 0.0015898462
gemcitabine B-Chemical 1 0.9980737
is O 0 0.000928991
well O 0 0.0008138418
tolerated O 0 0.010612116
and O 0 0.0012231651
shows O 0 0.000952798
high O 0 0.0020361042
activity O 0 0.0029724138
in O 0 0.004070178
metastatic O 0 0.99624795
NSCLC B-Disease 2 0.99936
. O 0 0.012562121

This O 0 0.0130847925
treatment O 0 0.008214074
merits O 0 0.00566815
further O 0 0.004525421
comparison O 0 0.0037117659
with O 0 0.0043506613
other O 0 0.006325738
cisplatin B-Chemical 1 0.99954647
- O 0 0.014690789
based O 0 0.0077643925
regimens O 0 0.06604701
. O 0 0.012170969

Serotonergic B-Chemical 0 0.9935063
antidepressants I-Chemical 1 0.99910873
and O 0 0.05645253
urinary B-Disease 0 0.9824646
incontinence I-Disease 2 0.9972242
. O 0 0.04467322

Many O 0 0.017782805
new O 0 0.016037492
serotonergic B-Chemical 0 0.99591947
antidepressants I-Chemical 1 0.9997919
have O 0 0.00741281
been O 0 0.0059109814
introduced O 0 0.004142636
over O 0 0.0038257113
the O 0 0.005910419
past O 0 0.010982187
decade O 0 0.017722057
. O 0 0.012722457

Although O 0 0.008153638
urinary B-Disease 0 0.7709126
incontinence I-Disease 2 0.9973807
is O 0 0.003130062
listed O 0 0.0013978507
as O 0 0.0012824648
one O 0 0.000948577
side O 0 0.010884073
effect O 0 0.0008008937
of O 0 0.0008889569
these O 0 0.0010185757
drugs O 0 0.58199143
in O 0 0.00073261367
their O 0 0.0009120151
package O 0 0.0021461474
inserts O 0 0.0016202112
there O 0 0.00058307283
is O 0 0.00083334465
only O 0 0.0009697034
one O 0 0.0012548459
report O 0 0.003598737
in O 0 0.0026810165
the O 0 0.0042020762
literature O 0 0.009717815
. O 0 0.0089809215

This O 0 0.014429559
concerns O 0 0.011938792
2 O 0 0.0066811037
male O 0 0.0096424185
patients O 0 0.0073852134
who O 0 0.007067097
experienced O 0 0.009447349
incontinence B-Disease 2 0.99754816
while O 0 0.007875714
taking O 0 0.07237559
venlafaxine B-Chemical 1 0.9997514
. O 0 0.014670448

In O 0 0.006963924
the O 0 0.00461145
present O 0 0.0026625392
paper O 0 0.0028692589
the O 0 0.0016764904
authors O 0 0.0012921952
describe O 0 0.0010876319
2 O 0 0.001034556
female O 0 0.0023754349
patients O 0 0.0017754261
who O 0 0.0014940005
developed O 0 0.0014247923
incontinence B-Disease 2 0.99878985
secondary O 0 0.0051514227
to O 0 0.0006023553
the O 0 0.0006991079
selective O 0 0.04879662
serotonin B-Chemical 1 0.9999801
reuptake O 0 0.9999386
inhibitors O 0 0.76789075
paroxetine B-Chemical 1 0.9999956
and O 0 0.0027428782
sertraline B-Chemical 1 0.9999914
, O 0 0.00086224126
as O 0 0.000451743
well O 0 0.000420877
as O 0 0.0005182247
a O 0 0.0007554971
third O 0 0.00079987285
who O 0 0.0014369197
developed O 0 0.0013850762
this O 0 0.0013992698
side O 0 0.042587437
effect O 0 0.0030584056
on O 0 0.0040472373
venlafaxine B-Chemical 1 0.99982005
. O 0 0.009689726

In O 0 0.007386847
2 O 0 0.0047363574
of O 0 0.0034466702
the O 0 0.002411426
3 O 0 0.001700086
cases O 0 0.0018052653
the O 0 0.0011141808
patients O 0 0.002009993
were O 0 0.0008742665
also O 0 0.00089058693
taking O 0 0.0052260794
lithium B-Chemical 1 0.9999281
carbonate I-Chemical 0 0.9994679
and O 0 0.0044356263
beta O 0 0.9230835
- O 0 0.016067473
blockers O 0 0.99897766
, O 0 0.0013533256
both O 0 0.00069623033
of O 0 0.0010013522
which O 0 0.0012768484
could O 0 0.000953838
have O 0 0.0013485233
contributed O 0 0.0028784683
to O 0 0.002549932
the O 0 0.0050387806
incontinence B-Disease 2 0.99808407
. O 0 0.010850367

Animal O 0 0.017494174
studies O 0 0.0060979286
suggest O 0 0.00315583
that O 0 0.0029156236
incontinence B-Disease 2 0.99683654
secondary O 0 0.012718814
to O 0 0.002599847
serotonergic B-Chemical 0 0.99941826
antidepressants I-Chemical 1 0.9999807
could O 0 0.0012857976
be O 0 0.0012330678
mediated O 0 0.0010322202
by O 0 0.0014277636
the O 0 0.0017781799
5HT4 O 0 0.9966008
receptors O 0 0.075547285
found O 0 0.0021126915
on O 0 0.0023480353
the O 0 0.004775707
bladder O 0 0.9245008
. O 0 0.010465313

Further O 0 0.00960947
research O 0 0.006418051
is O 0 0.0035280506
needed O 0 0.0020072067
to O 0 0.0016471369
delineate O 0 0.0012472371
the O 0 0.0011708818
frequency O 0 0.0012261161
of O 0 0.001306857
this O 0 0.0012084645
troubling O 0 0.027119208
side O 0 0.041857764
effect O 0 0.0014702114
and O 0 0.0017256265
how O 0 0.001535845
best O 0 0.0022897732
to O 0 0.0028310996
treat O 0 0.011477596
it O 0 0.008180556
. O 0 0.008897337

Acute O 0 0.9901427
cocaine B-Chemical 1 0.99976486
- O 0 0.031472873
induced O 0 0.009981021
seizures B-Disease 2 0.9999
: O 0 0.0069444594
differential O 0 0.004299372
sensitivity O 0 0.004410888
of O 0 0.0034629973
six O 0 0.002949494
inbred O 0 0.0071206936
mouse O 0 0.0072144037
strains O 0 0.0090272175
. O 0 0.010512446

Mature O 0 0.030104069
male O 0 0.015142834
and O 0 0.005561377
female O 0 0.0071026497
mice O 0 0.0021474292
from O 0 0.0017802549
six O 0 0.0011356112
inbred O 0 0.0020669028
stains O 0 0.0036161798
were O 0 0.00094357965
tested O 0 0.0006231967
for O 0 0.00062452717
susceptibility O 0 0.001970484
to O 0 0.001025504
behavioral O 0 0.32844463
seizures B-Disease 2 0.9999745
induced O 0 0.0021911846
by O 0 0.0018485683
a O 0 0.0021315536
single O 0 0.0021272677
injection O 0 0.0063298456
of O 0 0.008276211
cocaine B-Chemical 1 0.9997775
. O 0 0.011423404

Cocaine B-Chemical 1 0.99961436
was O 0 0.006570863
injected O 0 0.0038252648
ip O 0 0.27630267
over O 0 0.0014135427
a O 0 0.0016733826
range O 0 0.0014956653
of O 0 0.0013383031
doses O 0 0.041438665
( O 0 0.0019759492
50 O 0 0.0015419922
- O 0 0.0012327941
100 O 0 0.0011764975
mg O 0 0.121685594
/ O 0 0.0019195946
kg O 0 0.004319564
) O 0 0.0015660804
and O 0 0.0010858016
behavior O 0 0.0024514555
was O 0 0.0012790728
monitored O 0 0.0011064654
for O 0 0.0018234644
20 O 0 0.0032729157
minutes O 0 0.0041046105
. O 0 0.0067347265

Seizure B-Disease 2 0.99532926
end O 0 0.0055302926
points O 0 0.0044658864
included O 0 0.00260003
latency O 0 0.0037041174
to O 0 0.0017189891
forelimb O 0 0.2515049
or O 0 0.0015814429
hindlimb O 0 0.6770163
clonus O 0 0.9997805
, O 0 0.0025530872
latency O 0 0.004657917
to O 0 0.0013749184
clonic O 0 0.9998983
running O 0 0.033614956
seizure B-Disease 2 0.9996592
and O 0 0.00251927
latency O 0 0.006189927
to O 0 0.0028939287
jumping O 0 0.5299593
bouncing O 0 0.51035655
seizure B-Disease 2 0.99944216
. O 0 0.01184704

A O 0 0.028166138
range O 0 0.0070125028
of O 0 0.00437681
strain O 0 0.0026276181
specific O 0 0.0018814639
sensitivities O 0 0.002513316
was O 0 0.0015557982
documented O 0 0.0018515764
with O 0 0.0015409149
A O 0 0.16897862
/ O 0 0.014008466
J O 0 0.84520644
and O 0 0.0017041179
SJL O 0 0.36127436
mice O 0 0.00087987195
being O 0 0.0014750831
most O 0 0.0015216141
sensitive O 0 0.0013508402
and O 0 0.002651817
C57BL O 0 0.9099348
/ O 0 0.017084029
6J O 0 0.109030664
most O 0 0.006262601
resistant O 0 0.008792957
. O 0 0.009359723

DBA O 0 0.94090676
/ O 0 0.04391699
2J O 0 0.81471187
, O 0 0.01097188
BALB O 0 0.28860795
/ O 0 0.009334969
cByJ O 0 0.01083749
and O 0 0.004481295
NZW O 0 0.164775
/ O 0 0.0068621947
LacJ O 0 0.014002263
strains O 0 0.0039046807
exhibited O 0 0.00413252
intermediate O 0 0.010026246
sensitivity O 0 0.014238238
. O 0 0.011606503

EEG O 0 0.61906517
recordings O 0 0.015057416
were O 0 0.0052186926
made O 0 0.0037976545
in O 0 0.0032738396
SJL O 0 0.47090998
, O 0 0.0040725274
A O 0 0.075121514
/ O 0 0.008978489
J O 0 0.7904896
and O 0 0.002467726
C57BL O 0 0.8887567
/ O 0 0.0059640952
6J O 0 0.02622104
mice O 0 0.00082271354
revealing O 0 0.0014203388
a O 0 0.0012889323
close O 0 0.0010175118
correspondence O 0 0.0021757816
between O 0 0.001363542
electrical O 0 0.3426549
activity O 0 0.0041903043
and O 0 0.0056663416
behavior O 0 0.023783598
. O 0 0.009421107

Additionally O 0 0.010108492
, O 0 0.006968565
levels O 0 0.003643431
of O 0 0.0041398
cocaine B-Chemical 1 0.99974996
determined O 0 0.0020648164
in O 0 0.0019468248
hippocampus O 0 0.26740047
and O 0 0.0020073566
cortex O 0 0.084126055
were O 0 0.001091228
not O 0 0.0009442294
different O 0 0.0010445849
between O 0 0.0011616078
sensitive O 0 0.0020261267
and O 0 0.0035210066
resistant O 0 0.005577613
strains O 0 0.007988799
. O 0 0.009394337

Additional O 0 0.0069078733
studies O 0 0.005490836
of O 0 0.004138368
these O 0 0.0034707384
murine O 0 0.0054646702
strains O 0 0.002384863
may O 0 0.0016045527
be O 0 0.0013312699
useful O 0 0.0011441889
for O 0 0.0008051593
investigating O 0 0.0010184958
genetic O 0 0.002857796
influences O 0 0.0019703112
on O 0 0.00220924
cocaine B-Chemical 1 0.9999255
- O 0 0.039256737
induced O 0 0.021782106
seizures B-Disease 2 0.999907
. O 0 0.013866556

Hypotension B-Disease 2 0.99727744
following O 0 0.0058247345
the O 0 0.0037400671
initiation O 0 0.0030526533
of O 0 0.0035791525
tizanidine B-Chemical 0 0.99996674
in O 0 0.0019026126
a O 0 0.0019229237
patient O 0 0.0019254395
treated O 0 0.0016243305
with O 0 0.0017059923
an O 0 0.005729339
angiotensin B-Chemical 1 0.9999366
converting O 0 0.6907261
enzyme O 0 0.54573154
inhibitor O 0 0.33772308
for O 0 0.0046495833
chronic O 0 0.9965354
hypertension B-Disease 2 0.9999074
. O 0 0.015724974

Centrally O 0 0.9415144
acting O 0 0.034406736
alpha O 0 0.6053739
- O 0 0.00826279
2 O 0 0.0029152317
adrenergic O 0 0.9947119
agonists O 0 0.8388787
are O 0 0.0012635298
one O 0 0.0006651899
of O 0 0.0007622136
several O 0 0.00071972946
pharmacologic O 0 0.23470381
agents O 0 0.15564743
used O 0 0.00063448603
in O 0 0.0005175398
the O 0 0.0005550499
treatment O 0 0.0010449562
of O 0 0.0016240536
spasticity B-Disease 0 0.99994195
related O 0 0.0009091313
to O 0 0.001221443
disorders B-Disease 0 0.81950283
of I-Disease 0 0.002250941
the I-Disease 0 0.0025111695
central I-Disease 0 0.014211033
nervous I-Disease 0 0.97587
system I-Disease 0 0.013603926
. O 0 0.008999303

In O 0 0.007838169
addition O 0 0.0043753264
to O 0 0.0038362262
their O 0 0.0033774565
effects O 0 0.0039260373
on O 0 0.00246488
spasticity B-Disease 0 0.9998728
, O 0 0.003930558
certain O 0 0.0031053703
adverse O 0 0.95751905
cardiorespiratory O 0 0.9517152
effects O 0 0.0076313685
have O 0 0.003955764
been O 0 0.0058003366
reported O 0 0.00856799
. O 0 0.009668937

Adults O 0 0.036986858
chronically O 0 0.019779533
treated O 0 0.006253379
with O 0 0.006056801
angiotensin B-Chemical 1 0.99987197
converting O 0 0.7284513
enzyme O 0 0.4711813
inhibitors O 0 0.1399053
may O 0 0.0010614046
have O 0 0.00068506354
a O 0 0.0008873724
limited O 0 0.0005516449
ability O 0 0.00060511124
to O 0 0.00058557064
respond O 0 0.0007115215
to O 0 0.0009812878
hypotension B-Disease 2 0.9999261
when O 0 0.0009307416
the O 0 0.0014809071
sympathetic O 0 0.9126708
response O 0 0.0030685398
is O 0 0.0029748487
simultaneously O 0 0.0046392577
blocked O 0 0.010345972
. O 0 0.008878158

The O 0 0.007143567
authors O 0 0.004921964
present O 0 0.0030137214
a O 0 0.003558486
10 O 0 0.0025828416
- O 0 0.0026318603
year O 0 0.0014662384
- O 0 0.0016453892
old O 0 0.0011614773
boy O 0 0.0044271066
chronically O 0 0.01787545
treated O 0 0.0015238834
with O 0 0.002263189
lisinopril B-Chemical 0 0.9999932
, O 0 0.004740446
an O 0 0.003944485
angiotensin B-Chemical 1 0.9999664
converting O 0 0.5683278
enzyme O 0 0.41793278
inhibitor O 0 0.19224891
, O 0 0.0011075422
to O 0 0.00040577567
control O 0 0.00061832817
hypertension B-Disease 2 0.9999156
who O 0 0.0030151885
developed O 0 0.0017493955
hypotension B-Disease 2 0.99996245
following O 0 0.0005155486
the O 0 0.00041209077
addition O 0 0.00028911704
of O 0 0.0012879439
tizanidine B-Chemical 0 0.9999937
, O 0 0.0017755292
an O 0 0.0014355015
alpha O 0 0.3941309
- O 0 0.0025083618
2 O 0 0.0010470838
agonist O 0 0.551707
, O 0 0.0016057747
for O 0 0.0010271682
the O 0 0.0016843862
treatment O 0 0.0040797377
of O 0 0.009482443
spasticity B-Disease 0 0.9998266
. O 0 0.011182412

The O 0 0.0065418733
possible O 0 0.004523454
interaction O 0 0.0035135343
of O 0 0.004111462
tizanidine B-Chemical 0 0.99996614
and O 0 0.0030774144
other O 0 0.0017781509
antihypertensive O 0 0.99538475
agents O 0 0.2631942
should O 0 0.00054484955
be O 0 0.00061760726
kept O 0 0.00040195975
in O 0 0.00048101746
mind O 0 0.0009799835
when O 0 0.00040533452
prescribing O 0 0.010160225
therapy O 0 0.0028382863
to O 0 0.00067076075
treat O 0 0.0032441835
either O 0 0.0022576808
hypertension B-Disease 2 0.9999411
or O 0 0.0049178507
spasticity B-Disease 0 0.99991167
in O 0 0.0031179728
such O 0 0.004391613
patients O 0 0.025919365
. O 0 0.008550627

Two O 0 0.008850249
mouse O 0 0.0064091054
lines O 0 0.0064975866
selected O 0 0.002258189
for O 0 0.0014917082
differential O 0 0.0020869044
sensitivities O 0 0.0022961588
to O 0 0.0016057908
beta B-Chemical 0 0.97223973
- I-Chemical 0 0.034306195
carboline I-Chemical 0 0.99938416
- O 0 0.010837032
induced O 0 0.0022672694
seizures B-Disease 2 0.99998343
are O 0 0.0008938952
also O 0 0.0005949711
differentially O 0 0.0006193131
sensitive O 0 0.0004699839
to O 0 0.0004678469
various O 0 0.0010578735
pharmacological O 0 0.3026351
effects O 0 0.0027321072
of O 0 0.0021468839
other O 0 0.006414361
GABA B-Chemical 1 0.9999714
( O 0 0.009707313
A O 0 0.2952734
) O 0 0.010260818
receptor O 0 0.17710382
ligands O 0 0.2521376
. O 0 0.010211262

Two O 0 0.009379604
mouse O 0 0.00719496
lines O 0 0.009212826
were O 0 0.0031639512
selectively O 0 0.0033668957
bred O 0 0.0037060815
according O 0 0.0011996574
to O 0 0.0009372244
their O 0 0.0010982224
sensitivity O 0 0.0028929089
( O 0 0.002405331
BS O 0 0.9654379
line O 0 0.002871871
) O 0 0.0017453764
or O 0 0.00066305936
resistance O 0 0.007824328
( O 0 0.0017715506
BR O 0 0.76468545
line O 0 0.0022848023
) O 0 0.0015628977
to O 0 0.0006195911
seizures B-Disease 2 0.99997425
induced O 0 0.0008271647
by O 0 0.00063445704
a O 0 0.00063892675
single O 0 0.00049907214
i O 0 0.002170421
. O 0 0.0003466777
p O 0 0.0005725264
. O 0 0.00030117517
injection O 0 0.00095560943
of O 0 0.0011191869
methyl B-Chemical 0 0.9950304
beta I-Chemical 0 0.9928404
- I-Chemical 0 0.041790858
carboline I-Chemical 0 0.9993543
- I-Chemical 0 0.006405772
3 I-Chemical 0 0.0007872146
- I-Chemical 0 0.0017054506
carboxylate I-Chemical 0 0.94701535
( O 0 0.0038238112
beta B-Chemical 0 0.9377031
- I-Chemical 0 0.0077673905
CCM I-Chemical 0 0.9834999
) O 0 0.0021296376
, O 0 0.0007858183
an O 0 0.00071395625
inverse O 0 0.0011224026
agonist O 0 0.74779576
of O 0 0.0017791544
the O 0 0.0029377297
GABA B-Chemical 1 0.9999703
( O 0 0.0064476565
A O 0 0.25581896
) O 0 0.009155774
receptor O 0 0.39680266
benzodiazepine B-Chemical 1 0.99984
site O 0 0.008574922
. O 0 0.008983069

Our O 0 0.007899339
aim O 0 0.0060894005
was O 0 0.0037051432
to O 0 0.0023289896
characterize O 0 0.0013750076
both O 0 0.0016396224
lines O 0 0.0064364616
' O 0 0.0016559329
sensitivities O 0 0.0012813311
to O 0 0.00073193887
various O 0 0.0011585486
physiological O 0 0.0023516405
effects O 0 0.0015706365
of O 0 0.0012013968
other O 0 0.0012956724
ligands O 0 0.08082448
of O 0 0.0027861625
the O 0 0.004683589
GABA B-Chemical 1 0.99995255
( O 0 0.010463358
A O 0 0.28505182
) O 0 0.012542145
receptor O 0 0.14192952
. O 0 0.0097200405

We O 0 0.008653884
measured O 0 0.006176723
diazepam B-Chemical 1 0.999925
- O 0 0.015668243
induced O 0 0.0040822476
anxiolysis O 0 0.9991222
with O 0 0.0018905624
the O 0 0.001198739
elevated O 0 0.0039431546
plus O 0 0.0011028501
- O 0 0.0021635692
maze O 0 0.022728749
test O 0 0.00095607206
, O 0 0.0019108214
diazepam B-Chemical 1 0.9999926
- O 0 0.002355392
induced O 0 0.0006577824
sedation O 0 0.6168533
by O 0 0.0005055995
recording O 0 0.0008083767
the O 0 0.00042507803
vigilance O 0 0.080509566
states O 0 0.0019654676
, O 0 0.0012578946
and O 0 0.0019869257
picrotoxin B-Chemical 1 0.99999666
- O 0 0.014868069
and O 0 0.0033858293
pentylenetetrazol B-Chemical 0 0.9999981
- O 0 0.014763204
induced O 0 0.002542343
seizures B-Disease 2 0.99996674
after O 0 0.0010208179
i O 0 0.0058207847
. O 0 0.0015869214
p O 0 0.0030057214
. O 0 0.0029114734
injections O 0 0.0115578
. O 0 0.0075623174

Results O 0 0.010793075
presented O 0 0.005625814
here O 0 0.003425587
show O 0 0.00208679
that O 0 0.0015333433
the O 0 0.0013510898
differential O 0 0.0017554832
sensitivities O 0 0.0019021544
of O 0 0.0020563742
BS O 0 0.9848087
and O 0 0.0021862586
BR O 0 0.88978213
lines O 0 0.020941388
to O 0 0.0009885568
beta B-Chemical 0 0.9512148
- I-Chemical 0 0.0073016547
CCM I-Chemical 0 0.9554556
can O 0 0.0004655673
be O 0 0.00049133156
extended O 0 0.0004067045
to O 0 0.00066816434
diazepam B-Chemical 1 0.99999523
, O 0 0.018155916
picrotoxin B-Chemical 1 0.99999714
, O 0 0.0041112155
and O 0 0.0019009563
pentylenetetrazol B-Chemical 0 0.9999981
, O 0 0.0013911779
suggesting O 0 0.00035968298
a O 0 0.00060301524
genetic O 0 0.00093832833
selection O 0 0.00055417395
of O 0 0.0005302515
a O 0 0.000687155
general O 0 0.0005322801
sensitivity O 0 0.0011005988
and O 0 0.00074831775
resistance O 0 0.0017813137
to O 0 0.00058852095
several O 0 0.0008561829
ligands O 0 0.03382469
of O 0 0.0022327874
the O 0 0.0039897272
GABA B-Chemical 1 0.99995065
( O 0 0.009575666
A O 0 0.27425823
) O 0 0.012172934
receptor O 0 0.13868704
. O 0 0.009559544

Propylthiouracil B-Chemical 0 0.9993273
- O 0 0.017034918
induced O 0 0.006030615
perinuclear O 0 0.0086189695
- O 0 0.0046607293
staining O 0 0.0028443309
antineutrophil O 0 0.89409333
cytoplasmic O 0 0.0055873864
autoantibody O 0 0.94780993
- O 0 0.0070397523
positive O 0 0.0034939272
vasculitis B-Disease 2 0.9998234
in O 0 0.00401148
conjunction O 0 0.0058271238
with O 0 0.00902045
pericarditis B-Disease 2 0.9994198
. O 0 0.015247668

OBJECTIVE O 0 0.3964997
: O 0 0.009438206
To O 0 0.0042575193
describe O 0 0.0035199947
a O 0 0.0038937095
case O 0 0.0032313466
of O 0 0.005841126
propylthiouracil B-Chemical 1 0.99995494
- O 0 0.047949176
induced O 0 0.010907723
vasculitis B-Disease 2 0.9999205
manifesting O 0 0.98322034
with O 0 0.047911465
pericarditis B-Disease 2 0.9995944
. O 0 0.019645901

METHODS O 0 0.010600323
: O 0 0.007022208
We O 0 0.003387777
present O 0 0.0019229109
the O 0 0.0017123397
first O 0 0.001227222
case O 0 0.0012406572
report O 0 0.0020681422
of O 0 0.0012535152
a O 0 0.0015853551
woman O 0 0.05414168
with O 0 0.002481783
hyperthyroidism B-Disease 2 0.99997306
treated O 0 0.00434828
with O 0 0.0026920382
propylthiouracil B-Chemical 1 0.9999783
in O 0 0.0010253545
whom O 0 0.0040554334
a O 0 0.0015843638
syndrome O 0 0.8329248
of O 0 0.0040939017
pericarditis B-Disease 2 0.9998919
, O 0 0.06094619
fever B-Disease 2 0.999881
, O 0 0.010019245
and O 0 0.008519382
glomerulonephritis B-Disease 2 0.99990106
developed O 0 0.05807679
. O 0 0.01158056

Serologic O 0 0.2222217
testing O 0 0.008774372
and O 0 0.0067684394
immunologic O 0 0.064689144
studies O 0 0.0047452133
were O 0 0.0033375141
done O 0 0.0025428096
, O 0 0.0030488493
and O 0 0.002719079
a O 0 0.0036240055
pericardial O 0 0.20743036
biopsy O 0 0.02605545
was O 0 0.006209534
performed O 0 0.007493404
. O 0 0.010306086

RESULTS O 0 0.030021187
: O 0 0.010919622
A O 0 0.017971562
25 O 0 0.005759288
- O 0 0.0043808427
year O 0 0.0024254653
- O 0 0.0024185115
old O 0 0.0016483732
woman O 0 0.0064145196
with O 0 0.0016772591
Graves B-Disease 2 0.9936433
' I-Disease 2 0.002666084
disease I-Disease 2 0.82723254
had O 0 0.0010102753
a O 0 0.0020037813
febrile B-Disease 0 0.999413
illness I-Disease 0 0.9974245
and O 0 0.0015386714
evidence O 0 0.0011487271
of O 0 0.0024602108
pericarditis B-Disease 2 0.99977237
, O 0 0.0048729223
which O 0 0.0026053872
was O 0 0.0022942026
confirmed O 0 0.0029657376
by O 0 0.0052024163
biopsy O 0 0.042010915
. O 0 0.009566973

Serologic O 0 0.15665796
evaluation O 0 0.007039339
revealed O 0 0.0041975114
the O 0 0.0029419006
presence O 0 0.0021545168
of O 0 0.002508764
perinuclear O 0 0.0052603437
- O 0 0.002850621
staining O 0 0.0017598303
antineutrophil O 0 0.9253642
cytoplasmic O 0 0.0044670627
autoantibodies O 0 0.83313924
( O 0 0.006230243
pANCA O 0 0.33946753
) O 0 0.005094522
against O 0 0.0027771771
myeloperoxidase O 0 0.996911
( O 0 0.03009392
MPO O 0 0.995301
) O 0 0.021392602
. O 0 0.009614027

Propylthiouracil B-Chemical 0 0.9989768
therapy O 0 0.051762972
was O 0 0.004539345
withdrawn O 0 0.009054785
, O 0 0.0028082738
and O 0 0.0017218284
she O 0 0.0013168651
was O 0 0.0010245909
treated O 0 0.0010890606
with O 0 0.0009846837
a O 0 0.0013768642
1 O 0 0.0010768669
- O 0 0.0010858297
month O 0 0.0005713783
course O 0 0.0009441709
of O 0 0.0018313951
prednisone B-Chemical 1 0.9997931
, O 0 0.003919205
which O 0 0.0037843697
alleviated O 0 0.27290922
her O 0 0.019429797
symptoms O 0 0.9442538
. O 0 0.010445471

A O 0 0.032077752
literature O 0 0.008091859
review O 0 0.0053061894
revealed O 0 0.0026759822
no O 0 0.0016453116
prior O 0 0.0012751586
reports O 0 0.0018266767
of O 0 0.0021836283
pericarditis B-Disease 2 0.9995908
in O 0 0.0022224677
anti O 0 0.10585811
- O 0 0.01550324
MPO O 0 0.99495846
pANCA O 0 0.4743451
- O 0 0.0031861297
positive O 0 0.0018892464
vasculitis B-Disease 2 0.99988616
associated O 0 0.004981634
with O 0 0.0051423325
propylthio B-Chemical 0 0.93193376
- I-Chemical 0 0.029801792
uracil I-Chemical 0 0.9130298
therapy O 0 0.1315252
. O 0 0.009406166

CONCLUSION O 0 0.8663734
: O 0 0.016908398
Pericarditis B-Disease 0 0.9974643
may O 0 0.003996995
be O 0 0.0024911938
the O 0 0.0016768497
initial O 0 0.0015555891
manifestation O 0 0.06639545
of O 0 0.0026235287
drug O 0 0.90638936
- O 0 0.007826687
induced O 0 0.0028940386
vasculitis B-Disease 2 0.99991035
attributable O 0 0.003100164
to O 0 0.0032596241
propylthio B-Chemical 0 0.9020252
- I-Chemical 0 0.024701744
uracil I-Chemical 0 0.90522856
therapy O 0 0.12858486
. O 0 0.009560845

Repeated O 0 0.031999968
transient O 0 0.08461047
anuria B-Disease 2 0.9986432
following O 0 0.009033609
losartan B-Chemical 1 0.9998863
administration O 0 0.3016468
in O 0 0.003214719
a O 0 0.0039211996
patient O 0 0.004499969
with O 0 0.0042353463
a O 0 0.007457939
solitary O 0 0.32562345
kidney O 0 0.9549554
. O 0 0.014332644

We O 0 0.007902883
report O 0 0.006887394
the O 0 0.0034986322
case O 0 0.0025765658
of O 0 0.0022304305
a O 0 0.002288525
70 O 0 0.0018917703
- O 0 0.0018552833
year O 0 0.0010509344
- O 0 0.0013636954
old O 0 0.0011649445
hypertensive B-Disease 2 0.99818665
man O 0 0.14672044
with O 0 0.0008820149
a O 0 0.0011611141
solitary O 0 0.099213846
kidney O 0 0.91912585
and O 0 0.0022077868
chronic B-Disease 0 0.9949537
renal I-Disease 0 0.9992132
insufficiency I-Disease 0 0.9996574
who O 0 0.0051762424
developed O 0 0.0011759531
two O 0 0.0007410315
episodes O 0 0.16100201
of O 0 0.0018865033
transient O 0 0.23575817
anuria B-Disease 2 0.9997639
after O 0 0.0038000399
losartan B-Chemical 1 0.9999305
administration O 0 0.6559596
. O 0 0.010449493

He O 0 0.016604224
was O 0 0.0069090314
hospitalized O 0 0.016193084
for O 0 0.003207265
a O 0 0.005333202
myocardial B-Disease 0 0.9997358
infarction I-Disease 2 0.99998176
with O 0 0.0059166728
pulmonary B-Disease 0 0.99242836
edema I-Disease 2 0.9999459
, O 0 0.00555553
treated O 0 0.0027542673
with O 0 0.0025736906
high O 0 0.0041125356
- O 0 0.008276345
dose O 0 0.18342383
diuretics O 0 0.99967766
. O 0 0.01220004

Due O 0 0.018783314
to O 0 0.014363902
severe O 0 0.38764876
systolic B-Disease 0 0.99387026
dysfunction I-Disease 0 0.9987669
losartan B-Chemical 1 0.9998715
was O 0 0.019726936
prescribed O 0 0.18277463
. O 0 0.017106984

Surprisingly O 0 0.008405315
, O 0 0.0057755047
the O 0 0.0029878633
first O 0 0.0019084857
dose O 0 0.0042458544
of O 0 0.0018387634
50 O 0 0.0020744265
mg O 0 0.33878598
of O 0 0.0020306413
losartan B-Chemical 1 0.9999591
resulted O 0 0.0008366745
in O 0 0.00065386225
a O 0 0.0012904461
sudden O 0 0.997051
anuria B-Disease 2 0.9998565
, O 0 0.0013993316
which O 0 0.00068210973
lasted O 0 0.0004840352
eight O 0 0.00037646145
hours O 0 0.0004063751
despite O 0 0.00059109845
high O 0 0.0012641461
- O 0 0.0026004529
dose O 0 0.06494529
furosemide B-Chemical 1 0.99995697
and O 0 0.013986947
amine B-Chemical 0 0.9988632
infusion O 0 0.24839418
. O 0 0.009267717

One O 0 0.010251311
week O 0 0.0047690757
later O 0 0.0035579451
, O 0 0.0035541398
by O 0 0.002722378
mistake O 0 0.04802403
, O 0 0.0036581582
losartan B-Chemical 1 0.99992347
was O 0 0.0012179288
prescribed O 0 0.0057952604
again O 0 0.0006667394
and O 0 0.00053507934
after O 0 0.0002768465
the O 0 0.00036565223
second O 0 0.0004003274
dose O 0 0.0020037948
of O 0 0.0006405397
50 O 0 0.0010190635
mg O 0 0.22549368
, O 0 0.00065997016
the O 0 0.0004209986
patient O 0 0.00072197855
developed O 0 0.0007524498
a O 0 0.0008385869
second O 0 0.00077198585
episode O 0 0.005551147
of O 0 0.0017132357
transient O 0 0.16506366
anuria B-Disease 2 0.99962246
lasting O 0 0.010809232
10 O 0 0.004349034
hours O 0 0.0042994553
. O 0 0.00688784

During O 0 0.007056932
these O 0 0.005802598
two O 0 0.0041154977
episodes O 0 0.12454092
, O 0 0.0042038504
his O 0 0.003507626
blood O 0 0.009027785
pressure O 0 0.049262848
diminished O 0 0.0029075409
but O 0 0.0020659294
no O 0 0.0021386722
severe O 0 0.6966548
hypotension B-Disease 2 0.99991846
was O 0 0.0076855198
noted O 0 0.007399812
. O 0 0.009824491

Ultimately O 0 0.023407416
, O 0 0.010792048
an O 0 0.0082371505
arteriography O 0 0.049260575
showed O 0 0.004445272
a O 0 0.005173287
70 O 0 0.004728883
- O 0 0.0051691732
80 O 0 0.0045405193
% O 0 0.0061777127
renal B-Disease 0 0.98256344
artery I-Disease 0 0.7567495
stenosis I-Disease 0 0.99631304
. O 0 0.015167194

In O 0 0.00727914
this O 0 0.005090222
patient O 0 0.0054251854
, O 0 0.0043343897
renal B-Disease 0 0.98161834
artery I-Disease 0 0.61494327
stenosis I-Disease 0 0.9972817
combined O 0 0.0024243155
with O 0 0.0013527257
heart B-Disease 0 0.7811729
failure I-Disease 0 0.74015826
and O 0 0.0019133914
diuretic O 0 0.9999329
therapy O 0 0.030549651
certainly O 0 0.0010652357
resulted O 0 0.0005036627
in O 0 0.0005213288
a O 0 0.0008121708
strong O 0 0.00087550556
activation O 0 0.0015844685
of O 0 0.0013355236
the O 0 0.0018981718
renin O 0 0.99793243
- O 0 0.0384021
angiotensin B-Chemical 1 0.99987376
system O 0 0.02033851
( O 0 0.015000003
RAS O 0 0.9834554
) O 0 0.01622547
. O 0 0.008662949

Under O 0 0.014256863
such O 0 0.006984309
conditions O 0 0.0077582593
, O 0 0.011213939
angiotensin B-Chemical 1 0.9999205
II I-Chemical 1 0.91890424
receptor O 0 0.57600623
blockade O 0 0.69773847
by O 0 0.0049136756
losartan B-Chemical 1 0.9999589
probably O 0 0.00483043
induced O 0 0.001833696
a O 0 0.0021558704
critical O 0 0.0016080085
fall O 0 0.0042548077
in O 0 0.0025369783
glomerular O 0 0.8755022
filtration O 0 0.09231436
pressure O 0 0.20861037
. O 0 0.009325696

This O 0 0.009629704
case O 0 0.0051277652
report O 0 0.005028182
highlights O 0 0.0026212663
the O 0 0.0017881801
fact O 0 0.0011794908
that O 0 0.0011171344
the O 0 0.0020326383
angiotensin B-Chemical 1 0.99998176
II I-Chemical 1 0.96767443
receptor O 0 0.8324361
antagonist O 0 0.99840575
losartan B-Chemical 1 0.9999893
can O 0 0.0008529693
cause O 0 0.006895931
serious O 0 0.31869704
unexpected O 0 0.002842981
complications O 0 0.7172118
in O 0 0.0006772575
patients O 0 0.0043169237
with O 0 0.0012842346
renovascular B-Disease 0 0.99998105
disease I-Disease 0 0.99057543
and O 0 0.0015385404
should O 0 0.0005331279
be O 0 0.0007833601
used O 0 0.00077084464
with O 0 0.0011223701
extreme O 0 0.0024939126
caution O 0 0.002157731
in O 0 0.002274685
this O 0 0.0034516132
setting O 0 0.0062095136
. O 0 0.0077235755

Calcineurin O 0 0.97602886
- O 0 0.017729715
inhibitor O 0 0.076508306
induced O 0 0.009048498
pain B-Disease 2 0.99942976
syndrome O 0 0.99464464
( O 0 0.058155015
CIPS B-Disease 0 0.9995896
) O 0 0.009596039
: O 0 0.002905827
a O 0 0.0025738531
severe O 0 0.3281438
disabling O 0 0.98707193
complication O 0 0.735293
after O 0 0.003243666
organ O 0 0.39590245
transplantation O 0 0.5813939
. O 0 0.011085095

Bone O 0 0.42638
pain B-Disease 2 0.99004436
after O 0 0.004687954
transplantation O 0 0.045295265
is O 0 0.0030966029
a O 0 0.0030969528
frequent O 0 0.0052218447
complication O 0 0.31436104
that O 0 0.0020575467
can O 0 0.002048982
be O 0 0.0026223573
caused O 0 0.0033839825
by O 0 0.0048727323
several O 0 0.006735636
diseases O 0 0.9077027
. O 0 0.013532383

Treatment O 0 0.0285489
strategies O 0 0.011013073
depend O 0 0.0069218487
on O 0 0.004783376
the O 0 0.005097012
correct O 0 0.005731926
diagnosis O 0 0.013626204
of O 0 0.009179641
the O 0 0.012418824
pain B-Disease 2 0.99783593
. O 0 0.01778847

Nine O 0 0.0156147005
patients O 0 0.01030101
with O 0 0.005819929
severe O 0 0.31241846
pain B-Disease 2 0.9974905
in O 0 0.0028137444
their O 0 0.0026129496
feet O 0 0.11411089
, O 0 0.002505351
which O 0 0.0017755716
was O 0 0.0014308842
registered O 0 0.0018225688
after O 0 0.0013649013
transplantation O 0 0.06237114
, O 0 0.0045023705
were O 0 0.00426944
investigated O 0 0.0053522806
. O 0 0.00899304

Bone O 0 0.1455168
scans O 0 0.018482374
showed O 0 0.007506562
an O 0 0.008151027
increased O 0 0.007063912
tracer O 0 0.021384118
uptake O 0 0.014983132
of O 0 0.007327595
the O 0 0.008397851
foot O 0 0.29853365
bones O 0 0.37770486
. O 0 0.016671963

Magnetic O 0 0.88610727
resonance O 0 0.2362657
imaging O 0 0.024215464
demonstrated O 0 0.010369977
bone B-Disease 0 0.42541218
marrow I-Disease 0 0.9439955
oedema I-Disease 0 0.9996369
in O 0 0.013110357
the O 0 0.013999546
painful O 0 0.9927892
bones O 0 0.6444779
. O 0 0.0203396

Pain B-Disease 2 0.9881136
was O 0 0.006421275
not O 0 0.0036560597
explained O 0 0.002664528
by O 0 0.002322454
other O 0 0.0020137401
diseases O 0 0.75909036
causing O 0 0.045087002
foot O 0 0.6886516
pain B-Disease 2 0.9997378
, O 0 0.0032276853
like O 0 0.0012574083
reflex B-Disease 0 0.97179496
sympathetic I-Disease 0 0.9951969
dystrophy I-Disease 0 0.9986879
, O 0 0.008776182
polyneuropathy B-Disease 2 0.99995923
, O 0 0.0039189965
Morton B-Disease 0 0.43778533
' I-Disease 0 0.0011749654
s I-Disease 0 0.0013966543
neuralgia I-Disease 0 0.9999865
, O 0 0.011588992
gout B-Disease 0 0.99999
, O 0 0.024876311
osteoporosis B-Disease 2 0.9999639
, O 0 0.013282264
avascular B-Disease 0 0.9969446
necrosis I-Disease 2 0.9999094
, O 0 0.0039024558
intermittent B-Disease 0 0.21119478
claudication I-Disease 0 0.9969043
, O 0 0.0017720205
orthopaedic O 0 0.011014502
foot B-Disease 0 0.22218654
deformities I-Disease 0 0.90903234
, O 0 0.008838395
stress B-Disease 0 0.97052675
fractures I-Disease 2 0.99952376
, O 0 0.023716385
and O 0 0.019947566
hyperparathyroidism B-Disease 0 0.9998926
. O 0 0.014439769

The O 0 0.0077438955
reduction O 0 0.0070625274
of O 0 0.0066905343
cyclosporine B-Chemical 1 0.9999553
- O 0 0.021781519
or O 0 0.002796905
tacrolimus B-Chemical 1 0.9999504
trough O 0 0.31445947
levels O 0 0.0010812228
and O 0 0.0010416533
the O 0 0.0008875029
administration O 0 0.05409834
of O 0 0.0029356328
calcium B-Chemical 1 0.9997309
channel O 0 0.77027434
blockers O 0 0.99933857
led O 0 0.0029585948
to O 0 0.0026171491
relief O 0 0.40506288
of O 0 0.0096037
pain B-Disease 2 0.9986314
. O 0 0.011407906

The O 0 0.013117683
Calcineurin O 0 0.9622669
- O 0 0.014899425
inhibitor O 0 0.22275384
Induced O 0 0.8821925
Pain B-Disease 2 0.9996929
Syndrome O 0 0.99620605
( O 0 0.011926288
CIPS B-Disease 0 0.99936336
) O 0 0.0032256474
is O 0 0.0007829686
a O 0 0.00092005543
rare O 0 0.0057768845
but O 0 0.00080560683
severe O 0 0.12732065
side O 0 0.07303323
effect O 0 0.00074819016
of O 0 0.0017629308
cyclosporine B-Chemical 1 0.9999932
or O 0 0.002653574
tacrolimus B-Chemical 1 0.9999851
and O 0 0.0013416217
is O 0 0.0006003813
accurately O 0 0.0005290706
diagnosed O 0 0.005942134
by O 0 0.00073337194
its O 0 0.0010835682
typical O 0 0.0011098186
presentation O 0 0.006381566
, O 0 0.002586088
magnetic O 0 0.15734392
resonance O 0 0.2944154
imaging O 0 0.009045078
and O 0 0.004438954
bone O 0 0.35187596
scans O 0 0.06626755
. O 0 0.010156781

Incorrect O 0 0.054769687
diagnosis O 0 0.011974179
of O 0 0.005086775
the O 0 0.0037965472
syndrome O 0 0.70825046
will O 0 0.00209006
lead O 0 0.008825178
to O 0 0.0012709396
a O 0 0.0015451853
significant O 0 0.0013142345
reduction O 0 0.0017129332
of O 0 0.0016111243
life O 0 0.003364084
quality O 0 0.0017470171
in O 0 0.002064135
patients O 0 0.012228919
suffering O 0 0.95872766
from O 0 0.014261366
CIPS B-Disease 0 0.9988164
. O 0 0.012466847

Brain O 0 0.6788722
natriuretic O 0 0.97018605
peptide O 0 0.019730939
is O 0 0.0069212914
a O 0 0.0063024503
predictor O 0 0.0045949235
of O 0 0.008433228
anthracycline B-Chemical 1 0.99976856
- O 0 0.0870227
induced O 0 0.0459095
cardiotoxicity B-Disease 2 0.99993765
. O 0 0.022498688

Anthracyclines B-Chemical 0 0.99733293
are O 0 0.008913102
effective O 0 0.0066059423
antineoplastic O 0 0.9545374
drugs O 0 0.94889635
, O 0 0.005298687
but O 0 0.0023476747
they O 0 0.0020717485
frequently O 0 0.0031858843
cause O 0 0.009571171
dose O 0 0.13063508
- O 0 0.011896173
related O 0 0.0066945185
cardiotoxicity B-Disease 2 0.999931
. O 0 0.014562284

The O 0 0.009718659
cardiotoxicity B-Disease 2 0.9996313
of O 0 0.006188953
conventional O 0 0.0048995996
anthracycline B-Chemical 1 0.99962234
therapy O 0 0.04422122
highlights O 0 0.001688731
a O 0 0.0014466757
need O 0 0.000723257
to O 0 0.00062008534
search O 0 0.00062986574
for O 0 0.00048976287
methods O 0 0.00069088634
that O 0 0.0005772463
are O 0 0.00081649335
highly O 0 0.0010360978
sensitive O 0 0.0009082482
and O 0 0.00132542
capable O 0 0.0017819427
of O 0 0.0024216403
predicting O 0 0.004027953
cardiac B-Disease 2 0.9902761
dysfunction I-Disease 2 0.9976793
. O 0 0.011521392

We O 0 0.007528553
measured O 0 0.0041652825
the O 0 0.0034992706
plasma O 0 0.0072326916
level O 0 0.0017505175
of O 0 0.0023451585
brain O 0 0.2665205
natriuretic O 0 0.9976483
peptide O 0 0.07033605
( O 0 0.008653515
BNP O 0 0.99732625
) O 0 0.001688202
to O 0 0.0004512687
determine O 0 0.00026403138
whether O 0 0.00033339983
BNP O 0 0.9860277
might O 0 0.00034532824
serve O 0 0.0005824407
as O 0 0.00042443746
a O 0 0.00055751443
simple O 0 0.00066924805
diagnostic O 0 0.0007304619
indicator O 0 0.0003924099
of O 0 0.0012347584
anthracycline B-Chemical 1 0.999967
- O 0 0.019521544
induced O 0 0.0031071021
cardiotoxicity B-Disease 2 0.9999956
in O 0 0.0009434506
patients O 0 0.01229782
with O 0 0.0019351855
acute B-Disease 0 0.99956197
leukemia I-Disease 0 0.9999906
treated O 0 0.010959132
with O 0 0.0020876762
a O 0 0.0078520505
daunorubicin B-Chemical 1 0.99993837
( O 0 0.024167834
DNR B-Chemical 0 0.9991447
) O 0 0.0075397408
- O 0 0.0043963315
containing O 0 0.003362436
regimen O 0 0.01339733
. O 0 0.007973776

Thirteen O 0 0.020702397
patients O 0 0.014371741
with O 0 0.009485185
acute B-Disease 0 0.9975745
leukemia I-Disease 0 0.9999124
were O 0 0.0071189413
treated O 0 0.005273439
with O 0 0.004416434
a O 0 0.008669758
DNR B-Chemical 0 0.99829584
- O 0 0.008990381
containing O 0 0.005552349
regimen O 0 0.020993024
. O 0 0.010685719

Cardiac O 0 0.5461487
functions O 0 0.012833712
were O 0 0.009108923
evaluated O 0 0.0069596847
with O 0 0.007898442
radionuclide O 0 0.18959229
angiography O 0 0.21665014
before O 0 0.008063243
chemotherapies O 0 0.69097406
. O 0 0.017061384

The O 0 0.00871079
plasma O 0 0.013238546
levels O 0 0.0044106534
of O 0 0.005036835
atrial O 0 0.9862563
natriuretic O 0 0.99757844
peptide O 0 0.10921678
( O 0 0.021040155
ANP O 1 0.99973744
) O 0 0.0054571494
and O 0 0.002059453
BNP O 0 0.9788493
were O 0 0.0012597278
measured O 0 0.0008980587
at O 0 0.0009948915
the O 0 0.001362901
time O 0 0.0016826735
of O 0 0.003491753
radionuclide O 0 0.38935345
angiography O 0 0.35849866
. O 0 0.009095839

Three O 0 0.012872336
patients O 0 0.012237181
developed O 0 0.0101355575
congestive B-Disease 0 0.9996306
heart I-Disease 0 0.87366337
failure I-Disease 0 0.55026805
after O 0 0.003203316
the O 0 0.0038842259
completion O 0 0.0038560631
of O 0 0.0073776077
chemotherapy O 0 0.8751474
. O 0 0.013407355

Five O 0 0.013296597
patients O 0 0.010003558
were O 0 0.005455072
diagnosed O 0 0.009150714
as O 0 0.0033339742
having O 0 0.003680722
subclinical O 0 0.78247005
heart B-Disease 0 0.82363355
failure I-Disease 0 0.5507669
after O 0 0.0018110676
the O 0 0.0025066468
completion O 0 0.0026614456
of O 0 0.005743743
chemotherapy O 0 0.879817
. O 0 0.011300927

The O 0 0.007799957
plasma O 0 0.0128986705
levels O 0 0.003705575
of O 0 0.0039671925
BNP O 0 0.97575605
in O 0 0.0016075646
all O 0 0.0010370011
the O 0 0.0008871453
patients O 0 0.001718877
with O 0 0.00078540575
clinical O 0 0.007383093
and O 0 0.0010465683
subclinical O 0 0.85786176
heart B-Disease 0 0.8758045
failure I-Disease 0 0.63816255
increased O 0 0.00073323806
above O 0 0.0003537546
the O 0 0.00041101503
normal O 0 0.0008161328
limit O 0 0.0007465495
( O 0 0.0007315942
40 O 0 0.00048381905
pg O 0 0.009163989
/ O 0 0.0013447867
ml O 0 0.0016748202
) O 0 0.00077784323
before O 0 0.0002659872
the O 0 0.0003940986
detection O 0 0.0005546015
of O 0 0.00076734286
clinical O 0 0.0058294036
or O 0 0.001296348
subclinical O 0 0.8834469
heart B-Disease 0 0.902539
failure I-Disease 0 0.79596746
by O 0 0.005053945
radionuclide O 0 0.5654516
angiography O 0 0.40389392
. O 0 0.008384267

On O 0 0.00883229
the O 0 0.0052320473
other O 0 0.003980445
hand O 0 0.004987511
, O 0 0.004509459
BNP O 0 0.9787336
did O 0 0.0014371359
not O 0 0.0009699262
increase O 0 0.00064976444
in O 0 0.00060458254
the O 0 0.0006021036
patients O 0 0.0014342592
without O 0 0.0006905928
heart B-Disease 0 0.6512687
failure I-Disease 0 0.55727583
given O 0 0.0007144259
DNR B-Chemical 0 0.9983626
, O 0 0.001038646
even O 0 0.0006180247
at O 0 0.00047374048
more O 0 0.00071268185
than O 0 0.00064521586
700 O 0 0.0027027242
mg O 0 0.19163196
/ O 0 0.0044006123
m O 0 0.009523685
( O 0 0.0043814713
2 O 0 0.0042962087
) O 0 0.007961325
. O 0 0.0074650757

The O 0 0.008469171
plasma O 0 0.013553774
level O 0 0.0039413944
of O 0 0.005264337
ANP O 1 0.9988226
did O 0 0.0022501037
not O 0 0.0014836206
always O 0 0.0012792465
increase O 0 0.00083100575
in O 0 0.0008339444
all O 0 0.00083180703
the O 0 0.0009591102
patients O 0 0.0023501755
with O 0 0.0015664233
clinical O 0 0.014213898
and O 0 0.003776495
subclinical O 0 0.94518536
heart B-Disease 0 0.96122116
failure I-Disease 0 0.92877555
. O 0 0.011253508

These O 0 0.009202286
preliminary O 0 0.00714813
results O 0 0.0042833057
suggest O 0 0.002624598
that O 0 0.0026345819
BNP O 0 0.9835782
may O 0 0.0019544596
be O 0 0.0014476726
useful O 0 0.0012064277
as O 0 0.0010337111
an O 0 0.0013808693
early O 0 0.0016633959
and O 0 0.0013381495
sensitive O 0 0.0010816606
indicator O 0 0.0012519037
of O 0 0.0039580213
anthracycline B-Chemical 1 0.99989915
- O 0 0.062816024
induced O 0 0.03407207
cardiotoxicity B-Disease 2 0.9999609
. O 0 0.016128484

Nephrotoxicity B-Disease 2 0.9960775
of O 0 0.02259416
combined O 0 0.029131887
cephalothin B-Chemical 1 0.9985208
- O 0 0.06787914
gentamicin B-Chemical 1 0.9973686
regimen O 0 0.13862823
. O 0 0.02166525

Two O 0 0.009258525
patients O 0 0.009583791
developed O 0 0.00741672
acute B-Disease 2 0.9910171
tubular I-Disease 2 0.9964205
necrosis I-Disease 2 0.99995804
, O 0 0.017100306
characterized O 0 0.004195622
clinically O 0 0.13813764
by O 0 0.002021602
acute O 0 0.98917997
oliguric B-Disease 0 0.9999701
renal I-Disease 0 0.9991998
failure I-Disease 0 0.94941944
, O 0 0.0015985683
while O 0 0.0005302126
they O 0 0.0004967187
were O 0 0.0005063103
receiving O 0 0.00082250906
a O 0 0.0008902716
combination O 0 0.0015145708
of O 0 0.0030804672
cephalothin B-Chemical 1 0.9999229
sodium I-Chemical 0 0.9999294
and O 0 0.027379317
gentamicin B-Chemical 1 0.99987125
sulfate I-Chemical 0 0.999642
therapy O 0 0.43551275
. O 0 0.011110644

Patients O 0 0.014320684
who O 0 0.0077294754
are O 0 0.003997395
given O 0 0.0022385716
this O 0 0.0021528567
drug O 0 0.20196183
regimen O 0 0.004282582
should O 0 0.0009911101
be O 0 0.0011586999
observed O 0 0.0008390048
very O 0 0.0013724118
carefully O 0 0.0012347138
for O 0 0.0014632221
early O 0 0.0041189855
signs O 0 0.4931898
of O 0 0.023937289
nephrotoxicity B-Disease 2 0.99995697
. O 0 0.016811157

High O 0 0.026991587
doses O 0 0.016647374
of O 0 0.0059723645
this O 0 0.0040816856
antibiotic O 0 0.06661262
combination O 0 0.005036888
should O 0 0.002088489
be O 0 0.0026305853
avoided O 0 0.0029909855
especially O 0 0.003912567
in O 0 0.004624199
elderly O 0 0.6157806
patients O 0 0.033003323
. O 0 0.010982963

Patients O 0 0.021962691
with O 0 0.012063902
renal B-Disease 0 0.9685525
insufficiency I-Disease 0 0.9908155
should O 0 0.0050513274
not O 0 0.0049817073
be O 0 0.0050341403
given O 0 0.0042423997
this O 0 0.0065998645
regimen O 0 0.020088963
. O 0 0.0127060795

In O 0 0.008183187
vivo O 0 0.0070512746
protection O 0 0.008845753
of O 0 0.0051300162
dna O 0 0.37624508
damage O 0 0.84915245
associated O 0 0.004611178
apoptotic O 0 0.84002364
and O 0 0.0030803008
necrotic B-Disease 2 0.9620444
cell O 0 0.13325374
deaths O 2 0.96918845
during O 0 0.0011811992
acetaminophen B-Chemical 1 0.9999974
- O 0 0.025844792
induced O 0 0.0052422746
nephrotoxicity B-Disease 2 0.99999774
, O 0 0.046924457
amiodarone B-Chemical 1 0.99999535
- O 0 0.01043321
induced O 0 0.0015307246
lung B-Disease 0 0.99163765
toxicity I-Disease 2 0.99994147
and O 0 0.015235425
doxorubicin B-Chemical 1 0.9999651
- O 0 0.019141657
induced O 0 0.003605927
cardiotoxicity B-Disease 2 0.9999914
by O 0 0.0022277369
a O 0 0.0025786185
novel O 0 0.0059846
IH636 B-Chemical 1 0.9957872
grape I-Chemical 1 0.98560053
seed I-Chemical 1 0.30803588
proanthocyanidin I-Chemical 1 0.9996555
extract I-Chemical 1 0.674519
. O 0 0.016071286

Grape B-Chemical 0 0.9863175
seed I-Chemical 0 0.028076246
extract I-Chemical 0 0.12112503
, O 0 0.0057179425
primarily O 0 0.003474575
a O 0 0.0026585106
mixture O 0 0.0038523246
of O 0 0.0037209094
proanthocyanidins B-Chemical 0 0.9999224
, O 0 0.0055992603
has O 0 0.00091291586
been O 0 0.0008389709
shown O 0 0.00048251453
to O 0 0.00049964007
modulate O 0 0.0004457743
a O 0 0.0009028083
wide O 0 0.0015218541
- O 0 0.0011841356
range O 0 0.0007699537
of O 0 0.0007437624
biological O 0 0.0019698725
, O 0 0.0014431936
pharmacological O 0 0.20129581
and O 0 0.0015844438
toxicological O 0 0.57032716
effects O 0 0.0038863628
which O 0 0.003044775
are O 0 0.0034374157
mainly O 0 0.008057997
cytoprotective O 0 0.9866887
. O 0 0.0109046465

This O 0 0.010114845
study O 0 0.00545209
assessed O 0 0.003011421
the O 0 0.0024494473
ability O 0 0.0020798785
of O 0 0.0030199212
IH636 B-Chemical 1 0.9954659
grape I-Chemical 1 0.9888242
seed I-Chemical 1 0.21541934
proanthocyanidin I-Chemical 1 0.99992037
extract I-Chemical 1 0.7852489
( O 0 0.15073086
GSPE B-Chemical 1 0.9999975
) O 0 0.019191867
to O 0 0.00089871173
prevent O 0 0.0020925712
acetaminophen B-Chemical 1 0.9999974
( O 0 0.027308045
AAP B-Chemical 1 0.9981906
) O 0 0.00977904
- O 0 0.0024027922
induced O 0 0.0016995376
nephrotoxicity B-Disease 2 0.9999969
, O 0 0.03134954
amiodarone B-Chemical 1 0.9999951
( O 0 0.030686207
AMI B-Chemical 1 0.9999845
) O 0 0.01053322
- O 0 0.0018568469
induced O 0 0.0010205426
lung B-Disease 0 0.98553574
toxicity I-Disease 2 0.9999286
, O 0 0.0058482187
and O 0 0.0026192425
doxorubicin B-Chemical 1 0.9999211
( O 0 0.02398502
DOX B-Chemical 1 0.99989974
) O 0 0.01577968
- O 0 0.004926948
induced O 0 0.004609338
cardiotoxicity B-Disease 2 0.9999658
in O 0 0.0054021273
mice O 0 0.005688922
. O 0 0.008740569

Experimental O 0 0.014138589
design O 0 0.0080176275
consisted O 0 0.0037195438
of O 0 0.0030298366
four O 0 0.0018830048
groups O 0 0.0023392518
: O 0 0.0022227967
control O 0 0.0013591859
( O 0 0.0017833775
vehicle O 0 0.04058221
alone O 0 0.0019759377
) O 0 0.006927226
, O 0 0.0044096336
GSPE B-Chemical 1 0.9999908
alone O 0 0.003424839
, O 0 0.0029596216
drug O 0 0.55734617
alone O 0 0.0033740555
and O 0 0.011816511
GSPE B-Chemical 1 0.99998415
+ O 0 0.033470616
drug O 0 0.8851418
. O 0 0.010786013

For O 0 0.0075045615
the O 0 0.006671765
cytoprotection O 0 0.972867
study O 0 0.004938285
, O 0 0.0028951974
animals O 0 0.0013888989
were O 0 0.0011782971
orally O 0 0.005223244
gavaged O 0 0.07327826
100 O 0 0.0023271067
mg O 0 0.4156641
/ O 0 0.0048322044
Kg O 0 0.3558111
GSPE B-Chemical 1 0.99999046
for O 0 0.00069259247
7 O 0 0.00066565437
- O 0 0.0006712493
10 O 0 0.0003103672
days O 0 0.00023094009
followed O 0 0.00025539426
by O 0 0.00042404214
i O 0 0.0015042922
. O 0 0.00032126924
p O 0 0.0005056124
. O 0 0.00026354016
injections O 0 0.000753121
of O 0 0.000421597
organ O 0 0.0248217
specific O 0 0.00036117868
three O 0 0.00034794485
drugs O 0 0.75824255
( O 0 0.0024309242
AAP B-Chemical 1 0.9842524
: O 0 0.00093078474
500 O 0 0.0014692119
mg O 0 0.1357191
/ O 0 0.0011934008
Kg O 0 0.013008417
for O 0 0.00028711784
24 O 0 0.00032071964
h O 0 0.00038130587
; O 0 0.0012519384
AMI B-Chemical 1 0.9998803
: O 0 0.00086056517
50 O 0 0.0006874392
mg O 0 0.09779808
/ O 0 0.0012441605
Kg O 0 0.01775105
/ O 0 0.00077386334
day O 0 0.00031617333
for O 0 0.00029168132
four O 0 0.00034322144
days O 0 0.00052647176
; O 0 0.0017765285
DOX B-Chemical 1 0.9992912
: O 0 0.0014044663
20 O 0 0.000969508
mg O 0 0.13650976
/ O 0 0.002955176
Kg O 0 0.020494958
for O 0 0.0015229624
48 O 0 0.0023594967
h O 0 0.003232019
) O 0 0.0076277405
. O 0 0.0072938823

Parameters O 0 0.0268374
of O 0 0.006579348
study O 0 0.004383223
included O 0 0.0025872875
analysis O 0 0.002490264
of O 0 0.0024579496
serum O 0 0.27098262
chemistry O 0 0.7337915
( O 0 0.025274111
ALT O 0 0.9998122
, O 0 0.011906953
BUN O 0 0.99995196
and O 0 0.0027829183
CPK O 0 0.99994624
) O 0 0.0032627117
, O 0 0.0008851484
and O 0 0.00062896684
orderly O 0 0.0031370984
fragmentation O 0 0.0038117175
of O 0 0.0007700539
genomic O 0 0.0022994776
DNA O 0 0.21195213
( O 0 0.0012615828
both O 0 0.0006428288
endonuclease O 0 0.11393428
- O 0 0.0010421656
dependent O 0 0.0003561207
and O 0 0.00052151276
independent O 0 0.00048592922
) O 0 0.0008567018
in O 0 0.00033216793
addition O 0 0.00025568056
to O 0 0.00038361
microscopic O 0 0.0017043346
evaluation O 0 0.0007497679
of O 0 0.0011036866
damage O 0 0.6541333
and O 0 0.0016570204
/ O 0 0.0041512786
or O 0 0.0011498684
protection O 0 0.004324573
in O 0 0.0017372591
corresponding O 0 0.002306595
PAS O 0 0.6611593
stained O 0 0.007791971
tissues O 0 0.024030928
. O 0 0.010077149

Results O 0 0.012489199
indicate O 0 0.0058207987
that O 0 0.0052487287
GSPE B-Chemical 1 0.99994385
preexposure O 0 0.23870923
prior O 0 0.0018371425
to O 0 0.0021582164
AAP B-Chemical 1 0.99533856
, O 0 0.006681138
AMI B-Chemical 1 0.9999466
and O 0 0.002850548
DOX B-Chemical 1 0.99985933
, O 0 0.0013487199
provided O 0 0.00054866954
near O 0 0.000560865
complete O 0 0.0004228663
protection O 0 0.0013161139
in O 0 0.00044061715
terms O 0 0.00039608686
of O 0 0.0008188297
serum O 0 0.23402618
chemistry O 0 0.4133362
changes O 0 0.004052197
( O 0 0.0095934
ALT O 0 0.99980634
, O 0 0.008537693
BUN O 0 0.9999441
and O 0 0.002980834
CPK O 0 0.99991536
) O 0 0.0041562263
, O 0 0.0019528145
and O 0 0.0018537387
significantly O 0 0.002976195
reduced O 0 0.004143203
DNA O 0 0.30525336
fragmentation O 0 0.109973036
. O 0 0.009993402

Histopathological O 0 0.4190719
examination O 0 0.008390219
of O 0 0.005625539
kidney O 0 0.82662976
, O 0 0.004501947
heart O 0 0.42390352
and O 0 0.0019403462
lung O 0 0.2912033
sections O 0 0.0017305302
revealed O 0 0.0008591388
moderate O 0 0.0043260925
to O 0 0.0006704584
massive O 0 0.07674844
tissue B-Disease 0 0.43839446
damage I-Disease 0 0.96062446
with O 0 0.0009299337
a O 0 0.00088382734
variety O 0 0.0013437675
of O 0 0.00076923537
morphological O 0 0.0124671245
aberrations O 0 0.73520505
by O 0 0.00066943787
all O 0 0.00040716477
the O 0 0.00039568907
three O 0 0.00034242924
drugs O 0 0.23875898
in O 0 0.0005535381
the O 0 0.0006303471
absence O 0 0.0005877559
of O 0 0.0032895864
GSPE B-Chemical 1 0.9999926
preexposure O 0 0.27594826
than O 0 0.0019877995
in O 0 0.0028898157
its O 0 0.006060907
presence O 0 0.0064736544
. O 0 0.008932668

GSPE B-Chemical 1 0.9998006
+ O 0 0.0185248
drug O 0 0.45240414
exposed O 0 0.0052092695
tissues O 0 0.008128254
exhibited O 0 0.0032394594
minor O 0 0.0062369364
residual O 0 0.005417449
damage O 0 0.62529933
or O 0 0.0045055305
near O 0 0.005243021
total O 0 0.0057901
recovery O 0 0.013595182
. O 0 0.0104112085

Additionally O 0 0.011770353
, O 0 0.009121818
histopathological O 0 0.19900228
alterations O 0 0.011691296
mirrored O 0 0.0046472247
both O 0 0.0029142168
serum O 0 0.11887845
chemistry O 0 0.18422668
changes O 0 0.0032010027
and O 0 0.0025962354
the O 0 0.0023853874
pattern O 0 0.0027977414
of O 0 0.0056775105
DNA O 0 0.35864195
fragmentation O 0 0.1390752
. O 0 0.01161659

Interestingly O 0 0.00795564
, O 0 0.0059938068
all O 0 0.00312548
the O 0 0.0025728692
drugs O 0 0.48145637
, O 0 0.0025279915
such O 0 0.0013383719
as O 0 0.0016000089
, O 0 0.0031841344
AAP B-Chemical 1 0.9944469
, O 0 0.004534633
AMI B-Chemical 1 0.99995637
and O 0 0.0024593635
DOX B-Chemical 1 0.99989116
induced O 0 0.002579142
apoptotic O 0 0.95434546
death O 2 0.9992249
in O 0 0.00066444546
addition O 0 0.0004050348
to O 0 0.00073009863
necrosis B-Disease 2 0.9960025
in O 0 0.0007193674
the O 0 0.00066335587
respective O 0 0.00070036104
organs O 0 0.025083037
which O 0 0.0016439814
was O 0 0.0014095596
very O 0 0.0020798973
effectively O 0 0.0036436715
blocked O 0 0.0105830375
by O 0 0.018695196
GSPE B-Chemical 1 0.999956
. O 0 0.01614881

Since O 0 0.01045558
AAP B-Chemical 1 0.9710352
, O 0 0.013136061
AMI B-Chemical 1 0.99969685
and O 0 0.0066581937
DOX B-Chemical 1 0.9995708
undergo O 0 0.0022155503
biotransformation O 0 0.98068535
and O 0 0.0016363404
are O 0 0.0009825672
known O 0 0.0009227364
to O 0 0.0006218923
produce O 0 0.00066354964
damaging O 0 0.4085682
radicals O 0 0.9988293
in O 0 0.00096643885
vivo O 0 0.0019374061
, O 0 0.0009836653
the O 0 0.000566702
protection O 0 0.008369029
by O 0 0.0025736266
GSPE B-Chemical 1 0.9999964
may O 0 0.00099502
be O 0 0.0007629927
linked O 0 0.00058932137
to O 0 0.00051546417
both O 0 0.0006253419
inhibition O 0 0.0020863535
of O 0 0.0013917548
metabolism O 0 0.38181636
and O 0 0.0019363832
/ O 0 0.006328511
or O 0 0.0020011219
detoxification O 0 0.7855861
of O 0 0.0065355855
cytotoxic O 0 0.97770566
radicals O 0 0.998901
. O 0 0.0152829075

In O 0 0.0074698725
addition O 0 0.0044091293
, O 0 0.004769488
its O 0 0.0039767623
' O 0 0.0027878562
presumed O 0 0.003172897
contribution O 0 0.0011513727
to O 0 0.0012769724
DNA O 0 0.07534881
repair O 0 0.0020236552
may O 0 0.0008617451
be O 0 0.00079357636
another O 0 0.000789011
important O 0 0.00062232866
attribute O 0 0.001083453
, O 0 0.0013979438
which O 0 0.0012993023
played O 0 0.003254766
a O 0 0.0017623721
role O 0 0.0012773119
in O 0 0.0020003475
the O 0 0.0034110795
chemoprevention O 0 0.9544062
process O 0 0.0086261025
. O 0 0.009401987

Additionally O 0 0.010636165
, O 0 0.0074804076
this O 0 0.0040909788
may O 0 0.0029881555
have O 0 0.002134174
been O 0 0.0018541425
the O 0 0.0013582192
first O 0 0.0011398727
report O 0 0.0031974488
on O 0 0.0016073197
AMI B-Chemical 1 0.99994826
- O 0 0.007695829
induced O 0 0.0032055108
apoptotic O 0 0.939325
death O 2 0.99868506
in O 0 0.003317147
the O 0 0.0042996453
lung O 0 0.7842251
tissue O 0 0.2891321
. O 0 0.011868512

Taken O 0 0.010871698
together O 0 0.0068362774
, O 0 0.0054794247
these O 0 0.003614754
events O 0 0.015493897
undoubtedly O 0 0.0048433174
establish O 0 0.002197877
GSPE B-Chemical 1 0.9999894
' O 0 0.004362177
s O 0 0.0015183932
abundant O 0 0.0010202671
bioavailability O 0 0.9647056
, O 0 0.0012420967
and O 0 0.0006926763
the O 0 0.00055038696
power O 0 0.002529941
to O 0 0.00050389295
defend O 0 0.0021447705
multiple O 0 0.0010094182
target O 0 0.00054798863
organs O 0 0.016705744
from O 0 0.000860131
toxic O 0 0.89263284
assaults O 0 0.95174736
induced O 0 0.0013769908
by O 0 0.0013195315
structurally O 0 0.003679194
diverse O 0 0.0023071286
and O 0 0.0015230291
functionally O 0 0.0017783289
different O 0 0.0019317874
entities O 0 0.018146064
in O 0 0.004340904
vivo O 0 0.009316321
. O 0 0.008605446

Antidepressant B-Chemical 0 0.9994442
- O 0 0.028150236
induced O 0 0.012445287
mania B-Disease 0 0.99967396
in O 0 0.008162354
bipolar B-Disease 2 0.9945899
patients O 0 0.021262703
: O 0 0.006439799
identification O 0 0.005166113
of O 0 0.0072494363
risk O 0 0.25344765
factors O 0 0.075173
. O 0 0.013949958

BACKGROUND O 0 0.58617014
: O 0 0.009314153
Concerns O 0 0.011434093
about O 0 0.0027017067
possible O 0 0.0021135595
risks O 0 0.006259367
of O 0 0.0018339072
switching O 0 0.0024111324
to O 0 0.0014794609
mania B-Disease 0 0.99993885
associated O 0 0.0020690772
with O 0 0.0017181064
antidepressants B-Chemical 1 0.99995923
continue O 0 0.000843895
to O 0 0.00053990685
interfere O 0 0.0005595459
with O 0 0.0005635177
the O 0 0.0005692296
establishment O 0 0.0008963489
of O 0 0.00091399247
an O 0 0.0011973412
optimal O 0 0.0007872206
treatment O 0 0.0023449154
paradigm O 0 0.0036891426
for O 0 0.0037299213
bipolar B-Disease 2 0.9989139
depression I-Disease 0 0.9991973
. O 0 0.011372438

METHOD O 0 0.025394185
: O 0 0.007415028
The O 0 0.003385842
response O 0 0.0029566344
of O 0 0.002384669
44 O 0 0.0025425907
patients O 0 0.002884402
meeting O 0 0.0018823446
DSM O 0 0.27975205
- O 0 0.002445789
IV O 0 0.14271253
criteria O 0 0.0009928017
for O 0 0.0006774579
bipolar B-Disease 2 0.99747247
disorder I-Disease 0 0.9845941
to O 0 0.00068355707
naturalistic O 0 0.02892938
treatment O 0 0.00085765094
was O 0 0.0004389968
assessed O 0 0.0003170073
for O 0 0.00030132252
at O 0 0.00028807038
least O 0 0.0002643747
6 O 0 0.0003273723
weeks O 0 0.00031974635
using O 0 0.00048827444
the O 0 0.00085708237
Montgomery O 0 0.32463413
- O 0 0.004923999
Asberg O 0 0.96677357
Depression O 2 0.9993857
Rating O 0 0.83229923
Scale O 0 0.9310511
and O 0 0.0020329356
the O 0 0.0025352824
Bech O 0 0.6917168
- O 0 0.007836454
Rafaelson O 0 0.27408165
Mania O 2 0.9977482
Rating O 0 0.9005824
Scale O 0 0.9587303
. O 0 0.010780274

Patients O 0 0.014016516
who O 0 0.007819017
experienced O 0 0.0063616564
a O 0 0.00613421
manic B-Disease 2 0.99993443
or O 0 0.004876253
hypomanic B-Disease 0 0.9999505
switch O 0 0.0024941496
were O 0 0.0008774498
compared O 0 0.00044313943
with O 0 0.0005888815
those O 0 0.0007299842
who O 0 0.000897968
did O 0 0.00037934788
not O 0 0.0003399811
on O 0 0.0002442158
several O 0 0.00035316186
variables O 0 0.0007884481
including O 0 0.00047088342
age O 0 0.0028380787
, O 0 0.0010173395
sex O 0 0.0674273
, O 0 0.0010751172
diagnosis O 0 0.018222464
( O 0 0.0021696016
DSM B-Disease 0 0.5062442
- I-Disease 0 0.003230391
IV I-Disease 0 0.69034123
bipolar I-Disease 2 0.9996209
I I-Disease 0 0.38804716
vs O 0 0.0064982236
. O 0 0.0006707715
bipolar B-Disease 2 0.9995604
II I-Disease 0 0.74358654
) O 0 0.0019848628
, O 0 0.0005498931
number O 0 0.00030244555
of O 0 0.00046997628
previous O 0 0.0007214655
manic B-Disease 2 0.99999106
episodes O 0 0.7156039
, O 0 0.0010908995
type O 0 0.00050394615
of O 0 0.00091966277
antidepressant B-Chemical 1 0.9999217
therapy O 0 0.021567807
used O 0 0.00060977
( O 0 0.0012830805
electroconvulsive O 0 0.9969133
therapy O 0 0.02164396
vs O 0 0.0044023907
. O 0 0.0004203229
antidepressant B-Chemical 1 0.9998134
drugs O 0 0.7203718
and O 0 0.00080676714
, O 0 0.00071463216
more O 0 0.00047031956
particularly O 0 0.0008144897
, O 0 0.0010266614
selective O 0 0.024168476
serotonin B-Chemical 1 0.9999751
reuptake I-Chemical 0 0.9999193
inhibitors I-Chemical 0 0.6419539
[ O 0 0.05746047
SSRIs B-Chemical 0 0.9999627
] O 0 0.0032313343
) O 0 0.0011154892
, O 0 0.00047665308
use O 0 0.00034139233
and O 0 0.00039869436
type O 0 0.00043629672
of O 0 0.0010263128
mood O 0 0.99937063
stabilizers O 0 0.98324203
( O 0 0.0063733766
lithium B-Chemical 1 0.9999068
vs O 0 0.007361587
. O 0 0.0005072822
anticonvulsants O 0 0.99986005
) O 0 0.002140119
, O 0 0.0006571114
and O 0 0.0004988178
temperament O 0 0.3012865
of O 0 0.00049560494
the O 0 0.000429601
patient O 0 0.00079952844
, O 0 0.00057903334
assessed O 0 0.00031978905
during O 0 0.00032197297
a O 0 0.00076331996
normothymic O 0 0.8934354
period O 0 0.0005062331
using O 0 0.00056721864
the O 0 0.00079752936
hyperthymia O 0 0.6028738
component O 0 0.001152284
of O 0 0.0016275065
the O 0 0.0021542073
Semi O 0 0.3545628
- O 0 0.003932666
structured O 0 0.00344214
Affective O 0 0.61600125
Temperament O 0 0.89772546
Interview O 0 0.15702587
. O 0 0.008270909

RESULTS O 0 0.0328377
: O 0 0.011192301
Switches O 0 0.038006097
to O 0 0.00473638
hypomania B-Disease 0 0.9996512
or O 0 0.0038985966
mania B-Disease 0 0.99982834
occurred O 0 0.0019071528
in O 0 0.0009799453
27 O 0 0.0012469817
% O 0 0.000738063
of O 0 0.0006022433
all O 0 0.00054340827
patients O 0 0.0023646443
( O 0 0.0015133129
N O 0 0.95034695
= O 0 0.0009716617
12 O 0 0.00039984685
) O 0 0.0007846705
( O 0 0.0005483248
and O 0 0.00038686712
in O 0 0.00031480388
24 O 0 0.00027361966
% O 0 0.0003346663
of O 0 0.0003231603
the O 0 0.00032814816
subgroup O 0 0.00094973855
of O 0 0.00051124033
patients O 0 0.0020254094
treated O 0 0.0007882632
with O 0 0.001164153
SSRIs B-Chemical 0 0.99995255
[ O 0 0.0023065207
8 O 0 0.00050377887
/ O 0 0.0010661792
33 O 0 0.0009307168
] O 0 0.0011609364
) O 0 0.0010294572
; O 0 0.0007442431
16 O 0 0.00044708606
% O 0 0.0005688754
( O 0 0.0008078899
N O 0 0.8563565
= O 0 0.00080638786
7 O 0 0.00047604644
) O 0 0.00079673366
experienced O 0 0.0013411166
manic B-Disease 2 0.9999765
episodes O 0 0.49046534
, O 0 0.0012353695
and O 0 0.00085714203
11 O 0 0.0010576708
% O 0 0.0011624874
( O 0 0.0017509967
N O 0 0.8734876
= O 0 0.0020733627
5 O 0 0.0015081177
) O 0 0.0031955934
experienced O 0 0.00670455
hypomanic B-Disease 0 0.9998349
episodes O 0 0.7494444
. O 0 0.010452296

Sex O 0 0.6018857
, O 0 0.010027766
age O 0 0.0094001535
, O 0 0.005380182
diagnosis O 0 0.0224901
( O 0 0.0069945888
bipolar B-Disease 2 0.99924904
I I-Disease 0 0.40652594
vs O 0 0.010394649
. O 0 0.001460906
bipolar B-Disease 2 0.99945456
II I-Disease 0 0.783385
) O 0 0.0035461998
, O 0 0.0011672298
and O 0 0.0007868756
additional O 0 0.0005449036
treatment O 0 0.0011643902
did O 0 0.000914368
not O 0 0.0010719657
affect O 0 0.0010496307
the O 0 0.0020513684
risk O 0 0.059476398
of O 0 0.005666385
switching O 0 0.0124248145
. O 0 0.009460517

The O 0 0.007883484
incidence O 0 0.011439473
of O 0 0.006523157
mood O 0 0.99357295
switches O 0 0.01127701
seemed O 0 0.0022830723
not O 0 0.0012988861
to O 0 0.0009920388
differ O 0 0.0010100396
between O 0 0.00065012276
patients O 0 0.0023449007
receiving O 0 0.0020933494
an O 0 0.0023884054
anticonvulsant O 0 0.9996786
and O 0 0.0021410047
those O 0 0.0024944758
receiving O 0 0.0038212985
no O 0 0.0031219432
mood O 0 0.99798584
stabilizer O 0 0.8680522
. O 0 0.011243738

In O 0 0.007623474
contrast O 0 0.0060541644
, O 0 0.0063062226
mood O 0 0.9831665
switches O 0 0.006432828
were O 0 0.00155847
less O 0 0.0011182128
frequent O 0 0.0020739587
in O 0 0.0007970941
patients O 0 0.002486156
receiving O 0 0.004143366
lithium B-Chemical 1 0.9999143
( O 0 0.0017803318
15 O 0 0.000504981
% O 0 0.0006125272
, O 0 0.0005738616
4 O 0 0.0003863202
/ O 0 0.00080577104
26 O 0 0.00058873976
) O 0 0.0005741609
than O 0 0.000250011
in O 0 0.00032682935
patients O 0 0.0009041047
not O 0 0.00041667395
treated O 0 0.00071407977
with O 0 0.0010749701
lithium B-Chemical 1 0.9999049
( O 0 0.0017949031
44 O 0 0.0012086246
% O 0 0.0008453267
, O 0 0.0008744318
8 O 0 0.00072907866
/ O 0 0.0014964067
18 O 0 0.0010985439
; O 0 0.001813412
p O 0 0.0020195749
= O 0 0.0030080585
. O 0 0.0027102733
04 O 0 0.06841905
) O 0 0.008208365
. O 0 0.007528381

The O 0 0.006416458
number O 0 0.004262825
of O 0 0.0038408577
previous O 0 0.0035241467
manic B-Disease 2 0.9999436
episodes O 0 0.6694317
did O 0 0.0013612183
not O 0 0.00086948666
affect O 0 0.00049356406
the O 0 0.00053826923
probability O 0 0.0006424684
of O 0 0.00070600136
switching O 0 0.0012844305
, O 0 0.00080143765
whereas O 0 0.00040641284
a O 0 0.0005662271
high O 0 0.0005051788
score O 0 0.00056784716
on O 0 0.00029093592
the O 0 0.0005203107
hyperthymia O 0 0.6449417
component O 0 0.00054989994
of O 0 0.00061154424
the O 0 0.00059721724
Semistructured O 0 0.0035088293
Affective O 0 0.57650477
Temperament O 0 0.8927466
Interview O 0 0.028825661
was O 0 0.00044054454
associated O 0 0.00052059867
with O 0 0.00054870255
a O 0 0.0007872555
greater O 0 0.00063519453
risk O 0 0.015616791
of O 0 0.0012442264
switching O 0 0.0024929375
( O 0 0.0025372016
p O 0 0.002539137
= O 0 0.0032709793
. O 0 0.0025836576
008 O 0 0.032782637
) O 0 0.008204391
. O 0 0.007414235

CONCLUSION O 0 0.61608934
: O 0 0.008108097
The O 0 0.003610758
frequency O 0 0.0031160791
of O 0 0.0034047994
mood O 0 0.9920616
switching O 0 0.0036688747
associated O 0 0.0022293855
with O 0 0.0023641437
acute O 0 0.9917014
antidepressant B-Chemical 1 0.99995553
therapy O 0 0.09879288
may O 0 0.0020000907
be O 0 0.0023217364
reduced O 0 0.0027998872
by O 0 0.006035791
lithium B-Chemical 1 0.99966645
treatment O 0 0.02785878
. O 0 0.010586633

Particular O 0 0.00952236
attention O 0 0.007865398
should O 0 0.0031743725
be O 0 0.00292991
paid O 0 0.0035348628
to O 0 0.0017684972
patients O 0 0.003208015
with O 0 0.0017863697
a O 0 0.003833232
hyperthymic O 0 0.9997894
temperament O 0 0.94037807
, O 0 0.0023568247
who O 0 0.0021138156
have O 0 0.0011417234
a O 0 0.0019038718
greater O 0 0.0018894712
risk O 0 0.06621419
of O 0 0.0073542385
mood O 0 0.9982468
switches O 0 0.07313604
. O 0 0.010592105

Peritubular O 0 0.20699269
capillary O 0 0.07884388
basement O 0 0.180921
membrane O 0 0.01929212
reduplication O 0 0.04285428
in O 0 0.0027777213
allografts O 0 0.11869621
and O 0 0.0024504447
native O 0 0.002770458
kidney B-Disease 0 0.90172106
disease I-Disease 0 0.8846961
: O 0 0.0032712843
a O 0 0.002008181
clinicopathologic O 0 0.16290839
study O 0 0.002700443
of O 0 0.002905885
278 O 0 0.062091455
consecutive O 0 0.0042945934
renal O 0 0.9590743
specimens O 0 0.013056853
. O 0 0.010232469

BACKGROUND O 0 0.599403
: O 0 0.009770395
An O 0 0.0064788703
association O 0 0.002994137
has O 0 0.002450932
been O 0 0.0021170953
found O 0 0.0013895154
between O 0 0.001282808
transplant B-Disease 0 0.9710282
glomerulopathy I-Disease 0 0.9999825
( O 0 0.1142628
TG B-Disease 2 0.99925905
) O 0 0.004324569
and O 0 0.0015465242
reduplication O 0 0.020396689
of O 0 0.0019800551
peritubular O 0 0.5708197
capillary O 0 0.4295485
basement O 0 0.6862629
membranes O 0 0.32976022
( O 0 0.012847519
PTCR O 0 0.8431067
) O 0 0.014137931
. O 0 0.00928413

Although O 0 0.0066654445
such O 0 0.004548948
an O 0 0.004146777
association O 0 0.0021738582
is O 0 0.0018492979
of O 0 0.0016928738
practical O 0 0.0017315453
and O 0 0.0013415463
theoretical O 0 0.0029933767
importance O 0 0.0010035904
, O 0 0.0013060707
only O 0 0.00086855184
one O 0 0.0009199191
prospective O 0 0.0023340918
study O 0 0.0016186801
has O 0 0.001450278
tried O 0 0.0032321939
to O 0 0.0026189084
confirm O 0 0.0029643998
it O 0 0.0071394085
. O 0 0.008565686

METHODS O 0 0.011634748
: O 0 0.00785752
We O 0 0.0040223678
examined O 0 0.002629551
278 O 0 0.0069002816
consecutive O 0 0.002197597
renal O 0 0.8041544
specimens O 0 0.0027807518
( O 0 0.002010035
from O 0 0.0011195655
135 O 0 0.0024416938
transplants O 0 0.019356558
and O 0 0.0011490745
143 O 0 0.0027788128
native O 0 0.0013797533
kidneys O 0 0.039085414
) O 0 0.0025265492
for O 0 0.0013724522
ultrastructural O 0 0.012549802
evidence O 0 0.0038316862
of O 0 0.0075812903
PTCR O 0 0.89232415
. O 0 0.010642836

In O 0 0.007150266
addition O 0 0.004049793
to O 0 0.003947958
renal O 0 0.94652146
allografts O 0 0.5968622
with O 0 0.0046056467
TG B-Disease 2 0.997514
, O 0 0.0017718236
we O 0 0.0005623319
also O 0 0.0006239587
examined O 0 0.00046448503
grafts O 0 0.0023955912
with O 0 0.0010313699
acute O 0 0.9742843
rejection O 0 0.9988626
, O 0 0.010905357
recurrent O 0 0.97178686
glomerulonephritis B-Disease 2 0.9999924
, O 0 0.041037682
chronic B-Disease 0 0.99739516
allograft I-Disease 0 0.998691
nephropathy I-Disease 2 0.99999523
and O 0 0.0035374255
stable O 0 0.001813179
grafts O 0 0.008695216
( O 0 0.0025251785
" O 0 0.0023514961
protocol O 0 0.0027539567
biopsies O 0 0.010985502
" O 0 0.007441269
) O 0 0.010981131
. O 0 0.008429477

Native O 0 0.0675594
kidney O 0 0.37540638
specimens O 0 0.0057412847
included O 0 0.002927607
a O 0 0.002620045
wide O 0 0.0024334418
range O 0 0.0018938637
of O 0 0.001805835
glomerulopathies B-Disease 0 0.9988317
as O 0 0.0012829399
well O 0 0.0007403002
as O 0 0.0007399659
cases O 0 0.0015797692
of O 0 0.0023944653
thrombotic B-Disease 2 0.9999881
microangiopathy I-Disease 2 0.99999857
, O 0 0.11912752
malignant B-Disease 0 0.9999126
hypertension I-Disease 2 0.99999535
, O 0 0.027064705
acute O 0 0.9932073
interstitial B-Disease 2 0.9983045
nephritis I-Disease 2 0.99999416
, O 0 0.053316824
and O 0 0.011863369
acute B-Disease 2 0.9986149
tubular I-Disease 2 0.9984675
necrosis I-Disease 2 0.9998758
. O 0 0.022589589

RESULTS O 0 0.026212145
: O 0 0.008505297
We O 0 0.0042178044
found O 0 0.0028312746
PTCR O 0 0.10493843
in O 0 0.0018170323
14 O 0 0.0014111458
of O 0 0.001143717
15 O 0 0.0008419223
cases O 0 0.0012542008
of O 0 0.0014708863
TG B-Disease 2 0.99646676
, O 0 0.001303929
in O 0 0.00060996675
7 O 0 0.0005854406
transplant O 0 0.026356526
biopsy O 0 0.003464289
specimens O 0 0.0011353998
without O 0 0.0012061899
TG B-Disease 2 0.9966378
, O 0 0.0014752363
and O 0 0.0009965023
in O 0 0.0008764221
13 O 0 0.0012317853
of O 0 0.0014255457
143 O 0 0.0050067008
native O 0 0.0029527347
kidney O 0 0.74502814
biopsy O 0 0.04976569
specimens O 0 0.011503953
. O 0 0.010113198

These O 0 0.008722286
13 O 0 0.00576289
included O 0 0.0033010666
cases O 0 0.003685266
of O 0 0.003825657
malignant B-Disease 0 0.9995247
hypertension I-Disease 2 0.9999914
, O 0 0.11669982
thrombotic B-Disease 2 0.9999875
microangiopathy I-Disease 2 0.99999833
, O 0 0.15155505
lupus B-Disease 0 0.99998546
nephritis I-Disease 0 0.999995
, O 0 0.10118113
Henoch B-Disease 0 0.99982077
- I-Disease 0 0.061732598
Schonlein I-Disease 0 0.9998683
nephritis I-Disease 0 0.99998736
, O 0 0.027438326
crescentic O 0 0.99920505
glomerulonephritis B-Disease 2 0.99999094
, O 0 0.019169234
and O 0 0.0044029737
cocaine B-Chemical 1 0.9999385
- O 0 0.0063619697
related O 0 0.0023058974
acute B-Disease 0 0.9856849
renal I-Disease 0 0.9986204
failure I-Disease 0 0.97178406
. O 0 0.012011769

Mild O 0 0.9798529
PTCR O 0 0.64886385
in O 0 0.0054578846
allografts O 0 0.14750929
without O 0 0.0042151962
TG B-Disease 2 0.9899227
did O 0 0.0016473972
not O 0 0.0011307008
predict O 0 0.00089892757
renal B-Disease 0 0.98261064
failure I-Disease 0 0.7595216
or O 0 0.0011189027
significant O 0 0.0016010902
proteinuria B-Disease 2 0.999948
after O 0 0.0005418675
follow O 0 0.0006190894
- O 0 0.0010276986
up O 0 0.0005585457
periods O 0 0.0006970482
of O 0 0.00083904644
between O 0 0.00077942817
3 O 0 0.0013301932
months O 0 0.0013728791
and O 0 0.002583058
1 O 0 0.003939263
year O 0 0.005122854
. O 0 0.0073355106

CONCLUSIONS O 0 0.3929502
: O 0 0.0081637595
We O 0 0.0035951156
conclude O 0 0.002304997
that O 0 0.0017667934
in O 0 0.0016391603
transplants O 0 0.1152815
, O 0 0.001602259
there O 0 0.00059828034
is O 0 0.0006268268
a O 0 0.0006906974
strong O 0 0.00059850846
association O 0 0.00041555773
between O 0 0.0003658923
well O 0 0.0006705326
- O 0 0.0015110135
developed O 0 0.0010675102
PTCR O 0 0.76215446
and O 0 0.0012674229
TG B-Disease 2 0.99672806
, O 0 0.00083770155
while O 0 0.00038768377
the O 0 0.0003852713
significance O 0 0.0006003767
of O 0 0.00075472204
mild O 0 0.54789513
PTCR O 0 0.71219784
and O 0 0.000838829
its O 0 0.0010439741
predictive O 0 0.0012522617
value O 0 0.0008297671
in O 0 0.0007957515
the O 0 0.0010353157
absence O 0 0.0011038275
of O 0 0.004034792
TG B-Disease 2 0.99718153
is O 0 0.005236802
unclear O 0 0.0075686155
. O 0 0.00896338

PTCR O 0 0.31398317
also O 0 0.0066688233
occurs O 0 0.0038807734
in O 0 0.0027143643
certain O 0 0.0027540147
native O 0 0.0032785046
kidney B-Disease 0 0.937488
diseases I-Disease 0 0.9385436
, O 0 0.0030439934
though O 0 0.0010763096
the O 0 0.00085819134
association O 0 0.00075637375
is O 0 0.0009413025
not O 0 0.0009572309
as O 0 0.0012657015
strong O 0 0.0019758116
as O 0 0.002397815
that O 0 0.0028139907
for O 0 0.0049406216
TG B-Disease 2 0.9951265
. O 0 0.010685139

We O 0 0.007235449
suggest O 0 0.0037961411
that O 0 0.0030220426
repeated O 0 0.0032118645
endothelial B-Disease 0 0.9874233
injury I-Disease 0 0.9980482
, O 0 0.004492605
including O 0 0.0017767315
immunologic B-Disease 0 0.94438016
injury I-Disease 0 0.99924755
, O 0 0.003414349
may O 0 0.00078798586
be O 0 0.0007154212
the O 0 0.00063973834
cause O 0 0.0016636772
of O 0 0.0010604362
this O 0 0.0010554353
lesion O 0 0.046780072
both O 0 0.0014441559
in O 0 0.0018506602
allografts O 0 0.19668882
and O 0 0.004336702
native O 0 0.006900557
kidneys O 0 0.25149864
. O 0 0.009555938

Caffeine B-Chemical 1 0.99964154
- O 0 0.023681758
induced O 0 0.010829517
cardiac B-Disease 0 0.97893745
arrhythmia I-Disease 2 0.9998734
: O 0 0.011998761
an O 0 0.0066816504
unrecognised O 0 0.06444703
danger O 0 0.04390714
of O 0 0.008551281
healthfood O 0 0.22451948
products O 0 0.05000056
. O 0 0.013225479

We O 0 0.007953393
describe O 0 0.005120663
a O 0 0.005126043
25 O 0 0.0045440774
- O 0 0.003636825
year O 0 0.0019597777
- O 0 0.002013172
old O 0 0.0013429297
woman O 0 0.00525094
with O 0 0.0011576269
pre O 0 0.009196839
- O 0 0.001409706
existing O 0 0.0008274505
mitral B-Disease 0 0.07432183
valve I-Disease 0 0.022125738
prolapse I-Disease 0 0.8999957
who O 0 0.0014726394
developed O 0 0.001118737
intractable O 0 0.95902115
ventricular B-Disease 0 0.9982193
fibrillation I-Disease 0 0.99997807
after O 0 0.0004804117
consuming O 0 0.0021620297
a O 0 0.0009743297
" O 0 0.0009992241
natural O 0 0.002055343
energy O 0 0.014274839
" O 0 0.0025779817
guarana O 0 0.9974661
health O 0 0.045012396
drink O 0 0.51200765
containing O 0 0.0013362353
a O 0 0.0022031867
high O 0 0.0025467265
concentration O 0 0.005916485
of O 0 0.009829462
caffeine B-Chemical 1 0.9996586
. O 0 0.012275673

This O 0 0.011973751
case O 0 0.0066913925
highlights O 0 0.00510783
the O 0 0.0038632958
need O 0 0.0029766427
for O 0 0.00235656
adequate O 0 0.0028507758
labelling O 0 0.0044514975
and O 0 0.0034479676
regulation O 0 0.00310124
of O 0 0.004790984
such O 0 0.006709489
products O 0 0.05086468
. O 0 0.012373733

Conformationally O 0 0.7981507
restricted O 0 0.006329672
analogs O 0 0.1091835
of O 0 0.0065218443
BD1008 B-Chemical 0 0.9964091
and O 0 0.0034607549
an O 0 0.0031856876
antisense O 0 0.05429295
oligodeoxynucleotide B-Chemical 0 0.85635895
targeting O 0 0.001811434
sigma1 O 0 0.83306164
receptors O 0 0.18700185
produce O 0 0.0016613874
anti O 0 0.061668184
- O 0 0.017102629
cocaine B-Chemical 1 0.99980456
effects O 0 0.008008455
in O 0 0.0044168467
mice O 0 0.005260263
. O 0 0.008556501

Cocaine B-Chemical 1 0.9995766
' O 0 0.009786029
s O 0 0.0051248088
ability O 0 0.0030093745
to O 0 0.0021485812
interact O 0 0.0015418901
with O 0 0.0017418656
sigma O 0 0.015899781
receptors O 0 0.06192286
suggests O 0 0.0008252048
that O 0 0.00085900817
these O 0 0.001305072
proteins O 0 0.0019906606
mediate O 0 0.0013939091
some O 0 0.0019486925
of O 0 0.0028773888
its O 0 0.0062690023
behavioral O 0 0.16990466
effects O 0 0.017271835
. O 0 0.009545071

Therefore O 0 0.0070708594
, O 0 0.0056680776
three O 0 0.0026222465
novel O 0 0.003477424
sigma O 0 0.02155663
receptor O 0 0.23230152
ligands O 0 0.22269633
with O 0 0.002918002
antagonist O 0 0.97540593
activity O 0 0.0016202251
were O 0 0.0007100915
evaluated O 0 0.0005382657
in O 0 0.0006421412
Swiss O 0 0.018915206
Webster O 0 0.16657147
mice O 0 0.0005172242
: O 0 0.0017519705
BD1018 B-Chemical 0 0.9604877
( O 0 0.003099212
3S B-Chemical 0 0.850449
- I-Chemical 0 0.0018087486
1 I-Chemical 0 0.00076111755
- I-Chemical 0 0.0010817049
[ I-Chemical 0 0.0013194291
2 I-Chemical 0 0.0006085557
- I-Chemical 0 0.000909101
( I-Chemical 0 0.00065716245
3 I-Chemical 0 0.00042747185
, I-Chemical 0 0.00057718134
4 I-Chemical 0 0.00049382803
- I-Chemical 0 0.0012364897
dichlorophenyl I-Chemical 0 0.9832413
) I-Chemical 0 0.0073344097
ethyl I-Chemical 0 0.9990722
] I-Chemical 0 0.01945119
- I-Chemical 0 0.0017762434
1 I-Chemical 0 0.00057603774
, I-Chemical 0 0.0005970809
4 I-Chemical 0 0.00044792026
- I-Chemical 0 0.00081896887
diazabicyclo I-Chemical 0 0.17453302
[ I-Chemical 0 0.0014693085
4 I-Chemical 0 0.0003958789
. I-Chemical 0 0.00027731378
3 I-Chemical 0 0.00033773785
. I-Chemical 0 0.000288055
0 I-Chemical 0 0.0006147675
] I-Chemical 0 0.0012791747
nonane I-Chemical 0 0.97438204
) O 0 0.0039486196
, O 0 0.0019171962
BD1063 B-Chemical 0 0.9998652
( O 0 0.0013201078
1 B-Chemical 0 0.00071267475
- I-Chemical 0 0.0009730569
[ I-Chemical 0 0.0011803046
2 I-Chemical 0 0.0005589569
- I-Chemical 0 0.0008441508
( I-Chemical 0 0.0006233791
3 I-Chemical 0 0.00041187284
, I-Chemical 0 0.0005620817
4 I-Chemical 0 0.0004860825
- I-Chemical 0 0.0012230974
dichlorophenyl I-Chemical 0 0.98299706
) I-Chemical 0 0.0074633057
ethyl I-Chemical 0 0.9991054
] I-Chemical 0 0.02227186
- I-Chemical 0 0.0021959164
4 I-Chemical 0 0.00065421103
- I-Chemical 0 0.0014919661
methylpiperazine I-Chemical 0 0.82841474
) O 0 0.0020255658
, O 0 0.00085060054
and O 0 0.0008723177
LR132 B-Chemical 0 0.97269416
( O 0 0.003994125
1R O 0 0.9902962
, O 0 0.0020564136
2S O 0 0.8682562
- O 0 0.003058516
( O 0 0.0013286131
+ O 0 0.0010083434
) O 0 0.0017960995
- O 0 0.0013802318
cis O 0 0.015019932
- O 0 0.0032995264
N O 0 0.98279953
- O 0 0.002602914
[ O 0 0.0022186444
2 O 0 0.0007076275
- O 0 0.0010307403
( O 0 0.0007234787
3 O 0 0.00047178648
, O 0 0.0006440986
4 O 0 0.0005643428
- O 0 0.0013851585
dichlorophenyl O 0 0.98044384
) O 0 0.0077216127
ethyl O 0 0.99881625
] O 0 0.020347834
- O 0 0.0026606205
2 O 0 0.0011863009
- O 0 0.0018731101
( O 0 0.001810261
1 O 0 0.0018701197
- O 0 0.0037309192
pyrrolidinyl O 0 0.8863887
) O 0 0.03084739
cyclohexylamine O 0 0.99945265
) O 0 0.025168156
. O 0 0.009241396

Competition O 0 0.020998208
binding O 0 0.007075534
assays O 0 0.0052535855
demonstrated O 0 0.0032189295
that O 0 0.0024426943
all O 0 0.0022525375
three O 0 0.0019333996
compounds O 0 0.24057151
have O 0 0.0024702367
high O 0 0.0035851554
affinities O 0 0.0079069175
for O 0 0.004657647
sigma1 O 0 0.8570105
receptors O 0 0.43953237
. O 0 0.011968301

The O 0 0.0070262817
three O 0 0.004274576
compounds O 0 0.13356143
vary O 0 0.0033459982
in O 0 0.0018161554
their O 0 0.0016088907
affinities O 0 0.0022599355
for O 0 0.00092857145
sigma2 O 0 0.06302243
receptors O 0 0.06423293
and O 0 0.0009870195
exhibit O 0 0.0007182128
negligible O 0 0.0009731404
affinities O 0 0.0026359365
for O 0 0.00096929836
dopamine B-Chemical 1 0.9998779
, O 0 0.005688563
opioid O 0 0.99969196
, O 0 0.02067947
GABA B-Chemical 1 0.99995697
( O 0 0.0050080195
A O 0 0.1562419
) O 0 0.0063895863
and O 0 0.0076029436
NMDA B-Chemical 1 0.9999169
receptors O 0 0.48907572
. O 0 0.010673347

In O 0 0.0084161125
behavioral O 0 0.023175573
studies O 0 0.0051146275
, O 0 0.0043346225
pre O 0 0.009088665
- O 0 0.0029312116
treatment O 0 0.0017183992
of O 0 0.001364844
mice O 0 0.00089966366
with O 0 0.001699337
BD1018 B-Chemical 0 0.9892357
, O 0 0.00811715
BD1063 B-Chemical 0 0.99989176
, O 0 0.0017631223
or O 0 0.0011116068
LR132 B-Chemical 0 0.92996687
significantly O 0 0.002164489
attenuated O 0 0.013349003
cocaine B-Chemical 1 0.99996006
- O 0 0.022662403
induced O 0 0.009363123
convulsions B-Disease 2 0.99996066
and O 0 0.020800592
lethality O 0 0.8514297
. O 0 0.011353298

Moreover O 0 0.011347887
, O 0 0.008292335
post O 0 0.006517801
- O 0 0.005146408
treatment O 0 0.003542285
with O 0 0.0031018294
LR132 B-Chemical 0 0.97776914
prevented O 0 0.05155835
cocaine B-Chemical 1 0.99996746
- O 0 0.015913552
induced O 0 0.0025225373
lethality O 0 0.45901272
in O 0 0.0017206855
a O 0 0.0023778272
significant O 0 0.0022539524
proportion O 0 0.0025268244
of O 0 0.0047899745
animals O 0 0.006506886
. O 0 0.008980022

In O 0 0.0069823414
contrast O 0 0.004699561
to O 0 0.0031233842
the O 0 0.0024405734
protection O 0 0.0043645557
provided O 0 0.0015465977
by O 0 0.0013574548
the O 0 0.0010008155
putative O 0 0.0014344818
antagonists O 0 0.96887255
, O 0 0.0014031697
the O 0 0.0006031934
well O 0 0.00063869974
- O 0 0.0013666853
characterized O 0 0.0011431262
sigma O 0 0.03973119
receptor O 0 0.24968594
agonist O 0 0.94408983
di B-Chemical 0 0.14094429
- I-Chemical 0 0.0041620284
o I-Chemical 0 0.022491544
- I-Chemical 0 0.0024636
tolylguanidine I-Chemical 0 0.051711693
( O 0 0.003425441
DTG B-Chemical 0 0.9996637
) O 0 0.0011379854
and O 0 0.00045157893
the O 0 0.0003801552
novel O 0 0.0008328925
sigma O 0 0.026830142
receptor O 0 0.33251396
agonist O 0 0.9856332
BD1031 B-Chemical 0 0.99768925
( O 0 0.008107297
3R B-Chemical 0 0.93416685
- I-Chemical 0 0.0016697953
1 I-Chemical 0 0.00068934995
- I-Chemical 0 0.0009932985
[ I-Chemical 0 0.0012319109
2 I-Chemical 0 0.0005731947
- I-Chemical 0 0.00086687016
( I-Chemical 0 0.000633075
3 I-Chemical 0 0.00041569062
, I-Chemical 0 0.0005652202
4 I-Chemical 0 0.00048687783
- I-Chemical 0 0.0012227328
dichlorophenyl I-Chemical 0 0.98288697
) I-Chemical 0 0.0072279065
ethyl I-Chemical 0 0.9990489
] I-Chemical 0 0.019031206
- I-Chemical 0 0.001774093
1 I-Chemical 0 0.00058954
, I-Chemical 0 0.00061574974
4 I-Chemical 0 0.00046702966
- I-Chemical 0 0.0008541953
diazabicyclo I-Chemical 0 0.16551289
[ I-Chemical 0 0.0015064346
4 I-Chemical 0 0.00043786582
. I-Chemical 0 0.0003225435
3 I-Chemical 0 0.00040137468
. I-Chemical 0 0.00036482475
0 I-Chemical 0 0.0007621061
] I-Chemical 0 0.0013942862
nonane I-Chemical 0 0.9071567
) O 0 0.0015560412
each O 0 0.0006575324
worsened O 0 0.072988175
the O 0 0.0015641698
behavioral O 0 0.14315736
toxicity B-Disease 2 0.99798125
of O 0 0.023685534
cocaine B-Chemical 1 0.99984264
. O 0 0.011722307

At O 0 0.0061504645
doses O 0 0.009789125
where O 0 0.003421902
alone O 0 0.0029723493
, O 0 0.0023594922
they O 0 0.0011850982
produced O 0 0.00087122363
no O 0 0.0006321526
significant O 0 0.00084139465
effects O 0 0.0012891736
on O 0 0.0006025935
locomotion O 0 0.47539455
, O 0 0.0027971126
BD1018 B-Chemical 0 0.97814506
, O 0 0.0040761614
BD1063 B-Chemical 0 0.99984896
and O 0 0.0016534675
LR132 B-Chemical 0 0.9344226
significantly O 0 0.0015269744
attenuated O 0 0.0020433618
the O 0 0.0016088384
locomotor O 0 0.69964606
stimulatory O 0 0.030430363
effects O 0 0.010429391
of O 0 0.017439632
cocaine B-Chemical 1 0.9998416
. O 0 0.01203629

To O 0 0.005882443
further O 0 0.0040393816
validate O 0 0.002279298
the O 0 0.0019077739
hypothesis O 0 0.0016391298
that O 0 0.0010421129
the O 0 0.0011528746
anti O 0 0.030000893
- O 0 0.0069428813
cocaine B-Chemical 1 0.9999049
effects O 0 0.0018712565
of O 0 0.0008027182
the O 0 0.0005658659
novel O 0 0.0011969017
ligands O 0 0.08530632
involved O 0 0.0006439046
antagonism O 0 0.5218026
of O 0 0.0010985598
sigma O 0 0.05540967
receptors O 0 0.25166714
, O 0 0.0011682743
an O 0 0.0008860243
antisense O 0 0.031394787
oligodeoxynucleotide B-Chemical 0 0.79521817
against O 0 0.0007766611
sigma1 O 0 0.8545375
receptors O 0 0.16056101
was O 0 0.0005957218
also O 0 0.0005136244
shown O 0 0.00038282725
to O 0 0.0004716489
significantly O 0 0.0009699479
attenuate O 0 0.0040567513
the O 0 0.0017164112
convulsive B-Disease 2 0.99998283
and O 0 0.0047075343
locomotor O 0 0.87404734
stimulatory O 0 0.046700772
effects O 0 0.012079837
of O 0 0.01814101
cocaine B-Chemical 1 0.9998419
. O 0 0.011834709

Together O 0 0.016595645
, O 0 0.0074632745
the O 0 0.0038911025
data O 0 0.0031911207
suggests O 0 0.0015250782
that O 0 0.0013395803
functional O 0 0.0018782708
antagonism O 0 0.43291482
of O 0 0.00205834
sigma O 0 0.0522103
receptors O 0 0.17541751
is O 0 0.0010373376
capable O 0 0.0010831754
of O 0 0.0012008653
attenuating O 0 0.014786185
a O 0 0.0017281527
number O 0 0.0013754593
of O 0 0.0039617717
cocaine B-Chemical 1 0.9999248
- O 0 0.017707353
induced O 0 0.0069051883
behaviors O 0 0.48652768
. O 0 0.009969846

Ranitidine B-Chemical 0 0.9996517
- O 0 0.026459903
induced O 0 0.011689064
acute O 0 0.976073
interstitial B-Disease 2 0.99532384
nephritis I-Disease 2 0.99995685
in O 0 0.010704856
a O 0 0.011676742
cadaveric O 0 0.4546983
renal O 0 0.9962268
allograft O 0 0.99146384
. O 0 0.01865498

Ranitidine B-Chemical 0 0.99942577
frequently O 0 0.015581884
is O 0 0.007311117
used O 0 0.005058112
for O 0 0.0042496086
preventing O 0 0.0117716
peptic O 0 0.9994204
ulceration O 0 0.99967825
after O 0 0.008669213
renal O 0 0.99633104
transplantation O 0 0.81866777
. O 0 0.0155594

This O 0 0.013923096
drug O 0 0.2125068
occasionally O 0 0.011960579
has O 0 0.0045814253
been O 0 0.004053968
associated O 0 0.0038003
with O 0 0.0045255674
acute O 0 0.98921496
interstitial B-Disease 2 0.9977738
nephritis I-Disease 2 0.9999771
in O 0 0.012263955
native O 0 0.015199937
kidneys O 0 0.47169566
. O 0 0.01237996

There O 0 0.018469118
are O 0 0.013196008
no O 0 0.009310633
similar O 0 0.008898648
reports O 0 0.012908298
with O 0 0.014830952
renal O 0 0.99146515
transplantation O 0 0.79410315
. O 0 0.022029933

We O 0 0.007909364
report O 0 0.00722984
a O 0 0.004456915
case O 0 0.0030582412
of O 0 0.0045790435
ranitidine B-Chemical 1 0.99997866
- O 0 0.020630993
induced O 0 0.0026625113
acute O 0 0.9888498
interstitial B-Disease 2 0.9973417
nephritis I-Disease 2 0.99999547
in O 0 0.0016913475
a O 0 0.0012585556
recipient O 0 0.0014846686
of O 0 0.0007095013
a O 0 0.0009232479
cadaveric O 0 0.060917884
renal O 0 0.98623836
allograft O 0 0.9667941
presenting O 0 0.14884163
with O 0 0.0014936733
acute O 0 0.9746557
allograft O 0 0.9894581
dysfunction O 0 0.97477096
within O 0 0.0005387733
48 O 0 0.00069932453
hours O 0 0.0006163245
of O 0 0.0012077545
exposure O 0 0.0029011362
to O 0 0.002339861
the O 0 0.004047332
drug O 0 0.72468734
. O 0 0.00902497

The O 0 0.009067459
biopsy O 0 0.011886784
specimen O 0 0.006445885
showed O 0 0.0040205372
pathognomonic O 0 0.011694961
features O 0 0.0062815743
, O 0 0.004219501
including O 0 0.0032027315
eosinophilic O 0 0.99653685
infiltration O 0 0.9517524
of O 0 0.007169455
the O 0 0.005959136
interstitial O 0 0.81835663
compartment O 0 0.01999895
. O 0 0.011658328

Allograft O 0 0.173654
function O 0 0.009035901
improved O 0 0.008259395
rapidly O 0 0.0064290436
and O 0 0.0041037146
returned O 0 0.0031196587
to O 0 0.0024934094
baseline O 0 0.002900452
after O 0 0.0022807906
stopping O 0 0.008811941
the O 0 0.0058198213
drug O 0 0.67877084
. O 0 0.011687076

Liver B-Disease 0 0.9893216
disease I-Disease 0 0.9686627
caused O 0 0.05157211
by O 0 0.061296612
propylthiouracil B-Chemical 1 0.9992514
. O 0 0.050003376

This O 0 0.0101144
report O 0 0.0076167714
presents O 0 0.004522011
the O 0 0.002753898
clinical O 0 0.0077196294
, O 0 0.0024650944
laboratory O 0 0.0022226053
, O 0 0.0014002515
and O 0 0.00092173216
light O 0 0.0012207574
and O 0 0.0007984686
electron O 0 0.004414162
microscopic O 0 0.002101356
observations O 0 0.0007505306
on O 0 0.00039965328
a O 0 0.0007891746
patient O 0 0.0010432096
with O 0 0.0009438188
chronic B-Disease 0 0.9504528
active I-Disease 0 0.0155389495
( I-Disease 0 0.0059873606
aggressive I-Disease 0 0.6146709
) I-Disease 0 0.04901157
hepatitis I-Disease 2 0.999966
caused O 0 0.0048734103
by O 0 0.0026744464
the O 0 0.0024410891
administration O 0 0.19876932
of O 0 0.017454388
propylthiouracil B-Chemical 1 0.9998927
. O 0 0.0151508795

This O 0 0.01086068
is O 0 0.005408257
an O 0 0.004261724
addition O 0 0.002023132
to O 0 0.0018292494
the O 0 0.0014989239
list O 0 0.0012608562
of O 0 0.001476695
drugs O 0 0.45907375
that O 0 0.0009149737
must O 0 0.0006949655
be O 0 0.0008895504
considered O 0 0.000768957
in O 0 0.00093428214
the O 0 0.0012219165
evaluation O 0 0.0020631037
of O 0 0.004234759
chronic O 0 0.9974687
liver B-Disease 2 0.9992854
disease I-Disease 2 0.9989631
. O 0 0.01842351

Withdrawal B-Disease 0 0.96473175
- I-Disease 0 0.016622305
emergent I-Disease 0 0.014047913
rabbit I-Disease 0 0.042638924
syndrome I-Disease 0 0.9540815
during O 0 0.005415574
dose O 0 0.047380287
reduction O 0 0.0120378565
of O 0 0.021565251
risperidone B-Chemical 1 0.999913
. O 0 0.016514208

Rabbit B-Disease 0 0.4502524
syndrome I-Disease 0 0.9852326
( O 0 0.020290203
RS B-Disease 0 0.97331524
) O 0 0.007569847
is O 0 0.0025769498
a O 0 0.0029437991
rare O 0 0.048930198
extrapyramidal O 0 0.99998176
side O 0 0.38896528
effect O 0 0.0027555039
caused O 0 0.003328943
by O 0 0.0044512823
prolonged O 0 0.22121595
neuroleptic O 0 0.9999845
medication O 0 0.89385784
. O 0 0.011624697

Here O 0 0.009134943
we O 0 0.004231427
present O 0 0.002910116
a O 0 0.0032033345
case O 0 0.0022797412
of O 0 0.002677204
withdrawal B-Disease 0 0.92754734
- I-Disease 0 0.0048292954
emergent I-Disease 0 0.010551295
RS I-Disease 0 0.979837
, O 0 0.0020252033
which O 0 0.0012293993
is O 0 0.0008649192
the O 0 0.0008258255
first O 0 0.0008596449
of O 0 0.0016266056
its O 0 0.0030746548
kind O 0 0.004686079
to O 0 0.0031771841
be O 0 0.004869118
reported O 0 0.00771489
. O 0 0.008971979

The O 0 0.0134872515
patient O 0 0.013874852
developed O 0 0.012917299
RS B-Disease 0 0.7938325
during O 0 0.0070729647
dose O 0 0.027779944
reduction O 0 0.013530666
of O 0 0.02264108
risperidone B-Chemical 1 0.99988973
. O 0 0.01940216

The O 0 0.01330534
symptom O 0 0.12897159
was O 0 0.008691723
treated O 0 0.008005509
successfully O 0 0.008998312
with O 0 0.014071835
trihexyphenidyl B-Chemical 1 0.99998355
anticholinergic O 0 0.9998411
therapy O 0 0.58136934
. O 0 0.017369015

The O 0 0.006864792
underlying O 0 0.006350465
mechanism O 0 0.0039949375
of O 0 0.0039375536
withdrawal B-Disease 0 0.94317853
- I-Disease 0 0.0054395692
emergent I-Disease 0 0.008206413
RS I-Disease 0 0.9478398
in O 0 0.00087250833
the O 0 0.00065460487
present O 0 0.00043021943
case O 0 0.00063893956
may O 0 0.0005057824
have O 0 0.00045408815
been O 0 0.00049983204
related O 0 0.00031560115
to O 0 0.00036374974
the O 0 0.0004281693
pharmacological O 0 0.16297366
profile O 0 0.00075364043
of O 0 0.0023103973
risperidone B-Chemical 1 0.99999595
, O 0 0.0018457464
a O 0 0.0023066872
serotonin B-Chemical 1 0.9999342
- O 0 0.020518854
dopamine B-Chemical 1 0.99990976
antagonist O 0 0.97249764
, O 0 0.0009552139
suggesting O 0 0.00034178866
the O 0 0.0004274568
pathophysiologic O 0 0.012131342
influence O 0 0.0005216592
of O 0 0.0010020984
the O 0 0.0013261699
serotonin B-Chemical 1 0.99956125
system O 0 0.0022508833
in O 0 0.0014478216
the O 0 0.0020213788
development O 0 0.005052205
of O 0 0.007800662
RS B-Disease 0 0.98533845
. O 0 0.010618477

Pharmacokinetic O 0 0.6228138
/ O 0 0.010481644
pharmacodynamic O 0 0.13818806
assessment O 0 0.0029344328
of O 0 0.0021735933
the O 0 0.0015725004
effects O 0 0.0025946442
of O 0 0.004753618
E4031 B-Chemical 0 0.9999937
, O 0 0.025873952
cisapride B-Chemical 1 0.9999877
, O 0 0.010693517
terfenadine B-Chemical 1 0.9999902
and O 0 0.0024485793
terodiline B-Chemical 1 0.99989617
on O 0 0.0009022704
monophasic O 0 0.42477915
action O 0 0.005346554
potential O 0 0.0026465997
duration O 0 0.0033913865
in O 0 0.004118293
dog O 0 0.014516343
. O 0 0.008712364

1 O 0 0.13336578
. O 0 0.12343066

Torsades B-Disease 0 0.99820924
de I-Disease 0 0.5511399
pointes I-Disease 0 0.99997234
( O 0 0.18740958
TDP B-Disease 2 0.99900347
) O 0 0.008191388
is O 0 0.0018652776
a O 0 0.0018374264
potentially O 0 0.003873238
fatal O 0 0.99673563
ventricular B-Disease 2 0.9998503
tachycardia I-Disease 2 0.9999795
associated O 0 0.0022006626
with O 0 0.001072265
increases O 0 0.00087517535
in O 0 0.0009671869
QT O 0 0.99580437
interval O 0 0.0011849162
and O 0 0.0011196082
monophasic O 0 0.3477339
action O 0 0.004962372
potential O 0 0.0024187153
duration O 0 0.003786961
( O 0 0.008082464
MAPD O 0 0.90029603
) O 0 0.011607302
. O 0 0.008225005

TDP B-Disease 2 0.98553306
is O 0 0.0075277183
a O 0 0.0061735837
side O 0 0.12144628
- O 0 0.004467447
effect O 0 0.0016060744
that O 0 0.0010807646
has O 0 0.00088173384
led O 0 0.0009806205
to O 0 0.0007565266
withdrawal O 0 0.532457
of O 0 0.00093296124
several O 0 0.00078858074
drugs O 0 0.4739309
from O 0 0.0007380114
the O 0 0.0007561813
market O 0 0.007892395
( O 0 0.0014632366
e O 0 0.0020562296
. O 0 0.00086615514
g O 0 0.0023377636
. O 0 0.0016881243
terfenadine B-Chemical 1 0.9999547
and O 0 0.008740785
terodiline B-Chemical 1 0.9998615
) O 0 0.022979874
. O 0 0.00908009

2 O 0 0.13118877
. O 0 0.12387763

The O 0 0.00762091
potential O 0 0.0063913967
of O 0 0.0054384936
compounds O 0 0.5034112
to O 0 0.0035486678
cause O 0 0.03420047
TDP B-Disease 2 0.9982899
was O 0 0.0019102441
evaluated O 0 0.0012727372
by O 0 0.0015023993
monitoring O 0 0.0015583631
their O 0 0.0016995043
effects O 0 0.0029206027
on O 0 0.002220637
MAPD O 0 0.7709108
in O 0 0.0046985215
dog O 0 0.014656484
. O 0 0.009441328

Four O 0 0.012555338
compounds O 0 0.24263133
known O 0 0.0059797205
to O 0 0.003465486
increase O 0 0.0027887113
QT O 0 0.9935632
interval O 0 0.0028459565
and O 0 0.0021559165
cause O 0 0.019267228
TDP B-Disease 2 0.9984548
were O 0 0.0015348728
investigated O 0 0.0012687927
: O 0 0.0072964863
terfenadine B-Chemical 1 0.9999876
, O 0 0.015486161
terodiline B-Chemical 1 0.999938
, O 0 0.021089861
cisapride B-Chemical 1 0.9999348
and O 0 0.030632934
E4031 B-Chemical 0 0.9999044
. O 0 0.012509565

On O 0 0.008032048
the O 0 0.004475462
basis O 0 0.0032937787
that O 0 0.0019802246
only O 0 0.001629301
free O 0 0.002023292
drug O 0 0.3246407
in O 0 0.0009811206
the O 0 0.00088817044
systemic O 0 0.8187393
circulation O 0 0.028957762
will O 0 0.00049930316
elicit O 0 0.0004695048
a O 0 0.0008674266
pharmacological O 0 0.2101173
response O 0 0.0010709612
target O 0 0.0006354749
, O 0 0.000814999
free O 0 0.0007909702
concentrations O 0 0.0015603541
in O 0 0.0005811587
plasma O 0 0.008997865
were O 0 0.00063659024
selected O 0 0.0005629653
to O 0 0.00065839646
mimic O 0 0.0011101263
the O 0 0.0012241884
free O 0 0.0026133065
drug O 0 0.6418514
exposures O 0 0.109059945
in O 0 0.0056395577
man O 0 0.5417116
. O 0 0.010608799

Infusion O 0 0.30768248
regimens O 0 0.013737455
were O 0 0.0038619062
designed O 0 0.0025764315
that O 0 0.0015648878
rapidly O 0 0.0022265224
achieved O 0 0.0012876212
and O 0 0.0010856708
maintained O 0 0.0006767106
target O 0 0.00076627487
- O 0 0.0011358889
free O 0 0.0007531565
concentrations O 0 0.0010975668
of O 0 0.00061712594
these O 0 0.0007329373
drugs O 0 0.6057745
in O 0 0.000532812
plasma O 0 0.013663228
and O 0 0.00056861684
data O 0 0.0005198025
on O 0 0.00026005326
the O 0 0.0003416797
relationship O 0 0.0003085492
between O 0 0.00032252137
free O 0 0.00090801803
concentration O 0 0.0015106458
and O 0 0.0009915853
changes O 0 0.0011981362
in O 0 0.0011149293
MAPD O 0 0.6279719
were O 0 0.001429322
obtained O 0 0.0017077505
for O 0 0.002093895
these O 0 0.005126046
compounds O 0 0.76376694
. O 0 0.009747853

3 O 0 0.12448769
. O 0 0.12115983

These O 0 0.008842757
data O 0 0.00607135
indicate O 0 0.0030385458
that O 0 0.0021499638
the O 0 0.0019423576
free O 0 0.002842992
ED50 O 0 0.98879796
in O 0 0.001355814
plasma O 0 0.03455992
for O 0 0.0011233923
terfenadine B-Chemical 1 0.99999416
( O 0 0.0031877675
1 O 0 0.0008175915
. O 0 0.00042034572
9 O 0 0.00060424354
nM O 0 0.016360568
) O 0 0.0013627061
, O 0 0.0010215323
terodiline B-Chemical 1 0.9999274
( O 0 0.0012013629
76 O 0 0.0018377029
nM O 0 0.03244169
) O 0 0.0014365579
, O 0 0.0010267101
cisapride B-Chemical 1 0.999967
( O 0 0.0012251285
11 O 0 0.0008533013
nM O 0 0.02435239
) O 0 0.0012242484
and O 0 0.0009977146
E4031 B-Chemical 0 0.99998987
( O 0 0.0015737114
1 O 0 0.00060877437
. O 0 0.00035095814
9 O 0 0.00053017307
nM O 0 0.0062260884
) O 0 0.0008220279
closely O 0 0.00044218622
correlate O 0 0.0005152544
with O 0 0.00067532837
the O 0 0.0007646501
free O 0 0.0014328298
concentration O 0 0.002591815
in O 0 0.0019425433
man O 0 0.4002101
causing O 0 0.090646036
QT O 0 0.998971
effects O 0 0.029265458
. O 0 0.010288815

For O 0 0.0077918083
compounds O 0 0.1559531
that O 0 0.0037447643
have O 0 0.0027635768
shown O 0 0.0022667537
TDP B-Disease 2 0.9943059
in O 0 0.0014666595
the O 0 0.0012671708
clinic O 0 0.002569445
( O 0 0.00330577
terfenadine B-Chemical 1 0.9999937
, O 0 0.0066850823
terodiline B-Chemical 1 0.9999745
, O 0 0.004529083
cisapride B-Chemical 1 0.99998224
) O 0 0.001593994
there O 0 0.0002964476
is O 0 0.00036012693
little O 0 0.00034652997
differentiation O 0 0.0063108588
between O 0 0.00027911697
the O 0 0.00046173367
dog O 0 0.0028045734
ED50 O 0 0.9878781
and O 0 0.00066603866
the O 0 0.000516121
efficacious O 0 0.004545296
free O 0 0.00094308757
plasma O 0 0.025642913
concentrations O 0 0.002405069
in O 0 0.0006976962
man O 0 0.23444477
( O 0 0.0016200275
< O 0 0.00084691506
10 O 0 0.00077414996
- O 0 0.0011494884
fold O 0 0.0014759178
) O 0 0.001868199
reflecting O 0 0.0015152742
their O 0 0.0019096415
limited O 0 0.0024209989
safety O 0 0.0075063244
margins O 0 0.015453778
. O 0 0.008665878

These O 0 0.008537563
data O 0 0.0058679413
underline O 0 0.0037831028
the O 0 0.0025852122
need O 0 0.0016975469
to O 0 0.0012067426
maximize O 0 0.00076528714
the O 0 0.00086819276
therapeutic O 0 0.0040294304
ratio O 0 0.0011287878
with O 0 0.00075606816
respect O 0 0.00057555316
to O 0 0.00074433384
TDP B-Disease 2 0.99678504
in O 0 0.00052949943
potential O 0 0.00079335296
development O 0 0.0009366049
candidates O 0 0.00052814424
and O 0 0.0005609727
the O 0 0.00045262877
importance O 0 0.00041999161
of O 0 0.0006907541
using O 0 0.00065503677
free O 0 0.0012764253
drug O 0 0.45061603
concentrations O 0 0.0035853803
in O 0 0.0016109195
pharmacokinetic O 0 0.6022118
/ O 0 0.011492959
pharmacodynamic O 0 0.72052604
studies O 0 0.0075797224
. O 0 0.0077926787

Bladder O 0 0.8242109
retention B-Disease 0 0.014379016
of I-Disease 0 0.005210156
urine I-Disease 0 0.32296506
as O 0 0.0024625969
a O 0 0.0020743813
result O 0 0.0012389093
of O 0 0.0011905801
continuous O 0 0.0012127126
intravenous O 0 0.2652518
infusion O 0 0.019871037
of O 0 0.003450564
fentanyl B-Chemical 1 0.9999379
: O 0 0.0059303776
2 O 0 0.003256541
case O 0 0.0041267523
reports O 0 0.008119177
. O 0 0.008738826

Sedation O 0 0.37310988
has O 0 0.005767067
been O 0 0.0040026745
commonly O 0 0.0034839078
used O 0 0.001760199
in O 0 0.001290914
the O 0 0.0011100892
neonate O 0 0.007938189
to O 0 0.00082133646
decrease O 0 0.00078856153
the O 0 0.0007879689
stress O 0 0.26014993
and O 0 0.0016699408
pain B-Disease 2 0.9982253
from O 0 0.0006866761
the O 0 0.000614178
noxious O 0 0.88545614
stimuli O 0 0.008706428
and O 0 0.0007056554
invasive O 0 0.006901831
procedures O 0 0.0005686786
in O 0 0.00038430802
the O 0 0.00040118318
neonatal O 0 0.0019022053
intensive O 0 0.00048326666
care O 0 0.0007092228
unit O 0 0.00046494283
, O 0 0.0006867867
as O 0 0.00049495057
well O 0 0.00050221034
as O 0 0.0006148254
to O 0 0.0005976526
facilitate O 0 0.00058333966
synchrony O 0 0.0023926
between O 0 0.00094740774
ventilator O 0 0.02397184
and O 0 0.0031779804
spontaneous O 0 0.043779526
breaths O 0 0.06584007
. O 0 0.007972253

Fentanyl B-Chemical 0 0.99962676
, O 0 0.011484019
an O 0 0.0075811218
opioid O 0 0.9986099
analgesic O 0 0.99822944
, O 0 0.0046714633
is O 0 0.0015841014
frequently O 0 0.0015520708
used O 0 0.0009051373
in O 0 0.0008089769
the O 0 0.0008667438
neonatal O 0 0.0029816255
intensive O 0 0.0010995395
care O 0 0.001581857
unit O 0 0.0011953247
setting O 0 0.0016625023
for O 0 0.0016835876
these O 0 0.0033308733
very O 0 0.0050144177
purposes O 0 0.0074698296
. O 0 0.008690081

Various O 0 0.014635583
reported O 0 0.0067951754
side O 0 0.029032886
effects O 0 0.004799841
of O 0 0.004041734
fentanyl B-Chemical 1 0.99993086
administration O 0 0.2503317
include O 0 0.0023702797
chest B-Disease 0 0.9436843
wall I-Disease 0 0.39612335
rigidity I-Disease 2 0.9989122
, O 0 0.014888071
hypotension B-Disease 2 0.99996424
, O 0 0.008707976
respiratory B-Disease 0 0.9469119
depression I-Disease 2 0.9995085
, O 0 0.008508813
and O 0 0.009159443
bradycardia B-Disease 2 0.99927527
. O 0 0.010327436

Here O 0 0.011111199
, O 0 0.007373765
2 O 0 0.0038602562
cases O 0 0.0033579217
of O 0 0.0026731302
urinary B-Disease 0 0.93891877
bladder I-Disease 0 0.95254755
retention I-Disease 0 0.025682945
leading O 0 0.0021759567
to O 0 0.00096836244
renal O 0 0.9835015
pelvocalyceal O 0 0.60407835
dilatation O 0 0.8791652
mimicking O 0 0.03979683
hydronephrosis B-Disease 0 0.9997155
as O 0 0.0010868033
a O 0 0.001030158
result O 0 0.00066778774
of O 0 0.0008643804
continuous O 0 0.0011283644
infusion O 0 0.009943514
of O 0 0.0035970549
fentanyl B-Chemical 1 0.999892
are O 0 0.0058513633
reported O 0 0.008414315
. O 0 0.008750102

Fatal O 0 0.9281486
myeloencephalopathy B-Disease 0 0.97787756
due O 0 0.006143613
to O 0 0.0047248523
accidental O 0 0.81536055
intrathecal O 0 0.99312854
vincristin B-Chemical 0 0.99987185
administration O 0 0.5923939
: O 0 0.0056853895
a O 0 0.0036373462
report O 0 0.00590399
of O 0 0.0044239718
two O 0 0.005006098
cases O 0 0.013079251
. O 0 0.010458441

We O 0 0.0077078035
report O 0 0.0066729095
on O 0 0.002872846
two O 0 0.002474456
fatal O 0 0.91697645
cases O 0 0.0036829645
of O 0 0.0021801682
accidental O 0 0.9093097
intrathecal O 0 0.99469095
vincristine B-Chemical 1 0.9999746
instillation O 0 0.3001358
in O 0 0.0008830391
a O 0 0.001177514
5 O 0 0.0006258216
- O 0 0.0007844783
year O 0 0.0004283105
old O 0 0.0006285318
girl O 0 0.002864549
with O 0 0.0009870153
recurrent O 0 0.9548349
acute B-Disease 0 0.99968433
lymphoblastic I-Disease 0 0.9999933
leucemia I-Disease 0 0.9994375
and O 0 0.003290997
a O 0 0.0023478188
57 O 0 0.0033834227
- O 0 0.0019023945
year O 0 0.0013743462
old O 0 0.002572426
man O 0 0.2800448
with O 0 0.026238263
lymphoblastic B-Disease 0 0.9999753
lymphoma I-Disease 0 0.99985003
. O 0 0.03162987

The O 0 0.009055084
girl O 0 0.01145334
died O 0 0.0084062815
seven O 0 0.0033373795
days O 0 0.0024473055
, O 0 0.002669186
the O 0 0.0018816305
man O 0 0.012055403
four O 0 0.0014584879
weeks O 0 0.0013589225
after O 0 0.00143082
intrathecal O 0 0.82256997
injection O 0 0.015365637
of O 0 0.013498682
vincristine B-Chemical 1 0.99980885
. O 0 0.014198739

Clinically O 0 0.12873471
, O 0 0.00736356
the O 0 0.003939836
onset O 0 0.0059127784
was O 0 0.0023369817
characterized O 0 0.0025375406
by O 0 0.0018513226
the O 0 0.0014372364
signs O 0 0.1318814
of O 0 0.0021519933
opistothonus B-Disease 0 0.057673812
, I-Disease 0 0.0025616626
sensory I-Disease 0 0.07343823
and I-Disease 0 0.0025075984
motor I-Disease 0 0.26332247
dysfunction I-Disease 0 0.94781274
and O 0 0.0065005883
ascending O 0 0.36474273
paralysis B-Disease 2 0.9994455
. O 0 0.011871123

Histological O 0 0.18318285
and O 0 0.007890879
immunohistochemical O 0 0.0119405305
investigations O 0 0.007763562
( O 0 0.0076755662
HE O 0 0.9931636
- O 0 0.016573668
LFB O 0 0.996887
, O 0 0.0039353697
CD O 0 0.95004386
- O 0 0.0029685122
68 O 0 0.0021467253
, O 0 0.0014872509
Neurofilament O 0 0.8157648
) O 0 0.0015265733
revealed O 0 0.000706945
degeneration B-Disease 0 0.8895342
of I-Disease 0 0.0009804439
myelin I-Disease 0 0.18055218
and I-Disease 0 0.00093595544
axons I-Disease 0 0.011044929
as O 0 0.0004693562
well O 0 0.00043869892
as O 0 0.00063723064
pseudocystic B-Disease 0 0.7342623
transformation I-Disease 0 0.36304915
in O 0 0.0007505735
areas O 0 0.0021479332
exposed O 0 0.0006378474
to O 0 0.0009075276
vincristine B-Chemical 1 0.99994373
, O 0 0.0020893835
accompanied O 0 0.002041353
by O 0 0.00132594
secondary O 0 0.003531633
changes O 0 0.0022192695
with O 0 0.0023929735
numerous O 0 0.007426935
prominent O 0 0.034975637
macrophages O 0 0.07485978
. O 0 0.010202437

The O 0 0.009568569
clinical O 0 0.011016276
course O 0 0.0064526917
and O 0 0.0052098627
histopathological O 0 0.1400502
results O 0 0.004046559
of O 0 0.0040234756
the O 0 0.0035770603
two O 0 0.003651475
cases O 0 0.007311089
are O 0 0.0069516315
presented O 0 0.01004256
. O 0 0.011202296

A O 0 0.03695193
review O 0 0.012384473
of O 0 0.007830357
all O 0 0.005751771
reported O 0 0.005757661
cases O 0 0.006614753
in O 0 0.0047325785
the O 0 0.0051882206
literature O 0 0.008166391
is O 0 0.0070183054
given O 0 0.0074863187
. O 0 0.011899683

A O 0 0.029778576
better O 0 0.00792911
controlled O 0 0.005364789
regimen O 0 0.0068180882
for O 0 0.0033558973
administering O 0 0.04535711
vincristine B-Chemical 1 0.9998355
and O 0 0.008538055
intrathecal O 0 0.99214256
chemotherapy O 0 0.96752644
is O 0 0.008087788
recommended O 0 0.009607501
. O 0 0.010532082

Palpebral B-Disease 0 0.93208796
twitching I-Disease 0 0.9285977
in O 0 0.016115654
a O 0 0.018715298
depressed B-Disease 2 0.8419989
adolescent O 0 0.28513288
on O 0 0.016005287
citalopram B-Chemical 1 0.99977845
. O 0 0.024276538

Current O 0 0.017424107
estimates O 0 0.0055203335
suggest O 0 0.0027686632
that O 0 0.0021495526
between O 0 0.0015263407
0 O 0 0.0021180767
. O 0 0.0009947597
4 O 0 0.0008593176
% O 0 0.00093524414
and O 0 0.0008062058
8 O 0 0.00070463284
. O 0 0.0005101553
3 O 0 0.00056538463
% O 0 0.00072097784
of O 0 0.0008045657
children O 0 0.0018590407
and O 0 0.0014747229
adolescents O 0 0.023116654
are O 0 0.0018934617
affected O 0 0.0021979096
by O 0 0.00410902
major B-Disease 2 0.040923152
depression I-Disease 2 0.99958354
. O 0 0.012068147

We O 0 0.008042358
report O 0 0.007543338
a O 0 0.004696
favorable O 0 0.006574269
response O 0 0.0029090978
to O 0 0.0016291057
treatment O 0 0.0024210047
with O 0 0.0021008062
citalopram B-Chemical 1 0.9999863
by O 0 0.0013297291
a O 0 0.0011725555
15 O 0 0.0006552612
- O 0 0.0009173161
year O 0 0.0005724221
- O 0 0.00081078435
old O 0 0.0006354673
boy O 0 0.0021783123
with O 0 0.0007616117
major B-Disease 2 0.006158211
depression I-Disease 2 0.99981743
who O 0 0.0036504155
exhibited O 0 0.0009300458
palpebral B-Disease 0 0.82752603
twitching I-Disease 0 0.9682916
during O 0 0.00088244025
his O 0 0.0016586295
first O 0 0.001074853
2 O 0 0.0016232359
weeks O 0 0.0016171393
of O 0 0.0035525684
treatment O 0 0.008609156
. O 0 0.008637809

This O 0 0.012419153
may O 0 0.0064594857
have O 0 0.004302081
been O 0 0.0035739853
a O 0 0.0032872108
side O 0 0.024168454
effect O 0 0.002327943
of O 0 0.004314067
citalopram B-Chemical 1 0.99997807
as O 0 0.0030505091
it O 0 0.0031690942
remitted O 0 0.9531646
with O 0 0.0029793128
redistribution O 0 0.0062692403
of O 0 0.0059457007
doses O 0 0.20977636
. O 0 0.010505217

The O 0 0.017947264
3 O 0 0.015098091
- O 0 0.016483467
week O 0 0.012723013
sulphasalazine B-Chemical 1 0.99962294
syndrome O 0 0.98527664
strikes O 0 0.70729107
again O 0 0.023000892
. O 0 0.020100625

A O 0 0.038993567
34 O 0 0.010113756
- O 0 0.0069096014
year O 0 0.003646867
- O 0 0.0033218246
old O 0 0.0021469377
lady O 0 0.0048409095
developed O 0 0.0018373497
a O 0 0.0017015875
constellation O 0 0.027164835
of O 0 0.0029072545
dermatitis B-Disease 2 0.9999291
, O 0 0.055818807
fever B-Disease 2 0.9999622
, O 0 0.015984446
lymphadenopathy B-Disease 2 0.9997757
and O 0 0.008085951
hepatitis B-Disease 2 0.9999831
, O 0 0.0022470711
beginning O 0 0.00041903945
on O 0 0.00031683716
the O 0 0.0004497399
17th O 0 0.0024209023
day O 0 0.0003982518
of O 0 0.0005493388
a O 0 0.0007551817
course O 0 0.00077724305
of O 0 0.0011937295
oral O 0 0.865631
sulphasalazine B-Chemical 1 0.9999831
for O 0 0.0020862422
sero O 0 0.27883434
- O 0 0.0075040297
negative O 0 0.008918407
rheumatoid B-Disease 2 0.9997799
arthritis I-Disease 2 0.99992573
. O 0 0.030558946

Cervical O 0 0.5855782
and O 0 0.007337132
inguinal O 0 0.010323306
lymph O 0 0.054061133
node O 0 0.004752303
biopsies O 0 0.0044020703
showed O 0 0.0012794707
the O 0 0.0010658508
features O 0 0.001649384
of O 0 0.0014989045
severe O 0 0.56378543
necrotising O 0 0.9998627
lymphadenitis B-Disease 0 0.99992263
, O 0 0.009959472
associated O 0 0.0013120502
with O 0 0.0010043404
erythrophagocytosis O 0 0.9740132
and O 0 0.0012407994
prominent O 0 0.01982528
eosinophilic O 0 0.99894494
infiltrates O 0 0.99657625
, O 0 0.0022471694
without O 0 0.00056719757
viral O 0 0.01071995
inclusion O 0 0.00051744113
bodies O 0 0.0037152662
, O 0 0.0006575051
suggestive O 0 0.00078937353
of O 0 0.00055182836
an O 0 0.0008824238
adverse B-Disease 0 0.98049873
drug I-Disease 0 0.71140265
reaction I-Disease 0 0.12535106
. O 0 0.00045907893
A O 0 0.01888976
week O 0 0.0003190104
later O 0 0.00036400865
, O 0 0.000931715
fulminant O 0 0.99978477
drug B-Disease 0 0.9591263
- I-Disease 0 0.015119739
induced I-Disease 0 0.0039011175
hepatitis I-Disease 2 0.99999166
, O 0 0.0059697186
associated O 0 0.00079410925
with O 0 0.0005233064
the O 0 0.00041962945
presence O 0 0.00039794855
of O 0 0.0007714377
anti O 0 0.04020398
- O 0 0.0034143406
nuclear O 0 0.007888345
autoantibodies O 0 0.6356595
( O 0 0.0013927415
but O 0 0.00043525072
not O 0 0.00035019746
with O 0 0.00040134694
other O 0 0.00047974038
markers O 0 0.001635001
of O 0 0.0019708006
autoimmunity B-Disease 0 0.9995827
) O 0 0.017093495
, O 0 0.0011936596
and O 0 0.00078176643
accompanied O 0 0.0015246572
by O 0 0.0012154382
multi B-Disease 0 0.13256724
- I-Disease 0 0.0029170034
organ I-Disease 0 0.14309576
failure I-Disease 0 0.74727494
and O 0 0.0060119675
sepsis B-Disease 2 0.99940765
, O 0 0.0323325
supervened O 0 0.96438515
. O 0 0.0105698155

She O 0 0.01091346
subsequently O 0 0.0063483473
died O 0 0.006970449
some O 0 0.0027121552
5 O 0 0.0016172958
weeks O 0 0.0008958802
after O 0 0.00060378964
the O 0 0.0006713453
commencement O 0 0.0007722813
of O 0 0.0007550893
her O 0 0.0012856273
drug O 0 0.47841373
therapy O 0 0.025945328
. O 0 0.00061035895
Post O 0 0.07966445
- O 0 0.0010130946
mortem O 0 0.021124637
examination O 0 0.0006143261
showed O 0 0.00035301346
evidence O 0 0.00045436076
of O 0 0.0009350361
massive B-Disease 0 0.8196402
hepatocellular I-Disease 0 0.99999774
necrosis I-Disease 2 0.9999931
, O 0 0.060738068
acute O 0 0.99773514
hypersensitivity O 2 0.9998907
myocarditis B-Disease 0 0.9999987
, O 0 0.02871412
focal O 0 0.43803442
acute O 0 0.99081975
tubulo O 0 0.96237236
- O 0 0.025870947
interstitial O 2 0.98732567
nephritis B-Disease 2 0.99999464
and O 0 0.005268714
extensive O 0 0.0028150694
bone B-Disease 0 0.91100055
marrow I-Disease 0 0.97538084
necrosis I-Disease 2 0.99984336
, O 0 0.0039688637
with O 0 0.0017462224
no O 0 0.0015751924
evidence O 0 0.0032510187
of O 0 0.008663216
malignancy B-Disease 2 0.99942964
. O 0 0.014387879

It O 0 0.010121694
is O 0 0.0052618706
thought O 0 0.0038697603
that O 0 0.0022050615
the O 0 0.0021071436
clinico O 0 0.40565738
- O 0 0.004479351
pathological O 0 0.1994678
features O 0 0.0029169035
and O 0 0.0011790055
chronology O 0 0.013411575
of O 0 0.00079676067
this O 0 0.00055341545
case O 0 0.0005937263
bore O 0 0.0027545553
the O 0 0.000486772
hallmarks O 0 0.0014466585
of O 0 0.0007074768
the O 0 0.0005894262
so O 0 0.0006629491
- O 0 0.0012066191
called O 0 0.00072833075
" O 0 0.0008502553
3 O 0 0.00053371215
- O 0 0.0007400146
week O 0 0.00043494758
sulphasalazine B-Chemical 1 0.99997056
syndrome O 0 0.9480084
" O 0 0.0021799796
, O 0 0.0010810525
a O 0 0.0009813431
rare O 0 0.009766028
, O 0 0.0014508927
but O 0 0.0009807654
often O 0 0.0025348894
fatal O 0 0.9928582
, O 0 0.00589901
immunoallergic O 0 0.99680483
reaction O 0 0.20149411
to O 0 0.009415746
sulphasalazine B-Chemical 1 0.99992275
. O 0 0.012951446

Intravenous O 0 0.895905
administration O 0 0.11876503
of O 0 0.0068310583
prochlorperazine B-Chemical 1 0.9999497
by O 0 0.0031781257
15 O 0 0.0013071868
- O 0 0.001207222
minute O 0 0.0005885698
infusion O 0 0.0015788234
versus O 0 0.0005706547
2 O 0 0.0005917919
- O 0 0.000636901
minute O 0 0.00035505
bolus O 0 0.0051008877
does O 0 0.00034353914
not O 0 0.0003822673
affect O 0 0.00031518107
the O 0 0.0005415339
incidence O 0 0.010921457
of O 0 0.003625287
akathisia B-Disease 0 0.99999535
: O 0 0.003997093
a O 0 0.0019089088
prospective O 0 0.004060827
, O 0 0.0021016542
randomized O 0 0.0023579192
, O 0 0.0029540719
controlled O 0 0.0033070745
trial O 0 0.0068498603
. O 0 0.0071496437

STUDY O 0 0.02597988
OBJECTIVE O 0 0.39701775
: O 0 0.0061314986
We O 0 0.002763874
sought O 0 0.0022511275
to O 0 0.0013011328
compare O 0 0.00070252153
the O 0 0.0008626521
rate O 0 0.00086519495
of O 0 0.0016367277
akathisia B-Disease 0 0.9999926
after O 0 0.0005378108
administration O 0 0.032026492
of O 0 0.0010070129
intravenous O 0 0.84140986
prochlorperazine B-Chemical 1 0.99998915
as O 0 0.0009800721
a O 0 0.0011695593
2 O 0 0.0007988772
- O 0 0.0009213141
minute O 0 0.0006355557
bolus O 0 0.0057684532
or O 0 0.0012019335
15 O 0 0.0015438698
- O 0 0.0027486465
minute O 0 0.0027334534
infusion O 0 0.012634326
. O 0 0.007253625

METHODS O 0 0.011508844
: O 0 0.007897807
We O 0 0.004019148
conducted O 0 0.0027037724
a O 0 0.0029063823
prospective O 0 0.0035529851
, O 0 0.0020359764
randomized O 0 0.0015013817
, O 0 0.001354757
double O 0 0.0010903354
- O 0 0.0014966982
blind O 0 0.0025060817
study O 0 0.00085305714
in O 0 0.00066408777
the O 0 0.0008093142
emergency O 0 0.004443808
department O 0 0.0037659144
of O 0 0.001750785
a O 0 0.00271807
central O 0 0.0066853166
- O 0 0.0046774293
city O 0 0.010113623
teaching O 0 0.0072502736
hospital O 0 0.013021298
. O 0 0.008595394

Patients O 0 0.0141160935
aged O 0 0.008147089
18 O 0 0.0042813807
years O 0 0.003511555
or O 0 0.0022514914
older O 0 0.004106923
treated O 0 0.00203558
with O 0 0.0023864165
prochlorperazine B-Chemical 1 0.9999814
for O 0 0.0025892484
headache B-Disease 2 0.9999732
, O 0 0.028758666
nausea B-Disease 2 0.9999927
, O 0 0.0045227106
or O 0 0.0027937705
vomiting B-Disease 2 0.99988806
were O 0 0.003185842
eligible O 0 0.003677651
for O 0 0.0029900868
inclusion O 0 0.0052630208
. O 0 0.007908642

Study O 0 0.017426735
participants O 0 0.0055912407
were O 0 0.0033358382
randomized O 0 0.0023630832
to O 0 0.0014847373
receive O 0 0.0011643919
10 O 0 0.0010174385
mg O 0 0.089860275
of O 0 0.001338329
prochlorperazine B-Chemical 1 0.99997437
administered O 0 0.0015414753
intravenously O 0 0.002078648
by O 0 0.0005339126
means O 0 0.0006092588
of O 0 0.00056583364
2 O 0 0.00054504484
- O 0 0.00058648834
minute O 0 0.00032172102
push O 0 0.0021125537
( O 0 0.00060483447
bolus O 0 0.013045393
group O 0 0.0006166694
) O 0 0.00083393883
or O 0 0.00036079081
10 O 0 0.00040674524
mg O 0 0.07047593
diluted O 0 0.00089388626
in O 0 0.00034724167
50 O 0 0.0005606819
mL O 0 0.0009668703
of O 0 0.0004062792
normal O 0 0.0008227489
saline O 0 0.056698207
solution O 0 0.005142852
administered O 0 0.00069790904
by O 0 0.00041205465
means O 0 0.00048611034
of O 0 0.0004608253
intravenous O 0 0.18130907
infusion O 0 0.0052658226
during O 0 0.00040888635
a O 0 0.0008434119
15 O 0 0.0006474158
- O 0 0.0009867202
minute O 0 0.00074376096
period O 0 0.001034206
( O 0 0.0022926836
infusion O 0 0.007831502
group O 0 0.0049549635
) O 0 0.010522918
. O 0 0.007706061

The O 0 0.007522184
main O 0 0.006108429
outcome O 0 0.0059283986
was O 0 0.0029692347
the O 0 0.0020752558
number O 0 0.0016412179
of O 0 0.0018244246
study O 0 0.001904488
participants O 0 0.001969581
experiencing O 0 0.16828758
akathisia B-Disease 0 0.99997747
within O 0 0.0015169716
60 O 0 0.002083413
minutes O 0 0.0021025185
of O 0 0.004186842
administration O 0 0.14675069
. O 0 0.009390828

Akathisia O 2 0.99941325
was O 0 0.0066378014
defined O 0 0.0034469836
as O 0 0.0024905282
either O 0 0.0017916544
a O 0 0.001867221
spontaneous O 0 0.0114237275
report O 0 0.003074601
of O 0 0.0020896948
restlessness O 0 0.9997714
or O 0 0.001415996
agitation B-Disease 2 0.98482174
or O 0 0.000704266
a O 0 0.0007788939
change O 0 0.0004900449
of O 0 0.00053068576
2 O 0 0.00044435984
or O 0 0.0003443407
more O 0 0.00042014744
in O 0 0.00034432005
the O 0 0.0004233957
patient O 0 0.0012434551
- O 0 0.0014757491
reported O 0 0.001230547
akathisia B-Disease 0 0.99999416
rating O 0 0.021052644
scale O 0 0.0014133318
and O 0 0.00056186283
a O 0 0.0006228518
change O 0 0.00046131972
of O 0 0.0005183979
at O 0 0.0003821879
least O 0 0.0003679459
1 O 0 0.0006280341
in O 0 0.00059756736
the O 0 0.00091336225
investigator O 0 0.004297973
- O 0 0.002624028
observed O 0 0.0020602744
akathisia B-Disease 0 0.9999665
rating O 0 0.09321653
scale O 0 0.014568654
. O 0 0.008540817

The O 0 0.008097085
intensity O 0 0.0060175722
of O 0 0.007120465
headache B-Disease 2 0.99976414
and O 0 0.012623415
nausea B-Disease 2 0.99998045
was O 0 0.00344651
measured O 0 0.0017343401
with O 0 0.0021061501
a O 0 0.003130284
100 O 0 0.005045151
- O 0 0.004462574
mm O 0 0.0084707085
visual O 0 0.1250045
analog O 0 0.06934229
scale O 0 0.013269023
. O 0 0.009661598

RESULTS O 0 0.06309173
: O 0 0.03064313
One O 0 0.02512022
hundred O 0 0.022159325
patients O 0 0.025085663
were O 0 0.022296462
enrolled O 0 0.029934293
. O 0 0.02553371

One O 0 0.021182833
study O 0 0.013316272
participant O 0 0.00963605
was O 0 0.008871162
excluded O 0 0.009734008
after O 0 0.0074687125
protocol O 0 0.013722475
violation O 0 0.06935617
. O 0 0.01820681

Seventy O 0 0.019059153
- O 0 0.008267839
three O 0 0.0031773928
percent O 0 0.0030891132
( O 0 0.0032895831
73 O 0 0.0034550237
/ O 0 0.0029384338
99 O 0 0.0023345407
) O 0 0.0013529492
of O 0 0.0008096771
the O 0 0.0006812068
study O 0 0.0007592139
participants O 0 0.00067823473
were O 0 0.0005504132
treated O 0 0.0007507638
for O 0 0.00073451333
headache B-Disease 2 0.99989724
and O 0 0.001278254
70 O 0 0.0011644403
% O 0 0.0012546302
( O 0 0.0014539326
70 O 0 0.0014206937
/ O 0 0.0028817796
99 O 0 0.0036520374
) O 0 0.0041036946
for O 0 0.0043405844
nausea B-Disease 2 0.9999039
. O 0 0.011600751

In O 0 0.0068295477
the O 0 0.004825145
bolus O 0 0.019126166
group O 0 0.003547034
, O 0 0.0026932787
26 O 0 0.0019857131
. O 0 0.000912083
0 O 0 0.0010800358
% O 0 0.000976029
( O 0 0.00094042043
13 O 0 0.0007673136
/ O 0 0.0012128224
50 O 0 0.00086647866
) O 0 0.0008993474
had O 0 0.0005646169
akathisia B-Disease 0 0.9999839
compared O 0 0.00036081145
with O 0 0.0005210283
32 O 0 0.0007195751
. O 0 0.00030155992
7 O 0 0.000354664
% O 0 0.00046983743
( O 0 0.0005143633
16 O 0 0.00040396478
/ O 0 0.0007525023
49 O 0 0.0006893159
) O 0 0.00053970335
in O 0 0.0002741657
the O 0 0.00032247617
infusion O 0 0.0022195745
group O 0 0.0006953381
( O 0 0.0010078595
Delta O 0 0.037924167
= O 0 0.0007961588
- O 0 0.0006107079
6 O 0 0.00028223876
. O 0 0.00025959846
7 O 0 0.00034222816
% O 0 0.0005029183
; O 0 0.0006751746
95 O 0 0.0007118583
% O 0 0.00053043244
confidence O 0 0.0011989253
interval O 0 0.0008794377
[ O 0 0.0037542225
CI O 0 0.43468234
] O 0 0.0020632518
- O 0 0.0010588514
24 O 0 0.00048764417
. O 0 0.0004542722
6 O 0 0.00052546815
% O 0 0.0008510156
to O 0 0.00087904575
11 O 0 0.0016038334
. O 0 0.0014245774
2 O 0 0.0025235044
% O 0 0.004476535
) O 0 0.0080013815
. O 0 0.0075286054

The O 0 0.0059671355
difference O 0 0.0030427866
between O 0 0.0020312646
the O 0 0.001973174
bolus O 0 0.019120226
and O 0 0.0015378733
infusion O 0 0.0058890027
groups O 0 0.0009920658
in O 0 0.0005430298
the O 0 0.0004517882
percentage O 0 0.00033831064
of O 0 0.000545247
participants O 0 0.0005854889
who O 0 0.0008207326
saw O 0 0.0006615174
a O 0 0.0006412333
50 O 0 0.0006919963
% O 0 0.00049182214
reduction O 0 0.00050334574
in O 0 0.000338546
their O 0 0.00060020393
headache B-Disease 2 0.999877
intensity O 0 0.00039245948
within O 0 0.0002211284
30 O 0 0.00024758294
minutes O 0 0.00024044815
was O 0 0.00032083126
11 O 0 0.00045911438
. O 0 0.00029200414
8 O 0 0.00038571854
% O 0 0.0005546671
( O 0 0.0007061164
95 O 0 0.0009828743
% O 0 0.00086495513
CI O 0 0.10272983
- O 0 0.0009841903
9 O 0 0.0006240279
. O 0 0.0004769344
6 O 0 0.0005422457
% O 0 0.0008697063
to O 0 0.00089313276
33 O 0 0.0019057356
. O 0 0.0014211214
3 O 0 0.0023318967
% O 0 0.004348159
) O 0 0.007775793
. O 0 0.0074034235

The O 0 0.0062950095
difference O 0 0.0032988614
in O 0 0.0026147298
the O 0 0.0018918107
percentage O 0 0.0012600679
of O 0 0.0015212549
patients O 0 0.0026577117
with O 0 0.0010819811
a O 0 0.0012890337
50 O 0 0.0011837971
% O 0 0.0007790432
reduction O 0 0.00073766784
in O 0 0.00048828794
their O 0 0.00095695606
nausea B-Disease 2 0.99999356
was O 0 0.0007513629
12 O 0 0.00041561617
. O 0 0.00033017318
6 O 0 0.00034856255
% O 0 0.0005740109
( O 0 0.00072241627
95 O 0 0.001001656
% O 0 0.00088297937
CI O 0 0.10813122
- O 0 0.0009958546
4 O 0 0.0005555686
. O 0 0.0004907404
6 O 0 0.00056188134
% O 0 0.0009056687
to O 0 0.00093674107
29 O 0 0.0020863295
. O 0 0.0014593675
8 O 0 0.0024080272
% O 0 0.0043524234
) O 0 0.007876234
. O 0 0.0075280676

CONCLUSION O 0 0.7732462
: O 0 0.011025934
A O 0 0.021078758
50 O 0 0.004478497
% O 0 0.0028727204
reduction O 0 0.002102228
in O 0 0.0011705613
the O 0 0.0010698212
incidence O 0 0.0072848103
of O 0 0.002732474
akathisia B-Disease 0 0.99999523
when O 0 0.0012530729
prochlorperazine B-Chemical 1 0.99998844
was O 0 0.00078344706
administered O 0 0.00082026573
by O 0 0.00048296043
means O 0 0.0005565197
of O 0 0.0005026864
15 O 0 0.00040533143
- O 0 0.0005140785
minute O 0 0.00029984867
intravenous O 0 0.033897787
infusion O 0 0.0022872165
versus O 0 0.00054543617
a O 0 0.00091035344
2 O 0 0.0008211487
- O 0 0.0010865766
minute O 0 0.00084154063
intravenous O 0 0.11234403
push O 0 0.008650431
was O 0 0.002561258
not O 0 0.00316455
detected O 0 0.0042736405
. O 0 0.0077827307

The O 0 0.006735132
efficacy O 0 0.006747917
of O 0 0.00546609
prochlorperazine B-Chemical 1 0.9999224
in O 0 0.0022934198
the O 0 0.0015109227
treatment O 0 0.002037818
of O 0 0.002900877
headache B-Disease 2 0.9999757
and O 0 0.012286764
nausea B-Disease 2 0.999997
likewise O 0 0.101738244
did O 0 0.000725091
not O 0 0.00057716045
appear O 0 0.00050429365
to O 0 0.0004423224
be O 0 0.00050142687
affected O 0 0.00042376074
by O 0 0.00051001244
the O 0 0.00043697603
rate O 0 0.00048653592
of O 0 0.0008009894
administration O 0 0.06770293
, O 0 0.0011654533
although O 0 0.00068005087
no O 0 0.00073487114
formal O 0 0.0017322394
statistical O 0 0.004032987
comparisons O 0 0.002488592
were O 0 0.0035827546
made O 0 0.005048948
. O 0 0.0073835123

Combined O 0 0.031913403
antiretroviral O 0 0.12959729
therapy O 0 0.058078695
causes O 0 0.057787757
cardiomyopathy B-Disease 2 0.9999254
and O 0 0.012899187
elevates O 0 0.3390048
plasma O 0 0.29066965
lactate B-Chemical 0 0.98686635
in O 0 0.00483498
transgenic O 0 0.009658109
AIDS B-Disease 2 0.998662
mice O 0 0.008585679
. O 0 0.011638329

Highly O 0 0.0331981
active O 0 0.009117759
antiretroviral O 0 0.13015138
therapy O 0 0.071419165
( O 0 0.0069481735
HAART O 0 0.92514
) O 0 0.0043162103
is O 0 0.0012754549
implicated O 0 0.0011190205
in O 0 0.0014458828
cardiomyopathy B-Disease 2 0.9999819
( O 0 0.012750313
CM B-Disease 2 0.98264587
) O 0 0.002945472
and O 0 0.0008630632
in O 0 0.00069214345
elevated O 0 0.005420389
plasma O 0 0.11789121
lactate B-Chemical 0 0.99456406
( O 0 0.005812788
LA B-Chemical 0 0.9982187
) O 0 0.003060264
in O 0 0.0013744732
AIDS B-Disease 2 0.9977915
through O 0 0.0016077942
mechanisms O 0 0.003363937
of O 0 0.005884961
mitochondrial B-Disease 2 0.9824739
dysfunction I-Disease 2 0.998412
. O 0 0.011943159

To O 0 0.0065866825
determine O 0 0.0035392463
mitochondrial O 0 0.08958348
events O 0 0.03251316
from O 0 0.0025865517
HAART O 0 0.7102804
in O 0 0.001290469
vivo O 0 0.001838358
, O 0 0.0013667366
8 O 0 0.0007984012
- O 0 0.0009092049
week O 0 0.00045716707
- O 0 0.0007815802
old O 0 0.00068446837
hemizygous O 0 0.0071099573
transgenic O 0 0.0013755279
AIDS B-Disease 2 0.9994886
mice O 0 0.0008349156
( O 0 0.004329798
NL4 O 0 0.95546806
- O 0 0.0027704479
3Delta O 0 0.19956887
gag O 0 0.04116329
/ O 0 0.0046689766
pol O 0 0.042539787
; O 0 0.003463871
TG O 2 0.99608564
) O 0 0.0015434333
and O 0 0.00064333173
wild O 0 0.00058228255
- O 0 0.0009824749
type O 0 0.0005519294
FVB O 0 0.029089365
/ O 0 0.0010095888
n O 0 0.00041758837
littermates O 0 0.00022787398
were O 0 0.00034475885
treated O 0 0.00043409676
with O 0 0.0004407865
the O 0 0.00050621014
HAART O 0 0.6579104
combination O 0 0.00094646314
of O 0 0.0011504292
zidovudine B-Chemical 1 0.98819053
, O 0 0.006020642
lamivudine B-Chemical 1 0.999902
, O 0 0.0016154668
and O 0 0.00097200985
indinavir B-Chemical 1 0.9940136
or O 0 0.00073456374
vehicle O 0 0.022151908
control O 0 0.0007579973
for O 0 0.00068154576
10 O 0 0.0009952043
days O 0 0.0010201066
or O 0 0.0017761345
35 O 0 0.003087328
days O 0 0.0035814168
. O 0 0.0063071884

At O 0 0.0059112487
termination O 0 0.0057324204
of O 0 0.0035520482
the O 0 0.0024465176
experiments O 0 0.0018497759
, O 0 0.0018040178
mice O 0 0.0008714349
underwent O 0 0.001055751
echocardiography O 0 0.042166196
, O 0 0.0009172222
quantitation O 0 0.0010553132
of O 0 0.0005997327
abundance O 0 0.0005010704
of O 0 0.0006491074
molecular O 0 0.013433853
markers O 0 0.0022276687
of O 0 0.0014488545
CM B-Disease 2 0.98441017
( O 0 0.0027478808
ventricular O 0 0.9888347
mRNA O 0 0.0010673719
encoding O 0 0.000824049
atrial O 0 0.98530364
natriuretic O 0 0.9970566
factor O 0 0.16561583
[ O 0 0.05526393
ANF O 1 0.99983776
] O 0 0.0054888315
and O 0 0.001502422
sarcoplasmic O 0 0.9857471
calcium B-Chemical 1 0.9997131
ATPase O 0 0.7826926
[ O 0 0.036502082
SERCA2 O 0 0.9869048
] O 0 0.007399206
) O 0 0.0029930465
, O 0 0.0017862677
and O 0 0.0017380691
determination O 0 0.0032443146
of O 0 0.0042927098
plasma O 0 0.28573522
LA B-Chemical 0 0.99754226
. O 0 0.010616794

Myocardial O 0 0.84057987
histologic O 0 0.21253869
features O 0 0.009306157
were O 0 0.00465644
analyzed O 0 0.003322475
semiquantitatively O 0 0.005773112
and O 0 0.003099619
results O 0 0.0027868794
were O 0 0.0029208837
confirmed O 0 0.0030571204
by O 0 0.004304582
transmission O 0 0.00938462
electron O 0 0.0435777
microscopy O 0 0.011270732
. O 0 0.011468067

After O 0 0.006459085
35 O 0 0.0054405443
days O 0 0.0032829547
in O 0 0.0029795675
the O 0 0.0032408086
TG O 2 0.9911671
+ O 0 0.0039416305
HAART O 0 0.72254384
cohort O 0 0.004277463
, O 0 0.002012786
left O 0 0.0028446985
ventricular O 0 0.92966354
mass O 0 0.0051991995
increased O 0 0.0026130811
160 O 0 0.006273362
% O 0 0.0038709093
by O 0 0.0049000317
echocardiography O 0 0.1542047
. O 0 0.008556853

Molecularly O 0 0.52751726
, O 0 0.019525075
ANF O 1 0.99580693
mRNA O 0 0.008803512
increased O 0 0.0061131525
250 O 0 0.007097362
% O 0 0.0053911726
and O 0 0.005367889
SERCA2 O 0 0.89134914
mRNA O 0 0.0067779543
decreased O 0 0.007544359
57 O 0 0.011899269
% O 0 0.010766055
. O 0 0.010743409

Biochemically O 0 0.303259
, O 0 0.013300807
LA B-Chemical 0 0.98236406
was O 0 0.0050409273
elevated O 0 0.007259234
( O 0 0.0037629534
8 O 0 0.0020088807
. O 0 0.0014058487
5 O 0 0.0014915406
+ O 0 0.0019262066
/ O 0 0.0036880616
- O 0 0.0028870895
2 O 0 0.0021573296
. O 0 0.0022393346
0 O 0 0.0048278696
mM O 0 0.35973662
) O 0 0.01126899
. O 0 0.009011188

Pathologically O 0 0.58785254
, O 0 0.009504732
granular O 0 0.010870503
cytoplasmic O 0 0.0048001553
changes O 0 0.0036897734
were O 0 0.0023728372
found O 0 0.0016641786
in O 0 0.0018950973
cardiac O 0 0.4791713
myocytes O 0 0.14861296
, O 0 0.0032913473
indicating O 0 0.002407078
enlarged O 0 0.03979391
, O 0 0.006343633
damaged O 0 0.03513892
mitochondria O 0 0.40619022
. O 0 0.010519994

Findings O 0 0.07593677
were O 0 0.05071161
confirmed O 0 0.048533905
ultrastructurally O 0 0.13468559
. O 0 0.056502894

No O 0 0.025597686
changes O 0 0.01872793
were O 0 0.014795044
found O 0 0.011688668
in O 0 0.012835864
other O 0 0.01533281
cohorts O 0 0.023860363
. O 0 0.020458853

After O 0 0.0067685386
10 O 0 0.0053637004
days O 0 0.00362874
, O 0 0.003989253
only O 0 0.003133821
ANF O 1 0.99802244
was O 0 0.002657115
elevated O 0 0.00510657
, O 0 0.002388452
and O 0 0.0017581909
only O 0 0.0015590073
in O 0 0.001893368
the O 0 0.0032304463
TG O 2 0.99669373
+ O 0 0.008464088
HAART O 0 0.91850454
cohort O 0 0.024614152
. O 0 0.009717356

Results O 0 0.012738877
show O 0 0.0057360744
that O 0 0.004281592
cumulative O 0 0.010068629
HAART O 0 0.87887233
caused O 0 0.0060021845
mitochondrial O 0 0.7753597
CM B-Disease 2 0.98035944
with O 0 0.0045470097
elevated O 0 0.066155285
LA B-Chemical 0 0.99853814
in O 0 0.0058592134
AIDS B-Disease 2 0.99892837
transgenic O 0 0.008503564
mice O 0 0.007262413
. O 0 0.01061017

A O 0 0.07760042
Phase O 0 0.019902863
II O 0 0.017513767
trial O 0 0.004810677
of O 0 0.0039800256
cisplatin B-Chemical 1 0.999345
plus O 0 0.0053448784
WR B-Chemical 0 0.9932387
- I-Chemical 0 0.0203309
2721 I-Chemical 0 0.9991179
( O 0 0.0055651413
amifostine B-Chemical 1 0.99986625
) O 0 0.0036134627
for O 0 0.00093918026
metastatic O 0 0.9942806
breast B-Disease 2 0.99971384
carcinoma I-Disease 2 0.9999807
: O 0 0.01959537
an O 0 0.004057231
Eastern O 0 0.3470898
Cooperative O 0 0.17554162
Oncology O 0 0.05106225
Group O 0 0.05464569
Study O 0 0.0517776
( O 0 0.005889946
E8188 O 0 0.11802399
) O 0 0.012044811
. O 0 0.009019905

BACKGROUND O 0 0.819581
: O 0 0.017903311
Cisplatin B-Chemical 1 0.99935955
has O 0 0.0034214612
minimal O 0 0.0027711804
antitumor O 0 0.62536347
activity O 0 0.002112742
when O 0 0.0009098389
used O 0 0.00090769585
as O 0 0.0009791777
second O 0 0.0011647581
- O 0 0.0017087116
or O 0 0.0009590988
third O 0 0.0016363926
- O 0 0.0023596045
line O 0 0.0022365586
treatment O 0 0.0028603992
of O 0 0.0050418177
metastatic O 0 0.99862313
breast B-Disease 2 0.99966824
carcinoma I-Disease 2 0.99991167
. O 0 0.02392909

Older O 0 0.03813415
reports O 0 0.0063212463
suggest O 0 0.0030515317
an O 0 0.003440467
objective O 0 0.00322711
response O 0 0.002030938
rate O 0 0.0012899165
of O 0 0.0013077707
8 O 0 0.00091377227
% O 0 0.00082042994
when O 0 0.00048083297
60 O 0 0.0006519054
- O 0 0.00082487694
120 O 0 0.0006227929
mg O 0 0.059024677
/ O 0 0.0014963198
m2 O 0 0.0054952204
of O 0 0.0010669917
cisplatin B-Chemical 1 0.99915826
is O 0 0.0010008692
administered O 0 0.0013504493
every O 0 0.0008204871
3 O 0 0.0015770446
- O 0 0.0027550415
4 O 0 0.0026492167
weeks O 0 0.0034362301
. O 0 0.0062425896

Although O 0 0.007064682
a O 0 0.006402538
dose O 0 0.027871761
- O 0 0.0048970245
response O 0 0.0024282478
effect O 0 0.0015402422
has O 0 0.0010242064
been O 0 0.00094340753
observed O 0 0.0005567794
with O 0 0.0011390548
cisplatin B-Chemical 1 0.99981385
, O 0 0.0013867941
the O 0 0.0005762563
dose O 0 0.024997326
- O 0 0.0015537464
limiting O 0 0.0009316036
toxicities B-Disease 2 0.9997155
associated O 0 0.0012554444
with O 0 0.0013862664
cisplatin B-Chemical 1 0.99990976
( O 0 0.0023220992
e O 0 0.0024958085
. O 0 0.00041896515
g O 0 0.001193423
. O 0 0.000465106
, O 0 0.0014693085
nephrotoxicity B-Disease 2 0.9999933
, O 0 0.012693692
ototoxicity B-Disease 2 0.99998343
, O 0 0.0029039336
and O 0 0.0018265113
neurotoxicity B-Disease 2 0.99994767
) O 0 0.0022695162
have O 0 0.0005314167
limited O 0 0.0005858844
its O 0 0.0011090649
use O 0 0.0010304879
as O 0 0.0012475086
a O 0 0.002219302
treatment O 0 0.0037862235
for O 0 0.0039983387
breast B-Disease 2 0.99917954
carcinoma I-Disease 2 0.9998872
. O 0 0.019261785

WR B-Chemical 0 0.94110733
- I-Chemical 0 0.021020208
2721 I-Chemical 0 0.9841775
or O 0 0.0063443966
amifostine B-Chemical 1 0.9993205
initially O 0 0.0055413856
was O 0 0.0024220864
developed O 0 0.0024392528
to O 0 0.0016928053
protect O 0 0.00443526
military O 0 0.021942
personnel O 0 0.0041827126
in O 0 0.0017941804
the O 0 0.0022943683
event O 0 0.009858347
of O 0 0.0053888205
nuclear O 0 0.046333928
war O 0 0.09574422
. O 0 0.0107495235

Amifostine B-Chemical 0 0.99880457
subsequently O 0 0.00933732
was O 0 0.004126472
shown O 0 0.0021831817
to O 0 0.0017505842
protect O 0 0.0030639425
normal O 0 0.0026472842
tissues O 0 0.0031473613
from O 0 0.0009665733
the O 0 0.00088814244
toxic O 0 0.6989843
effects O 0 0.0027916196
of O 0 0.00200307
alkylating B-Chemical 0 0.9987872
agents I-Chemical 0 0.7173939
and O 0 0.0035115832
cisplatin B-Chemical 1 0.99979776
without O 0 0.001199738
decreasing O 0 0.0017603942
the O 0 0.0014293968
antitumor O 0 0.74297947
effect O 0 0.002159477
of O 0 0.003392352
the O 0 0.0047665285
chemotherapy O 0 0.9129847
. O 0 0.009586422

Early O 0 0.026436426
trials O 0 0.007176284
of O 0 0.005862194
cisplatin B-Chemical 1 0.99923706
and O 0 0.005959716
amifostine B-Chemical 1 0.99976414
also O 0 0.0017815874
suggested O 0 0.00090429076
that O 0 0.0006510752
the O 0 0.0007652299
incidence O 0 0.009054981
and O 0 0.0011986804
severity O 0 0.100108236
of O 0 0.0045453436
cisplatin B-Chemical 1 0.9999502
- O 0 0.027291693
induced O 0 0.00874552
nephrotoxicity B-Disease 2 0.99999607
, O 0 0.08791702
ototoxicity B-Disease 2 0.9999759
, O 0 0.009130347
and O 0 0.0065888045
neuropathy B-Disease 2 0.99986756
were O 0 0.006501352
reduced O 0 0.00705764
. O 0 0.008835004

METHODS O 0 0.012261535
: O 0 0.009850354
A O 0 0.022514058
Phase O 0 0.010434136
II O 0 0.009924361
study O 0 0.0019986075
of O 0 0.0014686771
the O 0 0.0010907017
combination O 0 0.0016093741
of O 0 0.0018443466
cisplatin B-Chemical 1 0.9998404
plus O 0 0.0022848265
amifostine B-Chemical 1 0.9999403
was O 0 0.00083052565
conducted O 0 0.0004508916
in O 0 0.0004128127
patients O 0 0.0013213974
with O 0 0.0006289018
progressive O 0 0.3562449
metastatic O 0 0.99834144
breast B-Disease 2 0.9997985
carcinoma I-Disease 2 0.9999852
who O 0 0.008405542
had O 0 0.0005502991
received O 0 0.00050860667
one O 0 0.00047076718
, O 0 0.00071561115
but O 0 0.00047431255
not O 0 0.00046559476
more O 0 0.00061026536
than O 0 0.00049688865
one O 0 0.00072972826
, O 0 0.0014896521
chemotherapy O 0 0.40384588
regimen O 0 0.0065476373
for O 0 0.002900295
metastatic O 0 0.9941188
disease O 0 0.96681356
. O 0 0.011955014

Patients O 0 0.019480988
received O 0 0.010858518
amifostine B-Chemical 1 0.99870133
, O 0 0.009872646
910 O 0 0.021897566
mg O 0 0.3366538
/ O 0 0.007881179
m2 O 0 0.013448814
intravenously O 0 0.0057476973
over O 0 0.0032186175
15 O 0 0.0046474608
minutes O 0 0.0060751117
. O 0 0.009300724

After O 0 0.005956756
completion O 0 0.0041215452
of O 0 0.003918479
the O 0 0.0035029608
amifostine B-Chemical 1 0.99951124
infusion O 0 0.14260317
, O 0 0.0044607655
cisplatin B-Chemical 1 0.999433
120 O 0 0.0024927051
mg O 0 0.35102996
/ O 0 0.0038147639
m2 O 0 0.010144748
was O 0 0.0015252278
administered O 0 0.002075738
over O 0 0.0017108943
30 O 0 0.002719967
minutes O 0 0.004141313
. O 0 0.0068701874

Intravenous O 0 0.91863847
hydration O 0 0.55450666
and O 0 0.012520301
mannitol B-Chemical 1 0.996763
was O 0 0.00659863
administered O 0 0.006019629
before O 0 0.003576829
and O 0 0.0061171786
after O 0 0.0060540866
cisplatin B-Chemical 1 0.9987558
. O 0 0.014655555

Treatment O 0 0.031180691
was O 0 0.010297322
administered O 0 0.007933564
every O 0 0.0047913115
3 O 0 0.00541241
weeks O 0 0.0047894227
until O 0 0.0056420523
disease O 0 0.56066656
progression O 0 0.72669
. O 0 0.018547302

RESULTS O 0 0.02734924
: O 0 0.009666728
Forty O 0 0.010023747
- O 0 0.0051828935
four O 0 0.00227723
patients O 0 0.0032023145
were O 0 0.0017493156
enrolled O 0 0.001795819
in O 0 0.0010683597
the O 0 0.0010438021
study O 0 0.001217607
of O 0 0.0013126387
which O 0 0.001723649
7 O 0 0.0015514984
( O 0 0.0021389155
16 O 0 0.0019937237
% O 0 0.0028905165
) O 0 0.004541897
were O 0 0.0044524614
ineligible O 0 0.0128106205
. O 0 0.008034719

A O 0 0.023013867
median O 0 0.0066112196
of O 0 0.005329528
2 O 0 0.0036383935
cycles O 0 0.0026776483
of O 0 0.0028835696
therapy O 0 0.0067525334
was O 0 0.00244044
administered O 0 0.0028960728
to O 0 0.0023103212
the O 0 0.0028813481
37 O 0 0.0045206635
eligible O 0 0.0058538746
patients O 0 0.010851954
. O 0 0.009205552

Six O 0 0.0121876905
partial O 0 0.008553117
responses O 0 0.006968476
were O 0 0.0040182886
observed O 0 0.0023996262
for O 0 0.0022316512
an O 0 0.0030513955
overall O 0 0.00277709
response O 0 0.0037015474
rate O 0 0.0034848184
of O 0 0.0052342643
16 O 0 0.0065726754
% O 0 0.0089870505
. O 0 0.009335102

Most O 0 0.0181608
patients O 0 0.015502462
( O 0 0.009845397
57 O 0 0.008611834
% O 0 0.006250259
) O 0 0.006022015
stopped O 0 0.0054705353
treatment O 0 0.0049808426
because O 0 0.0040174914
of O 0 0.007706619
disease O 0 0.9486718
progression O 0 0.92090476
. O 0 0.017024957

Neurologic B-Disease 0 0.99645644
toxicity I-Disease 2 0.99773324
was O 0 0.012747799
reported O 0 0.009447653
in O 0 0.0074798525
52 O 0 0.009929263
% O 0 0.009096192
of O 0 0.010031326
patients O 0 0.022003995
. O 0 0.015283861

Seven O 0 0.018011274
different O 0 0.008640966
life O 0 0.013864294
- O 0 0.009256431
threatening O 0 0.1625102
toxicities B-Disease 2 0.99917823
were O 0 0.0037743016
observed O 0 0.0021114997
in O 0 0.0026387775
patients O 0 0.005837168
while O 0 0.0037693584
receiving O 0 0.009013688
treatment O 0 0.013034959
. O 0 0.010950623

CONCLUSIONS O 0 0.4094363
: O 0 0.008424223
The O 0 0.003763654
combination O 0 0.0039232858
of O 0 0.003940987
cisplatin B-Chemical 1 0.99959177
and O 0 0.0054667774
amifostine B-Chemical 1 0.9998388
in O 0 0.0014532226
this O 0 0.0010709552
study O 0 0.0011906708
resulted O 0 0.00080306944
in O 0 0.00089797814
an O 0 0.0013966159
overall O 0 0.0014080167
response O 0 0.002194377
rate O 0 0.0022174118
of O 0 0.003685597
16 O 0 0.005000372
% O 0 0.0070884903
. O 0 0.0076648225

Neither O 0 0.010106551
a O 0 0.008587004
tumor B-Disease 2 0.9127098
- O 0 0.007367876
protective O 0 0.009052487
effect O 0 0.0018844428
nor O 0 0.0015970302
reduced O 0 0.0018326506
toxicity B-Disease 2 0.9973199
to O 0 0.0010169259
normal O 0 0.0022667255
tissues O 0 0.0034945083
was O 0 0.0006616511
observed O 0 0.000423728
with O 0 0.0006457658
the O 0 0.0006421996
addition O 0 0.0005548643
of O 0 0.0020472528
amifostine B-Chemical 1 0.9998437
to O 0 0.0028220518
cisplatin B-Chemical 1 0.9995695
in O 0 0.00325005
this O 0 0.0041805007
trial O 0 0.009153862
. O 0 0.007832175

Oral B-Chemical 0 0.98704785
contraceptives I-Chemical 0 0.9988105
and O 0 0.018610312
the O 0 0.013075306
risk O 0 0.12241621
of O 0 0.029863613
myocardial B-Disease 0 0.9996885
infarction I-Disease 2 0.9999136
. O 0 0.034184836

BACKGROUND O 0 0.57329154
: O 0 0.008560091
An O 0 0.005342278
association O 0 0.002221488
between O 0 0.001466718
the O 0 0.0014756956
use O 0 0.0013747428
of O 0 0.0017040864
oral B-Chemical 1 0.9466895
contraceptives I-Chemical 1 0.9999546
and O 0 0.0020134214
the O 0 0.0010721566
risk O 0 0.07794502
of O 0 0.0032882467
myocardial B-Disease 0 0.9999654
infarction I-Disease 2 0.9999956
has O 0 0.0012941868
been O 0 0.0010333607
found O 0 0.00067341735
in O 0 0.00085738505
some O 0 0.0012822021
, O 0 0.0018257481
but O 0 0.0014765811
not O 0 0.0017862888
all O 0 0.0026103707
, O 0 0.0050394596
studies O 0 0.006381206
. O 0 0.007817816

We O 0 0.007053819
investigated O 0 0.0040206807
this O 0 0.0031024492
association O 0 0.0021039716
, O 0 0.0023295847
according O 0 0.0011692797
to O 0 0.0008880461
the O 0 0.00083557505
type O 0 0.00089771225
of O 0 0.0015355656
progestagen B-Chemical 0 0.9999193
included O 0 0.00086747704
in O 0 0.0006119128
third O 0 0.0010584577
- O 0 0.0013491946
generation O 0 0.00088348764
( O 0 0.0010074668
i O 0 0.0026215354
. O 0 0.00041823133
e O 0 0.0015262899
. O 0 0.00047676556
, O 0 0.0010918644
desogestrel B-Chemical 1 0.99995697
or O 0 0.0010692088
gestodene B-Chemical 0 0.99998116
) O 0 0.0020844562
and O 0 0.0006175496
second O 0 0.0006428377
- O 0 0.0010845662
generation O 0 0.0007360678
( O 0 0.000871298
i O 0 0.0022311588
. O 0 0.00037786405
e O 0 0.0014039823
. O 0 0.00044320404
, O 0 0.0010694787
levonorgestrel B-Chemical 0 0.9999114
) O 0 0.0032630714
oral B-Chemical 1 0.9073987
contraceptives I-Chemical 1 0.99996734
, O 0 0.0012263253
the O 0 0.00044513648
dose O 0 0.007839182
of O 0 0.0015312422
estrogen B-Chemical 1 0.99993885
, O 0 0.0014478513
and O 0 0.00052893197
the O 0 0.00037691157
presence O 0 0.0003587542
or O 0 0.0003941307
absence O 0 0.00028216423
of O 0 0.000881119
prothrombotic O 0 0.98269546
mutations O 0 0.019874102
METHODS O 0 0.0017183354
: O 0 0.0008891857
In O 0 0.00036966766
a O 0 0.0005968738
nationwide O 0 0.0015577608
, O 0 0.000690325
population O 0 0.0011068407
- O 0 0.0008022533
based O 0 0.00046584517
, O 0 0.00062565395
case O 0 0.00053402816
- O 0 0.00077001064
control O 0 0.00037874043
study O 0 0.000526645
, O 0 0.00048791894
we O 0 0.00023571898
identified O 0 0.0003059874
and O 0 0.0004846377
enrolled O 0 0.0008506471
248 O 0 0.008926478
women O 0 0.004545529
18 O 0 0.00036379896
through O 0 0.0002754474
49 O 0 0.00052064605
years O 0 0.00040401405
of O 0 0.0003849884
age O 0 0.00086391973
who O 0 0.0007394277
had O 0 0.00036130022
had O 0 0.00036909315
a O 0 0.0006061754
first O 0 0.00053989195
myocardial B-Disease 0 0.9999182
infarction I-Disease 2 0.9999943
between O 0 0.00057341985
1990 O 0 0.0085199345
and O 0 0.00069998024
1995 O 0 0.004775354
and O 0 0.0005810236
925 O 0 0.025778888
control O 0 0.00041763252
women O 0 0.0066236076
who O 0 0.00072375376
had O 0 0.00035403293
not O 0 0.0003654729
had O 0 0.00042390052
a O 0 0.0012653907
myocardial B-Disease 0 0.99992776
infarction I-Disease 2 0.9999949
and O 0 0.0011792167
who O 0 0.001308784
were O 0 0.00043448343
matched O 0 0.00040178254
for O 0 0.00034819523
age O 0 0.0010968738
, O 0 0.0006905658
calendar O 0 0.0006622163
year O 0 0.00050632
of O 0 0.0006916895
the O 0 0.0008296359
index O 0 0.0016329925
event O 0 0.011616217
, O 0 0.002495542
and O 0 0.0024832236
area O 0 0.003933129
of O 0 0.0050165425
residence O 0 0.076733515
. O 0 0.008834919

Subjects O 0 0.014352435
supplied O 0 0.010153863
information O 0 0.0063801664
on O 0 0.004323731
oral B-Chemical 0 0.8183458
- I-Chemical 0 0.011963872
contraceptive I-Chemical 0 0.9859459
use O 0 0.004630505
and O 0 0.0045604715
major O 0 0.0069178613
cardiovascular O 0 0.9973079
risk O 0 0.5982067
factors O 0 0.124548204
. O 0 0.013774006

An O 0 0.012833199
analysis O 0 0.0075267144
for O 0 0.0046733553
factor O 1 0.0853174
V O 1 0.88349265
Leiden O 1 0.9860513
and O 0 0.0029658645
the O 0 0.0030082986
G20210A O 0 0.9998481
mutation O 0 0.009719669
in O 0 0.0008731189
the O 0 0.00094233546
prothrombin O 0 0.9477293
gene O 0 0.0010729486
was O 0 0.00056384486
conducted O 0 0.00043144534
in O 0 0.00045620714
217 O 0 0.005117355
patients O 0 0.0011479213
and O 0 0.0006968145
763 O 0 0.086445555
controls O 0 0.000992449
RESULTS O 0 0.020242041
: O 0 0.0005945292
The O 0 0.0003055274
odds O 0 0.0011303211
ratio O 0 0.0005674609
for O 0 0.0005171448
myocardial B-Disease 0 0.9999354
infarction I-Disease 2 0.9999962
among O 0 0.0023117508
women O 0 0.073528185
who O 0 0.0009997116
used O 0 0.0003353242
any O 0 0.0003125229
type O 0 0.00037748495
of O 0 0.00051013654
combined O 0 0.0011784189
oral B-Chemical 1 0.92800415
contraceptive I-Chemical 1 0.9987669
, O 0 0.0013848189
as O 0 0.0004648241
compared O 0 0.00028593882
with O 0 0.00057457696
nonusers O 0 0.85723895
, O 0 0.00076166214
was O 0 0.0004315268
2 O 0 0.00042656003
. O 0 0.00030594776
0 O 0 0.00052731653
( O 0 0.00052219175
95 O 0 0.0005993527
percent O 0 0.00038731255
confidence O 0 0.0012670789
interval O 0 0.0008243003
, O 0 0.0009578085
1 O 0 0.00080841134
. O 0 0.0006343887
5 O 0 0.0008159038
to O 0 0.0010457799
2 O 0 0.0016994752
. O 0 0.001902216
8 O 0 0.003360409
) O 0 0.0069968933
. O 0 0.0070472797

The O 0 0.007172147
adjusted O 0 0.0057048253
odds O 0 0.0068322
ratio O 0 0.0034680674
was O 0 0.0023032266
2 O 0 0.0016884416
. O 0 0.0010128882
5 O 0 0.00087320467
( O 0 0.0009739705
95 O 0 0.0009214397
percent O 0 0.00052402413
confidence O 0 0.0014590881
interval O 0 0.00080031727
, O 0 0.0007804333
1 O 0 0.00053346244
. O 0 0.00031319336
5 O 0 0.00030494135
to O 0 0.00030270635
4 O 0 0.0003662516
. O 0 0.00029777357
1 O 0 0.00044278306
) O 0 0.0006232662
among O 0 0.00047875545
women O 0 0.009287702
who O 0 0.0007751148
used O 0 0.00038282125
second O 0 0.00054069737
- O 0 0.0009799647
generation O 0 0.0007229176
oral B-Chemical 1 0.9070714
contraceptives I-Chemical 1 0.9999659
and O 0 0.0013829725
1 O 0 0.0007300381
. O 0 0.0003283231
3 O 0 0.00037734892
( O 0 0.00047221975
95 O 0 0.00050510763
percent O 0 0.00029743876
confidence O 0 0.0009811382
interval O 0 0.00056152744
, O 0 0.0005930357
0 O 0 0.0005464262
. O 0 0.00028697826
7 O 0 0.00033196338
to O 0 0.00033089635
2 O 0 0.0004601059
. O 0 0.00036155418
5 O 0 0.0004617672
) O 0 0.00080532895
among O 0 0.000665661
those O 0 0.0009313839
who O 0 0.0014828932
used O 0 0.001093969
third O 0 0.0020561004
- O 0 0.0036164962
generation O 0 0.0046971566
oral B-Chemical 1 0.9823513
contraceptives I-Chemical 1 0.99982256
. O 0 0.014055326

Among O 0 0.01453308
women O 0 0.025535237
who O 0 0.0063384287
used O 0 0.0031127038
oral B-Chemical 1 0.8869493
contraceptives I-Chemical 1 0.9999168
, O 0 0.0034893798
the O 0 0.0011368549
odds O 0 0.003583771
ratio O 0 0.0010855593
was O 0 0.0007499169
2 O 0 0.0006598422
. O 0 0.00041672305
1 O 0 0.0005267173
( O 0 0.00056917156
95 O 0 0.0005869569
percent O 0 0.00033636414
confidence O 0 0.0011194971
interval O 0 0.0006167323
, O 0 0.0006345356
1 O 0 0.0004466105
. O 0 0.0002642948
5 O 0 0.00026461176
to O 0 0.00026604862
3 O 0 0.0003310456
. O 0 0.00025934292
0 O 0 0.00045565912
) O 0 0.0004771354
for O 0 0.00022049091
those O 0 0.0003884488
without O 0 0.00033671383
a O 0 0.0007060371
prothrombotic O 0 0.9444261
mutation O 0 0.011367624
and O 0 0.000750844
1 O 0 0.0005703804
. O 0 0.0002922431
9 O 0 0.00039419177
( O 0 0.00043924584
95 O 0 0.00047524887
percent O 0 0.00027904008
confidence O 0 0.0009375746
interval O 0 0.00052648084
, O 0 0.00054704305
0 O 0 0.0004947364
. O 0 0.00024494313
6 O 0 0.00023352585
to O 0 0.00025694887
5 O 0 0.00030861716
. O 0 0.0002605039
5 O 0 0.00031335437
) O 0 0.0005052944
for O 0 0.00025077545
those O 0 0.00046834323
with O 0 0.00044695803
a O 0 0.0008372412
mutation O 0 0.007749492
CONCLUSIONS O 0 0.9387727
: O 0 0.00091925374
The O 0 0.00041592927
risk O 0 0.020285828
of O 0 0.0016330129
myocardial B-Disease 0 0.99996114
infarction I-Disease 2 0.99999607
was O 0 0.0013881424
increased O 0 0.0011551253
among O 0 0.0012855147
women O 0 0.039803203
who O 0 0.002011794
used O 0 0.0011913038
second O 0 0.0018197881
- O 0 0.0039182687
generation O 0 0.0049037067
oral B-Chemical 1 0.9837457
contraceptives I-Chemical 1 0.99982554
. O 0 0.014273653

The O 0 0.0068139215
results O 0 0.0048617255
with O 0 0.0033383803
respect O 0 0.0020489919
to O 0 0.001568073
the O 0 0.001265035
use O 0 0.0011414612
of O 0 0.001214181
third O 0 0.0016720719
- O 0 0.0019038481
generation O 0 0.0012564235
oral B-Chemical 1 0.93586206
contraceptives I-Chemical 1 0.9999639
were O 0 0.0011112659
inconclusive O 0 0.020095406
but O 0 0.00052447413
suggested O 0 0.0003823883
that O 0 0.00035834283
the O 0 0.0005168382
risk O 0 0.025351698
was O 0 0.00058204954
lower O 0 0.0005604185
than O 0 0.00043893527
the O 0 0.0007030251
risk O 0 0.026526127
associated O 0 0.0013505984
with O 0 0.0015768111
second O 0 0.00218887
- O 0 0.0048819436
generation O 0 0.005502548
oral B-Chemical 1 0.98678917
contraceptives I-Chemical 1 0.999835
. O 0 0.014465999

The O 0 0.008466101
risk O 0 0.021521503
of O 0 0.008346597
myocardial B-Disease 0 0.99970907
infarction I-Disease 2 0.99997795
was O 0 0.0031179625
similar O 0 0.0012029542
among O 0 0.0016439407
women O 0 0.028177278
who O 0 0.0020100006
used O 0 0.0010493047
oral B-Chemical 1 0.8796131
contraceptives I-Chemical 1 0.9998895
whether O 0 0.00082736375
or O 0 0.0012705546
not O 0 0.0012741789
they O 0 0.0015285426
had O 0 0.001990902
a O 0 0.0046369927
prothrombotic O 0 0.9786002
mutation O 0 0.113300845
. O 0 0.010405279

End B-Disease 0 0.1551819
- I-Disease 0 0.012724074
stage I-Disease 0 0.011032665
renal I-Disease 0 0.99741733
disease I-Disease 0 0.9965138
( O 0 0.06316482
ESRD B-Disease 2 0.9999354
) O 0 0.0053673093
after O 0 0.00087235257
orthotopic O 0 0.96282697
liver O 0 0.9615277
transplantation O 0 0.5670724
( O 0 0.0037180225
OLTX O 0 0.9657868
) O 0 0.00216325
using O 0 0.00087302487
calcineurin O 0 0.78793204
- O 0 0.0019296419
based O 0 0.0010444815
immunotherapy O 0 0.051204648
: O 0 0.0032622279
risk O 0 0.04082373
of O 0 0.0029218195
development O 0 0.0063344534
and O 0 0.005757014
treatment O 0 0.012187058
. O 0 0.009379684

BACKGROUND O 0 0.6276594
: O 0 0.011692216
The O 0 0.0059964694
calcineurin O 0 0.80020756
inhibitors O 0 0.45441446
cyclosporine B-Chemical 1 0.9999666
and O 0 0.026283776
tacrolimus B-Chemical 1 0.9999428
are O 0 0.004661371
both O 0 0.0031633377
known O 0 0.004437909
to O 0 0.004391459
be O 0 0.008050004
nephrotoxic B-Disease 2 0.99933845
. O 0 0.013588196

Their O 0 0.02160636
use O 0 0.008678069
in O 0 0.0064990544
orthotopic O 0 0.9242188
liver O 0 0.95441574
transplantation O 0 0.62471443
( O 0 0.009396261
OLTX O 0 0.9562372
) O 0 0.0055724396
has O 0 0.0025766385
dramatically O 0 0.0045686024
improved O 0 0.006303412
success O 0 0.010628306
rates O 0 0.008998325
. O 0 0.010764142

Recently O 0 0.01276036
, O 0 0.0076287687
however O 0 0.004788984
, O 0 0.0033481629
we O 0 0.0014996578
have O 0 0.001268504
had O 0 0.0010955292
an O 0 0.0012775138
increase O 0 0.00070493435
of O 0 0.0009801054
patients O 0 0.0023321917
who O 0 0.0016317944
are O 0 0.00081132696
presenting O 0 0.009091569
after O 0 0.00061114394
OLTX O 0 0.8404246
with O 0 0.0011198188
end B-Disease 2 0.0009173742
- I-Disease 2 0.0026201247
stage I-Disease 2 0.005763325
renal I-Disease 2 0.999321
disease I-Disease 2 0.99811184
( O 0 0.20725073
ESRD B-Disease 2 0.99989927
) O 0 0.050790757
. O 0 0.010263335

This O 0 0.011362738
retrospective O 0 0.012512551
study O 0 0.004659097
examines O 0 0.0039734887
the O 0 0.0024861973
incidence O 0 0.0078350445
and O 0 0.0023369975
treatment O 0 0.0029849228
of O 0 0.0041631297
ESRD B-Disease 2 0.99995756
and O 0 0.0070436867
chronic B-Disease 2 0.99796
renal I-Disease 2 0.99956125
failure I-Disease 2 0.99727184
( O 0 0.071442954
CRF B-Disease 2 0.99978155
) O 0 0.008245366
in O 0 0.003902189
OLTX O 0 0.9413475
patients O 0 0.018350156
. O 0 0.009103846

METHODS O 0 0.011692877
: O 0 0.008541286
Patients O 0 0.006615136
receiving O 0 0.0041149384
an O 0 0.0035246024
OLTX O 0 0.56137633
only O 0 0.0016213105
from O 0 0.0013581713
June O 0 0.0014381416
1985 O 0 0.0023340075
through O 0 0.00066813093
December O 0 0.0008860556
of O 0 0.0006986204
1994 O 0 0.0019423971
who O 0 0.00092777424
survived O 0 0.0007279542
6 O 0 0.00048737373
months O 0 0.00048467945
postoperatively O 0 0.0008952675
were O 0 0.00091241585
studied O 0 0.0013543455
( O 0 0.0024237146
n O 0 0.0027315875
= O 0 0.0047394424
834 O 0 0.058073472
) O 0 0.008354822
. O 0 0.007531061

Our O 0 0.014652801
prospectively O 0 0.0124561805
collected O 0 0.008589976
database O 0 0.008639214
was O 0 0.0071281106
the O 0 0.006960156
source O 0 0.0076501654
of O 0 0.010923322
information O 0 0.015142187
. O 0 0.016014097

Patients O 0 0.012815554
were O 0 0.005320577
divided O 0 0.0029731449
into O 0 0.0019117737
three O 0 0.0015333884
groups O 0 0.0020755562
: O 0 0.0023594832
Controls O 0 0.055824813
, O 0 0.0012975902
no O 0 0.0008151349
CRF B-Disease 2 0.99953187
or O 0 0.0016593973
ESRD B-Disease 2 0.9999536
, O 0 0.0014152545
n O 0 0.00092680147
= O 0 0.0011947835
748 O 0 0.05960714
; O 0 0.0019226476
CRF B-Disease 2 0.99956304
, O 0 0.0010109706
sustained O 0 0.003846437
serum O 0 0.23401801
creatinine B-Chemical 1 0.99922454
> O 0 0.0015777723
2 O 0 0.0004928053
. O 0 0.0003126352
5 O 0 0.0003648275
mg O 0 0.046982937
/ O 0 0.0013361973
dl O 0 0.0052779308
, O 0 0.0007727171
n O 0 0.0007655366
= O 0 0.0010689562
41 O 0 0.0016126175
; O 0 0.0016544106
and O 0 0.0018689096
ESRD B-Disease 2 0.99976796
, O 0 0.0033285313
n O 0 0.003328873
= O 0 0.0047201705
45 O 0 0.0048288647
. O 0 0.0064581423

Groups O 0 0.020088255
were O 0 0.0052098967
compared O 0 0.0025615103
for O 0 0.0020060493
preoperative O 0 0.005160416
laboratory O 0 0.0023536829
variables O 0 0.0025572486
, O 0 0.0016113528
diagnosis O 0 0.0045666685
, O 0 0.0011902862
postoperative O 0 0.015577261
variables O 0 0.0018946878
, O 0 0.0011790504
survival O 0 0.034771334
, O 0 0.0011282854
type O 0 0.00084695616
of O 0 0.0018688402
ESRD B-Disease 2 0.99995613
therapy O 0 0.058749992
, O 0 0.002219373
and O 0 0.0017572229
survival O 0 0.047779493
from O 0 0.0026448383
onset O 0 0.019939646
of O 0 0.013206704
ESRD B-Disease 2 0.9998336
. O 0 0.012531236

RESULTS O 0 0.023813918
: O 0 0.0077806795
At O 0 0.003100612
13 O 0 0.0029882495
years O 0 0.0024039173
after O 0 0.0012950024
OLTX O 0 0.58154297
, O 0 0.001562031
the O 0 0.0008896146
incidence O 0 0.003618156
of O 0 0.0014865897
severe O 0 0.591356
renal B-Disease 2 0.99974805
dysfunction I-Disease 2 0.99912685
was O 0 0.0011413639
18 O 0 0.00073333137
. O 0 0.00041427088
1 O 0 0.00057493796
% O 0 0.0007704363
( O 0 0.0011830555
CRF B-Disease 2 0.9987036
8 O 0 0.0007089403
. O 0 0.0004832966
6 O 0 0.00054161134
% O 0 0.0009468289
and O 0 0.0014775433
ESRD B-Disease 2 0.9997625
9 O 0 0.002138488
. O 0 0.0016221304
5 O 0 0.0024204405
% O 0 0.00449284
) O 0 0.007890827
. O 0 0.007471336

Compared O 0 0.0073071416
with O 0 0.0051698596
control O 0 0.003950344
patients O 0 0.008204632
, O 0 0.0057711257
CRF B-Disease 2 0.99958163
and O 0 0.0046538375
ESRD B-Disease 2 0.9999175
patients O 0 0.007397172
had O 0 0.0007812261
higher O 0 0.0006603115
preoperative O 0 0.030993024
serum O 0 0.36095732
creatinine B-Chemical 1 0.99925476
levels O 0 0.0007588724
, O 0 0.0006916957
a O 0 0.0004615823
greater O 0 0.00028139484
percentage O 0 0.00024093971
of O 0 0.0004836547
patients O 0 0.002592763
with O 0 0.00094293803
hepatorenal B-Disease 0 0.99997985
syndrome I-Disease 0 0.9877099
, O 0 0.0013097752
higher O 0 0.00034719534
percentage O 0 0.0002508826
requirement O 0 0.00025756747
for O 0 0.00027473978
dialysis O 0 0.008618697
in O 0 0.00035064784
the O 0 0.00035559232
first O 0 0.00032106382
3 O 0 0.0003989285
months O 0 0.00034698352
postoperatively O 0 0.0007395162
, O 0 0.00079026946
and O 0 0.00079613685
a O 0 0.0011838772
higher O 0 0.0011755583
1 O 0 0.0019788549
- O 0 0.0030184186
year O 0 0.0030218803
serum O 0 0.32589945
creatinine B-Chemical 1 0.9977022
. O 0 0.010193662

Multivariate O 0 0.026112644
stepwise O 0 0.013849163
logistic O 0 0.008248173
regression O 0 0.007672704
analysis O 0 0.0028832627
using O 0 0.0015972249
preoperative O 0 0.0049781627
and O 0 0.0012507024
postoperative O 0 0.0135713
variables O 0 0.0013714647
identified O 0 0.00053574884
that O 0 0.00046036052
an O 0 0.0007426533
increase O 0 0.00041676234
of O 0 0.0007859359
serum O 0 0.28795394
creatinine B-Chemical 1 0.9983802
compared O 0 0.00031990308
with O 0 0.00039653608
average O 0 0.00028436037
at O 0 0.00028241667
1 O 0 0.00038052318
year O 0 0.00033969257
, O 0 0.00045148208
3 O 0 0.0002932923
months O 0 0.00024068942
, O 0 0.00037847407
and O 0 0.00032130847
4 O 0 0.00025655475
weeks O 0 0.00018979197
postoperatively O 0 0.0003583227
were O 0 0.00028286967
independent O 0 0.00031560025
risk O 0 0.007901622
factors O 0 0.0016251442
for O 0 0.0003348134
the O 0 0.00044812696
development O 0 0.0011115834
of O 0 0.0015871405
CRF B-Disease 2 0.9999186
or O 0 0.001723292
ESRD B-Disease 2 0.9999683
with O 0 0.00083848415
odds O 0 0.006550094
ratios O 0 0.0006598476
of O 0 0.0006555024
2 O 0 0.0005837501
. O 0 0.00035380112
6 O 0 0.0003798914
, O 0 0.00060084835
2 O 0 0.0005316883
. O 0 0.00045399598
2 O 0 0.000675026
, O 0 0.00095494464
and O 0 0.0010965181
1 O 0 0.0014113042
. O 0 0.0013060719
6 O 0 0.0018880087
, O 0 0.0038441757
respectively O 0 0.0070038177
. O 0 0.0072913757

Overall O 0 0.011320518
survival O 0 0.014804681
from O 0 0.0038192624
the O 0 0.0025022847
time O 0 0.0016728617
of O 0 0.0019495226
OLTX O 0 0.84631455
was O 0 0.0011387867
not O 0 0.0007490859
significantly O 0 0.0008406666
different O 0 0.00058448943
among O 0 0.0008484579
groups O 0 0.0010482166
, O 0 0.0008505799
but O 0 0.00046050161
by O 0 0.00047937263
year O 0 0.00043021617
13 O 0 0.0005196406
, O 0 0.00045500326
the O 0 0.00032437893
survival O 0 0.004724643
of O 0 0.0005016563
the O 0 0.00045509613
patients O 0 0.0014569957
who O 0 0.0012864236
had O 0 0.00072622794
ESRD B-Disease 2 0.9999362
was O 0 0.00058003614
only O 0 0.00044500834
28 O 0 0.00057743944
. O 0 0.00032818667
2 O 0 0.00040978656
% O 0 0.00047654222
compared O 0 0.00032181188
with O 0 0.0006005455
54 O 0 0.001318455
. O 0 0.00059600605
6 O 0 0.00071144255
% O 0 0.0011877007
in O 0 0.0012885794
the O 0 0.0020008867
control O 0 0.0032253037
group O 0 0.006512686
. O 0 0.007920982

Patients O 0 0.020254502
developing O 0 0.02116226
ESRD B-Disease 2 0.9992095
had O 0 0.0037507836
a O 0 0.0032075683
6 O 0 0.0016329428
- O 0 0.001811309
year O 0 0.0009148573
survival O 0 0.0052895313
after O 0 0.0005166526
onset O 0 0.0023003991
of O 0 0.0014733647
ESRD B-Disease 2 0.99994123
of O 0 0.0011798008
27 O 0 0.0012479542
% O 0 0.0005293213
for O 0 0.00027606156
the O 0 0.00034685986
patients O 0 0.0008301103
receiving O 0 0.00073208526
hemodialysis O 0 0.2814202
versus O 0 0.0005597726
71 O 0 0.0021068589
. O 0 0.00034881552
4 O 0 0.00038348496
% O 0 0.00047967175
for O 0 0.00036984248
the O 0 0.00059724535
patients O 0 0.002430396
developing O 0 0.015809841
ESRD B-Disease 2 0.9998989
who O 0 0.0054399045
subsequently O 0 0.0033978021
received O 0 0.0037957411
kidney O 0 0.9295143
transplants O 0 0.7344549
. O 0 0.010405732

CONCLUSIONS O 0 0.48832825
: O 0 0.010662546
Patients O 0 0.007987617
who O 0 0.004716802
are O 0 0.0026442343
more O 0 0.002075896
than O 0 0.0012693425
10 O 0 0.00131501
years O 0 0.0016061348
post O 0 0.0018571402
- O 0 0.0024238208
OLTX O 0 0.78869396
have O 0 0.0019352756
CRF B-Disease 2 0.9995528
and O 0 0.0049945437
ESRD B-Disease 2 0.9998348
at O 0 0.0025039834
a O 0 0.004169502
high O 0 0.00506898
rate O 0 0.0065119895
. O 0 0.0091913445

The O 0 0.009227239
development O 0 0.009402276
of O 0 0.008195724
ESRD B-Disease 2 0.9996593
decreases O 0 0.0061024874
survival O 0 0.1655959
, O 0 0.0035305072
particularly O 0 0.0023858491
in O 0 0.0017082877
those O 0 0.0024545793
patients O 0 0.0043837144
treated O 0 0.0034429708
with O 0 0.0042533753
dialysis O 0 0.13674568
only O 0 0.007238768
. O 0 0.009512956

Patients O 0 0.016144106
who O 0 0.009623684
develop O 0 0.0066632284
ESRD B-Disease 2 0.9994042
have O 0 0.002493426
a O 0 0.0023155173
higher O 0 0.0013794183
preoperative O 0 0.012763057
and O 0 0.0016965339
1 O 0 0.0014746295
- O 0 0.0015488733
year O 0 0.0009457005
serum O 0 0.100092776
creatinine B-Chemical 1 0.9971898
and O 0 0.001536008
are O 0 0.0013291226
more O 0 0.0014521504
likely O 0 0.0014614535
to O 0 0.0019109962
have O 0 0.0037152926
hepatorenal B-Disease 0 0.9998741
syndrome I-Disease 0 0.99354845
. O 0 0.014423008

However O 0 0.009854401
, O 0 0.0070948694
an O 0 0.0047858753
increase O 0 0.0025431653
of O 0 0.0028809207
serum O 0 0.20308933
creatinine B-Chemical 1 0.99722856
at O 0 0.0009963191
various O 0 0.0012191323
times O 0 0.00067905156
postoperatively O 0 0.0010827379
is O 0 0.00074617617
more O 0 0.00087898615
predictive O 0 0.0014011106
of O 0 0.0013885945
the O 0 0.0016174798
development O 0 0.004064768
of O 0 0.0071872044
CRF B-Disease 2 0.99973804
or O 0 0.019806342
ESRD B-Disease 2 0.9998394
. O 0 0.013103353

New O 0 0.017070508
strategies O 0 0.008823303
for O 0 0.0051026135
long O 0 0.005107154
- O 0 0.005386391
term O 0 0.003408874
immunosuppression O 0 0.95649606
may O 0 0.0033572102
be O 0 0.0027528154
needed O 0 0.0019976613
to O 0 0.002663732
decrease O 0 0.0035937477
this O 0 0.005397129
complication O 0 0.6752958
. O 0 0.012010428

Epileptic B-Disease 0 0.99965334
seizures I-Disease 2 0.9998884
following O 0 0.008775441
cortical O 0 0.04543691
application O 0 0.0054147956
of O 0 0.0044061793
fibrin O 0 0.8456665
sealants O 0 0.55898345
containing O 0 0.0072006867
tranexamic B-Chemical 0 0.9997681
acid I-Chemical 0 0.98546046
in O 0 0.009710742
rats O 0 0.036985416
. O 0 0.012140947

BACKGROUND O 0 0.711349
: O 0 0.015173763
Fibrin O 0 0.60633606
sealants O 0 0.27144143
( O 0 0.009736794
FS O 0 0.413289
) O 0 0.0053547327
derived O 0 0.002806382
from O 0 0.0026040284
human O 0 0.00344842
plasma O 0 0.023717972
are O 0 0.0034829625
frequently O 0 0.0045439885
used O 0 0.0040601185
in O 0 0.0057363925
neurosurgery O 0 0.06434555
. O 0 0.010302575

In O 0 0.00817653
order O 0 0.004862177
to O 0 0.00397858
increase O 0 0.0029690922
clot O 0 0.12010643
stability O 0 0.0041135787
, O 0 0.0039465274
FS O 0 0.3400856
typically O 0 0.003077341
contain O 0 0.0019483448
aprotinin O 0 0.9892952
, O 0 0.0048533306
a O 0 0.0047807912
natural O 0 0.032807317
fibrinolysis O 0 0.9982293
inhibitor O 0 0.6471389
. O 0 0.013600139

Recently O 0 0.014053395
, O 0 0.008805489
synthetic O 0 0.008866548
fibrinolysis O 0 0.98912954
inhibitors O 0 0.1477711
such O 0 0.0031986134
as O 0 0.004216889
tranexamic B-Chemical 0 0.99991
acid I-Chemical 0 0.99684745
( O 0 0.040413525
tAMCA B-Chemical 1 0.98664284
) O 0 0.0034121773
have O 0 0.001263182
been O 0 0.0015365762
considered O 0 0.0014530342
as O 0 0.002351048
substitutes O 0 0.008677438
for O 0 0.004834484
aprotinin O 0 0.99312913
. O 0 0.011532676

However O 0 0.017831309
, O 0 0.017555794
tAMCA B-Chemical 1 0.80959576
has O 0 0.007921317
been O 0 0.007244569
shown O 0 0.005534721
to O 0 0.007396213
cause O 0 0.22246708
epileptic B-Disease 2 0.99992716
seizures I-Disease 0 0.99995244
. O 0 0.028709797

We O 0 0.009749842
wanted O 0 0.0078244805
to O 0 0.004711314
study O 0 0.004179707
whether O 0 0.002372107
tAMCA B-Chemical 1 0.8800958
retains O 0 0.003851588
its O 0 0.0076028355
convulsive B-Disease 2 0.9999511
action O 0 0.04354816
if O 0 0.002445461
incorporated O 0 0.0030091356
into O 0 0.002906825
a O 0 0.0078004105
FS O 0 0.6846188
. O 0 0.010821541

METHOD O 0 0.033959024
: O 0 0.009982591
FS O 0 0.14864916
containing O 0 0.0035548124
aprotinin O 0 0.9440703
or O 0 0.0021166077
different O 0 0.0013448943
concentrations O 0 0.0028501574
of O 0 0.0024264418
tAMCA B-Chemical 1 0.9859313
( O 0 0.0017859123
0 O 0 0.0009724536
. O 0 0.00041551157
5 O 0 0.000455927
- O 0 0.00067055045
47 O 0 0.00074069545
. O 0 0.0003122563
5 O 0 0.00035553268
mg O 0 0.043306623
/ O 0 0.0012123245
ml O 0 0.0018380107
) O 0 0.0009932843
were O 0 0.00046938128
applied O 0 0.0004295338
to O 0 0.0004813651
the O 0 0.0006823555
pial O 0 0.7627089
surface O 0 0.0019520815
of O 0 0.0016367417
the O 0 0.0019560738
cortex O 0 0.11651498
of O 0 0.0035506291
anaesthetized O 0 0.17040367
rats O 0 0.013265134
. O 0 0.0085224565

The O 0 0.0070364326
response O 0 0.00532551
of O 0 0.0037015793
the O 0 0.002436458
animals O 0 0.0017434112
was O 0 0.001377556
evaluated O 0 0.0010140109
using O 0 0.001017632
electroencephalography O 0 0.31012303
and O 0 0.0010046392
by O 0 0.00085473113
monitoring O 0 0.00082248193
the O 0 0.0007456196
clinical O 0 0.0030660348
behaviour O 0 0.0028935473
during O 0 0.0009225809
and O 0 0.0016094875
after O 0 0.001325088
recovery O 0 0.0042206217
from O 0 0.004326333
anaesthesia O 0 0.21740112
. O 0 0.008606865

FINDINGS O 0 0.16179805
: O 0 0.012604588
FS O 0 0.27451545
containing O 0 0.005280948
tAMCA B-Chemical 1 0.9200814
caused O 0 0.005785105
paroxysmal O 0 0.99985194
brain O 0 0.35378224
activity O 0 0.0031965612
which O 0 0.0026071079
was O 0 0.0020735129
associated O 0 0.0026064394
with O 0 0.0035333014
distinct O 0 0.007295235
convulsive B-Disease 2 0.99993205
behaviours O 0 0.8012857
. O 0 0.0125593245

The O 0 0.010323206
degree O 0 0.008819175
of O 0 0.007524263
these O 0 0.00906481
seizures B-Disease 2 0.99983
increased O 0 0.008382609
with O 0 0.0055644154
increasing O 0 0.0068170684
concentration O 0 0.014235849
of O 0 0.016575657
tAMCA B-Chemical 1 0.9886335
. O 0 0.0136877205

Thus O 0 0.009352469
, O 0 0.007949343
FS O 0 0.13070175
containing O 0 0.0028744559
47 O 0 0.0038739883
. O 0 0.0013331566
5 O 0 0.001080343
mg O 0 0.11070671
/ O 0 0.002697895
ml O 0 0.0072841486
tAMCA B-Chemical 1 0.9491453
evoked O 0 0.36747202
generalized B-Disease 0 0.90024054
seizures I-Disease 2 0.9999944
in O 0 0.000693687
all O 0 0.00044247677
tested O 0 0.00035154817
rats O 0 0.0014721069
( O 0 0.0006670595
n O 0 0.00051451434
= O 0 0.0005844897
6 O 0 0.00029243037
) O 0 0.00048225292
while O 0 0.00025926132
the O 0 0.00029220156
lowest O 0 0.0003823646
concentration O 0 0.00085504225
of O 0 0.0011010786
tAMCA B-Chemical 1 0.98364
( O 0 0.001080835
0 O 0 0.0006276249
. O 0 0.000269246
5 O 0 0.00031035743
mg O 0 0.050783265
/ O 0 0.001067559
ml O 0 0.0015505553
) O 0 0.000807549
only O 0 0.00038895148
evoked O 0 0.015208447
brief O 0 0.000687508
episodes O 0 0.104807615
of O 0 0.0012717751
jerk O 0 0.9792296
- O 0 0.0027105387
correlated O 0 0.001074099
convulsive B-Disease 2 0.999969
potentials O 0 0.31828874
in O 0 0.0017461268
1 O 0 0.0021306614
of O 0 0.0026089982
6 O 0 0.003133693
rats O 0 0.007910351
. O 0 0.007493255

In O 0 0.011161367
contrast O 0 0.009071092
, O 0 0.0092211515
FS O 0 0.24146917
containing O 0 0.005191956
aprotinin O 0 0.97337025
did O 0 0.0043847607
not O 0 0.0039644423
evoke O 0 0.0108503355
any O 0 0.0068561076
paroxysmal O 0 0.9995572
activity O 0 0.017940037
. O 0 0.013168951

INTERPRETATION O 0 0.35853347
: O 0 0.039451487
Tranexamic B-Chemical 0 0.99836725
acid I-Chemical 0 0.9818154
retains O 0 0.01665986
its O 0 0.026943898
convulsive B-Disease 2 0.9998487
action O 0 0.19129024
within O 0 0.009851224
FS O 0 0.781584
. O 0 0.016842298

Thus O 0 0.008921249
, O 0 0.006716802
use O 0 0.0039845253
of O 0 0.0037985095
FS O 0 0.46524543
containing O 0 0.0024029592
tAMCA B-Chemical 1 0.88671833
for O 0 0.0009405952
surgery O 0 0.0016927584
within O 0 0.0005031571
or O 0 0.00064563146
close O 0 0.0006009652
to O 0 0.00066446053
the O 0 0.0009345547
CNS O 0 0.7561657
may O 0 0.00097971
pose O 0 0.0016414516
a O 0 0.00172336
substantial O 0 0.0020724218
risk O 0 0.033204786
to O 0 0.002826705
the O 0 0.004232906
patient O 0 0.009075911
. O 0 0.00883649

Sequential O 0 0.01439492
observations O 0 0.006797364
of O 0 0.006468026
exencephaly B-Disease 2 0.99403834
and O 0 0.0031647906
subsequent O 0 0.0020390986
morphological O 0 0.0049569313
changes O 0 0.0018701117
by O 0 0.001347271
mouse O 0 0.0018163725
exo O 0 0.16855146
utero O 0 0.07494695
development O 0 0.002332304
system O 0 0.0016142856
: O 0 0.0011506474
analysis O 0 0.0007848559
of O 0 0.0008122537
the O 0 0.0008286842
mechanism O 0 0.0012033237
of O 0 0.0019596068
transformation O 0 0.069778256
from O 0 0.0048257313
exencephaly B-Disease 2 0.99791116
to O 0 0.007908795
anencephaly B-Disease 2 0.99653816
. O 0 0.010623723

Anencephaly B-Disease 0 0.78598434
has O 0 0.006335384
been O 0 0.0042634555
suggested O 0 0.0025216127
to O 0 0.001954906
develop O 0 0.0020441816
from O 0 0.0023052841
exencephaly B-Disease 2 0.9988273
; O 0 0.003264975
however O 0 0.0010954709
, O 0 0.00081468176
there O 0 0.00035209872
is O 0 0.00039703536
little O 0 0.00034065233
direct O 0 0.00041817993
experimental O 0 0.0005534503
evidence O 0 0.00054819963
to O 0 0.00052804186
support O 0 0.0006076533
this O 0 0.0007260307
, O 0 0.0011052028
and O 0 0.0009505203
the O 0 0.0009927957
mechanism O 0 0.0015519527
of O 0 0.002612003
transformation O 0 0.0652756
remains O 0 0.0043389406
unclear O 0 0.0072029475
. O 0 0.008566645

We O 0 0.0074701477
examined O 0 0.004153103
this O 0 0.0035186906
theory O 0 0.004630076
using O 0 0.0021487633
the O 0 0.0019200962
exo O 0 0.098341115
utero O 0 0.05950624
development O 0 0.002413082
system O 0 0.0013158952
that O 0 0.000557291
allows O 0 0.0005105077
direct O 0 0.0006054556
and O 0 0.0007438793
sequential O 0 0.0010151268
observations O 0 0.0010482126
of O 0 0.0014222729
mid O 0 0.005473963
- O 0 0.0023504193
to O 0 0.0014095273
late O 0 0.0055415677
- O 0 0.0043604714
gestation O 0 0.007520668
mouse O 0 0.005426912
embryos O 0 0.009885221
. O 0 0.008656965

We O 0 0.007631069
observed O 0 0.0043410272
the O 0 0.0046622586
exencephaly B-Disease 2 0.9927469
induced O 0 0.0037741275
by O 0 0.0028771793
5 B-Chemical 0 0.0017815975
- I-Chemical 0 0.0028252015
azacytidine I-Chemical 0 0.9684095
at O 0 0.000674779
embryonic O 0 0.014010475
day O 0 0.00054879487
13 O 0 0.00070387445
. O 0 0.00038223848
5 O 0 0.00045228115
( O 0 0.00078795984
E13 O 0 0.24257219
. O 0 0.00039428496
5 O 0 0.0004349708
) O 0 0.0007639734
, O 0 0.00054312916
let O 0 0.00065057713
the O 0 0.0003873439
embryos O 0 0.0007721173
develop O 0 0.00064812764
exo O 0 0.09690809
utero O 0 0.03401165
until O 0 0.00041212374
E18 O 0 0.17591639
. O 0 0.00041660626
5 O 0 0.0004554342
, O 0 0.0006349912
and O 0 0.000678192
re O 0 0.01221828
- O 0 0.0011261845
observed O 0 0.00051775936
the O 0 0.0008123558
same O 0 0.00085026014
embryos O 0 0.002404242
at O 0 0.001882143
E18 O 0 0.12741616
. O 0 0.0031018653
5 O 0 0.0048323395
. O 0 0.0068442537

We O 0 0.012770906
confirmed O 0 0.009034941
several O 0 0.0077205496
cases O 0 0.00899764
of O 0 0.008318292
transformation O 0 0.05651137
from O 0 0.011744424
exencephaly B-Disease 2 0.99671435
to O 0 0.01571041
anencephaly B-Disease 2 0.99546486
. O 0 0.01741907

However O 0 0.009554908
, O 0 0.0067579583
in O 0 0.0035801409
many O 0 0.003074107
cases O 0 0.0037202025
, O 0 0.0024994675
the O 0 0.001621262
exencephalic B-Disease 2 0.68806696
brain O 0 0.075848654
tissue O 0 0.018111283
was O 0 0.0011846421
preserved O 0 0.0014460054
with O 0 0.0010700225
more O 0 0.0012715242
or O 0 0.0012360646
less O 0 0.0015152387
reduction O 0 0.0025220418
during O 0 0.001934365
this O 0 0.0034358888
period O 0 0.004935228
. O 0 0.007688208

To O 0 0.0059995847
analyze O 0 0.0034085147
the O 0 0.003307785
transformation O 0 0.008595455
patterns O 0 0.0019544852
, O 0 0.00185709
we O 0 0.00079791475
classified O 0 0.0011106943
the O 0 0.0011702937
exencephaly B-Disease 2 0.9959121
by O 0 0.0010627983
size O 0 0.00093288044
and O 0 0.00066027377
shape O 0 0.00078672636
of O 0 0.00069664576
the O 0 0.0007119515
exencephalic B-Disease 2 0.663544
tissue O 0 0.006672091
into O 0 0.00045011684
several O 0 0.00067573786
types O 0 0.00088964455
at O 0 0.00089212327
E13 O 0 0.3505552
. O 0 0.0010553675
5 O 0 0.0013869439
and O 0 0.0023947249
E18 O 0 0.09871781
. O 0 0.0031711296
5 O 0 0.00492005
. O 0 0.0069807675

It O 0 0.009798643
was O 0 0.0050400333
found O 0 0.002826938
that O 0 0.0020650958
the O 0 0.0019101158
transformation O 0 0.00918659
of O 0 0.0022025693
exencephalic B-Disease 2 0.86623895
tissue O 0 0.028704911
was O 0 0.00089708884
not O 0 0.0006167893
simply O 0 0.0008300525
size O 0 0.0010617523
- O 0 0.0010623768
dependent O 0 0.00045000785
, O 0 0.0006847934
and O 0 0.00047280194
all O 0 0.00038707003
cases O 0 0.0008263698
of O 0 0.00097030145
anencephaly B-Disease 2 0.99561006
at O 0 0.00053836725
E18 O 0 0.22464888
. O 0 0.00036214647
5 O 0 0.00034200962
resulted O 0 0.00031406077
from O 0 0.00041691572
embryos O 0 0.00074671424
with O 0 0.00053497043
a O 0 0.0007404781
large O 0 0.0007119064
amount O 0 0.0005486471
of O 0 0.0015449978
exencephalic B-Disease 2 0.8348103
tissue O 0 0.041667104
at O 0 0.0025609792
E13 O 0 0.5046732
. O 0 0.0034313675
5 O 0 0.005131009
. O 0 0.007083297

Microscopic O 0 0.06858368
observation O 0 0.0055807303
showed O 0 0.0033312787
the O 0 0.0026314685
configuration O 0 0.0026950801
of O 0 0.0031756777
exencephaly B-Disease 2 0.9979773
at O 0 0.0014173493
E13 O 0 0.66637063
. O 0 0.0007223144
5 O 0 0.0006137391
, O 0 0.0007807941
frequent O 0 0.0020674928
hemorrhaging B-Disease 0 0.998906
and O 0 0.0010603181
detachment O 0 0.8204832
of O 0 0.0007629494
the O 0 0.0005483757
neural O 0 0.0059563606
plate O 0 0.0012608911
from O 0 0.0004856838
surface O 0 0.0013596992
ectoderm O 0 0.5655955
in O 0 0.0004849214
the O 0 0.0005726306
exencephalic B-Disease 2 0.72979957
head O 0 0.05320676
at O 0 0.00054760487
E15 O 0 0.7984762
. O 0 0.00040014542
5 O 0 0.00039806392
, O 0 0.00049446535
and O 0 0.00043242035
multiple O 0 0.00073067984
modes O 0 0.00068753824
of O 0 0.00078410574
reduction O 0 0.0011966012
in O 0 0.0007900662
the O 0 0.001201323
exencephalic B-Disease 2 0.73542607
tissue O 0 0.026936542
at O 0 0.0023024313
E18 O 0 0.19523877
. O 0 0.0031978334
5 O 0 0.0049054036
. O 0 0.00688831

From O 0 0.009170255
observations O 0 0.006126944
of O 0 0.0046714926
the O 0 0.0036287506
vasculature O 0 0.2993655
, O 0 0.003177571
altered O 0 0.0018388963
distribution O 0 0.0011498914
patterns O 0 0.0012325794
of O 0 0.0018959327
vessels O 0 0.06831932
were O 0 0.0020184221
identified O 0 0.001858341
in O 0 0.0025983588
the O 0 0.0043935315
exencephalic B-Disease 2 0.85482633
head O 0 0.2823168
. O 0 0.010911875

These O 0 0.008455023
findings O 0 0.00661501
suggest O 0 0.0028165635
that O 0 0.0022975972
overgrowth O 0 0.124204725
of O 0 0.0021345944
the O 0 0.0015425708
exencephalic B-Disease 2 0.8133379
neural O 0 0.025729856
tissue O 0 0.019569846
causes O 0 0.0019276446
the O 0 0.00058789586
altered O 0 0.0005607014
distribution O 0 0.00032912006
patterns O 0 0.00035582442
of O 0 0.0006366079
vessels O 0 0.13785422
, O 0 0.0008005335
subsequent O 0 0.0005119611
peripheral O 0 0.070644654
circulatory B-Disease 0 0.9897742
failure I-Disease 0 0.97418594
and O 0 0.0013571291
/ O 0 0.0053321035
or O 0 0.00064220146
hemorrhaging B-Disease 0 0.9990362
in O 0 0.00045149092
various O 0 0.0007270641
parts O 0 0.0005585004
of O 0 0.0005379764
the O 0 0.0005755734
exencephalic B-Disease 2 0.81622523
head O 0 0.089894205
, O 0 0.00092007255
leading O 0 0.00075946504
to O 0 0.00039170316
the O 0 0.00042465032
multiple O 0 0.0008407007
modes O 0 0.000780446
of O 0 0.00094037736
tissue O 0 0.016955836
reduction O 0 0.0019995274
during O 0 0.0010761946
transformation O 0 0.035757624
from O 0 0.0041145245
exencephaly B-Disease 2 0.99753535
to O 0 0.007425831
anencephaly B-Disease 2 0.9963469
. O 0 0.010380425

99mTc B-Chemical 1 0.9643083
- I-Chemical 1 0.026547128
glucarate I-Chemical 1 0.9706989
for O 0 0.004767119
detection O 0 0.0049334415
of O 0 0.006984478
isoproterenol B-Chemical 1 0.9998605
- O 0 0.033381935
induced O 0 0.012731229
myocardial B-Disease 0 0.99989843
infarction I-Disease 2 0.9999734
in O 0 0.011865083
rats O 0 0.046220977
. O 0 0.011947828

Infarct B-Disease 0 0.99833125
- O 0 0.015322232
avid O 0 0.018189011
radiopharmaceuticals O 0 0.17605811
are O 0 0.003341817
necessary O 0 0.0017690674
for O 0 0.0016576822
rapid O 0 0.002994188
and O 0 0.0023013668
timely O 0 0.0033949045
diagnosis O 0 0.014479098
of O 0 0.008001436
acute O 2 0.9992021
myocardial B-Disease 2 0.9999466
infarction I-Disease 2 0.99998116
. O 0 0.024492923

The O 0 0.007566219
animal O 0 0.0063865115
model O 0 0.004394103
used O 0 0.0027996167
to O 0 0.0022746117
produce O 0 0.0023589693
infarction B-Disease 2 0.99995613
implies O 0 0.0018739267
artery O 0 0.21816936
ligation O 0 0.004951008
but O 0 0.0014989796
chemical O 0 0.021011991
induction O 0 0.0019116966
can O 0 0.0014946621
be O 0 0.0019958415
easily O 0 0.0025788574
obtained O 0 0.003172464
with O 0 0.007014664
isoproterenol B-Chemical 1 0.99961287
. O 0 0.011716193

A O 0 0.05617581
new O 0 0.013680615
infarct B-Disease 0 0.99858934
- O 0 0.010468958
avid O 0 0.018067753
radiopharmaceutical O 0 0.19876312
based O 0 0.0026741275
on O 0 0.001911199
glucaric B-Chemical 0 0.99947566
acid I-Chemical 0 0.9702172
was O 0 0.0021007403
prepared O 0 0.0021643084
in O 0 0.0015052662
the O 0 0.0017773184
hospital O 0 0.0048185457
radiopharmacy O 0 0.003661163
of O 0 0.0041642543
the O 0 0.006261194
INCMNSZ O 0 0.75250536
. O 0 0.010193084

99mTc B-Chemical 1 0.97021145
- I-Chemical 1 0.0265299
glucarate I-Chemical 1 0.98189837
was O 0 0.004020473
easy O 0 0.0033083037
to O 0 0.0017097308
prepare O 0 0.0017885971
, O 0 0.0015612919
stable O 0 0.0009743287
for O 0 0.00061491516
96 O 0 0.0010785902
h O 0 0.0004620912
and O 0 0.00057724933
was O 0 0.00049127353
used O 0 0.0004357909
to O 0 0.00044823714
study O 0 0.0006774956
its O 0 0.0010095364
biodistribution O 0 0.10843848
in O 0 0.0007753157
rats O 0 0.003537187
with O 0 0.002421562
isoproterenol B-Chemical 1 0.99993896
- O 0 0.01867728
induced O 0 0.007112162
acute O 2 0.99938226
myocardial B-Disease 2 0.9999577
infarction I-Disease 2 0.9999844
. O 0 0.021405265

Histological O 0 0.18227027
studies O 0 0.0077817366
demonstrated O 0 0.0043260474
that O 0 0.0031246126
the O 0 0.0029600717
rats O 0 0.0048329723
developed O 0 0.003639004
an O 0 0.004773288
infarct B-Disease 0 0.9989146
18 O 0 0.0030811673
h O 0 0.0025070938
after O 0 0.0028765693
isoproterenol B-Chemical 1 0.9994708
administration O 0 0.49178773
. O 0 0.011510308

The O 0 0.010720618
rat O 0 0.013738805
biodistribution O 0 0.052062243
studies O 0 0.0056121405
showed O 0 0.0037901502
a O 0 0.0046335235
rapid O 0 0.0061634895
blood O 0 0.017723164
clearance O 0 0.06931233
via O 0 0.005781647
the O 0 0.00752733
kidneys O 0 0.21909098
. O 0 0.012878154

Thirty O 0 0.011537928
minutes O 0 0.0052387174
after O 0 0.003589517
99mTc B-Chemical 1 0.9251891
- I-Chemical 1 0.008858326
glucarate I-Chemical 1 0.98838705
administration O 0 0.0586729
the O 0 0.0012068484
standardised O 0 0.0013803284
heart O 0 0.4911036
uptake O 0 0.017723445
value O 0 0.0012809486
S O 0 0.8594255
( O 0 0.001452777
h O 0 0.00064685766
) O 0 0.001679318
UV O 0 0.55750096
was O 0 0.0006031552
4 O 0 0.00045774746
. O 0 0.000321492
7 O 0 0.00036297707
in O 0 0.00038338554
infarcted O 0 0.15204664
rat O 0 0.0023725147
heart O 0 0.2754531
which O 0 0.000907104
is O 0 0.0006562156
six O 0 0.00054635457
times O 0 0.0007020158
more O 0 0.0012437702
than O 0 0.0012525884
in O 0 0.0022668885
normal O 0 0.0059349416
rats O 0 0.0119007025
. O 0 0.008228468

ROIs O 0 0.015594353
drawn O 0 0.007642719
over O 0 0.004015925
the O 0 0.004310323
gamma O 0 0.10146896
camera O 0 0.0072242976
images O 0 0.0041440395
showed O 0 0.0024084144
a O 0 0.0031915363
ratio O 0 0.0033931276
of O 0 0.0039954837
4 O 0 0.0041814023
. O 0 0.0042774407
4 O 0 0.0063953702
. O 0 0.008643233

The O 0 0.0073949588
high O 0 0.0057837693
image O 0 0.0047496427
quality O 0 0.002568267
suggests O 0 0.0013702998
that O 0 0.0011892992
high O 0 0.001374231
contrast O 0 0.001117558
images O 0 0.0015626111
can O 0 0.00062668737
be O 0 0.0006181788
obtained O 0 0.0005507452
in O 0 0.0005189303
humans O 0 0.0011842415
and O 0 0.00060293823
the O 0 0.00048476981
96 O 0 0.0007981042
h O 0 0.00032054354
stability O 0 0.0004648223
makes O 0 0.00042522736
it O 0 0.00051297515
an O 0 0.0006228553
ideal O 0 0.0005842834
agent O 0 0.03142449
to O 0 0.0007321806
detect O 0 0.0006940743
, O 0 0.0015581511
in O 0 0.0011916397
patients O 0 0.0051038116
, O 0 0.0034060017
early O 0 0.008530635
cardiac B-Disease 0 0.9962405
infarction I-Disease 2 0.9999765
. O 0 0.016091088

Bupropion B-Chemical 0 0.9989749
( O 0 0.11632554
Zyban B-Chemical 0 0.99740595
) O 0 0.084031165
toxicity B-Disease 2 0.99279857
. O 0 0.03801875

Bupropion B-Chemical 0 0.99928397
is O 0 0.014212561
a O 0 0.014559278
monocyclic O 0 0.99332726
antidepressant B-Chemical 1 0.99963427
structurally O 0 0.0500269
related O 0 0.0087452065
to O 0 0.013503624
amphetamine B-Chemical 1 0.9998666
. O 0 0.020176906

Zyban B-Chemical 0 0.9979679
, O 0 0.009749307
a O 0 0.006052141
sustained O 0 0.016890977
- O 0 0.0051576556
release O 0 0.028945426
formulation O 0 0.13054597
of O 0 0.0058203125
bupropion B-Chemical 1 0.9999958
hydrochloride I-Chemical 0 0.99993896
, O 0 0.004261299
was O 0 0.0010606585
recently O 0 0.0010454745
released O 0 0.0019833613
in O 0 0.0013266362
Ireland O 0 0.10233449
, O 0 0.001911349
as O 0 0.0017806377
a O 0 0.0035745506
smoking O 1 0.9368869
cessation O 0 0.051956594
aid O 0 0.012191962
. O 0 0.00927737

In O 0 0.007140804
the O 0 0.0047522355
initial O 0 0.0034190982
6 O 0 0.0021497102
months O 0 0.0014386764
since O 0 0.0011240548
it O 0 0.0013011786
' O 0 0.0013519786
s O 0 0.0011457506
introduction O 0 0.0009387576
, O 0 0.001263019
12 O 0 0.00083011505
overdose B-Disease 2 0.9996327
cases O 0 0.002112241
have O 0 0.0010728054
been O 0 0.0013502486
reported O 0 0.0015734236
to O 0 0.001576624
The O 0 0.0021931662
National O 0 0.007347186
Poisons O 0 0.92827183
Information O 0 0.01816123
Centre O 0 0.021127263
. O 0 0.008342466

8 O 0 0.025188709
patients O 0 0.027430883
developed O 0 0.02565992
symptoms O 0 0.7810541
of O 0 0.037108716
toxicity B-Disease 2 0.99662846
. O 0 0.03430904

Common O 0 0.032763425
features O 0 0.016530806
included O 0 0.011692915
tachycardia B-Disease 2 0.99921477
, O 0 0.036894422
drowsiness O 0 0.99981827
, O 0 0.07559973
hallucinations B-Disease 2 0.99987185
and O 0 0.07301565
convulsions B-Disease 2 0.99983275
. O 0 0.021033093

Two O 0 0.0097226715
patients O 0 0.009193937
developed O 0 0.0065267617
severe O 0 0.3095245
cardiac B-Disease 2 0.9902906
arrhythmias I-Disease 2 0.99998057
, O 0 0.004618229
including O 0 0.0015256011
one O 0 0.0012170132
patient O 0 0.0018839409
who O 0 0.0025068892
was O 0 0.0017146611
resuscitated O 0 0.016113551
following O 0 0.002647239
a O 0 0.0064397645
cardiac B-Disease 2 0.9780423
arrest I-Disease 2 0.9714876
. O 0 0.011447932

All O 0 0.032802705
patients O 0 0.034939587
recovered O 0 0.02826374
without O 0 0.032491565
sequelae O 0 0.84426504
. O 0 0.040449124

We O 0 0.0080726575
report O 0 0.00721904
a O 0 0.004331802
case O 0 0.002673677
of O 0 0.002213379
a O 0 0.002090149
31 O 0 0.0018287001
year O 0 0.00093238184
old O 0 0.0009907627
female O 0 0.0019142011
who O 0 0.0010827776
required O 0 0.00039482964
admission O 0 0.002227995
to O 0 0.00052367855
the O 0 0.0006732617
Intensive O 0 0.04167232
Care O 0 0.0024936656
Unit O 0 0.0014805939
for O 0 0.00034882533
ventilation O 0 0.007498385
and O 0 0.00056607905
full O 0 0.00044353332
supportive O 0 0.0016935235
therapy O 0 0.006298276
, O 0 0.0011376445
following O 0 0.0009071471
ingestion O 0 0.3323212
of O 0 0.0023180577
13 O 0 0.0031567076
. O 0 0.0024020246
5g O 0 0.10304296
bupropion B-Chemical 1 0.9998677
. O 0 0.009629999

Recurrent O 0 0.8287777
seizures B-Disease 2 0.9996507
were O 0 0.0067790714
treated O 0 0.0049404292
with O 0 0.004617122
diazepam B-Chemical 1 0.9999579
and O 0 0.0037207007
broad O 0 0.0033190725
complex O 0 0.0033941031
tachycardia B-Disease 2 0.9996991
was O 0 0.0029186306
successfully O 0 0.0037539368
treated O 0 0.00548126
with O 0 0.009031377
adenosine B-Chemical 1 0.9985506
. O 0 0.013083162

Zyban B-Chemical 0 0.9961916
caused O 0 0.01415387
significant O 0 0.012220709
neurological B-Disease 0 0.9919155
and I-Disease 0 0.02067558
cardiovascular I-Disease 0 0.99950445
toxicity I-Disease 2 0.9997179
in O 0 0.053421736
overdose B-Disease 2 0.9997923
. O 0 0.019908456

The O 0 0.008327481
potential O 0 0.0077239196
toxic O 0 0.539235
effects O 0 0.006308545
should O 0 0.0020003493
be O 0 0.0019604492
considered O 0 0.0013983698
when O 0 0.0012780129
prescribing O 0 0.0096585285
it O 0 0.0020991776
as O 0 0.002349054
a O 0 0.004606223
smoking O 1 0.9560761
cessation O 0 0.07300019
aid O 0 0.014216763
. O 0 0.01025765

GLEPP1 O 0 0.6956601
receptor O 0 0.6413492
tyrosine B-Chemical 1 0.99321896
phosphatase O 0 0.9445734
( O 0 0.026400061
Ptpro O 0 0.5890071
) O 0 0.012014843
in O 0 0.007479119
rat O 0 0.12825064
PAN B-Chemical 1 0.99936205
nephrosis B-Disease 2 0.9997925
. O 0 0.026044825

A O 0 0.06755482
marker O 0 0.029196937
of O 0 0.030558845
acute O 0 0.9841457
podocyte O 0 0.9917917
injury O 0 0.9935609
. O 0 0.037570033

Glomerular O 0 0.57956225
epithelial O 0 0.09992363
protein O 0 0.009918333
1 O 0 0.004746175
( O 0 0.0045354078
GLEPP1 O 0 0.3641298
) O 0 0.0031464773
is O 0 0.0012370723
a O 0 0.0017649543
podocyte O 0 0.90649354
receptor O 0 0.2851847
membrane O 0 0.043288276
protein O 0 0.01236573
tyrosine B-Chemical 1 0.99351233
phosphatase O 0 0.72992957
located O 0 0.00080123334
on O 0 0.00041357285
the O 0 0.00059276616
apical O 0 0.0010417392
cell O 0 0.004565119
membrane O 0 0.0052534207
of O 0 0.0015285974
visceral O 0 0.6056138
glomerular O 0 0.9682875
epithelial O 0 0.43282932
cell O 0 0.07841868
and O 0 0.006265834
foot O 0 0.28029677
processes O 0 0.017935626
. O 0 0.009596555

This O 0 0.015001165
receptor O 0 0.04931563
plays O 0 0.005730168
a O 0 0.0045637107
role O 0 0.0024899794
in O 0 0.0022287087
regulating O 0 0.0017433952
the O 0 0.0019248255
structure O 0 0.002568006
and O 0 0.0025210427
function O 0 0.0029591855
of O 0 0.0049612843
podocyte O 0 0.95873594
foot O 0 0.50973797
process O 0 0.01021478
. O 0 0.010566145

To O 0 0.0063815084
better O 0 0.004529341
understand O 0 0.002444754
the O 0 0.0021431737
utility O 0 0.0019898377
of O 0 0.0020043717
GLEPP1 O 0 0.28339368
as O 0 0.0011013751
a O 0 0.00116037
marker O 0 0.0009869557
of O 0 0.0013307311
glomerular B-Disease 0 0.9962606
injury I-Disease 0 0.9990006
, O 0 0.0014463003
the O 0 0.00042956456
amount O 0 0.0002657707
and O 0 0.00043359963
distribution O 0 0.00031962656
of O 0 0.0006936259
GLEPP1 O 0 0.37802818
protein O 0 0.0012926924
and O 0 0.000782844
mRNA O 0 0.00071120047
were O 0 0.00039930787
examined O 0 0.00030208015
by O 0 0.00056828547
immunohistochemistry O 0 0.00804027
, O 0 0.0009621346
Western O 0 0.0087466
blot O 0 0.00844838
and O 0 0.0010735262
RNase O 0 0.75908536
protection O 0 0.0057386253
assay O 0 0.0012528701
in O 0 0.00073418027
a O 0 0.0011156445
model O 0 0.001246553
of O 0 0.0023532598
podocyte O 0 0.9626775
injury O 0 0.98233587
in O 0 0.0036324628
the O 0 0.0049224547
rat O 0 0.03053519
. O 0 0.008800974

Puromycin B-Chemical 0 0.999263
aminonucleoside I-Chemical 0 0.99992514
nephrosis B-Disease 2 0.99992156
was O 0 0.007039428
induced O 0 0.002962565
by O 0 0.001927072
single O 0 0.0014472537
intraperitoneal O 0 0.15112016
injection O 0 0.009029628
of O 0 0.0038688618
puromycin B-Chemical 0 0.990595
aminonucleoside I-Chemical 0 0.99998164
( O 0 0.07968848
PAN B-Chemical 1 0.9997489
, O 0 0.003492553
20 O 0 0.0021263824
mg O 0 0.3624158
/ O 0 0.009323406
100g O 0 0.43697554
BW O 0 0.6333817
) O 0 0.012853556
. O 0 0.00912449

Tissues O 0 0.023001362
were O 0 0.0061886623
analyzed O 0 0.0038054085
at O 0 0.0026059968
0 O 0 0.0027935796
, O 0 0.002107332
5 O 0 0.0012522306
, O 0 0.0012814683
7 O 0 0.0008572036
, O 0 0.0008964233
11 O 0 0.000792088
, O 0 0.0007046712
21 O 0 0.000634476
, O 0 0.0005696877
45 O 0 0.0004146233
, O 0 0.0004569745
80 O 0 0.00040448888
and O 0 0.00035852683
126 O 0 0.0009837142
days O 0 0.00024402705
after O 0 0.00025265338
PAN B-Chemical 1 0.99617505
injection O 0 0.0014699748
so O 0 0.00039822483
as O 0 0.00038437542
to O 0 0.00032503583
include O 0 0.00040787298
both O 0 0.00038307277
the O 0 0.00048286238
acute O 0 0.8919413
phase O 0 0.0022836463
of O 0 0.0017838563
proteinuria B-Disease 2 0.99998546
associated O 0 0.0014690133
with O 0 0.0008017084
foot O 0 0.08962926
process O 0 0.00080756866
effacement O 0 0.15608494
( O 0 0.00065401656
days O 0 0.00031829558
5 O 0 0.00039361502
- O 0 0.0006356178
11 O 0 0.00052550365
) O 0 0.0006285192
and O 0 0.00045048082
the O 0 0.00051411724
chronic O 0 0.7751703
phase O 0 0.0023500235
of O 0 0.0023202973
proteinuria B-Disease 2 0.99998
associated O 0 0.0035099688
with O 0 0.0043772175
glomerulosclerosis B-Disease 2 0.99997306
( O 0 0.0072104395
days O 0 0.00165774
45 O 0 0.002353497
- O 0 0.004274588
126 O 0 0.011650722
) O 0 0.007859628
. O 0 0.007249079

At O 0 0.006014003
day O 0 0.004901306
5 O 0 0.0037118134
, O 0 0.0037072457
GLEPP1 O 0 0.06976752
protein O 0 0.0029191289
and O 0 0.001893213
mRNA O 0 0.0016019791
were O 0 0.0008896619
reduced O 0 0.0007204156
from O 0 0.00060998945
the O 0 0.0005738022
normal O 0 0.0010995615
range O 0 0.0011237827
( O 0 0.0011181416
265 O 0 0.018201666
. O 0 0.00037488458
2 O 0 0.00046951105
+ O 0 0.00055247656
/ O 0 0.0012534513
- O 0 0.0006956877
79 O 0 0.0006373941
. O 0 0.00025517985
6 O 0 0.00024922777
x O 0 0.00057353295
10 O 0 0.00041035298
( O 0 0.00051534723
6 O 0 0.00031586183
) O 0 0.0006162017
moles O 0 0.043370206
/ O 0 0.0015871101
glomerulus O 0 0.020983653
and O 0 0.00058783084
100 O 0 0.0010082407
% O 0 0.00058382633
) O 0 0.00059794314
to O 0 0.0002874671
15 O 0 0.00028586792
% O 0 0.00035905943
of O 0 0.0003894993
normal O 0 0.00094082905
( O 0 0.0007164512
41 O 0 0.0009248084
. O 0 0.00030089906
8 O 0 0.0003929508
+ O 0 0.00050526694
/ O 0 0.0012699593
- O 0 0.00071431015
4 O 0 0.00034842003
. O 0 0.00027403867
8 O 0 0.00033436174
x O 0 0.00068535184
10 O 0 0.00050548866
( O 0 0.0006635291
6 O 0 0.0004471839
) O 0 0.000932588
moles O 0 0.04494268
/ O 0 0.0026803135
glomerulus O 0 0.035522804
, O 0 0.0016276668
p O 0 0.0017157429
< O 0 0.0017661956
0 O 0 0.002477245
. O 0 0.0025090803
005 O 0 0.058691904
) O 0 0.007768118
. O 0 0.0073965485

This O 0 0.01004919
occurred O 0 0.0051467693
in O 0 0.003099607
association O 0 0.001974555
with O 0 0.0018554156
an O 0 0.0019528638
increase O 0 0.0009768741
in O 0 0.00096383336
urinary O 0 0.7928768
protein O 0 0.0021887815
content O 0 0.0008412889
from O 0 0.00072716153
1 O 0 0.00070848654
. O 0 0.00039215016
8 O 0 0.0004906918
+ O 0 0.000613831
/ O 0 0.0015489572
- O 0 0.0008218109
1 O 0 0.0004264922
to O 0 0.00035536388
99 O 0 0.0008868851
. O 0 0.0003490379
0 O 0 0.000621418
+ O 0 0.0006152959
/ O 0 0.0013905241
- O 0 0.0009095246
61 O 0 0.0010402373
mg O 0 0.07069214
/ O 0 0.0014854337
day O 0 0.00078125554
( O 0 0.0013945762
p O 0 0.0015665981
< O 0 0.0017468177
0 O 0 0.002532777
. O 0 0.0026477554
001 O 0 0.17885314
) O 0 0.008241923
. O 0 0.0076476573

In O 0 0.011550019
contrast O 0 0.009261824
, O 0 0.008868383
podocalyxin O 0 0.033640128
did O 0 0.004879892
not O 0 0.0042328853
change O 0 0.004335255
significantly O 0 0.0050344607
at O 0 0.004489774
this O 0 0.006004455
time O 0 0.0076553333
. O 0 0.0111966515

By O 0 0.0126544405
day O 0 0.0074537047
11 O 0 0.007028478
, O 0 0.00615166
GLEPP1 O 0 0.07122932
protein O 0 0.0051819566
and O 0 0.0039139776
mRNA O 0 0.0038211204
had O 0 0.0027990176
begun O 0 0.004084018
to O 0 0.0031276303
return O 0 0.0053520594
towards O 0 0.005097237
baseline O 0 0.008061572
. O 0 0.009361907

By O 0 0.010077967
day O 0 0.005585394
45 O 0 0.0045706737
- O 0 0.004409571
126 O 0 0.0054134713
, O 0 0.0019606822
at O 0 0.00094875554
a O 0 0.0010674548
time O 0 0.0006827927
when O 0 0.0006484566
glomerular O 0 0.8460469
scarring O 0 0.9919887
was O 0 0.000963618
present O 0 0.0005414583
, O 0 0.0012202
GLEPP1 O 0 0.19015221
was O 0 0.0005468453
absent O 0 0.0004948326
from O 0 0.0006023314
glomerulosclerotic O 0 0.8341614
areas O 0 0.0015114811
although O 0 0.00045449223
the O 0 0.00048295537
total O 0 0.000654749
glomerular O 0 0.65873444
content O 0 0.0011221349
of O 0 0.0017816086
GLEPP1 O 0 0.3441803
was O 0 0.0015595597
not O 0 0.0016571593
different O 0 0.0023215073
from O 0 0.0040380373
normal O 0 0.009357874
. O 0 0.008300025

We O 0 0.00901944
conclude O 0 0.005826148
that O 0 0.0048913783
GLEPP1 O 0 0.18409601
expression O 0 0.0048128874
, O 0 0.0039854394
unlike O 0 0.002458938
podocalyxin O 0 0.12851794
, O 0 0.003960299
reflects O 0 0.0028482394
podocyte O 0 0.95551866
injury O 0 0.9914683
induced O 0 0.012384111
by O 0 0.024110079
PAN B-Chemical 1 0.9992131
. O 0 0.014729175

GLEPP1 O 0 0.22292502
expression O 0 0.013957101
may O 0 0.009767452
be O 0 0.008188444
a O 0 0.008131482
useful O 0 0.0073353476
marker O 0 0.0085677225
of O 0 0.012679848
podocyte O 0 0.982702
injury O 0 0.99378586
. O 0 0.020027915

Antithymocyte B-Chemical 0 0.94142836
globulin I-Chemical 0 0.99582326
in O 0 0.0070923134
the O 0 0.0050943946
treatment O 0 0.006747246
of O 0 0.010071738
D B-Chemical 1 0.9974605
- I-Chemical 1 0.26153085
penicillamine I-Chemical 1 0.99998415
- O 0 0.22318573
induced O 0 0.08546655
aplastic B-Disease 2 0.9999467
anemia I-Disease 2 0.9999552
. O 0 0.059389923

A O 0 0.030498346
patient O 0 0.008648854
who O 0 0.0065314006
received O 0 0.0043041715
antithymocyte B-Chemical 0 0.9976509
globulin I-Chemical 0 0.9996903
therapy O 0 0.38516015
for O 0 0.0046425066
aplastic B-Disease 2 0.9999778
anemia I-Disease 2 0.9999907
due O 0 0.004563763
to O 0 0.005015897
D B-Chemical 1 0.9980205
- I-Chemical 1 0.12506615
penicillamine I-Chemical 1 0.99998105
therapy O 0 0.30583674
is O 0 0.0061505516
described O 0 0.0063641528
. O 0 0.009559728

Bone O 0 0.3135249
marrow O 0 0.31886902
recovery O 0 0.009174462
and O 0 0.0036404964
peripheral O 0 0.023926962
blood O 0 0.014115391
recovery O 0 0.0028548937
were O 0 0.001001022
complete O 0 0.0006821182
1 O 0 0.0006155548
month O 0 0.00039259452
and O 0 0.00050610374
3 O 0 0.00042805093
months O 0 0.0003449413
, O 0 0.0005904977
respectively O 0 0.000818102
, O 0 0.0005312255
after O 0 0.0002330725
treatment O 0 0.0006480615
, O 0 0.0005892739
and O 0 0.00044251466
blood O 0 0.004705149
transfusion O 0 0.06135332
or O 0 0.000503807
other O 0 0.00055304053
therapies O 0 0.009653667
were O 0 0.0004944342
not O 0 0.00038302207
necessary O 0 0.00029017663
in O 0 0.00044191693
a O 0 0.00074742653
follow O 0 0.00058709853
- O 0 0.0010714822
up O 0 0.00069431344
period O 0 0.00077266956
of O 0 0.0013286441
more O 0 0.0019643886
than O 0 0.0019460669
2 O 0 0.0037281727
years O 0 0.0066169566
. O 0 0.007146513

Use O 0 0.016884184
of O 0 0.009623049
antithymocyte B-Chemical 0 0.9964941
globulin I-Chemical 0 0.9992167
may O 0 0.004226491
be O 0 0.0024072542
the O 0 0.0015917708
optimal O 0 0.0011631377
treatment O 0 0.002855012
of O 0 0.0057932227
D B-Chemical 1 0.9982651
- I-Chemical 1 0.22869569
penicillamine I-Chemical 1 0.99998987
- O 0 0.18689105
induced O 0 0.072157204
aplastic B-Disease 2 0.9999573
anemia I-Disease 2 0.99996173
. O 0 0.053033967

Metamizol B-Chemical 0 0.99825495
potentiates O 0 0.7183763
morphine B-Chemical 1 0.9999062
antinociception O 0 0.9999138
but O 0 0.009666125
not O 0 0.007259495
constipation B-Disease 2 0.9997832
after O 0 0.0061610863
chronic O 0 0.97639686
treatment O 0 0.06398113
. O 0 0.014782698

This O 0 0.010367843
work O 0 0.0058762864
evaluates O 0 0.003936918
the O 0 0.0031405466
antinociceptive O 0 0.9982443
and O 0 0.0040241485
constipating B-Disease 0 0.9991584
effects O 0 0.003967603
of O 0 0.0012400706
the O 0 0.0007325183
combination O 0 0.0011188394
of O 0 0.00086547574
3 O 0 0.0006005521
. O 0 0.00034070498
2 O 0 0.0004125168
mg O 0 0.061150223
/ O 0 0.0010171094
kg O 0 0.0020209423
s O 0 0.0006143127
. O 0 0.00036284802
c O 0 0.0039539104
. O 0 0.0004290395
morphine B-Chemical 1 0.9998505
with O 0 0.0006744923
177 O 0 0.022647906
. O 0 0.00030680475
8 O 0 0.00034850193
mg O 0 0.038114678
/ O 0 0.0008958875
kg O 0 0.0017720035
s O 0 0.0006020046
. O 0 0.00036992677
c O 0 0.0047589657
. O 0 0.0004980966
metamizol B-Chemical 0 0.9999913
in O 0 0.0006598991
acutely O 0 0.04793408
and O 0 0.00081000756
chronically O 0 0.016898206
treated O 0 0.0011267242
( O 0 0.0011231002
once O 0 0.00059915055
a O 0 0.00083125086
day O 0 0.00073057535
for O 0 0.00086950656
12 O 0 0.0012307204
days O 0 0.0018018896
) O 0 0.005208041
rats O 0 0.008761971
. O 0 0.0077432757

On O 0 0.009122947
the O 0 0.0055932812
13th O 0 0.01113728
day O 0 0.003268964
, O 0 0.0035419213
antinociceptive O 0 0.9954912
effects O 0 0.0034448658
were O 0 0.0010967129
assessed O 0 0.0006477562
using O 0 0.0005900824
a O 0 0.00074876647
model O 0 0.000691915
of O 0 0.001112077
inflammatory O 0 0.98054606
nociception O 0 0.99974877
, O 0 0.023116857
pain B-Disease 2 0.9997472
- O 0 0.0043628393
induced O 0 0.0007411798
functional O 0 0.0011756211
impairment O 0 0.20151357
model O 0 0.000909665
, O 0 0.0009386432
and O 0 0.0006527042
the O 0 0.0006997505
charcoal B-Chemical 0 0.96449196
meal O 0 0.030478971
test O 0 0.0011760718
was O 0 0.0009163993
used O 0 0.0009476656
to O 0 0.001116715
evaluate O 0 0.0012044475
the O 0 0.0030112092
intestinal O 0 0.41389647
transit O 0 0.32989126
. O 0 0.009795039

Simultaneous O 0 0.019428913
administration O 0 0.05669518
of O 0 0.0068797264
morphine B-Chemical 1 0.9999162
with O 0 0.009339627
metamizol B-Chemical 0 0.9999944
resulted O 0 0.0018494786
in O 0 0.0010029371
a O 0 0.0016150421
markedly O 0 0.031354018
antinociceptive O 0 0.99981624
potentiation O 0 0.9466286
and O 0 0.0009471374
an O 0 0.0007593514
increasing O 0 0.0005384489
of O 0 0.0004982637
the O 0 0.00038702387
duration O 0 0.00049716205
of O 0 0.0005360042
action O 0 0.0020400293
after O 0 0.00025492185
a O 0 0.00061002024
single O 0 0.00064358197
( O 0 0.0012200349
298 O 0 0.17340817
+ O 0 0.00073556125
/ O 0 0.0018471824
- O 0 0.00075748673
7 O 0 0.00036251487
vs O 0 0.0006546972
. O 0 0.00032744533
139 O 0 0.0017078111
+ O 0 0.00058539596
/ O 0 0.0013021629
- O 0 0.0006711258
36 O 0 0.00038774882
units O 0 0.0003661067
area O 0 0.00076071196
( O 0 0.0011034985
ua O 0 0.86628675
) O 0 0.00196891
; O 0 0.0012269409
P O 0 0.029388146
< O 0 0.00053407496
0 O 0 0.00059232255
. O 0 0.00037365092
001 O 0 0.07985901
) O 0 0.0006179373
and O 0 0.00038049417
repeated O 0 0.00040674003
administration O 0 0.021726841
( O 0 0.0010989446
280 O 0 0.008392144
+ O 0 0.0006982709
/ O 0 0.0016181438
- O 0 0.00082646543
17 O 0 0.00064344826
vs O 0 0.0008280405
. O 0 0.0004549369
131 O 0 0.0028537048
+ O 0 0.0009008985
/ O 0 0.0020660472
- O 0 0.0014876632
22 O 0 0.0015101964
ua O 0 0.6201364
; O 0 0.0027713398
P O 0 0.03646978
< O 0 0.0020826785
0 O 0 0.0027954255
. O 0 0.002853127
001 O 0 0.172291
) O 0 0.008576731
. O 0 0.007934599

Antinociceptive O 0 0.9952716
effect O 0 0.006874119
of O 0 0.0071834284
morphine B-Chemical 1 0.99991083
was O 0 0.0031473495
reduced O 0 0.001795126
in O 0 0.0011835514
chronically O 0 0.020428428
treated O 0 0.0015089789
rats O 0 0.0068394104
( O 0 0.0014683852
39 O 0 0.0015602006
+ O 0 0.0008404732
/ O 0 0.001970541
- O 0 0.00084346056
10 O 0 0.00041300946
vs O 0 0.0006928843
. O 0 0.00031470068
18 O 0 0.00041831785
+ O 0 0.00050791854
/ O 0 0.0012343475
- O 0 0.00067648006
5 O 0 0.00032487226
au O 0 0.0038021961
) O 0 0.00086025934
while O 0 0.000350321
the O 0 0.00041309884
combination O 0 0.0017726016
- O 0 0.0025818532
induced O 0 0.0013080324
antinociception O 0 0.99997497
was O 0 0.0006431465
remained O 0 0.00048643112
similar O 0 0.00028029917
as O 0 0.00045459834
an O 0 0.0009087021
acute O 0 0.9096541
treatment O 0 0.005325591
( O 0 0.0030944396
298 O 0 0.32541248
+ O 0 0.001009875
/ O 0 0.0023261406
- O 0 0.0010665911
7 O 0 0.00061126746
vs O 0 0.0011553428
. O 0 0.0007728817
280 O 0 0.004101879
+ O 0 0.0016198254
/ O 0 0.0034898939
- O 0 0.0031833688
17 O 0 0.0037970233
au O 0 0.022202296
) O 0 0.011487193
. O 0 0.008609978

Acute O 0 0.97529715
antinociceptive O 0 0.9976186
effects O 0 0.008670311
of O 0 0.003608001
the O 0 0.0021489658
combination O 0 0.002854799
were O 0 0.0014944287
partially O 0 0.0013763031
prevented O 0 0.0024237656
by O 0 0.0013131859
3 O 0 0.0009547227
. O 0 0.000688447
2 O 0 0.0009540465
mg O 0 0.1031011
/ O 0 0.0035743942
kg O 0 0.033782285
naloxone B-Chemical 1 0.9999294
s O 0 0.0055085844
. O 0 0.004040207
c O 0 0.020260585
. O 0 0.008671992

( O 0 0.016545594
P O 0 0.049944967
< O 0 0.0064195287
0 O 0 0.004940575
. O 0 0.0029657683
05 O 0 0.04314265
) O 0 0.0030368217
, O 0 0.0017471751
suggesting O 0 0.00097078
the O 0 0.0010164004
partial O 0 0.0014374158
involvement O 0 0.0021560316
of O 0 0.0015784092
the O 0 0.0018890334
opioidergic O 0 0.99164724
system O 0 0.0032625115
in O 0 0.0022229212
the O 0 0.0031537183
synergism O 0 0.20077604
observed O 0 0.0053777737
. O 0 0.009308592

In O 0 0.0071299705
independent O 0 0.005064634
groups O 0 0.005001107
, O 0 0.005205786
morphine B-Chemical 1 0.9998503
inhibited O 0 0.0032270611
the O 0 0.0013582581
intestinal O 0 0.17855543
transit O 0 0.07825453
in O 0 0.000798451
48 O 0 0.00069317524
+ O 0 0.0008266553
/ O 0 0.0020450642
- O 0 0.0009047673
4 O 0 0.00039158872
% O 0 0.00046148553
and O 0 0.00044561073
38 O 0 0.0008367733
+ O 0 0.000616978
/ O 0 0.0016499998
- O 0 0.000748075
4 O 0 0.000326816
% O 0 0.00038958347
after O 0 0.00024033607
acute O 0 0.7016994
and O 0 0.001130283
chronic O 0 0.95027333
treatment O 0 0.007980478
, O 0 0.001948086
respectively O 0 0.0020642823
, O 0 0.00085998897
suggesting O 0 0.0004505603
that O 0 0.0005801774
tolerance O 0 0.043900963
did O 0 0.0009014299
not O 0 0.0010107128
develop O 0 0.0015248808
to O 0 0.001819723
the O 0 0.0034391934
constipating B-Disease 0 0.9985844
effects O 0 0.041430216
. O 0 0.010271601

The O 0 0.0071983556
combination O 0 0.006900824
inhibited O 0 0.004966923
intestinal O 0 0.14822352
transit O 0 0.058618054
similar O 0 0.0011348389
to O 0 0.00092543516
that O 0 0.00068276795
produced O 0 0.0007926472
by O 0 0.0011391264
morphine B-Chemical 1 0.9999107
regardless O 0 0.0003906171
of O 0 0.0006355706
the O 0 0.0004818024
time O 0 0.00037355817
of O 0 0.0006576339
treatment O 0 0.0013959907
, O 0 0.0010006588
suggesting O 0 0.00053199905
that O 0 0.0008488848
metamizol B-Chemical 0 0.99999285
did O 0 0.001335186
not O 0 0.0016280952
potentiate O 0 0.10325765
morphine B-Chemical 1 0.99996364
- O 0 0.040837046
induced O 0 0.018684097
constipation B-Disease 2 0.9998734
. O 0 0.014043653

These O 0 0.0085335
findings O 0 0.0068806577
show O 0 0.0031656811
a O 0 0.0030532237
significant O 0 0.0020452023
interaction O 0 0.001757739
between O 0 0.0011504102
morphine B-Chemical 1 0.99995613
and O 0 0.0063210703
metamizol B-Chemical 0 0.99999654
in O 0 0.0013126563
chronically O 0 0.046944845
treated O 0 0.0012614484
rats O 0 0.0049963053
, O 0 0.0008696114
suggesting O 0 0.00038872758
that O 0 0.00040060934
this O 0 0.0005132696
combination O 0 0.0010248956
could O 0 0.00055656454
be O 0 0.0007518063
useful O 0 0.0008301233
for O 0 0.00073865964
the O 0 0.0012362011
treatment O 0 0.0028777348
of O 0 0.005539718
chronic B-Disease 0 0.9957081
pain I-Disease 2 0.99954706
. O 0 0.014457176

Ifosfamide B-Chemical 1 0.99854076
encephalopathy B-Disease 2 0.99919933
presenting O 0 0.7466157
with O 0 0.09456877
asterixis B-Disease 2 0.9995468
. O 0 0.04792933

CNS O 0 0.8091904
toxic O 0 0.71963793
effects O 0 0.007027058
of O 0 0.0036440075
the O 0 0.0025330933
antineoplastic O 0 0.9774305
agent O 0 0.8763334
ifosfamide B-Chemical 1 0.99996746
( O 0 0.03641068
IFX B-Chemical 0 0.9998605
) O 0 0.0036779777
are O 0 0.00081907085
frequent O 0 0.0017337854
and O 0 0.0007488952
include O 0 0.00071325444
a O 0 0.0009445376
variety O 0 0.0019911428
of O 0 0.0021462599
neurological O 0 0.99961436
symptoms O 0 0.98671395
that O 0 0.0016463561
can O 0 0.0018425032
limit O 0 0.0041122017
drug O 0 0.6191779
use O 0 0.007872955
. O 0 0.008617182

We O 0 0.00815292
report O 0 0.0072853244
a O 0 0.004397442
case O 0 0.0027449748
of O 0 0.0023515641
a O 0 0.0024639934
51 O 0 0.003349936
- O 0 0.0020173294
year O 0 0.0010711974
- O 0 0.0012643881
old O 0 0.0009080786
man O 0 0.03627941
who O 0 0.0018837434
developed O 0 0.0016125053
severe O 0 0.41357225
, O 0 0.0031475527
disabling O 0 0.9725242
negative O 0 0.003976589
myoclonus B-Disease 2 0.9999851
of O 0 0.0011386176
the O 0 0.0006630076
upper O 0 0.0015743049
and O 0 0.0007681085
lower O 0 0.0007882467
extremities O 0 0.35410857
after O 0 0.0005741549
the O 0 0.0009895454
infusion O 0 0.0071519692
of O 0 0.0034410898
ifosfamide B-Chemical 1 0.9997305
for O 0 0.0059955767
plasmacytoma B-Disease 0 0.998858
. O 0 0.0121695055

He O 0 0.015516391
was O 0 0.006539658
awake O 0 0.008942239
, O 0 0.0036614535
revealed O 0 0.0021026854
no O 0 0.0014603838
changes O 0 0.0018690208
of O 0 0.0020633563
mental O 0 0.24320124
status O 0 0.002087406
and O 0 0.0013019447
at O 0 0.00084989413
rest O 0 0.0012666916
there O 0 0.00088088145
were O 0 0.0013810002
no O 0 0.0014933725
further O 0 0.0033233024
motor O 0 0.27417052
symptoms O 0 0.88748336
. O 0 0.010052131

Cranial O 0 0.70444685
magnetic O 0 0.11060697
resonance O 0 0.16352744
imaging O 0 0.010186659
and O 0 0.0034409265
extensive O 0 0.0025896202
laboratory O 0 0.0027781345
studies O 0 0.0017071156
failed O 0 0.0013808253
to O 0 0.0011037403
reveal O 0 0.0012639246
structural B-Disease 0 0.00293904
lesions I-Disease 0 0.2520117
of I-Disease 0 0.0025602411
the I-Disease 0 0.0026060962
brain I-Disease 0 0.17038107
and O 0 0.006231791
metabolic B-Disease 0 0.9450136
abnormalities I-Disease 0 0.9380002
. O 0 0.011703087

An O 0 0.0135273365
electroencephalogram O 0 0.2004985
showed O 0 0.0044447277
continuous O 0 0.0038889863
, O 0 0.003916014
generalized O 0 0.041208412
irregular O 0 0.006707665
slowing O 0 0.025857123
with O 0 0.0023181557
admixed O 0 0.07711256
periodic O 0 0.033000708
triphasic O 0 0.95669085
waves O 0 0.19112736
indicating O 0 0.0050130547
symptomatic O 0 0.8748492
encephalopathy B-Disease 2 0.9998791
. O 0 0.016000878

The O 0 0.008601707
administration O 0 0.020602677
of O 0 0.0069487453
ifosfamide B-Chemical 1 0.9993462
was O 0 0.003936295
discontinued O 0 0.017117659
and O 0 0.0022130725
within O 0 0.0013210846
12 O 0 0.0015412333
h O 0 0.0019193845
the O 0 0.0035233432
asterixis B-Disease 2 0.99990094
resolved O 0 0.02118327
completely O 0 0.009533735
. O 0 0.0103454795

In O 0 0.00689807
the O 0 0.0048450558
patient O 0 0.0045835488
described O 0 0.0023875784
, O 0 0.0023309519
the O 0 0.001305685
presence O 0 0.0011006792
of O 0 0.0022227946
asterixis B-Disease 2 0.99998367
during O 0 0.0007344147
infusion O 0 0.012057721
of O 0 0.0012682653
ifosfamide B-Chemical 1 0.9998927
, O 0 0.0011952546
normal O 0 0.0009322238
laboratory O 0 0.0007408341
findings O 0 0.00090698135
and O 0 0.0005962492
imaging O 0 0.0023656972
studies O 0 0.00044906512
and O 0 0.00043974738
the O 0 0.0004133663
resolution O 0 0.0029485377
of O 0 0.00065414683
symptoms O 0 0.60295606
following O 0 0.0004549343
the O 0 0.00046400842
discontinuation O 0 0.47460464
of O 0 0.00057666755
the O 0 0.00051303586
drug O 0 0.17311667
suggest O 0 0.00037681873
that O 0 0.000558494
negative O 0 0.0027937389
myoclonus B-Disease 2 0.9999851
is O 0 0.001563893
associated O 0 0.0016438788
with O 0 0.0017552015
the O 0 0.0020513856
use O 0 0.0033829855
of O 0 0.007818467
IFX B-Chemical 0 0.99936956
. O 0 0.010912734

Antagonism O 0 0.7004424
between O 0 0.00567118
interleukin O 0 0.7541829
3 O 0 0.0036586956
and O 0 0.003115712
erythropoietin O 0 0.98139566
in O 0 0.0018978645
mice O 0 0.0013021666
with O 0 0.0023900126
azidothymidine B-Chemical 1 0.9994419
- O 0 0.01803264
induced O 0 0.004893651
anemia B-Disease 2 0.9999404
and O 0 0.006047834
in O 0 0.003695022
bone O 0 0.7856012
marrow O 0 0.9708283
endothelial O 0 0.993612
cells O 0 0.072623886
. O 0 0.01221263

Azidothymidine B-Chemical 0 0.9958039
( O 0 0.028587395
AZT B-Chemical 1 0.9985519
) O 0 0.026253147
- O 0 0.0063456045
induced O 0 0.003721334
anemia B-Disease 2 0.99990034
in O 0 0.0018952559
mice O 0 0.0009375348
can O 0 0.0007440991
be O 0 0.0008024624
reversed O 0 0.001218112
by O 0 0.0007179018
the O 0 0.0006253953
administration O 0 0.067166865
of O 0 0.0036889971
IGF O 0 0.9997656
- O 0 0.031086072
IL O 0 0.99588877
- O 0 0.002525344
3 O 0 0.000585943
( O 0 0.00067588367
fusion O 0 0.0006231525
protein O 0 0.0009463274
of O 0 0.0012914945
insulin O 0 0.981506
- O 0 0.0025621634
like O 0 0.00096541044
growth O 0 0.015927685
factor O 0 0.05638772
II O 0 0.38424602
( O 0 0.007611381
IGF O 0 0.9978892
II O 0 0.22173198
) O 0 0.0046287384
and O 0 0.0035122707
interleukin O 0 0.8970828
3 O 0 0.005743879
) O 0 0.009916034
. O 0 0.008126696

Although O 0 0.009055833
interleukin O 0 0.76821005
3 O 0 0.0059558377
( O 0 0.0071086143
IL O 0 0.97822225
- O 0 0.0047743022
3 O 0 0.001539484
) O 0 0.0019164216
and O 0 0.0013685033
erythropoietin O 0 0.9965753
( O 0 0.0093671
EPO O 0 0.9997547
) O 0 0.0036150152
are O 0 0.00068512105
known O 0 0.0006894781
to O 0 0.0004936784
act O 0 0.0011266024
synergistically O 0 0.0037400296
on O 0 0.0004491692
hematopoietic O 0 0.9335084
cell O 0 0.08722916
proliferation O 0 0.8179729
in O 0 0.0006246608
vitro O 0 0.0012440385
, O 0 0.00085992337
injection O 0 0.0018485334
of O 0 0.0018474691
IGF O 0 0.99968624
- O 0 0.021602193
IL O 0 0.995284
- O 0 0.0020781802
3 O 0 0.0004948857
and O 0 0.00067868474
EPO O 0 0.9993212
in O 0 0.0009835843
AZT B-Chemical 1 0.9995603
- O 0 0.0018246865
treated O 0 0.00060648046
mice O 0 0.00032531482
resulted O 0 0.00036383903
in O 0 0.0003701321
a O 0 0.00059386145
reduction O 0 0.00067432
of O 0 0.0005842828
red O 0 0.0050645564
cells O 0 0.0014415989
and O 0 0.0006579587
an O 0 0.000703261
increase O 0 0.00036119795
of O 0 0.0007491823
plasma O 0 0.10297125
EPO O 0 0.9996159
levels O 0 0.0006418041
as O 0 0.00054453884
compared O 0 0.00034577592
to O 0 0.00049004226
animals O 0 0.00063470524
treated O 0 0.0013844484
with O 0 0.0028730154
IGF O 0 0.99950314
- O 0 0.028527047
IL O 0 0.9916688
- O 0 0.004324986
3 O 0 0.0022073719
or O 0 0.0033811566
EPO O 0 0.9980147
alone O 0 0.009437645
. O 0 0.009447341

We O 0 0.0072567672
tested O 0 0.0039860564
the O 0 0.0031987533
hypothesis O 0 0.0025450347
that O 0 0.0016180744
the O 0 0.0015054883
antagonistic O 0 0.0048809987
effect O 0 0.001585021
of O 0 0.0041569676
IL O 0 0.99793637
- O 0 0.0048590177
3 O 0 0.00094547175
and O 0 0.0012561758
EPO O 0 0.9988103
on O 0 0.0010995268
erythroid O 0 0.9588823
cells O 0 0.004961445
may O 0 0.0017898747
be O 0 0.0021899568
mediated O 0 0.0025286302
by O 0 0.005040416
endothelial O 0 0.9568016
cells O 0 0.02831486
. O 0 0.010711368

Bovine O 0 0.27565056
liver O 0 0.9277965
erythroid O 0 0.97343236
cells O 0 0.009067086
were O 0 0.0028400628
cultured O 0 0.002223823
on O 0 0.001181705
monolayers O 0 0.0057111336
of O 0 0.0017545786
human O 0 0.002659167
bone O 0 0.6206172
marrow O 0 0.92906463
endothelial O 0 0.9874687
cells O 0 0.0071862037
previously O 0 0.0014715741
treated O 0 0.002281038
with O 0 0.00326443
EPO O 0 0.99974483
and O 0 0.020463804
IGF O 0 0.99942774
- O 0 0.054289814
IL O 0 0.99170953
- O 0 0.0104964925
3 O 0 0.00644977
. O 0 0.007866411

There O 0 0.0087727085
was O 0 0.0054101474
a O 0 0.0042948686
significant O 0 0.0029546716
reduction O 0 0.003178976
of O 0 0.0030149764
thymidine B-Chemical 0 0.96868795
incorporation O 0 0.0056745335
into O 0 0.0007441154
both O 0 0.0010870404
erythroid O 0 0.9545683
and O 0 0.0019061754
endothelial O 0 0.9396863
cells O 0 0.0029293129
in O 0 0.00084689894
cultures O 0 0.0016216555
pre O 0 0.017803514
- O 0 0.0022636477
treated O 0 0.0017353087
with O 0 0.0032755223
IGF O 0 0.99933404
- O 0 0.030138142
IL O 0 0.9910301
- O 0 0.0060064476
3 O 0 0.003396787
and O 0 0.006098172
EPO O 0 0.9977049
. O 0 0.010862256

Endothelial O 0 0.9799622
cell O 0 0.020560637
culture O 0 0.005970548
supernatants O 0 0.002962917
separated O 0 0.002818021
by O 0 0.0021023422
ultrafiltration O 0 0.118518196
and O 0 0.0016346041
ultracentrifugation O 0 0.005950008
from O 0 0.0010306236
cells O 0 0.0016672218
treated O 0 0.0012432063
with O 0 0.0014422347
EPO O 0 0.99981564
and O 0 0.005683899
IL O 0 0.9977939
- O 0 0.0029907366
3 O 0 0.00050746993
significantly O 0 0.0006659003
reduced O 0 0.0008576016
thymidine B-Chemical 0 0.9677232
incorporation O 0 0.0044091856
into O 0 0.00040329798
erythroid O 0 0.9190912
cells O 0 0.0014796609
as O 0 0.0005105104
compared O 0 0.00029206814
to O 0 0.00035966205
identical O 0 0.00029167192
fractions O 0 0.00061559567
obtained O 0 0.0005721571
from O 0 0.00064736395
the O 0 0.0007638013
media O 0 0.0034254487
of O 0 0.0017004536
cells O 0 0.0038206468
cultured O 0 0.0041961404
with O 0 0.0061010653
EPO O 0 0.99922943
alone O 0 0.012075217
. O 0 0.009988511

These O 0 0.008715174
results O 0 0.005377695
suggest O 0 0.0030880915
that O 0 0.0027427308
endothelial O 0 0.79703254
cells O 0 0.004902939
treated O 0 0.0023653023
simultaneously O 0 0.0018388719
with O 0 0.002212183
EPO O 0 0.9997198
and O 0 0.006153783
IL O 0 0.99577016
- O 0 0.0028274427
3 O 0 0.0008515006
have O 0 0.0007358642
a O 0 0.0012184631
negative O 0 0.0015401037
effect O 0 0.0017963491
on O 0 0.002104294
erythroid O 0 0.97076327
cell O 0 0.14423445
production O 0 0.024702193
. O 0 0.011227895

The O 0 0.0066367066
relationship O 0 0.0039629964
between O 0 0.003091408
hippocampal O 0 0.8658894
acetylcholine B-Chemical 1 0.9998307
release O 0 0.3551656
and O 0 0.0033670042
cholinergic O 0 0.99441814
convulsant O 0 0.9999182
sensitivity O 0 0.009142037
in O 0 0.0011652047
withdrawal O 0 0.970633
seizure B-Disease 2 0.99994993
- O 0 0.006080184
prone O 0 0.0013284695
and O 0 0.0016624173
withdrawal O 0 0.9620526
seizure B-Disease 2 0.9998958
- O 0 0.006748997
resistant O 0 0.0028256741
selected O 0 0.0028994859
mouse O 0 0.006152091
lines O 0 0.0403319
. O 0 0.008810577

BACKGROUND O 0 0.59522057
: O 0 0.009212356
The O 0 0.0044932305
septo O 0 0.17811546
- O 0 0.0065398286
hippocampal O 0 0.7178263
cholinergic O 0 0.9792442
pathway O 0 0.0030048827
has O 0 0.0010465722
been O 0 0.0010578773
implicated O 0 0.00086655957
in O 0 0.0010182201
epileptogenesis O 0 0.9990927
, O 0 0.0015711585
and O 0 0.0007502675
genetic O 0 0.0016318766
factors O 0 0.002411068
influence O 0 0.0003986696
the O 0 0.00047193535
response O 0 0.0007857173
to O 0 0.0005871472
cholinergic O 0 0.97156984
agents O 0 0.25126633
, O 0 0.0010946889
but O 0 0.00050370366
limited O 0 0.00044961474
data O 0 0.0007047356
are O 0 0.0006359208
available O 0 0.00063178095
on O 0 0.00065178546
cholinergic O 0 0.9000352
involvement O 0 0.0047098272
in O 0 0.002631744
alcohol B-Chemical 1 0.9996561
withdrawal O 0 0.98364455
severity O 0 0.6273393
. O 0 0.011039654

Thus O 0 0.008035647
, O 0 0.005799691
the O 0 0.0030235054
relationship O 0 0.001812242
between O 0 0.0014237616
cholinergic O 0 0.9279916
activity O 0 0.0019616373
and O 0 0.0013199142
responsiveness O 0 0.001906915
and O 0 0.0015768837
alcohol B-Chemical 1 0.9997714
withdrawal O 0 0.94219816
was O 0 0.00087060494
investigated O 0 0.0005897377
in O 0 0.00072602136
a O 0 0.0011972772
genetic O 0 0.0021656177
animal O 0 0.0017768168
model O 0 0.0020214892
of O 0 0.0046347333
ethanol B-Chemical 1 0.9992937
withdrawal O 0 0.9872077
severity O 0 0.6588649
. O 0 0.011577472

METHODS O 0 0.012790242
: O 0 0.011701471
Cholinergic O 0 0.9818527
convulsant O 0 0.9993844
sensitivity O 0 0.007770501
was O 0 0.002130772
examined O 0 0.0013276676
in O 0 0.0019617623
alcohol B-Chemical 1 0.99980384
- O 0 0.06707962
na O 0 0.9994916
ve O 0 0.69625324
Withdrawal O 0 0.99893063
Seizure B-Disease 2 0.99994385
- O 0 0.01728785
Prone O 0 0.941018
( O 0 0.0037499499
WSP O 0 0.9438834
) O 0 0.0033763475
and O 0 0.0023962632
- O 0 0.004447419
Resistant O 0 0.1082213
( O 0 0.0061957845
WSR O 0 0.96507806
) O 0 0.0075557535
mice O 0 0.005337162
. O 0 0.008517043

Animals O 0 0.0123895025
were O 0 0.005999562
administered O 0 0.0067161787
nicotine B-Chemical 1 0.999338
, O 0 0.013089504
carbachol B-Chemical 1 0.999808
, O 0 0.0033997889
or O 0 0.0014096992
neostigmine B-Chemical 0 0.99993885
via O 0 0.00073955563
timed O 0 0.0013147846
tail O 0 0.00075203594
vein O 0 0.011418973
infusion O 0 0.009255211
, O 0 0.00072624657
and O 0 0.0004963041
the O 0 0.00044375408
latencies O 0 0.0045688
to O 0 0.00047091395
onset O 0 0.0023866915
of O 0 0.0015705408
tremor B-Disease 2 0.9999604
and O 0 0.0027890005
clonus O 0 0.9996357
were O 0 0.0013034684
recorded O 0 0.0013511047
and O 0 0.0015169517
converted O 0 0.0019369444
to O 0 0.0019377255
threshold O 0 0.0033670494
dose O 0 0.03242102
. O 0 0.007907337

We O 0 0.007860849
also O 0 0.0051981313
used O 0 0.0035600266
microdialysis O 0 0.09901455
to O 0 0.0019683337
measure O 0 0.001222277
basal O 0 0.0033157442
and O 0 0.0034612499
potassium B-Chemical 1 0.9999453
- O 0 0.015688844
stimulated O 0 0.0020698751
acetylcholine B-Chemical 1 0.99991536
( O 0 0.022317834
ACh B-Chemical 1 0.99990296
) O 0 0.00423332
release O 0 0.019755311
in O 0 0.0012081946
the O 0 0.001859954
CA1 O 0 0.90026915
region O 0 0.0024700114
of O 0 0.0034654057
the O 0 0.0052394904
hippocampus O 0 0.42272305
. O 0 0.008927571

Potassium B-Chemical 0 0.99826115
was O 0 0.01042909
applied O 0 0.006441562
by O 0 0.005964772
reverse O 0 0.012078142
dialysis O 0 0.056380287
twice O 0 0.0050195255
, O 0 0.005126997
separated O 0 0.005146011
by O 0 0.0059491335
75 O 0 0.008261618
min O 0 0.009033865
. O 0 0.0104730185

Hippocampal O 0 0.9536563
ACh B-Chemical 1 0.99827373
also O 0 0.0068799807
was O 0 0.0044568344
measured O 0 0.0028873147
during O 0 0.0025580479
testing O 0 0.0030411961
for O 0 0.0030903174
handling O 0 0.013553118
- O 0 0.01144272
induced O 0 0.015432484
convulsions B-Disease 2 0.9998802
. O 0 0.017712431

RESULTS O 0 0.030110959
: O 0 0.009713434
Sensitivity O 0 0.016193084
to O 0 0.0033109838
several O 0 0.0031245751
convulsion B-Disease 2 0.9997956
endpoints O 0 0.030985657
induced O 0 0.0026017567
by O 0 0.0031697748
nicotine B-Chemical 1 0.9998524
, O 0 0.015490662
carbachol B-Chemical 1 0.99988997
, O 0 0.0028889189
and O 0 0.001822012
neostigmine B-Chemical 0 0.99994063
were O 0 0.0013149299
significantly O 0 0.0015187582
greater O 0 0.0014401693
in O 0 0.0022285972
WSR O 0 0.9714665
versus O 0 0.004085467
WSP O 0 0.9148409
mice O 0 0.005785392
. O 0 0.008852403

In O 0 0.007875399
microdialysis O 0 0.10577436
experiments O 0 0.0040550022
, O 0 0.0035398162
the O 0 0.002110489
lines O 0 0.004640238
did O 0 0.0012781341
not O 0 0.0010384782
differ O 0 0.0010782831
in O 0 0.00088573893
basal O 0 0.0021971213
release O 0 0.04297347
of O 0 0.002470869
ACh B-Chemical 1 0.9999211
, O 0 0.0018124456
and O 0 0.001148155
50 O 0 0.0024807516
mM O 0 0.7765862
KCl B-Chemical 0 0.99929774
increased O 0 0.0026224111
ACh B-Chemical 1 0.9996686
output O 0 0.0020291517
in O 0 0.001335879
both O 0 0.0018995118
lines O 0 0.007968173
of O 0 0.004492874
mice O 0 0.0050497176
. O 0 0.008323552

However O 0 0.009455555
, O 0 0.0066906516
the O 0 0.0036692948
increase O 0 0.0023470302
in O 0 0.002040007
release O 0 0.027502028
of O 0 0.0030224866
ACh B-Chemical 1 0.9997981
produced O 0 0.0011495295
by O 0 0.00092427456
the O 0 0.00061333104
first O 0 0.00050419214
application O 0 0.0011099726
of O 0 0.0015573204
KCl B-Chemical 0 0.99956864
was O 0 0.0011935879
2 O 0 0.0011077062
- O 0 0.001397398
fold O 0 0.0015607331
higher O 0 0.0013192991
in O 0 0.002088986
WSP O 0 0.90725553
versus O 0 0.004505133
WSR O 0 0.96826136
mice O 0 0.005605357
. O 0 0.008646245

When O 0 0.008950348
hippocampal O 0 0.73631567
ACh B-Chemical 1 0.9992441
was O 0 0.0029621045
measured O 0 0.0013654395
during O 0 0.0009787816
testing O 0 0.0009742291
for O 0 0.00075392774
handling O 0 0.008343421
- O 0 0.0031499863
induced O 0 0.0024157474
convulsions B-Disease 2 0.9999933
, O 0 0.0081970235
extracellular O 0 0.31184873
ACh B-Chemical 1 0.9999417
was O 0 0.00083330093
significantly O 0 0.0010418314
elevated O 0 0.0065726507
( O 0 0.0013518217
192 O 0 0.0114156315
% O 0 0.0007689063
) O 0 0.0009411039
in O 0 0.0005395647
WSP O 0 0.83017296
mice O 0 0.000550021
, O 0 0.0009790895
but O 0 0.0007042808
was O 0 0.00087755104
nonsignificantly O 0 0.31081393
elevated O 0 0.0051485617
( O 0 0.0022801885
59 O 0 0.0028415988
% O 0 0.0023118968
) O 0 0.0034796523
in O 0 0.0032497921
WSR O 0 0.92876446
mice O 0 0.005296529
. O 0 0.008425533

CONCLUSIONS O 0 0.39837116
: O 0 0.007897856
These O 0 0.004048533
results O 0 0.0025938188
suggest O 0 0.0014603462
that O 0 0.0011991947
differences O 0 0.0008872019
in O 0 0.0010770432
cholinergic O 0 0.9461598
activity O 0 0.0014693995
and O 0 0.0012108192
postsynaptic O 0 0.9274409
sensitivity O 0 0.002402455
to O 0 0.0008334939
cholinergic O 0 0.9946195
convulsants B-Disease 0 0.99998593
may O 0 0.0008543627
be O 0 0.0006865865
associated O 0 0.0007794466
with O 0 0.0011276627
ethanol B-Chemical 1 0.9992181
withdrawal O 0 0.96251655
severity O 0 0.21912548
and O 0 0.0018750865
implicate O 0 0.0017809201
cholinergic O 0 0.9741459
mechanisms O 0 0.0046343347
in O 0 0.004295128
alcohol B-Chemical 1 0.9996513
withdrawal O 0 0.98220736
. O 0 0.010873882

Specifically O 0 0.010643228
, O 0 0.009020074
WSP O 0 0.6733426
mice O 0 0.002929125
may O 0 0.0021241582
have O 0 0.0014602758
lower O 0 0.0014513519
sensitivity O 0 0.0023157275
to O 0 0.0012433561
cholinergic O 0 0.9925443
convulsants B-Disease 0 0.9999778
compared O 0 0.000735983
with O 0 0.00122916
WSR O 0 0.9823753
because O 0 0.0005164561
of O 0 0.0010195402
postsynaptic O 0 0.95491123
receptor O 0 0.16362935
desensitization O 0 0.3164266
brought O 0 0.0014497048
on O 0 0.00071315514
by O 0 0.0012700447
higher O 0 0.0013397657
activity O 0 0.002432464
of O 0 0.0046388195
cholinergic O 0 0.9877192
neurons O 0 0.13154706
. O 0 0.008471534

Capsaicin B-Chemical 1 0.9995672
- O 0 0.020205118
induced O 0 0.007901616
muscle B-Disease 0 0.7667326
pain I-Disease 2 0.9994342
alters O 0 0.0033883823
the O 0 0.0030104478
excitability O 0 0.8608543
of O 0 0.0028279715
the O 0 0.00273856
human O 0 0.0054772454
jaw O 0 0.8715296
- O 0 0.016300935
stretch O 0 0.09709704
reflex O 0 0.9437012
. O 0 0.012055271

The O 0 0.008059258
pathophysiology O 0 0.067623645
of O 0 0.008080836
painful O 0 0.996956
temporomandibular B-Disease 0 0.9998599
disorders I-Disease 0 0.9990416
is O 0 0.0025007331
not O 0 0.001229571
fully O 0 0.0009674057
understood O 0 0.0019491414
, O 0 0.0011049818
but O 0 0.00061763026
evidence O 0 0.0006051381
suggests O 0 0.0004861752
that O 0 0.0008085392
muscle B-Disease 0 0.72781056
pain I-Disease 2 0.99973077
modulates O 0 0.0016995084
motor O 0 0.17831187
function O 0 0.002623928
in O 0 0.0028350896
characteristic O 0 0.005769451
ways O 0 0.011206301
. O 0 0.008816966

This O 0 0.009780204
study O 0 0.0051573473
tested O 0 0.002673901
the O 0 0.0022171512
hypothesis O 0 0.0019455734
that O 0 0.0012849541
activation O 0 0.0024767017
of O 0 0.0020174666
nociceptive B-Disease 0 0.9956552
muscle I-Disease 0 0.81613696
afferent O 0 0.62007433
fibers O 0 0.029399868
would O 0 0.0005495808
be O 0 0.00056512165
linked O 0 0.00047426825
to O 0 0.00041823412
an O 0 0.0007123051
increased O 0 0.00075822196
excitability O 0 0.80232686
of O 0 0.00058564544
the O 0 0.00053652615
human O 0 0.0011803961
jaw O 0 0.83542913
- O 0 0.002907817
stretch O 0 0.012521178
reflex O 0 0.76341146
and O 0 0.00061444525
whether O 0 0.0002863259
this O 0 0.00048572102
process O 0 0.00059798075
would O 0 0.00050313125
be O 0 0.00064416305
sensitive O 0 0.00058865896
to O 0 0.0007162651
length O 0 0.00089473714
and O 0 0.0014812992
velocity O 0 0.0026290233
of O 0 0.0028984863
the O 0 0.0042411056
stretch O 0 0.03637635
. O 0 0.008705252

Capsaicin B-Chemical 1 0.9994605
( O 0 0.012050395
10 O 0 0.0048073563
micro O 0 0.010411851
g O 0 0.005120075
) O 0 0.0032130324
was O 0 0.001423447
injected O 0 0.0010683784
into O 0 0.0008042576
the O 0 0.0010826791
masseter O 0 0.08114829
muscle O 0 0.021647876
to O 0 0.001400073
induce O 0 0.0017737655
pain B-Disease 2 0.9966877
in O 0 0.0028377252
11 O 0 0.0042946585
healthy O 0 0.013941145
volunteers O 0 0.017143678
. O 0 0.008667094

Short O 0 0.02541017
- O 0 0.009886193
latency O 0 0.0089566475
reflex O 0 0.6622411
responses O 0 0.004612054
were O 0 0.0019808298
evoked O 0 0.041832477
in O 0 0.0010014448
the O 0 0.0008815012
masseter O 0 0.07197143
and O 0 0.00083145284
temporalis O 0 0.009913745
muscles O 0 0.004347489
by O 0 0.00064399483
a O 0 0.0007601464
stretch O 0 0.0024278732
device O 0 0.001033084
with O 0 0.0005338342
different O 0 0.00049875217
velocities O 0 0.0012976761
and O 0 0.00075573
displacements O 0 0.008570858
before O 0 0.00056523096
, O 0 0.0012138103
during O 0 0.0008392031
, O 0 0.0017506824
and O 0 0.0018826885
after O 0 0.0017914191
the O 0 0.004653484
pain B-Disease 2 0.9968671
. O 0 0.010197256

The O 0 0.007317987
normalized O 0 0.0049710535
reflex O 0 0.53411055
amplitude O 0 0.012405954
increased O 0 0.0027026522
with O 0 0.0017144841
an O 0 0.001747116
increase O 0 0.0008299125
in O 0 0.0007485978
velocity O 0 0.0011457844
at O 0 0.0004620093
a O 0 0.00066690374
given O 0 0.00043241004
displacement O 0 0.002101244
, O 0 0.0009534913
but O 0 0.00061551674
remained O 0 0.00069706154
constant O 0 0.00062746817
with O 0 0.0008877034
different O 0 0.0010955011
displacements O 0 0.011004506
at O 0 0.0014847895
a O 0 0.0027444372
given O 0 0.0026780423
velocity O 0 0.007696521
. O 0 0.007517288

The O 0 0.007652505
normalized O 0 0.005228398
reflex O 0 0.48460567
amplitude O 0 0.01128454
was O 0 0.0024132815
significantly O 0 0.0020954073
higher O 0 0.0015389266
during O 0 0.0014082639
pain B-Disease 2 0.9980755
, O 0 0.0023986243
but O 0 0.0011524328
only O 0 0.001007796
at O 0 0.0009662128
faster O 0 0.0013042769
stretches O 0 0.004637556
in O 0 0.0024285247
the O 0 0.0044909893
painful B-Disease 0 0.9974789
muscle I-Disease 0 0.89112025
. O 0 0.011757623

Increased O 0 0.010995536
sensitivity O 0 0.0071698288
of O 0 0.00440047
the O 0 0.0032558679
fusimotor O 0 0.35262564
system O 0 0.0032243931
during O 0 0.0014833402
acute O 0 0.94666576
muscle B-Disease 0 0.94798625
pain I-Disease 2 0.99982065
could O 0 0.0013967095
be O 0 0.0013630514
one O 0 0.0010299319
likely O 0 0.0012105071
mechanism O 0 0.0017180296
to O 0 0.0019192438
explain O 0 0.002533631
the O 0 0.004194531
findings O 0 0.013187119
. O 0 0.00970043

Effects O 0 0.013961683
of O 0 0.0072860215
5 O 0 0.004892066
- O 0 0.00614101
HT1B O 0 0.42684692
receptor O 0 0.12170148
ligands O 0 0.09094273
microinjected O 0 0.006285439
into O 0 0.00073208596
the O 0 0.0010677156
accumbal O 0 0.99609107
shell O 0 0.010701288
or O 0 0.00075146987
core O 0 0.0007732917
on O 0 0.0005885106
the O 0 0.0013506274
cocaine B-Chemical 1 0.9999453
- O 0 0.01164071
induced O 0 0.0050102253
locomotor B-Disease 2 0.99741936
hyperactivity I-Disease 2 0.9999466
in O 0 0.007143303
rats O 0 0.039180562
. O 0 0.009196165

The O 0 0.00697249
present O 0 0.0040739877
study O 0 0.0038544443
was O 0 0.0024555835
designed O 0 0.0017964559
to O 0 0.0011250313
examine O 0 0.00065962435
the O 0 0.00082057936
effect O 0 0.0007705921
of O 0 0.0011361263
5 O 0 0.0009475274
- O 0 0.0020608148
HT1B O 0 0.5265884
receptor O 0 0.07101416
ligands O 0 0.054885693
microinjected O 0 0.0025890279
into O 0 0.00027354143
the O 0 0.0003915114
subregions O 0 0.0011678971
of O 0 0.00045960618
the O 0 0.0004931194
nucleus O 0 0.0013954843
accumbens O 0 0.8733712
( O 0 0.0006750267
the O 0 0.00040080817
shell O 0 0.0029633273
and O 0 0.00056474796
the O 0 0.00050884864
core O 0 0.0006942585
) O 0 0.0011772942
on O 0 0.00046878972
the O 0 0.0011106943
locomotor B-Disease 2 0.9907154
hyperactivity I-Disease 2 0.99997175
induced O 0 0.005144341
by O 0 0.0080331955
cocaine B-Chemical 1 0.99987304
in O 0 0.0054257307
rats O 0 0.025116645
. O 0 0.008690109

Male O 0 0.04893579
Wistar O 0 0.037849266
rats O 0 0.0073715737
were O 0 0.0032338875
implanted O 0 0.0036982251
bilaterally O 0 0.007254592
with O 0 0.001316734
cannulae O 0 0.002835567
into O 0 0.00063184055
the O 0 0.00087472517
accumbens O 0 0.82709414
shell O 0 0.00880218
or O 0 0.0006713153
core O 0 0.00073920644
, O 0 0.0008021023
and O 0 0.00051856786
then O 0 0.00040109718
were O 0 0.00043945442
locally O 0 0.0077227713
injected O 0 0.0005171
with O 0 0.0010401441
GR B-Chemical 1 0.9972312
55562 I-Chemical 1 0.99816704
( O 0 0.0014686595
an O 0 0.0010319282
antagonist O 0 0.84009063
of O 0 0.0010287107
5 O 0 0.0007572226
- O 0 0.0016470631
HT1B O 0 0.4936868
receptors O 0 0.10397564
) O 0 0.0020838084
or O 0 0.001012753
CP B-Chemical 0 0.9977841
93129 I-Chemical 0 0.9993845
( O 0 0.0024124149
an O 0 0.0017653223
agonist O 0 0.65919685
of O 0 0.002287737
5 O 0 0.0023201718
- O 0 0.005128087
HT1B O 0 0.6089336
receptors O 0 0.18929315
) O 0 0.013930975
. O 0 0.008562317

Given O 0 0.006967209
alone O 0 0.00538505
to O 0 0.003573345
any O 0 0.0033206942
accumbal O 0 0.9981875
subregion O 0 0.10512366
, O 0 0.0040355856
GR B-Chemical 1 0.99203026
55562 I-Chemical 1 0.99704033
( O 0 0.0020271982
0 O 0 0.001091879
. O 0 0.0004768253
1 O 0 0.00059611566
- O 0 0.0006645448
10 O 0 0.00038580917
microg O 0 0.0008528478
/ O 0 0.001512944
side O 0 0.036717374
) O 0 0.001545849
or O 0 0.00076862285
CP B-Chemical 0 0.9971922
93129 I-Chemical 0 0.99936587
( O 0 0.0016252587
0 O 0 0.0008318927
. O 0 0.0003761705
1 O 0 0.0005434669
- O 0 0.00066662574
10 O 0 0.00044665963
microg O 0 0.0010627551
/ O 0 0.002016552
side O 0 0.030594831
) O 0 0.0020080847
did O 0 0.0009992413
not O 0 0.0012804912
change O 0 0.0020198124
basal O 0 0.0055585504
locomotor O 0 0.6625698
activity O 0 0.007776253
. O 0 0.008296871

Systemic O 0 0.9687455
cocaine B-Chemical 1 0.999676
( O 0 0.010247421
10 O 0 0.0039113387
mg O 0 0.23855984
/ O 0 0.005576907
kg O 0 0.011841576
) O 0 0.003492002
significantly O 0 0.002289772
increased O 0 0.0024822352
the O 0 0.0027166149
locomotor O 0 0.56287104
activity O 0 0.0045274366
of O 0 0.006222319
rats O 0 0.022176202
. O 0 0.0101217795

GR B-Chemical 1 0.9859158
55562 I-Chemical 1 0.99497235
( O 0 0.008746653
0 O 0 0.004342456
. O 0 0.0019688362
1 O 0 0.0017642472
- O 0 0.0016343194
10 O 0 0.0008646061
microg O 0 0.0015026891
/ O 0 0.0022496027
side O 0 0.058579203
) O 0 0.0021311925
, O 0 0.0008419432
administered O 0 0.0008824933
intra O 0 0.036466546
- O 0 0.0023375768
accumbens O 0 0.8076489
shell O 0 0.0042034513
prior O 0 0.0003577368
to O 0 0.0006159804
cocaine B-Chemical 1 0.9999335
, O 0 0.001757848
dose O 0 0.04945969
- O 0 0.005437067
dependently O 0 0.912583
attenuated O 0 0.0033823007
the O 0 0.002324027
psychostimulant O 0 0.9998103
- O 0 0.025558205
induced O 0 0.011090826
locomotor B-Disease 2 0.99812394
hyperactivity I-Disease 2 0.9999193
. O 0 0.01432144

Such O 0 0.012498649
attenuation O 0 0.00877815
was O 0 0.004354426
not O 0 0.0028506722
found O 0 0.0019149291
in O 0 0.0017043152
animals O 0 0.0014997676
which O 0 0.001754733
had O 0 0.0013464707
been O 0 0.0014351563
injected O 0 0.0013609552
with O 0 0.0026538973
GR B-Chemical 1 0.99474335
55562 I-Chemical 1 0.99082524
into O 0 0.0022244195
the O 0 0.004203368
accumbens O 0 0.87733245
core O 0 0.0076431725
. O 0 0.009136847

When O 0 0.0064073806
injected O 0 0.004376563
into O 0 0.0026815427
the O 0 0.0029194981
accumbens O 0 0.90912914
shell O 0 0.05619024
( O 0 0.0023381172
but O 0 0.00095392374
not O 0 0.00068070967
the O 0 0.000641482
core O 0 0.00081067503
) O 0 0.0013548678
before O 0 0.00045576334
cocaine B-Chemical 1 0.99994266
, O 0 0.0041587707
CP B-Chemical 0 0.9980959
93129 I-Chemical 0 0.9995035
( O 0 0.001644274
0 O 0 0.0007794222
. O 0 0.00032152483
1 O 0 0.00044773176
- O 0 0.0005192727
10 O 0 0.0003060974
microg O 0 0.00074248447
/ O 0 0.0014249844
side O 0 0.03682969
) O 0 0.0011722624
enhanced O 0 0.0004472798
the O 0 0.00047637871
locomotor O 0 0.4488442
response O 0 0.000775405
to O 0 0.0006431049
cocaine B-Chemical 1 0.9999497
; O 0 0.0013139929
the O 0 0.00037485492
maximum O 0 0.00038806055
effect O 0 0.00042179436
being O 0 0.0006449982
observed O 0 0.0003713219
after O 0 0.00042034092
10 O 0 0.0007832354
microg O 0 0.0020166852
/ O 0 0.0036173947
side O 0 0.02494287
of O 0 0.0034711638
the O 0 0.005107993
agonist O 0 0.9158143
. O 0 0.009747815

The O 0 0.0076095704
later O 0 0.0051855883
enhancement O 0 0.0060360995
was O 0 0.0031545085
attenuated O 0 0.0031411692
after O 0 0.0013899615
intra O 0 0.062331717
- O 0 0.0061473814
accumbens O 0 0.9252285
shell O 0 0.025865953
treatment O 0 0.0027089317
with O 0 0.0027989778
GR B-Chemical 1 0.99747723
55562 I-Chemical 1 0.9972977
( O 0 0.0035924264
1 O 0 0.002228961
microg O 0 0.00478002
/ O 0 0.009211737
side O 0 0.111248605
) O 0 0.013422539
. O 0 0.008746823

Our O 0 0.007874128
findings O 0 0.0068444614
indicate O 0 0.0033567105
that O 0 0.0030020713
cocaine B-Chemical 1 0.9999027
induced O 0 0.037874613
hyperlocomotion B-Disease 0 0.9999907
is O 0 0.0021808902
modified O 0 0.0017161367
by O 0 0.0011599759
5 O 0 0.000842212
- O 0 0.001675005
HT1B O 0 0.46048218
receptor O 0 0.064631805
ligands O 0 0.059091657
microinjected O 0 0.0033874693
into O 0 0.0002989672
the O 0 0.00053999026
accumbens O 0 0.8974967
shell O 0 0.019559309
, O 0 0.0007567522
but O 0 0.00037895315
not O 0 0.00033814926
core O 0 0.00043749993
, O 0 0.00054585806
this O 0 0.00033169705
modification O 0 0.00070385967
consisting O 0 0.00037196404
in O 0 0.00040013687
inhibitory O 0 0.008553258
and O 0 0.00077591283
facilitatory O 0 0.732523
effects O 0 0.0011991062
of O 0 0.00071352767
the O 0 0.0006280389
5 O 0 0.00066351256
- O 0 0.001807401
HT1B O 0 0.6616418
receptor O 0 0.2856014
antagonist O 0 0.99175173
( O 0 0.015216055
GR B-Chemical 1 0.99737513
55562 I-Chemical 1 0.9977436
) O 0 0.0037192164
and O 0 0.0017595179
agonist O 0 0.92723656
( O 0 0.010477071
CP B-Chemical 0 0.99799854
93129 I-Chemical 0 0.9991518
) O 0 0.01326753
, O 0 0.00628885
respectively O 0 0.008965938
. O 0 0.007845652

In O 0 0.0073188413
other O 0 0.005146958
words O 0 0.005177126
, O 0 0.0031912785
the O 0 0.0016636612
present O 0 0.0009989139
results O 0 0.0010404047
suggest O 0 0.0006677553
that O 0 0.0007354361
the O 0 0.0011231375
accumbal O 0 0.9985043
shell O 0 0.05227532
5 O 0 0.0010037648
- O 0 0.0018655707
HT1B O 0 0.39157245
receptors O 0 0.035017565
play O 0 0.0008725246
a O 0 0.00092770223
permissive O 0 0.00076769834
role O 0 0.00057295925
in O 0 0.0007838625
the O 0 0.0010892929
behavioural O 0 0.015003469
response O 0 0.0025954414
to O 0 0.0026200002
the O 0 0.0048704185
psychostimulant O 0 0.9991266
. O 0 0.010274492

Cocaine B-Chemical 1 0.99935895
related O 0 0.010727265
chest B-Disease 0 0.811693
pain I-Disease 2 0.9974546
: O 0 0.008479424
are O 0 0.004180074
we O 0 0.0029063632
seeing O 0 0.00687714
the O 0 0.0039073983
tip O 0 0.00687785
of O 0 0.006999652
an O 0 0.012099194
iceberg O 0 0.17723393
? O 0 0.0368351

The O 0 0.01459064
recreational O 0 0.07022499
use O 0 0.0098031685
of O 0 0.011003961
cocaine B-Chemical 1 0.99944097
is O 0 0.008707585
on O 0 0.006215923
the O 0 0.008496255
increase O 0 0.009627757
. O 0 0.013941412

The O 0 0.009430053
emergency O 0 0.010110043
nurse O 0 0.0078109577
ought O 0 0.0052539892
to O 0 0.0028850643
be O 0 0.0024789432
familiar O 0 0.0033070585
with O 0 0.0017284801
some O 0 0.0017109138
of O 0 0.0020352935
the O 0 0.0023471264
cardiovascular O 0 0.99259734
consequences O 0 0.026456634
of O 0 0.011414668
cocaine B-Chemical 1 0.99984133
use O 0 0.013527789
. O 0 0.010565254

In O 0 0.006860684
particular O 0 0.00420833
, O 0 0.0039128554
the O 0 0.0022476707
tendency O 0 0.0026107682
of O 0 0.002326953
cocaine B-Chemical 1 0.9998524
to O 0 0.0012337838
produce O 0 0.000957076
chest B-Disease 0 0.8324895
pain I-Disease 2 0.99863786
ought O 0 0.0015933577
to O 0 0.00053410756
be O 0 0.00050175964
in O 0 0.00038592966
the O 0 0.00042312374
mind O 0 0.0007846308
of O 0 0.0005258559
the O 0 0.0004886227
emergency O 0 0.001179775
nurse O 0 0.000963407
when O 0 0.00037437852
faced O 0 0.0012620661
with O 0 0.00063817576
a O 0 0.0009712738
young O 0 0.0049213846
victim O 0 0.026315723
of O 0 0.0014136557
chest B-Disease 0 0.8848804
pain I-Disease 2 0.99875104
who O 0 0.006008797
is O 0 0.0019197682
otherwise O 0 0.0039964593
at O 0 0.0023187415
low O 0 0.0050561414
risk O 0 0.17202322
. O 0 0.009678202

The O 0 0.0076597393
mechanism O 0 0.0060317814
of O 0 0.005476801
chest B-Disease 0 0.72323877
pain I-Disease 2 0.99710566
related O 0 0.0024593617
to O 0 0.002541672
cocaine B-Chemical 1 0.9998362
use O 0 0.0026830721
is O 0 0.0018167202
discussed O 0 0.0015722255
and O 0 0.0026329232
treatment O 0 0.0046103364
dilemmas O 0 0.020705048
are O 0 0.005857253
discussed O 0 0.006282128
. O 0 0.009387188

Finally O 0 0.011783948
, O 0 0.009264589
moral O 0 0.016102988
issues O 0 0.0052869353
relating O 0 0.0025207405
to O 0 0.0020336555
the O 0 0.001853084
testing O 0 0.0017737519
of O 0 0.0022564526
potential O 0 0.0053510494
cocaine B-Chemical 1 0.9998661
users O 0 0.06019487
will O 0 0.0035412393
be O 0 0.0049486645
addressed O 0 0.0053137294
. O 0 0.00868278

Crossover O 0 0.07669104
comparison O 0 0.00525932
of O 0 0.004357321
efficacy O 0 0.0046503665
and O 0 0.002709746
preference O 0 0.002437289
for O 0 0.0017867914
rizatriptan B-Chemical 1 0.99996567
10 O 0 0.0022008794
mg O 0 0.35166886
versus O 0 0.0031389734
ergotamine B-Chemical 1 0.999982
/ O 0 0.14116912
caffeine B-Chemical 1 0.99975747
in O 0 0.014003699
migraine B-Disease 2 0.9999049
. O 0 0.013936458

Rizatriptan B-Chemical 0 0.9994272
is O 0 0.0072151036
a O 0 0.0054639494
selective O 0 0.008423382
5 B-Chemical 0 0.0030934804
- I-Chemical 0 0.0054646544
HT I-Chemical 0 0.9926375
( O 0 0.0029438802
1B O 0 0.0020216894
/ O 0 0.0038369477
1D O 0 0.011919076
) O 0 0.002308492
receptor O 0 0.076196596
agonist O 0 0.78418714
with O 0 0.000876341
rapid O 0 0.0023919598
oral O 0 0.5323371
absorption O 0 0.41398183
and O 0 0.0009967373
early O 0 0.0014146939
onset O 0 0.0038422754
of O 0 0.0012001279
action O 0 0.006435779
in O 0 0.0011321986
the O 0 0.0017359293
acute O 0 0.949377
treatment O 0 0.018834744
of O 0 0.038803294
migraine B-Disease 2 0.99994314
. O 0 0.014108915

This O 0 0.00980351
randomized O 0 0.005341305
double O 0 0.0041695377
- O 0 0.0040237294
blind O 0 0.005062224
crossover O 0 0.0054321187
outpatient O 0 0.0018450383
study O 0 0.0009883426
assessed O 0 0.00057034125
the O 0 0.0005756184
preference O 0 0.000721715
for O 0 0.00048291532
1 O 0 0.0008367367
rizatriptan B-Chemical 1 0.9999776
10 O 0 0.000659707
mg O 0 0.18931758
tablet O 0 0.688459
to O 0 0.0005220813
2 O 0 0.0007526098
ergotamine B-Chemical 1 0.9999876
1 O 0 0.0008160862
mg O 0 0.32487896
/ O 0 0.004056064
caffeine B-Chemical 1 0.9996779
100 O 0 0.0023201306
mg O 0 0.3273565
tablets O 0 0.77184826
in O 0 0.0006531423
439 O 0 0.00976676
patients O 0 0.0013602062
treating O 0 0.0016971324
a O 0 0.0016022361
single O 0 0.002431098
migraine B-Disease 2 0.9999659
attack O 0 0.7163078
with O 0 0.003804019
each O 0 0.0031751646
therapy O 0 0.03871227
. O 0 0.008569638

Of O 0 0.010228452
patients O 0 0.0075598415
expressing O 0 0.0029865382
a O 0 0.0032249512
preference O 0 0.0028926216
( O 0 0.002556232
89 O 0 0.0026302899
. O 0 0.00084727263
1 O 0 0.00086158083
% O 0 0.0009508826
) O 0 0.0010970649
, O 0 0.00065377814
more O 0 0.00046174426
than O 0 0.00029220962
twice O 0 0.00038232782
as O 0 0.0003523981
many O 0 0.0004440228
preferred O 0 0.0005439444
rizatriptan B-Chemical 1 0.9999887
to O 0 0.00091161474
ergotamine B-Chemical 1 0.9999962
/ O 0 0.044118397
caffeine B-Chemical 1 0.9999163
( O 0 0.0014383065
69 O 0 0.00088156236
. O 0 0.00029634277
9 O 0 0.0003744192
vs O 0 0.0006014898
. O 0 0.00031564807
30 O 0 0.00033157787
. O 0 0.0003382656
1 O 0 0.0005039208
% O 0 0.00067055493
, O 0 0.0007970659
p O 0 0.0009320684
< O 0 0.000960675
or O 0 0.0011390835
= O 0 0.0021939103
0 O 0 0.002467808
. O 0 0.0025305478
001 O 0 0.19504139
) O 0 0.0079923095
. O 0 0.0074065044

Faster O 0 0.15296596
relief O 0 0.14754322
of O 0 0.007698826
headache B-Disease 2 0.9997193
was O 0 0.0027720358
the O 0 0.0015357718
most O 0 0.0014283232
important O 0 0.0007719032
reason O 0 0.0007253634
for O 0 0.00055713614
preference O 0 0.0010068058
, O 0 0.00097089325
cited O 0 0.0017182095
by O 0 0.0006551023
67 O 0 0.0012097083
. O 0 0.0003246475
3 O 0 0.00033792172
% O 0 0.0003917642
of O 0 0.00041593245
patients O 0 0.0014446415
preferring O 0 0.055690486
rizatriptan B-Chemical 1 0.9999857
and O 0 0.00090552634
54 O 0 0.0014380969
. O 0 0.00044098968
2 O 0 0.0005523175
% O 0 0.00069369166
of O 0 0.0008224462
patients O 0 0.002187751
who O 0 0.0029014482
preferred O 0 0.0031070893
ergotamine B-Chemical 1 0.9999778
/ O 0 0.22273722
caffeine B-Chemical 1 0.99959224
. O 0 0.011510574

The O 0 0.00965226
co O 0 0.21103196
- O 0 0.0070781205
primary O 0 0.003474991
endpoint O 0 0.003663449
of O 0 0.0025786501
being O 0 0.003729085
pain B-Disease 2 0.99646556
free O 0 0.0026097016
at O 0 0.0010970655
2 O 0 0.0011730527
h O 0 0.0009910761
was O 0 0.0011770799
also O 0 0.0014767493
in O 0 0.0019328633
favor O 0 0.0040668915
of O 0 0.009891816
rizatriptan B-Chemical 1 0.9999374
. O 0 0.01184771

Forty O 0 0.017582657
- O 0 0.0075841
nine O 0 0.0034371417
percent O 0 0.0024408323
of O 0 0.0022827685
patients O 0 0.0036589373
were O 0 0.0017850505
pain B-Disease 2 0.99347323
free O 0 0.0018412241
2 O 0 0.0008196087
h O 0 0.00049769453
after O 0 0.00042457547
rizatriptan B-Chemical 1 0.9999813
, O 0 0.000823614
compared O 0 0.00028585838
with O 0 0.0004292817
24 O 0 0.00034955805
. O 0 0.00027078856
3 O 0 0.00031742826
% O 0 0.00040678305
treated O 0 0.00047812835
with O 0 0.000833133
ergotamine B-Chemical 1 0.99999595
/ O 0 0.044844072
caffeine B-Chemical 1 0.99991727
( O 0 0.0014475432
p O 0 0.00073169614
< O 0 0.00048683185
or O 0 0.0004334639
= O 0 0.0007206845
0 O 0 0.00064401387
. O 0 0.00044748708
001 O 0 0.14359948
) O 0 0.0011458937
, O 0 0.0011504047
rizatriptan B-Chemical 1 0.99994826
being O 0 0.0013646544
superior O 0 0.0015532594
within O 0 0.00083158
1 O 0 0.0016202936
h O 0 0.0018273374
of O 0 0.0035026441
treatment O 0 0.0082392655
. O 0 0.008353282

Headache B-Disease 2 0.9889309
relief O 0 0.24351852
at O 0 0.0036199754
2 O 0 0.0025489829
h O 0 0.0015749584
was O 0 0.0013449045
75 O 0 0.0014521077
. O 0 0.0007113103
9 O 0 0.000711513
% O 0 0.0007147074
for O 0 0.00053701934
rizatriptan B-Chemical 1 0.9999664
and O 0 0.00086572027
47 O 0 0.001451878
. O 0 0.00036801293
3 O 0 0.00038504586
% O 0 0.00049004954
for O 0 0.0004257758
ergotamine B-Chemical 1 0.9999919
/ O 0 0.02324904
caffeine B-Chemical 1 0.999894
( O 0 0.0013350523
p O 0 0.0007010751
< O 0 0.00046152578
or O 0 0.0004038508
= O 0 0.00066272524
0 O 0 0.00057906867
. O 0 0.00037666428
001 O 0 0.15002576
) O 0 0.00084059814
, O 0 0.0005989199
with O 0 0.0006216019
rizatriptan B-Chemical 1 0.9999795
being O 0 0.0010431599
superior O 0 0.0012852534
to O 0 0.0008957713
ergotamine B-Chemical 1 0.9999901
/ O 0 0.02307313
caffeine B-Chemical 1 0.99950624
within O 0 0.0009421002
30 O 0 0.0012785852
min O 0 0.002069621
of O 0 0.0033832686
dosing O 0 0.047535103
. O 0 0.007631563

Almost O 0 0.011893675
36 O 0 0.005612369
% O 0 0.0040102457
of O 0 0.002756791
patients O 0 0.0036962018
taking O 0 0.004978513
rizatriptan B-Chemical 1 0.9999753
were O 0 0.0021463917
pain B-Disease 2 0.99614066
free O 0 0.0015221895
at O 0 0.00053307565
2 O 0 0.0005132897
h O 0 0.00034474372
and O 0 0.00041150863
had O 0 0.0003273539
no O 0 0.00030493786
recurrence O 0 0.4884814
or O 0 0.00047504733
need O 0 0.00032248476
for O 0 0.0002480198
additional O 0 0.00022903409
medication O 0 0.014251343
within O 0 0.00020346421
24 O 0 0.00025978414
h O 0 0.00025498407
, O 0 0.00038234124
compared O 0 0.00020307135
to O 0 0.0002935007
20 O 0 0.0003719607
% O 0 0.00039859096
of O 0 0.0004202628
patients O 0 0.0012911839
on O 0 0.0005296519
ergotamine B-Chemical 1 0.9999939
/ O 0 0.044311907
caffeine B-Chemical 1 0.99987936
( O 0 0.002153165
p O 0 0.0013504218
< O 0 0.0010981619
or O 0 0.0011908234
= O 0 0.0022403565
0 O 0 0.0024647743
. O 0 0.0025069665
001 O 0 0.19623639
) O 0 0.00793707
. O 0 0.0073597585

Rizatriptan B-Chemical 0 0.99945277
was O 0 0.0064943917
also O 0 0.0038358402
superior O 0 0.004481089
to O 0 0.002727499
ergotamine B-Chemical 1 0.9999832
/ O 0 0.060430784
caffeine B-Chemical 1 0.99978656
in O 0 0.00091207953
the O 0 0.0006231115
proportions O 0 0.00061684544
of O 0 0.00069657515
patients O 0 0.0018963387
with O 0 0.0006414509
no O 0 0.00076982606
nausea B-Disease 2 0.9999987
, O 0 0.027534306
vomiting B-Disease 2 0.9999949
, O 0 0.03779983
phonophobia B-Disease 0 0.9999982
or O 0 0.0029932074
photophobia B-Disease 0 0.9999789
and O 0 0.0010141631
for O 0 0.00040622306
patients O 0 0.0013251927
with O 0 0.0004934758
normal O 0 0.0009620026
function O 0 0.0005483452
2 O 0 0.00044172068
h O 0 0.00032912227
after O 0 0.00030739122
drug O 0 0.25946257
intake O 0 0.6184602
( O 0 0.0016802504
p O 0 0.0012943371
< O 0 0.0011106742
or O 0 0.0012179207
= O 0 0.0023098225
0 O 0 0.002517733
. O 0 0.0025298689
001 O 0 0.20858122
) O 0 0.0079859635
. O 0 0.0073681753

More O 0 0.016793063
patients O 0 0.010436736
were O 0 0.0049130605
( O 0 0.0043298714
completely O 0 0.0025606733
, O 0 0.002093172
very O 0 0.0014238103
or O 0 0.0011047701
somewhat O 0 0.0023415587
) O 0 0.0016536706
satisfied O 0 0.0008267325
2 O 0 0.0004894996
h O 0 0.00032966209
after O 0 0.00025668635
treatment O 0 0.0006651036
with O 0 0.0008757693
rizatriptan B-Chemical 1 0.99999356
( O 0 0.0013480668
69 O 0 0.0009220492
. O 0 0.0003017362
8 O 0 0.00035096315
% O 0 0.00045817293
) O 0 0.00055576244
than O 0 0.00023766792
at O 0 0.00024643744
2 O 0 0.0003006169
h O 0 0.0002363543
after O 0 0.00020677251
treatment O 0 0.0006214754
with O 0 0.000968637
ergotamine B-Chemical 1 0.99999666
/ O 0 0.056462985
caffeine B-Chemical 1 0.9999237
( O 0 0.0017227058
38 O 0 0.0010681541
. O 0 0.00038124504
6 O 0 0.00040279387
% O 0 0.0006523491
, O 0 0.0007833802
p O 0 0.0009231172
< O 0 0.0009545143
or O 0 0.0011344679
= O 0 0.0021921115
0 O 0 0.0024654742
. O 0 0.0025259953
001 O 0 0.19694251
) O 0 0.007987881
. O 0 0.007398166

Recurrence O 0 0.3711777
rates O 0 0.0070608594
were O 0 0.0047220117
31 O 0 0.0043676603
. O 0 0.0020122516
4 O 0 0.0016217112
% O 0 0.001759884
with O 0 0.0016919305
rizatriptan B-Chemical 1 0.9999486
and O 0 0.0019469935
15 O 0 0.001247735
. O 0 0.001039429
3 O 0 0.0013192828
% O 0 0.0021166531
with O 0 0.0034977715
ergotamine B-Chemical 1 0.9999652
/ O 0 0.17989495
caffeine B-Chemical 1 0.9994981
. O 0 0.012359134

Both O 0 0.027304925
active O 0 0.023928985
treatments O 0 0.025483673
were O 0 0.018914815
well O 0 0.018478258
tolerated O 0 0.13515374
. O 0 0.026404204

The O 0 0.0072283414
most O 0 0.0061640125
common O 0 0.0050248583
adverse O 0 0.89437056
events O 0 0.20681442
( O 0 0.004187502
incidence O 0 0.018617984
> O 0 0.002288109
or O 0 0.0009462256
= O 0 0.0011002849
5 O 0 0.00048306264
% O 0 0.0005275139
in O 0 0.00036025466
one O 0 0.00035747085
group O 0 0.0006262398
) O 0 0.0009883648
after O 0 0.00034802879
rizatriptan B-Chemical 1 0.9999894
and O 0 0.0018809708
ergotamine B-Chemical 1 0.9999968
/ O 0 0.05514189
caffeine B-Chemical 1 0.9999385
, O 0 0.0019507571
respectively O 0 0.0017412407
, O 0 0.0007738874
were O 0 0.0006304802
dizziness B-Disease 2 0.9999646
( O 0 0.00096587965
6 O 0 0.00032629888
. O 0 0.00024631975
7 O 0 0.00028263486
and O 0 0.00033487508
5 O 0 0.00031525292
. O 0 0.0002601083
3 O 0 0.0003342776
% O 0 0.00052229926
) O 0 0.0009329732
, O 0 0.0010872927
nausea B-Disease 2 0.9999937
( O 0 0.0012697787
4 O 0 0.00044133974
. O 0 0.00028484527
2 O 0 0.0003345477
and O 0 0.0003777236
8 O 0 0.00038516242
. O 0 0.00028853852
5 O 0 0.0003511894
% O 0 0.00056217064
) O 0 0.00086025277
and O 0 0.0008990895
somnolence B-Disease 2 0.99995244
( O 0 0.0013214068
5 O 0 0.00062983145
. O 0 0.00053323014
5 O 0 0.000671769
and O 0 0.0009950943
2 O 0 0.001302166
. O 0 0.0013603008
3 O 0 0.0022671507
% O 0 0.004254084
) O 0 0.0076377415
. O 0 0.0072844764

Severe O 0 0.8430944
ocular B-Disease 0 0.6687423
and I-Disease 0 0.008596439
orbital I-Disease 0 0.08631844
toxicity I-Disease 2 0.99271446
after O 0 0.0026866344
intracarotid O 0 0.98218024
injection O 0 0.00900094
of O 0 0.0052546677
carboplatin B-Chemical 1 0.9993882
for O 0 0.005602253
recurrent O 0 0.97869974
glioblastomas B-Disease 0 0.99933463
. O 0 0.01501323

BACKGROUND O 0 0.8136059
: O 0 0.023417981
Glioblastoma B-Disease 0 0.9955047
is O 0 0.0061051175
a O 0 0.0065747146
malignant B-Disease 0 0.99558794
tumor I-Disease 2 0.99075764
that O 0 0.0032713043
occurs O 0 0.0028686326
in O 0 0.0031158335
the O 0 0.004360579
cerebrum O 0 0.626335
during O 0 0.0058346614
adulthood O 0 0.4202385
. O 0 0.011028088

With O 0 0.008644137
current O 0 0.0064944504
treatment O 0 0.004310765
regimens O 0 0.006120324
including O 0 0.0018458412
combined O 0 0.0023142223
surgery O 0 0.005165829
, O 0 0.0017296505
radiation O 0 0.087799646
and O 0 0.0012692532
chemotherapy O 0 0.64032835
, O 0 0.0010052511
the O 0 0.0005051057
average O 0 0.0004334007
life O 0 0.0012083793
expectancy O 0 0.0016010954
of O 0 0.00084719027
the O 0 0.0008594212
patients O 0 0.002357068
is O 0 0.0010849694
limited O 0 0.0011681429
to O 0 0.0015695721
approximately O 0 0.0023911053
1 O 0 0.0039782603
year O 0 0.0051286654
. O 0 0.00732729

Therefore O 0 0.008256462
, O 0 0.0073726373
patients O 0 0.006918566
with O 0 0.0044951397
glioblastoma B-Disease 2 0.99798346
sometimes O 0 0.008178092
have O 0 0.0018304837
intracarotid O 0 0.9833656
injection O 0 0.0053644483
of O 0 0.0024553637
carcinostatics O 0 0.80949765
added O 0 0.0024253044
to O 0 0.002180746
the O 0 0.0029525242
treatment O 0 0.006767869
regimen O 0 0.027978353
. O 0 0.009310373

Generally O 0 0.011292997
, O 0 0.009157738
carboplatin B-Chemical 1 0.9945504
is O 0 0.0038594604
said O 0 0.0036754154
to O 0 0.0016460159
have O 0 0.0013450544
milder O 0 0.058518436
side O 0 0.083767146
effects O 0 0.0032940062
than O 0 0.0011214088
cisplatin B-Chemical 1 0.99972135
, O 0 0.0019775839
whose O 0 0.0018409247
ocular B-Disease 0 0.7703001
and I-Disease 0 0.0028785123
orbital I-Disease 0 0.2216369
toxicity I-Disease 2 0.99775594
are O 0 0.0040606777
well O 0 0.0041685915
known O 0 0.008267887
. O 0 0.00888899

However O 0 0.00894896
, O 0 0.006108212
we O 0 0.002744843
experienced O 0 0.003144266
a O 0 0.0023001211
case O 0 0.001590935
of O 0 0.0018213632
severe O 0 0.25501126
ocular B-Disease 0 0.89101714
and I-Disease 0 0.0023314795
orbital I-Disease 0 0.14138636
toxicity I-Disease 2 0.9971877
after O 0 0.00070763496
intracarotid O 0 0.98550224
injection O 0 0.0042594415
of O 0 0.002351786
carboplatin B-Chemical 1 0.99960285
, O 0 0.00332722
which O 0 0.0028019475
is O 0 0.0030298622
infrequently O 0 0.008544444
reported O 0 0.0074157543
. O 0 0.008553165

CASE O 0 0.4018366
: O 0 0.011887378
A O 0 0.020348087
58 O 0 0.006878153
- O 0 0.0044987425
year O 0 0.0024451728
- O 0 0.0024075473
old O 0 0.0016080674
man O 0 0.0150005445
received O 0 0.0011305963
an O 0 0.0015515382
intracarotid O 0 0.97524774
injection O 0 0.0033980086
of O 0 0.0017383833
carboplatin B-Chemical 1 0.9993624
for O 0 0.0013391005
recurrent O 0 0.92018753
glioblastomas B-Disease 0 0.9993774
in O 0 0.0025840825
his O 0 0.004862163
left O 0 0.00801474
temporal O 0 0.054945808
lobe O 0 0.6191256
. O 0 0.009536627

He O 0 0.018976785
complained O 0 0.20479721
of O 0 0.008543207
pain B-Disease 2 0.99572855
and I-Disease 0 0.0060897693
visual I-Disease 0 0.6770225
disturbance I-Disease 0 0.6372793
in I-Disease 0 0.0018184478
the I-Disease 0 0.0017138792
ipsilateral I-Disease 0 0.012744431
eye I-Disease 0 0.018142838
30 O 0 0.0015449257
h O 0 0.0016772554
after O 0 0.0017699904
the O 0 0.00353575
injection O 0 0.010478917
. O 0 0.008566536

Various O 0 0.024130493
ocular O 0 0.6990747
symptoms O 0 0.8339009
and O 0 0.008237492
findings O 0 0.009606775
caused O 0 0.0071871164
by O 0 0.009871136
carboplatin B-Chemical 1 0.9996055
toxicity B-Disease 2 0.9988741
were O 0 0.010663985
seen O 0 0.009623816
. O 0 0.011823139

RESULTS O 0 0.031144641
: O 0 0.010139619
He O 0 0.0077610067
was O 0 0.0033169708
treated O 0 0.0025972282
with O 0 0.002025018
intravenous O 0 0.33913773
administration O 0 0.10407114
of O 0 0.00294694
corticosteroids O 1 0.99967515
and O 0 0.004557057
glycerin B-Chemical 0 0.99868375
for O 0 0.0014592326
6 O 0 0.0012740727
days O 0 0.0013039266
after O 0 0.0015800806
the O 0 0.0033273231
injection O 0 0.010570749
. O 0 0.0082947975

Although O 0 0.0070386524
the O 0 0.0055317823
intraocular O 0 0.84070146
pressure O 0 0.21226889
elevation O 0 0.32118255
caused O 0 0.0023741631
by O 0 0.0018184511
secondary O 0 0.009586341
acute O 0 0.98456556
angle O 0 0.27388927
- O 0 0.007238045
closure O 0 0.01936439
glaucoma B-Disease 2 0.9998271
decreased O 0 0.0031556394
and O 0 0.001746713
ocular B-Disease 0 0.9964149
pain I-Disease 2 0.99994445
diminished O 0 0.012545641
, O 0 0.004159166
inexorable O 0 0.42513135
papilledema B-Disease 0 0.9999777
and O 0 0.0053039524
exudative O 0 0.99972016
retinal B-Disease 0 0.9825001
detachment I-Disease 0 0.9699682
continued O 0 0.0028686505
for O 0 0.0022205398
3 O 0 0.0033829533
weeks O 0 0.0038381838
. O 0 0.006665142

Finally O 0 0.009506425
, O 0 0.006664987
6 O 0 0.0030961642
weeks O 0 0.001994257
later O 0 0.0018478323
, O 0 0.0025140496
diffuse O 0 0.10065563
chorioretinal B-Disease 0 0.9993981
atrophy I-Disease 2 0.99991393
with O 0 0.006282503
optic B-Disease 0 0.99348986
atrophy I-Disease 2 0.99926275
occurred O 0 0.0015995989
and O 0 0.0013492537
the O 0 0.0012960889
vision O 0 0.12092934
in O 0 0.001562055
his O 0 0.0031465476
left O 0 0.0051303497
eye O 0 0.033062108
was O 0 0.0046219323
lost O 0 0.0069789337
. O 0 0.008438454

CONCLUSION O 0 0.5825901
: O 0 0.0077482387
When O 0 0.0034593837
performing O 0 0.0029532937
intracarotid O 0 0.9100259
injection O 0 0.0047219447
of O 0 0.0027150395
carboplatin B-Chemical 1 0.9993742
, O 0 0.0020551144
we O 0 0.0007526485
must O 0 0.0007060734
be O 0 0.000938522
aware O 0 0.0011742981
of O 0 0.0016047078
its O 0 0.0031481874
potentially O 0 0.008073691
blinding O 0 0.07794195
ocular B-Disease 0 0.997335
toxicity I-Disease 2 0.99970466
. O 0 0.014858448

It O 0 0.010202937
is O 0 0.005259076
recommended O 0 0.0034446598
that O 0 0.0021782282
further O 0 0.0019929262
studies O 0 0.001843777
and O 0 0.00160442
investigations O 0 0.0018205039
are O 0 0.0011204013
undertaken O 0 0.000818357
in O 0 0.00084262947
the O 0 0.00093016314
effort O 0 0.0012342246
to O 0 0.0010226557
minimize O 0 0.0011527482
such O 0 0.0025158513
severe O 0 0.4513705
side O 0 0.36667317
effects O 0 0.03311047
. O 0 0.0103748515

Visual B-Disease 0 0.98671305
hallucinations I-Disease 2 0.99939084
associated O 0 0.049891654
with O 0 0.049754
zonisamide B-Chemical 1 0.9995448
. O 0 0.04300526

Zonisamide B-Chemical 0 0.99847466
is O 0 0.007568905
a O 0 0.005835956
broad O 0 0.0052003986
- O 0 0.0047386126
spectrum O 0 0.0035539507
antiepileptic O 0 0.9994128
drug O 0 0.73093414
used O 0 0.0021577524
to O 0 0.0018834199
treat O 0 0.0049072495
various O 0 0.004874846
types O 0 0.005134114
of O 0 0.018239565
seizures B-Disease 2 0.99989164
. O 0 0.014151276

Although O 0 0.0097757345
visual B-Disease 2 0.78857553
hallucinations I-Disease 2 0.9999232
have O 0 0.0033440397
not O 0 0.0021600947
been O 0 0.001577538
reported O 0 0.0013060058
as O 0 0.00095250655
an O 0 0.0012051642
adverse O 0 0.7869538
effect O 0 0.0007319524
of O 0 0.00080348767
this O 0 0.00063582323
agent O 0 0.11801531
, O 0 0.00074011687
we O 0 0.0002516444
describe O 0 0.00031305963
three O 0 0.00028815388
patients O 0 0.0010285352
who O 0 0.0009187537
experienced O 0 0.0011034948
complex O 0 0.0010052866
visual B-Disease 2 0.9520938
hallucinations I-Disease 2 0.99999654
and O 0 0.001828982
altered O 0 0.0016614437
mental O 0 0.41754746
status O 0 0.0014353908
after O 0 0.0005904036
zonisamide B-Chemical 1 0.9999677
treatment O 0 0.0021014053
was O 0 0.001294437
begun O 0 0.0021349317
or O 0 0.0018324021
its O 0 0.004692324
dosage O 0 0.30845997
increased O 0 0.008216949
. O 0 0.008982597

All O 0 0.00853173
three O 0 0.0049541076
had O 0 0.0043184613
been O 0 0.003693779
diagnosed O 0 0.008316184
earlier O 0 0.0027002117
with O 0 0.0033301672
epilepsy B-Disease 2 0.9999
, O 0 0.0035020055
and O 0 0.001845981
their O 0 0.0020164214
electroencephalogram O 0 0.8735889
( O 0 0.004426266
EEG O 0 0.92888665
) O 0 0.0048401835
findings O 0 0.005587476
were O 0 0.005497392
abnormal O 0 0.031443305
. O 0 0.00932218

During O 0 0.007461314
monitoring O 0 0.0071436274
, O 0 0.0072311275
visual B-Disease 2 0.7652681
hallucinations I-Disease 2 0.9999596
did O 0 0.0024424535
not O 0 0.0014490162
correlate O 0 0.0011437531
with O 0 0.0013505304
EEG O 0 0.928309
readings O 0 0.0016682507
, O 0 0.0010994199
nor O 0 0.00073869637
did O 0 0.00076736335
video O 0 0.0018913426
recording O 0 0.0014850688
capture O 0 0.0012098985
any O 0 0.0012672914
of O 0 0.0021691383
the O 0 0.0028022618
described O 0 0.003922244
events O 0 0.08470722
. O 0 0.00947916

None O 0 0.018093875
of O 0 0.009694535
the O 0 0.0070357635
patients O 0 0.008724966
had O 0 0.005422451
experienced O 0 0.010966531
visual B-Disease 2 0.92846584
hallucinations I-Disease 2 0.9999379
before O 0 0.005556732
this O 0 0.0077770553
event O 0 0.05064694
. O 0 0.012595535

The O 0 0.007924652
only O 0 0.005511247
recent O 0 0.004284723
change O 0 0.0031603032
in O 0 0.0022380436
their O 0 0.0021713234
treatment O 0 0.0025751607
was O 0 0.0016681475
the O 0 0.0015058588
introduction O 0 0.0016351499
or O 0 0.0020203555
increased O 0 0.0034709629
dosage O 0 0.40437827
of O 0 0.021351483
zonisamide B-Chemical 1 0.99992704
. O 0 0.0122843385

With O 0 0.009541267
either O 0 0.0058721458
discontinuation O 0 0.4863293
or O 0 0.0032345303
decreased O 0 0.003303169
dosage O 0 0.070237085
of O 0 0.0020523465
the O 0 0.0016576366
drug O 0 0.44973534
the O 0 0.0021359834
symptoms O 0 0.82427275
disappeared O 0 0.0050373706
and O 0 0.0034204181
did O 0 0.0034921581
not O 0 0.005196152
recur O 0 0.1659432
. O 0 0.0104226945

Further O 0 0.013876829
observations O 0 0.011180382
and O 0 0.009173232
reports O 0 0.008303872
will O 0 0.005764145
help O 0 0.0062599815
clarify O 0 0.0044158073
this O 0 0.00711265
adverse O 0 0.93974507
effect O 0 0.014772209
. O 0 0.014958013

Until O 0 0.010914278
then O 0 0.0066436455
, O 0 0.005884058
clinicians O 0 0.0048086406
need O 0 0.002548327
to O 0 0.0020633787
be O 0 0.0018863803
aware O 0 0.0018634275
of O 0 0.0019112454
this O 0 0.0018646991
possible O 0 0.0026287432
complication O 0 0.6102528
associated O 0 0.007201263
with O 0 0.01967839
zonisamide B-Chemical 1 0.99992037
. O 0 0.012960964

Anti O 0 0.6691406
- O 0 0.034415882
epileptic B-Disease 2 0.9989856
drugs O 0 0.96577984
- O 0 0.01616525
induced O 0 0.00866587
de O 0 0.11049534
novo O 0 0.15133348
absence B-Disease 0 0.040060412
seizures I-Disease 2 0.9999213
. O 0 0.02673032

The O 0 0.007430606
authors O 0 0.0050672386
present O 0 0.003004033
three O 0 0.0022897818
patients O 0 0.0036557524
with O 0 0.0021920186
de O 0 0.021149324
novo O 0 0.028284373
absence B-Disease 0 0.00425327
epilepsy I-Disease 2 0.99996877
after O 0 0.0019295058
administration O 0 0.25129426
of O 0 0.01710542
carbamazepine B-Chemical 1 0.99998605
and O 0 0.06572848
vigabatrin B-Chemical 1 0.99993205
. O 0 0.012388416

Despite O 0 0.008260414
the O 0 0.0054791006
underlying O 0 0.0070740897
diseases O 0 0.73161393
, O 0 0.0043466636
the O 0 0.0020414938
prognosis O 0 0.74357224
for O 0 0.0012241908
drug O 0 0.81455123
- O 0 0.0030018573
induced O 0 0.0009187256
de O 0 0.03033319
novo O 0 0.021852823
absence B-Disease 0 0.0016799626
seizure I-Disease 2 0.9999734
is O 0 0.0009109678
good O 0 0.00082120666
because O 0 0.00046949222
it O 0 0.0006990346
subsides O 0 0.0019778344
rapidly O 0 0.0010908922
after O 0 0.0004852749
discontinuing O 0 0.10427139
the O 0 0.0010040991
use O 0 0.0014174815
of O 0 0.0021344176
the O 0 0.0031062728
offending O 0 0.7020407
drugs O 0 0.93225527
. O 0 0.010030806

The O 0 0.0106846215
gamma B-Chemical 1 0.7505118
- I-Chemical 1 0.048784327
aminobutyric I-Chemical 1 0.9994655
acid I-Chemical 1 0.99385166
- O 0 0.012564948
transmitted O 0 0.0032604765
thalamocortical O 0 0.64182097
circuitry O 0 0.025955968
accounts O 0 0.0012123007
for O 0 0.000634236
a O 0 0.0009348228
major O 0 0.0009137043
part O 0 0.0007124378
of O 0 0.0009657748
the O 0 0.0010932101
underlying O 0 0.0027376318
neurophysiology O 0 0.12206497
of O 0 0.0029965348
the O 0 0.003786799
absence B-Disease 0 0.008383648
epilepsy I-Disease 2 0.9999144
. O 0 0.013935088

Because O 0 0.008052048
drug O 0 0.48323765
- O 0 0.0074997405
induced O 0 0.0033194146
de O 0 0.023086108
novo O 0 0.026386155
absence B-Disease 0 0.0034806132
seizure I-Disease 2 0.9999573
is O 0 0.0026856854
rare O 0 0.05997825
, O 0 0.003305173
pro O 0 0.2253892
- O 0 0.0021331252
absence O 0 0.000686968
drugs O 0 0.47360572
can O 0 0.0010591883
only O 0 0.0012933895
be O 0 0.0017034416
considered O 0 0.0018681384
a O 0 0.003940238
promoting O 0 0.00597096
factor O 0 0.049212147
. O 0 0.009526318

The O 0 0.0070732157
underlying O 0 0.006944344
epileptogenecity O 0 0.021778775
of O 0 0.0030792933
the O 0 0.001972593
patients O 0 0.0030075267
or O 0 0.0011558325
the O 0 0.0009424166
synergistic O 0 0.002354188
effects O 0 0.0016801833
of O 0 0.0010585362
the O 0 0.00084202114
accompanying O 0 0.0031024015
drugs O 0 0.69303554
is O 0 0.0008448033
required O 0 0.0005063118
to O 0 0.00082369416
trigger O 0 0.0013640162
the O 0 0.0016648077
de O 0 0.039186027
novo O 0 0.05911633
absence B-Disease 0 0.014069703
seizure I-Disease 2 0.999869
. O 0 0.0151420655

The O 0 0.0065885726
possibility O 0 0.0046083797
of O 0 0.0045810123
drug O 0 0.77156556
- O 0 0.007267606
induced O 0 0.0025316216
aggravation O 0 0.94541216
should O 0 0.0007665649
be O 0 0.00076084863
considered O 0 0.00048338136
whenever O 0 0.0005758357
an O 0 0.0006876165
unexpected O 0 0.00091800414
increase O 0 0.0004487004
in O 0 0.00061665615
seizure B-Disease 2 0.9997346
frequency O 0 0.0011215231
and O 0 0.0009624257
/ O 0 0.0021709308
or O 0 0.00061850226
new O 0 0.0012900837
seizure B-Disease 2 0.99961805
types O 0 0.0011154265
appear O 0 0.0009650949
following O 0 0.0010279582
a O 0 0.0017792535
change O 0 0.0018136072
in O 0 0.0024518743
drug O 0 0.6004373
treatment O 0 0.0120933475
. O 0 0.009010618

By O 0 0.009558992
understanding O 0 0.0049537504
the O 0 0.0034291442
underlying O 0 0.003733763
mechanism O 0 0.0024671976
of O 0 0.0025405842
absence B-Disease 0 0.0028685916
epilepsy I-Disease 2 0.99998426
, O 0 0.0025783717
we O 0 0.0004927198
can O 0 0.0004402477
avoid O 0 0.00045642376
the O 0 0.00050048804
inappropriate O 0 0.0023868403
use O 0 0.0006337119
of O 0 0.0010470101
anticonvulsants O 0 0.9998604
in O 0 0.00083720835
children O 0 0.0042064465
with O 0 0.0017170763
epilepsy B-Disease 2 0.9999447
and O 0 0.0022263953
prevent O 0 0.0023538622
drug O 0 0.89266074
- O 0 0.00841718
induced O 0 0.0044356007
absence B-Disease 0 0.012434595
seizures I-Disease 2 0.9999583
. O 0 0.014039066

Prenatal O 0 0.8134965
dexamethasone B-Chemical 1 0.9985954
programs O 0 0.027697459
hypertension B-Disease 2 0.9996935
and O 0 0.020412827
renal B-Disease 2 0.9989968
injury I-Disease 2 0.9978161
in O 0 0.008834673
the O 0 0.0092992745
rat O 0 0.041298922
. O 0 0.013083739

Dexamethasone O 1 0.99883336
is O 0 0.009351317
frequently O 0 0.0069041783
administered O 0 0.0051571755
to O 0 0.003332913
the O 0 0.003330772
developing O 0 0.0077060903
fetus O 0 0.030766888
to O 0 0.0042563933
accelerate O 0 0.006433144
pulmonary O 0 0.9574139
development O 0 0.037284732
. O 0 0.0129475985

The O 0 0.006611539
purpose O 0 0.0048627267
of O 0 0.0035748868
the O 0 0.0024121555
present O 0 0.001487834
study O 0 0.0017344309
was O 0 0.0011008935
to O 0 0.00076109153
determine O 0 0.00045867567
if O 0 0.0006426781
prenatal O 0 0.08466339
dexamethasone B-Chemical 1 0.99982613
programmed O 0 0.54839367
a O 0 0.0016491085
progressive O 0 0.13639882
increase B-Disease 0 0.00073601806
in I-Disease 0 0.00087551307
blood I-Disease 0 0.015352766
pressure I-Disease 0 0.08890241
and O 0 0.003296504
renal B-Disease 2 0.9990834
injury I-Disease 2 0.99794227
in O 0 0.0062357783
rats O 0 0.03308622
. O 0 0.00909131

Pregnant O 0 0.1403941
rats O 0 0.009018204
were O 0 0.0035516922
given O 0 0.0018890495
either O 0 0.0017313458
vehicle O 0 0.014582537
or O 0 0.0011356518
2 O 0 0.000820848
daily O 0 0.0010782944
intraperitoneal O 0 0.04484198
injections O 0 0.0064107906
of O 0 0.0014524686
dexamethasone B-Chemical 1 0.9998555
( O 0 0.0025208436
0 O 0 0.00088585634
. O 0 0.0003224574
2 O 0 0.00039505365
mg O 0 0.04822899
/ O 0 0.00093423866
kg O 0 0.0015925756
body O 0 0.0020619377
weight O 0 0.0036959825
) O 0 0.00075783185
on O 0 0.00025198245
gestational O 0 0.0057816906
days O 0 0.0002901227
11 O 0 0.00044311746
and O 0 0.00039233046
12 O 0 0.000319604
, O 0 0.00045996558
13 O 0 0.00043741945
and O 0 0.00042814497
14 O 0 0.00050904247
, O 0 0.0005412325
15 O 0 0.00038948967
and O 0 0.0005235962
16 O 0 0.00065531395
, O 0 0.0008068844
17 O 0 0.00095822744
and O 0 0.0009417286
18 O 0 0.0011856142
, O 0 0.0016095947
or O 0 0.00177268
19 O 0 0.0035969948
and O 0 0.0038036213
20 O 0 0.005585124
. O 0 0.0069639077

Offspring O 0 0.044553142
of O 0 0.0063192765
rats O 0 0.0069211214
administered O 0 0.004399572
dexamethasone B-Chemical 1 0.99684566
on O 0 0.0010768136
days O 0 0.00079621346
15 O 0 0.0006443626
and O 0 0.000635154
16 O 0 0.00056840194
gestation O 0 0.0010303251
had O 0 0.0004114382
a O 0 0.00062760484
20 O 0 0.0005103071
% O 0 0.00052388076
reduction B-Disease 2 0.00054809643
in I-Disease 2 0.00037108053
glomerular I-Disease 2 0.4619625
number I-Disease 2 0.00041140502
compared O 0 0.00025873753
with O 0 0.00038899577
control O 0 0.00036767736
at O 0 0.0002591553
6 O 0 0.0002455244
to O 0 0.00024888417
9 O 0 0.00031313003
months O 0 0.00022617824
of O 0 0.00039596003
age O 0 0.0013314765
( O 0 0.0008063207
22 O 0 0.0007187407
527 O 0 0.009586571
+ O 0 0.000650292
/ O 0 0.001509338
- O 0 0.0008138744
509 O 0 0.003352333
versus O 0 0.0003613578
28 O 0 0.0005583966
050 O 0 0.042334266
+ O 0 0.00062806084
/ O 0 0.0016412787
- O 0 0.0010604414
561 O 0 0.031597525
, O 0 0.00070154906
P O 0 0.019800415
< O 0 0.0005187404
0 O 0 0.00059382984
. O 0 0.00038290085
05 O 0 0.0377333
) O 0 0.0007193715
, O 0 0.00050086173
which O 0 0.000432841
was O 0 0.00034599061
comparable O 0 0.00026293908
to O 0 0.00034095132
the O 0 0.00040364105
percent O 0 0.0005026557
reduction O 0 0.0009129646
in O 0 0.00072218943
glomeruli O 0 0.012726224
measured O 0 0.000822525
at O 0 0.0009974409
3 O 0 0.0014290375
weeks O 0 0.0015815287
of O 0 0.0035187239
age O 0 0.010533126
. O 0 0.00815132

Six O 0 0.012689957
- O 0 0.00825758
to O 0 0.0038718013
9 O 0 0.003254313
- O 0 0.0025883953
month O 0 0.0011410214
old O 0 0.001267219
rats O 0 0.0017248242
receiving O 0 0.0016262394
prenatal O 0 0.045791626
dexamethasone B-Chemical 1 0.9989543
on O 0 0.00047211171
days O 0 0.00044356458
17 O 0 0.00065060257
and O 0 0.00043652684
18 O 0 0.00037789
of O 0 0.0004074024
gestation O 0 0.001242608
had O 0 0.000380389
a O 0 0.00062658044
17 O 0 0.0007259179
% O 0 0.0005456733
reduction O 0 0.00061706157
in O 0 0.00046052708
glomeruli O 0 0.040656704
( O 0 0.0010394437
23 O 0 0.000929238
380 O 0 0.005599693
+ O 0 0.0007167219
/ O 0 0.001959938
- O 0 0.0012210609
587 O 0 0.038718533
) O 0 0.00080360484
compared O 0 0.00034811173
with O 0 0.00060562044
control O 0 0.00081701134
rats O 0 0.0028369182
( O 0 0.0023190812
P O 0 0.068934135
< O 0 0.002103427
0 O 0 0.0028265102
. O 0 0.002770349
05 O 0 0.05638341
) O 0 0.0077167368
. O 0 0.0075299274

Male O 0 0.033907026
rats O 0 0.008214486
that O 0 0.0032460915
received O 0 0.0027126689
prenatal O 0 0.03175841
dexamethasone B-Chemical 1 0.9981456
on O 0 0.0009422164
days O 0 0.0007286074
15 O 0 0.0006099915
and O 0 0.0006551766
16 O 0 0.0006538305
, O 0 0.00064856326
17 O 0 0.0006192767
and O 0 0.00047432023
18 O 0 0.00047079503
, O 0 0.0004965014
and O 0 0.00041861626
13 O 0 0.0004533477
and O 0 0.00037417997
14 O 0 0.0003681666
of O 0 0.0003872771
gestation O 0 0.0013761661
had O 0 0.0003989879
elevated B-Disease 0 0.0030597956
blood I-Disease 0 0.007852381
pressures I-Disease 0 0.015816974
at O 0 0.00031452102
6 O 0 0.0002836875
months O 0 0.00025370778
of O 0 0.00044871363
age O 0 0.0015004862
; O 0 0.00096522877
the O 0 0.0005006357
latter O 0 0.0011605949
group O 0 0.00089738716
did O 0 0.0007369515
not O 0 0.0008489636
have O 0 0.0010181202
a O 0 0.002027749
reduction B-Disease 2 0.0028821249
in I-Disease 2 0.0030230167
glomerular I-Disease 2 0.86305773
number I-Disease 2 0.007439593
. O 0 0.0089188665

Adult O 0 0.016145093
rats O 0 0.008893154
given O 0 0.0037286424
dexamethasone B-Chemical 1 0.9910703
on O 0 0.0018328809
days O 0 0.0013485933
15 O 0 0.0011146782
and O 0 0.00108617
16 O 0 0.0009551051
of O 0 0.0009927299
gestation O 0 0.0024416905
had O 0 0.001024306
more O 0 0.0015853099
glomeruli O 0 0.0679446
with O 0 0.0039729304
glomerulosclerosis B-Disease 2 0.9999206
than O 0 0.003652662
control O 0 0.005148283
rats O 0 0.01630865
. O 0 0.00878013

This O 0 0.009642837
study O 0 0.005163781
shows O 0 0.0025501784
that O 0 0.0022003883
prenatal O 0 0.058485303
dexamethasone B-Chemical 1 0.9994783
in O 0 0.0016825653
rats O 0 0.0033180395
results O 0 0.00094756525
in O 0 0.00072863896
a O 0 0.0010199867
reduction B-Disease 2 0.0010896521
in I-Disease 2 0.00063777785
glomerular I-Disease 2 0.79777414
number I-Disease 2 0.001110819
, O 0 0.003680278
glomerulosclerosis B-Disease 2 0.99997544
, O 0 0.005208629
and O 0 0.0018637051
hypertension B-Disease 2 0.999874
when O 0 0.00084293063
administered O 0 0.0015801145
at O 0 0.0009871823
specific O 0 0.0014300123
points O 0 0.002912128
during O 0 0.0028307654
gestation O 0 0.0133057395
. O 0 0.007523028

Hypertension B-Disease 2 0.9938718
was O 0 0.005797775
observed O 0 0.0026575436
in O 0 0.0021157386
animals O 0 0.0015201747
that O 0 0.0010678824
had O 0 0.0009716826
a O 0 0.0012209987
reduction O 0 0.0012647616
in O 0 0.00065288966
glomeruli O 0 0.025318606
as O 0 0.00061778
well O 0 0.00047741242
as O 0 0.0004928462
in O 0 0.0004129756
a O 0 0.0005913402
group O 0 0.0005222843
that O 0 0.00032878888
did O 0 0.0003550087
not O 0 0.00035565806
have O 0 0.00033102097
a O 0 0.0005925159
reduction B-Disease 2 0.00071523414
in I-Disease 2 0.00041960226
glomerular I-Disease 2 0.7436023
number I-Disease 2 0.0005989769
, O 0 0.00070065534
suggesting O 0 0.00030699465
that O 0 0.00032079333
a O 0 0.00060799276
reduction B-Disease 2 0.0007478904
in I-Disease 2 0.0004668374
glomerular I-Disease 2 0.66283274
number I-Disease 2 0.00062635617
is O 0 0.0005784872
not O 0 0.00054831954
the O 0 0.0006752904
sole O 0 0.0023917288
cause O 0 0.003373013
for O 0 0.0012527568
the O 0 0.0020166698
development O 0 0.0056596026
of O 0 0.011491172
hypertension B-Disease 2 0.999841
. O 0 0.012432248

Kidney O 0 0.3077753
function O 0 0.0064416234
and O 0 0.0043262406
morphology O 0 0.004835553
after O 0 0.0015997422
short O 0 0.0016483996
- O 0 0.002106897
term O 0 0.001097181
combination O 0 0.002085097
therapy O 0 0.020341739
with O 0 0.003173696
cyclosporine B-Chemical 1 0.99999464
A I-Chemical 0 0.94576144
, O 0 0.012631727
tacrolimus B-Chemical 1 0.9999498
and O 0 0.006670195
sirolimus B-Chemical 1 0.9997533
in O 0 0.0038881681
the O 0 0.0049848566
rat O 0 0.0241134
. O 0 0.008812567

BACKGROUND O 0 0.8150408
: O 0 0.022684239
Sirolimus B-Chemical 1 0.9980539
( O 0 0.025618603
SRL B-Chemical 1 0.99950814
) O 0 0.010179983
may O 0 0.0036143898
supplement O 0 0.03448245
calcineurin O 0 0.9257576
inhibitors O 0 0.19390616
in O 0 0.004573
clinical O 0 0.0571791
organ O 0 0.5027069
transplantation O 0 0.6179568
. O 0 0.012197448

These O 0 0.010988917
are O 0 0.008423598
nephrotoxic B-Disease 2 0.99908507
, O 0 0.009905062
but O 0 0.0043729157
SRL B-Chemical 1 0.9996339
seems O 0 0.0015862416
to O 0 0.0010239742
act O 0 0.0013797422
differently O 0 0.0008295488
displaying O 0 0.0010569384
only O 0 0.0008485014
minor O 0 0.004591623
nephrotoxic B-Disease 2 0.99979216
effects O 0 0.012242901
, O 0 0.0022133328
although O 0 0.0011420147
this O 0 0.0014205193
question O 0 0.002231781
is O 0 0.002613064
still O 0 0.0035638597
open O 0 0.0057162615
. O 0 0.007599749

In O 0 0.007246122
a O 0 0.0056862733
number O 0 0.003291734
of O 0 0.0030363912
treatment O 0 0.0032234495
protocols O 0 0.0025190746
where O 0 0.0019858908
SRL B-Chemical 1 0.99976546
was O 0 0.0012841013
combined O 0 0.0013412295
with O 0 0.0010389597
a O 0 0.0017401006
calcineurin O 0 0.8660899
inhibitor O 0 0.06576348
indications O 0 0.0017555201
of O 0 0.0015318415
a O 0 0.002387125
synergistic O 0 0.034582634
nephrotoxic B-Disease 2 0.999796
effect O 0 0.00543466
were O 0 0.005096181
described O 0 0.005340018
. O 0 0.008466133

The O 0 0.0067287106
aim O 0 0.005335317
of O 0 0.0037674892
this O 0 0.0025060973
study O 0 0.0021613757
was O 0 0.0012942157
to O 0 0.0008349267
examine O 0 0.00049837626
further O 0 0.00074856565
the O 0 0.00076921267
renal O 0 0.9663635
function O 0 0.001245199
, O 0 0.00084059493
including O 0 0.00043411745
morphological O 0 0.0016731244
analysis O 0 0.00060541724
of O 0 0.0005313952
the O 0 0.00047709444
kidneys O 0 0.028030341
of O 0 0.00076226995
male O 0 0.01957337
Sprague O 0 0.56048423
- O 0 0.0018370856
Dawley O 0 0.04654323
rats O 0 0.0010862723
treated O 0 0.00067019847
with O 0 0.000700618
either O 0 0.0014132336
cyclosporine B-Chemical 1 0.99999666
A I-Chemical 0 0.95361835
( O 0 0.019480592
CsA B-Chemical 1 0.99997497
) O 0 0.014398108
, O 0 0.0029387523
tacrolimus B-Chemical 1 0.9999788
( O 0 0.013372495
FK506 B-Chemical 1 0.99995625
) O 0 0.0075228466
or O 0 0.0015790142
SRL B-Chemical 1 0.99977213
as O 0 0.0017200802
monotherapies O 0 0.65068585
or O 0 0.0017886568
in O 0 0.002144756
different O 0 0.0030764784
combinations O 0 0.0061671766
. O 0 0.008037645

METHODS O 0 0.010515652
: O 0 0.0070120376
For O 0 0.003105762
a O 0 0.0029668543
period O 0 0.0017491506
of O 0 0.0016896162
2 O 0 0.0012994189
weeks O 0 0.0008552859
, O 0 0.0014393902
CsA B-Chemical 1 0.9996687
15 O 0 0.0007618719
mg O 0 0.1436078
/ O 0 0.0015201314
kg O 0 0.0029786667
/ O 0 0.0011559746
day O 0 0.00044068485
( O 0 0.00058279664
given O 0 0.0003001115
orally O 0 0.007834237
) O 0 0.0018433217
, O 0 0.0010672925
FK506 B-Chemical 1 0.99986684
3 O 0 0.00060160103
. O 0 0.0003149411
0 O 0 0.00048945803
mg O 0 0.05288615
/ O 0 0.0009787113
kg O 0 0.0020353345
/ O 0 0.0009119953
day O 0 0.00036089864
( O 0 0.00049993687
given O 0 0.0002609016
orally O 0 0.005126793
) O 0 0.0012109557
or O 0 0.000646426
SRL B-Chemical 1 0.99981314
0 O 0 0.0008373968
. O 0 0.00028738132
4 O 0 0.0003198753
mg O 0 0.041575614
/ O 0 0.00091071264
kg O 0 0.0019273749
/ O 0 0.0008746093
day O 0 0.00034374863
( O 0 0.0004744355
given O 0 0.0002447132
intraperitoneally O 0 0.003900943
) O 0 0.00092924194
was O 0 0.000327259
administered O 0 0.00042591605
once O 0 0.00027482648
a O 0 0.00035748008
day O 0 0.00026907556
as O 0 0.00033020685
these O 0 0.00047713178
doses O 0 0.0059713
have O 0 0.00044883965
earlier O 0 0.00059567153
been O 0 0.0005544434
found O 0 0.00040537587
to O 0 0.00047082084
achieve O 0 0.00045001088
a O 0 0.0009231832
significant O 0 0.0011048481
immunosuppressive O 0 0.9025217
effect O 0 0.0023355223
in O 0 0.0028097015
Sprague O 0 0.6127862
- O 0 0.008684184
Dawley O 0 0.14673468
rats O 0 0.011308592
. O 0 0.009031121

In O 0 0.0074566933
the O 0 0.0053616506
' O 0 0.004651629
conscious O 0 0.0062774983
catheterized O 0 0.0035231772
rat O 0 0.004243152
' O 0 0.0018484137
model O 0 0.0013472608
, O 0 0.001251396
the O 0 0.0008226932
glomerular O 0 0.6654899
filtration O 0 0.016967334
rate O 0 0.0011558066
( O 0 0.002205329
GFR O 0 0.9937954
) O 0 0.0017142342
was O 0 0.0006831924
measured O 0 0.00056245684
as O 0 0.0008756057
the O 0 0.0011673316
clearance O 0 0.04911266
of O 0 0.0066700494
Cr O 1 0.99987376
( O 0 0.034560736
EDTA O 0 0.99836606
) O 0 0.023015639
. O 0 0.009717117

The O 0 0.007132502
morphological O 0 0.008328821
analysis O 0 0.0044167675
of O 0 0.0030637719
the O 0 0.002193997
kidneys O 0 0.02463636
included O 0 0.0013744496
a O 0 0.001654105
semi O 0 0.009522197
- O 0 0.0014315766
quantitative O 0 0.00088255457
scoring O 0 0.0015113004
system O 0 0.00074699323
analysing O 0 0.00050744764
the O 0 0.0004648467
degree O 0 0.000645055
of O 0 0.00083336997
striped O 0 0.062363368
fibrosis B-Disease 2 0.9992531
, O 0 0.0058521377
subcapsular O 0 0.82774574
fibrosis B-Disease 2 0.9967525
and O 0 0.0008180068
the O 0 0.00044224947
number O 0 0.00040271206
of O 0 0.00079470844
basophilic O 0 0.9388789
tubules O 0 0.065819964
, O 0 0.0009081089
plus O 0 0.00039977406
an O 0 0.000530068
additional O 0 0.00026464427
stereological O 0 0.0009489395
analysis O 0 0.000519147
of O 0 0.0005236961
the O 0 0.0005125847
total O 0 0.0006984982
grade O 0 0.2733927
of O 0 0.001819892
fibrosis B-Disease 2 0.9966714
in O 0 0.0018715666
the O 0 0.0023955693
cortex O 0 0.23009464
stained O 0 0.0048550116
with O 0 0.0063735675
Sirius O 0 0.8514341
Red O 0 0.48139536
. O 0 0.009848197

RESULTS O 0 0.04618673
: O 0 0.020051194
CsA B-Chemical 1 0.99910045
, O 0 0.018809065
FK506 B-Chemical 1 0.9996152
and O 0 0.015324073
SRL B-Chemical 1 0.9993735
all O 0 0.0054022963
significantly O 0 0.006561196
decreased O 0 0.008513437
the O 0 0.009445855
GFR O 0 0.9936287
. O 0 0.013941681

A O 0 0.036561612
further O 0 0.006622697
deterioration O 0 0.1065826
was O 0 0.0031408689
seen O 0 0.0019826717
when O 0 0.0015808897
CsA B-Chemical 1 0.99982953
was O 0 0.0013894226
combined O 0 0.00135635
with O 0 0.00097127014
either O 0 0.0013428457
FK506 B-Chemical 1 0.9999635
or O 0 0.003815509
SRL B-Chemical 1 0.9999541
, O 0 0.0013131809
whereas O 0 0.0004781726
the O 0 0.00055360165
GFR O 0 0.9900815
remained O 0 0.00058826804
unchanged O 0 0.00044313943
in O 0 0.0003349852
the O 0 0.00037562082
group O 0 0.00056846027
treated O 0 0.0007416002
with O 0 0.0010385807
FK506 B-Chemical 1 0.99995947
plus O 0 0.0020827157
SRL B-Chemical 1 0.9998852
when O 0 0.0004931201
compared O 0 0.00042377162
with O 0 0.000753047
treatment O 0 0.0012613552
with O 0 0.0010858605
any O 0 0.0012065826
of O 0 0.0020913673
the O 0 0.0027378872
single O 0 0.0049121506
substances O 0 0.8901298
. O 0 0.010191212

The O 0 0.018971514
morphological O 0 0.024369232
changes O 0 0.017163109
presented O 0 0.015486036
a O 0 0.016788198
similar O 0 0.013524118
pattern O 0 0.01782584
. O 0 0.022181692

The O 0 0.008828692
semi O 0 0.016417127
- O 0 0.0062084426
quantitative O 0 0.003770019
scoring O 0 0.004787243
was O 0 0.0018653149
significantly O 0 0.0017535749
worst O 0 0.017759224
in O 0 0.00090096326
the O 0 0.00078979856
group O 0 0.000968011
treated O 0 0.001111358
with O 0 0.0014724307
CsA B-Chemical 1 0.9999664
plus O 0 0.0034295581
SRL B-Chemical 1 0.99996364
( O 0 0.003183078
P O 0 0.13524699
< O 0 0.0005887034
0 O 0 0.00058764045
. O 0 0.0003188696
001 O 0 0.023064105
compared O 0 0.00021638119
with O 0 0.00035733765
controls O 0 0.00093634706
) O 0 0.0007521953
and O 0 0.00036779654
the O 0 0.00030327917
analysis O 0 0.00038300853
of O 0 0.00036945543
the O 0 0.0003317179
total O 0 0.00041814405
grade O 0 0.24743043
of O 0 0.0009050545
fibrosis B-Disease 2 0.99601495
also O 0 0.0006345583
showed O 0 0.00035813265
the O 0 0.00034351702
highest O 0 0.0003385108
proportion O 0 0.00030371314
in O 0 0.00032643578
the O 0 0.00034619024
same O 0 0.00026887015
group O 0 0.0005748585
and O 0 0.00060723757
was O 0 0.0005195277
significantly O 0 0.00067121413
different O 0 0.0005834742
from O 0 0.00082420127
controls O 0 0.0023334404
( O 0 0.0022160977
P O 0 0.058194023
< O 0 0.0018813385
0 O 0 0.002530242
. O 0 0.002486798
02 O 0 0.030989973
) O 0 0.0076325755
. O 0 0.0073334235

The O 0 0.009727061
FK506 B-Chemical 1 0.9991295
plus O 0 0.008784151
SRL B-Chemical 1 0.9995295
combination O 0 0.005245598
showed O 0 0.001457766
only O 0 0.0011364829
a O 0 0.0013570103
marginally O 0 0.0015672066
higher O 0 0.00072589505
degree O 0 0.0010089951
of O 0 0.0013614828
fibrosis B-Disease 2 0.9960736
as O 0 0.0011659464
compared O 0 0.000615993
with O 0 0.0010817683
controls O 0 0.0033198108
( O 0 0.002734962
P O 0 0.10229447
= O 0 0.0028172894
0 O 0 0.0029021571
. O 0 0.0027794589
05 O 0 0.0629157
) O 0 0.0077381628
. O 0 0.0075007523

CONCLUSION O 0 0.7480331
: O 0 0.00982291
This O 0 0.005742929
rat O 0 0.0059432215
study O 0 0.0026253385
demonstrated O 0 0.0015826779
a O 0 0.0021059227
synergistic O 0 0.0124000665
nephrotoxic B-Disease 2 0.99980825
effect O 0 0.0024677448
of O 0 0.0060854023
CsA B-Chemical 1 0.9999751
plus O 0 0.00806769
SRL B-Chemical 1 0.9999496
, O 0 0.0032222944
whereas O 0 0.0017824534
FK506 B-Chemical 1 0.99990726
plus O 0 0.0060383026
SRL B-Chemical 1 0.99979573
was O 0 0.003606088
better O 0 0.004682578
tolerated O 0 0.08559493
. O 0 0.0085415775

Evaluation O 0 0.012968566
of O 0 0.007781939
cardiac O 0 0.62594557
troponin O 0 0.9938784
I O 0 0.051895514
and O 0 0.0033336892
T O 0 0.57705563
levels O 0 0.0013874129
as O 0 0.0011963288
markers O 0 0.0025607515
of O 0 0.003178246
myocardial B-Disease 2 0.9999778
damage I-Disease 2 0.9943348
in O 0 0.0025624959
doxorubicin B-Chemical 1 0.9999529
- O 0 0.013681058
induced O 0 0.0024463744
cardiomyopathy B-Disease 2 0.9999833
rats O 0 0.020399986
, O 0 0.0013740689
and O 0 0.0008978996
their O 0 0.00088587234
relationship O 0 0.00084688514
with O 0 0.0016440479
echocardiographic O 0 0.104658596
and O 0 0.0038014627
histological O 0 0.48891735
findings O 0 0.024275724
. O 0 0.010131286

BACKGROUND O 0 0.74017376
: O 0 0.016795557
Cardiac O 0 0.9139619
troponins O 0 0.9902637
I O 0 0.101521574
( O 0 0.0068745087
cTnI O 0 0.889776
) O 0 0.0038502722
and O 0 0.002290891
T O 0 0.81052315
( O 0 0.0039020234
cTnT O 0 0.9658221
) O 0 0.0018663938
have O 0 0.0007061108
been O 0 0.0007642945
shown O 0 0.0005165359
to O 0 0.00059131265
be O 0 0.0007264903
highly O 0 0.0008848912
sensitive O 0 0.0007772534
and O 0 0.001100015
specific O 0 0.001128171
markers O 0 0.0040404024
of O 0 0.0066823727
myocardial B-Disease 0 0.9998964
cell I-Disease 0 0.5127212
injury I-Disease 0 0.99743783
. O 0 0.012325868

We O 0 0.00725346
investigated O 0 0.0041302047
the O 0 0.0033604344
diagnostic O 0 0.0035345203
value O 0 0.002160344
of O 0 0.0024833065
cTnI O 0 0.907583
and O 0 0.0019068152
cTnT O 0 0.90977603
for O 0 0.0005879329
the O 0 0.00064678554
diagnosis O 0 0.0051110685
of O 0 0.0021219603
myocardial B-Disease 2 0.9999796
damage I-Disease 2 0.98552865
in O 0 0.0007663359
a O 0 0.000913056
rat O 0 0.002522217
model O 0 0.0006555757
of O 0 0.0013900382
doxorubicin B-Chemical 1 0.9999505
( O 0 0.019160163
DOX B-Chemical 1 0.99995244
) O 0 0.013966909
- O 0 0.0023162125
induced O 0 0.0011294031
cardiomyopathy B-Disease 2 0.99998415
, O 0 0.0011443371
and O 0 0.00045210312
we O 0 0.00022425552
examined O 0 0.00022810721
the O 0 0.00030017874
relationship O 0 0.0002677502
between O 0 0.00028052667
serial O 0 0.0013551376
cTnI O 0 0.9062881
and O 0 0.0008413057
cTnT O 0 0.9235979
with O 0 0.0004884942
the O 0 0.00047340104
development O 0 0.0009163993
of O 0 0.00096597953
cardiac B-Disease 0 0.9696303
disorders I-Disease 0 0.98135763
monitored O 0 0.00054707314
by O 0 0.0010581027
echocardiography O 0 0.069053985
and O 0 0.001419591
histological O 0 0.17662343
examinations O 0 0.004512202
in O 0 0.0025730012
this O 0 0.0036846604
model O 0 0.0068951077
. O 0 0.008549163

METHODS O 0 0.011475882
: O 0 0.008258876
Thirty O 0 0.0074865557
- O 0 0.0043274094
five O 0 0.0019307936
Wistar O 0 0.010113985
rats O 0 0.0025472762
were O 0 0.0011368813
given O 0 0.0007352648
1 O 0 0.00088363414
. O 0 0.0005348269
5 O 0 0.00052971754
mg O 0 0.061962735
/ O 0 0.0016500147
kg O 0 0.012296291
DOX B-Chemical 1 0.9996697
, O 0 0.0011427085
i O 0 0.0025948836
. O 0 0.00044270643
v O 0 0.010475434
. O 0 0.00036131646
, O 0 0.00047252685
weekly O 0 0.00043978356
for O 0 0.00026390227
up O 0 0.00032457444
to O 0 0.00032025398
8 O 0 0.00034405128
weeks O 0 0.00024947335
for O 0 0.0002957481
a O 0 0.000532616
total O 0 0.0005269754
cumulative O 0 0.0016237074
dose O 0 0.004491595
of O 0 0.0015981284
12 O 0 0.001591035
mg O 0 0.29205588
/ O 0 0.008510336
kg O 0 0.0355783
BW O 0 0.5334623
. O 0 0.009258561

Ten O 0 0.024040304
rats O 0 0.01860722
received O 0 0.011984937
saline O 0 0.05863769
as O 0 0.0108450055
a O 0 0.012541519
control O 0 0.011704586
group O 0 0.016801741
. O 0 0.017549746

cTnI O 0 0.6254693
was O 0 0.007344094
measured O 0 0.004169169
with O 0 0.0042418977
Access O 0 0.016349467
( O 0 0.0049531274
R O 0 0.91998994
) O 0 0.004175672
( O 0 0.0018063216
ng O 0 0.0032917387
/ O 0 0.002711829
ml O 0 0.0035415087
) O 0 0.0014638777
and O 0 0.0007291506
a O 0 0.000879558
research O 0 0.00087334635
immunoassay O 0 0.046564184
( O 0 0.0011953111
pg O 0 0.029551722
/ O 0 0.0022955725
ml O 0 0.0034253856
) O 0 0.0015931374
, O 0 0.0008750878
and O 0 0.0007210407
compared O 0 0.0005797894
with O 0 0.0014902422
cTnT O 0 0.9840121
, O 0 0.004410811
CK O 0 0.9982907
- O 0 0.016969506
MB O 0 0.99741495
mass O 0 0.021951672
and O 0 0.008953775
CK O 0 0.99546534
. O 0 0.010921436

By O 0 0.01063756
using O 0 0.0057076467
transthoracic O 0 0.018878587
echocardiography O 0 0.08148631
, O 0 0.003251805
anterior O 0 0.0041211066
and O 0 0.0015162836
posterior O 0 0.003745999
wall O 0 0.02500482
thickness O 0 0.062349185
, O 0 0.0020423157
LV O 0 0.99573284
diameters O 0 0.009253314
and O 0 0.0011764063
LV O 0 0.9977296
fractional O 0 0.03909053
shortening O 0 0.039917186
( O 0 0.0018594612
FS O 0 0.6105221
) O 0 0.0011664412
were O 0 0.00040220912
measured O 0 0.00026960252
in O 0 0.0003223818
all O 0 0.00035326747
rats O 0 0.00095343357
before O 0 0.00034519492
DOX B-Chemical 1 0.9995034
or O 0 0.0006489095
saline O 0 0.1974486
, O 0 0.0008206206
and O 0 0.0005120158
at O 0 0.00033309168
weeks O 0 0.0003263586
6 O 0 0.000385284
and O 0 0.0005716676
9 O 0 0.00068969955
after O 0 0.00055502506
treatment O 0 0.0014454933
in O 0 0.0015726853
all O 0 0.0024282855
surviving O 0 0.010547244
rats O 0 0.013968065
. O 0 0.008464735

Histology O 0 0.15381582
was O 0 0.0068438584
performed O 0 0.0042288518
in O 0 0.0039874194
DOX B-Chemical 1 0.99935037
- O 0 0.004948233
rats O 0 0.0028191227
at O 0 0.00089861284
6 O 0 0.00072182517
and O 0 0.0007639967
9 O 0 0.00068104704
weeks O 0 0.00044681958
after O 0 0.00043639867
the O 0 0.00073001307
last O 0 0.0009216636
DOX B-Chemical 1 0.9990644
dose O 0 0.017362747
and O 0 0.0026117382
in O 0 0.0026360718
all O 0 0.003769677
controls O 0 0.009748911
. O 0 0.008218054

RESULTS O 0 0.027106533
: O 0 0.0092496155
Eighteen O 0 0.007995665
of O 0 0.004386908
the O 0 0.0037909565
DOX B-Chemical 1 0.9988481
rats O 0 0.0073842565
died O 0 0.012138493
prematurely O 0 0.013083006
of O 0 0.0018087529
general O 0 0.0019753405
toxicity B-Disease 2 0.99164337
during O 0 0.0014472633
the O 0 0.0020217057
9 O 0 0.0027743052
- O 0 0.0038142402
week O 0 0.0030102343
period O 0 0.0046073277
. O 0 0.007582384

End O 0 0.19241029
- O 0 0.015640829
diastolic O 0 0.8638858
( O 0 0.0071849315
ED O 0 0.4243528
) O 0 0.0039092996
and O 0 0.0018645372
end O 0 0.001179097
- O 0 0.0024509612
systolic O 0 0.73477036
( O 0 0.0019935397
ES O 0 0.4456423
) O 0 0.0030524735
LV O 0 0.9969543
diameters O 0 0.015327144
/ O 0 0.003429115
BW O 0 0.2843813
significantly O 0 0.0008544192
increased O 0 0.00092814694
, O 0 0.0009898371
whereas O 0 0.0007121653
LV O 0 0.9990434
FS O 0 0.5840817
was O 0 0.0005518368
decreased O 0 0.0006020367
after O 0 0.0002855182
9 O 0 0.00043786917
weeks O 0 0.00030385767
in O 0 0.0004457713
the O 0 0.0007954991
DOX B-Chemical 1 0.9994159
group O 0 0.0017338721
( O 0 0.0020197385
p O 0 0.0018660732
< O 0 0.0018561726
0 O 0 0.002586019
. O 0 0.002609831
001 O 0 0.19878568
) O 0 0.00812916
. O 0 0.0075077093

These O 0 0.026210183
parameters O 0 0.022663288
remained O 0 0.019236896
unchanged O 0 0.016684571
in O 0 0.017471747
controls O 0 0.028127233
. O 0 0.023913613

Histological O 0 0.13080215
evaluation O 0 0.0070779603
of O 0 0.004894878
hearts O 0 0.008720272
from O 0 0.0023732292
all O 0 0.0017195106
rats O 0 0.0027564554
given O 0 0.0012695482
DOX B-Chemical 1 0.9988809
revealed O 0 0.001423243
significant O 0 0.0015158901
slight O 0 0.0020293167
degrees O 0 0.005037817
of O 0 0.0034799846
perivascular O 0 0.8463757
and O 0 0.009850391
interstitial O 0 0.99276406
fibrosis B-Disease 2 0.999634
. O 0 0.02006395

In O 0 0.00999602
7 O 0 0.0069660614
of O 0 0.005670273
the O 0 0.0045608543
18 O 0 0.0042452845
rats O 0 0.006967499
, O 0 0.0060646264
degeneration O 0 0.94444394
and O 0 0.007189927
myocyte O 0 0.9656891
vacuolisation O 0 0.9291919
were O 0 0.008016266
found O 0 0.007728086
. O 0 0.011027634

Only O 0 0.010787268
five O 0 0.0055021048
of O 0 0.005255989
the O 0 0.004088058
controls O 0 0.0046717124
exhibited O 0 0.0029103162
evidence O 0 0.0032665317
of O 0 0.0042448915
very O 0 0.005606691
slight O 0 0.009421459
perivascular O 0 0.9509952
fibrosis B-Disease 2 0.9984705
. O 0 0.01859291

A O 0 0.03263643
significant O 0 0.006839244
rise O 0 0.0064151813
in O 0 0.0038657922
cTnT O 0 0.9146044
was O 0 0.0020155981
found O 0 0.001184654
in O 0 0.0013298721
DOX B-Chemical 1 0.9994137
rats O 0 0.0024520818
after O 0 0.00039371877
cumulative O 0 0.0018335809
doses O 0 0.012161683
of O 0 0.00084816397
7 O 0 0.00060062314
. O 0 0.00033979383
5 O 0 0.00033850825
and O 0 0.00040006917
12 O 0 0.00034274536
mg O 0 0.04279394
/ O 0 0.0011174829
kg O 0 0.001640501
in O 0 0.00048964523
comparison O 0 0.00052285363
with O 0 0.00078162376
baseline O 0 0.0012292338
( O 0 0.0016240105
p O 0 0.0017473589
< O 0 0.001868985
0 O 0 0.002653058
. O 0 0.0026809126
05 O 0 0.054797076
) O 0 0.0075861313
. O 0 0.007424426

cTnT O 0 0.80624443
found O 0 0.0055293953
in O 0 0.0038408977
rats O 0 0.004117843
after O 0 0.0014895414
12 O 0 0.0013040593
mg O 0 0.095235266
/ O 0 0.0025154613
kg O 0 0.003491491
were O 0 0.00086108886
significantly O 0 0.000867213
greater O 0 0.00065731246
than O 0 0.00050559035
that O 0 0.00054387667
found O 0 0.0006062831
after O 0 0.00059533183
7 O 0 0.0009832232
. O 0 0.0009453155
5 O 0 0.0014690359
mg O 0 0.14108679
/ O 0 0.0079982495
kg O 0 0.06262083
DOX B-Chemical 1 0.9989011
. O 0 0.010425238

Maximal O 0 0.0367519
cTnI O 0 0.77790064
( O 0 0.007540526
pg O 0 0.03988522
/ O 0 0.0066485372
ml O 0 0.00808183
) O 0 0.0037788225
and O 0 0.0020498908
cTnT O 0 0.9124467
levels O 0 0.00092689815
were O 0 0.0007948224
significantly O 0 0.00093519426
increased O 0 0.0009959661
in O 0 0.0008849731
DOX B-Chemical 1 0.9997389
rats O 0 0.0023546685
compared O 0 0.00039335914
with O 0 0.0006702824
controls O 0 0.0017738988
( O 0 0.0011736574
p O 0 0.001066225
= O 0 0.0012165096
0 O 0 0.0011658198
. O 0 0.0009459773
006 O 0 0.041331194
, O 0 0.0020732032
0 O 0 0.0026223348
. O 0 0.0026467934
007 O 0 0.15015233
) O 0 0.00837201
. O 0 0.0076568257

cTnI O 0 0.7832784
( O 0 0.011356772
ng O 0 0.012477937
/ O 0 0.009046654
ml O 0 0.011915622
) O 0 0.0070369365
, O 0 0.004925497
CK O 0 0.99765813
- O 0 0.014020525
MB O 0 0.99762803
mass O 0 0.008762331
and O 0 0.00223474
CK O 0 0.994393
remained O 0 0.0017315518
unchanged O 0 0.0015294178
in O 0 0.0018267392
DOX B-Chemical 1 0.999461
rats O 0 0.005792807
compared O 0 0.0021203433
with O 0 0.0046273717
controls O 0 0.012485254
. O 0 0.008757947

All O 0 0.026275685
markers O 0 0.027274383
remained O 0 0.020715116
stable O 0 0.0195622
in O 0 0.019451862
controls O 0 0.030637408
. O 0 0.026025176

Analysis O 0 0.012180012
of O 0 0.006032227
data O 0 0.0045369323
revealed O 0 0.0027590021
a O 0 0.0023984804
significant O 0 0.0015615477
correlation O 0 0.0009788658
between O 0 0.0007817441
maximal O 0 0.0014057296
cTnT O 0 0.93823874
and O 0 0.0012218968
ED O 0 0.45647168
and O 0 0.0012416273
ES O 0 0.62513816
LV O 0 0.99849236
diameters O 0 0.0202563
/ O 0 0.0040357495
BW O 0 0.34334388
( O 0 0.0009789589
r O 0 0.0007619798
= O 0 0.0007793809
0 O 0 0.0006229791
. O 0 0.0003770503
81 O 0 0.00080729043
and O 0 0.00059129455
0 O 0 0.00081733137
. O 0 0.00056452997
65 O 0 0.0010603777
; O 0 0.0014055135
p O 0 0.0014209677
< O 0 0.0016510519
0 O 0 0.0023913146
. O 0 0.0025092368
0001 O 0 0.022774963
) O 0 0.007827816
. O 0 0.0075857798

A O 0 0.024561917
significant O 0 0.0054455567
relationship O 0 0.002914085
was O 0 0.0023717538
observed O 0 0.0013145637
between O 0 0.0010346773
maximal O 0 0.0016338713
cTnT O 0 0.8917568
and O 0 0.0010038214
the O 0 0.00069852313
extent O 0 0.00054282433
of O 0 0.0012050827
myocardial O 0 0.9997223
morphological O 0 0.017398506
changes O 0 0.00179742
, O 0 0.001352769
and O 0 0.001041778
between O 0 0.0009278269
LV O 0 0.99778336
diameters O 0 0.028532464
/ O 0 0.00842298
BW O 0 0.35151088
and O 0 0.0041815527
histological O 0 0.4362149
findings O 0 0.022033226
. O 0 0.010663703

CONCLUSIONS O 0 0.4646109
: O 0 0.009332429
Among O 0 0.0072127543
markers O 0 0.006099967
of O 0 0.005862637
ischemic B-Disease 0 0.99992573
injury I-Disease 0 0.9988938
after O 0 0.001580615
DOX B-Chemical 1 0.9998147
in O 0 0.0011653735
rats O 0 0.008579193
, O 0 0.0017277759
cTnT O 0 0.8907664
showed O 0 0.00046354005
the O 0 0.00048559168
greatest O 0 0.0008430085
ability O 0 0.00060954044
to O 0 0.0006343246
detect O 0 0.00074851996
myocardial B-Disease 2 0.9999496
damage I-Disease 2 0.9621307
assessed O 0 0.001280951
by O 0 0.0017632338
echocardiographic O 0 0.08425914
detection O 0 0.002630454
and O 0 0.0039464203
histological O 0 0.4961887
changes O 0 0.010496764
. O 0 0.009372961

Although O 0 0.006392057
there O 0 0.0036461407
was O 0 0.003097093
a O 0 0.0025740685
discrepancy O 0 0.0017509868
between O 0 0.00090918323
the O 0 0.0009592414
amount O 0 0.00067544007
of O 0 0.0014895059
cTnI O 0 0.949552
and O 0 0.0014448204
cTnT O 0 0.9676705
after O 0 0.00052256964
DOX B-Chemical 1 0.9997212
, O 0 0.0009677158
probably O 0 0.00074837334
due O 0 0.0003216858
to O 0 0.00035535204
heterogeneity O 0 0.00067171204
in O 0 0.0004067039
cross O 0 0.0011821908
- O 0 0.0010173386
reactivities O 0 0.017223476
of O 0 0.0006343397
mAbs O 0 0.0015922147
to O 0 0.00041209828
various O 0 0.00119261
cTnI O 0 0.94079953
and O 0 0.0008453671
cTnT O 0 0.9630891
forms O 0 0.0006476901
, O 0 0.00073566637
it O 0 0.0004558481
is O 0 0.0003631138
likely O 0 0.00034526965
that O 0 0.00037831315
cTnT O 0 0.9323956
in O 0 0.00039995232
rats O 0 0.0014553776
after O 0 0.00035035508
DOX B-Chemical 1 0.99970835
indicates O 0 0.0005276474
cell O 0 0.022880582
damage O 0 0.6313763
determined O 0 0.00040015575
by O 0 0.00049087283
the O 0 0.00037186936
magnitude O 0 0.00035583036
of O 0 0.00079123134
injury O 0 0.9607734
induced O 0 0.00095799373
and O 0 0.0008903777
that O 0 0.000547093
cTnT O 0 0.94882166
should O 0 0.00027136254
be O 0 0.00039067963
a O 0 0.00047526523
useful O 0 0.0004182756
marker O 0 0.00046661627
for O 0 0.00032714018
the O 0 0.00042705768
prediction O 0 0.00053864083
of O 0 0.0008630632
experimentally O 0 0.0013650551
induced O 0 0.003725827
cardiotoxicity B-Disease 2 0.9999896
and O 0 0.0039136508
possibly O 0 0.009881022
for O 0 0.0028878574
cardioprotective O 0 0.95492005
experiments O 0 0.0068134237
. O 0 0.009015729

Octreotide B-Chemical 0 0.9989361
- O 0 0.023135923
induced O 0 0.011682368
hypoxemia B-Disease 0 0.99756
and O 0 0.013641518
pulmonary B-Disease 2 0.9976834
hypertension I-Disease 2 0.9999331
in O 0 0.012855562
premature O 0 0.49309334
neonates O 0 0.18188085
. O 0 0.014257452

The O 0 0.008398098
authors O 0 0.0062881974
report O 0 0.006877388
2 O 0 0.003649437
cases O 0 0.0034963542
of O 0 0.0028689557
premature O 0 0.030439368
neonates O 0 0.008992641
who O 0 0.0038668094
had O 0 0.0026997493
enterocutaneous O 0 0.99034613
fistula B-Disease 0 0.9730767
complicating O 0 0.937727
necrotizing B-Disease 0 0.9999143
enterocolitis I-Disease 0 0.99984026
. O 0 0.04568965

Pulmonary B-Disease 0 0.95425105
hypertension I-Disease 2 0.99972516
developed O 0 0.007396065
after O 0 0.0021444447
administration O 0 0.024917223
of O 0 0.002549122
a O 0 0.0040754783
somatostatin O 0 0.9967204
analogue O 0 0.60565174
, O 0 0.0060366425
octreotide B-Chemical 1 0.99960667
, O 0 0.0026553809
to O 0 0.0014774742
enhance O 0 0.0014795256
resolution O 0 0.008983642
of O 0 0.0040312945
the O 0 0.005761221
fistula B-Disease 0 0.82194364
. O 0 0.0109941065

The O 0 0.0065625045
authors O 0 0.0043785977
discuss O 0 0.0027907195
the O 0 0.0022627413
mechanism O 0 0.0018543378
of O 0 0.0015611782
the O 0 0.0011263776
occurrence O 0 0.0019922273
of O 0 0.0011619262
this O 0 0.000900965
complication O 0 0.30302492
and O 0 0.00094983773
recommend O 0 0.0005415804
caution O 0 0.00079831417
of O 0 0.0009397898
its O 0 0.0015941238
use O 0 0.00128958
in O 0 0.0013530098
high O 0 0.002732845
- O 0 0.005667427
risk O 0 0.13647455
premature O 0 0.28566286
neonates O 0 0.12441719
. O 0 0.009794507

The O 0 0.007928627
risk O 0 0.014366398
of O 0 0.0053743958
venous B-Disease 0 0.87717354
thromboembolism I-Disease 0 0.9999695
in O 0 0.003948507
women O 0 0.32009676
prescribed O 0 0.47557968
cyproterone B-Chemical 0 0.99999666
acetate I-Chemical 0 0.99972373
in O 0 0.0019536484
combination O 0 0.007499574
with O 0 0.0063599893
ethinyl B-Chemical 0 0.9999951
estradiol I-Chemical 1 0.99998367
: O 0 0.005661841
a O 0 0.0014667623
nested O 0 0.0019268685
cohort O 0 0.0023562864
analysis O 0 0.0016089841
and O 0 0.0019289312
case O 0 0.0026555224
- O 0 0.004508093
control O 0 0.0038004336
study O 0 0.0071214153
. O 0 0.008056781

BACKGROUND O 0 0.92267734
: O 0 0.063329905
Cyproterone B-Chemical 0 0.99989235
acetate I-Chemical 0 0.99931085
combined O 0 0.02515104
with O 0 0.014566922
ethinyl B-Chemical 0 0.9999918
estradiol I-Chemical 1 0.99998903
( O 0 0.12447387
CPA B-Chemical 1 0.99990726
/ O 0 0.08273959
EE B-Chemical 1 0.9944224
) O 0 0.002731412
is O 0 0.00064917334
licensed O 0 0.0014897302
in O 0 0.00045574317
the O 0 0.00053835526
UK O 0 0.008744313
for O 0 0.00031202685
the O 0 0.00039174632
treatment O 0 0.00067252107
of O 0 0.000774299
women O 0 0.10331959
with O 0 0.0013028055
acne B-Disease 2 0.9997844
and O 0 0.008759865
hirsutism B-Disease 0 0.99995005
and O 0 0.0016671377
is O 0 0.00073525746
also O 0 0.0006884742
a O 0 0.0010128146
treatment O 0 0.0013301165
option O 0 0.0017315149
for O 0 0.0014848171
polycystic B-Disease 0 0.99978036
ovary I-Disease 0 0.99484384
syndrome I-Disease 0 0.99642605
( O 0 0.15222022
PCOS B-Disease 2 0.9997404
) O 0 0.038595438
. O 0 0.010078681

Previous O 0 0.009334175
studies O 0 0.0057504997
have O 0 0.0033142336
demonstrated O 0 0.002386217
an O 0 0.0027287065
increased O 0 0.0022571017
risk O 0 0.029199144
of O 0 0.0022535857
venous B-Disease 0 0.97045624
thromboembolism I-Disease 0 0.999995
( O 0 0.049765103
VTE B-Disease 2 0.9999683
) O 0 0.004368594
associated O 0 0.0012106138
with O 0 0.0015576896
CPA B-Chemical 1 0.9998012
/ O 0 0.018092938
EE B-Chemical 1 0.9418903
compared O 0 0.00056691543
with O 0 0.00093499414
conventional O 0 0.0014787714
combined O 0 0.011925524
oral B-Chemical 1 0.99106264
contraceptives I-Chemical 1 0.9999714
( O 0 0.10308798
COCs O 0 0.99431336
) O 0 0.021133743
. O 0 0.009571461

We O 0 0.00943366
believe O 0 0.006428152
the O 0 0.0047377017
results O 0 0.0039499667
of O 0 0.0038754425
those O 0 0.0038726784
studies O 0 0.0031624536
may O 0 0.0025368023
have O 0 0.0024643007
been O 0 0.0030803517
affected O 0 0.0029743337
by O 0 0.004396515
residual O 0 0.006780182
confounding O 0 0.016621336
. O 0 0.010160869

METHODS O 0 0.012118274
: O 0 0.008535594
Using O 0 0.0049031805
the O 0 0.0036637818
General O 0 0.0061146594
Practice O 0 0.00764536
Research O 0 0.005870807
Database O 0 0.002349394
we O 0 0.00062451285
conducted O 0 0.0006116486
a O 0 0.0007814432
cohort O 0 0.0011370623
analysis O 0 0.00071803044
and O 0 0.0006625061
case O 0 0.0007247574
- O 0 0.00091459544
control O 0 0.00040988618
study O 0 0.0004886404
nested O 0 0.0006843263
within O 0 0.00024482078
a O 0 0.0005111497
population O 0 0.0007195669
of O 0 0.000593049
women O 0 0.018847374
aged O 0 0.0008349438
between O 0 0.00028605334
15 O 0 0.00036628736
and O 0 0.00044127082
39 O 0 0.0007520126
years O 0 0.0006869972
with O 0 0.000789451
acne B-Disease 2 0.9996886
, O 0 0.012078244
hirsutism B-Disease 0 0.9999275
or O 0 0.0022165722
PCOS B-Disease 2 0.9997954
to O 0 0.00071467715
estimate O 0 0.00056314556
the O 0 0.000913599
risk O 0 0.04797321
of O 0 0.0034985242
VTE B-Disease 2 0.9999255
associated O 0 0.0048976745
with O 0 0.00918936
CPA B-Chemical 1 0.9996666
/ O 0 0.1664902
EE B-Chemical 1 0.9869539
. O 0 0.010805632

RESULTS O 0 0.024530562
: O 0 0.008204787
The O 0 0.0040958715
age O 0 0.0057235346
- O 0 0.0034988583
adjusted O 0 0.0020209635
incidence O 0 0.0036532416
rate O 0 0.0012193338
ratio O 0 0.0014673524
for O 0 0.0010408745
CPA B-Chemical 1 0.99967754
/ O 0 0.015243052
EE B-Chemical 1 0.9486726
versus O 0 0.0006994681
conventional O 0 0.0009587205
COCs O 0 0.9456714
was O 0 0.000667559
2 O 0 0.0005673224
. O 0 0.00037681154
20 O 0 0.0005200647
[ O 0 0.000970631
95 O 0 0.00090403925
% O 0 0.00065015507
confidence O 0 0.0014222587
interval O 0 0.0010014961
( O 0 0.001635758
CI O 0 0.24551907
) O 0 0.0015840734
1 O 0 0.00095134706
. O 0 0.0007623589
35 O 0 0.0012661947
- O 0 0.0018864054
3 O 0 0.0016522635
. O 0 0.0020473106
58 O 0 0.0052520814
] O 0 0.0077764434
. O 0 0.007457957

Using O 0 0.008333125
as O 0 0.0049301283
the O 0 0.0033564826
reference O 0 0.0023287802
group O 0 0.002318254
women O 0 0.015835505
who O 0 0.0021715164
were O 0 0.0009611012
not O 0 0.0007345071
using O 0 0.0007188517
oral O 0 0.7654612
contraception O 0 0.9867922
, O 0 0.0010755002
had O 0 0.00041803683
no O 0 0.00032898327
recent O 0 0.0005861871
pregnancy O 0 0.35315198
or O 0 0.0011680919
menopausal O 0 0.99994135
symptoms O 0 0.99615896
, O 0 0.0014162678
the O 0 0.00049582205
case O 0 0.00063098903
- O 0 0.00080674374
control O 0 0.00035269654
analysis O 0 0.0004698634
gave O 0 0.00044555933
an O 0 0.0005174752
adjusted O 0 0.0005716698
odds O 0 0.0023795925
ratio O 0 0.0009092136
( O 0 0.0013764073
OR O 0 0.16720298
( O 0 0.0012560921
adj O 0 0.1840914
) O 0 0.0013866482
) O 0 0.0007735744
of O 0 0.00047694164
7 O 0 0.00043231505
. O 0 0.00029942274
44 O 0 0.00062288146
( O 0 0.000578334
95 O 0 0.0007842301
% O 0 0.00061526045
CI O 0 0.04193857
3 O 0 0.00040185612
. O 0 0.00031594522
67 O 0 0.0008279974
- O 0 0.0006318032
15 O 0 0.00035598953
. O 0 0.00034718637
08 O 0 0.007156297
) O 0 0.0007219053
for O 0 0.00042153266
CPA B-Chemical 1 0.9993
/ O 0 0.00588273
EE B-Chemical 1 0.9202193
use O 0 0.0005066808
compared O 0 0.0002920907
with O 0 0.00052338914
an O 0 0.0010819295
OR O 0 0.20003682
( O 0 0.0012911573
adj O 0 0.13474375
) O 0 0.0009794775
of O 0 0.0005710419
2 O 0 0.00053104886
. O 0 0.00034165476
58 O 0 0.0007753467
( O 0 0.0006585703
95 O 0 0.0008844221
% O 0 0.000715885
CI O 0 0.046301343
1 O 0 0.00055361324
. O 0 0.00039925083
60 O 0 0.0005528434
- O 0 0.0007995878
4 O 0 0.0005508987
. O 0 0.0005474498
18 O 0 0.000833605
) O 0 0.0013368247
for O 0 0.0009901337
use O 0 0.001844266
of O 0 0.0032322956
conventional O 0 0.0069211735
COCs O 0 0.98104286
. O 0 0.010026971

CONCLUSIONS O 0 0.43360242
: O 0 0.008844696
We O 0 0.003996074
have O 0 0.002509863
demonstrated O 0 0.0018940693
an O 0 0.002320644
increased O 0 0.002084371
risk O 0 0.0553422
of O 0 0.0030416949
VTE B-Disease 2 0.99994326
associated O 0 0.0016441293
with O 0 0.00089749746
the O 0 0.000685297
use O 0 0.0007766304
of O 0 0.0015336893
CPA B-Chemical 1 0.99986887
/ O 0 0.03158707
EE B-Chemical 1 0.98101586
in O 0 0.0007544602
women O 0 0.07097356
with O 0 0.001454233
acne B-Disease 2 0.99982065
, O 0 0.019769067
hirsutism B-Disease 0 0.9999306
or O 0 0.0028059832
PCOS B-Disease 2 0.9998242
although O 0 0.0010445516
residual O 0 0.0014429656
confounding O 0 0.0026943858
by O 0 0.0017649627
indication O 0 0.0020340339
cannot O 0 0.009998602
be O 0 0.0047970405
excluded O 0 0.0082298145
. O 0 0.008408882

The O 0 0.008096352
effect O 0 0.005380557
of O 0 0.0048652235
treatment O 0 0.005154561
with O 0 0.0041188933
gum B-Chemical 1 0.99347186
Arabic I-Chemical 1 0.6914559
on O 0 0.0024960365
gentamicin B-Chemical 1 0.9996966
nephrotoxicity B-Disease 2 0.99998665
in O 0 0.003987029
rats O 0 0.013451736
: O 0 0.0049039954
a O 0 0.004606348
preliminary O 0 0.0076790387
study O 0 0.008683816
. O 0 0.009307098

In O 0 0.0071542785
the O 0 0.004791111
present O 0 0.002766448
work O 0 0.0026336042
we O 0 0.001299019
assessed O 0 0.001089318
the O 0 0.0009933591
effect O 0 0.00086256705
of O 0 0.0010600899
treatment O 0 0.0014527243
of O 0 0.001198859
rats O 0 0.0048954817
with O 0 0.0013101159
gum B-Chemical 1 0.9942638
Arabic I-Chemical 1 0.62736577
on O 0 0.0007819974
acute B-Disease 0 0.97477484
renal I-Disease 0 0.99846137
failure I-Disease 0 0.93823874
induced O 0 0.0037311793
by O 0 0.0060140425
gentamicin B-Chemical 1 0.9996536
( O 0 0.033916876
GM B-Chemical 1 0.9967713
) O 0 0.107463405
nephrotoxicity B-Disease 2 0.9999362
. O 0 0.013533949

Rats O 0 0.023811253
were O 0 0.0059803105
treated O 0 0.0042245793
with O 0 0.0028842343
the O 0 0.0022998916
vehicle O 0 0.066384874
( O 0 0.0025885403
2 O 0 0.0011723187
mL O 0 0.002606126
/ O 0 0.0015626366
kg O 0 0.0021254348
of O 0 0.0008085593
distilled O 0 0.0063333614
water O 0 0.0058628144
and O 0 0.00075377536
5 O 0 0.000492973
% O 0 0.0006012139
w O 0 0.0014794763
/ O 0 0.0016948582
v O 0 0.022278508
cellulose O 0 0.8444541
, O 0 0.0010172005
10 O 0 0.00047036528
days O 0 0.00038461993
) O 0 0.0009876159
, O 0 0.0008243796
gum B-Chemical 1 0.9651379
Arabic I-Chemical 1 0.5293893
( O 0 0.0011051375
2 O 0 0.00052259857
mL O 0 0.0013686782
/ O 0 0.0008724394
kg O 0 0.0011726996
of O 0 0.00046398543
a O 0 0.00061187014
10 O 0 0.00045608974
% O 0 0.0005242024
w O 0 0.0013861319
/ O 0 0.0015156548
v O 0 0.012619386
aqueous O 0 0.2259753
suspension O 0 0.0056615667
of O 0 0.0012073823
gum B-Chemical 1 0.9956173
Arabic I-Chemical 1 0.8116299
powder O 0 0.65008473
, O 0 0.0010580992
orally O 0 0.0030508735
for O 0 0.00032580245
10 O 0 0.0003955156
days O 0 0.00033681164
) O 0 0.00086470204
, O 0 0.0005819591
or O 0 0.0005088457
gum B-Chemical 1 0.9798202
Arabic I-Chemical 1 0.54017407
concomitantly O 0 0.016848294
with O 0 0.0011624193
GM B-Chemical 1 0.9954835
( O 0 0.0022047805
80mg O 0 0.98779416
/ O 0 0.0017474114
kg O 0 0.0028756217
/ O 0 0.0010022504
day O 0 0.00041002023
intramuscularly O 0 0.0039663767
, O 0 0.00062823656
during O 0 0.00034291466
the O 0 0.0004441874
last O 0 0.00041150078
six O 0 0.00047795728
days O 0 0.0006758583
of O 0 0.001285111
the O 0 0.0017896395
treatment O 0 0.0039476654
period O 0 0.0038969726
) O 0 0.010388193
. O 0 0.008024047

Nephrotoxicity B-Disease 2 0.99801874
was O 0 0.0063033192
assessed O 0 0.0031095522
by O 0 0.0025711993
measuring O 0 0.001488495
the O 0 0.0013889412
concentrations O 0 0.0024830396
of O 0 0.0022180658
creatinine B-Chemical 1 0.9992187
and O 0 0.0026473687
urea B-Chemical 1 0.9989208
in O 0 0.0007554005
the O 0 0.0007197514
plasma O 0 0.027898526
and O 0 0.0013043346
reduced O 0 0.010394561
glutathione B-Chemical 1 0.9999912
( O 0 0.07872299
GSH B-Chemical 1 0.999987
) O 0 0.0035829744
in O 0 0.000625532
the O 0 0.000800972
kidney O 0 0.9110541
cortex O 0 0.36382645
, O 0 0.0012937258
and O 0 0.001004981
by O 0 0.0011323057
light O 0 0.0019127012
microscopic O 0 0.0045750607
examination O 0 0.0034175906
of O 0 0.004579206
kidney O 0 0.9322878
sections O 0 0.019297406
. O 0 0.009920435

The O 0 0.006813305
results O 0 0.004787875
indicated O 0 0.0029634063
that O 0 0.0021136808
concomitant O 0 0.0043008127
treatment O 0 0.003166319
with O 0 0.0022895029
gum B-Chemical 1 0.9965383
Arabic I-Chemical 1 0.82018685
and O 0 0.0025832164
GM B-Chemical 1 0.9910256
significantly O 0 0.0018201154
increased O 0 0.001989243
creatinine B-Chemical 1 0.9991479
and O 0 0.0016766781
urea B-Chemical 1 0.9985605
by O 0 0.00073839014
about O 0 0.0004874964
183 O 0 0.012002589
and O 0 0.00059271423
239 O 0 0.013067641
% O 0 0.0006278082
, O 0 0.00062080234
respectively O 0 0.00080586196
( O 0 0.00054039643
compared O 0 0.00023537538
to O 0 0.00035994162
432 O 0 0.024729146
and O 0 0.00052799005
346 O 0 0.03559509
% O 0 0.0005839098
, O 0 0.0005939649
respectively O 0 0.0008057561
, O 0 0.00053998665
in O 0 0.00034111092
rats O 0 0.0010013093
treated O 0 0.00062947714
with O 0 0.0007854672
cellulose O 0 0.9573734
and O 0 0.0031894813
GM B-Chemical 1 0.99770975
) O 0 0.004200287
, O 0 0.0007781869
and O 0 0.00050279085
decreased O 0 0.0005895677
that O 0 0.0003407753
of O 0 0.0008280649
cortical O 0 0.29918516
GSH B-Chemical 1 0.99998295
by O 0 0.000920033
21 O 0 0.0007979262
% O 0 0.00057505956
( O 0 0.00049323624
compared O 0 0.0002177916
to O 0 0.00031001022
27 O 0 0.00059613556
% O 0 0.00041736427
in O 0 0.00031022102
the O 0 0.0004387332
cellulose O 0 0.76670736
plus O 0 0.0009308862
GM B-Chemical 1 0.9900973
group O 0 0.0013625516
) O 0 0.0015906957
The O 0 0.00055173744
GM B-Chemical 1 0.9904502
- O 0 0.0015807977
induced O 0 0.0006465698
proximal O 0 0.0019274122
tubular B-Disease 2 0.97919935
necrosis I-Disease 2 0.999925
appeared O 0 0.001036456
to O 0 0.0004915089
be O 0 0.00048098995
slightly O 0 0.0004857481
less O 0 0.0004568508
severe O 0 0.05045348
in O 0 0.0005049062
rats O 0 0.0014454026
given O 0 0.000477031
GM B-Chemical 1 0.95162576
together O 0 0.00077442883
with O 0 0.0011918525
gum B-Chemical 1 0.98858184
Arabic I-Chemical 1 0.4352771
than O 0 0.0009174219
in O 0 0.0012146424
those O 0 0.0021777807
given O 0 0.0021217905
GM B-Chemical 1 0.9754498
and O 0 0.00808079
cellulose O 0 0.96136385
. O 0 0.012420241

It O 0 0.010554616
could O 0 0.0049548675
be O 0 0.0038089731
inferred O 0 0.003075235
that O 0 0.0022656606
gum B-Chemical 1 0.9837016
Arabic I-Chemical 1 0.60194033
treatment O 0 0.003328324
has O 0 0.0010428792
induced O 0 0.0011730962
a O 0 0.0014210282
modest O 0 0.00163977
amelioration O 0 0.3015054
of O 0 0.0011011055
some O 0 0.0009041641
of O 0 0.0010551775
the O 0 0.0010897703
histological O 0 0.24635865
and O 0 0.0021452939
biochemical O 0 0.039827082
indices O 0 0.005555528
of O 0 0.010989441
GM B-Chemical 1 0.9989254
nephrotoxicity B-Disease 2 0.9999622
. O 0 0.016853888

Further O 0 0.008805289
work O 0 0.005976998
is O 0 0.003268647
warranted O 0 0.0018708932
on O 0 0.0011989035
the O 0 0.001110615
effect O 0 0.0008835155
of O 0 0.0009900305
the O 0 0.0007814179
treatments O 0 0.0017440112
on O 0 0.0004998997
renal O 0 0.9604821
functional O 0 0.0010372803
aspects O 0 0.00055121025
in O 0 0.00048692583
models O 0 0.00083054305
of O 0 0.0013302312
chronic B-Disease 2 0.995148
renal I-Disease 2 0.99917907
failure I-Disease 2 0.9856917
, O 0 0.0019671444
and O 0 0.00096883584
on O 0 0.00065698987
the O 0 0.0011057483
mechanism O 0 0.0019576468
( O 0 0.0034665302
s O 0 0.0037921926
) O 0 0.0061631333
involved O 0 0.005196472
. O 0 0.007883902

Increased O 0 0.0093808975
frequency O 0 0.005190924
of O 0 0.004444483
venous B-Disease 0 0.81202155
thromboembolism I-Disease 0 0.9999591
with O 0 0.0027179099
the O 0 0.0014485995
combination O 0 0.0019411609
of O 0 0.001995647
docetaxel B-Chemical 1 0.9997322
and O 0 0.0027601712
thalidomide B-Chemical 1 0.9999254
in O 0 0.0015129606
patients O 0 0.008113031
with O 0 0.0025650128
metastatic O 0 0.99828905
androgen O 0 0.99981874
- O 0 0.021430971
independent O 0 0.0053800163
prostate B-Disease 2 0.9992262
cancer I-Disease 2 0.9995592
. O 0 0.01743644

STUDY O 0 0.023957774
OBJECTIVE O 0 0.30451474
: O 0 0.0052350336
To O 0 0.002125032
evaluate O 0 0.0012047407
the O 0 0.0012946596
frequency O 0 0.0012730749
of O 0 0.0015512968
venous B-Disease 0 0.9450023
thromboembolism I-Disease 0 0.99999464
( O 0 0.036151703
VTE B-Disease 2 0.9999672
) O 0 0.0028076128
in O 0 0.0006059518
patients O 0 0.0017913576
with O 0 0.00082620967
advanced O 0 0.24688217
androgen O 0 0.9998858
- O 0 0.005132031
independent O 0 0.000903542
prostate B-Disease 2 0.9994517
cancer I-Disease 2 0.9998142
who O 0 0.009560154
were O 0 0.00086054794
treated O 0 0.0010615926
with O 0 0.0013140154
docetaxel B-Chemical 1 0.9994103
alone O 0 0.0015737998
or O 0 0.0015079365
in O 0 0.0018715148
combination O 0 0.0055842926
with O 0 0.008754702
thalidomide B-Chemical 1 0.99983037
. O 0 0.012892553

DESIGN O 0 0.032941885
: O 0 0.017947039
Retrospective O 0 0.035178486
analysis O 0 0.010773188
of O 0 0.009510202
a O 0 0.0105916
randomized O 0 0.010714466
phase O 0 0.01378576
II O 0 0.08025593
trial O 0 0.01880322
. O 0 0.016041555

SETTING O 0 0.04273012
: O 0 0.022178126
National O 0 0.019770507
Institutes O 0 0.026695661
of O 0 0.012350318
Health O 0 0.016907904
clinical O 0 0.019981975
research O 0 0.014115636
center O 0 0.015008417
. O 0 0.015623337

PATIENTS O 0 0.016450275
: O 0 0.009512138
Seventy O 0 0.010929309
men O 0 0.038260274
, O 0 0.0048090406
aged O 0 0.0043425546
50 O 0 0.0033616482
- O 0 0.0027254983
80 O 0 0.0019384162
years O 0 0.0021272132
, O 0 0.002087221
with O 0 0.0021648277
advanced O 0 0.2129958
androgen O 0 0.9996117
- O 0 0.015819803
independent O 0 0.00601058
prostate B-Disease 2 0.99912065
cancer I-Disease 2 0.9995246
. O 0 0.018811077

INTERVENTION O 0 0.014395913
: O 0 0.006223009
Each O 0 0.002839578
patient O 0 0.0026379153
received O 0 0.0015971657
either O 0 0.0013858106
intravenous O 0 0.40144882
docetaxel B-Chemical 1 0.99952364
30 O 0 0.0008840329
mg O 0 0.28990692
/ O 0 0.0022337183
m2 O 0 0.012691708
/ O 0 0.0010214507
week O 0 0.00029251043
for O 0 0.00025413558
3 O 0 0.0002796169
consecutive O 0 0.0003043915
weeks O 0 0.00024563234
, O 0 0.00040838812
followed O 0 0.00025728374
by O 0 0.0003954468
1 O 0 0.0003621617
week O 0 0.00024433807
off O 0 0.00041176207
, O 0 0.0004571531
or O 0 0.0003012343
the O 0 0.00031550907
combination O 0 0.0005048626
of O 0 0.0004743216
continuous O 0 0.00063674926
oral O 0 0.6250101
thalidomide B-Chemical 1 0.9999486
200 O 0 0.0063190036
mg O 0 0.15087004
every O 0 0.0004817581
evening O 0 0.0015844121
plus O 0 0.000930005
the O 0 0.001437233
same O 0 0.0019651495
docetaxel B-Chemical 1 0.9989498
regimen O 0 0.03351476
. O 0 0.008565196

This O 0 0.01192621
4 O 0 0.0063340967
- O 0 0.0053524044
week O 0 0.002464323
cycle O 0 0.0032348498
was O 0 0.0015895782
repeated O 0 0.0012674385
until O 0 0.00087481143
there O 0 0.0008638716
was O 0 0.0011307219
evidence O 0 0.0013243448
of O 0 0.0024016635
excessive O 0 0.26311207
toxicity B-Disease 2 0.99898094
or O 0 0.008997224
disease O 0 0.9779182
progression O 0 0.9397777
. O 0 0.014197503

MEASUREMENTS O 0 0.04010358
AND O 0 0.012269728
MAIN O 0 0.18104675
RESULTS O 0 0.012028752
: O 0 0.0038964527
None O 0 0.00353449
of O 0 0.0019907923
23 O 0 0.0019236249
patients O 0 0.0018739945
who O 0 0.0015357543
received O 0 0.0009670384
docetaxel B-Chemical 1 0.9988992
alone O 0 0.0012288046
developed O 0 0.0031010658
VTE B-Disease 2 0.999961
, O 0 0.0011562208
whereas O 0 0.00046617034
9 O 0 0.0004460253
of O 0 0.00044645256
47 O 0 0.0010003948
patients O 0 0.0013305879
( O 0 0.00076088775
19 O 0 0.000766288
% O 0 0.0005999202
) O 0 0.0007176125
who O 0 0.0007094505
received O 0 0.0005524052
docetaxel B-Chemical 1 0.9985372
plus O 0 0.0010314059
thalidomide B-Chemical 1 0.99994624
developed O 0 0.01989307
VTE B-Disease 2 0.9999589
( O 0 0.0031660362
p O 0 0.0022550325
= O 0 0.0025395027
0 O 0 0.0025974964
. O 0 0.002499306
025 O 0 0.12500751
) O 0 0.008523085
. O 0 0.00751738

CONCLUSION O 0 0.634365
: O 0 0.008158988
The O 0 0.0034768987
addition O 0 0.002162065
of O 0 0.003141708
thalidomide B-Chemical 1 0.9997814
to O 0 0.0027405743
docetaxel B-Chemical 1 0.99945515
in O 0 0.0012150933
the O 0 0.001016523
treatment O 0 0.0016699113
of O 0 0.0024684183
prostate B-Disease 2 0.9996846
cancer I-Disease 2 0.99983037
significantly O 0 0.006053105
increases O 0 0.0020133818
the O 0 0.0022409586
frequency O 0 0.003931493
of O 0 0.010738192
VTE B-Disease 2 0.9997781
. O 0 0.011577701

Clinicians O 0 0.012945206
should O 0 0.004824765
be O 0 0.0040678713
aware O 0 0.0032822883
of O 0 0.0027041053
this O 0 0.0020853488
potential O 0 0.002792031
complication O 0 0.32787642
when O 0 0.002041936
adding O 0 0.006727165
thalidomide B-Chemical 1 0.9998566
to O 0 0.006033888
chemotherapeutic O 0 0.98292094
regimens O 0 0.301455
. O 0 0.011743704

Ticlopidine B-Chemical 0 0.9987386
- O 0 0.08917179
induced O 0 0.0794539
cholestatic B-Disease 0 0.999752
hepatitis I-Disease 2 0.99968755
. O 0 0.11130985

OBJECTIVE O 0 0.43109262
: O 0 0.007928838
To O 0 0.0034752288
report O 0 0.004612317
2 O 0 0.0021879682
cases O 0 0.0025128196
of O 0 0.0030567541
ticlopidine B-Chemical 1 0.99998975
- O 0 0.041926347
induced O 0 0.010037916
cholestatic B-Disease 0 0.99999726
hepatitis I-Disease 2 0.9999957
, O 0 0.009607401
investigate O 0 0.00046187674
its O 0 0.0016112946
mechanism O 0 0.0009523292
, O 0 0.0008544999
and O 0 0.0005115443
compare O 0 0.00027895282
the O 0 0.0004610977
observed O 0 0.00040087008
main O 0 0.0008103666
characteristics O 0 0.0009890434
with O 0 0.0011977946
those O 0 0.0018527085
of O 0 0.002144504
the O 0 0.0026580796
published O 0 0.0038770402
cases O 0 0.009613469
. O 0 0.008374567

CASE O 0 0.48034862
SUMMARIES O 0 0.11124092
: O 0 0.0066672037
Two O 0 0.0037302722
patients O 0 0.004326224
developed O 0 0.003285994
prolonged O 0 0.08068362
cholestatic B-Disease 0 0.99999213
hepatitis I-Disease 2 0.9999888
after O 0 0.0014250963
receiving O 0 0.010586618
ticlopidine B-Chemical 1 0.9999802
following O 0 0.0009469706
percutaneous O 0 0.0035090148
coronary O 0 0.7391465
angioplasty O 0 0.78092164
, O 0 0.0012215792
with O 0 0.0007683837
complete O 0 0.00080524303
remission O 0 0.114592426
during O 0 0.0009052891
the O 0 0.001424167
follow O 0 0.0017615098
- O 0 0.0036909133
up O 0 0.0033277504
period O 0 0.00458495
. O 0 0.007265638

T O 0 0.83840716
- O 0 0.013300708
cell O 0 0.01222775
stimulation O 0 0.0051945406
by O 0 0.0028101078
therapeutic O 0 0.011871967
concentration O 0 0.00363013
of O 0 0.0030871965
ticlopidine B-Chemical 1 0.99998665
was O 0 0.0014676277
demonstrated O 0 0.0007717969
in O 0 0.000732668
vitro O 0 0.0011029057
in O 0 0.0007522843
the O 0 0.0009239197
patients O 0 0.0033124932
, O 0 0.0018108314
but O 0 0.0014236518
not O 0 0.001686827
in O 0 0.0024993808
healthy O 0 0.023345767
controls O 0 0.011438164
. O 0 0.008513367

DISCUSSION O 0 0.15871103
: O 0 0.02510899
Cholestatic B-Disease 0 0.999826
hepatitis I-Disease 2 0.9999069
is O 0 0.0051947813
a O 0 0.0033393565
rare O 0 0.012596817
complication O 0 0.40463266
of O 0 0.0017774149
the O 0 0.0013435807
antiplatelet O 0 0.9871295
agent O 0 0.831951
ticlopidine B-Chemical 1 0.9999938
; O 0 0.0063996688
several O 0 0.000954668
cases O 0 0.0016451323
have O 0 0.0008967837
been O 0 0.0011491063
reported O 0 0.001357133
but O 0 0.0012860285
few O 0 0.0012197072
in O 0 0.0019968294
the O 0 0.0031936516
English O 0 0.008529679
literature O 0 0.008635079
. O 0 0.008616444

Our O 0 0.007924713
patients O 0 0.008377055
developed O 0 0.0061174883
jaundice B-Disease 2 0.9987784
following O 0 0.0029936642
treatment O 0 0.0037079148
with O 0 0.0024761846
ticlopidine B-Chemical 1 0.99998105
and O 0 0.001704566
showed O 0 0.00069479365
the O 0 0.0006569642
clinical O 0 0.0031797981
and O 0 0.00074864016
laboratory O 0 0.0010120411
characteristics O 0 0.0008071193
of O 0 0.0028156517
cholestatic B-Disease 0 0.99999666
hepatitis I-Disease 2 0.9999943
, O 0 0.01746225
which O 0 0.0018554934
resolved O 0 0.0024168957
after O 0 0.0009681161
discontinuation O 0 0.50721955
of O 0 0.0031168226
the O 0 0.004423199
drug O 0 0.7394205
. O 0 0.009252334

Hepatitis B-Disease 0 0.9979759
may O 0 0.00675794
develop O 0 0.0039564446
weeks O 0 0.0019311659
after O 0 0.0012215787
discontinuation O 0 0.23908721
of O 0 0.0013887984
the O 0 0.0010577112
drug O 0 0.37208548
and O 0 0.0010811822
may O 0 0.0006628651
run O 0 0.0007798408
a O 0 0.0008035119
prolonged O 0 0.0021037895
course O 0 0.0010568007
, O 0 0.0011139367
but O 0 0.000701553
complete O 0 0.00074648514
remission O 0 0.20583643
was O 0 0.0010596925
observed O 0 0.0009393647
in O 0 0.0016219444
all O 0 0.0023727717
reported O 0 0.0046623447
cases O 0 0.010697046
. O 0 0.008750453

An O 0 0.012577295
objective O 0 0.008140525
causality O 0 0.009078416
assessment O 0 0.003194016
revealed O 0 0.0022112466
that O 0 0.001540548
the O 0 0.0016503636
adverse O 0 0.88665974
drug O 0 0.7205055
event O 0 0.029916568
was O 0 0.0014764147
probably O 0 0.0018792705
related O 0 0.0011642644
to O 0 0.0015186758
the O 0 0.002076629
use O 0 0.0035428773
of O 0 0.009615917
ticlopidine B-Chemical 1 0.99992406
. O 0 0.013439321

The O 0 0.011684758
mechanisms O 0 0.010818254
of O 0 0.009279807
this O 0 0.009883182
ticlopidine B-Chemical 1 0.99992406
- O 0 0.06217889
induced O 0 0.019968899
cholestasis B-Disease 2 0.99992144
are O 0 0.021993082
unclear O 0 0.015933136
. O 0 0.014523701

Immune O 0 0.50077903
mechanisms O 0 0.009743905
may O 0 0.004662398
be O 0 0.0031075426
involved O 0 0.001916603
in O 0 0.0014734223
the O 0 0.0013774255
drug O 0 0.37656778
' O 0 0.0023641165
s O 0 0.0024626087
hepatotoxicity B-Disease 2 0.99998605
, O 0 0.002225312
as O 0 0.00092552725
suggested O 0 0.00081545033
by O 0 0.0011699906
the O 0 0.0014492575
T O 0 0.83687216
- O 0 0.0037257525
cell O 0 0.008635821
stimulation O 0 0.0042477525
study O 0 0.0039937757
reported O 0 0.005113853
here O 0 0.006007937
. O 0 0.00838559

CONCLUSIONS O 0 0.84416723
: O 0 0.050887916
Cholestatic B-Disease 0 0.999833
hepatitis I-Disease 2 0.9998957
is O 0 0.0068275365
a O 0 0.004664828
rare O 0 0.017863909
adverse O 0 0.93353146
effect O 0 0.0030090716
of O 0 0.0057242783
ticlopidine B-Chemical 1 0.9999684
that O 0 0.0032485132
may O 0 0.003640114
be O 0 0.005072446
immune O 0 0.45645756
mediated O 0 0.010229668
. O 0 0.011636327

Patients O 0 0.013556964
receiving O 0 0.0072439443
the O 0 0.0041923285
drug O 0 0.1582877
should O 0 0.0017657005
be O 0 0.0016564352
monitored O 0 0.00096568314
with O 0 0.0014120626
liver O 0 0.6762553
function O 0 0.0018393762
tests O 0 0.0026263713
along O 0 0.001460002
with O 0 0.0018426338
complete O 0 0.0021863272
blood O 0 0.020318499
cell O 0 0.02607699
counts O 0 0.008700882
. O 0 0.009022728

This O 0 0.011480842
complication O 0 0.11313063
will O 0 0.003700638
be O 0 0.0026057863
observed O 0 0.0014442247
even O 0 0.0014754428
less O 0 0.001175364
often O 0 0.001444517
in O 0 0.00082605536
the O 0 0.0007915448
future O 0 0.0008080948
as O 0 0.0011958207
ticlopidine B-Chemical 1 0.99997795
is O 0 0.0012921182
being O 0 0.0015433531
replaced O 0 0.0011050988
by O 0 0.0013428719
the O 0 0.0015549822
newer O 0 0.0909539
antiplatelet O 0 0.99156487
agent O 0 0.9138776
clopidogrel B-Chemical 1 0.9998566
. O 0 0.01294989

Epithelial O 0 0.8643011
sodium B-Chemical 1 0.99888283
channel O 0 0.6827172
( O 0 0.011477596
ENaC O 0 0.95604616
) O 0 0.005445051
subunit O 0 0.0043284204
mRNA O 0 0.0018680796
and O 0 0.0012951646
protein O 0 0.0017958737
expression O 0 0.0014838036
in O 0 0.0011361258
rats O 0 0.004900008
with O 0 0.003005454
puromycin B-Chemical 0 0.98901165
aminonucleoside I-Chemical 0 0.99996984
- O 0 0.12767349
induced O 0 0.045653727
nephrotic B-Disease 2 0.9999784
syndrome I-Disease 0 0.9974349
. O 0 0.01826079

In O 0 0.009186305
experimental O 0 0.010674364
nephrotic B-Disease 2 0.99988234
syndrome I-Disease 0 0.9930178
, O 0 0.022594413
urinary O 0 0.9924482
sodium B-Chemical 1 0.9999095
excretion O 0 0.98913527
is O 0 0.0021370864
decreased O 0 0.0020938464
during O 0 0.0011202744
the O 0 0.001550596
early O 0 0.0029628498
phase O 0 0.003698406
of O 0 0.004012149
the O 0 0.005709398
disease O 0 0.889432
. O 0 0.011648766

The O 0 0.009475404
molecular O 0 0.016131481
mechanism O 0 0.007149877
( O 0 0.0064370595
s O 0 0.0048777824
) O 0 0.0050165164
leading O 0 0.0040998706
to O 0 0.0029953425
salt O 1 0.97836703
retention O 0 0.009609978
has O 0 0.0029056529
not O 0 0.003480595
been O 0 0.0048409607
completely O 0 0.006291619
elucidated O 0 0.011583104
. O 0 0.010761039

The O 0 0.008701414
rate O 0 0.0070029823
- O 0 0.0062086047
limiting O 0 0.0038479285
constituent O 0 0.0056681423
of O 0 0.0031182633
collecting O 0 0.006319561
duct O 0 0.9191428
sodium B-Chemical 1 0.9997936
transport O 0 0.026089828
is O 0 0.0019525787
the O 0 0.0021512797
epithelial O 0 0.41506287
sodium B-Chemical 1 0.9998197
channel O 0 0.7476181
( O 0 0.029569903
ENaC O 0 0.9638107
) O 0 0.016797645
. O 0 0.009168029

We O 0 0.0077572945
examined O 0 0.004282832
the O 0 0.0036642272
abundance O 0 0.0028958898
of O 0 0.0037172043
ENaC O 0 0.94803095
subunit O 0 0.012793361
mRNAs O 0 0.0032340537
and O 0 0.001652568
proteins O 0 0.0026962287
in O 0 0.0020226873
puromycin B-Chemical 0 0.9829081
aminonucleoside I-Chemical 0 0.9999765
( O 0 0.13577501
PAN B-Chemical 1 0.9998523
) O 0 0.05305317
- O 0 0.010250734
induced O 0 0.0104231285
nephrotic B-Disease 2 0.9999659
syndrome I-Disease 0 0.9962065
. O 0 0.016667206

The O 0 0.0071662962
time O 0 0.004656759
courses O 0 0.0047609354
of O 0 0.0042568417
urinary O 0 0.9799202
sodium B-Chemical 1 0.99991536
excretion O 0 0.9964187
, O 0 0.008377189
plasma O 0 0.24498035
aldosterone B-Chemical 1 0.99993086
concentration O 0 0.009718659
and O 0 0.0022130902
proteinuria B-Disease 2 0.9999703
were O 0 0.0008889408
studied O 0 0.00069752475
in O 0 0.0006049913
male O 0 0.008607415
Sprague O 0 0.415981
- O 0 0.0018331662
Dawley O 0 0.034161802
rats O 0 0.0012486113
treated O 0 0.0008601544
with O 0 0.00083574856
a O 0 0.0011733656
single O 0 0.0011043955
dose O 0 0.0053578783
of O 0 0.002316318
either O 0 0.0040992424
PAN B-Chemical 1 0.9992142
or O 0 0.007185027
vehicle O 0 0.4267565
. O 0 0.010059336

The O 0 0.0067972546
relative O 0 0.004245498
amounts O 0 0.0035105722
of O 0 0.004169036
alphaENaC O 0 0.23866975
, O 0 0.0033731542
betaENaC O 0 0.2046079
and O 0 0.0018136142
gammaENaC O 0 0.5583141
mRNAs O 0 0.0012394901
were O 0 0.0005576759
determined O 0 0.00038972474
in O 0 0.00046357448
kidneys O 0 0.011585572
from O 0 0.0004901371
these O 0 0.0005944989
rats O 0 0.0012702389
by O 0 0.00062036345
real O 0 0.00086044054
- O 0 0.0009500495
time O 0 0.00043269084
quantitative O 0 0.0009555416
TaqMan O 0 0.05973122
PCR O 0 0.037703138
, O 0 0.0011991988
and O 0 0.00095232605
the O 0 0.0009510738
amounts O 0 0.0011922427
of O 0 0.0021532767
proteins O 0 0.0045857355
by O 0 0.0051140715
Western O 0 0.120474316
blot O 0 0.07302244
. O 0 0.009320921

The O 0 0.00803283
kinetics O 0 0.0071431478
of O 0 0.0062713614
urinary O 0 0.9660613
sodium B-Chemical 1 0.9997942
excretion O 0 0.97437376
and O 0 0.0025439253
the O 0 0.0015716809
appearance O 0 0.0040331767
of O 0 0.0032453155
proteinuria B-Disease 2 0.999938
were O 0 0.0022315527
comparable O 0 0.0013750297
with O 0 0.0023481683
those O 0 0.0038818906
reported O 0 0.0049676774
previously O 0 0.006697348
. O 0 0.008991825

Sodium B-Chemical 0 0.99866486
retention O 0 0.012939631
occurred O 0 0.0052622794
on O 0 0.0030806256
days O 0 0.002734851
2 O 0 0.0029162627
, O 0 0.0030992914
3 O 0 0.0023528277
and O 0 0.0027947754
6 O 0 0.0027152884
after O 0 0.0032719825
PAN B-Chemical 1 0.9960218
injection O 0 0.03519376
. O 0 0.011556255

A O 0 0.030648096
significant O 0 0.0069664703
up O 0 0.005133595
- O 0 0.004836081
regulation O 0 0.0021036512
of O 0 0.0024473348
alphaENaC O 0 0.09958055
and O 0 0.0017515728
betaENaC O 0 0.14234172
mRNA O 0 0.0009363725
abundance O 0 0.0005537088
on O 0 0.00040639273
days O 0 0.00048733054
1 O 0 0.0006547315
and O 0 0.0007152031
2 O 0 0.00079830235
preceded O 0 0.0014524381
sodium B-Chemical 1 0.99854636
retention O 0 0.0027013056
on O 0 0.0010811894
days O 0 0.0015786011
2 O 0 0.0025260937
and O 0 0.0037839187
3 O 0 0.005345279
. O 0 0.007082666

Conversely O 0 0.012029092
, O 0 0.008117587
down O 0 0.005984969
- O 0 0.004719995
regulation O 0 0.0019466699
of O 0 0.0024567307
alphaENaC O 0 0.22640753
, O 0 0.0022706587
betaENaC O 0 0.18476926
and O 0 0.0012434551
gammaENaC O 0 0.46664327
mRNA O 0 0.0007102874
expression O 0 0.00048502494
on O 0 0.00026907865
day O 0 0.0003353613
3 O 0 0.0003320055
occurred O 0 0.00033880337
in O 0 0.0003126951
the O 0 0.00035966752
presence O 0 0.00039800434
of O 0 0.0008037014
high O 0 0.0024399676
aldosterone B-Chemical 1 0.99995697
concentrations O 0 0.016154533
, O 0 0.0012419701
and O 0 0.0006911027
was O 0 0.0005531192
followed O 0 0.00046097024
by O 0 0.00073497335
a O 0 0.0010548674
return O 0 0.0015610661
of O 0 0.0021134615
sodium B-Chemical 1 0.9997087
excretion O 0 0.9490885
to O 0 0.0028726303
control O 0 0.0039065396
values O 0 0.0059949346
. O 0 0.0076589854

The O 0 0.008121428
amounts O 0 0.005896802
of O 0 0.0062019066
alphaENaC O 0 0.17466272
, O 0 0.004718199
betaENaC O 0 0.15246487
and O 0 0.002644794
gammaENaC O 0 0.37578556
proteins O 0 0.0022146124
were O 0 0.0014102584
not O 0 0.0012624686
increased O 0 0.0019581758
during O 0 0.002081643
PAN B-Chemical 1 0.99956244
- O 0 0.020358723
induced O 0 0.009565749
sodium B-Chemical 1 0.99958855
retention O 0 0.07387483
. O 0 0.01130129

In O 0 0.0076855663
conclusion O 0 0.0054153423
, O 0 0.0069205156
ENaC O 0 0.88489264
mRNA O 0 0.0035798226
expression O 0 0.0025694158
, O 0 0.0021772813
especially O 0 0.0018271288
alphaENaC O 0 0.16331807
, O 0 0.0011863415
is O 0 0.0005803057
increased O 0 0.00061501685
in O 0 0.00043539933
the O 0 0.00044305582
very O 0 0.0005420741
early O 0 0.0007734177
phase O 0 0.0006944603
of O 0 0.00047968182
the O 0 0.00039234167
experimental O 0 0.0005067864
model O 0 0.0006685153
of O 0 0.002020044
PAN B-Chemical 1 0.9999325
- O 0 0.016432622
induced O 0 0.0033075837
nephrotic B-Disease 2 0.9999957
syndrome I-Disease 0 0.9910731
in O 0 0.0012253409
rats O 0 0.013024032
, O 0 0.0011769744
but O 0 0.0006015664
appears O 0 0.00046325778
to O 0 0.0005318662
escape O 0 0.0021150745
from O 0 0.00081621594
the O 0 0.00092499517
regulation O 0 0.0010880465
by O 0 0.0022964212
aldosterone B-Chemical 1 0.9995722
after O 0 0.0018648764
day O 0 0.00319981
3 O 0 0.0049102334
. O 0 0.0066914246

Sub O 0 0.6833961
- O 0 0.013783426
chronic O 0 0.62331223
low O 0 0.005825585
dose O 0 0.12138773
gamma B-Chemical 0 0.9315694
- I-Chemical 0 0.04007482
vinyl I-Chemical 0 0.9969812
GABA I-Chemical 1 0.9999871
( O 0 0.05099631
vigabatrin B-Chemical 1 0.9999871
) O 0 0.013316725
inhibits O 0 0.002320582
cocaine B-Chemical 1 0.9999536
- O 0 0.006177637
induced O 0 0.0019003554
increases O 0 0.0020573265
in O 0 0.002890018
nucleus O 0 0.01634824
accumbens O 0 0.9872363
dopamine B-Chemical 1 0.9991967
. O 0 0.009798495

RATIONALE O 0 0.09385682
: O 0 0.017350249
gamma B-Chemical 0 0.6115375
- I-Chemical 0 0.027485682
Vinyl I-Chemical 0 0.9890717
GABA I-Chemical 1 0.99991393
( O 0 0.100275114
GVG B-Chemical 0 0.9999646
) O 0 0.05803674
irreversibly O 0 0.7568271
inhibits O 0 0.02542801
GABA B-Chemical 1 0.99993014
- O 0 0.20111397
transaminase O 0 0.9998049
. O 0 0.01598932

This O 0 0.013112746
non O 0 0.013359905
- O 0 0.010449858
receptor O 0 0.08005452
mediated O 0 0.0035300292
inhibition O 0 0.0051420545
requires O 0 0.0015541451
de O 0 0.02364801
novo O 0 0.031713333
synthesis O 0 0.09232221
for O 0 0.0022443614
restoration O 0 0.0045105633
of O 0 0.004761532
functional O 0 0.033787902
GABA B-Chemical 1 0.99991345
catabolism O 0 0.96218973
. O 0 0.012796178

OBJECTIVES O 0 0.02446573
: O 0 0.007076412
Given O 0 0.0032299564
its O 0 0.0037213494
preclinical O 0 0.0061070397
success O 0 0.0038605162
for O 0 0.0011992817
treating O 0 0.011223999
substance B-Disease 0 0.99932015
abuse I-Disease 0 0.9998939
and O 0 0.0020579523
the O 0 0.0008524143
increased O 0 0.0010591223
risk O 0 0.05158328
of O 0 0.0011553735
visual B-Disease 2 0.5476147
field I-Disease 2 0.001657886
defects I-Disease 2 0.0060479664
( O 0 0.0024022942
VFD B-Disease 0 0.99648464
) O 0 0.0012298233
associated O 0 0.00048253476
with O 0 0.00042529448
cumulative O 0 0.0030162025
lifetime O 0 0.045524813
exposure O 0 0.0025683308
, O 0 0.00067459117
we O 0 0.0002342995
explored O 0 0.00029551302
the O 0 0.0003443719
effects O 0 0.0007371914
of O 0 0.0008064985
sub O 0 0.06587312
- O 0 0.003856246
chronic O 0 0.87649834
low O 0 0.0017062317
dose O 0 0.18429363
GVG B-Chemical 0 0.9999949
on O 0 0.0007191563
cocaine B-Chemical 1 0.9999777
- O 0 0.0046192547
induced O 0 0.0008242374
increases O 0 0.0007631366
in O 0 0.00086432975
nucleus O 0 0.0036123027
accumbens O 0 0.95500106
( O 0 0.0033562288
NAcc O 0 0.40975603
) O 0 0.008512003
dopamine B-Chemical 1 0.9995807
( O 0 0.014321566
DA B-Chemical 1 0.99879587
) O 0 0.012213205
. O 0 0.007947387

METHODS O 0 0.010811434
: O 0 0.007547994
Using O 0 0.0040857624
in O 0 0.0026860673
vivo O 0 0.0028932928
microdialysis O 0 0.26907942
, O 0 0.0016758392
we O 0 0.00068474433
compared O 0 0.000614486
acute O 0 0.7990433
exposure O 0 0.009774577
( O 0 0.0019658755
450 O 0 0.0042832447
mg O 0 0.2172389
/ O 0 0.0017269372
kg O 0 0.0047033923
) O 0 0.000872326
to O 0 0.00036593832
an O 0 0.00054573733
identical O 0 0.00031418446
sub O 0 0.009388225
- O 0 0.0016866792
chronic O 0 0.81245786
exposure O 0 0.008628207
( O 0 0.0012939372
150 O 0 0.0009980378
mg O 0 0.10750032
/ O 0 0.000851437
kg O 0 0.0009427727
per O 0 0.00023068325
day O 0 0.00028906658
for O 0 0.00028000987
3 O 0 0.00036825842
days O 0 0.00037365078
) O 0 0.0009349835
, O 0 0.0007094624
followed O 0 0.0004961788
by O 0 0.0008973257
1 O 0 0.0011223183
- O 0 0.0014940446
or O 0 0.0012069225
3 O 0 0.0017415738
- O 0 0.0029462297
day O 0 0.002732567
washout O 0 0.0086079035
. O 0 0.006950641

Finally O 0 0.009162204
, O 0 0.0060730823
we O 0 0.0026146565
examined O 0 0.0019003791
the O 0 0.0017777077
low O 0 0.0017351989
dose O 0 0.0047643282
of O 0 0.0015276298
150 O 0 0.0023456083
mg O 0 0.3169736
/ O 0 0.0025229105
kg O 0 0.005536952
( O 0 0.0011200663
50 O 0 0.0009532829
mg O 0 0.061697558
/ O 0 0.001359338
kg O 0 0.0017095113
per O 0 0.0005855941
day O 0 0.00091040647
) O 0 0.0017387262
using O 0 0.0012393361
a O 0 0.0019981177
similar O 0 0.0019367888
washout O 0 0.0066344063
period O 0 0.0047784187
. O 0 0.007604487

RESULTS O 0 0.039723422
: O 0 0.014150696
Sub O 0 0.5865943
- O 0 0.010888504
chronic O 0 0.9653248
GVG B-Chemical 0 0.99997854
exposure O 0 0.032498613
inhibited O 0 0.0023667722
the O 0 0.0009884551
effect O 0 0.0008186822
of O 0 0.0013787484
cocaine B-Chemical 1 0.9999304
for O 0 0.0005909894
3 O 0 0.00052654586
days O 0 0.00039305887
, O 0 0.000628482
which O 0 0.0005643583
exceeded O 0 0.0004558511
in O 0 0.00052685785
magnitude O 0 0.00062743225
and O 0 0.0010424583
duration O 0 0.0014053442
the O 0 0.0016223514
identical O 0 0.0019550845
acute O 0 0.9415376
dose O 0 0.22197072
. O 0 0.009733332

CONCLUSIONS O 0 0.69775337
: O 0 0.016267903
Sub O 0 0.61448497
- O 0 0.008104471
chronic O 0 0.7243908
low O 0 0.0045468328
dose O 0 0.30469564
GVG B-Chemical 0 0.9999919
potentiates O 0 0.23520705
and O 0 0.0015843759
extends O 0 0.0010281908
the O 0 0.0006925878
inhibition O 0 0.002283203
of O 0 0.0019655423
cocaine B-Chemical 1 0.99998224
- O 0 0.0077298195
induced O 0 0.00091335434
increases O 0 0.00084761943
in O 0 0.0010274209
dopamine B-Chemical 1 0.99984014
, O 0 0.0012644791
effectively O 0 0.00086493697
reducing O 0 0.0010928368
cumulative O 0 0.0050915387
exposures O 0 0.043700706
and O 0 0.0023607835
the O 0 0.0025731728
risk O 0 0.12088016
for O 0 0.0049323486
VFDS O 0 0.7422046
. O 0 0.009558108

MR O 2 0.8678776
imaging O 0 0.016245233
with O 0 0.0057067517
quantitative O 0 0.005339679
diffusion O 0 0.009824974
mapping O 0 0.0030552505
of O 0 0.0049748737
tacrolimus B-Chemical 1 0.9999589
- O 0 0.043720845
induced O 0 0.008350044
neurotoxicity B-Disease 2 0.99988675
in O 0 0.0050456226
organ O 0 0.48771438
transplant O 0 0.8085513
patients O 0 0.06630637
. O 0 0.010696573

Our O 0 0.008090585
objective O 0 0.0069931378
was O 0 0.0036857806
to O 0 0.0023746192
investigate O 0 0.0015716793
brain O 0 0.14517096
MR O 2 0.9812881
imaging O 0 0.006171474
findings O 0 0.0017993947
and O 0 0.0009426456
the O 0 0.0006592139
utility O 0 0.0007633625
of O 0 0.0009030574
diffusion O 0 0.04577388
- O 0 0.0019673898
weighted O 0 0.0015591246
( O 0 0.001780526
DW O 0 0.809687
) O 0 0.0014121125
imaging O 0 0.001800314
in O 0 0.00053181493
organ O 0 0.024989048
transplant O 0 0.19996257
patients O 0 0.0033360445
who O 0 0.0023966508
developed O 0 0.0028740675
neurologic O 0 0.998911
symptoms O 0 0.94941163
during O 0 0.0036381122
tacrolimus B-Chemical 1 0.999925
therapy O 0 0.32854286
. O 0 0.010412604

Brain O 0 0.7308228
MR O 2 0.9301304
studies O 0 0.0067371544
, O 0 0.004834544
including O 0 0.0031768677
DW O 0 0.7326516
imaging O 0 0.008308809
, O 0 0.0018618618
were O 0 0.0010103171
prospectively O 0 0.0011199937
performed O 0 0.0006724502
in O 0 0.00067403214
14 O 0 0.0008272818
organ O 0 0.011871011
transplant O 0 0.16681609
patients O 0 0.0046641775
receiving O 0 0.006741055
tacrolimus B-Chemical 1 0.99993956
who O 0 0.026132902
developed O 0 0.020670319
neurologic B-Disease 0 0.99975437
complications I-Disease 0 0.99494284
. O 0 0.013547784

In O 0 0.0069773044
each O 0 0.0040635057
patient O 0 0.0043779197
who O 0 0.003765666
had O 0 0.002071034
abnormalities O 0 0.016171055
on O 0 0.0010082062
the O 0 0.0010893444
initial O 0 0.0014341677
MR O 2 0.96681523
study O 0 0.0014754018
, O 0 0.0012564607
a O 0 0.0011119144
follow O 0 0.0008361899
- O 0 0.001613622
up O 0 0.0011956039
MR O 2 0.8889775
study O 0 0.0016417367
was O 0 0.0014889245
performed O 0 0.0017390795
1 O 0 0.002690969
month O 0 0.0028990402
later O 0 0.0046477937
. O 0 0.0075834077

Apparent O 0 0.022164315
diffusion O 0 0.018782638
coefficient O 0 0.010696003
( O 0 0.0064413734
ADC O 0 0.6672886
) O 0 0.0033491177
values O 0 0.0014221483
on O 0 0.0009257694
the O 0 0.0011060716
initial O 0 0.0015243813
MR O 2 0.9451878
study O 0 0.0016875096
were O 0 0.0013480643
correlated O 0 0.0012351784
with O 0 0.0020126451
reversibility O 0 0.08996624
of O 0 0.00445832
the O 0 0.0059056887
lesions O 0 0.7021832
. O 0 0.0112262415

Of O 0 0.0099131465
the O 0 0.005347969
14 O 0 0.003980916
patients O 0 0.00464137
, O 0 0.0028194445
5 O 0 0.0015522733
( O 0 0.0015895738
35 O 0 0.0010684208
. O 0 0.0006505293
7 O 0 0.00065455376
% O 0 0.0007986413
) O 0 0.0008994159
had O 0 0.00050049706
white B-Disease 0 0.0057571754
matter I-Disease 0 0.0046478333
abnormalities I-Disease 0 0.34927696
, O 0 0.0010711071
1 O 0 0.00063989876
( O 0 0.00066025706
7 O 0 0.00041255302
. O 0 0.0003038603
1 O 0 0.0004197007
% O 0 0.0005268051
) O 0 0.00070597586
had O 0 0.00050561916
putaminal B-Disease 0 0.9972536
hemorrhage I-Disease 2 0.9999143
, O 0 0.0010756119
and O 0 0.00066312513
8 O 0 0.0005792144
( O 0 0.00071879005
57 O 0 0.0009477237
. O 0 0.00043113905
1 O 0 0.0006216727
% O 0 0.00082460506
) O 0 0.001113375
had O 0 0.00079174805
normal O 0 0.0015955847
findings O 0 0.0023706653
on O 0 0.0017142068
initial O 0 0.004131945
MR O 2 0.98055124
images O 0 0.011927497
. O 0 0.009338374

Among O 0 0.011533345
the O 0 0.005542664
5 O 0 0.0034616664
patients O 0 0.00387022
with O 0 0.0021728727
white B-Disease 0 0.01876527
matter I-Disease 0 0.010771583
abnormalities I-Disease 0 0.3952307
, O 0 0.0015173669
4 O 0 0.00069555844
patients O 0 0.0014071654
( O 0 0.00085854303
80 O 0 0.00065724796
. O 0 0.00035780243
0 O 0 0.000542777
% O 0 0.00052882964
) O 0 0.00060962525
showed O 0 0.0002994307
higher O 0 0.00034041144
than O 0 0.00030605015
normal O 0 0.00088471675
ADC O 0 0.46038777
values O 0 0.00044685448
on O 0 0.00030983088
initial O 0 0.0006591939
MR O 2 0.9575878
images O 0 0.0012370098
, O 0 0.00086609565
and O 0 0.00067343947
all O 0 0.00061466906
showed O 0 0.00068055006
complete O 0 0.0009263076
resolution O 0 0.0035317002
on O 0 0.0012339201
follow O 0 0.0019311014
- O 0 0.004119048
up O 0 0.0038512892
images O 0 0.008598028
. O 0 0.0081521915

The O 0 0.007017136
remaining O 0 0.0051350296
1 O 0 0.003947217
patient O 0 0.0038013114
( O 0 0.002872726
20 O 0 0.0016858893
. O 0 0.0010486325
0 O 0 0.0012238146
% O 0 0.0011216343
) O 0 0.0011460606
showed O 0 0.00057696545
lower O 0 0.0006639599
than O 0 0.0005408525
normal O 0 0.0014544422
ADC O 0 0.5558865
value O 0 0.0009171915
and O 0 0.0010171798
showed O 0 0.0009812253
incomplete O 0 0.002507706
resolution O 0 0.012625727
with O 0 0.00331252
cortical B-Disease 0 0.38736314
laminar I-Disease 0 0.10216124
necrosis I-Disease 2 0.99904114
. O 0 0.0126820905

Diffusion O 0 0.4826046
- O 0 0.010970416
weighted O 0 0.0065875934
imaging O 0 0.007838189
may O 0 0.0026413838
be O 0 0.0019745764
useful O 0 0.0015328601
in O 0 0.0010953139
predicting O 0 0.0010392626
the O 0 0.0010499997
outcomes O 0 0.0019784067
of O 0 0.0014481677
the O 0 0.0016068668
lesions O 0 0.45169047
of O 0 0.01083959
tacrolimus B-Chemical 1 0.9999716
- O 0 0.08938873
induced O 0 0.029993596
neurotoxicity B-Disease 2 0.9998554
. O 0 0.01467795

L B-Chemical 1 0.9438894
- I-Chemical 1 0.035891734
arginine I-Chemical 1 0.91635734
transport O 0 0.018178659
in O 0 0.006224413
humans O 0 0.011088472
with O 0 0.008995566
cortisol B-Chemical 1 0.99795675
- O 0 0.030170217
induced O 0 0.019354781
hypertension B-Disease 2 0.9997539
. O 0 0.018586917

A O 0 0.11415048
deficient O 0 0.011841866
L B-Chemical 1 0.95038563
- I-Chemical 1 0.050835315
arginine I-Chemical 1 0.9909758
- O 0 0.058924455
nitric B-Chemical 0 0.99968123
oxide I-Chemical 0 0.9988311
system O 0 0.01015454
is O 0 0.0029573992
implicated O 0 0.0028616593
in O 0 0.003865177
cortisol B-Chemical 1 0.99780387
- O 0 0.01864779
induced O 0 0.013672492
hypertension B-Disease 2 0.9998067
. O 0 0.014797916

We O 0 0.0096953735
investigate O 0 0.0050687515
whether O 0 0.0039976514
abnormalities O 0 0.10199791
in O 0 0.00597382
L B-Chemical 1 0.9775548
- I-Chemical 1 0.03775767
arginine I-Chemical 1 0.9745694
uptake O 0 0.064907305
contribute O 0 0.003884593
to O 0 0.004438499
this O 0 0.006789347
deficiency O 0 0.7589362
. O 0 0.013096041

Eight O 0 0.055170152
healthy O 0 0.060361423
men O 0 0.1470334
were O 0 0.036613718
recruited O 0 0.03711897
. O 0 0.037178528

Hydrocortisone B-Chemical 0 0.9998228
acetate I-Chemical 0 0.9991528
( O 0 0.011572562
50 O 0 0.004993044
mg O 0 0.4052478
) O 0 0.002788165
was O 0 0.0009805234
given O 0 0.00056760205
orally O 0 0.0015373359
every O 0 0.00036025053
6 O 0 0.00035256005
hours O 0 0.00027436495
for O 0 0.00027629512
24 O 0 0.0002836239
hours O 0 0.00024228527
after O 0 0.0002445341
a O 0 0.00055993046
5 O 0 0.00047963203
- O 0 0.000711863
day O 0 0.00047519233
fixed O 0 0.00085501577
- O 0 0.0025590234
salt O 1 0.97477233
diet O 0 0.3041158
( O 0 0.004060413
150 O 0 0.0047374503
mmol O 0 0.57250863
/ O 0 0.008930519
d O 0 0.0061661713
) O 0 0.009965817
. O 0 0.008113396

Crossover O 0 0.11891056
studies O 0 0.019886108
were O 0 0.015637018
performed O 0 0.0128713595
2 O 0 0.013658993
weeks O 0 0.012315329
apart O 0 0.019098954
. O 0 0.021544896

Thirty O 0 0.010766588
milliliters O 0 0.0064314688
of O 0 0.004583109
blood O 0 0.00792222
was O 0 0.0025307392
obtained O 0 0.001863793
for O 0 0.0012945277
isolation O 0 0.0016753903
of O 0 0.0017858936
peripheral O 0 0.058612954
blood O 0 0.040972993
mononuclear O 0 0.38986552
cells O 0 0.0042527816
after O 0 0.0016560386
each O 0 0.0021795065
treatment O 0 0.0054869293
period O 0 0.0057196366
. O 0 0.008525825

L B-Chemical 1 0.9584563
- I-Chemical 1 0.03468669
arginine I-Chemical 1 0.92583954
uptake O 0 0.030475596
was O 0 0.0024466305
assessed O 0 0.001421411
in O 0 0.0013260625
mononuclear O 0 0.23486361
cells O 0 0.0031849034
incubated O 0 0.00078925095
with O 0 0.0019273371
L B-Chemical 1 0.9872656
- I-Chemical 1 0.02162212
arginine I-Chemical 1 0.9768182
( O 0 0.0018378263
1 O 0 0.00061926
to O 0 0.00044005804
300 O 0 0.001713376
micromol O 0 0.13075577
/ O 0 0.004072717
L O 0 0.5459307
) O 0 0.0015243044
, O 0 0.000660891
incorporating O 0 0.00055634225
100 O 0 0.0013330545
nmol O 0 0.684724
/ O 0 0.008183365
L O 0 0.7489064
[ B-Chemical 0 0.017040554
3H I-Chemical 0 0.7990639
] I-Chemical 0 0.005827657
- I-Chemical 0 0.00204378
l I-Chemical 0 0.010402378
- I-Chemical 0 0.0024236112
arginine I-Chemical 0 0.7192392
for O 0 0.0005843789
a O 0 0.0009026875
period O 0 0.00064879603
of O 0 0.0010138631
5 O 0 0.0010627381
minutes O 0 0.0011583219
at O 0 0.0015972225
37 O 0 0.003571371
degrees O 0 0.0116252275
C O 0 0.9264858
. O 0 0.010669852

Forearm O 0 0.5237658
[ B-Chemical 0 0.045442015
3H I-Chemical 0 0.830994
] I-Chemical 0 0.027521221
- I-Chemical 0 0.013185877
L I-Chemical 1 0.94987077
- I-Chemical 1 0.011733757
arginine I-Chemical 1 0.9065721
extraction O 0 0.0031579023
was O 0 0.0008626587
calculated O 0 0.00054054015
after O 0 0.0003979194
infusion O 0 0.0033269308
of O 0 0.0012479122
[ B-Chemical 0 0.02784673
3H I-Chemical 0 0.90041006
] I-Chemical 0 0.017435508
- I-Chemical 0 0.007237709
L I-Chemical 1 0.95086896
- I-Chemical 1 0.0038733447
arginine I-Chemical 1 0.76349807
into O 0 0.0003800628
the O 0 0.0005511233
brachial O 0 0.39428067
artery O 0 0.05151677
at O 0 0.0004262605
a O 0 0.00065346295
rate O 0 0.0005801901
of O 0 0.0009729605
100 O 0 0.0024534373
nCi O 0 0.15267238
/ O 0 0.002743105
min O 0 0.0018055352
for O 0 0.0017734986
80 O 0 0.0034960748
minutes O 0 0.003923204
. O 0 0.0064491658

Deep O 0 0.04930936
forearm O 0 0.041925244
venous O 0 0.20949152
samples O 0 0.006180855
were O 0 0.004365192
collected O 0 0.003349618
for O 0 0.0031271933
determination O 0 0.005932031
of O 0 0.007887185
L B-Chemical 1 0.9788005
- I-Chemical 1 0.05402118
arginine I-Chemical 1 0.979278
extraction O 0 0.04176184
. O 0 0.014395813

Plasma O 0 0.523738
cortisol B-Chemical 1 0.986471
concentrations O 0 0.009108695
were O 0 0.0030258177
significantly O 0 0.0022942657
raised O 0 0.0019023817
during O 0 0.00094074843
the O 0 0.0009931187
active O 0 0.0016724204
phase O 0 0.0022476409
( O 0 0.0018629761
323 O 0 0.058014557
+ O 0 0.0010345668
/ O 0 0.0022087672
- O 0 0.0010335315
43 O 0 0.00088089705
to O 0 0.00057331764
1082 O 0 0.16375509
+ O 0 0.000983254
/ O 0 0.0024006432
- O 0 0.0015130708
245 O 0 0.011992934
mmol O 0 0.44189045
/ O 0 0.0051511857
L O 0 0.41944504
, O 0 0.002547205
P O 0 0.054180544
< O 0 0.0022822416
0 O 0 0.0029862854
. O 0 0.0029485293
05 O 0 0.052532695
) O 0 0.00803973
. O 0 0.007829457

Systolic O 0 0.69175684
blood O 0 0.02169747
pressure O 0 0.030052206
was O 0 0.0062761772
elevated O 0 0.0074026207
by O 0 0.0048039155
an O 0 0.0048014307
average O 0 0.0036005105
of O 0 0.0057989955
7 O 0 0.0070315106
mm O 0 0.022606963
Hg O 0 0.883991
. O 0 0.012922675

Neither O 0 0.016779007
L B-Chemical 1 0.94078076
- I-Chemical 1 0.022717774
arginine I-Chemical 1 0.916356
transport O 0 0.008507304
into O 0 0.0013720172
mononuclear O 0 0.2591331
cells O 0 0.00554716
( O 0 0.002135712
placebo O 0 0.09755051
vs O 0 0.0017200343
active O 0 0.0012723482
, O 0 0.0008890311
26 O 0 0.0007475725
. O 0 0.0003378114
3 O 0 0.00041744625
+ O 0 0.0005468469
/ O 0 0.001390901
- O 0 0.0007318512
3 O 0 0.00033995905
. O 0 0.00024163749
6 O 0 0.00024084785
vs O 0 0.00047854855
29 O 0 0.00058812683
. O 0 0.00027746268
0 O 0 0.00051365874
+ O 0 0.00050755625
/ O 0 0.0014212107
- O 0 0.0007560945
2 O 0 0.00037866892
. O 0 0.00025996528
1 O 0 0.0003456148
pmol O 0 0.0015990143
/ O 0 0.00075550354
10 O 0 0.00029342543
000 O 0 0.00034324732
cells O 0 0.00035868926
per O 0 0.00020871087
5 O 0 0.00026448033
minutes O 0 0.00026537522
, O 0 0.0004925644
respectively O 0 0.0007055434
, O 0 0.00051847764
at O 0 0.00027854144
an O 0 0.0006214382
l B-Chemical 0 0.009329142
- I-Chemical 0 0.00238892
arginine I-Chemical 0 0.84357774
concentration O 0 0.0013180086
of O 0 0.00081603095
300 O 0 0.006975343
micromol O 0 0.28955513
/ O 0 0.0068835686
L O 0 0.6333701
) O 0 0.0017395738
nor O 0 0.000837025
L B-Chemical 1 0.96642584
- I-Chemical 1 0.00676887
arginine I-Chemical 1 0.909836
extraction O 0 0.0016510952
in O 0 0.0004560906
the O 0 0.00050028774
forearm O 0 0.09087404
( O 0 0.0006934329
at O 0 0.00025676718
80 O 0 0.00037488458
minutes O 0 0.0002570687
, O 0 0.00043521405
placebo O 0 0.01072755
vs O 0 0.0008003658
active O 0 0.0008479115
, O 0 0.0007479667
1 O 0 0.00056551275
868 O 0 0.0309076
904 O 0 0.020166513
+ O 0 0.00064594095
/ O 0 0.001519915
- O 0 0.00087022025
434 O 0 0.0019835483
962 O 0 0.021494983
vs O 0 0.00070214696
2 O 0 0.0004742375
013 O 0 0.010881548
910 O 0 0.002838876
+ O 0 0.00059828005
/ O 0 0.0013149262
- O 0 0.0008512516
770 O 0 0.01365772
619 O 0 0.008521526
disintegrations O 0 0.0010203379
per O 0 0.00023498072
minute O 0 0.0003659502
) O 0 0.0007110623
was O 0 0.00039584038
affected O 0 0.00042134587
by O 0 0.00078570226
cortisol B-Chemical 1 0.99441975
treatment O 0 0.002309584
; O 0 0.0017471743
ie O 0 0.0020427052
, O 0 0.00097487564
that O 0 0.0006631725
L B-Chemical 1 0.9673986
- I-Chemical 1 0.010941161
arginine I-Chemical 1 0.9568144
uptake O 0 0.027909705
is O 0 0.00082381774
not O 0 0.0007915368
affected O 0 0.0009525366
by O 0 0.001487608
short O 0 0.0016547889
- O 0 0.003779266
term O 0 0.0035333314
cortisol B-Chemical 1 0.99456847
treatment O 0 0.016296422
. O 0 0.009590126

We O 0 0.0077851503
conclude O 0 0.005047854
that O 0 0.0044157947
cortisol B-Chemical 1 0.99516135
- O 0 0.0064649195
induced O 0 0.002089501
increases B-Disease 0 0.0014165625
in I-Disease 0 0.0010705941
blood I-Disease 0 0.014750102
pressure I-Disease 0 0.058755267
are O 0 0.00096950016
not O 0 0.0007604898
associated O 0 0.0010140128
with O 0 0.0012120896
abnormalities O 0 0.10543767
in O 0 0.001283754
the O 0 0.0018513544
l B-Chemical 0 0.039615776
- I-Chemical 0 0.013294812
arginine I-Chemical 0 0.9626226
transport O 0 0.03468081
system O 0 0.011227185
. O 0 0.00891157

Amount O 0 0.020836307
of O 0 0.009831554
bleeding B-Disease 2 0.9973008
and O 0 0.0091914
hematoma B-Disease 2 0.9985806
size O 0 0.004940497
in O 0 0.0025990224
the O 0 0.0029378303
collagenase O 0 0.9275723
- O 0 0.011023688
induced O 0 0.0063441233
intracerebral B-Disease 0 0.9994937
hemorrhage I-Disease 2 0.9998822
rat O 0 0.11152034
model O 0 0.01139302
. O 0 0.010949534

The O 0 0.00962859
aggravated O 0 0.42460614
risk O 0 0.057734568
on O 0 0.0039416067
intracerebral B-Disease 0 0.9988716
hemorrhage I-Disease 2 0.9999546
( O 0 0.07324559
ICH B-Disease 2 0.9999534
) O 0 0.0044251713
with O 0 0.0014450983
drugs O 0 0.4828252
used O 0 0.0012689292
for O 0 0.0013059537
stroke B-Disease 2 0.99859315
patients O 0 0.0051806075
should O 0 0.0015927692
be O 0 0.0027057647
estimated O 0 0.0033367104
carefully O 0 0.0051502944
. O 0 0.007814979

We O 0 0.008227574
therefore O 0 0.0057131136
established O 0 0.004305005
sensitive O 0 0.0026098073
quantification O 0 0.0022899767
methods O 0 0.0020821877
and O 0 0.001922457
provided O 0 0.0015653201
a O 0 0.0023598245
rat O 0 0.028820774
ICH B-Disease 2 0.9998611
model O 0 0.0024717187
for O 0 0.0018284251
detection O 0 0.0035392293
of O 0 0.009467147
ICH B-Disease 2 0.9998808
deterioration O 0 0.7556135
. O 0 0.011306522

In O 0 0.01185068
ICH B-Disease 2 0.99942255
intrastriatally O 0 0.9840679
induced O 0 0.004464572
by O 0 0.0030146427
0 O 0 0.0025061592
. O 0 0.0011295646
014 O 0 0.01521029
- O 0 0.0012859704
unit O 0 0.0006614553
, O 0 0.0008995655
0 O 0 0.0008241459
. O 0 0.000466689
070 O 0 0.020895723
- O 0 0.00072447
unit O 0 0.00039289126
, O 0 0.0005728531
and O 0 0.00049424387
0 O 0 0.0006235288
. O 0 0.0003135698
350 O 0 0.0008186295
- O 0 0.000575546
unit O 0 0.00034656172
collagenase O 0 0.5188311
, O 0 0.0006884233
the O 0 0.0003306195
amount O 0 0.00024327855
of O 0 0.0006726918
bleeding B-Disease 2 0.99947494
was O 0 0.000558535
measured O 0 0.0003168801
using O 0 0.00038341255
a O 0 0.0006665867
hemoglobin O 0 0.79714555
assay O 0 0.00089083007
developed O 0 0.0007450392
in O 0 0.00043247212
the O 0 0.00044599362
present O 0 0.00037775422
study O 0 0.00074669335
and O 0 0.0007782333
was O 0 0.00070769084
compared O 0 0.0005807622
with O 0 0.0011089859
the O 0 0.0014752874
morphologically O 0 0.005695404
determined O 0 0.003403796
hematoma B-Disease 2 0.9989064
volume O 0 0.033577282
. O 0 0.009525495

The O 0 0.007343786
blood O 0 0.010405108
amounts O 0 0.0041577676
and O 0 0.0044011343
hematoma B-Disease 2 0.9983125
volumes O 0 0.00765866
were O 0 0.0015338004
significantly O 0 0.001419755
correlated O 0 0.00092374906
, O 0 0.0012208198
and O 0 0.00089425175
the O 0 0.0009403152
hematoma B-Disease 2 0.9992943
induced O 0 0.0012135733
by O 0 0.0011663741
0 O 0 0.001284023
. O 0 0.0006221997
014 O 0 0.020216102
- O 0 0.0012250195
unit O 0 0.00082137017
collagenase O 0 0.4557874
was O 0 0.0014992323
adequate O 0 0.0017103024
to O 0 0.0020615563
detect O 0 0.0033441621
ICH B-Disease 2 0.9998487
deterioration O 0 0.6653656
. O 0 0.010420255

In O 0 0.011047377
ICH B-Disease 2 0.99887913
induction O 0 0.005438816
using O 0 0.0030716707
0 O 0 0.0029536563
. O 0 0.0014836122
014 O 0 0.016314466
- O 0 0.0016396504
unit O 0 0.00085921976
collagenase O 0 0.70057756
, O 0 0.002125651
heparin B-Chemical 1 0.99645185
enhanced O 0 0.0010679425
the O 0 0.00088876096
hematoma B-Disease 2 0.99943525
volume O 0 0.0049612564
3 O 0 0.0005794728
. O 0 0.00034089797
4 O 0 0.00039643666
- O 0 0.0005354778
fold O 0 0.00051224814
over O 0 0.00024852637
that O 0 0.0003124269
seen O 0 0.00040347214
in O 0 0.00049234007
control O 0 0.00088668807
ICH B-Disease 2 0.9999089
animals O 0 0.00071096397
and O 0 0.00097068
the O 0 0.0012088917
bleeding B-Disease 2 0.9986634
7 O 0 0.0018629425
. O 0 0.0015500756
6 O 0 0.0021752445
- O 0 0.00461655
fold O 0 0.007495248
. O 0 0.008048854

Data O 0 0.0121351145
suggest O 0 0.004098183
that O 0 0.0030917902
this O 0 0.0025567717
sensitive O 0 0.002045461
hemoglobin O 0 0.84373814
assay O 0 0.0027660548
is O 0 0.0011792965
useful O 0 0.0010552454
for O 0 0.0008589971
ICH B-Disease 2 0.9999342
detection O 0 0.001160008
, O 0 0.000927066
and O 0 0.0005374321
that O 0 0.00035574829
a O 0 0.00057519285
model O 0 0.0005278315
with O 0 0.0005197119
a O 0 0.0008274371
small O 0 0.0013129602
ICH B-Disease 2 0.999962
induced O 0 0.0007703916
with O 0 0.00070479955
a O 0 0.0009985294
low O 0 0.0011145454
- O 0 0.0015549584
dose O 0 0.010616824
collagenase O 0 0.753793
should O 0 0.00044683364
be O 0 0.00060198444
used O 0 0.0005244874
for O 0 0.00051573495
evaluation O 0 0.00093643577
of O 0 0.001455516
drugs O 0 0.63489026
that O 0 0.0019501706
may O 0 0.0031195267
affect O 0 0.00444636
ICH B-Disease 2 0.99979943
. O 0 0.010055696

Estradiol B-Chemical 0 0.9996228
reduces O 0 0.024529593
seizure B-Disease 2 0.99969935
- O 0 0.028754655
induced O 0 0.0067072646
hippocampal B-Disease 0 0.9905036
injury I-Disease 0 0.9977235
in O 0 0.003588813
ovariectomized O 0 0.84419674
female O 0 0.016342683
but O 0 0.0026157845
not O 0 0.0026399624
in O 0 0.0035516785
male O 0 0.021587469
rats O 0 0.016952269
. O 0 0.010326388

Estrogens O 0 0.9948454
protect O 0 0.035557255
ovariectomized O 0 0.8323374
rats O 0 0.014533154
from O 0 0.0047051446
hippocampal B-Disease 0 0.98691285
injury I-Disease 0 0.9984296
induced O 0 0.012500143
by O 0 0.03718295
kainic B-Chemical 0 0.99999416
acid I-Chemical 0 0.9979703
- O 0 0.030647159
induced O 0 0.0042463266
status B-Disease 0 0.05706597
epilepticus I-Disease 0 0.9999634
( O 0 0.061278656
SE B-Disease 2 0.9797233
) O 0 0.018769952
. O 0 0.010209464

We O 0 0.0076278592
compared O 0 0.0040024957
the O 0 0.0037928717
effects O 0 0.005311268
of O 0 0.015447675
17beta B-Chemical 1 0.99997985
- I-Chemical 1 0.24921371
estradiol I-Chemical 1 0.9999733
in O 0 0.0016284666
adult O 0 0.002362426
male O 0 0.011279542
and O 0 0.0014652447
ovariectomized O 0 0.6655958
female O 0 0.008398408
rats O 0 0.0028216732
subjected O 0 0.00097506057
to O 0 0.0019912794
lithium B-Chemical 1 0.9999026
- O 0 0.10106986
pilocarpine B-Chemical 1 0.9999696
- O 0 0.027763072
induced O 0 0.010023209
SE B-Disease 2 0.97790444
. O 0 0.01101209

Rats O 0 0.018974371
received O 0 0.005829198
subcutaneous O 0 0.06946
injections O 0 0.028697835
of O 0 0.017229538
17beta B-Chemical 1 0.9999777
- I-Chemical 1 0.2880841
estradiol I-Chemical 1 0.99998045
( O 0 0.0054622297
2 O 0 0.0011238868
microg O 0 0.0022757004
/ O 0 0.00305874
rat O 0 0.004651139
) O 0 0.0017755148
or O 0 0.0010050826
oil O 0 0.65816605
once O 0 0.0012587431
daily O 0 0.0019027585
for O 0 0.0012218712
four O 0 0.0017033345
consecutive O 0 0.0035232091
days O 0 0.004314012
. O 0 0.007153658

SE B-Disease 2 0.73059624
was O 0 0.008512554
induced O 0 0.005602755
20 O 0 0.0038937887
h O 0 0.0024762175
following O 0 0.0020889244
the O 0 0.0020005277
second O 0 0.0021181996
injection O 0 0.004182689
and O 0 0.003205101
terminated O 0 0.005065962
3 O 0 0.0035433923
h O 0 0.0041389535
later O 0 0.005651341
. O 0 0.008623297

The O 0 0.008474487
extent O 0 0.005572664
of O 0 0.006898694
silver B-Chemical 0 0.99359703
- O 0 0.013040629
stained O 0 0.008552947
CA3 O 0 0.9920665
and O 0 0.005259587
CA1 O 0 0.9768325
hippocampal O 0 0.71267474
neurons O 0 0.015025957
was O 0 0.0017728523
evaluated O 0 0.0017139821
2 O 0 0.0023363559
days O 0 0.00248154
after O 0 0.0035466715
SE B-Disease 2 0.7955061
. O 0 0.010076768

17beta B-Chemical 1 0.9997335
- I-Chemical 1 0.30991828
Estradiol I-Chemical 1 0.9999033
did O 0 0.0042748805
not O 0 0.0023657817
alter O 0 0.0016517445
the O 0 0.001383556
onset O 0 0.0032518378
of O 0 0.0015848106
first O 0 0.0014681405
clonus O 0 0.9996573
in O 0 0.0022188027
ovariectomized O 0 0.831625
rats O 0 0.0068787755
but O 0 0.002392318
accelerated O 0 0.0050479784
it O 0 0.0039160214
in O 0 0.004503623
males O 0 0.012711201
. O 0 0.008742809

17beta B-Chemical 1 0.99972075
- I-Chemical 1 0.3335837
Estradiol I-Chemical 1 0.99990857
reduced O 0 0.0070452476
the O 0 0.0040360303
argyrophilic O 0 0.95801103
neurons O 0 0.070292786
in O 0 0.0021142352
the O 0 0.0027132274
CA1 O 0 0.9801907
and O 0 0.0057920087
CA3 O 0 0.99707747
- O 0 0.010647422
C O 0 0.92694384
sectors O 0 0.051377736
of O 0 0.0063931346
ovariectomized O 0 0.8558689
rats O 0 0.026660759
. O 0 0.010861223

In O 0 0.016989937
males O 0 0.022683145
, O 0 0.018805942
estradiol B-Chemical 1 0.99870527
increased O 0 0.012309207
the O 0 0.009307189
total O 0 0.010925877
damage O 0 0.7404365
score O 0 0.02266273
. O 0 0.016788134

These O 0 0.008658917
findings O 0 0.006756813
suggest O 0 0.002870009
that O 0 0.0022138108
the O 0 0.001961289
effects O 0 0.00304768
of O 0 0.0038919193
estradiol B-Chemical 1 0.99994373
on O 0 0.0013206726
seizure B-Disease 2 0.99985325
threshold O 0 0.0015834452
and O 0 0.0015873489
damage O 0 0.63685226
may O 0 0.0008631331
be O 0 0.00083977316
altered O 0 0.0009926358
by O 0 0.0012069196
sex O 0 0.10444816
- O 0 0.0019143122
related O 0 0.00088196783
differences O 0 0.0010397051
in O 0 0.0017787878
the O 0 0.0030946191
hormonal O 0 0.7799092
environment O 0 0.014829859
. O 0 0.009469785

Pseudoacromegaly B-Disease 0 0.26782787
induced O 0 0.012864341
by O 0 0.010107991
the O 0 0.007709734
long O 0 0.007735366
- O 0 0.008877328
term O 0 0.0064339736
use O 0 0.008815566
of O 0 0.018565226
minoxidil B-Chemical 0 0.9998803
. O 0 0.02333495

Acromegaly B-Disease 0 0.99694985
is O 0 0.009271604
an O 0 0.009905019
endocrine B-Disease 0 0.9965958
disorder I-Disease 0 0.9989808
caused O 0 0.008500071
by O 0 0.0054964274
chronic O 0 0.98747617
excessive O 0 0.74222565
growth O 0 0.35074878
hormone O 0 0.99698156
secretion O 0 0.13011345
from O 0 0.0033358412
the O 0 0.003919319
anterior O 0 0.078657605
pituitary O 0 0.9588038
gland O 0 0.700095
. O 0 0.011772505

Significant O 0 0.013047603
disfiguring O 0 0.109099284
changes O 0 0.005609379
occur O 0 0.0030664674
as O 0 0.002084186
a O 0 0.0020178757
result O 0 0.0013154423
of O 0 0.0016758634
bone O 0 0.38950843
, O 0 0.0029587438
cartilage O 0 0.1302604
, O 0 0.0013281038
and O 0 0.0008075378
soft O 0 0.0330363
tissue O 0 0.10987965
hypertrophy B-Disease 2 0.9992022
, O 0 0.0011090979
including O 0 0.00048123117
the O 0 0.0005376849
thickening O 0 0.30127865
of O 0 0.0007938547
the O 0 0.0007442527
skin O 0 0.08951638
, O 0 0.0018572577
coarsening O 0 0.5144548
of O 0 0.0015928114
facial O 0 0.30219093
features O 0 0.005849908
, O 0 0.0036722438
and O 0 0.00437856
cutis B-Disease 0 0.9713083
verticis I-Disease 0 0.99762493
gyrata I-Disease 0 0.9960626
. O 0 0.016010199

Pseudoacromegaly B-Disease 0 0.29606462
, O 0 0.007019123
on O 0 0.0029494825
the O 0 0.0024624027
other O 0 0.0019872107
hand O 0 0.0025311713
, O 0 0.0018644631
is O 0 0.0009116837
the O 0 0.0007026414
presence O 0 0.00061172084
of O 0 0.00083082565
similar O 0 0.00058114313
acromegaloid O 0 0.6946092
features O 0 0.0018311528
in O 0 0.0006226443
the O 0 0.0005908098
absence O 0 0.00044129812
of O 0 0.0012038775
elevated O 0 0.017959125
growth O 0 0.08085357
hormone O 0 0.99360365
or O 0 0.0032343655
insulin O 0 0.9896993
- O 0 0.0063187517
like O 0 0.0029659984
growth O 0 0.026952405
factor O 0 0.03676933
levels O 0 0.0069647483
. O 0 0.008874945

We O 0 0.0077033853
present O 0 0.0042320336
a O 0 0.0044967146
patient O 0 0.004124916
with O 0 0.0028694991
pseudoacromegaly B-Disease 0 0.6725329
that O 0 0.0013197552
resulted O 0 0.0010454337
from O 0 0.0010048413
the O 0 0.00095350173
long O 0 0.0011559316
- O 0 0.0014846615
term O 0 0.0008648949
use O 0 0.0012498107
of O 0 0.0025259806
minoxidil B-Chemical 0 0.9999703
at O 0 0.001979256
an O 0 0.003464258
unusually O 0 0.01768004
high O 0 0.0061507937
dose O 0 0.092675835
. O 0 0.0098182885

This O 0 0.011381941
is O 0 0.005778172
the O 0 0.003906471
first O 0 0.002728791
case O 0 0.0026946724
report O 0 0.004270012
of O 0 0.0033242065
pseudoacromegaly B-Disease 0 0.8533408
as O 0 0.002575064
a O 0 0.0033645045
side O 0 0.06681828
effect O 0 0.0037087537
of O 0 0.010875504
minoxidil B-Chemical 0 0.9999486
use O 0 0.018940635
. O 0 0.011980776

Combined O 0 0.21307659
androgen O 0 0.9985915
blockade O 0 0.8912761
- O 0 0.01993483
induced O 0 0.009857592
anemia B-Disease 2 0.99986386
in O 0 0.010670346
prostate B-Disease 2 0.999548
cancer I-Disease 2 0.9997303
patients O 0 0.13834482
without O 0 0.007874407
bone O 0 0.7178076
involvement O 0 0.1123778
. O 0 0.013089837

BACKGROUND O 0 0.47401854
: O 0 0.0073632323
To O 0 0.0029453111
determine O 0 0.001586799
the O 0 0.0018121653
onset O 0 0.0036230416
and O 0 0.0014473874
extent O 0 0.00082668057
of O 0 0.0013735461
combined O 0 0.005669626
androgen O 0 0.9998677
blockade O 0 0.8562259
( O 0 0.0076289997
CAB O 0 0.4839305
) O 0 0.0053859237
- O 0 0.002333558
induced O 0 0.0019022089
anemia B-Disease 2 0.9999397
in O 0 0.0038532382
prostate B-Disease 2 0.99971646
cancer I-Disease 2 0.9998142
patients O 0 0.10272623
without O 0 0.0054270024
bone O 0 0.7004108
involvement O 0 0.099206135
. O 0 0.010746658

PATIENTS O 0 0.016165534
AND O 0 0.0088805165
METHODS O 0 0.0066910065
: O 0 0.0052423966
Forty O 0 0.006025064
- O 0 0.003277986
two O 0 0.0015717235
patients O 0 0.002378944
with O 0 0.0014608273
biopsy O 0 0.02418381
- O 0 0.0029947602
proven O 0 0.009244216
prostatic B-Disease 0 0.9998617
adenocarcinoma I-Disease 0 0.99998045
[ O 0 0.034957845
26 O 0 0.0014344095
with O 0 0.0008002235
stage O 0 0.0052240537
C O 0 0.98058873
( O 0 0.004618017
T3N0M0 O 0 0.9990231
) O 0 0.0019508863
and O 0 0.0007547724
16 O 0 0.00067618716
with O 0 0.00069204887
stage O 0 0.003392355
D1 O 0 0.9938578
( O 0 0.0043560932
T3N1M0 O 0 0.99887604
) O 0 0.0044103623
] O 0 0.0026264025
were O 0 0.001546091
included O 0 0.0017392584
in O 0 0.0023212172
this O 0 0.003587553
study O 0 0.0070320363
. O 0 0.008093107

All O 0 0.008659493
patients O 0 0.008795241
received O 0 0.0054735667
CAB O 0 0.33750805
[ O 0 0.06227091
leuprolide B-Chemical 0 0.99992454
acetate I-Chemical 0 0.99989223
( O 0 0.12702622
LHRH B-Chemical 0 0.9999027
- I-Chemical 0 0.022696545
A I-Chemical 0 0.48642024
) O 0 0.0020179322
3 O 0 0.0006001121
. O 0 0.00037200164
75 O 0 0.0005885709
mg O 0 0.056350794
, O 0 0.0005949006
intramuscularly O 0 0.0031605854
, O 0 0.00042742744
every O 0 0.00018041067
28 O 0 0.00027111947
days O 0 0.0002039323
plus O 0 0.0003071003
250 O 0 0.0009922505
mg O 0 0.56781447
flutamide B-Chemical 0 0.999982
, O 0 0.0021916202
tid O 0 0.99690115
, O 0 0.00071205775
per O 0 0.00038506533
Os O 0 0.9899082
] O 0 0.001288528
and O 0 0.00050426816
were O 0 0.00039319866
evaluated O 0 0.0003549221
for O 0 0.00046390694
anemia B-Disease 2 0.99991655
by O 0 0.0010837395
physical O 0 0.025834816
examination O 0 0.0009018875
and O 0 0.00054690323
laboratory O 0 0.0007535248
tests O 0 0.00076461065
at O 0 0.00027452037
baseline O 0 0.00041003939
and O 0 0.00041064335
4 O 0 0.00034532166
subsequent O 0 0.0003989472
intervals O 0 0.00045803186
( O 0 0.0007584565
1 O 0 0.00059097173
, O 0 0.00068494637
2 O 0 0.00058147556
, O 0 0.0007261576
3 O 0 0.00060560426
and O 0 0.0007952615
6 O 0 0.00082509825
months O 0 0.0010595729
post O 0 0.0026616757
- O 0 0.0049365093
CAB O 0 0.10515354
) O 0 0.01022794
. O 0 0.008247629

Hb O 0 0.9412375
, O 0 0.032995608
PSA O 0 0.95049536
and O 0 0.028912306
Testosterone B-Chemical 1 0.99905914
measurements O 0 0.015174625
were O 0 0.015596849
recorded O 0 0.01828208
. O 0 0.019056352

Patients O 0 0.01525746
with O 0 0.0067751585
stage O 0 0.011200986
D2 O 0 0.9848055
- O 0 0.0063450127
3 O 0 0.0019391157
disease O 0 0.42747095
, O 0 0.0020203288
abnormal O 0 0.013453103
hemoglobin O 0 0.8634405
level O 0 0.0006374527
or O 0 0.0007982829
renal O 0 0.97986126
and O 0 0.0013173993
liver O 0 0.8549259
function O 0 0.00087404915
tests O 0 0.0011169746
that O 0 0.00041105927
were O 0 0.0005026184
higher O 0 0.0004585384
than O 0 0.00043058168
the O 0 0.0006553365
upper O 0 0.0016755959
limits O 0 0.0017103952
were O 0 0.0014226135
excluded O 0 0.0022049837
from O 0 0.0024716507
the O 0 0.0035378558
study O 0 0.006805136
. O 0 0.007739079

The O 0 0.014307351
duration O 0 0.012303979
of O 0 0.011448958
the O 0 0.009972331
study O 0 0.010576788
was O 0 0.009413878
six O 0 0.008816308
months O 0 0.011323156
. O 0 0.015046669

RESULTS O 0 0.023565046
: O 0 0.007585586
The O 0 0.003624486
mean O 0 0.0031897817
hemoglobin O 0 0.84079295
( O 0 0.0055345898
Hb O 0 0.97885233
) O 0 0.0030425405
levels O 0 0.0009304553
were O 0 0.00078633823
significantly O 0 0.0008695347
declined O 0 0.00095204206
in O 0 0.00043783497
all O 0 0.00040739734
patients O 0 0.00084701553
from O 0 0.00038795883
baseline O 0 0.00043972177
of O 0 0.00046216036
14 O 0 0.0005155241
. O 0 0.00028572165
2 O 0 0.0003568131
g O 0 0.0006530091
/ O 0 0.0009651608
dl O 0 0.0026765356
to O 0 0.0003448453
14 O 0 0.0004476697
. O 0 0.000277161
0 O 0 0.0004465696
g O 0 0.00067092245
/ O 0 0.0011332947
dl O 0 0.007971447
, O 0 0.0006110225
13 O 0 0.0004993792
. O 0 0.00027538725
5 O 0 0.00030309593
g O 0 0.00063288317
/ O 0 0.0010494281
dl O 0 0.006980398
, O 0 0.0006101813
13 O 0 0.0005078892
. O 0 0.00028451686
2 O 0 0.00035195748
g O 0 0.00064854906
/ O 0 0.0009895741
dl O 0 0.0033145547
and O 0 0.00047478432
12 O 0 0.0003303804
. O 0 0.00028311953
7 O 0 0.0003494654
g O 0 0.0006865966
/ O 0 0.0011009848
dl O 0 0.0037073058
at O 0 0.000399258
1 O 0 0.00058385334
, O 0 0.00066655746
2 O 0 0.0005504526
, O 0 0.0006685637
3 O 0 0.0005335479
and O 0 0.0006725768
6 O 0 0.00066495273
months O 0 0.00081240723
post O 0 0.002008361
- O 0 0.0035526033
CAB O 0 0.06878026
, O 0 0.005654833
respectively O 0 0.008937776
. O 0 0.008191404

Severe O 0 0.78963995
and O 0 0.008084832
clinically O 0 0.033680048
evident O 0 0.004809497
anemia B-Disease 2 0.999713
of O 0 0.005963697
Hb O 0 0.98815966
< O 0 0.0016679332
11 O 0 0.0011693815
g O 0 0.0014649578
/ O 0 0.0018252652
dl O 0 0.0057005696
with O 0 0.00074031716
clinical O 0 0.0075259623
symptoms O 0 0.6686204
was O 0 0.00074229494
detected O 0 0.00048604407
in O 0 0.00065286097
6 O 0 0.00067875325
patients O 0 0.0018567445
( O 0 0.0017169389
14 O 0 0.0015389777
. O 0 0.0014201208
3 O 0 0.0023461597
% O 0 0.004378265
) O 0 0.007843781
. O 0 0.0074446304

This O 0 0.028565725
CAB O 0 0.18463528
- O 0 0.022854565
induced O 0 0.019802924
anemia B-Disease 2 0.9994185
was O 0 0.029433863
normochromic O 0 0.99468505
and O 0 0.036314502
normocytic O 0 0.99396306
. O 0 0.027914885

At O 0 0.0058393106
six O 0 0.0038098076
months O 0 0.0029693504
post O 0 0.0035982565
- O 0 0.0036633501
CAB O 0 0.040727813
, O 0 0.0019919039
patients O 0 0.0024398514
with O 0 0.0013651255
severe O 0 0.50891966
anemia B-Disease 2 0.9999498
had O 0 0.001202015
a O 0 0.0013883144
Hb O 0 0.91223735
mean O 0 0.0004876581
value O 0 0.00047372736
of O 0 0.0005698767
10 O 0 0.00054871297
. O 0 0.00033933058
2 O 0 0.00046083448
+ O 0 0.0005666918
/ O 0 0.0015003834
- O 0 0.0008122219
0 O 0 0.0005440307
. O 0 0.00028715073
1 O 0 0.00038964156
g O 0 0.0007087636
/ O 0 0.0013002228
dl O 0 0.018868431
( O 0 0.0012033449
X O 0 0.59510386
+ O 0 0.0010128587
/ O 0 0.004990801
- O 0 0.0021307261
SE O 2 0.9089034
) O 0 0.0012944413
, O 0 0.00054965785
whereas O 0 0.0003058877
the O 0 0.0003259836
other O 0 0.0003939769
patients O 0 0.0014159555
had O 0 0.00057715387
mild O 0 0.7768459
anemia B-Disease 2 0.9999609
with O 0 0.0014867455
Hb O 0 0.97079885
mean O 0 0.0004600436
value O 0 0.00045440553
of O 0 0.0005573449
13 O 0 0.00070946617
. O 0 0.00037618054
2 O 0 0.00054370385
+ O 0 0.00070726743
/ O 0 0.0017598749
- O 0 0.0011297695
0 O 0 0.00088456075
. O 0 0.00060629175
17 O 0 0.0013342046
( O 0 0.0018860669
X O 0 0.4191346
+ O 0 0.0029073444
/ O 0 0.008865328
- O 0 0.008075907
SE O 2 0.88517565
) O 0 0.011983598
. O 0 0.008662179

The O 0 0.0076595144
development O 0 0.0072663366
of O 0 0.00543046
severe O 0 0.5096841
anemia B-Disease 2 0.99985754
at O 0 0.0018229663
6 O 0 0.0010207959
months O 0 0.0007113463
post O 0 0.0012007424
- O 0 0.001362901
CAB O 0 0.023329955
was O 0 0.00058011163
predictable O 0 0.0012327195
by O 0 0.0005367875
the O 0 0.00044248474
reduction O 0 0.0006774837
of O 0 0.0006572611
Hb O 0 0.94021976
baseline O 0 0.00053167663
value O 0 0.00037125868
of O 0 0.00043064202
more O 0 0.0004696538
than O 0 0.00030741227
2 O 0 0.00042509794
. O 0 0.00028212016
5 O 0 0.00032263916
g O 0 0.0006627226
/ O 0 0.0009673951
dl O 0 0.0020978146
after O 0 0.00031166268
3 O 0 0.00045146272
months O 0 0.00041614662
of O 0 0.0008329992
CAB O 0 0.06908739
( O 0 0.0017701833
p O 0 0.0018419042
= O 0 0.0023659999
0 O 0 0.0025413358
. O 0 0.0024394381
01 O 0 0.012715031
) O 0 0.0076053906
. O 0 0.0073467726

The O 0 0.007834199
development O 0 0.007424928
of O 0 0.005470644
severe O 0 0.4071254
CAB O 0 0.66678745
- O 0 0.00818465
induced O 0 0.0038429778
anemia B-Disease 2 0.99994826
in O 0 0.0042020464
prostate B-Disease 2 0.9997986
cancer I-Disease 2 0.9999031
patients O 0 0.040239315
did O 0 0.0007153333
not O 0 0.0005647931
correlate O 0 0.000547069
with O 0 0.0007830071
T O 0 0.6368968
baseline O 0 0.0007607065
values O 0 0.00068156974
( O 0 0.0010812882
T O 0 0.40925062
< O 0 0.0005069932
3 O 0 0.00034881636
ng O 0 0.00090438384
/ O 0 0.0009653253
ml O 0 0.0011372442
versus O 0 0.00055337854
T O 0 0.513545
> O 0 0.0008569881
or O 0 0.00042557874
= O 0 0.00059992936
3 O 0 0.0003366526
ng O 0 0.0009883313
/ O 0 0.0012820497
ml O 0 0.002261424
) O 0 0.0011335851
, O 0 0.0005815005
with O 0 0.00043828008
age O 0 0.0012913775
( O 0 0.0007190028
< O 0 0.00043221348
76 O 0 0.000597613
yrs O 0 0.0009038364
versus O 0 0.00039135624
> O 0 0.000672045
or O 0 0.00042426033
= O 0 0.00066679827
76 O 0 0.0008267226
yrs O 0 0.0021018952
) O 0 0.0010507946
, O 0 0.0007772797
and O 0 0.00074157515
clinical O 0 0.003608244
stage O 0 0.002754372
( O 0 0.002357118
stage O 0 0.004792207
C O 0 0.9135966
versus O 0 0.0035099452
stage O 0 0.029300604
D1 O 0 0.9941175
) O 0 0.016626801
. O 0 0.009229353

Severe O 0 0.8075961
and O 0 0.007951351
clinically O 0 0.041910607
evident O 0 0.004898316
anemia B-Disease 2 0.99978703
was O 0 0.0025485933
easily O 0 0.0016851544
corrected O 0 0.0009019777
by O 0 0.0008425966
subcutaneous O 0 0.047267683
injections O 0 0.0063541466
( O 0 0.0009940014
3 O 0 0.00045036533
times O 0 0.00033409696
/ O 0 0.00079964916
week O 0 0.00033667442
for O 0 0.00035675286
1 O 0 0.000532842
month O 0 0.0004616945
) O 0 0.0009892441
of O 0 0.0009118697
recombinant O 0 0.0017737232
erythropoietin O 0 0.99822706
( O 0 0.021350497
rHuEPO O 0 0.995034
- O 0 0.017749894
beta O 0 0.575863
) O 0 0.0145214
. O 0 0.008457191

CONCLUSION O 0 0.5971261
: O 0 0.00849629
Our O 0 0.004200914
data O 0 0.0034186335
suggest O 0 0.0018409973
that O 0 0.001979763
rHuEPO O 0 0.99104464
- O 0 0.0107315965
beta O 0 0.71741676
correctable O 0 0.38031787
CAB O 0 0.589778
- O 0 0.0037447356
induced O 0 0.0017294637
anemia B-Disease 2 0.99995244
occurs O 0 0.001008997
in O 0 0.0006886352
14 O 0 0.0007644431
. O 0 0.00041000338
3 O 0 0.00048032813
% O 0 0.00065915176
of O 0 0.0009802169
prostate B-Disease 2 0.9986493
cancer I-Disease 2 0.99960333
patients O 0 0.011230912
after O 0 0.0009788428
6 O 0 0.0013647818
months O 0 0.0016508122
of O 0 0.003585864
therapy O 0 0.033991743
. O 0 0.008358548

Delirium B-Disease 2 0.99474084
during O 0 0.013457124
clozapine B-Chemical 1 0.99975723
treatment O 0 0.020347858
: O 0 0.011040627
incidence O 0 0.022427585
and O 0 0.008601809
associated O 0 0.010444277
risk O 0 0.30854678
factors O 0 0.09692175
. O 0 0.016506566

BACKGROUND O 0 0.6872814
: O 0 0.013763561
Incidence O 0 0.10841727
and O 0 0.0062015685
risk O 0 0.03619104
factors O 0 0.011198183
for O 0 0.0036824956
delirium B-Disease 2 0.99980146
during O 0 0.003949239
clozapine B-Chemical 1 0.9999516
treatment O 0 0.0071651083
require O 0 0.0032168175
further O 0 0.0054415297
clarification O 0 0.010275864
. O 0 0.010010173

METHODS O 0 0.011106934
: O 0 0.0075262156
We O 0 0.0038188307
used O 0 0.002691988
computerized O 0 0.004702082
pharmacy O 0 0.006346901
records O 0 0.0019529326
to O 0 0.00091100694
identify O 0 0.0006657708
all O 0 0.00073269353
adult O 0 0.0019767324
psychiatric B-Disease 2 0.9924229
inpatients O 0 0.095437564
treated O 0 0.0011659887
with O 0 0.001703607
clozapine B-Chemical 1 0.9999937
( O 0 0.0038475667
1995 O 0 0.029665045
- O 0 0.0011218063
96 O 0 0.000982503
) O 0 0.0007663898
, O 0 0.0005128376
reviewed O 0 0.00059063215
their O 0 0.00045023914
medical O 0 0.002225688
records O 0 0.0007029531
to O 0 0.00036971873
score O 0 0.0006790292
incidence O 0 0.004656555
and O 0 0.0008759942
severity O 0 0.07000766
of O 0 0.0033151123
delirium B-Disease 2 0.9999578
, O 0 0.0020353505
and O 0 0.0011554285
tested O 0 0.0008974556
associations O 0 0.0014815517
with O 0 0.0022065067
potential O 0 0.0050836103
risk O 0 0.25306275
factors O 0 0.06637238
. O 0 0.010046245

RESULTS O 0 0.02694634
: O 0 0.009324511
Subjects O 0 0.006367799
( O 0 0.0041523227
n O 0 0.0028436505
= O 0 0.0026734404
139 O 0 0.0037406092
) O 0 0.0018162109
were O 0 0.0009148311
72 O 0 0.0007958259
women O 0 0.002943158
and O 0 0.00078123616
67 O 0 0.0014443609
men O 0 0.034315918
, O 0 0.00075307937
aged O 0 0.00084666495
40 O 0 0.00052676897
. O 0 0.00033763322
8 O 0 0.00042316268
+ O 0 0.0005322273
/ O 0 0.0012556799
- O 0 0.00068921037
12 O 0 0.0002875077
. O 0 0.0002555431
1 O 0 0.00033739416
years O 0 0.00047045766
, O 0 0.00047091936
hospitalized O 0 0.0049597262
for O 0 0.00027510492
24 O 0 0.00030303118
. O 0 0.00025850922
9 O 0 0.00039521971
+ O 0 0.0004745547
/ O 0 0.00128224
- O 0 0.00068121264
23 O 0 0.0005041264
. O 0 0.00022235082
3 O 0 0.00023808726
days O 0 0.00022002112
, O 0 0.00039370352
and O 0 0.00036550633
given O 0 0.0003447937
clozapine B-Chemical 1 0.9999863
, O 0 0.0008837031
gradually O 0 0.0010208631
increased O 0 0.00044462082
to O 0 0.00029823353
an O 0 0.00040626296
average O 0 0.00024016405
daily O 0 0.00064279325
dose O 0 0.0018040799
of O 0 0.00068915426
282 O 0 0.07183055
+ O 0 0.0008149842
/ O 0 0.002589346
- O 0 0.0009628664
203 O 0 0.007816977
mg O 0 0.1779187
( O 0 0.00068973866
3 O 0 0.00037375288
. O 0 0.00027456536
45 O 0 0.00036770885
+ O 0 0.00049874355
/ O 0 0.0012397635
- O 0 0.00072998006
2 O 0 0.0003882741
. O 0 0.00027833862
45 O 0 0.00035662059
mg O 0 0.035393037
/ O 0 0.0011335205
kg O 0 0.0026113233
) O 0 0.0009226592
for O 0 0.00042168217
18 O 0 0.0006029526
. O 0 0.0004911532
9 O 0 0.0007886366
+ O 0 0.0010524809
/ O 0 0.0023820887
- O 0 0.0019316578
16 O 0 0.0015738418
. O 0 0.001564563
4 O 0 0.0024944346
days O 0 0.0034824144
. O 0 0.0063091307

Delirium B-Disease 2 0.99536407
was O 0 0.007520668
diagnosed O 0 0.011405358
in O 0 0.002970654
14 O 0 0.002579628
( O 0 0.002214342
10 O 0 0.0012410359
. O 0 0.0007831738
1 O 0 0.0007917488
% O 0 0.0008291411
incidence O 0 0.0025513966
, O 0 0.0009219593
or O 0 0.00058191165
1 O 0 0.0006010958
. O 0 0.0003336612
48 O 0 0.00034099355
cases O 0 0.0006384185
/ O 0 0.0011639601
person O 0 0.0010681265
- O 0 0.0008249213
years O 0 0.0006124621
of O 0 0.0006105949
exposure O 0 0.0027773276
) O 0 0.0026227552
; O 0 0.001306109
71 O 0 0.0015221881
. O 0 0.00046432234
4 O 0 0.00056118
% O 0 0.0008008952
of O 0 0.0010028711
cases O 0 0.0021336246
were O 0 0.00210728
moderate O 0 0.008278129
or O 0 0.004748063
severe O 0 0.48424038
. O 0 0.009862322

Associated O 0 0.031623732
factors O 0 0.013055294
were O 0 0.005310102
co O 0 0.42947063
- O 0 0.005108819
treatment O 0 0.002415267
with O 0 0.0013903283
other O 0 0.0012509705
centrally O 0 0.060702723
antimuscarinic O 0 0.99963
agents O 0 0.49903458
, O 0 0.0016527411
poor O 0 0.003121744
clinical O 0 0.0059150434
outcome O 0 0.0040016444
, O 0 0.0009679003
older O 0 0.0024386235
age O 0 0.001405403
, O 0 0.00061725336
and O 0 0.00044244216
longer O 0 0.0002780917
hospitalization O 0 0.055558637
( O 0 0.0007569556
by O 0 0.00048039336
17 O 0 0.000609847
. O 0 0.00024290725
5 O 0 0.0002434319
days O 0 0.00023730313
, O 0 0.00042729222
increasing O 0 0.0004746712
cost O 0 0.0011871842
) O 0 0.0017926557
; O 0 0.0011194556
sex O 0 0.024745831
, O 0 0.00069997093
diagnosis O 0 0.0024673669
or O 0 0.0005962682
medical O 0 0.032850776
co O 0 0.7201924
- O 0 0.005124264
morbidity O 0 0.7348333
, O 0 0.0011013498
and O 0 0.00074096944
daily O 0 0.0038483045
clozapine B-Chemical 1 0.99997544
dose O 0 0.022384886
, O 0 0.001440141
which O 0 0.0012782253
fell O 0 0.0024928786
with O 0 0.0017182668
age O 0 0.0050546546
, O 0 0.0039050125
were O 0 0.004207353
unrelated O 0 0.012082318
. O 0 0.008470092

CONCLUSIONS O 0 0.7194717
: O 0 0.017963989
Delirium B-Disease 2 0.9957445
was O 0 0.0039101425
found O 0 0.002064301
in O 0 0.001721055
10 O 0 0.0014724236
% O 0 0.0014834759
of O 0 0.0018737412
clozapine B-Chemical 1 0.9999839
- O 0 0.0037141016
treated O 0 0.0013964049
inpatients O 0 0.0701112
, O 0 0.0011767368
particularly O 0 0.0010225158
in O 0 0.0008558843
older O 0 0.003225474
patients O 0 0.0022944815
exposed O 0 0.0013467368
to O 0 0.0017304937
other O 0 0.0031472358
central O 0 0.036793403
anticholinergics O 0 0.99946517
. O 0 0.010019991

Delirium B-Disease 2 0.99623907
was O 0 0.007832076
inconsistently O 0 0.014720554
recognized O 0 0.0036281266
clinically O 0 0.019155545
in O 0 0.0018039062
milder O 0 0.080130294
cases O 0 0.0028901743
and O 0 0.0013025543
was O 0 0.0008622075
associated O 0 0.0008684327
with O 0 0.0008003272
increased O 0 0.0010188353
length O 0 0.00078773167
- O 0 0.0013319636
of O 0 0.0009778795
- O 0 0.001416396
stay O 0 0.0011437099
and O 0 0.0010130656
higher O 0 0.0010556228
costs O 0 0.0040018745
, O 0 0.002294888
and O 0 0.0024764119
inferior O 0 0.0171615
clinical O 0 0.014706591
outcome O 0 0.015599052
. O 0 0.008799996

Neuroprotective O 0 0.99152243
action O 0 0.062046845
of O 0 0.018641915
MPEP B-Chemical 1 0.9999827
, O 0 0.008127814
a O 0 0.0032590542
selective O 0 0.043869104
mGluR5 O 0 0.99923265
antagonist O 0 0.9921296
, O 0 0.003322633
in O 0 0.0012916106
methamphetamine B-Chemical 1 0.9999906
- O 0 0.013713933
induced O 0 0.0020776778
dopaminergic O 0 0.998156
neurotoxicity B-Disease 2 0.99997044
is O 0 0.00097463094
associated O 0 0.00085623015
with O 0 0.0007218007
a O 0 0.0010309849
decrease O 0 0.0007724079
in O 0 0.0010629067
dopamine B-Chemical 1 0.99982077
outflow O 0 0.9782381
and O 0 0.0019059697
inhibition O 0 0.0047439956
of O 0 0.0040477216
hyperthermia B-Disease 2 0.9994923
in O 0 0.0057671405
rats O 0 0.02990138
. O 0 0.00887961

The O 0 0.006840029
aim O 0 0.0054413984
of O 0 0.0038624515
this O 0 0.0025892977
study O 0 0.0022544854
was O 0 0.0013767035
to O 0 0.0009133018
examine O 0 0.00056751503
the O 0 0.0008181624
role O 0 0.00067056005
of O 0 0.003460691
metabotropic O 0 0.9999858
glutamate B-Chemical 1 0.999977
receptor O 0 0.55091965
5 O 0 0.0010974428
( O 0 0.001805182
mGluR5 O 0 0.99254084
) O 0 0.0012787952
in O 0 0.0005200702
the O 0 0.00067231915
toxic O 0 0.6082193
action O 0 0.011904288
of O 0 0.0029761472
methamphetamine B-Chemical 1 0.99997115
on O 0 0.0020483658
dopaminergic O 0 0.9909093
neurones O 0 0.5928524
in O 0 0.0040921657
rats O 0 0.013360861
. O 0 0.008172745

Methamphetamine B-Chemical 1 0.9996681
( O 0 0.010679924
10 O 0 0.0042121843
mg O 0 0.15939629
/ O 0 0.004506803
kg O 0 0.009263847
sc O 0 0.18752317
) O 0 0.002630803
, O 0 0.0011017475
administered O 0 0.0007781954
five O 0 0.00040288063
times O 0 0.00040501318
, O 0 0.0006507818
reduced O 0 0.0004572499
the O 0 0.0004478349
levels O 0 0.00049012335
of O 0 0.0011400719
dopamine B-Chemical 1 0.99982136
and O 0 0.0009857537
its O 0 0.002030216
metabolites O 0 0.8190224
in O 0 0.0007620117
striatal O 0 0.88180476
tissue O 0 0.005497275
when O 0 0.0005356288
measured O 0 0.0005823663
72 O 0 0.0008865961
h O 0 0.0008340453
after O 0 0.0009181946
the O 0 0.0018211622
last O 0 0.0024871244
injection O 0 0.009366666
. O 0 0.0077367323

A O 0 0.0749511
selective O 0 0.025113301
antagonist O 0 0.9393474
of O 0 0.00913039
mGluR5 O 0 0.9985139
, O 0 0.005360524
2 B-Chemical 0 0.0022347823
- I-Chemical 0 0.003852025
methyl I-Chemical 0 0.9697267
- I-Chemical 0 0.0037182416
6 I-Chemical 0 0.00085987465
- I-Chemical 0 0.0016865362
( I-Chemical 0 0.0014913895
phenylethynyl I-Chemical 0 0.91729563
) I-Chemical 0 0.011932202
pyridine I-Chemical 0 0.99938345
( O 0 0.023746224
MPEP B-Chemical 1 0.99999607
; O 0 0.0024013869
5 O 0 0.0004625694
mg O 0 0.088609464
/ O 0 0.0012070684
kg O 0 0.0049858927
ip O 0 0.6881459
) O 0 0.0012437529
, O 0 0.0005045131
when O 0 0.00023922842
administered O 0 0.00040250595
five O 0 0.00022985994
times O 0 0.00023869914
immediately O 0 0.00031633466
before O 0 0.00025113125
each O 0 0.0003828822
methamphetamine B-Chemical 1 0.99993455
injection O 0 0.0035651587
reversed O 0 0.0017429539
the O 0 0.0011098005
above O 0 0.0012963344
- O 0 0.003343196
mentioned O 0 0.0028307696
methamphetamine B-Chemical 1 0.99987805
effects O 0 0.027107121
. O 0 0.009262682

A O 0 0.07344215
single O 0 0.0132750105
MPEP B-Chemical 1 0.99992764
( O 0 0.007812621
5 O 0 0.002384498
mg O 0 0.19519652
/ O 0 0.0036124745
kg O 0 0.013887233
ip O 0 0.8032708
) O 0 0.0020529472
injection O 0 0.001659631
reduced O 0 0.0006689917
the O 0 0.0006139604
basal O 0 0.0021138147
extracellular O 0 0.14733896
dopamine B-Chemical 1 0.99984515
level O 0 0.00041825487
in O 0 0.00042352045
the O 0 0.00054302043
striatum O 0 0.3673767
, O 0 0.00062199804
as O 0 0.0003909621
well O 0 0.0004121815
as O 0 0.0007657351
dopamine B-Chemical 1 0.9998271
release O 0 0.04610792
stimulated O 0 0.00047638782
either O 0 0.00059554464
by O 0 0.0010735691
methamphetamine B-Chemical 1 0.9999852
( O 0 0.0014170185
10 O 0 0.00054697617
mg O 0 0.1226929
/ O 0 0.0013391585
kg O 0 0.0038496614
sc O 0 0.10056218
) O 0 0.0013564767
or O 0 0.0007419925
by O 0 0.0012838019
intrastriatally O 0 0.9794311
administered O 0 0.014398466
veratridine B-Chemical 0 0.9999424
( O 0 0.010882343
100 O 0 0.016245857
microM O 0 0.8228571
) O 0 0.012054256
. O 0 0.007807063

Moreover O 0 0.01093035
, O 0 0.007644004
it O 0 0.004597013
transiently O 0 0.0065817013
diminished O 0 0.003439316
the O 0 0.0027125964
methamphetamine B-Chemical 1 0.99996233
( O 0 0.0036141172
10 O 0 0.0012156304
mg O 0 0.18479635
/ O 0 0.0023587013
kg O 0 0.0076672966
sc O 0 0.22712052
) O 0 0.0036367334
- O 0 0.0023089699
induced O 0 0.0020165404
hyperthermia B-Disease 2 0.9995054
and O 0 0.003759055
reduced O 0 0.0032910237
basal O 0 0.0077719344
body O 0 0.038148377
temperature O 0 0.012253147
. O 0 0.009421299

MPEP B-Chemical 1 0.999793
administered O 0 0.009804441
into O 0 0.0028117786
the O 0 0.0026241902
striatum O 0 0.21054545
at O 0 0.001164581
high O 0 0.0015034309
concentrations O 0 0.004433992
( O 0 0.0023463885
500 O 0 0.012132006
microM O 0 0.78881043
) O 0 0.002064563
increased O 0 0.0009985073
extracellular O 0 0.14990674
dopamine B-Chemical 1 0.9998801
levels O 0 0.0008070589
, O 0 0.0008354508
while O 0 0.00045167835
lower O 0 0.0005785931
concentrations O 0 0.002310406
( O 0 0.0013516342
50 O 0 0.001378918
- O 0 0.0014434836
100 O 0 0.0020143478
microM O 0 0.4708827
) O 0 0.0020041512
were O 0 0.0012187219
devoid O 0 0.0012558134
of O 0 0.0023757683
any O 0 0.0032418144
effect O 0 0.00568533
. O 0 0.008042031

The O 0 0.0069187456
results O 0 0.0049626683
of O 0 0.0039203838
this O 0 0.002585457
study O 0 0.0020701236
suggest O 0 0.0010735145
that O 0 0.0010239322
the O 0 0.0012247044
blockade O 0 0.20163535
of O 0 0.0034800097
mGluR5 O 0 0.9992699
by O 0 0.009628886
MPEP B-Chemical 1 0.9999944
may O 0 0.0018277674
protect O 0 0.019161621
dopaminergic O 0 0.9933368
neurones O 0 0.7501233
against O 0 0.0031888934
methamphetamine B-Chemical 1 0.999969
- O 0 0.026918098
induced O 0 0.009688408
toxicity B-Disease 2 0.9986926
. O 0 0.011772333

Neuroprotection O 0 0.9806795
rendered O 0 0.019178793
by O 0 0.01167057
MPEP B-Chemical 1 0.999966
may O 0 0.0032742536
be O 0 0.0018245425
associated O 0 0.0013904587
with O 0 0.0010049543
the O 0 0.0008072528
reduction O 0 0.0011146261
of O 0 0.0009390845
the O 0 0.001381264
methamphetamine B-Chemical 1 0.9999933
- O 0 0.02073332
induced O 0 0.0028649373
dopamine B-Chemical 1 0.99994004
efflux O 0 0.30415735
in O 0 0.0004967869
the O 0 0.0005601675
striatum O 0 0.17101175
due O 0 0.00032797022
to O 0 0.0003895361
the O 0 0.00051447947
blockade O 0 0.093272604
of O 0 0.001748493
extrastriatal O 0 0.9971757
mGluR5 O 0 0.99647105
, O 0 0.0016269943
and O 0 0.0012692641
with O 0 0.0015033967
a O 0 0.002524764
decrease O 0 0.0026731242
in O 0 0.0047907475
hyperthermia B-Disease 2 0.999129
. O 0 0.011369119

Protective O 0 0.62048805
efficacy O 0 0.015980516
of O 0 0.010560016
neuroactive O 0 0.99780685
steroids B-Chemical 1 0.9997137
against O 0 0.015854614
cocaine B-Chemical 1 0.99995756
kindled O 0 0.99972194
- O 0 0.15160215
seizures B-Disease 2 0.9998772
in O 0 0.007794035
mice O 0 0.007608202
. O 0 0.010940278

Neuroactive O 0 0.9912424
steroids B-Chemical 1 0.9975472
demonstrate O 0 0.0045160307
pharmacological O 0 0.4287949
actions O 0 0.035883326
that O 0 0.0017498436
have O 0 0.0013726956
relevance O 0 0.0011758405
for O 0 0.0011295635
a O 0 0.0020314
host O 0 0.005408423
of O 0 0.004646863
neurological B-Disease 0 0.99827194
and I-Disease 0 0.03164445
psychiatric I-Disease 2 0.99966335
disorders I-Disease 0 0.99786264
. O 0 0.01412786

They O 0 0.013833907
offer O 0 0.007424401
protection O 0 0.008961034
against O 0 0.0041909986
seizures B-Disease 2 0.99986637
in O 0 0.0022873515
a O 0 0.0019794463
range O 0 0.0015679619
of O 0 0.0012122736
models O 0 0.0014777457
and O 0 0.001246876
seem O 0 0.0009592405
to O 0 0.000743756
inhibit O 0 0.00076547754
certain O 0 0.0012604701
stages O 0 0.0016190716
of O 0 0.0019967393
drug B-Disease 0 0.9300149
dependence I-Disease 0 0.06785349
in O 0 0.003337689
preclinical O 0 0.06544997
assessments O 0 0.008065775
. O 0 0.007919091

The O 0 0.0069235903
present O 0 0.004040648
study O 0 0.0038190046
was O 0 0.00242604
designed O 0 0.0017638892
to O 0 0.0010907062
evaluate O 0 0.0006202272
two O 0 0.0006997645
endogenous O 0 0.0010663779
and O 0 0.00087906996
one O 0 0.00060529605
synthetic O 0 0.0028714628
neuroactive O 0 0.99828726
steroid B-Chemical 1 0.9993369
that O 0 0.00060650415
positively O 0 0.0007582544
modulate O 0 0.00046268848
the O 0 0.00095803937
gamma B-Chemical 1 0.9344625
- I-Chemical 1 0.062004432
aminobutyric I-Chemical 1 0.9999076
acid I-Chemical 1 0.99744713
( O 0 0.06153763
GABA B-Chemical 1 0.9999894
( O 0 0.0036094165
A O 0 0.200101
) O 0 0.0023261108
) O 0 0.0012460841
receptor O 0 0.010346933
against O 0 0.0003651097
the O 0 0.00039912178
increase O 0 0.00031454832
in O 0 0.0003589085
sensitivity O 0 0.0007732703
to O 0 0.00039222906
the O 0 0.0005551748
convulsant O 0 0.9997205
effects O 0 0.002414337
of O 0 0.0019645062
cocaine B-Chemical 1 0.9999585
engendered O 0 0.02080142
by O 0 0.0012251093
repeated O 0 0.0015681247
cocaine B-Chemical 1 0.9999268
administration O 0 0.53585297
( O 0 0.033856105
seizure B-Disease 2 0.9998652
kindling O 0 0.9992501
) O 0 0.037598092
. O 0 0.009158024

Allopregnanolone B-Chemical 0 0.9994136
( O 0 0.052693605
3alpha B-Chemical 0 0.9959869
- I-Chemical 0 0.059897892
hydroxy I-Chemical 0 0.999579
- I-Chemical 0 0.06409178
5alpha I-Chemical 0 0.9966607
- I-Chemical 0 0.015196819
pregnan I-Chemical 0 0.771749
- I-Chemical 0 0.002931599
20 I-Chemical 0 0.0010575183
- I-Chemical 0 0.0011823626
one I-Chemical 0 0.00063593633
) O 0 0.0019392862
, O 0 0.0022016177
pregnanolone B-Chemical 0 0.9999912
( O 0 0.015078333
3alpha B-Chemical 0 0.9978364
- I-Chemical 0 0.025606228
hydroxy I-Chemical 0 0.99982566
- I-Chemical 0 0.036658134
5beta I-Chemical 0 0.9974868
- I-Chemical 0 0.0068569775
pregnan I-Chemical 0 0.6954136
- I-Chemical 0 0.0016820438
20 I-Chemical 0 0.00061297655
- I-Chemical 0 0.0007485685
one I-Chemical 0 0.0003921053
) O 0 0.0009956568
and O 0 0.0008121445
ganaxolone B-Chemical 0 0.9998473
( O 0 0.0011723646
a O 0 0.0007434843
synthetic O 0 0.001626587
derivative O 0 0.102346435
of O 0 0.008906231
allopregnanolone B-Chemical 0 0.9999988
3alpha B-Chemical 0 0.9997384
- I-Chemical 0 0.11162367
hydroxy I-Chemical 0 0.99992454
- I-Chemical 0 0.100846924
3beta I-Chemical 0 0.9992725
- I-Chemical 0 0.026226325
methyl I-Chemical 0 0.9948086
- I-Chemical 0 0.030509923
5alpha I-Chemical 0 0.99672604
- I-Chemical 0 0.008855781
pregnan I-Chemical 0 0.71416175
- I-Chemical 0 0.00163149
20 I-Chemical 0 0.00057446305
- I-Chemical 0 0.0006708701
one I-Chemical 0 0.00033233926
) O 0 0.00062636484
were O 0 0.00029780483
tested O 0 0.0002299781
for O 0 0.00024965516
their O 0 0.00037010858
ability O 0 0.000367884
to O 0 0.00035686002
suppress O 0 0.00034107646
the O 0 0.00046882004
expression O 0 0.0010861249
( O 0 0.0017683969
anticonvulsant O 0 0.9997391
effect O 0 0.0009348815
) O 0 0.0022051947
and O 0 0.00072131003
development O 0 0.0024625733
( O 0 0.0017642336
antiepileptogenic O 0 0.99313426
effect O 0 0.0009175587
) O 0 0.0021416547
of O 0 0.0016381136
cocaine B-Chemical 1 0.99997675
- O 0 0.03151751
kindled O 0 0.9993393
seizures B-Disease 2 0.9999682
in O 0 0.0017966041
male O 0 0.02583923
, O 0 0.0038226545
Swiss O 0 0.036412835
- O 0 0.0066963704
Webster O 0 0.14006793
mice O 0 0.0048607285
. O 0 0.008007872

Kindled O 0 0.9961694
seizures B-Disease 2 0.9996772
were O 0 0.0065305415
induced O 0 0.003941605
by O 0 0.0029407844
daily O 0 0.0034993936
administration O 0 0.016184382
of O 0 0.0019614676
60 O 0 0.0017738675
mg O 0 0.26971027
/ O 0 0.00479625
kg O 0 0.0259953
cocaine B-Chemical 1 0.999569
for O 0 0.0030434162
5 O 0 0.003929018
days O 0 0.00468416
. O 0 0.007629058

All O 0 0.007843872
of O 0 0.0060177376
these O 0 0.0049373405
positive O 0 0.00640471
GABA B-Chemical 1 0.99993455
( O 0 0.011662844
A O 0 0.25263283
) O 0 0.0040949364
modulators O 0 0.042539008
suppressed O 0 0.0011965078
the O 0 0.00082012627
expression O 0 0.0010978883
of O 0 0.0020067014
kindled O 0 0.9996836
seizures B-Disease 2 0.9999895
, O 0 0.0026763014
whereas O 0 0.0009285529
only O 0 0.0015332586
allopregnanolone B-Chemical 0 0.9999925
and O 0 0.006966202
ganaxolone B-Chemical 0 0.99985814
inhibited O 0 0.0034031605
the O 0 0.0025969234
development O 0 0.00633721
of O 0 0.009644285
kindling O 0 0.9984724
. O 0 0.0112130605

Allopregnanolone B-Chemical 0 0.99904746
and O 0 0.020524558
pregnanolone B-Chemical 0 0.99991953
, O 0 0.008870752
but O 0 0.00326787
not O 0 0.002932186
ganaxolone B-Chemical 0 0.9996166
, O 0 0.0032414894
also O 0 0.0019296224
reduced O 0 0.0022108087
cumulative O 0 0.020121152
lethality O 0 0.70524067
associated O 0 0.008190922
with O 0 0.015231604
kindling O 0 0.99875736
. O 0 0.013049697

These O 0 0.008444157
findings O 0 0.0065717106
demonstrate O 0 0.0027015754
that O 0 0.0022475873
some O 0 0.0028777923
neuroactive O 0 0.9981342
steroids B-Chemical 1 0.99990404
attenuate O 0 0.20844439
convulsant O 0 0.9999516
and O 0 0.002238116
sensitizing O 0 0.14089178
properties O 0 0.0016879537
of O 0 0.0018961275
cocaine B-Chemical 1 0.99996066
and O 0 0.0009662952
add O 0 0.00059837353
to O 0 0.00040754728
a O 0 0.0005954698
growing O 0 0.0006069763
literature O 0 0.00070748216
on O 0 0.0003118169
their O 0 0.00048418881
potential O 0 0.0006829879
use O 0 0.0006411398
in O 0 0.0005652881
the O 0 0.0006873047
modulation O 0 0.0012062289
of O 0 0.0013135856
effects O 0 0.0028849135
of O 0 0.0033322289
drugs O 0 0.9098515
of O 0 0.013075423
abuse O 0 0.9989166
. O 0 0.012462199

Effect O 0 0.012457077
of O 0 0.009106388
humoral O 0 0.7251183
modulators O 0 0.29761463
of O 0 0.015782665
morphine B-Chemical 1 0.9999653
- O 0 0.02235561
induced O 0 0.0029342286
increase B-Disease 0 0.002031518
in I-Disease 0 0.0026973805
locomotor I-Disease 0 0.6378943
activity I-Disease 0 0.004368023
of O 0 0.0055220476
mice O 0 0.0059955823
. O 0 0.009531862

The O 0 0.0075342613
effect O 0 0.0050968337
of O 0 0.005046918
humoral O 0 0.66565
modulators O 0 0.13045867
on O 0 0.0017161529
the O 0 0.00263129
morphine B-Chemical 1 0.9999683
- O 0 0.008944116
induced O 0 0.001573175
increase B-Disease 0 0.0010965528
in I-Disease 0 0.0014264147
locomotor I-Disease 0 0.56523806
activity I-Disease 0 0.0021117325
of O 0 0.0025066733
mice O 0 0.002463302
was O 0 0.004165348
studied O 0 0.00696744
. O 0 0.008980063

The O 0 0.006939062
subcutaneous O 0 0.026572138
administration O 0 0.021918641
of O 0 0.0032575037
10 O 0 0.0021927853
mg O 0 0.25302625
/ O 0 0.0032778364
kg O 0 0.0062091933
of O 0 0.0023875365
morphine B-Chemical 1 0.9999738
- O 0 0.027669873
HC1 O 0 0.9993887
produced O 0 0.0013188203
a O 0 0.0016863678
marked O 0 0.002172914
increase B-Disease 0 0.0011452133
in I-Disease 0 0.0018327511
locomotor I-Disease 0 0.57340753
activity I-Disease 0 0.0035210804
in O 0 0.0037760178
mice O 0 0.0049770055
. O 0 0.008390652

The O 0 0.012930675
morphine B-Chemical 1 0.9996842
- O 0 0.027101798
induced O 0 0.011258746
hyperactivity B-Disease 2 0.99983966
was O 0 0.007433989
potentiated O 0 0.49772638
by O 0 0.014136788
scopolamine B-Chemical 1 0.99998474
and O 0 0.010603194
attenuated O 0 0.02121477
by O 0 0.02532172
physostigmine B-Chemical 0 0.99993026
. O 0 0.015064503

In O 0 0.0076062544
contrast O 0 0.005769714
, O 0 0.004952242
both O 0 0.0032886392
methscopolamine B-Chemical 0 0.9996872
and O 0 0.005589262
neostigmine B-Chemical 0 0.99996746
, O 0 0.0027873772
which O 0 0.0011316561
do O 0 0.0006111635
not O 0 0.00059761066
penetrate O 0 0.0010746988
the O 0 0.00063577533
blood O 0 0.024443537
- O 0 0.0020332935
brain O 0 0.048805796
barrier O 0 0.008846937
, O 0 0.000933807
had O 0 0.00052883435
no O 0 0.00050148653
effect O 0 0.000796586
on O 0 0.00083795824
the O 0 0.0021476715
hyperactivity B-Disease 2 0.9997985
produced O 0 0.00462605
by O 0 0.012912327
morphine B-Chemical 1 0.9998524
. O 0 0.011152545

Pretreatment O 0 0.44195327
of O 0 0.0071288296
mice O 0 0.0038404854
with O 0 0.004113495
alpha B-Chemical 0 0.8779333
- I-Chemical 0 0.013604649
methyltyrosine I-Chemical 0 0.9201501
( O 0 0.002144509
20 O 0 0.00095959427
mg O 0 0.12265761
/ O 0 0.0016108595
kg O 0 0.0029506355
i O 0 0.0020360965
. O 0 0.00045688
p O 0 0.0007060324
. O 0 0.00038972183
, O 0 0.000537543
one O 0 0.00033467144
hour O 0 0.00035853437
) O 0 0.00101946
, O 0 0.0006729557
an O 0 0.0007465026
inhibitor O 0 0.032078028
of O 0 0.0027046374
tyrosine B-Chemical 1 0.99689686
hydroxylase O 0 0.99830306
, O 0 0.0015998604
significantly O 0 0.0010509042
decreased O 0 0.0012351378
the O 0 0.00096575957
activity O 0 0.0016882408
- O 0 0.0023631162
increasing O 0 0.0020100449
effects O 0 0.0054207747
of O 0 0.012445666
morphine B-Chemical 1 0.9998834
. O 0 0.01150523

On O 0 0.008719269
the O 0 0.005129308
other O 0 0.0038373782
hand O 0 0.0045324704
, O 0 0.00359692
pretreatment O 0 0.11874793
with O 0 0.0022726054
p B-Chemical 0 0.010936404
- I-Chemical 0 0.0039827507
chlorophenylalamine I-Chemical 0 0.14160627
( O 0 0.0016591192
3 O 0 0.00078196754
X O 0 0.23608571
320 O 0 0.008267058
mg O 0 0.12739863
/ O 0 0.0012981261
kg O 0 0.0024063818
i O 0 0.0017214982
. O 0 0.00040152753
p O 0 0.00065013644
. O 0 0.00037445314
, O 0 0.0005534186
24 O 0 0.0003399244
hr O 0 0.00059266
) O 0 0.0010077822
, O 0 0.0007824483
a O 0 0.001253486
serotonin B-Chemical 1 0.9998271
depletor O 0 0.99981683
, O 0 0.0016009529
caused O 0 0.0009428132
no O 0 0.0008103279
significant O 0 0.0015508088
change O 0 0.0019783098
in O 0 0.0026226556
the O 0 0.005608036
hyperactivity B-Disease 2 0.9996389
. O 0 0.010844381

The O 0 0.007187562
study O 0 0.005188322
suggests O 0 0.0025136685
that O 0 0.002055215
the O 0 0.0019537415
activity O 0 0.0024242015
- O 0 0.0022598063
increasing O 0 0.0012408172
effects O 0 0.0019693288
of O 0 0.0024641096
morphine B-Chemical 1 0.99997544
are O 0 0.0013943712
mediated O 0 0.00083776895
by O 0 0.00094709964
the O 0 0.00085646845
release O 0 0.03231881
of O 0 0.0022192653
catecholamines B-Chemical 1 0.9997888
from O 0 0.0026864926
adrenergic O 0 0.9977119
neurons O 0 0.026769599
in O 0 0.0026277816
the O 0 0.004118664
brain O 0 0.15487629
. O 0 0.008535279

And O 0 0.015877098
the O 0 0.005528701
results O 0 0.0039301487
are O 0 0.0028464547
consistent O 0 0.0018238237
with O 0 0.0015306912
the O 0 0.0012371648
hypothesis O 0 0.001430015
that O 0 0.0012062897
morphine B-Chemical 1 0.9999578
acts O 0 0.0051525813
by O 0 0.001530206
retarding O 0 0.37631553
the O 0 0.0013123107
release O 0 0.05856405
of O 0 0.0029133856
acetylcholine B-Chemical 1 0.99963796
at O 0 0.001604581
some O 0 0.0025946244
central O 0 0.011927597
cholinergic O 0 0.9779995
synapses O 0 0.4401129
. O 0 0.008898465

It O 0 0.009773516
is O 0 0.004916861
also O 0 0.0032700517
suggested O 0 0.002141399
from O 0 0.0016351271
collected O 0 0.0011239627
evidence O 0 0.001004804
that O 0 0.0007660212
the O 0 0.00087075186
activity O 0 0.0013315096
- O 0 0.0013493418
increasing O 0 0.0007107868
effects O 0 0.0013003881
of O 0 0.0015528308
morphine B-Chemical 1 0.99997663
in O 0 0.00066586025
mice O 0 0.00041497248
are O 0 0.00054200593
mediated O 0 0.0004489333
by O 0 0.00054952636
mechanisms O 0 0.0006671574
different O 0 0.00041213084
from O 0 0.00048189587
those O 0 0.000683068
which O 0 0.0006482191
mediate O 0 0.00051486463
the O 0 0.0007027552
activity O 0 0.0012332104
- O 0 0.0015883377
increasing O 0 0.0011892793
effects O 0 0.0028021059
of O 0 0.0050105555
morphine B-Chemical 1 0.9999199
in O 0 0.005446407
rats O 0 0.029148294
. O 0 0.008653339

Effects O 0 0.0150215905
of O 0 0.008051429
uninephrectomy O 0 0.7370257
and O 0 0.0042461893
high O 0 0.0032191959
protein O 0 0.003813599
feeding O 0 0.0059249997
on O 0 0.0020141024
lithium B-Chemical 1 0.99987996
- O 0 0.012754995
induced O 0 0.004412703
chronic B-Disease 2 0.99752635
renal I-Disease 2 0.9992681
failure I-Disease 2 0.98995286
in O 0 0.0073837605
rats O 0 0.035401992
. O 0 0.010021936

Rats O 0 0.048718628
with O 0 0.010094751
lithium B-Chemical 1 0.9996245
- O 0 0.018147282
induced O 0 0.0058082757
nephropathy B-Disease 2 0.99994266
were O 0 0.0022437668
subjected O 0 0.00087113195
to O 0 0.0008291995
high O 0 0.0011064627
protein O 0 0.0026075763
( O 0 0.0028269805
HP O 0 0.613061
) O 0 0.002262415
feeding O 0 0.0028396011
, O 0 0.0014036854
uninephrectomy O 0 0.93039066
( O 0 0.0032320803
NX O 0 0.9965957
) O 0 0.0011824527
or O 0 0.00041012224
a O 0 0.0005418582
combination O 0 0.0006083466
of O 0 0.00055680965
these O 0 0.0007203154
, O 0 0.00077945966
in O 0 0.00044075117
an O 0 0.00067658396
attempt O 0 0.0006548164
to O 0 0.0005984745
induce O 0 0.00076409057
glomerular O 0 0.9655986
hyperfiltration O 0 0.99962723
and O 0 0.0024826743
further O 0 0.0023780875
progression O 0 0.4788589
of O 0 0.0082782265
renal B-Disease 0 0.9979373
failure I-Disease 0 0.9640798
. O 0 0.011436304

Newborn O 0 0.0303343
female O 0 0.015953396
Wistar O 0 0.05197116
rats O 0 0.007110597
were O 0 0.0029683767
fed O 0 0.003211785
a O 0 0.0038343302
lithium B-Chemical 1 0.9998292
- O 0 0.0049975445
containing O 0 0.0011590663
diet O 0 0.12876649
( O 0 0.0018151945
50 O 0 0.0013683321
mmol O 0 0.46445432
/ O 0 0.0021650791
kg O 0 0.0050650425
) O 0 0.00088700844
for O 0 0.00031741013
8 O 0 0.0003420553
weeks O 0 0.00023237067
and O 0 0.00034600872
then O 0 0.0003175799
randomized O 0 0.0004412262
to O 0 0.0003575905
normal O 0 0.0010187392
diet O 0 0.07308916
, O 0 0.0014763611
HP O 0 0.4165426
diet O 0 0.09849775
( O 0 0.0010773579
40 O 0 0.00059418596
vs O 0 0.00091453176
. O 0 0.00042699906
19 O 0 0.0008601921
% O 0 0.000852193
) O 0 0.0014025082
, O 0 0.0014263286
NX O 0 0.97524875
or O 0 0.0013598733
HP O 0 0.53359616
+ O 0 0.0031182042
NX O 0 0.9752289
for O 0 0.0016707971
another O 0 0.0028743024
8 O 0 0.0033857229
weeks O 0 0.0038278548
. O 0 0.0067376457

Corresponding O 0 0.031864647
non O 0 0.027274692
- O 0 0.027958525
lithium B-Chemical 1 0.9982913
pretreated O 0 0.08642801
groups O 0 0.01609612
were O 0 0.013821832
generated O 0 0.013381551
. O 0 0.017583355

When O 0 0.0062086047
comparing O 0 0.0034983829
all O 0 0.0035216692
lithium B-Chemical 1 0.99871886
treated O 0 0.0031071128
versus O 0 0.0019274858
non O 0 0.014324685
- O 0 0.019130252
lithium B-Chemical 1 0.9999293
- O 0 0.0049825823
treated O 0 0.0012323334
groups O 0 0.001713952
, O 0 0.0019736784
lithium B-Chemical 1 0.99981135
caused O 0 0.0009359002
a O 0 0.0009885601
reduction O 0 0.0009285202
in O 0 0.0004570616
glomerular O 0 0.8103915
filtration O 0 0.020229205
rate O 0 0.000744085
( O 0 0.0015770671
GFR O 0 0.99504256
) O 0 0.0009784125
without O 0 0.00035779175
significant O 0 0.00044509963
changes O 0 0.0005404624
in O 0 0.0003850264
effective O 0 0.00070889096
renal O 0 0.9807403
plasma O 0 0.067433916
flow O 0 0.015362483
( O 0 0.00083934865
as O 0 0.00043865692
determined O 0 0.00037042118
by O 0 0.00057988
a O 0 0.0007558247
marker O 0 0.0008002353
secreted O 0 0.0010784843
into O 0 0.000613659
the O 0 0.0010491827
proximal O 0 0.0023854442
tubules O 0 0.031098599
) O 0 0.006324935
or O 0 0.0045578917
lithium B-Chemical 1 0.99967396
clearance O 0 0.47191298
. O 0 0.010192194

Consequently O 0 0.011543613
, O 0 0.011287211
lithium B-Chemical 1 0.999062
pretreatment O 0 0.39092985
caused O 0 0.0041861576
a O 0 0.0035469567
fall O 0 0.004212999
in O 0 0.0015127872
filtration O 0 0.004470553
fraction O 0 0.0014949867
and O 0 0.0019935465
an O 0 0.0026074091
increase O 0 0.0020353775
in O 0 0.0034189164
fractional O 0 0.20471336
Li B-Chemical 1 0.9890892
excretion O 0 0.9767011
. O 0 0.011755253

Lithium B-Chemical 1 0.99909794
also O 0 0.012250181
caused O 0 0.013183943
proteinuria B-Disease 2 0.9997807
and O 0 0.014276524
systolic O 0 0.9799185
hypertension B-Disease 2 0.99978036
in O 0 0.005828416
absence O 0 0.004761826
of O 0 0.016954908
glomerulosclerosis B-Disease 2 0.9998574
. O 0 0.024307666

HP O 0 0.17093544
failed O 0 0.007195419
to O 0 0.004568392
accentuante O 0 0.015497019
progression O 0 0.17970969
of O 0 0.003929914
renal B-Disease 0 0.99359965
failure I-Disease 0 0.8633777
and O 0 0.001820053
in O 0 0.0008854357
fact O 0 0.00062636484
tended O 0 0.0007092904
to O 0 0.0006641358
increase O 0 0.00078222546
GFR O 0 0.99236745
and O 0 0.0012740943
decrease O 0 0.0012107078
plasma O 0 0.08677918
creatinine B-Chemical 1 0.99831605
levels O 0 0.0021095052
in O 0 0.0031414262
lithium B-Chemical 1 0.99973303
pretreated O 0 0.19053969
rats O 0 0.06090475
. O 0 0.009925607

NX O 0 0.96926886
caused O 0 0.009862248
an O 0 0.008036598
additive O 0 0.018453274
deterioration O 0 0.35731718
in O 0 0.0043546986
GFR O 0 0.9938432
which O 0 0.0045857443
, O 0 0.0038683123
however O 0 0.0034069766
, O 0 0.004186321
was O 0 0.0039738533
ameliorated O 0 0.3976622
by O 0 0.010674938
HP O 0 0.7602833
. O 0 0.011920076

NX O 0 0.9869459
+ O 0 0.014274919
HP O 0 0.1594675
caused O 0 0.0053649703
a O 0 0.0044825887
further O 0 0.003129055
rise O 0 0.0037423167
in O 0 0.0025770685
blood O 0 0.018885037
pressure O 0 0.13596565
in O 0 0.004972571
Li B-Chemical 1 0.9741353
- O 0 0.010883457
pretreated O 0 0.050983917
rats O 0 0.031519797
. O 0 0.011408041

The O 0 0.0076915114
results O 0 0.0057162913
indicate O 0 0.003863088
that O 0 0.0037652992
Li B-Chemical 1 0.98003525
- O 0 0.008518811
induced O 0 0.004417457
nephropathy B-Disease 2 0.99997663
, O 0 0.004275715
even O 0 0.001002158
when O 0 0.0005639674
the O 0 0.0008212398
GFR O 0 0.9907278
is O 0 0.00072159123
only O 0 0.0006702591
modestly O 0 0.020285968
reduced O 0 0.0010962099
, O 0 0.0014218753
is O 0 0.0009008921
associated O 0 0.0013413279
with O 0 0.0024999147
proteinuria B-Disease 2 0.99994457
and O 0 0.0057544075
arterial O 0 0.94574493
systolic O 0 0.9905945
hypertension B-Disease 2 0.9997923
. O 0 0.010784455

In O 0 0.0069361045
this O 0 0.004640229
model O 0 0.0038422863
of O 0 0.004133599
chronic B-Disease 2 0.98981535
renal I-Disease 2 0.99843496
failure I-Disease 2 0.9798661
the O 0 0.0017722968
decline O 0 0.0043690787
in O 0 0.0009173257
GFR O 0 0.99511564
is O 0 0.00066029286
not O 0 0.0004960149
accompanied O 0 0.0009934225
by O 0 0.00059142924
a O 0 0.0006463948
corresponding O 0 0.00037551232
fall O 0 0.0013489054
in O 0 0.00040782863
effective O 0 0.0007318711
renal O 0 0.9790243
plasma O 0 0.06548147
flow O 0 0.014913367
, O 0 0.00084702566
which O 0 0.00060358515
may O 0 0.00044153232
be O 0 0.00048261392
the O 0 0.00046336043
functional O 0 0.0007124718
expression O 0 0.00089863816
of O 0 0.0011298519
the O 0 0.0013402372
formation O 0 0.0038453045
of O 0 0.0036308907
nonfiltrating O 0 0.15930653
atubular O 0 0.5687094
glomeruli O 0 0.55458367
. O 0 0.01077945

The O 0 0.008697552
fractional O 0 0.021260336
reabsorption O 0 0.58006674
of O 0 0.004178125
tubular O 0 0.35381547
fluid O 0 0.06003403
by O 0 0.0019476234
the O 0 0.0012301626
proximal O 0 0.0018857509
tubules O 0 0.014298391
is O 0 0.0009993222
reduced O 0 0.0009884915
, O 0 0.0011270979
leaving O 0 0.0009577423
the O 0 0.00068327953
distal O 0 0.0010474391
delivery O 0 0.001423081
unchanged O 0 0.001342071
. O 0 0.0012767956
( O 0 0.0028060593
ABSTRACT O 0 0.011891775
TRUNCATED O 0 0.017314782
AT O 0 0.049602687
250 O 0 0.010620746
WORDS O 0 0.021996638
) O 0 0.030575335

Treatment O 0 0.025824433
of O 0 0.009264122
Crohn B-Disease 0 0.9957871
' I-Disease 0 0.0076918458
s I-Disease 0 0.0047300365
disease I-Disease 0 0.69653165
with O 0 0.0056841173
fusidic B-Chemical 0 0.99967945
acid I-Chemical 0 0.9889522
: O 0 0.00487227
an O 0 0.0022152057
antibiotic O 0 0.08135703
with O 0 0.002388587
immunosuppressive O 0 0.9590318
properties O 0 0.006253868
similar O 0 0.0033751654
to O 0 0.0073586055
cyclosporin B-Chemical 0 0.99988973
. O 0 0.015722545

Fusidic O 0 0.99831414
acid O 0 0.9830514
is O 0 0.006782077
an O 0 0.005448515
antibiotic O 0 0.11698859
with O 0 0.004583322
T O 0 0.92634356
- O 0 0.0049598725
cell O 0 0.005894814
specific O 0 0.0015597416
immunosuppressive O 0 0.9332037
effects O 0 0.005020455
similar O 0 0.0016947057
to O 0 0.0023750847
those O 0 0.0048601264
of O 0 0.010921544
cyclosporin B-Chemical 0 0.99989986
. O 0 0.015732465

Because O 0 0.006298241
of O 0 0.004945069
the O 0 0.003145468
need O 0 0.0020210422
for O 0 0.0013374207
the O 0 0.0012525468
development O 0 0.0016412477
of O 0 0.0011544703
new O 0 0.00127077
treatments O 0 0.0024965308
for O 0 0.0007469168
Crohn B-Disease 0 0.99930155
' I-Disease 0 0.0021151963
s I-Disease 0 0.0010707736
disease I-Disease 0 0.6111535
, O 0 0.001044294
a O 0 0.00072545046
pilot O 0 0.0008875033
study O 0 0.00053400063
was O 0 0.00036545287
undertaken O 0 0.0002886593
to O 0 0.0002891766
estimate O 0 0.0002687574
the O 0 0.0004382007
pharmacodynamics O 0 0.48630357
and O 0 0.00078543497
tolerability O 0 0.36154798
of O 0 0.0028817423
fusidic B-Chemical 0 0.99976844
acid I-Chemical 0 0.97798127
treatment O 0 0.0048674867
in O 0 0.0013066392
chronic O 0 0.9566782
active O 0 0.013756176
, O 0 0.0043776836
therapy O 0 0.043682408
- O 0 0.0059497044
resistant O 0 0.0050153933
patients O 0 0.019890958
. O 0 0.008356635

Eight O 0 0.03342031
Crohn B-Disease 0 0.9822313
' I-Disease 0 0.020556677
s I-Disease 0 0.016685119
disease I-Disease 0 0.4531831
patients O 0 0.024361435
were O 0 0.015204591
included O 0 0.015667118
. O 0 0.01804997

Fusidic B-Chemical 0 0.99844104
acid I-Chemical 0 0.9818324
was O 0 0.0053998013
administered O 0 0.0038460337
orally O 0 0.007578733
in O 0 0.0013703521
a O 0 0.0014232805
dose O 0 0.003557666
of O 0 0.0011525874
500 O 0 0.003396943
mg O 0 0.28433192
t O 0 0.0033621022
. O 0 0.0004854898
d O 0 0.0007167841
. O 0 0.00044266615
s O 0 0.0006690899
. O 0 0.00045408602
and O 0 0.0006416038
the O 0 0.0006934931
treatment O 0 0.0012427813
was O 0 0.0010909484
planned O 0 0.0015689116
to O 0 0.0014367801
last O 0 0.0017659712
8 O 0 0.0030422776
weeks O 0 0.003685502
. O 0 0.0066615436

The O 0 0.01151389
disease O 0 0.23878261
activity O 0 0.0076683336
was O 0 0.005049499
primarily O 0 0.0048589665
measured O 0 0.0031637826
by O 0 0.0040211086
a O 0 0.004620033
modified O 0 0.0051179132
individual O 0 0.0053910455
grading O 0 0.11754668
score O 0 0.013789215
. O 0 0.012211198

Five O 0 0.011093708
of O 0 0.0065180915
8 O 0 0.0043322938
patients O 0 0.0054103984
( O 0 0.0035062411
63 O 0 0.0033239692
% O 0 0.0022340817
) O 0 0.0022476579
improved O 0 0.0018239573
during O 0 0.0010656873
fusidic B-Chemical 0 0.99901545
acid I-Chemical 0 0.96460307
treatment O 0 0.0046561398
: O 0 0.0018350196
3 O 0 0.000717
at O 0 0.00052786927
two O 0 0.00063731417
weeks O 0 0.0007201678
and O 0 0.0012596679
2 O 0 0.0015078266
after O 0 0.001386495
four O 0 0.0025038559
weeks O 0 0.0039441832
. O 0 0.0068630134

There O 0 0.008524757
were O 0 0.0051364424
no O 0 0.0032643527
serious O 0 0.04205573
clinical O 0 0.011037879
side O 0 0.10205364
effects O 0 0.005514599
, O 0 0.0023917924
but O 0 0.001149098
dose O 0 0.007036413
reduction O 0 0.0015964766
was O 0 0.00086365803
required O 0 0.0005964146
in O 0 0.00095316215
two O 0 0.0012314286
patients O 0 0.0037018533
because O 0 0.0025475381
of O 0 0.011068892
nausea B-Disease 2 0.9999598
. O 0 0.013613059

Biochemically O 0 0.22570778
, O 0 0.008169224
an O 0 0.005219128
increase O 0 0.0027448079
in O 0 0.0025923895
alkaline O 0 0.55879724
phosphatases O 0 0.5523376
was O 0 0.0013121851
noted O 0 0.00073118554
in O 0 0.00063739833
5 O 0 0.0005117553
of O 0 0.00057900714
8 O 0 0.00054286554
cases O 0 0.00092246936
( O 0 0.00085795426
63 O 0 0.0010561474
% O 0 0.0007088279
) O 0 0.0008966718
, O 0 0.0005600858
and O 0 0.00043105028
the O 0 0.0003890262
greatest O 0 0.00074095844
increases O 0 0.0005224658
were O 0 0.0005711643
seen O 0 0.0005146409
in O 0 0.00058791717
those O 0 0.0010052943
who O 0 0.0016218656
had O 0 0.0010648324
elevated O 0 0.0030529029
levels O 0 0.0016962464
prior O 0 0.0018318081
to O 0 0.0033685104
treatment O 0 0.009137951
. O 0 0.008597597

All O 0 0.012289843
reversed O 0 0.011244328
to O 0 0.006945229
pre O 0 0.015283904
- O 0 0.007441076
treatment O 0 0.0051807105
levels O 0 0.0038004373
after O 0 0.0031925559
cessation O 0 0.012371042
of O 0 0.0077675744
treatment O 0 0.016588004
. O 0 0.012651826

The O 0 0.007009064
results O 0 0.0050766543
of O 0 0.0040966016
this O 0 0.0028113695
pilot O 0 0.0032318453
study O 0 0.0018713813
suggest O 0 0.0010310812
that O 0 0.0014578146
fusidic B-Chemical 0 0.9995659
acid I-Chemical 0 0.9805336
may O 0 0.0011544174
be O 0 0.0008022648
of O 0 0.00077241595
benefit O 0 0.0012628122
in O 0 0.0005165014
selected O 0 0.0005993724
chronic O 0 0.85718447
active O 0 0.0068215863
Crohn B-Disease 0 0.99964213
' I-Disease 0 0.0023094015
s I-Disease 0 0.0012014619
disease I-Disease 0 0.37107164
patients O 0 0.002970791
in O 0 0.0010850375
whom O 0 0.0032458527
conventional O 0 0.00235313
treatment O 0 0.004611958
is O 0 0.00469479
ineffective O 0 0.07796286
. O 0 0.009170555

Because O 0 0.006503274
there O 0 0.0038449503
seems O 0 0.0030365326
to O 0 0.0021654086
exist O 0 0.0017219047
a O 0 0.0018059475
scientific O 0 0.0022510525
rationale O 0 0.0013951693
for O 0 0.0006538644
the O 0 0.00070949865
use O 0 0.0008723847
of O 0 0.001823459
fusidic B-Chemical 0 0.99969816
acid I-Chemical 0 0.96567667
at O 0 0.00055383967
the O 0 0.0005630409
cytokine O 0 0.06861781
level O 0 0.00042593956
in O 0 0.00057933666
inflammatory B-Disease 0 0.9771792
bowel I-Disease 0 0.99599683
disease I-Disease 0 0.99134797
, O 0 0.0013637453
we O 0 0.00033725426
suggest O 0 0.00031698248
that O 0 0.00041427522
the O 0 0.0005587928
role O 0 0.00051363424
of O 0 0.0009869613
this O 0 0.00108548
treatment O 0 0.002021827
should O 0 0.0012707809
be O 0 0.0023546685
further O 0 0.0032561244
investigated O 0 0.004837989
. O 0 0.008365639

Changes O 0 0.018549629
in O 0 0.013531251
depressive B-Disease 2 0.9993249
status O 0 0.013788574
associated O 0 0.008331078
with O 0 0.009019844
topical O 0 0.9933981
beta O 0 0.9766674
- O 0 0.19617763
blockers O 0 0.99867404
. O 0 0.01802359

Depression B-Disease 2 0.9950159
and O 0 0.012265028
sexual B-Disease 2 0.91993845
dysfunction I-Disease 2 0.989609
have O 0 0.003443226
been O 0 0.0025913857
related O 0 0.0015994428
to O 0 0.0017414179
side O 0 0.040694848
effects O 0 0.0044617206
of O 0 0.005226605
topical O 0 0.9949803
beta O 0 0.9747547
- O 0 0.16106322
blockers O 0 0.99888223
. O 0 0.0129383225

We O 0 0.0073577617
performed O 0 0.0043867286
a O 0 0.003962044
preliminary O 0 0.0034378474
study O 0 0.002210573
in O 0 0.0012878149
order O 0 0.0008238526
to O 0 0.00070493476
determine O 0 0.00039232222
any O 0 0.0005034162
difference O 0 0.00034844043
between O 0 0.00033490185
a O 0 0.0007373635
non O 0 0.0017225416
selective O 0 0.020526383
beta O 0 0.8915804
- O 0 0.015403624
blocker O 0 0.9945686
( O 0 0.008715343
timolol B-Chemical 1 0.99998724
) O 0 0.002479454
and O 0 0.0007125057
a O 0 0.00094696064
selective O 0 0.0075139585
beta O 0 0.7440361
- O 0 0.009584195
blocker O 0 0.9904282
( O 0 0.0146484785
betaxolol B-Chemical 0 0.9999864
) O 0 0.005054715
regarding O 0 0.0020990877
CNS O 0 0.92802346
side O 0 0.17176789
effects O 0 0.01632603
. O 0 0.009187727

Eight O 0 0.019263074
glaucomatous B-Disease 0 0.9970757
patients O 0 0.01596791
chronically O 0 0.027066566
treated O 0 0.0032298737
with O 0 0.0026986275
timolol B-Chemical 1 0.9999652
0 O 0 0.0029232271
. O 0 0.0007169634
5 O 0 0.000633962
% O 0 0.0008527815
/ O 0 0.0016693852
12h O 0 0.012250186
, O 0 0.00096049096
suffering O 0 0.6811706
from O 0 0.0012841356
depression B-Disease 2 0.99927014
diagnosed O 0 0.087488554
through O 0 0.0014154607
DMS O 0 0.9988079
- O 0 0.0081788935
III O 0 0.25167334
- O 0 0.003812121
R O 0 0.8363842
criteria O 0 0.0018694141
, O 0 0.0018716075
were O 0 0.0014805107
included O 0 0.0016975938
in O 0 0.002283179
the O 0 0.003607713
study O 0 0.0069952505
. O 0 0.007991736

During O 0 0.006949246
the O 0 0.0051786
six O 0 0.003369271
- O 0 0.0037170474
month O 0 0.0017108951
follow O 0 0.0013811706
up O 0 0.0015166432
, O 0 0.002305408
depression B-Disease 2 0.9940176
was O 0 0.0011928492
quantified O 0 0.0009375968
through O 0 0.0009739371
the O 0 0.0014346554
Beck O 0 0.80586755
and O 0 0.0025085122
Zung O 0 0.96286476
- O 0 0.0034751347
Conde O 0 0.24155068
scales O 0 0.0025960638
every O 0 0.0017856471
two O 0 0.0031657636
months O 0 0.0048038056
. O 0 0.0076078023

In O 0 0.007320072
a O 0 0.0060223686
double O 0 0.003961781
blind O 0 0.007265212
cross O 0 0.0037372482
- O 0 0.002390805
over O 0 0.0008027531
study O 0 0.00096241245
with O 0 0.00073589035
control O 0 0.0006834506
group O 0 0.00087473064
, O 0 0.0007872562
the O 0 0.00046352544
patients O 0 0.0013056813
under O 0 0.00041433368
timolol B-Chemical 1 0.99997234
treatment O 0 0.0012198838
presented O 0 0.0007155576
higher O 0 0.0006597532
depression B-Disease 2 0.9973794
values O 0 0.0005718828
measured O 0 0.00034106718
through O 0 0.0004254007
the O 0 0.00063019985
Beck O 0 0.69068325
and O 0 0.0006978039
the O 0 0.00095196505
Zung O 0 0.97283
- O 0 0.0018227736
Conde O 0 0.40742865
scales O 0 0.0013261612
( O 0 0.0012492031
p O 0 0.0011859054
< O 0 0.0011345267
0 O 0 0.001470798
. O 0 0.0013312888
001 O 0 0.07206828
vs O 0 0.0037011532
control O 0 0.0038706316
) O 0 0.008811891
. O 0 0.0078006242

These O 0 0.009202829
results O 0 0.005756113
suggest O 0 0.0034455669
that O 0 0.0034047393
betaxolol B-Chemical 0 0.9999517
could O 0 0.0020772843
be O 0 0.0016349569
less O 0 0.0012301144
of O 0 0.0016508122
a O 0 0.0040312805
depression B-Disease 2 0.99958354
- O 0 0.008132482
inducer O 0 0.05880133
than O 0 0.0023769496
timolol B-Chemical 1 0.9999379
in O 0 0.004493644
predisposed O 0 0.26197955
patients O 0 0.051573493
. O 0 0.009828009

Protection O 0 0.050306275
against O 0 0.009696509
amphetamine B-Chemical 1 0.9999516
- O 0 0.055525776
induced O 0 0.009055542
neurotoxicity B-Disease 2 0.9999304
toward O 0 0.010501055
striatal O 0 0.99674773
dopamine B-Chemical 1 0.99988973
neurons O 0 0.054653436
in O 0 0.0011758858
rodents O 0 0.007078851
by O 0 0.0028414947
LY274614 B-Chemical 1 0.99988675
, O 0 0.0036808585
an O 0 0.004988547
excitatory O 0 0.997364
amino B-Chemical 1 0.9936778
acid I-Chemical 1 0.99844044
antagonist O 0 0.9962836
. O 0 0.014502822

LY274614 B-Chemical 1 0.99925965
, O 0 0.016406879
3SR B-Chemical 0 0.3774085
, I-Chemical 0 0.0065993806
4aRS I-Chemical 0 0.04105478
, I-Chemical 0 0.004721342
6SR I-Chemical 0 0.7553017
, I-Chemical 0 0.0030990413
8aRS I-Chemical 0 0.04188312
- I-Chemical 0 0.0024348684
6 I-Chemical 0 0.0009463455
- I-Chemical 0 0.0017920809
[ I-Chemical 0 0.0033815743
phosphonomethyl I-Chemical 0 0.9498314
] I-Chemical 0 0.004807026
decahydr I-Chemical 0 0.040933028
oisoquinoline I-Chemical 0 0.08631817
- I-Chemical 0 0.0026636792
3 I-Chemical 0 0.0008294742
- I-Chemical 0 0.0023763867
carboxylic I-Chemical 0 0.997695
acid I-Chemical 0 0.97258973
, O 0 0.0018157181
has O 0 0.00048330906
been O 0 0.0005194609
described O 0 0.00035916865
as O 0 0.00050772686
a O 0 0.0009094241
potent O 0 0.021542493
antagonist O 0 0.9178291
of O 0 0.0012733447
the O 0 0.0014988768
N B-Chemical 1 0.9974369
- I-Chemical 1 0.028092064
methyl I-Chemical 1 0.9961701
- I-Chemical 1 0.060684703
D I-Chemical 1 0.99128765
- I-Chemical 1 0.08126198
aspartate I-Chemical 1 0.9999356
( O 0 0.06474229
NMDA B-Chemical 1 0.9999821
) O 0 0.016678799
subtype O 0 0.1678972
of O 0 0.012396726
glutamate B-Chemical 1 0.99977344
receptor O 0 0.5515133
. O 0 0.010668192

Here O 0 0.009812026
its O 0 0.007367667
ability O 0 0.0040113083
to O 0 0.0027981182
antagonize O 0 0.006714995
the O 0 0.0017550639
prolonged O 0 0.008357904
depletion O 0 0.0032951287
of O 0 0.0029467451
dopamine B-Chemical 1 0.9998443
in O 0 0.0010154307
the O 0 0.0011168788
striatum O 0 0.53043574
by O 0 0.0019724276
amphetamine B-Chemical 1 0.9999877
in O 0 0.0038585109
iprindole B-Chemical 0 0.99999535
- O 0 0.0081616435
treated O 0 0.003514755
rats O 0 0.008221583
is O 0 0.0043948125
reported O 0 0.007738196
. O 0 0.008911771

A O 0 0.026584357
single O 0 0.0066445894
18 O 0 0.0043484927
. O 0 0.0024607705
4 O 0 0.0019402253
mg O 0 0.07073485
/ O 0 0.0031633393
kg O 0 0.007274514
( O 0 0.001717261
i O 0 0.0025335827
. O 0 0.0006465643
p O 0 0.00094091793
. O 0 0.00051776355
) O 0 0.0008846619
dose O 0 0.0020357624
of O 0 0.0008959139
( O 0 0.0016402933
+ O 0 0.0010595042
/ O 0 0.007131921
- O 0 0.0025705514
) O 0 0.0030646694
- O 0 0.0043105767
amphetamine B-Chemical 1 0.9999938
hemisulfate O 0 0.9999176
, O 0 0.0009986578
given O 0 0.00028108325
to O 0 0.0003732207
rats O 0 0.0016032205
pretreated O 0 0.010081318
with O 0 0.002269255
iprindole B-Chemical 0 0.99999833
, O 0 0.0017746792
resulted O 0 0.0005230191
in O 0 0.0005696909
persistent O 0 0.025942182
depletion O 0 0.002151331
of O 0 0.0023760612
dopamine B-Chemical 1 0.99973816
in O 0 0.0013706197
the O 0 0.0018596452
striatum O 0 0.2612916
1 O 0 0.002598381
week O 0 0.0025268183
later O 0 0.004036686
. O 0 0.0067555658

This O 0 0.01044382
prolonged O 0 0.010958616
depletion O 0 0.0062582167
of O 0 0.0052404823
dopamine B-Chemical 1 0.99966633
in O 0 0.0019108888
the O 0 0.0016694694
striatum O 0 0.6068071
was O 0 0.0013713338
antagonized O 0 0.77043676
by O 0 0.005048692
dizocilpine B-Chemical 0 0.99999595
( O 0 0.025924668
MK B-Chemical 0 0.99614966
- I-Chemical 0 0.0048322137
801 I-Chemical 0 0.6246549
, O 0 0.00071751466
a O 0 0.0006368194
non O 0 0.0017922667
- O 0 0.0016552481
competitive O 0 0.024951382
antagonist O 0 0.9656543
of O 0 0.008623845
NMDA B-Chemical 1 0.9999956
receptors O 0 0.52678436
) O 0 0.0031196852
or O 0 0.0008130962
by O 0 0.0016954134
LY274614 B-Chemical 1 0.9999087
( O 0 0.0018767043
a O 0 0.0016379912
competitive O 0 0.041921034
antagonist O 0 0.9706354
of O 0 0.025972335
NMDA B-Chemical 1 0.9999738
receptors O 0 0.7028974
) O 0 0.025262007
. O 0 0.008699088

The O 0 0.0077171605
protective O 0 0.0108121885
effect O 0 0.0040891394
of O 0 0.005659522
LY274614 B-Chemical 1 0.999858
was O 0 0.002450729
dose O 0 0.035294615
- O 0 0.0022451659
dependent O 0 0.00081636617
, O 0 0.0010803343
being O 0 0.0008846101
maximum O 0 0.00064785837
at O 0 0.00055278547
10 O 0 0.0008168058
- O 0 0.001193713
40 O 0 0.0010584036
mgkg O 0 0.6575265
( O 0 0.0021701627
i O 0 0.003846737
. O 0 0.0017293921
p O 0 0.0033605811
. O 0 0.0033837077
) O 0 0.008604297
. O 0 0.007699322

A O 0 0.033408303
10 O 0 0.0064822137
mg O 0 0.16603488
/ O 0 0.005851694
kg O 0 0.007745217
dose O 0 0.010444031
of O 0 0.0035821027
LY274614 B-Chemical 1 0.9999144
was O 0 0.0013545388
effective O 0 0.001069815
in O 0 0.000686878
antagonizing O 0 0.025080312
the O 0 0.0006397649
depletion O 0 0.001463034
of O 0 0.0015215982
dopamine B-Chemical 1 0.9998487
in O 0 0.0005450771
the O 0 0.0006018356
striatum O 0 0.324491
, O 0 0.00050354196
when O 0 0.00022141657
given O 0 0.00021797461
as O 0 0.00033436716
long O 0 0.0003752296
as O 0 0.00039137786
8 O 0 0.00037368017
hr O 0 0.00040313267
prior O 0 0.00028264566
to O 0 0.0005670446
amphetamine B-Chemical 1 0.9999788
but O 0 0.0007345693
not O 0 0.00056728034
when O 0 0.0004892276
given O 0 0.0005915691
24 O 0 0.0008708017
hr O 0 0.0015324894
prior O 0 0.0015996789
to O 0 0.0041850414
amphetamine B-Chemical 1 0.9999013
. O 0 0.010343839

Depletion O 0 0.051534995
of O 0 0.009173943
dopamine B-Chemical 1 0.99915636
in O 0 0.003081428
the O 0 0.0023642606
striatum O 0 0.4520134
was O 0 0.001273432
also O 0 0.0011779733
antagonized O 0 0.616916
when O 0 0.0009448562
LY274614 B-Chemical 1 0.99991727
was O 0 0.00054570165
given O 0 0.00027224154
after O 0 0.0002256049
the O 0 0.0003472331
injection O 0 0.0012699818
of O 0 0.0015753831
amphetamine B-Chemical 1 0.9999969
; O 0 0.034295462
LY274614 B-Chemical 1 0.99992216
protected O 0 0.00075057894
when O 0 0.00027425407
given O 0 0.00024147281
up O 0 0.00031896538
to O 0 0.0003156815
4 O 0 0.00033459387
hr O 0 0.0004015915
after O 0 0.0002515926
but O 0 0.00040313898
not O 0 0.00041064297
when O 0 0.00039478595
given O 0 0.00048739693
8 O 0 0.0007887998
or O 0 0.0009389127
24 O 0 0.0012324478
hr O 0 0.002423242
after O 0 0.002737197
amphetamine B-Chemical 1 0.9998665
. O 0 0.009710668

The O 0 0.0071795424
prolonged O 0 0.009977907
depletion O 0 0.0059797238
of O 0 0.004967159
dopamine B-Chemical 1 0.9996239
in O 0 0.0017591688
the O 0 0.0014221274
striatum O 0 0.29204607
in O 0 0.0007184826
mice O 0 0.00052668416
, O 0 0.0007062969
given O 0 0.0003312745
multiple O 0 0.0008726187
injections O 0 0.003075744
of O 0 0.0015189903
methamphetamine B-Chemical 1 0.99998784
, O 0 0.002114718
was O 0 0.0007654564
also O 0 0.0009820657
antagonized O 0 0.6791976
dose O 0 0.15595217
- O 0 0.012986084
dependently O 0 0.9168976
and O 0 0.0038015784
completely O 0 0.004590091
by O 0 0.010143143
LY274614 B-Chemical 1 0.99957997
. O 0 0.009833072

The O 0 0.007227561
data O 0 0.0058696293
strengthen O 0 0.0036137567
the O 0 0.0023606957
evidence O 0 0.0018033828
that O 0 0.0013260203
the O 0 0.0015768867
neurotoxic B-Disease 2 0.99861455
effect O 0 0.0015791375
of O 0 0.003718224
amphetamine B-Chemical 1 0.99999464
and O 0 0.001944
related O 0 0.00069868704
compounds O 0 0.8631692
toward O 0 0.0032168864
nigrostriatal O 0 0.9992213
dopamine B-Chemical 1 0.9999291
neurons O 0 0.08612409
involves O 0 0.0012898368
NMDA B-Chemical 1 0.99999344
receptors O 0 0.20820054
and O 0 0.00087179785
that O 0 0.00066967524
LY274614 B-Chemical 1 0.9999356
is O 0 0.00082902814
an O 0 0.0037644154
NMDA B-Chemical 1 0.9999926
receptor O 0 0.46149087
antagonist O 0 0.9655514
with O 0 0.0012960513
long O 0 0.0012904648
- O 0 0.001848426
lasting O 0 0.0017048384
in O 0 0.0012737258
vivo O 0 0.00251936
effects O 0 0.0041622147
in O 0 0.0040338454
rats O 0 0.015969783
. O 0 0.008470019

Ketoconazole B-Chemical 0 0.99889046
- O 0 0.069414854
induced O 0 0.04836455
neurologic B-Disease 0 0.99813217
sequelae I-Disease 0 0.9932597
. O 0 0.04461574

A O 0 0.042439293
77 O 0 0.014582256
- O 0 0.007664863
y O 0 0.010772568
- O 0 0.0039350875
old O 0 0.002271119
patient O 0 0.0022960214
developed O 0 0.0024616648
weakness B-Disease 2 0.9938799
of I-Disease 0 0.0025789235
extremities I-Disease 0 0.988453
, O 0 0.0070060673
legs B-Disease 0 0.9707919
paralysis I-Disease 2 0.9999831
, O 0 0.019722363
dysarthria B-Disease 0 0.9999455
and O 0 0.0028531407
tremor B-Disease 2 0.99996173
1 O 0 0.000789354
h O 0 0.00037543965
after O 0 0.00028940415
ingestion O 0 0.090008676
of O 0 0.0009069606
200 O 0 0.0030804381
mg O 0 0.64178985
ketoconazole B-Chemical 1 0.9999665
for O 0 0.000970153
the O 0 0.0011345359
first O 0 0.0012011812
time O 0 0.0016519104
in O 0 0.0027534175
his O 0 0.00680738
life O 0 0.013420311
. O 0 0.0088411765

All O 0 0.02755217
complaints O 0 0.36843556
faded O 0 0.036845896
away O 0 0.02005971
within O 0 0.012655455
24 O 0 0.014636218
h O 0 0.017462369
. O 0 0.021071097

Few O 0 0.009376415
days O 0 0.0044274093
later O 0 0.0032285815
, O 0 0.0028884658
the O 0 0.001714542
patient O 0 0.0018378578
used O 0 0.001051501
another O 0 0.0012174253
200 O 0 0.0023262622
mg O 0 0.63528174
ketoconazole B-Chemical 1 0.99998784
tablet O 0 0.9819186
, O 0 0.0013119376
and O 0 0.00060455874
within O 0 0.00029514532
an O 0 0.00054708833
hour O 0 0.00033764355
experienced O 0 0.00070764904
a O 0 0.0006565242
similar O 0 0.00044452885
clinical O 0 0.0028412067
picture O 0 0.001685314
, O 0 0.0014652273
which O 0 0.0013952863
resolved O 0 0.0025341928
again O 0 0.0020948418
spontaneously O 0 0.0065861642
within O 0 0.0023436588
hours O 0 0.0041963076
. O 0 0.006878719

Laboratory O 0 0.030882444
evaluations O 0 0.014424623
, O 0 0.011882063
including O 0 0.008920177
head O 0 0.07970328
CT O 0 0.6593127
scan O 0 0.016669314
, O 0 0.010889599
were O 0 0.010253169
normal O 0 0.015913254
. O 0 0.014610177

This O 0 0.009898881
case O 0 0.005208298
illustrates O 0 0.0034967242
the O 0 0.0026491953
need O 0 0.00188744
for O 0 0.0013732028
close O 0 0.0013853096
vigilance O 0 0.052267313
in O 0 0.0016133699
adverse B-Disease 0 0.9822143
drug I-Disease 0 0.83579904
reactions I-Disease 0 0.38712618
, O 0 0.0039524063
particularly O 0 0.0032906109
in O 0 0.0032218797
the O 0 0.005122125
elderly O 0 0.6098539
. O 0 0.009602552

Development O 0 0.027486887
of O 0 0.010425557
levodopa B-Chemical 1 0.9999293
- O 0 0.030508267
induced O 0 0.0059665693
dyskinesias B-Disease 2 0.99996746
in O 0 0.0032000002
parkinsonian B-Disease 2 0.9999474
monkeys O 0 0.0012776677
may O 0 0.0007047195
depend O 0 0.00059727335
upon O 0 0.00051324855
rate O 0 0.00068136776
of O 0 0.0011271987
symptom O 0 0.4214199
onset O 0 0.009104495
and O 0 0.0019680667
/ O 0 0.0042918012
or O 0 0.00190536
duration O 0 0.0033268486
of O 0 0.0061467984
symptoms O 0 0.9391543
. O 0 0.010229311

Levodopa B-Chemical 1 0.9997961
- O 0 0.035510283
induced O 0 0.0112547865
dyskinesias B-Disease 2 0.9999558
( O 0 0.057195794
LIDs B-Disease 2 0.9996798
) O 0 0.0031587726
present O 0 0.0007391364
a O 0 0.0010181512
major O 0 0.00094226626
problem O 0 0.001267336
for O 0 0.0005214618
the O 0 0.00066054094
long O 0 0.00085192017
- O 0 0.0011546557
term O 0 0.00066660024
management O 0 0.001621533
of O 0 0.0018177504
Parkinson B-Disease 0 0.99983835
' I-Disease 0 0.0030296303
s I-Disease 0 0.0024859277
disease I-Disease 0 0.7898833
( O 0 0.013012294
PD B-Disease 2 0.9984149
) O 0 0.0116914995
patients O 0 0.016911497
. O 0 0.008608639

Due O 0 0.008269959
to O 0 0.004743263
the O 0 0.0034683244
interdependence O 0 0.0040175524
of O 0 0.002804992
risk O 0 0.049734585
factors O 0 0.0074645784
in O 0 0.0012327865
clinical O 0 0.011036738
populations O 0 0.0026155876
, O 0 0.0012294949
it O 0 0.0007334404
is O 0 0.00054289366
difficult O 0 0.00046950587
to O 0 0.00047786455
independently O 0 0.00052152964
examine O 0 0.0004381974
factors O 0 0.002518878
that O 0 0.00085296
may O 0 0.0010864503
influence O 0 0.0012676669
the O 0 0.002187807
development O 0 0.006674736
of O 0 0.0140181575
LIDs B-Disease 2 0.9995264
. O 0 0.01050601

Using O 0 0.008127469
macaque O 0 0.004652084
monkeys O 0 0.0033733563
with O 0 0.0024409543
different O 0 0.0018004623
types O 0 0.0018981573
of O 0 0.0053606816
MPTP B-Chemical 1 0.9999949
- O 0 0.029392017
induced O 0 0.0042880126
parkinsonism B-Disease 2 0.99999094
, O 0 0.0017044588
the O 0 0.0005173593
current O 0 0.0007641559
study O 0 0.00046659092
evaluated O 0 0.00031523642
the O 0 0.00036196012
degree O 0 0.00050036894
to O 0 0.0003536973
which O 0 0.00048179433
rate O 0 0.00039190275
of O 0 0.00068632147
symptom O 0 0.65461075
progression O 0 0.6110832
, O 0 0.0020131173
symptom O 0 0.56046253
severity O 0 0.14268252
, O 0 0.0010474588
and O 0 0.00054176216
response O 0 0.00061913254
to O 0 0.0003979167
and O 0 0.0005144133
duration O 0 0.0006738805
of O 0 0.0013178312
levodopa B-Chemical 1 0.9999858
therapy O 0 0.034015786
may O 0 0.00096217956
be O 0 0.0010656001
involved O 0 0.0009629105
in O 0 0.0013025313
the O 0 0.0019774295
development O 0 0.005477082
of O 0 0.010781738
LIDs B-Disease 2 0.99945825
. O 0 0.010100361

Monkeys O 0 0.0304722
with O 0 0.00782146
acute O 0 0.86310154
( O 0 0.0064574787
short O 0 0.0027402525
- O 0 0.003376147
term O 0 0.0019490145
) O 0 0.01337254
MPTP B-Chemical 1 0.9999876
exposure O 0 0.012543284
, O 0 0.0014162239
rapid O 0 0.0017611318
symptom O 0 0.30171052
onset O 0 0.003537918
and O 0 0.00059674296
short O 0 0.00041395353
symptom O 0 0.11844028
duration O 0 0.00051845174
prior O 0 0.00027295263
to O 0 0.00035641226
initiation O 0 0.0005175847
of O 0 0.0009645909
levodopa B-Chemical 1 0.99998784
therapy O 0 0.044359475
developed O 0 0.0047080438
dyskinesia B-Disease 2 0.9999945
between O 0 0.0005766849
11 O 0 0.00096748216
and O 0 0.00071742205
24 O 0 0.0006110674
days O 0 0.00069696584
of O 0 0.0016003547
daily O 0 0.011757884
levodopa B-Chemical 1 0.9999267
administration O 0 0.47492495
. O 0 0.009471543

In O 0 0.0075666555
contrast O 0 0.005560517
, O 0 0.0044078045
monkeys O 0 0.0025656242
with O 0 0.002057811
long O 0 0.0021499558
- O 0 0.0027610273
term O 0 0.0018411068
MPTP B-Chemical 1 0.99998903
exposure O 0 0.01671593
, O 0 0.0016930569
slow O 0 0.0029984156
symptom O 0 0.53252107
progression O 0 0.40625665
and O 0 0.0010960444
/ O 0 0.0024704412
or O 0 0.00042206084
long O 0 0.00044836837
symptom O 0 0.092683986
duration O 0 0.00045889214
prior O 0 0.00024515527
to O 0 0.0003195358
initiation O 0 0.0004624195
of O 0 0.0008441926
levodopa B-Chemical 1 0.9999881
therapy O 0 0.020507723
were O 0 0.0005206733
more O 0 0.00049889577
resistant O 0 0.00056211115
to O 0 0.00047290942
developing O 0 0.021612354
LIDs B-Disease 2 0.99985397
( O 0 0.0013890754
e O 0 0.0016923107
. O 0 0.0003903405
g O 0 0.0009940767
. O 0 0.00042110615
, O 0 0.0009725897
dyskinesia B-Disease 2 0.99998677
developed O 0 0.00091469556
no O 0 0.00047328667
sooner O 0 0.0015637649
than O 0 0.0005088242
146 O 0 0.0021681343
days O 0 0.00070037297
of O 0 0.0017481353
chronic O 0 0.98892856
levodopa B-Chemical 1 0.99998164
administration O 0 0.79315424
) O 0 0.042117096
. O 0 0.0088762455

All O 0 0.007844309
animals O 0 0.005222122
were O 0 0.003862501
similarly O 0 0.0030141338
symptomatic O 0 0.016915388
at O 0 0.0013762324
the O 0 0.0012150604
start O 0 0.0010309732
of O 0 0.0017261994
levodopa B-Chemical 1 0.99996686
treatment O 0 0.0032096924
and O 0 0.0015024042
had O 0 0.0010993048
similar O 0 0.0009979226
therapeutic O 0 0.009623803
responses O 0 0.0041105147
to O 0 0.0028586672
the O 0 0.0045194016
drug O 0 0.71972626
. O 0 0.009480133

These O 0 0.008264208
data O 0 0.0055654654
suggest O 0 0.0025760964
distinct O 0 0.0023177245
differences O 0 0.0013266898
in O 0 0.0011951103
the O 0 0.0010433706
propensity O 0 0.002998638
to O 0 0.0008815024
develop O 0 0.0015284299
LIDs B-Disease 2 0.9995571
in O 0 0.0005683074
monkeys O 0 0.00046945576
with O 0 0.00040004362
different O 0 0.00034693195
rates O 0 0.00046845156
of O 0 0.0006783624
symptom O 0 0.5270134
progression O 0 0.3217907
or O 0 0.00063817546
symptom O 0 0.27964246
durations O 0 0.00055562635
prior O 0 0.00027952524
to O 0 0.00046897022
levodopa B-Chemical 1 0.999964
and O 0 0.0005485305
demonstrate O 0 0.0002724953
the O 0 0.00040302507
value O 0 0.00043748552
of O 0 0.0005302262
these O 0 0.0006736564
models O 0 0.0008810355
for O 0 0.00062967103
further O 0 0.0009906801
studying O 0 0.0016130767
the O 0 0.0021559165
pathophysiology O 0 0.39650953
of O 0 0.020860704
LIDs B-Disease 2 0.99957603
. O 0 0.010123443

A O 0 0.08679439
diet O 0 0.11857594
promoting O 0 0.008986957
sugar B-Disease 0 0.77655476
dependency I-Disease 0 0.061366186
causes O 0 0.0117288865
behavioral B-Disease 0 0.19345003
cross I-Disease 0 0.0061367503
- I-Disease 0 0.0039712074
sensitization I-Disease 0 0.06656621
to O 0 0.0017695961
a O 0 0.0026707773
low O 0 0.0031996274
dose O 0 0.048146274
of O 0 0.016977271
amphetamine B-Chemical 1 0.99993944
. O 0 0.013959464

Previous O 0 0.00954582
research O 0 0.006107204
in O 0 0.0033816323
this O 0 0.0024729702
laboratory O 0 0.0028352381
has O 0 0.0013697898
shown O 0 0.000925824
that O 0 0.00077736116
a O 0 0.0012214361
diet O 0 0.02787255
of O 0 0.0011514862
intermittent O 0 0.15348093
excessive O 0 0.16770513
sugar O 0 0.6601959
consumption O 0 0.30761087
produces O 0 0.0012121121
a O 0 0.0012590435
state O 0 0.001265473
with O 0 0.0011693143
neurochemical O 0 0.8299809
and O 0 0.001913243
behavioral O 0 0.04023059
similarities O 0 0.002265184
to O 0 0.0030817066
drug B-Disease 0 0.9410392
dependency I-Disease 0 0.13714597
. O 0 0.009604049

The O 0 0.0066776196
present O 0 0.0037850745
study O 0 0.0033198483
examined O 0 0.0017541101
whether O 0 0.0011150516
female O 0 0.004020842
rats O 0 0.0023177115
on O 0 0.0006730856
various O 0 0.0012643003
regimens O 0 0.005408798
of O 0 0.0012877077
sugar O 0 0.33033717
access O 0 0.0007605927
would O 0 0.0004894087
show O 0 0.0005186861
behavioral B-Disease 0 0.027677886
cross I-Disease 0 0.0021201486
- I-Disease 0 0.0020453776
sensitization I-Disease 0 0.03867428
to O 0 0.0011612882
a O 0 0.0019545103
low O 0 0.0024646888
dose O 0 0.040489465
of O 0 0.014461554
amphetamine B-Chemical 1 0.99994385
. O 0 0.012574679

After O 0 0.00605178
a O 0 0.005971158
30 O 0 0.0034705997
- O 0 0.003303339
min O 0 0.0018616633
baseline O 0 0.0013214477
measure O 0 0.0007172662
of O 0 0.0012217049
locomotor O 0 0.5606642
activity O 0 0.0012234831
( O 0 0.0009834864
day O 0 0.00052922947
0 O 0 0.0008432833
) O 0 0.00093552575
, O 0 0.0005615725
animals O 0 0.00034251474
were O 0 0.00035609442
maintained O 0 0.00027983935
on O 0 0.00025842694
a O 0 0.00064417045
cyclic O 0 0.16084173
diet O 0 0.052798618
of O 0 0.0008470712
12 O 0 0.00050704676
- O 0 0.0007812611
h O 0 0.0003392416
deprivation O 0 0.003258753
followed O 0 0.00033142394
by O 0 0.00050051213
12 O 0 0.00036496038
- O 0 0.0005639325
h O 0 0.00026426406
access O 0 0.0002990168
to O 0 0.00030983973
10 O 0 0.00043157034
% O 0 0.0006026441
sucrose B-Chemical 0 0.8002773
solution O 0 0.014834185
and O 0 0.00084811985
chow O 0 0.13258746
pellets O 0 0.046458412
( O 0 0.00078934454
12 O 0 0.00028217473
h O 0 0.0002539348
access O 0 0.00028346037
starting O 0 0.00031199114
4 O 0 0.00032762272
h O 0 0.00030196295
after O 0 0.00028531003
onset O 0 0.0010884517
of O 0 0.0007982362
the O 0 0.00088180054
dark O 0 0.0012253643
period O 0 0.0012559958
) O 0 0.0027110092
for O 0 0.0018642091
21 O 0 0.0037590298
days O 0 0.003845854
. O 0 0.0066747647

Locomotor O 0 0.31915897
activity O 0 0.0063557876
was O 0 0.0036831815
measured O 0 0.0021263205
again O 0 0.0019926052
for O 0 0.0012718273
30 O 0 0.0010419481
min O 0 0.001058563
at O 0 0.00070849754
the O 0 0.0007704213
beginning O 0 0.0007055282
of O 0 0.0010276786
days O 0 0.0010177643
1 O 0 0.0014706256
and O 0 0.001795231
21 O 0 0.0026023707
of O 0 0.0034981533
sugar O 0 0.2988991
access O 0 0.0076405318
. O 0 0.008915976

Beginning O 0 0.018156385
on O 0 0.006490643
day O 0 0.0056679267
22 O 0 0.0058097383
, O 0 0.0047458573
all O 0 0.0034441212
rats O 0 0.0051312353
were O 0 0.0037018128
maintained O 0 0.0033968657
on O 0 0.003771067
ad O 0 0.011203912
libitum O 0 0.021539114
chow O 0 0.23754816
. O 0 0.013340372

Nine O 0 0.012033191
days O 0 0.004726217
later O 0 0.003604329
locomotor O 0 0.22298348
activity O 0 0.002468966
was O 0 0.001464057
measured O 0 0.00089509104
in O 0 0.00086808525
response O 0 0.0010885446
to O 0 0.0007019794
a O 0 0.00091060164
single O 0 0.00071825157
low O 0 0.00085558434
dose O 0 0.008803533
of O 0 0.0025720324
amphetamine B-Chemical 1 0.9999906
( O 0 0.003700983
0 O 0 0.001711309
. O 0 0.0009713101
5 O 0 0.0014346247
mg O 0 0.11435442
/ O 0 0.0065206485
kg O 0 0.0155366175
) O 0 0.010150978
. O 0 0.008307364

The O 0 0.0068629878
animals O 0 0.004546776
that O 0 0.0029995719
had O 0 0.002527905
experienced O 0 0.00440838
cyclic O 0 0.64719075
sucrose B-Chemical 0 0.98621434
and O 0 0.0031389915
chow O 0 0.29666972
were O 0 0.0011467698
hyperactive B-Disease 0 0.6700295
in O 0 0.0005980756
response O 0 0.0008930754
to O 0 0.0006840403
amphetamine B-Chemical 1 0.99998474
compared O 0 0.00035217343
with O 0 0.00044448776
four O 0 0.00030847805
control O 0 0.00044012352
groups O 0 0.00077744486
( O 0 0.00083440065
ad O 0 0.0012808437
libitum O 0 0.0016051633
10 O 0 0.00048997346
% O 0 0.000616116
sucrose B-Chemical 0 0.727879
and O 0 0.00071293087
chow O 0 0.068318
followed O 0 0.00038312576
by O 0 0.0008188612
amphetamine B-Chemical 1 0.9999906
injection O 0 0.014791062
, O 0 0.0014482787
cyclic O 0 0.3397584
chow O 0 0.15671794
followed O 0 0.000436055
by O 0 0.0009269243
amphetamine B-Chemical 1 0.9999901
injection O 0 0.012391211
, O 0 0.0012095898
ad O 0 0.0022197096
libitum O 0 0.0038213818
chow O 0 0.08854683
with O 0 0.0010606061
amphetamine B-Chemical 1 0.99999034
, O 0 0.0014928216
or O 0 0.0007415603
cyclic O 0 0.23288618
10 O 0 0.0009971464
% O 0 0.0012891773
sucrose B-Chemical 0 0.816153
and O 0 0.0017416186
chow O 0 0.08681334
with O 0 0.0017788082
a O 0 0.0031618825
saline O 0 0.23801602
injection O 0 0.015561908
) O 0 0.012335722
. O 0 0.008088465

These O 0 0.008342841
results O 0 0.0050650733
suggest O 0 0.0028093702
that O 0 0.0022763177
a O 0 0.0027266315
diet O 0 0.025667422
comprised O 0 0.0015044828
of O 0 0.0015018956
alternating O 0 0.014157724
deprivation O 0 0.03959346
and O 0 0.0010070023
access O 0 0.00061480905
to O 0 0.00050031254
a O 0 0.00095138245
sugar O 0 0.31208578
solution O 0 0.037560035
and O 0 0.0010874122
chow O 0 0.17674018
produces O 0 0.000922167
bingeing O 0 0.99744946
on O 0 0.0003913331
sugar O 0 0.16941734
that O 0 0.0004106739
leads O 0 0.00045836178
to O 0 0.00036924746
a O 0 0.0005601363
long O 0 0.00042495734
lasting O 0 0.000795562
state O 0 0.00060917693
of O 0 0.0005940919
increased O 0 0.00079654204
sensitivity O 0 0.0018371433
to O 0 0.0009091318
amphetamine B-Chemical 1 0.9999927
, O 0 0.0017729094
possibly O 0 0.0015772277
due O 0 0.00053527317
to O 0 0.0006630436
a O 0 0.0011987687
lasting O 0 0.0020631647
alteration O 0 0.0022536747
in O 0 0.00207024
the O 0 0.004108483
dopamine B-Chemical 1 0.9993057
system O 0 0.012371724
. O 0 0.008762957

Reversible O 0 0.94261944
dilated B-Disease 2 0.98894554
cardiomyopathy I-Disease 2 0.99970454
related O 0 0.0155102
to O 0 0.017145133
amphotericin B-Chemical 1 0.9996419
B I-Chemical 1 0.98206985
therapy O 0 0.44227043
. O 0 0.02344466

We O 0 0.0073060943
describe O 0 0.004547575
a O 0 0.0042687636
patient O 0 0.00371907
who O 0 0.003831568
developed O 0 0.004269882
dilated B-Disease 2 0.9911233
cardiomyopathy I-Disease 2 0.99998736
and O 0 0.003194731
clinical O 0 0.076780215
congestive O 0 0.9999739
heart B-Disease 0 0.9023224
failure I-Disease 0 0.54845977
after O 0 0.000424552
2 O 0 0.00053776876
months O 0 0.00037697033
of O 0 0.00067258516
therapy O 0 0.006939045
with O 0 0.002139178
amphotericin B-Chemical 1 0.99996436
B I-Chemical 1 0.9866968
( O 0 0.03861109
AmB B-Chemical 1 0.99983156
) O 0 0.0089096865
for O 0 0.0034925134
disseminated O 0 0.99172944
coccidioidomycosis B-Disease 0 0.999688
. O 0 0.015066576

His O 0 0.021044368
echocardiographic O 0 0.050774153
abnormalities O 0 0.058304463
and O 0 0.005782658
heart B-Disease 0 0.50017124
failure I-Disease 0 0.56993186
resolved O 0 0.0073587163
after O 0 0.0027703766
posaconazole B-Chemical 0 0.99979705
was O 0 0.0057239365
substituted O 0 0.024153147
for O 0 0.0076606493
AmB B-Chemical 1 0.9992648
. O 0 0.014022022

It O 0 0.013042911
is O 0 0.0071510524
important O 0 0.004653349
to O 0 0.0038032928
recognize O 0 0.0032620975
the O 0 0.0033565832
rare O 0 0.01041081
and O 0 0.0044946317
potentially O 0 0.011724725
reversible O 0 0.81014
toxicity B-Disease 2 0.9990429
of O 0 0.06269894
AmB B-Chemical 1 0.9996859
. O 0 0.015718516

NO B-Chemical 0 0.9971334
- O 0 0.023412969
induced O 0 0.011314159
migraine B-Disease 2 0.999943
attack O 0 0.9327103
: O 0 0.0049933754
strong O 0 0.001995289
increase O 0 0.0010883792
in O 0 0.0011173228
plasma O 0 0.08291106
calcitonin B-Chemical 1 0.99595034
gene I-Chemical 0 0.0043950146
- I-Chemical 0 0.0023692257
related I-Chemical 0 0.00068150443
peptide I-Chemical 0 0.00945911
( O 0 0.0055167847
CGRP B-Chemical 1 0.9995615
) O 0 0.002452599
concentration O 0 0.0015019028
and O 0 0.0011089478
negative O 0 0.0014057135
correlation O 0 0.001311924
with O 0 0.0033250214
platelet O 0 0.99478084
serotonin B-Chemical 1 0.99979895
release O 0 0.44021443
. O 0 0.0097205555

The O 0 0.006776182
aim O 0 0.005319901
of O 0 0.003697466
the O 0 0.0024567726
present O 0 0.0014957108
study O 0 0.0017346257
was O 0 0.0010840601
to O 0 0.0007376229
investigate O 0 0.00048223865
changes O 0 0.0009782028
in O 0 0.0006308339
the O 0 0.0007474244
plasma O 0 0.07160807
calcitonin B-Chemical 1 0.99596584
gene I-Chemical 0 0.003892115
- I-Chemical 0 0.0020473036
related I-Chemical 0 0.00048456975
peptide I-Chemical 0 0.010714444
( O 0 0.0055832495
CGRP B-Chemical 1 0.9997559
) O 0 0.0021702368
concentration O 0 0.0012609451
and O 0 0.00086590176
platelet O 0 0.98388666
serotonin B-Chemical 1 0.9999336
( O 0 0.0019564359
5 B-Chemical 0 0.0005556401
- I-Chemical 0 0.000864156
hydroxytriptamine I-Chemical 0 0.006206581
, O 0 0.0008096502
5 B-Chemical 0 0.000543559
- I-Chemical 0 0.001380362
HT I-Chemical 0 0.9878628
) O 0 0.0010168047
content O 0 0.00042637103
during O 0 0.00032901653
the O 0 0.0005084383
immediate O 0 0.002477966
headache B-Disease 2 0.9999223
and O 0 0.0012301438
the O 0 0.0010661616
delayed O 0 0.010490795
genuine O 0 0.04355278
migraine B-Disease 2 0.99998057
attack O 0 0.9487831
provoked O 0 0.6917068
by O 0 0.033550907
nitroglycerin B-Chemical 1 0.9999459
. O 0 0.012940539

Fifteen O 0 0.018806282
female O 0 0.034885786
migraineurs B-Disease 0 0.99763584
( I-Disease 0 0.00996634
without I-Disease 0 0.0067680525
aura I-Disease 0 0.9999112
) I-Disease 0 0.008906264
and O 0 0.003280693
eight O 0 0.0024835037
controls O 0 0.0049241926
participated O 0 0.0071916184
in O 0 0.0039843833
the O 0 0.0054136766
study O 0 0.009326973
. O 0 0.010197217

Sublingual O 0 0.9915555
nitroglycerin B-Chemical 1 0.9998234
( O 0 0.017792951
0 O 0 0.008589984
. O 0 0.004950816
5 O 0 0.0051762788
mg O 0 0.18287914
) O 0 0.010156984
was O 0 0.0077052037
administered O 0 0.012013688
. O 0 0.012514212

Blood O 0 0.036625627
was O 0 0.005665243
collected O 0 0.0033073006
from O 0 0.0024944285
the O 0 0.0018227563
antecubital O 0 0.0024217523
vein O 0 0.0042493423
four O 0 0.0008346694
times O 0 0.0006815835
: O 0 0.0009366005
60 O 0 0.00052866584
min O 0 0.00046607392
before O 0 0.00027348535
and O 0 0.00041694992
after O 0 0.0002756029
the O 0 0.0005748793
nitroglycerin B-Chemical 1 0.9999864
application O 0 0.002218258
, O 0 0.000821002
and O 0 0.00047906634
60 O 0 0.0003728413
and O 0 0.00035181406
120 O 0 0.0003715887
min O 0 0.00029993302
after O 0 0.0001916669
the O 0 0.00029238494
beginning O 0 0.00028943198
of O 0 0.00057407824
the O 0 0.0010010037
migraine B-Disease 2 0.9999864
attack O 0 0.7790748
( O 0 0.0017224326
mean O 0 0.00086835155
344 O 0 0.011285354
and O 0 0.0012452475
404 O 0 0.008958387
min O 0 0.0017422148
; O 0 0.0026335306
12 O 0 0.001895341
subjects O 0 0.0044404133
) O 0 0.0077543114
. O 0 0.007338431

In O 0 0.007794921
those O 0 0.0060855695
subjects O 0 0.004928428
who O 0 0.004014453
had O 0 0.0021943308
no O 0 0.0021259766
migraine B-Disease 2 0.99995935
attack O 0 0.87831634
( O 0 0.003553144
11 O 0 0.0017757913
subjects O 0 0.0019667812
) O 0 0.0019691845
a O 0 0.001542183
similar O 0 0.0012397291
time O 0 0.00175974
schedule O 0 0.00341315
was O 0 0.0038410947
used O 0 0.0056592803
. O 0 0.008383791

Plasma O 0 0.5284279
CGRP B-Chemical 1 0.99732023
concentration O 0 0.0101262815
increased O 0 0.004605699
significantly O 0 0.0040956717
( O 0 0.0038099596
P O 0 0.09966013
< O 0 0.0014248873
0 O 0 0.001262737
. O 0 0.0006992492
01 O 0 0.0033814071
) O 0 0.00096764445
during O 0 0.00046582747
the O 0 0.0008675056
migraine B-Disease 2 0.99997354
attack O 0 0.5761007
and O 0 0.0011320735
returned O 0 0.0007611604
to O 0 0.0005984877
baseline O 0 0.00082613516
after O 0 0.00061503856
the O 0 0.0011790454
cessation O 0 0.0052145426
of O 0 0.0033894256
the O 0 0.0070451135
migraine B-Disease 2 0.9999021
. O 0 0.012061425

In O 0 0.0073768585
addition O 0 0.0042760135
, O 0 0.004360173
both O 0 0.002430658
change O 0 0.0020352672
and O 0 0.0017066296
peak O 0 0.0015820491
, O 0 0.0012603975
showed O 0 0.0006527148
significant O 0 0.0007400344
positive O 0 0.00081014266
correlations O 0 0.0009745442
with O 0 0.0025881466
migraine B-Disease 2 0.99999666
headache B-Disease 0 0.9999896
intensity O 0 0.0026512607
( O 0 0.004120394
P O 0 0.119968936
< O 0 0.002273877
0 O 0 0.0029377663
. O 0 0.0028712077
001 O 0 0.19803555
) O 0 0.008608729
. O 0 0.007894184

However O 0 0.011162156
, O 0 0.009381402
plasma O 0 0.060200967
CGRP B-Chemical 1 0.99849594
concentrations O 0 0.0068030707
failed O 0 0.002106035
to O 0 0.0013260292
change O 0 0.0012507192
during O 0 0.00085297704
immediate O 0 0.0037774618
headache B-Disease 2 0.9999052
and O 0 0.0017335362
in O 0 0.0011715156
the O 0 0.0013240965
subjects O 0 0.0025570723
with O 0 0.0024606357
no O 0 0.0038281258
migraine B-Disease 2 0.9999343
attack O 0 0.93763626
. O 0 0.012790061

Basal O 0 0.4114876
CGRP B-Chemical 1 0.9969921
concentration O 0 0.0090019265
was O 0 0.0031948742
significantly O 0 0.0024885375
higher O 0 0.0016421761
and O 0 0.0019541988
platelet O 0 0.9490081
5 B-Chemical 0 0.0019753943
- I-Chemical 0 0.0037276184
HT I-Chemical 0 0.98485756
content O 0 0.00096574443
tended O 0 0.00077014574
to O 0 0.00069142546
be O 0 0.00081679266
lower O 0 0.0008246137
in O 0 0.0009218112
subjects O 0 0.002008204
who O 0 0.002959741
experienced O 0 0.004669105
a O 0 0.0111504365
migraine B-Disease 2 0.99994195
attack O 0 0.9403561
. O 0 0.0126259485

Platelet O 0 0.9791012
serotonin B-Chemical 1 0.9989397
content O 0 0.0061212988
decreased O 0 0.0051123057
significantly O 0 0.0038481986
( O 0 0.0035993473
P O 0 0.09432072
< O 0 0.0013524622
0 O 0 0.0011942846
. O 0 0.0006403301
01 O 0 0.0035694984
) O 0 0.0009085438
after O 0 0.0004012073
nitroglycerin B-Chemical 1 0.99996185
in O 0 0.0005510752
subjects O 0 0.0009280355
with O 0 0.0005398173
no O 0 0.0006097194
migraine B-Disease 2 0.9999863
attack O 0 0.6636554
but O 0 0.0007076733
no O 0 0.00043268115
consistent O 0 0.000578977
change O 0 0.0007649474
was O 0 0.0007655881
observed O 0 0.00072359724
in O 0 0.0013913919
patients O 0 0.007987159
with O 0 0.0076484033
migraine B-Disease 2 0.9999558
attack O 0 0.95066404
. O 0 0.012319309

In O 0 0.007143093
conclusion O 0 0.0046323077
, O 0 0.0043151467
the O 0 0.0023744118
fact O 0 0.0015468686
that O 0 0.0014178419
plasma O 0 0.07935086
CGRP B-Chemical 1 0.99953413
concentration O 0 0.003264644
correlates O 0 0.00094530516
with O 0 0.0007112506
the O 0 0.00056421955
timing O 0 0.00056591316
and O 0 0.00076090003
severity O 0 0.037873883
of O 0 0.0014868134
a O 0 0.012779061
migraine B-Disease 2 0.9999975
headache B-Disease 0 0.9999893
suggests O 0 0.0009300941
a O 0 0.0015680768
direct O 0 0.0012829945
relationship O 0 0.0014600694
between O 0 0.002433964
CGRP B-Chemical 1 0.99936944
and O 0 0.030121636
migraine B-Disease 2 0.9999144
. O 0 0.013643468

In O 0 0.00794532
contrast O 0 0.0065446226
, O 0 0.007328649
serotonin B-Chemical 1 0.99912804
release O 0 0.11624476
from O 0 0.002046091
platelets O 0 0.36804205
does O 0 0.001091124
not O 0 0.0011066619
provoke O 0 0.17460284
migraine B-Disease 2 0.9999906
, O 0 0.002787008
it O 0 0.00087721914
may O 0 0.0005821283
even O 0 0.00068347825
counteract O 0 0.0015652762
the O 0 0.0013146519
headache B-Disease 2 0.9999424
and O 0 0.0015764651
the O 0 0.0013763765
concomitant O 0 0.025608078
CGRP B-Chemical 1 0.99953866
release O 0 0.084082864
in O 0 0.00293956
this O 0 0.0039141006
model O 0 0.0070507633
. O 0 0.008538089

Hyperbaric O 0 0.96384287
oxygen B-Chemical 1 0.96626794
therapy O 0 0.018982803
for O 0 0.003752147
control O 0 0.003513773
of O 0 0.004998223
intractable O 0 0.9940646
cyclophosphamide B-Chemical 1 0.99993765
- O 0 0.09374008
induced O 0 0.033971153
hemorrhagic B-Disease 2 0.9998889
cystitis I-Disease 0 0.9999579
. O 0 0.052166335

We O 0 0.008652788
report O 0 0.007848893
a O 0 0.004926707
case O 0 0.0033203948
of O 0 0.003800842
intractable O 0 0.98661625
hemorrhagic B-Disease 2 0.9999223
cystitis I-Disease 0 0.9999838
due O 0 0.0030839164
to O 0 0.0026072254
cyclophosphamide B-Chemical 1 0.999871
therapy O 0 0.052422754
for O 0 0.002437731
Wegener B-Disease 0 0.9745875
' I-Disease 0 0.006588542
s I-Disease 0 0.00688031
granulomatosis I-Disease 0 0.98059344
. O 0 0.012716732

Conservative O 0 0.16244532
treatment O 0 0.0096857725
, O 0 0.005617196
including O 0 0.0031830464
bladder O 0 0.74599004
irrigation O 0 0.032783005
with O 0 0.001973128
physiological O 0 0.00589934
saline O 0 0.21068013
and O 0 0.0016035533
instillation O 0 0.13150582
of O 0 0.014184356
prostaglandin B-Chemical 0 0.9999956
F2 I-Chemical 0 0.98863107
alpha I-Chemical 0 0.9263218
, O 0 0.00330503
failed O 0 0.0020178729
to O 0 0.0021320607
totally O 0 0.006533403
control O 0 0.0064931735
hemorrhage B-Disease 2 0.99957806
. O 0 0.011080842

We O 0 0.0077849403
then O 0 0.0049153944
used O 0 0.0036834406
hyperbaric O 0 0.76140296
oxygen B-Chemical 1 0.9543346
at O 0 0.001525787
an O 0 0.0015265006
absolute O 0 0.0012846641
pressure O 0 0.012439469
of O 0 0.0012998693
2 O 0 0.0011901831
atm O 0 0.1500366
, O 0 0.0012055351
5 O 0 0.00068839284
days O 0 0.00062937033
a O 0 0.0010881117
week O 0 0.00096221396
for O 0 0.001252087
8 O 0 0.002046619
consecutive O 0 0.0032128708
weeks O 0 0.0039614276
. O 0 0.0069138133

The O 0 0.010048469
bleeding B-Disease 2 0.9939924
ceased O 0 0.012306703
completely O 0 0.0039834715
by O 0 0.0027354236
the O 0 0.0018168396
end O 0 0.0012009094
of O 0 0.0015814503
treatment O 0 0.002125649
and O 0 0.0016866525
the O 0 0.0014786454
patient O 0 0.0024060088
remained O 0 0.0022485137
free O 0 0.003724195
of O 0 0.007614999
hematuria B-Disease 2 0.99985707
thereafter O 0 0.013187236
. O 0 0.009668683

No O 0 0.016427375
side O 0 0.03002894
effect O 0 0.007647448
was O 0 0.006182668
noted O 0 0.004707244
during O 0 0.004099374
the O 0 0.005014877
course O 0 0.0068130596
of O 0 0.009516906
therapy O 0 0.106933154
. O 0 0.014124345

In O 0 0.007909118
future O 0 0.005501147
, O 0 0.004390391
this O 0 0.0024686276
form O 0 0.0019393455
of O 0 0.0019582214
therapy O 0 0.006528184
can O 0 0.0009830142
offer O 0 0.0011920303
a O 0 0.0011271777
safe O 0 0.0014695814
alternative O 0 0.0008281548
in O 0 0.0007308205
the O 0 0.00087468885
treatment O 0 0.0017669885
of O 0 0.0035150626
cyclophosphamide B-Chemical 1 0.99994445
- O 0 0.040029306
induced O 0 0.019750262
hemorrhagic B-Disease 2 0.9999176
cystitis I-Disease 0 0.99996686
. O 0 0.042636514

Acute B-Disease 0 0.9963903
psychosis I-Disease 0 0.999617
due O 0 0.0077689276
to O 0 0.0055511934
treatment O 0 0.007472771
with O 0 0.007884584
phenytoin B-Chemical 1 0.99995136
in O 0 0.006764597
a O 0 0.012163874
nonepileptic O 0 0.99886656
patient O 0 0.017423494
. O 0 0.012421644

The O 0 0.0075744735
development O 0 0.0074303877
of O 0 0.0058769775
psychosis B-Disease 0 0.99955827
related O 0 0.0021383213
to O 0 0.001822234
antiepileptic O 0 0.9996513
drug O 0 0.8349158
treatment O 0 0.0031802228
is O 0 0.00087259494
usually O 0 0.0010992393
attributed O 0 0.0005688748
to O 0 0.00051227066
the O 0 0.0005443998
interaction O 0 0.0006657223
between O 0 0.0005252663
the O 0 0.0013066808
epileptic B-Disease 2 0.99986196
brain O 0 0.22628084
substratum O 0 0.15432267
and O 0 0.0029597776
the O 0 0.0036763253
antiepileptic O 0 0.99959356
drugs O 0 0.95170534
. O 0 0.010493536

The O 0 0.0075702667
case O 0 0.0054591475
of O 0 0.004527527
a O 0 0.0048940787
nonepileptic O 0 0.9976406
patient O 0 0.004393715
who O 0 0.0040773503
developed O 0 0.00426726
psychosis B-Disease 0 0.9998698
following O 0 0.0038552538
phenytoin B-Chemical 1 0.99998546
treatment O 0 0.0067118094
for O 0 0.0027508433
trigeminal B-Disease 0 0.97632706
neuralgia I-Disease 0 0.9999455
is O 0 0.0067216675
described O 0 0.00631033
. O 0 0.00923372

This O 0 0.0095089935
case O 0 0.00484509
suggests O 0 0.0025700391
that O 0 0.0022515678
the O 0 0.003239715
psychotic B-Disease 2 0.9999838
symptoms I-Disease 2 0.99361503
that O 0 0.0011919268
occur O 0 0.0011504698
following O 0 0.0012601647
phenytoin B-Chemical 1 0.99999213
treatment O 0 0.0022964135
in O 0 0.00069509796
some O 0 0.0010924814
epileptic B-Disease 2 0.9998779
patients O 0 0.005992159
may O 0 0.00061592023
be O 0 0.0006030552
the O 0 0.0005328125
direct O 0 0.0006698319
result O 0 0.0008710879
of O 0 0.0016116964
medication O 0 0.29414967
, O 0 0.003315136
unrelated O 0 0.009474126
to O 0 0.0062049637
seizures B-Disease 2 0.99986434
. O 0 0.011086539

Risks O 0 0.11889801
of O 0 0.016409649
the O 0 0.013167519
consumption O 0 0.07128804
of O 0 0.017817352
beverages O 0 0.987485
containing O 0 0.027370822
quinine B-Chemical 1 0.99917185
. O 0 0.024342645

Although O 0 0.008462494
the O 0 0.006872426
United O 0 0.008726616
States O 0 0.011542443
Food O 0 0.52799857
and O 0 0.0034553716
Drug O 0 0.97777176
Administration O 0 0.45837727
banned O 0 0.048509076
its O 0 0.001525896
use O 0 0.0008387259
for O 0 0.0006007579
nocturnal B-Disease 0 0.8422167
leg I-Disease 0 0.8173394
cramps I-Disease 0 0.9999882
due O 0 0.00056961924
to O 0 0.00044532263
lack O 0 0.0003947897
of O 0 0.0005667566
safety O 0 0.0015269034
and O 0 0.00070610375
efficacy O 0 0.005194065
, O 0 0.00204149
quinine B-Chemical 1 0.99966466
is O 0 0.0007987791
widely O 0 0.00107782
available O 0 0.00079354725
in O 0 0.0010230932
beverages O 0 0.9406909
including O 0 0.0025159996
tonic O 0 0.88979536
water O 0 0.09531812
and O 0 0.009113426
bitter O 0 0.9823428
lemon O 0 0.99110764
. O 0 0.015518881

Numerous O 0 0.011169075
anecdotal O 0 0.015018875
reports O 0 0.0047211805
suggest O 0 0.0022043157
that O 0 0.0018583232
products O 0 0.0068506612
containing O 0 0.0019437234
quinine B-Chemical 1 0.9997658
may O 0 0.0012271993
produce O 0 0.0010292075
neurological B-Disease 0 0.9995376
complications I-Disease 0 0.99235314
, O 0 0.002375129
including O 0 0.00096141896
confusion B-Disease 2 0.9667721
, O 0 0.001733263
altered O 0 0.001254993
mental O 0 0.43291652
status O 0 0.003055964
, O 0 0.004495549
seizures B-Disease 2 0.9999763
, O 0 0.0031673277
and O 0 0.0029397781
coma B-Disease 2 0.9998902
, O 0 0.0033854079
particularly O 0 0.00305907
in O 0 0.0032026523
older O 0 0.026586974
women O 0 0.12889647
. O 0 0.008811021

Psychologists O 0 0.020651195
need O 0 0.0059352224
to O 0 0.004168809
inquire O 0 0.0055481885
about O 0 0.0025134974
consumption O 0 0.047964327
of O 0 0.00500407
quinine B-Chemical 1 0.99985564
- O 0 0.0065316483
containing O 0 0.0018618556
beverages O 0 0.94116443
as O 0 0.0023109766
part O 0 0.001918014
of O 0 0.0027199243
an O 0 0.0043669245
evaluation O 0 0.005492485
process O 0 0.007296044
. O 0 0.009463039

Transient O 0 0.60830814
platypnea B-Disease 0 0.9476662
- I-Disease 0 0.017821142
orthodeoxia I-Disease 0 0.9894029
- I-Disease 0 0.0069068265
like I-Disease 0 0.0028798992
syndrome I-Disease 0 0.8456489
induced O 0 0.003647212
by O 0 0.006609216
propafenone B-Chemical 0 0.9999949
overdose B-Disease 2 0.9999621
in O 0 0.0017802346
a O 0 0.0023579549
young O 0 0.008827332
woman O 0 0.022360826
with O 0 0.0032881577
Ebstein B-Disease 0 0.48536006
' I-Disease 0 0.0059848046
s I-Disease 0 0.0068805413
anomaly I-Disease 0 0.13559325
. O 0 0.0096829515

In O 0 0.007207683
this O 0 0.004763867
report O 0 0.0045787715
we O 0 0.0018170875
describe O 0 0.0015590073
the O 0 0.0013376588
case O 0 0.0011615593
of O 0 0.0012179797
a O 0 0.0014792553
37 O 0 0.0014160015
- O 0 0.0012970804
year O 0 0.0006959981
- O 0 0.0008896336
old O 0 0.00063935795
white O 0 0.0015856179
woman O 0 0.0069477777
with O 0 0.00076370925
Ebstein B-Disease 0 0.30265367
' I-Disease 0 0.000940192
s I-Disease 0 0.0007250223
anomaly I-Disease 0 0.043438613
, O 0 0.0007046645
who O 0 0.00082628516
developed O 0 0.0006572414
a O 0 0.00078489893
rare O 0 0.015191981
syndrome O 0 0.91058147
called O 0 0.0026608151
platypnea B-Disease 0 0.98038095
- I-Disease 0 0.007409674
orthodeoxia I-Disease 0 0.9890854
, O 0 0.0010074176
characterized O 0 0.00088801596
by O 0 0.00073106674
massive O 0 0.035173044
right O 0 0.006361156
- O 0 0.0013939914
to O 0 0.000634509
- O 0 0.001195549
left O 0 0.001337171
interatrial O 0 0.013931144
shunting O 0 0.11956111
with O 0 0.0013611141
transient O 0 0.037534524
profound O 0 0.14101368
hypoxia B-Disease 2 0.9964128
and O 0 0.02332136
cyanosis B-Disease 0 0.999164
. O 0 0.01153681

This O 0 0.010183298
shunt O 0 0.011760816
of O 0 0.0043188445
blood O 0 0.007939751
via O 0 0.0023430747
a O 0 0.002559911
patent B-Disease 0 0.04842909
foramen I-Disease 0 0.102548756
ovale I-Disease 0 0.867374
occurred O 0 0.00094695296
in O 0 0.00060913106
the O 0 0.00055540394
presence O 0 0.0004990451
of O 0 0.0006806033
a O 0 0.00085058354
normal O 0 0.0012901826
pulmonary O 0 0.79169405
artery O 0 0.3628705
pressure O 0 0.11975211
, O 0 0.0012978208
and O 0 0.0010013797
was O 0 0.0010132664
probably O 0 0.0018736592
precipitated O 0 0.009949561
by O 0 0.0033622142
a O 0 0.016175106
propafenone B-Chemical 0 0.99998343
overdose B-Disease 2 0.9998764
. O 0 0.012215449

This O 0 0.011186541
drug O 0 0.2787749
caused O 0 0.0069143465
biventricular B-Disease 0 0.96797
dysfunction I-Disease 0 0.9975441
, O 0 0.0032387157
due O 0 0.0009541842
to O 0 0.00083745853
its O 0 0.0012999281
negative O 0 0.0013263645
inotropic O 0 0.99566287
effect O 0 0.0016136972
, O 0 0.0020374265
and O 0 0.0020655901
hypotension B-Disease 2 0.99996424
, O 0 0.0021742089
due O 0 0.0009648174
to O 0 0.0013372093
its O 0 0.0033255557
peripheral O 0 0.22731318
vasodilatory O 0 0.996136
effect O 0 0.010224884
. O 0 0.009659572

These O 0 0.008696487
effects O 0 0.0063756756
gave O 0 0.0043454138
rise O 0 0.003541852
to O 0 0.0017977931
an O 0 0.0018546405
increase O 0 0.0009170211
in O 0 0.0007849943
the O 0 0.00076397957
right O 0 0.002387651
atrial O 0 0.9395678
pressure O 0 0.041456815
and O 0 0.0006605535
a O 0 0.000667818
decrease O 0 0.00042458926
in O 0 0.00035574386
the O 0 0.000385156
left O 0 0.0007481128
one O 0 0.00032055945
with O 0 0.0003981645
a O 0 0.00060057273
consequent O 0 0.0013132878
stretching O 0 0.010284563
of O 0 0.00068561547
the O 0 0.00067039137
foramen O 0 0.087503016
ovale O 0 0.62999666
and O 0 0.00063307985
the O 0 0.0005731537
creation O 0 0.00094357156
of O 0 0.0010693041
massive O 0 0.044608478
right O 0 0.009106979
- O 0 0.0032349268
to O 0 0.0021257945
- O 0 0.004780174
left O 0 0.007510233
shunting O 0 0.41711393
. O 0 0.0080935005

In O 0 0.008862656
our O 0 0.005993849
case O 0 0.0049112653
this O 0 0.0038789304
interatrial O 0 0.011735638
shunt O 0 0.01120787
was O 0 0.0025528253
very O 0 0.002495529
accurately O 0 0.0021878683
detected O 0 0.001979308
at O 0 0.0025735213
bubble O 0 0.024843402
contrast O 0 0.006217915
echocardiography O 0 0.35983038
. O 0 0.010357538

Noxious O 0 0.9766846
chemical O 0 0.05070348
stimulation O 0 0.00643487
of O 0 0.0036549312
rat O 0 0.009347264
facial O 0 0.28792256
mucosa O 0 0.66100705
increases O 0 0.0016940725
intracranial O 0 0.9609263
blood O 0 0.023820251
flow O 0 0.004756125
through O 0 0.0006572843
a O 0 0.0011620988
trigemino O 0 0.12791301
- O 0 0.0039614043
parasympathetic O 0 0.9979716
reflex O 0 0.96801364
- O 0 0.0036602153
- O 0 0.0012089078
an O 0 0.0008029186
experimental O 0 0.00083987677
model O 0 0.0011750757
for O 0 0.0012668817
vascular B-Disease 0 0.98503715
dysfunctions I-Disease 0 0.99706763
in O 0 0.0045770356
cluster B-Disease 0 0.03597368
headache I-Disease 2 0.99982303
. O 0 0.011171144

Cluster B-Disease 0 0.8136303
headache I-Disease 2 0.99972016
is O 0 0.007113413
characterized O 0 0.005881498
by O 0 0.00402045
typical O 0 0.0043182457
autonomic O 0 0.98424906
dysfunctions O 0 0.95179695
including O 0 0.003644911
facial O 0 0.48178783
and O 0 0.007959069
intracranial B-Disease 0 0.9980294
vascular I-Disease 0 0.98304075
disturbances I-Disease 0 0.9811451
. O 0 0.012742998

Both O 0 0.010895435
the O 0 0.0074601807
trigeminal O 0 0.23556128
and O 0 0.0049230503
the O 0 0.003834277
cranial O 0 0.4260153
parasympathetic O 0 0.99543095
systems O 0 0.0049815513
may O 0 0.0024246927
be O 0 0.0024513097
involved O 0 0.0022160406
in O 0 0.0027339228
mediating O 0 0.0038945118
these O 0 0.00836219
dysfunctions O 0 0.9736945
. O 0 0.012183907

An O 0 0.0108511355
experimental O 0 0.00577749
model O 0 0.0043787765
was O 0 0.002963667
developed O 0 0.0025738531
in O 0 0.0014952187
the O 0 0.0012621911
rat O 0 0.002698417
to O 0 0.00077872607
measure O 0 0.00050882995
changes O 0 0.000998654
in O 0 0.0009230952
lacrimation O 0 0.9997594
and O 0 0.0016046201
intracranial O 0 0.9613526
blood O 0 0.017528312
flow O 0 0.0045008897
following O 0 0.001286434
noxious O 0 0.89285153
chemical O 0 0.06425752
stimulation O 0 0.005560633
of O 0 0.0054642837
facial O 0 0.74695814
mucosa O 0 0.92309326
. O 0 0.011856177

Blood O 0 0.048145667
flow O 0 0.0123432195
was O 0 0.0048324955
monitored O 0 0.0025707118
in O 0 0.0025814846
arteries O 0 0.099996366
of O 0 0.0022245825
the O 0 0.001694266
exposed O 0 0.0017817213
cranial O 0 0.3946918
dura O 0 0.58740395
mater O 0 0.7533746
and O 0 0.0023540612
the O 0 0.0023101398
parietal O 0 0.57248515
cortex O 0 0.06820214
using O 0 0.003150124
laser O 0 0.013412269
Doppler O 0 0.36524063
flowmetry O 0 0.45033813
. O 0 0.010602494

Capsaicin B-Chemical 1 0.99946374
( O 0 0.013563732
0 O 0 0.0065010167
. O 0 0.003180167
01 O 0 0.010215928
- O 0 0.0029419202
1 O 0 0.0015496674
mm O 0 0.0027249812
) O 0 0.0015266903
applied O 0 0.00070587365
to O 0 0.0006544645
oral O 0 0.10830427
or O 0 0.00080196554
nasal O 0 0.03210084
mucosa O 0 0.6791381
induced O 0 0.0013522853
increases B-Disease 0 0.00102471
in I-Disease 0 0.0010822224
dural I-Disease 0 0.91190094
and I-Disease 0 0.0017714249
cortical I-Disease 0 0.04140681
blood I-Disease 0 0.021924233
flow I-Disease 0 0.0130311325
and O 0 0.004577789
provoked O 0 0.5552295
lacrimation O 0 0.9995902
. O 0 0.013159713

These O 0 0.010335876
responses O 0 0.008843902
were O 0 0.0049651894
blocked O 0 0.0049632364
by O 0 0.0033541578
systemic O 0 0.87425286
pre O 0 0.09258116
- O 0 0.0049106106
administration O 0 0.117896736
of O 0 0.01574073
hexamethonium B-Chemical 1 0.99999726
chloride I-Chemical 0 0.9999713
( O 0 0.01348089
20 O 0 0.0032284076
mg O 0 0.43350238
/ O 0 0.009599093
kg O 0 0.023263296
) O 0 0.011338289
. O 0 0.008892062

The O 0 0.007713941
evoked O 0 0.037150256
increases B-Disease 0 0.003603406
in I-Disease 0 0.0025657057
dural I-Disease 0 0.78204304
blood I-Disease 0 0.019351047
flow I-Disease 0 0.0066860644
were O 0 0.0010930997
also O 0 0.0009228565
abolished O 0 0.0014595503
by O 0 0.0010401887
topical O 0 0.9397889
pre O 0 0.07047101
- O 0 0.0023368138
administration O 0 0.047020532
of O 0 0.002211238
atropine B-Chemical 1 0.9999889
( O 0 0.0034965684
1 O 0 0.00078553753
mm O 0 0.0025829691
) O 0 0.0010934736
and O 0 0.0007560873
[ O 0 0.0035752025
Lys1 O 0 0.10877384
, O 0 0.0012735145
Pro2 O 0 0.2663081
, O 0 0.00071169616
5 O 0 0.00045014045
, O 0 0.0007932252
Arg3 O 0 0.42022958
, O 0 0.00074179954
4 O 0 0.00048338136
, O 0 0.00083641027
Tyr6 O 0 0.7225261
] O 0 0.0029751766
- O 0 0.0017581183
VIP O 0 0.98345816
( O 0 0.0009794207
0 O 0 0.0006828516
. O 0 0.0003396886
1 O 0 0.0004858486
mm O 0 0.00131773
) O 0 0.000945674
, O 0 0.00065549515
a O 0 0.0007230341
vasoactive O 0 0.76627576
intestinal O 0 0.417556
polypeptide O 0 0.3911121
( O 0 0.0095412
VIP O 0 0.9975496
) O 0 0.009485803
antagonist O 0 0.91575503
, O 0 0.002458539
onto O 0 0.0018376226
the O 0 0.0023689633
exposed O 0 0.004285208
dura O 0 0.76500934
mater O 0 0.9261104
. O 0 0.01133839

We O 0 0.0073561436
conclude O 0 0.0045691226
that O 0 0.0036137328
noxious O 0 0.7439689
stimulation O 0 0.004409663
of O 0 0.0026276095
facial O 0 0.35459352
mucosa O 0 0.72390306
increases O 0 0.0018919962
intracranial O 0 0.9706556
blood O 0 0.03581342
flow O 0 0.012575791
and O 0 0.0024387527
lacrimation O 0 0.9996039
via O 0 0.0022984475
a O 0 0.0041618864
trigemino O 0 0.23324776
- O 0 0.0179714
parasympathetic O 0 0.99723274
reflex O 0 0.94599587
. O 0 0.01121497

The O 0 0.00822683
blood O 0 0.013052971
flow O 0 0.010860029
responses O 0 0.0060823807
seem O 0 0.0032036176
to O 0 0.0021124342
be O 0 0.0019336444
mediated O 0 0.0015805253
by O 0 0.0017861741
the O 0 0.0016275801
release O 0 0.04229379
of O 0 0.004150593
acetylcholine B-Chemical 1 0.99975246
and O 0 0.006200907
VIP O 0 0.9903831
within O 0 0.0027589756
the O 0 0.0054660724
meninges O 0 0.69502014
. O 0 0.010415861

Similar O 0 0.011576783
mechanisms O 0 0.010919035
may O 0 0.0073561184
be O 0 0.0059176125
involved O 0 0.0043951543
in O 0 0.0041342215
the O 0 0.004514952
pathogenesis O 0 0.013600112
of O 0 0.009958369
cluster B-Disease 0 0.05173758
headache I-Disease 2 0.99976
. O 0 0.016830225

Organophosphate B-Chemical 0 0.9991571
- O 0 0.032843452
induced O 0 0.019124778
convulsions B-Disease 2 0.9997563
and O 0 0.016527494
prevention O 0 0.054578457
of O 0 0.020742353
neuropathological B-Disease 0 0.9968479
damages I-Disease 0 0.9940526
. O 0 0.023277577

Such O 0 0.032260116
organophosphorus B-Chemical 0 0.99973565
( O 0 0.06088783
OP B-Chemical 0 0.99921024
) O 0 0.018677225
compounds O 0 0.82944626
as O 0 0.007178227
diisopropylfluorophosphate B-Chemical 0 0.9999616
( O 0 0.10501363
DFP B-Chemical 1 0.9999652
) O 0 0.02605512
, O 0 0.004224573
sarin B-Chemical 0 0.999926
and O 0 0.0035768847
soman B-Chemical 0 0.99990714
are O 0 0.001402328
potent O 0 0.027054626
inhibitors O 0 0.07745375
of O 0 0.0026103486
acetylcholinesterases O 0 0.93187475
( O 0 0.007134242
AChEs O 0 0.8418255
) O 0 0.003450564
and O 0 0.0025818234
butyrylcholinesterases O 0 0.74809915
( O 0 0.007563084
BChEs O 0 0.4129312
) O 0 0.011661307
. O 0 0.007964903

The O 0 0.009124378
acute O 0 0.87359947
toxicity B-Disease 2 0.9967527
of O 0 0.010051814
OPs B-Chemical 0 0.9864574
is O 0 0.0017469291
the O 0 0.0010509052
result O 0 0.0008599287
of O 0 0.000999126
their O 0 0.0011030366
irreversible O 0 0.4103883
binding O 0 0.0010394334
with O 0 0.0010362926
AChEs O 0 0.6483433
in O 0 0.00050390133
the O 0 0.0005500283
central O 0 0.0022329108
nervous O 0 0.96604574
system O 0 0.0033473563
( O 0 0.002745817
CNS O 0 0.9451071
) O 0 0.0031572867
, O 0 0.0015429013
which O 0 0.00187695
elevates O 0 0.2308339
acetylcholine B-Chemical 1 0.9998324
( O 0 0.035039123
ACh B-Chemical 1 0.99968994
) O 0 0.009844998
levels O 0 0.0059274156
. O 0 0.0077906293

The O 0 0.0075526107
protective O 0 0.0105939545
action O 0 0.008144508
of O 0 0.0036361818
subcutaneously O 0 0.022436349
( O 0 0.0045120437
SC O 0 0.5143676
) O 0 0.0025505943
administered O 0 0.0014701384
antidotes O 0 0.76938516
or O 0 0.00069961447
their O 0 0.00068090815
combinations O 0 0.00078962406
in O 0 0.0010306598
DFP B-Chemical 1 0.99994445
( O 0 0.0016478851
2 O 0 0.00057132065
. O 0 0.0003366333
0 O 0 0.00054445706
mg O 0 0.066173516
/ O 0 0.001318725
kg O 0 0.0066852095
BW O 0 0.53294194
) O 0 0.0022971968
intoxication O 0 0.99834836
was O 0 0.0007051625
studied O 0 0.00067293074
in O 0 0.00062926963
9 O 0 0.00087886263
- O 0 0.0010953858
10 O 0 0.00075345405
- O 0 0.0011135817
weeks O 0 0.0007153595
- O 0 0.001692935
old O 0 0.0021972896
Han O 0 0.6638792
- O 0 0.004601969
Wistar O 0 0.06902025
male O 0 0.014698054
rats O 0 0.013929933
. O 0 0.009482443

The O 0 0.00832723
rats O 0 0.009404818
received O 0 0.005510073
AChE O 0 0.9242136
reactivator O 0 0.92544377
pralidoxime B-Chemical 0 0.99976844
- I-Chemical 0 0.011892514
2 I-Chemical 0 0.0019526267
- I-Chemical 0 0.0045523
chloride I-Chemical 0 0.99984384
( O 0 0.0065414524
2PAM B-Chemical 1 0.9948685
) O 0 0.002614655
( O 0 0.0008887316
30 O 0 0.0003743878
. O 0 0.00030749847
0 O 0 0.0004834735
mg O 0 0.04654608
/ O 0 0.0012076884
kg O 0 0.0064353
BW O 0 0.54810053
) O 0 0.0020608373
, O 0 0.001222132
anticonvulsant O 0 0.99989045
diazepam B-Chemical 1 0.99999535
( O 0 0.0019589562
2 O 0 0.00053986645
. O 0 0.00031019413
0 O 0 0.0004993044
mg O 0 0.05647978
/ O 0 0.0011977461
kg O 0 0.005735506
BW O 0 0.49042925
) O 0 0.0017493189
, O 0 0.00095545873
A O 0 0.05258718
( O 0 0.0010579561
1 O 0 0.00072039134
) O 0 0.0016051298
- O 0 0.0018873528
adenosine B-Chemical 1 0.9984413
receptor O 0 0.40209344
agonist O 0 0.9827795
N B-Chemical 0 0.9964922
( I-Chemical 0 0.0017452618
6 I-Chemical 0 0.00052960444
) I-Chemical 0 0.0016359276
- I-Chemical 0 0.002335385
cyclopentyl I-Chemical 0 0.99865085
adenosine I-Chemical 1 0.99974257
( O 0 0.012481263
CPA B-Chemical 1 0.99985874
) O 0 0.0041170125
( O 0 0.00087123114
2 O 0 0.0004365632
. O 0 0.0002859023
0 O 0 0.00046676042
mg O 0 0.04974559
/ O 0 0.0011904042
kg O 0 0.0071695945
BW O 0 0.6335823
) O 0 0.0041777226
, O 0 0.0041071377
NMDA B-Chemical 1 0.99999404
- O 0 0.013593385
receptor O 0 0.42330784
antagonist O 0 0.99823725
dizocilpine B-Chemical 0 0.9999987
maleate I-Chemical 0 0.99999917
( O 0 0.03957665
+ O 0 0.0062043457
- O 0 0.024359228
MK801 O 1 0.99999833
hydrogen O 0 0.9999747
maleate O 0 0.9999989
) O 0 0.028065436
( O 0 0.00121028
2 O 0 0.00046554778
. O 0 0.0002850088
0 O 0 0.00045815564
mg O 0 0.049588054
/ O 0 0.0010877728
kg O 0 0.004456551
BW O 0 0.34788418
) O 0 0.000879193
or O 0 0.0003595359
their O 0 0.0004032199
combinations O 0 0.0004731218
with O 0 0.0007422202
cholinolytic O 0 0.9998834
drug O 0 0.97593874
atropine B-Chemical 1 0.9999975
sulfate I-Chemical 0 0.99993265
( O 0 0.0042366
50 O 0 0.0010142374
. O 0 0.0003335865
0 O 0 0.0005313532
mg O 0 0.058970068
/ O 0 0.001202765
kg O 0 0.004070627
BW O 0 0.2784217
) O 0 0.0009919642
immediately O 0 0.00047523194
or O 0 0.00048236325
30 O 0 0.0004557747
min O 0 0.00061068224
after O 0 0.00049325766
the O 0 0.00093675125
single O 0 0.0017184664
SC O 0 0.21377246
injection O 0 0.008880995
of O 0 0.011448352
DFP B-Chemical 1 0.999689
. O 0 0.011675488

The O 0 0.0074265203
control O 0 0.0054920083
rats O 0 0.0069853906
received O 0 0.005080061
atropine B-Chemical 1 0.9999713
sulfate I-Chemical 0 0.9998123
, O 0 0.005649894
but O 0 0.0014400445
also O 0 0.0012885783
saline O 0 0.1575095
and O 0 0.0017875178
olive O 0 0.7434244
oil O 0 0.9284581
instead O 0 0.0017434245
of O 0 0.0020288709
other O 0 0.0026914363
antidotes O 0 0.9814866
and O 0 0.017684577
DFP B-Chemical 1 0.99984705
, O 0 0.0122246295
respectively O 0 0.014129844
. O 0 0.009197161

All O 0 0.010009412
rats O 0 0.009738486
were O 0 0.005266452
terminated O 0 0.005013901
either O 0 0.0028770263
24 O 0 0.001984981
h O 0 0.0017165451
or O 0 0.0017695221
3 O 0 0.0017788775
weeks O 0 0.0015701528
after O 0 0.0018868353
the O 0 0.0045470805
DFP B-Chemical 1 0.99939966
injection O 0 0.041871626
. O 0 0.011005872

The O 0 0.009636113
rats O 0 0.010926886
treated O 0 0.007285649
with O 0 0.008739169
DFP B-Chemical 1 0.9998481
- O 0 0.062628694
atropine B-Chemical 1 0.9999199
showed O 0 0.0035742738
severe O 0 0.4755145
typical O 0 0.014811004
OP B-Chemical 0 0.9996717
- O 0 0.02343603
induced O 0 0.009732937
toxicity B-Disease 2 0.9991358
signs O 0 0.910824
. O 0 0.013572703

When O 0 0.010717919
CPA B-Chemical 1 0.99799025
, O 0 0.013933163
diazepam B-Chemical 1 0.9999405
or O 0 0.0048725246
2PAM B-Chemical 1 0.98509324
was O 0 0.0014315102
given O 0 0.0007334292
immediately O 0 0.00090090575
after O 0 0.00076946197
DFP B-Chemical 1 0.9999391
- O 0 0.020218963
atropine B-Chemical 1 0.9999757
, O 0 0.0015583661
these O 0 0.0008580736
treatments O 0 0.0032169048
prevented O 0 0.0031267507
, O 0 0.0012851524
delayed O 0 0.002860971
or O 0 0.000772204
shortened O 0 0.0013764238
the O 0 0.00090587017
occurrence O 0 0.0027419575
of O 0 0.0026545348
serious O 0 0.6540433
signs O 0 0.77072865
of O 0 0.026015934
poisoning B-Disease 2 0.9997354
. O 0 0.01466417

Atropine B-Chemical 0 0.9998293
- O 0 0.13995297
MK801 B-Chemical 1 0.99989855
did O 0 0.006127986
not O 0 0.0039222315
offer O 0 0.0037891562
any O 0 0.0030398634
additional O 0 0.0029219643
protection O 0 0.01290025
against O 0 0.01025507
DFP B-Chemical 1 0.9998122
toxicity B-Disease 2 0.99910516
. O 0 0.0180255

In O 0 0.0077919755
conclusion O 0 0.0056400844
, O 0 0.00837345
CPA B-Chemical 1 0.9991738
, O 0 0.012622792
diazepam B-Chemical 1 0.99997616
and O 0 0.005125042
2PAM B-Chemical 1 0.9904541
in O 0 0.0010792345
combination O 0 0.0019737761
with O 0 0.001662386
atropine B-Chemical 1 0.99997854
prevented O 0 0.004872663
the O 0 0.00068803335
occurrence O 0 0.0019907693
of O 0 0.0011000255
serious O 0 0.4690297
signs O 0 0.5072834
of O 0 0.0032263189
poisoning B-Disease 2 0.9999052
and O 0 0.0020152796
thus O 0 0.0020153807
reduced O 0 0.001415839
the O 0 0.0019777964
toxicity B-Disease 2 0.99824166
of O 0 0.018236367
DFP B-Chemical 1 0.99985516
in O 0 0.006250541
rat O 0 0.060387164
. O 0 0.009335556

A O 0 0.5923843
pyridoxine B-Chemical 1 0.9997309
- O 0 0.026796352
dependent O 0 0.010788455
behavioral B-Disease 0 0.8127642
disorder I-Disease 0 0.99841607
unmasked O 0 0.937648
by O 0 0.038607072
isoniazid B-Chemical 1 0.999703
. O 0 0.019608678

A O 0 0.045820296
3 O 0 0.0076058367
- O 0 0.006512733
year O 0 0.0035219102
- O 0 0.0032640637
old O 0 0.0021534662
girl O 0 0.004626733
had O 0 0.0015674201
behavioral B-Disease 0 0.46013963
deterioration I-Disease 0 0.890526
, O 0 0.002553256
with O 0 0.0020263244
hyperkinesis B-Disease 0 0.9998055
, O 0 0.012431827
irritability B-Disease 2 0.99996233
, O 0 0.0019716441
and O 0 0.001204626
sleeping B-Disease 0 0.5726505
difficulties I-Disease 0 0.036944166
after O 0 0.0006948211
the O 0 0.0012329099
therapeutic O 0 0.022439046
administration O 0 0.22450113
of O 0 0.015742479
isoniazid B-Chemical 1 0.99986243
. O 0 0.010957033

The O 0 0.008442313
administration O 0 0.019522885
of O 0 0.005967664
pharmacologic O 0 0.45606312
doses O 0 0.26391983
of O 0 0.041909974
pyridoxine B-Chemical 1 0.99999404
hydrochloride I-Chemical 0 0.9999045
led O 0 0.0053458083
to O 0 0.002750044
a O 0 0.0042291004
disappearance O 0 0.011374232
of O 0 0.007954132
symptoms O 0 0.94311446
. O 0 0.011809887

After O 0 0.0071703037
discontinuing O 0 0.38356847
isoniazid B-Chemical 1 0.99961144
therapy O 0 0.019835113
a O 0 0.0028074326
similar O 0 0.0013272768
pattern O 0 0.001314987
of O 0 0.0017846571
behavior O 0 0.005416537
was O 0 0.001608958
noted O 0 0.0014223347
that O 0 0.0016424317
was O 0 0.002539777
controlled O 0 0.0038362227
by O 0 0.009144923
pyridoxine B-Chemical 1 0.9998988
. O 0 0.013832847

A O 0 0.041761294
placebo O 0 0.06114328
had O 0 0.0052738516
no O 0 0.0036486206
effect O 0 0.0040096724
, O 0 0.0054329024
but O 0 0.0049329717
niacinamide B-Chemical 0 0.9998747
was O 0 0.0048812074
as O 0 0.004500935
effective O 0 0.007149738
as O 0 0.013303768
pyridoxine B-Chemical 1 0.99990714
. O 0 0.017128149

Periodic O 0 0.040464275
withdrawal O 0 0.7835176
of O 0 0.019779148
pyridoxine B-Chemical 1 0.9999056
was O 0 0.007837755
associated O 0 0.0057331272
with O 0 0.0050931307
return O 0 0.0070745493
of O 0 0.006715568
the O 0 0.00987467
hyperkinesis B-Disease 0 0.9986524
. O 0 0.015200228

The O 0 0.00930926
level O 0 0.0062475377
of O 0 0.008026279
pyridoxal B-Chemical 0 0.9995408
in O 0 0.0041542724
the O 0 0.0030067547
blood O 0 0.009712324
was O 0 0.0026031157
normal O 0 0.0033364028
during O 0 0.0020313514
the O 0 0.0028625599
periods O 0 0.00444163
of O 0 0.0075615556
relapse O 0 0.99053824
. O 0 0.013387495

Metabolic O 0 0.24924175
studies O 0 0.010183385
suggested O 0 0.0064574415
a O 0 0.0066492083
block O 0 0.0061990265
in O 0 0.0045100027
the O 0 0.00581362
kynurenine B-Chemical 0 0.99917394
pathway O 0 0.012740563
of O 0 0.015016743
tryptophan B-Chemical 0 0.9979138
metabolism O 0 0.88132006
. O 0 0.014273237

The O 0 0.00782731
patient O 0 0.0071072048
has O 0 0.0037253029
been O 0 0.002822755
followed O 0 0.00167531
for O 0 0.0012489652
six O 0 0.0009924736
years O 0 0.0015487928
and O 0 0.0011676052
has O 0 0.000828642
required O 0 0.0006603023
pharmacologic O 0 0.16172461
doses O 0 0.082118705
of O 0 0.0077602793
pyridoxine B-Chemical 1 0.9999752
to O 0 0.0031879565
control O 0 0.0037493922
her O 0 0.0075794146
behavior O 0 0.022411885
. O 0 0.00917846

Recurrent O 0 0.47145933
excitation O 0 0.22948541
in O 0 0.006623856
the O 0 0.0058773397
dentate O 0 0.2295231
gyrus O 0 0.36294672
of O 0 0.003824102
a O 0 0.0040823445
murine O 0 0.0061978167
model O 0 0.004611522
of O 0 0.0067949113
temporal B-Disease 2 0.538875
lobe I-Disease 2 0.9759902
epilepsy I-Disease 2 0.9998362
. O 0 0.01656671

Similar O 0 0.007139287
to O 0 0.0052017695
rats O 0 0.008389041
, O 0 0.0047506397
systemic O 0 0.9473729
pilocarpine B-Chemical 1 0.9999821
injection O 0 0.06953279
causes O 0 0.023633467
status B-Disease 0 0.036219638
epilepticus I-Disease 0 0.99999106
( O 0 0.021065706
SE B-Disease 2 0.98021334
) O 0 0.0018098733
and O 0 0.0006112622
the O 0 0.00047836083
eventual O 0 0.008074211
development O 0 0.0011096178
of O 0 0.0009119718
spontaneous O 0 0.24673167
seizures B-Disease 2 0.9999889
and O 0 0.002275876
mossy O 0 0.97429365
fiber O 0 0.05780189
sprouting O 0 0.91433793
in O 0 0.00085207284
C57BL O 0 0.90441304
/ O 0 0.0023399936
6 O 0 0.000395794
and O 0 0.00051242195
CD1 O 0 0.054337367
mice O 0 0.000432841
, O 0 0.0007073039
but O 0 0.00043849403
the O 0 0.00043946822
physiological O 0 0.0011245131
correlates O 0 0.00064675405
of O 0 0.00086516526
these O 0 0.0011858469
events O 0 0.015062735
have O 0 0.0011968748
not O 0 0.0015237986
been O 0 0.0020265395
identified O 0 0.0022094608
in O 0 0.0035060216
mice O 0 0.004908502
. O 0 0.008458151

Population O 0 0.025021007
responses O 0 0.0087845875
in O 0 0.0043579647
granule O 0 0.12986594
cells O 0 0.0041127056
of O 0 0.002513722
the O 0 0.0021522453
dentate O 0 0.32138643
gyrus O 0 0.4103344
were O 0 0.00085321924
examined O 0 0.00054511445
in O 0 0.0006765942
transverse O 0 0.0026784367
slices O 0 0.0073818564
of O 0 0.0008665927
the O 0 0.0009055927
ventral O 0 0.0038301433
hippocampus O 0 0.17851086
from O 0 0.0019373252
pilocarpine B-Chemical 1 0.99997103
- O 0 0.0048926896
treated O 0 0.0027705636
and O 0 0.0033670415
untreated O 0 0.0054713786
mice O 0 0.005188854
. O 0 0.008530616

In O 0 0.014202764
Mg B-Chemical 0 0.99898773
( O 0 0.010174238
2 O 0 0.0042761816
+ O 0 0.0037228544
) O 0 0.0038371598
- O 0 0.0022408522
free O 0 0.0016246971
bathing O 0 0.04337084
medium O 0 0.007991978
containing O 0 0.0014527576
bicuculline B-Chemical 1 0.9999933
, O 0 0.002363467
conditions O 0 0.00080713123
designed O 0 0.0005912655
to O 0 0.00041723682
increase O 0 0.00041269028
excitability O 0 0.78430825
in O 0 0.00039240633
the O 0 0.00048436335
slices O 0 0.030532856
, O 0 0.00071818987
electrical O 0 0.15859085
stimulation O 0 0.0007126395
of O 0 0.0005449612
the O 0 0.00051720644
hilus O 0 0.07096502
resulted O 0 0.00036735742
in O 0 0.0003522883
a O 0 0.0005174717
single O 0 0.00043506536
population O 0 0.0008583078
spike O 0 0.0043871016
in O 0 0.0005214779
granule O 0 0.11849637
cells O 0 0.0011403222
from O 0 0.00053643
control O 0 0.0005382772
mice O 0 0.0004927081
and O 0 0.0016847181
pilocarpine B-Chemical 1 0.99998546
- O 0 0.0032013224
treated O 0 0.0013282779
mice O 0 0.000948464
that O 0 0.0012602546
did O 0 0.0018932329
not O 0 0.0029401206
experience O 0 0.012973654
SE B-Disease 2 0.95133686
. O 0 0.010048625

In O 0 0.009966829
SE B-Disease 2 0.7479597
survivors O 0 0.029349508
, O 0 0.0039515244
similar O 0 0.001646381
stimulation O 0 0.002233831
resulted O 0 0.0010839278
in O 0 0.0008730998
a O 0 0.0010896148
population O 0 0.0013935851
spike O 0 0.005515043
followed O 0 0.00054851687
, O 0 0.0007188595
at O 0 0.00031919204
a O 0 0.0004956517
variable O 0 0.0004903327
latency O 0 0.0025153358
, O 0 0.0007284522
by O 0 0.0004877102
negative O 0 0.00073847605
DC O 0 0.25518623
shifts O 0 0.0010189052
and O 0 0.00061426347
repetitive O 0 0.0039640474
afterdischarges O 0 0.99619675
of O 0 0.0008329429
3 O 0 0.00063394936
- O 0 0.00071352324
60 O 0 0.00039752884
s O 0 0.00048367342
duration O 0 0.0006436217
, O 0 0.0009273439
which O 0 0.0009987312
were O 0 0.001168004
blocked O 0 0.002695507
by O 0 0.004469388
ionotropic O 0 0.99978846
glutamate B-Chemical 1 0.9999056
receptor O 0 0.8511059
antagonists O 0 0.99310595
. O 0 0.011318257

Focal O 0 0.81426245
glutamate B-Chemical 1 0.9992199
photostimulation O 0 0.123203814
of O 0 0.0036796418
the O 0 0.0024378155
granule O 0 0.23056144
cell O 0 0.016403448
layer O 0 0.0059945537
at O 0 0.0007385961
sites O 0 0.00076496997
distant O 0 0.00771933
from O 0 0.0006013574
the O 0 0.0005318251
recording O 0 0.0011487155
pipette O 0 0.04484106
resulted O 0 0.00045271206
in O 0 0.0004317938
population O 0 0.000873297
responses O 0 0.00089021993
of O 0 0.0007477286
1 O 0 0.00074601255
- O 0 0.00072466553
30 O 0 0.00032515582
s O 0 0.0004560524
duration O 0 0.0005499636
in O 0 0.0006546994
slices O 0 0.011694762
from O 0 0.0013285808
SE B-Disease 2 0.853575
survivors O 0 0.013725313
but O 0 0.0019746593
not O 0 0.002310028
other O 0 0.0038061065
groups O 0 0.007915986
. O 0 0.00844589

These O 0 0.008815959
data O 0 0.006220219
support O 0 0.0035465185
the O 0 0.002617347
hypothesis O 0 0.002458889
that O 0 0.0020531465
SE B-Disease 2 0.9747243
- O 0 0.004721429
induced O 0 0.001965303
mossy O 0 0.9735381
fiber O 0 0.09505033
sprouting O 0 0.9319312
and O 0 0.001410513
synaptic O 0 0.13153887
reorganization O 0 0.0063135745
are O 0 0.00052184693
relevant O 0 0.00040169293
characteristics O 0 0.0004905155
of O 0 0.0008951395
seizure B-Disease 2 0.99983394
development O 0 0.0018924872
in O 0 0.0005493598
these O 0 0.0007627026
murine O 0 0.00275623
strains O 0 0.0010591052
, O 0 0.0012197973
resembling O 0 0.0013650851
rat O 0 0.0039164377
models O 0 0.0018273419
of O 0 0.002460342
human O 0 0.0057750833
temporal B-Disease 2 0.5347157
lobe I-Disease 2 0.97314936
epilepsy I-Disease 2 0.9998722
. O 0 0.012764137

Urinary B-Disease 0 0.97189945
bladder I-Disease 2 0.9888127
cancer I-Disease 2 0.99888223
in O 0 0.0065497747
Wegener B-Disease 0 0.93999946
' I-Disease 0 0.0053501786
s I-Disease 0 0.003982497
granulomatosis I-Disease 0 0.96529984
: O 0 0.006652917
risks O 0 0.022640983
and O 0 0.004272073
relation O 0 0.0037361975
to O 0 0.0069919555
cyclophosphamide B-Chemical 1 0.9996481
. O 0 0.01394934

OBJECTIVE O 0 0.41371143
: O 0 0.0077336677
To O 0 0.0031444272
assess O 0 0.0016832413
and O 0 0.0019511472
characterise O 0 0.0013216559
the O 0 0.0013742769
risk O 0 0.027359592
of O 0 0.0022286824
bladder B-Disease 2 0.998456
cancer I-Disease 2 0.99988246
, O 0 0.0035424798
and O 0 0.0010065383
its O 0 0.001091529
relation O 0 0.0005474827
to O 0 0.00090578
cyclophosphamide B-Chemical 1 0.99986374
, O 0 0.0018213799
in O 0 0.0010227584
patients O 0 0.0030262752
with O 0 0.0022213084
Wegener B-Disease 0 0.96622324
' I-Disease 0 0.0055660782
s I-Disease 0 0.006045089
granulomatosis I-Disease 0 0.9774613
. O 0 0.011761698

METHODS O 0 0.011305463
: O 0 0.0077370866
In O 0 0.0038026005
the O 0 0.0030502814
population O 0 0.0033584675
based O 0 0.0024640828
, O 0 0.002570467
nationwide O 0 0.003538913
Swedish O 0 0.003338804
Inpatient O 0 0.025699802
Register O 0 0.0012778114
a O 0 0.0007790758
cohort O 0 0.0011435585
of O 0 0.0009159662
1065 O 0 0.32263538
patients O 0 0.0014018448
with O 0 0.0008683177
Wegener B-Disease 0 0.9281254
' I-Disease 0 0.0016132104
s I-Disease 0 0.0013977514
granulomatosis I-Disease 0 0.96436876
, O 0 0.003825348
1969 O 0 0.026917873
- O 0 0.0033443526
95 O 0 0.0038001882
, O 0 0.0034053754
was O 0 0.003599929
identified O 0 0.005184769
. O 0 0.008213503

Through O 0 0.01467531
linkage O 0 0.012384608
with O 0 0.005351966
the O 0 0.0043260804
Swedish O 0 0.008592615
Cancer B-Disease 2 0.83196
Register O 0 0.0036274442
, O 0 0.0015954799
all O 0 0.000987784
subjects O 0 0.0014150322
in O 0 0.0009673776
this O 0 0.0011431049
cohort O 0 0.0032070165
diagnosed O 0 0.024987517
with O 0 0.0038347105
bladder B-Disease 2 0.9979377
cancer I-Disease 2 0.99955815
were O 0 0.008785493
identified O 0 0.0072754957
. O 0 0.009519971

Nested O 0 0.0282354
within O 0 0.004393623
the O 0 0.0038626478
cohort O 0 0.0044811084
, O 0 0.002519826
a O 0 0.0017466332
matched O 0 0.0011871782
case O 0 0.0012766648
- O 0 0.0014154231
control O 0 0.000653001
study O 0 0.0007106057
was O 0 0.00048193304
performed O 0 0.00037967888
to O 0 0.00034586134
estimate O 0 0.0003001247
the O 0 0.00039220665
association O 0 0.00037596008
between O 0 0.00044635596
cyclophosphamide B-Chemical 1 0.9998871
and O 0 0.0022831007
bladder B-Disease 2 0.9984384
cancer I-Disease 2 0.9998109
using O 0 0.0015751955
odds O 0 0.018267438
ratios O 0 0.0021787095
( O 0 0.0028103855
ORs O 0 0.017374558
) O 0 0.0032379262
as O 0 0.0025813682
relative O 0 0.003374041
risk O 0 0.13536638
. O 0 0.009216996

In O 0 0.0069571403
the O 0 0.0047447514
cohort O 0 0.004268005
the O 0 0.0022662177
cumulative O 0 0.004379363
risk O 0 0.03459945
of O 0 0.0025192522
bladder B-Disease 2 0.9968272
cancer I-Disease 2 0.9997129
after O 0 0.00083760696
Wegener B-Disease 0 0.9725691
' I-Disease 0 0.001419599
s I-Disease 0 0.00084510853
granulomatosis I-Disease 0 0.96077245
, O 0 0.0011049996
and O 0 0.00054438703
the O 0 0.00038361805
relative O 0 0.00031033345
prevalence O 0 0.00070256897
of O 0 0.00055853766
a O 0 0.0007674076
history O 0 0.012906506
of O 0 0.0012447839
bladder B-Disease 2 0.9978428
cancer I-Disease 2 0.9997162
at O 0 0.0005334574
the O 0 0.00047715966
time O 0 0.000378019
of O 0 0.00062409067
diagnosis O 0 0.0030938892
of O 0 0.0013031977
Wegener B-Disease 0 0.9702205
' I-Disease 0 0.002227781
s I-Disease 0 0.0019061873
granulomatosis I-Disease 0 0.96041024
, O 0 0.003971653
were O 0 0.0030023525
also O 0 0.0037807995
estimated O 0 0.005552755
. O 0 0.00828266

RESULTS O 0 0.02161015
: O 0 0.0068187923
The O 0 0.0030222265
median O 0 0.0022849783
cumulative O 0 0.0034269288
doses O 0 0.011814267
of O 0 0.0025549352
cyclophosphamide B-Chemical 1 0.9998716
among O 0 0.0022530516
cases O 0 0.002840599
( O 0 0.0012140174
n O 0 0.0008022759
= O 0 0.00084859156
11 O 0 0.0006639529
) O 0 0.0007273766
and O 0 0.00050394144
controls O 0 0.000921849
( O 0 0.00077807705
n O 0 0.0006735849
= O 0 0.00086056924
25 O 0 0.0008450006
) O 0 0.001054132
were O 0 0.0007970447
113 O 0 0.0024576518
g O 0 0.0016784318
and O 0 0.0016240978
25 O 0 0.0025933317
g O 0 0.0044663656
, O 0 0.0051898407
respectively O 0 0.008404748
. O 0 0.0081269

The O 0 0.007959615
risk O 0 0.015384782
of O 0 0.0058816844
bladder B-Disease 2 0.98890555
cancer I-Disease 2 0.999212
doubled O 0 0.004015157
for O 0 0.0009106789
every O 0 0.00055211806
10 O 0 0.00064738805
g O 0 0.0009349884
increment O 0 0.0006713498
in O 0 0.0007037712
cyclophosphamide B-Chemical 1 0.99990153
( O 0 0.0029895992
OR O 0 0.16634914
= O 0 0.00093949813
2 O 0 0.0004911935
. O 0 0.0003446034
0 O 0 0.00056596904
, O 0 0.00056643476
95 O 0 0.000790711
% O 0 0.0005928594
confidence O 0 0.0012899609
interval O 0 0.0009263305
( O 0 0.0014780033
CI O 0 0.19437954
) O 0 0.0014051374
0 O 0 0.0009980169
. O 0 0.00065184257
8 O 0 0.00086606847
to O 0 0.0010367137
4 O 0 0.0015612638
. O 0 0.0019211912
9 O 0 0.0036537258
) O 0 0.007101352
. O 0 0.0071250442

Treatment O 0 0.017678846
duration O 0 0.005409349
longer O 0 0.0027267402
than O 0 0.0019713757
1 O 0 0.0018123749
year O 0 0.0013010943
was O 0 0.0010521128
associated O 0 0.0010541802
with O 0 0.00096448825
an O 0 0.0013414134
eightfold O 0 0.003411994
increased O 0 0.0013304891
risk O 0 0.1385638
( O 0 0.0023270717
OR O 0 0.13023703
= O 0 0.0010827441
7 O 0 0.000576559
. O 0 0.00044854067
7 O 0 0.0005881806
, O 0 0.0008465789
95 O 0 0.001331017
% O 0 0.0012824136
CI O 0 0.034380116
0 O 0 0.0015050095
. O 0 0.0011880809
9 O 0 0.0018629974
to O 0 0.0023609113
69 O 0 0.0058387234
) O 0 0.008132105
. O 0 0.0077038226

The O 0 0.006977675
absolute O 0 0.005898563
risk O 0 0.01636719
for O 0 0.0030515885
bladder B-Disease 2 0.9886063
cancer I-Disease 2 0.9993467
in O 0 0.0017121971
the O 0 0.0010887297
cohort O 0 0.0017214533
reached O 0 0.00072725053
10 O 0 0.000555566
% O 0 0.0005305381
16 O 0 0.00038621566
years O 0 0.00041379803
after O 0 0.00022827499
diagnosis O 0 0.001077364
of O 0 0.00065003237
Wegener B-Disease 0 0.9565869
' I-Disease 0 0.0010412753
s I-Disease 0 0.0006791872
granulomatosis I-Disease 0 0.9591804
, O 0 0.001058565
and O 0 0.00056815095
a O 0 0.00067496294
history O 0 0.009472511
of O 0 0.0011741808
bladder B-Disease 2 0.9985794
cancer I-Disease 2 0.99990714
was O 0 0.0018836629
( O 0 0.0014504968
non O 0 0.0029994021
- O 0 0.0015347295
significantly O 0 0.0008100716
) O 0 0.0009728362
twice O 0 0.00042674757
as O 0 0.00039197135
common O 0 0.00056663674
as O 0 0.00047793816
expected O 0 0.00037572466
at O 0 0.0003705441
the O 0 0.00048564834
time O 0 0.0005249988
of O 0 0.0009837431
diagnosis O 0 0.0050483258
of O 0 0.0027713778
Wegener B-Disease 0 0.9809911
' I-Disease 0 0.0061688107
s I-Disease 0 0.006239091
granulomatosis I-Disease 0 0.9800852
. O 0 0.011782639

CONCLUSION O 0 0.64409417
: O 0 0.007915862
The O 0 0.0033465326
results O 0 0.0025658084
indicate O 0 0.0016977101
a O 0 0.0021319543
dose O 0 0.021809688
- O 0 0.0021078475
response O 0 0.0009814674
relationship O 0 0.0005346704
between O 0 0.0005092201
cyclophosphamide B-Chemical 1 0.99986136
and O 0 0.0010144396
the O 0 0.0006432514
risk O 0 0.03667311
of O 0 0.0012642328
bladder B-Disease 2 0.99864763
cancer I-Disease 2 0.9999074
, O 0 0.0021583335
high O 0 0.0006703022
cumulative O 0 0.0033196672
risks O 0 0.0154932365
in O 0 0.00042659548
the O 0 0.00041955907
entire O 0 0.0003589304
cohort O 0 0.0012971645
, O 0 0.0006171968
and O 0 0.00045282408
also O 0 0.0004241527
the O 0 0.00041665824
possibility O 0 0.00046479216
of O 0 0.00091966585
risk O 0 0.05183724
factors O 0 0.004911708
operating O 0 0.0019619826
even O 0 0.0013324737
before O 0 0.0011966388
Wegener B-Disease 0 0.9282734
' I-Disease 0 0.0048495913
s I-Disease 0 0.005676872
granulomatosis I-Disease 0 0.976222
. O 0 0.011482277

Differential O 0 0.019367903
modulation O 0 0.010796029
by O 0 0.008091035
estrogen B-Chemical 1 0.9994418
of O 0 0.014134289
alpha2 O 0 0.98299456
- O 0 0.020935178
adrenergic O 0 0.9982145
and O 0 0.004490437
I1 O 0 0.98884577
- O 0 0.015544195
imidazoline B-Chemical 0 0.9998337
receptor O 0 0.54146063
- O 0 0.007283566
mediated O 0 0.0031225919
hypotension B-Disease 2 0.99990296
in O 0 0.0046484754
female O 0 0.047384914
rats O 0 0.021045595
. O 0 0.009653029

We O 0 0.008069111
have O 0 0.004873299
recently O 0 0.0040424606
shown O 0 0.0024359864
that O 0 0.0022925898
estrogen B-Chemical 1 0.9996729
negatively O 0 0.0041185007
modulates O 0 0.0010661555
the O 0 0.0011964627
hypotensive B-Disease 2 0.9991918
effect O 0 0.001281588
of O 0 0.0037057984
clonidine B-Chemical 1 0.9999931
( O 0 0.0039002488
mixed O 0 0.015827473
alpha2 O 0 0.9632276
- O 0 0.006613782
/ O 0 0.012427027
I1 O 0 0.97348636
- O 0 0.0029187207
receptor O 0 0.12683193
agonist O 0 0.92032695
) O 0 0.001925983
in O 0 0.00051253673
female O 0 0.002827177
rats O 0 0.0016139084
and O 0 0.00081507233
implicates O 0 0.0009938901
the O 0 0.0011520205
cardiovascular O 0 0.9952573
autonomic O 0 0.97953737
control O 0 0.0021478054
in O 0 0.0024174005
this O 0 0.0035045573
interaction O 0 0.0063599655
. O 0 0.008202487

The O 0 0.006961286
present O 0 0.003996987
study O 0 0.0035593063
investigated O 0 0.0020015198
whether O 0 0.0011837836
this O 0 0.0013469836
effect O 0 0.001366501
of O 0 0.0027453862
estrogen B-Chemical 1 0.99985886
involves O 0 0.0015938735
interaction O 0 0.0017715312
with O 0 0.0024274713
alpha2 O 0 0.9374399
- O 0 0.004603782
and O 0 0.0022787515
/ O 0 0.006854101
or O 0 0.0036532348
I1 O 0 0.9633262
- O 0 0.0114083905
receptors O 0 0.16136214
. O 0 0.009736839

Changes O 0 0.010674102
evoked O 0 0.04398224
by O 0 0.004031015
a O 0 0.00292718
single O 0 0.0019554398
intraperitoneal O 0 0.07042041
injection O 0 0.0057013156
of O 0 0.003315774
rilmenidine B-Chemical 0 0.99999166
( O 0 0.0033226833
600 O 0 0.0027458977
microg O 0 0.0015774881
/ O 0 0.0018848967
kg O 0 0.007442657
) O 0 0.0012152721
or O 0 0.00067311095
alpha B-Chemical 1 0.83120227
- I-Chemical 1 0.012444875
methyldopa I-Chemical 1 0.99999785
( O 0 0.0023310801
100 O 0 0.0014830309
mg O 0 0.23696607
/ O 0 0.0016022399
kg O 0 0.0068978867
) O 0 0.0012114114
, O 0 0.00069645
selective O 0 0.0037460632
I1 O 0 0.9483083
- O 0 0.0013486819
and O 0 0.000812739
alpha2 O 0 0.90546733
- O 0 0.003991918
receptor O 0 0.14123856
agonists O 0 0.92602277
, O 0 0.0013598979
respectively O 0 0.0012708573
, O 0 0.000540669
in O 0 0.0003008959
blood O 0 0.004561839
pressure O 0 0.039868604
, O 0 0.00063607993
hemodynamic O 0 0.22431308
variability O 0 0.00053527416
, O 0 0.0006438059
and O 0 0.0005375653
locomotor O 0 0.3866763
activity O 0 0.0004937216
were O 0 0.00035370572
assessed O 0 0.0002832761
in O 0 0.0003839023
radiotelemetered O 0 0.05694192
sham O 0 0.00077430636
- O 0 0.0010816474
operated O 0 0.0018376495
and O 0 0.0009872669
ovariectomized O 0 0.853804
( O 0 0.0041212044
Ovx O 0 0.98970056
) O 0 0.0028243067
Sprague O 0 0.3217902
- O 0 0.0016146209
Dawley O 0 0.022761976
female O 0 0.0020049603
rats O 0 0.001564362
with O 0 0.00094996125
or O 0 0.0010726562
without O 0 0.0013759499
12 O 0 0.0015716284
- O 0 0.0032056067
wk O 0 0.0030446593
estrogen B-Chemical 1 0.9990884
replacement O 0 0.045782406
. O 0 0.01023214

Three O 0 0.008510427
time O 0 0.0045830267
domain O 0 0.0037075875
indexes O 0 0.003223416
of O 0 0.0022954424
hemodynamic O 0 0.30230224
variability O 0 0.0014689812
were O 0 0.000971336
employed O 0 0.0009410586
: O 0 0.00087706785
the O 0 0.00044938334
standard O 0 0.0004766181
deviation O 0 0.00094751833
of O 0 0.00041009797
mean O 0 0.00038645632
arterial O 0 0.29867467
pressure O 0 0.021635935
as O 0 0.00039190837
a O 0 0.00043326456
measure O 0 0.00019829327
of O 0 0.00040941502
blood O 0 0.006343933
pressure O 0 0.019498074
variability O 0 0.00038056416
and O 0 0.00037787092
the O 0 0.00032472055
standard O 0 0.000408306
deviation O 0 0.0013012791
of O 0 0.0006080533
beat O 0 0.09390131
- O 0 0.001294194
to O 0 0.0005010059
- O 0 0.0010971527
beat O 0 0.01595743
intervals O 0 0.00055227784
( O 0 0.0010810127
SDRR O 0 0.6983432
) O 0 0.000779603
and O 0 0.00040289178
the O 0 0.00035017062
root O 0 0.00095931446
mean O 0 0.0003719426
square O 0 0.0008126244
of O 0 0.00046677064
successive O 0 0.00050974847
differences O 0 0.0003510689
in O 0 0.0006701777
R O 0 0.95888346
- O 0 0.0023591486
wave O 0 0.04285199
- O 0 0.0017112095
to O 0 0.0007766996
- O 0 0.0031744915
R O 0 0.9134396
- O 0 0.0017080122
wave O 0 0.004649431
intervals O 0 0.0007779051
as O 0 0.0009257491
measures O 0 0.0012453425
of O 0 0.0021088026
heart O 0 0.4479959
rate O 0 0.0038385342
variability O 0 0.005774319
. O 0 0.0076431213

In O 0 0.007983258
sham O 0 0.0074087977
- O 0 0.006223587
operated O 0 0.006340475
rats O 0 0.008095526
, O 0 0.0046449974
rilmenidine B-Chemical 0 0.999972
or O 0 0.003405338
alpha B-Chemical 1 0.95623827
- I-Chemical 1 0.02552332
methyldopa I-Chemical 1 0.9999964
elicited O 0 0.0025561103
similar O 0 0.000708019
hypotension B-Disease 2 0.99995184
that O 0 0.000476574
lasted O 0 0.0004734809
at O 0 0.00028260416
least O 0 0.00025246653
5 O 0 0.00033618574
h O 0 0.00032382214
and O 0 0.000491061
was O 0 0.0004903444
associated O 0 0.00062882784
with O 0 0.00070368336
reductions O 0 0.0009147087
in O 0 0.00074146315
standard O 0 0.0010986913
deviation O 0 0.0025883385
of O 0 0.0018069339
mean O 0 0.002567994
arterial O 0 0.6130536
pressure O 0 0.17950632
. O 0 0.008282209

SDRR O 0 0.56039745
was O 0 0.016624082
reduced O 0 0.013426032
only O 0 0.01204833
by O 0 0.016218515
alpha B-Chemical 1 0.89541763
- I-Chemical 1 0.17603879
methyldopa I-Chemical 1 0.9999281
. O 0 0.029474372

Ovx O 0 0.95232606
significantly O 0 0.008345105
enhanced O 0 0.0050961613
the O 0 0.0037730234
hypotensive B-Disease 2 0.9982753
response O 0 0.0052445377
to O 0 0.0025596274
alpha B-Chemical 1 0.9474861
- I-Chemical 1 0.043909334
methyldopa I-Chemical 1 0.99999595
, O 0 0.002979769
in O 0 0.0009905149
contrast O 0 0.0010071857
to O 0 0.0009999579
no O 0 0.0010941759
effect O 0 0.0021127516
on O 0 0.0033100666
rilmenidine B-Chemical 0 0.99997365
hypotension B-Disease 2 0.99991596
. O 0 0.014212099

The O 0 0.008713905
enhanced O 0 0.008487265
alpha B-Chemical 1 0.8656891
- I-Chemical 1 0.058239482
methyldopa I-Chemical 1 0.9999943
hypotension B-Disease 2 0.9999857
in O 0 0.0072364383
Ovx O 0 0.9956441
rats O 0 0.0069719544
was O 0 0.0010739956
paralleled O 0 0.0011320453
with O 0 0.0009675112
further O 0 0.0011027544
reduction O 0 0.0018960815
in O 0 0.0014554092
SDRR O 0 0.75355214
and O 0 0.0020599
a B-Disease 0 0.003090982
reduced I-Disease 0 0.0038043642
locomotor I-Disease 0 0.7334701
activity I-Disease 0 0.008576383
. O 0 0.008827762

Estrogen O 0 0.99962413
replacement O 0 0.2308205
( O 0 0.08093874
17beta B-Chemical 1 0.9999387
- I-Chemical 1 0.12644029
estradiol I-Chemical 1 0.99994636
subcutaneous O 0 0.5594316
pellet O 0 0.009249729
, O 0 0.0015618223
14 O 0 0.0008094944
. O 0 0.0004128449
2 O 0 0.0004221524
microg O 0 0.000773602
/ O 0 0.000950489
day O 0 0.00038877223
, O 0 0.00051215396
12 O 0 0.0002795865
wk O 0 0.00029238968
) O 0 0.00069191697
of O 0 0.0007048404
Ovx O 0 0.97352386
rats O 0 0.0017743354
restored O 0 0.0005397381
the O 0 0.0005072003
hemodynamic O 0 0.4316704
and O 0 0.0010617219
locomotor O 0 0.5772606
effects O 0 0.0016237244
of O 0 0.001910314
alpha B-Chemical 1 0.9334771
- I-Chemical 1 0.031135632
methyldopa I-Chemical 1 0.9999927
to O 0 0.002222505
sham O 0 0.0034596764
- O 0 0.0053553935
operated O 0 0.008700606
levels O 0 0.0058190133
. O 0 0.008141549

These O 0 0.009177506
findings O 0 0.00762002
suggest O 0 0.003543537
that O 0 0.0037359167
estrogen B-Chemical 1 0.9997887
downregulates O 0 0.07617013
alpha2 O 0 0.9848948
- O 0 0.007016239
but O 0 0.0011496263
not O 0 0.0011400746
I1 O 0 0.9732151
- O 0 0.004417374
receptor O 0 0.18587841
- O 0 0.0026460586
mediated O 0 0.0008741203
hypotension B-Disease 2 0.9999604
and O 0 0.00084060576
highlight O 0 0.0004706604
a O 0 0.00071949424
role O 0 0.00035928335
for O 0 0.0003821414
the O 0 0.00059179746
cardiac O 0 0.5153051
autonomic O 0 0.9484731
control O 0 0.0010068944
in O 0 0.0013493077
alpha B-Chemical 1 0.89326614
- I-Chemical 1 0.07497189
methyldopa I-Chemical 1 0.9999945
- O 0 0.16178
estrogen B-Chemical 1 0.9996673
interaction O 0 0.013642537
. O 0 0.009931518

Severe O 0 0.7775285
reversible O 0 0.22342068
left B-Disease 0 0.013787737
ventricular I-Disease 0 0.97917616
systolic I-Disease 0 0.8675877
and I-Disease 0 0.005250649
diastolic I-Disease 0 0.9942551
dysfunction I-Disease 0 0.9889092
due O 0 0.002478369
to O 0 0.0031222266
accidental O 0 0.953353
iatrogenic O 0 0.99201125
epinephrine B-Chemical 1 0.9998958
overdose B-Disease 2 0.999897
. O 0 0.01588014

Catecholamine B-Chemical 0 0.99869376
- O 0 0.017286157
induced O 0 0.007428323
cardiomyopathy B-Disease 2 0.9998134
due O 0 0.0026537813
to O 0 0.0020628995
chronic O 0 0.90450907
excess O 0 0.0061472678
of O 0 0.0023358625
endogenous O 0 0.007889095
catecholamines B-Chemical 1 0.9998485
has O 0 0.0012333639
been O 0 0.0012721991
recognized O 0 0.0014087241
for O 0 0.0011725543
decades O 0 0.0027199476
as O 0 0.0023180293
a O 0 0.004224589
clinical O 0 0.034996446
phenomenon O 0 0.05256499
. O 0 0.009168301

In O 0 0.009084479
contrast O 0 0.006938494
, O 0 0.006013775
reports O 0 0.0049458146
of O 0 0.006320127
myocardial B-Disease 0 0.9998888
dysfunction I-Disease 0 0.99810046
due O 0 0.0029694876
to O 0 0.0032916432
acute O 0 0.9891649
iatrogenic O 0 0.99483997
overdose B-Disease 2 0.99993527
are O 0 0.013663779
rare O 0 0.16979986
. O 0 0.012337331

A O 0 0.036791544
35 O 0 0.0086470265
- O 0 0.00667744
year O 0 0.0035513649
- O 0 0.0031617803
old O 0 0.0020271973
woman O 0 0.0055809338
whose O 0 0.0023474277
cervix O 0 0.94394416
uteri O 0 0.64031214
was O 0 0.0010654994
inadvertently O 0 0.0037228032
injected O 0 0.0005631016
with O 0 0.0005962214
8 O 0 0.00054570293
mg O 0 0.10729297
of O 0 0.0009260328
epinephrine B-Chemical 1 0.9997651
developed O 0 0.0039783893
myocardial B-Disease 0 0.9999087
stunning I-Disease 0 0.9798584
that O 0 0.00047183756
was O 0 0.00049317844
characterized O 0 0.0008271773
by O 0 0.0007134679
severe O 0 0.16261777
hemodynamic O 0 0.74035
compromise O 0 0.0064933123
, O 0 0.0011677125
profound O 0 0.024283884
, O 0 0.00097586773
albeit O 0 0.0013188029
transient O 0 0.018301722
, O 0 0.00076268666
left B-Disease 0 0.0013391146
ventricular I-Disease 0 0.9764439
systolic I-Disease 0 0.79073787
and I-Disease 0 0.0009934992
diastolic I-Disease 0 0.9965917
dysfunction I-Disease 0 0.9938116
, O 0 0.0013304435
and O 0 0.0008344658
only O 0 0.00081884756
modestly O 0 0.019119635
elevated O 0 0.004759194
biochemical O 0 0.053959783
markers O 0 0.015284306
of O 0 0.025943248
myocardial B-Disease 0 0.99994874
necrosis I-Disease 2 0.9997631
. O 0 0.019064466

Our O 0 0.007529015
case O 0 0.0049635596
illustrates O 0 0.003429635
the O 0 0.002835241
serious O 0 0.08401086
consequences O 0 0.005045785
of O 0 0.0022512923
medical O 0 0.02590977
errors O 0 0.004506189
that O 0 0.0008249583
can O 0 0.00078376924
be O 0 0.0009298181
avoided O 0 0.0010427018
through O 0 0.0009961255
improved O 0 0.0022102315
medication O 0 0.11110687
labeling O 0 0.0037413891
and O 0 0.0038637728
staff O 0 0.0075760228
supervision O 0 0.013209022
. O 0 0.008254143

Cardioprotective O 0 0.94852287
effect O 0 0.008720571
of O 0 0.008540215
tincture B-Chemical 0 0.98906213
of I-Chemical 0 0.012726434
Crataegus I-Chemical 0 0.99891865
on O 0 0.0052553704
isoproterenol B-Chemical 1 0.9999167
- O 0 0.038095217
induced O 0 0.012215334
myocardial B-Disease 0 0.99991083
infarction I-Disease 2 0.9999757
in O 0 0.011035074
rats O 0 0.04443246
. O 0 0.011404971

Tincture B-Chemical 0 0.9833634
of I-Chemical 0 0.016893994
Crataegus I-Chemical 0 0.99798965
( O 0 0.028841978
TCR B-Chemical 1 0.9650553
) O 0 0.007932236
, O 0 0.002738279
an O 0 0.002355639
alcoholic B-Chemical 0 0.99916315
extract I-Chemical 0 0.032509934
of I-Chemical 0 0.0019781203
the I-Chemical 0 0.0014893216
berries I-Chemical 0 0.79531264
of I-Chemical 0 0.004215192
hawthorn I-Chemical 0 0.9973454
( O 0 0.026415767
Crataegus B-Chemical 0 0.99961
oxycantha I-Chemical 0 0.9948155
) O 0 0.017473198
, O 0 0.0019783631
is O 0 0.0011581427
used O 0 0.0012470697
in O 0 0.0017873342
herbal O 0 0.93326825
and O 0 0.006932904
homeopathic O 0 0.9140078
medicine O 0 0.331239
. O 0 0.0111871725

The O 0 0.007339223
present O 0 0.004333098
study O 0 0.004108122
was O 0 0.0026459352
done O 0 0.0016792301
to O 0 0.0013011737
investigate O 0 0.00086181983
the O 0 0.0011930424
protective O 0 0.0052479547
effect O 0 0.001368138
of O 0 0.0021479393
TCR B-Chemical 1 0.8677173
on O 0 0.0010702747
experimentally O 0 0.002222934
induced O 0 0.0064965673
myocardial B-Disease 0 0.99993706
infarction I-Disease 2 0.99998164
in O 0 0.008973632
rats O 0 0.044107523
. O 0 0.009972025

Pretreatment O 0 0.56621176
of O 0 0.009835111
TCR B-Chemical 1 0.8741617
, O 0 0.004427968
at O 0 0.0016362439
a O 0 0.0016671676
dose O 0 0.003163455
of O 0 0.0013028285
0 O 0 0.0013049452
. O 0 0.0005293652
5 O 0 0.0004996251
mL O 0 0.0013727419
/ O 0 0.00095878576
100 O 0 0.00064100843
g O 0 0.0005905973
bodyweight O 0 0.012318184
per O 0 0.00024177918
day O 0 0.00032661943
, O 0 0.00045313127
orally O 0 0.0010868893
for O 0 0.00026385745
30 O 0 0.00025926257
days O 0 0.00026778568
, O 0 0.0004980144
prevented O 0 0.0007192944
the O 0 0.0004320755
increase O 0 0.00039644388
in O 0 0.00064331025
lipid O 0 0.9781472
peroxidation O 0 0.99998796
and O 0 0.0014889026
activity O 0 0.00079278153
of O 0 0.0006664037
marker O 0 0.0009353217
enzymes O 0 0.08111501
observed O 0 0.00040114764
in O 0 0.00081856915
isoproterenol B-Chemical 1 0.99996567
- O 0 0.00466292
induced O 0 0.00076729245
rats O 0 0.005111789
( O 0 0.00089491525
85 O 0 0.0007307453
mg O 0 0.10552378
kg O 0 0.007658167
( O 0 0.0011494127
- O 0 0.000985634
1 O 0 0.00054107583
) O 0 0.0007292092
s O 0 0.00056115235
. O 0 0.00038315004
c O 0 0.0019153921
. O 0 0.00037964957
for O 0 0.0003743275
2 O 0 0.00050904974
days O 0 0.00044753056
at O 0 0.0005619879
an O 0 0.0011281424
interval O 0 0.0013919087
of O 0 0.0019338458
24 O 0 0.002276279
h O 0 0.0032553726
) O 0 0.007947519
. O 0 0.007297771

TCR B-Chemical 1 0.84525424
prevented O 0 0.016288903
the O 0 0.007038146
isoproterenol B-Chemical 1 0.9998367
- O 0 0.015187181
induced O 0 0.0025066326
decrease O 0 0.0017710878
in O 0 0.001496423
antioxidant O 0 0.99897087
enzymes O 0 0.30522987
in O 0 0.00082072633
the O 0 0.0007456494
heart O 0 0.47304174
and O 0 0.0008170347
increased O 0 0.00074579153
the O 0 0.0005902596
rate O 0 0.0007263318
of O 0 0.0020602273
ADP B-Chemical 1 0.99976546
- O 0 0.005341208
stimulated O 0 0.0014108561
oxygen B-Chemical 1 0.9818856
uptake O 0 0.032647364
and O 0 0.0030027435
respiratory O 0 0.71386415
coupling O 0 0.03714635
ratio O 0 0.009507354
. O 0 0.009005663

TCR B-Chemical 1 0.6892928
protected O 0 0.013380279
against O 0 0.007774766
pathological O 0 0.23855722
changes O 0 0.008406214
induced O 0 0.007171845
by O 0 0.009841112
isoproterenol B-Chemical 1 0.99966764
in O 0 0.008454332
rat O 0 0.08165049
heart O 0 0.85995495
. O 0 0.013812937

The O 0 0.0073635974
results O 0 0.005352588
show O 0 0.00342126
that O 0 0.0027716653
pretreatment O 0 0.13745923
with O 0 0.003601813
TCR B-Chemical 1 0.9282773
may O 0 0.0016635099
be O 0 0.0012910147
useful O 0 0.0011325426
in O 0 0.00093130843
preventing O 0 0.0021524942
the O 0 0.0016232374
damage O 0 0.7016078
induced O 0 0.0033228635
by O 0 0.0056797503
isoproterenol B-Chemical 1 0.9998286
in O 0 0.0046452684
rat O 0 0.06636093
heart O 0 0.8470695
. O 0 0.010065383

Treatment O 0 0.027988372
of O 0 0.0091686305
tinnitus B-Disease 2 0.9983979
by O 0 0.005742196
intratympanic O 0 0.9972638
instillation O 0 0.25915745
of O 0 0.006931065
lignocaine B-Chemical 1 0.9999614
( O 0 0.02588279
lidocaine B-Chemical 1 0.9999206
) O 0 0.0037325856
2 O 0 0.0013721373
per O 0 0.001095706
cent O 0 0.0018696658
through O 0 0.0026747277
ventilation O 0 0.0391578
tubes O 0 0.010656461
. O 0 0.009336534

Idiopathic B-Disease 0 0.96231693
subjective I-Disease 0 0.32841563
tinnitus I-Disease 2 0.9996131
( O 0 0.0258014
IST B-Disease 0 0.9585921
) O 0 0.0060650143
is O 0 0.0026001784
one O 0 0.0020803357
of O 0 0.0026150392
the O 0 0.0028932185
most O 0 0.0051184474
obscure O 0 0.11227364
otological O 0 0.9025838
pathologies O 0 0.9118954
. O 0 0.0137869725

This O 0 0.010276421
paper O 0 0.0064442144
presents O 0 0.0042049903
the O 0 0.0025010267
results O 0 0.0020123215
of O 0 0.0022079297
treating O 0 0.011478061
IST B-Disease 0 0.97101194
by O 0 0.0016316443
intratympanic O 0 0.9979317
instillation O 0 0.18260375
of O 0 0.004202807
lignocaine B-Chemical 1 0.99998033
( O 0 0.014975074
lidocaine B-Chemical 1 0.999954
) O 0 0.0019714825
2 O 0 0.00053410145
per O 0 0.00035666855
cent O 0 0.00054283574
through O 0 0.00068026804
a O 0 0.0013251359
grommet O 0 0.17199194
, O 0 0.0020090253
for O 0 0.0014116617
five O 0 0.0019532803
weekly O 0 0.004502719
courses O 0 0.0076975124
. O 0 0.0077468012

Fifty O 0 0.021900307
- O 0 0.00873321
two O 0 0.003877468
patients O 0 0.0057366863
suffering O 0 0.7251574
from O 0 0.0033873226
intractable O 0 0.97993886
tinnitus B-Disease 2 0.99973935
entered O 0 0.0031724689
this O 0 0.0011644219
therapeutic O 0 0.00903454
trial O 0 0.002242518
, O 0 0.0015468615
but O 0 0.0010874703
only O 0 0.0011710185
nine O 0 0.0017391194
finished O 0 0.003356339
all O 0 0.0024634723
five O 0 0.0031822596
courses O 0 0.008413824
. O 0 0.008331397

In O 0 0.007286594
one O 0 0.0048056305
patient O 0 0.0050607785
, O 0 0.003589797
the O 0 0.0024720507
tinnitus B-Disease 2 0.9988217
was O 0 0.0018157356
almost O 0 0.0011164598
completely O 0 0.0012307151
abolished O 0 0.0019564677
, O 0 0.0012170022
but O 0 0.0006089235
in O 0 0.00048449126
all O 0 0.00047238005
the O 0 0.0005117796
nine O 0 0.000663715
patients O 0 0.0018016292
the O 0 0.0012344928
decompensated O 0 0.99964666
tinnitus B-Disease 2 0.99974173
changed O 0 0.002844098
to O 0 0.00219616
a O 0 0.0040214867
compensated O 0 0.0070662005
one O 0 0.005472954
. O 0 0.007946039

We O 0 0.007088041
suggest O 0 0.0037408753
this O 0 0.0031378472
mode O 0 0.0027640264
of O 0 0.0022226844
treatment O 0 0.0022680396
for O 0 0.0010133967
patients O 0 0.0022356086
that O 0 0.00072014215
were O 0 0.0007870923
previously O 0 0.0007237514
treated O 0 0.0010537654
by O 0 0.0011768054
drugs O 0 0.72560805
, O 0 0.0019047129
acupuncture O 0 0.07967749
and O 0 0.0019403333
biofeedback O 0 0.21413387
, O 0 0.0033334687
with O 0 0.0033997968
disappointing O 0 0.021220941
results O 0 0.0064854324
. O 0 0.008587146

Patients O 0 0.013266407
should O 0 0.004235676
be O 0 0.0036037313
warned O 0 0.0060325214
about O 0 0.0018075558
the O 0 0.0015282474
side O 0 0.023797972
effects O 0 0.0027689452
of O 0 0.0037220395
vertigo B-Disease 0 0.9999902
and O 0 0.01165907
vomiting B-Disease 2 0.9999876
, O 0 0.0025206294
which O 0 0.00095958967
subsides O 0 0.0031657293
gradually O 0 0.0010240049
with O 0 0.00039890571
every O 0 0.00022236863
new O 0 0.00048098902
instillation O 0 0.024299514
, O 0 0.00080241
and O 0 0.0004798972
that O 0 0.00034750262
the O 0 0.0005841163
tinnitus B-Disease 2 0.9995548
may O 0 0.00055666774
not O 0 0.00051606644
disappear O 0 0.0012749381
but O 0 0.0005054891
will O 0 0.00037424255
be O 0 0.0005579157
alleviated O 0 0.049765807
, O 0 0.00082743075
enabling O 0 0.0006029658
them O 0 0.00089633535
to O 0 0.0005050142
cope O 0 0.0017110556
more O 0 0.00076313375
easily O 0 0.00083437643
with O 0 0.00078772305
the O 0 0.0010308645
disease O 0 0.57612723
and O 0 0.0023864189
lead O 0 0.026386285
a O 0 0.0032413094
more O 0 0.0036661758
normal O 0 0.007319961
life O 0 0.014121344
. O 0 0.008766258

The O 0 0.009110679
alpha3 O 0 0.76791793
and O 0 0.00812748
beta4 O 0 0.9815294
nicotinic O 0 0.99983096
acetylcholine B-Chemical 1 0.99991727
receptor O 0 0.5701919
subunits O 0 0.010089291
are O 0 0.0012865707
necessary O 0 0.0006996158
for O 0 0.0010432125
nicotine B-Chemical 1 0.99968064
- O 0 0.009779853
induced O 0 0.0047561456
seizures B-Disease 2 0.99997413
and O 0 0.021665508
hypolocomotion B-Disease 0 0.999833
in O 0 0.0053112907
mice O 0 0.0055866023
. O 0 0.008625079

Binding O 0 0.010646492
of O 0 0.007856068
nicotine B-Chemical 1 0.99876404
to O 0 0.0060754223
nicotinic O 0 0.99986744
acetylcholine B-Chemical 1 0.9999521
receptors O 0 0.88680923
( O 0 0.017121375
nAChRs O 0 0.9898886
) O 0 0.0017877509
elicits O 0 0.0008153139
a O 0 0.0006907945
series O 0 0.00075092766
of O 0 0.00064224185
dose O 0 0.019827751
- O 0 0.0011705089
dependent O 0 0.00041665824
behaviors O 0 0.029876629
that O 0 0.00041232616
go O 0 0.00084582553
from O 0 0.0005119108
altered O 0 0.000700824
exploration O 0 0.0013336875
, O 0 0.0013681353
sedation O 0 0.7005904
, O 0 0.0015938386
and O 0 0.0020853349
tremors B-Disease 2 0.9998435
, O 0 0.0037524607
to O 0 0.003248933
seizures B-Disease 2 0.9999249
and O 0 0.016994722
death B-Disease 2 0.9981427
. O 0 0.011174179

nAChRs O 0 0.91612995
are O 0 0.011493589
pentameric O 0 0.0317101
ion O 0 0.19541012
channels O 0 0.04331156
usually O 0 0.005439218
composed O 0 0.0044209235
of O 0 0.005630001
alpha O 0 0.35424703
and O 0 0.009663186
beta O 0 0.70414954
subunits O 0 0.04369094
. O 0 0.013199087

A O 0 0.030946795
gene O 0 0.007836824
cluster O 0 0.0053810296
comprises O 0 0.0034421645
the O 0 0.0031385766
alpha3 O 0 0.9052072
, O 0 0.004922857
alpha5 O 0 0.97114456
and O 0 0.0029709856
beta4 O 0 0.912519
subunits O 0 0.007669082
, O 0 0.002646684
which O 0 0.00243717
coassemble O 0 0.021501554
to O 0 0.0022195734
form O 0 0.0033283825
functional O 0 0.006722594
receptors O 0 0.28361532
. O 0 0.01031763

We O 0 0.007096254
examined O 0 0.0038418137
the O 0 0.003143157
role O 0 0.0019166779
of O 0 0.0020502303
the O 0 0.0018493148
beta4 O 0 0.9250856
subunits O 0 0.011002368
in O 0 0.0015644558
nicotine B-Chemical 1 0.9998828
- O 0 0.015182688
induced O 0 0.0031112363
seizures B-Disease 2 0.9999912
and O 0 0.007390474
hypolocomotion B-Disease 0 0.99996376
in O 0 0.0009650753
beta4 O 0 0.9327442
homozygous O 0 0.0016094943
null O 0 0.0005421206
( O 0 0.0017394494
beta4 O 0 0.94911224
- O 0 0.0030544065
/ O 0 0.0052986164
- O 0 0.0017088205
) O 0 0.0013195693
and O 0 0.0010517486
alpha3 O 0 0.80852246
heterozygous O 0 0.002448646
( O 0 0.0028695425
+ O 0 0.0025338982
/ O 0 0.0068613566
- O 0 0.0048664496
) O 0 0.0056735673
mice O 0 0.004462095
. O 0 0.007577578

beta4 O 0 0.95066994
- O 0 0.01583595
/ O 0 0.011513347
- O 0 0.004525954
mice O 0 0.0016479024
were O 0 0.0014060511
less O 0 0.0010283872
sensitive O 0 0.00073843944
to O 0 0.00060716557
the O 0 0.00058748137
effects O 0 0.001075849
of O 0 0.0012175041
nicotine B-Chemical 1 0.9995956
both O 0 0.0006662266
at O 0 0.00037477436
low O 0 0.00064477086
doses O 0 0.022602767
, O 0 0.0007226063
measured O 0 0.0002875172
as O 0 0.00042014342
decreased O 0 0.00064277346
exploration O 0 0.00074118975
in O 0 0.0004042034
an O 0 0.00063816
open O 0 0.0005069903
field O 0 0.00077002164
, O 0 0.00066759624
and O 0 0.00050264224
at O 0 0.00035112447
high O 0 0.0006287082
doses O 0 0.012624556
, O 0 0.0009711591
measured O 0 0.00052503275
as O 0 0.0009176488
sensitivity O 0 0.0022765417
to O 0 0.0020494277
nicotine B-Chemical 1 0.9996363
- O 0 0.024000334
induced O 0 0.015853684
seizures B-Disease 2 0.9999101
. O 0 0.012623012

Using O 0 0.008810251
in O 0 0.005223326
situ O 0 0.006442954
hybridization O 0 0.0041442104
probes O 0 0.003097932
for O 0 0.0014064513
the O 0 0.0015241025
alpha3 O 0 0.8478409
and O 0 0.0021016942
alpha5 O 0 0.9864732
subunits O 0 0.005982655
, O 0 0.0009438072
we O 0 0.00034879704
showed O 0 0.00040540914
that O 0 0.00050464034
alpha5 O 0 0.98017293
mRNA O 0 0.0009565104
levels O 0 0.00047840097
are O 0 0.00052394177
unchanged O 0 0.00059397926
, O 0 0.00070611876
whereas O 0 0.00049973105
alpha3 O 0 0.89068276
mRNA O 0 0.0007801322
levels O 0 0.0004091082
are O 0 0.00044536864
selectively O 0 0.00069752475
decreased O 0 0.00063055404
in O 0 0.00036571932
the O 0 0.00044165293
mitral O 0 0.12156458
cell O 0 0.0037254537
layer O 0 0.0019667186
of O 0 0.00055795885
the O 0 0.00052632485
olfactory O 0 0.010374274
bulb O 0 0.061575137
, O 0 0.0007206934
and O 0 0.000514843
the O 0 0.00049685984
inferior O 0 0.0023678942
and O 0 0.0006583225
the O 0 0.00070006563
superior O 0 0.0017417521
colliculus O 0 0.031159561
of O 0 0.001955174
beta4 O 0 0.936607
- O 0 0.0069174715
/ O 0 0.010290884
- O 0 0.0068077245
brains O 0 0.009921574
. O 0 0.008035662

alpha3 O 0 0.92143816
+ O 0 0.012019796
/ O 0 0.012537421
- O 0 0.005199049
mice O 0 0.0019825774
were O 0 0.0018260386
partially O 0 0.0016446984
resistant O 0 0.0016820534
to O 0 0.0015356928
nicotine B-Chemical 1 0.99979
- O 0 0.009712906
induced O 0 0.0027029659
seizures B-Disease 2 0.99996424
when O 0 0.0011132079
compared O 0 0.0009941601
to O 0 0.0015924475
wild O 0 0.0023980993
- O 0 0.004424371
type O 0 0.0040026978
littermates O 0 0.004259551
. O 0 0.008076297

mRNA O 0 0.010712136
levels O 0 0.005370079
for O 0 0.003567838
the O 0 0.0035881172
alpha5 O 0 0.92564166
and O 0 0.0028747453
the O 0 0.002237557
beta4 O 0 0.8474821
subunits O 0 0.004876981
were O 0 0.0017604722
unchanged O 0 0.0017497728
in O 0 0.0021275473
alpha3 O 0 0.9168147
+ O 0 0.005253496
/ O 0 0.012580696
- O 0 0.007865811
brains O 0 0.011126509
. O 0 0.008740181

Together O 0 0.016208088
, O 0 0.007221785
these O 0 0.004072516
results O 0 0.0027256887
suggest O 0 0.0015777295
that O 0 0.0013929873
the O 0 0.0015883454
beta4 O 0 0.8087001
and O 0 0.0015667413
the O 0 0.0013395483
alpha3 O 0 0.8954846
subunits O 0 0.0050452566
are O 0 0.0013739564
mediators O 0 0.054487906
of O 0 0.0051101954
nicotine B-Chemical 1 0.99986386
- O 0 0.028881446
induced O 0 0.011533943
seizures B-Disease 2 0.9999647
and O 0 0.06789738
hypolocomotion B-Disease 0 0.9997912
. O 0 0.01230687

The O 0 0.012508392
effects O 0 0.011621557
of O 0 0.0113407215
sevoflurane B-Chemical 1 0.99813145
on O 0 0.0100895045
lidocaine B-Chemical 1 0.99979776
- O 0 0.06414934
induced O 0 0.03597957
convulsions B-Disease 2 0.99984765
. O 0 0.02357001

The O 0 0.008636082
influence O 0 0.005756075
of O 0 0.0064327368
sevoflurane B-Chemical 1 0.9982743
on O 0 0.004780424
lidocaine B-Chemical 1 0.999905
- O 0 0.024493745
induced O 0 0.008734326
convulsions B-Disease 2 0.99994576
was O 0 0.00561546
studied O 0 0.0055950484
in O 0 0.00627864
cats O 0 0.026576025
. O 0 0.011458091

The O 0 0.010215441
convulsive B-Disease 2 0.9994518
threshold O 0 0.0066230088
( O 0 0.0045873616
mean O 0 0.0025623962
+ O 0 0.0028697539
/ O 0 0.005567657
- O 0 0.0032823307
SD O 0 0.3135121
) O 0 0.0020390605
was O 0 0.00096293294
41 O 0 0.0016216077
. O 0 0.00073977065
4 O 0 0.0009215632
+ O 0 0.0013219045
/ O 0 0.0027982208
- O 0 0.002272003
6 O 0 0.0015131539
. O 0 0.0019097304
5 O 0 0.0032694393
mg O 0 0.14504339
. O 0 0.007820075

l O 0 0.020284573
( O 0 0.012171626
- O 0 0.007736487
1 O 0 0.003646756
) O 0 0.0034061798
with O 0 0.0020454396
lidocaine B-Chemical 1 0.99980205
infusion O 0 0.06394846
( O 0 0.0017246536
6 O 0 0.0006331649
mg O 0 0.10669604
. O 0 0.00053050625
kg O 0 0.005037772
( O 0 0.001304839
- O 0 0.0011601731
1 O 0 0.00062592205
) O 0 0.00084979273
. O 0 0.00035966703
min O 0 0.00058746454
( O 0 0.0008867287
- O 0 0.00093785947
1 O 0 0.00059308606
) O 0 0.0009772615
) O 0 0.0009027442
, O 0 0.00056746416
increasing O 0 0.0005051726
significantly O 0 0.0006329465
to O 0 0.00053190725
66 O 0 0.0012749133
. O 0 0.0004993053
6 O 0 0.00061286817
+ O 0 0.0010523138
/ O 0 0.0025255003
- O 0 0.0020550878
10 O 0 0.0016070182
. O 0 0.0017778024
9 O 0 0.003462489
mg O 0 0.156402
. O 0 0.0073286453

l O 0 0.021169936
( O 0 0.01295239
- O 0 0.008283521
1 O 0 0.004055636
) O 0 0.0034564917
when O 0 0.0015469091
the O 0 0.0015248124
end O 0 0.0011992553
- O 0 0.0020176768
tidal O 0 0.038625814
concentration O 0 0.0021650048
of O 0 0.0023299628
sevoflurane B-Chemical 1 0.99922407
was O 0 0.0025741202
0 O 0 0.003212678
. O 0 0.0024120125
8 O 0 0.0038222554
% O 0 0.0065432927
. O 0 0.007709088

However O 0 0.009000975
, O 0 0.0063279746
the O 0 0.0035646828
threshold O 0 0.0029099802
( O 0 0.0029415553
61 O 0 0.0027096118
. O 0 0.0010207075
6 O 0 0.0008378616
+ O 0 0.0010220853
/ O 0 0.0019447576
- O 0 0.001087345
8 O 0 0.0005189996
. O 0 0.0003546437
7 O 0 0.00040779056
mg O 0 0.043102924
. O 0 0.0003892399
l O 0 0.0011442901
( O 0 0.0010966534
- O 0 0.0010465751
1 O 0 0.00057667226
) O 0 0.0008611061
) O 0 0.0006875683
during O 0 0.00028082987
1 O 0 0.00041861786
. O 0 0.00026182685
6 O 0 0.0002699392
% O 0 0.00046495395
sevoflurane B-Chemical 1 0.9925166
was O 0 0.00039852486
not O 0 0.00034198386
significant O 0 0.00041688254
from O 0 0.0004111036
that O 0 0.00036554673
during O 0 0.00039454928
0 O 0 0.0007957102
. O 0 0.00047111014
8 O 0 0.00067988504
% O 0 0.0012095869
sevoflurane B-Chemical 1 0.9953685
, O 0 0.002192396
indicating O 0 0.0017771552
a O 0 0.003945236
celling O 0 0.02131851
effect O 0 0.0065346197
. O 0 0.008617087

There O 0 0.010106755
was O 0 0.0061737057
no O 0 0.0038249379
significant O 0 0.0036778483
difference O 0 0.0023683582
in O 0 0.0026793529
the O 0 0.0034014224
convulsive B-Disease 2 0.9998728
threshold O 0 0.004491124
between O 0 0.003522687
sevoflurane B-Chemical 1 0.9992079
and O 0 0.020671738
enflurane B-Chemical 1 0.99971765
. O 0 0.014615739

The O 0 0.0071254484
rise O 0 0.006294774
in O 0 0.0034165094
blood O 0 0.008340715
pressure O 0 0.03561746
became O 0 0.0022707505
less O 0 0.0010933048
marked O 0 0.0013757214
when O 0 0.00056209235
higher O 0 0.00061362097
concentrations O 0 0.0014785257
of O 0 0.0011994895
sevoflurane B-Chemical 1 0.99977225
or O 0 0.0013235756
enflurane B-Chemical 1 0.99996555
were O 0 0.00060759246
administered O 0 0.00072357693
and O 0 0.00045788888
the O 0 0.0003907022
blood O 0 0.008185068
pressure O 0 0.057377953
at O 0 0.00047523217
convulsions B-Disease 2 0.9999807
decreased O 0 0.0013817177
significantly O 0 0.00087843154
in O 0 0.0004968622
1 O 0 0.0005490844
. O 0 0.00029307065
6 O 0 0.00030302888
% O 0 0.0005530492
sevoflurane B-Chemical 1 0.9966574
, O 0 0.0007604013
and O 0 0.0005766711
in O 0 0.0005280978
0 O 0 0.0008304148
. O 0 0.00047544285
8 O 0 0.00064033526
% O 0 0.00091573235
and O 0 0.0011048365
1 O 0 0.0014337472
. O 0 0.001366255
6 O 0 0.0020407652
% O 0 0.0050201947
enflurane B-Chemical 1 0.9989613
. O 0 0.009001799

However O 0 0.008874303
, O 0 0.0060219434
there O 0 0.0026311574
was O 0 0.0022011339
no O 0 0.0013937664
significant O 0 0.0014225676
difference O 0 0.00086034875
in O 0 0.0009611411
the O 0 0.0012092262
lidocaine B-Chemical 1 0.9998379
concentrations O 0 0.0027285805
measured O 0 0.00070738303
when O 0 0.00070515316
the O 0 0.0011135055
systolic O 0 0.55412054
blood O 0 0.009962553
pressure O 0 0.04422712
became O 0 0.004162052
70 O 0 0.0045239157
mmHg O 0 0.015287945
. O 0 0.0068660695

Apamin B-Chemical 0 0.9991879
, O 0 0.010780412
a O 0 0.00625521
selective O 0 0.016547564
blocker O 0 0.9845583
of O 0 0.009822735
calcium B-Chemical 1 0.9998142
- O 0 0.0169644
dependent O 0 0.0016388849
potassium B-Chemical 1 0.99994934
channels O 0 0.35610807
, O 0 0.0012611564
was O 0 0.0005325744
administered O 0 0.0009309482
intracerebroventricularly O 0 0.88296545
in O 0 0.00043313985
rats O 0 0.0011575229
anesthetized O 0 0.0026534733
with O 0 0.0005282507
0 O 0 0.00075858546
. O 0 0.00035071833
8 O 0 0.00044192155
% O 0 0.00065985793
sevoflurane B-Chemical 1 0.983818
to O 0 0.0005720905
investigate O 0 0.00050565484
the O 0 0.0010075714
mechanism O 0 0.0015514747
of O 0 0.0025086494
the O 0 0.004071638
anticonvulsive O 0 0.9997472
effects O 0 0.047697153
. O 0 0.010336189

Apamin B-Chemical 0 0.99910295
( O 0 0.01109012
10 O 0 0.0044823377
ng O 0 0.006831984
) O 0 0.003496043
had O 0 0.0014184855
a O 0 0.001491601
tendency O 0 0.0015296973
to O 0 0.0007835074
decrease O 0 0.0007903807
the O 0 0.00092214945
convulsive B-Disease 2 0.9999747
threshold O 0 0.0013978606
( O 0 0.0011968862
21 O 0 0.0006889842
. O 0 0.00032897794
6 O 0 0.00034781118
+ O 0 0.00053394935
/ O 0 0.0014392971
- O 0 0.0007984978
2 O 0 0.0004034079
. O 0 0.00027207573
2 O 0 0.00031323067
to O 0 0.00028952557
19 O 0 0.0005929772
. O 0 0.0002907111
9 O 0 0.00044002532
+ O 0 0.00053233636
/ O 0 0.0014401876
- O 0 0.0007914723
2 O 0 0.00040903562
. O 0 0.0002898686
5 O 0 0.00034487998
mg O 0 0.039851896
. O 0 0.00040748433
l O 0 0.0012146599
( O 0 0.0012588715
- O 0 0.0013111107
1 O 0 0.00088540657
) O 0 0.0014389696
) O 0 0.0014300026
but O 0 0.00093542057
this O 0 0.0011394694
was O 0 0.001550043
not O 0 0.0019839553
statistically O 0 0.0031689843
significant O 0 0.0057395534
. O 0 0.00791784

It O 0 0.0101806065
is O 0 0.0052154185
suggested O 0 0.003327138
that O 0 0.0026420474
sevoflurane B-Chemical 1 0.9984037
reduces O 0 0.002746744
the O 0 0.0025074505
convulsive B-Disease 2 0.99997103
effect O 0 0.0023828489
of O 0 0.0048357625
lidocaine B-Chemical 1 0.9999777
toxicity B-Disease 2 0.9994854
but O 0 0.0019802162
carries O 0 0.0020618085
some O 0 0.0017839769
risk O 0 0.045784492
due O 0 0.002042584
to O 0 0.0036070717
circulatory O 0 0.97912985
depression B-Disease 2 0.9992436
. O 0 0.011903317

Cardiac B-Disease 0 0.97855806
toxicity I-Disease 2 0.9963404
observed O 0 0.0038045447
in O 0 0.002720509
association O 0 0.0018171673
with O 0 0.0019820877
high O 0 0.002606691
- O 0 0.003347439
dose O 0 0.054865286
cyclophosphamide B-Chemical 1 0.9999161
- O 0 0.005332688
based O 0 0.002172617
chemotherapy O 0 0.7415332
for O 0 0.0033967851
metastatic O 0 0.9980306
breast B-Disease 2 0.9995517
cancer I-Disease 2 0.9996823
. O 0 0.021084536

INTRODUCTION O 0 0.08865968
: O 0 0.015185311
Cyclophosphamide B-Chemical 1 0.9990742
is O 0 0.005076411
an O 0 0.0049404674
alkylating O 0 0.98860687
agent O 0 0.28944302
given O 0 0.0017262568
frequently O 0 0.002610704
as O 0 0.0018452404
a O 0 0.0023510663
component O 0 0.0021744962
of O 0 0.0028593456
many O 0 0.0040675215
conditioning O 0 0.03135428
regimens O 0 0.085688315
. O 0 0.010326958

In O 0 0.010148732
high O 0 0.008645477
doses O 0 0.030314362
, O 0 0.0073733563
its O 0 0.008781565
nonhematological O 0 0.99948704
dose O 0 0.29227364
- O 0 0.010714783
limiting O 0 0.0081199715
toxicity B-Disease 2 0.9984565
is O 0 0.019137066
cardiomyopathy B-Disease 2 0.9998375
. O 0 0.0159972

STUDY O 0 0.021354275
DESIGN O 0 0.01197419
: O 0 0.0055331625
We O 0 0.0031300653
combined O 0 0.0035049305
paclitaxel B-Chemical 1 0.9979013
, O 0 0.004887351
melphalan B-Chemical 1 0.99986386
and O 0 0.0022599667
high O 0 0.0019920715
- O 0 0.002250306
dose O 0 0.038471766
cyclophosphamide B-Chemical 1 0.9999585
, O 0 0.008090756
thiotepa B-Chemical 0 0.99994004
, O 0 0.0017476594
and O 0 0.0008658468
carboplatin B-Chemical 1 0.99826044
in O 0 0.0004868936
a O 0 0.00068051834
triple O 0 0.0008992579
sequential O 0 0.000988295
high O 0 0.0010334969
- O 0 0.0014030882
dose O 0 0.003662466
regimen O 0 0.0023077037
for O 0 0.0009762198
patients O 0 0.0047575543
with O 0 0.0037382727
metastatic O 0 0.9981918
breast B-Disease 2 0.9995777
cancer I-Disease 2 0.9996995
. O 0 0.020228384

Analysis O 0 0.012758929
was O 0 0.0054456764
performed O 0 0.0032655909
on O 0 0.0022569196
61 O 0 0.0034287188
women O 0 0.01017334
with O 0 0.0017529239
chemotherapy O 0 0.8219959
- O 0 0.0037036897
responsive O 0 0.0013639947
metastatic O 0 0.99493575
breast B-Disease 2 0.9996567
cancer I-Disease 2 0.9998945
receiving O 0 0.021325974
96 O 0 0.007532151
- O 0 0.0010098992
h O 0 0.00037333815
infusional O 0 0.963041
cyclophosphamide B-Chemical 1 0.99985385
as O 0 0.00054039905
part O 0 0.00032767488
of O 0 0.00040318337
a O 0 0.0005407873
triple O 0 0.00073788763
sequential O 0 0.0007880409
high O 0 0.0007796847
- O 0 0.0009554596
dose O 0 0.0025099947
regimen O 0 0.00095246313
to O 0 0.0002618256
assess O 0 0.00015118576
association O 0 0.00024248214
between O 0 0.00021202519
presence O 0 0.00035131734
of O 0 0.0007135947
peritransplant O 0 0.56558365
congestive B-Disease 0 0.99999106
heart I-Disease 0 0.9762117
failure I-Disease 0 0.9625993
( O 0 0.016516207
CHF B-Disease 2 0.99997985
) O 0 0.0019379071
and O 0 0.0004686496
the O 0 0.0003471573
following O 0 0.00038394256
pretreatment O 0 0.046542995
characteristics O 0 0.00064316246
: O 0 0.0007584084
presence O 0 0.00037513088
of O 0 0.0008066983
electrocardiogram O 0 0.9423758
( O 0 0.0016233565
EKG O 0 0.90244675
) O 0 0.0013213803
abnormalities O 0 0.06261103
, O 0 0.000751832
age O 0 0.0018224576
, O 0 0.0012185426
hypertension B-Disease 2 0.99991345
, O 0 0.0008043717
prior O 0 0.0003105166
cardiac O 0 0.42299065
history O 0 0.05657322
, O 0 0.0020966919
smoking O 1 0.9838648
, O 0 0.0035065382
diabetes B-Disease 2 0.9990946
mellitus I-Disease 0 0.99966395
, O 0 0.0013815
prior O 0 0.00044343487
use O 0 0.00075843686
of O 0 0.0014577494
anthracyclines B-Chemical 0 0.9999161
, O 0 0.0026001018
and O 0 0.0018954832
left O 0 0.0049796132
- O 0 0.004662066
sided O 0 0.6481636
chest O 0 0.7231213
irradiation O 0 0.12765113
. O 0 0.010224813

RESULTS O 0 0.024940219
: O 0 0.0082463175
Six O 0 0.005171179
of O 0 0.0037268607
61 O 0 0.0046605375
women O 0 0.024497015
( O 0 0.0024590385
10 O 0 0.0012787372
% O 0 0.0013252236
) O 0 0.0013365077
developed O 0 0.00096537505
clinically O 0 0.015038347
reversible O 0 0.2527217
grade O 0 0.6322072
3 O 0 0.001106663
CHF B-Disease 2 0.9998888
following O 0 0.000810731
infusional O 0 0.9913863
cyclophosphamide B-Chemical 1 0.9998802
with O 0 0.0008981442
a O 0 0.0008816922
median O 0 0.000608616
percent O 0 0.0007634974
decline O 0 0.0016669164
in O 0 0.0011869412
ejection O 0 0.6305261
fraction O 0 0.0021058326
of O 0 0.0035936777
31 O 0 0.0066503924
% O 0 0.006933968
. O 0 0.007452259

Incidence O 0 0.08740445
of O 0 0.008308793
transient O 0 0.16815133
cyclophosphamide B-Chemical 1 0.9998578
- O 0 0.013907596
related O 0 0.002279966
cardiac B-Disease 2 0.9801616
toxicity I-Disease 2 0.99980253
( O 0 0.00501684
10 O 0 0.001505654
% O 0 0.0016217158
) O 0 0.0018512987
is O 0 0.0011250832
comparable O 0 0.0010764982
to O 0 0.0016847564
previous O 0 0.002528601
recorded O 0 0.00475432
literature O 0 0.008877383
. O 0 0.008752229

Older O 0 0.063681185
age O 0 0.009578456
was O 0 0.0042146593
significantly O 0 0.0031556454
correlated O 0 0.0019298843
with O 0 0.001896196
the O 0 0.002236944
CHF B-Disease 2 0.9999324
development O 0 0.009439963
; O 0 0.0019693945
with O 0 0.00065004773
median O 0 0.0005401385
ages O 0 0.0007461001
for O 0 0.0003741038
the O 0 0.00044463144
entire O 0 0.00039991664
group O 0 0.0006169407
and O 0 0.00066309347
for O 0 0.00053613505
patients O 0 0.0027924282
developing O 0 0.014149174
CHF B-Disease 2 0.99989915
of O 0 0.0021018342
45 O 0 0.0018580086
and O 0 0.0023505378
59 O 0 0.005025359
, O 0 0.0048003783
respectively O 0 0.007945212
. O 0 0.007738386

No O 0 0.0195908
association O 0 0.010985336
was O 0 0.010382081
found O 0 0.008231125
with O 0 0.009482622
other O 0 0.011244083
pretreatment O 0 0.33661416
characteristics O 0 0.019617267
. O 0 0.018461088

CONCLUSIONS O 0 0.44899708
: O 0 0.009235181
As O 0 0.0035591386
a O 0 0.0034504575
result O 0 0.002241749
of O 0 0.0020583489
these O 0 0.0020197988
findings O 0 0.0035274504
, O 0 0.0022400166
oncologists O 0 0.0029263017
should O 0 0.0008341895
carefully O 0 0.0009887527
monitor O 0 0.0010988001
fluid O 0 0.007913013
balance O 0 0.0058069234
in O 0 0.0033647555
older O 0 0.0184131
patients O 0 0.015788741
. O 0 0.009003355

Routine O 0 0.02098254
EKG O 0 0.22025116
monitoring O 0 0.008094148
during O 0 0.005553387
infusional O 0 0.9760358
cyclophosphamide B-Chemical 1 0.9996376
did O 0 0.0063706934
not O 0 0.005642695
predict O 0 0.007066588
CHF B-Disease 2 0.99974173
development O 0 0.052089162
. O 0 0.015102848

Tremor B-Disease 0 0.98759705
side O 0 0.10489198
effects O 0 0.010945811
of O 0 0.009720303
salbutamol B-Chemical 1 0.9997602
, O 0 0.008216389
quantified O 0 0.004190832
by O 0 0.004826473
a O 0 0.0062934733
laser O 0 0.01867213
pointer O 0 0.015777243
technique O 0 0.013585811
. O 0 0.012541223

OBJECTIVE O 0 0.47685105
: O 0 0.008621978
To O 0 0.0039416417
study O 0 0.0045226137
tremor B-Disease 2 0.99964905
side O 0 0.15397961
effects O 0 0.0038174356
of O 0 0.002878143
salbutamol B-Chemical 1 0.99992216
an O 0 0.0026107656
easily O 0 0.0015558291
applicable O 0 0.0010419402
, O 0 0.0012881277
quick O 0 0.0025305888
and O 0 0.0015449683
low O 0 0.0024024004
- O 0 0.0044857394
priced O 0 0.10121067
method O 0 0.004051332
is O 0 0.003992449
needed O 0 0.0046695997
. O 0 0.00808654

A O 0 0.03181712
new O 0 0.009832576
method O 0 0.007375538
using O 0 0.0045594024
a O 0 0.00466815
commercially O 0 0.008517075
available O 0 0.0034542785
, O 0 0.0042409366
pen O 0 0.009824056
- O 0 0.004981277
shaped O 0 0.005195235
laser O 0 0.014280678
pointer O 0 0.011212226
was O 0 0.0062420457
developed O 0 0.0107458625
. O 0 0.011244954

Aim O 0 0.17642346
of O 0 0.006997109
the O 0 0.004332752
study O 0 0.0034508002
was O 0 0.0021785204
to O 0 0.001495745
determine O 0 0.0009136834
sensitivity O 0 0.0024827463
, O 0 0.00175128
reproducibility O 0 0.0015692
, O 0 0.0013752457
reference O 0 0.0009202786
values O 0 0.001115992
and O 0 0.0014577007
the O 0 0.0016382375
agreement O 0 0.0028682821
with O 0 0.0032280858
a O 0 0.00588028
questionnaire O 0 0.008198865
. O 0 0.008192662

METHODS O 0 0.02342344
: O 0 0.02159759
Tremor B-Disease 0 0.9596825
was O 0 0.01008531
measured O 0 0.0070335516
using O 0 0.007610179
a O 0 0.010193416
laser O 0 0.02187493
pointer O 0 0.021080382
technique O 0 0.019188078
. O 0 0.017411957

To O 0 0.006323023
determine O 0 0.0031612304
sensitivity O 0 0.0041280678
we O 0 0.0019619165
assessed O 0 0.002052546
tremor B-Disease 2 0.9997347
in O 0 0.0015540178
44 O 0 0.0018346842
patients O 0 0.0020381273
with O 0 0.0012468381
obstructive B-Disease 0 0.9985297
lung I-Disease 0 0.92451894
disease I-Disease 0 0.97448254
after O 0 0.00090717355
administration O 0 0.041519277
of O 0 0.0019788512
cumulative O 0 0.015609849
doses O 0 0.16519167
of O 0 0.015279433
salbutamol B-Chemical 1 0.9998294
. O 0 0.011618228

Subjects O 0 0.011486309
were O 0 0.0056011113
asked O 0 0.0034860342
to O 0 0.0025177645
aim O 0 0.0024404875
at O 0 0.0014059464
the O 0 0.0013094759
centre O 0 0.0014065679
of O 0 0.0012466426
a O 0 0.0014566128
target O 0 0.0011003755
, O 0 0.0015328323
subdivided O 0 0.0013497182
in O 0 0.0011071765
concentric O 0 0.056172505
circles O 0 0.0021446613
, O 0 0.0025361895
from O 0 0.002239425
5 O 0 0.0028121262
m O 0 0.0087101245
distance O 0 0.0065637575
. O 0 0.008076769

The O 0 0.009332381
circle O 0 0.0085636685
in O 0 0.00471577
which O 0 0.0040863324
the O 0 0.003021623
participant O 0 0.0026778942
succeeded O 0 0.006341138
to O 0 0.0023440286
aim O 0 0.0034184272
was O 0 0.0030679698
recorded O 0 0.003954526
in O 0 0.0044259024
millimetres O 0 0.0094347205
radius O 0 0.018820262
. O 0 0.010834028

In O 0 0.00705583
another O 0 0.0051944763
series O 0 0.0042121024
of O 0 0.0027791322
measurements O 0 0.001912115
, O 0 0.0018327554
reproducibility O 0 0.0013249037
and O 0 0.0009281876
reference O 0 0.00061072735
values O 0 0.00058578386
of O 0 0.00069623167
the O 0 0.0008251325
tremor B-Disease 2 0.99992406
was O 0 0.00059695175
assessed O 0 0.00036020143
in O 0 0.00037902215
65 O 0 0.0005425357
healthy O 0 0.0012558425
subjects O 0 0.0005787889
in O 0 0.00030189502
three O 0 0.00025955142
sessions O 0 0.00041199458
, O 0 0.00047092026
at O 0 0.00026033956
9 O 0 0.00035596848
a O 0 0.00046048447
. O 0 0.00032171796
m O 0 0.0018740321
. O 0 0.00035123798
, O 0 0.00051680184
4 O 0 0.0003468539
p O 0 0.00047816618
. O 0 0.00034481665
m O 0 0.0015421963
. O 0 0.00037254678
and O 0 0.0005203578
9 O 0 0.00055299845
a O 0 0.00071580004
. O 0 0.0005710473
m O 0 0.0027934227
. O 0 0.0008326279
, O 0 0.0015560115
respectively O 0 0.002284564
, O 0 0.0023782277
1 O 0 0.0024249854
week O 0 0.0025568546
later O 0 0.0041423473
. O 0 0.0069235275

Postural O 0 0.9722589
tremor B-Disease 2 0.9994259
was O 0 0.0048001013
measured O 0 0.0021762662
with O 0 0.0018123516
the O 0 0.0014241914
arm O 0 0.0019643924
horizontally O 0 0.0017239099
outstretched O 0 0.018983977
rest O 0 0.0017918497
tremor B-Disease 2 0.9998672
with O 0 0.0008356937
the O 0 0.0006136047
arm O 0 0.0010036812
supported O 0 0.0005998362
by O 0 0.0006170724
an O 0 0.0008536926
armrest O 0 0.0353749
and O 0 0.00085509324
finally O 0 0.0043239817
tremor B-Disease 2 0.9999101
was O 0 0.00070858403
measured O 0 0.00045920283
after O 0 0.00046166367
holding O 0 0.0019227836
a O 0 0.0013971692
2 O 0 0.0014764504
- O 0 0.002356124
kg O 0 0.005513722
weight O 0 0.00655963
until O 0 0.003221166
exhaustion O 0 0.17376831
. O 0 0.008485115

Inter O 0 0.13355878
- O 0 0.012000847
observer O 0 0.008833851
variability O 0 0.0043194103
was O 0 0.0034462826
measured O 0 0.002471191
in O 0 0.002668807
a O 0 0.0034773613
series O 0 0.0043158536
of O 0 0.0042110304
10 O 0 0.004753919
healthy O 0 0.015805703
subjects O 0 0.011890144
. O 0 0.0101921735

Tremor B-Disease 0 0.9796434
was O 0 0.015799666
measured O 0 0.010014129
simultaneously O 0 0.010594283
by O 0 0.010697835
two O 0 0.009297756
independent O 0 0.0114299655
observers O 0 0.02196264
. O 0 0.017632624

RESULTS O 0 0.039215174
: O 0 0.014646722
Salbutamol B-Chemical 0 0.99925476
significantly O 0 0.00691547
increased O 0 0.006587587
tremor B-Disease 2 0.9998485
severity O 0 0.23209411
in O 0 0.0024623554
patients O 0 0.004977384
in O 0 0.0020887395
a O 0 0.0034752472
dose O 0 0.03448858
- O 0 0.0064120577
dependent O 0 0.0042809676
way O 0 0.008636736
. O 0 0.009447211

Within O 0 0.006401595
healthy O 0 0.009574191
adults O 0 0.0055662156
no O 0 0.0024686437
age O 0 0.0053917915
- O 0 0.003100721
dependency O 0 0.0024080295
could O 0 0.00096498505
be O 0 0.0010164058
found O 0 0.0007816312
( O 0 0.0013392753
b O 0 0.0017528046
= O 0 0.0011563139
0 O 0 0.00088020146
. O 0 0.00055251794
262 O 0 0.0033954699
mm O 0 0.0018651977
/ O 0 0.0017833639
year O 0 0.0011113686
; O 0 0.0021696598
P O 0 0.03147738
= O 0 0.0022900694
0 O 0 0.0022970669
. O 0 0.0020860692
72 O 0 0.003834357
) O 0 0.0070249145
. O 0 0.0071823066

There O 0 0.008513557
was O 0 0.0050099515
no O 0 0.0029232635
agreement O 0 0.0030200777
between O 0 0.0015898985
the O 0 0.0017210959
questionnaire O 0 0.002061104
and O 0 0.0020690588
tremor B-Disease 2 0.999912
severity O 0 0.27428162
( O 0 0.002383263
r O 0 0.001434443
= O 0 0.0013768735
0 O 0 0.0011210105
. O 0 0.0007737808
093 O 0 0.020034017
; O 0 0.002092938
P O 0 0.022452228
= O 0 0.0022739386
0 O 0 0.0023533278
. O 0 0.0022267194
53 O 0 0.006039906
) O 0 0.007747967
. O 0 0.0074701402

Postural O 0 0.96474
tremor B-Disease 2 0.99916947
showed O 0 0.00398592
no O 0 0.0022081765
significant O 0 0.001963406
difference O 0 0.0010900742
between O 0 0.0008903217
the O 0 0.0010429627
first O 0 0.00090311846
and O 0 0.0012376987
third O 0 0.0014835083
session O 0 0.0016214557
( O 0 0.002636325
P O 0 0.07307721
= O 0 0.003147819
0 O 0 0.0031630788
. O 0 0.0029711484
07 O 0 0.015232992
) O 0 0.008574413
. O 0 0.008041772

Support O 0 0.020677734
of O 0 0.0077613913
the O 0 0.0055398154
arm O 0 0.007089151
decreased O 0 0.008927106
tremor B-Disease 2 0.9998629
severity O 0 0.587963
, O 0 0.009636172
exhaustion O 0 0.55962795
increased O 0 0.010752936
tremor B-Disease 2 0.99987864
severity O 0 0.620025
significantly O 0 0.021249533
. O 0 0.012591112

A O 0 0.027733337
good O 0 0.007894689
agreement O 0 0.005938569
was O 0 0.0035448957
found O 0 0.0021487202
between O 0 0.0014953354
two O 0 0.0014962258
independent O 0 0.0015388884
observers O 0 0.002883213
( O 0 0.00208012
interclass O 0 0.0028750543
correlation O 0 0.0014033406
coefficient O 0 0.0036343094
0 O 0 0.0031325477
. O 0 0.0024356537
72 O 0 0.004314053
) O 0 0.007723717
. O 0 0.0075687263

DISCUSSION O 0 0.04161694
: O 0 0.009026249
Quantifying O 0 0.009176049
tremor B-Disease 2 0.9994117
by O 0 0.003626341
using O 0 0.0018448674
an O 0 0.002010877
inexpensive O 0 0.010936424
laser O 0 0.007199716
pointer O 0 0.0037210118
is O 0 0.0009965901
, O 0 0.0009798277
with O 0 0.00061817793
the O 0 0.00056239014
exception O 0 0.00052646926
of O 0 0.0008428644
children O 0 0.0026227054
( O 0 0.001283141
< O 0 0.000788775
12 O 0 0.0005982151
years O 0 0.0011339978
) O 0 0.0015959563
a O 0 0.0015799633
sensitive O 0 0.0016088224
and O 0 0.0027990818
reproducible O 0 0.0053271675
method O 0 0.0073448736
. O 0 0.008173405

Safety O 0 0.05875079
and O 0 0.009533353
adverse O 0 0.7388675
effects O 0 0.0095232865
associated O 0 0.005954946
with O 0 0.006891622
raloxifene B-Chemical 0 0.99986374
: O 0 0.008607895
multiple O 0 0.0061289906
outcomes O 0 0.009503205
of O 0 0.009633047
raloxifene B-Chemical 0 0.99976104
evaluation O 0 0.016961759
. O 0 0.011970811

OBJECTIVE O 0 0.42477918
: O 0 0.007930683
To O 0 0.0032403956
examine O 0 0.0018684666
the O 0 0.0019700956
effect O 0 0.001689134
of O 0 0.0026629914
raloxifene B-Chemical 0 0.99982435
on O 0 0.0010196228
major O 0 0.0016887384
adverse O 0 0.94033706
events O 0 0.057172842
that O 0 0.0011288401
occur O 0 0.0016872911
with O 0 0.0032280965
postmenopausal O 0 0.9994486
estrogen B-Chemical 1 0.99990046
therapy O 0 0.35390145
or O 0 0.014587643
tamoxifen B-Chemical 1 0.9995529
. O 0 0.012961672

METHODS O 0 0.012578528
: O 0 0.008857991
The O 0 0.0047348025
Multiple O 0 0.010132191
Outcomes O 0 0.007190741
of O 0 0.004285859
Raloxifene B-Chemical 1 0.99991727
Evaluation O 0 0.012099543
, O 0 0.0018000022
a O 0 0.0014391203
multicenter O 0 0.023678374
, O 0 0.001154169
randomized O 0 0.0009136291
, O 0 0.00087940594
double O 0 0.00078077544
- O 0 0.0012664403
blind O 0 0.0026722776
trial O 0 0.0012313765
, O 0 0.0011515894
enrolled O 0 0.0015063473
7 O 0 0.0012177906
, O 0 0.002130728
705 O 0 0.03700274
postmenopausal O 0 0.9875366
women O 0 0.23795854
with O 0 0.011326873
osteoporosis B-Disease 2 0.99972457
. O 0 0.014976777

Women O 0 0.027786242
were O 0 0.006267897
randomly O 0 0.0032298078
assigned O 0 0.00267248
to O 0 0.0027864962
raloxifene B-Chemical 0 0.999405
60 O 0 0.0026276559
mg O 0 0.28531688
/ O 0 0.0032969585
d O 0 0.0017430501
or O 0 0.0014339931
120 O 0 0.0020651391
mg O 0 0.15288092
/ O 0 0.004721705
d O 0 0.0037506002
or O 0 0.004526831
placebo O 0 0.23433042
. O 0 0.009081333

Outcomes O 0 0.016527727
included O 0 0.0074661714
venous B-Disease 0 0.74543095
thromboembolism I-Disease 0 0.99993837
, O 0 0.037078943
cataracts B-Disease 2 0.99907315
, O 0 0.01012326
gallbladder B-Disease 2 0.9947088
disease I-Disease 2 0.9935023
, O 0 0.009437672
and O 0 0.0069962484
endometrial B-Disease 0 0.99896264
hyperplasia I-Disease 0 0.9996247
or I-Disease 0 0.03412979
cancer I-Disease 2 0.9984302
. O 0 0.016476937

RESULTS O 0 0.023588281
: O 0 0.007645009
During O 0 0.00320044
a O 0 0.0030440106
mean O 0 0.0020429688
follow O 0 0.0016128449
- O 0 0.0018733775
up O 0 0.0009412541
of O 0 0.0010109233
3 O 0 0.00079918717
. O 0 0.0005085721
3 O 0 0.00051829213
years O 0 0.0008517319
, O 0 0.0010908856
raloxifene B-Chemical 0 0.99980706
was O 0 0.00066609355
associated O 0 0.00063103857
with O 0 0.00055934914
an O 0 0.00080221856
increased O 0 0.000748861
risk O 0 0.03513849
for O 0 0.00047701946
venous B-Disease 0 0.91085535
thromboembolism I-Disease 0 0.9999944
( O 0 0.0018611099
relative O 0 0.00053846074
risk O 0 0.14972965
[ O 0 0.01346267
RR O 0 0.90792304
] O 0 0.0023236943
2 O 0 0.0006279917
. O 0 0.0003932821
1 O 0 0.00056289096
; O 0 0.00076208723
95 O 0 0.00080169656
% O 0 0.0005956296
confidence O 0 0.001325964
interval O 0 0.000987589
[ O 0 0.0037163324
CI O 0 0.35904598
] O 0 0.0019134204
1 O 0 0.0010226367
. O 0 0.000781572
2 O 0 0.001201846
- O 0 0.0018921618
3 O 0 0.0016129053
. O 0 0.0019248006
8 O 0 0.0033470304
) O 0 0.0069304095
. O 0 0.00706005

The O 0 0.0073977676
excess O 0 0.007039359
event O 0 0.00872201
rate O 0 0.0028205547
was O 0 0.002119391
1 O 0 0.0015556375
. O 0 0.0008524106
8 O 0 0.0007078264
per O 0 0.00050841254
1 O 0 0.00068867794
, O 0 0.0007113926
000 O 0 0.0007786976
woman O 0 0.004699128
- O 0 0.0011491053
years O 0 0.00097183115
( O 0 0.0009045553
95 O 0 0.0011409149
% O 0 0.0008422289
CI O 0 0.15270703
- O 0 0.00086248125
0 O 0 0.000589622
. O 0 0.00031843642
5 O 0 0.00037798873
- O 0 0.0005900605
4 O 0 0.00034514724
. O 0 0.0002892982
1 O 0 0.00043396934
) O 0 0.00064576644
, O 0 0.0004458735
and O 0 0.0003419001
the O 0 0.0002942684
number O 0 0.00028988713
needed O 0 0.00025421943
to O 0 0.000342424
treat O 0 0.0011179763
to O 0 0.00050696224
cause O 0 0.0028006576
1 O 0 0.00070482865
event O 0 0.002976484
was O 0 0.0006099592
170 O 0 0.0023903945
( O 0 0.00089292775
95 O 0 0.0011627765
% O 0 0.000971173
CI O 0 0.06590585
100 O 0 0.0015512538
- O 0 0.0015285006
582 O 0 0.012045447
) O 0 0.001477743
over O 0 0.00088303315
3 O 0 0.0015133511
. O 0 0.0017810565
3 O 0 0.003001719
years O 0 0.0059211757
. O 0 0.006894338

Risk O 0 0.04694972
in O 0 0.005981739
the O 0 0.005006169
raloxifene B-Chemical 0 0.99938965
group O 0 0.0038374914
was O 0 0.0016210405
higher O 0 0.0010018065
than O 0 0.00062319974
in O 0 0.0006028285
the O 0 0.00060201576
placebo O 0 0.033401627
group O 0 0.0006176794
for O 0 0.00034634536
the O 0 0.00039547263
first O 0 0.00035938405
2 O 0 0.0004856319
years O 0 0.0007057196
, O 0 0.00063654786
but O 0 0.0004408234
decreased O 0 0.00058246346
to O 0 0.0003988084
about O 0 0.00040646945
the O 0 0.00048342056
same O 0 0.0004306897
rate O 0 0.0007088208
as O 0 0.00096023805
in O 0 0.0011408181
the O 0 0.0017322528
placebo O 0 0.1230318
group O 0 0.0047851535
thereafter O 0 0.006110742
. O 0 0.0070616645

Raloxifene B-Chemical 1 0.99927145
did O 0 0.0070893755
not O 0 0.004166127
increase O 0 0.0027602827
risk O 0 0.045350328
for O 0 0.0024027466
cataracts B-Disease 2 0.99939203
( O 0 0.0070294663
RR O 0 0.81913143
0 O 0 0.0015601321
. O 0 0.00058952026
9 O 0 0.0007197033
; O 0 0.00091469864
95 O 0 0.0009681438
% O 0 0.0007512999
CI O 0 0.041786883
0 O 0 0.0006429207
. O 0 0.00035361235
8 O 0 0.00046033793
- O 0 0.00066902995
1 O 0 0.00045410678
. O 0 0.00032726434
1 O 0 0.00048962515
) O 0 0.00079812924
, O 0 0.0007336955
gallbladder B-Disease 2 0.9749069
disease I-Disease 2 0.9878154
( O 0 0.0050329273
RR O 0 0.83711845
1 O 0 0.00068935193
. O 0 0.00036557764
0 O 0 0.0006289009
; O 0 0.0006924743
95 O 0 0.00077527866
% O 0 0.00061213353
CI O 0 0.03960835
0 O 0 0.00055594847
. O 0 0.00031122525
7 O 0 0.0004159261
- O 0 0.0006254647
1 O 0 0.00042398457
. O 0 0.0003050059
3 O 0 0.000414631
) O 0 0.00082983746
, O 0 0.0008476033
endometrial B-Disease 0 0.99720937
hyperplasia I-Disease 0 0.9998609
( O 0 0.008125339
RR O 0 0.85150754
1 O 0 0.00070157077
. O 0 0.00035713162
3 O 0 0.00043365403
; O 0 0.00067121285
95 O 0 0.00075180555
% O 0 0.00060151704
CI O 0 0.0396491
0 O 0 0.0005506589
. O 0 0.00030490907
4 O 0 0.00038454658
- O 0 0.0005818066
5 O 0 0.00033935707
. O 0 0.00030476289
1 O 0 0.00046687832
) O 0 0.00074064947
, O 0 0.00060242787
or O 0 0.0006227229
endometrial B-Disease 2 0.9996816
cancer I-Disease 2 0.9998908
( O 0 0.009526336
RR O 0 0.8402041
0 O 0 0.0010282883
. O 0 0.0004304434
9 O 0 0.0006144573
; O 0 0.0008767102
95 O 0 0.0010306172
% O 0 0.00092536985
CI O 0 0.034947872
0 O 0 0.0010264027
. O 0 0.0007381338
3 O 0 0.0011015391
- O 0 0.0018879924
2 O 0 0.001753337
. O 0 0.0019901376
7 O 0 0.0034487182
) O 0 0.007171169
. O 0 0.007240451

CONCLUSION O 0 0.9259461
: O 0 0.02682915
Raloxifene B-Chemical 1 0.9996742
was O 0 0.004055099
associated O 0 0.002676626
with O 0 0.0018338104
an O 0 0.0020150668
increased O 0 0.00166131
risk O 0 0.038589165
for O 0 0.0008493727
venous B-Disease 0 0.9221461
thromboembolism I-Disease 0 0.9999933
, O 0 0.0022269145
but O 0 0.0006111018
there O 0 0.0003451344
was O 0 0.0004322108
no O 0 0.00037085987
increased O 0 0.000867089
risk O 0 0.07093573
for O 0 0.0010431956
cataracts B-Disease 2 0.99956805
, O 0 0.0060006655
gallbladder B-Disease 2 0.99693596
disease I-Disease 2 0.9965406
, O 0 0.029512702
endometrial B-Disease 0 0.9995189
hyperplasia I-Disease 0 0.9998072
, O 0 0.017947154
or O 0 0.007961572
endometrial B-Disease 2 0.9996331
cancer I-Disease 2 0.9995931
. O 0 0.017682025

LEVEL O 0 0.36858916
OF O 0 0.146426
EVIDENCE O 0 0.41217962
: O 0 0.09537384
I O 0 0.14617063

Optimization O 0 0.06753764
of O 0 0.054835726
levodopa B-Chemical 1 0.9990676
therapy O 0 0.5371137
. O 0 0.04876132

While O 0 0.0069127562
there O 0 0.0035089813
is O 0 0.0026854337
no O 0 0.0016059742
single O 0 0.0015359867
correct O 0 0.0011995073
starting O 0 0.0009252751
dose O 0 0.0056493394
for O 0 0.00084499177
levodopa B-Chemical 1 0.9999815
therapy O 0 0.051266287
, O 0 0.0010632931
many O 0 0.0005827028
individuals O 0 0.00093333283
can O 0 0.0003455568
be O 0 0.00037801216
started O 0 0.00035749678
on O 0 0.00022820076
either O 0 0.00034974868
the O 0 0.0003850407
25 O 0 0.00065891055
/ O 0 0.0010711316
100 O 0 0.0006986327
or O 0 0.0003557771
controlled O 0 0.0004942175
- O 0 0.0008877863
release O 0 0.009113095
formula O 0 0.005042365
, O 0 0.00054030947
following O 0 0.00031121046
the O 0 0.00033146693
general O 0 0.00037787127
rule O 0 0.00072008616
not O 0 0.00036315658
to O 0 0.0003335671
attempt O 0 0.0004999717
to O 0 0.000467259
titrate O 0 0.00697864
carbidopa B-Chemical 0 0.99999595
- O 0 0.011004413
levodopa B-Chemical 1 0.99996936
to O 0 0.0005150752
the O 0 0.00048841035
point O 0 0.00046017824
of O 0 0.0008261569
" O 0 0.001483365
normality O 0 0.073371455
, O 0 0.001678089
" O 0 0.0017434517
which O 0 0.001847425
can O 0 0.0018947193
lead O 0 0.023451503
to O 0 0.00495082
toxicity B-Disease 2 0.9974021
. O 0 0.010591554

The O 0 0.007189573
physician O 0 0.008704799
should O 0 0.0024198762
also O 0 0.0019943444
determine O 0 0.0009910469
the O 0 0.0011240419
proper O 0 0.0009252301
use O 0 0.0008803034
of O 0 0.0008674899
any O 0 0.00070415024
adjunctive O 0 0.039495848
medications O 0 0.6922661
; O 0 0.0016534084
such O 0 0.0006512458
combined O 0 0.0012426487
therapy O 0 0.006509156
has O 0 0.0008643953
become O 0 0.0013612119
the O 0 0.0012296487
standard O 0 0.0017911948
approach O 0 0.0029384114
to O 0 0.0034497622
treatment O 0 0.00885619
. O 0 0.0085521145

Following O 0 0.007054126
the O 0 0.0042778645
initial O 0 0.0029826006
period O 0 0.0020381992
of O 0 0.0020984714
therapy O 0 0.009219518
, O 0 0.0018302082
emerging O 0 0.001579294
difficulties O 0 0.004240107
require O 0 0.00049847557
a O 0 0.0007999011
reassessment O 0 0.002152313
of O 0 0.000746493
therapeutic O 0 0.010584941
approaches O 0 0.001702023
, O 0 0.00095018663
such O 0 0.00056812225
as O 0 0.00074556237
dosage O 0 0.05885325
adjustment O 0 0.0013073351
or O 0 0.0010216824
introduction O 0 0.0013711138
of O 0 0.0026958147
a O 0 0.012433887
dopamine B-Chemical 1 0.99975246
agonist O 0 0.96896553
. O 0 0.010553825

Other O 0 0.013569136
possible O 0 0.005946118
adverse O 0 0.8194503
effects O 0 0.020252561
- O 0 0.009149223
- O 0 0.00271292
such O 0 0.0011520562
as O 0 0.001606957
gastrointestinal B-Disease 0 0.999828
disorders I-Disease 0 0.99957865
, O 0 0.04476358
orthostatic B-Disease 2 0.9999813
hypotension I-Disease 2 0.9999982
, O 0 0.05999198
levodopa B-Chemical 1 0.9999958
- O 0 0.016962918
induced O 0 0.0025070165
psychosis B-Disease 0 0.9999758
, O 0 0.0040731207
sleep B-Disease 0 0.9452977
disturbances I-Disease 0 0.95832306
or O 0 0.0012520279
parasomnias B-Disease 0 0.99950063
, O 0 0.001208388
or O 0 0.00064755837
drug O 0 0.43599215
interactions O 0 0.0039900793
- O 0 0.0031466775
- O 0 0.0014212447
also O 0 0.0008780257
require O 0 0.0007940481
carefully O 0 0.0011709247
monitored O 0 0.0013240996
individual O 0 0.0029041308
treatment O 0 0.007199041
. O 0 0.007927468

Nonpharmacologic O 0 0.073394835
concerns O 0 0.009138115
can O 0 0.0034029423
help O 0 0.0030352979
the O 0 0.0024153248
Parkinson B-Disease 0 0.9993332
' I-Disease 0 0.0026388653
s I-Disease 0 0.0015409309
disease I-Disease 0 0.2883138
patient O 0 0.0013883685
achieve O 0 0.00052550767
and O 0 0.00065842184
maintain O 0 0.00037856714
optimal O 0 0.00037182224
functioning O 0 0.0038245632
, O 0 0.0007061434
including O 0 0.0004920778
daily O 0 0.0015137604
exercise O 0 0.020679336
, O 0 0.0011331183
physical O 0 0.014027395
therapy O 0 0.0108436905
, O 0 0.0017951005
and O 0 0.0016982583
involvement O 0 0.0038496947
with O 0 0.0028463493
support O 0 0.0037789482
groups O 0 0.007738529
. O 0 0.008139554

Long O 0 0.032053553
term O 0 0.013742824
audiological O 0 0.023894105
evaluation O 0 0.011666326
of O 0 0.013550755
beta B-Disease 0 0.92540354
- I-Disease 0 0.052851927
thalassemic I-Disease 0 0.9965155
patients O 0 0.1129737
. O 0 0.018364968

OBJECTIVE O 0 0.46418744
: O 0 0.008006569
The O 0 0.0034836063
objective O 0 0.0034915106
of O 0 0.0022624915
this O 0 0.0015929746
study O 0 0.0015195286
was O 0 0.0009551967
to O 0 0.00067490636
identify O 0 0.00053354684
the O 0 0.0006605308
incidence O 0 0.0046036076
and O 0 0.00077124144
to O 0 0.000496004
monitor O 0 0.00039768236
the O 0 0.0005907161
progression O 0 0.15303224
of O 0 0.0013741317
hearing B-Disease 0 0.9528288
loss I-Disease 0 0.0020265586
in O 0 0.0007494036
children O 0 0.002176172
and O 0 0.0012296009
young O 0 0.010142793
adults O 0 0.00498563
with O 0 0.0030017446
beta B-Disease 0 0.94051766
- I-Disease 0 0.05824817
thalassemia I-Disease 0 0.99988735
major O 0 0.014249285
. O 0 0.010558403

METHODS O 0 0.011867074
: O 0 0.008273785
One O 0 0.0053808917
hundred O 0 0.0035682854
and O 0 0.0027565078
four O 0 0.001793197
( O 0 0.0022289136
104 O 0 0.002275796
) O 0 0.0017718296
patients O 0 0.00160419
aged O 0 0.0014654589
6 O 0 0.00070665067
- O 0 0.0009639449
35 O 0 0.0006696723
years O 0 0.0008418184
( O 0 0.0008282448
mean O 0 0.00065718096
17 O 0 0.0011583511
, O 0 0.0011368889
2 O 0 0.0010910325
years O 0 0.0018618025
) O 0 0.002835877
participated O 0 0.0041148113
in O 0 0.0025955401
the O 0 0.0039021792
study O 0 0.0073163165
. O 0 0.008346703

All O 0 0.008118646
patients O 0 0.0075337305
were O 0 0.0038498188
on O 0 0.0022434324
a O 0 0.0025919923
regular O 0 0.002544287
transfusion O 0 0.26594836
- O 0 0.00618125
chelation O 0 0.97107905
program O 0 0.0015089082
maintaining O 0 0.0009008998
a O 0 0.0010318435
mean O 0 0.00084107363
hemoglobin O 0 0.6722669
level O 0 0.0008683424
of O 0 0.001492253
9 O 0 0.0016981101
. O 0 0.0013625023
5 O 0 0.002101554
gr O 0 0.014239162
/ O 0 0.009781991
dl O 0 0.040146872
. O 0 0.008821877

Subjects O 0 0.012301429
were O 0 0.0066779647
receiving O 0 0.01263426
desferrioxamine B-Chemical 1 0.99995315
( O 0 0.116940975
DFO B-Chemical 1 0.99996865
) O 0 0.037410147
chelation O 0 0.9880795
treatment O 0 0.0022213482
with O 0 0.0007974063
a O 0 0.0007576145
mean O 0 0.00044653134
daily O 0 0.00084523705
dose O 0 0.0019284803
of O 0 0.0006591084
50 O 0 0.0011214911
- O 0 0.000774699
60 O 0 0.0003974535
mg O 0 0.0634834
/ O 0 0.0010778495
kg O 0 0.0026412886
, O 0 0.00062361255
5 O 0 0.00036917813
- O 0 0.0004640896
6 O 0 0.00020854814
days O 0 0.00018824705
a O 0 0.00030964724
week O 0 0.0002133185
during O 0 0.00020057856
the O 0 0.00025643833
first O 0 0.00023594788
six O 0 0.00023308628
years O 0 0.0004751565
of O 0 0.00042970257
the O 0 0.00044339616
study O 0 0.0006612668
, O 0 0.00065466604
which O 0 0.00052930013
was O 0 0.00041019658
then O 0 0.00037880073
reduced O 0 0.0004631085
to O 0 0.00048068745
40 O 0 0.0007466912
- O 0 0.00095413387
50 O 0 0.00091415836
mg O 0 0.090385355
/ O 0 0.0019373724
kg O 0 0.0027300005
for O 0 0.0010339771
the O 0 0.0015708654
following O 0 0.002218167
eight O 0 0.0032372556
years O 0 0.007715584
. O 0 0.0076758265

Patients O 0 0.02605133
were O 0 0.014096453
followed O 0 0.010378251
for O 0 0.009686583
8 O 0 0.011112966
- O 0 0.013793361
14 O 0 0.0124971885
years O 0 0.016956665
. O 0 0.016814947

RESULTS O 0 0.025087383
: O 0 0.008415127
Overall O 0 0.006116418
, O 0 0.0038142384
21 O 0 0.0023336902
out O 0 0.0014022373
of O 0 0.0013622649
104 O 0 0.0019181326
patients O 0 0.0025256237
( O 0 0.0013558128
20 O 0 0.0007926332
. O 0 0.00049801107
2 O 0 0.00056238717
% O 0 0.0006915877
) O 0 0.00080663146
presented O 0 0.0005515729
with O 0 0.00059409696
high O 0 0.00094277546
frequency O 0 0.002495836
sensorineural B-Disease 2 0.9999728
hearing I-Disease 2 0.9933241
loss I-Disease 2 0.091431364
( O 0 0.020713476
SNHL B-Disease 0 0.9999634
) O 0 0.005642979
, O 0 0.0023373074
either O 0 0.0021426436
unilateral O 0 0.12324888
or O 0 0.004699128
bilateral O 0 0.21477053
. O 0 0.008744979

No O 0 0.01544846
ototoxic B-Disease 0 0.9958307
factor O 0 0.07321322
, O 0 0.005916992
other O 0 0.0034088162
than O 0 0.0028755984
DFO B-Chemical 1 0.99988663
, O 0 0.0038857684
was O 0 0.0017647258
present O 0 0.0013413178
in O 0 0.0017875077
any O 0 0.0022243042
of O 0 0.003780557
the O 0 0.005084056
patients O 0 0.019337624
. O 0 0.009951911

Patients O 0 0.018897949
with O 0 0.009057913
SNHL B-Disease 0 0.9994454
presented O 0 0.0043322877
with O 0 0.0024237826
relatively O 0 0.0021449334
lower O 0 0.0018310203
serum O 0 0.22495162
ferritin O 0 0.99681264
levels O 0 0.0011535031
than O 0 0.00059656217
those O 0 0.0009211238
with O 0 0.0007835306
normal O 0 0.002355931
hearing O 0 0.92197406
, O 0 0.0013976615
however O 0 0.0010197229
, O 0 0.0010231214
no O 0 0.00067691517
statistically O 0 0.0010993698
significant O 0 0.0016133024
difference O 0 0.001643806
was O 0 0.0029877597
observed O 0 0.0038477383
. O 0 0.007552969

Subjects O 0 0.021217706
with O 0 0.01496921
SNHL B-Disease 0 0.99903584
were O 0 0.00840613
submitted O 0 0.0062617697
to O 0 0.00663074
DFO B-Chemical 1 0.99964
reduction O 0 0.011332063
or O 0 0.0075570806
temporary O 0 0.17442074
withdrawal O 0 0.9465216
. O 0 0.01472786

Following O 0 0.009048513
intervention O 0 0.006508045
, O 0 0.004678693
7 O 0 0.0025560495
out O 0 0.0017860382
of O 0 0.0017650693
21 O 0 0.0016965017
affected O 0 0.0011311366
patients O 0 0.0021814737
recovered O 0 0.00119677
, O 0 0.0017147764
10 O 0 0.0011888021
remained O 0 0.0013160356
stable O 0 0.0016993217
and O 0 0.002326859
4 O 0 0.00268032
demonstrated O 0 0.003878505
aggravation O 0 0.94596153
. O 0 0.011168243

CONCLUSION O 0 0.6413296
: O 0 0.009458927
The O 0 0.004392314
findings O 0 0.0049804407
are O 0 0.0030705081
indicative O 0 0.0023811802
of O 0 0.0038679172
DFO B-Chemical 1 0.9999113
' O 0 0.003657434
s O 0 0.002014486
contributing O 0 0.0017953814
role O 0 0.0011786664
in O 0 0.0015195105
the O 0 0.0020305957
development O 0 0.004584556
of O 0 0.0065972856
hearing B-Disease 0 0.9878721
impairment I-Disease 0 0.80255705
. O 0 0.010809563

Regular O 0 0.029765807
audiologic O 0 0.047599025
evaluation O 0 0.004744524
is O 0 0.0027881493
imperative O 0 0.0022659148
in O 0 0.0014359675
all O 0 0.0013310746
thalassemic B-Disease 0 0.96651554
patients O 0 0.0038106255
so O 0 0.00075287843
that O 0 0.0005349212
early O 0 0.0011287633
changes O 0 0.00094245037
may O 0 0.0005629846
be O 0 0.0005903893
recognized O 0 0.00071602286
and O 0 0.0007688265
treatment O 0 0.0010800817
may O 0 0.0005912106
be O 0 0.0006388771
judiciously O 0 0.0011216758
adjusted O 0 0.00088176574
in O 0 0.00066817197
order O 0 0.00069136254
to O 0 0.001057132
prevent O 0 0.0018024266
or O 0 0.0028691893
reverse O 0 0.15356319
hearing B-Disease 0 0.9879373
impairment I-Disease 0 0.76547515
. O 0 0.009660969

Individual O 0 0.011154859
differences O 0 0.0048237755
in O 0 0.004764457
renal O 0 0.9766534
ACE O 0 0.99912304
activity O 0 0.0038555798
in O 0 0.0018785936
healthy O 0 0.009441445
rats O 0 0.0031555612
predict O 0 0.00125223
susceptibility O 0 0.0056497925
to O 0 0.003136517
adriamycin B-Chemical 1 0.9999027
- O 0 0.03017419
induced O 0 0.011160547
renal B-Disease 2 0.9995203
damage I-Disease 2 0.99653935
. O 0 0.016438259

BACKGROUND O 0 0.6143897
: O 0 0.009788489
In O 0 0.004538091
man O 0 0.060221463
, O 0 0.0037326617
differences O 0 0.0016522967
in O 0 0.0023152374
angiotensin B-Chemical 1 0.9999263
- O 0 0.024030214
converting O 0 0.29742098
enzyme O 0 0.47610492
( O 0 0.008399384
ACE O 0 0.9996315
) O 0 0.0027231753
levels O 0 0.00070904306
, O 0 0.0008648546
related O 0 0.0004969043
to O 0 0.0008588404
ACE O 0 0.99950874
( O 0 0.0029473198
I O 0 0.043396268
/ O 0 0.010066244
D O 0 0.8832435
) O 0 0.0036270786
genotype O 0 0.003197397
, O 0 0.0021114857
are O 0 0.001844285
associated O 0 0.00267165
with O 0 0.0048060813
renal O 0 0.9965148
prognosis O 0 0.986485
. O 0 0.0129143195

This O 0 0.009691583
raises O 0 0.0042829663
the O 0 0.0033666347
hypothesis O 0 0.0026398066
that O 0 0.0016484846
individual O 0 0.0014698643
differences O 0 0.0010429259
in O 0 0.00149754
renal O 0 0.9946867
ACE O 0 0.99972385
activity O 0 0.0026061607
are O 0 0.0015511549
involved O 0 0.0012930396
in O 0 0.0018435777
renal O 0 0.9839118
susceptibility O 0 0.027076649
to O 0 0.0054890793
inflicted O 0 0.9444808
damage O 0 0.95721036
. O 0 0.013397751

Therefore O 0 0.007274228
, O 0 0.0057733804
we O 0 0.0025709865
studied O 0 0.0023535474
the O 0 0.0017369235
predictive O 0 0.0021999467
effect O 0 0.0012726258
of O 0 0.0020636222
renal O 0 0.99780256
ACE O 0 0.9998211
activity O 0 0.0014984543
for O 0 0.00052451785
the O 0 0.00064707367
severity O 0 0.043174185
of O 0 0.0021825656
renal B-Disease 2 0.999676
damage I-Disease 2 0.9913811
induced O 0 0.0021339895
by O 0 0.0013816395
a O 0 0.0014337936
single O 0 0.0012627032
injection O 0 0.0033908177
of O 0 0.0038267185
adriamycin B-Chemical 1 0.9997774
in O 0 0.005525757
rats O 0 0.031226408
. O 0 0.009089519

METHODS O 0 0.014283377
: O 0 0.012825824
Renal O 0 0.8164246
ACE O 0 0.9971616
activity O 0 0.0072095995
( O 0 0.0062389765
Hip B-Chemical 0 0.575808
- I-Chemical 0 0.0051812413
His I-Chemical 0 0.021272624
- I-Chemical 0 0.004524493
Leu I-Chemical 0 0.9562459
cleavage O 0 0.0038484694
by O 0 0.001178745
cortical O 0 0.03492472
homogenates O 0 0.024596483
) O 0 0.0017697933
was O 0 0.0006638808
determined O 0 0.0005724964
by O 0 0.0010841469
renal O 0 0.9408572
biopsy O 0 0.014942292
in O 0 0.0015540335
27 O 0 0.0027748963
adult O 0 0.0031391543
male O 0 0.012135754
Wistar O 0 0.15456335
rats O 0 0.01378991
. O 0 0.00949152

After O 0 0.0060839774
1 O 0 0.0046567344
week O 0 0.0027176465
of O 0 0.0026840575
recovery O 0 0.00504742
, O 0 0.0040890737
proteinuria B-Disease 2 0.9999254
was O 0 0.0018144517
induced O 0 0.0014897754
by O 0 0.0020791325
adriamycin B-Chemical 1 0.99994695
[ O 0 0.017974624
1 O 0 0.00082587893
. O 0 0.000375137
5 O 0 0.0003773137
mg O 0 0.044445712
/ O 0 0.00095948775
kg O 0 0.0018255302
intravenously O 0 0.0016034205
( O 0 0.0007793512
i O 0 0.0015863004
. O 0 0.0003928952
v O 0 0.0074957632
. O 0 0.00037934352
) O 0 0.00068571354
n O 0 0.00050597935
= O 0 0.00062988827
18 O 0 0.00046834414
; O 0 0.00068534864
controls O 0 0.000818667
, O 0 0.00082873274
saline O 0 0.024915183
i O 0 0.0024096442
. O 0 0.00079189596
v O 0 0.0056318645
. O 0 0.0010803292
n O 0 0.0019642746
= O 0 0.0032132098
9 O 0 0.0036365308
] O 0 0.007220632
. O 0 0.00705873

Proteinuria B-Disease 2 0.9959643
was O 0 0.022026524
measured O 0 0.014484031
every O 0 0.012366785
2 O 0 0.016728759
weeks O 0 0.016375782
. O 0 0.021972736

After O 0 0.008818791
12 O 0 0.0065443777
weeks O 0 0.004974333
, O 0 0.005882864
rats O 0 0.0060712686
were O 0 0.0043414044
sacrificed O 0 0.004048989
and O 0 0.005373236
their O 0 0.0067744753
kidneys O 0 0.10163707
harvested O 0 0.010612743
. O 0 0.013578694

RESULTS O 0 0.028267814
: O 0 0.00922897
As O 0 0.0039979587
anticipated O 0 0.004104209
, O 0 0.0047821277
adriamycin B-Chemical 1 0.9995516
elicited O 0 0.01867853
nephrotic B-Disease 2 0.99997914
range O 0 0.09815861
proteinuria B-Disease 2 0.9999795
, O 0 0.02017899
renal B-Disease 0 0.9987268
interstitial I-Disease 0 0.9619992
damage I-Disease 0 0.9869228
and O 0 0.011128744
mild O 0 0.96104056
focal B-Disease 0 0.9870762
glomerulosclerosis I-Disease 2 0.99996376
. O 0 0.032087732

Baseline O 0 0.023497326
renal O 0 0.97335017
ACE O 0 0.99793625
positively O 0 0.004520919
correlated O 0 0.0019431444
with O 0 0.0015082691
the O 0 0.0010799308
relative O 0 0.00077986304
rise O 0 0.0015076726
in O 0 0.0010468154
proteinuria B-Disease 2 0.9999597
after O 0 0.00074651395
adriamycin B-Chemical 1 0.9999182
( O 0 0.0017481536
r O 0 0.00088605477
= O 0 0.00077942375
0 O 0 0.00056951994
. O 0 0.00030365933
62 O 0 0.0007641773
, O 0 0.0005867425
P O 0 0.013588622
< O 0 0.0004819648
0 O 0 0.0005472782
. O 0 0.00034073618
01 O 0 0.0031502272
) O 0 0.00073059485
, O 0 0.0005963697
renal O 0 0.8896645
interstitial O 0 0.65189785
alpha O 0 0.56616795
- O 0 0.0015751265
smooth O 0 0.008363028
muscle O 0 0.046105504
actin O 0 0.037714247
( O 0 0.0008990116
r O 0 0.0006654962
= O 0 0.00066074997
0 O 0 0.0005131737
. O 0 0.00028201984
49 O 0 0.00064716965
, O 0 0.0005662582
P O 0 0.014222399
< O 0 0.0004870106
0 O 0 0.00057361386
. O 0 0.00036931646
05 O 0 0.04277631
) O 0 0.0007308389
, O 0 0.00056955195
interstitial O 0 0.16809003
macrophage O 0 0.18452725
influx O 0 0.74341124
( O 0 0.0011018477
r O 0 0.0007125437
= O 0 0.0006757437
0 O 0 0.0005071744
. O 0 0.00027413352
56 O 0 0.0005515613
, O 0 0.0005593928
P O 0 0.013983506
< O 0 0.0004892839
0 O 0 0.00057652325
. O 0 0.00037486493
05 O 0 0.039945416
) O 0 0.00073531555
, O 0 0.00058273866
interstitial O 0 0.17029768
collagen O 0 0.640952
III O 0 0.24888918
( O 0 0.0010680238
r O 0 0.00074685196
= O 0 0.00072153355
0 O 0 0.00055190787
. O 0 0.0003017005
53 O 0 0.0007778991
, O 0 0.0005985342
P O 0 0.013835085
< O 0 0.00050109427
0 O 0 0.0005828423
. O 0 0.00038047347
05 O 0 0.03495298
) O 0 0.00073933013
, O 0 0.00060987315
glomerular O 0 0.5987518
alpha O 0 0.3025153
- O 0 0.0011712539
smooth O 0 0.005274985
muscle O 0 0.035712007
actin O 0 0.032258354
( O 0 0.0008896323
r O 0 0.00066608435
= O 0 0.00066353794
0 O 0 0.0005174214
. O 0 0.00028747725
74 O 0 0.000696593
, O 0 0.0005715052
P O 0 0.011693329
< O 0 0.00049461523
0 O 0 0.00056889385
. O 0 0.00036693184
01 O 0 0.0024713015
) O 0 0.00070642075
and O 0 0.00057736353
glomerular O 0 0.6858164
desmin O 0 0.4455073
( O 0 0.0011602152
r O 0 0.0008759241
= O 0 0.00092510844
0 O 0 0.0007836482
. O 0 0.0005222086
48 O 0 0.00073300366
, O 0 0.00128642
P O 0 0.014114362
< O 0 0.0018505686
0 O 0 0.002627712
. O 0 0.002700055
05 O 0 0.0505922
) O 0 0.007639909
. O 0 0.007497483

Baseline O 0 0.025965588
renal O 0 0.9732762
ACE O 0 0.9976421
did O 0 0.004464867
not O 0 0.0028007473
correlate O 0 0.002255481
with O 0 0.0028008763
focal B-Disease 0 0.87669426
glomerulosclerosis I-Disease 2 0.999987
( O 0 0.018938474
r O 0 0.0029773614
= O 0 0.002543873
0 O 0 0.0020394702
. O 0 0.0015389931
22 O 0 0.0030936631
, O 0 0.0047917385
NS O 0 0.7843994
) O 0 0.011209043
. O 0 0.008693375

In O 0 0.010925238
controls O 0 0.010379479
, O 0 0.0071914075
no O 0 0.004125126
predictive O 0 0.005597739
values O 0 0.0042821732
for O 0 0.0040034084
renal O 0 0.9444405
parameters O 0 0.0094425585
were O 0 0.0072942995
observed O 0 0.006819374
. O 0 0.011254617

CONCLUSION O 0 0.69331706
: O 0 0.009027929
Individual O 0 0.0055205217
differences O 0 0.0024348984
in O 0 0.00254975
renal O 0 0.97799075
ACE O 0 0.99921644
activity O 0 0.001997937
predict O 0 0.0008421238
the O 0 0.0010142806
severity O 0 0.05450904
of O 0 0.0038604026
adriamycin B-Chemical 1 0.9999639
- O 0 0.018981418
induced O 0 0.0033607315
renal B-Disease 2 0.9996101
damage I-Disease 2 0.98848057
in O 0 0.0026085773
this O 0 0.0028414084
outbred O 0 0.015030743
rat O 0 0.013370186
strain O 0 0.0062585487
. O 0 0.008826243

This O 0 0.009709444
supports O 0 0.004427829
the O 0 0.0033386995
assumption O 0 0.0027326609
that O 0 0.0016930067
differences O 0 0.0012808363
in O 0 0.0016974387
renal O 0 0.9938454
ACE O 0 0.9997179
activity O 0 0.0028032705
predispose O 0 0.004904447
to O 0 0.0011682421
a O 0 0.00166207
less O 0 0.0014146644
favourable O 0 0.004541416
course O 0 0.0030849634
of O 0 0.006616919
renal B-Disease 2 0.9993273
damage I-Disease 2 0.9952101
. O 0 0.014536952

Recurrent O 0 0.7643181
acute O 0 0.97388905
interstitial B-Disease 2 0.992649
nephritis I-Disease 2 0.99988246
induced O 0 0.11458241
by O 0 0.05119792
azithromycin B-Chemical 1 0.99877053
. O 0 0.02577411

A O 0 0.03722861
14 O 0 0.008804148
- O 0 0.006986753
year O 0 0.0038848675
- O 0 0.0036601075
old O 0 0.0025072012
girl O 0 0.005449877
is O 0 0.0017031796
reported O 0 0.0017793534
with O 0 0.0018385622
recurrent O 0 0.8785356
, O 0 0.008569453
azithromycin B-Chemical 1 0.99958915
- O 0 0.007581563
induced O 0 0.0032736526
, O 0 0.0076713427
acute O 0 0.991184
interstitial B-Disease 2 0.9983935
nephritis I-Disease 2 0.9999726
. O 0 0.036318123

The O 0 0.0069772126
second O 0 0.005208303
episode O 0 0.009439865
was O 0 0.0027950224
more O 0 0.00231432
severe O 0 0.042446725
than O 0 0.00096873153
the O 0 0.0009362815
first O 0 0.00080665114
; O 0 0.0014805186
and O 0 0.0007563284
although O 0 0.00056545786
both O 0 0.00057308987
were O 0 0.00061754306
treated O 0 0.0007649996
with O 0 0.00078778976
intensive O 0 0.0010948235
corticosteroid O 0 0.99950504
therapy O 0 0.1173558
, O 0 0.0048261387
renal O 0 0.98475987
function O 0 0.004815375
remained O 0 0.0055077644
impaired O 0 0.008503171
. O 0 0.008250483

Although O 0 0.0066247494
most O 0 0.005535456
cases O 0 0.0045855264
of O 0 0.0031507818
antibiotic O 0 0.16189022
induced O 0 0.0040735044
acute O 0 0.9915469
interstitial B-Disease 2 0.9980165
nephritis I-Disease 2 0.99999535
are O 0 0.010121401
benign O 0 0.98549795
and O 0 0.002040309
self O 0 0.061167266
- O 0 0.0017538153
limited O 0 0.0006721721
, O 0 0.00094858784
some O 0 0.0008082761
patients O 0 0.0020021477
are O 0 0.001154885
at O 0 0.0010538001
risk O 0 0.02122213
for O 0 0.0022373293
permanent O 0 0.14766347
renal B-Disease 2 0.99921167
injury I-Disease 2 0.99854445
. O 0 0.013944322

Spironolactone B-Chemical 0 0.9996439
- O 0 0.023817949
induced O 0 0.009584634
renal B-Disease 0 0.9928974
insufficiency I-Disease 0 0.99860424
and O 0 0.020531118
hyperkalemia B-Disease 2 0.9999504
in O 0 0.0053240624
patients O 0 0.014084735
with O 0 0.0067872372
heart B-Disease 0 0.9093335
failure I-Disease 0 0.90073335
. O 0 0.013151481

BACKGROUND O 0 0.674891
: O 0 0.010113213
A O 0 0.014110415
previous O 0 0.00272711
randomized O 0 0.0020834052
controlled O 0 0.00132034
trial O 0 0.0012417784
evaluating O 0 0.0006159205
the O 0 0.0006923437
use O 0 0.0008122884
of O 0 0.0014539273
spironolactone B-Chemical 1 0.9999876
in O 0 0.0010381178
heart B-Disease 0 0.8181474
failure I-Disease 0 0.6638477
patients O 0 0.0048787664
reported O 0 0.00080386334
a O 0 0.0008694627
low O 0 0.00091559015
risk O 0 0.0653954
of O 0 0.0028579496
hyperkalemia B-Disease 2 0.99999297
( O 0 0.004076434
2 O 0 0.0010160563
% O 0 0.0011662141
) O 0 0.0015787896
and O 0 0.0014710628
renal B-Disease 0 0.9905591
insufficiency I-Disease 0 0.9980538
( O 0 0.006687159
0 O 0 0.00464078
% O 0 0.0053214347
) O 0 0.008712438
. O 0 0.007638454

Because O 0 0.006937876
treatments O 0 0.007589697
for O 0 0.0034389058
heart B-Disease 0 0.45384288
failure I-Disease 0 0.4659307
have O 0 0.001486439
changed O 0 0.0012785193
since O 0 0.0006720649
the O 0 0.0007172942
benefits O 0 0.0010830098
of O 0 0.0015323274
spironolactone B-Chemical 1 0.9999876
were O 0 0.0011013288
reported O 0 0.0010359788
, O 0 0.0008538316
the O 0 0.0005161717
prevalence O 0 0.00093208393
of O 0 0.00083167123
these O 0 0.0012090195
complications O 0 0.5659634
may O 0 0.001323049
differ O 0 0.0017000968
in O 0 0.0019252369
current O 0 0.004474551
clinical O 0 0.028032806
practice O 0 0.008094761
. O 0 0.007960271

We O 0 0.0074892812
therefore O 0 0.0049733897
sought O 0 0.00377522
to O 0 0.0021258865
determine O 0 0.0011002697
the O 0 0.0013322426
prevalence O 0 0.0019194137
and O 0 0.0012483924
clinical O 0 0.003894723
associations O 0 0.0009759732
of O 0 0.0020969275
hyperkalemia B-Disease 2 0.99998844
and O 0 0.0038769522
renal B-Disease 0 0.9979728
insufficiency I-Disease 0 0.9987011
in O 0 0.0018408614
heart B-Disease 0 0.8566008
failure I-Disease 0 0.7624035
patients O 0 0.017302018
treated O 0 0.0059085954
with O 0 0.014423056
spironolactone B-Chemical 1 0.9999331
. O 0 0.012791157

METHODS O 0 0.011269984
: O 0 0.00759518
We O 0 0.0038101622
performed O 0 0.0025399004
a O 0 0.0025374126
case O 0 0.0017924665
control O 0 0.0014287857
study O 0 0.0014349615
of O 0 0.0015608841
heart B-Disease 0 0.6636157
failure I-Disease 0 0.6624715
patients O 0 0.008230441
treated O 0 0.002425048
with O 0 0.0034858184
spironolactone B-Chemical 1 0.9999634
in O 0 0.0027640734
our O 0 0.003003159
clinical O 0 0.0240762
practice O 0 0.008287808
. O 0 0.008242048

Cases O 0 0.043167822
were O 0 0.006586601
patients O 0 0.006664728
who O 0 0.0057175434
developed O 0 0.0069125593
hyperkalemia B-Disease 2 0.9999759
( O 0 0.054165203
K B-Chemical 1 0.9992767
( O 0 0.00557609
+ O 0 0.001865068
) O 0 0.0018514389
> O 0 0.0011418386
5 O 0 0.0005023645
. O 0 0.0004106673
0 O 0 0.00076652283
mEq O 0 0.7686838
/ O 0 0.002270689
L O 0 0.39979133
) O 0 0.0013447391
or O 0 0.0006859318
renal B-Disease 0 0.9947429
insufficiency I-Disease 0 0.9994998
( O 0 0.021412656
Cr B-Chemical 1 0.99994123
> O 0 0.0013602768
or O 0 0.0005139315
= O 0 0.0007172371
2 O 0 0.00039220948
. O 0 0.00027453658
5 O 0 0.00032912666
mg O 0 0.05575015
/ O 0 0.0016170794
dL O 0 0.011654004
) O 0 0.0010517852
, O 0 0.0006540892
and O 0 0.0005161889
they O 0 0.00047638643
were O 0 0.0005021488
compared O 0 0.00040164485
to O 0 0.0006071999
2 O 0 0.0007790067
randomly O 0 0.00066694507
selected O 0 0.0011679416
controls O 0 0.0027814778
per O 0 0.0024034109
case O 0 0.0054951585
. O 0 0.0075441236

Clinical O 0 0.036877718
characteristics O 0 0.0075850724
, O 0 0.0065108393
medications O 0 0.36591315
, O 0 0.0041149505
and O 0 0.0026038985
serum O 0 0.057176746
chemistries O 0 0.18738766
at O 0 0.0011992336
baseline O 0 0.0013861794
and O 0 0.0013740048
follow O 0 0.0012179032
- O 0 0.0020372327
up O 0 0.0014707897
time O 0 0.0016709944
periods O 0 0.0027820836
were O 0 0.0036977155
compared O 0 0.0041993437
. O 0 0.007971122

RESULTS O 0 0.0263486
: O 0 0.009203063
Sixty O 0 0.00969238
- O 0 0.00465295
seven O 0 0.0022531226
of O 0 0.0023134602
926 O 0 0.24888068
patients O 0 0.003965098
( O 0 0.0017504516
7 O 0 0.00087700685
. O 0 0.0005610797
2 O 0 0.0006032923
% O 0 0.0007089214
) O 0 0.0007564984
required O 0 0.00029090873
discontinuation O 0 0.32389414
of O 0 0.0011158648
spironolactone B-Chemical 1 0.9999858
due O 0 0.0006244816
to O 0 0.0008744568
hyperkalemia B-Disease 2 0.9999883
( O 0 0.0015683008
n O 0 0.00083376793
= O 0 0.00092465064
33 O 0 0.0009731932
) O 0 0.0010322557
or O 0 0.0008259789
renal B-Disease 0 0.97093046
failure I-Disease 0 0.7180221
( O 0 0.0030736101
n O 0 0.0025554905
= O 0 0.003700536
34 O 0 0.004728847
) O 0 0.0072606364
. O 0 0.006918618

Patients O 0 0.014922148
who O 0 0.009003177
developed O 0 0.0077574486
hyperkalemia B-Disease 2 0.99989235
were O 0 0.003419594
older O 0 0.0055944542
and O 0 0.001444775
more O 0 0.001141943
likely O 0 0.0007769557
to O 0 0.0006923592
have O 0 0.00080532936
diabetes B-Disease 2 0.9978613
, O 0 0.0012709553
had O 0 0.00050840434
higher O 0 0.00048755424
baseline O 0 0.00086496334
serum O 0 0.29750896
potassium B-Chemical 1 0.99993646
levels O 0 0.0007261576
and O 0 0.0006933163
lower O 0 0.00061317236
baseline O 0 0.0013164788
potassium B-Chemical 1 0.99990976
supplement O 0 0.053063102
doses O 0 0.08208385
, O 0 0.0010254905
and O 0 0.00055594
were O 0 0.00044652878
more O 0 0.00046528358
likely O 0 0.00038545902
to O 0 0.00038717742
be O 0 0.00049044937
treated O 0 0.00069580873
with O 0 0.0009852579
beta O 0 0.75993335
- O 0 0.0064399363
blockers O 0 0.99623764
than O 0 0.00085587
controls O 0 0.002499577
( O 0 0.002238033
n O 0 0.0023067358
= O 0 0.0037499976
134 O 0 0.009218041
) O 0 0.0074599124
. O 0 0.0069086524

Patients O 0 0.013958289
who O 0 0.00801614
developed O 0 0.006010332
renal B-Disease 0 0.9744889
insufficiency I-Disease 0 0.99386436
had O 0 0.0018629656
lower O 0 0.0012620132
baseline O 0 0.0011171047
body O 0 0.0036052214
weight O 0 0.004646925
and O 0 0.00079349277
higher O 0 0.0005776123
baseline O 0 0.0008783775
serum O 0 0.20401116
creatinine B-Chemical 1 0.9991067
, O 0 0.0008166564
required O 0 0.00023847006
higher O 0 0.00035454266
doses O 0 0.004528249
of O 0 0.0007261733
loop O 0 0.001924408
diuretics O 0 0.99993277
, O 0 0.0014547976
and O 0 0.00070739014
were O 0 0.00057893456
more O 0 0.00062126847
likely O 0 0.00055495044
to O 0 0.0006093671
be O 0 0.00086018146
treated O 0 0.0013841175
with O 0 0.0028205693
thiazide B-Chemical 0 0.9999844
diuretics O 0 0.99990916
than O 0 0.0044059698
controls O 0 0.015610025
. O 0 0.008263297

CONCLUSIONS O 0 0.8386138
: O 0 0.03741981
Spironolactone B-Chemical 0 0.99985266
- O 0 0.017015854
induced O 0 0.0058952197
hyperkalemia B-Disease 2 0.99996257
and O 0 0.006533456
renal B-Disease 0 0.9971493
insufficiency I-Disease 0 0.99845064
are O 0 0.0018052178
more O 0 0.0013333788
common O 0 0.0013813956
in O 0 0.0010445894
our O 0 0.0011313517
clinical O 0 0.0051478385
experience O 0 0.0036520825
than O 0 0.0021933485
reported O 0 0.0046857432
previously O 0 0.006435596
. O 0 0.008738694

This O 0 0.010812373
difference O 0 0.004620148
is O 0 0.004047639
explained O 0 0.003151553
by O 0 0.0029500155
patient O 0 0.0037161189
comorbidities O 0 0.52038217
and O 0 0.002692353
more O 0 0.0025046861
frequent O 0 0.0050790007
use O 0 0.0031254902
of O 0 0.0054982756
beta O 0 0.882647
- O 0 0.0764803
blockers O 0 0.9985661
. O 0 0.012476761

Acute O 0 0.99380577
reserpine B-Chemical 1 0.9999274
and O 0 0.05208084
subchronic O 0 0.99986494
haloperidol B-Chemical 1 0.99999523
treatments O 0 0.13238788
change O 0 0.0051015364
synaptosomal O 0 0.99377537
brain O 0 0.77630806
glutamate B-Chemical 1 0.99990785
uptake O 0 0.079941705
and O 0 0.0025389676
elicit O 0 0.0030378886
orofacial B-Disease 0 0.99968576
dyskinesia I-Disease 2 0.99999356
in O 0 0.009011052
rats O 0 0.043913834
. O 0 0.009910727

Reserpine B-Chemical 1 0.9998241
- O 0 0.032339808
and O 0 0.011057519
haloperidol B-Chemical 1 0.999987
- O 0 0.029591963
induced O 0 0.0049385456
orofacial B-Disease 0 0.99969256
dyskinesia I-Disease 2 0.99999833
are O 0 0.0021120182
putative O 0 0.0011244221
animal O 0 0.0012048326
models O 0 0.0013337765
of O 0 0.005399182
tardive B-Disease 0 0.99999905
dyskinesia I-Disease 2 0.99999917
( O 0 0.06957408
TD B-Disease 0 0.99963534
) O 0 0.0024382202
whose O 0 0.0012483817
pathophysiology O 0 0.15459993
has O 0 0.0007480332
been O 0 0.0008392031
related O 0 0.0006383911
to O 0 0.0009132892
free O 0 0.0021787675
radical O 0 0.7773578
generation O 0 0.005590203
and O 0 0.007503354
oxidative O 0 0.9933695
stress O 0 0.9236113
. O 0 0.014222318

In O 0 0.0074497056
the O 0 0.0050905286
present O 0 0.003084601
study O 0 0.0033137829
, O 0 0.0026213287
the O 0 0.0015813818
authors O 0 0.001561866
induced O 0 0.0030125894
orofacial B-Disease 0 0.99976224
dyskinesia I-Disease 2 0.9999988
by O 0 0.02721699
acute O 0 0.99867356
reserpine B-Chemical 1 0.9999951
and O 0 0.06437363
subchronic O 0 0.9999548
haloperidol B-Chemical 1 0.9999956
administration O 0 0.5814503
to O 0 0.005563096
rats O 0 0.026480526
. O 0 0.009099355

Reserpine B-Chemical 1 0.9996661
injection O 0 0.031351693
( O 0 0.0051956866
one O 0 0.0020479797
dose O 0 0.00422838
of O 0 0.0017169529
1 O 0 0.0013093536
mg O 0 0.19311708
/ O 0 0.0020052877
kg O 0 0.0035540522
s O 0 0.00091545156
. O 0 0.00049164693
c O 0 0.0032124876
. O 0 0.00039833228
) O 0 0.00056351523
every O 0 0.00018972918
other O 0 0.0002636123
day O 0 0.0002627669
for O 0 0.00023750842
3 O 0 0.0002812355
days O 0 0.00022786138
caused O 0 0.00036906163
a O 0 0.0005479839
significant O 0 0.0004744111
increase O 0 0.00037568595
in O 0 0.00058108784
vacuous O 0 0.99142176
chewing O 0 0.9875271
, O 0 0.0020653943
tongue O 0 0.24009204
protrusion O 0 0.08318211
and O 0 0.0007600478
duration O 0 0.00085113244
of O 0 0.001182349
facial O 0 0.41062525
twitching O 0 0.89002204
, O 0 0.002203258
compared O 0 0.0012355719
to O 0 0.0020939521
the O 0 0.0032811672
control O 0 0.005315537
. O 0 0.0076633785

Haloperidol B-Chemical 1 0.9999207
administration O 0 0.44829568
( O 0 0.0054583508
one O 0 0.0019633344
dose O 0 0.0037373798
of O 0 0.0014608206
12 O 0 0.0008474478
mg O 0 0.13029385
/ O 0 0.0016842129
kg O 0 0.002106805
once O 0 0.00048614465
a O 0 0.00055739644
week O 0 0.00036701336
s O 0 0.0005843753
. O 0 0.00039426502
c O 0 0.0035464389
. O 0 0.00039843938
) O 0 0.0006703063
for O 0 0.00026829963
4 O 0 0.00029732197
weeks O 0 0.00021810872
caused O 0 0.00036682098
an O 0 0.0005821937
increase O 0 0.00036940907
in O 0 0.000581684
vacuous O 0 0.9914487
chewing O 0 0.98789793
, O 0 0.00213317
tongue O 0 0.24559928
protrusion O 0 0.08375092
and O 0 0.00077387184
duration O 0 0.00085442653
of O 0 0.0011446882
facial O 0 0.28070855
twitching O 0 0.71198934
observed O 0 0.0011434925
in O 0 0.0016883179
four O 0 0.0020482906
weekly O 0 0.004597812
evaluations O 0 0.0061601023
. O 0 0.0074934117

After O 0 0.0065096216
the O 0 0.0054991306
treatments O 0 0.0064678974
and O 0 0.004166887
behavioral O 0 0.05433264
observation O 0 0.0031933922
, O 0 0.0062401113
glutamate B-Chemical 1 0.99974316
uptake O 0 0.039724305
by O 0 0.0021058854
segments O 0 0.0023346718
of O 0 0.0022888777
the O 0 0.0028126945
brain O 0 0.087727405
was O 0 0.004737212
analyzed O 0 0.006138069
. O 0 0.008994053

A O 0 0.16150442
decreased O 0 0.020427551
glutamate B-Chemical 1 0.9993938
uptake O 0 0.046886086
was O 0 0.0021982181
observed O 0 0.0010993745
in O 0 0.0010804057
the O 0 0.0011373888
subcortical O 0 0.7096005
parts O 0 0.001092572
of O 0 0.000931399
animals O 0 0.0007775183
treated O 0 0.0013356578
with O 0 0.0023949596
reserpine B-Chemical 1 0.99999106
and O 0 0.021264166
haloperidol B-Chemical 1 0.99999464
, O 0 0.0030969915
compared O 0 0.0013599122
to O 0 0.0021900816
the O 0 0.0033522071
control O 0 0.0053561884
. O 0 0.0076763136

Importantly O 0 0.008662807
, O 0 0.007274952
a O 0 0.005144856
decrease O 0 0.0035351235
in O 0 0.0033460855
glutamate B-Chemical 1 0.9996991
uptake O 0 0.04590001
correlates O 0 0.0018083664
negatively O 0 0.0019476644
with O 0 0.0014657784
an O 0 0.0017842334
increase O 0 0.0010536863
in O 0 0.0013422078
the O 0 0.0018747706
incidence O 0 0.026432782
of O 0 0.009845239
orofacial B-Disease 0 0.99942017
diskinesia I-Disease 0 0.998517
. O 0 0.014336275

These O 0 0.008900995
results O 0 0.005514875
indicate O 0 0.0033327022
that O 0 0.0024832427
early O 0 0.0035794862
changes O 0 0.0031175697
in O 0 0.00251044
glutamate B-Chemical 1 0.99984396
transport O 0 0.014263418
may O 0 0.0010145076
be O 0 0.0008756224
related O 0 0.0006146336
to O 0 0.0007351037
the O 0 0.00092017464
development O 0 0.0019912499
of O 0 0.0027664301
vacuous O 0 0.99538165
chewing O 0 0.9883287
movements O 0 0.038018033
in O 0 0.0048487405
rats O 0 0.016730906
. O 0 0.009019552

Ceftriaxone B-Chemical 0 0.9929705
- O 0 0.021257363
associated O 0 0.013268024
biliary B-Disease 0 0.99078304
pseudolithiasis I-Disease 2 0.99850285
in O 0 0.010535347
paediatric O 0 0.01361372
surgical O 0 0.016039936
patients O 0 0.029000536
. O 0 0.015657702

It O 0 0.012876088
is O 0 0.007231233
well O 0 0.0052185813
known O 0 0.0052968827
that O 0 0.0041960413
ceftriaxone B-Chemical 1 0.9980009
leads O 0 0.004792983
to O 0 0.004526455
pseudolithiasis B-Disease 2 0.9893115
in O 0 0.0058286847
some O 0 0.00786267
patients O 0 0.02325414
. O 0 0.011856634

Clinical O 0 0.034454055
and O 0 0.006046436
experimental O 0 0.003957211
studies O 0 0.0027102616
also O 0 0.0017784067
suggest O 0 0.0010464271
that O 0 0.0010175752
situations O 0 0.0020171595
causing O 0 0.014940929
gallbladder B-Disease 0 0.9984847
dysfunction I-Disease 0 0.9992873
, O 0 0.002468907
such O 0 0.0008249383
as O 0 0.0010577816
fasting O 0 0.4644174
, O 0 0.0011280521
may O 0 0.00067043985
have O 0 0.0007021413
a O 0 0.0011790539
role O 0 0.0008592661
for O 0 0.0011384115
the O 0 0.0019521381
development O 0 0.00496168
of O 0 0.008104537
pseudolithiasis B-Disease 2 0.9974152
. O 0 0.01204888

In O 0 0.007303351
this O 0 0.0049883225
study O 0 0.003994651
, O 0 0.0027847427
we O 0 0.0012433163
prospectively O 0 0.0015066902
evaluated O 0 0.0008674337
the O 0 0.00087115646
incidence O 0 0.004445198
and O 0 0.00094393035
clinical O 0 0.003380927
importance O 0 0.0005302772
of O 0 0.00094359583
pseudolithiasis B-Disease 2 0.99391395
in O 0 0.000604497
paediatric O 0 0.00093755
surgical O 0 0.0010114628
patients O 0 0.0020590827
receiving O 0 0.0021677003
ceftriaxone B-Chemical 1 0.99936026
treatment O 0 0.0018322434
, O 0 0.0010271447
who O 0 0.0011645966
often O 0 0.00093129865
had O 0 0.00063070044
to O 0 0.0006965203
fast O 0 0.0016218069
in O 0 0.001014627
the O 0 0.001479775
post O 0 0.0030330934
- O 0 0.00417091
operative O 0 0.0063566514
period O 0 0.0051422543
. O 0 0.007848166

Fifty O 0 0.021457966
children O 0 0.01150523
who O 0 0.0080976095
were O 0 0.0049504447
given O 0 0.0036864637
ceftriaxone B-Chemical 1 0.99366415
were O 0 0.0041287676
evaluated O 0 0.0035106626
by O 0 0.0049198815
serial O 0 0.008642607
abdominal O 0 0.60553664
sonograms O 0 0.35712036
. O 0 0.013324526

Of O 0 0.018008862
those O 0 0.012449894
, O 0 0.010281922
13 O 0 0.007972481
( O 0 0.0074799894
26 O 0 0.0065670665
% O 0 0.0067707384
) O 0 0.008387272
developed O 0 0.009378309
biliary O 0 0.9495481
pathology O 0 0.5558414
. O 0 0.016879607

Comparison O 0 0.0067247115
of O 0 0.0051120166
the O 0 0.003435342
patients O 0 0.0041871383
with O 0 0.0019529958
or O 0 0.0014556464
without O 0 0.0013864383
pseudolithiasis B-Disease 2 0.9845675
revealed O 0 0.00091973646
no O 0 0.00050501566
significant O 0 0.00065347477
difference O 0 0.0003849963
with O 0 0.00052332634
respect O 0 0.00045090858
to O 0 0.0005369385
age O 0 0.0019454318
, O 0 0.0011384223
sex O 0 0.022957124
, O 0 0.00103951
duration O 0 0.00094211765
of O 0 0.0012594212
the O 0 0.00152421
treatment O 0 0.0032899086
and O 0 0.0039486685
starvation O 0 0.07674669
variables O 0 0.01823014
. O 0 0.009160473

After O 0 0.007585464
cessation O 0 0.009763354
of O 0 0.0051565864
the O 0 0.00398656
treatment O 0 0.0054705553
, O 0 0.005473102
pseudolithiasis B-Disease 2 0.9886741
resolved O 0 0.008254429
spontaneously O 0 0.012162091
within O 0 0.0024982009
a O 0 0.004775911
short O 0 0.0047909156
period O 0 0.006599159
. O 0 0.009744925

The O 0 0.014407929
incidence O 0 0.019628469
of O 0 0.013742088
pseudolithiasis B-Disease 2 0.98687893
is O 0 0.010725561
not O 0 0.00872907
affected O 0 0.009422901
by O 0 0.014079258
fasting O 0 0.69101584
. O 0 0.016687872

Coronary B-Disease 0 0.8525248
aneurysm I-Disease 2 0.9639697
after O 0 0.0076611177
implantation O 0 0.010032809
of O 0 0.00814962
a O 0 0.012032958
paclitaxel B-Chemical 1 0.9985442
- O 0 0.021833412
eluting O 0 0.17696925
stent O 0 0.15606654
. O 0 0.015519428

Formation O 0 0.029776484
of O 0 0.007519188
coronary B-Disease 0 0.62630445
aneurysm I-Disease 2 0.9771484
is O 0 0.002806713
a O 0 0.0024098079
rare O 0 0.007006299
complication O 0 0.34067193
of O 0 0.0018020053
stenting O 0 0.2359041
with O 0 0.0010454999
bare O 0 0.020301998
metal O 0 0.2928692
stents O 0 0.11679507
, O 0 0.0010062319
but O 0 0.0004498102
based O 0 0.00040713217
on O 0 0.00027146528
experimental O 0 0.00051496964
studies O 0 0.0006681528
drug O 0 0.6275477
- O 0 0.0020206019
eluting O 0 0.027733235
stents O 0 0.050205205
may O 0 0.0004959173
induce O 0 0.00042537434
toxic O 0 0.6619361
effects O 0 0.0011445464
on O 0 0.00029655083
the O 0 0.00042204757
vessel O 0 0.03424665
wall O 0 0.027778324
with O 0 0.0006100145
incomplete O 0 0.0011702753
stent O 0 0.026394976
apposition O 0 0.00803351
, O 0 0.0014164026
aneurysm B-Disease 2 0.9674213
formation O 0 0.0023017784
and O 0 0.00087414606
with O 0 0.0007528928
the O 0 0.00074254215
potential O 0 0.0012311186
of O 0 0.0017636342
stent O 0 0.16263069
thrombosis B-Disease 2 0.99965703
or O 0 0.0061279396
vessel B-Disease 0 0.9349947
rupture I-Disease 0 0.9988403
. O 0 0.01294504

We O 0 0.008070549
present O 0 0.0045110905
a O 0 0.005013378
43 O 0 0.0054195644
- O 0 0.0037360769
year O 0 0.0019953344
- O 0 0.002060038
old O 0 0.0013823279
man O 0 0.02239379
who O 0 0.0017949364
developed O 0 0.0011765138
a O 0 0.0012015702
coronary B-Disease 0 0.701211
aneurysm I-Disease 2 0.96638894
in O 0 0.00067016453
the O 0 0.0006096976
right O 0 0.0014171507
coronary O 0 0.3022816
artery O 0 0.043005027
6 O 0 0.0005767635
months O 0 0.0005053267
after O 0 0.0005384376
receiving O 0 0.0016618399
a O 0 0.0030546798
paclitaxel B-Chemical 1 0.9989699
- O 0 0.0093110595
eluting O 0 0.12481499
stent O 0 0.116222575
. O 0 0.0091926865

The O 0 0.009438072
patient O 0 0.008908209
was O 0 0.005941024
asymptomatic O 0 0.015216706
and O 0 0.004425085
the O 0 0.0039425762
aneurysm B-Disease 2 0.94742423
was O 0 0.0034783033
detected O 0 0.0025805945
in O 0 0.0033570027
a O 0 0.0052927313
routine O 0 0.0059114783
control O 0 0.007702984
. O 0 0.010441332

Angiography O 0 0.049179256
and O 0 0.00693599
intracoronary O 0 0.7620272
ultrasound O 0 0.027018702
demonstrated O 0 0.001885358
lack O 0 0.0013864816
of O 0 0.0013795233
contact O 0 0.0013432859
between O 0 0.00063621846
stent O 0 0.011949343
and O 0 0.0009342978
vessel O 0 0.03729874
wall O 0 0.026367677
in O 0 0.00067938684
a O 0 0.00095716165
15 O 0 0.0006461072
- O 0 0.0009788162
mm O 0 0.0012894585
long O 0 0.0006223444
segment O 0 0.00088574574
with O 0 0.000729738
maximal O 0 0.0011234757
aneurysm B-Disease 2 0.924277
diameter O 0 0.0044240938
of O 0 0.0019766674
6 O 0 0.0018351959
. O 0 0.002163176
0 O 0 0.0045430306
mm O 0 0.01011095
. O 0 0.0076873414

The O 0 0.01405175
patient O 0 0.013767769
was O 0 0.0098856045
successfully O 0 0.009664117
treated O 0 0.009500155
with O 0 0.009222214
a O 0 0.012646592
graft O 0 0.08120187
stent O 0 0.21854815
. O 0 0.018561004

Causes O 0 0.18150112
of O 0 0.016124753
acute O 0 0.98890215
thrombotic B-Disease 2 0.9999045
microangiopathy I-Disease 2 0.9999713
in O 0 0.012925259
patients O 0 0.037061363
receiving O 0 0.02649437
kidney O 0 0.9715019
transplantation O 0 0.78054804
. O 0 0.01585564

OBJECTIVES O 0 0.06680587
: O 0 0.020879809
Thrombotic B-Disease 0 0.9993717
microangiopathy I-Disease 0 0.99994993
is O 0 0.0065730303
a O 0 0.004389624
well O 0 0.002777391
- O 0 0.003725802
known O 0 0.0025583825
problem O 0 0.0034565
in O 0 0.002270941
patients O 0 0.0062744142
following O 0 0.004627776
renal O 0 0.993475
transplantation O 0 0.73796386
. O 0 0.0119910985

In O 0 0.01129789
postrenal O 0 0.9679896
transplantation O 0 0.5177787
, O 0 0.017866302
thrombotic B-Disease 2 0.9999002
microangiopathy I-Disease 2 0.99998343
is O 0 0.0063982136
often O 0 0.004937179
a O 0 0.0038871286
reflection O 0 0.0045034774
of O 0 0.010178781
hemolytic B-Disease 2 0.9999232
uremic I-Disease 2 0.99993217
syndrome I-Disease 2 0.9989429
. O 0 0.024709057

We O 0 0.007868286
aimed O 0 0.0049650245
to O 0 0.0030896096
determine O 0 0.001617613
the O 0 0.0019479627
causes O 0 0.0036831428
of O 0 0.004892969
thrombotic B-Disease 2 0.99997675
microangiopathy I-Disease 2 0.9999957
in O 0 0.002436231
a O 0 0.0019715175
population O 0 0.0020488882
of O 0 0.001670176
renal O 0 0.98540944
transplantation O 0 0.29054967
recipients O 0 0.007839547
and O 0 0.0026421552
discuss O 0 0.0026149412
the O 0 0.0042465227
literature O 0 0.009532862
. O 0 0.00878686

MATERIALS O 0 0.025490448
AND O 0 0.008600386
METHODS O 0 0.0061888
: O 0 0.0045137443
We O 0 0.0024092016
investigated O 0 0.0016007967
the O 0 0.0015558648
causes O 0 0.0026575108
of O 0 0.0033331378
thrombotic B-Disease 2 0.9999752
microangiopathy I-Disease 2 0.9999962
during O 0 0.0013374984
a O 0 0.0018752819
1 O 0 0.0010027838
- O 0 0.00091433007
year O 0 0.0004625793
period O 0 0.00042373265
, O 0 0.0006269669
from O 0 0.00048578196
June O 0 0.0006692206
2003 O 0 0.00077365583
to O 0 0.00039561556
June O 0 0.0006734478
2004 O 0 0.0009554533
, O 0 0.0005432076
at O 0 0.00034152158
the O 0 0.00051940983
King O 0 0.018822175
Fahad O 0 0.008762788
National O 0 0.0012000313
Guard O 0 0.001979989
Hospital O 0 0.0013532289
in O 0 0.00053126476
Riyadh O 0 0.0030072182
, O 0 0.0009256834
Saudi O 0 0.0045861187
Arabia O 0 0.0119527895
, O 0 0.0006764421
by O 0 0.00047855565
reviewing O 0 0.0007779088
the O 0 0.00042709347
slides O 0 0.0013300837
of O 0 0.00058966805
all O 0 0.0005262204
transplant O 0 0.0682696
biopsies O 0 0.0049025943
( O 0 0.001252443
n O 0 0.0010175932
= O 0 0.0013150057
25 O 0 0.0013413993
) O 0 0.0017497169
performed O 0 0.0013545816
during O 0 0.001711705
this O 0 0.003185615
interval O 0 0.0060149403
. O 0 0.007533898

Pre O 0 0.17312689
- O 0 0.018501373
and O 0 0.0119814025
posttransplant O 0 0.109745994
crossmatching O 0 0.015851788
was O 0 0.008731865
done O 0 0.0076384135
when O 0 0.00795269
possible O 0 0.012250775
. O 0 0.015527378

RESULTS O 0 0.041401576
: O 0 0.01773136
Five O 0 0.015096019
cases O 0 0.013662566
of O 0 0.01679469
thrombotic B-Disease 2 0.99975127
microangiopathy I-Disease 2 0.9999398
were O 0 0.028409503
found O 0 0.015534479
. O 0 0.017890908

Three O 0 0.008768069
of O 0 0.005616664
these O 0 0.0041608824
cases O 0 0.003906339
were O 0 0.002089621
from O 0 0.0014979906
the O 0 0.0012211186
25 O 0 0.001376231
transplantations O 0 0.017501675
performed O 0 0.00082010945
at O 0 0.0006954813
King O 0 0.015259522
Fahad O 0 0.007912537
National O 0 0.0013922944
Guard O 0 0.002226855
Hospital O 0 0.0015420319
, O 0 0.0006307491
while O 0 0.00038928702
the O 0 0.00041389672
other O 0 0.000495836
2 O 0 0.00055523193
transplantations O 0 0.018392205
had O 0 0.0005590138
been O 0 0.00060949894
performed O 0 0.0005651593
abroad O 0 0.002488862
and O 0 0.00086126325
were O 0 0.0008517319
referred O 0 0.0010305606
to O 0 0.0010530344
us O 0 0.0020329289
for O 0 0.0017220418
follow O 0 0.0025783372
- O 0 0.0056748698
up O 0 0.0054206457
. O 0 0.007644785

Three O 0 0.010199677
cases O 0 0.0077572437
were O 0 0.004396298
related O 0 0.0028202056
to O 0 0.0030387135
cyclosporine B-Chemical 1 0.9999486
, O 0 0.0046815295
and O 0 0.0020208806
1 O 0 0.0014443176
case O 0 0.0012378083
was O 0 0.001261625
secondary O 0 0.0026183508
to O 0 0.0018674948
both O 0 0.0035138181
cyclosporine B-Chemical 1 0.99995375
and O 0 0.042138025
tacrolimus B-Chemical 1 0.9998945
. O 0 0.014651865

The O 0 0.007602231
fifth O 0 0.008041708
case O 0 0.0038715142
had O 0 0.0026630205
features O 0 0.0037899017
of O 0 0.0047039967
thrombotic B-Disease 2 0.99996245
microangiopathy I-Disease 2 0.99999404
related O 0 0.0021030298
to O 0 0.0014019294
an O 0 0.002744851
antiphospholipid B-Disease 0 0.9998976
syndrome I-Disease 0 0.9700808
in O 0 0.0015894346
a O 0 0.0021612337
patient O 0 0.00285631
with O 0 0.003720505
systemic B-Disease 0 0.99847144
lupus I-Disease 0 0.9999795
erythematosus I-Disease 0 0.9999783
. O 0 0.050837565

CONCLUSIONS O 0 0.40154687
: O 0 0.008537152
In O 0 0.0037867418
the O 0 0.0029798807
literature O 0 0.0033304794
, O 0 0.002300389
the O 0 0.00139005
most O 0 0.0020014942
- O 0 0.0022660594
frequent O 0 0.0032857268
cause O 0 0.005969421
of O 0 0.004463038
hemolytic B-Disease 2 0.999984
uremic I-Disease 2 0.99998534
syndrome I-Disease 2 0.99841535
in O 0 0.001313189
patients O 0 0.00626782
following O 0 0.0010264115
renal O 0 0.9885134
transplantation O 0 0.3516054
is O 0 0.0015664742
recurrence O 0 0.77661926
of O 0 0.0032778769
the O 0 0.005987023
hemolytic B-Disease 2 0.99993885
uremic I-Disease 2 0.99994063
syndrome I-Disease 2 0.9989097
. O 0 0.020454813

Other O 0 0.016750459
causes O 0 0.009362341
include O 0 0.005222077
drug O 0 0.72681147
- O 0 0.006277664
related O 0 0.0019264686
( O 0 0.005348489
cyclosporine B-Chemical 1 0.9999832
, O 0 0.02654936
tacrolimus B-Chemical 1 0.99998367
) O 0 0.052957654
toxicity B-Disease 2 0.9991443
, O 0 0.004257345
procoagulant O 0 0.94542164
status O 0 0.004938892
, O 0 0.0027025393
and O 0 0.0025039834
antibody O 0 0.019728273
- O 0 0.007207115
mediated O 0 0.0054589487
rejection O 0 0.9924555
. O 0 0.012546905

We O 0 0.007965198
found O 0 0.004439511
that O 0 0.0031768882
the O 0 0.0028421823
most O 0 0.003508801
- O 0 0.0035841116
frequent O 0 0.004406026
cause O 0 0.0068140407
of O 0 0.0061049215
thrombotic B-Disease 2 0.99998343
microangiopathy I-Disease 2 0.9999968
was O 0 0.0065871286
drug O 0 0.7387091
related O 0 0.0015791391
, O 0 0.0027295568
secondary O 0 0.004859974
mainly O 0 0.005227252
to O 0 0.0062373984
cyclosporine B-Chemical 1 0.9999151
. O 0 0.012904416

In O 0 0.007124197
the O 0 0.0049615055
current O 0 0.0047223633
study O 0 0.0031259463
, O 0 0.0022945167
the O 0 0.0013213318
frequency O 0 0.0015002519
of O 0 0.0027557265
thrombotic B-Disease 2 0.9999764
microangiopathy I-Disease 2 0.9999964
was O 0 0.0019656182
similar O 0 0.0005995013
to O 0 0.0006002652
the O 0 0.0006169924
percentage O 0 0.0005753425
reported O 0 0.001074877
in O 0 0.0010241943
the O 0 0.0014213157
literature O 0 0.0031650611
( O 0 0.0036613836
20 O 0 0.0032546888
% O 0 0.0050830045
) O 0 0.0085406145
. O 0 0.0076667955

Comparison O 0 0.0073752375
of O 0 0.006126853
developmental O 0 0.008294378
toxicity B-Disease 2 0.9887494
of O 0 0.0037048408
selective O 0 0.01225127
and O 0 0.0020494792
non O 0 0.009905899
- O 0 0.005392426
selective O 0 0.040515978
cyclooxygenase O 0 0.9999422
- O 0 0.011047263
2 O 0 0.0009437244
inhibitors O 0 0.015739694
in O 0 0.001044183
CRL O 0 0.9375491
: O 0 0.0030514502
( O 0 0.0027575265
WI O 0 0.4055431
) O 0 0.002672604
WUBR O 0 0.26406437
Wistar O 0 0.09472299
rats O 0 0.0064404756
- O 0 0.006012737
- O 0 0.009510171
DFU B-Chemical 1 0.99991095
and O 0 0.014569744
piroxicam B-Chemical 1 0.99990356
study O 0 0.01834697
. O 0 0.01079995

BACKGROUND O 0 0.8954871
: O 0 0.039520886
Cyclooxygenase O 0 0.9996271
( O 0 0.04998202
COX O 0 0.99968517
) O 0 0.01231417
inhibitors O 0 0.03349838
are O 0 0.0020631216
one O 0 0.0013282214
of O 0 0.0015520148
the O 0 0.0015252539
most O 0 0.0023317158
often O 0 0.0034552962
ingested O 0 0.14247195
drugs O 0 0.8554283
during O 0 0.005043513
pregnancy O 0 0.713308
. O 0 0.010837734

Unlike O 0 0.009713984
general O 0 0.008143321
toxicity B-Disease 2 0.9798093
data O 0 0.0069103017
, O 0 0.004556425
their O 0 0.0032157472
prenatal O 0 0.04487042
toxic O 0 0.85175806
effects O 0 0.007537892
were O 0 0.0032033252
not O 0 0.0028406924
extensively O 0 0.004611518
studied O 0 0.0053943647
before O 0 0.0050669773
. O 0 0.009176297

The O 0 0.0066597923
aim O 0 0.005211377
of O 0 0.0036104377
the O 0 0.0023858196
experiment O 0 0.0015151688
was O 0 0.0012611697
to O 0 0.0008420215
evaluate O 0 0.00051763945
the O 0 0.0007997814
developmental O 0 0.0027229863
toxicity B-Disease 2 0.9938361
of O 0 0.001077789
the O 0 0.00074311055
non O 0 0.0067535373
- O 0 0.003324931
selective O 0 0.013409171
( O 0 0.0037979537
piroxicam B-Chemical 1 0.9999875
) O 0 0.005935383
and O 0 0.0008799851
selective O 0 0.014845437
( O 0 0.004578452
DFU B-Chemical 1 0.9999862
; O 0 0.002507719
5 B-Chemical 0 0.0004918086
, I-Chemical 0 0.00062662817
5 I-Chemical 0 0.00047620843
- I-Chemical 0 0.0011635621
dimethyl I-Chemical 0 0.9967217
- I-Chemical 0 0.0025643955
3 I-Chemical 0 0.0006326178
- I-Chemical 0 0.0009970113
( I-Chemical 0 0.000729038
3 I-Chemical 0 0.00053981063
- I-Chemical 0 0.0011849432
fluorophenyl I-Chemical 0 0.9342079
) I-Chemical 0 0.0023459853
- I-Chemical 0 0.0010979117
4 I-Chemical 0 0.00051755115
- I-Chemical 0 0.00087120826
( I-Chemical 0 0.0007202955
4 I-Chemical 0 0.00055118924
- I-Chemical 0 0.0012406607
methylsulphonyl I-Chemical 0 0.90010685
) I-Chemical 0 0.0054955436
phenyl I-Chemical 0 0.9969682
- I-Chemical 0 0.0030971444
2 I-Chemical 0 0.0010129106
( I-Chemical 0 0.0017213735
5H I-Chemical 0 0.04705116
) I-Chemical 0 0.0026661898
- I-Chemical 0 0.002559256
furanon I-Chemical 0 0.035917483
) O 0 0.013612605
COX O 0 0.999739
- O 0 0.008933065
2 O 0 0.004963752
inhibitors O 0 0.071662195
. O 0 0.009290966

METHODS O 0 0.012349155
: O 0 0.010025759
Drugs O 0 0.60638934
were O 0 0.0034761287
separately O 0 0.0020518037
, O 0 0.0020141236
orally O 0 0.0030688245
once O 0 0.0009767797
daily O 0 0.0013957188
dosed O 0 0.002377886
to O 0 0.0006749469
pregnant O 0 0.008609718
rats O 0 0.0013488303
from O 0 0.0006591213
day O 0 0.00063228933
8 O 0 0.0007117426
to O 0 0.00076100806
21 O 0 0.0014596636
( O 0 0.002004453
GD1 O 0 0.045931093
= O 0 0.0032429902
plug O 0 0.00607358
day O 0 0.0039027242
) O 0 0.009037776
. O 0 0.007971417

Doses O 0 0.22282186
were O 0 0.0059410636
set O 0 0.0033910465
at O 0 0.0022720355
0 O 0 0.0023977847
. O 0 0.0012529476
3 O 0 0.0010829257
, O 0 0.0011108716
3 O 0 0.00071227254
. O 0 0.0005027846
0 O 0 0.00062595523
and O 0 0.0005339422
30 O 0 0.00043896955
. O 0 0.0004260182
0mg O 0 0.88737154
/ O 0 0.0017418092
kg O 0 0.0031646295
for O 0 0.0005361407
piroxicam B-Chemical 1 0.99996245
and O 0 0.0011691009
0 O 0 0.0010539021
. O 0 0.00041355312
2 O 0 0.00053122756
, O 0 0.00064946007
2 O 0 0.00053855183
. O 0 0.00045111167
0 O 0 0.0007369428
and O 0 0.0007987973
20 O 0 0.0010700285
. O 0 0.0011531273
0mg O 0 0.91399014
/ O 0 0.007240705
kg O 0 0.01739175
for O 0 0.005527477
DFU B-Chemical 1 0.9998011
. O 0 0.012465023

Fetuses O 0 0.041567322
were O 0 0.013156996
delivered O 0 0.009591176
on O 0 0.008719504
GD O 0 0.86056316
21 O 0 0.010688895
and O 0 0.009499998
routinely O 0 0.010071262
examined O 0 0.0111722555
. O 0 0.016396372

Comprehensive O 0 0.03566715
clinical O 0 0.027309904
and O 0 0.01770256
developmental O 0 0.019254599
measurements O 0 0.013753252
were O 0 0.015897444
done O 0 0.016307076
. O 0 0.020160912

The O 0 0.0067835995
pooled O 0 0.0049026483
statistical O 0 0.0060077463
analysis O 0 0.0033596074
for O 0 0.0021041208
ventricular B-Disease 0 0.9473287
septal I-Disease 0 0.11713295
( I-Disease 0 0.0030641889
VSD I-Disease 0 0.58841467
) I-Disease 0 0.0017721157
and I-Disease 0 0.0009821913
midline I-Disease 0 0.006929966
( I-Disease 0 0.0018453442
MD I-Disease 0 0.9840329
) I-Disease 0 0.0015877933
defects I-Disease 0 0.00075648114
was O 0 0.00041448124
performed O 0 0.00033780574
for O 0 0.00031388446
rat O 0 0.0014219296
fetuses O 0 0.0028916467
exposed O 0 0.0004884593
to O 0 0.00069556775
piroxicam B-Chemical 1 0.9999852
, O 0 0.001970435
selective O 0 0.0036327853
and O 0 0.0008297774
non O 0 0.0043856045
- O 0 0.0031895211
selective O 0 0.026120257
COX O 0 0.99992967
- O 0 0.003924087
2 O 0 0.001057139
inhibitor O 0 0.0054597096
based O 0 0.001277116
on O 0 0.001079684
present O 0 0.0015782485
and O 0 0.0037120534
historic O 0 0.047464553
data O 0 0.008168858
. O 0 0.008468939

RESULTS O 0 0.032516655
: O 0 0.011314847
Maternal O 0 0.08495515
toxicity B-Disease 2 0.9950145
, O 0 0.007238005
intrauterine B-Disease 0 0.96244067
growth I-Disease 0 0.53474075
retardation I-Disease 0 0.99841046
, O 0 0.0023934813
and O 0 0.0009928737
increase B-Disease 0 0.0005401195
of I-Disease 0 0.00074348605
external I-Disease 0 0.0013049651
and I-Disease 0 0.00085340376
skeletal I-Disease 0 0.02545321
variations I-Disease 0 0.00057988946
were O 0 0.0005726017
found O 0 0.0004669208
in O 0 0.0006256069
rats O 0 0.0016623248
treated O 0 0.0011374056
with O 0 0.0011843283
the O 0 0.001343158
highest O 0 0.0019532954
dose O 0 0.033166353
of O 0 0.012469984
piroxicam B-Chemical 1 0.99991465
. O 0 0.01435649

Decrease O 0 0.022469483
of O 0 0.0066219945
fetal O 0 0.081012435
length O 0 0.0028182408
was O 0 0.001984586
the O 0 0.0014547164
only O 0 0.0012540281
signs O 0 0.0630065
of O 0 0.0017012755
the O 0 0.0019850007
DFU B-Chemical 1 0.99997914
developmental O 0 0.03149656
toxicity B-Disease 2 0.99765235
observed O 0 0.0008127336
in O 0 0.0009667271
pups O 0 0.0016157574
exposed O 0 0.0010972469
to O 0 0.0012965753
the O 0 0.0018089294
highest O 0 0.00296697
compound O 0 0.28816456
dose O 0 0.13216877
. O 0 0.009418006

Lack O 0 0.017988585
of O 0 0.012911901
teratogenicity O 0 0.9979241
was O 0 0.0070290673
found O 0 0.00445303
in O 0 0.0058468743
piroxicam B-Chemical 1 0.9999229
and O 0 0.06720422
DFU B-Chemical 1 0.99994385
- O 0 0.028648358
exposed O 0 0.007953533
groups O 0 0.012401304
. O 0 0.011845997

Prenatal O 0 0.32215685
exposure O 0 0.008975885
to O 0 0.0039969264
non O 0 0.008981727
- O 0 0.0067752134
selective O 0 0.039880306
COX O 0 0.9998634
inhibitors O 0 0.20498225
increases O 0 0.0012750353
the O 0 0.00093140523
risk O 0 0.03768766
of O 0 0.0014002982
VSD O 0 0.7736619
and O 0 0.0011353565
MD O 0 0.960626
when O 0 0.0004279534
compared O 0 0.000362738
to O 0 0.00052490673
historic O 0 0.0059333746
control O 0 0.00074382615
but O 0 0.0008193322
not O 0 0.0009377827
with O 0 0.0016751542
selective O 0 0.0659704
COX O 0 0.999866
- O 0 0.01336335
2 O 0 0.0050584623
inhibitors O 0 0.09577194
. O 0 0.009173475

CONCLUSION O 0 0.7239934
: O 0 0.009370136
Both O 0 0.0050190873
selective O 0 0.0062664775
and O 0 0.0031775904
non O 0 0.0065591885
- O 0 0.0053186845
selective O 0 0.042962216
COX O 0 0.9999237
- O 0 0.00827895
2 O 0 0.0010746599
inhibitors O 0 0.012081469
were O 0 0.0009752929
toxic O 0 0.5178643
for O 0 0.00072349375
rats O 0 0.0020398363
fetuses O 0 0.00348504
when O 0 0.00078517455
administered O 0 0.0016816364
in O 0 0.0015061981
the O 0 0.0021900462
highest O 0 0.003618182
dose O 0 0.049256433
. O 0 0.008698522

Unlike O 0 0.019593932
DFU B-Chemical 1 0.9994708
, O 0 0.028673062
piroxicam B-Chemical 1 0.9997862
was O 0 0.008193399
also O 0 0.0059776744
highly O 0 0.0074069607
toxic O 0 0.79885983
to O 0 0.0074464767
the O 0 0.009261142
dams O 0 0.11759326
. O 0 0.0137510365

Prenatal O 0 0.3715312
exposure O 0 0.010049217
to O 0 0.0045400397
selective O 0 0.06555756
COX O 0 0.99987495
- O 0 0.016215654
2 O 0 0.00152932
inhibitors O 0 0.0114036
does O 0 0.000683402
not O 0 0.00057493855
increase O 0 0.000444428
the O 0 0.0005408355
risk O 0 0.014811381
of O 0 0.00097194605
ventricular B-Disease 0 0.98968595
septal I-Disease 0 0.06405858
and I-Disease 0 0.00088707136
midline I-Disease 0 0.02984653
defects I-Disease 0 0.0017596344
in O 0 0.0005144603
rat O 0 0.0015911161
when O 0 0.0004007696
compared O 0 0.0004134461
to O 0 0.00069056475
non O 0 0.002851703
- O 0 0.0029042605
selective O 0 0.0063381884
drugs O 0 0.68945646
and O 0 0.0041824784
historic O 0 0.06170417
control O 0 0.0060262633
. O 0 0.0078079584

Lone O 0 0.41455936
atrial B-Disease 0 0.9854456
fibrillation I-Disease 0 0.9995072
associated O 0 0.028756417
with O 0 0.03399448
creatine B-Chemical 1 0.99978906
monohydrate O 0 0.9996908
supplementation O 0 0.99366367
. O 0 0.02904802

Atrial B-Disease 0 0.9866593
fibrillation I-Disease 0 0.9996718
in O 0 0.008775245
young O 0 0.013231611
patients O 0 0.007909379
without O 0 0.004650799
structural O 0 0.009818056
heart B-Disease 0 0.85257655
disease I-Disease 0 0.91838753
is O 0 0.011094844
rare O 0 0.11241953
. O 0 0.014790967

Therefore O 0 0.0076530874
, O 0 0.0063183154
when O 0 0.0031788899
the O 0 0.0032892332
arrhythmia B-Disease 2 0.9991805
is O 0 0.0020862634
present O 0 0.0011171475
in O 0 0.0011887272
this O 0 0.0012357233
population O 0 0.0028431895
, O 0 0.0023076267
reversible O 0 0.15264337
causes O 0 0.0037317292
must O 0 0.0015483203
be O 0 0.0023256307
identified O 0 0.0026147894
and O 0 0.005171608
resolved O 0 0.0124882115
. O 0 0.009255189

Thyroid B-Disease 0 0.9934541
disorders I-Disease 0 0.9917966
, O 0 0.0107117975
illicit O 0 0.9964116
drug O 0 0.7839964
or O 0 0.0030411351
stimulant O 0 0.99227494
use O 0 0.003002321
, O 0 0.0027102097
and O 0 0.0025643164
acute B-Disease 0 0.99721414
alcohol I-Disease 1 0.9999267
intoxication I-Disease 0 0.9999211
are O 0 0.0054354277
among O 0 0.005103957
these O 0 0.0064272895
causes O 0 0.01850998
. O 0 0.010226917

We O 0 0.007963592
report O 0 0.00694396
the O 0 0.0035345794
case O 0 0.0026078396
of O 0 0.002264597
a O 0 0.0023511315
30 O 0 0.0013499839
- O 0 0.0017596848
year O 0 0.0010503574
- O 0 0.0013457155
old O 0 0.001089375
Caucasian O 0 0.1857875
man O 0 0.048559066
who O 0 0.0016766796
came O 0 0.0012138434
to O 0 0.0006474454
the O 0 0.0007769099
emergency O 0 0.005820567
department O 0 0.005133651
in O 0 0.0015713187
atrial B-Disease 0 0.9938829
fibrillation I-Disease 0 0.9999385
with O 0 0.0037648287
rapid O 0 0.015419419
ventricular O 0 0.99029154
response O 0 0.012158
. O 0 0.009482125

His O 0 0.021051396
medical O 0 0.018156243
history O 0 0.021711309
was O 0 0.005200215
unremarkable O 0 0.1170438
, O 0 0.0036446082
except O 0 0.0019463596
for O 0 0.0019814407
minor O 0 0.005781044
fractures B-Disease 2 0.9599239
of O 0 0.0042655943
the O 0 0.0042527816
fingers O 0 0.07926313
and O 0 0.009076464
foot O 0 0.32470018
. O 0 0.01170995

Thyroid O 0 0.9780953
- O 0 0.020143004
stimulating O 0 0.020693624
hormone O 0 0.992471
, O 0 0.019984508
magnesium B-Chemical 1 0.9998313
, O 0 0.0061126333
and O 0 0.0028869936
potassium B-Chemical 1 0.99984837
levels O 0 0.0010525254
were O 0 0.00071974593
within O 0 0.00039158552
normal O 0 0.001042376
limits O 0 0.0013103506
, O 0 0.0010643278
urine O 0 0.12930498
drug O 0 0.26180997
screen O 0 0.0010469083
was O 0 0.0009175508
negative O 0 0.0014630562
, O 0 0.002059669
and O 0 0.0024992775
alcohol B-Chemical 1 0.99883395
use O 0 0.004904554
was O 0 0.0052610068
denied O 0 0.029890059
. O 0 0.009086372

However O 0 0.008849308
, O 0 0.006050337
when O 0 0.00282444
the O 0 0.0024048781
patient O 0 0.0026008114
was O 0 0.0015405436
questioned O 0 0.0015174329
about O 0 0.00093671115
use O 0 0.0010624677
of O 0 0.0014074831
herbal O 0 0.976719
products O 0 0.049195327
and O 0 0.0027763192
supplements O 0 0.9171246
, O 0 0.0022706958
the O 0 0.0012948377
use O 0 0.0019302306
of O 0 0.005462976
creatine B-Chemical 1 0.99994946
monohydrate O 0 0.99979573
was O 0 0.0073007005
revealed O 0 0.007926969
. O 0 0.009367242

The O 0 0.007082767
patient O 0 0.00632246
was O 0 0.0036130748
admitted O 0 0.004315651
to O 0 0.0018221517
the O 0 0.0015685419
hospital O 0 0.0041784486
, O 0 0.001628859
anticoagulated O 0 0.021337053
with O 0 0.0008611902
unfractionated O 0 0.2107832
heparin B-Chemical 1 0.9989513
, O 0 0.0015130998
and O 0 0.00064667646
given O 0 0.0004023157
intravenous O 0 0.60573137
diltiazem B-Chemical 1 0.9999939
for O 0 0.0005426733
rate O 0 0.0005984907
control O 0 0.00064129743
and O 0 0.00097034714
intravenous O 0 0.69248444
amiodarone B-Chemical 1 0.99996674
for O 0 0.0014249132
rate O 0 0.0020536496
and O 0 0.0035122505
rhythm O 0 0.07434642
control O 0 0.0053841365
. O 0 0.0076215058

When O 0 0.0068273717
discharged O 0 0.010120318
less O 0 0.0032426761
than O 0 0.0017742062
24 O 0 0.0012737013
hours O 0 0.00088210235
later O 0 0.00085127517
, O 0 0.0010841266
he O 0 0.0009806224
was O 0 0.0007164184
receiving O 0 0.0022290153
metoprolol B-Chemical 1 0.9999956
and O 0 0.002530643
aspirin B-Chemical 1 0.9999665
, O 0 0.0016605256
with O 0 0.0007414423
follow O 0 0.0005882249
- O 0 0.0010018225
up O 0 0.00055156555
plans O 0 0.001173934
for O 0 0.0006280209
echocardiography O 0 0.032991756
and O 0 0.00137719
nuclear O 0 0.0042746617
imaging O 0 0.0051873256
to O 0 0.0021951306
assess O 0 0.0024529612
perfusion O 0 0.4348668
. O 0 0.00873437

Exogenous O 0 0.8815215
creatine B-Chemical 1 0.999079
is O 0 0.009466637
used O 0 0.0058610914
by O 0 0.0058946554
athletes O 0 0.033589937
to O 0 0.0042497613
theoretically O 0 0.005792698
improve O 0 0.0045210538
exercise O 0 0.043381173
performance O 0 0.011882495
. O 0 0.010998778

Vegetarians O 0 0.5003151
may O 0 0.007546251
also O 0 0.0051632565
take O 0 0.0037315732
creatine B-Chemical 1 0.9991786
to O 0 0.0023736185
replace O 0 0.0017794252
what O 0 0.0017195973
they O 0 0.0011454179
are O 0 0.0011028165
not O 0 0.0010124606
consuming O 0 0.0026179648
from O 0 0.001474833
meat O 0 0.12552291
, O 0 0.0030974196
fish O 0 0.026192693
, O 0 0.0029200949
and O 0 0.0026684196
other O 0 0.003394087
animal O 0 0.0069852057
products O 0 0.0311089
. O 0 0.010071315

Previous O 0 0.014874217
anecdotal O 0 0.022367079
reports O 0 0.009865979
have O 0 0.006752683
linked O 0 0.0077003166
creatine B-Chemical 1 0.99936265
to O 0 0.0057903975
the O 0 0.0056162826
development O 0 0.010355921
of O 0 0.01577343
arrhythmia B-Disease 2 0.9995702
. O 0 0.017183753

Clinicians O 0 0.011518753
must O 0 0.004439551
be O 0 0.0035612597
diligent O 0 0.0035229411
when O 0 0.0016235219
interviewing O 0 0.0038526617
patients O 0 0.0020712486
about O 0 0.0008793045
their O 0 0.0010041518
drug O 0 0.2877403
therapy O 0 0.0077082785
histories O 0 0.0040203044
and O 0 0.0008898532
include O 0 0.0007963413
questions O 0 0.001212787
about O 0 0.0006476145
their O 0 0.000906977
use O 0 0.0011440134
of O 0 0.0019452334
herbal O 0 0.97862375
products O 0 0.072374366
and O 0 0.008124513
dietary O 0 0.91094357
supplements O 0 0.9802434
. O 0 0.013131586

In O 0 0.0074271075
addition O 0 0.0043869186
, O 0 0.0047277138
it O 0 0.0029033052
is O 0 0.0018138221
important O 0 0.001194441
to O 0 0.0010677049
report O 0 0.0027207357
adverse O 0 0.89949733
effects O 0 0.003362719
associated O 0 0.0013122208
with O 0 0.0010113057
frequently O 0 0.0018326935
consumed O 0 0.018617157
supplements O 0 0.8686215
and O 0 0.0015808542
herbal O 0 0.97327846
products O 0 0.0158324
to O 0 0.000995129
the O 0 0.001312165
Food O 0 0.8074535
and O 0 0.0024733336
Drug O 0 0.9897175
Administration O 0 0.42031997
and O 0 0.0028556108
in O 0 0.0028612157
the O 0 0.004201911
literature O 0 0.009430613
. O 0 0.008809235

Seizures B-Disease 2 0.99863476
induced O 0 0.015821079
by O 0 0.011738172
the O 0 0.010968951
cocaine B-Chemical 1 0.9997507
metabolite O 0 0.99364704
benzoylecgonine B-Chemical 1 0.99993384
in O 0 0.016105965
rats O 0 0.049073994
. O 0 0.015268934

The O 0 0.008064505
half O 0 0.0056839664
- O 0 0.0063297735
life O 0 0.0061554913
( O 0 0.003659516
t1 O 0 0.0037702285
/ O 0 0.002766906
2 O 0 0.0011886333
) O 0 0.0013432064
of O 0 0.0010657269
cocaine B-Chemical 1 0.9998673
is O 0 0.0007778658
relatively O 0 0.0007129768
short O 0 0.0005308821
, O 0 0.00072854315
but O 0 0.00039800018
some O 0 0.0003843124
of O 0 0.00046283583
the O 0 0.00043047906
consequences O 0 0.0011650736
of O 0 0.0006510696
its O 0 0.0011677835
use O 0 0.0007458782
, O 0 0.00081954116
such O 0 0.0006049192
as O 0 0.001302957
seizures B-Disease 2 0.9999778
and O 0 0.0032053264
strokes B-Disease 2 0.99926966
, O 0 0.0023322173
can O 0 0.0011702881
occur O 0 0.0016758409
hours O 0 0.0017641042
after O 0 0.0022474334
exposure O 0 0.008983543
. O 0 0.00813229

This O 0 0.011013025
led O 0 0.006246034
us O 0 0.00487972
to O 0 0.0026418515
hypothesize O 0 0.0021089832
that O 0 0.0015925824
a O 0 0.0024690656
metabolite O 0 0.68522173
of O 0 0.0034225283
cocaine B-Chemical 1 0.9999347
may O 0 0.0015042602
be O 0 0.001258622
responsible O 0 0.0010930832
for O 0 0.0010472923
some O 0 0.001701733
of O 0 0.0026517955
those O 0 0.00520101
delayed O 0 0.04984247
sequelae O 0 0.9312189
. O 0 0.011352419

We O 0 0.0074642035
evaluated O 0 0.0043691243
the O 0 0.0033150243
potential O 0 0.00288103
of O 0 0.0023335712
the O 0 0.0017592191
major O 0 0.0022703186
metabolite O 0 0.7484703
of O 0 0.004643655
cocaine B-Chemical 1 0.9999683
, O 0 0.03296214
benzoylecgonine B-Chemical 1 0.9999887
( O 0 0.030961413
BE B-Chemical 0 0.9969505
) O 0 0.006932602
, O 0 0.0035658432
to O 0 0.00330764
cause O 0 0.07271309
seizures B-Disease 2 0.9998728
. O 0 0.012460762

Two O 0 0.008621619
separate O 0 0.0052801715
equimolar O 0 0.042319294
doses O 0 0.04773802
( O 0 0.0039493022
0 O 0 0.0022001183
. O 0 0.00096115115
2 O 0 0.00085764076
and O 0 0.0008215647
0 O 0 0.00092924724
. O 0 0.00048947486
4 O 0 0.0005456723
mumol O 0 0.02073426
) O 0 0.0010002041
of O 0 0.0006805598
either O 0 0.00095537683
cocaine B-Chemical 1 0.999895
or O 0 0.0014395467
BE B-Chemical 0 0.9885206
were O 0 0.0011679394
injected O 0 0.0011525557
ventricularly O 0 0.0655968
in O 0 0.002082394
unanesthetized O 0 0.081865385
juvenile O 0 0.15239319
rats O 0 0.022064393
. O 0 0.009343907

Treated O 0 0.24232659
rats O 0 0.010219399
were O 0 0.004172152
then O 0 0.0026141747
evaluated O 0 0.0018944578
for O 0 0.0015093565
incidence O 0 0.010305979
, O 0 0.002279942
latency O 0 0.0055193
, O 0 0.0016839859
and O 0 0.0014097522
seizure B-Disease 2 0.99948055
pattern O 0 0.0010131457
or O 0 0.0010602797
for O 0 0.0010378759
locomotor O 0 0.51361454
activity O 0 0.0019055676
in O 0 0.0018528019
animals O 0 0.0028456007
without O 0 0.0066671874
seizures B-Disease 2 0.9998714
. O 0 0.0118255

BE B-Chemical 0 0.98716533
- O 0 0.026053509
Induced O 0 0.4985539
seizures B-Disease 2 0.9998085
occurred O 0 0.0040341
more O 0 0.002375966
frequently O 0 0.0021008363
and O 0 0.0014330563
had O 0 0.0009911743
significantly O 0 0.0011770889
longer O 0 0.00066884706
latencies O 0 0.0056142034
than O 0 0.00078092096
those O 0 0.001456262
induced O 0 0.0016116796
by O 0 0.0023631116
equimolar O 0 0.10339012
amounts O 0 0.0032499754
of O 0 0.010388255
cocaine B-Chemical 1 0.999801
. O 0 0.01172813

Whereas O 0 0.012164978
cocaine B-Chemical 1 0.9997024
- O 0 0.018043527
induced O 0 0.0057951803
seizures B-Disease 2 0.9999292
were O 0 0.0019634445
best O 0 0.0012273974
characterized O 0 0.001466318
as O 0 0.00093526277
brief O 0 0.0012094503
, O 0 0.0012638043
generalized O 0 0.118680485
, O 0 0.0012279289
and O 0 0.00078481506
tonic O 0 0.6531849
and O 0 0.0007868471
resulted O 0 0.000539709
in O 0 0.000731435
death B-Disease 2 0.99834037
, O 0 0.0010951598
those O 0 0.00076225214
induced O 0 0.0006714038
by O 0 0.00095798366
BE B-Chemical 0 0.9895259
were O 0 0.00064947223
prolonged O 0 0.0035423823
, O 0 0.00081805367
often O 0 0.0007681374
multiple O 0 0.0010677406
and O 0 0.0007715307
mixed O 0 0.0018649545
in O 0 0.0009163023
type O 0 0.0013639604
, O 0 0.0019792155
and O 0 0.0019168284
rarely O 0 0.0031473434
resulted O 0 0.002876427
in O 0 0.0056595597
death B-Disease 2 0.99718106
. O 0 0.010822277

Electrical O 0 0.4986708
recordings O 0 0.013583217
from O 0 0.004705752
the O 0 0.0035576066
hippocampus O 0 0.055783786
showed O 0 0.0017955678
a O 0 0.0022549455
rhythmic O 0 0.041346997
progression O 0 0.1570059
in O 0 0.0017302763
EEG O 0 0.9093204
frequency O 0 0.0019718278
and O 0 0.0022816067
voltage O 0 0.09363101
with O 0 0.0031060171
clinical O 0 0.12085507
seizure B-Disease 2 0.99957746
expression O 0 0.01395575
. O 0 0.010120911

BE B-Chemical 0 0.9804166
- O 0 0.015442334
Injected O 0 0.02017894
rats O 0 0.0056336755
that O 0 0.0021514958
did O 0 0.0017867932
not O 0 0.0015109458
have O 0 0.0015280726
seizures B-Disease 2 0.99993646
had O 0 0.0013561316
significantly O 0 0.0015303893
more O 0 0.0014527569
locomotor O 0 0.5893662
activity O 0 0.001398296
than O 0 0.001113653
cocaine B-Chemical 1 0.9998915
- O 0 0.0038454542
injected O 0 0.0018116531
animals O 0 0.0027099033
without O 0 0.0062590735
seizures B-Disease 2 0.9998629
. O 0 0.0114246

The O 0 0.0075279754
finding O 0 0.006471759
that O 0 0.0044206083
cocaine B-Chemical 1 0.9998317
- O 0 0.012652381
and O 0 0.0036091716
BE B-Chemical 0 0.9974687
- O 0 0.0074705365
induced O 0 0.0025050426
seizures B-Disease 2 0.99997616
differ O 0 0.0012985131
in O 0 0.00063275895
several O 0 0.0006089049
respects O 0 0.0011161768
suggests O 0 0.00029918307
more O 0 0.00047273948
than O 0 0.00029395884
one O 0 0.00033425054
mechanism O 0 0.00053858024
for O 0 0.0005672354
cocaine B-Chemical 1 0.99997103
- O 0 0.0066662026
induced O 0 0.0017211401
seizures B-Disease 2 0.9999795
and O 0 0.0011118175
emphasizes O 0 0.00096471125
the O 0 0.0007842638
importance O 0 0.000832468
of O 0 0.0016718593
a O 0 0.005491235
cocaine B-Chemical 1 0.99992204
metabolite O 0 0.9735381
, O 0 0.022100827
BE B-Chemical 0 0.9933134
. O 0 0.010103731

The O 0 0.008195967
selective O 0 0.011496238
5 O 0 0.005078401
- O 0 0.006989381
HT6 O 0 0.78065014
receptor O 0 0.36107677
antagonist O 0 0.9908183
Ro4368554 B-Chemical 1 0.9774515
restores O 0 0.0018675216
memory O 0 0.14925086
performance O 0 0.0017575561
in O 0 0.0009598483
cholinergic O 0 0.94495803
and O 0 0.0016835484
serotonergic O 0 0.9760099
models O 0 0.0019943975
of O 0 0.003014184
memory B-Disease 0 0.8973835
deficiency I-Disease 0 0.9396295
in O 0 0.003893746
the O 0 0.00518334
rat O 0 0.038724255
. O 0 0.008953081

Antagonists O 0 0.7852696
at O 0 0.0067411405
serotonin B-Chemical 1 0.99722075
type O 0 0.0042117382
6 O 0 0.0022824316
( O 0 0.0026215557
5 B-Chemical 0 0.0016056417
- I-Chemical 0 0.002945259
HT I-Chemical 0 0.98622245
( O 0 0.001961639
6 O 0 0.00089431345
) O 0 0.0016606932
) O 0 0.0015905775
receptors O 0 0.009251556
show O 0 0.00081893575
activity O 0 0.0012424823
in O 0 0.0011587704
models O 0 0.0020949265
of O 0 0.0029548006
learning O 0 0.010388961
and O 0 0.006299524
memory O 0 0.3434429
. O 0 0.009687155

Although O 0 0.00671838
the O 0 0.0048829443
underlying O 0 0.005160426
mechanism O 0 0.0038563963
( O 0 0.003578
s O 0 0.0024752
) O 0 0.002278138
are O 0 0.0010140024
not O 0 0.0007734391
well O 0 0.0007617823
understood O 0 0.0016006093
, O 0 0.00097052794
these O 0 0.00075975346
effects O 0 0.0012911987
may O 0 0.00075035903
involve O 0 0.00088003714
an O 0 0.0013518383
increase O 0 0.0010346678
in O 0 0.0021709627
acetylcholine B-Chemical 1 0.9998128
( O 0 0.03574022
ACh B-Chemical 1 0.99970466
) O 0 0.010269005
levels O 0 0.0060180654
. O 0 0.007881989

The O 0 0.0067753666
present O 0 0.0038986744
study O 0 0.0035199814
sought O 0 0.0027323281
to O 0 0.0015571535
characterize O 0 0.0009473099
the O 0 0.0015422982
cognitive O 0 0.88748974
- O 0 0.0022221347
enhancing O 0 0.00089183723
effects O 0 0.0010799344
of O 0 0.0008282606
the O 0 0.0007438177
5 B-Chemical 0 0.00078345934
- I-Chemical 0 0.002643157
HT I-Chemical 0 0.99560887
( O 0 0.0012204179
6 O 0 0.00050477695
) O 0 0.0013564068
antagonist O 0 0.93395984
Ro4368554 B-Chemical 1 0.9610204
( O 0 0.0015780148
3 B-Chemical 0 0.00074429024
- I-Chemical 0 0.0020070241
benzenesulfonyl I-Chemical 0 0.9938647
- I-Chemical 0 0.002013089
7 I-Chemical 0 0.0006328391
- I-Chemical 0 0.0010048433
( I-Chemical 0 0.0007607521
4 I-Chemical 0 0.0005632755
- I-Chemical 0 0.0014789678
methyl I-Chemical 0 0.9680855
- I-Chemical 0 0.008574494
piperazin I-Chemical 0 0.9700123
- I-Chemical 0 0.0035431786
1 I-Chemical 0 0.00097451813
- I-Chemical 0 0.0024926497
yl I-Chemical 0 0.9367239
) I-Chemical 0 0.012019667
1H I-Chemical 0 0.9484413
- I-Chemical 0 0.0029336098
indole I-Chemical 0 0.97589487
) O 0 0.0014910415
in O 0 0.00039423196
a O 0 0.00056503376
rat O 0 0.0013656619
object O 0 0.0008222786
recognition O 0 0.00062816404
task O 0 0.0006786731
employing O 0 0.0005481171
a O 0 0.0011111049
cholinergic O 0 0.98858184
( O 0 0.008347252
scopolamine B-Chemical 1 0.99999726
pretreatment O 0 0.63841087
) O 0 0.0037328247
and O 0 0.00071548263
a O 0 0.0014460054
serotonergic O 0 0.9961492
- O 0 0.006403357
( O 0 0.0025006924
tryptophan B-Chemical 0 0.9968976
( O 0 0.00690459
TRP B-Chemical 0 0.9996574
) O 0 0.0025541636
depletion O 0 0.0015839626
) O 0 0.001175747
deficient O 0 0.00033929496
model O 0 0.0005866138
, O 0 0.0006496217
and O 0 0.00044441634
compared O 0 0.00028680128
its O 0 0.0006848605
pattern O 0 0.00047350393
of O 0 0.00081136246
action O 0 0.0031500284
with O 0 0.0009514907
that O 0 0.0009082742
of O 0 0.0018932094
the O 0 0.0030926322
acetylcholinesterase O 0 0.99900925
inhibitor O 0 0.817929
metrifonate B-Chemical 0 0.99979764
. O 0 0.011171202

Initial O 0 0.011960106
testing O 0 0.0052994993
in O 0 0.00348077
a O 0 0.003272934
time O 0 0.002077229
- O 0 0.002444947
dependent O 0 0.0011437082
forgetting O 0 0.098133706
task O 0 0.0012119296
employing O 0 0.0008091875
a O 0 0.00092466257
24 O 0 0.0005449199
- O 0 0.00073228247
h O 0 0.00033253516
delay O 0 0.0005762436
between O 0 0.0002585176
training O 0 0.00041965386
and O 0 0.0004442516
testing O 0 0.00038567584
showed O 0 0.00032982114
that O 0 0.0003957302
metrifonate B-Chemical 0 0.99962413
improved O 0 0.0011791369
object O 0 0.0015210202
recognition O 0 0.0010992335
( O 0 0.00086379587
at O 0 0.00030241237
10 O 0 0.0003637686
and O 0 0.00038998754
30 O 0 0.00033873555
mg O 0 0.055521313
/ O 0 0.0012506703
kg O 0 0.0028345413
, O 0 0.00087565323
p O 0 0.00089228514
. O 0 0.0006221555
o O 0 0.0028364395
. O 0 0.00097264815
) O 0 0.0023591905
, O 0 0.002129892
whereas O 0 0.0022282326
Ro4368554 B-Chemical 1 0.7700296
was O 0 0.004508887
inactive O 0 0.010218436
. O 0 0.008260126

Both O 0 0.011839691
, O 0 0.01014707
Ro4368554 B-Chemical 1 0.7344151
( O 0 0.005034819
3 O 0 0.0021098263
and O 0 0.0016921171
10 O 0 0.0013039873
mg O 0 0.11149939
/ O 0 0.002332721
kg O 0 0.0053955014
, O 0 0.0011483376
intraperitoneally O 0 0.0052185813
( O 0 0.0011549258
i O 0 0.0021734238
. O 0 0.00044981748
p O 0 0.0007670479
. O 0 0.00045981057
) O 0 0.0011590044
) O 0 0.0009541061
and O 0 0.00065896305
metrifonate B-Chemical 0 0.99970007
( O 0 0.00093435484
10 O 0 0.00045430724
mg O 0 0.09653654
/ O 0 0.0011438446
kg O 0 0.0028724421
, O 0 0.00062251586
p O 0 0.00058319623
. O 0 0.0003327362
o O 0 0.0021331303
. O 0 0.00039087527
, O 0 0.0007252732
respectively O 0 0.001352868
) O 0 0.0014699425
reversed O 0 0.0020731636
memory B-Disease 0 0.84525573
deficits I-Disease 0 0.93939453
induced O 0 0.0013266576
by O 0 0.0042492575
scopolamine B-Chemical 1 0.9999981
and O 0 0.005972653
TRP B-Chemical 0 0.9997682
depletion O 0 0.0039542257
( O 0 0.0010322005
10 O 0 0.00046774893
mg O 0 0.11877289
/ O 0 0.0012097592
kg O 0 0.0030322426
, O 0 0.00066718855
i O 0 0.0014036588
. O 0 0.00036383903
p O 0 0.0006153105
. O 0 0.00037452273
, O 0 0.0005800414
and O 0 0.0005145677
3 O 0 0.00051953463
mg O 0 0.07894225
/ O 0 0.0016202851
kg O 0 0.0034080062
, O 0 0.0012201802
p O 0 0.0013019138
. O 0 0.0010262565
o O 0 0.003975788
. O 0 0.0018066234
, O 0 0.003821834
respectively O 0 0.006484201
) O 0 0.009625221
. O 0 0.007746831

In O 0 0.007330998
conclusion O 0 0.0049128663
, O 0 0.0050801863
although O 0 0.002990179
Ro4368554 B-Chemical 1 0.64361197
did O 0 0.0015784303
not O 0 0.0010964893
improve O 0 0.0007086681
a O 0 0.0010742863
time O 0 0.00071672944
- O 0 0.0012930101
related O 0 0.00053406996
retention O 0 0.024730537
deficit O 0 0.6244995
, O 0 0.0012854843
it O 0 0.00065285043
reversed O 0 0.0011148375
a O 0 0.00097143586
cholinergic O 0 0.94248503
and O 0 0.00072939624
a O 0 0.0013105202
serotonergic O 0 0.9935027
memory B-Disease 0 0.85358244
deficit I-Disease 0 0.6863871
, O 0 0.0008709784
suggesting O 0 0.00030408922
that O 0 0.00029610528
both O 0 0.00038515526
mechanisms O 0 0.000762901
may O 0 0.0004148307
be O 0 0.00042185187
involved O 0 0.00031621798
in O 0 0.00033490855
the O 0 0.00039952033
facilitation O 0 0.013373778
of O 0 0.0005683854
object O 0 0.0018607448
memory O 0 0.16894
by O 0 0.0010206072
Ro4368554 B-Chemical 1 0.88300925
and O 0 0.0009532083
, O 0 0.0010497337
possibly O 0 0.0016882383
, O 0 0.0010243937
other O 0 0.0008627618
5 B-Chemical 0 0.0011171475
- I-Chemical 0 0.0030931851
HT I-Chemical 0 0.9906792
( O 0 0.002962888
6 O 0 0.0019919397
) O 0 0.005233363
receptor O 0 0.17474668
antagonists O 0 0.97210467
. O 0 0.010303966

Evaluation O 0 0.014142404
of O 0 0.007854908
the O 0 0.005741445
anticocaine O 0 0.015345615
monoclonal O 0 0.017681802
antibody O 0 0.022489462
GNC92H2 B-Chemical 1 0.8006494
as O 0 0.0034668683
an O 0 0.004515795
immunotherapy O 0 0.13765067
for O 0 0.00792749
cocaine B-Disease 1 0.9999591
overdose I-Disease 2 0.9999448
. O 0 0.018279187

The O 0 0.009052988
illicit O 0 0.9571413
use O 0 0.005660182
of O 0 0.0054911776
cocaine B-Chemical 1 0.9998118
continues O 0 0.0035792273
in O 0 0.0019153274
epidemic O 0 0.011918446
proportions O 0 0.0019205605
and O 0 0.0021423101
treatment O 0 0.003678738
for O 0 0.0032655785
cocaine B-Disease 1 0.99997747
overdose I-Disease 2 0.99997115
remains O 0 0.00914742
elusive O 0 0.05397457
. O 0 0.010264135

Current O 0 0.030928988
protein O 0 0.01074682
- O 0 0.006357058
based O 0 0.0030745396
technology O 0 0.003455004
offers O 0 0.0017522208
a O 0 0.001624258
new O 0 0.0014716261
therapeutic O 0 0.0073316195
venue O 0 0.0038095214
by O 0 0.00095792895
which O 0 0.0008977045
antibodies O 0 0.0017508649
bind O 0 0.00045943225
the O 0 0.00066790485
drug O 0 0.1947731
in O 0 0.00076153036
the O 0 0.00091032585
blood O 0 0.009599184
stream O 0 0.0033032417
, O 0 0.002736913
inactivating O 0 0.011042783
its O 0 0.006389392
toxic O 0 0.92174727
effects O 0 0.04133456
. O 0 0.010180511

The O 0 0.007708862
therapeutic O 0 0.008975303
potential O 0 0.0046668393
of O 0 0.0035327913
the O 0 0.0026759186
anticocaine O 0 0.028379451
antibody O 0 0.01452503
GNC92H2 B-Chemical 1 0.79511046
was O 0 0.0016429909
examined O 0 0.001201659
using O 0 0.0015628107
a O 0 0.0024172545
model O 0 0.003200084
of O 0 0.010815158
cocaine B-Disease 1 0.9999678
overdose I-Disease 2 0.99995136
. O 0 0.016321838

Swiss O 0 0.022506535
albino O 0 0.017598163
mice O 0 0.0036938055
prepared O 0 0.0036771495
with O 0 0.002482503
intrajugular O 0 0.50084376
catheters O 0 0.022137368
were O 0 0.0010746401
tested O 0 0.00064834044
in O 0 0.0006981319
photocell O 0 0.011130496
cages O 0 0.0007823007
after O 0 0.00031631565
administration O 0 0.0046051675
of O 0 0.0006723939
93 O 0 0.0018408159
mg O 0 0.2530976
/ O 0 0.001966158
kg O 0 0.008562224
( O 0 0.0012674822
LD50 O 0 0.85888666
) O 0 0.0012825228
of O 0 0.00095567456
cocaine B-Chemical 1 0.9999001
and O 0 0.0014093819
GNC92H2 B-Chemical 1 0.79005796
infusions O 0 0.026946327
ranging O 0 0.002322833
from O 0 0.001067076
30 O 0 0.0009668874
to O 0 0.0013369246
190 O 0 0.009499154
mg O 0 0.26603317
/ O 0 0.0094026895
kg O 0 0.018648215
. O 0 0.008383371

GNC92H2 B-Chemical 1 0.41392604
was O 0 0.007058572
delivered O 0 0.004139099
30 O 0 0.0028700966
min O 0 0.0027637947
before O 0 0.0016985493
, O 0 0.0024386307
concomitantly O 0 0.0041771885
or O 0 0.0020443692
3 O 0 0.0021143046
min O 0 0.0027308525
after O 0 0.0026881031
cocaine B-Chemical 1 0.99945873
treatment O 0 0.016357051
. O 0 0.010720738

Significant O 0 0.011569159
blockade O 0 0.11818853
of O 0 0.007590254
cocaine B-Chemical 1 0.99989855
toxicity B-Disease 2 0.9991886
was O 0 0.00199877
observed O 0 0.0007602409
with O 0 0.00082172477
the O 0 0.0006556357
higher O 0 0.0005683096
dose O 0 0.005334978
of O 0 0.0012265425
GNC92H2 B-Chemical 1 0.9362757
( O 0 0.0013234811
190 O 0 0.00937339
mg O 0 0.20064251
/ O 0 0.0016249493
kg O 0 0.0059974235
) O 0 0.001142431
, O 0 0.0006230301
where O 0 0.00043940998
premorbid O 0 0.86738944
behaviors O 0 0.041715097
were O 0 0.0004914679
reduced O 0 0.00044168532
up O 0 0.0004097674
to O 0 0.00041287838
40 O 0 0.00059935846
% O 0 0.00077747746
, O 0 0.0011467509
seizures B-Disease 2 0.9998741
up O 0 0.00083542283
to O 0 0.00084952934
77 O 0 0.0023408863
% O 0 0.0016060873
and O 0 0.002267797
death B-Disease 2 0.9892145
by O 0 0.0039997636
72 O 0 0.004799003
% O 0 0.006618051
. O 0 0.007365281

Importantly O 0 0.0145202195
, O 0 0.015668642
GNC92H2 B-Chemical 1 0.7117936
prevented O 0 0.029728565
death B-Disease 2 0.9953187
even O 0 0.009320191
post O 0 0.012523343
- O 0 0.01949408
cocaine B-Chemical 1 0.9995359
injection O 0 0.082569204
. O 0 0.014595067

The O 0 0.008076235
results O 0 0.005926112
support O 0 0.0041813385
the O 0 0.003157668
important O 0 0.002273386
potential O 0 0.0028047068
of O 0 0.003279979
GNC92H2 B-Chemical 1 0.7980068
as O 0 0.0023835918
a O 0 0.0029847794
therapeutic O 0 0.017803898
tool O 0 0.0043498925
against O 0 0.006568227
cocaine B-Disease 1 0.9999629
overdose I-Disease 2 0.9999473
. O 0 0.016420346

Electrocardiographic O 0 0.6980589
evidence O 0 0.01231989
of O 0 0.014754474
myocardial B-Disease 2 0.9996227
injury I-Disease 2 0.9974757
in O 0 0.010800726
psychiatrically O 0 0.99123317
hospitalized O 0 0.84034336
cocaine B-Chemical 1 0.99985003
abusers O 0 0.9992692
. O 0 0.017889157

The O 0 0.009808077
electrocardiograms O 0 0.45837256
( O 0 0.009057285
ECG O 0 0.81675506
) O 0 0.004635246
of O 0 0.0026623341
99 O 0 0.005912835
cocaine B-Chemical 1 0.99986017
- O 0 0.0056132977
abusing O 0 0.8740998
patients O 0 0.0032020374
were O 0 0.0010433656
compared O 0 0.0007047064
with O 0 0.001136439
the O 0 0.0014816441
ECGs O 0 0.15922728
of O 0 0.0025707406
50 O 0 0.0060968115
schizophrenic B-Disease 2 0.998863
controls O 0 0.013563483
. O 0 0.00864511

Eleven O 0 0.01463564
of O 0 0.00627025
the O 0 0.0048910235
cocaine B-Chemical 1 0.99977714
abusers O 0 0.9989956
and O 0 0.0022911327
none O 0 0.001319886
of O 0 0.0010721281
the O 0 0.0007985918
controls O 0 0.0013178462
had O 0 0.0007338085
ECG O 0 0.8187261
evidence O 0 0.00057516404
of O 0 0.0008279572
significant O 0 0.0015207914
myocardial B-Disease 2 0.99996257
injury I-Disease 2 0.99742895
defined O 0 0.0013370487
as O 0 0.002575451
myocardial B-Disease 0 0.9999622
infarction I-Disease 2 0.9999956
, O 0 0.044406094
ischemia B-Disease 2 0.99991596
, O 0 0.004263845
and O 0 0.0032392966
bundle B-Disease 0 0.039331805
branch I-Disease 0 0.0099830385
block I-Disease 0 0.01183065
. O 0 0.008455688

Behavioral O 0 0.16718367
effects O 0 0.015617721
of O 0 0.015750594
urotensin B-Chemical 0 0.9985765
- I-Chemical 0 0.04456439
II I-Chemical 0 0.4299268
centrally O 0 0.060974136
administered O 0 0.008998881
in O 0 0.007422352
mice O 0 0.008602582
. O 0 0.0126481755

Urotensin B-Chemical 0 0.98180467
- I-Chemical 0 0.031069295
II I-Chemical 0 0.44827354
( O 0 0.014022647
U B-Chemical 1 0.9873903
- I-Chemical 1 0.015492655
II I-Chemical 1 0.3869105
) O 0 0.0059325933
receptors O 0 0.058592476
are O 0 0.002294844
widely O 0 0.0025391828
distributed O 0 0.002032065
in O 0 0.0019583043
the O 0 0.0027731906
central O 0 0.009366993
nervous O 0 0.9635508
system O 0 0.014770342
. O 0 0.01047947

Intracerebroventricular O 0 0.9937099
( O 0 0.010507369
i O 0 0.009366295
. O 0 0.0028009098
c O 0 0.008738232
. O 0 0.0015790022
v O 0 0.015498372
. O 0 0.0010515823
) O 0 0.001535624
injection O 0 0.0017440593
of O 0 0.0018658023
U B-Chemical 1 0.9965649
- I-Chemical 1 0.012400662
II I-Chemical 1 0.47251725
causes O 0 0.019325972
hypertension B-Disease 2 0.99996126
and O 0 0.008875482
bradycardia B-Disease 2 0.99987054
and O 0 0.0035362241
stimulates O 0 0.0030343225
prolactin O 0 0.9974583
and O 0 0.013512189
thyrotropin O 0 0.9993012
secretion O 0 0.36404786
. O 0 0.0114982715

However O 0 0.010419218
, O 0 0.0076803686
the O 0 0.0046464987
behavioral O 0 0.012902939
effects O 0 0.004161661
of O 0 0.0034602978
centrally O 0 0.07253367
administered O 0 0.013022364
U B-Chemical 1 0.9944114
- I-Chemical 1 0.009266866
II I-Chemical 1 0.12997724
have O 0 0.0026755317
received O 0 0.0035114381
little O 0 0.0045275656
attention O 0 0.011661207
. O 0 0.009847545

In O 0 0.0071903146
the O 0 0.004874164
present O 0 0.0029007208
study O 0 0.0030416427
, O 0 0.0022109698
we O 0 0.0009609812
tested O 0 0.0007978434
the O 0 0.000814891
effects O 0 0.0012208987
of O 0 0.0011221035
i O 0 0.008793316
. O 0 0.00062928675
c O 0 0.011927525
. O 0 0.0004934573
v O 0 0.009968048
. O 0 0.00039459675
injections O 0 0.0015409823
of O 0 0.0011544264
U B-Chemical 1 0.9946175
- I-Chemical 1 0.004285023
II I-Chemical 1 0.11690951
on O 0 0.0005535236
behavioral O 0 0.05155722
, O 0 0.0017176062
metabolic O 0 0.19544227
, O 0 0.0022954107
and O 0 0.0022587886
endocrine O 0 0.92401373
responses O 0 0.007176813
in O 0 0.0041996487
mice O 0 0.0050262604
. O 0 0.008234354

Administration O 0 0.079748645
of O 0 0.007167144
graded O 0 0.02195884
doses O 0 0.05784982
of O 0 0.007304043
U B-Chemical 1 0.9972076
- I-Chemical 1 0.025756525
II I-Chemical 1 0.48724535
( O 0 0.0024054376
1 O 0 0.0011620434
- O 0 0.001112345
10 O 0 0.0005687599
, O 0 0.00058975857
000 O 0 0.0006214532
ng O 0 0.0012463668
/ O 0 0.0014240802
mouse O 0 0.0008910949
) O 0 0.0013809457
provoked O 0 0.054854687
: O 0 0.0016020591
( O 0 0.0009194622
1 O 0 0.0005379928
) O 0 0.0006497326
a O 0 0.0005034785
dose O 0 0.0055989497
- O 0 0.00079246814
dependent O 0 0.00029999277
reduction O 0 0.0005628312
in O 0 0.00029761577
the O 0 0.00030679276
number O 0 0.0003108223
of O 0 0.00054325757
head O 0 0.05297756
dips O 0 0.013292499
in O 0 0.0004282233
the O 0 0.00050708983
hole O 0 0.02425276
- O 0 0.0012982608
board O 0 0.0010493732
test O 0 0.0007968449
; O 0 0.0013102588
( O 0 0.00072453084
2 O 0 0.0004471792
) O 0 0.00060561846
a O 0 0.00048240164
dose O 0 0.0057382993
- O 0 0.00078425405
dependent O 0 0.00029269452
reduction O 0 0.00055517163
in O 0 0.00028796136
the O 0 0.00029306673
number O 0 0.0002873205
of O 0 0.0004473664
entries O 0 0.00091217994
in O 0 0.00031999307
the O 0 0.0003616293
white O 0 0.0015831753
chamber O 0 0.0006905105
in O 0 0.00034834098
the O 0 0.00042620444
black O 0 0.0037754618
- O 0 0.0013471422
and O 0 0.00066770945
- O 0 0.0009294438
white O 0 0.0013234394
compartment O 0 0.000555341
test O 0 0.0005781218
, O 0 0.0005505623
and O 0 0.00037350692
in O 0 0.00028193163
the O 0 0.00028356878
number O 0 0.00027927724
of O 0 0.0004337286
entries O 0 0.00086776505
in O 0 0.00031182193
the O 0 0.00034577624
central O 0 0.00083962706
platform O 0 0.000572093
and O 0 0.00041190223
open O 0 0.00038163006
arms O 0 0.0009175062
in O 0 0.00031863136
the O 0 0.0003693654
plus O 0 0.00049266446
- O 0 0.0011352381
maze O 0 0.010500594
test O 0 0.000635888
; O 0 0.0009303404
and O 0 0.000559593
( O 0 0.0007603503
3 O 0 0.00041762055
) O 0 0.0006076081
a O 0 0.00048555373
dose O 0 0.005605311
- O 0 0.00078241114
dependent O 0 0.0002932663
increase O 0 0.00028932714
in O 0 0.00032215135
the O 0 0.00035975873
duration O 0 0.00055243523
of O 0 0.0008585512
immobility O 0 0.9423509
in O 0 0.000690075
the O 0 0.0008483317
forced O 0 0.015806109
- O 0 0.002073732
swimming O 0 0.03484493
test O 0 0.0016864825
and O 0 0.0021373162
tail O 0 0.003756465
suspension O 0 0.0148329735
test O 0 0.0076892255
. O 0 0.008269991

Intracerebroventricular O 0 0.98791844
injection O 0 0.01494392
of O 0 0.008542141
U B-Chemical 1 0.99446326
- I-Chemical 1 0.016456086
II I-Chemical 1 0.18386063
also O 0 0.0014598678
caused O 0 0.0013620653
an O 0 0.0014417183
increase O 0 0.0006890025
in O 0 0.0007419187
: O 0 0.0012654905
food O 0 0.0134397885
intake O 0 0.45860374
at O 0 0.0004286414
doses O 0 0.005610728
of O 0 0.0007108972
100 O 0 0.0013151973
and O 0 0.0005641373
1 O 0 0.0005091385
, O 0 0.00047893342
000 O 0 0.0005084509
ng O 0 0.0010622664
/ O 0 0.0011958412
mouse O 0 0.0006761617
, O 0 0.0006889933
water O 0 0.00480558
intake O 0 0.28649706
at O 0 0.00034026938
doses O 0 0.0043693446
of O 0 0.00070143637
100 O 0 0.0022609183
- O 0 0.00086262706
10 O 0 0.0003960861
, O 0 0.00043423753
000 O 0 0.000481445
ng O 0 0.0009865293
/ O 0 0.0011082332
mouse O 0 0.0006484329
, O 0 0.00062471675
and O 0 0.0005056843
horizontal O 0 0.0010805489
locomotion O 0 0.049590416
activity O 0 0.00062633236
at O 0 0.0004096268
a O 0 0.00073673634
dose O 0 0.002292368
of O 0 0.0012014741
10 O 0 0.0013907003
, O 0 0.001886876
000 O 0 0.0026976266
ng O 0 0.005581291
/ O 0 0.0079984525
mouse O 0 0.007302844
. O 0 0.007908376

Whatever O 0 0.028467635
was O 0 0.005696025
the O 0 0.0036324419
dose O 0 0.009051948
, O 0 0.0026621213
the O 0 0.0014088819
central O 0 0.0025287361
administration O 0 0.04577397
of O 0 0.0030391612
U B-Chemical 1 0.9977069
- I-Chemical 1 0.009340228
II I-Chemical 1 0.12526102
had O 0 0.00048239934
no O 0 0.00033906315
effect O 0 0.00043728395
on O 0 0.00034491633
body O 0 0.008103333
temperature O 0 0.0022697193
, O 0 0.001949199
nociception O 0 0.997401
, O 0 0.009517134
apomorphine B-Chemical 1 0.99999404
- O 0 0.004459992
induced O 0 0.0009724628
penile B-Disease 0 0.96467465
erection I-Disease 0 0.99616337
and O 0 0.001568649
climbing O 0 0.39390162
behavior O 0 0.008429873
, O 0 0.0016567687
and O 0 0.0016969588
stress O 0 0.5552736
- O 0 0.008009425
induced O 0 0.0037904403
plasma O 0 0.4544416
corticosterone B-Chemical 1 0.9993845
level O 0 0.006762685
. O 0 0.00935243

Taken O 0 0.010294401
together O 0 0.006370992
, O 0 0.0049511017
the O 0 0.002594612
present O 0 0.0015203746
study O 0 0.0015660401
demonstrates O 0 0.00086144457
that O 0 0.0007241729
the O 0 0.00076809607
central O 0 0.0016742055
injection O 0 0.0022622277
of O 0 0.0020251223
U B-Chemical 1 0.9976465
- I-Chemical 1 0.009091972
II I-Chemical 1 0.17326154
at O 0 0.00041230064
doses O 0 0.004645381
of O 0 0.000806376
1 O 0 0.00081293925
- O 0 0.00084585324
10 O 0 0.00044330975
, O 0 0.0005051663
000 O 0 0.000579543
ng O 0 0.0012193286
/ O 0 0.0014422517
mouse O 0 0.00091405085
induces O 0 0.0009037611
anxiogenic O 0 0.999201
- O 0 0.005615921
and O 0 0.0023822947
depressant O 0 0.99984646
- O 0 0.0053508356
like O 0 0.0023895828
effects O 0 0.0051526083
in O 0 0.0042901305
mouse O 0 0.008951453
. O 0 0.008560556

These O 0 0.011161168
data O 0 0.008207217
suggest O 0 0.0045293304
that O 0 0.00489563
U B-Chemical 1 0.98624367
- I-Chemical 1 0.0145656895
II I-Chemical 1 0.20750359
may O 0 0.0024069978
be O 0 0.0021392684
involved O 0 0.0017220742
in O 0 0.0018598754
some O 0 0.0025249862
aspects O 0 0.003178387
of O 0 0.00948016
psychiatric B-Disease 2 0.9995915
disorders I-Disease 0 0.9978542
. O 0 0.015118355

Learning O 0 0.06308204
of O 0 0.017555593
rats O 0 0.020639926
under O 0 0.01311948
amnesia B-Disease 2 0.9982516
caused O 0 0.022244431
by O 0 0.028958002
pentobarbital B-Chemical 1 0.9993309
. O 0 0.022654451

Dissociated O 0 0.07648905
learning O 0 0.010191319
of O 0 0.0045357523
rats O 0 0.0048629874
in O 0 0.0019210321
the O 0 0.0015316964
normal O 0 0.0020416528
state O 0 0.0014951775
and O 0 0.0010378328
the O 0 0.00080856885
state O 0 0.0011964485
of O 0 0.0016093903
amnesia B-Disease 2 0.99979585
produced O 0 0.0011497878
by O 0 0.001854861
pentobarbital B-Chemical 1 0.9998846
( O 0 0.0014824902
15 O 0 0.00069710164
mg O 0 0.10723574
/ O 0 0.0023700646
kg O 0 0.0060698045
, O 0 0.0024279587
ip O 0 0.6746548
) O 0 0.0040834146
was O 0 0.0026659577
carried O 0 0.0031118826
out O 0 0.0051641776
. O 0 0.0077435835

Rats O 0 0.02793915
were O 0 0.00938901
trained O 0 0.0069622523
to O 0 0.004998529
approach O 0 0.005156109
a O 0 0.005317484
shelf O 0 0.007990826
where O 0 0.003939991
they O 0 0.0044119037
received O 0 0.005342668
food O 0 0.026105564
reinforcement O 0 0.024650475
. O 0 0.012792193

In O 0 0.009043215
Group O 0 0.015113407
1 O 0 0.004010861
the O 0 0.002637252
rats O 0 0.0031768929
were O 0 0.0015515685
trained O 0 0.0012202141
under O 0 0.00072216196
the O 0 0.0007663338
influence O 0 0.00066659483
of O 0 0.0013925397
pentobarbital B-Chemical 1 0.99974746
to O 0 0.0008076767
run O 0 0.0009446789
to O 0 0.00065625523
the O 0 0.000750335
same O 0 0.00073926034
shelf O 0 0.0028016677
as O 0 0.0015795331
in O 0 0.0019311742
the O 0 0.0028245244
normal O 0 0.0063628503
state O 0 0.008434696
. O 0 0.008644566

In O 0 0.010451505
Group O 0 0.015911551
2 O 0 0.0048774243
the O 0 0.003537941
rats O 0 0.004347048
were O 0 0.002497223
trained O 0 0.0022119484
to O 0 0.0017589084
approach O 0 0.0022413211
different O 0 0.0021438776
shelves O 0 0.00781393
in O 0 0.002764339
different O 0 0.0037869394
drug O 0 0.6083173
states O 0 0.017302148
. O 0 0.010658614

It O 0 0.01574149
was O 0 0.00947231
shown O 0 0.0063635674
that O 0 0.006085812
memory B-Disease 0 0.33721405
dissociation I-Disease 0 0.080758505
occurred O 0 0.007101247
in O 0 0.0061989827
both O 0 0.007621095
groups O 0 0.012891648
. O 0 0.012848305

Differences O 0 0.007428988
in O 0 0.0047255354
the O 0 0.0034387654
parameters O 0 0.003039326
of O 0 0.0022954282
training O 0 0.0016378049
under O 0 0.0010072874
the O 0 0.0010768982
influence O 0 0.000970116
of O 0 0.002108905
pentobarbital B-Chemical 1 0.99976796
between O 0 0.0013754986
Groups O 0 0.071870305
1 O 0 0.0021703125
and O 0 0.0024623733
2 O 0 0.0030094974
were O 0 0.0038722297
revealed O 0 0.0057767374
. O 0 0.008253417

These O 0 0.008821843
findings O 0 0.0070587704
show O 0 0.003284818
that O 0 0.0024074144
the O 0 0.0024056446
brain O 0 0.14456694
- O 0 0.0033087723
dissociated O 0 0.0025696822
state O 0 0.0016160766
induced O 0 0.0012939796
by O 0 0.0018045581
pentobarbital B-Chemical 1 0.99983954
is O 0 0.00088636886
formed O 0 0.0009750411
with O 0 0.0008376062
the O 0 0.0008474139
participation O 0 0.0015619232
of O 0 0.0012289351
the O 0 0.001412308
mechanisms O 0 0.0025661304
of O 0 0.0034367281
information O 0 0.0055207293
perception O 0 0.043724805
. O 0 0.009271582

The O 0 0.007542249
effects O 0 0.0062290626
of O 0 0.004565067
short O 0 0.0033001783
- O 0 0.0042298194
term O 0 0.0025371246
raloxifene B-Chemical 0 0.9998313
therapy O 0 0.046899505
on O 0 0.0012955322
fibrinolysis O 0 0.99692506
markers O 0 0.028896935
: O 0 0.016589653
TAFI O 0 0.99919075
, O 0 0.00599348
tPA O 0 0.9113223
, O 0 0.0036018929
and O 0 0.0039745173
PAI O 0 0.486981
- O 0 0.0075395126
1 O 0 0.0068808766
. O 0 0.008018625

BACKGROUND O 0 0.7516853
: O 0 0.012760405
Markers O 0 0.15240312
of O 0 0.0057957033
fibrinolysis O 0 0.995555
, O 0 0.008548639
thrombin O 0 0.9800046
- O 0 0.010180022
activatable O 0 0.18768364
fibrinolysis O 0 0.9987093
inhibitor O 0 0.5525189
( O 0 0.01727691
TAFI O 0 0.99953544
) O 0 0.0055108755
, O 0 0.0011442427
tissue O 0 0.025848197
- O 0 0.0018747475
type O 0 0.00083645835
plasminogen O 0 0.9804717
activator O 0 0.058217417
( O 0 0.00527498
tPA O 0 0.957177
) O 0 0.0025048198
, O 0 0.00088788226
and O 0 0.0007798055
plasminogen O 0 0.96681845
activator O 0 0.030965656
inhibitor O 0 0.27950546
- O 0 0.0052149924
1 O 0 0.0008558659
( O 0 0.0011240719
PAI O 0 0.32685754
- O 0 0.0011455815
1 O 0 0.00055060454
) O 0 0.0006630171
levels O 0 0.0003372716
were O 0 0.00036492458
studied O 0 0.00038574173
for O 0 0.00030936924
the O 0 0.0003977794
evaluation O 0 0.0005346649
of O 0 0.00067633257
short O 0 0.00068845483
- O 0 0.0012459803
term O 0 0.0007355721
effects O 0 0.0021633336
of O 0 0.004187864
raloxifene B-Chemical 0 0.99994266
administration O 0 0.55398685
in O 0 0.0060532377
postmenopausal O 0 0.99862826
women O 0 0.5772861
. O 0 0.010723739

METHODS O 0 0.012784067
: O 0 0.009499055
Thirty O 0 0.009227889
- O 0 0.0058811633
nine O 0 0.0037580158
postmenopausal O 0 0.9818819
women O 0 0.20391165
with O 0 0.0046094367
osteopenia B-Disease 0 0.99985325
or O 0 0.0069549703
osteoporosis B-Disease 2 0.9999094
were O 0 0.0020049396
included O 0 0.0012369881
in O 0 0.0011557512
this O 0 0.0014425396
prospective O 0 0.004214266
, O 0 0.0027933614
controlled O 0 0.0027887512
clinical O 0 0.0114191305
study O 0 0.007729882
. O 0 0.008359703

Twenty O 0 0.015522474
- O 0 0.008673542
five O 0 0.0036886937
women O 0 0.010314134
were O 0 0.0025823982
given O 0 0.0019378399
raloxifene B-Chemical 0 0.9998729
hydrochloride I-Chemical 0 0.99968874
( O 0 0.0034978827
60 O 0 0.0011334512
mg O 0 0.15577805
/ O 0 0.0019153008
day O 0 0.0008469538
) O 0 0.0016375047
plus O 0 0.0013113167
calcium B-Chemical 1 0.9984321
( O 0 0.0038241313
500 O 0 0.006807074
mg O 0 0.3406393
/ O 0 0.0063836793
day O 0 0.0038294685
) O 0 0.008747702
. O 0 0.007744294

Age O 0 0.28721228
- O 0 0.011216038
matched O 0 0.0055869306
controls O 0 0.006183427
( O 0 0.004970832
n O 0 0.0037821215
= O 0 0.0039708023
14 O 0 0.003139851
) O 0 0.0039943
were O 0 0.0032230956
given O 0 0.0032672486
only O 0 0.0063977465
calcium B-Chemical 1 0.99628264
. O 0 0.013827976

Plasma O 0 0.63135487
TAFI O 0 0.9963561
, O 0 0.013031899
tPA O 0 0.85771775
, O 0 0.004507907
and O 0 0.0030294852
PAI O 0 0.3708381
- O 0 0.002677656
1 O 0 0.0010822614
antigen O 0 0.003179688
levels O 0 0.0007789028
were O 0 0.00065364916
measured O 0 0.00043567337
at O 0 0.0004097545
baseline O 0 0.00056779874
and O 0 0.0005597849
after O 0 0.00038094603
3 O 0 0.0005497621
months O 0 0.00050035975
of O 0 0.00090818206
treatment O 0 0.0018462075
by O 0 0.0021016323
commercially O 0 0.015664026
available O 0 0.003795979
ELISA O 0 0.45899156
kits O 0 0.30167532
. O 0 0.009807344

Variations O 0 0.02024247
of O 0 0.011637562
individuals O 0 0.010637821
were O 0 0.0073942104
assessed O 0 0.0058482797
by O 0 0.0075289155
Wilcoxon O 0 0.03092639
' O 0 0.009108604
s O 0 0.009858571
test O 0 0.012179368
. O 0 0.013902607

Relationship O 0 0.016578564
between O 0 0.0085019935
those O 0 0.009817699
markers O 0 0.010902555
and O 0 0.008565244
demographic O 0 0.013614961
characteristics O 0 0.008776923
were O 0 0.009514231
investigated O 0 0.010291127
. O 0 0.014732475

RESULTS O 0 0.024266731
: O 0 0.007656406
Three O 0 0.004420613
months O 0 0.0024864397
of O 0 0.0030385253
raloxifene B-Chemical 0 0.99971527
treatment O 0 0.0050029824
was O 0 0.0013178939
associated O 0 0.0011165986
with O 0 0.0008505153
a O 0 0.0009842926
significant O 0 0.00072464475
decrease O 0 0.0005862447
in O 0 0.00048848294
the O 0 0.00061981555
plasma O 0 0.07936776
TAFI O 0 0.9991358
antigen O 0 0.09246022
concentrations O 0 0.0098305335
( O 0 0.0011033224
16 O 0 0.0005245319
% O 0 0.0005026492
change O 0 0.00045706358
, O 0 0.0006628724
P O 0 0.02653093
< O 0 0.00050605554
0 O 0 0.00057588506
. O 0 0.00034647255
01 O 0 0.0037873352
) O 0 0.00073217356
, O 0 0.00050444796
and O 0 0.0004078415
a O 0 0.00051287346
significant O 0 0.00048544447
increase O 0 0.00040883257
in O 0 0.000601811
tPA O 0 0.8411112
antigen O 0 0.027374005
concentrations O 0 0.0059088836
( O 0 0.0014268088
25 O 0 0.0010479799
% O 0 0.0009800643
change O 0 0.0009781083
, O 0 0.001664742
P O 0 0.032456182
< O 0 0.0019842822
0 O 0 0.0027361156
. O 0 0.0027367182
05 O 0 0.054235894
) O 0 0.0076770913
. O 0 0.0075051626

A O 0 0.025135698
significant O 0 0.005625662
correlation O 0 0.003118656
was O 0 0.0026079223
found O 0 0.001584661
between O 0 0.0011625859
baseline O 0 0.0021889564
TAFI O 0 0.9958431
antigen O 0 0.04858088
concentrations O 0 0.003174591
and O 0 0.000926749
the O 0 0.0006408191
duration O 0 0.00090004085
of O 0 0.0016705506
amenorrhea B-Disease 0 0.9998965
( O 0 0.004046978
P O 0 0.1457143
< O 0 0.0010013102
0 O 0 0.0010867274
. O 0 0.0007775242
05 O 0 0.02267612
; O 0 0.0014581289
r O 0 0.0013745558
= O 0 0.0018936574
0 O 0 0.0020948309
. O 0 0.0020313922
33 O 0 0.0048531783
) O 0 0.0073628137
. O 0 0.007200902

CONCLUSION O 0 0.63538563
: O 0 0.0082602035
We O 0 0.0036043823
suggest O 0 0.0019731252
that O 0 0.0016294578
the O 0 0.0015398492
increased O 0 0.0017450716
risk O 0 0.02811226
of O 0 0.0017809023
venous B-Disease 0 0.9483651
thromboembolism I-Disease 0 0.99999154
due O 0 0.0011309966
to O 0 0.0012824604
raloxifene B-Chemical 0 0.9999354
treatment O 0 0.003270891
may O 0 0.00076447666
be O 0 0.000729381
related O 0 0.0005375681
to O 0 0.0007756091
increased O 0 0.0017526026
tPA O 0 0.9147945
levels O 0 0.0015904943
, O 0 0.002543377
but O 0 0.0022341497
not O 0 0.003445362
TAFI O 0 0.99572974
levels O 0 0.0072540054
. O 0 0.008984936

Valproate B-Chemical 1 0.9988172
- O 0 0.096263245
induced O 0 0.070487306
encephalopathy B-Disease 2 0.9986707
. O 0 0.061581403

Valproate B-Chemical 1 0.9997929
- O 0 0.028246466
induced O 0 0.010110649
encephalopathy B-Disease 2 0.9998185
is O 0 0.004415811
a O 0 0.0039084195
rare O 0 0.030687628
syndrome O 0 0.87714237
that O 0 0.0019978182
may O 0 0.0021213596
manifest O 0 0.018951297
in O 0 0.0026146937
otherwise O 0 0.009180525
normal O 0 0.015699338
epileptic B-Disease 2 0.9996302
individuals O 0 0.026326902
. O 0 0.0102274

It O 0 0.011523532
may O 0 0.006142678
even O 0 0.004387408
present O 0 0.0026845785
in O 0 0.0025934041
patients O 0 0.004084858
who O 0 0.0034119114
have O 0 0.0018583232
tolerated O 0 0.014785477
this O 0 0.00228701
medicine O 0 0.013821825
well O 0 0.0027561714
in O 0 0.0035674889
the O 0 0.0051928596
past O 0 0.010672153
. O 0 0.009991963

It O 0 0.018534388
is O 0 0.0115821
usually O 0 0.011423578
but O 0 0.008385971
not O 0 0.007510105
necessarily O 0 0.008718762
associated O 0 0.011016636
with O 0 0.020825868
hyperammonemia B-Disease 2 0.99980253
. O 0 0.024583971

The O 0 0.010871263
EEG O 0 0.32387304
shows O 0 0.005145307
characteristic O 0 0.0064752526
triphasic O 0 0.7895487
waves O 0 0.0585493
in O 0 0.0040754047
most O 0 0.005140813
patients O 0 0.0080593
with O 0 0.005620692
this O 0 0.007322332
complication O 0 0.73465526
. O 0 0.013809975

A O 0 0.04602022
case O 0 0.014046876
of O 0 0.01697358
valproate B-Chemical 0 0.99987173
- O 0 0.051389843
induced O 0 0.02130874
encephalopathy B-Disease 2 0.9997954
is O 0 0.016132833
presented O 0 0.017480092
. O 0 0.016157579

The O 0 0.014339133
problems O 0 0.020610807
in O 0 0.009116139
diagnosing O 0 0.012740402
this O 0 0.0080109695
condition O 0 0.011471106
are O 0 0.009424045
subsequently O 0 0.012011001
discussed O 0 0.011052233
. O 0 0.014747959

Recurrent O 0 0.8600607
dysphonia B-Disease 0 0.9951067
and O 0 0.093007594
acitretin B-Chemical 0 0.99827373
. O 0 0.06482876

We O 0 0.008868153
report O 0 0.007846387
the O 0 0.004181142
case O 0 0.003226135
of O 0 0.002913973
a O 0 0.003200586
woman O 0 0.025741993
complaining O 0 0.38017517
of O 0 0.0043367655
dysphonia B-Disease 0 0.999589
while O 0 0.0029533189
she O 0 0.002991536
was O 0 0.0031160198
treated O 0 0.00550075
by O 0 0.010070663
acitretin B-Chemical 0 0.9996984
. O 0 0.015109654

Her O 0 0.023334306
symptoms O 0 0.47514743
totally O 0 0.010799554
regressed O 0 0.012259371
after O 0 0.0027761618
drug O 0 0.43768907
withdrawal O 0 0.85703063
and O 0 0.0048332643
reappeared O 0 0.016621236
when O 0 0.0042203264
acitretin B-Chemical 0 0.9997385
was O 0 0.009721248
reintroduced O 0 0.014336491
. O 0 0.010883374

To O 0 0.007849989
our O 0 0.0058131656
knowledge O 0 0.005828408
, O 0 0.0043815253
this O 0 0.002684226
is O 0 0.002240751
the O 0 0.001941148
first O 0 0.0017898132
case O 0 0.0026475438
of O 0 0.0060661
acitretin B-Chemical 0 0.9999068
- O 0 0.06683024
induced O 0 0.019176943
dysphonia B-Disease 0 0.9996146
. O 0 0.015617494

This O 0 0.011783038
effect O 0 0.0058678775
may O 0 0.004278422
be O 0 0.0031425
related O 0 0.001959898
to O 0 0.0017850233
the O 0 0.0017730438
pharmacological O 0 0.15177263
effect O 0 0.0018981537
of O 0 0.002337065
this O 0 0.0024241968
drug O 0 0.56129676
on O 0 0.0034313367
mucous O 0 0.95194596
membranes O 0 0.4143449
. O 0 0.012045305

Nitro B-Chemical 0 0.9819479
- I-Chemical 0 0.04834814
L I-Chemical 1 0.9582957
- I-Chemical 1 0.055332117
arginine I-Chemical 1 0.99278706
methyl I-Chemical 0 0.9976973
ester I-Chemical 0 0.9963983
: O 0 0.010267953
a O 0 0.004948399
potential O 0 0.0056098127
protector O 0 0.33651936
against O 0 0.0084722955
gentamicin B-Chemical 1 0.9996449
ototoxicity B-Disease 2 0.99989986
. O 0 0.01799744

The O 0 0.01315106
nitric B-Chemical 0 0.9986916
oxide I-Chemical 0 0.9986998
( O 0 0.0594675
NO B-Chemical 0 0.9993173
) O 0 0.02985884
inhibitor O 0 0.44671908
nitro B-Chemical 0 0.99979097
- I-Chemical 0 0.11935942
L I-Chemical 1 0.9940327
- I-Chemical 1 0.0694604
arginine I-Chemical 1 0.99743795
methyl I-Chemical 0 0.99937844
ester I-Chemical 0 0.99950135
( O 0 0.09655176
L B-Chemical 1 0.99594265
- I-Chemical 1 0.07017779
NAME I-Chemical 1 0.9999292
) O 0 0.0039356067
may O 0 0.000534859
act O 0 0.00083902566
as O 0 0.00050200266
an O 0 0.00077671546
otoprotectant O 0 0.046353687
against O 0 0.00046184243
high B-Disease 0 0.0009933728
- I-Disease 0 0.0013151717
frequency I-Disease 0 0.00072984886
hearing I-Disease 0 0.9266744
loss I-Disease 0 0.0018320541
caused O 0 0.0008669833
by O 0 0.0012101049
gentamicin B-Chemical 1 0.99945885
, O 0 0.0011139192
but O 0 0.0004105678
further O 0 0.00039516966
studies O 0 0.0004325486
are O 0 0.0003472185
needed O 0 0.00023061244
to O 0 0.00027547157
confirm O 0 0.00022772499
this O 0 0.0004929998
. O 0 0.0004932598
Aminoglycoside B-Chemical 0 0.99612683
antibiotics O 0 0.38482645
are O 0 0.0007178142
still O 0 0.00057006354
widely O 0 0.0008539261
used O 0 0.0006378322
by O 0 0.0008681037
virtue O 0 0.0026628396
of O 0 0.0013842678
their O 0 0.0017285477
efficacy O 0 0.0050571547
and O 0 0.0034981435
low O 0 0.0053472463
cost O 0 0.009745939
. O 0 0.008651904

Their O 0 0.08021268
ototoxicity B-Disease 2 0.9995029
is O 0 0.0056247655
a O 0 0.004432572
serious O 0 0.19801736
health O 0 0.021407763
problem O 0 0.0033968964
and O 0 0.0015427558
, O 0 0.0013016986
as O 0 0.00074884924
their O 0 0.0009134941
ototoxic B-Disease 0 0.9987502
mechanism O 0 0.0010938514
involves O 0 0.0005853527
the O 0 0.00057374727
production O 0 0.0011302717
of O 0 0.0016428775
NO B-Chemical 0 0.9994318
, O 0 0.0009104342
we O 0 0.00027839275
need O 0 0.00029962035
to O 0 0.00028518142
assess O 0 0.0002007724
the O 0 0.00040279116
use O 0 0.00057519175
of O 0 0.0011875479
NO B-Chemical 0 0.999311
inhibitors O 0 0.07436201
for O 0 0.00065015693
the O 0 0.0008333931
prevention O 0 0.0061858045
of O 0 0.0027701263
aminoglycoside B-Chemical 1 0.998901
- O 0 0.024673581
induced O 0 0.013978103
sensorineural B-Disease 2 0.99994767
hearing I-Disease 2 0.99542266
loss I-Disease 2 0.11936952
. O 0 0.009979999

In O 0 0.0075982823
this O 0 0.005032232
experimental O 0 0.003965318
study O 0 0.0030477103
we O 0 0.0016406039
used O 0 0.0015977086
30 O 0 0.0013705557
Sprague O 0 0.12244672
- O 0 0.002426226
Dawley O 0 0.028457984
rats O 0 0.0021518047
, O 0 0.0013075243
27 O 0 0.0012146141
of O 0 0.00095957407
which O 0 0.0012939391
had O 0 0.0013830476
gentamicin B-Chemical 1 0.9960097
instilled O 0 0.026218228
into O 0 0.0016769599
the O 0 0.002986528
middle O 0 0.007977436
ear O 0 0.05494992
. O 0 0.010129614

The O 0 0.0142154675
otoprotectant O 0 0.33815354
L B-Chemical 1 0.9627618
- I-Chemical 1 0.04502816
NAME I-Chemical 1 0.9987991
was O 0 0.004960101
administered O 0 0.005239401
topically O 0 0.5824021
to O 0 0.0039268876
12 O 0 0.0035625529
/ O 0 0.0073604025
27 O 0 0.0070768096
animals O 0 0.0065634213
. O 0 0.009664095

Its O 0 0.061106443
effect O 0 0.0056013283
was O 0 0.0036702172
determined O 0 0.0021215563
in O 0 0.0016982227
terms O 0 0.0012374864
of O 0 0.0015057693
attenuation O 0 0.0026699542
of O 0 0.0019412051
hearing B-Disease 0 0.95935106
loss I-Disease 0 0.004112184
, O 0 0.0013998703
measured O 0 0.00065581757
by O 0 0.0010352586
shifts O 0 0.0014505859
in O 0 0.0010876199
the O 0 0.0016175383
auditory O 0 0.085123226
brainstem O 0 0.6194307
response O 0 0.005569967
threshold O 0 0.0062892344
. O 0 0.007906109

L B-Chemical 1 0.9637437
- I-Chemical 1 0.07152754
NAME I-Chemical 1 0.9989484
reduced O 0 0.010067864
gentamicin B-Chemical 1 0.9994116
- O 0 0.010510076
induced O 0 0.0024760668
hearing B-Disease 0 0.9319433
loss I-Disease 0 0.002637805
in O 0 0.0007977179
the O 0 0.00075780007
high O 0 0.0011164508
- O 0 0.0013254326
frequency O 0 0.00077254773
range O 0 0.0011601837
, O 0 0.00093508913
but O 0 0.00059102406
gave O 0 0.0006809959
no O 0 0.00056364987
protection O 0 0.0021334896
in O 0 0.0011332083
the O 0 0.0015071521
middle O 0 0.0033342976
or O 0 0.002690543
low O 0 0.0047546765
frequencies O 0 0.007040155
. O 0 0.008667349

Safety O 0 0.033341665
profile O 0 0.005789749
of O 0 0.004520089
a O 0 0.005066597
nicotine B-Chemical 1 0.9993284
lozenge O 0 0.9930099
compared O 0 0.0010511931
with O 0 0.0010318201
that O 0 0.0006935591
of O 0 0.0014256305
nicotine B-Chemical 1 0.9997557
gum O 0 0.97925663
in O 0 0.0010125957
adult O 0 0.0017899387
smokers O 0 0.09882461
with O 0 0.0006782086
underlying O 0 0.0016142844
medical O 0 0.018129904
conditions O 0 0.0010394279
: O 0 0.0011063996
a O 0 0.0008146899
12 O 0 0.0005537094
- O 0 0.0009440383
week O 0 0.000595407
, O 0 0.0011126853
randomized O 0 0.0014109482
, O 0 0.0018870967
open O 0 0.002112271
- O 0 0.004027429
label O 0 0.006870164
study O 0 0.006736625
. O 0 0.007728375

BACKGROUND O 0 0.85541487
: O 0 0.028873447
Nicotine B-Chemical 1 0.99986386
polacrilex O 0 0.9986149
lozenges O 0 0.9897377
deliver O 0 0.0023868459
25 O 0 0.0022137458
% O 0 0.001447888
to O 0 0.00089683116
27 O 0 0.0013062696
% O 0 0.0009986587
more O 0 0.0010117703
nicotine B-Chemical 1 0.9948743
compared O 0 0.00069478864
with O 0 0.0010753558
equivalent O 0 0.0013097217
doses O 0 0.033136144
of O 0 0.0058649965
nicotine B-Chemical 1 0.9998078
polacrilex O 0 0.99918586
gum O 0 0.9914655
. O 0 0.015988227

The O 0 0.008186485
increased O 0 0.0076957126
nicotine B-Chemical 1 0.9969176
exposure O 0 0.0076926467
from O 0 0.0024395313
the O 0 0.0020272185
lozenge O 0 0.96244985
has O 0 0.0011987367
raised O 0 0.0014275855
questions O 0 0.0015553967
about O 0 0.00081425917
the O 0 0.0008996551
relative O 0 0.0009084027
safety O 0 0.0024335366
of O 0 0.0022343008
the O 0 0.0032528888
lozenge O 0 0.98202735
and O 0 0.0098062055
gum O 0 0.97428924
. O 0 0.014693931

OBJECTIVE O 0 0.46701157
: O 0 0.007898131
The O 0 0.0034155743
objective O 0 0.003413598
of O 0 0.0021918642
this O 0 0.001524438
study O 0 0.0014225052
was O 0 0.00086727657
to O 0 0.00058577827
compare O 0 0.00034945743
the O 0 0.0004903869
safety O 0 0.0008697137
profiles O 0 0.000410158
of O 0 0.00059578026
the O 0 0.0005698079
4 O 0 0.0006073962
- O 0 0.0010470982
mg O 0 0.42290083
nicotine B-Chemical 1 0.9995395
lozenge O 0 0.99091303
and O 0 0.0011034649
4 O 0 0.0007587275
- O 0 0.001252583
mg O 0 0.43346098
nicotine B-Chemical 1 0.99926084
gum O 0 0.943959
in O 0 0.0014688204
smokers O 0 0.13144486
with O 0 0.0014959038
selected O 0 0.0017751692
label O 0 0.008421988
- O 0 0.0049344325
restricted O 0 0.0034567646
diseases O 0 0.776666
. O 0 0.010877282

METHODS O 0 0.011139465
: O 0 0.008143051
This O 0 0.0052595274
was O 0 0.0031203406
a O 0 0.0030553434
multicenter O 0 0.013739781
, O 0 0.0021416824
randomized O 0 0.0014886084
, O 0 0.0012912749
open O 0 0.0009537771
- O 0 0.0011469923
label O 0 0.0013135456
study O 0 0.0006545434
in O 0 0.00047807733
adult O 0 0.00096430496
smokers O 0 0.07018243
with O 0 0.00078653044
heart B-Disease 0 0.8264266
disease I-Disease 0 0.9247868
, O 0 0.0054410547
hypertension B-Disease 2 0.9999155
not O 0 0.0007774178
controlled O 0 0.000744782
by O 0 0.0009936753
medication O 0 0.122616775
, O 0 0.0017509316
and O 0 0.001929796
/ O 0 0.0062000905
or O 0 0.00410958
diabetes B-Disease 2 0.9991025
mellitus I-Disease 0 0.99941933
. O 0 0.0136161335

Patients O 0 0.0139444545
were O 0 0.0056827725
randomized O 0 0.0039166184
in O 0 0.0026413726
a O 0 0.0028042316
1 O 0 0.0020069918
: O 0 0.0018532393
1 O 0 0.0010525234
ratio O 0 0.0009337465
to O 0 0.00068275497
receive O 0 0.00064988184
the O 0 0.00071254914
4 O 0 0.0008212406
- O 0 0.0014344382
mg O 0 0.43924263
nicotine B-Chemical 1 0.99944454
lozenge O 0 0.98865056
or O 0 0.0019577942
4 O 0 0.002135844
- O 0 0.004385748
mg O 0 0.7783391
nicotine B-Chemical 1 0.9992623
gum O 0 0.9853108
. O 0 0.0146736605

Safety O 0 0.0378092
assessments O 0 0.0068522026
were O 0 0.0038864159
made O 0 0.0026922042
at O 0 0.0017198216
baseline O 0 0.0017052231
and O 0 0.0014237954
at O 0 0.00093977194
2 O 0 0.0010130145
, O 0 0.0010609728
4 O 0 0.0007075691
, O 0 0.0008293185
6 O 0 0.0005411335
, O 0 0.0007188003
and O 0 0.00065375725
12 O 0 0.0005269934
weeks O 0 0.00051000173
after O 0 0.0006003086
the O 0 0.0011268235
start O 0 0.001579888
of O 0 0.0029536183
product O 0 0.007624878
use O 0 0.0072614783
. O 0 0.008518448

RESULTS O 0 0.025616724
: O 0 0.008598889
Nine O 0 0.006858956
hundred O 0 0.0037016177
one O 0 0.0023591076
patients O 0 0.0029511394
were O 0 0.0015115804
randomized O 0 0.0012974115
to O 0 0.0009288883
treatment O 0 0.0015501522
, O 0 0.0014745088
447 O 0 0.013690257
who O 0 0.0010327918
received O 0 0.00060689164
the O 0 0.0007638547
lozenge O 0 0.9383513
and O 0 0.0012399328
454 O 0 0.0029549745
who O 0 0.0014045883
received O 0 0.0010149581
the O 0 0.0015382131
gum O 0 0.91551167
( O 0 0.0064213905
safety O 0 0.008971547
population O 0 0.009806723
) O 0 0.012213638
. O 0 0.0084811365

The O 0 0.013226854
majority O 0 0.011926839
were O 0 0.01049677
women O 0 0.029390229
( O 0 0.010289384
52 O 0 0.0091476785
. O 0 0.0059091477
7 O 0 0.0072458377
% O 0 0.010754747
) O 0 0.015586399
. O 0 0.014020188

Patients O 0 0.013455193
' O 0 0.0065464675
mean O 0 0.0036342612
age O 0 0.0042628893
was O 0 0.0022469503
53 O 0 0.0027889737
. O 0 0.0010700985
9 O 0 0.00097331835
years O 0 0.0010105987
, O 0 0.0007872656
their O 0 0.00055906293
mean O 0 0.0005140839
weight O 0 0.001969726
was O 0 0.0006588368
193 O 0 0.007118529
. O 0 0.00039631122
9 O 0 0.00048100462
pounds O 0 0.0010642345
, O 0 0.00060276274
and O 0 0.0004813904
they O 0 0.0004624208
smoked O 0 0.011378073
a O 0 0.00061259547
mean O 0 0.0005019514
of O 0 0.00078486267
25 O 0 0.0011187253
. O 0 0.0006587702
2 O 0 0.0009454609
cigarettes O 0 0.034450337
per O 0 0.0011929093
day O 0 0.0019428458
at O 0 0.002668982
baseline O 0 0.0054709297
. O 0 0.0072395364

Five O 0 0.011866028
hundred O 0 0.0070645907
fifty O 0 0.006105957
- O 0 0.004360707
three O 0 0.0018427235
patients O 0 0.0032473537
, O 0 0.0020524238
264 O 0 0.0053903623
taking O 0 0.001419347
the O 0 0.00086784246
lozenge O 0 0.9366536
and O 0 0.0010643267
289 O 0 0.010473395
taking O 0 0.00095508643
the O 0 0.0005905005
gum O 0 0.8733703
, O 0 0.0011527614
used O 0 0.00045245385
the O 0 0.00043860023
study O 0 0.000559469
product O 0 0.0009100786
for O 0 0.00037170458
> O 0 0.0007428943
or O 0 0.00039239848
= O 0 0.000514151
4 O 0 0.00026150353
days O 0 0.00021881357
per O 0 0.00024023229
week O 0 0.00031479367
during O 0 0.0003513247
the O 0 0.00053907686
first O 0 0.0006383534
2 O 0 0.001015943
weeks O 0 0.00100766
( O 0 0.002347056
evaluable O 0 0.010318822
population O 0 0.0063149454
) O 0 0.009542745
. O 0 0.0075801252

The O 0 0.009657721
nicotine B-Chemical 1 0.9977975
lozenge O 0 0.9943809
and O 0 0.008064154
nicotine B-Chemical 1 0.9995426
gum O 0 0.9838118
were O 0 0.0026428564
equally O 0 0.0020134682
well O 0 0.0013313054
tolerated O 0 0.02966572
, O 0 0.0018372026
despite O 0 0.001228412
increased O 0 0.0025929317
nicotine B-Chemical 1 0.9991666
exposure O 0 0.01121564
from O 0 0.004164195
the O 0 0.006130612
lozenge O 0 0.98597115
. O 0 0.010843215

The O 0 0.007272493
incidence O 0 0.009097369
of O 0 0.0045896615
adverse O 0 0.8477814
events O 0 0.057271194
in O 0 0.0016066938
the O 0 0.0012145529
2 O 0 0.00092324347
groups O 0 0.00081835996
was O 0 0.00053455477
similar O 0 0.00034950936
during O 0 0.00031932382
the O 0 0.00037049394
first O 0 0.00032329588
2 O 0 0.00037156855
weeks O 0 0.00024110885
of O 0 0.0004161093
product O 0 0.0010093163
use O 0 0.000582519
( O 0 0.00067445845
evaluation O 0 0.00048937177
population O 0 0.0009462329
: O 0 0.0007236193
55 O 0 0.0005601718
. O 0 0.00027581112
3 O 0 0.00033052682
% O 0 0.00049513485
lozenge O 0 0.863883
, O 0 0.00068672386
54 O 0 0.0008422939
. O 0 0.0002861256
7 O 0 0.00034669854
% O 0 0.00051521853
gum O 0 0.74965984
) O 0 0.0020630134
, O 0 0.0006272449
as O 0 0.00037278657
well O 0 0.00033208905
as O 0 0.00036964897
during O 0 0.00026736912
the O 0 0.0003564867
entire O 0 0.00033817894
study O 0 0.0005807149
( O 0 0.0006737913
safety O 0 0.0009120878
population O 0 0.0010342218
: O 0 0.0008564317
63 O 0 0.0009740745
. O 0 0.00038509723
8 O 0 0.00048091848
% O 0 0.00064508524
and O 0 0.0007376511
58 O 0 0.0013268561
. O 0 0.0008011444
6 O 0 0.0010650225
% O 0 0.0020878173
, O 0 0.0032363802
respectively O 0 0.0057988665
) O 0 0.009102341
. O 0 0.0076726247

Stratification O 0 0.18402728
of O 0 0.0065934686
patients O 0 0.0072331303
by O 0 0.0037011043
sex O 0 0.06449448
, O 0 0.002554059
age O 0 0.0029349867
, O 0 0.0012415934
extent O 0 0.00055176957
of O 0 0.00081089634
concurrent O 0 0.004673735
smoking O 1 0.9837087
, O 0 0.0011216882
extent O 0 0.00037282135
of O 0 0.0006443285
product O 0 0.001584483
use O 0 0.00068087387
, O 0 0.000738317
and O 0 0.000553939
severity O 0 0.016443131
of O 0 0.00084994425
adverse O 0 0.9279992
events O 0 0.025693353
revealed O 0 0.00062658725
no O 0 0.0004998478
clinically O 0 0.0075559597
significant O 0 0.0009955174
differences O 0 0.0007950262
between O 0 0.0010837979
the O 0 0.0026471533
lozenge O 0 0.9759922
and O 0 0.008690783
gum O 0 0.97156143
. O 0 0.01377179

The O 0 0.0072736503
most O 0 0.006168793
common O 0 0.004944332
adverse O 0 0.86064905
events O 0 0.1434911
were O 0 0.004185444
nausea B-Disease 2 0.99999046
( O 0 0.0045507774
17 O 0 0.0017475662
. O 0 0.0006054115
2 O 0 0.0005875833
% O 0 0.0006193857
and O 0 0.0005484073
16 O 0 0.00056435243
. O 0 0.0003712424
1 O 0 0.0004971559
% O 0 0.00063107745
; O 0 0.0008176858
95 O 0 0.0009116347
% O 0 0.00074897235
CI O 0 0.1240483
, O 0 0.0007968259
- O 0 0.0007487654
3 O 0 0.00036577007
. O 0 0.00026306824
7 O 0 0.00028399352
to O 0 0.0002671036
6 O 0 0.00028840234
. O 0 0.00027621925
0 O 0 0.00055015524
) O 0 0.00082191825
, O 0 0.000839563
hiccups B-Disease 2 0.9994179
( O 0 0.0009515446
10 O 0 0.00043626557
. O 0 0.00026574568
7 O 0 0.00030122022
% O 0 0.0003640805
and O 0 0.0003567459
6 O 0 0.00029302706
. O 0 0.00025910465
6 O 0 0.00028756357
% O 0 0.0004928523
; O 0 0.000682986
95 O 0 0.00077936164
% O 0 0.0006367556
CI O 0 0.066206
, O 0 0.00056947104
0 O 0 0.0005046759
. O 0 0.00026297593
5 O 0 0.0002701722
to O 0 0.00027550885
7 O 0 0.0003487266
. O 0 0.00027616025
8 O 0 0.0003866824
) O 0 0.0006921052
, O 0 0.00057842437
and O 0 0.00072538236
headache B-Disease 2 0.9999454
( O 0 0.0011241266
8 O 0 0.0004529592
. O 0 0.00028289988
7 O 0 0.0003300501
% O 0 0.00040940585
and O 0 0.0004157132
9 O 0 0.00045851606
. O 0 0.00032266896
9 O 0 0.00046568716
% O 0 0.00063236675
; O 0 0.0008909506
95 O 0 0.0010682304
% O 0 0.0010841531
Cl O 0 0.9989039
, O 0 0.001422241
- O 0 0.0012822803
5 O 0 0.0006815903
. O 0 0.00065596076
0 O 0 0.0010705369
to O 0 0.0010561143
2 O 0 0.001698238
. O 0 0.0018722275
6 O 0 0.0028864557
) O 0 0.0068548024
. O 0 0.007009767

Serious O 0 0.60666597
adverse O 0 0.85234773
events O 0 0.056277383
were O 0 0.005062109
reported O 0 0.003817028
in O 0 0.0026961956
11 O 0 0.002814459
and O 0 0.002369705
13 O 0 0.0025399558
patients O 0 0.0035749988
in O 0 0.002592811
the O 0 0.003361089
respective O 0 0.004467061
groups O 0 0.009331627
. O 0 0.0099450825

Fewer O 0 0.016509617
than O 0 0.004690049
6 O 0 0.0031245113
% O 0 0.0027996849
of O 0 0.0020260054
patients O 0 0.0027065235
in O 0 0.0011250296
either O 0 0.0010087038
group O 0 0.0010736755
were O 0 0.000727044
considered O 0 0.00053815485
by O 0 0.00064364664
the O 0 0.0005573544
investigator O 0 0.0013210331
to O 0 0.00047315154
have O 0 0.000494693
a O 0 0.00094701647
worsening O 0 0.3120398
of O 0 0.0010552318
their O 0 0.0011873958
overall O 0 0.0016459547
disease O 0 0.6539783
condition O 0 0.0052235094
during O 0 0.002313421
the O 0 0.0040129796
study O 0 0.007511445
. O 0 0.008164404

The O 0 0.007446967
majority O 0 0.0059001315
of O 0 0.0050492
patients O 0 0.008114855
( O 0 0.0045467806
> O 0 0.0031995287
60 O 0 0.0016442226
% O 0 0.0017414147
) O 0 0.0017687104
experienced O 0 0.0014051048
no O 0 0.0009362642
change O 0 0.0013272755
in O 0 0.0014399716
their O 0 0.0023743594
disease O 0 0.554469
status O 0 0.0062444424
from O 0 0.005032937
baseline O 0 0.007901422
. O 0 0.00859084

CONCLUSION O 0 0.6530832
: O 0 0.008683067
The O 0 0.003982289
4 O 0 0.0032075911
- O 0 0.0036367518
mg O 0 0.37085333
nicotine B-Chemical 1 0.9994124
lozenge O 0 0.9946096
and O 0 0.002095163
4 O 0 0.0011829947
- O 0 0.0016195417
mg O 0 0.4264893
nicotine B-Chemical 1 0.99928576
gum O 0 0.92464715
had O 0 0.0007975116
comparable O 0 0.0004510081
safety O 0 0.0010787458
profiles O 0 0.00055654434
in O 0 0.0006347025
these O 0 0.0009923781
patients O 0 0.002591504
with O 0 0.0016137239
label O 0 0.00832986
- O 0 0.0034689545
restricted O 0 0.0021582854
medical O 0 0.015163677
conditions O 0 0.0074073886
. O 0 0.008493109

Pharmacological O 0 0.92346495
modulation O 0 0.011605946
of O 0 0.00919594
pain B-Disease 2 0.99880624
- O 0 0.007658167
related O 0 0.0019861583
brain O 0 0.042792246
activity O 0 0.0019940075
during O 0 0.0011756725
normal O 0 0.0024083904
and O 0 0.0020747683
central O 0 0.004856173
sensitization O 0 0.14120176
states O 0 0.007914126
in O 0 0.0051055504
humans O 0 0.016711975
. O 0 0.009869004

Abnormal O 0 0.020085618
processing O 0 0.005602532
of O 0 0.0043173786
somatosensory O 0 0.30074635
inputs O 0 0.0076067797
in O 0 0.0013441354
the O 0 0.0011442166
central O 0 0.0029704338
nervous O 0 0.9601445
system O 0 0.0028620076
( O 0 0.0014151656
central O 0 0.0020031293
sensitization O 0 0.1606883
) O 0 0.0016883888
is O 0 0.00043920378
the O 0 0.00037924515
mechanism O 0 0.0004763301
accounting O 0 0.000866035
for O 0 0.00036559487
the O 0 0.0005261031
enhanced O 0 0.0009023129
pain B-Disease 2 0.9982496
sensitivity O 0 0.00196982
in O 0 0.00066986063
the O 0 0.0008010043
skin O 0 0.06413321
surrounding O 0 0.0045256726
tissue B-Disease 0 0.65275794
injury I-Disease 0 0.9989189
( O 0 0.03531593
secondary B-Disease 2 0.67658323
hyperalgesia I-Disease 2 0.9999604
) O 0 0.121701814
. O 0 0.010173833

Secondary B-Disease 0 0.47166166
hyperalgesia I-Disease 2 0.9996642
shares O 0 0.016264152
clinical O 0 0.01565532
characteristics O 0 0.0049021505
with O 0 0.005770395
neurogenic B-Disease 0 0.99925214
hyperalgesia I-Disease 2 0.9999676
in O 0 0.0063850284
patients O 0 0.06059416
with O 0 0.027405275
neuropathic B-Disease 2 0.9999722
pain I-Disease 2 0.99979097
. O 0 0.021945838

Abnormal O 0 0.027838651
brain O 0 0.02642238
responses O 0 0.0060548466
to O 0 0.0030518714
somatosensory O 0 0.38109127
stimuli O 0 0.0066533796
have O 0 0.0012974327
been O 0 0.0011111579
found O 0 0.00068123563
in O 0 0.0007458548
patients O 0 0.0026635977
with O 0 0.0014389051
hyperalgesia B-Disease 2 0.99991834
as O 0 0.0011112448
well O 0 0.0007770031
as O 0 0.00084791996
in O 0 0.000844838
normal O 0 0.0016880479
subjects O 0 0.0019560265
during O 0 0.0012620793
experimental O 0 0.0029348216
central O 0 0.010354462
sensitization O 0 0.31606087
. O 0 0.0097052045

The O 0 0.00673784
aim O 0 0.0053444067
of O 0 0.0037801457
this O 0 0.0025165956
study O 0 0.0021767933
was O 0 0.0013051658
to O 0 0.0008430153
assess O 0 0.00046474126
the O 0 0.0006782334
effects O 0 0.0013788469
of O 0 0.0019632762
gabapentin B-Chemical 1 0.9999913
, O 0 0.0017219089
a O 0 0.000965226
drug O 0 0.4145554
effective O 0 0.001077329
in O 0 0.0010545289
neuropathic B-Disease 2 0.9999943
pain I-Disease 2 0.9999465
patients O 0 0.03861195
, O 0 0.0010494132
on O 0 0.00039401327
brain O 0 0.02220156
processing O 0 0.00065958005
of O 0 0.0009984161
nociceptive O 0 0.8278447
information O 0 0.0012691444
in O 0 0.0010996107
normal O 0 0.002417465
and O 0 0.0023713368
central O 0 0.006848741
sensitization O 0 0.21368934
states O 0 0.016769899
. O 0 0.009099992

Using O 0 0.009237135
functional O 0 0.0068669445
magnetic O 0 0.06481895
resonance O 0 0.25827166
imaging O 0 0.016510243
( O 0 0.0041458337
fMRI O 0 0.025336266
) O 0 0.0018471263
in O 0 0.00080151326
normal O 0 0.0011874104
volunteers O 0 0.0021319857
, O 0 0.0007736123
we O 0 0.0003471725
studied O 0 0.00057147414
the O 0 0.0008142219
gabapentin B-Chemical 1 0.9999889
- O 0 0.0029094848
induced O 0 0.0006697751
modulation O 0 0.0010705864
of O 0 0.0008581504
brain O 0 0.11496258
activity O 0 0.00076247595
in O 0 0.0004382914
response O 0 0.00072000804
to O 0 0.0005467224
nociceptive O 0 0.835721
mechanical O 0 0.050972052
stimulation O 0 0.0016008606
of O 0 0.0011026327
normal O 0 0.0029142946
skin O 0 0.18126282
and O 0 0.0078037623
capsaicin B-Chemical 1 0.9999285
- O 0 0.035302773
induced O 0 0.00741896
secondary B-Disease 2 0.76883996
hyperalgesia I-Disease 2 0.9999428
. O 0 0.017011203

The O 0 0.007730719
dose O 0 0.011305244
of O 0 0.0066834805
gabapentin B-Chemical 1 0.99990904
was O 0 0.0038405145
1 O 0 0.0024208364
, O 0 0.0021003888
800 O 0 0.0028783756
mg O 0 0.038226567
per O 0 0.0012816332
os O 0 0.07481038
, O 0 0.0029355183
in O 0 0.002326291
a O 0 0.0040185335
single O 0 0.005137983
administration O 0 0.14845107
. O 0 0.009930688

We O 0 0.00802538
found O 0 0.004653091
that O 0 0.0036467682
( O 0 0.0044451756
i O 0 0.008295077
) O 0 0.0056596827
gabapentin B-Chemical 1 0.99994195
reduced O 0 0.0014676207
the O 0 0.00092105445
activations O 0 0.015679456
in O 0 0.00053734245
the O 0 0.0005585159
bilateral O 0 0.04320817
operculoinsular O 0 0.046644144
cortex O 0 0.15161651
, O 0 0.00059864105
independently O 0 0.00031131253
of O 0 0.00039361237
the O 0 0.00034930123
presence O 0 0.0003481655
of O 0 0.0006242974
central O 0 0.0045693424
sensitization O 0 0.41805813
; O 0 0.005872294
( O 0 0.0011207147
ii O 0 0.0025514439
) O 0 0.0034595875
gabapentin B-Chemical 1 0.99997306
reduced O 0 0.00054455415
the O 0 0.00044219635
activation O 0 0.00083675457
in O 0 0.00036292238
the O 0 0.0004621007
brainstem O 0 0.5626759
, O 0 0.00060645735
only O 0 0.00031673722
during O 0 0.00027159706
central O 0 0.0015294215
sensitization O 0 0.2565535
; O 0 0.0041230693
( O 0 0.0011116555
iii O 0 0.004970627
) O 0 0.0045624655
gabapentin B-Chemical 1 0.9999814
suppressed O 0 0.00084906275
stimulus O 0 0.012754995
- O 0 0.0020716863
induced O 0 0.0007011751
deactivations O 0 0.13181446
, O 0 0.00054786797
only O 0 0.00031804532
during O 0 0.0002824536
central O 0 0.0013025563
sensitization O 0 0.11852517
; O 0 0.0012578538
this O 0 0.00043899656
effect O 0 0.00051381404
was O 0 0.00055613817
more O 0 0.00066187687
robust O 0 0.00065791723
than O 0 0.0006648891
the O 0 0.0010845736
effect O 0 0.0015807293
on O 0 0.0019741536
brain O 0 0.18285105
activation O 0 0.013390178
. O 0 0.008576626

The O 0 0.007980275
observed O 0 0.0051532094
drug O 0 0.49229667
- O 0 0.0068102465
induced O 0 0.0029623809
effects O 0 0.0035106272
were O 0 0.0018359892
not O 0 0.0013543139
due O 0 0.0011233371
to O 0 0.0012966704
changes O 0 0.0018713074
in O 0 0.0017300014
the O 0 0.0023568715
baseline O 0 0.00412717
fMRI O 0 0.034303617
signal O 0 0.006878312
. O 0 0.008524496

These O 0 0.008647868
findings O 0 0.0070398254
indicate O 0 0.0033137735
that O 0 0.0027845227
gabapentin B-Chemical 1 0.9999292
has O 0 0.0017083179
a O 0 0.001831315
measurable O 0 0.0023737024
antinociceptive O 0 0.9990308
effect O 0 0.0011524255
and O 0 0.0009533991
a O 0 0.0010238532
stronger O 0 0.0009727835
antihyperalgesic O 0 0.99938333
effect O 0 0.0007236396
most O 0 0.00081770605
evident O 0 0.00044731138
in O 0 0.0003679259
the O 0 0.0004372156
brain O 0 0.034492124
areas O 0 0.0012257601
undergoing O 0 0.00063956255
deactivation O 0 0.007817931
, O 0 0.00056022627
thus O 0 0.00044653896
supporting O 0 0.0003338556
the O 0 0.00035768532
concept O 0 0.0006843944
that O 0 0.0005039818
gabapentin B-Chemical 1 0.9999789
is O 0 0.00061510067
more O 0 0.00063237135
effective O 0 0.0007082144
in O 0 0.00062334526
modulating O 0 0.0011260954
nociceptive O 0 0.9029164
transmission O 0 0.0038220861
when O 0 0.0011253919
central O 0 0.004759618
sensitization O 0 0.13018432
is O 0 0.004021945
present O 0 0.004602952
. O 0 0.008110411

Investigation O 0 0.021465406
of O 0 0.009482635
mitochondrial O 0 0.16002302
involvement O 0 0.007700535
in O 0 0.0031404826
the O 0 0.002659135
experimental O 0 0.0029543343
model O 0 0.0037110276
of O 0 0.00777328
epilepsy B-Disease 2 0.9998939
induced O 0 0.019290587
by O 0 0.046092838
pilocarpine B-Chemical 1 0.99991083
. O 0 0.015737776

Mitochondrial B-Disease 0 0.977985
abnormalities I-Disease 0 0.5304909
have O 0 0.004012985
been O 0 0.0028540716
associated O 0 0.0020522263
with O 0 0.0014180162
several O 0 0.0011350374
aspects O 0 0.0009882344
of O 0 0.0018644938
epileptogenesis O 0 0.9991726
, O 0 0.0014581784
such O 0 0.00059509726
as O 0 0.00064925716
energy O 0 0.0062986435
generation O 0 0.0010643713
, O 0 0.00084088894
control O 0 0.00051727
of O 0 0.00094456103
cell O 0 0.10157291
death B-Disease 2 0.99968064
, O 0 0.0071184016
neurotransmitter O 0 0.9931457
synthesis O 0 0.072557904
, O 0 0.0016973134
and O 0 0.0013689707
free O 0 0.0026236163
radical O 0 0.87548184
( O 0 0.011651577
FR O 0 0.7424911
) O 0 0.009471767
production O 0 0.009303036
. O 0 0.009214288

Increased O 0 0.012666853
production O 0 0.008003218
of O 0 0.006295484
FRs O 0 0.4685364
may O 0 0.0031545446
cause O 0 0.016469263
mtDNA O 0 0.14395678
damage O 0 0.7414411
leading O 0 0.0035483926
to O 0 0.0011163832
decreased O 0 0.0017618687
activities O 0 0.0018768464
of O 0 0.0018567205
oxidative O 0 0.9831691
phosphorylation O 0 0.10477652
complexes O 0 0.0043096514
containing O 0 0.0024515337
mtDNA O 0 0.121268556
- O 0 0.00585722
encoded O 0 0.0041081985
subunits O 0 0.013253024
. O 0 0.0088106

In O 0 0.007331831
this O 0 0.005033429
study O 0 0.004073433
, O 0 0.0028474971
we O 0 0.0012329886
investigated O 0 0.0010024145
whether O 0 0.0006470777
increased O 0 0.001130904
generation O 0 0.0012568502
of O 0 0.0014606814
FR O 0 0.6990659
during O 0 0.000637741
status B-Disease 0 0.0054887934
epilepticus I-Disease 0 0.9999783
would O 0 0.00059747347
be O 0 0.00052386435
sufficient O 0 0.0002863671
to O 0 0.00042003932
provoke O 0 0.022976855
abnormalities O 0 0.17548874
in O 0 0.0005775677
mtDNA O 0 0.017950904
and O 0 0.0005147051
in O 0 0.0003585966
the O 0 0.00038476993
expression O 0 0.0005666475
and O 0 0.0005617465
activity O 0 0.00067697995
of O 0 0.0011799526
cytochrome O 0 0.9984616
c O 0 0.2626786
oxidase O 0 0.9986528
( O 0 0.005506072
CCO O 0 0.9590616
) O 0 0.001310222
, O 0 0.0005676789
complex O 0 0.0004452434
IV O 0 0.05972864
of O 0 0.00047972208
the O 0 0.0004946695
respiratory O 0 0.48519874
chain O 0 0.013556281
, O 0 0.0010379773
in O 0 0.00050952064
the O 0 0.0006732912
chronic O 0 0.79430544
phase O 0 0.0020555016
of O 0 0.0013768065
the O 0 0.0018880005
pilocarpine B-Chemical 1 0.99996066
model O 0 0.003106556
of O 0 0.0049411166
temporal B-Disease 2 0.5695941
lobe I-Disease 2 0.97484994
epilepsy I-Disease 2 0.99987733
. O 0 0.012572583

DNA O 0 0.03235066
analysis O 0 0.0069069057
revealed O 0 0.0040583625
low O 0 0.003137953
amounts O 0 0.0019459124
of O 0 0.0019692257
a O 0 0.0019999156
4 O 0 0.0011157953
. O 0 0.00070246187
8 O 0 0.0007269204
kb O 0 0.002119718
mtDNA O 0 0.0052809403
deletion O 0 0.0009225818
but O 0 0.0005172754
with O 0 0.00045572512
no O 0 0.00034264376
differences O 0 0.00034666448
in O 0 0.00046665722
frequency O 0 0.00070355524
or O 0 0.00067358196
quantity O 0 0.0007347251
in O 0 0.00091057085
the O 0 0.0011939859
control O 0 0.0016356986
and O 0 0.0026966212
experimental O 0 0.00425327
groups O 0 0.008016444
. O 0 0.008284606

We O 0 0.00808261
did O 0 0.0050898674
not O 0 0.0034456155
find O 0 0.0024908753
abnormalities O 0 0.028002897
in O 0 0.0014430878
the O 0 0.0011185101
expression O 0 0.0011366344
and O 0 0.00086274254
distribution O 0 0.0005393727
of O 0 0.00089001935
an O 0 0.0016753991
mtDNA O 0 0.07672919
- O 0 0.0014876164
encoded O 0 0.00050939195
subunit O 0 0.0015663833
of O 0 0.0012435651
CCO O 0 0.9814361
( O 0 0.00255921
CCO O 0 0.9648778
- O 0 0.0018853615
I O 0 0.0106671
) O 0 0.00087956426
or O 0 0.00038796104
a O 0 0.0005220648
relative O 0 0.0003372729
decrease O 0 0.00049113494
in O 0 0.00060069805
CCO O 0 0.9563847
- O 0 0.0013688756
I O 0 0.002630819
when O 0 0.00031444157
compared O 0 0.00031529198
with O 0 0.0006528784
nuclear O 0 0.009610869
- O 0 0.001751305
encoded O 0 0.00076463405
subunits O 0 0.0047469293
( O 0 0.0032715858
CCO O 0 0.9495035
- O 0 0.0036665155
IV O 0 0.34573773
and O 0 0.004140487
SDH O 0 0.99897015
- O 0 0.014129433
fp O 0 0.43525544
) O 0 0.012936435
. O 0 0.008754909

No O 0 0.021726873
abnormality O 0 0.039998602
in O 0 0.0117509505
CCO O 0 0.65520376
activity O 0 0.009680907
was O 0 0.007919582
observed O 0 0.0067842687
through O 0 0.009924755
histochemistry O 0 0.06900962
. O 0 0.01667944

Although O 0 0.0070332554
evidences O 0 0.00738188
of O 0 0.006018839
mitochondrial B-Disease 0 0.85655177
abnormalities I-Disease 0 0.7377756
were O 0 0.0018129338
found O 0 0.00093095977
in O 0 0.0008250609
previously O 0 0.0007854095
published O 0 0.00067357044
studies O 0 0.00071119244
, O 0 0.00065931515
our O 0 0.0003574409
results O 0 0.00042214274
do O 0 0.00034804837
not O 0 0.00034372674
suggest O 0 0.00025659607
that O 0 0.000342031
the O 0 0.00054760533
FRs O 0 0.42518675
, O 0 0.0006398911
generated O 0 0.00030206432
during O 0 0.00028981912
the O 0 0.00048113946
acute O 0 0.8909908
phase O 0 0.0026716094
, O 0 0.00081065536
determined O 0 0.00034165313
important O 0 0.00044221993
abnormalities O 0 0.08218401
in O 0 0.00069715193
mtDNA O 0 0.031745303
, O 0 0.0009266738
in O 0 0.00056223274
expression O 0 0.00096328807
of O 0 0.0017007297
CCO O 0 0.97420305
- O 0 0.003863896
I O 0 0.017391285
, O 0 0.0024428521
and O 0 0.0026014945
in O 0 0.0035400235
CCO O 0 0.8644466
activity O 0 0.007639155
. O 0 0.008485395

Adverse O 0 0.31515324
effect O 0 0.006797654
of O 0 0.0059309956
the O 0 0.00554656
calcium B-Chemical 1 0.9992299
channel O 0 0.8878803
blocker O 0 0.9993561
nitrendipine B-Chemical 1 0.9999951
on O 0 0.0050537027
nephrosclerosis B-Disease 0 0.9999927
in O 0 0.004800802
rats O 0 0.031143932
with O 0 0.0123641575
renovascular B-Disease 0 0.999959
hypertension I-Disease 2 0.99995446
. O 0 0.019643605

The O 0 0.0068049817
effect O 0 0.004313772
of O 0 0.0036649795
a O 0 0.0034187573
6 O 0 0.0018376958
- O 0 0.001982016
week O 0 0.00084129773
treatment O 0 0.0011548025
with O 0 0.000987408
the O 0 0.0012866454
calcium B-Chemical 1 0.99969435
channel O 0 0.84681046
blocker O 0 0.9993813
nitrendipine B-Chemical 1 0.9999987
or O 0 0.0018527285
the O 0 0.001906583
angiotensin B-Chemical 1 0.99997663
converting O 0 0.63532245
enzyme O 0 0.5177098
inhibitor O 0 0.42359096
enalapril B-Chemical 1 0.99999344
on O 0 0.00040939142
blood O 0 0.03109492
pressure O 0 0.19247898
, O 0 0.0022397563
albuminuria B-Disease 2 0.9999559
, O 0 0.0018057912
renal O 0 0.9873344
hemodynamics O 0 0.97751015
, O 0 0.00095524394
and O 0 0.0005019883
morphology O 0 0.0010505359
of O 0 0.00055012014
the O 0 0.0005698441
nonclipped O 0 0.5289214
kidney O 0 0.8332478
was O 0 0.0006795553
studied O 0 0.0006433446
in O 0 0.00059551623
rats O 0 0.0015890124
with O 0 0.00086942036
two O 0 0.0010409738
- O 0 0.0031485315
kidney O 0 0.7944504
, O 0 0.0031135087
one O 0 0.0023509837
clip O 0 0.14149733
renovascular B-Disease 0 0.9999404
hypertension I-Disease 2 0.9999455
. O 0 0.01591677

Six O 0 0.008835036
weeks O 0 0.0039003391
after O 0 0.0024098367
clipping O 0 0.004500804
of O 0 0.002071359
one O 0 0.0015970332
renal O 0 0.9595442
artery O 0 0.6362594
, O 0 0.0038244196
hypertensive B-Disease 2 0.99935955
rats O 0 0.009870694
( O 0 0.0016070387
178 O 0 0.017816633
+ O 0 0.00090090325
/ O 0 0.0021098517
- O 0 0.00093618245
4 O 0 0.00044323955
mm O 0 0.0014808689
Hg O 0 0.742645
) O 0 0.0006682675
were O 0 0.0003054453
randomly O 0 0.00019704708
assigned O 0 0.00021859942
to O 0 0.0002556318
three O 0 0.00024475335
groups O 0 0.0005499093
: O 0 0.00067935284
untreated O 0 0.0007618302
hypertensive B-Disease 2 0.9986841
controls O 0 0.0016653182
( O 0 0.00070274447
n O 0 0.00051200454
= O 0 0.0006282808
8 O 0 0.00043199933
) O 0 0.0008835172
, O 0 0.001002437
enalapril B-Chemical 1 0.9999856
- O 0 0.0014791974
treated O 0 0.0006930318
( O 0 0.00075381604
n O 0 0.0006021524
= O 0 0.00075555645
8 O 0 0.00053821824
) O 0 0.0009762206
, O 0 0.000901866
or O 0 0.0011603002
nitrendipine B-Chemical 1 0.9999933
- O 0 0.0037894805
treated O 0 0.0019017814
( O 0 0.0024122715
n O 0 0.002335868
= O 0 0.0034906035
10 O 0 0.003546355
) O 0 0.007126839
. O 0 0.00686542

Sham O 0 0.5635388
- O 0 0.01112557
operated O 0 0.008013092
rats O 0 0.005719596
served O 0 0.003823219
as O 0 0.0026636284
normotensive O 0 0.9712271
controls O 0 0.0043816394
( O 0 0.002586969
128 O 0 0.0051780515
+ O 0 0.0016545147
/ O 0 0.002969523
- O 0 0.0018178559
3 O 0 0.0011264742
mm O 0 0.0031664846
Hg O 0 0.5826159
, O 0 0.002154763
n O 0 0.0024107376
= O 0 0.003643208
8 O 0 0.0037696376
) O 0 0.0074603045
. O 0 0.0074925604

After O 0 0.00566739
6 O 0 0.0037408967
weeks O 0 0.0023080881
of O 0 0.0023902387
treatment O 0 0.002985966
, O 0 0.0027799308
renal O 0 0.9800152
hemodynamics O 0 0.9851865
( O 0 0.0029962112
glomerular O 0 0.79764926
filtration O 0 0.012333289
rate O 0 0.00088964583
and O 0 0.0011456393
renal O 0 0.9770636
plasma O 0 0.069788344
flow O 0 0.015473211
) O 0 0.002159019
were O 0 0.0011121915
measured O 0 0.001008344
in O 0 0.0016018432
the O 0 0.0025438634
anesthetized O 0 0.016043216
rats O 0 0.011154002
. O 0 0.008577493

Renal O 0 0.621462
tissue O 0 0.02247673
was O 0 0.0073926286
obtained O 0 0.0055439253
for O 0 0.0042432956
determination O 0 0.0063429954
of O 0 0.006474424
glomerular O 0 0.89434355
size O 0 0.01328291
and O 0 0.014721993
sclerosis O 0 0.9943922
. O 0 0.016414275

Enalapril B-Chemical 0 0.9995827
but O 0 0.019880215
not O 0 0.016792448
nitrendipine B-Chemical 1 0.9998698
reduced O 0 0.01594624
blood O 0 0.09565843
pressure O 0 0.26145247
significantly O 0 0.019925095
. O 0 0.018046511

After O 0 0.0062415306
6 O 0 0.0042207297
weeks O 0 0.0026951802
of O 0 0.0028886332
therapy O 0 0.006667975
, O 0 0.0030336874
glomerular O 0 0.61634505
filtration O 0 0.010708058
rate O 0 0.0016694091
was O 0 0.0015029522
not O 0 0.0014226122
different O 0 0.0016499447
among O 0 0.0027701159
the O 0 0.003178745
studied O 0 0.00529678
groups O 0 0.009554796
. O 0 0.009740211

Renal O 0 0.7274854
plasma O 0 0.03432495
flow O 0 0.01473838
increased O 0 0.005778413
, O 0 0.0047116852
but O 0 0.00323501
albumin O 0 0.9911801
excretion O 0 0.97791857
and O 0 0.0061897044
glomerulosclerosis B-Disease 2 0.9999368
did O 0 0.0027742179
not O 0 0.0022104534
change O 0 0.0027320995
after O 0 0.0028228138
enalapril B-Chemical 1 0.999931
treatment O 0 0.025550522
. O 0 0.0106793

In O 0 0.0077925986
contrast O 0 0.0058893147
, O 0 0.004912424
in O 0 0.0028690621
the O 0 0.0035667329
nitrendipine B-Chemical 1 0.9999908
- O 0 0.009900358
treated O 0 0.0018684105
group O 0 0.0025960759
albuminuria B-Disease 2 0.9999311
increased O 0 0.0014163966
from O 0 0.0006860612
12 O 0 0.00043738275
. O 0 0.0003425105
8 O 0 0.00044107356
+ O 0 0.00055908045
/ O 0 0.0014109972
- O 0 0.0007400417
2 O 0 0.00037354178
progressively O 0 0.0005879183
to O 0 0.0003946953
163 O 0 0.012441283
+ O 0 0.00068309664
/ O 0 0.0016056241
- O 0 0.0006890308
55 O 0 0.0004335984
compared O 0 0.00023211446
with O 0 0.0004124612
19 O 0 0.0007842735
. O 0 0.00035061
2 O 0 0.00050651113
+ O 0 0.000658791
/ O 0 0.0015519009
- O 0 0.0009794077
9 O 0 0.00067550445
mg O 0 0.06720368
/ O 0 0.0016296671
24 O 0 0.00076726166
hr O 0 0.0012223241
in O 0 0.00142107
the O 0 0.0027942967
hypertensive B-Disease 2 0.99833363
controls O 0 0.015085007
. O 0 0.008484721

Furthermore O 0 0.011033329
, O 0 0.010528371
glomerulosclerosis B-Disease 2 0.9995442
index O 0 0.008520584
was O 0 0.0024651987
significantly O 0 0.0020961552
increased O 0 0.0017062097
in O 0 0.0011353381
the O 0 0.001851201
nitrendipine B-Chemical 1 0.99999714
- O 0 0.005138012
treated O 0 0.0008309381
group O 0 0.0006732367
compared O 0 0.0003067041
with O 0 0.00049493805
the O 0 0.0006038877
hypertensive B-Disease 2 0.9990501
controls O 0 0.002654723
( O 0 0.0009482381
0 O 0 0.00063695316
. O 0 0.0003075589
38 O 0 0.0006906277
+ O 0 0.0005738173
/ O 0 0.0013782574
- O 0 0.0008042315
0 O 0 0.0005653037
. O 0 0.00032141016
1 O 0 0.0004194751
versus O 0 0.00043135407
0 O 0 0.0007235183
. O 0 0.0005127733
13 O 0 0.0009739854
+ O 0 0.0012373904
/ O 0 0.002999174
- O 0 0.0026371188
0 O 0 0.0026794889
. O 0 0.0025776091
04 O 0 0.07199364
) O 0 0.008045995
. O 0 0.0073915925

In O 0 0.0073253545
addition O 0 0.0043462263
, O 0 0.0049947333
glomerular O 0 0.5382903
size O 0 0.0034293446
was O 0 0.0016493151
higher O 0 0.0011525726
in O 0 0.0010778254
the O 0 0.0017199516
nitrendipine B-Chemical 1 0.9999963
- O 0 0.0051718564
treated O 0 0.0010303593
group O 0 0.0011088353
( O 0 0.0010039816
14 O 0 0.0005710484
. O 0 0.00032810096
9 O 0 0.0004647107
+ O 0 0.00053739984
/ O 0 0.0013152655
- O 0 0.0007556727
0 O 0 0.00051454036
. O 0 0.00027639128
17 O 0 0.00048891816
10 O 0 0.00039414552
( O 0 0.0006292408
- O 0 0.00066799787
3 O 0 0.000387008
) O 0 0.0006712845
mm2 O 0 0.0014232505
) O 0 0.00078003696
but O 0 0.00035738468
lower O 0 0.00036791895
in O 0 0.0003825797
the O 0 0.000691021
enalapril B-Chemical 1 0.9999932
- O 0 0.0021719176
treated O 0 0.000668602
group O 0 0.00084767153
( O 0 0.00085524074
11 O 0 0.0005724124
. O 0 0.00028275617
5 O 0 0.00034160653
+ O 0 0.00048509016
/ O 0 0.0012067558
- O 0 0.00069492566
0 O 0 0.00047137428
. O 0 0.00024844127
15 O 0 0.00027728284
10 O 0 0.00035485066
( O 0 0.0005789418
- O 0 0.0006260363
3 O 0 0.00036644455
) O 0 0.0006206982
mm2 O 0 0.0011853414
) O 0 0.000610858
compared O 0 0.0002160874
with O 0 0.00036407533
the O 0 0.00048057063
hypertensive B-Disease 2 0.9986212
controls O 0 0.0020173425
( O 0 0.0007922303
12 O 0 0.0003202296
. O 0 0.00028610596
1 O 0 0.00044005722
+ O 0 0.00052657566
/ O 0 0.0012799175
- O 0 0.00077498885
0 O 0 0.00055242045
. O 0 0.00031967106
17 O 0 0.00058027153
10 O 0 0.0004949251
( O 0 0.00081430934
- O 0 0.0009232426
3 O 0 0.00063468737
) O 0 0.0012154139
mm2 O 0 0.002514925
) O 0 0.0020357117
. O 0 0.0011707603
( O 0 0.0024978681
ABSTRACT O 0 0.008182645
TRUNCATED O 0 0.01303823
AT O 0 0.03846817
250 O 0 0.010452678
WORDS O 0 0.02190514
) O 0 0.03027361

Ketoconazole B-Chemical 0 0.9995401
induced O 0 0.020071533
torsades B-Disease 0 0.99978334
de I-Disease 0 0.50451916
pointes I-Disease 0 0.99995506
without O 0 0.006559061
concomitant O 0 0.010761384
use O 0 0.0041105757
of O 0 0.0058386903
QT O 0 0.9983809
interval O 0 0.0070724795
- O 0 0.00827021
prolonging O 0 0.023443792
drug O 0 0.79927284
. O 0 0.011982492

Ketoconazole B-Chemical 0 0.9994461
is O 0 0.007900101
not O 0 0.004380656
known O 0 0.0036835575
to O 0 0.0024246464
be O 0 0.0023231667
proarrhythmic O 0 0.9836145
without O 0 0.0018607076
concomitant O 0 0.004460466
use O 0 0.0022719132
of O 0 0.0037797326
QT O 0 0.9986241
interval O 0 0.0052806977
- O 0 0.0068936846
prolonging O 0 0.02428422
drugs O 0 0.89441466
. O 0 0.01069173

We O 0 0.008193119
report O 0 0.007594508
a O 0 0.004835537
woman O 0 0.009588604
with O 0 0.00269746
coronary B-Disease 0 0.59945834
artery I-Disease 0 0.39914528
disease I-Disease 0 0.7032209
who O 0 0.0031957668
developed O 0 0.0014568701
a O 0 0.001330095
markedly O 0 0.007148452
prolonged B-Disease 0 0.10452308
QT I-Disease 0 0.99881124
interval I-Disease 0 0.002644052
and O 0 0.0014284484
torsades B-Disease 0 0.9999726
de I-Disease 0 0.40306437
pointes I-Disease 0 0.9999968
( O 0 0.102644384
TdP B-Disease 2 0.99998176
) O 0 0.002938726
after O 0 0.0006371047
taking O 0 0.0031259065
ketoconazole B-Chemical 1 0.9999598
for O 0 0.0015953341
treatment O 0 0.0036562853
of O 0 0.0048828907
fungal B-Disease 0 0.87915266
infection I-Disease 2 0.9819848
. O 0 0.014144393

Her O 0 0.034211263
QT O 0 0.9524249
interval O 0 0.010243925
returned O 0 0.006769658
to O 0 0.005397625
normal O 0 0.0071602287
upon O 0 0.005830428
withdrawal O 0 0.8333346
of O 0 0.029642235
ketoconazole B-Chemical 1 0.99990666
. O 0 0.021971678

Genetic O 0 0.033344336
study O 0 0.008031087
did O 0 0.0046898797
not O 0 0.0032767057
find O 0 0.0024218434
any O 0 0.0022616412
mutation O 0 0.004618359
in O 0 0.0019219432
her O 0 0.0028586076
genes O 0 0.002605266
that O 0 0.0018143187
encode O 0 0.0027743883
cardiac O 0 0.87263775
IKr O 0 0.998648
channel O 0 0.31766492
proteins O 0 0.01594906
. O 0 0.010505113

We O 0 0.0077487584
postulate O 0 0.007012924
that O 0 0.0034961377
by O 0 0.0032153258
virtue O 0 0.0056472295
of O 0 0.0023384977
its O 0 0.002543781
direct O 0 0.0014787912
blocking O 0 0.0039909626
action O 0 0.010956668
on O 0 0.0010820146
IKr O 0 0.9994242
, O 0 0.0057584886
ketoconazole B-Chemical 1 0.9999819
alone O 0 0.0022431351
may O 0 0.0015191067
prolong O 0 0.004370486
QT O 0 0.9980268
interval O 0 0.0036376647
and O 0 0.0043638465
induce O 0 0.0061239745
TdP B-Disease 2 0.9998412
. O 0 0.011493799

This O 0 0.010607075
calls O 0 0.0070753703
for O 0 0.003417448
attention O 0 0.004414309
when O 0 0.0023182628
ketoconazole B-Chemical 1 0.99995244
is O 0 0.0022330564
administered O 0 0.0020672411
to O 0 0.0011477608
patients O 0 0.0029943557
with O 0 0.001648702
risk O 0 0.066621296
factors O 0 0.00840648
for O 0 0.0021100845
acquired O 0 0.013561211
long B-Disease 0 0.010880384
QT I-Disease 0 0.9990238
syndrome I-Disease 0 0.98967767
. O 0 0.013028599

Cerebral B-Disease 0 0.9696805
vasculitis I-Disease 2 0.9995209
following O 0 0.009258674
oral O 0 0.8942299
methylphenidate B-Chemical 1 0.99994123
intake O 0 0.89885235
in O 0 0.0034544833
an O 0 0.0043333783
adult O 0 0.0053496812
: O 0 0.0055108834
a O 0 0.0054689115
case O 0 0.0065913675
report O 0 0.018339079
. O 0 0.011564945

Methylphenidate B-Chemical 0 0.9986419
is O 0 0.016016819
structurally O 0 0.016951172
and O 0 0.011008062
functionally O 0 0.010014716
similar O 0 0.008483547
to O 0 0.014176415
amphetamine B-Chemical 1 0.99980515
. O 0 0.022692986

Cerebral B-Disease 0 0.97949654
vasculitis I-Disease 2 0.99973303
associated O 0 0.012091871
with O 0 0.008948732
amphetamine B-Disease 1 0.9999938
abuse I-Disease 0 0.9998989
is O 0 0.0024758663
well O 0 0.0011537349
documented O 0 0.0019926415
, O 0 0.0012431478
and O 0 0.00083261286
in O 0 0.00071651227
rare O 0 0.017034935
cases O 0 0.026748294
ischaemic B-Disease 0 0.99999404
stroke I-Disease 2 0.99996734
has O 0 0.001489035
been O 0 0.0014298706
reported O 0 0.0016423527
after O 0 0.0014094864
methylphenidate B-Chemical 1 0.999931
intake O 0 0.7633233
in O 0 0.005117462
children O 0 0.02037803
. O 0 0.00890703

We O 0 0.007979203
report O 0 0.006967084
the O 0 0.0035536352
case O 0 0.002632535
of O 0 0.0023157606
a O 0 0.002487029
63 O 0 0.0036030158
- O 0 0.0020377433
year O 0 0.0010784761
- O 0 0.0012588607
old O 0 0.00087853573
female O 0 0.0021372274
who O 0 0.0013991824
was O 0 0.00069437857
treated O 0 0.00094176177
with O 0 0.0012800022
methylphenidate B-Chemical 1 0.9999616
due O 0 0.00092031143
to O 0 0.0014938554
hyperactivity B-Disease 2 0.99987936
and O 0 0.003063529
suffered O 0 0.46204916
from O 0 0.003468585
multiple O 0 0.07179457
ischaemic B-Disease 0 0.99996996
strokes I-Disease 2 0.9997733
. O 0 0.015190646

We O 0 0.0073466054
consider O 0 0.0041896855
drug O 0 0.4509648
- O 0 0.006446536
induced O 0 0.0033986615
cerebral B-Disease 0 0.9954047
vasculitis I-Disease 2 0.9999714
as O 0 0.0020349624
the O 0 0.0009574831
most O 0 0.0010492007
likely O 0 0.00064668385
cause O 0 0.0022182874
of O 0 0.0015707713
recurrent O 0 0.9840566
ischaemic B-Disease 0 0.999997
strokes I-Disease 2 0.9999503
in O 0 0.0008465923
the O 0 0.0005641378
absence O 0 0.00035532494
of O 0 0.0007098164
any O 0 0.00072060176
pathological O 0 0.1537049
findings O 0 0.0026643125
during O 0 0.0010387113
the O 0 0.0016914374
diagnostic O 0 0.0041379905
work O 0 0.004538856
- O 0 0.006479196
up O 0 0.005632505
. O 0 0.0078082974

We O 0 0.007470335
conclude O 0 0.004761997
that O 0 0.004133187
methylphenidate B-Chemical 1 0.99986494
mediated O 0 0.0049730027
vasculitis B-Disease 2 0.9998411
should O 0 0.0013054007
be O 0 0.0011842733
considered O 0 0.00076710305
in O 0 0.0007925226
patients O 0 0.0025316998
with O 0 0.0016092507
neurological O 0 0.9995303
symptoms O 0 0.98972917
and O 0 0.0024027205
a O 0 0.0028574157
history O 0 0.06434373
of O 0 0.009761284
methylphenidate B-Chemical 1 0.99993634
therapy O 0 0.20034793
. O 0 0.009913113

This O 0 0.010104752
potential O 0 0.006896329
side O 0 0.12131506
- O 0 0.0057193195
effect O 0 0.0023412516
, O 0 0.002254422
though O 0 0.0012336535
very O 0 0.0013482447
rare O 0 0.010217471
, O 0 0.0013391216
represents O 0 0.00070811727
one O 0 0.00056531176
more O 0 0.00069371914
reason O 0 0.0006305022
to O 0 0.0006695189
be O 0 0.00084871246
very O 0 0.0010442382
restrictive O 0 0.0017008
in O 0 0.0012317603
the O 0 0.0017392938
use O 0 0.0030382324
of O 0 0.007835186
methylphenidate B-Chemical 1 0.9998752
. O 0 0.010339989

MDMA B-Chemical 1 0.99989736
polydrug O 0 0.9997242
users O 0 0.045229178
show O 0 0.002905725
process O 0 0.0030335954
- O 0 0.0028708347
specific O 0 0.0013334551
central O 0 0.0040296484
executive O 0 0.479285
impairments O 0 0.3398538
coupled O 0 0.0019148946
with O 0 0.0018767947
impaired B-Disease 0 0.0031314758
social I-Disease 0 0.11593115
and I-Disease 0 0.004133426
emotional I-Disease 0 0.5701412
judgement I-Disease 0 0.064427115
processes I-Disease 0 0.015416986
. O 0 0.009887149

In O 0 0.008367256
recent O 0 0.0062813363
years O 0 0.0057712733
working O 0 0.0062436843
memory B-Disease 0 0.68595207
deficits I-Disease 0 0.84965587
have O 0 0.001652243
been O 0 0.0014449826
reported O 0 0.00128039
in O 0 0.00093046675
users O 0 0.008865023
of O 0 0.0027300254
MDMA B-Chemical 1 0.9999969
( O 0 0.0030958992
3 B-Chemical 0 0.0011706465
, I-Chemical 0 0.0015038233
4 I-Chemical 0 0.001425148
- I-Chemical 0 0.003944816
methylenedioxymethamphetamine I-Chemical 0 0.9998814
, O 0 0.014340064
ecstasy B-Chemical 1 0.9998317
) O 0 0.020739622
. O 0 0.008932724

The O 0 0.0070856917
current O 0 0.0062932232
study O 0 0.0037336089
aimed O 0 0.002347077
to O 0 0.0014686813
assess O 0 0.0007681133
the O 0 0.0009426371
impact O 0 0.000792589
of O 0 0.0018146711
MDMA B-Chemical 1 0.9999958
use O 0 0.0008352772
on O 0 0.00033885473
three O 0 0.00029996847
separate O 0 0.00038027405
central O 0 0.0013426015
executive O 0 0.22213425
processes O 0 0.0015834642
( O 0 0.00080942654
set O 0 0.00037973572
shifting O 0 0.00090595736
, O 0 0.0007222473
inhibition O 0 0.0011552691
and O 0 0.00070470845
memory O 0 0.09810924
updating O 0 0.0015707181
) O 0 0.0010797334
and O 0 0.0005876611
also O 0 0.0005984395
on O 0 0.00053350563
" O 0 0.0015713904
prefrontal O 0 0.20309879
" O 0 0.0015170181
mediated O 0 0.0013711778
social O 0 0.057882514
and O 0 0.0034327868
emotional O 0 0.49040198
judgement O 0 0.05335726
processes O 0 0.014302227
. O 0 0.00945971

Fifteen O 0 0.018447919
polydrug O 0 0.99940133
ecstasy B-Chemical 1 0.9998154
users O 0 0.04489146
and O 0 0.0027669086
15 O 0 0.0016835683
polydrug O 0 0.99976856
non O 0 0.009023811
- O 0 0.004106336
ecstasy B-Chemical 1 0.9998925
user O 0 0.0012311501
controls O 0 0.0010205947
completed O 0 0.00047825463
a O 0 0.00053184334
general O 0 0.00045659434
drug O 0 0.12650768
use O 0 0.00062116986
questionnaire O 0 0.0008041384
, O 0 0.00065149163
the O 0 0.0005224611
Brixton O 0 0.26525807
Spatial O 0 0.013080968
Anticipation O 0 0.2616393
task O 0 0.00081064994
( O 0 0.0006638728
set O 0 0.00038822187
shifting O 0 0.0010525705
) O 0 0.0014985707
, O 0 0.0010459631
Backward O 0 0.15419535
Digit O 0 0.9866261
Span O 0 0.951175
procedure O 0 0.00067483523
( O 0 0.0009396176
memory O 0 0.052851852
updating O 0 0.0016908362
) O 0 0.001570795
, O 0 0.0008590839
Inhibition O 0 0.00218308
of O 0 0.0008769404
Return O 0 0.24162626
( O 0 0.001134297
inhibition O 0 0.0023448453
) O 0 0.0014594169
, O 0 0.0007325225
an O 0 0.0008045657
emotional O 0 0.24308355
intelligence O 0 0.18957327
scale O 0 0.0020763425
, O 0 0.0010755551
the O 0 0.0009054702
Tromso O 0 0.108703785
Social O 0 0.09128693
Intelligence O 0 0.11794099
Scale O 0 0.923078
and O 0 0.0016945532
the O 0 0.0022911613
Dysexecutive O 0 0.9569719
Questionnaire O 0 0.11566044
( O 0 0.0077194762
DEX O 0 0.99785894
) O 0 0.01681583
. O 0 0.008943136

Compared O 0 0.008942662
with O 0 0.008989077
MDMA B-Chemical 1 0.9999659
- O 0 0.009270375
free O 0 0.0043596798
polydrug O 0 0.99988294
controls O 0 0.01673799
, O 0 0.0059575434
MDMA B-Chemical 1 0.9999963
polydrug O 0 0.999969
users O 0 0.0313388
showed O 0 0.0007124432
impairments O 0 0.1266838
in O 0 0.00050006126
set O 0 0.000464549
shifting O 0 0.0009395732
and O 0 0.0008366733
memory O 0 0.08735025
updating O 0 0.0017069369
, O 0 0.0010795265
and O 0 0.00092724926
also O 0 0.0010575117
in O 0 0.0013524544
social O 0 0.06455174
and O 0 0.003403015
emotional O 0 0.5109618
judgement O 0 0.05531693
processes O 0 0.014380976
. O 0 0.00936641

The O 0 0.009411046
latter O 0 0.009860768
two O 0 0.005437965
deficits O 0 0.10549913
remained O 0 0.0036635937
significant O 0 0.00288047
after O 0 0.0019232479
controlling O 0 0.0028771206
for O 0 0.0027478626
other O 0 0.0047615543
drug O 0 0.6854332
use O 0 0.0109057985
. O 0 0.011084427

These O 0 0.009446556
data O 0 0.0068846606
lend O 0 0.0058591524
further O 0 0.002970815
support O 0 0.0020809427
to O 0 0.0015070589
the O 0 0.0013393275
proposal O 0 0.002668657
that O 0 0.0010785876
cognitive O 0 0.72431487
processes O 0 0.0028390542
mediated O 0 0.0010546091
by O 0 0.0012678498
the O 0 0.0013546511
prefrontal O 0 0.6024732
cortex O 0 0.10094737
may O 0 0.0011424321
be O 0 0.0014750732
impaired O 0 0.0022218197
by O 0 0.003078481
recreational O 0 0.8233311
ecstasy B-Chemical 1 0.99984133
use O 0 0.009660854
. O 0 0.009173779

Phase O 0 0.024704572
II O 0 0.020175386
study O 0 0.0055047614
of O 0 0.0043307203
the O 0 0.0044679395
amsacrine B-Chemical 0 0.99985015
analogue O 0 0.88583636
CI B-Chemical 0 0.93830186
- I-Chemical 0 0.009239275
921 I-Chemical 0 0.46569934
( O 0 0.0035638835
NSC B-Chemical 0 0.99441
343499 I-Chemical 0 0.80173457
) O 0 0.0027250592
in O 0 0.0013675451
non B-Disease 2 0.0037817082
- I-Disease 2 0.0037794742
small I-Disease 2 0.0034703754
cell I-Disease 2 0.07332284
lung I-Disease 2 0.9939824
cancer I-Disease 2 0.9996111
. O 0 0.018673487

CI B-Chemical 0 0.6883146
- I-Chemical 0 0.018128382
921 I-Chemical 0 0.26703104
( O 0 0.009113797
NSC B-Chemical 0 0.98920643
343499 I-Chemical 0 0.83509576
; O 0 0.0048446073
9 B-Chemical 0 0.0022014629
- I-Chemical 0 0.0025678251
[ I-Chemical 0 0.0030110574
[ I-Chemical 0 0.0027085617
2 I-Chemical 0 0.0011801196
- I-Chemical 0 0.002267581
methoxy I-Chemical 0 0.9954293
- I-Chemical 0 0.0030302932
4 I-Chemical 0 0.0008484845
- I-Chemical 0 0.0016239764
[ I-Chemical 0 0.0029367092
( I-Chemical 0 0.0017284726
methylsulphonyl I-Chemical 0 0.958692
) I-Chemical 0 0.0055873496
amino I-Chemical 0 0.8977633
] I-Chemical 0 0.020082409
phenyl I-Chemical 0 0.9987558
] I-Chemical 0 0.020917824
amino I-Chemical 0 0.92015827
] I-Chemical 0 0.013940805
- I-Chemical 0 0.003496982
N I-Chemical 0 0.9648971
, I-Chemical 0 0.0011167953
5 I-Chemical 0 0.0006508643
- I-Chemical 0 0.0016598111
dimethyl I-Chemical 0 0.997529
- I-Chemical 0 0.003029904
4 I-Chemical 0 0.00073102873
- I-Chemical 0 0.0012165965
acridinecarboxamide I-Chemical 0 0.051787265
) O 0 0.0014917785
is O 0 0.00073122734
a O 0 0.0014181201
topoisomerase O 0 0.82746387
II O 0 0.18106355
poison O 0 0.23486468
with O 0 0.0020741709
high O 0 0.0029463782
experimental O 0 0.0048284843
antitumour O 0 0.9765658
activity O 0 0.012240572
. O 0 0.00945828

It O 0 0.009380286
was O 0 0.0049389666
administered O 0 0.003657318
by O 0 0.0024887896
15 O 0 0.0014840502
min O 0 0.0013049111
infusion O 0 0.002107332
to O 0 0.00071567594
16 O 0 0.00067315006
evaluable O 0 0.0018081777
patients O 0 0.0011385797
with O 0 0.0006017872
non B-Disease 2 0.0020932278
- I-Disease 2 0.0012783031
small I-Disease 2 0.0007472884
cell I-Disease 2 0.02406429
lung I-Disease 2 0.9918066
cancer I-Disease 2 0.99995697
( O 0 0.048992638
NSCLC B-Disease 2 0.9998673
) O 0 0.007165014
( O 0 0.00083099026
7 O 0 0.00032587882
with O 0 0.0002646173
no O 0 0.00021921475
prior O 0 0.00024488664
treatment O 0 0.00068855943
, O 0 0.00062409154
9 O 0 0.00039973404
patients O 0 0.0007345438
in O 0 0.00037992132
relapse O 0 0.8990229
following O 0 0.0005285212
surgery O 0 0.0031140654
/ O 0 0.0033889038
radiotherapy O 0 0.6017941
) O 0 0.0011631658
at O 0 0.00028861774
a O 0 0.0005215416
dose O 0 0.005270008
( O 0 0.0009417716
648 O 0 0.038311113
mg O 0 0.12881668
/ O 0 0.0010904975
m2 O 0 0.002246234
divided O 0 0.00026664743
over O 0 0.00023215917
3 O 0 0.00031431028
days O 0 0.00028654796
, O 0 0.0004585428
repeated O 0 0.00038785863
every O 0 0.0003417238
3 O 0 0.0005686336
weeks O 0 0.00061804004
) O 0 0.0015217108
determined O 0 0.001177551
by O 0 0.0024709182
phase O 0 0.005053552
I O 0 0.033816654
trial O 0 0.008818287
. O 0 0.008075005

Patients O 0 0.013519373
had O 0 0.0056385016
a O 0 0.0046939035
median O 0 0.0030895453
performance O 0 0.003207872
status O 0 0.0028437588
of O 0 0.0025342286
1 O 0 0.0024570862
( O 0 0.0028460864
WHO O 0 0.0068997364
) O 0 0.0027275258
, O 0 0.0018799638
and O 0 0.001689084
median O 0 0.0018301795
age O 0 0.0039894613
of O 0 0.0040512644
61 O 0 0.009016657
years O 0 0.008920459
. O 0 0.008590727

The O 0 0.0086140325
histology O 0 0.06657128
comprised O 0 0.007907756
squamous B-Disease 0 0.99962723
carcinoma I-Disease 2 0.9999232
( O 0 0.01203137
11 O 0 0.0031197253
) O 0 0.0028854785
, O 0 0.00202082
adenocarcinoma B-Disease 0 0.99945885
( O 0 0.0026199636
1 O 0 0.001042989
) O 0 0.001208559
, O 0 0.00074352353
mixed O 0 0.0013200608
histology O 0 0.38446552
( O 0 0.001498707
2 O 0 0.0007594013
) O 0 0.0012053754
, O 0 0.0008822994
bronchio B-Disease 0 0.020045582
- I-Disease 0 0.0018163355
alveolar I-Disease 0 0.11155018
carcinoma I-Disease 2 0.99992347
( O 0 0.004012566
1 O 0 0.0011484924
) O 0 0.0013530395
and O 0 0.0009887316
large O 0 0.0015268851
cell O 0 0.033414643
undifferentiated B-Disease 0 0.9760927
carcinoma I-Disease 2 0.9999492
( O 0 0.02941051
1 O 0 0.0065638074
) O 0 0.009742708
. O 0 0.00787939

Neutropenia B-Disease 0 0.99799794
grade O 0 0.3126955
greater O 0 0.004081174
than O 0 0.0020465986
or O 0 0.0016276862
equal O 0 0.0011941117
to O 0 0.0009801666
3 O 0 0.00082175963
was O 0 0.0006475818
seen O 0 0.000534353
in O 0 0.00053456036
15 O 0 0.00051771937
patients O 0 0.0014263387
, O 0 0.0010189597
infections B-Disease 2 0.5979638
with O 0 0.0009380445
recovery O 0 0.0018630488
in O 0 0.0007723542
3 O 0 0.0008874218
, O 0 0.0011678432
and O 0 0.0013803723
grand O 0 0.21313024
mal O 0 0.999458
seizures B-Disease 2 0.9999715
in O 0 0.0044423905
1 O 0 0.005439672
patient O 0 0.007873844
. O 0 0.00817765

Grade O 0 0.45738065
less O 0 0.0057399236
than O 0 0.0029444413
or O 0 0.0023335568
equal O 0 0.0017178432
to O 0 0.0015369174
2 O 0 0.0020051072
nausea B-Disease 2 0.9999851
and O 0 0.003643078
vomiting B-Disease 2 0.99995434
occurred O 0 0.0014525529
in O 0 0.00080723973
66 O 0 0.0014246703
% O 0 0.00083496096
courses O 0 0.001050784
and O 0 0.0011507389
phlebitis B-Disease 0 0.9996166
in O 0 0.0012072243
the O 0 0.001341365
infusion O 0 0.0075539905
arm O 0 0.0032198634
in O 0 0.0026770935
37 O 0 0.005168947
% O 0 0.0067889807
. O 0 0.0074051274

1 O 0 0.012154789
patient O 0 0.010320439
with O 0 0.008342995
squamous B-Disease 0 0.9985398
cell I-Disease 0 0.25190115
carcinoma I-Disease 2 0.9996861
achieved O 0 0.005286943
a O 0 0.0042391126
partial O 0 0.0041844375
response O 0 0.004700328
lasting O 0 0.006828451
5 O 0 0.0050732023
months O 0 0.0057931757
. O 0 0.008667092

Further O 0 0.009680351
testing O 0 0.0060316096
in O 0 0.0042065703
this O 0 0.0033452192
and O 0 0.0031781825
other O 0 0.002890801
tumour B-Disease 0 0.89212304
types O 0 0.00276443
using O 0 0.0021727954
multiple O 0 0.0037516442
daily O 0 0.004684567
schedules O 0 0.00549421
is O 0 0.0044979746
warranted O 0 0.005776088
. O 0 0.0087203365

Pharmacokinetics O 0 0.9244082
of O 0 0.031319976
desipramine B-Chemical 1 0.9999666
HCl I-Chemical 0 0.9996414
when O 0 0.008069439
administered O 0 0.014191452
with O 0 0.020540494
cinacalcet B-Chemical 1 0.99994457
HCl I-Chemical 0 0.9997155
. O 0 0.021697614

OBJECTIVE O 0 0.5659963
: O 0 0.00981293
In O 0 0.004376968
vitro O 0 0.0041357432
work O 0 0.0031072134
has O 0 0.001732288
demonstrated O 0 0.001466293
that O 0 0.001603518
cinacalcet B-Chemical 1 0.99993896
is O 0 0.0016081126
a O 0 0.0016914101
strong O 0 0.0017858988
inhibitor O 0 0.11319212
of O 0 0.008930912
cytochrome O 0 0.9996171
P450 O 0 0.99991286
isoenzyme O 0 0.99943584
( O 0 0.09724006
CYP O 0 0.9999342
) O 0 0.15256481
2D6 O 0 0.9997404
. O 0 0.01162674

The O 0 0.0066392943
purpose O 0 0.0049407906
of O 0 0.0037048194
this O 0 0.0025122643
study O 0 0.0021948782
was O 0 0.0013428063
to O 0 0.00088381016
evaluate O 0 0.00053810613
the O 0 0.00075376173
effect O 0 0.00082189165
of O 0 0.0018813119
cinacalcet B-Chemical 1 0.9999776
on O 0 0.0009332191
CYP2D6 O 0 0.9998461
activity O 0 0.0015722563
, O 0 0.001300969
using O 0 0.0009363011
desipramine B-Chemical 1 0.99998486
as O 0 0.0010105699
a O 0 0.0013142426
probe O 0 0.001250469
substrate O 0 0.0037695083
, O 0 0.0027012725
in O 0 0.002417773
healthy O 0 0.018740248
subjects O 0 0.0095134415
. O 0 0.007850022

METHODS O 0 0.0110733975
: O 0 0.007789804
Seventeen O 0 0.008294266
subjects O 0 0.0040182695
who O 0 0.0032299338
were O 0 0.0018035072
genotyped O 0 0.0022552267
as O 0 0.0015073832
CYP2D6 O 0 0.9991062
extensive O 0 0.0014250597
metabolizers O 0 0.98548746
were O 0 0.0005979685
enrolled O 0 0.000718762
in O 0 0.00038896056
this O 0 0.0004155809
randomized O 0 0.000622625
, O 0 0.0006218869
open O 0 0.0005253812
- O 0 0.00081122445
label O 0 0.0013279035
, O 0 0.00057715556
crossover O 0 0.0023501338
study O 0 0.00044614327
to O 0 0.00029108822
receive O 0 0.0002922843
a O 0 0.0004348626
single O 0 0.00040729484
oral O 0 0.16574946
dose O 0 0.016602354
of O 0 0.0024107837
desipramine B-Chemical 1 0.9999976
( O 0 0.0018160803
50 O 0 0.00088467414
mg O 0 0.17556936
) O 0 0.00060334563
on O 0 0.0001983536
two O 0 0.00023519168
separate O 0 0.0002827071
occasions O 0 0.00086355634
, O 0 0.00048590326
once O 0 0.0003120789
alone O 0 0.00037169925
and O 0 0.00042192749
once O 0 0.0003397653
after O 0 0.00024584416
multiple O 0 0.00086431653
doses O 0 0.014243367
of O 0 0.0021394957
cinacalcet B-Chemical 1 0.99997365
( O 0 0.002345117
90 O 0 0.0011178874
mg O 0 0.06567497
for O 0 0.0013111314
7 O 0 0.0021373823
days O 0 0.002709019
) O 0 0.0074509606
. O 0 0.0071231583

Blood O 0 0.03839187
samples O 0 0.010467826
were O 0 0.0074374033
obtained O 0 0.0063084103
predose O 0 0.09480343
and O 0 0.0055954624
up O 0 0.004730028
to O 0 0.0046674926
72 O 0 0.005781285
h O 0 0.006311864
postdose O 0 0.023048352
. O 0 0.010434988

RESULTS O 0 0.045760788
: O 0 0.020458328
Fourteen O 0 0.020903934
subjects O 0 0.014002658
completed O 0 0.01064384
both O 0 0.010483964
treatment O 0 0.016391534
arms O 0 0.03363447
. O 0 0.019695241

Relative O 0 0.010138888
to O 0 0.0069772187
desipramine B-Chemical 1 0.9999162
alone O 0 0.004810202
, O 0 0.0027074788
mean O 0 0.0014565686
AUC O 0 0.051405165
and O 0 0.0020876643
C O 0 0.9640806
( O 0 0.0031408214
max O 0 0.041682746
) O 0 0.0017367335
of O 0 0.0013227426
desipramine B-Chemical 1 0.9999933
increased O 0 0.0013073675
3 O 0 0.00066054467
. O 0 0.00040284218
6 O 0 0.00043704058
- O 0 0.00074390986
and O 0 0.00061172846
1 O 0 0.00071028003
. O 0 0.0005384514
8 O 0 0.00078804017
- O 0 0.001257552
fold O 0 0.0016980949
when O 0 0.0015131437
coadministered O 0 0.8166116
with O 0 0.009547705
cinacalcet B-Chemical 1 0.99987435
. O 0 0.011157474

The O 0 0.008981387
t O 0 0.013464126
( O 0 0.0063687917
1 O 0 0.0035358237
/ O 0 0.004123152
2 O 0 0.0019346541
, O 0 0.0019269208
z O 0 0.0143467365
) O 0 0.0019141629
of O 0 0.0015807579
desipramine B-Chemical 1 0.99999106
was O 0 0.0008654044
longer O 0 0.00040947497
when O 0 0.00057079096
desipramine B-Chemical 1 0.9999927
was O 0 0.0009595045
coadministered O 0 0.7710598
with O 0 0.0016590378
cinacalcet B-Chemical 1 0.999977
( O 0 0.0018876627
21 O 0 0.0009881327
. O 0 0.0005436248
0 O 0 0.00087445014
versus O 0 0.0008667962
43 O 0 0.0020038397
. O 0 0.0014090696
3 O 0 0.0024603838
hs O 0 0.027059434
) O 0 0.0090598175
. O 0 0.0077180876

The O 0 0.014476765
t O 0 0.020876573
( O 0 0.013340548
max O 0 0.023078071
) O 0 0.009904837
was O 0 0.005857764
similar O 0 0.004644389
between O 0 0.0050708293
the O 0 0.008339765
regimens O 0 0.042145327
. O 0 0.015032126

Fewer O 0 0.017645158
subjects O 0 0.007504356
reported O 0 0.0044580386
adverse O 0 0.7784837
events O 0 0.053197395
following O 0 0.0018566736
treatment O 0 0.0028719285
with O 0 0.002427341
desipramine B-Chemical 1 0.99999416
alone O 0 0.0013665959
than O 0 0.00045657303
when O 0 0.00041054827
receiving O 0 0.0049006087
desipramine B-Chemical 1 0.9999964
with O 0 0.0028182098
cinacalcet B-Chemical 1 0.99998724
( O 0 0.0014459091
33 O 0 0.0007385028
versus O 0 0.0003585294
86 O 0 0.000809984
% O 0 0.0005457872
) O 0 0.0006995515
, O 0 0.00043090488
the O 0 0.00029774322
most O 0 0.00046902837
frequent O 0 0.0010793519
of O 0 0.00066644285
which O 0 0.001367786
( O 0 0.0056600585
nausea B-Disease 2 0.99999666
and O 0 0.005562712
headache B-Disease 2 0.99998033
) O 0 0.003416256
have O 0 0.000588166
been O 0 0.0006834375
reported O 0 0.00074602326
for O 0 0.00058573816
patients O 0 0.0023419266
treated O 0 0.0016116197
with O 0 0.0020863772
either O 0 0.006177625
desipramine B-Chemical 1 0.9999851
or O 0 0.02049468
cinacalcet B-Chemical 1 0.9998988
. O 0 0.011701155

CONCLUSION O 0 0.7213227
: O 0 0.012305565
This O 0 0.0075270343
study O 0 0.0049819956
demonstrates O 0 0.0033769605
that O 0 0.0038772046
cinacalcet B-Chemical 1 0.9998084
is O 0 0.00434491
a O 0 0.0048675397
strong O 0 0.005742305
inhibitor O 0 0.21738563
of O 0 0.023457654
CYP2D6 O 0 0.99944323
. O 0 0.013375809

These O 0 0.008418532
data O 0 0.0057185385
suggest O 0 0.0026492167
that O 0 0.0020579295
during O 0 0.0014905041
concomitant O 0 0.003938255
treatment O 0 0.0034239383
with O 0 0.0029523836
cinacalcet B-Chemical 1 0.9999826
, O 0 0.0026164413
dose O 0 0.015523173
adjustment O 0 0.001098029
may O 0 0.00046631345
be O 0 0.0004465922
necessary O 0 0.0002733482
for O 0 0.00035203982
drugs O 0 0.15431239
that O 0 0.00042133423
demonstrate O 0 0.0003984238
a O 0 0.0010141437
narrow O 0 0.0016768626
therapeutic O 0 0.008931372
index O 0 0.0024198142
and O 0 0.0024905682
are O 0 0.003569573
metabolized O 0 0.8588178
by O 0 0.008591186
CYP2D6 O 0 0.99925166
. O 0 0.009292854

Case O 0 0.0716469
report O 0 0.032081068
: O 0 0.027296536
acute O 0 0.9708161
unintentional O 0 0.9945009
carbachol B-Chemical 1 0.99967134
intoxication O 0 0.9994438
. O 0 0.037418105

INTRODUCTION O 0 0.08496919
: O 0 0.015965654
Intoxications O 0 0.87672275
with O 0 0.009912626
carbachol B-Chemical 1 0.9994948
, O 0 0.008988194
a O 0 0.0077097584
muscarinic O 0 0.9986865
cholinergic O 0 0.99673045
receptor O 0 0.70716786
agonist O 0 0.9683346
are O 0 0.010497934
rare O 0 0.09960788
. O 0 0.012458936

We O 0 0.011539718
report O 0 0.010792098
an O 0 0.0073189004
interesting O 0 0.0041855536
case O 0 0.004407076
investigating O 0 0.0040839813
a O 0 0.0065600583
( O 0 0.007744961
near O 0 0.0074173235
) O 0 0.019975994
fatal O 0 0.9971288
poisoning B-Disease 2 0.999597
. O 0 0.02053687

METHODS O 0 0.011484458
: O 0 0.007917219
The O 0 0.004028263
son O 0 0.006128985
of O 0 0.0028287554
an O 0 0.002820812
84 O 0 0.0031099957
- O 0 0.0022142553
year O 0 0.0012352136
- O 0 0.0014066803
old O 0 0.0009894958
male O 0 0.0023311246
discovered O 0 0.001033018
a O 0 0.0011554181
newspaper O 0 0.0016333961
report O 0 0.001977676
stating O 0 0.002091161
clinical O 0 0.004652084
success O 0 0.0026482085
with O 0 0.0015017069
plant O 0 0.03870544
extracts O 0 0.023484312
in O 0 0.00400754
Alzheimer B-Disease 0 0.9998766
' I-Disease 0 0.008339717
s I-Disease 0 0.0071561933
disease I-Disease 0 0.75457937
. O 0 0.010666384

The O 0 0.0075623095
mode O 0 0.0061042756
of O 0 0.0045134374
action O 0 0.0077817845
was O 0 0.0024538015
said O 0 0.0027418348
to O 0 0.0012221669
be O 0 0.0010098336
comparable O 0 0.0005970454
to O 0 0.0006305378
that O 0 0.00055569364
of O 0 0.0008459367
the O 0 0.0008671994
synthetic O 0 0.0025575734
compound O 0 0.24042384
' O 0 0.0032006192
carbamylcholin B-Chemical 0 0.5319668
' O 0 0.0030445692
; O 0 0.0029511238
that O 0 0.0018000072
is O 0 0.0033490546
, O 0 0.008568001
carbachol B-Chemical 1 0.9990079
. O 0 0.010716522

He O 0 0.018657912
bought O 0 0.020579489
25 O 0 0.00595143
g O 0 0.005380864
of O 0 0.004062714
carbachol B-Chemical 1 0.9992399
as O 0 0.0025061115
pure O 0 0.013717467
substance O 0 0.9741269
in O 0 0.0013616384
a O 0 0.0018581834
pharmacy O 0 0.039845854
, O 0 0.0013021451
and O 0 0.0009941378
the O 0 0.000997399
father O 0 0.005472533
was O 0 0.0013431744
administered O 0 0.0023313554
400 O 0 0.0040633106
to O 0 0.0025198539
500 O 0 0.009798965
mg O 0 0.394663
. O 0 0.008188251

Carbachol B-Chemical 0 0.99938416
concentrations O 0 0.015205469
in O 0 0.0043968908
serum O 0 0.052876916
and O 0 0.0028463656
urine O 0 0.07893067
on O 0 0.0010046193
day O 0 0.0009953148
1 O 0 0.0009696018
and O 0 0.0008935694
2 O 0 0.00080295047
of O 0 0.00091567315
hospital O 0 0.0024755935
admission O 0 0.005100312
were O 0 0.001429642
analysed O 0 0.0018989615
by O 0 0.0034448549
HPLC O 0 0.83598286
- O 0 0.0068752314
mass O 0 0.013546381
spectrometry O 0 0.06278626
. O 0 0.01026008

RESULTS O 0 0.029641833
: O 0 0.010597687
Minutes O 0 0.20689578
after O 0 0.0028725949
oral O 0 0.122181684
administration O 0 0.07963705
, O 0 0.0024825826
the O 0 0.001371176
patient O 0 0.002320867
developed O 0 0.0054836464
nausea B-Disease 2 0.99999356
, O 0 0.022482064
sweating O 0 0.999747
and O 0 0.010183096
hypotension B-Disease 2 0.9999442
, O 0 0.006681176
and O 0 0.004795349
finally O 0 0.010857437
collapsed O 0 0.01817071
. O 0 0.009107478

Bradycardia B-Disease 2 0.99612564
, O 0 0.031281188
cholinergic O 0 0.9674791
symptoms O 0 0.92374605
and O 0 0.027466701
asystole B-Disease 2 0.9980579
occurred O 0 0.024364913
. O 0 0.021471929

Initial O 0 0.011802387
cardiopulmonary O 0 0.010240175
resuscitation O 0 0.009088527
and O 0 0.0037804872
immediate O 0 0.0046208883
treatment O 0 0.0039805244
with O 0 0.0041666715
adrenaline B-Chemical 1 0.9999579
( O 0 0.03816822
epinephrine B-Chemical 1 0.99984753
) O 0 0.019556785
, O 0 0.0061677704
atropine B-Chemical 1 0.99991953
and O 0 0.00892871
furosemide B-Chemical 1 0.99992204
was O 0 0.0062930207
successful O 0 0.008283956
. O 0 0.008897866

On O 0 0.01002371
hospital O 0 0.00970459
admission O 0 0.012034641
, O 0 0.004149837
blood O 0 0.006354068
pressure O 0 0.011890929
of O 0 0.002062339
the O 0 0.0016997332
intubated O 0 0.007678959
, O 0 0.0024860764
bradyarrhythmic O 0 0.46652764
patient O 0 0.0030577425
was O 0 0.0024186315
100 O 0 0.0044796555
/ O 0 0.0061378563
65 O 0 0.005717525
mmHg O 0 0.0146289375
. O 0 0.0076975473

Further O 0 0.010166404
signs O 0 0.12021642
were O 0 0.0070444336
hyperhidrosis B-Disease 0 0.99952257
, O 0 0.021680638
hypersalivation B-Disease 0 0.99995136
, O 0 0.0097224135
bronchorrhoea B-Disease 0 0.905414
, O 0 0.0025402904
and O 0 0.0018334707
severe O 0 0.636786
miosis B-Disease 0 0.99997544
; O 0 0.004331971
the O 0 0.0012626613
electrocardiographic O 0 0.88407123
finding O 0 0.002322913
was O 0 0.0021682107
atrio B-Disease 0 0.10704058
- I-Disease 0 0.007639678
ventricular I-Disease 0 0.97879285
dissociation I-Disease 0 0.04338721
. O 0 0.009599556

High O 0 0.028997334
doses O 0 0.02748416
of O 0 0.009020906
atropine B-Chemical 1 0.99990165
( O 0 0.005383955
up O 0 0.0016743123
to O 0 0.0011811717
50 O 0 0.0014242815
mg O 0 0.036940392
per O 0 0.0006853512
24 O 0 0.00075953815
hours O 0 0.0008002159
) O 0 0.0021122242
, O 0 0.0025820876
adrenaline B-Chemical 1 0.99978274
and O 0 0.0054835216
dopamine B-Chemical 1 0.99931073
were O 0 0.0047731833
necessary O 0 0.004188522
. O 0 0.0075653032

The O 0 0.019318435
patient O 0 0.01943469
was O 0 0.015231875
extubated O 0 0.017915145
1 O 0 0.014306853
week O 0 0.012968073
later O 0 0.016005326
. O 0 0.020535583

However O 0 0.01925416
, O 0 0.01738956
increased O 0 0.016087659
dyspnoea B-Disease 0 0.99744225
and O 0 0.023075318
bronchospasm B-Disease 0 0.99957377
necessitated O 0 0.097737685
reintubation O 0 0.88055766
. O 0 0.021195006

Respiratory B-Disease 0 0.9721514
insufficiency I-Disease 0 0.99600935
was O 0 0.008498644
further O 0 0.0066203387
worsened O 0 0.39618933
by O 0 0.007393133
Proteus B-Disease 0 0.9908681
mirabilis I-Disease 0 0.3670118
infection I-Disease 2 0.8850492
and O 0 0.015571012
severe O 0 0.90900666
bronchoconstriction O 0 0.9995371
. O 0 0.019638177

One O 0 0.010476404
week O 0 0.0048406157
later O 0 0.003518548
, O 0 0.003238776
the O 0 0.0020089727
patient O 0 0.0021858094
was O 0 0.0013785693
again O 0 0.0012339966
extubated O 0 0.0016081325
and O 0 0.0010667371
3 O 0 0.0008850451
days O 0 0.0007632828
later O 0 0.0009450769
was O 0 0.0012822717
transferred O 0 0.0017313482
to O 0 0.002095439
a O 0 0.0041806255
peripheral O 0 0.058035985
ward O 0 0.009310884
. O 0 0.009314776

On O 0 0.009879132
the O 0 0.005753407
next O 0 0.0035295966
day O 0 0.003452757
he O 0 0.003972721
died O 0 0.0080350265
, O 0 0.0034713356
probably O 0 0.003298062
as O 0 0.0025776643
a O 0 0.0034193113
result O 0 0.003238037
of O 0 0.0057557966
heart B-Disease 0 0.89563566
failure I-Disease 0 0.8994617
. O 0 0.012685304

Serum O 0 0.16524714
samples O 0 0.0062808776
from O 0 0.0037208917
the O 0 0.0024396158
first O 0 0.0015927607
and O 0 0.0015159653
second O 0 0.0011103557
days O 0 0.0007735268
contained O 0 0.0006645189
3 O 0 0.00076394354
. O 0 0.0005599436
6 O 0 0.000539791
and O 0 0.00073534885
1 O 0 0.00084917084
. O 0 0.0006845232
9 O 0 0.0010751945
mg O 0 0.09922872
/ O 0 0.0042767827
l O 0 0.0072140894
carbachol B-Chemical 1 0.9993648
, O 0 0.009141263
respectively O 0 0.011294026
. O 0 0.008527237

The O 0 0.011129016
corresponding O 0 0.008104015
urine O 0 0.07193283
concentrations O 0 0.009353129
amounted O 0 0.009459098
to O 0 0.005193392
374 O 0 0.02622467
and O 0 0.0059405817
554 O 0 0.04211096
mg O 0 0.41863814
/ O 0 0.015345833
l O 0 0.015771093
. O 0 0.012405357

CONCLUSION O 0 0.7101287
: O 0 0.00899969
This O 0 0.0050226413
case O 0 0.0028342488
started O 0 0.0022309038
with O 0 0.0016752077
a O 0 0.0018316949
media O 0 0.0036808513
report O 0 0.0027175464
in O 0 0.0008707394
a O 0 0.0011975699
popular O 0 0.0027750388
newspaper O 0 0.0021684335
, O 0 0.0009554097
initiated O 0 0.00064859854
by O 0 0.0006851308
published O 0 0.0006392874
, O 0 0.0009935417
peer O 0 0.043575414
- O 0 0.0012456402
reviewed O 0 0.00093249424
research O 0 0.0006478686
on O 0 0.00037740252
herbals O 0 0.8867581
, O 0 0.0010258816
and O 0 0.0006237552
involved O 0 0.00048158268
human O 0 0.00091216643
failure O 0 0.32302943
in O 0 0.000650037
a O 0 0.0009951072
case O 0 0.0010022584
history O 0 0.02394777
, O 0 0.0022242258
medical O 0 0.008156928
examination O 0 0.0028868977
and O 0 0.0032865065
clinical O 0 0.026832243
treatment O 0 0.010720972
. O 0 0.009020181

For O 0 0.0066190157
the O 0 0.0048057553
first O 0 0.0031257789
time O 0 0.002539777
, O 0 0.002647234
an O 0 0.0021557084
analytical O 0 0.0043210927
method O 0 0.0017229221
for O 0 0.00089278264
the O 0 0.0010078793
determination O 0 0.0019855723
of O 0 0.0024894278
carbachol B-Chemical 1 0.9997904
in O 0 0.0021259978
plasma O 0 0.05759993
and O 0 0.003343447
urine O 0 0.3870758
has O 0 0.0032840783
been O 0 0.005195299
developed O 0 0.008678947
. O 0 0.009221552

The O 0 0.008061843
analysed O 0 0.007047309
carbachol B-Chemical 1 0.9979716
concentration O 0 0.0057551195
exceeded O 0 0.0019451178
the O 0 0.0015188162
supposed O 0 0.0021070694
serum O 0 0.042150572
level O 0 0.0008317564
resulting O 0 0.0010553731
from O 0 0.00089239655
a O 0 0.0011823006
therapeutic O 0 0.0063820616
dose O 0 0.011700814
by O 0 0.0015900204
a O 0 0.0021662703
factor O 0 0.0060157212
of O 0 0.0031165297
130 O 0 0.007194152
to O 0 0.004177778
260 O 0 0.019583061
. O 0 0.00757413

Especially O 0 0.014818187
in O 0 0.0057627424
old O 0 0.0050224364
patients O 0 0.005929076
, O 0 0.0032065823
intensivists O 0 0.0030978818
should O 0 0.0009928102
consider O 0 0.0010448163
intoxications O 0 0.9996137
( O 0 0.0041625225
with O 0 0.0019894284
cholinergics O 0 0.9926817
) O 0 0.0034360178
as O 0 0.001309847
a O 0 0.0019950923
cause O 0 0.005184846
of O 0 0.0052042156
acute B-Disease 0 0.99829763
cardiovascular I-Disease 0 0.9995372
failure I-Disease 0 0.993166
. O 0 0.013375199

Pharmacological O 0 0.85946256
evidence O 0 0.008042799
for O 0 0.004781939
the O 0 0.004047797
potential O 0 0.004389639
of O 0 0.005259046
Daucus O 0 0.89896035
carota O 0 0.8936589
in O 0 0.0041005155
the O 0 0.003908002
management O 0 0.007943133
of O 0 0.009277633
cognitive B-Disease 0 0.97656256
dysfunctions I-Disease 0 0.99050236
. O 0 0.014695816

The O 0 0.007152569
present O 0 0.0042125382
study O 0 0.0040116836
was O 0 0.002578959
aimed O 0 0.0019034658
at O 0 0.0011313877
investigating O 0 0.0009789777
the O 0 0.0010094753
effects O 0 0.001755149
of O 0 0.002005847
Daucus O 0 0.93649167
carota O 0 0.9360021
seeds O 0 0.05515024
on O 0 0.0009368696
cognitive O 0 0.82565916
functions O 0 0.0015744684
, O 0 0.0012520517
total O 0 0.00095885026
serum O 0 0.33324337
cholesterol B-Chemical 1 0.999602
levels O 0 0.0017741496
and O 0 0.0025258919
brain O 0 0.41364825
cholinesterase O 0 0.9993838
activity O 0 0.004306322
in O 0 0.003879065
mice O 0 0.0048911837
. O 0 0.0081607625

The O 0 0.010404307
ethanolic O 0 0.8296215
extract B-Chemical 0 0.033215947
of I-Chemical 0 0.008666533
Daucus I-Chemical 0 0.9425697
carota I-Chemical 0 0.96912754
seeds I-Chemical 0 0.32566106
( O 0 0.015017555
DCE B-Chemical 1 0.99398994
) O 0 0.0028357676
was O 0 0.0008216324
administered O 0 0.0008949516
orally O 0 0.0024427974
in O 0 0.00048770045
three O 0 0.00038948224
doses O 0 0.016496714
( O 0 0.0011323445
100 O 0 0.001201065
, O 0 0.00066894013
200 O 0 0.0008880858
, O 0 0.00056913897
400 O 0 0.0009853974
mg O 0 0.06245478
/ O 0 0.0011021396
kg O 0 0.0021719208
) O 0 0.00071511825
for O 0 0.00029777642
seven O 0 0.00035845337
successive O 0 0.00047402145
days O 0 0.00042317176
to O 0 0.00054183387
different O 0 0.00072781625
groups O 0 0.0013807274
of O 0 0.0019005329
young O 0 0.01080366
and O 0 0.0035146982
aged O 0 0.0074427277
mice O 0 0.004904112
. O 0 0.008302404

Elevated O 0 0.04917713
plus O 0 0.006282414
maze O 0 0.013403084
and O 0 0.0033769812
passive O 0 0.0038642297
avoidance O 0 0.008255463
apparatus O 0 0.0027236533
served O 0 0.0024357163
as O 0 0.0016412756
the O 0 0.001833394
exteroceptive O 0 0.9049263
behavioral O 0 0.06214555
models O 0 0.003586425
for O 0 0.00287901
testing O 0 0.005170821
memory O 0 0.24302523
. O 0 0.009809396

Diazepam B-Chemical 0 0.9998692
- O 0 0.051539004
, O 0 0.015791496
scopolamine B-Chemical 1 0.9999676
- O 0 0.014296924
and O 0 0.004203
ageing O 0 0.37024575
- O 0 0.0066272197
induced O 0 0.00390756
amnesia B-Disease 2 0.9996673
served O 0 0.0046567544
as O 0 0.0026079065
the O 0 0.0031931128
interoceptive O 0 0.7416492
behavioral O 0 0.1277388
models O 0 0.01078818
. O 0 0.009963782

DCE B-Chemical 1 0.94921213
( O 0 0.010822981
200 O 0 0.0074683735
, O 0 0.004328912
400 O 0 0.00458379
mg O 0 0.14069895
/ O 0 0.0036017662
kg O 0 0.0063862116
, O 0 0.0016651539
p O 0 0.0013792817
. O 0 0.0007534598
o O 0 0.0027146393
. O 0 0.0006935132
) O 0 0.0011009229
showed O 0 0.0005349166
significant O 0 0.0007566993
improvement O 0 0.00094480265
in O 0 0.0008590692
memory O 0 0.034753963
scores O 0 0.001826646
of O 0 0.0020857896
young O 0 0.012063629
and O 0 0.0037019548
aged O 0 0.0077515086
mice O 0 0.005059717
. O 0 0.008474121

The O 0 0.0070048436
extent O 0 0.004252325
of O 0 0.004314866
memory O 0 0.07051882
improvement O 0 0.0031032336
evoked O 0 0.1243992
by O 0 0.0022563192
DCE B-Chemical 1 0.9763391
was O 0 0.000924264
23 O 0 0.0009760551
% O 0 0.0006137237
at O 0 0.00033461303
the O 0 0.00037319332
dose O 0 0.001323628
of O 0 0.00061642233
200 O 0 0.0014494611
mg O 0 0.20172656
/ O 0 0.0013511573
kg O 0 0.0020256697
and O 0 0.00052765943
35 O 0 0.0004922471
% O 0 0.00043907232
at O 0 0.00026591774
the O 0 0.00033355402
dose O 0 0.0012696323
of O 0 0.00069546635
400 O 0 0.002730567
mg O 0 0.2087162
/ O 0 0.0019477365
kg O 0 0.0030454393
in O 0 0.0009374718
young O 0 0.0036295608
mice O 0 0.0012078654
using O 0 0.0019441682
elevated O 0 0.005827433
plus O 0 0.004679841
maze O 0 0.11875973
. O 0 0.008143636

Similarly O 0 0.011077665
, O 0 0.007550842
significant O 0 0.0045131934
improvements O 0 0.003285087
in O 0 0.002511609
memory O 0 0.034314696
scores O 0 0.0024689985
were O 0 0.0015444697
observed O 0 0.0010921514
using O 0 0.001421204
passive O 0 0.00290285
avoidance O 0 0.010958332
apparatus O 0 0.004271995
and O 0 0.004360533
aged O 0 0.008624451
mice O 0 0.0056687873
. O 0 0.009232655

Furthermore O 0 0.011016132
, O 0 0.009881758
DCE B-Chemical 1 0.9416909
reversed O 0 0.007191779
the O 0 0.0035852494
amnesia B-Disease 2 0.99963343
induced O 0 0.003988414
by O 0 0.005613139
scopolamine B-Chemical 1 0.9999957
( O 0 0.0042772796
0 O 0 0.0011925072
. O 0 0.00042954445
4 O 0 0.000442862
mg O 0 0.049367387
/ O 0 0.001220958
kg O 0 0.0028892236
, O 0 0.0007690027
i O 0 0.0015694571
. O 0 0.00041898797
p O 0 0.0007318687
. O 0 0.00046422056
) O 0 0.0010885249
and O 0 0.0010106993
diazepam B-Chemical 1 0.9999858
( O 0 0.0016895529
1 O 0 0.0008960846
mg O 0 0.12169069
/ O 0 0.0021901857
kg O 0 0.0044077043
, O 0 0.0018170133
i O 0 0.0034728714
. O 0 0.001708619
p O 0 0.0033431468
. O 0 0.0033889182
) O 0 0.008626316
. O 0 0.0077244597

Daucus B-Chemical 0 0.9205957
carota I-Chemical 0 0.9103774
extract I-Chemical 0 0.2928618
( O 0 0.009358529
200 O 0 0.0064795637
, O 0 0.0030825036
400 O 0 0.003578102
mg O 0 0.17051786
/ O 0 0.0027632115
kg O 0 0.005550988
, O 0 0.0012569255
p O 0 0.001068033
. O 0 0.0005749922
o O 0 0.0026976678
. O 0 0.00057211996
) O 0 0.0010489798
reduced O 0 0.00055826624
significantly O 0 0.0007969588
the O 0 0.0007557674
brain O 0 0.17407782
acetylcholinesterase O 0 0.99758875
activity O 0 0.0018151202
and O 0 0.0019736192
cholesterol B-Chemical 1 0.9991346
levels O 0 0.0016816126
in O 0 0.001808331
young O 0 0.010822318
and O 0 0.0035593857
aged O 0 0.0074975123
mice O 0 0.0049680737
. O 0 0.008388054

The O 0 0.006889357
extent O 0 0.004107426
of O 0 0.003971019
inhibition O 0 0.0053194663
of O 0 0.0032125087
brain O 0 0.3245707
cholinesterase O 0 0.99958163
activity O 0 0.002619898
evoked O 0 0.24289043
by O 0 0.0014173202
DCE B-Chemical 1 0.96529293
at O 0 0.00039251446
the O 0 0.00041472135
dose O 0 0.0016727453
of O 0 0.000707963
400 O 0 0.002777139
mg O 0 0.20637463
/ O 0 0.0015713964
kg O 0 0.0024309475
was O 0 0.0006339946
22 O 0 0.000832954
% O 0 0.00080136047
in O 0 0.0007466296
young O 0 0.0027019083
and O 0 0.0015388174
19 O 0 0.0024917095
% O 0 0.0023115254
in O 0 0.0024536685
aged O 0 0.0061002355
mice O 0 0.0049117175
. O 0 0.008433273

There O 0 0.008684593
was O 0 0.0053668227
a O 0 0.004291497
remarkable O 0 0.0038768419
reduction O 0 0.0029766026
in O 0 0.001516841
total O 0 0.0016911968
cholesterol B-Chemical 1 0.99815947
level O 0 0.0008466085
as O 0 0.00083142676
well O 0 0.00069716753
, O 0 0.0008150273
to O 0 0.00042403184
the O 0 0.00042508534
extent O 0 0.00034541677
of O 0 0.00062159565
23 O 0 0.0009160143
% O 0 0.0006074969
in O 0 0.00045750773
young O 0 0.0019174935
and O 0 0.00071477966
21 O 0 0.00084230665
% O 0 0.0007623836
in O 0 0.0006474004
aged O 0 0.0013973169
animals O 0 0.0009748673
with O 0 0.001471839
this O 0 0.0020026662
dose O 0 0.018488519
of O 0 0.008007288
DCE B-Chemical 1 0.9912593
. O 0 0.009229885

Therefore O 0 0.0087060165
, O 0 0.0091486685
DCE B-Chemical 1 0.8800775
may O 0 0.0031249197
prove O 0 0.002483668
to O 0 0.001499742
be O 0 0.001283754
a O 0 0.0012762322
useful O 0 0.0009763519
remedy O 0 0.008586452
for O 0 0.0005516359
the O 0 0.00060468685
management O 0 0.0012585064
of O 0 0.0011465182
cognitive B-Disease 0 0.9133623
dysfunctions I-Disease 0 0.9112357
on O 0 0.00034162967
account O 0 0.0004641913
of O 0 0.0005399763
its O 0 0.0010665589
multifarious O 0 0.024754038
beneficial O 0 0.0019383514
effects O 0 0.0012825936
such O 0 0.0006203046
as O 0 0.00086847815
, O 0 0.0013960508
memory O 0 0.08708947
improving O 0 0.00100309
property O 0 0.014164707
, O 0 0.00355491
cholesterol B-Chemical 1 0.99935347
lowering O 0 0.1814368
property O 0 0.042457223
and O 0 0.0072830142
anticholinesterase O 0 0.99955004
activity O 0 0.014916568
. O 0 0.009366175

Valproic B-Chemical 1 0.99986565
acid I-Chemical 1 0.9968021
induced O 0 0.0642402
encephalopathy B-Disease 2 0.9999479
- O 0 0.059611257
- O 0 0.003956749
19 O 0 0.0019135369
new O 0 0.0012835235
cases O 0 0.0015569867
in O 0 0.0009608512
Germany O 0 0.008512059
from O 0 0.0007898016
1994 O 0 0.0030121254
to O 0 0.0006364113
2003 O 0 0.002391128
- O 0 0.0014001649
- O 0 0.0009075553
a O 0 0.0007010588
side O 0 0.012536076
effect O 0 0.0007573709
associated O 0 0.0011998902
to O 0 0.0016264251
VPA B-Chemical 1 0.99998665
- O 0 0.0048115877
therapy O 0 0.006072311
not O 0 0.0014097246
only O 0 0.0017566168
in O 0 0.0026796765
young O 0 0.022242412
children O 0 0.014336349
. O 0 0.008474884

Valproic B-Chemical 1 0.9998698
acid I-Chemical 1 0.9979113
( O 0 0.10180442
VPA B-Chemical 1 0.9999292
) O 0 0.010050092
is O 0 0.0021850367
a O 0 0.0021281333
broad O 0 0.0022912158
- O 0 0.0024057045
spectrum O 0 0.0020025442
antiepileptic O 0 0.99957365
drug O 0 0.7392792
and O 0 0.0024209828
is O 0 0.0019544852
usually O 0 0.0032591843
well O 0 0.0033023248
- O 0 0.008343306
tolerated O 0 0.07643047
. O 0 0.008994647

Rare O 0 0.52743804
serious O 0 0.31163082
complications O 0 0.70109534
may O 0 0.0037418902
occur O 0 0.0024183898
in O 0 0.0015350635
some O 0 0.001509226
patients O 0 0.0041269143
, O 0 0.0018435525
including O 0 0.0017392872
haemorrhagic O 0 0.9999672
pancreatitis B-Disease 0 0.9999974
, O 0 0.09669736
bone B-Disease 2 0.9759631
marrow I-Disease 2 0.99688256
suppression I-Disease 2 0.8111586
, O 0 0.0670933
VPA B-Chemical 1 0.9999926
- O 0 0.022263609
induced O 0 0.008049806
hepatotoxicity B-Disease 2 0.99999344
and O 0 0.08855855
VPA B-Chemical 1 0.9999845
- O 0 0.054175593
induced O 0 0.023072656
encephalopathy B-Disease 2 0.99989855
. O 0 0.0148129035

The O 0 0.00750788
typical O 0 0.0066880467
signs O 0 0.19047666
of O 0 0.012148258
VPA B-Chemical 1 0.99997485
- O 0 0.04055157
induced O 0 0.0061346632
encephalopathy B-Disease 2 0.999972
are O 0 0.0034059337
impaired B-Disease 0 0.038291533
consciousness I-Disease 0 0.99784493
, O 0 0.001772901
sometimes O 0 0.002344283
marked O 0 0.0020619505
EEG O 0 0.93916017
background O 0 0.0010195713
slowing O 0 0.038191214
, O 0 0.0013217308
increased O 0 0.0014911826
seizure B-Disease 2 0.9997334
frequency O 0 0.0025386973
, O 0 0.0025450517
with O 0 0.002158416
or O 0 0.0031405736
without O 0 0.007297198
hyperammonemia B-Disease 2 0.99989116
. O 0 0.01253806

There O 0 0.008643867
is O 0 0.0049626683
still O 0 0.003032276
no O 0 0.0019081498
proof O 0 0.0023613977
of O 0 0.001935728
causative O 0 0.008366398
effect O 0 0.0016371649
of O 0 0.0041990764
VPA B-Chemical 1 0.99998724
in O 0 0.001221744
patients O 0 0.00972617
with O 0 0.0021072438
encephalopathy B-Disease 2 0.99997914
, O 0 0.0021805076
but O 0 0.0007282901
only O 0 0.0006057681
of O 0 0.00088431383
an O 0 0.0012154069
association O 0 0.00094060146
with O 0 0.0015774125
an O 0 0.002567195
assumed O 0 0.0026752797
causal O 0 0.0073385
relation O 0 0.005480792
. O 0 0.0088574095

We O 0 0.008736968
report O 0 0.008484489
19 O 0 0.0059626056
patients O 0 0.0064530773
with O 0 0.0048506414
VPA B-Chemical 1 0.99997044
- O 0 0.01716468
associated O 0 0.0039121932
encephalopathy B-Disease 2 0.99995637
in O 0 0.0018107847
Germany O 0 0.021312134
from O 0 0.0007864492
the O 0 0.00072820514
years O 0 0.0011915427
1994 O 0 0.0024965163
to O 0 0.000741314
2003 O 0 0.0016983009
, O 0 0.0010243196
none O 0 0.0009807532
of O 0 0.0013637306
whom O 0 0.0036082251
had O 0 0.0021239908
been O 0 0.0030056718
published O 0 0.0035588057
previously O 0 0.0058155083
. O 0 0.008443107

Cerebral B-Disease 0 0.981824
haemorrhage I-Disease 0 0.9996542
induced O 0 0.0108891055
by O 0 0.008615474
warfarin B-Chemical 1 0.9996388
- O 0 0.0066983565
the O 0 0.0025268293
influence O 0 0.002175819
of O 0 0.0039893934
drug O 0 0.8605409
- O 0 0.0148639
drug O 0 0.7319339
interactions O 0 0.017566709
. O 0 0.010999291

PURPOSE O 0 0.02213014
: O 0 0.006355531
To O 0 0.0026527338
evaluate O 0 0.0015171062
the O 0 0.0016693128
frequency O 0 0.0019158791
, O 0 0.0018973678
severity O 0 0.033442173
and O 0 0.0014484932
preventability O 0 0.9331084
of O 0 0.0037505305
warfarin B-Chemical 1 0.99996376
- O 0 0.009599909
induced O 0 0.0016030923
cerebral B-Disease 0 0.99830866
haemorrhages I-Disease 0 0.99997187
due O 0 0.00063590927
to O 0 0.00070557697
warfarin B-Chemical 1 0.9998324
and O 0 0.0016410181
warfarin B-Chemical 1 0.9999236
- O 0 0.0025207214
drug O 0 0.28018233
interactions O 0 0.0012090562
in O 0 0.0006428975
patients O 0 0.0022192397
living O 0 0.0045199622
in O 0 0.0008689094
the O 0 0.0011893682
county O 0 0.009009671
of O 0 0.002775258
Osterg O 0 0.12799774
tland O 0 0.08746788
, O 0 0.008289293
Sweden O 0 0.033633757
. O 0 0.00812127

METHODS O 0 0.011326402
: O 0 0.007567745
All O 0 0.004148639
patients O 0 0.004444011
with O 0 0.0026321695
a O 0 0.0030277616
diagnosed O 0 0.04261958
cerebral B-Disease 2 0.99488527
haemorrhage I-Disease 2 0.9999497
at O 0 0.0011911301
three O 0 0.0008815243
hospitals O 0 0.001948866
during O 0 0.00089138065
the O 0 0.0012914705
period O 0 0.0016385377
2000 O 0 0.0047598467
- O 0 0.0041397517
2002 O 0 0.005892401
were O 0 0.0040651695
identified O 0 0.005352357
. O 0 0.008328002

Medical O 0 0.015513863
records O 0 0.007835979
were O 0 0.003943763
studied O 0 0.0028126116
retrospectively O 0 0.0024459104
to O 0 0.0013565839
evaluate O 0 0.0008124952
whether O 0 0.00082519895
warfarin B-Chemical 1 0.9997383
and O 0 0.0034129068
warfarin B-Chemical 1 0.99991775
- O 0 0.0054901573
drug O 0 0.43393767
interactions O 0 0.002314644
could O 0 0.0011036783
have O 0 0.0014333705
caused O 0 0.0027408008
the O 0 0.00499663
cerebral B-Disease 2 0.998599
haemorrhage I-Disease 2 0.9999062
. O 0 0.013359698

The O 0 0.008879732
proportion O 0 0.005991883
of O 0 0.0060280715
possibly O 0 0.008291292
avoidable O 0 0.0845898
cases O 0 0.0059669316
due O 0 0.0029523026
to O 0 0.0033149358
drug O 0 0.48515993
interactions O 0 0.008434414
was O 0 0.006207287
estimated O 0 0.0076411464
. O 0 0.010532156

RESULTS O 0 0.027319662
: O 0 0.00936733
Among O 0 0.007949906
593 O 0 0.0382821
patients O 0 0.0050031957
with O 0 0.0030024892
cerebral B-Disease 2 0.99310327
haemorrhage I-Disease 2 0.9999682
, O 0 0.0037138686
59 O 0 0.0028564131
( O 0 0.0014468346
10 O 0 0.0009122186
% O 0 0.0011256064
) O 0 0.0013478473
were O 0 0.0009058326
assessed O 0 0.00089582097
as O 0 0.0013893897
related O 0 0.0016552734
to O 0 0.0033040252
warfarin B-Chemical 1 0.99945146
treatment O 0 0.015925061
. O 0 0.00982291

This O 0 0.011828627
imply O 0 0.005749093
an O 0 0.006207258
incidence O 0 0.008880777
of O 0 0.0046047107
1 O 0 0.0035864285
. O 0 0.002317447
7 O 0 0.002469075
/ O 0 0.0041894317
100 O 0 0.0039833086
, O 0 0.0036791714
000 O 0 0.004670256
treatment O 0 0.0058894437
years O 0 0.009583135
. O 0 0.009340073

Of O 0 0.010390236
the O 0 0.0056997375
59 O 0 0.0057933438
cases O 0 0.004404667
, O 0 0.0030265343
26 O 0 0.0023870287
( O 0 0.0017965476
44 O 0 0.0015506736
% O 0 0.0012041584
) O 0 0.0011842054
had O 0 0.0006026975
a O 0 0.0009954347
fatal O 0 0.9514121
outcome O 0 0.0055567743
, O 0 0.00092781894
compared O 0 0.00034521404
to O 0 0.0004911082
136 O 0 0.0070581012
( O 0 0.000773288
25 O 0 0.0006699628
% O 0 0.00063682423
) O 0 0.00073881744
among O 0 0.00051497354
the O 0 0.0005308163
non O 0 0.0021041357
- O 0 0.002979361
warfarin B-Chemical 1 0.99950445
patients O 0 0.00612805
( O 0 0.0019659458
p O 0 0.0018370514
< O 0 0.001826681
0 O 0 0.0025005592
. O 0 0.002433178
01 O 0 0.012290831
) O 0 0.0075571407
. O 0 0.0073480518

A O 0 0.2042509
warfarin B-Chemical 1 0.99925894
- O 0 0.011652434
drug O 0 0.31979808
interaction O 0 0.0025955217
could O 0 0.0012628946
have O 0 0.001007711
contributed O 0 0.0015054876
to O 0 0.00075307145
the O 0 0.0009712156
haemorrhage B-Disease 0 0.99986506
in O 0 0.00074043503
24 O 0 0.0005411712
( O 0 0.0007029786
41 O 0 0.00091853924
% O 0 0.00057231577
) O 0 0.00061338244
of O 0 0.00042444636
the O 0 0.0004947933
warfarin B-Chemical 1 0.9994011
patients O 0 0.002047789
and O 0 0.00054967956
in O 0 0.00040086417
7 O 0 0.00038091585
of O 0 0.0004311041
these O 0 0.00063675956
( O 0 0.0008210807
12 O 0 0.00039779267
% O 0 0.0006430583
) O 0 0.0008944029
the O 0 0.00070000265
bleeding B-Disease 2 0.9984964
complication O 0 0.44652233
was O 0 0.0013977309
considered O 0 0.0013240724
being O 0 0.0024333468
possible O 0 0.0025015732
to O 0 0.0034313693
avoid O 0 0.005632615
. O 0 0.008434079

CONCLUSIONS O 0 0.7439448
: O 0 0.021757705
Warfarin B-Chemical 1 0.999418
- O 0 0.0110787265
induced O 0 0.005187316
cerebral B-Disease 0 0.9948047
haemorrhages I-Disease 0 0.99989533
are O 0 0.0027492885
a O 0 0.0022009308
major O 0 0.0020068735
clinical O 0 0.00683411
problem O 0 0.0033730776
with O 0 0.0024130808
a O 0 0.0038117643
high O 0 0.005208343
fatality O 0 0.9777574
rate O 0 0.00914284
. O 0 0.011119753

Almost O 0 0.013283184
half O 0 0.005702867
of O 0 0.0051611164
the O 0 0.004019327
cases O 0 0.004731366
was O 0 0.0030252282
related O 0 0.0023143378
to O 0 0.0027258212
a O 0 0.005844118
warfarin B-Chemical 1 0.9996494
- O 0 0.0148765575
drug O 0 0.6766185
interaction O 0 0.010638117
. O 0 0.011116744

A O 0 0.024699828
significant O 0 0.005627497
proportion O 0 0.0034540812
of O 0 0.0044603264
warfarin B-Chemical 1 0.9997695
- O 0 0.0074525727
related O 0 0.00153218
cerebral B-Disease 0 0.99620444
haemorrhages I-Disease 0 0.99995625
might O 0 0.0008656881
have O 0 0.00073870696
been O 0 0.00077745045
prevented O 0 0.0011139244
if O 0 0.0004120882
greater O 0 0.00046208725
caution O 0 0.0006413564
had O 0 0.0005342083
been O 0 0.00057586696
taken O 0 0.00043219657
when O 0 0.0004946195
prescribing O 0 0.013594996
drugs O 0 0.44127613
known O 0 0.0020423776
to O 0 0.0018933745
interact O 0 0.0024206752
with O 0 0.006597786
warfarin B-Chemical 1 0.9995579
. O 0 0.010045604

Antipsychotic O 0 0.9966288
- O 0 0.012901276
like O 0 0.0051831985
profile O 0 0.0044964966
of O 0 0.007149122
thioperamide B-Chemical 0 0.9999492
, O 0 0.007877429
a O 0 0.004231033
selective O 0 0.034732092
H3 O 0 0.8065316
- O 0 0.011297162
receptor O 0 0.31049064
antagonist O 0 0.963584
in O 0 0.005913507
mice O 0 0.0062856153
. O 0 0.0095156655

Experimental O 0 0.014794545
and O 0 0.00708378
clinical O 0 0.007869998
evidence O 0 0.0034064257
points O 0 0.0030887902
to O 0 0.0019094697
a O 0 0.0021108366
role O 0 0.0012325011
of O 0 0.0018806494
central O 0 0.0067418786
histaminergic O 0 0.9785911
system O 0 0.0031110412
in O 0 0.0019885104
the O 0 0.0026750686
pathogenesis O 0 0.02439142
of O 0 0.020441916
schizophrenia B-Disease 2 0.99964166
. O 0 0.012720378

The O 0 0.0070716087
present O 0 0.0041509955
study O 0 0.003954056
was O 0 0.002552751
designed O 0 0.001929201
to O 0 0.0013008224
study O 0 0.0012762441
the O 0 0.0008866721
effect O 0 0.0009036835
of O 0 0.0023476356
histamine B-Chemical 1 0.9999579
H O 0 0.99991274
( O 0 0.006637056
3 O 0 0.000985511
) O 0 0.0020698574
- O 0 0.0013536348
receptor O 0 0.030644724
ligands O 0 0.049821597
on O 0 0.00063764566
neuroleptic O 0 0.9999981
- O 0 0.025243621
induced O 0 0.007798691
catalepsy B-Disease 2 0.9999975
, O 0 0.03355958
apomorphine B-Chemical 1 0.9999951
- O 0 0.005187173
induced O 0 0.0010022527
climbing O 0 0.3840234
behavior O 0 0.009911334
and O 0 0.0029326824
amphetamine B-Chemical 1 0.9999907
- O 0 0.009316906
induced O 0 0.002751886
locomotor O 0 0.7621382
activities O 0 0.00458006
in O 0 0.0035333384
mice O 0 0.0046394765
. O 0 0.007925972

Catalepsy B-Disease 0 0.9989667
was O 0 0.007985959
induced O 0 0.0056951772
by O 0 0.0067486227
haloperidol B-Chemical 1 0.99998677
( O 0 0.005455261
2 O 0 0.0015007464
mg O 0 0.18760802
/ O 0 0.0022027893
kg O 0 0.0037265264
p O 0 0.0010837772
. O 0 0.0005460662
o O 0 0.0028401695
. O 0 0.00055224623
) O 0 0.0012184706
, O 0 0.0007610524
while O 0 0.0006549959
apomorphine B-Chemical 1 0.9999888
( O 0 0.0015726463
1 O 0 0.00053769286
. O 0 0.0002822544
5 O 0 0.00030414783
mg O 0 0.029509109
/ O 0 0.00084603106
kg O 0 0.0016292887
s O 0 0.00058414915
. O 0 0.00036172176
c O 0 0.0037855601
. O 0 0.00040854735
) O 0 0.00093949813
and O 0 0.0007982373
amphetamine B-Chemical 1 0.9999888
( O 0 0.0013241254
2 O 0 0.0005152266
mg O 0 0.086994454
/ O 0 0.0010657797
kg O 0 0.001975458
s O 0 0.0006556345
. O 0 0.00041289924
c O 0 0.0034838677
. O 0 0.0004673993
) O 0 0.00085230876
were O 0 0.0004635312
used O 0 0.000443878
for O 0 0.00045332225
studying O 0 0.0009485662
climbing O 0 0.13640435
behavior O 0 0.0043684463
and O 0 0.0024378097
locomotor O 0 0.67040753
activities O 0 0.005454335
, O 0 0.0056648618
respectively O 0 0.008883555
. O 0 0.0077795936

( B-Chemical 0 0.02378665
R I-Chemical 0 0.91792077
) I-Chemical 0 0.016920686
- I-Chemical 0 0.008982635
alpha I-Chemical 0 0.464588
- I-Chemical 0 0.011556559
methylhistamine I-Chemical 0 0.9973737
( O 0 0.015182732
RAMH B-Chemical 1 0.99987924
) O 0 0.0042361687
( O 0 0.0011807722
5 O 0 0.0005120339
microg O 0 0.00096252427
i O 0 0.0018630702
. O 0 0.00046788878
c O 0 0.00526371
. O 0 0.0004484244
v O 0 0.015312034
. O 0 0.00046852342
) O 0 0.0011854029
and O 0 0.0011352765
thioperamide B-Chemical 0 0.9999857
( O 0 0.012712357
THP B-Chemical 1 0.9999199
) O 0 0.0037981502
( O 0 0.0008214274
15 O 0 0.00039512143
mg O 0 0.042370666
/ O 0 0.0010543966
kg O 0 0.0019912794
i O 0 0.0016614982
. O 0 0.0004919118
p O 0 0.000864649
. O 0 0.0006059599
) O 0 0.0012857083
, O 0 0.0009789525
per O 0 0.00072017335
se O 0 0.0019005528
did O 0 0.0019196256
not O 0 0.0032352943
cause O 0 0.15713134
catalepsy B-Disease 2 0.9999471
. O 0 0.013614602

Administration O 0 0.15561308
of O 0 0.010929217
THP B-Chemical 1 0.99934036
( O 0 0.007363762
3 O 0 0.0022866335
. O 0 0.0012901783
75 O 0 0.0015100705
, O 0 0.0011267297
7 O 0 0.0007164088
. O 0 0.00047898595
5 O 0 0.00043805456
and O 0 0.0004774038
15 O 0 0.0004199296
mg O 0 0.039215624
/ O 0 0.0011112606
kg O 0 0.0022343379
i O 0 0.0017748211
. O 0 0.00039994254
p O 0 0.0006749478
. O 0 0.00039245203
) O 0 0.0007753323
1 O 0 0.000374607
h O 0 0.00025724864
prior O 0 0.0002474019
to O 0 0.0004938469
haloperidol B-Chemical 1 0.9999938
resulted O 0 0.00047285762
in O 0 0.00043295164
a O 0 0.0007263494
dose O 0 0.013542458
- O 0 0.0010737721
dependent O 0 0.00039843292
increase O 0 0.0004326921
in O 0 0.00061080564
the O 0 0.0012249536
catalepsy B-Disease 2 0.9999815
times O 0 0.0011412615
( O 0 0.002467317
P O 0 0.060886882
< O 0 0.0020348663
0 O 0 0.0027375186
. O 0 0.0027114656
05 O 0 0.052450106
) O 0 0.0076048216
. O 0 0.007456599

However O 0 0.010328864
, O 0 0.008273229
pretreatment O 0 0.12727952
with O 0 0.0060593905
RAMH B-Chemical 1 0.9997347
significantly O 0 0.004175238
reversed O 0 0.003199237
such O 0 0.0012137087
an O 0 0.0014954353
effect O 0 0.0010447506
of O 0 0.0021205493
THP B-Chemical 1 0.99987864
( O 0 0.0025793582
15 O 0 0.0009529572
mg O 0 0.13001966
/ O 0 0.0026769547
kg O 0 0.004981152
i O 0 0.0042034173
. O 0 0.0019017126
p O 0 0.0036329217
. O 0 0.0036203659
) O 0 0.0090356115
. O 0 0.008046364

RAMH B-Chemical 1 0.9961138
per O 0 0.005045704
se O 0 0.0052164127
showed O 0 0.0024168256
significant O 0 0.0021523547
reduction O 0 0.0023485892
in O 0 0.0012865191
locomotor O 0 0.4100535
time O 0 0.0007606087
, O 0 0.00093536795
distance O 0 0.0007016269
traveled O 0 0.0017906722
and O 0 0.00054154533
average O 0 0.00038586822
speed O 0 0.00081653974
but O 0 0.0007682941
THP B-Chemical 1 0.99977
( O 0 0.0011961567
15 O 0 0.00046204144
mg O 0 0.074292764
/ O 0 0.0011786607
kg O 0 0.0022275723
i O 0 0.0017028676
. O 0 0.0004553409
p O 0 0.00074644893
. O 0 0.00048145186
) O 0 0.00084736425
per O 0 0.00045179334
se O 0 0.0010176712
had O 0 0.00087791734
no O 0 0.0009670301
effect O 0 0.0015885767
on O 0 0.0018244281
these O 0 0.0043030987
parameters O 0 0.00830545
. O 0 0.008449662

On O 0 0.0153988525
amphetamine B-Chemical 1 0.9998802
- O 0 0.027279122
induced O 0 0.00927638
hyperactivity B-Disease 2 0.9999113
, O 0 0.023906458
THP B-Chemical 1 0.99986506
( O 0 0.0035425911
3 O 0 0.0009008865
. O 0 0.0005001809
75 O 0 0.0006606763
and O 0 0.0005027017
7 O 0 0.00044716234
. O 0 0.0003187143
5 O 0 0.00035199354
mg O 0 0.030515665
/ O 0 0.0009944614
kg O 0 0.0020116754
i O 0 0.0016664062
. O 0 0.0003973292
p O 0 0.00067963294
. O 0 0.0004090247
) O 0 0.0008377705
reduced O 0 0.0005320092
locomotor O 0 0.2463764
time O 0 0.00044141844
, O 0 0.0006861236
distance O 0 0.0006181741
traveled O 0 0.0017369259
and O 0 0.0006872588
average O 0 0.00061608077
speed O 0 0.0014993121
( O 0 0.0021117376
P O 0 0.046850696
< O 0 0.0020912557
0 O 0 0.0028358528
. O 0 0.0028124966
05 O 0 0.05508936
) O 0 0.007815483
. O 0 0.00761644

Pretreatment O 0 0.72966397
with O 0 0.011824207
RAMH B-Chemical 1 0.9994247
( O 0 0.005859436
5 O 0 0.00200314
microg O 0 0.0027377307
i O 0 0.0039044656
. O 0 0.0009990529
c O 0 0.007218951
. O 0 0.00072772504
v O 0 0.017385444
. O 0 0.00059053587
) O 0 0.0009804668
could O 0 0.00038451323
partially O 0 0.0005593331
reverse O 0 0.002864462
such O 0 0.00052178773
effects O 0 0.001347667
of O 0 0.0017820302
THP B-Chemical 1 0.99993014
( O 0 0.0021795481
3 O 0 0.00066714664
. O 0 0.0004677055
75 O 0 0.0008875461
mg O 0 0.05573986
/ O 0 0.0020188226
kg O 0 0.0038301027
i O 0 0.0035903414
. O 0 0.0017158949
p O 0 0.0033551522
. O 0 0.003399065
) O 0 0.008633751
. O 0 0.007738653

Climbing O 0 0.5509814
behavior O 0 0.019505432
induced O 0 0.008959077
by O 0 0.010224345
apomorphine B-Chemical 1 0.999931
was O 0 0.0058530564
reduced O 0 0.004138383
in O 0 0.0036456161
animals O 0 0.0042054714
treated O 0 0.00774601
with O 0 0.013264172
THP B-Chemical 1 0.9994111
. O 0 0.016173825

Such O 0 0.015296554
an O 0 0.010127328
effect O 0 0.0063872677
was O 0 0.0057571726
, O 0 0.005801146
however O 0 0.0049906024
, O 0 0.0053514373
reversed O 0 0.005789815
in O 0 0.0043454873
presence O 0 0.0059555443
of O 0 0.017812971
RAMH B-Chemical 1 0.99944085
. O 0 0.015093587

THP B-Chemical 1 0.99702257
exhibited O 0 0.0068399995
an O 0 0.007232647
antipsychotic O 0 0.99941623
- O 0 0.0061836643
like O 0 0.0017579868
profile O 0 0.0017754431
by O 0 0.0021990007
potentiating O 0 0.8988882
haloperidol B-Chemical 1 0.9999988
- O 0 0.058449984
induced O 0 0.011527176
catalepsy B-Disease 2 0.99999666
, O 0 0.0069090156
reducing O 0 0.011069221
amphetamine B-Chemical 1 0.9999964
- O 0 0.021290055
induced O 0 0.0035235037
hyperactivity B-Disease 2 0.9999558
and O 0 0.0030927863
reducing O 0 0.022041595
apomorphine B-Chemical 1 0.9999908
- O 0 0.013930988
induced O 0 0.0035605424
climbing O 0 0.42927366
in O 0 0.004086946
mice O 0 0.0050033815
. O 0 0.008226413

Such O 0 0.01230843
effects O 0 0.008012857
of O 0 0.0072483392
THP B-Chemical 1 0.99943966
were O 0 0.0041626845
reversed O 0 0.005606909
by O 0 0.0034252517
RAMH B-Chemical 1 0.9996805
indicating O 0 0.0013414691
the O 0 0.0012997993
involvement O 0 0.0034953207
of O 0 0.0043280837
histamine B-Chemical 1 0.9999145
H O 0 0.99974746
( O 0 0.010272469
3 O 0 0.0036868982
) O 0 0.007039902
- O 0 0.008102766
receptors O 0 0.096836746
. O 0 0.009669833

Findings O 0 0.013821955
suggest O 0 0.005182333
a O 0 0.0052972594
potential O 0 0.004635415
for O 0 0.0036507777
H O 1 0.9985267
( O 0 0.005740935
3 O 0 0.0022240798
) O 0 0.0038048483
- O 0 0.0030563094
receptor O 0 0.0903851
antagonists O 0 0.92192304
in O 0 0.0014841188
improving O 0 0.0016073089
the O 0 0.0018246208
refractory O 0 0.26892292
cases O 0 0.010248844
of O 0 0.013169173
schizophrenia B-Disease 2 0.999585
. O 0 0.011575425

Cauda B-Disease 0 0.9492348
equina I-Disease 0 0.7934358
syndrome I-Disease 0 0.9166336
after O 0 0.005721934
epidural O 0 0.9113938
steroid B-Chemical 1 0.9984097
injection O 0 0.052585553
: O 0 0.009153131
a O 0 0.0074458737
case O 0 0.008167443
report O 0 0.021448415
. O 0 0.013027734

OBJECTIVE O 0 0.5548275
: O 0 0.0096604945
Conventional O 0 0.009476219
treatment O 0 0.003991478
methods O 0 0.0026613178
of O 0 0.0028887677
lumbusacral O 0 0.14969957
radiculopathy B-Disease 0 0.9999447
are O 0 0.0020872133
physical O 0 0.04795646
therapy O 0 0.021054666
, O 0 0.0016689473
epidural O 0 0.89408237
steroid B-Chemical 1 0.99881625
injections O 0 0.041014563
, O 0 0.002092442
oral O 0 0.5458728
medications O 0 0.70349425
, O 0 0.0028457197
and O 0 0.0028626337
spinal O 0 0.29033908
manipulative O 0 0.17463112
therapy O 0 0.07736847
. O 0 0.0088604195

Cauda B-Disease 0 0.95600516
equina I-Disease 0 0.84809
syndrome I-Disease 0 0.9434767
is O 0 0.0096228765
a O 0 0.009264231
rare O 0 0.021516588
complication O 0 0.5419035
of O 0 0.013579122
epidural O 0 0.9649048
anesthesia O 0 0.6179525
. O 0 0.016630232

The O 0 0.0072143422
following O 0 0.004888123
case O 0 0.0038606192
is O 0 0.0027871388
a O 0 0.0026735452
report O 0 0.0034861248
of O 0 0.0025486227
cauda B-Disease 0 0.9308446
equina I-Disease 0 0.95979905
syndrome I-Disease 0 0.989277
possibly O 0 0.012249119
caused O 0 0.0020456598
by O 0 0.0020912138
epidural O 0 0.82743114
injection O 0 0.0074163335
of O 0 0.0061465367
triamcinolone B-Chemical 0 0.9999707
and O 0 0.06329817
bupivacaine B-Chemical 1 0.9998963
. O 0 0.013266096

CLINICAL O 0 0.037981853
FEATURES O 0 0.028037276
: O 0 0.008237114
A O 0 0.016955463
50 O 0 0.004757114
- O 0 0.003544881
year O 0 0.0019784104
- O 0 0.0020622364
old O 0 0.0014338312
woman O 0 0.004889947
with O 0 0.0012044263
low B-Disease 0 0.0014605756
back I-Disease 0 0.0033134804
and I-Disease 0 0.0012710849
right I-Disease 0 0.0036600793
leg I-Disease 0 0.14073734
pain I-Disease 2 0.9967631
was O 0 0.0014798668
scheduled O 0 0.0012648002
for O 0 0.0017028798
epidural O 0 0.8970055
steroid B-Chemical 1 0.99831045
injection O 0 0.07087907
. O 0 0.009996153

INTERVENTION O 0 0.017557435
AND O 0 0.009687008
OUTCOME O 0 0.017520789
: O 0 0.0053038667
An O 0 0.004435563
18 O 0 0.002783391
- O 0 0.0026361695
gauge O 0 0.0022847685
Touhy O 0 0.011053761
needle O 0 0.0028990733
was O 0 0.0011411762
inserted O 0 0.00083030487
until O 0 0.0006375851
loss O 0 0.0012389082
of O 0 0.001221495
resistance O 0 0.003178943
occurred O 0 0.0014286946
at O 0 0.0012127317
the O 0 0.0019863881
L4 O 0 0.062577315
- O 0 0.005055485
5 O 0 0.0036543668
level O 0 0.0044645933
. O 0 0.0077005057

Spread O 0 0.024338227
of O 0 0.007973558
the O 0 0.005395629
contrast O 0 0.0049531464
medium O 0 0.008077801
within O 0 0.002022413
the O 0 0.0024856606
epidural O 0 0.52686614
space O 0 0.0032463893
was O 0 0.002738718
determined O 0 0.0027867295
by O 0 0.0052050306
radiographic O 0 0.12153286
imaging O 0 0.049121518
. O 0 0.011030739

After O 0 0.007581563
verifying O 0 0.0068592676
the O 0 0.005583149
epidural O 0 0.42793667
space O 0 0.0060367063
, O 0 0.0073835854
bupivacaine B-Chemical 1 0.9998528
and O 0 0.021136919
triamcinolone B-Chemical 1 0.9999808
diacetate I-Chemical 1 0.9988612
were O 0 0.012137876
injected O 0 0.010043424
. O 0 0.011982317

After O 0 0.008521876
the O 0 0.007618336
injection O 0 0.009067116
, O 0 0.0062445225
there O 0 0.0035157856
was O 0 0.0041709854
a O 0 0.005349631
reduction O 0 0.006974712
in O 0 0.007835415
radicular O 0 0.99877983
symptoms O 0 0.9791741
. O 0 0.016782027

Three O 0 0.012168359
hours O 0 0.0064351903
later O 0 0.0054740906
, O 0 0.005640686
she O 0 0.0044805356
complained O 0 0.10887447
of O 0 0.0056851874
perineal O 0 0.7653931
numbness B-Disease 0 0.99940336
and O 0 0.00966357
lower B-Disease 0 0.012718277
extremity I-Disease 0 0.9510033
weakness I-Disease 2 0.9979208
. O 0 0.0152643025

The O 0 0.0092890095
neurologic O 0 0.92834014
evaluation O 0 0.0054737427
revealed O 0 0.0035074544
loss B-Disease 0 0.00542943
of I-Disease 0 0.003151418
sensation I-Disease 0 0.96757746
in O 0 0.0017855868
the O 0 0.0016113251
saddle O 0 0.03791264
area O 0 0.002429865
and O 0 0.0020574764
medial O 0 0.0060669924
aspect O 0 0.001994295
of O 0 0.002869506
her O 0 0.0055762883
right O 0 0.0122953355
leg O 0 0.14534406
. O 0 0.009873692

There O 0 0.014612923
was O 0 0.010183237
a O 0 0.00922523
decrease O 0 0.0064969864
in O 0 0.0057548312
the O 0 0.006063781
perception O 0 0.013794807
of O 0 0.011041356
pinprick O 0 0.9693276
test O 0 0.017109213
. O 0 0.0148694515

Deep O 0 0.19289804
- O 0 0.020496162
tendon O 0 0.22329241
reflexes O 0 0.9414807
were O 0 0.007548409
decreased O 0 0.0068661086
especially O 0 0.006077035
in O 0 0.005613189
the O 0 0.0069110864
right O 0 0.017504448
leg O 0 0.17810391
. O 0 0.0142809

She O 0 0.05048635
was O 0 0.033731718
unable O 0 0.028474307
to O 0 0.033872798
urinate O 0 0.21351355
. O 0 0.04102138

The O 0 0.009968024
patient O 0 0.009550194
' O 0 0.0075548273
s O 0 0.0064606583
symptoms O 0 0.3333247
improved O 0 0.0057398877
slightly O 0 0.0036605247
over O 0 0.0025498983
the O 0 0.0033370848
next O 0 0.0032461488
few O 0 0.00437904
hours O 0 0.0062632035
. O 0 0.0096579855

She O 0 0.013741667
had O 0 0.0068786577
a O 0 0.006124076
gradual O 0 0.0049031973
return O 0 0.0043527144
of O 0 0.0034675337
motor O 0 0.037309654
function O 0 0.0030971433
and O 0 0.0031552042
ability O 0 0.0032396044
of O 0 0.005258155
feeling O 0 0.62350905
Foley O 0 0.24386606
catheter O 0 0.017862879
. O 0 0.010374039

All O 0 0.010087391
of O 0 0.00814616
the O 0 0.006450513
symptoms O 0 0.43413374
were O 0 0.004550254
completely O 0 0.0036609822
resolved O 0 0.0043256697
over O 0 0.0022903285
the O 0 0.0030491436
next O 0 0.0030985288
8 O 0 0.0049298103
hours O 0 0.0056334613
. O 0 0.008924419

CONCLUSION O 0 0.75141877
: O 0 0.018049266
Complications O 0 0.073474996
associated O 0 0.008414415
with O 0 0.008013229
epidural O 0 0.9376832
steroid B-Chemical 1 0.9984413
injections O 0 0.15435041
are O 0 0.012785685
rare O 0 0.09835304
. O 0 0.016025726

Clinical O 0 0.030671773
examination O 0 0.008600003
and O 0 0.0052811885
continued O 0 0.004049574
vigilance O 0 0.06522765
for O 0 0.0029217529
neurologic B-Disease 0 0.9991954
deterioration I-Disease 0 0.85484457
after O 0 0.002088344
epidural O 0 0.9544217
steroid B-Chemical 1 0.99897873
injections O 0 0.08748059
is O 0 0.0057631093
important O 0 0.0065017496
. O 0 0.0096980855

High O 0 0.08891451
- O 0 0.017540328
dose O 0 0.092087805
testosterone B-Chemical 1 0.9993279
is O 0 0.008089669
associated O 0 0.007577908
with O 0 0.009900139
atherosclerosis B-Disease 2 0.9996507
in O 0 0.01745447
postmenopausal O 0 0.9984686
women O 0 0.6759444
. O 0 0.016119095

OBJECTIVES O 0 0.025411043
: O 0 0.00812525
To O 0 0.003846196
study O 0 0.003522675
the O 0 0.0025776033
long O 0 0.0025316842
- O 0 0.0027768442
term O 0 0.0015521507
effects O 0 0.0028783453
of O 0 0.0038959957
androgen O 0 0.9996123
treatment O 0 0.010184836
on O 0 0.002938182
atherosclerosis B-Disease 2 0.99979883
in O 0 0.010728591
postmenopausal O 0 0.9987618
women O 0 0.62851244
. O 0 0.012256657

METHODS O 0 0.011120257
: O 0 0.007722998
In O 0 0.003851242
a O 0 0.0038399675
population O 0 0.00423086
- O 0 0.0028857037
based O 0 0.0015125019
study O 0 0.0014417622
in O 0 0.0010927989
513 O 0 0.030139338
naturally O 0 0.005256507
postmenopausal O 0 0.9935562
women O 0 0.084097594
aged O 0 0.0019159355
54 O 0 0.0018231412
- O 0 0.00088383834
67 O 0 0.0008187976
years O 0 0.00057409273
, O 0 0.0004484385
we O 0 0.00023365945
studied O 0 0.0003442918
the O 0 0.0003338114
association O 0 0.0003079591
between O 0 0.00032079822
self O 0 0.036696266
- O 0 0.001458163
reported O 0 0.0006330403
intramuscularly O 0 0.020921594
administered O 0 0.0010894985
high O 0 0.0010792222
- O 0 0.0026095058
dose O 0 0.106545836
estrogen B-Chemical 1 0.9999701
- O 0 0.08170721
testosterone B-Chemical 1 0.9999589
therapy O 0 0.28243363
( O 0 0.034189243
estradiol B-Chemical 1 0.9999727
- I-Chemical 0 0.02154372
and I-Chemical 0 0.006037358
testosterone I-Chemical 1 0.9999392
esters I-Chemical 0 0.99803036
) O 0 0.030013232
and O 0 0.0066648736
aortic O 0 0.84993905
atherosclerosis B-Disease 2 0.9996227
. O 0 0.014493564

Aortic O 0 0.6602611
atherosclerosis B-Disease 2 0.9983191
was O 0 0.0067119673
diagnosed O 0 0.014740757
by O 0 0.003119749
radiographic O 0 0.016619138
detection O 0 0.0019397635
of O 0 0.0018972325
calcified O 0 0.18097986
deposits O 0 0.14006606
in O 0 0.0010574462
the O 0 0.0010721975
abdominal O 0 0.39743072
aorta O 0 0.15144323
, O 0 0.001747696
which O 0 0.0013659709
have O 0 0.001141315
been O 0 0.0015175383
shown O 0 0.0013484309
to O 0 0.0020831055
reflect O 0 0.0037021136
intima O 0 0.98999184
atherosclerosis B-Disease 2 0.99969935
. O 0 0.016481131

Hormone O 0 0.971066
therapy O 0 0.04012554
users O 0 0.024338307
were O 0 0.010594877
compared O 0 0.0075101717
with O 0 0.010731942
never O 0 0.018319637
users O 0 0.048746813
. O 0 0.017207503

RESULTS O 0 0.036575675
: O 0 0.013463316
Intramuscular O 0 0.8915963
hormone O 0 0.9497344
therapy O 0 0.0143262865
use O 0 0.0027409482
for O 0 0.0016708464
1 O 0 0.0017659543
year O 0 0.0014512147
or O 0 0.0014693309
longer O 0 0.0013082374
was O 0 0.0020511027
reported O 0 0.003166437
by O 0 0.004367741
25 O 0 0.0071870335
women O 0 0.07316766
. O 0 0.009447163

In O 0 0.006915143
almost O 0 0.004331375
half O 0 0.0026644364
of O 0 0.0025550188
these O 0 0.0025037203
women O 0 0.096765004
severe O 0 0.514942
atherosclerosis B-Disease 2 0.99981815
of O 0 0.0021811873
the O 0 0.0010125136
aorta O 0 0.07518098
was O 0 0.0005904442
present O 0 0.00038910855
( O 0 0.00072070333
n O 0 0.00057929946
= O 0 0.00069839734
11 O 0 0.00060011755
) O 0 0.0007523821
, O 0 0.000500045
while O 0 0.00033018543
in O 0 0.0003825502
women O 0 0.019962901
without O 0 0.0006393124
hormone O 0 0.9745164
use O 0 0.00106332
severe O 0 0.53221804
atherosclerosis B-Disease 2 0.9999045
of O 0 0.00122755
the O 0 0.00061783096
aorta O 0 0.06862357
was O 0 0.00038742702
present O 0 0.00024563796
in O 0 0.00032092974
less O 0 0.0003510093
than O 0 0.00028254488
20 O 0 0.0004402624
% O 0 0.00056399265
( O 0 0.0006968649
OR O 0 0.02409663
3 O 0 0.0004326562
. O 0 0.00032186462
1 O 0 0.00048483914
; O 0 0.0006929444
95 O 0 0.0008111877
% O 0 0.0006665936
CI O 0 0.08855218
, O 0 0.0006331348
1 O 0 0.0004777143
. O 0 0.0003252916
1 O 0 0.00047378973
- O 0 0.0006027274
8 O 0 0.00036428432
. O 0 0.00028256592
5 O 0 0.00032703666
, O 0 0.00042716513
adjusted O 0 0.00043486382
for O 0 0.0003453009
age O 0 0.0011073289
, O 0 0.0008119486
years O 0 0.0009274388
since O 0 0.00065464893
menopause O 0 0.9511975
, O 0 0.002785907
smoking O 1 0.9453557
, O 0 0.0024115478
and O 0 0.002201053
body O 0 0.00985932
mass O 0 0.010656582
index O 0 0.0073180976
) O 0 0.012675245
. O 0 0.008645223

The O 0 0.0066639003
association O 0 0.0038910394
remained O 0 0.0031671352
after O 0 0.0015946416
additional O 0 0.0013310543
adjustment O 0 0.0019801755
for O 0 0.0014192396
diabetes B-Disease 2 0.99840647
, O 0 0.0059416266
cholesterol B-Chemical 1 0.9991941
level O 0 0.0012192125
, O 0 0.0020564974
systolic O 0 0.6199413
blood O 0 0.012718372
pressure O 0 0.06422255
, O 0 0.0032352803
or O 0 0.0035490433
alcohol B-Chemical 1 0.9986388
use O 0 0.009921222
. O 0 0.009316256

No O 0 0.014179816
association O 0 0.0073870397
was O 0 0.006581477
found O 0 0.0048231506
for O 0 0.004759435
hormone O 0 0.9007983
use O 0 0.0054600537
less O 0 0.00465576
than O 0 0.0042743282
1 O 0 0.006859989
year O 0 0.008102589
. O 0 0.010451969

CONCLUSION O 0 0.5883706
: O 0 0.007952844
Our O 0 0.0037995563
results O 0 0.0026583865
suggest O 0 0.0016089656
that O 0 0.0014947731
high O 0 0.0024488205
- O 0 0.0036285697
dose O 0 0.08671703
testosterone B-Chemical 1 0.99993026
therapy O 0 0.07530345
may O 0 0.0010605789
adversely O 0 0.06545105
affect O 0 0.00087436853
atherosclerosis B-Disease 2 0.99992466
in O 0 0.0019973894
postmenopausal O 0 0.9985598
women O 0 0.17644313
and O 0 0.0009754605
indicate O 0 0.0006362511
that O 0 0.0008835213
androgen O 0 0.9993129
replacement O 0 0.0050830455
in O 0 0.0012221902
these O 0 0.0020196638
women O 0 0.056481943
may O 0 0.002218618
not O 0 0.00292757
be O 0 0.0047770673
harmless O 0 0.053988304
. O 0 0.009144646

Optimising O 0 0.03417243
stroke B-Disease 2 0.9932365
prevention O 0 0.025239808
in O 0 0.009343943
non O 0 0.015926804
- O 0 0.016849352
valvular O 0 0.9333934
atrial B-Disease 0 0.99744105
fibrillation I-Disease 0 0.99977714
. O 0 0.022782901

Atrial B-Disease 0 0.9887122
fibrillation I-Disease 0 0.99962807
is O 0 0.013332811
associated O 0 0.009779918
with O 0 0.008509581
substantial O 0 0.011004335
morbidity O 0 0.8169642
and O 0 0.017914256
mortality O 0 0.7620809
. O 0 0.01885084

Pooled O 0 0.018812355
data O 0 0.0065119653
from O 0 0.003576514
trials O 0 0.002746958
comparing O 0 0.0013442968
antithrombotic O 0 0.89726573
treatment O 0 0.0027091792
with O 0 0.0013390508
placebo O 0 0.1693343
have O 0 0.00063467416
shown O 0 0.0004724877
that O 0 0.00051582983
warfarin B-Chemical 1 0.9995939
reduces O 0 0.0006708701
the O 0 0.0006657493
risk O 0 0.05166593
of O 0 0.0014779534
stroke B-Disease 2 0.99969053
by O 0 0.0010511917
62 O 0 0.0019812908
% O 0 0.0007764569
, O 0 0.00071889797
and O 0 0.0006391801
that O 0 0.00068298954
aspirin B-Chemical 1 0.9998783
alone O 0 0.001641597
reduces O 0 0.0014538047
the O 0 0.001981556
risk O 0 0.083879925
by O 0 0.0041013393
22 O 0 0.0059521496
% O 0 0.0069155125
. O 0 0.0074740667

Overall O 0 0.013495832
, O 0 0.0076266536
in O 0 0.0041548964
high O 0 0.004436603
- O 0 0.004725549
risk O 0 0.03879776
patients O 0 0.008795897
, O 0 0.0028645014
warfarin B-Chemical 1 0.9996271
is O 0 0.0010901112
superior O 0 0.0016127181
to O 0 0.00084893906
aspirin B-Chemical 1 0.9999205
in O 0 0.0010633507
preventing O 0 0.007866295
strokes B-Disease 2 0.99937916
, O 0 0.001821489
with O 0 0.0009877326
a O 0 0.0013193582
relative O 0 0.0010432315
risk O 0 0.03481899
reduction O 0 0.0031693608
of O 0 0.0035536569
36 O 0 0.004984866
% O 0 0.0067879097
. O 0 0.0073729833

Ximelagatran B-Chemical 0 0.9967899
, O 0 0.008932698
an O 0 0.005483361
oral O 0 0.29363486
direct O 0 0.006342587
thrombin O 0 0.9854086
inhibitor O 0 0.7686547
, O 0 0.0032715762
was O 0 0.0009371489
found O 0 0.00056041585
to O 0 0.0005613841
be O 0 0.00059095345
as O 0 0.00055813906
efficient O 0 0.00054118724
as O 0 0.0014386317
vitamin B-Chemical 0 0.9999863
K I-Chemical 1 0.9999622
antagonist O 0 0.99584514
drugs O 0 0.9174117
in O 0 0.0006132626
the O 0 0.00055107154
prevention O 0 0.0031014816
of O 0 0.0010412931
embolic B-Disease 0 0.999263
events I-Disease 0 0.67712563
, O 0 0.0017185401
but O 0 0.0007166919
has O 0 0.0005797408
been O 0 0.0007480329
recently O 0 0.0008218016
withdrawn O 0 0.0025775575
because O 0 0.0008877208
of O 0 0.0020091934
abnormal B-Disease 0 0.18374637
liver I-Disease 0 0.93547016
function I-Disease 0 0.011995307
tests O 0 0.015590329
. O 0 0.0085199345

The O 0 0.012986182
ACTIVE O 0 0.42802364
- O 0 0.014359723
W O 0 0.82686204
( O 0 0.012621621
Atrial B-Disease 2 0.995484
Fibrillation I-Disease 2 0.98190224
Clopidogrel B-Chemical 0 0.99990714
Trial O 0 0.18178658
with O 0 0.0019947137
Irbesartan B-Chemical 0 0.9998971
for O 0 0.00089150935
Prevention O 0 0.016706983
of O 0 0.001358657
Vascular O 0 0.98461825
Events O 0 0.72313595
) O 0 0.0012127355
study O 0 0.0005614659
has O 0 0.00033822955
demonstrated O 0 0.00035518844
that O 0 0.00043071958
warfarin B-Chemical 1 0.99961865
is O 0 0.00054916454
superior O 0 0.00095139915
to O 0 0.00048506772
platelet O 0 0.91437364
therapy O 0 0.054328322
( O 0 0.0030030815
clopidogrel B-Chemical 1 0.99987805
plus O 0 0.0017410681
aspirin B-Chemical 1 0.99996424
) O 0 0.0045042047
in O 0 0.0012474409
the O 0 0.001719206
prevention O 0 0.020214051
af O 0 0.65123403
embolic B-Disease 0 0.9990387
events I-Disease 0 0.81375253
. O 0 0.01162434

Idraparinux B-Chemical 0 0.91786385
, O 0 0.013006238
a O 0 0.011275925
Factor O 1 0.97695494
Xa O 1 0.9901636
inhibitor O 0 0.15411851
, O 0 0.0046245265
is O 0 0.002413766
being O 0 0.002609492
evaluated O 0 0.0019320182
in O 0 0.0023845965
patients O 0 0.006622196
with O 0 0.006207705
atrial B-Disease 0 0.99705696
fibrillation I-Disease 0 0.9998517
. O 0 0.014963896

Angiotensin B-Chemical 0 0.99963963
- O 0 0.036648948
converting O 0 0.2275705
enzyme O 0 0.30766594
inhibitors O 0 0.28215164
and O 0 0.012499977
angiotensin B-Chemical 1 0.9999727
II I-Chemical 1 0.9580401
receptor O 0 0.6485775
- O 0 0.005215287
blocking O 0 0.00417518
drugs O 0 0.6338966
hold O 0 0.0022020012
promise O 0 0.0025791703
in O 0 0.0017883391
atrial B-Disease 0 0.9912883
fibrillation I-Disease 0 0.999918
through O 0 0.0051353876
cardiac B-Disease 0 0.9782683
remodelling I-Disease 0 0.8157845
. O 0 0.011165504

Preliminary O 0 0.01733195
studies O 0 0.007240283
suggest O 0 0.004009477
that O 0 0.0038184752
statins B-Chemical 1 0.99760497
could O 0 0.0027614357
interfere O 0 0.0024844264
with O 0 0.0021983248
the O 0 0.0022234537
risk O 0 0.040997293
of O 0 0.0039226525
recurrence O 0 0.8917736
after O 0 0.0037247278
electrical O 0 0.8076887
cardioversion O 0 0.8799269
. O 0 0.01104795

Finally O 0 0.009212616
, O 0 0.006307436
percutaneous O 0 0.0049861125
methods O 0 0.0027229683
for O 0 0.0016153897
the O 0 0.001448834
exclusion O 0 0.0015904383
of O 0 0.0014134202
left O 0 0.0029872423
atrial O 0 0.92761314
appendage O 0 0.02256109
are O 0 0.0012611314
under O 0 0.00093032856
investigation O 0 0.0018130719
in O 0 0.0018333521
high O 0 0.0035779506
- O 0 0.0071397736
risk O 0 0.12037059
patients O 0 0.02867517
. O 0 0.009838789

Anti O 0 0.64766264
- O 0 0.019543936
oxidant O 0 0.9740131
effects O 0 0.010999841
of O 0 0.008813691
atorvastatin B-Chemical 0 0.99995863
in O 0 0.009325458
dexamethasone B-Chemical 1 0.99987376
- O 0 0.03891215
induced O 0 0.007997788
hypertension B-Disease 2 0.99987173
in O 0 0.005466894
the O 0 0.0064485604
rat O 0 0.03457901
. O 0 0.010301195

1 O 0 0.13336578
. O 0 0.12343066

Dexamethasone B-Chemical 1 0.99960536
( O 0 0.05982534
Dex B-Chemical 1 0.99909425
) O 0 0.03673847
- O 0 0.0062920903
induced O 0 0.0034386546
hypertension B-Disease 2 0.99991345
is O 0 0.0020655675
characterized O 0 0.0029067528
by O 0 0.0020442188
endothelial O 0 0.98319626
dysfunction O 0 0.99119395
associated O 0 0.0030240347
with O 0 0.0048071994
nitric B-Chemical 0 0.99994695
oxide I-Chemical 0 0.9998017
( O 0 0.051538955
NO B-Chemical 0 0.9997538
) O 0 0.0155925155
deficiency O 0 0.56956416
and O 0 0.0023781192
increased O 0 0.0072162384
superoxide B-Chemical 1 0.9999211
( O 0 0.050331637
O2 B-Chemical 0 0.99916065
- I-Chemical 0 0.010320883
) O 0 0.00808074
production O 0 0.008840976
. O 0 0.009145398

Atorvastatin B-Chemical 0 0.9995714
( O 0 0.019930065
Ato B-Chemical 1 0.9750566
) O 0 0.0067719477
possesses O 0 0.0028287126
pleiotropic O 0 0.00863961
properties O 0 0.002203611
that O 0 0.0010540687
have O 0 0.0009381965
been O 0 0.00096610654
reported O 0 0.0008872256
to O 0 0.00058897096
improve O 0 0.00049006776
endothelial O 0 0.7856693
function O 0 0.00088468386
through O 0 0.00052221306
increased O 0 0.0007343513
availability O 0 0.00082833203
of O 0 0.0014027541
NO B-Chemical 0 0.99928397
and O 0 0.001702323
reduced O 0 0.00219015
O2 B-Chemical 0 0.9994149
- I-Chemical 0 0.0028453968
production O 0 0.0017105051
in O 0 0.0014197524
various O 0 0.0030346857
forms O 0 0.0038237134
of O 0 0.011970135
hypertension B-Disease 2 0.9998375
. O 0 0.012304136

In O 0 0.007149592
the O 0 0.0048310193
present O 0 0.002863329
study O 0 0.0029835112
, O 0 0.0021561012
we O 0 0.0009355525
investigated O 0 0.0007920974
whether O 0 0.0005408664
50 O 0 0.0011396658
mg O 0 0.16091552
/ O 0 0.0013511903
kg O 0 0.0014916408
per O 0 0.00033052743
day O 0 0.00044383339
, O 0 0.00064165477
p O 0 0.00065726426
. O 0 0.00039217077
o O 0 0.002343002
. O 0 0.0004603717
, O 0 0.00087591534
Ato B-Chemical 1 0.93075395
could O 0 0.00042174914
prevent O 0 0.0008553116
endothelial O 0 0.98927593
NO B-Chemical 0 0.99988854
synthase O 0 0.9787564
( O 0 0.010439928
eNOS O 0 0.7158926
) O 0 0.0015164461
downregulation O 0 0.000974578
and O 0 0.0005308386
the O 0 0.00045796594
increase O 0 0.00043439603
in O 0 0.0007438907
O2 B-Chemical 0 0.99891603
- I-Chemical 0 0.0015775582
in O 0 0.000713526
Sprague O 0 0.32332492
- O 0 0.0020938043
Dawley O 0 0.0853636
( O 0 0.0017127888
SD O 0 0.33160344
) O 0 0.0023189434
rats O 0 0.0028621354
, O 0 0.0021408927
thereby O 0 0.002997461
reducing O 0 0.0040694727
blood O 0 0.061591353
pressure O 0 0.23062558
. O 0 0.009225688

2 O 0 0.13118877
. O 0 0.12387763

Male O 0 0.076147586
SD O 0 0.20458664
rats O 0 0.009465894
( O 0 0.004483896
n O 0 0.0028766952
= O 0 0.00255373
30 O 0 0.0012345185
) O 0 0.0015531316
were O 0 0.000856748
treated O 0 0.00094576686
with O 0 0.001089043
Ato B-Chemical 1 0.97900414
( O 0 0.0012575703
50 O 0 0.0009135259
mg O 0 0.07033603
/ O 0 0.0011133468
kg O 0 0.0012801003
per O 0 0.0003748603
day O 0 0.0005087937
in O 0 0.0006679788
drinking O 0 0.41712096
water O 0 0.020140717
) O 0 0.0025258195
or O 0 0.0013618626
tap O 0 0.010956222
water O 0 0.0069867405
for O 0 0.0021570667
15 O 0 0.003060309
days O 0 0.0039811106
. O 0 0.0068563865

Dexamethasone B-Chemical 1 0.9992205
( O 0 0.009597271
10 O 0 0.0036677786
microg O 0 0.0038038837
/ O 0 0.0030748113
kg O 0 0.0031712942
per O 0 0.000834159
day O 0 0.0008792425
, O 0 0.0010647962
s O 0 0.00095583027
. O 0 0.0005745071
c O 0 0.004439199
. O 0 0.0005085561
) O 0 0.00086453155
or O 0 0.00044216999
saline O 0 0.03372505
was O 0 0.00039159541
started O 0 0.0003712495
after O 0 0.00021869136
4 O 0 0.00029338093
days O 0 0.00027253994
in O 0 0.00045671014
Ato B-Chemical 1 0.972985
- O 0 0.0010330589
treated O 0 0.0006314216
and O 0 0.00071896304
non O 0 0.0024803043
- O 0 0.001580238
treated O 0 0.00094479416
rats O 0 0.0019631288
and O 0 0.0011018954
continued O 0 0.0012192021
for O 0 0.0011806171
11 O 0 0.002492302
- O 0 0.0032161113
13 O 0 0.0034866899
days O 0 0.0038334304
. O 0 0.0066680815

Systolic O 0 0.73293036
blood O 0 0.0235658
pressure O 0 0.09340024
( O 0 0.007544552
SBP O 0 0.5913316
) O 0 0.003953323
was O 0 0.0017184892
measured O 0 0.001129548
on O 0 0.0010001503
alternate O 0 0.0017039104
days O 0 0.0012039148
using O 0 0.0015050904
the O 0 0.0019583437
tail O 0 0.004068047
- O 0 0.0057811155
cuff O 0 0.011522375
method O 0 0.008938593
. O 0 0.009180048

Endothelial O 0 0.9552874
function O 0 0.008033385
was O 0 0.0049100164
assessed O 0 0.0033823107
by O 0 0.005024434
acetylcholine B-Chemical 1 0.9997558
- O 0 0.01585614
induced O 0 0.005192798
vasorelaxation O 0 0.9999008
and O 0 0.023142586
phenylephrine B-Chemical 1 0.9999608
- O 0 0.022326613
induced O 0 0.0052350783
vasoconstriction O 0 0.9993808
in O 0 0.005251652
aortic O 0 0.5140698
segments O 0 0.011845332
. O 0 0.009629382

Vascular O 0 0.91838104
eNOS O 0 0.5257812
mRNA O 0 0.0080872215
was O 0 0.004618544
assessed O 0 0.0032892143
by O 0 0.00388185
semi O 0 0.012267727
- O 0 0.0046190536
quantitative O 0 0.0038933505
reverse O 0 0.020460276
transcription O 0 0.012208437
- O 0 0.008611565
polymerase O 0 0.096611455
chain O 0 0.038897157
reaction O 0 0.108395144
. O 0 0.0139379

3 O 0 0.12448769
. O 0 0.12115983

In O 0 0.008210594
rats O 0 0.009208953
treated O 0 0.0053086383
with O 0 0.0049101333
Dex B-Chemical 1 0.998811
alone O 0 0.0049201427
, O 0 0.0035343375
SBP O 0 0.7429375
was O 0 0.0009302638
increased O 0 0.00085158215
from O 0 0.0007165861
109 O 0 0.0029870265
+ O 0 0.0009596147
/ O 0 0.0022553855
- O 0 0.0009438116
2 O 0 0.000444107
to O 0 0.0003997154
133 O 0 0.0042033955
+ O 0 0.00070484506
/ O 0 0.0016302958
- O 0 0.0008061935
2 O 0 0.00043263848
mmHg O 0 0.0011254766
on O 0 0.00030326238
Days O 0 0.038097017
4 O 0 0.00042938077
and O 0 0.0005414096
Day O 0 0.0021046614
14 O 0 0.0007610509
, O 0 0.001015853
respectively O 0 0.0016901803
( O 0 0.002000696
P O 0 0.037115153
< O 0 0.0019679572
0 O 0 0.002689099
. O 0 0.0027320501
001 O 0 0.18005897
) O 0 0.008356442
. O 0 0.0077351024

In O 0 0.00865732
the O 0 0.00726196
Ato B-Chemical 1 0.96763456
+ O 0 0.008113746
Dex B-Chemical 1 0.9971163
group O 0 0.004584362
, O 0 0.0031071336
SBP O 0 0.64365244
was O 0 0.0010024757
increased O 0 0.00092569535
from O 0 0.00081438024
113 O 0 0.011058339
+ O 0 0.001021377
/ O 0 0.0023760858
- O 0 0.0009598739
2 O 0 0.00044184283
to O 0 0.00038971292
119 O 0 0.0025226562
+ O 0 0.00066738186
/ O 0 0.0015793393
- O 0 0.00075846765
2 O 0 0.0003855373
mmHg O 0 0.0010348433
on O 0 0.0002437278
Days O 0 0.039008126
4 O 0 0.00030994698
to O 0 0.00029246605
14 O 0 0.0004553456
, O 0 0.0005602813
respectively O 0 0.0009155946
( O 0 0.0008377738
P O 0 0.03160541
< O 0 0.000514251
0 O 0 0.00059171795
. O 0 0.00037675258
001 O 0 0.1623776
) O 0 0.0008432175
, O 0 0.0005455904
but O 0 0.0003693387
was O 0 0.00036216012
significantly O 0 0.00049288303
lower O 0 0.0004681473
than O 0 0.000382768
SBP O 0 0.47353366
in O 0 0.00041572057
the O 0 0.00047343943
group O 0 0.000740843
treated O 0 0.0010716491
with O 0 0.0016284155
Dex B-Chemical 1 0.9994191
alone O 0 0.0026837892
( O 0 0.0037744753
P O 0 0.12745284
< O 0 0.0021746722
0 O 0 0.0028422247
. O 0 0.0027365254
05 O 0 0.059664864
) O 0 0.007630184
. O 0 0.00743356

Endothelial O 0 0.9882185
- O 0 0.011696372
dependent O 0 0.0045291944
relaxation O 0 0.12858164
and O 0 0.0042483713
eNOS O 0 0.548749
mRNA O 0 0.0020676474
expression O 0 0.001276443
were O 0 0.00081905053
greater O 0 0.0006383336
in O 0 0.00063349504
the O 0 0.0009339023
Dex B-Chemical 1 0.99945027
+ O 0 0.0018573639
Ato B-Chemical 1 0.96791446
group O 0 0.00069643906
than O 0 0.00034511267
in O 0 0.00042542626
the O 0 0.000612582
Dex B-Chemical 1 0.99704164
only O 0 0.00061133946
group O 0 0.0010819595
( O 0 0.001395955
P O 0 0.063265525
< O 0 0.00072368066
0 O 0 0.0008126786
. O 0 0.0005570108
05 O 0 0.0130739845
and O 0 0.00088293647
P O 0 0.017128292
< O 0 0.0012225396
0 O 0 0.0015671693
. O 0 0.0014265329
0001 O 0 0.013877794
, O 0 0.003510514
respectively O 0 0.005989382
) O 0 0.009191015
. O 0 0.007918079

Aortic O 0 0.7357633
superoxide B-Chemical 1 0.99898964
production O 0 0.009270298
was O 0 0.0034080576
lower O 0 0.0023183334
in O 0 0.0016914246
the O 0 0.0020377086
Dex B-Chemical 1 0.9993643
+ O 0 0.0030823397
Ato B-Chemical 1 0.9678728
group O 0 0.00095560483
compared O 0 0.00042431368
with O 0 0.00060003577
the O 0 0.0006030093
group O 0 0.00089955993
treated O 0 0.0012315953
with O 0 0.0017985462
Dex B-Chemical 1 0.9994542
alone O 0 0.0028155781
( O 0 0.003826748
P O 0 0.12794785
< O 0 0.002118746
0 O 0 0.0027185509
. O 0 0.0026016505
0001 O 0 0.02836364
) O 0 0.007930637
. O 0 0.0075783674

4 O 0 0.12320249
. O 0 0.12067318

Treatment O 0 0.03539811
with O 0 0.008609245
Ato B-Chemical 1 0.9544983
improved O 0 0.009229476
endothelial O 0 0.8641038
function O 0 0.0047347303
, O 0 0.0038655517
reduced O 0 0.0032055762
superoxide B-Chemical 1 0.99983096
production O 0 0.006078173
and O 0 0.0026133596
reduced O 0 0.0026093668
SBP O 0 0.92852134
in O 0 0.0030298738
Dex B-Chemical 1 0.9994222
- O 0 0.009939647
treated O 0 0.006818521
SD O 0 0.725072
rats O 0 0.019815246
. O 0 0.009798744

Severe O 0 0.9660195
citrate B-Chemical 0 0.99334466
toxicity B-Disease 2 0.9970669
complicating O 0 0.662249
volunteer O 0 0.10248502
apheresis O 0 0.66395366
platelet O 0 0.98975533
donation O 0 0.61804277
. O 0 0.022088727

We O 0 0.009844663
report O 0 0.009146019
a O 0 0.0059855534
case O 0 0.004221084
of O 0 0.0048442967
severe O 0 0.600823
citrate B-Chemical 0 0.9983107
toxicity B-Disease 2 0.99871004
during O 0 0.002744339
volunteer O 0 0.0093554
donor O 0 0.006551922
apheresis O 0 0.39747107
platelet O 0 0.98026854
collection O 0 0.024457475
. O 0 0.010886302

The O 0 0.008492026
donor O 0 0.00790878
was O 0 0.0048147882
a O 0 0.0043815523
40 O 0 0.0034992357
- O 0 0.0034601481
year O 0 0.0021524276
- O 0 0.0024935496
old O 0 0.0019876151
female O 0 0.004566176
, O 0 0.0023653023
first O 0 0.001718203
- O 0 0.0031762556
time O 0 0.002286714
apheresis O 0 0.119860716
platelet O 0 0.95622224
donor O 0 0.023998858
. O 0 0.01134708

Past O 0 0.13980423
medical O 0 0.024906352
history O 0 0.023320025
was O 0 0.005775017
remarkable O 0 0.0069484296
for O 0 0.005287219
hypertension B-Disease 2 0.9998511
, O 0 0.07217596
hyperlipidemia B-Disease 0 0.99993074
, O 0 0.026132071
and O 0 0.016003536
depression B-Disease 2 0.99832445
. O 0 0.014374666

Reported O 0 0.033766925
medications O 0 0.44761497
included O 0 0.01432014
bumetanide B-Chemical 0 0.9998292
, O 0 0.064017445
pravastatin B-Chemical 1 0.9999045
, O 0 0.028230842
and O 0 0.023781357
paroxetine B-Chemical 1 0.9998579
. O 0 0.017957093

Thirty O 0 0.011161947
minutes O 0 0.0048342207
from O 0 0.0036031872
the O 0 0.0025624763
start O 0 0.0017909196
of O 0 0.0017029981
the O 0 0.0013772091
procedure O 0 0.0014150343
, O 0 0.0014172709
the O 0 0.000916787
donor O 0 0.0015510545
noted O 0 0.0011682877
tingling O 0 0.9850991
around O 0 0.001460018
the O 0 0.0016794043
mouth O 0 0.13934037
, O 0 0.003783694
hands O 0 0.007762989
, O 0 0.0052558235
and O 0 0.0062057106
feet O 0 0.19665602
. O 0 0.009856141

She O 0 0.0139163425
then O 0 0.0072687003
very O 0 0.00648531
rapidly O 0 0.006802694
developed O 0 0.0059855217
acute O 0 0.8850901
onset O 0 0.029975953
of O 0 0.006149811
severe O 0 0.58823794
facial O 0 0.7270797
and O 0 0.013845588
extremity O 0 0.9833264
tetany B-Disease 2 0.9997353
. O 0 0.017969988

Empirical O 0 0.023969218
treatment O 0 0.008134367
with O 0 0.0051920475
intravenous O 0 0.8709701
calcium B-Chemical 1 0.9997408
gluconate I-Chemical 0 0.9991053
was O 0 0.0023649582
initiated O 0 0.0017568809
, O 0 0.0016546989
and O 0 0.0013218732
muscle B-Disease 0 0.40799853
contractions I-Disease 0 0.97972864
slowly O 0 0.0073440466
subsided O 0 0.028886197
over O 0 0.00085381255
approximately O 0 0.001311653
10 O 0 0.0016821128
to O 0 0.0019473567
15 O 0 0.002809215
minutes O 0 0.003992638
. O 0 0.006689526

The O 0 0.008213243
events O 0 0.014701472
are O 0 0.004351665
consistent O 0 0.0027433971
with O 0 0.002381587
a O 0 0.0029645208
severe O 0 0.2114121
reaction O 0 0.056232005
to O 0 0.0026745815
calcium B-Chemical 1 0.9997881
chelation O 0 0.99913836
by O 0 0.022186128
sodium B-Chemical 1 0.9999714
citrate I-Chemical 1 0.9997824
anticoagulant O 0 0.9980731
resulting O 0 0.0041007786
in O 0 0.003142785
symptomatic O 0 0.66356915
systemic O 0 0.9968401
hypocalcemia B-Disease 2 0.99993443
. O 0 0.01793982

Upon O 0 0.010229968
additional O 0 0.004817325
retrospective O 0 0.010128293
analysis O 0 0.00430308
, O 0 0.003319186
it O 0 0.0021004556
was O 0 0.0014772267
noted O 0 0.0011689411
that O 0 0.001324177
bumetanide B-Chemical 0 0.9999411
is O 0 0.0016693089
a O 0 0.002149247
loop B-Chemical 0 0.0070545743
diuretic I-Chemical 0 0.99991274
that O 0 0.0023354026
may O 0 0.0029643883
cause O 0 0.023946699
significant O 0 0.019358253
hypocalcemia B-Disease 2 0.9998919
. O 0 0.015838165

We O 0 0.006923337
conclude O 0 0.0040741563
that O 0 0.002827631
careful O 0 0.00305947
screening O 0 0.0023255078
for O 0 0.0012178904
medications O 0 0.24549778
and O 0 0.0013764729
underlying O 0 0.0021195505
conditions O 0 0.0015289955
predisposing O 0 0.12900761
to O 0 0.00154854
hypocalcemia B-Disease 2 0.99998105
is O 0 0.0012689795
recommended O 0 0.0009450916
to O 0 0.0007247867
help O 0 0.001199272
prevent O 0 0.001433862
severe O 0 0.3007858
reactions O 0 0.0870029
due O 0 0.0023616338
to O 0 0.004305066
citrate B-Chemical 0 0.9981762
toxicity B-Disease 2 0.99897325
. O 0 0.0122783175

Laboratory O 0 0.017764956
measurement O 0 0.00561034
of O 0 0.005243125
pre O 0 0.012677035
- O 0 0.0047571994
procedure O 0 0.0027494517
serum O 0 0.19239095
calcium B-Chemical 1 0.9987155
levels O 0 0.0017432617
in O 0 0.0012417253
selected O 0 0.0011767829
donors O 0 0.0036275266
may O 0 0.0014006577
identify O 0 0.0014572914
cases O 0 0.0036669318
requiring O 0 0.0039483123
heightened O 0 0.07612525
vigilance O 0 0.48670328
. O 0 0.010230199

The O 0 0.006827795
case O 0 0.004725888
also O 0 0.0032320223
illustrates O 0 0.002333346
the O 0 0.0018133327
importance O 0 0.0013363651
of O 0 0.0016092415
maintaining O 0 0.0014528469
preparedness O 0 0.0027526421
for O 0 0.00087362813
managing O 0 0.007036039
rare O 0 0.015856013
but O 0 0.0015966987
serious O 0 0.27676755
reactions O 0 0.05133752
in O 0 0.0021317727
volunteer O 0 0.010470483
apheresis O 0 0.15936548
blood O 0 0.06588281
donors O 0 0.054824445
. O 0 0.009872143

Sirolimus B-Chemical 1 0.99505746
- O 0 0.036718242
associated O 0 0.025924113
proteinuria B-Disease 2 0.9994367
and O 0 0.05952742
renal B-Disease 2 0.99863964
dysfunction I-Disease 2 0.9981177
. O 0 0.029798372

Sirolimus B-Chemical 1 0.9927757
is O 0 0.006551484
a O 0 0.0048471205
novel O 0 0.004627396
immunosuppressant O 0 0.98912907
with O 0 0.0042295544
potent O 0 0.13274753
antiproliferative O 0 0.9877577
actions O 0 0.10997138
through O 0 0.00093598844
its O 0 0.0014480449
ability O 0 0.0007863184
to O 0 0.0007088403
inhibit O 0 0.0007410308
the O 0 0.001009951
raptor O 0 0.12482503
- O 0 0.002101246
containing O 0 0.0009522063
mammalian O 0 0.001927207
target O 0 0.0016603407
of O 0 0.003682732
rapamycin B-Chemical 1 0.9918635
protein O 0 0.057870653
kinase O 0 0.81811106
. O 0 0.011176455

Sirolimus B-Chemical 1 0.98682725
represents O 0 0.006547652
a O 0 0.004816262
major O 0 0.003589425
therapeutic O 0 0.007924059
advance O 0 0.0027923682
in O 0 0.001434001
the O 0 0.0013751802
prevention O 0 0.004363047
of O 0 0.0025541089
acute O 0 0.98524344
renal O 0 0.99882096
allograft O 0 0.9971529
rejection O 0 0.9991315
and O 0 0.038445406
chronic O 0 0.9987884
allograft O 0 0.9992355
nephropathy B-Disease 2 0.99997413
. O 0 0.031901427

Its O 0 0.05201628
role O 0 0.0053367745
in O 0 0.003906354
the O 0 0.003089351
therapy O 0 0.0076718265
of O 0 0.005120405
glomerulonephritis B-Disease 2 0.9999709
, O 0 0.05691142
autoimmunity B-Disease 0 0.999329
, O 0 0.0073727183
cystic B-Disease 0 0.9424673
renal I-Disease 0 0.9985328
diseases I-Disease 0 0.9925546
and O 0 0.015180627
renal B-Disease 0 0.9996848
cancer I-Disease 2 0.99974245
is O 0 0.005486123
under O 0 0.003937024
investigation O 0 0.009611281
. O 0 0.009291242

Because O 0 0.008127199
sirolimus B-Chemical 1 0.99743146
does O 0 0.0038060215
not O 0 0.002415897
share O 0 0.00219374
the O 0 0.001961796
vasomotor O 0 0.9988757
renal O 0 0.9962949
adverse O 0 0.9872825
effects O 0 0.007071267
exhibited O 0 0.001047738
by O 0 0.001499168
calcineurin O 0 0.9434733
inhibitors O 0 0.23128006
, O 0 0.0018475085
it O 0 0.0008609772
has O 0 0.000615476
been O 0 0.00078578014
designated O 0 0.0007898686
a O 0 0.001415481
' O 0 0.0019487268
non O 0 0.0048758667
- O 0 0.010825951
nephrotoxic B-Disease 2 0.999645
drug O 0 0.932694
' O 0 0.015178688
. O 0 0.008891339

However O 0 0.0093316175
, O 0 0.006718816
clinical O 0 0.006355197
reports O 0 0.0032183272
suggest O 0 0.0016077239
that O 0 0.0014972362
, O 0 0.0017651827
under O 0 0.000859212
some O 0 0.0011729689
circumstances O 0 0.0030128127
, O 0 0.002397846
sirolimus B-Chemical 1 0.9997588
is O 0 0.0014971264
associated O 0 0.0018341693
with O 0 0.0034290303
proteinuria B-Disease 2 0.99996066
and O 0 0.020508708
acute B-Disease 0 0.9990503
renal I-Disease 2 0.9998011
dysfunction I-Disease 2 0.9996244
. O 0 0.015993718

A O 0 0.05255286
common O 0 0.011193251
risk O 0 0.06439827
factor O 0 0.017118614
appears O 0 0.0033142143
to O 0 0.0026085493
be O 0 0.0023935041
presence O 0 0.0019967926
of O 0 0.003112757
pre O 0 0.029892735
- O 0 0.0061313733
existing O 0 0.0061819064
chronic B-Disease 0 0.9967079
renal I-Disease 2 0.99968135
damage I-Disease 2 0.9986313
. O 0 0.01886711

The O 0 0.007519344
mechanisms O 0 0.0068156742
of O 0 0.0062984857
sirolimus B-Chemical 1 0.99977833
- O 0 0.02038621
associated O 0 0.004774366
proteinuria B-Disease 2 0.99995804
are O 0 0.002850941
multifactorial O 0 0.5405239
and O 0 0.0014832965
may O 0 0.00078912755
be O 0 0.00069704925
due O 0 0.00047617944
to O 0 0.00055891846
an O 0 0.0008942709
increase O 0 0.00060173863
in O 0 0.00089061225
glomerular O 0 0.85588783
capillary O 0 0.2997868
pressure O 0 0.14775652
following O 0 0.0030553348
calcineurin O 0 0.9650633
inhibitor O 0 0.6755438
withdrawal O 0 0.9796651
. O 0 0.010861642

It O 0 0.010312723
has O 0 0.00499105
also O 0 0.0038848107
been O 0 0.0028566697
suggested O 0 0.0018078131
that O 0 0.0015349047
sirolimus B-Chemical 1 0.99963737
directly O 0 0.0019677998
causes O 0 0.004945711
increased O 0 0.0022790877
glomerular O 0 0.9786486
permeability O 0 0.9684889
/ O 0 0.043047052
injury O 0 0.9741237
, O 0 0.001724092
but O 0 0.00081453
evidence O 0 0.0008608682
for O 0 0.0008657549
this O 0 0.0013062141
mechanism O 0 0.0022007255
is O 0 0.0027732553
currently O 0 0.00525311
inconclusive O 0 0.07303839
. O 0 0.008579537

The O 0 0.009456149
acute B-Disease 0 0.9760139
renal I-Disease 2 0.9990983
dysfunction I-Disease 2 0.9994344
associated O 0 0.006537614
with O 0 0.0034747815
sirolimus B-Chemical 1 0.99991536
( O 0 0.002969646
such O 0 0.00079401844
as O 0 0.0007205368
in O 0 0.0005924385
delayed O 0 0.002879076
graft O 0 0.018113084
function O 0 0.0012902484
) O 0 0.0016949767
may O 0 0.00047412855
be O 0 0.00048434784
due O 0 0.00035586226
to O 0 0.00045787403
suppression O 0 0.0010359051
of O 0 0.0009818256
compensatory O 0 0.0051352386
renal O 0 0.9950293
cell O 0 0.17402789
proliferation O 0 0.8691799
and O 0 0.0035887193
survival O 0 0.23675412
/ O 0 0.016941011
repair O 0 0.0076446105
processes O 0 0.012275512
. O 0 0.009182216

Although O 0 0.0065683923
these O 0 0.005431792
adverse O 0 0.6973692
effects O 0 0.005487551
occur O 0 0.002124389
in O 0 0.0012384929
some O 0 0.0011965272
patients O 0 0.003139854
, O 0 0.0011020225
their O 0 0.0006889789
occurrence O 0 0.0015270516
could O 0 0.0004459286
be O 0 0.0004982048
minimised O 0 0.0005100172
by O 0 0.00047005108
knowledge O 0 0.00053060846
of O 0 0.00047697715
the O 0 0.0004341042
molecular O 0 0.008042834
effects O 0 0.0011907613
of O 0 0.0008979795
sirolimus B-Chemical 1 0.99983597
on O 0 0.0003395027
the O 0 0.00052846584
kidney O 0 0.85946465
, O 0 0.00080671604
the O 0 0.00035204555
use O 0 0.00040250595
of O 0 0.00060471945
sirolimus B-Chemical 1 0.9997868
in O 0 0.00042136095
appropriate O 0 0.00036350032
patient O 0 0.00070067367
populations O 0 0.00093915337
, O 0 0.00050643296
close O 0 0.00027365645
monitoring O 0 0.00042598828
of O 0 0.0007828668
proteinuria B-Disease 2 0.999977
and O 0 0.0014355642
renal O 0 0.9902034
function O 0 0.001320833
, O 0 0.00088087807
use O 0 0.0005829928
of O 0 0.0016702007
angiotensin B-Chemical 1 0.99998057
- O 0 0.019300114
converting O 0 0.23374811
enzyme O 0 0.26314163
inhibitors O 0 0.20093688
or O 0 0.0034667922
angiotensin B-Chemical 1 0.9999895
II I-Chemical 1 0.95000994
receptor O 0 0.6201562
blockers O 0 0.999556
if O 0 0.0016920723
proteinuria B-Disease 2 0.99995804
occurs O 0 0.0020990737
and O 0 0.0032740685
withdrawal O 0 0.7458869
if O 0 0.0031945189
needed O 0 0.004346037
. O 0 0.0074975407

Further O 0 0.009348186
long O 0 0.0065302784
- O 0 0.005205875
term O 0 0.0026084743
analysis O 0 0.0025000433
of O 0 0.0024155085
renal O 0 0.978519
allograft O 0 0.9603726
studies O 0 0.0019730378
using O 0 0.0010406437
sirolimus B-Chemical 1 0.9996123
as O 0 0.0009565937
de O 0 0.020275539
novo O 0 0.01569066
immunosuppression O 0 0.9845712
along O 0 0.0010138081
with O 0 0.0009034373
clinical O 0 0.007392048
and O 0 0.0010455637
laboratory O 0 0.0014523496
studies O 0 0.0010422932
will O 0 0.0008699076
refine O 0 0.0019090325
these O 0 0.001805693
issues O 0 0.0033282624
in O 0 0.002510563
the O 0 0.0036801677
future O 0 0.0057367156
. O 0 0.0077091386

Proteinuria B-Disease 2 0.9974644
after O 0 0.010161915
conversion O 0 0.014823375
to O 0 0.009060653
sirolimus B-Chemical 1 0.9987833
in O 0 0.010903609
renal O 0 0.99091256
transplant O 0 0.86716884
recipients O 0 0.112272754
. O 0 0.016111435

Sirolimus B-Chemical 1 0.9967822
( O 0 0.03810353
SRL B-Chemical 1 0.99887866
) O 0 0.014401943
is O 0 0.0060225856
a O 0 0.0063595404
new O 0 0.0071567073
, O 0 0.00837547
potent O 0 0.072055966
immunosuppressive O 0 0.9923368
agent O 0 0.8965784
. O 0 0.018916577

More O 0 0.020035487
recently O 0 0.008690582
, O 0 0.009308198
proteinuria B-Disease 2 0.9997367
has O 0 0.003137233
been O 0 0.0021552285
reported O 0 0.0016647371
as O 0 0.0011746013
a O 0 0.0013055444
consequence O 0 0.0008091651
of O 0 0.0015689303
sirolimus B-Chemical 1 0.9998728
therapy O 0 0.058770146
, O 0 0.0018943236
although O 0 0.0010762879
the O 0 0.0013665401
mechanism O 0 0.0021672
has O 0 0.0024346833
remained O 0 0.0045826524
unclear O 0 0.0067752837
. O 0 0.008620277

We O 0 0.0076573333
retrospectively O 0 0.005508513
examined O 0 0.0028550364
the O 0 0.0025326575
records O 0 0.002825693
of O 0 0.001992579
25 O 0 0.002281409
renal O 0 0.9330332
transplant O 0 0.45575076
patients O 0 0.008172021
, O 0 0.0015855453
who O 0 0.0017416237
developed O 0 0.0014064527
or O 0 0.0011897937
displayed O 0 0.0014085704
increased O 0 0.004466457
proteinuria B-Disease 2 0.99994063
after O 0 0.004607153
SRL B-Chemical 1 0.99972194
conversion O 0 0.08100452
. O 0 0.010198334

The O 0 0.0075948746
patient O 0 0.0071317498
cohort O 0 0.0066551035
( O 0 0.004056562
14 O 0 0.0024288439
men O 0 0.044375144
, O 0 0.0019751666
11 O 0 0.0015060891
women O 0 0.02047607
) O 0 0.0016071927
was O 0 0.0006891513
treated O 0 0.00086065533
with O 0 0.0011549453
SRL B-Chemical 1 0.9998617
as O 0 0.0009137435
conversion O 0 0.0068882774
therapy O 0 0.013084724
, O 0 0.0008299354
due O 0 0.00038464338
to O 0 0.0005988491
chronic B-Disease 0 0.99205303
allograft I-Disease 0 0.9989982
nephropathy I-Disease 2 0.99999857
( O 0 0.09680502
CAN B-Disease 0 0.99972814
) O 0 0.0035560725
( O 0 0.0007552131
n O 0 0.00052536343
= O 0 0.0005973376
15 O 0 0.00037218293
) O 0 0.00086836936
neoplasia B-Disease 0 0.9978206
( O 0 0.00090838235
n O 0 0.0005881831
= O 0 0.0006770064
8 O 0 0.0004607862
) O 0 0.00092154066
; O 0 0.0011582429
Kaposi B-Disease 0 0.9993655
' I-Disease 0 0.0012338468
s I-Disease 0 0.0010053564
sarcoma I-Disease 0 0.9993993
, O 0 0.0012392995
Four O 0 0.0012681228
skin B-Disease 0 0.6596083
cancers I-Disease 2 0.999801
, O 0 0.0024531013
One O 0 0.0017288094
intestinal B-Disease 0 0.8488857
tumors I-Disease 2 0.9992448
, O 0 0.0024198142
One O 0 0.0020813022
renal B-Disease 0 0.99659747
cell I-Disease 0 0.09180547
carsinom I-Disease 0 0.43847924
) O 0 0.0043989746
or O 0 0.0015664398
BK O 0 0.9992136
virus O 0 0.49356633
nephropathy B-Disease 2 0.99998
( O 0 0.008736799
n O 0 0.0033665148
= O 0 0.0041536237
2 O 0 0.003954682
) O 0 0.007539098
. O 0 0.0071643414

SRL B-Chemical 1 0.99718934
was O 0 0.007821524
started O 0 0.004626836
at O 0 0.0025269312
a O 0 0.0025055537
mean O 0 0.0017248769
of O 0 0.0019519812
78 O 0 0.0035818815
+ O 0 0.0020345722
/ O 0 0.0035079676
- O 0 0.0020205728
42 O 0 0.0015993173
( O 0 0.0014287164
15 O 0 0.0010099029
to O 0 0.0012157763
163 O 0 0.005974816
) O 0 0.0029272356
months O 0 0.0020661494
after O 0 0.0026418765
transplantation O 0 0.084892854
. O 0 0.008715507

Mean O 0 0.009654082
follow O 0 0.0061939415
- O 0 0.005963728
up O 0 0.0033212407
on O 0 0.0026102366
SRL B-Chemical 1 0.9989503
therapy O 0 0.017496765
was O 0 0.0019063198
20 O 0 0.0017062464
+ O 0 0.0017762325
/ O 0 0.0032429225
- O 0 0.002007004
12 O 0 0.0010730072
( O 0 0.0016416853
6 O 0 0.0012787032
to O 0 0.0017779717
43 O 0 0.004210205
) O 0 0.005519587
months O 0 0.0047252798
. O 0 0.007358786

Proteinuria B-Disease 2 0.99856794
increased O 0 0.008060315
from O 0 0.004332407
0 O 0 0.0038113208
. O 0 0.0019233632
445 O 0 0.008060666
( O 0 0.0016908417
0 O 0 0.0011011064
to O 0 0.0006987562
1 O 0 0.00075890723
. O 0 0.00047993794
5 O 0 0.0004922565
) O 0 0.00076695386
g O 0 0.00082542066
/ O 0 0.00092546194
d O 0 0.00049852213
before O 0 0.0002683848
conversion O 0 0.0009536598
to O 0 0.00039068057
3 O 0 0.00042799703
. O 0 0.00030060636
2 O 0 0.00038167558
g O 0 0.0007269055
/ O 0 0.0012836598
dL O 0 0.0068425
( O 0 0.00073810876
0 O 0 0.00061285886
. O 0 0.00033222616
2 O 0 0.00039917353
to O 0 0.00038425744
12 O 0 0.0004345323
) O 0 0.000826536
after O 0 0.0004672897
conversion O 0 0.0025921725
( O 0 0.0021517978
P O 0 0.07411437
= O 0 0.0026008908
0 O 0 0.0027401145
. O 0 0.0026839937
001 O 0 0.2114843
) O 0 0.008273679
. O 0 0.0075895535

Before O 0 0.010941697
conversion O 0 0.011089571
8 O 0 0.0049283165
( O 0 0.004267077
32 O 0 0.003089103
% O 0 0.002604079
) O 0 0.0024615454
patients O 0 0.00221807
had O 0 0.0012394282
no O 0 0.0013692366
proteinuria B-Disease 2 0.9999089
, O 0 0.003271222
whereas O 0 0.0016886356
afterwards O 0 0.002710514
all O 0 0.0021220825
patients O 0 0.006657187
had O 0 0.006372825
proteinuria B-Disease 2 0.9997843
. O 0 0.012631501

In O 0 0.008369262
28 O 0 0.006482902
% O 0 0.004897651
of O 0 0.0037430031
patients O 0 0.008799041
proteinuria B-Disease 2 0.99986637
remained O 0 0.0037776616
unchanged O 0 0.0021878746
, O 0 0.0019954229
whereas O 0 0.0012591208
it O 0 0.0015434384
increased O 0 0.0017350361
in O 0 0.00185705
68 O 0 0.0038788547
% O 0 0.0034570391
of O 0 0.004529212
patients O 0 0.0144261215
. O 0 0.009041429

In O 0 0.012986909
40 O 0 0.010750608
% O 0 0.009674441
it O 0 0.0075959386
increased O 0 0.0068648863
by O 0 0.007013721
more O 0 0.0071217385
than O 0 0.006092296
100 O 0 0.012531247
% O 0 0.012939679
. O 0 0.012595702

Twenty O 0 0.016666915
- O 0 0.009233183
eight O 0 0.004125112
percent O 0 0.0037294289
of O 0 0.0038207627
patients O 0 0.005720399
showed O 0 0.0031750572
increased O 0 0.006292842
proteinuria B-Disease 2 0.9998678
to O 0 0.0058613745
the O 0 0.0088113295
nephrotic B-Disease 2 0.99990606
range O 0 0.05289117
. O 0 0.013334184

Biopsies O 0 0.023189675
performed O 0 0.006419155
in O 0 0.004466332
five O 0 0.0030236593
patients O 0 0.0041884324
revealed O 0 0.00266614
new O 0 0.0033398168
pathological O 0 0.21875046
changes O 0 0.004796721
: O 0 0.005818387
One O 0 0.010862227
membranoproliferative B-Disease 0 0.99995327
glomerulopathy I-Disease 0 0.99996436
and O 0 0.12768456
interstitial B-Disease 2 0.9984242
nephritis I-Disease 2 0.99996793
. O 0 0.036091805

These O 0 0.024197802
patients O 0 0.023213934
showed O 0 0.015803566
persistently O 0 0.03455617
good O 0 0.019912574
graft O 0 0.049057666
function O 0 0.023974685
. O 0 0.023244973

Serum O 0 0.6215741
creatinine B-Chemical 1 0.9895906
values O 0 0.0049246973
did O 0 0.0027581507
not O 0 0.0019687002
change O 0 0.0017246439
significantly O 0 0.0018762233
: O 0 0.0019894198
1 O 0 0.0010299894
. O 0 0.0005932567
98 O 0 0.0012927632
+ O 0 0.0007978958
/ O 0 0.0016575765
- O 0 0.00091793033
0 O 0 0.00059516873
. O 0 0.0003105255
8 O 0 0.0003774943
mg O 0 0.053649828
/ O 0 0.001322593
dL O 0 0.004505894
before O 0 0.00035480148
SRL B-Chemical 1 0.99953854
therapy O 0 0.004933243
and O 0 0.0006480603
2 O 0 0.0005300251
. O 0 0.00033103392
53 O 0 0.00097583374
+ O 0 0.00061831874
/ O 0 0.0016838994
- O 0 0.0008651237
1 O 0 0.000462063
. O 0 0.00031267124
9 O 0 0.00043965428
mg O 0 0.042367034
/ O 0 0.0012712132
dL O 0 0.0021350964
at O 0 0.00040535658
last O 0 0.00044266446
follow O 0 0.00061535015
- O 0 0.0013215049
up O 0 0.0010531482
( O 0 0.0021782117
P O 0 0.058221098
= O 0 0.0028476366
. O 0 0.002132896
14 O 0 0.0038729303
) O 0 0.007176664
. O 0 0.007169377

Five O 0 0.019538188
grafts O 0 0.017051207
were O 0 0.009622913
lost O 0 0.008295811
and O 0 0.0070599928
the O 0 0.0063175433
patients O 0 0.009986465
returned O 0 0.0075095007
to O 0 0.008078214
dialysis O 0 0.11086029
. O 0 0.014620485

Five O 0 0.024887731
patients O 0 0.020939417
displayed O 0 0.014435099
CAN B-Disease 0 0.9857378
and O 0 0.020881778
Kaposi B-Disease 0 0.9984648
' I-Disease 0 0.025225604
s I-Disease 0 0.023687499
sarcoma I-Disease 0 0.997577
. O 0 0.024927592

Mean O 0 0.008601861
urinary O 0 0.2898405
protein O 0 0.00548232
of O 0 0.0032664507
patients O 0 0.0041221827
who O 0 0.0025200993
returned O 0 0.0011074387
to O 0 0.0007622383
dialysis O 0 0.02035609
was O 0 0.0007880416
1 O 0 0.0006881318
. O 0 0.0003994076
26 O 0 0.000649844
( O 0 0.0005920169
0 O 0 0.00051414734
. O 0 0.00027335758
5 O 0 0.00027963854
to O 0 0.00028331234
3 O 0 0.00034606946
. O 0 0.000271189
5 O 0 0.0003228176
) O 0 0.0005612348
g O 0 0.0006309692
/ O 0 0.00074406795
d O 0 0.00041238312
before O 0 0.00022904894
and O 0 0.00042826336
4 O 0 0.00038699104
. O 0 0.0002959258
7 O 0 0.00037967926
( O 0 0.00049718405
3 O 0 0.00033639302
to O 0 0.0003332181
12 O 0 0.0003738478
) O 0 0.0007541653
g O 0 0.00094550557
/ O 0 0.0012320541
d O 0 0.00084867293
after O 0 0.00060352695
conversion O 0 0.0035122458
( O 0 0.0028800126
P O 0 0.11817698
= O 0 0.0036127367
. O 0 0.0027635165
01 O 0 0.015364094
) O 0 0.007934494
. O 0 0.0074909935

Mean O 0 0.009508747
serum O 0 0.05814384
creatinine B-Chemical 1 0.98598367
level O 0 0.002501016
before O 0 0.0014608484
conversion O 0 0.0033410932
was O 0 0.0012980662
2 O 0 0.0010055653
. O 0 0.0006290214
21 O 0 0.00081823376
mg O 0 0.087934814
/ O 0 0.0018897651
dL O 0 0.004664164
and O 0 0.00070646853
thereafter O 0 0.0007125159
, O 0 0.0007479685
4 O 0 0.00052846735
. O 0 0.00046916524
93 O 0 0.001205708
mg O 0 0.086115934
/ O 0 0.0028234583
dL O 0 0.012829937
( O 0 0.00261264
P O 0 0.0586771
= O 0 0.0035604953
. O 0 0.002895057
02 O 0 0.039807595
) O 0 0.008183384
. O 0 0.007692625

Heavy O 0 0.9740927
proteinuria B-Disease 2 0.9995066
was O 0 0.0067375884
common O 0 0.004341776
after O 0 0.0019961824
the O 0 0.0020991457
use O 0 0.0022738327
of O 0 0.0036446603
SRL B-Chemical 1 0.99968016
as O 0 0.002916152
rescue O 0 0.0031317144
therapy O 0 0.01655437
for O 0 0.0038106546
renal O 0 0.99351114
transplantation O 0 0.740143
. O 0 0.011674217

Therefore O 0 0.008924255
, O 0 0.008020109
conversion O 0 0.007268938
should O 0 0.002507513
be O 0 0.002358887
considered O 0 0.0016360905
for O 0 0.0014232341
patients O 0 0.0030152863
who O 0 0.002800762
have O 0 0.0016460598
not O 0 0.0020568636
developed O 0 0.0043367366
advanced O 0 0.36859572
CAN B-Disease 0 0.99912876
and O 0 0.03689279
proteinuria B-Disease 2 0.99986327
. O 0 0.0153969005

The O 0 0.007543795
possibility O 0 0.0052707284
of O 0 0.0048173815
de O 0 0.0148624
novo O 0 0.02514421
glomerular O 0 0.9545039
pathology O 0 0.37835643
under O 0 0.0027938134
SRL B-Chemical 1 0.99972004
treatment O 0 0.0038381985
requires O 0 0.001456864
further O 0 0.0023548924
investigation O 0 0.0040952456
by O 0 0.005533884
renal O 0 0.99094546
biopsy O 0 0.21725
. O 0 0.011817686

Long O 0 0.03432727
- O 0 0.009193026
term O 0 0.004389564
follow O 0 0.0031551744
- O 0 0.0033848512
up O 0 0.0017333925
of O 0 0.0023153739
ifosfamide B-Chemical 1 0.9998603
renal B-Disease 2 0.9997571
toxicity I-Disease 2 0.9998914
in O 0 0.001498809
children O 0 0.0038326383
treated O 0 0.0013052026
for O 0 0.0010002919
malignant B-Disease 0 0.9990734
mesenchymal I-Disease 0 0.9976675
tumors I-Disease 2 0.99982077
: O 0 0.007329402
an O 0 0.0027358227
International O 0 0.008863355
Society O 0 0.004069689
of O 0 0.002941056
Pediatric O 0 0.007613309
Oncology O 0 0.040862903
report O 0 0.011780285
. O 0 0.008795497

The O 0 0.007998927
renal O 0 0.68476033
function O 0 0.0042571067
of O 0 0.003129095
74 O 0 0.0036596481
children O 0 0.0029663662
with O 0 0.0017961987
malignant B-Disease 0 0.9984975
mesenchymal I-Disease 0 0.9961159
tumors I-Disease 2 0.99973077
in O 0 0.0010001836
complete O 0 0.0006925159
remission O 0 0.28094208
and O 0 0.0006496676
who O 0 0.00085434265
have O 0 0.0003316714
received O 0 0.00036250398
the O 0 0.00037356172
same O 0 0.00034965004
ifosfamide B-Chemical 1 0.999673
chemotherapy O 0 0.8050037
protocol O 0 0.0019239014
( O 0 0.0015159083
International O 0 0.0037043286
Society O 0 0.0012487979
of O 0 0.00070266804
Pediatric O 0 0.0021349348
Oncology O 0 0.046242055
Malignant B-Disease 0 0.9933781
Mesenchymal I-Disease 0 0.9885924
Tumor I-Disease 0 0.999647
Study O 0 0.04615427
84 O 0 0.001271069
[ O 0 0.0014988625
SIOP O 0 0.0057428065
MMT O 0 0.7449443
84 O 0 0.0013128739
] O 0 0.0013313784
) O 0 0.001044574
were O 0 0.0006135426
studied O 0 0.0007318046
1 O 0 0.0008577262
year O 0 0.00082077674
after O 0 0.00076264306
the O 0 0.0013886966
completion O 0 0.0017246864
of O 0 0.0037987332
treatment O 0 0.009379134
. O 0 0.008799751

Total O 0 0.010128505
cumulative O 0 0.008720291
doses O 0 0.013447763
were O 0 0.0027950888
36 O 0 0.0018909303
or O 0 0.001249863
60 O 0 0.0010825616
g O 0 0.0015691739
/ O 0 0.001839649
m2 O 0 0.005988996
of O 0 0.0011642249
ifosfamide B-Chemical 1 0.99967873
( O 0 0.0011355543
six O 0 0.00037658383
or O 0 0.0004692173
10 O 0 0.0004823044
cycles O 0 0.00044924178
of O 0 0.00096202054
ifosfamide B-Chemical 1 0.99981457
, I-Chemical 0 0.005133105
vincristine I-Chemical 1 0.99992156
, I-Chemical 0 0.003298303
and I-Chemical 0 0.0032232627
dactinomycin I-Chemical 0 0.9980878
[ O 0 0.14035138
IVA B-Chemical 0 0.999772
] O 0 0.053918973
) O 0 0.01640454
. O 0 0.009096136

None O 0 0.03161366
of O 0 0.019152738
them O 0 0.019922238
had O 0 0.014303915
received O 0 0.017684717
cisplatin B-Chemical 1 0.9986657
chemotherapy O 0 0.97818506
. O 0 0.026392275

Ages O 0 0.022627462
ranged O 0 0.008624268
from O 0 0.005164883
4 O 0 0.0034223462
months O 0 0.0022516064
to O 0 0.0020850254
17 O 0 0.002625647
years O 0 0.0026583716
; O 0 0.0027797944
58 O 0 0.0026089835
patients O 0 0.0031021305
were O 0 0.0024781486
males O 0 0.0044398834
and O 0 0.0041854824
42 O 0 0.0068715275
females O 0 0.010349044
. O 0 0.009159451

The O 0 0.011511307
most O 0 0.010419394
common O 0 0.008638679
primary O 0 0.008449516
tumor B-Disease 2 0.84675586
site O 0 0.0065944185
was O 0 0.00555709
the O 0 0.006061867
head O 0 0.0892742
and O 0 0.012589453
neck O 0 0.81636775
. O 0 0.015789969

Renal O 0 0.5771051
function O 0 0.006213997
was O 0 0.0035976754
investigated O 0 0.0021598912
by O 0 0.0021041627
measuring O 0 0.0013214042
plasma O 0 0.01592108
and O 0 0.001950617
urinary O 0 0.9695301
electrolytes O 0 0.9984181
, O 0 0.014860403
glucosuria B-Disease 0 0.9999659
, O 0 0.021006621
proteinuria B-Disease 2 0.9999894
, O 0 0.033030324
aminoaciduria B-Disease 0 0.99998724
, O 0 0.009493986
urinary O 0 0.9873072
pH O 0 0.9046027
, O 0 0.0029007501
osmolarity O 0 0.9672792
, O 0 0.0034566922
creatinine B-Chemical 1 0.9987949
clearance O 0 0.23856895
, O 0 0.0033766187
phosphate B-Chemical 1 0.9977581
tubular O 0 0.92706674
reabsorption O 0 0.98519415
, O 0 0.0046281544
beta O 0 0.48415387
2 O 0 0.0026770667
microglobulinuria O 0 0.4559012
, O 0 0.004784629
and O 0 0.0060837297
lysozymuria O 0 0.95935404
. O 0 0.009760159

Fifty O 0 0.02163375
- O 0 0.008774188
eight O 0 0.003790096
patients O 0 0.00556278
( O 0 0.0035632534
78 O 0 0.003350162
% O 0 0.002067414
) O 0 0.0018261871
had O 0 0.0009421846
normal O 0 0.0017081545
renal O 0 0.93472767
tests O 0 0.003451417
, O 0 0.0012873035
whereas O 0 0.00076638116
16 O 0 0.00096427876
patients O 0 0.0020151704
( O 0 0.0017251888
22 O 0 0.0017710953
% O 0 0.002073732
) O 0 0.0033381376
had O 0 0.0034022327
renal B-Disease 0 0.9973271
abnormalities I-Disease 0 0.9250286
. O 0 0.011199765

Two O 0 0.00804272
subsets O 0 0.005492897
of O 0 0.003973993
patients O 0 0.004461458
were O 0 0.0018462277
identified O 0 0.0011374446
from O 0 0.0010049787
this O 0 0.0008163179
latter O 0 0.0015489248
group O 0 0.0010084785
: O 0 0.00090280187
the O 0 0.00042069267
first O 0 0.0003288215
included O 0 0.00037063722
four O 0 0.00032457628
patients O 0 0.0015405172
( O 0 0.00071682653
5 O 0 0.000335205
% O 0 0.00036762547
of O 0 0.00033126978
the O 0 0.00032071536
total O 0 0.00039534786
population O 0 0.001166703
) O 0 0.000954584
who O 0 0.0008075264
developed O 0 0.0006508643
major O 0 0.0008344646
toxicity B-Disease 2 0.9964675
resulting O 0 0.0010790979
in O 0 0.00078468164
Fanconi B-Disease 0 0.9949222
' I-Disease 0 0.0021552304
s I-Disease 0 0.0012189395
syndrome I-Disease 0 0.9336502
( O 0 0.0075685256
TDFS B-Disease 0 0.99414885
) O 0 0.0031899756
; O 0 0.00094124203
and O 0 0.00043106053
the O 0 0.00035911283
second O 0 0.000391747
group O 0 0.00050509296
included O 0 0.00042515548
five O 0 0.00038673513
patients O 0 0.0014327235
with O 0 0.00092882453
elevated O 0 0.007472567
beta O 0 0.5054431
2 O 0 0.0022503822
microglobulinuria O 0 0.42748135
and O 0 0.0036800536
low O 0 0.008513698
phosphate B-Chemical 1 0.9987783
reabsorption O 0 0.986616
. O 0 0.011942336

The O 0 0.0126629155
remaining O 0 0.010017736
seven O 0 0.008733309
patients O 0 0.011155127
had O 0 0.007991539
isolated O 0 0.01003713
beta O 0 0.48030078
2 O 0 0.015393459
microglobulinuria O 0 0.6231396
. O 0 0.01752222

Severe O 0 0.934163
toxicity B-Disease 2 0.99295133
was O 0 0.0047624363
correlated O 0 0.0022753
with O 0 0.0017010124
the O 0 0.001201601
higher O 0 0.0008687637
cumulative O 0 0.0021396047
dose O 0 0.005894862
of O 0 0.0009223721
60 O 0 0.0006904039
g O 0 0.0011114785
/ O 0 0.0014165477
m2 O 0 0.0071912576
of O 0 0.0008460375
ifosfamide B-Chemical 1 0.99976355
, O 0 0.0009962186
a O 0 0.0007390766
younger O 0 0.009253419
age O 0 0.0015296538
( O 0 0.0007132194
less O 0 0.00040596948
than O 0 0.00033253388
2 O 0 0.00047610563
1 O 0 0.0004939537
/ O 0 0.0008686292
2 O 0 0.0004912023
years O 0 0.0006951248
old O 0 0.00088726444
) O 0 0.001444654
, O 0 0.0010912311
and O 0 0.0010377519
a O 0 0.0015047486
predominance O 0 0.0025758103
of O 0 0.0032644952
vesicoprostatic O 0 0.23731267
tumor B-Disease 2 0.9747308
involvement O 0 0.064061746
. O 0 0.010115179

This O 0 0.010309352
low O 0 0.0059647313
percentage O 0 0.0035398111
( O 0 0.0041206134
5 O 0 0.0020993554
% O 0 0.0022398077
) O 0 0.0021712945
of O 0 0.0016265746
TDFS O 0 0.9059712
must O 0 0.00062536664
be O 0 0.0006391643
evaluated O 0 0.00047905257
with O 0 0.0005489204
respect O 0 0.00043215413
to O 0 0.0004496267
the O 0 0.0004986058
efficacy O 0 0.0013749648
of O 0 0.0011907626
ifosfamide B-Chemical 1 0.9997087
in O 0 0.0009025279
the O 0 0.001027825
treatment O 0 0.0021673732
of O 0 0.003405325
mesenchymal B-Disease 0 0.9920216
tumors I-Disease 2 0.9989236
in O 0 0.006479662
children O 0 0.033506963
. O 0 0.00893049

Progressive O 0 0.37894532
myopathy B-Disease 2 0.9942397
with O 0 0.008296137
up O 0 0.005695693
- O 0 0.0055682873
regulation O 0 0.0027658737
of O 0 0.0037164963
MHC O 0 0.35380432
- O 0 0.009127906
I O 0 0.021411898
associated O 0 0.004454478
with O 0 0.0065577533
statin B-Chemical 1 0.9987639
therapy O 0 0.23676147
. O 0 0.012525107

Statins B-Chemical 0 0.99846435
can O 0 0.008446992
cause O 0 0.0114731705
a O 0 0.008278121
necrotizing O 0 0.99958104
myopathy B-Disease 2 0.9997788
and O 0 0.017600127
hyperCKaemia B-Disease 0 0.964758
which O 0 0.0030948767
is O 0 0.0019497565
reversible O 0 0.07923846
on O 0 0.0015551576
cessation O 0 0.0073261796
of O 0 0.003596055
the O 0 0.0050400384
drug O 0 0.75631577
. O 0 0.010234758

What O 0 0.02409278
is O 0 0.005598642
less O 0 0.0035655333
well O 0 0.0024796475
known O 0 0.0025511077
is O 0 0.0017085936
a O 0 0.0019346246
phenomenon O 0 0.008062601
whereby O 0 0.0019470294
statins B-Chemical 1 0.99963343
may O 0 0.0012060542
induce O 0 0.00086496084
a O 0 0.0028609587
myopathy B-Disease 2 0.99957436
, O 0 0.0023197676
which O 0 0.0012452654
persists O 0 0.0009278149
or O 0 0.0009951114
may O 0 0.0011124287
progress O 0 0.0021162783
after O 0 0.0012071731
stopping O 0 0.008446426
the O 0 0.004010301
drug O 0 0.6870158
. O 0 0.009061317

We O 0 0.013936524
investigated O 0 0.009266262
the O 0 0.009306474
muscle O 0 0.040188897
pathology O 0 0.051862936
in O 0 0.007895584
8 O 0 0.0078121847
such O 0 0.0087768445
cases O 0 0.01812567
. O 0 0.01550121

All O 0 0.01350706
had O 0 0.010822981
myofibre O 0 0.26841584
necrosis B-Disease 2 0.98905635
but O 0 0.0069941976
only O 0 0.005077895
3 O 0 0.004710028
had O 0 0.0049399184
an O 0 0.009111011
inflammatory O 0 0.9543887
infiltrate O 0 0.9728483
. O 0 0.020430928

In O 0 0.0072221877
all O 0 0.004770169
cases O 0 0.004410325
there O 0 0.002155504
was O 0 0.0021895524
diffuse O 0 0.010047487
or O 0 0.0019195188
multifocal O 0 0.85505694
up O 0 0.0017857567
- O 0 0.0019709263
regulation O 0 0.0008040258
of O 0 0.001348029
MHC O 0 0.32089365
- O 0 0.0043006293
I O 0 0.010048497
expression O 0 0.001625617
even O 0 0.0016444932
in O 0 0.0019805213
non O 0 0.009226406
- O 0 0.0142743355
necrotic B-Disease 2 0.92191786
fibres O 0 0.4648236
. O 0 0.010886743

Progressive O 0 0.07604374
improvement O 0 0.0070775575
occurred O 0 0.004060132
in O 0 0.0026184628
7 O 0 0.0019666054
cases O 0 0.0019097605
after O 0 0.0009093705
commencement O 0 0.0013737717
of O 0 0.0018241475
prednisolone B-Chemical 1 0.99992716
and O 0 0.0062547713
methotrexate B-Chemical 1 0.99992704
, O 0 0.003896847
and O 0 0.0022903625
in O 0 0.0021379404
one O 0 0.0026203615
case O 0 0.0046584764
spontaneously O 0 0.035668954
. O 0 0.008923832

These O 0 0.008650764
observations O 0 0.0059723873
suggest O 0 0.0032115942
that O 0 0.002967066
statins B-Chemical 1 0.9986279
may O 0 0.0023375466
initiate O 0 0.0014574828
an O 0 0.0028091976
immune O 0 0.7026034
- O 0 0.009513958
mediated O 0 0.0013797112
myopathy B-Disease 2 0.9989305
that O 0 0.00075553224
persists O 0 0.0007353727
after O 0 0.00045570606
withdrawal O 0 0.486468
of O 0 0.0010969479
the O 0 0.0011226283
drug O 0 0.47814628
and O 0 0.0020941603
responds O 0 0.0032013024
to O 0 0.0029318277
immunosuppressive O 0 0.9830771
therapy O 0 0.28620738
. O 0 0.010200124

The O 0 0.006992824
mechanism O 0 0.005311132
of O 0 0.004277471
this O 0 0.0035081645
myopathy B-Disease 2 0.9982962
is O 0 0.002473517
uncertain O 0 0.0047419667
but O 0 0.0011627466
may O 0 0.00075211935
involve O 0 0.0006995795
the O 0 0.0006219903
induction O 0 0.0007793705
by O 0 0.0010245967
statins B-Chemical 1 0.99935013
of O 0 0.0012570353
an O 0 0.0021727837
endoplasmic O 0 0.59740454
reticulum O 0 0.8746604
stress O 0 0.47461912
response O 0 0.0016197423
with O 0 0.0008513347
associated O 0 0.00096416817
up O 0 0.0007756752
- O 0 0.0011711154
regulation O 0 0.00048778317
of O 0 0.0009604768
MHC O 0 0.31180596
- O 0 0.0036756892
I O 0 0.009705983
expression O 0 0.0014592381
and O 0 0.0017824534
antigen O 0 0.023001473
presentation O 0 0.01755784
by O 0 0.0053138305
muscle O 0 0.2851728
fibres O 0 0.27533543
. O 0 0.009924918

Use O 0 0.01814779
of O 0 0.010021951
chromosome O 0 0.024368696
substitution O 0 0.030882662
strains O 0 0.0045126537
to O 0 0.0035238971
identify O 0 0.0036580386
seizure B-Disease 2 0.9995048
susceptibility O 0 0.032672487
loci O 0 0.012966479
in O 0 0.0064097918
mice O 0 0.007327931
. O 0 0.01105507

Seizure B-Disease 2 0.9953053
susceptibility O 0 0.031678047
varies O 0 0.019202441
among O 0 0.018271914
inbred O 0 0.023734078
mouse O 0 0.019754287
strains O 0 0.020343902
. O 0 0.021314092

Chromosome O 0 0.42055407
substitution O 0 0.060607467
strains O 0 0.0062046256
( O 0 0.0073773884
CSS O 0 0.96534806
) O 0 0.005499814
, O 0 0.0019436384
in O 0 0.0009491759
which O 0 0.0009726152
a O 0 0.0009363528
single O 0 0.0007559652
chromosome O 0 0.0032041965
from O 0 0.0005791073
one O 0 0.0004760809
inbred O 0 0.0010826209
strain O 0 0.00055726414
( O 0 0.0009253249
donor O 0 0.0012756814
) O 0 0.0012458841
has O 0 0.00037610956
been O 0 0.00041939714
transferred O 0 0.00036641659
onto O 0 0.00035654005
a O 0 0.0005201773
second O 0 0.0004345302
strain O 0 0.00047648998
( O 0 0.0009329284
host O 0 0.0026877106
) O 0 0.0011928595
by O 0 0.00048755936
repeated O 0 0.0005173894
backcrossing O 0 0.004026312
, O 0 0.0007412148
may O 0 0.0004021907
be O 0 0.0004302801
used O 0 0.00037144954
to O 0 0.0003767167
identify O 0 0.00039177915
quantitative O 0 0.0009263163
trait O 0 0.008288286
loci O 0 0.0037794954
( O 0 0.0023958462
QTLs O 0 0.028868645
) O 0 0.00230839
that O 0 0.0011706538
contribute O 0 0.0018546722
to O 0 0.003423937
seizure B-Disease 2 0.99961144
susceptibility O 0 0.07689342
. O 0 0.010625919

QTLs O 0 0.026279278
for O 0 0.005277277
susceptibility O 0 0.007681786
to O 0 0.0046957107
pilocarpine B-Chemical 1 0.99997497
- O 0 0.030785592
induced O 0 0.0051780837
seizures B-Disease 2 0.9999802
, O 0 0.002449714
a O 0 0.0010745985
model O 0 0.00080107996
of O 0 0.001039211
temporal B-Disease 2 0.19272377
lobe I-Disease 2 0.91245675
epilepsy I-Disease 2 0.9999832
, O 0 0.0015917807
have O 0 0.00051290554
not O 0 0.0005523162
been O 0 0.0006257852
reported O 0 0.0008317183
, O 0 0.0010089123
and O 0 0.00097538857
CSS O 0 0.91229725
have O 0 0.0006825224
not O 0 0.00075972156
previously O 0 0.00091282855
been O 0 0.0010788102
used O 0 0.001049909
to O 0 0.0013394869
localize O 0 0.0016295337
seizure B-Disease 2 0.99953413
susceptibility O 0 0.03471824
genes O 0 0.01439745
. O 0 0.009549161

We O 0 0.009372167
report O 0 0.009543642
QTLs O 0 0.012425997
identified O 0 0.0029210476
using O 0 0.00239683
a O 0 0.0033192649
B6 O 0 0.6205148
( O 0 0.0030400108
host O 0 0.0061040507
) O 0 0.0027437622
x O 0 0.0034485003
A O 0 0.12415865
/ O 0 0.0102866115
J O 0 0.8652174
( O 0 0.0015180337
donor O 0 0.0017491316
) O 0 0.0021232157
CSS O 0 0.84037817
panel O 0 0.0009223093
to O 0 0.00057652
localize O 0 0.00041215323
genes O 0 0.0010211063
involved O 0 0.00076756923
in O 0 0.001021655
susceptibility O 0 0.005340413
to O 0 0.0033761312
pilocarpine B-Chemical 1 0.9999764
- O 0 0.041176964
induced O 0 0.020899871
seizures B-Disease 2 0.99990964
. O 0 0.013187454

Three O 0 0.010364987
hundred O 0 0.007162259
fifty O 0 0.006220901
- O 0 0.0044817547
five O 0 0.0020026595
adult O 0 0.0027607135
male O 0 0.008921127
CSS O 0 0.91782427
mice O 0 0.0013987548
, O 0 0.0018505597
58 O 0 0.0022423156
B6 O 0 0.30116302
, O 0 0.0013013731
and O 0 0.0009477441
39 O 0 0.0016153436
A O 0 0.036897127
/ O 0 0.0040986273
J O 0 0.582592
were O 0 0.0008951021
tested O 0 0.0007061888
for O 0 0.0008952624
susceptibility O 0 0.0041954773
to O 0 0.003309307
pilocarpine B-Chemical 1 0.9999739
- O 0 0.040761154
induced O 0 0.021025795
seizures B-Disease 2 0.9999074
. O 0 0.013475209

Highest O 0 0.042368837
stage O 0 0.011429174
reached O 0 0.006164424
and O 0 0.0049132
latency O 0 0.005805151
to O 0 0.0028575826
each O 0 0.0022276987
stage O 0 0.0042243083
were O 0 0.0030801247
recorded O 0 0.0035392463
for O 0 0.003250005
all O 0 0.004859165
mice O 0 0.0063164206
. O 0 0.010155335

B6 O 0 0.3154652
mice O 0 0.006375328
were O 0 0.004966641
resistant O 0 0.004173267
to O 0 0.0034664692
seizures B-Disease 2 0.99986625
and O 0 0.003093135
slower O 0 0.0018304959
to O 0 0.0013892706
reach O 0 0.0015596524
stages O 0 0.0020419522
compared O 0 0.0014022598
to O 0 0.0025318253
A O 0 0.15457505
/ O 0 0.023106327
J O 0 0.81759995
mice O 0 0.0071006096
. O 0 0.010407249

The O 0 0.010557037
CSS O 0 0.6831232
for O 0 0.005616965
Chromosomes O 0 0.42597985
10 O 0 0.0028424999
and O 0 0.0020996472
18 O 0 0.0015735137
progressed O 0 0.0022198067
to O 0 0.0009880653
the O 0 0.0010218321
most O 0 0.0016194137
severe O 0 0.1294737
stages O 0 0.0027461143
, O 0 0.0024316655
diverging O 0 0.0040898346
dramatically O 0 0.0027286732
from O 0 0.0026445463
the O 0 0.0037922317
B6 O 0 0.64628696
phenotype O 0 0.011807238
. O 0 0.009959115

Latencies O 0 0.23714563
to O 0 0.009057249
stages O 0 0.008058679
were O 0 0.005351722
also O 0 0.00439248
significantly O 0 0.004577917
shorter O 0 0.0035972393
for O 0 0.004166774
CSS10 O 0 0.26222867
and O 0 0.008711982
CSS18 O 0 0.3080412
mice O 0 0.009345417
. O 0 0.012887104

CSS O 0 0.76441723
mapping O 0 0.010609919
suggests O 0 0.007157914
seizure B-Disease 2 0.99816763
susceptibility O 0 0.015540885
loci O 0 0.00913834
on O 0 0.004045091
mouse O 0 0.00784915
Chromosomes O 0 0.8285996
10 O 0 0.005931294
and O 0 0.0070226532
18 O 0 0.0087227775
. O 0 0.00996792

This O 0 0.010710962
approach O 0 0.0061969473
provides O 0 0.0034547395
a O 0 0.0035088563
framework O 0 0.0025611243
for O 0 0.0016002085
identifying O 0 0.001788032
potentially O 0 0.0025896537
novel O 0 0.0023832242
homologous O 0 0.001645249
candidate O 0 0.002140085
genes O 0 0.0026990923
for O 0 0.0020395003
human O 0 0.0052999565
temporal B-Disease 2 0.46606925
lobe I-Disease 2 0.97082424
epilepsy I-Disease 2 0.9998543
. O 0 0.014087535

In O 0 0.008616839
vitro O 0 0.0069825593
characterization O 0 0.005278534
of O 0 0.005467532
parasympathetic O 0 0.9951271
and O 0 0.0042595025
sympathetic O 0 0.94401735
responses O 0 0.005204673
in O 0 0.0028767607
cyclophosphamide B-Chemical 1 0.99991524
- O 0 0.020271996
induced O 0 0.006479709
cystitis B-Disease 2 0.9999509
in O 0 0.0067468365
the O 0 0.0068844776
rat O 0 0.046486385
. O 0 0.010207562

In O 0 0.010554204
cyclophosphamide B-Chemical 1 0.9994543
- O 0 0.016052712
induced O 0 0.00589094
cystitis B-Disease 2 0.999928
in O 0 0.0027919991
the O 0 0.0017849078
rat O 0 0.012655847
, O 0 0.0020882427
detrusor O 0 0.9924884
function O 0 0.0013649708
is O 0 0.00089037727
impaired O 0 0.0010958972
and O 0 0.00090295635
the O 0 0.0008453123
expression O 0 0.0012885832
and O 0 0.0015247938
effects O 0 0.0033597145
of O 0 0.0055591622
muscarinic O 0 0.99895275
receptors O 0 0.53708804
altered O 0 0.01151325
. O 0 0.009505334

Whether O 0 0.009731678
or O 0 0.0062486036
not O 0 0.0045741685
the O 0 0.004020648
neuronal O 0 0.2691015
transmission O 0 0.0077443086
may O 0 0.002634429
be O 0 0.002643109
affected O 0 0.0026229126
by O 0 0.0051734042
cystitis B-Disease 2 0.9999323
was O 0 0.007535207
presently O 0 0.016886177
investigated O 0 0.00732568
. O 0 0.010855967

Responses O 0 0.0138256075
of O 0 0.006606355
urinary O 0 0.5307068
strip O 0 0.007095863
preparations O 0 0.0041134073
from O 0 0.0016485496
control O 0 0.0013719936
and O 0 0.0019352168
cyclophosphamide B-Chemical 1 0.99994195
- O 0 0.0071447436
pretreated O 0 0.0097957095
rats O 0 0.002785083
to O 0 0.0006017103
electrical O 0 0.35979754
field O 0 0.0010147649
stimulation O 0 0.0010284903
and O 0 0.00065299385
to O 0 0.00052196084
agonists O 0 0.606062
were O 0 0.0005128554
assessed O 0 0.0003481532
in O 0 0.00038811308
the O 0 0.00043031294
absence O 0 0.00035140308
and O 0 0.0007351947
presence O 0 0.00075778994
of O 0 0.0021773723
muscarinic O 0 0.99904305
, O 0 0.008535707
adrenergic O 0 0.9980623
and O 0 0.005960108
purinergic O 0 0.9908998
receptor O 0 0.7419944
antagonists O 0 0.9913174
. O 0 0.0110393055

Generally O 0 0.011308282
, O 0 0.01056475
atropine B-Chemical 1 0.9997365
reduced O 0 0.00602956
contractions O 0 0.94949627
, O 0 0.0030496365
but O 0 0.0011506234
in O 0 0.0007510436
contrast O 0 0.0007083069
to O 0 0.0006151309
controls O 0 0.0015847901
, O 0 0.00089426443
it O 0 0.0005541497
also O 0 0.0004987578
reduced O 0 0.0005447133
responses O 0 0.0010013317
to O 0 0.0004972317
low O 0 0.00078341906
electrical O 0 0.2988015
field O 0 0.0010417014
stimulation O 0 0.0011525464
intensity O 0 0.00080840784
( O 0 0.0015072111
1 O 0 0.001164358
- O 0 0.001582382
5 O 0 0.0012173812
Hz O 0 0.12693366
) O 0 0.0031353857
in O 0 0.0025859848
inflamed O 0 0.05352857
preparations O 0 0.01742756
. O 0 0.009525275

In O 0 0.007390477
both O 0 0.005232705
types O 0 0.0046101585
, O 0 0.0055215927
purinoceptor O 0 0.9939235
desensitization O 0 0.6903198
with O 0 0.0026218721
alpha B-Chemical 0 0.5869194
, I-Chemical 0 0.0036651883
beta I-Chemical 0 0.8028138
- I-Chemical 0 0.008806763
methylene I-Chemical 0 0.9646092
adenosine I-Chemical 1 0.9998017
- I-Chemical 0 0.0061292085
5 I-Chemical 0 0.000654964
' I-Chemical 0 0.0010702065
- I-Chemical 0 0.0014168452
triphosphate I-Chemical 0 0.81324494
( O 0 0.0017630953
alpha B-Chemical 0 0.27671957
, I-Chemical 0 0.0018361605
beta I-Chemical 0 0.74131954
- I-Chemical 0 0.011613492
meATP I-Chemical 0 0.99591064
) O 0 0.0014349682
caused O 0 0.0006497951
further O 0 0.00068206165
reductions O 0 0.0008334756
at O 0 0.0005719194
low O 0 0.0010738004
frequencies O 0 0.0015049607
( O 0 0.0025661157
< O 0 0.0021954484
10 O 0 0.0028948176
Hz O 0 0.20261005
) O 0 0.0084195435
. O 0 0.0074105966

The O 0 0.009769654
muscarinic O 0 0.99496055
receptor O 0 0.7083191
antagonists O 0 0.99748516
atropine B-Chemical 1 0.9999759
, O 0 0.010488996
4 B-Chemical 0 0.0018362997
- I-Chemical 0 0.002324413
diphenylacetoxy I-Chemical 0 0.03537061
- I-Chemical 0 0.0047461772
N I-Chemical 0 0.98606825
- I-Chemical 0 0.004672845
methylpiperidine I-Chemical 0 0.93468916
( O 0 0.0016245423
4 B-Chemical 0 0.0007725662
- I-Chemical 0 0.0015611255
DAMP I-Chemical 0 0.98819274
) O 0 0.0030578037
( O 0 0.001265035
' O 0 0.0013006495
M O 0 0.8744383
( O 0 0.0012918708
1 O 0 0.0007573637
) O 0 0.0012195725
/ O 0 0.002879161
M O 0 0.8597862
( O 0 0.0011323366
3 O 0 0.00059879484
) O 0 0.0011112685
/ O 0 0.0026102082
M O 0 0.8513495
( O 0 0.001073612
5 O 0 0.0005223378
) O 0 0.0010371736
- O 0 0.0007998659
selective O 0 0.0015068571
' O 0 0.0010027852
) O 0 0.0014797562
, O 0 0.0013451747
methoctramine B-Chemical 0 0.99996996
( O 0 0.002040097
' O 0 0.0014454328
M O 0 0.8876952
( O 0 0.0011178987
2 O 0 0.00061378244
) O 0 0.0010703646
- O 0 0.0007990158
selective O 0 0.0014448629
' O 0 0.0009030664
) O 0 0.0011041699
and O 0 0.0009826594
pirenzepine B-Chemical 0 0.99999154
( O 0 0.0028225349
' O 0 0.0018030033
M O 0 0.9238152
( O 0 0.0013233816
1 O 0 0.000708425
) O 0 0.0011622849
- O 0 0.0008433568
selective O 0 0.0017067638
' O 0 0.0009884074
) O 0 0.0012508585
antagonized O 0 0.22450593
the O 0 0.0005331854
tonic O 0 0.40741783
component O 0 0.00054138066
of O 0 0.0005781262
the O 0 0.0005477802
electrical O 0 0.31110004
field O 0 0.0011282982
stimulation O 0 0.0019060022
- O 0 0.0018653593
evoked O 0 0.1064777
contractile O 0 0.6641867
response O 0 0.0018439429
more O 0 0.0017799633
potently O 0 0.02403164
than O 0 0.0015728335
the O 0 0.0028644798
phasic O 0 0.4535784
component O 0 0.006964537
. O 0 0.008216981

4 B-Chemical 0 0.012852882
- I-Chemical 0 0.013495584
DAMP I-Chemical 0 0.9428251
inhibited O 0 0.0061488794
the O 0 0.0036703967
tonic O 0 0.7557803
contractions O 0 0.88965255
in O 0 0.002384694
controls O 0 0.004007152
more O 0 0.0030708746
potently O 0 0.072983466
than O 0 0.0040805805
methoctramine B-Chemical 0 0.9999082
and O 0 0.052268475
pirenzepine B-Chemical 0 0.99992096
. O 0 0.014190198

In O 0 0.0077612563
inflamed O 0 0.022243647
preparations O 0 0.009897367
, O 0 0.004438518
the O 0 0.0026657623
muscarinic O 0 0.9972364
receptor O 0 0.34064633
antagonism O 0 0.5768211
on O 0 0.00064766087
the O 0 0.00072029856
phasic O 0 0.25525704
component O 0 0.0006367371
of O 0 0.000637586
the O 0 0.00056764757
electrical O 0 0.34588823
field O 0 0.0010984658
stimulation O 0 0.00200212
- O 0 0.0016547842
evoked O 0 0.11679166
contraction O 0 0.47592148
was O 0 0.00052439194
decreased O 0 0.0006902138
and O 0 0.0005975694
the O 0 0.00075777486
pirenzepine B-Chemical 0 0.99998987
and O 0 0.001186459
4 B-Chemical 0 0.0007963049
- I-Chemical 0 0.0015910221
DAMP I-Chemical 0 0.9813362
antagonism O 0 0.31200716
on O 0 0.0004000939
the O 0 0.0006235758
tonic O 0 0.40554717
component O 0 0.00093783234
was O 0 0.0008196703
much O 0 0.0007407456
less O 0 0.0010393383
efficient O 0 0.001253662
than O 0 0.0016450211
in O 0 0.003083081
controls O 0 0.0087982295
. O 0 0.0076171425

In O 0 0.007397011
contrast O 0 0.00513711
to O 0 0.0037058142
controls O 0 0.0059599504
, O 0 0.005783816
methoctramine B-Chemical 0 0.99993813
increased O 0 0.008754023
- O 0 0.0057991305
- O 0 0.0018644443
instead O 0 0.00094904884
of O 0 0.0013380054
decreased O 0 0.0030733163
- O 0 0.0037983905
- O 0 0.0020786794
the O 0 0.0013840424
tonic O 0 0.44786388
responses O 0 0.003903863
at O 0 0.0023541609
high O 0 0.004308934
frequencies O 0 0.006567347
. O 0 0.008333824

While O 0 0.009526947
contractions O 0 0.653183
to O 0 0.005700967
carbachol B-Chemical 1 0.9994892
and O 0 0.0061805886
ATP B-Chemical 1 0.9960115
were O 0 0.0014054573
the O 0 0.0008280191
same O 0 0.0005215466
in O 0 0.0006289443
inflamed O 0 0.019715656
and O 0 0.00080876227
in O 0 0.00052073534
control O 0 0.0005206202
strips O 0 0.0019576887
when O 0 0.00035139872
related O 0 0.00036901768
to O 0 0.00046347195
a O 0 0.00084705785
reference O 0 0.00082462945
potassium B-Chemical 1 0.9998518
response O 0 0.0037999032
, O 0 0.0069351564
isoprenaline B-Chemical 0 0.9999486
- O 0 0.006566118
induced O 0 0.0022352003
relaxations O 0 0.99827075
were O 0 0.0023230796
smaller O 0 0.002118756
in O 0 0.0028900218
inflamed O 0 0.10878947
strips O 0 0.05733305
. O 0 0.009213701

Thus O 0 0.011793538
, O 0 0.010001004
in O 0 0.0068947123
cystitis B-Disease 2 0.99961543
substantial O 0 0.0069816145
changes O 0 0.004758674
of O 0 0.004077563
the O 0 0.003975703
efferent O 0 0.26096058
functional O 0 0.0063527166
responses O 0 0.011898942
occur O 0 0.010225788
. O 0 0.01128918

While O 0 0.0112863965
postjunctional O 0 0.99199146
beta O 0 0.9172632
- O 0 0.034532778
adrenoceptor O 0 0.99984026
- O 0 0.014624538
mediated O 0 0.0026287234
relaxations O 0 0.9988341
are O 0 0.0021491705
reduced O 0 0.0016520268
, O 0 0.0017725838
effects O 0 0.002388427
by O 0 0.0022626272
prejunctional O 0 0.9987696
inhibitory O 0 0.28905675
muscarinic O 0 0.99931395
receptors O 0 0.41226414
may O 0 0.00379245
be O 0 0.0048368317
increased O 0 0.0069337906
. O 0 0.008550821

Direct O 0 0.017898582
inhibition O 0 0.011157558
of O 0 0.0072336877
cardiac O 0 0.81027067
hyperpolarization O 0 0.99628264
- O 0 0.010058473
activated O 0 0.0046236
cyclic B-Chemical 0 0.8911598
nucleotide I-Chemical 0 0.71553457
- O 0 0.007011098
gated O 0 0.028597897
pacemaker O 0 0.3567749
channels O 0 0.08521432
by O 0 0.009659856
clonidine B-Chemical 1 0.9998419
. O 0 0.012575394

BACKGROUND O 0 0.72892326
: O 0 0.010755994
Inhibition O 0 0.0084476685
of O 0 0.003828048
cardiac O 0 0.5040883
sympathetic O 0 0.9571311
tone O 0 0.5670664
represents O 0 0.0012831592
an O 0 0.0011785957
important O 0 0.0006045472
strategy O 0 0.00074313296
for O 0 0.000474821
treatment O 0 0.0009631486
of O 0 0.001200548
cardiovascular B-Disease 0 0.998485
disease I-Disease 0 0.95420456
, O 0 0.0024000783
including O 0 0.0011730036
arrhythmia B-Disease 2 0.9999168
, O 0 0.0021246204
coronary B-Disease 0 0.78788954
heart I-Disease 0 0.8220397
disease I-Disease 0 0.8462591
, O 0 0.0034841592
and O 0 0.003284303
chronic O 0 0.9693749
heart B-Disease 0 0.97215354
failure I-Disease 0 0.9337326
. O 0 0.010756842

Activation O 0 0.022208361
of O 0 0.007834793
presynaptic O 0 0.77597064
alpha2 O 0 0.96265364
- O 0 0.012163454
adrenoceptors O 0 0.997799
is O 0 0.0014022813
the O 0 0.0009081054
most O 0 0.0011005056
widely O 0 0.0011144404
accepted O 0 0.0014110223
mechanism O 0 0.0006364532
of O 0 0.00067448063
action O 0 0.0029536546
of O 0 0.0006933411
the O 0 0.00070777856
antisympathetic O 0 0.903437
drug O 0 0.9287392
clonidine B-Chemical 1 0.9999938
; O 0 0.003619351
however O 0 0.0007554391
, O 0 0.0006191969
other O 0 0.00039854855
target O 0 0.00041886335
proteins O 0 0.00082085846
have O 0 0.0005088873
been O 0 0.0006400317
postulated O 0 0.0010142854
to O 0 0.0006210038
contribute O 0 0.00069849327
to O 0 0.0008032018
the O 0 0.0010558591
in O 0 0.0013705088
vivo O 0 0.0031352427
actions O 0 0.056860965
of O 0 0.01106453
clonidine B-Chemical 1 0.99991095
. O 0 0.0114062615

METHODS O 0 0.011593918
AND O 0 0.008246106
RESULTS O 0 0.0107082
: O 0 0.003953367
To O 0 0.0018662954
test O 0 0.0018490639
whether O 0 0.0010399577
clonidine B-Chemical 1 0.9999409
elicits O 0 0.0032554404
pharmacological O 0 0.41327563
effects O 0 0.0020787308
independent O 0 0.0006906546
of O 0 0.0016115651
alpha2 O 0 0.9694662
- O 0 0.010098182
adrenoceptors O 0 0.9987639
, O 0 0.0007292249
we O 0 0.00026241565
have O 0 0.00029738664
generated O 0 0.00029712814
mice O 0 0.00030030668
with O 0 0.00044854067
a O 0 0.0006197834
targeted O 0 0.00040591572
deletion O 0 0.0006341705
of O 0 0.00057046005
all O 0 0.00056201743
3 O 0 0.00081081066
alpha2 O 0 0.7414171
- O 0 0.00529375
adrenoceptor O 0 0.99982315
subtypes O 0 0.08863238
( O 0 0.004832867
alpha2ABC O 0 0.12184736
- O 0 0.005696382
/ O 0 0.009327458
- O 0 0.007021333
) O 0 0.0089484025
. O 0 0.0076530194

Alpha2ABC O 0 0.09776018
- O 0 0.013046326
/ O 0 0.010598672
- O 0 0.004628947
mice O 0 0.0017462308
were O 0 0.0015432055
completely O 0 0.0012787008
unresponsive O 0 0.0022706673
to O 0 0.0007678139
the O 0 0.0008115874
analgesic O 0 0.9883559
and O 0 0.0014017619
hypnotic O 0 0.99716115
effects O 0 0.0036955366
of O 0 0.0038672853
clonidine B-Chemical 1 0.99999416
; O 0 0.006618627
however O 0 0.0012246409
, O 0 0.001734151
clonidine B-Chemical 1 0.99997437
significantly O 0 0.0013662577
lowered O 0 0.0076933196
heart O 0 0.51389486
rate O 0 0.0007178163
in O 0 0.00078154035
alpha2ABC O 0 0.08128767
- O 0 0.0024420018
/ O 0 0.0031144149
- O 0 0.0015655273
mice O 0 0.0008898145
by O 0 0.0015247836
up O 0 0.0017538988
to O 0 0.002359911
150 O 0 0.0059524626
bpm O 0 0.024314592
. O 0 0.007348365

Clonidine B-Chemical 1 0.9998795
- O 0 0.021772588
induced O 0 0.006712441
bradycardia B-Disease 2 0.9993038
in O 0 0.0028047068
conscious O 0 0.080700904
alpha2ABC O 0 0.16588667
- O 0 0.0040395544
/ O 0 0.004261159
- O 0 0.0012857218
mice O 0 0.0004605205
was O 0 0.00054707314
32 O 0 0.0007089917
. O 0 0.00035374783
3 O 0 0.0003945346
% O 0 0.00051587896
( O 0 0.00052618433
10 O 0 0.00035228056
microg O 0 0.00073711347
/ O 0 0.0011413133
kg O 0 0.0031619938
) O 0 0.0008553593
and O 0 0.00049028685
26 O 0 0.0006239072
. O 0 0.00029844634
6 O 0 0.00031195665
% O 0 0.00049496896
( O 0 0.00057563215
100 O 0 0.0006740315
microg O 0 0.0009734918
/ O 0 0.0014597838
kg O 0 0.0031799853
) O 0 0.0011276067
of O 0 0.0007929274
the O 0 0.0008697311
effect O 0 0.0011340621
in O 0 0.0015197914
wild O 0 0.0023408441
- O 0 0.0045744637
type O 0 0.004125547
mice O 0 0.0050355424
. O 0 0.008515134

A O 0 0.038578957
similar O 0 0.0062476387
bradycardic O 0 0.99886847
effect O 0 0.0039642053
of O 0 0.004759463
clonidine B-Chemical 1 0.99996257
was O 0 0.0017921056
observed O 0 0.00075202156
in O 0 0.0007765694
isolated O 0 0.00092638884
spontaneously O 0 0.010046363
beating O 0 0.06793271
right O 0 0.0029465687
atria O 0 0.357016
from O 0 0.0011717264
alpha2ABC O 0 0.048195504
- O 0 0.0021966144
knockout O 0 0.0015040032
and O 0 0.0020206182
wild O 0 0.0024673208
- O 0 0.0045024343
type O 0 0.0042315777
mice O 0 0.0051747216
. O 0 0.008657845

Clonidine B-Chemical 1 0.99979156
inhibited O 0 0.009451688
the O 0 0.003808123
native O 0 0.0035734177
pacemaker O 0 0.1758169
current O 0 0.0044743954
( O 0 0.0031098598
I O 0 0.020205973
( O 0 0.0018731055
f O 0 0.002153447
) O 0 0.0021243545
) O 0 0.0011821723
in O 0 0.0004930346
isolated O 0 0.00064195297
sinoatrial O 0 0.6193859
node O 0 0.0019012693
pacemaker O 0 0.18179664
cells O 0 0.0011748866
and O 0 0.00072423817
the O 0 0.00068353716
I O 0 0.022552045
( O 0 0.0011294484
f O 0 0.001670802
) O 0 0.0022149866
- O 0 0.0011183344
generating O 0 0.00070764904
hyperpolarization O 0 0.98692364
- O 0 0.002172974
activated O 0 0.0011160898
cyclic B-Chemical 0 0.8464134
nucleotide I-Chemical 0 0.6771082
- O 0 0.0036116466
gated O 0 0.029117702
( O 0 0.0020391655
HCN O 0 0.9571274
) O 0 0.00215465
2 O 0 0.0011302923
and O 0 0.0016765862
HCN4 O 0 0.9338618
channels O 0 0.0151223885
in O 0 0.0022727877
transfected O 0 0.0055563734
HEK293 O 0 0.8320255
cells O 0 0.0132901855
. O 0 0.0093469275

As O 0 0.006519635
a O 0 0.0057157734
consequence O 0 0.0031903002
of O 0 0.0032470948
blocking O 0 0.008521329
I O 0 0.06142151
( O 0 0.0031604955
f O 0 0.0035588208
) O 0 0.0036011555
, O 0 0.0018828864
clonidine B-Chemical 1 0.9999484
reduced O 0 0.0008075832
the O 0 0.0005522481
slope O 0 0.0019013743
of O 0 0.0005998436
the O 0 0.0006276715
diastolic O 0 0.9493917
depolarization O 0 0.6387311
and O 0 0.00050138764
the O 0 0.00037535196
frequency O 0 0.00047442285
of O 0 0.00059741875
pacemaker O 0 0.19060369
potentials O 0 0.058368955
in O 0 0.00063091173
sinoatrial O 0 0.6939559
node O 0 0.0020752598
cells O 0 0.0015398383
from O 0 0.0009638338
wild O 0 0.0011091918
- O 0 0.0019940198
type O 0 0.001457841
and O 0 0.002465606
alpha2ABC O 0 0.10769397
- O 0 0.0053878557
knockout O 0 0.004247974
mice O 0 0.004818065
. O 0 0.008064226

CONCLUSIONS O 0 0.5203854
: O 0 0.009461479
Direct O 0 0.00804127
inhibition O 0 0.0051586903
of O 0 0.0032153348
cardiac O 0 0.72774553
HCN O 0 0.9849834
pacemaker O 0 0.5597699
channels O 0 0.048827197
contributes O 0 0.00060930377
to O 0 0.0005809704
the O 0 0.000762486
bradycardic O 0 0.99985826
effects O 0 0.0030304315
of O 0 0.002643509
clonidine B-Chemical 1 0.9999919
gene O 0 0.004835129
- O 0 0.0017185719
targeted O 0 0.00038731808
mice O 0 0.00031201766
in O 0 0.00040840992
vivo O 0 0.000891463
, O 0 0.0007509062
and O 0 0.00058900745
thus O 0 0.0011277259
, O 0 0.0020599382
clonidine B-Chemical 1 0.9999808
- O 0 0.0020784223
like O 0 0.0007568114
drugs O 0 0.41344485
represent O 0 0.0010854944
novel O 0 0.0016323033
structures O 0 0.001945979
for O 0 0.0014125723
future O 0 0.002839997
HCN O 0 0.9703409
channel O 0 0.28454185
inhibitors O 0 0.34212282
. O 0 0.010159549

Granulomatous B-Disease 0 0.9638733
hepatitis I-Disease 2 0.9993155
due O 0 0.010128891
to O 0 0.007329558
combination B-Chemical 0 0.009764862
of I-Chemical 0 0.011847927
amoxicillin I-Chemical 1 0.99920875
and I-Chemical 0 0.069528356
clavulanic I-Chemical 0 0.99969757
acid I-Chemical 0 0.9938432
. O 0 0.02196594

We O 0 0.008282807
report O 0 0.0072935787
the O 0 0.0037794954
case O 0 0.0028471018
of O 0 0.0025181572
a O 0 0.0026427358
patient O 0 0.003063676
with O 0 0.0029727365
amoxicillin B-Chemical 1 0.99975747
- I-Chemical 0 0.09905806
clavulanic I-Chemical 0 0.9999107
acid I-Chemical 0 0.9964414
- O 0 0.035094734
induced O 0 0.008142381
hepatitis B-Disease 2 0.9999504
with O 0 0.014424453
histologic O 0 0.9258291
multiple O 0 0.08238111
granulomas B-Disease 0 0.99411523
. O 0 0.0145424735

This O 0 0.0100035975
type O 0 0.0053325067
of O 0 0.0043143565
lesion O 0 0.04286573
broadens O 0 0.005946467
the O 0 0.0017026715
spectrum O 0 0.0018482676
of O 0 0.0022687765
liver B-Disease 2 0.9958016
injury I-Disease 2 0.997535
due O 0 0.0008891535
to O 0 0.00072888343
this O 0 0.0007641737
drug O 0 0.37851155
combination O 0 0.002294213
, O 0 0.0015074314
mainly O 0 0.0015080071
represented O 0 0.0016114985
by O 0 0.0021890658
a O 0 0.0053279856
benign O 0 0.9969416
cholestatic B-Disease 0 0.99998856
syndrome I-Disease 0 0.99922264
. O 0 0.021084704

The O 0 0.011106285
association O 0 0.0075096
of O 0 0.008767882
granulomas B-Disease 0 0.9314689
and O 0 0.013026926
eosinophilia B-Disease 2 0.9990533
favor O 0 0.017826334
an O 0 0.016427878
immunoallergic O 0 0.99723154
mechanism O 0 0.029584363
. O 0 0.016861884

As O 0 0.008883665
penicillin B-Chemical 1 0.99912673
derivatives O 0 0.5137983
and O 0 0.005178919
amoxicillin B-Chemical 1 0.9980399
alone O 0 0.0026868226
are O 0 0.0014260277
known O 0 0.001200037
to O 0 0.00069580844
induce O 0 0.00050847314
such O 0 0.0005902104
types O 0 0.0006671952
of O 0 0.0010373758
lesions O 0 0.5887373
, O 0 0.0013197735
the O 0 0.00065718096
amoxicillin B-Chemical 1 0.9975133
component O 0 0.0009904342
, O 0 0.0008941116
with O 0 0.000507933
or O 0 0.00048735747
without O 0 0.00054756796
a O 0 0.0010191877
potentiating O 0 0.12910227
effect O 0 0.0011748687
of O 0 0.0055238926
clavulanic B-Chemical 0 0.9999279
acid I-Chemical 0 0.9864399
, O 0 0.0035233882
might O 0 0.0013194851
have O 0 0.0019031523
a O 0 0.0036475076
major O 0 0.0049772705
role O 0 0.0053793327
. O 0 0.008600309

Dobutamine B-Chemical 1 0.99847215
stress O 0 0.5675062
echocardiography O 0 0.36555254
: O 0 0.004506613
a O 0 0.002456685
sensitive O 0 0.0013060878
indicator O 0 0.0009782742
of O 0 0.0014547602
diminished O 0 0.0030814384
myocardial O 0 0.9997441
function O 0 0.0017591103
in O 0 0.0010663788
asymptomatic O 0 0.33792263
doxorubicin B-Chemical 1 0.9998926
- O 0 0.004237704
treated O 0 0.0016004385
long O 0 0.0016103259
- O 0 0.0023897588
term O 0 0.001822083
survivors O 0 0.028927984
of O 0 0.006485159
childhood O 0 0.9913003
cancer B-Disease 2 0.9989635
. O 0 0.015357767

Doxorubicin B-Chemical 1 0.99935085
is O 0 0.008709791
an O 0 0.0066945623
effective O 0 0.0051925667
anticancer O 0 0.955854
chemotherapeutic O 0 0.98056066
agent O 0 0.66631985
known O 0 0.0050032577
to O 0 0.0029108494
cause O 0 0.04335842
acute O 0 0.9910505
and O 0 0.039124522
chronic O 0 0.998423
cardiomyopathy B-Disease 2 0.99994457
. O 0 0.021119377

To O 0 0.006671822
develop O 0 0.0049817665
a O 0 0.003985922
more O 0 0.002709264
sensitive O 0 0.0017104375
echocardiographic O 0 0.02467944
screening O 0 0.0015239504
test O 0 0.0011404342
for O 0 0.0007624563
cardiac B-Disease 0 0.9448381
damage I-Disease 0 0.94298065
due O 0 0.00068004435
to O 0 0.0007920853
doxorubicin B-Chemical 1 0.9998455
, O 0 0.0011960748
a O 0 0.0006953941
cohort O 0 0.0011422689
study O 0 0.00048866513
was O 0 0.00034297304
performed O 0 0.00031194417
using O 0 0.00039974548
dobutamine B-Chemical 1 0.9996043
infusion O 0 0.0059009423
to O 0 0.00041859152
differentiate O 0 0.0012293181
asymptomatic O 0 0.06538977
long O 0 0.00078229845
- O 0 0.0010116469
term O 0 0.00054804026
survivors O 0 0.0099885585
of O 0 0.0014343917
childhood O 0 0.9745302
cancer B-Disease 2 0.99907756
treated O 0 0.0045248237
with O 0 0.003200075
doxorubicin B-Chemical 1 0.9997546
from O 0 0.0027150935
healthy O 0 0.02979507
control O 0 0.0038247325
subjects O 0 0.009078059
. O 0 0.0075058267

Echocardiographic O 0 0.090376265
data O 0 0.006421467
from O 0 0.003485918
the O 0 0.0023377235
experimental O 0 0.0019042488
group O 0 0.001582596
of O 0 0.0013816562
21 O 0 0.00129906
patients O 0 0.001796634
( O 0 0.00092692155
mean O 0 0.00053370453
age O 0 0.0012238555
16 O 0 0.00072632794
+ O 0 0.0007642669
/ O 0 0.0019160714
- O 0 0.00087942265
5 O 0 0.00037478577
years O 0 0.0005995299
) O 0 0.0006582133
treated O 0 0.0004462875
from O 0 0.00042015663
1 O 0 0.00044597406
. O 0 0.00024955376
6 O 0 0.00022702062
to O 0 0.00024078997
14 O 0 0.0003505502
. O 0 0.00023433572
3 O 0 0.0002792061
years O 0 0.00043372202
( O 0 0.00041944868
median O 0 0.0002984207
5 O 0 0.00031513182
. O 0 0.00025913503
3 O 0 0.0003165199
) O 0 0.00044399739
before O 0 0.00018886532
this O 0 0.00028381302
study O 0 0.00040602524
with O 0 0.00039233832
27 O 0 0.0006601696
to O 0 0.0003875053
532 O 0 0.10478833
mg O 0 0.19239321
/ O 0 0.0014711525
m2 O 0 0.007553576
of O 0 0.0007287886
doxorubicin B-Chemical 1 0.99968636
( O 0 0.00094342686
mean O 0 0.00047974678
196 O 0 0.012583882
) O 0 0.00074091676
were O 0 0.0003704124
compared O 0 0.00027346317
with O 0 0.00047602874
echocardiographic O 0 0.0127353575
data O 0 0.0007574481
from O 0 0.00066351105
12 O 0 0.0006355679
normal O 0 0.0013447334
age O 0 0.0026283092
- O 0 0.0024485246
matched O 0 0.0022033823
control O 0 0.0032302008
subjects O 0 0.007793697
. O 0 0.007408549

Graded O 0 0.36518687
dobutamine B-Chemical 1 0.9986743
infusions O 0 0.12646349
of O 0 0.003971676
0 O 0 0.003065188
. O 0 0.0012914324
5 O 0 0.001091676
, O 0 0.0012086435
2 O 0 0.00085249724
. O 0 0.0006035626
5 O 0 0.0006234647
, O 0 0.000776647
5 O 0 0.0005700288
and O 0 0.0007072317
10 O 0 0.0008077472
micrograms O 0 0.021664275
/ O 0 0.002308791
kg O 0 0.0033368613
per O 0 0.0013747764
min O 0 0.0028242748
were O 0 0.0036313862
administered O 0 0.0067432835
. O 0 0.0077624456

Echocardiographic O 0 0.1891016
Doppler O 0 0.058178578
studies O 0 0.0050709397
were O 0 0.0031135043
performed O 0 0.0019950105
before O 0 0.0013050672
infusion O 0 0.0031651487
and O 0 0.0014822149
after O 0 0.000898997
15 O 0 0.0010862796
min O 0 0.0013604511
of O 0 0.0017242184
infusion O 0 0.0053400337
at O 0 0.002219831
each O 0 0.0027763783
rate O 0 0.005486846
. O 0 0.0084420135

Dobutamine B-Chemical 1 0.99706596
infusion O 0 0.022871705
at O 0 0.0029555499
10 O 0 0.0022848826
micrograms O 0 0.044678383
/ O 0 0.0026249292
kg O 0 0.0029060757
per O 0 0.00069309305
min O 0 0.00089488196
was O 0 0.0006596479
discontinued O 0 0.0017402254
after O 0 0.00036563078
six O 0 0.0003988875
studies O 0 0.0006349533
secondary O 0 0.0012597386
to O 0 0.00072729774
a O 0 0.0012077924
50 O 0 0.0014373042
% O 0 0.0013763633
incidence O 0 0.0034833513
rate O 0 0.0019687293
of O 0 0.0041291146
adverse O 0 0.9857222
symptoms O 0 0.9679359
. O 0 0.011197812

The O 0 0.0070215524
most O 0 0.0056024496
important O 0 0.0031186235
findings O 0 0.0036492932
were O 0 0.0018305994
that O 0 0.0010822533
compared O 0 0.00072160916
with O 0 0.00082681
values O 0 0.000747417
in O 0 0.00054666895
control O 0 0.0005675856
subjects O 0 0.0010750905
, O 0 0.0007032928
end O 0 0.00035183417
- O 0 0.0008516565
systolic O 0 0.26480192
left O 0 0.0009505556
ventricular O 0 0.90631807
posterior O 0 0.0024406074
wall O 0 0.0077849915
dimension O 0 0.00091867405
and O 0 0.00036973885
percent O 0 0.00030335982
of O 0 0.00043583574
left O 0 0.0012055401
ventricular O 0 0.9519014
posterior O 0 0.005326384
wall O 0 0.032646447
thickening O 0 0.7030055
in O 0 0.0008298524
doxorubicin B-Chemical 1 0.99989045
- O 0 0.0022890817
treated O 0 0.00069297804
patients O 0 0.0018936151
were O 0 0.0004980635
decreased O 0 0.0006092474
at O 0 0.0003268817
baseline O 0 0.0005062022
study O 0 0.000553059
and O 0 0.0005742348
these O 0 0.0007254328
findings O 0 0.0014004816
were O 0 0.00095482776
more O 0 0.0011318641
clearly O 0 0.0012781692
delineated O 0 0.003603163
with O 0 0.003770497
dobutamine B-Chemical 1 0.99971956
stimulation O 0 0.018967992
. O 0 0.009508536

End O 0 0.101692066
- O 0 0.010514154
systolic O 0 0.21591383
left O 0 0.00565862
ventricular O 0 0.8861598
posterior O 0 0.0071264063
wall O 0 0.016078696
dimension O 0 0.002392079
at O 0 0.00064530224
baseline O 0 0.00071343384
for O 0 0.00046601798
the O 0 0.0007443651
doxorubicin B-Chemical 1 0.99980026
- O 0 0.0020002201
treated O 0 0.0006911274
group O 0 0.0007265186
was O 0 0.00054045
11 O 0 0.0007383666
+ O 0 0.00065837917
/ O 0 0.002020819
- O 0 0.00089058396
1 O 0 0.00043317743
. O 0 0.0002685397
9 O 0 0.00033600262
mm O 0 0.0006258078
versus O 0 0.00032946822
13 O 0 0.0004930553
. O 0 0.00030243892
1 O 0 0.00046081407
+ O 0 0.0005540134
/ O 0 0.0015081113
- O 0 0.0008476473
1 O 0 0.00045914156
. O 0 0.0003011617
5 O 0 0.00033692614
mm O 0 0.00072734023
for O 0 0.00033095665
control O 0 0.0004974119
subjects O 0 0.0010675401
( O 0 0.0010592657
p O 0 0.0010159381
less O 0 0.0009828438
than O 0 0.0011364754
0 O 0 0.0025526723
. O 0 0.0023833534
01 O 0 0.013923331
) O 0 0.007554177
. O 0 0.0072139637

End O 0 0.10061422
- O 0 0.010562871
systolic O 0 0.2111654
left O 0 0.005661035
ventricular O 0 0.8797362
posterior O 0 0.0068469993
wall O 0 0.014582269
dimension O 0 0.0023722358
at O 0 0.0006722522
the O 0 0.0006871786
5 O 0 0.00062889786
- O 0 0.0008677878
micrograms O 0 0.033987988
/ O 0 0.0010475433
kg O 0 0.0012722651
per O 0 0.00029052596
min O 0 0.00056301145
dobutamine B-Chemical 1 0.99934095
infusion O 0 0.004860507
for O 0 0.00034186817
the O 0 0.00059383863
doxorubicin B-Chemical 1 0.9998648
- O 0 0.0018014025
treated O 0 0.0005752603
group O 0 0.00061396783
was O 0 0.00043662044
14 O 0 0.00047576017
. O 0 0.000286882
1 O 0 0.00044377524
+ O 0 0.0005258073
/ O 0 0.001488208
- O 0 0.0007570141
2 O 0 0.00037134613
. O 0 0.0002484709
4 O 0 0.0002775701
mm O 0 0.0005914974
versus O 0 0.00031652531
19 O 0 0.00059334666
. O 0 0.00027596127
3 O 0 0.00036502405
+ O 0 0.0005003411
/ O 0 0.0013519659
- O 0 0.0007390758
2 O 0 0.00037269344
. O 0 0.00025248795
6 O 0 0.00025176772
mm O 0 0.0005811166
for O 0 0.00024626034
control O 0 0.00035709076
subjects O 0 0.0007627288
( O 0 0.00064924784
p O 0 0.0005455248
less O 0 0.00044737165
than O 0 0.00043427388
0 O 0 0.0009130752
. O 0 0.0006467501
01 O 0 0.0052711205
) O 0 0.001652015
. O 0 0.001089073
( O 0 0.0023692392
ABSTRACT O 0 0.0077555217
TRUNCATED O 0 0.012629455
AT O 0 0.037796795
250 O 0 0.010366592
WORDS O 0 0.021789586
) O 0 0.030152613

Influence O 0 0.0358362
of O 0 0.028264867
smoking B-Chemical 1 0.86192435
on O 0 0.019885058
developing O 0 0.050274797
cochlea O 0 0.34973013
. O 0 0.029553412

Does O 0 0.026147777
smoking B-Chemical 1 0.79225725
during O 0 0.0052456725
pregnancy O 0 0.14119288
affect O 0 0.002566231
the O 0 0.0026013188
amplitudes O 0 0.0060996776
of O 0 0.0032725064
transient O 0 0.0914798
evoked O 0 0.6666659
otoacoustic O 0 0.9994929
emissions O 0 0.6419147
in O 0 0.006874106
newborns O 0 0.050387338
? O 0 0.021133764

OBJECTIVE O 0 0.59915334
: O 0 0.017764041
Maternal O 0 0.059081487
tobacco O 0 0.3022292
smoking B-Chemical 1 0.9460375
has O 0 0.005488376
negative O 0 0.006323149
effects O 0 0.00851171
on O 0 0.0058705956
fetal O 0 0.58358836
growth O 0 0.1034093
. O 0 0.014388691

The O 0 0.006932345
influence O 0 0.004351768
of O 0 0.0044167675
smoking B-Chemical 1 0.8597304
during O 0 0.0018141564
pregnancy O 0 0.14883135
on O 0 0.0008871234
the O 0 0.0010027885
developing O 0 0.0036408564
cochlea O 0 0.048734985
has O 0 0.0006750147
not O 0 0.0006586167
been O 0 0.00066270307
estimated O 0 0.0006363189
, O 0 0.0009922893
although O 0 0.0007609563
smoking B-Chemical 1 0.9238022
has O 0 0.00085167034
been O 0 0.001085236
positively O 0 0.0012442175
associated O 0 0.0018917054
with O 0 0.002855939
hearing B-Disease 0 0.965291
loss I-Disease 0 0.007952013
in O 0 0.004586608
adults O 0 0.024319421
. O 0 0.008486093

The O 0 0.0070744413
objective O 0 0.006250659
of O 0 0.0038662273
this O 0 0.0025764336
study O 0 0.0022377989
was O 0 0.0013712359
to O 0 0.00090997975
determine O 0 0.0005215237
the O 0 0.00073811586
effects O 0 0.001201132
of O 0 0.0011145523
maternal O 0 0.013992833
smoking B-Chemical 1 0.95992357
on O 0 0.00071157946
transient O 0 0.06397888
evoked O 0 0.53135353
otoacoustic O 0 0.9997594
emissions O 0 0.7432966
( O 0 0.004147047
TEOAEs O 0 0.86660874
) O 0 0.0034114704
of O 0 0.0030843155
healthy O 0 0.023628341
neonates O 0 0.037309457
. O 0 0.008450298

METHODS O 0 0.011315557
: O 0 0.008217851
This O 0 0.0052215667
study O 0 0.0033050037
was O 0 0.0021306877
undertaken O 0 0.001401244
as O 0 0.0013039173
part O 0 0.0010278338
of O 0 0.0011985895
neonatal O 0 0.0067075565
screening O 0 0.001724629
for O 0 0.0010548544
hearing B-Disease 0 0.946729
impairment I-Disease 0 0.320432
and O 0 0.0016682602
involved O 0 0.001314637
both O 0 0.0017680215
ears O 0 0.024023399
of O 0 0.0043029943
200 O 0 0.010424736
newborns O 0 0.022333425
. O 0 0.008409931

Newborns O 0 0.038992453
whose O 0 0.006992919
mothers O 0 0.006598043
reported O 0 0.0037505056
smoking B-Chemical 1 0.86139226
during O 0 0.001496374
pregnancy O 0 0.3522611
( O 0 0.0017330329
n O 0 0.0010819992
= O 0 0.0010769977
200 O 0 0.0011212912
ears O 0 0.0081311595
) O 0 0.0010321259
were O 0 0.00040322103
compared O 0 0.0002518578
to O 0 0.0003169985
a O 0 0.0004624453
control O 0 0.00036141116
group O 0 0.0004695133
of O 0 0.0005743711
newborns O 0 0.006081256
( O 0 0.00085991557
n O 0 0.0006903477
= O 0 0.0008643363
200 O 0 0.0011307035
ears O 0 0.00703184
) O 0 0.0017631408
, O 0 0.0012104155
whose O 0 0.0014344272
mothers O 0 0.0026827292
were O 0 0.0021101146
non O 0 0.005902185
- O 0 0.00856899
smokers O 0 0.2334907
. O 0 0.008463591

Exposure O 0 0.02502355
to O 0 0.0057152077
tobacco O 0 0.11015923
was O 0 0.0032960782
characterized O 0 0.0031200515
as O 0 0.0019208622
low O 0 0.002136653
( O 0 0.0017862387
< O 0 0.000816106
5 O 0 0.0004961336
cigarettes O 0 0.021401431
per O 0 0.0003381886
day O 0 0.00041337303
, O 0 0.0005538732
n O 0 0.0005288671
= O 0 0.00064110744
88 O 0 0.0008024112
ears O 0 0.006934749
) O 0 0.0012161423
, O 0 0.0006706073
moderate O 0 0.0028997257
( O 0 0.0006905487
5 O 0 0.00032426824
< O 0 0.0003137989
or O 0 0.00028599988
= O 0 0.00042103432
cigarettes O 0 0.022246996
per O 0 0.00021408587
day O 0 0.0002878313
< O 0 0.00034542187
10 O 0 0.00031686225
, O 0 0.0003869468
n O 0 0.0004022892
= O 0 0.0005334817
76 O 0 0.0007250903
) O 0 0.0006030612
or O 0 0.00038139074
high O 0 0.0006526624
( O 0 0.0009012312
> O 0 0.0007978289
or O 0 0.0004754066
= O 0 0.0006994228
10 O 0 0.00048507948
cigarettes O 0 0.02018321
per O 0 0.0005331287
day O 0 0.00086464325
, O 0 0.0015634975
n O 0 0.002001075
= O 0 0.0032831018
36 O 0 0.0037705097
) O 0 0.0069565675
. O 0 0.006889334

RESULTS O 0 0.026004525
: O 0 0.008169351
In O 0 0.0037783182
exposed O 0 0.002899938
neonates O 0 0.007407521
, O 0 0.002753243
TEOAEs O 0 0.44534144
mean O 0 0.0011126926
response O 0 0.0013880552
( O 0 0.0011723231
across O 0 0.00046139865
frequency O 0 0.0008165147
) O 0 0.0010869919
and O 0 0.00057329034
mean O 0 0.0005206257
amplitude O 0 0.002422947
at O 0 0.0005397741
4000Hz O 0 0.18566276
was O 0 0.0007115299
significantly O 0 0.0009458587
lower O 0 0.0009507517
than O 0 0.00085783936
in O 0 0.0014266823
non O 0 0.0049766945
- O 0 0.005155092
exposed O 0 0.0042426814
neonates O 0 0.05011968
. O 0 0.00880171

Comparisons O 0 0.012330989
between O 0 0.007012167
exposed O 0 0.006952188
newborns O 0 0.012245976
' O 0 0.007315268
subgroups O 0 0.006858443
revealed O 0 0.0050888457
no O 0 0.004798003
significant O 0 0.007587647
differences O 0 0.008119216
. O 0 0.0125675285

However O 0 0.008685674
, O 0 0.005978575
by O 0 0.0032548017
comparing O 0 0.0015307217
each O 0 0.0012249465
subgroup O 0 0.0021360186
to O 0 0.0009635753
control O 0 0.0009355738
group O 0 0.0011532836
, O 0 0.0009880911
we O 0 0.0004252053
found O 0 0.00045504514
statistically O 0 0.00056248956
significant O 0 0.00069874857
decreases B-Disease 0 0.0007907538
of I-Disease 0 0.0012258581
TEOAEs I-Disease 0 0.8821723
amplitudes I-Disease 0 0.0040146327
at O 0 0.001066765
4000Hz O 0 0.085964605
for O 0 0.0013896464
all O 0 0.0020483348
three O 0 0.0026327916
groups O 0 0.00647068
. O 0 0.0077245184

Mean O 0 0.010181909
TEOAEs O 0 0.24543233
responses O 0 0.005867699
of O 0 0.0035496592
highly O 0 0.0027814987
exposed O 0 0.0019158907
newborns O 0 0.005359469
were O 0 0.0014294187
also O 0 0.0012566226
significantly O 0 0.0015369919
lower O 0 0.0013355381
in O 0 0.0012568227
comparison O 0 0.0013699469
to O 0 0.0017704724
our O 0 0.0023270606
control O 0 0.0037173163
group O 0 0.0073191472
. O 0 0.008565151

CONCLUSION O 0 0.69073784
: O 0 0.009939379
In O 0 0.0046674903
utero O 0 0.016559884
, O 0 0.0036277317
exposure O 0 0.0033810218
to O 0 0.0018875513
tobacco O 0 0.35925844
smoking B-Chemical 1 0.97795963
seems O 0 0.0014500087
to O 0 0.0011452935
have O 0 0.0011267908
a O 0 0.0017504783
small O 0 0.0017965143
impact O 0 0.0017086107
on O 0 0.0020893458
outer O 0 0.02286052
hair O 0 0.6622683
cells O 0 0.03368174
. O 0 0.012071474

These O 0 0.010144379
effects O 0 0.0077421623
seem O 0 0.0046327477
to O 0 0.002838281
be O 0 0.0022523704
equally O 0 0.0019230538
true O 0 0.001438071
for O 0 0.0009318268
all O 0 0.00096867426
exposed O 0 0.0010764316
newborns O 0 0.005030509
, O 0 0.0015752721
regardless O 0 0.00090089504
of O 0 0.0018396657
the O 0 0.0021943946
degree O 0 0.003855942
of O 0 0.0059203054
exposure O 0 0.029118676
. O 0 0.010358576

Further O 0 0.009029123
studies O 0 0.005802004
are O 0 0.0037070909
needed O 0 0.002044155
in O 0 0.0016709617
order O 0 0.0011212219
to O 0 0.0009972901
establish O 0 0.0007754035
a O 0 0.0010493677
potential O 0 0.001009928
negative O 0 0.0010154805
effect O 0 0.00082429405
of O 0 0.0011790954
maternal O 0 0.010136855
smoking B-Chemical 1 0.921634
on O 0 0.0009860393
the O 0 0.0015972947
neonate O 0 0.027833758
' O 0 0.0044441875
s O 0 0.00586567
hearing O 0 0.9684976
acuity O 0 0.9931601
. O 0 0.010851631

Simvastatin B-Chemical 0 0.9996865
- O 0 0.0206719
induced O 0 0.008172999
bilateral O 0 0.08438917
leg O 0 0.16784512
compartment B-Disease 0 0.03609216
syndrome I-Disease 0 0.99140453
and O 0 0.015958777
myonecrosis B-Disease 0 0.9997507
associated O 0 0.025317201
with O 0 0.04030877
hypothyroidism B-Disease 2 0.9997634
. O 0 0.01805799

A O 0 0.043255195
54 O 0 0.013284115
- O 0 0.0077580353
year O 0 0.004169858
- O 0 0.0040855715
old O 0 0.0030661705
hypothyroid B-Disease 2 0.9307212
male O 0 0.0134031745
taking O 0 0.0071975207
thyroxine B-Chemical 1 0.9997161
and O 0 0.0037774672
simvastatin B-Chemical 1 0.9999566
presented O 0 0.0024546713
with O 0 0.0020161031
bilateral O 0 0.1425175
leg O 0 0.19968057
compartment B-Disease 0 0.041835155
syndrome I-Disease 0 0.994169
and O 0 0.031171793
myonecrosis B-Disease 0 0.9996979
. O 0 0.01488859

Urgent O 0 0.024100354
fasciotomies O 0 0.027683588
were O 0 0.005021388
performed O 0 0.0031894387
and O 0 0.0028670973
the O 0 0.0021753625
patient O 0 0.0024300907
made O 0 0.0017517953
an O 0 0.0021188061
uneventful O 0 0.002586014
recovery O 0 0.00316319
with O 0 0.0024640677
the O 0 0.0032820236
withdrawal O 0 0.8697947
of O 0 0.019801248
simvastatin B-Chemical 1 0.99990284
. O 0 0.016009126

It O 0 0.01015292
is O 0 0.0052105417
likely O 0 0.0032624386
that O 0 0.0021466047
this O 0 0.0019372312
complication O 0 0.19507709
will O 0 0.0011723315
be O 0 0.0010209437
seen O 0 0.00072721066
more O 0 0.00081135816
often O 0 0.0009878597
with O 0 0.0006661647
the O 0 0.000635036
increased O 0 0.00090013054
worldwide O 0 0.019932762
use O 0 0.0007770812
of O 0 0.00082760665
this O 0 0.000798038
drug O 0 0.3550923
and O 0 0.0013360267
its O 0 0.002031775
approval O 0 0.00256688
for O 0 0.0016006076
all O 0 0.00314478
arteriopathic B-Disease 0 0.99669516
patients O 0 0.039749954
. O 0 0.0089647565

Neuroinflammation B-Disease 0 0.97262436
and O 0 0.010349468
behavioral B-Disease 0 0.38643727
abnormalities I-Disease 0 0.41389322
after O 0 0.0023620394
neonatal O 0 0.03501788
terbutaline B-Chemical 1 0.99992645
treatment O 0 0.00779543
in O 0 0.0028835738
rats O 0 0.009157162
: O 0 0.0052967723
implications O 0 0.00525243
for O 0 0.0053253584
autism B-Disease 0 0.96520483
. O 0 0.011119879

Autism B-Disease 2 0.94727445
is O 0 0.007381611
a O 0 0.007218381
neurodevelopmental B-Disease 0 0.9831807
disorder I-Disease 0 0.9964533
presenting O 0 0.06321799
before O 0 0.0010684924
3 O 0 0.0010137338
years O 0 0.0011039737
of O 0 0.0009765639
age O 0 0.0021625028
with O 0 0.0013138351
deficits B-Disease 0 0.2888809
in I-Disease 0 0.0012057797
communication I-Disease 0 0.0044472395
and I-Disease 0 0.0022498437
social I-Disease 0 0.12942843
skills I-Disease 0 0.008963817
and O 0 0.004313895
repetitive B-Disease 0 0.13280831
behaviors I-Disease 0 0.78791976
. O 0 0.010203163

In O 0 0.007206959
addition O 0 0.0039963457
to O 0 0.0035688705
genetic O 0 0.00487135
influences O 0 0.0028115776
, O 0 0.0024521493
recent O 0 0.0013897318
studies O 0 0.0011156768
suggest O 0 0.0006668351
that O 0 0.00080112
prenatal O 0 0.022777488
drug O 0 0.51240176
or O 0 0.0015352177
chemical O 0 0.068544276
exposures O 0 0.12671477
are O 0 0.0031380574
risk O 0 0.1483185
factors O 0 0.0297595
for O 0 0.005522174
autism B-Disease 0 0.9793691
. O 0 0.010472273

Terbutaline B-Chemical 0 0.9990301
, O 0 0.00998753
a O 0 0.0068887603
beta2 O 0 0.953946
- O 0 0.012102163
adrenoceptor O 0 0.99978215
agonist O 0 0.93712604
used O 0 0.0014592868
to O 0 0.0011670626
arrest O 0 0.52229536
preterm B-Disease 0 0.9264189
labor I-Disease 0 0.92297095
, O 0 0.0019949481
has O 0 0.00074494095
been O 0 0.00086450524
associated O 0 0.0009464582
with O 0 0.0010391938
increased O 0 0.0014257105
concordance O 0 0.0025919012
for O 0 0.0018097293
autism B-Disease 0 0.9181072
in O 0 0.0036750436
dizygotic O 0 0.3199199
twins O 0 0.17601822
. O 0 0.009591136

We O 0 0.007731173
studied O 0 0.005142865
the O 0 0.003544386
effects O 0 0.003616197
of O 0 0.0035330763
terbutaline B-Chemical 1 0.9999325
on O 0 0.0016463168
microglial O 0 0.83277076
activation O 0 0.00354816
in O 0 0.0010101844
different O 0 0.0010294166
brain O 0 0.052721046
regions O 0 0.0016943136
and O 0 0.0017660023
behavioral O 0 0.036217418
outcomes O 0 0.005046249
in O 0 0.003058321
developing O 0 0.018371014
rats O 0 0.02095794
. O 0 0.009175708

Newborn O 0 0.026619412
rats O 0 0.008974396
were O 0 0.0040756213
given O 0 0.0026753305
terbutaline B-Chemical 1 0.9998597
( O 0 0.003915947
10 O 0 0.0014042439
mg O 0 0.17437792
/ O 0 0.0022531399
kg O 0 0.004565607
) O 0 0.0011033819
daily O 0 0.0007824312
on O 0 0.00034083947
postnatal O 0 0.0011313069
days O 0 0.00044299712
( O 0 0.00097061344
PN O 0 0.37498596
) O 0 0.0010847109
2 O 0 0.00043082968
to O 0 0.00033427155
5 O 0 0.00034993084
or O 0 0.00040063742
PN O 0 0.105879925
11 O 0 0.0005349321
to O 0 0.0003384534
14 O 0 0.00043156007
and O 0 0.0004051976
examined O 0 0.00033405784
24 O 0 0.0004000432
h O 0 0.00040147704
after O 0 0.00038347015
the O 0 0.0006645967
last O 0 0.0007729569
dose O 0 0.004486557
and O 0 0.0024721236
at O 0 0.0026087922
PN O 0 0.40916464
30 O 0 0.004918507
. O 0 0.0070073577

Immunohistochemical O 0 0.019695304
studies O 0 0.0056248507
showed O 0 0.0030319605
that O 0 0.002098074
administration O 0 0.019233463
of O 0 0.0026990792
terbutaline B-Chemical 1 0.99994934
on O 0 0.0011176079
PN O 0 0.60491097
2 O 0 0.00077107537
to O 0 0.00047895397
5 O 0 0.00041325917
produced O 0 0.00038231286
a O 0 0.00057486346
robust O 0 0.0004079877
increase O 0 0.00036147147
in O 0 0.00047090274
microglial O 0 0.5697428
activation O 0 0.0013630708
on O 0 0.00037046336
PN O 0 0.2806546
30 O 0 0.00034669193
in O 0 0.00034744895
the O 0 0.0005210184
cerebral O 0 0.8668107
cortex O 0 0.16738437
, O 0 0.00084108766
as O 0 0.0006021558
well O 0 0.0006707365
as O 0 0.0009949574
in O 0 0.0014057732
cerebellar O 0 0.7853483
and O 0 0.0039662505
cerebrocortical O 0 0.99378705
white O 0 0.05316782
matter O 0 0.029995061
. O 0 0.008657402

None O 0 0.014561593
of O 0 0.0072535486
these O 0 0.005297066
effects O 0 0.0049523376
occurred O 0 0.0030992855
in O 0 0.0021854911
animals O 0 0.0019895025
given O 0 0.001974776
terbutaline B-Chemical 1 0.99983084
on O 0 0.0028547703
PN O 0 0.52582836
11 O 0 0.0048137507
to O 0 0.004291487
14 O 0 0.0070957495
. O 0 0.00821916

In O 0 0.007798492
behavioral O 0 0.0223995
tests O 0 0.0070628957
, O 0 0.0034745878
animals O 0 0.0017631205
treated O 0 0.0018048356
with O 0 0.0017360367
terbutaline B-Chemical 1 0.9999435
on O 0 0.0009292477
PN O 0 0.54442656
2 O 0 0.00067284895
to O 0 0.0004194479
5 O 0 0.00035962946
showed O 0 0.00028872697
consistent O 0 0.0003134679
patterns O 0 0.0003503875
of O 0 0.0007989485
hyper O 0 0.83176947
- O 0 0.0020259048
reactivity O 0 0.0016806272
to O 0 0.0004805899
novelty O 0 0.14235066
and O 0 0.0007296608
aversive O 0 0.48121062
stimuli O 0 0.004684894
when O 0 0.00034837006
assessed O 0 0.00034138988
in O 0 0.00038093512
a O 0 0.0005826031
novel O 0 0.00072555273
open O 0 0.00059032993
field O 0 0.00087406446
, O 0 0.0007784617
as O 0 0.0005823947
well O 0 0.00062475004
as O 0 0.0008412865
in O 0 0.00097280944
the O 0 0.0014725962
acoustic O 0 0.11485772
startle O 0 0.99069136
response O 0 0.007379578
test O 0 0.00820175
. O 0 0.008138346

Our O 0 0.007945666
findings O 0 0.006813218
indicate O 0 0.0033463053
that O 0 0.0028301894
beta2 O 0 0.9643068
- O 0 0.014809669
adrenoceptor O 0 0.9998729
overstimulation O 0 0.99659866
during O 0 0.00085393415
an O 0 0.0010694747
early O 0 0.000988158
critical O 0 0.0004985059
period O 0 0.00042364237
results O 0 0.0005396681
in O 0 0.00059706124
microglial O 0 0.7239995
activation O 0 0.0029219755
associated O 0 0.001017048
with O 0 0.0011068375
innate O 0 0.2835531
neuroinflammatory O 0 0.9982863
pathways O 0 0.026573552
and O 0 0.0020319906
behavioral B-Disease 0 0.6685744
abnormalities I-Disease 0 0.74905694
, O 0 0.0015834544
similar O 0 0.0008107851
to O 0 0.0012188188
those O 0 0.0023555916
described O 0 0.0023810011
in O 0 0.004856514
autism B-Disease 0 0.9610491
. O 0 0.00946475

This O 0 0.0112202205
study O 0 0.0063027996
provides O 0 0.0034963952
a O 0 0.003581097
useful O 0 0.0025817992
animal O 0 0.0024398793
model O 0 0.0019951349
for O 0 0.0013645956
understanding O 0 0.0016368157
the O 0 0.0020367769
neuropathological O 0 0.824236
processes O 0 0.009782703
underlying O 0 0.02990023
autism B-Disease 0 0.9964736
spectrum I-Disease 0 0.029218746
disorders I-Disease 0 0.9944617
. O 0 0.01248068

Upregulation O 0 0.024408663
of O 0 0.0071619
brain O 0 0.040016685
expression O 0 0.0040513435
of O 0 0.0040418436
P O 0 0.53713506
- O 0 0.005542853
glycoprotein O 0 0.49999747
in O 0 0.0024368973
MRP2 O 0 0.99968207
- O 0 0.0048914882
deficient O 0 0.000981732
TR O 0 0.9595949
( O 0 0.0026570293
- O 0 0.0019638913
) O 0 0.0012045893
rats O 0 0.0015580886
resembles O 0 0.00087455224
seizure B-Disease 2 0.99990416
- O 0 0.0032223952
induced O 0 0.00087563915
up O 0 0.00085869484
- O 0 0.0012637813
regulation O 0 0.00051908015
of O 0 0.00086292834
this O 0 0.0010879703
drug O 0 0.7598992
efflux O 0 0.5094719
transporter O 0 0.130206
in O 0 0.00269954
normal O 0 0.007310079
rats O 0 0.014433241
. O 0 0.008196147

PURPOSE O 0 0.029159835
: O 0 0.008447952
The O 0 0.0041391957
multidrug O 0 0.22249568
resistance O 0 0.0075466665
protein O 0 0.0044809952
2 O 0 0.002380068
( O 0 0.0037645837
MRP2 O 0 0.99901164
) O 0 0.0026146972
is O 0 0.00072150666
a O 0 0.0009956786
drug O 0 0.60069525
efflux O 0 0.3273556
transporter O 0 0.04179295
that O 0 0.0003538214
is O 0 0.00037706416
expressed O 0 0.00027033457
predominantly O 0 0.00043322862
at O 0 0.00026281603
the O 0 0.00034386534
apical O 0 0.00060751603
domain O 0 0.0005211361
of O 0 0.0007349559
hepatocytes O 0 0.35972178
but O 0 0.0006155651
seems O 0 0.00036306013
also O 0 0.0003932943
to O 0 0.00034653826
be O 0 0.00037372313
expressed O 0 0.00025490727
at O 0 0.00024284564
the O 0 0.0003252296
apical O 0 0.00055658515
membrane O 0 0.0017286347
of O 0 0.0007497822
brain O 0 0.12366856
capillary O 0 0.22096479
endothelial O 0 0.90755254
cells O 0 0.0016092653
that O 0 0.0005733154
form O 0 0.00075597496
the O 0 0.00095596915
blood O 0 0.030975373
- O 0 0.00411701
brain O 0 0.1251938
barrier O 0 0.05821655
( O 0 0.01222907
BBB O 0 0.994514
) O 0 0.01273889
. O 0 0.008279874

MRP2 O 0 0.9902714
is O 0 0.007034421
absent O 0 0.0040405854
in O 0 0.0027498992
the O 0 0.002416784
transport O 0 0.009459925
- O 0 0.0035157423
deficient O 0 0.0012964548
( O 0 0.0031395499
TR O 0 0.9492747
( O 0 0.0029978997
- O 0 0.0024359457
) O 0 0.0017148978
) O 0 0.0012243411
Wistar O 0 0.024827166
rat O 0 0.0017055058
mutant O 0 0.0003826695
, O 0 0.0005800519
so O 0 0.0003323095
that O 0 0.00028221536
this O 0 0.00036586125
rat O 0 0.0016576966
strain O 0 0.00039436546
was O 0 0.0004349944
very O 0 0.0004983055
helpful O 0 0.0005827022
in O 0 0.00033502866
defining O 0 0.0004237595
substrates O 0 0.0013335161
of O 0 0.0011703126
MRP2 O 0 0.99894613
by O 0 0.0005026552
comparing O 0 0.00026051508
tissue O 0 0.008056708
concentrations O 0 0.001622237
or O 0 0.00048293974
functional O 0 0.0006891924
activities O 0 0.0009039488
of O 0 0.00082644424
compounds O 0 0.7993376
in O 0 0.0014507248
MRP2 O 0 0.99973017
- O 0 0.0021658868
deficient O 0 0.0005745386
rats O 0 0.0018351908
with O 0 0.0009487732
those O 0 0.0015459278
in O 0 0.0013697075
transport O 0 0.0076702978
- O 0 0.0036995327
competent O 0 0.0029387663
Wistar O 0 0.103789955
rats O 0 0.011236918
. O 0 0.008483229

By O 0 0.01026852
using O 0 0.0049516144
this O 0 0.003331146
strategy O 0 0.002703015
to O 0 0.0017757778
study O 0 0.0016792462
the O 0 0.0011941105
involvement O 0 0.0025757807
of O 0 0.0021228956
MRP2 O 0 0.99915147
in O 0 0.0008393767
brain O 0 0.04319836
access O 0 0.00057300273
of O 0 0.0008698911
antiepileptic O 0 0.99978703
drugs O 0 0.9451567
( O 0 0.0045007123
AEDs O 0 0.9919533
) O 0 0.0014276257
, O 0 0.0006161747
we O 0 0.00030622818
recently O 0 0.000521299
reported O 0 0.0007508851
that O 0 0.0007915312
phenytoin B-Chemical 1 0.9999865
is O 0 0.0011709728
a O 0 0.0017277201
substrate O 0 0.0044315644
for O 0 0.002064026
MRP2 O 0 0.99804294
in O 0 0.0032611722
the O 0 0.0057601375
BBB O 0 0.99277496
. O 0 0.009312648

However O 0 0.00884195
, O 0 0.006126929
one O 0 0.003066857
drawback O 0 0.0032456948
of O 0 0.002016197
such O 0 0.0014803662
studies O 0 0.0015214427
in O 0 0.0010630549
genetically O 0 0.0030631109
deficient O 0 0.00077776355
rats O 0 0.0021469318
is O 0 0.0006452866
the O 0 0.00055010803
fact O 0 0.00044435452
that O 0 0.0005299124
compensatory O 0 0.0014077706
changes O 0 0.0011360218
with O 0 0.0011419458
upregulation O 0 0.0023473706
of O 0 0.0020128242
other O 0 0.002800031
transporters O 0 0.19094752
can O 0 0.0036475686
occur O 0 0.0064996188
. O 0 0.008291081

This O 0 0.009791936
prompted O 0 0.005525517
us O 0 0.004580825
to O 0 0.0025109272
study O 0 0.002172765
the O 0 0.0015410653
brain O 0 0.02526778
expression O 0 0.0015714181
of O 0 0.0019517693
P O 0 0.6067728
- O 0 0.005288982
glycoprotein O 0 0.6943683
( O 0 0.006673424
Pgp O 0 0.9949214
) O 0 0.0024665806
, O 0 0.0007306421
a O 0 0.0005956375
major O 0 0.0006826473
drug O 0 0.6359972
efflux O 0 0.3426334
transporter O 0 0.049666576
in O 0 0.0003982685
many O 0 0.0005331168
tissues O 0 0.002948772
, O 0 0.00073199073
including O 0 0.00044333335
the O 0 0.00068684097
BBB O 0 0.99569136
, O 0 0.0009833394
in O 0 0.00068314996
TR O 0 0.93494105
( O 0 0.0017821767
- O 0 0.0015123383
) O 0 0.0010508823
rats O 0 0.0010634819
compared O 0 0.00044807378
with O 0 0.0010526163
nonmutant O 0 0.21316192
( O 0 0.0025152112
wild O 0 0.0016402142
- O 0 0.0031412172
type O 0 0.0027136558
) O 0 0.0068605277
Wistar O 0 0.14280705
rats O 0 0.012399977
. O 0 0.008839321

METHODS O 0 0.010807533
: O 0 0.0073852628
The O 0 0.003608143
expression O 0 0.0033670205
of O 0 0.003834625
MRP2 O 0 0.9981712
and O 0 0.0032637941
Pgp O 0 0.98292935
in O 0 0.0011876519
brain O 0 0.061609913
and O 0 0.0011767604
liver O 0 0.8145123
sections O 0 0.0016637952
of O 0 0.0016383483
TR O 0 0.97646403
( O 0 0.0027391894
- O 0 0.0018250309
) O 0 0.001008379
rats O 0 0.0009954103
and O 0 0.00052680314
normal O 0 0.0010810888
Wistar O 0 0.045487512
rats O 0 0.0011470623
was O 0 0.00040794956
determined O 0 0.0003054619
with O 0 0.00048517526
immunohistochemistry O 0 0.0086579565
, O 0 0.0007906277
by O 0 0.00050113484
using O 0 0.0003977358
a O 0 0.0006043507
novel O 0 0.00089721795
, O 0 0.00084053644
highly O 0 0.0007381039
selective O 0 0.0038595295
monoclonal O 0 0.06266533
MRP2 O 0 0.9991636
antibody O 0 0.0047680666
and O 0 0.0012005348
the O 0 0.0011996141
monoclonal O 0 0.040290467
Pgp O 0 0.9923604
antibody O 0 0.031352956
C219 O 0 0.6509644
, O 0 0.0067505753
respectively O 0 0.009262397
. O 0 0.007959258

RESULTS O 0 0.026419505
: O 0 0.008678439
Immunofluorescence O 0 0.00883451
staining O 0 0.0040724003
with O 0 0.0027364525
the O 0 0.0025995849
MRP2 O 0 0.99664485
antibody O 0 0.006777935
was O 0 0.0010653596
found O 0 0.00060823275
to O 0 0.00058736774
label O 0 0.0014222424
a O 0 0.00066754594
high O 0 0.00052614877
number O 0 0.00038673938
of O 0 0.0005697089
microvessels O 0 0.22245777
throughout O 0 0.00035774705
the O 0 0.00046005016
brain O 0 0.02114769
in O 0 0.00047537984
normal O 0 0.0012988793
Wistar O 0 0.06715919
rats O 0 0.001840561
, O 0 0.00080002536
whereas O 0 0.0004926825
such O 0 0.0006250442
labeling O 0 0.0013659806
was O 0 0.00089726236
absent O 0 0.0010906043
in O 0 0.0017549009
TR O 0 0.91925126
( O 0 0.005185293
- O 0 0.0059131593
) O 0 0.007036413
rats O 0 0.010517234
. O 0 0.008198177

TR O 0 0.9106131
( O 0 0.015929945
- O 0 0.009118939
) O 0 0.0051174667
rats O 0 0.0036930651
exhibited O 0 0.0015401416
a O 0 0.0017391954
significant O 0 0.0013838053
up O 0 0.0012751616
- O 0 0.0016788609
regulation O 0 0.000703389
of O 0 0.0012079899
Pgp O 0 0.98282015
in O 0 0.00093040214
brain O 0 0.11568486
capillary O 0 0.24790776
endothelial O 0 0.9270324
cells O 0 0.002984487
compared O 0 0.0010339947
with O 0 0.0019757252
wild O 0 0.0025493936
- O 0 0.00476438
type O 0 0.0043450897
controls O 0 0.011077257
. O 0 0.008590243

No O 0 0.01382925
such O 0 0.008178126
obvious O 0 0.0072758533
upregulation O 0 0.008483683
of O 0 0.00794293
Pgp O 0 0.9844093
was O 0 0.0051759765
observed O 0 0.0039020383
in O 0 0.0064082253
liver O 0 0.91761553
sections O 0 0.022452973
. O 0 0.013570271

A O 0 0.027789826
comparable O 0 0.0051377295
overexpression O 0 0.00553616
of O 0 0.0046451655
Pgp O 0 0.9748897
in O 0 0.002040682
the O 0 0.0019387807
BBB O 0 0.98958707
was O 0 0.0011489695
obtained O 0 0.0010460289
after O 0 0.0009423058
pilocarpine B-Chemical 1 0.9999819
- O 0 0.010113652
induced O 0 0.0036527677
seizures B-Disease 2 0.99996865
in O 0 0.002391566
wild O 0 0.0026472479
- O 0 0.0046862573
type O 0 0.003996479
Wistar O 0 0.21004638
rats O 0 0.014909662
. O 0 0.009501784

Experiments O 0 0.010527506
with O 0 0.005758464
systemic O 0 0.6275711
administration O 0 0.12948176
of O 0 0.0033566088
the O 0 0.0025262977
Pgp O 0 0.9953739
substrate O 0 0.05857518
phenobarbital B-Chemical 1 0.9999958
and O 0 0.0016968474
the O 0 0.00093319325
selective O 0 0.024149317
Pgp O 0 0.9971107
inhibitor O 0 0.32886633
tariquidar B-Chemical 0 0.99992824
in O 0 0.0011550708
TR O 0 0.9788521
( O 0 0.002429068
- O 0 0.0017230419
) O 0 0.001021508
rats O 0 0.0011453371
substantiated O 0 0.0012093409
that O 0 0.00049986114
Pgp O 0 0.9691161
is O 0 0.0005402369
functional O 0 0.00067625736
and O 0 0.0007047766
compensates O 0 0.0005673793
for O 0 0.00055909215
the O 0 0.0008456788
lack O 0 0.0011496263
of O 0 0.002936526
MRP2 O 0 0.99861515
in O 0 0.0033681807
the O 0 0.0059237108
BBB O 0 0.99353033
. O 0 0.009351601

CONCLUSIONS O 0 0.37563154
: O 0 0.008829443
The O 0 0.0040748646
data O 0 0.0039745746
on O 0 0.002629181
TR O 0 0.85508466
( O 0 0.004928166
- O 0 0.0034018864
) O 0 0.0020571896
rats O 0 0.0016850766
indicate O 0 0.0006821358
that O 0 0.0007960754
Pgp O 0 0.9722054
plays O 0 0.0008295468
an O 0 0.0009608512
important O 0 0.0005846366
role O 0 0.0005583062
in O 0 0.00074334716
the O 0 0.0009923215
compensation O 0 0.0040093944
of O 0 0.0036652302
MRP2 O 0 0.99959654
deficiency O 0 0.7067558
in O 0 0.004167736
the O 0 0.006978362
BBB O 0 0.99548894
. O 0 0.009700814

Because O 0 0.0062097344
such O 0 0.00438319
a O 0 0.004162924
compensatory O 0 0.003953289
mechanism O 0 0.0021858967
most O 0 0.0019921893
likely O 0 0.0011514677
occurs O 0 0.0008428262
to O 0 0.0007255672
reduce O 0 0.00073824107
injury B-Disease 0 0.9038123
to I-Disease 0 0.000635375
the I-Disease 0 0.0006519597
brain I-Disease 0 0.06056929
from O 0 0.0007353268
cytotoxic O 0 0.76283896
compounds O 0 0.84714526
, O 0 0.0009757878
the O 0 0.00041525756
present O 0 0.0003124144
data O 0 0.0005532667
substantiate O 0 0.00044842353
the O 0 0.0005643519
concept O 0 0.0011160753
that O 0 0.000907066
MRP2 O 0 0.9979602
performs O 0 0.0013308858
a O 0 0.00178532
protective O 0 0.007196894
role O 0 0.0019515195
in O 0 0.003128829
the O 0 0.0058314367
BBB O 0 0.9937416
. O 0 0.009458008

Furthermore O 0 0.009237529
, O 0 0.0062772934
our O 0 0.003234112
data O 0 0.0029456287
suggest O 0 0.0015993142
that O 0 0.001846888
TR O 0 0.94722056
( O 0 0.0047415397
- O 0 0.0030472104
) O 0 0.0016540344
rats O 0 0.0014553136
are O 0 0.0006024836
an O 0 0.00064424163
interesting O 0 0.0003253288
tool O 0 0.0005216485
to O 0 0.0003919312
study O 0 0.0005529636
consequences O 0 0.0011259029
of O 0 0.0006401532
overexpression O 0 0.0013570304
of O 0 0.0012133734
Pgp O 0 0.9911116
in O 0 0.0004729428
the O 0 0.00058035256
BBB O 0 0.9805895
on O 0 0.0002575763
access O 0 0.0003274775
of O 0 0.0004528243
drugs O 0 0.40746433
in O 0 0.0004099628
the O 0 0.0004815079
brain O 0 0.054447927
, O 0 0.00064644596
without O 0 0.00036646688
the O 0 0.000388075
need O 0 0.00037067232
of O 0 0.0007036046
inducing O 0 0.005265093
seizures B-Disease 2 0.99998045
or O 0 0.0013248193
other O 0 0.0019860535
Pgp O 0 0.9960592
- O 0 0.003050947
enhancing O 0 0.0019036435
events O 0 0.017996596
for O 0 0.002189344
this O 0 0.0035772177
purpose O 0 0.0070278356
. O 0 0.00833447

Role O 0 0.02383455
of O 0 0.0233949
xanthine B-Chemical 0 0.9999213
oxidase O 0 0.99864
in O 0 0.014093463
dexamethasone B-Chemical 1 0.9997491
- O 0 0.047135584
induced O 0 0.013064925
hypertension B-Disease 2 0.9998184
in O 0 0.010646074
rats O 0 0.04231781
. O 0 0.012761291

1 O 0 0.13336578
. O 0 0.12343066

Glucocorticoid O 0 0.99685436
- O 0 0.022827895
induced O 0 0.010954431
hypertension B-Disease 2 0.99986506
( O 0 0.037720323
GC O 0 0.9061371
- O 0 0.02556685
HT B-Disease 0 0.99672973
) O 0 0.0033206958
in O 0 0.0011181042
the O 0 0.0011747287
rat O 0 0.004227601
is O 0 0.0014499325
associated O 0 0.0021604686
with O 0 0.004652102
nitric B-Chemical 0 0.99982905
oxide I-Chemical 0 0.9994228
- O 0 0.07345287
redox O 0 0.90856814
imbalance O 0 0.46941176
. O 0 0.011260381

2 O 0 0.13118877
. O 0 0.12387763

We O 0 0.008293736
studied O 0 0.0057331813
the O 0 0.004137318
role O 0 0.002926516
of O 0 0.008821686
xanthine B-Chemical 0 0.9999914
oxidase O 0 0.9998305
( O 0 0.15998048
XO O 0 0.99998236
) O 0 0.012499554
, O 0 0.0013190944
which O 0 0.00085900817
is O 0 0.0006019804
implicated O 0 0.00052134524
in O 0 0.00046859935
the O 0 0.0005144373
production O 0 0.0009134928
of O 0 0.0010760173
reactive O 0 0.55508703
oxygen O 1 0.99550724
species O 0 0.002827267
, O 0 0.0016611374
in O 0 0.0010986986
dexamethasone B-Chemical 1 0.99983644
- O 0 0.013945143
induced O 0 0.0055201165
hypertension B-Disease 2 0.9999696
( O 0 0.08307824
dex B-Chemical 1 0.99961096
- O 0 0.12086731
HT B-Disease 0 0.9979431
) O 0 0.020959718
. O 0 0.009253033

3 O 0 0.12448769
. O 0 0.12115983

Thirty O 0 0.015336742
male O 0 0.017645033
Sprague O 0 0.26803386
- O 0 0.007417769
Dawley O 0 0.022459462
rats O 0 0.0034546982
were O 0 0.0015178481
divided O 0 0.00089704053
randomly O 0 0.0006172665
into O 0 0.0005140927
four O 0 0.00052190456
treatment O 0 0.0010171643
groups O 0 0.0011905846
: O 0 0.0016373673
saline O 0 0.288358
, O 0 0.0028946165
dexamethasone B-Chemical 1 0.9998355
( O 0 0.012140511
dex B-Chemical 1 0.9994831
) O 0 0.013085038
, O 0 0.002973624
allopurinol B-Chemical 0 0.9999782
plus O 0 0.0017941949
saline O 0 0.42568743
, O 0 0.0031660877
and O 0 0.0043113665
allopurinol B-Chemical 0 0.99996567
plus O 0 0.017120587
dex B-Chemical 1 0.9989699
. O 0 0.012143176

4 O 0 0.12320249
. O 0 0.12067318

Systolic O 0 0.693696
blood O 0 0.023363838
pressures O 0 0.02445432
( O 0 0.009928124
SBP O 0 0.5497563
) O 0 0.006658865
and O 0 0.0041698483
bodyweights O 0 0.031127777
were O 0 0.0035399962
recorded O 0 0.0037407598
each O 0 0.0032402785
alternate O 0 0.0070357607
day O 0 0.0072754063
. O 0 0.010302498

Thymus O 0 0.26696312
weight O 0 0.019571932
was O 0 0.0050225775
used O 0 0.003059086
as O 0 0.0024856036
a O 0 0.0025630738
marker O 0 0.0022981314
of O 0 0.0028636353
glucocorticoid O 0 0.98411554
activity O 0 0.004712394
, O 0 0.003269759
and O 0 0.0027626227
serum O 0 0.47971746
urate B-Chemical 0 0.9995328
to O 0 0.004058229
assess O 0 0.00361558
XO O 0 0.99985445
inhibition O 0 0.083349764
. O 0 0.011140179

5 O 0 0.12639783
. O 0 0.12266984

Dex B-Chemical 1 0.9959054
increased B-Disease 0 0.05327743
SBP I-Disease 0 0.97326034
( O 0 0.0067721466
110 O 0 0.0064828433
+ O 0 0.0027685883
/ O 0 0.004200052
- O 0 0.0022254167
2 O 0 0.0011502211
- O 0 0.001394444
126 O 0 0.003354161
+ O 0 0.0009463546
/ O 0 0.0019090135
- O 0 0.0010238191
3 O 0 0.0005354676
mmHg O 0 0.0037967886
; O 0 0.00088507717
P O 0 0.011933505
< O 0 0.00053632935
0 O 0 0.0006127508
. O 0 0.00040782092
001 O 0 0.09519838
) O 0 0.00076411176
and O 0 0.0005274357
decreased B-Disease 0 0.0008264887
thymus I-Disease 0 0.018557338
( I-Disease 0 0.0015209124
P I-Disease 0 0.067355804
< I-Disease 0 0.0007095784
0 I-Disease 0 0.00079240365
. I-Disease 0 0.00053845503
001 I-Disease 0 0.100611374
) I-Disease 0 0.001111449
and I-Disease 0 0.0009299625
bodyweights I-Disease 0 0.07582215
( O 0 0.0019724446
P O 0 0.040621515
" O 0 0.002189323
< O 0 0.0020051608
0 O 0 0.002674201
. O 0 0.0026354766
01 O 0 0.012341905
) O 0 0.0079347845
. O 0 0.007710598

Allopurinol B-Chemical 0 0.99980706
decreased O 0 0.029227568
serum O 0 0.40891913
urate B-Chemical 0 0.9990388
from O 0 0.0033134082
76 O 0 0.004998242
+ O 0 0.0019448273
/ O 0 0.003193289
- O 0 0.0013578403
5 O 0 0.00055063993
to O 0 0.00048354408
30 O 0 0.00048179203
+ O 0 0.00069450133
/ O 0 0.0016528174
- O 0 0.0009391507
3 O 0 0.00049562135
micromol O 0 0.063713185
/ O 0 0.002881174
L O 0 0.46975067
( O 0 0.0012307602
P O 0 0.047067165
< O 0 0.0005793607
0 O 0 0.0006298072
. O 0 0.00038980242
001 O 0 0.09787477
) O 0 0.00066742074
in O 0 0.00035432857
saline O 0 0.014594725
and O 0 0.00049157
from O 0 0.00045484764
84 O 0 0.00089767115
+ O 0 0.0006129173
/ O 0 0.0014099247
- O 0 0.0006934491
13 O 0 0.00042705928
to O 0 0.00032745625
28 O 0 0.0005561222
+ O 0 0.0006206148
/ O 0 0.0017809431
- O 0 0.00096320035
2 O 0 0.0005603796
micromol O 0 0.07865378
/ O 0 0.0031795062
L O 0 0.40645772
in O 0 0.0010199809
dex B-Chemical 1 0.99896955
- O 0 0.0038145047
treated O 0 0.0017567714
( O 0 0.0024643557
P O 0 0.08137684
< O 0 0.00163069
0 O 0 0.002028132
. O 0 0.0018009825
01 O 0 0.00873919
) O 0 0.005038358
groups O 0 0.006195362
. O 0 0.0076504378

6 O 0 0.11668804
. O 0 0.118481934

Allopurinol B-Chemical 0 0.99928063
did O 0 0.02419031
not O 0 0.019173894
prevent O 0 0.02549701
dex B-Chemical 1 0.9979673
- O 0 0.23256716
HT B-Disease 0 0.9944179
. O 0 0.027795615

This O 0 0.011058777
, O 0 0.006102667
together O 0 0.003286766
with O 0 0.0023583095
our O 0 0.0015932394
previous O 0 0.0013249175
findings O 0 0.0025348773
that O 0 0.0013435768
allopurinol B-Chemical 0 0.9999851
failed O 0 0.0018054105
to O 0 0.0009851631
prevent O 0 0.0026068822
adrenocorticotrophic O 0 0.9998976
hormone O 0 0.9989305
induced O 0 0.016032903
hypertension B-Disease 2 0.9999869
, O 0 0.002882069
suggests O 0 0.00045056676
that O 0 0.00080178335
XO O 0 0.9999678
activity O 0 0.0011458545
is O 0 0.00061164773
not O 0 0.00054230925
a O 0 0.00081073534
major O 0 0.00092256075
determinant O 0 0.0007747921
of O 0 0.0023124006
GC O 0 0.8584114
- O 0 0.020092234
HT B-Disease 0 0.99296725
in O 0 0.0033459028
the O 0 0.0047892476
rat O 0 0.022335416
. O 0 0.009010388

Side O 0 0.82977754
effects O 0 0.008350533
of O 0 0.0050272616
postoperative O 0 0.06041975
administration O 0 0.07510893
of O 0 0.004180959
methylprednisolone B-Chemical 1 0.9999267
and O 0 0.0049808654
gentamicin B-Chemical 1 0.9982988
into O 0 0.0010830557
the O 0 0.0014793298
posterior O 0 0.008345551
sub O 0 0.013974082
- O 0 0.0043446915
Tenon O 0 0.20010477
' O 0 0.004967364
s O 0 0.0053820247
space O 0 0.00716479
. O 0 0.008502672

PURPOSE O 0 0.022497315
: O 0 0.0063909
To O 0 0.0026687065
assess O 0 0.0014294554
the O 0 0.0016035533
incidence O 0 0.003957546
of O 0 0.0016522682
postoperative O 0 0.14909486
emetic O 0 0.998251
side O 0 0.18808515
effects O 0 0.001953336
after O 0 0.0003686095
the O 0 0.000511692
administration O 0 0.029944824
of O 0 0.001282827
methylprednisolone B-Chemical 1 0.99996483
and O 0 0.0019154634
gentamicin B-Chemical 1 0.9981476
into O 0 0.00037348163
the O 0 0.00053990685
posterior O 0 0.004348233
sub O 0 0.00835943
- O 0 0.0014004216
Tenon O 0 0.105387054
' O 0 0.0010050348
s O 0 0.0008091342
space O 0 0.00079368154
at O 0 0.0006608028
the O 0 0.00092631014
end O 0 0.0010037897
of O 0 0.0021914868
routine O 0 0.004007999
cataract B-Disease 2 0.979622
surgery O 0 0.031541273
. O 0 0.00944288

SETTING O 0 0.1444002
: O 0 0.09722081
St O 0 0.13971813
. O 0 0.07724896

Luke O 0 0.07490752
' O 0 0.028967066
s O 0 0.02586108
Hospital O 0 0.034776192
, O 0 0.026098024
Gwardamangia O 0 0.11850557
, O 0 0.028617596
Malta O 0 0.076423705
. O 0 0.02487583

METHODS O 0 0.011879674
: O 0 0.009224812
A O 0 0.015179286
double O 0 0.004425707
- O 0 0.004298749
blind O 0 0.005750699
double O 0 0.0021450173
- O 0 0.002573383
armed O 0 0.0071422346
prospective O 0 0.0018964787
study O 0 0.000852405
comprised O 0 0.00067695347
40 O 0 0.0006319869
patients O 0 0.0009311798
who O 0 0.00081454834
had O 0 0.00045248732
uneventful O 0 0.00081731577
sutureless O 0 0.005557723
phacoemulsification O 0 0.24508967
under O 0 0.00053741486
sub O 0 0.0080995355
- O 0 0.0015159739
Tenon O 0 0.10823482
' O 0 0.001059317
s O 0 0.0008710282
local O 0 0.0014085283
infiltration O 0 0.35619253
of O 0 0.0019580317
3 O 0 0.0019150794
mL O 0 0.0054894513
of O 0 0.003751582
plain O 0 0.23410667
lignocaine B-Chemical 1 0.9995983
. O 0 0.011163093

At O 0 0.0059419987
the O 0 0.004530081
end O 0 0.0027043754
of O 0 0.002623238
the O 0 0.0020281137
procedure O 0 0.0020835232
, O 0 0.002385343
Group O 0 0.02694025
A O 0 0.03852154
( O 0 0.001236293
n O 0 0.0008483615
= O 0 0.00086862134
20 O 0 0.0005468495
) O 0 0.00066394784
had O 0 0.00035737923
20 O 0 0.0004337962
mg O 0 0.06750462
/ O 0 0.0011485222
0 O 0 0.0005614365
. O 0 0.00027101143
5 O 0 0.00029131008
mL O 0 0.000789266
of O 0 0.00049922446
methylprednisolone B-Chemical 1 0.9998086
and O 0 0.00070596917
10 O 0 0.0005144216
mg O 0 0.15983228
/ O 0 0.0012998705
0 O 0 0.0005491402
. O 0 0.0002576819
5 O 0 0.00028072842
mL O 0 0.0007500791
of O 0 0.00044181375
gentamicin B-Chemical 1 0.9844691
injected O 0 0.00035393744
into O 0 0.00023811792
the O 0 0.00037031595
posterior O 0 0.0024968062
sub O 0 0.006316268
- O 0 0.0010387222
Tenon O 0 0.101025335
' O 0 0.0006673367
s O 0 0.00049337215
space O 0 0.000487925
and O 0 0.0006314529
Group O 0 0.03739877
B O 0 0.14792001
( O 0 0.00079516746
n O 0 0.0005724713
= O 0 0.0006378124
20 O 0 0.00043118853
) O 0 0.0005574942
had O 0 0.0003056393
the O 0 0.00033424256
same O 0 0.000296299
combination O 0 0.000662063
injected O 0 0.00052923197
into O 0 0.0004779046
the O 0 0.0008823756
anterior O 0 0.0051665884
sub O 0 0.0087985415
- O 0 0.0034575644
Tenon O 0 0.17531301
' O 0 0.0043030274
s O 0 0.004772327
space O 0 0.006497676
. O 0 0.007868259

Postoperatively O 0 0.03366071
, O 0 0.0077440017
all O 0 0.0041497615
patients O 0 0.0047564497
were O 0 0.0026413195
assessed O 0 0.0018969362
for O 0 0.0018648372
symptoms O 0 0.7031844
of O 0 0.012331273
nausea B-Disease 2 0.99999464
, I-Disease 0 0.11632424
vomiting I-Disease 2 0.9999598
, O 0 0.019259166
and O 0 0.015548931
headache B-Disease 2 0.99975187
. O 0 0.013647858

A O 0 0.094188906
chi O 0 0.3614218
- O 0 0.00994556
square O 0 0.007214244
test O 0 0.004078454
was O 0 0.0028899407
used O 0 0.0022229808
to O 0 0.0019705065
assess O 0 0.0014454629
the O 0 0.0024513025
statistical O 0 0.006327033
significance O 0 0.005305067
of O 0 0.006322564
results O 0 0.009168916
. O 0 0.011256804

RESULTS O 0 0.024921307
: O 0 0.008400473
Sixty O 0 0.0073935315
percent O 0 0.0035506391
in O 0 0.0029642729
Group O 0 0.013070194
A O 0 0.02077494
developed O 0 0.0024118894
postoperative B-Disease 0 0.36071137
emetic I-Disease 0 0.9993094
symptoms I-Disease 0 0.9967167
, O 0 0.016212005
headache B-Disease 2 0.99995947
, O 0 0.0021949573
or O 0 0.001010296
both O 0 0.0011262081
; O 0 0.0020091573
1 O 0 0.001182401
patient O 0 0.0017206831
in O 0 0.0019103558
Group O 0 0.09504916
B O 0 0.31299937
developed O 0 0.009944922
symptoms O 0 0.9216646
. O 0 0.010799075

CONCLUSIONS O 0 0.4307953
: O 0 0.00793882
The O 0 0.0034893067
administration O 0 0.014233374
of O 0 0.0035614222
methylprednisolone B-Chemical 1 0.9998951
and O 0 0.0043829903
gentamicin B-Chemical 1 0.99865806
in O 0 0.0009956947
the O 0 0.0008284418
posterior O 0 0.0057535428
sub O 0 0.011466941
- O 0 0.0014418734
Tenon O 0 0.12292874
' O 0 0.0008040223
s O 0 0.0005583531
space O 0 0.0004975923
was O 0 0.00039803665
related O 0 0.00032006993
to O 0 0.00039304956
a O 0 0.00063670013
high O 0 0.0006674767
incidence O 0 0.004018869
of O 0 0.0010509749
side O 0 0.085341506
effects O 0 0.0050776703
including O 0 0.005041583
nausea B-Disease 2 0.99999726
, I-Disease 0 0.0782805
vomiting I-Disease 2 0.9999708
, O 0 0.014647597
and O 0 0.013033155
headache B-Disease 2 0.9997888
. O 0 0.01154382

All O 0 0.023532318
adverse O 0 0.53887194
effects O 0 0.024599351
were O 0 0.019309156
self O 0 0.06103183
- O 0 0.025353221
limiting O 0 0.022718243
. O 0 0.022181476

Assessment O 0 0.011399622
of O 0 0.006090486
a O 0 0.004903123
new O 0 0.0039518825
non O 0 0.0051054005
- O 0 0.0034950136
invasive O 0 0.004955008
index O 0 0.0020302457
of O 0 0.0016596287
cardiac O 0 0.38019183
performance O 0 0.0017473955
for O 0 0.0008597779
detection O 0 0.0014567648
of O 0 0.0029844784
dobutamine B-Chemical 1 0.9999107
- O 0 0.02071012
induced O 0 0.012263614
myocardial B-Disease 0 0.99988234
ischemia I-Disease 2 0.99986947
. O 0 0.015905377

BACKGROUND O 0 0.6600798
: O 0 0.013523146
Electrocardiography O 0 0.3352183
has O 0 0.0040460667
a O 0 0.003885879
very O 0 0.0031057573
low O 0 0.0029355404
sensitivity O 0 0.0035825502
in O 0 0.0022590293
detecting O 0 0.0032208688
dobutamine B-Chemical 1 0.99986196
- O 0 0.025112063
induced O 0 0.014885225
myocardial B-Disease 0 0.9998578
ischemia I-Disease 2 0.99985397
. O 0 0.018118633

OBJECTIVES O 0 0.022753822
: O 0 0.006647564
To O 0 0.0028083003
assess O 0 0.0015104536
the O 0 0.0016279976
added O 0 0.0013704983
diagnostic O 0 0.0016936484
value O 0 0.00091502507
of O 0 0.0008779684
a O 0 0.0009855541
new O 0 0.0009713044
cardiac O 0 0.29128334
performance O 0 0.0011907093
index O 0 0.0013584663
( O 0 0.0016795723
dP O 0 0.080154814
/ O 0 0.0027500477
dtejc O 0 0.01167404
) O 0 0.0009377228
measurement O 0 0.00033101498
, O 0 0.00045987547
based O 0 0.00033387056
on O 0 0.00026595223
brachial O 0 0.3488112
artery O 0 0.094569735
flow O 0 0.0033403195
changes O 0 0.0006015921
, O 0 0.00050209305
as O 0 0.00031310917
compared O 0 0.00021289424
to O 0 0.00028800667
standard O 0 0.00040890698
12 O 0 0.000370964
- O 0 0.0007555391
lead O 0 0.009468873
ECG O 0 0.9395376
, O 0 0.00056372985
for O 0 0.00029205004
detecting O 0 0.00051369646
dobutamine B-Chemical 1 0.9999448
- O 0 0.0047220383
induced O 0 0.0016167277
myocardial B-Disease 0 0.9999633
ischemia I-Disease 2 0.9999838
, O 0 0.0035524096
using O 0 0.00086714193
Tc99m B-Chemical 0 0.9986557
- I-Chemical 0 0.0032619084
Sestamibi I-Chemical 0 0.9950028
single O 0 0.00057372916
- O 0 0.0008483883
photon O 0 0.014761498
emission O 0 0.022041624
computed O 0 0.00071624323
tomography O 0 0.024734674
as O 0 0.00043338852
the O 0 0.00046776567
gold O 0 0.21980302
standard O 0 0.0005753255
of O 0 0.00063682697
comparison O 0 0.0005157905
to O 0 0.0005532783
assess O 0 0.0004443488
the O 0 0.00092928833
presence O 0 0.0012520148
or O 0 0.0018723345
absence O 0 0.0021051134
of O 0 0.011203199
ischemia B-Disease 2 0.9998103
. O 0 0.012220806

METHODS O 0 0.012008719
: O 0 0.008212505
The O 0 0.004133998
study O 0 0.00360719
group O 0 0.002778407
comprised O 0 0.0022920833
40 O 0 0.0020799162
patients O 0 0.0031149387
undergoing O 0 0.003425763
Sestamibi B-Chemical 0 0.9946937
- O 0 0.0059136865
SPECT O 0 0.9509035
/ O 0 0.01171432
dobutamine B-Chemical 1 0.9995572
stress O 0 0.60444784
test O 0 0.013029341
. O 0 0.0109470235

Simultaneous O 0 0.015490299
measurements O 0 0.006314033
of O 0 0.006096129
ECG O 0 0.7409932
and O 0 0.004394983
brachial O 0 0.58641386
artery O 0 0.39096496
dP O 0 0.1507741
/ O 0 0.005529551
dtejc O 0 0.0069216914
were O 0 0.0019022339
performed O 0 0.001696899
at O 0 0.00184011
each O 0 0.002523927
dobutamine B-Chemical 1 0.99864906
level O 0 0.0061851265
. O 0 0.009328723

In O 0 0.0087348325
19 O 0 0.007367227
of O 0 0.0045890673
the O 0 0.0033549564
40 O 0 0.002935317
patients O 0 0.004089551
perfusion O 0 0.14497805
defects O 0 0.0034173862
compatible O 0 0.003483699
with O 0 0.0041928547
ischemia B-Disease 2 0.99976724
were O 0 0.0043078475
detected O 0 0.003326137
on O 0 0.0048760423
SPECT O 0 0.9641194
. O 0 0.010096848

The O 0 0.0076083858
increase O 0 0.00487071
in O 0 0.0041301795
dP O 0 0.051226493
/ O 0 0.0052498546
dtejc O 0 0.0059104306
during O 0 0.00103774
infusion O 0 0.0035447325
of O 0 0.0014468753
dobutamine B-Chemical 1 0.9998148
in O 0 0.0008299929
this O 0 0.0006950006
group O 0 0.0009810766
was O 0 0.00080733513
severely O 0 0.0051279403
impaired O 0 0.0010318254
as O 0 0.0007696542
compared O 0 0.00061374466
to O 0 0.0009741441
the O 0 0.0015084702
non O 0 0.008093647
- O 0 0.019449707
ischemic O 0 0.9994796
group O 0 0.01353281
. O 0 0.009555824

dP O 0 0.10621066
/ O 0 0.013022439
dtejc O 0 0.011931099
outcome O 0 0.0056811483
was O 0 0.0025113083
combined O 0 0.0022351886
with O 0 0.0015879142
the O 0 0.0015155582
ECG O 0 0.87144774
results O 0 0.001218202
, O 0 0.0013122857
giving O 0 0.0011812565
an O 0 0.0017567696
ECG O 0 0.9667303
- O 0 0.0018895458
enhanced O 0 0.0010556369
value O 0 0.0012658546
, O 0 0.0016773319
and O 0 0.001607325
compared O 0 0.0014584673
to O 0 0.0030387207
ECG O 0 0.92940605
alone O 0 0.0071199657
. O 0 0.008672901

RESULTS O 0 0.024668751
: O 0 0.0077875196
The O 0 0.0036867247
sensitivity O 0 0.0040376806
improved O 0 0.003198738
dramatically O 0 0.0023367316
from O 0 0.0013712888
16 O 0 0.001132328
% O 0 0.0009463644
to O 0 0.000609451
79 O 0 0.0010807017
% O 0 0.0007038684
, O 0 0.00056903646
positive O 0 0.0004429186
predictive O 0 0.0007394767
value O 0 0.00048165777
increased O 0 0.00051322073
from O 0 0.00043732193
60 O 0 0.00042311448
% O 0 0.0004247633
to O 0 0.00031173605
68 O 0 0.0006384438
% O 0 0.00042955636
and O 0 0.00037074622
negative O 0 0.0004550046
predictive O 0 0.000705042
value O 0 0.0004552196
from O 0 0.00043889257
54 O 0 0.00086515455
% O 0 0.0005107917
to O 0 0.00040059656
78 O 0 0.0009901136
% O 0 0.000695964
, O 0 0.00073598546
and O 0 0.0007090641
specificity O 0 0.0012272123
decreased O 0 0.0013096568
from O 0 0.0012237465
90 O 0 0.0014129571
% O 0 0.0020632718
to O 0 0.0022822993
67 O 0 0.0061062207
% O 0 0.0063633802
. O 0 0.0072364896

CONCLUSIONS O 0 0.46531147
: O 0 0.009068898
If O 0 0.0042637805
ECG O 0 0.6188862
alone O 0 0.0026822507
is O 0 0.0016362485
used O 0 0.0010935487
for O 0 0.0008043059
specificity O 0 0.0016039594
, O 0 0.0010581445
the O 0 0.0006028075
combination O 0 0.0010796068
with O 0 0.0009837451
dP O 0 0.1611386
/ O 0 0.0034699007
dtejc O 0 0.007515861
improved O 0 0.00079638715
the O 0 0.00040588304
sensitivity O 0 0.0006962187
of O 0 0.0004959433
the O 0 0.00042451636
test O 0 0.00056450575
and O 0 0.00051731686
could O 0 0.00032883434
be O 0 0.0004290947
a O 0 0.0006043165
cost O 0 0.0010580921
- O 0 0.00090770103
savings O 0 0.0032235596
alternative O 0 0.0004387853
to O 0 0.0004009886
cardiac O 0 0.28162238
imaging O 0 0.0025893284
or O 0 0.00048792711
perfusion O 0 0.12393119
studies O 0 0.0005898823
to O 0 0.00050065265
detect O 0 0.00062546023
myocardial B-Disease 0 0.9999089
ischemia I-Disease 2 0.99995875
, O 0 0.0027919277
especially O 0 0.0015806772
in O 0 0.0014225959
patients O 0 0.0036466103
unable O 0 0.002142822
to O 0 0.0037884545
exercise O 0 0.07493593
. O 0 0.008200291

Cocaine B-Chemical 1 0.9997075
- O 0 0.028662411
induced O 0 0.0142893195
myocardial B-Disease 0 0.99962604
infarction I-Disease 2 0.99995804
: O 0 0.015115614
clinical O 0 0.014949522
observations O 0 0.006463695
and O 0 0.0073879343
pathogenetic O 0 0.17864163
considerations O 0 0.01756759
. O 0 0.013598432

Clinical O 0 0.032358598
and O 0 0.0064066704
experimental O 0 0.004329929
data O 0 0.0035247598
published O 0 0.0020079259
to O 0 0.0014010778
date O 0 0.0011399362
suggest O 0 0.00070527924
several O 0 0.00089464535
possible O 0 0.0009815178
mechanisms O 0 0.0016304477
by O 0 0.0014548842
which O 0 0.0026091223
cocaine B-Chemical 1 0.9999052
may O 0 0.0016714494
result O 0 0.0020068092
in O 0 0.0032068486
acute B-Disease 2 0.99879044
myocardial I-Disease 2 0.9999467
infarction I-Disease 2 0.9999825
. O 0 0.020434126

In O 0 0.007594935
individuals O 0 0.0067083007
with O 0 0.003970906
preexisting O 0 0.019307116
, O 0 0.0034950352
high O 0 0.0026015665
- O 0 0.0028725485
grade O 0 0.23122662
coronary O 0 0.76466066
arterial O 0 0.79815173
narrowing O 0 0.08190406
, O 0 0.0029820078
acute B-Disease 2 0.9968911
myocardial I-Disease 2 0.9999807
infarction I-Disease 2 0.99999833
may O 0 0.00092106714
result O 0 0.0006161565
from O 0 0.0005125026
an O 0 0.00068734464
increase O 0 0.00041044262
in O 0 0.00063788274
myocardial O 0 0.99981016
oxygen B-Chemical 1 0.9909321
demand O 0 0.004078703
associated O 0 0.0011213694
with O 0 0.0018520701
cocaine B-Chemical 1 0.9999696
- O 0 0.0052700727
induced O 0 0.0012996311
increase O 0 0.001089866
in O 0 0.0015157012
rate O 0 0.0023988273
- O 0 0.0055894214
pressure O 0 0.0737293
product O 0 0.011235483
. O 0 0.008128357

In O 0 0.0072438
other O 0 0.004992511
individuals O 0 0.004499738
with O 0 0.0024346968
no O 0 0.0016595529
underlying O 0 0.0046780263
atherosclerotic B-Disease 2 0.9996978
obstruction I-Disease 0 0.9985644
, O 0 0.004291646
coronary B-Disease 0 0.80352193
occlusion I-Disease 0 0.3105841
may O 0 0.00096112955
be O 0 0.0009402896
due O 0 0.00079490314
to O 0 0.001444969
spasm B-Disease 2 0.999846
, O 0 0.0062509845
thrombus B-Disease 0 0.99732107
, O 0 0.005192924
or O 0 0.004073891
both O 0 0.0059792954
. O 0 0.008277956

With O 0 0.009258754
regard O 0 0.005539408
to O 0 0.004808262
spasm B-Disease 2 0.9993092
, O 0 0.0039559896
the O 0 0.0017365903
clinical O 0 0.0040653856
findings O 0 0.0024076835
are O 0 0.001219328
largely O 0 0.0014345708
circumstantial O 0 0.0060204077
, O 0 0.001405699
and O 0 0.0009616031
the O 0 0.00087091327
locus O 0 0.0011742008
of O 0 0.0025172564
cocaine B-Chemical 1 0.99994993
- O 0 0.015212969
induced O 0 0.0053950967
vasoconstriction O 0 0.9994604
remains O 0 0.0060449806
speculative O 0 0.061289832
. O 0 0.009200337

Although O 0 0.0064121736
certain O 0 0.005156315
clinical O 0 0.006735831
and O 0 0.0026536046
experimental O 0 0.0019754677
findings O 0 0.002329382
support O 0 0.0010975051
the O 0 0.00089903385
hypothesis O 0 0.0010648613
that O 0 0.00089451636
spasm B-Disease 2 0.9998417
involves O 0 0.0008812328
the O 0 0.0008484845
epicardial O 0 0.2819983
, O 0 0.0014673887
medium O 0 0.0043498226
- O 0 0.0017145526
size O 0 0.0012533492
vessels O 0 0.037568443
, O 0 0.0018215802
other O 0 0.0015980173
data O 0 0.002666135
suggest O 0 0.002659525
intramural O 0 0.85483426
vasoconstriction O 0 0.99915814
. O 0 0.011689901

Diffuse O 0 0.4102106
intramural O 0 0.6255738
vasoconstriction O 0 0.9978625
is O 0 0.00527479
not O 0 0.0032596984
consistent O 0 0.0025538597
with O 0 0.0026508623
reports O 0 0.0035420407
of O 0 0.0040176115
segmental O 0 0.046766814
, O 0 0.008079475
discrete O 0 0.015267965
infarction B-Disease 2 0.9999006
. O 0 0.014967509

Whereas O 0 0.008126623
certain O 0 0.0057880534
in O 0 0.0035609282
vivo O 0 0.0032631566
data O 0 0.0022249932
suggest O 0 0.0010715256
that O 0 0.00097327854
these O 0 0.0012593295
effects O 0 0.0022505235
are O 0 0.0016020836
alpha O 0 0.5219521
- O 0 0.0032900209
mediated O 0 0.0010917988
, O 0 0.0015000047
other O 0 0.0011044577
in O 0 0.0012359563
vitro O 0 0.002158114
data O 0 0.0023293102
suggest O 0 0.0019329691
the O 0 0.003916814
opposite O 0 0.007957584
. O 0 0.008955839

The O 0 0.0073466054
finding O 0 0.0064213243
of O 0 0.006533818
cocaine B-Chemical 1 0.99989045
- O 0 0.020499524
induced O 0 0.0037087803
vasoconstriction O 0 0.99953604
in O 0 0.0013565179
segments O 0 0.0015225438
of O 0 0.0012561427
( O 0 0.0015965102
noninnervated O 0 0.074624404
) O 0 0.0010414396
human O 0 0.00059323275
umbilical O 0 0.004017539
artery O 0 0.06871066
suggests O 0 0.00027731564
that O 0 0.00029798035
the O 0 0.00035462982
presence O 0 0.000356039
or O 0 0.00038395723
absence O 0 0.00025668586
of O 0 0.00057565735
intact O 0 0.0006046273
innervation O 0 0.096643254
is O 0 0.0004233061
not O 0 0.00034977306
sufficient O 0 0.00025308033
to O 0 0.00033501172
explain O 0 0.00034961067
the O 0 0.00045323753
discrepant O 0 0.0014315043
data O 0 0.00076699705
involving O 0 0.0007648942
the O 0 0.00079738424
possibility O 0 0.0010354749
of O 0 0.002609898
alpha O 0 0.5731269
- O 0 0.007929204
mediated O 0 0.0042893607
effects O 0 0.01483983
. O 0 0.009301014

Finally O 0 0.009866565
, O 0 0.0068309773
the O 0 0.0037130164
contribution O 0 0.0023676034
of O 0 0.0025615357
a O 0 0.002692764
primary O 0 0.002813259
, O 0 0.0035651622
thrombotic B-Disease 2 0.99919254
effect O 0 0.0027294946
of O 0 0.0050118156
cocaine B-Chemical 1 0.9998857
has O 0 0.0031077035
not O 0 0.0036060403
been O 0 0.005183926
excluded O 0 0.00879576
. O 0 0.009122145

Proteomic O 0 0.039812885
analysis O 0 0.008589679
of O 0 0.006579204
striatal O 0 0.8158067
proteins O 0 0.0048603313
in O 0 0.0024329138
the O 0 0.002162723
rat O 0 0.00524728
model O 0 0.002788856
of O 0 0.0057260157
L B-Chemical 1 0.9930661
- I-Chemical 1 0.18488681
DOPA I-Chemical 1 0.99993896
- O 0 0.0348586
induced O 0 0.02351486
dyskinesia B-Disease 2 0.999962
. O 0 0.016061543

L B-Chemical 1 0.97349685
- I-Chemical 1 0.13444819
DOPA I-Chemical 1 0.9998388
- O 0 0.025857909
induced O 0 0.009478481
dyskinesia B-Disease 2 0.99999225
( O 0 0.07946032
LID B-Disease 2 0.99973065
) O 0 0.004172124
is O 0 0.0008559846
among O 0 0.0007813017
the O 0 0.0006477953
motor O 0 0.03784715
complications O 0 0.3087165
that O 0 0.0005041483
arise O 0 0.0010075034
in O 0 0.000781753
Parkinson B-Disease 0 0.9998191
' I-Disease 0 0.0014800795
s I-Disease 0 0.0010287063
disease I-Disease 0 0.72743255
( O 0 0.0038854068
PD B-Disease 2 0.9986412
) O 0 0.0019038572
patients O 0 0.0015869122
after O 0 0.00053847604
a O 0 0.0013322314
prolonged O 0 0.004797029
treatment O 0 0.004234269
with O 0 0.0065145544
L B-Chemical 1 0.9918189
- I-Chemical 1 0.17999648
DOPA I-Chemical 1 0.9998043
. O 0 0.011755835

To O 0 0.0063222568
this O 0 0.0044191126
day O 0 0.003251023
, O 0 0.002851006
transcriptome O 0 0.002008855
analysis O 0 0.0018727321
has O 0 0.0010926906
been O 0 0.000980063
performed O 0 0.0006773959
in O 0 0.0006337246
a O 0 0.00090677047
rat O 0 0.0021913117
model O 0 0.00092610985
of O 0 0.0022462127
LID B-Disease 2 0.9998697
[ O 0 0.051541667
Neurobiol O 0 0.9691945
. O 0 0.0007420088
Dis O 0 0.6883282
. O 0 0.00054154766
, O 0 0.00080333085
17 O 0 0.00088836503
( O 0 0.0008825593
2004 O 0 0.0014476796
) O 0 0.0011291923
, O 0 0.00093070255
219 O 0 0.0067246486
] O 0 0.0011048716
but O 0 0.0006399561
information O 0 0.0008145059
regarding O 0 0.0007851843
the O 0 0.001290927
proteome O 0 0.0030694457
is O 0 0.002654276
still O 0 0.003450515
lacking O 0 0.004346049
. O 0 0.007828034

In O 0 0.00707252
the O 0 0.0047818143
present O 0 0.0028328798
study O 0 0.0029716243
, O 0 0.002152615
we O 0 0.00092934293
investigated O 0 0.0008181464
the O 0 0.0008474203
changes O 0 0.0009904739
occurring O 0 0.0011104342
at O 0 0.00045569608
the O 0 0.0004958695
protein O 0 0.00087697845
level O 0 0.00038897726
in O 0 0.00048512575
striatal O 0 0.7495749
samples O 0 0.00046860604
obtained O 0 0.00038657957
from O 0 0.0003749643
the O 0 0.0004082844
unilaterally O 0 0.04128141
6 B-Chemical 0 0.0004517697
- I-Chemical 0 0.0010486891
hydroxydopamine I-Chemical 0 0.83621687
- O 0 0.0011013981
lesion O 0 0.019889113
rat O 0 0.001923634
model O 0 0.00057530793
of O 0 0.001004523
PD B-Disease 2 0.9986941
treated O 0 0.0011077062
with O 0 0.0009717858
saline O 0 0.58297217
, O 0 0.0055339234
L B-Chemical 1 0.984663
- I-Chemical 1 0.025201498
DOPA I-Chemical 1 0.9999702
or O 0 0.0012762593
bromocriptine B-Chemical 1 0.99997306
using O 0 0.0007045208
two O 0 0.0006218807
- O 0 0.0011157953
dimensional O 0 0.0010578508
difference O 0 0.0006109017
gel O 0 0.012835948
electrophoresis O 0 0.03307019
and O 0 0.002205348
mass O 0 0.009362019
spectrometry O 0 0.09846068
( O 0 0.012387704
MS O 2 0.99038786
) O 0 0.016472131
. O 0 0.009537465

Rats O 0 0.032720145
treated O 0 0.009563138
with O 0 0.0086708935
L B-Chemical 1 0.9725404
- I-Chemical 1 0.04713549
DOPA I-Chemical 1 0.99983037
were O 0 0.00213144
allocated O 0 0.0011561839
to O 0 0.0009555052
two O 0 0.0008696532
groups O 0 0.0011544769
based O 0 0.0010557676
on O 0 0.00083736517
the O 0 0.0012487217
presence O 0 0.0016108403
or O 0 0.0023427736
absence O 0 0.0026024722
of O 0 0.012120472
LID B-Disease 2 0.99918336
. O 0 0.011394461

Among O 0 0.012111335
the O 0 0.0060087424
2000 O 0 0.006060727
spots O 0 0.0036951713
compared O 0 0.0013818099
for O 0 0.0011142042
statistical O 0 0.0023928196
difference O 0 0.0007455364
, O 0 0.0010677506
67 O 0 0.0012007625
spots O 0 0.0010444665
were O 0 0.00056088873
significantly O 0 0.0006462873
changed O 0 0.00056080485
in O 0 0.00042608008
abundance O 0 0.00047454087
and O 0 0.00055392267
identified O 0 0.00042807905
using O 0 0.0005344238
matrix O 0 0.021822367
- O 0 0.0016407219
assisted O 0 0.0016453939
laser O 0 0.007380026
desorption O 0 0.41409236
/ O 0 0.004957242
ionization O 0 0.08534878
time O 0 0.0005345354
- O 0 0.0009867258
of O 0 0.0007789154
- O 0 0.0015464063
flight O 0 0.0039332677
MS O 2 0.9887068
, O 0 0.0010814057
atmospheric O 0 0.06484783
pressure O 0 0.056286503
matrix O 0 0.031924058
- O 0 0.0017233815
assisted O 0 0.0017318685
laser O 0 0.0077222083
desorption O 0 0.43550208
/ O 0 0.007228495
ionization O 0 0.13950022
and O 0 0.0015510957
HPLC O 0 0.72568613
coupled O 0 0.0015132789
tandem O 0 0.002747609
MS O 2 0.9926085
( O 0 0.0053799143
LC O 0 0.75038415
/ O 0 0.038257856
MS O 2 0.99428326
/ O 0 0.0751643
MS O 2 0.9923551
) O 0 0.016847204
. O 0 0.00954999

Out O 0 0.016573131
of O 0 0.0063649304
these O 0 0.0046231244
67 O 0 0.005473281
proteins O 0 0.0044144993
, O 0 0.0041900733
LID B-Disease 2 0.9980673
significantly O 0 0.0017556702
changed O 0 0.0010057857
the O 0 0.00066212664
expression O 0 0.0007174832
level O 0 0.00039033827
of O 0 0.0005724953
five O 0 0.0004132568
proteins O 0 0.0013949648
: O 0 0.0020886837
alphabeta O 0 0.77293
- O 0 0.002559888
crystalin O 0 0.026621897
, O 0 0.0016044223
gamma O 0 0.59075844
- O 0 0.0034551925
enolase O 0 0.9360701
, O 0 0.0021724775
guanidoacetate O 0 0.8694641
methyltransferase O 0 0.4838935
, O 0 0.0024623626
vinculin O 0 0.4235665
, O 0 0.001992231
and O 0 0.001958308
proteasome O 0 0.52450806
alpha O 0 0.54312044
- O 0 0.0069675925
2 O 0 0.0044077667
subunit O 0 0.009485275
. O 0 0.008139602

Complementary O 0 0.013631024
techniques O 0 0.0071669533
such O 0 0.0039017517
as O 0 0.0030324014
western O 0 0.0046689836
immunoblotting O 0 0.0025373842
and O 0 0.0017337789
immunohistochemistry O 0 0.004142855
were O 0 0.0010335181
performed O 0 0.0007226332
to O 0 0.00062270777
investigate O 0 0.00047083828
the O 0 0.0007604478
validity O 0 0.0015322011
of O 0 0.0010613499
the O 0 0.0011122222
data O 0 0.0016105997
obtained O 0 0.0016458944
using O 0 0.0019857518
the O 0 0.0027198168
proteomic O 0 0.0071115666
approach O 0 0.007851879
. O 0 0.008778054

In O 0 0.008340463
conclusion O 0 0.0055609285
, O 0 0.0054232483
this O 0 0.0031892145
study O 0 0.0028290947
provides O 0 0.0017787691
new O 0 0.002316993
insights O 0 0.0020334986
into O 0 0.0014192254
the O 0 0.0019540696
protein O 0 0.0037176602
changes O 0 0.004337649
occurring O 0 0.008454001
in O 0 0.009050456
LID B-Disease 2 0.9987702
. O 0 0.012155676

Cardiac O 0 0.78683436
Angiography O 0 0.10679274
in O 0 0.0061930544
Renally O 0 0.37945458
Impaired O 0 0.037063774
Patients O 0 0.009860177
( O 0 0.0032792778
CARE O 0 0.122626185
) O 0 0.002012991
study O 0 0.0011165646
: O 0 0.0010421377
a O 0 0.0007818834
randomized O 0 0.0007287479
double O 0 0.00070237886
- O 0 0.0010493122
blind O 0 0.0019121297
trial O 0 0.0007850725
of O 0 0.00074450625
contrast O 0 0.0010681541
- O 0 0.0027213164
induced O 0 0.0021263063
nephropathy B-Disease 2 0.9999739
in O 0 0.0023693405
patients O 0 0.017654005
with O 0 0.0046548406
chronic B-Disease 0 0.9970956
kidney I-Disease 0 0.99654704
disease I-Disease 0 0.9958133
. O 0 0.014748009

BACKGROUND O 0 0.51676697
: O 0 0.007578417
No O 0 0.0043643652
direct O 0 0.002569962
comparisons O 0 0.0017895595
exist O 0 0.0013010473
of O 0 0.0012584133
the O 0 0.0011170683
renal O 0 0.95496136
tolerability O 0 0.32703555
of O 0 0.0011216652
the O 0 0.00080709055
low O 0 0.0014923746
- O 0 0.0025872013
osmolality O 0 0.7953847
contrast B-Chemical 0 0.0012788421
medium I-Chemical 0 0.054656185
iopamidol B-Chemical 1 0.99969316
with O 0 0.00066746515
that O 0 0.00042781184
of O 0 0.00077287847
the O 0 0.0010595502
iso O 0 0.97265065
- O 0 0.004241924
osmolality O 0 0.8014117
contrast B-Chemical 0 0.0019017273
medium I-Chemical 0 0.08417462
iodixanol B-Chemical 1 0.9991447
in O 0 0.0021832255
high O 0 0.0038455548
- O 0 0.0074200057
risk O 0 0.12899248
patients O 0 0.028664073
. O 0 0.009280719

METHODS O 0 0.012337785
AND O 0 0.008848931
RESULTS O 0 0.011534313
: O 0 0.004387195
The O 0 0.0021450839
present O 0 0.0014606563
study O 0 0.001698187
is O 0 0.0012448906
a O 0 0.0015160106
multicenter O 0 0.023606373
, O 0 0.0012044786
randomized O 0 0.00087056524
, O 0 0.0007755185
double O 0 0.00062180543
- O 0 0.0008654002
blind O 0 0.001421805
comparison O 0 0.00034781118
of O 0 0.0006833363
iopamidol B-Chemical 1 0.9996556
and O 0 0.0010247232
iodixanol B-Chemical 1 0.9987589
in O 0 0.0005631929
patients O 0 0.0028361413
with O 0 0.00083974714
chronic B-Disease 0 0.9929705
kidney I-Disease 0 0.9929067
disease I-Disease 0 0.99227893
( O 0 0.0019345527
estimated O 0 0.00053765136
glomerular O 0 0.7592621
filtration O 0 0.009931645
rate O 0 0.00057389657
, O 0 0.0006564066
20 O 0 0.00041467664
to O 0 0.00036162382
59 O 0 0.00089477794
mL O 0 0.0016034265
/ O 0 0.0012019932
min O 0 0.00073164346
) O 0 0.0009704803
who O 0 0.0010106652
underwent O 0 0.00097439095
cardiac O 0 0.16922328
angiography O 0 0.06503748
or O 0 0.0018202973
percutaneous O 0 0.0058315173
coronary O 0 0.6702304
interventions O 0 0.0083220415
. O 0 0.008261832

Serum O 0 0.79273593
creatinine B-Chemical 1 0.9976496
( O 0 0.015419584
SCr O 0 0.9719215
) O 0 0.004464428
levels O 0 0.0015946917
and O 0 0.0014115536
estimated O 0 0.0011328124
glomerular O 0 0.58994085
filtration O 0 0.008339492
rate O 0 0.00087681634
were O 0 0.00070539175
assessed O 0 0.00052339316
at O 0 0.0004961998
baseline O 0 0.00073071115
and O 0 0.0008024712
2 O 0 0.00079308613
to O 0 0.00074369146
5 O 0 0.00090410205
days O 0 0.0010000451
after O 0 0.0013326292
receiving O 0 0.005003106
medications O 0 0.55058527
. O 0 0.008410211

The O 0 0.0072218217
primary O 0 0.005572992
outcome O 0 0.00594996
was O 0 0.0028878034
a O 0 0.002977851
postdose O 0 0.04033936
SCr O 0 0.88635516
increase O 0 0.0009776233
> O 0 0.0013890285
or O 0 0.0007609044
= O 0 0.0010305038
0 O 0 0.0007465756
. O 0 0.00041283213
5 O 0 0.00047497806
mg O 0 0.05348201
/ O 0 0.001831423
dL O 0 0.00696005
( O 0 0.0010866811
44 O 0 0.0011335064
. O 0 0.0006756406
2 O 0 0.0010650682
micromol O 0 0.046608005
/ O 0 0.0050783767
L O 0 0.30028924
) O 0 0.0046739564
over O 0 0.0027245134
baseline O 0 0.0060138255
. O 0 0.0075688628

Secondary O 0 0.0207354
outcomes O 0 0.008573163
were O 0 0.004118792
a O 0 0.003862211
postdose O 0 0.032170437
SCr O 0 0.8666382
increase O 0 0.0011923999
> O 0 0.0015785124
or O 0 0.00083517336
= O 0 0.0010571777
25 O 0 0.000773033
% O 0 0.0006683907
, O 0 0.00058004196
a O 0 0.0005423131
postdose O 0 0.0020377995
estimated O 0 0.00036549868
glomerular O 0 0.37445033
filtration O 0 0.003883235
rate O 0 0.0005088751
decrease O 0 0.00048524898
of O 0 0.0007014116
> O 0 0.0011087852
or O 0 0.0005883573
= O 0 0.0009084754
25 O 0 0.00076841965
% O 0 0.0007891968
, O 0 0.0008425363
and O 0 0.0008219582
the O 0 0.0009161326
mean O 0 0.0012341928
peak O 0 0.0021111662
change O 0 0.002788926
in O 0 0.0046126316
SCr O 0 0.97336143
. O 0 0.008620404

In O 0 0.008420363
414 O 0 0.017173463
patients O 0 0.0068803714
, O 0 0.0034528323
contrast O 0 0.0020013093
volume O 0 0.0037868244
, O 0 0.0017765167
presence O 0 0.0010199778
of O 0 0.002069247
diabetes B-Disease 2 0.99944216
mellitus I-Disease 0 0.99983215
, O 0 0.002798448
use O 0 0.001006731
of O 0 0.0020562764
N B-Chemical 0 0.9991968
- I-Chemical 0 0.012156099
acetylcysteine I-Chemical 0 0.99992085
, O 0 0.001096543
mean O 0 0.0005247529
baseline O 0 0.0009143527
SCr O 0 0.9529059
, O 0 0.0007479717
and O 0 0.0005692594
estimated O 0 0.000582692
glomerular O 0 0.5622712
filtration O 0 0.0055819103
rate O 0 0.0009225625
were O 0 0.0010173697
comparable O 0 0.00090379856
in O 0 0.0015200373
the O 0 0.0023006839
2 O 0 0.0036077301
groups O 0 0.0061282422
. O 0 0.007607276

SCr O 0 0.89428693
increases O 0 0.0071252086
> O 0 0.0058703646
or O 0 0.0029032046
= O 0 0.0029182201
0 O 0 0.0018377064
. O 0 0.00090967066
5 O 0 0.0008019159
mg O 0 0.06481388
/ O 0 0.0019227528
dL O 0 0.0039301487
occurred O 0 0.00058274757
in O 0 0.00047289586
4 O 0 0.00046563562
. O 0 0.00032869363
4 O 0 0.00036333018
% O 0 0.00048625589
( O 0 0.0005001287
9 O 0 0.0003404011
of O 0 0.00038647567
204 O 0 0.002589017
patients O 0 0.0011261256
) O 0 0.00074770185
after O 0 0.00027270472
iopamidol B-Chemical 1 0.99853253
and O 0 0.00055251684
6 O 0 0.00034115202
. O 0 0.00026469273
7 O 0 0.00032331623
% O 0 0.0004238878
( O 0 0.00043904697
14 O 0 0.0003162339
of O 0 0.0003619156
210 O 0 0.0016276325
patients O 0 0.0011287611
) O 0 0.00077917526
after O 0 0.00029608523
iodixanol B-Chemical 1 0.9982407
( O 0 0.0014969812
P O 0 0.09582193
= O 0 0.00072111416
0 O 0 0.00053546706
. O 0 0.00028608387
39 O 0 0.00068342185
) O 0 0.0006926275
, O 0 0.00046196152
whereas O 0 0.0003012412
rates O 0 0.00042657755
of O 0 0.00072275096
SCr O 0 0.97731584
increases O 0 0.00052575464
> O 0 0.0008492655
or O 0 0.00042426473
= O 0 0.0006170842
25 O 0 0.0004648985
% O 0 0.0004064328
were O 0 0.00032950935
9 O 0 0.00036484314
. O 0 0.00025816172
8 O 0 0.00031806988
% O 0 0.00040033465
and O 0 0.0004070171
12 O 0 0.00034433248
. O 0 0.0003393477
4 O 0 0.00045036018
% O 0 0.00071329175
, O 0 0.00094353565
respectively O 0 0.0015272305
( O 0 0.0018062759
P O 0 0.04026094
= O 0 0.0021740163
0 O 0 0.002200403
. O 0 0.0020395324
44 O 0 0.004793816
) O 0 0.0072135637
. O 0 0.007117431

In O 0 0.008323277
patients O 0 0.00996292
with O 0 0.006170732
diabetes B-Disease 2 0.9968702
, O 0 0.0081863655
SCr O 0 0.9755432
increases O 0 0.0016602402
> O 0 0.0017959576
or O 0 0.0008582747
= O 0 0.0010865466
0 O 0 0.00073816226
. O 0 0.00037086997
5 O 0 0.00039380376
mg O 0 0.049582858
/ O 0 0.0013078108
dL O 0 0.0031704938
were O 0 0.00042305316
5 O 0 0.00036367326
. O 0 0.00029213246
1 O 0 0.0003861435
% O 0 0.00045883746
( O 0 0.0004681203
4 O 0 0.0002794485
of O 0 0.00034907882
78 O 0 0.0007925421
patients O 0 0.0011126874
) O 0 0.0008259356
with O 0 0.00052375125
iopamidol B-Chemical 1 0.99924695
and O 0 0.00061307737
13 O 0 0.00060204533
. O 0 0.00029145007
0 O 0 0.00046813278
% O 0 0.00044050376
( O 0 0.0004390499
12 O 0 0.00022809092
of O 0 0.00033020935
92 O 0 0.0007541174
patients O 0 0.0011127223
) O 0 0.0008723622
with O 0 0.0005953693
iodixanol B-Chemical 1 0.99918014
( O 0 0.0018362899
P O 0 0.110566214
= O 0 0.0007391223
0 O 0 0.0005415572
. O 0 0.00029120647
11 O 0 0.000522467
) O 0 0.000704602
, O 0 0.0005370004
whereas O 0 0.0004421192
SCr O 0 0.93410337
increases O 0 0.00046149126
> O 0 0.000765927
or O 0 0.00040636753
= O 0 0.0005991854
25 O 0 0.0004594892
% O 0 0.00040361795
were O 0 0.00032716422
10 O 0 0.00034477332
. O 0 0.00026140932
3 O 0 0.00031538642
% O 0 0.00041215442
and O 0 0.00042269402
15 O 0 0.00039345497
. O 0 0.00036012332
2 O 0 0.0005139345
% O 0 0.00074922433
, O 0 0.0009775269
respectively O 0 0.0015683103
( O 0 0.0018470067
P O 0 0.04139079
= O 0 0.002225762
0 O 0 0.0022436727
. O 0 0.0020526045
37 O 0 0.004403927
) O 0 0.0074295434
. O 0 0.007238134

Mean O 0 0.009226406
post O 0 0.008612364
- O 0 0.007929066
SCr O 0 0.81042755
increases O 0 0.0023037987
were O 0 0.0016364931
significantly O 0 0.0014753127
less O 0 0.001101419
with O 0 0.0012936926
iopamidol B-Chemical 1 0.9997019
( O 0 0.0014218849
all O 0 0.00055623276
patients O 0 0.0016041868
: O 0 0.00091135805
0 O 0 0.0006833252
. O 0 0.00034625013
07 O 0 0.0016551968
versus O 0 0.00033752542
0 O 0 0.00048190093
. O 0 0.00025420438
12 O 0 0.00026243218
mg O 0 0.040466875
/ O 0 0.0012431584
dL O 0 0.005715958
, O 0 0.0005328491
6 O 0 0.00028856107
. O 0 0.0002384455
2 O 0 0.0002784071
versus O 0 0.00027671532
10 O 0 0.00034475047
. O 0 0.00025647355
6 O 0 0.0002945005
micromol O 0 0.029051032
/ O 0 0.0019554046
L O 0 0.36542168
, O 0 0.0009698389
P O 0 0.059339877
= O 0 0.00075035903
0 O 0 0.000597137
. O 0 0.0003509113
03 O 0 0.020329548
; O 0 0.0006683688
patients O 0 0.00088600663
with O 0 0.0006371007
diabetes B-Disease 2 0.9969105
: O 0 0.0013792929
0 O 0 0.0007352277
. O 0 0.00032267728
07 O 0 0.0017426684
versus O 0 0.00032033306
0 O 0 0.0004723197
. O 0 0.00025409437
16 O 0 0.0003625852
mg O 0 0.055120423
/ O 0 0.0013410272
dL O 0 0.0058211954
, O 0 0.00056751096
6 O 0 0.00031600095
. O 0 0.00027214215
2 O 0 0.00032915143
versus O 0 0.00034293492
14 O 0 0.00050404615
. O 0 0.0003923476
1 O 0 0.0006585126
micromol O 0 0.044383872
/ O 0 0.0032624311
L O 0 0.36928543
, O 0 0.0022853264
P O 0 0.07031873
= O 0 0.0026668948
0 O 0 0.00271462
. O 0 0.0025626742
01 O 0 0.012770352
) O 0 0.0077967723
. O 0 0.0075315735

CONCLUSIONS O 0 0.37855792
: O 0 0.007797876
The O 0 0.0033767151
rate O 0 0.0026302563
of O 0 0.0025082591
contrast O 0 0.0025569152
- O 0 0.0042820843
induced O 0 0.003016965
nephropathy B-Disease 2 0.9999814
, O 0 0.0034668483
defined O 0 0.0007477753
by O 0 0.0007072284
multiple O 0 0.0010096959
end O 0 0.0003504094
points O 0 0.00071293936
, O 0 0.00065939745
is O 0 0.00036301411
not O 0 0.00030181845
statistically O 0 0.00028692218
different O 0 0.00025597372
after O 0 0.0001994954
the O 0 0.0003313759
intraarterial O 0 0.3559655
administration O 0 0.025255552
of O 0 0.0009940512
iopamidol B-Chemical 1 0.99979514
or O 0 0.0009194587
iodixanol B-Chemical 1 0.9988714
to O 0 0.0007360549
high O 0 0.001366726
- O 0 0.0022554907
risk O 0 0.038512036
patients O 0 0.004889183
, O 0 0.001705129
with O 0 0.0015282705
or O 0 0.0021751132
without O 0 0.0045895046
diabetes B-Disease 2 0.9993512
mellitus I-Disease 0 0.9995171
. O 0 0.0143480385

Any O 0 0.013140735
true O 0 0.006100392
difference O 0 0.003074459
between O 0 0.0023308075
the O 0 0.0026024908
agents O 0 0.053294506
is O 0 0.0023482454
small O 0 0.0024016062
and O 0 0.0023433978
not O 0 0.0020122535
likely O 0 0.0021557966
to O 0 0.002502364
be O 0 0.0038239115
clinically O 0 0.04344634
significant O 0 0.008104406
. O 0 0.00973634

A O 0 0.041891903
novel O 0 0.010192814
compound O 0 0.19642474
, O 0 0.0066089462
maltolyl B-Chemical 1 0.24929954
p I-Chemical 1 0.007045881
- I-Chemical 1 0.011045891
coumarate I-Chemical 1 0.97846985
, O 0 0.005191005
attenuates O 0 0.15393583
cognitive B-Disease 2 0.99596184
deficits I-Disease 2 0.95131433
and O 0 0.0013733376
shows O 0 0.00072589226
neuroprotective O 0 0.8744688
effects O 0 0.0030413505
in O 0 0.0012175298
vitro O 0 0.0022499112
and O 0 0.0021139423
in O 0 0.0023402616
vivo O 0 0.008898179
dementia B-Disease 2 0.99926645
models O 0 0.012528834
. O 0 0.009675967

To O 0 0.0066250917
develop O 0 0.0049646264
a O 0 0.004044694
novel O 0 0.0034762993
and O 0 0.0023834081
effective O 0 0.001987621
drug O 0 0.3376521
that O 0 0.00087938795
could O 0 0.0006722429
enhance O 0 0.00060853246
cognitive O 0 0.7705777
function O 0 0.0011662773
and O 0 0.001366175
neuroprotection O 0 0.9635575
, O 0 0.00097399566
we O 0 0.00035057525
newly O 0 0.0011117349
synthesized O 0 0.0078096897
maltolyl B-Chemical 1 0.33999547
p I-Chemical 1 0.0028888118
- I-Chemical 1 0.0052037444
coumarate I-Chemical 1 0.9245617
by O 0 0.0014263006
the O 0 0.0014517134
esterification O 0 0.99624914
of O 0 0.010303475
maltol B-Chemical 0 0.9999546
and O 0 0.007813464
p B-Chemical 0 0.012482215
- I-Chemical 0 0.052608736
coumaric I-Chemical 0 0.99953043
acid I-Chemical 0 0.98958755
. O 0 0.014813342

In O 0 0.007170056
the O 0 0.004862445
present O 0 0.0028974256
study O 0 0.0030554074
, O 0 0.0022448963
we O 0 0.000990172
investigated O 0 0.0008893187
whether O 0 0.000674788
maltolyl B-Chemical 1 0.24780181
p I-Chemical 1 0.0040082633
- I-Chemical 1 0.0067684166
coumarate I-Chemical 1 0.9296798
could O 0 0.00060385204
improve O 0 0.000529589
cognitive B-Disease 0 0.77836776
decline I-Disease 0 0.0041268365
in O 0 0.0009807196
scopolamine B-Chemical 1 0.99999726
- O 0 0.002843967
injected O 0 0.00052707334
rats O 0 0.0015447169
and O 0 0.0007217034
in O 0 0.0007725066
amyloid B-Chemical 0 0.996396
beta I-Chemical 0 0.7832151
peptide I-Chemical 0 0.018016133
( I-Chemical 0 0.0029304493
1 I-Chemical 0 0.0015711316
- I-Chemical 0 0.0020550995
42 I-Chemical 0 0.0022497613
) I-Chemical 0 0.0032830108
- O 0 0.003790377
infused O 0 0.0059576565
rats O 0 0.009733852
. O 0 0.007940356

Maltolyl B-Chemical 0 0.2640839
p I-Chemical 0 0.014615229
- I-Chemical 0 0.012747145
coumarate I-Chemical 0 0.8690784
was O 0 0.003025343
found O 0 0.0016261782
to O 0 0.0015885662
attenuate O 0 0.017473059
cognitive B-Disease 2 0.9944126
deficits I-Disease 2 0.9376474
in O 0 0.0007400625
both O 0 0.0006100307
rat O 0 0.0024329072
models O 0 0.000700371
using O 0 0.00042689077
passive O 0 0.0010210673
avoidance O 0 0.007103299
test O 0 0.00068132626
and O 0 0.0005737091
to O 0 0.00043768805
reduce O 0 0.0005238738
apoptotic O 0 0.8091748
cell O 0 0.11933598
death O 2 0.9989114
observed O 0 0.0004231068
in O 0 0.00049050705
the O 0 0.00058140355
hippocampus O 0 0.07902241
of O 0 0.0006816448
the O 0 0.0008229095
amyloid B-Chemical 0 0.99667645
beta I-Chemical 0 0.7898173
peptide I-Chemical 0 0.018414304
( I-Chemical 0 0.0029081586
1 I-Chemical 0 0.001541185
- I-Chemical 0 0.0020204026
42 I-Chemical 0 0.0022166036
) I-Chemical 0 0.0032413525
- O 0 0.0037497326
infused O 0 0.0059061507
rats O 0 0.00966529
. O 0 0.007895379

We O 0 0.008132213
also O 0 0.00532689
examined O 0 0.003343266
the O 0 0.003350901
neuroprotective O 0 0.72198886
effects O 0 0.005209074
of O 0 0.0036495742
maltolyl B-Chemical 1 0.57077086
p I-Chemical 1 0.00736969
- I-Chemical 1 0.009880387
coumarate I-Chemical 1 0.932866
in O 0 0.0022314147
vitro O 0 0.004232737
using O 0 0.004160037
SH O 0 0.99890065
- O 0 0.056681022
SY5Y O 0 0.99893063
cells O 0 0.028969372
. O 0 0.011534399

Cells O 0 0.021327425
were O 0 0.00721367
pretreated O 0 0.009840704
with O 0 0.004426182
maltolyl B-Chemical 1 0.29108343
p I-Chemical 1 0.0072638025
- I-Chemical 1 0.008819247
coumarate I-Chemical 1 0.9454791
, O 0 0.0019796093
before O 0 0.0006290426
exposed O 0 0.0007987151
to O 0 0.0009823233
amyloid B-Chemical 0 0.996145
beta I-Chemical 0 0.8169605
peptide I-Chemical 0 0.022343433
( I-Chemical 0 0.0031979247
1 I-Chemical 0 0.0016139954
- I-Chemical 0 0.002060636
42 I-Chemical 0 0.0022320729
) I-Chemical 0 0.0034576487
, O 0 0.0046865577
glutamate B-Chemical 1 0.9993691
or O 0 0.009257634
H2O2 B-Chemical 0 0.99928683
. O 0 0.011799679

We O 0 0.008255463
found O 0 0.004811794
that O 0 0.0038157804
maltolyl B-Chemical 1 0.13818343
p I-Chemical 1 0.007267275
- I-Chemical 1 0.009008658
coumarate I-Chemical 1 0.94672793
significantly O 0 0.0036819289
decreased O 0 0.00504663
apoptotic O 0 0.8927972
cell O 0 0.22576249
death O 2 0.9994247
and O 0 0.0018424821
reduced O 0 0.001392083
reactive O 0 0.55056655
oxygen O 1 0.99540174
species O 0 0.0042463974
, O 0 0.003599681
cytochrome O 0 0.9944154
c O 0 0.067509525
release O 0 0.08071958
, O 0 0.0028609587
and O 0 0.0030916887
caspase O 0 0.63357687
3 O 0 0.0044430615
activation O 0 0.008160502
. O 0 0.007959562

Taking O 0 0.008785813
these O 0 0.0054985154
in O 0 0.0035550788
vitro O 0 0.0033666715
and O 0 0.0022541755
in O 0 0.0013968912
vivo O 0 0.0015332586
results O 0 0.0010034043
together O 0 0.00091021217
, O 0 0.0009757334
our O 0 0.0005030782
study O 0 0.00061625894
suggests O 0 0.0003316183
that O 0 0.0004743358
maltolyl B-Chemical 1 0.21680877
p I-Chemical 1 0.0026816716
- I-Chemical 1 0.0055168658
coumarate I-Chemical 1 0.9331869
is O 0 0.0006134999
a O 0 0.0006544682
potentially O 0 0.0009557574
effective O 0 0.00058617594
candidate O 0 0.00065942196
against O 0 0.0006893437
Alzheimer B-Disease 0 0.99995804
' I-Disease 0 0.0013633954
s I-Disease 0 0.0007428316
disease I-Disease 0 0.27605087
that O 0 0.00045832232
is O 0 0.00056584284
characterized O 0 0.0010596855
by O 0 0.0009448239
wide O 0 0.0020418463
spread O 0 0.02501046
neuronal B-Disease 0 0.977532
death I-Disease 2 0.999775
and O 0 0.0030532833
progressive O 0 0.3778097
decline B-Disease 0 0.008427764
of I-Disease 0 0.0044971076
cognitive I-Disease 0 0.88468885
function I-Disease 0 0.008388208
. O 0 0.008387537

Attenuation O 0 0.17914486
of O 0 0.016820086
methamphetamine B-Chemical 1 0.9999051
- O 0 0.050954007
induced O 0 0.010861873
nigrostriatal O 0 0.9988695
dopaminergic O 0 0.9987643
neurotoxicity B-Disease 2 0.99990416
in O 0 0.004310171
mice O 0 0.0034657165
by O 0 0.0073012817
lipopolysaccharide B-Chemical 1 0.9978569
pretreatment O 0 0.89713115
. O 0 0.014904543

Immunological O 0 0.494546
activation O 0 0.014094093
has O 0 0.005403244
been O 0 0.004178792
proposed O 0 0.0033152762
to O 0 0.0023861749
play O 0 0.0025346421
a O 0 0.0025923548
role O 0 0.001734662
in O 0 0.003170241
methamphetamine B-Chemical 1 0.9999671
- O 0 0.025716342
induced O 0 0.008023325
dopaminergic B-Disease 0 0.9981877
terminal I-Disease 0 0.10914583
damage I-Disease 0 0.97559273
. O 0 0.013206885

In O 0 0.0075437166
this O 0 0.0051960973
study O 0 0.0042122705
, O 0 0.0029788024
we O 0 0.0013310214
examined O 0 0.0010644384
the O 0 0.0011314217
roles O 0 0.0010296087
of O 0 0.0016498726
lipopolysaccharide B-Chemical 1 0.9970798
, O 0 0.003559027
a O 0 0.0018641141
pro O 0 0.32106346
- O 0 0.0033479116
inflammatory O 0 0.835998
and O 0 0.0020742726
inflammatory O 0 0.9604252
factor O 0 0.13760617
, O 0 0.0016360538
treatment O 0 0.0011793015
in O 0 0.00074101985
modulating O 0 0.001214148
the O 0 0.0021546183
methamphetamine B-Chemical 1 0.99998355
- O 0 0.030567251
induced O 0 0.012402682
nigrostriatal O 0 0.99959403
dopamine B-Chemical 1 0.9999012
neurotoxicity B-Disease 2 0.9998747
. O 0 0.01321578

Lipopolysaccharide B-Chemical 0 0.9939207
pretreatment O 0 0.3874713
did O 0 0.0048060496
not O 0 0.0029738403
affect O 0 0.0017275432
the O 0 0.0017352286
basal O 0 0.0028408677
body O 0 0.009316656
temperature O 0 0.003248493
or O 0 0.0026888265
methamphetamine B-Chemical 1 0.99997103
- O 0 0.0079892045
elicited O 0 0.004066274
hyperthermia B-Disease 2 0.99882346
three O 0 0.0028503756
days O 0 0.0036487195
later O 0 0.005176721
. O 0 0.007985921

Such O 0 0.014209368
systemic O 0 0.8790464
lipopolysaccharide B-Chemical 1 0.9967873
treatment O 0 0.066705585
mitigated O 0 0.61701614
methamphetamine B-Chemical 1 0.9999902
- O 0 0.057292532
induced O 0 0.004050093
striatal O 0 0.99590176
dopamine B-Chemical 1 0.9998883
and O 0 0.0016457259
3 B-Chemical 0 0.0009893978
, I-Chemical 0 0.0012350648
4 I-Chemical 0 0.0010573504
- I-Chemical 0 0.006311684
dihydroxyphenylacetic I-Chemical 0 0.9999738
acid I-Chemical 0 0.9527162
depletions O 0 0.27950245
in O 0 0.0012429475
a O 0 0.0021879466
dose O 0 0.021416659
- O 0 0.0045635914
dependent O 0 0.0032103334
manner O 0 0.0065909545
. O 0 0.008107719

As O 0 0.006305918
the O 0 0.0047960775
most O 0 0.004348491
potent O 0 0.010013967
dose O 0 0.045787342
( O 0 0.0031392928
1 O 0 0.0014025037
mg O 0 0.22861214
/ O 0 0.0026471145
kg O 0 0.009531205
) O 0 0.0013708775
of O 0 0.00085870246
lipopolysaccharide B-Chemical 1 0.9841064
was O 0 0.00071111636
administered O 0 0.00064841803
two O 0 0.0003115593
weeks O 0 0.00027240536
, O 0 0.0003973464
one O 0 0.00022627012
day O 0 0.00022855592
before O 0 0.00017667623
or O 0 0.00027105355
after O 0 0.0002108161
the O 0 0.00048150143
methamphetamine B-Chemical 1 0.99997663
dosing O 0 0.05684959
regimen O 0 0.012273542
, O 0 0.004015374
methamphetamine B-Chemical 1 0.9999912
- O 0 0.007934811
induced O 0 0.0014712372
striatal O 0 0.9932608
dopamine B-Chemical 1 0.99983764
and O 0 0.0012752338
3 B-Chemical 0 0.00097149104
, I-Chemical 0 0.0013653602
4 I-Chemical 0 0.001380479
- I-Chemical 0 0.008357074
dihydroxyphenylacetic I-Chemical 0 0.99995637
acid I-Chemical 0 0.9667572
depletions O 0 0.5381433
remained O 0 0.0049635638
unaltered O 0 0.0062099113
. O 0 0.007766556

Moreover O 0 0.010823675
, O 0 0.0084922705
systemic O 0 0.89108574
lipopolysaccharide B-Chemical 1 0.99818975
pretreatment O 0 0.89171517
( O 0 0.006418626
1 O 0 0.0016836462
mg O 0 0.33331493
/ O 0 0.003192497
kg O 0 0.014263634
) O 0 0.0016751186
attenuated O 0 0.0011577068
local O 0 0.0036129137
methamphetamine B-Chemical 1 0.9999862
infusion O 0 0.18077412
- O 0 0.0028103667
produced O 0 0.00078831584
dopamine B-Chemical 1 0.99978477
and O 0 0.0008892518
3 B-Chemical 0 0.0006231569
, I-Chemical 0 0.0008212614
4 I-Chemical 0 0.0006879957
- I-Chemical 0 0.005554008
dihydroxyphenylacetic I-Chemical 0 0.99998546
acid I-Chemical 0 0.95432377
depletions O 0 0.27889457
in O 0 0.00042726245
the O 0 0.00051827234
striatum O 0 0.31612158
, O 0 0.0005384756
indicating O 0 0.00026796627
that O 0 0.00026509658
the O 0 0.000362254
protective O 0 0.003439896
effect O 0 0.0005802786
of O 0 0.0011561266
lipopolysaccharide B-Chemical 1 0.9962794
is O 0 0.0009209412
less O 0 0.00059023406
likely O 0 0.0005117186
due O 0 0.0004420973
to O 0 0.0005972187
interrupted O 0 0.0012844078
peripheral O 0 0.01358728
distribution O 0 0.0011871656
or O 0 0.0021589643
metabolism O 0 0.4741432
of O 0 0.01633432
methamphetamine B-Chemical 1 0.9999182
. O 0 0.011796539

We O 0 0.007880829
concluded O 0 0.005396988
a O 0 0.0042990507
critical O 0 0.0025709071
time O 0 0.0017759546
window O 0 0.0019680003
for O 0 0.0012522587
systemic O 0 0.9282714
lipopolysaccharide B-Chemical 1 0.9989807
pretreatment O 0 0.78745383
in O 0 0.0016813515
exerting O 0 0.12250399
effective O 0 0.0023537043
protection O 0 0.019357057
against O 0 0.0029381362
methamphetamine B-Chemical 1 0.9999863
- O 0 0.044506803
induced O 0 0.01501917
nigrostriatal O 0 0.9996026
dopamine B-Chemical 1 0.99990094
neurotoxicity B-Disease 2 0.9998735
. O 0 0.013553616

Acute O 0 0.98932755
myocarditis B-Disease 2 0.9990646
associated O 0 0.06488125
with O 0 0.067715086
clozapine B-Chemical 1 0.99965036
. O 0 0.044567198

OBJECTIVE O 0 0.63444936
: O 0 0.010667456
A O 0 0.01794997
case O 0 0.003581473
of O 0 0.0039133253
acute O 0 0.9837727
myocarditis B-Disease 2 0.99997246
associated O 0 0.0054698195
with O 0 0.0014562045
the O 0 0.0009327142
commencement O 0 0.0011773586
of O 0 0.0015319663
clozapine B-Chemical 1 0.99998665
is O 0 0.00096254906
described O 0 0.0006363789
, O 0 0.00090741605
highlighting O 0 0.00068459194
the O 0 0.00085152173
onset O 0 0.003978629
, O 0 0.0017706678
course O 0 0.0017504742
and O 0 0.0022537124
possible O 0 0.0029390012
contributing O 0 0.0058169635
factors O 0 0.030201763
. O 0 0.009171212

There O 0 0.010247059
is O 0 0.0063685323
an O 0 0.0054048663
urgent O 0 0.0048052766
need O 0 0.002602871
to O 0 0.0020658956
raise O 0 0.002064675
awareness O 0 0.004277268
about O 0 0.0015747892
this O 0 0.0017832331
potentially O 0 0.006006399
fatal O 0 0.9948177
complication O 0 0.90159696
of O 0 0.03356488
clozapine B-Chemical 1 0.9999516
use O 0 0.014134428
. O 0 0.011002031

RESULTS O 0 0.029888835
: O 0 0.010837529
A O 0 0.017237302
20 O 0 0.0047745514
- O 0 0.0042182514
year O 0 0.0024146368
- O 0 0.0024356213
old O 0 0.0016865107
male O 0 0.004348604
with O 0 0.0019043247
schizophrenia B-Disease 2 0.9995024
developed O 0 0.0024555568
a O 0 0.0023875842
sudden O 0 0.9924663
onset O 0 0.02032487
of O 0 0.0044959034
myocarditis B-Disease 2 0.9999484
after O 0 0.0022904137
commencement O 0 0.0054925475
of O 0 0.010906817
clozapine B-Chemical 1 0.99992764
. O 0 0.0117336465

The O 0 0.018638879
patient O 0 0.018396845
recovered O 0 0.014027712
with O 0 0.014427177
intensive O 0 0.015299083
medical O 0 0.043388344
support O 0 0.01953206
. O 0 0.021461446

The O 0 0.009901733
symptoms O 0 0.25858665
occurred O 0 0.00548321
around O 0 0.0037217438
2 O 0 0.0027731273
weeks O 0 0.0017687675
after O 0 0.0015490907
starting O 0 0.0027862578
clozapine B-Chemical 1 0.99987996
in O 0 0.003817601
an O 0 0.006174877
inpatient O 0 0.015895871
setting O 0 0.008680786
. O 0 0.01006514

Possible O 0 0.029738305
contributing O 0 0.010157238
factors O 0 0.01118519
may O 0 0.004703673
have O 0 0.0034908224
been O 0 0.0035955922
concomitant O 0 0.012691911
antidepressant B-Chemical 1 0.9997073
use O 0 0.0054365927
and O 0 0.005832336
unaccustomed O 0 0.11896029
physical O 0 0.095328405
activity O 0 0.011088056
. O 0 0.010687362

CONCLUSIONS O 0 0.7543534
: O 0 0.021898478
Myocarditis B-Disease 0 0.99730706
is O 0 0.0054244315
an O 0 0.004642952
increasingly O 0 0.004565845
recognized O 0 0.0037508674
complication O 0 0.3953225
associated O 0 0.0038065875
with O 0 0.0034010008
the O 0 0.00352794
use O 0 0.005293342
of O 0 0.013715808
clozapine B-Chemical 1 0.9999161
. O 0 0.014030745

It O 0 0.017868627
can O 0 0.010412092
be O 0 0.009880289
fatal O 0 0.8214681
if O 0 0.0063167824
not O 0 0.0061692754
recognized O 0 0.0077823633
and O 0 0.008969826
treated O 0 0.012426477
early O 0 0.01982916
. O 0 0.015533736

Considering O 0 0.0070907655
that O 0 0.0054217493
clozapine B-Chemical 1 0.9998161
remains O 0 0.002861112
the O 0 0.0019050074
gold O 0 0.43243375
standard O 0 0.0013716462
in O 0 0.0008794491
treatment O 0 0.0012905482
of O 0 0.0012743094
resistant O 0 0.0031257488
psychosis B-Disease 0 0.99995506
, O 0 0.0012812238
there O 0 0.00036146975
is O 0 0.00043713307
an O 0 0.000560403
urgent O 0 0.00080691796
need O 0 0.0003925616
to O 0 0.00040448923
raise O 0 0.0005338577
awareness O 0 0.0031862508
among O 0 0.0009550633
medical O 0 0.014227715
and O 0 0.0011018168
paramedical O 0 0.008936789
staff O 0 0.0015149941
involved O 0 0.0007862744
in O 0 0.00096428156
the O 0 0.0013133453
care O 0 0.002221043
of O 0 0.0027044835
these O 0 0.004836437
patients O 0 0.018300423
. O 0 0.008577453

There O 0 0.011189658
are O 0 0.0072891535
also O 0 0.005124084
implications O 0 0.004447351
for O 0 0.0028255198
recommendations O 0 0.004070903
and O 0 0.0031257665
regulations O 0 0.004871322
regarding O 0 0.0023986285
the O 0 0.003248635
use O 0 0.0051189815
of O 0 0.012785533
clozapine B-Chemical 1 0.99991035
. O 0 0.014252815

Severe O 0 0.9706053
rhabdomyolysis B-Disease 2 0.999899
and O 0 0.014528614
acute B-Disease 0 0.98038155
renal I-Disease 0 0.99742174
failure I-Disease 0 0.89240104
secondary O 0 0.009247729
to O 0 0.00148751
concomitant O 0 0.003933053
use O 0 0.0018313443
of O 0 0.003930896
simvastatin B-Chemical 1 0.9999794
, O 0 0.050075017
amiodarone B-Chemical 1 0.9999672
, O 0 0.00867615
and O 0 0.007841697
atazanavir B-Chemical 0 0.99148446
. O 0 0.009475804

OBJECTIVE O 0 0.43714365
: O 0 0.007869117
To O 0 0.003397232
report O 0 0.0041763303
a O 0 0.0025020514
case O 0 0.0016122245
of O 0 0.0015635936
a O 0 0.0018797796
severe O 0 0.12503962
interaction O 0 0.0014765208
between O 0 0.0009302979
simvastatin B-Chemical 1 0.9999875
, O 0 0.024061242
amiodarone B-Chemical 1 0.9999887
, O 0 0.0025785153
and O 0 0.0014659613
atazanavir B-Chemical 0 0.9790644
resulting O 0 0.0015633672
in O 0 0.002038139
rhabdomyolysis B-Disease 2 0.9999833
and O 0 0.010780843
acute B-Disease 0 0.9953767
renal I-Disease 0 0.9990588
failure I-Disease 0 0.97843593
. O 0 0.012399634

BACKGROUND O 0 0.65254915
: O 0 0.011407058
A O 0 0.022500116
72 O 0 0.004232689
- O 0 0.0037876375
year O 0 0.0020776808
- O 0 0.0020973333
old O 0 0.0014111317
white O 0 0.0030266002
man O 0 0.062023528
with O 0 0.0011627044
underlying O 0 0.0034600808
human B-Disease 0 0.018108858
immunodeficiency I-Disease 0 0.9990864
virus I-Disease 0 0.72024286
, O 0 0.005773293
atrial B-Disease 0 0.9950165
fibrillation I-Disease 0 0.99998355
, O 0 0.0016001756
coronary B-Disease 0 0.6759585
artery I-Disease 0 0.37432125
disease I-Disease 0 0.8341857
, O 0 0.0015564826
and O 0 0.0011478624
hyperlipidemia B-Disease 0 0.9999713
presented O 0 0.0011506223
with O 0 0.0010234759
generalized O 0 0.52428657
pain B-Disease 2 0.9997471
, O 0 0.008966977
fatigue B-Disease 2 0.9989135
, O 0 0.0019749731
and O 0 0.0013328989
dark O 0 0.0016391978
orange O 0 0.05496469
urine O 0 0.27884677
for O 0 0.0022570235
3 O 0 0.0033975616
days O 0 0.004072518
. O 0 0.006857676

The O 0 0.007097702
patient O 0 0.006262064
was O 0 0.0036251782
taking O 0 0.0037327271
80 O 0 0.0027523008
mg O 0 0.5005453
simvastatin B-Chemical 1 0.99992824
at O 0 0.0013317899
bedtime O 0 0.45403796
( O 0 0.0011691573
initiated O 0 0.00064807053
27 O 0 0.00076261174
days O 0 0.00037966424
earlier O 0 0.0006257023
) O 0 0.0018240266
; O 0 0.0017161041
amiodarone B-Chemical 1 0.9999523
at O 0 0.00033874082
a O 0 0.00049596175
dose O 0 0.0016400807
of O 0 0.0005298178
400 O 0 0.001745471
mg O 0 0.07260171
daily O 0 0.0006112133
for O 0 0.00024149423
7 O 0 0.00028213172
days O 0 0.00023614934
, O 0 0.00039099375
then O 0 0.00028915843
200 O 0 0.0006879436
mg O 0 0.058399238
daily O 0 0.0009309713
( O 0 0.0005536201
initiated O 0 0.00037777945
19 O 0 0.0005221609
days O 0 0.00028015647
earlier O 0 0.0004987607
) O 0 0.0012029925
; O 0 0.0008629457
and O 0 0.0005597579
400 O 0 0.001706048
mg O 0 0.21200304
atazanavir B-Chemical 0 0.94090307
daily O 0 0.001693084
( O 0 0.0010616201
initiated O 0 0.0008017504
at O 0 0.0007260768
least O 0 0.0008587054
2 O 0 0.001676785
years O 0 0.0029386866
previously O 0 0.0037542314
) O 0 0.009610441
. O 0 0.007769394

Laboratory O 0 0.01867069
evaluation O 0 0.0070492583
revealed O 0 0.0047980556
66 O 0 0.005959865
, O 0 0.004086092
680 O 0 0.020704864
U O 0 0.826769
/ O 0 0.018341659
L O 0 0.891864
creatine B-Chemical 1 0.99994826
kinase O 0 0.6524515
, O 0 0.0018878881
93 O 0 0.0020429532
mg O 0 0.24500881
/ O 0 0.0029160187
dL O 0 0.021679612
blood B-Chemical 1 0.1621625
urea I-Chemical 1 0.99986565
nitrogen I-Chemical 1 0.9983022
, O 0 0.0016432608
4 O 0 0.0005399444
. O 0 0.0003470646
6 O 0 0.00036187624
mg O 0 0.06528651
/ O 0 0.0019761634
dL O 0 0.025793465
creatinine B-Chemical 1 0.9959358
, O 0 0.0015753756
1579 O 0 0.27641883
U O 0 0.9011923
/ O 0 0.01877906
L O 0 0.92856604
aspartate B-Chemical 1 0.9999236
aminotransferase O 0 0.9994885
, O 0 0.0030302645
and O 0 0.0022752425
738 O 0 0.2756988
U O 0 0.91083
/ O 0 0.028345456
L O 0 0.88550717
alanine B-Chemical 1 0.99544096
aminotransferase O 0 0.9988098
. O 0 0.012258999

Simvastatin B-Chemical 0 0.99978036
, O 0 0.025405748
amiodarone B-Chemical 1 0.9998747
, O 0 0.0055186823
and O 0 0.0022534397
the O 0 0.0014475267
patient O 0 0.0018387546
' O 0 0.0015211535
s O 0 0.0013180093
human B-Disease 0 0.0033461114
immunodeficiency I-Disease 0 0.99673045
virus I-Disease 0 0.4246426
medications O 0 0.6638733
were O 0 0.00068907876
all O 0 0.0004950209
temporarily O 0 0.0024094929
discontinued O 0 0.0043313703
and O 0 0.0005661281
the O 0 0.00051292824
patient O 0 0.0008750544
was O 0 0.0006423031
given O 0 0.000608927
forced O 0 0.0125448145
alkaline O 0 0.58787423
diuresis O 0 0.9990607
and O 0 0.002862963
started O 0 0.003082496
on O 0 0.0029490592
dialysis O 0 0.12011747
. O 0 0.008656871

Nine O 0 0.012187255
days O 0 0.004716587
later O 0 0.0033197855
the O 0 0.0027597398
patient O 0 0.0032627147
' O 0 0.0029988105
s O 0 0.0033055816
creatine B-Chemical 1 0.99985147
kinase O 0 0.3288508
had O 0 0.0013640838
dropped O 0 0.0028225256
to O 0 0.001134022
1695 O 0 0.122276634
U O 0 0.8626871
/ O 0 0.0073747146
L O 0 0.44504312
and O 0 0.001886268
creatinine B-Chemical 1 0.99596965
was O 0 0.0013931738
3 O 0 0.0012804045
. O 0 0.0012281928
3 O 0 0.0020049184
mg O 0 0.16751033
/ O 0 0.009934013
dL O 0 0.029957967
. O 0 0.008368566

The O 0 0.008007011
patient O 0 0.0072511355
was O 0 0.004401444
discharged O 0 0.008159058
and O 0 0.0027517593
continued O 0 0.0021189807
outpatient O 0 0.0026197508
dialysis O 0 0.01158091
for O 0 0.0013504364
1 O 0 0.0015715236
month O 0 0.0012204336
until O 0 0.001331422
his O 0 0.0035996416
renal O 0 0.9327856
function O 0 0.0060226563
recovered O 0 0.0068812184
. O 0 0.0094887605

DISCUSSION O 0 0.036168702
: O 0 0.008100987
The O 0 0.0040781284
risk O 0 0.01310445
of O 0 0.0051180474
rhabdomyolysis B-Disease 2 0.9999702
is O 0 0.0031104747
increased O 0 0.002065656
in O 0 0.0011722841
the O 0 0.0010732061
presence O 0 0.0010403165
of O 0 0.0016982316
concomitant O 0 0.014907589
drugs O 0 0.8941279
that O 0 0.0028373771
inhibit O 0 0.007102929
simvastatin B-Chemical 1 0.99995685
metabolism O 0 0.9352761
. O 0 0.012350634

Simvastatin B-Chemical 0 0.99884206
is O 0 0.054186285
metabolized O 0 0.92611927
by O 0 0.060429353
CYP3A4 O 0 0.9990609
. O 0 0.04396218

Amiodarone B-Chemical 1 0.99899703
and O 0 0.030034868
atazanavir B-Chemical 0 0.98412377
are O 0 0.019452013
recognized O 0 0.028613146
CYP3A4 O 0 0.9996511
inhibitors O 0 0.7515635
. O 0 0.025727836

CONCLUSIONS O 0 0.49807006
: O 0 0.010084868
Pharmacokinetic O 0 0.36012825
differences O 0 0.0028959394
in O 0 0.0027915293
statins B-Chemical 1 0.9969593
are O 0 0.0021718687
an O 0 0.0017892997
important O 0 0.000997721
consideration O 0 0.0009920644
for O 0 0.0008424098
assessing O 0 0.000949388
the O 0 0.0014268326
risk O 0 0.024276776
of O 0 0.002983525
potential O 0 0.0061450163
drug O 0 0.8128578
interactions O 0 0.019785073
. O 0 0.010135505

In O 0 0.0067958254
patients O 0 0.0063012796
requiring O 0 0.0033118497
the O 0 0.0022192376
concurrent O 0 0.0030440947
use O 0 0.0018836483
of O 0 0.002655675
statins B-Chemical 1 0.99983704
and O 0 0.016247086
CYP3A4 O 0 0.99998903
inhibitors O 0 0.61416227
, O 0 0.017237583
pravastatin B-Chemical 1 0.9999937
, O 0 0.017422965
fluvastatin B-Chemical 0 0.9999924
, O 0 0.002789714
and O 0 0.0010765208
rosuvastatin B-Chemical 0 0.9999646
carry O 0 0.0005208703
the O 0 0.00045623328
lowest O 0 0.00053483585
risk O 0 0.021913921
of O 0 0.00076894526
drug O 0 0.66712624
interactions O 0 0.007591623
; O 0 0.007909559
atorvastatin B-Chemical 0 0.99997747
carries O 0 0.001998439
moderate O 0 0.042794056
risk O 0 0.21458355
, O 0 0.0014035205
whereas O 0 0.0007915949
simvastatin B-Chemical 1 0.9999839
and O 0 0.0031983776
lovastatin B-Chemical 1 0.9999715
have O 0 0.0006256036
the O 0 0.00057906203
highest O 0 0.0006712263
risk O 0 0.03306732
and O 0 0.0008579043
should O 0 0.00046413872
be O 0 0.000722291
avoided O 0 0.00086176646
in O 0 0.0009422007
patients O 0 0.0035200217
taking O 0 0.0048607443
concomitant O 0 0.0739056
CYP3A4 O 0 0.99993813
inhibitors O 0 0.6036598
. O 0 0.01087134

Interaction O 0 0.027290776
between O 0 0.012952056
warfarin B-Chemical 1 0.9978421
and O 0 0.021129018
levofloxacin B-Chemical 1 0.99807477
: O 0 0.020126043
case O 0 0.013911055
series O 0 0.021431772
. O 0 0.01767936

Warfarin B-Chemical 1 0.99804425
is O 0 0.0073702405
the O 0 0.004456911
most O 0 0.0041561667
widely O 0 0.003593681
used O 0 0.0023697375
oral O 0 0.520942
anticoagulant O 0 0.9917218
and O 0 0.0033514616
is O 0 0.0021007303
indicated O 0 0.0018144223
for O 0 0.0020522235
many O 0 0.003836881
clinical O 0 0.018514032
conditions O 0 0.009330728
. O 0 0.0099354135

Levofloxacin B-Chemical 0 0.99482465
, O 0 0.008925043
a O 0 0.005915383
fluoroquinolone B-Chemical 0 0.99277097
, O 0 0.0035749292
is O 0 0.0014223901
one O 0 0.0008784052
of O 0 0.0009104437
the O 0 0.0007336123
most O 0 0.00094055576
commonly O 0 0.0013756912
prescribed O 0 0.018084498
antibiotics O 0 0.36160722
in O 0 0.000651778
clinical O 0 0.00838475
practice O 0 0.0009079047
and O 0 0.000681749
is O 0 0.00056503067
effective O 0 0.0007039932
against O 0 0.00069892546
Gram O 0 0.6601178
- O 0 0.0017198249
positive O 0 0.001159602
, O 0 0.0019641737
Gram O 0 0.55539346
- O 0 0.002622108
negative O 0 0.0022668247
, O 0 0.0031527742
and O 0 0.0036721933
atypical O 0 0.25328818
bacteria O 0 0.105135374
. O 0 0.010496616

While O 0 0.0078629
small O 0 0.0058409716
prospective O 0 0.0053034336
studies O 0 0.0026015241
have O 0 0.001517518
not O 0 0.0011834837
revealed O 0 0.0009598685
any O 0 0.0007917148
significant O 0 0.0010570886
drug O 0 0.71014225
- O 0 0.0025013387
drug O 0 0.30514526
interaction O 0 0.0007196001
between O 0 0.00043533646
warfarin B-Chemical 1 0.9998348
and O 0 0.0014031415
levofloxacin B-Chemical 1 0.9994211
, O 0 0.0008690387
several O 0 0.000430686
case O 0 0.00046972907
reports O 0 0.0006220503
have O 0 0.00040214544
indicated O 0 0.00044872795
that O 0 0.0005793767
levofloxacin B-Chemical 1 0.9983525
may O 0 0.00086724444
significantly O 0 0.0015598463
potentiate O 0 0.007431809
the O 0 0.0017175488
anticoagulation O 0 0.8587076
effect O 0 0.0030426593
of O 0 0.008937491
warfarin B-Chemical 1 0.999652
. O 0 0.010165962

We O 0 0.0080970805
report O 0 0.007499574
3 O 0 0.0035514305
cases O 0 0.0033192758
of O 0 0.002671133
serious O 0 0.37457636
bleeding B-Disease 2 0.9996412
complications O 0 0.85436827
that O 0 0.0012073921
appear O 0 0.0009897513
to O 0 0.00075352617
be O 0 0.00076917827
the O 0 0.0006669467
result O 0 0.00074298104
of O 0 0.0010323644
the O 0 0.0011147662
interaction O 0 0.0016257718
between O 0 0.0018580405
warfarin B-Chemical 1 0.9996909
and O 0 0.012112612
levofloxacin B-Chemical 1 0.99905735
. O 0 0.010910965

Physicians O 0 0.012107159
should O 0 0.004297835
be O 0 0.003480499
aware O 0 0.002685057
of O 0 0.0021070112
this O 0 0.0014763125
potential O 0 0.0016870945
interaction O 0 0.0013983046
and O 0 0.0012740949
use O 0 0.0010769505
caution O 0 0.0011629415
when O 0 0.0008743302
prescribing O 0 0.04882515
levofloxacin B-Chemical 1 0.9969373
to O 0 0.002241415
patients O 0 0.010396411
taking O 0 0.022147672
warfarin B-Chemical 1 0.9993986
. O 0 0.0100270035

Mutations O 0 0.02452919
associated O 0 0.008007735
with O 0 0.007448972
lamivudine B-Chemical 1 0.99977845
- O 0 0.0155955525
resistance O 0 0.007614306
in O 0 0.0017828599
therapy O 0 0.08258389
- O 0 0.028948203
na B-Chemical 0 0.9997011
ve O 0 0.91992456
hepatitis B-Disease 2 0.9999957
B I-Disease 2 0.99826425
virus I-Disease 0 0.7355735
( I-Disease 0 0.027248427
HBV I-Disease 0 0.99818856
) I-Disease 0 0.0027717312
infected I-Disease 0 0.00062996725
patients O 0 0.001553733
with O 0 0.00059984165
and O 0 0.0007215404
without O 0 0.000789632
HIV B-Disease 0 0.91378725
co I-Disease 0 0.824046
- I-Disease 0 0.005650226
infection I-Disease 2 0.2330932
: O 0 0.0013285163
implications O 0 0.00072880875
for O 0 0.00046812472
antiretroviral O 0 0.05944313
therapy O 0 0.012315938
in O 0 0.0012482937
HBV B-Disease 0 0.99552816
and I-Disease 0 0.0035218801
HIV I-Disease 0 0.9448996
co I-Disease 0 0.75798273
- I-Disease 0 0.005644236
infected I-Disease 0 0.0030610033
South O 0 0.014296555
African O 0 0.030313734
patients O 0 0.012699871
. O 0 0.008526743

This O 0 0.010830871
was O 0 0.0056989966
an O 0 0.0048445063
exploratory O 0 0.006256639
study O 0 0.0025960796
to O 0 0.0017071627
investigate O 0 0.0014116793
lamivudine B-Chemical 1 0.9999248
- O 0 0.049693804
resistant O 0 0.026755149
hepatitis B-Disease 2 0.9999957
B I-Disease 2 0.99851197
virus O 0 0.76651955
( O 0 0.031285923
HBV O 0 0.9983329
) O 0 0.002969022
strains O 0 0.0007167663
in O 0 0.0005842288
selected O 0 0.00085551006
lamivudine B-Chemical 1 0.9999304
- O 0 0.030469298
na B-Chemical 0 0.99950385
ve O 0 0.46266025
HBV O 0 0.9957985
carriers O 0 0.029017849
with O 0 0.0008483915
and O 0 0.00086790987
without O 0 0.0008576403
human B-Disease 0 0.011792838
immunodeficiency I-Disease 0 0.99913114
virus I-Disease 0 0.8115231
( I-Disease 0 0.01618366
HIV I-Disease 0 0.9421201
) I-Disease 0 0.0068167457
co I-Disease 0 0.5717371
- I-Disease 0 0.0048032356
infection I-Disease 2 0.15278396
in O 0 0.003081062
South O 0 0.016052404
African O 0 0.031983793
patients O 0 0.012691488
. O 0 0.00842312

Thirty O 0 0.018871976
- O 0 0.010632322
five O 0 0.0054131346
lamivudine B-Chemical 1 0.9995369
- O 0 0.056127016
na B-Chemical 0 0.99906
ve O 0 0.67099017
HBV B-Disease 0 0.9986362
infected I-Disease 0 0.0037245015
patients O 0 0.004274142
with O 0 0.0011255152
or O 0 0.0009419526
without O 0 0.0011335808
HIV B-Disease 0 0.9233361
co I-Disease 0 0.8393364
- I-Disease 0 0.004792201
infection I-Disease 2 0.14052181
were O 0 0.00074892957
studied O 0 0.00078017527
: O 0 0.0011740989
15 O 0 0.0006315642
chronic O 0 0.9089179
HBV B-Disease 0 0.9988686
mono I-Disease 0 0.87944
- I-Disease 0 0.0025999956
infected I-Disease 0 0.00080515235
patients O 0 0.0025335248
and O 0 0.0013596565
20 O 0 0.0018865545
HBV B-Disease 0 0.99375314
- I-Disease 0 0.009864008
HIV I-Disease 0 0.8707561
co I-Disease 0 0.65526164
- I-Disease 0 0.0070276163
infected I-Disease 0 0.0047563645
patients O 0 0.01662228
. O 0 0.009115837

The O 0 0.0073947916
latter O 0 0.0076712845
group O 0 0.004364916
was O 0 0.002832744
further O 0 0.0022725654
sub O 0 0.008398424
- O 0 0.0023371307
divided O 0 0.00089581154
into O 0 0.00073182717
13 O 0 0.0013368279
occult O 0 0.42363858
HBV O 0 0.9985598
( O 0 0.012922857
HBsAg B-Chemical 1 0.9996412
- O 0 0.0026803012
negative O 0 0.0013155501
) O 0 0.001770297
and O 0 0.0010659564
7 O 0 0.0011674722
overt O 0 0.33882168
HBV O 0 0.99713385
( O 0 0.0152709475
HBsAg B-Chemical 1 0.9993049
- O 0 0.005665406
positive O 0 0.0037819794
) O 0 0.007921863
patients O 0 0.01246487
. O 0 0.008263099

HBsAg B-Chemical 1 0.9950539
, O 0 0.013562652
anti O 0 0.038296014
- O 0 0.012842233
HBs O 0 0.99599636
, O 0 0.0054253116
anti O 0 0.033747014
- O 0 0.006387286
HBc O 0 0.8979335
, O 0 0.0018874607
and O 0 0.0011774069
anti O 0 0.020100564
- O 0 0.0037523108
HIV O 0 0.71890455
1 O 0 0.0008640613
/ O 0 0.0012355008
2 O 0 0.00044940173
were O 0 0.00036334194
determined O 0 0.00029782383
as O 0 0.0004104383
part O 0 0.00037713317
of O 0 0.00053023535
routine O 0 0.0006609849
diagnosis O 0 0.0043952335
using O 0 0.00094149547
Axsym O 0 0.6905237
assays O 0 0.0013888465
( O 0 0.002540357
Abbott O 0 0.8061421
Laboratories O 0 0.2925239
, O 0 0.0027321787
North O 0 0.006519031
Chicago O 0 0.25313538
, O 0 0.0056342473
IL O 0 0.95933497
) O 0 0.011755375
. O 0 0.008153622

Serum O 0 0.2391607
samples O 0 0.00824314
were O 0 0.005658513
PCR O 0 0.025275191
amplified O 0 0.004610377
with O 0 0.0037849033
HBV O 0 0.99388546
reverse O 0 0.21162792
transcriptase O 0 0.8495725
( O 0 0.0057504294
RT O 0 0.07267956
) O 0 0.0023924613
primers O 0 0.0022535224
, O 0 0.00085452106
followed O 0 0.0004044395
by O 0 0.0004993363
direct O 0 0.00048279265
sequencing O 0 0.0008399175
across O 0 0.00035418858
the O 0 0.00077177293
tyrosine B-Chemical 1 0.9930449
- O 0 0.048673347
methionine B-Chemical 0 0.999811
- O 0 0.10176482
aspartate B-Chemical 1 0.9999728
- O 0 0.07338622
aspartate B-Chemical 1 0.99994755
( O 0 0.009090305
YMDD O 0 0.995488
) O 0 0.0022456015
motif O 0 0.000781238
of O 0 0.0005750667
the O 0 0.0005247659
major O 0 0.0008328675
catalytic O 0 0.017632352
region O 0 0.0009552071
in O 0 0.00081745436
the O 0 0.0012971435
C O 0 0.8856293
domain O 0 0.0020651037
of O 0 0.0027926085
the O 0 0.0040761805
HBV O 0 0.9967895
RT O 0 0.41973022
enzyme O 0 0.384341
. O 0 0.010745933

HBV O 0 0.9547486
viral O 0 0.03941348
load O 0 0.007824951
was O 0 0.0041104797
performed O 0 0.0029019695
with O 0 0.0034684779
Amplicor O 0 0.83672523
HBV O 0 0.99261063
Monitor O 0 0.075426474
test O 0 0.0023443857
v2 O 0 0.030120812
. O 0 0.0011804354
0 O 0 0.0019596582
( O 0 0.0025398955
Roche O 0 0.23617952
Diagnostics O 0 0.148882
, O 0 0.0045869197
Penzberg O 0 0.21265815
, O 0 0.0058982917
Germany O 0 0.036209293
) O 0 0.009924556
. O 0 0.008235522

HBV O 0 0.9932828
lamivudine B-Chemical 1 0.9996107
- O 0 0.016683875
resistant O 0 0.004124354
strains O 0 0.0023796288
were O 0 0.0016104187
detected O 0 0.0009278728
in O 0 0.00090620894
3 O 0 0.0007669916
of O 0 0.00084151933
15 O 0 0.00076987786
mono O 0 0.3177749
- O 0 0.0023683715
infected O 0 0.0013334709
chronic O 0 0.9988844
hepatitis B-Disease 2 0.9999974
B I-Disease 2 0.9985856
patients O 0 0.027156275
and O 0 0.0012787775
10 O 0 0.00092746096
of O 0 0.0011501849
20 O 0 0.0018093649
HBV B-Disease 0 0.9932389
- I-Disease 0 0.00947733
HIV I-Disease 0 0.86911273
co I-Disease 0 0.65293974
- I-Disease 0 0.0070148967
infected I-Disease 0 0.00475247
patients O 0 0.016622428
. O 0 0.009110408

To O 0 0.006131501
the O 0 0.004277089
best O 0 0.0030854414
of O 0 0.0024994465
our O 0 0.0017021218
knowledge O 0 0.0021165938
, O 0 0.0015036572
this O 0 0.0008038277
constitutes O 0 0.00066481397
the O 0 0.000616983
first O 0 0.0005454625
report O 0 0.0021555217
of O 0 0.0023857222
HBV O 0 0.99953485
lamivudine B-Chemical 1 0.9999734
- O 0 0.01014447
resistant O 0 0.0011413471
strains O 0 0.0009400065
in O 0 0.0009499364
therapy O 0 0.046048004
- O 0 0.01530371
na B-Chemical 0 0.9991986
ve O 0 0.6251396
HBV B-Disease 0 0.9983972
- I-Disease 0 0.0213341
HIV I-Disease 0 0.9003421
co I-Disease 0 0.6955135
- I-Disease 0 0.007679904
infected I-Disease 0 0.0050824257
patients O 0 0.01725829
. O 0 0.00950068

The O 0 0.010892901
HBV O 0 0.92855585
viral O 0 0.03228237
loads O 0 0.006299745
for O 0 0.0025367236
mono O 0 0.58200926
- O 0 0.0037969134
infected O 0 0.0013446612
and O 0 0.001581293
co O 0 0.5529873
- O 0 0.0019557863
infected O 0 0.0006445948
patients O 0 0.0013073724
ranged O 0 0.0007817277
from O 0 0.0005339152
3 O 0 0.0004620177
. O 0 0.000303796
32 O 0 0.0004677051
x O 0 0.0007300026
10 O 0 0.0004718796
( O 0 0.0005784167
2 O 0 0.0004143673
) O 0 0.0005508221
to O 0 0.00030466323
3 O 0 0.00034931384
. O 0 0.00026206012
82 O 0 0.00057421456
x O 0 0.0006718394
10 O 0 0.00044019948
( O 0 0.0005442867
7 O 0 0.00039031522
) O 0 0.0005825085
and O 0 0.00042886124
< O 0 0.00042452972
200 O 0 0.0005718817
to O 0 0.00032619468
4 O 0 0.00037207577
. O 0 0.00031367742
40 O 0 0.00044628582
x O 0 0.0009014159
10 O 0 0.0006998719
( O 0 0.0009949475
3 O 0 0.00085790997
) O 0 0.0015850352
copies O 0 0.0016359548
/ O 0 0.003635083
ml O 0 0.00624512
, O 0 0.0054013026
respectively O 0 0.008254995
. O 0 0.007785356

It O 0 0.009789616
remains O 0 0.0045954273
to O 0 0.0031098023
be O 0 0.0023042457
seen O 0 0.001421434
whether O 0 0.0007831805
such O 0 0.0011031647
pre O 0 0.017678961
- O 0 0.0020784284
existing O 0 0.001079612
antiviral O 0 0.15552448
mutations O 0 0.011254574
could O 0 0.00043065683
result O 0 0.0004898574
in O 0 0.00043793514
widespread O 0 0.0015799259
emergence O 0 0.0011868174
of O 0 0.0015501016
HBV O 0 0.997813
resistant O 0 0.0013832295
strains O 0 0.0007684698
when O 0 0.00059646444
lamivudine B-Chemical 1 0.9999236
- O 0 0.0021295953
containing O 0 0.00038779984
highly O 0 0.00061574
active O 0 0.001214063
antiretroviral O 0 0.20121635
( O 0 0.0018019429
ARV O 0 0.61662096
) O 0 0.0014102014
treatment O 0 0.001206731
( O 0 0.0014956333
HAART O 0 0.86688125
) O 0 0.0012623257
regimens O 0 0.0027214095
become O 0 0.0006284955
widely O 0 0.0006168067
applied O 0 0.00040858358
in O 0 0.00048382021
South O 0 0.0051301913
Africa O 0 0.004490251
, O 0 0.0005421465
as O 0 0.00037319722
this O 0 0.00038038645
is O 0 0.00039146666
likely O 0 0.00035612308
to O 0 0.00034478118
have O 0 0.00035806728
potential O 0 0.0006604037
implications O 0 0.0007364906
in O 0 0.00055764033
the O 0 0.0007297373
management O 0 0.0020777204
of O 0 0.003011944
HBV B-Disease 0 0.9989322
- I-Disease 0 0.03207356
HIV I-Disease 0 0.9359058
co I-Disease 0 0.75010616
- I-Disease 0 0.0076345173
infected I-Disease 0 0.00473181
patients O 0 0.01754097
. O 0 0.00900237

Rabbit B-Disease 0 0.38911974
syndrome I-Disease 0 0.9735233
, O 0 0.01581871
antidepressant B-Chemical 1 0.9992582
use O 0 0.0072246226
, O 0 0.005881136
and O 0 0.005122937
cerebral O 0 0.8973567
perfusion O 0 0.7507077
SPECT O 0 0.9753234
scan O 0 0.0135076
findings O 0 0.014862371
. O 0 0.012494129

The O 0 0.009926881
rabbit B-Disease 0 0.02579984
syndrome I-Disease 0 0.9426001
is O 0 0.005536104
an O 0 0.0077304523
extrapyramidal O 0 0.99996173
side O 0 0.41181064
effect O 0 0.003844112
associated O 0 0.004428674
with O 0 0.0067088115
chronic O 0 0.997684
neuroleptic O 0 0.99998844
therapy O 0 0.68157077
. O 0 0.01443704

Its O 0 0.06795373
occurrence O 0 0.008954841
in O 0 0.0038839823
a O 0 0.0035025745
patient O 0 0.0031752777
being O 0 0.002431927
treated O 0 0.0020202422
with O 0 0.0023691559
imipramine B-Chemical 0 0.99998903
is O 0 0.0012919563
described O 0 0.0007101456
, O 0 0.0008776134
representing O 0 0.0005835184
the O 0 0.00052903505
first O 0 0.00048607515
reported O 0 0.00079986907
case O 0 0.0008387943
of O 0 0.0012067977
this O 0 0.0015146667
syndrome O 0 0.8357702
in O 0 0.0025051555
conjunction O 0 0.0047648097
with O 0 0.009425091
antidepressants B-Chemical 1 0.9998524
. O 0 0.010586068

Repeated O 0 0.029542241
cerebral O 0 0.6687292
perfusion O 0 0.47073466
SPECT O 0 0.9162327
scans O 0 0.0054859146
revealed O 0 0.0017455393
decreased B-Disease 0 0.002004741
basal I-Disease 0 0.0026440506
ganglia I-Disease 0 0.086675994
perfusion I-Disease 0 0.18866478
while O 0 0.0006954279
the O 0 0.00067036424
movement B-Disease 0 0.0025070428
disorder I-Disease 0 0.9535648
was O 0 0.0007115103
present O 0 0.00046808153
, O 0 0.000871792
and O 0 0.0006723717
a O 0 0.0008317334
return O 0 0.00095760723
to O 0 0.0006352865
normal O 0 0.0014758222
perfusion O 0 0.087344915
when O 0 0.0011038729
the O 0 0.0020848487
rabbit B-Disease 0 0.08277413
syndrome I-Disease 0 0.98957866
resolved O 0 0.052294515
. O 0 0.010047013

Estrogen O 0 0.9996495
prevents O 0 0.16877295
cholesteryl B-Chemical 0 0.9996929
ester I-Chemical 0 0.9987803
accumulation O 0 0.030251173
in O 0 0.0041332105
macrophages O 0 0.020300929
induced O 0 0.0044136173
by O 0 0.0043468145
the O 0 0.0043561463
HIV O 0 0.94029146
protease O 0 0.5545236
inhibitor O 0 0.8361782
ritonavir B-Chemical 1 0.99948573
. O 0 0.013932736

Individuals O 0 0.02256439
with O 0 0.007708176
HIV O 0 0.29682675
can O 0 0.0032666076
now O 0 0.002791577
live O 0 0.0029323907
long O 0 0.0019416275
lives O 0 0.004661269
with O 0 0.0015316213
drug O 0 0.4420944
therapy O 0 0.009363331
that O 0 0.0010233091
often O 0 0.0021993723
includes O 0 0.0016609927
protease O 0 0.097645484
inhibitors O 0 0.15127237
such O 0 0.00406707
as O 0 0.008410953
ritonavir B-Chemical 1 0.9991418
. O 0 0.010412529

Many O 0 0.012271154
patients O 0 0.011762329
, O 0 0.0064304997
however O 0 0.004357681
, O 0 0.0034377982
develop O 0 0.0022713123
negative O 0 0.0024280814
long O 0 0.002254836
- O 0 0.002670663
term O 0 0.0016791063
side O 0 0.04340807
effects O 0 0.004413789
such O 0 0.0034818489
as O 0 0.007020186
premature B-Disease 0 0.9619018
atherosclerosis I-Disease 2 0.9998752
. O 0 0.021133365

We O 0 0.007782756
have O 0 0.004538718
previously O 0 0.0033008754
demonstrated O 0 0.002245328
that O 0 0.0018882593
ritonavir B-Chemical 1 0.9982338
treatment O 0 0.004529395
increases O 0 0.0020985682
atherosclerotic B-Disease 2 0.9997892
lesion I-Disease 0 0.9071351
formation O 0 0.008802426
in O 0 0.0009242566
male O 0 0.004251667
mice O 0 0.0006371448
to O 0 0.00078202353
a O 0 0.0012177953
greater O 0 0.0010279239
extent O 0 0.0011211802
than O 0 0.0014802612
in O 0 0.0026172155
female O 0 0.011015327
mice O 0 0.005190028
. O 0 0.008662336

Furthermore O 0 0.01063898
, O 0 0.007879279
peripheral O 0 0.01834229
blood O 0 0.019322494
monocytes O 0 0.061025698
isolated O 0 0.0034362823
from O 0 0.0036086831
ritonavir B-Chemical 1 0.9993918
- O 0 0.0054547326
treated O 0 0.002814083
females O 0 0.0048311152
had O 0 0.0028620046
less O 0 0.0056387736
cholesteryl B-Chemical 0 0.99971133
ester I-Chemical 0 0.9987606
accumulation O 0 0.1438518
. O 0 0.014665445

In O 0 0.0072322437
the O 0 0.004907487
present O 0 0.0029319278
study O 0 0.00308338
, O 0 0.0022664894
we O 0 0.0010028282
have O 0 0.00086836814
investigated O 0 0.0007344343
the O 0 0.00084429403
molecular O 0 0.0125420615
mechanisms O 0 0.0017571108
by O 0 0.001080748
which O 0 0.0013286176
female O 0 0.037216485
hormones O 0 0.98316264
influence O 0 0.0015831264
cholesterol B-Chemical 1 0.9998907
metabolism O 0 0.7294114
in O 0 0.001023491
macrophages O 0 0.007615964
in O 0 0.0009982398
response O 0 0.001625131
to O 0 0.0013495106
the O 0 0.002175583
HIV O 0 0.9177304
protease O 0 0.4623884
inhibitor O 0 0.8044277
ritonavir B-Chemical 1 0.9995296
. O 0 0.011485827

We O 0 0.008381761
have O 0 0.0048800907
utilized O 0 0.0035155583
the O 0 0.0028730293
human O 0 0.0031785152
monocyte O 0 0.27226165
cell O 0 0.043112442
line O 0 0.007666934
, O 0 0.004725245
THP O 1 0.9997986
- O 0 0.0039998144
1 O 0 0.0013112368
as O 0 0.0011456569
a O 0 0.0016495654
model O 0 0.0018015107
to O 0 0.001895533
address O 0 0.002065357
this O 0 0.0036988438
question O 0 0.006845505
. O 0 0.008433129

Briefly O 0 0.009692261
, O 0 0.007310837
cells O 0 0.0054020835
were O 0 0.0029613627
differentiated O 0 0.0039133346
for O 0 0.0012716849
72 O 0 0.0011590277
h O 0 0.0007742414
with O 0 0.00093124463
100 O 0 0.0028207626
nM O 0 0.10505265
PMA O 0 0.93784845
to O 0 0.00055519544
obtain O 0 0.0003559155
a O 0 0.00089048117
macrophage O 0 0.14309649
- O 0 0.0016473469
like O 0 0.0004970114
phenotype O 0 0.0007052308
in O 0 0.000395424
the O 0 0.000399412
presence O 0 0.00039719552
or O 0 0.00044457102
absence O 0 0.00032253243
of O 0 0.0011490034
1 O 0 0.0023750777
nM O 0 0.67289144
17beta B-Chemical 1 0.99999297
- I-Chemical 1 0.22965924
estradiol I-Chemical 1 0.99999416
( O 0 0.07876188
E2 B-Chemical 1 0.9999559
) O 0 0.01391415
, O 0 0.0015313472
100 O 0 0.0026666156
nM O 0 0.1184494
progesterone B-Chemical 1 0.9998416
or O 0 0.0012165816
vehicle O 0 0.113784194
( O 0 0.002296112
0 O 0 0.0018536663
. O 0 0.0013478511
01 O 0 0.008984716
% O 0 0.0039716284
ethanol B-Chemical 1 0.9849748
) O 0 0.013570541
. O 0 0.008526801

Cells O 0 0.018053323
were O 0 0.006087081
then O 0 0.003748482
treated O 0 0.0031245335
with O 0 0.002271062
30 O 0 0.0015141352
ng O 0 0.003542325
/ O 0 0.003287572
ml O 0 0.0056105866
ritonavir B-Chemical 1 0.9973515
or O 0 0.0011685371
vehicle O 0 0.02528021
in O 0 0.00087765383
the O 0 0.0009183213
presence O 0 0.0010556687
of O 0 0.0020019845
aggregated O 0 0.0053503215
LDL O 0 0.9994474
for O 0 0.0031338122
24 O 0 0.0037206903
h O 0 0.0048904247
. O 0 0.007226877

Cell O 0 0.58665067
extracts O 0 0.018603599
were O 0 0.008149431
harvested O 0 0.005972953
, O 0 0.0068649054
and O 0 0.005825881
lipid O 0 0.529268
or O 0 0.005516395
total O 0 0.006056787
RNA O 0 0.04507993
was O 0 0.007917908
isolated O 0 0.010650168
. O 0 0.01332573

E2 B-Chemical 1 0.99729925
decreased O 0 0.016243381
the O 0 0.0077304486
accumulation O 0 0.01013905
of O 0 0.01546937
cholesteryl B-Chemical 0 0.99979025
esters I-Chemical 0 0.9990748
in O 0 0.0072533675
macrophages O 0 0.0574559
following O 0 0.009685019
ritonavir B-Chemical 1 0.9992373
treatment O 0 0.032200336
. O 0 0.012851171

Ritonavir B-Chemical 0 0.9974529
increased O 0 0.007798566
the O 0 0.003989454
expression O 0 0.0033117174
of O 0 0.0029868365
the O 0 0.0030000512
scavenger O 0 0.99740535
receptor O 0 0.7813438
, O 0 0.010281647
CD36 O 0 0.9020497
mRNA O 0 0.0028358835
, O 0 0.0020213875
responsible O 0 0.0014691225
for O 0 0.0015370199
the O 0 0.0025479659
uptake O 0 0.026365304
of O 0 0.0100294
LDL O 0 0.9993507
. O 0 0.013625345

Additionally O 0 0.010368875
, O 0 0.008561559
ritonavir B-Chemical 1 0.99378234
treatment O 0 0.0051977695
selectively O 0 0.003363972
increased O 0 0.0018511218
the O 0 0.0010835
relative O 0 0.0007838808
levels O 0 0.00092712464
of O 0 0.0018496263
PPARgamma O 0 0.9614642
mRNA O 0 0.0019018069
, O 0 0.0011686105
a O 0 0.0010298475
transcription O 0 0.0018326419
factor O 0 0.003365592
responsible O 0 0.0008843274
for O 0 0.0008111947
the O 0 0.0012087338
regulation O 0 0.001472789
of O 0 0.0033818989
CD36 O 0 0.8955414
mRNA O 0 0.007406003
expression O 0 0.008602781
. O 0 0.008910769

Treatment O 0 0.08522401
with O 0 0.013571574
E2 B-Chemical 1 0.9991172
, O 0 0.008327442
however O 0 0.0044728513
, O 0 0.0032853086
failed O 0 0.002113161
to O 0 0.0016948791
prevent O 0 0.0019182255
these O 0 0.0023756304
increases O 0 0.0021801614
at O 0 0.002212944
the O 0 0.003291577
mRNA O 0 0.0056701987
level O 0 0.0053249495
. O 0 0.008743958

E2 B-Chemical 1 0.9973404
did O 0 0.010026701
, O 0 0.0075936993
however O 0 0.005323697
, O 0 0.004484445
significantly O 0 0.0035726065
suppress O 0 0.0026204935
CD36 O 0 0.76618797
protein O 0 0.00443582
levels O 0 0.002369175
as O 0 0.0026120164
measured O 0 0.002465323
by O 0 0.004612993
fluorescent O 0 0.013174157
immunocytochemistry O 0 0.036893714
. O 0 0.010057888

This O 0 0.010786128
data O 0 0.0066196746
suggests O 0 0.0032909748
that O 0 0.0032951445
E2 B-Chemical 1 0.99919885
modifies O 0 0.0040003597
the O 0 0.0015160571
expression O 0 0.0015665286
of O 0 0.0015990889
CD36 O 0 0.73210824
at O 0 0.0005356064
the O 0 0.00050866464
level O 0 0.00036077196
of O 0 0.000604805
protein O 0 0.0011594474
expression O 0 0.00096051116
in O 0 0.0006608948
monocyte O 0 0.43628117
- O 0 0.0019329193
derived O 0 0.00074174406
macrophages O 0 0.006208711
resulting O 0 0.0014662195
in O 0 0.0013069141
reduced O 0 0.00409424
cholesteryl B-Chemical 0 0.99991846
ester I-Chemical 0 0.99924755
accumulation O 0 0.039385602
following O 0 0.007651549
ritonavir B-Chemical 1 0.999495
treatment O 0 0.026869442
. O 0 0.009853341

Acute O 0 0.9921923
hepatitis B-Disease 2 0.9993388
attack O 0 0.8719962
after O 0 0.013557461
exposure O 0 0.023467518
to O 0 0.018605113
telithromycin B-Chemical 1 0.99663687
. O 0 0.025209354

INTRODUCTION O 0 0.10031269
: O 0 0.028223662
Antibiotic O 0 0.7331047
- O 0 0.02395318
associated O 0 0.022020565
hepatotoxicity B-Disease 2 0.9998136
is O 0 0.026020894
rare O 0 0.17336448
. O 0 0.023329822

With O 0 0.008957948
widespread O 0 0.0072631314
use O 0 0.0038539465
of O 0 0.0033147577
antimicrobial O 0 0.1420468
agents O 0 0.49889156
, O 0 0.003379727
however O 0 0.0021517712
, O 0 0.0023616424
hepatic B-Disease 2 0.9968459
injury I-Disease 2 0.99823904
occurs O 0 0.0011562741
frequently O 0 0.0020883947
, O 0 0.0011588325
and O 0 0.00077536516
among O 0 0.0010281189
adverse B-Disease 0 0.98441887
drug I-Disease 0 0.782437
reactions I-Disease 0 0.3413052
, O 0 0.0029635585
idiosyncratic O 0 0.5520641
reactions O 0 0.043022722
are O 0 0.0025764203
the O 0 0.0027719026
most O 0 0.0058256066
serious O 0 0.47896424
. O 0 0.009761164

CASE O 0 0.37009093
SUMMARY O 0 0.040401284
: O 0 0.008409236
A O 0 0.016094716
25 O 0 0.004475934
- O 0 0.003415032
year O 0 0.0018522128
- O 0 0.0018557159
old O 0 0.0012283347
male O 0 0.0027881584
patient O 0 0.0015005934
, O 0 0.0010389669
with O 0 0.0006507471
a O 0 0.0008186447
height O 0 0.0013326044
of O 0 0.00067052484
175 O 0 0.0028685685
cm O 0 0.0011178727
and O 0 0.00053031516
weight O 0 0.0013228221
of O 0 0.00054318714
72 O 0 0.000511845
kg O 0 0.0014151752
presented O 0 0.00058460585
to O 0 0.00059719844
Marmara O 0 0.3685199
University O 0 0.002015584
Hospital O 0 0.0039721658
Emergency O 0 0.011901568
Department O 0 0.0027137464
, O 0 0.0010208753
Istanbul O 0 0.050464932
, O 0 0.00090295885
Turkey O 0 0.017653434
, O 0 0.0006051467
with O 0 0.00041128974
5 O 0 0.00035679236
days O 0 0.00033018415
' O 0 0.00064815907
history O 0 0.0035108193
of O 0 0.0017140532
jaundice B-Disease 2 0.99989426
, O 0 0.035608876
malaise O 0 0.9999528
, O 0 0.05543334
nausea B-Disease 2 0.99998605
, O 0 0.012600839
and O 0 0.012253262
vomiting B-Disease 2 0.9998042
. O 0 0.0128766745

He O 0 0.015592587
had O 0 0.0061147576
been O 0 0.0045321537
prescribed O 0 0.01273082
telithromycin B-Chemical 1 0.9952172
400 O 0 0.009992944
mg O 0 0.4173838
/ O 0 0.003873856
d O 0 0.0019365436
PO O 0 0.7715895
to O 0 0.0009868433
treat O 0 0.0021489554
an O 0 0.0016591604
upper B-Disease 0 0.003536896
respiratory I-Disease 0 0.6266699
tract I-Disease 0 0.47765014
infection I-Disease 2 0.33893672
7 O 0 0.0033978217
days O 0 0.003087126
prior O 0 0.004298245
. O 0 0.007853317

Admission O 0 0.022163354
laboratory O 0 0.007862693
tests O 0 0.005978604
were O 0 0.003207274
as O 0 0.0025073995
follows O 0 0.0043397625
: O 0 0.004692598
alanine B-Chemical 1 0.99031794
aminotransferase O 0 0.9992679
, O 0 0.0023211478
67 O 0 0.0029478003
U O 0 0.8282255
/ O 0 0.005446562
L O 0 0.41977495
( O 0 0.001001835
reference O 0 0.00048579212
range O 0 0.0007996046
, O 0 0.0007751015
10 O 0 0.000593207
- O 0 0.00082136394
37 O 0 0.00074913865
U O 0 0.79026556
/ O 0 0.008873615
L O 0 0.79655135
) O 0 0.008377843
; O 0 0.00808794
aspartate B-Chemical 1 0.9999112
aminotransferase O 0 0.99945396
, O 0 0.0014419929
98 O 0 0.0019477607
U O 0 0.76895547
/ O 0 0.0038958737
L O 0 0.43468437
( O 0 0.0010384199
10 O 0 0.0006148047
- O 0 0.0007887096
40 O 0 0.00062473014
U O 0 0.734787
/ O 0 0.0070273965
L O 0 0.7358716
) O 0 0.0046530603
; O 0 0.0023895816
alkaline O 0 0.48014176
phosphatase O 0 0.6984248
, O 0 0.0021319492
513 O 0 0.10623395
U O 0 0.89539164
/ O 0 0.0072002853
L O 0 0.5427331
( O 0 0.0012335336
0 O 0 0.0009923786
- O 0 0.0010213834
270 O 0 0.0063201054
U O 0 0.78383815
/ O 0 0.0063881148
L O 0 0.6779512
) O 0 0.0033723451
; O 0 0.0021132396
gamma O 0 0.5538913
- O 0 0.00535208
glutamyltransferase O 0 0.98979807
, O 0 0.0012493149
32 O 0 0.0011351174
U O 0 0.83021384
/ O 0 0.0058318907
L O 0 0.52026355
( O 0 0.0011336186
7 O 0 0.0006161483
- O 0 0.0008435682
49 O 0 0.0010963237
U O 0 0.7664176
/ O 0 0.006803503
L O 0 0.6894113
) O 0 0.0031631826
; O 0 0.0017199935
amylase O 0 0.93343246
, O 0 0.0010909392
46 O 0 0.0013170311
U O 0 0.8094237
/ O 0 0.005125397
L O 0 0.50399673
( O 0 0.0011942192
0 O 0 0.0009626573
- O 0 0.0009731714
220 O 0 0.0034696697
U O 0 0.7779282
/ O 0 0.005751013
L O 0 0.60592526
) O 0 0.0019341294
; O 0 0.00093076914
total O 0 0.00058239914
bilirubin B-Chemical 1 0.99975663
, O 0 0.0009970741
20 O 0 0.000509939
. O 0 0.00030233138
1 O 0 0.00040922133
mg O 0 0.06583842
/ O 0 0.00144483
dL O 0 0.008050449
( O 0 0.0006675988
0 O 0 0.0005610556
. O 0 0.000300502
2 O 0 0.00042452163
- O 0 0.0005960706
1 O 0 0.00038575588
. O 0 0.0002742525
0 O 0 0.00046821532
mg O 0 0.07382189
/ O 0 0.0017800007
dL O 0 0.01666626
) O 0 0.001111306
; O 0 0.0007518041
direct O 0 0.00052692014
bilirubin B-Chemical 1 0.99974614
, O 0 0.00089326507
14 O 0 0.000497723
. O 0 0.00027419417
8 O 0 0.0003436251
mg O 0 0.05359219
/ O 0 0.0013894512
dL O 0 0.008066188
( O 0 0.0007005041
0 O 0 0.0006504835
- O 0 0.0006252636
0 O 0 0.0004736251
. O 0 0.0002664436
3 O 0 0.00033868093
mg O 0 0.06634769
/ O 0 0.0017299668
dL O 0 0.017362822
) O 0 0.0012070013
; O 0 0.0008599295
and O 0 0.0005958127
albumin O 0 0.9708174
, O 0 0.0008554808
4 O 0 0.00040664806
. O 0 0.00029088822
7 O 0 0.000372705
mg O 0 0.05431341
/ O 0 0.0015482457
dL O 0 0.007774428
( O 0 0.0008181885
3 O 0 0.0005239657
. O 0 0.00044543832
5 O 0 0.00058598444
- O 0 0.0009636965
5 O 0 0.0007074158
. O 0 0.0007824786
4 O 0 0.0012754131
mg O 0 0.098822005
/ O 0 0.006864102
dL O 0 0.026855795
) O 0 0.00922768
. O 0 0.00789941

No O 0 0.019624183
toxin O 0 0.20685169
, O 0 0.015791688
alcohol B-Chemical 1 0.99766326
, O 0 0.010298935
or O 0 0.0059898957
other O 0 0.006844001
drugs O 0 0.7962734
were O 0 0.010169758
reported O 0 0.013008932
. O 0 0.0133519685

The O 0 0.007678548
patient O 0 0.006858173
had O 0 0.004072226
suffered O 0 0.05906299
a O 0 0.003099666
previous O 0 0.0018670842
episode O 0 0.011507113
of O 0 0.0026328494
" O 0 0.0061729373
acute O 0 0.9991203
hepatitis B-Disease 2 0.999992
of O 0 0.015184328
unknown O 0 0.036143795
origin O 0 0.007838258
, O 0 0.0024019512
" O 0 0.0018144249
that O 0 0.0011865066
occurred O 0 0.001986751
after O 0 0.0020780386
telithromycin B-Chemical 1 0.9944652
usage O 0 0.0084186485
. O 0 0.008782627

Both O 0 0.032068174
incidents O 0 0.052426167
occurred O 0 0.021746147
within O 0 0.015892835
a O 0 0.024393523
year O 0 0.024993684
. O 0 0.027065676

DISCUSSION O 0 0.072422534
: O 0 0.011227327
Telithromycin B-Chemical 0 0.71633655
is O 0 0.002909752
the O 0 0.001876667
first O 0 0.0012982471
of O 0 0.0014878516
the O 0 0.0014059687
ketolide O 0 0.4910242
antibacterials O 0 0.92575186
to O 0 0.0013890353
receive O 0 0.0015165934
US O 0 0.19729443
Food O 0 0.7944294
and O 0 0.002683437
Drug O 0 0.9875044
Administration O 0 0.4245849
approval O 0 0.0041199513
for O 0 0.0025623448
clinical O 0 0.014523644
use O 0 0.0074390294
. O 0 0.008680667

It O 0 0.014377464
has O 0 0.007793003
been O 0 0.006430652
associated O 0 0.0051385337
with O 0 0.004476741
infrequent O 0 0.015291327
and O 0 0.005013166
usually O 0 0.008023211
reversible O 0 0.70337296
severe O 0 0.90729034
hepatic B-Disease 0 0.99929595
dysfunction I-Disease 0 0.99900275
. O 0 0.018125111

Based O 0 0.011855835
on O 0 0.0043891077
a O 0 0.00419998
score O 0 0.0030190386
of O 0 0.0021344267
8 O 0 0.001379704
on O 0 0.0008098404
the O 0 0.000997669
Naranjo O 0 0.98630965
adverse B-Disease 0 0.98620796
drug I-Disease 0 0.70121783
reaction I-Disease 0 0.07020726
probability O 0 0.0012714383
scale O 0 0.003374022
, O 0 0.0011287782
telithromycin B-Chemical 1 0.99363315
was O 0 0.00048282926
the O 0 0.00043145975
probable O 0 0.008476069
cause O 0 0.0061737504
of O 0 0.0038091308
acute O 0 0.99968994
hepatitis B-Disease 2 0.9999969
in O 0 0.0016877265
this O 0 0.0008635354
patient O 0 0.0016481588
, O 0 0.0011181367
and O 0 0.0009564342
pathological O 0 0.19452903
findings O 0 0.0037965723
suggested O 0 0.001794622
drug O 0 0.8847646
- O 0 0.016139088
induced O 0 0.01150504
toxic B-Disease 0 0.99924016
hepatitis I-Disease 2 0.99997187
. O 0 0.05807626

Recurrence O 0 0.706052
of O 0 0.016386418
hepatitis B-Disease 2 0.99979764
attack O 0 0.8657437
might O 0 0.002517139
have O 0 0.0017338316
been O 0 0.0014191611
avoided O 0 0.0011014253
if O 0 0.00062556996
the O 0 0.0006620125
initial O 0 0.0007524026
incident O 0 0.014174804
had O 0 0.0007846282
been O 0 0.00076287385
communicated O 0 0.0008110092
to O 0 0.0005321785
the O 0 0.0006506934
attending O 0 0.0014239589
physician O 0 0.0038802607
who O 0 0.002290213
prescribed O 0 0.02548477
telithromycin B-Chemical 1 0.9929543
the O 0 0.0028111248
second O 0 0.0038166253
time O 0 0.004919503
. O 0 0.0078030527

CONCLUSION O 0 0.5065364
: O 0 0.008685526
Here O 0 0.0054432517
we O 0 0.002889688
report O 0 0.004174409
a O 0 0.0029032545
case O 0 0.0023206177
of O 0 0.004076002
acute O 0 0.99933547
hepatitis B-Disease 2 0.99999094
probably O 0 0.06968721
associated O 0 0.0038048194
with O 0 0.002716995
the O 0 0.002842349
administration O 0 0.17395982
of O 0 0.010450874
telithromycin B-Chemical 1 0.99873704
. O 0 0.011467537

A O 0 0.028200718
study O 0 0.006652973
on O 0 0.0033259443
the O 0 0.0027651372
effect O 0 0.0019624992
of O 0 0.001891177
the O 0 0.0014523475
duration O 0 0.0016027938
of O 0 0.0019185935
subcutaneous O 0 0.3283625
heparin B-Chemical 1 0.99831676
injection O 0 0.02281254
on O 0 0.0031919186
bruising B-Disease 2 0.9990652
and O 0 0.028083684
pain B-Disease 2 0.99882895
. O 0 0.013381588

AIM O 0 0.56699973
: O 0 0.009460424
This O 0 0.0053393724
study O 0 0.0032171493
was O 0 0.0020091583
carried O 0 0.0012235874
out O 0 0.0010007885
to O 0 0.0007518248
determine O 0 0.0004291716
the O 0 0.0005781587
effect O 0 0.00052738923
of O 0 0.0006558507
injection O 0 0.0014411947
duration O 0 0.0007910746
on O 0 0.00054024253
bruising B-Disease 2 0.9991924
and O 0 0.0021837614
pain B-Disease 2 0.9980848
following O 0 0.00082926237
the O 0 0.0007961064
administration O 0 0.017724382
of O 0 0.0012412535
the O 0 0.0014127202
subcutaneous O 0 0.13482729
injection O 0 0.008655013
of O 0 0.007496235
heparin B-Chemical 1 0.99842924
. O 0 0.01166152

BACKGROUND O 0 0.5478107
: O 0 0.007826612
Although O 0 0.003092725
different O 0 0.002167398
methods O 0 0.0019773638
to O 0 0.0014914703
prevent O 0 0.00200993
bruising B-Disease 2 0.9992274
and O 0 0.0029844926
pain B-Disease 2 0.9979395
following O 0 0.0007517267
the O 0 0.0005663424
subcutaneous O 0 0.050966553
injection O 0 0.0016928584
of O 0 0.00091554446
heparin B-Chemical 1 0.99818486
have O 0 0.0006434207
been O 0 0.0006416931
widely O 0 0.0007246779
studied O 0 0.00055523304
and O 0 0.00063148106
described O 0 0.00043092828
, O 0 0.0006151613
the O 0 0.00034228398
effect O 0 0.00034745075
of O 0 0.00047688303
injection O 0 0.0010116566
duration O 0 0.0005659881
on O 0 0.00036248914
the O 0 0.00059671537
occurrence O 0 0.0021327
of O 0 0.002562395
bruising B-Disease 2 0.99949694
and O 0 0.008355379
pain B-Disease 2 0.9988588
is O 0 0.0036157642
little O 0 0.0037410944
documented O 0 0.009202125
. O 0 0.00879201

DESIGN O 0 0.020313727
: O 0 0.009796227
This O 0 0.006681856
study O 0 0.00456448
was O 0 0.0032718717
designed O 0 0.0028420028
as O 0 0.0024310574
within O 0 0.0017996259
- O 0 0.0032365262
subject O 0 0.0021269126
, O 0 0.003416909
quasi O 0 0.0088783605
- O 0 0.0060747573
experimental O 0 0.0057835826
research O 0 0.00948273
. O 0 0.009588462

METHOD O 0 0.025257515
: O 0 0.007835837
The O 0 0.0036501482
sample O 0 0.0030972017
for O 0 0.0018376679
the O 0 0.0016917797
study O 0 0.001605362
consisted O 0 0.0011857529
of O 0 0.0014263401
50 O 0 0.0017723037
patients O 0 0.0021506515
to O 0 0.0012934234
whom O 0 0.0039880257
subcutaneous O 0 0.29565156
heparin B-Chemical 1 0.99759007
was O 0 0.005869572
administered O 0 0.011095973
. O 0 0.0088426145

Heparin B-Chemical 1 0.9937429
was O 0 0.0061152913
injected O 0 0.0033107796
over O 0 0.0019141965
10 O 0 0.0016882279
seconds O 0 0.0013298114
on O 0 0.00088241376
the O 0 0.0010251757
right O 0 0.002093165
abdominal O 0 0.11104279
site O 0 0.0011642771
and O 0 0.0012114448
30 O 0 0.0009027343
seconds O 0 0.0011069287
on O 0 0.0010830532
the O 0 0.0019672061
left O 0 0.0054197107
abdominal O 0 0.32199723
site O 0 0.0074248617
. O 0 0.009176739

Injections O 0 0.088281214
areas O 0 0.009020927
were O 0 0.0041052676
assessed O 0 0.0024577547
for O 0 0.0017950663
the O 0 0.0016996184
presence O 0 0.0015246186
of O 0 0.0025721572
bruising B-Disease 2 0.99848676
at O 0 0.0013348089
48 O 0 0.0011962651
and O 0 0.0013158908
72 O 0 0.0013927519
hours O 0 0.001199949
after O 0 0.0014694743
each O 0 0.0024719646
injection O 0 0.008546246
. O 0 0.00792041

Dimensions O 0 0.022365995
of O 0 0.0077368193
the O 0 0.0059191496
bruising B-Disease 2 0.98898333
on O 0 0.0029326251
the O 0 0.0030416877
heparin B-Chemical 1 0.9926968
applied O 0 0.0026851832
areas O 0 0.0040800967
were O 0 0.0019231469
measured O 0 0.0015735705
using O 0 0.002193953
transparent O 0 0.0047722682
millimetric O 0 0.01146751
measuring O 0 0.004599709
paper O 0 0.01013222
. O 0 0.009674278

The O 0 0.009131753
visual O 0 0.06344386
analog O 0 0.044623733
scale O 0 0.008888251
( O 0 0.0058690766
VAS O 0 0.9275576
) O 0 0.0028571426
was O 0 0.0010901527
used O 0 0.00078330183
to O 0 0.0006964321
measure O 0 0.0005898845
pain B-Disease 2 0.9911765
intensity O 0 0.0008893598
and O 0 0.0010584197
a O 0 0.0014793905
stop O 0 0.010850879
- O 0 0.001973764
watch O 0 0.0016685985
was O 0 0.00096748635
used O 0 0.0010305921
to O 0 0.0012677254
time O 0 0.0016710438
the O 0 0.0032528762
pain B-Disease 2 0.99437803
period O 0 0.0065089827
. O 0 0.008773675

Data O 0 0.015622566
were O 0 0.0068619153
analysed O 0 0.0051158355
using O 0 0.0041771033
chi O 0 0.19991566
- O 0 0.004938555
square O 0 0.004532511
test O 0 0.00304032
, O 0 0.0037358014
Mann O 0 0.6790052
- O 0 0.0061995997
Whitney O 0 0.9107699
U O 0 0.8542611
, O 0 0.0031561672
Wilcoxon O 0 0.019502485
signed O 0 0.0035386174
ranks O 0 0.006857621
tests O 0 0.0050727203
and O 0 0.005023781
correlation O 0 0.005752411
. O 0 0.009074702

RESULTS O 0 0.022386294
: O 0 0.00704775
The O 0 0.0031571486
percentage O 0 0.0022187943
of O 0 0.0028963953
bruising B-Disease 2 0.99691606
occurrence O 0 0.007964048
was O 0 0.0015133072
64 O 0 0.0015500616
% O 0 0.0008797864
with O 0 0.00057679426
the O 0 0.0005211818
injection O 0 0.00093682355
of O 0 0.00063437386
10 O 0 0.0005327323
seconds O 0 0.00048231173
duration O 0 0.000598324
and O 0 0.0007746233
42 O 0 0.001110295
% O 0 0.000994967
in O 0 0.0008973304
the O 0 0.0012867048
30 O 0 0.0015793699
- O 0 0.003095543
second O 0 0.003242562
injection O 0 0.009997192
. O 0 0.007923079

It O 0 0.010394424
was O 0 0.0054356214
determined O 0 0.0031909947
that O 0 0.002395117
the O 0 0.0021578409
size O 0 0.002201929
of O 0 0.0019854768
the O 0 0.0021361094
bruising B-Disease 2 0.99807584
was O 0 0.0019303481
smaller O 0 0.0014775447
in O 0 0.0014698319
the O 0 0.0018553379
30 O 0 0.0020707834
- O 0 0.0038007766
second O 0 0.0037919148
injection O 0 0.011187991
. O 0 0.008632034

Pain B-Disease 2 0.9809909
intensity O 0 0.0067308526
and O 0 0.0057793777
pain B-Disease 2 0.9876002
period O 0 0.002220032
were O 0 0.0015372739
statistically O 0 0.0010831057
significantly O 0 0.0011238107
lower O 0 0.00084503397
for O 0 0.00058333745
the O 0 0.0007092772
30 O 0 0.000624865
- O 0 0.0009015829
second O 0 0.0005919131
injection O 0 0.0012292607
than O 0 0.000627406
for O 0 0.00081570446
the O 0 0.0013500301
10 O 0 0.0020142384
- O 0 0.003279909
second O 0 0.0032553913
injection O 0 0.010354222
. O 0 0.0078054164

CONCLUSIONS O 0 0.5254203
: O 0 0.0097808
It O 0 0.004888664
was O 0 0.0026515508
determined O 0 0.0015992092
that O 0 0.0012406618
injection O 0 0.0019227882
duration O 0 0.0012726015
had O 0 0.0008934838
an O 0 0.0011469901
effect O 0 0.000864338
on O 0 0.0008133619
bruising B-Disease 2 0.99893516
and O 0 0.0030677686
pain B-Disease 2 0.9978618
following O 0 0.0014936236
the O 0 0.0016887664
subcutaneous O 0 0.18662733
administration O 0 0.16708939
of O 0 0.00939982
heparin B-Chemical 1 0.99860483
. O 0 0.012380938

This O 0 0.018773142
study O 0 0.011888173
should O 0 0.0069093322
be O 0 0.007257179
repeated O 0 0.0063483994
on O 0 0.005901225
a O 0 0.009319468
larger O 0 0.009450198
sample O 0 0.013402707
. O 0 0.014508501

RELEVANCE O 0 0.034298386
TO O 0 0.0695502
CLINICAL O 0 0.016903259
PRACTICE O 0 0.004384397
: O 0 0.0032097201
When O 0 0.0016769262
administering O 0 0.0033085553
subcutaneous O 0 0.10007154
heparin B-Chemical 1 0.9976992
injections O 0 0.045033433
, O 0 0.0019213249
it O 0 0.0010828422
is O 0 0.0008171195
important O 0 0.0007134686
to O 0 0.00084911985
extend O 0 0.00092721
the O 0 0.001239584
duration O 0 0.0020365994
of O 0 0.0030851993
the O 0 0.004261908
injection O 0 0.017627578
. O 0 0.008800654

Acute B-Disease 0 0.98956585
liver I-Disease 0 0.92611855
failure I-Disease 0 0.8417071
in O 0 0.0038219918
two O 0 0.0024710596
patients O 0 0.0040153246
with O 0 0.002221752
regular O 0 0.003451866
alcohol B-Chemical 1 0.99941075
consumption O 0 0.64410794
ingesting O 0 0.96604294
paracetamol B-Chemical 1 0.999961
at O 0 0.0042112004
therapeutic O 0 0.115421906
dosage O 0 0.5520585
. O 0 0.01064013

BACKGROUND O 0 0.52903503
: O 0 0.007957756
The O 0 0.00337565
possible O 0 0.0025391309
role O 0 0.0016445614
of O 0 0.0022644384
alcohol B-Chemical 1 0.9991062
in O 0 0.0013815402
the O 0 0.0010959803
development O 0 0.0021923564
of O 0 0.0027814314
hepatotoxicity B-Disease 2 0.9999939
associated O 0 0.0025212958
with O 0 0.0011898266
therapeutic O 0 0.036829736
doses O 0 0.08461626
of O 0 0.0057343883
paracetamol B-Chemical 1 0.9999907
( O 0 0.05156755
acetaminophen B-Chemical 1 0.9999882
) O 0 0.011107103
is O 0 0.003171205
currently O 0 0.005368353
debated O 0 0.01293454
. O 0 0.008247798

CASE O 0 0.34169114
REPORT O 0 0.036412872
: O 0 0.0065426202
We O 0 0.0031783292
describe O 0 0.002267088
2 O 0 0.0019145373
patients O 0 0.0022457691
who O 0 0.0018260751
were O 0 0.0009650215
regular O 0 0.0010506596
consumers O 0 0.010452461
of O 0 0.0011890557
alcohol B-Chemical 1 0.9995394
and O 0 0.0011962992
who O 0 0.0019690243
developed O 0 0.0012590501
liver B-Disease 0 0.9160123
failure I-Disease 0 0.62735814
within O 0 0.0003484004
3 O 0 0.0005235144
- O 0 0.0005930747
5 O 0 0.00025268807
days O 0 0.00021415486
after O 0 0.00021354643
hospitalization O 0 0.010862499
and O 0 0.00059027283
stopping O 0 0.014411166
alcohol B-Chemical 1 0.999476
consumption O 0 0.20323735
while O 0 0.0008595621
being O 0 0.0013220549
treated O 0 0.0012427209
with O 0 0.0013400351
4 O 0 0.0015990571
g O 0 0.0053723874
paracetamol B-Chemical 1 0.9998859
/ O 0 0.014288662
day O 0 0.00538612
. O 0 0.007530423

A O 0 0.18895803
paracetamol B-Chemical 1 0.9996654
serum O 0 0.15989509
level O 0 0.0030605202
obtained O 0 0.002482998
in O 0 0.0018314577
one O 0 0.0014317137
of O 0 0.0016188186
these O 0 0.001894457
patients O 0 0.003809507
was O 0 0.0018327554
not O 0 0.0018663523
in O 0 0.0023881623
the O 0 0.003840949
toxic O 0 0.8343343
range O 0 0.015693171
. O 0 0.010471531

Possible O 0 0.036937673
risk O 0 0.034993976
factors O 0 0.0094508
for O 0 0.002778662
the O 0 0.0024531211
development O 0 0.0036720957
of O 0 0.0041078553
hepatotoxicity B-Disease 2 0.9999858
in O 0 0.002086399
patients O 0 0.0058895666
treated O 0 0.0017793042
with O 0 0.0016133637
therapeutic O 0 0.036027562
doses O 0 0.10875991
of O 0 0.008635519
paracetamol B-Chemical 1 0.9999517
are O 0 0.00673221
discussed O 0 0.0061436393
. O 0 0.00887071

CONCLUSION O 0 0.6699912
: O 0 0.008834328
In O 0 0.0039451034
patients O 0 0.004804698
with O 0 0.0027011517
risk O 0 0.04144813
factors O 0 0.013291435
, O 0 0.0024158212
e O 0 0.0029545422
. O 0 0.0007778688
g O 0 0.0013772281
. O 0 0.0005232164
regular O 0 0.0007228432
consumption O 0 0.02273314
of O 0 0.0015450513
alcohol B-Chemical 1 0.99981886
, O 0 0.004595683
liver B-Disease 0 0.9444309
failure I-Disease 0 0.7136272
is O 0 0.0011538536
possible O 0 0.0011560506
when O 0 0.0011439457
therapeutic O 0 0.023961026
doses O 0 0.097074464
are O 0 0.0058173114
ingested O 0 0.21899983
. O 0 0.009686358

We O 0 0.00684228
propose O 0 0.00410588
that O 0 0.002964607
the O 0 0.002946985
paracetamol B-Chemical 1 0.9998853
dose O 0 0.030705065
should O 0 0.0007821666
not O 0 0.00074394816
exceed O 0 0.00063432433
2 O 0 0.00059453433
g O 0 0.0009031029
/ O 0 0.0009330698
day O 0 0.000372675
in O 0 0.0003647552
such O 0 0.00043258135
patients O 0 0.0013094123
and O 0 0.00057516707
that O 0 0.00042006254
their O 0 0.00069857185
liver O 0 0.73200136
function O 0 0.00087034714
should O 0 0.00043098413
be O 0 0.00063528406
monitored O 0 0.00046889207
closely O 0 0.0008558908
while O 0 0.0012198142
being O 0 0.0025604467
treated O 0 0.003809507
with O 0 0.00845807
paracetamol B-Chemical 1 0.9999114
. O 0 0.010919014

Associations O 0 0.011178701
between O 0 0.0038304795
use O 0 0.003579408
of O 0 0.0037260002
benzodiazepines B-Chemical 1 0.9997893
or O 0 0.0021265573
related O 0 0.0011827055
drugs O 0 0.7157165
and O 0 0.0017412772
health O 0 0.025616586
, O 0 0.0014153677
physical O 0 0.016556166
abilities O 0 0.0057711913
and O 0 0.0010961883
cognitive O 0 0.6881726
function O 0 0.0010560286
: O 0 0.0012429252
a O 0 0.0010322925
non O 0 0.0024064835
- O 0 0.0019832482
randomised O 0 0.0017164038
clinical O 0 0.0035004984
study O 0 0.002270906
in O 0 0.0024840366
the O 0 0.0043135816
elderly O 0 0.5480258
. O 0 0.008848317

OBJECTIVE O 0 0.39749113
: O 0 0.0073018
To O 0 0.0029655725
describe O 0 0.0021554108
associations O 0 0.0016064888
between O 0 0.0009735697
the O 0 0.0010547136
use O 0 0.0010698661
of O 0 0.0015057779
benzodiazepines B-Chemical 1 0.9999281
or O 0 0.0010299442
related O 0 0.00071205705
drugs O 0 0.8997071
( O 0 0.006011802
BZDs B-Chemical 1 0.9999405
/ O 0 0.0058106664
RDs O 0 0.03687736
) O 0 0.0011669387
and O 0 0.0007406323
health O 0 0.0037204889
, O 0 0.00096220156
functional O 0 0.0009797848
abilities O 0 0.0035874746
and O 0 0.0017413466
cognitive O 0 0.6066861
function O 0 0.0023934587
in O 0 0.002673513
the O 0 0.0044729197
elderly O 0 0.6134309
. O 0 0.008742932

METHODS O 0 0.011929604
: O 0 0.009360036
A O 0 0.016048908
non O 0 0.0067226263
- O 0 0.004276817
randomised O 0 0.002375584
clinical O 0 0.0028988738
study O 0 0.0013348954
of O 0 0.0011747311
patients O 0 0.002277386
aged O 0 0.0020467297
> O 0 0.0013864883
or O 0 0.00076476193
= O 0 0.0010337634
65 O 0 0.00082306564
years O 0 0.0008870921
admitted O 0 0.0016861334
to O 0 0.0010373238
acute O 0 0.775886
hospital O 0 0.009227147
wards O 0 0.0040610074
during O 0 0.0022573876
1 O 0 0.00419044
month O 0 0.0045260657
. O 0 0.0074262246

164 O 0 0.020125741
patients O 0 0.010264678
( O 0 0.0055198963
mean O 0 0.0030712148
age O 0 0.004898144
+ O 0 0.0029050836
/ O 0 0.0042152354
- O 0 0.002004117
standard O 0 0.0011767807
deviation O 0 0.0045563965
[ O 0 0.003444869
SD O 0 0.39745474
] O 0 0.0018964778
81 O 0 0.0015219548
. O 0 0.0005402147
6 O 0 0.00056870794
+ O 0 0.0008581218
/ O 0 0.001825524
- O 0 0.0013352017
6 O 0 0.0007748677
. O 0 0.0008671819
8 O 0 0.001319345
years O 0 0.0024157981
) O 0 0.0038868664
were O 0 0.0039876546
admitted O 0 0.01148226
. O 0 0.008037464

Of O 0 0.010473879
these O 0 0.0064048623
, O 0 0.0046298453
nearly O 0 0.002657934
half O 0 0.0017494813
( O 0 0.002002788
n O 0 0.0014892181
= O 0 0.0015232024
78 O 0 0.001654521
) O 0 0.0011500042
had O 0 0.00059109787
used O 0 0.00073681993
BZDs B-Chemical 1 0.9998123
/ O 0 0.002151543
RDs O 0 0.004323259
before O 0 0.0003181378
admission O 0 0.0024825695
, O 0 0.0006631554
and O 0 0.0005462213
the O 0 0.0005395154
remainder O 0 0.0009540487
( O 0 0.00106223
n O 0 0.0009851811
= O 0 0.0013785094
86 O 0 0.0019111488
) O 0 0.0020826077
were O 0 0.0018768553
non O 0 0.004698606
- O 0 0.0068535437
users O 0 0.01764476
. O 0 0.007857528

Cognitive O 0 0.5948662
ability O 0 0.009218124
was O 0 0.006587181
assessed O 0 0.0047228723
by O 0 0.0053370474
the O 0 0.005261249
Mini O 0 0.039109763
- O 0 0.0076849777
Mental O 0 0.08374424
State O 0 0.0103283515
Examination O 0 0.006698788
( O 0 0.008276176
MMSE O 0 0.9481794
) O 0 0.0128482785
. O 0 0.010916188

Patients O 0 0.015852137
scoring O 0 0.012519486
> O 0 0.006185376
or O 0 0.0030703011
= O 0 0.002979834
20 O 0 0.0018064772
MMSE O 0 0.6179408
sum O 0 0.0010516925
points O 0 0.0009900102
were O 0 0.0007521366
interviewed O 0 0.0014416331
( O 0 0.00083532743
n O 0 0.00067726197
= O 0 0.0007778184
79 O 0 0.00089256576
) O 0 0.00074124016
and O 0 0.0004851868
questioned O 0 0.0006076078
regarding O 0 0.00047430577
symptoms O 0 0.49111602
and O 0 0.00095088314
functional O 0 0.0011215237
abilities O 0 0.0028956006
during O 0 0.00078168116
the O 0 0.0011581461
week O 0 0.001250531
prior O 0 0.0016067144
to O 0 0.0032120065
admission O 0 0.034184504
. O 0 0.007892574

Data O 0 0.0134343915
on O 0 0.004906453
use O 0 0.004429465
of O 0 0.0048945616
BZDs B-Chemical 1 0.9997309
/ O 0 0.008772239
RDs O 0 0.009626453
before O 0 0.0008208772
admission O 0 0.00396972
, O 0 0.0012080433
current O 0 0.0014018707
medications O 0 0.1615058
and O 0 0.0013704767
discharge O 0 0.007885438
diagnoses O 0 0.008604114
were O 0 0.0018159774
collected O 0 0.0019282043
from O 0 0.0030724003
medical O 0 0.016835053
records O 0 0.010142095
. O 0 0.008337745

Health O 0 0.016019428
, O 0 0.008145978
physical O 0 0.014229173
abilities O 0 0.008788051
and O 0 0.0031818738
cognitive O 0 0.6060015
function O 0 0.0016085835
were O 0 0.0009696656
compared O 0 0.0005555072
between O 0 0.0006530116
BZD O 0 0.9996551
/ O 0 0.01535613
RD O 0 0.9758195
users O 0 0.0075520035
and O 0 0.00087398826
non O 0 0.0027649647
- O 0 0.0021317392
users O 0 0.0056005795
, O 0 0.0011216888
and O 0 0.00097527984
adjustments O 0 0.001292307
were O 0 0.0011928015
made O 0 0.0014087798
for O 0 0.001761493
confounding O 0 0.0052215173
variables O 0 0.009122353
. O 0 0.007959358

The O 0 0.0101763755
residual O 0 0.009254668
serum O 0 0.059507668
concentrations O 0 0.010769307
of O 0 0.011761946
oxazepam B-Chemical 0 0.9999825
, O 0 0.0612946
temazepam B-Chemical 0 0.9999771
and O 0 0.019515403
zopiclone B-Chemical 0 0.99992883
were O 0 0.008861592
analysed O 0 0.009679368
. O 0 0.011152608

RESULTS O 0 0.023742894
: O 0 0.007926905
The O 0 0.0038354832
mean O 0 0.003359055
+ O 0 0.00353696
/ O 0 0.0051439623
- O 0 0.0029750962
SD O 0 0.07694671
duration O 0 0.0013712555
of O 0 0.0018218401
BZD O 0 0.99972934
/ O 0 0.01842293
RD O 0 0.96331406
use O 0 0.0009909978
was O 0 0.0007896834
7 O 0 0.000782265
+ O 0 0.0009772895
/ O 0 0.0020631608
- O 0 0.0013552951
7 O 0 0.0008739279
years O 0 0.001400191
( O 0 0.0017408775
range O 0 0.0022394604
1 O 0 0.0026039788
- O 0 0.0041220463
31 O 0 0.0055175624
) O 0 0.0078296345
. O 0 0.0074236593

Two O 0 0.009694569
or O 0 0.005984226
three O 0 0.0041278126
BZDs B-Chemical 1 0.9994265
/ O 0 0.00900145
RDs O 0 0.0124198655
were O 0 0.0014579277
concomitantly O 0 0.0024615757
taken O 0 0.0009001318
by O 0 0.0011189192
26 O 0 0.0013285517
% O 0 0.001181425
of O 0 0.0013193507
users O 0 0.00555256
( O 0 0.0024916383
n O 0 0.002553918
= O 0 0.003820427
20 O 0 0.0040078335
) O 0 0.007720659
. O 0 0.0073776823

Long O 0 0.035507992
- O 0 0.00820712
term O 0 0.0036393863
use O 0 0.0027287104
of O 0 0.0022112853
these O 0 0.002023787
drugs O 0 0.6472051
was O 0 0.0013171409
associated O 0 0.0011225038
with O 0 0.00092440663
female O 0 0.008937258
sex O 0 0.046090078
and O 0 0.0007165082
use O 0 0.00055982906
of O 0 0.00057295983
a O 0 0.00064255536
higher O 0 0.00037998703
number O 0 0.0003828457
of O 0 0.00063673255
drugs O 0 0.5361737
with O 0 0.00063899736
effects O 0 0.0010817447
on O 0 0.00041893503
the O 0 0.0008221908
CNS O 0 0.91726875
, O 0 0.0013574703
which O 0 0.0010881315
tended O 0 0.0009479621
to O 0 0.0010346659
be O 0 0.0014914192
related O 0 0.0015817696
to O 0 0.0030861192
diagnosed O 0 0.3478381
dementia B-Disease 2 0.9993863
. O 0 0.011365293

After O 0 0.0057177194
adjustment O 0 0.0047438964
for O 0 0.0024233216
these O 0 0.0022340582
variables O 0 0.0024988875
as O 0 0.001437745
confounders O 0 0.0029177135
, O 0 0.0012407854
use O 0 0.00087846164
of O 0 0.0014735324
BZDs B-Chemical 1 0.99994016
/ O 0 0.0066679297
RDs O 0 0.019757465
was O 0 0.00060120097
not O 0 0.0005596675
associated O 0 0.0008259781
with O 0 0.0011430244
cognitive O 0 0.61387044
function O 0 0.0015008735
as O 0 0.001599022
measured O 0 0.0016411999
by O 0 0.0033145943
the O 0 0.0050941426
MMSE O 0 0.98086435
. O 0 0.008014283

However O 0 0.009320891
, O 0 0.006630121
use O 0 0.0039996305
of O 0 0.004474723
BZDs B-Chemical 1 0.9998241
/ O 0 0.01546963
RDs O 0 0.029721746
was O 0 0.0010279239
associated O 0 0.0010665983
with O 0 0.0015040209
dizziness B-Disease 2 0.99997985
, O 0 0.0016734733
inability B-Disease 0 0.0009841806
to I-Disease 0 0.00050317636
sleep I-Disease 0 0.37766495
after O 0 0.00031740408
awaking O 0 0.36547488
at O 0 0.00033084874
night O 0 0.0008144734
and O 0 0.00066361914
tiredness B-Disease 0 0.9980167
in O 0 0.00042929398
the O 0 0.0004549534
mornings O 0 0.07598173
during O 0 0.00026054788
the O 0 0.000309918
week O 0 0.00025067938
prior O 0 0.00023437211
to O 0 0.00034728606
admission O 0 0.0034880354
and O 0 0.0006077546
with O 0 0.0007355059
stronger O 0 0.002148704
depressive B-Disease 2 0.9999933
symptoms I-Disease 0 0.9853231
measured O 0 0.0007780542
at O 0 0.0007104093
the O 0 0.0009232589
beginning O 0 0.0010138478
of O 0 0.0019017758
the O 0 0.0027348502
hospital O 0 0.010334165
stay O 0 0.008927385
. O 0 0.008744793

Use O 0 0.016540932
of O 0 0.009852679
BZDs B-Chemical 1 0.99956876
/ O 0 0.01747826
RDs O 0 0.022424042
tended O 0 0.0016361705
to O 0 0.0011297432
be O 0 0.0010365443
associated O 0 0.0009789804
with O 0 0.00085850985
a O 0 0.0010623125
reduced O 0 0.00072192866
ability O 0 0.0006413904
to O 0 0.00060380466
walk O 0 0.0056720455
and O 0 0.00066906185
shorter O 0 0.00049953244
night O 0 0.0013613856
- O 0 0.0010705527
time O 0 0.0006026872
sleep O 0 0.030420769
during O 0 0.0007533194
the O 0 0.0011278103
week O 0 0.0012529017
prior O 0 0.0016271492
to O 0 0.003242158
admission O 0 0.03263739
. O 0 0.0079827905

A O 0 0.030248277
higher O 0 0.00610717
residual O 0 0.00533661
serum O 0 0.05520458
concentration O 0 0.0050088153
of O 0 0.00416178
temazepam B-Chemical 0 0.9999862
correlated O 0 0.0015817983
with O 0 0.0013656579
a O 0 0.0015974346
lower O 0 0.0013783828
MMSE O 0 0.9246586
sum O 0 0.0010987122
score O 0 0.0013557179
after O 0 0.00091363344
adjustment O 0 0.0019619484
for O 0 0.0018945416
confounding O 0 0.0057085264
variables O 0 0.009888755
. O 0 0.008311234

CONCLUSIONS O 0 0.58889395
: O 0 0.012069632
Long O 0 0.019568412
- O 0 0.0048451447
term O 0 0.002256925
use O 0 0.0019188739
and O 0 0.001583082
concomitant O 0 0.0024191835
use O 0 0.0011226904
of O 0 0.0010444139
more O 0 0.0009445124
than O 0 0.00056406826
one O 0 0.0007961452
BZD O 0 0.99956506
/ O 0 0.0109189525
RD O 0 0.9600621
were O 0 0.0008217718
common O 0 0.0010326983
in O 0 0.00094724033
elderly O 0 0.29187018
patients O 0 0.005510058
hospitalised O 0 0.36476684
because O 0 0.0018261148
of O 0 0.004929481
acute O 0 0.99270415
illnesses O 0 0.99467635
. O 0 0.013494663

Long O 0 0.03954954
- O 0 0.008700686
term O 0 0.0039633806
use O 0 0.0031854967
was O 0 0.002255392
associated O 0 0.0018890117
with O 0 0.0015767758
daytime O 0 0.060777377
and O 0 0.0012490888
night O 0 0.0022779254
- O 0 0.0012315342
time O 0 0.0005291311
symptoms O 0 0.3141599
indicative O 0 0.00064835505
of O 0 0.00094626757
poorer O 0 0.003554746
health O 0 0.007215405
and O 0 0.0008535128
potentially O 0 0.001640571
caused O 0 0.0011062567
by O 0 0.0012301514
the O 0 0.001250557
adverse O 0 0.85997146
effects O 0 0.0040592393
of O 0 0.0036406266
these O 0 0.0066428236
drugs O 0 0.91465926
. O 0 0.00958257

Acute O 0 0.94734913
vocal B-Disease 0 0.4543776
fold I-Disease 0 0.04276973
palsy I-Disease 0 0.999421
after O 0 0.012839537
acute O 0 0.99555176
disulfiram B-Chemical 1 0.999948
intoxication O 0 0.99964106
. O 0 0.036675025

Acute O 0 0.9864044
peripheral B-Disease 2 0.9232904
neuropathy I-Disease 2 0.9999112
caused O 0 0.010714168
by O 0 0.0042779283
a O 0 0.0074158213
disulfiram B-Chemical 1 0.9999888
overdose B-Disease 2 0.9999769
is O 0 0.0017409987
very O 0 0.0013167307
rare O 0 0.0075991172
and O 0 0.0009887052
there O 0 0.0005270314
is O 0 0.0006424819
no O 0 0.00057848636
report O 0 0.0018946578
of O 0 0.0014740089
it O 0 0.0017664083
leading O 0 0.0028707653
to O 0 0.0026252188
vocal B-Disease 0 0.46430215
fold I-Disease 0 0.050150268
palsy I-Disease 0 0.9998098
. O 0 0.011658729

A O 0 0.041845962
49 O 0 0.0116573
- O 0 0.007021576
year O 0 0.0036421332
- O 0 0.0033123703
old O 0 0.0021145018
woman O 0 0.0065423045
was O 0 0.00124162
transferred O 0 0.00095780025
to O 0 0.0007069265
our O 0 0.00061508006
department O 0 0.0011416308
because O 0 0.0006219172
of O 0 0.0020445455
quadriparesis B-Disease 0 0.9999809
, O 0 0.01596739
lancinating O 0 0.9998599
pain B-Disease 2 0.99972373
, O 0 0.0043583396
sensory B-Disease 0 0.6542619
loss I-Disease 0 0.02219595
, O 0 0.0023174514
and O 0 0.0024443516
paresthesia B-Disease 0 0.9994679
of O 0 0.0032547538
the O 0 0.0035202054
distal O 0 0.006882705
limbs O 0 0.4524191
. O 0 0.009529333

One O 0 0.0102689555
month O 0 0.0046900134
previously O 0 0.0036023774
, O 0 0.0031696982
she O 0 0.0018328567
had O 0 0.0012047808
taken O 0 0.0008600713
a O 0 0.0010473651
single O 0 0.00084759085
high O 0 0.00090906024
dose O 0 0.008353203
of O 0 0.0023733906
disulfiram B-Chemical 1 0.99999213
( O 0 0.0051982775
130 O 0 0.004612886
tablets O 0 0.8213125
of O 0 0.0015573575
ALCOHOL B-Chemical 0 0.9746012
STOP O 0 0.41304374
TAB O 0 0.8669815
, O 0 0.0024466643
Shin O 0 0.69589144
- O 0 0.008125166
Poong O 0 0.99762636
Pharm O 0 0.98902214
. O 0 0.0012250703
Co O 0 0.99843234
. O 0 0.0009859989
, O 0 0.0019026143
Ansan O 0 0.7334358
, O 0 0.0021782657
Korea O 0 0.0076597254
) O 0 0.002956522
in O 0 0.0021749008
a O 0 0.0047351485
suicide O 0 0.9239215
attempt O 0 0.00820322
. O 0 0.009148095

She O 0 0.048096094
was O 0 0.032729547
not O 0 0.030578587
an O 0 0.04449568
alcoholic O 0 0.9950093
. O 0 0.052521184

For O 0 0.006267202
the O 0 0.0043477886
first O 0 0.0025917308
few O 0 0.001705876
days O 0 0.0014157911
after O 0 0.0010703631
ingestion O 0 0.28650627
, O 0 0.0019917984
she O 0 0.001120443
was O 0 0.0008960095
in O 0 0.0007943787
a O 0 0.001277116
confused O 0 0.004112055
state O 0 0.0014324731
and O 0 0.0013173937
had O 0 0.0014042993
mild O 0 0.3737041
to O 0 0.002457314
moderate O 0 0.2613715
ataxia B-Disease 2 0.9999174
and O 0 0.067726366
giddiness B-Disease 0 0.999912
. O 0 0.01437422

She O 0 0.013416711
noticed O 0 0.009185333
hoarseness B-Disease 2 0.9959125
and O 0 0.00608947
distally O 0 0.0073535317
accentuated O 0 0.014996861
motor O 0 0.097869985
and O 0 0.002710157
sensory O 0 0.18347213
dysfunction O 0 0.87739253
after O 0 0.0012194396
she O 0 0.0017481867
had O 0 0.0017384944
recovered O 0 0.0021752748
from O 0 0.00323433
this O 0 0.004367859
state O 0 0.008886987
. O 0 0.009238732

A O 0 0.06702318
nerve O 0 0.36771858
conduction O 0 0.085345395
study O 0 0.0073045096
was O 0 0.005168704
consistent O 0 0.004395991
with O 0 0.005937817
severe O 0 0.6105385
sensorimotor O 0 0.94311285
axonal O 0 0.9546889
polyneuropathy B-Disease 2 0.99979776
. O 0 0.020998895

Laryngeal O 0 0.4508814
electromyography O 0 0.81255466
( O 0 0.016703326
thyroarytenoid O 0 0.076873995
muscle O 0 0.05251433
) O 0 0.011521381
showed O 0 0.007395453
ample O 0 0.015099189
denervation O 0 0.9731119
potentials O 0 0.48947722
. O 0 0.017712854

Laryngoscopy O 0 0.04666709
revealed O 0 0.01597027
asymmetric O 0 0.019007035
vocal O 0 0.117850244
fold O 0 0.018639665
movements O 0 0.02213583
during O 0 0.012814047
phonation O 0 0.32119885
. O 0 0.020906486

Her O 0 0.018999461
vocal O 0 0.060734954
change O 0 0.0063417754
and O 0 0.0054876264
weakness O 2 0.9384171
began O 0 0.003488357
to O 0 0.0021627469
improve O 0 0.0017329174
spontaneously O 0 0.005139811
about O 0 0.0020304702
3 O 0 0.002354048
weeks O 0 0.0022567348
after O 0 0.002903442
transfer O 0 0.0075261234
. O 0 0.008916337

This O 0 0.010249423
was O 0 0.0052430555
a O 0 0.004194471
case O 0 0.002816119
of O 0 0.003191621
acute O 0 0.9754508
palsy B-Disease 0 0.999956
of O 0 0.0025509864
the O 0 0.001313448
recurrent O 0 0.76924247
laryngeal O 0 0.95520407
nerve O 0 0.80814445
and O 0 0.0012266815
superimposed O 0 0.009705964
severe O 0 0.56264716
acute O 0 0.99213
sensorimotor O 0 0.95801955
axonal O 0 0.8866159
polyneuropathy B-Disease 2 0.99995863
caused O 0 0.0038250796
by O 0 0.0025716226
high O 0 0.0033886654
- O 0 0.008377498
dose O 0 0.3199907
disulfiram B-Chemical 1 0.99997485
intoxication O 0 0.9997353
. O 0 0.01647505

Encephalopathy B-Disease 0 0.9967691
induced O 0 0.024878083
by O 0 0.024519272
levetiracetam B-Chemical 1 0.99960786
added O 0 0.022598729
to O 0 0.022296825
valproate B-Chemical 0 0.99976593
. O 0 0.025981443

BACKGROUND O 0 0.5122833
: O 0 0.009768809
We O 0 0.004724105
report O 0 0.0047551687
on O 0 0.002233814
the O 0 0.0023320895
manifestation O 0 0.045884192
of O 0 0.0032534732
a O 0 0.0069788042
levetiracetam B-Chemical 1 0.9999672
( O 0 0.038248934
LEV B-Chemical 0 0.9997825
) O 0 0.015145407
- O 0 0.008780122
induced O 0 0.010434126
encephalopathy B-Disease 2 0.99983203
. O 0 0.015160131

FINDINGS O 0 0.10780641
: O 0 0.010695685
A O 0 0.018819062
28 O 0 0.004820087
- O 0 0.003995852
year O 0 0.0022218123
- O 0 0.0023173874
old O 0 0.0016814059
man O 0 0.10625638
suffering O 0 0.9352171
from O 0 0.0030505033
idiopathic B-Disease 2 0.99972767
epilepsy I-Disease 2 0.9999945
with O 0 0.012198982
generalized O 0 0.986094
seizures B-Disease 2 0.9999974
was O 0 0.001466922
treated O 0 0.0012490561
with O 0 0.0013514328
LEV B-Chemical 0 0.9998784
( O 0 0.001640184
3000 O 0 0.0027082518
mg O 0 0.2263558
) O 0 0.0013234685
added O 0 0.00083095435
to O 0 0.0012572242
valproate B-Chemical 0 0.9999825
( O 0 0.028556393
VPA B-Chemical 1 0.99997675
) O 0 0.011354447
( O 0 0.0046681543
2000 O 0 0.007691155
mg O 0 0.4316471
) O 0 0.0100525245
. O 0 0.007837039

Frequency O 0 0.018036922
of O 0 0.008224078
generalized O 0 0.30241394
tonic B-Disease 0 0.983496
- I-Disease 0 0.10855186
clonic I-Disease 0 0.999974
seizures I-Disease 2 0.99998784
increased O 0 0.003603355
from O 0 0.0013876205
one O 0 0.0009528842
per O 0 0.000814118
6 O 0 0.00097006524
months O 0 0.0010130098
to O 0 0.0014025597
two O 0 0.0019879094
per O 0 0.0027132325
month O 0 0.0047304095
. O 0 0.0076825856

Neuropsychological O 0 0.29428965
testing O 0 0.008463399
showed O 0 0.00581532
impaired B-Disease 0 0.006370765
word I-Disease 0 0.00932256
fluency I-Disease 0 0.86546725
, I-Disease 0 0.007994716
psychomotor I-Disease 0 0.98793334
speed I-Disease 0 0.007081543
and I-Disease 0 0.0066449987
working I-Disease 0 0.012195304
memory I-Disease 0 0.28456438
. O 0 0.012447653

The O 0 0.0089559825
interictal O 0 0.9476197
electroencephalogram O 0 0.8952813
( O 0 0.0075411964
EEG O 0 0.9037518
) O 0 0.0035371112
showed O 0 0.0012646387
a O 0 0.0015808097
generalized O 0 0.035703316
slowing O 0 0.014465007
to O 0 0.0007344364
5 O 0 0.00057758036
per O 0 0.0004448099
second O 0 0.0007451089
theta O 0 0.053672157
rhythms O 0 0.0055205096
with O 0 0.0012815977
bilateral O 0 0.073840074
generalized O 0 0.1659268
high O 0 0.0044988943
- O 0 0.0077464487
amplitude O 0 0.033140037
discharges O 0 0.7697867
. O 0 0.009288079

OUTCOME O 0 0.04237321
: O 0 0.008552187
Following O 0 0.004797894
discontinuation O 0 0.2863793
of O 0 0.0049075778
LEV B-Chemical 0 0.99949
, O 0 0.00464586
EEG O 0 0.89112854
and O 0 0.002657469
neuropsychological O 0 0.47276896
findings O 0 0.003944777
improved O 0 0.0041895187
and O 0 0.004910217
seizure B-Disease 2 0.99956626
frequency O 0 0.0098182885
decreased O 0 0.0133957155
. O 0 0.01056457

Norepinephrine B-Chemical 0 0.9995136
signaling O 0 0.013346041
through O 0 0.0056427615
beta O 0 0.69487065
- O 0 0.011341209
adrenergic O 0 0.9973537
receptors O 0 0.2147553
is O 0 0.0018917198
critical O 0 0.0013890635
for O 0 0.0012478437
expression O 0 0.0023220133
of O 0 0.004939757
cocaine B-Chemical 1 0.99992466
- O 0 0.03242754
induced O 0 0.011981781
anxiety B-Disease 0 0.9988463
. O 0 0.012356054

BACKGROUND O 0 0.8372266
: O 0 0.024479602
Cocaine B-Chemical 1 0.99977714
is O 0 0.0057135737
a O 0 0.004867034
widely O 0 0.0052745994
abused O 0 0.9612058
psychostimulant O 0 0.99925977
that O 0 0.002525768
has O 0 0.0022471135
both O 0 0.0030584491
rewarding O 0 0.45344797
and O 0 0.0063619395
aversive O 0 0.76683044
properties O 0 0.016679704
. O 0 0.011538641

While O 0 0.0074469345
the O 0 0.004891455
mechanisms O 0 0.0046096747
underlying O 0 0.0065865326
cocaine B-Chemical 1 0.99985063
' O 0 0.004113663
s O 0 0.0020929181
rewarding O 0 0.22969395
effects O 0 0.0018708657
have O 0 0.0007553383
been O 0 0.0007752536
studied O 0 0.00075067976
extensively O 0 0.0010578724
, O 0 0.00088521006
less O 0 0.0005154548
attention O 0 0.0011042925
has O 0 0.00046001025
been O 0 0.0005657705
paid O 0 0.0009548363
to O 0 0.00046883346
the O 0 0.00065668824
unpleasant O 0 0.60876054
behavioral O 0 0.083120525
states O 0 0.0027859663
induced O 0 0.0016105666
by O 0 0.0031849095
cocaine B-Chemical 1 0.9999118
, O 0 0.0039916164
such O 0 0.0031044912
as O 0 0.0065105185
anxiety B-Disease 0 0.9981427
. O 0 0.010012824

METHODS O 0 0.010593479
: O 0 0.0072633135
In O 0 0.0034846854
this O 0 0.0026674885
study O 0 0.0023818621
, O 0 0.0017706293
we O 0 0.00079965946
evaluated O 0 0.0007579105
the O 0 0.00077688205
performance O 0 0.001267794
of O 0 0.0017646435
dopamine B-Chemical 1 0.99993205
beta O 0 0.9567034
- O 0 0.021414995
hydroxylase O 0 0.99344313
knockout O 0 0.0014546445
( O 0 0.0018355822
Dbh O 0 0.18839352
- O 0 0.0014585574
/ O 0 0.0029029094
- O 0 0.001168727
) O 0 0.0007900749
mice O 0 0.00032372432
, O 0 0.0005966296
which O 0 0.0005730319
lack O 0 0.00072725705
norepinephrine B-Chemical 1 0.99997544
( O 0 0.005864143
NE B-Chemical 0 0.9995648
) O 0 0.0020849383
, O 0 0.0006103308
in O 0 0.00033063276
the O 0 0.0003825766
elevated O 0 0.0011916034
plus O 0 0.0005537201
maze O 0 0.07651822
( O 0 0.0015196189
EPM O 0 0.90799683
) O 0 0.000942321
to O 0 0.00035931283
examine O 0 0.00027558111
the O 0 0.00049478596
contribution O 0 0.0005165211
of O 0 0.0015723372
noradrenergic O 0 0.9976017
signaling O 0 0.0033495303
to O 0 0.0026125717
cocaine B-Chemical 1 0.99992204
- O 0 0.021620981
induced O 0 0.009596374
anxiety B-Disease 0 0.9988298
. O 0 0.010965589

RESULTS O 0 0.025660284
: O 0 0.007987942
We O 0 0.0038223714
found O 0 0.0024146629
that O 0 0.0021870928
cocaine B-Chemical 1 0.99979883
dose O 0 0.31720614
- O 0 0.017493725
dependently O 0 0.96921194
increased O 0 0.007282156
anxiety B-Disease 0 0.99974066
- O 0 0.0031802745
like O 0 0.0006805556
behavior O 0 0.0027096544
in O 0 0.00054496696
control O 0 0.0007222524
( O 0 0.001449372
Dbh O 0 0.11495728
+ O 0 0.00091857684
/ O 0 0.003112192
- O 0 0.0013341485
) O 0 0.00096787355
mice O 0 0.00043496685
, O 0 0.00077256176
as O 0 0.0006078971
measured O 0 0.0005769751
by O 0 0.0010094171
a O 0 0.0014647348
decrease O 0 0.001355756
in O 0 0.0017701118
open O 0 0.002781495
arm O 0 0.005563028
exploration O 0 0.008077025
. O 0 0.008032253

The O 0 0.0099732075
Dbh O 0 0.15312268
- O 0 0.008428059
/ O 0 0.0072496734
- O 0 0.0033252977
mice O 0 0.0012954553
had O 0 0.0011338043
normal O 0 0.0015230073
baseline O 0 0.0010276381
performance O 0 0.0010855172
in O 0 0.0007094641
the O 0 0.0009596784
EPM O 0 0.8850791
but O 0 0.00089862704
were O 0 0.0008599881
completely O 0 0.00093369395
resistant O 0 0.0011824854
to O 0 0.0010846396
the O 0 0.0018038427
anxiogenic O 0 0.9967933
effects O 0 0.012268807
of O 0 0.018549899
cocaine B-Chemical 1 0.999843
. O 0 0.011888991

Cocaine B-Chemical 1 0.99982953
- O 0 0.025493301
induced O 0 0.007533164
anxiety B-Disease 0 0.99767417
was O 0 0.002835765
also O 0 0.0018990139
attenuated O 0 0.0025922982
in O 0 0.0014461217
Dbh O 0 0.25851804
+ O 0 0.001528758
/ O 0 0.0034827853
- O 0 0.0010680793
mice O 0 0.00038487502
following O 0 0.00053009583
administration O 0 0.03577868
of O 0 0.0023142826
disulfiram B-Chemical 1 0.9999925
, O 0 0.005713225
a O 0 0.00559321
dopamine B-Chemical 1 0.9998927
beta O 0 0.917164
- O 0 0.037025604
hydroxylase O 0 0.9962161
( O 0 0.012553235
DBH O 0 0.98176277
) O 0 0.010742365
inhibitor O 0 0.140304
. O 0 0.0094522135

In O 0 0.0071601644
experiments O 0 0.004778011
using O 0 0.0034550335
specific O 0 0.0028538217
adrenergic O 0 0.99803036
antagonists O 0 0.98797977
, O 0 0.0023873693
we O 0 0.00063234323
found O 0 0.0005578663
that O 0 0.00054190215
pretreatment O 0 0.06547764
with O 0 0.0008419761
the O 0 0.0009612788
beta O 0 0.88482916
- O 0 0.01672701
adrenergic O 0 0.9994424
receptor O 0 0.67302215
antagonist O 0 0.99823666
propranolol B-Chemical 1 0.999998
blocked O 0 0.082154326
cocaine B-Chemical 1 0.9999906
- O 0 0.017042728
induced O 0 0.0020241223
anxiety B-Disease 0 0.99974436
- O 0 0.0022218048
like O 0 0.0005050445
behavior O 0 0.003338874
in O 0 0.0005801014
Dbh O 0 0.18277822
+ O 0 0.0008399904
/ O 0 0.0029227147
- O 0 0.00091240194
and O 0 0.0005090488
wild O 0 0.0005195975
- O 0 0.0009699063
type O 0 0.0005791871
C57BL6 O 0 0.06754182
/ O 0 0.0053433417
J O 0 0.73014617
mice O 0 0.00043270903
, O 0 0.0006472412
while O 0 0.0003837384
the O 0 0.0005162897
alpha O 0 0.24854614
( O 0 0.0014873856
1 O 0 0.00080977916
) O 0 0.0017991944
antagonist O 0 0.9643867
prazosin B-Chemical 1 0.99999404
and O 0 0.001300258
the O 0 0.00097043766
alpha O 0 0.3245643
( O 0 0.0021619764
2 O 0 0.001364985
) O 0 0.0037829515
antagonist O 0 0.98204666
yohimbine B-Chemical 1 0.999984
had O 0 0.003473986
no O 0 0.0031841618
effect O 0 0.0059962473
. O 0 0.008206425

CONCLUSIONS O 0 0.39513925
: O 0 0.008529874
These O 0 0.004528146
results O 0 0.0030491436
indicate O 0 0.0020437615
that O 0 0.0019240003
noradrenergic O 0 0.995002
signaling O 0 0.0035390512
via O 0 0.0016543816
beta O 0 0.8066452
- O 0 0.009268162
adrenergic O 0 0.9979869
receptors O 0 0.13474777
is O 0 0.0009771675
required O 0 0.00059554353
for O 0 0.0011609023
cocaine B-Chemical 1 0.9999143
- O 0 0.008341173
induced O 0 0.0042877477
anxiety B-Disease 0 0.9984097
in O 0 0.004857399
mice O 0 0.0054591373
. O 0 0.0086141145

Hypothalamic O 0 0.98262215
prolactin O 0 0.99760497
receptor O 0 0.8067079
messenger O 0 0.8140693
ribonucleic B-Chemical 0 0.99829334
acid I-Chemical 0 0.9977761
levels O 0 0.005548567
, O 0 0.007183789
prolactin O 0 0.997689
signaling O 0 0.0059912247
, O 0 0.0023081792
and O 0 0.0019111927
hyperprolactinemic B-Disease 0 0.9997602
inhibition O 0 0.007746332
of O 0 0.002284136
pulsatile O 0 0.64209914
luteinizing O 0 0.99925
hormone O 0 0.9977514
secretion O 0 0.15509596
are O 0 0.0034017377
dependent O 0 0.00316041
on O 0 0.0048827794
estradiol B-Chemical 1 0.9997404
. O 0 0.01247117

Hyperprolactinemia B-Disease 0 0.9973834
can O 0 0.029415777
reduce O 0 0.025053393
fertility O 0 0.27722475
and O 0 0.040683106
libido O 0 0.99604994
. O 0 0.037882708

Although O 0 0.0090420395
central O 0 0.01359779
prolactin O 0 0.9824982
actions O 0 0.056241885
are O 0 0.0033895192
thought O 0 0.002813113
to O 0 0.0016974541
contribute O 0 0.0014911762
to O 0 0.001447925
this O 0 0.0016555941
, O 0 0.0023693766
the O 0 0.001972488
mechanisms O 0 0.0035971142
are O 0 0.0043062684
poorly O 0 0.011334469
understood O 0 0.012992907
. O 0 0.009270925

We O 0 0.0070710136
first O 0 0.0040549836
tested O 0 0.002830109
whether O 0 0.0020104598
chronic O 0 0.9820993
hyperprolactinemia B-Disease 2 0.9999907
inhibited O 0 0.009844895
two O 0 0.0012773131
neuroendocrine O 0 0.9443945
parameters O 0 0.0017224597
necessary O 0 0.0004822428
for O 0 0.0005537537
female O 0 0.0068858014
fertility O 0 0.1362059
: O 0 0.0025886367
pulsatile O 0 0.30900344
LH O 0 0.9979226
secretion O 0 0.04620307
and O 0 0.0025185032
the O 0 0.0036248234
estrogen B-Chemical 1 0.9998648
- O 0 0.042103563
induced O 0 0.01433494
LH O 0 0.9986368
surge O 0 0.7966
. O 0 0.0114105735

Chronic O 0 0.99674255
hyperprolactinemia B-Disease 2 0.999926
induced O 0 0.012627767
by O 0 0.005161542
the O 0 0.004417667
dopamine B-Chemical 1 0.9999217
antagonist O 0 0.99906176
sulpiride B-Chemical 1 0.9999975
caused O 0 0.0033356687
a O 0 0.0016674226
40 O 0 0.00087757525
% O 0 0.00080368534
reduction O 0 0.0012234802
LH O 0 0.9861768
pulse O 0 0.004761663
frequency O 0 0.0007642403
in O 0 0.0006380116
ovariectomized O 0 0.66871196
rats O 0 0.0036450154
, O 0 0.0009531148
but O 0 0.0005420026
only O 0 0.0004986904
in O 0 0.0005521115
the O 0 0.0006845858
presence O 0 0.0008906067
of O 0 0.0020464172
chronic O 0 0.95109314
low O 0 0.005291885
levels O 0 0.00442709
of O 0 0.023133209
estradiol B-Chemical 1 0.9998435
. O 0 0.013801171

Sulpiride B-Chemical 0 0.9997495
did O 0 0.0069457255
not O 0 0.0037549357
affect O 0 0.0019983994
the O 0 0.0017141609
magnitude O 0 0.0013265092
of O 0 0.0018283468
a O 0 0.003902144
steroid B-Chemical 1 0.9996811
- O 0 0.02224835
induced O 0 0.003606383
LH O 0 0.9988526
surge O 0 0.37918124
or O 0 0.00095701485
the O 0 0.00083911594
percentage O 0 0.0007849988
of O 0 0.0021822483
GnRH O 0 0.9866144
neurons O 0 0.033564918
activated O 0 0.0030222265
during O 0 0.002495886
the O 0 0.0049978793
surge O 0 0.4530415
. O 0 0.009194524

Estradiol B-Chemical 0 0.9995345
is O 0 0.007435876
known O 0 0.004517656
to O 0 0.002417571
influence O 0 0.0015853235
expression O 0 0.001662742
of O 0 0.001412571
the O 0 0.0010554666
long O 0 0.0010254752
form O 0 0.0009968204
of O 0 0.0022183585
prolactin O 0 0.9992461
receptors O 0 0.74754643
( O 0 0.03266739
PRL O 0 0.99991226
- O 0 0.019928923
R O 0 0.9571844
) O 0 0.0023840184
and O 0 0.0011730074
components O 0 0.0013653146
of O 0 0.0025941704
prolactin O 0 0.9941824
' O 0 0.004534775
s O 0 0.004198421
signaling O 0 0.0063368822
pathway O 0 0.009209989
. O 0 0.009033784

To O 0 0.0064675454
test O 0 0.0052349092
the O 0 0.0034708637
hypothesis O 0 0.0032524203
that O 0 0.0027396765
estrogen B-Chemical 1 0.9998566
increases O 0 0.01989604
PRL O 0 0.9999471
- O 0 0.04875878
R O 0 0.96125686
expression O 0 0.0014743865
and O 0 0.0010246779
sensitivity O 0 0.0017845875
to O 0 0.00083455804
prolactin O 0 0.99376327
, O 0 0.0009519305
we O 0 0.0003670683
next O 0 0.000389995
demonstrated O 0 0.0006387916
that O 0 0.0010793591
estradiol B-Chemical 1 0.99994457
greatly O 0 0.09292734
augments O 0 0.22311524
prolactin O 0 0.9994616
- O 0 0.03299544
induced O 0 0.00848493
STAT5 O 0 0.95037675
activation O 0 0.021437591
. O 0 0.009991491

Lastly O 0 0.011376543
, O 0 0.0072847684
we O 0 0.003555361
measured O 0 0.0035223959
PRL O 0 0.9994863
- O 0 0.020615824
R O 0 0.9246121
and O 0 0.002235514
suppressor O 0 0.036883302
of O 0 0.0019111999
cytokine O 0 0.541035
signaling O 0 0.012042972
( O 0 0.0052755876
SOCS O 0 0.6903236
- O 0 0.0022954415
1 O 0 0.0006919591
and O 0 0.0007153306
- O 0 0.0009962224
3 O 0 0.00046242215
and O 0 0.0006458886
CIS O 0 0.89965683
, O 0 0.00077142083
which O 0 0.00052430836
reflect O 0 0.00036902117
the O 0 0.00043759125
level O 0 0.00040779563
of O 0 0.0011870571
prolactin O 0 0.99770576
signaling O 0 0.0053223483
) O 0 0.0039133476
mRNAs O 0 0.0017691734
in O 0 0.0011241202
response O 0 0.0025539764
to O 0 0.0039812336
sulpiride B-Chemical 1 0.9999852
and O 0 0.043934427
estradiol B-Chemical 1 0.99981683
. O 0 0.012893973

Sulpiride B-Chemical 0 0.9998061
induced O 0 0.010819571
only O 0 0.0060341205
SOCS O 0 0.63820416
- O 0 0.005697478
1 O 0 0.0017839548
in O 0 0.0011396572
the O 0 0.0011446069
medial O 0 0.011190603
preoptic O 0 0.41438898
area O 0 0.0013010361
, O 0 0.0009841097
where O 0 0.00066681614
GnRH O 0 0.939201
neurons O 0 0.009822456
are O 0 0.00059679965
regulated O 0 0.00044297217
, O 0 0.000662933
but O 0 0.00041666502
in O 0 0.00038713645
the O 0 0.0005159196
arcuate O 0 0.074787796
nucleus O 0 0.00086606684
and O 0 0.00076190935
choroid O 0 0.7849149
plexus O 0 0.89720285
, O 0 0.004537113
PRL O 0 0.9998752
- O 0 0.013512728
R O 0 0.970156
, O 0 0.002580428
SOCS O 0 0.522326
- O 0 0.002193667
3 O 0 0.00090742996
, O 0 0.0012481735
and O 0 0.001531146
CIS O 0 0.90857357
mRNA O 0 0.0022819897
levels O 0 0.001936584
were O 0 0.002798169
also O 0 0.0038781455
induced O 0 0.007037526
. O 0 0.009376951

Estradiol B-Chemical 0 0.9990314
enhanced O 0 0.014560655
these O 0 0.010487547
effects O 0 0.011154271
on O 0 0.0072393613
SOCS O 0 0.6383048
- O 0 0.01421009
3 O 0 0.008482062
and O 0 0.012319925
CIS O 0 0.9397301
. O 0 0.016403316

Interestingly O 0 0.011974157
, O 0 0.014044247
estradiol B-Chemical 1 0.9994431
also O 0 0.007371133
induced O 0 0.014622614
PRL O 0 0.9998548
- O 0 0.09031848
R O 0 0.98576015
, O 0 0.006911656
SOCS O 0 0.644218
- O 0 0.004369784
3 O 0 0.001923008
, O 0 0.002555877
and O 0 0.0031275593
CIS O 0 0.90868056
mRNA O 0 0.004886073
levels O 0 0.0045421603
independently O 0 0.006522607
. O 0 0.009048494

These O 0 0.009544751
data O 0 0.006875636
show O 0 0.003734398
that O 0 0.0031138996
GnRH O 0 0.91956335
pulse O 0 0.018779501
frequency O 0 0.0026614303
is O 0 0.0018477838
inhibited O 0 0.0024462151
by O 0 0.002986832
chronic O 0 0.99514776
hyperprolactinemia B-Disease 2 0.9999918
in O 0 0.0040695947
a O 0 0.01240739
steroid B-Chemical 1 0.99927026
- O 0 0.012347538
dependent O 0 0.0043323105
manner O 0 0.007983748
. O 0 0.0091404645

They O 0 0.012514524
also O 0 0.0057050553
provide O 0 0.003552713
evidence O 0 0.0032504527
for O 0 0.00305684
estradiol B-Chemical 1 0.99989593
- O 0 0.005845162
dependent O 0 0.0012107943
and O 0 0.0015509701
brain O 0 0.1080426
region O 0 0.0015367072
- O 0 0.0015029216
specific O 0 0.00066964165
regulation O 0 0.0008333315
of O 0 0.002614128
PRL O 0 0.9998925
- O 0 0.020690802
R O 0 0.9360311
expression O 0 0.0025284388
and O 0 0.002648614
signaling O 0 0.0045196256
responses O 0 0.009115708
by O 0 0.008890402
prolactin O 0 0.9955994
. O 0 0.01071154

Clonidine B-Chemical 1 0.9995479
for O 0 0.012517826
attention B-Disease 0 0.019375604
- I-Disease 0 0.014756208
deficit I-Disease 0 0.27991748
/ I-Disease 0 0.13306737
hyperactivity I-Disease 2 0.99978703
disorder I-Disease 0 0.9975768
: O 0 0.055114146
II O 0 0.33737394
. O 0 0.014987728

ECG O 0 0.7215528
changes O 0 0.028863568
and O 0 0.026497908
adverse O 0 0.8850834
events O 0 0.18868321
analysis O 0 0.035729837
. O 0 0.03054814

OBJECTIVE O 0 0.41817346
: O 0 0.007439741
To O 0 0.0029724764
examine O 0 0.0016794051
the O 0 0.0017664724
safety O 0 0.0027325347
and O 0 0.00155052
tolerability O 0 0.21714097
of O 0 0.0025867496
clonidine B-Chemical 1 0.9999784
used O 0 0.0009462914
alone O 0 0.00088286994
or O 0 0.00070214167
with O 0 0.0010712919
methylphenidate B-Chemical 1 0.99996674
in O 0 0.00070919853
children O 0 0.001920203
with O 0 0.00091095566
attention B-Disease 0 0.0049077338
- I-Disease 0 0.0038868485
deficit I-Disease 0 0.22416013
/ I-Disease 0 0.087699465
hyperactivity I-Disease 2 0.9999473
disorder I-Disease 0 0.9987564
( O 0 0.11003244
ADHD B-Disease 0 0.9997503
) O 0 0.018550055
. O 0 0.008593047

METHOD O 0 0.026128782
: O 0 0.007951588
In O 0 0.0037687279
a O 0 0.0036547019
16 O 0 0.0026845129
- O 0 0.0024364856
week O 0 0.0011496379
multicenter O 0 0.006364862
, O 0 0.0013509553
double O 0 0.0010225616
- O 0 0.0013815311
blind O 0 0.0027419752
trial O 0 0.000994558
, O 0 0.0007846578
122 O 0 0.0024037685
children O 0 0.0010644636
with O 0 0.00075635564
ADHD B-Disease 0 0.9996625
were O 0 0.00042160504
randomly O 0 0.00023285483
assigned O 0 0.00027504406
to O 0 0.00045359842
clonidine B-Chemical 1 0.9999701
( O 0 0.00093858
n O 0 0.0005927487
= O 0 0.0006777553
31 O 0 0.0007487126
) O 0 0.0008320615
, O 0 0.00073239126
methylphenidate B-Chemical 1 0.9999206
( O 0 0.0006852026
n O 0 0.0005042862
= O 0 0.0006112136
29 O 0 0.0007794645
) O 0 0.0008489297
, O 0 0.0008017022
clonidine B-Chemical 1 0.9999535
and O 0 0.0011430852
methylphenidate B-Chemical 1 0.99996746
( O 0 0.0009779306
n O 0 0.00066252
= O 0 0.00077693164
32 O 0 0.00076832005
) O 0 0.00097108196
, O 0 0.0007990463
or O 0 0.00076570886
placebo O 0 0.04809761
( O 0 0.0019096641
n O 0 0.0019912962
= O 0 0.0030345211
30 O 0 0.0027258531
) O 0 0.0064570107
. O 0 0.0065524774

Doses O 0 0.2619101
were O 0 0.006104195
flexibly O 0 0.004715453
titrated O 0 0.0034039011
up O 0 0.0018465196
to O 0 0.0013778041
0 O 0 0.0014882357
. O 0 0.0007258357
6 O 0 0.00060244167
mg O 0 0.03951677
/ O 0 0.0011951239
day O 0 0.00049369014
for O 0 0.00051737827
clonidine B-Chemical 1 0.99993813
and O 0 0.00086809514
60 O 0 0.0006739884
mg O 0 0.110880055
/ O 0 0.001291254
day O 0 0.00057027873
for O 0 0.00074691465
methylphenidate B-Chemical 1 0.9999254
( O 0 0.0019021953
both O 0 0.0012569292
with O 0 0.0018522445
divided O 0 0.0021923669
dosing O 0 0.05123607
) O 0 0.010516168
. O 0 0.007821208

Groups O 0 0.02094098
were O 0 0.0057369987
compared O 0 0.0029167843
regarding O 0 0.0026382143
adverse O 0 0.6863999
events O 0 0.03789372
and O 0 0.0022105942
changes O 0 0.001751045
from O 0 0.0012027754
baseline O 0 0.0012117011
to O 0 0.0009657928
week O 0 0.00095282693
16 O 0 0.0013081458
in O 0 0.0015728957
electrocardiograms O 0 0.31990024
and O 0 0.003956681
vital O 0 0.021194119
signs O 0 0.37130502
. O 0 0.0102570895

RESULTS O 0 0.026002062
: O 0 0.0081212055
There O 0 0.004345684
were O 0 0.0030065577
more O 0 0.002464561
incidents O 0 0.017422998
of O 0 0.0024296388
bradycardia B-Disease 2 0.99957734
in O 0 0.0010839775
subjects O 0 0.0015979367
treated O 0 0.0010178937
with O 0 0.0011547353
clonidine B-Chemical 1 0.9999771
compared O 0 0.00042941308
with O 0 0.00056727923
those O 0 0.00069165323
not O 0 0.00041713935
treated O 0 0.0006706898
with O 0 0.0010310496
clonidine B-Chemical 1 0.9999893
( O 0 0.0016574141
17 O 0 0.0008079978
. O 0 0.0002729563
5 O 0 0.0002756121
% O 0 0.0003445185
versus O 0 0.0002951324
3 O 0 0.00033469978
. O 0 0.00025826265
4 O 0 0.00031857
% O 0 0.00047484727
; O 0 0.00062594714
p O 0 0.00055653113
= O 0 0.0006862205
. O 0 0.00037626058
02 O 0 0.025377886
) O 0 0.0007568387
, O 0 0.0005012509
but O 0 0.00032699958
no O 0 0.000281768
other O 0 0.0004380314
significant O 0 0.000595124
group O 0 0.0007338682
differences O 0 0.00053722924
regarding O 0 0.0008362791
electrocardiogram O 0 0.61063063
and O 0 0.0021715993
other O 0 0.0033577492
cardiovascular O 0 0.99480045
outcomes O 0 0.049881585
. O 0 0.009330393

There O 0 0.010072346
were O 0 0.0062327953
no O 0 0.0038930879
suggestions O 0 0.004559731
of O 0 0.0036184413
interactions O 0 0.0045131
between O 0 0.0028072416
clonidine B-Chemical 1 0.9999374
and O 0 0.011176202
methylphenidate B-Chemical 1 0.9999113
regarding O 0 0.0054566837
cardiovascular O 0 0.99673957
outcomes O 0 0.07849577
. O 0 0.011847375

Moderate O 0 0.46158117
or O 0 0.0066943406
severe O 0 0.12966615
adverse O 0 0.9256885
events O 0 0.075848386
were O 0 0.0017522824
more O 0 0.0013029625
common O 0 0.0011838863
in O 0 0.0007402984
subjects O 0 0.0012696099
on O 0 0.00059048244
clonidine B-Chemical 1 0.99997735
( O 0 0.0015638379
79 O 0 0.0011615732
. O 0 0.0003251815
4 O 0 0.00032492398
% O 0 0.0003862451
versus O 0 0.000333356
49 O 0 0.00068435847
. O 0 0.0003076275
2 O 0 0.00040216304
% O 0 0.0005492467
; O 0 0.00071569096
p O 0 0.00063514314
= O 0 0.00078362395
. O 0 0.00043022103
0006 O 0 0.0065909117
) O 0 0.00090589916
but O 0 0.00051029783
not O 0 0.0005326815
associated O 0 0.00078422274
with O 0 0.00093494204
higher O 0 0.001034659
rates O 0 0.0016113007
of O 0 0.0025230367
early O 0 0.0054978374
study O 0 0.0073836897
withdrawal O 0 0.9121548
. O 0 0.009658332

Drowsiness B-Disease 0 0.9942306
was O 0 0.008240406
common O 0 0.006285963
on O 0 0.00418588
clonidine B-Chemical 1 0.9998908
, O 0 0.005655096
but O 0 0.0024996772
generally O 0 0.0027219479
resolved O 0 0.0038317281
by O 0 0.0027196242
6 O 0 0.0022170795
to O 0 0.0027329621
8 O 0 0.003979372
weeks O 0 0.0045680865
. O 0 0.007795002

CONCLUSIONS O 0 0.8021695
: O 0 0.02570035
Clonidine B-Chemical 1 0.99989283
, O 0 0.006265534
used O 0 0.0023794363
alone O 0 0.0020744514
or O 0 0.001706394
with O 0 0.002409362
methylphenidate B-Chemical 1 0.99996424
, O 0 0.0025333539
appears O 0 0.0010354157
safe O 0 0.0021043199
and O 0 0.001544597
well O 0 0.0017825756
tolerated O 0 0.046528287
in O 0 0.004705189
childhood O 0 0.9910315
ADHD B-Disease 0 0.9997168
. O 0 0.01194613

Physicians O 0 0.014359312
prescribing O 0 0.056824252
clonidine B-Chemical 1 0.9997166
should O 0 0.0024860871
monitor O 0 0.0017986951
for O 0 0.0017018926
bradycardia B-Disease 2 0.99904245
and O 0 0.0019295682
advise O 0 0.0041126395
patients O 0 0.0023884769
about O 0 0.0010818467
the O 0 0.001301623
high O 0 0.0019074721
likelihood O 0 0.0032421765
of O 0 0.0040652603
initial O 0 0.008369167
drowsiness B-Disease 0 0.99980575
. O 0 0.011884801

Renal B-Disease 0 0.98559326
Fanconi I-Disease 2 0.99768686
syndrome I-Disease 2 0.99752325
and O 0 0.01439112
myopathy B-Disease 2 0.9988758
after O 0 0.0032070728
liver O 0 0.95066524
transplantation O 0 0.6249687
: O 0 0.009488083
drug O 0 0.78328997
- O 0 0.007787431
related O 0 0.004282389
mitochondrial B-Disease 0 0.7793801
cytopathy I-Disease 0 0.993683
? O 0 0.0940881

Advances O 0 0.014308365
in O 0 0.0055359863
the O 0 0.003921769
field O 0 0.003517054
of O 0 0.002491055
transplantation O 0 0.020139974
provide O 0 0.0011623679
a O 0 0.0013162607
better O 0 0.0009332053
quality O 0 0.00080285483
of O 0 0.0009819196
life O 0 0.0019878198
and O 0 0.000878052
allow O 0 0.0005808884
more O 0 0.0009040512
favorable O 0 0.0030086464
conditions O 0 0.0014127634
for O 0 0.0011702504
growth O 0 0.0063552246
and O 0 0.0027545593
development O 0 0.0049908604
in O 0 0.004337692
children O 0 0.015687097
. O 0 0.008613015

However O 0 0.010249433
, O 0 0.007301122
combinations O 0 0.004181263
of O 0 0.0036384698
different O 0 0.0026542156
therapeutic O 0 0.008596736
regimens O 0 0.0073701288
require O 0 0.001723325
consideration O 0 0.0021150128
of O 0 0.0031365573
potential O 0 0.0066405083
adverse O 0 0.98069924
reactions O 0 0.38005534
. O 0 0.012792271

We O 0 0.008599057
describe O 0 0.005584097
a O 0 0.0055537634
15 O 0 0.00375632
- O 0 0.004016171
yr O 0 0.00405477
- O 0 0.0025885627
old O 0 0.0018322042
girl O 0 0.0037618792
who O 0 0.002387734
had O 0 0.0014949199
orthotopic O 0 0.9670292
liver O 0 0.94574183
transplantation O 0 0.25485322
because O 0 0.0018521918
of O 0 0.0034854345
Wilson B-Disease 0 0.62366265
' I-Disease 0 0.0056960066
s I-Disease 0 0.00650656
disease I-Disease 0 0.70287293
. O 0 0.010826586

Tacrolimus B-Chemical 1 0.99915695
, O 0 0.03974986
MMF B-Chemical 0 0.9995857
, O 0 0.014211064
and O 0 0.00939665
steroids B-Chemical 1 0.9978389
were O 0 0.007501093
given O 0 0.005418025
as O 0 0.009508208
immunosuppressant O 0 0.9949131
. O 0 0.018297581

Lamivudine B-Chemical 1 0.99516124
was O 0 0.008584498
added O 0 0.005367931
because O 0 0.0035273232
of O 0 0.00406018
de O 0 0.074997015
nova O 0 0.72462624
hepatitis B-Disease 2 0.9999863
B I-Disease 2 0.9954432
infection I-Disease 0 0.9025795
during O 0 0.003705323
her O 0 0.0065457914
follow O 0 0.0044561154
- O 0 0.008302073
up O 0 0.0073841587
. O 0 0.009707495

Three O 0 0.009948538
yr O 0 0.008113696
after O 0 0.0032233638
transplantation O 0 0.013785499
she O 0 0.0029012756
developed O 0 0.004183724
renal B-Disease 0 0.99895215
Fanconi I-Disease 2 0.99983513
syndrome I-Disease 2 0.9996101
with O 0 0.01236301
severe O 0 0.92501116
metabolic B-Disease 2 0.9975158
acidosis I-Disease 2 0.9999926
, O 0 0.27364776
hypophosphatemia B-Disease 0 0.99998796
, O 0 0.10063366
glycosuria B-Disease 2 0.9998895
, O 0 0.01509612
and O 0 0.015384803
aminoaciduria B-Disease 0 0.9998472
. O 0 0.014241171

Although O 0 0.008901493
tacrolimus B-Chemical 1 0.9995509
was O 0 0.0052426704
suspected O 0 0.014684725
to O 0 0.0019616578
be O 0 0.0015043577
the O 0 0.001118281
cause O 0 0.0022983493
of O 0 0.0013077236
late O 0 0.0055221007
post O 0 0.0022901937
- O 0 0.0019571483
transplant O 0 0.43733412
renal O 0 0.9982135
acidosis B-Disease 2 0.99996436
and O 0 0.001945853
was O 0 0.00092967186
replaced O 0 0.00089486927
by O 0 0.0015039294
sirolimus B-Chemical 1 0.99990606
, O 0 0.013233242
acidosis B-Disease 2 0.9998976
, O 0 0.0041186297
and O 0 0.003200017
electrolyte O 0 0.96739376
imbalance O 0 0.28640163
got O 0 0.018849773
worse O 0 0.030495856
. O 0 0.008914383

Proximal O 0 0.08853159
muscle B-Disease 0 0.14695355
weakness I-Disease 2 0.959463
has O 0 0.008133535
developed O 0 0.008320121
during O 0 0.005802826
her O 0 0.009172314
follow O 0 0.0071556806
- O 0 0.011866482
up O 0 0.010665263
. O 0 0.013174199

Fanconi B-Disease 2 0.9949508
syndrome I-Disease 2 0.9896348
, O 0 0.0078037954
as O 0 0.0031492992
well O 0 0.0021983448
as O 0 0.0026116646
myopathy B-Disease 2 0.99931145
, O 0 0.0031018504
is O 0 0.0009988473
well O 0 0.0007486581
recognized O 0 0.0010156585
in O 0 0.00081086153
patients O 0 0.003377524
with O 0 0.0015975162
mitochondrial B-Disease 0 0.96192664
disorders I-Disease 0 0.9964796
and O 0 0.002991732
caused O 0 0.002910487
by O 0 0.0033263273
depletion O 0 0.0067277933
of O 0 0.0071720798
mtDNA O 0 0.21292424
. O 0 0.009130873

We O 0 0.007116859
suggest O 0 0.0036852327
that O 0 0.0027931372
our O 0 0.0022600407
patient O 0 0.0029008891
' O 0 0.002448937
s O 0 0.0022958643
tubular B-Disease 0 0.935249
dysfunction I-Disease 0 0.9987293
and O 0 0.007413119
myopathy B-Disease 2 0.99969316
may O 0 0.001128911
have O 0 0.00071784406
resulted O 0 0.0007173827
from O 0 0.001055803
mitochondrial B-Disease 2 0.9301891
dysfunction I-Disease 2 0.9972435
which O 0 0.0021129206
is O 0 0.0011501313
triggered O 0 0.0021008004
by O 0 0.0030345689
tacrolimus B-Chemical 1 0.99994993
and O 0 0.0049769916
augmented O 0 0.009575395
by O 0 0.011939726
lamivudine B-Chemical 1 0.9996642
. O 0 0.011525401

Higher O 0 0.0222051
optical O 0 0.016988024
density O 0 0.00640495
of O 0 0.0044189175
an O 0 0.0041073128
antigen O 0 0.014760797
assay O 0 0.0037591225
predicts O 0 0.002949111
thrombosis B-Disease 2 0.9995919
in O 0 0.0025838688
patients O 0 0.007933711
with O 0 0.0043706493
heparin B-Chemical 1 0.9992093
- O 0 0.039165232
induced O 0 0.016992524
thrombocytopenia B-Disease 2 0.9998085
. O 0 0.015969032

OBJECTIVES O 0 0.024298301
: O 0 0.007211437
To O 0 0.0032999967
correlate O 0 0.002711231
optical O 0 0.007314482
density O 0 0.0025618598
and O 0 0.0015385967
percent O 0 0.0010902263
inhibition O 0 0.0019107533
of O 0 0.001019024
a O 0 0.00112953
two O 0 0.00072615873
- O 0 0.0015892772
step O 0 0.0008620868
heparin B-Chemical 1 0.99907
- O 0 0.008031224
induced O 0 0.002117192
thrombocytopenia B-Disease 2 0.9999821
( O 0 0.020675797
HIT B-Disease 2 0.9994837
) O 0 0.0022254314
antigen O 0 0.014905699
assay O 0 0.0012053008
with O 0 0.0010004888
thrombosis B-Disease 2 0.99988973
; O 0 0.0020276161
the O 0 0.0005673877
assay O 0 0.00086299
utilizes O 0 0.0006046492
reaction O 0 0.0035047322
inhibition O 0 0.0021056102
characteristics O 0 0.0012725167
of O 0 0.001825731
a O 0 0.0031075738
high O 0 0.0048717107
heparin B-Chemical 1 0.9980465
concentration O 0 0.045894727
. O 0 0.010138797

PATIENTS O 0 0.015037063
AND O 0 0.008171593
METHODS O 0 0.006107082
: O 0 0.0047886767
Patients O 0 0.003986857
with O 0 0.0018848141
more O 0 0.0015976964
than O 0 0.0009335117
50 O 0 0.0012730621
% O 0 0.00092715607
decrease O 0 0.00059662445
in O 0 0.0005414235
platelet O 0 0.701883
count O 0 0.0045078835
or O 0 0.0010360201
thrombocytopenia B-Disease 2 0.99995244
( O 0 0.0019976231
< O 0 0.0005896945
150 O 0 0.0006537046
x O 0 0.0007747374
10 O 0 0.00046940008
( O 0 0.0005772793
9 O 0 0.00047617397
) O 0 0.00078377855
/ O 0 0.0015035396
L O 0 0.28684387
) O 0 0.0008300154
after O 0 0.0002369249
exposure O 0 0.0007635629
to O 0 0.00048572704
heparin B-Chemical 1 0.99741334
, O 0 0.0010041628
who O 0 0.00083457713
had O 0 0.00034044296
a O 0 0.00046857295
positive O 0 0.00044066293
two O 0 0.0004463777
- O 0 0.0009420948
step O 0 0.0004462143
antigen O 0 0.0110201845
assay O 0 0.0015924823
[ O 0 0.002945587
optical O 0 0.011873278
density O 0 0.0015426744
( O 0 0.0016489993
OD O 0 0.3143874
) O 0 0.0015704155
> O 0 0.00089044095
0 O 0 0.0005642928
. O 0 0.00028890875
4 O 0 0.00033311773
and O 0 0.0004527509
> O 0 0.0007460563
50 O 0 0.000615476
inhibition O 0 0.0008119897
with O 0 0.00053166604
high O 0 0.00074061286
concentration O 0 0.0013973912
of O 0 0.001703448
heparin B-Chemical 1 0.99903274
] O 0 0.0070158
were O 0 0.0016533195
included O 0 0.0017283724
in O 0 0.0022384578
the O 0 0.0035182605
study O 0 0.0068113464
. O 0 0.007773022

RESULTS O 0 0.025337469
: O 0 0.008825846
Forty O 0 0.007887737
of O 0 0.004411152
94 O 0 0.004693186
HIT B-Disease 2 0.9604196
patients O 0 0.004514773
had O 0 0.0019975626
thrombosis B-Disease 2 0.9992587
at O 0 0.0014392601
diagnosis O 0 0.0112257395
; O 0 0.0026628242
54 O 0 0.0022757354
/ O 0 0.0021776462
94 O 0 0.0015707884
had O 0 0.0012909416
isolated O 0 0.0022587841
- O 0 0.0063094716
HIT B-Disease 2 0.9926473
without O 0 0.0073627788
thrombosis B-Disease 2 0.9994368
. O 0 0.01284218

Eight O 0 0.010977641
of O 0 0.006079662
the O 0 0.0041450355
isolated O 0 0.0040184874
- O 0 0.0058318744
HIT B-Disease 2 0.98910683
patients O 0 0.0049569057
developed O 0 0.0022598752
thrombosis B-Disease 2 0.99935406
within O 0 0.0005753771
the O 0 0.0005922359
next O 0 0.00042158738
30 O 0 0.0004729013
d O 0 0.0007550526
; O 0 0.0009719229
thus O 0 0.0007587041
, O 0 0.00073001685
a O 0 0.00064140325
total O 0 0.00056697323
of O 0 0.00080565515
48 O 0 0.0008065193
patients O 0 0.0017741777
had O 0 0.0015614883
thrombosis B-Disease 2 0.9988398
at O 0 0.0023617449
day O 0 0.0031944166
30 O 0 0.0042703366
. O 0 0.006573186

At O 0 0.0063261455
diagnosis O 0 0.0077597
there O 0 0.0028150855
was O 0 0.002371234
no O 0 0.0015266169
significant O 0 0.0016032968
difference O 0 0.0010207129
in O 0 0.0012370292
OD O 0 0.07667023
between O 0 0.001028186
HIT B-Disease 2 0.9947291
patients O 0 0.004793385
with O 0 0.0020483453
thrombosis B-Disease 2 0.9997009
and O 0 0.0027824605
those O 0 0.0030796903
with O 0 0.0031226494
isolated O 0 0.005306977
- O 0 0.025098605
HIT B-Disease 2 0.9956773
. O 0 0.010714201

However O 0 0.009957428
, O 0 0.0078665335
OD O 0 0.05606856
was O 0 0.0030167226
significantly O 0 0.0022360734
higher O 0 0.0013648649
in O 0 0.0010281826
all O 0 0.00085423
patients O 0 0.0019013055
with O 0 0.0011006959
thrombosis B-Disease 2 0.99983263
( O 0 0.0015623062
n O 0 0.0007825856
= O 0 0.0007433157
48 O 0 0.00039004927
, O 0 0.00050898694
1 O 0 0.0004128457
. O 0 0.00028816404
34 O 0 0.000552242
+ O 0 0.0005273902
/ O 0 0.0013448361
- O 0 0.0007720731
0 O 0 0.0005389898
. O 0 0.00029159154
89 O 0 0.0008300023
) O 0 0.00066923397
, O 0 0.00045574427
including O 0 0.00034202205
isolated O 0 0.0006077544
- O 0 0.0017677558
HIT B-Disease 2 0.9920283
patients O 0 0.0013669787
who O 0 0.0008092383
later O 0 0.0003275178
developed O 0 0.00072241214
thrombosis B-Disease 2 0.9994363
within O 0 0.00028050845
30 O 0 0.00031275535
d O 0 0.00046186705
( O 0 0.0005084087
n O 0 0.00044127458
= O 0 0.00054282846
8 O 0 0.00035476594
, O 0 0.00045220787
1 O 0 0.00037871083
. O 0 0.00026547114
84 O 0 0.0005800022
+ O 0 0.0004926865
/ O 0 0.0012159547
- O 0 0.000711612
0 O 0 0.0004953895
. O 0 0.0002648399
64 O 0 0.0005451896
) O 0 0.0005005935
as O 0 0.00029180484
compared O 0 0.00022133069
to O 0 0.0003308503
isolated O 0 0.0006113036
- O 0 0.0020561065
HIT B-Disease 2 0.99400055
patients O 0 0.0017244417
who O 0 0.0009569273
did O 0 0.00037936337
not O 0 0.00041387655
develop O 0 0.00075043016
thrombosis B-Disease 2 0.9998809
( O 0 0.0017603155
0 O 0 0.0008339413
. O 0 0.00034260587
96 O 0 0.0008031964
+ O 0 0.0005702852
/ O 0 0.0013469054
- O 0 0.000815629
0 O 0 0.0005948872
. O 0 0.00035474647
75 O 0 0.0007312106
; O 0 0.00092884846
P O 0 0.013481536
= O 0 0.00091110676
0 O 0 0.0008509272
. O 0 0.0006635806
011 O 0 0.025570655
and O 0 0.0013109614
P O 0 0.038445845
= O 0 0.0024811814
0 O 0 0.0026107507
. O 0 0.0025347131
008 O 0 0.020755053
) O 0 0.008317808
. O 0 0.007687276

The O 0 0.01152427
Receiver O 0 0.98392695
Operative O 0 0.05842527
Characteristic O 0 0.13859835
Curve O 0 0.93753046
showed O 0 0.0023857811
that O 0 0.0017511043
OD O 0 0.16686365
> O 0 0.0024962244
1 O 0 0.0010584138
. O 0 0.000598766
27 O 0 0.00078564417
in O 0 0.000478865
the O 0 0.0005480544
isolated O 0 0.00085616653
- O 0 0.0021803426
HIT B-Disease 2 0.9901175
group O 0 0.0008751053
had O 0 0.00059888815
a O 0 0.0008644603
significantly O 0 0.0009051226
higher O 0 0.00078299554
chance O 0 0.0019149347
of O 0 0.0016794524
developing O 0 0.024992922
thrombosis B-Disease 2 0.999655
by O 0 0.0041431263
day O 0 0.0037179266
30 O 0 0.0044887722
. O 0 0.0066677122

None O 0 0.018734409
of O 0 0.009980564
these O 0 0.007906237
groups O 0 0.006566149
showed O 0 0.004683298
significant O 0 0.0050343866
difference O 0 0.0039167134
in O 0 0.005510413
percent O 0 0.0077780373
inhibition O 0 0.019406587
. O 0 0.013508833

Multivariate O 0 0.029093571
analysis O 0 0.008656216
showed O 0 0.004995293
a O 0 0.0051575303
2 O 0 0.0036079355
. O 0 0.0024319284
8 O 0 0.0024297102
- O 0 0.0028752263
fold O 0 0.0030995228
increased O 0 0.0030847725
risk O 0 0.05305709
of O 0 0.007001344
thrombosis B-Disease 2 0.9996107
in O 0 0.0084350435
females O 0 0.022008708
. O 0 0.010950288

Similarly O 0 0.017815592
, O 0 0.016749853
thrombotic B-Disease 2 0.9973999
risk O 0 0.23281045
increased O 0 0.010015835
with O 0 0.008219296
age O 0 0.015241163
and O 0 0.010870847
OD O 0 0.43728456
values O 0 0.0130842505
. O 0 0.014026161

CONCLUSION O 0 0.79246575
: O 0 0.011402483
Higher O 0 0.016642386
OD O 0 0.11276117
is O 0 0.0027140172
associated O 0 0.0020739401
with O 0 0.0015034841
significant O 0 0.0014931728
risk O 0 0.026462745
of O 0 0.0013203474
subsequent O 0 0.001469226
thrombosis B-Disease 2 0.9997981
in O 0 0.0009531974
patients O 0 0.0027462023
with O 0 0.0009025313
isolated O 0 0.0013594526
- O 0 0.006365811
HIT B-Disease 2 0.9976311
; O 0 0.0018340957
percent O 0 0.00093207636
inhibition O 0 0.0027567414
, O 0 0.0019447079
however O 0 0.0019838144
, O 0 0.002670744
was O 0 0.0024656935
not O 0 0.003352325
predictive O 0 0.00834451
. O 0 0.008392445

Thalidomide B-Chemical 1 0.9989624
has O 0 0.0061125783
limited O 0 0.0039307666
single O 0 0.0038897311
- O 0 0.004133187
agent O 0 0.078104086
activity O 0 0.0020929496
in O 0 0.0013011178
relapsed O 0 0.94577265
or O 0 0.0013654075
refractory O 0 0.4907294
indolent O 0 0.9164108
non B-Disease 0 0.0503445
- I-Disease 0 0.018688101
Hodgkin I-Disease 0 0.99948967
lymphomas I-Disease 0 0.99936765
: O 0 0.0036430191
a O 0 0.0014772661
phase O 0 0.0019117856
II O 0 0.027516449
trial O 0 0.0016682174
of O 0 0.001759487
the O 0 0.002784352
Cancer B-Disease 2 0.9894996
and O 0 0.015004898
Leukemia B-Disease 0 0.9997634
Group O 0 0.6081528
B O 0 0.62134385
. O 0 0.0111266505

Thalidomide B-Chemical 1 0.999196
is O 0 0.008434983
an O 0 0.0065546413
immunomodulatory O 0 0.44291186
agent O 0 0.3279034
with O 0 0.0030081756
demonstrated O 0 0.0018168264
activity O 0 0.0020994183
in O 0 0.0015851008
multiple B-Disease 0 0.0087890895
myeloma I-Disease 0 0.999426
, O 0 0.011006635
mantle B-Disease 0 0.8511846
cell I-Disease 0 0.26073095
lymphoma I-Disease 0 0.9997507
and O 0 0.05686758
lymphoplasmacytic B-Disease 0 0.99977857
lymphoma I-Disease 0 0.9998197
. O 0 0.025640164

Its O 0 0.11770039
activity O 0 0.008149933
is O 0 0.0047448487
believed O 0 0.0045709494
to O 0 0.0022639388
be O 0 0.0018145423
due O 0 0.0011660813
modulation O 0 0.0016609597
of O 0 0.001430278
the O 0 0.0014506591
tumour B-Disease 0 0.9768158
milieu O 0 0.02895466
, O 0 0.0024127306
including O 0 0.0014848962
downregulation O 0 0.004550224
of O 0 0.004079961
angiogenesis O 0 0.9947747
and O 0 0.010860418
inflammatory O 0 0.9878187
cytokines O 0 0.951494
. O 0 0.01475695

Between O 0 0.0151169915
July O 0 0.008312023
2001 O 0 0.0071694143
and O 0 0.0036079423
April O 0 0.0032997034
2004 O 0 0.0032175132
, O 0 0.0015574093
24 O 0 0.0008024112
patients O 0 0.0013303921
with O 0 0.0009525438
relapsed O 0 0.96048445
/ O 0 0.011804607
refractory O 0 0.44581938
indolent O 0 0.9467387
lymphomas B-Disease 0 0.99920434
received O 0 0.0017110457
thalidomide B-Chemical 1 0.9999546
200 O 0 0.0074779014
mg O 0 0.27199778
daily O 0 0.0010145062
with O 0 0.0004439134
escalation O 0 0.03409631
by O 0 0.0004666376
100 O 0 0.00076270435
mg O 0 0.051992975
daily O 0 0.00060638913
every O 0 0.00023038762
1 O 0 0.0004433469
- O 0 0.0005495101
2 O 0 0.00033399122
weeks O 0 0.00026284135
as O 0 0.00044602426
tolerated O 0 0.005043435
, O 0 0.0008355375
up O 0 0.0005877813
to O 0 0.0006469834
a O 0 0.0010894923
maximum O 0 0.0011535567
of O 0 0.002105003
800 O 0 0.009171959
mg O 0 0.35181454
daily O 0 0.008920494
. O 0 0.007425374

Patients O 0 0.01365661
had O 0 0.0056969216
received O 0 0.0039415727
a O 0 0.003617094
median O 0 0.0024818045
of O 0 0.0026891604
2 O 0 0.0023982292
( O 0 0.0026143666
range O 0 0.0025582896
, O 0 0.0025945823
1 O 0 0.0022388296
- O 0 0.002847684
4 O 0 0.0021972875
) O 0 0.0037651171
prior O 0 0.0030601188
regimens O 0 0.014036829
. O 0 0.008875205

Of O 0 0.009596134
24 O 0 0.0042872718
evaluable O 0 0.006570758
patients O 0 0.0044926903
, O 0 0.002209937
two O 0 0.0011063004
achieved O 0 0.0010566043
a O 0 0.0010963473
complete O 0 0.00074392254
remission O 0 0.17074287
and O 0 0.00074654847
one O 0 0.00044756068
achieved O 0 0.00049371034
a O 0 0.0006097947
partial O 0 0.0007700737
remission O 0 0.19867185
for O 0 0.000344173
an O 0 0.000540754
overall O 0 0.0004480236
response O 0 0.00055364816
rate O 0 0.00041584717
of O 0 0.00054040214
12 O 0 0.00036486684
. O 0 0.00029941046
5 O 0 0.00035199922
% O 0 0.00053357845
( O 0 0.00063071604
95 O 0 0.0007737745
% O 0 0.00056279893
confidence O 0 0.0011302868
interval O 0 0.00074629026
: O 0 0.00094764424
2 O 0 0.0006807376
. O 0 0.0005777412
6 O 0 0.0007315797
- O 0 0.0013848268
32 O 0 0.0015322721
. O 0 0.0013314284
4 O 0 0.0021694347
% O 0 0.004132251
) O 0 0.0075022043
. O 0 0.0072544217

Eleven O 0 0.059928447
patients O 0 0.04204534
progressed O 0 0.04358083
during O 0 0.02609549
therapy O 0 0.058879226
. O 0 0.03523856

Grade O 0 0.71958154
3 O 0 0.007717883
- O 0 0.006153759
4 O 0 0.0029143626
adverse O 0 0.3878118
effects O 0 0.0038688285
included O 0 0.0027289442
myelosuppression B-Disease 2 0.99996436
, O 0 0.016765505
fatigue B-Disease 2 0.9994863
, O 0 0.021438506
somnolence B-Disease 2 0.9999753
/ O 0 0.12299657
depressed B-Disease 2 0.9977137
mood I-Disease 0 0.99978787
, O 0 0.037637103
neuropathy B-Disease 2 0.9998889
and O 0 0.029529257
dyspnea B-Disease 0 0.9996425
. O 0 0.012395681

Of O 0 0.019254727
concern O 0 0.015949944
was O 0 0.008749588
the O 0 0.007216481
occurrence O 0 0.009603573
of O 0 0.008789746
four O 0 0.009340581
thromboembolic B-Disease 2 0.999772
events O 0 0.6178423
. O 0 0.01951343

Our O 0 0.007626376
results O 0 0.005070945
failed O 0 0.0036211347
to O 0 0.002231042
demonstrate O 0 0.0013370404
an O 0 0.0018311283
important O 0 0.0009825844
response O 0 0.0012420517
rate O 0 0.00083531067
to O 0 0.0006579769
single O 0 0.00087488233
agent O 0 0.2828888
thalidomide B-Chemical 1 0.9999639
in O 0 0.0015496445
indolent O 0 0.95843923
lymphomas B-Disease 0 0.999295
and O 0 0.0012495469
contrast O 0 0.00063934433
with O 0 0.0005718861
the O 0 0.00050072995
higher O 0 0.0004862104
activity O 0 0.0006679803
level O 0 0.00043040852
reported O 0 0.00075518526
with O 0 0.0007547991
the O 0 0.00084632053
second O 0 0.0011535424
generation O 0 0.0024300597
immunomodulatory O 0 0.81758225
agent O 0 0.8148797
, O 0 0.049942505
lenalidomide B-Chemical 0 0.99974495
. O 0 0.012467329

Sex O 0 0.4524514
differences O 0 0.0056692767
in O 0 0.0064174216
NMDA B-Chemical 1 0.9999491
antagonist O 0 0.991334
enhancement O 0 0.015056278
of O 0 0.0041446183
morphine B-Chemical 1 0.99997914
antihyperalgesia O 0 0.99960715
in O 0 0.0012097682
a O 0 0.0019717105
capsaicin B-Chemical 1 0.9998037
model O 0 0.0013227805
of O 0 0.0014132775
persistent O 0 0.24068329
pain B-Disease 2 0.9993716
: O 0 0.0021300013
comparisons O 0 0.00087502185
to O 0 0.0008569639
two O 0 0.0010915627
models O 0 0.0024461942
of O 0 0.0050717653
acute B-Disease 0 0.99507964
pain I-Disease 2 0.99940765
. O 0 0.013616442

In O 0 0.009953405
acute B-Disease 0 0.88579124
pain I-Disease 2 0.9980064
models O 0 0.014574939
, O 0 0.013461777
N B-Chemical 1 0.99616206
- I-Chemical 1 0.047826078
methyl I-Chemical 1 0.9967296
- I-Chemical 1 0.08129251
D I-Chemical 1 0.993168
- I-Chemical 1 0.102150224
aspartate I-Chemical 1 0.9999591
( O 0 0.06269814
NMDA B-Chemical 1 0.99999416
) O 0 0.014887847
antagonists O 0 0.91560036
enhance O 0 0.00047188523
the O 0 0.0006993785
antinociceptive O 0 0.99821633
effects O 0 0.0023171029
of O 0 0.0018912246
morphine B-Chemical 1 0.9999502
to O 0 0.0009354175
a O 0 0.0012999423
greater O 0 0.0009793646
extent O 0 0.0010627275
in O 0 0.0017867541
males O 0 0.004499213
than O 0 0.0029240295
females O 0 0.009399421
. O 0 0.007664949

The O 0 0.0065029543
purpose O 0 0.0048068473
of O 0 0.0035692386
this O 0 0.0023985056
investigation O 0 0.0023191452
was O 0 0.0014066696
to O 0 0.0009380195
extend O 0 0.0007086299
these O 0 0.00081908004
findings O 0 0.0013291895
to O 0 0.0006268549
a O 0 0.0010911173
persistent O 0 0.0921786
pain B-Disease 2 0.99880004
model O 0 0.001122739
which O 0 0.0008663825
could O 0 0.0003784023
be O 0 0.0004513711
distinguished O 0 0.0007868056
from O 0 0.0006028248
acute B-Disease 0 0.9519571
pain I-Disease 2 0.99895906
models O 0 0.0009170806
on O 0 0.00029775992
the O 0 0.00035979977
basis O 0 0.00041167712
of O 0 0.00057580415
the O 0 0.00066656066
nociceptive O 0 0.9290934
fibers O 0 0.042183876
activated O 0 0.0014445859
, O 0 0.0015315324
neurochemical O 0 0.7916518
substrates O 0 0.00315874
, O 0 0.0013966584
and O 0 0.0011081521
duration O 0 0.0014552985
of O 0 0.0021619662
the O 0 0.0032545389
nociceptive O 0 0.92949396
stimulus O 0 0.03414707
. O 0 0.009585552

To O 0 0.0065290653
this O 0 0.0047344523
end O 0 0.003096479
, O 0 0.004079457
persistent O 0 0.17115225
hyperalgesia B-Disease 2 0.9999242
was O 0 0.0024463036
induced O 0 0.0015801251
by O 0 0.0012973313
administration O 0 0.07932409
of O 0 0.0019106388
capsaicin B-Chemical 1 0.9999238
in O 0 0.0007311437
the O 0 0.0005413585
tail O 0 0.0008763628
of O 0 0.0008202236
gonadally O 0 0.046602897
intact O 0 0.00071400445
F344 O 0 0.43748915
rats O 0 0.002752352
, O 0 0.00068199146
following O 0 0.00039036953
which O 0 0.00051891897
the O 0 0.0004165884
tail O 0 0.0007939497
was O 0 0.00051583425
immersed O 0 0.0008712436
in O 0 0.0005089527
a O 0 0.000985012
mildly O 0 0.26893002
noxious O 0 0.9267619
thermal O 0 0.095977284
stimulus O 0 0.010596143
, O 0 0.0019679966
and O 0 0.0015845923
tail O 0 0.003074709
- O 0 0.004747123
withdrawal O 0 0.7041263
latencies O 0 0.054585602
measured O 0 0.0048307
. O 0 0.007928672

For O 0 0.006918775
comparison O 0 0.004993684
, O 0 0.0046076123
tests O 0 0.003913184
were O 0 0.0020646662
conducted O 0 0.0013717624
in O 0 0.0011640787
two O 0 0.0011606605
acute B-Disease 0 0.9396197
pain I-Disease 2 0.999288
models O 0 0.0038041617
, O 0 0.0020517488
the O 0 0.00123851
hotplate O 0 0.34559324
and O 0 0.0018105066
warm O 0 0.007509771
water O 0 0.017532926
tail O 0 0.005053715
- O 0 0.0074921916
withdrawal O 0 0.73880154
procedures O 0 0.008067873
. O 0 0.009234344

In O 0 0.007971212
males O 0 0.008987229
, O 0 0.004790405
the O 0 0.0028787998
non O 0 0.0063349158
- O 0 0.0067790197
competitive O 0 0.2837732
NMDA B-Chemical 1 0.9999931
antagonist O 0 0.9989029
dextromethorphan B-Chemical 0 0.99999285
enhanced O 0 0.0017209419
the O 0 0.0009677103
antihyperalgesic O 0 0.9992149
effect O 0 0.0006867317
of O 0 0.00073629693
low O 0 0.00075497164
to O 0 0.0004903159
moderate O 0 0.008412357
doses O 0 0.026955606
of O 0 0.0016679124
morphine B-Chemical 1 0.99995947
in O 0 0.0009143427
a O 0 0.0014990738
dose O 0 0.022965126
- O 0 0.002524412
and O 0 0.0017103201
time O 0 0.001767527
- O 0 0.003794268
dependent O 0 0.003101719
manner O 0 0.0064861705
. O 0 0.00808682

Across O 0 0.011962823
the O 0 0.0062674168
doses O 0 0.012283402
and O 0 0.0045229173
pretreatment O 0 0.06469279
times O 0 0.0021724568
examined O 0 0.001998804
, O 0 0.0032394119
enhancement O 0 0.0039363867
was O 0 0.0024569046
not O 0 0.0025362112
observed O 0 0.0027546734
in O 0 0.0051473603
females O 0 0.013936753
. O 0 0.00995411

Enhancement O 0 0.056103453
of O 0 0.01175423
morphine B-Chemical 1 0.9999162
antinociception O 0 0.9999627
by O 0 0.018247902
dextromethorphan B-Chemical 0 0.99997675
was O 0 0.0016690776
seen O 0 0.000812973
in O 0 0.0006364368
both O 0 0.0006185557
males O 0 0.0013336746
and O 0 0.00066091394
females O 0 0.0011619367
in O 0 0.00047324764
the O 0 0.0006549837
acute B-Disease 0 0.95730686
pain I-Disease 2 0.99941754
models O 0 0.0025158308
, O 0 0.0011835209
with O 0 0.00063071004
the O 0 0.00059452694
magnitude O 0 0.0005958473
of O 0 0.0010073076
this O 0 0.0010789642
effect O 0 0.0014581872
being O 0 0.0026843983
greater O 0 0.0024346402
in O 0 0.0038444002
males O 0 0.011871402
. O 0 0.0079002995

These O 0 0.008896113
findings O 0 0.007125132
demonstrate O 0 0.0032066246
a O 0 0.004601659
sexually O 0 0.29331088
- O 0 0.0047843065
dimorphic O 0 0.010326617
interaction O 0 0.0018083922
between O 0 0.0012927835
NMDA B-Chemical 1 0.99999285
antagonists O 0 0.9951384
and O 0 0.0035277416
morphine B-Chemical 1 0.9999666
in O 0 0.0007770172
a O 0 0.0011507877
persistent O 0 0.07849197
pain B-Disease 2 0.9980971
model O 0 0.0010012215
that O 0 0.00056023535
can O 0 0.0005453977
be O 0 0.00069844926
distinguished O 0 0.0011414455
from O 0 0.0008968889
those O 0 0.0013198948
observed O 0 0.0010492636
in O 0 0.0023962585
acute B-Disease 0 0.9858779
pain I-Disease 2 0.9992324
models O 0 0.024715818
. O 0 0.010770246

Development O 0 0.025738105
of O 0 0.00955577
proteinuria B-Disease 2 0.99945515
after O 0 0.0028931594
switch O 0 0.003461794
to O 0 0.0025142985
sirolimus B-Chemical 1 0.99975556
- O 0 0.0049303644
based O 0 0.0019975118
immunosuppression O 0 0.95976883
in O 0 0.0020904366
long O 0 0.0024613298
- O 0 0.003393655
term O 0 0.0026783783
cardiac O 0 0.63732755
transplant O 0 0.5935893
patients O 0 0.039049853
. O 0 0.009794092

Calcineurin O 0 0.9734821
- O 0 0.018308543
inhibitor O 0 0.051287014
therapy O 0 0.020624056
can O 0 0.0038384139
lead O 0 0.021158215
to O 0 0.0037827182
renal B-Disease 2 0.9987703
dysfunction I-Disease 2 0.99798334
in O 0 0.005396714
heart O 0 0.8804139
transplantation O 0 0.5249059
patients O 0 0.04508782
. O 0 0.010726693

The O 0 0.007901627
novel O 0 0.008095013
immunosuppressive O 0 0.9622433
( O 0 0.01377968
IS O 0 0.68746775
) O 0 0.006390513
drug O 0 0.7094788
sirolmus B-Chemical 0 0.6974867
( O 0 0.006616947
Srl B-Chemical 1 0.9715427
) O 0 0.0024315708
lacks O 0 0.00079604506
nephrotoxic B-Disease 2 0.99955744
effects O 0 0.011266981
; O 0 0.0033283355
however O 0 0.0013641918
, O 0 0.0023198272
proteinuria B-Disease 2 0.9999523
associated O 0 0.0021597329
with O 0 0.0024101152
Srl B-Chemical 1 0.9646435
has O 0 0.0012445392
been O 0 0.0016899026
reported O 0 0.0023005777
following O 0 0.0033483794
renal O 0 0.9921949
transplantation O 0 0.6963
. O 0 0.010421652

In O 0 0.010963516
cardiac O 0 0.19092883
transplantation O 0 0.10285736
, O 0 0.006175365
the O 0 0.0037969744
incidence O 0 0.011100704
of O 0 0.007285214
proteinuria B-Disease 2 0.99990726
associated O 0 0.010594603
with O 0 0.00984049
Srl B-Chemical 1 0.9784534
is O 0 0.0074516023
unknown O 0 0.021414682
. O 0 0.011258009

In O 0 0.008372144
this O 0 0.0059422185
study O 0 0.0051362985
, O 0 0.004169698
long O 0 0.0028586453
- O 0 0.00289336
term O 0 0.0016240753
cardiac O 0 0.29137444
transplant O 0 0.25778654
patients O 0 0.0043271324
were O 0 0.0013846258
switched O 0 0.0021368747
from O 0 0.0021446468
cyclosporine B-Chemical 1 0.99995327
to O 0 0.0043804725
Srl B-Chemical 1 0.98097587
- O 0 0.0069430517
based O 0 0.005620489
IS O 0 0.518198
. O 0 0.009287547

Concomitant O 0 0.075206816
IS O 0 0.111360535
consisted O 0 0.0097066695
of O 0 0.013156996
mycophenolate B-Chemical 0 0.9999305
mofetil I-Chemical 0 0.99996924
+ O 0 0.12826726
/ O 0 0.13451664
- O 0 0.0448785
steroids B-Chemical 1 0.99864787
. O 0 0.01851944

Proteinuria O 2 0.99880636
increased O 0 0.007924547
significantly O 0 0.004119721
from O 0 0.002360185
a O 0 0.0019627684
median O 0 0.0012107355
of O 0 0.0013099324
0 O 0 0.0013408464
. O 0 0.0005943998
13 O 0 0.00069120683
g O 0 0.00092328177
/ O 0 0.0010251339
day O 0 0.00048631473
( O 0 0.00069601665
range O 0 0.0007048485
0 O 0 0.00078200444
- O 0 0.0007239567
5 O 0 0.0003640149
. O 0 0.00030124266
7 O 0 0.00038697763
) O 0 0.0006339943
preswitch O 0 0.004892205
to O 0 0.0003769854
0 O 0 0.00056152215
. O 0 0.00027925937
23 O 0 0.00048202727
g O 0 0.0006032886
/ O 0 0.0007602785
day O 0 0.0003902378
( O 0 0.0006758342
0 O 0 0.00068651704
- O 0 0.00069499726
9 O 0 0.0004643234
. O 0 0.00034748044
88 O 0 0.0008171562
) O 0 0.00067246176
at O 0 0.00034700456
24 O 0 0.00039692564
months O 0 0.00044598785
postswitch O 0 0.0016655766
( O 0 0.0012848489
p O 0 0.0015110982
= O 0 0.0020667315
0 O 0 0.0023260177
. O 0 0.0023407994
0024 O 0 0.0706822
) O 0 0.008067119
. O 0 0.007383963

Before O 0 0.008710735
the O 0 0.005246603
switch O 0 0.0048780716
, O 0 0.0036699083
11 O 0 0.0024757404
. O 0 0.0012148937
5 O 0 0.0009484089
% O 0 0.00095569814
of O 0 0.000808869
patients O 0 0.0014932601
had O 0 0.0007052019
high O 0 0.0012620311
- O 0 0.00307005
grade O 0 0.8146727
proteinuria B-Disease 2 0.999987
( O 0 0.005141674
> O 0 0.0014224855
1 O 0 0.0005148322
. O 0 0.00030499106
0 O 0 0.0004496805
g O 0 0.0006221374
/ O 0 0.00083944463
day O 0 0.00044201827
) O 0 0.000980771
; O 0 0.0007212358
this O 0 0.00037748943
increased O 0 0.00052630727
to O 0 0.00047027873
22 O 0 0.0007731275
. O 0 0.00042337592
9 O 0 0.0006068566
% O 0 0.00081252604
postswitch O 0 0.0020262618
( O 0 0.00139096
p O 0 0.0015961522
= O 0 0.0021707832
0 O 0 0.002451241
. O 0 0.0024809698
006 O 0 0.09643506
) O 0 0.007860491
. O 0 0.00733383

ACE B-Chemical 1 0.99807346
inhibitor I-Chemical 1 0.74877506
and O 0 0.025342286
angiotensin B-Chemical 1 0.99984086
- I-Chemical 0 0.0803358
releasing I-Chemical 0 0.5530098
blocker I-Chemical 0 0.9982414
( O 0 0.072312124
ARB B-Chemical 0 0.99988055
) O 0 0.014646963
therapy O 0 0.045092423
reduced O 0 0.008323127
proteinuria B-Disease 2 0.99988616
development O 0 0.06940971
. O 0 0.012269467

Patients O 0 0.015374217
without O 0 0.0072229165
proteinuria B-Disease 2 0.9995789
had O 0 0.0036836204
increased O 0 0.0033010994
renal O 0 0.9714533
function O 0 0.0024083331
( O 0 0.0014585644
median O 0 0.0006860501
42 O 0 0.0009137313
. O 0 0.00040555486
5 O 0 0.00039191137
vs O 0 0.0006957495
. O 0 0.00034115347
64 O 0 0.00061131
. O 0 0.00030083713
1 O 0 0.0003940798
, O 0 0.0004455742
p O 0 0.0004931779
= O 0 0.0005518755
0 O 0 0.00047281318
. O 0 0.00027159238
25 O 0 0.000513527
) O 0 0.0006514228
, O 0 0.0004409109
whereas O 0 0.00029738434
patients O 0 0.0008342937
who O 0 0.00081750663
developed O 0 0.0007366401
high O 0 0.0010635939
- O 0 0.0032092393
grade O 0 0.76802075
proteinuria B-Disease 2 0.9999821
showed O 0 0.00076262414
decreased O 0 0.005709198
renal O 0 0.98281294
function O 0 0.0012899787
at O 0 0.0002902765
the O 0 0.0003165202
end O 0 0.00023335802
of O 0 0.00043757042
follow O 0 0.000401917
- O 0 0.00079663016
up O 0 0.0003938811
( O 0 0.00052706833
median O 0 0.00034707622
39 O 0 0.00066849834
. O 0 0.0002998292
6 O 0 0.00031449585
vs O 0 0.0006644846
. O 0 0.00040217378
29 O 0 0.00084550877
. O 0 0.0004760891
2 O 0 0.0007014748
, O 0 0.0010208553
p O 0 0.0013629501
= O 0 0.0019138431
0 O 0 0.0021529314
. O 0 0.0021301382
125 O 0 0.009526355
) O 0 0.0077182935
. O 0 0.0071504153

Thus O 0 0.010193666
, O 0 0.010525962
proteinuria B-Disease 2 0.99957734
may O 0 0.0035180203
develop O 0 0.00237141
in O 0 0.0015711915
cardiac O 0 0.32601303
transplant O 0 0.23059046
patients O 0 0.0026897283
after O 0 0.00048396506
switch O 0 0.0009817436
to O 0 0.0008441294
Srl B-Chemical 1 0.94046307
, O 0 0.0010135416
which O 0 0.00072193524
may O 0 0.0005205011
have O 0 0.00052129803
an O 0 0.0009980805
adverse O 0 0.71909523
effect O 0 0.0010830371
on O 0 0.0009799211
renal O 0 0.9646664
function O 0 0.002687639
in O 0 0.0025617355
these O 0 0.0047827153
patients O 0 0.017942147
. O 0 0.008374432

Srl B-Chemical 1 0.6717805
should O 0 0.00594457
be O 0 0.004941302
used O 0 0.0034612352
with O 0 0.0042895274
ACEi B-Chemical 0 0.99986196
/ O 0 0.105597086
ARB B-Chemical 0 0.9998554
therapy O 0 0.023093455
and O 0 0.001684252
patients O 0 0.0028210669
monitored O 0 0.0009282522
for O 0 0.0016823001
proteinuria B-Disease 2 0.99991035
and O 0 0.0056614326
increased O 0 0.011565474
renal B-Disease 2 0.9994836
dysfunction I-Disease 2 0.99895775
. O 0 0.014295042

Ginsenoside B-Chemical 0 0.99947184
Rg1 I-Chemical 1 0.9997904
restores O 0 0.00952092
the O 0 0.0052062133
impairment B-Disease 0 0.4419109
of I-Disease 0 0.0039902767
learning I-Disease 0 0.037772797
induced O 0 0.0032711523
by O 0 0.0046440805
chronic O 0 0.994574
morphine B-Chemical 1 0.9999691
administration O 0 0.68688405
in O 0 0.0067907707
rats O 0 0.03367438
. O 0 0.01009456

Rg1 B-Chemical 1 0.99887997
, O 0 0.014363299
as O 0 0.007363507
a O 0 0.008842129
ginsenoside B-Chemical 0 0.99948335
extracted O 0 0.0051886328
from O 0 0.0054058796
Panax O 0 0.99046385
ginseng O 0 0.98914146
, O 0 0.008031429
could O 0 0.0034176153
ameliorate O 0 0.16349085
spatial O 0 0.05717149
learning B-Disease 0 0.34898832
impairment I-Disease 0 0.94161564
. O 0 0.0127816945

Previous O 0 0.009985145
studies O 0 0.0063010594
have O 0 0.0037889855
demonstrated O 0 0.0029048298
that O 0 0.0028758855
Rg1 B-Chemical 1 0.9998392
might O 0 0.0014813371
be O 0 0.0013301
a O 0 0.0013155864
useful O 0 0.0010280375
agent O 0 0.033925746
for O 0 0.00068300095
the O 0 0.0008536771
prevention O 0 0.0038188272
and O 0 0.0012147599
treatment O 0 0.0015652142
of O 0 0.0015224048
the O 0 0.0017984794
adverse O 0 0.9339324
effects O 0 0.011837363
of O 0 0.01927569
morphine B-Chemical 1 0.9998852
. O 0 0.0121601885

The O 0 0.0069031836
aim O 0 0.005501935
of O 0 0.0039094626
this O 0 0.0026271197
study O 0 0.0022884489
was O 0 0.0013951614
to O 0 0.000925455
investigate O 0 0.0005861816
the O 0 0.00082921697
effect O 0 0.00090210664
of O 0 0.002183964
Rg1 B-Chemical 1 0.99996424
on O 0 0.00079705234
learning B-Disease 0 0.15144657
impairment I-Disease 0 0.8771301
by O 0 0.0017885581
chronic O 0 0.98999095
morphine B-Chemical 1 0.99998736
administration O 0 0.3160881
and O 0 0.0014876489
the O 0 0.0011268808
mechanism O 0 0.0015385691
responsible O 0 0.0017602829
for O 0 0.0019896291
this O 0 0.0033665118
effect O 0 0.0057118726
. O 0 0.008043569

Male O 0 0.03537962
rats O 0 0.008710087
were O 0 0.0038410514
subcutaneously O 0 0.004239704
injected O 0 0.0020335799
with O 0 0.0023630308
morphine B-Chemical 1 0.9999386
( O 0 0.002987586
10 O 0 0.000975739
mg O 0 0.17013402
/ O 0 0.0018148627
kg O 0 0.0039811293
) O 0 0.0008863849
twice O 0 0.00042149032
a O 0 0.0004289698
day O 0 0.0002981824
at O 0 0.00024640924
12 O 0 0.00022575037
hour O 0 0.0001992874
intervals O 0 0.0002450193
for O 0 0.00023173635
10 O 0 0.0003180644
days O 0 0.00029483452
, O 0 0.0006042197
and O 0 0.0008335305
Rg1 B-Chemical 1 0.99995744
( O 0 0.0012232861
30 O 0 0.0003778007
mg O 0 0.10691887
/ O 0 0.0012483037
kg O 0 0.003908165
) O 0 0.00079461874
was O 0 0.00034795975
intraperitoneally O 0 0.0011111156
injected O 0 0.00033679494
2 O 0 0.0003329923
hours O 0 0.000217775
after O 0 0.00020270419
the O 0 0.000323172
second O 0 0.000423292
injection O 0 0.001170073
of O 0 0.0012222218
morphine B-Chemical 1 0.9999145
once O 0 0.0011377415
a O 0 0.0014855029
day O 0 0.0012855319
for O 0 0.0016478646
10 O 0 0.002959236
days O 0 0.0037287094
. O 0 0.0065128314

Spatial O 0 0.035414424
learning O 0 0.01839465
capacity O 0 0.011378522
was O 0 0.008106675
assessed O 0 0.006475427
in O 0 0.007192252
the O 0 0.00878833
Morris O 0 0.11893828
water O 0 0.046387512
maze O 0 0.11412634
. O 0 0.014907974

The O 0 0.007175186
results O 0 0.0052004084
showed O 0 0.0033640808
that O 0 0.0025024677
rats O 0 0.004596583
treated O 0 0.003000783
with O 0 0.004893656
Morphine B-Chemical 1 0.99999285
/ O 0 0.18479729
Rg1 B-Chemical 1 0.99996257
decreased O 0 0.0038284385
escape O 0 0.011341362
latency O 0 0.004906416
and O 0 0.00096321414
increased O 0 0.0008946288
the O 0 0.0007327376
time O 0 0.00068341015
spent O 0 0.0008799238
in O 0 0.0010703686
platform O 0 0.0023113317
quadrant O 0 0.021956446
and O 0 0.003239755
entering O 0 0.005938437
frequency O 0 0.006799109
. O 0 0.008492364

By O 0 0.0097933
implantation O 0 0.006592032
of O 0 0.0039696917
electrodes O 0 0.013079135
and O 0 0.0024324406
electrophysiological O 0 0.055258326
recording O 0 0.0024499062
in O 0 0.0009822822
vivo O 0 0.0013908983
, O 0 0.0010062256
the O 0 0.00056849077
results O 0 0.00061608956
showed O 0 0.0005736634
that O 0 0.00077539834
Rg1 B-Chemical 1 0.9999517
restored O 0 0.0010058087
the O 0 0.0006942727
long O 0 0.0008966437
- O 0 0.0015807368
term O 0 0.0008965211
potentiation O 0 0.9499443
( O 0 0.011208085
LTP O 0 0.99716216
) O 0 0.0026426958
impaired O 0 0.0012597061
by O 0 0.0012864935
morphine B-Chemical 1 0.9998957
in O 0 0.0010625842
both O 0 0.0011917352
freely O 0 0.0018684728
moving O 0 0.0035686109
and O 0 0.0032924537
anaesthetised O 0 0.120156504
rats O 0 0.011912967
. O 0 0.0083698565

The O 0 0.0072546955
electrophysiological O 0 0.029190201
recording O 0 0.006063752
in O 0 0.00269238
vitro O 0 0.0027285158
showed O 0 0.0016107414
that O 0 0.001749224
Rg1 B-Chemical 1 0.9999367
restored O 0 0.0022648035
the O 0 0.0015545062
LTP O 0 0.99321187
in O 0 0.0007856655
slices O 0 0.016024914
from O 0 0.0005114407
the O 0 0.00048338735
rats O 0 0.0013343226
treated O 0 0.0007774189
with O 0 0.0011620395
morphine B-Chemical 1 0.9999815
, O 0 0.00176353
but O 0 0.00053720415
not O 0 0.0004670891
changed O 0 0.0007879719
LTP O 0 0.9809348
in O 0 0.00042601308
the O 0 0.0004646159
slices O 0 0.008913296
from O 0 0.00044500918
normal O 0 0.0011942413
saline O 0 0.2441359
- O 0 0.0015741264
or O 0 0.0007693183
morphine B-Chemical 1 0.99998116
/ O 0 0.12109482
Rg1 B-Chemical 1 0.9999856
- O 0 0.0046640737
treated O 0 0.00096035923
rats O 0 0.005046384
; O 0 0.0011373416
this O 0 0.0004394892
restoration O 0 0.00084601535
could O 0 0.0004076275
be O 0 0.0006288721
inhibited O 0 0.0010353028
by O 0 0.0017932993
N B-Chemical 1 0.99695635
- I-Chemical 1 0.026901603
methyl I-Chemical 1 0.9960771
- I-Chemical 1 0.064767174
D I-Chemical 1 0.9915671
- I-Chemical 1 0.093908615
aspartate I-Chemical 1 0.99993193
( O 0 0.09232956
NMDA B-Chemical 1 0.99998105
) O 0 0.05208115
receptor O 0 0.6789922
antagonist O 0 0.9981469
MK801 B-Chemical 1 0.9999672
. O 0 0.0143805165

We O 0 0.008195495
conclude O 0 0.005420855
that O 0 0.0049559395
Rg1 B-Chemical 1 0.9996642
may O 0 0.0028747045
significantly O 0 0.002197164
improve O 0 0.0009960886
the O 0 0.001019312
spatial O 0 0.002651343
learning O 0 0.0031509537
capacity O 0 0.0014288293
impaired O 0 0.0013947603
by O 0 0.0012474948
chonic O 0 0.89466834
morphine B-Chemical 1 0.9999776
administration O 0 0.29964453
and O 0 0.001931087
restore O 0 0.001366851
the O 0 0.0029088047
morphine B-Chemical 1 0.9999496
- O 0 0.044968814
inhibited O 0 0.020365827
LTP O 0 0.9964288
. O 0 0.010791008

This O 0 0.033683576
effect O 0 0.024113871
is O 0 0.031130105
NMDA B-Chemical 1 0.99958235
receptor O 0 0.66028535
dependent O 0 0.025191795
. O 0 0.026315387

Synthesis O 0 0.33153
of O 0 0.015996832
N B-Chemical 0 0.9805531
- I-Chemical 0 0.021487433
pyrimidinyl I-Chemical 0 0.90779984
- I-Chemical 0 0.008942159
2 I-Chemical 0 0.004133091
- I-Chemical 0 0.0052024415
phenoxyacetamides I-Chemical 0 0.0608192
as O 0 0.0065373885
adenosine B-Chemical 1 0.99956864
A2A O 0 0.9996325
receptor O 0 0.887781
antagonists O 0 0.99410254
. O 0 0.015523896

A O 0 0.032541104
series O 0 0.010666351
of O 0 0.009216326
N B-Chemical 0 0.98396045
- I-Chemical 0 0.018461224
pyrimidinyl I-Chemical 0 0.93060124
- I-Chemical 0 0.006823664
2 I-Chemical 0 0.0026508395
- I-Chemical 0 0.0038539753
phenoxyacetamide I-Chemical 0 0.5791554
adenosine B-Chemical 1 0.9992281
A O 0 0.51445866
( O 0 0.005307783
2A O 0 0.0055979276
) O 0 0.007413
antagonists O 0 0.9016425
is O 0 0.005307138
described O 0 0.005952096
. O 0 0.0092188595

SAR O 0 0.55238026
studies O 0 0.00769741
led O 0 0.0050194757
to O 0 0.0031827013
compound O 0 0.03947348
14 O 0 0.0020735306
with O 0 0.0013683268
excellent O 0 0.0024882285
potency O 0 0.18519194
( O 0 0.00618152
K O 1 0.9983266
( O 0 0.0019915637
i O 0 0.004631652
) O 0 0.0016179156
= O 0 0.0008331612
0 O 0 0.0006048388
. O 0 0.00032585496
4 O 0 0.00042977813
nM O 0 0.010015405
) O 0 0.0011151641
, O 0 0.0007353075
selectivity O 0 0.005244219
( O 0 0.0010473931
A O 0 0.049521428
( O 0 0.000958158
1 O 0 0.0006286593
) O 0 0.000971847
/ O 0 0.0016263004
A O 0 0.0438085
( O 0 0.0010180484
2A O 0 0.0011664879
) O 0 0.0011649028
> O 0 0.000882674
100 O 0 0.0009721108
) O 0 0.00084865105
, O 0 0.0005264287
and O 0 0.000432775
efficacy O 0 0.0015094903
( O 0 0.0009815075
MED O 0 0.29030657
10 O 0 0.00047241966
mg O 0 0.09327181
/ O 0 0.0010860262
kg O 0 0.0020414295
p O 0 0.0006718151
. O 0 0.0003803513
o O 0 0.002067685
. O 0 0.0004366036
) O 0 0.0008147962
in O 0 0.00041787644
the O 0 0.0006139995
rat O 0 0.043562207
haloperidol B-Chemical 1 0.999997
- O 0 0.009048509
induced O 0 0.0033713658
catalepsy B-Disease 2 0.99998474
model O 0 0.0028715474
for O 0 0.0022236067
Parkinson B-Disease 0 0.9997255
' I-Disease 0 0.0060954355
s I-Disease 0 0.00602618
disease I-Disease 0 0.7117628
. O 0 0.0097318385

Evidence O 0 0.01620142
for O 0 0.0055676745
an O 0 0.0056187413
involvement O 0 0.0059817815
of O 0 0.0049808514
D1 O 0 0.9939644
and O 0 0.0064568515
D2 O 0 0.99756855
dopamine B-Chemical 1 0.9998746
receptors O 0 0.31422257
in O 0 0.001780087
mediating O 0 0.0025129286
nicotine B-Chemical 1 0.9997899
- O 0 0.022085004
induced O 0 0.008061099
hyperactivity B-Disease 2 0.9998535
in O 0 0.006940166
rats O 0 0.034635417
. O 0 0.009671367

Previous O 0 0.008940984
studies O 0 0.0053951805
have O 0 0.0029949022
suggested O 0 0.0020340937
that O 0 0.0013632013
repeated O 0 0.001256028
exposure O 0 0.0018761542
of O 0 0.0012706285
rats O 0 0.002340097
to O 0 0.00064099376
the O 0 0.0006528974
drug O 0 0.23943284
or O 0 0.00058988197
to O 0 0.00047265252
the O 0 0.00049284595
experimental O 0 0.00067492813
environment O 0 0.0011024913
is O 0 0.00061737094
necessary O 0 0.0004443041
to O 0 0.00072237843
observe O 0 0.0009281903
nicotine B-Chemical 1 0.9996232
- O 0 0.010349547
induced O 0 0.0048994557
locomotor O 0 0.89510965
stimulation O 0 0.015322569
. O 0 0.009127271

In O 0 0.0070830053
the O 0 0.0047265743
present O 0 0.0027321137
study O 0 0.0026326478
the O 0 0.001708892
role O 0 0.0010889713
of O 0 0.0014062941
habituation O 0 0.04627075
to O 0 0.0007615544
the O 0 0.0006743213
experimental O 0 0.00078572554
environment O 0 0.0010497837
on O 0 0.0004810945
the O 0 0.0008060652
stimulant O 0 0.97151214
effect O 0 0.0013189234
of O 0 0.0028107488
nicotine B-Chemical 1 0.9995239
in O 0 0.002706148
rats O 0 0.0087587
was O 0 0.003910605
examined O 0 0.004743371
. O 0 0.00855464

In O 0 0.007050239
addition O 0 0.004067408
, O 0 0.004159391
the O 0 0.0023501203
role O 0 0.0015501627
of O 0 0.0029565077
dopamine B-Chemical 1 0.999861
receptors O 0 0.38042971
in O 0 0.001139529
mediating O 0 0.0013834481
nicotine B-Chemical 1 0.99990237
- O 0 0.009259983
induced O 0 0.0011365522
locomotor O 0 0.7871637
stimulation O 0 0.0012512897
was O 0 0.00044590014
investigated O 0 0.0003199034
by O 0 0.00042704341
examining O 0 0.00027308645
the O 0 0.00040743191
effects O 0 0.0009104134
of O 0 0.0009993061
selective O 0 0.044048615
D1 O 0 0.99743444
and O 0 0.0031371566
D2 O 0 0.9981711
dopamine B-Chemical 1 0.99991024
receptor O 0 0.43952852
antagonists O 0 0.96141124
on O 0 0.0013147884
activity O 0 0.0026280868
induced O 0 0.0035972274
by O 0 0.008334603
nicotine B-Chemical 1 0.99920577
. O 0 0.010570075

Locomotor O 0 0.2994905
activity O 0 0.008623474
was O 0 0.0055740313
assessed O 0 0.0038779431
in O 0 0.0038848438
male O 0 0.0124225225
Sprague O 0 0.39443088
- O 0 0.0071171885
Dawley O 0 0.047639273
rats O 0 0.005641406
tested O 0 0.0035879093
in O 0 0.0054599866
photocell O 0 0.06590021
cages O 0 0.012942811
. O 0 0.011230849

Nicotine B-Chemical 1 0.9996673
( O 0 0.012278536
1 O 0 0.004396127
. O 0 0.0022769284
0 O 0 0.0022233266
mg O 0 0.11406125
/ O 0 0.0032588602
kg O 0 0.010611457
) O 0 0.0018055247
caused O 0 0.0008659632
a O 0 0.00094143435
significant O 0 0.0007039922
increase B-Disease 0 0.0004856736
in I-Disease 0 0.000581413
locomotor I-Disease 0 0.5531728
activity I-Disease 0 0.00065645855
in O 0 0.00041160043
rats O 0 0.0009883341
that O 0 0.0003149573
were O 0 0.00038996595
habituated O 0 0.0005239761
to O 0 0.00030459557
the O 0 0.0003525406
test O 0 0.0005354093
environment O 0 0.0009606517
, O 0 0.00070400327
but O 0 0.0003877043
had O 0 0.0003394438
only O 0 0.00036092603
a O 0 0.0006067002
weak O 0 0.0011064785
and O 0 0.00074925786
delayed O 0 0.0099582365
stimulant O 0 0.98833615
action O 0 0.009735042
in O 0 0.0007858722
rats O 0 0.0019789152
that O 0 0.0008048141
were O 0 0.0012873275
unfamiliar O 0 0.004648793
with O 0 0.0019969286
the O 0 0.0026369796
test O 0 0.004646779
environment O 0 0.009070985
. O 0 0.0084078945

The O 0 0.0077480953
stimulant O 0 0.9238546
action O 0 0.020725835
of O 0 0.0055642514
nicotine B-Chemical 1 0.99964464
was O 0 0.002714381
blocked O 0 0.0027232945
by O 0 0.0012235601
the O 0 0.00095737824
central O 0 0.012895108
nicotinic O 0 0.99991775
antagonist O 0 0.99870026
mecamylamine B-Chemical 0 0.9999969
but O 0 0.0009872913
not O 0 0.0005059302
by O 0 0.0005373645
the O 0 0.000531872
peripheral O 0 0.21229006
nicotinic O 0 0.9999428
blocker O 0 0.99951875
hexamethonium B-Chemical 1 0.99999774
, O 0 0.0023521003
indicating O 0 0.00049992825
that O 0 0.000455905
the O 0 0.00061599823
response O 0 0.0011547749
is O 0 0.001045018
probably O 0 0.0020061494
mediated O 0 0.0016766166
by O 0 0.0031416095
central O 0 0.043639943
nicotinic O 0 0.9995017
receptors O 0 0.5426852
. O 0 0.010136065

Nicotine B-Chemical 1 0.99980646
- O 0 0.035037726
induced O 0 0.010107886
hyperactivity B-Disease 2 0.99982125
was O 0 0.0037673977
blocked O 0 0.003348717
by O 0 0.0015838057
the O 0 0.0012416482
selective O 0 0.037868015
D1 O 0 0.99894804
antagonist O 0 0.99847776
SCH B-Chemical 1 0.9999894
23390 I-Chemical 1 0.9999845
, O 0 0.0021390354
the O 0 0.0008206942
selective O 0 0.0202885
D2 O 0 0.9964611
antagonist O 0 0.9963814
raclopride B-Chemical 0 0.99998343
and O 0 0.0024404968
the O 0 0.002465586
D1 O 0 0.9952905
/ O 0 0.062948786
D2 O 0 0.9962895
antagonist O 0 0.9974732
fluphenazine B-Chemical 0 0.99997747
. O 0 0.01343506

Pretreatment O 0 0.5962539
with O 0 0.0073730103
the O 0 0.0063005807
D2 O 0 0.99204016
agonist O 0 0.9938985
PHNO B-Chemical 0 0.9999125
enhanced O 0 0.01162594
nicotine B-Chemical 1 0.9999037
- O 0 0.028537368
induced O 0 0.0053808326
hyperactivity B-Disease 2 0.9999628
, O 0 0.0032136466
whereas O 0 0.0011308646
the O 0 0.001835452
D1 O 0 0.9984059
agonist O 0 0.99667513
SKF B-Chemical 0 0.9999862
38393 I-Chemical 0 0.99999166
had O 0 0.0036240262
no O 0 0.0032281638
effect O 0 0.0058862614
. O 0 0.008154941

The O 0 0.007110691
results O 0 0.0050997944
indicate O 0 0.0032483153
that O 0 0.0027547507
acute O 0 0.9516028
nicotine B-Chemical 1 0.99976736
injection O 0 0.038525358
induces O 0 0.0016061141
a O 0 0.0026062725
pronounced O 0 0.006317378
hyperactivity B-Disease 2 0.9998846
in O 0 0.0017998009
rats O 0 0.0043050623
habituated O 0 0.0025500655
to O 0 0.0019317404
the O 0 0.0027724535
test O 0 0.0049123233
environment O 0 0.009456404
. O 0 0.008892011

The O 0 0.0072151003
effect O 0 0.0047921436
appears O 0 0.0030931365
to O 0 0.0022835266
be O 0 0.0019224142
mediated O 0 0.0014711553
by O 0 0.0016078776
central O 0 0.00861958
nicotine B-Chemical 1 0.99975425
receptors O 0 0.4937152
, O 0 0.0018097914
possibly O 0 0.001823769
located O 0 0.00061152177
on O 0 0.00044163398
dopaminergic O 0 0.95349413
neurons O 0 0.018620493
, O 0 0.00079640467
and O 0 0.0005510343
also O 0 0.0005175679
requires O 0 0.00036951827
the O 0 0.0006475349
activation O 0 0.0013841704
of O 0 0.0013900792
both O 0 0.0021683709
D1 O 0 0.9942584
and O 0 0.0072133997
D2 O 0 0.99782556
dopamine B-Chemical 1 0.99968934
receptors O 0 0.5187752
. O 0 0.010416579

Central O 0 0.02396829
retinal B-Disease 0 0.28693596
vein I-Disease 0 0.07309752
occlusion I-Disease 0 0.342812
associated O 0 0.011777709
with O 0 0.016196245
clomiphene B-Chemical 0 0.9999285
- O 0 0.07947668
induced O 0 0.020342508
ovulation O 0 0.98930806
. O 0 0.017900797

OBJECTIVE O 0 0.41959903
: O 0 0.008638586
To O 0 0.003866718
report O 0 0.0046851565
a O 0 0.0029380452
case O 0 0.0019991098
of O 0 0.0020064597
central O 0 0.003920873
retinal B-Disease 0 0.61719483
vein I-Disease 0 0.09455304
occlusion I-Disease 0 0.41990477
associated O 0 0.003482795
with O 0 0.009454663
clomiphene B-Chemical 0 0.99999154
citrate I-Chemical 0 0.9997142
( O 0 0.10966694
CC B-Chemical 1 0.98582006
) O 0 0.020963946
. O 0 0.010022801

DESIGN O 0 0.108223185
: O 0 0.06977521
Case O 0 0.094684534
study O 0 0.058146685
. O 0 0.054987483

SETTING O 0 0.045645647
: O 0 0.024415797
Ophthalmology O 0 0.028066905
clinic O 0 0.015077775
of O 0 0.013603215
an O 0 0.017279653
academic O 0 0.026430305
hospital O 0 0.03203709
. O 0 0.020473108

PATIENT O 0 0.027695669
( O 0 0.015016998
S O 0 0.5611881
) O 0 0.009282052
: O 0 0.0054533673
A O 0 0.014570673
36 O 0 0.0028372584
- O 0 0.0027220591
year O 0 0.0016777919
- O 0 0.0020195001
old O 0 0.0016042771
woman O 0 0.0059791342
referred O 0 0.0018381658
from O 0 0.0018018658
the O 0 0.0024678386
infertility B-Disease 0 0.9954484
clinic O 0 0.0070766862
for O 0 0.0047859373
blurred B-Disease 0 0.97757304
vision I-Disease 0 0.9501538
. O 0 0.01234401

INTERVENTION O 0 0.036776055
( O 0 0.022981865
S O 0 0.50909215
) O 0 0.017808158
: O 0 0.013327523
Ophthalmic O 0 0.049974155
examination O 0 0.011276181
after O 0 0.007946857
CC B-Chemical 1 0.8737612
therapy O 0 0.0909219
. O 0 0.01693629

MAIN O 0 0.41634026
OUTCOME O 0 0.07342016
MEASURE O 0 0.043389883
( O 0 0.010086695
S O 0 0.44509098
) O 0 0.0072259563
: O 0 0.0045629744
Central O 0 0.00491499
retinal B-Disease 0 0.23893754
vein I-Disease 0 0.03645666
occlusion I-Disease 0 0.21647273
after O 0 0.002670038
ovulation O 0 0.90949833
induction O 0 0.0061894516
with O 0 0.0099694505
CC B-Chemical 1 0.97298336
. O 0 0.012478431

RESULT O 0 0.07881156
( O 0 0.015471687
S O 0 0.6012023
) O 0 0.008999579
: O 0 0.0051227957
A O 0 0.014468386
36 O 0 0.002564353
- O 0 0.0024077764
year O 0 0.0014270968
- O 0 0.0017117423
old O 0 0.0013319764
Chinese O 0 0.006279259
woman O 0 0.007262496
developed O 0 0.0015917259
central O 0 0.0027631563
retinal B-Disease 0 0.4720034
vein I-Disease 0 0.031404108
occlusion I-Disease 0 0.08697316
after O 0 0.0011839529
eight O 0 0.0018330241
courses O 0 0.0044837547
of O 0 0.006676608
CC B-Chemical 1 0.95919234
. O 0 0.010124169

A O 0 0.024312237
search O 0 0.005283965
of O 0 0.0039205267
the O 0 0.0026463731
literature O 0 0.0025569177
on O 0 0.0012103516
the O 0 0.0015665442
thromboembolic B-Disease 2 0.99994886
complications O 0 0.92618227
of O 0 0.0036159186
CC B-Chemical 1 0.9660532
does O 0 0.00060558174
not O 0 0.00051237614
include O 0 0.0005810734
this O 0 0.0005929103
severe O 0 0.14007878
ophthalmic O 0 0.7167828
complication O 0 0.73601013
, O 0 0.0015944936
although O 0 0.00084804883
mild O 0 0.58085734
visual B-Disease 0 0.7817229
disturbance I-Disease 0 0.7799908
after O 0 0.0012683705
CC B-Chemical 1 0.963176
intake O 0 0.71555495
is O 0 0.0035612683
not O 0 0.0044609834
uncommon O 0 0.08984782
. O 0 0.0098701855

CONCLUSION O 0 0.89026517
( O 0 0.018308012
S O 0 0.7077354
) O 0 0.008592985
: O 0 0.0042233756
This O 0 0.002640329
is O 0 0.0014642823
the O 0 0.0011362106
first O 0 0.0009070382
reported O 0 0.0011403392
case O 0 0.0010287781
of O 0 0.0013042743
central O 0 0.0032977078
retinal B-Disease 0 0.5967939
vein I-Disease 0 0.05846113
occlusion I-Disease 0 0.20086049
after O 0 0.0017379721
treatment O 0 0.0049219476
with O 0 0.007238045
CC B-Chemical 1 0.9701375
. O 0 0.010445796

Extra O 0 0.037237085
caution O 0 0.0067728455
is O 0 0.004059796
warranted O 0 0.0024330136
in O 0 0.0020118896
treating O 0 0.0070372294
infertility B-Disease 0 0.9979894
patients O 0 0.021837559
with O 0 0.0023523385
CC B-Chemical 1 0.9772091
, O 0 0.0015602103
and O 0 0.0008456538
patients O 0 0.0014035684
should O 0 0.00038422435
be O 0 0.0005128603
well O 0 0.00047095172
informed O 0 0.0010073018
of O 0 0.0008204632
this O 0 0.00091301504
side O 0 0.018421395
effect O 0 0.0013702726
before O 0 0.001169053
commencement O 0 0.0028208364
of O 0 0.004250557
therapy O 0 0.067400694
. O 0 0.008694152

Acute O 0 0.9615341
bronchodilating O 0 0.9956866
effects O 0 0.015475878
of O 0 0.0121867135
ipratropium B-Chemical 0 0.99996114
bromide I-Chemical 0 0.99990344
and O 0 0.028172644
theophylline B-Chemical 1 0.9999299
in O 0 0.0060915886
chronic B-Disease 0 0.99197793
obstructive I-Disease 0 0.99943537
pulmonary I-Disease 0 0.9979214
disease I-Disease 0 0.99177027
. O 0 0.017375518

The O 0 0.007039812
bronchodilator O 0 0.6773086
effects O 0 0.005034078
of O 0 0.0027841057
a O 0 0.0022489952
single O 0 0.0014561495
dose O 0 0.007574008
of O 0 0.0023574505
ipratropium B-Chemical 0 0.9999856
bromide I-Chemical 0 0.9999516
aerosol O 0 0.574626
( O 0 0.0023840305
36 O 0 0.000794493
micrograms O 0 0.1651654
) O 0 0.0011759625
and O 0 0.00056827115
short O 0 0.00052319514
- O 0 0.0012788335
acting O 0 0.007928975
theophylline B-Chemical 1 0.9999732
tablets O 0 0.98674774
( O 0 0.0013058627
dose O 0 0.0049448903
titrated O 0 0.00096833194
to O 0 0.00034508502
produce O 0 0.00033695184
serum O 0 0.041080274
levels O 0 0.00042071973
of O 0 0.0005925267
10 O 0 0.0005837245
- O 0 0.0006647386
20 O 0 0.000374834
micrograms O 0 0.058342237
/ O 0 0.0018647414
mL O 0 0.0031984143
) O 0 0.00071377115
were O 0 0.0003081291
compared O 0 0.00020768159
in O 0 0.0002977673
a O 0 0.0005167328
double O 0 0.00055022055
- O 0 0.0010228935
blind O 0 0.005058296
, O 0 0.00076252205
placebo O 0 0.08178914
- O 0 0.00080457795
controlled O 0 0.00040888795
crossover O 0 0.0020857202
study O 0 0.00059024803
in O 0 0.00048053262
21 O 0 0.0007367872
patients O 0 0.001208377
with O 0 0.00093589444
stable O 0 0.0015864356
, O 0 0.0028888567
chronic B-Disease 0 0.9589604
obstructive I-Disease 0 0.99919754
pulmonary I-Disease 0 0.9970891
disease I-Disease 0 0.9884412
. O 0 0.013937853

Mean O 0 0.0074884836
peak O 0 0.005268351
forced O 0 0.006875668
expiratory O 0 0.10062525
volume O 0 0.0036208683
in O 0 0.001435452
1 O 0 0.0011878103
second O 0 0.0009857632
( O 0 0.0013115578
FEV1 O 0 0.332974
) O 0 0.00097565906
increases O 0 0.00040802622
over O 0 0.0002734874
baseline O 0 0.00043699352
and O 0 0.00039793874
the O 0 0.0003269927
proportion O 0 0.0002992153
of O 0 0.0004937762
patients O 0 0.0015322134
attaining O 0 0.0022122294
at O 0 0.00026169457
least O 0 0.00021847482
a O 0 0.0004522837
15 O 0 0.0003130217
% O 0 0.0003835383
increase O 0 0.00024513894
in O 0 0.00030141676
the O 0 0.00041343566
FEV1 O 0 0.45734966
( O 0 0.00068288355
responders O 0 0.0026303753
) O 0 0.00074909226
were O 0 0.00037553057
31 O 0 0.0005530727
% O 0 0.00040999032
and O 0 0.00038854845
90 O 0 0.00037532262
% O 0 0.00050933054
, O 0 0.0005837941
respectively O 0 0.00079976994
, O 0 0.00062925764
for O 0 0.00043499313
ipratropium B-Chemical 0 0.9996524
and O 0 0.0009192046
17 O 0 0.0010863779
% O 0 0.0008336743
and O 0 0.0008699292
50 O 0 0.0013584811
% O 0 0.0014801993
, O 0 0.0019226786
respectively O 0 0.0030112779
, O 0 0.0035345103
for O 0 0.0038357344
theophylline B-Chemical 1 0.9996549
. O 0 0.010156031

The O 0 0.0066609033
average O 0 0.0044045034
FEV1 O 0 0.05734263
increases O 0 0.0024999944
during O 0 0.0015534128
the O 0 0.0014704968
6 O 0 0.0011275047
- O 0 0.0012812596
hour O 0 0.00059431966
observation O 0 0.0006480232
period O 0 0.00063980476
were O 0 0.0007695243
18 O 0 0.00081446866
% O 0 0.0009986511
for O 0 0.00094280817
ipratropium B-Chemical 0 0.999495
and O 0 0.0024410018
8 O 0 0.002334686
% O 0 0.0033922584
for O 0 0.00398121
theophylline B-Chemical 1 0.99962115
. O 0 0.010772695

The O 0 0.0065153223
mean O 0 0.004427781
duration O 0 0.0036198946
of O 0 0.00309743
action O 0 0.0060349093
was O 0 0.0018692199
3 O 0 0.0012934665
. O 0 0.0008311115
8 O 0 0.0007803206
hours O 0 0.0006044383
with O 0 0.0010499906
ipratropium B-Chemical 0 0.9997098
and O 0 0.0018369613
2 O 0 0.0015030946
. O 0 0.0011464856
4 O 0 0.0015459293
hours O 0 0.001876224
with O 0 0.0047148373
theophylline B-Chemical 1 0.9996766
. O 0 0.010501422

While O 0 0.008984266
side O 0 0.024721282
effects O 0 0.006471428
were O 0 0.003655554
rare O 0 0.012104616
, O 0 0.0028959753
those O 0 0.0019469581
experienced O 0 0.0022148192
after O 0 0.0010196276
theophylline B-Chemical 1 0.9998418
use O 0 0.0018500085
did O 0 0.0013165978
involve O 0 0.0015985287
the O 0 0.0022027334
cardiovascular B-Disease 0 0.9928237
and I-Disease 0 0.008227004
gastrointestinal I-Disease 0 0.99697685
systems I-Disease 0 0.03061948
. O 0 0.010559232

These O 0 0.008882514
results O 0 0.005577886
show O 0 0.0035135762
that O 0 0.0030030946
ipratropium B-Chemical 0 0.99964404
is O 0 0.0024908467
a O 0 0.0021252704
more O 0 0.0016258328
potent O 0 0.012917397
bronchodilator O 0 0.96519333
than O 0 0.0011082095
oral O 0 0.78148115
theophylline B-Chemical 1 0.9999428
in O 0 0.0019886324
patients O 0 0.008867025
with O 0 0.0038291716
chronic B-Disease 0 0.9950523
airflow I-Disease 0 0.99190265
obstruction I-Disease 0 0.99486107
. O 0 0.011629786

Methamphetamine B-Chemical 1 0.99977666
- O 0 0.034869976
induced O 0 0.011633565
neurotoxicity B-Disease 2 0.99977356
and O 0 0.009211116
microglial O 0 0.91107416
activation O 0 0.009310536
are O 0 0.0029602337
not O 0 0.002453042
mediated O 0 0.0030238475
by O 0 0.0054497966
fractalkine O 0 0.98244804
receptor O 0 0.5907864
signaling O 0 0.026186764
. O 0 0.011861004

Methamphetamine B-Chemical 1 0.9998048
( O 0 0.075300984
METH B-Chemical 1 0.9999306
) O 0 0.06697668
damages O 0 0.96568274
dopamine B-Chemical 1 0.9999145
( O 0 0.03561129
DA B-Chemical 1 0.9997482
) O 0 0.0047797156
nerve O 0 0.50583184
endings O 0 0.4321019
by O 0 0.00080089096
a O 0 0.0007922322
process O 0 0.0005695514
that O 0 0.00043578006
has O 0 0.00047261786
been O 0 0.0005918434
linked O 0 0.0005358771
to O 0 0.00056741
microglial O 0 0.7175253
activation O 0 0.0025504646
but O 0 0.0006764563
the O 0 0.00064959325
signaling O 0 0.001269368
pathways O 0 0.0016503674
that O 0 0.00064297003
mediate O 0 0.00079057645
this O 0 0.0010342747
response O 0 0.0018121031
have O 0 0.0016442771
not O 0 0.0022587583
yet O 0 0.0038574627
been O 0 0.0047856625
delineated O 0 0.011596672
. O 0 0.008567637

Cardona O 0 0.47345525
et O 0 0.11716942
al O 0 0.1217768
. O 0 0.08340719

[ O 0 0.029416677
Nat O 0 0.2442806
. O 0 0.006794493
Neurosci O 0 0.83010954
. O 0 0.0028500082
9 O 0 0.00244353
( O 0 0.002392433
2006 O 0 0.0027139655
) O 0 0.0022092054
, O 0 0.0016241436
917 O 0 0.3017356
] O 0 0.0012732766
recently O 0 0.0005970632
identified O 0 0.0004647935
the O 0 0.0006507911
microglial O 0 0.77734876
- O 0 0.0019725987
specific O 0 0.0005970963
fractalkine O 0 0.97014934
receptor O 0 0.4910405
( O 0 0.0055173417
CX3CR1 O 0 0.9330318
) O 0 0.0016680745
as O 0 0.0006111574
an O 0 0.0008467569
important O 0 0.0006275226
mediator O 0 0.007439639
of O 0 0.00997414
MPTP B-Chemical 1 0.999995
- O 0 0.0280132
induced O 0 0.00726264
neurodegeneration B-Disease 0 0.99959594
of O 0 0.057177495
DA B-Chemical 1 0.9997136
neurons O 0 0.22484061
. O 0 0.00918239

Because O 0 0.007744789
the O 0 0.0070880437
CNS B-Disease 0 0.9840184
damage I-Disease 0 0.96530914
caused O 0 0.0065510897
by O 0 0.006987316
METH B-Chemical 1 0.999987
and O 0 0.02267542
MPTP B-Chemical 1 0.9999943
is O 0 0.0012257155
highly O 0 0.0009998835
selective O 0 0.0030753845
for O 0 0.00047484678
the O 0 0.000847659
DA B-Chemical 1 0.99970967
neuronal O 0 0.37837783
system O 0 0.0009901993
in O 0 0.0004084693
mouse O 0 0.0006375551
models O 0 0.0007692148
of O 0 0.0015461649
neurotoxicity B-Disease 2 0.9999604
, O 0 0.0009953285
we O 0 0.00027273517
hypothesized O 0 0.0003658365
that O 0 0.0003921141
the O 0 0.0006704552
CX3CR1 O 0 0.8323445
plays O 0 0.00071811327
a O 0 0.0009833989
role O 0 0.00067128544
in O 0 0.0015900296
METH B-Chemical 1 0.9999876
- O 0 0.016028201
induced O 0 0.0064435494
neurotoxicity B-Disease 2 0.9999355
and O 0 0.015526221
microglial O 0 0.95762247
activation O 0 0.03986271
. O 0 0.0097166635

Mice O 0 0.008651417
in O 0 0.0052431077
which O 0 0.004383414
the O 0 0.003339601
CX3CR1 O 0 0.7554396
gene O 0 0.0032564371
has O 0 0.0014406559
been O 0 0.0013174477
deleted O 0 0.0014333712
and O 0 0.0010012425
replaced O 0 0.0007922609
with O 0 0.00076869613
a O 0 0.0011470956
cDNA O 0 0.0013563739
encoding O 0 0.0006747893
enhanced O 0 0.0007003209
green O 0 0.0016765862
fluorescent O 0 0.003650129
protein O 0 0.0028433
( O 0 0.002290978
eGFP O 0 0.0028202273
) O 0 0.001228405
were O 0 0.0006779303
treated O 0 0.001013841
with O 0 0.0017029584
METH B-Chemical 1 0.99996364
and O 0 0.0022367067
examined O 0 0.0018308033
for O 0 0.0035409518
striatal O 0 0.9946243
neurotoxicity B-Disease 2 0.99980885
. O 0 0.012189843

METH B-Chemical 1 0.99971265
depleted O 0 0.015131717
DA B-Chemical 1 0.9993923
, O 0 0.0065423297
caused O 0 0.0034733186
microglial O 0 0.87407976
activation O 0 0.0112000145
, O 0 0.0018371799
and O 0 0.0009971291
increased O 0 0.0009874013
body O 0 0.00974835
temperature O 0 0.0015900467
in O 0 0.0007225533
CX3CR1 O 0 0.821536
knockout O 0 0.000695236
mice O 0 0.000342129
to O 0 0.00035907762
the O 0 0.00036525572
same O 0 0.00027808957
extent O 0 0.00031973506
and O 0 0.0004904683
over O 0 0.00031064928
the O 0 0.0004497506
same O 0 0.00041090537
time O 0 0.0005666334
course O 0 0.0010216301
seen O 0 0.0011176794
in O 0 0.0015631336
wild O 0 0.002388968
- O 0 0.0046370807
type O 0 0.004299004
controls O 0 0.011304743
. O 0 0.008552162

The O 0 0.0075616227
effects O 0 0.0069932337
of O 0 0.00722106
METH B-Chemical 1 0.9999336
in O 0 0.0041711293
CX3CR1 O 0 0.9084349
knockout O 0 0.0021081504
mice O 0 0.00097545265
were O 0 0.0010353724
not O 0 0.0009631077
gender O 0 0.031394005
- O 0 0.0018347559
dependent O 0 0.000891813
and O 0 0.0013832365
did O 0 0.0012820044
not O 0 0.0015344283
extend O 0 0.0018395111
beyond O 0 0.0028148324
the O 0 0.004880753
striatum O 0 0.5359653
. O 0 0.008644635

Striatal O 0 0.98967195
microglia O 0 0.27494833
expressing O 0 0.0045970087
eGFP O 0 0.006202165
constitutively O 0 0.0024613847
show O 0 0.0017961321
morphological O 0 0.0048360974
changes O 0 0.0028040118
after O 0 0.0018054507
METH B-Chemical 1 0.999918
that O 0 0.0023051188
are O 0 0.003109885
characteristic O 0 0.004603118
of O 0 0.0067784484
activation O 0 0.017993908
. O 0 0.010357643

This O 0 0.010275674
response O 0 0.005942536
was O 0 0.0034866002
restricted O 0 0.001968549
to O 0 0.0016715523
the O 0 0.0016359005
striatum O 0 0.2222433
and O 0 0.001305458
contrasted O 0 0.002333519
sharply O 0 0.005381014
with O 0 0.0010573742
unresponsive O 0 0.01468843
eGFP O 0 0.0112951435
- O 0 0.0018601028
microglia O 0 0.07057205
in O 0 0.0007645677
surrounding O 0 0.00152251
brain O 0 0.047581185
areas O 0 0.0024886585
that O 0 0.0010828334
are O 0 0.0017641968
not O 0 0.0022197298
damaged O 0 0.018584253
by O 0 0.0092715295
METH B-Chemical 1 0.99988353
. O 0 0.011186061

We O 0 0.008168493
conclude O 0 0.005044775
from O 0 0.0041656513
these O 0 0.003601263
studies O 0 0.0030943074
that O 0 0.0023638692
CX3CR1 O 0 0.8609889
signaling O 0 0.004179727
does O 0 0.0016837752
not O 0 0.0019389929
modulate O 0 0.0027845397
METH B-Chemical 1 0.9999844
neurotoxicity B-Disease 2 0.9999449
or O 0 0.014476812
microglial O 0 0.96939653
activation O 0 0.05128863
. O 0 0.010852016

Furthermore O 0 0.0100284815
, O 0 0.0072570755
it O 0 0.0042401454
appears O 0 0.0024599722
that O 0 0.002045767
striatal O 0 0.9561187
- O 0 0.0036149311
resident O 0 0.002262246
microglia O 0 0.16762237
respond O 0 0.0010163961
to O 0 0.0011003625
METH B-Chemical 1 0.9999813
with O 0 0.001129515
an O 0 0.0014122187
activation O 0 0.0019526333
cascade O 0 0.00274717
and O 0 0.00084760896
then O 0 0.00062510534
return O 0 0.00097109535
to O 0 0.000614431
a O 0 0.0010600195
surveying O 0 0.001864447
state O 0 0.0015225341
without O 0 0.0015634834
undergoing O 0 0.00402024
apoptosis O 0 0.93532884
or O 0 0.006491965
migration O 0 0.12108584
. O 0 0.009520018

Nicotine B-Chemical 1 0.99943835
- O 0 0.034769446
induced O 0 0.018730918
nystagmus B-Disease 0 0.9962902
correlates O 0 0.015130899
with O 0 0.016686356
midpontine O 0 0.87705845
activation O 0 0.030522026
. O 0 0.018300844

The O 0 0.011707197
pathomechanism O 0 0.33583477
of O 0 0.013574912
nicotine B-Chemical 1 0.9994854
- O 0 0.03245864
induced O 0 0.0114693
nystagmus B-Disease 0 0.99951756
( O 0 0.043194022
NIN B-Disease 0 0.989913
) O 0 0.012585115
is O 0 0.0074200486
unknown O 0 0.017721267
. O 0 0.012129663

The O 0 0.0080198115
aim O 0 0.0065912423
of O 0 0.0048435978
this O 0 0.0034455634
study O 0 0.0031556962
was O 0 0.0021853196
to O 0 0.0017164845
delineate O 0 0.0016733141
brain O 0 0.033465724
structures O 0 0.002919059
that O 0 0.0018757934
are O 0 0.0027592713
involved O 0 0.0029506355
in O 0 0.004893359
NIN B-Disease 0 0.97431225
generation O 0 0.011079054
. O 0 0.010688578

Eight O 0 0.011084959
healthy O 0 0.01042351
volunteers O 0 0.008712645
inhaled O 0 0.92158496
nicotine B-Chemical 1 0.99946886
in O 0 0.00212514
darkness O 0 0.0029864882
during O 0 0.0007387048
a O 0 0.0010524502
functional O 0 0.0011694835
magnetic O 0 0.123131566
resonance O 0 0.3234062
imaging O 0 0.0096471375
( O 0 0.0017153878
fMRI O 0 0.02101083
) O 0 0.0012446572
experiment O 0 0.000675453
; O 0 0.001542147
eye O 0 0.00562443
movements O 0 0.0023327996
were O 0 0.0013119114
registered O 0 0.0019301543
using O 0 0.0021266674
video O 0 0.0077780993
- O 0 0.0070500793
oculography O 0 0.11006932
. O 0 0.0081563685

NIN B-Disease 0 0.81700987
correlated O 0 0.006739593
with O 0 0.004874874
blood O 0 0.023711631
oxygen B-Chemical 1 0.9719516
level O 0 0.002468854
- O 0 0.0031456621
dependent O 0 0.0014429435
( O 0 0.0027218119
BOLD O 0 0.3757625
) O 0 0.0019583025
activity O 0 0.0010250469
levels O 0 0.0008244896
in O 0 0.0009361491
a O 0 0.0018068521
midpontine O 0 0.3051514
site O 0 0.0014771397
in O 0 0.0016235281
the O 0 0.0023414276
posterior O 0 0.008906992
basis O 0 0.0056179315
pontis O 0 0.059143092
. O 0 0.008524999

NIN B-Disease 0 0.97396857
- O 0 0.015313176
induced O 0 0.006776317
midpontine O 0 0.6214429
activation O 0 0.0051558185
may O 0 0.0017377678
correspond O 0 0.0010607494
to O 0 0.00093303504
activation O 0 0.0014360222
of O 0 0.0009871742
the O 0 0.0009796484
dorsomedial O 0 0.47216624
pontine O 0 0.86588246
nuclei O 0 0.0017304937
and O 0 0.00058252737
the O 0 0.0005088887
nucleus O 0 0.00092429045
reticularis O 0 0.06524066
tegmenti O 0 0.0016067107
pontis O 0 0.005766055
, O 0 0.0007078541
structures O 0 0.0006877109
known O 0 0.0006384282
to O 0 0.0004904482
participate O 0 0.00048722327
in O 0 0.00048116976
the O 0 0.0005873504
generation O 0 0.000940951
of O 0 0.0013324649
multidirectional O 0 0.16214257
saccades O 0 0.18474197
and O 0 0.0023242536
smooth O 0 0.024853244
pursuit O 0 0.05520028
eye O 0 0.07964978
movements O 0 0.01595603
. O 0 0.0081060855

Acute O 0 0.9026636
effects O 0 0.011302888
of O 0 0.009562045
N B-Chemical 0 0.99216664
- I-Chemical 0 0.012429966
( I-Chemical 0 0.0037950107
2 I-Chemical 0 0.002041965
- I-Chemical 0 0.0025371038
propylpentanoyl I-Chemical 0 0.02391495
) I-Chemical 0 0.004304196
urea I-Chemical 1 0.9971501
on O 0 0.000998919
hippocampal O 0 0.93614155
amino B-Chemical 1 0.9935368
acid I-Chemical 1 0.9984848
neurotransmitters O 0 0.9962165
in O 0 0.00489367
pilocarpine B-Chemical 1 0.9999864
- O 0 0.019727064
induced O 0 0.005662361
seizure B-Disease 2 0.99971753
in O 0 0.006043099
rats O 0 0.026637692
. O 0 0.009343952

The O 0 0.0067367335
present O 0 0.0038902413
study O 0 0.0035413487
aimed O 0 0.0023074094
to O 0 0.0014708483
investigate O 0 0.0008806289
the O 0 0.0013882363
anticonvulsant O 0 0.99970716
activity O 0 0.0015605282
as O 0 0.00072267343
well O 0 0.00052272086
as O 0 0.0005100255
the O 0 0.00043721308
effects O 0 0.00069753005
on O 0 0.0002873794
the O 0 0.00040931493
level O 0 0.00034131992
of O 0 0.00106075
hippocampal O 0 0.9717885
amino B-Chemical 1 0.9970214
acid I-Chemical 1 0.9994136
neurotransmitters O 0 0.999231
( O 0 0.057671305
glutamate B-Chemical 1 0.9999739
, O 0 0.020529695
aspartate B-Chemical 1 0.99995244
, O 0 0.008061636
glycine B-Chemical 1 0.9995142
and O 0 0.0033546707
GABA B-Chemical 1 0.999982
) O 0 0.002032487
of O 0 0.001156761
N B-Chemical 0 0.99236333
- I-Chemical 0 0.002871699
( I-Chemical 0 0.001051892
2 I-Chemical 0 0.00067220896
- I-Chemical 0 0.0010712751
propylpentanoyl I-Chemical 0 0.019961473
) I-Chemical 0 0.0047955425
urea I-Chemical 1 0.9992774
( O 0 0.004147181
VPU B-Chemical 1 0.9779839
) O 0 0.0011911279
in O 0 0.00045714914
comparison O 0 0.0004604538
to O 0 0.0005827578
its O 0 0.0013641787
parent O 0 0.0020163578
compound O 0 0.4245065
, O 0 0.026059994
valproic B-Chemical 0 0.99998343
acid I-Chemical 0 0.99636453
( O 0 0.19575235
VPA B-Chemical 1 0.9999443
) O 0 0.036081057
. O 0 0.009426034

VPU B-Chemical 1 0.9020526
was O 0 0.00754104
more O 0 0.0054020965
potent O 0 0.014079258
than O 0 0.002963037
VPA B-Chemical 1 0.9999454
, O 0 0.0026404294
exhibiting O 0 0.001272685
the O 0 0.00073232985
median O 0 0.0006462298
effective O 0 0.00084246846
dose O 0 0.021193257
( O 0 0.0019617223
ED O 0 0.6692156
( O 0 0.0011536628
50 O 0 0.0010019705
) O 0 0.0009937785
) O 0 0.0006813201
of O 0 0.00045266718
49 O 0 0.000869229
mg O 0 0.13092473
/ O 0 0.0012439697
kg O 0 0.0022462937
in O 0 0.00045236977
protecting O 0 0.007851278
rats O 0 0.0038764642
against O 0 0.0010070134
pilocarpine B-Chemical 1 0.9999939
- O 0 0.007963622
induced O 0 0.0013454247
seizure B-Disease 2 0.99981934
whereas O 0 0.00076826225
the O 0 0.00068848795
corresponding O 0 0.0006309165
value O 0 0.0010370663
for O 0 0.0013031543
VPA B-Chemical 1 0.999949
was O 0 0.002600464
322 O 0 0.052108835
mg O 0 0.40287834
/ O 0 0.010583463
kg O 0 0.021006003
. O 0 0.00847411

In O 0 0.0071639954
vivo O 0 0.006148287
microdialysis O 0 0.14950548
demonstrated O 0 0.0020984428
that O 0 0.001382651
an O 0 0.0018051536
intraperitoneal O 0 0.17474695
administration O 0 0.19658683
of O 0 0.0055028093
pilocarpine B-Chemical 1 0.9999926
induced O 0 0.0019945444
a O 0 0.0015653633
pronounced O 0 0.0011785154
increment O 0 0.0008087111
of O 0 0.0014075668
hippocampal O 0 0.979878
glutamate B-Chemical 1 0.99996173
and O 0 0.003898084
aspartate B-Chemical 1 0.9998467
whereas O 0 0.0005410252
no O 0 0.00035458637
significant O 0 0.000580755
change O 0 0.00059197855
was O 0 0.0005302222
observed O 0 0.00045462657
on O 0 0.0005880999
the O 0 0.0010302995
level O 0 0.0012502164
of O 0 0.004426196
glycine B-Chemical 1 0.9993456
and O 0 0.045203157
GABA B-Chemical 1 0.9998416
. O 0 0.01108518

Pretreatment O 0 0.58567476
with O 0 0.007960176
either O 0 0.0068139085
VPU B-Chemical 1 0.9698665
( O 0 0.004352481
50 O 0 0.0024088968
and O 0 0.0015266867
100 O 0 0.0019870384
mg O 0 0.19928047
/ O 0 0.0026208926
kg O 0 0.009960752
) O 0 0.0019067081
or O 0 0.0011744547
VPA B-Chemical 1 0.99998116
( O 0 0.0017198304
300 O 0 0.0017068215
and O 0 0.00061788346
600 O 0 0.0017265698
mg O 0 0.1359088
/ O 0 0.001676805
kg O 0 0.0066592316
) O 0 0.0014392958
completely O 0 0.0009178394
abolished O 0 0.0054103425
pilocarpine B-Chemical 1 0.9999883
- O 0 0.007583662
evoked O 0 0.18997861
increases O 0 0.0015091139
in O 0 0.002107207
extracellular O 0 0.47409672
glutamate B-Chemical 1 0.9998646
and O 0 0.038345773
aspartate B-Chemical 1 0.9996412
. O 0 0.011876505

In O 0 0.0071848338
addition O 0 0.004149829
, O 0 0.0042375913
a O 0 0.0028267978
statistically O 0 0.001651562
significant O 0 0.001484752
reduction O 0 0.0016641429
was O 0 0.00083779456
also O 0 0.00066859846
observed O 0 0.0004308773
on O 0 0.00039848915
the O 0 0.00054166355
level O 0 0.00047462372
of O 0 0.0017916007
GABA B-Chemical 1 0.9999825
and O 0 0.0026684625
glycine B-Chemical 1 0.9991767
but O 0 0.0008279584
less O 0 0.0006154595
than O 0 0.00048402505
a O 0 0.000997066
drastic O 0 0.001797994
reduction O 0 0.0022048515
of O 0 0.0041152984
glutamate B-Chemical 1 0.9998424
and O 0 0.015381574
aspartate B-Chemical 1 0.9996172
level O 0 0.0063890377
. O 0 0.008544339

Based O 0 0.0124039315
on O 0 0.004665311
the O 0 0.00395416
finding O 0 0.003923537
that O 0 0.0028245298
VPU B-Chemical 1 0.9827983
and O 0 0.005154872
VPA B-Chemical 1 0.9999702
could O 0 0.0010879688
protect O 0 0.0023774246
the O 0 0.0007986919
animals O 0 0.0007250433
against O 0 0.0010551065
pilocarpine B-Chemical 1 0.9999945
- O 0 0.01213668
induced O 0 0.0015702791
seizure B-Disease 2 0.9999081
it O 0 0.0009164678
is O 0 0.00046361357
suggested O 0 0.00033721115
that O 0 0.00030775982
the O 0 0.00041382012
reduction O 0 0.0008252952
of O 0 0.000866113
inhibitory O 0 0.16631359
amino B-Chemical 1 0.9956938
acid I-Chemical 1 0.9983986
neurotransmitters O 0 0.9909046
was O 0 0.00080704206
comparatively O 0 0.0015935017
minor O 0 0.0016307257
and O 0 0.00086637464
offset O 0 0.0014523752
by O 0 0.00095962844
a O 0 0.0013313892
pronounced O 0 0.0017888458
reduction O 0 0.0029404406
of O 0 0.005959605
glutamate B-Chemical 1 0.9998331
and O 0 0.0321659
aspartate B-Chemical 1 0.9996437
. O 0 0.011699413

Therefore O 0 0.008318441
, O 0 0.007914967
like O 0 0.0060315924
VPA B-Chemical 1 0.99988794
, O 0 0.0042709038
the O 0 0.0016704458
finding O 0 0.0018461294
that O 0 0.0012402997
VPU B-Chemical 1 0.9737124
could O 0 0.00079551036
drastically O 0 0.0070325225
reduce O 0 0.0014563231
pilocarpine B-Chemical 1 0.99999547
- O 0 0.013731778
induced O 0 0.0010728886
increases O 0 0.0009577962
in O 0 0.0011484826
glutamate B-Chemical 1 0.99994695
and O 0 0.0033653118
aspartate B-Chemical 1 0.99985766
should O 0 0.0003414568
account O 0 0.00050219713
, O 0 0.0005066521
at O 0 0.00024130593
least O 0 0.00022736266
partly O 0 0.0005987675
, O 0 0.0005641825
for O 0 0.00034083572
its O 0 0.001281698
anticonvulsant O 0 0.99971515
activity O 0 0.0010767156
observed O 0 0.0005928908
in O 0 0.0015297163
pilocarpine B-Chemical 1 0.9999876
- O 0 0.010557988
induced O 0 0.0033504136
seizure B-Disease 2 0.9997205
in O 0 0.0031203465
experimental O 0 0.004864042
animals O 0 0.006006618
. O 0 0.008270788

Some O 0 0.0136994785
other O 0 0.007639101
mechanism O 0 0.0061508347
than O 0 0.0037413037
those O 0 0.004353132
being O 0 0.004365434
reported O 0 0.0036743365
herein O 0 0.00496043
should O 0 0.0029663478
be O 0 0.0043915794
further O 0 0.005276832
investigated O 0 0.007105768
. O 0 0.011133929

Protective O 0 0.56210345
effect O 0 0.00934944
of O 0 0.010719375
verapamil B-Chemical 1 0.99988353
on O 0 0.005954952
gastric B-Disease 0 0.99839705
hemorrhagic I-Disease 2 0.9999652
ulcers B-Disease 0 0.9999304
in O 0 0.017813599
severe O 0 0.91777194
atherosclerotic B-Disease 2 0.9992436
rats O 0 0.2086927
. O 0 0.013825309

Studies O 0 0.017118437
concerning O 0 0.0063058613
with O 0 0.0049972935
pathogenesis O 0 0.009018213
of O 0 0.005858494
gastric B-Disease 0 0.9980196
hemorrhage I-Disease 2 0.9999758
and O 0 0.007903724
mucosal O 0 0.9200392
ulceration O 0 0.9997937
produced O 0 0.0040751817
in O 0 0.0036952202
atherosclerotic B-Disease 2 0.9982475
rats O 0 0.03439242
are O 0 0.0060474044
lacking O 0 0.005577029
. O 0 0.009101355

The O 0 0.0068799346
aim O 0 0.005485572
of O 0 0.0039042004
this O 0 0.0026310633
study O 0 0.002308456
is O 0 0.0013890973
to O 0 0.0009189235
examine O 0 0.0005624351
the O 0 0.0007646304
role O 0 0.00057227875
of O 0 0.0012834979
gastric O 0 0.9849186
acid O 0 0.99178654
back O 0 0.13290341
- O 0 0.0051804795
diffusion O 0 0.038576603
, O 0 0.0014182945
mast O 0 0.9266993
cell O 0 0.17499314
histamine B-Chemical 1 0.9999449
release O 0 0.56515545
, O 0 0.0068166936
lipid O 0 0.9855262
peroxide O 0 0.99994624
( O 0 0.090642095
LPO O 0 0.99999464
) O 0 0.0050272564
generation O 0 0.00083038077
and O 0 0.0006839819
mucosal O 0 0.46378225
microvascular O 0 0.9770785
permeability O 0 0.8598295
in O 0 0.0007002068
modulating O 0 0.0013637486
gastric B-Disease 0 0.99863285
hemorrhage I-Disease 2 0.99999344
and O 0 0.005701148
ulcer B-Disease 2 0.99984574
in O 0 0.0013187402
rats O 0 0.010665353
with O 0 0.0020577153
atherosclerosis B-Disease 2 0.99990964
induced O 0 0.0037988885
by O 0 0.004082818
coadministration O 0 0.9974717
of O 0 0.03441838
vitamin B-Chemical 0 0.9999676
D2 I-Chemical 0 0.9995939
and O 0 0.052935556
cholesterol B-Chemical 1 0.9994266
. O 0 0.013894695

Additionally O 0 0.011891612
, O 0 0.0086618075
the O 0 0.005230784
protective O 0 0.008874768
effect O 0 0.0037545126
of O 0 0.0057285647
verapamil B-Chemical 1 0.9999349
on O 0 0.0028130757
this O 0 0.0040058107
ulcer B-Disease 2 0.9991079
model O 0 0.008863443
was O 0 0.0065952432
evaluated O 0 0.0076321554
. O 0 0.010615116

Male O 0 0.05199849
Wistar O 0 0.040642403
rats O 0 0.0073529715
were O 0 0.0030763142
challenged O 0 0.0021255636
intragastrically O 0 0.025729842
once O 0 0.0013051422
daily O 0 0.0015239257
for O 0 0.00061742857
9 O 0 0.00063926145
days O 0 0.00043374024
with O 0 0.0005849152
1 O 0 0.0006561627
. O 0 0.0004202592
0 O 0 0.00063027145
ml O 0 0.0012839241
/ O 0 0.001511643
kg O 0 0.00300539
of O 0 0.0014194954
corn O 0 0.9764787
oil O 0 0.9925351
containing O 0 0.010466487
vitamin B-Chemical 0 0.9999783
D2 I-Chemical 0 0.999665
and O 0 0.017041547
cholesterol B-Chemical 1 0.9995522
to O 0 0.0053537176
induce O 0 0.0072922735
atherosclerosis B-Disease 2 0.9996767
. O 0 0.015726957

Control O 0 0.05314734
rats O 0 0.03902047
received O 0 0.03141339
corn O 0 0.9576732
oil O 0 0.97142
only O 0 0.039437443
. O 0 0.036109474

After O 0 0.0078053125
gastric O 0 0.31557944
surgery O 0 0.010957499
, O 0 0.004878961
rat O 0 0.0064574694
stomachs O 0 0.017558588
were O 0 0.0021197824
irrigated O 0 0.0147504825
for O 0 0.0011515664
3 O 0 0.0011096596
h O 0 0.0009105977
with O 0 0.0010681265
either O 0 0.0012696281
simulated O 0 0.0017184222
gastric O 0 0.93008876
juice O 0 0.9965848
or O 0 0.0061038625
normal O 0 0.018756203
saline O 0 0.5083798
. O 0 0.0098513495

Gastric O 0 0.91353863
acid O 0 0.93880576
back O 0 0.06454414
- O 0 0.008399217
diffusion O 0 0.03855167
, O 0 0.0044248286
mucosal O 0 0.8762828
LPO O 0 0.9999825
generation O 0 0.013865975
, O 0 0.0048945616
histamine B-Chemical 1 0.9996927
concentration O 0 0.010147155
, O 0 0.0021346644
microvascular O 0 0.9381494
permeability O 0 0.8779009
, O 0 0.0023998565
luminal B-Chemical 1 0.3768954
hemoglobin O 0 0.9464802
content O 0 0.0020611698
and O 0 0.0036045702
ulcer B-Disease 2 0.9994357
areas O 0 0.027934596
were O 0 0.0050278367
determined O 0 0.0051111314
. O 0 0.008415015

Elevated O 0 0.21736045
atherosclerotic B-Disease 2 0.98615557
parameters O 0 0.009741595
, O 0 0.0043901536
such O 0 0.0022497396
as O 0 0.002398331
serum O 0 0.38050365
calcium B-Chemical 1 0.99958295
, O 0 0.003056914
total O 0 0.0015873323
cholesterol B-Chemical 1 0.99928635
and O 0 0.0020613433
low O 0 0.0025353162
- O 0 0.003423029
density O 0 0.0029416431
lipoprotein O 0 0.9993536
concentration O 0 0.006994483
were O 0 0.0021028386
obtained O 0 0.002341815
in O 0 0.003541514
atherosclerotic B-Disease 2 0.99733645
rats O 0 0.06715843
. O 0 0.010198884

Severe O 0 0.9226945
gastric O 0 0.9695132
ulcers B-Disease 0 0.99967265
accompanied O 0 0.035426475
with O 0 0.0038526582
increased O 0 0.0047040908
ulcerogenic O 0 0.9998348
factors O 0 0.13364293
, O 0 0.0027793888
including O 0 0.001275422
gastric O 0 0.98205364
acid O 0 0.99032354
back O 0 0.12063004
- O 0 0.0055136234
diffusion O 0 0.05267068
, O 0 0.002567387
histamine B-Chemical 1 0.99979645
release O 0 0.37534273
, O 0 0.008186125
LPO O 0 0.99998283
generation O 0 0.0016379701
and O 0 0.0012070191
luminal B-Chemical 1 0.40741867
hemoglobin O 0 0.9415511
content O 0 0.0012424387
were O 0 0.0011985657
also O 0 0.0012788129
observed O 0 0.0012873373
in O 0 0.002372063
these O 0 0.004784658
rats O 0 0.014234546
. O 0 0.008521119

Moreover O 0 0.010352438
, O 0 0.006824862
a O 0 0.0043028006
positive O 0 0.0027747035
correlation O 0 0.0018175357
of O 0 0.0029174138
histamine B-Chemical 1 0.99951386
to O 0 0.002846693
gastric B-Disease 0 0.9982508
hemorrhage I-Disease 2 0.9999827
and O 0 0.0034456488
to O 0 0.0019336056
ulcer B-Disease 2 0.99953055
was O 0 0.0023481292
found O 0 0.0016804727
in O 0 0.0023475068
those O 0 0.0057197157
atherosclerotic B-Disease 2 0.9974208
rats O 0 0.073118106
. O 0 0.010435853

This O 0 0.016965425
hemorrhagic B-Disease 2 0.99839586
ulcer B-Disease 0 0.999171
and O 0 0.008041418
various O 0 0.007724496
ulcerogenic O 0 0.9996538
parameters O 0 0.0086376835
were O 0 0.0025565163
dose O 0 0.085410625
- O 0 0.011805514
dependently O 0 0.9619584
ameliorated O 0 0.66484576
by O 0 0.0047210637
daily O 0 0.02953359
intragastric O 0 0.9885387
verapamil B-Chemical 1 0.99993014
. O 0 0.014268475

Atherosclerosis B-Disease 0 0.9821299
could O 0 0.006203523
produce O 0 0.0046971035
gastric B-Disease 0 0.99160427
hemorrhagic I-Disease 2 0.9999498
ulcer B-Disease 0 0.9999075
via O 0 0.0050091003
aggravation O 0 0.98382115
of O 0 0.0059388336
gastric O 0 0.9941964
acid O 0 0.99473107
back O 0 0.16901864
- O 0 0.007830479
diffusion O 0 0.08242995
, O 0 0.005449407
LPO O 0 0.9999863
generation O 0 0.0036071027
, O 0 0.0030698031
histamine B-Chemical 1 0.9997085
release O 0 0.10713637
and O 0 0.0012673138
microvascular O 0 0.94325393
permeability O 0 0.740768
that O 0 0.0008964225
could O 0 0.000949469
be O 0 0.001716091
ameliorated O 0 0.45108575
by O 0 0.0077137654
verapamil B-Chemical 1 0.9999566
in O 0 0.006070325
rats O 0 0.033456706
. O 0 0.009175576

Lamivudine B-Chemical 1 0.99459165
for O 0 0.006130394
the O 0 0.004841704
prevention O 0 0.014253344
of O 0 0.018239575
hepatitis B-Disease 2 0.9999881
B I-Disease 2 0.99777776
virus O 0 0.67251754
reactivation O 0 0.7493401
in O 0 0.0060548787
hepatitis B-Chemical 2 0.9999869
- I-Chemical 0 0.08664658
B I-Chemical 0 0.5652227
surface I-Chemical 0 0.0049441718
antigen I-Chemical 0 0.16237819
( O 0 0.009867051
HBSAG B-Chemical 0 0.99392277
) O 0 0.0048280926
seropositive O 0 0.046813305
cancer B-Disease 2 0.9941421
patients O 0 0.01676258
undergoing O 0 0.0059303213
cytotoxic O 0 0.9181378
chemotherapy O 0 0.9713855
. O 0 0.011494682

Hepatitis B-Disease 2 0.99949586
B I-Disease 2 0.96921533
virus O 0 0.41915655
( O 0 0.018095221
HBV O 0 0.9899469
) O 0 0.0067243013
is O 0 0.0021846187
one O 0 0.0014956761
of O 0 0.0016489791
the O 0 0.0015619955
major O 0 0.0022653264
causes O 0 0.004998031
of O 0 0.006596871
chronic O 0 0.9984957
liver B-Disease 2 0.99947804
disease I-Disease 2 0.99933475
worldwide O 0 0.85925657
. O 0 0.015631787

Cancer B-Disease 2 0.771486
patients O 0 0.011646779
who O 0 0.0071516572
are O 0 0.003797851
chronic O 0 0.8706695
carriers O 0 0.07364033
of O 0 0.004121584
HBV O 0 0.99488056
have O 0 0.0010645073
a O 0 0.0012896395
higher O 0 0.0008361541
hepatic B-Disease 0 0.99181867
complication I-Disease 0 0.9227101
rate O 0 0.00085730036
while O 0 0.0006299009
receiving O 0 0.0018168913
cytotoxic O 0 0.78417957
chemotherapy O 0 0.9478244
( O 0 0.0054027447
CT O 0 0.75852233
) O 0 0.0015112753
and O 0 0.000870381
this O 0 0.00084721285
has O 0 0.000944619
mainly O 0 0.0020621382
been O 0 0.002086525
attributed O 0 0.0023552533
to O 0 0.0042103906
HBV O 0 0.99594504
reactivation O 0 0.6495429
. O 0 0.012057334

In O 0 0.007655714
this O 0 0.0054211756
study O 0 0.004851488
, O 0 0.0045707547
cancer B-Disease 2 0.97542614
patients O 0 0.006495596
who O 0 0.0028498215
have O 0 0.0010613945
solid O 0 0.14085875
and O 0 0.0029595904
hematological B-Disease 0 0.9997465
malignancies I-Disease 2 0.99997807
with O 0 0.020884354
chronic O 0 0.99858046
HBV B-Disease 0 0.9999418
infection I-Disease 2 0.95998234
received O 0 0.0011406661
the O 0 0.00077703426
antiviral O 0 0.337319
agent O 0 0.6480061
lamivudine B-Chemical 1 0.99988365
prior O 0 0.00049591064
and O 0 0.0007351086
during O 0 0.00047659536
CT O 0 0.26115882
compared O 0 0.00038228152
with O 0 0.0006755595
historical O 0 0.003902259
control O 0 0.0008857196
group O 0 0.0013613622
who O 0 0.002511387
did O 0 0.0017158262
not O 0 0.002544301
receive O 0 0.0051182383
lamivudine B-Chemical 1 0.9993394
. O 0 0.010741925

The O 0 0.007621303
objectives O 0 0.00577726
were O 0 0.0034034871
to O 0 0.002126441
assess O 0 0.0011137055
the O 0 0.001316322
efficacy O 0 0.0026132378
of O 0 0.0022731407
lamivudine B-Chemical 1 0.9998074
in O 0 0.0010885446
reducing O 0 0.0014182931
the O 0 0.00095672125
incidence O 0 0.018493174
of O 0 0.0029333388
HBV O 0 0.9985453
reactivation O 0 0.48951423
, O 0 0.00259761
and O 0 0.0017450367
diminishing O 0 0.0061290376
morbidity O 0 0.7616719
and O 0 0.0045591397
mortality O 0 0.53252524
during O 0 0.005149347
CT O 0 0.8114039
. O 0 0.00954963

Two O 0 0.022301788
groups O 0 0.016975734
were O 0 0.013952462
compared O 0 0.010063327
in O 0 0.012728525
this O 0 0.014639958
study O 0 0.02049622
. O 0 0.020733938

The O 0 0.008575977
prophylactic O 0 0.015715703
lamivudin B-Chemical 0 0.880476
group O 0 0.004757396
consisted O 0 0.002846908
of O 0 0.0028433816
37 O 0 0.0029224714
patients O 0 0.0037875727
who O 0 0.003795238
received O 0 0.0031061794
prophylactic O 0 0.13071595
lamivudine B-Chemical 1 0.99970716
treatment O 0 0.048597403
. O 0 0.012741193

The O 0 0.008340967
historical O 0 0.010212269
controls O 0 0.0054958723
consisted O 0 0.0031721129
of O 0 0.0029286593
50 O 0 0.0027651386
consecutive O 0 0.0021027105
patients O 0 0.0032191118
who O 0 0.0033400892
underwent O 0 0.0030445028
CT O 0 0.29163527
without O 0 0.0040450008
prophylactic O 0 0.18265313
lamivudine B-Chemical 1 0.99960774
. O 0 0.015017245

They O 0 0.017918928
were O 0 0.009059514
followed O 0 0.0059932237
up O 0 0.0054603103
during O 0 0.0040888716
and O 0 0.004736142
for O 0 0.0038297263
8 O 0 0.0044965055
weeks O 0 0.0041427133
after O 0 0.005354812
CT O 0 0.4054489
. O 0 0.012560878

The O 0 0.017623417
outcomes O 0 0.017571408
were O 0 0.012477843
compared O 0 0.008782388
for O 0 0.009946937
both O 0 0.012862881
groups O 0 0.019284569
. O 0 0.019650659

Of O 0 0.0100798
our O 0 0.0050549763
control O 0 0.0038318338
group O 0 0.003445177
( O 0 0.0030737005
n O 0 0.0022108443
= O 0 0.0022470935
50 O 0 0.0018900676
) O 0 0.0019616308
, O 0 0.001367127
21 O 0 0.0012511623
patients O 0 0.0020484074
( O 0 0.0019050029
42 O 0 0.002129672
% O 0 0.0024068214
) O 0 0.003648777
were O 0 0.0034917337
established O 0 0.008947751
hepatitis B-Disease 2 0.9997702
. O 0 0.017253365

Twelve O 0 0.022619583
( O 0 0.0119352825
24 O 0 0.0060675847
% O 0 0.006671796
) O 0 0.0061884783
of O 0 0.004493576
them O 0 0.005820649
were O 0 0.0043991897
evaluated O 0 0.0044452236
as O 0 0.0078418935
severe O 0 0.88435614
hepatitis B-Disease 2 0.9998516
. O 0 0.031127878

In O 0 0.00720846
the O 0 0.00528572
prophylactic O 0 0.030660748
lamivudine B-Chemical 1 0.99963987
group O 0 0.013989911
severe O 0 0.8751033
hepatitis B-Disease 2 0.99997246
were O 0 0.0021364042
observed O 0 0.0006739361
only O 0 0.00069233804
in O 0 0.00063587655
1 O 0 0.00069581973
patient O 0 0.00095707877
( O 0 0.00091693905
2 O 0 0.0005652946
. O 0 0.00038983367
7 O 0 0.00047675121
% O 0 0.0006532326
) O 0 0.0008318189
of O 0 0.00067357556
37 O 0 0.00097395055
patients O 0 0.0018307188
( O 0 0.0015682754
p O 0 0.0016690149
< O 0 0.0017759579
0 O 0 0.002521363
. O 0 0.002557982
006 O 0 0.0915864
) O 0 0.007983522
. O 0 0.007460835

Comparison O 0 0.007090225
of O 0 0.005402655
the O 0 0.0037149114
mean O 0 0.0033118844
ALT O 0 0.9950689
values O 0 0.0019074269
revealed O 0 0.0012619399
significantly O 0 0.0012980247
higher O 0 0.0009139324
mean O 0 0.0012491025
alanine B-Chemical 1 0.9969067
aminotransferase O 0 0.999845
( O 0 0.018428382
ALT O 0 0.9996867
) O 0 0.0014231734
values O 0 0.00043919645
in O 0 0.00031990092
the O 0 0.00032536263
control O 0 0.00034058155
group O 0 0.00043762126
than O 0 0.0002789909
the O 0 0.00041388624
prophylactic O 0 0.01710906
lamivudine B-Chemical 1 0.9998306
group O 0 0.0021599291
; O 0 0.002279274
154 O 0 0.013296008
: O 0 0.0011497972
64 O 0 0.001248472
( O 0 0.0011693995
p O 0 0.0013107955
< O 0 0.001439984
0 O 0 0.0019906303
. O 0 0.0019478896
32 O 0 0.0042772093
) O 0 0.0070647583
. O 0 0.007048143

Our O 0 0.007817139
study O 0 0.005291118
suggests O 0 0.0025664126
that O 0 0.0021549
prophylactic O 0 0.034299638
lamivudine B-Chemical 1 0.9997745
significantly O 0 0.0034566133
decreases O 0 0.0015214288
the O 0 0.0010427277
incidence O 0 0.016888632
of O 0 0.0026077009
HBV O 0 0.9980444
reactivation O 0 0.29107222
and O 0 0.0013634233
overall O 0 0.0013727314
morbidity O 0 0.75380343
in O 0 0.0014745999
cancer B-Disease 2 0.99632543
patients O 0 0.00952262
during O 0 0.0012128131
and O 0 0.0022170953
after O 0 0.0019387824
immunosuppressive O 0 0.97200483
therapy O 0 0.2427063
. O 0 0.010232004

Further O 0 0.008666083
studies O 0 0.0055021513
are O 0 0.0034534265
needed O 0 0.0018453809
to O 0 0.0014342455
determine O 0 0.0007766437
the O 0 0.000983588
most O 0 0.0012218114
appropriate O 0 0.0009643565
nucleoside B-Chemical 0 0.97483915
or O 0 0.0013595639
nucleotide B-Chemical 0 0.22850092
analogue O 0 0.14486653
for O 0 0.0005200682
antiviral O 0 0.104688704
prophylaxis O 0 0.028307116
during O 0 0.00057003583
CT O 0 0.38617015
and O 0 0.00062602054
the O 0 0.00051766215
optimal O 0 0.00043659465
duration O 0 0.00090084743
of O 0 0.0013093125
administration O 0 0.035011612
after O 0 0.0012977798
completion O 0 0.002114002
of O 0 0.0053913314
CT O 0 0.80942523
. O 0 0.008702931

Recovery O 0 0.0361198
of O 0 0.0103438925
tacrolimus B-Chemical 1 0.9998666
- O 0 0.021615624
associated O 0 0.005182242
brachial B-Disease 0 0.99334115
neuritis I-Disease 0 0.999966
after O 0 0.0012635756
conversion O 0 0.006772942
to O 0 0.0010039031
everolimus B-Chemical 1 0.99946934
in O 0 0.00078030356
a O 0 0.0010527861
pediatric O 0 0.0026475915
renal O 0 0.97724074
transplant O 0 0.6059197
recipient O 0 0.015772676
- O 0 0.0034257828
- O 0 0.0015635252
case O 0 0.0010638635
report O 0 0.0026121642
and O 0 0.00197114
review O 0 0.0034437892
of O 0 0.0033009064
the O 0 0.004422141
literature O 0 0.010005566
. O 0 0.00897387

TAC B-Chemical 1 0.9844246
has O 0 0.008030227
been O 0 0.0054746876
shown O 0 0.0030047998
to O 0 0.0025089195
be O 0 0.0023251108
a O 0 0.002678521
potent O 0 0.02034224
immunosuppressive O 0 0.97731304
agent O 0 0.535761
for O 0 0.002650832
solid O 0 0.33030686
organ O 0 0.6001096
transplantation O 0 0.54163337
in O 0 0.0066896244
pediatrics O 0 0.10486274
. O 0 0.010270143

Neurotoxicity B-Disease 0 0.99692947
is O 0 0.021031702
a O 0 0.019320486
potentially O 0 0.024092682
serious O 0 0.64173454
toxic O 0 0.96365875
effect O 0 0.028666435
. O 0 0.023703206

It O 0 0.013537668
is O 0 0.008093616
characterized O 0 0.008811705
by O 0 0.0100719845
encephalopathy B-Disease 2 0.9998877
, O 0 0.0759439
headaches B-Disease 0 0.9999336
, O 0 0.06663936
seizures B-Disease 2 0.9999362
, O 0 0.011580043
or O 0 0.0082498
neurological B-Disease 0 0.99928087
deficits I-Disease 0 0.98330957
. O 0 0.013159076

Here O 0 0.011092501
, O 0 0.006964537
we O 0 0.003085698
describe O 0 0.0026662047
an O 0 0.0029573233
eight O 0 0.0019494764
- O 0 0.0029439458
and O 0 0.001939747
- O 0 0.002254626
a O 0 0.0016565835
- O 0 0.0016530786
half O 0 0.00078819646
- O 0 0.0015493481
yr O 0 0.0020707077
- O 0 0.0014560567
old O 0 0.0013014823
male O 0 0.005064691
renal O 0 0.96372885
transplant O 0 0.53262347
recipient O 0 0.008986957
with O 0 0.0050276434
right O 0 0.04466996
BN O 0 0.98380727
. O 0 0.010630286

MRI O 0 0.56240475
demonstrated O 0 0.008594703
hyperintense O 0 0.5376163
T2 O 0 0.04055014
signals O 0 0.0037972068
in O 0 0.0021111972
the O 0 0.0019329267
cervical O 0 0.4573127
cord O 0 0.19223876
and O 0 0.0017848152
right O 0 0.004919851
brachial O 0 0.7770761
plexus O 0 0.6749374
roots O 0 0.008936409
indicative O 0 0.0012279061
of O 0 0.00186997
both O 0 0.0027960008
myelitis B-Disease 0 0.99988437
and O 0 0.006294147
right O 0 0.058847465
brachial B-Disease 0 0.9918196
plexitis I-Disease 0 0.9963231
. O 0 0.0122767845

Symptoms O 0 0.6186317
persisted O 0 0.0056494228
for O 0 0.0028513623
three O 0 0.0018466321
months O 0 0.001482599
despite O 0 0.0015284263
TAC B-Chemical 1 0.99038893
dose O 0 0.021131989
reduction O 0 0.0024280988
, O 0 0.0014293534
administration O 0 0.022684274
of O 0 0.0015197449
IVIG O 0 0.9963456
and O 0 0.0015209465
four O 0 0.0010166412
doses O 0 0.022703098
of O 0 0.004295566
methylprednisolone B-Chemical 1 0.9999044
pulse O 0 0.22809222
therapy O 0 0.1528527
. O 0 0.009416298

Improvement O 0 0.023671439
and O 0 0.00697174
eventually O 0 0.0071488214
full O 0 0.0028720265
recovery O 0 0.003542034
only O 0 0.001856376
occurred O 0 0.0018111961
after O 0 0.001269946
TAC B-Chemical 1 0.9930392
was O 0 0.0016435259
completely O 0 0.0017635972
discontinued O 0 0.015658466
and O 0 0.0023775185
successfully O 0 0.0035032618
replaced O 0 0.004129051
by O 0 0.00784638
everolimus B-Chemical 1 0.9993693
. O 0 0.011472348

Omitting O 0 0.040076934
fentanyl B-Chemical 1 0.99957424
reduces O 0 0.016958572
nausea B-Disease 2 0.99997807
and O 0 0.026325928
vomiting B-Disease 2 0.9999521
, O 0 0.0049233795
without O 0 0.0020183425
increasing O 0 0.0035118836
pain B-Disease 2 0.99873596
, O 0 0.0033813512
after O 0 0.0015526118
sevoflurane B-Chemical 1 0.99662495
for O 0 0.0028212066
day O 0 0.004161396
surgery O 0 0.0115049705
. O 0 0.008853115

BACKGROUND O 0 0.33215553
AND O 0 0.010386089
OBJECTIVE O 0 0.30186707
: O 0 0.004835019
Despite O 0 0.0024990886
advantages O 0 0.001534547
of O 0 0.0016586524
induction O 0 0.0015002948
and O 0 0.0014110357
maintenance O 0 0.0015994278
of O 0 0.0013625912
anaesthesia O 0 0.1500472
with O 0 0.0017938577
sevoflurane B-Chemical 1 0.99966776
, O 0 0.0037914286
postoperative B-Disease 0 0.48016092
nausea I-Disease 2 0.99998856
and I-Disease 0 0.021317083
vomiting I-Disease 2 0.9999219
occurs O 0 0.007084283
frequently O 0 0.014994169
. O 0 0.0100317

Fentanyl B-Chemical 0 0.9994548
is O 0 0.007638703
a O 0 0.005454989
commonly O 0 0.0047139777
used O 0 0.002481631
supplement O 0 0.006957441
that O 0 0.0014195172
may O 0 0.0013130703
contribute O 0 0.0011344608
to O 0 0.0011180505
this O 0 0.0013104391
, O 0 0.0018929932
although O 0 0.0013609811
it O 0 0.0018882774
may O 0 0.001965521
also O 0 0.0031034728
improve O 0 0.0040853666
analgesia O 0 0.9925896
. O 0 0.010344542

METHODS O 0 0.010702368
: O 0 0.007711641
This O 0 0.0050065685
double O 0 0.0033694394
- O 0 0.0033155975
blind O 0 0.0037440897
study O 0 0.0012891011
examined O 0 0.0007141093
the O 0 0.00081808947
incidence O 0 0.0048133195
and O 0 0.0010205231
severity O 0 0.035328295
of O 0 0.0013130802
postoperative B-Disease 0 0.5488693
nausea I-Disease 2 0.99999726
and I-Disease 0 0.007354214
vomiting I-Disease 2 0.99998486
and O 0 0.0032072223
pain B-Disease 2 0.99861515
in O 0 0.0005904732
the O 0 0.000472973
first O 0 0.00037238657
24 O 0 0.00037854043
h O 0 0.0003870036
after O 0 0.0004186095
sevoflurane B-Chemical 1 0.9966876
anaesthesia O 0 0.059313513
in O 0 0.0012224342
216 O 0 0.0069040307
adult O 0 0.0022436257
day O 0 0.0021821486
surgery O 0 0.006329113
patients O 0 0.011602763
. O 0 0.008333402

Patients O 0 0.012577165
were O 0 0.00508018
randomly O 0 0.0025755065
allocated O 0 0.00207808
to O 0 0.0016358076
either O 0 0.0013555693
receive O 0 0.0010339471
or O 0 0.0008857601
not O 0 0.00074955646
receive O 0 0.0006909766
1 O 0 0.00077142706
1 O 0 0.00079039
fentanyl B-Chemical 1 0.99981874
, O 0 0.0009903781
while O 0 0.00054423144
a O 0 0.0007894946
third O 0 0.00083255646
group O 0 0.0011015047
received O 0 0.0014357262
dexamethasone B-Chemical 1 0.99875426
in O 0 0.0020579814
addition O 0 0.0019985416
to O 0 0.0051730922
fentanyl B-Chemical 1 0.9998091
. O 0 0.010336875

RESULTS O 0 0.028844392
: O 0 0.009149513
Omission O 0 0.03555854
of O 0 0.0045648417
fentanyl B-Chemical 1 0.9997652
did O 0 0.0019939288
not O 0 0.0011858805
reduce O 0 0.00079961907
the O 0 0.00074117945
overall O 0 0.0008405356
incidence O 0 0.0058630644
of O 0 0.0012341411
postoperative B-Disease 0 0.5441257
nausea I-Disease 2 0.9999975
and I-Disease 0 0.0108706625
vomiting I-Disease 2 0.99998915
, O 0 0.0025540784
but O 0 0.000570705
did O 0 0.00037071033
reduce O 0 0.00033183018
the O 0 0.00043679398
incidence O 0 0.007615417
of O 0 0.001594965
vomiting B-Disease 2 0.99998415
and O 0 0.0015414534
/ O 0 0.0041138404
or O 0 0.00048369658
moderate O 0 0.0061015366
to O 0 0.0005208357
severe O 0 0.4646457
nausea B-Disease 2 0.9999962
prior O 0 0.00039233567
to O 0 0.00040244954
discharge O 0 0.0027833458
from O 0 0.00038430837
20 O 0 0.0004093563
% O 0 0.00042544375
and O 0 0.00039455606
17 O 0 0.00054308155
% O 0 0.00044078272
with O 0 0.000486333
fentanyl B-Chemical 1 0.99993944
and O 0 0.0015379112
fentanyl B-Chemical 1 0.99998546
- O 0 0.014363699
dexamethasone B-Chemical 1 0.9997373
, O 0 0.0018918593
respectively O 0 0.001663746
, O 0 0.0008674266
to O 0 0.0005689074
5 O 0 0.0006850576
% O 0 0.0011133882
( O 0 0.0016317322
P O 0 0.02937185
= O 0 0.002294163
0 O 0 0.0024754556
. O 0 0.002448272
013 O 0 0.047838796
) O 0 0.008024737
. O 0 0.0074450383

Antiemetic O 0 0.9147434
requirements O 0 0.0063045914
were O 0 0.0042821188
reduced O 0 0.0029962985
from O 0 0.002170719
24 O 0 0.0014685302
% O 0 0.0016141245
and O 0 0.0013231004
31 O 0 0.0015973594
% O 0 0.001208834
to O 0 0.000933751
7 O 0 0.0011266158
% O 0 0.0016216295
( O 0 0.0022678776
P O 0 0.03509419
= O 0 0.0030151487
0 O 0 0.003127278
. O 0 0.0029946833
0012 O 0 0.029786194
) O 0 0.009653632
. O 0 0.008621646

Dexamethasone B-Chemical 1 0.9983535
had O 0 0.0060127247
no O 0 0.0032910001
significant O 0 0.002957811
effect O 0 0.0020798193
on O 0 0.0014558973
the O 0 0.0016761281
incidence O 0 0.0069267997
or O 0 0.0021082289
severity O 0 0.07018659
of O 0 0.004882736
postoperative B-Disease 0 0.8062383
nausea I-Disease 2 0.9999833
and I-Disease 0 0.089511134
vomiting I-Disease 2 0.99986565
. O 0 0.01654641

Combining O 0 0.008951994
the O 0 0.004750707
two O 0 0.0033323362
fentanyl B-Chemical 1 0.9996013
groups O 0 0.0027065312
revealed O 0 0.0012840696
further O 0 0.00096408866
significant O 0 0.0008682531
benefits O 0 0.00091682415
from O 0 0.0005667101
the O 0 0.0005361033
avoidance O 0 0.0063456106
of O 0 0.0011033713
opioids O 0 0.9997024
, O 0 0.0013528068
reducing O 0 0.0010944335
postoperative B-Disease 0 0.4130368
nausea I-Disease 2 0.9999975
and I-Disease 0 0.005238451
vomiting I-Disease 2 0.99998677
and O 0 0.004885957
nausea B-Disease 2 0.9999956
prior O 0 0.00042537678
to O 0 0.0004213192
discharge O 0 0.002427976
from O 0 0.00039551902
35 O 0 0.0004467553
% O 0 0.00043345665
and O 0 0.00039900272
33 O 0 0.0005859263
% O 0 0.00041819146
to O 0 0.00030985542
22 O 0 0.00048876525
% O 0 0.00043813474
and O 0 0.00043375138
19 O 0 0.00070704677
% O 0 0.0006045235
( O 0 0.00074472546
P O 0 0.02761952
= O 0 0.0006991659
0 O 0 0.00057463115
. O 0 0.00033956973
049 O 0 0.0709651
and O 0 0.00055033725
P O 0 0.044143353
= O 0 0.0007180325
0 O 0 0.00058413966
. O 0 0.00033893064
035 O 0 0.043218054
) O 0 0.00088591967
, O 0 0.00060102507
respectively O 0 0.00079956645
, O 0 0.00060284405
while O 0 0.0005166632
nausea B-Disease 2 0.9999912
in O 0 0.00044106218
the O 0 0.0003749564
first O 0 0.00029870737
24 O 0 0.00030460343
h O 0 0.0002971423
was O 0 0.00037617516
decreased O 0 0.0005585337
from O 0 0.00050567364
42 O 0 0.00078299886
% O 0 0.00065472594
to O 0 0.00055562245
27 O 0 0.0011727817
% O 0 0.0011867122
( O 0 0.0017356633
P O 0 0.03316462
= O 0 0.0024305196
0 O 0 0.002622467
. O 0 0.0026013078
034 O 0 0.20039438
) O 0 0.008642318
. O 0 0.007696681

Pain B-Disease 2 0.991012
severity O 0 0.09437952
and O 0 0.008424262
analgesic O 0 0.9756368
requirements O 0 0.004415327
were O 0 0.0037782802
unaffected O 0 0.0035930255
by O 0 0.0036714256
the O 0 0.0036832304
omission O 0 0.015974488
of O 0 0.010474704
fentanyl B-Chemical 1 0.9997938
. O 0 0.013898281

Fentanyl B-Chemical 0 0.99932516
did O 0 0.006408535
reduce O 0 0.0035868662
minor O 0 0.004576344
intraoperative O 0 0.015529253
movement O 0 0.0038409363
but O 0 0.0013094934
had O 0 0.0009373553
no O 0 0.0009076564
sevoflurane B-Chemical 1 0.99960834
- O 0 0.0032806247
sparing O 0 0.01839469
effect O 0 0.0010352081
and O 0 0.0013821509
increased O 0 0.0023245343
respiratory B-Disease 0 0.9621021
depression I-Disease 2 0.9997913
, O 0 0.040799063
hypotension B-Disease 2 0.9999348
and O 0 0.031404223
bradycardia B-Disease 2 0.9995617
. O 0 0.010738266

CONCLUSION O 0 0.7442262
: O 0 0.008861969
As O 0 0.0036303129
fentanyl B-Chemical 1 0.9996681
exacerbated O 0 0.108537495
postoperative B-Disease 0 0.6266006
nausea I-Disease 2 0.9999939
and I-Disease 0 0.010275087
vomiting I-Disease 2 0.9999691
without O 0 0.0013791097
an O 0 0.0012782144
improvement O 0 0.00085408596
in O 0 0.00057910394
postoperative B-Disease 0 0.56451726
pain I-Disease 2 0.99973506
and O 0 0.0009502137
also O 0 0.0006004073
had O 0 0.00052535697
adverse O 0 0.91838175
cardiorespiratory O 0 0.94587183
effects O 0 0.0036172695
, O 0 0.0010900706
it O 0 0.0005525416
appears O 0 0.000358992
to O 0 0.00038496434
be O 0 0.00047893458
an O 0 0.00066413323
unnecessary O 0 0.001258272
and O 0 0.00093181885
possibly O 0 0.0024395497
detrimental O 0 0.0038227874
supplement O 0 0.024609782
to O 0 0.0019477718
sevoflurane B-Chemical 1 0.99863094
in O 0 0.002910268
day O 0 0.0038417773
surgery O 0 0.0112654995
. O 0 0.0081946

Valvular B-Disease 0 0.6805664
heart I-Disease 0 0.62620056
disease I-Disease 0 0.8238934
in O 0 0.0055161775
patients O 0 0.008324954
with O 0 0.005212569
Parkinson B-Disease 0 0.99948657
' I-Disease 0 0.00631068
s I-Disease 0 0.004917459
disease I-Disease 0 0.6148918
treated O 0 0.009253681
with O 0 0.018420229
pergolide B-Chemical 1 0.9999224
. O 0 0.015879186

Course O 0 0.06832661
following O 0 0.03767582
treatment O 0 0.044601608
modifications O 0 0.054416392
. O 0 0.044794355

Valvular B-Disease 0 0.7028387
heart I-Disease 0 0.6547526
abnormalities I-Disease 0 0.3603197
have O 0 0.003555008
been O 0 0.0027500505
reported O 0 0.002178729
in O 0 0.0015257674
patients O 0 0.0033950452
with O 0 0.0020937608
Parkinson B-Disease 0 0.9997621
' I-Disease 0 0.0031476903
s I-Disease 0 0.002353
disease I-Disease 0 0.79588205
( O 0 0.010037348
PD B-Disease 2 0.99868816
) O 0 0.007071676
treated O 0 0.0051891715
with O 0 0.010645889
pergolide B-Chemical 1 0.9999238
. O 0 0.012497024

However O 0 0.008891767
, O 0 0.0063130725
the O 0 0.0035911922
incidence O 0 0.0067442968
and O 0 0.0026016494
severity O 0 0.022253793
of O 0 0.001779355
these O 0 0.0016703057
abnormalities O 0 0.10300663
vary O 0 0.0011413308
from O 0 0.0007402847
study O 0 0.0007704092
to O 0 0.00051738246
study O 0 0.0006908762
and O 0 0.00063291506
their O 0 0.0006300437
course O 0 0.00077955256
after O 0 0.0005311577
drug O 0 0.4797377
withdrawal O 0 0.78202254
has O 0 0.0014899379
not O 0 0.0018974112
been O 0 0.0026377172
systematically O 0 0.0031579817
assessed O 0 0.0046774447
. O 0 0.007893799

OBJECTIVES O 0 0.02189074
: O 0 0.006424355
To O 0 0.0027263088
estimate O 0 0.0018580316
the O 0 0.001671109
frequency O 0 0.0016263578
and O 0 0.0014700979
severity O 0 0.024358856
of O 0 0.0016206516
valvular B-Disease 0 0.9655609
heart I-Disease 0 0.9050335
abnormality I-Disease 0 0.3968618
and O 0 0.0008731155
its O 0 0.0009972593
possible O 0 0.0006387861
reversibility O 0 0.042308453
after O 0 0.00050594175
drug O 0 0.4945156
withdrawal O 0 0.76848507
in O 0 0.0013268054
a O 0 0.0022977982
case O 0 0.002603938
- O 0 0.004486638
control O 0 0.0036522504
study O 0 0.0069336453
. O 0 0.007829908

METHODS O 0 0.011795505
: O 0 0.008259407
All O 0 0.005047732
PD B-Disease 2 0.93172777
patients O 0 0.0051472774
in O 0 0.0020029882
the O 0 0.0017697613
Amiens O 0 0.044792395
area O 0 0.001983267
treated O 0 0.001637107
with O 0 0.0020166861
pergolide B-Chemical 1 0.99997807
were O 0 0.0015383813
invited O 0 0.0014917977
to O 0 0.00093375985
attend O 0 0.0013749464
a O 0 0.0015269788
cardiologic O 0 0.01108633
assessment O 0 0.0020235192
including O 0 0.00286524
transthoracic O 0 0.17088367
echocardiography O 0 0.2836092
. O 0 0.008748713

Thirty O 0 0.045230247
PD B-Disease 2 0.97650856
patients O 0 0.035452943
participated O 0 0.029823989
in O 0 0.016355371
the O 0 0.017685952
study O 0 0.023343582
. O 0 0.02318284

A O 0 0.026579522
second O 0 0.006721266
echocardiography O 0 0.029000917
was O 0 0.003160245
performed O 0 0.002137441
( O 0 0.0021478247
median O 0 0.0012800118
interval O 0 0.0014302746
: O 0 0.0014048397
13 O 0 0.0009970565
months O 0 0.0006765059
) O 0 0.001244618
after O 0 0.000690152
pergolide B-Chemical 1 0.9999695
withdrawal O 0 0.8732667
( O 0 0.002558127
n O 0 0.0020074616
= O 0 0.0026422858
10 O 0 0.0024664104
patients O 0 0.006186288
) O 0 0.008652632
. O 0 0.0075989366

Controls O 0 0.036358234
were O 0 0.007985897
age O 0 0.009380836
- O 0 0.005841348
and O 0 0.003480638
sex O 0 0.04961458
- O 0 0.0032984097
matched O 0 0.0018053169
non O 0 0.004625745
- O 0 0.0057508927
PD B-Disease 2 0.9949393
patients O 0 0.005490584
referred O 0 0.002660299
to O 0 0.0025338659
the O 0 0.0037489843
cardiology O 0 0.02671775
department O 0 0.012154782
. O 0 0.010069651

RESULTS O 0 0.024882847
: O 0 0.007907831
Compared O 0 0.0036725942
to O 0 0.0027984788
controls O 0 0.0037060361
, O 0 0.0031234466
aortic B-Disease 0 0.70560706
regurgitation I-Disease 0 0.9990871
( O 0 0.0045857225
OR O 0 0.17597753
: O 0 0.0014733043
3 O 0 0.00067457446
. O 0 0.00046009274
1 O 0 0.00059975416
; O 0 0.0007776998
95 O 0 0.00079948345
% O 0 0.0005994199
IC O 0 0.097373
: O 0 0.000824785
1 O 0 0.000516118
. O 0 0.0003364466
1 O 0 0.00048010683
- O 0 0.00059748197
8 O 0 0.0003553417
. O 0 0.0002753623
8 O 0 0.0003612837
) O 0 0.0005811119
and O 0 0.00052709744
mitral B-Disease 2 0.65514237
regurgitation I-Disease 2 0.9985067
( O 0 0.0018849128
OR O 0 0.1111853
: O 0 0.00082359946
10 O 0 0.00044899626
. O 0 0.00030642885
7 O 0 0.00039756222
; O 0 0.00061680516
95 O 0 0.0006824583
% O 0 0.0005380495
IC O 0 0.086085655
: O 0 0.0007805694
2 O 0 0.00049136014
. O 0 0.00036301377
1 O 0 0.0005562198
- O 0 0.00075859134
53 O 0 0.0009836181
) O 0 0.0008016305
were O 0 0.0005082832
more O 0 0.00065282115
frequent O 0 0.0016661999
in O 0 0.0011670109
PD B-Disease 2 0.99709237
patients O 0 0.011502248
( O 0 0.0044657546
tricuspid O 0 0.4807995
: O 0 0.008811021
NS O 0 0.91648775
) O 0 0.011958777
. O 0 0.008320192

The O 0 0.0066848095
number O 0 0.0044306805
of O 0 0.0038639766
affected O 0 0.002661033
valves O 0 0.01707572
( O 0 0.002392978
n O 0 0.001531919
= O 0 0.0014361577
2 O 0 0.00077216176
. O 0 0.0005078972
4 O 0 0.00054351037
+ O 0 0.0006807071
/ O 0 0.0014895386
- O 0 0.0008848685
0 O 0 0.0005927741
. O 0 0.00030822813
7 O 0 0.00036656996
) O 0 0.0005071613
and O 0 0.00032690354
the O 0 0.00029390195
sum O 0 0.00036904265
of O 0 0.0005686689
regurgitation O 0 0.984074
grades O 0 0.17316097
( O 0 0.0008297694
n O 0 0.0005434937
= O 0 0.0005976653
2 O 0 0.00037025067
. O 0 0.00027262178
8 O 0 0.0003725979
+ O 0 0.0005017462
/ O 0 0.001426302
- O 0 0.0008459222
1 O 0 0.0004844086
. O 0 0.000354118
09 O 0 0.011348123
) O 0 0.00061988475
were O 0 0.0003555567
higher O 0 0.00037136348
( O 0 0.00061920605
p O 0 0.0005968226
= O 0 0.0006430184
0 O 0 0.00054706744
. O 0 0.0003383721
008 O 0 0.002247493
and O 0 0.000493501
p O 0 0.0007255701
= O 0 0.00084379734
0 O 0 0.0007988148
. O 0 0.0005856817
006 O 0 0.044891253
, O 0 0.0011898164
respectively O 0 0.0017901676
) O 0 0.002145447
in O 0 0.0016361948
the O 0 0.0033128257
pergolide B-Chemical 1 0.99991405
group O 0 0.0107940845
. O 0 0.008996502

Severity O 0 0.042257797
of O 0 0.013046916
regurgitation O 0 0.9501856
was O 0 0.007265074
not O 0 0.005392669
correlated O 0 0.0048807207
with O 0 0.008083534
pergolide B-Chemical 1 0.9999101
cumulative O 0 0.1498047
dose O 0 0.2957533
. O 0 0.014815368

A O 0 0.026188772
restrictive O 0 0.00706513
pattern O 0 0.003525602
of O 0 0.0036298884
valvular B-Disease 0 0.96290755
regurgitation I-Disease 0 0.999271
, O 0 0.0028189013
suggestive O 0 0.0020963626
of O 0 0.001033269
the O 0 0.00073239655
role O 0 0.00052075915
of O 0 0.0015679918
pergolide B-Chemical 1 0.9999933
, O 0 0.0016040404
was O 0 0.0005025561
observed O 0 0.00031721892
in O 0 0.00043060756
12 O 0 0.00040314536
/ O 0 0.00097055157
30 O 0 0.00043217064
( O 0 0.0006838796
40 O 0 0.00061293156
% O 0 0.0008296556
) O 0 0.0011794547
patients O 0 0.0015224078
including O 0 0.0011591486
two O 0 0.0016344159
with O 0 0.003373661
heart B-Disease 0 0.84963226
failure I-Disease 0 0.8595493
. O 0 0.009993166

Pergolide B-Chemical 0 0.9994572
was O 0 0.0066657984
discontinued O 0 0.01197268
in O 0 0.0022541324
10 O 0 0.0016409828
patients O 0 0.0020783225
with O 0 0.0012258652
valvular B-Disease 2 0.9061765
heart I-Disease 2 0.89352113
disease I-Disease 2 0.9693897
, O 0 0.0014893982
resulting O 0 0.00071696786
in O 0 0.00048418238
a O 0 0.00069866236
lower O 0 0.0006616454
regurgitation O 0 0.98495287
grade O 0 0.61085457
( O 0 0.0012209405
p O 0 0.00079165865
= O 0 0.00073889375
0 O 0 0.00058767176
. O 0 0.00033511966
01 O 0 0.0021508867
) O 0 0.00050084264
at O 0 0.00022733083
the O 0 0.0002741853
second O 0 0.00034553077
transthoracic O 0 0.010305129
echocardiography O 0 0.018199654
and O 0 0.0004670234
the O 0 0.00040673808
two O 0 0.00041825208
patients O 0 0.001332235
with O 0 0.0008639181
heart B-Disease 0 0.6091652
failure I-Disease 0 0.40835878
returned O 0 0.0012756462
to O 0 0.0011450158
nearly O 0 0.0017615855
normal O 0 0.0037190362
clinical O 0 0.012764559
examination O 0 0.008555746
. O 0 0.00818609

This O 0 0.009567312
study O 0 0.005107399
supports O 0 0.0027200822
the O 0 0.0021238674
high O 0 0.0018171673
frequency O 0 0.0014568347
of O 0 0.001404508
restrictive O 0 0.0026979577
valve B-Disease 0 0.425395
regurgitation I-Disease 0 0.99901044
in O 0 0.0012348766
PD B-Disease 2 0.99876773
patients O 0 0.0055329655
treated O 0 0.0010332695
with O 0 0.0012388097
pergolide B-Chemical 1 0.9999912
and O 0 0.0008586465
reveals O 0 0.00052272214
that O 0 0.000346457
a O 0 0.00057050656
significant O 0 0.00050709903
improvement O 0 0.0005782083
is O 0 0.00039040044
usual O 0 0.0005430971
when O 0 0.00034389453
the O 0 0.0005267303
treatment O 0 0.0010734331
is O 0 0.00085960305
converted O 0 0.0012268458
to O 0 0.0011583318
non O 0 0.011221331
- O 0 0.04659487
ergot O 0 0.999931
dopamine B-Chemical 1 0.9998814
agonists O 0 0.9848112
. O 0 0.011123104

Adriamycin B-Chemical 1 0.9993237
- O 0 0.024434902
induced O 0 0.008383394
autophagic O 0 0.65417117
cardiomyocyte O 0 0.99395484
death B-Disease 2 0.9990544
plays O 0 0.0028352395
a O 0 0.0024872099
pathogenic O 0 0.0040621203
role O 0 0.0013351247
in O 0 0.0015148383
a O 0 0.002372291
rat O 0 0.005172761
model O 0 0.0030445203
of O 0 0.005070832
heart B-Disease 0 0.9107173
failure I-Disease 0 0.8998846
. O 0 0.011415491

BACKGROUND O 0 0.5272315
: O 0 0.009174957
The O 0 0.0042054798
mechanisms O 0 0.0043059983
underlying O 0 0.005283022
heart B-Disease 0 0.71551615
failure I-Disease 0 0.7671769
induced O 0 0.003862351
by O 0 0.0044863354
adriamycin B-Chemical 1 0.9998165
are O 0 0.0029948785
very O 0 0.0030206176
complicated O 0 0.013777276
and O 0 0.004609102
still O 0 0.0050084474
unclear O 0 0.007869286
. O 0 0.009480642

The O 0 0.0067707165
aim O 0 0.0053860517
of O 0 0.0038224712
this O 0 0.0025634053
study O 0 0.0022532514
was O 0 0.001375441
to O 0 0.0009087386
investigate O 0 0.0005703255
whether O 0 0.0005677374
autophagy O 0 0.39592397
was O 0 0.00081226596
involved O 0 0.000501575
in O 0 0.000473042
the O 0 0.00055263063
progression O 0 0.16513759
of O 0 0.0011881934
heart B-Disease 0 0.8781801
failure I-Disease 0 0.7794917
induced O 0 0.0012683237
by O 0 0.0017492796
adriamycin B-Chemical 1 0.9999287
, O 0 0.0011903883
so O 0 0.0004716282
that O 0 0.00037708663
we O 0 0.0003646158
can O 0 0.0004735274
develop O 0 0.00076586066
a O 0 0.0011545022
novel O 0 0.0016740516
treatment O 0 0.002295616
strategy O 0 0.0024549887
for O 0 0.002727167
heart B-Disease 0 0.86084664
failure I-Disease 0 0.8738319
. O 0 0.010019698

METHODS O 0 0.012022985
: O 0 0.009498428
3 B-Chemical 0 0.0056884526
- I-Chemical 0 0.0069562113
methyladenine I-Chemical 0 0.5879965
( O 0 0.008653594
3MA B-Chemical 1 0.9986972
) O 0 0.0051214374
, O 0 0.0015954152
a O 0 0.0011363259
specific O 0 0.0007539231
inhibitor O 0 0.021931974
on O 0 0.0006833317
autophagy O 0 0.32419792
was O 0 0.0007789792
used O 0 0.00059416075
in O 0 0.0006111398
a O 0 0.0011107886
heart B-Disease 0 0.46151194
failure I-Disease 0 0.3753336
model O 0 0.0016798154
of O 0 0.0022804933
rats O 0 0.008546027
induced O 0 0.0045111286
by O 0 0.011662345
adriamycin B-Chemical 1 0.99972993
. O 0 0.0119354455

Neonatal O 0 0.09624841
cardiomyocytes O 0 0.07935917
were O 0 0.004503311
isolated O 0 0.0032619673
from O 0 0.0028637468
Sprague O 0 0.31655324
- O 0 0.003542234
Dawley O 0 0.030654669
rat O 0 0.0026944652
hearts O 0 0.0037171163
and O 0 0.0007574146
randomly O 0 0.00040454743
divided O 0 0.0004043741
into O 0 0.00036444166
controls O 0 0.0010915223
, O 0 0.00093826174
an O 0 0.0013394813
adriamycin B-Chemical 1 0.9999013
- O 0 0.0024954265
treated O 0 0.0010128731
group O 0 0.0012996817
, O 0 0.0013708345
and O 0 0.0012264245
a O 0 0.0027387454
3MA B-Chemical 1 0.99859816
plus O 0 0.0037162087
adriamycin B-Chemical 1 0.9998858
- O 0 0.01250467
treated O 0 0.006297107
group O 0 0.008933782
. O 0 0.008803254

We O 0 0.0072999923
then O 0 0.0044284393
examined O 0 0.0028080666
the O 0 0.0026709638
morphology O 0 0.0052391104
, O 0 0.0025511552
expression O 0 0.0017775536
of O 0 0.0020344101
beclin O 0 0.9692821
1 O 0 0.0014787636
gene O 0 0.0014791341
, O 0 0.0015794955
mitochondrial O 0 0.37111983
permeability O 0 0.8442262
transition O 0 0.053139623
( O 0 0.01084169
MPT O 0 0.9999018
) O 0 0.006770165
, O 0 0.0018236595
and O 0 0.002263833
Na O 1 0.9998534
+ O 0 0.0042225076
- O 0 0.0099155
K B-Chemical 1 0.9972379
+ O 0 0.0036786466
ATPase O 0 0.11515703
activity O 0 0.0033469063
in O 0 0.0037970631
vivo O 0 0.008398677
. O 0 0.008406026

We O 0 0.008326648
also O 0 0.005727411
assessed O 0 0.004072674
cell O 0 0.013705512
viability O 0 0.17483155
, O 0 0.00422198
mitochondrial O 0 0.20317678
membrane O 0 0.0069570546
potential O 0 0.0021840867
changes O 0 0.0019637193
and O 0 0.0017844491
counted O 0 0.0016159527
autophagic O 0 0.20629579
vacuoles O 0 0.011263376
in O 0 0.0036176026
cultured O 0 0.008733929
cardiomyocytes O 0 0.5575761
. O 0 0.010473215

In O 0 0.007296755
addition O 0 0.004147262
, O 0 0.004032162
we O 0 0.0018481365
analyzed O 0 0.0016097854
the O 0 0.0014272023
expression O 0 0.0016287845
of O 0 0.0018983075
autophagy O 0 0.5137771
associated O 0 0.0021428089
gene O 0 0.0027386034
, O 0 0.0025882204
beclin O 0 0.9427019
1 O 0 0.0011973418
using O 0 0.00089841604
RT O 0 0.024790658
- O 0 0.0020026776
PCR O 0 0.01958255
and O 0 0.0016198138
Western O 0 0.0139101865
blotting O 0 0.01105988
in O 0 0.0020921344
an O 0 0.0037005804
animal O 0 0.005497681
model O 0 0.0077499943
. O 0 0.009320613

RESULTS O 0 0.051922712
: O 0 0.020316375
3MA B-Chemical 1 0.9799397
significantly O 0 0.009086879
improved O 0 0.009278094
cardiac O 0 0.38266364
function O 0 0.0065727937
and O 0 0.007243269
reduced O 0 0.009494009
mitochondrial O 0 0.9770946
injury O 0 0.99783534
. O 0 0.017935125

Furthermore O 0 0.010668182
, O 0 0.009492427
adriamycin B-Chemical 1 0.9990608
induced O 0 0.0044390345
the O 0 0.0024726982
formation O 0 0.004562333
of O 0 0.0025580635
autophagic O 0 0.48485312
vacuoles O 0 0.040381815
, O 0 0.002643794
and O 0 0.001845677
3MA B-Chemical 1 0.99879223
strongly O 0 0.0010805081
downregulated O 0 0.00080948434
the O 0 0.000553011
expression O 0 0.0007762024
of O 0 0.0010926021
beclin O 0 0.9725549
1 O 0 0.0009771615
in O 0 0.0007791314
adriamycin B-Chemical 1 0.9999263
- O 0 0.0034020937
induced O 0 0.0009633656
failing O 0 0.025987057
heart O 0 0.6518325
and O 0 0.0015957155
inhibited O 0 0.0018436917
the O 0 0.0017530632
formation O 0 0.005334986
of O 0 0.005095197
autophagic O 0 0.6539952
vacuoles O 0 0.08742344
. O 0 0.0099576255

CONCLUSION O 0 0.8939905
: O 0 0.020170314
Autophagic O 0 0.8889991
cardiomyocyte O 0 0.97873026
death B-Disease 2 0.99736553
plays O 0 0.003044937
an O 0 0.002334264
important O 0 0.0011890329
role O 0 0.00091439625
in O 0 0.00096154626
the O 0 0.0010524868
pathogenesis O 0 0.0042975987
of O 0 0.002321271
heart B-Disease 0 0.88573
failure I-Disease 0 0.7709798
in O 0 0.0023213464
rats O 0 0.008614192
induced O 0 0.004773353
by O 0 0.011770941
adriamycin B-Chemical 1 0.99971455
. O 0 0.012345493

Mitochondrial O 0 0.9170645
injury O 0 0.91570115
may O 0 0.0052612363
be O 0 0.0033366217
involved O 0 0.002071503
in O 0 0.0016566584
the O 0 0.0016255782
progression O 0 0.14033924
of O 0 0.0025472823
heart B-Disease 0 0.8692487
failure I-Disease 0 0.80128396
caused O 0 0.003278056
by O 0 0.0045102895
adriamycin B-Chemical 1 0.99982697
via O 0 0.0033419316
the O 0 0.0045213266
autophagy O 0 0.71599346
pathway O 0 0.015411885
. O 0 0.0102035245

mToR O 0 0.21851778
inhibitors O 0 0.20621653
- O 0 0.016223263
induced O 0 0.010735577
proteinuria B-Disease 2 0.99985147
: O 0 0.013407083
mechanisms O 0 0.007068937
, O 0 0.0059394026
significance O 0 0.0061190515
, O 0 0.006832903
and O 0 0.0073803714
management O 0 0.015235309
. O 0 0.011705602

Massive O 0 0.58339876
urinary O 0 0.88173044
protein O 0 0.08720653
excretion O 0 0.98940814
has O 0 0.0023322538
been O 0 0.0015333332
observed O 0 0.00075200107
after O 0 0.00059866335
conversion O 0 0.0027942294
from O 0 0.00094908953
calcineurin O 0 0.87452185
inhibitors O 0 0.08071068
to O 0 0.00066130055
mammalian O 0 0.0010562284
target O 0 0.00055108155
of O 0 0.0012295528
rapamycin B-Chemical 1 0.99502414
( O 0 0.008955857
mToR O 0 0.31344086
) O 0 0.0022824632
inhibitors O 0 0.0369199
, O 0 0.00112681
especially O 0 0.0010930143
sirolimus B-Chemical 1 0.9998216
, O 0 0.0015148801
in O 0 0.00091031974
renal O 0 0.96900386
transplant O 0 0.5213598
recipients O 0 0.018937843
with O 0 0.004404958
chronic B-Disease 0 0.99728703
allograft I-Disease 0 0.9990202
nephropathy I-Disease 2 0.9999751
. O 0 0.026609726

Because O 0 0.009886434
proteinuria B-Disease 2 0.99926406
is O 0 0.0049795685
a O 0 0.0035284762
major O 0 0.0025972356
predictive O 0 0.003084339
factor O 0 0.0059939683
of O 0 0.0017458916
poor O 0 0.0057850853
transplantation O 0 0.105224356
outcome O 0 0.0052825017
, O 0 0.0012716139
many O 0 0.0008139396
studies O 0 0.00079576287
focused O 0 0.0007112937
on O 0 0.00060548016
this O 0 0.0010515292
adverse O 0 0.8200519
event O 0 0.011607719
during O 0 0.0017588305
the O 0 0.0029628172
past O 0 0.00629158
years O 0 0.009333955
. O 0 0.008363685

Whether O 0 0.012098705
proteinuria B-Disease 2 0.9995245
was O 0 0.004742964
due O 0 0.0022351427
to O 0 0.001909089
sirolimus B-Chemical 1 0.9994398
or O 0 0.0013623219
only O 0 0.00084384676
a O 0 0.0009768788
consequence O 0 0.00056714186
of O 0 0.0010664003
calcineurin O 0 0.9362941
inhibitors O 0 0.23105228
withdrawal O 0 0.9374893
remained O 0 0.0010647912
unsolved O 0 0.0062309485
until O 0 0.0002965542
high O 0 0.0005915073
range O 0 0.0015092618
proteinuria B-Disease 2 0.9999716
has O 0 0.000565996
been O 0 0.00051403587
observed O 0 0.00031021543
during O 0 0.00041793683
sirolimus B-Chemical 1 0.99977475
therapy O 0 0.013975337
in O 0 0.0006888686
islet O 0 0.35986894
transplantation O 0 0.10399856
and O 0 0.0010540716
in O 0 0.00088692724
patients O 0 0.002526708
who O 0 0.0026455151
received O 0 0.0025550432
sirolimus B-Chemical 1 0.99961346
de O 0 0.23856916
novo O 0 0.13086726
. O 0 0.011885697

Podocyte O 0 0.9180814
injury O 0 0.906779
and O 0 0.0069682286
focal O 0 0.32369742
segmental O 0 0.21001665
glomerulosclerosis B-Disease 2 0.9999653
have O 0 0.0024027466
been O 0 0.0015075927
related O 0 0.0007951731
to O 0 0.0009427844
mToR O 0 0.083140336
inhibition O 0 0.0019714502
in O 0 0.0006463603
some O 0 0.0008102368
patients O 0 0.0027158195
, O 0 0.0012180749
but O 0 0.00084623456
the O 0 0.00097397383
pathways O 0 0.0023002983
underlying O 0 0.0027680406
these O 0 0.0032755923
lesions O 0 0.4475784
remain O 0 0.00539013
hypothetic O 0 0.09962247
. O 0 0.009632043

We O 0 0.008059246
discuss O 0 0.004827531
herein O 0 0.005140009
the O 0 0.003338176
possible O 0 0.002727919
mechanisms O 0 0.0031752684
and O 0 0.0024852478
the O 0 0.0020096141
significance O 0 0.0029853312
of O 0 0.003961028
mToR O 0 0.49113992
blockade O 0 0.6953613
- O 0 0.015742423
induced O 0 0.013655223
proteinuria B-Disease 2 0.99987113
. O 0 0.015449563

Neuropsychiatric O 0 0.8915693
side O 0 0.067807905
effects O 0 0.013267289
after O 0 0.0069256783
the O 0 0.008185781
use O 0 0.010106708
of O 0 0.016817389
mefloquine B-Chemical 1 0.99911267
. O 0 0.019011697

This O 0 0.012931685
study O 0 0.00811642
describes O 0 0.008340446
neuropsychiatric O 0 0.9939685
side O 0 0.20621067
effects O 0 0.006585256
in O 0 0.003207219
patients O 0 0.0064403145
after O 0 0.0025382217
treatment O 0 0.0067407866
with O 0 0.010400508
mefloquine B-Chemical 1 0.9994624
. O 0 0.012311324

Reactions O 0 0.021336313
consisted O 0 0.0061437464
mainly O 0 0.005992508
of O 0 0.007150303
seizures B-Disease 2 0.9999471
, O 0 0.02376707
acute O 0 0.9953852
psychoses B-Disease 0 0.9999658
, O 0 0.07931726
anxiety B-Disease 0 0.99993443
neurosis I-Disease 0 0.99994123
, O 0 0.0042597675
and O 0 0.0017668171
major O 0 0.002237441
disturbances B-Disease 0 0.5193958
of I-Disease 0 0.0038240948
sleep I-Disease 0 0.74045354
- I-Disease 0 0.008405857
wake I-Disease 0 0.009819225
rhythm I-Disease 0 0.09098318
. O 0 0.008258134

Side O 0 0.8666348
effects O 0 0.009431236
occurred O 0 0.0045721605
after O 0 0.0021889762
both O 0 0.0021058246
therapeutic O 0 0.0063874675
and O 0 0.0022571718
prophylactic O 0 0.02445176
intake O 0 0.6904088
and O 0 0.002616312
were O 0 0.0022212532
graded O 0 0.013652096
from O 0 0.003009226
moderate O 0 0.014701134
to O 0 0.0053012837
severe O 0 0.47508675
. O 0 0.010946244

In O 0 0.0077889455
a O 0 0.0068159313
risk O 0 0.013992707
analysis O 0 0.0037664673
of O 0 0.0035579298
neuropsychiatric O 0 0.997988
side O 0 0.30192307
effects O 0 0.0062157116
in O 0 0.0015411195
Germany O 0 0.06071129
, O 0 0.0011590526
it O 0 0.0006670302
is O 0 0.00047733236
estimated O 0 0.0004380738
that O 0 0.0004024281
one O 0 0.00045513298
of O 0 0.0007324401
8 O 0 0.0007882937
, O 0 0.0010312092
000 O 0 0.0015368616
mefloquine B-Chemical 1 0.99754936
users O 0 0.0063625784
suffers O 0 0.012525649
from O 0 0.0025714978
such O 0 0.0039314227
reactions O 0 0.10518908
. O 0 0.009509507

The O 0 0.0070656883
incidence O 0 0.007934657
calculation O 0 0.003344191
revealed O 0 0.0023333116
that O 0 0.0014948288
one O 0 0.0012028888
of O 0 0.0014320544
215 O 0 0.013722836
therapeutic O 0 0.0072245644
users O 0 0.0066630836
had O 0 0.00063808705
reactions O 0 0.018930223
, O 0 0.0008116509
compared O 0 0.00028029302
with O 0 0.00039433572
one O 0 0.00031806077
of O 0 0.0004697843
13 O 0 0.0005818121
, O 0 0.00046327367
000 O 0 0.00042002686
in O 0 0.00025668246
the O 0 0.00030238213
prophylaxis O 0 0.0033062825
group O 0 0.00068960094
, O 0 0.00066425034
making O 0 0.00052697386
the O 0 0.00044641344
risk O 0 0.024376795
of O 0 0.0011054266
neuropsychiatric O 0 0.9990688
reactions O 0 0.07846073
after O 0 0.000580693
mefloquine B-Chemical 1 0.9994024
treatment O 0 0.0012018135
60 O 0 0.0008149232
times O 0 0.00065977144
higher O 0 0.0010450324
than O 0 0.0013494053
after O 0 0.0020026565
prophylaxis O 0 0.03797045
. O 0 0.00796641

Therefore O 0 0.008840287
, O 0 0.007565045
certain O 0 0.005089102
limitations O 0 0.004145181
for O 0 0.0027951447
malaria B-Disease 0 0.7766554
prophylaxis O 0 0.06199084
and O 0 0.0038922185
treatment O 0 0.005587702
with O 0 0.0061191614
mefloquine B-Chemical 1 0.9995834
are O 0 0.006921652
recommended O 0 0.008276705
. O 0 0.009509298

Prenatal O 0 0.45007154
protein O 0 0.014485257
deprivation O 0 0.10904572
alters O 0 0.0074505378
dopamine B-Chemical 1 0.99979633
- O 0 0.012374702
mediated O 0 0.0031803376
behaviors O 0 0.2459909
and O 0 0.0052668946
dopaminergic O 0 0.99029315
and O 0 0.008721341
glutamatergic O 0 0.99722004
receptor O 0 0.34146115
binding O 0 0.010350382
. O 0 0.010361157

Epidemiological O 0 0.03125769
evidence O 0 0.008045166
indicates O 0 0.0053700055
that O 0 0.004328957
prenatal O 0 0.037624344
nutritional O 0 0.26901278
deprivation O 0 0.10069764
may O 0 0.0034187278
increase O 0 0.0028316018
the O 0 0.004130366
risk O 0 0.20388511
of O 0 0.020429594
schizophrenia B-Disease 2 0.9995728
. O 0 0.014814325

The O 0 0.007039422
goal O 0 0.0056044897
of O 0 0.0035144943
these O 0 0.00271919
studies O 0 0.0020928592
was O 0 0.0013562377
to O 0 0.0009341176
use O 0 0.0009323242
an O 0 0.0009984605
animal O 0 0.00092069386
model O 0 0.0007092837
to O 0 0.00046325687
examine O 0 0.00030093812
the O 0 0.00050157163
effects O 0 0.00094520435
of O 0 0.0008894484
prenatal O 0 0.043994926
protein O 0 0.0023287702
deprivation O 0 0.043323785
on O 0 0.0006660882
behaviors O 0 0.14394164
and O 0 0.0017847549
receptor O 0 0.0754628
binding O 0 0.0019048116
with O 0 0.0022747265
relevance O 0 0.0027445545
to O 0 0.005231457
schizophrenia B-Disease 2 0.9994407
. O 0 0.010004409

We O 0 0.00825334
report O 0 0.0075782696
that O 0 0.003739953
prenatally O 0 0.24382553
protein O 0 0.005539274
deprived O 0 0.011018386
( O 0 0.0046862285
PD O 2 0.99855274
) O 0 0.003130531
female O 0 0.004391896
rats O 0 0.0017993023
showed O 0 0.00057473034
an O 0 0.0009882136
increased O 0 0.0011119839
stereotypic O 0 0.8408669
response O 0 0.0016262045
to O 0 0.0012038733
apomorphine B-Chemical 1 0.9999882
and O 0 0.0015344312
an O 0 0.0016385925
increased O 0 0.0017879027
locomotor O 0 0.66841656
response O 0 0.0029799088
to O 0 0.0034214824
amphetamine B-Chemical 1 0.9999622
in O 0 0.007256825
adulthood O 0 0.63791823
. O 0 0.009142235

These O 0 0.021520348
differences O 0 0.013053247
were O 0 0.014019765
not O 0 0.012295169
observed O 0 0.011239918
during O 0 0.014879347
puberty O 0 0.8723707
. O 0 0.023659438

No O 0 0.012073181
changes O 0 0.0085380925
in O 0 0.0073528606
haloperidol B-Chemical 1 0.9999809
- O 0 0.040221933
induced O 0 0.010687715
catalepsy B-Disease 2 0.99998546
or O 0 0.009455314
MK B-Chemical 0 0.99786
- I-Chemical 0 0.020752277
801 I-Chemical 0 0.8622151
- O 0 0.0031445946
induced O 0 0.0021321743
locomotion O 0 0.1737563
were O 0 0.0027451538
seen O 0 0.0031320043
following O 0 0.0059133247
PD O 2 0.9973629
. O 0 0.010501515

In O 0 0.0077442285
addition O 0 0.00480377
, O 0 0.0065238434
PD O 2 0.98902124
female O 0 0.016778419
rats O 0 0.0048682215
showed O 0 0.0014693715
increased O 0 0.0021998922
( O 0 0.0024447192
3 O 0 0.0013601893
) O 0 0.0052176747
H B-Chemical 1 0.999413
- O 0 0.012512462
MK B-Chemical 0 0.9897251
- I-Chemical 0 0.0035360071
801 I-Chemical 0 0.4052548
binding O 0 0.00069592317
in O 0 0.0006199996
the O 0 0.0008499256
striatum O 0 0.29764503
and O 0 0.0014841625
hippocampus O 0 0.24019185
, O 0 0.0017852443
but O 0 0.0013748456
not O 0 0.0016429096
in O 0 0.0024164142
the O 0 0.004423157
cortex O 0 0.25381762
. O 0 0.008098245

PD O 2 0.9833233
female O 0 0.022892782
rats O 0 0.00851726
also O 0 0.0034540056
showed O 0 0.0024408302
increased O 0 0.003239047
( O 0 0.0034421824
3 O 0 0.0019821152
) O 0 0.0067899935
H B-Chemical 1 0.99937016
- O 0 0.027921611
haloperidol B-Chemical 1 0.99999094
binding O 0 0.0021350526
and O 0 0.0024212478
decreased O 0 0.009802076
dopamine B-Chemical 1 0.9998153
transporter O 0 0.25418478
binding O 0 0.003827762
in O 0 0.00514004
striatum O 0 0.5934166
. O 0 0.008315008

No O 0 0.009201691
statistically O 0 0.0044821883
significant O 0 0.0034076741
changes O 0 0.0028329631
in O 0 0.0017887795
behavior O 0 0.0044032573
or O 0 0.0015320174
receptor O 0 0.0798131
binding O 0 0.0011650071
were O 0 0.0008075098
found O 0 0.0005602823
in O 0 0.000759074
PD O 2 0.99643034
males O 0 0.0016693296
with O 0 0.00054919336
the O 0 0.0004959664
exception O 0 0.00047790102
of O 0 0.00081667275
increased O 0 0.0013812258
( O 0 0.0020166007
3 O 0 0.0012505631
) O 0 0.0057969424
H B-Chemical 1 0.99915636
- O 0 0.015167111
MK B-Chemical 0 0.986489
- I-Chemical 0 0.0073448666
801 I-Chemical 0 0.5540375
binding O 0 0.0034561385
in O 0 0.0048654615
cortex O 0 0.2523736
. O 0 0.0084247915

This O 0 0.010128882
animal O 0 0.0063712276
model O 0 0.0042972
may O 0 0.0026817452
be O 0 0.0019190967
useful O 0 0.0013873079
to O 0 0.00087502936
explore O 0 0.00061501714
the O 0 0.00076053396
mechanisms O 0 0.0011996204
by O 0 0.00092761463
which O 0 0.0012076325
prenatal O 0 0.13732833
nutritional B-Disease 0 0.92494303
deficiency I-Disease 0 0.9827976
enhances O 0 0.001151579
risk O 0 0.3234343
for O 0 0.0008941047
schizophrenia B-Disease 2 0.999871
in O 0 0.0006894893
humans O 0 0.002599742
and O 0 0.0006629507
may O 0 0.00042463577
also O 0 0.00046197453
have O 0 0.00039364726
implications O 0 0.00064196094
for O 0 0.0004144522
developmental O 0 0.0014950621
processes O 0 0.0015178475
leading O 0 0.0014053187
to O 0 0.0008085512
differential O 0 0.0017140704
sensitivity O 0 0.0026490248
to O 0 0.0020107746
drugs O 0 0.7804859
of O 0 0.009223548
abuse O 0 0.9986778
. O 0 0.011895742

Adverse O 0 0.34113607
effects O 0 0.014893422
of O 0 0.01252569
topical O 0 0.98512036
papaverine B-Chemical 1 0.99980897
on O 0 0.010071357
auditory O 0 0.38810986
nerve O 0 0.8200017
function O 0 0.015681883
. O 0 0.014888456

BACKGROUND O 0 0.83637077
: O 0 0.020815518
Papaverine B-Chemical 0 0.99954283
hydrochloride I-Chemical 0 0.9994622
is O 0 0.003949616
a O 0 0.0030772213
direct O 0 0.0024524853
- O 0 0.003454804
acting O 0 0.007984013
vasodilator O 0 0.99762625
used O 0 0.0018310474
to O 0 0.0017036088
manage O 0 0.009287152
vasospasm B-Disease 2 0.9999397
during O 0 0.0024358195
various O 0 0.005761508
neurosurgical O 0 0.021103548
operations O 0 0.011210226
. O 0 0.009122828

Transient O 0 0.58866173
cranial B-Disease 0 0.79827714
nerve I-Disease 0 0.8594667
dysfunction I-Disease 0 0.9853254
has O 0 0.0040819994
been O 0 0.0032070882
described O 0 0.002124522
in O 0 0.0021795304
a O 0 0.0027682248
few O 0 0.0020425764
cases O 0 0.0048017
with O 0 0.006091583
topical O 0 0.9949157
papaverine B-Chemical 1 0.9998901
. O 0 0.018139977

This O 0 0.010409168
study O 0 0.0057216957
supports O 0 0.0031378996
previous O 0 0.0024320509
reports O 0 0.002626325
and O 0 0.0019681128
provides O 0 0.001243535
neurophysiological O 0 0.016108511
evidence O 0 0.0013395541
of O 0 0.0017207853
an O 0 0.0024632367
adverse O 0 0.84918183
effect O 0 0.002314613
on O 0 0.0019919274
the O 0 0.003833647
auditory O 0 0.24517113
nerve O 0 0.8063304
. O 0 0.010269217

METHODS O 0 0.011350189
: O 0 0.0076976283
We O 0 0.003873812
conducted O 0 0.0025461195
a O 0 0.0026453072
retrospective O 0 0.0050311657
review O 0 0.0020439432
of O 0 0.0012419187
70 O 0 0.0010015392
consecutive O 0 0.0008715313
microvascular O 0 0.45838958
decompression O 0 0.0122737195
operations O 0 0.0014558932
and O 0 0.0009189047
studied O 0 0.00090796576
those O 0 0.0012166973
patients O 0 0.002203676
who O 0 0.0022562032
received O 0 0.0019907441
topical O 0 0.9867148
papaverine B-Chemical 1 0.99995434
for O 0 0.013611626
vasospasm B-Disease 2 0.99992347
. O 0 0.014114614

Topical O 0 0.9971353
papaverine B-Chemical 1 0.99975806
was O 0 0.00658278
used O 0 0.003073207
as O 0 0.0023110656
a O 0 0.0022238414
direct O 0 0.00166297
therapeutic O 0 0.008565722
action O 0 0.006834789
to O 0 0.0015424724
manage O 0 0.010415615
vasospasm B-Disease 2 0.99995995
in O 0 0.0020496899
a O 0 0.0025102668
total O 0 0.0022457105
of O 0 0.0036108869
11 O 0 0.005728225
patients O 0 0.011250149
. O 0 0.008587311

The O 0 0.00748735
timing O 0 0.005678197
of O 0 0.00583625
papaverine B-Chemical 1 0.99976057
application O 0 0.006551769
and O 0 0.002549686
ongoing O 0 0.0021434736
operative O 0 0.003578527
events O 0 0.016391113
was O 0 0.0015063107
reviewed O 0 0.0021164485
relative O 0 0.0012712586
to O 0 0.0016954844
changes O 0 0.0027652963
in O 0 0.0031557204
neurophysiological O 0 0.1422791
recordings O 0 0.034191865
. O 0 0.008702667

Brainstem O 0 0.72743
auditory O 0 0.076118164
evoked O 0 0.13609837
potentials O 0 0.18410441
( O 0 0.005785433
BAEPs O 0 0.840859
) O 0 0.0030256303
were O 0 0.00129917
routinely O 0 0.0010856226
used O 0 0.001006147
to O 0 0.0010374035
monitor O 0 0.0011248903
cochlear O 0 0.059460025
nerve O 0 0.3399095
function O 0 0.0026197957
during O 0 0.0023203879
these O 0 0.00499498
operations O 0 0.009960795
. O 0 0.008866476

FINDINGS O 0 0.120118365
: O 0 0.010570199
A O 0 0.017558515
temporal O 0 0.007426014
relationship O 0 0.0022864474
was O 0 0.0020448111
found O 0 0.0013890907
between O 0 0.0012395929
topical O 0 0.97101283
papaverine B-Chemical 1 0.99996734
and O 0 0.005269648
BAEP O 0 0.9831766
changes O 0 0.0025794413
leading O 0 0.0030387882
to O 0 0.0022458825
complete O 0 0.0029604293
waveform O 0 0.014862902
loss O 0 0.009937413
. O 0 0.008594127

The O 0 0.0072966516
average O 0 0.004882233
temporal O 0 0.008107078
delay O 0 0.004972186
between O 0 0.002294184
papaverine B-Chemical 1 0.99983513
and O 0 0.002794228
the O 0 0.0016459312
onset O 0 0.0036927229
of O 0 0.0018759847
an O 0 0.0028172706
adverse O 0 0.95949197
BAEP O 0 0.98547345
change O 0 0.0030260966
was O 0 0.0030883937
5 O 0 0.0036951113
min O 0 0.0061004814
. O 0 0.0077274577

In O 0 0.008002786
10 O 0 0.0053467336
of O 0 0.0041791927
11 O 0 0.0035876723
patients O 0 0.0043646772
, O 0 0.0031274194
BAEP O 0 0.91627014
waves O 0 0.06423584
II O 0 0.12589908
/ O 0 0.008820059
III O 0 0.15572661
- O 0 0.0030772707
V O 0 0.24752152
completely O 0 0.0011872767
disappeared O 0 0.0015739271
within O 0 0.0007819281
2 O 0 0.0012447935
to O 0 0.001332482
25 O 0 0.0024396405
min O 0 0.0029572472
after O 0 0.003295478
papaverine B-Chemical 1 0.99959546
. O 0 0.010972821

Eight O 0 0.012419994
of O 0 0.0069721327
these O 0 0.0053156028
10 O 0 0.0037940228
patients O 0 0.0041078124
had O 0 0.0023073414
complete O 0 0.0020569514
loss O 0 0.0029893804
of O 0 0.0030731661
BAEP O 0 0.935949
waveforms O 0 0.008150792
within O 0 0.0025862665
10 O 0 0.004465772
min O 0 0.006765344
. O 0 0.0083522145

One O 0 0.011916578
patient O 0 0.007518298
showed O 0 0.003948059
no O 0 0.002948361
recovery O 0 0.0042339065
of O 0 0.0030585218
later O 0 0.0024074032
waves O 0 0.017210018
and O 0 0.0032204327
a O 0 0.004215928
delayed O 0 0.03198424
profound O 0 0.5036203
sensorineural B-Disease 2 0.9999243
hearing I-Disease 2 0.99581844
loss I-Disease 2 0.14389202
. O 0 0.011994257

The O 0 0.007675238
average O 0 0.0049809227
recovery O 0 0.005468237
time O 0 0.0030093961
of O 0 0.0032970351
BAEP O 0 0.83311415
waveforms O 0 0.0066502728
to O 0 0.0020394605
pre O 0 0.010129608
- O 0 0.00499892
papaverine B-Chemical 1 0.9997917
baseline O 0 0.0032615333
values O 0 0.0028215256
was O 0 0.003342597
39 O 0 0.0062031406
min O 0 0.0066152513
. O 0 0.008124079

CONCLUSIONS O 0 0.7185188
: O 0 0.015461294
Topical O 0 0.99726284
papaverine B-Chemical 1 0.99986136
for O 0 0.002605511
the O 0 0.0018116642
treatment O 0 0.0022598149
of O 0 0.0028595033
vasospasm B-Disease 2 0.9999845
was O 0 0.001387804
associated O 0 0.00095878856
with O 0 0.0007020998
the O 0 0.00060614414
onset O 0 0.0020724486
of O 0 0.00078896026
a O 0 0.0011080243
transient O 0 0.033930607
disturbance O 0 0.15671147
in O 0 0.0007617685
neurophysiological O 0 0.031014597
function O 0 0.0010655589
of O 0 0.0013874632
the O 0 0.0017660721
ascending O 0 0.041353296
auditory O 0 0.2766835
brainstem O 0 0.8508021
pathway O 0 0.010438493
. O 0 0.008687509

The O 0 0.0070662266
complete O 0 0.0046678404
disappearance O 0 0.005688409
of O 0 0.0034724444
BAEP O 0 0.84520143
waveforms O 0 0.005789875
with O 0 0.0013902355
a O 0 0.0014028437
consistent O 0 0.0009079704
temporal O 0 0.0038828456
delay O 0 0.0015513271
suggests O 0 0.000592407
a O 0 0.0011474632
possible O 0 0.0011597145
adverse B-Disease 0 0.78523254
effect I-Disease 0 0.0016923506
on I-Disease 0 0.0014500376
the I-Disease 0 0.0025919604
proximal I-Disease 0 0.006054471
eighth I-Disease 0 0.2305247
nerve I-Disease 0 0.8234311
. O 0 0.010207387

Recommendations O 0 0.016088972
to O 0 0.008755206
avoid O 0 0.0073686847
potential O 0 0.008877932
cranial B-Disease 0 0.7666646
nerve I-Disease 0 0.8749672
deficits I-Disease 0 0.8843649
from O 0 0.009454055
papaverine B-Chemical 1 0.9997906
are O 0 0.011311835
provided O 0 0.010508529
. O 0 0.012202592

Simvastatin B-Chemical 0 0.99981934
- I-Chemical 0 0.20879784
ezetimibe I-Chemical 0 0.9997905
- O 0 0.025371812
induced O 0 0.009906835
hepatic B-Disease 0 0.97737813
failure I-Disease 0 0.90768707
necessitating O 0 0.041418817
liver O 0 0.97886205
transplantation O 0 0.7650715
. O 0 0.016353853

Abstract O 0 0.6719731
Serum O 0 0.847365
aminotransferase O 0 0.9971253
elevations O 0 0.3133777
are O 0 0.0025386938
a O 0 0.002099799
commonly O 0 0.0021406512
known O 0 0.0016476387
adverse O 0 0.8558484
effect O 0 0.0011541513
of O 0 0.0015391221
3 O 0 0.00147927
- O 0 0.005820506
hydroxy O 0 0.99957067
- O 0 0.0082629
3 O 0 0.0013294257
- O 0 0.0039451895
methylglutaryl O 0 0.9636683
coenzyme O 0 0.9999527
A O 0 0.8664344
reductase O 0 0.9992613
inhibitor O 0 0.4626568
( O 0 0.017330341
statin B-Chemical 1 0.99873704
) O 0 0.016406333
therapy O 0 0.051879745
. O 0 0.008818371

However O 0 0.011247339
, O 0 0.010225662
hepatotoxic B-Disease 2 0.99884087
events O 0 0.105290554
have O 0 0.0026314503
not O 0 0.0021009003
been O 0 0.0018330344
widely O 0 0.0019929677
published O 0 0.0013741958
with O 0 0.0018406442
ezetimibe B-Chemical 0 0.9998549
or O 0 0.0018589372
the O 0 0.001879411
combination O 0 0.009349025
agent O 0 0.92528224
simvastatin B-Chemical 1 0.99998796
- I-Chemical 0 0.4796938
ezetimibe I-Chemical 0 0.9999039
. O 0 0.015050827

We O 0 0.007896436
describe O 0 0.00505289
a O 0 0.004964586
70 O 0 0.0039505484
- O 0 0.0036271445
year O 0 0.002043959
- O 0 0.00224907
old O 0 0.0016855603
Hispanic O 0 0.52613926
woman O 0 0.013146944
who O 0 0.0023281004
developed O 0 0.0024537083
fulminant B-Disease 2 0.99994266
hepatic I-Disease 2 0.9962174
failure I-Disease 2 0.9648408
necessitating O 0 0.0058595305
liver O 0 0.9140286
transplantation O 0 0.15300402
10 O 0 0.0004982903
weeks O 0 0.00024773474
after O 0 0.00022574606
conversion O 0 0.0011108593
from O 0 0.00058930204
simvastatin B-Chemical 1 0.9999527
40 O 0 0.0008660606
mg O 0 0.21021028
/ O 0 0.0012339243
day O 0 0.0004789371
to O 0 0.0006835704
simvastatin B-Chemical 1 0.99993706
10 I-Chemical 0 0.0015330059
mg I-Chemical 0 0.58365995
- I-Chemical 0 0.004450684
ezetimibe I-Chemical 0 0.9996716
40 I-Chemical 0 0.0031209
mg I-Chemical 0 0.3596143
/ O 0 0.008133212
day O 0 0.0050662723
. O 0 0.0074564037

The O 0 0.007825405
patient O 0 0.0073468555
' O 0 0.0053881053
s O 0 0.004140957
lipid O 0 0.30941665
panel O 0 0.002960794
had O 0 0.0016892329
been O 0 0.0013831082
maintained O 0 0.00094016414
with O 0 0.0013701455
simvastatin B-Chemical 1 0.99993324
for O 0 0.0008950884
18 O 0 0.00084566715
months O 0 0.0005571324
before O 0 0.0005315884
the O 0 0.0009575078
conversion O 0 0.0027464957
without O 0 0.0018595062
evidence O 0 0.0034111363
of O 0 0.01371726
hepatotoxicity B-Disease 2 0.9999571
. O 0 0.014802713

A O 0 0.030700102
routine O 0 0.008324367
laboratory O 0 0.007691915
work O 0 0.0056164535
- O 0 0.004394929
up O 0 0.0023432863
10 O 0 0.001889992
weeks O 0 0.0013093145
after O 0 0.0012419275
conversion O 0 0.0036699467
revealed O 0 0.0027771483
elevated O 0 0.013567724
serum O 0 0.66741157
aminotransferase O 0 0.9988864
levels O 0 0.01073058
. O 0 0.010847687

Simvastatinezetimibe B-Chemical 0 0.2371341
and O 0 0.0100635355
escitalopram B-Chemical 0 0.99963534
( O 0 0.0057022567
which O 0 0.002644935
she O 0 0.0017133394
was O 0 0.0012774215
taking O 0 0.0018810048
for O 0 0.0010768053
depression B-Disease 2 0.99890816
) O 0 0.0027317225
were O 0 0.0008896264
discontinued O 0 0.009571145
, O 0 0.0010375779
and O 0 0.00085189677
other O 0 0.0009307208
potential O 0 0.0017930245
causes O 0 0.0049208617
of O 0 0.009309648
hepatotoxicity B-Disease 2 0.9999771
were O 0 0.0076175397
excluded O 0 0.010608207
. O 0 0.008675757

A O 0 0.040481318
repeat O 0 0.009435928
work O 0 0.006672735
- O 0 0.0047757095
up O 0 0.0021692303
revealed O 0 0.0017180737
further O 0 0.0016888638
elevations O 0 0.18246728
in O 0 0.0015637944
aminotransferase O 0 0.99823594
levels O 0 0.0012092498
, O 0 0.0012321596
and O 0 0.00090530637
liver O 0 0.64278805
biopsy O 0 0.0074502057
revealed O 0 0.0007905256
evidence O 0 0.00083542767
of O 0 0.0014364594
moderate O 0 0.04381376
- O 0 0.00397766
to O 0 0.0019036832
- O 0 0.0062068813
severe O 0 0.5647811
drug B-Disease 0 0.9946765
toxicity I-Disease 2 0.9996729
. O 0 0.013951244

She O 0 0.022733152
underwent O 0 0.015162409
liver O 0 0.42915344
transplantation O 0 0.0854947
with O 0 0.0098744845
an O 0 0.010876836
uneventful O 0 0.013249839
postoperative O 0 0.057864826
course O 0 0.01693339
. O 0 0.01681594

Her O 0 0.029055404
aminotransferase O 0 0.9809163
levels O 0 0.0039011138
returned O 0 0.0025603825
to O 0 0.0016469
normal O 0 0.001971448
by O 0 0.0012644412
postoperative O 0 0.0066527333
day O 0 0.0008592975
23 O 0 0.0012428068
, O 0 0.00094128546
and O 0 0.000825429
her O 0 0.0012549214
2 O 0 0.0009613255
- O 0 0.0012102425
year O 0 0.0008219797
follow O 0 0.00087387377
- O 0 0.0016189419
up O 0 0.0011985743
showed O 0 0.0014689607
no O 0 0.0022720764
adverse O 0 0.9153685
events O 0 0.16982801
. O 0 0.010144624

Ezetimibe B-Chemical 0 0.9986174
undergoes O 0 0.007617003
extensive O 0 0.0066390806
glucuronidation O 0 0.99916863
by O 0 0.009504162
uridine B-Chemical 0 0.9993357
diphosphate I-Chemical 0 0.9992493
glucoronosyltransferases O 0 0.87273484
( O 0 0.014997573
UGT O 0 0.9993544
) O 0 0.0023866154
in O 0 0.0005772089
the O 0 0.0005879777
intestine O 0 0.015790245
and O 0 0.000988824
liver O 0 0.89461464
and O 0 0.0010799143
may O 0 0.0005761695
have O 0 0.0005160329
inhibited O 0 0.0010192455
the O 0 0.0010111545
glucuronidation O 0 0.9997646
of O 0 0.014729742
simvastatin B-Chemical 1 0.99999833
hydroxy I-Chemical 0 0.9999721
acid I-Chemical 0 0.99927086
, O 0 0.0051299063
resulting O 0 0.0014162719
in O 0 0.0011738049
increased O 0 0.0030961286
simvastatin B-Chemical 1 0.9999615
exposure O 0 0.02718948
and O 0 0.006162411
subsequent O 0 0.015924277
hepatotoxicity B-Disease 2 0.9999566
. O 0 0.013889402

To O 0 0.006560152
our O 0 0.0046614376
knowledge O 0 0.004602148
, O 0 0.0032017073
this O 0 0.0017676817
is O 0 0.0013297505
the O 0 0.001006741
first O 0 0.0007912963
case O 0 0.0010135425
report O 0 0.003159737
of O 0 0.0044634617
simvastatin B-Chemical 1 0.9999958
- I-Chemical 0 0.19201444
ezetimibe I-Chemical 0 0.99998736
- O 0 0.0140970675
induced O 0 0.0021706345
liver B-Disease 0 0.96644294
failure I-Disease 0 0.7702455
that O 0 0.001746673
resulted O 0 0.0021547424
in O 0 0.0035205178
liver O 0 0.95638263
transplantation O 0 0.66013855
. O 0 0.010488309

We O 0 0.007475325
postulate O 0 0.0066059227
that O 0 0.0031849246
the O 0 0.0025585091
mechanism O 0 0.0022456122
of O 0 0.002163877
the O 0 0.0020204566
simvastatinezetimibe B-Chemical 0 0.6733873
- O 0 0.007327265
induced O 0 0.003180855
hepatotoxicity B-Disease 2 0.9999924
is O 0 0.0016685056
the O 0 0.0011789616
increased O 0 0.002733963
simvastatin B-Chemical 1 0.9999752
exposure O 0 0.037675317
by O 0 0.0066469214
ezetimibe B-Chemical 0 0.9999324
inhibition O 0 0.04225754
of O 0 0.013158655
UGT O 0 0.9993926
enzymes O 0 0.66363996
. O 0 0.011104118

Clinicians O 0 0.011513857
should O 0 0.0040483447
be O 0 0.0033357143
aware O 0 0.0027037724
of O 0 0.0025344722
potential O 0 0.0062758923
hepatotoxicity B-Disease 2 0.9999914
with O 0 0.041365042
simvastatin B-Chemical 1 0.999997
- I-Chemical 0 0.13726231
ezetimibe I-Chemical 0 0.99998
especially O 0 0.0020708996
in O 0 0.00080419175
elderly O 0 0.33849484
patients O 0 0.0021273398
and O 0 0.000607204
should O 0 0.0003026532
carefully O 0 0.0003741081
monitor O 0 0.0004358569
serum O 0 0.16747047
aminotransferase O 0 0.9980325
levels O 0 0.0007832168
when O 0 0.0005889486
starting O 0 0.0009341252
therapy O 0 0.004314952
and O 0 0.0021354577
titrating O 0 0.012285414
the O 0 0.0039088596
dosage O 0 0.29317573
. O 0 0.00830516

Massive O 0 0.81598485
proteinuria B-Disease 2 0.99961984
and O 0 0.010808476
acute B-Disease 0 0.9671232
renal I-Disease 0 0.99664235
failure I-Disease 0 0.88769287
after O 0 0.0015667054
oral O 0 0.88506585
bisphosphonate B-Chemical 0 0.99994504
( O 0 0.068881504
alendronate B-Chemical 0 0.9999485
) O 0 0.01163663
administration O 0 0.058210585
in O 0 0.0012494399
a O 0 0.0019589553
patient O 0 0.0026879995
with O 0 0.0031956027
focal B-Disease 0 0.6065826
segmental I-Disease 0 0.537479
glomerulosclerosis I-Disease 2 0.9999329
. O 0 0.019707518

A O 0 0.044149727
61 O 0 0.013224812
- O 0 0.007574398
year O 0 0.004021407
- O 0 0.0038009286
old O 0 0.0026528894
Japanese O 0 0.013733244
man O 0 0.17142573
with O 0 0.003509218
nephrotic B-Disease 2 0.9999852
syndrome I-Disease 0 0.98336005
due O 0 0.0011922698
to O 0 0.0011194492
focal B-Disease 0 0.3879142
segmental I-Disease 0 0.21222208
glomerulosclerosis I-Disease 2 0.9999838
was O 0 0.002153328
initially O 0 0.0022879862
responding O 0 0.0036000828
well O 0 0.0019714928
to O 0 0.0032759658
steroid B-Chemical 1 0.99829596
therapy O 0 0.19983894
. O 0 0.009935747

The O 0 0.007080373
amount O 0 0.004131723
of O 0 0.004182101
daily O 0 0.005634706
urinary O 0 0.7025646
protein O 0 0.004532264
decreased O 0 0.0028695753
from O 0 0.0016786723
15 O 0 0.0013164035
. O 0 0.001069463
6 O 0 0.0011173832
to O 0 0.0014190401
2 O 0 0.0021177018
. O 0 0.0022835678
8 O 0 0.0037257383
g O 0 0.008043416
. O 0 0.008115983

Within O 0 0.0053707976
14 O 0 0.0042454153
days O 0 0.002428636
of O 0 0.0024217258
the O 0 0.0021838322
oral O 0 0.774145
bisphosphonate B-Chemical 0 0.9999404
( O 0 0.12432436
alendronate B-Chemical 0 0.9999896
sodium I-Chemical 1 0.9999862
) O 0 0.030841466
administration O 0 0.14116983
, O 0 0.0008833437
the O 0 0.00038377824
amount O 0 0.0002615761
of O 0 0.0005140672
daily O 0 0.0015542612
urinary O 0 0.789234
protein O 0 0.0016431691
increased O 0 0.00097255554
rapidly O 0 0.0013417086
up O 0 0.00057785626
to O 0 0.00055472885
12 O 0 0.00055258686
. O 0 0.0005759669
8 O 0 0.00086649356
g O 0 0.0018296264
with O 0 0.0022622398
acute B-Disease 0 0.9705175
renal I-Disease 0 0.998237
failure I-Disease 0 0.9678761
. O 0 0.011890727

After O 0 0.0064030476
discontinuing O 0 0.08188807
the O 0 0.004456337
oral O 0 0.6287833
alendronate B-Chemical 0 0.99981266
, O 0 0.0034624096
the O 0 0.0012753761
patient O 0 0.0013889604
underwent O 0 0.0009116243
six O 0 0.0006009865
cycles O 0 0.0007523796
of O 0 0.0011619725
hemodialysis O 0 0.3017582
and O 0 0.0017006802
four O 0 0.0013932614
cycles O 0 0.0022241443
of O 0 0.0055609103
LDL O 0 0.9994615
apheresis O 0 0.6983887
. O 0 0.012731161

Urinary O 0 0.77807105
volume O 0 0.013065656
and O 0 0.005754828
serum O 0 0.14418484
creatinine B-Chemical 1 0.9955237
levels O 0 0.001838912
recovered O 0 0.0012239238
to O 0 0.001023081
the O 0 0.001004939
normal O 0 0.0017447254
range O 0 0.0016504279
, O 0 0.001434818
with O 0 0.0012375265
urinary O 0 0.81118906
protein O 0 0.004011831
disappearing O 0 0.01774721
completely O 0 0.0022003506
within O 0 0.0017617062
40 O 0 0.0035055582
days O 0 0.0040434427
. O 0 0.0068919994

This O 0 0.0102019925
report O 0 0.007178091
demonstrates O 0 0.002987704
that O 0 0.0021614886
not O 0 0.0018063517
only O 0 0.0015550487
intravenous O 0 0.45736828
, O 0 0.0023462132
but O 0 0.0011933639
also O 0 0.0014327733
oral O 0 0.872375
bisphosphonates B-Chemical 0 0.9999567
can O 0 0.002887426
aggravate O 0 0.95240426
proteinuria B-Disease 2 0.9999753
and O 0 0.023598557
acute B-Disease 0 0.9964206
renal I-Disease 0 0.9991111
failure I-Disease 0 0.98028576
. O 0 0.013014014

Serum O 0 0.7293202
- O 0 0.016626243
and O 0 0.009087471
glucocorticoid O 0 0.9843746
- O 0 0.013602984
inducible O 0 0.050212357
kinase O 0 0.41969755
1 O 0 0.003730639
in O 0 0.0034290268
doxorubicin B-Chemical 1 0.9996786
- O 0 0.023832995
induced O 0 0.018743036
nephrotic B-Disease 2 0.9999641
syndrome I-Disease 0 0.9970061
. O 0 0.019849027

Doxorubicin B-Chemical 1 0.99968207
- O 0 0.03296413
induced O 0 0.0107957795
nephropathy B-Disease 2 0.9998863
leads O 0 0.0057335235
to O 0 0.0029342151
epithelial O 0 0.4891049
sodium B-Chemical 1 0.99988174
channel O 0 0.7960547
( O 0 0.012057203
ENaC O 0 0.97399694
) O 0 0.0050878944
- O 0 0.0022208274
dependent O 0 0.0012603728
volume B-Disease 0 0.015335566
retention I-Disease 0 0.022668423
and O 0 0.0058557703
renal O 0 0.99727255
fibrosis B-Disease 2 0.9989631
. O 0 0.015487929

The O 0 0.01199805
aldosterone B-Chemical 1 0.99928135
- O 0 0.012337936
sensitive O 0 0.0035781174
serum O 0 0.26113445
- O 0 0.006276183
and O 0 0.0027938145
glucocorticoid O 0 0.99445623
- O 0 0.015919453
inducible O 0 0.086678416
kinase O 0 0.75479
SGK1 O 0 0.98754233
has O 0 0.00076943374
been O 0 0.0007247349
shown O 0 0.00042279233
to O 0 0.00044593198
participate O 0 0.000433066
in O 0 0.0004082289
the O 0 0.0004809991
stimulation O 0 0.0009585784
of O 0 0.0011302567
ENaC O 0 0.90371054
and O 0 0.0009499743
to O 0 0.00076533714
mediate O 0 0.0010865207
renal O 0 0.99623126
fibrosis B-Disease 2 0.9994235
following O 0 0.0133606335
mineralocorticoid O 0 0.99973947
and O 0 0.017914778
salt O 1 0.99559915
excess O 0 0.057376895
. O 0 0.0111003695

The O 0 0.0073568574
present O 0 0.004344149
study O 0 0.004115362
was O 0 0.0026688408
performed O 0 0.0017752773
to O 0 0.0013857267
elucidate O 0 0.0009130621
the O 0 0.001152862
role O 0 0.0009060044
of O 0 0.0018331251
SGK1 O 0 0.9501474
in O 0 0.0010972322
the O 0 0.0012179171
volume B-Disease 0 0.01932158
retention I-Disease 0 0.02295215
and O 0 0.0036398217
fibrosis B-Disease 2 0.9983083
during O 0 0.0070219957
nephrotic B-Disease 2 0.9999709
syndrome I-Disease 0 0.9966922
. O 0 0.017298425

To O 0 0.006799302
this O 0 0.004942054
end O 0 0.0032831512
, O 0 0.004448916
doxorubicin B-Chemical 1 0.99921155
( O 0 0.0030860165
15 O 0 0.0010190911
mug O 0 0.0015280829
/ O 0 0.001841921
g O 0 0.0013063953
body O 0 0.003030547
wt O 0 0.00077183987
) O 0 0.0011372658
was O 0 0.00041651077
injected O 0 0.00035174342
intravenously O 0 0.0009318086
into O 0 0.00028917304
gene O 0 0.00080526224
- O 0 0.00091696176
targeted O 0 0.00037972757
mice O 0 0.00036256446
lacking O 0 0.00046165957
SGK1 O 0 0.97746
( O 0 0.0018136237
sgk1 O 0 0.18026394
( O 0 0.0022265394
- O 0 0.0019708073
/ O 0 0.004323128
- O 0 0.0016081901
) O 0 0.0012253643
) O 0 0.00089437916
and O 0 0.0005410712
their O 0 0.0006082484
wild O 0 0.0006737063
- O 0 0.0011672627
type O 0 0.00074250327
littermates O 0 0.0006232974
( O 0 0.0019375853
sgk1 O 0 0.08845349
( O 0 0.0030716236
+ O 0 0.002669599
/ O 0 0.0068849795
+ O 0 0.004272559
) O 0 0.007461223
) O 0 0.009348238
. O 0 0.007698965

Doxorubicin B-Chemical 1 0.9994373
treatment O 0 0.011819892
resulted O 0 0.003921142
in O 0 0.0031038017
heavy O 0 0.75712293
proteinuria B-Disease 2 0.99997115
( O 0 0.013039199
> O 0 0.0026515357
100 O 0 0.001682147
mg O 0 0.16174921
protein O 0 0.0015038628
/ O 0 0.0032684912
mg O 0 0.45156616
crea O 0 0.7826597
) O 0 0.0013370003
in O 0 0.00044764663
15 O 0 0.0004097065
/ O 0 0.0008092943
44 O 0 0.0005785468
of O 0 0.0005366187
sgk1 O 0 0.083839536
( O 0 0.0013485112
+ O 0 0.00084683386
/ O 0 0.002319644
+ O 0 0.00073496706
) O 0 0.0007782121
and O 0 0.00044335323
15 O 0 0.00035310973
/ O 0 0.0007255562
44 O 0 0.00053384696
of O 0 0.0005132024
sgk1 O 0 0.10821127
( O 0 0.0018007049
- O 0 0.0017542352
/ O 0 0.0038137424
- O 0 0.0012897403
) O 0 0.000813272
mice O 0 0.0003253409
leading O 0 0.0008585107
to O 0 0.0006235033
severe O 0 0.6050963
nephrotic B-Disease 2 0.9999944
syndrome I-Disease 0 0.99251693
with O 0 0.008697318
ascites B-Disease 2 0.9999336
, O 0 0.037408724
lipidemia B-Disease 0 0.9998085
, O 0 0.004138973
and O 0 0.0034800854
hypoalbuminemia B-Disease 0 0.9998468
in O 0 0.0036788916
both O 0 0.0047802194
genotypes O 0 0.01806204
. O 0 0.00927287

Plasma O 0 0.6789168
aldosterone B-Chemical 1 0.9992613
levels O 0 0.00548649
increased O 0 0.004545507
in O 0 0.0030517494
nephrotic B-Disease 2 0.99995124
mice O 0 0.0014931223
of O 0 0.00155957
both O 0 0.0010377122
genotypes O 0 0.002666959
and O 0 0.000998208
was O 0 0.0007006594
followed O 0 0.0005257973
by O 0 0.0008532949
increased O 0 0.0013861615
SGK1 O 0 0.9572084
protein O 0 0.002070414
expression O 0 0.0016316389
in O 0 0.001304021
sgk1 O 0 0.20118144
( O 0 0.0038470034
+ O 0 0.0028582187
/ O 0 0.0070068003
+ O 0 0.0039452943
) O 0 0.0060254266
mice O 0 0.004613194
. O 0 0.007782848

Urinary O 0 0.9775073
sodium B-Chemical 1 0.99923074
excretion O 0 0.9383856
reached O 0 0.0040621664
signficantly O 0 0.10559443
lower O 0 0.0016438633
values O 0 0.0012979343
in O 0 0.0010964251
sgk1 O 0 0.16146936
( O 0 0.0023891758
+ O 0 0.0013242016
/ O 0 0.003414041
+ O 0 0.0010091363
) O 0 0.0010356151
mice O 0 0.00040771396
( O 0 0.0007628458
15 O 0 0.00043018415
+ O 0 0.0005875184
/ O 0 0.0014895939
- O 0 0.0007915953
5 O 0 0.00037220068
mumol O 0 0.026492698
/ O 0 0.0015618956
mg O 0 0.29126272
crea O 0 0.7103437
) O 0 0.0011531459
than O 0 0.00033017286
in O 0 0.00047135135
sgk1 O 0 0.10384219
( O 0 0.0017626532
- O 0 0.001699113
/ O 0 0.003575216
- O 0 0.0012723688
) O 0 0.0008306324
mice O 0 0.00034291335
( O 0 0.0006754597
35 O 0 0.0005281088
+ O 0 0.0005668338
/ O 0 0.001501205
- O 0 0.0007563078
5 O 0 0.00035094275
mumol O 0 0.027833866
/ O 0 0.0015701998
mg O 0 0.31455448
crea O 0 0.7565724
) O 0 0.0012652953
and O 0 0.0005036533
was O 0 0.00039415978
associated O 0 0.0004458194
with O 0 0.00043442834
a O 0 0.00059672765
significantly O 0 0.00055957725
higher O 0 0.00042006414
body O 0 0.0041475673
weight B-Disease 0 0.006217597
gain I-Disease 0 0.0014634032
in O 0 0.0005887022
sgk1 O 0 0.19987291
( O 0 0.0018058926
+ O 0 0.0009386319
/ O 0 0.0031294117
+ O 0 0.0007559652
) O 0 0.00075682934
compared O 0 0.00026214783
with O 0 0.0005524468
sgk1 O 0 0.16862899
( O 0 0.0020775166
- O 0 0.0018480583
/ O 0 0.0040008156
- O 0 0.0012979066
) O 0 0.00083904964
mice O 0 0.0003482289
( O 0 0.0007689712
+ O 0 0.00049907883
6 O 0 0.00029243482
. O 0 0.00025751785
6 O 0 0.0002955756
+ O 0 0.00046632678
/ O 0 0.0011919134
- O 0 0.00072203565
0 O 0 0.000499863
. O 0 0.00027194814
7 O 0 0.00034140373
vs O 0 0.0006627167
. O 0 0.00037735936
+ O 0 0.00056384545
4 O 0 0.00046202863
. O 0 0.00043502217
1 O 0 0.00071818166
+ O 0 0.0009528678
/ O 0 0.0022052082
- O 0 0.0017849231
0 O 0 0.0016051808
. O 0 0.0013558334
8 O 0 0.0022730604
g O 0 0.0052359574
) O 0 0.007988891
. O 0 0.0074683656

During O 0 0.006376427
the O 0 0.0048070853
course O 0 0.0043229084
of O 0 0.0056913765
nephrotic B-Disease 2 0.9999721
syndrome I-Disease 0 0.9971961
, O 0 0.022103569
serum O 0 0.70562
urea B-Chemical 1 0.9997105
concentrations O 0 0.011412371
increased O 0 0.0012514543
significantly O 0 0.0010642005
faster O 0 0.0006115609
in O 0 0.00063892675
sgk1 O 0 0.22105676
( O 0 0.0026575362
- O 0 0.0022116473
/ O 0 0.004795859
- O 0 0.001335243
) O 0 0.0007701577
mice O 0 0.00028470246
than O 0 0.00029219623
in O 0 0.00043946697
sgk1 O 0 0.09774933
( O 0 0.001411483
+ O 0 0.0008574859
/ O 0 0.0029359425
+ O 0 0.0007612917
) O 0 0.0008176375
mice O 0 0.00030384117
leading O 0 0.0009012866
to O 0 0.0006174878
uremia B-Disease 0 0.9999342
and O 0 0.0009970142
a O 0 0.0008117533
reduced O 0 0.00047771292
median O 0 0.00046954278
survival O 0 0.036944356
in O 0 0.0006611196
sgk1 O 0 0.24311015
( O 0 0.0026641123
- O 0 0.0021513258
/ O 0 0.004365513
- O 0 0.0013631007
) O 0 0.00087336014
mice O 0 0.0003622347
( O 0 0.0006874412
29 O 0 0.0007254573
vs O 0 0.000717475
. O 0 0.00034291335
40 O 0 0.0004293173
days O 0 0.00039108173
in O 0 0.0006540069
sgk1 O 0 0.046117775
( O 0 0.0022957155
+ O 0 0.002021785
/ O 0 0.005050822
+ O 0 0.0029360906
) O 0 0.0045058513
mice O 0 0.003334437
) O 0 0.0095066
. O 0 0.007737512

In O 0 0.007597725
conclusion O 0 0.0051647904
, O 0 0.0054866592
gene O 0 0.004703263
- O 0 0.0037481044
targeted O 0 0.0014848
mice O 0 0.0011159856
lacking O 0 0.0010070518
SGK1 O 0 0.93376285
showed O 0 0.0010492057
blunted O 0 0.12073137
volume B-Disease 0 0.057965018
retention I-Disease 0 0.038483374
, O 0 0.0014179485
yet O 0 0.0008938552
were O 0 0.0006623223
not O 0 0.0006321185
protected O 0 0.0011390146
against O 0 0.0011935391
renal O 0 0.9939733
fibrosis B-Disease 2 0.99867105
during O 0 0.002633146
experimental O 0 0.02190312
nephrotic B-Disease 2 0.9999708
syndrome I-Disease 0 0.99632215
. O 0 0.016038703

Severe O 0 0.9651383
thrombocytopenia B-Disease 2 0.99956936
and O 0 0.023014743
haemolytic B-Disease 0 0.9995364
anaemia I-Disease 0 0.99995375
associated O 0 0.022840684
with O 0 0.007430627
ciprofloxacin B-Chemical 1 0.9997714
: O 0 0.0053148516
a O 0 0.0030198784
case O 0 0.0027971256
report O 0 0.0071485466
with O 0 0.0059371335
fatal O 0 0.993518
outcome O 0 0.09813874
. O 0 0.012307619

Haematological O 0 0.95986867
adverse O 0 0.9078756
reactions O 0 0.091836385
associated O 0 0.0070149763
with O 0 0.0055408212
fatal O 0 0.98349714
outcome O 0 0.017771056
are O 0 0.0040128157
rare O 0 0.014372557
during O 0 0.0030710292
treatment O 0 0.007648653
with O 0 0.011309878
ciprofloxacin B-Chemical 1 0.9994301
. O 0 0.013845314

A O 0 0.0355022
30 O 0 0.0065102843
- O 0 0.005698316
year O 0 0.002956796
old O 0 0.002911555
Caucasian O 0 0.13952714
man O 0 0.0649549
reported O 0 0.0017902366
with O 0 0.0014546659
abdominal B-Disease 0 0.77406913
pain I-Disease 2 0.9991898
and O 0 0.0024962365
jaundice B-Disease 2 0.99977905
after O 0 0.000607193
3 O 0 0.00074398424
- O 0 0.00080562517
day O 0 0.00042096528
administration O 0 0.0069105667
of O 0 0.0010376511
oral O 0 0.77337587
ciprofloxacin B-Chemical 1 0.999703
for O 0 0.0010742034
a O 0 0.001887085
suspect O 0 0.004870925
of O 0 0.0037834153
urinary B-Disease 0 0.9780753
tract I-Disease 0 0.8835243
infection I-Disease 2 0.84541583
. O 0 0.01253643

Clinical O 0 0.033634998
evaluations O 0 0.009483832
suggested O 0 0.0059268144
an O 0 0.0061670975
initial O 0 0.004966942
diagnosis O 0 0.012601787
of O 0 0.008473172
severe O 0 0.8940536
thrombocytopenia B-Disease 2 0.99988365
and O 0 0.13624007
haemolysis B-Disease 0 0.9997371
. O 0 0.022560604

The O 0 0.010106121
patient O 0 0.009856328
progressively O 0 0.0096884305
developed O 0 0.008868764
petechiae B-Disease 0 0.994616
and O 0 0.010781714
purpura B-Disease 0 0.99938107
on O 0 0.005390452
thorax O 0 0.1460713
and O 0 0.0075651165
lower O 0 0.008738851
limbs O 0 0.47386172
. O 0 0.01326923

Despite O 0 0.009977093
pharmacological O 0 0.14036012
and O 0 0.0056488737
supportive O 0 0.007531025
interventions O 0 0.0036322623
, O 0 0.0024877777
laboratory O 0 0.0022407956
parameters O 0 0.0021912071
worsened O 0 0.1561129
and O 0 0.0015826391
the O 0 0.0013483159
patient O 0 0.0022708026
died O 0 0.006451509
17 O 0 0.0028237135
hours O 0 0.0019767785
after O 0 0.0026042056
admission O 0 0.018276384
. O 0 0.0082153445

An O 0 0.019857647
accurate O 0 0.01298479
autopsy O 0 0.020067845
revealed O 0 0.008507979
most O 0 0.009335745
organs O 0 0.038941972
with O 0 0.011046335
diffuse O 0 0.53412795
petechial O 0 0.9969355
haemorrhages B-Disease 0 0.9994754
. O 0 0.02382646

No O 0 0.026668323
signs O 0 0.12797911
of O 0 0.02213095
bone B-Disease 0 0.8638906
marrow I-Disease 0 0.97115123
depression I-Disease 2 0.9990959
were O 0 0.020008987
found O 0 0.015728487
. O 0 0.019048288

No O 0 0.016966928
thrombi B-Disease 2 0.9189433
or O 0 0.009006513
signs O 0 0.1998942
of O 0 0.010379161
microangiopathies B-Disease 0 0.99949205
were O 0 0.0072878804
observed O 0 0.0043143863
in O 0 0.0064227507
arterial O 0 0.75626296
vessels O 0 0.4153686
. O 0 0.013853358

Blood O 0 0.07100198
and O 0 0.013974534
urine O 0 0.085549854
cultures O 0 0.009393194
did O 0 0.0067354
not O 0 0.005882931
show O 0 0.0055983923
any O 0 0.0075190132
bacterial O 0 0.04330959
growth O 0 0.09454201
. O 0 0.017153362

This O 0 0.009790115
case O 0 0.005263937
report O 0 0.005342207
shows O 0 0.0021123046
that O 0 0.0020601714
ciprofloxacin B-Chemical 1 0.99920255
may O 0 0.0019444979
precipitate O 0 0.21072751
life O 0 0.034761615
- O 0 0.0065867943
threatening O 0 0.3893502
thrombocytopenia B-Disease 2 0.9999683
and O 0 0.009880322
haemolytic B-Disease 0 0.99992
anaemia I-Disease 0 0.99999344
, O 0 0.007877858
even O 0 0.000867082
in O 0 0.0005844766
the O 0 0.0006211166
early O 0 0.0011595655
phases O 0 0.0014968977
of O 0 0.001190986
treatment O 0 0.0019729713
and O 0 0.0017547798
without O 0 0.0018781375
apparent O 0 0.0027580103
previous O 0 0.0041419636
exposures O 0 0.13471888
. O 0 0.009326516

Alpha B-Chemical 0 0.9207697
- I-Chemical 0 0.07635064
lipoic I-Chemical 0 0.9997322
acid I-Chemical 0 0.99072534
prevents O 0 0.033958808
mitochondrial B-Disease 0 0.9822174
damage I-Disease 0 0.99337864
and O 0 0.025622867
neurotoxicity B-Disease 2 0.9998778
in O 0 0.0052877213
experimental O 0 0.0103039
chemotherapy O 0 0.99017113
neuropathy B-Disease 2 0.99986017
. O 0 0.017008524

The O 0 0.0076585943
study O 0 0.0059675085
investigates O 0 0.0058123223
if O 0 0.0033169058
alpha B-Chemical 1 0.7640587
- I-Chemical 1 0.07727712
lipoic I-Chemical 1 0.999966
acid I-Chemical 1 0.99535596
is O 0 0.003042104
neuroprotective O 0 0.9475321
against O 0 0.0012424132
chemotherapy O 0 0.95096004
induced O 0 0.012043001
neurotoxicity B-Disease 2 0.9999863
, O 0 0.0052954457
if O 0 0.0006552103
mitochondrial B-Disease 0 0.93673235
damage I-Disease 0 0.9727093
plays O 0 0.00075511594
a O 0 0.0008070429
critical O 0 0.0004505672
role O 0 0.00039527478
in O 0 0.00069706654
toxic B-Disease 0 0.9930575
neurodegenerative I-Disease 0 0.9990369
cascade I-Disease 0 0.35469946
, O 0 0.002141286
and O 0 0.0007758803
if O 0 0.0005034896
neuroprotective O 0 0.7946862
effects O 0 0.0024553498
of O 0 0.0026525876
alpha B-Chemical 1 0.86973673
- I-Chemical 1 0.07518616
lipoic I-Chemical 1 0.99995625
acid I-Chemical 1 0.9712035
depend O 0 0.0029442064
on O 0 0.0027191043
mitochondria O 0 0.43691543
protection O 0 0.054418374
. O 0 0.009868117

We O 0 0.007594228
used O 0 0.0045812214
an O 0 0.004170963
in O 0 0.0024515206
vitro O 0 0.0023907686
model O 0 0.0017894248
of O 0 0.0019012386
chemotherapy O 0 0.8520136
induced O 0 0.0035774393
peripheral B-Disease 2 0.9431629
neuropathy I-Disease 2 0.99999
that O 0 0.000802571
closely O 0 0.00061807036
mimic O 0 0.0007814592
the O 0 0.0005392716
in O 0 0.00044654365
vivo O 0 0.00078799104
condition O 0 0.001140941
by O 0 0.00054119754
exposing O 0 0.0010594437
primary O 0 0.00061213557
cultures O 0 0.00073729013
of O 0 0.0007585674
dorsal O 0 0.007324061
root O 0 0.01824394
ganglion O 0 0.9547288
( O 0 0.0026744963
DRG O 0 0.87702453
) O 0 0.0017642976
sensory O 0 0.052273665
neurons O 0 0.0069116135
to O 0 0.00059041823
paclitaxel B-Chemical 1 0.9985697
and O 0 0.0014810228
cisplatin B-Chemical 1 0.99973685
, O 0 0.0012631244
two O 0 0.00063411327
widely O 0 0.0011655277
used O 0 0.0009717229
and O 0 0.0014850688
highly O 0 0.0021842269
effective O 0 0.0039156536
chemotherapeutic O 0 0.9713966
drugs O 0 0.96715933
. O 0 0.010238266

This O 0 0.009407247
approach O 0 0.0050861766
allowed O 0 0.0029178495
investigating O 0 0.002073291
the O 0 0.0017886704
efficacy O 0 0.003181154
of O 0 0.0029242437
alpha B-Chemical 1 0.9011349
- I-Chemical 1 0.097216785
lipoic I-Chemical 1 0.9999821
acid I-Chemical 1 0.9937342
in O 0 0.0017036425
preventing O 0 0.02199109
axonal B-Disease 0 0.9745316
damage I-Disease 0 0.99025154
and O 0 0.0037703356
apoptosis O 0 0.953887
and O 0 0.00083593855
the O 0 0.0005052793
function O 0 0.0005692285
and O 0 0.00058564934
ultrastructural O 0 0.017553981
morphology O 0 0.0031389243
of O 0 0.0010531683
mitochondria O 0 0.15424956
after O 0 0.00046202735
exposure O 0 0.0018333104
to O 0 0.0010903993
toxic O 0 0.9099515
agents O 0 0.6010899
and O 0 0.0077821305
alpha B-Chemical 1 0.88455224
- I-Chemical 1 0.16512269
lipoic I-Chemical 1 0.9999044
acid I-Chemical 1 0.9937192
. O 0 0.014976968

Our O 0 0.007454495
results O 0 0.004817211
demonstrate O 0 0.0026421628
that O 0 0.0022860297
both O 0 0.0025348002
cisplatin B-Chemical 1 0.9995946
and O 0 0.004937453
paclitaxel B-Chemical 1 0.99967444
cause O 0 0.039070733
early O 0 0.012456027
mitochondrial B-Disease 0 0.96892583
impairment I-Disease 0 0.9084532
with O 0 0.0011102115
loss O 0 0.0017321595
of O 0 0.00101226
membrane O 0 0.0068053557
potential O 0 0.0015629417
and O 0 0.001459141
induction O 0 0.0016408914
of O 0 0.0029014451
autophagic O 0 0.51661223
vacuoles O 0 0.032350674
in O 0 0.0051899003
neurons O 0 0.08576235
. O 0 0.0083882315

Alpha B-Chemical 0 0.9343199
- I-Chemical 0 0.074042656
lipoic I-Chemical 0 0.99980956
acid I-Chemical 0 0.98924774
exerts O 0 0.08226153
neuroprotective O 0 0.97330046
effects O 0 0.0126178
against O 0 0.0016021171
chemotherapy O 0 0.954103
induced O 0 0.011360842
neurotoxicity B-Disease 2 0.9999784
in O 0 0.0013538856
sensory O 0 0.39381236
neurons O 0 0.057083666
: O 0 0.0011873092
it O 0 0.00056342746
rescues O 0 0.00086925185
the O 0 0.0006320369
mitochondrial B-Disease 0 0.91994524
toxicity I-Disease 2 0.9998104
and O 0 0.001196587
induces O 0 0.0004983121
the O 0 0.00052054826
expression O 0 0.0007828664
of O 0 0.0012580574
frataxin O 0 0.9963961
, O 0 0.001480133
an O 0 0.00095309305
essential O 0 0.0007544168
mitochondrial O 0 0.2244671
protein O 0 0.00230667
with O 0 0.0018192658
anti O 0 0.076663665
- O 0 0.014773437
oxidant O 0 0.99513763
and O 0 0.0063169976
chaperone O 0 0.08586739
properties O 0 0.013944224
. O 0 0.00976736

In O 0 0.008507963
conclusion O 0 0.006337498
mitochondrial B-Disease 0 0.83516896
toxicity I-Disease 2 0.99928504
is O 0 0.0037926175
an O 0 0.0030456434
early O 0 0.002966475
common O 0 0.002633474
event O 0 0.014836736
both O 0 0.0018734819
in O 0 0.0024746223
paclitaxel B-Chemical 1 0.99935085
and O 0 0.010904444
cisplatin B-Chemical 1 0.99980575
induced O 0 0.07259238
neurotoxicity B-Disease 2 0.9998796
. O 0 0.015936881

Alpha B-Chemical 0 0.92415565
- I-Chemical 0 0.06349424
lipoic I-Chemical 0 0.99977976
acid I-Chemical 0 0.9857308
protects O 0 0.079683974
sensory O 0 0.40817437
neurons O 0 0.038122807
through O 0 0.0012931973
its O 0 0.0024296239
anti O 0 0.04352748
- O 0 0.008071351
oxidant O 0 0.9959
and O 0 0.0023126022
mitochondrial O 0 0.44739985
regulatory O 0 0.0022927863
functions O 0 0.0017394645
, O 0 0.0017791679
possibly O 0 0.0027624296
inducing O 0 0.002674346
the O 0 0.0022046692
expression O 0 0.003978052
of O 0 0.0074831056
frataxin O 0 0.9948841
. O 0 0.010766055

These O 0 0.0091871815
findings O 0 0.0074409097
suggest O 0 0.0034532347
that O 0 0.0033617446
alpha B-Chemical 1 0.7658318
- I-Chemical 1 0.06961451
lipoic I-Chemical 1 0.9999583
acid I-Chemical 1 0.9855897
might O 0 0.0010573565
reduce O 0 0.00083015894
the O 0 0.00089246884
risk O 0 0.038275365
of O 0 0.00118644
developing O 0 0.013050969
peripheral B-Disease 0 0.5477722
nerve I-Disease 0 0.93140763
toxicity I-Disease 2 0.99937266
in O 0 0.0008464238
patients O 0 0.0024106437
undergoing O 0 0.0012926143
chemotherapy O 0 0.5116067
and O 0 0.0015409413
encourage O 0 0.0015078713
further O 0 0.0019781704
confirmatory O 0 0.069698185
clinical O 0 0.018877883
trials O 0 0.008151628
. O 0 0.007634793

Toxicity B-Disease 2 0.9340525
in O 0 0.0051525445
rhesus O 0 0.0030018145
monkeys O 0 0.002197112
following O 0 0.0015699355
administration O 0 0.009087909
of O 0 0.0014180999
the O 0 0.0011119955
8 B-Chemical 0 0.0011131349
- I-Chemical 0 0.001591767
aminoquinoline I-Chemical 0 0.69637644
8 B-Chemical 0 0.0010449005
- I-Chemical 0 0.001576518
[ I-Chemical 0 0.002032159
( I-Chemical 0 0.000980765
4 I-Chemical 0 0.0006168084
- I-Chemical 0 0.0011480702
amino I-Chemical 0 0.5457993
- I-Chemical 0 0.0016089918
l I-Chemical 0 0.0024005794
- I-Chemical 0 0.0022433696
methylbutyl I-Chemical 0 0.5322506
) I-Chemical 0 0.003871932
amino I-Chemical 0 0.8307252
] I-Chemical 0 0.0058244085
- I-Chemical 0 0.0013910857
5 I-Chemical 0 0.00055483775
- I-Chemical 0 0.000944525
( I-Chemical 0 0.00079192844
l I-Chemical 0 0.0015332672
- I-Chemical 0 0.0017614118
hexyloxy I-Chemical 0 0.6879515
) I-Chemical 0 0.0031081839
- I-Chemical 0 0.0015205467
6 I-Chemical 0 0.0007320634
- I-Chemical 0 0.0019636594
methoxy I-Chemical 0 0.9908921
- I-Chemical 0 0.003426494
4 I-Chemical 0 0.0016538327
- I-Chemical 0 0.0032641168
methylquinoline I-Chemical 0 0.16878378
( O 0 0.008651127
WR242511 B-Chemical 1 0.9887594
) O 0 0.01356726
. O 0 0.008546375

INTRODUCTION O 0 0.043596696
: O 0 0.0105166985
Many O 0 0.007217089
substances O 0 0.34971467
that O 0 0.003648891
form O 0 0.004651499
methemoglobin O 0 0.99972945
( O 0 0.018306019
MHb O 0 0.98703396
) O 0 0.004152259
effectively O 0 0.0029713344
counter O 0 0.061486688
cyanide O 0 0.99980444
( O 0 0.038576987
CN O 0 0.99302024
) O 0 0.040470243
toxicity B-Disease 2 0.9971445
. O 0 0.011834463

Although O 0 0.009916315
MHb O 0 0.9196784
formers O 0 0.8746621
are O 0 0.0036476727
generally O 0 0.0025541089
applied O 0 0.0014895131
as O 0 0.0013467118
treatments O 0 0.0030160833
for O 0 0.0011805767
CN O 0 0.9954921
poisoning B-Disease 2 0.999926
, O 0 0.0028999697
it O 0 0.00088623504
has O 0 0.0005175127
been O 0 0.00056659884
proposed O 0 0.0005589771
that O 0 0.0004273142
a O 0 0.00081861345
stable O 0 0.0008868385
, O 0 0.0011297205
long O 0 0.00096118724
- O 0 0.0018232282
acting O 0 0.006657395
MHb O 0 0.9533224
former O 0 0.0047373427
could O 0 0.0010422738
serve O 0 0.002137546
as O 0 0.0024748163
a O 0 0.0059297737
CN O 0 0.98375225
pretreatment O 0 0.49812597
. O 0 0.0108477725

Using O 0 0.008515203
this O 0 0.0050359936
rationale O 0 0.0050960258
, O 0 0.0036947797
the O 0 0.0022266665
8 B-Chemical 0 0.0020772151
- I-Chemical 0 0.0029149402
aminoquinoline I-Chemical 0 0.8815022
WR242511 B-Chemical 1 0.9967229
, O 0 0.0017686001
a O 0 0.0011949746
potent O 0 0.0075354925
long O 0 0.0009986066
- O 0 0.001416263
lasting O 0 0.0016953688
MHb O 0 0.93379766
former O 0 0.0036886625
in O 0 0.00046954546
rodents O 0 0.0016550864
and O 0 0.0006084699
beagle O 0 0.004532251
dogs O 0 0.0030708907
, O 0 0.00087444345
was O 0 0.0004745644
studied O 0 0.0005031068
in O 0 0.00045354053
the O 0 0.0004924581
rhesus O 0 0.0005051909
monkey O 0 0.0010724922
for O 0 0.000664873
advanced O 0 0.01789405
development O 0 0.002683571
as O 0 0.0019727862
a O 0 0.0033938708
potential O 0 0.007381349
CN O 0 0.9912669
pretreatment O 0 0.5892909
. O 0 0.010941708

METHODS O 0 0.010640938
: O 0 0.0073473426
In O 0 0.0035583186
this O 0 0.0028092875
study O 0 0.0028661718
, O 0 0.0029783554
WR242511 B-Chemical 1 0.96834373
was O 0 0.0011998351
administered O 0 0.0013487552
intravenously O 0 0.004930545
( O 0 0.0016797314
IV O 0 0.33237013
) O 0 0.0012368596
in O 0 0.00045526295
2 O 0 0.00046301624
female O 0 0.0011064017
and O 0 0.00047344976
4 O 0 0.00034601366
male O 0 0.0007812756
rhesus O 0 0.00027219456
monkeys O 0 0.00031779282
in O 0 0.0003121786
doses O 0 0.0032772615
of O 0 0.00060001377
3 O 0 0.0004775663
. O 0 0.00028282736
5 O 0 0.0002964058
and O 0 0.00039252886
/ O 0 0.00085164834
or O 0 0.00036434946
7 O 0 0.00038528087
. O 0 0.00027541484
0 O 0 0.00047125883
mg O 0 0.056796074
/ O 0 0.0011768821
kg O 0 0.0031972348
; O 0 0.0007630145
a O 0 0.0004951676
single O 0 0.00044496215
male O 0 0.0014767598
also O 0 0.000545845
received O 0 0.0007799225
WR242511 B-Chemical 1 0.9895097
orally O 0 0.045780793
( O 0 0.0028724503
PO O 0 0.95226496
) O 0 0.001765245
at O 0 0.00076792255
7 O 0 0.0010531297
. O 0 0.0011124075
0 O 0 0.002352886
mg O 0 0.12692457
/ O 0 0.00861807
kg O 0 0.017910602
. O 0 0.008521039

Health O 0 0.025057727
status O 0 0.015674828
and O 0 0.013020643
MHb O 0 0.8638271
levels O 0 0.0072630662
were O 0 0.007024131
monitored O 0 0.0053983317
following O 0 0.0082651265
exposure O 0 0.018868258
. O 0 0.015205327

RESULTS O 0 0.023843816
: O 0 0.0074248617
The O 0 0.003383661
selected O 0 0.002513954
doses O 0 0.007994599
of O 0 0.0034112984
WR242511 B-Chemical 1 0.9958072
, O 0 0.0023104027
which O 0 0.0011825942
produced O 0 0.00083325605
significant O 0 0.0014256476
methemoglobinemia B-Disease 0 0.99995244
in O 0 0.0008808668
beagle O 0 0.010274201
dogs O 0 0.0023946143
in O 0 0.00052206777
earlier O 0 0.00056708674
studies O 0 0.00057509553
conducted O 0 0.00045555577
elsewhere O 0 0.00059185695
, O 0 0.0006155613
produced O 0 0.00040943554
very O 0 0.0005841475
little O 0 0.00059498474
MHb O 0 0.9343919
( O 0 0.0007422634
mean O 0 0.0004922143
< O 0 0.00062445743
2 O 0 0.00060850807
. O 0 0.0005620415
0 O 0 0.001009661
% O 0 0.0012658166
) O 0 0.0018611761
in O 0 0.0015262745
the O 0 0.0022631255
rhesus O 0 0.0032080943
monkey O 0 0.00786593
. O 0 0.0076351725

Furthermore O 0 0.009057285
, O 0 0.00696422
transient O 0 0.06748098
hemoglobinuria B-Disease 0 0.99987316
was O 0 0.0026102366
noted O 0 0.0011415483
approximately O 0 0.0008843067
60 O 0 0.0006979157
minutes O 0 0.00050434604
postinjection O 0 0.0009895392
of O 0 0.0008047827
WR242511 B-Chemical 1 0.98752606
( O 0 0.0012055696
3 O 0 0.0005060341
. O 0 0.00031751484
5 O 0 0.0003093309
or O 0 0.00032296352
7 O 0 0.00036789526
. O 0 0.0002807236
0 O 0 0.00047155988
mg O 0 0.054684006
/ O 0 0.0012478052
kg O 0 0.0052413447
) O 0 0.0011812971
, O 0 0.0006494787
and O 0 0.0005362736
2 O 0 0.0005525663
lethalities O 0 0.82279724
occurred O 0 0.000778614
( O 0 0.0008367622
one O 0 0.00045351588
IV O 0 0.08452741
and O 0 0.00066004694
one O 0 0.0006341795
PO O 0 0.9144036
) O 0 0.001218593
following O 0 0.0006113062
the O 0 0.00074386614
7 O 0 0.0008822027
. O 0 0.00084488874
0 O 0 0.001733097
mg O 0 0.106997
/ O 0 0.0056489455
kg O 0 0.012653071
dose O 0 0.025760023
. O 0 0.008606634

Myoglobinuria B-Disease 0 0.9921858
was O 0 0.007958855
also O 0 0.004870465
observed O 0 0.0029568553
following O 0 0.0028839917
the O 0 0.0027673813
7 O 0 0.0026429296
. O 0 0.0022110194
0 O 0 0.0034541783
mg O 0 0.15144666
/ O 0 0.008787062
kg O 0 0.018078387
dose O 0 0.034279075
. O 0 0.01110038

Histopathology O 0 0.12669477
analyses O 0 0.0072946586
in O 0 0.003942473
the O 0 0.002870143
2 O 0 0.0020528918
animals O 0 0.0013719974
that O 0 0.0010728576
died O 0 0.003849409
revealed O 0 0.0012909047
liver B-Disease 0 0.86843646
and I-Disease 0 0.0025281177
kidney I-Disease 0 0.97829765
toxicity I-Disease 2 0.99941134
, O 0 0.0022432962
with O 0 0.0009780221
greater O 0 0.00093539787
severity O 0 0.029326357
in O 0 0.0012851745
the O 0 0.0017494847
orally O 0 0.04799571
- O 0 0.005707991
treated O 0 0.0052620578
animal O 0 0.009314803
. O 0 0.00895978

CONCLUSIONS O 0 0.36540353
: O 0 0.010539236
These O 0 0.0059831482
data O 0 0.004678311
demonstrate O 0 0.002552132
direct O 0 0.003095109
and O 0 0.0035978565
/ O 0 0.0058429814
or O 0 0.0029302626
indirect O 0 0.008115633
drug O 0 0.85858256
- O 0 0.015553164
induced O 0 0.011422257
toxicity B-Disease 2 0.9986094
. O 0 0.014435114

It O 0 0.01057581
is O 0 0.005501113
concluded O 0 0.004139091
that O 0 0.0029366799
WR242511 B-Chemical 1 0.96306545
should O 0 0.0013237598
not O 0 0.0012509908
be O 0 0.0011291843
pursued O 0 0.0022142113
as O 0 0.00084867206
a O 0 0.0011844154
pretreatment O 0 0.120460026
for O 0 0.00086285936
CN O 0 0.99527466
poisoning B-Disease 2 0.99989724
unless O 0 0.0017520037
the O 0 0.00075007946
anti O 0 0.022845961
- O 0 0.002956432
CN O 0 0.9000343
characteristics O 0 0.00060433627
of O 0 0.0007184596
this O 0 0.00071828265
compound O 0 0.07770327
can O 0 0.0006773078
be O 0 0.0008575615
successfully O 0 0.0011649044
dissociated O 0 0.002206639
from O 0 0.0014943635
those O 0 0.002579077
producing O 0 0.0041566486
undesirable O 0 0.6266654
toxicity B-Disease 2 0.99880636
. O 0 0.011640369

Repetitive O 0 0.1386365
transcranial O 0 0.5004791
magnetic O 0 0.095677786
stimulation O 0 0.007885718
for O 0 0.004515647
levodopa B-Chemical 1 0.99995327
- O 0 0.025898738
induced O 0 0.0077623506
dyskinesias B-Disease 2 0.9999529
in O 0 0.0069953436
Parkinson B-Disease 0 0.9997181
' I-Disease 0 0.0100465715
s I-Disease 0 0.008636384
disease I-Disease 0 0.75679636
. O 0 0.012085487

In O 0 0.007791507
a O 0 0.007199471
placebo O 0 0.19375896
- O 0 0.0050335336
controlled O 0 0.0022135517
, O 0 0.0021545743
single O 0 0.0016353279
- O 0 0.001835597
blinded O 0 0.0012316604
, O 0 0.0009801325
crossover O 0 0.003405649
study O 0 0.00078208605
, O 0 0.00061759015
we O 0 0.0002777835
assessed O 0 0.00030047822
the O 0 0.00035358538
effect O 0 0.00038261223
of O 0 0.00057773455
" O 0 0.0007069976
real O 0 0.00060167705
" O 0 0.0006925582
repetitive O 0 0.0020206207
transcranial O 0 0.6005717
magnetic O 0 0.071833685
stimulation O 0 0.0015939539
( O 0 0.0014501163
rTMS O 0 0.8535186
) O 0 0.00079475046
versus O 0 0.00038510497
" O 0 0.0005590815
sham O 0 0.0005214457
" O 0 0.0008489026
rTMS O 0 0.8268687
( O 0 0.0007959662
placebo O 0 0.04318929
) O 0 0.00070731796
on O 0 0.00026884786
peak O 0 0.000535657
dose O 0 0.013907871
dyskinesias B-Disease 2 0.99996626
in O 0 0.00080817216
patients O 0 0.003257242
with O 0 0.0015699636
Parkinson B-Disease 0 0.9997999
' I-Disease 0 0.0031599412
s I-Disease 0 0.0028981916
disease I-Disease 0 0.7967688
( O 0 0.018658174
PD B-Disease 2 0.9983741
) O 0 0.017360445
. O 0 0.0089076655

Ten O 0 0.012233332
patients O 0 0.0095821265
with O 0 0.005425759
PD B-Disease 2 0.9923511
and O 0 0.0039024039
prominent O 0 0.03256164
dyskinesias B-Disease 2 0.99996054
had O 0 0.0024780252
rTMS O 0 0.96231306
( O 0 0.0016472286
1 O 0 0.000785206
, O 0 0.0007407741
800 O 0 0.001264549
pulses O 0 0.0031240673
; O 0 0.0009942017
1 O 0 0.0005268764
Hz O 0 0.03710045
rate O 0 0.0004258101
) O 0 0.00059346604
delivered O 0 0.00026246396
over O 0 0.00020478203
the O 0 0.000338972
motor O 0 0.031862933
cortex O 0 0.023222372
for O 0 0.00023564193
4 O 0 0.00023443291
consecutive O 0 0.0002437996
days O 0 0.00020794413
twice O 0 0.00031943343
, O 0 0.00037067232
once O 0 0.00025375132
real O 0 0.00037347557
stimuli O 0 0.0012056178
and O 0 0.00046289669
once O 0 0.00035271203
sham O 0 0.00042254053
stimulation O 0 0.00065756775
were O 0 0.00044636748
used O 0 0.00043998047
; O 0 0.0007471253
evaluations O 0 0.00042428492
were O 0 0.00033527243
done O 0 0.00027139232
at O 0 0.00024400053
the O 0 0.0003109738
baseline O 0 0.00043510145
and O 0 0.00045798798
1 O 0 0.0004309465
day O 0 0.0003364097
after O 0 0.00030679393
the O 0 0.0005062881
end O 0 0.00049043883
of O 0 0.0009075064
each O 0 0.00088503794
of O 0 0.0019440564
the O 0 0.0026629036
treatment O 0 0.006101441
series O 0 0.011473582
. O 0 0.008791532

Direct O 0 0.011838212
comparison O 0 0.0045233853
between O 0 0.0027493234
sham O 0 0.0029159854
and O 0 0.0023605141
real O 0 0.002621865
rTMS O 0 0.67578477
effects O 0 0.0018473001
showed O 0 0.0008819569
no O 0 0.0007548666
significant O 0 0.0011073147
difference O 0 0.0008473021
in O 0 0.0013621948
clinician O 0 0.01006116
- O 0 0.0045771697
assessed O 0 0.0039366316
dyskinesia B-Disease 2 0.99996996
severity O 0 0.6258297
. O 0 0.0123183355

However O 0 0.008875368
, O 0 0.006061545
comparison O 0 0.0029490087
with O 0 0.0023499327
the O 0 0.0017454122
baseline O 0 0.0015325157
showed O 0 0.0009839606
small O 0 0.0012165583
but O 0 0.0009389127
significant O 0 0.0010421079
reduction O 0 0.0017139754
in O 0 0.0013908315
dyskinesia B-Disease 2 0.999992
severity O 0 0.13803026
following O 0 0.001718607
real O 0 0.0029819906
rTMS O 0 0.87546
but O 0 0.0026689689
not O 0 0.003681663
placebo O 0 0.20434615
. O 0 0.008027198

The O 0 0.019192258
major O 0 0.018678056
effect O 0 0.014450588
was O 0 0.015431512
on O 0 0.016343279
dystonia B-Disease 2 0.9997627
subscore O 0 0.85782605
. O 0 0.024090566

Similarly O 0 0.009776902
, O 0 0.006522496
in O 0 0.003434668
patient O 0 0.0037416914
diaries O 0 0.005470076
, O 0 0.0019934638
although O 0 0.0009785161
both O 0 0.0008509754
treatments O 0 0.0021561144
caused O 0 0.0010601768
reduction O 0 0.0015749437
in O 0 0.0006633779
subjective O 0 0.08380515
dyskinesia B-Disease 2 0.9999956
scores O 0 0.0012005371
during O 0 0.00030104915
the O 0 0.00032931907
days O 0 0.00027450442
of O 0 0.0004531615
intervention O 0 0.0006033912
, O 0 0.00055654865
the O 0 0.00034653625
effect O 0 0.000400587
was O 0 0.00042727386
sustained O 0 0.0012225336
for O 0 0.00034076022
3 O 0 0.0003962523
days O 0 0.00032925347
after O 0 0.00034447727
the O 0 0.0006204758
intervention O 0 0.0009469984
for O 0 0.0009266588
the O 0 0.0016384014
real O 0 0.0036169032
rTMS O 0 0.82894903
only O 0 0.0051948237
. O 0 0.0075286017

Following O 0 0.010134165
rTMS O 0 0.57660043
, O 0 0.0046525523
no O 0 0.0023050373
side O 0 0.011972476
effects O 0 0.002925303
and O 0 0.0017104424
no O 0 0.0010947349
adverse O 0 0.8030237
effects O 0 0.0026925346
on O 0 0.0010814391
motor O 0 0.089963906
function O 0 0.0021960565
and O 0 0.0038852775
PD B-Disease 2 0.99903274
symptoms O 0 0.9124648
were O 0 0.005591463
noted O 0 0.0059395772
. O 0 0.008485612

The O 0 0.006622481
results O 0 0.0045482353
suggest O 0 0.002548225
the O 0 0.0022291932
existence O 0 0.0018184668
of O 0 0.0016908257
residual O 0 0.0017675807
beneficial O 0 0.0030169697
clinical O 0 0.012853863
aftereffects O 0 0.11610226
of O 0 0.0008666933
consecutive O 0 0.0008060168
daily O 0 0.0012014493
applications O 0 0.0008577747
of O 0 0.0009167605
low O 0 0.0014826822
- O 0 0.0021214108
frequency O 0 0.001815419
rTMS O 0 0.89380574
on O 0 0.0021737802
dyskinesias B-Disease 2 0.9999151
in O 0 0.0074666915
PD B-Disease 2 0.9981881
. O 0 0.010190212

The O 0 0.012282192
effects O 0 0.0112058
may O 0 0.0076611247
be O 0 0.006370171
further O 0 0.0054546655
exploited O 0 0.0072477614
for O 0 0.004705408
potential O 0 0.008183573
therapeutic O 0 0.06430908
uses O 0 0.012050349
. O 0 0.013379952

Intracavernous O 0 0.98365015
epinephrine B-Chemical 1 0.998604
: O 0 0.010258705
a O 0 0.005725049
minimally O 0 0.005232543
invasive O 0 0.010090933
treatment O 0 0.0053132684
for O 0 0.003717994
priapism B-Disease 0 0.9995295
in O 0 0.0055051004
the O 0 0.0062003518
emergency O 0 0.06657249
department O 0 0.064001314
. O 0 0.013335923

Priapism B-Disease 0 0.99203616
is O 0 0.008145178
the O 0 0.005310447
prolonged O 0 0.009445012
erection O 0 0.7986988
of O 0 0.0038841553
the O 0 0.0029221058
penis O 0 0.06682633
in O 0 0.0025378813
the O 0 0.0026113742
absence O 0 0.002463873
of O 0 0.0063302354
sexual O 0 0.9051261
arousal O 0 0.9890026
. O 0 0.01342487

A O 0 0.03681794
45 O 0 0.0080250865
- O 0 0.006713113
year O 0 0.003646749
- O 0 0.0034197643
old O 0 0.0023214524
man O 0 0.05779572
, O 0 0.0019570515
an O 0 0.0014332925
admitted O 0 0.0032655834
frequent O 0 0.006502596
cocaine B-Chemical 1 0.9999125
user O 0 0.0020063329
, O 0 0.0009514204
presented O 0 0.000618079
to O 0 0.0004963301
the O 0 0.0006532161
Emergency O 0 0.01661032
Department O 0 0.0037048
( O 0 0.0011674266
ED O 0 0.3334883
) O 0 0.00084822346
on O 0 0.00030613656
two O 0 0.00036682238
separate O 0 0.0004471805
occasions O 0 0.0010658448
with O 0 0.00073645345
a O 0 0.0012700573
history O 0 0.015504725
of O 0 0.0034931125
priapism B-Disease 0 0.999848
after O 0 0.003784438
cocaine B-Chemical 1 0.99980587
use O 0 0.01104609
. O 0 0.009658633

The O 0 0.00741771
management O 0 0.007050747
options O 0 0.0052726837
in O 0 0.0026373772
the O 0 0.0023458605
ED O 0 0.47914213
, O 0 0.0019492501
as O 0 0.0010190256
exemplified O 0 0.0014670576
by O 0 0.00076723605
four O 0 0.00042826153
individual O 0 0.00048882765
case O 0 0.0005718201
reports O 0 0.0008778713
, O 0 0.000710146
in O 0 0.00037524357
particular O 0 0.00031332954
the O 0 0.00041567124
use O 0 0.00048766553
of O 0 0.0005922655
a O 0 0.00080226135
minimally O 0 0.0010019
invasive O 0 0.0056053936
method O 0 0.001333408
of O 0 0.0015224983
intracorporal O 0 0.36249492
epinephrine B-Chemical 1 0.99968827
instillation O 0 0.2894732
, O 0 0.0059805256
are O 0 0.0046571605
discussed O 0 0.0052405116
. O 0 0.008207559

Prophylactic O 0 0.11948767
use O 0 0.0094695045
of O 0 0.009937024
lamivudine B-Chemical 1 0.9994023
with O 0 0.009233688
chronic O 0 0.9855985
immunosuppressive O 0 0.99768126
therapy O 0 0.5168597
for O 0 0.010267618
rheumatologic B-Disease 0 0.9995229
disorders I-Disease 0 0.9987941
. O 0 0.020440925

The O 0 0.006870278
objective O 0 0.006025915
of O 0 0.0036976875
this O 0 0.0024393303
study O 0 0.002106021
was O 0 0.0013054443
to O 0 0.000917168
report O 0 0.0015711042
our O 0 0.0006335225
experience O 0 0.0010362482
concerning O 0 0.0004828601
the O 0 0.0004690029
effectiveness O 0 0.0004630145
of O 0 0.0005581811
the O 0 0.00048336756
prophylactic O 0 0.01041655
administration O 0 0.12883502
of O 0 0.004674263
lamivudine B-Chemical 1 0.9999665
in O 0 0.0087430235
hepatitis B-Chemical 2 0.999997
B I-Chemical 2 0.9968508
virus I-Chemical 0 0.33480674
surface I-Chemical 0 0.013562742
antigen I-Chemical 0 0.25280616
( O 0 0.013113975
HBs B-Chemical 0 0.9996232
Ag I-Chemical 0 0.9463003
) O 0 0.003736137
positive O 0 0.0020160414
patients O 0 0.0069837505
with O 0 0.005224163
rheumatologic B-Disease 0 0.9991266
disease I-Disease 0 0.99629956
. O 0 0.014937624

From O 0 0.01152571
June O 0 0.008040878
2004 O 0 0.006414701
to O 0 0.0030497583
October O 0 0.0030989498
2006 O 0 0.0031101776
, O 0 0.001966682
11 O 0 0.0018073681
HBs B-Chemical 0 0.9949964
Ag I-Chemical 0 0.6313574
positive O 0 0.0012914625
patients O 0 0.0037956203
with O 0 0.0014466487
rheumatologic B-Disease 0 0.99934155
diseases I-Disease 0 0.9962041
, O 0 0.002996428
who O 0 0.0015768337
were O 0 0.0005314861
on O 0 0.0003507086
both O 0 0.000582614
immunosuppressive O 0 0.8887264
and O 0 0.0017880839
prophylactic O 0 0.16088155
lamivudine B-Chemical 1 0.9999063
therapies O 0 0.20761463
, O 0 0.0038727925
were O 0 0.0028327412
retrospectively O 0 0.004814669
assessed O 0 0.004697799
. O 0 0.007718059

Liver O 0 0.9387962
function O 0 0.009605678
tests O 0 0.016120546
, O 0 0.018290468
hepatitis B-Disease 2 0.9999646
B I-Disease 2 0.99505794
virus O 0 0.67761207
( O 0 0.025137724
HBV O 0 0.9975465
) O 0 0.0055592945
serologic O 0 0.26466694
markers O 0 0.0058985124
, O 0 0.001779362
and O 0 0.0013701733
HBV O 0 0.9941333
DNA O 0 0.100730196
levels O 0 0.0006319953
of O 0 0.0007045416
the O 0 0.0006218117
patients O 0 0.0014353578
during O 0 0.00052632584
follow O 0 0.0006835655
- O 0 0.0012756287
up O 0 0.00080839434
were O 0 0.0009980015
obtained O 0 0.0012428197
from O 0 0.0018095166
hospital O 0 0.005039586
file O 0 0.0029398846
records O 0 0.0073261107
. O 0 0.007424471

Eleven O 0 0.018601008
patients O 0 0.010862089
( O 0 0.005531192
six O 0 0.0024538576
male O 0 0.006079054
) O 0 0.0027366541
with O 0 0.0012491025
median O 0 0.0010036826
age O 0 0.0017462573
47 O 0 0.0016213964
years O 0 0.0011548365
( O 0 0.00093042955
range O 0 0.00085906015
27 O 0 0.0011137181
- O 0 0.00089729787
73 O 0 0.0011282262
) O 0 0.00077346567
, O 0 0.00047873307
median O 0 0.00035229302
disease O 0 0.08840321
duration O 0 0.00063141854
50 O 0 0.0007016667
months O 0 0.00035199922
( O 0 0.00056719215
range O 0 0.00059809105
9 O 0 0.0005535949
- O 0 0.0007140488
178 O 0 0.0026792982
) O 0 0.00059773057
and O 0 0.00035584733
median O 0 0.0003269821
follow O 0 0.00032949616
- O 0 0.0005573629
up O 0 0.00028638516
period O 0 0.00026460266
of O 0 0.00040802234
patients O 0 0.0011155169
13 O 0 0.00060166727
. O 0 0.00032997678
8 O 0 0.00039368158
months O 0 0.00036523712
( O 0 0.0006873619
range O 0 0.0008307331
5 O 0 0.0007191851
- O 0 0.0012276071
27 O 0 0.0013949622
) O 0 0.0016134423
were O 0 0.001330678
enrolled O 0 0.00235969
in O 0 0.0021556674
this O 0 0.0034336057
study O 0 0.006820352
. O 0 0.007897438

Lamivudine B-Chemical 1 0.99598867
therapy O 0 0.026228666
was O 0 0.0048446096
started O 0 0.003645273
3 O 0 0.0025613373
- O 0 0.002492237
7 O 0 0.0013450467
days O 0 0.0010055831
prior O 0 0.0010109474
to O 0 0.0015123781
immunosuppressive O 0 0.89057016
therapy O 0 0.03810509
in O 0 0.0036224786
all O 0 0.004760576
patients O 0 0.01696564
. O 0 0.009451483

Baseline O 0 0.019257497
, O 0 0.00842289
liver O 0 0.4192024
function O 0 0.003726489
tests O 0 0.003980203
were O 0 0.0017603942
elevated O 0 0.002456733
in O 0 0.0009263615
two O 0 0.0007761199
patients O 0 0.002763385
( O 0 0.0012860512
fourth O 0 0.0017029373
patient O 0 0.0016985242
: O 0 0.0026594072
ALT O 0 0.999313
: O 0 0.0014937588
122 O 0 0.007407518
IU O 0 0.45253804
/ O 0 0.0017678736
l O 0 0.001573629
, O 0 0.0013183986
AST O 0 0.9985514
: O 0 0.0012468664
111 O 0 0.0060562096
IU O 0 0.34197485
/ O 0 0.0013353176
l O 0 0.0010496685
, O 0 0.00069322484
tenth O 0 0.0012001902
patient O 0 0.001100091
: O 0 0.0018828365
ALT O 0 0.9992211
: O 0 0.001522462
294 O 0 0.023881454
IU O 0 0.42234033
/ O 0 0.0016897009
l O 0 0.0015525942
, O 0 0.0013592312
AST O 0 0.99876535
: O 0 0.0014990381
274 O 0 0.05042021
IU O 0 0.42942718
/ O 0 0.0015953372
l O 0 0.0012219866
, O 0 0.0007789658
with O 0 0.0005703255
minimal O 0 0.0006754945
changes O 0 0.0009818233
in O 0 0.0008977387
the O 0 0.0013633617
liver O 0 0.809064
biopsy O 0 0.032226983
in O 0 0.0032826709
both O 0 0.0049225036
) O 0 0.012471615
. O 0 0.008415723

Shortly O 0 0.027190486
after O 0 0.0040618503
treatment O 0 0.0039964346
their O 0 0.0026336873
tests O 0 0.002796639
normalized O 0 0.0012701892
and O 0 0.0013528629
during O 0 0.00085992663
follow O 0 0.00086037244
- O 0 0.001244503
up O 0 0.0006545063
period O 0 0.0005813487
none O 0 0.0007638489
of O 0 0.0009723632
the O 0 0.0011018631
patients O 0 0.0029876274
had O 0 0.0019130508
abnormal B-Disease 0 0.12024871
liver I-Disease 0 0.9160406
function I-Disease 0 0.011546236
tests O 0 0.015461362
. O 0 0.008992013

In O 0 0.010541106
four O 0 0.0073663415
patients O 0 0.013570501
HBV O 0 0.977418
DNA O 0 0.1164986
levels O 0 0.004352694
were O 0 0.0039150026
higher O 0 0.00333224
than O 0 0.0031752368
normal O 0 0.0062143384
at O 0 0.0049822247
baseline O 0 0.00856122
. O 0 0.01010636

Two O 0 0.015199187
of O 0 0.011077915
these O 0 0.009296749
normalized O 0 0.006754689
and O 0 0.007933407
the O 0 0.007745614
others O 0 0.013719332
increased O 0 0.011555458
later O 0 0.011778198
. O 0 0.014918679

In O 0 0.0085398555
three O 0 0.0050843675
additional O 0 0.0041517937
patients O 0 0.008055134
, O 0 0.0069900295
HBV O 0 0.9853763
DNA O 0 0.14383416
levels O 0 0.0031322099
were O 0 0.0030206207
increased O 0 0.0032662707
during O 0 0.0028466338
follow O 0 0.0039290763
- O 0 0.0077720047
up O 0 0.0071750237
. O 0 0.009556235

None O 0 0.018613098
of O 0 0.010047985
the O 0 0.007302166
patients O 0 0.008633592
had O 0 0.0052018072
significant O 0 0.005628896
clinical O 0 0.01870812
sings O 0 0.10457309
of O 0 0.01277559
HBV O 0 0.9950635
activation O 0 0.05494083
. O 0 0.015771033

Lamivudine B-Chemical 1 0.99467766
was O 0 0.010628862
well O 0 0.0072266576
tolerated O 0 0.0188569
and O 0 0.0065099015
was O 0 0.0053005377
continued O 0 0.005319824
in O 0 0.0055282554
all O 0 0.0070861885
patients O 0 0.017588027
. O 0 0.012991915

Prophylactic O 0 0.20830688
administration O 0 0.11391323
of O 0 0.0076416815
lamivudine B-Chemical 1 0.99960405
in O 0 0.0024195057
patients O 0 0.0039264513
who O 0 0.0020733965
required O 0 0.0006175737
immunosuppressive O 0 0.92300135
therapy O 0 0.03776186
seems O 0 0.0007916982
to O 0 0.00066138944
be O 0 0.0007765594
safe O 0 0.0017015233
, O 0 0.0010226181
well O 0 0.000790375
tolerated O 0 0.012519486
and O 0 0.0015897312
effective O 0 0.0021255438
in O 0 0.0025085886
preventing O 0 0.022569459
HBV O 0 0.9978035
reactivation O 0 0.72324365
. O 0 0.012200838

Effect O 0 0.013181264
of O 0 0.009923696
green B-Chemical 1 0.06099369
tea I-Chemical 1 0.99948114
and O 0 0.07866861
vitamin B-Chemical 1 0.9999466
E I-Chemical 1 0.99949753
combination O 0 0.04470138
in O 0 0.0053614373
isoproterenol B-Chemical 1 0.9999119
induced O 0 0.05680916
myocardial B-Disease 0 0.99994445
infarction I-Disease 2 0.99998105
in O 0 0.011297316
rats O 0 0.04906845
. O 0 0.011082138

The O 0 0.0068930513
present O 0 0.004022862
study O 0 0.0037987912
was O 0 0.0024123243
aimed O 0 0.0017492614
to O 0 0.0011414976
investigate O 0 0.000681186
the O 0 0.0008732986
combined O 0 0.0011792285
effects O 0 0.0016259707
of O 0 0.0015284336
green B-Chemical 1 0.07916898
tea I-Chemical 1 0.9999237
and O 0 0.037204742
vitamin B-Chemical 1 0.99998724
E I-Chemical 1 0.99950385
on O 0 0.00068312336
heart O 0 0.7418379
weight O 0 0.020725438
, O 0 0.0009812318
body O 0 0.0058810106
weight O 0 0.014729652
, O 0 0.0011265487
serum O 0 0.10026729
marker O 0 0.001689918
enzymes O 0 0.4163448
, O 0 0.0056022373
lipid O 0 0.98657334
peroxidation O 0 0.9999919
, O 0 0.0062868153
endogenous O 0 0.003583006
antioxidants O 0 0.99965453
and O 0 0.0015545379
membrane O 0 0.013343285
bound O 0 0.0006745662
ATPases O 0 0.67004377
in O 0 0.0011046901
isoproterenol B-Chemical 1 0.9999435
( O 0 0.011752241
ISO B-Chemical 1 0.98998624
) O 0 0.0057039405
- O 0 0.0030865828
induced O 0 0.0033458376
myocardial B-Disease 0 0.9999106
infarction I-Disease 2 0.9999784
in O 0 0.00760185
rats O 0 0.03430583
. O 0 0.009393845

Adult O 0 0.017475178
male O 0 0.015512493
albino O 0 0.026760412
rats O 0 0.008891339
, O 0 0.003713445
treated O 0 0.0025371846
with O 0 0.0024459474
ISO B-Chemical 1 0.9747942
( O 0 0.002184811
200 O 0 0.0019035998
mg O 0 0.17973454
/ O 0 0.0018205157
kg O 0 0.0037971241
, O 0 0.0008418815
s O 0 0.00070627127
. O 0 0.00042213284
c O 0 0.0033176483
. O 0 0.00039953997
) O 0 0.0006531426
for O 0 0.0002656851
2 O 0 0.0003086813
days O 0 0.00022310387
at O 0 0.00022536196
an O 0 0.00039576492
interval O 0 0.00038067444
of O 0 0.0003928952
24 O 0 0.00029471455
h O 0 0.00026059806
caused O 0 0.0003955005
a O 0 0.0006342896
significant O 0 0.00068587036
( O 0 0.0011456328
P O 0 0.067936175
< O 0 0.0005610952
0 O 0 0.00062668166
. O 0 0.000374552
05 O 0 0.046775617
) O 0 0.0006829619
elevation O 0 0.014780261
of O 0 0.00054607895
heart O 0 0.5171832
weight O 0 0.016187534
, O 0 0.001050632
serum O 0 0.088218644
marker O 0 0.0015313872
enzymes O 0 0.37294105
, O 0 0.0043843305
lipid O 0 0.9812429
peroxidation O 0 0.99999
and O 0 0.013661036
Ca B-Chemical 1 0.9999528
+ O 0 0.0015781365
2 O 0 0.0006043914
ATPase O 0 0.019319754
level O 0 0.0002567872
whereas O 0 0.00030321063
there O 0 0.00024451799
was O 0 0.00035423075
a O 0 0.0005200782
significant O 0 0.000601032
( O 0 0.0010166682
P O 0 0.052010518
< O 0 0.00056372077
0 O 0 0.0006358445
. O 0 0.0003876799
05 O 0 0.032388296
) O 0 0.0006213682
decrease O 0 0.00034952373
in O 0 0.00037491802
body O 0 0.002692075
weight O 0 0.010178887
, O 0 0.0012476565
endogenous O 0 0.0024003522
antioxidants O 0 0.9998398
, O 0 0.038791526
Na B-Chemical 1 0.99993384
+ O 0 0.0037071332
/ O 0 0.033321436
K B-Chemical 1 0.99854124
+ O 0 0.0030290703
ATPase O 0 0.24047086
and O 0 0.0042527327
Mg B-Chemical 0 0.99986005
+ O 0 0.004637662
2 O 0 0.0038353023
ATPase O 0 0.083204575
levels O 0 0.0057499106
. O 0 0.008078597

Administration O 0 0.10047878
of O 0 0.008798674
green B-Chemical 1 0.0454202
tea I-Chemical 1 0.99938965
( O 0 0.008294665
100 O 0 0.004481012
mg O 0 0.3414406
/ O 0 0.0031498221
kg O 0 0.005155777
/ O 0 0.0018161624
day O 0 0.0007082951
, O 0 0.0008891145
p O 0 0.00084970903
. O 0 0.00049184426
o O 0 0.0027625887
. O 0 0.00057008007
) O 0 0.0014956639
and O 0 0.0014896279
vitamin B-Chemical 1 0.99997413
E I-Chemical 1 0.99965715
( O 0 0.0033806874
100 O 0 0.0017535656
mg O 0 0.23066199
/ O 0 0.0013896893
kg O 0 0.0026286568
/ O 0 0.0009812949
day O 0 0.00038392242
, O 0 0.0005497322
p O 0 0.00054829835
. O 0 0.00032234858
o O 0 0.0017294926
. O 0 0.00034262415
) O 0 0.0005641989
together O 0 0.00027077485
for O 0 0.00022063854
30 O 0 0.00020716639
consecutive O 0 0.00025491408
days O 0 0.00022416317
and O 0 0.00034827404
challenged O 0 0.0003672923
with O 0 0.0005771182
ISO B-Chemical 1 0.8495903
on O 0 0.000265161
the O 0 0.00035309728
day O 0 0.00038629552
29th O 0 0.005698946
and O 0 0.00056466676
30th O 0 0.0034797152
, O 0 0.0005599187
showed O 0 0.00032936488
a O 0 0.0005788303
significant O 0 0.0006478726
( O 0 0.0010706716
P O 0 0.056237254
< O 0 0.00056980056
0 O 0 0.0006333503
. O 0 0.00037723887
05 O 0 0.03535024
) O 0 0.00059603614
decrease O 0 0.0003315971
in O 0 0.00035721945
heart O 0 0.32891107
weight O 0 0.011551603
, O 0 0.0010070892
serum O 0 0.0856581
marker O 0 0.001546645
enzymes O 0 0.38700697
, O 0 0.0050465777
lipid O 0 0.9864492
peroxidation O 0 0.99999297
, O 0 0.03453597
Ca B-Chemical 1 0.99993896
+ O 0 0.0014607781
2 O 0 0.0006136531
ATPase O 0 0.025733167
and O 0 0.0004446238
a O 0 0.00050881744
significant O 0 0.0004202574
increase O 0 0.0003029948
in O 0 0.0003392093
the O 0 0.0004117009
body O 0 0.005152972
weight O 0 0.016569858
, O 0 0.0012305949
endogenous O 0 0.0024426545
antioxidants O 0 0.99987173
, O 0 0.03724093
Na B-Chemical 1 0.9999548
+ O 0 0.0032130815
/ O 0 0.030703008
K B-Chemical 1 0.9990283
+ O 0 0.0018512037
ATPase O 0 0.22429168
and O 0 0.0018599682
Mg B-Chemical 0 0.9999573
+ O 0 0.0012957162
2 O 0 0.0006111358
ATPase O 0 0.014361881
when O 0 0.0002921071
compared O 0 0.0003031635
with O 0 0.0007069002
ISO B-Chemical 1 0.924855
treated O 0 0.000934755
group O 0 0.0011305549
and O 0 0.0014366831
green B-Chemical 1 0.037447155
tea I-Chemical 1 0.9997918
or O 0 0.026007913
vitamin B-Chemical 1 0.9999678
E I-Chemical 1 0.9994412
alone O 0 0.009896274
treated O 0 0.010960859
groups O 0 0.012494564
. O 0 0.009826176

These O 0 0.009437493
findings O 0 0.0075955354
indicate O 0 0.0036518257
the O 0 0.0030276116
synergistic O 0 0.0057085534
protective O 0 0.017633334
effect O 0 0.0021766068
of O 0 0.0029885706
green B-Chemical 1 0.12369509
tea I-Chemical 1 0.9998939
and O 0 0.077892646
vitamin B-Chemical 1 0.99998116
E I-Chemical 1 0.9996977
during O 0 0.0030265313
ISO B-Chemical 1 0.99354196
induced O 0 0.0128941545
myocardial B-Disease 0 0.9999343
infarction I-Disease 2 0.99998033
in O 0 0.009509783
rats O 0 0.0424927
. O 0 0.010313385

Irreversible O 0 0.8880006
damage O 0 0.43568045
to O 0 0.006186279
the O 0 0.004998299
medullary O 0 0.7076311
interstitium O 0 0.10549118
in O 0 0.0033883306
experimental O 0 0.0055948575
analgesic O 0 0.9990676
nephropathy B-Disease 2 0.9999573
in O 0 0.014129911
F344 O 0 0.905808
rats O 0 0.05165169
. O 0 0.012264781

Renal B-Disease 0 0.96919245
papillary I-Disease 0 0.9959193
necrosis I-Disease 2 0.9997502
( O 0 0.05739985
RPN B-Disease 2 0.99740237
) O 0 0.0050613936
and O 0 0.0017113561
a O 0 0.0015912895
decreased O 0 0.0016667489
urinary O 0 0.81767046
concentrating O 0 0.11440357
ability O 0 0.0008002151
developed O 0 0.0008878954
during O 0 0.00040949797
continuous O 0 0.0006352856
long O 0 0.0007768683
- O 0 0.0010928016
term O 0 0.0006075525
treatment O 0 0.0013697649
with O 0 0.0016722414
aspirin B-Chemical 1 0.99995816
and O 0 0.006530847
paracetamol B-Chemical 1 0.9999683
in O 0 0.002702907
female O 0 0.035737544
Fischer O 0 0.58408624
344 O 0 0.09255915
rats O 0 0.011182796
. O 0 0.008446816

Renal O 0 0.6131863
structure O 0 0.0075515313
and O 0 0.0045820083
concentrating O 0 0.027998345
ability O 0 0.0020672707
were O 0 0.001365427
examined O 0 0.0007816361
after O 0 0.0005674365
a O 0 0.00086486817
recovery O 0 0.0010343494
period O 0 0.00045343506
of O 0 0.00056414807
up O 0 0.00046729326
to O 0 0.00039483487
18 O 0 0.00040575906
weeks O 0 0.0002676198
, O 0 0.0004127426
when O 0 0.00024180894
no O 0 0.00031201792
analgesics O 0 0.98207885
were O 0 0.0005220942
given O 0 0.00036185936
, O 0 0.00062317954
to O 0 0.00038868998
investigate O 0 0.0003306107
whether O 0 0.0004423241
the O 0 0.0011952013
analgesic O 0 0.99645954
- O 0 0.0057102535
induced O 0 0.002657833
changes O 0 0.0045177164
were O 0 0.0052656736
reversible O 0 0.38473067
. O 0 0.009033801

There O 0 0.00829749
was O 0 0.0048425547
no O 0 0.0027997217
evidence O 0 0.0025679376
of O 0 0.0025128864
repair O 0 0.0025882598
to O 0 0.0012297677
the O 0 0.0011964338
damaged O 0 0.012317929
medullary O 0 0.8853434
interstitial O 0 0.8066255
matrix O 0 0.17232968
, O 0 0.0018669404
or O 0 0.0007700084
proliferation O 0 0.3044665
of O 0 0.0006948986
remaining O 0 0.0005896338
undamaged O 0 0.0032616311
type O 0 0.00076086784
1 O 0 0.000852122
medullary O 0 0.59385115
interstitial O 0 0.4462776
cells O 0 0.0019875073
after O 0 0.0005837106
the O 0 0.000937433
recovery O 0 0.0020306983
period O 0 0.0014121667
following O 0 0.0026673954
analgesic O 0 0.9927004
treatment O 0 0.0181289
. O 0 0.00965602

The O 0 0.007270937
recovery O 0 0.0071028555
of O 0 0.00466215
urinary O 0 0.75508326
concentrating O 0 0.16071746
ability O 0 0.0019005239
was O 0 0.0012368278
related O 0 0.000726502
to O 0 0.0006747552
the O 0 0.00064776454
length O 0 0.00056932884
of O 0 0.00091930357
analgesic O 0 0.98807144
treatment O 0 0.001860652
and O 0 0.0010002557
the O 0 0.0007632268
extent O 0 0.0006544421
of O 0 0.0012183719
the O 0 0.0013922851
resulting O 0 0.0025305622
inner O 0 0.098886125
medullary O 0 0.94204336
structural O 0 0.050947044
damage O 0 0.92303026
. O 0 0.011737651

During O 0 0.006404225
the O 0 0.0047920486
early O 0 0.0046622385
stages O 0 0.0034590813
of O 0 0.0029303727
analgesic O 0 0.9932266
treatment O 0 0.006531027
, O 0 0.0018414581
the O 0 0.0008200001
changes O 0 0.00094841525
in O 0 0.0006778858
urinary O 0 0.8653221
concentrating O 0 0.1634119
ability O 0 0.0007409079
were O 0 0.00071641186
reversible O 0 0.19796045
, O 0 0.00091074914
but O 0 0.00045140207
after O 0 0.00029758626
prolonged O 0 0.0029763195
analgesic O 0 0.98839766
treatment O 0 0.0022515752
, O 0 0.0014170144
maximum O 0 0.001136642
urinary O 0 0.8527598
concentrating O 0 0.1472544
ability O 0 0.002381674
failed O 0 0.003154843
to O 0 0.0037103517
recover O 0 0.007220424
. O 0 0.008225748

This O 0 0.009532674
study O 0 0.0050486396
shows O 0 0.002441435
that O 0 0.0019967097
prolonged O 0 0.0062627196
analgesic O 0 0.9919831
treatment O 0 0.004453831
in O 0 0.0014300585
Fischer O 0 0.5621818
344 O 0 0.056477293
rats O 0 0.0023071745
causes O 0 0.0023096676
progressive O 0 0.29115254
and O 0 0.0016887746
irreversible O 0 0.7196771
damage O 0 0.71894604
to O 0 0.00069777935
the O 0 0.0007366798
interstitial O 0 0.44856793
matrix O 0 0.04875736
and O 0 0.0016257787
type O 0 0.0015871284
1 O 0 0.0019271382
interstitial O 0 0.38907716
cells O 0 0.008082927
leading O 0 0.00974663
to O 0 0.00717519
RPN B-Disease 2 0.99631965
. O 0 0.0101175755

The O 0 0.008224367
associated O 0 0.0070129647
urinary O 0 0.7109427
concentrating O 0 0.21255286
defect O 0 0.0030472742
is O 0 0.002003196
reversible O 0 0.06681887
only O 0 0.0012396512
during O 0 0.00085783406
the O 0 0.0010198398
early O 0 0.0017524975
stages O 0 0.0017861751
of O 0 0.0019776085
structural O 0 0.007086507
damage O 0 0.6874212
to O 0 0.0031384605
the O 0 0.0044699754
inner O 0 0.17125063
medulla O 0 0.8943755
. O 0 0.010633768

Testosterone B-Chemical 1 0.99951875
- O 0 0.01862705
dependent O 0 0.007032686
hypertension B-Disease 2 0.9995846
and O 0 0.0059988564
upregulation O 0 0.0057628006
of O 0 0.0045749936
intrarenal O 0 0.9939926
angiotensinogen O 0 0.99875593
in O 0 0.007238614
Dahl O 0 0.989777
salt B-Chemical 1 0.9961125
- O 0 0.015780576
sensitive O 0 0.005663626
rats O 0 0.016168747
. O 0 0.01012092

Blood O 0 0.12220492
pressure O 0 0.10748525
( O 0 0.012324579
BP O 0 0.7517276
) O 0 0.0072354823
is O 0 0.0034832833
more O 0 0.0038662348
salt B-Chemical 1 0.9469045
sensitive O 0 0.0030492882
in O 0 0.0030104509
men O 0 0.14034316
than O 0 0.0030611588
in O 0 0.0053445385
premenopausal O 0 0.98785883
women O 0 0.3832776
. O 0 0.012526174

In O 0 0.0130798165
Dahl O 0 0.89551675
salt B-Chemical 1 0.9922678
- O 0 0.009922628
sensitive O 0 0.0030889898
rats O 0 0.008809301
( O 0 0.005171525
DS O 0 0.9714362
) O 0 0.004935549
, O 0 0.0019554065
high O 0 0.0019647765
- O 0 0.0053895568
salt B-Chemical 1 0.9931809
( O 0 0.007573584
HS O 0 0.9079921
) O 0 0.004603996
diet O 0 0.07526519
increases O 0 0.0017114426
BP O 0 0.79745215
more O 0 0.001981101
in O 0 0.002044774
males O 0 0.004764642
than O 0 0.003155681
females O 0 0.009648367
. O 0 0.008025884

In O 0 0.0070868325
contrast O 0 0.0048400457
to O 0 0.0033519522
the O 0 0.00310491
systemic O 0 0.9615024
renin O 0 0.9994518
- O 0 0.0796589
angiotensin B-Chemical 1 0.99993753
system O 0 0.01020362
, O 0 0.0016994292
which O 0 0.001015276
is O 0 0.0006731424
suppressed O 0 0.00066314335
in O 0 0.0005185662
response O 0 0.0008608908
to O 0 0.0006454369
HS O 0 0.7394134
in O 0 0.0006891648
male O 0 0.043156534
DS O 0 0.98276466
, O 0 0.0017970916
intrarenal O 0 0.9795786
angiotensinogen O 0 0.99672085
expression O 0 0.001569324
is O 0 0.0007807866
increased O 0 0.0010543921
, O 0 0.0012236999
and O 0 0.0011162971
intrarenal O 0 0.92063
levels O 0 0.0016697396
of O 0 0.0050073806
ANG O 0 0.99974364
II O 0 0.33590725
are O 0 0.003854144
not O 0 0.0042526075
suppressed O 0 0.00711188
. O 0 0.0091887135

In O 0 0.0072958097
this O 0 0.005022232
study O 0 0.0041206093
, O 0 0.00300538
the O 0 0.0016734336
hypothesis O 0 0.0015385675
was O 0 0.001047649
tested O 0 0.00064062857
that O 0 0.00056336995
there O 0 0.00046743985
is O 0 0.0006084565
a O 0 0.0009778243
sexual O 0 0.47380498
dimorphism O 0 0.068172395
in O 0 0.0009793838
HS O 0 0.94750834
- O 0 0.0034098916
induced O 0 0.00083247316
upregulation O 0 0.0017166988
of O 0 0.0012905777
intrarenal O 0 0.9946572
angiotensinogen O 0 0.99893457
mediated O 0 0.0014270056
by O 0 0.0024266033
testosterone B-Chemical 1 0.9998802
that O 0 0.0008023753
also O 0 0.001106666
causes O 0 0.0031250415
increases O 0 0.0015676462
in O 0 0.0022142956
BP O 0 0.9381569
and O 0 0.0062055136
renal B-Disease 2 0.9991585
injury I-Disease 2 0.9984302
. O 0 0.013071432

On O 0 0.011162799
a O 0 0.008698358
low O 0 0.008317576
- O 0 0.0114646675
salt B-Chemical 1 0.9906736
( O 0 0.010054547
LS O 0 0.43541354
) O 0 0.0053828675
diet O 0 0.1077346
, O 0 0.002466149
male O 0 0.01438068
DS O 0 0.8719112
had O 0 0.001190224
higher O 0 0.001115944
levels O 0 0.0013163371
of O 0 0.002621513
intrarenal O 0 0.99215734
angiotensinogen O 0 0.99780947
mRNA O 0 0.0065487446
than O 0 0.003865116
females O 0 0.011503431
. O 0 0.008489452

HS O 0 0.54953283
diet O 0 0.067071326
for O 0 0.0039237835
4 O 0 0.0026859727
wk O 0 0.0017688946
increased O 0 0.002243628
renal O 0 0.9814851
cortical O 0 0.36969423
angiotensinogen O 0 0.9971771
mRNA O 0 0.0022839655
and O 0 0.0011803078
protein O 0 0.0015187539
only O 0 0.0009360393
in O 0 0.0010775281
male O 0 0.02890415
DS O 0 0.96443784
, O 0 0.002753872
which O 0 0.0024975794
was O 0 0.002661539
prevented O 0 0.006477078
by O 0 0.0075770766
castration O 0 0.9396078
. O 0 0.010868705

Ovariectomy O 0 0.95153123
of O 0 0.010224059
female O 0 0.022629723
DS O 0 0.76665086
had O 0 0.0035290164
no O 0 0.002385833
effect O 0 0.002533947
on O 0 0.0023708493
intrarenal O 0 0.9762889
angiotensinogen O 0 0.9957196
expression O 0 0.005918182
on O 0 0.0036261375
either O 0 0.0068911156
diet O 0 0.2902641
. O 0 0.012022791

Radiotelemetric O 0 0.18700539
BP O 0 0.48128247
was O 0 0.0074368855
similar O 0 0.004543793
between O 0 0.003878654
males O 0 0.0075581535
and O 0 0.0061695683
castrated O 0 0.40929034
rats O 0 0.012641668
on O 0 0.0066649267
LS O 0 0.45452642
diet O 0 0.37943026
. O 0 0.016258858

HS O 0 0.5653117
diet O 0 0.072038054
for O 0 0.0037345614
4 O 0 0.0024901384
wk O 0 0.0015215063
caused O 0 0.0015631157
a O 0 0.001876106
progressive O 0 0.121635236
increase O 0 0.0010136844
in O 0 0.0011253684
BP O 0 0.94007605
, O 0 0.0012282787
protein O 0 0.0013229946
and O 0 0.0012667122
albumin O 0 0.9961904
excretion O 0 0.9788791
, O 0 0.001623423
and O 0 0.0011691104
glomerular B-Disease 2 0.99637055
sclerosis I-Disease 2 0.9995252
in O 0 0.0013780172
male O 0 0.06906414
DS O 0 0.9748482
rats O 0 0.00815864
, O 0 0.0022058715
which O 0 0.0021593918
were O 0 0.0025403097
attenuated O 0 0.0048357625
by O 0 0.006892829
castration O 0 0.93202883
. O 0 0.010412303

Testosterone B-Chemical 1 0.9993912
replacement O 0 0.025060434
in O 0 0.0061427974
castrated O 0 0.7899263
DS O 0 0.96898705
rats O 0 0.015646871
increased O 0 0.0042573274
BP O 0 0.96405524
, O 0 0.0043454366
renal B-Disease 2 0.99895006
injury I-Disease 2 0.9988397
, O 0 0.0035065396
and O 0 0.0016033044
upregulation O 0 0.0024420584
of O 0 0.0026483496
renal O 0 0.99744844
angiotensinogen O 0 0.9982493
associated O 0 0.006712368
with O 0 0.007995564
HS O 0 0.9657537
diet O 0 0.5843365
. O 0 0.011883782

Testosterone B-Chemical 1 0.9992799
contributes O 0 0.005601198
to O 0 0.0034287644
the O 0 0.0026093333
development O 0 0.0034339516
of O 0 0.003384118
hypertension B-Disease 2 0.99993086
and O 0 0.0061644833
renal B-Disease 2 0.9995871
injury I-Disease 2 0.9989058
in O 0 0.0013857055
male O 0 0.06048266
DS O 0 0.9676472
rats O 0 0.0033504297
on O 0 0.0006484025
HS O 0 0.81698346
diet O 0 0.15966459
possibly O 0 0.0037954324
through O 0 0.00093966495
upregulation O 0 0.0018380923
of O 0 0.001620063
the O 0 0.00222822
intrarenal O 0 0.99482924
renin O 0 0.9991886
- O 0 0.10647718
angiotensin B-Chemical 1 0.9997764
system O 0 0.027553635
. O 0 0.010056018

Explicit O 0 0.0358546
episodic O 0 0.81492126
memory O 0 0.15048814
for O 0 0.003530693
sensory O 0 0.16455516
- O 0 0.004024792
discriminative O 0 0.013618874
components O 0 0.001991865
of O 0 0.0039542783
capsaicin B-Chemical 1 0.99994206
- O 0 0.027767416
induced O 0 0.004595425
pain B-Disease 2 0.99931586
: O 0 0.0059187263
immediate O 0 0.0050811768
and O 0 0.004512611
delayed O 0 0.020991426
ratings O 0 0.030873662
. O 0 0.009395732

Pain B-Disease 2 0.9932817
memory O 0 0.21110918
is O 0 0.005463276
thought O 0 0.004143089
to O 0 0.002488881
affect O 0 0.0017083179
future O 0 0.0022455226
pain B-Disease 2 0.99623555
sensitivity O 0 0.004579073
and O 0 0.002274801
thus O 0 0.0025934672
contribute O 0 0.0020023345
to O 0 0.002655079
clinical O 0 0.09176288
pain B-Disease 2 0.9982192
conditions O 0 0.0140109435
. O 0 0.010643816

Systematic O 0 0.012682688
investigations O 0 0.0077587888
of O 0 0.0052576493
the O 0 0.0038261116
human O 0 0.003663312
capacity O 0 0.0034365957
to O 0 0.0023189434
remember O 0 0.0049178763
sensory O 0 0.0450634
features O 0 0.0041162563
of O 0 0.00371998
experimental O 0 0.0068907533
pain B-Disease 2 0.9982607
are O 0 0.008559731
sparse O 0 0.011841581
. O 0 0.010468839

In O 0 0.007159791
order O 0 0.004090969
to O 0 0.003146528
address O 0 0.0018750305
long O 0 0.0021919487
- O 0 0.0025354126
term O 0 0.0015956827
pain B-Disease 2 0.9984781
memory O 0 0.40634105
, O 0 0.0012699744
nine O 0 0.0006566625
healthy O 0 0.0025792082
male O 0 0.0019041237
volunteers O 0 0.0012178677
received O 0 0.00040638886
intradermal O 0 0.036046047
injections O 0 0.0020563838
of O 0 0.00050072593
three O 0 0.00031599225
doses O 0 0.011392322
of O 0 0.0014001542
capsaicin B-Chemical 1 0.9999572
( O 0 0.0036981972
0 O 0 0.0011077769
. O 0 0.00040927512
05 O 0 0.052519158
, O 0 0.00047699534
1 O 0 0.00034169972
and O 0 0.00032944404
20 O 0 0.00033853634
microg O 0 0.000713428
, O 0 0.0005309
separated O 0 0.0004441214
by O 0 0.00043517814
15 O 0 0.00033665722
min O 0 0.000472485
breaks O 0 0.009919288
) O 0 0.0008941647
, O 0 0.000449784
each O 0 0.00021948095
given O 0 0.00023009763
three O 0 0.00025775316
times O 0 0.0002969033
in O 0 0.00040924668
a O 0 0.0006802032
balanced O 0 0.0011266302
design O 0 0.0011356042
across O 0 0.0005399444
three O 0 0.00069179956
sessions O 0 0.0011031086
at O 0 0.0011867745
one O 0 0.0017705245
week O 0 0.002476884
intervals O 0 0.004153155
. O 0 0.0067967013

Pain B-Disease 2 0.98759055
rating O 0 0.017297743
was O 0 0.0042098593
performed O 0 0.0025205226
using O 0 0.0019314896
a O 0 0.0021274327
computerized O 0 0.004827575
visual O 0 0.07575235
analogue O 0 0.085659444
scale O 0 0.003361361
( O 0 0.0015813292
0 O 0 0.0012519973
- O 0 0.0011238364
100 O 0 0.0011432454
) O 0 0.0010028563
digitized O 0 0.002390407
at O 0 0.0003903256
1 O 0 0.00052952877
/ O 0 0.0009194231
s O 0 0.00061509217
, O 0 0.0006107783
either O 0 0.00046194965
immediately O 0 0.00051231595
online O 0 0.00056989846
or O 0 0.0005255743
one O 0 0.00057186483
hour O 0 0.00062070176
or O 0 0.0009866069
one O 0 0.0012436215
day O 0 0.0017358178
after O 0 0.0021566607
injection O 0 0.009271579
. O 0 0.007615012

Subjects O 0 0.025203701
also O 0 0.016397288
recalled O 0 0.024576355
their O 0 0.015879767
pains B-Disease 0 0.98785883
one O 0 0.013208574
week O 0 0.011723124
later O 0 0.013741733
. O 0 0.017564619

Capsaicin B-Chemical 1 0.9993344
injection O 0 0.017113214
reliably O 0 0.0050041405
induced O 0 0.0030325342
a O 0 0.0030170071
dose O 0 0.041499395
- O 0 0.0031039447
dependent O 0 0.0011899513
flare O 0 0.9737767
( O 0 0.0022849229
p O 0 0.001315938
< O 0 0.00090099376
0 O 0 0.00097087986
. O 0 0.00064441236
001 O 0 0.07022652
) O 0 0.0010552589
without O 0 0.00066783297
any O 0 0.0007947316
difference O 0 0.000791882
within O 0 0.0010176688
or O 0 0.0019837797
across O 0 0.0024678807
sessions O 0 0.005132426
. O 0 0.006968641

The O 0 0.014005477
strong O 0 0.014838701
burning O 0 0.9201178
pain B-Disease 2 0.9977672
decayed O 0 0.057852235
exponentially O 0 0.011079346
within O 0 0.0051119006
a O 0 0.007959253
few O 0 0.0066771177
minutes O 0 0.009374447
. O 0 0.013064941

Subjects O 0 0.010890657
were O 0 0.0051805284
able O 0 0.002834669
to O 0 0.0023196784
reliably O 0 0.002206214
discriminate O 0 0.0017953677
pain B-Disease 2 0.99268895
magnitude O 0 0.0010471238
and O 0 0.00097402895
duration O 0 0.0010010407
across O 0 0.00059173483
capsaicin B-Chemical 1 0.99988914
doses O 0 0.17868522
( O 0 0.0013019039
both O 0 0.0004960724
p O 0 0.0007242992
< O 0 0.00053127843
0 O 0 0.00060932356
. O 0 0.0003745106
001 O 0 0.12771565
) O 0 0.0006951781
, O 0 0.00040325566
regardless O 0 0.00020102908
of O 0 0.00035565603
whether O 0 0.00022562665
first O 0 0.0003895792
- O 0 0.00079396134
time O 0 0.00034140568
ratings O 0 0.0012692519
were O 0 0.0004863087
requested O 0 0.0006883646
immediately O 0 0.00056332385
, O 0 0.00074306247
after O 0 0.00043866885
one O 0 0.0006697831
hour O 0 0.0007897264
or O 0 0.0013271467
after O 0 0.0014636136
one O 0 0.0027566561
day O 0 0.00438422
. O 0 0.0070212972

Pain B-Disease 2 0.9782849
recall O 0 0.009233597
after O 0 0.0026593227
one O 0 0.0020837074
week O 0 0.0014670505
was O 0 0.0013034783
similarly O 0 0.0012050311
precise O 0 0.0011956465
( O 0 0.0013676402
magnitude O 0 0.00078100874
: O 0 0.0012403711
p O 0 0.0010239098
< O 0 0.00081773254
0 O 0 0.00090285117
. O 0 0.0006004843
01 O 0 0.0025944896
, O 0 0.0008933366
duration O 0 0.0009977658
: O 0 0.0016544515
p O 0 0.0017669188
< O 0 0.0019587458
0 O 0 0.0027802002
. O 0 0.0028345664
05 O 0 0.054175645
) O 0 0.007901365
. O 0 0.0076977373

Correlation O 0 0.008944927
with O 0 0.0054103164
rating O 0 0.007454273
recall O 0 0.003941442
after O 0 0.0012010558
one O 0 0.0010234377
week O 0 0.00074768445
was O 0 0.00067207275
best O 0 0.00060095894
when O 0 0.00043943324
first O 0 0.0005121783
- O 0 0.0008883345
time O 0 0.0003755839
ratings O 0 0.0012566401
were O 0 0.00042554556
requested O 0 0.00054618117
as O 0 0.00040667815
late O 0 0.00094159675
as O 0 0.0003849317
one O 0 0.00029758087
day O 0 0.00030062548
after O 0 0.00025102904
injection O 0 0.002075246
( O 0 0.0018978014
R O 0 0.9408857
( O 0 0.0012080543
2 O 0 0.00062002416
) O 0 0.0009089031
= O 0 0.0006619556
0 O 0 0.0005565125
. O 0 0.00034811706
79 O 0 0.0008003494
) O 0 0.0007326098
indicating O 0 0.0004386312
that O 0 0.0005281223
both O 0 0.0008254864
rating O 0 0.0029314514
retrievals O 0 0.0014418268
utilized O 0 0.0016045138
similar O 0 0.002198927
memory O 0 0.12486584
traces O 0 0.018268388
. O 0 0.008624053

These O 0 0.010158633
results O 0 0.006487609
indicate O 0 0.0042000175
a O 0 0.0044289436
reliable O 0 0.0037074005
memory O 0 0.027318846
for O 0 0.001954796
magnitude O 0 0.001928305
and O 0 0.0024864776
duration O 0 0.0029539957
of O 0 0.0038940734
experimentally O 0 0.005859939
induced O 0 0.013723061
pain B-Disease 2 0.9990146
. O 0 0.014539725

The O 0 0.0070924344
data O 0 0.005642147
further O 0 0.0032662926
suggest O 0 0.0018863139
that O 0 0.001568589
the O 0 0.0015425355
consolidation O 0 0.019723367
of O 0 0.0015259585
this O 0 0.0012304813
memory O 0 0.12888452
is O 0 0.00095438055
an O 0 0.0010958853
important O 0 0.0007345833
interim O 0 0.0065818573
stage O 0 0.002472223
, O 0 0.0016192226
and O 0 0.0013116928
may O 0 0.0011971164
take O 0 0.0011845485
up O 0 0.0016855724
to O 0 0.0021862607
one O 0 0.0031446635
day O 0 0.004785803
. O 0 0.0074597327

Severe O 0 0.7306258
and O 0 0.007427543
long O 0 0.004773509
lasting O 0 0.008586923
cholestasis B-Disease 2 0.9999201
after O 0 0.0018062494
high O 0 0.0027720158
- O 0 0.003096588
dose O 0 0.03627434
co B-Chemical 0 0.9461711
- I-Chemical 0 0.007230549
trimoxazole I-Chemical 0 0.47099635
treatment O 0 0.0016415563
for O 0 0.0007980639
Pneumocystis B-Disease 0 0.9990767
pneumonia I-Disease 0 0.9999629
in O 0 0.0028280586
HIV B-Disease 2 0.99273175
- I-Disease 2 0.0032878623
infected I-Disease 2 0.0014386004
patients O 0 0.009395568
- O 0 0.0031382232
- O 0 0.0020454463
a O 0 0.0018173973
report O 0 0.003515099
of O 0 0.003058321
two O 0 0.003818132
cases O 0 0.010858067
. O 0 0.008892743

Pneumocystis B-Disease 0 0.99227387
pneumonia I-Disease 0 0.9997048
( O 0 0.05461647
PCP B-Disease 0 0.9988115
) O 0 0.009029431
, O 0 0.0025028237
a O 0 0.0017841501
common O 0 0.0018414318
opportunistic B-Disease 0 0.4691461
infection I-Disease 2 0.59602964
in O 0 0.0019944669
HIV B-Disease 2 0.98975825
- I-Disease 2 0.0028962714
infected I-Disease 2 0.0011128336
individuals O 0 0.0019396234
, O 0 0.0010987375
is O 0 0.0006687301
generally O 0 0.00089899317
treated O 0 0.0010957526
with O 0 0.0011977302
high O 0 0.0019027356
doses O 0 0.056141514
of O 0 0.005659055
co B-Chemical 0 0.96907413
- I-Chemical 0 0.045942478
trimoxazole I-Chemical 0 0.8172782
. O 0 0.010407332

However O 0 0.016400933
, O 0 0.013736661
treatment O 0 0.010747282
is O 0 0.008135421
often O 0 0.009045172
limited O 0 0.0073463065
by O 0 0.010313662
adverse O 0 0.95729387
effects O 0 0.046814475
. O 0 0.017196089

Here O 0 0.010570687
, O 0 0.006654353
we O 0 0.0029646775
report O 0 0.0036967988
two O 0 0.0017922975
cases O 0 0.0024521446
of O 0 0.0021962905
severely O 0 0.081082165
immunocompromised O 0 0.9941507
HIV B-Disease 2 0.9958851
- I-Disease 2 0.003433403
infected I-Disease 2 0.0009613549
patients O 0 0.001871303
who O 0 0.001429488
developed O 0 0.0013286833
severe O 0 0.50442517
intrahepatic B-Disease 0 0.99966407
cholestasis I-Disease 2 0.9999988
, O 0 0.007961664
and O 0 0.00078880956
in O 0 0.00043908422
one O 0 0.0003859359
patient O 0 0.0008466202
lesions O 0 0.21345058
mimicking O 0 0.014634347
liver B-Disease 0 0.96748304
abscess I-Disease 0 0.9879062
formation O 0 0.0040180297
on O 0 0.0006417138
radiologic O 0 0.14067212
exams O 0 0.01704077
, O 0 0.0016138301
during O 0 0.0010591212
co B-Chemical 0 0.81825286
- I-Chemical 0 0.007410755
trimoxazole I-Chemical 0 0.56903034
treatment O 0 0.006757725
for O 0 0.005422333
PCP B-Disease 0 0.9978655
. O 0 0.010581586

Whereas O 0 0.008302404
patient O 0 0.006908017
1 O 0 0.003748744
showed O 0 0.002341548
lesions O 0 0.042806573
of O 0 0.0020084288
up O 0 0.0012847595
to O 0 0.000966699
1 O 0 0.00091512967
cm O 0 0.0013842928
readily O 0 0.0006731228
detectable O 0 0.0004154581
on O 0 0.0004415371
magnetic O 0 0.045292523
resonance O 0 0.14433217
imaging O 0 0.0022803457
under O 0 0.00047835356
prolonged O 0 0.0076261414
co B-Chemical 0 0.9256146
- I-Chemical 0 0.006787109
trimoxazole I-Chemical 0 0.51631624
treatment O 0 0.0021528793
, O 0 0.0014778381
therapy O 0 0.0032988924
of O 0 0.001468356
patient O 0 0.0025877452
2 O 0 0.002159363
was O 0 0.0025112436
switched O 0 0.005373131
early O 0 0.008523992
. O 0 0.008389553

Bradykinin B-Chemical 0 0.9995454
receptors O 0 0.85136116
antagonists O 0 0.9942411
and O 0 0.027451308
nitric B-Chemical 0 0.9998479
oxide I-Chemical 0 0.9996648
synthase O 0 0.98090875
inhibitors O 0 0.386502
in O 0 0.0029091889
vincristine B-Chemical 1 0.99995935
and O 0 0.014334369
streptozotocin B-Chemical 1 0.9999888
induced O 0 0.028016862
hyperalgesia B-Disease 2 0.99997103
in O 0 0.003232595
chemotherapy O 0 0.95780385
and O 0 0.018282773
diabetic B-Disease 2 0.9998611
neuropathy I-Disease 0 0.99997485
rat O 0 0.24196848
model O 0 0.012268651
. O 0 0.010103574

PURPOSE O 0 0.025934959
: O 0 0.0073696156
The O 0 0.0033109856
influence O 0 0.0022765473
of O 0 0.0025297173
an O 0 0.0032850462
irreversible O 0 0.6098895
inhibitor O 0 0.15899175
of O 0 0.002995522
constitutive O 0 0.02476283
NO B-Chemical 0 0.9998271
synthase O 0 0.9781349
( O 0 0.012045962
L O 0 0.89943314
- O 0 0.006538751
NOArg O 0 0.74219126
; O 0 0.0013186076
1 O 0 0.0005193
. O 0 0.00031317605
0 O 0 0.00048731797
mg O 0 0.048605915
/ O 0 0.0011286278
kg O 0 0.0051493044
ip O 0 0.72879654
) O 0 0.0014890706
, O 0 0.0006070536
a O 0 0.0005257757
relatively O 0 0.00054210617
selective O 0 0.003288328
inhibitor O 0 0.036616467
of O 0 0.0013338717
inducible O 0 0.13417982
NO B-Chemical 0 0.99983406
synthase O 0 0.9667985
( O 0 0.008147519
L O 0 0.8789504
- O 0 0.00506031
NIL O 0 0.60509366
; O 0 0.0014443122
1 O 0 0.00051651226
. O 0 0.00030403127
0 O 0 0.00047986407
mg O 0 0.051262308
/ O 0 0.0011061928
kg O 0 0.004669892
ip O 0 0.6596256
) O 0 0.0010487279
and O 0 0.00046572837
a O 0 0.0005374741
relatively O 0 0.00048482622
specific O 0 0.0004172207
inhibitor O 0 0.038521998
of O 0 0.0018986461
neuronal O 0 0.9138991
NO B-Chemical 0 0.99984825
synthase O 0 0.94635326
( O 0 0.0021149758
7 O 0 0.00068327365
- O 0 0.0011624193
NI O 0 0.46488094
; O 0 0.0009229229
0 O 0 0.0005596155
. O 0 0.00028190773
1 O 0 0.0003868767
mg O 0 0.0507672
/ O 0 0.0011062645
kg O 0 0.005502772
ip O 0 0.7467675
) O 0 0.00153399
, O 0 0.00061418215
on O 0 0.00031572665
antihyperalgesic O 0 0.9984622
action O 0 0.006576662
of O 0 0.0008404083
selective O 0 0.022405243
antagonists O 0 0.97468024
of O 0 0.0031628145
B2 O 0 0.98959535
and O 0 0.0031990008
B1 O 0 0.9967963
receptors O 0 0.5301803
: O 0 0.012740749
D O 0 0.9799733
- O 0 0.02148217
Arg O 0 0.9962316
- O 0 0.010260474
[ O 0 0.013478931
Hyp3 O 0 0.9843211
, O 0 0.002627296
Thi5 O 0 0.95094573
, O 0 0.002049219
D O 0 0.9213284
- O 0 0.0032319976
Tic7 O 0 0.05519262
, O 0 0.0020526466
Oic8 O 0 0.9990381
] O 0 0.017415186
bradykinin B-Chemical 1 0.99996185
( O 0 0.014160372
HOE B-Chemical 0 0.99995065
140 I-Chemical 0 0.01983235
; O 0 0.0009866472
70 O 0 0.0005407628
nmol O 0 0.24107683
/ O 0 0.0013100116
kg O 0 0.004424371
ip O 0 0.616474
) O 0 0.0011211867
or O 0 0.0005521096
des B-Chemical 0 0.0159495
Arg10 I-Chemical 0 0.9956339
HOE I-Chemical 0 0.9999647
140 I-Chemical 0 0.022727435
( O 0 0.00084051996
70 O 0 0.00055559777
nmol O 0 0.29243782
/ O 0 0.0014147285
kg O 0 0.0059809303
ip O 0 0.73406225
) O 0 0.0015745019
respectively O 0 0.0011053407
, O 0 0.0005958016
in O 0 0.00035406635
model O 0 0.0005585755
of O 0 0.001161051
diabetic B-Disease 2 0.998976
( I-Disease 0 0.022238193
streptozotocin I-Disease 1 0.99999154
- I-Disease 0 0.011366606
induced I-Disease 0 0.0014549042
) I-Disease 0 0.0035655096
and I-Disease 0 0.0014248114
toxic I-Disease 0 0.95270246
( I-Disease 0 0.023891507
vincristine I-Disease 1 0.99996126
- I-Disease 0 0.013758449
induced I-Disease 0 0.003864107
) I-Disease 0 0.047845293
neuropathy I-Disease 2 0.9998599
was O 0 0.005263054
investigated O 0 0.005753696
. O 0 0.009040757

METHODS O 0 0.010456408
: O 0 0.0071359854
The O 0 0.003487127
changes O 0 0.0032495882
in O 0 0.0024474487
pain B-Disease 2 0.98880744
thresholds O 0 0.003168671
were O 0 0.0010965489
determined O 0 0.0006787578
using O 0 0.0007219486
mechanical O 0 0.03290061
stimuli O 0 0.047876783
- O 0 0.00481909
- O 0 0.0012060937
the O 0 0.000531167
modification O 0 0.00095803477
of O 0 0.00078685686
the O 0 0.00085516775
classic O 0 0.14059065
paw O 0 0.9971445
withdrawal O 0 0.91497284
test O 0 0.002604452
described O 0 0.0019687256
by O 0 0.0041035814
Randall O 0 0.2829474
- O 0 0.013826329
Selitto O 0 0.97909534
. O 0 0.009330983

RESULTS O 0 0.023574091
: O 0 0.007406099
The O 0 0.0033592593
results O 0 0.0026634852
of O 0 0.002304099
this O 0 0.0016466805
paper O 0 0.0016762095
confirm O 0 0.0007116948
that O 0 0.00081336766
inhibition O 0 0.0032789938
of O 0 0.0031488035
bradykinin B-Chemical 1 0.9999751
receptors O 0 0.6797909
and O 0 0.002756255
inducible O 0 0.14233068
NO B-Chemical 0 0.9997292
synthase O 0 0.9040284
but O 0 0.0014119899
not O 0 0.0013741034
neuronal O 0 0.76876694
NO B-Chemical 0 0.999579
synthase O 0 0.9323314
activity O 0 0.006591726
reduces O 0 0.008882447
diabetic B-Disease 2 0.9997991
hyperalgesia I-Disease 0 0.999946
. O 0 0.020338194

Pretreatment O 0 0.69875216
with O 0 0.011788304
L O 0 0.8279971
- O 0 0.014377564
NOArg O 0 0.65757155
and O 0 0.004523746
L O 0 0.8262492
- O 0 0.0066242316
NIL O 0 0.38181227
but O 0 0.0012596835
not O 0 0.0009812103
7 O 0 0.0010752428
- O 0 0.0018036882
NI O 0 0.4621298
, O 0 0.0011790663
significantly O 0 0.0011045301
increases O 0 0.0011863348
antihyperalgesic O 0 0.99939275
activity O 0 0.0024821644
both O 0 0.002416799
HOE B-Chemical 0 0.9998988
140 I-Chemical 0 0.02409639
and O 0 0.0035134878
des B-Chemical 0 0.07242458
Arg10 I-Chemical 0 0.99647385
HOE I-Chemical 0 0.9998116
140 I-Chemical 0 0.098420076
. O 0 0.010104042

It O 0 0.010001448
was O 0 0.0052714082
also O 0 0.0035760966
shown O 0 0.0021303105
that O 0 0.001572245
both O 0 0.0014968029
products O 0 0.004580647
of O 0 0.0021814043
inducible O 0 0.13835648
NO B-Chemical 0 0.99978477
synthase O 0 0.95658845
and O 0 0.0038682334
neuronal O 0 0.89606947
NO B-Chemical 0 0.99976355
synthase O 0 0.8970231
activation O 0 0.0027042327
as O 0 0.00081885536
well O 0 0.0008097567
as O 0 0.001466913
bradykinin B-Chemical 1 0.9998945
are O 0 0.0019425285
involved O 0 0.0015181842
in O 0 0.0025409055
hyperalgesia B-Disease 2 0.9998431
produced O 0 0.005423058
by O 0 0.013822319
vincristine B-Chemical 1 0.9998023
. O 0 0.011928975

Moreover O 0 0.013419767
, O 0 0.011992721
L O 0 0.61868733
- O 0 0.010168434
NOArg O 0 0.423975
and O 0 0.0030136367
7 O 0 0.0021876467
- O 0 0.0027616273
NI O 0 0.28395092
but O 0 0.0011878014
not O 0 0.0012206993
L O 0 0.7446219
- O 0 0.004955353
NIL O 0 0.5485618
intensify O 0 0.005281705
antihyperalgesic O 0 0.9995117
activity O 0 0.0019339406
of O 0 0.0026679905
HOE B-Chemical 0 0.99993634
140 I-Chemical 0 0.01480603
or O 0 0.0013619503
des B-Chemical 0 0.010289806
- I-Chemical 0 0.0044556437
Arg10HOE I-Chemical 0 0.038085576
140 I-Chemical 0 0.005358681
in O 0 0.003911298
toxic B-Disease 0 0.99607193
neuropathy I-Disease 2 0.99993575
. O 0 0.016393602

CONCLUSIONS O 0 0.40666035
: O 0 0.008964223
Results O 0 0.0059875934
of O 0 0.003426154
these O 0 0.002643818
studies O 0 0.0019854917
suggest O 0 0.0011756512
that O 0 0.0014795004
B1 O 0 0.98359275
and O 0 0.004029907
B2 O 0 0.98462206
receptors O 0 0.26211333
are O 0 0.0012830114
engaged O 0 0.0012169593
in O 0 0.00071101746
transmission O 0 0.0017740459
of O 0 0.0013557236
nociceptive O 0 0.92288417
stimuli O 0 0.016065437
in O 0 0.0016914392
both O 0 0.0025656086
diabetic B-Disease 2 0.99694127
and I-Disease 0 0.017133817
toxic I-Disease 0 0.9989256
neuropathy I-Disease 2 0.99995756
. O 0 0.0190098

In O 0 0.01255434
streptozotocin B-Chemical 1 0.9998055
- O 0 0.04470029
induced O 0 0.01247923
hyperalgesia B-Disease 2 0.99994016
, O 0 0.021407252
inducible O 0 0.21105483
NO B-Chemical 0 0.9997607
synthase O 0 0.94833434
participates O 0 0.0018184052
in O 0 0.0010189413
pronociceptive O 0 0.98319006
activity O 0 0.0014137593
of O 0 0.0021502525
bradykinin B-Chemical 1 0.99996996
, O 0 0.0028185651
whereas O 0 0.0007718943
in O 0 0.0011066282
vincristine B-Chemical 1 0.99997294
- O 0 0.016558666
induced O 0 0.0069573983
hyperalgesia B-Disease 2 0.9999864
bradykinin B-Chemical 1 0.999977
seemed O 0 0.004298596
to O 0 0.0018992445
activate O 0 0.0022823696
neuronal O 0 0.8718989
NO B-Chemical 0 0.99942565
synthase O 0 0.9568902
pathway O 0 0.018360691
. O 0 0.010172836

Therefore O 0 0.006849727
, O 0 0.005657807
concomitant O 0 0.0052549117
administration O 0 0.026266463
of O 0 0.0022525834
small O 0 0.0020602334
doses O 0 0.06721627
of O 0 0.0077617774
bradykinin B-Chemical 1 0.9999839
receptor O 0 0.9159373
antagonists O 0 0.9978987
and O 0 0.013191985
NO B-Chemical 0 0.9998505
synthase O 0 0.94222116
inhibitors O 0 0.13376704
can O 0 0.00063705037
be O 0 0.00066236116
effective O 0 0.0007272786
in O 0 0.0007152065
alleviation O 0 0.524367
of O 0 0.0077031082
neuropathic B-Disease 2 0.9999938
pain I-Disease 2 0.9999348
, O 0 0.0071704932
even O 0 0.0026713843
in O 0 0.003031126
hospital O 0 0.012522713
care O 0 0.008495097
. O 0 0.008274075

Confusion B-Disease 0 0.7802943
, O 0 0.008895083
a O 0 0.0054623433
rather O 0 0.003562839
serious O 0 0.20959263
adverse O 0 0.9927296
drug O 0 0.91931695
reaction O 0 0.4582275
with O 0 0.013755025
valproic B-Chemical 0 0.9999895
acid I-Chemical 0 0.99203366
: O 0 0.00524894
a O 0 0.0023239553
review O 0 0.002789157
of O 0 0.0023653228
the O 0 0.002976791
French O 0 0.015248249
Pharmacovigilance O 0 0.22929676
database O 0 0.007076164
. O 0 0.008002756

INTRODUCTION O 0 0.06541594
: O 0 0.015076324
Confusion B-Disease 0 0.5232786
is O 0 0.006007974
an O 0 0.0062694186
adverse O 0 0.9578184
drug O 0 0.78769314
reaction O 0 0.18008396
frequently O 0 0.0076011447
observed O 0 0.004274302
with O 0 0.017905409
valproic B-Chemical 0 0.9999523
acid I-Chemical 0 0.9945734
. O 0 0.018891698

Some O 0 0.011270195
case O 0 0.0061899736
reports O 0 0.005055093
are O 0 0.0032219759
published O 0 0.0020885943
in O 0 0.001543201
the O 0 0.0013579994
literature O 0 0.001758524
but O 0 0.0009911328
no O 0 0.000733797
systematic O 0 0.0011045586
study O 0 0.001132684
from O 0 0.0010063061
a O 0 0.0014029333
sample O 0 0.0015327507
of O 0 0.0020135995
patients O 0 0.005743844
has O 0 0.0029654033
been O 0 0.004875485
published O 0 0.006148943
. O 0 0.008436352

We O 0 0.008285939
performed O 0 0.0050562285
this O 0 0.0038396572
study O 0 0.0032157064
in O 0 0.002079293
order O 0 0.0014378333
to O 0 0.0013372641
describe O 0 0.0012671411
the O 0 0.0013245643
main O 0 0.0016427884
characteristics O 0 0.0018071324
of O 0 0.0024878453
this O 0 0.0032708533
adverse O 0 0.99278486
drug O 0 0.92731565
reaction O 0 0.40104076
. O 0 0.011860182

METHODS O 0 0.0123464465
: O 0 0.008632948
Using O 0 0.004940671
the O 0 0.0036351215
French O 0 0.0057364334
Pharmacovigilance O 0 0.03634791
database O 0 0.0020536291
, O 0 0.0015157582
we O 0 0.00078199216
selected O 0 0.0008536038
the O 0 0.0009731065
cases O 0 0.0018067111
of O 0 0.002083977
confusion B-Disease 2 0.92092425
reported O 0 0.0032163651
since O 0 0.0022469556
1985 O 0 0.054257102
with O 0 0.008939408
valproic B-Chemical 0 0.99995434
acid I-Chemical 0 0.9913305
. O 0 0.014648615

RESULTS O 0 0.030306028
: O 0 0.011120749
272 O 0 0.015180513
cases O 0 0.0059463033
of O 0 0.004708039
confusion B-Disease 2 0.8160558
were O 0 0.003410838
reported O 0 0.0035884497
with O 0 0.0053578834
valproic B-Chemical 0 0.99997735
acid I-Chemical 0 0.9916682
: O 0 0.013378222
153 O 0 0.090921625
women O 0 0.044815782
and O 0 0.005571439
119 O 0 0.025717378
men O 0 0.18472539
. O 0 0.009978355

Confusion B-Disease 0 0.56168836
mostly O 0 0.008363831
occurred O 0 0.0044388324
during O 0 0.002387501
the O 0 0.0019496119
two O 0 0.0014117801
first O 0 0.0012153144
weeks O 0 0.0011189299
following O 0 0.0020113105
valproic B-Chemical 0 0.99997795
acid I-Chemical 0 0.9845009
exposure O 0 0.03329785
( O 0 0.004428952
39 O 0 0.003615182
. O 0 0.0018626915
7 O 0 0.0028148552
% O 0 0.004852515
) O 0 0.008460951
. O 0 0.007954338

It O 0 0.010916524
was O 0 0.006339486
" O 0 0.005582455
serious O 0 0.06451272
" O 0 0.0032785716
for O 0 0.0014139357
almost O 0 0.0012237057
2 O 0 0.0011004533
/ O 0 0.001539196
3 O 0 0.0005865113
of O 0 0.0005825019
the O 0 0.0005761959
patients O 0 0.001920299
( O 0 0.0009803262
62 O 0 0.0011609792
. O 0 0.00037051656
5 O 0 0.00039735987
% O 0 0.00057410944
) O 0 0.0007201559
and O 0 0.00049975293
its O 0 0.00073580525
outcome O 0 0.001293982
favourable O 0 0.0021712482
in O 0 0.0006601639
most O 0 0.0010228793
of O 0 0.0011656703
the O 0 0.0013791253
cases O 0 0.0036480245
( O 0 0.0038503748
82 O 0 0.0055574384
% O 0 0.0049910285
) O 0 0.008267031
. O 0 0.0074869664

The O 0 0.0079489
occurrence O 0 0.0076638795
of O 0 0.0052504614
this O 0 0.0044352473
ADR O 1 0.9996599
was O 0 0.0027856908
more O 0 0.0022111675
frequent O 0 0.0033985418
in O 0 0.001643357
patients O 0 0.0033798744
aged O 0 0.003045752
between O 0 0.0016895351
61 O 0 0.004568687
and O 0 0.003722198
80 O 0 0.005465339
years O 0 0.008033594
. O 0 0.008314093

CONCLUSION O 0 0.724488
: O 0 0.009909632
This O 0 0.0056763985
work O 0 0.003471177
shows O 0 0.0018118056
that O 0 0.0018408683
confusion B-Disease 2 0.9163127
with O 0 0.0060956175
valproic B-Chemical 0 0.9999895
acid I-Chemical 0 0.9901102
is O 0 0.0018033448
a O 0 0.0019110761
serious O 0 0.26069736
, O 0 0.0017236391
rather O 0 0.0010653806
frequent O 0 0.004083151
but O 0 0.0020588338
reversible O 0 0.462148
adverse O 0 0.9956096
drug O 0 0.929669
reaction O 0 0.3774693
. O 0 0.010659593

It O 0 0.011610815
occurs O 0 0.005970751
especially O 0 0.004984573
in O 0 0.0035820452
older O 0 0.0060185622
patients O 0 0.0042482684
and O 0 0.0023351237
during O 0 0.001521751
the O 0 0.0017190113
first O 0 0.0016668042
two O 0 0.0021047408
weeks O 0 0.0025002274
of O 0 0.0049363407
treatment O 0 0.01123881
. O 0 0.010322198

Reversible O 0 0.78059137
inferior B-Disease 0 0.20531432
colliculus I-Disease 0 0.2291114
lesion I-Disease 0 0.25280482
in O 0 0.003829341
metronidazole B-Chemical 1 0.99959904
- O 0 0.0102690235
induced O 0 0.0036973539
encephalopathy B-Disease 2 0.9999628
: O 0 0.0063934918
magnetic O 0 0.20311196
resonance O 0 0.18864463
findings O 0 0.0017947373
on O 0 0.0007845067
diffusion O 0 0.021183427
- O 0 0.0021935813
weighted O 0 0.001760613
and O 0 0.0017313276
fluid O 0 0.026380252
attenuated O 0 0.005263008
inversion O 0 0.059213642
recovery O 0 0.011296757
imaging O 0 0.03899804
. O 0 0.009084178

OBJECTIVE O 0 0.6008312
: O 0 0.009743518
This O 0 0.005437725
is O 0 0.002792533
to O 0 0.0018776319
present O 0 0.0013792975
reversible O 0 0.19724604
inferior B-Disease 0 0.21898931
colliculus I-Disease 0 0.27859783
lesions I-Disease 0 0.6833416
in O 0 0.0013551246
metronidazole B-Chemical 1 0.9998399
- O 0 0.007843489
induced O 0 0.0021120203
encephalopathy B-Disease 2 0.9999809
, O 0 0.0015026726
to O 0 0.00045127817
focus O 0 0.00046275416
on O 0 0.00029772762
the O 0 0.0004878362
diffusion O 0 0.0137191
- O 0 0.001236379
weighted O 0 0.001067972
imaging O 0 0.0071658036
( O 0 0.0018753115
DWI O 0 0.98913807
) O 0 0.0016151683
and O 0 0.0010123121
fluid O 0 0.015814168
attenuated O 0 0.0029534423
inversion O 0 0.044908665
recovery O 0 0.009095892
( O 0 0.009376964
FLAIR O 0 0.98896945
) O 0 0.009451062
imaging O 0 0.01885393
. O 0 0.008884836

MATERIALS O 0 0.029138848
AND O 0 0.010136926
METHODS O 0 0.007538816
: O 0 0.005782357
From O 0 0.0037536176
November O 0 0.003133714
2005 O 0 0.0026037798
to O 0 0.0013868884
September O 0 0.001639606
2007 O 0 0.0017216948
, O 0 0.0010397988
8 O 0 0.0006842486
patients O 0 0.0012712906
( O 0 0.0009271592
5 O 0 0.000526072
men O 0 0.012668831
and O 0 0.00065682345
3 O 0 0.0005811149
women O 0 0.013658595
) O 0 0.0010051592
were O 0 0.0005054431
diagnosed O 0 0.003342986
as O 0 0.0006470121
having O 0 0.0014079617
metronidazole B-Chemical 1 0.99980754
- O 0 0.006242007
induced O 0 0.0025091807
encephalopathy B-Disease 2 0.99997544
( O 0 0.0038040457
age O 0 0.0037424716
range O 0 0.0024885552
; O 0 0.003059304
43 O 0 0.0031429986
- O 0 0.0031442558
78 O 0 0.0045602676
years O 0 0.005095682
) O 0 0.008219156
. O 0 0.007626657

They O 0 0.013232887
had O 0 0.005964294
been O 0 0.004424671
taking O 0 0.0056980355
metronidazole B-Chemical 1 0.9986149
( O 0 0.0030179047
total O 0 0.0013721902
dosage O 0 0.09257275
, O 0 0.0014772296
45 O 0 0.0008312346
- O 0 0.0009466783
120 O 0 0.0006162076
g O 0 0.0008852711
; O 0 0.0007554135
duration O 0 0.0005445176
, O 0 0.00059437
30 O 0 0.00032461033
days O 0 0.00030930142
to O 0 0.00041134426
2 O 0 0.0005557095
months O 0 0.0005160934
) O 0 0.0011100428
to O 0 0.00076640083
treat O 0 0.0023794037
the O 0 0.0017879674
infection B-Disease 2 0.19118264
in O 0 0.0033141926
various O 0 0.008751889
organs O 0 0.26373374
. O 0 0.010486033

Initial O 0 0.014635662
brain O 0 0.03795102
magnetic O 0 0.12257979
resonance O 0 0.3082836
imaging O 0 0.019671952
( O 0 0.004898512
MRI O 0 0.7680634
) O 0 0.0023838843
were O 0 0.00089616963
obtained O 0 0.0006852993
after O 0 0.0004364369
the O 0 0.0006165868
hospitalization O 0 0.05391635
, O 0 0.0010303103
including O 0 0.0008388226
DWI O 0 0.99496657
( O 0 0.0010738054
8 O 0 0.00053425017
/ O 0 0.0010225227
8 O 0 0.0004761381
) O 0 0.0007121384
, O 0 0.00048301707
apparent O 0 0.00038272052
diffusion O 0 0.0034115093
coefficient O 0 0.002110702
( O 0 0.001271517
ADC O 0 0.8522519
) O 0 0.0011900334
map O 0 0.0005603769
( O 0 0.0007531135
4 O 0 0.00043042534
/ O 0 0.0009480719
8 O 0 0.00050792313
) O 0 0.00096412044
, O 0 0.0009943974
FLAIR O 0 0.93822354
( O 0 0.00081692723
7 O 0 0.00051910296
/ O 0 0.0010383651
8 O 0 0.0006010761
) O 0 0.0010137414
, O 0 0.0008758294
and O 0 0.0009829637
T2 O 0 0.053816248
- O 0 0.0016752015
weighted O 0 0.001602472
image O 0 0.0020944523
( O 0 0.002442378
8 O 0 0.0021550902
/ O 0 0.0047107213
8 O 0 0.003921183
) O 0 0.0076466664
. O 0 0.0074838563

Follow O 0 0.037356175
- O 0 0.010068696
up O 0 0.0051858937
MRIs O 0 0.023205532
were O 0 0.0024943585
performed O 0 0.0016185312
on O 0 0.0011741011
5 O 0 0.0011434216
patients O 0 0.0016058695
from O 0 0.0010016762
third O 0 0.0011495831
to O 0 0.0009946384
14th O 0 0.012904694
days O 0 0.00096533267
after O 0 0.0010213573
discontinuation O 0 0.5731943
of O 0 0.005373758
metronidazole B-Chemical 1 0.99956805
administration O 0 0.58666474
. O 0 0.010865819

Findings O 0 0.012942469
of O 0 0.0061684866
initial O 0 0.004085368
and O 0 0.003311969
follow O 0 0.002146037
- O 0 0.0025112387
up O 0 0.001301972
MRIs O 0 0.04363915
were O 0 0.0007527199
retrospectively O 0 0.0007954005
evaluated O 0 0.0005342713
by O 0 0.00070698204
2 O 0 0.0006155731
neuroradiologists O 0 0.0033868686
by O 0 0.0005433285
consensus O 0 0.0005083738
, O 0 0.0005596536
to O 0 0.0003018041
analyze O 0 0.00023205164
the O 0 0.00036736112
presence O 0 0.0003717223
of O 0 0.00061605254
abnormal O 0 0.010293599
signal O 0 0.00069648976
intensities O 0 0.0004899828
, O 0 0.0007357109
their O 0 0.0005839519
locations O 0 0.0007409503
, O 0 0.0009237631
and O 0 0.00084198255
signal O 0 0.0010942449
changes O 0 0.0013297969
on O 0 0.0011178805
follow O 0 0.001813798
- O 0 0.00394086
up O 0 0.003691455
images O 0 0.008324041
. O 0 0.007902505

RESULTS O 0 0.025847739
: O 0 0.0088404585
Initial O 0 0.0074679777
MRIs O 0 0.028784465
showed O 0 0.0022581879
abnormal O 0 0.0046063135
high O 0 0.0017078584
signal O 0 0.0014655035
intensities O 0 0.00095602614
on O 0 0.0008918041
DWI O 0 0.9881648
and O 0 0.0019478025
FLAIR O 0 0.9876151
( O 0 0.0014192538
or O 0 0.0008513129
T2 O 0 0.108409084
- O 0 0.0012190661
weighted O 0 0.00089517795
image O 0 0.0009555257
) O 0 0.0009166154
at O 0 0.00033208367
the O 0 0.00047382805
dentate O 0 0.02307605
nucleus O 0 0.00084611645
( O 0 0.00065351644
8 O 0 0.00041912397
/ O 0 0.0008321583
8 O 0 0.00043978106
) O 0 0.00072196405
, O 0 0.0005817145
inferior O 0 0.0029470215
colliculus O 0 0.02561545
( O 0 0.0006001979
6 O 0 0.00032212003
/ O 0 0.0007457233
8 O 0 0.0004164645
) O 0 0.0006867278
, O 0 0.0005621797
corpus O 0 0.002071351
callosum O 0 0.35776624
( O 0 0.00080616045
2 O 0 0.00046488876
/ O 0 0.0009338773
8 O 0 0.00046255396
) O 0 0.000843686
, O 0 0.00078269216
pons O 0 0.7576661
( O 0 0.0007740135
2 O 0 0.00047211535
/ O 0 0.0009319235
8 O 0 0.0004852076
) O 0 0.00087176886
, O 0 0.0007869259
medulla O 0 0.39319092
( O 0 0.00089449587
1 O 0 0.0005738033
/ O 0 0.0010234875
8 O 0 0.0005338363
) O 0 0.00085623015
, O 0 0.00068351306
and O 0 0.0006975117
bilateral O 0 0.026684042
cerebral O 0 0.8002793
white O 0 0.008441236
matter O 0 0.0064967927
( O 0 0.0026399347
1 O 0 0.0023712665
/ O 0 0.0047309888
8 O 0 0.0037817296
) O 0 0.007381203
. O 0 0.007215299

High O 0 0.04727859
- O 0 0.008944339
signal O 0 0.004733987
intensity O 0 0.0031071599
lesions O 0 0.0895168
on O 0 0.00198467
DWI O 0 0.97311664
tended O 0 0.0012341341
to O 0 0.0007987196
show O 0 0.00062402466
low O 0 0.00085629715
signal O 0 0.0007951289
intensity O 0 0.00055509125
on O 0 0.000463719
ADC O 0 0.7332245
map O 0 0.000794939
( O 0 0.0009973533
3 O 0 0.0005115153
/ O 0 0.0011120093
4 O 0 0.00046294942
) O 0 0.0007734177
, O 0 0.00051582983
but O 0 0.00033467432
in O 0 0.00030596266
one O 0 0.00031371455
patient O 0 0.0006584316
, O 0 0.0005755899
high O 0 0.0004846686
signal O 0 0.0005455462
intensity O 0 0.0004425159
was O 0 0.00047785844
shown O 0 0.0003852825
at O 0 0.00043910474
bilateral O 0 0.028240804
dentate O 0 0.032817207
nuclei O 0 0.0015151268
on O 0 0.00061737426
not O 0 0.0009978105
only O 0 0.0016110052
DWI O 0 0.9781185
but O 0 0.0025204935
also O 0 0.004017539
ADC O 0 0.8411607
map O 0 0.008129375
. O 0 0.009190486

All O 0 0.0082597425
the O 0 0.0063167354
lesions O 0 0.10300533
in O 0 0.0041125887
dentate O 0 0.12756146
, O 0 0.0033354892
inferior O 0 0.016090564
colliculus O 0 0.13663134
, O 0 0.0022155598
pons O 0 0.8445531
, O 0 0.0013171108
and O 0 0.0008969457
medullas O 0 0.01416139
had O 0 0.0005982199
been O 0 0.00060860673
resolved O 0 0.0009185524
completely O 0 0.00052873284
on O 0 0.00034631038
follow O 0 0.0004444013
- O 0 0.000829937
up O 0 0.00047894302
MRIs O 0 0.067254335
in O 0 0.00040042266
5 O 0 0.00042151785
patients O 0 0.0010463235
, O 0 0.00073578383
but O 0 0.00053031766
in O 0 0.0005490101
1 O 0 0.00071731297
patient O 0 0.0009769441
of O 0 0.0012042847
them O 0 0.002935051
, O 0 0.0028203682
corpus O 0 0.010681023
callosal B-Disease 0 0.6616597
lesion I-Disease 0 0.55244
persisted O 0 0.0074633844
. O 0 0.008420866

CONCLUSIONS O 0 0.61684275
: O 0 0.013135171
Reversible O 0 0.75100505
inferior B-Disease 0 0.19462249
colliculus I-Disease 0 0.24013688
lesions I-Disease 0 0.427682
could O 0 0.0014953833
be O 0 0.0011991515
considered O 0 0.0007672643
as O 0 0.0007656665
the O 0 0.0007128222
characteristic O 0 0.0011249541
for O 0 0.0009467044
metronidazole B-Chemical 1 0.9998141
- O 0 0.00847835
induced O 0 0.0029817638
encephalopathy B-Disease 2 0.99996877
, O 0 0.0025535487
next O 0 0.0009903616
to O 0 0.0015544255
the O 0 0.002576864
dentate O 0 0.119822524
nucleus O 0 0.0062311883
involvement O 0 0.010846688
. O 0 0.008322675

Clinically O 0 0.099406786
significant O 0 0.010580443
proteinuria B-Disease 2 0.99935836
following O 0 0.005014696
the O 0 0.0036748652
administration O 0 0.05041035
of O 0 0.0055910624
sirolimus B-Chemical 1 0.99968874
to O 0 0.005799573
renal O 0 0.9942451
transplant O 0 0.8691671
recipients O 0 0.1010059
. O 0 0.0117413355

BACKGROUND O 0 0.772877
: O 0 0.0133272605
Sirolimus B-Chemical 1 0.9926351
is O 0 0.0034031786
the O 0 0.0021245617
latest O 0 0.002669218
immunosuppressive O 0 0.9234419
agent O 0 0.3604108
used O 0 0.001270796
to O 0 0.00094335317
prevent O 0 0.0013734989
rejection O 0 0.9952918
, O 0 0.002367191
and O 0 0.00094670214
may O 0 0.000638497
have O 0 0.0006365053
less O 0 0.0012108322
nephrotoxicity B-Disease 2 0.9999887
than O 0 0.0013625473
calcineurin O 0 0.97356546
inhibitor O 0 0.5608024
( O 0 0.034895755
CNI O 0 0.9998485
) O 0 0.011647849
- O 0 0.00475201
based O 0 0.0039628837
regimens O 0 0.024219576
. O 0 0.008311828

To O 0 0.007216518
date O 0 0.0051412988
there O 0 0.0029849298
has O 0 0.0025296598
been O 0 0.002119829
little O 0 0.0015249054
documentation O 0 0.0021505838
of O 0 0.0018026136
clinically O 0 0.04683386
significant O 0 0.0035144943
proteinuria B-Disease 2 0.9999386
linked O 0 0.0026861373
with O 0 0.0023881337
the O 0 0.0024609107
use O 0 0.0037147666
of O 0 0.00789147
sirolimus B-Chemical 1 0.99964356
. O 0 0.012173305

We O 0 0.009560274
have O 0 0.005799787
encountered O 0 0.0052736616
several O 0 0.0039143795
patients O 0 0.005565878
who O 0 0.0049717333
developed O 0 0.0042084805
substantial O 0 0.0058474154
proteinuria B-Disease 2 0.99989676
associated O 0 0.008908803
with O 0 0.010423345
sirolimus B-Chemical 1 0.9997166
use O 0 0.015014388
. O 0 0.01149322

In O 0 0.0066845254
each O 0 0.0039015587
patient O 0 0.0044496423
, O 0 0.0029641148
the O 0 0.0016659453
close O 0 0.0012228871
temporal O 0 0.0028266676
association O 0 0.0007027344
between O 0 0.00051161816
the O 0 0.0006524057
commencement O 0 0.000870949
of O 0 0.0010523354
sirolimus B-Chemical 1 0.9998903
therapy O 0 0.06836553
and O 0 0.0030532833
proteinuria B-Disease 2 0.9999826
implicated O 0 0.0022719826
sirolimus B-Chemical 1 0.9998833
as O 0 0.0012887684
the O 0 0.0010823903
most O 0 0.001646679
likely O 0 0.0015998229
etiology O 0 0.15331134
of O 0 0.004976704
the O 0 0.008657505
proteinuria B-Disease 2 0.99987495
. O 0 0.012709478

METHODS O 0 0.010561376
: O 0 0.0070544
We O 0 0.0034866051
analyzed O 0 0.002348331
the O 0 0.0019485239
clinical O 0 0.0034814917
and O 0 0.001493522
laboratory O 0 0.0015468193
information O 0 0.0009792174
available O 0 0.0006388379
for O 0 0.0004631178
all O 0 0.00052985153
119 O 0 0.0019071181
patients O 0 0.001036502
transplanted O 0 0.001881471
at O 0 0.00040816356
the O 0 0.0005766648
Washington O 0 0.007245145
Hospital O 0 0.002191497
Center O 0 0.0012663864
between O 0 0.0004051978
1999 O 0 0.0032712778
- O 0 0.0010724948
2003 O 0 0.0009785747
for O 0 0.00042321326
whom O 0 0.0019777317
sirolimus B-Chemical 1 0.9995677
was O 0 0.0010502518
a O 0 0.0013034397
component O 0 0.0013510622
of O 0 0.002081137
their O 0 0.0035268757
immunosuppressant O 0 0.99538404
regimen O 0 0.12736957
. O 0 0.009667587

In O 0 0.007004797
these O 0 0.0055562733
patients O 0 0.0065514967
, O 0 0.003281362
the O 0 0.0017614833
magnitude O 0 0.0013414928
of O 0 0.0022512602
proteinuria B-Disease 2 0.9999472
was O 0 0.0012178232
assessed O 0 0.00057143794
on O 0 0.00043085308
morning O 0 0.0021552222
urine O 0 0.063599974
samples O 0 0.0006204696
by O 0 0.0005833124
turbidometric O 0 0.0099098645
measurement O 0 0.00037302193
or O 0 0.00045141927
random O 0 0.0008695405
urine O 0 0.2104629
protein O 0 0.0019813841
: O 0 0.0024818645
creatinine B-Chemical 1 0.9952865
ratios O 0 0.0011580472
, O 0 0.0009484839
an O 0 0.00081821356
estimate O 0 0.00062333664
of O 0 0.0012927491
grams O 0 0.0037167931
of O 0 0.004573523
proteinuria B-Disease 2 0.99991775
/ O 0 0.05288134
day O 0 0.0060947333
. O 0 0.007996259

Laboratory O 0 0.021012584
results O 0 0.008013245
were O 0 0.0056553157
compared O 0 0.0032323475
between O 0 0.0027643496
prior O 0 0.0028183425
, O 0 0.0040183277
during O 0 0.002709764
and O 0 0.004256939
following O 0 0.0058583776
sirolimus B-Chemical 1 0.99941957
use O 0 0.013515043
. O 0 0.011848323

RESULTS O 0 0.026597008
: O 0 0.00927581
Twenty O 0 0.0076200524
- O 0 0.0047323448
eight O 0 0.0022313283
patients O 0 0.0037384736
( O 0 0.0024147308
24 O 0 0.0011875881
% O 0 0.0015027153
) O 0 0.0016942644
developed O 0 0.0013935288
increased O 0 0.0018357289
proteinuria B-Disease 2 0.99990714
from O 0 0.001436958
baseline O 0 0.001397917
during O 0 0.0009765546
their O 0 0.0018022318
post O 0 0.0033762192
- O 0 0.0048350873
transplantation O 0 0.087998554
course O 0 0.008011705
. O 0 0.008797568

In O 0 0.0077806916
21 O 0 0.006063534
patients O 0 0.0053228387
an O 0 0.0034904592
alternative O 0 0.0026262305
cause O 0 0.0049562426
of O 0 0.0039142044
proteinuria B-Disease 2 0.99995375
was O 0 0.0018641772
either O 0 0.0011489296
obvious O 0 0.0010548373
or O 0 0.0010527201
insufficient O 0 0.0013004804
data O 0 0.001840241
was O 0 0.001672168
available O 0 0.001972974
to O 0 0.0026065784
be O 0 0.0044161556
conclusive O 0 0.011275341
. O 0 0.008427143

In O 0 0.007207451
7 O 0 0.0046306476
of O 0 0.0033774616
the O 0 0.0023547178
28 O 0 0.0019547106
patients O 0 0.0020420018
there O 0 0.00081404863
was O 0 0.0008607931
a O 0 0.0009469706
striking O 0 0.00090262765
temporal O 0 0.0027461955
association O 0 0.000520387
between O 0 0.00041844428
the O 0 0.00062626245
initiation O 0 0.0007925682
of O 0 0.0012399099
sirolimus B-Chemical 1 0.9998053
and O 0 0.0015785423
the O 0 0.0012677696
development O 0 0.0031748838
of O 0 0.006644278
nephrotic B-Disease 2 0.9999788
- O 0 0.07701881
range O 0 0.04501834
proteinuria B-Disease 2 0.9998698
. O 0 0.012699706

Proteinuria B-Disease 2 0.9983645
correlated O 0 0.006598136
most O 0 0.005310044
strongly O 0 0.0039261957
with O 0 0.003446202
sirolimus B-Chemical 1 0.9996394
therapy O 0 0.022316223
when O 0 0.0012366563
compared O 0 0.0010212454
to O 0 0.0013533811
other O 0 0.001876667
demographic O 0 0.006291348
and O 0 0.0037917872
clinical O 0 0.021058401
variables O 0 0.012889828
. O 0 0.0091253

In O 0 0.007891914
most O 0 0.006795675
patients O 0 0.0080079315
, O 0 0.004548914
discontinuation O 0 0.56152546
of O 0 0.003450656
sirolimus B-Chemical 1 0.99975854
resulted O 0 0.0017031967
in O 0 0.0012803106
a O 0 0.0017835151
decrease O 0 0.0014403769
, O 0 0.0019121441
but O 0 0.0014984829
not O 0 0.0018627278
resolution O 0 0.014970138
, O 0 0.005058299
of O 0 0.0085672885
proteinuria B-Disease 2 0.9998356
. O 0 0.013083567

CONCLUSIONS O 0 0.69098425
: O 0 0.015345082
Sirolimus B-Chemical 1 0.9944084
induces O 0 0.004482632
or O 0 0.0037484237
aggravates O 0 0.7421809
pre O 0 0.08769296
- O 0 0.004778069
existing O 0 0.003039612
proteinuria B-Disease 2 0.99990296
in O 0 0.0017806327
an O 0 0.0022693607
unpredictable O 0 0.008170674
subset O 0 0.002193207
of O 0 0.00395639
renal O 0 0.99520326
allograft O 0 0.9900574
recipients O 0 0.19804741
. O 0 0.01103305

Proteinuria B-Disease 2 0.99847895
may O 0 0.0095288325
improve O 0 0.00542222
, O 0 0.005453729
but O 0 0.0033950435
does O 0 0.0025321334
not O 0 0.0025560993
resolve O 0 0.0028392475
, O 0 0.0039925054
when O 0 0.003285146
sirolimus B-Chemical 1 0.9994137
is O 0 0.007673982
withdrawn O 0 0.0402546
. O 0 0.0101684

Components O 0 0.04964346
of O 0 0.017461715
lemon O 0 0.93910867
essential O 0 0.015491957
oil O 0 0.98522586
attenuate O 0 0.42955825
dementia B-Disease 2 0.99961543
induced O 0 0.043024894
by O 0 0.0923334
scopolamine B-Chemical 1 0.9999479
. O 0 0.02302797

The O 0 0.0090746805
anti O 0 0.022909317
- O 0 0.012994839
dementia B-Disease 2 0.99734735
effects O 0 0.005474433
of O 0 0.0033499105
s B-Chemical 0 0.01087697
- I-Chemical 0 0.008654681
limonene I-Chemical 0 0.9998299
and O 0 0.0025261429
s B-Chemical 0 0.002446655
- I-Chemical 0 0.003928649
perillyl I-Chemical 1 0.99982196
alcohol I-Chemical 1 0.99993753
were O 0 0.0009547026
observed O 0 0.00038952308
using O 0 0.00042972062
the O 0 0.00043211214
passive O 0 0.0010842709
avoidance O 0 0.010845332
test O 0 0.001449074
( O 0 0.002439097
PA O 0 0.89100033
) O 0 0.0015995762
and O 0 0.00082249095
the O 0 0.0007919239
open O 0 0.001034523
field O 0 0.0018444642
habituation O 0 0.049794342
test O 0 0.0035076712
( O 0 0.007521109
OFH O 0 0.91442144
) O 0 0.012548783
. O 0 0.008469524

These O 0 0.01212932
lemon O 0 0.84110236
essential O 0 0.0065624435
oils O 0 0.96348876
showed O 0 0.0030149021
strong O 0 0.0025996033
ability O 0 0.0016831356
to O 0 0.0012411788
improve O 0 0.0009944168
memory B-Disease 0 0.7457319
impaired I-Disease 0 0.023260605
by O 0 0.0041793995
scopolamine B-Chemical 1 0.99999774
; O 0 0.0064731305
however O 0 0.0010409422
, O 0 0.00098367
s B-Chemical 0 0.0009701567
- I-Chemical 0 0.0020438402
perillyl I-Chemical 1 0.9998313
alcohol I-Chemical 1 0.99996567
relieved O 0 0.4263676
the O 0 0.0007715509
deficit B-Disease 0 0.048409566
of I-Disease 0 0.0008091497
associative I-Disease 0 0.118788674
memory I-Disease 0 0.21962754
in O 0 0.00080238946
PA O 0 0.86101454
only O 0 0.0006534006
, O 0 0.00087613566
and O 0 0.00064780645
did O 0 0.0005356937
not O 0 0.00059764064
improve O 0 0.00059897866
non O 0 0.0029302223
- O 0 0.003461916
associative O 0 0.06817946
memory O 0 0.1864037
significantly O 0 0.005343053
in O 0 0.0063761533
OFH O 0 0.95410895
. O 0 0.00982144

Analysis O 0 0.013253442
of O 0 0.0072781765
neurotransmitter O 0 0.94156396
concentration O 0 0.0048629874
in O 0 0.0017754108
some O 0 0.0015787911
brain O 0 0.031356774
regions O 0 0.0010588443
on O 0 0.00046505855
the O 0 0.00050157687
test O 0 0.0005580263
day O 0 0.0004031972
showed O 0 0.0003843476
that O 0 0.0004843426
dopamine B-Chemical 1 0.99959344
concentration O 0 0.001162648
of O 0 0.00059995765
the O 0 0.00052410155
vehicle O 0 0.1611619
/ O 0 0.03607146
scopolamine B-Chemical 1 0.9999962
group O 0 0.0010784231
was O 0 0.00044573264
significantly O 0 0.00049547123
lower O 0 0.0003601012
than O 0 0.00022150611
that O 0 0.00022885445
of O 0 0.0003868977
the O 0 0.00040185478
vehicle O 0 0.057787642
/ O 0 0.0035903887
vehicle O 0 0.03689619
group O 0 0.0008589047
, O 0 0.00071267545
but O 0 0.0003784367
this O 0 0.00038123122
phenomenon O 0 0.0038390902
was O 0 0.00046772938
reversed O 0 0.0008143783
when O 0 0.0004073224
s B-Chemical 0 0.0021512613
- I-Chemical 0 0.0027495094
limonene I-Chemical 0 0.99978155
or O 0 0.0010842563
s B-Chemical 0 0.0017771712
- I-Chemical 0 0.0035373904
perillyl I-Chemical 1 0.9998047
alcohol I-Chemical 1 0.9999157
were O 0 0.0015488229
administered O 0 0.0015880262
before O 0 0.0008035007
the O 0 0.0015421653
injection O 0 0.0060419785
of O 0 0.011072348
scopolamine B-Chemical 1 0.9999653
. O 0 0.012014876

Simultaneously O 0 0.018537521
, O 0 0.0072453613
we O 0 0.0030842344
found O 0 0.0022797403
that O 0 0.0017453823
these O 0 0.001924888
two O 0 0.0016458615
lemon O 0 0.9385042
essential O 0 0.0024516387
oil O 0 0.95610446
components O 0 0.0026159934
could O 0 0.0012530496
inhibit O 0 0.0016397967
acetylcholinesterase O 0 0.9974842
activity O 0 0.0022761854
in O 0 0.0015480578
vitro O 0 0.002757693
using O 0 0.0023851297
the O 0 0.003666655
Ellman O 0 0.8504755
method O 0 0.009054724
. O 0 0.008950094

Attentional O 0 0.33223605
modulation O 0 0.010437308
of O 0 0.0075711333
perceived O 0 0.021534212
pain B-Disease 2 0.99681
intensity O 0 0.0055330102
in O 0 0.006322681
capsaicin B-Chemical 1 0.99983406
- O 0 0.051673107
induced O 0 0.012355823
secondary O 2 0.80113304
hyperalgesia B-Disease 2 0.99992514
. O 0 0.023187796

Perceived O 0 0.20011422
pain B-Disease 2 0.98332375
intensity O 0 0.018723242
is O 0 0.016319541
modulated O 0 0.014843965
by O 0 0.019659137
attention O 0 0.030761939
. O 0 0.02219971

However O 0 0.009811563
, O 0 0.0072073
it O 0 0.004270456
is O 0 0.0026519443
not O 0 0.0018698038
known O 0 0.0017302623
that O 0 0.0011252065
how O 0 0.0012403033
pain B-Disease 2 0.9948242
intensity O 0 0.0012549565
ratings O 0 0.005197377
are O 0 0.0011060653
affected O 0 0.0009865862
by O 0 0.001376518
attention O 0 0.0033420252
in O 0 0.0023593262
capsaicin B-Chemical 1 0.999902
- O 0 0.033049654
induced O 0 0.007890118
secondary O 2 0.7853827
hyperalgesia B-Disease 2 0.9999428
. O 0 0.017981064

Here O 0 0.008738423
we O 0 0.0040617804
show O 0 0.0029642025
that O 0 0.002404773
perceived O 0 0.00895518
pain B-Disease 2 0.99702793
intensity O 0 0.0018450771
in O 0 0.0014776995
secondary O 2 0.222754
hyperalgesia B-Disease 2 0.9999876
is O 0 0.0016890285
decreased O 0 0.0014142891
when O 0 0.00055550144
attention O 0 0.0016746463
is O 0 0.0007730297
distracted O 0 0.011216968
away O 0 0.0009907637
from O 0 0.00083088654
the O 0 0.0011496498
painful O 0 0.97594917
pinprick O 0 0.95376974
stimulus O 0 0.0066940584
with O 0 0.0029189622
a O 0 0.00482843
visual O 0 0.16627409
task O 0 0.008126804
. O 0 0.007988044

Furthermore O 0 0.0097236335
, O 0 0.0069125495
it O 0 0.003940635
was O 0 0.00237927
found O 0 0.0014076789
that O 0 0.0010667682
the O 0 0.0009831594
magnitude O 0 0.00080926187
of O 0 0.0012356937
attentional O 0 0.331273
modulation O 0 0.0019972953
in O 0 0.00094107294
secondary O 2 0.2165453
hyperalgesia B-Disease 2 0.9999883
is O 0 0.0011471364
very O 0 0.00083996914
similar O 0 0.00046595797
to O 0 0.0005910732
that O 0 0.0006719259
of O 0 0.0021814688
capsaicin B-Chemical 1 0.9999162
- O 0 0.013003189
untreated O 0 0.003939744
, O 0 0.0040356256
control O 0 0.0037210633
condition O 0 0.009314891
. O 0 0.0081386855

Our O 0 0.008052525
findings O 0 0.007886091
, O 0 0.0044729514
showing O 0 0.0023659144
no O 0 0.0014833036
interaction O 0 0.0016549078
between O 0 0.0011143071
capsaicin B-Chemical 1 0.99985254
treatment O 0 0.0066281394
and O 0 0.0016789263
attentional O 0 0.35495153
modulation O 0 0.001309338
suggest O 0 0.00046750446
that O 0 0.00083892094
capsaicin B-Chemical 1 0.99996495
- O 0 0.01628208
induced O 0 0.001675509
secondary O 2 0.39238662
hyperalgesia B-Disease 2 0.9999896
and O 0 0.002446564
attention O 0 0.0028989562
might O 0 0.00072615803
affect O 0 0.00086935837
mechanical O 0 0.18067236
pain B-Disease 2 0.998679
through O 0 0.0030390196
independent O 0 0.004052979
mechanisms O 0 0.008672009
. O 0 0.008716513

Cardioprotective O 0 0.9735156
effect O 0 0.012489235
of O 0 0.034025196
salvianolic B-Chemical 1 0.9999715
acid I-Chemical 1 0.9992594
A I-Chemical 1 0.92489856
on O 0 0.0045867935
isoproterenol B-Chemical 1 0.99989915
- O 0 0.03189763
induced O 0 0.011175027
myocardial B-Disease 0 0.9999063
infarction I-Disease 2 0.99997497
in O 0 0.01091186
rats O 0 0.043446846
. O 0 0.0113971615

The O 0 0.00738325
present O 0 0.0043776473
study O 0 0.004196539
was O 0 0.002738499
designed O 0 0.0020674781
to O 0 0.0013557075
evaluate O 0 0.00085920835
the O 0 0.0013474899
cardioprotective O 0 0.9122744
potential O 0 0.004823865
of O 0 0.02673864
salvianolic B-Chemical 1 0.99999666
acid I-Chemical 1 0.9996842
A I-Chemical 1 0.9480562
on O 0 0.0020049766
isoproterenol B-Chemical 1 0.9999465
- O 0 0.02179965
induced O 0 0.0077999863
myocardial B-Disease 0 0.99993384
infarction I-Disease 2 0.9999807
in O 0 0.008667088
rats O 0 0.03970639
. O 0 0.009834948

Hemodynamic O 0 0.53487843
parameters O 0 0.014193953
and O 0 0.010502908
lead O 0 0.036352083
II O 0 0.08859684
electrocardiograph O 0 0.55110025
were O 0 0.005393567
monitored O 0 0.003755264
and O 0 0.0060910834
recorded O 0 0.007951179
continuously O 0 0.010173488
. O 0 0.011887422

Cardiac O 0 0.7166921
marker O 0 0.011689582
enzymes O 0 0.07199979
and O 0 0.0074617798
antioxidative O 0 0.9921882
parameters O 0 0.007793067
in O 0 0.003733965
serum O 0 0.16386372
and O 0 0.0054050973
heart O 0 0.73409194
tissues O 0 0.017270703
were O 0 0.0065134494
measured O 0 0.006232505
. O 0 0.009908261

Assay O 0 0.106143765
for O 0 0.0072150663
mitochondrial O 0 0.113112316
respiratory O 0 0.42957616
function O 0 0.00449316
and O 0 0.0037922338
histopathological O 0 0.32001373
examination O 0 0.00506634
of O 0 0.0045559425
heart O 0 0.71938604
tissues O 0 0.017881954
were O 0 0.006568831
performed O 0 0.0072065424
. O 0 0.009824659

Isoproterenol B-Chemical 1 0.999778
- O 0 0.014214371
treated O 0 0.0045434
rats O 0 0.0048543573
showed O 0 0.0016248788
significant O 0 0.0015457224
increases O 0 0.0011428937
in O 0 0.0008675344
the O 0 0.00083611254
levels O 0 0.00082176825
of O 0 0.0020519092
lactate B-Chemical 0 0.9983432
dehydrogenase O 0 0.9996075
, O 0 0.05141434
aspartate B-Chemical 1 0.99998176
transaminase O 0 0.99999547
, O 0 0.039635047
creatine B-Chemical 1 0.9999819
kinase O 0 0.71574116
and O 0 0.0038915274
malondialdehyde B-Chemical 1 0.9999924
and O 0 0.0011434894
significant O 0 0.00072974386
decreases O 0 0.00061575667
in O 0 0.0004731389
the O 0 0.0005752356
activities O 0 0.0013698236
of O 0 0.00315072
superoxide B-Chemical 1 0.9999795
dismutase O 0 0.99999595
, O 0 0.079367384
catalase O 0 0.9997539
and O 0 0.015309848
glutathione B-Chemical 1 0.9999465
peroxidase O 0 0.98885506
in O 0 0.0035192838
serum O 0 0.34609535
and O 0 0.008090485
heart O 0 0.8580948
. O 0 0.009847717

These O 0 0.008835555
rats O 0 0.007692796
also O 0 0.0036395749
showed O 0 0.0023912212
declines O 0 0.003012849
in O 0 0.0013587483
left O 0 0.002661143
ventricular O 0 0.9733891
systolic O 0 0.7990994
pressure O 0 0.039690316
, O 0 0.00074312335
maximum O 0 0.00042095964
and O 0 0.00041011284
minimum O 0 0.00027048975
rate O 0 0.00034937414
of O 0 0.00048683974
developed O 0 0.0007442942
left O 0 0.001797533
ventricular O 0 0.97941774
pressure O 0 0.082283325
, O 0 0.0008594331
and O 0 0.00063413323
elevation O 0 0.0409185
of O 0 0.0007670892
left O 0 0.0022848197
ventricular O 0 0.95821613
end O 0 0.00080160564
- O 0 0.002330209
diastolic O 0 0.84456116
pressure O 0 0.044277534
and O 0 0.003540575
ST O 0 0.94698244
- O 0 0.0075243027
segment O 0 0.008288266
. O 0 0.007951441

In O 0 0.0074285762
addition O 0 0.00450425
, O 0 0.005759313
mitochondrial O 0 0.35064638
respiratory B-Disease 0 0.98495364
dysfunction I-Disease 0 0.9983222
characterized O 0 0.009202098
by O 0 0.0020327545
decreased O 0 0.0022635746
respiratory O 0 0.6044701
control O 0 0.001099176
ratio O 0 0.0015779202
and O 0 0.0023558852
ADP B-Chemical 1 0.9997013
/ O 0 0.05875643
O O 0 0.99446636
was O 0 0.0014673271
observed O 0 0.001107895
in O 0 0.0024624236
isoproterenol B-Chemical 1 0.99982506
- O 0 0.010838384
treated O 0 0.006944476
rats O 0 0.020152425
. O 0 0.009210137

Administration O 0 0.4274579
of O 0 0.031206945
salvianolic B-Chemical 1 0.99995506
acid I-Chemical 1 0.99866724
A I-Chemical 1 0.72329485
for O 0 0.0017447701
a O 0 0.0016597369
period O 0 0.00083856296
of O 0 0.0009229154
8 O 0 0.0007021072
days O 0 0.000515943
significantly O 0 0.0010588716
attenuated O 0 0.0055754716
isoproterenol B-Chemical 1 0.99996614
- O 0 0.010785625
induced O 0 0.0017866147
cardiac B-Disease 2 0.9910802
dysfunction I-Disease 2 0.99863017
and O 0 0.010178642
myocardial B-Disease 2 0.99997413
injury I-Disease 2 0.9987452
and O 0 0.0045413016
improved O 0 0.008676781
mitochondrial O 0 0.68887067
respiratory O 0 0.88740826
function O 0 0.010835791
. O 0 0.008943853

The O 0 0.009743233
protective O 0 0.01632862
role O 0 0.005346501
of O 0 0.015372876
salvianolic B-Chemical 1 0.9999838
acid I-Chemical 1 0.9995396
A I-Chemical 1 0.95239097
against O 0 0.0052339807
isoproterenol B-Chemical 1 0.99995935
- O 0 0.032068286
induced O 0 0.0056639626
myocardial B-Disease 2 0.99996483
damage I-Disease 2 0.9885908
was O 0 0.0023614417
further O 0 0.002068857
confirmed O 0 0.0025366733
by O 0 0.004184872
histopathological O 0 0.63019633
examination O 0 0.014347559
. O 0 0.010210365

The O 0 0.0071630664
results O 0 0.0051883124
of O 0 0.0041439766
our O 0 0.0027602434
study O 0 0.0026204635
suggest O 0 0.0015628189
that O 0 0.0028334064
salvianolic B-Chemical 1 0.9999926
acid I-Chemical 1 0.9996822
A I-Chemical 1 0.9642494
possessing O 0 0.021877622
antioxidant O 0 0.999328
activity O 0 0.0026485906
has O 0 0.00078492396
a O 0 0.0011521747
significant O 0 0.0010597522
protective O 0 0.009721674
effect O 0 0.0016266073
against O 0 0.0025095935
isoproterenol B-Chemical 1 0.99993944
- O 0 0.035801377
induced O 0 0.01874117
myocardial B-Disease 0 0.9999218
infarction I-Disease 2 0.9999703
. O 0 0.018051438

Long O 0 0.07066571
- O 0 0.015350357
term O 0 0.009835682
glutamate B-Chemical 1 0.9994529
supplementation O 0 0.9223925
failed O 0 0.005138295
to O 0 0.0034171264
protect O 0 0.007806731
against O 0 0.004638327
peripheral B-Disease 0 0.94682115
neurotoxicity I-Disease 2 0.9999517
of O 0 0.09826871
paclitaxel B-Chemical 1 0.999549
. O 0 0.014645098

Toxic O 0 0.96881
peripheral B-Disease 2 0.9080089
neuropathy I-Disease 2 0.99989104
is O 0 0.004740174
still O 0 0.0021047655
a O 0 0.0019165073
significant O 0 0.0013295568
limiting O 0 0.0014733346
factor O 0 0.005976006
for O 0 0.00071712094
chemotherapy O 0 0.67634606
with O 0 0.0017924733
paclitaxel B-Chemical 1 0.9998393
( O 0 0.009769906
PAC B-Chemical 1 0.99324846
) O 0 0.0034685684
, O 0 0.0010045681
although O 0 0.0007234773
glutamate B-Chemical 1 0.9996635
and O 0 0.00088582264
its O 0 0.0011669903
closely O 0 0.00075770763
related O 0 0.0009968546
amino B-Chemical 1 0.9901574
acid I-Chemical 1 0.99876934
glutamine B-Chemical 0 0.9997718
were O 0 0.0029175775
claimed O 0 0.005478612
to O 0 0.0029336598
ameliorate O 0 0.5526515
PAC B-Chemical 1 0.998475
neurotoxicity B-Disease 2 0.9998512
. O 0 0.013820063

This O 0 0.010898754
pilot O 0 0.007128644
trial O 0 0.004371627
aimed O 0 0.0025226648
to O 0 0.0016052413
evaluate O 0 0.00092367764
the O 0 0.0011762046
role O 0 0.0009165639
of O 0 0.0032284185
glutamate B-Chemical 1 0.99995697
supplementation O 0 0.96727216
for O 0 0.00095790066
preventing O 0 0.020615004
PAC B-Chemical 1 0.99821305
- O 0 0.006287021
induced O 0 0.0012735424
peripheral B-Disease 2 0.8967023
neuropathy I-Disease 2 0.99999094
in O 0 0.0008374167
a O 0 0.0010545844
randomized O 0 0.000887522
, O 0 0.0008637794
placebo O 0 0.10074013
- O 0 0.0010391334
controlled O 0 0.00056900445
, O 0 0.00081745203
double O 0 0.000763368
- O 0 0.0012902851
blinded O 0 0.0011960041
clinical O 0 0.0035896318
and O 0 0.0023105424
electro O 0 0.42523825
- O 0 0.005746014
diagnostic O 0 0.0063371914
study O 0 0.0076892707
. O 0 0.008265462

Forty O 0 0.0202454
- O 0 0.009274671
three O 0 0.004064922
ovarian B-Disease 2 0.99293065
cancer I-Disease 2 0.9991334
patients O 0 0.01718376
were O 0 0.0014268142
available O 0 0.0008221376
for O 0 0.0005251479
analysis O 0 0.00065026345
following O 0 0.00042642342
six O 0 0.0003000254
cycles O 0 0.00035084574
of O 0 0.00045724688
the O 0 0.0004480843
same O 0 0.0004047592
PAC B-Chemical 1 0.9767452
- O 0 0.0012260653
containing O 0 0.00040289387
regimen O 0 0.0019970795
: O 0 0.0008259246
23 O 0 0.0006445855
had O 0 0.00036811747
been O 0 0.00047418865
supplemented O 0 0.0015520164
by O 0 0.0008546257
glutamate B-Chemical 1 0.9996587
all O 0 0.00038448046
along O 0 0.00033347614
the O 0 0.00033255128
treatment O 0 0.00054738094
period O 0 0.00034541546
, O 0 0.00047220534
at O 0 0.00022738868
a O 0 0.0003734763
daily O 0 0.00051762024
dose O 0 0.0009581539
of O 0 0.0003755349
three O 0 0.0002550259
times O 0 0.00029506683
500 O 0 0.0013289269
mg O 0 0.18464904
( O 0 0.0008808186
group O 0 0.0010164116
G O 0 0.7271639
) O 0 0.0019637267
, O 0 0.0008428463
and O 0 0.0006414559
20 O 0 0.0006071795
had O 0 0.0005585116
received O 0 0.00076978473
a O 0 0.0015974987
placebo O 0 0.12950549
( O 0 0.003489574
group O 0 0.0045274883
P O 0 0.2566526
) O 0 0.0114565035
. O 0 0.00847312

Patients O 0 0.015184733
were O 0 0.0067449547
evaluated O 0 0.0046007894
by O 0 0.0050736135
neurological O 0 0.96562386
examinations O 0 0.008731766
, O 0 0.0037993093
questionnaires O 0 0.0035306294
and O 0 0.0028466412
sensory O 0 0.14645
- O 0 0.0060947426
motor O 0 0.14687577
nerve O 0 0.65710247
conduction O 0 0.24352503
studies O 0 0.0088482285
. O 0 0.00948713

There O 0 0.0078215
was O 0 0.004455134
no O 0 0.0025051404
significant O 0 0.0021916118
difference O 0 0.0011881532
in O 0 0.0010748217
the O 0 0.00090616243
frequency O 0 0.0009646252
of O 0 0.0010705705
signs O 0 0.20357022
or O 0 0.0009339997
symptoms O 0 0.62352526
between O 0 0.00038497426
the O 0 0.0004978381
two O 0 0.0004415792
groups O 0 0.0008975801
although O 0 0.0009007281
neurotoxicity B-Disease 2 0.9999434
symptoms O 0 0.88025993
presented O 0 0.0010510896
mostly O 0 0.0012564685
with O 0 0.0009181674
lower O 0 0.0010334227
scores O 0 0.0016449662
of O 0 0.002001513
severity O 0 0.11118172
in O 0 0.0037434322
group O 0 0.01099705
G O 0 0.8895126
. O 0 0.010588737

However O 0 0.009111841
, O 0 0.0062638237
this O 0 0.0031876687
difference O 0 0.0017796227
reached O 0 0.0017954286
statistical O 0 0.0029339318
significance O 0 0.001585679
only O 0 0.0010108429
with O 0 0.0009905626
regard O 0 0.00087482686
to O 0 0.00096519577
reported O 0 0.0022558654
pain B-Disease 2 0.99926835
sensation O 0 0.9905139
( O 0 0.0063795405
P O 0 0.21248059
= O 0 0.0033118336
0 O 0 0.003186513
. O 0 0.0029833494
011 O 0 0.13185073
) O 0 0.008924887
. O 0 0.008058728

Also O 0 0.008385404
the O 0 0.0046122815
frequency O 0 0.003415147
of O 0 0.00303306
abnormal O 0 0.027897319
electro O 0 0.63003016
- O 0 0.0031859009
diagnostic O 0 0.0016873241
findings O 0 0.0015272165
showed O 0 0.00062162767
similarity O 0 0.0006218326
between O 0 0.00038724052
the O 0 0.0005295086
two O 0 0.00050950045
groups O 0 0.001168211
( O 0 0.0018417081
G O 0 0.59103
: O 0 0.0010845424
7 O 0 0.0005117245
/ O 0 0.00092711195
23 O 0 0.0006751402
= O 0 0.00055641815
30 O 0 0.0003284878
. O 0 0.0003293451
4 O 0 0.00043603024
% O 0 0.00072416844
; O 0 0.001162163
P O 0 0.01363123
: O 0 0.0011942146
6 O 0 0.00078209536
/ O 0 0.0018243436
20 O 0 0.0014175166
= O 0 0.0020621214
30 O 0 0.0019288402
% O 0 0.003972985
) O 0 0.0071766307
. O 0 0.007130213

This O 0 0.011297433
pilot O 0 0.007527063
study O 0 0.004321014
leads O 0 0.0027252922
to O 0 0.0018209491
the O 0 0.0014911636
conclusion O 0 0.0011803494
that O 0 0.0016465841
glutamate B-Chemical 1 0.9998957
supplementation O 0 0.90744996
at O 0 0.0007651675
the O 0 0.0007187444
chosen O 0 0.0007316738
regimen O 0 0.0020572492
fails O 0 0.0009728567
to O 0 0.0010244397
protect O 0 0.0035889016
against O 0 0.0024631454
peripheral B-Disease 0 0.93668437
neurotoxicity I-Disease 2 0.99996257
of O 0 0.05256444
PAC B-Chemical 1 0.99521977
. O 0 0.010940666

Development O 0 0.026653523
of O 0 0.01071395
ocular B-Disease 0 0.9698841
myasthenia I-Disease 0 0.9996562
during O 0 0.0072770314
pegylated B-Chemical 0 0.99924135
interferon I-Chemical 0 0.99989116
and O 0 0.06994908
ribavirin B-Chemical 1 0.99980146
treatment O 0 0.04794284
for O 0 0.008017123
chronic B-Disease 2 0.9994752
hepatitis I-Disease 2 0.9999858
C I-Disease 2 0.9996867
. O 0 0.031748902

A O 0 0.041890237
63 O 0 0.012275512
- O 0 0.0069635017
year O 0 0.003566411
- O 0 0.0031260327
old O 0 0.0019642294
male O 0 0.0040211906
experienced O 0 0.003040754
sudden O 0 0.99544626
diplopia B-Disease 0 0.999569
after O 0 0.00057558384
9 O 0 0.0005971658
weeks O 0 0.00032209547
of O 0 0.00052534544
administration O 0 0.028683342
of O 0 0.001845186
pegylated B-Chemical 0 0.99970156
interferon I-Chemical 0 0.99998426
( I-Chemical 0 0.1737702
IFN I-Chemical 0 0.9999229
) I-Chemical 0 0.029971393
alpha I-Chemical 0 0.5819256
- I-Chemical 0 0.0026827226
2b I-Chemical 0 0.0013613823
and O 0 0.0016304485
ribavirin B-Chemical 1 0.99952316
for O 0 0.002777428
chronic B-Disease 2 0.99955505
hepatitis I-Disease 2 0.9999957
C I-Disease 2 0.9998945
( O 0 0.26193243
CHC B-Disease 0 0.99837214
) O 0 0.048676938
. O 0 0.010430125

Ophthalmologic O 0 0.51372975
examinations O 0 0.0104417605
showed O 0 0.004517332
ptosis B-Disease 0 0.7401891
on I-Disease 0 0.0020472743
the I-Disease 0 0.0018010177
right I-Disease 0 0.0027903558
upper I-Disease 0 0.0026530721
lid I-Disease 0 0.005956905
and O 0 0.0013978678
restricted B-Disease 0 0.0009078303
right I-Disease 0 0.0024764673
eye I-Disease 0 0.010416322
movement I-Disease 0 0.0023833876
without O 0 0.0015148715
any O 0 0.002053216
other O 0 0.0041498737
neurological O 0 0.9965161
signs O 0 0.8041401
. O 0 0.01121011

A O 0 0.05230801
brain O 0 0.04399534
imaging O 0 0.014826772
study O 0 0.006383232
and O 0 0.005248789
repetitive O 0 0.009243562
nerve O 0 0.47002602
stimulation O 0 0.006395935
test O 0 0.0050569195
indicated O 0 0.0044147507
no O 0 0.005668975
abnormality O 0 0.20568293
. O 0 0.012520195

The O 0 0.010337515
acetylcholine B-Chemical 1 0.9987785
receptor O 0 0.29387134
antibody O 0 0.014435446
titer O 0 0.009730607
and O 0 0.0023987563
response O 0 0.002239488
to O 0 0.001444299
acetylcholinesterase O 0 0.99689204
inhibitors O 0 0.09304115
were O 0 0.0010458933
negative O 0 0.0011878884
, O 0 0.0011228428
and O 0 0.00081111275
the O 0 0.00074352854
results O 0 0.0009999956
of O 0 0.0018113677
thyroid O 0 0.9190294
function O 0 0.0031544548
tests O 0 0.006006681
were O 0 0.0045148046
normal O 0 0.00865114
. O 0 0.007992871

The O 0 0.007602282
patient O 0 0.007031074
' O 0 0.0051185656
s O 0 0.0040042605
ophthalmological O 0 0.24721602
symptoms O 0 0.6919217
improved O 0 0.003228936
rapidly O 0 0.00228076
3 O 0 0.00091811793
weeks O 0 0.0005750535
after O 0 0.00054563745
discontinuation O 0 0.39152804
of O 0 0.002333528
pegylated B-Chemical 0 0.99815243
IFN I-Chemical 0 0.99988735
alpha I-Chemical 0 0.92045945
- I-Chemical 0 0.01440912
2b I-Chemical 0 0.0057987315
and O 0 0.008108792
ribavirin B-Chemical 1 0.99907863
. O 0 0.011868795

The O 0 0.008958985
ocular B-Disease 0 0.91717565
myasthenia I-Disease 0 0.9994147
associated O 0 0.0069393935
with O 0 0.0028462056
combination O 0 0.0039220303
therapy O 0 0.02549402
of O 0 0.0036001664
pegylated B-Chemical 0 0.99913603
IFN I-Chemical 0 0.99995494
alpha I-Chemical 0 0.96660966
- I-Chemical 0 0.011565156
2b I-Chemical 0 0.0014866501
and O 0 0.0011676225
ribavirin B-Chemical 1 0.99953234
for O 0 0.0007945052
CHC B-Disease 0 0.99422616
is O 0 0.00072827033
very O 0 0.0007324401
rarely O 0 0.0010560096
reported O 0 0.0010066384
; O 0 0.0011391182
therefore O 0 0.0005378005
, O 0 0.0005271412
we O 0 0.00024638246
present O 0 0.00026620718
this O 0 0.00039007084
case O 0 0.0005142383
with O 0 0.0005892781
a O 0 0.0008776037
review O 0 0.0010960966
of O 0 0.0008678685
the O 0 0.0009538698
various O 0 0.0023429873
eye O 0 0.14742208
complications O 0 0.8530614
of O 0 0.012837193
IFN B-Chemical 0 0.9995914
therapy O 0 0.35798824
. O 0 0.011031456

Learning B-Disease 0 0.1254327
and I-Disease 0 0.009921367
memory I-Disease 0 0.60991114
deficits I-Disease 0 0.8258949
in O 0 0.003927231
ecstasy B-Chemical 1 0.99988043
users O 0 0.03133652
and O 0 0.0019131955
their O 0 0.001640785
neural O 0 0.005962892
correlates O 0 0.0016775939
during O 0 0.0014134303
a O 0 0.0029732166
face O 0 0.0058747875
- O 0 0.0065568965
learning O 0 0.009352236
task O 0 0.008485178
. O 0 0.008705869

It O 0 0.012401222
has O 0 0.0063968496
been O 0 0.004892542
consistently O 0 0.0033335323
shown O 0 0.0023575167
that O 0 0.0024078588
ecstasy B-Chemical 1 0.9998516
users O 0 0.04026956
display O 0 0.0024848247
impairments B-Disease 0 0.26340553
in I-Disease 0 0.002497438
learning I-Disease 0 0.007262736
and I-Disease 0 0.0049683237
memory I-Disease 0 0.2346778
performance O 0 0.011413512
. O 0 0.00946568

In O 0 0.007417309
addition O 0 0.004392526
, O 0 0.004838301
working O 0 0.004313115
memory O 0 0.0679266
processing O 0 0.0019878119
in O 0 0.001665387
ecstasy B-Chemical 1 0.9999454
users O 0 0.056612812
has O 0 0.0008064301
been O 0 0.000767983
shown O 0 0.00043903364
to O 0 0.000461603
be O 0 0.0005199051
associated O 0 0.00058567495
with O 0 0.00062266533
neural O 0 0.021622967
alterations O 0 0.008292598
in O 0 0.00062989065
hippocampal O 0 0.6753385
and O 0 0.0009045363
/ O 0 0.0022387954
or O 0 0.0005778612
cortical O 0 0.014239545
regions O 0 0.00076038914
as O 0 0.0006116235
measured O 0 0.0005426102
by O 0 0.00095891877
functional O 0 0.0016304477
magnetic O 0 0.18004212
resonance O 0 0.39610735
imaging O 0 0.017286157
( O 0 0.005913406
fMRI O 0 0.05576703
) O 0 0.009160425
. O 0 0.00808178

Using O 0 0.008797418
functional O 0 0.006052356
imaging O 0 0.007878466
and O 0 0.0033042578
a O 0 0.0030083521
face O 0 0.0041217934
- O 0 0.0027583933
learning O 0 0.0026339917
task O 0 0.0013385413
, O 0 0.0008543582
we O 0 0.00038259392
investigated O 0 0.00042462643
neural O 0 0.0034538992
correlates O 0 0.00060022395
of O 0 0.0007171203
encoding O 0 0.0006786245
and O 0 0.0007312043
recalling O 0 0.019025454
face O 0 0.0021945888
- O 0 0.0011166108
name O 0 0.00053759676
associations O 0 0.00044060583
in O 0 0.00043236674
20 O 0 0.0005675528
recreational O 0 0.12231859
drug O 0 0.21515931
users O 0 0.0033733759
whose O 0 0.0008831022
predominant O 0 0.0011047722
drug O 0 0.44509912
use O 0 0.0017099183
was O 0 0.0022648587
ecstasy B-Chemical 1 0.99984515
and O 0 0.0038862852
20 O 0 0.0042586005
controls O 0 0.0078037693
. O 0 0.0074278065

To O 0 0.0058968742
address O 0 0.0030040147
the O 0 0.002420437
potential O 0 0.0021161828
confounding O 0 0.0025032845
effects O 0 0.0017991371
of O 0 0.0013275146
the O 0 0.001167332
cannabis B-Chemical 1 0.99988055
use O 0 0.0010139666
of O 0 0.0008708747
the O 0 0.0008440165
ecstasy B-Chemical 1 0.9999589
using O 0 0.00062403805
group O 0 0.00078326964
, O 0 0.00062424806
a O 0 0.00047613677
second O 0 0.00035652987
analysis O 0 0.00044518444
included O 0 0.0003383811
14 O 0 0.00038093296
previously O 0 0.00033078532
tested O 0 0.00040242655
cannabis B-Chemical 1 0.99990463
users O 0 0.0576238
( O 0 0.0017013021
Nestor O 0 0.5254049
, O 0 0.0014025068
L O 0 0.5221824
. O 0 0.00054978835
, O 0 0.0010213631
Roberts O 0 0.12458942
, O 0 0.0012580706
G O 0 0.6199607
. O 0 0.00059078756
, O 0 0.0013148205
Garavan O 0 0.92779607
, O 0 0.0018875073
H O 1 0.99874073
. O 0 0.000645076
, O 0 0.0012152964
Hester O 0 0.2617378
, O 0 0.001258652
R O 0 0.8756309
. O 0 0.0005124738
, O 0 0.0008150801
2008 O 0 0.0012504433
. O 0 0.00038594805
Deficits B-Disease 0 0.023403026
in I-Disease 0 0.00036049567
learning I-Disease 0 0.0012950597
and I-Disease 0 0.00070903223
memory I-Disease 0 0.27609897
: O 0 0.005437258
parahippocampal O 0 0.95118296
hyperactivity B-Disease 2 0.9999335
and O 0 0.0025005736
frontocortical O 0 0.9894908
hypoactivity O 0 0.99964833
in O 0 0.0011347154
cannabis B-Chemical 1 0.9998976
users O 0 0.03664264
. O 0 0.0011035448
Neuroimage O 0 0.14512607
40 O 0 0.0018037321
, O 0 0.0029003283
1328 O 0 0.06868481
- O 0 0.005868311
1339 O 0 0.7592436
) O 0 0.00985791
. O 0 0.008085336

Ecstasy B-Chemical 1 0.99892324
users O 0 0.024399579
performed O 0 0.0045290296
significantly O 0 0.0040637986
worse O 0 0.005209884
in O 0 0.0022462017
learning O 0 0.00440738
and O 0 0.0023714437
memory O 0 0.0495467
compared O 0 0.0014300906
to O 0 0.0020285598
controls O 0 0.0049375
and O 0 0.006067662
cannabis B-Chemical 1 0.9996928
users O 0 0.16764323
. O 0 0.010378435

A O 0 0.027844928
conjunction O 0 0.0063631274
analysis O 0 0.0043198
of O 0 0.0030129077
the O 0 0.0020595752
encode O 0 0.0014528878
and O 0 0.0014369327
recall O 0 0.0023269695
phases O 0 0.0013594577
of O 0 0.0008352032
the O 0 0.00066634564
task O 0 0.00095501373
revealed O 0 0.0008942956
ecstasy B-Chemical 1 0.99997747
- O 0 0.0033515093
specific O 0 0.0007248354
hyperactivity B-Disease 2 0.9999176
in O 0 0.00071283715
bilateral O 0 0.13255931
frontal O 0 0.33091545
regions O 0 0.0007435399
, O 0 0.00066162134
left O 0 0.00088937976
temporal O 0 0.002585376
, O 0 0.0008041058
right O 0 0.0016688807
parietal O 0 0.297931
, O 0 0.0011098968
bilateral O 0 0.015331428
temporal O 0 0.006555275
, O 0 0.0018604693
and O 0 0.0020859027
bilateral O 0 0.15454179
occipital O 0 0.9206129
brain O 0 0.16177018
regions O 0 0.008411988
. O 0 0.008235771

Ecstasy B-Chemical 1 0.9995123
- O 0 0.016636075
specific O 0 0.0051629627
hypoactivity O 0 0.9981324
was O 0 0.002619559
evident O 0 0.0015810649
in O 0 0.0011869586
the O 0 0.0011648944
right O 0 0.0030056185
dorsal O 0 0.0063477126
anterior O 0 0.05064981
cingulated O 0 0.9717461
cortex O 0 0.24438265
( O 0 0.0030194777
ACC O 0 0.83897966
) O 0 0.0028589906
and O 0 0.0022697786
left O 0 0.005588012
posterior O 0 0.06400485
cingulated O 0 0.96072745
cortex O 0 0.19213113
. O 0 0.0086953435

In O 0 0.007607486
both O 0 0.00601044
ecstasy B-Chemical 1 0.99961746
and O 0 0.0064737285
cannabis B-Chemical 1 0.9998149
groups O 0 0.0051095146
brain O 0 0.16136977
activation O 0 0.0029928358
was O 0 0.0009133927
decreased O 0 0.0009589352
in O 0 0.0005718
the O 0 0.0006306637
right O 0 0.0024293798
medial O 0 0.028683728
frontal O 0 0.53690726
gyrus O 0 0.52140534
, O 0 0.0011759726
left O 0 0.0029224213
parahippocampal O 0 0.7877037
gyrus O 0 0.28833178
, O 0 0.0012953263
left O 0 0.0020943338
dorsal O 0 0.008572953
cingulate O 0 0.95698905
gyrus O 0 0.32991344
, O 0 0.002969798
and O 0 0.0033563438
left O 0 0.008098873
caudate O 0 0.41520327
. O 0 0.008472952

These O 0 0.010533658
results O 0 0.007663669
elucidated O 0 0.00942893
ecstasy B-Chemical 1 0.9998516
- O 0 0.009893407
related O 0 0.0022598354
deficits O 0 0.3576089
, O 0 0.0020203046
only O 0 0.0010869513
some O 0 0.001184606
of O 0 0.0014798942
which O 0 0.0018073888
might O 0 0.0012405147
be O 0 0.0019177719
attributed O 0 0.002158465
to O 0 0.0037578265
cannabis B-Chemical 1 0.99964
use O 0 0.010928324
. O 0 0.009960809

These O 0 0.012873131
ecstasy B-Chemical 1 0.9995421
- O 0 0.0090473555
specific O 0 0.0026589998
effects O 0 0.0032662584
may O 0 0.0016041915
be O 0 0.0012445435
related O 0 0.00077167293
to O 0 0.00078411284
the O 0 0.00088277494
vulnerability O 0 0.0409118
of O 0 0.0017438484
isocortical O 0 0.9630253
and O 0 0.0019262964
allocortical O 0 0.55767024
regions O 0 0.0015075312
to O 0 0.0012068254
the O 0 0.0020049338
neurotoxic B-Disease 2 0.99842167
effects O 0 0.016090602
of O 0 0.021283893
ecstasy B-Chemical 1 0.99988174
. O 0 0.012357004

Disulfiram B-Chemical 0 0.99965036
- O 0 0.01798689
like O 0 0.006197605
syndrome O 0 0.8231211
after O 0 0.0038207357
hydrogen B-Chemical 0 0.9998387
cyanamide I-Chemical 0 0.99995863
professional O 0 0.07245933
skin O 0 0.29348263
exposure O 0 0.013413885
: O 0 0.0037301283
two O 0 0.001957153
case O 0 0.0029448727
reports O 0 0.0050224178
in O 0 0.00564182
France O 0 0.1602746
. O 0 0.009840517

Hydrogen B-Chemical 0 0.99842155
cyanamide I-Chemical 0 0.9996748
is O 0 0.00938768
a O 0 0.0072553554
plant O 0 0.054519534
growth O 0 0.018508023
regulator O 0 0.0028938542
used O 0 0.0021802743
in O 0 0.002325551
agriculture O 0 0.34615624
to O 0 0.002431223
induce O 0 0.0025533251
bud O 0 0.066956826
break O 0 0.009756822
in O 0 0.0054385117
fruit O 0 0.38850883
trees O 0 0.033047266
. O 0 0.012735256

Contact O 0 0.13410734
with O 0 0.0063429778
the O 0 0.004271281
skin O 0 0.023974093
can O 0 0.0021200792
result O 0 0.001613983
in O 0 0.0011725108
percutaneous O 0 0.0028688305
absorption O 0 0.14248644
of O 0 0.0013068819
the O 0 0.0011440542
substance O 0 0.9798538
that O 0 0.00111483
inhibits O 0 0.0035506359
aldehyde B-Chemical 0 0.9999583
dehydrogenase O 0 0.99915504
and O 0 0.0020436798
can O 0 0.0009217234
induce O 0 0.00130717
acetaldehyde B-Chemical 0 0.9999685
syndrome O 0 0.960358
in O 0 0.002103193
case O 0 0.00276693
of O 0 0.005529123
alcohol B-Chemical 1 0.9993455
use O 0 0.01229892
. O 0 0.009832217

The O 0 0.0067690196
purpose O 0 0.005045328
of O 0 0.003811804
this O 0 0.0026469168
report O 0 0.0037882095
is O 0 0.0015335901
to O 0 0.001010062
describe O 0 0.0008671188
two O 0 0.0007902766
cases O 0 0.0014739997
of O 0 0.0013202361
a O 0 0.0036586225
disulfiram B-Chemical 1 0.9999883
- O 0 0.007882932
like O 0 0.0015630502
syndrome O 0 0.8510727
following O 0 0.0021364111
occupational O 0 0.09949762
exposure O 0 0.024036186
to O 0 0.00839836
hydrogen B-Chemical 0 0.9998741
cyanamide I-Chemical 0 0.9999182
. O 0 0.023880098

The O 0 0.0070113637
first O 0 0.0044314614
case O 0 0.0036801607
involved O 0 0.002576065
a O 0 0.0027968648
59 O 0 0.0038005095
- O 0 0.0023523732
year O 0 0.0012760345
- O 0 0.0014761566
old O 0 0.0010626682
man O 0 0.0382235
who O 0 0.0020103976
used O 0 0.0009479535
Dormex B-Chemical 0 0.8686166
, O 0 0.0012243923
which O 0 0.001008356
contains O 0 0.0008821066
hydrogen B-Chemical 0 0.9999378
cyanamide I-Chemical 0 0.9999862
, O 0 0.0031566147
without O 0 0.00076945056
protection O 0 0.0025842965
after O 0 0.00047618555
consuming O 0 0.0017635016
a O 0 0.001062532
large O 0 0.0010624926
amount O 0 0.000862634
of O 0 0.0026158667
alcohol B-Chemical 1 0.99914575
during O 0 0.0031760295
a O 0 0.007715459
meal O 0 0.1315767
. O 0 0.009754543

In O 0 0.0070985924
less O 0 0.004827147
than O 0 0.002740065
1 O 0 0.0022005087
hour O 0 0.0012088133
after O 0 0.0008489802
the O 0 0.0010151627
ingestion O 0 0.22959931
of O 0 0.0023689237
alcohol B-Chemical 1 0.99980646
, O 0 0.0029283995
he O 0 0.001541115
developed O 0 0.002443066
malaise O 0 0.99991024
with O 0 0.0017413499
flushing B-Disease 0 0.9382991
of I-Disease 0 0.0016565385
the I-Disease 0 0.0014717773
face I-Disease 0 0.0046653063
, O 0 0.0059508434
tachycardia B-Disease 2 0.9996824
, O 0 0.0064345556
and O 0 0.007945617
dyspnea B-Disease 0 0.99935883
. O 0 0.010815025

Manifestations O 0 0.432871
regressed O 0 0.03721294
spontaneously O 0 0.02380867
under O 0 0.009717172
surveillance O 0 0.012303271
in O 0 0.010656894
the O 0 0.012775667
hospital O 0 0.028431745
. O 0 0.019082138

The O 0 0.007982412
second O 0 0.0057835435
case O 0 0.004310963
occurred O 0 0.0033204088
in O 0 0.0024962327
a O 0 0.0029099153
55 O 0 0.0030412162
- O 0 0.0028084978
year O 0 0.0018321709
- O 0 0.0024340462
old O 0 0.0021723306
farmer O 0 0.00984799
following O 0 0.0027894967
cutaneous O 0 0.73325837
contact O 0 0.008740872
with O 0 0.009941487
Dormex B-Chemical 0 0.9427887
. O 0 0.011288807

Five O 0 0.010244705
hours O 0 0.004198419
after O 0 0.0026399258
exposure O 0 0.00407863
, O 0 0.0029507196
he O 0 0.0025179093
developed O 0 0.0038245926
disulfiram B-Chemical 1 0.9999857
- O 0 0.010790786
like O 0 0.0013834428
syndrome O 0 0.89375865
with O 0 0.0021007154
flushing B-Disease 0 0.9933682
, O 0 0.0090764
tachycardia B-Disease 2 0.99988806
, O 0 0.0018301585
and O 0 0.0013784439
arterial B-Disease 0 0.9753372
hypotension I-Disease 2 0.999977
after O 0 0.0012218968
consuming O 0 0.0043689795
three O 0 0.002060961
glasses O 0 0.10701731
of O 0 0.008991655
wine O 0 0.9804519
. O 0 0.012660716

The O 0 0.009317588
patient O 0 0.008312072
recovered O 0 0.0054535815
spontaneously O 0 0.009689708
in O 0 0.003789574
3 O 0 0.003110896
hours O 0 0.0023381996
under O 0 0.0024760948
surveillance O 0 0.0043355445
in O 0 0.004235057
the O 0 0.006097296
hospital O 0 0.018342571
. O 0 0.011508106

These O 0 0.008150125
cases O 0 0.0057004564
confirm O 0 0.0023335034
the O 0 0.0021005482
necessity O 0 0.0019923602
of O 0 0.001653299
avoiding O 0 0.003231847
alcohol B-Chemical 1 0.9996031
consumption O 0 0.38046807
as O 0 0.0011144818
recommended O 0 0.0008448416
in O 0 0.0005514425
the O 0 0.0005867657
instructions O 0 0.0011368071
for O 0 0.00048484514
use O 0 0.000739686
of O 0 0.0011724087
Dormex B-Chemical 0 0.74313134
and O 0 0.0012654219
of O 0 0.0016192736
preventing O 0 0.004661358
cutaneous O 0 0.83326006
contact O 0 0.005645219
during O 0 0.0034735166
use O 0 0.0072412947
. O 0 0.008565377

Sulpiride B-Chemical 0 0.99949455
- O 0 0.11220591
induced O 0 0.10507247
tardive B-Disease 0 0.9998926
dystonia I-Disease 2 0.9998191
. O 0 0.06857256

Sulpiride B-Chemical 0 0.99975306
is O 0 0.010072041
a O 0 0.008369976
selective O 0 0.044381503
D2 O 0 0.99357647
- O 0 0.016089652
receptor O 0 0.3488196
antagonist O 0 0.9778528
with O 0 0.00710108
antipsychotic O 0 0.99969757
and O 0 0.013170902
antidepressant B-Chemical 1 0.9997063
properties O 0 0.01936997
. O 0 0.011645358

Although O 0 0.0072453846
initially O 0 0.0064020557
thought O 0 0.004327463
to O 0 0.0024621508
be O 0 0.0019579427
free O 0 0.002076386
of O 0 0.0027032993
extrapyramidal O 0 0.99998844
side O 0 0.53537214
effects O 0 0.035451435
, O 0 0.036153223
sulpiride B-Chemical 1 0.99999774
- O 0 0.03277463
induced O 0 0.010715254
tardive B-Disease 0 0.99999845
dyskinesia I-Disease 2 0.9999976
and O 0 0.057458065
parkinsonism B-Disease 2 0.9999745
have O 0 0.0034806016
been O 0 0.0042641265
reported O 0 0.0058581643
occasionally O 0 0.015854897
. O 0 0.00935993

We O 0 0.008777765
studied O 0 0.0062071225
a O 0 0.0055631753
37 O 0 0.0046406696
- O 0 0.0039734794
year O 0 0.0021927506
- O 0 0.0023029395
old O 0 0.0016062673
man O 0 0.02796065
who O 0 0.002322107
developed O 0 0.0017511883
persistent O 0 0.055442654
segmental O 0 0.13359234
dystonia B-Disease 2 0.99998295
within O 0 0.0009612101
2 O 0 0.0012722603
months O 0 0.001006041
after O 0 0.0011776469
starting O 0 0.0037596587
sulpiride B-Chemical 1 0.9999653
therapy O 0 0.184382
. O 0 0.009926732

We O 0 0.009936244
could O 0 0.00587422
not O 0 0.004492179
find O 0 0.0032910686
any O 0 0.0028797032
previous O 0 0.002712185
reports O 0 0.004484175
of O 0 0.014207111
sulpiride B-Chemical 1 0.9999919
- O 0 0.13202986
induced O 0 0.085455075
tardive B-Disease 0 0.9999924
dystonia I-Disease 2 0.9999702
. O 0 0.0275976

Comparative O 0 0.017920299
cognitive O 0 0.41940635
and O 0 0.0054887175
subjective O 0 0.012604672
side O 0 0.03927581
effects O 0 0.0035775376
of O 0 0.0025689953
immediate O 0 0.0101057915
- O 0 0.005406131
release O 0 0.14765307
oxycodone B-Chemical 1 0.9999747
in O 0 0.001721948
healthy O 0 0.023896536
middle O 0 0.0046908613
- O 0 0.0034434355
aged O 0 0.003964055
and O 0 0.0038017447
older O 0 0.015143929
adults O 0 0.014069703
. O 0 0.008668829

This O 0 0.009595204
study O 0 0.005095446
measured O 0 0.002629391
the O 0 0.0022244079
objective O 0 0.0027680143
and O 0 0.0018113141
subjective O 0 0.019388348
neurocognitive O 0 0.72055936
effects O 0 0.001497711
of O 0 0.0009043736
a O 0 0.0009524961
single O 0 0.000700654
10 O 0 0.0006657226
- O 0 0.0008478699
mg O 0 0.08007931
dose O 0 0.0023829183
of O 0 0.00066048553
immediate O 0 0.003921205
- O 0 0.0024602942
release O 0 0.07287782
oxycodone B-Chemical 1 0.999987
in O 0 0.00064248615
healthy O 0 0.021944128
, O 0 0.0009593245
older O 0 0.0036803004
( O 0 0.00080693973
> O 0 0.0007129798
65 O 0 0.0005208312
years O 0 0.00062847964
) O 0 0.0008128521
, O 0 0.0005606841
and O 0 0.0005089981
middle O 0 0.0012475847
- O 0 0.0008988266
aged O 0 0.00091321254
( O 0 0.00062369107
35 O 0 0.00041642957
to O 0 0.00033287518
55 O 0 0.00056572334
years O 0 0.00069240376
) O 0 0.00087178964
adults O 0 0.0010322636
who O 0 0.0009559532
were O 0 0.0006448547
not O 0 0.0007490823
suffering O 0 0.6857604
from O 0 0.0017426593
chronic O 0 0.88613963
or O 0 0.0027344588
significant O 0 0.004211595
daily O 0 0.03671192
pain B-Disease 2 0.99784577
. O 0 0.010241833

Seventy O 0 0.019459622
- O 0 0.00860861
one O 0 0.0035778775
participants O 0 0.002771444
completed O 0 0.0017828684
2 O 0 0.0012340647
separate O 0 0.0008795584
study O 0 0.0009196303
days O 0 0.0006233773
and O 0 0.0008001961
were O 0 0.00073099666
blind O 0 0.0022612175
to O 0 0.000641204
medication O 0 0.05440371
condition O 0 0.0021214099
( O 0 0.0018729639
placebo O 0 0.11623371
, O 0 0.0018552266
10 O 0 0.00170257
- O 0 0.0034196505
mg O 0 0.75935733
oxycodone B-Chemical 1 0.9999219
) O 0 0.016810833
. O 0 0.00863329

Plasma O 0 0.38212872
oxycodone B-Chemical 1 0.99978024
concentration O 0 0.008684521
peaked O 0 0.003924711
between O 0 0.0013314474
60 O 0 0.001274058
and O 0 0.0009980316
90 O 0 0.00072204665
minutes O 0 0.00057958986
postdose O 0 0.0043162494
( O 0 0.0009182855
P O 0 0.020354522
< O 0 0.0006794532
. O 0 0.00044112487
01 O 0 0.0029332666
) O 0 0.0006826729
and O 0 0.00045320689
pupil O 0 0.011531496
size O 0 0.00061794644
, O 0 0.00051194814
an O 0 0.0004069471
indication O 0 0.00028559772
of O 0 0.00044974292
physiological O 0 0.0013020315
effects O 0 0.00084771035
of O 0 0.0005932022
the O 0 0.00053087214
medication O 0 0.15360537
, O 0 0.00070846995
peaked O 0 0.0006577135
at O 0 0.00030105
approximately O 0 0.00036436453
90 O 0 0.0003858226
to O 0 0.00038812458
120 O 0 0.00059697987
minutes O 0 0.000568321
postdose O 0 0.0043777246
( O 0 0.0017048538
P O 0 0.023313595
< O 0 0.002364164
. O 0 0.0025588498
01 O 0 0.012646579
) O 0 0.007624106
. O 0 0.0073879557

Significant O 0 0.011014749
declines B-Disease 0 0.00765991
in I-Disease 0 0.0034617386
simple I-Disease 0 0.0036951378
and I-Disease 0 0.0025220742
sustained I-Disease 0 0.005529881
attention I-Disease 0 0.0039082435
, I-Disease 0 0.0017952431
working I-Disease 0 0.0020465201
memory I-Disease 0 0.1524663
, I-Disease 0 0.001159223
and I-Disease 0 0.00080681324
verbal I-Disease 0 0.10585811
memory I-Disease 0 0.064355545
were O 0 0.00047195944
observed O 0 0.00027877843
at O 0 0.00027923356
1 O 0 0.00033228734
hour O 0 0.00021735014
postdose O 0 0.0011843031
compared O 0 0.0001793808
to O 0 0.00025176225
baseline O 0 0.00036001916
for O 0 0.00025573833
both O 0 0.000366697
age O 0 0.0009872002
groups O 0 0.0006495295
with O 0 0.0005814983
a O 0 0.00085130153
trend O 0 0.0009756544
toward O 0 0.0007451199
return O 0 0.0011161716
to O 0 0.00079264335
baseline O 0 0.0013064127
by O 0 0.001618347
5 O 0 0.0018625841
hours O 0 0.0023903216
postdose O 0 0.01604857
. O 0 0.0059510022

For O 0 0.0063772947
almost O 0 0.0045371153
all O 0 0.0034508922
cognitive O 0 0.26299226
measures O 0 0.0022084308
, O 0 0.0016903132
there O 0 0.00070337893
were O 0 0.00070197467
no O 0 0.0005209811
medication O 0 0.03650611
by O 0 0.00084084243
age O 0 0.0029931604
- O 0 0.0011593999
interaction O 0 0.0005962776
effects O 0 0.0013467014
, O 0 0.00084888685
which O 0 0.00056533766
indicates O 0 0.0003561959
that O 0 0.00034987277
the O 0 0.00047588084
2 O 0 0.0005442532
age O 0 0.0009926022
groups O 0 0.00079568295
exhibited O 0 0.0006616757
similar O 0 0.00073911843
responses O 0 0.0019993181
to O 0 0.0016000285
the O 0 0.0025297427
medication O 0 0.17902797
challenge O 0 0.006887302
. O 0 0.008209973

This O 0 0.00993951
study O 0 0.005258285
suggests O 0 0.0024913999
that O 0 0.00198962
for O 0 0.0015695737
healthy O 0 0.0073252223
older O 0 0.005404131
adults O 0 0.002532226
who O 0 0.0015842145
are O 0 0.0007487761
not O 0 0.0006664059
suffering O 0 0.8310199
from O 0 0.0013119977
chronic B-Disease 0 0.9898085
pain I-Disease 2 0.99988306
, O 0 0.0055112
neurocognitive O 0 0.8837139
and O 0 0.0006286219
pharmacodynamic O 0 0.42480516
changes O 0 0.0006930285
in O 0 0.00037633907
response O 0 0.00056873437
to O 0 0.00037515955
a O 0 0.00064613856
10 O 0 0.0005270332
- O 0 0.0007113392
mg O 0 0.067698844
dose O 0 0.0019914717
of O 0 0.00064679206
immediate O 0 0.003382831
- O 0 0.002436722
release O 0 0.0738513
oxycodone B-Chemical 1 0.9999808
are O 0 0.00077115244
similar O 0 0.0004735308
to O 0 0.0006136695
those O 0 0.0010074986
observed O 0 0.00077492936
for O 0 0.0012931149
middle O 0 0.004625975
- O 0 0.00480936
aged O 0 0.006985854
adults O 0 0.012410346
. O 0 0.007993112

PERSPECTIVE O 0 0.07704968
: O 0 0.009686144
Study O 0 0.009303423
findings O 0 0.0041415053
indicate O 0 0.001884476
that O 0 0.0014581998
the O 0 0.0016754055
metabolism O 0 0.32031864
, O 0 0.0025523733
neurocognitive O 0 0.8251238
effects O 0 0.0025443279
, O 0 0.0011756832
and O 0 0.0007593203
physical O 0 0.014789263
side O 0 0.034097616
effects O 0 0.0013189209
of O 0 0.0010991148
oral O 0 0.8461081
oxycodone B-Chemical 1 0.99998987
are O 0 0.0009418825
similar O 0 0.0005498591
for O 0 0.0006996675
healthy O 0 0.009119464
middle O 0 0.0034439443
- O 0 0.0028467644
aged O 0 0.0034542226
and O 0 0.0033982156
older O 0 0.0149870515
adults O 0 0.013487194
. O 0 0.008163412

Therefore O 0 0.007225871
, O 0 0.0060042385
clinicians O 0 0.00438539
should O 0 0.0016158205
not O 0 0.0014116524
avoid O 0 0.0012205768
prescribing O 0 0.020526934
oral O 0 0.55196667
opioids O 0 0.9994777
to O 0 0.0010105324
older O 0 0.0046742517
adults O 0 0.0013083764
based O 0 0.0004990475
on O 0 0.00033033217
the O 0 0.00048768046
belief O 0 0.0027414516
that O 0 0.00049300946
older O 0 0.0034358758
adults O 0 0.0017398073
are O 0 0.00064361776
at O 0 0.00048143195
higher O 0 0.00068530976
risk O 0 0.015788985
for O 0 0.0010177682
side O 0 0.04267057
effects O 0 0.004038127
than O 0 0.0025041765
younger O 0 0.09949934
adults O 0 0.0191906
. O 0 0.008172536

The O 0 0.01141293
glycine B-Chemical 1 0.99747247
transporter O 0 0.45461598
- O 0 0.0078982245
1 O 0 0.002769876
inhibitor O 0 0.050860032
SSR103800 B-Chemical 1 0.98447126
displays O 0 0.0013351795
a O 0 0.0013211877
selective O 0 0.0024516548
and O 0 0.0010205159
specific O 0 0.00094621204
antipsychotic O 0 0.99966407
- O 0 0.002324759
like O 0 0.0010682283
profile O 0 0.0013877816
in O 0 0.0015098454
normal O 0 0.003350909
and O 0 0.0033583653
transgenic O 0 0.0048982278
mice O 0 0.005305827
. O 0 0.008723474

Schizophrenia B-Disease 0 0.9703973
has O 0 0.011174907
been O 0 0.008768294
initially O 0 0.008484385
associated O 0 0.007469611
with O 0 0.008727479
dysfunction O 0 0.985269
in O 0 0.017867506
dopamine B-Chemical 1 0.9997271
neurotransmission O 0 0.9966703
. O 0 0.015929265

However O 0 0.008941655
, O 0 0.006216335
the O 0 0.0033922407
observation O 0 0.0024275868
that O 0 0.0019185058
antagonists O 0 0.8920039
of O 0 0.0030180367
the O 0 0.0035853463
glutamate B-Chemical 1 0.9999646
N B-Chemical 0 0.9994104
- I-Chemical 0 0.06512348
methyl I-Chemical 0 0.9976234
- I-Chemical 0 0.0735349
D I-Chemical 0 0.993543
- I-Chemical 0 0.07994099
aspartate I-Chemical 1 0.9999645
( O 0 0.044526562
NMDA B-Chemical 1 0.99999464
) O 0 0.008586565
receptor O 0 0.07959081
produce O 0 0.00073325314
schizophrenic B-Disease 2 0.9998872
- O 0 0.0019686522
like O 0 0.0005883452
symptoms O 0 0.7103938
in O 0 0.0005234106
humans O 0 0.0015272798
has O 0 0.00039504308
led O 0 0.0004996275
to O 0 0.0003917407
the O 0 0.0004452273
idea O 0 0.00067048246
of O 0 0.00076543447
a O 0 0.001263347
dysfunctioning O 0 0.32255372
of O 0 0.0013138998
the O 0 0.0016563941
glutamatergic O 0 0.9900506
system O 0 0.003554069
via O 0 0.002657901
its O 0 0.03116405
NMDA B-Chemical 1 0.9999484
receptor O 0 0.56321704
. O 0 0.010696381

As O 0 0.0066141454
a O 0 0.00594667
result O 0 0.0038151229
, O 0 0.003090359
there O 0 0.0014084739
is O 0 0.001328331
a O 0 0.0013364383
growing O 0 0.0012003565
interest O 0 0.0010007208
in O 0 0.0006303531
the O 0 0.0006287432
development O 0 0.0011061592
of O 0 0.00088535936
pharmacological O 0 0.49329165
agents O 0 0.24868421
with O 0 0.00073809474
potential O 0 0.0014745243
antipsychotic O 0 0.9995654
properties O 0 0.0009284079
that O 0 0.000393609
enhance O 0 0.00031489096
the O 0 0.0004681406
activity O 0 0.000629362
of O 0 0.00075711
the O 0 0.00095570274
glutamatergic O 0 0.98630536
system O 0 0.001583569
via O 0 0.00092229265
a O 0 0.0015750335
modulation O 0 0.0022809966
of O 0 0.0031402914
the O 0 0.00732859
NMDA B-Chemical 1 0.99994934
receptor O 0 0.5927492
. O 0 0.010907399

Among O 0 0.014645382
them O 0 0.011450301
are O 0 0.0073480518
glycine B-Chemical 1 0.99886996
transporter O 0 0.55543685
- O 0 0.006829383
1 O 0 0.0020978067
( O 0 0.0028259999
GlyT1 O 0 0.99883646
) O 0 0.0020940597
inhibitors O 0 0.012697696
such O 0 0.0007285807
as O 0 0.0010711608
SSR103800 B-Chemical 1 0.99578345
, O 0 0.0011205876
which O 0 0.0007912058
indirectly O 0 0.0040610647
enhance O 0 0.0006763209
NMDA B-Chemical 1 0.99999416
receptor O 0 0.17572482
function O 0 0.0008202424
by O 0 0.0005883191
increasing O 0 0.00078821974
the O 0 0.00092307164
glycine B-Chemical 1 0.99955195
( O 0 0.0018717241
a O 0 0.0012481059
co O 0 0.6444555
- O 0 0.0042774184
agonist O 0 0.71671176
for O 0 0.0008059922
the O 0 0.0019646839
NMDA B-Chemical 1 0.99998605
receptor O 0 0.3568995
) O 0 0.004520389
levels O 0 0.0018671838
in O 0 0.0024667282
the O 0 0.004089516
synapse O 0 0.11585771
. O 0 0.008716175

This O 0 0.010114673
study O 0 0.005412126
aimed O 0 0.0032358156
at O 0 0.0017890212
investigating O 0 0.0013748083
the O 0 0.0012669355
potential O 0 0.0021016041
antipsychotic O 0 0.99978334
- O 0 0.0029901536
like O 0 0.000754502
properties O 0 0.001150082
of O 0 0.001685346
SSR103800 B-Chemical 1 0.99702734
, O 0 0.0009853228
with O 0 0.00045194238
a O 0 0.0005011774
particular O 0 0.0002621086
focus O 0 0.0003725872
on O 0 0.0002444236
models O 0 0.00064574805
of O 0 0.0016598593
hyperactivity B-Disease 2 0.99996996
, O 0 0.0013246891
involving O 0 0.00054107787
either O 0 0.00048758145
drug O 0 0.35929146
challenge O 0 0.0008596146
( O 0 0.0010763111
ie O 0 0.0029371546
, O 0 0.0018633292
amphetamine B-Chemical 1 0.9999908
and O 0 0.0025346628
MK B-Chemical 0 0.9964541
- I-Chemical 0 0.0055494593
801 I-Chemical 0 0.729089
) O 0 0.00097071286
or O 0 0.00041794797
transgenic O 0 0.00059739547
mice O 0 0.000443169
( O 0 0.0010376673
ie O 0 0.003506623
, O 0 0.004299204
NMDA B-Chemical 1 0.9999908
Nr1 O 0 0.9372254
( O 0 0.0022692073
neo O 0 0.25225744
- O 0 0.0024787998
/ O 0 0.004317299
- O 0 0.0019274601
) O 0 0.0017267187
and O 0 0.0015657919
DAT O 0 0.9783611
( O 0 0.0032944712
- O 0 0.003917549
/ O 0 0.0069761844
- O 0 0.0055644317
) O 0 0.0071364646
) O 0 0.009158504
. O 0 0.007761245

Results O 0 0.012084839
showed O 0 0.0056922487
that O 0 0.0045237183
SSR103800 B-Chemical 1 0.97820354
( O 0 0.0045103948
10 O 0 0.0020311996
- O 0 0.0018370225
30 O 0 0.0008115762
mg O 0 0.055161633
/ O 0 0.0016879403
kg O 0 0.0030151745
p O 0 0.0010198822
. O 0 0.00052987103
o O 0 0.0036502678
. O 0 0.0005826078
) O 0 0.001664486
blocked O 0 0.0027021074
hyperactivity B-Disease 2 0.99993217
induced O 0 0.0010262731
by O 0 0.0007448249
the O 0 0.0005583743
non O 0 0.005864543
- O 0 0.0053307414
competitive O 0 0.20687354
NMDA B-Chemical 1 0.9999962
receptor O 0 0.7061283
antagonist O 0 0.99507153
, O 0 0.00957857
MK B-Chemical 0 0.9950323
- I-Chemical 0 0.003912407
801 I-Chemical 0 0.53173786
and O 0 0.00064073666
partially O 0 0.0006910434
reversed O 0 0.0018859861
spontaneous O 0 0.21798682
hyperactivity B-Disease 2 0.9999579
of O 0 0.02744293
NMDA B-Chemical 1 0.9999943
Nr1 O 0 0.9753186
( O 0 0.005309314
neo O 0 0.3256094
- O 0 0.0048996317
/ O 0 0.0073943706
- O 0 0.0049854997
) O 0 0.0058044964
mice O 0 0.0046125357
. O 0 0.007773295

In O 0 0.007823399
contrast O 0 0.006360535
, O 0 0.006707837
SSR103800 B-Chemical 1 0.961757
failed O 0 0.0026083754
to O 0 0.0016645619
affect O 0 0.0014000254
hyperactivity B-Disease 2 0.99992144
induced O 0 0.0033754718
by O 0 0.0036974014
amphetamine B-Chemical 1 0.9999933
or O 0 0.0011880765
naturally O 0 0.0087979715
observed O 0 0.00053338584
in O 0 0.0010858724
dopamine B-Chemical 1 0.999931
transporter O 0 0.4143384
( O 0 0.0031838997
DAT O 0 0.98893213
( O 0 0.001678816
- O 0 0.0016029617
/ O 0 0.003289336
- O 0 0.0014530371
) O 0 0.0011787348
) O 0 0.0008853366
knockout O 0 0.0005283791
mice O 0 0.00042037058
( O 0 0.00087199564
10 O 0 0.00061660854
- O 0 0.00082402024
30 O 0 0.00050633535
mg O 0 0.038764063
/ O 0 0.001942867
kg O 0 0.003660577
p O 0 0.0020422963
. O 0 0.0017947997
o O 0 0.006718412
. O 0 0.0036203316
) O 0 0.009066623
. O 0 0.007844665

Importantly O 0 0.007876014
, O 0 0.006391651
both O 0 0.0036580735
classical O 0 0.008349148
( O 0 0.010799476
haloperidol B-Chemical 1 0.99999106
) O 0 0.009856694
and O 0 0.0018929942
atypical O 0 0.41203552
( O 0 0.012939532
olanzapine B-Chemical 1 0.9999925
, O 0 0.006789787
clozapine B-Chemical 1 0.99998665
and O 0 0.0030110646
aripiprazole B-Chemical 0 0.99997663
) O 0 0.0052310643
antipsychotics O 0 0.999348
were O 0 0.00091360894
effective O 0 0.0009406131
in O 0 0.0008782863
all O 0 0.0011170822
these O 0 0.0019696467
models O 0 0.0038069002
of O 0 0.010567128
hyperactivity B-Disease 2 0.9997632
. O 0 0.011747389

However O 0 0.009193746
, O 0 0.006476796
unlike O 0 0.0033258623
these O 0 0.0031416726
latter O 0 0.0062751486
, O 0 0.004151729
SSR103800 B-Chemical 1 0.98227006
did O 0 0.001259585
not O 0 0.001071145
produce O 0 0.0013157919
catalepsy B-Disease 2 0.9999907
( O 0 0.0022323448
retention O 0 0.0013018716
on O 0 0.00040922168
the O 0 0.0005896782
bar O 0 0.0070749843
test O 0 0.0010389833
) O 0 0.0012865914
up O 0 0.0006591644
to O 0 0.0007129268
30 O 0 0.00085360673
mg O 0 0.08843664
/ O 0 0.00347886
kg O 0 0.0066371253
p O 0 0.0038048667
. O 0 0.0036871138
o O 0 0.013122679
. O 0 0.008660714

Together O 0 0.013211359
these O 0 0.006307637
findings O 0 0.005702608
show O 0 0.00255648
that O 0 0.0020119136
the O 0 0.002717558
GlyT1 O 0 0.99946505
inhibitor O 0 0.38349035
, O 0 0.0070971604
SSR103800 B-Chemical 1 0.9956995
, O 0 0.0014457392
produces O 0 0.0009952384
antipsychotic O 0 0.9997571
- O 0 0.0017230863
like O 0 0.00052133977
effects O 0 0.0013966584
, O 0 0.00079410773
which O 0 0.00052817375
differ O 0 0.00043883277
from O 0 0.00038282963
those O 0 0.00050287135
observed O 0 0.00026711382
with O 0 0.0005090217
compounds O 0 0.48284027
primarily O 0 0.0008460448
targeting O 0 0.00037505443
the O 0 0.00055433833
dopaminergic O 0 0.95828986
system O 0 0.0012294814
, O 0 0.0007439389
and O 0 0.0005147134
has O 0 0.00038093366
a O 0 0.00068732037
reduced O 0 0.0006784328
side O 0 0.0881248
- O 0 0.0014935745
effect O 0 0.00064336363
potential O 0 0.0010804532
as O 0 0.0010388459
compared O 0 0.00090313435
with O 0 0.0018273776
these O 0 0.0032772648
latter O 0 0.011442995
drugs O 0 0.88844246
. O 0 0.009335172

Pyrrolidine B-Chemical 0 0.9993636
dithiocarbamate I-Chemical 0 0.9997265
protects O 0 0.13221867
the O 0 0.008529905
piriform O 0 0.67775327
cortex O 0 0.15816607
in O 0 0.003731334
the O 0 0.0052782483
pilocarpine B-Chemical 1 0.9999093
status B-Disease 0 0.085588075
epilepticus I-Disease 0 0.9998696
model O 0 0.019985626
. O 0 0.014149745

Pyrrolidine B-Chemical 0 0.9996338
dithiocarbamate I-Chemical 0 0.99990904
( O 0 0.2947281
PDTC B-Chemical 1 0.99997735
) O 0 0.01720539
has O 0 0.0015413329
a O 0 0.0015903566
dual O 0 0.0020023154
mechanism O 0 0.0011312617
of O 0 0.0011722316
action O 0 0.006519586
as O 0 0.001028756
an O 0 0.0021779153
antioxidant O 0 0.9979255
and O 0 0.0018619391
an O 0 0.0019994532
inhibitor O 0 0.038861386
of O 0 0.0018926203
the O 0 0.0018402445
transcription O 0 0.0067074397
factor O 0 0.04372335
kappa O 0 0.36146748
- O 0 0.017326998
beta O 0 0.5274293
. O 0 0.010278809

Both O 0 0.010587463
, O 0 0.007458729
production O 0 0.0050570294
of O 0 0.004039451
reactive O 0 0.3482698
oxygen B-Chemical 1 0.9862651
species O 0 0.0025187691
as O 0 0.0011613833
well O 0 0.0008345982
as O 0 0.0008806704
activation O 0 0.0016742495
of O 0 0.0016257284
NF O 0 0.9928798
- O 0 0.006269133
kappaB O 0 0.16701636
have O 0 0.00059050776
been O 0 0.0006720782
implicated O 0 0.0005766816
in O 0 0.0006679864
severe O 0 0.47731754
neuronal B-Disease 2 0.9735919
damage I-Disease 2 0.9700047
in O 0 0.00070878834
different O 0 0.00063261815
sub O 0 0.023353571
- O 0 0.0014120342
regions O 0 0.00064576766
of O 0 0.00069978525
the O 0 0.00081807235
hippocampus O 0 0.09076492
as O 0 0.00090823695
well O 0 0.0010022619
as O 0 0.0014216345
in O 0 0.0017887352
the O 0 0.0028251894
surrounding O 0 0.008441367
cortices O 0 0.7948519
. O 0 0.008659645

The O 0 0.0076467744
effect O 0 0.0055365902
of O 0 0.0077754064
PDTC B-Chemical 1 0.9999529
on O 0 0.002942439
status B-Disease 0 0.025712978
epilepticus I-Disease 0 0.9999814
- O 0 0.013385341
associated O 0 0.001729728
cell O 0 0.016251413
loss O 0 0.0022731253
in O 0 0.00073663454
the O 0 0.0008920573
hippocampus O 0 0.25085708
and O 0 0.0013446836
piriform O 0 0.47613975
cortex O 0 0.05379427
was O 0 0.0007185342
evaluated O 0 0.0007148263
in O 0 0.00097155245
the O 0 0.0014431456
rat O 0 0.0076779737
fractionated O 0 0.0359892
pilocarpine B-Chemical 1 0.9999138
model O 0 0.012257475
. O 0 0.010050205

Treatment O 0 0.02579739
with O 0 0.0068124337
150 O 0 0.0071082143
mg O 0 0.38381833
/ O 0 0.008556045
kg O 0 0.08769562
PDTC B-Chemical 1 0.9999641
before O 0 0.0012240671
and O 0 0.0014507172
following O 0 0.0012753244
status B-Disease 0 0.0044929613
epilepticus I-Disease 0 0.9999584
significantly O 0 0.0026966468
increased O 0 0.0019913067
the O 0 0.0017904704
mortality O 0 0.2236978
rate O 0 0.002647666
to O 0 0.0033034205
100 O 0 0.008035369
% O 0 0.0077784127
. O 0 0.007936932

Administration O 0 0.076037385
of O 0 0.0073229354
50 O 0 0.0062253354
mg O 0 0.4384223
/ O 0 0.009980578
kg O 0 0.18132815
PDTC B-Chemical 1 0.9999844
( O 0 0.006305981
low O 0 0.0024404249
- O 0 0.0023945714
dose O 0 0.015221202
) O 0 0.0016360242
did O 0 0.0005370629
not O 0 0.00050449214
exert O 0 0.00092717464
major O 0 0.0007205866
effects O 0 0.0010266678
on O 0 0.00043140052
the O 0 0.00065877964
development O 0 0.00130101
of O 0 0.0011967717
a O 0 0.0020697264
status B-Disease 0 0.006761493
epilepticus I-Disease 0 0.9999368
or O 0 0.0030027519
the O 0 0.0037175948
mortality O 0 0.43242377
rate O 0 0.0074123433
. O 0 0.009553234

In O 0 0.008646499
vehicle O 0 0.07636818
- O 0 0.007177099
treated O 0 0.0038682574
rats O 0 0.008992255
, O 0 0.0035884872
status B-Disease 0 0.0069386517
epilepticus I-Disease 0 0.9999664
caused O 0 0.004223281
pronounced O 0 0.010466572
neuronal B-Disease 2 0.97333115
damage I-Disease 2 0.97621244
in O 0 0.0013431917
the O 0 0.001535782
piriform O 0 0.5445367
cortex O 0 0.07783228
comprising O 0 0.0014715265
both O 0 0.0021120422
pyramidal O 0 0.89537764
cells O 0 0.006537735
and O 0 0.0072362875
interneurons O 0 0.68701094
. O 0 0.008846654

Low O 0 0.23568746
- O 0 0.016199604
dose O 0 0.16008697
PDTC B-Chemical 1 0.9999342
treatment O 0 0.010821001
almost O 0 0.0031092742
completely O 0 0.0029475086
protected O 0 0.0035956928
from O 0 0.00304646
lesions O 0 0.29276267
in O 0 0.003902728
the O 0 0.0058006123
piriform O 0 0.7252276
cortex O 0 0.28273806
. O 0 0.009966505

A O 0 0.032643687
significant O 0 0.006381974
decrease O 0 0.004122218
in O 0 0.002932218
neuronal O 0 0.16002092
density O 0 0.0025570188
of O 0 0.0018081461
the O 0 0.0014914022
hippocampal O 0 0.7947732
hilar O 0 0.9712394
formation O 0 0.0046258476
was O 0 0.0008844385
identified O 0 0.0006527736
in O 0 0.0008556405
vehicle O 0 0.16864538
- O 0 0.0057500014
and O 0 0.0042455685
PDTC B-Chemical 1 0.9999919
- O 0 0.010006714
treated O 0 0.0028276271
rats O 0 0.0064898864
following O 0 0.0037529098
status B-Disease 0 0.034238663
epilepticus I-Disease 0 0.9998759
. O 0 0.012847783

In O 0 0.007994845
conclusion O 0 0.0054299626
, O 0 0.005736618
the O 0 0.0042515215
NF O 0 0.97647434
- O 0 0.013263226
kappaB O 0 0.4092599
inhibitor O 0 0.18250751
and O 0 0.006230285
antioxidant O 0 0.9998491
PDTC B-Chemical 1 0.99999654
protected O 0 0.01320038
the O 0 0.0019700523
piriform O 0 0.7040641
cortex O 0 0.1768786
, O 0 0.0012779385
whereas O 0 0.00084094185
it O 0 0.0011199324
did O 0 0.0011114156
not O 0 0.0015047486
affect O 0 0.0019468257
hilar O 0 0.97942114
neuronal B-Disease 0 0.9539181
loss I-Disease 0 0.1308036
. O 0 0.010445209

These O 0 0.008934712
data O 0 0.0062176315
might O 0 0.0029488727
indicate O 0 0.0020290406
that O 0 0.001500965
the O 0 0.0013939992
generation O 0 0.0016232863
of O 0 0.0017134903
reactive O 0 0.5016085
oxygen B-Chemical 1 0.993968
species O 0 0.0020407399
and O 0 0.0010923129
activation O 0 0.0017581683
of O 0 0.0015772757
NF O 0 0.99327093
- O 0 0.0055164318
kappaB O 0 0.1326332
plays O 0 0.0005497925
a O 0 0.0006468496
more O 0 0.0005500288
central O 0 0.0010902637
role O 0 0.00039252007
in O 0 0.000723225
seizure B-Disease 2 0.99993134
- O 0 0.005688455
associated O 0 0.001540232
neuronal B-Disease 2 0.94796085
damage I-Disease 2 0.9541112
in O 0 0.00083845627
the O 0 0.000901366
temporal O 0 0.023581434
cortex O 0 0.09608172
as O 0 0.0010795236
compared O 0 0.0009631105
to O 0 0.0017307426
the O 0 0.0032410827
hippocampal O 0 0.8431374
hilus O 0 0.42763722
. O 0 0.009045385

However O 0 0.009391073
, O 0 0.006580635
future O 0 0.0034649877
investigations O 0 0.003186278
are O 0 0.0018699159
necessary O 0 0.0009827287
to O 0 0.000909705
exactly O 0 0.000699007
analyze O 0 0.00051608944
the O 0 0.0007599573
biochemical O 0 0.01495967
mechanisms O 0 0.0021228914
by O 0 0.0016039686
which O 0 0.005764907
PDTC B-Chemical 1 0.9999931
exerted O 0 0.029390806
its O 0 0.004411087
beneficial O 0 0.0063955523
effects O 0 0.0044193496
in O 0 0.002553061
the O 0 0.0043930933
piriform O 0 0.78289247
cortex O 0 0.31247
. O 0 0.0082266005

Anaesthetists O 0 0.032285903
' O 0 0.012236738
nightmare O 0 0.08078986
: O 0 0.008722056
masseter B-Disease 0 0.8252576
spasm I-Disease 2 0.9997614
after O 0 0.0023858775
induction O 0 0.0026742304
in O 0 0.0023573772
an O 0 0.0037809538
undiagnosed O 0 0.119529404
case O 0 0.00479618
of O 0 0.011340128
myotonia B-Disease 0 0.9996929
congenita I-Disease 0 0.6250696
. O 0 0.017436307

We O 0 0.00816191
report O 0 0.007838589
an O 0 0.0053392253
undiagnosed O 0 0.031225618
case O 0 0.0027285367
of O 0 0.003738495
myotonia B-Disease 0 0.9998172
congenita I-Disease 0 0.131895
in O 0 0.0013233841
a O 0 0.0014862019
24 O 0 0.0007284842
- O 0 0.0010223122
year O 0 0.0005982552
- O 0 0.0007916847
old O 0 0.0005610663
previously O 0 0.0005025283
healthy O 0 0.0064943894
primigravida O 0 0.23452221
, O 0 0.0008811085
who O 0 0.001043803
developed O 0 0.000873669
life O 0 0.0024754733
threatening O 0 0.14378405
masseter B-Disease 0 0.95591116
spasm I-Disease 2 0.99996316
following O 0 0.0007279483
a O 0 0.00079651474
standard O 0 0.0005860352
dose O 0 0.002349859
of O 0 0.0010664916
intravenous O 0 0.6829897
suxamethonium B-Chemical 1 0.9997774
for O 0 0.0019008045
induction O 0 0.0032551698
of O 0 0.006005016
anaesthesia O 0 0.47127065
. O 0 0.00910203

Neither O 0 0.008816016
the O 0 0.005237748
patient O 0 0.00468074
nor O 0 0.0028763274
the O 0 0.0022175193
anaesthetist O 0 0.0048454306
was O 0 0.0015210957
aware O 0 0.0014632179
of O 0 0.001451878
the O 0 0.0013617409
diagnosis O 0 0.0046926206
before O 0 0.0011027639
this O 0 0.0017710439
potentially O 0 0.005390401
lethal O 0 0.20070852
complication O 0 0.87090045
occurred O 0 0.011234189
. O 0 0.010262492

Twin O 0 0.035533953
preterm O 0 0.15000533
neonates O 0 0.018993365
with O 0 0.0070098564
cardiac B-Disease 2 0.9563124
toxicity I-Disease 2 0.999231
related O 0 0.0041043144
to O 0 0.0049355254
lopinavir B-Chemical 0 0.9966928
/ I-Chemical 0 0.118826956
ritonavir I-Chemical 1 0.99960285
therapy O 0 0.19824219
. O 0 0.0117422985

We O 0 0.008709417
report O 0 0.008258642
twin O 0 0.01416016
neonates O 0 0.008343089
who O 0 0.0037541722
were O 0 0.0018679162
born O 0 0.0021000607
prematurely O 0 0.003939342
at O 0 0.00076610665
32 O 0 0.0009131282
weeks O 0 0.0005194591
of O 0 0.00079195556
gestation O 0 0.0020900262
to O 0 0.00090124406
a O 0 0.0016882279
mother O 0 0.0077186646
with O 0 0.00287248
human B-Disease 0 0.035282023
immunodeficiency I-Disease 0 0.99895215
virus I-Disease 0 0.88222575
infection I-Disease 2 0.92393893
. O 0 0.014320564

One O 0 0.009895307
of O 0 0.0056164744
the O 0 0.0038335137
twins O 0 0.009976993
developed O 0 0.002838856
complete O 0 0.0016190783
heart B-Disease 0 0.35409132
block I-Disease 0 0.0023872093
and O 0 0.0021093998
dilated B-Disease 2 0.9924959
cardiomyopathy I-Disease 2 0.99999106
related O 0 0.0009780057
to O 0 0.0010874849
lopinavir B-Chemical 0 0.9959461
/ I-Chemical 0 0.022874651
ritonavir I-Chemical 1 0.99977773
therapy O 0 0.028174717
, O 0 0.0010270469
a O 0 0.0008582363
boosted O 0 0.0013062808
protease O 0 0.15206128
- O 0 0.0037446218
inhibitor O 0 0.052517008
agent O 0 0.2328477
, O 0 0.0014647382
while O 0 0.00082687475
the O 0 0.0010349016
other O 0 0.0016152067
twin O 0 0.07630306
developed O 0 0.0069759637
mild O 0 0.93957824
bradycardia B-Disease 2 0.9995845
. O 0 0.010906015

We O 0 0.00833727
recommend O 0 0.004693605
caution O 0 0.004220242
in O 0 0.003005266
the O 0 0.0024938772
use O 0 0.0024632914
of O 0 0.0034656757
lopinavir B-Chemical 0 0.9951149
/ I-Chemical 0 0.036359437
ritonavir I-Chemical 1 0.9993967
in O 0 0.0024455986
the O 0 0.0026988531
immediate O 0 0.0056748325
neonatal O 0 0.017753687
period O 0 0.0065347995
. O 0 0.009188904

When O 0 0.009202002
drugs O 0 0.27547273
disappear O 0 0.008167189
from O 0 0.0037629784
the O 0 0.0029730855
patient O 0 0.0037648773
: O 0 0.0032850276
elimination O 0 0.003387606
of O 0 0.0030673603
intravenous O 0 0.6392963
medication O 0 0.4553598
by O 0 0.007915967
hemodiafiltration O 0 0.6990571
. O 0 0.010996875

Twenty O 0 0.013689549
- O 0 0.007153923
three O 0 0.0026530141
hours O 0 0.0018597479
after O 0 0.0013524108
heart O 0 0.17866875
transplantation O 0 0.14684327
, O 0 0.0022453642
life O 0 0.0048132394
- O 0 0.002282364
threatening O 0 0.084535144
acute O 0 0.94012177
right B-Disease 0 0.069800265
heart I-Disease 0 0.8430311
failure I-Disease 0 0.88606083
was O 0 0.000821162
diagnosed O 0 0.006443039
in O 0 0.0005760795
a O 0 0.0008003593
patient O 0 0.00089513266
requiring O 0 0.0007994766
continuous O 0 0.0011124596
venovenous O 0 0.007379205
hemodiafiltration O 0 0.48646337
( O 0 0.008021549
CVVHDF O 0 0.88703066
) O 0 0.011246581
. O 0 0.008162195

Increasing O 0 0.012683488
doses O 0 0.029510323
of O 0 0.00851024
catecholamines B-Chemical 1 0.99965775
, O 0 0.009010895
sedatives O 0 0.99866545
, O 0 0.0028971692
and O 0 0.0016273739
muscle O 0 0.05352414
relaxants O 0 0.9808987
administered O 0 0.0019439916
through O 0 0.001069245
a O 0 0.0016890174
central O 0 0.0030826856
venous O 0 0.3253201
catheter O 0 0.007348222
were O 0 0.0048195478
ineffective O 0 0.028597651
. O 0 0.0088545075

However O 0 0.01011474
, O 0 0.0073712873
a O 0 0.0052124257
bolus O 0 0.024698546
of O 0 0.0043413965
epinephrine B-Chemical 1 0.998949
injected O 0 0.0023671733
through O 0 0.0017258443
an O 0 0.002216051
alternative O 0 0.0021784927
catheter O 0 0.0069025303
provoked O 0 0.1112872
a O 0 0.011742718
hypertensive B-Disease 2 0.9994165
crisis O 0 0.92472094
. O 0 0.01348047

Thus O 0 0.010052297
, O 0 0.007914372
interference O 0 0.005938169
with O 0 0.003249554
the O 0 0.0025573897
central O 0 0.0038938792
venous O 0 0.32328215
infusion O 0 0.009685668
by O 0 0.0023429294
the O 0 0.0022318421
dialysis O 0 0.034935154
catheter O 0 0.009729505
was O 0 0.0053913314
suspected O 0 0.075375885
. O 0 0.010545195

The O 0 0.009973376
catheters O 0 0.017156169
were O 0 0.0068908646
changed O 0 0.0056444905
, O 0 0.00529515
and O 0 0.0045924596
hemodynamics O 0 0.81855106
stabilized O 0 0.0075223525
at O 0 0.0038999543
lower O 0 0.006930822
catecholamine B-Chemical 1 0.99949
doses O 0 0.42515263
. O 0 0.01356125

When O 0 0.0065653753
the O 0 0.004665818
effects O 0 0.004230856
of O 0 0.0036555056
IV O 0 0.43325114
drugs O 0 0.75537676
are O 0 0.0015621457
inadequate O 0 0.0018372402
in O 0 0.0007500522
patients O 0 0.0018691915
receiving O 0 0.0018638266
CVVHDF O 0 0.8941825
, O 0 0.0009526109
interference O 0 0.0010255128
with O 0 0.0005405938
adjacent O 0 0.00079802616
catheters O 0 0.007817076
resulting O 0 0.00067995815
in O 0 0.0005637116
elimination O 0 0.001206176
of O 0 0.0009025666
the O 0 0.0010503519
drug O 0 0.420813
by O 0 0.0024316865
CVVHDF O 0 0.7613778
should O 0 0.0018967685
be O 0 0.0039889542
suspected O 0 0.060194068
. O 0 0.00867014

Less O 0 0.33150443
frequent O 0 0.04624155
lithium B-Chemical 1 0.99860185
administration O 0 0.36401772
and O 0 0.014562214
lower O 0 0.0134357875
urine O 0 0.5095901
volume O 0 0.035739534
. O 0 0.017829865

OBJECTIVE O 0 0.6007009
: O 0 0.009541933
This O 0 0.0053204303
study O 0 0.0031607465
was O 0 0.0019747484
designed O 0 0.0014605903
to O 0 0.00091990555
determine O 0 0.0004953801
whether O 0 0.00044268515
patients O 0 0.0014161698
maintained O 0 0.00045957242
on O 0 0.00035188918
a O 0 0.0006838574
regimen O 0 0.0014502476
of O 0 0.00094883726
lithium B-Chemical 1 0.99975353
on O 0 0.0003832602
a O 0 0.00074260304
once O 0 0.0005088213
- O 0 0.00069056445
per O 0 0.0002926395
- O 0 0.0005935812
day O 0 0.00030920998
schedule O 0 0.000472694
have O 0 0.00035611275
lower O 0 0.0005129312
urine O 0 0.07306577
volumes O 0 0.0014832569
than O 0 0.0004630717
do O 0 0.0006008175
patients O 0 0.0015702943
receiving O 0 0.0016790854
multiple O 0 0.0027787518
doses O 0 0.018777112
per O 0 0.002623158
day O 0 0.004732902
. O 0 0.007136705

METHOD O 0 0.029214343
: O 0 0.008888637
This O 0 0.0054771546
was O 0 0.0032295838
a O 0 0.00307532
cross O 0 0.00361199
- O 0 0.0030039947
sectional O 0 0.003804664
study O 0 0.00124834
of O 0 0.0011452858
85 O 0 0.0014327788
patients O 0 0.0016686964
from O 0 0.0010433343
a O 0 0.0019598615
lithium B-Chemical 1 0.9994211
clinic O 0 0.0024333703
who O 0 0.0025860448
received O 0 0.0018149534
different O 0 0.0024753178
dose O 0 0.025906797
schedules O 0 0.013561083
. O 0 0.008595976

Patients O 0 0.013636758
were O 0 0.005703594
admitted O 0 0.0059647313
to O 0 0.0026080203
the O 0 0.0020416647
hospital O 0 0.0031144074
for O 0 0.0010980926
measurement O 0 0.000980259
of O 0 0.0018492935
lithium B-Chemical 1 0.9998061
level O 0 0.0012668854
, O 0 0.0028753304
creatinine B-Chemical 1 0.9976926
clearance O 0 0.11902218
, O 0 0.002343478
urine O 0 0.1681008
volume O 0 0.0046042763
, O 0 0.002925178
and O 0 0.0031256867
maximum O 0 0.004488547
osmolality O 0 0.86174434
. O 0 0.009095384

RESULTS O 0 0.03206944
: O 0 0.011590494
Multiple O 0 0.0126107205
daily O 0 0.0073224735
doses O 0 0.014528915
of O 0 0.006485897
lithium B-Chemical 1 0.9995511
were O 0 0.004678786
associated O 0 0.0042328015
with O 0 0.0044810013
higher O 0 0.0053471373
urine O 0 0.50713825
volumes O 0 0.031099303
. O 0 0.011043376

The O 0 0.0068743043
dosing O 0 0.010791186
schedule O 0 0.004693413
, O 0 0.002948808
duration O 0 0.002089165
of O 0 0.0025550616
lithium B-Chemical 1 0.99981934
treatment O 0 0.005840368
, O 0 0.0016676503
and O 0 0.0009403478
daily O 0 0.0015759314
dose O 0 0.0060988595
of O 0 0.0016902206
lithium B-Chemical 1 0.9998074
did O 0 0.0010729044
not O 0 0.0010036272
affect O 0 0.0008710731
maximum O 0 0.0018122663
osmolality O 0 0.8657625
or O 0 0.0047460287
creatinine B-Chemical 1 0.9984888
clearance O 0 0.3698033
. O 0 0.009573523

CONCLUSIONS O 0 0.5518047
: O 0 0.011429113
Urine O 0 0.23400702
volume O 0 0.006479957
can O 0 0.0024543223
be O 0 0.001992978
reduced O 0 0.0016072363
by O 0 0.0015655303
giving O 0 0.0021113069
lithium B-Chemical 1 0.9995931
once O 0 0.0011419676
daily O 0 0.0018713678
and O 0 0.0011771226
/ O 0 0.0023632497
or O 0 0.0010436415
by O 0 0.0014188673
lowering O 0 0.0076404847
the O 0 0.0017562272
total O 0 0.0025372463
daily O 0 0.0066590197
dose O 0 0.035809133
. O 0 0.008328229

Lithium B-Chemical 1 0.99964464
- O 0 0.024659414
induced O 0 0.009217388
polyuria B-Disease 2 0.99941325
seems O 0 0.0033963718
to O 0 0.0021352477
be O 0 0.0018228673
related O 0 0.0012655435
to O 0 0.0015174818
extrarenal O 0 0.9299129
as O 0 0.0021812692
well O 0 0.0020328176
as O 0 0.0027897153
to O 0 0.0037645928
renal O 0 0.9865262
effects O 0 0.03568833
. O 0 0.010792557

Antibacterial O 0 0.37787613
medication O 0 0.13067792
use O 0 0.006203135
during O 0 0.0037913604
pregnancy O 0 0.18068369
and O 0 0.004031354
risk O 0 0.037650116
of O 0 0.0039356127
birth B-Disease 0 0.014931479
defects I-Disease 0 0.0060323505
: O 0 0.0072873426
National O 0 0.010978733
Birth B-Disease 2 0.53764844
Defects I-Disease 2 0.24827777
Prevention O 0 0.18324684
Study O 0 0.11634931
. O 0 0.010306112

OBJECTIVE O 0 0.38814333
: O 0 0.009774692
To O 0 0.00435037
estimate O 0 0.003173657
the O 0 0.0030211937
association O 0 0.0023181725
between O 0 0.0022006147
antibacterial O 0 0.35415
medications O 0 0.68577665
and O 0 0.0051976508
selected O 0 0.0049634976
birth B-Disease 0 0.016194634
defects I-Disease 0 0.011882965
. O 0 0.011046887

DESIGN O 0 0.023266044
, O 0 0.01156628
SETTING O 0 0.011581488
, O 0 0.0051969015
AND O 0 0.00414689
PARTICIPANTS O 0 0.005177966
: O 0 0.002985618
Population O 0 0.0076935785
- O 0 0.0020274075
based O 0 0.0011915297
, O 0 0.0013010832
multisite O 0 0.003854488
, O 0 0.0009820577
case O 0 0.0007527141
- O 0 0.00091480935
control O 0 0.00043697478
study O 0 0.0005283956
of O 0 0.0005957019
women O 0 0.022467397
who O 0 0.0010208897
had O 0 0.00047300363
pregnancies O 0 0.3313423
affected O 0 0.00045209838
by O 0 0.00052445586
1 O 0 0.00041064905
of O 0 0.000376432
more O 0 0.00040423946
than O 0 0.00024949503
30 O 0 0.0002433196
eligible O 0 0.00033170337
major O 0 0.0003622107
birth B-Disease 0 0.0011141171
defects I-Disease 0 0.00055057957
identified O 0 0.00032879203
via O 0 0.00038540503
birth B-Disease 0 0.001586511
defect I-Disease 0 0.00043559418
surveillance O 0 0.00063951954
programs O 0 0.0005388406
in O 0 0.00036387888
10 O 0 0.00041325876
states O 0 0.0007349867
( O 0 0.0005782474
n O 0 0.00046948306
= O 0 0.00054889976
13 O 0 0.0004600563
155 O 0 0.0014045782
) O 0 0.0006129924
and O 0 0.00039966468
control O 0 0.00039618238
women O 0 0.002174247
randomly O 0 0.0002778619
selected O 0 0.00037813614
from O 0 0.000478991
the O 0 0.00054274785
same O 0 0.00054803165
geographical O 0 0.0022075986
regions O 0 0.0017740729
( O 0 0.002376703
n O 0 0.0025689185
= O 0 0.00427334
4941 O 0 0.022851393
) O 0 0.008484135
. O 0 0.007473684

MAIN O 0 0.47137052
EXPOSURE O 0 0.026618514
: O 0 0.006760923
Reported O 0 0.007288919
maternal O 0 0.0046817935
use O 0 0.0021605932
of O 0 0.0023135936
antibacterials O 0 0.96129036
( O 0 0.0026905278
1 O 0 0.0010289268
month O 0 0.0006226885
before O 0 0.000540295
pregnancy O 0 0.032135565
through O 0 0.0008153501
the O 0 0.0009383802
end O 0 0.00086249725
of O 0 0.0016250296
the O 0 0.0021550623
first O 0 0.0031060274
trimester O 0 0.5754616
) O 0 0.01419611
. O 0 0.008932466

MAIN O 0 0.36551115
OUTCOME O 0 0.051817607
MEASURE O 0 0.024980312
: O 0 0.0061758864
Odds O 0 0.024480248
ratios O 0 0.0035225428
( O 0 0.0032678114
ORs O 0 0.0065628807
) O 0 0.001937378
measuring O 0 0.00078372145
the O 0 0.00076568616
association O 0 0.0006221048
between O 0 0.0005931773
antibacterial O 0 0.11720084
use O 0 0.0012449097
and O 0 0.0011829608
selected O 0 0.001053906
birth B-Disease 0 0.0034375465
defects I-Disease 0 0.0020941026
adjusted O 0 0.002285811
for O 0 0.0020479858
potential O 0 0.0048987954
confounders O 0 0.014106304
. O 0 0.0076947953

RESULTS O 0 0.026863033
: O 0 0.009017208
The O 0 0.004400775
reported O 0 0.003727142
use O 0 0.0029156974
of O 0 0.0030386422
antibacterials O 0 0.9119568
increased O 0 0.0032749851
during O 0 0.0018230346
pregnancy O 0 0.44837922
, O 0 0.00353929
peaking O 0 0.010817653
during O 0 0.002050438
the O 0 0.0030946718
third O 0 0.0050838822
month O 0 0.0055800686
. O 0 0.008597654

Sulfonamides B-Chemical 0 0.9919103
were O 0 0.0078488095
associated O 0 0.005551404
with O 0 0.0049711056
anencephaly B-Disease 2 0.9948826
( O 0 0.004214491
adjusted O 0 0.002858621
OR O 0 0.25216258
[ O 0 0.010198653
AOR O 0 0.95806855
] O 0 0.0030308636
= O 0 0.0011727555
3 O 0 0.0005586447
. O 0 0.00039729735
4 O 0 0.00045543027
; O 0 0.0006998989
95 O 0 0.0007398478
% O 0 0.00053319556
confidence O 0 0.0011937773
interval O 0 0.0008395063
[ O 0 0.003835738
CI O 0 0.4610907
] O 0 0.0016659303
, O 0 0.0007535625
1 O 0 0.000500941
. O 0 0.00031072216
3 O 0 0.00039016976
- O 0 0.0005590512
8 O 0 0.00033859478
. O 0 0.00026544687
8 O 0 0.000367466
) O 0 0.00065327954
, O 0 0.00056681386
hypoplastic B-Disease 0 0.08831712
left I-Disease 0 0.0013168148
heart I-Disease 0 0.6353415
syndrome I-Disease 0 0.9285384
( O 0 0.0031904152
AOR O 0 0.94475085
= O 0 0.00086287817
3 O 0 0.00041010854
. O 0 0.0003024545
2 O 0 0.0004248352
; O 0 0.0006584956
95 O 0 0.00078070705
% O 0 0.0006463234
CI O 0 0.08481628
, O 0 0.0006050925
1 O 0 0.00044760574
. O 0 0.0002981301
3 O 0 0.00037842712
- O 0 0.0005458679
7 O 0 0.00033177453
. O 0 0.0002624034
6 O 0 0.00029614876
) O 0 0.0005802985
, O 0 0.0004715907
coarctation B-Disease 0 0.03909072
of I-Disease 0 0.000495488
the I-Disease 0 0.000517866
aorta I-Disease 0 0.123885415
( O 0 0.001517697
AOR O 0 0.89312226
= O 0 0.000791334
2 O 0 0.00042929398
. O 0 0.0002999922
7 O 0 0.00039761525
; O 0 0.00064271275
95 O 0 0.0007743912
% O 0 0.00065165653
CI O 0 0.08311497
, O 0 0.0006176938
1 O 0 0.00045940507
. O 0 0.00030785313
3 O 0 0.00039357107
- O 0 0.0005706664
5 O 0 0.0003217999
. O 0 0.0002790265
6 O 0 0.00031614563
) O 0 0.00062591286
, O 0 0.0005454294
choanal B-Disease 0 0.008885811
atresia I-Disease 0 0.74240124
( O 0 0.0017950534
AOR O 0 0.8860229
= O 0 0.000773658
8 O 0 0.0004074568
. O 0 0.00030302483
0 O 0 0.0005494201
; O 0 0.00066095026
95 O 0 0.00078993634
% O 0 0.00065617956
CI O 0 0.075199045
, O 0 0.0005980653
2 O 0 0.00042269359
. O 0 0.00030522756
7 O 0 0.00039928732
- O 0 0.00058061286
23 O 0 0.000544874
. O 0 0.00029149067
5 O 0 0.0003611928
) O 0 0.00069301046
, O 0 0.0005855037
transverse B-Disease 0 0.0056788856
limb I-Disease 0 0.32291436
deficiency I-Disease 0 0.8935955
( O 0 0.0037807005
AOR O 0 0.954749
= O 0 0.0009294115
2 O 0 0.00045661963
. O 0 0.00030657783
5 O 0 0.00037257373
; O 0 0.0006504835
95 O 0 0.0007706665
% O 0 0.00064451527
CI O 0 0.07495125
, O 0 0.00060570985
1 O 0 0.00045381553
. O 0 0.0003132907
0 O 0 0.0005534677
- O 0 0.0005821333
5 O 0 0.0003262304
. O 0 0.00028477845
9 O 0 0.00041753778
) O 0 0.0006314708
, O 0 0.00048980344
and O 0 0.000491111
diaphragmatic B-Disease 0 0.49368668
hernia I-Disease 0 0.8424307
( O 0 0.0036698163
AOR O 0 0.9445555
= O 0 0.00097098714
2 O 0 0.00050312694
. O 0 0.00035575914
4 O 0 0.00045854977
; O 0 0.0007901984
95 O 0 0.0009752835
% O 0 0.0008982932
CI O 0 0.06890703
, O 0 0.001005873
1 O 0 0.0008753922
. O 0 0.00074332376
1 O 0 0.0012215956
- O 0 0.0018237906
5 O 0 0.0015164338
. O 0 0.0018666408
4 O 0 0.0031775634
) O 0 0.0068700896
. O 0 0.0070160627

Nitrofurantoins B-Chemical 0 0.45528004
were O 0 0.0068964986
associated O 0 0.0051017124
with O 0 0.004593317
anophthalmia B-Disease 0 0.9938678
or O 0 0.0045212214
microphthalmos B-Disease 0 0.99854773
( O 0 0.0077438587
AOR O 0 0.95449466
= O 0 0.0015872159
3 O 0 0.00066486985
. O 0 0.00045513862
7 O 0 0.00053609465
; O 0 0.0008083624
95 O 0 0.0009283379
% O 0 0.0007655315
CI O 0 0.08747793
, O 0 0.00069491554
1 O 0 0.00050933566
. O 0 0.00033881143
1 O 0 0.0004726318
- O 0 0.00057297625
12 O 0 0.00028661572
. O 0 0.00027619844
2 O 0 0.0004018055
) O 0 0.0007018751
, O 0 0.0005923928
hypoplastic B-Disease 0 0.094218604
left I-Disease 0 0.0013507374
heart I-Disease 0 0.6390623
syndrome I-Disease 0 0.9284907
( O 0 0.003134685
AOR O 0 0.9422966
= O 0 0.00084635394
4 O 0 0.00039547356
. O 0 0.00030173446
2 O 0 0.00042622472
; O 0 0.00066411105
95 O 0 0.0007891057
% O 0 0.0006553552
CI O 0 0.08247547
, O 0 0.00061185414
1 O 0 0.00045325983
. O 0 0.00030647233
9 O 0 0.0004431441
- O 0 0.00057897205
9 O 0 0.0004015532
. O 0 0.00029497794
1 O 0 0.00045120713
) O 0 0.0007207416
, O 0 0.0006327878
atrial B-Disease 0 0.939988
septal I-Disease 0 0.02064898
defects I-Disease 0 0.0020280967
( O 0 0.0012188142
AOR O 0 0.8758045
= O 0 0.00079327583
1 O 0 0.0004560728
. O 0 0.00029944413
9 O 0 0.00043856137
; O 0 0.00063590537
95 O 0 0.00076339557
% O 0 0.00064109155
CI O 0 0.08457531
, O 0 0.00061873195
1 O 0 0.00046762254
. O 0 0.00031640855
1 O 0 0.0004646345
- O 0 0.0005980965
3 O 0 0.00035137963
. O 0 0.00028368234
4 O 0 0.000372478
) O 0 0.0006820282
, O 0 0.0005357417
and O 0 0.00052556733
cleft B-Disease 0 0.019749416
lip I-Disease 0 0.07400266
with O 0 0.0009406382
cleft B-Disease 0 0.11605132
palate I-Disease 0 0.32723254
( O 0 0.0033542532
AOR O 0 0.93796986
= O 0 0.0010050093
2 O 0 0.0005319448
. O 0 0.00038524225
1 O 0 0.0005744286
; O 0 0.0008475145
95 O 0 0.0010169075
% O 0 0.0009205631
CI O 0 0.068375744
, O 0 0.0010149819
1 O 0 0.0008775895
. O 0 0.00074212975
2 O 0 0.0011603545
- O 0 0.0018583924
3 O 0 0.0016178133
. O 0 0.0019530664
9 O 0 0.003647158
) O 0 0.0070286277
. O 0 0.007080108

Other O 0 0.017217552
antibacterial O 0 0.1741425
agents O 0 0.10293875
that O 0 0.0026844812
showed O 0 0.0018202785
associations O 0 0.0016507022
included O 0 0.001817494
erythromycins B-Chemical 0 0.99829906
( O 0 0.0031411692
2 O 0 0.0010242591
defects O 0 0.0014032926
) O 0 0.0020528976
, O 0 0.0013739876
penicillins B-Chemical 0 0.9938328
( O 0 0.0014490022
1 O 0 0.00068895106
defect O 0 0.0006141845
) O 0 0.0013820726
, O 0 0.0012166093
cephalosporins B-Chemical 1 0.9979711
( O 0 0.0013933541
1 O 0 0.00083033973
defect O 0 0.0008112148
) O 0 0.0016846154
, O 0 0.0014513734
and O 0 0.0018546175
quinolones B-Chemical 0 0.9884886
( O 0 0.0041959393
1 O 0 0.0033421237
defect O 0 0.0038977575
) O 0 0.008696216
. O 0 0.0075555784

CONCLUSIONS O 0 0.56713015
: O 0 0.011115869
Reassuringly O 0 0.01587642
, O 0 0.006095935
penicillins B-Chemical 0 0.9939017
, O 0 0.006425758
erythromycins B-Chemical 0 0.9972389
, O 0 0.0032229712
and O 0 0.001997164
cephalosporins B-Chemical 1 0.9988952
, O 0 0.0015141923
although O 0 0.0006629014
used O 0 0.0006343881
commonly O 0 0.0013095563
by O 0 0.0011146957
pregnant O 0 0.061024997
women O 0 0.06526829
, O 0 0.0014981854
were O 0 0.0010697793
not O 0 0.0011017999
associated O 0 0.0017340166
with O 0 0.002363811
many O 0 0.0038977114
birth B-Disease 0 0.013989064
defects I-Disease 0 0.009429338
. O 0 0.009045201

Sulfonamides B-Chemical 0 0.9941104
and O 0 0.011164409
nitrofurantoins B-Chemical 0 0.4571823
were O 0 0.0042099147
associated O 0 0.0030611837
with O 0 0.0022785163
several O 0 0.0020618672
birth B-Disease 0 0.0054352884
defects I-Disease 0 0.0028902325
, O 0 0.0023599681
indicating O 0 0.0015470528
a O 0 0.00241368
need O 0 0.002105976
for O 0 0.002451002
additional O 0 0.0034232861
scrutiny O 0 0.014307606
. O 0 0.00936454

Differential O 0 0.01479542
impact O 0 0.0054569007
of O 0 0.00544367
immune O 0 0.3886227
escape O 0 0.081261754
mutations O 0 0.07217684
G145R O 0 0.8385465
and O 0 0.0023019144
P120T O 0 0.13830446
on O 0 0.0006661986
the O 0 0.00087281823
replication O 0 0.0047000027
of O 0 0.0031099676
lamivudine B-Chemical 1 0.9999608
- O 0 0.031399798
resistant O 0 0.015975356
hepatitis B-Chemical 2 0.99999464
B I-Chemical 2 0.9955585
virus I-Chemical 0 0.32573524
e I-Chemical 0 0.018640522
antigen I-Chemical 0 0.11218095
- O 0 0.0037441629
positive O 0 0.00213027
and O 0 0.0031612646
- O 0 0.004703033
negative O 0 0.004699877
strains O 0 0.00726286
. O 0 0.008819958

Immune O 0 0.50931865
escape O 0 0.018282805
variants O 0 0.00643673
of O 0 0.00512741
the O 0 0.006801048
hepatitis B-Disease 2 0.9999838
B I-Disease 2 0.99737287
virus O 0 0.74494284
( O 0 0.02767952
HBV O 0 0.99743325
) O 0 0.0029842276
represent O 0 0.000864731
an O 0 0.0008411879
emerging O 0 0.0009561532
clinical O 0 0.004021842
challenge O 0 0.0008719325
, O 0 0.0008217216
because O 0 0.00038989537
they O 0 0.00046914467
can O 0 0.00040284067
be O 0 0.0005391494
associated O 0 0.000680222
with O 0 0.00081191433
vaccine O 0 0.006059259
escape O 0 0.03830921
, O 0 0.0043968284
HBV O 0 0.99598026
reactivation O 0 0.31960845
, O 0 0.002635969
and O 0 0.0021216108
failure O 0 0.35655075
of O 0 0.0036656898
diagnostic O 0 0.008420363
tests O 0 0.012774435
. O 0 0.008637994

Recent O 0 0.011341433
data O 0 0.0065653627
suggest O 0 0.0031642308
a O 0 0.003405694
preferential O 0 0.0025506017
selection O 0 0.0024716768
of O 0 0.00236556
immune O 0 0.36660042
escape O 0 0.02202225
mutants O 0 0.001105505
in O 0 0.0009565992
distinct O 0 0.0011474284
peripheral O 0 0.032517165
blood O 0 0.023941582
leukocyte O 0 0.29538113
compartments O 0 0.003293577
of O 0 0.003670503
infected O 0 0.004904833
individuals O 0 0.012385511
. O 0 0.00899548

We O 0 0.0070578177
therefore O 0 0.004580956
systematically O 0 0.0026986315
analyzed O 0 0.0019295902
the O 0 0.0015402789
functional O 0 0.0013620061
impact O 0 0.00084297726
of O 0 0.0010154485
the O 0 0.00083932705
most O 0 0.0013281336
prevalent O 0 0.0058412175
immune O 0 0.4779645
escape O 0 0.043611813
variants O 0 0.0024852385
, O 0 0.0011038191
the O 0 0.00060778006
sG145R O 0 0.2550868
and O 0 0.0007743794
sP120T O 0 0.022635445
mutants O 0 0.0004162335
, O 0 0.00053726364
on O 0 0.0002433275
the O 0 0.00040040797
viral O 0 0.01472043
replication O 0 0.0068029324
efficacy O 0 0.0031418472
and O 0 0.000709092
antiviral O 0 0.1721669
drug O 0 0.65312624
susceptibility O 0 0.0031217902
of O 0 0.0008649996
common O 0 0.0015416545
treatment O 0 0.0044746757
- O 0 0.0021642016
associated O 0 0.0007259671
mutants O 0 0.0005129141
with O 0 0.00077310606
resistance O 0 0.0054270104
to O 0 0.0012222276
lamivudine B-Chemical 1 0.99990046
( O 0 0.011368196
LAM B-Chemical 1 0.99848
) O 0 0.005047336
and O 0 0.002764172
/ O 0 0.008336732
or O 0 0.005400811
HBeAg B-Chemical 1 0.9996811
negativity O 0 0.7069925
. O 0 0.010680307

Replication O 0 0.06112105
- O 0 0.011484317
competent O 0 0.0057316083
HBV O 0 0.9171327
strains O 0 0.003511133
with O 0 0.0028000392
sG145R O 0 0.28222555
or O 0 0.0018018539
sP120T O 0 0.048184223
and O 0 0.0020460295
LAM B-Chemical 1 0.9985299
resistance O 0 0.037311453
( O 0 0.0038751515
rtM204I O 0 0.94396293
or O 0 0.0013354339
rtL180M O 0 0.99384403
/ O 0 0.016299259
rtM204V O 0 0.59635335
) O 0 0.0010169473
were O 0 0.00040799705
generated O 0 0.0003218545
on O 0 0.00034783737
an O 0 0.0014326063
HBeAg B-Chemical 1 0.99993086
- O 0 0.0015941627
positive O 0 0.0006480501
and O 0 0.0008591359
an O 0 0.002315494
HBeAg B-Chemical 1 0.9999461
- O 0 0.0020166498
negative O 0 0.0008546912
background O 0 0.00089696364
with O 0 0.0012871933
precore O 0 0.95554256
( O 0 0.0065238066
PC O 0 0.84451133
) O 0 0.0024166715
and O 0 0.0012232559
basal O 0 0.0021172967
core O 0 0.0017702719
promoter O 0 0.0030721743
( O 0 0.0057375915
BCP O 0 0.8049087
) O 0 0.009658815
mutants O 0 0.0058090435
. O 0 0.008411268

The O 0 0.009317021
sG145R O 0 0.17317331
mutation O 0 0.011157663
strongly O 0 0.0045433417
reduced O 0 0.0043480857
HBsAg B-Chemical 1 0.99898785
levels O 0 0.001989328
and O 0 0.0015093724
was O 0 0.0008901568
able O 0 0.0005186015
to O 0 0.00056019955
fully O 0 0.0005167378
restore O 0 0.0004275664
the O 0 0.00053125416
impaired O 0 0.0009935464
replication O 0 0.0042486563
of O 0 0.0017621169
LAM B-Chemical 1 0.99968433
- O 0 0.007654138
resistant O 0 0.0015241199
HBV O 0 0.99186885
mutants O 0 0.000505717
to O 0 0.00041482257
the O 0 0.00043482237
levels O 0 0.00045152643
of O 0 0.0007431389
wild O 0 0.00083264534
- O 0 0.0020585929
type O 0 0.0012137677
HBV O 0 0.996117
, O 0 0.0022485873
and O 0 0.0015137411
PC O 0 0.69651675
or O 0 0.0016612704
BCP O 0 0.8264085
mutations O 0 0.01885832
further O 0 0.0027873246
enhanced O 0 0.0039799255
viral O 0 0.15573327
replication O 0 0.106480494
. O 0 0.0102835735

Although O 0 0.007970971
the O 0 0.0063811094
sP120T O 0 0.029763922
substitution O 0 0.03867495
also O 0 0.0036730655
impaired O 0 0.007366725
HBsAg B-Chemical 1 0.99954045
secretion O 0 0.20780683
, O 0 0.0026638184
it O 0 0.0013094342
did O 0 0.00091354636
not O 0 0.00090778404
enhance O 0 0.00079449714
the O 0 0.0013476072
replication O 0 0.0061147395
of O 0 0.0046783746
LAM B-Chemical 1 0.9989881
- O 0 0.011438363
resistant O 0 0.0065589366
clones O 0 0.0107091945
. O 0 0.009299194

However O 0 0.0090859
, O 0 0.006359565
the O 0 0.0035714747
concomitant O 0 0.0048609134
occurrence O 0 0.005994741
of O 0 0.0063327253
HBeAg B-Chemical 1 0.9999354
negativity O 0 0.8987944
( O 0 0.009140982
PC O 0 0.8888949
/ O 0 0.019389905
BCP O 0 0.8931438
) O 0 0.004090931
, O 0 0.0013411541
sP120T O 0 0.022497462
, O 0 0.000997589
and O 0 0.0008913292
LAM B-Chemical 1 0.9953199
resistance O 0 0.0030340194
resulted O 0 0.0005069207
in O 0 0.0005074675
the O 0 0.0005797684
restoration O 0 0.0010665648
of O 0 0.0010364625
replication O 0 0.0039306455
to O 0 0.0010348097
levels O 0 0.0013211851
of O 0 0.0023299982
wild O 0 0.0030524533
- O 0 0.0073205153
type O 0 0.006936877
HBV O 0 0.99397427
. O 0 0.01231456

In O 0 0.0072986586
all O 0 0.0048720897
clones O 0 0.0045890254
with O 0 0.0028807959
combined O 0 0.0034844056
immune O 0 0.36698508
escape O 0 0.050317086
and O 0 0.0033183405
LAM B-Chemical 1 0.9988967
resistance O 0 0.027082812
mutations O 0 0.023797741
, O 0 0.0013875398
the O 0 0.0008342186
nucleotide B-Chemical 0 0.18443811
analogues O 0 0.84647757
adefovir B-Chemical 0 0.99969554
and O 0 0.0033546202
tenofovir B-Chemical 0 0.99852365
remained O 0 0.0015744383
effective O 0 0.0014526332
in O 0 0.0013161736
suppressing O 0 0.0040822825
viral O 0 0.09329685
replication O 0 0.035746694
in O 0 0.00474143
vitro O 0 0.010308742
. O 0 0.008760775

These O 0 0.008507835
findings O 0 0.006761186
reveal O 0 0.003547688
the O 0 0.0024225102
differential O 0 0.0025496944
impact O 0 0.0013707763
of O 0 0.0018832737
immune O 0 0.4081433
escape O 0 0.027555523
variants O 0 0.00147906
on O 0 0.00047235258
the O 0 0.0006521502
replication O 0 0.003775076
and O 0 0.0007758673
drug O 0 0.45043176
susceptibility O 0 0.002576049
of O 0 0.0009668012
complex O 0 0.0013317304
HBV O 0 0.99652195
mutants O 0 0.000605168
, O 0 0.0006615256
supporting O 0 0.00035125169
the O 0 0.00033486803
need O 0 0.00029417445
of O 0 0.00041189045
close O 0 0.00036731263
surveillance O 0 0.0006746105
and O 0 0.00057442416
treatment O 0 0.0008551457
adjustment O 0 0.00086540764
in O 0 0.00054824556
response O 0 0.0009114914
to O 0 0.0007408733
the O 0 0.0009254312
selection O 0 0.0015047723
of O 0 0.0019850915
distinct O 0 0.0029792702
mutational O 0 0.04299576
patterns O 0 0.005887774
. O 0 0.0084014535

Hemolytic B-Disease 0 0.99493814
anemia I-Disease 2 0.9995433
associated O 0 0.021966916
with O 0 0.012686086
the O 0 0.01079134
use O 0 0.012473448
of O 0 0.020631697
omeprazole B-Chemical 1 0.9994733
. O 0 0.02394793

Omeprazole B-Chemical 0 0.9993197
is O 0 0.006645291
the O 0 0.0036711865
first O 0 0.0024084535
drug O 0 0.16775891
designed O 0 0.0020117117
to O 0 0.0012580911
block O 0 0.0015138887
the O 0 0.0009878615
final O 0 0.0011566383
step O 0 0.0010703473
in O 0 0.0009977239
the O 0 0.0014056688
acid O 0 0.8443737
secretory O 0 0.017431727
process O 0 0.0022531194
within O 0 0.0016939589
the O 0 0.0037550908
parietal O 0 0.73242146
cell O 0 0.042596713
. O 0 0.010048772

It O 0 0.011257477
has O 0 0.00568605
been O 0 0.0042467844
shown O 0 0.002354879
to O 0 0.0019112298
be O 0 0.0016838168
extremely O 0 0.0025637762
effective O 0 0.0013237749
in O 0 0.0008439891
the O 0 0.00081952557
treatment O 0 0.0013630682
of O 0 0.0020374195
peptic B-Disease 0 0.999936
ulcer I-Disease 2 0.9999596
disease I-Disease 0 0.9985347
, O 0 0.030258678
reflux B-Disease 0 0.9997441
esophagitis I-Disease 0 0.9999584
, O 0 0.007547987
and O 0 0.0029303252
the O 0 0.0033011495
Zollinger B-Disease 0 0.932242
- I-Disease 0 0.009772584
Ellison I-Disease 0 0.09466638
syndrome I-Disease 0 0.89569896
. O 0 0.0107328035

Although O 0 0.0072410814
clinical O 0 0.009669256
experience O 0 0.0062703276
with O 0 0.0036688363
omeprazole B-Chemical 1 0.99971396
is O 0 0.002098816
still O 0 0.001223072
limited O 0 0.0010018755
, O 0 0.0011569088
many O 0 0.0008096144
controlled O 0 0.0007042999
studies O 0 0.0007364043
have O 0 0.0006040585
established O 0 0.0009732933
the O 0 0.0008908292
short O 0 0.0010311868
- O 0 0.001888723
term O 0 0.0013717106
safety O 0 0.0034588284
of O 0 0.003192759
this O 0 0.004496316
drug O 0 0.73947144
. O 0 0.009668106

We O 0 0.007956694
report O 0 0.0068674968
the O 0 0.003405479
first O 0 0.0021882216
case O 0 0.001957956
of O 0 0.0018779966
a O 0 0.0021740887
serious O 0 0.1563756
short O 0 0.0014438453
- O 0 0.001915062
term O 0 0.0009999151
adverse O 0 0.868855
reaction O 0 0.014686877
with O 0 0.0013739164
the O 0 0.0012591496
use O 0 0.0017699021
of O 0 0.004274324
omeprazole B-Chemical 1 0.99992526
: O 0 0.16799086
hemolytic B-Disease 2 0.9999436
anemia I-Disease 2 0.9999591
. O 0 0.037859924

The O 0 0.008041259
patient O 0 0.007962583
developed O 0 0.0074244994
weakness O 2 0.98988146
, O 0 0.0099661555
lethargy B-Disease 0 0.99985504
, O 0 0.003611235
and O 0 0.0020917044
shortness B-Disease 0 0.9869222
of I-Disease 0 0.002056799
breath I-Disease 0 0.8004092
2 O 0 0.0012687154
days O 0 0.000910063
after O 0 0.00093023985
starting O 0 0.0018189515
therapy O 0 0.010805995
with O 0 0.0073770746
omeprazole B-Chemical 1 0.99970156
. O 0 0.011659674

Two O 0 0.007440783
weeks O 0 0.0035106174
after O 0 0.0020730174
the O 0 0.0019439796
initiation O 0 0.0016824155
of O 0 0.0016995602
therapy O 0 0.013461276
, O 0 0.0016798619
her O 0 0.0015221707
hematocrit O 0 0.6285044
had O 0 0.00067853276
decreased O 0 0.0008719006
from O 0 0.00057541375
44 O 0 0.0009466881
. O 0 0.0003468539
1 O 0 0.0004149246
% O 0 0.0004218386
to O 0 0.0003196948
20 O 0 0.00041651097
. O 0 0.00029611742
4 O 0 0.00035243054
% O 0 0.0004911101
, O 0 0.00052091014
and O 0 0.0004686503
she O 0 0.00048116886
had O 0 0.0004598454
a O 0 0.00070152665
positive O 0 0.00077978545
direct O 0 0.0012054144
Coombs O 0 0.96514845
antiglobulin O 0 0.9333796
test O 0 0.0023413051
and O 0 0.0022986608
an O 0 0.0035071527
elevated O 0 0.01271387
indirect O 0 0.04322424
bilirubin B-Chemical 1 0.99957055
. O 0 0.012785402

After O 0 0.0074220435
she O 0 0.0065242765
discontinued O 0 0.0106304465
the O 0 0.004562238
omeprazole B-Chemical 1 0.999508
, O 0 0.0053822314
her O 0 0.0046833917
hemoglobin O 0 0.8590795
and O 0 0.004190229
hematocrit O 0 0.80892104
gradually O 0 0.0071909484
returned O 0 0.004265548
to O 0 0.0045739184
normal O 0 0.010290175
. O 0 0.009519998

The O 0 0.0072368155
mechanism O 0 0.0056878207
by O 0 0.004308293
which O 0 0.0039451183
omeprazole B-Chemical 1 0.9996481
caused O 0 0.002576545
the O 0 0.0014152396
patient O 0 0.0021048798
' O 0 0.0018440763
s O 0 0.0023509737
hemolytic B-Disease 2 0.99997044
anemia I-Disease 2 0.99999297
is O 0 0.00328516
uncertain O 0 0.011202666
, O 0 0.0016447947
but O 0 0.00084028736
physicians O 0 0.0018689728
should O 0 0.000571812
be O 0 0.00094168016
alerted O 0 0.0019999726
to O 0 0.0011503631
this O 0 0.0016290668
possible O 0 0.0029762278
adverse O 0 0.9328577
effect O 0 0.008123057
. O 0 0.009287894

Phenylephrine B-Chemical 0 0.99919933
but O 0 0.008935742
not O 0 0.006190414
ephedrine B-Chemical 1 0.99967027
reduces B-Disease 0 0.006200225
frontal I-Disease 0 0.5794347
lobe I-Disease 0 0.48897228
oxygenation I-Disease 0 0.4201901
following O 0 0.0037235797
anesthesia O 0 0.36764973
- O 0 0.010295946
induced O 0 0.012045151
hypotension B-Disease 2 0.9998379
. O 0 0.015441579

BACKGROUND O 0 0.7183239
: O 0 0.015887838
Vasopressor O 0 0.84522885
agents O 0 0.15531394
are O 0 0.0052917874
used O 0 0.0036058142
to O 0 0.0033284617
correct O 0 0.004440793
anesthesia O 0 0.29859012
- O 0 0.011817246
induced O 0 0.014264804
hypotension B-Disease 2 0.99982196
. O 0 0.017501948

We O 0 0.007166957
describe O 0 0.004361736
the O 0 0.0033316805
effect O 0 0.0024601524
of O 0 0.0034882575
phenylephrine B-Chemical 1 0.99990904
and O 0 0.0046431
ephedrine B-Chemical 1 0.9999386
on O 0 0.0011026752
frontal O 0 0.5037314
lobe O 0 0.5129365
oxygenation O 0 0.71635747
( O 0 0.0034825967
S O 0 0.8277891
( O 0 0.002008206
c O 0 0.030277649
) O 0 0.005656753
O O 0 0.99318236
( O 0 0.0022901946
2 O 0 0.0012870951
) O 0 0.0019908056
) O 0 0.0019842102
following O 0 0.0015761153
anesthesia O 0 0.17616306
- O 0 0.006385276
induced O 0 0.008419357
hypotension B-Disease 2 0.99986124
. O 0 0.012552821

METHODS O 0 0.010249578
: O 0 0.006986231
Following O 0 0.0036180373
induction O 0 0.002605267
of O 0 0.0024172002
anesthesia O 0 0.113067165
by O 0 0.0025671513
fentanyl B-Chemical 1 0.99994826
( O 0 0.0026964375
0 O 0 0.0011464121
. O 0 0.00046358732
15 O 0 0.0004479583
mg O 0 0.039332293
kg O 0 0.0062397867
( O 0 0.0013314195
- O 0 0.0011909781
1 O 0 0.0006476108
) O 0 0.0009714451
) O 0 0.00083450874
and O 0 0.0006222382
propofol B-Chemical 1 0.99935514
( O 0 0.0010453477
2 O 0 0.00047029986
. O 0 0.0002926775
0 O 0 0.00046698828
mg O 0 0.04634283
kg O 0 0.0059609786
( O 0 0.0011399948
- O 0 0.001050058
1 O 0 0.0005770824
) O 0 0.0009124168
) O 0 0.00079691556
, O 0 0.00048676226
13 O 0 0.00039785527
patients O 0 0.00064903754
received O 0 0.00051208795
phenylephrine B-Chemical 1 0.99993193
( O 0 0.0012743523
0 O 0 0.0006696876
. O 0 0.00028230445
1 O 0 0.00038111783
mg O 0 0.049017314
iv O 0 0.0025282307
) O 0 0.00078049727
and O 0 0.00040953702
12 O 0 0.00027889168
patients O 0 0.00066423323
received O 0 0.0005417575
ephedrine B-Chemical 1 0.99993193
( O 0 0.0012507329
10 O 0 0.000629386
mg O 0 0.13022974
iv O 0 0.004012168
) O 0 0.0012808765
to O 0 0.00065282296
restore O 0 0.0007186212
mean O 0 0.0010970781
arterial O 0 0.48503456
pressure O 0 0.17075181
( O 0 0.007977392
MAP O 0 0.8960214
) O 0 0.013619041
. O 0 0.008487498

Heart O 0 0.1969822
rate O 0 0.00865633
( O 0 0.009041022
HR O 0 0.4571668
) O 0 0.0070935665
, O 0 0.003958407
MAP O 0 0.82688594
, O 0 0.00344803
stroke B-Disease 2 0.99857163
volume O 0 0.014401444
( O 0 0.002692308
SV O 0 0.8060612
) O 0 0.0020265065
, O 0 0.0009818835
cardiac O 0 0.21226893
output O 0 0.0016220106
( O 0 0.0018276705
CO O 1 0.99544525
) O 0 0.0018550431
, O 0 0.00084062334
and O 0 0.00077561167
frontal O 0 0.21831381
lobe O 0 0.31357467
oxygenation O 0 0.5932226
( O 0 0.0028569498
S O 0 0.7880953
( O 0 0.0021776326
c O 0 0.030461451
) O 0 0.0067960448
O O 0 0.99178725
( O 0 0.0035690689
2 O 0 0.0023987473
) O 0 0.004012913
) O 0 0.0045803776
were O 0 0.004076527
registered O 0 0.006823938
. O 0 0.007690179

RESULTS O 0 0.029041672
: O 0 0.00893214
Induction O 0 0.0062491433
of O 0 0.0036883012
anesthesia O 0 0.07083386
was O 0 0.0019641859
followed O 0 0.0012195627
by O 0 0.0013361832
a B-Disease 0 0.0013919682
decrease I-Disease 0 0.0010034264
in I-Disease 0 0.0010268977
MAP I-Disease 0 0.93548644
, I-Disease 0 0.0027680497
HR I-Disease 0 0.64651173
, I-Disease 0 0.0017033702
SV I-Disease 0 0.7229035
, I-Disease 0 0.0010976944
and I-Disease 0 0.0009524231
CO I-Disease 1 0.985886
concomitant O 0 0.0022975488
with O 0 0.00096136495
an O 0 0.0016774876
elevation O 0 0.31457192
in O 0 0.0016265073
S O 0 0.8944002
( O 0 0.0042044916
c O 0 0.06486043
) O 0 0.0146305105
O O 0 0.99239117
( O 0 0.0073715663
2 O 0 0.005568824
) O 0 0.00961011
. O 0 0.008390953

After O 0 0.0063171024
administration O 0 0.019559802
of O 0 0.0071438644
phenylephrine B-Chemical 1 0.9998784
, O 0 0.009868783
MAP O 0 0.9094441
increased O 0 0.0028158752
( O 0 0.0021463004
51 O 0 0.0022182749
+ O 0 0.0011689361
/ O 0 0.0021208783
- O 0 0.00097238965
12 O 0 0.00039203805
to O 0 0.0004219472
81 O 0 0.0011288197
+ O 0 0.0007271351
/ O 0 0.0015867278
- O 0 0.00093909935
13 O 0 0.000719475
mmHg O 0 0.0039966106
; O 0 0.0010511039
P O 0 0.0112882275
< O 0 0.0007415663
0 O 0 0.0008971026
. O 0 0.0007184021
001 O 0 0.06352441
; O 0 0.0015081706
mean O 0 0.0012315412
+ O 0 0.0023472202
/ O 0 0.006145357
- O 0 0.0063202754
SD O 0 0.396061
) O 0 0.010843052
. O 0 0.008508197

However O 0 0.009540212
, O 0 0.006887315
a O 0 0.0047254777
14 O 0 0.0032595063
% O 0 0.0028701744
( O 0 0.002197992
from O 0 0.0013373696
70 O 0 0.0013836207
+ O 0 0.0013077067
/ O 0 0.0022772665
- O 0 0.0011950481
8 O 0 0.0005620474
% O 0 0.00057740265
to O 0 0.0004285167
60 O 0 0.00055077113
+ O 0 0.0006638592
/ O 0 0.0016094405
- O 0 0.0008896094
7 O 0 0.00045367025
% O 0 0.00060817733
) O 0 0.0008021722
reduction O 0 0.0007165099
in O 0 0.0006161333
S O 0 0.81140953
( O 0 0.0015715027
c O 0 0.036825325
) O 0 0.00606308
O O 0 0.9956155
( O 0 0.0016390263
2 O 0 0.0007366152
) O 0 0.0011455979
( O 0 0.0008613338
P O 0 0.025826387
< O 0 0.00053146883
0 O 0 0.00059560686
. O 0 0.00036288815
05 O 0 0.025438648
) O 0 0.00053720415
followed O 0 0.00025031227
with O 0 0.00031263672
no O 0 0.00027585498
change O 0 0.00047619434
in O 0 0.0005521436
CO O 1 0.9955363
( O 0 0.00096286595
3 O 0 0.00043472456
. O 0 0.00029687327
7 O 0 0.00039173584
+ O 0 0.00052392425
/ O 0 0.0014920215
- O 0 0.00082619744
1 O 0 0.00043822202
. O 0 0.000279449
1 O 0 0.0003421019
to O 0 0.00029795847
3 O 0 0.00037250554
. O 0 0.00030647643
4 O 0 0.00040969517
+ O 0 0.0005890193
/ O 0 0.0013868104
- O 0 0.0009341337
0 O 0 0.0007129867
. O 0 0.00046840755
9 O 0 0.00069760747
l O 0 0.0013342439
min O 0 0.001517638
( O 0 0.0025609767
- O 0 0.0032915943
1 O 0 0.0032324092
) O 0 0.0061138477
) O 0 0.008556927
. O 0 0.007613673

The O 0 0.0073488173
administration O 0 0.02197874
of O 0 0.006055245
ephedrine B-Chemical 1 0.99980825
led O 0 0.0031809302
to O 0 0.001461544
a O 0 0.0015248442
similar O 0 0.00076135516
increase O 0 0.0009788742
in O 0 0.0009826885
MAP O 0 0.97685766
( O 0 0.0017142211
53 O 0 0.0020653836
+ O 0 0.00085785857
/ O 0 0.0018144387
- O 0 0.0008194404
9 O 0 0.00041668804
to O 0 0.0003448331
79 O 0 0.0008641676
+ O 0 0.00060428825
/ O 0 0.0014504935
- O 0 0.0007962305
8 O 0 0.00044431025
mmHg O 0 0.0032091835
; O 0 0.000772377
P O 0 0.011978016
< O 0 0.00048910687
0 O 0 0.0005754862
. O 0 0.00038568687
001 O 0 0.15361494
) O 0 0.00091414806
, O 0 0.0006551248
restored O 0 0.0006423122
CO O 1 0.99122214
( O 0 0.0008838118
3 O 0 0.00043244884
. O 0 0.00030411477
2 O 0 0.00042327383
+ O 0 0.00053836365
/ O 0 0.0015362274
- O 0 0.0008214336
1 O 0 0.00042345785
. O 0 0.0002630617
2 O 0 0.00030187142
to O 0 0.00027334015
5 O 0 0.00031914545
. O 0 0.0002795138
0 O 0 0.00052453036
+ O 0 0.00052242016
/ O 0 0.0014534717
- O 0 0.00079134334
1 O 0 0.00042109413
. O 0 0.00027284154
3 O 0 0.00032029368
l O 0 0.0006385871
min O 0 0.0006225081
( O 0 0.0009663675
- O 0 0.0010475498
1 O 0 0.000710813
) O 0 0.0012110545
) O 0 0.0012373109
, O 0 0.00092889403
and O 0 0.00095354754
preserved O 0 0.0022709072
S O 0 0.79002243
( O 0 0.003333228
c O 0 0.047320146
) O 0 0.011997682
O O 0 0.9914852
( O 0 0.0070939753
2 O 0 0.005447182
) O 0 0.009447761
. O 0 0.008289583

CONCLUSIONS O 0 0.45406276
: O 0 0.008403937
The O 0 0.0036560928
utilization O 0 0.0035569745
of O 0 0.0032490506
phenylephrine B-Chemical 1 0.9997881
to O 0 0.0016965873
correct O 0 0.0021399986
hypotension B-Disease 2 0.99995875
induced O 0 0.0018585462
by O 0 0.0012702974
anesthesia O 0 0.11524507
has O 0 0.00051332935
a O 0 0.00071599823
negative O 0 0.0006846514
impact O 0 0.00051150314
on O 0 0.0005450576
S O 0 0.89131856
( O 0 0.002105165
c O 0 0.05443794
) O 0 0.008247971
O O 0 0.9961784
( O 0 0.001679872
2 O 0 0.0007138093
) O 0 0.0009512669
while O 0 0.00060187466
ephedrine B-Chemical 1 0.99988604
maintains O 0 0.0011201864
frontal O 0 0.3150723
lobe O 0 0.25566825
oxygenation O 0 0.21456242
potentially O 0 0.0018942261
related O 0 0.0010210575
to O 0 0.0014442034
an O 0 0.0027402916
increase O 0 0.0025505894
in O 0 0.005336007
CO O 1 0.992424
. O 0 0.009509749

Prolonged O 0 0.117856234
elevation O 0 0.13474126
of O 0 0.005486037
plasma O 0 0.054467253
argatroban B-Chemical 1 0.998243
in O 0 0.001924768
a O 0 0.0020345342
cardiac O 0 0.28962973
transplant O 0 0.16421284
patient O 0 0.0016295788
with O 0 0.00094049476
a O 0 0.001262357
suspected O 0 0.017739406
history O 0 0.041351095
of O 0 0.0038116828
heparin B-Chemical 1 0.9995654
- O 0 0.026362518
induced O 0 0.007714207
thrombocytopenia B-Disease 2 0.99990296
with O 0 0.04163476
thrombosis B-Disease 2 0.99973637
. O 0 0.013936609

BACKGROUND O 0 0.727639
: O 0 0.011500091
Direct O 0 0.028966881
thrombin O 0 0.9354759
inhibitors O 0 0.5759897
( O 0 0.005825177
DTIs O 0 0.29738182
) O 0 0.0018191715
provide O 0 0.00060099293
an O 0 0.00074061425
alternative O 0 0.0005838756
method O 0 0.00071884796
of O 0 0.0006818342
anticoagulation O 0 0.7122173
for O 0 0.00041110517
patients O 0 0.0013669293
with O 0 0.0005038424
a O 0 0.0007615784
history O 0 0.016778456
of O 0 0.0016018854
heparin B-Chemical 1 0.9997336
- O 0 0.016686779
induced O 0 0.0028052323
thrombocytopenia B-Disease 2 0.9999825
( O 0 0.021334894
HIT B-Disease 2 0.9993949
) O 0 0.002516198
or O 0 0.0009106997
HIT B-Disease 2 0.9969056
with O 0 0.0014929468
thrombosis B-Disease 2 0.999902
( O 0 0.009262187
HITT B-Disease 2 0.9993635
) O 0 0.0023752768
undergoing O 0 0.0015888936
cardiopulmonary O 0 0.0057026395
bypass O 0 0.0053774905
( O 0 0.006052087
CPB O 0 0.42817932
) O 0 0.011343658
. O 0 0.0085204905

In O 0 0.0073337737
the O 0 0.005077016
following O 0 0.0036074747
report O 0 0.0053636087
, O 0 0.0029287683
a O 0 0.0022230633
65 O 0 0.0021176867
- O 0 0.0017684292
year O 0 0.0010054224
- O 0 0.0012149208
old O 0 0.0008985231
critically B-Disease 0 0.003559585
ill I-Disease 0 0.47585428
patient O 0 0.0011984817
with O 0 0.000652562
a O 0 0.0008770465
suspected O 0 0.01740243
history O 0 0.03502769
of O 0 0.002116501
HITT B-Disease 2 0.9997342
was O 0 0.0009488445
administered O 0 0.0017400408
argatroban B-Chemical 1 0.9970149
for O 0 0.00085353834
anticoagulation O 0 0.50331396
on O 0 0.0010248716
bypass O 0 0.0032119942
during O 0 0.0022697216
heart O 0 0.68153405
transplantation O 0 0.3877593
. O 0 0.009340598

The O 0 0.006714467
patient O 0 0.005549491
required O 0 0.0024930232
massive O 0 0.009549783
transfusion O 0 0.07898174
support O 0 0.0020606685
( O 0 0.0019096815
55 O 0 0.0011518219
units O 0 0.00069349597
of O 0 0.0008035766
red O 0 0.0027222615
blood O 0 0.015085553
cells O 0 0.0019041335
, O 0 0.0008982118
42 O 0 0.0006354149
units O 0 0.00037746152
of O 0 0.00052332407
fresh O 0 0.0014536668
- O 0 0.0012526136
frozen O 0 0.0013424794
plasma O 0 0.012802326
, O 0 0.0006712541
40 O 0 0.00039667028
units O 0 0.00031997933
of O 0 0.00050099654
cryoprecipitate O 0 0.67808604
, O 0 0.0007646912
40 O 0 0.00041370693
units O 0 0.00033239127
of O 0 0.00052307494
platelets O 0 0.2948527
, O 0 0.0008424392
and O 0 0.00050334976
three O 0 0.00034020707
doses O 0 0.004265317
of O 0 0.0009244454
recombinant O 0 0.0019146812
Factor O 1 0.996642
VIIa O 1 0.9856743
) O 0 0.0025845869
for O 0 0.0009941033
severe O 0 0.06689321
intraoperative B-Disease 0 0.025977734
and I-Disease 0 0.0044060196
postoperative I-Disease 0 0.45111692
bleeding I-Disease 2 0.99898
. O 0 0.011590225

STUDY O 0 0.025388695
DESIGN O 0 0.0144284265
AND O 0 0.007051849
METHODS O 0 0.0058995835
: O 0 0.0049696835
Plasma O 0 0.0120226
samples O 0 0.0019594503
from O 0 0.0013324863
before O 0 0.00075110164
and O 0 0.0008921453
after O 0 0.0005322344
CPB O 0 0.047213748
were O 0 0.00061331055
analyzed O 0 0.00050066935
postoperatively O 0 0.00080727827
for O 0 0.0005149097
argatroban B-Chemical 1 0.9961189
concentration O 0 0.001599628
using O 0 0.0007303004
a O 0 0.0011137223
modified O 0 0.0014665044
ecarin O 0 0.11825119
clotting O 0 0.51759654
time O 0 0.0018398907
( O 0 0.0046820627
ECT O 0 0.98561144
) O 0 0.007907434
assay O 0 0.007862224
. O 0 0.008461655

RESULTS O 0 0.027049122
: O 0 0.008331286
Unexpectedly O 0 0.0059335385
high O 0 0.0033562402
concentrations O 0 0.0034299868
of O 0 0.002508856
argatroban B-Chemical 1 0.9981724
were O 0 0.0011943352
measured O 0 0.00059678993
in O 0 0.0005681228
these O 0 0.0006925034
samples O 0 0.0008045756
( O 0 0.00094840623
range O 0 0.0008714027
, O 0 0.0007764225
0 O 0 0.0007172884
- O 0 0.00062182266
32 O 0 0.00047367098
microg O 0 0.0009052459
/ O 0 0.0018967864
mL O 0 0.004559339
) O 0 0.0010318093
, O 0 0.00054025743
and O 0 0.00040352906
a O 0 0.0005161116
prolonged O 0 0.001804206
plasma O 0 0.02120624
argatroban B-Chemical 1 0.99808633
half O 0 0.00042158092
life O 0 0.0022502667
( O 0 0.0010216638
t O 0 0.0038802905
( O 0 0.0008051329
1 O 0 0.0005174915
/ O 0 0.0010042561
2 O 0 0.00047680005
) O 0 0.00074172387
) O 0 0.0005958379
of O 0 0.00043490194
514 O 0 0.004728645
minutes O 0 0.0002608536
was O 0 0.00030762076
observed O 0 0.00026931375
( O 0 0.0005861279
published O 0 0.0003713985
elimination O 0 0.0010070216
t O 0 0.0036714084
( O 0 0.000848723
1 O 0 0.00055412384
/ O 0 0.001052749
2 O 0 0.00049832737
) O 0 0.00070628
is O 0 0.0004167602
39 O 0 0.00081133435
- O 0 0.0006566162
51 O 0 0.0006654771
minutes O 0 0.00039739732
[ O 0 0.0009976974
< O 0 0.00059828203
or O 0 0.0006268522
= O 0 0.0011088549
181 O 0 0.0034705224
minutes O 0 0.00087950774
with O 0 0.001831858
hepatic B-Disease 0 0.9954724
impairment I-Disease 0 0.96085113
] O 0 0.03471609
) O 0 0.015064963
. O 0 0.008443367

CONCLUSIONS O 0 0.4276458
: O 0 0.008065036
Correlation O 0 0.004290165
of O 0 0.0033098734
plasma O 0 0.024646278
argatroban B-Chemical 1 0.9977342
concentration O 0 0.0026570796
versus O 0 0.00091979903
the O 0 0.0007082455
patient O 0 0.0010355446
' O 0 0.00084322627
s O 0 0.0006871399
coagulation O 0 0.55351436
variables O 0 0.001256466
and O 0 0.00057752867
clinical O 0 0.0019607546
course O 0 0.00051326817
suggest O 0 0.00027547183
that O 0 0.00036770676
prolonged O 0 0.0047449972
elevated O 0 0.0035926807
levels O 0 0.00055113615
of O 0 0.00092170486
plasma O 0 0.09266334
argatroban B-Chemical 1 0.9993056
may O 0 0.0007283335
have O 0 0.0006674665
contributed O 0 0.0012322452
to O 0 0.0007880447
the O 0 0.0010658453
patient O 0 0.0021579477
' O 0 0.0027656064
s O 0 0.0034337554
extended O 0 0.004509467
coagulopathy B-Disease 2 0.9996087
. O 0 0.011722511

Because O 0 0.0076354533
DTIs O 0 0.02961242
do O 0 0.0034604243
not O 0 0.002428957
have O 0 0.001694416
reversal O 0 0.0040927744
agents O 0 0.15021044
, O 0 0.0018918819
surgical O 0 0.0017621757
teams O 0 0.0015461956
and O 0 0.00088018895
transfusion O 0 0.07650356
services O 0 0.0015156239
should O 0 0.0003258596
remain O 0 0.00039764633
aware O 0 0.00048630175
of O 0 0.00053085334
the O 0 0.0004779971
possibility O 0 0.0004943678
of O 0 0.0008991607
massive O 0 0.051862415
transfusion O 0 0.22894846
events O 0 0.047421217
during O 0 0.0013375073
anticoagulation O 0 0.7927675
with O 0 0.003198998
these O 0 0.005629568
agents O 0 0.45371455
. O 0 0.009808633

This O 0 0.01061047
is O 0 0.00525385
the O 0 0.003479328
first O 0 0.0023729752
report O 0 0.0034546577
to O 0 0.0016019272
measure O 0 0.0010819379
plasma O 0 0.03325064
argatroban B-Chemical 1 0.9988944
concentration O 0 0.003012863
in O 0 0.0011591382
the O 0 0.0011609846
context O 0 0.0010282913
of O 0 0.0023037854
CPB O 0 0.39538726
and O 0 0.0045203823
extended O 0 0.006041938
coagulopathy B-Disease 2 0.9997086
. O 0 0.013079153

The O 0 0.006588492
effects O 0 0.0052678087
of O 0 0.0035638309
the O 0 0.0025180783
adjunctive O 0 0.09352614
bupropion B-Chemical 1 0.99996996
on O 0 0.0011941548
male O 0 0.059947815
sexual B-Disease 2 0.9835877
dysfunction I-Disease 2 0.9985322
induced O 0 0.0020571435
by O 0 0.0012890557
a O 0 0.0017024663
selective B-Chemical 0 0.047280934
serotonin I-Chemical 1 0.9999378
reuptake I-Chemical 0 0.9998747
inhibitor I-Chemical 0 0.09242581
: O 0 0.0014001076
a O 0 0.0008647853
double O 0 0.0008512621
- O 0 0.0015333403
blind O 0 0.005953199
placebo O 0 0.10032409
- O 0 0.002224189
controlled O 0 0.0016550762
and O 0 0.0026359379
randomized O 0 0.0043881405
study O 0 0.006139387
. O 0 0.0073178895

OBJECTIVE O 0 0.43065202
: O 0 0.0073140906
To O 0 0.002889394
determine O 0 0.001513558
the O 0 0.0016450156
safety O 0 0.0024342812
and O 0 0.0012916125
efficacy O 0 0.0020943475
of O 0 0.0012683957
adjunctive O 0 0.2392367
bupropion B-Chemical 1 0.9999927
sustained O 0 0.12834308
- O 0 0.0064660776
release O 0 0.09382186
( O 0 0.0018828094
SR O 0 0.8578564
) O 0 0.0010215056
on O 0 0.00031718324
male O 0 0.011517223
sexual B-Disease 2 0.9676945
dysfunction I-Disease 2 0.9990909
( O 0 0.0086859735
SD B-Disease 0 0.8142859
) O 0 0.0016405227
induced O 0 0.00058402447
by O 0 0.0006329764
a O 0 0.0009666194
selective B-Chemical 0 0.02683961
serotonin I-Chemical 1 0.99993825
reuptake I-Chemical 0 0.9999068
inhibitor I-Chemical 0 0.24706635
( O 0 0.007635306
SSRI B-Chemical 0 0.99997056
) O 0 0.0017554573
, O 0 0.00062349264
as O 0 0.0004636452
SD B-Disease 0 0.18256147
is O 0 0.00039104142
a O 0 0.00055332604
common O 0 0.00076582376
side O 0 0.10650419
- O 0 0.0013681586
effect O 0 0.0005209002
of O 0 0.0011498486
SSRIs B-Chemical 0 0.99988294
and O 0 0.0007479431
the O 0 0.00064856914
most O 0 0.0010238166
effective O 0 0.0011947659
treatments O 0 0.002677638
have O 0 0.0014769109
yet O 0 0.0024219584
to O 0 0.002318682
be O 0 0.0037228793
determined O 0 0.0043273047
. O 0 0.0077385437

PATIENTS O 0 0.016354263
AND O 0 0.00889202
METHODS O 0 0.0065433113
: O 0 0.0047410354
The O 0 0.0024589943
randomized O 0 0.0021087544
sample O 0 0.001782506
consisted O 0 0.0013654942
of O 0 0.0017291583
234 O 0 0.043663714
euthymic O 0 0.84782124
men O 0 0.07368138
who O 0 0.0024750421
were O 0 0.001534899
receiving O 0 0.0023711424
some O 0 0.0024682495
type O 0 0.0038167557
of O 0 0.010793224
SSRI B-Chemical 0 0.9998118
. O 0 0.011368814

The O 0 0.008542522
men O 0 0.02119451
were O 0 0.003907864
randomly O 0 0.0020086018
assigned O 0 0.0016776369
to O 0 0.0019242255
bupropion B-Chemical 1 0.99996233
SR O 0 0.9628848
( O 0 0.0019584687
150 O 0 0.0013752484
mg O 0 0.055131532
twice O 0 0.00066174945
daily O 0 0.0010797267
, O 0 0.00082867866
117 O 0 0.0023025472
) O 0 0.0009299907
or O 0 0.0005811676
placebo O 0 0.05121131
( O 0 0.0010330348
twice O 0 0.0008228469
daily O 0 0.0015128613
, O 0 0.0015690192
117 O 0 0.0039299587
) O 0 0.0023684767
for O 0 0.0017263924
12 O 0 0.002482274
weeks O 0 0.0034064355
. O 0 0.0062568053

Efficacy O 0 0.031416886
was O 0 0.0062085344
evaluated O 0 0.0037935472
using O 0 0.0030492882
the O 0 0.002768325
Clinical O 0 0.107012965
Global O 0 0.05672703
Impression O 0 0.59354866
- O 0 0.0035232964
Sexual O 0 0.6623034
Function O 0 0.11555375
( O 0 0.002236512
CGI O 0 0.6622417
- O 0 0.0018422517
SF O 0 0.20350932
; O 0 0.0010559633
the O 0 0.00044245605
primary O 0 0.0005848226
outcome O 0 0.0013083353
measure O 0 0.00039908278
) O 0 0.0014483221
, O 0 0.0007183546
the O 0 0.0005254849
International O 0 0.002102206
Index O 0 0.0016101819
of O 0 0.00073047366
Erectile O 0 0.56275475
Function O 0 0.112040974
( O 0 0.0015131709
IIEF O 0 0.5621995
) O 0 0.0015501871
, O 0 0.0011376141
Arizona O 0 0.04710687
Sexual O 0 0.66996
Experience O 0 0.4228601
Scale O 0 0.98902017
( O 0 0.0027500282
ASEX O 0 0.99936384
) O 0 0.0017107283
, O 0 0.0009994175
and O 0 0.0010661291
Erectile B-Disease 2 0.9122193
Dysfunction I-Disease 2 0.86521345
Inventory O 0 0.24847928
of O 0 0.0011994392
Treatment O 0 0.13934776
Satisfaction O 0 0.19018228
( O 0 0.003293219
EDITS O 0 0.8719659
) O 0 0.002695975
( O 0 0.0021793852
secondary O 0 0.0034700788
outcome O 0 0.006561352
measures O 0 0.0049502
) O 0 0.011013981
. O 0 0.007933985

Participants O 0 0.023001628
were O 0 0.015869005
followed O 0 0.012591088
biweekly O 0 0.017792754
during O 0 0.012095153
study O 0 0.016348768
period O 0 0.01617201
. O 0 0.0202598

RESULTS O 0 0.021741185
: O 0 0.006887902
After O 0 0.002717508
12 O 0 0.0019361823
weeks O 0 0.0012755538
of O 0 0.0014202413
treatment O 0 0.0017454464
, O 0 0.0013129164
the O 0 0.00076453126
mean O 0 0.00080953457
( O 0 0.001329015
sd O 0 0.012173128
) O 0 0.0012545437
scores O 0 0.000849259
for O 0 0.0005748522
CGI O 0 0.7126724
- O 0 0.0013858842
SF O 0 0.1278096
were O 0 0.00051057927
significantly O 0 0.0006117363
lower O 0 0.00057240686
, O 0 0.0007553214
i O 0 0.0019737189
. O 0 0.0003661718
e O 0 0.0010401114
. O 0 0.00032256654
better O 0 0.00041158512
, O 0 0.0004954835
in O 0 0.0003176659
patients O 0 0.0010138516
on O 0 0.0003848486
bupropion B-Chemical 1 0.99998736
SR O 0 0.93864036
, O 0 0.0007708197
at O 0 0.00029833423
2 O 0 0.00038712056
. O 0 0.00026460242
4 O 0 0.0003352932
( O 0 0.0004967637
1 O 0 0.00039422707
. O 0 0.00027150646
2 O 0 0.0003873598
) O 0 0.00062386645
, O 0 0.0004190898
than O 0 0.00021856316
in O 0 0.00027232824
the O 0 0.00034178048
placebo O 0 0.03334662
group O 0 0.00063518906
, O 0 0.0006258565
at O 0 0.00030570867
3 O 0 0.0003954594
. O 0 0.0003222844
9 O 0 0.0004966411
( O 0 0.0006765337
1 O 0 0.0005940693
. O 0 0.0004905541
1 O 0 0.0008306364
) O 0 0.0015042273
( O 0 0.001705048
P O 0 0.030862927
= O 0 0.0023423263
0 O 0 0.002513134
. O 0 0.0024424153
01 O 0 0.0121727735
) O 0 0.0075845122
. O 0 0.0073748296

Men O 0 0.24392046
who O 0 0.009281386
received O 0 0.0052777072
bupropion B-Chemical 1 0.99985516
had O 0 0.0023318322
a O 0 0.0019221058
significant O 0 0.0012417884
increase O 0 0.0007502661
in O 0 0.00066776236
the O 0 0.00063511287
total O 0 0.0007448032
IIEF O 0 0.2904418
score O 0 0.0010064911
( O 0 0.0008940714
54 O 0 0.0010005843
. O 0 0.00032421848
4 O 0 0.00034319787
% O 0 0.0004476791
vs O 0 0.00068522745
1 O 0 0.00047323454
. O 0 0.000322069
2 O 0 0.00042734478
% O 0 0.0006094763
; O 0 0.0008959767
P O 0 0.019424578
= O 0 0.0007772349
0 O 0 0.0006900575
. O 0 0.00046411215
003 O 0 0.037191924
) O 0 0.0010065688
, O 0 0.00073689356
and O 0 0.0006421889
in O 0 0.00062146096
the O 0 0.00075144955
five O 0 0.00079270155
different O 0 0.0012552417
domains O 0 0.0020281768
of O 0 0.003598942
the O 0 0.0054702032
IIEF O 0 0.66764563
. O 0 0.0083562285

Total O 0 0.01699772
ASEX O 0 0.9885006
scores O 0 0.0057217926
were O 0 0.0029696596
significantly O 0 0.002427497
lower O 0 0.0019296583
, O 0 0.0019507887
i O 0 0.0033823506
. O 0 0.00079789344
e O 0 0.0017193796
. O 0 0.0005543967
better O 0 0.00064874993
, O 0 0.0007580145
among O 0 0.00066050445
men O 0 0.052670583
who O 0 0.0010512887
received O 0 0.0006428895
bupropion B-Chemical 1 0.99997497
than O 0 0.00040375107
placebo O 0 0.10908097
, O 0 0.00058837293
at O 0 0.0002672786
15 O 0 0.0002997229
. O 0 0.00025156548
5 O 0 0.0003045015
( O 0 0.0004539631
4 O 0 0.00031486456
. O 0 0.0002596168
3 O 0 0.00033853683
) O 0 0.0005585366
vs O 0 0.0006194701
21 O 0 0.00052250794
. O 0 0.0003233258
5 O 0 0.00040404487
( O 0 0.00062368275
4 O 0 0.00048248607
. O 0 0.00046837114
7 O 0 0.00071753457
) O 0 0.001453343
( O 0 0.001713368
P O 0 0.029050011
= O 0 0.0024261728
0 O 0 0.0026481661
. O 0 0.0026819368
002 O 0 0.12724666
) O 0 0.007993544
. O 0 0.0075994404

The O 0 0.009650755
EDITS O 0 0.3073471
scores O 0 0.0049515297
were O 0 0.0029855883
67 O 0 0.0035737697
. O 0 0.0014058233
4 O 0 0.0011785295
( O 0 0.001282008
10 O 0 0.00082108384
. O 0 0.0005580676
2 O 0 0.00060946547
) O 0 0.0007630239
for O 0 0.00037008198
the O 0 0.00059211056
bupropion B-Chemical 1 0.99996233
and O 0 0.00072507374
36 O 0 0.00060772017
. O 0 0.0003265416
3 O 0 0.00039746857
( O 0 0.0005424031
11 O 0 0.00050441
. O 0 0.0003136855
7 O 0 0.00040787572
) O 0 0.0006072981
for O 0 0.00034362482
the O 0 0.00054067315
placebo O 0 0.036118086
group O 0 0.0013788121
( O 0 0.0022903897
P O 0 0.08862845
= O 0 0.002562261
0 O 0 0.0026905136
. O 0 0.0026371428
001 O 0 0.2108233
) O 0 0.008180346
. O 0 0.007518305

The O 0 0.012987106
ASEX O 0 0.9826785
score O 0 0.008590836
and O 0 0.006775586
CGI O 0 0.6060381
- O 0 0.006062419
SF O 0 0.09790066
score O 0 0.0032417143
were O 0 0.0022718692
correlated O 0 0.0020484144
( O 0 0.0039239046
P O 0 0.09757771
= O 0 0.0041607125
0 O 0 0.003959313
. O 0 0.0036450513
003 O 0 0.07806392
) O 0 0.009893859
. O 0 0.008914425

In O 0 0.007784226
linear O 0 0.0073525263
regression O 0 0.009081475
analyses O 0 0.004446741
the O 0 0.0035007824
CGI O 0 0.71847564
- O 0 0.003928959
SF O 0 0.14097911
score O 0 0.0017444304
was O 0 0.00093955576
not O 0 0.00073725317
affected O 0 0.00067668
significantly O 0 0.0009310232
by O 0 0.0007928776
the O 0 0.0006360254
duration O 0 0.00093599694
of O 0 0.0014694378
SD B-Disease 0 0.621282
, O 0 0.0018345255
type O 0 0.0015744203
of O 0 0.003425942
SSRI B-Chemical 0 0.9998565
used O 0 0.0034811108
and O 0 0.0055923164
age O 0 0.014014251
. O 0 0.00883974

CONCLUSIONS O 0 0.7571468
: O 0 0.023231087
Bupropion B-Chemical 0 0.9996196
is O 0 0.0055181794
an O 0 0.0047108065
effective O 0 0.0036210557
treatment O 0 0.004143464
for O 0 0.0029190178
male O 0 0.03354706
SD B-Disease 0 0.63035303
induced O 0 0.0077097006
by O 0 0.016356707
SSRIs B-Chemical 0 0.9995995
. O 0 0.012190985

These O 0 0.011033096
results O 0 0.0071514472
provide O 0 0.0048337067
empirical O 0 0.0055912086
support O 0 0.0035349068
for O 0 0.0027402183
conducting O 0 0.003376086
a O 0 0.0038458891
further O 0 0.0038125394
study O 0 0.005858142
of O 0 0.011470338
bupropion B-Chemical 1 0.9998845
. O 0 0.014073488

Prevention O 0 0.029060496
of O 0 0.010242045
seizures B-Disease 2 0.9997633
and O 0 0.0058788443
reorganization O 0 0.013187571
of O 0 0.0028208308
hippocampal O 0 0.67252105
functions O 0 0.0019963917
by O 0 0.0014356967
transplantation O 0 0.083641544
of O 0 0.0018513675
bone O 0 0.53497565
marrow O 0 0.8086035
cells O 0 0.005327066
in O 0 0.00138605
the O 0 0.0017464858
acute O 0 0.91641957
phase O 0 0.0059980294
of O 0 0.0049852678
experimental O 0 0.019461751
epilepsy B-Disease 2 0.99982375
. O 0 0.012883338

In O 0 0.00754778
this O 0 0.0051995893
study O 0 0.004219688
, O 0 0.002979718
we O 0 0.0013246717
investigated O 0 0.0011183993
the O 0 0.0010964245
therapeutic O 0 0.004293672
potential O 0 0.0015861146
of O 0 0.0018037192
bone O 0 0.6498902
marrow O 0 0.9247761
mononuclear O 0 0.8807856
cells O 0 0.02802064
( O 0 0.0044956645
BMCs O 0 0.7207596
) O 0 0.0018073984
in O 0 0.000631253
a O 0 0.00097291695
model O 0 0.0011120209
of O 0 0.0026168183
epilepsy B-Disease 2 0.9999392
induced O 0 0.0052633453
by O 0 0.011867327
pilocarpine B-Chemical 1 0.9999541
in O 0 0.006065928
rats O 0 0.02860701
. O 0 0.009173908

BMCs O 0 0.10625559
obtained O 0 0.006501211
from O 0 0.0044928654
green O 0 0.00546009
fluorescent O 0 0.0063832076
protein O 0 0.005101919
( O 0 0.0035610332
GFP O 0 0.006667425
) O 0 0.0019742844
transgenic O 0 0.0010033385
mice O 0 0.00059077574
or O 0 0.00071002083
rats O 0 0.0015841858
were O 0 0.0006763489
transplanted O 0 0.0023959808
intravenously O 0 0.0018022989
after O 0 0.0005478429
induction O 0 0.0011174196
of O 0 0.0021338298
status B-Disease 0 0.02485484
epilepticus I-Disease 0 0.9999639
( O 0 0.04460294
SE B-Disease 2 0.9777399
) O 0 0.017098464
. O 0 0.009443593

Spontaneous B-Disease 0 0.2950506
recurrent I-Disease 0 0.9292508
seizures I-Disease 2 0.999925
( O 0 0.04111199
SRS B-Disease 0 0.9559642
) O 0 0.0057345186
were O 0 0.0025179426
monitored O 0 0.0016581899
using O 0 0.0023839183
Racine O 0 0.04304285
' O 0 0.0038191283
s O 0 0.0049945414
seizure B-Disease 2 0.99892527
severity O 0 0.30727252
scale O 0 0.024311455
. O 0 0.011279424

All O 0 0.0072213565
of O 0 0.0054346416
the O 0 0.003688832
rats O 0 0.004438145
in O 0 0.0019428061
the O 0 0.0018010186
saline O 0 0.31746027
- O 0 0.003077973
treated O 0 0.0017582731
epileptic B-Disease 2 0.99978834
control O 0 0.00096180424
group O 0 0.0010704539
developed O 0 0.0018414572
SRS B-Disease 0 0.96156085
, O 0 0.0007843068
whereas O 0 0.0003847905
none O 0 0.00048212515
of O 0 0.0006320992
the O 0 0.000882992
BMC O 0 0.9800218
- O 0 0.0031925817
treated O 0 0.0013891886
epileptic B-Disease 2 0.9998895
animals O 0 0.0007188171
had O 0 0.0008142557
seizures B-Disease 2 0.9999672
in O 0 0.0005161938
the O 0 0.0004502602
short O 0 0.0003923622
term O 0 0.0005222754
( O 0 0.00078559935
15 O 0 0.00038460028
days O 0 0.00035739798
after O 0 0.0004090951
transplantation O 0 0.038867272
) O 0 0.0021231438
, O 0 0.0014004696
regardless O 0 0.00096658996
of O 0 0.0024846084
the O 0 0.0039021776
BMC O 0 0.90786487
source O 0 0.007188157
. O 0 0.009252071

Over O 0 0.009843846
the O 0 0.005809815
long O 0 0.004776111
- O 0 0.004470544
term O 0 0.0024555146
chronic O 0 0.8364681
phase O 0 0.0049282503
( O 0 0.0018326325
120 O 0 0.00083643576
days O 0 0.0004506488
after O 0 0.000379731
transplantation O 0 0.042168614
) O 0 0.0014865537
, O 0 0.00067378517
only O 0 0.00041660346
25 O 0 0.00063889293
% O 0 0.00058184314
of O 0 0.0008219069
BMC O 0 0.9653742
- O 0 0.0023861572
treated O 0 0.0012881119
epileptic B-Disease 2 0.9998851
animals O 0 0.00078604
had O 0 0.0010378666
seizures B-Disease 2 0.9999846
, O 0 0.0013967095
but O 0 0.00052205333
with O 0 0.0004916778
a O 0 0.0006557919
lower O 0 0.0005163995
frequency O 0 0.00068227266
and O 0 0.00076866464
duration O 0 0.0009289582
compared O 0 0.00070650823
to O 0 0.0012799375
the O 0 0.0024648705
epileptic B-Disease 2 0.9995846
control O 0 0.0047104037
group O 0 0.0081610335
. O 0 0.008414951

The O 0 0.008318909
density O 0 0.007215227
of O 0 0.005904538
hippocampal O 0 0.58452517
neurons O 0 0.018411636
in O 0 0.0019432174
the O 0 0.0016523547
brains O 0 0.0025838136
of O 0 0.0017985249
animals O 0 0.0016676463
treated O 0 0.0026764849
with O 0 0.003273499
BMCs O 0 0.74613106
was O 0 0.004429596
markedly O 0 0.01773375
preserved O 0 0.012825555
. O 0 0.009965196

At O 0 0.008358398
hippocampal O 0 0.3210294
Schaeffer O 0 0.14453551
collateral O 0 0.5875498
- O 0 0.013423845
CA1 O 0 0.9523489
synapses O 0 0.24921691
, O 0 0.0025180373
long O 0 0.001619494
- O 0 0.0019641416
term O 0 0.0011711988
potentiation O 0 0.6869446
was O 0 0.0011819021
preserved O 0 0.0018093531
in O 0 0.0014212229
BMC O 0 0.95358056
- O 0 0.0033270037
transplanted O 0 0.008025679
rats O 0 0.0037216858
compared O 0 0.001623311
to O 0 0.003715291
epileptic B-Disease 2 0.99958056
controls O 0 0.024956819
. O 0 0.009464607

The O 0 0.009016555
donor O 0 0.009682961
- O 0 0.007036503
derived O 0 0.0041504363
GFP O 0 0.010098763
( O 0 0.004561094
+ O 0 0.0029276798
) O 0 0.0027295437
cells O 0 0.0021104722
were O 0 0.0012782709
rarely O 0 0.0014785384
found O 0 0.00096193113
in O 0 0.0011596197
the O 0 0.0014525115
brains O 0 0.0034645856
of O 0 0.003487346
transplanted O 0 0.20947139
epileptic B-Disease 2 0.9997757
rats O 0 0.072442934
. O 0 0.010450154

In O 0 0.0072796084
conclusion O 0 0.0048516034
, O 0 0.0048991228
treatment O 0 0.0037622347
with O 0 0.002551701
BMCs O 0 0.4468025
can O 0 0.0011616495
prevent O 0 0.0011080955
the O 0 0.00091603
development O 0 0.0018089112
of O 0 0.0020432344
chronic O 0 0.9963664
seizures B-Disease 2 0.9999956
, O 0 0.006525203
reduce O 0 0.00096766197
neuronal B-Disease 0 0.9254269
loss I-Disease 0 0.029985674
, O 0 0.0013128751
and O 0 0.00079930294
influence O 0 0.00064166734
the O 0 0.0009693174
reorganization O 0 0.0047341124
of O 0 0.0018530382
the O 0 0.0026673526
hippocampal O 0 0.8752303
neuronal O 0 0.59628093
network O 0 0.010210934
. O 0 0.008644803

Normalizing O 0 0.019025408
effects O 0 0.0108181685
of O 0 0.009999986
modafinil B-Chemical 1 0.9996747
on O 0 0.0058048237
sleep O 0 0.49474496
in O 0 0.007410256
chronic O 0 0.99218667
cocaine B-Chemical 1 0.9998709
users O 0 0.44196078
. O 0 0.014673056

OBJECTIVE O 0 0.45296153
: O 0 0.00772476
The O 0 0.003268417
purpose O 0 0.0026429757
of O 0 0.0020906397
the O 0 0.0014832605
present O 0 0.0009574836
study O 0 0.0012331946
was O 0 0.0007859179
to O 0 0.00055059063
determine O 0 0.0003335604
the O 0 0.0005182625
effect O 0 0.00053914887
of O 0 0.0008457481
morning O 0 0.016443571
- O 0 0.0015463192
dosed O 0 0.015310328
modafinil B-Chemical 1 0.99991596
on O 0 0.0006339716
sleep O 0 0.288956
and O 0 0.0016424872
daytime B-Disease 0 0.6835141
sleepiness I-Disease 0 0.99795616
in O 0 0.002556903
chronic O 0 0.98981476
cocaine B-Chemical 1 0.9999156
users O 0 0.3014323
. O 0 0.009635636

METHOD O 0 0.02747241
: O 0 0.008533746
Twenty O 0 0.008442437
cocaine B-Chemical 1 0.99952817
- O 0 0.0045543103
dependent O 0 0.0014174134
participants O 0 0.0012394234
were O 0 0.0007972087
randomly O 0 0.00046565762
assigned O 0 0.00045414144
to O 0 0.00050012086
receive O 0 0.0006721952
modafinil B-Chemical 1 0.99995255
, O 0 0.0012481207
400 O 0 0.0025713304
mg O 0 0.32280582
( O 0 0.0013130101
N O 0 0.9317837
= O 0 0.0008677014
10 O 0 0.00049098185
) O 0 0.0007344573
, O 0 0.0004968948
or O 0 0.00039477577
placebo O 0 0.094909675
( O 0 0.0011538139
N O 0 0.93078256
= O 0 0.0007375547
10 O 0 0.00039129728
) O 0 0.0004744285
every O 0 0.00018958739
morning O 0 0.000615877
at O 0 0.00024530073
7 O 0 0.00032731236
: O 0 0.0004425636
30 O 0 0.00026215857
a O 0 0.0004401583
. O 0 0.0003235509
m O 0 0.0013781472
. O 0 0.00031726796
for O 0 0.00029912285
16 O 0 0.0004132759
days O 0 0.0003411919
in O 0 0.0005070758
an O 0 0.0010622113
inpatient O 0 0.0037418262
, O 0 0.0016926732
double O 0 0.0017275161
- O 0 0.0033357623
blind O 0 0.0076673683
randomized O 0 0.0045111477
trial O 0 0.007066398
. O 0 0.0072415993

Participants O 0 0.008310181
underwent O 0 0.0050326097
polysomnographic O 0 0.018586362
sleep O 0 0.037623398
recordings O 0 0.0039832443
on O 0 0.0010911314
days O 0 0.00090734527
1 O 0 0.00089555676
to O 0 0.00066951214
3 O 0 0.00066931697
, O 0 0.00072467106
7 O 0 0.00047415344
to O 0 0.00041769547
9 O 0 0.00054249156
, O 0 0.00056447886
and O 0 0.0004836796
14 O 0 0.0004832501
to O 0 0.00039435565
16 O 0 0.00056948845
( O 0 0.00065710297
first O 0 0.00046297564
, O 0 0.00085783686
second O 0 0.0007689071
, O 0 0.0011591292
and O 0 0.0011071791
third O 0 0.0014670045
weeks O 0 0.0013814613
of O 0 0.003388303
abstinence O 0 0.9493809
) O 0 0.014045074
. O 0 0.00842729

The O 0 0.010329712
Multiple O 0 0.023953637
Sleep O 0 0.41360676
Latency O 0 0.17395957
Test O 0 0.026317155
was O 0 0.0017297528
performed O 0 0.0011418315
at O 0 0.00085880404
11 O 0 0.0010521886
: O 0 0.00094698503
30 O 0 0.0005030636
a O 0 0.0007111537
. O 0 0.00048887334
m O 0 0.0022731794
. O 0 0.0004852266
, O 0 0.0006997121
2 O 0 0.00051502406
: O 0 0.00070677017
00 O 0 0.0039307424
p O 0 0.00056104996
. O 0 0.0003669224
m O 0 0.001781137
. O 0 0.00038710123
, O 0 0.0005550388
and O 0 0.0004712413
4 O 0 0.00041700117
: O 0 0.0005474088
30 O 0 0.00032476077
p O 0 0.0005165048
. O 0 0.00040166936
m O 0 0.001463094
. O 0 0.00045240961
on O 0 0.00045090704
days O 0 0.00066425034
2 O 0 0.0010922472
, O 0 0.0016457605
8 O 0 0.0017370483
, O 0 0.0027576122
and O 0 0.0036838094
15 O 0 0.0047537624
. O 0 0.006723117

For O 0 0.0060096406
comparison O 0 0.003989797
of O 0 0.003771081
sleep O 0 0.13889933
architecture O 0 0.0037560775
variables O 0 0.0029153547
, O 0 0.0015259105
12 O 0 0.00065563765
healthy O 0 0.0013778586
comparison O 0 0.0004764718
participants O 0 0.0005604567
underwent O 0 0.00049969624
a O 0 0.0005903378
single O 0 0.0005385508
night O 0 0.00079476414
of O 0 0.0006103101
experimental O 0 0.0007889847
polysomnography O 0 0.0022795906
that O 0 0.00065412215
followed O 0 0.0008575631
1 O 0 0.0014528178
night O 0 0.0023358092
of O 0 0.0028419446
accommodation O 0 0.035310473
polysomnography O 0 0.02169341
. O 0 0.0070001907

RESULTS O 0 0.029401736
: O 0 0.010585911
Progressive O 0 0.065332584
abstinence O 0 0.782017
from O 0 0.004456331
cocaine B-Chemical 1 0.9997311
was O 0 0.0026815466
associated O 0 0.0021914511
with O 0 0.002109507
worsening O 0 0.52516824
of O 0 0.0023064297
all O 0 0.0019952927
measured O 0 0.002154884
polysomnographic O 0 0.32310355
sleep O 0 0.364453
outcomes O 0 0.014964773
. O 0 0.009349825

Compared O 0 0.007416538
with O 0 0.0056650876
placebo O 0 0.21024428
, O 0 0.0057507507
modafinil B-Chemical 1 0.9998721
decreased O 0 0.0043794205
nighttime O 0 0.0900017
sleep O 0 0.26336607
latency O 0 0.0037748413
and O 0 0.0012229669
increased O 0 0.0013231875
slow O 0 0.0038140772
- O 0 0.002151722
wave O 0 0.015366929
sleep O 0 0.21054329
time O 0 0.0011790913
in O 0 0.0020999168
cocaine B-Chemical 1 0.9998323
- O 0 0.006420746
dependent O 0 0.0034438742
participants O 0 0.0067236833
. O 0 0.0075746523

The O 0 0.006762707
effect O 0 0.00450804
of O 0 0.004804554
modafinil B-Chemical 1 0.9998472
interacted O 0 0.0026948624
with O 0 0.0015003269
the O 0 0.0011928412
abstinence O 0 0.7951327
week O 0 0.0006397261
and O 0 0.0007248979
was O 0 0.00056968
associated O 0 0.0005950204
with O 0 0.00051345903
longer O 0 0.00031710917
total O 0 0.00050894835
sleep O 0 0.07869896
time O 0 0.0004521346
and O 0 0.0006897834
shorter O 0 0.0006557729
REM O 0 0.9702566
sleep O 0 0.19175647
latency O 0 0.0025009234
in O 0 0.001041971
the O 0 0.0012775855
third O 0 0.0019746583
week O 0 0.0020058567
of O 0 0.004629545
abstinence O 0 0.93585056
. O 0 0.009192607

Comparison O 0 0.0075550345
of O 0 0.006282985
slow O 0 0.008985913
- O 0 0.0050518406
wave O 0 0.013353849
sleep O 0 0.19713777
time O 0 0.0011672499
, O 0 0.0012095206
total O 0 0.00081523746
sleep O 0 0.10153549
time O 0 0.0005923409
, O 0 0.0008306205
and O 0 0.00067719223
sleep O 0 0.18006366
latency O 0 0.003491707
in O 0 0.0007681012
cocaine B-Chemical 1 0.9999565
- O 0 0.0017028042
dependent O 0 0.00040619983
and O 0 0.0005854077
healthy O 0 0.0030859609
participants O 0 0.0005512848
revealed O 0 0.00044750003
a O 0 0.00066199165
normalizing O 0 0.00090629584
effect O 0 0.0007102496
of O 0 0.0018025913
modafinil B-Chemical 1 0.9999628
in O 0 0.002976525
cocaine B-Chemical 1 0.9999075
- O 0 0.007330602
dependent O 0 0.0033001695
participants O 0 0.006487357
. O 0 0.007235818

Modafinil B-Chemical 0 0.99945587
was O 0 0.007008416
associated O 0 0.004222702
with O 0 0.0027693622
increased O 0 0.0027883984
daytime O 0 0.11447817
sleep O 0 0.34307906
latency O 0 0.0064557376
, O 0 0.0013028781
as O 0 0.0007263453
measured O 0 0.00052537996
by O 0 0.00075987115
the O 0 0.0007809087
Multiple O 0 0.046652723
Sleep O 0 0.6174991
Latency O 0 0.27665597
Test O 0 0.06329435
, O 0 0.0008727084
and O 0 0.0007247988
a O 0 0.0009295159
nearly O 0 0.0008905126
significant O 0 0.0012236545
decrease O 0 0.001461821
in O 0 0.002104991
subjective O 0 0.06831642
daytime B-Disease 0 0.8471603
sleepiness I-Disease 0 0.99770194
. O 0 0.008678832

CONCLUSIONS O 0 0.6634503
: O 0 0.014463239
Morning O 0 0.558389
- O 0 0.0071829325
dosed O 0 0.024175843
modafinil B-Chemical 1 0.9998776
promotes O 0 0.0021060219
nocturnal O 0 0.68905574
sleep O 0 0.69402564
, O 0 0.002428997
normalizes O 0 0.054822978
sleep O 0 0.4062745
architecture O 0 0.0035236613
, O 0 0.0014949711
and O 0 0.0011983692
decreases O 0 0.0015729811
daytime B-Disease 0 0.66820645
sleepiness I-Disease 0 0.9979405
in O 0 0.0027449552
abstinent O 0 0.97251207
cocaine B-Chemical 1 0.9997764
users O 0 0.14218435
. O 0 0.0091334665

These O 0 0.0131245
effects O 0 0.010129025
may O 0 0.006401367
be O 0 0.0049612965
relevant O 0 0.0036508022
in O 0 0.0033306691
the O 0 0.0035873298
treatment O 0 0.0059629004
of O 0 0.0096690515
cocaine B-Chemical 1 0.99978215
dependence O 0 0.11713483
. O 0 0.013574466

Safety O 0 0.033135325
of O 0 0.010577532
transesophageal O 0 0.25196838
echocardiography O 0 0.104586326
in O 0 0.0053198147
adults O 0 0.008452586
: O 0 0.005774998
study O 0 0.004566571
in O 0 0.0042699673
a O 0 0.0068876534
multidisciplinary O 0 0.012859891
hospital O 0 0.02270053
. O 0 0.012573151

BACKGROUND O 0 0.6255887
: O 0 0.011263906
TEE O 0 0.121114336
is O 0 0.0038784165
a O 0 0.0036077283
semi O 0 0.009497467
- O 0 0.003070577
invasive O 0 0.004324902
tool O 0 0.0014394041
broadly O 0 0.0009567254
used O 0 0.00079564605
and O 0 0.0009397648
its O 0 0.0013234685
utilization O 0 0.0012797755
associated O 0 0.0009709021
to O 0 0.00097327115
sedatives O 0 0.99855524
drugs O 0 0.7333619
might O 0 0.0010588877
to O 0 0.0013582037
affect O 0 0.0013458411
the O 0 0.0024778175
procedure O 0 0.0040697088
safety O 0 0.012665546
. O 0 0.00836766

OBJECTIVE O 0 0.4797279
: O 0 0.008025702
to O 0 0.0035623547
analyze O 0 0.002006498
aspects O 0 0.0019031069
of O 0 0.0020558673
TEE O 0 0.24357165
safety O 0 0.0023257257
associated O 0 0.0010595195
to O 0 0.0006916437
the O 0 0.00066546886
use O 0 0.0007863696
of O 0 0.0013848837
Midazolan B-Chemical 0 0.9828183
( O 0 0.003309769
MZ B-Chemical 1 0.9249516
) O 0 0.0030066373
and O 0 0.0018628035
Flumazenil B-Chemical 1 0.9999932
( O 0 0.0036372633
FL B-Chemical 0 0.8940466
) O 0 0.0011719982
and O 0 0.0005572073
the O 0 0.00046986787
influence O 0 0.00044314578
of O 0 0.0007576528
the O 0 0.00083224475
clinical O 0 0.0033216572
variables O 0 0.0022070485
on O 0 0.0013337801
the O 0 0.0024963717
event O 0 0.012784909
rate O 0 0.005818133
. O 0 0.008297273

METHOD O 0 0.031694338
: O 0 0.010098043
prospective O 0 0.0072223796
study O 0 0.004308755
with O 0 0.003151835
137 O 0 0.006254114
patients O 0 0.00316201
that O 0 0.0016209008
underwent O 0 0.0021970544
TEE O 0 0.15166067
with O 0 0.0027810307
MZ B-Chemical 1 0.6872892
associated O 0 0.003722775
to O 0 0.0039039392
moderate O 0 0.06106983
sedation O 0 0.90542436
. O 0 0.010861755

We O 0 0.007650409
analyzed O 0 0.004700886
the O 0 0.0036055332
following O 0 0.0028107837
events O 0 0.01892822
: O 0 0.003215639
complications O 0 0.30686733
related O 0 0.0011136862
with O 0 0.0012100743
the O 0 0.0012002569
topical O 0 0.93123686
anesthesia O 0 0.4671288
, O 0 0.0024423758
with O 0 0.0019183371
MZ B-Chemical 1 0.75715166
use O 0 0.002188562
and O 0 0.0025819032
with O 0 0.0031415173
the O 0 0.004151031
procedure O 0 0.0064905044
. O 0 0.008690765

Uni O 0 0.9496842
- O 0 0.0107570905
and O 0 0.004686629
multivariate O 0 0.006867578
analyses O 0 0.0029220222
were O 0 0.0016725941
used O 0 0.0010869597
to O 0 0.0008260253
test O 0 0.0008590184
the O 0 0.00059268984
influence O 0 0.0004490874
of O 0 0.00063830655
the O 0 0.000544372
clinical O 0 0.0032868076
variables O 0 0.0018214725
: O 0 0.0010815474
age O 0 0.001917948
, O 0 0.00096505316
sex O 0 0.07398192
, O 0 0.0018142695
stroke B-Disease 2 0.99975723
, O 0 0.0063084434
myocardiopathy B-Disease 0 0.99996805
( O 0 0.009687781
MP B-Disease 0 0.9909416
) O 0 0.0019117921
, O 0 0.000619481
duration O 0 0.00046637526
of O 0 0.00053563854
the O 0 0.00054983963
test O 0 0.0009173594
, O 0 0.0014407055
mitral B-Disease 2 0.7894116
regurgitation I-Disease 2 0.9988686
( O 0 0.0073262285
MR B-Disease 2 0.9850809
) O 0 0.0033980021
and O 0 0.0024759173
the O 0 0.0033399754
MZ B-Chemical 1 0.8103977
dose O 0 0.057850808
. O 0 0.009063813

RESULTS O 0 0.026789667
: O 0 0.009308452
All O 0 0.005266452
patients O 0 0.006466427
( O 0 0.0046311845
65 O 0 0.0035662549
+ O 0 0.0028212788
/ O 0 0.003916903
- O 0 0.0024617773
16 O 0 0.0015640238
yrs O 0 0.0038196254
; O 0 0.0022922056
58 O 0 0.002280736
% O 0 0.0021598253
males O 0 0.003493298
) O 0 0.0040136203
finished O 0 0.005151572
the O 0 0.00444058
examination O 0 0.0090280315
. O 0 0.009456354

The O 0 0.006762006
mean O 0 0.004855113
doses O 0 0.009791391
of O 0 0.0045666685
MZ B-Chemical 1 0.8199977
and O 0 0.0035613936
FL B-Chemical 0 0.81455594
were O 0 0.0013262192
4 O 0 0.00088342454
. O 0 0.0005975421
3 O 0 0.00064884766
+ O 0 0.00080586085
/ O 0 0.0018290561
- O 0 0.0010303034
1 O 0 0.00053738034
. O 0 0.000348057
9 O 0 0.00044570668
mg O 0 0.020905714
and O 0 0.0005983485
0 O 0 0.0007427538
. O 0 0.00043238903
28 O 0 0.0007205091
+ O 0 0.00086750725
/ O 0 0.0020201039
- O 0 0.0015238719
0 O 0 0.0013063791
. O 0 0.0010228363
2 O 0 0.001822586
mg O 0 0.14069507
, O 0 0.005166383
respectively O 0 0.00821763
. O 0 0.007816022

The O 0 0.006449178
duration O 0 0.0047194418
of O 0 0.003533449
the O 0 0.0024020039
examination O 0 0.002444305
and O 0 0.0015565375
the O 0 0.0010810245
mean O 0 0.0010072191
ejection O 0 0.6862359
fraction O 0 0.0012079512
( O 0 0.0021548346
EF O 0 0.7926937
) O 0 0.0013810225
were O 0 0.00055220095
16 O 0 0.0005410031
. O 0 0.0003532449
4 O 0 0.00043223987
+ O 0 0.0005892315
/ O 0 0.0013498077
- O 0 0.0008001057
6 O 0 0.0003641944
. O 0 0.00033078028
1 O 0 0.0004260395
minutes O 0 0.00038382763
and O 0 0.000642062
60 O 0 0.0008296769
+ O 0 0.001171683
/ O 0 0.002708924
- O 0 0.0022780055
9 O 0 0.0019704085
% O 0 0.003005373
, O 0 0.004480087
respectively O 0 0.0075837914
. O 0 0.0076494385

Mild O 0 0.9926023
hypoxia B-Disease 2 0.9928711
( O 0 0.015669914
SO2 O 0 0.9896549
< O 0 0.0030505543
90 O 0 0.0017132586
% O 0 0.0017045155
) O 0 0.0015546255
was O 0 0.0007708557
the O 0 0.0006469698
most O 0 0.0008500649
common O 0 0.0010171069
event O 0 0.014902401
( O 0 0.001170073
11 O 0 0.00076516095
patients O 0 0.0018493782
) O 0 0.001437767
; O 0 0.000882352
3 O 0 0.00039033752
patients O 0 0.0010018055
( O 0 0.0006643377
2 O 0 0.00042635846
% O 0 0.00051824073
) O 0 0.0006247182
presented O 0 0.0004441053
transient O 0 0.015483836
hypoxia B-Disease 2 0.9624653
due O 0 0.00035771378
to O 0 0.00035708633
upper O 0 0.0010900914
airway B-Disease 0 0.11736775
obstruction I-Disease 0 0.85331786
by O 0 0.00060781953
probe O 0 0.00047011318
introduction O 0 0.00044225279
and O 0 0.000589447
8 O 0 0.00055076747
( O 0 0.00067105325
5 O 0 0.00042429625
. O 0 0.00037741064
8 O 0 0.0005190481
% O 0 0.00077869574
) O 0 0.0011185729
due O 0 0.0007209782
to O 0 0.001283727
hypoxia B-Disease 2 0.97319806
caused O 0 0.004118925
by O 0 0.0064289644
MZ B-Chemical 1 0.92628187
use O 0 0.008527196
. O 0 0.009041809

Transient O 0 0.8692821
hypotension B-Disease 2 0.9997718
( O 0 0.02223235
SAP O 0 0.93463284
< O 0 0.004877683
90mmHg O 0 0.22907272
) O 0 0.0033050445
occurred O 0 0.0017193584
in O 0 0.0014744876
1 O 0 0.0016615124
patient O 0 0.0022544481
( O 0 0.0026088727
0 O 0 0.00250413
. O 0 0.0019901064
7 O 0 0.0030477059
% O 0 0.005271766
) O 0 0.009032742
. O 0 0.008506998

The O 0 0.0073530865
multivariate O 0 0.009327537
analysis O 0 0.004618983
showed O 0 0.0026647563
that O 0 0.0022976976
severe O 0 0.4132171
MR B-Disease 2 0.9957985
, O 0 0.005229293
MP B-Disease 0 0.9848914
( O 0 0.0031289717
EF O 0 0.65317255
< O 0 0.0009024905
45 O 0 0.0006052949
% O 0 0.0007286716
) O 0 0.00081803335
and O 0 0.00052605744
high O 0 0.00062727893
doses O 0 0.0082267085
of O 0 0.0013534776
MZ B-Chemical 1 0.9578685
( O 0 0.002438602
> O 0 0.0022259506
5mg O 0 0.97581506
) O 0 0.0013642904
were O 0 0.0006273023
associated O 0 0.00076056767
with O 0 0.00097374513
events O 0 0.02639415
( O 0 0.0020101203
p O 0 0.0018847695
< O 0 0.0018868659
0 O 0 0.002631356
. O 0 0.0026602624
001 O 0 0.1968325
) O 0 0.008224926
. O 0 0.0075899563

The O 0 0.009083805
EF O 0 0.29428148
was O 0 0.0046079406
40 O 0 0.0033255666
% O 0 0.002823958
, O 0 0.0019976061
in O 0 0.0011352153
the O 0 0.0009937405
group O 0 0.0011574946
with O 0 0.0011465685
MP B-Disease 0 0.95664364
and O 0 0.0010661448
44 O 0 0.0011181793
% O 0 0.0006173892
in O 0 0.000387747
the O 0 0.00042528028
group O 0 0.0006275364
with O 0 0.0007500034
severe O 0 0.4264296
MR B-Disease 2 0.9916556
and O 0 0.00092130713
it O 0 0.0007263082
can O 0 0.00047055454
be O 0 0.0006077873
a O 0 0.0008631944
factor O 0 0.0031652555
associated O 0 0.0010257321
with O 0 0.0011523602
clinical O 0 0.010403079
events O 0 0.018130848
in O 0 0.0018136434
the O 0 0.002404129
last O 0 0.0028018036
group O 0 0.0066377097
. O 0 0.008123057

CONCLUSION O 0 0.6849262
: O 0 0.015768997
TEE O 0 0.07711267
with O 0 0.007529571
sedation O 0 0.42903134
presents O 0 0.007569238
a O 0 0.006833928
low O 0 0.006681328
rate O 0 0.0066091153
of O 0 0.0105158705
events O 0 0.15932013
. O 0 0.015240411

There O 0 0.010249065
were O 0 0.0065364526
no O 0 0.0044428585
severe O 0 0.0375186
events O 0 0.020422708
and O 0 0.003448102
there O 0 0.0020065065
was O 0 0.002231078
no O 0 0.001912006
need O 0 0.0024711604
to O 0 0.00299565
interrupt O 0 0.0050418535
the O 0 0.0054371655
examinations O 0 0.014018039
. O 0 0.010454051

Effect O 0 0.0100314785
of O 0 0.0062696263
direct O 0 0.004841461
intracoronary O 0 0.9316206
administration O 0 0.1832312
of O 0 0.005728256
methylergonovine B-Chemical 0 0.99978286
in O 0 0.0026292845
patients O 0 0.0059580803
with O 0 0.0027442242
and O 0 0.0037458318
without O 0 0.0049254806
variant B-Disease 2 0.23960441
angina I-Disease 2 0.99996567
. O 0 0.017675517

The O 0 0.00657398
effects O 0 0.005414236
of O 0 0.0040767575
intracoronary O 0 0.94433486
administration O 0 0.17563058
of O 0 0.0037065693
methylergonovine B-Chemical 0 0.9998599
were O 0 0.0011838761
studied O 0 0.00081617525
in O 0 0.0005791653
21 O 0 0.0007173123
patients O 0 0.001130353
with O 0 0.00070422806
variant B-Disease 2 0.02598556
angina I-Disease 2 0.99999666
and O 0 0.0012810975
22 O 0 0.0008947055
patients O 0 0.001080992
with O 0 0.0005850005
atypical O 0 0.14805165
chest B-Disease 0 0.8785789
pain I-Disease 2 0.99877685
and O 0 0.0012380688
in O 0 0.0008711083
others O 0 0.0031969643
without O 0 0.0026349965
angina B-Disease 0 0.9999924
pectoris I-Disease 0 0.9999926
( O 0 0.008540797
control O 0 0.0033617727
group O 0 0.0058225975
) O 0 0.011414707
. O 0 0.008026339

Methylergonovine B-Chemical 0 0.843277
was O 0 0.006824323
administered O 0 0.004639727
continuously O 0 0.003082798
at O 0 0.0018569583
a O 0 0.0020644974
rate O 0 0.0015583987
of O 0 0.0018086599
10 O 0 0.0017827224
micrograms O 0 0.0948364
/ O 0 0.0039509535
min O 0 0.0023411738
up O 0 0.0023137257
to O 0 0.002953684
50 O 0 0.0062728385
micrograms O 0 0.20912258
. O 0 0.009271709

In O 0 0.0072018295
all O 0 0.0049152193
patients O 0 0.0059903497
with O 0 0.0037701211
variant B-Disease 2 0.058605745
angina I-Disease 2 0.9999918
, O 0 0.017316869
coronary B-Disease 2 0.9953832
spasm I-Disease 2 0.99997985
was O 0 0.0016330625
provoked O 0 0.03175411
at O 0 0.00047614402
a O 0 0.00060654985
mean O 0 0.00043512296
dose O 0 0.0017256949
of O 0 0.00076362985
28 O 0 0.0009624637
+ O 0 0.0009178848
/ O 0 0.002200666
- O 0 0.0011767133
13 O 0 0.00090591214
micrograms O 0 0.045330238
( O 0 0.0015316731
mean O 0 0.0013107731
+ O 0 0.002481729
/ O 0 0.0070400517
- O 0 0.0065952744
SD O 0 0.43201104
) O 0 0.01076853
. O 0 0.0083482545

In O 0 0.009392608
the O 0 0.006844179
control O 0 0.005374217
group O 0 0.005312689
neither O 0 0.005711158
ischemic O 0 0.9995617
ST O 0 0.9772514
change O 0 0.004804015
nor O 0 0.004485339
localized O 0 0.0073624505
spasm B-Disease 2 0.99956125
occurred O 0 0.014379402
. O 0 0.01250384

The O 0 0.008000477
basal O 0 0.008002638
tone O 0 0.09023092
of O 0 0.0035770754
the O 0 0.0024489951
right O 0 0.003975471
coronary O 0 0.45201162
artery O 0 0.14848354
was O 0 0.0013937544
significantly O 0 0.0013702372
lower O 0 0.0011458428
than O 0 0.00088119006
that O 0 0.0010578894
of O 0 0.0018024747
the O 0 0.00232386
left O 0 0.0066081956
coronary O 0 0.78651464
artery O 0 0.39289945
. O 0 0.0099064885

The O 0 0.006657509
percentage O 0 0.004253831
of O 0 0.0047672093
vasoconstriction O 0 0.99507976
of O 0 0.0029341786
the O 0 0.0017606247
right O 0 0.0033658433
coronary O 0 0.5220897
artery O 0 0.1523082
was O 0 0.0010994184
significantly O 0 0.0011185494
higher O 0 0.00087453594
than O 0 0.00076642865
that O 0 0.00094696286
of O 0 0.0016646595
the O 0 0.0021770317
left O 0 0.006343356
coronary O 0 0.7842633
artery O 0 0.38737
. O 0 0.009635858

These O 0 0.008219401
results O 0 0.0050287666
suggest O 0 0.002910268
that O 0 0.0028842194
spasm B-Disease 2 0.9997111
provocation O 0 0.95286196
tests O 0 0.0092510665
, O 0 0.001657485
which O 0 0.0009545125
use O 0 0.00073112623
an O 0 0.00087512116
intracoronary O 0 0.8831239
injection O 0 0.0016122872
of O 0 0.0006186088
a O 0 0.00069547334
relatively O 0 0.00055092975
low O 0 0.0006064221
dose O 0 0.008439136
of O 0 0.0013429896
methylergonovine B-Chemical 0 0.999931
, O 0 0.0010569849
have O 0 0.00035819752
a O 0 0.0005760234
high O 0 0.0005419145
sensitivity O 0 0.0010050386
in O 0 0.0005394331
variant B-Disease 2 0.026743751
angina I-Disease 2 0.99999726
and O 0 0.0011599306
the O 0 0.0006767687
vasoreactivity O 0 0.98422295
of O 0 0.0006354213
the O 0 0.00050613587
right O 0 0.0015684159
coronary O 0 0.49315342
artery O 0 0.09416379
may O 0 0.00059128384
be O 0 0.0006014792
greater O 0 0.00054763193
than O 0 0.0005373127
that O 0 0.0007211012
of O 0 0.001355059
the O 0 0.0017779616
other O 0 0.0031966057
coronary O 0 0.9038266
arteries O 0 0.8429179
. O 0 0.009536617

Oral O 0 0.8950613
manifestations O 0 0.700852
of O 0 0.014210751
" O 0 0.016809823
meth B-Disease 2 0.99915063
mouth I-Disease 2 0.92622125
" O 0 0.012259727
: O 0 0.009221543
a O 0 0.008111943
case O 0 0.009019486
report O 0 0.021299155
. O 0 0.014238973

AIM O 0 0.41338992
: O 0 0.0076896343
The O 0 0.0032631753
aim O 0 0.0028616837
of O 0 0.0021414184
the O 0 0.0015282516
documentation O 0 0.0017520438
of O 0 0.0011376905
this O 0 0.00084708614
clinical O 0 0.003486438
case O 0 0.00083995477
is O 0 0.00062200165
to O 0 0.00048797502
make O 0 0.00048917223
clinicians O 0 0.00095868355
aware O 0 0.00066008465
of O 0 0.0009538243
" O 0 0.0023680967
meth B-Disease 2 0.99976677
mouth I-Disease 2 0.83310366
" O 0 0.0017911879
and O 0 0.0010273354
the O 0 0.0009691742
medical O 0 0.010704892
risks O 0 0.017066639
associated O 0 0.0021583193
with O 0 0.0025740222
this O 0 0.0034136563
serious O 0 0.49274448
condition O 0 0.02441622
. O 0 0.009871882

BACKGROUND O 0 0.84669834
: O 0 0.021758832
Methamphetamine B-Chemical 1 0.99978524
is O 0 0.0038866026
a O 0 0.0030554293
very O 0 0.0026915118
addictive O 0 0.99506384
, O 0 0.0025185582
powerful O 0 0.0048951334
stimulant O 0 0.9729215
that O 0 0.00067038374
increases O 0 0.0008089731
wakefulness O 0 0.6625455
and O 0 0.0008226877
physical O 0 0.021272058
activity O 0 0.000737528
and O 0 0.00057937205
can O 0 0.00035338488
produce O 0 0.00034491564
other O 0 0.0004681859
effects O 0 0.00094032014
such O 0 0.00063544826
as O 0 0.0011785884
cardiac B-Disease 0 0.9943558
dysrhythmias I-Disease 0 0.9999956
, O 0 0.047519147
hypertension B-Disease 2 0.9999715
, O 0 0.047446813
hallucinations B-Disease 2 0.9999722
, O 0 0.006702825
and O 0 0.00595187
violent B-Disease 0 0.9967278
behavior I-Disease 0 0.24999571
. O 0 0.009772075

Dental O 0 0.028442591
patients O 0 0.01535981
abusing O 0 0.96488357
methamphetamine B-Chemical 1 0.9998988
can O 0 0.002541661
present O 0 0.0013737599
with O 0 0.0016190021
poor O 0 0.008337824
oral O 0 0.7129812
hygiene O 0 0.15896446
, O 0 0.008946986
xerostomia B-Disease 0 0.99994016
, O 0 0.008259321
rampant O 0 0.33818465
caries B-Disease 0 0.99742764
( O 0 0.005264799
" O 0 0.003650247
meth B-Disease 2 0.9997063
mouth I-Disease 2 0.89532804
" O 0 0.0052220575
) O 0 0.004593824
, O 0 0.0029159798
and O 0 0.0032633815
excessive O 0 0.09989979
tooth B-Disease 0 0.3044703
wear I-Disease 0 0.34313664
. O 0 0.011398692

Oral O 0 0.804404
rehabilitation O 0 0.02153798
of O 0 0.011201203
patients O 0 0.016335685
using O 0 0.010879049
methamphetamine B-Chemical 1 0.9997162
can O 0 0.009885941
be O 0 0.011157179
challenging O 0 0.014323761
. O 0 0.0139159225

CASE O 0 0.4179726
DESCRIPTION O 0 0.14080639
: O 0 0.008354736
A O 0 0.01464631
30 O 0 0.0031091976
- O 0 0.0032623287
year O 0 0.001962969
- O 0 0.0021373476
old O 0 0.001626282
Caucasian O 0 0.11811927
woman O 0 0.008075502
presented O 0 0.0013263657
with O 0 0.0013415017
dental O 0 0.01742373
pain B-Disease 2 0.9992066
, O 0 0.0038348124
bad B-Disease 0 0.5060464
breath I-Disease 0 0.96918654
, O 0 0.00274341
and O 0 0.0023357624
self O 0 0.032594196
- O 0 0.0052209627
reported O 0 0.004702671
poor O 0 0.02885043
esthetics O 0 0.42558646
. O 0 0.0108316215

A O 0 0.024409147
comprehensive O 0 0.0057302956
examination O 0 0.0048780623
including O 0 0.0029585976
her O 0 0.0036086896
medical O 0 0.011981222
history O 0 0.043814193
, O 0 0.0026997544
panoramic O 0 0.14747551
radiograph O 0 0.09838167
, O 0 0.0012251006
and O 0 0.0008069705
intraoral O 0 0.0029121337
examination O 0 0.0010313091
revealed O 0 0.000768141
19 O 0 0.0015876052
carious B-Disease 0 0.4268374
lesions I-Disease 0 0.8375484
, O 0 0.001778224
which O 0 0.0011574125
is O 0 0.0008944498
not O 0 0.0008969727
very O 0 0.0013477844
common O 0 0.00199792
for O 0 0.0018125958
a O 0 0.004133069
healthy O 0 0.034584895
adult O 0 0.010486618
. O 0 0.008990309

She O 0 0.011684383
reported O 0 0.0062760054
her O 0 0.004981213
use O 0 0.0030285849
of O 0 0.0032963927
methamphetamine B-Chemical 1 0.99989927
for O 0 0.0012517583
five O 0 0.00081275695
years O 0 0.0012251858
and O 0 0.0008422052
had O 0 0.00064136257
not O 0 0.0006127858
experienced O 0 0.0009955374
any O 0 0.0006879714
major O 0 0.0013270936
carious B-Disease 0 0.5427481
episodes I-Disease 0 0.69864887
before O 0 0.0010239322
she O 0 0.0017074115
started O 0 0.0021808667
using O 0 0.0024851733
the O 0 0.0039826427
drug O 0 0.61061305
. O 0 0.0092817275

SUMMARY O 0 0.027822709
: O 0 0.007440318
The O 0 0.003515485
patient O 0 0.003629261
' O 0 0.0028242678
s O 0 0.0021371737
medical O 0 0.004534965
and O 0 0.00138312
dental O 0 0.0023479
histories O 0 0.0028077594
along O 0 0.00076868583
with O 0 0.00075969193
radiographic O 0 0.028388435
and O 0 0.0008524753
clinical O 0 0.0068491334
findings O 0 0.0018848528
lead O 0 0.013208805
to O 0 0.0004567755
a O 0 0.0007186835
diagnosis O 0 0.0038109857
of O 0 0.0009771604
" O 0 0.0024933133
meth B-Disease 2 0.9998367
mouth I-Disease 2 0.8792025
. O 0 0.00051517587
" O 0 0.0005843953
Although O 0 0.00027446146
three O 0 0.00022670548
different O 0 0.00031985153
dental O 0 0.0013662595
treatment O 0 0.00096892164
modalities O 0 0.012115592
( O 0 0.00086746423
either O 0 0.00040907427
conventional O 0 0.0005188551
or O 0 0.0004946082
implant O 0 0.011119072
- O 0 0.0015847643
supported O 0 0.0006760293
) O 0 0.0010698058
have O 0 0.0003931859
been O 0 0.0004609588
offered O 0 0.00047976052
to O 0 0.00035460497
the O 0 0.00042126072
patient O 0 0.0007280781
since O 0 0.00043467688
August O 0 0.0008607005
2007 O 0 0.0010261773
, O 0 0.000713608
the O 0 0.00061842334
patient O 0 0.0011869383
has O 0 0.0009445002
yet O 0 0.0015990112
to O 0 0.001521786
initiate O 0 0.0020298874
any O 0 0.0035423823
treatment O 0 0.009409198
. O 0 0.008951807

CLINICAL O 0 0.03694499
SIGNIFICANCE O 0 0.024205053
: O 0 0.0060651805
This O 0 0.0036166764
clinical O 0 0.0037380455
case O 0 0.0017012537
showing O 0 0.0014859919
oral O 0 0.4201159
manifestations O 0 0.8598584
of O 0 0.005464126
meth B-Disease 2 0.99990416
mouth I-Disease 2 0.9155034
was O 0 0.0010643054
presented O 0 0.00085054216
to O 0 0.0006235294
help O 0 0.0009475351
dental O 0 0.0023070145
practitioners O 0 0.0019443784
recognize O 0 0.00077026273
and O 0 0.0012420849
manage O 0 0.002433752
patients O 0 0.0042061047
who O 0 0.0037310626
may O 0 0.0025282283
be O 0 0.0047505223
abusing O 0 0.9925565
methamphetamines B-Chemical 0 0.9999018
. O 0 0.012989024

Dental O 0 0.02577392
practitioners O 0 0.010010422
also O 0 0.0044095563
may O 0 0.0030048655
be O 0 0.0022337588
skeptical O 0 0.0027102872
about O 0 0.0011101167
the O 0 0.0009606845
reliability O 0 0.001016336
of O 0 0.00095745636
appointment O 0 0.0018008326
keeping O 0 0.00079566205
by O 0 0.00074452616
these O 0 0.0008537779
patients O 0 0.0024401904
, O 0 0.0011003296
as O 0 0.0007986744
they O 0 0.00088513916
frequently O 0 0.0014631454
miss O 0 0.003592264
their O 0 0.0017186514
appointments O 0 0.0054475046
without O 0 0.0021870297
reasonable O 0 0.0031416246
justification O 0 0.0079691205
. O 0 0.007835149

Antituberculosis B-Chemical 0 0.9859514
therapy O 0 0.14702243
- O 0 0.010702174
induced O 0 0.005449603
acute B-Disease 2 0.992284
liver I-Disease 2 0.9924523
failure I-Disease 2 0.9865621
: O 0 0.0046890853
magnitude O 0 0.0014466321
, O 0 0.0019385223
profile O 0 0.0017041829
, O 0 0.0026598333
prognosis O 0 0.7559586
, O 0 0.0030128388
and O 0 0.0024613533
predictors O 0 0.0030371593
of O 0 0.0050936644
outcome O 0 0.023043469
. O 0 0.009591345

Antituberculosis B-Chemical 0 0.9822014
therapy O 0 0.1188474
( O 0 0.013389491
ATT O 0 0.8669137
) O 0 0.009605342
- O 0 0.004189582
associated O 0 0.0026534128
acute B-Disease 2 0.9912549
liver I-Disease 2 0.99442494
failure I-Disease 2 0.9948849
( O 0 0.03060516
ATT O 0 0.97586614
- O 0 0.014478548
ALF B-Disease 2 0.9998529
) O 0 0.0032444566
is O 0 0.000943501
the O 0 0.0010478232
commonest O 0 0.27718905
drug O 0 0.90120625
- O 0 0.010314232
induced O 0 0.005683691
ALF B-Disease 2 0.99973553
in O 0 0.006083372
South O 0 0.06344629
Asia O 0 0.1336532
. O 0 0.009252798

Prospective O 0 0.054078594
studies O 0 0.020648452
on O 0 0.016926654
ATT O 0 0.7762087
- O 0 0.03648661
ALF B-Disease 2 0.9972579
are O 0 0.022044424
lacking O 0 0.017097495
. O 0 0.021848459

The O 0 0.007188287
current O 0 0.006164538
study O 0 0.0037530346
prospectively O 0 0.002932463
evaluated O 0 0.0016400372
the O 0 0.0014631887
magnitude O 0 0.001278976
, O 0 0.0016680633
clinical O 0 0.003487369
course O 0 0.0015608884
, O 0 0.001649362
outcome O 0 0.0030751082
, O 0 0.0018160052
and O 0 0.001625466
prognostic O 0 0.011114061
factors O 0 0.013466356
in O 0 0.004433702
ATT O 0 0.9604644
- O 0 0.032046363
ALF B-Disease 2 0.9991868
. O 0 0.012185405

From O 0 0.01120059
January O 0 0.007174059
1986 O 0 0.008673607
to O 0 0.0031686195
January O 0 0.0029046612
2009 O 0 0.0034914962
, O 0 0.0020705115
1223 O 0 0.016768688
consecutive O 0 0.0015103804
ALF B-Disease 2 0.9992243
patients O 0 0.0030571697
were O 0 0.00083500595
evaluated O 0 0.0007409669
: O 0 0.0016435089
ATT O 0 0.4676656
alone O 0 0.0007596843
was O 0 0.00062857306
the O 0 0.00063349504
cause O 0 0.0018224872
in O 0 0.00084458035
70 O 0 0.0011841975
( O 0 0.0013754672
5 O 0 0.0009839166
. O 0 0.0010466694
7 O 0 0.0016569368
% O 0 0.0029126864
) O 0 0.0052295486
patients O 0 0.009160364
. O 0 0.007835126

Another O 0 0.015471105
15 O 0 0.00795567
( O 0 0.007487427
1 O 0 0.004666792
. O 0 0.0030422022
2 O 0 0.0029409355
% O 0 0.0034017942
) O 0 0.0038725205
had O 0 0.0028458661
ATT O 0 0.46674433
and O 0 0.0044555315
simultaneous O 0 0.034172084
hepatitis B-Disease 2 0.9999472
virus I-Disease 0 0.9072984
infection I-Disease 2 0.9817742
. O 0 0.018379606

In O 0 0.0090448
44 O 0 0.008676773
( O 0 0.005972443
62 O 0 0.005030378
. O 0 0.002194162
8 O 0 0.0018806073
% O 0 0.002049844
) O 0 0.002239471
patients O 0 0.002706202
, O 0 0.0021260919
ATT O 0 0.37414727
was O 0 0.0011527967
prescribed O 0 0.0033239895
empirically O 0 0.0021520997
without O 0 0.0015266641
definitive O 0 0.0030359973
evidence O 0 0.0033461777
of O 0 0.0069017103
tuberculosis B-Disease 2 0.96781844
. O 0 0.012292511

ATT O 0 0.8483185
- O 0 0.022743136
ALF B-Disease 2 0.9981975
patients O 0 0.012026803
were O 0 0.0034326885
younger O 0 0.021710258
( O 0 0.0025917026
32 O 0 0.0017756382
. O 0 0.00087499694
87 O 0 0.0017127369
[ O 0 0.0019161636
+ O 0 0.0010718865
/ O 0 0.0020602685
- O 0 0.0010458162
15 O 0 0.00048269235
. O 0 0.00040245397
8 O 0 0.0005148199
] O 0 0.0008804237
years O 0 0.00091755606
) O 0 0.0011703958
, O 0 0.00085364946
and O 0 0.0007981042
49 O 0 0.0014254552
( O 0 0.0011614293
70 O 0 0.0010772378
% O 0 0.0014510507
) O 0 0.002117386
of O 0 0.00217062
them O 0 0.0047574528
were O 0 0.004895103
women O 0 0.06689836
. O 0 0.00857802

Most O 0 0.013567286
had O 0 0.007226022
hyperacute O 0 0.93273157
presentation O 0 0.023915386
; O 0 0.0047268006
the O 0 0.0018969398
median O 0 0.002268113
icterus B-Disease 0 0.999859
encephalopathy B-Disease 2 0.9999647
interval O 0 0.0033906628
was O 0 0.0013080761
4 O 0 0.0010175239
. O 0 0.00083072117
5 O 0 0.0010331932
( O 0 0.0017022517
0 O 0 0.0019975835
- O 0 0.002519271
30 O 0 0.002088153
) O 0 0.004421209
days O 0 0.0041815257
. O 0 0.0070421356

The O 0 0.008018924
median O 0 0.005823194
duration O 0 0.005110882
of O 0 0.0053619
ATT O 0 0.5848826
before O 0 0.0028866397
ALF B-Disease 2 0.99923825
was O 0 0.003195904
30 O 0 0.0021759246
( O 0 0.0030833564
7 O 0 0.0026117838
- O 0 0.003973713
350 O 0 0.0053020255
) O 0 0.0061679278
days O 0 0.0052786767
. O 0 0.00830205

At O 0 0.0070047146
presentation O 0 0.01056623
, O 0 0.0064446395
advanced O 0 0.10067717
encephalopathy B-Disease 2 0.99989676
and O 0 0.006540089
cerebral B-Disease 0 0.98505104
edema I-Disease 2 0.999899
were O 0 0.0013737665
present O 0 0.0006225452
in O 0 0.0007259529
51 O 0 0.0015541931
( O 0 0.0009773221
76 O 0 0.0011816127
% O 0 0.00081439654
) O 0 0.0009822457
and O 0 0.00072181073
29 O 0 0.001253486
( O 0 0.0010113751
41 O 0 0.001362769
. O 0 0.0007018683
4 O 0 0.00096816086
% O 0 0.0016632851
) O 0 0.002830268
patients O 0 0.004829921
, O 0 0.0052701286
respectively O 0 0.008597853
. O 0 0.008038114

Gastrointestinal B-Disease 0 0.9839252
bleed I-Disease 0 0.98649085
, O 0 0.020299487
seizures B-Disease 2 0.99991524
, O 0 0.008387375
infection B-Disease 2 0.36467242
, O 0 0.0028274902
and O 0 0.0017265707
acute B-Disease 0 0.9550517
renal I-Disease 0 0.99741733
failure I-Disease 0 0.8644818
were O 0 0.00088685844
documented O 0 0.0009055677
in O 0 0.00047019785
seven O 0 0.00052991044
( O 0 0.0008183998
10 O 0 0.0005029083
% O 0 0.00062375556
) O 0 0.0008041081
, O 0 0.00051023846
five O 0 0.00030701954
( O 0 0.00061117805
7 O 0 0.00039494594
. O 0 0.00029955947
1 O 0 0.00042573092
% O 0 0.0005538054
) O 0 0.00078472955
, O 0 0.0005819979
26 O 0 0.0006244054
( O 0 0.0005788435
37 O 0 0.0005371673
. O 0 0.00034631765
1 O 0 0.00049517327
% O 0 0.0006637897
) O 0 0.00095912354
, O 0 0.00074145856
and O 0 0.00069288665
seven O 0 0.00079101126
( O 0 0.001405031
10 O 0 0.0011547894
% O 0 0.00177786
) O 0 0.0029091698
patients O 0 0.0049040886
, O 0 0.005179052
respectively O 0 0.008436372
. O 0 0.007877686

Compared O 0 0.011556188
with O 0 0.015149441
hepatitis B-Disease 2 0.99993503
E I-Disease 0 0.999571
virus O 0 0.73047674
( O 0 0.017895073
HEV O 0 0.9254978
) O 0 0.0040475004
and O 0 0.0015440463
non O 0 0.0036408836
- O 0 0.0028574385
A O 0 0.05706721
non O 0 0.0078826975
- O 0 0.013247819
E O 0 0.9950315
- O 0 0.005975173
induced O 0 0.0023102183
ALF B-Disease 2 0.9999496
, O 0 0.009162706
ATT O 0 0.9523982
- O 0 0.004579482
ALF B-Disease 2 0.9996855
patients O 0 0.002070281
had O 0 0.00048609273
nearly O 0 0.000483108
similar O 0 0.00037832037
presentations O 0 0.0021299925
except O 0 0.00051978865
for O 0 0.0005929351
older O 0 0.0025451314
age O 0 0.001978695
and O 0 0.0014704592
less O 0 0.0017694697
elevation O 0 0.22760913
of O 0 0.0052367793
liver O 0 0.9801733
enzymes O 0 0.68962544
. O 0 0.011002705

The O 0 0.008155157
mortality O 0 0.044891264
rate O 0 0.0044573275
among O 0 0.0036310926
patients O 0 0.00551589
with O 0 0.003298316
ATT O 0 0.9479881
- O 0 0.012340017
ALF B-Disease 2 0.9997522
was O 0 0.0013169465
high O 0 0.0012793537
( O 0 0.0012822797
67 O 0 0.0014095703
. O 0 0.0004251802
1 O 0 0.00048790174
% O 0 0.0005300044
, O 0 0.00051459967
n O 0 0.000504529
= O 0 0.00065888854
47 O 0 0.0009321447
) O 0 0.00081408845
, O 0 0.0005585835
and O 0 0.0004635241
only O 0 0.00045171587
23 O 0 0.0008503396
( O 0 0.00074680714
32 O 0 0.0007363818
. O 0 0.00046558774
9 O 0 0.0006959172
% O 0 0.0009834743
) O 0 0.0014847597
patients O 0 0.0020157516
recovered O 0 0.0016165728
with O 0 0.003082345
medical O 0 0.03938735
treatment O 0 0.010335393
. O 0 0.0089182425

In O 0 0.0075838272
multivariate O 0 0.010195677
analysis O 0 0.0050866446
, O 0 0.0034183087
three O 0 0.001580736
factors O 0 0.0030648354
independently O 0 0.0012791222
predicted O 0 0.0012111635
mortality O 0 0.45469573
: O 0 0.0032524064
serum O 0 0.40688774
bilirubin B-Chemical 1 0.99994516
( O 0 0.0036343306
> O 0 0.0012761299
or O 0 0.0005340366
= O 0 0.0007072425
10 O 0 0.00039247313
. O 0 0.00027522637
8 O 0 0.00034875784
mg O 0 0.054816227
/ O 0 0.0016187679
dL O 0 0.014779768
) O 0 0.0011581823
, O 0 0.00083390303
prothrombin O 0 0.8164417
time O 0 0.00048193766
( O 0 0.0010102007
PT O 0 0.042094417
) O 0 0.0011680385
prolongation O 0 0.026823496
( O 0 0.00095880724
> O 0 0.0007982768
or O 0 0.00045700368
= O 0 0.0006764647
26 O 0 0.00059197686
seconds O 0 0.00055914494
) O 0 0.0010478643
, O 0 0.00095816626
and O 0 0.0011833896
grade O 0 0.45701867
III O 0 0.23665309
/ O 0 0.015788108
IV O 0 0.80830806
encephalopathy B-Disease 2 0.9998416
at O 0 0.00493997
presentation O 0 0.030437518
. O 0 0.009992953

CONCLUSION O 0 0.83918655
: O 0 0.017695896
ATT O 0 0.7685109
- O 0 0.012852969
ALF B-Disease 2 0.998547
constituted O 0 0.0058185803
5 O 0 0.002112973
. O 0 0.0013370647
7 O 0 0.001223306
% O 0 0.0013685536
of O 0 0.00160854
ALF B-Disease 2 0.99905926
at O 0 0.0010183608
our O 0 0.0010109007
center O 0 0.0013564811
and O 0 0.0015913629
had O 0 0.0016842785
a O 0 0.0029394552
high O 0 0.004140304
mortality O 0 0.3516281
rate O 0 0.0077424217
. O 0 0.010083715

Because O 0 0.007562904
the O 0 0.005969597
mortality O 0 0.053645786
rate O 0 0.003693902
is O 0 0.0026995607
so O 0 0.0020974025
high O 0 0.0022646594
, O 0 0.0021114363
determining O 0 0.0012787402
which O 0 0.0020346052
factors O 0 0.0049339784
are O 0 0.0023198933
predictors O 0 0.0026641958
is O 0 0.0031802137
less O 0 0.004003492
important O 0 0.005535309
. O 0 0.008791333

A O 0 0.02821469
high O 0 0.0075354637
proportion O 0 0.004342883
of O 0 0.004265827
patients O 0 0.005667379
had O 0 0.002931989
consumed O 0 0.014340428
ATT O 0 0.7576771
empirically O 0 0.006032233
, O 0 0.0035519234
which O 0 0.0031021272
could O 0 0.0026456998
have O 0 0.003749321
been O 0 0.006300754
prevented O 0 0.013654716
. O 0 0.011086214

Design O 0 0.09996752
and O 0 0.0068510445
analysis O 0 0.0047555114
of O 0 0.0035546226
the O 0 0.003015702
HYPREN O 0 0.3003149
- O 0 0.0034057882
trial O 0 0.0019867455
: O 0 0.0014412366
safety O 0 0.0016667122
of O 0 0.001647667
enalapril B-Chemical 1 0.99998987
and O 0 0.0044216225
prazosin B-Chemical 1 0.9999932
in O 0 0.00088031136
the O 0 0.0006778337
initial O 0 0.00072587986
treatment O 0 0.0012744197
phase O 0 0.0015189348
of O 0 0.0014788467
patients O 0 0.007353244
with O 0 0.004126272
congestive B-Disease 0 0.9999416
heart I-Disease 0 0.9721639
failure I-Disease 0 0.932764
. O 0 0.010671362

Since O 0 0.0067373933
the O 0 0.0050316863
introduction O 0 0.0038489944
of O 0 0.005285975
angiotensin B-Chemical 1 0.9998827
converting I-Chemical 0 0.80251235
enzyme I-Chemical 0 0.77867454
( I-Chemical 0 0.020832445
ACE I-Chemical 0 0.99974865
) I-Chemical 0 0.0041082683
inhibitors I-Chemical 0 0.015302222
into O 0 0.00034175703
the O 0 0.00040740162
adjunctive O 0 0.0069000567
treatment O 0 0.0007297536
of O 0 0.0006253291
patients O 0 0.0035395592
with O 0 0.000898645
congestive B-Disease 0 0.99998176
heart I-Disease 0 0.9331893
failure I-Disease 0 0.8201311
, O 0 0.0010263084
cases O 0 0.0009170653
of O 0 0.0008214336
severe O 0 0.583123
hypotension B-Disease 2 0.9999856
, O 0 0.001335556
especially O 0 0.0005984674
on O 0 0.00032160943
the O 0 0.00043231735
first O 0 0.00042612557
day O 0 0.00058681716
of O 0 0.0010767597
treatment O 0 0.002399706
, O 0 0.0024586176
have O 0 0.0020196806
occasionally O 0 0.006806945
been O 0 0.0047514215
reported O 0 0.007432075
. O 0 0.008704737

To O 0 0.005993236
assess O 0 0.0029453656
the O 0 0.002946262
safety O 0 0.0036127593
of O 0 0.0025516113
the O 0 0.0026884906
ACE B-Chemical 1 0.99986136
inhibitor I-Chemical 1 0.91875
enalapril B-Chemical 0 0.9999944
a O 0 0.0072359797
multicenter O 0 0.16137658
, O 0 0.0013059214
randomized O 0 0.0010480898
, O 0 0.0016224402
prazosin B-Chemical 1 0.99999356
- O 0 0.0020279682
controlled O 0 0.0004600721
trial O 0 0.00061160396
was O 0 0.00034834014
designed O 0 0.00035788145
that O 0 0.00026113307
compared O 0 0.00024152182
the O 0 0.00040667172
incidence O 0 0.004026098
and O 0 0.0007850119
severity O 0 0.03462113
of O 0 0.0013510487
symptomatic O 0 0.5204399
hypotension B-Disease 2 0.9999441
on O 0 0.0009074584
the O 0 0.0012089307
first O 0 0.0013013032
day O 0 0.001983811
of O 0 0.003970582
treatment O 0 0.009964812
. O 0 0.008860502

Trial O 0 0.041102972
medication O 0 0.08640252
was O 0 0.006161874
2 O 0 0.0043794042
. O 0 0.0029011718
5 O 0 0.0028318937
mg O 0 0.36856097
enalapril B-Chemical 1 0.99990785
or O 0 0.0044158767
0 O 0 0.005179855
. O 0 0.003661027
5 O 0 0.0064909346
prazosin B-Chemical 1 0.99981123
. O 0 0.013159602

Subjects O 0 0.014742169
were O 0 0.008949088
1210 O 0 0.27829865
inpatients O 0 0.021444043
with O 0 0.004759056
New O 0 0.007994129
York O 0 0.022233175
Heart O 0 0.15596473
Association O 0 0.0037248144
( O 0 0.0035577237
NYHA O 0 0.9419065
) O 0 0.0040497384
functional O 0 0.0033766446
class O 0 0.007578987
II O 0 0.109817035
and O 0 0.008585779
III O 0 0.2432233
. O 0 0.011463451

Patients O 0 0.01373697
who O 0 0.007651842
received O 0 0.004981844
enalapril B-Chemical 1 0.99992526
experienced O 0 0.008295336
clinically O 0 0.044361573
and O 0 0.0014423609
statistically O 0 0.00088226283
significantly O 0 0.0009845697
less O 0 0.0008037948
symptomatic O 0 0.3596259
hypotension B-Disease 2 0.99998367
( O 0 0.0025661315
5 O 0 0.000560096
. O 0 0.00036559382
2 O 0 0.00044444308
% O 0 0.0005598371
) O 0 0.00065829547
than O 0 0.00030698147
the O 0 0.00043425322
patients O 0 0.0011087048
who O 0 0.0013233462
received O 0 0.0013776905
prazosin B-Chemical 1 0.9999876
( O 0 0.0033211112
12 O 0 0.0013058368
. O 0 0.0014373534
9 O 0 0.0025377607
% O 0 0.004227769
) O 0 0.00760357
. O 0 0.0072717085

All O 0 0.06297826
patients O 0 0.06971812
recovered O 0 0.06168257
. O 0 0.06503157

It O 0 0.009840067
was O 0 0.005132813
concluded O 0 0.0035881088
that O 0 0.002276776
treatment O 0 0.003193292
with O 0 0.002887392
enalapril B-Chemical 1 0.9999831
was O 0 0.0015723392
well O 0 0.0009023379
tolerated O 0 0.01893847
and O 0 0.0009538025
it O 0 0.00081791094
is O 0 0.0006653605
, O 0 0.0008231621
therefore O 0 0.00070818845
, O 0 0.0008697
unreasonable O 0 0.0019087401
to O 0 0.00047590848
restrict O 0 0.0004628618
the O 0 0.0006531883
initiation O 0 0.0009270156
of O 0 0.0013728831
treatment O 0 0.0033499966
with O 0 0.005270131
enalapril B-Chemical 1 0.99996936
to O 0 0.0058083665
inpatients O 0 0.34835836
. O 0 0.008672049

Central B-Disease 0 0.019095175
nervous I-Disease 0 0.8020615
system I-Disease 0 0.008778072
complications I-Disease 0 0.37903857
during O 0 0.0029540884
treatment O 0 0.004266682
of O 0 0.006579815
acute B-Disease 2 0.99954814
lymphoblastic I-Disease 2 0.9999889
leukemia I-Disease 2 0.99997437
in O 0 0.0061992677
a O 0 0.005822689
single O 0 0.004851917
pediatric O 0 0.011777638
institution O 0 0.010479296
. O 0 0.0102553945

Central B-Disease 0 0.019819848
nervous I-Disease 0 0.8850288
system I-Disease 0 0.011292012
( I-Disease 0 0.0076764957
CNS I-Disease 0 0.8727072
) I-Disease 0 0.0050679646
complications I-Disease 0 0.34855807
during O 0 0.001173284
treatment O 0 0.0019595725
of O 0 0.0027163154
childhood O 0 0.99429506
acute B-Disease 2 0.9998771
lymphoblastic I-Disease 2 0.99999654
leukemia I-Disease 2 0.99999464
( O 0 0.3187988
ALL B-Disease 0 0.9997683
) O 0 0.006857835
remain O 0 0.001995685
a O 0 0.0029582893
challenging O 0 0.0038792011
clinical O 0 0.01731996
problem O 0 0.01163154
. O 0 0.008840781

Outcome O 0 0.017633978
improvement O 0 0.006424805
with O 0 0.003913357
more O 0 0.003083072
intensive O 0 0.0023657118
chemotherapy O 0 0.5034109
has O 0 0.0016955577
significantly O 0 0.002085631
increased O 0 0.0019559928
the O 0 0.0017022645
incidence O 0 0.016480291
and O 0 0.0031498694
severity O 0 0.11523576
of O 0 0.0070518847
adverse O 0 0.9889759
events O 0 0.39148444
. O 0 0.011553214

This O 0 0.009725847
study O 0 0.005234865
analyzed O 0 0.003077268
the O 0 0.0024946718
incidence O 0 0.006223
of O 0 0.0033601439
neurological B-Disease 0 0.9993692
complications I-Disease 0 0.99136895
during O 0 0.0015571158
ALL B-Disease 0 0.99928826
treatment O 0 0.0021520949
in O 0 0.00068514387
a O 0 0.00087681465
single O 0 0.00068553473
pediatric O 0 0.0015043605
institution O 0 0.00107333
, O 0 0.0009837592
focusing O 0 0.0011075996
on O 0 0.0006301588
clinical O 0 0.0063701742
, O 0 0.0021175123
radiological O 0 0.056785878
, O 0 0.0032684202
and O 0 0.0035147818
electrophysiological O 0 0.23085748
findings O 0 0.013201783
. O 0 0.009251325

Exclusion O 0 0.39188728
criteria O 0 0.0074936603
included O 0 0.0048105214
CNS O 0 0.9175385
leukemic B-Disease 0 0.99880886
infiltration I-Disease 0 0.9279392
at O 0 0.0016480449
diagnosis O 0 0.023402905
, O 0 0.002259367
therapy O 0 0.024679927
- O 0 0.0022126778
related O 0 0.0007716571
peripheral B-Disease 2 0.85238934
neuropathy I-Disease 2 0.99999166
, O 0 0.0068931626
late O 0 0.02063754
- O 0 0.0042706323
onset O 0 0.04053777
encephalopathy B-Disease 2 0.99996555
, O 0 0.0032623035
or O 0 0.0016890992
long O 0 0.002330598
- O 0 0.004039102
term O 0 0.0037453938
neurocognitive B-Disease 0 0.9882637
defects I-Disease 0 0.047335155
. O 0 0.0097931195

During O 0 0.0071509834
a O 0 0.0066436925
9 O 0 0.004704421
- O 0 0.0037696715
year O 0 0.0019030863
period O 0 0.0013391133
, O 0 0.0012971035
we O 0 0.00065305387
retrospectively O 0 0.0009039996
collected O 0 0.0006262723
27 O 0 0.0012331011
neurological O 0 0.95851874
events O 0 0.0457379
( O 0 0.0012421819
11 O 0 0.00079505565
% O 0 0.00070047914
) O 0 0.0007660358
in O 0 0.00038573326
as O 0 0.00046182086
many O 0 0.0005963308
patients O 0 0.001718082
, O 0 0.00086636894
from O 0 0.00067570823
253 O 0 0.0097101815
children O 0 0.0012824965
enrolled O 0 0.0012352049
in O 0 0.0009278467
the O 0 0.0017045236
ALL B-Disease 0 0.99835396
front O 0 0.008661046
- O 0 0.006247662
line O 0 0.0061415345
protocol O 0 0.007539134
. O 0 0.008396295

CNS O 0 0.7159194
complications O 0 0.4928016
included O 0 0.004753643
posterior O 0 0.018895006
reversible O 0 0.60707265
leukoencephalopathy B-Disease 2 0.99976176
syndrome O 0 0.9864933
( O 0 0.0032423951
n O 0 0.001366257
= O 0 0.0012560143
10 O 0 0.0007185377
) O 0 0.0011458665
, O 0 0.0009360714
stroke B-Disease 2 0.9978454
( O 0 0.00084799953
n O 0 0.00057825237
= O 0 0.0006489522
5 O 0 0.0003820695
) O 0 0.0007186753
, O 0 0.00059251476
temporal B-Disease 2 0.017888537
lobe I-Disease 2 0.62277126
epilepsy I-Disease 2 0.99997306
( O 0 0.0011197467
n O 0 0.00062137825
= O 0 0.0006839383
2 O 0 0.00044109876
) O 0 0.0007194547
, O 0 0.000516908
high O 0 0.00055435515
- O 0 0.0008912974
dose O 0 0.013585728
methotrexate B-Chemical 1 0.99995816
toxicity B-Disease 2 0.9992949
( O 0 0.0014364606
n O 0 0.0006679788
= O 0 0.0007328346
2 O 0 0.0004507128
) O 0 0.00079377036
, O 0 0.0006087421
syndrome O 0 0.4566387
of O 0 0.0008864478
inappropriate B-Disease 0 0.078688554
antidiuretic I-Disease 0 0.9993703
hormone I-Disease 0 0.9973801
secretion I-Disease 0 0.13340843
( O 0 0.0014070917
n O 0 0.00078088406
= O 0 0.00091471476
1 O 0 0.00063362555
) O 0 0.0009312752
, O 0 0.0006951797
and O 0 0.00064300996
other O 0 0.0008180817
unclassified O 0 0.03559995
events O 0 0.035822492
( O 0 0.0025568157
n O 0 0.0024026209
= O 0 0.0035149206
7 O 0 0.0034717016
) O 0 0.007095212
. O 0 0.0069742827

In O 0 0.007625752
conclusion O 0 0.0052858195
, O 0 0.0062396447
CNS O 0 0.7420603
complications O 0 0.64482486
are O 0 0.002445352
frequent O 0 0.004708866
events O 0 0.040852442
during O 0 0.0012369992
ALL B-Disease 0 0.99903584
therapy O 0 0.04401789
, O 0 0.0015207654
and O 0 0.0008855045
require O 0 0.00053801073
rapid O 0 0.0013574782
detection O 0 0.001075846
and O 0 0.0013143953
prompt O 0 0.0045727957
treatment O 0 0.002708982
to O 0 0.0022948594
limit O 0 0.005259789
permanent O 0 0.13590755
damage O 0 0.86849487
. O 0 0.010986093

Cocaine B-Chemical 1 0.99970347
causes O 0 0.027898142
memory B-Disease 0 0.22527201
and I-Disease 0 0.004289702
learning I-Disease 0 0.010066486
impairments I-Disease 0 0.29188862
in O 0 0.0014509729
rats O 0 0.0041129864
: O 0 0.0016786978
involvement O 0 0.0017404964
of O 0 0.0011752571
nuclear O 0 0.01007814
factor O 0 0.029916886
kappa O 0 0.31290948
B O 0 0.5971819
and O 0 0.0030514344
oxidative O 0 0.9903564
stress O 0 0.852184
, O 0 0.0062396503
and O 0 0.003702515
prevention O 0 0.051724836
by O 0 0.015390828
topiramate B-Chemical 0 0.999938
. O 0 0.011146052

Different O 0 0.012239436
mechanisms O 0 0.0073460634
have O 0 0.0037077141
been O 0 0.002838498
suggested O 0 0.001811066
for O 0 0.0016328356
cocaine B-Chemical 1 0.999938
toxicity B-Disease 2 0.99920624
including O 0 0.0014531327
an O 0 0.0016041481
increase O 0 0.0006569098
in O 0 0.00084428594
oxidative O 0 0.9830882
stress O 0 0.67269504
but O 0 0.00084974023
the O 0 0.0005231129
association O 0 0.00042895853
between O 0 0.00044141005
oxidative O 0 0.94924414
status O 0 0.0022368375
in O 0 0.0006777317
the O 0 0.0008238369
brain O 0 0.105419435
and O 0 0.0023803194
cocaine B-Chemical 1 0.9999341
induced O 0 0.0037227448
- O 0 0.006046121
behaviour O 0 0.008563912
is O 0 0.0031889328
poorly O 0 0.009895261
understood O 0 0.011451278
. O 0 0.008278794

Nuclear O 0 0.29788515
factor O 0 0.038963906
kappa O 0 0.38046554
B O 0 0.7151988
( O 0 0.010141574
NFkappaB O 0 0.776409
) O 0 0.004147701
is O 0 0.0012928747
a O 0 0.0013014922
sensor O 0 0.0012420553
of O 0 0.0015823932
oxidative O 0 0.9863805
stress O 0 0.7790904
and O 0 0.002127782
participates O 0 0.0011311818
in O 0 0.0008055088
memory O 0 0.16021565
formation O 0 0.0021029275
that O 0 0.00063905347
could O 0 0.00063025247
be O 0 0.0008923328
involved O 0 0.0008572097
in O 0 0.001408439
drug O 0 0.9769942
toxicity B-Disease 2 0.9997565
and O 0 0.016369738
addiction O 0 0.9969177
mechanisms O 0 0.021014037
. O 0 0.0099228425

Therefore O 0 0.009060315
NFkappaB O 0 0.46518323
activity O 0 0.007624799
, O 0 0.006984114
oxidative O 0 0.9822933
stress O 0 0.9196225
, O 0 0.024072697
neuronal O 0 0.948499
nitric B-Chemical 0 0.99994564
oxide I-Chemical 0 0.9998259
synthase O 0 0.99129057
( O 0 0.014436788
nNOS O 0 0.6065352
) O 0 0.0014723128
activity O 0 0.0006786796
, O 0 0.0006427832
spatial O 0 0.0010427138
learning O 0 0.0013708312
and O 0 0.0005566356
memory O 0 0.047489926
as O 0 0.00041785155
well O 0 0.00034783574
as O 0 0.00037744665
the O 0 0.00035602954
effect O 0 0.0004191435
of O 0 0.0011807678
topiramate B-Chemical 0 0.99999475
, O 0 0.0010260815
a O 0 0.00060162373
previously O 0 0.00040267676
proposed O 0 0.0005525763
therapy O 0 0.0070501626
for O 0 0.0006454739
cocaine B-Disease 1 0.99999285
addiction I-Disease 0 0.99974304
, O 0 0.001650765
were O 0 0.0005208118
evaluated O 0 0.00041799736
in O 0 0.0004920196
an O 0 0.00078053743
experimental O 0 0.0008535445
model O 0 0.0012674917
of O 0 0.0029208488
cocaine B-Chemical 1 0.99991775
administration O 0 0.3524627
in O 0 0.00474743
rats O 0 0.022638949
. O 0 0.008554515

NFkappaB O 0 0.47556663
activity O 0 0.007197609
was O 0 0.0039417576
decreased O 0 0.0033334168
in O 0 0.0018167832
the O 0 0.0017942487
frontal O 0 0.38222682
cortex O 0 0.12588333
of O 0 0.0015784777
cocaine B-Chemical 1 0.9999273
treated O 0 0.0019294416
rats O 0 0.006579507
, O 0 0.0009690833
as O 0 0.0005698541
well O 0 0.0005891619
as O 0 0.0012525294
GSH B-Chemical 1 0.99998105
concentration O 0 0.009732373
and O 0 0.003490811
glutathione B-Chemical 1 0.9999722
peroxidase O 0 0.98764837
activity O 0 0.0013067181
in O 0 0.00061061536
the O 0 0.00082502596
hippocampus O 0 0.2843198
, O 0 0.001256359
whereas O 0 0.0009132018
nNOS O 0 0.16071844
activity O 0 0.0012490668
in O 0 0.0013015702
the O 0 0.00216845
hippocampus O 0 0.23004074
was O 0 0.003881592
increased O 0 0.006457065
. O 0 0.00821702

Memory O 0 0.4282342
retrieval O 0 0.007851602
of O 0 0.004745929
experiences O 0 0.0074073714
acquired O 0 0.0041710925
prior O 0 0.0013415284
to O 0 0.0016290111
cocaine B-Chemical 1 0.99990547
administration O 0 0.2816735
was O 0 0.0014157142
impaired O 0 0.0015971512
and O 0 0.001226271
negatively O 0 0.0015629892
correlated O 0 0.0011254771
with O 0 0.002112973
NFkappaB O 0 0.77692336
activity O 0 0.0025522131
in O 0 0.0023089577
the O 0 0.0039248164
frontal O 0 0.6947702
cortex O 0 0.33695632
. O 0 0.0084284935

In O 0 0.0076415157
contrast O 0 0.00569152
, O 0 0.0047220876
learning O 0 0.004452197
of O 0 0.0022298608
new O 0 0.0022383686
tasks O 0 0.002930508
was O 0 0.0011395627
enhanced O 0 0.0010293293
and O 0 0.00100094
correlated O 0 0.0006738497
with O 0 0.00081302406
the O 0 0.0007673941
increase O 0 0.000666538
of O 0 0.0014266083
nNOS O 0 0.3294468
activity O 0 0.0013242073
and O 0 0.0014246411
the O 0 0.0015550533
decrease O 0 0.0022714506
of O 0 0.0074214987
glutathione B-Chemical 1 0.99986434
peroxidase O 0 0.9942204
. O 0 0.012555876

These O 0 0.008393048
results O 0 0.0051327744
provide O 0 0.0030942203
evidence O 0 0.0024934497
for O 0 0.0016662427
a O 0 0.0018997912
possible O 0 0.0013252305
mechanistic O 0 0.0021697155
role O 0 0.0009288706
of O 0 0.0020518086
oxidative O 0 0.98998547
and O 0 0.014378058
nitrosative O 0 0.99973804
stress O 0 0.9319785
and O 0 0.007782436
NFkappaB O 0 0.8472419
in O 0 0.0015930542
the O 0 0.0019086655
alterations O 0 0.01255765
induced O 0 0.004707072
by O 0 0.012460651
cocaine B-Chemical 1 0.99978894
. O 0 0.011767945

Topiramate B-Chemical 0 0.99957293
prevented O 0 0.017523484
all O 0 0.005995116
the O 0 0.004950188
alterations O 0 0.008339456
observed O 0 0.003426183
, O 0 0.0052403254
showing O 0 0.004688978
novel O 0 0.009603945
neuroprotective O 0 0.9567141
properties O 0 0.022885276
. O 0 0.0138615025

Efficacy O 0 0.03248677
and O 0 0.006230332
safety O 0 0.0060089165
of O 0 0.00443559
asenapine B-Chemical 1 0.99982893
in O 0 0.002001081
a O 0 0.002387567
placebo O 0 0.3687036
- O 0 0.0034507758
and O 0 0.0024732533
haloperidol B-Chemical 1 0.999995
- O 0 0.0029801512
controlled O 0 0.0008837006
trial O 0 0.0011986421
in O 0 0.0008679276
patients O 0 0.0028449066
with O 0 0.0022293727
acute O 0 0.9844602
exacerbation O 0 0.9945569
of O 0 0.066384435
schizophrenia B-Disease 2 0.9997559
. O 0 0.012640812

Asenapine B-Chemical 0 0.998016
is O 0 0.007239655
approved O 0 0.004986193
by O 0 0.0035463497
the O 0 0.0027376579
Food O 0 0.7179607
and O 0 0.0029498695
Drugs O 0 0.98688203
Administration O 0 0.39600033
in O 0 0.0008783624
adults O 0 0.0022546388
for O 0 0.00054417306
acute O 0 0.8671682
treatment O 0 0.0023100325
of O 0 0.0022709032
schizophrenia B-Disease 2 0.99987257
or O 0 0.00089238293
of O 0 0.0023543595
manic B-Disease 2 0.99998975
or O 0 0.0009067264
mixed O 0 0.006128616
episodes O 0 0.5430903
associated O 0 0.0018603136
with O 0 0.0037556246
bipolar B-Disease 2 0.9999242
I I-Disease 0 0.8268784
disorder I-Disease 0 0.9969464
with O 0 0.0027177986
or O 0 0.002965237
without O 0 0.0063811424
psychotic B-Disease 0 0.99992704
features O 0 0.04940347
. O 0 0.010584776

In O 0 0.007734858
a O 0 0.0066222055
double O 0 0.0048192916
- O 0 0.0046986514
blind O 0 0.0060783485
6 O 0 0.0015490501
- O 0 0.0016297216
week O 0 0.0007414804
trial O 0 0.001099096
, O 0 0.0010000846
458 O 0 0.0036581345
patients O 0 0.0012894266
with O 0 0.0007936871
acute O 0 0.97259134
schizophrenia B-Disease 2 0.99984765
were O 0 0.00056955783
randomly O 0 0.00025024067
assigned O 0 0.00025943812
to O 0 0.00030920174
fixed O 0 0.00047296172
- O 0 0.0008250861
dose O 0 0.0029804194
treatment O 0 0.00085453084
with O 0 0.00077603856
asenapine B-Chemical 1 0.99995327
at O 0 0.00031191533
5 O 0 0.00031729724
mg O 0 0.03003201
twice O 0 0.00040546147
daily O 0 0.0010134589
( O 0 0.00097288546
BID O 0 0.9851339
) O 0 0.0014514371
, O 0 0.0008786915
asenapine B-Chemical 1 0.9998203
at O 0 0.00030414376
10 O 0 0.00041322605
mg O 0 0.15855213
BID O 0 0.9761253
, O 0 0.00076776126
placebo O 0 0.06232325
, O 0 0.00078722776
or O 0 0.0007624337
haloperidol B-Chemical 1 0.99999154
at O 0 0.0005407597
4 O 0 0.00069359323
mg O 0 0.26412967
BID O 0 0.9731713
( O 0 0.001541366
to O 0 0.0010730722
verify O 0 0.0010497116
assay O 0 0.003632145
sensitivity O 0 0.007821027
) O 0 0.012100841
. O 0 0.008055824

With O 0 0.009316384
last O 0 0.00476099
observations O 0 0.004505802
carried O 0 0.003036012
forward O 0 0.015224296
( O 0 0.005000906
LOCF O 0 0.83519137
) O 0 0.0021724405
, O 0 0.0011392123
mean O 0 0.0007560076
Positive O 0 0.0073469914
and O 0 0.0011391486
Negative O 0 0.34169838
Syndrome O 0 0.96938634
Scale O 0 0.9397638
total O 0 0.0005168496
score O 0 0.00064578425
reductions O 0 0.00048393503
from O 0 0.0003460579
baseline O 0 0.0004048198
to O 0 0.00029057972
endpoint O 0 0.0007223453
were O 0 0.0003690129
significantly O 0 0.00046755347
greater O 0 0.0003905627
with O 0 0.00064025866
asenapine B-Chemical 1 0.9999405
at O 0 0.00032190178
5 O 0 0.00037228633
mg O 0 0.20828289
BID O 0 0.98698866
( O 0 0.0010501002
- O 0 0.000793167
16 O 0 0.00042564774
. O 0 0.00027697132
2 O 0 0.0004034089
) O 0 0.0007356411
and O 0 0.00081331155
haloperidol B-Chemical 1 0.99999654
( O 0 0.0020495134
- O 0 0.00093882956
15 O 0 0.00032436656
. O 0 0.0002531134
4 O 0 0.00030862805
) O 0 0.0004919099
than O 0 0.00025772175
placebo O 0 0.05333672
( O 0 0.00089141296
- O 0 0.0007570775
10 O 0 0.00038093296
. O 0 0.0002729802
7 O 0 0.00035481583
; O 0 0.0005245794
both O 0 0.00036856259
P O 0 0.024080317
< O 0 0.0005021667
0 O 0 0.00058916444
. O 0 0.00037255316
05 O 0 0.0483124
) O 0 0.0007450159
; O 0 0.0005600308
using O 0 0.00027426844
mixed O 0 0.00056598306
model O 0 0.00040071114
for O 0 0.00026474553
repeated O 0 0.00037336914
measures O 0 0.00055260427
( O 0 0.0011725293
MMRM O 0 0.9666072
) O 0 0.0010084906
, O 0 0.0004911059
changes O 0 0.00036372824
at O 0 0.00021638283
day O 0 0.0002532457
42 O 0 0.00041307558
were O 0 0.00028636685
significantly O 0 0.0003952985
greater O 0 0.0003625918
with O 0 0.00060977903
asenapine B-Chemical 1 0.9999362
at O 0 0.00030614063
5 O 0 0.00030357655
and O 0 0.00035983213
10 O 0 0.0004055576
mg O 0 0.2034853
BID O 0 0.98622847
( O 0 0.0010091638
- O 0 0.000761052
21 O 0 0.00046811494
. O 0 0.00025674392
3 O 0 0.0003081697
and O 0 0.00043456542
- O 0 0.0006948767
19 O 0 0.000606052
. O 0 0.00027137625
4 O 0 0.00033878913
, O 0 0.00051130523
respectively O 0 0.0008884176
) O 0 0.0010748428
and O 0 0.000982929
haloperidol B-Chemical 1 0.9999968
( O 0 0.0021666833
- O 0 0.0009905446
20 O 0 0.00043520264
. O 0 0.0002938529
0 O 0 0.0005025647
) O 0 0.0005735904
than O 0 0.0003092265
placebo O 0 0.047915634
( O 0 0.0010193333
- O 0 0.0009086156
14 O 0 0.00059032487
. O 0 0.00045064796
6 O 0 0.00056046504
; O 0 0.0010722904
all O 0 0.0009477395
P O 0 0.020017793
< O 0 0.0019023429
0 O 0 0.0026723284
. O 0 0.0027103722
05 O 0 0.052422956
) O 0 0.0076361946
. O 0 0.0074825673

On O 0 0.01024073
the O 0 0.006595536
Positive O 0 0.014286116
and O 0 0.0050640735
Negative O 0 0.31739774
Syndrome O 0 0.969047
Scale O 0 0.95545924
positive O 0 0.0018568558
subscale O 0 0.030506268
, O 0 0.0010594431
all O 0 0.0005566234
treatments O 0 0.0011677447
were O 0 0.0005528798
superior O 0 0.00079683884
to O 0 0.00043913702
placebo O 0 0.053858437
with O 0 0.00077521
LOCF O 0 0.8584142
and O 0 0.0007598298
MMRM O 0 0.9812821
; O 0 0.0016261147
asenapine B-Chemical 1 0.9998393
at O 0 0.00030681555
5 O 0 0.00034043615
mg O 0 0.08760596
BID O 0 0.92530155
was O 0 0.00037053844
superior O 0 0.0005409783
to O 0 0.00031476852
placebo O 0 0.007814399
on O 0 0.000256086
the O 0 0.0003790088
negative O 0 0.00068659463
subscale O 0 0.014203746
with O 0 0.00075891847
MMRM O 0 0.9110257
and O 0 0.0006612671
on O 0 0.0004695061
the O 0 0.000771082
general O 0 0.001332984
psychopathology O 0 0.9833588
subscale O 0 0.055038717
with O 0 0.0035252837
LOCF O 0 0.9080457
and O 0 0.0055010086
MMRM O 0 0.9486138
. O 0 0.00810502

Treatment O 0 0.08077972
- O 0 0.009455601
related O 0 0.0038247486
adverse O 0 0.830857
events O 0 0.17343529
( O 0 0.00505167
AEs O 0 0.9678963
) O 0 0.0024579554
occurred O 0 0.00090798084
in O 0 0.00065789005
44 O 0 0.0009697076
% O 0 0.00067051605
and O 0 0.0005728959
52 O 0 0.00081845484
% O 0 0.0006349706
, O 0 0.00061719504
57 O 0 0.0007990234
% O 0 0.00056011253
, O 0 0.0005272417
and O 0 0.00044667965
41 O 0 0.0007825945
% O 0 0.0004492775
of O 0 0.00044539204
the O 0 0.00056654785
asenapine B-Chemical 1 0.9998797
at O 0 0.0003693971
5 O 0 0.00037968758
and O 0 0.00047029176
10 O 0 0.0005661416
mg O 0 0.26165664
BID O 0 0.99061614
, O 0 0.002865361
haloperidol B-Chemical 1 0.9999894
, O 0 0.0020472305
and O 0 0.0018175918
placebo O 0 0.113540076
groups O 0 0.0037636398
, O 0 0.005424388
respectively O 0 0.008514965
. O 0 0.0076046493

Extrapyramidal B-Disease 0 0.9997267
symptoms I-Disease 0 0.98473907
reported O 0 0.006332806
as O 0 0.0034055065
AEs O 0 0.902611
occurred O 0 0.0017848245
in O 0 0.0010473322
15 O 0 0.0008015858
% O 0 0.00086040364
and O 0 0.0007010361
18 O 0 0.00062643713
% O 0 0.00069382397
, O 0 0.0006613528
34 O 0 0.00066533696
% O 0 0.0005888425
, O 0 0.0005548113
and O 0 0.00045867614
10 O 0 0.00041259118
% O 0 0.00043308616
of O 0 0.00043682609
the O 0 0.0005619869
asenapine B-Chemical 1 0.99987876
at O 0 0.00036692692
5 O 0 0.00037762494
and O 0 0.0004679539
10 O 0 0.0005636703
mg O 0 0.26001278
BID O 0 0.9905476
, O 0 0.002853713
haloperidol B-Chemical 1 0.9999894
, O 0 0.0020433033
and O 0 0.0018153051
placebo O 0 0.1133435
groups O 0 0.003760991
, O 0 0.0054214355
respectively O 0 0.008511246
. O 0 0.0076021957

Across O 0 0.011174564
all O 0 0.0054189344
groups O 0 0.004517789
, O 0 0.0033916784
no O 0 0.0018239662
more O 0 0.002009468
than O 0 0.0013095582
5 O 0 0.001333194
% O 0 0.001550339
of O 0 0.001533176
patients O 0 0.0030232682
had O 0 0.0019858058
clinically O 0 0.019645156
significant O 0 0.004252353
weight O 0 0.017766898
change O 0 0.0074501773
. O 0 0.008910878

Post O 0 0.049463365
hoc O 0 0.016533751
analyses O 0 0.0051397798
indicated O 0 0.0027198002
that O 0 0.0018963675
efficacy O 0 0.003018513
was O 0 0.0014202495
similar O 0 0.00090970757
with O 0 0.001629141
asenapine B-Chemical 1 0.99996185
and O 0 0.0045924135
haloperidol B-Chemical 1 0.99999595
; O 0 0.0027444747
greater O 0 0.0007507942
contrasts O 0 0.0012302111
were O 0 0.00086065044
seen O 0 0.0008688705
in O 0 0.0013206562
AEs O 0 0.9606764
, O 0 0.0036482792
especially O 0 0.009277839
extrapyramidal B-Disease 2 0.99998546
symptoms I-Disease 2 0.99672145
. O 0 0.012303138

Salvage O 0 0.1469504
therapy O 0 0.018062573
with O 0 0.005994502
nelarabine B-Chemical 1 0.96943104
, O 0 0.008412191
etoposide B-Chemical 1 0.99959177
, O 0 0.003652204
and O 0 0.0022398736
cyclophosphamide B-Chemical 1 0.9998646
in O 0 0.001892814
relapsed O 0 0.98696053
/ O 0 0.01954794
refractory O 0 0.4479681
paediatric O 0 0.015947526
T B-Disease 0 0.95458865
- I-Disease 0 0.017033849
cell I-Disease 0 0.41006514
lymphoblastic I-Disease 0 0.9999777
leukaemia I-Disease 0 0.9999602
and I-Disease 0 0.21133506
lymphoma I-Disease 0 0.9994166
. O 0 0.017721077

A O 0 0.027390776
combination O 0 0.006940847
of O 0 0.004428895
5 O 0 0.002595371
d O 0 0.0023703058
of O 0 0.0023056185
nelarabine B-Chemical 1 0.964804
( O 0 0.0040221843
AraG B-Chemical 1 0.820016
) O 0 0.0016739999
with O 0 0.00066630944
5 O 0 0.00049813354
d O 0 0.0006348971
of O 0 0.0009820958
etoposide B-Chemical 1 0.9998418
( O 0 0.006233007
VP B-Chemical 0 0.99327904
) O 0 0.0018430916
and O 0 0.0009155685
cyclophosphamide B-Chemical 1 0.99993813
( O 0 0.004274442
CPM B-Chemical 0 0.99842876
) O 0 0.0012837675
and O 0 0.00045887113
prophylactic O 0 0.00506348
intrathecal O 0 0.9443628
chemotherapy O 0 0.8070819
was O 0 0.00056106795
used O 0 0.0003967701
as O 0 0.0004512618
salvage O 0 0.010082849
therapy O 0 0.0027081203
in O 0 0.00044283058
seven O 0 0.00050680427
children O 0 0.0013954472
with O 0 0.0008652049
refractory O 0 0.28633666
or O 0 0.0021866227
relapsed O 0 0.99643147
T B-Disease 0 0.9762235
- I-Disease 0 0.01734382
cell I-Disease 0 0.22423449
leukaemia I-Disease 0 0.9999026
or I-Disease 0 0.037122644
lymphoma I-Disease 0 0.9992847
. O 0 0.015231868

The O 0 0.0072815665
most O 0 0.0061505055
common O 0 0.0047787726
side O 0 0.038627513
effects O 0 0.003919183
attributable O 0 0.0016667957
to O 0 0.0012976886
the O 0 0.0013770504
AraG B-Chemical 1 0.6259365
included O 0 0.0012168555
Grade O 0 0.8206428
2 O 0 0.00092587963
and O 0 0.0009312406
3 O 0 0.0009630417
sensory O 0 0.020091277
and O 0 0.0023373899
motor O 0 0.88670117
neuropathy B-Disease 2 0.99995947
and O 0 0.020187464
musculoskeletal B-Disease 0 0.9969553
pain I-Disease 2 0.9993161
. O 0 0.013140474

Haematological B-Disease 0 0.99641126
toxicity I-Disease 2 0.9982919
was O 0 0.004659217
greater O 0 0.002343215
for O 0 0.0013867524
the O 0 0.0012590933
combination O 0 0.0017731013
than O 0 0.0008679884
AraG B-Chemical 1 0.6552348
alone O 0 0.0009917527
, O 0 0.00085431506
although O 0 0.00041744707
median O 0 0.0004157136
time O 0 0.00038237555
to O 0 0.00049586
neutrophil O 0 0.11935938
and O 0 0.001369169
platelet O 0 0.914243
recovery O 0 0.0038787331
was O 0 0.0012132862
consistent O 0 0.0011934676
with O 0 0.0019292092
other O 0 0.0031145774
salvage O 0 0.14386617
therapies O 0 0.18512079
. O 0 0.0096158935

All O 0 0.0075855143
patients O 0 0.0070804274
had O 0 0.003359553
some O 0 0.0025922023
response O 0 0.002235062
to O 0 0.001296095
the O 0 0.0010538248
combined O 0 0.0013200318
therapy O 0 0.0036212343
and O 0 0.00076494593
five O 0 0.00041458735
of O 0 0.000592162
the O 0 0.0005045653
seven O 0 0.00049744983
went O 0 0.0008984301
into O 0 0.00032671783
complete O 0 0.00044876177
remission O 0 0.06352377
after O 0 0.00036882985
one O 0 0.0004945191
or O 0 0.0006147839
two O 0 0.0007365834
courses O 0 0.001823184
of O 0 0.0025040708
AraG B-Chemical 1 0.92847747
/ O 0 0.04040222
VP B-Chemical 0 0.9879216
/ O 0 0.04067438
CPM B-Chemical 0 0.99353373
. O 0 0.009712007

Our O 0 0.007862693
experience O 0 0.006562403
supports O 0 0.002987586
the O 0 0.002340258
safety O 0 0.002889526
of O 0 0.001862829
giving O 0 0.0023004056
AraG B-Chemical 1 0.6855045
as O 0 0.0010505419
salvage O 0 0.019461561
therapy O 0 0.006945446
in O 0 0.0007118643
synchrony O 0 0.00847318
with O 0 0.0012464948
etoposide B-Chemical 1 0.9997576
and O 0 0.0029454345
cyclophosphamide B-Chemical 1 0.9999491
, O 0 0.003467382
although O 0 0.0017541257
neurological B-Disease 0 0.9996364
toxicity I-Disease 2 0.9996476
must O 0 0.0018612994
be O 0 0.0027490573
closely O 0 0.0031936564
monitored O 0 0.0036475568
. O 0 0.0072275815

Effect O 0 0.012592428
of O 0 0.009731288
adriamycin B-Chemical 1 0.9989182
combined O 0 0.0073680505
with O 0 0.0038472775
whole O 0 0.0037312857
body O 0 0.042523913
hyperthermia B-Disease 2 0.99922967
on O 0 0.003735037
tumor B-Disease 2 0.9506427
and O 0 0.007473741
normal O 0 0.012793145
tissues O 0 0.033577975
. O 0 0.011867052

Thermal O 0 0.26412314
enhancement O 0 0.013070029
of O 0 0.009481163
Adriamycin B-Chemical 1 0.9998479
- O 0 0.016528636
mediated O 0 0.0025282833
antitumor O 0 0.815317
activity O 0 0.002283535
and O 0 0.0014180669
normal O 0 0.0024530895
tissue O 0 0.049852144
toxicities B-Disease 2 0.99970824
by O 0 0.001339295
whole O 0 0.0011272992
body O 0 0.024209898
hyperthermia B-Disease 2 0.9994481
were O 0 0.0015136963
compared O 0 0.00095748407
using O 0 0.0015664002
a O 0 0.0032012188
F344 O 0 0.3909034
rat O 0 0.013823789
model O 0 0.007988305
. O 0 0.00918949

Antitumor O 0 0.8344871
activity O 0 0.0141797215
was O 0 0.009359329
studied O 0 0.007940134
using O 0 0.00694939
a O 0 0.009612901
tumor B-Disease 2 0.9070976
growth O 0 0.061249964
delay O 0 0.019348234
assay O 0 0.016806846
. O 0 0.015138958

Acute O 0 0.9305606
normal O 0 0.013062484
tissue O 0 0.07860161
toxicities B-Disease 2 0.9995383
( O 0 0.0073000505
i O 0 0.008145027
. O 0 0.0012753425
e O 0 0.0027819686
. O 0 0.0009402923
, O 0 0.0016425413
leukopenia B-Disease 2 0.99993324
and O 0 0.0029544032
thrombocytopenia B-Disease 2 0.99996364
) O 0 0.005023764
and O 0 0.00080571586
late O 0 0.0019846908
normal O 0 0.0015800949
tissue O 0 0.053843096
toxicities B-Disease 2 0.9998846
( O 0 0.0022433568
i O 0 0.0046726633
. O 0 0.00042901744
e O 0 0.0014010973
. O 0 0.00046273737
, O 0 0.000947243
myocardial B-Disease 0 0.99940014
and I-Disease 0 0.0013784743
kidney I-Disease 0 0.9953252
injury I-Disease 0 0.99889106
) O 0 0.0038238678
were O 0 0.0005993724
evaluated O 0 0.0005084031
by O 0 0.0007581717
functional O 0 0.0010918364
/ O 0 0.0025579918
physiological O 0 0.002524771
assays O 0 0.0018647753
and O 0 0.00242185
by O 0 0.0032038535
morphological O 0 0.012217566
techniques O 0 0.009538122
. O 0 0.008906925

Whole O 0 0.025218192
body O 0 0.03204904
hyperthermia B-Disease 2 0.9979971
( O 0 0.0065109874
120 O 0 0.0028113774
min O 0 0.001883288
at O 0 0.0011410015
41 O 0 0.0018681323
. O 0 0.0008351778
5 O 0 0.0008478711
degrees O 0 0.0031532447
C O 0 0.927369
) O 0 0.002704272
enhanced O 0 0.0011728717
both O 0 0.0015909199
Adriamycin B-Chemical 1 0.99994564
- O 0 0.0057137962
mediated O 0 0.0015855379
antitumor O 0 0.8767171
activity O 0 0.0034682688
and O 0 0.0039777393
toxic O 0 0.94226706
side O 0 0.49256262
effects O 0 0.040131696
. O 0 0.010397333

The O 0 0.01030812
thermal O 0 0.020356806
enhancement O 0 0.009062554
ratio O 0 0.0054335822
calculated O 0 0.0036292267
for O 0 0.0033985996
antitumor O 0 0.74597883
activity O 0 0.005786012
was O 0 0.004417655
1 O 0 0.004884386
. O 0 0.004431247
6 O 0 0.00595145
. O 0 0.008661889

Thermal O 0 0.19918144
enhancement O 0 0.009434365
ratios O 0 0.004638498
estimated O 0 0.0029554006
for O 0 0.002053818
" O 0 0.0030919414
acute O 0 0.9037318
" O 0 0.0035937426
hematological O 0 0.9813912
changes O 0 0.001968525
were O 0 0.0008850168
1 O 0 0.00073133747
. O 0 0.0003922829
3 O 0 0.00041789757
, O 0 0.00047600173
whereas O 0 0.00032261916
those O 0 0.00046962607
estimated O 0 0.00037791414
for O 0 0.00037182646
" O 0 0.00077664445
late O 0 0.0021421267
" O 0 0.001227374
damage O 0 0.51208127
( O 0 0.0008806473
based O 0 0.00043114854
on O 0 0.00029346044
morphological O 0 0.0024370179
cardiac B-Disease 0 0.58685476
and I-Disease 0 0.0012892522
renal I-Disease 0 0.9991942
lesions I-Disease 0 0.97315776
) O 0 0.003430096
varied O 0 0.0009780155
between O 0 0.00056072045
2 O 0 0.0009585297
. O 0 0.00076054013
4 O 0 0.0010432712
and O 0 0.0015889005
4 O 0 0.0020331212
. O 0 0.0024690116
3 O 0 0.004374621
. O 0 0.006335451

Thus O 0 0.008216001
, O 0 0.0061158794
while O 0 0.003269461
whole O 0 0.0029634074
body O 0 0.030379584
hyperthermia B-Disease 2 0.9996574
enhances O 0 0.0055467496
Adriamycin B-Chemical 1 0.99997723
- O 0 0.02154679
mediated O 0 0.0012214902
antitumor O 0 0.8696346
effect O 0 0.0012794195
, O 0 0.0013384394
normal O 0 0.0018097163
tissue O 0 0.054456297
toxicity B-Disease 2 0.99831176
is O 0 0.00070432446
also O 0 0.0006103535
increased O 0 0.00085106795
, O 0 0.0008045313
and O 0 0.0005316665
the O 0 0.0004510317
potential O 0 0.0007415479
therapeutic O 0 0.0052264635
gain O 0 0.0014973574
of O 0 0.0010776535
the O 0 0.0011399151
combined O 0 0.0022866107
modality O 0 0.014022159
treatment O 0 0.00678379
is O 0 0.00583342
eroded O 0 0.07412413
. O 0 0.009679976

Permeability O 0 0.38683525
, O 0 0.008567257
ultrastructural O 0 0.01442147
changes O 0 0.004954517
, O 0 0.0032227084
and O 0 0.001868534
distribution O 0 0.0011293979
of O 0 0.0013954658
novel O 0 0.0018384133
proteins O 0 0.0019970436
in O 0 0.0012052228
the O 0 0.0014601848
glomerular O 0 0.8882245
barrier O 0 0.0507396
in O 0 0.002674112
early O 0 0.019979648
puromycin B-Chemical 0 0.9941366
aminonucleoside I-Chemical 0 0.9999591
nephrosis B-Disease 2 0.99993944
. O 0 0.031149024

BACKGROUND O 0 0.70755863
/ O 0 0.022794489
AIMS O 0 0.38530022
: O 0 0.006644259
It O 0 0.0038735839
is O 0 0.0024309417
still O 0 0.0020734891
unclear O 0 0.002071362
what O 0 0.0024587763
happens O 0 0.0021184564
in O 0 0.0018564757
the O 0 0.0025276644
glomerulus O 0 0.109995626
when O 0 0.004485982
proteinuria B-Disease 2 0.9998504
starts O 0 0.018848274
. O 0 0.010855405

Using O 0 0.014103684
puromycin B-Chemical 0 0.9447917
aminonucleoside I-Chemical 0 0.99991167
nephrosis B-Disease 2 0.99996746
( O 0 0.22056839
PAN O 1 0.9998292
) O 0 0.01563437
rats O 0 0.004963655
, O 0 0.0011300585
we O 0 0.0004494244
studied O 0 0.0006225956
early O 0 0.0010321691
ultrastructural O 0 0.02954527
and O 0 0.0011780412
permeability O 0 0.61504763
changes O 0 0.00083896244
in O 0 0.00039751027
relation O 0 0.00029987644
to O 0 0.0003377369
the O 0 0.00036255916
expression O 0 0.0004943423
of O 0 0.00058248796
the O 0 0.00072168553
podocyte O 0 0.96051747
- O 0 0.003395868
associated O 0 0.0007868524
molecules O 0 0.0036270684
nephrin O 0 0.9727023
, O 0 0.0016074895
a O 0 0.0012524709
- O 0 0.0018780001
actinin O 0 0.6127531
, O 0 0.0011748485
dendrin O 0 0.05531434
, O 0 0.00083297945
and O 0 0.0006574371
plekhh2 O 0 0.013193058
, O 0 0.0006940895
the O 0 0.0004290767
last O 0 0.00037272615
two O 0 0.0004871717
of O 0 0.00087597454
which O 0 0.0012593655
were O 0 0.0012533086
only O 0 0.0013483164
recently O 0 0.002217992
discovered O 0 0.0038906108
in O 0 0.004946394
podocytes O 0 0.6365988
. O 0 0.010325784

METHODS O 0 0.014284055
: O 0 0.010623363
Using O 0 0.0067293826
immune O 0 0.035701346
stainings O 0 0.011139275
, O 0 0.0045628897
semiquantitative O 0 0.0053723925
measurement O 0 0.0024997173
was O 0 0.0027013237
performed O 0 0.0026203415
under O 0 0.0028429327
the O 0 0.0045495653
electron O 0 0.024538629
microscope O 0 0.011553954
. O 0 0.011465807

Permeability O 0 0.21047363
was O 0 0.013022286
assessed O 0 0.008984644
using O 0 0.008577817
isolated O 0 0.009930266
kidney O 0 0.8367542
perfusion O 0 0.69266075
with O 0 0.015717098
tracers O 0 0.18871675
. O 0 0.016743267

Possible O 0 0.049807083
effects O 0 0.024943199
of O 0 0.025110837
ACE O 0 0.99732757
inhibition O 0 0.05581407
were O 0 0.017164476
tested O 0 0.015267092
. O 0 0.019788397

RESULTS O 0 0.024639266
: O 0 0.008773143
By O 0 0.005825599
day O 0 0.003541995
2 O 0 0.0029761938
, O 0 0.0027028413
some O 0 0.0021316712
patchy O 0 0.005469218
foot O 0 0.04418878
process O 0 0.002799252
effacement O 0 0.17903419
, O 0 0.002982921
but O 0 0.00229999
no O 0 0.0030161822
proteinuria B-Disease 2 0.99984694
, O 0 0.011558192
appeared O 0 0.008240454
. O 0 0.009345103

The O 0 0.009538639
amount O 0 0.0061996076
of O 0 0.0074751945
nephrin O 0 0.78602153
was O 0 0.0049770954
reduced O 0 0.0038844524
in O 0 0.0033348636
both O 0 0.0036909026
diseased O 0 0.013621641
and O 0 0.0069228983
normal O 0 0.011925322
areas O 0 0.019232817
. O 0 0.011489233

The O 0 0.009293047
other O 0 0.0068814205
proteins O 0 0.00653004
showed O 0 0.0037675055
few O 0 0.0028310404
changes O 0 0.003855847
, O 0 0.0038426127
which O 0 0.0032684929
were O 0 0.003054773
limited O 0 0.003020411
to O 0 0.004001061
diseased O 0 0.022087505
areas O 0 0.018923152
. O 0 0.011060611

By O 0 0.010177773
day O 0 0.0055713146
4 O 0 0.004025907
, O 0 0.0037698576
foot O 0 0.011095408
process O 0 0.0025394652
effacement O 0 0.06375788
was O 0 0.0013977987
complete O 0 0.0011422215
and O 0 0.0019014938
proteinuria B-Disease 2 0.9999174
appeared O 0 0.00155317
in O 0 0.0011209629
parallel O 0 0.0014632973
with O 0 0.0017140352
signs O 0 0.1443047
of O 0 0.0035011652
size O 0 0.00589199
barrier O 0 0.084293924
damage O 0 0.8694583
. O 0 0.011666033

Nephrin O 0 0.08653642
decreased O 0 0.008734029
further O 0 0.005143377
, O 0 0.004663708
while O 0 0.0028413434
dendrin O 0 0.038122263
and O 0 0.002716703
plekhh2 O 0 0.025043188
also O 0 0.0021212979
decreased O 0 0.0029371658
but O 0 0.0023455315
a O 0 0.003994516
- O 0 0.0065253517
actinin O 0 0.5802658
remained O 0 0.00621841
unchanged O 0 0.0076002893
. O 0 0.009221194

ACE O 0 0.98959595
inhibition O 0 0.029305179
had O 0 0.014184129
no O 0 0.011416376
significant O 0 0.014879192
protective O 0 0.044017687
effect O 0 0.021738024
. O 0 0.021948839

CONCLUSIONS O 0 0.6777121
: O 0 0.016461024
PAN O 1 0.9936904
glomeruli O 0 0.0712421
already O 0 0.0033437477
showed O 0 0.0022385498
significant O 0 0.0023767608
pathology O 0 0.025891192
by O 0 0.002151628
day O 0 0.001675179
4 O 0 0.0017529007
, O 0 0.0023444055
despite O 0 0.0022903853
relatively O 0 0.004948805
mild O 0 0.93487334
proteinuria B-Disease 2 0.9998722
. O 0 0.015302998

This O 0 0.01268448
was O 0 0.007041479
preceded O 0 0.0063475296
by O 0 0.004941473
altered O 0 0.0050026546
nephrin O 0 0.8699088
expression O 0 0.004467222
, O 0 0.003210886
supporting O 0 0.002149388
its O 0 0.003381113
pivotal O 0 0.0036614554
role O 0 0.0026962287
in O 0 0.0047170124
podocyte O 0 0.9459583
morphology O 0 0.09678457
. O 0 0.011801855

The O 0 0.007860008
novel O 0 0.0072031054
proteins O 0 0.00654368
dendrin O 0 0.0713454
and O 0 0.003472211
plekhh2 O 0 0.027409632
were O 0 0.001662537
both O 0 0.0012689632
reduced O 0 0.001424085
, O 0 0.0015537952
suggesting O 0 0.00083998876
roles O 0 0.0010895743
in O 0 0.0014759689
PAN O 1 0.9993686
, O 0 0.0028245517
whereas O 0 0.001659225
a O 0 0.0033861413
- O 0 0.0057351226
actinin O 0 0.5639059
was O 0 0.0047731176
unchanged O 0 0.0065529332
. O 0 0.008372056

A O 0 0.034681905
novel O 0 0.010028954
, O 0 0.006699575
multiple O 0 0.0058612553
symptom O 0 0.16717313
model O 0 0.0040222006
of O 0 0.007973363
obsessive B-Disease 0 0.999841
- I-Disease 0 0.11416212
compulsive I-Disease 0 0.9998833
- I-Disease 0 0.010704416
like I-Disease 0 0.004051401
behaviors I-Disease 0 0.13251722
in O 0 0.005163893
animals O 0 0.0071303486
. O 0 0.0096260905

BACKGROUND O 0 0.62621117
: O 0 0.009786649
Current O 0 0.012545097
animal O 0 0.004061547
models O 0 0.0034837022
of O 0 0.006369927
obsessive B-Disease 0 0.99989605
- I-Disease 0 0.11788678
compulsive I-Disease 0 0.9999695
disorder I-Disease 0 0.99942124
( O 0 0.060510308
OCD B-Disease 2 0.9999794
) O 0 0.0035902285
typically O 0 0.0011440476
involve O 0 0.00083956786
acute O 0 0.94958466
, O 0 0.0024510766
drug O 0 0.7447634
- O 0 0.002124411
induced O 0 0.00088453887
symptom O 0 0.56473064
provocation O 0 0.83121234
or O 0 0.001060204
a O 0 0.001599807
genetic O 0 0.0029933543
association O 0 0.0015653797
with O 0 0.0048140753
stereotypies O 0 0.99984014
or O 0 0.0116043985
anxiety B-Disease 0 0.99889994
. O 0 0.0107931625

None O 0 0.017783688
of O 0 0.009377955
these O 0 0.0073450166
current O 0 0.007037473
models O 0 0.005795785
demonstrate O 0 0.0041033514
multiple O 0 0.03471524
OCD B-Disease 2 0.9998499
- O 0 0.018691817
like O 0 0.009836313
behaviors O 0 0.3512994
. O 0 0.013547498

METHODS O 0 0.011341813
: O 0 0.00878472
Neonatal O 0 0.025894385
rats O 0 0.0052987193
were O 0 0.002222322
treated O 0 0.0018443991
with O 0 0.0014475713
the O 0 0.0015689655
tricyclic O 0 0.9999249
antidepressant B-Chemical 1 0.99996877
clomipramine B-Chemical 0 0.99999547
or O 0 0.0010333434
vehicle O 0 0.0202198
between O 0 0.00038201537
days O 0 0.0004557043
9 O 0 0.00056668743
and O 0 0.0005906656
16 O 0 0.0006582029
twice O 0 0.00073886244
daily O 0 0.0013917972
and O 0 0.0015347982
behaviorally O 0 0.015930472
tested O 0 0.0022651895
in O 0 0.0045339875
adulthood O 0 0.39029464
. O 0 0.008677925

RESULTS O 0 0.047452416
: O 0 0.015726425
Clomipramine B-Chemical 0 0.99980646
exposure O 0 0.008365745
in O 0 0.0023222333
immature O 0 0.004364957
rats O 0 0.0033351043
produced O 0 0.0010681087
significant O 0 0.0011703065
behavioral O 0 0.04441937
and O 0 0.00092744327
biochemical O 0 0.015450375
changes O 0 0.0009091989
that O 0 0.0004417485
include O 0 0.0007604883
enhanced O 0 0.0013949982
anxiety B-Disease 0 0.99966705
( O 0 0.001840602
elevated O 0 0.002095474
plus O 0 0.0005071414
maze O 0 0.02667862
and O 0 0.0006313656
marble O 0 0.09759657
burying O 0 0.5810165
) O 0 0.005628584
, O 0 0.0011792581
behavioral B-Disease 0 0.42601776
inflexibility I-Disease 0 0.8677309
( O 0 0.0017481975
perseveration O 0 0.9644479
in O 0 0.00035872177
the O 0 0.00037264478
spontaneous O 0 0.009672244
alternation O 0 0.008340778
task O 0 0.00063908636
and O 0 0.0005043605
impaired O 0 0.0006929609
reversal O 0 0.0029352056
learning O 0 0.007266158
) O 0 0.0020204308
, O 0 0.0008162389
working O 0 0.0014453965
memory B-Disease 2 0.7209566
impairment I-Disease 2 0.85128623
( O 0 0.0014598038
e O 0 0.0018652546
. O 0 0.00044608754
g O 0 0.0011150808
. O 0 0.00049253175
, O 0 0.0009479766
win O 0 0.0068826852
- O 0 0.0012962685
shift O 0 0.0011175099
paradigm O 0 0.001636822
) O 0 0.0032993848
, O 0 0.003025231
hoarding B-Disease 0 0.98550606
, O 0 0.004473177
and O 0 0.0058787246
corticostriatal B-Disease 0 0.99851686
dysfunction I-Disease 0 0.9968035
. O 0 0.010977299

Dopamine B-Chemical 1 0.99941254
D2 O 0 0.9907672
receptors O 0 0.28972548
were O 0 0.0035680346
elevated O 0 0.00447621
in O 0 0.0015398588
the O 0 0.0015584388
striatum O 0 0.5313292
, O 0 0.0016568556
whereas O 0 0.0010570136
serotonin B-Chemical 1 0.99974483
2C O 0 0.0028750792
, O 0 0.0010691085
but O 0 0.0006368658
not O 0 0.00076763687
serotonin B-Chemical 1 0.99957806
1A O 0 0.002443208
, O 0 0.0014377033
receptors O 0 0.026026571
were O 0 0.0011826982
elevated O 0 0.002410426
in O 0 0.001477926
the O 0 0.0023803057
orbital O 0 0.15449212
frontal O 0 0.78461105
cortex O 0 0.35381502
. O 0 0.008299899

CONCLUSIONS O 0 0.49087405
: O 0 0.009520219
This O 0 0.005373735
is O 0 0.0028153115
the O 0 0.0019512344
first O 0 0.00137552
demonstration O 0 0.0016198595
of O 0 0.001594822
multiple O 0 0.0032458864
symptoms O 0 0.75574595
consistent O 0 0.001389747
with O 0 0.001858111
an O 0 0.007763963
OCD B-Disease 2 0.9999435
- O 0 0.0049929423
like O 0 0.0024910152
profile O 0 0.0034553949
in O 0 0.0040978994
animals O 0 0.006171492
. O 0 0.008771593

Moreover O 0 0.010596053
, O 0 0.007243461
these O 0 0.004855938
behaviors O 0 0.05395201
are O 0 0.0028321096
accompanied O 0 0.0034721107
by O 0 0.0020598716
biochemical O 0 0.017389314
changes O 0 0.0021233743
in O 0 0.0014153961
brain O 0 0.058694117
regions O 0 0.0018595691
previously O 0 0.0015014581
identified O 0 0.0016201632
as O 0 0.0024693697
relevant O 0 0.0035547446
to O 0 0.0063058254
OCD B-Disease 2 0.9997228
. O 0 0.01093349

This O 0 0.009588998
novel O 0 0.0061340644
model O 0 0.004332481
of O 0 0.0050234166
OCD B-Disease 2 0.9998141
demonstrates O 0 0.001514198
that O 0 0.0010448402
drug O 0 0.36209503
exposure O 0 0.0025452285
during O 0 0.0005557566
a O 0 0.000848229
sensitive O 0 0.00048376352
period O 0 0.00043719308
can O 0 0.00043375182
program O 0 0.00081918243
disease O 0 0.7748732
- O 0 0.0020931887
like O 0 0.0005924132
systems O 0 0.0013580038
permanently O 0 0.008057509
, O 0 0.0007446489
which O 0 0.0005281425
could O 0 0.0003138345
have O 0 0.00034555348
implications O 0 0.0005503498
for O 0 0.00035443684
current O 0 0.00086856924
and O 0 0.00065847154
future O 0 0.00060580403
therapeutic O 0 0.0038258862
strategies O 0 0.0012439947
for O 0 0.00087096635
this O 0 0.0013453567
and O 0 0.0025201738
other O 0 0.0055929637
psychiatric B-Disease 2 0.99957246
disorders I-Disease 0 0.9974413
. O 0 0.01250689

Elevation O 0 0.47649997
of O 0 0.012590366
ADAM10 O 0 0.9876574
, O 0 0.012761892
ADAM17 O 0 0.9864851
, O 0 0.008858024
MMP O 0 0.9962096
- O 0 0.0049529443
2 O 0 0.0013830859
and O 0 0.0015166729
MMP O 0 0.9926502
- O 0 0.002363595
9 O 0 0.00081597804
expression O 0 0.00078473403
with O 0 0.0008509475
media O 0 0.016215716
degeneration O 0 0.98417205
features O 0 0.029142478
CaCl2 B-Chemical 1 0.99982554
- O 0 0.0042904215
induced O 0 0.0016282495
thoracic B-Disease 0 0.32250327
aortic I-Disease 0 0.6438551
aneurysm I-Disease 2 0.99494284
in O 0 0.0028115297
a O 0 0.0046507334
rat O 0 0.011694893
model O 0 0.007477456
. O 0 0.008824329

PURPOSE O 0 0.030409602
: O 0 0.008546161
This O 0 0.005174894
study O 0 0.0032040104
was O 0 0.0020630192
designed O 0 0.0015742112
to O 0 0.0010482615
establish O 0 0.0007985568
a O 0 0.0011190531
rat O 0 0.0019413993
model O 0 0.0008255154
of O 0 0.0009928913
thoracic B-Disease 0 0.27351984
aortic I-Disease 0 0.7348277
aneurysm I-Disease 2 0.9994814
( O 0 0.017005712
TAA B-Disease 0 0.99863017
) O 0 0.005937871
by O 0 0.0016732869
calcium B-Chemical 1 0.99985373
chloride I-Chemical 0 0.99997556
( O 0 0.03928839
CaCl B-Chemical 0 0.99992573
( I-Chemical 0 0.002403912
2 I-Chemical 0 0.0007785128
) I-Chemical 0 0.0014363149
) O 0 0.0013834467
- O 0 0.0008496252
induced O 0 0.00056198525
arterial B-Disease 0 0.95297325
injury I-Disease 0 0.9933827
and O 0 0.00069705554
to O 0 0.00034688896
explore O 0 0.00025483678
the O 0 0.00036026188
potential O 0 0.0005466041
role O 0 0.0003078986
of O 0 0.000604701
a O 0 0.0011904984
disintegrin O 0 0.9842718
and O 0 0.0037053125
metalloproteinase O 0 0.9972951
( O 0 0.015016878
ADAM O 0 0.9974832
) O 0 0.0073185377
, O 0 0.0014457721
matrix O 0 0.06097715
metalloproteinases O 0 0.9993705
( O 0 0.013479481
MMPs O 0 0.9973031
) O 0 0.0026003527
and O 0 0.000964954
their O 0 0.0010249971
endogenous O 0 0.0019952327
inhibitors O 0 0.21170622
( O 0 0.012520106
TIMPs O 0 0.9977192
) O 0 0.008603753
in O 0 0.004084043
TAA B-Disease 0 0.9937365
formation O 0 0.022060897
. O 0 0.009709957

METHODS O 0 0.012477231
: O 0 0.00956018
Thoracic O 0 0.01265054
aorta O 0 0.013801107
of O 0 0.0034251378
male O 0 0.0119353505
Sprague O 0 0.44861847
- O 0 0.0039413255
Dawley O 0 0.04165479
rats O 0 0.002292074
was O 0 0.0010018512
exposed O 0 0.0008559744
to O 0 0.00089742994
0 O 0 0.001527362
. O 0 0.00096750475
5M O 0 0.67586946
CaCl B-Chemical 0 0.9995442
( I-Chemical 0 0.0023330403
2 I-Chemical 0 0.0013142513
) I-Chemical 0 0.0018399111
or O 0 0.0013982089
normal O 0 0.003659492
saline O 0 0.3216652
( O 0 0.011111089
NaCl B-Chemical 1 0.99767107
) O 0 0.016367028
. O 0 0.008860762

After O 0 0.006856562
12weeks O 0 0.010421712
, O 0 0.0043859812
animals O 0 0.0024031603
were O 0 0.0019694516
euthanized O 0 0.0019630445
, O 0 0.0020680202
and O 0 0.002259945
CaCl B-Chemical 0 0.999706
( I-Chemical 0 0.0028853498
2 I-Chemical 0 0.0011622183
) I-Chemical 0 0.0018386976
- O 0 0.0012357939
treated O 0 0.0009988871
, O 0 0.0021082738
CaCl B-Chemical 0 0.9997569
( I-Chemical 0 0.0016010833
2 I-Chemical 0 0.0007046201
) I-Chemical 0 0.001100167
- O 0 0.0007249331
untreated O 0 0.00057295925
( O 0 0.00062671804
n O 0 0.00050535373
= O 0 0.0006010924
12 O 0 0.00033775717
) O 0 0.0007303512
and O 0 0.0007476453
NaCl B-Chemical 1 0.9977144
- O 0 0.0012709249
treated O 0 0.00068276864
aortic O 0 0.09971663
segments O 0 0.0009953594
( O 0 0.0008303839
n O 0 0.00067356817
= O 0 0.0008159112
12 O 0 0.0004957183
) O 0 0.00091853656
were O 0 0.00070409046
collected O 0 0.0007967265
for O 0 0.0011036205
histological O 0 0.097758114
and O 0 0.0040535834
molecular O 0 0.045788646
assessments O 0 0.008625629
. O 0 0.008235078

MMP O 0 0.987986
- O 0 0.025378974
TIMP O 0 0.9365585
and O 0 0.008395175
ADAM O 0 0.97802484
mRNAs O 0 0.006094731
were O 0 0.0027557688
semi O 0 0.008276045
- O 0 0.0025674195
quantitatively O 0 0.0014677522
analyzed O 0 0.0013499054
and O 0 0.0018073785
protein O 0 0.0027983552
expressions O 0 0.0030942278
were O 0 0.0027868962
determined O 0 0.0027780358
by O 0 0.005529991
immunohistochemistry O 0 0.042750247
. O 0 0.009833876

RESULTS O 0 0.024189863
: O 0 0.0077798143
Despite O 0 0.004193555
similar O 0 0.002533718
external O 0 0.0034721687
diameters O 0 0.009612983
among O 0 0.004052317
CaCl B-Chemical 0 0.9997336
( I-Chemical 0 0.0038527495
2 I-Chemical 0 0.0013908076
) I-Chemical 0 0.0020128149
- O 0 0.0012365128
treated O 0 0.0008628975
, O 0 0.0010394894
non O 0 0.003694994
- O 0 0.009081265
CaCl B-Chemical 0 0.999818
( I-Chemical 0 0.0018492603
2 I-Chemical 0 0.0007657402
) I-Chemical 0 0.0013155481
- O 0 0.0008729542
treated O 0 0.0006588434
and O 0 0.0011723265
NaCl B-Chemical 1 0.99929714
- O 0 0.0018792428
treated O 0 0.0007097421
segments O 0 0.0009750039
, O 0 0.0007640109
aneurymal O 0 0.00674246
alteration O 0 0.0009710444
( O 0 0.00065486546
n O 0 0.0004924626
= O 0 0.0005595608
6 O 0 0.00029039718
, O 0 0.00044330594
50 O 0 0.0005371587
% O 0 0.0005682213
) O 0 0.00086322596
, O 0 0.0006067446
media O 0 0.003138232
degeneration O 0 0.9082248
with O 0 0.00054747745
regional O 0 0.0018623468
disruption O 0 0.00080578716
, O 0 0.00073921174
fragmentation O 0 0.0027077002
of O 0 0.0005859282
elastic O 0 0.026362035
fiber O 0 0.039168753
, O 0 0.0011254316
and O 0 0.0006329978
increased O 0 0.0007980308
collagen O 0 0.4785331
deposition O 0 0.05265896
( O 0 0.0012080576
n O 0 0.00068107375
= O 0 0.0007072182
12 O 0 0.00035032418
, O 0 0.0005633072
100 O 0 0.00082448643
% O 0 0.0007159307
) O 0 0.00091315777
were O 0 0.00058716093
demonstrated O 0 0.00065445824
in O 0 0.0013044098
CaCl B-Chemical 0 0.9996388
( I-Chemical 0 0.0034095866
2 I-Chemical 0 0.0022227184
) I-Chemical 0 0.0039512916
- O 0 0.0041206484
treated O 0 0.0047690356
segments O 0 0.008178142
. O 0 0.008233995

MMP O 0 0.98326635
- O 0 0.016632097
2 O 0 0.0062089553
, O 0 0.006050263
MMP O 0 0.9773467
- O 0 0.0051876307
9 O 0 0.0021303592
, O 0 0.0022272523
ADAM O 0 0.9708592
- O 0 0.0023462644
10 O 0 0.00087866717
and O 0 0.0010341534
ADAM O 0 0.9872363
- O 0 0.0021263873
17 O 0 0.0009651368
mRNA O 0 0.0006467584
levels O 0 0.00044426494
were O 0 0.00050517597
increased O 0 0.00070748385
in O 0 0.00085636845
CaCl B-Chemical 0 0.9998665
( I-Chemical 0 0.0019307854
2 I-Chemical 0 0.00073868403
) I-Chemical 0 0.0012407096
- O 0 0.0007574369
treated O 0 0.0005157905
segments O 0 0.00072645297
( O 0 0.0005981451
all O 0 0.00034490548
p O 0 0.00055051554
< O 0 0.00046468078
0 O 0 0.000551268
. O 0 0.00034078586
01 O 0 0.0038164586
) O 0 0.00072976225
, O 0 0.00049797504
with O 0 0.000378381
trends O 0 0.0006014961
of O 0 0.000718205
elevation O 0 0.3159582
in O 0 0.0010749784
CaCl B-Chemical 0 0.9998747
( I-Chemical 0 0.001978934
2 I-Chemical 0 0.0008166917
) I-Chemical 0 0.0013383036
- O 0 0.0009373432
untreated O 0 0.0008018364
segments O 0 0.0011087882
, O 0 0.0010845218
as O 0 0.00093265466
compared O 0 0.00094300986
with O 0 0.0027818654
NaCl B-Chemical 1 0.9987388
- O 0 0.007851743
treated O 0 0.0059303804
segments O 0 0.00912559
. O 0 0.008453086

Immunohistochemistry O 0 0.02667556
displayed O 0 0.0053103613
significantly O 0 0.0044752406
increased O 0 0.0034831446
expressions O 0 0.003365454
of O 0 0.0039409758
MMP O 0 0.9984041
- O 0 0.008906963
2 O 0 0.0014981705
, O 0 0.0018107565
MMP O 0 0.99135464
- O 0 0.0022780295
9 O 0 0.0008747709
, O 0 0.0010618758
ADAM O 0 0.97177225
- O 0 0.0014309577
10 O 0 0.00056865066
and O 0 0.00072739157
ADAM O 0 0.98307186
- O 0 0.0015811461
17 O 0 0.0008254663
( O 0 0.00057807274
all O 0 0.0003723075
p O 0 0.00059512875
< O 0 0.0005278592
0 O 0 0.0006327765
. O 0 0.0004204387
01 O 0 0.0030084464
) O 0 0.00084854354
in O 0 0.0005765705
intima O 0 0.6822116
and O 0 0.0012015816
media O 0 0.007213075
for O 0 0.0015178504
CaCl B-Chemical 0 0.99972874
( I-Chemical 0 0.0037913024
2 I-Chemical 0 0.0023101533
) I-Chemical 0 0.0040371916
- O 0 0.00418106
treated O 0 0.004821835
segments O 0 0.008257068
. O 0 0.008307925

TIMP O 0 0.90781635
mRNA O 0 0.01152715
and O 0 0.007048353
tissue O 0 0.0124544315
levels O 0 0.0037555138
did O 0 0.0030132972
not O 0 0.0026325027
differ O 0 0.002915503
obviously O 0 0.006193295
among O 0 0.0036489088
the O 0 0.0034217802
three O 0 0.003734526
aortic O 0 0.2576995
segments O 0 0.012138024
. O 0 0.010769373

CONCLUSION O 0 0.73232406
: O 0 0.009624493
This O 0 0.0054662847
study O 0 0.0033674429
establishes O 0 0.002784871
a O 0 0.0031905337
TAA B-Disease 0 0.96832085
model O 0 0.0023532105
by O 0 0.0024215092
periarterial O 0 0.9895527
CaCl B-Chemical 0 0.9999294
( I-Chemical 0 0.003934796
2 I-Chemical 0 0.0009325854
) I-Chemical 0 0.0010525095
exposure O 0 0.0009778225
in O 0 0.00050639623
rats O 0 0.0021309038
, O 0 0.00072264625
and O 0 0.00047667485
demonstrates O 0 0.00032676457
a O 0 0.0006082214
significant O 0 0.0005996785
elevation O 0 0.09641984
of O 0 0.00071344577
expression O 0 0.00094368483
of O 0 0.0015927698
MMP O 0 0.99894136
- O 0 0.0048028394
2 O 0 0.0008888024
, O 0 0.0013107774
MMP O 0 0.9924696
- O 0 0.0021859664
9 O 0 0.00096382323
, O 0 0.001334927
ADAM10 O 0 0.94832224
and O 0 0.0018253861
ADAM17 O 0 0.9424843
in O 0 0.0013896008
the O 0 0.0017273369
pathogenesis O 0 0.009281053
of O 0 0.0061223833
vascular O 0 0.9536964
remodeling O 0 0.40653846
. O 0 0.011056372

Suxamethonium B-Chemical 1 0.9880965
induced O 0 0.012646496
prolonged O 0 0.039826952
apnea B-Disease 2 0.9957639
in O 0 0.006154147
a O 0 0.006585472
patient O 0 0.0076765423
receiving O 0 0.015092391
electroconvulsive O 0 0.9987337
therapy O 0 0.35771734
. O 0 0.015287041

Suxamethonium B-Chemical 1 0.99009913
causes O 0 0.014272021
prolonged O 0 0.03648068
apnea B-Disease 2 0.99720615
in O 0 0.003163679
patients O 0 0.0053211823
in O 0 0.0018960445
whom O 0 0.012659275
pseudocholinesterase O 0 0.99903935
enzyme O 0 0.41873747
gets O 0 0.011207537
deactivated O 0 0.11102073
by O 0 0.006756282
organophosphorus B-Chemical 0 0.9999536
( I-Chemical 0 0.093815416
OP I-Chemical 0 0.99945396
) I-Chemical 0 0.051080447
poisons I-Chemical 0 0.938129
. O 0 0.012332422

Here O 0 0.011211653
, O 0 0.007065059
we O 0 0.003109128
present O 0 0.0022641001
a O 0 0.0026331511
similar O 0 0.0015776408
incident O 0 0.009056736
in O 0 0.0015313181
a O 0 0.0022430879
severely O 0 0.022399427
depressed B-Disease 2 0.7451308
patient O 0 0.0021769416
who O 0 0.0026460963
received O 0 0.0020250895
electroconvulsive O 0 0.99875176
therapy O 0 0.19223762
( O 0 0.022868479
ECT O 0 0.9962513
) O 0 0.016402956
. O 0 0.009220023

Prolonged O 0 0.13338955
apnea B-Disease 2 0.98587185
in O 0 0.0041446686
our O 0 0.002529472
case O 0 0.0022228602
ensued O 0 0.01135157
because O 0 0.0011429917
the O 0 0.0010835195
information O 0 0.0012801003
about O 0 0.001206689
suicidal O 0 0.99947435
attempt O 0 0.0018592565
by O 0 0.002618682
OP B-Chemical 0 0.99978775
compound I-Chemical 0 0.68128693
was O 0 0.0021689
concealed O 0 0.00573186
from O 0 0.0024065042
the O 0 0.0031426419
treating O 0 0.01066155
team O 0 0.009947899
. O 0 0.0092377635

Curcumin B-Chemical 0 0.999678
ameliorates O 0 0.99218583
cognitive B-Disease 0 0.99162525
dysfunction I-Disease 0 0.9939037
and O 0 0.013724185
oxidative O 0 0.9950447
damage O 0 0.97071314
in O 0 0.008036567
phenobarbitone B-Chemical 1 0.9999764
and O 0 0.036897607
carbamazepine B-Chemical 1 0.99997914
administered O 0 0.039819136
rats O 0 0.03445071
. O 0 0.010338539

The O 0 0.009111411
antiepileptic O 0 0.9979761
drugs O 0 0.95583177
, O 0 0.015752444
phenobarbitone B-Chemical 1 0.9999641
and O 0 0.010216863
carbamazepine B-Chemical 1 0.99998665
are O 0 0.002141945
well O 0 0.0013055475
known O 0 0.0017279438
to O 0 0.0015104221
cause O 0 0.013959826
cognitive B-Disease 0 0.92667717
impairment I-Disease 0 0.45469844
on O 0 0.0030283157
chronic O 0 0.96157694
use O 0 0.013132772
. O 0 0.010283505

The O 0 0.0076081553
increase O 0 0.0046602674
in O 0 0.0035376824
free O 0 0.0040410873
radical O 0 0.632432
generation O 0 0.0037855185
has O 0 0.0015592463
been O 0 0.001402143
implicated O 0 0.0009773133
as O 0 0.0008733161
one O 0 0.00065681717
of O 0 0.00085611024
the O 0 0.0007929743
important O 0 0.00075577927
mechanisms O 0 0.0016504081
of O 0 0.0026045374
cognitive B-Disease 0 0.9471613
impairment I-Disease 0 0.6407651
by O 0 0.0066001434
antiepileptic O 0 0.9997522
drugs O 0 0.96848196
. O 0 0.010631566

Curcumin B-Chemical 0 0.99936336
has O 0 0.011098313
shown O 0 0.0074790623
antioxidant O 0 0.9969194
, O 0 0.011260407
anti O 0 0.06482764
- O 0 0.011635016
inflammatory O 0 0.9121189
and O 0 0.011103149
neuro O 0 0.91785276
- O 0 0.0144811
protective O 0 0.048591584
properties O 0 0.017080035
. O 0 0.012666124

Therefore O 0 0.007281728
, O 0 0.0059119766
the O 0 0.0031875565
present O 0 0.001923135
study O 0 0.0020887107
was O 0 0.0013525641
carried O 0 0.00083959306
out O 0 0.00072584086
to O 0 0.00057274906
investigate O 0 0.00038205166
the O 0 0.00058547186
effect O 0 0.0006489061
of O 0 0.0014884307
chronic O 0 0.99290186
curcumin B-Chemical 1 0.99997926
administration O 0 0.6345109
on O 0 0.0010806945
phenobarbitone B-Chemical 1 0.99999607
- O 0 0.01524706
and O 0 0.0034042299
carbamazepine B-Chemical 1 0.9999963
- O 0 0.007623713
induced O 0 0.0019720504
cognitive B-Disease 0 0.9484303
impairment I-Disease 0 0.58114654
and O 0 0.0039409758
oxidative O 0 0.9906735
stress O 0 0.8211676
in O 0 0.0066590444
rats O 0 0.040805496
. O 0 0.009284272

Pharmacokinetic O 0 0.5699025
interactions O 0 0.014251274
of O 0 0.012141238
curcumin B-Chemical 1 0.999483
with O 0 0.026517916
phenobarbitone B-Chemical 1 0.9999651
and O 0 0.052649222
carbamazepine B-Chemical 1 0.9999696
were O 0 0.007947782
also O 0 0.0071998117
studied O 0 0.010396142
. O 0 0.011823034

Vehicle O 0 0.7639738
/ O 0 0.017202849
drugs O 0 0.33229876
were O 0 0.005416468
administered O 0 0.004705678
daily O 0 0.0049664425
for O 0 0.00294545
21days O 0 0.067277126
to O 0 0.0041422746
male O 0 0.020427523
Wistar O 0 0.21019578
rats O 0 0.019020438
. O 0 0.012399763

Passive O 0 0.038062874
avoidance O 0 0.01831038
paradigm O 0 0.0070456606
and O 0 0.004604005
elevated O 0 0.0058095143
plus O 0 0.0027809949
maze O 0 0.021169905
test O 0 0.0025487964
were O 0 0.0021407981
used O 0 0.0020358174
to O 0 0.0023448707
assess O 0 0.0024174051
cognitive O 0 0.6815687
function O 0 0.009020339
. O 0 0.00985777

At O 0 0.0061606537
the O 0 0.004762576
end O 0 0.0029011306
of O 0 0.0029084173
study O 0 0.0025605406
period O 0 0.001759383
, O 0 0.0024262655
serum O 0 0.2845805
phenobarbitone B-Chemical 1 0.9999869
and O 0 0.010606862
carbamazepine B-Chemical 1 0.9999944
, O 0 0.0030645602
whole O 0 0.0017126357
brain O 0 0.4783591
malondialdehyde B-Chemical 1 0.99998474
and O 0 0.00578089
reduced O 0 0.016987696
glutathione B-Chemical 1 0.9999194
levels O 0 0.004888332
were O 0 0.0051717428
estimated O 0 0.006008193
. O 0 0.008601061

The O 0 0.0073554325
administration O 0 0.030647099
of O 0 0.006956574
phenobarbitone B-Chemical 1 0.9999609
and O 0 0.012850052
carbamazepine B-Chemical 1 0.99998915
for O 0 0.001501318
21days O 0 0.23536813
caused O 0 0.0011635787
a O 0 0.0012808663
significant O 0 0.0011186188
impairment B-Disease 0 0.34744167
of I-Disease 0 0.0011294838
learning I-Disease 0 0.01572672
and I-Disease 0 0.0011732137
memory I-Disease 0 0.08103289
as O 0 0.0010809785
well O 0 0.0011420796
as O 0 0.001693346
an O 0 0.0032211123
increased O 0 0.0053730756
oxidative O 0 0.9917591
stress O 0 0.92317635
. O 0 0.014523939

Concomitant O 0 0.3188656
curcumin B-Chemical 1 0.9993248
administration O 0 0.5164547
prevented O 0 0.0184245
the O 0 0.0035506748
cognitive B-Disease 0 0.9301968
impairment I-Disease 0 0.4682156
and O 0 0.0019512548
decreased O 0 0.002082376
the O 0 0.0013512083
increased O 0 0.0027408218
oxidative O 0 0.99064785
stress O 0 0.8180159
induced O 0 0.004362724
by O 0 0.0039529395
these O 0 0.0073175402
antiepileptic O 0 0.9997416
drugs O 0 0.9710839
. O 0 0.011234513

Curcumin B-Chemical 0 0.9996637
co O 0 0.9239942
- O 0 0.013877645
administration O 0 0.066153154
did O 0 0.0022400806
not O 0 0.0015987213
cause O 0 0.0027753024
any O 0 0.001028111
significant O 0 0.0011676374
alteration O 0 0.0016542326
in O 0 0.0008185293
the O 0 0.0009327026
serum O 0 0.10041849
concentrations O 0 0.0034581246
of O 0 0.0016621129
both O 0 0.0021814299
phenobarbitone B-Chemical 1 0.9999685
as O 0 0.002789921
well O 0 0.003245496
as O 0 0.008436782
carbamazepine B-Chemical 1 0.999951
. O 0 0.010839196

These O 0 0.00852246
results O 0 0.005409747
show O 0 0.0034237746
that O 0 0.0030275672
curcumin B-Chemical 1 0.99956983
has O 0 0.0021172422
beneficial O 0 0.0041950326
effect O 0 0.0012230905
in O 0 0.00086513476
mitigating O 0 0.010776401
the O 0 0.00089661335
deterioration B-Disease 0 0.21694419
of I-Disease 0 0.0014410815
cognitive I-Disease 0 0.90431875
functions I-Disease 0 0.0015386232
and O 0 0.0015437831
oxidative O 0 0.98964113
damage O 0 0.9094263
in O 0 0.0008745852
rats O 0 0.004285973
treated O 0 0.0011992257
with O 0 0.0017778795
phenobarbitone B-Chemical 1 0.9999912
and O 0 0.0055719614
carbamazepine B-Chemical 1 0.999992
without O 0 0.0016597259
significantly O 0 0.0026659651
altering O 0 0.0035519167
their O 0 0.003938646
serum O 0 0.410619
concentrations O 0 0.054202933
. O 0 0.009482578

The O 0 0.0074097095
findings O 0 0.00701072
suggest O 0 0.0032471297
that O 0 0.0031357466
curcumin B-Chemical 1 0.99957067
can O 0 0.0019842233
be O 0 0.0013904792
considered O 0 0.0008118628
as O 0 0.00078557164
a O 0 0.0009140935
potential O 0 0.00096552266
safe O 0 0.0017907983
and O 0 0.0007701735
effective O 0 0.0008546659
adjuvant O 0 0.2593616
to O 0 0.0011751294
phenobarbitone B-Chemical 1 0.99999225
and O 0 0.005341928
carbamazepine B-Chemical 1 0.9999956
therapy O 0 0.037791114
in O 0 0.001050606
preventing O 0 0.006894798
cognitive B-Disease 0 0.93503743
impairment I-Disease 0 0.4171882
associated O 0 0.002694255
with O 0 0.003291588
these O 0 0.0062929075
drugs O 0 0.9064858
. O 0 0.009363459

Can O 0 0.15851595
angiogenesis O 0 0.8922963
be O 0 0.007929017
a O 0 0.006048411
target O 0 0.0040010223
of O 0 0.004456716
treatment O 0 0.006425992
for O 0 0.005262384
ribavirin B-Chemical 1 0.99962354
associated O 0 0.15815553
hemolytic B-Disease 2 0.99994326
anemia I-Disease 2 0.9999565
? O 0 0.65402806

BACKGROUND O 0 0.7158568
/ O 0 0.02127442
AIMS O 0 0.45955598
: O 0 0.0059864954
Recently O 0 0.0047948277
ribavirin B-Chemical 1 0.9986014
has O 0 0.0019882985
been O 0 0.0014951875
found O 0 0.00087908166
to O 0 0.00093944435
inhibit O 0 0.0010796747
angiogenesis O 0 0.97697234
and O 0 0.0010648877
a O 0 0.0008882703
number O 0 0.00056383415
of O 0 0.0011521978
angiogenesis O 0 0.988698
inhibitors O 0 0.09623675
such O 0 0.0009642664
as O 0 0.0014362069
sunitinib B-Chemical 0 0.99990475
and O 0 0.0028839535
sorafenib B-Chemical 1 0.99987996
have O 0 0.0012615565
been O 0 0.001435217
found O 0 0.0012464479
to O 0 0.0021109972
cause O 0 0.048895095
acute O 0 0.99742055
hemolysis B-Disease 2 0.999833
. O 0 0.017468745

We O 0 0.0075022834
aimed O 0 0.004671701
to O 0 0.002827169
investigate O 0 0.001497908
whether O 0 0.0010424723
there O 0 0.0009296523
is O 0 0.00096926786
a O 0 0.0010096816
relation O 0 0.0005697819
between O 0 0.00057355565
hemoglobin O 0 0.9657584
, O 0 0.003000292
haptoglobin O 0 0.9845064
and O 0 0.0023405992
angiogenesis O 0 0.9899138
soluble O 0 0.016855055
markers O 0 0.0037811657
which O 0 0.0012832931
are O 0 0.00099301
modifiable O 0 0.06843169
and O 0 0.0011073896
can O 0 0.00086494803
help O 0 0.0014976013
in O 0 0.0015310855
developing O 0 0.006533623
strategies O 0 0.005221062
against O 0 0.007407458
anemia B-Disease 2 0.9997918
. O 0 0.015241577

METHODS O 0 0.01230773
: O 0 0.008912145
Fourteen O 0 0.0092055295
patients O 0 0.006851414
chronically B-Disease 0 0.013652245
infected I-Disease 0 0.0035872157
with I-Disease 0 0.008212754
hepatitis I-Disease 2 0.99998915
C I-Disease 0 0.99967325
virus I-Disease 0 0.3963487
were O 0 0.002452434
treated O 0 0.0026117705
by O 0 0.0032671187
pegylated B-Chemical 0 0.9991015
interferon I-Chemical 0 0.99991107
alpha I-Chemical 0 0.9247641
2a I-Chemical 0 0.013780158
and O 0 0.012804904
ribavirin B-Chemical 1 0.9992823
. O 0 0.013083802

Serum O 0 0.5863117
hemoglobin O 0 0.94933456
, O 0 0.010604475
haptoglobin O 0 0.95912623
and O 0 0.0054677967
angiogenesis O 0 0.97425133
markers O 0 0.0053939167
of O 0 0.0025449912
vascular O 0 0.9206899
endothelial O 0 0.98360866
growth O 0 0.054217044
factor O 0 0.033019572
and O 0 0.0020361354
angiopoetin O 0 0.37628093
- O 0 0.0024721622
2 O 0 0.0010291189
were O 0 0.0009764662
investigated O 0 0.0010105083
before O 0 0.0012009785
and O 0 0.0026236987
after O 0 0.0026072543
therapy O 0 0.027673341
. O 0 0.008454037

RESULTS O 0 0.026995132
: O 0 0.008781864
We O 0 0.004298955
observed O 0 0.002568013
a O 0 0.003005047
significant O 0 0.0023697251
decrease O 0 0.0019957388
in O 0 0.0018639395
haptoglobin O 0 0.9276901
levels O 0 0.0017452867
at O 0 0.0012100269
the O 0 0.0013913652
end O 0 0.0012834013
of O 0 0.0023196384
the O 0 0.0030520146
treatment O 0 0.006304741
period O 0 0.006029371
. O 0 0.008745393

Hemoglobin O 0 0.99065584
levels O 0 0.01525875
also O 0 0.01295506
decreased O 0 0.014690066
but O 0 0.01244354
insignificantly O 0 0.36809403
by O 0 0.01636702
treatment O 0 0.023607647
. O 0 0.018559752

In O 0 0.0074674683
contrast O 0 0.0051612584
with O 0 0.0037455577
the O 0 0.002929005
literature O 0 0.0039066584
, O 0 0.0028403467
serum O 0 0.057433475
levels O 0 0.0014167891
of O 0 0.002182868
angiogenesis O 0 0.98760843
factors O 0 0.01560541
did O 0 0.0009703397
not O 0 0.0009003544
change O 0 0.0010726311
significantly O 0 0.0017361309
by O 0 0.0028722086
pegylated B-Chemical 0 0.9991504
interferon I-Chemical 0 0.9999012
and O 0 0.085645854
ribavirin B-Chemical 1 0.9997725
therapy O 0 0.40764657
. O 0 0.01108714

We O 0 0.00957507
found O 0 0.0054973736
no O 0 0.0040197107
correlation O 0 0.0034626466
of O 0 0.005231437
angiogenesis O 0 0.9762332
soluble O 0 0.030997092
markers O 0 0.009046736
with O 0 0.0043407655
either O 0 0.0051703183
hemoglobin O 0 0.96274465
or O 0 0.0107643595
haptoglobin O 0 0.9923006
. O 0 0.014536652

CONCLUSION O 0 0.73324114
: O 0 0.009156414
This O 0 0.005071491
is O 0 0.0026035816
the O 0 0.0017878123
first O 0 0.001243718
study O 0 0.0013012206
in O 0 0.00085789285
the O 0 0.00077866786
literature O 0 0.001023428
investigating O 0 0.0005832112
a O 0 0.000913223
link O 0 0.00072385167
between O 0 0.00054065714
angiogenesis O 0 0.9857675
soluble O 0 0.024813987
markers O 0 0.009933145
and O 0 0.0027057102
ribavirin B-Chemical 1 0.99986565
induced O 0 0.008197313
anemia B-Disease 2 0.9999765
in O 0 0.001624455
patients O 0 0.030893348
with O 0 0.008161058
hepatitis B-Disease 2 0.99999523
C I-Disease 0 0.999451
and O 0 0.0025183966
we O 0 0.0010467208
could O 0 0.0012231277
not O 0 0.0016709357
find O 0 0.002207733
any O 0 0.003368541
relation O 0 0.0049371957
. O 0 0.008528349

Future O 0 0.009412865
research O 0 0.0055919606
with O 0 0.0031805553
larger O 0 0.002202657
number O 0 0.0015838781
of O 0 0.0017009687
patients O 0 0.002934698
is O 0 0.0010257199
needed O 0 0.0006421247
to O 0 0.0006770193
find O 0 0.0006650213
out O 0 0.00077017205
modifiable O 0 0.034317214
factors O 0 0.002354719
that O 0 0.0007610567
will O 0 0.000778738
improve O 0 0.00078721275
the O 0 0.0012871173
safety O 0 0.0038169678
of O 0 0.004944008
ribavirin B-Chemical 1 0.99953914
therapy O 0 0.2646745
. O 0 0.010233513

Reduction O 0 0.020990055
in O 0 0.0071008783
injection O 0 0.013429468
pain B-Disease 2 0.9966954
using O 0 0.0049146507
buffered O 0 0.83301187
lidocaine B-Chemical 1 0.9997899
as O 0 0.002856136
a O 0 0.0029409074
local O 0 0.0040331003
anesthetic O 0 0.32976738
before O 0 0.0030845923
cardiac O 0 0.6191924
catheterization O 0 0.08734079
. O 0 0.009614037

Previous O 0 0.009139135
reports O 0 0.0063391314
have O 0 0.0034778754
suggested O 0 0.0025974282
that O 0 0.002232452
pain B-Disease 2 0.9962708
associated O 0 0.0022688338
with O 0 0.0013450837
the O 0 0.001035807
injection O 0 0.0026006668
of O 0 0.0019435541
lidocaine B-Chemical 1 0.9999273
is O 0 0.0012830378
related O 0 0.0009102472
to O 0 0.0011967014
the O 0 0.0017906381
acidic O 0 0.120040715
pH O 0 0.5077828
of O 0 0.004274927
the O 0 0.0052738334
solution O 0 0.07312554
. O 0 0.00971809

To O 0 0.005902456
determine O 0 0.0028267466
if O 0 0.0022766343
the O 0 0.0018332126
addition O 0 0.0010862693
of O 0 0.0014937039
a O 0 0.00175754
buffering O 0 0.13060895
solution O 0 0.012917676
to O 0 0.00064949854
adjust O 0 0.0005474678
the O 0 0.00065041374
pH O 0 0.17797011
of O 0 0.0008773805
lidocaine B-Chemical 1 0.99987936
into O 0 0.00032672935
the O 0 0.0004271476
physiologic O 0 0.0044324393
range O 0 0.0007817225
would O 0 0.00038089158
reduce O 0 0.0004960315
pain B-Disease 2 0.99673444
during O 0 0.0004261565
injection O 0 0.0019337982
, O 0 0.0006847091
we O 0 0.00032330173
performed O 0 0.00044783534
a O 0 0.0007441871
blinded O 0 0.0009077585
randomized O 0 0.00093710487
study O 0 0.001065331
in O 0 0.0011454124
patients O 0 0.0032514108
undergoing O 0 0.0037020976
cardiac O 0 0.6370383
catheterization O 0 0.08601783
. O 0 0.008196945

Twenty O 0 0.0116336895
patients O 0 0.00791575
were O 0 0.0036886989
asked O 0 0.0022449328
to O 0 0.0015531072
quantify O 0 0.0009866802
the O 0 0.0011822748
severity O 0 0.024764892
of O 0 0.002092735
pain B-Disease 2 0.99819237
after O 0 0.00054914516
receiving O 0 0.0013822793
standard O 0 0.000987948
lidocaine B-Chemical 1 0.9998621
in O 0 0.0007227589
one O 0 0.0006533353
femoral O 0 0.0068597062
area O 0 0.0014887176
and O 0 0.001522902
buffered O 0 0.8352159
lidocaine B-Chemical 1 0.99978536
in O 0 0.0018171438
the O 0 0.0022297066
opposite O 0 0.0040251515
femoral O 0 0.045450144
area O 0 0.009812444
. O 0 0.008192016

The O 0 0.0070839603
mean O 0 0.005789895
pain B-Disease 2 0.9806716
score O 0 0.0048038056
for O 0 0.002195277
buffered O 0 0.76049113
lidocaine B-Chemical 1 0.9998995
was O 0 0.0013627969
significantly O 0 0.0010353216
lower O 0 0.0006535925
than O 0 0.0003684626
the O 0 0.000390898
mean O 0 0.0003768812
score O 0 0.00056604564
for O 0 0.00033627663
standard O 0 0.000691495
lidocaine B-Chemical 1 0.9999397
( O 0 0.0013751776
2 O 0 0.00052493595
. O 0 0.00031503086
7 O 0 0.0004061344
+ O 0 0.0005320353
/ O 0 0.0014663619
- O 0 0.0007930801
1 O 0 0.00041614546
. O 0 0.0002662808
9 O 0 0.0003478223
vs O 0 0.0005783257
. O 0 0.00029892102
3 O 0 0.0003578463
. O 0 0.0003060207
8 O 0 0.00043375554
+ O 0 0.000604021
/ O 0 0.0015228674
- O 0 0.0010157721
2 O 0 0.00063282525
. O 0 0.0005382373
2 O 0 0.000827316
, O 0 0.0013608191
P O 0 0.02362569
= O 0 0.0022814132
0 O 0 0.0024945568
. O 0 0.002459387
03 O 0 0.03347082
) O 0 0.007966237
. O 0 0.007467041

The O 0 0.008977959
pH O 0 0.06492115
adjustment O 0 0.0044426396
of O 0 0.0029921632
standard O 0 0.002807713
lidocaine B-Chemical 1 0.9997956
can O 0 0.0013392052
be O 0 0.0010460889
accomplished O 0 0.0010244114
easily O 0 0.00076009094
in O 0 0.0004739058
the O 0 0.00047521357
catheterization O 0 0.0034527471
laboratory O 0 0.0006336213
before O 0 0.00027466932
injection O 0 0.0008556018
and O 0 0.0005199463
results O 0 0.00051283394
in O 0 0.00048615067
a O 0 0.0007683336
reduction O 0 0.0008672556
of O 0 0.00083922833
the O 0 0.0011183834
pain B-Disease 2 0.9968586
occurring O 0 0.0026419214
during O 0 0.001266741
the O 0 0.0022540714
infiltration O 0 0.7258892
of O 0 0.0072538517
tissues O 0 0.06436755
. O 0 0.010222275

Effect O 0 0.014704823
of O 0 0.012220386
L B-Chemical 0 0.7813538
- I-Chemical 0 0.016963158
alpha I-Chemical 0 0.6323355
- I-Chemical 0 0.03372446
glyceryl I-Chemical 0 0.99988604
- I-Chemical 0 0.03709686
phosphorylcholine I-Chemical 0 0.8999885
on O 0 0.0050370027
amnesia B-Disease 2 0.99966383
caused O 0 0.014678535
by O 0 0.04366608
scopolamine B-Chemical 1 0.99995863
. O 0 0.01657285

The O 0 0.0072133685
present O 0 0.0042439583
study O 0 0.0040174453
was O 0 0.002564786
carried O 0 0.0015628322
out O 0 0.001283325
to O 0 0.0010101214
test O 0 0.0010789637
the O 0 0.00082371064
effects O 0 0.0014479926
of O 0 0.0019416873
L B-Chemical 0 0.9304139
- I-Chemical 0 0.010873442
alpha I-Chemical 0 0.66123194
- I-Chemical 0 0.01154369
glycerylphosphorylcholine I-Chemical 0 0.98822683
( O 0 0.004458322
L B-Chemical 0 0.8179116
- I-Chemical 0 0.003992612
alpha I-Chemical 0 0.4088391
- I-Chemical 0 0.0063914154
GFC I-Chemical 0 0.98931503
) O 0 0.002168601
on O 0 0.0008603691
memory B-Disease 2 0.6794502
impairment I-Disease 2 0.8296203
induced O 0 0.0037466614
by O 0 0.013698862
scopolamine B-Chemical 1 0.999982
in O 0 0.007843297
man O 0 0.66106135
. O 0 0.011098783

Thirty O 0 0.018481681
- O 0 0.009983608
two O 0 0.0049180374
healthy O 0 0.008249594
young O 0 0.0072365305
volunteers O 0 0.0054060435
were O 0 0.0026644948
randomly O 0 0.0018092383
allocated O 0 0.002132229
to O 0 0.0025199568
four O 0 0.0029974165
different O 0 0.0047104643
groups O 0 0.009506937
. O 0 0.010393198

They O 0 0.012135291
were O 0 0.0053315554
given O 0 0.0028564932
a O 0 0.0028638383
ten O 0 0.0016549667
day O 0 0.0015263349
pretreatment O 0 0.031966884
with O 0 0.0015252699
either O 0 0.001803261
L B-Chemical 0 0.8820921
- I-Chemical 0 0.0067789815
alpha I-Chemical 0 0.52324456
- I-Chemical 0 0.005328815
GFC I-Chemical 0 0.98073626
or O 0 0.000744655
placebo O 0 0.14588335
, O 0 0.000879944
p O 0 0.000744286
. O 0 0.00040112354
o O 0 0.0020048202
. O 0 0.00041936318
, O 0 0.00059148425
and O 0 0.00045292143
on O 0 0.00032189256
the O 0 0.0005001692
eleventh O 0 0.008746062
day O 0 0.00066366437
either O 0 0.0012788895
scopolamine B-Chemical 1 0.9999877
or O 0 0.0020918974
placebo O 0 0.3437062
, O 0 0.003577789
i O 0 0.0075490624
. O 0 0.003608049
m O 0 0.018473614
. O 0 0.008023344

Before O 0 0.009633988
and O 0 0.006450199
0 O 0 0.004971889
. O 0 0.0024689375
5 O 0 0.0019508351
, O 0 0.0019960243
1 O 0 0.0013923808
, O 0 0.0013162286
2 O 0 0.0009077222
, O 0 0.00094351993
3 O 0 0.00063208805
, O 0 0.0006965555
and O 0 0.0005628633
6 O 0 0.0004015712
h O 0 0.00036754803
after O 0 0.00032027595
injection O 0 0.000869109
the O 0 0.0006559945
subjects O 0 0.0012823438
were O 0 0.0010243166
given O 0 0.0010232496
attention O 0 0.0029645714
and O 0 0.0034050902
mnemonic O 0 0.064013585
tests O 0 0.012042252
. O 0 0.008604306

The O 0 0.0072612166
findings O 0 0.0068232697
of O 0 0.0042031873
this O 0 0.0026960738
study O 0 0.0021566565
indicate O 0 0.0011955827
that O 0 0.0009939314
the O 0 0.0011399041
drug O 0 0.39018556
is O 0 0.0010386049
able O 0 0.0006657017
to O 0 0.0009075501
antagonize O 0 0.012601373
impairment B-Disease 0 0.21161117
of I-Disease 0 0.0016928721
attention I-Disease 0 0.004436319
and I-Disease 0 0.0027457776
memory I-Disease 0 0.32390243
induced O 0 0.0056479895
by O 0 0.026769875
scopolamine B-Chemical 1 0.9999672
. O 0 0.012780395

Safety O 0 0.09466366
of O 0 0.033912268
capecitabine B-Chemical 1 0.9967841
: O 0 0.03610753
a O 0 0.029350284
review O 0 0.037319884
. O 0 0.029550897

IMPORTANCE O 0 0.05037175
OF O 0 0.024514431
THE O 0 0.018601717
FIELD O 0 0.28606644
: O 0 0.0062306332
Fluoropyrimidines B-Chemical 0 0.9336492
, O 0 0.0025636882
in O 0 0.0012234482
particular O 0 0.00091545505
5 B-Chemical 0 0.0010793756
- I-Chemical 0 0.002074695
fluorouracil I-Chemical 0 0.9994456
( O 0 0.0016994576
5 B-Chemical 0 0.00074454176
- I-Chemical 0 0.0013628223
FU I-Chemical 0 0.79262143
) O 0 0.0013676599
, O 0 0.0006457243
have O 0 0.00035649788
been O 0 0.00040628266
the O 0 0.0003604093
mainstay O 0 0.004422063
of O 0 0.00065382675
treatment O 0 0.00089801336
for O 0 0.00037758463
several O 0 0.00059619977
solid O 0 0.23696925
tumors B-Disease 2 0.9935795
, O 0 0.0015689087
including O 0 0.00082284294
colorectal B-Disease 0 0.99570316
, I-Disease 0 0.0030020783
breast I-Disease 0 0.9604663
and I-Disease 0 0.0015563953
head I-Disease 0 0.078780584
and I-Disease 0 0.0021316295
neck I-Disease 0 0.8696777
cancers I-Disease 2 0.9983411
, O 0 0.003907788
for O 0 0.0020153276
> O 0 0.00424196
40 O 0 0.0038371652
years O 0 0.0065004225
. O 0 0.007023368

AREAS O 0 0.03469021
COVERED O 0 0.03891213
IN O 0 0.08334453
THIS O 0 0.14297296
REVIEW O 0 0.04722765
: O 0 0.004165437
This O 0 0.0026339677
article O 0 0.0019165257
reviews O 0 0.002179266
the O 0 0.001201921
pharmacology O 0 0.056568157
and O 0 0.001235739
efficacy O 0 0.0022913206
of O 0 0.0017671383
capecitabine B-Chemical 1 0.99949944
with O 0 0.001515548
a O 0 0.001837395
special O 0 0.0018224559
emphasis O 0 0.003142391
on O 0 0.0022998399
its O 0 0.006475504
safety O 0 0.015474271
. O 0 0.008962458

WHAT O 0 0.047129694
THE O 0 0.025506966
READER O 0 0.45938256
WILL O 0 0.12400044
GAIN O 0 0.18649434
: O 0 0.0035924588
The O 0 0.0016939604
reader O 0 0.0024842208
will O 0 0.00094975356
gain O 0 0.0012732489
better O 0 0.000772783
insight O 0 0.0006304874
into O 0 0.00038821893
the O 0 0.00047984053
safety O 0 0.0010412099
of O 0 0.0008337445
capecitabine B-Chemical 1 0.9994246
in O 0 0.0005075732
special O 0 0.0005887299
populations O 0 0.0009030543
such O 0 0.000556394
as O 0 0.0007283404
patients O 0 0.0021741705
with O 0 0.001094691
advanced O 0 0.05605834
age O 0 0.00986959
, O 0 0.0038878173
renal B-Disease 0 0.9846711
and I-Disease 0 0.007884036
kidney I-Disease 0 0.97875756
disease I-Disease 0 0.9707088
. O 0 0.012564896

We O 0 0.011164031
also O 0 0.0075405785
explore O 0 0.004915334
different O 0 0.004753824
dosing O 0 0.012639639
and O 0 0.005330645
schedules O 0 0.008306418
of O 0 0.009379791
capecitabine B-Chemical 1 0.99957496
administration O 0 0.6289187
. O 0 0.014013222

TAKE O 0 0.18503176
HOME O 0 0.2551481
MESSAGE O 0 0.15805966
: O 0 0.008008977
Capecitabine B-Chemical 0 0.99734503
is O 0 0.0023018345
an O 0 0.002259817
oral O 0 0.42640808
prodrug O 0 0.9313145
of O 0 0.0019516931
5 B-Chemical 0 0.0011254407
- I-Chemical 0 0.0017832322
FU I-Chemical 0 0.66094613
and O 0 0.00071908435
was O 0 0.0005398446
developed O 0 0.0006438473
to O 0 0.00042097972
fulfill O 0 0.00052938337
the O 0 0.00041735516
need O 0 0.0003657946
for O 0 0.00033894196
a O 0 0.0006118591
more O 0 0.0005887073
convenient O 0 0.0009106398
therapy O 0 0.0019801792
and O 0 0.00083652977
provide O 0 0.0007345421
an O 0 0.0014777549
improved O 0 0.0022551108
safety O 0 0.004649349
/ O 0 0.006810911
efficacy O 0 0.007776253
profile O 0 0.0068793
. O 0 0.0083324965

It O 0 0.0100593325
has O 0 0.0047890586
shown O 0 0.0028904038
promising O 0 0.0031309696
results O 0 0.0019192592
alone O 0 0.0016973353
or O 0 0.001179046
in O 0 0.00088383834
combination O 0 0.0013820876
with O 0 0.0008566308
other O 0 0.0008816854
chemotherapeutic O 0 0.92369175
agents O 0 0.42482334
in O 0 0.0012326081
colorectal B-Disease 0 0.99818426
, I-Disease 0 0.0063718013
breast I-Disease 0 0.98777604
, I-Disease 0 0.0028136198
pancreaticobiliary I-Disease 0 0.9809575
, I-Disease 0 0.0023705119
gastric I-Disease 0 0.897627
, I-Disease 0 0.0031873384
renal I-Disease 0 0.9828484
cell I-Disease 0 0.035736
and I-Disease 0 0.0034540223
head I-Disease 0 0.13915949
and I-Disease 0 0.006664542
neck I-Disease 0 0.93180025
cancers I-Disease 2 0.9981383
. O 0 0.013092934

The O 0 0.007549552
most O 0 0.0064567784
commonly O 0 0.0058892313
reported O 0 0.004313698
toxic O 0 0.7542924
effects O 0 0.0063219503
of O 0 0.0044653565
capecitabine B-Chemical 1 0.9998919
are O 0 0.0054732887
diarrhea B-Disease 2 0.99995184
, O 0 0.07073764
nausea B-Disease 2 0.99999785
, O 0 0.04742029
vomiting B-Disease 2 0.9999851
, O 0 0.017192347
stomatitis B-Disease 2 0.9992887
and O 0 0.004359593
hand B-Disease 2 0.005636227
- I-Disease 2 0.009436784
foot I-Disease 2 0.29506266
syndrome I-Disease 2 0.95968175
. O 0 0.011499114

Capecitabine B-Chemical 0 0.9954419
has O 0 0.0057358723
a O 0 0.0048050866
well O 0 0.0030629141
- O 0 0.0033870526
established O 0 0.0018500446
safety O 0 0.0022490185
profile O 0 0.001256694
and O 0 0.0011581195
can O 0 0.00070814893
be O 0 0.0007108678
given O 0 0.00049126137
safely O 0 0.0012993617
to O 0 0.000676858
patients O 0 0.0018835588
with O 0 0.0011732383
advanced O 0 0.05414718
age O 0 0.010315128
, O 0 0.0038373526
hepatic B-Disease 0 0.960851
and I-Disease 0 0.008311156
renal I-Disease 0 0.9976743
dysfunctions I-Disease 0 0.993194
. O 0 0.011777309

Levodopa B-Chemical 1 0.9997749
- O 0 0.025204815
induced O 0 0.008133622
dyskinesias B-Disease 2 0.99988353
in O 0 0.0032786212
patients O 0 0.0059671863
with O 0 0.002564714
Parkinson B-Disease 0 0.9997249
' I-Disease 0 0.0028717658
s I-Disease 0 0.0018804345
disease I-Disease 0 0.50543624
: O 0 0.0025346242
filling O 0 0.0047136224
the O 0 0.0016265993
bench O 0 0.044948783
- O 0 0.0033860127
to O 0 0.0024671697
- O 0 0.00523201
bedside O 0 0.010002472
gap O 0 0.00914494
. O 0 0.008748087

Levodopa B-Chemical 1 0.9994541
is O 0 0.007819953
the O 0 0.0045486093
most O 0 0.004170488
effective O 0 0.0033638638
drug O 0 0.2626411
for O 0 0.0019288046
the O 0 0.0021179789
treatment O 0 0.0035677904
of O 0 0.00523341
Parkinson B-Disease 0 0.99973875
' I-Disease 0 0.009389995
s I-Disease 0 0.008156457
disease I-Disease 0 0.77486885
. O 0 0.011641088

However O 0 0.0097202845
, O 0 0.0070469617
the O 0 0.004118084
long O 0 0.0035172778
- O 0 0.0032957585
term O 0 0.0016596295
use O 0 0.0016067153
of O 0 0.0017940454
this O 0 0.0020107164
dopamine B-Chemical 1 0.9997813
precursor O 0 0.04718574
is O 0 0.0015684845
complicated O 0 0.009127738
by O 0 0.0022270996
highly O 0 0.003634904
disabling O 0 0.98281866
fluctuations O 0 0.017283712
and O 0 0.015704984
dyskinesias B-Disease 2 0.9998946
. O 0 0.012056551

Although O 0 0.0067450535
preclinical O 0 0.009006858
and O 0 0.0037794865
clinical O 0 0.005585765
findings O 0 0.002869922
suggest O 0 0.0010481178
pulsatile O 0 0.06576315
stimulation O 0 0.0025447153
of O 0 0.0020375506
striatal O 0 0.9864617
postsynaptic O 0 0.9739899
receptors O 0 0.11690707
as O 0 0.00072777906
a O 0 0.0007838835
key O 0 0.00062243035
mechanism O 0 0.0008334447
underlying O 0 0.008133933
levodopa B-Chemical 1 0.9999931
- O 0 0.016073067
induced O 0 0.0037634145
dyskinesias B-Disease 2 0.9999831
, O 0 0.0032294425
their O 0 0.0019995149
pathogenesis O 0 0.011145149
is O 0 0.0031534515
still O 0 0.003906592
unclear O 0 0.006609604
. O 0 0.008320467

In O 0 0.0076863826
recent O 0 0.0056334212
years O 0 0.0049353074
, O 0 0.0031064008
evidence O 0 0.0017994058
from O 0 0.0014333376
animal O 0 0.0015291738
models O 0 0.001411776
of O 0 0.0017790062
Parkinson B-Disease 0 0.9998448
' I-Disease 0 0.001975776
s I-Disease 0 0.0010321052
disease I-Disease 0 0.38738886
has O 0 0.00048634296
provided O 0 0.00044414343
important O 0 0.00034902923
information O 0 0.00047850312
to O 0 0.00033047266
understand O 0 0.0002577313
the O 0 0.00038438753
effect O 0 0.00040064775
of O 0 0.00057469716
specific O 0 0.0005287979
receptor O 0 0.085511595
and O 0 0.0010001046
post O 0 0.0017954772
- O 0 0.0017065882
receptor O 0 0.02308079
molecular O 0 0.013146944
mechanisms O 0 0.0016853951
underlying O 0 0.0023693014
the O 0 0.0016941186
development O 0 0.00456824
of O 0 0.0090655135
dyskinetic B-Disease 0 0.99990666
movements I-Disease 0 0.36981288
. O 0 0.009391068

Recent O 0 0.011206701
preclinical O 0 0.010329566
and O 0 0.0044013807
clinical O 0 0.0062386272
data O 0 0.002480669
from O 0 0.0014893025
promising O 0 0.002033493
lines O 0 0.0038163753
of O 0 0.0010931893
research O 0 0.0008981014
focus O 0 0.0005549875
on O 0 0.00031422547
the O 0 0.0003950009
differential O 0 0.0006699717
role O 0 0.00033599112
of O 0 0.0006747249
presynaptic O 0 0.4427676
versus O 0 0.0006232496
postsynaptic O 0 0.9399963
mechanisms O 0 0.0030392017
, O 0 0.0042614727
dopamine B-Chemical 1 0.9999057
receptor O 0 0.3411732
subtypes O 0 0.11186829
, O 0 0.0035865288
ionotropic O 0 0.99960786
and O 0 0.0058174552
metabotropic O 0 0.99998546
glutamate B-Chemical 1 0.9999695
receptors O 0 0.4248005
, O 0 0.0012111334
and O 0 0.00067610765
non O 0 0.003711221
- O 0 0.003713683
dopaminergic O 0 0.9741742
neurotransmitter O 0 0.9707587
systems O 0 0.0012892165
in O 0 0.0006662424
the O 0 0.00089846994
pathophysiology O 0 0.17521587
of O 0 0.007465991
levodopa B-Chemical 1 0.99998343
- O 0 0.04367791
induced O 0 0.02069571
dyskinesias B-Disease 2 0.99992406
. O 0 0.012253561

Effects O 0 0.016757216
of O 0 0.010074262
pallidal O 0 0.9949557
neurotensin B-Chemical 1 0.99933165
on O 0 0.0055744834
haloperidol B-Chemical 1 0.9999927
- O 0 0.047265172
induced O 0 0.017630922
parkinsonian B-Disease 2 0.99999404
catalepsy I-Disease 0 0.99999595
: O 0 0.03129345
behavioral O 0 0.14281653
and O 0 0.005108235
electrophysiological O 0 0.30983818
studies O 0 0.0084572
. O 0 0.008952645

OBJECTIVE O 0 0.5563477
: O 0 0.016029596
The O 0 0.009639695
globus O 0 0.97019136
pallidus O 0 0.9871739
plays O 0 0.0064170323
a O 0 0.0059059295
critical O 0 0.004608096
role O 0 0.004361121
in O 0 0.0058046696
movement O 0 0.012360117
regulation O 0 0.009063372
. O 0 0.011975116

Previous O 0 0.0093831625
studies O 0 0.0057283617
have O 0 0.0032466499
indicated O 0 0.002248828
that O 0 0.0017537611
the O 0 0.0021272758
globus O 0 0.9873876
pallidus O 0 0.9940252
receives O 0 0.0021905247
neurotensinergic O 0 0.03174285
innervation O 0 0.056711655
from O 0 0.0007254241
the O 0 0.0007895127
striatum O 0 0.33101505
, O 0 0.0009521981
and O 0 0.000765553
systemic O 0 0.7550344
administration O 0 0.09451253
of O 0 0.0016674966
a O 0 0.0045819473
neurotensin B-Chemical 1 0.9994874
analog O 0 0.10864056
could O 0 0.0017489291
produce O 0 0.0028521952
antiparkinsonian O 0 0.9988555
effects O 0 0.02239456
. O 0 0.0093094185

The O 0 0.007571714
present O 0 0.0044982727
study O 0 0.0041836146
aimed O 0 0.0028408475
to O 0 0.0018953967
investigate O 0 0.0011842924
the O 0 0.0015177766
effects O 0 0.0026245972
of O 0 0.0032767165
pallidal O 0 0.99892443
neurotensin B-Chemical 1 0.9996964
on O 0 0.0032284847
haloperidol B-Chemical 1 0.99999404
- O 0 0.033884086
induced O 0 0.019001836
parkinsonian B-Disease 2 0.9999751
symptoms I-Disease 0 0.9974375
. O 0 0.013630314

METHODS O 0 0.015033553
: O 0 0.011961707
Behavioral O 0 0.025724454
experiments O 0 0.004605719
and O 0 0.004349969
electrophysiological O 0 0.031393703
recordings O 0 0.007660004
were O 0 0.003193195
performed O 0 0.0027994942
in O 0 0.0032451863
the O 0 0.0040669423
present O 0 0.0047395867
study O 0 0.009919237
. O 0 0.01086609

RESULTS O 0 0.028505066
: O 0 0.010038977
Bilateral O 0 0.028855208
infusions O 0 0.024582047
of O 0 0.004513335
neurotensin B-Chemical 1 0.997198
into O 0 0.0016564911
the O 0 0.002331096
globus O 0 0.9953296
pallidus O 0 0.9989207
reversed O 0 0.09892903
haloperidol B-Chemical 1 0.99999595
- O 0 0.036661834
induced O 0 0.020654513
parkinsonian B-Disease 2 0.99999285
catalepsy I-Disease 0 0.9999912
in O 0 0.00974245
rats O 0 0.047861196
. O 0 0.009728444

Electrophysiological O 0 0.2986497
recordings O 0 0.01279535
showed O 0 0.0039063906
that O 0 0.0028363557
microinjection O 0 0.028136892
of O 0 0.003791501
neurotensin B-Chemical 1 0.9992884
induced O 0 0.0033808867
excitation O 0 0.532285
of O 0 0.0024569903
pallidal O 0 0.9942321
neurons O 0 0.016831605
in O 0 0.0009908457
the O 0 0.0010929247
presence O 0 0.0013829917
of O 0 0.0035855903
systemic O 0 0.99688596
haloperidol B-Chemical 1 0.99999166
administration O 0 0.77888304
. O 0 0.011269873

The O 0 0.010519627
neurotensin B-Chemical 1 0.9957865
type I-Chemical 0 0.008508458
- I-Chemical 0 0.008565394
1 I-Chemical 0 0.0036555575
receptor I-Chemical 0 0.35007265
antagonist I-Chemical 0 0.9973774
SR48692 B-Chemical 0 0.9999665
blocked O 0 0.0047659175
both O 0 0.0011673276
the O 0 0.0010972751
behavioral O 0 0.019949028
and O 0 0.0014203178
the O 0 0.0014376644
electrophysiological O 0 0.15113515
effects O 0 0.0050142817
induced O 0 0.005310054
by O 0 0.012915256
neurotensin B-Chemical 1 0.9989115
. O 0 0.01117449

CONCLUSION O 0 0.8187069
: O 0 0.0136724375
Activation O 0 0.015177369
of O 0 0.0065630367
pallidal O 0 0.996093
neurotensin B-Chemical 1 0.9995419
receptors O 0 0.44366217
may O 0 0.0026425084
be O 0 0.0022078233
involved O 0 0.0018378795
in O 0 0.0027693254
neurotensin B-Chemical 1 0.9993325
- O 0 0.010048317
induced O 0 0.0060443417
antiparkinsonian O 0 0.99923027
effects O 0 0.038206402
. O 0 0.010957334

Carmofur B-Chemical 0 0.98090667
- O 0 0.043176927
induced O 0 0.032635536
organic B-Disease 0 0.9892763
mental I-Disease 0 0.9563482
disorders I-Disease 0 0.99230266
. O 0 0.03584098

Organic B-Disease 0 0.9896723
mental I-Disease 0 0.74401736
disorder I-Disease 0 0.9893686
was O 0 0.0036184967
observed O 0 0.0016700226
in O 0 0.0015406574
a O 0 0.0019163314
29 O 0 0.0025726024
- O 0 0.0016644478
year O 0 0.0009350156
- O 0 0.001135176
old O 0 0.0008046726
female O 0 0.001660241
in O 0 0.0005831223
the O 0 0.0006006737
prognostic O 0 0.0020853134
period O 0 0.0005969913
after O 0 0.00050348864
the O 0 0.0009168451
onset O 0 0.0045671198
of O 0 0.0043704985
carmofur B-Chemical 0 0.99983835
- O 0 0.03227657
induced O 0 0.014395345
leukoencephalopathy B-Disease 2 0.9997197
. O 0 0.014944242

Symptoms O 0 0.6621041
such O 0 0.0062842
as O 0 0.0060071023
euphoria O 0 0.99961543
, O 0 0.007309816
emotional O 0 0.6641201
lability O 0 0.7198294
and O 0 0.002091743
puerile O 0 0.029502964
attitude O 0 0.017779507
noted O 0 0.0006406371
in O 0 0.00055019744
the O 0 0.0005493168
patient O 0 0.0009028281
were O 0 0.0006293443
diagnosed O 0 0.010291157
as O 0 0.00095468934
organic B-Disease 0 0.99440295
personality I-Disease 0 0.99794
syndrome I-Disease 0 0.9843454
according O 0 0.00083995436
to O 0 0.00060510053
the O 0 0.0006459678
criteria O 0 0.0009266431
defined O 0 0.00085502025
in O 0 0.0011767093
the O 0 0.0019810598
DSM O 0 0.53182703
- O 0 0.008870274
III O 0 0.300488
- O 0 0.014770897
R O 0 0.91335464
. O 0 0.010734787

It O 0 0.019887064
is O 0 0.012369178
referred O 0 0.010568165
to O 0 0.008830854
as O 0 0.009654917
a O 0 0.014883647
frontal B-Disease 0 0.8773073
lobe I-Disease 0 0.881267
syndrome I-Disease 0 0.9845287
. O 0 0.021252966

Brain O 0 0.49925157
CT O 0 0.23901431
revealed O 0 0.0051194187
a O 0 0.0047673383
periventricular O 0 0.35892382
low O 0 0.0027606532
density O 0 0.002315514
area O 0 0.0018574109
in O 0 0.0009853805
the O 0 0.0010345378
frontal O 0 0.13275436
white O 0 0.0030726956
matter O 0 0.0023743322
and O 0 0.00086988084
moderate O 0 0.0048889588
dilatation O 0 0.39029077
of O 0 0.001052149
the O 0 0.000988215
lateral O 0 0.0061674896
ventricles O 0 0.050988376
especially O 0 0.0014508415
at O 0 0.0012871573
the O 0 0.002198075
bilateral O 0 0.08476836
anterior O 0 0.047977295
horns O 0 0.3389481
. O 0 0.0091671925

Consequently O 0 0.011747522
, O 0 0.012125651
carmofur B-Chemical 0 0.99907255
- O 0 0.0140153635
induced O 0 0.005954782
leukoencephalopathy B-Disease 2 0.9996061
may O 0 0.0035982088
uncommonly O 0 0.46600237
result O 0 0.002244702
in O 0 0.0022903308
organic B-Disease 0 0.9953838
personality I-Disease 0 0.9983217
syndrome I-Disease 0 0.9888059
in O 0 0.0034186663
the O 0 0.0037431775
residual O 0 0.006374902
state O 0 0.010061922
. O 0 0.009400518

It O 0 0.014950027
may O 0 0.008560495
be O 0 0.006467217
attributed O 0 0.0046129143
to O 0 0.0039773183
the O 0 0.004088998
structural B-Disease 0 0.008098222
damage I-Disease 0 0.5527706
to I-Disease 0 0.005642288
the I-Disease 0 0.007644629
frontal I-Disease 0 0.73693466
lobe I-Disease 0 0.71903986
. O 0 0.013083382

Butyrylcholinesterase O 0 0.34061632
gene O 0 0.00961737
mutations O 0 0.009917504
in O 0 0.0037477557
patients O 0 0.005445878
with O 0 0.0030564112
prolonged O 0 0.023960417
apnea B-Disease 2 0.998346
after O 0 0.002631574
succinylcholine B-Chemical 1 0.99957424
for O 0 0.0050500287
electroconvulsive O 0 0.9990639
therapy O 0 0.2981481
. O 0 0.012029862

BACKGROUND O 0 0.5856731
: O 0 0.009301567
patients O 0 0.006962031
undergoing O 0 0.0049600513
electroconvulsive O 0 0.9963354
therapy O 0 0.15784194
( O 0 0.0074084266
ECT O 0 0.99439937
) O 0 0.003257233
often O 0 0.001819471
receive O 0 0.001332338
succinylcholine B-Chemical 1 0.99897087
as O 0 0.0016995894
part O 0 0.0014844367
of O 0 0.0021707336
the O 0 0.0029644785
anesthetic O 0 0.48308417
procedure O 0 0.0075051095
. O 0 0.009306992

The O 0 0.006630558
duration O 0 0.005095731
of O 0 0.004093239
action O 0 0.0072288066
may O 0 0.0019512465
be O 0 0.0014953243
prolonged O 0 0.0033389549
in O 0 0.00093238446
patients O 0 0.002437079
with O 0 0.0008732054
genetic O 0 0.0024018073
variants O 0 0.001109771
of O 0 0.0009383968
the O 0 0.00096935476
butyrylcholinesterase O 0 0.9861713
enzyme O 0 0.46493116
( O 0 0.005749753
BChE O 0 0.9945334
) O 0 0.0018476758
, O 0 0.00068663293
the O 0 0.00045260336
most O 0 0.0007196458
common O 0 0.00095529266
being O 0 0.0014716162
the O 0 0.0015579538
K O 1 0.9978974
- O 0 0.0035911603
and O 0 0.0021881154
the O 0 0.0027536491
A O 0 0.16175309
- O 0 0.0076706395
variants O 0 0.008445416
. O 0 0.008912247

The O 0 0.0067604436
aim O 0 0.00534244
of O 0 0.003764789
the O 0 0.0025788131
study O 0 0.0021883047
was O 0 0.0013093262
to O 0 0.00084685616
assess O 0 0.0004702711
the O 0 0.00066546415
clinical O 0 0.0024219572
significance O 0 0.000925802
of O 0 0.0008744497
genetic O 0 0.003180855
variants O 0 0.0014454644
in O 0 0.00076096243
butyrylcholinesterase O 0 0.9731776
gene O 0 0.0028972875
( O 0 0.004384353
BCHE O 0 0.9960026
) O 0 0.0014607412
in O 0 0.00044925185
patients O 0 0.001189084
with O 0 0.0005453114
a O 0 0.00080107886
suspected O 0 0.007579515
prolonged O 0 0.0026672562
duration O 0 0.0011818222
of O 0 0.0015063873
action O 0 0.009391317
of O 0 0.0037557883
succinylcholine B-Chemical 1 0.9997111
after O 0 0.0042410856
ECT O 0 0.9950977
. O 0 0.009319698

METHODS O 0 0.011209525
: O 0 0.007654833
a O 0 0.0048454003
total O 0 0.0031852997
of O 0 0.0028267547
13 O 0 0.002489416
patients O 0 0.0028497023
were O 0 0.001515315
referred O 0 0.0014383105
to O 0 0.0012231028
the O 0 0.0015680962
Danish O 0 0.012653632
Cholinesterase O 0 0.99693847
Research O 0 0.030655546
Unit O 0 0.0060323477
after O 0 0.0014020843
ECT O 0 0.92401975
during O 0 0.002393289
38 O 0 0.0056923833
months O 0 0.0046239165
. O 0 0.007261306

We O 0 0.00798745
determined O 0 0.0047865165
the O 0 0.004418873
BChE O 0 0.9239146
activity O 0 0.003052575
and O 0 0.0020595079
the O 0 0.001767638
BCHE O 0 0.98665875
genotype O 0 0.0027998644
using O 0 0.00080296345
molecular O 0 0.0126310075
genetic O 0 0.0023185916
methods O 0 0.00080532354
, O 0 0.0006997072
the O 0 0.00039440717
duration O 0 0.0005571463
of O 0 0.0009064733
apnea B-Disease 2 0.9989492
, O 0 0.0010087062
time O 0 0.00039363958
to O 0 0.00041054355
sufficient O 0 0.00037417212
spontaneous O 0 0.004016648
ventilation O 0 0.02489743
and O 0 0.0011666857
whether O 0 0.0008949742
neuromuscular O 0 0.82187253
monitoring O 0 0.0033910496
was O 0 0.003676493
used O 0 0.005202555
. O 0 0.007568998

The O 0 0.008920325
duration O 0 0.007380462
of O 0 0.0073363394
apnea B-Disease 2 0.99216276
was O 0 0.004474814
compared O 0 0.002540722
with O 0 0.003180194
published O 0 0.0031561123
data O 0 0.0040559694
on O 0 0.003420901
normal O 0 0.00820755
subjects O 0 0.0121763125
. O 0 0.0105724335

RESULTS O 0 0.026516624
: O 0 0.008522561
in O 0 0.0044664904
11 O 0 0.004016402
patients O 0 0.004684992
, O 0 0.0029457088
mutations O 0 0.0038303777
were O 0 0.0013669877
found O 0 0.0009371235
in O 0 0.0010276762
the O 0 0.0013964335
BCHE O 0 0.9883435
gene O 0 0.0021523915
, O 0 0.0019928985
the O 0 0.0018148402
K O 1 0.99748933
- O 0 0.00380683
variant O 0 0.002645248
being O 0 0.003177364
the O 0 0.0029113228
most O 0 0.0057287584
frequent O 0 0.020842338
. O 0 0.009296341

The O 0 0.0069679017
duration O 0 0.0055118427
of O 0 0.0052493936
apnea B-Disease 2 0.99436545
was O 0 0.0031385766
5 O 0 0.0018185939
- O 0 0.0018252044
15 O 0 0.0008607792
min O 0 0.00086482
compared O 0 0.00058916694
with O 0 0.00091962115
3 O 0 0.0010520382
- O 0 0.0014551432
5 O 0 0.00090679375
. O 0 0.0008934592
3 O 0 0.0012263054
min O 0 0.0018064893
from O 0 0.002352344
the O 0 0.0035856136
literature O 0 0.008313789
. O 0 0.008479636

Severe O 0 0.9185734
distress O 0 0.88743967
was O 0 0.008254296
noted O 0 0.0052364785
in O 0 0.0046224813
the O 0 0.004564857
recovery O 0 0.0071426877
phase O 0 0.00657759
in O 0 0.0051798825
two O 0 0.0063454993
patients O 0 0.019060748
. O 0 0.012399207

Neuromuscular O 0 0.1932981
monitoring O 0 0.018292421
was O 0 0.013976869
used O 0 0.011666401
in O 0 0.011996902
two O 0 0.013257379
patients O 0 0.027236551
. O 0 0.020994464

CONCLUSION O 0 0.6199471
: O 0 0.0078608105
eleven O 0 0.004453725
of O 0 0.0031005146
13 O 0 0.0024254862
patients O 0 0.002478665
with O 0 0.00119324
a O 0 0.0012503451
prolonged O 0 0.0021282274
duration O 0 0.0009316134
of O 0 0.0008981074
action O 0 0.0048339777
of O 0 0.0012496803
succinylcholine B-Chemical 1 0.9998735
had O 0 0.00094563846
mutations O 0 0.01895324
in O 0 0.0009536526
BCHE O 0 0.9963631
, O 0 0.0009181323
indicating O 0 0.00038493134
that O 0 0.00036523014
this O 0 0.00045867614
is O 0 0.0004886297
the O 0 0.00050503877
possible O 0 0.00063754467
reason O 0 0.00074960245
for O 0 0.0008187711
a O 0 0.0017756983
prolonged O 0 0.0045385915
period O 0 0.0025078538
of O 0 0.0064015556
apnea B-Disease 2 0.9985958
. O 0 0.0110968165

We O 0 0.01337252
recommend O 0 0.0088359555
objective O 0 0.011525499
neuromuscular O 0 0.5202452
monitoring O 0 0.008597215
during O 0 0.00603761
the O 0 0.0076426216
first O 0 0.009622994
ECT O 0 0.9885925
. O 0 0.016571755

Perhexiline B-Chemical 0 0.9988167
maleate I-Chemical 0 0.999816
and O 0 0.13835597
peripheral B-Disease 2 0.97757655
neuropathy I-Disease 2 0.99961084
. O 0 0.051764693

Peripheral B-Disease 2 0.97865903
neuropathy I-Disease 2 0.99975115
has O 0 0.005380455
been O 0 0.0030459994
noted O 0 0.0016406532
as O 0 0.0014320873
a O 0 0.0016852843
complication O 0 0.27715728
of O 0 0.0016945564
therapy O 0 0.03685163
with O 0 0.0034678981
perhexiline B-Chemical 1 0.999998
maleate I-Chemical 1 0.9999993
, O 0 0.006409822
a O 0 0.0012192299
drug O 0 0.41031158
widely O 0 0.00095150527
used O 0 0.0004977942
in O 0 0.0005503771
France O 0 0.041589066
( O 0 0.0008149912
and O 0 0.0005054288
in O 0 0.00041211516
clinical O 0 0.002008469
trials O 0 0.00072981336
in O 0 0.00048560783
the O 0 0.00066906697
United O 0 0.0025646053
States O 0 0.0039637084
) O 0 0.0011245534
for O 0 0.0005574846
the O 0 0.00084751326
prophylactic O 0 0.005210129
treatment O 0 0.004178286
of O 0 0.019652193
angina B-Disease 0 0.99998367
pectoris I-Disease 0 0.9999752
. O 0 0.015781695

In O 0 0.0070473556
24 O 0 0.0041418257
patients O 0 0.0044577615
with O 0 0.0024608898
this O 0 0.0019630848
complication O 0 0.32026815
, O 0 0.002027228
the O 0 0.0010296229
marked O 0 0.0017497836
slowing O 0 0.012075001
of O 0 0.001198263
motor O 0 0.14028503
nerve O 0 0.49918842
conduction O 0 0.07385834
velocity O 0 0.0012560125
and O 0 0.00082471705
the O 0 0.00085084216
electromyographic O 0 0.24307545
changes O 0 0.0014730492
imply O 0 0.0011924459
mainly O 0 0.0034633216
a O 0 0.009672345
demyelinating B-Disease 0 0.9997037
disorder I-Disease 0 0.9993844
. O 0 0.015942985

Improvement O 0 0.04138642
was O 0 0.016256317
noted O 0 0.012472401
with O 0 0.013215744
cessation O 0 0.024585644
of O 0 0.017675849
therapy O 0 0.117783464
. O 0 0.021509225

In O 0 0.008099716
a O 0 0.006373577
few O 0 0.0033044661
cases O 0 0.003824596
the O 0 0.0023895565
presence O 0 0.0018929212
of O 0 0.0023836144
active O 0 0.0043978617
denervation O 0 0.9866829
signified O 0 0.06409257
a O 0 0.0030795832
poor O 0 0.01842992
prognosis O 0 0.8910689
, O 0 0.003781437
with O 0 0.002700891
only O 0 0.0030722604
slight O 0 0.0054724133
improvement O 0 0.007850205
. O 0 0.00841675

The O 0 0.0071447846
underlying O 0 0.00692554
mechanism O 0 0.0046519716
causing O 0 0.00884868
the O 0 0.00390929
neuropathy B-Disease 2 0.99988675
is O 0 0.0020669901
not O 0 0.0011481523
yet O 0 0.0011426981
fully O 0 0.0007168975
known O 0 0.0010081581
, O 0 0.0009898484
although O 0 0.0005531181
some O 0 0.0006561383
evidence O 0 0.0007221925
indicates O 0 0.00071451813
that O 0 0.00082315813
it O 0 0.0013300494
may O 0 0.0013070045
be O 0 0.0018887456
a O 0 0.003344235
lipid O 0 0.8043139
storage O 0 0.018655982
process O 0 0.008189413
. O 0 0.009707106

A O 0 0.05099714
phase O 0 0.016425258
I O 0 0.018956076
study O 0 0.008197558
of O 0 0.007117101
4 B-Chemical 0 0.0061893724
' I-Chemical 0 0.008231044
- I-Chemical 0 0.00910496
0 I-Chemical 0 0.008868178
- I-Chemical 0 0.01199255
tetrahydropyranyladriamycin I-Chemical 0 0.3619356
. O 0 0.014183655

Clinical O 0 0.18468179
pharmacology O 0 0.37425667
and O 0 0.050846457
pharmacokinetics O 0 0.937188
. O 0 0.04740375

A O 0 0.06908887
Phase O 0 0.017519208
I O 0 0.010495616
study O 0 0.0035118219
of O 0 0.0027933111
intravenous O 0 0.53928035
( O 0 0.0042009167
IV O 0 0.37157515
) O 0 0.00225439
bolus O 0 0.0317481
4 B-Chemical 0 0.0007908695
' I-Chemical 0 0.0010695144
- I-Chemical 0 0.0011507734
0 I-Chemical 0 0.00095580425
- I-Chemical 0 0.0011185559
tetrahydropyranyladriamycin I-Chemical 0 0.28994647
( O 0 0.0017864394
Pirarubicin B-Chemical 0 0.9939989
) O 0 0.001292359
was O 0 0.00048564628
done O 0 0.00040754495
in O 0 0.00047672167
55 O 0 0.0007741884
patients O 0 0.0011415465
in O 0 0.0007770272
good O 0 0.0013734467
performance O 0 0.0019994588
status O 0 0.0030069065
with O 0 0.004032332
refractory O 0 0.8266438
tumors B-Disease 2 0.9950145
. O 0 0.012356631

Twenty O 0 0.014010619
- O 0 0.0073878295
six O 0 0.0027769739
had O 0 0.0021979306
minimal O 0 0.0017615376
prior O 0 0.0012246538
therapy O 0 0.0069492618
( O 0 0.0018891367
good O 0 0.0014803206
risk O 0 0.08241184
) O 0 0.0025035536
, O 0 0.0009514363
23 O 0 0.00073069584
had O 0 0.00038378267
extensive O 0 0.00048057843
prior O 0 0.00037961392
therapy O 0 0.006391715
( O 0 0.0012887113
poor O 0 0.005355084
risk O 0 0.10909419
) O 0 0.00245421
, O 0 0.0009806103
and O 0 0.0007360619
six O 0 0.0005839031
had O 0 0.001035997
renal B-Disease 0 0.9594449
and I-Disease 0 0.0030614005
/ I-Disease 0 0.01063
or I-Disease 0 0.004365907
hepatic I-Disease 0 0.9983796
dysfunction I-Disease 0 0.9983791
. O 0 0.012157577

A O 0 0.023856815
total O 0 0.006963366
of O 0 0.0055563604
167 O 0 0.007763541
courses O 0 0.0037520595
at O 0 0.0019122589
doses O 0 0.004694862
of O 0 0.0020886469
15 O 0 0.001571056
to O 0 0.0015424312
70 O 0 0.0022979206
mg O 0 0.18898518
/ O 0 0.006788588
m2 O 0 0.017538767
were O 0 0.005249267
evaluable O 0 0.021811306
. O 0 0.0087942425

Maximum O 0 0.01793834
tolerated O 0 0.015763588
dose O 0 0.011988838
in O 0 0.0029411395
good O 0 0.0034758763
- O 0 0.0034191504
risk O 0 0.018971104
patients O 0 0.0030311188
was O 0 0.0010213641
70 O 0 0.0010198638
mg O 0 0.18053891
/ O 0 0.0026265013
m2 O 0 0.016705519
, O 0 0.0010876355
and O 0 0.00084665726
in O 0 0.0008346054
poor O 0 0.0048117917
- O 0 0.002301173
risk O 0 0.026272025
patients O 0 0.004773201
, O 0 0.0026662503
60 O 0 0.0025479342
mg O 0 0.2865951
/ O 0 0.011303033
m2 O 0 0.056802146
. O 0 0.008451763

The O 0 0.011958449
dose O 0 0.024933066
- O 0 0.011220972
limiting O 0 0.008084709
toxic O 0 0.70664436
effect O 0 0.0066637876
was O 0 0.006633646
transient O 0 0.24155879
noncumulative O 0 0.98715067
granulocytopenia B-Disease 0 0.99981326
. O 0 0.01977424

Granulocyte O 0 0.38047448
nadir O 0 0.01726892
was O 0 0.006012292
on O 0 0.003669931
day O 0 0.0035706686
14 O 0 0.0038000762
( O 0 0.004207105
range O 0 0.0042336895
, O 0 0.004634542
4 O 0 0.004034851
- O 0 0.0063276445
22 O 0 0.0072306753
) O 0 0.010636963
. O 0 0.009935654

Less O 0 0.23188655
frequent O 0 0.01637585
toxic O 0 0.71756184
effects O 0 0.009279263
included O 0 0.0048265005
thrombocytopenia B-Disease 2 0.99993455
, O 0 0.055011608
anemia B-Disease 2 0.9999639
, O 0 0.088367656
nausea B-Disease 2 0.999995
, O 0 0.020975988
mild O 0 0.96241474
alopecia B-Disease 0 0.9999615
, O 0 0.0522764
phlebitis B-Disease 0 0.9998839
, O 0 0.016809415
and O 0 0.015767554
mucositis B-Disease 2 0.99991465
. O 0 0.015100905

Myelosuppression B-Disease 0 0.9970902
was O 0 0.01602557
more O 0 0.012314205
in O 0 0.010109747
patients O 0 0.016790817
with O 0 0.015683718
hepatic B-Disease 0 0.99751186
dysfunction I-Disease 0 0.99811244
. O 0 0.024750846

Pharmacokinetic O 0 0.4120279
analyses O 0 0.007194006
in O 0 0.0039125783
21 O 0 0.003261358
patients O 0 0.0034290268
revealed O 0 0.0021655208
Pirarubicin B-Chemical 0 0.9928738
plasma O 0 0.117132306
T O 0 0.8310216
1 O 0 0.0013542434
/ O 0 0.0019692294
2 O 0 0.0008083448
alpha O 0 0.09019139
( O 0 0.0014820454
+ O 0 0.0010126237
/ O 0 0.0036129686
- O 0 0.0018809768
SE O 2 0.8477842
) O 0 0.0009958599
of O 0 0.00057177764
2 O 0 0.00051663537
. O 0 0.00031767468
5 O 0 0.00037173537
+ O 0 0.0005191074
/ O 0 0.0012689311
- O 0 0.00071706285
0 O 0 0.00047734127
. O 0 0.0002484657
85 O 0 0.00041238312
minutes O 0 0.00028334203
, O 0 0.0005806842
T O 0 0.3057299
beta O 0 0.16943628
1 O 0 0.0006047788
/ O 0 0.00089794834
2 O 0 0.0003532481
of O 0 0.000394479
25 O 0 0.00057459885
. O 0 0.00028763045
6 O 0 0.0003107749
+ O 0 0.00047563005
/ O 0 0.0012111715
- O 0 0.00065948954
6 O 0 0.00027597102
. O 0 0.00023421085
5 O 0 0.00025556673
minutes O 0 0.0002658493
, O 0 0.00048627582
and O 0 0.00055685797
T O 0 0.38480976
1 O 0 0.0006385369
/ O 0 0.0010511797
2 O 0 0.00051928806
gamma O 0 0.02027671
of O 0 0.0007214077
23 O 0 0.001065733
. O 0 0.00050885906
6 O 0 0.0006183532
+ O 0 0.0010458226
/ O 0 0.002469978
- O 0 0.001983571
7 O 0 0.0014845469
. O 0 0.0016019715
6 O 0 0.0023256948
hours O 0 0.0034442572
. O 0 0.0061683697

The O 0 0.007542124
area O 0 0.0061231325
under O 0 0.003041115
the O 0 0.0027101093
curve O 0 0.0036750154
was O 0 0.0023383629
537 O 0 0.11526052
+ O 0 0.001858265
/ O 0 0.0030341118
- O 0 0.001476681
149 O 0 0.0031943303
ng O 0 0.001727646
/ O 0 0.0013848018
ml O 0 0.0013634904
x O 0 0.0010770509
hours O 0 0.0003742575
, O 0 0.00051372085
volume O 0 0.00067613303
of O 0 0.00045332138
distribution O 0 0.0004195279
( O 0 0.00096691353
Vd O 0 0.21838294
) O 0 0.0012611346
3504 O 0 0.2182612
+ O 0 0.0007213211
/ O 0 0.0017168999
- O 0 0.0009280523
644 O 0 0.015406676
l O 0 0.0008720488
/ O 0 0.001316272
m2 O 0 0.008898482
, O 0 0.00060078595
and O 0 0.00044489553
total O 0 0.0004907809
clearance O 0 0.035616092
( O 0 0.0015449462
ClT O 0 0.82328045
) O 0 0.0012588006
was O 0 0.00065672945
204 O 0 0.003259017
+ O 0 0.00082087447
39 O 0 0.0011340214
. O 0 0.00068486895
3 O 0 0.0009801545
l O 0 0.002111609
/ O 0 0.0034452786
hour O 0 0.0023461215
/ O 0 0.008119707
m2 O 0 0.038690444
. O 0 0.007941359

Adriamycinol B-Chemical 0 0.8480208
, O 0 0.01311187
doxorubicin B-Chemical 1 0.9991898
, O 0 0.0091181
adriamycinone B-Chemical 0 0.802789
, O 0 0.0032252672
and O 0 0.0018330144
tetrahydropyranyladriamycinol B-Chemical 0 0.13126414
were O 0 0.0009864583
the O 0 0.0008288405
metabolites O 0 0.547478
detected O 0 0.0004701947
in O 0 0.00054374145
plasma O 0 0.007366205
and O 0 0.0005903243
the O 0 0.00042250546
amount O 0 0.0003060974
of O 0 0.00084493693
doxorubicin B-Chemical 1 0.99970764
was O 0 0.00065989536
less O 0 0.0005065444
than O 0 0.00038998123
or O 0 0.0005364254
equal O 0 0.00060144544
to O 0 0.0007371331
10 O 0 0.0010088922
% O 0 0.0013642033
of O 0 0.0016842721
the O 0 0.002384643
total O 0 0.0042958288
metabolites O 0 0.87037057
. O 0 0.009198205

Urinary O 0 0.9140024
excretion O 0 0.7918565
of O 0 0.006714435
Pirarubicin B-Chemical 0 0.98056364
in O 0 0.0020722935
the O 0 0.0014300505
first O 0 0.0010160999
24 O 0 0.0008673741
hours O 0 0.000723144
was O 0 0.00089636387
less O 0 0.0009587224
than O 0 0.0009433509
or O 0 0.0014328258
equal O 0 0.0018324256
to O 0 0.0025582921
10 O 0 0.004072779
% O 0 0.0066462043
. O 0 0.0074017914

Activity O 0 0.028410645
was O 0 0.009122611
noted O 0 0.0062660202
in O 0 0.006289121
mesothelioma B-Disease 0 0.97186464
, O 0 0.013306047
leiomyosarcoma B-Disease 0 0.99885297
, O 0 0.010233736
and O 0 0.007908822
basal B-Disease 0 0.034996126
cell I-Disease 0 0.28740937
carcinoma I-Disease 2 0.9996301
. O 0 0.019767663

The O 0 0.007425444
recommended O 0 0.0050576073
starting O 0 0.0035293347
dose O 0 0.006816116
for O 0 0.0022366906
Phase O 0 0.010924057
II O 0 0.013734845
trials O 0 0.0017368764
is O 0 0.0011419627
60 O 0 0.0011723019
mg O 0 0.11217969
/ O 0 0.0031776421
m2 O 0 0.014378964
IV O 0 0.10229067
bolus O 0 0.014030217
every O 0 0.0017392922
3 O 0 0.0030927618
weeks O 0 0.0038849418
. O 0 0.0068783322

Ocular B-Disease 0 0.7817671
and I-Disease 0 0.017223572
auditory I-Disease 0 0.19252849
toxicity I-Disease 2 0.99315053
in O 0 0.011803155
hemodialyzed O 0 0.9963897
patients O 0 0.11117069
receiving O 0 0.17867616
desferrioxamine B-Chemical 1 0.99984634
. O 0 0.025249189

During O 0 0.0071211183
an O 0 0.0066518546
18 O 0 0.0043756636
- O 0 0.003451166
month O 0 0.001494157
period O 0 0.0011662473
of O 0 0.0012467359
study O 0 0.0013456923
41 O 0 0.0024608874
hemodialyzed O 0 0.9888571
patients O 0 0.0077495654
receiving O 0 0.0107126525
desferrioxamine B-Chemical 1 0.9999908
( O 0 0.0044917096
10 O 0 0.00083365035
- O 0 0.0008290155
40 O 0 0.00047825577
mg O 0 0.06673566
/ O 0 0.0011696222
kg O 0 0.0034241776
BW O 0 0.2187362
/ O 0 0.0011783274
3 O 0 0.00037316312
times O 0 0.00027822374
weekly O 0 0.00058279885
) O 0 0.0006813249
for O 0 0.00033254086
the O 0 0.00043145788
first O 0 0.00044363586
time O 0 0.0005370582
were O 0 0.00073545263
monitored O 0 0.0006127724
for O 0 0.000987139
detection O 0 0.002104336
of O 0 0.0040998324
audiovisual B-Disease 0 0.5586516
toxicity I-Disease 2 0.9994611
. O 0 0.012180827

6 O 0 0.010886968
patients O 0 0.011164658
presented O 0 0.007936733
clinical O 0 0.014066596
symptoms O 0 0.6023711
of O 0 0.008735786
visual B-Disease 0 0.2492175
or I-Disease 0 0.009223473
auditory I-Disease 0 0.537579
toxicity I-Disease 2 0.9976585
. O 0 0.016624799

Moreover O 0 0.0120052695
, O 0 0.008493916
detailed O 0 0.004908162
ophthalmologic O 0 0.047288172
and O 0 0.0041939174
audiologic O 0 0.068603836
studies O 0 0.0032034868
disclosed O 0 0.0056536593
abnormalities O 0 0.06519706
in O 0 0.00274406
7 O 0 0.0031035468
more O 0 0.0041613095
asymptomatic O 0 0.092008814
patients O 0 0.020112425
. O 0 0.010436799

Visual B-Disease 0 0.9767867
toxicity I-Disease 2 0.99736625
was O 0 0.0051072873
of O 0 0.0038414889
retinal O 0 0.6908568
origin O 0 0.0047770985
and O 0 0.0019436142
was O 0 0.0012591867
characterized O 0 0.0017108137
by O 0 0.0013817672
a O 0 0.00239069
tritan O 0 0.989823
- O 0 0.00280336
type O 0 0.0010702331
dyschromatopsy B-Disease 0 0.5922226
, O 0 0.0013619899
sometimes O 0 0.001898536
associated O 0 0.00091480935
with O 0 0.0009110008
a B-Disease 0 0.0013426283
loss I-Disease 0 0.001878531
of I-Disease 0 0.0021079488
visual I-Disease 0 0.57465804
acuity I-Disease 0 0.9944929
and O 0 0.0067915497
pigmentary B-Disease 0 0.9980546
retinal I-Disease 0 0.98562497
deposits I-Disease 0 0.9307077
. O 0 0.0127225155

Auditory B-Disease 0 0.9327997
toxicity I-Disease 2 0.99734014
was O 0 0.0055626957
characterized O 0 0.004494444
by O 0 0.002877007
a O 0 0.002747468
mid O 0 0.0050847656
- O 0 0.0021723567
to O 0 0.00095970114
high O 0 0.0014913646
- O 0 0.0020446738
frequency O 0 0.0017086157
neurosensorial B-Disease 0 0.9980274
hearing I-Disease 0 0.97268593
loss I-Disease 0 0.007817635
and O 0 0.0013020514
the O 0 0.0012066966
lesion O 0 0.048118908
was O 0 0.0016495647
of O 0 0.0023373598
the O 0 0.0031859146
cochlear O 0 0.17524368
type O 0 0.0075255283
. O 0 0.009118858

Desferrioxamine B-Chemical 0 0.9993612
withdrawal O 0 0.9104672
resulted O 0 0.0038126428
in O 0 0.0022263655
a O 0 0.0020311128
complete O 0 0.0011442858
recovery O 0 0.0017011887
of O 0 0.001150001
visual O 0 0.06291172
function O 0 0.0008312913
in O 0 0.0005494336
1 O 0 0.00054630515
patient O 0 0.00060804776
and O 0 0.0004827883
partial O 0 0.00066722924
recovery O 0 0.0010110061
in O 0 0.00044440382
3 O 0 0.00048243566
, O 0 0.0005359169
and O 0 0.00043115055
a O 0 0.0005150462
complete O 0 0.00037146473
reversal O 0 0.0011232691
of O 0 0.00081688055
hearing B-Disease 0 0.89584917
loss I-Disease 0 0.0016247064
in O 0 0.0007356548
3 O 0 0.0008341542
patients O 0 0.00175034
and O 0 0.0014613512
partial O 0 0.00247058
recovery O 0 0.0042273183
in O 0 0.0034504165
3 O 0 0.005400452
. O 0 0.0068989424

This O 0 0.013612982
toxicity B-Disease 2 0.97000825
appeared O 0 0.004377637
in O 0 0.0025140415
patients O 0 0.003325562
receiving O 0 0.0022630752
the O 0 0.0011859805
higher O 0 0.0010336618
doses O 0 0.026790483
of O 0 0.0031852303
desferrioxamine B-Chemical 1 0.9999858
or O 0 0.0016226224
coincided O 0 0.0017299427
with O 0 0.00096303254
the O 0 0.0009453713
normalization O 0 0.0013749892
of O 0 0.002271095
ferritin O 0 0.9965928
or O 0 0.005635671
aluminium B-Chemical 0 0.9984004
serum O 0 0.6911228
levels O 0 0.009729151
. O 0 0.010014233

The O 0 0.0082643535
data O 0 0.006822817
indicate O 0 0.003827473
that O 0 0.0032289268
audiovisual B-Disease 0 0.11392648
toxicity I-Disease 2 0.99901545
is O 0 0.0025315664
not O 0 0.0016577534
an O 0 0.002285409
infrequent O 0 0.01855851
complication O 0 0.57720625
in O 0 0.0034106905
hemodialyzed O 0 0.9979133
patients O 0 0.07871122
receiving O 0 0.1270312
desferrioxamine B-Chemical 1 0.9999105
. O 0 0.016771685

Periodical O 0 0.0131125925
audiovisual O 0 0.009971028
monitoring O 0 0.0041833944
should O 0 0.0020137697
be O 0 0.0018186527
performed O 0 0.0012582697
on O 0 0.0010181211
hemodialyzed O 0 0.97699946
patients O 0 0.0036028586
receiving O 0 0.0016672695
the O 0 0.0008646115
drug O 0 0.25114894
in O 0 0.00072308234
order O 0 0.0005712939
to O 0 0.0007085891
detect O 0 0.00074951217
adverse O 0 0.84864086
effects O 0 0.003631003
as O 0 0.002459601
early O 0 0.004637633
as O 0 0.004348672
possible O 0 0.006624266
. O 0 0.00862921

Serial O 0 0.05124297
epilepsy B-Disease 2 0.99888533
caused O 0 0.011821144
by O 0 0.011462156
levodopa B-Chemical 1 0.9999751
/ I-Chemical 0 0.45077395
carbidopa I-Chemical 0 0.99998605
administration O 0 0.33197972
in O 0 0.0029497882
two O 0 0.002840765
patients O 0 0.0071099773
on O 0 0.004445872
hemodialysis O 0 0.7712682
. O 0 0.011269165

Two O 0 0.008464792
patients O 0 0.0071415175
with O 0 0.003398797
similar O 0 0.0019783108
clinical O 0 0.004510728
features O 0 0.0027933163
are O 0 0.0013718264
presented O 0 0.0012826298
: O 0 0.0012539912
both O 0 0.00065050647
patients O 0 0.0017809379
had O 0 0.00077806076
chronic B-Disease 2 0.98707855
renal I-Disease 2 0.99865085
failure I-Disease 2 0.98081183
, O 0 0.0011828302
on O 0 0.00032324597
hemodialysis O 0 0.23069072
for O 0 0.00033238172
many O 0 0.00048200568
years O 0 0.0006939036
but O 0 0.0003991195
recently O 0 0.00042640234
begun O 0 0.0006093264
on O 0 0.00027071626
a O 0 0.0006394053
high O 0 0.00082219945
- O 0 0.0012846384
flux O 0 0.0057568178
dialyzer O 0 0.29481503
; O 0 0.0012229722
both O 0 0.00039719173
had O 0 0.000416727
been O 0 0.00047166555
receiving O 0 0.0011150971
a O 0 0.0028104882
carbidopa B-Chemical 0 0.9999976
/ I-Chemical 0 0.07924601
levodopa I-Chemical 1 0.9999945
preparation O 0 0.003309609
; O 0 0.0013984352
and O 0 0.0004749319
both O 0 0.00037322927
had O 0 0.0003699659
the O 0 0.00044103278
onset O 0 0.0027051289
of O 0 0.0019452632
hallucinosis B-Disease 0 0.9999906
and O 0 0.006587281
recurrent O 0 0.9882349
seizures B-Disease 2 0.99998784
, O 0 0.0041918093
which O 0 0.0022630533
were O 0 0.0023319453
refractory O 0 0.2567149
to O 0 0.005362299
anticonvulsants O 0 0.9996125
. O 0 0.010159601

The O 0 0.0067854184
first O 0 0.0043143583
patient O 0 0.00445766
died O 0 0.005861075
without O 0 0.0021299862
a O 0 0.0025178841
diagnosis O 0 0.0114717325
; O 0 0.0022497568
the O 0 0.0008955968
second O 0 0.0008532867
patient O 0 0.0011803461
had O 0 0.00077159604
a O 0 0.0011188596
dramatic O 0 0.0013599187
recovery O 0 0.0019399325
following O 0 0.0012870859
the O 0 0.0018501255
administration O 0 0.17169975
of O 0 0.01977057
vitamin B-Chemical 0 0.99991393
B6 I-Chemical 0 0.9948407
. O 0 0.015947293

Neither O 0 0.010047444
patient O 0 0.0077122548
was O 0 0.004310159
considered O 0 0.0026888421
to O 0 0.0022129095
have O 0 0.0018487955
a O 0 0.0026723118
renal O 0 0.933768
state O 0 0.0031812117
sufficiently O 0 0.002475113
severe O 0 0.08400327
enough O 0 0.0023233749
to O 0 0.0023816118
explain O 0 0.002956567
their O 0 0.0053262273
presentation O 0 0.027902048
. O 0 0.010438839

Randomized O 0 0.03164129
, O 0 0.012772174
double O 0 0.009014426
- O 0 0.009478128
blind O 0 0.01205605
trial O 0 0.0075542736
of O 0 0.009348852
mazindol B-Chemical 1 0.999859
in O 0 0.015357956
Duchenne B-Disease 0 0.99897623
dystrophy I-Disease 0 0.998912
. O 0 0.019113619

There O 0 0.010426375
is O 0 0.0065282397
evidence O 0 0.0048727253
that O 0 0.0038278005
growth O 0 0.021223448
hormone O 0 0.9753302
may O 0 0.00255041
be O 0 0.0019120579
related O 0 0.0012791977
to O 0 0.0014512092
the O 0 0.0018994343
progression O 0 0.30782178
of O 0 0.0070558963
weakness B-Disease 2 0.9973187
in O 0 0.008028854
Duchenne B-Disease 0 0.99926883
dystrophy I-Disease 0 0.9990938
. O 0 0.014084913

We O 0 0.00810067
conducted O 0 0.00478472
a O 0 0.0045447154
12 O 0 0.002645281
- O 0 0.0026404157
month O 0 0.0012082688
controlled O 0 0.0011188169
trial O 0 0.001486485
of O 0 0.00181301
mazindol B-Chemical 1 0.99997246
, O 0 0.0022373716
a O 0 0.0014221043
putative O 0 0.0015073224
growth O 0 0.050851215
hormone O 0 0.99472
secretion O 0 0.1922718
inhibitor O 0 0.24536307
, O 0 0.0028889272
in O 0 0.0016485959
83 O 0 0.0042339023
boys O 0 0.015289776
with O 0 0.0047826087
Duchenne B-Disease 0 0.9986601
dystrophy I-Disease 0 0.9987081
. O 0 0.012290357

Muscle O 0 0.5881394
strength O 0 0.016707828
, O 0 0.008448127
contractures O 0 0.99521494
, O 0 0.0037177042
functional O 0 0.0018513217
ability O 0 0.0012199024
and O 0 0.0012241307
pulmonary O 0 0.6979124
function O 0 0.0010999653
were O 0 0.00061343383
tested O 0 0.0003935013
at O 0 0.00036183727
baseline O 0 0.0005743412
, O 0 0.0005800121
and O 0 0.00045471496
6 O 0 0.00031588983
and O 0 0.00036986367
12 O 0 0.00027756323
months O 0 0.0002565303
after O 0 0.00025830473
treatment O 0 0.00079258444
with O 0 0.0012610536
mazindol B-Chemical 1 0.999979
( O 0 0.0022886412
3 O 0 0.001109972
mg O 0 0.20452149
/ O 0 0.003471837
d O 0 0.0025939483
) O 0 0.0040634205
or O 0 0.003752382
placebo O 0 0.21699098
. O 0 0.007976618

The O 0 0.007639093
study O 0 0.0058456804
was O 0 0.0036359814
designed O 0 0.002612927
to O 0 0.0016991186
have O 0 0.0012463167
a O 0 0.0014359497
power O 0 0.0027798328
of O 0 0.0009681318
greater O 0 0.00071133405
than O 0 0.00050477026
0 O 0 0.0007910547
. O 0 0.00035381582
90 O 0 0.0003482392
to O 0 0.0002969118
detect O 0 0.00027454706
a O 0 0.0006117232
slowing O 0 0.0042655943
to O 0 0.00040719137
25 O 0 0.0006064258
% O 0 0.0004549534
of O 0 0.0004049669
the O 0 0.000383102
expected O 0 0.00033442743
rate O 0 0.00046597532
of O 0 0.0008220913
progression O 0 0.24452378
of O 0 0.0022136476
weakness B-Disease 2 0.9923381
at O 0 0.0011087423
P O 0 0.05151691
less O 0 0.0014987868
than O 0 0.0016845086
0 O 0 0.0037555438
. O 0 0.0036185018
05 O 0 0.07114132
. O 0 0.0069796746

Mazindol B-Chemical 0 0.996433
did O 0 0.010592999
not O 0 0.007123839
benefit O 0 0.007880806
strength O 0 0.0077075413
at O 0 0.003778982
any O 0 0.0039719585
point O 0 0.0042830114
in O 0 0.005212055
the O 0 0.0070100063
study O 0 0.011586741
. O 0 0.012200452

Side O 0 0.9016522
effects O 0 0.010012626
attributable O 0 0.0043946407
to O 0 0.003825741
mazindol B-Chemical 1 0.999928
included O 0 0.0030630017
decreased B-Disease 0 0.04835267
appetite I-Disease 0 0.9998006
( O 0 0.003345246
36 O 0 0.0011129852
% O 0 0.0010462292
) O 0 0.001351532
, O 0 0.0009416415
dry B-Disease 2 0.092515126
mouth I-Disease 2 0.70853585
( O 0 0.0013951666
10 O 0 0.00059346715
% O 0 0.0006897581
) O 0 0.00091330486
, O 0 0.000607909
behavioral O 0 0.006677266
change O 0 0.00055767276
( O 0 0.0006982537
22 O 0 0.0005990826
% O 0 0.0005889466
) O 0 0.0008421326
, O 0 0.0006027291
and O 0 0.00067500665
gastrointestinal B-Disease 0 0.99936074
symptoms I-Disease 0 0.99459004
( O 0 0.002024286
18 O 0 0.0007365173
% O 0 0.00091693905
) O 0 0.0017096268
; O 0 0.002141246
mazindol B-Chemical 1 0.999941
dosage O 0 0.12802994
was O 0 0.001066794
reduced O 0 0.0011509769
in O 0 0.0013997835
43 O 0 0.0030401724
% O 0 0.0028650737
of O 0 0.003927559
patients O 0 0.013579244
. O 0 0.0082925325

The O 0 0.007241657
effect O 0 0.005009678
of O 0 0.006059084
mazindol B-Chemical 1 0.9999174
on O 0 0.002993949
GH O 0 0.99660313
secretion O 0 0.06264076
was O 0 0.0011584483
estimated O 0 0.000823026
indirectly O 0 0.0018022114
by O 0 0.00071180396
comparing O 0 0.00039405312
the O 0 0.0007718164
postabsorptive O 0 0.9315915
IGF O 0 0.99924845
- O 0 0.0032287072
I O 0 0.0062418566
levels O 0 0.00040266867
obtained O 0 0.00042420975
following O 0 0.00044965584
3 O 0 0.0004747644
, O 0 0.0005483606
6 O 0 0.00033012722
, O 0 0.0004830751
9 O 0 0.0004155003
, O 0 0.00045064322
and O 0 0.0003979061
12 O 0 0.00030379312
months O 0 0.00029704062
in O 0 0.00042348367
the O 0 0.00078890874
mazindol B-Chemical 1 0.9999378
treated O 0 0.0014164796
to O 0 0.0010339383
those O 0 0.0016937499
in O 0 0.0015597765
the O 0 0.0024900564
placebo O 0 0.17708488
groups O 0 0.0075600347
. O 0 0.008021196

Although O 0 0.01030529
mazindol B-Chemical 1 0.9997905
- O 0 0.008758161
treated O 0 0.0030694008
patients O 0 0.0037116813
gained O 0 0.0022881473
less O 0 0.0011683154
weight O 0 0.0034883802
and O 0 0.0010502122
height O 0 0.002244497
than O 0 0.0005741954
placebo O 0 0.15104546
- O 0 0.001256226
treated O 0 0.00077611173
patients O 0 0.0020778044
, O 0 0.00084611966
no O 0 0.0004900682
significant O 0 0.00090561865
effect O 0 0.001154065
on O 0 0.0014006677
IGF O 0 0.9983487
- O 0 0.0063064108
I O 0 0.02021202
levels O 0 0.0028072896
was O 0 0.003804386
observed O 0 0.0044881226
. O 0 0.008495254

Mazindol B-Chemical 0 0.9972283
doses O 0 0.05757646
not O 0 0.00765131
slow O 0 0.009436611
the O 0 0.0058211684
progression O 0 0.2878818
of O 0 0.01210717
weakness B-Disease 2 0.9967198
in O 0 0.012752912
Duchenne B-Disease 0 0.9990501
dystrophy I-Disease 0 0.9989851
. O 0 0.018357795

Facilitation O 0 0.10897171
of O 0 0.007340085
memory O 0 0.057197135
retrieval O 0 0.0047513875
by O 0 0.0029064626
pre O 0 0.010952343
- O 0 0.0026844929
test O 0 0.0017872727
morphine B-Chemical 1 0.9998919
and O 0 0.0013664191
its O 0 0.001405257
state O 0 0.0010303123
dependency O 0 0.0012847363
in O 0 0.00059398834
the O 0 0.00068470713
step O 0 0.000886173
- O 0 0.0012091601
through O 0 0.0006236658
type O 0 0.00092011766
passive O 0 0.002157227
avoidance O 0 0.01413732
learning O 0 0.0057486217
test O 0 0.0032469386
in O 0 0.0036063795
mice O 0 0.0047915773
. O 0 0.008162849

Amnesia B-Disease 0 0.9720232
produced O 0 0.008033557
by O 0 0.009017016
scopolamine B-Chemical 1 0.99997735
and O 0 0.013538942
cycloheximide B-Chemical 1 0.9984817
were O 0 0.002205499
reversed O 0 0.0031067508
by O 0 0.0014333446
morphine B-Chemical 1 0.99991393
given O 0 0.00046883905
30 O 0 0.0003720307
min O 0 0.00037896037
before O 0 0.00022156209
the O 0 0.00032575894
test O 0 0.0004947511
trial O 0 0.0008376939
( O 0 0.00080072094
pre O 0 0.0043044453
- O 0 0.00096719054
test O 0 0.00067375373
) O 0 0.0011565158
, O 0 0.0006148351
and O 0 0.00052325247
pre O 0 0.0052398136
- O 0 0.00095663464
test O 0 0.0007075125
morphine B-Chemical 1 0.99989784
also O 0 0.0005780463
facilitated O 0 0.00056447997
the O 0 0.0005389043
memory O 0 0.042761795
retrieval O 0 0.00086827256
in O 0 0.0005382436
the O 0 0.00064294407
animals O 0 0.00081810047
administered O 0 0.0037426264
naloxone B-Chemical 1 0.99995327
during O 0 0.0016163536
the O 0 0.0025107923
training O 0 0.0036371774
trial O 0 0.0073191365
. O 0 0.0072059226

Similarly O 0 0.0108601255
, O 0 0.0081424005
pre O 0 0.014034929
- O 0 0.005630433
test O 0 0.0043361518
scopolamine B-Chemical 1 0.99998164
partially O 0 0.003617151
reversed O 0 0.006466004
the O 0 0.002824844
scopolamine B-Chemical 1 0.9999975
- O 0 0.029676702
induced O 0 0.0040542767
amnesia B-Disease 2 0.9999379
, O 0 0.00202386
but O 0 0.00065100164
not O 0 0.0005503682
significantly O 0 0.0010513118
; O 0 0.0014465317
and O 0 0.0007927695
pre O 0 0.0098462105
- O 0 0.001611069
test O 0 0.0012557189
cycloheximide B-Chemical 1 0.9910014
failed O 0 0.0013952949
to O 0 0.00125731
reverse O 0 0.028528208
the O 0 0.003348459
cycloheximide B-Chemical 1 0.99898404
- O 0 0.040494695
induced O 0 0.016225765
amnesia B-Disease 2 0.9996394
. O 0 0.012517614

These O 0 0.008230063
results O 0 0.0049563814
suggest O 0 0.0027103515
that O 0 0.0021548623
the O 0 0.001982174
facilitation O 0 0.026145788
of O 0 0.0018740768
memory O 0 0.1282123
retrieval O 0 0.0018715586
by O 0 0.0011742633
pre O 0 0.01322157
- O 0 0.0016136504
test O 0 0.0011000119
morphine B-Chemical 1 0.9999118
might O 0 0.0004895747
be O 0 0.00055295834
the O 0 0.00046429265
direct O 0 0.0005756179
action O 0 0.0024177365
of O 0 0.0014436657
morphine B-Chemical 1 0.9999181
rather O 0 0.0012528367
than O 0 0.0011339968
a O 0 0.002333002
state O 0 0.0031539781
dependent O 0 0.0030741582
effect O 0 0.005880405
. O 0 0.008195332

Naloxone B-Chemical 1 0.9996972
reverses O 0 0.3144323
the O 0 0.015388011
antihypertensive O 0 0.98919547
effect O 0 0.016030464
of O 0 0.03552745
clonidine B-Chemical 1 0.9998159
. O 0 0.026139986

In O 0 0.007927664
unanesthetized O 0 0.044675842
, O 0 0.0057672365
spontaneously O 0 0.026962453
hypertensive B-Disease 2 0.997959
rats O 0 0.0052352445
the O 0 0.0011903073
decrease O 0 0.0008939889
in O 0 0.0006666845
blood O 0 0.007819007
pressure O 0 0.041715976
and O 0 0.00076667225
heart O 0 0.3250414
rate O 0 0.00051573594
produced O 0 0.0004807287
by O 0 0.000669829
intravenous O 0 0.7253484
clonidine B-Chemical 1 0.9999895
, O 0 0.0011847973
5 O 0 0.00036337282
to O 0 0.0003009232
20 O 0 0.00040452316
micrograms O 0 0.04701398
/ O 0 0.0015278334
kg O 0 0.005478339
, O 0 0.00078292424
was O 0 0.0005072305
inhibited O 0 0.00066969974
or O 0 0.00063131563
reversed O 0 0.0016329794
by O 0 0.0011457583
nalozone B-Chemical 0 0.73908883
, O 0 0.0014457727
0 O 0 0.0011575718
. O 0 0.0006899382
2 O 0 0.0009830415
to O 0 0.0011595859
2 O 0 0.002105019
mg O 0 0.18721828
/ O 0 0.009267012
kg O 0 0.019575393
. O 0 0.008495299

The O 0 0.009027469
hypotensive B-Disease 2 0.98214185
effect O 0 0.0046585
of O 0 0.0040410548
100 O 0 0.005211931
mg O 0 0.4882419
/ O 0 0.0061485004
kg O 0 0.038420804
alpha B-Chemical 1 0.85780567
- I-Chemical 1 0.02389608
methyldopa I-Chemical 1 0.99999094
was O 0 0.0028544865
also O 0 0.0025839314
partially O 0 0.0034907644
reversed O 0 0.009213971
by O 0 0.013310554
naloxone B-Chemical 1 0.99992275
. O 0 0.012759271

Naloxone B-Chemical 1 0.9997441
alone O 0 0.012319107
did O 0 0.006431971
not O 0 0.004675299
affect O 0 0.0031913952
either O 0 0.0037457226
blood O 0 0.015716199
pressure O 0 0.08415212
or O 0 0.006156726
heart O 0 0.6630625
rate O 0 0.009757569
. O 0 0.011822983

In O 0 0.008137276
brain O 0 0.028406294
membranes O 0 0.017463032
from O 0 0.0035118572
spontaneously O 0 0.053328164
hypertensive B-Disease 2 0.9993755
rats O 0 0.06606965
clonidine B-Chemical 1 0.9999802
, O 0 0.0032098943
10 O 0 0.0011209452
( O 0 0.0012855165
- O 0 0.0010501232
8 O 0 0.0005271979
) O 0 0.00070075155
to O 0 0.0004035029
10 O 0 0.00056401093
( O 0 0.0008615813
- O 0 0.0009064608
5 O 0 0.00047948296
) O 0 0.0012104207
M O 0 0.76067746
, O 0 0.0007294782
did O 0 0.0003607982
not O 0 0.00036314255
influence O 0 0.00039379662
stereoselective O 0 0.68125904
binding O 0 0.00068469474
of O 0 0.0014319759
[ B-Chemical 0 0.04133494
3H I-Chemical 0 0.9217858
] I-Chemical 0 0.01941871
- I-Chemical 0 0.009305937
naloxone I-Chemical 1 0.99999106
( O 0 0.0020252226
8 O 0 0.0006552328
nM O 0 0.029689953
) O 0 0.0012430021
, O 0 0.00068320084
and O 0 0.00077618944
naloxone B-Chemical 1 0.9999871
, O 0 0.0012080872
10 O 0 0.00059167703
( O 0 0.00078369153
- O 0 0.0007231777
8 O 0 0.0003879056
) O 0 0.00055426854
to O 0 0.00033246668
10 O 0 0.0004926654
( O 0 0.0007752868
- O 0 0.0008371203
4 O 0 0.0004793793
) O 0 0.001173131
M O 0 0.7612706
, O 0 0.0007624632
did O 0 0.0004012983
not O 0 0.00045038576
influence O 0 0.00066391873
clonidine B-Chemical 1 0.9999906
- O 0 0.010168721
suppressible O 0 0.1503133
binding O 0 0.0009351202
of O 0 0.001834852
[ B-Chemical 0 0.042434372
3H I-Chemical 0 0.8908975
] I-Chemical 0 0.0160924
- I-Chemical 0 0.00882231
dihydroergocryptine I-Chemical 0 0.998389
( O 0 0.004969243
1 O 0 0.003969281
nM O 0 0.06140424
) O 0 0.009635317
. O 0 0.007656051

These O 0 0.008972089
findings O 0 0.0070825326
indicate O 0 0.0032666775
that O 0 0.0023222642
in O 0 0.002157621
spontaneously O 0 0.037378777
hypertensive B-Disease 2 0.9990019
rats O 0 0.004193679
the O 0 0.00094667193
effects O 0 0.0014108488
of O 0 0.0012762344
central O 0 0.0077688904
alpha O 0 0.59065324
- O 0 0.009433735
adrenoceptor O 0 0.99974245
stimulation O 0 0.0037929453
involve O 0 0.0021189516
activation O 0 0.004605946
of O 0 0.006670972
opiate O 0 0.9997706
receptors O 0 0.6509772
. O 0 0.01092002

As O 0 0.00889115
naloxone B-Chemical 1 0.9998179
and O 0 0.009973434
clonidine B-Chemical 1 0.999913
do O 0 0.0022558633
not O 0 0.0014488774
appear O 0 0.0010165675
to O 0 0.0007398489
interact O 0 0.00054056285
with O 0 0.0006080672
the O 0 0.0005415696
same O 0 0.0003966293
receptor O 0 0.045558605
site O 0 0.0006620074
, O 0 0.00066853536
the O 0 0.000356274
observed O 0 0.00027499135
functional O 0 0.0006870034
antagonism O 0 0.34506002
suggests O 0 0.0002871272
the O 0 0.00044822393
release O 0 0.0154627925
of O 0 0.00061867654
an O 0 0.00090035313
endogenous O 0 0.001656455
opiate O 0 0.9999175
by O 0 0.0025529622
clonidine B-Chemical 1 0.9999901
or O 0 0.0014634548
alpha B-Chemical 1 0.94880605
- I-Chemical 1 0.017034184
methyldopa I-Chemical 1 0.999997
and O 0 0.00088578294
the O 0 0.0004944257
possible O 0 0.00047702173
role O 0 0.00037288395
of O 0 0.0007171018
the O 0 0.000915319
opiate O 0 0.99957114
in O 0 0.0010258104
the O 0 0.0011628163
central O 0 0.0026462523
control O 0 0.0019123316
of O 0 0.0040587764
sympathetic O 0 0.9784546
tone O 0 0.78206944
. O 0 0.009451453

Neurotoxicity B-Disease 0 0.998116
of O 0 0.01785709
halogenated B-Chemical 0 0.994793
hydroxyquinolines I-Chemical 0 0.98316646
: O 0 0.009025405
clinical O 0 0.009843366
analysis O 0 0.0047267154
of O 0 0.0047053546
cases O 0 0.007576496
reported O 0 0.0073883114
outside O 0 0.008527337
Japan O 0 0.25646672
. O 0 0.011913456

An O 0 0.012665742
analysis O 0 0.0072830766
is O 0 0.0044263583
presented O 0 0.0034315242
of O 0 0.0030406194
220 O 0 0.0056994455
cases O 0 0.0025948144
of O 0 0.0019926147
possible O 0 0.0023036299
neurotoxic B-Disease 2 0.99919194
reactions O 0 0.19740717
to O 0 0.0032252672
halogenated B-Chemical 0 0.99819475
hydroxyquinolines I-Chemical 0 0.98758465
reported O 0 0.0053963554
from O 0 0.004455637
outside O 0 0.005952852
Japan O 0 0.23941505
. O 0 0.0091095

In O 0 0.0072414554
80 O 0 0.0056392024
cases O 0 0.0042119888
insufficient O 0 0.0025763588
information O 0 0.0021932789
was O 0 0.001491969
available O 0 0.0010795617
for O 0 0.0007758593
adequate O 0 0.0009493373
comment O 0 0.0029925187
and O 0 0.0009630031
in O 0 0.0007258218
29 O 0 0.0011367437
a O 0 0.0007559818
relationship O 0 0.0005486277
to O 0 0.00074140413
the O 0 0.0010509704
administration O 0 0.065932125
of O 0 0.0050887885
clioquinol B-Chemical 0 0.9999225
could O 0 0.0033715821
be O 0 0.005114525
excluded O 0 0.008663994
. O 0 0.008509227

Of O 0 0.011018668
the O 0 0.006094947
remainder O 0 0.0057690577
, O 0 0.0039736754
a O 0 0.0027903204
relationship O 0 0.0016491422
to O 0 0.0021326228
clioquinol B-Chemical 0 0.9998933
was O 0 0.0017824569
considered O 0 0.0012044596
probable O 0 0.006256218
in O 0 0.0014529187
42 O 0 0.0022044007
and O 0 0.0018638195
possible O 0 0.0022298458
in O 0 0.0030491569
69 O 0 0.0066941953
cases O 0 0.009058534
. O 0 0.00867912

In O 0 0.006349677
six O 0 0.0034321572
of O 0 0.0031629857
the O 0 0.0022757049
probable O 0 0.006455395
cases O 0 0.0031153506
the O 0 0.0017614278
neurological B-Disease 0 0.99910116
disturbance I-Disease 0 0.82364327
consisted O 0 0.00082111894
of O 0 0.0009998345
an O 0 0.0018159515
acute O 0 0.9785953
reversible O 0 0.9123281
encephalopathy B-Disease 2 0.9999852
usually O 0 0.0029010642
related O 0 0.0004942038
to O 0 0.00049630983
the O 0 0.00056928437
ingestion O 0 0.23038606
of O 0 0.00096021884
a O 0 0.0011574936
high O 0 0.0011052823
dose O 0 0.012390003
of O 0 0.002936656
clioquinol B-Chemical 0 0.9998939
over O 0 0.0016863532
a O 0 0.0036009587
short O 0 0.003439906
period O 0 0.0049942117
. O 0 0.007725542

The O 0 0.008379323
most O 0 0.0073842043
common O 0 0.006285743
manifestation O 0 0.13147122
, O 0 0.0042076805
observed O 0 0.0017590264
in O 0 0.0018283833
15 O 0 0.0016142197
further O 0 0.0018228499
cases O 0 0.0036091513
, O 0 0.003615326
was O 0 0.0032029503
isolated O 0 0.005800925
optic B-Disease 0 0.9874215
atrophy I-Disease 2 0.99853027
. O 0 0.01326976

This O 0 0.010963955
was O 0 0.0057258876
most O 0 0.0046626767
frequently O 0 0.0036323385
found O 0 0.001958789
in O 0 0.0017760247
children O 0 0.003189621
, O 0 0.0016173196
many O 0 0.0010747398
of O 0 0.0011527747
whom O 0 0.0023828459
had O 0 0.0011110234
received O 0 0.0018161158
clioquinol B-Chemical 0 0.9999093
as O 0 0.0026914557
treatment O 0 0.0062214336
for O 0 0.00421506
acrodermatitis B-Disease 0 0.9992079
enteropathica I-Disease 0 0.9995084
. O 0 0.03098328

In O 0 0.007138922
the O 0 0.004860798
remaining O 0 0.0036388242
cases O 0 0.004460242
, O 0 0.0029269545
a O 0 0.0021853393
combination O 0 0.0025753495
of O 0 0.004032627
myelopathy B-Disease 0 0.99997926
, O 0 0.009867149
visual B-Disease 0 0.86384296
disturbance I-Disease 0 0.89867544
, O 0 0.0022921907
and O 0 0.0018414512
peripheral B-Disease 2 0.81262726
neuropathy I-Disease 2 0.99997354
was O 0 0.0025362184
the O 0 0.0022963022
most O 0 0.0040591927
common O 0 0.007431133
manifestation O 0 0.6140512
. O 0 0.011315077

Isolated O 0 0.046767782
myelopathy B-Disease 0 0.9994098
or O 0 0.010716219
peripheral B-Disease 2 0.88781893
neuropathy I-Disease 2 0.999941
, O 0 0.007380333
or O 0 0.0026775787
these O 0 0.0031526424
manifestations O 0 0.724016
occurring O 0 0.006680983
together O 0 0.0042812424
, O 0 0.006174125
were O 0 0.0059346324
infrequent O 0 0.030839013
. O 0 0.010041625

The O 0 0.0077291653
onset O 0 0.008268728
of O 0 0.0044859736
all O 0 0.003275114
manifestations O 0 0.74918103
( O 0 0.0045788344
except O 0 0.001920289
toxic O 0 0.97678775
encephalopathy B-Disease 2 0.99997973
) O 0 0.020851657
was O 0 0.0017886816
usually O 0 0.0037661898
subacute O 0 0.9946852
, O 0 0.0036731057
with O 0 0.0025826823
subsequent O 0 0.003429835
partial O 0 0.0063025635
recovery O 0 0.012297444
. O 0 0.008795923

Older O 0 0.05915731
subjects O 0 0.017563425
tended O 0 0.011956083
to O 0 0.010068747
display O 0 0.010231899
more O 0 0.013119591
side O 0 0.12688076
effects O 0 0.030267227
. O 0 0.020123556

The O 0 0.0073514404
full O 0 0.0053094593
syndrome O 0 0.47964758
of O 0 0.0069908234
subacute O 0 0.9986437
myelo B-Disease 0 0.9797804
- I-Disease 0 0.08706507
optic I-Disease 0 0.9989447
neuropathy I-Disease 2 0.99998355
was O 0 0.00164377
more O 0 0.001120277
frequent O 0 0.002908069
in O 0 0.00084408233
women O 0 0.0669017
, O 0 0.001139592
but O 0 0.0006633346
they O 0 0.0006282778
tended O 0 0.00063024013
to O 0 0.0006294675
have O 0 0.00071112043
taken O 0 0.0007971613
greater O 0 0.001091098
quantities O 0 0.002022415
of O 0 0.0030589537
the O 0 0.00448873
drug O 0 0.74165165
. O 0 0.009407638

Prazosin B-Chemical 0 0.9994122
- O 0 0.070688166
induced O 0 0.04313535
stress B-Disease 2 0.9775784
incontinence I-Disease 2 0.9988825
. O 0 0.0485612

A O 0 0.027473353
case O 0 0.0067261294
of O 0 0.005482872
genuine O 0 0.011220814
stress B-Disease 2 0.92107433
incontinence I-Disease 2 0.9997979
due O 0 0.0027208559
to O 0 0.0029718715
prazosin B-Chemical 1 0.9999895
, O 0 0.004010297
a O 0 0.0022648566
common O 0 0.0030694606
antihypertensive O 0 0.99693215
drug O 0 0.8521717
, O 0 0.0060530887
is O 0 0.004508162
presented O 0 0.007430876
. O 0 0.008758079

Prazosin B-Chemical 0 0.99980265
exerts O 0 0.03574634
its O 0 0.010059365
antihypertensive O 0 0.9932059
effects O 0 0.012376171
through O 0 0.002793144
vasodilatation O 0 0.9997104
caused O 0 0.0030329179
by O 0 0.0020888099
selective O 0 0.013149537
blockade O 0 0.2628706
of O 0 0.0031267311
postsynaptic O 0 0.9831377
alpha O 0 0.69677657
- O 0 0.009546676
1 O 0 0.005169097
adrenergic O 0 0.9948533
receptors O 0 0.28147462
. O 0 0.009870087

As O 0 0.007917248
an O 0 0.008920207
alpha O 0 0.38588586
- O 0 0.01190657
blocker O 0 0.978692
, O 0 0.0037556668
it O 0 0.0017945442
also O 0 0.0013479771
exerts O 0 0.002368173
a O 0 0.0016577265
significant O 0 0.001605129
relaxant O 0 0.9695855
effect O 0 0.0016084481
on O 0 0.0012924998
the O 0 0.0024482217
bladder O 0 0.94452786
neck O 0 0.8217553
and O 0 0.010040191
urethra O 0 0.560608
. O 0 0.010454228

The O 0 0.0072826724
patient O 0 0.006641616
' O 0 0.004630237
s O 0 0.0032185414
clinical O 0 0.0041657058
course O 0 0.0020644285
is O 0 0.0013360152
described O 0 0.0008932779
and O 0 0.0010186736
correlated O 0 0.0006668729
with O 0 0.0007317194
initial O 0 0.0008069091
urodynamic O 0 0.29227152
studies O 0 0.0009723766
while O 0 0.0007683793
on O 0 0.0008522588
prazosin B-Chemical 1 0.9999832
and O 0 0.0020684435
subsequent O 0 0.0018599285
studies O 0 0.0023905537
while O 0 0.0027749978
taking O 0 0.024877908
verapamil B-Chemical 1 0.9998816
. O 0 0.011187289

Her O 0 0.03966943
incontinence B-Disease 2 0.9881914
resolved O 0 0.018860236
with O 0 0.010518192
the O 0 0.009470904
change O 0 0.009887565
of O 0 0.013299544
medication O 0 0.49245578
. O 0 0.01793508

The O 0 0.0074532605
restoration O 0 0.006602354
of O 0 0.0043196236
continence O 0 0.0659333
was O 0 0.0023102127
accompanied O 0 0.00260728
by O 0 0.0015101691
a O 0 0.0013340431
substantial O 0 0.0010531383
rise O 0 0.0011086267
in O 0 0.0006236667
maximum O 0 0.00066360814
urethral O 0 0.032654103
pressure O 0 0.02567915
, O 0 0.00091716007
maximum O 0 0.00066568103
urethral O 0 0.01920342
closure O 0 0.0028842194
pressure O 0 0.023888873
, O 0 0.0020055864
and O 0 0.0019894235
functional O 0 0.0031675522
urethral O 0 0.094537415
length O 0 0.0056709857
. O 0 0.007848917

Patients O 0 0.013198163
who O 0 0.0069298446
present O 0 0.0030682397
with O 0 0.003561703
stress B-Disease 2 0.89750177
incontinence I-Disease 2 0.99985754
while O 0 0.0023024455
taking O 0 0.016016196
prazosin B-Chemical 1 0.99999166
should O 0 0.00053660077
change O 0 0.0006009572
their O 0 0.00057113
antihypertensive O 0 0.9774483
medication O 0 0.06229017
before O 0 0.00025697876
considering O 0 0.00038214578
surgery O 0 0.0014059051
, O 0 0.0006421816
because O 0 0.00038184482
their O 0 0.0007605906
incontinence B-Disease 2 0.9977816
may O 0 0.00078836025
resolve O 0 0.0008457836
spontaneously O 0 0.007422205
with O 0 0.0012418777
a O 0 0.0019178714
change O 0 0.0018443457
in O 0 0.0024717129
drug O 0 0.6601445
therapy O 0 0.08613877
. O 0 0.008869326

Myocardial B-Disease 0 0.99457693
infarction I-Disease 2 0.99979633
following O 0 0.017344356
sublingual O 0 0.9808944
administration O 0 0.5442448
of O 0 0.12219987
isosorbide B-Chemical 0 0.99998987
dinitrate I-Chemical 0 0.9999832
. O 0 0.04441193

A O 0 0.041267574
78 O 0 0.01316672
- O 0 0.00744022
year O 0 0.0038872561
- O 0 0.0034514104
old O 0 0.0021571417
with O 0 0.0016930479
healed O 0 0.018853618
septal O 0 0.10133157
necrosis B-Disease 2 0.9979888
suffered O 0 0.6123284
a O 0 0.002903576
recurrent O 0 0.9473657
myocardial B-Disease 0 0.9999615
infarction I-Disease 2 0.9999937
of O 0 0.0017102405
the O 0 0.00087072235
anterior O 0 0.0042363983
wall O 0 0.008648527
following O 0 0.00072695565
the O 0 0.0008751071
administration O 0 0.06430903
of O 0 0.010657612
isosorbide B-Chemical 0 0.9999988
dinitrate I-Chemical 0 0.9999975
5 O 0 0.007237784
mg O 0 0.8822653
sublingually O 0 0.9968029
. O 0 0.010123738

After O 0 0.005706226
detailing O 0 0.005604017
the O 0 0.0031932613
course O 0 0.0026409845
of O 0 0.0023047118
events O 0 0.023212316
, O 0 0.0015603377
we O 0 0.00057927734
discuss O 0 0.0005416749
the O 0 0.0005718921
role O 0 0.00041864262
of O 0 0.0007640069
paradoxical O 0 0.23916051
coronary O 2 0.99667054
spasm B-Disease 2 0.9999918
and O 0 0.015996045
hypotension B-Disease 2 0.99999285
- O 0 0.01595341
mediated O 0 0.0011763569
myocardial B-Disease 0 0.999944
ischemia I-Disease 2 0.9999695
occurring O 0 0.0038752253
downstream O 0 0.00090640597
to O 0 0.00047343987
significant O 0 0.00071222533
coronary B-Disease 0 0.8645699
arterial I-Disease 0 0.78696734
stenosis I-Disease 0 0.99462885
in O 0 0.0009797978
the O 0 0.0012185049
pathophysiology O 0 0.141868
of O 0 0.0045735603
acute B-Disease 0 0.9973073
coronary I-Disease 0 0.995401
insufficiency I-Disease 0 0.999331
. O 0 0.012898804

Comparison O 0 0.007079904
of O 0 0.0054479884
the O 0 0.0038552354
respiratory O 0 0.20060475
effects O 0 0.003929348
of O 0 0.002637909
i O 0 0.010625668
. O 0 0.0011889038
v O 0 0.018426966
. O 0 0.0008244719
infusions O 0 0.014149647
of O 0 0.0018496456
morphine B-Chemical 1 0.9999157
and O 0 0.0025694915
regional O 0 0.012672268
analgesia O 0 0.99298215
by O 0 0.005925042
extradural O 0 0.97388273
block O 0 0.011649177
. O 0 0.009319116

The O 0 0.006809547
incidence O 0 0.008057982
of O 0 0.0040208013
postoperative O 0 0.07594416
respiratory O 0 0.80190504
apnoea B-Disease 2 0.99910444
was O 0 0.0014263128
compared O 0 0.00055124646
between O 0 0.00042529937
five O 0 0.00041756924
patients O 0 0.0010383176
receiving O 0 0.0007577618
a O 0 0.0005930858
continuous O 0 0.0005349939
i O 0 0.0026856256
. O 0 0.0003957283
v O 0 0.011405176
. O 0 0.00030318115
infusion O 0 0.0018677358
of O 0 0.0007187383
morphine B-Chemical 1 0.9999647
( O 0 0.0008910007
mean O 0 0.00037438064
73 O 0 0.000971138
. O 0 0.00025245617
6 O 0 0.0002589893
mg O 0 0.04927483
) O 0 0.0005908456
and O 0 0.00032252845
five O 0 0.00022327177
patients O 0 0.00062932924
receiving O 0 0.0004940969
a O 0 0.00042909352
continuous O 0 0.00042790934
extradural O 0 0.82841843
infusion O 0 0.0041028955
of O 0 0.0005700239
0 O 0 0.00073685317
. O 0 0.00030036198
25 O 0 0.00054041814
% O 0 0.0006404509
bupivacaine B-Chemical 1 0.9999007
( O 0 0.00078220305
mean O 0 0.0004610555
192 O 0 0.004963312
mg O 0 0.14693017
) O 0 0.0009744328
in O 0 0.00048397892
the O 0 0.0005929566
24 O 0 0.0006427091
- O 0 0.0010229709
h O 0 0.0007391012
period O 0 0.00093253376
following O 0 0.0015326673
upper O 0 0.0055084643
abdominal O 0 0.49775764
surgery O 0 0.016591575
. O 0 0.008847743

Monitoring O 0 0.011769542
consisted O 0 0.005032266
of O 0 0.0043593035
airflow O 0 0.3616628
detection O 0 0.0030606133
by O 0 0.002231115
a O 0 0.0024670078
carbon B-Chemical 0 0.9136885
dioxide I-Chemical 0 0.9900401
analyser O 0 0.21884829
, O 0 0.001452606
chest O 0 0.25949574
wall O 0 0.018217195
movement O 0 0.0014255755
detected O 0 0.00044223515
by O 0 0.00068501
pneumatic O 0 0.0139541365
capsules O 0 0.055751078
, O 0 0.0010843648
and O 0 0.00077372656
continuous O 0 0.00094677386
electrocardiograph O 0 0.3296986
recorded O 0 0.0013621047
with O 0 0.0015589612
a O 0 0.0031169225
Holter O 0 0.8279911
ambulatory O 0 0.0049398458
monitor O 0 0.004240562
. O 0 0.0073404554

Both O 0 0.012030146
obstructive B-Disease 0 0.9746903
( I-Disease 0 0.009929844
P I-Disease 0 0.057558686
less I-Disease 0 0.002379107
than I-Disease 0 0.0014429317
0 I-Disease 0 0.0019242284
. I-Disease 0 0.0010559341
05 I-Disease 0 0.05004125
) I-Disease 0 0.0012540233
and I-Disease 0 0.00080062466
central I-Disease 0 0.0022832693
apnoea I-Disease 2 0.99857247
( O 0 0.0017115175
P O 0 0.03435356
less O 0 0.00053979334
than O 0 0.00042564856
0 O 0 0.00081686804
. O 0 0.00049536454
05 O 0 0.035875764
) O 0 0.00079547375
occurred O 0 0.0005312673
more O 0 0.0006504829
frequently O 0 0.00092538045
in O 0 0.00079603365
patients O 0 0.0022664722
who O 0 0.0024111415
had O 0 0.0018744636
a O 0 0.005450404
morphine B-Chemical 1 0.9998586
infusion O 0 0.20056179
. O 0 0.009250027

There O 0 0.008736779
was O 0 0.0053221215
also O 0 0.0036134871
a O 0 0.0032490797
higher O 0 0.0020668614
incidence O 0 0.0073174946
of O 0 0.0037321332
tachyarrhythmias B-Disease 0 0.9999777
( O 0 0.006177783
P O 0 0.08873693
less O 0 0.0007385721
than O 0 0.0005113793
0 O 0 0.00089442934
. O 0 0.0005066763
05 O 0 0.03789808
) O 0 0.00077607296
and O 0 0.00060904544
ventricular B-Disease 0 0.97983736
ectopic I-Disease 0 0.012862973
beats I-Disease 0 0.9391673
( O 0 0.0013860362
P O 0 0.02171127
less O 0 0.0005719673
than O 0 0.00050593214
0 O 0 0.0010190275
. O 0 0.0007214098
05 O 0 0.03435339
) O 0 0.0013777483
in O 0 0.0010662234
the O 0 0.0019681738
morphine B-Chemical 1 0.9998
infusion O 0 0.07125026
group O 0 0.008304701
. O 0 0.008378964

Effects O 0 0.015915118
of O 0 0.009348711
aminophylline B-Chemical 1 0.9997193
on O 0 0.003392908
the O 0 0.0027465525
threshold O 0 0.0023496442
for O 0 0.0019580035
initiating O 0 0.0059240754
ventricular B-Disease 0 0.9969524
fibrillation I-Disease 0 0.9999205
during O 0 0.005153195
respiratory B-Disease 0 0.9212819
failure I-Disease 0 0.9330073
. O 0 0.013083604

Cardiac B-Disease 0 0.9868052
arrhythmias I-Disease 2 0.99969304
have O 0 0.00876106
frequently O 0 0.008318744
been O 0 0.0053162384
reported O 0 0.0046330593
in O 0 0.003870902
association O 0 0.0039322944
with O 0 0.0070279087
respiratory B-Disease 0 0.92122436
failure I-Disease 0 0.9464466
. O 0 0.015428059

The O 0 0.006987253
possible O 0 0.005020783
additive O 0 0.007555285
role O 0 0.0022579709
of O 0 0.0027181995
pharmacologic O 0 0.49097568
agents O 0 0.45190433
in O 0 0.001869832
precipitating O 0 0.9688803
cardiac B-Disease 0 0.9931706
disturbances I-Disease 0 0.97236586
in O 0 0.0011277185
patients O 0 0.0037003201
with O 0 0.0014697002
respiratory B-Disease 0 0.7803424
failure I-Disease 0 0.73068887
has O 0 0.001899982
only O 0 0.0023692765
recently O 0 0.0037144383
been O 0 0.0049726036
emphasized O 0 0.006265513
. O 0 0.008886785

The O 0 0.0069439434
effects O 0 0.0059272354
of O 0 0.004950806
aminophylline B-Chemical 1 0.9998721
on O 0 0.001761795
the O 0 0.0018879386
ventricular B-Disease 0 0.99421096
fibrillation I-Disease 0 0.99996305
threshold O 0 0.0014357871
during O 0 0.00069628336
normal O 0 0.0034136954
acid O 0 0.9524342
- O 0 0.0029174052
base O 0 0.0011642494
conditions O 0 0.00087414234
and O 0 0.0008171632
during O 0 0.0005795485
respiratory B-Disease 0 0.5369297
failure I-Disease 0 0.56088805
were O 0 0.0012288368
studied O 0 0.0013153396
in O 0 0.0014886906
anesthetized O 0 0.007580149
open O 0 0.0031732377
chest O 0 0.5375315
dogs O 0 0.016282395
. O 0 0.0090531595

The O 0 0.008748783
ventricular B-Disease 0 0.96233404
fibrillation I-Disease 0 0.9997136
threshold O 0 0.0037922428
was O 0 0.0019312642
measured O 0 0.0010950519
by O 0 0.001184435
passing O 0 0.0018676263
a O 0 0.0010295518
gated O 0 0.0025691383
train O 0 0.000972279
of O 0 0.00058486004
12 O 0 0.00036938093
constant O 0 0.00034596387
current O 0 0.0006502021
pulses O 0 0.00198288
through O 0 0.00046336043
the O 0 0.0006280967
ventricular O 0 0.963604
myocardium O 0 0.46216255
during O 0 0.00061395625
the O 0 0.00088184257
vulnerable O 0 0.002177849
period O 0 0.0011163971
of O 0 0.0020247523
the O 0 0.0031319892
cardiac O 0 0.7288031
cycle O 0 0.022221683
. O 0 0.008542601

During O 0 0.0059354957
the O 0 0.0044292524
infusion O 0 0.007337684
of O 0 0.004103784
aminophylline B-Chemical 1 0.99995446
, O 0 0.0036302214
the O 0 0.0015168577
ventricular B-Disease 0 0.99432206
fibrillation I-Disease 0 0.9999695
threshold O 0 0.001166468
was O 0 0.0006610705
reduced O 0 0.00054694904
by O 0 0.00052447687
30 O 0 0.00030353398
to O 0 0.0002669338
40 O 0 0.000298929
percent O 0 0.00025428509
of O 0 0.0003671166
the O 0 0.00036282692
control O 0 0.0004120448
when O 0 0.00037396204
pH O 0 0.12895988
and O 0 0.00051754026
partial O 0 0.00070986856
pressures O 0 0.003961653
of O 0 0.000905199
oxygen B-Chemical 1 0.9927436
( O 0 0.0040358244
PO2 B-Chemical 0 0.9993073
) O 0 0.001815967
and O 0 0.0010625978
carbon B-Chemical 0 0.89939195
dioxide I-Chemical 0 0.9870574
( O 0 0.0036794527
CO2 B-Chemical 1 0.51630586
) O 0 0.0021617294
were O 0 0.0013508591
kept O 0 0.0013726328
within O 0 0.001696626
normal O 0 0.005141257
limits O 0 0.008514241
. O 0 0.00823805

When O 0 0.008076274
respiratory B-Disease 0 0.3786623
failure I-Disease 0 0.5009647
was O 0 0.0034976713
produced O 0 0.0024518287
by O 0 0.0032917527
hypoventilation B-Disease 0 0.99954647
( O 0 0.005941472
pH O 0 0.36029083
7 O 0 0.0009841023
. O 0 0.00061324186
05 O 0 0.010892763
to O 0 0.00045125277
7 O 0 0.00049544335
. O 0 0.00038354195
25 O 0 0.00068283465
; O 0 0.0008666364
PC02 O 0 0.05530392
70 O 0 0.00046428078
to O 0 0.00036976213
100 O 0 0.0008304212
mm O 0 0.0017592777
Hg O 0 0.74824727
: O 0 0.0007561748
P02 O 0 0.010656089
20 O 0 0.00037546648
to O 0 0.0003125756
40 O 0 0.00045529875
mm O 0 0.0015798183
Hg O 0 0.84827274
) O 0 0.00091335876
, O 0 0.000535192
infusion O 0 0.0015631813
of O 0 0.00070401607
aminophylline B-Chemical 1 0.99998057
resulted O 0 0.0005293062
in O 0 0.00043593673
an O 0 0.0006112479
even O 0 0.00043640114
greater O 0 0.00040185882
decrease O 0 0.00047419273
in O 0 0.0005998636
ventricular B-Disease 0 0.99297017
fibrillation I-Disease 0 0.9999523
threshold O 0 0.00092929543
to O 0 0.0007413059
60 O 0 0.000831399
percent O 0 0.0009193724
of O 0 0.0015809053
the O 0 0.002159556
control O 0 0.003241004
level O 0 0.004285847
. O 0 0.007450925

These O 0 0.007934428
experiments O 0 0.004418452
suggest O 0 0.0025265068
that O 0 0.0020006772
although O 0 0.0016100003
many O 0 0.0015724128
factors O 0 0.004266072
may O 0 0.0009794972
contribute O 0 0.00072122837
to O 0 0.00058847305
the O 0 0.00059774716
increased O 0 0.000813641
incidence O 0 0.011515664
of O 0 0.002088877
ventricular B-Disease 2 0.9998491
arrhythmias I-Disease 2 0.9999963
in O 0 0.0012732119
respiratory B-Disease 0 0.9015985
failure I-Disease 0 0.8990818
, O 0 0.0021586348
pharmacologic O 0 0.38409096
agents O 0 0.38823897
, O 0 0.0022176513
particularly O 0 0.00352345
aminophylline B-Chemical 1 0.99997926
, O 0 0.0033457642
may O 0 0.0016807897
play O 0 0.0023483257
a O 0 0.0034172658
significant O 0 0.00423636
role O 0 0.005127186
. O 0 0.008269943

Pentoxifylline B-Chemical 0 0.999463
( O 0 0.03831749
Trental B-Chemical 0 0.9995388
) O 0 0.009629204
does O 0 0.0021986512
not O 0 0.0018682542
inhibit O 0 0.0021135714
dipyridamole B-Chemical 1 0.99996877
- O 0 0.008468091
induced O 0 0.0018286426
coronary O 0 0.9558983
hyperemia B-Disease 2 0.99978405
: O 0 0.0027616455
implications O 0 0.0015151398
for O 0 0.0013408285
dipyridamole B-Chemical 1 0.99996257
- O 0 0.032422896
thallium B-Chemical 1 0.9996252
- O 0 0.009996738
201 O 0 0.22443278
myocardial O 0 0.9991009
imaging O 0 0.065868415
. O 0 0.009419954

Dipyridamole B-Chemical 0 0.99957544
- O 0 0.04182513
thallium B-Chemical 1 0.9985172
- O 0 0.008411875
201 O 0 0.014622312
imaging O 0 0.004914459
is O 0 0.0016029289
often O 0 0.0016587534
performed O 0 0.0010545116
in O 0 0.0010215475
patients O 0 0.0018984644
unable O 0 0.0009216203
to O 0 0.0011958407
exercise O 0 0.008245974
because O 0 0.0014280253
of O 0 0.0030631823
peripheral B-Disease 0 0.6021397
vascular I-Disease 0 0.97409105
disease I-Disease 0 0.9900677
. O 0 0.013257203

Many O 0 0.009970872
of O 0 0.006149692
these O 0 0.0046013854
patients O 0 0.00574362
are O 0 0.0028422433
taking O 0 0.007669619
pentoxifylline B-Chemical 1 0.99994767
( O 0 0.03753441
Trental B-Chemical 0 0.9999089
) O 0 0.009492176
, O 0 0.0020737436
a O 0 0.0024691464
methylxanthine B-Chemical 0 0.99992466
derivative O 0 0.20493257
which O 0 0.0029810157
may O 0 0.0023199446
improve O 0 0.0026087526
intermittent B-Disease 0 0.3140794
claudication I-Disease 0 0.99664104
. O 0 0.010630292

Whether O 0 0.012549411
pentoxifylline B-Chemical 1 0.9997298
inhibits O 0 0.023651782
dipyridamole B-Chemical 1 0.9999598
- O 0 0.024879402
induced O 0 0.0027399878
coronary O 0 0.94093114
hyperemia B-Disease 2 0.9997191
like O 0 0.001419818
other O 0 0.001406724
methylxanthines B-Chemical 0 0.99993634
such O 0 0.0011036897
as O 0 0.0013406326
theophylline B-Chemical 1 0.9999553
and O 0 0.0010103711
should O 0 0.0003848682
be O 0 0.0005424742
stopped O 0 0.00088498736
prior O 0 0.00047912388
to O 0 0.0010489898
dipyridamole B-Chemical 1 0.9999682
- O 0 0.023186779
thallium B-Chemical 1 0.99964654
- O 0 0.0055946847
201 O 0 0.04415084
imaging O 0 0.007691697
is O 0 0.0040953564
unknown O 0 0.011641747
. O 0 0.0088803815

Therefore O 0 0.0071549057
, O 0 0.0056757736
we O 0 0.0025413963
studied O 0 0.002434002
the O 0 0.0020963077
hyperemic O 0 0.82626474
response O 0 0.0023949246
to O 0 0.0013910314
dipyridamole B-Chemical 1 0.9999387
in O 0 0.00083034486
seven O 0 0.00064789667
open O 0 0.0007625155
- O 0 0.0011004719
chest O 0 0.1986404
anesthetized O 0 0.0041006925
dogs O 0 0.0010840198
after O 0 0.0002978991
pretreatment O 0 0.04536044
with O 0 0.0006745064
either O 0 0.0010305361
pentoxifylline B-Chemical 1 0.99997735
( O 0 0.0026113195
0 O 0 0.0009139125
, O 0 0.00057694956
7 O 0 0.00037268637
. O 0 0.00026475007
5 O 0 0.00029781618
, O 0 0.00038575238
or O 0 0.00030612954
15 O 0 0.00032791926
mg O 0 0.047195237
/ O 0 0.0010207813
kg O 0 0.0021979474
i O 0 0.0018669368
. O 0 0.00045392194
v O 0 0.012905047
. O 0 0.0004828021
) O 0 0.0010334887
or O 0 0.00073988806
theophylline B-Chemical 1 0.99992824
( O 0 0.0016258546
3 O 0 0.0008198055
mg O 0 0.11399068
/ O 0 0.0023631433
kg O 0 0.0046346774
i O 0 0.004197039
. O 0 0.0019322544
v O 0 0.020238698
. O 0 0.0035759518
) O 0 0.008803495
. O 0 0.007682782

Baseline O 0 0.01937014
circumflex O 0 0.048794225
coronary O 0 0.22556558
blood O 0 0.016421953
flows O 0 0.015694689
did O 0 0.0039700987
not O 0 0.0034795594
differ O 0 0.003935153
significantly O 0 0.005078254
among O 0 0.006691564
treatment O 0 0.011042215
groups O 0 0.013228454
. O 0 0.012087937

Dipyridamole B-Chemical 0 0.9992605
significantly O 0 0.0080340495
increased O 0 0.00450915
coronary O 0 0.39183348
blood O 0 0.015638502
flow O 0 0.0043488066
before O 0 0.00075234694
and O 0 0.00088224525
after O 0 0.0004952125
7 O 0 0.00061880134
. O 0 0.00041953826
5 O 0 0.00040557337
or O 0 0.00041408217
15 O 0 0.00043269747
mm O 0 0.0011205322
/ O 0 0.0010782019
kg O 0 0.0021420983
i O 0 0.0019298714
. O 0 0.0005743283
v O 0 0.013313835
. O 0 0.00077271345
pentoxifylline B-Chemical 1 0.99986875
( O 0 0.0019614797
p O 0 0.0013588105
less O 0 0.0011428642
than O 0 0.001254506
0 O 0 0.0027875206
. O 0 0.0026773668
002 O 0 0.17964968
) O 0 0.008006432
. O 0 0.007482815

Neither O 0 0.00846239
dose O 0 0.01285871
of O 0 0.005968674
pentoxifylline B-Chemical 1 0.9998734
significantly O 0 0.0069515062
decreased O 0 0.0043332917
the O 0 0.0024065168
dipyridamole B-Chemical 1 0.9999844
- O 0 0.017820925
induced O 0 0.0023127748
hyperemia B-Disease 2 0.9997954
, O 0 0.0013060878
while O 0 0.00047448892
peak O 0 0.00055948744
coronary O 0 0.31340337
blood O 0 0.0076733716
flow O 0 0.0030371116
was O 0 0.0004900673
significantly O 0 0.0006202109
lower O 0 0.0006098243
after O 0 0.0005237714
theophylline B-Chemical 1 0.9999151
( O 0 0.001875224
p O 0 0.001291703
less O 0 0.0010793498
than O 0 0.0011801065
0 O 0 0.002613756
. O 0 0.0023902548
01 O 0 0.0141902035
) O 0 0.0075441236
. O 0 0.007194129

We O 0 0.008426892
conclude O 0 0.005363879
that O 0 0.004308416
pentoxyifylline B-Chemical 0 0.09981407
does O 0 0.0027546028
not O 0 0.002507106
inhibit O 0 0.0030306722
dipyridamole B-Chemical 1 0.9999585
- O 0 0.0112366965
induced O 0 0.0031047652
coronary O 0 0.9569763
hyperemia B-Disease 2 0.999448
even O 0 0.0035953475
at O 0 0.0028274374
high O 0 0.0053332527
doses O 0 0.10497344
. O 0 0.009942062

Cause O 0 0.20730035
of O 0 0.010901511
death B-Disease 2 0.9870269
among O 0 0.0053686127
patients O 0 0.006868632
with O 0 0.0034276387
Parkinson B-Disease 0 0.9996138
' I-Disease 0 0.0035774524
s I-Disease 0 0.0023491972
disease I-Disease 0 0.5316259
: O 0 0.0028371608
a O 0 0.0022403854
rare O 0 0.013699145
mortality O 0 0.35238892
due O 0 0.002762267
to O 0 0.0048694964
cerebral B-Disease 2 0.99820495
haemorrhage I-Disease 2 0.99988675
. O 0 0.014043773

Causes O 0 0.18851973
of O 0 0.010623077
death B-Disease 2 0.9940308
, O 0 0.0048001716
with O 0 0.00202402
special O 0 0.0015951168
reference O 0 0.0011039758
to O 0 0.0011461441
cerebral B-Disease 2 0.9941466
haemorrhage I-Disease 2 0.9999844
, O 0 0.0020554664
among O 0 0.00090119033
240 O 0 0.0014773351
patients O 0 0.0010147919
with O 0 0.00056822976
pathologically O 0 0.54932106
verified O 0 0.0007556958
Parkinson B-Disease 0 0.9998062
' I-Disease 0 0.0012178161
s I-Disease 0 0.00077532674
disease I-Disease 0 0.23858675
were O 0 0.0005839343
investigated O 0 0.00045677985
using O 0 0.00058011716
the O 0 0.00072205806
Annuals O 0 0.046928436
of O 0 0.0009270183
the O 0 0.0011626679
Pathological O 0 0.87710226
Autopsy O 0 0.87963384
Cases O 0 0.21875328
in O 0 0.0019831199
Japan O 0 0.062167574
from O 0 0.0028614765
1981 O 0 0.00904571
to O 0 0.004134518
1985 O 0 0.01896208
. O 0 0.007950041

The O 0 0.007718183
leading O 0 0.0075783883
causes O 0 0.006666477
of O 0 0.0053210207
death B-Disease 2 0.9975266
were O 0 0.0034649477
pneumonia B-Disease 0 0.9996482
and O 0 0.010141898
bronchitis B-Disease 0 0.999918
( O 0 0.007300107
44 O 0 0.0020205432
. O 0 0.0005142275
1 O 0 0.0006000666
% O 0 0.00071093964
) O 0 0.0010033672
, O 0 0.00082527084
malignant O 0 0.9767014
neoplasms B-Disease 0 0.9991171
( O 0 0.0019915313
11 O 0 0.0007375365
. O 0 0.00031017372
6 O 0 0.00030625096
% O 0 0.00050497666
) O 0 0.00076680887
, O 0 0.00061892933
heart B-Disease 0 0.42134267
diseases I-Disease 0 0.75540566
( O 0 0.0014340202
4 O 0 0.00046885404
. O 0 0.00031030475
1 O 0 0.00043020386
% O 0 0.00055929634
) O 0 0.0008803164
, O 0 0.000804233
cerebral B-Disease 0 0.92644423
infarction I-Disease 2 0.9999927
( O 0 0.0017672898
3 O 0 0.00056483515
. O 0 0.000382211
7 O 0 0.0004928922
% O 0 0.00074258953
) O 0 0.0011648751
and O 0 0.0012091611
septicaemia B-Disease 0 0.99852884
( O 0 0.0032419548
3 O 0 0.0016492908
. O 0 0.0015235397
3 O 0 0.0024149306
% O 0 0.0044030547
) O 0 0.007780683
. O 0 0.0073736287

Cerebral B-Disease 0 0.976967
haemorrhage I-Disease 0 0.9996711
was O 0 0.0053151413
the O 0 0.0030859371
11th O 0 0.013371569
most O 0 0.0023156
frequent O 0 0.0042055477
cause O 0 0.0050083427
of O 0 0.0027937177
death B-Disease 2 0.9991097
, O 0 0.001547704
accounting O 0 0.0011746455
for O 0 0.0003984637
only O 0 0.0004472542
0 O 0 0.00064543914
. O 0 0.000291895
8 O 0 0.00032790174
% O 0 0.000381325
of O 0 0.00045305962
deaths B-Disease 2 0.45401272
among O 0 0.00058372173
the O 0 0.0004804685
patients O 0 0.0021662435
, O 0 0.0007000344
whereas O 0 0.00040833864
it O 0 0.00049103383
was O 0 0.0004001693
the O 0 0.00042369042
5th O 0 0.0016492805
most O 0 0.00073040684
common O 0 0.0010239327
cause O 0 0.004238404
of O 0 0.002450629
death B-Disease 2 0.9983815
among O 0 0.0020320516
the O 0 0.0016837898
Japanese O 0 0.025956158
general O 0 0.0023249667
population O 0 0.005027207
in O 0 0.004550382
1985 O 0 0.038962293
. O 0 0.007978758

The O 0 0.007249608
low O 0 0.00598771
incidence O 0 0.0093636755
of O 0 0.00501285
cerebral B-Disease 2 0.9958139
haemorrhage I-Disease 2 0.999967
as O 0 0.0023088853
a O 0 0.002022257
cause O 0 0.0044331257
of O 0 0.002072847
death B-Disease 2 0.9983736
in O 0 0.0007902006
patients O 0 0.0033284773
with O 0 0.0009847044
Parkinson B-Disease 0 0.9998765
' I-Disease 0 0.0014319132
s I-Disease 0 0.00077126385
disease I-Disease 0 0.35318428
may O 0 0.0004391362
reflect O 0 0.00036931367
the O 0 0.00050263316
hypotensive B-Disease 2 0.99820054
effect O 0 0.0006999889
of O 0 0.0016298286
levodopa B-Chemical 1 0.99998987
and O 0 0.0012169279
a O 0 0.0016461726
hypotensive B-Disease 2 0.9990139
mechanism O 0 0.0011223771
due O 0 0.0006471608
to O 0 0.000882886
reduced O 0 0.0019769552
noradrenaline B-Chemical 1 0.99991345
levels O 0 0.001739857
in O 0 0.002135969
the O 0 0.004257337
parkinsonian B-Disease 2 0.99989843
brain O 0 0.48489156
. O 0 0.0095824795

Possible O 0 0.0696449
intramuscular O 0 0.8461949
midazolam B-Chemical 1 0.9997801
- O 0 0.03456833
associated O 0 0.01529292
cardiorespiratory B-Disease 0 0.99560356
arrest I-Disease 0 0.9876425
and O 0 0.034151427
death B-Disease 2 0.99766076
. O 0 0.020150159

Midazolam B-Chemical 0 0.9997044
hydrochloride I-Chemical 0 0.9991418
is O 0 0.010456896
commonly O 0 0.009389516
used O 0 0.0054934355
for O 0 0.004697113
dental O 0 0.01028199
or O 0 0.006974797
endoscopic O 0 0.022108568
procedures O 0 0.012876687
. O 0 0.014026371

Although O 0 0.0067574345
generally O 0 0.005127313
consisted O 0 0.0031464072
safe O 0 0.0034628443
when O 0 0.0014437764
given O 0 0.0011528361
intramuscularly O 0 0.020806871
, O 0 0.0017850064
intravenous O 0 0.33074513
administration O 0 0.0905692
is O 0 0.0012764065
known O 0 0.0015741849
to O 0 0.0014532952
cause O 0 0.013009306
respiratory B-Disease 0 0.9078062
and I-Disease 0 0.023953075
cardiovascular I-Disease 0 0.9997938
depression I-Disease 2 0.9998049
. O 0 0.015017272

This O 0 0.010721519
report O 0 0.007935249
describes O 0 0.0047863964
the O 0 0.002732619
first O 0 0.0018508345
published O 0 0.001637868
case O 0 0.0015809279
of O 0 0.0023664953
cardiorespiratory B-Disease 0 0.9960477
arrest I-Disease 0 0.9823481
and O 0 0.0045198714
death B-Disease 2 0.9984244
associated O 0 0.0027284743
with O 0 0.002683792
intramuscular O 0 0.7549694
administration O 0 0.3403429
of O 0 0.02018673
midazolam B-Chemical 1 0.99988544
. O 0 0.012214482

Information O 0 0.017691107
regarding O 0 0.0080417795
midazolam B-Chemical 1 0.9993616
use O 0 0.006821867
is O 0 0.004325723
reviewed O 0 0.005004872
to O 0 0.0029842772
provide O 0 0.0028397145
recommendation O 0 0.005967732
for O 0 0.0038665188
safe O 0 0.012674427
administration O 0 0.23530981
. O 0 0.01175286

Myasthenia B-Disease 0 0.9899042
gravis I-Disease 0 0.9973986
presenting O 0 0.41690162
as O 0 0.019212896
weakness O 2 0.9921284
after O 0 0.011971021
magnesium B-Chemical 1 0.9991922
administration O 0 0.79314053
. O 0 0.021141827

We O 0 0.0076815165
studied O 0 0.005171807
a O 0 0.004242832
patient O 0 0.0032990118
with O 0 0.0018195766
no O 0 0.0011614392
prior O 0 0.0009788405
history O 0 0.010811194
of O 0 0.002237407
neuromuscular B-Disease 0 0.9961104
disease I-Disease 0 0.9866073
who O 0 0.010235832
became O 0 0.0023383133
virtually O 0 0.0016732542
quadriplegic B-Disease 0 0.99195963
after O 0 0.0011301037
parenteral O 0 0.9557454
magnesium B-Chemical 1 0.99987507
administration O 0 0.68670654
for O 0 0.0085529955
preeclampsia B-Disease 0 0.9998617
. O 0 0.013805339

The O 0 0.010482743
serum O 0 0.1712079
magnesium B-Chemical 1 0.9990213
concentration O 0 0.009769141
was O 0 0.0031391738
3 O 0 0.0021064107
. O 0 0.0015096155
0 O 0 0.0023234014
mEq O 0 0.83280283
/ O 0 0.00497817
L O 0 0.32641098
, O 0 0.0025640076
which O 0 0.0022582586
is O 0 0.0022490076
usually O 0 0.003919056
well O 0 0.0043283603
tolerated O 0 0.09840374
. O 0 0.009633107

The O 0 0.015166405
magnesium B-Chemical 1 0.99602014
was O 0 0.008649688
stopped O 0 0.008506024
and O 0 0.0055258707
she O 0 0.0045283483
recovered O 0 0.003914761
over O 0 0.003494492
a O 0 0.0058596916
few O 0 0.005276496
days O 0 0.007452456
. O 0 0.011253757

While O 0 0.008336881
she O 0 0.005747074
was O 0 0.004072295
weak O 0 0.0051535126
, O 0 0.0034469785
2 O 0 0.0021230308
- O 0 0.002491835
Hz O 0 0.13164312
repetitive O 0 0.0023231106
stimulation O 0 0.0012458634
revealed O 0 0.0007260584
a O 0 0.0009095151
decrement O 0 0.0027570478
without O 0 0.0005695145
significant O 0 0.00077152334
facilitation O 0 0.024441332
at O 0 0.0004567998
rapid O 0 0.0010324208
rates O 0 0.0007437114
or O 0 0.000772476
after O 0 0.00068067526
exercise O 0 0.029514741
, O 0 0.002278306
suggesting O 0 0.0022278237
postsynaptic B-Disease 0 0.99335104
neuromuscular I-Disease 0 0.99811894
blockade I-Disease 0 0.9873404
. O 0 0.010957582

After O 0 0.0068681184
her O 0 0.0070931427
strength O 0 0.006533112
returned O 0 0.0034262156
, O 0 0.0029320703
repetitive O 0 0.0036428494
stimulation O 0 0.0025687595
was O 0 0.0015343276
normal O 0 0.0023673219
, O 0 0.0016843798
but O 0 0.0011363509
single O 0 0.0013828408
fiber O 0 0.009151796
EMG O 0 0.7482427
revealed O 0 0.0021698074
increased O 0 0.003363277
jitter O 0 0.14286624
and O 0 0.0065047466
blocking O 0 0.020843009
. O 0 0.010193542

Her O 0 0.06161565
acetylcholine B-Chemical 1 0.9980439
receptor O 0 0.3558572
antibody O 0 0.025940273
level O 0 0.009496172
was O 0 0.011230191
markedly O 0 0.027819658
elevated O 0 0.044649124
. O 0 0.018801263

Although O 0 0.00957885
paralysis B-Disease 2 0.99805754
after O 0 0.0042552757
magnesium B-Chemical 1 0.9994918
administration O 0 0.33363947
has O 0 0.0016700258
been O 0 0.001297602
described O 0 0.00073379657
in O 0 0.0007229966
patients O 0 0.0019405963
with O 0 0.0008201071
known O 0 0.0014683427
myasthenia B-Disease 0 0.99971706
gravis I-Disease 0 0.9996861
, O 0 0.005148789
it O 0 0.0009126867
has O 0 0.00049457705
not O 0 0.0005260304
previously O 0 0.0006031713
been O 0 0.00065646356
reported O 0 0.0006999746
to O 0 0.00054827385
be O 0 0.00063735276
the O 0 0.0006052517
initial O 0 0.00079883315
or O 0 0.0010564198
only O 0 0.0014430054
manifestation O 0 0.115253
of O 0 0.004324518
the O 0 0.0056740707
disease O 0 0.9112405
. O 0 0.011084379

Patients O 0 0.014615726
who O 0 0.008043385
are O 0 0.0042829555
unusually O 0 0.0076704384
sensitive O 0 0.0019924394
to O 0 0.0014499935
the O 0 0.0013880169
neuromuscular O 0 0.7802209
effects O 0 0.0036192122
of O 0 0.0030922194
magnesium B-Chemical 1 0.9998592
should O 0 0.0006553527
be O 0 0.00083002716
suspected O 0 0.006112627
of O 0 0.0011342462
having O 0 0.0014262416
an O 0 0.001965234
underlying O 0 0.005738422
disorder B-Disease 0 0.9857551
of I-Disease 0 0.007617673
neuromuscular I-Disease 0 0.98614013
transmission I-Disease 0 0.077746965
. O 0 0.009699326

No O 0 0.012799892
enhancement O 0 0.011678526
by O 0 0.007921722
phenobarbital B-Chemical 1 0.99994004
of O 0 0.0054974933
the O 0 0.0035894285
hepatocarcinogenicity O 0 0.99786013
of O 0 0.0051367935
a O 0 0.011488692
choline B-Chemical 1 0.99967206
- O 0 0.006986482
devoid O 0 0.0023695414
diet O 0 0.07133149
in O 0 0.0038722833
the O 0 0.005546747
rat O 0 0.026947765
. O 0 0.010132152

An O 0 0.011146117
experiment O 0 0.004814566
was O 0 0.003590575
performed O 0 0.0022801417
to O 0 0.001706983
test O 0 0.0015371918
whether O 0 0.00073726376
inclusion O 0 0.0009818163
of O 0 0.002217067
phenobarbital B-Chemical 1 0.9999949
in O 0 0.001590989
a O 0 0.005360046
choline B-Chemical 1 0.9997781
- O 0 0.0035808976
devoid O 0 0.00088815344
diet O 0 0.042490546
would O 0 0.0010087289
increase O 0 0.0011098677
the O 0 0.002060954
hepatocarcinogenicity O 0 0.99567044
of O 0 0.00528989
the O 0 0.0059702187
diet O 0 0.35131776
. O 0 0.0104585495

Groups O 0 0.020730589
of O 0 0.0071867853
5 O 0 0.004480646
- O 0 0.0038220317
week O 0 0.001753646
old O 0 0.0019656362
male O 0 0.006135429
Fischer O 0 0.3979822
- O 0 0.0026785121
344 O 0 0.01170559
rats O 0 0.001623641
were O 0 0.0007114774
fed O 0 0.00084615033
for O 0 0.00051802886
7 O 0 0.0006918437
- O 0 0.0008927342
25 O 0 0.00067703193
months O 0 0.0004689756
semipurified O 0 0.19817062
choline B-Chemical 1 0.9997309
- O 0 0.0025030605
devoid O 0 0.0005998579
or O 0 0.0012586573
choline B-Chemical 1 0.9998056
- O 0 0.005077175
supplemented O 0 0.0047924756
diets O 0 0.11729293
, O 0 0.0013802364
containing O 0 0.00078294886
or O 0 0.0010366659
not O 0 0.0012758335
0 O 0 0.002207329
. O 0 0.0018353674
06 O 0 0.046267886
% O 0 0.0068496973
phenobarbital B-Chemical 1 0.99990153
. O 0 0.010001231

No O 0 0.013377976
hepatic O 0 0.887476
preneoplastic O 0 0.9842755
nodules O 0 0.9108426
or O 0 0.007916409
hepatocellular B-Disease 0 0.999974
carcinomas I-Disease 0 0.99975485
developed O 0 0.0064162235
in O 0 0.0012026333
rats O 0 0.0027061969
fed O 0 0.0012411091
the O 0 0.0009498314
plain O 0 0.1992916
choline B-Chemical 1 0.99982375
- O 0 0.005344691
supplemented O 0 0.0041510076
diet O 0 0.11141443
, O 0 0.0009822747
while O 0 0.00048881094
one O 0 0.00052731857
preneoplastic O 0 0.9595213
nodule O 0 0.7112881
and O 0 0.001298697
one O 0 0.0011747277
hepatocellular B-Disease 2 0.9999914
carcinoma I-Disease 2 0.9999826
developed O 0 0.0040652775
in O 0 0.0008840132
two O 0 0.00081280485
rats O 0 0.0022121347
fed O 0 0.0016316833
the O 0 0.0014699164
same O 0 0.0016848703
diet O 0 0.14645086
containing O 0 0.008917063
phenobarbital B-Chemical 1 0.9999628
. O 0 0.012689461

The O 0 0.007829849
incidence O 0 0.010676095
of O 0 0.005839056
preneoplastic O 0 0.9659899
nodules O 0 0.82969046
and O 0 0.0033857618
of O 0 0.0045827306
hepatocellular B-Disease 0 0.99998474
carcinomas I-Disease 0 0.9998023
was O 0 0.0017298416
10 O 0 0.00084735174
% O 0 0.00072717055
and O 0 0.0005929221
37 O 0 0.00069148676
% O 0 0.00068079657
, O 0 0.0007012405
respectively O 0 0.00093910424
, O 0 0.0006409596
in O 0 0.00040507922
rats O 0 0.0010773677
fed O 0 0.00071638793
the O 0 0.0006314026
plain O 0 0.14320979
choline B-Chemical 1 0.99976295
- O 0 0.002420765
devoid O 0 0.0005025647
diet O 0 0.073082455
, O 0 0.0009255361
and O 0 0.0006044717
17 O 0 0.00075296673
% O 0 0.00053628837
and O 0 0.0004940856
30 O 0 0.0003940516
% O 0 0.00060672965
, O 0 0.0006450846
in O 0 0.000511432
rats O 0 0.0014563064
fed O 0 0.0013193041
the O 0 0.0018437305
phenobarbital B-Chemical 1 0.9999937
- O 0 0.011771978
containing O 0 0.003146006
choline B-Chemical 1 0.9995084
- O 0 0.009600458
devoid O 0 0.004544882
diet O 0 0.24081679
. O 0 0.010073022

The O 0 0.008110088
results O 0 0.0062999264
evinced O 0 0.013522139
no O 0 0.0031851833
enhancement O 0 0.004551704
of O 0 0.0030501583
the O 0 0.0029134357
hepatocarcinogenicity O 0 0.9971787
of O 0 0.0046712174
the O 0 0.0047471933
choline B-Chemical 1 0.9996506
- O 0 0.009277739
devoid O 0 0.0032386635
diet O 0 0.30394977
by O 0 0.019536559
phenobarbital B-Chemical 1 0.99995935
. O 0 0.013930282

Sporadic O 0 0.7080415
neoplastic O 0 0.8261786
lesions O 0 0.3939886
were O 0 0.0034264012
observed O 0 0.0016531692
in O 0 0.0015097046
organs O 0 0.008890103
other O 0 0.0011984103
than O 0 0.00072805036
the O 0 0.0008584652
liver O 0 0.55281603
of O 0 0.0010879273
some O 0 0.0008818098
of O 0 0.0009951523
the O 0 0.0009413047
animals O 0 0.001049343
, O 0 0.0015551323
irrespective O 0 0.001082734
of O 0 0.0025730245
the O 0 0.0036423544
diet O 0 0.21542384
fed O 0 0.012584629
. O 0 0.0101232985

On O 0 0.00864394
two O 0 0.004904093
paradoxical O 0 0.033972338
side O 0 0.1694952
- O 0 0.0048932657
effects O 0 0.00306184
of O 0 0.0031471502
prednisolone B-Chemical 1 0.9999436
in O 0 0.002111379
rats O 0 0.014092331
, O 0 0.0024767641
ribosomal O 0 0.0154482145
RNA O 0 0.1443913
biosyntheses O 0 0.8121009
, O 0 0.003104641
and O 0 0.002241879
a O 0 0.0029613962
mechanism O 0 0.0034568105
of O 0 0.0057911277
action O 0 0.047135986
. O 0 0.009396921

Liver B-Disease 0 0.99304813
enlargement I-Disease 0 0.7611679
and O 0 0.0078860065
muscle B-Disease 0 0.38919675
wastage I-Disease 0 0.52931106
occurred O 0 0.0030898803
in O 0 0.0021273326
Wistar O 0 0.040468946
rats O 0 0.0030637602
following O 0 0.0016548865
the O 0 0.0020315582
subcutaneous O 0 0.14726482
administration O 0 0.19009389
of O 0 0.014766817
prednisolone B-Chemical 1 0.99985945
. O 0 0.014533204

In O 0 0.007510794
the O 0 0.005605848
liver O 0 0.3574026
both O 0 0.002877037
the O 0 0.0020341405
content O 0 0.001606076
of O 0 0.0017799734
RNA O 0 0.028350463
and O 0 0.0014166528
the O 0 0.0010535368
biosynthesis O 0 0.07844044
of O 0 0.0013442041
ribosomal O 0 0.016369358
RNA O 0 0.046504945
increased O 0 0.00096724904
while O 0 0.0005693951
both O 0 0.00056035235
the O 0 0.0006592365
RNA O 0 0.012274229
content O 0 0.0008453074
and O 0 0.0011994392
ribosomal O 0 0.014054096
RNA O 0 0.10025725
biosynthesis O 0 0.20193657
were O 0 0.0017900952
reduced O 0 0.0017342807
in O 0 0.0020633766
the O 0 0.0031850215
gastrocnemius O 0 0.062161457
muscle O 0 0.10606956
. O 0 0.008642311

It O 0 0.009944706
is O 0 0.0050059715
suggested O 0 0.0030469699
that O 0 0.0021066787
the O 0 0.0019685812
drug O 0 0.35590106
acted O 0 0.011479522
in O 0 0.001061491
a O 0 0.0013331834
selective O 0 0.003443213
and O 0 0.0011210938
tissue O 0 0.0405795
- O 0 0.0016103114
specific O 0 0.0005056761
manner O 0 0.0006712023
to O 0 0.0005006717
enhance O 0 0.00044250285
ribosomal O 0 0.007913639
RNA O 0 0.063131854
synthesis O 0 0.03181428
in O 0 0.0008086278
the O 0 0.0010144076
liver O 0 0.87424994
and O 0 0.0022747566
depress O 0 0.11559103
such O 0 0.0020967687
synthesis O 0 0.045855027
in O 0 0.0031258024
the O 0 0.0046749907
muscle O 0 0.18382335
. O 0 0.0091619445

This O 0 0.011559919
view O 0 0.007708048
supports O 0 0.00397422
the O 0 0.0033822076
contention O 0 0.0046762023
that O 0 0.002053298
the O 0 0.0022401358
liver O 0 0.7277239
and O 0 0.0030347982
muscle O 0 0.066302724
are O 0 0.0022307371
independent O 0 0.0020944183
sites O 0 0.0029386138
of O 0 0.006126412
prednisolone B-Chemical 1 0.9998492
action O 0 0.2001608
. O 0 0.011355625

Differential O 0 0.019351268
effects O 0 0.01130275
of O 0 0.0111192595
gamma B-Chemical 0 0.9782106
- I-Chemical 0 0.14148842
hexachlorocyclohexane I-Chemical 0 0.99984574
( O 0 0.064613484
lindane B-Chemical 1 0.99989104
) O 0 0.011695898
on O 0 0.0030365156
pharmacologically O 0 0.9618902
- O 0 0.016933016
induced O 0 0.015431188
seizures B-Disease 2 0.9998745
. O 0 0.015095723

Gamma B-Chemical 0 0.9078338
- I-Chemical 0 0.059724044
hexachlorocyclohexane I-Chemical 0 0.9995127
( O 0 0.023985883
gamma B-Chemical 1 0.96656114
- I-Chemical 1 0.03521321
HCH I-Chemical 1 0.99895835
) O 0 0.00578503
, O 0 0.0015069427
the O 0 0.0008084722
active O 0 0.0013042395
ingredient O 0 0.33299193
of O 0 0.0012323615
the O 0 0.0011912006
insecticide O 0 0.98845774
lindane B-Chemical 1 0.9999832
, O 0 0.0034244317
has O 0 0.0005475907
been O 0 0.00055714365
shown O 0 0.00032880864
to O 0 0.00038936973
decrease O 0 0.0006070688
seizure B-Disease 2 0.9996884
threshold O 0 0.00071193493
to O 0 0.0006649915
pentylenetrazol O 0 0.98769
( O 0 0.012869429
PTZ B-Chemical 1 0.99999845
) O 0 0.0025171703
3 O 0 0.00038710356
h O 0 0.00025544813
after O 0 0.00020782342
exposure O 0 0.00078284927
to O 0 0.0005964431
gamma B-Chemical 1 0.9488575
- I-Chemical 1 0.012529336
HCH I-Chemical 1 0.9985361
and O 0 0.0008562616
conversely O 0 0.014325587
increase O 0 0.00039606233
threshold O 0 0.00059241377
to O 0 0.00095615815
PTZ B-Chemical 1 0.9999988
- O 0 0.008150735
induced O 0 0.0016161051
seizures B-Disease 2 0.99998105
24 O 0 0.00052678405
h O 0 0.0003780698
after O 0 0.00031867635
exposure O 0 0.0012364774
to O 0 0.0010482336
gamma B-Chemical 1 0.94829637
- I-Chemical 1 0.029668469
HCH I-Chemical 1 0.99921227
( O 0 0.0057522636
Vohland O 0 0.31951475
et O 0 0.005300047
al O 0 0.009724489
. O 0 0.0031593945
1981 O 0 0.015308668
) O 0 0.009301558
. O 0 0.007990534

In O 0 0.007246342
this O 0 0.0049861954
study O 0 0.0041083316
, O 0 0.0030659796
the O 0 0.0018098044
severity O 0 0.01429077
of O 0 0.0016618303
response O 0 0.0016788489
to O 0 0.00095488725
other O 0 0.0016177655
seizure B-Disease 2 0.99995255
- O 0 0.0095156515
inducing O 0 0.002048395
agents O 0 0.17645065
was O 0 0.00060130615
tested O 0 0.00036618157
in O 0 0.0004264771
mice O 0 0.0003612131
1 O 0 0.00049286475
and O 0 0.00043332466
24 O 0 0.00031591093
h O 0 0.00029503898
after O 0 0.0002738467
intraperitoneal O 0 0.020462425
administration O 0 0.021559123
of O 0 0.0012307164
80 O 0 0.0019209719
mg O 0 0.40041652
/ O 0 0.006731534
kg O 0 0.04711192
gamma B-Chemical 1 0.8947758
- I-Chemical 1 0.037980117
HCH I-Chemical 1 0.9967926
. O 0 0.011021411

One O 0 0.009065967
hour O 0 0.0037712923
after O 0 0.0023053358
the O 0 0.00224188
administration O 0 0.023324208
of O 0 0.0036665606
gamma B-Chemical 1 0.98033583
- I-Chemical 1 0.036912885
HCH I-Chemical 1 0.99912196
, O 0 0.0015897797
the O 0 0.000671322
activity O 0 0.0008107542
of O 0 0.0014156657
seizure B-Disease 2 0.99995506
- O 0 0.008010856
inducing O 0 0.0018881345
agents O 0 0.21192777
was O 0 0.00066492934
increased O 0 0.00072974357
, O 0 0.000599491
regardless O 0 0.00023633403
of O 0 0.0005009997
their O 0 0.0005569089
mechanism O 0 0.0006975314
, O 0 0.00075196207
while O 0 0.00042206247
24 O 0 0.0003857388
h O 0 0.00041469606
after O 0 0.0004922042
gamma B-Chemical 1 0.73820794
- I-Chemical 1 0.0057406942
HCH I-Chemical 1 0.994491
a O 0 0.0021979022
differential O 0 0.0029654384
response O 0 0.0039412566
was O 0 0.0039097024
observed O 0 0.004292655
. O 0 0.008068919

Seizure B-Disease 2 0.9976483
activity O 0 0.008828609
due O 0 0.0042989203
to O 0 0.0048740185
PTZ B-Chemical 1 0.99999
and O 0 0.051907077
picrotoxin B-Chemical 1 0.99999547
( O 0 0.07674122
PTX B-Chemical 0 0.99985576
) O 0 0.006647057
was O 0 0.0008180934
significantly O 0 0.0010189461
decreased O 0 0.0016579775
; O 0 0.0015466507
however O 0 0.0008650762
, O 0 0.0012224657
seizure B-Disease 2 0.99966073
activity O 0 0.00081096054
due O 0 0.0003985241
to O 0 0.00052879285
3 B-Chemical 0 0.0008773729
- I-Chemical 0 0.005672447
mercaptopropionic I-Chemical 0 0.9995437
acid I-Chemical 0 0.99410605
( O 0 0.0340831
MPA B-Chemical 0 0.99997425
) O 0 0.018219892
, O 0 0.0047127027
bicuculline B-Chemical 1 0.99999404
( O 0 0.014161017
BCC B-Chemical 0 0.9998815
) O 0 0.007337511
, O 0 0.0014151939
methyl B-Chemical 0 0.8975083
6 I-Chemical 0 0.0005234191
, I-Chemical 0 0.00068315875
7 I-Chemical 0 0.00055373146
- I-Chemical 0 0.0011827169
dimethoxy I-Chemical 0 0.9745721
- I-Chemical 0 0.0019901558
4 I-Chemical 0 0.0007060317
- I-Chemical 0 0.0022703295
ethyl I-Chemical 0 0.9985441
- I-Chemical 0 0.014961155
B I-Chemical 0 0.7155469
- I-Chemical 0 0.008488473
carboline I-Chemical 0 0.99354124
- I-Chemical 0 0.003461847
3 I-Chemical 0 0.00080009544
- I-Chemical 0 0.0018552629
carboxylate I-Chemical 0 0.96656615
( O 0 0.016304214
DMCM B-Chemical 0 0.9999963
) O 0 0.007025268
, O 0 0.0013813361
or O 0 0.0013144077
strychnine B-Chemical 0 0.99998474
( O 0 0.00969835
STR B-Chemical 0 0.9743479
) O 0 0.0024739783
was O 0 0.0012807631
not O 0 0.001439045
different O 0 0.002027805
from O 0 0.0034483315
control O 0 0.005344901
. O 0 0.0076263146

In O 0 0.009071988
vitro O 0 0.009347135
, O 0 0.009182859
gamma B-Chemical 1 0.9370242
- I-Chemical 1 0.041702654
HCH I-Chemical 1 0.99932134
, O 0 0.024192905
pentylenetetrazol B-Chemical 0 0.99999595
and O 0 0.029021079
picrotoxin B-Chemical 1 0.9999951
were O 0 0.0016031485
shown O 0 0.00062445324
to O 0 0.0007030888
inhibit O 0 0.0012017721
3H B-Chemical 1 0.9856227
- I-Chemical 1 0.013196232
TBOB I-Chemical 1 0.9932781
binding O 0 0.0006027676
in O 0 0.00043395712
mouse O 0 0.0006373923
whole O 0 0.0005734808
brain O 0 0.051538687
, O 0 0.00080169656
with O 0 0.00056584174
IC50 O 0 0.4352311
values O 0 0.00051721034
of O 0 0.00060182187
4 O 0 0.0005241478
. O 0 0.00038510663
6 O 0 0.00043710205
, O 0 0.00074348
404 O 0 0.0024965864
and O 0 0.00083884655
9 O 0 0.0010460499
. O 0 0.0009668151
4 O 0 0.0017229196
microM O 0 0.31555542
, O 0 0.005232342
respectively O 0 0.0081610605
. O 0 0.007535777

MPA B-Chemical 0 0.9989792
, O 0 0.02982178
BCC B-Chemical 0 0.9989543
, O 0 0.033069227
DMCM B-Chemical 0 0.9999771
, O 0 0.005929883
and O 0 0.0026517347
STR B-Chemical 0 0.89360815
showed O 0 0.0009039863
no O 0 0.0007146652
inhibition O 0 0.0028173912
of O 0 0.0035144615
3H B-Chemical 1 0.9918018
- I-Chemical 1 0.034919675
TBOB I-Chemical 1 0.9985436
( O 0 0.0030323078
t B-Chemical 0 0.028295396
- I-Chemical 0 0.0078024557
butyl I-Chemical 0 0.99961394
bicyclo I-Chemical 0 0.99779046
- I-Chemical 0 0.01910727
orthobenzoate I-Chemical 0 0.62823796
) O 0 0.002635168
binding O 0 0.0013100298
at O 0 0.0012149718
concentrations O 0 0.0032745774
of O 0 0.0037370156
100 O 0 0.010391124
micron O 0 0.2875807
. O 0 0.00869749

The O 0 0.0073658284
pharmacological O 0 0.081334874
challenge O 0 0.0042227223
data O 0 0.0029639993
suggest O 0 0.0013922885
that O 0 0.0013730655
tolerance O 0 0.11778782
may O 0 0.0012198142
occur O 0 0.001125987
to O 0 0.0010521957
seizure B-Disease 2 0.9998715
activity O 0 0.0020374912
induced O 0 0.0014731775
by O 0 0.004158267
PTZ B-Chemical 1 0.99999845
and O 0 0.0032776806
PTX B-Chemical 0 0.99964905
24 O 0 0.00049265736
h O 0 0.00036831867
after O 0 0.00035606383
gamma B-Chemical 1 0.8527213
- I-Chemical 1 0.0072710887
HCH I-Chemical 1 0.9981578
, O 0 0.00090467255
since O 0 0.000354829
the O 0 0.0004413528
response O 0 0.0006523397
to O 0 0.00049113727
only O 0 0.0005453026
these O 0 0.0009008456
two O 0 0.001199926
seizure B-Disease 2 0.9998474
- O 0 0.007886481
inducing O 0 0.005515794
agents O 0 0.42882326
is O 0 0.0053976458
decreased O 0 0.009745708
. O 0 0.0091002425

The O 0 0.0072414307
in O 0 0.0048827683
vitro O 0 0.0040901806
data O 0 0.0028712347
suggest O 0 0.0013518371
that O 0 0.0011463927
the O 0 0.0011103976
site O 0 0.0009425626
responsible O 0 0.0007622692
for O 0 0.00053467375
the O 0 0.0006232398
decrease O 0 0.00065748754
in O 0 0.00071551604
seizure B-Disease 2 0.9997596
activity O 0 0.0009636859
24 O 0 0.00043219287
h O 0 0.0003890267
after O 0 0.00041283428
gamma B-Chemical 1 0.8393363
- I-Chemical 1 0.008226468
HCH I-Chemical 1 0.99773467
may O 0 0.0009166185
be O 0 0.0011257651
the O 0 0.0017747452
GABA B-Chemical 1 0.9999671
- O 0 0.008787034
A O 0 0.2556957
receptor O 0 0.2588056
- O 0 0.008700553
linked O 0 0.005672527
chloride O 0 0.99960905
channel O 0 0.5630084
. O 0 0.010435313

Tolerance O 0 0.33263287
and O 0 0.010677707
antiviral O 0 0.06734422
effect O 0 0.005846046
of O 0 0.007456362
ribavirin B-Chemical 1 0.99924266
in O 0 0.0054165837
patients O 0 0.01596557
with O 0 0.008304222
Argentine B-Disease 0 0.90942925
hemorrhagic I-Disease 2 0.99983454
fever I-Disease 0 0.999864
. O 0 0.024858689

Tolerance O 0 0.37073192
and O 0 0.007543791
antiviral O 0 0.06700238
effect O 0 0.0033262558
of O 0 0.0039771497
ribavirin B-Chemical 1 0.9995677
was O 0 0.0018673392
studied O 0 0.0012124683
in O 0 0.00083457195
6 O 0 0.0006349657
patients O 0 0.0014283307
with O 0 0.0010686284
Argentine B-Disease 0 0.64263225
hemorrhagic I-Disease 2 0.99995685
fever I-Disease 0 0.9999883
( O 0 0.06502563
AHF B-Disease 0 0.99993384
) O 0 0.0027230459
of O 0 0.0011793266
more O 0 0.0012357456
than O 0 0.0009737498
8 O 0 0.0014544539
days O 0 0.0016325372
of O 0 0.0035184699
evolution O 0 0.0072515137
. O 0 0.008271047

Administration O 0 0.1752709
of O 0 0.011069081
ribavirin B-Chemical 1 0.9985039
resulted O 0 0.004259474
in O 0 0.0026976613
a O 0 0.0030581497
neutralization O 0 0.019425644
of O 0 0.0034635486
viremia B-Disease 0 0.94488066
and O 0 0.0027366397
a O 0 0.002844912
drop O 0 0.004349207
of O 0 0.003653752
endogenous O 0 0.011375654
interferon O 0 0.9992902
titers O 0 0.23231958
. O 0 0.012964612

The O 0 0.01799144
average O 0 0.013855157
time O 0 0.013958381
of O 0 0.019290032
death B-Disease 2 0.9912463
was O 0 0.022879414
delayed O 0 0.05242426
. O 0 0.023921775

A O 0 0.13886075
reversible O 0 0.6450827
anemia B-Disease 2 0.99917597
was O 0 0.011597947
the O 0 0.008171014
only O 0 0.008017962
adverse O 0 0.8724053
effect O 0 0.011196039
observed O 0 0.010280525
. O 0 0.015471753

From O 0 0.008460058
these O 0 0.005380909
results O 0 0.0039408333
, O 0 0.0031437892
we O 0 0.0013846685
conclude O 0 0.0012746212
that O 0 0.0013454489
ribavirin B-Chemical 1 0.99938655
has O 0 0.0011274044
an O 0 0.0016018113
antiviral O 0 0.116329305
effect O 0 0.0008799403
in O 0 0.00066333055
advanced O 0 0.04181272
cases O 0 0.0026783757
of O 0 0.0025091642
AHF B-Disease 0 0.9999634
, O 0 0.001641318
and O 0 0.00080754823
that O 0 0.00071609893
anemia B-Disease 2 0.99993265
, O 0 0.0015521891
the O 0 0.0006582769
only O 0 0.00068098743
secondary O 0 0.0022939763
reaction O 0 0.009880939
observed O 0 0.0012238321
, O 0 0.0025578907
can O 0 0.0018798242
be O 0 0.003033543
easily O 0 0.004640932
managed O 0 0.008481284
. O 0 0.008030433

The O 0 0.008177206
possible O 0 0.006011879
beneficial O 0 0.006390979
effect O 0 0.0034485774
of O 0 0.004434763
ribavirin B-Chemical 1 0.9990338
during O 0 0.0019157933
the O 0 0.0017984383
initial O 0 0.0019261477
days O 0 0.002131847
of O 0 0.0051684394
AHF B-Disease 0 0.9996917
is O 0 0.0065409713
discussed O 0 0.0068186116
. O 0 0.009931264

Is O 0 0.04563325
the O 0 0.02511331
treatment O 0 0.027516589
of O 0 0.031759918
scabies B-Disease 0 0.9866105
hazardous O 0 0.88826346
? O 0 0.09192721

Treatment O 0 0.033521302
for O 0 0.0060869656
scabies B-Disease 0 0.87386066
is O 0 0.003841772
usually O 0 0.0034548445
initiated O 0 0.0021678745
by O 0 0.0018126235
general O 0 0.001549084
practitioners O 0 0.0044066375
; O 0 0.0019284611
most O 0 0.0012673783
consider O 0 0.0010357039
lindane B-Chemical 1 0.9999465
( O 0 0.02015786
gamma B-Chemical 0 0.98712766
benzene I-Chemical 0 0.99996376
hexachloride I-Chemical 0 0.9999354
) O 0 0.017021006
the O 0 0.0026115866
treatment O 0 0.004356959
of O 0 0.0052742544
choice O 0 0.00880836
. O 0 0.00924013

Lindane B-Chemical 0 0.9985165
is O 0 0.0075037633
also O 0 0.0044727772
widely O 0 0.003877503
used O 0 0.002140321
as O 0 0.0018924241
an O 0 0.0025123009
agricultural O 0 0.30505425
and O 0 0.0021382582
industrial O 0 0.4335081
pesticide O 0 0.9547527
, O 0 0.0018606333
and O 0 0.000929776
as O 0 0.00074466027
a O 0 0.00093112927
result O 0 0.00071987073
the O 0 0.00084898423
toxic O 0 0.55854005
profile O 0 0.0014685392
of O 0 0.0018732579
this O 0 0.002189072
insecticide O 0 0.89664066
is O 0 0.0034018233
well O 0 0.00430402
understood O 0 0.012033695
. O 0 0.008790502

Evidence O 0 0.019696005
is O 0 0.006968921
accumulating O 0 0.006702006
that O 0 0.0040727365
lindane B-Chemical 1 0.99972075
can O 0 0.0025294141
be O 0 0.0021259442
toxic B-Disease 0 0.58707523
to I-Disease 0 0.0012962258
the I-Disease 0 0.0012447165
central I-Disease 0 0.0040594456
nervous I-Disease 0 0.9605786
system I-Disease 0 0.0029425647
and O 0 0.0018991015
may O 0 0.0016774605
be O 0 0.0022377935
associated O 0 0.0035156389
with O 0 0.012257268
aplastic B-Disease 0 0.9999409
anaemia I-Disease 0 0.999936
. O 0 0.034172866

Preparations O 0 0.050416786
containing O 0 0.008890873
lindane B-Chemical 1 0.99912864
continue O 0 0.0045705177
to O 0 0.0025855948
be O 0 0.0022015593
sold O 0 0.005205448
over O 0 0.00096448517
the O 0 0.0011603733
counter O 0 0.003052665
and O 0 0.0013904328
may O 0 0.0011560853
represent O 0 0.0015263857
a O 0 0.0022105689
hazard O 0 0.07462661
to O 0 0.002426405
poorly O 0 0.006472741
informed O 0 0.007518554
patients O 0 0.014948988
. O 0 0.009030823

This O 0 0.010549692
literature O 0 0.0068151215
review O 0 0.0047765803
suggests O 0 0.0019251892
that O 0 0.0015847258
general O 0 0.0016119496
practitioners O 0 0.0027052537
should O 0 0.0007083508
prescribe O 0 0.0066988766
scabicides O 0 0.6564164
with O 0 0.0009113524
increased O 0 0.00083878904
caution O 0 0.00074783765
for O 0 0.00045994096
certain O 0 0.0008728486
at O 0 0.0006147525
- O 0 0.0015559078
risk O 0 0.021077227
groups O 0 0.0013183501
, O 0 0.0012665492
and O 0 0.001028112
give O 0 0.0010476793
adequate O 0 0.001475371
warnings O 0 0.02171016
regarding O 0 0.0022285273
potential O 0 0.008523528
toxicity B-Disease 2 0.99801743
. O 0 0.010923641

Mouse O 0 0.031134423
strain O 0 0.008732847
- O 0 0.007860298
dependent O 0 0.0037976205
effect O 0 0.003388622
of O 0 0.005351405
amantadine B-Chemical 1 0.99959713
on O 0 0.0034616285
motility O 0 0.6619702
and O 0 0.0081276065
brain O 0 0.7046671
biogenic O 0 0.9981674
amines B-Chemical 0 0.998703
. O 0 0.01525597

The O 0 0.0068836175
effect O 0 0.0047812266
of O 0 0.006217126
amantadine B-Chemical 1 0.9999002
hydrochloride I-Chemical 0 0.9998797
, O 0 0.0042793686
injected O 0 0.0012158725
i O 0 0.0042285863
. O 0 0.0006220692
p O 0 0.0008311115
. O 0 0.00039294313
in O 0 0.0003717687
6 O 0 0.00031194356
increments O 0 0.0005143716
of O 0 0.00043341162
100 O 0 0.000869606
mg O 0 0.11229295
/ O 0 0.000893856
kg O 0 0.0010021557
each O 0 0.00021507485
over O 0 0.00020826799
30 O 0 0.0002537039
hr O 0 0.00039249688
, O 0 0.00040286797
on O 0 0.00022986784
mouse O 0 0.00055348827
motility O 0 0.101830795
and O 0 0.00053338363
whole O 0 0.0005270332
brain O 0 0.020463489
content O 0 0.00048648907
of O 0 0.0006575374
selected O 0 0.00074172666
biogenic O 0 0.99496174
amines B-Chemical 0 0.9987643
and O 0 0.0012447205
major O 0 0.001446675
metabolites O 0 0.78931916
was O 0 0.0010491097
studied O 0 0.0011878014
in O 0 0.0012718361
4 O 0 0.0015783801
strains O 0 0.0023242007
of O 0 0.0040480834
mice O 0 0.0048866523
. O 0 0.008226192

These O 0 0.010364523
were O 0 0.0066223615
the O 0 0.0049907914
albino O 0 0.017541248
Sprague O 0 0.34116912
- O 0 0.005696736
Dawley O 0 0.06114739
ICR O 0 0.039099563
and O 0 0.002622763
BALB O 0 0.44252506
/ O 0 0.008697387
C O 0 0.8709243
, O 0 0.0017351253
the O 0 0.001038841
black O 0 0.0037756213
C57BL O 0 0.81944215
/ O 0 0.0029924945
6 O 0 0.00087927777
and O 0 0.0011561872
the O 0 0.0014562688
brown O 0 0.007185204
CDF O 0 0.7517717
- O 0 0.006961059
I O 0 0.022854192
mouse O 0 0.006136245
strains O 0 0.008023352
. O 0 0.00967492

Amantadine B-Chemical 0 0.99799347
treatment O 0 0.016484765
produced O 0 0.009102925
a O 0 0.009702098
biphasic O 0 0.052059848
effect O 0 0.0076469993
on O 0 0.006778224
mouse O 0 0.014333089
motility O 0 0.68960434
. O 0 0.016256899

The O 0 0.006450458
initial O 0 0.004717487
dose O 0 0.01008463
of O 0 0.005694578
amantadine B-Chemical 1 0.9998658
depressed B-Disease 2 0.98867655
locomotor O 0 0.8926574
activity O 0 0.0015217839
in O 0 0.0007655425
all O 0 0.00066718156
mouse O 0 0.00091085496
strains O 0 0.00077074626
studied O 0 0.0008617459
with O 0 0.00097653875
the O 0 0.001310931
BALB O 0 0.5252678
/ O 0 0.009246662
C O 0 0.81164527
mice O 0 0.0015664786
being O 0 0.002985523
the O 0 0.002782168
most O 0 0.0051834974
sensitive O 0 0.00585662
. O 0 0.008334533

Subsequent O 0 0.015375863
amantadine B-Chemical 1 0.9982174
treatments O 0 0.010798372
produced O 0 0.003105574
enhancement O 0 0.0040282975
of O 0 0.0022196958
motility O 0 0.2576347
from O 0 0.001085811
corresponding O 0 0.00066602975
control O 0 0.0006791823
in O 0 0.00057353923
all O 0 0.0005721047
mouse O 0 0.00084172824
strains O 0 0.0007656946
with O 0 0.0008818409
the O 0 0.0011924186
BALB O 0 0.47639254
/ O 0 0.00762302
C O 0 0.77801144
mice O 0 0.0014419641
being O 0 0.002663137
the O 0 0.0024283782
least O 0 0.002757866
sensitive O 0 0.0052578487
. O 0 0.0079916045

The O 0 0.008013829
locomotor O 0 0.34968203
activity O 0 0.0043438207
was O 0 0.0025108042
decreased O 0 0.002187164
from O 0 0.0012304396
corresponding O 0 0.00082606403
controls O 0 0.0013198992
in O 0 0.00063084567
all O 0 0.0005427022
strains O 0 0.00062159856
studied O 0 0.00070661295
, O 0 0.00073567906
except O 0 0.00034227484
for O 0 0.00034198846
the O 0 0.0004953064
ICR O 0 0.0335297
mice O 0 0.00043827965
, O 0 0.00074110535
during O 0 0.00036963876
an O 0 0.00073123386
overnight O 0 0.0005609992
drug O 0 0.32923177
- O 0 0.0014086771
free O 0 0.001032172
period O 0 0.0008191332
following O 0 0.0011509368
the O 0 0.0019005842
fourth O 0 0.015676005
amantadine B-Chemical 1 0.9995395
treatment O 0 0.020756822
. O 0 0.0095662195

Readministration O 0 0.5470112
of O 0 0.00999822
amantadine B-Chemical 1 0.9994374
, O 0 0.0046477607
after O 0 0.0013264075
a O 0 0.001970241
drug O 0 0.5514528
- O 0 0.002166357
free O 0 0.0010727855
overnight O 0 0.0005408445
period O 0 0.00053606916
, O 0 0.000740951
increased O 0 0.0006562684
motility O 0 0.12417268
from O 0 0.00047717674
respective O 0 0.00041010854
saline O 0 0.04476038
control O 0 0.0004227363
in O 0 0.00035466874
all O 0 0.00035523923
strains O 0 0.00044656429
with O 0 0.00046554866
exception O 0 0.00044248352
of O 0 0.0007242609
the O 0 0.0009772484
BALB O 0 0.5346526
/ O 0 0.008521006
C O 0 0.8257415
mice O 0 0.0011185457
where O 0 0.0015957125
suppression B-Disease 0 0.0058454946
of I-Disease 0 0.0045568277
motility I-Disease 0 0.85103095
occurred O 0 0.008398189
. O 0 0.00890263

Treatment O 0 0.05428005
with O 0 0.008352058
amantadine B-Chemical 1 0.9991266
did O 0 0.003192855
not O 0 0.0019184026
alter O 0 0.0014367008
whole O 0 0.0016252927
brain O 0 0.3013047
dopamine B-Chemical 1 0.9998253
levels O 0 0.0010030217
but O 0 0.0007125641
decreased O 0 0.0008048452
the O 0 0.00048008026
amounts O 0 0.00047910467
of O 0 0.00079836766
3 B-Chemical 0 0.0007415048
, I-Chemical 0 0.001013769
4 I-Chemical 0 0.00085500814
- I-Chemical 0 0.0052316273
dihydroxyphenylacetic I-Chemical 0 0.9999753
acid I-Chemical 0 0.8586879
in O 0 0.0008945764
the O 0 0.0011260529
BALB O 0 0.4459777
/ O 0 0.0063049416
C O 0 0.7472132
mice O 0 0.0012346021
compared O 0 0.0013793579
to O 0 0.002567361
saline O 0 0.15444425
control O 0 0.006020861
. O 0 0.007998692

Conversely O 0 0.013124895
, O 0 0.010041783
brain O 0 0.2861072
normetanephrine B-Chemical 0 0.9998599
concentration O 0 0.00767481
was O 0 0.0020247465
increased O 0 0.0017256916
from O 0 0.0013910208
saline O 0 0.07679222
control O 0 0.0014268162
by O 0 0.002131007
amantadine B-Chemical 1 0.9994566
in O 0 0.0020221495
the O 0 0.0029214614
BALB O 0 0.5678681
/ O 0 0.02115271
C O 0 0.8924068
mice O 0 0.006645978
. O 0 0.009740099

The O 0 0.006941398
results O 0 0.0049312213
suggest O 0 0.0029238276
a O 0 0.003524614
strain O 0 0.0023181613
- O 0 0.0026499147
dependent O 0 0.0010208106
effect O 0 0.0010220882
of O 0 0.0017918847
amantadine B-Chemical 1 0.999788
on O 0 0.0006933411
motility O 0 0.32576033
and O 0 0.00077959406
indicate O 0 0.00046918174
a O 0 0.00077113375
differential O 0 0.0009898979
response O 0 0.0010333302
to O 0 0.0007582064
the O 0 0.0010457912
acute O 0 0.8565669
and O 0 0.0022543932
multiple O 0 0.0046051024
dose O 0 0.04037739
regimens O 0 0.033932585
used O 0 0.0061589642
. O 0 0.008198512

The O 0 0.010228187
BALB O 0 0.31201673
/ O 0 0.013956628
C O 0 0.7017064
mouse O 0 0.003676587
was O 0 0.0018679358
the O 0 0.0013303661
most O 0 0.0014596316
sensitive O 0 0.0008899248
strain O 0 0.0007514431
and O 0 0.0008779692
could O 0 0.0005193576
serve O 0 0.0007907264
as O 0 0.0005874145
the O 0 0.0005420121
strain O 0 0.000509174
of O 0 0.0007318631
choice O 0 0.0008706009
for O 0 0.0006227247
evaluating O 0 0.00073811586
the O 0 0.0013887401
side O 0 0.05462451
effects O 0 0.0077356813
of O 0 0.015225982
amantadine B-Chemical 1 0.99969506
. O 0 0.0115237655

The O 0 0.007203453
biochemical O 0 0.01086151
results O 0 0.004205102
of O 0 0.004244123
brain O 0 0.30078557
biogenic O 0 0.9974948
amines B-Chemical 0 0.9993249
of O 0 0.0058710156
BALB O 0 0.8543406
/ O 0 0.019367704
C O 0 0.8985719
mouse O 0 0.0010796697
strain O 0 0.00048798684
suggest O 0 0.0003406423
a O 0 0.0007386213
probable O 0 0.00940766
decrease O 0 0.0006574377
of O 0 0.0013773692
catecholamine B-Chemical 1 0.99993
turnover O 0 0.00787521
rate O 0 0.0006309214
and O 0 0.0008422627
/ O 0 0.0041138795
or O 0 0.0006686188
metabolism O 0 0.4387459
by O 0 0.0022504998
monoamine O 0 0.999977
oxidase O 0 0.9977932
and O 0 0.0008872138
a O 0 0.0007269131
resulting O 0 0.00058282947
increase O 0 0.0004257829
in O 0 0.00074015424
O O 0 0.99844474
- O 0 0.0036165752
methylation O 0 0.03959932
of O 0 0.0015749332
norepinephrine B-Chemical 1 0.9999616
which O 0 0.0008182809
may O 0 0.0004240864
account O 0 0.00045817357
for O 0 0.00036195858
a O 0 0.0010159547
behavioral B-Disease 0 0.6587233
depression I-Disease 2 0.99987197
caused O 0 0.002236346
by O 0 0.0030757047
amantadine B-Chemical 1 0.99975854
in O 0 0.0017130392
the O 0 0.0025636908
BALB O 0 0.6079301
/ O 0 0.021971688
C O 0 0.8969279
mice O 0 0.0060415003
. O 0 0.009054477

Chloroacetaldehyde B-Chemical 0 0.9762921
and O 0 0.009741559
its O 0 0.0075254673
contribution O 0 0.0040130955
to O 0 0.0045082048
urotoxicity O 0 0.99932575
during O 0 0.0033662685
treatment O 0 0.0062355152
with O 0 0.007159948
cyclophosphamide B-Chemical 1 0.9998375
or O 0 0.025174921
ifosfamide B-Chemical 1 0.99970704
. O 0 0.014306181

An O 0 0.03717131
experimental O 0 0.026809094
study O 0 0.027386196
/ O 0 0.033264272
short O 0 0.023656903
communication O 0 0.04172308
. O 0 0.030247312

Based O 0 0.012477771
on O 0 0.004731581
clinical O 0 0.008044667
data O 0 0.004226182
, O 0 0.00303786
indicating O 0 0.0015844926
that O 0 0.0017063973
chloroacetaldehyde B-Chemical 0 0.99987626
( O 0 0.029259356
CAA B-Chemical 0 0.99889636
) O 0 0.003094466
is O 0 0.0006500735
an O 0 0.00072939903
important O 0 0.00046567514
metabolite O 0 0.5026385
of O 0 0.0011677981
oxazaphosphorine O 0 0.99620855
cytostatics O 0 0.9979665
, O 0 0.0020135334
an O 0 0.00073639484
experimental O 0 0.0005694751
study O 0 0.0006160814
was O 0 0.00041533023
carried O 0 0.0003068138
out O 0 0.00034899497
in O 0 0.00035221473
order O 0 0.0003192739
to O 0 0.00039273454
elucidate O 0 0.00033337603
the O 0 0.0006152261
role O 0 0.0005901938
of O 0 0.0016698486
CAA B-Chemical 0 0.9954984
in O 0 0.0012761635
the O 0 0.0016478034
development O 0 0.0043510166
of O 0 0.010577659
hemorrhagic B-Disease 2 0.9999018
cystitis I-Disease 0 0.99996436
. O 0 0.03758493

The O 0 0.008231792
data O 0 0.0066983243
demonstrate O 0 0.0034184307
that O 0 0.0034513383
CAA B-Chemical 0 0.9613318
after O 0 0.0018421417
i O 0 0.005356999
. O 0 0.0015629967
v O 0 0.017943222
. O 0 0.0012941201
administration O 0 0.016399218
does O 0 0.0014525944
not O 0 0.0018305898
contribute O 0 0.0024830194
to O 0 0.004348014
bladder B-Disease 0 0.99634856
damage I-Disease 0 0.9916488
. O 0 0.01427539

When O 0 0.007294152
instilled O 0 0.010825033
directly O 0 0.0037055907
into O 0 0.002045538
the O 0 0.0022188937
bladder O 0 0.9068252
, O 0 0.0063746604
CAA B-Chemical 0 0.99654084
exerts O 0 0.020942016
urotoxic O 0 0.9986822
effects O 0 0.014507738
, O 0 0.0022257885
it O 0 0.0011131379
is O 0 0.00096047414
, O 0 0.0013237054
however O 0 0.0013405813
, O 0 0.0017463939
susceptible O 0 0.0017809888
to O 0 0.00229906
detoxification O 0 0.81691736
with O 0 0.010382511
mesna B-Chemical 1 0.9997321
. O 0 0.011096235

Source O 0 0.10107957
of O 0 0.013766585
pain B-Disease 2 0.99283594
and O 0 0.009661453
primitive O 0 0.1330973
dysfunction O 0 0.9790284
in O 0 0.009808251
migraine B-Disease 2 0.9999287
: O 0 0.013520932
an O 0 0.00769173
identical O 0 0.0055901106
site O 0 0.01007521
? O 0 0.021588998

Twenty O 0 0.013427395
common O 0 0.010121215
migraine B-Disease 2 0.9997749
patients O 0 0.009672491
received O 0 0.0022901478
a O 0 0.0021544676
one O 0 0.0013938247
sided O 0 0.7771975
frontotemporal O 0 0.98876417
application O 0 0.0023098104
of O 0 0.0024935682
nitroglycerin B-Chemical 1 0.99999404
( O 0 0.0028137902
10 O 0 0.0007269003
patients O 0 0.0016882183
) O 0 0.0010845482
or O 0 0.000614802
placebo O 0 0.19839412
ointment O 0 0.9922879
( O 0 0.0018622439
10 O 0 0.000965284
patients O 0 0.002198262
) O 0 0.001958961
in O 0 0.0013159659
a O 0 0.0024306686
double O 0 0.0029438874
blind O 0 0.013609013
study O 0 0.007195328
. O 0 0.00808003

Early O 0 0.09072101
onset O 0 0.10120779
migraine B-Disease 2 0.9999238
attacks O 0 0.9954796
were O 0 0.0036489088
induced O 0 0.0026654555
by O 0 0.0029071926
nitroglycerin B-Chemical 1 0.9999758
in O 0 0.0011071112
seven O 0 0.0007562883
out O 0 0.00062565785
of O 0 0.0007859561
10 O 0 0.0007142802
patients O 0 0.0011532836
versus O 0 0.0007163362
no O 0 0.00076456985
patient O 0 0.0017621507
in O 0 0.0016534786
the O 0 0.0026501692
placebo O 0 0.18359481
group O 0 0.0077013443
. O 0 0.008469671

Subsequently O 0 0.01141001
20 O 0 0.008022274
migraine B-Disease 2 0.99971634
patients O 0 0.017126966
, O 0 0.0033373097
who O 0 0.0027005519
developed O 0 0.0017661838
an O 0 0.0015610245
early O 0 0.0019052239
onset O 0 0.014101516
attack O 0 0.72088695
with O 0 0.004734657
frontotemporal O 0 0.999445
nitroglycerin B-Chemical 1 0.99999523
, O 0 0.0017181155
received O 0 0.000602934
the O 0 0.00060402014
drug O 0 0.19513899
in O 0 0.0007027069
a O 0 0.0010727905
second O 0 0.00094621023
induction O 0 0.0012656586
test O 0 0.0018053778
at O 0 0.0016015453
other O 0 0.0029946947
body O 0 0.022197958
areas O 0 0.017688047
. O 0 0.008582207

No O 0 0.03252116
early O 0 0.031401187
onset O 0 0.12046516
migraine B-Disease 2 0.9994998
was O 0 0.027545618
observed O 0 0.020133622
. O 0 0.026043411

Thus O 0 0.008620779
the O 0 0.00820594
migraine B-Disease 2 0.9999131
- O 0 0.014348309
inducing O 0 0.00395077
effect O 0 0.0018309044
of O 0 0.003235631
nitroglycerin B-Chemical 1 0.99998915
seems O 0 0.0010163138
to O 0 0.0005613268
depend O 0 0.00045530353
on O 0 0.00030867042
direct O 0 0.00044812227
stimulation O 0 0.00074007735
of O 0 0.00057943474
the O 0 0.0005123795
habitual O 0 0.15511397
site O 0 0.0005601916
of O 0 0.0011824224
pain B-Disease 2 0.99932885
, O 0 0.0011343164
suggesting O 0 0.00036994056
that O 0 0.0003897887
the O 0 0.00070590386
frontotemporal O 0 0.98427397
region O 0 0.00070327066
is O 0 0.0005089413
of O 0 0.00063471915
crucial O 0 0.0005723032
importance O 0 0.00065126043
in O 0 0.00085420796
the O 0 0.0012016777
development O 0 0.002776529
of O 0 0.0035029675
a O 0 0.022796676
migraine B-Disease 2 0.9999528
crisis O 0 0.96132684
. O 0 0.012861761

This O 0 0.015516455
is O 0 0.0087031415
not O 0 0.0063736
consistent O 0 0.0052197194
with O 0 0.005482311
a O 0 0.007847649
CNS O 0 0.8854377
origin O 0 0.015269759
of O 0 0.024106791
migraine B-Disease 2 0.9999255
attack O 0 0.9708946
. O 0 0.018862816

Hypersensitivity B-Disease 0 0.95861745
to O 0 0.009834187
carbamazepine B-Chemical 1 0.9999231
presenting O 0 0.15028933
with O 0 0.0038376043
a O 0 0.004593515
leukemoid B-Disease 0 0.98393387
reaction I-Disease 0 0.21378472
, O 0 0.011821396
eosinophilia B-Disease 2 0.9997274
, O 0 0.02582537
erythroderma B-Disease 0 0.9988188
, O 0 0.009195506
and O 0 0.007195743
renal B-Disease 0 0.9955149
failure I-Disease 0 0.947082
. O 0 0.0126682585

We O 0 0.0078496365
report O 0 0.007218633
a O 0 0.0044066245
patient O 0 0.0036279126
in O 0 0.00201745
whom O 0 0.0049561653
hypersensitivity B-Disease 2 0.9379011
to O 0 0.0022445954
carbamazepine B-Chemical 1 0.99999166
presented O 0 0.0017756122
with O 0 0.0012626072
generalized O 0 0.48273972
erythroderma B-Disease 0 0.9995679
, O 0 0.0032905592
a O 0 0.0017472211
severe O 0 0.39164314
leukemoid B-Disease 0 0.9940122
reaction I-Disease 0 0.26259416
, O 0 0.013920067
eosinophilia B-Disease 2 0.99983346
, O 0 0.041625928
hyponatremia B-Disease 2 0.9999498
, O 0 0.0067844805
and O 0 0.0055765477
renal B-Disease 0 0.9951244
failure I-Disease 0 0.9370899
. O 0 0.010996631

This O 0 0.013170734
is O 0 0.007032979
the O 0 0.0050087394
first O 0 0.0037354007
report O 0 0.0055167354
of O 0 0.003847124
such O 0 0.0035333366
an O 0 0.0054803193
unusual O 0 0.014798777
reaction O 0 0.078250535
to O 0 0.0129212765
carbamazepine B-Chemical 1 0.99993837
. O 0 0.016305324

Fluoxetine B-Chemical 1 0.9997315
- O 0 0.035130925
induced O 0 0.01978382
akathisia B-Disease 0 0.9999027
: O 0 0.020557102
clinical O 0 0.024941593
and O 0 0.011082357
theoretical O 0 0.022702431
implications O 0 0.017205268
. O 0 0.01534785

Five O 0 0.012370256
patients O 0 0.010001175
receiving O 0 0.00996977
fluoxetine B-Chemical 1 0.99988997
for O 0 0.0025753053
the O 0 0.0021871442
treatment O 0 0.0035220773
of O 0 0.009363318
obsessive B-Disease 0 0.999959
compulsive I-Disease 0 0.9999714
disorder I-Disease 0 0.99939144
or O 0 0.005696655
major B-Disease 2 0.106014565
depression I-Disease 2 0.9998629
developed O 0 0.23513669
akathisia B-Disease 0 0.99996996
. O 0 0.015593715

The O 0 0.007840398
typical O 0 0.009002199
fluoxetine B-Chemical 1 0.999928
- O 0 0.011332127
induced O 0 0.0030950813
symptoms O 0 0.81888294
of O 0 0.004044373
restlessness O 0 0.9997923
, O 0 0.0017616524
constant O 0 0.00071222906
pacing O 0 0.32542163
, O 0 0.0011676046
purposeless O 0 0.90888107
movements O 0 0.0015372253
of O 0 0.0005637696
the O 0 0.00053508976
feet O 0 0.03945844
and O 0 0.00090234226
legs O 0 0.21607016
, O 0 0.0010549598
and O 0 0.000752314
marked O 0 0.0022507473
anxiety B-Disease 0 0.996132
were O 0 0.000769649
indistinguishable O 0 0.00061759545
from O 0 0.00090275495
those O 0 0.001565037
of O 0 0.0035188156
neuroleptic O 0 0.99999094
- O 0 0.047749657
induced O 0 0.027731156
akathisia B-Disease 0 0.9999685
. O 0 0.013527329

Three O 0 0.009282228
patients O 0 0.007929265
who O 0 0.0054313126
had O 0 0.0029073844
experienced O 0 0.0075903903
neuroleptic O 0 0.9999918
- O 0 0.036101576
induced O 0 0.004319855
akathisia B-Disease 0 0.99999297
in O 0 0.0011223642
the O 0 0.0007973968
past O 0 0.0010882651
reported O 0 0.00072011363
that O 0 0.00046618062
the O 0 0.0006956582
symptoms O 0 0.78268975
of O 0 0.0046771364
fluoxetine B-Chemical 1 0.99999475
- O 0 0.013882579
induced O 0 0.0035740547
akathisia B-Disease 0 0.9999919
were O 0 0.001918883
identical O 0 0.0012295839
, O 0 0.0026159885
although O 0 0.0024945007
somewhat O 0 0.0071945135
milder O 0 0.2403893
. O 0 0.009389353

Akathisia B-Disease 2 0.99939144
appeared O 0 0.0072747623
to O 0 0.003908685
be O 0 0.0027789343
a O 0 0.0024232387
common O 0 0.0021310893
side O 0 0.03996205
effect O 0 0.0013583298
of O 0 0.0025604565
fluoxetine B-Chemical 1 0.9999888
and O 0 0.0013639915
generally O 0 0.0010290165
responded O 0 0.0010218506
well O 0 0.0004614512
to O 0 0.0004419955
treatment O 0 0.0007905275
with O 0 0.0006442168
the O 0 0.00086139626
beta O 0 0.81137
- O 0 0.01433862
adrenergic O 0 0.9994343
antagonist O 0 0.9970011
propranolol B-Chemical 1 0.9999932
, O 0 0.004532916
dose O 0 0.028734742
reduction O 0 0.0036323422
, O 0 0.0033819748
or O 0 0.0033246041
both O 0 0.005323035
. O 0 0.007628321

The O 0 0.00693448
authors O 0 0.0048431563
suggest O 0 0.0030070664
that O 0 0.0033831205
fluoxetine B-Chemical 1 0.9999764
- O 0 0.032359257
induced O 0 0.006352776
akathisia B-Disease 0 0.99999464
may O 0 0.001658906
be O 0 0.0010351638
caused O 0 0.0010595688
by O 0 0.0012216595
serotonergically O 0 0.57626027
mediated O 0 0.00072420435
inhibition O 0 0.0043721846
of O 0 0.0016318727
dopaminergic O 0 0.99581224
neurotransmission O 0 0.98751533
and O 0 0.000582695
that O 0 0.00033553047
the O 0 0.00046302335
pathophysiology O 0 0.17430861
of O 0 0.004675314
fluoxetine B-Chemical 1 0.9999969
- O 0 0.014294854
induced O 0 0.0031057054
akathisia B-Disease 0 0.9999974
and O 0 0.007505557
tricyclic O 0 0.9999745
antidepressant B-Chemical 1 0.99996376
- O 0 0.007463059
induced O 0 0.0020239046
" O 0 0.0064854356
jitteriness O 0 0.99965405
" O 0 0.00433425
may O 0 0.0029486832
be O 0 0.00396854
identical O 0 0.004078543
. O 0 0.0076282527

Effect O 0 0.012901361
of O 0 0.009203073
converting O 0 0.11197875
enzyme O 0 0.12770303
inhibition O 0 0.006886206
on O 0 0.0022319849
the O 0 0.0024652788
course O 0 0.0033468173
of O 0 0.0065274136
adriamycin B-Chemical 1 0.9998833
- O 0 0.065052815
induced O 0 0.030779993
nephropathy B-Disease 2 0.99992204
. O 0 0.022652466

The O 0 0.007247206
effect O 0 0.0047008633
of O 0 0.0041456134
the O 0 0.003360904
converting O 0 0.1740323
enzyme O 0 0.44624704
inhibitor O 0 0.51321787
( O 0 0.02318569
CEI O 0 0.9994885
) O 0 0.020063648
enalapril B-Chemical 1 0.9999801
was O 0 0.0011553713
assessed O 0 0.00080199953
in O 0 0.0011218811
Munich O 0 0.064836234
- O 0 0.0024835074
Wistar O 0 0.039104246
rats O 0 0.0032783365
with O 0 0.0028306136
established O 0 0.015363048
adriamycin B-Chemical 1 0.99989796
nephrosis B-Disease 2 0.9998884
. O 0 0.019144421

Rats O 0 0.01957595
were O 0 0.0052502924
given O 0 0.0027627777
a O 0 0.0028329268
single O 0 0.0020027978
dose O 0 0.004766128
of O 0 0.0022167282
adriamycin B-Chemical 1 0.9997824
and O 0 0.0013615243
one O 0 0.00060783833
month O 0 0.00043439688
later O 0 0.0003831776
divided O 0 0.0003419591
into O 0 0.0002985317
four O 0 0.00035338555
groups O 0 0.0006289045
matched O 0 0.0006374038
for O 0 0.0007434889
albuminuria B-Disease 2 0.9999088
, O 0 0.00207041
blood O 0 0.017915366
pressure O 0 0.08717386
, O 0 0.0024198072
and O 0 0.0025795666
plasma O 0 0.08692061
albumin O 0 0.9915148
concentration O 0 0.02623403
. O 0 0.009373738

Groups O 0 0.02902916
1 O 0 0.007892872
and O 0 0.00562507
3 O 0 0.0037526032
remained O 0 0.0031217725
untreated O 0 0.0031573346
while O 0 0.00258146
groups O 0 0.003197475
2 O 0 0.0028951175
and O 0 0.0033405263
4 O 0 0.0038094677
received O 0 0.0065853344
enalapril B-Chemical 1 0.9998331
. O 0 0.0131561095

Groups O 0 0.034294087
1 O 0 0.011418839
and O 0 0.008786191
2 O 0 0.006684557
underwent O 0 0.0061083334
micropuncture O 0 0.009672386
studies O 0 0.006024479
after O 0 0.00464677
10 O 0 0.0069862576
days O 0 0.0077819056
. O 0 0.011611199

These O 0 0.009390128
short O 0 0.005895083
- O 0 0.005316205
term O 0 0.002606386
studies O 0 0.0022007988
showed O 0 0.001439326
that O 0 0.0014060107
enalapril B-Chemical 1 0.9999747
reduced O 0 0.0017041162
arterial O 0 0.70369226
blood O 0 0.044893377
pressure O 0 0.15439539
( O 0 0.0014328532
101 O 0 0.012079779
+ O 0 0.0008170689
/ O 0 0.001915272
- O 0 0.0008398111
2 O 0 0.00041784238
vs O 0 0.0007150355
. O 0 0.0003427712
124 O 0 0.0022556346
+ O 0 0.0006108429
/ O 0 0.0015558116
- O 0 0.0007867714
3 O 0 0.00039379625
mm O 0 0.001329914
Hg O 0 0.7113167
, O 0 0.0005045225
group O 0 0.00043571796
2 O 0 0.0003886374
vs O 0 0.00069244526
. O 0 0.0003103062
1 O 0 0.00042934145
, O 0 0.00051969703
P O 0 0.0065194718
less O 0 0.000347575
than O 0 0.00030066105
0 O 0 0.000615171
. O 0 0.0003634516
05 O 0 0.04232015
) O 0 0.0005984629
and O 0 0.00043970876
glomerular O 0 0.63135684
capillary O 0 0.15179047
pressure O 0 0.10263809
( O 0 0.0009408524
54 O 0 0.0012086717
+ O 0 0.00061526895
/ O 0 0.0016077429
- O 0 0.00077304157
1 O 0 0.00041201885
vs O 0 0.0006615779
. O 0 0.00031821398
61 O 0 0.0008534079
+ O 0 0.0005811254
/ O 0 0.001520098
- O 0 0.000819047
2 O 0 0.0004518718
mm O 0 0.0015399453
Hg O 0 0.7833151
, O 0 0.00066810515
P O 0 0.008858586
less O 0 0.00037413373
than O 0 0.000314056
0 O 0 0.0006329737
. O 0 0.00037440352
05 O 0 0.043648124
) O 0 0.0006072199
without O 0 0.0004003354
reducing O 0 0.0013260375
albuminuria B-Disease 2 0.99996555
( O 0 0.003475815
617 O 0 0.1718256
+ O 0 0.000797613
/ O 0 0.0019136582
- O 0 0.00078701286
50 O 0 0.0005662501
vs O 0 0.00077221356
. O 0 0.00036492597
570 O 0 0.010357486
+ O 0 0.0005630516
/ O 0 0.0012520003
- O 0 0.0006843366
47 O 0 0.0007311075
mg O 0 0.06767276
/ O 0 0.00092288863
day O 0 0.00039605593
) O 0 0.00079259503
or O 0 0.00054749835
GFR O 0 0.99452376
( O 0 0.0010395339
1 O 0 0.0005670257
. O 0 0.00037951785
03 O 0 0.022481509
+ O 0 0.0006175352
/ O 0 0.0014372831
- O 0 0.00082452653
0 O 0 0.00060092687
. O 0 0.0003616286
04 O 0 0.018521182
vs O 0 0.0008189038
. O 0 0.00039853284
1 O 0 0.00055656454
. O 0 0.00047683713
04 O 0 0.029754745
+ O 0 0.000876711
/ O 0 0.0018366169
- O 0 0.0013137119
0 O 0 0.0010808813
. O 0 0.00083216117
11 O 0 0.0015357381
ml O 0 0.0036634617
/ O 0 0.005357177
min O 0 0.004763589
) O 0 0.008518444
. O 0 0.0076720864

Groups O 0 0.023728829
3 O 0 0.005696836
and O 0 0.004122645
4 O 0 0.0025056417
were O 0 0.0018268949
studied O 0 0.0014272748
at O 0 0.0008940204
four O 0 0.0007130576
and O 0 0.0008115773
at O 0 0.0004971988
six O 0 0.00040022744
months O 0 0.0003882141
to O 0 0.00038451873
assess O 0 0.00027614395
the O 0 0.0005023042
effect O 0 0.0006480578
of O 0 0.0016299915
enalapril B-Chemical 1 0.9999856
on O 0 0.0009720613
progression O 0 0.4637165
of O 0 0.0057778354
renal B-Disease 2 0.99968576
injury I-Disease 2 0.9993206
in O 0 0.021966524
adriamycin B-Chemical 1 0.9999398
nephrosis B-Disease 2 0.9999161
. O 0 0.020303423

Chronic O 0 0.99428517
enalapril B-Chemical 1 0.9998895
treatment O 0 0.01617164
reduced O 0 0.005440722
blood O 0 0.025482146
pressure O 0 0.08547783
without O 0 0.0037794793
reducing O 0 0.009316303
albuminuria B-Disease 2 0.9998062
in O 0 0.0059081055
group O 0 0.008058736
4 O 0 0.007734897
. O 0 0.009092385

Untreated O 0 0.17828354
group O 0 0.0070195156
3 O 0 0.0037390082
rats O 0 0.0039878474
exhibited O 0 0.0017342692
a O 0 0.0021424987
progressive O 0 0.10112684
reduction O 0 0.0025846926
in O 0 0.0012617116
GFR O 0 0.9965899
( O 0 0.0016259552
0 O 0 0.0009237869
. O 0 0.00041246967
35 O 0 0.00057483115
+ O 0 0.0006372064
/ O 0 0.0014593648
- O 0 0.0008606389
0 O 0 0.00060270465
. O 0 0.00034351018
08 O 0 0.0030007728
ml O 0 0.00095858256
/ O 0 0.0008987015
min O 0 0.00042017468
at O 0 0.00027811472
4 O 0 0.00031709915
months O 0 0.00029105053
, O 0 0.00050600345
0 O 0 0.0005420457
. O 0 0.000341517
27 O 0 0.0007478302
+ O 0 0.0006738202
/ O 0 0.0015953493
- O 0 0.0010699598
0 O 0 0.0008482359
. O 0 0.00058873947
07 O 0 0.003068836
ml O 0 0.0018666061
/ O 0 0.0021166953
min O 0 0.0014396083
at O 0 0.0013565748
6 O 0 0.0019003159
months O 0 0.0027798936
) O 0 0.007161361
. O 0 0.007264696

Enalapril B-Chemical 0 0.9998517
treatment O 0 0.028722664
blunted O 0 0.23531346
but O 0 0.003271867
did O 0 0.0018509595
not O 0 0.0013785383
prevent O 0 0.0013506506
reduction O 0 0.0018487445
in O 0 0.0009730403
GFR O 0 0.9902749
in O 0 0.00065851473
group O 0 0.0008316462
4 O 0 0.00057555916
( O 0 0.0006969539
0 O 0 0.00058583973
. O 0 0.00031227685
86 O 0 0.0007598161
+ O 0 0.0005545362
/ O 0 0.0012901876
- O 0 0.0007213564
0 O 0 0.0004752806
. O 0 0.00024731774
15 O 0 0.00026251824
ml O 0 0.00071771746
/ O 0 0.00077201426
min O 0 0.0003749368
at O 0 0.00024815107
4 O 0 0.0002838471
months O 0 0.00025657332
, O 0 0.00044585246
0 O 0 0.0004686208
. O 0 0.0002751608
69 O 0 0.0006205618
+ O 0 0.00051943754
/ O 0 0.0012423948
- O 0 0.0007108678
0 O 0 0.00047741196
. O 0 0.00025510273
13 O 0 0.00037313855
ml O 0 0.0008245571
/ O 0 0.0008465487
min O 0 0.00040328104
at O 0 0.00026926983
6 O 0 0.0002812505
months O 0 0.00028958794
, O 0 0.00049700995
both O 0 0.00046488433
P O 0 0.012901744
less O 0 0.00055637886
than O 0 0.00052742613
0 O 0 0.0010831817
. O 0 0.00078839704
05 O 0 0.023409564
vs O 0 0.0017816281
. O 0 0.0013588495
group O 0 0.0026265625
3 O 0 0.0036037008
) O 0 0.0074759345
. O 0 0.007133603

Reduction O 0 0.02230854
in O 0 0.006684756
GFR O 0 0.9608048
was O 0 0.0034515841
associated O 0 0.0023850321
with O 0 0.0016712188
the O 0 0.0013479129
development O 0 0.0020839383
of O 0 0.00205777
glomerular B-Disease 2 0.9978656
sclerosis I-Disease 2 0.9996153
in O 0 0.0012188932
both O 0 0.00090273813
treated O 0 0.0012228923
and O 0 0.0011781366
untreated O 0 0.0018486346
rats O 0 0.0048719416
. O 0 0.0014355478
( O 0 0.0030876906
ABSTRACT O 0 0.013137049
TRUNCATED O 0 0.01775519
AT O 0 0.04953618
250 O 0 0.010898086
WORDS O 0 0.022461208
) O 0 0.031069234

Clotiazepam B-Chemical 0 0.9418608
- O 0 0.056577675
induced O 0 0.050982237
acute O 0 0.9966421
hepatitis B-Disease 2 0.9997055
. O 0 0.098839134

We O 0 0.0076650907
report O 0 0.006710741
the O 0 0.003366862
case O 0 0.0024596807
of O 0 0.0021211202
a O 0 0.002098782
patient O 0 0.0021623918
who O 0 0.0030427275
developed O 0 0.0048379283
acute O 0 0.99945503
hepatitis B-Disease 2 0.99999595
with O 0 0.017411817
extensive B-Disease 0 0.06622129
hepatocellular I-Disease 0 0.9999963
necrosis I-Disease 2 0.9999838
, O 0 0.0038897628
7 O 0 0.0005718256
months O 0 0.000321702
after O 0 0.0002744604
the O 0 0.00046337568
onset O 0 0.0015570853
of O 0 0.0010930934
administration O 0 0.11006016
of O 0 0.005675763
clotiazepam B-Chemical 0 0.9999672
, O 0 0.006551156
a O 0 0.0075651063
thienodiazepine B-Chemical 0 0.9958144
derivative O 0 0.3481753
. O 0 0.0100667095

Clotiazepam B-Chemical 0 0.8707001
withdrawal O 0 0.7681269
was O 0 0.016535053
followed O 0 0.012786665
by O 0 0.016012894
prompt O 0 0.03130432
recovery O 0 0.031685427
. O 0 0.022273181

The O 0 0.0070224744
administration O 0 0.015066845
of O 0 0.0042771846
several O 0 0.0036166522
benzodiazepines B-Chemical 1 0.99989104
, O 0 0.0048282365
chemically O 0 0.09136796
related O 0 0.0010836022
to O 0 0.0014155431
clotiazepam B-Chemical 0 0.9999732
, O 0 0.0018012809
did O 0 0.0006639014
not O 0 0.0006329447
interfere O 0 0.000690836
with O 0 0.00081715465
recovery O 0 0.0019256346
and O 0 0.0011561172
did O 0 0.00099683
not O 0 0.0011687407
induce O 0 0.0013648628
any O 0 0.0027738067
relapse O 0 0.9918739
of O 0 0.04576659
hepatitis B-Disease 2 0.99990845
. O 0 0.025450287

This O 0 0.009607011
observation O 0 0.0048628575
shows O 0 0.0029529063
that O 0 0.00300434
clotiazepam B-Chemical 0 0.9998965
can O 0 0.002442132
induce O 0 0.0023203823
acute O 0 0.9994161
hepatitis B-Disease 2 0.9999939
and O 0 0.005645513
suggests O 0 0.0006885277
that O 0 0.0006339855
there O 0 0.00053567893
is O 0 0.0007082967
no O 0 0.00070209877
cross O 0 0.003548437
hepatotoxicity B-Disease 2 0.99998045
between O 0 0.0024393164
clotiazepam B-Chemical 0 0.99994075
and O 0 0.005615668
several O 0 0.007648309
benzodiazepines B-Chemical 1 0.99975437
. O 0 0.010611531

5 B-Chemical 0 0.015947003
- I-Chemical 0 0.018424258
azacytidine I-Chemical 0 0.9806159
potentiates O 0 0.1491
initiation B-Disease 0 0.008043015
induced I-Disease 0 0.0073618246
by I-Disease 0 0.008869988
carcinogens I-Disease 0 0.98024666
in O 0 0.009220663
rat O 0 0.123248965
liver O 0 0.9729891
. O 0 0.016438799

To O 0 0.0061181313
test O 0 0.004796307
the O 0 0.0030487303
validity O 0 0.0033500127
of O 0 0.0018579412
the O 0 0.0013442442
hypothesis O 0 0.001407591
that O 0 0.0010026112
hypomethylation O 0 0.55348897
of O 0 0.0019080153
DNA O 0 0.19411185
plays O 0 0.00077637134
an O 0 0.00082188146
important O 0 0.00041755888
role O 0 0.00034788434
in O 0 0.00040399944
the O 0 0.0004415098
initiation B-Disease 0 0.0005672213
of I-Disease 0 0.0009230051
carcinogenic I-Disease 0 0.9966648
process I-Disease 0 0.0013507104
, O 0 0.0015226731
5 B-Chemical 0 0.00062057463
- I-Chemical 0 0.0017308744
azacytidine I-Chemical 0 0.99155384
( O 0 0.0017338166
5 B-Chemical 0 0.00062555086
- I-Chemical 0 0.0015719187
AzC I-Chemical 0 0.84232503
) O 0 0.001376674
( O 0 0.00064481446
10 O 0 0.00039703006
mg O 0 0.08002636
/ O 0 0.0012402134
kg O 0 0.0057700695
) O 0 0.0011380721
, O 0 0.00059926393
an O 0 0.0005837123
inhibitor O 0 0.010955913
of O 0 0.0009437271
DNA O 0 0.20559254
methylation O 0 0.09468373
, O 0 0.0007882881
was O 0 0.00034245042
given O 0 0.00022589377
to O 0 0.00030288732
rats O 0 0.0007929992
during O 0 0.00026170182
the O 0 0.00037895783
phase O 0 0.00070999714
of O 0 0.0006667093
repair O 0 0.0016672139
synthesis O 0 0.030454597
induced O 0 0.00069817115
by O 0 0.00061492267
the O 0 0.00046069836
three O 0 0.00041434396
carcinogens O 0 0.98021
, O 0 0.0051497836
benzo B-Chemical 0 0.99826485
[ I-Chemical 0 0.012311457
a I-Chemical 0 0.0017627688
] I-Chemical 0 0.006175304
- I-Chemical 0 0.0022616931
pyrene I-Chemical 0 0.93567294
( O 0 0.0010719524
200 O 0 0.0011648652
mg O 0 0.16110821
/ O 0 0.0015811245
kg O 0 0.007704945
) O 0 0.0017348503
, O 0 0.0013812876
N B-Chemical 0 0.9852608
- I-Chemical 0 0.0065433425
methyl I-Chemical 0 0.9887693
- I-Chemical 0 0.017818011
N I-Chemical 0 0.99453163
- I-Chemical 0 0.0071189376
nitrosourea I-Chemical 0 0.999509
( O 0 0.0015651996
60 O 0 0.0005561159
mg O 0 0.12785226
/ O 0 0.0014133655
kg O 0 0.0044811335
) O 0 0.0010246085
and O 0 0.00061157026
1 B-Chemical 0 0.0006303919
, I-Chemical 0 0.00070643355
2 I-Chemical 0 0.0006355388
- I-Chemical 0 0.0012670796
dimethylhydrazine I-Chemical 0 0.9948331
( O 0 0.0018003996
1 B-Chemical 0 0.00089199067
, I-Chemical 0 0.0010113644
2 I-Chemical 0 0.00097247574
- I-Chemical 0 0.0021398417
DMH I-Chemical 0 0.9859589
) O 0 0.0029270924
( O 0 0.0022145377
100 O 0 0.0030992518
mg O 0 0.25074804
/ O 0 0.007335028
kg O 0 0.016926087
) O 0 0.010140008
. O 0 0.008244944

The O 0 0.007767439
initiated O 0 0.006072918
hepatocytes O 0 0.06252609
in O 0 0.0028562108
the O 0 0.0022987286
liver O 0 0.70475435
were O 0 0.0014646378
assayed O 0 0.00078949647
as O 0 0.00092733814
the O 0 0.0010710337
gamma O 0 0.7829792
- O 0 0.01771965
glutamyltransferase O 0 0.9974125
( O 0 0.0052363593
gamma O 0 0.77563405
- O 0 0.0063662184
GT O 0 0.97467846
) O 0 0.0009947593
positive O 0 0.0004647488
foci O 0 0.00063482084
formed O 0 0.0005491195
following O 0 0.00042944826
a O 0 0.00069818477
2 O 0 0.00052416505
- O 0 0.0005678434
week O 0 0.0002441525
selection O 0 0.0003856788
regimen O 0 0.00072866917
consisting O 0 0.0003667699
of O 0 0.0006786738
dietary O 0 0.42694128
0 O 0 0.0013328203
. O 0 0.00051220803
02 O 0 0.030533662
% O 0 0.00077712163
2 B-Chemical 0 0.0007733757
- I-Chemical 0 0.0014724531
acetylaminofluorene I-Chemical 0 0.8860999
coupled O 0 0.0013779687
with O 0 0.001461725
a O 0 0.0029924037
necrogenic O 0 0.9632435
dose O 0 0.16414456
of O 0 0.028820759
CCl4 B-Chemical 0 0.99994457
. O 0 0.013150119

The O 0 0.006827927
results O 0 0.0047911773
obtained O 0 0.0033699884
indicate O 0 0.002050285
that O 0 0.001491902
with O 0 0.0013503046
all O 0 0.0010042604
three O 0 0.00078406057
carcinogens O 0 0.9526713
, O 0 0.0017337292
administration O 0 0.03560334
of O 0 0.0011162168
5 B-Chemical 0 0.0008404363
- I-Chemical 0 0.0018280891
AzC I-Chemical 0 0.6970855
during O 0 0.0003750987
repair O 0 0.0010465513
synthesis O 0 0.014265249
increased O 0 0.0006581499
the O 0 0.00048048998
incidence O 0 0.007344581
of O 0 0.0008059281
initiated O 0 0.00087865506
hepatocytes O 0 0.3741754
, O 0 0.0008478876
for O 0 0.00031294295
example O 0 0.00041299214
10 O 0 0.00051877653
- O 0 0.0006189018
20 O 0 0.00034983805
foci O 0 0.0005233939
/ O 0 0.0010434977
cm2 O 0 0.0011153665
in O 0 0.00042697342
5 B-Chemical 0 0.0005163606
- I-Chemical 0 0.0011253736
AzC I-Chemical 0 0.6845396
and O 0 0.0008539821
carcinogen O 0 0.9891432
- O 0 0.0018847749
treated O 0 0.0006489843
rats O 0 0.0012284647
compared O 0 0.00031618692
with O 0 0.0005993082
3 O 0 0.00065174716
- O 0 0.0008550732
5 O 0 0.0004668832
foci O 0 0.00084033184
/ O 0 0.0017057233
cm2 O 0 0.0020048537
in O 0 0.0010520403
rats O 0 0.0027779855
treated O 0 0.0027267078
with O 0 0.0042734887
carcinogen O 0 0.9839033
only O 0 0.0075974376
. O 0 0.00921475

Administration O 0 0.15220763
of O 0 0.010887882
[ B-Chemical 0 0.03273975
3H I-Chemical 0 0.8340765
] I-Chemical 0 0.013601942
- I-Chemical 0 0.004214938
5 I-Chemical 0 0.0015551976
- I-Chemical 0 0.0018798546
azadeoxycytidine I-Chemical 0 0.040461395
during O 0 0.0006171598
the O 0 0.0007327767
repair O 0 0.0014970346
synthesis O 0 0.024198072
induced O 0 0.0010025803
by O 0 0.0010434183
1 B-Chemical 0 0.000843401
, I-Chemical 0 0.0008199477
2 I-Chemical 0 0.0006321914
- I-Chemical 0 0.0011105865
DMH I-Chemical 0 0.9491874
further O 0 0.0004252029
showed O 0 0.00033910447
that O 0 0.0003516303
0 O 0 0.00069442956
. O 0 0.00035380147
019 O 0 0.017487643
mol O 0 0.046496004
% O 0 0.0006313202
of O 0 0.0007674855
cytosine B-Chemical 0 0.9678931
residues O 0 0.025050502
in O 0 0.00064456894
DNA O 0 0.078824885
were O 0 0.00062175235
substituted O 0 0.0027587556
by O 0 0.0006248501
the O 0 0.0006410201
analogue O 0 0.08672236
, O 0 0.0008740702
indicating O 0 0.00045158886
that O 0 0.000510115
incorporation O 0 0.0016713963
of O 0 0.0012568934
5 B-Chemical 0 0.0013858501
- I-Chemical 0 0.003198104
AzC I-Chemical 0 0.6973642
occurs O 0 0.0018802385
during O 0 0.002268278
repair O 0 0.0072757746
synthesis O 0 0.12379601
. O 0 0.009560325

In O 0 0.006956394
the O 0 0.004633363
absence O 0 0.0025410505
of O 0 0.0028461597
the O 0 0.0025955932
carcinogen O 0 0.9876166
, O 0 0.0038967894
5 B-Chemical 0 0.0013206254
- I-Chemical 0 0.0018890691
AzC I-Chemical 0 0.35091633
given O 0 0.00037580702
after O 0 0.0002889688
a O 0 0.0004854274
two O 0 0.00033355373
thirds O 0 0.00058815675
partial O 0 0.00080469256
hepatectomy O 0 0.8932026
, O 0 0.0007078656
when O 0 0.0003210889
its O 0 0.00078166364
incorporation O 0 0.0010834985
should O 0 0.00030157226
be O 0 0.00046781878
maximum O 0 0.00053319964
, O 0 0.00079347624
failed O 0 0.00067277555
to O 0 0.00068921596
induce O 0 0.00082657253
any O 0 0.0016058038
gamma O 0 0.58833724
- O 0 0.009751522
GT O 0 0.94906735
positive O 0 0.0052954005
foci O 0 0.010689663
. O 0 0.009100238

The O 0 0.008085301
results O 0 0.005895812
suggest O 0 0.003621682
that O 0 0.0033543936
hypomethylation O 0 0.23468524
of O 0 0.003575767
DNA O 0 0.05008919
per O 0 0.0016571633
se O 0 0.0031311202
may O 0 0.0021130433
not O 0 0.0021884567
be O 0 0.0026002515
sufficient O 0 0.002262219
for O 0 0.0036175924
initiation O 0 0.0074033644
. O 0 0.00932263

Perhaps O 0 0.0103533715
two O 0 0.00496587
events O 0 0.011072249
might O 0 0.0023166302
be O 0 0.0018796544
necessary O 0 0.001008945
for O 0 0.00092572835
initiation O 0 0.0012275787
, O 0 0.0011561684
the O 0 0.00068446115
first O 0 0.000593246
caused O 0 0.00095353543
by O 0 0.0011394222
the O 0 0.0011868705
carcinogen O 0 0.9661035
and O 0 0.0017982619
a O 0 0.002042544
second O 0 0.0018972467
involving O 0 0.0034170628
hypomethylation O 0 0.6432043
of O 0 0.008299527
DNA O 0 0.45584437
. O 0 0.010540607

Antihypertensive O 0 0.9954146
drugs O 0 0.93558306
and O 0 0.03666737
depression B-Disease 2 0.99679524
: O 0 0.030149141
a O 0 0.02482723
reappraisal O 0 0.40580744
. O 0 0.024729582

Eighty O 0 0.019612087
- O 0 0.008617112
nine O 0 0.004208648
new O 0 0.0039831023
referral O 0 0.0061757104
hypertensive B-Disease 2 0.9967182
out O 0 0.0018818716
- O 0 0.0020000974
patients O 0 0.0016821985
and O 0 0.0008715122
46 O 0 0.0010374181
new O 0 0.0007868913
referral O 0 0.0016540264
non O 0 0.00271975
- O 0 0.0039132284
hypertensive B-Disease 2 0.9992353
chronically O 0 0.04119537
physically O 0 0.0037961071
ill O 0 0.2044438
out O 0 0.00068734295
- O 0 0.0011204659
patients O 0 0.0011717611
completed O 0 0.0006076504
a O 0 0.0010534694
mood O 0 0.98603815
rating O 0 0.0054226858
scale O 0 0.0016546187
at O 0 0.00082823145
regular O 0 0.0014114871
intervals O 0 0.0014342552
for O 0 0.0018325206
one O 0 0.003075107
year O 0 0.005333164
. O 0 0.007564765

The O 0 0.0070210006
results O 0 0.0050943363
showed O 0 0.003342532
a O 0 0.0033542502
high O 0 0.0025946626
prevalence O 0 0.0030190053
of O 0 0.0029470774
depression B-Disease 2 0.9986638
in O 0 0.0011613739
both O 0 0.0009098713
groups O 0 0.0010883077
of O 0 0.0011063943
patients O 0 0.0036728948
, O 0 0.0013148573
with O 0 0.0009600157
no O 0 0.000928899
preponderance O 0 0.00457525
in O 0 0.0021020554
the O 0 0.003751074
hypertensive B-Disease 2 0.9989079
group O 0 0.0106965825
. O 0 0.009328714

Hypertensive B-Disease 0 0.99650913
patients O 0 0.018136563
with O 0 0.0068414733
psychiatric B-Disease 2 0.97486967
histories O 0 0.00995928
had O 0 0.0022542626
a O 0 0.0023515585
higher O 0 0.0016461309
prevalence O 0 0.0030108986
of O 0 0.003574892
depression B-Disease 2 0.9980379
than O 0 0.0022296612
the O 0 0.0030726532
comparison O 0 0.00396323
patients O 0 0.014538592
. O 0 0.009182794

This O 0 0.010664971
was O 0 0.005467547
accounted O 0 0.0038829842
for O 0 0.0023475438
by O 0 0.0022743477
a O 0 0.001990848
significant O 0 0.0014574621
number O 0 0.0012411634
of O 0 0.002230246
depressions B-Disease 0 0.9964079
occurring O 0 0.0070681036
in O 0 0.0032224169
methyl B-Chemical 0 0.9991685
dopa I-Chemical 0 0.9999609
treated O 0 0.009834425
patients O 0 0.027397027
with O 0 0.0068045855
psychiatric B-Disease 2 0.99680185
histories O 0 0.11423133
. O 0 0.01043774

Chronic B-Disease 0 0.9940415
active I-Disease 0 0.1312923
hepatitis I-Disease 2 0.99974114
associated O 0 0.046677593
with O 0 0.070044875
diclofenac B-Chemical 1 0.9999782
sodium I-Chemical 0 0.9998266
therapy O 0 0.7358065
. O 0 0.022306278

Diclofenac B-Chemical 0 0.99983907
sodium I-Chemical 1 0.9997868
( O 0 0.07521394
Voltarol B-Chemical 0 0.9996959
, O 0 0.017246373
Geigy O 0 0.99881905
Pharmaceuticals O 0 0.9569611
) O 0 0.003202369
is O 0 0.001193799
a O 0 0.0014792059
non O 0 0.0034756402
- O 0 0.0045132022
steroidal O 0 0.99479747
anti O 0 0.14865693
- O 0 0.018891012
inflammatory O 0 0.9659927
derivative O 0 0.62546176
of O 0 0.05726271
phenylacetic B-Chemical 1 0.9998878
acid I-Chemical 1 0.99811137
. O 0 0.018344285

Although O 0 0.0070448364
generally O 0 0.005851436
well O 0 0.0041317935
- O 0 0.005195627
tolerated O 0 0.029518163
, O 0 0.00276639
asymptomatic O 0 0.052133843
abnormalities B-Disease 0 0.07918982
of I-Disease 0 0.0015532869
liver I-Disease 0 0.8584709
function I-Disease 0 0.001293475
have O 0 0.0007020275
been O 0 0.0007663797
recorded O 0 0.00083413714
and O 0 0.00093147706
, O 0 0.0011469639
less O 0 0.00090520974
commonly O 0 0.0026996492
, O 0 0.0039967173
severe O 0 0.78956133
hepatitis B-Disease 2 0.9999646
induced O 0 0.04909141
by O 0 0.072910145
diclofenac B-Chemical 1 0.99996316
. O 0 0.014025146

The O 0 0.0073037595
patient O 0 0.006690914
described O 0 0.0036064426
developed O 0 0.0049621793
chronic B-Disease 0 0.9836373
active I-Disease 0 0.05217442
hepatitis I-Disease 2 0.99997604
after O 0 0.0010162881
six O 0 0.0006317508
months O 0 0.0005998642
therapy O 0 0.004592662
with O 0 0.0016994729
diclofenac B-Chemical 1 0.99999833
sodium I-Chemical 0 0.9999696
which O 0 0.002123744
progressed O 0 0.0069570947
despite O 0 0.0005198834
the O 0 0.0006097177
withdrawal O 0 0.47296652
of O 0 0.0009504252
the O 0 0.0009923431
drug O 0 0.5259686
, O 0 0.001926731
a O 0 0.0018521847
finding O 0 0.0023412202
not O 0 0.002347325
previously O 0 0.0038019647
reported O 0 0.007611961
. O 0 0.008663179

Arterial O 0 0.86499417
hypertension B-Disease 2 0.9983683
as O 0 0.011459572
a O 0 0.010596309
complication O 0 0.31387976
of O 0 0.011642312
prolonged O 0 0.2556281
ketoconazole B-Chemical 1 0.99992156
treatment O 0 0.1259039
. O 0 0.018544922

Two O 0 0.008809309
of O 0 0.006060891
14 O 0 0.004307154
patients O 0 0.00478144
with O 0 0.0031097266
Cushing B-Disease 0 0.9989631
' I-Disease 0 0.0035489087
s I-Disease 0 0.0021480005
syndrome I-Disease 0 0.5582239
treated O 0 0.0015438388
on O 0 0.0007783848
a O 0 0.0014288891
long O 0 0.0012819524
- O 0 0.0016529086
term O 0 0.0010449203
basis O 0 0.0016255929
with O 0 0.0032823838
ketoconazole B-Chemical 1 0.9999716
developed O 0 0.02330055
sustained O 0 0.32530355
hypertension B-Disease 2 0.99982697
. O 0 0.012847125

In O 0 0.007100458
both O 0 0.0048551154
cases O 0 0.005021269
normal O 0 0.0045481967
plasma O 0 0.017693426
and O 0 0.0024274876
urinary O 0 0.8834747
free O 0 0.005758308
cortisol B-Chemical 1 0.9965634
levels O 0 0.0009853477
had O 0 0.0006992552
been O 0 0.00061567075
achieved O 0 0.0005679392
following O 0 0.00072488515
ketoconazole B-Chemical 1 0.9999907
therapy O 0 0.045604754
, O 0 0.0008571535
yet O 0 0.0004408132
continuous O 0 0.00036799573
blood O 0 0.0037569911
pressure O 0 0.018552346
monitoring O 0 0.0005630979
demonstrated O 0 0.00055682345
hypertension B-Disease 2 0.9999155
31 O 0 0.002099796
( O 0 0.00083496096
patient O 0 0.0008498431
1 O 0 0.000681449
) O 0 0.00089173316
and O 0 0.00064737815
52 O 0 0.0009717336
weeks O 0 0.0005846173
( O 0 0.0012399724
patient O 0 0.001693064
2 O 0 0.0018448542
) O 0 0.0032213558
after O 0 0.002281967
treatment O 0 0.006969136
. O 0 0.007946876

In O 0 0.009863608
patient O 0 0.009737087
1 O 0 0.00619935
, O 0 0.0053705885
plasma O 0 0.010018649
levels O 0 0.0033627157
of O 0 0.006801866
deoxycorticosterone B-Chemical 0 0.9999503
and O 0 0.0074650017
11 B-Chemical 0 0.0076134275
- I-Chemical 0 0.010353821
deoxycortisol I-Chemical 0 0.9718617
were O 0 0.006958073
elevated O 0 0.01640244
. O 0 0.010365922

In O 0 0.007684956
patient O 0 0.0072447225
2 O 0 0.0040722447
, O 0 0.0031027528
in O 0 0.0016457636
addition O 0 0.0010109319
to O 0 0.0010727523
an O 0 0.001397239
increase O 0 0.0007696416
in O 0 0.0008519754
both O 0 0.0014487933
deoxycorticosterone B-Chemical 0 0.99998665
and O 0 0.0020854382
11 B-Chemical 0 0.0027428388
- I-Chemical 0 0.003637158
deoxycortisol I-Chemical 0 0.9836376
levels O 0 0.00079512503
, O 0 0.0012917786
plasma O 0 0.061398532
aldosterone B-Chemical 1 0.9998441
values O 0 0.00090042053
were O 0 0.00070653786
raised O 0 0.0010121815
, O 0 0.0010878273
with O 0 0.0009078433
a O 0 0.0015454701
concomitant O 0 0.004306117
suppression O 0 0.0051991357
of O 0 0.005999804
renin O 0 0.99485356
levels O 0 0.0077263825
. O 0 0.009041155

Our O 0 0.008108907
findings O 0 0.0070136483
show O 0 0.0033765594
that O 0 0.0025156946
long O 0 0.002656865
- O 0 0.0026640543
term O 0 0.0012553098
treatment O 0 0.0017220529
with O 0 0.0011277039
high O 0 0.001354984
doses O 0 0.04989292
of O 0 0.0040157726
ketoconazole B-Chemical 1 0.99999297
may O 0 0.0015820052
induce O 0 0.0011354776
enzyme O 0 0.30334502
blockade O 0 0.5057047
leading O 0 0.006451938
to O 0 0.0032951287
mineralocorticoid O 0 0.99964976
- O 0 0.017091557
related O 0 0.005313876
hypertension B-Disease 2 0.9997812
. O 0 0.0116320895

Effects O 0 0.014234296
of O 0 0.007029167
an O 0 0.006653241
inhibitor O 0 0.08253621
of O 0 0.009166729
angiotensin B-Chemical 1 0.999936
converting O 0 0.84238213
enzyme O 0 0.79103184
( O 0 0.029671319
Captopril B-Chemical 1 0.9999875
) O 0 0.0024799292
on O 0 0.0005354819
pulmonary B-Disease 0 0.6920413
and I-Disease 0 0.0016002222
renal I-Disease 0 0.9935042
insufficiency I-Disease 0 0.9965389
due O 0 0.0011570932
to O 0 0.0015519394
intravascular B-Disease 0 0.98024505
coagulation I-Disease 0 0.9955018
in O 0 0.0038685638
the O 0 0.005041593
rat O 0 0.029626274
. O 0 0.008960451

Induction O 0 0.012530904
of O 0 0.0069335965
intravascular B-Disease 0 0.9495624
coagulation I-Disease 0 0.9953513
and O 0 0.004742332
inhibition O 0 0.006517474
of O 0 0.002523507
fibrinolysis O 0 0.9961283
by O 0 0.0015979961
injection O 0 0.0036126112
of O 0 0.001506264
thrombin O 0 0.9775079
and O 0 0.0055616614
tranexamic B-Chemical 0 0.99995685
acid I-Chemical 0 0.9961986
( O 0 0.021314748
AMCA B-Chemical 1 0.99911016
) O 0 0.0016211732
in O 0 0.0003988643
the O 0 0.00040558114
rat O 0 0.001235894
gives O 0 0.00041147368
rise O 0 0.0006301104
to O 0 0.0004415607
pulmonary B-Disease 0 0.72645056
and I-Disease 0 0.0012560401
renal I-Disease 0 0.9938205
insufficiency I-Disease 0 0.9967884
resembling O 0 0.0018802412
that O 0 0.0008063413
occurring O 0 0.0019086448
after O 0 0.0010761793
trauma B-Disease 0 0.9577028
or O 0 0.0040082065
sepsis B-Disease 2 0.99915874
in O 0 0.0075132404
man O 0 0.67551726
. O 0 0.011093028

Injection O 0 0.3049723
of O 0 0.014862575
Captopril B-Chemical 1 0.99991393
( O 0 0.008212342
1 O 0 0.0026404331
mg O 0 0.2461592
/ O 0 0.003931045
kg O 0 0.015650112
) O 0 0.002547498
, O 0 0.0012815916
an O 0 0.0011829574
inhibitor O 0 0.030413806
of O 0 0.0031929913
angiotensin B-Chemical 1 0.9999714
converting O 0 0.71538705
enzyme O 0 0.64503366
( O 0 0.011382822
ACE O 0 0.9997055
) O 0 0.00318401
, O 0 0.00089701376
reduced O 0 0.0005876186
both O 0 0.0006884706
pulmonary B-Disease 0 0.7482471
and I-Disease 0 0.0021691169
renal I-Disease 0 0.9953245
insufficiency I-Disease 0 0.9971244
in O 0 0.0025295469
this O 0 0.003128906
rat O 0 0.013450787
model O 0 0.0073321112
. O 0 0.00863185

The O 0 0.0088063795
lung O 0 0.055044312
weights O 0 0.006287459
were O 0 0.0035720614
lower O 0 0.0027856007
and O 0 0.0028392123
PaO2 O 0 0.8084838
was O 0 0.0017231151
improved O 0 0.0019636734
in O 0 0.0013090888
rats O 0 0.002602414
given O 0 0.0013118559
this O 0 0.002349258
enzyme O 0 0.22978356
- O 0 0.009681091
blocking O 0 0.019105364
agent O 0 0.55278254
. O 0 0.011404067

The O 0 0.007866138
contents O 0 0.008464796
of O 0 0.0054162703
albumin O 0 0.93962884
in O 0 0.0024476768
the O 0 0.0017812124
lungs O 0 0.0054175877
were O 0 0.0013297348
not O 0 0.0010145955
changed O 0 0.0011830656
, O 0 0.0012898897
indicating O 0 0.0008154075
that O 0 0.001163663
Captopril B-Chemical 1 0.9999695
did O 0 0.0011863359
not O 0 0.0011345163
influence O 0 0.0012451583
the O 0 0.0022489608
extravasation O 0 0.8650416
of O 0 0.0061529223
protein O 0 0.016182126
. O 0 0.010253613

Renal B-Disease 0 0.9722015
damage I-Disease 0 0.8429453
as O 0 0.005541265
reflected O 0 0.0033779028
by O 0 0.0029470464
an O 0 0.0027762635
increase O 0 0.0015624899
in O 0 0.0017738871
serum O 0 0.3439196
urea B-Chemical 1 0.99908864
and O 0 0.0026435577
in O 0 0.0020688332
kidney O 0 0.8869529
weight O 0 0.048884995
was O 0 0.0036373122
prevented O 0 0.011068156
by O 0 0.015716467
Captopril B-Chemical 1 0.9999211
. O 0 0.012450163

The O 0 0.0066588903
amount O 0 0.0038718123
of O 0 0.0040202346
fibrin O 0 0.30622467
in O 0 0.00241375
the O 0 0.0018827468
kidneys O 0 0.043860342
was O 0 0.0012877464
also O 0 0.0010511832
considerably O 0 0.001342161
lower O 0 0.00096419983
than O 0 0.0006926769
in O 0 0.0008816537
animals O 0 0.0010604135
which O 0 0.0017835286
received O 0 0.002355733
thrombin O 0 0.9400947
and O 0 0.009611667
AMCA B-Chemical 1 0.9973809
alone O 0 0.0097743
. O 0 0.00949683

It O 0 0.009878969
is O 0 0.0049624946
suggested O 0 0.0030030815
that O 0 0.0020421487
the O 0 0.001790028
effects O 0 0.0026214197
of O 0 0.0032773083
Captopril B-Chemical 1 0.99998033
on O 0 0.0006973668
the O 0 0.0007421269
lungs O 0 0.007726946
may O 0 0.0005911004
be O 0 0.0005282276
attributable O 0 0.00040861632
to O 0 0.00042292656
a O 0 0.00085316313
vasodilatory O 0 0.98456347
effect O 0 0.0006230067
due O 0 0.0003656942
to O 0 0.00039364427
a O 0 0.00065390806
reduction O 0 0.0007202886
in O 0 0.00036977956
the O 0 0.00042457547
circulating O 0 0.002502332
level O 0 0.000420479
of O 0 0.001161208
Angiotension B-Chemical 0 0.9464463
II I-Chemical 0 0.3012423
and O 0 0.0008344618
an O 0 0.0009830189
increase O 0 0.00060935196
in O 0 0.0011438314
prostacyclin B-Chemical 0 0.9999782
( O 0 0.003398306
secondary O 0 0.0032765905
to O 0 0.0012980691
an O 0 0.002248215
increase O 0 0.001918495
in O 0 0.004295828
bradykinin B-Chemical 1 0.9998054
) O 0 0.05525362
. O 0 0.009700082

Captopril B-Chemical 1 0.9996624
may O 0 0.0076823896
, O 0 0.0049991906
by O 0 0.0026853033
the O 0 0.0016650003
same O 0 0.0010501685
mechanism O 0 0.0014726394
, O 0 0.0013218422
reduce O 0 0.00063817936
the O 0 0.0006347664
increase O 0 0.00047783635
in O 0 0.0005362398
glomerular O 0 0.79032844
filtration O 0 0.013781676
that O 0 0.0004197883
is O 0 0.00044601146
known O 0 0.0005151859
to O 0 0.00036125546
occur O 0 0.00039293154
after O 0 0.00021896885
an O 0 0.00049030513
injection O 0 0.0010602414
of O 0 0.0007692442
thrombin O 0 0.96067584
, O 0 0.0011399265
thereby O 0 0.0009221714
diminishing O 0 0.0012145952
the O 0 0.0004162081
aggregation O 0 0.020425988
of O 0 0.000766742
fibrin O 0 0.79068583
monomers O 0 0.011913854
in O 0 0.00049545185
the O 0 0.0005321973
glomeruli O 0 0.061273243
, O 0 0.00074766873
with O 0 0.0004245002
the O 0 0.00039436205
result O 0 0.0004037784
that O 0 0.00035874092
less O 0 0.0005338699
fibrin O 0 0.3875256
will O 0 0.0005876875
be O 0 0.00073224894
deposited O 0 0.0012775845
and O 0 0.0010251388
thus O 0 0.0016103084
less O 0 0.001884529
kidney B-Disease 0 0.9903921
damage I-Disease 0 0.9754656
will O 0 0.0033646612
be O 0 0.004554978
produced O 0 0.0058212453
. O 0 0.008507578

Stroke B-Disease 0 0.97901285
associated O 0 0.038409352
with O 0 0.038029894
cocaine B-Chemical 1 0.99852896
use O 0 0.04557219
. O 0 0.035060328

We O 0 0.0073413937
describe O 0 0.00444199
eight O 0 0.003079463
patients O 0 0.0040844814
in O 0 0.0021232998
whom O 0 0.0054005776
cocaine B-Chemical 1 0.99981433
use O 0 0.002096676
was O 0 0.0012559275
related O 0 0.00092908967
to O 0 0.0013482164
stroke B-Disease 2 0.9986368
and O 0 0.002068792
review O 0 0.0029442739
39 O 0 0.0028196238
cases O 0 0.003021491
from O 0 0.0029153589
the O 0 0.004067583
literature O 0 0.009112268
. O 0 0.008818021

Among O 0 0.01131767
these O 0 0.006132687
47 O 0 0.005631742
patients O 0 0.004000717
the O 0 0.0020364928
mean O 0 0.0018237238
( O 0 0.0026124797
+ O 0 0.0018929284
/ O 0 0.0043839137
- O 0 0.002347727
SD O 0 0.30508903
) O 0 0.0013812692
age O 0 0.0012648591
was O 0 0.00058221706
32 O 0 0.00075368385
. O 0 0.0003920872
5 O 0 0.00045423064
+ O 0 0.0006315386
/ O 0 0.0013736179
- O 0 0.0008245571
12 O 0 0.00038333033
. O 0 0.0003730351
1 O 0 0.0005343367
years O 0 0.0008116621
; O 0 0.0010606854
76 O 0 0.0012711381
% O 0 0.0010718175
( O 0 0.0013563125
34 O 0 0.0016476419
/ O 0 0.0026582503
45 O 0 0.0020902466
) O 0 0.0038683987
were O 0 0.004247904
men O 0 0.09162688
. O 0 0.008415309

Stroke B-Disease 0 0.9841675
followed O 0 0.008485981
cocaine B-Chemical 1 0.9992125
use O 0 0.0054760273
by O 0 0.0041056145
inhalation O 0 0.48052812
, O 0 0.004110622
intranasal O 0 0.1255346
, O 0 0.0044576707
intravenous O 0 0.55413985
, O 0 0.0048364415
and O 0 0.004852506
intramuscular O 0 0.6578538
routes O 0 0.16321188
. O 0 0.010589186

Intracranial B-Disease 0 0.9650706
aneurysms I-Disease 2 0.9941596
or O 0 0.005929618
arteriovenous B-Disease 0 0.9563918
malformations I-Disease 0 0.9933745
were O 0 0.0020670807
present O 0 0.0009954708
in O 0 0.0009508414
17 O 0 0.0010955579
of O 0 0.0007934724
32 O 0 0.00093208527
patients O 0 0.0012011977
studied O 0 0.00081515807
angiographically O 0 0.91065806
or O 0 0.0007783174
at O 0 0.0006459373
autopsy O 0 0.052267455
; O 0 0.0034176426
cerebral B-Disease 0 0.991979
vasculitis I-Disease 2 0.99995255
was O 0 0.0022504828
present O 0 0.0015311365
in O 0 0.0023632129
two O 0 0.003423547
patients O 0 0.013299136
. O 0 0.008437707

Cerebral B-Disease 0 0.98639804
infarction I-Disease 2 0.9999031
occurred O 0 0.006078986
in O 0 0.002764484
10 O 0 0.0020578778
patients O 0 0.0031062798
( O 0 0.001885909
22 O 0 0.001397084
% O 0 0.0012603682
) O 0 0.0015807677
, O 0 0.0012582768
intracerebral B-Disease 0 0.99564135
hemorrhage I-Disease 2 0.9998981
in O 0 0.0008477152
22 O 0 0.0011062071
( O 0 0.00088635157
49 O 0 0.0010368269
% O 0 0.00085393747
) O 0 0.0011992427
, O 0 0.0009782765
and O 0 0.0012681975
subarachnoid B-Disease 0 0.9996401
hemorrhage I-Disease 2 0.9998808
in O 0 0.0018907477
13 O 0 0.0026823294
( O 0 0.0031759902
29 O 0 0.0044630654
% O 0 0.0049001873
) O 0 0.008360778
. O 0 0.0076972274

These O 0 0.008940629
data O 0 0.0063029495
indicate O 0 0.0033326373
that O 0 0.0026422257
( O 0 0.0033535617
1 O 0 0.0018343262
) O 0 0.0017048522
the O 0 0.0008110277
apparent O 0 0.0008034552
incidence O 0 0.00465717
of O 0 0.0015195532
stroke B-Disease 2 0.9995591
related O 0 0.0006111888
to O 0 0.0007485717
cocaine B-Chemical 1 0.9999341
use O 0 0.0009203295
is O 0 0.0005959638
increasing O 0 0.0011035259
; O 0 0.0023756134
( O 0 0.0009673375
2 O 0 0.0005925036
) O 0 0.0016145748
cocaine B-Chemical 1 0.999941
- O 0 0.0024378747
associated O 0 0.0009369485
stroke B-Disease 2 0.99952495
occurs O 0 0.00048353485
primarily O 0 0.0007609972
in O 0 0.00047403958
young O 0 0.012717024
adults O 0 0.00803353
; O 0 0.0017773319
( O 0 0.00083232485
3 O 0 0.0004861465
) O 0 0.0010157112
stroke B-Disease 2 0.9964079
may O 0 0.00033014614
follow O 0 0.00024234511
any O 0 0.00027596758
route O 0 0.0014951241
of O 0 0.00096086215
cocaine B-Chemical 1 0.9999726
administration O 0 0.46583936
; O 0 0.005876164
( O 0 0.00096657604
4 O 0 0.00045688
) O 0 0.00097419793
stroke B-Disease 2 0.9976146
after O 0 0.00031319697
cocaine B-Chemical 1 0.9998729
use O 0 0.0006018044
is O 0 0.00042198942
frequently O 0 0.00063229055
associated O 0 0.0005793751
with O 0 0.00081066304
intracranial B-Disease 0 0.9991762
aneurysms I-Disease 2 0.9996741
and O 0 0.0016545004
arteriovenous B-Disease 0 0.9942972
malformations I-Disease 0 0.99947983
; O 0 0.00408222
and O 0 0.00083613495
( O 0 0.00096055283
5 O 0 0.0004539216
) O 0 0.0007763048
in O 0 0.00051887514
cocaine B-Chemical 1 0.99993896
- O 0 0.0025245997
associated O 0 0.0011051444
stroke B-Disease 2 0.9995652
, O 0 0.00094818394
the O 0 0.00049709814
frequency O 0 0.0007248153
of O 0 0.0013836707
intracranial B-Disease 0 0.9990963
hemorrhage I-Disease 2 0.99996316
exceeds O 0 0.0014840121
that O 0 0.0017075869
of O 0 0.0049821897
cerebral B-Disease 0 0.9956884
infarction I-Disease 2 0.9999559
. O 0 0.012989618

A O 0 0.034833055
randomized O 0 0.009963771
comparison O 0 0.006946515
of O 0 0.0103414515
labetalol B-Chemical 1 0.99996424
and O 0 0.06770056
nitroprusside B-Chemical 1 0.99996805
for O 0 0.010773152
induced O 0 0.041382063
hypotension B-Disease 2 0.9998486
. O 0 0.02098633

In O 0 0.0076990053
a O 0 0.006413823
randomized O 0 0.0043540415
study O 0 0.0039899773
, O 0 0.0053460593
labetalol B-Chemical 1 0.9999914
- O 0 0.023038916
induced O 0 0.0051493775
hypotension B-Disease 2 0.9999863
and O 0 0.051680557
nitroprusside B-Chemical 1 0.99999845
- O 0 0.036778934
induced O 0 0.0026082387
hypotension B-Disease 2 0.9999782
were O 0 0.00076102803
compared O 0 0.00033399728
in O 0 0.00043491894
20 O 0 0.0005296978
patients O 0 0.001232267
( O 0 0.0007888355
10 O 0 0.0004915555
in O 0 0.00045052124
each O 0 0.0004714457
group O 0 0.001058323
) O 0 0.0016644716
scheduled O 0 0.0010213169
for O 0 0.001316018
major O 0 0.0030703626
orthopedic O 0 0.030739129
procedures O 0 0.0070654913
. O 0 0.008576115

Each O 0 0.0066785314
patient O 0 0.005821306
was O 0 0.0032499265
subjected O 0 0.001876315
to O 0 0.0015949119
an O 0 0.001654951
identical O 0 0.00082578295
anesthetic O 0 0.1854616
protocol O 0 0.0014355629
and O 0 0.00096917927
similar O 0 0.0005994581
drug O 0 0.68804985
- O 0 0.0020676416
induced O 0 0.000694647
reductions B-Disease 0 0.00073593605
in I-Disease 0 0.00043483463
mean I-Disease 0 0.00050699076
arterial I-Disease 0 0.33720127
blood I-Disease 0 0.020990722
pressure I-Disease 0 0.13683866
( O 0 0.0027269698
BP O 0 0.8797584
) O 0 0.0024621307
( O 0 0.0018016299
50 O 0 0.0017697747
to O 0 0.0016385091
55 O 0 0.003491491
mmHg O 0 0.010967921
) O 0 0.007461982
. O 0 0.0071154237

Nitroprusside O 0 0.9991357
infusion O 0 0.058684967
was O 0 0.00393182
associated O 0 0.002718851
with O 0 0.0018808577
a O 0 0.0019427577
significant O 0 0.0015396029
( O 0 0.0015171675
p O 0 0.0009986969
less O 0 0.00063989207
than O 0 0.00048604317
0 O 0 0.00088702614
. O 0 0.000493533
05 O 0 0.050436925
) O 0 0.0006885936
increase B-Disease 0 0.000306178
in I-Disease 0 0.00037255243
heart I-Disease 0 0.1621136
rate I-Disease 0 0.00049390574
and I-Disease 0 0.0006449247
cardiac I-Disease 0 0.4152388
output I-Disease 0 0.0017470954
; O 0 0.0019120842
rebound O 0 0.47044215
hypertension B-Disease 2 0.99991536
was O 0 0.00074532226
observed O 0 0.00046148244
in O 0 0.00064596685
three O 0 0.000677465
patients O 0 0.0023529641
after O 0 0.0012627417
discontinuation O 0 0.8335709
of O 0 0.015222137
nitroprusside B-Chemical 1 0.99996936
. O 0 0.013702399

Labetalol B-Chemical 0 0.9995245
administration O 0 0.22708666
was O 0 0.0076708426
not O 0 0.0054031005
associated O 0 0.005241981
with O 0 0.0048569795
any O 0 0.0048197345
of O 0 0.0067427983
these O 0 0.009549567
findings O 0 0.02158653
. O 0 0.014294654

Arterial O 0 0.8249742
PO2 B-Chemical 0 0.9838448
decreased O 0 0.028792154
in O 0 0.020712655
both O 0 0.021324564
groups O 0 0.028218646
. O 0 0.028018508

It O 0 0.017865682
was O 0 0.0110977
concluded O 0 0.009653084
that O 0 0.009022002
labetalol B-Chemical 1 0.9998913
offers O 0 0.011440337
advantages O 0 0.007926901
over O 0 0.009739617
nitroprusside B-Chemical 1 0.9998728
. O 0 0.021493118

Sodium B-Chemical 0 0.99850523
status O 0 0.021217503
influences O 0 0.01564307
chronic O 0 0.99217075
amphotericin B-Chemical 1 0.9999018
B I-Chemical 1 0.99772066
nephrotoxicity B-Disease 2 0.9999598
in O 0 0.025999254
rats O 0 0.09202503
. O 0 0.017494004

The O 0 0.008775097
nephrotoxic B-Disease 2 0.995155
potential O 0 0.007010982
of O 0 0.0069528795
amphotericin B-Chemical 1 0.99991906
B I-Chemical 1 0.9789219
( O 0 0.0042977426
5 O 0 0.0010726873
mg O 0 0.10988022
/ O 0 0.0014169153
kg O 0 0.0014585839
per O 0 0.00034581745
day O 0 0.00040024688
intraperitoneally O 0 0.0011582227
for O 0 0.0003656778
3 O 0 0.00042136014
weeks O 0 0.00033550395
) O 0 0.00077197707
has O 0 0.00038030598
been O 0 0.0004931826
investigated O 0 0.0004520281
in O 0 0.0008564904
salt O 1 0.99525297
- O 0 0.0044740555
depleted O 0 0.0008956481
, O 0 0.0016553766
normal O 0 0.0039985436
- O 0 0.0057661915
salt O 1 0.98643494
, O 0 0.004147451
and O 0 0.003793565
salt O 1 0.99254626
- O 0 0.011452638
loaded O 0 0.0070122103
rats O 0 0.014377307
. O 0 0.008775805

In O 0 0.011582851
salt O 1 0.9822107
- O 0 0.010031033
depleted O 0 0.0036578388
rats O 0 0.010976931
, O 0 0.005521302
amphotericin B-Chemical 1 0.9998995
B I-Chemical 1 0.9622309
decreased O 0 0.012439732
creatinine B-Chemical 1 0.99886227
clearance O 0 0.09892681
linearly O 0 0.0018169873
with O 0 0.000957532
time O 0 0.00076102547
, O 0 0.0011572471
with O 0 0.00094849925
an O 0 0.0014796031
85 O 0 0.0018454829
% O 0 0.0017518837
reduction O 0 0.0022311395
by O 0 0.0026670531
week O 0 0.0029544593
3 O 0 0.004820192
. O 0 0.0068702195

In O 0 0.0076753506
contrast O 0 0.005800403
, O 0 0.0048505077
in O 0 0.0028360954
normal O 0 0.00639618
- O 0 0.0063695763
salt O 1 0.988915
rats O 0 0.04264216
creatinine B-Chemical 1 0.99902594
clearance O 0 0.1562338
was O 0 0.00089140615
decreased O 0 0.0010130284
but O 0 0.0005481986
to O 0 0.0004325729
a O 0 0.0006757932
lesser O 0 0.00092678465
extent O 0 0.00033008787
at O 0 0.00030150125
week O 0 0.00029793885
2 O 0 0.0003659755
and O 0 0.00042950155
3 O 0 0.00043282224
, O 0 0.00054662937
and O 0 0.0005216589
in O 0 0.00061206095
salt O 1 0.99350846
- O 0 0.0028560942
loaded O 0 0.00094969926
rats O 0 0.0050333333
creatinine B-Chemical 1 0.99748343
clearance O 0 0.03872361
did O 0 0.00044189626
not O 0 0.0004116557
change O 0 0.00044982607
for O 0 0.0003489151
2 O 0 0.0004734245
weeks O 0 0.00035925492
and O 0 0.00065245107
was O 0 0.0007524993
decreased O 0 0.0012185611
by O 0 0.0013789547
43 O 0 0.002342116
% O 0 0.0019616268
at O 0 0.0017636125
week O 0 0.0025366659
3 O 0 0.0043776203
. O 0 0.0064977743

All O 0 0.008231335
rats O 0 0.008361929
in O 0 0.0041471557
the O 0 0.004110451
sodium B-Chemical 1 0.9994592
- O 0 0.004597339
depleted O 0 0.0012115332
group O 0 0.0012321607
had O 0 0.00080659456
histopathological O 0 0.22673401
evidence O 0 0.00083867315
of O 0 0.0011149612
patchy O 0 0.02639234
tubular O 0 0.68586195
cytoplasmic O 0 0.0052330075
degeneration O 0 0.98839253
in O 0 0.000780211
tubules O 0 0.009923263
that O 0 0.00047094407
was O 0 0.0005201173
not O 0 0.00044583337
observed O 0 0.0003789181
in O 0 0.00058357266
any O 0 0.00080646237
normal O 0 0.0037832423
- O 0 0.0061319894
salt O 1 0.98552006
or O 0 0.00506026
salt O 1 0.9966282
- O 0 0.019254047
loaded O 0 0.008180838
rat O 0 0.028158825
. O 0 0.00898295

Concentrations O 0 0.14736734
of O 0 0.011455134
amphotericin B-Chemical 1 0.9996698
B I-Chemical 1 0.9133585
in O 0 0.0035732465
plasma O 0 0.023353972
were O 0 0.001677356
not O 0 0.0011305389
significantly O 0 0.0011835237
different O 0 0.0008486648
among O 0 0.0010577615
the O 0 0.0008478807
three O 0 0.0007072466
groups O 0 0.0012114173
at O 0 0.0009140391
any O 0 0.0012261978
time O 0 0.0015400136
during O 0 0.001984878
the O 0 0.0036885135
study O 0 0.007275716
. O 0 0.008304654

However O 0 0.009196526
, O 0 0.0062511424
at O 0 0.0028064942
the O 0 0.0021922358
end O 0 0.0013576954
of O 0 0.0015218201
3 O 0 0.001125555
weeks O 0 0.0007974899
, O 0 0.0015684667
amphotericin B-Chemical 1 0.9998745
B I-Chemical 1 0.85637933
levels O 0 0.0008750506
in O 0 0.0005900779
the O 0 0.00061203405
kidneys O 0 0.06245802
and O 0 0.00092345505
liver O 0 0.8677776
were O 0 0.00068017887
significantly O 0 0.00075865624
higher O 0 0.0005455813
in O 0 0.0007200317
salt O 1 0.9958067
- O 0 0.0029004384
depleted O 0 0.00049027824
and O 0 0.0007521903
normal O 0 0.0051248153
- O 0 0.0036520825
salt O 1 0.97961295
rats O 0 0.0036969217
than O 0 0.0003539381
those O 0 0.00076529005
in O 0 0.00063674257
salt O 1 0.994772
- O 0 0.0030491494
loaded O 0 0.00089320133
rats O 0 0.0026527036
, O 0 0.00073783164
with O 0 0.00052021816
plasma O 0 0.02540779
/ O 0 0.003285226
kidney O 0 0.6035519
ratios O 0 0.00070638943
of O 0 0.00059473776
21 O 0 0.0007116605
, O 0 0.00054718426
14 O 0 0.00045254076
, O 0 0.00047936462
and O 0 0.00044940857
8 O 0 0.00045098743
in O 0 0.0005251022
salt O 1 0.98655903
- O 0 0.0023327547
depleted O 0 0.00068746746
, O 0 0.0012637934
normal O 0 0.0031530275
- O 0 0.0044116876
salt O 1 0.986479
, O 0 0.0029311446
and O 0 0.0024904867
salt O 1 0.9929404
- O 0 0.0063991207
loaded O 0 0.0036657522
rats O 0 0.008111972
, O 0 0.006135111
respectively O 0 0.009712118
. O 0 0.008280189

In O 0 0.007344731
conclusion O 0 0.0048728064
, O 0 0.004887875
reductions O 0 0.0032470978
in O 0 0.0023225758
creatinine B-Chemical 1 0.99663
clearance O 0 0.15280052
and O 0 0.0024860401
renal O 0 0.9978036
amphotericin B-Chemical 1 0.9999815
B I-Chemical 1 0.9817353
accumulation O 0 0.0070896717
after O 0 0.00071830006
chronic O 0 0.98933136
amphotericin B-Chemical 1 0.9999876
B I-Chemical 1 0.9878349
administration O 0 0.40030733
were O 0 0.0012082786
enhanced O 0 0.0011363336
by O 0 0.0017303092
salt O 1 0.99241155
depletion O 0 0.0073951865
and O 0 0.0022239897
attenuated O 0 0.0046254746
by O 0 0.0043859994
sodium B-Chemical 1 0.9995877
loading O 0 0.018424258
in O 0 0.0048103575
rats O 0 0.020219728
. O 0 0.008834481

Flestolol B-Chemical 1 0.9346072
: O 0 0.013494258
an O 0 0.009612525
ultra O 0 0.075494744
- O 0 0.008376401
short O 0 0.0044849045
- O 0 0.0067079444
acting O 0 0.018009637
beta O 0 0.79789543
- O 0 0.0288354
adrenergic O 0 0.9975285
blocking O 0 0.06766847
agent O 0 0.6857227
. O 0 0.014209836

Flestolol B-Chemical 1 0.9804115
( O 0 0.019930981
ACC B-Chemical 0 0.94666696
- I-Chemical 0 0.0094851535
9089 I-Chemical 0 0.08648473
) O 0 0.003983021
is O 0 0.0016736039
a O 0 0.0020154754
nonselective O 0 0.8214391
, O 0 0.002141228
competitive O 0 0.018676806
, O 0 0.0016677434
ultra O 0 0.08567387
- O 0 0.0016173011
short O 0 0.00069242355
- O 0 0.0014543396
acting O 0 0.005919828
beta O 0 0.7500184
- O 0 0.0064473785
adrenergic O 0 0.99660325
blocking O 0 0.0075489376
agent O 0 0.25195983
, O 0 0.0019628522
without O 0 0.0013416908
any O 0 0.0018646216
intrinsic O 0 0.006730093
sympathomimetic O 0 0.9991117
activity O 0 0.010857795
. O 0 0.008916118

Flestolol B-Chemical 1 0.9671026
is O 0 0.010112089
metabolized O 0 0.69539976
by O 0 0.0051704557
plasma O 0 0.07821387
esterases O 0 0.9415798
and O 0 0.002583407
has O 0 0.0012550307
an O 0 0.0015777007
elimination O 0 0.0020647123
half O 0 0.0009837702
- O 0 0.0018031286
life O 0 0.0019067925
of O 0 0.0014014802
approximately O 0 0.0015059672
6 O 0 0.0015805825
. O 0 0.00183192
5 O 0 0.0028049292
minutes O 0 0.0040000333
. O 0 0.006698655

This O 0 0.011297753
agent O 0 0.036470633
was O 0 0.004329364
well O 0 0.0028261715
tolerated O 0 0.009139367
in O 0 0.0017916952
healthy O 0 0.0050385273
volunteers O 0 0.0033276582
at O 0 0.0010002757
doses O 0 0.004219982
up O 0 0.0012233654
to O 0 0.0012854357
100 O 0 0.0029508376
micrograms O 0 0.14341539
/ O 0 0.006597042
kg O 0 0.014087151
/ O 0 0.009327123
min O 0 0.0075232023
. O 0 0.008457471

In O 0 0.007974644
long O 0 0.006270514
- O 0 0.0051300502
term O 0 0.002560576
infusion O 0 0.009456828
studies O 0 0.0022232197
, O 0 0.0021785093
flestolol B-Chemical 1 0.96813333
was O 0 0.00090113765
well O 0 0.00065195624
tolerated O 0 0.0065814992
at O 0 0.0004142922
the O 0 0.0005006388
effective O 0 0.0008898201
beta O 0 0.5815106
- O 0 0.0016892697
blocking O 0 0.0016443759
dose O 0 0.01580476
( O 0 0.0010398682
5 O 0 0.0004961291
micrograms O 0 0.039364588
/ O 0 0.0016695219
kg O 0 0.0035666989
/ O 0 0.0019771568
min O 0 0.0011896277
) O 0 0.0016052321
for O 0 0.0009908916
up O 0 0.0014977126
to O 0 0.0019293516
seven O 0 0.0030930971
days O 0 0.004385567
. O 0 0.0072415583

Flestolol B-Chemical 1 0.9202101
blood O 0 0.030098762
concentrations O 0 0.0070853494
increased O 0 0.0035753676
linearly O 0 0.00312962
with O 0 0.0015894693
increasing O 0 0.001604468
dose O 0 0.008953334
and O 0 0.0010433064
good O 0 0.00087742554
correlation O 0 0.0005070603
exists O 0 0.00055749284
between O 0 0.0005013083
blood O 0 0.0084351795
concentrations O 0 0.0027449303
of O 0 0.0022403067
flestolol B-Chemical 1 0.99493307
and O 0 0.004674305
beta O 0 0.85318047
- O 0 0.0384891
adrenergic O 0 0.99817026
blockade O 0 0.6384729
. O 0 0.009875976

Flestolol B-Chemical 1 0.8489723
produced O 0 0.008902268
a O 0 0.00798696
dose O 0 0.027468221
- O 0 0.006776279
dependent O 0 0.0033959362
attenuation O 0 0.007136417
of O 0 0.009536492
isoproterenol B-Chemical 1 0.99986935
- O 0 0.057486817
induced O 0 0.020568652
tachycardia B-Disease 2 0.9996344
. O 0 0.0154448915

Electrophysiologic O 0 0.75989294
and O 0 0.008660914
hemodynamic O 0 0.23093794
effects O 0 0.0062286616
of O 0 0.004791409
flestolol B-Chemical 1 0.9848177
are O 0 0.002692823
similar O 0 0.001613642
to O 0 0.0018737555
those O 0 0.0028501821
of O 0 0.0035626679
other O 0 0.005996435
beta O 0 0.9139962
blockers O 0 0.9991019
. O 0 0.013529933

In O 0 0.00723884
contrast O 0 0.0050554154
with O 0 0.0037885248
other O 0 0.003646723
beta O 0 0.8467098
blockers O 0 0.9997365
, O 0 0.015251264
flestolol B-Chemical 1 0.9983046
- O 0 0.0041129612
induced O 0 0.0010126256
effects O 0 0.0026155345
reverse O 0 0.036578704
rapidly O 0 0.0031885232
( O 0 0.00093216693
within O 0 0.00029284385
30 O 0 0.00034594408
minutes O 0 0.0003726892
) O 0 0.00074621814
following O 0 0.0005371893
discontinuation O 0 0.23333918
because O 0 0.000707931
of O 0 0.0013092931
its O 0 0.0023195692
short O 0 0.0019204783
half O 0 0.0025021513
- O 0 0.0066481116
life O 0 0.0112407915
. O 0 0.008315699

Flestolol B-Chemical 1 0.89466995
effectively O 0 0.012028333
reduced O 0 0.008294092
heart O 0 0.25682807
rate O 0 0.005788069
in O 0 0.005292713
patients O 0 0.011617614
with O 0 0.012038003
supraventricular B-Disease 0 0.9998869
tachyarrhythmia I-Disease 0 0.99988663
. O 0 0.023091985

In O 0 0.008164161
patients O 0 0.009150463
with O 0 0.005758515
unstable B-Disease 0 0.65700096
angina I-Disease 0 0.9999882
, O 0 0.0154906195
flestolol B-Chemical 1 0.9928093
infusion O 0 0.038948987
was O 0 0.0012201465
found O 0 0.00082684436
to O 0 0.00092225743
be O 0 0.0011186401
safe O 0 0.0020212943
and O 0 0.0014841004
effective O 0 0.0018564767
in O 0 0.0020761252
controlling O 0 0.004411401
chest B-Disease 0 0.93835306
pain I-Disease 2 0.9985678
. O 0 0.012025137

It O 0 0.010353723
is O 0 0.005328037
concluded O 0 0.0039041094
that O 0 0.0027214435
flestolol B-Chemical 1 0.9680159
is O 0 0.002188233
a O 0 0.0023033088
potent O 0 0.019023757
, O 0 0.0018935194
well O 0 0.0011250811
- O 0 0.0021942412
tolerated O 0 0.022616664
, O 0 0.0016665077
ultra O 0 0.07067398
- O 0 0.002038915
short O 0 0.001059361
- O 0 0.002437519
acting O 0 0.010512343
beta O 0 0.7313198
- O 0 0.017396893
adrenergic O 0 0.99720395
blocking O 0 0.04019965
agent O 0 0.61288244
. O 0 0.010703539

Use O 0 0.01805767
of O 0 0.010086296
flestolol B-Chemical 1 0.9282354
in O 0 0.0050264127
the O 0 0.0039444477
critical O 0 0.0034927188
care O 0 0.004369809
setting O 0 0.00364363
is O 0 0.0037173901
currently O 0 0.0052703083
undergoing O 0 0.007509437
investigation O 0 0.011600089
. O 0 0.011692404

Immunohistochemical O 0 0.028496088
, O 0 0.009015098
electron O 0 0.011546546
microscopic O 0 0.0084296055
and O 0 0.0039001955
morphometric O 0 0.008062033
studies O 0 0.003247559
of O 0 0.005357677
estrogen B-Chemical 1 0.99987483
- O 0 0.020562697
induced O 0 0.0040372536
rat O 0 0.13988107
prolactinomas B-Disease 0 0.9997439
after O 0 0.004876253
bromocriptine B-Chemical 1 0.99992394
treatment O 0 0.039663687
. O 0 0.011468781

To O 0 0.0059890747
clarify O 0 0.0032032584
the O 0 0.003038098
effects O 0 0.0036571648
of O 0 0.004293224
bromocriptine B-Chemical 1 0.99997413
on O 0 0.0018992425
prolactinoma B-Disease 2 0.9999466
cells O 0 0.008337178
in O 0 0.0008901588
vivo O 0 0.0014713794
, O 0 0.0009371494
immunohistochemical O 0 0.004752073
, O 0 0.000822107
ultrastructural O 0 0.007857412
and O 0 0.0006755126
morphometrical O 0 0.015160544
analyses O 0 0.0007665692
were O 0 0.0005065097
applied O 0 0.0004786012
to O 0 0.0007400883
estrogen B-Chemical 1 0.999938
- O 0 0.0066848607
induced O 0 0.0010008381
rat O 0 0.06140249
prolactinoma B-Disease 2 0.9999603
cells O 0 0.0051175538
1 O 0 0.0006523762
h O 0 0.00033275684
and O 0 0.00041629298
6 O 0 0.00028536635
h O 0 0.00026451162
after O 0 0.00023717238
injection O 0 0.0009404742
of O 0 0.0012843943
bromocriptine B-Chemical 1 0.999982
( O 0 0.0022957984
3 O 0 0.0010350522
mg O 0 0.15376641
/ O 0 0.0028449204
kg O 0 0.0044948193
of O 0 0.002646061
body O 0 0.018726492
weight O 0 0.03942713
) O 0 0.0137069505
. O 0 0.008607487

One O 0 0.01648577
h O 0 0.008575799
after O 0 0.0058670123
treatment O 0 0.008839096
, O 0 0.009671075
serum O 0 0.36874205
prolactin O 0 0.99605954
levels O 0 0.009510912
decreased O 0 0.015278731
markedly O 0 0.08033792
. O 0 0.015643854

Electron O 0 0.03021989
microscopy O 0 0.008791523
disclosed O 0 0.008240914
many O 0 0.004698301
secretory O 0 0.010610525
granules O 0 0.019741261
, O 0 0.003627451
slightly O 0 0.0023330238
distorted O 0 0.004741666
rough O 0 0.00363783
endoplasmic O 0 0.50094277
reticulum O 0 0.8040487
, O 0 0.0025644747
and O 0 0.0017085618
partially O 0 0.0020468808
dilated O 0 0.71592224
Golgi O 0 0.0125043355
cisternae O 0 0.015352182
in O 0 0.0026919253
the O 0 0.0049729296
prolactinoma B-Disease 2 0.99968576
cells O 0 0.03899547
. O 0 0.011379591

Morphometric O 0 0.056041718
analysis O 0 0.007155881
revealed O 0 0.0041144383
that O 0 0.002582461
the O 0 0.0022438855
volume O 0 0.0035329722
density O 0 0.0023367116
of O 0 0.0020323175
secretory O 0 0.01483783
granules O 0 0.020112814
increased O 0 0.0022664042
, O 0 0.0017785954
while O 0 0.0009839662
the O 0 0.0011125527
volume O 0 0.0027328867
density O 0 0.002389387
of O 0 0.0028572637
cytoplasmic O 0 0.0054260963
microtubules O 0 0.34287208
decreased O 0 0.012264787
. O 0 0.009809957

These O 0 0.008995761
findings O 0 0.007337629
suggest O 0 0.0032047767
that O 0 0.0027666115
lowered O 0 0.017905267
serum O 0 0.44593602
prolactin O 0 0.9978168
levels O 0 0.0014333177
in O 0 0.00084375794
the O 0 0.0007387238
early O 0 0.0012757021
phase O 0 0.0014531264
of O 0 0.0017652593
bromocriptine B-Chemical 1 0.9999877
treatment O 0 0.0029464106
may O 0 0.0006022993
result O 0 0.00058986904
from O 0 0.00061202
an O 0 0.0010409486
impaired O 0 0.0012772158
secretion O 0 0.01901499
of O 0 0.0018144345
prolactin O 0 0.99440515
due O 0 0.0009121104
to O 0 0.0010701561
decreasing O 0 0.0017696238
numbers O 0 0.0018579299
of O 0 0.0033066266
cytoplasmic O 0 0.0069408333
microtubules O 0 0.37917528
. O 0 0.009321934

At O 0 0.006622713
6 O 0 0.004467417
h O 0 0.0031455995
after O 0 0.002103537
injection O 0 0.0042699105
, O 0 0.0034062625
serum O 0 0.18727858
prolactin O 0 0.9943955
levels O 0 0.00187238
were O 0 0.0016208746
still O 0 0.0014487428
considerably O 0 0.0022769156
lower O 0 0.0022467792
than O 0 0.0022479063
in O 0 0.003910588
controls O 0 0.010454691
. O 0 0.008710713

The O 0 0.0108822
prolactinoma B-Disease 2 0.99814105
cells O 0 0.008237859
at O 0 0.0027517066
this O 0 0.0021149507
time O 0 0.0015608981
were O 0 0.0015352981
well O 0 0.0014083023
granulated O 0 0.070464365
, O 0 0.0024231419
with O 0 0.0018485974
vesiculated O 0 0.13189529
rough O 0 0.004806533
endoplasmic O 0 0.5220037
reticulum O 0 0.7646107
and O 0 0.0046641044
markedly O 0 0.06238227
dilated O 0 0.93064606
Golgi O 0 0.07339845
cisternae O 0 0.087327585
. O 0 0.010452304

Electron O 0 0.028075043
microscopical O 0 0.012738673
immunohistochemistry O 0 0.010133726
revealed O 0 0.0035794654
positive O 0 0.0029090578
reaction O 0 0.0082757175
products O 0 0.0053505646
noted O 0 0.001229136
on O 0 0.0008512289
the O 0 0.0010668341
secretory O 0 0.006689811
granules O 0 0.019060409
, O 0 0.0022348624
Golgi O 0 0.0076064845
cisternae O 0 0.020137358
, O 0 0.0015413448
and O 0 0.0014274169
endoplasmic O 0 0.23510957
reticulum O 0 0.44540974
of O 0 0.0020265558
the O 0 0.002093883
untreated O 0 0.005134087
rat O 0 0.1374913
prolactinoma B-Disease 2 0.9997869
cells O 0 0.051405955
. O 0 0.011273474

However O 0 0.009896895
, O 0 0.0070939055
only O 0 0.003943468
secretory O 0 0.007358814
granules O 0 0.0068667624
showed O 0 0.00164289
the O 0 0.0013376117
positive O 0 0.0014240178
reaction O 0 0.012338383
products O 0 0.010060657
for O 0 0.0011266158
prolactin O 0 0.9898775
6 O 0 0.00086906744
h O 0 0.00078958075
after O 0 0.00085015077
bromocriptine B-Chemical 1 0.9999136
treatment O 0 0.003622484
of O 0 0.0036185565
the O 0 0.0054868488
adenoma B-Disease 0 0.9993998
cells O 0 0.053180005
. O 0 0.011155864

An O 0 0.011624614
increase O 0 0.0048148385
in O 0 0.003381758
the O 0 0.002584254
volume O 0 0.003782977
density O 0 0.0023567763
of O 0 0.0019218022
secretory O 0 0.012694034
granules O 0 0.014175997
and O 0 0.0012684888
a O 0 0.0011240311
decrease O 0 0.00062349613
in O 0 0.00046238644
the O 0 0.00046746596
volume O 0 0.0011711859
densities O 0 0.00061487936
of O 0 0.0006621422
rough O 0 0.0020477176
endoplasmic O 0 0.4649678
reticulum O 0 0.7019207
and O 0 0.0009923653
microtubules O 0 0.05821788
was O 0 0.00046700786
determined O 0 0.00030834926
by O 0 0.00046958265
morphometric O 0 0.0027844338
analysis O 0 0.000754644
, O 0 0.0007055441
suggesting O 0 0.00037132276
that O 0 0.0005599251
bromocriptine B-Chemical 1 0.9999846
inhibits O 0 0.00095157867
protein O 0 0.0026274098
synthesis O 0 0.03754038
as O 0 0.0007210139
well O 0 0.000629857
as O 0 0.000787661
bringing O 0 0.0017586765
about O 0 0.000872082
a O 0 0.0018196927
disturbance O 0 0.113452375
of O 0 0.0029411507
the O 0 0.0046827383
prolactin O 0 0.99716455
secretion O 0 0.2613293
. O 0 0.010678363

Sulfasalazine B-Chemical 0 0.99809295
- O 0 0.06848307
induced O 0 0.055590566
lupus B-Disease 0 0.9995621
erythematosus I-Disease 0 0.99972564
. O 0 0.07835262

Pneumonitis B-Disease 0 0.98883086
, O 0 0.008281657
bilateral O 0 0.020510325
pleural B-Disease 0 0.72356004
effusions I-Disease 0 0.988597
, O 0 0.0034820505
echocardiographic O 0 0.024006456
evidence O 0 0.0010037038
of O 0 0.0011789477
cardiac B-Disease 0 0.54673547
tamponade I-Disease 0 0.9573061
, O 0 0.0013124776
and O 0 0.00066059345
positive O 0 0.00066486537
autoantibodies O 0 0.24637544
developed O 0 0.0010488578
in O 0 0.00051173085
a O 0 0.0008109196
43 O 0 0.001390797
- O 0 0.0009099
year O 0 0.00053664995
- O 0 0.0008149749
old O 0 0.0006713747
man O 0 0.06434198
, O 0 0.0009494056
who O 0 0.0011032051
was O 0 0.0005801962
receiving O 0 0.0010876801
long O 0 0.0009443378
- O 0 0.0016802609
term O 0 0.0013697298
sulfasalazine B-Chemical 1 0.9999778
therapy O 0 0.085160546
for O 0 0.0030490453
chronic O 0 0.99809676
ulcerative B-Disease 0 0.99999225
colitis I-Disease 0 0.9999819
. O 0 0.1110114

After O 0 0.0059885043
cessation O 0 0.008037331
of O 0 0.0038574168
the O 0 0.0032484587
sulfasalazine B-Chemical 1 0.99992156
and O 0 0.0021877426
completion O 0 0.000863194
of O 0 0.00095408154
a O 0 0.0010232622
six O 0 0.0005435637
- O 0 0.00093087734
week O 0 0.00038080369
course O 0 0.0005418719
of O 0 0.00083513005
corticosteroids O 1 0.9991953
, O 0 0.001297183
these O 0 0.0008273425
problems O 0 0.006996327
resolved O 0 0.0012072554
over O 0 0.0004926809
a O 0 0.0009439367
period O 0 0.0007987615
of O 0 0.0012742856
four O 0 0.0013834176
to O 0 0.002069752
six O 0 0.0027232517
months O 0 0.004506138
. O 0 0.0071436814

It O 0 0.0098507255
is O 0 0.004948768
suggested O 0 0.0030042573
that O 0 0.0020644797
the O 0 0.0018530161
patient O 0 0.0025885354
had O 0 0.002103182
sulfasalazine B-Chemical 1 0.9999882
- O 0 0.019628448
induced O 0 0.0026913607
lupus B-Disease 0 0.999961
, O 0 0.005197804
which O 0 0.0013837907
manifested O 0 0.051506437
with O 0 0.0017191977
serositis B-Disease 0 0.99997103
and O 0 0.0021564069
pulmonary O 0 0.9418149
parenchymal O 0 0.9326033
involvement O 0 0.005392794
in O 0 0.0011858726
the O 0 0.0013689753
absence O 0 0.0013959813
of O 0 0.0041293143
joint O 0 0.62909406
symptoms O 0 0.9758001
. O 0 0.010782701

Physicians O 0 0.012699759
who O 0 0.00821315
use O 0 0.0056609223
sulfasalazine B-Chemical 1 0.99988115
to O 0 0.002892869
treat O 0 0.005716893
patients O 0 0.0067259036
with O 0 0.0019622731
inflammatory B-Disease 0 0.9900192
bowel I-Disease 0 0.997009
disease I-Disease 0 0.98764604
should O 0 0.00071943115
be O 0 0.0007757535
aware O 0 0.0007801285
of O 0 0.0009115174
the O 0 0.0010358981
signs O 0 0.27680564
of O 0 0.0070175347
sulfasalazine B-Chemical 1 0.9999881
- O 0 0.052342907
induced O 0 0.022577748
lupus B-Disease 0 0.99996376
syndrome I-Disease 0 0.9991347
. O 0 0.019658871

Chronic O 0 0.9941598
carbamazepine B-Chemical 1 0.99993765
treatment O 0 0.011863049
in O 0 0.0029116354
the O 0 0.0022807114
rat O 0 0.009955647
: O 0 0.0026677055
efficacy O 0 0.0054621263
, O 0 0.0028700666
toxicity B-Disease 2 0.996807
, O 0 0.0021087662
and O 0 0.0012610464
effect O 0 0.0011279645
on O 0 0.0010555328
plasma O 0 0.030854858
and O 0 0.003936835
tissue O 0 0.29754594
folate B-Chemical 0 0.9995333
concentrations O 0 0.13643287
. O 0 0.011434837

Folate B-Chemical 1 0.9994066
depletion O 0 0.015753124
has O 0 0.0049486407
often O 0 0.005234515
been O 0 0.0030930396
a O 0 0.0029870279
problem O 0 0.0036967602
in O 0 0.002303218
chronic O 0 0.9802524
antiepileptic O 0 0.9999087
drug O 0 0.9774802
( O 0 0.034941424
AED O 0 0.99159265
) O 0 0.012900613
therapy O 0 0.0448498
. O 0 0.009410854

Carbamazepine B-Chemical 1 0.99990404
( O 0 0.09920034
CBZ B-Chemical 1 0.9999598
) O 0 0.016333645
, O 0 0.0040349835
a O 0 0.0028233887
commonly O 0 0.003106153
used O 0 0.0022213757
AED O 0 0.9681179
, O 0 0.0028663122
has O 0 0.0016179102
been O 0 0.0020555593
implicated O 0 0.0020378036
in O 0 0.0024514473
some O 0 0.0038911207
clinical O 0 0.021484545
studies O 0 0.008666464
. O 0 0.009373027

A O 0 0.036736634
rat O 0 0.011842308
model O 0 0.005104267
was O 0 0.0033031947
developed O 0 0.0027137436
to O 0 0.0015342225
examine O 0 0.0009243274
the O 0 0.0012167217
effects O 0 0.0022495366
of O 0 0.0030657318
chronic O 0 0.99682957
CBZ B-Chemical 1 0.99999714
treatment O 0 0.014511248
on O 0 0.0020049566
folate B-Chemical 0 0.9995621
concentrations O 0 0.020970093
in O 0 0.0036361285
the O 0 0.005074927
rat O 0 0.029854206
. O 0 0.009184811

In O 0 0.0068245623
the O 0 0.0046212287
course O 0 0.0036060833
of O 0 0.0028446175
developing O 0 0.0045499173
this O 0 0.0015491033
model O 0 0.001728736
, O 0 0.0015765566
a O 0 0.0012618497
common O 0 0.0015451787
vehicle O 0 0.29699683
, O 0 0.0072137583
propylene B-Chemical 0 0.99983835
glycol I-Chemical 0 0.9990515
, O 0 0.0027593104
by O 0 0.0007777124
itself O 0 0.0009045752
in O 0 0.00045420203
high O 0 0.0007285998
doses O 0 0.034562573
, O 0 0.0010058904
was O 0 0.0004906272
found O 0 0.00038982995
to O 0 0.00048680077
exhibit O 0 0.0006600532
protective O 0 0.007484632
properties O 0 0.0019168367
against O 0 0.0014302349
induced O 0 0.007570969
seizures B-Disease 2 0.99997354
and O 0 0.0063350545
inhibited O 0 0.007194659
weight B-Disease 0 0.06416777
gain I-Disease 0 0.015551785
. O 0 0.009319355

Seizures B-Disease 2 0.99930644
induced O 0 0.011830511
by O 0 0.0092955325
hexafluorodiethyl B-Chemical 0 0.997357
ether I-Chemical 0 0.9994448
( O 0 0.037825692
HFDE B-Chemical 0 0.9430379
) O 0 0.003521544
were O 0 0.0009930411
also O 0 0.0007780834
found O 0 0.0005595533
to O 0 0.00056823273
be O 0 0.00058960234
a O 0 0.00067103765
more O 0 0.00056150014
sensitive O 0 0.00041371837
measure O 0 0.00031107044
of O 0 0.0007671341
protection O 0 0.009861466
by O 0 0.002702033
CBZ B-Chemical 1 0.9999957
than O 0 0.0013264637
seizures B-Disease 2 0.9999695
induced O 0 0.0022401721
by O 0 0.0024380274
maximal O 0 0.0042147674
electroshock O 0 0.9999502
( O 0 0.052761137
MES O 0 0.99896204
) O 0 0.022532646
. O 0 0.009270375

Oral O 0 0.8684941
administration O 0 0.1510532
of O 0 0.009513212
CBZ B-Chemical 1 0.99997807
as O 0 0.003204571
an O 0 0.002653125
aqueous O 0 0.3069246
suspension O 0 0.0048017413
every O 0 0.0005273669
8 O 0 0.00055061636
h O 0 0.00038322256
at O 0 0.00031955104
a O 0 0.00048770348
dose O 0 0.0014078217
of O 0 0.000620048
250 O 0 0.0012689135
mg O 0 0.22347668
/ O 0 0.0014186887
kg O 0 0.0022936044
was O 0 0.00042393504
continuously O 0 0.000507029
protective O 0 0.0039568013
against O 0 0.00078362547
HFDE B-Chemical 0 0.9679597
- O 0 0.0037258165
induced O 0 0.0014817168
seizures B-Disease 2 0.9999838
and O 0 0.0011153654
was O 0 0.0006594106
minimally O 0 0.001068687
toxic O 0 0.54340374
as O 0 0.00076834974
measured O 0 0.0005494587
by O 0 0.00088304834
weight B-Disease 0 0.0025887191
gain I-Disease 0 0.001552742
over O 0 0.0008286905
8 O 0 0.001411809
weeks O 0 0.0014837967
of O 0 0.0033422555
treatment O 0 0.008197997
. O 0 0.008428837

The O 0 0.010845133
CBZ B-Chemical 1 0.9998336
levels O 0 0.004840528
measured O 0 0.0024902665
in O 0 0.0020975042
plasma O 0 0.010206241
and O 0 0.0019061002
brain O 0 0.02328762
of O 0 0.0013193822
these O 0 0.001274569
animals O 0 0.0010876184
, O 0 0.0014937344
however O 0 0.0013351216
, O 0 0.0014896641
were O 0 0.001175041
below O 0 0.001116897
those O 0 0.0021674333
normally O 0 0.0027192077
considered O 0 0.0035245367
protective O 0 0.031440157
. O 0 0.009711751

This O 0 0.011095294
treatment O 0 0.007466274
with O 0 0.005638213
CBZ B-Chemical 1 0.9999584
had O 0 0.002194968
no O 0 0.0011309352
apparent O 0 0.0013152813
adverse O 0 0.85527235
effect O 0 0.0012557615
on O 0 0.0007844873
folate B-Chemical 0 0.9996201
concentrations O 0 0.0073413146
in O 0 0.0006176261
the O 0 0.00061940105
rat O 0 0.008164674
, O 0 0.0009360861
and O 0 0.0006780427
, O 0 0.0007585652
indeed O 0 0.00059489114
, O 0 0.00075062906
the O 0 0.00058736076
folate B-Chemical 0 0.99919397
concentration O 0 0.0025754403
increased O 0 0.00081074494
in O 0 0.00052471185
liver O 0 0.71203876
after O 0 0.00031119562
6 O 0 0.00032827022
weeks O 0 0.0002732445
of O 0 0.0005164603
treatment O 0 0.0009787244
and O 0 0.00093449996
in O 0 0.0008922656
plasma O 0 0.008010417
at O 0 0.0010266845
8 O 0 0.0014156698
weeks O 0 0.0014599296
of O 0 0.003287867
treatment O 0 0.0080530085
. O 0 0.008309623

Dipyridamole B-Chemical 0 0.9985752
- O 0 0.06655075
induced O 0 0.050168518
myocardial B-Disease 0 0.99872476
ischemia I-Disease 2 0.99926454
. O 0 0.050383467

Angina B-Disease 0 0.998466
and O 0 0.011749007
ischemic O 0 0.9988745
electrocardiographic O 0 0.9675253
changes O 0 0.0034178912
occurred O 0 0.0016895691
after O 0 0.0008431422
administration O 0 0.012671421
of O 0 0.0016422012
oral O 0 0.81956947
dipyridamole B-Chemical 1 0.9999633
in O 0 0.0013361445
four O 0 0.001032414
patients O 0 0.0033035541
awaiting O 0 0.0084690945
urgent O 0 0.009531309
myocardial O 0 0.99952686
revascularization O 0 0.7440845
procedures O 0 0.008624479
. O 0 0.009358811

To O 0 0.006388245
our O 0 0.004521419
knowledge O 0 0.0044966787
, O 0 0.0031329917
this O 0 0.0017196366
has O 0 0.0011975408
not O 0 0.0010388844
previously O 0 0.0009778668
been O 0 0.0008840039
reported O 0 0.0008157161
as O 0 0.0006281907
a O 0 0.00083778653
side O 0 0.01827282
effect O 0 0.00053533236
of O 0 0.0007632141
preoperative O 0 0.14590119
dipyridamole B-Chemical 1 0.9999863
therapy O 0 0.086964995
, O 0 0.0016491108
although O 0 0.00090336544
dipyridamole B-Chemical 1 0.99998844
- O 0 0.00892428
induced O 0 0.0020232017
myocardial B-Disease 0 0.9999635
ischemia I-Disease 2 0.9999778
has O 0 0.0008482787
been O 0 0.00071733585
demonstrated O 0 0.000488395
to O 0 0.0005530943
occur O 0 0.0007190861
in O 0 0.00071193936
animals O 0 0.0008868089
and O 0 0.0014241522
humans O 0 0.003110061
with O 0 0.0026992564
coronary B-Disease 0 0.8907818
artery I-Disease 0 0.6568482
disease I-Disease 0 0.9163414
. O 0 0.010845952

Epicardial O 0 0.092182614
coronary O 0 0.27339247
collateral O 0 0.18072887
vessels O 0 0.05205634
were O 0 0.0023144544
demonstrated O 0 0.0013404225
in O 0 0.0010557631
all O 0 0.00084869965
four O 0 0.0006925311
patients O 0 0.0022554027
; O 0 0.0014049105
a O 0 0.0009961749
coronary O 0 0.55079126
" O 0 0.0016083163
steal O 0 0.37742844
" O 0 0.0014038554
phenomenon O 0 0.0036200099
may O 0 0.000620894
be O 0 0.00063753745
the O 0 0.0005980204
mechanism O 0 0.00085539103
of O 0 0.0013223586
the O 0 0.0022745575
dipyridamole B-Chemical 1 0.9999666
- O 0 0.020111376
induced O 0 0.007906596
ischemia B-Disease 2 0.99982196
observed O 0 0.006550277
. O 0 0.010030601

Inhibition O 0 0.028009214
of O 0 0.014810066
sympathoadrenal O 0 0.92967784
activity O 0 0.011311163
by O 0 0.0105372565
atrial O 0 0.9860293
natriuretic O 0 0.9949885
factor O 0 0.10162745
in O 0 0.0100297695
dogs O 0 0.025643492
. O 0 0.014356302

In O 0 0.007114183
six O 0 0.0042903754
conscious O 0 0.011257933
, O 0 0.0034662355
trained O 0 0.0021839775
dogs O 0 0.0031530606
, O 0 0.0015728154
maintained O 0 0.0007515866
on O 0 0.00057275343
a O 0 0.0010850519
normal O 0 0.002776274
sodium B-Chemical 1 0.9996669
intake O 0 0.71609396
of O 0 0.0011055102
2 O 0 0.0006518647
to O 0 0.00044833802
4 O 0 0.0005548802
mEq O 0 0.7610081
/ O 0 0.001145708
kg O 0 0.0026497785
/ O 0 0.0010570689
day O 0 0.00040709786
, O 0 0.0006419796
sympathetic O 0 0.7225157
activity O 0 0.0004933467
was O 0 0.00034501302
assessed O 0 0.000275027
as O 0 0.0003761142
the O 0 0.00042169626
release O 0 0.010718317
rate O 0 0.00051059463
of O 0 0.0013086781
norepinephrine B-Chemical 1 0.9999684
and O 0 0.0011978796
epinephrine B-Chemical 1 0.9994597
during O 0 0.00039751103
15 O 0 0.00043703432
- O 0 0.00058457855
minute O 0 0.0003665004
i O 0 0.0012251186
. O 0 0.00046442947
v O 0 0.0051109786
. O 0 0.0005315338
infusions O 0 0.0064792996
of O 0 0.001230179
human O 0 0.0027413794
alpha O 0 0.53077346
- O 0 0.01471595
atrial O 0 0.9904593
natriuretic O 0 0.99577856
factor O 0 0.16680788
. O 0 0.010128327

Mean O 0 0.00853448
arterial O 0 0.1844922
pressure O 0 0.06029186
( O 0 0.004073777
as O 0 0.0019070475
a O 0 0.0016135336
percentage O 0 0.0008997733
of O 0 0.0011882528
control O 0 0.0012003792
+ O 0 0.0014963369
/ O 0 0.004648058
- O 0 0.0016139469
SEM O 0 0.021983353
) O 0 0.00087321294
during O 0 0.00030440663
randomized O 0 0.00046107394
infusions O 0 0.0032075166
of O 0 0.00054221414
0 O 0 0.0007584936
. O 0 0.0003606653
03 O 0 0.021959651
, O 0 0.0005304279
0 O 0 0.00050059543
. O 0 0.0002747167
1 O 0 0.00038066506
, O 0 0.00044530543
0 O 0 0.00045225784
. O 0 0.000255693
3 O 0 0.00031427343
, O 0 0.0004021922
or O 0 0.00033009922
1 O 0 0.00041583928
. O 0 0.00026692057
0 O 0 0.00044571096
microgram O 0 0.032292187
/ O 0 0.001162937
kg O 0 0.0027785841
/ O 0 0.0011070289
min O 0 0.00049127376
was O 0 0.00041769585
99 O 0 0.0010039428
+ O 0 0.0005958782
/ O 0 0.0015708864
- O 0 0.0008734009
1 O 0 0.0004933472
, O 0 0.00057244947
95 O 0 0.00089197495
+ O 0 0.00056951016
/ O 0 0.0015050404
- O 0 0.000833127
1 O 0 0.0004533633
( O 0 0.00048103172
p O 0 0.00040530247
less O 0 0.00032461155
than O 0 0.00029219597
0 O 0 0.00060820254
. O 0 0.00037047768
05 O 0 0.05123949
) O 0 0.0007191398
, O 0 0.0005407819
93 O 0 0.0009131548
+ O 0 0.0005522341
/ O 0 0.0014222763
- O 0 0.0007917862
1 O 0 0.00043649724
( O 0 0.00046490075
p O 0 0.00039208253
less O 0 0.00031380338
than O 0 0.0002804093
0 O 0 0.00056818564
. O 0 0.00033085066
01 O 0 0.0040617883
) O 0 0.00068341114
, O 0 0.0004702895
or O 0 0.0003554764
79 O 0 0.00088389264
+ O 0 0.0005615559
/ O 0 0.0013986763
- O 0 0.000692342
6 O 0 0.00029188665
% O 0 0.00043557183
( O 0 0.00045510897
p O 0 0.00038684465
less O 0 0.00030980253
than O 0 0.0002784854
0 O 0 0.0005906628
. O 0 0.00036002844
001 O 0 0.22572748
) O 0 0.00087842817
, O 0 0.00059540727
respectively O 0 0.00078982796
, O 0 0.0005186672
but O 0 0.00032026315
no O 0 0.00031244417
tachycardia B-Disease 2 0.9994937
and O 0 0.0004916432
no O 0 0.00029650866
augmentation O 0 0.0031143317
of O 0 0.0006543345
the O 0 0.0008667731
norepinephrine B-Chemical 1 0.99996173
release O 0 0.036321703
rate O 0 0.0005803804
( O 0 0.0006754777
up O 0 0.00032884252
to O 0 0.0003222518
0 O 0 0.00051048223
. O 0 0.000255137
3 O 0 0.0003170481
microgram O 0 0.030750845
/ O 0 0.0011714747
kg O 0 0.0032449206
/ O 0 0.0013660671
min O 0 0.00059520133
) O 0 0.0007313186
were O 0 0.000374502
observed O 0 0.0003025808
, O 0 0.00062177225
which O 0 0.00056077866
is O 0 0.00045796792
in O 0 0.000438934
contrast O 0 0.0005621128
to O 0 0.0006505917
comparable O 0 0.0008827144
hypotension B-Disease 2 0.99994254
induced O 0 0.0038676562
by O 0 0.011941886
hydralazine B-Chemical 0 0.99998605
or O 0 0.034802184
nitroglycerin B-Chemical 1 0.9999554
. O 0 0.013096628

The O 0 0.0078837145
release O 0 0.014569264
rate O 0 0.004082608
of O 0 0.004706994
epinephrine B-Chemical 1 0.9995858
( O 0 0.0039843833
control O 0 0.0014865813
, O 0 0.001398647
6 O 0 0.0006571433
. O 0 0.0005044097
7 O 0 0.0005727305
+ O 0 0.000693204
/ O 0 0.001513504
- O 0 0.00087023346
0 O 0 0.00056083914
. O 0 0.0002873219
6 O 0 0.00028121783
ng O 0 0.0008155987
/ O 0 0.0010295862
kg O 0 0.00273242
/ O 0 0.0013121756
min O 0 0.00059334806
) O 0 0.00073723705
declined O 0 0.0005078636
immediately O 0 0.00030954098
during O 0 0.00024600196
infusions O 0 0.0074913716
of O 0 0.0007182201
atrial O 0 0.9868753
natriuretic O 0 0.9937186
factor O 0 0.01074927
to O 0 0.00038030415
a O 0 0.00046321977
minimum O 0 0.0002490114
of O 0 0.00048497503
49 O 0 0.0012582168
+ O 0 0.00067409186
/ O 0 0.0019499589
- O 0 0.0007513379
5 O 0 0.0003014458
% O 0 0.00035794047
of O 0 0.0003549035
control O 0 0.00041197255
( O 0 0.00057052006
p O 0 0.00043377787
less O 0 0.00032674588
than O 0 0.00028426904
0 O 0 0.0005878188
. O 0 0.00034637144
001 O 0 0.11882672
) O 0 0.00059730036
during O 0 0.00026275212
0 O 0 0.00049388123
. O 0 0.00026619143
1 O 0 0.00037446813
microgram O 0 0.03028772
/ O 0 0.0011411373
kg O 0 0.0026638336
/ O 0 0.0010581228
min O 0 0.00045427697
and O 0 0.00041738973
to O 0 0.0003798925
63 O 0 0.0011036231
+ O 0 0.0006389585
/ O 0 0.0017017962
- O 0 0.0007806881
5 O 0 0.000344794
% O 0 0.00048365426
( O 0 0.00052520423
0 O 0 0.0004608459
. O 0 0.00024395515
1 O 0 0.00028840484
greater O 0 0.00024326603
than O 0 0.00022762685
p O 0 0.000389169
greater O 0 0.00031001112
than O 0 0.00029850408
0 O 0 0.0006336626
. O 0 0.00036817082
05 O 0 0.041092563
) O 0 0.00061310566
or O 0 0.00039365178
95 O 0 0.0009974332
+ O 0 0.00058310956
/ O 0 0.0014117345
- O 0 0.0007621061
13 O 0 0.00050936354
% O 0 0.0005237989
( O 0 0.000522818
not O 0 0.00034291597
significant O 0 0.00050996593
) O 0 0.00084970775
during O 0 0.00035213048
0 O 0 0.0006676917
. O 0 0.00037775133
3 O 0 0.0004711771
or O 0 0.00055797875
1 O 0 0.0008164797
. O 0 0.0007105393
0 O 0 0.0014142387
microgram O 0 0.05414941
/ O 0 0.005145076
kg O 0 0.011581925
/ O 0 0.0084012635
min O 0 0.0068655885
. O 0 0.007835088

Steady O 0 0.435308
state O 0 0.009521158
arterial O 0 0.3828184
plasma O 0 0.03167541
concentrations O 0 0.004715974
of O 0 0.0031281686
atrial O 0 0.98929787
natriuretic O 0 0.9966587
factor O 0 0.03710985
were O 0 0.0010785481
39 O 0 0.0016277661
+ O 0 0.00093356764
/ O 0 0.0019863055
- O 0 0.00090369984
10 O 0 0.00045531263
pg O 0 0.0056516756
/ O 0 0.0011408031
ml O 0 0.0014209624
( O 0 0.0006369845
n O 0 0.00048153038
= O 0 0.00054597773
6 O 0 0.0002858355
) O 0 0.0004681627
during O 0 0.0002267714
infusions O 0 0.0036052624
of O 0 0.0005125255
saline O 0 0.08949014
and O 0 0.000726428
284 O 0 0.024001332
+ O 0 0.0006858285
/ O 0 0.0016621343
- O 0 0.0006722378
24 O 0 0.00028944633
pg O 0 0.0034039658
/ O 0 0.00096388115
ml O 0 0.0012624394
( O 0 0.0005995804
n O 0 0.00047088703
= O 0 0.00055797264
6 O 0 0.00031429232
) O 0 0.00058610004
and O 0 0.000501024
1520 O 0 0.029169567
+ O 0 0.00061875145
/ O 0 0.0014888281
- O 0 0.0007749058
300 O 0 0.00094761
pg O 0 0.007025497
/ O 0 0.0010562823
ml O 0 0.001284631
( O 0 0.00059756794
n O 0 0.00046534548
= O 0 0.0005512817
9 O 0 0.00039510787
) O 0 0.00051878294
during O 0 0.00026159105
0 O 0 0.00051605166
. O 0 0.00030793442
03 O 0 0.006407102
and O 0 0.00042545184
0 O 0 0.00055055815
. O 0 0.00029768643
1 O 0 0.00041937115
microgram O 0 0.026876781
/ O 0 0.0012375856
kg O 0 0.0025534637
/ O 0 0.0012052922
min O 0 0.00063112006
infusions O 0 0.003518752
of O 0 0.0008294256
the O 0 0.001003973
factor O 0 0.008079284
. O 0 0.0013361883
( O 0 0.002858777
ABSTRACT O 0 0.01207867
TRUNCATED O 0 0.017190285
AT O 0 0.049015902
250 O 0 0.010578786
WORDS O 0 0.022014441
) O 0 0.03054497

Inhibition O 0 0.019157339
of O 0 0.008606706
immunoreactive O 0 0.030334495
corticotropin O 0 0.9998585
- O 0 0.020621544
releasing O 0 0.112487316
factor O 0 0.029288424
secretion O 0 0.0212013
into O 0 0.001085525
the O 0 0.0016127173
hypophysial O 0 0.61355156
- O 0 0.0034892817
portal O 0 0.082648575
circulation O 0 0.018118363
by O 0 0.0034699007
delayed O 0 0.048612226
glucocorticoid O 0 0.9849791
feedback O 0 0.0267272
. O 0 0.010228316

Nitroprusside B-Chemical 0 0.9995956
- O 0 0.025002075
induced O 0 0.010350753
hypotension B-Disease 2 0.99993634
evokes O 0 0.8926146
ACTH O 0 0.99995434
secretion O 0 0.25083196
which O 0 0.0025446112
is O 0 0.0010802513
primarily O 0 0.0013835982
mediated O 0 0.0008622355
by O 0 0.0010576396
enhanced O 0 0.0010040413
secretion O 0 0.025903856
of O 0 0.0015092273
immunoreactive O 0 0.05184293
corticotropin O 0 0.999979
- O 0 0.0133489035
releasing O 0 0.12392866
factor O 0 0.066822745
( O 0 0.004543514
irCRF O 0 0.7491005
) O 0 0.0019738954
into O 0 0.00088261685
the O 0 0.0017637232
hypophysial O 0 0.45007175
- O 0 0.00584381
portal O 0 0.14679171
circulation O 0 0.04309172
. O 0 0.008537103

Portal O 0 0.46799964
plasma O 0 0.031667877
concentrations O 0 0.007914668
of O 0 0.005070055
neither O 0 0.0048598014
arginine B-Chemical 0 0.9629293
vasopressin I-Chemical 1 0.9996997
nor O 0 0.006113176
oxytocin B-Chemical 1 0.9991799
are O 0 0.003200373
significantly O 0 0.003405531
altered O 0 0.003500026
in O 0 0.0033622715
this O 0 0.004638912
paradigm O 0 0.009704287
. O 0 0.009620862

Application O 0 0.013066413
of O 0 0.0058542774
a O 0 0.00476207
delayed O 0 0.0069807153
feedback O 0 0.0039607985
signal O 0 0.0023553416
, O 0 0.0017143795
in O 0 0.00081918866
the O 0 0.0007124802
form O 0 0.00064912194
of O 0 0.0008023328
a O 0 0.0011453087
2 O 0 0.00080850447
- O 0 0.0009850308
h O 0 0.00043508486
systemic O 0 0.89806163
corticosterone B-Chemical 1 0.99981827
infusion O 0 0.066568665
in O 0 0.0008436329
urethane B-Chemical 0 0.9961669
- O 0 0.0024800424
anesthetized O 0 0.008051245
rats O 0 0.0014783862
with O 0 0.00057837967
pharmacological O 0 0.49631664
blockade O 0 0.39929792
of O 0 0.0021847792
glucocorticoid O 0 0.99570435
synthesis O 0 0.2618681
, O 0 0.0012632747
is O 0 0.00040021638
without O 0 0.00034339062
effect O 0 0.0003587308
on O 0 0.00026336938
the O 0 0.00043087505
resting O 0 0.0013678565
secretion O 0 0.018493779
of O 0 0.0022765172
arginine B-Chemical 0 0.9820389
vasopressin I-Chemical 1 0.99984884
and O 0 0.004380918
oxytocin B-Chemical 1 0.99877816
at O 0 0.0010921173
any O 0 0.001755515
corticosterone B-Chemical 1 0.9984609
feedback O 0 0.006376395
dose O 0 0.03329262
tested O 0 0.0052751303
. O 0 0.0084366305

Resting O 0 0.222645
irCRF O 0 0.56949055
levels O 0 0.0045365407
are O 0 0.0032726699
suppressed O 0 0.0023086327
only O 0 0.0014367966
at O 0 0.0009236007
the O 0 0.000932528
highest O 0 0.0012205881
corticosterone B-Chemical 1 0.99932253
infusion O 0 0.03272746
rate O 0 0.0010007446
, O 0 0.0011680368
which O 0 0.0008664671
resulted O 0 0.00064996537
in O 0 0.0009006964
systemic O 0 0.9628731
corticosterone B-Chemical 1 0.99964225
levels O 0 0.0016989617
of O 0 0.0023459932
40 O 0 0.00309519
micrograms O 0 0.32949585
/ O 0 0.016389545
dl O 0 0.07306046
. O 0 0.008459743

Suppression O 0 0.027159277
of O 0 0.010981348
irCRF O 0 0.8454355
secretion O 0 0.052090324
in O 0 0.0027472563
response O 0 0.003764251
to O 0 0.003525979
nitroprusside B-Chemical 1 0.9999964
- O 0 0.03769722
induced O 0 0.0037334457
hypotension B-Disease 2 0.99998105
is O 0 0.0010747649
observed O 0 0.00049555243
and O 0 0.00080973515
occurs O 0 0.00057119207
at O 0 0.00047016356
a O 0 0.0010368569
plasma O 0 0.053247537
corticosterone B-Chemical 1 0.99892455
level O 0 0.00078921515
between O 0 0.00080171524
8 O 0 0.0014775714
- O 0 0.0021838476
12 O 0 0.0016658858
micrograms O 0 0.09751321
/ O 0 0.0109039685
dl O 0 0.050662056
. O 0 0.00837982

These O 0 0.008511424
studies O 0 0.0051679933
provide O 0 0.002875348
further O 0 0.0022630265
evidence O 0 0.0017563633
for O 0 0.0011934413
a O 0 0.0014418487
strong O 0 0.0012224108
central O 0 0.0018881254
component O 0 0.0008938764
of O 0 0.00092246145
the O 0 0.00081852265
delayed O 0 0.0036663066
feedback O 0 0.0017703427
process O 0 0.001034193
which O 0 0.0014184598
is O 0 0.0012218364
mediated O 0 0.0013969303
by O 0 0.002264628
modulation O 0 0.0044478476
of O 0 0.0070792832
irCRF O 0 0.9541591
release O 0 0.2450625
. O 0 0.009714075

Noradrenergic O 0 0.95102495
involvement O 0 0.022673452
in O 0 0.0130053805
catalepsy B-Disease 2 0.99986756
induced O 0 0.012467166
by O 0 0.010632182
delta B-Chemical 0 0.27067396
9 I-Chemical 0 0.010902534
- I-Chemical 0 0.020720437
tetrahydrocannabinol I-Chemical 0 0.99965286
. O 0 0.017990667

In O 0 0.0068855537
order O 0 0.0038632755
to O 0 0.0028488731
elucidate O 0 0.0016217575
the O 0 0.001598057
role O 0 0.0010216336
of O 0 0.0013166756
the O 0 0.0012046316
catecholaminergic O 0 0.966042
system O 0 0.0015113802
in O 0 0.00062552845
the O 0 0.00074587046
cataleptogenic O 0 0.9992124
effect O 0 0.00066667976
of O 0 0.001064123
delta B-Chemical 0 0.24053594
9 I-Chemical 0 0.0012477754
- I-Chemical 0 0.0036049646
tetrahydrocannabinol I-Chemical 0 0.9999877
( O 0 0.021256488
THC B-Chemical 0 0.99999535
) O 0 0.0045135403
, O 0 0.000639146
the O 0 0.000326433
effect O 0 0.00034157792
of O 0 0.00056129845
pretreatment O 0 0.11807663
with O 0 0.0007654126
6 B-Chemical 0 0.0005770191
- I-Chemical 0 0.0014558537
hydroxydopamine I-Chemical 0 0.8726187
( O 0 0.0010316736
6 B-Chemical 0 0.0004743566
- I-Chemical 0 0.0012923453
OHDA I-Chemical 0 0.96924084
) O 0 0.0010499937
or O 0 0.0004884178
with O 0 0.0009200033
desipramine B-Chemical 1 0.9999937
and O 0 0.0010337073
6 B-Chemical 0 0.000649545
- I-Chemical 0 0.0014937288
OHDA I-Chemical 0 0.9290712
and O 0 0.0008880164
lesions O 0 0.10752677
of O 0 0.0012147409
the O 0 0.0012479357
locus O 0 0.0020331757
coeruleus O 0 0.8741215
were O 0 0.0019155936
investigated O 0 0.0021291056
in O 0 0.0038727447
rats O 0 0.012700589
. O 0 0.00864757

The O 0 0.008797701
cataleptogenic O 0 0.9965334
effect O 0 0.004791816
of O 0 0.0070100524
THC B-Chemical 0 0.99997926
was O 0 0.0026923104
significantly O 0 0.0018774942
reduced O 0 0.0011341489
in O 0 0.0007919763
rats O 0 0.0021231328
treated O 0 0.000937688
with O 0 0.0008488225
6 B-Chemical 0 0.0006906635
- I-Chemical 0 0.0017565656
OHDA I-Chemical 0 0.9550211
and O 0 0.0005924634
in O 0 0.0004415117
rats O 0 0.0012642521
with O 0 0.000553826
lesions O 0 0.16775285
of O 0 0.00071431283
the O 0 0.00057959376
locus O 0 0.00081449904
coeruleus O 0 0.90786153
but O 0 0.00046346776
not O 0 0.00038872738
in O 0 0.00040630208
rats O 0 0.0013073724
treated O 0 0.0008526223
with O 0 0.0014603442
desipramine B-Chemical 1 0.9999945
and O 0 0.0014484022
6 B-Chemical 0 0.000904573
- I-Chemical 0 0.0023157573
OHDA I-Chemical 0 0.9570385
, O 0 0.0014555812
as O 0 0.0011888196
compared O 0 0.0011595733
with O 0 0.0024574343
control O 0 0.0037870689
rats O 0 0.011775046
. O 0 0.008059913

On O 0 0.008355857
the O 0 0.004860115
contrary O 0 0.004157659
, O 0 0.0036982642
the O 0 0.002418745
cataleptogenic O 0 0.9991641
effect O 0 0.0020045864
of O 0 0.005435701
haloperidol B-Chemical 1 0.99999726
was O 0 0.0013736134
significantly O 0 0.0012008025
reduced O 0 0.0007399222
in O 0 0.0005601568
rats O 0 0.0021479086
treated O 0 0.0009420216
with O 0 0.0014506273
desipramine B-Chemical 1 0.9999962
and O 0 0.0012524984
6 B-Chemical 0 0.0006324078
- I-Chemical 0 0.0015776731
OHDA I-Chemical 0 0.9493858
but O 0 0.0004481402
not O 0 0.00037993633
in O 0 0.0003938417
rats O 0 0.0011397569
treated O 0 0.0006966019
with O 0 0.0007421517
6 B-Chemical 0 0.000695969
- I-Chemical 0 0.0017591788
OHDA I-Chemical 0 0.93252116
or O 0 0.00075269403
in O 0 0.00085150474
rats O 0 0.0024115227
with O 0 0.0016468123
lesions O 0 0.2714669
of O 0 0.003395989
the O 0 0.0040287026
locus O 0 0.0079576075
coeruleus O 0 0.96360725
. O 0 0.008878113

These O 0 0.008574862
results O 0 0.0053684236
indicate O 0 0.0033424555
that O 0 0.00282056
noradrenergic O 0 0.99223846
neurons O 0 0.023500353
have O 0 0.0011092362
an O 0 0.0012905949
important O 0 0.00066231407
role O 0 0.0005189403
in O 0 0.00058065983
the O 0 0.0006979789
manifestation O 0 0.2003342
of O 0 0.009790761
catalepsy B-Disease 2 0.99999654
induced O 0 0.004990053
by O 0 0.008412938
THC B-Chemical 0 0.9999956
, O 0 0.0028710482
whereas O 0 0.001035223
dopaminergic O 0 0.9726204
neurons O 0 0.015612295
are O 0 0.0010550041
important O 0 0.0010577665
in O 0 0.0024788901
catalepsy B-Disease 2 0.99997604
induced O 0 0.008956613
by O 0 0.03986088
haloperidol B-Chemical 1 0.9999734
. O 0 0.01163629

Reversibility O 0 0.42412907
of O 0 0.01460177
captopril B-Chemical 1 0.9998927
- O 0 0.022142584
induced O 0 0.0045718607
renal B-Disease 0 0.9942173
insufficiency I-Disease 0 0.9975056
after O 0 0.00122585
prolonged O 0 0.005038824
use O 0 0.0015561855
in O 0 0.001312252
an O 0 0.0021368726
unusual O 0 0.0054313047
case O 0 0.0033682832
of O 0 0.011441102
renovascular B-Disease 0 0.9999616
hypertension I-Disease 2 0.9999577
. O 0 0.020299742

We O 0 0.007887661
report O 0 0.007131236
a O 0 0.0043223025
case O 0 0.0028058006
of O 0 0.0030404879
severe O 0 0.50542647
hypertension B-Disease 2 0.9999193
with O 0 0.0020758554
an O 0 0.0017885615
occluded O 0 0.0037784907
renal O 0 0.9630274
artery O 0 0.20194872
to O 0 0.0006623255
a O 0 0.0009819394
solitary O 0 0.06611073
kidney O 0 0.8867334
, O 0 0.0013973622
who O 0 0.0014888452
developed O 0 0.0014112921
sudden B-Disease 0 0.99248296
deterioration I-Disease 0 0.2709376
of I-Disease 0 0.0018497953
renal I-Disease 0 0.98568
function I-Disease 0 0.0024211656
following O 0 0.002162145
treatment O 0 0.0061395844
with O 0 0.010934455
captopril B-Chemical 1 0.99989796
. O 0 0.01192439

His O 0 0.022109348
renal O 0 0.856387
function O 0 0.0052292356
remained O 0 0.0033723773
impaired O 0 0.0027310215
but O 0 0.0014241243
stable O 0 0.0011812538
during O 0 0.0007014748
2 O 0 0.00077568035
years O 0 0.0009589174
' O 0 0.0008717456
treatment O 0 0.00097041193
with O 0 0.0010956419
captopril B-Chemical 1 0.99996746
but O 0 0.0008691918
returned O 0 0.00065901235
to O 0 0.00054984173
pre O 0 0.005179688
- O 0 0.0012923514
treatment O 0 0.000957345
levels O 0 0.00077633146
soon O 0 0.001147788
after O 0 0.00082595536
cessation O 0 0.0045477306
of O 0 0.0027294112
the O 0 0.0041850535
drug O 0 0.7403455
. O 0 0.009164862

This O 0 0.010274738
indicates O 0 0.00500653
reversibility O 0 0.081531785
in O 0 0.00463869
captopril B-Chemical 1 0.9999527
- O 0 0.01760334
induced O 0 0.0025275492
renal B-Disease 0 0.99373263
failure I-Disease 0 0.81190014
even O 0 0.0009982565
after O 0 0.0004079558
its O 0 0.0009731005
prolonged O 0 0.002643686
use O 0 0.0006781126
and O 0 0.00062564766
suggests O 0 0.0003357321
that O 0 0.0004259932
no O 0 0.0005679262
organic O 0 0.95525736
damage O 0 0.80505943
occurs O 0 0.0011803833
to O 0 0.0013146194
glomerular O 0 0.9439398
arterioles O 0 0.92437035
following O 0 0.0043099257
chronic O 0 0.9947336
ACE O 0 0.99975055
inhibition O 0 0.124091364
. O 0 0.01060327

HMG O 0 0.9795949
CoA O 1 0.9961234
reductase O 0 0.9940719
inhibitors O 0 0.79298943
. O 0 0.061466374

Current O 0 0.11722956
clinical O 0 0.09258704
experience O 0 0.082619786
. O 0 0.06421971

Lovastatin B-Chemical 1 0.999607
and O 0 0.015357833
simvastatin B-Chemical 1 0.9997844
are O 0 0.0043497626
the O 0 0.002333083
2 O 0 0.0016729301
best O 0 0.0014897613
- O 0 0.001784276
known O 0 0.0010905166
members O 0 0.00094468525
of O 0 0.0009198407
the O 0 0.0008564839
class O 0 0.0022104133
of O 0 0.002099738
hypolipidaemic O 0 0.9997075
agents O 0 0.6904478
known O 0 0.0070361397
as O 0 0.010373999
HMG O 0 0.9985299
CoA O 1 0.9998677
reductase O 0 0.9992237
inhibitors O 0 0.6717709
. O 0 0.012346282

Clinical O 0 0.048213575
experience O 0 0.009723369
with O 0 0.0053916075
lovastatin B-Chemical 1 0.9997329
includes O 0 0.002483198
over O 0 0.0011182139
5000 O 0 0.0025467204
patients O 0 0.0021547289
, O 0 0.001123831
700 O 0 0.0013526123
of O 0 0.0006149564
whom O 0 0.0012086885
have O 0 0.00046815156
been O 0 0.00051259686
treated O 0 0.00053913344
for O 0 0.0003574348
2 O 0 0.00044256236
years O 0 0.0005333239
or O 0 0.00038735164
more O 0 0.00055505417
, O 0 0.00063332455
and O 0 0.0004943136
experience O 0 0.0010603509
with O 0 0.0007400442
simvastatin B-Chemical 1 0.999967
includes O 0 0.0005656231
over O 0 0.00032737013
3500 O 0 0.001524766
patients O 0 0.0009838562
, O 0 0.0006133655
of O 0 0.00057788106
whom O 0 0.0015179061
350 O 0 0.0012662754
have O 0 0.00063973106
been O 0 0.00088995276
treated O 0 0.0011629597
for O 0 0.0010820085
18 O 0 0.0017321216
months O 0 0.0017567036
or O 0 0.0031183404
more O 0 0.0060746307
. O 0 0.0076545756

Lovastatin B-Chemical 1 0.9993498
has O 0 0.011901499
been O 0 0.00888097
marketed O 0 0.124114335
in O 0 0.005095777
the O 0 0.004835326
United O 0 0.007875588
States O 0 0.0076997597
for O 0 0.0030961067
over O 0 0.003166572
6 O 0 0.004493059
months O 0 0.005844749
. O 0 0.009014101

Both O 0 0.0089310305
agents O 0 0.026989039
show O 0 0.0032923047
substantial O 0 0.003163813
clinical O 0 0.008313403
efficacy O 0 0.0067040916
, O 0 0.0019285475
with O 0 0.0010035016
reductions O 0 0.0010026686
in O 0 0.00060667645
total O 0 0.0008047873
cholesterol B-Chemical 1 0.9974999
of O 0 0.0009318242
over O 0 0.00042302534
30 O 0 0.0004881383
% O 0 0.0007109301
and O 0 0.00079062843
in O 0 0.0011366778
LDL O 0 0.99981433
- O 0 0.011067066
cholesterol B-Chemical 1 0.9982798
of O 0 0.0022481927
40 O 0 0.0020970611
% O 0 0.0023506843
in O 0 0.0023776137
clinical O 0 0.010394552
studies O 0 0.006948887
. O 0 0.008093091

Modest O 0 0.6245707
increases O 0 0.010799232
in O 0 0.009651898
HDL O 0 0.9995553
- O 0 0.036005825
cholesterol B-Chemical 1 0.9977829
levels O 0 0.003202591
of O 0 0.0031008509
about O 0 0.0025339068
10 O 0 0.0029261194
% O 0 0.003684613
are O 0 0.0038054122
also O 0 0.0049958047
reported O 0 0.008902625
. O 0 0.0102982195

Clinical O 0 0.042560425
tolerability O 0 0.09519024
of O 0 0.0047907867
both O 0 0.002926366
agents O 0 0.11637554
has O 0 0.0017591503
been O 0 0.0014471165
good O 0 0.0014451294
, O 0 0.0011498585
with O 0 0.00069538417
fewer O 0 0.0006927377
than O 0 0.00047447035
3 O 0 0.0005492258
% O 0 0.0006157675
of O 0 0.0006283629
patients O 0 0.0015353259
withdrawn O 0 0.0023185518
from O 0 0.00086672103
treatment O 0 0.0013909295
because O 0 0.0010996803
of O 0 0.002323663
clinical O 0 0.052102014
adverse O 0 0.9735217
experiences O 0 0.12269055
. O 0 0.009683377

Ophthalmological O 0 0.06753351
examinations O 0 0.008488333
in O 0 0.0036402682
over O 0 0.002198693
1100 O 0 0.004583501
patients O 0 0.0024713683
treated O 0 0.001376973
with O 0 0.0010088988
one O 0 0.0007016098
or O 0 0.0006410707
the O 0 0.00060022395
other O 0 0.00065275555
agent O 0 0.043554153
have O 0 0.0004913035
revealed O 0 0.00048722464
no O 0 0.00035488114
evidence O 0 0.000511215
of O 0 0.00070610776
significant O 0 0.00076930365
short O 0 0.0006461235
term O 0 0.0009013914
( O 0 0.0014578957
up O 0 0.00092952396
to O 0 0.0010692914
2 O 0 0.0016099811
years O 0 0.0028754359
) O 0 0.004955751
cataractogenic O 0 0.70551944
potential O 0 0.010877874
. O 0 0.009199847

One O 0 0.011143814
to O 0 0.005569006
2 O 0 0.0040297206
% O 0 0.0032916977
of O 0 0.002415204
patients O 0 0.0033882759
have O 0 0.0014536238
elevations O 0 0.10713421
of O 0 0.0019655556
serum O 0 0.40957722
transaminases O 0 0.9997348
to O 0 0.0010006317
greater O 0 0.000812016
than O 0 0.00063751295
3 O 0 0.0007881859
times O 0 0.0007223991
the O 0 0.001181723
upper O 0 0.0029903813
limit O 0 0.003321588
of O 0 0.004751331
normal O 0 0.011025028
. O 0 0.0086558275

These O 0 0.015427639
episodes O 0 0.11523256
are O 0 0.009731857
asymptomatic O 0 0.038037274
and O 0 0.0076247416
reversible O 0 0.15797205
when O 0 0.005404677
therapy O 0 0.027157975
is O 0 0.009034608
discontinued O 0 0.11663818
. O 0 0.012558407

Minor O 0 0.7466781
elevations O 0 0.25338995
of O 0 0.013613394
creatine B-Chemical 1 0.9997515
kinase O 0 0.58218735
levels O 0 0.0035408512
are O 0 0.0029148364
reported O 0 0.002722383
in O 0 0.0022201668
about O 0 0.0023343496
5 O 0 0.002783568
% O 0 0.0041374597
of O 0 0.005331502
patients O 0 0.015277812
. O 0 0.010175241

Myopathy B-Disease 0 0.994128
, O 0 0.00912234
associated O 0 0.004322808
in O 0 0.0025210117
some O 0 0.002242246
cases O 0 0.0035464677
with O 0 0.0033874277
myoglobinuria B-Disease 0 0.99999225
, O 0 0.0034566412
and O 0 0.0010372922
in O 0 0.0006351951
2 O 0 0.0005862966
cases O 0 0.0007945763
with O 0 0.0006060135
transient O 0 0.052541018
renal B-Disease 0 0.9953376
failure I-Disease 0 0.91333896
, O 0 0.0016816924
has O 0 0.00047650043
been O 0 0.0005613519
rarely O 0 0.00080823613
reported O 0 0.0008555786
with O 0 0.0012570901
lovastatin B-Chemical 1 0.9999827
, O 0 0.0021002125
especially O 0 0.00087638455
in O 0 0.00062702765
patients O 0 0.002784467
concomitantly O 0 0.010764857
treated O 0 0.0022494262
with O 0 0.0048185186
cyclosporin B-Chemical 0 0.9999831
, O 0 0.12378388
gemfibrozil B-Chemical 0 0.99997413
or O 0 0.041855477
niacin B-Chemical 0 0.99994445
. O 0 0.015681598

Lovastatin B-Chemical 1 0.999635
and O 0 0.017114282
simvastatin B-Chemical 1 0.9998167
are O 0 0.0046882755
both O 0 0.0023675987
effective O 0 0.0021970302
and O 0 0.0018336007
well O 0 0.0015577578
- O 0 0.0029031495
tolerated O 0 0.024809716
agents O 0 0.13297749
for O 0 0.0013591121
lowering O 0 0.061512593
elevated O 0 0.009646299
levels O 0 0.002842465
of O 0 0.0063004713
serum O 0 0.85872746
cholesterol B-Chemical 1 0.9995172
. O 0 0.014600156

As O 0 0.006580856
wider O 0 0.005587673
use O 0 0.0034609293
confirms O 0 0.0021823966
their O 0 0.0020434065
safety O 0 0.0028192436
profile O 0 0.0016854078
, O 0 0.001538312
they O 0 0.00084787747
will O 0 0.00064437336
gain O 0 0.0011289353
increasing O 0 0.00087160856
importance O 0 0.0006715321
in O 0 0.0007496471
the O 0 0.0009138924
therapeutic O 0 0.009647409
approach O 0 0.0021482888
to O 0 0.0024561386
hypercholesterolaemia B-Disease 0 0.9999293
and O 0 0.0059907134
its O 0 0.010067346
consequences O 0 0.031898744
. O 0 0.009345144

Hepatic O 0 0.7844561
reactions O 0 0.069275744
associated O 0 0.015799925
with O 0 0.016412266
ketoconazole B-Chemical 1 0.9998338
in O 0 0.014030997
the O 0 0.013304057
United O 0 0.027409617
Kingdom O 0 0.069325365
. O 0 0.015834292

Ketoconazole B-Chemical 0 0.9989759
was O 0 0.017546639
introduced O 0 0.010993079
in O 0 0.010426885
the O 0 0.011183809
United O 0 0.018800216
Kingdom O 0 0.028273458
in O 0 0.012321423
1981 O 0 0.03234372
. O 0 0.015978288

By O 0 0.012851419
November O 0 0.008386955
1984 O 0 0.008591689
the O 0 0.0032498594
Committee O 0 0.003804966
on O 0 0.001612983
Safety O 0 0.019347899
of O 0 0.0016833671
Medicines O 0 0.021178545
had O 0 0.0007655742
received O 0 0.00070924306
82 O 0 0.0012035382
reports O 0 0.0007969406
of O 0 0.0009162745
possible O 0 0.0015124818
hepatotoxicity B-Disease 2 0.99998856
associated O 0 0.0021860276
with O 0 0.0015083216
the O 0 0.0015901476
drug O 0 0.5570796
, O 0 0.0031285107
including O 0 0.0027140365
five O 0 0.0038541385
deaths B-Disease 2 0.83138317
. O 0 0.009397157

An O 0 0.011158258
analysis O 0 0.0060995216
of O 0 0.004112362
the O 0 0.002824503
75 O 0 0.0026917218
cases O 0 0.0021056721
that O 0 0.0010675738
had O 0 0.0009818967
been O 0 0.00088085886
adequately O 0 0.0007638758
followed O 0 0.00045892975
up O 0 0.00049158314
suggested O 0 0.00043529723
that O 0 0.00042442736
16 O 0 0.0006106805
, O 0 0.000612865
including O 0 0.00046058092
three O 0 0.0005015205
deaths B-Disease 2 0.6722189
, O 0 0.0011866705
were O 0 0.00079883006
probably O 0 0.0011686806
related O 0 0.00082011416
to O 0 0.0012124284
treatment O 0 0.0025654838
with O 0 0.0029395183
the O 0 0.004408855
drug O 0 0.7599096
. O 0 0.00922815

Of O 0 0.010399011
the O 0 0.0056993105
remainder O 0 0.005385239
, O 0 0.0036167398
48 O 0 0.0018409089
were O 0 0.0014946159
possibly O 0 0.0018859342
related O 0 0.00088824105
to O 0 0.0009191757
treatment O 0 0.0015853991
, O 0 0.0012036568
five O 0 0.0006022177
were O 0 0.00079118094
unlikely O 0 0.0007503719
to O 0 0.000828724
be O 0 0.0011333595
so O 0 0.0012504499
, O 0 0.0019923088
and O 0 0.0020890676
six O 0 0.0021619166
were O 0 0.0045423754
unclassifiable O 0 0.4702105
. O 0 0.009652619

The O 0 0.006709006
mean O 0 0.0046900865
age O 0 0.004854016
of O 0 0.0029457577
patients O 0 0.0035503982
in O 0 0.0014652879
the O 0 0.0012082097
16 O 0 0.0011005349
probable O 0 0.0031474512
cases O 0 0.0017696096
was O 0 0.000977693
57 O 0 0.0016503485
. O 0 0.00066432194
9 O 0 0.0009107504
, O 0 0.0012068006
with O 0 0.0016435775
hepatotoxicity B-Disease 2 0.99996996
being O 0 0.004045225
more O 0 0.0028852345
common O 0 0.0042619887
in O 0 0.004942026
women O 0 0.20093508
. O 0 0.009224891

The O 0 0.0075749247
average O 0 0.0048380005
duration O 0 0.00439442
of O 0 0.0038254936
treatment O 0 0.0037102164
before O 0 0.0018658014
the O 0 0.0023473685
onset O 0 0.006660361
of O 0 0.0053834156
jaundice B-Disease 2 0.99956745
was O 0 0.0064996863
61 O 0 0.010256101
days O 0 0.005963471
. O 0 0.0088883145

None O 0 0.013894241
of O 0 0.0068475413
these O 0 0.0048823445
well O 0 0.0032559265
validated O 0 0.0027785457
cases O 0 0.003006009
occurred O 0 0.001926676
within O 0 0.0011967871
the O 0 0.0015715611
first O 0 0.0015965012
10 O 0 0.002139176
days O 0 0.0021949753
after O 0 0.0027978814
treatment O 0 0.008138762
. O 0 0.009214924

The O 0 0.007431042
results O 0 0.005564909
of O 0 0.0050109643
serum O 0 0.10486758
liver O 0 0.86992854
function O 0 0.0031476214
tests O 0 0.0044788434
suggested O 0 0.0021412016
hepatocellular B-Disease 0 0.9999826
injury I-Disease 0 0.99914324
in O 0 0.0015677864
10 O 0 0.0012799466
( O 0 0.0013113105
63 O 0 0.001588927
% O 0 0.0012124805
) O 0 0.0016704481
; O 0 0.0014681518
the O 0 0.0010234953
rest O 0 0.0016659255
showed O 0 0.0016637999
a O 0 0.0034583057
mixed O 0 0.007608501
pattern O 0 0.0063647134
. O 0 0.009163546

In O 0 0.0082876235
contrast O 0 0.006072598
, O 0 0.0048560626
the O 0 0.002807853
results O 0 0.0023264296
of O 0 0.0024634781
histological O 0 0.13729323
examination O 0 0.003013091
of O 0 0.0022404408
the O 0 0.0022067209
liver O 0 0.8346525
often O 0 0.0044608964
showed O 0 0.002660868
evidence O 0 0.0044457093
of O 0 0.014819363
cholestasis B-Disease 2 0.9999273
. O 0 0.018895552

The O 0 0.008680507
characteristics O 0 0.0065165227
of O 0 0.0053985748
the O 0 0.00405922
48 O 0 0.003146739
patients O 0 0.0042161527
in O 0 0.0027691291
the O 0 0.0030128418
possible O 0 0.003703714
cases O 0 0.006929484
were O 0 0.0062373537
similar O 0 0.006431618
. O 0 0.010357339

Allergic O 0 0.9834216
manifestations O 0 0.77956885
such O 0 0.012944399
as O 0 0.014527883
rash B-Disease 2 0.99927884
and O 0 0.0276703
eosinophilia B-Disease 2 0.9991054
were O 0 0.02156497
rare O 0 0.1352737
. O 0 0.019117836

Hepatitis B-Disease 0 0.9983797
was O 0 0.0076952395
usually O 0 0.0061090626
reversible O 0 0.10556302
when O 0 0.0018554667
treatment O 0 0.002502094
was O 0 0.001386693
stopped O 0 0.002502856
, O 0 0.0011743483
with O 0 0.000665271
the O 0 0.000560899
results O 0 0.00059809163
of O 0 0.00087386544
liver O 0 0.82618946
function O 0 0.0009824071
tests O 0 0.0015127741
returning O 0 0.0011354916
to O 0 0.00049019576
normal O 0 0.0008834389
after O 0 0.00042024997
an O 0 0.0008673088
average O 0 0.0007230007
of O 0 0.0015143753
3 O 0 0.0018253408
. O 0 0.0018537103
1 O 0 0.0033514868
months O 0 0.0039327615
. O 0 0.006542333

In O 0 0.006652815
two O 0 0.0040219985
of O 0 0.0034131294
the O 0 0.0023476959
three O 0 0.0015614302
deaths B-Disease 2 0.5576603
probably O 0 0.0027683552
associated O 0 0.0016868624
with O 0 0.0018670576
ketoconazole B-Chemical 1 0.9999893
treatment O 0 0.0035428535
the O 0 0.00085103017
drug O 0 0.41344735
had O 0 0.0006566306
been O 0 0.0005834052
continued O 0 0.00051422993
after O 0 0.00033743982
the O 0 0.00058831065
onset O 0 0.0024932555
of O 0 0.002003091
jaundice B-Disease 2 0.9997509
and O 0 0.0037526104
other O 0 0.004209819
symptoms O 0 0.9575445
of O 0 0.038234316
hepatitis B-Disease 2 0.99991107
. O 0 0.024376886

Clinical O 0 0.035802282
and O 0 0.0063678375
biochemical O 0 0.009590012
monitoring O 0 0.003226
at O 0 0.0016227191
regular O 0 0.0016354045
intervals O 0 0.0010134364
for O 0 0.000745773
evidence O 0 0.0009817479
of O 0 0.0023965735
hepatitis B-Disease 2 0.9999709
is O 0 0.001744879
advised O 0 0.0024749765
during O 0 0.0005258509
long O 0 0.0006855312
term O 0 0.00073818397
treatment O 0 0.0016964612
with O 0 0.002111622
ketoconazole B-Chemical 1 0.9999814
to O 0 0.0017442304
prevent O 0 0.0022165026
possible O 0 0.003409098
serious O 0 0.8377578
hepatic B-Disease 2 0.9992113
injury I-Disease 2 0.99882025
. O 0 0.014389638

Glyburide B-Chemical 0 0.99665314
- O 0 0.09115237
induced O 0 0.076695785
hepatitis B-Disease 2 0.9984156
. O 0 0.07379874

Drug O 0 0.9745049
- O 0 0.0203743
induced O 0 0.011307633
hepatotoxicity B-Disease 2 0.99994624
, O 0 0.008601272
although O 0 0.0027708905
common O 0 0.0036375332
, O 0 0.0032833104
has O 0 0.0018387344
been O 0 0.0022382245
reported O 0 0.0026635448
only O 0 0.0028918886
infrequently O 0 0.010038228
with O 0 0.009195006
sulfonylureas B-Chemical 0 0.9995616
. O 0 0.012236726

For O 0 0.010461122
glyburide B-Chemical 0 0.9990088
, O 0 0.0074431393
a O 0 0.004640894
second O 0 0.0035567414
- O 0 0.0043146103
generation O 0 0.0036641299
sulfonylurea B-Chemical 0 0.99963737
, O 0 0.002692855
only O 0 0.001413186
two O 0 0.0014069456
brief O 0 0.0022612186
reports O 0 0.0037374615
of O 0 0.008156881
hepatotoxicity B-Disease 2 0.9999584
exist O 0 0.013170908
. O 0 0.010881003

Two O 0 0.00965908
patients O 0 0.008885975
with O 0 0.0048845042
type B-Disease 0 0.00476601
II I-Disease 0 0.2300497
diabetes I-Disease 2 0.9987884
mellitus I-Disease 0 0.9996611
developed O 0 0.0146171115
an O 0 0.016212406
acute B-Disease 0 0.99967635
hepatitis I-Disease 2 0.99999607
- I-Disease 0 0.10346304
like I-Disease 0 0.0024036579
syndrome I-Disease 0 0.8778263
soon O 0 0.0022687379
after O 0 0.0011516112
initiation O 0 0.0024832094
of O 0 0.005917943
glyburide B-Chemical 0 0.9998442
therapy O 0 0.1965512
. O 0 0.01037496

There O 0 0.008509678
was O 0 0.0050954022
no O 0 0.0031048069
serologic O 0 0.024831068
evidence O 0 0.0026535566
of O 0 0.003177763
viral B-Disease 0 0.4211909
infection I-Disease 2 0.9329717
, O 0 0.0030304615
and O 0 0.0012453059
a O 0 0.0013651112
liver O 0 0.6967084
biopsy O 0 0.0094226515
sample O 0 0.0009831369
showed O 0 0.0006440182
a O 0 0.0010985814
histologic O 0 0.16882752
pattern O 0 0.0011638546
consistent O 0 0.0013528409
with O 0 0.002479125
drug B-Disease 0 0.88492036
- I-Disease 0 0.020672893
induced I-Disease 0 0.01796176
hepatitis I-Disease 2 0.99989855
. O 0 0.023245828

Both O 0 0.008813467
patients O 0 0.007387791
recovered O 0 0.0035805677
quickly O 0 0.0037826318
after O 0 0.001553809
stopping O 0 0.0139932465
glyburide B-Chemical 0 0.99984086
therapy O 0 0.019691525
and O 0 0.0013171027
have O 0 0.000792581
remained O 0 0.00090406067
well O 0 0.0007227324
for O 0 0.0007016751
a O 0 0.0012587574
follow O 0 0.0010132988
- O 0 0.0018326725
up O 0 0.0013226337
period O 0 0.0015609352
of O 0 0.0028589529
1 O 0 0.0044666817
year O 0 0.005561978
. O 0 0.007736874

Glyburide B-Chemical 0 0.99773526
can O 0 0.0097593535
produce O 0 0.007079683
an O 0 0.012373478
acute B-Disease 0 0.9986694
hepatitis I-Disease 2 0.99997437
- I-Disease 0 0.1312393
like I-Disease 0 0.008019968
illness I-Disease 0 0.9687061
in O 0 0.0065567284
some O 0 0.008725301
persons O 0 0.033339266
. O 0 0.012071953

Intracranial O 0 0.6146956
pressure O 0 0.04662252
increases O 0 0.011946056
during O 0 0.010977527
alfentanil B-Chemical 1 0.9995987
- O 0 0.033595502
induced O 0 0.020990591
rigidity B-Disease 2 0.99034053
. O 0 0.022704666

Intracranial O 0 0.7500364
pressure O 0 0.1597153
( O 0 0.011734642
ICP O 0 0.95306367
) O 0 0.006539742
was O 0 0.002913851
measured O 0 0.0021303024
during O 0 0.002509399
alfentanil B-Chemical 1 0.999861
- O 0 0.010206062
induced O 0 0.0060480237
rigidity B-Disease 2 0.9848395
in O 0 0.007534151
rats O 0 0.027205547
. O 0 0.0113068065

Ten O 0 0.013179841
rats O 0 0.009384186
had O 0 0.004802422
arterial O 0 0.2601462
, O 0 0.0041068564
central O 0 0.0044740858
venous O 0 0.58519346
( O 0 0.0047483533
CVP O 0 0.9904041
) O 0 0.0038404143
, O 0 0.0021972812
and O 0 0.002192969
subdural O 0 0.99641293
cannulae O 0 0.009424966
inserted O 0 0.0023971265
under O 0 0.003132847
halothane B-Chemical 1 0.99893934
anesthesia O 0 0.46414068
. O 0 0.011079896

The O 0 0.0074976366
animals O 0 0.0051476755
were O 0 0.0039751483
mechanically O 0 0.006474084
ventilated O 0 0.0043688654
to O 0 0.0015952855
achieve O 0 0.0012087858
normocarbia O 0 0.11510775
( O 0 0.0022782984
PCO2 O 0 0.94319844
= O 0 0.0015116667
42 O 0 0.0012449151
+ O 0 0.0010639224
/ O 0 0.0021254143
- O 0 0.001387165
1 O 0 0.0009480163
mmHg O 0 0.002940185
, O 0 0.001225463
mean O 0 0.0012656671
+ O 0 0.0024425131
/ O 0 0.0069207014
- O 0 0.00747666
SE O 2 0.87596357
) O 0 0.012022887
. O 0 0.008763867

Following O 0 0.009541069
instrumentation O 0 0.019125862
, O 0 0.0069712414
halothane B-Chemical 1 0.99815
was O 0 0.002990009
discontinued O 0 0.017273705
and O 0 0.0024879859
alfentanil B-Chemical 1 0.9999285
( O 0 0.0033393912
125 O 0 0.012252891
mu O 0 0.14151457
/ O 0 0.0028031708
kg O 0 0.005699078
) O 0 0.0017759688
administered O 0 0.0014283954
iv O 0 0.0031414782
during O 0 0.0012126362
emergence O 0 0.003083717
from O 0 0.0040746727
halothane B-Chemical 1 0.9993994
anesthesia O 0 0.5434929
. O 0 0.010094255

In O 0 0.0069035767
the O 0 0.0046156147
five O 0 0.0027925542
rats O 0 0.00378357
that O 0 0.0017351535
developed O 0 0.0028833172
somatic B-Disease 0 0.36615887
rigidity I-Disease 2 0.99925226
, O 0 0.0069854306
ICP O 0 0.99046385
and O 0 0.001483418
CVP O 0 0.9905344
increased O 0 0.0008209093
significantly O 0 0.00070234004
above O 0 0.00041884917
baseline O 0 0.0007592675
( O 0 0.0009985522
delta O 0 0.06756198
ICP O 0 0.9687937
7 O 0 0.0005310921
. O 0 0.00032952728
5 O 0 0.00038726343
+ O 0 0.00054899364
/ O 0 0.0013793848
- O 0 0.0007990379
1 O 0 0.00044514434
. O 0 0.00030548696
0 O 0 0.00052384235
mmHg O 0 0.0019388666
, O 0 0.00065118127
delta O 0 0.014323479
CVP O 0 0.9558541
5 O 0 0.0005552864
. O 0 0.00047036706
9 O 0 0.00072241353
+ O 0 0.00095019984
/ O 0 0.0022411826
- O 0 0.001788427
1 O 0 0.001413863
. O 0 0.0013728773
3 O 0 0.0023325647
mmHg O 0 0.009231212
) O 0 0.0071191494
. O 0 0.006924885

These O 0 0.0122914165
variables O 0 0.009749276
returned O 0 0.006070734
to O 0 0.0044819377
baseline O 0 0.004599667
when O 0 0.0039511337
rigidity B-Disease 2 0.93032587
was O 0 0.0062311236
abolished O 0 0.009445101
with O 0 0.011893069
metocurine B-Chemical 0 0.9991197
. O 0 0.015413166

In O 0 0.0081319325
five O 0 0.0050003286
rats O 0 0.005972339
that O 0 0.0028928474
did O 0 0.0025076964
not O 0 0.0021263952
become O 0 0.0024283933
rigid O 0 0.0033489512
, O 0 0.0033530612
ICP O 0 0.9620838
and O 0 0.0028328272
CVP O 0 0.9750244
did O 0 0.0019828368
not O 0 0.002213971
change O 0 0.0031785574
following O 0 0.0054983227
alfentanil B-Chemical 1 0.9997365
. O 0 0.011611243

These O 0 0.008320514
observations O 0 0.0056870817
suggest O 0 0.0029943944
that O 0 0.0026915988
rigidity B-Disease 2 0.92366403
should O 0 0.0012939211
be O 0 0.0013208367
prevented O 0 0.002030871
when O 0 0.000894166
alfentanil B-Chemical 1 0.9999602
, O 0 0.0019779683
and O 0 0.0009894058
, O 0 0.0010098553
presumably O 0 0.0015591817
, O 0 0.00088832027
other O 0 0.00076653674
opiates O 0 0.9998253
, O 0 0.0013348591
are O 0 0.0006253735
used O 0 0.00050216384
in O 0 0.00052973826
the O 0 0.00070344633
anesthetic O 0 0.19110978
management O 0 0.0024757653
of O 0 0.0022448164
patients O 0 0.011824198
with O 0 0.005428411
ICP O 0 0.99274904
problems O 0 0.14767618
. O 0 0.009511141

Verapamil B-Chemical 1 0.9997904
withdrawal O 0 0.89397925
as O 0 0.004709765
a O 0 0.0036559904
possible O 0 0.0024008318
cause O 0 0.005401341
of O 0 0.0048342478
myocardial B-Disease 0 0.9999329
infarction I-Disease 2 0.9999912
in O 0 0.0024885011
a O 0 0.004016803
hypertensive B-Disease 2 0.9991424
woman O 0 0.0477226
with O 0 0.0026888202
a O 0 0.003986757
normal O 0 0.007212154
coronary O 0 0.8899191
angiogram O 0 0.777129
. O 0 0.010098043

Verapamil B-Chemical 1 0.99959487
is O 0 0.011620012
an O 0 0.009237309
effective O 0 0.0067327046
and O 0 0.0064070807
relatively O 0 0.0069408
- O 0 0.009404794
safe O 0 0.015054778
antihypertensive O 0 0.99574125
drug O 0 0.9027146
. O 0 0.01575455

Serious O 0 0.6255598
adverse O 0 0.845177
effects O 0 0.009231988
are O 0 0.0037853175
uncommon O 0 0.016937591
and O 0 0.0020776473
mainly O 0 0.0020407059
have O 0 0.0009978546
been O 0 0.0008990621
related O 0 0.00053164875
to O 0 0.00058661465
the O 0 0.0007990036
depression B-Disease 2 0.9975504
of O 0 0.0011655731
cardiac O 0 0.815299
contractility O 0 0.9742046
and O 0 0.0009260617
conduction O 0 0.13386677
, O 0 0.00074539013
especially O 0 0.0005540214
when O 0 0.0003855318
the O 0 0.0006085002
drug O 0 0.24439183
is O 0 0.000971972
combined O 0 0.0017250904
with O 0 0.0024470447
beta O 0 0.7293873
- O 0 0.00899628
blocking O 0 0.017873114
agents O 0 0.55508846
. O 0 0.009949243

We O 0 0.007946124
report O 0 0.00726275
a O 0 0.0044198954
case O 0 0.0028677406
in O 0 0.002186063
which O 0 0.0036339436
myocardial B-Disease 0 0.9998764
infarction I-Disease 2 0.9999913
coincided O 0 0.0042279805
with O 0 0.0009798285
the O 0 0.00070850935
introduction O 0 0.0006631024
of O 0 0.0012570275
captopril B-Chemical 1 0.99996936
and O 0 0.0011575471
the O 0 0.0008130489
withdrawal O 0 0.77472144
of O 0 0.0024197395
verapamil B-Chemical 1 0.9999833
in O 0 0.0011565941
a O 0 0.0016387096
previously O 0 0.0014750795
asymptomatic O 0 0.12073375
woman O 0 0.0803937
with O 0 0.005957894
severe O 0 0.91582507
hypertension B-Disease 2 0.9998692
. O 0 0.014211418

Possible O 0 0.0239991
mechanisms O 0 0.0074853157
that O 0 0.0037188593
involve O 0 0.003430223
a O 0 0.0054661194
verapamil B-Chemical 1 0.9999738
- O 0 0.00673502
related O 0 0.0009285109
increase O 0 0.0007676793
in O 0 0.00083607365
platelet O 0 0.8890161
and O 0 0.0015132884
/ O 0 0.0030193946
or O 0 0.0008847778
vascular O 0 0.78222954
alpha O 0 0.48297033
2 O 0 0.0019054397
- O 0 0.003916245
adrenoreceptor O 0 0.9994141
affinity O 0 0.006787926
for O 0 0.0027085321
catecholamines B-Chemical 1 0.99933773
are O 0 0.005300796
discussed O 0 0.0054919175
. O 0 0.008285405

Haemolytic B-Disease 0 0.9693879
- I-Disease 0 0.04288075
uraemic I-Disease 0 0.9972717
syndrome I-Disease 0 0.9497781
after O 0 0.009506963
treatment O 0 0.017020527
with O 0 0.019517528
metronidazole B-Chemical 1 0.9989729
. O 0 0.022816356

This O 0 0.010510007
paper O 0 0.0066060233
describes O 0 0.004495276
the O 0 0.002724174
clinical O 0 0.0043079145
features O 0 0.0026120672
of O 0 0.001632348
six O 0 0.0009377112
children O 0 0.0019988576
who O 0 0.0018400353
developed O 0 0.0015238784
the O 0 0.0014813485
haemolytic B-Disease 0 0.9978765
- I-Disease 0 0.04906965
uraemic I-Disease 0 0.9997135
syndrome I-Disease 0 0.9678822
after O 0 0.0020077445
treatment O 0 0.0070851985
with O 0 0.009437788
metronidazole B-Chemical 1 0.99943143
. O 0 0.011805542

These O 0 0.010096413
children O 0 0.008414729
were O 0 0.004468796
older O 0 0.005508783
and O 0 0.0024569703
were O 0 0.001724185
more O 0 0.0014478167
likely O 0 0.0010205567
to O 0 0.00083626475
have O 0 0.00074778846
undergone O 0 0.0008177068
recent O 0 0.0010318089
bowel O 0 0.7936358
surgery O 0 0.0040215957
than O 0 0.0009224267
are O 0 0.0013548989
other O 0 0.0016083736
children O 0 0.003772756
with O 0 0.0029168422
this O 0 0.0040101507
condition O 0 0.011062745
. O 0 0.008807894

While O 0 0.007494787
the O 0 0.004941968
involvement O 0 0.0052686683
of O 0 0.003695777
metronidazole B-Chemical 1 0.9987556
in O 0 0.0016996281
the O 0 0.0012875979
aetiology O 0 0.16869795
of O 0 0.0015853886
the O 0 0.0014000501
haemolytic B-Disease 0 0.9991053
- I-Disease 0 0.053325366
uraemic I-Disease 0 0.9998356
syndrome I-Disease 0 0.97756815
is O 0 0.0008859256
not O 0 0.0005229463
established O 0 0.0007375288
firmly O 0 0.0010530675
, O 0 0.0006282342
the O 0 0.0003593385
action O 0 0.001131503
of O 0 0.00047418234
this O 0 0.00044019317
drug O 0 0.3645738
in O 0 0.0004822097
sensitizing O 0 0.09984642
tissues O 0 0.011958851
to O 0 0.00074192754
oxidation O 0 0.9675945
injury O 0 0.9666435
and O 0 0.00077665335
the O 0 0.0004787527
reported O 0 0.0005739658
evidence O 0 0.00046947345
of O 0 0.000937269
oxidation O 0 0.9290397
changes O 0 0.0008889714
in O 0 0.00046364038
the O 0 0.00066894584
haemolytic B-Disease 0 0.9983242
- I-Disease 0 0.026083836
uraemic I-Disease 0 0.9997185
syndrome I-Disease 0 0.910237
suggest O 0 0.00040584567
a O 0 0.00077572843
possible O 0 0.00051449053
link O 0 0.00058041804
between O 0 0.00045902518
metronidazole B-Chemical 1 0.99926263
treatment O 0 0.0015863482
and O 0 0.0009762792
some O 0 0.0009574143
cases O 0 0.0017718956
of O 0 0.0017376975
the O 0 0.0025949848
haemolytic B-Disease 0 0.9982323
- I-Disease 0 0.15635324
uraemic I-Disease 0 0.9996853
syndrome I-Disease 0 0.9925057
. O 0 0.01415522

Adverse O 0 0.4709647
cardiac O 0 0.3220633
effects O 0 0.006948324
during O 0 0.0028897843
induction O 0 0.0031834107
chemotherapy O 0 0.68886906
treatment O 0 0.0055193515
with O 0 0.0035643543
cis B-Chemical 0 0.37524477
- I-Chemical 0 0.011818626
platin I-Chemical 0 0.9911675
and O 0 0.0049293777
5 B-Chemical 0 0.004487358
- I-Chemical 0 0.010840576
fluorouracil I-Chemical 0 0.9987931
. O 0 0.010429494

Survival O 0 0.040957425
for O 0 0.0058915825
patients O 0 0.0068973023
with O 0 0.0038376024
advanced O 0 0.03126174
head B-Disease 0 0.10432876
and I-Disease 0 0.0037435726
neck I-Disease 0 0.88258374
carcinoma I-Disease 2 0.9998636
and O 0 0.0068628513
esophageal B-Disease 0 0.9990969
carcinoma I-Disease 2 0.9999598
is O 0 0.0028677094
poor O 0 0.0072584604
with O 0 0.0023117696
radiotherapy O 0 0.6584485
and O 0 0.0038702474
/ O 0 0.008935779
or O 0 0.004739292
surgery O 0 0.014379382
. O 0 0.008883103

Obviously O 0 0.02046952
, O 0 0.013159268
there O 0 0.007211542
is O 0 0.0074276235
a O 0 0.008000209
need O 0 0.006537431
for O 0 0.0065599834
effective O 0 0.01152684
chemotherapy O 0 0.8761253
. O 0 0.017397122

In O 0 0.00744474
the O 0 0.0051411716
present O 0 0.0031864021
study O 0 0.0038336832
, O 0 0.003928705
cis B-Chemical 0 0.12489174
- I-Chemical 0 0.005293156
platin I-Chemical 0 0.9905778
( O 0 0.002478466
80 O 0 0.001356965
- O 0 0.0011025403
120 O 0 0.00070284924
mg O 0 0.11346034
/ O 0 0.0019796311
m2BSA O 0 0.015134913
) O 0 0.0010940093
and O 0 0.00062077626
5 B-Chemical 0 0.0005455256
- I-Chemical 0 0.0010096297
FU I-Chemical 0 0.6665793
( O 0 0.00075195375
1000 O 0 0.0008755616
mg O 0 0.09756631
/ O 0 0.0011431256
m2BSA O 0 0.0027664576
daily O 0 0.0006017642
as O 0 0.00031921483
a O 0 0.00040068917
continuous O 0 0.00036397294
infusion O 0 0.0014472301
during O 0 0.0002965395
5 O 0 0.00036669755
days O 0 0.00037135108
) O 0 0.0007928092
were O 0 0.00049360615
given O 0 0.00043154033
to O 0 0.00067661225
76 O 0 0.0016223538
patients O 0 0.001958258
before O 0 0.001263146
radiotherapy O 0 0.33107802
and O 0 0.005090696
surgery O 0 0.014499859
. O 0 0.008379983

The O 0 0.0072172564
aim O 0 0.005782908
of O 0 0.0041386606
the O 0 0.002907607
study O 0 0.0025344265
was O 0 0.0015962517
to O 0 0.001097847
clarify O 0 0.00073059276
the O 0 0.0010544765
incidence O 0 0.00681628
and O 0 0.0015754693
severity O 0 0.04582914
of O 0 0.0023195292
adverse O 0 0.97367066
cardiac O 0 0.7918924
effects O 0 0.004958338
to O 0 0.0028836655
this O 0 0.0040896055
treatment O 0 0.0101893945
. O 0 0.009080072

Before O 0 0.009735093
treatment O 0 0.0065824026
all O 0 0.0038714332
patients O 0 0.004616517
had O 0 0.0023304727
a O 0 0.002687138
cardiac O 0 0.19105418
evaluation O 0 0.0021227996
and O 0 0.001842962
during O 0 0.0013212053
treatment O 0 0.0025926384
serial O 0 0.004374782
ECG O 0 0.905013
recordings O 0 0.009716177
were O 0 0.0046505653
performed O 0 0.0058095865
. O 0 0.008568067

In O 0 0.008078543
the O 0 0.0061278585
pre O 0 0.011890963
- O 0 0.005156071
treatment O 0 0.0031529437
evaluation O 0 0.0025370903
, O 0 0.0023570973
signs O 0 0.09456852
of O 0 0.002360424
cardiovascular B-Disease 0 0.9972337
disease I-Disease 0 0.8929097
were O 0 0.0016104548
found O 0 0.0010154224
in O 0 0.0012563062
33 O 0 0.0024629273
patients O 0 0.0040171826
( O 0 0.003645661
43 O 0 0.005023275
% O 0 0.005412506
) O 0 0.008919364
. O 0 0.008008292

During O 0 0.008016436
treatment O 0 0.007936068
, O 0 0.006229541
adverse O 0 0.7609835
cardiac O 0 0.5147036
effects O 0 0.004372393
were O 0 0.0020583244
observed O 0 0.00132036
in O 0 0.0016888485
14 O 0 0.0022135337
patients O 0 0.004308272
( O 0 0.0040759575
18 O 0 0.0037450988
% O 0 0.00573906
) O 0 0.009584086
. O 0 0.008730652

The O 0 0.0071427412
mean O 0 0.005027887
age O 0 0.005119914
of O 0 0.0030825944
these O 0 0.0026075023
patients O 0 0.0035930972
was O 0 0.0015632914
the O 0 0.0012338355
same O 0 0.000949511
as O 0 0.0012406424
for O 0 0.0011205588
the O 0 0.0015062002
entire O 0 0.0016772425
group O 0 0.0030777405
, O 0 0.0046037515
64 O 0 0.006365666
years O 0 0.007709008
. O 0 0.007989098

The O 0 0.007879099
incidence O 0 0.012584179
of O 0 0.007538306
cardiotoxicity B-Disease 2 0.99993885
was O 0 0.0032213617
not O 0 0.0014996377
higher O 0 0.0010611933
in O 0 0.0008947581
patients O 0 0.00212555
with O 0 0.00094623823
signs O 0 0.17203487
of O 0 0.0016198849
cardiovascular B-Disease 0 0.99771607
disease I-Disease 0 0.85900426
than O 0 0.0007123159
in O 0 0.00073348935
those O 0 0.001061977
without O 0 0.0009000958
in O 0 0.0011258153
the O 0 0.0016577943
pre O 0 0.011924069
- O 0 0.0047494033
treatment O 0 0.0052468493
evaluation O 0 0.0073623047
. O 0 0.0085042715

The O 0 0.008025519
most O 0 0.0069257505
common O 0 0.0056955772
signs O 0 0.16849488
of O 0 0.0069079977
cardiotoxicity B-Disease 2 0.99996996
were O 0 0.004762142
chest B-Disease 0 0.93527097
pain I-Disease 2 0.99951196
, O 0 0.010363244
ST O 0 0.9779659
- O 0 0.0054581645
T O 0 0.5020164
wave O 0 0.01900807
changes O 0 0.0038550815
and O 0 0.005814571
atrial B-Disease 0 0.9958456
fibrillation I-Disease 0 0.99984074
. O 0 0.013536547

This O 0 0.012102483
was O 0 0.0065739425
followed O 0 0.0044791303
by O 0 0.005250392
ventricular B-Disease 0 0.9839717
fibrillation I-Disease 0 0.9998629
in O 0 0.0032582516
one O 0 0.002438408
patient O 0 0.004143718
and O 0 0.0055822222
sudden B-Disease 0 0.9995049
death I-Disease 2 0.99955827
in O 0 0.008099237
another O 0 0.011347315
. O 0 0.011009079

It O 0 0.009994586
is O 0 0.0050599887
concluded O 0 0.0035338337
that O 0 0.0022541152
patients O 0 0.003346795
on O 0 0.0013439448
5 B-Chemical 0 0.0014625248
- I-Chemical 0 0.002185468
FU I-Chemical 0 0.56626874
treatment O 0 0.0011559977
should O 0 0.00043218504
be O 0 0.00051713054
under O 0 0.00034593156
close O 0 0.00042833047
supervision O 0 0.0011985336
and O 0 0.0005323257
that O 0 0.00038131754
the O 0 0.00048843696
treatment O 0 0.00079224777
should O 0 0.0003824364
be O 0 0.0006364502
discontinued O 0 0.0040395083
if O 0 0.0007474116
chest B-Disease 0 0.7247916
pain I-Disease 2 0.99841595
or O 0 0.004274101
tachyarrhythmia B-Disease 0 0.9998343
is O 0 0.0050934423
observed O 0 0.0047909752
. O 0 0.008463199

Death B-Disease 0 0.841815
from O 0 0.021830797
chemotherapy O 0 0.42450285
in O 0 0.018033216
gestational B-Disease 0 0.37893358
trophoblastic I-Disease 0 0.9915093
disease I-Disease 0 0.9767022
. O 0 0.030749714

Multiple O 0 0.03175994
cytotoxic O 0 0.49829793
drug O 0 0.66313744
administration O 0 0.16813958
is O 0 0.002351411
the O 0 0.0015420979
generally O 0 0.001703907
accepted O 0 0.0022898559
treatment O 0 0.0014696821
of O 0 0.0013288516
patients O 0 0.0033540619
with O 0 0.0014187158
a O 0 0.0022135065
high O 0 0.0027456968
- O 0 0.004969823
risk O 0 0.06789768
stage O 0 0.009660402
of O 0 0.0129043
choriocarcinoma B-Disease 0 0.99965656
. O 0 0.015171135

Based O 0 0.011957965
on O 0 0.004450862
this O 0 0.0034879623
principle O 0 0.0032871515
a O 0 0.0029580265
27 O 0 0.0031300546
- O 0 0.0020501348
year O 0 0.0010069074
old O 0 0.001161924
woman O 0 0.01076633
, O 0 0.0011959518
classified O 0 0.00082464045
as O 0 0.0006705747
being O 0 0.000858413
in O 0 0.0005054235
the O 0 0.00058024994
high O 0 0.0010708628
- O 0 0.0018825495
risk O 0 0.037009947
group O 0 0.0014658566
( O 0 0.0018941828
Goldstein O 0 0.3223759
and O 0 0.00097651413
Berkowitz O 0 0.4315587
score O 0 0.0010660965
: O 0 0.0011746124
11 O 0 0.0010527752
) O 0 0.0014056615
, O 0 0.0011366393
was O 0 0.0009543215
treated O 0 0.0015220229
with O 0 0.0020998328
multiple O 0 0.007517772
cytotoxic O 0 0.916927
drugs O 0 0.9657996
. O 0 0.0104585895

The O 0 0.0075637205
multiple O 0 0.0072343457
drug O 0 0.18109217
schema O 0 0.0074449223
consisted O 0 0.0022444332
of O 0 0.0027848764
: O 0 0.0058781873
Etoposide B-Chemical 0 0.99990153
16 O 0 0.0019124155
. O 0 0.00093043316
213 O 0 0.029878268
, O 0 0.0021743372
Methotrexate B-Chemical 0 0.99982893
, O 0 0.0060202195
Cyclophosphamide B-Chemical 1 0.99993396
, O 0 0.007258866
Actomycin B-Chemical 0 0.95375913
- I-Chemical 0 0.012562511
D I-Chemical 0 0.9711239
, O 0 0.007438734
and O 0 0.010032563
Cisplatin B-Chemical 1 0.9997491
. O 0 0.011094101

On O 0 0.008262236
the O 0 0.0045522978
first O 0 0.0027995924
day O 0 0.0022147633
of O 0 0.0020556916
the O 0 0.001656999
schedule O 0 0.0021517938
, O 0 0.0017917757
moderate O 0 0.004188799
high O 0 0.0016191286
doses O 0 0.047372475
of O 0 0.0062295613
Methotrexate B-Chemical 0 0.9999522
, O 0 0.03702459
Etoposide B-Chemical 0 0.99994445
and O 0 0.010330298
Cyclophosphamide B-Chemical 1 0.9998685
were O 0 0.005649733
administered O 0 0.009515256
. O 0 0.007941299

Within O 0 0.005476994
8 O 0 0.004071808
hours O 0 0.0021476122
after O 0 0.001389342
initiation O 0 0.0014364135
of O 0 0.0013541841
therapy O 0 0.0034237436
the O 0 0.0008822065
patient O 0 0.0012650832
died O 0 0.0041026385
with O 0 0.0006954571
a O 0 0.00085765583
clinical O 0 0.002655339
picture O 0 0.0010055854
resembling O 0 0.0011621497
massive O 0 0.094685055
pulmonary B-Disease 0 0.99411184
obstruction I-Disease 0 0.9935027
due O 0 0.00078883814
to O 0 0.0008478655
choriocarcinomic O 0 0.024916893
tissue O 0 0.025733264
plugs O 0 0.016837193
, O 0 0.0021533617
probably O 0 0.0023388248
originating O 0 0.0033093796
from O 0 0.0032031534
the O 0 0.0047076554
uterus O 0 0.26667458
. O 0 0.009473687

Formation O 0 0.027004618
of O 0 0.0061487276
these O 0 0.004397989
plugs O 0 0.008392104
was O 0 0.002357567
probably O 0 0.0022355153
due O 0 0.0010320068
to O 0 0.000939695
extensive O 0 0.0013691663
tumor B-Disease 2 0.96813196
necrosis B-Disease 0 0.99869436
at O 0 0.0006005435
the O 0 0.00049430795
level O 0 0.000316894
of O 0 0.00047222633
the O 0 0.0004342853
walls O 0 0.013971428
of O 0 0.0005278657
the O 0 0.00042190577
major O 0 0.0006281354
uterine O 0 0.7215858
veins O 0 0.45976365
, O 0 0.0009409469
which O 0 0.0005557487
resulted O 0 0.0003477671
in O 0 0.0003499508
an O 0 0.00052459637
open O 0 0.00040884755
exchange O 0 0.0006008954
of O 0 0.00055379566
tumor B-Disease 2 0.8741219
plugs O 0 0.0065407455
to O 0 0.0004212668
the O 0 0.00048127156
vascular O 0 0.62231886
spaces O 0 0.0085065
; O 0 0.0012276547
decrease O 0 0.000436407
in O 0 0.00045165216
tumor B-Disease 2 0.86339957
tissue O 0 0.030679898
coherence O 0 0.04821295
secondary O 0 0.001957136
to O 0 0.0006472517
chemotherapy O 0 0.5073018
may O 0 0.00064680836
have O 0 0.0006055508
further O 0 0.000885485
contributed O 0 0.0015133158
to O 0 0.0010267323
the O 0 0.0014921713
formation O 0 0.004359395
of O 0 0.005299964
tumor B-Disease 2 0.9894968
emboli O 0 0.9972063
. O 0 0.012267212

In O 0 0.0071760113
view O 0 0.0059260954
of O 0 0.0036129118
the O 0 0.0023139843
close O 0 0.0015039186
time O 0 0.001057341
association O 0 0.00075780944
between O 0 0.00056422676
the O 0 0.000679792
start O 0 0.0005586679
of O 0 0.00076398643
chemotherapy O 0 0.5728849
and O 0 0.00083877944
the O 0 0.0006492018
acute O 0 0.88038874
onset O 0 0.008931456
of O 0 0.000971553
massive O 0 0.17862232
embolism B-Disease 0 0.99987674
other O 0 0.000810723
explanations O 0 0.00072533503
, O 0 0.00086967467
such O 0 0.000606544
as O 0 0.0009596097
spontaneous O 0 0.124870926
necrosis B-Disease 2 0.9987048
, O 0 0.002774511
must O 0 0.0011483753
be O 0 0.0018034565
considered O 0 0.0020876704
less O 0 0.0033343357
likely O 0 0.005211548
. O 0 0.007395869

Patients O 0 0.013696323
with O 0 0.006021703
large O 0 0.0055391113
pelvic B-Disease 0 0.8968173
tumor I-Disease 2 0.990404
loads O 0 0.008393861
are O 0 0.0020864925
, O 0 0.0016475352
according O 0 0.0008089982
to O 0 0.0006886947
existing O 0 0.00095254835
classifications O 0 0.0013856573
, O 0 0.0010648887
at O 0 0.00056890526
high O 0 0.0010172845
risk O 0 0.02115956
to O 0 0.001170874
die O 0 0.0035612194
and O 0 0.0019187242
to O 0 0.0019696879
develop O 0 0.0038650432
drug O 0 0.79380614
resistance O 0 0.054428756
. O 0 0.009319574

Notwithstanding O 0 0.010537336
these O 0 0.005685753
facts O 0 0.0072551696
our O 0 0.0025269766
findings O 0 0.0027782368
suggest O 0 0.0011211956
that O 0 0.00096258335
these O 0 0.0011878659
patients O 0 0.0023156195
might O 0 0.0005599113
benefit O 0 0.0011859906
from O 0 0.0006022749
relatively O 0 0.00079262984
mild O 0 0.24806629
initial O 0 0.00071756594
treatment O 0 0.0013881411
, O 0 0.00094184076
especially O 0 0.0007009676
true O 0 0.0007110161
for O 0 0.00056287675
patients O 0 0.0018316373
not O 0 0.000953296
previously O 0 0.0012666023
exposed O 0 0.0017269504
to O 0 0.0023464586
this O 0 0.004015218
drug O 0 0.7234129
. O 0 0.009249057

Close O 0 0.01954578
observation O 0 0.0052556046
of O 0 0.0040130103
the O 0 0.0027050595
response O 0 0.0026820658
status O 0 0.0024302562
both O 0 0.0012595281
clinically O 0 0.027431455
and O 0 0.0013169779
with O 0 0.0013713144
beta O 0 0.8500486
- O 0 0.006519663
hCG O 0 0.9565242
values O 0 0.00062352733
may O 0 0.00037538493
indicate O 0 0.0002918366
whether O 0 0.00022985665
and O 0 0.0004762811
when O 0 0.0003237746
more O 0 0.0005834542
agressive O 0 0.24986541
combination O 0 0.002183162
chemotherapy O 0 0.64931685
should O 0 0.0005422845
be O 0 0.00089496904
started O 0 0.0011841661
. O 0 0.0011100555
( O 0 0.0025413213
ABSTRACT O 0 0.010440746
TRUNCATED O 0 0.016095752
AT O 0 0.04773832
250 O 0 0.010357535
WORDS O 0 0.0215584
) O 0 0.030131098

Pulmonary O 0 0.25263128
shunt O 0 0.0325683
and O 0 0.008328296
cardiovascular O 0 0.9627432
responses O 0 0.009429704
to O 0 0.004877285
CPAP O 0 0.96117437
during O 0 0.0058086254
nitroprusside B-Chemical 1 0.99997985
- O 0 0.07578065
induced O 0 0.027570289
hypotension B-Disease 2 0.99986005
. O 0 0.017696252

The O 0 0.006436395
effects O 0 0.004850549
of O 0 0.0030804412
continuous O 0 0.0021131036
positive O 0 0.0018716913
airway O 0 0.1850274
pressure O 0 0.278217
( O 0 0.0029207836
CPAP O 0 0.9391414
) O 0 0.0014544879
on O 0 0.00044336886
cardiovascular O 0 0.9624066
dynamics O 0 0.0008437676
and O 0 0.0007568886
pulmonary O 0 0.83784366
shunt O 0 0.18565883
( O 0 0.001849276
QS O 0 0.40885934
/ O 0 0.009619441
QT O 0 0.9977849
) O 0 0.0011379421
were O 0 0.00038492
investigated O 0 0.0002902483
in O 0 0.0003424697
12 O 0 0.00028413007
dogs O 0 0.0006122144
before O 0 0.0002556418
and O 0 0.0005979839
during O 0 0.00061872794
sodium B-Chemical 1 0.9999716
nitroprusside I-Chemical 1 0.9999987
infusion O 0 0.06427256
that O 0 0.0005278466
decreased O 0 0.00082088856
mean O 0 0.0006362988
arterial O 0 0.32957727
blood O 0 0.012461988
pressure O 0 0.0394339
40 O 0 0.0017550454
- O 0 0.0022792253
50 O 0 0.0023724874
per O 0 0.0022008333
cent O 0 0.004629041
. O 0 0.007201059

Before O 0 0.01602732
nitroprusside B-Chemical 1 0.99987185
infusion O 0 0.13545354
, O 0 0.0042647263
5 O 0 0.0018779194
cm O 0 0.0041619614
H2O B-Chemical 1 0.919767
CPAP O 0 0.9001335
significantly O 0 0.001780127
, O 0 0.0015279608
P O 0 0.036736157
less O 0 0.000642975
than O 0 0.0004877065
. O 0 0.00052189024
05 O 0 0.058248762
, O 0 0.0005654562
decreased O 0 0.0005640304
arterial O 0 0.27423513
blood O 0 0.016107392
pressure O 0 0.08769208
, O 0 0.00081485533
but O 0 0.0004172211
did O 0 0.00034365527
not O 0 0.00036977677
significantly O 0 0.000593849
alter O 0 0.000504572
heart O 0 0.4603264
rate O 0 0.0007020028
, O 0 0.0010046498
cardiac O 0 0.27575824
output O 0 0.001363424
, O 0 0.0012660885
systemic O 0 0.82368815
vascular O 0 0.8996419
resistance O 0 0.025277741
, O 0 0.0032613596
or O 0 0.0030597155
QS O 0 0.6175706
/ O 0 0.0601214
QT O 0 0.99686545
. O 0 0.01005786

Ten O 0 0.013967867
cm O 0 0.016506078
H2O B-Chemical 1 0.90518683
CPAP O 0 0.9121967
before O 0 0.0029009157
nitroprusside B-Chemical 1 0.9999727
infusion O 0 0.05754182
produced O 0 0.0011871374
a O 0 0.0012109812
further O 0 0.0007656402
decrease B-Disease 0 0.00063921907
in I-Disease 0 0.00054681406
arterial I-Disease 0 0.37716627
blood I-Disease 0 0.016052417
pressure I-Disease 0 0.047297027
and O 0 0.00074565824
significantly O 0 0.00088828127
increased O 0 0.000981703
heart O 0 0.4597722
rate O 0 0.00094156805
and O 0 0.0013094996
decreased B-Disease 0 0.0033195678
cardiac I-Disease 0 0.55870944
output I-Disease 0 0.0057700262
and O 0 0.0038077703
QS O 0 0.6099811
/ O 0 0.05874235
QT O 0 0.996725
. O 0 0.010154304

Nitroprusside B-Chemical 0 0.9991435
caused O 0 0.007206635
significant O 0 0.0039076107
decreases B-Disease 0 0.0026422695
in I-Disease 0 0.0016739211
arterial I-Disease 0 0.3902121
blood I-Disease 0 0.025655057
pressure I-Disease 0 0.07545788
and O 0 0.0012468072
systemic O 0 0.8947733
vascular O 0 0.91861194
resistance O 0 0.011764995
and O 0 0.0008714407
increases O 0 0.00060814427
in O 0 0.00059248635
heart O 0 0.4617763
rate O 0 0.0008380009
, O 0 0.001067853
but O 0 0.00065189943
did O 0 0.00062131556
not O 0 0.0007425407
change O 0 0.0010949601
cardiac O 0 0.2364663
output O 0 0.002760917
or O 0 0.002984416
QS O 0 0.60949606
/ O 0 0.062228948
QT O 0 0.99690163
. O 0 0.010159525

Five O 0 0.015487253
cm O 0 0.019060258
H2O B-Chemical 1 0.9211849
CPAP O 0 0.9350586
during O 0 0.004662416
nitroprusside B-Chemical 1 0.9999583
did O 0 0.0025655937
not O 0 0.0016267225
further O 0 0.001452907
alter O 0 0.0012528462
any O 0 0.0012819933
of O 0 0.0018548259
the O 0 0.0019971575
above O 0 0.0022371272
- O 0 0.0045349346
mentioned O 0 0.003518762
variables O 0 0.009480357
. O 0 0.008717279

However O 0 0.01068068
, O 0 0.008006737
10 O 0 0.004768587
cm O 0 0.0076525914
H2O B-Chemical 1 0.8571173
CPAP O 0 0.8408769
decreased O 0 0.0032680952
arterial O 0 0.38341415
blood O 0 0.024888566
pressure O 0 0.090445854
, O 0 0.002782863
cardiac O 0 0.30220076
output O 0 0.0034144789
, O 0 0.0034613865
and O 0 0.004122421
QS O 0 0.495132
/ O 0 0.04915687
QT O 0 0.99620515
. O 0 0.011227449

These O 0 0.009162226
data O 0 0.0065483106
indicate O 0 0.0035754729
that O 0 0.0033528956
nitroprusside B-Chemical 1 0.9999701
infusion O 0 0.06359285
rates O 0 0.0013904943
that O 0 0.0007047322
decrease O 0 0.000647231
mean O 0 0.0005627056
arterial O 0 0.27162462
blood O 0 0.010661726
pressure O 0 0.03270794
by O 0 0.00071717706
40 O 0 0.00068484223
- O 0 0.0006906948
50 O 0 0.00048837217
per O 0 0.00030258892
cent O 0 0.00045939593
do O 0 0.000561657
not O 0 0.00071647536
change O 0 0.001072946
cardiac O 0 0.20736636
output O 0 0.002759619
or O 0 0.0029972042
QS O 0 0.6025251
/ O 0 0.06142462
QT O 0 0.9968748
. O 0 0.01022322

During O 0 0.009589814
nitroprusside B-Chemical 1 0.99983764
infusion O 0 0.059200205
low O 0 0.0034318797
levels O 0 0.0016997642
of O 0 0.0019545355
CPAP O 0 0.9080772
do O 0 0.0008870828
not O 0 0.0008070789
markedly O 0 0.004302539
alter O 0 0.00090076117
cardiovascular O 0 0.9952987
dynamics O 0 0.0018561507
, O 0 0.0011779616
but O 0 0.000500107
high O 0 0.00054199045
levels O 0 0.00042369365
of O 0 0.000750059
CPAP O 0 0.95943314
( O 0 0.00096257887
10 O 0 0.0005246371
cm O 0 0.0021270085
H2O B-Chemical 1 0.95528555
) O 0 0.0013016621
, O 0 0.00064132747
while O 0 0.00042014822
decreasing O 0 0.00087798334
QS O 0 0.389863
/ O 0 0.0110624
QT O 0 0.9975944
, O 0 0.000996943
produce O 0 0.00051967776
marked O 0 0.0012073554
decreases B-Disease 0 0.0008270323
in I-Disease 0 0.00091801427
arterial I-Disease 0 0.40772015
blood I-Disease 0 0.02065848
pressure I-Disease 0 0.06658177
and I-Disease 0 0.0037460772
cardiac I-Disease 0 0.59641147
output I-Disease 0 0.008858568
. O 0 0.00796265

Systolic O 0 0.7038533
pressure O 0 0.022042746
variation O 0 0.0043737795
is O 0 0.0030141426
greater O 0 0.0023583767
during O 0 0.002057026
hemorrhage B-Disease 2 0.9996797
than O 0 0.0019008277
during O 0 0.0023002042
sodium B-Chemical 1 0.9999608
nitroprusside I-Chemical 1 0.999998
- O 0 0.08889277
induced O 0 0.009742
hypotension B-Disease 2 0.99993145
in O 0 0.005167398
ventilated O 0 0.040022418
dogs O 0 0.01705242
. O 0 0.009494731

The O 0 0.008060528
systolic O 0 0.32484886
pressure O 0 0.038041417
variation O 0 0.0037120995
( O 0 0.0043410813
SPV O 0 0.88560253
) O 0 0.003549332
, O 0 0.0014493451
which O 0 0.00093457964
is O 0 0.00058896816
the O 0 0.00044875022
difference O 0 0.00028754768
between O 0 0.00026415096
the O 0 0.00036937528
maximal O 0 0.00041691872
and O 0 0.0004037782
minimal O 0 0.0003586041
values O 0 0.000376213
of O 0 0.0004377262
the O 0 0.00046668586
systolic O 0 0.6423012
blood O 0 0.011919895
pressure O 0 0.0997163
( O 0 0.0012934104
SBP O 0 0.6957263
) O 0 0.0007166984
after O 0 0.00023035359
one O 0 0.00030876696
positive O 0 0.00055546174
- O 0 0.0010737838
pressure O 0 0.023547253
breath O 0 0.5584717
, O 0 0.0010332592
was O 0 0.0006692314
studied O 0 0.00083439983
in O 0 0.0009915923
ventilated O 0 0.0034118365
dogs O 0 0.0033050552
subjected O 0 0.0022782073
to O 0 0.0052346317
hypotension B-Disease 2 0.99978596
. O 0 0.011422457

Mean O 0 0.008429128
arterial O 0 0.14729123
pressure O 0 0.034670398
was O 0 0.0031835472
decreased O 0 0.002714709
to O 0 0.0015580137
50 O 0 0.0019886268
mm O 0 0.003634869
Hg O 0 0.6123502
for O 0 0.0005488056
30 O 0 0.00043424105
minutes O 0 0.00037948255
either O 0 0.0005036276
by O 0 0.00093245297
hemorrhage B-Disease 2 0.9999436
( O 0 0.005596428
HEM B-Disease 0 0.9995394
, O 0 0.00087410025
n O 0 0.00061664294
= O 0 0.00067263644
7 O 0 0.00041245
) O 0 0.00058789697
or O 0 0.00035094493
by O 0 0.00044081046
continuous O 0 0.000540337
infusion O 0 0.0075629624
of O 0 0.0028973222
sodium B-Chemical 1 0.99998116
nitroprusside I-Chemical 1 0.9999987
( O 0 0.051830318
SNP B-Chemical 1 0.89753526
, O 0 0.002595713
n O 0 0.0025026142
= O 0 0.0035739287
7 O 0 0.0035068828
) O 0 0.0071274727
. O 0 0.0070074606

During O 0 0.010394796
HEM B-Disease 0 0.99720675
- O 0 0.010473472
induced O 0 0.005143411
hypotension B-Disease 2 0.9998436
the O 0 0.002648287
cardiac O 0 0.47405562
output O 0 0.0021730028
was O 0 0.00092087104
significantly O 0 0.0009826837
lower O 0 0.00081512757
and O 0 0.0009928425
systemic O 0 0.8812847
vascular O 0 0.893465
resistance O 0 0.0073722503
higher O 0 0.0008743093
compared O 0 0.00070022617
with O 0 0.0012534633
that O 0 0.0012916955
in O 0 0.0020166314
the O 0 0.0034963407
SNP B-Chemical 1 0.77428603
group O 0 0.008735957
. O 0 0.008871599

The O 0 0.008000284
systemic O 0 0.5039063
, O 0 0.0058374167
central O 0 0.0050959704
venous O 0 0.394684
, O 0 0.0028341922
pulmonary O 0 0.62163174
capillary O 0 0.13360785
wedge O 0 0.3323605
pressures O 0 0.021019716
, O 0 0.0015028312
and O 0 0.00113217
heart O 0 0.2945073
rates O 0 0.001416124
, O 0 0.0015844934
were O 0 0.0011617712
similar O 0 0.0010503423
in O 0 0.0016224957
the O 0 0.0023231115
two O 0 0.003280102
groups O 0 0.007373793
. O 0 0.008351853

Analysis O 0 0.01285862
of O 0 0.006569369
the O 0 0.0046356767
respiratory O 0 0.2023371
changes O 0 0.0035179032
in O 0 0.0019916848
the O 0 0.0018106641
arterial O 0 0.31091806
pressure O 0 0.041686796
waveform O 0 0.006925665
enabled O 0 0.0020983398
differentiation O 0 0.011251974
between O 0 0.0018100713
the O 0 0.0030094604
two O 0 0.0039337385
groups O 0 0.008425087
. O 0 0.009190671

The O 0 0.009102762
SPV O 0 0.5225595
during O 0 0.004902672
hypotension B-Disease 2 0.99965537
was O 0 0.0031257847
15 O 0 0.0016665307
. O 0 0.001081709
7 O 0 0.0010424524
+ O 0 0.0011288105
/ O 0 0.0021044349
- O 0 0.001151433
6 O 0 0.00047157967
. O 0 0.00038260195
7 O 0 0.00044608928
mm O 0 0.0012415277
Hg O 0 0.54277605
in O 0 0.0004220355
the O 0 0.0006097779
HEM B-Disease 0 0.99882036
group O 0 0.0008512316
, O 0 0.000642654
compared O 0 0.00026470964
with O 0 0.00045196654
9 O 0 0.0005270296
. O 0 0.0003231603
1 O 0 0.00049234007
+ O 0 0.00058161194
/ O 0 0.0015400053
- O 0 0.00084158627
2 O 0 0.00044837262
. O 0 0.00033397565
0 O 0 0.0005761706
mm O 0 0.0013004971
Hg O 0 0.48219967
in O 0 0.00049177953
the O 0 0.00070653344
SNP B-Chemical 1 0.43456155
group O 0 0.0013244553
( O 0 0.0018190207
P O 0 0.029781811
less O 0 0.0011615354
than O 0 0.001253179
0 O 0 0.0027393207
. O 0 0.002550729
02 O 0 0.046709348
) O 0 0.007886003
. O 0 0.007377842

The O 0 0.008553016
delta O 0 0.04375803
down O 0 0.005719935
, O 0 0.0038302576
which O 0 0.0023264694
is O 0 0.0013722361
the O 0 0.00095471763
measure O 0 0.00055989693
of O 0 0.00086653815
decrease O 0 0.0007207192
of O 0 0.00092496845
SBP O 0 0.6694022
after O 0 0.00031295756
a O 0 0.0006123693
mechanical O 0 0.028106825
breath O 0 0.7988341
, O 0 0.00093507033
was O 0 0.0004548654
20 O 0 0.00044747003
. O 0 0.00029513097
3 O 0 0.0003801853
+ O 0 0.00050852983
/ O 0 0.0013192978
- O 0 0.00070687657
8 O 0 0.00034519986
. O 0 0.0002418636
4 O 0 0.00027138845
and O 0 0.00033941696
10 O 0 0.00037638572
. O 0 0.00028381165
1 O 0 0.00043483358
+ O 0 0.0005175975
/ O 0 0.0013723379
- O 0 0.00074520474
3 O 0 0.00036157074
. O 0 0.0002736815
8 O 0 0.00035260475
mm O 0 0.001036887
Hg O 0 0.50454295
in O 0 0.00038863625
the O 0 0.00062413135
HEM B-Disease 0 0.9991806
and O 0 0.0010958168
SNP B-Chemical 1 0.74731886
groups O 0 0.0011114448
, O 0 0.001058078
respectively O 0 0.0013512848
, O 0 0.0009568936
during O 0 0.0006667017
hypotension B-Disease 2 0.9999478
( O 0 0.00288899
P O 0 0.05562477
less O 0 0.0011646099
than O 0 0.0012316316
0 O 0 0.002689847
. O 0 0.0024987212
02 O 0 0.04597137
) O 0 0.0077701253
. O 0 0.0072924183

It O 0 0.010223051
is O 0 0.005192648
concluded O 0 0.0036498571
that O 0 0.0022702806
increases O 0 0.0018965408
in O 0 0.0014919419
the O 0 0.0015120554
SPV O 0 0.7648124
and O 0 0.0012537021
the O 0 0.0009865358
delta O 0 0.03552507
down O 0 0.0009777687
are O 0 0.00068712974
characteristic O 0 0.0008131682
of O 0 0.00091435574
a O 0 0.0015724323
hypotensive B-Disease 2 0.998516
state O 0 0.0017514735
due O 0 0.0008541629
to O 0 0.0010800095
a O 0 0.0019011906
predominant O 0 0.0024786757
decrease O 0 0.002895599
in O 0 0.004471308
preload O 0 0.9381839
. O 0 0.009250228

They O 0 0.01679963
are O 0 0.008398053
thus O 0 0.0067124073
more O 0 0.004804426
important O 0 0.0032611736
during O 0 0.0027385226
absolute O 0 0.0046981783
hypovolemia B-Disease 0 0.9993073
than O 0 0.0039305203
during O 0 0.0045577665
deliberate O 0 0.55047494
hypotension B-Disease 2 0.9998166
. O 0 0.01576032

Ventricular B-Disease 0 0.99327713
tachyarrhythmias I-Disease 0 0.9996728
during O 0 0.005449081
cesarean O 0 0.012139711
section O 0 0.0035011068
after O 0 0.0027309784
ritodrine B-Chemical 0 0.9995017
therapy O 0 0.05483599
: O 0 0.0066652303
interaction O 0 0.0052331295
with O 0 0.008464236
anesthetics O 0 0.99682534
. O 0 0.01365954

This O 0 0.008873469
case O 0 0.004511146
illustrates O 0 0.0028998617
that O 0 0.001965449
patients O 0 0.003222279
receiving O 0 0.003407297
ritodrine B-Chemical 0 0.99983823
for O 0 0.0011918197
preterm B-Disease 0 0.9263341
labor I-Disease 0 0.8997483
may O 0 0.0009732424
risk O 0 0.03951489
interactions O 0 0.0011373158
between O 0 0.00036096424
the O 0 0.0005112408
residual O 0 0.00085679494
betamimetic O 0 0.8083693
effects O 0 0.0016371859
of O 0 0.0016005482
ritodrine B-Chemical 0 0.99991536
and O 0 0.0012389157
the O 0 0.0009436637
effects O 0 0.0018520823
of O 0 0.0022497461
anesthetics O 0 0.9908434
during O 0 0.0024382432
cesarean O 0 0.05753942
section O 0 0.0063164257
. O 0 0.008535923

Such O 0 0.01224875
interactions O 0 0.0078619905
may O 0 0.0043981397
result O 0 0.0032753523
in O 0 0.002749525
serious O 0 0.41704464
cardiovascular B-Disease 0 0.999469
complications I-Disease 0 0.9863674
even O 0 0.0023623563
after O 0 0.0011024537
cessation O 0 0.0050723837
of O 0 0.0021424622
an O 0 0.0034279383
infusion O 0 0.032086175
of O 0 0.009446244
ritodrine B-Chemical 0 0.9997248
. O 0 0.012027574

Preoperative O 0 0.035386108
assessment O 0 0.008977017
should O 0 0.005096249
focus O 0 0.0053997757
on O 0 0.0044329506
cardiovascular O 0 0.9781798
status O 0 0.012132908
and O 0 0.009847936
serum O 0 0.7899074
potassium B-Chemical 1 0.9996233
level O 0 0.011473924
. O 0 0.013619361

Delaying O 0 0.022185367
induction O 0 0.011152425
of O 0 0.010306257
anesthesia O 0 0.07607622
should O 0 0.0060411026
be O 0 0.006982222
considered O 0 0.006327746
whenever O 0 0.008927958
possible O 0 0.011210581
. O 0 0.014089279

Careful O 0 0.014761643
fluid O 0 0.017259536
administration O 0 0.030616876
and O 0 0.0049054944
cautious O 0 0.0055642566
use O 0 0.002970356
of O 0 0.0030597257
titrated O 0 0.0055982964
doses O 0 0.05772324
of O 0 0.008758129
ephedrine B-Chemical 1 0.9998466
are O 0 0.010122381
advised O 0 0.02265376
. O 0 0.0108131785

After O 0 0.0056665884
delivery O 0 0.0049612867
of O 0 0.0034865371
the O 0 0.0025429367
infant O 0 0.005579581
, O 0 0.0019377909
there O 0 0.00075331586
should O 0 0.0005315307
be O 0 0.0005604869
no O 0 0.00037887227
contraindication O 0 0.00058784714
to O 0 0.000408869
the O 0 0.00043452898
use O 0 0.0005026907
of O 0 0.0006627024
an O 0 0.0013236084
alpha O 0 0.5262871
- O 0 0.0049151117
adrenergic O 0 0.9969379
vasopressor O 0 0.9882776
such O 0 0.0010419273
as O 0 0.001712528
phenylephrine B-Chemical 1 0.999908
to O 0 0.001497215
treat O 0 0.021246117
hypotensive B-Disease 2 0.9994777
patients O 0 0.06493697
with O 0 0.011881722
tachycardia B-Disease 2 0.9996691
. O 0 0.011010507

Verapamil B-Chemical 1 0.9994615
- O 0 0.089145645
induced O 0 0.0757172
carbamazepine B-Chemical 1 0.99988484
neurotoxicity B-Disease 2 0.9996075
. O 0 0.04963679

A O 0 0.07671823
report O 0 0.04205795
of O 0 0.031595953
two O 0 0.028612884
cases O 0 0.042709466
. O 0 0.036540538

Two O 0 0.008869183
patients O 0 0.008175017
with O 0 0.0042934315
signs O 0 0.20299892
of O 0 0.008011509
carbamazepine B-Chemical 1 0.9999933
neurotoxicity B-Disease 2 0.999961
after O 0 0.0009786586
combined O 0 0.0017684577
treatment O 0 0.0021088698
with O 0 0.0017566001
verapamil B-Chemical 1 0.9999819
showed O 0 0.00086363906
complete O 0 0.00074424024
recovery O 0 0.0015226245
after O 0 0.0006590465
discontinuation O 0 0.5594131
of O 0 0.0022857003
the O 0 0.003656103
calcium B-Chemical 1 0.99923587
entry O 0 0.05498245
blocker O 0 0.99176157
. O 0 0.011231982

Use O 0 0.016381223
of O 0 0.009410375
verapamil B-Chemical 1 0.99986684
in O 0 0.0036602898
combination O 0 0.004813235
with O 0 0.0031694316
carbamazepine B-Chemical 1 0.99998915
should O 0 0.0007471791
either O 0 0.0007812696
be O 0 0.0006215809
avoided O 0 0.0005820357
or O 0 0.0004751669
prescribed O 0 0.0034125212
only O 0 0.00039258483
with O 0 0.00041749357
appropriate O 0 0.00036981504
adjustment O 0 0.0005593502
of O 0 0.0005274125
the O 0 0.00074350403
carbamazepine B-Chemical 1 0.9999939
dose O 0 0.05198503
( O 0 0.0012672879
usually O 0 0.0009499318
reduction O 0 0.00094404817
of O 0 0.0009077067
the O 0 0.0013855352
carbamazepine B-Chemical 1 0.99998426
dose O 0 0.030609969
by O 0 0.0024395683
one O 0 0.002324162
half O 0 0.002958592
) O 0 0.00860165
. O 0 0.0072943307

Paracetamol B-Chemical 0 0.9997764
- O 0 0.030060574
associated O 0 0.014094616
coma B-Disease 2 0.999683
, O 0 0.01993522
metabolic B-Disease 2 0.97410256
acidosis I-Disease 2 0.9999366
, O 0 0.035075977
renal B-Disease 0 0.9946426
and I-Disease 0 0.014790339
hepatic I-Disease 0 0.993374
failure I-Disease 0 0.9539939
. O 0 0.014481528

A O 0 0.03307337
case O 0 0.0072536585
of O 0 0.0071133613
metabolic B-Disease 2 0.94024414
acidosis I-Disease 2 0.9999559
, O 0 0.02779061
acute B-Disease 0 0.987986
renal I-Disease 0 0.9986052
failure I-Disease 0 0.94302106
and I-Disease 0 0.0041241543
hepatic I-Disease 0 0.98647726
failure I-Disease 0 0.8784955
following O 0 0.0050609848
paracetamol B-Chemical 1 0.99996924
ingestion O 0 0.9062361
is O 0 0.0062856507
presented O 0 0.008858961
. O 0 0.00941821

The O 0 0.019249128
diagnostic O 0 0.020624142
difficulty O 0 0.024325274
at O 0 0.013397971
presentation O 0 0.023401126
is O 0 0.016727323
highlighted O 0 0.01780157
. O 0 0.0216473

Continuous O 0 0.019237218
arteriovenous O 0 0.7731557
haemofiltration O 0 0.8518214
proved O 0 0.008993611
a O 0 0.00512434
valuable O 0 0.003984705
means O 0 0.0039023573
of O 0 0.003669544
maintaining O 0 0.004017026
fluid O 0 0.0366679
and O 0 0.008477921
electrolyte O 0 0.9719167
balance O 0 0.07372599
. O 0 0.013138855

The O 0 0.056631055
patient O 0 0.06260933
recovered O 0 0.058666974
. O 0 0.06288117

Sexual B-Disease 0 0.93716836
dysfunction I-Disease 0 0.97817457
among O 0 0.027024278
patients O 0 0.03903806
with O 0 0.03148882
arthritis B-Disease 2 0.99865997
. O 0 0.037904304

The O 0 0.0066299043
relationship O 0 0.0040526246
of O 0 0.0052970513
arthritis B-Disease 2 0.9993351
and O 0 0.0096658245
sexual B-Disease 2 0.9881788
dysfunction I-Disease 2 0.9978381
was O 0 0.0014039382
investigated O 0 0.000734855
among O 0 0.0010937508
169 O 0 0.016305506
patients O 0 0.0022234058
with O 0 0.0012484208
rheumatoid B-Disease 2 0.9999064
arthritis I-Disease 2 0.99999046
, O 0 0.054097205
osteoarthritis B-Disease 0 0.9993754
and O 0 0.004915063
spondyloarthropathy B-Disease 0 0.99976367
, O 0 0.00216317
130 O 0 0.0017210918
of O 0 0.00082334847
whom O 0 0.001955022
were O 0 0.0011603389
pair O 0 0.0016393447
- O 0 0.0024591007
matched O 0 0.0022101998
to O 0 0.0031096512
controls O 0 0.008603582
. O 0 0.007752704

Assessments O 0 0.012750932
of O 0 0.008512884
marital O 0 0.792252
happiness O 0 0.6177687
and O 0 0.006483581
depressed B-Disease 2 0.9937873
mood I-Disease 0 0.99948907
were O 0 0.0018852125
also O 0 0.00124037
made O 0 0.001063685
using O 0 0.0010312707
the O 0 0.0014257377
CES O 0 0.95792526
- O 0 0.004288469
D O 0 0.65893024
and O 0 0.0022806646
the O 0 0.0026166814
Azrin O 0 0.612357
Marital O 0 0.9889816
Happiness O 0 0.9254601
Scale O 0 0.9896331
( O 0 0.00927326
AMHS O 0 0.29222798
) O 0 0.010489873
. O 0 0.008631723

Sexual B-Disease 0 0.9468532
dysfunctions I-Disease 0 0.97489536
were O 0 0.004823012
found O 0 0.0024167313
to O 0 0.0018581713
be O 0 0.0015681292
common O 0 0.0015404851
among O 0 0.0013552719
patients O 0 0.0025956181
and O 0 0.0010953206
controls O 0 0.0017989898
, O 0 0.0010148315
the O 0 0.0006180148
majority O 0 0.00077689317
in O 0 0.00074009004
both O 0 0.00092294323
groups O 0 0.0015358304
reporting O 0 0.0025137125
one O 0 0.0017342592
or O 0 0.0027925966
more O 0 0.0057529053
dysfunctions O 0 0.9557061
. O 0 0.009624717

Impotence B-Disease 2 0.9482159
was O 0 0.0063560884
more O 0 0.004199788
common O 0 0.0032470808
among O 0 0.002398527
male O 0 0.0062220744
patients O 0 0.0029716934
than O 0 0.0008255646
controls O 0 0.0015953036
and O 0 0.0010165796
was O 0 0.00075768813
found O 0 0.00056699215
to O 0 0.0006501791
be O 0 0.00078663346
associated O 0 0.0009796208
with O 0 0.0013495402
co O 0 0.70163476
- O 0 0.0058595357
morbidity O 0 0.5598175
and O 0 0.0021855722
the O 0 0.0021420158
taking O 0 0.005010986
of O 0 0.0071864454
methotrexate B-Chemical 1 0.9997689
. O 0 0.011328356

Depressed B-Disease 0 0.99655604
mood I-Disease 0 0.99769586
was O 0 0.0054333764
more O 0 0.003463461
common O 0 0.002850472
among O 0 0.002255744
patients O 0 0.0038029386
and O 0 0.0016444636
was O 0 0.0011962531
associated O 0 0.0012511528
with O 0 0.001254135
certain O 0 0.0021192208
sexual O 0 0.65100944
difficulties O 0 0.052575402
, O 0 0.002985662
but O 0 0.002262696
not O 0 0.0028883943
with O 0 0.0060091326
impotence B-Disease 0 0.99769896
. O 0 0.011629392

Marital O 0 0.9564539
unhappiness O 0 0.97995573
, O 0 0.007188109
as O 0 0.0032714133
indicated O 0 0.002168677
by O 0 0.002527347
AMHS O 0 0.1522033
scores O 0 0.0019091044
, O 0 0.0013271251
was O 0 0.0007587387
not O 0 0.0006535127
associated O 0 0.00092377106
with O 0 0.0013426264
arthritis B-Disease 2 0.9998178
but O 0 0.0016344035
was O 0 0.0009728177
associated O 0 0.0011754693
with O 0 0.0017235669
sexual B-Disease 2 0.9839453
dysfunction I-Disease 2 0.9987459
, O 0 0.0072249207
sexual O 0 0.7565157
dissatisfaction O 0 0.5625865
and O 0 0.004306643
being O 0 0.007269086
female O 0 0.028420229
. O 0 0.008902228

Does O 0 0.064966515
paracetamol B-Chemical 1 0.999526
cause O 0 0.23796336
urothelial B-Disease 0 0.9991605
cancer I-Disease 2 0.99929094
or O 0 0.05051108
renal B-Disease 2 0.9991074
papillary I-Disease 2 0.9992436
necrosis I-Disease 2 0.9997181
? O 0 0.3225875

The O 0 0.0081876395
risk O 0 0.015702773
of O 0 0.0053269654
developing O 0 0.01553641
renal B-Disease 2 0.9980465
papillary I-Disease 2 0.9993973
necrosis I-Disease 2 0.9999367
or O 0 0.0043826383
cancer B-Disease 2 0.9973635
of I-Disease 0 0.0017483332
the I-Disease 0 0.0010787566
renal I-Disease 0 0.9887794
pelvis I-Disease 0 0.75528306
, I-Disease 0 0.0013387077
ureter I-Disease 0 0.15015
or I-Disease 0 0.0006159678
bladder I-Disease 0 0.8659577
associated O 0 0.0008256933
with O 0 0.00063868874
consumption O 0 0.079783514
of O 0 0.00090995635
either O 0 0.0013335187
phenacetin B-Chemical 1 0.99999607
or O 0 0.0016130937
paracetamol B-Chemical 1 0.9999839
was O 0 0.0006496257
calculated O 0 0.00045175033
from O 0 0.00057863165
data O 0 0.0008571396
acquired O 0 0.0017104733
by O 0 0.0010568973
questionnaire O 0 0.0013943219
from O 0 0.0013466028
381 O 0 0.00961891
cases O 0 0.0031949375
and O 0 0.0039416226
808 O 0 0.14487003
controls O 0 0.008469532
. O 0 0.007744422

The O 0 0.008216344
risk O 0 0.017284125
of O 0 0.006372405
renal B-Disease 2 0.9966767
papillary I-Disease 2 0.99914694
necrosis I-Disease 2 0.9999119
was O 0 0.002676023
increased O 0 0.0015430776
nearly O 0 0.0009983168
20 O 0 0.00094184617
- O 0 0.0009809907
fold O 0 0.0008929477
by O 0 0.0006525767
consumption O 0 0.05709616
of O 0 0.0019503718
phenacetin B-Chemical 1 0.99999666
, O 0 0.0017665209
which O 0 0.0006881213
also O 0 0.0005061516
increased O 0 0.0006219106
the O 0 0.00055269804
risk O 0 0.03163329
for O 0 0.0005837852
cancer B-Disease 2 0.9910137
of I-Disease 0 0.0011742649
the I-Disease 0 0.0010581369
renal I-Disease 0 0.98628366
pelvis I-Disease 0 0.6452112
and I-Disease 0 0.0021264288
bladder I-Disease 0 0.9067893
but O 0 0.0020630094
not O 0 0.0021644083
for O 0 0.0030888577
ureteric B-Disease 0 0.95891535
cancer I-Disease 2 0.9993864
. O 0 0.014451628

By O 0 0.0106294835
contrast O 0 0.0057866266
, O 0 0.004347587
we O 0 0.0019272685
were O 0 0.0016902543
unable O 0 0.0010574698
to O 0 0.00093848526
substantiate O 0 0.00087380095
an O 0 0.0012911734
increased O 0 0.0012695319
risk O 0 0.07129821
from O 0 0.0012145193
paracetamol B-Chemical 1 0.9999845
consumption O 0 0.29734817
for O 0 0.00075911626
renal B-Disease 2 0.9987947
papillary I-Disease 2 0.9995832
necrosis I-Disease 2 0.99995375
or O 0 0.0008457937
any O 0 0.00047759636
of O 0 0.00063810835
these O 0 0.00097313104
cancers B-Disease 2 0.99354666
although O 0 0.00059578224
there O 0 0.00037903045
was O 0 0.0005260891
a O 0 0.0007503611
suggestion O 0 0.0015077204
of O 0 0.0010251786
an O 0 0.0014423857
association O 0 0.0011806183
with O 0 0.0025729986
cancer B-Disease 2 0.9949374
of I-Disease 0 0.005759468
the I-Disease 0 0.0063118674
ureter I-Disease 0 0.5983282
. O 0 0.010003044

Dapsone B-Chemical 0 0.9989429
- O 0 0.021310546
associated O 0 0.009541276
Heinz O 0 0.7073243
body O 0 0.30798787
hemolytic B-Disease 2 0.999938
anemia I-Disease 2 0.9999732
in O 0 0.0068412432
a O 0 0.0065463316
Cambodian O 0 0.08506823
woman O 0 0.06844433
with O 0 0.007167331
hemoglobin O 0 0.992276
E O 0 0.9966518
trait O 0 0.27279785
. O 0 0.0143490825

A O 0 0.050317757
Cambodian O 0 0.02422088
woman O 0 0.021268504
with O 0 0.0053443937
hemoglobin O 0 0.9796729
E O 0 0.99597245
trait O 0 0.21609126
( O 0 0.006186156
AE O 0 0.98011816
) O 0 0.003732543
and O 0 0.0014205673
leprosy B-Disease 0 0.98748857
developed O 0 0.0019348963
a O 0 0.0017756305
Heinz O 0 0.7655546
body O 0 0.1586903
hemolytic B-Disease 2 0.99998796
anemia I-Disease 2 0.9999951
while O 0 0.0015662594
taking O 0 0.0025009234
a O 0 0.00080858084
dose O 0 0.0070582354
of O 0 0.001326712
dapsone B-Chemical 1 0.99995804
( O 0 0.0019941889
50 O 0 0.0011654305
mg O 0 0.19479813
/ O 0 0.0016336257
day O 0 0.00072171126
) O 0 0.0013783167
not O 0 0.0009110043
usually O 0 0.0018710035
associated O 0 0.0023050858
with O 0 0.0037457212
clinical O 0 0.24508584
hemolysis B-Disease 2 0.9996257
. O 0 0.012839319

Her O 0 0.017779624
red O 0 0.013656551
blood O 0 0.021234961
cells O 0 0.008424486
( O 0 0.0051416056
RBCs O 0 0.095446326
) O 0 0.0032946027
had O 0 0.0011893893
increased O 0 0.0012759453
incubated O 0 0.00078603625
Heinz O 0 0.475646
body O 0 0.02420609
formation O 0 0.008860318
, O 0 0.002171936
decreased O 0 0.0025600304
reduced O 0 0.013988024
glutathione B-Chemical 1 0.9999858
( O 0 0.14232805
GSH B-Chemical 1 0.99997735
) O 0 0.020129653
, O 0 0.0036062356
and O 0 0.0036092058
decreased O 0 0.012054915
GSH B-Chemical 1 0.99984264
stability O 0 0.013546988
. O 0 0.010709144

The O 0 0.012400727
pentose B-Chemical 0 0.97412723
phosphate I-Chemical 1 0.9963415
shunt O 0 0.10811449
activity O 0 0.0032960968
of O 0 0.0025483451
the O 0 0.0025666896
dapsone B-Chemical 1 0.9999244
- O 0 0.007283276
exposed O 0 0.0018491221
AE O 0 0.96715987
RBCs O 0 0.13031942
was O 0 0.001751295
increased O 0 0.0019921607
compared O 0 0.001668165
to O 0 0.0029975106
normal O 0 0.008243064
RBCs O 0 0.19965194
. O 0 0.009424743

Although O 0 0.0074080685
the O 0 0.005937606
AE O 0 0.7251295
RBCs O 0 0.0388959
from O 0 0.0022613402
an O 0 0.0019468239
individual O 0 0.0011930935
not O 0 0.001048778
taking O 0 0.0026949856
dapsone B-Chemical 1 0.99985373
had O 0 0.0011073062
increased O 0 0.0011918118
incubated O 0 0.00068970094
Heinz O 0 0.5671558
body O 0 0.024064003
formation O 0 0.007718403
, O 0 0.0023108302
the O 0 0.001962772
GSH B-Chemical 1 0.99993896
content O 0 0.0027369552
and O 0 0.006066851
GSH B-Chemical 1 0.9999026
stability O 0 0.0060897274
were O 0 0.0058316775
normal O 0 0.010836461
. O 0 0.008910554

The O 0 0.012042757
pentose B-Chemical 0 0.9733046
phosphate I-Chemical 1 0.996166
shunt O 0 0.09441836
activity O 0 0.0029359048
of O 0 0.0020822037
the O 0 0.0016551181
non O 0 0.006992085
- O 0 0.011536673
dapsone B-Chemical 1 0.9999366
- O 0 0.0056912526
exposed O 0 0.0015218245
AE O 0 0.96618974
RBCs O 0 0.124601595
was O 0 0.0016269067
decreased O 0 0.0021005322
compared O 0 0.0015462192
to O 0 0.0028245517
normal O 0 0.00787049
RBCs O 0 0.19211422
. O 0 0.009159304

Thus O 0 0.00957857
, O 0 0.008565174
AE O 0 0.7927058
RBCs O 0 0.0679308
appear O 0 0.002303582
to O 0 0.0014426564
have O 0 0.001076914
an O 0 0.0014976856
increased O 0 0.0013114886
sensitivity O 0 0.0023127925
to O 0 0.0010513053
oxidant O 0 0.99849474
stress O 0 0.710178
both O 0 0.0009344683
in O 0 0.0006236667
vitro O 0 0.0010520562
and O 0 0.00069541595
in O 0 0.00051094836
vivo O 0 0.0011289287
, O 0 0.00089246925
since O 0 0.00046203946
dapsone B-Chemical 1 0.9998703
does O 0 0.0005972782
not O 0 0.0007885969
cause O 0 0.041455943
hemolytic B-Disease 2 0.99998677
anemia I-Disease 2 0.99999166
at O 0 0.001517401
this O 0 0.0014385462
dose O 0 0.017121654
in O 0 0.0024081601
hematologically O 0 0.90781116
normal O 0 0.008779332
individuals O 0 0.01135819
. O 0 0.008270361

Given O 0 0.0074064136
the O 0 0.006101812
influx O 0 0.20357576
of O 0 0.0050341766
Southeast O 0 0.08909059
Asians O 0 0.5095848
into O 0 0.0010645367
the O 0 0.0012274525
United O 0 0.0032947592
States O 0 0.008379019
, O 0 0.0013504686
oxidant O 0 0.9876274
medications O 0 0.51364315
should O 0 0.00035808145
be O 0 0.00044487262
used O 0 0.00035373576
with O 0 0.0004061387
caution O 0 0.00058979064
, O 0 0.0006081631
especially O 0 0.0004765976
if O 0 0.00031723856
an O 0 0.0007144939
infection B-Disease 2 0.105288
is O 0 0.0005380613
present O 0 0.00036929286
, O 0 0.00069805933
in O 0 0.00042953462
individuals O 0 0.00091273454
of O 0 0.0008317052
ethnic O 0 0.046939515
backgrounds O 0 0.0016211662
that O 0 0.00065545517
have O 0 0.000829726
an O 0 0.0016063536
increased O 0 0.0019382144
prevalence O 0 0.004849069
of O 0 0.00694545
hemoglobin O 0 0.9945116
E O 0 0.9966311
. O 0 0.013276816

Severe O 0 0.8009796
complications O 0 0.5526285
of O 0 0.006649224
antianginal O 0 0.9983646
drug O 0 0.8212073
therapy O 0 0.026329927
in O 0 0.0012576908
a O 0 0.0013659559
patient O 0 0.0012901175
identified O 0 0.0006855779
as O 0 0.00082044164
a O 0 0.0012147503
poor O 0 0.00546831
metabolizer O 0 0.96223974
of O 0 0.0025716922
metoprolol B-Chemical 1 0.9999964
, O 0 0.023750586
propafenone B-Chemical 0 0.99999106
, O 0 0.027579617
diltiazem B-Chemical 1 0.99998283
, O 0 0.007965763
and O 0 0.008286745
sparteine B-Chemical 1 0.9993699
. O 0 0.009959661

A O 0 0.041031245
47 O 0 0.013004188
- O 0 0.007372376
year O 0 0.003849367
- O 0 0.0034105575
old O 0 0.0022059903
patient O 0 0.0023807131
suffering O 0 0.5535774
from O 0 0.0017509166
coronary B-Disease 0 0.68565464
artery I-Disease 0 0.37501034
disease I-Disease 0 0.7017372
was O 0 0.0014227483
admitted O 0 0.0029966345
to O 0 0.0012250633
the O 0 0.0017525343
CCU O 0 0.13718417
in O 0 0.0030985815
shock B-Disease 2 0.9909827
with O 0 0.01137368
III O 0 0.53462183
. O 0 0.010847338

AV B-Disease 0 0.78621197
block I-Disease 0 0.026432855
, O 0 0.012738553
severe O 0 0.55120796
hypotension B-Disease 2 0.9998559
, O 0 0.011960106
and O 0 0.006927341
impairment B-Disease 0 0.25602037
of I-Disease 0 0.008924761
ventricular I-Disease 0 0.99132854
function I-Disease 0 0.013426162
. O 0 0.012012048

One O 0 0.009159269
week O 0 0.003950128
prior O 0 0.0024016656
to O 0 0.0020866282
admission O 0 0.004909592
a O 0 0.0019070457
therapy O 0 0.003695115
with O 0 0.0010212181
standard O 0 0.0009521505
doses O 0 0.020866876
of O 0 0.002538072
metoprolol B-Chemical 1 0.99999774
( O 0 0.0024198373
100 O 0 0.0015261444
mg O 0 0.21874961
t O 0 0.0025488483
. O 0 0.0003778529
i O 0 0.0012264403
. O 0 0.00035231718
d O 0 0.00055509125
. O 0 0.00032743628
and O 0 0.0004369531
then O 0 0.00042806315
100 O 0 0.0009573952
mg O 0 0.100583434
b O 0 0.0014354208
. O 0 0.00060332194
i O 0 0.0019460057
. O 0 0.00081061677
d O 0 0.0015696484
. O 0 0.0013404939
) O 0 0.0030976245
had O 0 0.0025256237
been O 0 0.004119412
initiated O 0 0.0062169307
. O 0 0.008224725

Two O 0 0.0080225635
days O 0 0.004349678
before O 0 0.002910726
admission O 0 0.019813387
diltiazem B-Chemical 1 0.99996686
( O 0 0.0041021435
60 O 0 0.0016045392
mg O 0 0.13093588
b O 0 0.0024665971
. O 0 0.00092950056
i O 0 0.0023725256
. O 0 0.0009160139
d O 0 0.0015426141
. O 0 0.001178826
) O 0 0.0024829367
was O 0 0.0018704596
prescribed O 0 0.006190833
in O 0 0.0034102043
addition O 0 0.0042461026
. O 0 0.0084508

Analyses O 0 0.010612353
of O 0 0.005956956
a O 0 0.004674637
blood O 0 0.007155813
sample O 0 0.0026640971
revealed O 0 0.0018258004
unusually O 0 0.0070430995
high O 0 0.0018991153
plasma O 0 0.035123337
concentrations O 0 0.0043639755
of O 0 0.0031213567
metoprolol B-Chemical 1 0.999997
( O 0 0.0019062761
greater O 0 0.0006160981
than O 0 0.0004755775
3000 O 0 0.0014562994
ng O 0 0.0017374214
/ O 0 0.0020468235
ml O 0 0.0032730661
) O 0 0.0021625666
and O 0 0.002036462
diltiazem B-Chemical 1 0.999985
( O 0 0.0045656697
526 O 0 0.094236314
ng O 0 0.006354531
/ O 0 0.00797156
ml O 0 0.012772155
) O 0 0.010684711
. O 0 0.008208513

The O 0 0.009520398
patient O 0 0.008334218
recovered O 0 0.0051416107
within O 0 0.0034017183
1 O 0 0.003698143
week O 0 0.0027436425
following O 0 0.0032276898
discontinuation O 0 0.5410531
of O 0 0.007950775
antianginal O 0 0.99918073
therapy O 0 0.26258668
. O 0 0.013660125

Three O 0 0.008297223
months O 0 0.0040215687
later O 0 0.002697393
the O 0 0.002183348
patient O 0 0.0023920587
was O 0 0.0013808293
exposed O 0 0.0009888978
to O 0 0.0007996853
a O 0 0.0009855378
single O 0 0.0007642315
dose O 0 0.0076207086
of O 0 0.0024769737
metoprolol B-Chemical 1 0.99999845
, O 0 0.021623181
diltiazem B-Chemical 1 0.99999774
, O 0 0.01242069
propafenone B-Chemical 0 0.99999547
( O 0 0.0012242515
since O 0 0.00031931954
he O 0 0.0004826541
had O 0 0.0002994484
received O 0 0.00032040547
this O 0 0.00035056175
drug O 0 0.13774182
in O 0 0.00040197297
the O 0 0.0004744301
past O 0 0.0013261498
) O 0 0.0018086196
, O 0 0.00082001416
and O 0 0.00082695147
sparteine B-Chemical 1 0.999838
( O 0 0.00093903794
as O 0 0.00044535974
a O 0 0.0005624257
probe O 0 0.00045086752
for O 0 0.00040824173
the O 0 0.0008640498
debrisoquine B-Chemical 0 0.999962
/ O 0 0.016368203
sparteine B-Chemical 1 0.99974626
type O 0 0.0015295779
polymorphism O 0 0.012318137
of O 0 0.003554866
oxidative O 0 0.99449545
drug O 0 0.98187697
metabolism O 0 0.9120716
) O 0 0.041973155
. O 0 0.009208497

It O 0 0.010192161
was O 0 0.0053468402
found O 0 0.0030907115
that O 0 0.002349546
he O 0 0.0026390057
was O 0 0.0016452059
a O 0 0.001753509
poor O 0 0.0035674446
metabolizer O 0 0.8225425
of O 0 0.00088378997
all O 0 0.0006296272
four O 0 0.00055287086
drugs O 0 0.46122402
, O 0 0.0010768345
indicating O 0 0.00055097864
that O 0 0.0005880405
their O 0 0.001051955
metabolism O 0 0.12061785
is O 0 0.0011339681
under O 0 0.0009946394
the O 0 0.0016143465
same O 0 0.0018732331
genetic O 0 0.0068819122
control O 0 0.0061513246
. O 0 0.008253331

Therefore O 0 0.007293588
, O 0 0.006168296
patients O 0 0.004869323
belonging O 0 0.002272285
to O 0 0.0017607505
the O 0 0.0016440941
poor O 0 0.010159612
- O 0 0.0033494842
metabolizer O 0 0.9373446
phenotype O 0 0.0012165622
of O 0 0.0017213506
sparteine B-Chemical 1 0.9999553
/ O 0 0.09372785
debrisoquine B-Chemical 0 0.99997926
polymorphism O 0 0.01542584
in O 0 0.0005835123
drug O 0 0.67820525
metabolism O 0 0.4252245
, O 0 0.0008566236
which O 0 0.0005104622
constitutes O 0 0.00036624895
6 O 0 0.00030740755
. O 0 0.00023964618
4 O 0 0.0002694658
% O 0 0.0003263225
of O 0 0.00033813284
the O 0 0.00038495247
German O 0 0.001079506
population O 0 0.00094355404
, O 0 0.000634123
may O 0 0.00037624582
experience O 0 0.0011385297
adverse B-Disease 0 0.97520894
drug I-Disease 0 0.6264301
reactions I-Disease 0 0.09852497
when O 0 0.0004396262
treated O 0 0.0007459575
with O 0 0.0006634304
standard O 0 0.00077406847
doses O 0 0.0062342715
of O 0 0.0011994872
one O 0 0.0011084989
of O 0 0.0019273096
these O 0 0.0035873146
drugs O 0 0.82867914
alone O 0 0.0084475605
. O 0 0.008751963

Moreover O 0 0.010124674
, O 0 0.0068105077
the O 0 0.0039112554
coadministration O 0 0.88359547
of O 0 0.002692042
these O 0 0.0020477106
frequently O 0 0.0020716616
used O 0 0.0011768367
drugs O 0 0.5399874
is O 0 0.0009974688
expected O 0 0.000671359
to O 0 0.00076200406
be O 0 0.0009536984
especially O 0 0.0013059902
harmful O 0 0.05617014
in O 0 0.0015551286
this O 0 0.0019772977
subgroup O 0 0.0066877804
of O 0 0.0050894977
patients O 0 0.029966215
. O 0 0.008988665

Clinical O 0 0.04904456
experiences O 0 0.017614676
in O 0 0.007533563
an O 0 0.0075432495
open O 0 0.005643305
and O 0 0.005590211
a O 0 0.0065868753
double O 0 0.0067054415
- O 0 0.010527447
blind O 0 0.02195632
trial O 0 0.01369595
. O 0 0.012307955

A O 0 0.021655876
total O 0 0.0056454353
of O 0 0.0042147734
sixty O 0 0.003914331
patients O 0 0.004060635
were O 0 0.0019094415
trated O 0 0.049410027
with O 0 0.0019590072
bromperidol B-Chemical 0 0.9999802
first O 0 0.0008188616
in O 0 0.00067809346
open O 0 0.0006959338
conditions O 0 0.00084194803
( O 0 0.00092996116
20 O 0 0.00053445157
patients O 0 0.0013894545
) O 0 0.0010014566
, O 0 0.0005282565
then O 0 0.00031512612
on O 0 0.00026075065
a O 0 0.0005042816
double O 0 0.00046762702
blind O 0 0.001933475
basis O 0 0.00064921787
( O 0 0.0009446826
40 O 0 0.00072473806
patients O 0 0.0018657765
) O 0 0.0019264035
with O 0 0.001969012
haloperidol B-Chemical 1 0.9999838
as O 0 0.0025135477
the O 0 0.0029219335
reference O 0 0.004359107
substance O 0 0.95913553
. O 0 0.009689616

The O 0 0.0076039797
open O 0 0.005341753
study O 0 0.0037707929
lasted O 0 0.0025962957
for O 0 0.0015603646
four O 0 0.001258284
weeks O 0 0.0011118207
; O 0 0.001675758
the O 0 0.0009832911
drug O 0 0.19005267
was O 0 0.0011886826
administrated O 0 0.008973937
in O 0 0.0011018405
the O 0 0.0013012468
form O 0 0.0016657242
of O 0 0.002795433
1 O 0 0.004337692
mg O 0 0.68675053
tablets O 0 0.94816166
. O 0 0.010025126

The O 0 0.00681815
daily O 0 0.0068717976
dose O 0 0.010812225
( O 0 0.0033833103
initial O 0 0.0018044139
dose O 0 0.011600763
: O 0 0.0022104091
1 O 0 0.0011044071
mg O 0 0.17199092
; O 0 0.0010623402
mean O 0 0.00045976124
dose O 0 0.0014587742
at O 0 0.00034233584
the O 0 0.00036943972
end O 0 0.00027773398
of O 0 0.00047089576
the O 0 0.0004941633
trial O 0 0.0009430342
: O 0 0.00084214506
4 O 0 0.00047171995
. O 0 0.00039064317
47 O 0 0.0010541998
mg O 0 0.12689814
) O 0 0.0013402866
was O 0 0.00076137367
always O 0 0.0009468307
administered O 0 0.0014592744
in O 0 0.0014504449
one O 0 0.001976138
single O 0 0.0036163824
dose O 0 0.029063448
. O 0 0.008204791

Nineteen O 0 0.020652864
patients O 0 0.010350484
finished O 0 0.0074526817
the O 0 0.0034167888
trial O 0 0.0035947808
, O 0 0.0025055027
and O 0 0.0016682222
in O 0 0.001224789
18 O 0 0.0011489559
cases O 0 0.0014286743
the O 0 0.0010541813
therapeutic O 0 0.0046831244
result O 0 0.0014696757
was O 0 0.0015061835
considered O 0 0.0015653977
very O 0 0.0025670119
good O 0 0.0037040766
to O 0 0.003922945
good O 0 0.008061191
. O 0 0.008691532

These O 0 0.023285381
results O 0 0.017810453
were O 0 0.016335554
confirmed O 0 0.014759154
by O 0 0.016969847
statistical O 0 0.027996652
analysis O 0 0.024378626
. O 0 0.023438264

Nine O 0 0.014940361
patients O 0 0.00957081
exhibited O 0 0.0045817755
mild O 0 0.21315399
to O 0 0.0031860573
moderate O 0 0.1034252
extrapyramidal B-Disease 0 0.99999094
concomitant I-Disease 0 0.16748199
symptoms I-Disease 0 0.99221075
; O 0 0.0040170946
no O 0 0.0013070287
other O 0 0.002196562
side O 0 0.06389937
effects O 0 0.0064155036
were O 0 0.004909024
observed O 0 0.004834764
. O 0 0.008808494

The O 0 0.00691831
results O 0 0.00494118
of O 0 0.0038726893
detailed O 0 0.002424108
laboratory O 0 0.0028416042
tests O 0 0.0026297898
and O 0 0.0014709646
evaluations O 0 0.0012320405
of O 0 0.0010555862
various O 0 0.0013361552
quantitative O 0 0.001357881
and O 0 0.0010784648
qualitative O 0 0.0019193005
tolerability O 0 0.12500463
parameters O 0 0.0017707346
were O 0 0.0013278926
not O 0 0.0013279621
indicative O 0 0.0018238098
of O 0 0.004006486
toxic O 0 0.9303106
effects O 0 0.047251463
. O 0 0.010547876

In O 0 0.0070427055
the O 0 0.0049170717
double O 0 0.003812067
blind O 0 0.007737244
study O 0 0.002815969
with O 0 0.0030478248
haloperidol B-Chemical 1 0.9999927
, O 0 0.0029512697
both O 0 0.0010233383
substances O 0 0.7230633
were O 0 0.0008480306
found O 0 0.0004973906
to O 0 0.0005082091
be O 0 0.00054408173
highly O 0 0.000600165
effective O 0 0.00061109563
in O 0 0.00045728625
the O 0 0.00053882675
treatment O 0 0.0011492103
of O 0 0.0025918568
psychotic B-Disease 0 0.9999882
syndromes I-Disease 0 0.9297386
belonging I-Disease 0 0.0014872496
predominantly I-Disease 0 0.00207622
to I-Disease 0 0.0019769236
the I-Disease 0 0.0036915129
schizophrenia I-Disease 2 0.9993856
group I-Disease 0 0.01058637
. O 0 0.008933374

Certain O 0 0.023019327
clues O 0 0.0089764055
, O 0 0.0057495567
including O 0 0.003058519
the O 0 0.0024784422
onset O 0 0.0045943083
of O 0 0.0024995059
action O 0 0.017201656
, O 0 0.0023703035
seem O 0 0.0013498411
to O 0 0.0010548856
be O 0 0.0012014009
indicative O 0 0.0011380349
of O 0 0.0017807581
the O 0 0.0021846187
superiority O 0 0.0059814067
of O 0 0.010001401
bromperidol B-Chemical 0 0.9999486
. O 0 0.012033576

No O 0 0.011828103
differences O 0 0.005514224
were O 0 0.0049116937
observed O 0 0.0030918943
with O 0 0.003279586
respect O 0 0.002708822
to O 0 0.0029960885
side O 0 0.044287205
effects O 0 0.0068848077
and O 0 0.0059635183
general O 0 0.0071711424
tolerability O 0 0.70526403
. O 0 0.011941121

Prolonged O 0 0.45241567
cholestasis B-Disease 2 0.9996542
after O 0 0.01820329
troleandomycin B-Chemical 0 0.9999217
- O 0 0.13874325
induced O 0 0.045229465
acute O 0 0.9992034
hepatitis B-Disease 2 0.9999347
. O 0 0.093281604

We O 0 0.008162678
report O 0 0.007178414
the O 0 0.0036914637
case O 0 0.0027550454
of O 0 0.002397829
a O 0 0.0023954965
patient O 0 0.0023941475
in O 0 0.0015179674
whom O 0 0.021967918
troleandomycin B-Chemical 0 0.99999094
- O 0 0.03428438
induced O 0 0.006639364
hepatitis B-Disease 2 0.99996614
was O 0 0.0038083238
followed O 0 0.0021536374
by O 0 0.0038784642
prolonged O 0 0.13501208
anicteric O 0 0.9997154
cholestasis B-Disease 2 0.99996233
. O 0 0.025945436

Jaundice B-Disease 0 0.98665655
occurred O 0 0.006964923
after O 0 0.0032698293
administration O 0 0.022206564
of O 0 0.004752418
troleandomycin B-Chemical 0 0.9999584
for O 0 0.0022158255
7 O 0 0.0018424225
days O 0 0.0014721781
and O 0 0.0023294308
was O 0 0.0027330234
associated O 0 0.0044405693
with O 0 0.009201916
hypereosinophilia B-Disease 0 0.9996586
. O 0 0.015862651

Jaundice B-Disease 0 0.9878043
disappeared O 0 0.008480759
within O 0 0.0026950133
3 O 0 0.0022168376
months O 0 0.0013894353
but O 0 0.0012251735
was O 0 0.0010121029
followed O 0 0.0007832272
by O 0 0.0011587467
prolonged O 0 0.02667668
anicteric O 0 0.9998368
cholestasis B-Disease 2 0.9999949
marked O 0 0.05938407
by O 0 0.004941712
pruritus B-Disease 2 0.99997675
and O 0 0.002450264
high O 0 0.0018825148
levels O 0 0.0015375657
of O 0 0.0033645427
alkaline O 0 0.8637835
phosphatase O 0 0.8907383
and O 0 0.010161798
gammaglutamyltransferase O 0 0.847076
activities O 0 0.016425604
. O 0 0.009124184

Finally O 0 0.010986684
, O 0 0.0102433795
pruritus B-Disease 2 0.9995283
disappeared O 0 0.006699752
within O 0 0.0017510244
19 O 0 0.0023419713
months O 0 0.0011524991
, O 0 0.0013906194
and O 0 0.0012091255
liver O 0 0.54952604
tests O 0 0.0021380954
returned O 0 0.0009181568
to O 0 0.00074890634
normal O 0 0.001362614
27 O 0 0.0013432801
months O 0 0.0008024992
after O 0 0.00089060713
the O 0 0.0018560534
onset O 0 0.0098824585
of O 0 0.012677328
hepatitis B-Disease 2 0.9998828
. O 0 0.022052385

This O 0 0.01175276
observation O 0 0.00625497
demonstrates O 0 0.0042658215
that O 0 0.0039002353
prolonged O 0 0.034199882
cholestasis B-Disease 2 0.9999441
can O 0 0.0047441074
follow O 0 0.0047119963
troleandomycin B-Chemical 0 0.9999765
- O 0 0.06612836
induced O 0 0.02338951
acute O 0 0.9995241
hepatitis B-Disease 2 0.99996614
. O 0 0.07214456

Serial O 0 0.023358742
studies O 0 0.011285622
of O 0 0.010901417
auditory B-Disease 0 0.73496807
neurotoxicity I-Disease 2 0.99980885
in O 0 0.008042867
patients O 0 0.02664914
receiving O 0 0.080910996
deferoxamine B-Chemical 1 0.99991214
therapy O 0 0.56867576
. O 0 0.016261587

Visual B-Disease 0 0.7236118
and I-Disease 0 0.009546369
auditory I-Disease 0 0.68618375
neurotoxicity I-Disease 2 0.99988294
was O 0 0.003105586
previously O 0 0.0016128556
documented O 0 0.0016449465
in O 0 0.0008548028
42 O 0 0.00102864
of O 0 0.0007667241
89 O 0 0.0013566052
patients O 0 0.0012234469
with O 0 0.00071387895
transfusion O 0 0.23562734
- O 0 0.0022568197
dependent O 0 0.0008447032
anemia B-Disease 2 0.99993086
who O 0 0.008181261
were O 0 0.0011144791
receiving O 0 0.005951907
iron B-Chemical 1 0.9998417
chelation O 0 0.9967722
therapy O 0 0.063387886
with O 0 0.0029774802
daily O 0 0.022845058
subcutaneous O 0 0.815898
deferoxamine B-Chemical 1 0.99992335
. O 0 0.013470912

Twenty O 0 0.01399926
- O 0 0.00751684
two O 0 0.0031953054
patients O 0 0.0038720386
in O 0 0.0018080118
the O 0 0.0014414918
affected O 0 0.0011158373
group O 0 0.0011936107
had O 0 0.0008428952
abnormal B-Disease 0 0.015143183
audiograms I-Disease 0 0.59683204
with I-Disease 0 0.00093542907
deficits I-Disease 0 0.25314483
mostly I-Disease 0 0.00082596246
in I-Disease 0 0.00040529185
the I-Disease 0 0.0003875489
high I-Disease 0 0.0004738638
frequency I-Disease 0 0.0004906441
range I-Disease 0 0.0006073693
of I-Disease 0 0.0005297675
4 I-Disease 0 0.00043211874
, I-Disease 0 0.0004650829
000 I-Disease 0 0.0004525481
to I-Disease 0 0.00030784225
8 I-Disease 0 0.00037891595
, I-Disease 0 0.00047760454
000 I-Disease 0 0.00062669127
Hz I-Disease 0 0.029056227
and O 0 0.000534296
in O 0 0.0004920956
the O 0 0.00066313305
hearing O 0 0.5450506
threshold O 0 0.00093498477
levels O 0 0.00097624067
of O 0 0.0015405362
30 O 0 0.0015070597
to O 0 0.0021391658
100 O 0 0.005936118
decibels O 0 0.036680963
. O 0 0.0072356774

When O 0 0.009731904
deferoxamine B-Chemical 1 0.9997062
therapy O 0 0.058789793
was O 0 0.002967297
discontinued O 0 0.011701344
and O 0 0.0014554954
serial O 0 0.0015311124
studies O 0 0.00096950156
were O 0 0.0007089055
performed O 0 0.0005981748
, O 0 0.00082275947
audiograms O 0 0.1128117
in O 0 0.0004381882
seven O 0 0.00043449443
cases O 0 0.00090323674
reverted O 0 0.0017213688
to O 0 0.00039800245
normal O 0 0.00076904416
or O 0 0.00040975862
near O 0 0.00046636412
normal O 0 0.0006025723
within O 0 0.0002268497
two O 0 0.00029539922
to O 0 0.0003275518
three O 0 0.0003096224
weeks O 0 0.00036771307
, O 0 0.00064514583
and O 0 0.00059227593
nine O 0 0.0006772933
of O 0 0.00096734246
13 O 0 0.0013972983
patients O 0 0.0027283733
with O 0 0.002514027
symptoms O 0 0.86792743
became O 0 0.010155115
asymptomatic O 0 0.32896078
. O 0 0.009445096

Audiograms O 0 0.07113429
from O 0 0.0066800374
15 O 0 0.0042045633
patients O 0 0.004579843
remained O 0 0.002890716
abnormal O 0 0.0057705315
and O 0 0.002091144
four O 0 0.0014382113
patients O 0 0.0029383022
required O 0 0.0013738112
hearing O 0 0.73159504
aids O 0 0.0051548695
because O 0 0.0026311358
of O 0 0.005715996
permanent B-Disease 0 0.666396
disability I-Disease 0 0.9919253
. O 0 0.011930975

Since O 0 0.0065371213
18 O 0 0.0045743855
of O 0 0.003326096
the O 0 0.002368866
22 O 0 0.0022003131
patients O 0 0.0023090853
were O 0 0.0011133002
initially O 0 0.0014069269
receiving O 0 0.0036229037
deferoxamine B-Chemical 1 0.99998367
doses O 0 0.1331613
in O 0 0.0006765317
excess O 0 0.0011700725
of O 0 0.0006575803
the O 0 0.00049644697
commonly O 0 0.0010144544
recommended O 0 0.00058283145
50 O 0 0.0007490595
mg O 0 0.16893269
/ O 0 0.0010216497
kg O 0 0.0013371124
per O 0 0.00025263024
dose O 0 0.0037405894
, O 0 0.00068567233
therapy O 0 0.0024473371
was O 0 0.00043440185
restarted O 0 0.0016540971
with O 0 0.00039303268
lower O 0 0.00044825856
doses O 0 0.016304467
, O 0 0.00069124857
usually O 0 0.0006539638
50 O 0 0.0006645565
mg O 0 0.12030999
/ O 0 0.00085166463
kg O 0 0.0010355248
per O 0 0.00021980579
dose O 0 0.0011194939
or O 0 0.00033019332
less O 0 0.00031736624
depending O 0 0.00039445827
on O 0 0.00023492966
the O 0 0.00034249286
degree O 0 0.00053848216
of O 0 0.0008234092
auditory B-Disease 0 0.65121126
abnormality I-Disease 0 0.64548963
, O 0 0.0009900418
and O 0 0.0005595219
with O 0 0.00048793716
the O 0 0.0004622181
exception O 0 0.00045079231
of O 0 0.0006731052
two O 0 0.0006677751
cases O 0 0.0015085398
no O 0 0.0010368505
further O 0 0.0026325865
toxicity B-Disease 2 0.996546
was O 0 0.004605649
demonstrated O 0 0.0055300333
. O 0 0.0083595645

Auditory O 0 0.47656983
deterioration O 0 0.13530923
and O 0 0.0049642
improvement O 0 0.0036410496
, O 0 0.0023459096
demonstrated O 0 0.0011178086
serially O 0 0.0011336682
in O 0 0.00071753113
individual O 0 0.0006730519
patients O 0 0.0014504374
receiving O 0 0.001149472
and O 0 0.0007353755
not O 0 0.0006049518
receiving O 0 0.0050865044
deferoxamine B-Chemical 1 0.999992
, O 0 0.0043045105
respectively O 0 0.0024869782
, O 0 0.0007274262
provided O 0 0.00038226548
convincing O 0 0.0008208484
evidence O 0 0.00045814866
for O 0 0.00042235045
a O 0 0.0010051554
cause O 0 0.009037037
- O 0 0.002579792
and O 0 0.0011233827
- O 0 0.0014423961
effect O 0 0.00075502787
relation O 0 0.0008365038
between O 0 0.0014661511
deferoxamine B-Chemical 1 0.99997354
administration O 0 0.75284517
and O 0 0.04421562
ototoxicity B-Disease 2 0.99990964
. O 0 0.012837809

Based O 0 0.012721743
on O 0 0.004845582
these O 0 0.004562303
data O 0 0.0042614345
, O 0 0.003216915
a O 0 0.0023765087
plan O 0 0.002306704
of O 0 0.0016934209
management O 0 0.0026413437
was O 0 0.0012532847
developed O 0 0.0014187348
that O 0 0.0009094341
allows O 0 0.001030456
effective O 0 0.0016905537
yet O 0 0.0022433738
safe O 0 0.004983795
administration O 0 0.13870198
of O 0 0.01625104
deferoxamine B-Chemical 1 0.9999225
. O 0 0.0155191785

A O 0 0.030078202
dose O 0 0.013746916
of O 0 0.0063140956
50 O 0 0.0058949296
mg O 0 0.32231617
/ O 0 0.0065496345
kg O 0 0.008745238
is O 0 0.0025097644
recommended O 0 0.0024107907
in O 0 0.0024387157
those O 0 0.0038747468
without O 0 0.0047423295
audiogram O 0 0.7496973
abnormalities O 0 0.464089
. O 0 0.011604152

With O 0 0.012031461
mild O 0 0.593845
toxicity B-Disease 2 0.99663407
, O 0 0.0055389535
a O 0 0.002777552
reduction O 0 0.0020380062
to O 0 0.0009695099
30 O 0 0.00067403086
or O 0 0.0006015595
40 O 0 0.0006768925
mg O 0 0.081841335
/ O 0 0.0011700803
kg O 0 0.0014247124
per O 0 0.0003254594
dose O 0 0.0013428438
should O 0 0.00029606608
result O 0 0.00041735792
in O 0 0.00042176378
a O 0 0.0006632566
reversal O 0 0.0012252021
of O 0 0.0007394334
the O 0 0.0007820056
abnormal O 0 0.0049444325
results O 0 0.0011111065
to O 0 0.0012244508
normal O 0 0.002414826
within O 0 0.0014981391
four O 0 0.002606245
weeks O 0 0.004004398
. O 0 0.0068304404

Moderate O 0 0.6138716
abnormalities O 0 0.07327544
require O 0 0.0039890655
a O 0 0.0040668645
reduction O 0 0.0037653102
of O 0 0.003792207
deferoxamine B-Chemical 1 0.99993646
to O 0 0.0021543026
25 O 0 0.002523106
mg O 0 0.26532564
/ O 0 0.0031316292
kg O 0 0.003857496
per O 0 0.0013687529
dose O 0 0.005322596
with O 0 0.003401542
careful O 0 0.005760913
monitoring O 0 0.007549931
. O 0 0.008956564

In O 0 0.0074329553
those O 0 0.00593929
with O 0 0.004157965
symptoms O 0 0.586869
of O 0 0.0038607733
hearing B-Disease 0 0.9565807
loss I-Disease 0 0.00638685
, O 0 0.0016272113
the O 0 0.0007860258
drug O 0 0.20320737
should O 0 0.0003781015
be O 0 0.00046165672
stopped O 0 0.0006780463
for O 0 0.0002840585
four O 0 0.00027682245
weeks O 0 0.00028762635
, O 0 0.00046928148
and O 0 0.00037050984
when O 0 0.00026170557
the O 0 0.0003957253
audiogram O 0 0.23123421
is O 0 0.00044692965
stable O 0 0.0005071457
or O 0 0.0004929641
improved O 0 0.0011592353
, O 0 0.0008250448
therapy O 0 0.0019258691
should O 0 0.00033785184
be O 0 0.0005634517
restarted O 0 0.0014871277
at O 0 0.0004511315
10 O 0 0.00060633285
to O 0 0.0006585524
25 O 0 0.0013652041
mg O 0 0.107521966
/ O 0 0.0035569242
kg O 0 0.005749824
per O 0 0.0026865015
dose O 0 0.016678127
. O 0 0.008204005

Serial O 0 0.017000796
audiograms O 0 0.07633149
should O 0 0.0030572368
be O 0 0.002361401
performed O 0 0.0014145229
every O 0 0.0008269248
six O 0 0.00069782755
months O 0 0.00061564194
in O 0 0.0005943553
those O 0 0.0007715314
without O 0 0.00064557476
problems O 0 0.0081262225
and O 0 0.00072574435
more O 0 0.0006769258
frequently O 0 0.0008334803
in O 0 0.0005375417
young O 0 0.004324454
patients O 0 0.0018448514
with O 0 0.0007747274
normal O 0 0.0023229392
serum O 0 0.22649166
ferritin O 0 0.9954893
values O 0 0.0015268466
and O 0 0.0015043104
in O 0 0.0014579019
those O 0 0.002766559
with O 0 0.0039252914
auditory B-Disease 0 0.8316176
dysfunction I-Disease 0 0.99649566
. O 0 0.010643182

Lidocaine B-Chemical 0 0.99858785
- O 0 0.05757858
induced O 0 0.041553747
cardiac B-Disease 0 0.9834816
asystole I-Disease 2 0.9987533
. O 0 0.04367459

Intravenous O 0 0.8582548
administration O 0 0.053175323
of O 0 0.0040120194
a O 0 0.0030969766
single O 0 0.0021217563
50 O 0 0.0023978816
- O 0 0.0018182469
mg O 0 0.1156044
bolus O 0 0.028308645
of O 0 0.0012174184
lidocaine B-Chemical 1 0.9998975
in O 0 0.0007204857
a O 0 0.0010277316
67 O 0 0.0020866035
- O 0 0.0009891281
year O 0 0.00057097926
- O 0 0.00082889386
old O 0 0.00064804766
man O 0 0.03695928
resulted O 0 0.0005700136
in O 0 0.00065462355
profound O 0 0.04919921
depression B-Disease 2 0.9986066
of O 0 0.0011259849
the O 0 0.0008576853
activity O 0 0.0010484684
of O 0 0.0012461096
the O 0 0.0015817266
sinoatrial O 0 0.7615722
and O 0 0.0032844795
atrioventricular O 0 0.656509
nodal O 0 0.45703688
pacemakers O 0 0.60739213
. O 0 0.009073853

The O 0 0.0067848656
patient O 0 0.005682689
had O 0 0.0029377213
no O 0 0.0019205476
apparent O 0 0.0019471917
associated O 0 0.0018515888
conditions O 0 0.0016802065
which O 0 0.0014428514
might O 0 0.0006783301
have O 0 0.0007636648
predisposed O 0 0.061391365
him O 0 0.004492008
to O 0 0.0005480387
the O 0 0.0005710419
development O 0 0.0011941282
of O 0 0.0014953869
bradyarrhythmias B-Disease 0 0.9999654
; O 0 0.0036721148
and O 0 0.00091385096
, O 0 0.00096407905
thus O 0 0.0009136956
, O 0 0.0008992125
this O 0 0.0006597583
probably O 0 0.0012225138
represented O 0 0.001224568
a O 0 0.0018904165
true O 0 0.0025467833
idiosyncrasy O 0 0.7105934
to O 0 0.0059888
lidocaine B-Chemical 1 0.9997396
. O 0 0.010829292

Flurbiprofen B-Chemical 0 0.9979114
in O 0 0.016083833
the O 0 0.012514461
treatment O 0 0.014271808
of O 0 0.016970921
juvenile B-Disease 0 0.9437473
rheumatoid I-Disease 2 0.9996654
arthritis I-Disease 2 0.9999068
. O 0 0.081260346

Thirty O 0 0.01541692
- O 0 0.0077621145
four O 0 0.003191101
patients O 0 0.0045932075
with O 0 0.0029536379
juvenile B-Disease 0 0.7314117
rheumatoid I-Disease 2 0.9999027
arthritis I-Disease 2 0.9999914
, O 0 0.022168573
who O 0 0.0041994336
were O 0 0.00079938024
treated O 0 0.0009081379
with O 0 0.0010567755
flurbiprofen B-Chemical 0 0.9999846
at O 0 0.00043139764
a O 0 0.0005374741
maximum O 0 0.0003701229
dose O 0 0.0015509665
of O 0 0.0005238453
4 O 0 0.000443161
mg O 0 0.12929061
/ O 0 0.0012431145
kg O 0 0.002790101
/ O 0 0.0010313003
day O 0 0.00038349902
, O 0 0.00050115207
had O 0 0.000314153
statistically O 0 0.00034521997
significant O 0 0.00043108768
decreases O 0 0.00046265233
from O 0 0.0004635533
baseline O 0 0.0006097886
in O 0 0.00054852
6 O 0 0.00067694386
arthritis B-Disease 2 0.9965341
indices O 0 0.0017757
after O 0 0.00084991433
12 O 0 0.0011783761
weeks O 0 0.0014284878
of O 0 0.003272007
treatment O 0 0.008160949
. O 0 0.00836662

Improvements O 0 0.010134224
were O 0 0.0051780962
seen O 0 0.0031628686
in O 0 0.0022153324
the O 0 0.0016783974
number O 0 0.0013219669
of O 0 0.0018088476
tender B-Disease 0 0.67402947
joints I-Disease 0 0.7798594
, O 0 0.0017453267
the O 0 0.00076275645
severity O 0 0.03146816
of O 0 0.0016453194
swelling B-Disease 0 0.99835616
and O 0 0.0029368526
tenderness B-Disease 0 0.9991015
, O 0 0.0010547035
the O 0 0.00043652847
time O 0 0.00034014386
of O 0 0.0005527652
walk O 0 0.0065807565
50 O 0 0.0007848548
feet O 0 0.011839328
, O 0 0.00063609815
the O 0 0.0004070732
duration O 0 0.00057177054
of O 0 0.0008356339
morning B-Disease 0 0.030600647
stiffness I-Disease 0 0.5698147
and O 0 0.0014322726
the O 0 0.0014464008
circumference O 0 0.020267848
of O 0 0.0024771257
the O 0 0.0032220525
left O 0 0.009788843
knee O 0 0.5152646
. O 0 0.0088394815

The O 0 0.0069902213
most O 0 0.0057648686
frequently O 0 0.004122437
observed O 0 0.0020782372
side O 0 0.028035179
effect O 0 0.0018329761
was O 0 0.0014654316
fecal B-Disease 0 0.42766228
occult I-Disease 0 0.5673533
blood I-Disease 0 0.29121605
( O 0 0.0017505076
25 O 0 0.0009141097
% O 0 0.00063476065
of O 0 0.00061479764
patients O 0 0.0032112128
) O 0 0.0018281118
; O 0 0.0009911017
however O 0 0.00057740096
, O 0 0.000547693
there O 0 0.00027263895
was O 0 0.000350721
no O 0 0.00030919263
other O 0 0.0004972223
evidence O 0 0.0006792018
of O 0 0.0014717941
gastrointestinal B-Disease 0 0.9982216
( I-Disease 0 0.014330637
GI I-Disease 0 0.99313354
) I-Disease 0 0.013737481
bleeding I-Disease 2 0.9983637
in O 0 0.0032066582
these O 0 0.0053189113
patients O 0 0.016122136
. O 0 0.008684759

One O 0 0.012874166
patient O 0 0.008686401
was O 0 0.0053956485
prematurely O 0 0.010495576
discontinued O 0 0.008908231
from O 0 0.002527923
the O 0 0.0022114126
study O 0 0.00260877
for O 0 0.0022949292
severe O 0 0.59546506
headache B-Disease 2 0.99989617
and O 0 0.014150497
abdominal B-Disease 0 0.963514
pain I-Disease 2 0.99882215
. O 0 0.014999029

Most O 0 0.019265678
side O 0 0.04014322
effects O 0 0.01146197
were O 0 0.007866067
mild O 0 0.31480685
and O 0 0.0064576524
related O 0 0.0046015233
to O 0 0.0054282276
the O 0 0.007937558
GI O 0 0.9842457
tract O 0 0.7268304
. O 0 0.016620638

Hyperkalemia B-Disease 0 0.99650335
associated O 0 0.03998932
with O 0 0.043499384
sulindac B-Chemical 1 0.9997737
therapy O 0 0.7441392
. O 0 0.037864126

Hyperkalemia B-Disease 0 0.9984108
has O 0 0.0069503845
recently O 0 0.0049791834
been O 0 0.003322633
recognized O 0 0.0026084594
as O 0 0.0018977624
a O 0 0.0022708059
complication O 0 0.385971
of O 0 0.0043401476
nonsteroidal O 0 0.9999845
antiinflammatory O 0 0.99972147
agents O 0 0.9605046
( O 0 0.0990698
NSAID O 0 0.9999882
) O 0 0.02127444
such O 0 0.004437492
as O 0 0.010001289
indomethacin B-Chemical 1 0.9998652
. O 0 0.014378915

Several O 0 0.009819641
recent O 0 0.0060898685
studies O 0 0.004161471
have O 0 0.002538817
stressed O 0 0.002764121
the O 0 0.0019324834
renal O 0 0.9538743
sparing O 0 0.10039383
features O 0 0.0042548575
of O 0 0.004464364
sulindac B-Chemical 1 0.9999943
, O 0 0.003863782
owing O 0 0.0012746333
to O 0 0.0008436578
its O 0 0.0013972038
lack O 0 0.0010022579
of O 0 0.0017118629
interference O 0 0.0050898236
with O 0 0.0048928712
renal O 0 0.99921083
prostacyclin B-Chemical 0 0.99996674
synthesis O 0 0.7803654
. O 0 0.0128082745

We O 0 0.007176107
describe O 0 0.004488508
4 O 0 0.0032386961
patients O 0 0.0035666656
in O 0 0.0018671491
whom O 0 0.004905536
hyperkalemia B-Disease 2 0.99995244
ranging O 0 0.009697403
from O 0 0.0010936538
6 O 0 0.0006417291
. O 0 0.00045343765
1 O 0 0.00048557823
to O 0 0.00039451357
6 O 0 0.00039246693
. O 0 0.00036751194
9 O 0 0.0005753068
mEq O 0 0.51644385
/ O 0 0.0010981356
l O 0 0.00093060243
developed O 0 0.00074507936
within O 0 0.00044740346
3 O 0 0.0006688017
to O 0 0.000718357
8 O 0 0.0010036884
days O 0 0.0011886434
of O 0 0.0038039177
sulindac B-Chemical 1 0.9999695
administration O 0 0.7581149
. O 0 0.011194497

In O 0 0.007856357
all O 0 0.005238427
of O 0 0.004618143
them O 0 0.0054489514
normal O 0 0.0060004834
serum O 0 0.35099113
potassium B-Chemical 1 0.9998074
levels O 0 0.0019091361
reached O 0 0.0014744707
within O 0 0.00083438674
2 O 0 0.0011328225
to O 0 0.0010513258
4 O 0 0.0012753607
days O 0 0.0014264038
of O 0 0.0033091055
stopping O 0 0.2023371
sulindac B-Chemical 1 0.9999478
. O 0 0.015115224

As O 0 0.0056238025
no O 0 0.003667418
other O 0 0.0033488777
medications O 0 0.26793736
known O 0 0.0028046723
to O 0 0.0015482936
effect O 0 0.0017097846
serum O 0 0.53712195
potassium B-Chemical 1 0.9999398
had O 0 0.0011226059
been O 0 0.00071514794
given O 0 0.00038118794
concomitantly O 0 0.005839266
, O 0 0.00071589183
this O 0 0.00037772217
course O 0 0.0005005157
of O 0 0.0006099813
events O 0 0.019790933
is O 0 0.00051771244
suggestive O 0 0.0010878759
of O 0 0.0007986664
a O 0 0.0013735205
cause O 0 0.0132622
- O 0 0.0029736664
and O 0 0.0012662441
- O 0 0.0016438108
effect O 0 0.0009224377
relationship O 0 0.0011384255
between O 0 0.0021112303
sulindac B-Chemical 1 0.9999831
and O 0 0.10712995
hyperkalemia B-Disease 2 0.999951
. O 0 0.014612909

These O 0 0.008577287
observations O 0 0.0057964725
indicate O 0 0.00315244
that O 0 0.0022399547
initial O 0 0.0022713763
hopes O 0 0.015489615
that O 0 0.0018366056
sulindac B-Chemical 1 0.9999881
may O 0 0.0015967337
not O 0 0.0009611679
be O 0 0.0008109273
associated O 0 0.0007953376
with O 0 0.000740682
the O 0 0.00080281805
adverse O 0 0.93259853
renal O 0 0.98716706
effects O 0 0.0035793395
of O 0 0.0019750257
other O 0 0.0034319386
NSAID O 0 0.9999845
are O 0 0.0039893673
probably O 0 0.0056738257
not O 0 0.0044016964
justified O 0 0.013479463
. O 0 0.008321318

Drug O 0 0.9575351
- O 0 0.027802149
induced O 0 0.017832879
arterial O 0 0.9094894
spasm B-Disease 2 0.9995351
relieved O 0 0.8304061
by O 0 0.03409245
lidocaine B-Chemical 1 0.9995078
. O 0 0.024512893

Case O 0 0.20553096
report O 0 0.12067233
. O 0 0.09154606

Following O 0 0.0083725955
major O 0 0.006963406
intracranial O 0 0.74510056
surgery O 0 0.0062155053
in O 0 0.0022339541
a O 0 0.0024058905
35 O 0 0.0020064514
- O 0 0.002015954
year O 0 0.0012008041
- O 0 0.001559509
old O 0 0.0013122158
man O 0 0.16566579
, O 0 0.003961896
sodium B-Chemical 1 0.99990475
pentothal I-Chemical 0 0.99964464
was O 0 0.0015768545
intravenously O 0 0.0041717044
infused O 0 0.0031596937
to O 0 0.0019027184
minimize O 0 0.0029961444
cerebral B-Disease 0 0.99821174
ischaemia I-Disease 0 0.9999373
. O 0 0.013961802

Intense O 0 0.065310396
vasospasm B-Disease 2 0.9995009
with O 0 0.010673321
threatened O 0 0.086840905
gangrene B-Disease 0 0.99759185
arose O 0 0.006643847
in O 0 0.0032583724
the O 0 0.0030468514
arm O 0 0.0043821493
used O 0 0.0030533792
for O 0 0.0032616667
the O 0 0.0052820956
infusion O 0 0.042986613
. O 0 0.010396956

Since O 0 0.0065328707
the O 0 0.0050292276
cranial O 0 0.04552798
condition O 0 0.0036364775
precluded O 0 0.0025372778
use O 0 0.0014408819
of O 0 0.0012594543
more O 0 0.0010790348
usual O 0 0.001200325
methods O 0 0.001042846
, O 0 0.001495777
lidocaine B-Chemical 1 0.9998393
was O 0 0.0006492117
given O 0 0.0004188865
intra O 0 0.02075017
- O 0 0.0015695153
arterially O 0 0.028433846
, O 0 0.0008412343
with O 0 0.0006767664
careful O 0 0.0012836881
cardiovascular O 0 0.98170596
monitoring O 0 0.0020702642
, O 0 0.002221396
to O 0 0.0018284154
counteract O 0 0.005830027
the O 0 0.0072871214
vasospasm B-Disease 2 0.9999018
. O 0 0.012039671

The O 0 0.030508166
treatment O 0 0.031611793
was O 0 0.028548019
rapidly O 0 0.03473708
successful O 0 0.033000935
. O 0 0.032238703

Regional O 0 0.012378594
localization O 0 0.0059513003
of O 0 0.0052202796
the O 0 0.004286545
antagonism O 0 0.56467694
of O 0 0.012444899
amphetamine B-Chemical 1 0.9999865
- O 0 0.058078486
induced O 0 0.011504277
hyperactivity B-Disease 2 0.9999056
by O 0 0.019955933
intracerebral O 0 0.9994056
calcitonin B-Chemical 1 0.99802375
injections O 0 0.18758623
. O 0 0.011030281

Calcitonin B-Chemical 0 0.98991126
receptors O 0 0.21877468
are O 0 0.0049991715
found O 0 0.0026160383
in O 0 0.0021534981
the O 0 0.0020440894
brain O 0 0.06503331
, O 0 0.0024663715
and O 0 0.0020307773
intracerebral O 0 0.994938
infusions O 0 0.14450958
of O 0 0.003486789
calcitonin B-Chemical 1 0.9893469
can O 0 0.0025298933
produce O 0 0.0031584818
behavioral O 0 0.1254054
effects O 0 0.015265321
. O 0 0.009544178

Among O 0 0.012319113
these O 0 0.00697243
behavioral O 0 0.025902124
effects O 0 0.00503717
are O 0 0.0026612454
decreases O 0 0.0021065332
in O 0 0.001620903
food O 0 0.03339582
intake O 0 0.70722204
and O 0 0.0023934904
decreases O 0 0.0023545632
in O 0 0.0032616418
amphetamine B-Chemical 1 0.9999839
- O 0 0.023420457
induced O 0 0.006419754
locomotor O 0 0.8863853
activity O 0 0.010227491
. O 0 0.009359643

In O 0 0.0068271873
previous O 0 0.0042647403
experiments O 0 0.002943736
we O 0 0.0017940436
found O 0 0.0014247448
that O 0 0.0011686449
decreases O 0 0.00132911
in O 0 0.001059098
food O 0 0.030871848
intake O 0 0.68942964
were O 0 0.0010048351
induced O 0 0.00091286807
by O 0 0.0008928206
local O 0 0.001642159
administration O 0 0.05760881
of O 0 0.0015761647
calcitonin B-Chemical 1 0.98828363
into O 0 0.00064423884
several O 0 0.0011492529
hypothalamic O 0 0.45101863
sites O 0 0.0013665792
and O 0 0.0016658921
into O 0 0.0013966875
the O 0 0.0028851428
nucleus O 0 0.008626993
accumbens O 0 0.8779847
. O 0 0.007951561

In O 0 0.0073006866
the O 0 0.0049519525
present O 0 0.0029894318
experiment O 0 0.0027276569
calcitonin B-Chemical 1 0.98038876
decreased O 0 0.00574438
locomotor O 0 0.70413846
activity O 0 0.0014550725
when O 0 0.00073681114
locally O 0 0.008903343
injected O 0 0.00078924117
into O 0 0.0005602204
the O 0 0.000771032
same O 0 0.00073252566
sites O 0 0.0012480405
where O 0 0.0014658121
it O 0 0.002351174
decreases O 0 0.0033592717
food O 0 0.076828524
intake O 0 0.8369622
. O 0 0.011194852

The O 0 0.007855089
areas O 0 0.008091284
where O 0 0.0042082323
calcitonin B-Chemical 1 0.96115136
is O 0 0.0024046472
most O 0 0.0019957724
effective O 0 0.0014502504
in O 0 0.0009176102
decreasing O 0 0.0017903271
locomotor O 0 0.7320211
activity O 0 0.0009981081
are O 0 0.00061221054
located O 0 0.000477958
in O 0 0.00041119824
the O 0 0.00053354434
hypothalamus O 0 0.07544296
and O 0 0.0006605129
nucleus O 0 0.0015479386
accumbens O 0 0.8736067
, O 0 0.00057143933
suggesting O 0 0.00027380235
that O 0 0.0002762738
these O 0 0.00046832298
areas O 0 0.00094891863
are O 0 0.0004147186
the O 0 0.0003785946
major O 0 0.00054644473
sites O 0 0.0005250957
of O 0 0.0007225912
action O 0 0.005024029
of O 0 0.0016631157
calcitonin B-Chemical 1 0.99557143
in O 0 0.0018019532
inhibiting O 0 0.03929094
amphetamine B-Chemical 1 0.9999906
- O 0 0.026804566
induced O 0 0.005804034
locomotor O 0 0.88613683
activity O 0 0.009238392
. O 0 0.0085272845

The O 0 0.008363933
hematologic O 0 0.8616568
effects O 0 0.006852239
of O 0 0.004371361
cefonicid B-Chemical 1 0.9896436
and O 0 0.0039932225
cefazedone B-Chemical 1 0.99728715
in O 0 0.0013548627
the O 0 0.0011593627
dog O 0 0.0027426407
: O 0 0.0016059054
a O 0 0.0012346884
potential O 0 0.0014937416
model O 0 0.0019066046
of O 0 0.0046297307
cephalosporin B-Chemical 0 0.99977213
hematotoxicity B-Disease 0 0.99994755
in O 0 0.010072204
man O 0 0.72294486
. O 0 0.011934192

Cephalosporin B-Chemical 0 0.96720624
antibiotics O 0 0.54197234
cause O 0 0.01167606
a O 0 0.004286443
variety O 0 0.0050386894
of O 0 0.0039682644
hematologic B-Disease 0 0.9995365
disturbances I-Disease 0 0.9892541
in O 0 0.0018810977
man O 0 0.3242088
, O 0 0.001986232
the O 0 0.0011523091
pathogeneses O 0 0.11370149
and O 0 0.0020458202
hematopathology O 0 0.004131037
of O 0 0.0023261784
which O 0 0.0030596722
remain O 0 0.0033279995
poorly O 0 0.009999655
characterized O 0 0.011129557
. O 0 0.0097879935

There O 0 0.00964103
is O 0 0.005835046
a O 0 0.004599349
need O 0 0.0026739135
for O 0 0.0018568505
a O 0 0.0022241117
well O 0 0.0016527654
- O 0 0.002083403
defined O 0 0.0010294406
animal O 0 0.0014591286
model O 0 0.0013473885
in O 0 0.0011671331
which O 0 0.0017187395
these O 0 0.002436043
blood B-Disease 0 0.48233002
dyscrasias I-Disease 0 0.9996032
can O 0 0.004180858
be O 0 0.005458071
studied O 0 0.007542838
. O 0 0.009308671

In O 0 0.0075357663
four O 0 0.00527948
subacute O 0 0.9844549
toxicity B-Disease 2 0.99761295
studies O 0 0.0038738614
, O 0 0.002059108
the O 0 0.0010002394
intravenous O 0 0.26788235
administration O 0 0.06383247
of O 0 0.0013478916
cefonicid B-Chemical 1 0.99364823
or O 0 0.0011818142
cefazedone B-Chemical 1 0.99858534
to O 0 0.00057929556
beagle O 0 0.006767318
dogs O 0 0.0023188067
caused O 0 0.0007115001
a O 0 0.0010427127
dose O 0 0.029653642
- O 0 0.0013423772
dependent O 0 0.00043030432
incidence O 0 0.012965528
of O 0 0.0028925776
anemia B-Disease 2 0.999982
, O 0 0.020366644
neutropenia B-Disease 2 0.99991405
, O 0 0.0025576744
and O 0 0.0016167108
thrombocytopenia B-Disease 2 0.99987125
after O 0 0.00084762875
1 O 0 0.0015524834
- O 0 0.001870701
3 O 0 0.0013922163
months O 0 0.0015952582
of O 0 0.0033138774
treatment O 0 0.0079614865
. O 0 0.008252879

A O 0 0.15456729
nonregenerative O 0 0.89937466
anemia B-Disease 2 0.99964476
was O 0 0.0047068936
the O 0 0.0023788887
most O 0 0.0022231287
compromising O 0 0.0032007683
of O 0 0.0015203137
the O 0 0.0014765046
cytopenias B-Disease 0 0.99989414
and O 0 0.0016772855
occurred O 0 0.0008442175
in O 0 0.0005011903
approximately O 0 0.000488612
50 O 0 0.0006614427
% O 0 0.0004809313
of O 0 0.00045030398
dogs O 0 0.0010712757
receiving O 0 0.0011473781
400 O 0 0.0035222804
- O 0 0.0009883256
500 O 0 0.0013317531
mg O 0 0.092193566
/ O 0 0.0014549589
kg O 0 0.0031417485
cefonicid B-Chemical 1 0.91013086
or O 0 0.0013182643
540 O 0 0.02811364
- O 0 0.0024550813
840 O 0 0.015494954
mg O 0 0.21460718
/ O 0 0.007688164
kg O 0 0.04656332
cefazedone B-Chemical 1 0.9955947
. O 0 0.010237608

All O 0 0.007835894
three O 0 0.0051486376
cytopenias B-Disease 0 0.9987674
were O 0 0.0039072908
completely O 0 0.0025638323
reversible O 0 0.09195534
following O 0 0.0012439679
cessation O 0 0.0067426604
of O 0 0.001089348
treatment O 0 0.0019139961
; O 0 0.0012477754
the O 0 0.00041378033
time O 0 0.00029753093
required O 0 0.00021730064
for O 0 0.00027166
recovery O 0 0.00067071663
of O 0 0.0005064853
the O 0 0.0005832346
erythron O 0 0.98221576
( O 0 0.0010833467
approximately O 0 0.00041525497
1 O 0 0.00041541416
month O 0 0.00029542347
) O 0 0.0006145138
was O 0 0.0003189277
considerably O 0 0.0004392687
longer O 0 0.0002296251
than O 0 0.00024941485
that O 0 0.00029335744
of O 0 0.00052881805
the O 0 0.00062529836
granulocytes O 0 0.48841804
and O 0 0.0015256343
platelets O 0 0.5305407
( O 0 0.0018491757
hours O 0 0.00082875637
to O 0 0.0010992284
a O 0 0.0019203237
few O 0 0.0017757913
days O 0 0.0030473582
) O 0 0.008350281
. O 0 0.0075639994

Upon O 0 0.011067295
rechallenge O 0 0.25155914
with O 0 0.004444956
either O 0 0.0036427956
cephalosporin B-Chemical 0 0.9985902
, O 0 0.0034136123
the O 0 0.0016851366
hematologic B-Disease 0 0.99937445
syndrome I-Disease 0 0.9963839
was O 0 0.0013072329
reproduced O 0 0.0012812689
in O 0 0.00052977965
most O 0 0.00076226593
dogs O 0 0.0016767684
tested O 0 0.0005183687
; O 0 0.0018941782
cefonicid B-Chemical 1 0.98373216
( O 0 0.001133244
but O 0 0.00051760586
not O 0 0.00059853244
cefazedone B-Chemical 1 0.99904615
) O 0 0.0046565887
- O 0 0.000976576
treated O 0 0.00049449975
dogs O 0 0.0010883937
showed O 0 0.0003434889
a O 0 0.00059750595
substantially O 0 0.00062491506
reduced O 0 0.0004933336
induction O 0 0.00052235846
period O 0 0.00043890977
( O 0 0.00074438064
15 O 0 0.0004017557
+ O 0 0.0005460417
/ O 0 0.0013943531
- O 0 0.0006393337
5 O 0 0.0002688658
days O 0 0.0002516235
) O 0 0.00048245845
compared O 0 0.00019662759
to O 0 0.00025874868
that O 0 0.00025033948
of O 0 0.00040153324
the O 0 0.00037813938
first O 0 0.00034766403
exposure O 0 0.00096366764
to O 0 0.0005259597
the O 0 0.00072310993
drug O 0 0.51674265
( O 0 0.0019628971
61 O 0 0.00269543
+ O 0 0.0015843862
/ O 0 0.0034328583
- O 0 0.00250345
24 O 0 0.0018339613
days O 0 0.0025541936
) O 0 0.0070037423
. O 0 0.0069015697

This O 0 0.009976084
observation O 0 0.0052790274
, O 0 0.0042254473
along O 0 0.0023161178
with O 0 0.0017334083
the O 0 0.0013298031
rapid O 0 0.0018819387
rate O 0 0.00094409677
of O 0 0.0010878246
decline O 0 0.0020385908
in O 0 0.0006350251
red O 0 0.0035278995
cell O 0 0.0073434133
mass O 0 0.0035000294
parameters O 0 0.00083438435
of O 0 0.00067917164
affected O 0 0.0005501259
dogs O 0 0.003407883
, O 0 0.000698695
suggests O 0 0.00025662425
that O 0 0.00034943307
a O 0 0.00096523104
hemolytic B-Disease 0 0.9996755
component O 0 0.0012552579
complicated O 0 0.013475848
the O 0 0.0007461573
red O 0 0.008124948
cell O 0 0.015212512
production O 0 0.0017156465
problem O 0 0.0018998763
and O 0 0.0008708971
that O 0 0.0006555124
multiple O 0 0.0020795965
toxicologic O 0 0.23322254
mechanisms O 0 0.0029189705
contributed O 0 0.0038379598
to O 0 0.0028499607
the O 0 0.0058173086
cytopenia B-Disease 0 0.99976605
. O 0 0.013058106

We O 0 0.0066301366
conclude O 0 0.0038585933
that O 0 0.0026408248
the O 0 0.002210832
administration O 0 0.01775722
of O 0 0.0018041057
high O 0 0.0015989261
doses O 0 0.02844169
of O 0 0.0015760717
cefonicid B-Chemical 1 0.993946
or O 0 0.0013102518
cefazedone B-Chemical 1 0.99864954
to O 0 0.00063336286
dogs O 0 0.002868612
can O 0 0.00047884625
induce O 0 0.0006045143
hematotoxicity B-Disease 0 0.99996364
similar O 0 0.00042131997
to O 0 0.00047072454
the O 0 0.00071028265
cephalosporin B-Chemical 0 0.9996049
- O 0 0.003998874
induced O 0 0.0009009071
blood B-Disease 0 0.53028226
dyscrasias I-Disease 0 0.9998373
described O 0 0.00067759154
in O 0 0.0006025493
man O 0 0.109263875
and O 0 0.00075275684
thus O 0 0.0007934721
provides O 0 0.0004187994
a O 0 0.0007004033
useful O 0 0.0006405418
model O 0 0.00071716675
for O 0 0.00061952794
studying O 0 0.0011418543
the O 0 0.0013150413
mechanisms O 0 0.0024953126
of O 0 0.0035435134
these O 0 0.0075011244
disorders O 0 0.96804976
. O 0 0.010549415

Cerebral O 0 0.49213344
blood O 0 0.019411977
flow O 0 0.012306621
and O 0 0.004835239
metabolism O 0 0.14050673
during O 0 0.0024300502
isoflurane B-Chemical 1 0.9989298
- O 0 0.0065244157
induced O 0 0.0030796095
hypotension B-Disease 2 0.9999417
in O 0 0.0018118538
patients O 0 0.0035535605
subjected O 0 0.0012513917
to O 0 0.0017490298
surgery O 0 0.0049748765
for O 0 0.003540018
cerebral B-Disease 0 0.99588925
aneurysms I-Disease 2 0.9990023
. O 0 0.012445182

Cerebral O 0 0.44808796
blood O 0 0.016254349
flow O 0 0.0099473735
and O 0 0.0038748812
cerebral O 0 0.6913413
metabolic O 0 0.14375806
rate O 0 0.0015291716
for O 0 0.0009774811
oxygen B-Chemical 1 0.9417728
were O 0 0.00083831244
measured O 0 0.0005096722
during O 0 0.00059232453
isoflurane B-Chemical 1 0.99882656
- O 0 0.0029093218
induced O 0 0.0013917336
hypotension B-Disease 2 0.99996746
in O 0 0.0008189151
10 O 0 0.0007135528
patients O 0 0.0011192317
subjected O 0 0.0005153354
to O 0 0.0007797487
craniotomy O 0 0.021334466
for O 0 0.0010439064
clipping O 0 0.0046570105
of O 0 0.0026521867
a O 0 0.0064219963
cerebral B-Disease 0 0.99610764
aneurysm I-Disease 2 0.99838793
. O 0 0.012262533

Flow O 0 0.54775196
and O 0 0.008746249
metabolism O 0 0.059911415
were O 0 0.0030990443
measured O 0 0.0017650335
5 O 0 0.0015173086
- O 0 0.0015112882
13 O 0 0.0008277048
days O 0 0.0004793166
after O 0 0.00039409072
the O 0 0.0007826571
subarachnoid B-Disease 0 0.9999312
haemorrhage I-Disease 0 0.9999852
by O 0 0.0011740532
a O 0 0.00092862896
modification O 0 0.0009770814
of O 0 0.0006269537
the O 0 0.0005676427
classical O 0 0.0034685617
Kety O 0 0.7335881
- O 0 0.0016704949
Schmidt O 0 0.04900737
technique O 0 0.0007856378
using O 0 0.00053857977
xenon B-Chemical 0 0.9080121
- O 0 0.0013835534
133 O 0 0.0050133327
i O 0 0.0016848654
. O 0 0.00037386353
v O 0 0.012012799
. O 0 0.00037210446
Anaesthesia O 0 0.16431206
was O 0 0.0003566589
maintained O 0 0.0002780031
with O 0 0.0003713281
an O 0 0.0005990466
inspired O 0 0.007314115
isoflurane B-Chemical 1 0.99600214
concentration O 0 0.0010858933
of O 0 0.00067719736
0 O 0 0.00081850117
. O 0 0.00030412694
75 O 0 0.0005504269
% O 0 0.00048250626
( O 0 0.0004864056
plus O 0 0.00033679255
67 O 0 0.000996921
% O 0 0.0006882206
nitrous B-Chemical 0 0.9927522
oxide I-Chemical 0 0.9953472
in O 0 0.00081624906
oxygen B-Chemical 1 0.99343216
) O 0 0.002791699
, O 0 0.0006596715
during O 0 0.00029485588
which O 0 0.0006431655
CBF O 0 0.77145535
and O 0 0.00071361
CMRO2 O 0 0.96421105
were O 0 0.0004480001
34 O 0 0.00060530304
. O 0 0.0002892541
3 O 0 0.00037814621
+ O 0 0.00051566167
/ O 0 0.001431704
- O 0 0.0007647477
2 O 0 0.00038331535
. O 0 0.0002627073
1 O 0 0.00033910418
ml O 0 0.0008247807
/ O 0 0.0009126137
100 O 0 0.00065103703
g O 0 0.00067521125
min O 0 0.0005473319
- O 0 0.0006783537
1 O 0 0.00038738304
and O 0 0.0004020262
2 O 0 0.0004099636
. O 0 0.0002894709
32 O 0 0.0005485588
+ O 0 0.00052432134
/ O 0 0.0013159355
- O 0 0.00072001724
0 O 0 0.00047363888
. O 0 0.0002466217
16 O 0 0.0003213281
ml O 0 0.00079498417
/ O 0 0.00091186055
100 O 0 0.00066400284
g O 0 0.0006962366
min O 0 0.00056593935
- O 0 0.00068565394
1 O 0 0.0003936501
at O 0 0.0003058451
PaCO2 O 0 0.44224486
4 O 0 0.00039750987
. O 0 0.0003267116
1 O 0 0.00049615273
+ O 0 0.00060525344
/ O 0 0.0014076277
- O 0 0.0009419736
0 O 0 0.0007244521
. O 0 0.0004683716
1 O 0 0.000754305
kPa O 0 0.0063326564
( O 0 0.0012796742
mean O 0 0.0011932617
+ O 0 0.0022620587
/ O 0 0.0057096826
- O 0 0.005372171
SEM O 0 0.050000317
) O 0 0.009465998
. O 0 0.008196546

Controlled O 0 0.015510398
hypotension B-Disease 2 0.99904126
to O 0 0.0043556876
an O 0 0.0035256306
average O 0 0.0019956545
MAP O 0 0.5444397
of O 0 0.0022430024
50 O 0 0.0026318566
- O 0 0.0017765261
55 O 0 0.0011317413
mm O 0 0.0025432366
Hg B-Chemical 0 0.7605444
was O 0 0.0005681677
induced O 0 0.0005496379
by O 0 0.0005619092
increasing O 0 0.0005762628
the O 0 0.0004516026
dose O 0 0.0052691833
of O 0 0.0011640509
isoflurane B-Chemical 1 0.99924755
, O 0 0.001127493
and O 0 0.00056961057
maintained O 0 0.00036608995
at O 0 0.00031502522
an O 0 0.00056889874
inspired O 0 0.0018344905
concentration O 0 0.001023702
of O 0 0.0008588024
2 O 0 0.00083822984
. O 0 0.0005767332
2 O 0 0.000887338
+ O 0 0.0012357349
/ O 0 0.002996737
- O 0 0.0023562976
0 O 0 0.0021742315
. O 0 0.0018831984
2 O 0 0.0033429705
% O 0 0.005810545
. O 0 0.006927017

This O 0 0.010404386
resulted O 0 0.0048365835
in O 0 0.0033385723
a O 0 0.0030728625
significant O 0 0.0022014377
decrease O 0 0.0017534673
in O 0 0.0016085622
CMRO2 O 0 0.9870947
( O 0 0.0017247209
to O 0 0.0007482907
1 O 0 0.00079315103
. O 0 0.00047902754
73 O 0 0.0012090195
+ O 0 0.0007371412
/ O 0 0.0015774403
- O 0 0.0008832292
0 O 0 0.0005880788
. O 0 0.0003217781
16 O 0 0.0004178408
ml O 0 0.0010019657
/ O 0 0.0011801858
100 O 0 0.0009392143
g O 0 0.0010778346
min O 0 0.00099338
- O 0 0.0014250969
1 O 0 0.0011450383
) O 0 0.0019094142
, O 0 0.0018539919
while O 0 0.0019164907
CBF O 0 0.628642
was O 0 0.003813197
unchanged O 0 0.005627711
. O 0 0.0076824254

After O 0 0.0066528306
the O 0 0.005586478
clipping O 0 0.007866235
of O 0 0.0036160594
the O 0 0.0030695798
aneurysm B-Disease 2 0.9441796
the O 0 0.0029671027
isoflurane B-Chemical 1 0.99706537
concentration O 0 0.0047205845
was O 0 0.0020070376
reduced O 0 0.0019721226
to O 0 0.0021284656
0 O 0 0.003439007
. O 0 0.0026924002
75 O 0 0.005423234
% O 0 0.0070257536
. O 0 0.007940909

There O 0 0.009331266
was O 0 0.00581767
a O 0 0.0046544294
significant O 0 0.0031643033
increase O 0 0.002098748
in O 0 0.00212866
CBF O 0 0.8325791
, O 0 0.0023495425
although O 0 0.0013972776
CMRO2 O 0 0.9649407
was O 0 0.0012186888
unchanged O 0 0.001237457
, O 0 0.0014789255
compared O 0 0.00094010367
with O 0 0.002004346
pre O 0 0.020842165
- O 0 0.008495399
hypotensive B-Disease 2 0.9976096
values O 0 0.008563118
. O 0 0.009064005

These O 0 0.011535085
changes O 0 0.008110472
might O 0 0.004569639
offer O 0 0.0047728345
protection O 0 0.0068213926
to O 0 0.0032764408
brain O 0 0.053828526
tissue O 0 0.015796589
during O 0 0.0025676335
periods O 0 0.0038374986
of O 0 0.0054961694
induced O 0 0.016174044
hypotension B-Disease 2 0.9998642
. O 0 0.01664181

Triazolam B-Chemical 0 0.9994568
- O 0 0.016079282
induced O 0 0.0065714424
brief O 0 0.0059086652
episodes O 0 0.18912216
of O 0 0.006003362
secondary O 0 0.05106405
mania B-Disease 0 0.9998393
in O 0 0.0063760197
a O 0 0.010295654
depressed B-Disease 2 0.8940675
patient O 0 0.015233928
. O 0 0.0120429145

Large O 0 0.019704698
doses O 0 0.021658504
of O 0 0.009408411
triazolam B-Chemical 0 0.9999491
repeatedly O 0 0.006104554
induced O 0 0.0031903153
brief O 0 0.0033952456
episodes O 0 0.39888632
of O 0 0.006358462
mania B-Disease 0 0.9998847
in O 0 0.004058699
a O 0 0.007874002
depressed B-Disease 2 0.94910496
elderly O 0 0.8105304
woman O 0 0.25332183
. O 0 0.012515945

Features O 0 0.06270138
of O 0 0.015812187
organic B-Disease 0 0.9868129
mental I-Disease 0 0.9302105
disorder I-Disease 0 0.9984812
( O 0 0.071114354
delirium B-Disease 2 0.9997658
) O 0 0.015411944
were O 0 0.006545848
not O 0 0.006297098
present O 0 0.0074315625
. O 0 0.011732663

Manic B-Disease 0 0.99670756
excitement O 0 0.5118253
was O 0 0.00905123
coincident O 0 0.0073816916
with O 0 0.0050910143
the O 0 0.0044940645
duration O 0 0.005094426
of O 0 0.006442142
action O 0 0.040506948
of O 0 0.028073942
triazolam B-Chemical 0 0.9999441
. O 0 0.017563846

The O 0 0.00775346
possible O 0 0.0054061054
contribution O 0 0.0034989866
of O 0 0.0038238643
the O 0 0.0037103873
triazolo B-Chemical 0 0.9882725
group O 0 0.003459974
to O 0 0.0021990791
changes O 0 0.002997036
in O 0 0.0029985397
affective O 0 0.9409643
status O 0 0.007783486
is O 0 0.005520404
discussed O 0 0.006465949
. O 0 0.009819679

The O 0 0.008450892
correlation O 0 0.005444561
between O 0 0.0046831267
neurotoxic B-Disease 2 0.99893254
esterase O 0 0.98734415
inhibition O 0 0.100552835
and O 0 0.01753902
mipafox B-Chemical 0 0.99993575
- O 0 0.04619352
induced O 0 0.019117378
neuropathic B-Disease 0 0.9999794
damage I-Disease 0 0.9962876
in O 0 0.010151089
rats O 0 0.05384085
. O 0 0.011107229

The O 0 0.0070211175
correlation O 0 0.0044851815
between O 0 0.0040166196
neuropathic B-Disease 0 0.9999485
damage I-Disease 0 0.99406874
and O 0 0.0054358193
inhibition O 0 0.0176234
of O 0 0.005277092
neurotoxic B-Disease 2 0.99989045
esterase O 0 0.9948538
or O 0 0.007218438
neuropathy B-Disease 2 0.9999782
target O 0 0.0019502447
enzyme O 0 0.560423
( O 0 0.011021546
NTE O 0 0.9984164
) O 0 0.0017588406
was O 0 0.00043154488
examined O 0 0.00030559473
in O 0 0.00045773436
rats O 0 0.0017603313
acutely O 0 0.028843123
exposed O 0 0.0006994012
to O 0 0.0010864303
Mipafox B-Chemical 0 0.99991393
( O 0 0.0054131267
N B-Chemical 0 0.98430854
, I-Chemical 0 0.0026845427
N I-Chemical 0 0.9662483
' I-Chemical 0 0.002537951
- I-Chemical 0 0.0027533243
diisopropylphosphorodiamidofluoridate I-Chemical 0 0.026409509
) O 0 0.0045204656
, O 0 0.0035616034
a O 0 0.0067873085
neurotoxic B-Disease 2 0.9996196
organophosphate B-Chemical 0 0.99991214
. O 0 0.015159441

Brain O 0 0.4303779
and O 0 0.009296723
spinal O 0 0.23597439
cord O 0 0.6242422
NTE O 0 0.99537414
activities O 0 0.004021248
were O 0 0.0014731543
measured O 0 0.00088957045
in O 0 0.0010402966
Long O 0 0.036315218
- O 0 0.0018942279
Evans O 0 0.3413622
male O 0 0.0040632547
rats O 0 0.001730699
1 O 0 0.00062016124
hr O 0 0.0006470679
post O 0 0.00084162
- O 0 0.0008382329
exposure O 0 0.0007877857
to O 0 0.00044054285
various O 0 0.0009931698
dosages O 0 0.2269107
of O 0 0.0032761635
Mipafox B-Chemical 0 0.9999398
( O 0 0.0043605063
ip O 0 0.84686035
, O 0 0.0016988396
1 O 0 0.0012967235
- O 0 0.0016788617
15 O 0 0.0013335821
mg O 0 0.10357519
/ O 0 0.006314128
kg O 0 0.015321655
) O 0 0.010015225
. O 0 0.008202809

These O 0 0.009438461
data O 0 0.0068736686
were O 0 0.0040946077
correlated O 0 0.0025958526
with O 0 0.0023906773
histologically O 0 0.17537159
scored O 0 0.005473805
cervical O 0 0.8555398
cord B-Disease 0 0.9297602
damage I-Disease 0 0.95458645
in O 0 0.0008989811
a O 0 0.00088374485
separate O 0 0.0004993122
group O 0 0.0006502904
of O 0 0.0006895773
similarly O 0 0.000785931
dosed O 0 0.0046335342
rats O 0 0.0014148193
sampled O 0 0.00073158
14 O 0 0.001112318
- O 0 0.001440715
21 O 0 0.0013510216
days O 0 0.0013258782
post O 0 0.0032897335
- O 0 0.0054368763
exposure O 0 0.009200437
. O 0 0.008646368

Those O 0 0.015534712
dosages O 0 0.12977242
( O 0 0.005410168
greater O 0 0.0024240757
than O 0 0.0013913998
or O 0 0.0011893003
equal O 0 0.0009147187
to O 0 0.0007905448
10 O 0 0.0008177162
mg O 0 0.18194522
/ O 0 0.0021383436
kg O 0 0.0078086485
) O 0 0.0011260593
that O 0 0.00041677625
inhibited O 0 0.00071076443
mean O 0 0.0006930804
NTE O 0 0.9928323
activity O 0 0.00070786825
in O 0 0.00039872818
the O 0 0.00045353707
spinal O 0 0.063620985
cord O 0 0.073307864
greater O 0 0.00037979294
than O 0 0.0002583109
or O 0 0.00030874752
equal O 0 0.0002967935
to O 0 0.00031444125
73 O 0 0.0008797214
% O 0 0.00041698213
and O 0 0.00038174397
brain O 0 0.006572964
greater O 0 0.0003146278
than O 0 0.00023761125
or O 0 0.00029340555
equal O 0 0.00028798392
to O 0 0.00030447508
67 O 0 0.0007291718
% O 0 0.00036362404
of O 0 0.00032983336
control O 0 0.00032839386
values O 0 0.00038719515
produced O 0 0.000442786
severe O 0 0.14634323
( O 0 0.0008342337
greater O 0 0.0003645525
than O 0 0.00028435307
or O 0 0.00036922956
equal O 0 0.00038965567
to O 0 0.0004616945
3 O 0 0.00063598086
) O 0 0.0012876549
cervical O 0 0.4164999
cord O 0 0.22208808
pathology O 0 0.05489678
in O 0 0.001291527
85 O 0 0.0021600784
% O 0 0.0019922508
of O 0 0.002479179
the O 0 0.003697291
rats O 0 0.010934584
. O 0 0.00824402

In O 0 0.0075264433
contrast O 0 0.005701197
, O 0 0.0049547637
dosages O 0 0.104346454
of O 0 0.005469923
Mipafox B-Chemical 0 0.99982065
( O 0 0.0027261896
less O 0 0.0008822343
than O 0 0.00050486694
or O 0 0.0005102774
equal O 0 0.00044666624
to O 0 0.0004376935
5 O 0 0.00044896844
mg O 0 0.12353744
/ O 0 0.0016011762
kg O 0 0.006865009
) O 0 0.0010812631
which O 0 0.00061828893
inhibited O 0 0.0006849219
mean O 0 0.00065561826
NTE O 0 0.99359554
activity O 0 0.00073166855
in O 0 0.00045240228
spinal O 0 0.07982647
cord O 0 0.088935435
less O 0 0.00039398627
than O 0 0.00025011925
or O 0 0.00029868688
equal O 0 0.00028950706
to O 0 0.00031081252
61 O 0 0.00077275146
% O 0 0.00042222827
and O 0 0.00039443647
brain O 0 0.0076226275
less O 0 0.0003431985
than O 0 0.00024520018
or O 0 0.0003052726
equal O 0 0.000304218
to O 0 0.00032441173
60 O 0 0.00038471125
% O 0 0.00041670175
produced O 0 0.00034176713
this O 0 0.00042328433
degree O 0 0.0007269972
of O 0 0.0012478646
cord B-Disease 0 0.86884695
damage I-Disease 0 0.9356822
in O 0 0.0011748453
only O 0 0.0011739235
9 O 0 0.0015087101
% O 0 0.0018739555
of O 0 0.002366321
the O 0 0.0033675265
animals O 0 0.005223841
. O 0 0.007900314

These O 0 0.008878037
data O 0 0.006124499
indicate O 0 0.0030739373
that O 0 0.002171658
a O 0 0.002248476
critical O 0 0.001361186
percentage O 0 0.0010333478
of O 0 0.0022429193
NTE O 0 0.9973687
inhibition O 0 0.007688135
in O 0 0.00090881693
brain O 0 0.07160308
and O 0 0.0010474495
spinal O 0 0.126847
cord O 0 0.107175596
sampled O 0 0.00051968417
shortly O 0 0.0010802416
after O 0 0.00048808273
Mipafox B-Chemical 0 0.99961627
exposure O 0 0.0023320208
can O 0 0.0007627869
predict O 0 0.0011994472
neuropathic B-Disease 0 0.9999882
damage I-Disease 0 0.98705566
in O 0 0.002331891
rats O 0 0.0052893856
several O 0 0.0027333365
weeks O 0 0.0029466737
later O 0 0.004558662
. O 0 0.0073785684

Allergic B-Disease 0 0.99086857
reaction I-Disease 0 0.21245165
to O 0 0.018210417
5 B-Chemical 0 0.016383795
- I-Chemical 0 0.02418744
fluorouracil I-Chemical 0 0.99782807
infusion O 0 0.2127398
. O 0 0.022592094

An O 0 0.0168357
allergic B-Disease 2 0.9979838
reaction I-Disease 2 0.29478917
consisting O 0 0.0045149317
of O 0 0.011178104
angioneurotic B-Disease 0 0.999979
edema I-Disease 2 0.999984
secondary O 0 0.03415278
to O 0 0.00096901855
continuous O 0 0.00092385896
infusion O 0 0.014683931
5 B-Chemical 0 0.00070958416
- I-Chemical 0 0.0013520404
fluorouracil I-Chemical 0 0.9985676
occurred O 0 0.0005613032
in O 0 0.00039852108
a O 0 0.00059135765
patient O 0 0.00072814815
with O 0 0.0006427354
recurrent O 0 0.8351504
carcinoma B-Disease 2 0.999874
of I-Disease 0 0.0012820904
the I-Disease 0 0.00080537883
oral I-Disease 0 0.55563205
cavity I-Disease 0 0.03617261
, O 0 0.00750733
cirrhosis B-Disease 2 0.99998546
, O 0 0.0051315133
and O 0 0.0031294269
cisplatin B-Chemical 1 0.99981445
- O 0 0.0074066697
induced O 0 0.0032454205
impaired B-Disease 0 0.023926273
renal I-Disease 0 0.9936825
function I-Disease 0 0.028658474
. O 0 0.0093110455

This O 0 0.013953361
reaction O 0 0.014087329
occurred O 0 0.006333028
during O 0 0.0039477907
the O 0 0.0039646155
sixth O 0 0.009881115
and O 0 0.0042543765
seventh O 0 0.011401423
courses O 0 0.005960272
of O 0 0.0066876695
infusional O 0 0.99594253
chemotherapy O 0 0.96037084
. O 0 0.013560062

Oral O 0 0.98249924
diphenhydramine B-Chemical 0 0.99995005
and O 0 0.016217792
prednisone B-Chemical 1 0.9996381
were O 0 0.004688444
ineffective O 0 0.01784684
in O 0 0.0022007863
preventing O 0 0.0036704752
the O 0 0.0026455238
recurrence O 0 0.78349394
of O 0 0.0053993147
the O 0 0.0072160163
allergic B-Disease 2 0.99975365
reaction I-Disease 2 0.8996199
. O 0 0.01676578

Discontinuance O 0 0.20810808
of O 0 0.00749278
effective O 0 0.005276031
chemotherapy O 0 0.3712194
in O 0 0.002570379
this O 0 0.0019715438
patient O 0 0.0024540655
during O 0 0.0014119671
partial O 0 0.002897023
remission O 0 0.4894359
resulted O 0 0.0025425325
in O 0 0.003925049
fatal O 0 0.9966749
disease O 0 0.98212737
progression O 0 0.9402454
. O 0 0.0149415955

Myasthenia B-Disease 0 0.9920184
gravis I-Disease 0 0.99828655
caused O 0 0.02186106
by O 0 0.01649113
penicillamine B-Chemical 1 0.9999305
and O 0 0.03513512
chloroquine B-Chemical 1 0.99911433
therapy O 0 0.2064469
for O 0 0.008602761
rheumatoid B-Disease 2 0.9997137
arthritis I-Disease 2 0.9999083
. O 0 0.042322516

We O 0 0.007912313
have O 0 0.0046352195
described O 0 0.0031061324
a O 0 0.003059076
unique O 0 0.0022993356
patient O 0 0.0023270892
who O 0 0.0022477221
had O 0 0.0011799982
reversible O 0 0.13247436
and O 0 0.001435001
dose O 0 0.038794227
- O 0 0.0021366114
related O 0 0.00079967093
myasthenia B-Disease 0 0.99954295
gravis I-Disease 0 0.9995233
after O 0 0.0020796629
penicillamine B-Chemical 1 0.9999858
and O 0 0.018137433
chloroquine B-Chemical 1 0.99940467
therapy O 0 0.11828067
for O 0 0.0049632248
rheumatoid B-Disease 2 0.9998041
arthritis I-Disease 2 0.9999318
. O 0 0.033459403

Although O 0 0.010526096
acetylcholine B-Chemical 1 0.99880004
receptor O 0 0.22922419
antibodies O 0 0.008176108
were O 0 0.002480714
not O 0 0.0016106471
detectable O 0 0.0011592408
, O 0 0.0015203087
the O 0 0.0010348847
time O 0 0.000957734
course O 0 0.0014269297
was O 0 0.001441205
consistent O 0 0.0015734477
with O 0 0.002693945
an O 0 0.006130385
autoimmune O 0 0.99253994
process O 0 0.013461796
. O 0 0.01130575

On O 0 0.0091156
the O 0 0.005356999
mechanisms O 0 0.004574616
of O 0 0.0033756208
the O 0 0.002500933
development O 0 0.0032985366
of O 0 0.0025046435
tolerance O 0 0.103182286
to O 0 0.001550565
the O 0 0.0017431248
muscular B-Disease 0 0.77339
rigidity I-Disease 2 0.9877601
produced O 0 0.003208527
by O 0 0.0063949376
morphine B-Chemical 1 0.9998851
in O 0 0.0061943224
rats O 0 0.026345821
. O 0 0.009566897

The O 0 0.008688963
development O 0 0.008157722
of O 0 0.0055710874
tolerance O 0 0.047198072
to O 0 0.002879331
the O 0 0.0026683041
muscular B-Disease 0 0.69892436
rigidity I-Disease 2 0.9863057
produced O 0 0.0031914106
by O 0 0.005115088
morphine B-Chemical 1 0.9999093
was O 0 0.0037918843
studied O 0 0.004288797
in O 0 0.0051641627
rats O 0 0.016484441
. O 0 0.009968445

Saline O 0 0.9932594
- O 0 0.010911818
pretreated O 0 0.0073169367
controls O 0 0.0036983024
given O 0 0.0014562674
a O 0 0.0016586462
test O 0 0.0013338679
dose O 0 0.0054554134
of O 0 0.002009146
morphine B-Chemical 1 0.9999709
( O 0 0.0022667754
20 O 0 0.00076059415
mg O 0 0.14741717
/ O 0 0.0014221381
kg O 0 0.002753415
i O 0 0.0019471517
. O 0 0.00045376364
p O 0 0.000760651
. O 0 0.00046326304
) O 0 0.00085381215
showed O 0 0.00044619304
a O 0 0.00084286556
pronounced O 0 0.0012983227
rigidity B-Disease 2 0.91284853
recorded O 0 0.0015427044
as O 0 0.0016077919
tonic O 0 0.58429545
activity O 0 0.0027483252
in O 0 0.0027618492
the O 0 0.0045729913
electromyogram O 0 0.8722979
. O 0 0.009443299

Rats O 0 0.020374205
treated O 0 0.0057484447
for O 0 0.003053222
11 O 0 0.0026765293
days O 0 0.0014771072
with O 0 0.0017149918
morphine B-Chemical 1 0.9998692
and O 0 0.0015764906
withdrawn O 0 0.003908525
for O 0 0.00056037534
36 O 0 0.0007724189
- O 0 0.00075319456
40 O 0 0.0003974106
h O 0 0.00026885993
showed O 0 0.0002544867
differences O 0 0.00022797675
in O 0 0.00030006314
the O 0 0.00036988058
development O 0 0.0007826963
of O 0 0.0007332489
tolerance O 0 0.1512769
: O 0 0.00084095594
about O 0 0.00027647745
half O 0 0.00022146474
of O 0 0.00035635536
the O 0 0.00032858457
animals O 0 0.00031666172
showed O 0 0.0003174652
a O 0 0.00070565095
rigidity B-Disease 2 0.89142966
after O 0 0.00023981258
the O 0 0.00032919823
test O 0 0.0004440778
dose O 0 0.0036656812
of O 0 0.0009043804
morphine B-Chemical 1 0.9999604
that O 0 0.00044292913
was O 0 0.00045237085
not O 0 0.00037489852
significantly O 0 0.00054658164
less O 0 0.00044076587
than O 0 0.0003447536
in O 0 0.0004614046
the O 0 0.00059531454
controls O 0 0.0014126315
and O 0 0.001299389
were O 0 0.0019261056
akinetic B-Disease 2 0.9976948
( O 0 0.0046768836
A O 0 0.089439884
group O 0 0.005939802
) O 0 0.011366991
. O 0 0.008165458

The O 0 0.0068581346
other O 0 0.0048927157
rats O 0 0.005442893
showed O 0 0.0022095258
a O 0 0.0022602733
strong O 0 0.0017809523
decrease O 0 0.0012498094
in O 0 0.0009067687
the O 0 0.0009940795
rigidity B-Disease 2 0.94114065
and O 0 0.0009188623
the O 0 0.00061425
occurrence O 0 0.0017524542
of O 0 0.0014123236
stereotyped O 0 0.9632674
( O 0 0.0059654866
S O 0 0.918622
) O 0 0.0027867055
licking O 0 0.81542826
and O 0 0.0009011659
/ O 0 0.002730928
or O 0 0.0006543217
gnawing O 0 0.95225483
in O 0 0.00046496213
presence O 0 0.00045493216
of O 0 0.0010517265
akinetic B-Disease 2 0.9994124
or O 0 0.0015722375
hyperkinetic B-Disease 0 0.99995244
( O 0 0.019322766
K O 1 0.99923706
) O 0 0.003504792
behaviour O 0 0.010362796
( O 0 0.0018205468
AS O 0 0.69314647
/ O 0 0.009780458
KS O 0 0.993327
group O 0 0.0021077392
) O 0 0.0028686107
, O 0 0.0015916122
suggesting O 0 0.0012579066
signs O 0 0.19838503
of O 0 0.0056700613
dopaminergic O 0 0.98993605
activation O 0 0.017760156
. O 0 0.009066429

The O 0 0.01055748
rigidity B-Disease 2 0.8113487
was O 0 0.006155089
considerably O 0 0.005279711
decreased O 0 0.0043248073
in O 0 0.002657057
both O 0 0.0024167774
groups O 0 0.002767859
after O 0 0.0018209958
20 O 0 0.002743842
days O 0 0.0028360253
' O 0 0.0058011757
treatment O 0 0.008750478
. O 0 0.009717636

In O 0 0.0072006295
a O 0 0.005708633
further O 0 0.0034804028
series O 0 0.0033686496
of O 0 0.002424651
experiments O 0 0.001990921
, O 0 0.004563568
haloperidol B-Chemical 1 0.9999926
( O 0 0.002884244
0 O 0 0.001173957
. O 0 0.00046640376
2 O 0 0.0005104219
mg O 0 0.051194742
/ O 0 0.0011701293
kg O 0 0.0023923956
i O 0 0.0018615652
. O 0 0.0004075784
p O 0 0.0006904763
. O 0 0.00039555298
) O 0 0.00076138607
was O 0 0.0003504961
used O 0 0.00030664247
in O 0 0.00029698142
order O 0 0.0002576839
to O 0 0.00033369113
block O 0 0.0006029296
the O 0 0.0005034999
dopaminergic O 0 0.94001424
activation O 0 0.00101946
and O 0 0.0004756999
to O 0 0.00031728187
estimate O 0 0.00026958965
the O 0 0.00037517204
real O 0 0.0005481223
degree O 0 0.0006341696
of O 0 0.0007789996
the O 0 0.00082483375
tolerance O 0 0.06078682
to O 0 0.0010039303
the O 0 0.0014826724
rigidity B-Disease 2 0.9535881
without O 0 0.002466794
any O 0 0.0037666
dopaminergic O 0 0.9821311
interference O 0 0.017500741
. O 0 0.008811308

Haloperidol B-Chemical 1 0.9997739
enhanced O 0 0.0208525
the O 0 0.014845437
rigidity B-Disease 2 0.92937225
in O 0 0.01228244
the O 0 0.0129019255
A O 0 0.13340834
group O 0 0.020012815
. O 0 0.018963082

However O 0 0.009789967
, O 0 0.0069786524
the O 0 0.003900369
level O 0 0.0024720607
in O 0 0.0022483198
the O 0 0.002357668
AS O 0 0.6617232
/ O 0 0.0152558405
KS O 0 0.98841673
group O 0 0.0021367082
remained O 0 0.0015733878
considerably O 0 0.0018497162
lower O 0 0.0015669396
than O 0 0.0013866356
in O 0 0.0021777102
the O 0 0.0034203432
A O 0 0.094327986
group O 0 0.008764962
. O 0 0.009482667

The O 0 0.0068162256
results O 0 0.0048294794
suggest O 0 0.002852907
that O 0 0.0027262229
rigidity B-Disease 2 0.96996003
, O 0 0.003290107
which O 0 0.0017618312
is O 0 0.0010033519
assumed O 0 0.00077932223
to O 0 0.00061410485
be O 0 0.00059202255
due O 0 0.00038863812
to O 0 0.00043212532
an O 0 0.00070138957
action O 0 0.0024056423
of O 0 0.0010682426
morphine B-Chemical 1 0.99996924
in O 0 0.00070226146
the O 0 0.00083093497
striatum O 0 0.56946456
, O 0 0.0009137574
can O 0 0.00043970626
be O 0 0.0006563603
antagonized O 0 0.2962319
by O 0 0.0008583585
another O 0 0.0009011505
process O 0 0.0009302722
leading O 0 0.0020137958
to O 0 0.0015132683
dopaminergic O 0 0.9717345
activation O 0 0.004138743
in O 0 0.002801284
the O 0 0.0047371783
striatum O 0 0.55971164
. O 0 0.00796523

Nevertheless O 0 0.013312214
, O 0 0.01055381
there O 0 0.0055866023
occurs O 0 0.005232059
some O 0 0.005665469
real O 0 0.0070808562
tolerance O 0 0.07043577
to O 0 0.00686618
this O 0 0.007963878
effect O 0 0.0108042965
. O 0 0.013268243

The O 0 0.007074823
rapid O 0 0.0074071772
alternations O 0 0.011246831
of O 0 0.004179163
rigidity B-Disease 2 0.956798
and O 0 0.002371692
the O 0 0.0014546737
signs O 0 0.17948309
of O 0 0.0019958243
dopaminergic O 0 0.982714
activation O 0 0.0018407669
observed O 0 0.00040472258
in O 0 0.00043998592
the O 0 0.00042634705
animals O 0 0.00039429474
of O 0 0.0005945204
the O 0 0.00070790335
AS O 0 0.8106088
/ O 0 0.014419192
KS O 0 0.99383587
group O 0 0.0008936841
might O 0 0.0003701813
be O 0 0.00046621836
due O 0 0.00033722274
to O 0 0.00042817765
rapid O 0 0.0010701932
shifts O 0 0.0009273125
in O 0 0.0005976679
the O 0 0.0007482803
predominance O 0 0.001759951
of O 0 0.0020123108
various O 0 0.018353255
DA O 1 0.99971527
- O 0 0.013356393
innervated O 0 0.12990631
structures O 0 0.008830094
. O 0 0.008495229

A O 0 0.042083792
case O 0 0.014265316
of O 0 0.014102263
massive O 0 0.39055774
rhabdomyolysis B-Disease 2 0.99991274
following O 0 0.13597351
molindone B-Chemical 0 0.9999721
administration O 0 0.90980357
. O 0 0.021850834

Rhabdomyolysis B-Disease 0 0.9987684
is O 0 0.008881726
a O 0 0.0068146503
potentially O 0 0.0077991346
lethal O 0 0.12131187
syndrome O 0 0.9300479
that O 0 0.00454505
psychiatric B-Disease 2 0.9966247
patients O 0 0.029014274
seem O 0 0.0052381638
predisposed O 0 0.10026428
to O 0 0.006043256
develop O 0 0.010132965
. O 0 0.011078428

The O 0 0.008201048
clinical O 0 0.011521701
signs O 0 0.12758738
and O 0 0.0054686316
symptoms O 0 0.7614241
, O 0 0.003521522
typical O 0 0.0023120334
laboratory O 0 0.0028986763
features O 0 0.0035308108
, O 0 0.0027638553
and O 0 0.002540346
complications O 0 0.67222357
of O 0 0.009865754
rhabdomyolysis B-Disease 2 0.9999689
are O 0 0.010211906
presented O 0 0.011041023
. O 0 0.010326026

The O 0 0.007015183
case O 0 0.005024246
of O 0 0.0041847867
a O 0 0.004829043
schizophrenic B-Disease 2 0.99880934
patient O 0 0.0041763694
is O 0 0.0015117164
reported O 0 0.0012840611
to O 0 0.00084429723
illustrate O 0 0.0009565627
massive O 0 0.24503966
rhabdomyolysis B-Disease 2 0.99999154
and O 0 0.0032691967
subsequent O 0 0.00275066
acute B-Disease 0 0.98802865
renal I-Disease 0 0.9988834
failure I-Disease 0 0.970199
following O 0 0.024612308
molindone B-Chemical 0 0.99999
administration O 0 0.7346398
. O 0 0.010969531

Physicians O 0 0.020909945
who O 0 0.016095772
prescribe O 0 0.081872046
molindone B-Chemical 0 0.9999299
should O 0 0.005955985
be O 0 0.005909621
aware O 0 0.0062388023
of O 0 0.0070707654
this O 0 0.0083290925
reaction O 0 0.060595572
. O 0 0.015147457

Compression B-Disease 0 0.7344055
neuropathy I-Disease 2 0.9984475
of I-Disease 0 0.009027426
the I-Disease 0 0.0056089936
radial I-Disease 0 0.011547901
nerve I-Disease 0 0.49593464
due O 0 0.0036210625
to O 0 0.005514264
pentazocine B-Chemical 1 0.99998474
- O 0 0.045498185
induced O 0 0.012787298
fibrous B-Disease 0 0.9888459
myopathy I-Disease 2 0.99976844
. O 0 0.0223233

Fibrous B-Disease 0 0.8464716
myopathy I-Disease 2 0.9986469
is O 0 0.0066880216
a O 0 0.0051591313
common O 0 0.0044664354
, O 0 0.0035896199
well O 0 0.0022427165
- O 0 0.003165239
known O 0 0.0022760686
side O 0 0.02821188
effect O 0 0.0022883005
of O 0 0.003552553
repeated O 0 0.0068601086
pentazocine B-Chemical 1 0.9999751
injection O 0 0.11386588
. O 0 0.011066493

However O 0 0.01117588
, O 0 0.01003028
compression B-Disease 0 0.7422718
neuropathy I-Disease 2 0.9998584
due O 0 0.0030192134
to O 0 0.0022423114
fibrotic O 0 0.6981771
muscle O 0 0.32946393
affected O 0 0.002122215
by O 0 0.0051086135
pentazocine B-Chemical 1 0.99999666
- O 0 0.027780723
induced O 0 0.0040977863
myopathy B-Disease 2 0.99945325
has O 0 0.0023600503
not O 0 0.002620166
previously O 0 0.003556691
been O 0 0.0052219536
reported O 0 0.008023466
. O 0 0.009260406

In O 0 0.00845703
a O 0 0.0074377833
37 O 0 0.005867991
- O 0 0.0048254794
year O 0 0.0026165496
- O 0 0.0025705735
old O 0 0.0016936887
woman O 0 0.007696456
with O 0 0.001559426
documented O 0 0.009215911
pentazocine B-Chemical 1 0.9999974
- O 0 0.016995464
induced O 0 0.0018220468
fibrous B-Disease 0 0.9551996
myopathy I-Disease 2 0.9999263
of O 0 0.0041178237
triceps O 0 0.9893387
and O 0 0.001026814
deltoid O 0 0.68344694
muscles O 0 0.015122871
bilaterally O 0 0.008049443
and O 0 0.00045916127
a O 0 0.00049501477
three O 0 0.00029446062
- O 0 0.0005693332
week O 0 0.00025023997
history O 0 0.0014080937
of O 0 0.00054505473
right O 0 0.0023338676
wrist O 0 0.33278802
drop O 0 0.002280619
, O 0 0.0007338703
electrodiagnostic O 0 0.1245009
examination O 0 0.0006131913
showed O 0 0.0003456856
a O 0 0.00066515093
severe O 0 0.06173279
but O 0 0.00048495238
partial O 0 0.00068989384
lesion O 0 0.018649437
of O 0 0.00053948606
the O 0 0.00046764576
right O 0 0.0014097595
radial O 0 0.0021387893
nerve O 0 0.19521901
distal O 0 0.0006673074
to O 0 0.0004338527
the O 0 0.0005091706
branches O 0 0.0012849803
to O 0 0.0006256859
the O 0 0.00093752006
triceps O 0 0.89887625
, O 0 0.0014231915
in O 0 0.0010106595
addition O 0 0.001027825
to O 0 0.0020087825
the O 0 0.0038927975
fibrous B-Disease 0 0.9598701
myopathy I-Disease 2 0.9997584
. O 0 0.016100977

Surgery O 0 0.017908236
revealed O 0 0.006377757
the O 0 0.0046343813
right O 0 0.006085546
radial O 0 0.0071146754
nerve O 0 0.3100134
to O 0 0.0020296085
be O 0 0.0018964724
severely O 0 0.0052050306
compressed O 0 0.0026776497
by O 0 0.0015850142
the O 0 0.0015347383
densely O 0 0.003481346
fibrotic O 0 0.6337628
lateral O 0 0.04201791
head O 0 0.07263199
of O 0 0.005251396
the O 0 0.007007221
triceps O 0 0.9601964
. O 0 0.0102729015

Decompression O 0 0.08817363
and O 0 0.011631837
neurolysis O 0 0.12961592
were O 0 0.006305464
performed O 0 0.0044746203
with O 0 0.004399317
good O 0 0.005138441
subsequent O 0 0.0050665056
recovery O 0 0.00867912
of O 0 0.00836453
function O 0 0.0115833385
. O 0 0.012452269

Recurrent O 0 0.6339852
reversible O 0 0.6053548
acute B-Disease 0 0.98056924
renal I-Disease 0 0.9960425
failure I-Disease 0 0.9667686
from O 0 0.034078665
amphotericin B-Chemical 0 0.99913377
. O 0 0.031689774

A O 0 0.03500438
patient O 0 0.009236647
with O 0 0.006506905
cryptogenic O 0 0.9995733
cirrhosis B-Disease 2 0.9999751
and O 0 0.015213455
disseminated O 0 0.9921016
sporotrichosis B-Disease 0 0.9996785
developed O 0 0.021824306
acute B-Disease 0 0.98956525
renal I-Disease 0 0.99828464
failure I-Disease 0 0.8320225
immediately O 0 0.0009576415
following O 0 0.00072766846
the O 0 0.0008294801
administration O 0 0.041564234
of O 0 0.0029701625
amphotericin B-Chemical 1 0.9999312
B I-Chemical 1 0.85012555
on O 0 0.0019367941
four O 0 0.0024041014
separate O 0 0.0037733389
occasions O 0 0.01029069
. O 0 0.008062679

The O 0 0.007554892
abruptness O 0 0.014237395
of O 0 0.0044347295
the O 0 0.0033179778
renal B-Disease 0 0.9668328
failure I-Disease 0 0.70554096
and O 0 0.0020730116
its O 0 0.001967652
reversibility O 0 0.037025753
within O 0 0.0004808836
days O 0 0.00049209606
suggests O 0 0.00040320755
that O 0 0.0005056341
there O 0 0.0005205776
was O 0 0.00077998644
a O 0 0.0011525989
functional O 0 0.0013875939
component O 0 0.0017396663
to O 0 0.0020527137
the O 0 0.003973057
renal B-Disease 2 0.9990927
dysfunction I-Disease 2 0.9986082
. O 0 0.012839579

We O 0 0.0073701916
propose O 0 0.0047251545
that O 0 0.003990781
amphotericin B-Chemical 0 0.99899286
, O 0 0.0045506237
in O 0 0.0015641659
the O 0 0.0011918582
setting O 0 0.0010300516
of O 0 0.0010222762
reduced O 0 0.0009114523
effective O 0 0.0010773266
arterial O 0 0.5955416
volume O 0 0.0073817126
, O 0 0.0011984291
may O 0 0.00064659223
activate O 0 0.00065914233
tubuloglomerular O 0 0.8682512
feedback O 0 0.0028718533
, O 0 0.0016278265
thereby O 0 0.0019973551
contributing O 0 0.0021498043
to O 0 0.002370466
acute B-Disease 0 0.9832665
renal I-Disease 0 0.9986118
failure I-Disease 0 0.97250676
. O 0 0.01197269

Cerebral B-Disease 0 0.9855527
infarction I-Disease 2 0.99979025
with O 0 0.012241021
a O 0 0.009889142
single O 0 0.008211504
oral O 0 0.43985116
dose O 0 0.13590941
of O 0 0.039125986
phenylpropanolamine B-Chemical 0 0.9999441
. O 0 0.022641985

Phenylpropanolamine B-Chemical 1 0.99932075
( O 0 0.030581951
PPA B-Chemical 1 0.99808973
) O 0 0.009264144
, O 0 0.0031398796
a O 0 0.0021523815
synthetic O 0 0.0028298642
sympathomimetic O 0 0.9981831
that O 0 0.0009704728
is O 0 0.0008976109
structurally O 0 0.0018711818
similar O 0 0.00052331534
to O 0 0.0008558929
amphetamine B-Chemical 1 0.9999906
, O 0 0.0014954623
is O 0 0.00051284273
available O 0 0.00040271666
over O 0 0.0002925684
the O 0 0.0004859996
counter O 0 0.0020219309
in O 0 0.00080859964
anorectics O 0 0.97859186
, O 0 0.00177004
nasal O 0 0.022975814
congestants O 0 0.035839226
, O 0 0.0033796723
and O 0 0.003672066
cold O 0 0.08522037
preparations O 0 0.027135557
. O 0 0.009625622

Its O 0 0.06761511
prolonged O 0 0.012501002
use O 0 0.005012947
or O 0 0.003906498
overuse O 0 0.9650302
has O 0 0.0021218734
been O 0 0.0017942437
associated O 0 0.0018187006
with O 0 0.0028989422
seizures B-Disease 2 0.99998593
, O 0 0.0152188
intracerebral B-Disease 0 0.999665
hemorrhage I-Disease 2 0.9999747
, O 0 0.021048585
neuropsychiatric B-Disease 0 0.9998975
symptoms I-Disease 0 0.9966229
, O 0 0.0057987175
and O 0 0.005786909
nonhemorrhagic O 0 0.9997888
cerebral B-Disease 0 0.99799794
infarction I-Disease 2 0.9999577
. O 0 0.013814853

We O 0 0.008059266
report O 0 0.0070818183
the O 0 0.0036302558
case O 0 0.002712337
of O 0 0.0024042695
a O 0 0.0025421577
young O 0 0.0066994983
woman O 0 0.019965336
who O 0 0.0035016227
suffered O 0 0.3143511
a O 0 0.0031265232
cerebral B-Disease 0 0.9813774
infarction I-Disease 2 0.9999839
after O 0 0.00087369274
taking O 0 0.0019613463
a O 0 0.0016196728
single O 0 0.0018399575
oral O 0 0.3703891
dose O 0 0.06577984
of O 0 0.012110097
PPA B-Chemical 1 0.9989918
. O 0 0.01108879

Remission O 0 0.87774676
induction O 0 0.011032747
of O 0 0.011845812
meningeal B-Disease 0 0.9992428
leukemia I-Disease 0 0.999894
with O 0 0.010680408
high O 0 0.008414673
- O 0 0.009490042
dose O 0 0.08956641
intravenous O 0 0.95840627
methotrexate B-Chemical 1 0.9997985
. O 0 0.01672958

Twenty O 0 0.013201119
children O 0 0.009886434
with O 0 0.0066845724
acute B-Disease 2 0.998257
lymphoblastic I-Disease 2 0.99997926
leukemia I-Disease 2 0.9999788
who O 0 0.08496145
developed O 0 0.009778769
meningeal B-Disease 0 0.9997491
disease I-Disease 0 0.99321574
were O 0 0.0012358527
treated O 0 0.0009706116
with O 0 0.0006866067
a O 0 0.00092938886
high O 0 0.0009385639
- O 0 0.0011594915
dose O 0 0.006569313
intravenous O 0 0.6450242
methotrexate B-Chemical 1 0.9999399
regimen O 0 0.0065308404
that O 0 0.00039164472
was O 0 0.0004350346
designed O 0 0.00043351678
to O 0 0.0003228878
achieve O 0 0.00028312707
and O 0 0.00047932623
maintain O 0 0.00035299527
CSF O 0 0.78636384
methotrexate B-Chemical 1 0.9998889
concentrations O 0 0.0030271541
of O 0 0.00091035006
10 O 0 0.0008416585
( O 0 0.0011373677
- O 0 0.001037393
5 O 0 0.00051514927
) O 0 0.0010540196
mol O 0 0.08161091
/ O 0 0.0029966487
L O 0 0.16031523
without O 0 0.00078722846
the O 0 0.00087997754
need O 0 0.00095625606
for O 0 0.0011713743
concomitant O 0 0.0064964388
intrathecal O 0 0.9795203
dosing O 0 0.27552402
. O 0 0.008613293

The O 0 0.008357722
methotrexate B-Chemical 1 0.99863154
was O 0 0.0042815153
administered O 0 0.0029970703
as O 0 0.0016074758
a O 0 0.0015139933
loading O 0 0.0017389345
dose O 0 0.0039497493
of O 0 0.0009810065
6 O 0 0.0005734822
, O 0 0.00067144
000 O 0 0.00069660624
mg O 0 0.085770436
/ O 0 0.0012507954
m2 O 0 0.0032759192
for O 0 0.0002916802
a O 0 0.00042511916
period O 0 0.00027280927
of O 0 0.00036743522
one O 0 0.00029769522
hour O 0 0.00025521417
followed O 0 0.0002907662
by O 0 0.0004404962
an O 0 0.00059875345
infusion O 0 0.002716791
of O 0 0.00074498105
1 O 0 0.0008249084
, O 0 0.0008976985
200 O 0 0.0014326007
mg O 0 0.15813152
/ O 0 0.002798266
m2 O 0 0.013904464
/ O 0 0.0027077647
h O 0 0.001498732
for O 0 0.0018311109
23 O 0 0.004097354
hours O 0 0.003778309
. O 0 0.006454264

Leucovorin B-Chemical 0 0.9986733
rescue O 0 0.007493951
was O 0 0.0034900513
initiated O 0 0.0022675465
12 O 0 0.0011791504
hours O 0 0.0007306203
after O 0 0.0005068026
the O 0 0.0005698427
end O 0 0.00039679927
of O 0 0.00056872197
the O 0 0.0005293786
infusion O 0 0.0041276496
with O 0 0.0005067719
a O 0 0.0006271862
loading O 0 0.0009777546
dose O 0 0.0037175172
of O 0 0.00063827675
200 O 0 0.0017694621
mg O 0 0.27775723
/ O 0 0.0015341509
m2 O 0 0.0057886103
followed O 0 0.000279204
by O 0 0.00037235787
12 O 0 0.00026886095
mg O 0 0.0511652
/ O 0 0.0008496261
m2 O 0 0.0016848638
every O 0 0.00016382267
three O 0 0.00017301376
hours O 0 0.00018173059
for O 0 0.00018797441
six O 0 0.00019609195
doses O 0 0.0017821098
and O 0 0.00036609187
then O 0 0.00025411037
every O 0 0.00016024637
six O 0 0.00017760317
hours O 0 0.00019923439
until O 0 0.00018917353
the O 0 0.00033534117
plasma O 0 0.016802764
methotrexate B-Chemical 1 0.9998553
level O 0 0.0004455005
decreased O 0 0.0007682205
to O 0 0.00046297564
less O 0 0.0005427043
than O 0 0.00049789285
1 O 0 0.0009803823
X O 0 0.24878304
10 O 0 0.0011677814
( O 0 0.0018533901
- O 0 0.002185517
7 O 0 0.0018055934
) O 0 0.0039500133
mol O 0 0.17662835
/ O 0 0.020692078
L O 0 0.59956837
. O 0 0.009913736

The O 0 0.006764633
mean O 0 0.004904337
steady O 0 0.0051661106
- O 0 0.004624035
state O 0 0.0029887722
plasma O 0 0.01704618
and O 0 0.0023052252
CSF O 0 0.88225293
methotrexate B-Chemical 1 0.99990785
concentrations O 0 0.0070403824
achieved O 0 0.0010257208
were O 0 0.00074206083
1 O 0 0.00067584415
. O 0 0.0004085505
1 O 0 0.000600979
X O 0 0.15892969
10 O 0 0.0006398609
( O 0 0.0009155562
- O 0 0.0008990347
3 O 0 0.00050466583
) O 0 0.0009289963
mol O 0 0.08302423
/ O 0 0.003055544
L O 0 0.25381988
and O 0 0.00074119435
3 O 0 0.000578774
. O 0 0.0004249812
6 O 0 0.0005125485
X O 0 0.10414969
10 O 0 0.0008771647
( O 0 0.0013763163
- O 0 0.0015475508
5 O 0 0.001091646
) O 0 0.002440623
mol O 0 0.12294028
/ O 0 0.0111098215
L O 0 0.5383373
, O 0 0.0070104175
respectively O 0 0.009982793
. O 0 0.00859771

All O 0 0.0077214562
20 O 0 0.0054421904
patients O 0 0.005054046
responded O 0 0.0033904598
to O 0 0.0018274767
this O 0 0.0015009327
regimen O 0 0.0033017108
, O 0 0.00159207
16 O 0 0.0010265509
/ O 0 0.0015754633
20 O 0 0.0007589564
( O 0 0.00082539587
80 O 0 0.00070714514
% O 0 0.0007214452
) O 0 0.0008164669
achieved O 0 0.0005195297
a O 0 0.0007113466
complete O 0 0.0006474352
remission O 0 0.22345962
, O 0 0.0012863133
and O 0 0.0010982404
20 O 0 0.0011760454
% O 0 0.0015004461
obtained O 0 0.0016698742
a O 0 0.0031590085
partial O 0 0.0057180906
remission O 0 0.655229
. O 0 0.009080677

The O 0 0.008180146
most O 0 0.0073608067
common O 0 0.0069288868
toxicities B-Disease 2 0.9988887
encountered O 0 0.0064542703
were O 0 0.002954097
transient O 0 0.11413898
serum O 0 0.77430934
transaminase O 0 0.9999763
and O 0 0.013337741
bilirubin B-Chemical 1 0.99990404
elevations O 0 0.8310264
, O 0 0.009952709
neutropenia B-Disease 2 0.9996748
, O 0 0.009053279
and O 0 0.011496915
mucositis B-Disease 2 0.99991
. O 0 0.01400071

One O 0 0.015653761
patient O 0 0.011102457
had O 0 0.007814802
focal O 0 0.19083783
seizures B-Disease 2 0.99985456
and O 0 0.014176916
transient B-Disease 0 0.8886755
hemiparesis I-Disease 0 0.9999081
but O 0 0.008839079
recovered O 0 0.007815712
completely O 0 0.01107777
. O 0 0.012204821

High O 0 0.062228948
- O 0 0.008804506
dose O 0 0.012438889
intravenous O 0 0.7359009
methotrexate B-Chemical 1 0.99988425
is O 0 0.0025230558
an O 0 0.001956479
effective O 0 0.0013085806
treatment O 0 0.0013302172
for O 0 0.0006266046
the O 0 0.00073057925
induction O 0 0.0008750619
of O 0 0.0013070778
remission O 0 0.55891144
after O 0 0.0010420504
meningeal O 0 0.9974413
relapse O 0 0.99734586
in O 0 0.008893936
acute B-Disease 2 0.99960583
lymphoblastic I-Disease 2 0.99998164
leukemia I-Disease 2 0.9999509
. O 0 0.04666365

Interaction O 0 0.04024089
of O 0 0.030707903
cyclosporin B-Chemical 1 0.99972254
A I-Chemical 1 0.8799883
with O 0 0.026234893
antineoplastic O 0 0.99188656
agents O 0 0.9101051
. O 0 0.028761765

A O 0 0.040483356
synergistic O 0 0.011040503
effect O 0 0.0047588227
of O 0 0.006278706
etoposide B-Chemical 1 0.99972385
and O 0 0.016809318
cyclosporin B-Chemical 1 0.99999
A I-Chemical 1 0.8837362
was O 0 0.0014940099
observed O 0 0.0007210995
in O 0 0.0008562004
a O 0 0.001295441
patient O 0 0.0017628906
with O 0 0.0019592135
acute B-Disease 0 0.9909932
T I-Disease 0 0.9905661
- I-Disease 0 0.08498962
lymphocytic I-Disease 0 0.999778
leukemia I-Disease 0 0.9999292
in O 0 0.030295387
relapse O 0 0.99733424
. O 0 0.014472983

The O 0 0.0073895296
concomitant O 0 0.008914797
administration O 0 0.071342066
of O 0 0.0071214456
etoposide B-Chemical 1 0.99974984
and O 0 0.017944198
cyclosporin B-Chemical 1 0.99998975
A I-Chemical 1 0.8864746
resulted O 0 0.0016007097
in O 0 0.0012307187
eradication O 0 0.014056408
of O 0 0.0020838233
hitherto O 0 0.11053189
refractory O 0 0.8628977
leukemic B-Disease 0 0.9996648
infiltration I-Disease 0 0.9830435
of O 0 0.023815555
bone O 0 0.9198762
marrow O 0 0.9693831
. O 0 0.015918639

Severe O 0 0.76253515
side O 0 0.07846391
effects O 0 0.0059638633
in O 0 0.00251474
terms O 0 0.0016550174
of O 0 0.0024273884
mental O 0 0.5896399
confusion B-Disease 2 0.95715445
and O 0 0.0021693707
progressive O 0 0.7247829
hyperbilirubinemia B-Disease 0 0.9999777
, O 0 0.0030574184
however O 0 0.0010523861
, O 0 0.0007470346
point O 0 0.00036646234
to O 0 0.00038009573
an O 0 0.0006395619
enhancement O 0 0.00093403744
not O 0 0.0004340442
only O 0 0.00044995043
of O 0 0.0008216547
antineoplastic O 0 0.9337669
effects O 0 0.0035892685
but O 0 0.001155559
also O 0 0.0013422008
of O 0 0.0028973098
toxicity B-Disease 2 0.9978836
in O 0 0.003541406
normal O 0 0.010631354
tissues O 0 0.035446305
. O 0 0.009214193

This O 0 0.009768891
report O 0 0.006815893
demonstrates O 0 0.0027514866
for O 0 0.0018540854
the O 0 0.0015019629
first O 0 0.0010103504
time O 0 0.00080121856
that O 0 0.00065136194
the O 0 0.00070519885
pharmacodynamic O 0 0.28800857
properties O 0 0.001649326
of O 0 0.0033138015
cyclosporin B-Chemical 1 0.9999951
A I-Chemical 1 0.8749765
may O 0 0.00091282633
not O 0 0.0007008944
be O 0 0.0006712315
confined O 0 0.0006052425
strictly O 0 0.0007643382
to O 0 0.00079497433
suppression O 0 0.0018034892
of O 0 0.0020433022
normal O 0 0.01104046
T O 0 0.8990021
- O 0 0.0080387145
cell O 0 0.023159228
functions O 0 0.009420564
. O 0 0.00890448

Incidence O 0 0.10220044
of O 0 0.010756603
neoplasms B-Disease 0 0.98328215
in O 0 0.0055405195
patients O 0 0.009422012
with O 0 0.005837871
rheumatoid B-Disease 2 0.99969447
arthritis I-Disease 2 0.99993587
exposed O 0 0.0067116627
to O 0 0.0037456143
different O 0 0.0040750075
treatment O 0 0.009667422
regimens O 0 0.09200289
. O 0 0.0112724705

Immunosuppressive O 0 0.9805567
drugs O 0 0.82964045
have O 0 0.004941991
been O 0 0.0032542306
used O 0 0.0018604189
during O 0 0.0012086072
the O 0 0.0011464406
last O 0 0.00086445943
30 O 0 0.00082044315
years O 0 0.0011335226
in O 0 0.0008960181
treatment O 0 0.001532679
of O 0 0.0018459448
patients O 0 0.007087947
with O 0 0.0042050523
severe O 0 0.9004051
rheumatoid B-Disease 2 0.9998683
arthritis I-Disease 2 0.99994147
. O 0 0.04503195

The O 0 0.007688252
drugs O 0 0.27853405
commonly O 0 0.0065884795
used O 0 0.0030013765
are O 0 0.0030723277
cyclophosphamide B-Chemical 1 0.9998467
and O 0 0.009937178
chlorambucil B-Chemical 0 0.9999758
( O 0 0.029192341
alkylating B-Chemical 0 0.9990846
agents I-Chemical 0 0.8817186
) O 0 0.028034896
, O 0 0.0058748773
azathioprine B-Chemical 1 0.99998987
( O 0 0.030748067
purine B-Chemical 0 0.9995346
analogue O 0 0.7000541
) O 0 0.008206107
, O 0 0.0020133175
and O 0 0.0025293424
methotrexate B-Chemical 1 0.9999366
( O 0 0.070458435
folic B-Chemical 0 0.9999453
acid I-Chemical 0 0.9961743
analogue O 0 0.85308504
) O 0 0.039203193
. O 0 0.00965991

There O 0 0.008681209
is O 0 0.0050501823
evidence O 0 0.0033418522
that O 0 0.0021673949
all O 0 0.0017093403
four O 0 0.0013006037
immunosuppressive O 0 0.91321105
drugs O 0 0.90714586
can O 0 0.0012870033
reduce O 0 0.001485445
synovitis B-Disease 0 0.99977046
, O 0 0.004998719
but O 0 0.0012700779
disease O 0 0.5954574
activity O 0 0.0014745465
almost O 0 0.0010344008
always O 0 0.0015091771
recurs O 0 0.074462526
after O 0 0.0014676835
therapy O 0 0.014127614
is O 0 0.004380481
stopped O 0 0.011397619
. O 0 0.008398599

Since O 0 0.0074655185
adverse O 0 0.62439936
reactions O 0 0.04768312
are O 0 0.0037541257
frequent O 0 0.0061161546
, O 0 0.002165321
less O 0 0.0010740779
than O 0 0.0006592228
50 O 0 0.0008184981
percent O 0 0.00054470677
of O 0 0.0007250112
patients O 0 0.0016276583
are O 0 0.0006651841
able O 0 0.00044886293
to O 0 0.0005447785
continue O 0 0.0006547312
a O 0 0.00085157243
particular O 0 0.0006787213
drug O 0 0.17123526
for O 0 0.001205543
more O 0 0.0019961474
than O 0 0.001881334
one O 0 0.0031151623
year O 0 0.0052945814
. O 0 0.007396171

Since O 0 0.0068325233
it O 0 0.005053624
takes O 0 0.002492634
three O 0 0.0016758186
to O 0 0.001473239
12 O 0 0.0010003662
months O 0 0.00070380943
to O 0 0.0006226294
achieve O 0 0.00049847504
maximal O 0 0.0006627438
effects O 0 0.0011653785
, O 0 0.0009148089
those O 0 0.0007619794
patients O 0 0.0014029633
who O 0 0.0011317681
are O 0 0.00059488066
unable O 0 0.0004475835
to O 0 0.00056469376
continue O 0 0.000733462
the O 0 0.0008460085
drug O 0 0.12717922
receive O 0 0.0013575907
little O 0 0.0016413383
benefit O 0 0.0042618937
from O 0 0.0039785784
it O 0 0.0063788844
. O 0 0.007748572

Patients O 0 0.014739031
treated O 0 0.006585044
with O 0 0.004953866
alkylating B-Chemical 0 0.992141
agents I-Chemical 0 0.46363765
have O 0 0.0018687494
an O 0 0.0022981795
increased O 0 0.0017937827
risk O 0 0.055997483
of O 0 0.0014324015
development O 0 0.0030928045
of O 0 0.003794304
acute B-Disease 0 0.99965405
nonlymphocytic I-Disease 0 0.99999344
leukemia I-Disease 0 0.9999957
, O 0 0.019580107
and O 0 0.0012040088
both O 0 0.0008555729
alkylating B-Chemical 0 0.99691284
agents I-Chemical 0 0.5895388
and O 0 0.0035153762
azathioprine B-Chemical 1 0.9999881
are O 0 0.0013189234
associated O 0 0.0009958788
with O 0 0.00083474815
the O 0 0.00082878093
development O 0 0.0016070495
of O 0 0.001627808
non B-Disease 0 0.009900008
- I-Disease 0 0.009688485
Hodgkin I-Disease 0 0.99748033
' I-Disease 0 0.008274614
s I-Disease 0 0.008501297
lymphoma I-Disease 0 0.9970426
. O 0 0.011875342

Cyclophosphamide B-Chemical 1 0.9983852
therapy O 0 0.043239333
increases O 0 0.008128029
the O 0 0.0070219887
risk O 0 0.054538883
of O 0 0.011254686
carcinoma B-Disease 2 0.9992211
of I-Disease 0 0.013544203
the I-Disease 0 0.011994873
bladder I-Disease 0 0.96716064
. O 0 0.016712992

There O 0 0.009250935
have O 0 0.005315442
been O 0 0.0039409683
several O 0 0.00268887
long O 0 0.0024658744
- O 0 0.0023885472
term O 0 0.0011238407
studies O 0 0.0010907062
of O 0 0.0011141924
patients O 0 0.0037350776
with O 0 0.0016464681
rheumatoid B-Disease 2 0.9999044
arthritis I-Disease 2 0.9999857
treated O 0 0.015520141
with O 0 0.0035878515
azathioprine B-Chemical 1 0.9999914
and O 0 0.004864986
cyclophosphamide B-Chemical 1 0.9999374
and O 0 0.0011245308
the O 0 0.00067764294
incidence O 0 0.004385265
of O 0 0.00093406235
most O 0 0.0011614105
of O 0 0.0012253888
the O 0 0.0014075555
common O 0 0.0042937123
cancers B-Disease 2 0.996968
is O 0 0.003873979
not O 0 0.0041520125
increased O 0 0.007323829
. O 0 0.008800351

Data O 0 0.012004295
on O 0 0.0042384746
the O 0 0.003430699
possible O 0 0.0026850787
increased O 0 0.0028255119
risk O 0 0.04957629
of O 0 0.003580864
malignancy B-Disease 2 0.9998281
in O 0 0.004099593
rheumatoid B-Disease 2 0.9999269
arthritis I-Disease 2 0.9999856
are O 0 0.0025932794
still O 0 0.0007405479
being O 0 0.0008326358
collected O 0 0.0004252673
, O 0 0.0005893001
and O 0 0.00040049464
until O 0 0.00021883383
further O 0 0.00032985257
information O 0 0.00045032034
is O 0 0.00037165245
available O 0 0.00036545514
, O 0 0.00045399598
the O 0 0.00029652394
use O 0 0.0003679929
of O 0 0.0005566984
immunosuppressive O 0 0.9731654
drugs O 0 0.96062976
, O 0 0.0018837362
particularly O 0 0.0014700853
alkylating B-Chemical 0 0.99770325
agents I-Chemical 0 0.62029546
, O 0 0.0012393998
in O 0 0.00038943306
the O 0 0.00041503378
treatment O 0 0.0008374154
of O 0 0.001428764
rheumatoid B-Disease 2 0.99992263
arthritis I-Disease 2 0.9999838
should O 0 0.000590238
be O 0 0.000654048
reserved O 0 0.00092838134
for O 0 0.00041450234
patients O 0 0.0014698298
with O 0 0.00092265697
severe O 0 0.23511723
progressive O 0 0.48204678
disease O 0 0.893832
or O 0 0.0033634412
life O 0 0.032602176
- O 0 0.012721224
threatening O 0 0.35869652
complications O 0 0.9153401
. O 0 0.011122701

Warfarin B-Chemical 1 0.9984603
- O 0 0.023461904
induced O 0 0.013190471
iliopsoas O 0 0.8678918
hemorrhage B-Disease 2 0.9993957
with O 0 0.010732321
subsequent O 0 0.011135147
femoral B-Disease 0 0.56145144
nerve I-Disease 0 0.98714024
palsy I-Disease 0 0.99985063
. O 0 0.02022997

We O 0 0.007274479
present O 0 0.0038240529
the O 0 0.0032121362
case O 0 0.0024676495
of O 0 0.0021788771
a O 0 0.0022816379
28 O 0 0.0019203594
- O 0 0.0017928759
year O 0 0.0009964212
- O 0 0.0012020172
old O 0 0.0008619927
man O 0 0.0347198
on O 0 0.00059765455
chronic O 0 0.95508426
warfarin B-Chemical 1 0.9999347
therapy O 0 0.028551824
who O 0 0.0021849058
sustained O 0 0.0036168946
a O 0 0.0009472323
minor O 0 0.0021410384
muscle B-Disease 0 0.5323241
tear I-Disease 0 0.7869107
and O 0 0.0011126769
developed O 0 0.0013883976
increasing O 0 0.0019040983
pain B-Disease 2 0.99820554
and O 0 0.0017521773
a O 0 0.0025161805
flexure O 0 0.7414487
contracture B-Disease 0 0.9967129
of O 0 0.0036733397
the O 0 0.003959491
right O 0 0.019438004
hip O 0 0.7439817
. O 0 0.009513019

Surgical O 0 0.01584627
exploration O 0 0.0077320077
revealed O 0 0.0045689777
an O 0 0.004965413
iliopsoas O 0 0.66604483
hematoma B-Disease 2 0.9989291
and O 0 0.003382288
femoral O 0 0.07851647
nerve B-Disease 0 0.97715455
entrapment I-Disease 0 0.9864515
, O 0 0.0022141363
resulting O 0 0.0011986775
in O 0 0.00094265194
a O 0 0.0016241913
femoral B-Disease 0 0.13682936
nerve I-Disease 0 0.93451494
palsy I-Disease 0 0.99996793
and O 0 0.002454974
partial B-Disease 0 0.0028845666
loss I-Disease 0 0.0037189885
of I-Disease 0 0.0042341417
quadriceps I-Disease 0 0.8215249
functions I-Disease 0 0.008455288
. O 0 0.008503555

Anticoagulant O 0 0.9482303
- O 0 0.013048077
induced O 0 0.005696933
femoral B-Disease 0 0.186234
nerve I-Disease 0 0.9358611
palsy I-Disease 0 0.99995947
represents O 0 0.0018386277
the O 0 0.0009878569
most O 0 0.0010814907
common O 0 0.0010684457
form O 0 0.0007890084
of O 0 0.0017842316
warfarin B-Chemical 1 0.9999597
- O 0 0.009518586
induced O 0 0.0015992016
peripheral B-Disease 2 0.95122373
neuropathy I-Disease 2 0.99999607
; O 0 0.01223202
it O 0 0.0006877836
is O 0 0.00045837733
characterized O 0 0.00085269014
by O 0 0.0008374449
severe O 0 0.38119256
pain B-Disease 2 0.9987668
in O 0 0.0005386018
the O 0 0.0004971924
inguinal O 0 0.0026676115
region O 0 0.00065487635
, O 0 0.0006527257
varying O 0 0.0005996253
degrees O 0 0.0015808572
of O 0 0.00086476514
motor B-Disease 0 0.09299687
and I-Disease 0 0.0010229484
sensory I-Disease 0 0.18531302
impairment I-Disease 0 0.30068484
, O 0 0.0015547645
and O 0 0.0015467443
flexure O 0 0.6908397
contracture B-Disease 0 0.99669456
of O 0 0.0033103328
the O 0 0.003353829
involved O 0 0.004569199
extremity O 0 0.7657247
. O 0 0.009571027

Pneumonitis O 0 0.97040796
with O 0 0.010171031
pleural B-Disease 0 0.54682624
and I-Disease 0 0.007816666
pericardial I-Disease 0 0.456458
effusion I-Disease 0 0.97635776
and O 0 0.018806282
neuropathy B-Disease 2 0.99982846
during O 0 0.009636992
amiodarone B-Chemical 1 0.9999175
therapy O 0 0.38228023
. O 0 0.01500874

A O 0 0.031475853
patient O 0 0.008440042
with O 0 0.0050023436
sinuatrial B-Disease 0 0.22442164
disease I-Disease 0 0.889161
and O 0 0.0026514588
implanted O 0 0.0037753
pacemaker O 0 0.2654115
was O 0 0.0009913807
treated O 0 0.001054466
with O 0 0.001256727
amiodarone B-Chemical 1 0.99998415
( O 0 0.0013126114
maximum O 0 0.0005176064
dose O 0 0.0042351657
1000 O 0 0.001356929
mg O 0 0.16862255
, O 0 0.0006214997
maintenance O 0 0.0005793557
dose O 0 0.002503606
800 O 0 0.0018856775
mg O 0 0.09673977
daily O 0 0.0012054191
) O 0 0.00088798
for O 0 0.0004170465
10 O 0 0.00059531967
months O 0 0.0005468714
, O 0 0.0009678362
for O 0 0.00082662696
control O 0 0.0015724533
of O 0 0.004831377
supraventricular B-Disease 0 0.9999459
tachyarrhythmias I-Disease 0 0.9999646
. O 0 0.014456669

He O 0 0.019130632
developed O 0 0.011210301
pneumonitis B-Disease 0 0.9988788
, O 0 0.0077856327
pleural B-Disease 0 0.69741756
and I-Disease 0 0.004138932
pericardial I-Disease 0 0.48512012
effusions I-Disease 0 0.9929824
, O 0 0.0052886885
and O 0 0.0032040377
a O 0 0.0038284278
predominantly O 0 0.0048731207
proximal B-Disease 0 0.023691358
motor I-Disease 0 0.96527874
neuropathy I-Disease 2 0.99993455
. O 0 0.017087929

Immediate O 0 0.026458872
but O 0 0.0074665817
gradual O 0 0.00603567
improvement O 0 0.004472353
followed O 0 0.0032257729
withdrawal O 0 0.6119336
of O 0 0.0073014093
amiodarone B-Chemical 1 0.99994373
and O 0 0.0077657327
treatment O 0 0.012298857
with O 0 0.0154326
prednisolone B-Chemical 1 0.9998398
. O 0 0.016422346

Review O 0 0.014029036
of O 0 0.0060267914
this O 0 0.003702212
and O 0 0.0029335148
previously O 0 0.0019605658
reported O 0 0.0018157415
cases O 0 0.001912936
indicates O 0 0.0007836493
the O 0 0.0006940455
need O 0 0.00052520476
for O 0 0.00043321622
early O 0 0.0009712457
diagnosis O 0 0.008029222
of O 0 0.0024390693
amiodarone B-Chemical 1 0.99999547
pneumonitis B-Disease 0 0.999982
, O 0 0.006543702
immediate O 0 0.004098479
withdrawal O 0 0.8527293
of O 0 0.002635479
amiodarone B-Chemical 1 0.9999914
, O 0 0.001716778
and O 0 0.0008424986
prompt O 0 0.0038284825
but O 0 0.0008970085
continued O 0 0.0013469798
steroid B-Chemical 1 0.9958544
therapy O 0 0.011630341
to O 0 0.0016598713
ensure O 0 0.0014539273
full O 0 0.0029229228
recovery O 0 0.008499351
. O 0 0.00772926

Amiodarone B-Chemical 1 0.9987412
- O 0 0.057860404
induced O 0 0.038415994
sinoatrial B-Disease 0 0.8843057
block I-Disease 0 0.04823602
. O 0 0.03662779

We O 0 0.007893546
observed O 0 0.0046418793
sinoatrial B-Disease 0 0.4481859
block I-Disease 0 0.0040425193
due O 0 0.001810099
to O 0 0.0017985103
chronic O 0 0.9699351
amiodarone B-Chemical 1 0.9999895
administration O 0 0.35834372
in O 0 0.000990356
a O 0 0.0013060923
5 O 0 0.00074683555
- O 0 0.001030297
year O 0 0.0006269807
- O 0 0.00089320046
old O 0 0.0007144789
boy O 0 0.0025202828
with O 0 0.00095427333
primary B-Disease 0 0.030225849
cardiomyopathy I-Disease 2 0.9999939
, O 0 0.02017946
Wolff B-Disease 0 0.9629436
- I-Disease 0 0.013376741
Parkinson I-Disease 0 0.9998636
- I-Disease 0 0.009463838
White I-Disease 0 0.27728242
syndrome I-Disease 0 0.8954225
and O 0 0.014491201
supraventricular B-Disease 0 0.99994624
tachycardia I-Disease 2 0.9998915
. O 0 0.013662862

Reduction O 0 0.017392531
in O 0 0.0051211296
the O 0 0.0037157217
dosage O 0 0.063469976
of O 0 0.0043097907
amiodarone B-Chemical 1 0.9999577
resulted O 0 0.0016623051
in O 0 0.0010280561
the O 0 0.0008891785
disappearance O 0 0.0021533822
of O 0 0.0010758439
the O 0 0.0010798826
sinoatrial B-Disease 0 0.7402062
block I-Disease 0 0.0015405685
and O 0 0.0012666736
the O 0 0.001227785
persistence O 0 0.0022760709
of O 0 0.0034808693
asymptomatic O 0 0.5989007
sinus B-Disease 2 0.97820264
bradycardia I-Disease 2 0.99977165
. O 0 0.011857695

Desipramine B-Chemical 0 0.9997944
- O 0 0.024874052
induced O 0 0.010639332
delirium B-Disease 2 0.9995141
at O 0 0.0044521736
" O 0 0.005937328
subtherapeutic O 0 0.97594017
" O 0 0.005623272
concentrations O 0 0.0076006562
: O 0 0.00593139
a O 0 0.00559732
case O 0 0.006647174
report O 0 0.018347466
. O 0 0.011576789

An O 0 0.014264317
elderly O 0 0.08637927
patient O 0 0.00611745
treated O 0 0.0036874323
with O 0 0.0026408965
low O 0 0.003077487
dose O 0 0.22445598
Desipramine B-Chemical 0 0.9999887
developed O 0 0.0034462202
a O 0 0.0030600892
delirium B-Disease 2 0.999882
while O 0 0.0010995719
her O 0 0.0017508082
plasma O 0 0.011416687
level O 0 0.000807172
was O 0 0.0010609289
in O 0 0.0011821183
the O 0 0.0017602929
" O 0 0.0038939528
subtherapeutic O 0 0.96807486
" O 0 0.006829942
range O 0 0.008867562
. O 0 0.008535997

Delirium B-Disease 2 0.99720603
, O 0 0.010305426
which O 0 0.005174914
may O 0 0.0029614444
be O 0 0.0022640594
induced O 0 0.0020499134
by O 0 0.0024057843
tricyclic O 0 0.9998522
drug O 0 0.7925489
therapy O 0 0.020576589
in O 0 0.00085927796
the O 0 0.000986714
elderly O 0 0.48648518
, O 0 0.0013587084
can O 0 0.00067111745
be O 0 0.0008930916
caused O 0 0.001225125
by O 0 0.0022988478
tricyclics O 0 0.99967515
with O 0 0.0028329715
low O 0 0.0067844
anticholinergic O 0 0.9998054
potency O 0 0.60944355
. O 0 0.010547622

Therapeutic O 0 0.07741032
ranges O 0 0.007964665
for O 0 0.0040566833
antidepressants B-Chemical 1 0.9994678
that O 0 0.0022007904
have O 0 0.0015525868
been O 0 0.001331675
derived O 0 0.0010744988
from O 0 0.0009921921
general O 0 0.00096254173
adult O 0 0.00152036
population O 0 0.0018209153
studies O 0 0.0012334196
may O 0 0.0010576487
not O 0 0.0012069534
be O 0 0.0015427712
appropriate O 0 0.001695896
for O 0 0.0022390469
the O 0 0.0044158744
elderly O 0 0.57070756
. O 0 0.009069176

Further O 0 0.008743967
studies O 0 0.005614736
of O 0 0.0042590215
specifically O 0 0.0029268833
elderly O 0 0.19601715
patients O 0 0.004616767
are O 0 0.0015163401
now O 0 0.0012229589
required O 0 0.000621333
to O 0 0.0007621152
establish O 0 0.00076394214
safer O 0 0.00241729
and O 0 0.0011834321
more O 0 0.0012683481
appropriate O 0 0.0012553977
guidelines O 0 0.0019115518
for O 0 0.0021979664
drug O 0 0.63537866
therapy O 0 0.0867299
. O 0 0.008985515

Indomethacin B-Chemical 1 0.9996276
- O 0 0.0308474
induced O 0 0.014966636
renal B-Disease 0 0.99283314
insufficiency I-Disease 0 0.99804544
: O 0 0.027436802
recurrence O 0 0.8837396
on O 0 0.010341281
rechallenge O 0 0.8626781
. O 0 0.017762387

We O 0 0.007962883
have O 0 0.004722657
reported O 0 0.0038564003
a O 0 0.0031701925
case O 0 0.002184628
of O 0 0.002740156
acute O 0 0.984992
oliguric O 0 0.9999572
renal B-Disease 0 0.99928975
failure I-Disease 0 0.96354276
with O 0 0.004888657
hyperkalemia B-Disease 2 0.9999895
in O 0 0.000992633
a O 0 0.0012220087
patient O 0 0.0015263407
with O 0 0.0017632229
cirrhosis B-Disease 2 0.9999889
, O 0 0.014767367
ascites B-Disease 2 0.9997758
, O 0 0.0053599416
and O 0 0.0044484176
cor B-Disease 0 0.9998845
pulmonale I-Disease 0 0.99999535
after O 0 0.0074947304
indomethacin B-Chemical 1 0.99994767
therapy O 0 0.48586354
. O 0 0.0115463985

Prompt O 0 0.14450549
restoration O 0 0.008301151
of O 0 0.0049699503
renal O 0 0.9278514
function O 0 0.0029995276
followed O 0 0.0014725548
drug O 0 0.57497126
withdrawal O 0 0.924458
, O 0 0.0019120122
while O 0 0.00089197874
re O 0 0.049622897
- O 0 0.0014304841
exposure O 0 0.0010701596
to O 0 0.0005262239
a O 0 0.0007724893
single O 0 0.0006903549
dose O 0 0.0063647735
of O 0 0.002203308
indomethacin B-Chemical 1 0.99997234
caused O 0 0.0063771866
recurrence O 0 0.97490376
of O 0 0.013248941
acute O 0 0.99688774
reversible O 0 0.9849508
oliguria B-Disease 0 0.9998901
. O 0 0.013952968

Our O 0 0.007352269
case O 0 0.0048193345
supports O 0 0.0028755888
the O 0 0.0023134188
hypothesis O 0 0.0020979114
that O 0 0.0013957097
endogenous O 0 0.0036285128
renal O 0 0.9985781
prostaglandins B-Chemical 1 0.9999627
play O 0 0.0025361918
a O 0 0.001379564
role O 0 0.00052106456
in O 0 0.0005455365
the O 0 0.00058078737
maintenance O 0 0.0009377326
of O 0 0.0010229137
renal O 0 0.98067904
blood O 0 0.040976144
flow O 0 0.0071940804
when O 0 0.0009807046
circulating O 0 0.008393112
plasma O 0 0.060321417
volume O 0 0.010651963
is O 0 0.004471033
diminished O 0 0.007961431
. O 0 0.00874247

Since O 0 0.008373031
nonsteroidal O 0 0.99969363
anti O 0 0.32411078
- O 0 0.02061674
inflammatory O 0 0.928198
agents O 0 0.59989685
interfere O 0 0.0020504042
with O 0 0.0012291939
this O 0 0.00090079085
compensatory O 0 0.0017996955
mechanism O 0 0.00095231243
and O 0 0.00093797746
may O 0 0.00071716605
cause O 0 0.010927588
acute B-Disease 0 0.98853046
renal I-Disease 0 0.99906164
failure I-Disease 0 0.94760716
, O 0 0.0018393357
they O 0 0.00071778137
should O 0 0.0004989115
be O 0 0.0007832584
used O 0 0.00083199894
with O 0 0.0012072416
caution O 0 0.0019040202
in O 0 0.0020997871
such O 0 0.0036923967
patients O 0 0.01917002
. O 0 0.008438331

Patterns O 0 0.035627745
of O 0 0.024912072
hepatic B-Disease 2 0.99209774
injury I-Disease 2 0.99596417
induced O 0 0.036042716
by O 0 0.064009205
methyldopa B-Chemical 1 0.9999094
. O 0 0.03225353

Twelve O 0 0.018098883
patients O 0 0.012558301
with O 0 0.0076871486
liver B-Disease 2 0.9765121
disease I-Disease 2 0.9701536
related O 0 0.0039642164
to O 0 0.0045904154
methyldopa B-Chemical 1 0.999974
were O 0 0.004540948
seen O 0 0.0031608609
between O 0 0.0031782477
1967 O 0 0.015993044
and O 0 0.0076246946
1977 O 0 0.054508377
. O 0 0.00998063

Illness O 0 0.21980788
occurred O 0 0.0061214524
within O 0 0.0030467599
1 O 0 0.0033462227
- O 0 0.0034740153
- O 0 0.002038763
9 O 0 0.0009669772
weeks O 0 0.0005186811
of O 0 0.0006131253
commencement O 0 0.00069580774
of O 0 0.00065911154
therapy O 0 0.0031288795
in O 0 0.00049853686
9 O 0 0.00053771597
patients O 0 0.0010118743
, O 0 0.0005081924
the O 0 0.0003098022
remaining O 0 0.00033006995
3 O 0 0.00034402078
patients O 0 0.00061517244
having O 0 0.00040155931
received O 0 0.0003629487
the O 0 0.00041233088
drug O 0 0.10827509
for O 0 0.00040788852
13 O 0 0.00063433754
months O 0 0.00041368286
, O 0 0.0006735364
15 O 0 0.0005107197
months O 0 0.0005332365
and O 0 0.0009263292
7 O 0 0.001150825
years O 0 0.0018923931
before O 0 0.001694834
experiencing O 0 0.098216005
symptoms O 0 0.88908637
. O 0 0.009567701

Jaundice B-Disease 0 0.991234
with O 0 0.008795572
tender O 0 0.49322674
hepatomegaly B-Disease 2 0.9995938
, O 0 0.0051177745
usually O 0 0.0028419527
preceded O 0 0.0022424753
by O 0 0.0017253892
symptoms O 0 0.7788509
of O 0 0.0044808867
malaise O 0 0.9999788
, O 0 0.029407684
anorexia B-Disease 0 0.99997115
, O 0 0.019699985
nausea B-Disease 2 0.99999666
and O 0 0.006514856
vomiting B-Disease 2 0.9999838
, O 0 0.0018961166
and O 0 0.00075735355
associated O 0 0.00070012436
with O 0 0.00069411955
upper O 0 0.0031046858
abdominal B-Disease 0 0.79667354
pain I-Disease 2 0.99920315
, O 0 0.0021132203
was O 0 0.0010825606
an O 0 0.0016142104
invariable O 0 0.008291441
finding O 0 0.00258917
in O 0 0.0025432946
all O 0 0.0038239025
patients O 0 0.013480598
. O 0 0.008516645

Biochemical O 0 0.48196152
liver O 0 0.74470085
function O 0 0.0058192117
tests O 0 0.006513613
indicated O 0 0.0032766447
hepatocellular O 0 0.9999708
necrosis B-Disease 2 0.9998975
and O 0 0.0033409041
correlated O 0 0.0009513348
with O 0 0.00095531775
histopathological O 0 0.42641687
evidence O 0 0.0009059276
of O 0 0.0016480323
hepatic B-Disease 2 0.99886775
injury I-Disease 2 0.99891067
, O 0 0.0015312029
the O 0 0.00051924476
spectrum O 0 0.00066069706
of O 0 0.00069154444
which O 0 0.0008193448
ranged O 0 0.0011602881
from O 0 0.0010269049
fatty B-Disease 0 0.99923575
change I-Disease 0 0.0033296798
and O 0 0.0019771885
focal O 0 0.597056
hepatocellular O 0 0.99998987
necrosis B-Disease 2 0.99989784
to O 0 0.005564447
massive B-Disease 0 0.58622915
hepatic I-Disease 0 0.9976367
necrosis I-Disease 2 0.9992742
. O 0 0.014920598

Most O 0 0.013740796
patients O 0 0.009927781
showed O 0 0.0048579155
moderate O 0 0.01081822
to O 0 0.004138081
severe O 0 0.76212823
acute B-Disease 0 0.9996189
hepatitis I-Disease 2 0.99999106
or O 0 0.08737749
chronic B-Disease 0 0.9992028
active I-Disease 0 0.44014964
hepatitis I-Disease 2 0.99997854
with O 0 0.07435195
associated O 0 0.11766309
cholestasis B-Disease 2 0.9999466
. O 0 0.022557072

The O 0 0.007862407
drug O 0 0.10839907
was O 0 0.0042004683
withdrawn O 0 0.0049062227
on O 0 0.0017453964
presentation O 0 0.0033042275
to O 0 0.0014504379
hospital O 0 0.0030219795
in O 0 0.0012068299
11 O 0 0.0015669275
patients O 0 0.002477075
, O 0 0.0017152531
with O 0 0.0015010007
rapid O 0 0.0031562455
clinical O 0 0.008826531
improvement O 0 0.00371196
in O 0 0.0038984779
9 O 0 0.0064381817
. O 0 0.007365421

One O 0 0.010796344
patient O 0 0.0073889596
died O 0 0.010512829
, O 0 0.003626565
having O 0 0.0022430539
presented O 0 0.0018388921
in O 0 0.0014572074
hepatic B-Disease 0 0.9561257
failure I-Disease 0 0.8638392
, O 0 0.0019767908
and O 0 0.0009441013
another O 0 0.00092789275
, O 0 0.00086078665
who O 0 0.0009359582
had O 0 0.00047553165
been O 0 0.00054453907
taking O 0 0.0015904678
methyldopa B-Chemical 1 0.99999
for O 0 0.0004934855
7 O 0 0.0005164207
years O 0 0.0006700059
, O 0 0.00056091073
showed O 0 0.0003642173
slower O 0 0.0004799366
clinical O 0 0.0018350318
and O 0 0.0008193916
biochemical O 0 0.010258367
resolution O 0 0.0050903712
over O 0 0.000766502
a O 0 0.0015368712
period O 0 0.0014017159
of O 0 0.0024673082
several O 0 0.003832165
months O 0 0.0049372613
. O 0 0.0074117337

The O 0 0.0066117835
remaining O 0 0.0046467525
patient O 0 0.004327204
in O 0 0.0024387653
the O 0 0.0019968923
series O 0 0.0030279388
developed O 0 0.0057207677
fulminant B-Disease 0 0.9999702
hepatitis I-Disease 2 0.9999932
when O 0 0.0015832718
the O 0 0.0011812032
drug O 0 0.5460193
was O 0 0.000940408
accidentally O 0 0.009209632
recommenced O 0 0.022845943
1 O 0 0.00068454014
year O 0 0.000521378
after O 0 0.00040636637
a O 0 0.0008499507
prior O 0 0.0006982699
episode O 0 0.01235566
of O 0 0.005739055
methyldopa B-Chemical 1 0.99999154
- O 0 0.08241084
induced O 0 0.03582185
hepatitis B-Disease 2 0.9999105
. O 0 0.0251291

In O 0 0.0071105734
this O 0 0.0048609087
latter O 0 0.0056782933
patient O 0 0.0044737607
, O 0 0.002857148
and O 0 0.0017518795
in O 0 0.0011979584
2 O 0 0.0010777214
others O 0 0.0017164635
, O 0 0.00088642206
the O 0 0.00050813495
causal O 0 0.00094286207
relationship O 0 0.00045173912
between O 0 0.00053302024
methyldopa B-Chemical 1 0.99999654
and O 0 0.005010251
hepatic B-Disease 0 0.99942315
dysfunction I-Disease 0 0.99901056
was O 0 0.00093868235
proved O 0 0.0011694023
with O 0 0.0005487051
the O 0 0.000606275
recurrence O 0 0.79664797
of O 0 0.0028648856
hepatitis B-Disease 2 0.99996996
within O 0 0.00068643404
2 O 0 0.0008297466
weeks O 0 0.00056089705
of O 0 0.0011637615
re O 0 0.039490547
- O 0 0.0028376682
exposure O 0 0.0030843765
to O 0 0.0025035155
the O 0 0.004203922
drug O 0 0.6937051
. O 0 0.009296824

Suxamethonium B-Chemical 1 0.9811291
infusion O 0 0.046803273
rate O 0 0.019159444
and O 0 0.020856036
observed O 0 0.020013796
fasciculations B-Disease 0 0.9991007
. O 0 0.032828838

A O 0 0.1005764
dose O 0 0.08270443
- O 0 0.0415059
response O 0 0.034981355
study O 0 0.03741449
. O 0 0.034343593

Suxamethonium B-Chemical 1 0.99913436
chloride I-Chemical 0 0.99983656
( O 0 0.10053328
Sch B-Chemical 0 0.99990046
) O 0 0.009372164
was O 0 0.001815331
administered O 0 0.0018173852
i O 0 0.0034701284
. O 0 0.0007784383
v O 0 0.009060969
. O 0 0.0004894363
to O 0 0.00044260456
36 O 0 0.0005029941
adult O 0 0.00060424843
males O 0 0.0007580218
at O 0 0.0003075014
six O 0 0.0002960937
rates O 0 0.0005505426
: O 0 0.0008421471
0 O 0 0.0006731731
. O 0 0.00038131516
25 O 0 0.00066601543
mg O 0 0.052035123
s O 0 0.0010394041
- O 0 0.0012383496
1 O 0 0.0008691248
to O 0 0.0008924977
20 O 0 0.0014804889
mg O 0 0.11413097
s O 0 0.0038155266
- O 0 0.005664655
1 O 0 0.0059221135
. O 0 0.007269726

The O 0 0.0068057585
infusion O 0 0.010229031
was O 0 0.0034093861
discontinued O 0 0.0062628468
either O 0 0.0015019794
when O 0 0.0008849452
there O 0 0.0006646157
was O 0 0.00071542396
no O 0 0.000568752
muscular O 0 0.18460865
response O 0 0.0013020401
to O 0 0.0008965565
tetanic B-Disease 0 0.996345
stimulation O 0 0.0014497269
of O 0 0.00097572734
the O 0 0.0009721117
ulnar O 0 0.43524125
nerve O 0 0.48198083
or O 0 0.001298183
when O 0 0.0015042273
Sch B-Chemical 0 0.9999018
120 O 0 0.0036292248
mg O 0 0.29175347
was O 0 0.0037833918
exceeded O 0 0.0047442135
. O 0 0.007418131

Six O 0 0.010596784
additional O 0 0.005214417
patients O 0 0.006121609
received O 0 0.003605809
a O 0 0.0038515914
30 O 0 0.0025906675
- O 0 0.0036578928
mg O 0 0.17217472
i O 0 0.0062405374
. O 0 0.0024167255
v O 0 0.012358105
. O 0 0.0031199595
bolus O 0 0.059986707
dose O 0 0.036155164
. O 0 0.009734394

Fasciculations B-Disease 0 0.66421187
in O 0 0.005833566
six O 0 0.0032159493
areas O 0 0.0038315314
of O 0 0.002333486
the O 0 0.001791795
body O 0 0.004383537
were O 0 0.0013678669
scored O 0 0.0016540705
from O 0 0.0010278093
0 O 0 0.0011574236
to O 0 0.00081280834
3 O 0 0.0009431186
and O 0 0.0012315753
summated O 0 0.0047080796
as O 0 0.001796302
a O 0 0.0030061658
total O 0 0.003959567
fasciculation B-Disease 2 0.9813952
score O 0 0.010050362
. O 0 0.009061778

The O 0 0.0073371697
times O 0 0.0045401384
to O 0 0.003760573
first O 0 0.0032659261
fasciculation B-Disease 2 0.98073465
, O 0 0.0048525035
twitch B-Disease 0 0.967949
suppression O 0 0.004431869
and O 0 0.0024670078
tetanus B-Disease 0 0.9350792
suppression O 0 0.004207117
were O 0 0.0015518937
inversely O 0 0.0013907877
related O 0 0.0013492254
to O 0 0.0018507112
the O 0 0.002752712
infusion O 0 0.024098076
rates O 0 0.007026099
. O 0 0.008946339

Fasciculations B-Disease 0 0.6725793
in O 0 0.0059610745
the O 0 0.0038927256
six O 0 0.002362316
areas O 0 0.003306466
and O 0 0.001938108
the O 0 0.0014800287
total O 0 0.0016638394
fasciculation B-Disease 2 0.96234936
score O 0 0.0020083275
were O 0 0.0012326279
related O 0 0.0009772666
directly O 0 0.0013439307
to O 0 0.001403104
the O 0 0.0018318081
rate O 0 0.0025440883
of O 0 0.0050118347
infusion O 0 0.083483376
. O 0 0.009010051

Total O 0 0.013954278
fasciculation B-Disease 2 0.9036073
scores O 0 0.0051577045
in O 0 0.0024862387
the O 0 0.0019254972
30 O 0 0.0013809772
- O 0 0.0017122648
mg O 0 0.07846106
bolus O 0 0.020439187
group O 0 0.000893409
and O 0 0.00073271175
the O 0 0.0006156484
5 O 0 0.0005895998
- O 0 0.000906336
mg O 0 0.10911079
s O 0 0.0008730964
- O 0 0.00092969224
1 O 0 0.0005075028
and O 0 0.00052746036
20 O 0 0.0006199583
- O 0 0.00089476135
mg O 0 0.08431867
s O 0 0.0010273708
- O 0 0.0012048326
1 O 0 0.000832954
infusion O 0 0.0021928884
groups O 0 0.0015004482
were O 0 0.001684933
not O 0 0.0020035678
significantly O 0 0.0039422936
different O 0 0.0054180147
. O 0 0.00818087

Treatment O 0 0.077901274
of O 0 0.042193532
psoriasis B-Disease 2 0.99644357
with O 0 0.12936418
azathioprine B-Chemical 1 0.9996357
. O 0 0.054459706

Azathioprine B-Chemical 1 0.9993305
treatment O 0 0.018799309
benefited O 0 0.080179654
19 O 0 0.0073362086
( O 0 0.0043296227
66 O 0 0.0038569681
% O 0 0.002672762
) O 0 0.0025050307
out O 0 0.0014943719
of O 0 0.0019019417
29 O 0 0.0031692705
patients O 0 0.0049083955
suffering O 0 0.85976434
from O 0 0.006850493
severe O 0 0.86616874
psoriasis B-Disease 2 0.99955374
. O 0 0.018555759

Haematological O 0 0.9568084
complications O 0 0.52580285
were O 0 0.006350399
not O 0 0.00434199
troublesome O 0 0.10585004
and O 0 0.0031909884
results O 0 0.0025316458
of O 0 0.0030524475
biochemical O 0 0.06193041
liver O 0 0.9248707
function O 0 0.0052373926
tests O 0 0.008598012
remained O 0 0.0064830217
normal O 0 0.011888609
. O 0 0.009942077

Minimal O 0 0.07277052
cholestasis B-Disease 2 0.9997008
was O 0 0.006628896
seen O 0 0.0032482755
in O 0 0.002278862
two O 0 0.0017807818
cases O 0 0.0027439739
and O 0 0.0022795298
portal O 0 0.15839957
fibrosis B-Disease 2 0.99317896
of O 0 0.0036890393
a O 0 0.0044745314
reversible O 0 0.24855848
degree O 0 0.0051173694
in O 0 0.0048110383
eight O 0 0.0061599356
. O 0 0.00898356

Liver O 0 0.8912578
biopsies O 0 0.01368302
should O 0 0.0033384834
be O 0 0.0026628408
undertaken O 0 0.0015456732
at O 0 0.0010965217
regular O 0 0.0012187975
intervals O 0 0.00084278925
if O 0 0.00076111755
azathioprine B-Chemical 1 0.99995315
therapy O 0 0.032640662
is O 0 0.0007781079
continued O 0 0.0006793053
so O 0 0.000540327
that O 0 0.0005237827
structural O 0 0.0033848493
liver B-Disease 2 0.99675316
damage I-Disease 2 0.984729
may O 0 0.0012857657
be O 0 0.001113854
detected O 0 0.00076758274
at O 0 0.0009727742
an O 0 0.001970847
early O 0 0.0033103374
and O 0 0.0043347566
reversible O 0 0.41487858
stage O 0 0.021619335
. O 0 0.009849945

Angiosarcoma B-Disease 0 0.7720126
of I-Disease 0 0.022829948
the I-Disease 0 0.019569736
liver I-Disease 0 0.8484688
associated O 0 0.026142016
with O 0 0.03712151
diethylstilbestrol B-Chemical 1 0.99955076
. O 0 0.033208836

Angiosarcoma B-Disease 0 0.75613683
of I-Disease 0 0.007181419
the I-Disease 0 0.004601659
liver I-Disease 0 0.600047
occurred O 0 0.002860878
in O 0 0.0016303982
a O 0 0.0019207004
76 O 0 0.0028932022
- O 0 0.0016289046
year O 0 0.0009097249
- O 0 0.0011351451
old O 0 0.00084616285
man O 0 0.031018037
who O 0 0.0015201819
had O 0 0.0006504274
been O 0 0.00063713535
treated O 0 0.0006840462
for O 0 0.00046055653
a O 0 0.0008808919
well O 0 0.0007738047
- O 0 0.0017993614
differentiated O 0 0.0058659334
adenocarcinoma B-Disease 0 0.99925655
of I-Disease 0 0.0017192658
the I-Disease 0 0.0016484043
liver I-Disease 0 0.9223939
with O 0 0.0059286575
diethylstilbestrol B-Chemical 1 0.9999068
for O 0 0.003490957
13 O 0 0.0058252537
years O 0 0.0077542965
. O 0 0.0075611654

Angiosarcoma B-Disease 0 0.8098272
was O 0 0.012680893
also O 0 0.008913405
present O 0 0.0064743413
within O 0 0.0060405135
pulmonary O 0 0.70375675
and O 0 0.015949275
renal O 0 0.9944437
arteries O 0 0.95564556
. O 0 0.019509936

The O 0 0.008326142
possibility O 0 0.005845561
that O 0 0.004259203
the O 0 0.004293831
intraarterial B-Disease 0 0.91541404
lesions I-Disease 0 0.785141
might O 0 0.0026568044
represent O 0 0.003230287
independent O 0 0.003019205
primary O 0 0.005810559
tumors B-Disease 2 0.9745861
is O 0 0.0068497797
considered O 0 0.00755864
. O 0 0.010185741

Galanthamine B-Chemical 0 0.9984717
hydrobromide I-Chemical 0 0.9997373
, O 0 0.008454949
a O 0 0.0037639097
longer O 0 0.0016650589
acting O 0 0.007238429
anticholinesterase O 0 0.99957055
drug O 0 0.89991355
, O 0 0.0020973824
in O 0 0.0007809333
the O 0 0.00073310913
treatment O 0 0.0010529812
of O 0 0.0009915545
the O 0 0.0009813318
central O 0 0.0026404217
effects O 0 0.003266398
of O 0 0.011550667
scopolamine B-Chemical 1 0.99999213
( O 0 0.11317834
Hyoscine B-Chemical 0 0.9994504
) O 0 0.02074989
. O 0 0.008807199

Galanthamine B-Chemical 0 0.9986124
hydrobromide I-Chemical 0 0.9997819
, O 0 0.010354955
an O 0 0.0052900035
anticholinesterase O 0 0.99897563
drug O 0 0.7283397
capable O 0 0.0019912943
of O 0 0.0015438102
penetrating O 0 0.7070985
the O 0 0.0010926822
blood O 0 0.06901237
- O 0 0.0028373268
brain O 0 0.07479595
barrier O 0 0.015695116
, O 0 0.0009553404
was O 0 0.000471138
used O 0 0.00040408797
in O 0 0.00041249048
a O 0 0.0006354661
patient O 0 0.0007699475
demonstrating O 0 0.000576825
central O 0 0.0017522124
effects O 0 0.0022099894
of O 0 0.0076389844
scopolamine B-Chemical 1 0.999995
( O 0 0.14882295
hyoscine B-Chemical 0 0.99998355
) O 0 0.23554489
overdosage B-Disease 0 0.9998265
. O 0 0.011636563

It O 0 0.010455895
is O 0 0.0054605464
longer O 0 0.0031940313
acting O 0 0.0061034774
than O 0 0.0026566996
physostigmine B-Chemical 0 0.99995506
and O 0 0.0029704252
is O 0 0.0014319351
used O 0 0.0010305454
in O 0 0.0010205184
anaesthesia O 0 0.0389717
to O 0 0.001167332
reverse O 0 0.0068733054
the O 0 0.0017417364
non O 0 0.0071280464
- O 0 0.0091741765
depolarizing O 0 0.94723487
neuromuscular O 0 0.96222985
block O 0 0.013317138
. O 0 0.009368826

However O 0 0.01115801
, O 0 0.008174584
studies O 0 0.004909562
into O 0 0.0028121485
the O 0 0.0028382
dose O 0 0.0061841626
necessary O 0 0.0020541796
to O 0 0.0030044415
combating O 0 0.29200372
scopolamine B-Chemical 1 0.99999034
intoxication O 0 0.99975735
are O 0 0.012575555
indicated O 0 0.008722195
. O 0 0.010897474

Comparison O 0 0.0070495247
of O 0 0.0054595615
the O 0 0.0038023207
subjective O 0 0.009871706
effects O 0 0.0036862202
and O 0 0.002335887
plasma O 0 0.02946068
concentrations O 0 0.0030876573
following O 0 0.0011797211
oral O 0 0.41961268
and O 0 0.001602111
i O 0 0.00689174
. O 0 0.00091032404
m O 0 0.0053716386
. O 0 0.0010016948
administration O 0 0.022107607
of O 0 0.003995146
flunitrazepam B-Chemical 0 0.99994314
in O 0 0.0047853035
volunteers O 0 0.037570234
. O 0 0.008384104

Flunitrazepam B-Chemical 0 0.999326
0 O 0 0.0095004095
. O 0 0.0034363053
5 O 0 0.0024535486
, O 0 0.0022945604
1 O 0 0.0014744904
. O 0 0.00087798206
0 O 0 0.00093824737
or O 0 0.0006569736
2 O 0 0.00066210644
. O 0 0.00043742155
0 O 0 0.0006059657
mg O 0 0.029957946
was O 0 0.0004053952
given O 0 0.0002905146
by O 0 0.0004487301
the O 0 0.00044422367
oral O 0 0.14569722
or O 0 0.0006492993
i O 0 0.004376137
. O 0 0.00049644266
m O 0 0.003238693
. O 0 0.00044648405
routes O 0 0.00198568
to O 0 0.0005661584
groups O 0 0.000874042
of O 0 0.0010701045
volunteers O 0 0.003919404
and O 0 0.0020318765
its O 0 0.0034727477
effects O 0 0.005506296
compared O 0 0.0041528246
. O 0 0.007790209

Plasma O 0 0.13446867
concentrations O 0 0.008026173
of O 0 0.0045004366
the O 0 0.0030514214
drug O 0 0.2339049
were O 0 0.0019049755
estimated O 0 0.0014426674
by O 0 0.0017557238
gas O 0 0.1737961
- O 0 0.002836705
liquid O 0 0.004301585
chromatography O 0 0.012493687
, O 0 0.0016138339
in O 0 0.0010653016
a O 0 0.0015559981
smaller O 0 0.001402881
number O 0 0.0017345845
of O 0 0.0029811123
the O 0 0.004138383
subjects O 0 0.009996955
. O 0 0.008457688

The O 0 0.0068557146
most O 0 0.005479487
striking O 0 0.0039195423
effect O 0 0.0025903496
was O 0 0.0021800532
sedation O 0 0.5713418
which O 0 0.001689868
increased O 0 0.0012657833
with O 0 0.0009072877
the O 0 0.0007996556
dose O 0 0.013037119
, O 0 0.0011515146
2 O 0 0.00067157694
mg O 0 0.05898411
producing O 0 0.00083893375
deep O 0 0.0022111812
sleep O 0 0.115174085
although O 0 0.0009327799
the O 0 0.0011839162
subjects O 0 0.0023844491
could O 0 0.0017703105
still O 0 0.0029926111
be O 0 0.0050517945
aroused O 0 0.06844309
. O 0 0.008712011

The O 0 0.0072872485
effects O 0 0.0060364516
of O 0 0.00454577
i O 0 0.008241351
. O 0 0.0020442235
m O 0 0.0069630104
. O 0 0.0011519208
administration O 0 0.009394255
were O 0 0.0009329324
apparent O 0 0.0008052871
earlier O 0 0.00083320093
and O 0 0.0009733987
sometimes O 0 0.0018291711
lasted O 0 0.00095474574
longer O 0 0.000694547
than O 0 0.0009240623
those O 0 0.0020161266
following O 0 0.0026209047
oral O 0 0.6859182
administration O 0 0.4335213
. O 0 0.009783083

Dizziness B-Disease 0 0.99575776
was O 0 0.008455669
less O 0 0.0054822327
marked O 0 0.0057308227
than O 0 0.0033811035
sedation O 0 0.62421596
, O 0 0.0049754754
but O 0 0.0034008615
increased O 0 0.004033506
with O 0 0.0047807912
the O 0 0.0061534266
dose O 0 0.07351945
. O 0 0.011397779

There O 0 0.010283932
was O 0 0.007629505
pain B-Disease 2 0.96131504
on O 0 0.003183178
i O 0 0.0063900882
. O 0 0.0018968151
m O 0 0.005414031
. O 0 0.0011627006
injection O 0 0.0020827258
of O 0 0.0021528404
flunitrazepam B-Chemical 0 0.9999684
significantly O 0 0.0026401833
more O 0 0.0020485236
often O 0 0.002674705
than O 0 0.0017734328
with O 0 0.0036803777
isotonic O 0 0.6520479
saline O 0 0.5466319
. O 0 0.009294676

Plasma O 0 0.15391812
concentrations O 0 0.009687785
varied O 0 0.0059036817
with O 0 0.0038008348
dose O 0 0.009917896
and O 0 0.0030967765
route O 0 0.0061552315
and O 0 0.0025569373
corresponded O 0 0.0019121835
qualitatively O 0 0.0027319228
with O 0 0.0029188956
the O 0 0.0037709933
subjective O 0 0.03164176
effects O 0 0.013415222
. O 0 0.010147534

The O 0 0.008278137
drug O 0 0.1263942
was O 0 0.0043900707
still O 0 0.0027171087
present O 0 0.0016893928
in O 0 0.0016209424
measurable O 0 0.0018878774
quantities O 0 0.0016712833
after O 0 0.0009406256
24 O 0 0.0010725664
h O 0 0.0011320572
even O 0 0.0015108995
with O 0 0.0020213334
the O 0 0.0027180999
smallest O 0 0.0044295066
dose O 0 0.040652864
. O 0 0.009094396

Possible O 0 0.29987705
teratogenicity O 0 0.994863
of O 0 0.12834261
sulphasalazine B-Chemical 1 0.9994485
. O 0 0.062482063

Three O 0 0.00982825
infants O 0 0.007952517
, O 0 0.0046418505
born O 0 0.0032454391
of O 0 0.0020301745
two O 0 0.0013676462
mothers O 0 0.002461466
with O 0 0.0014593911
inflammatory B-Disease 0 0.9801901
bowel I-Disease 0 0.99580765
disease I-Disease 0 0.9880531
who O 0 0.006147976
received O 0 0.00085785857
treatment O 0 0.0014546687
with O 0 0.00139538
sulphasalazine B-Chemical 1 0.9999825
throughout O 0 0.00092767837
pregnancy O 0 0.50148773
, O 0 0.0016268347
were O 0 0.001062662
found O 0 0.0009810331
to O 0 0.0013815
have O 0 0.0019882321
major O 0 0.004779303
congenital B-Disease 0 0.8817017
anomalies I-Disease 0 0.9200018
. O 0 0.011599374

In O 0 0.0072484277
the O 0 0.0051820446
singleton O 0 0.008458523
pregnancy O 0 0.19902112
, O 0 0.0029732706
the O 0 0.0016289761
mother O 0 0.005881425
had O 0 0.0020631766
ulcerative B-Disease 0 0.9999933
colitis I-Disease 0 0.99999607
, O 0 0.021240937
and O 0 0.001340985
the O 0 0.00083219004
infant O 0 0.004740441
, O 0 0.0010699313
a O 0 0.00093093404
male O 0 0.003413822
, O 0 0.000964293
had O 0 0.00069201255
coarctation B-Disease 0 0.104938105
of I-Disease 0 0.0011709103
the I-Disease 0 0.0012703271
aorta I-Disease 0 0.044677004
and O 0 0.0021990135
a O 0 0.0039890297
ventricular B-Disease 0 0.9945262
septal I-Disease 0 0.13016021
defect I-Disease 0 0.008236013
. O 0 0.008147567

In O 0 0.011341641
the O 0 0.009087017
twin O 0 0.024699848
pregnancy O 0 0.2650022
, O 0 0.0068370425
the O 0 0.0046886136
mother O 0 0.011116849
had O 0 0.0059231804
Crohn B-Disease 0 0.9982621
' I-Disease 0 0.012937006
s I-Disease 0 0.011432972
disease I-Disease 0 0.7884399
. O 0 0.014755361

The O 0 0.0077839685
first O 0 0.00532767
twin O 0 0.017086254
, O 0 0.0045300466
a O 0 0.0033607427
female O 0 0.0064954814
, O 0 0.0024701462
had O 0 0.001450224
a O 0 0.0018994695
left O 0 0.003436191
Potter B-Disease 0 0.06210871
- I-Disease 0 0.0024925
type I-Disease 0 0.0018373654
IIa I-Disease 0 0.7553128
polycystic I-Disease 0 0.9995565
kidney I-Disease 0 0.9715062
and O 0 0.0037377777
a O 0 0.0038718747
rudimentary B-Disease 0 0.006596074
left I-Disease 0 0.009503821
uterine I-Disease 0 0.82809263
cornu I-Disease 0 0.4256023
. O 0 0.010305168

The O 0 0.00754778
second O 0 0.0057672556
twin O 0 0.018300213
, O 0 0.0040835817
a O 0 0.0029326235
male O 0 0.006382258
, O 0 0.0019974655
had O 0 0.0010561222
some O 0 0.0010279347
features O 0 0.001633534
of O 0 0.0014584583
Potter B-Disease 0 0.054230373
' I-Disease 0 0.0013462404
s I-Disease 0 0.0011832155
facies I-Disease 0 0.45500666
, O 0 0.0022516374
hypoplastic B-Disease 0 0.84510446
lungs I-Disease 0 0.14404108
, O 0 0.0020041189
absent B-Disease 0 0.001260903
kidneys I-Disease 0 0.04749736
and I-Disease 0 0.002431542
ureters I-Disease 0 0.46622777
, O 0 0.0046565505
and O 0 0.006155206
talipes B-Disease 0 0.99348456
equinovarus I-Disease 0 0.99903524
. O 0 0.014033371

Despite O 0 0.010216556
reports O 0 0.0076116845
to O 0 0.004725074
the O 0 0.003837916
contrary O 0 0.003880088
, O 0 0.00403365
it O 0 0.0028645194
is O 0 0.0023223425
suggested O 0 0.0023162232
that O 0 0.0033137703
sulphasalazine B-Chemical 1 0.99993086
may O 0 0.0069250297
be O 0 0.010790796
teratogenic O 0 0.9987048
. O 0 0.014062921

Thrombotic B-Disease 0 0.99888307
microangiopathy I-Disease 0 0.9998541
and O 0 0.035382934
renal B-Disease 0 0.9943481
failure I-Disease 0 0.9048248
associated O 0 0.011779075
with O 0 0.011780196
antineoplastic O 0 0.99342257
chemotherapy O 0 0.98508793
. O 0 0.018659554

Five O 0 0.011997309
patients O 0 0.0099539915
with O 0 0.00620624
carcinoma B-Disease 2 0.99943715
developed O 0 0.052436218
thrombotic B-Disease 2 0.99997306
microangiopathy I-Disease 2 0.9999969
( O 0 0.053044118
characterized O 0 0.005933043
by O 0 0.0024508527
renal B-Disease 0 0.99832517
insufficiency I-Disease 0 0.9997162
, O 0 0.032403607
microangiopathic B-Disease 0 0.9999819
hemolytic I-Disease 2 0.9999968
anemia I-Disease 2 0.9999988
, O 0 0.033163514
and O 0 0.0017002845
usually O 0 0.0070016365
thrombocytopenia B-Disease 2 0.999964
) O 0 0.0036216027
after O 0 0.0004232803
treatment O 0 0.0011990701
with O 0 0.0015156795
cisplatin B-Chemical 1 0.9998386
, O 0 0.0067693023
bleomycin B-Chemical 0 0.99916565
, O 0 0.0039234124
and O 0 0.0031162007
a O 0 0.0077197975
vinca B-Chemical 0 0.9995048
alkaloid I-Chemical 0 0.9992624
. O 0 0.015598545

One O 0 0.0111082755
patient O 0 0.0077406606
had O 0 0.0053034094
thrombotic B-Disease 2 0.99971944
thrombocytopenic I-Disease 0 0.9999529
purpura I-Disease 0 0.99997556
, O 0 0.013145756
three O 0 0.0011358394
the O 0 0.0017117733
hemolytic B-Disease 0 0.99991393
- I-Disease 0 0.073102735
uremic I-Disease 0 0.99993753
syndrome I-Disease 0 0.99042237
, O 0 0.0026222575
and O 0 0.0009964003
one O 0 0.0006546645
an O 0 0.001000705
apparent O 0 0.0010190397
forme O 0 0.5333887
fruste O 0 0.95549303
of O 0 0.0032247764
one O 0 0.0023522656
of O 0 0.003914963
these O 0 0.007908983
disorders O 0 0.96613985
. O 0 0.011129447

Histologic O 0 0.12951109
examination O 0 0.0074942484
of O 0 0.0044673793
the O 0 0.0032380354
renal O 0 0.92647207
tissue O 0 0.024548845
showed O 0 0.0013330386
evidence O 0 0.0011753791
of O 0 0.001633089
intravascular B-Disease 0 0.98543614
coagulation I-Disease 0 0.9982901
, O 0 0.0025914414
primarily O 0 0.0015144071
affecting O 0 0.0014674207
the O 0 0.0010854355
small O 0 0.0018401307
arteries O 0 0.6647008
, O 0 0.003912641
arterioles O 0 0.6436028
, O 0 0.004944777
and O 0 0.005607286
glomeruli O 0 0.16518116
. O 0 0.009389002

Because O 0 0.0062179565
each O 0 0.0038233553
patient O 0 0.0045163846
was O 0 0.0031799388
tumor B-Disease 2 0.8580322
- O 0 0.003439548
free O 0 0.0016763132
or O 0 0.0009579846
had O 0 0.00071497954
only O 0 0.00060878834
a O 0 0.0008179734
small O 0 0.0008304877
tumor B-Disease 2 0.7667855
at O 0 0.00044935718
the O 0 0.0004946096
onset O 0 0.0015529061
of O 0 0.000762603
this O 0 0.0008413529
syndrome O 0 0.9082094
, O 0 0.0022373728
the O 0 0.0017230493
thrombotic B-Disease 2 0.99997663
microangiopathy I-Disease 2 0.999995
may O 0 0.0030738763
have O 0 0.0020893775
been O 0 0.0027255474
induced O 0 0.0035567856
by O 0 0.006609135
chemotherapy O 0 0.9187391
. O 0 0.010172825

Diagnosis O 0 0.07229969
of O 0 0.006312103
this O 0 0.0039193314
potentially O 0 0.00668589
fatal O 0 0.987519
complication O 0 0.80553
may O 0 0.0017503126
be O 0 0.0012483287
delayed O 0 0.0035199912
or O 0 0.00077885785
missed O 0 0.0014687834
if O 0 0.00049358053
renal O 0 0.96364236
tissue O 0 0.024575487
or O 0 0.0005562098
the O 0 0.00047202667
peripheral O 0 0.020843888
blood O 0 0.010360787
smear O 0 0.006443491
is O 0 0.0004530993
not O 0 0.00037383643
examined O 0 0.0003312183
, O 0 0.0007057788
because O 0 0.00043207756
renal B-Disease 0 0.9871842
failure I-Disease 0 0.7956479
may O 0 0.0006201004
be O 0 0.000586528
ascribed O 0 0.00075193524
to O 0 0.0007788872
cisplatin B-Chemical 1 0.99993026
nephrotoxicity B-Disease 2 0.99999607
and O 0 0.002584868
the O 0 0.0017281239
anemia B-Disease 2 0.9999628
and O 0 0.008853173
thrombocytopenia B-Disease 2 0.9999528
to O 0 0.0022451761
drug O 0 0.9086392
- O 0 0.010441174
induced O 0 0.005040813
bone B-Disease 2 0.96079844
marrow I-Disease 2 0.99531
suppression I-Disease 2 0.74767256
. O 0 0.013188584

International O 0 0.037741356
mexiletine B-Chemical 1 0.9995974
and O 0 0.014326853
placebo O 0 0.451603
antiarrhythmic O 0 0.99722195
coronary O 0 0.93667305
trial O 0 0.022126157
: O 0 0.018099142
I O 0 0.053995967
. O 0 0.015565027

Report O 0 0.0530759
on O 0 0.0237266
arrhythmia B-Disease 2 0.99519265
and O 0 0.026915675
other O 0 0.024045058
findings O 0 0.039932303
. O 0 0.030167628

Impact O 0 0.11131201
Research O 0 0.13057046
Group O 0 0.13486063
. O 0 0.06881076

The O 0 0.00761082
antiarrhythmic O 0 0.9497175
effects O 0 0.005847333
of O 0 0.0032130815
the O 0 0.0021312432
sustained O 0 0.009114107
release O 0 0.04660813
form O 0 0.0012958747
of O 0 0.002914803
mexiletine B-Chemical 1 0.9999957
( O 0 0.023729747
Mexitil B-Chemical 0 0.977091
- I-Chemical 0 0.0051189135
Perlongets I-Chemical 0 0.44430658
) O 0 0.0011052681
were O 0 0.00041473872
evaluated O 0 0.00034427174
in O 0 0.00039467344
a O 0 0.00065343495
double O 0 0.00066552084
- O 0 0.001118508
blind O 0 0.0031009687
placebo O 0 0.029482614
trial O 0 0.0010207832
in O 0 0.00077432254
630 O 0 0.016175684
patients O 0 0.00205029
with O 0 0.0015225398
recent O 0 0.0024983005
documented O 0 0.017076734
myocardial B-Disease 0 0.99987483
infarction I-Disease 2 0.99996316
. O 0 0.016468432

The O 0 0.006681429
primary O 0 0.004999745
response O 0 0.003701917
variable O 0 0.0024860129
was O 0 0.0015973344
based O 0 0.0011962651
on O 0 0.00071759673
central O 0 0.0016236455
reading O 0 0.0012053789
of O 0 0.0005786435
24 O 0 0.00035430407
hour O 0 0.00026672267
ambulatory O 0 0.00070674124
electrocardiographic O 0 0.60134286
recordings O 0 0.0019742993
and O 0 0.00043002484
was O 0 0.00032748064
defined O 0 0.0002795327
as O 0 0.00032045983
the O 0 0.00031487865
occurrence O 0 0.00076021085
of O 0 0.000494594
30 O 0 0.00029572358
or O 0 0.00028116957
more O 0 0.0003612379
single O 0 0.00040674894
premature O 0 0.036658198
ventricular O 0 0.9731214
complexes O 0 0.0006963763
in O 0 0.00029425157
any O 0 0.00024918644
two O 0 0.00022457048
consecutive O 0 0.00031552624
30 O 0 0.00021664852
minute O 0 0.0002292528
blocks O 0 0.00033361415
or O 0 0.00030270318
one O 0 0.00028407207
or O 0 0.0003269612
more O 0 0.00041435423
runs O 0 0.0006165636
of O 0 0.00042224312
two O 0 0.0003484481
or O 0 0.000441466
more O 0 0.0006534387
premature O 0 0.0508901
ventricular O 0 0.9734683
complexes O 0 0.0012546979
in O 0 0.000743639
the O 0 0.0008516921
entire O 0 0.00090067834
24 O 0 0.0011501577
hour O 0 0.0016048608
electrocardiographic O 0 0.72460747
recording O 0 0.008563944
. O 0 0.007262156

Large O 0 0.015495368
differences O 0 0.0047070836
, O 0 0.004524841
regarded O 0 0.0033730743
as O 0 0.0018468974
statistically O 0 0.0013351707
significant O 0 0.0013038421
, O 0 0.0011933482
between O 0 0.0005299028
the O 0 0.00091596105
mexiletine B-Chemical 1 0.999985
and O 0 0.0012343862
placebo O 0 0.14729123
groups O 0 0.0007650545
were O 0 0.00045647557
noted O 0 0.0003309601
in O 0 0.00033628976
that O 0 0.00029852288
end O 0 0.00026012195
point O 0 0.00031345565
at O 0 0.00030092633
months O 0 0.0003385739
1 O 0 0.00047075527
and O 0 0.00053883594
4 O 0 0.00055389834
, O 0 0.000736338
but O 0 0.0006105138
only O 0 0.00070234475
trends O 0 0.0012914661
were O 0 0.0012335888
observed O 0 0.0011792807
at O 0 0.0018383703
month O 0 0.00262955
12 O 0 0.003922958
. O 0 0.006274304

These O 0 0.007840718
differences O 0 0.0037750388
were O 0 0.003101461
observed O 0 0.001764499
even O 0 0.001745815
though O 0 0.0013395866
the O 0 0.0012468623
serum O 0 0.24417217
mexiletine B-Chemical 1 0.9999895
levels O 0 0.0009590011
obtained O 0 0.00068377727
in O 0 0.0005053903
this O 0 0.00048040616
study O 0 0.0005905165
were O 0 0.0004408155
generally O 0 0.00051979267
lower O 0 0.0004323602
than O 0 0.00031158363
those O 0 0.00053930614
observed O 0 0.0003305366
in O 0 0.00047529783
studies O 0 0.00060646405
that O 0 0.00047265977
have O 0 0.0005886851
used O 0 0.00075619
the O 0 0.0009526727
regular O 0 0.0015318225
form O 0 0.0016849708
of O 0 0.002929502
the O 0 0.004353312
drug O 0 0.7454795
. O 0 0.009259051

There O 0 0.008883027
were O 0 0.0056527955
more O 0 0.004552281
deaths B-Disease 2 0.32055208
in O 0 0.0022727111
the O 0 0.0021807319
mexiletine B-Chemical 1 0.99997115
group O 0 0.003496889
( O 0 0.0018649332
7 O 0 0.0007459273
. O 0 0.00044444326
6 O 0 0.00040284067
% O 0 0.0005822426
) O 0 0.0006611103
than O 0 0.00027825477
in O 0 0.0003321521
the O 0 0.00040714303
placebo O 0 0.036273945
group O 0 0.00079257006
( O 0 0.00090596813
4 O 0 0.0004816401
. O 0 0.0003829054
8 O 0 0.0005242875
% O 0 0.0008091913
) O 0 0.0012857626
; O 0 0.0011795947
the O 0 0.00079050194
difference O 0 0.00081729074
was O 0 0.001412501
not O 0 0.0018861513
statistically O 0 0.0030592112
significant O 0 0.0055962373
. O 0 0.007789084

The O 0 0.011652856
incidence O 0 0.014256924
of O 0 0.009039609
coronary O 0 0.51124555
events O 0 0.048821166
was O 0 0.0059543676
similar O 0 0.0045280643
in O 0 0.0058018337
both O 0 0.007532786
groups O 0 0.012831364
. O 0 0.01322663

Previously O 0 0.011638374
recognized O 0 0.006832589
side O 0 0.05105994
effects O 0 0.0071226726
, O 0 0.004078037
particularly O 0 0.0041572447
tremor B-Disease 2 0.99992275
and O 0 0.0040874197
gastrointestinal B-Disease 0 0.99969316
problems I-Disease 0 0.7128002
, O 0 0.0017693551
were O 0 0.00072188635
more O 0 0.0007155446
frequent O 0 0.0014808873
in O 0 0.00068082835
the O 0 0.0010496277
mexiletine B-Chemical 1 0.99997485
group O 0 0.0017729263
than O 0 0.0010330238
in O 0 0.0015399731
the O 0 0.0024297577
placebo O 0 0.16348824
group O 0 0.0071634254
. O 0 0.008045273

Changes O 0 0.012638562
in O 0 0.007386019
heart O 0 0.13283414
size O 0 0.0057872464
during O 0 0.0031683694
long O 0 0.0036276248
- O 0 0.0045837313
term O 0 0.0035275777
timolol B-Chemical 1 0.9999112
treatment O 0 0.0123911
after O 0 0.005089901
myocardial B-Disease 0 0.9998186
infarction I-Disease 2 0.99995303
. O 0 0.019754073

The O 0 0.006943065
effect O 0 0.0044883164
of O 0 0.0040140203
long O 0 0.003431061
- O 0 0.0034470537
term O 0 0.0017957969
timolol B-Chemical 1 0.99994886
treatment O 0 0.0024654733
on O 0 0.00065369153
heart O 0 0.47074488
size O 0 0.0011914979
after O 0 0.0005640822
myocardial B-Disease 0 0.99991286
infarction I-Disease 2 0.99999464
was O 0 0.00096144364
evaluated O 0 0.00061413494
by O 0 0.0011156247
X O 0 0.83222264
- O 0 0.0018080702
ray O 0 0.031330124
in O 0 0.0005167555
a O 0 0.0007844963
double O 0 0.0007297185
- O 0 0.0011309319
blind O 0 0.0021018041
study O 0 0.0006824008
including O 0 0.0006608564
241 O 0 0.010461837
patients O 0 0.002422744
( O 0 0.0018316339
placebo O 0 0.09877029
126 O 0 0.015632916
, O 0 0.003953356
timolol B-Chemical 1 0.99985945
115 O 0 0.061933137
) O 0 0.009863682
. O 0 0.007699919

The O 0 0.017645787
follow O 0 0.01378329
- O 0 0.0146022355
up O 0 0.010081461
period O 0 0.008932914
was O 0 0.009952954
12 O 0 0.009745433
months O 0 0.011282492
. O 0 0.015506772

The O 0 0.009815038
timolol B-Chemical 1 0.99974984
- O 0 0.009207743
treated O 0 0.0032927445
patients O 0 0.0037733999
showed O 0 0.001315986
a O 0 0.0015021574
small O 0 0.001221054
but O 0 0.0008405709
significant O 0 0.00079628214
increase O 0 0.0005546602
in O 0 0.00062042853
heart O 0 0.31257835
size O 0 0.00087228394
from O 0 0.0005793388
baseline O 0 0.0006751839
in O 0 0.0005470909
contrast O 0 0.000692254
to O 0 0.0007778558
a O 0 0.0013545982
decrease O 0 0.0012188705
in O 0 0.0015455908
the O 0 0.0025340698
placebo O 0 0.19194184
group O 0 0.007484133
. O 0 0.008262602

These O 0 0.009279921
differences O 0 0.0046896865
may O 0 0.0040415293
be O 0 0.0031741746
caused O 0 0.0030839222
by O 0 0.0041425438
timolol B-Chemical 1 0.9999783
- O 0 0.0146707045
induced O 0 0.0029578733
bradycardia B-Disease 2 0.9997795
and O 0 0.0019550964
a O 0 0.0019502931
compensatory O 0 0.0023776058
increase O 0 0.0012446416
in O 0 0.0017471652
end O 0 0.0019722353
- O 0 0.0061575486
diastolic O 0 0.9041278
volume O 0 0.01350739
. O 0 0.008387014

The O 0 0.010517994
timolol B-Chemical 1 0.9997296
- O 0 0.009352651
related O 0 0.002577244
increase O 0 0.0018059872
in O 0 0.0016180911
heart O 0 0.31505963
size O 0 0.0018349427
was O 0 0.0010095384
observed O 0 0.00068236596
only O 0 0.00088179886
in O 0 0.0009950859
patients O 0 0.0025796818
with O 0 0.0016691261
normal O 0 0.0034377559
and O 0 0.0034291034
borderline O 0 0.71836454
heart O 0 0.8347179
size O 0 0.010589685
. O 0 0.009154088

In O 0 0.0089997575
patients O 0 0.010088758
with O 0 0.0066776513
cardiomegaly B-Disease 0 0.9991805
, O 0 0.005125266
the O 0 0.00233377
increase O 0 0.0016629756
in O 0 0.0018200625
heart O 0 0.33901972
size O 0 0.0028254674
was O 0 0.0020675638
similar O 0 0.0019103531
in O 0 0.0029616542
both O 0 0.0044664424
groups O 0 0.008905498
. O 0 0.009528424

After O 0 0.008281022
re O 0 0.049855083
- O 0 0.016157124
infarction B-Disease 2 0.9998884
, O 0 0.006015069
heart O 0 0.4031017
size O 0 0.0024331436
increased O 0 0.001566683
in O 0 0.001033783
the O 0 0.0010639902
placebo O 0 0.06666776
group O 0 0.0014269747
and O 0 0.0014383579
remained O 0 0.0015708108
unchanged O 0 0.0016620803
in O 0 0.0019536668
the O 0 0.0036696943
timolol B-Chemical 1 0.99988556
group O 0 0.011564916
. O 0 0.009451992

Vitamin B-Chemical 0 0.9994764
D3 I-Chemical 0 0.9988965
toxicity B-Disease 2 0.9972746
in O 0 0.04153345
dairy O 0 0.7647089
cows O 0 0.37720594
. O 0 0.036085695

Large O 0 0.019462762
parenteral O 0 0.57027394
doses O 0 0.1434474
of O 0 0.022845749
vitamin B-Chemical 1 0.9999567
D3 I-Chemical 1 0.99993825
( O 0 0.0065032863
15 O 0 0.0010344058
to O 0 0.00074152387
17 O 0 0.0010085026
. O 0 0.00045637027
5 O 0 0.00043756943
x O 0 0.0008699408
10 O 0 0.0005756278
( O 0 0.00071323744
6 O 0 0.00045408166
) O 0 0.0013251788
IU O 0 0.91451657
vitamin B-Chemical 1 0.99997985
D3 I-Chemical 1 0.99997187
) O 0 0.009250376
were O 0 0.0006479581
associated O 0 0.00068575237
with O 0 0.0008162222
prolonged O 0 0.13503195
hypercalcemia B-Disease 2 0.9999981
, O 0 0.109238334
hyperphosphatemia B-Disease 0 0.99999785
, O 0 0.0032065257
and O 0 0.0007080771
large O 0 0.00069264864
increases O 0 0.0006146292
of O 0 0.0036385097
vitamin B-Chemical 1 0.9999894
D3 I-Chemical 1 0.99997246
and O 0 0.002660013
its O 0 0.004293542
metabolites O 0 0.82200694
in O 0 0.00069404516
the O 0 0.0007453425
blood O 0 0.009564836
plasma O 0 0.015328996
of O 0 0.0020054393
nonlactating O 0 0.2659259
nonpregnant O 0 0.2266286
and O 0 0.004264842
pregnant O 0 0.20524338
Jersey O 0 0.23969503
cows O 0 0.03075678
. O 0 0.009460429

Calcium B-Chemical 0 0.99844944
concentrations O 0 0.011354711
1 O 0 0.003916773
day O 0 0.0023763066
postpartum O 0 0.0056599434
were O 0 0.0014280858
higher O 0 0.0010754807
in O 0 0.0010224083
cows O 0 0.012891643
treated O 0 0.0017059068
with O 0 0.003223831
vitamin B-Chemical 1 0.9999815
D3 I-Chemical 1 0.9999398
about O 0 0.00088807906
32 O 0 0.0009242588
days O 0 0.0004241283
prepartum O 0 0.0337189
( O 0 0.0008135534
8 O 0 0.00044416075
. O 0 0.00030012755
8 O 0 0.00037371705
mg O 0 0.04730128
/ O 0 0.001122517
100 O 0 0.0008344714
ml O 0 0.0015015812
) O 0 0.0008686636
than O 0 0.0003320587
in O 0 0.0004388252
control O 0 0.00062654965
cows O 0 0.007947297
( O 0 0.0012231476
5 O 0 0.000728939
. O 0 0.00069264136
5 O 0 0.0010132355
mg O 0 0.07944592
/ O 0 0.0042406423
100 O 0 0.004611986
ml O 0 0.009412777
) O 0 0.009658145
. O 0 0.007843455

None O 0 0.013521426
of O 0 0.0068688923
the O 0 0.0046725236
cows O 0 0.021693686
treated O 0 0.00437977
with O 0 0.00662679
vitamin B-Chemical 1 0.99996793
D3 I-Chemical 1 0.9999411
showed O 0 0.002222232
signs O 0 0.4421769
of O 0 0.0027989566
milk B-Disease 2 0.9245251
fever I-Disease 2 0.9999696
during O 0 0.00075914303
the O 0 0.0007804422
peripartal O 0 0.102302276
period O 0 0.00066735264
; O 0 0.001156404
however O 0 0.0006833415
, O 0 0.0006983308
22 O 0 0.0005777535
% O 0 0.00046393386
of O 0 0.00045105795
the O 0 0.00047598834
control O 0 0.00060360495
cows O 0 0.004669688
developed O 0 0.0011816927
clinical O 0 0.010146798
signs O 0 0.24416679
of O 0 0.0033376303
milk B-Disease 2 0.92501086
fever I-Disease 2 0.99991167
during O 0 0.0034284468
this O 0 0.00473049
period O 0 0.0058362028
. O 0 0.008487346

Signs O 0 0.96582943
of O 0 0.033478096
vitamin B-Chemical 1 0.99987733
D3 I-Chemical 1 0.9998858
toxicity B-Disease 2 0.9993635
were O 0 0.0028799686
not O 0 0.0013502511
observed O 0 0.00080367766
in O 0 0.001019909
nonlactating O 0 0.15571903
nonpregnant O 0 0.28039947
cows O 0 0.050873686
; O 0 0.0019622957
however O 0 0.0010069367
, O 0 0.001056392
pregnant O 0 0.017582485
cows O 0 0.008649165
commonly O 0 0.00150512
developed O 0 0.0017805453
severe O 0 0.36579323
signs O 0 0.67428714
of O 0 0.020904528
vitamin B-Chemical 1 0.99998844
D3 I-Chemical 1 0.9999771
toxicity B-Disease 2 0.9996259
and O 0 0.0037333267
10 O 0 0.0022769885
of O 0 0.00275656
17 O 0 0.0050582513
cows O 0 0.020961393
died O 0 0.038934927
. O 0 0.0091820685

There O 0 0.016241295
was O 0 0.012207902
widespread O 0 0.016174477
metastatic O 0 0.9739246
calcification O 2 0.99406934
in O 0 0.008544477
the O 0 0.00813381
cows O 0 0.027216658
that O 0 0.009120313
died O 0 0.061323628
. O 0 0.015542423

Because O 0 0.006761654
of O 0 0.0056373733
the O 0 0.0041415133
extreme O 0 0.009330022
toxicity B-Disease 2 0.9978782
of O 0 0.045699418
vitamin B-Chemical 1 0.99998224
D3 I-Chemical 1 0.99996245
in O 0 0.002760477
pregnant O 0 0.29118162
Jersey O 0 0.14505295
cows O 0 0.0051018093
and O 0 0.00066353887
the O 0 0.00050283544
low O 0 0.00063082785
margin O 0 0.0013550898
of O 0 0.00059775426
safety O 0 0.00122699
between O 0 0.00034876014
doses O 0 0.0412808
of O 0 0.0072463863
vitamin B-Chemical 1 0.9999912
D3 I-Chemical 1 0.99997306
that O 0 0.00094978296
prevent O 0 0.0018983497
milk B-Disease 2 0.9556766
fever I-Disease 2 0.99998593
and O 0 0.0025132082
doses O 0 0.062667355
that O 0 0.0005738709
induce O 0 0.0007065069
milk B-Disease 2 0.9355099
fever I-Disease 2 0.99998534
, O 0 0.0022817694
we O 0 0.00041748086
concluded O 0 0.00080072624
that O 0 0.0010061315
vitamin B-Chemical 1 0.9999815
D3 I-Chemical 1 0.9999622
cannot O 0 0.06991052
be O 0 0.0010256218
used O 0 0.0006914864
practically O 0 0.0011774601
to O 0 0.00075667724
prevent O 0 0.0014219309
milk B-Disease 2 0.8398564
fever I-Disease 2 0.9999238
when O 0 0.0016224262
injected O 0 0.001987642
several O 0 0.0028253882
weeks O 0 0.0034577502
prepartum O 0 0.08685618
. O 0 0.008564632

Diseases B-Disease 0 0.03386815
of I-Disease 0 0.01349453
peripheral I-Disease 0 0.050473932
nerves I-Disease 0 0.35271034
as O 0 0.0088107465
seen O 0 0.007311099
in O 0 0.0076900776
the O 0 0.009697888
Nigerian O 0 0.111017
African O 0 0.095041715
. O 0 0.015438136

The O 0 0.0072466712
anatomical O 0 0.0069738664
and O 0 0.004326861
aetiological O 0 0.09883114
diagnoses O 0 0.026924841
of O 0 0.00275333
peripheral B-Disease 0 0.39207786
nerve I-Disease 0 0.8660682
disease I-Disease 0 0.9252501
excluding O 0 0.0028161858
its O 0 0.0018193221
primary O 0 0.0016788761
benign O 0 0.9682405
and O 0 0.0027266222
malignant O 0 0.9976077
disorders O 0 0.98510253
, O 0 0.0025797565
as O 0 0.001402224
seen O 0 0.0014699656
in O 0 0.0020464768
358 O 0 0.05722135
Nigerians O 0 0.15833461
are O 0 0.004437244
presented O 0 0.006981832
. O 0 0.008425414

There O 0 0.011187532
is O 0 0.0071952795
a O 0 0.006334048
male O 0 0.009020023
preponderance O 0 0.007681705
and O 0 0.003744465
the O 0 0.002975352
peak O 0 0.0033539664
incidence O 0 0.009564529
is O 0 0.0034040082
in O 0 0.0035612818
the O 0 0.0048221964
fourth O 0 0.011876415
decade O 0 0.016682819
. O 0 0.011021089

Sensori B-Disease 0 0.04110282
- I-Disease 0 0.019582227
motor I-Disease 0 0.7329563
neuropathy I-Disease 2 0.9997478
was O 0 0.0067432136
the O 0 0.004912002
commonest O 0 0.2386051
presentation O 0 0.04390784
( O 0 0.009669715
50 O 0 0.008464447
% O 0 0.009014085
) O 0 0.0128961755
. O 0 0.010796977

Guillain B-Disease 0 0.9948986
- I-Disease 0 0.03685502
Barr I-Disease 0 0.7675461
syndrome I-Disease 0 0.7844015
was O 0 0.0031579635
the O 0 0.0021341394
commonest O 0 0.16273543
identifiable O 0 0.03329855
cause O 0 0.012275194
( O 0 0.0019691281
15 O 0 0.0007224015
. O 0 0.0005040692
6 O 0 0.00048476842
% O 0 0.0007561965
) O 0 0.0010154592
, O 0 0.00073564495
accounting O 0 0.00088920986
for O 0 0.00055391627
half O 0 0.00061253016
of O 0 0.0011328548
the O 0 0.0015134657
cases O 0 0.0040747174
with O 0 0.005276654
motor B-Disease 0 0.9662693
neuropathy I-Disease 2 0.9999212
. O 0 0.013868511

Peripheral B-Disease 2 0.97484016
neuropathy I-Disease 2 0.99971765
due O 0 0.005555815
to O 0 0.004011158
nutritional B-Disease 0 0.84983253
deficiency I-Disease 0 0.97719246
of O 0 0.031385593
thiamine B-Chemical 0 0.9999796
and O 0 0.0220649
riboflavin B-Chemical 0 0.99996173
was O 0 0.0016211594
common O 0 0.0018893336
( O 0 0.0014745971
10 O 0 0.00067546614
. O 0 0.00042202562
1 O 0 0.00056151865
% O 0 0.0006834261
) O 0 0.000859527
and O 0 0.0006037396
presented O 0 0.0007453937
mainly O 0 0.001167322
as O 0 0.0012803888
sensory O 0 0.09837118
and O 0 0.002976552
sensori B-Disease 0 0.3098787
- I-Disease 0 0.019090166
motor I-Disease 0 0.93782854
neuropathy I-Disease 2 0.9999057
. O 0 0.013213237

Diabetes B-Disease 0 0.9938599
mellitus I-Disease 0 0.99792516
was O 0 0.01210928
the O 0 0.0084670335
major O 0 0.009720142
cause O 0 0.019845916
of O 0 0.023227356
autonomic B-Disease 2 0.9992636
neuropathy I-Disease 2 0.9998932
. O 0 0.027661093

Isoniazid B-Chemical 0 0.9981116
was O 0 0.009655943
the O 0 0.006381901
most O 0 0.0065236087
frequent O 0 0.010339633
agent O 0 0.23183799
in O 0 0.0064760814
drug O 0 0.9145594
- O 0 0.031099303
induced O 0 0.023238525
neuropathy B-Disease 2 0.9997992
. O 0 0.019477641

Migraine B-Disease 0 0.9995074
( O 0 0.011976549
20 O 0 0.004808231
% O 0 0.003996254
) O 0 0.003235499
was O 0 0.0015152949
not O 0 0.0011375097
an O 0 0.0014808063
uncommon O 0 0.011589193
cause O 0 0.0049192044
of O 0 0.0026101274
cranial B-Disease 0 0.98975265
neuropathy I-Disease 2 0.9999913
although O 0 0.0020821798
malignancies B-Disease 2 0.99964225
arising O 0 0.0050443155
from O 0 0.0007440006
the O 0 0.0006741697
reticuloendothelial O 0 0.9805642
system O 0 0.0011047448
or O 0 0.00048119537
related O 0 0.00038070278
structures O 0 0.00073120155
of O 0 0.0006739226
the O 0 0.00072070956
head O 0 0.03314481
and O 0 0.0013779917
neck O 0 0.42363945
were O 0 0.0013596532
more O 0 0.0016217591
frequent O 0 0.0051198704
( O 0 0.0035812755
26 O 0 0.0038877605
% O 0 0.0047512385
) O 0 0.008145674
. O 0 0.007396447

In O 0 0.008747654
26 O 0 0.0074335253
. O 0 0.003652697
5 O 0 0.0026661772
% O 0 0.0024776903
of O 0 0.0018633292
all O 0 0.0014750148
the O 0 0.0014820865
cases O 0 0.0024986216
, O 0 0.0020834366
the O 0 0.0016199918
aetiology O 0 0.15647669
of O 0 0.0039180475
the O 0 0.0055893236
neuropathy B-Disease 2 0.99987185
was O 0 0.008796898
undetermined O 0 0.5603301
. O 0 0.011330081

Heredofamilial O 0 0.6198585
and O 0 0.027342515
connective B-Disease 0 0.6035958
tissue I-Disease 0 0.27868804
disorders I-Disease 0 0.9836557
were O 0 0.026597219
rare O 0 0.09245021
. O 0 0.026395755

Some O 0 0.011154486
of O 0 0.0066161915
the O 0 0.004396857
factors O 0 0.0056991642
related O 0 0.0020990258
to O 0 0.0017614109
the O 0 0.0016229986
clinical O 0 0.00506056
presentation O 0 0.0056179506
and O 0 0.002269678
pathogenesis O 0 0.009225666
of O 0 0.0035689755
the O 0 0.0046564336
neuropathies B-Disease 0 0.99985266
are O 0 0.006457169
briefly O 0 0.008306868
discussed O 0 0.006553921
. O 0 0.009521163

Reduction O 0 0.052918375
in O 0 0.028245943
caffeine B-Chemical 1 0.9987355
toxicity B-Disease 2 0.9981098
by O 0 0.13945532
acetaminophen B-Chemical 1 0.99984753
. O 0 0.037105527

A O 0 0.02926109
patient O 0 0.008281984
who O 0 0.0064521604
allegedly O 0 0.026491983
consumed O 0 0.008324158
100 O 0 0.003596486
tablets O 0 0.66234183
of O 0 0.0014757251
an O 0 0.0013868429
over O 0 0.00063132594
- O 0 0.0013291826
the O 0 0.0007261504
- O 0 0.0013067474
counter O 0 0.00539415
analgesic O 0 0.9931051
containing O 0 0.0016403594
sodium B-Chemical 1 0.9999865
acetylsalicylate I-Chemical 0 0.9999993
, O 0 0.042375363
caffeine B-Chemical 1 0.99996483
, O 0 0.0026892216
and O 0 0.0011318049
acetaminophen B-Chemical 1 0.99999166
displayed O 0 0.00041543873
no O 0 0.0003184662
significant O 0 0.000646873
CNS O 0 0.7940628
stimulation O 0 0.0008751199
despite O 0 0.00043248385
the O 0 0.00046557462
presence O 0 0.00050025905
of O 0 0.00087204715
175 O 0 0.0077917795
micrograms O 0 0.09309417
of O 0 0.001947783
caffeine B-Chemical 1 0.99959105
per O 0 0.001910125
mL O 0 0.012187742
of O 0 0.0053213267
serum O 0 0.34193075
. O 0 0.009855788

Because O 0 0.009444362
salicylates O 0 0.99950206
have O 0 0.0049048075
been O 0 0.0032813074
reported O 0 0.0023171713
to O 0 0.0013199778
augment O 0 0.0012039593
the O 0 0.000983887
stimulatory O 0 0.010597933
effects O 0 0.0022660368
of O 0 0.0018212309
caffeine B-Chemical 1 0.9998964
on O 0 0.0005137111
the O 0 0.0008155104
CNS O 0 0.93888944
, O 0 0.0009448194
attention O 0 0.0009239232
was O 0 0.00036842047
focused O 0 0.00032377028
on O 0 0.00022820751
the O 0 0.0003064978
possibility O 0 0.00031102417
that O 0 0.00031060222
the O 0 0.00040516417
presence O 0 0.00048781623
of O 0 0.0017340468
acetaminophen B-Chemical 1 0.99999595
( O 0 0.002317275
52 O 0 0.0013800792
micrograms O 0 0.14282905
/ O 0 0.0032858893
mL O 0 0.005149114
) O 0 0.0017710413
reduced O 0 0.0011960029
the O 0 0.0018847076
CNS O 0 0.96166193
toxicity B-Disease 2 0.99800247
of O 0 0.021331899
caffeine B-Chemical 1 0.99972135
. O 0 0.012346498

Studies O 0 0.02233001
in O 0 0.007856134
DBA O 0 0.93788135
/ O 0 0.025512533
2J O 0 0.64038295
mice O 0 0.0017624191
showed O 0 0.0012876862
that O 0 0.0010999481
: O 0 0.0018900827
1 O 0 0.0011393602
) O 0 0.0015142701
pretreatment O 0 0.07065655
with O 0 0.0016017007
acetaminophen B-Chemical 1 0.9999957
( O 0 0.0026964673
100 O 0 0.0016157234
mg O 0 0.25210312
/ O 0 0.0016338993
kg O 0 0.00512379
) O 0 0.00084074144
increased O 0 0.00044120726
the O 0 0.00035020747
interval O 0 0.00040582826
between O 0 0.00022102386
the O 0 0.00038044938
administration O 0 0.022823172
of O 0 0.0012318556
caffeine B-Chemical 1 0.9999473
( O 0 0.0019702637
300 O 0 0.001626152
to O 0 0.00035563842
450 O 0 0.0016451047
mg O 0 0.097566545
/ O 0 0.0010976886
kg O 0 0.003269001
IP O 0 0.06630497
) O 0 0.0008919392
and O 0 0.0004219291
the O 0 0.00037376976
onset O 0 0.0017748643
of O 0 0.001061582
fatal O 0 0.9987386
convulsions B-Disease 2 0.9999937
by O 0 0.0011261195
a O 0 0.0009083291
factor O 0 0.0028278208
of O 0 0.0005188136
about O 0 0.0003763739
two O 0 0.000438104
; O 0 0.0010203653
and O 0 0.00055735494
2 O 0 0.0005685448
) O 0 0.0009437397
pretreatment O 0 0.057927918
with O 0 0.0011776809
acetaminophen B-Chemical 1 0.9999962
( O 0 0.0016928908
75 O 0 0.00084978633
mg O 0 0.16509356
/ O 0 0.0013766026
kg O 0 0.004649691
) O 0 0.00084317965
reduced O 0 0.00040651826
the O 0 0.00043418613
incidence O 0 0.010310824
of O 0 0.0032745837
audiogenic O 0 0.9999833
seizures B-Disease 2 0.99999154
produced O 0 0.0008373804
in O 0 0.0005113627
the O 0 0.00046827606
presence O 0 0.000499156
of O 0 0.0013188984
caffeine B-Chemical 1 0.99991715
( O 0 0.0019058099
12 O 0 0.0005469673
. O 0 0.00048034714
5 O 0 0.0005871371
to O 0 0.0007284369
75 O 0 0.0016345358
mg O 0 0.11725603
/ O 0 0.0049811876
kg O 0 0.01396905
IP O 0 0.17539121
) O 0 0.011537096
. O 0 0.00850313

The O 0 0.006869933
frequency O 0 0.005245451
of O 0 0.004509202
sound O 0 0.022315899
- O 0 0.005359983
induced O 0 0.0031141036
seizures B-Disease 2 0.99993944
after O 0 0.0008891721
12 O 0 0.000703446
. O 0 0.0005021041
5 O 0 0.00046819128
or O 0 0.00047854971
25 O 0 0.0007789028
mg O 0 0.11488851
/ O 0 0.0018781966
kg O 0 0.010372502
caffeine B-Chemical 1 0.9995801
was O 0 0.0010221789
reduced O 0 0.0009515116
from O 0 0.0010633852
50 O 0 0.0015906338
to O 0 0.0012549274
5 O 0 0.0017652954
% O 0 0.0032325503
by O 0 0.0056267744
acetaminophen B-Chemical 1 0.9999063
. O 0 0.010713166

In O 0 0.00704406
the O 0 0.004809194
absence O 0 0.0028021869
of O 0 0.0044173007
caffeine B-Chemical 1 0.99985766
, O 0 0.026268452
acetaminophen B-Chemical 1 0.9999914
( O 0 0.0032045937
up O 0 0.0007885563
to O 0 0.0006197524
300 O 0 0.0018324502
mg O 0 0.20515297
/ O 0 0.0018861962
kg O 0 0.0065835626
) O 0 0.0010068384
did O 0 0.0003841835
not O 0 0.00038462086
modify O 0 0.00047724004
the O 0 0.0007773883
seizures B-Disease 2 0.99998236
induced O 0 0.0011008243
by O 0 0.00086774776
maximal O 0 0.0010950487
electroshock O 0 0.99997735
and O 0 0.0009655521
did O 0 0.000448974
not O 0 0.00040509118
alter O 0 0.00040004664
the O 0 0.0005593275
convulsant O 0 0.99977344
dose O 0 0.027625281
of O 0 0.001182656
pentylenetetrezol B-Chemical 0 0.3258011
in O 0 0.00062714564
mice O 0 0.00053906103
( O 0 0.0010404217
tests O 0 0.0011656737
performed O 0 0.00071625964
by O 0 0.0011409313
the O 0 0.0017368036
Anticonvulsant O 0 0.999864
Screening O 0 0.05952259
Project O 0 0.06977512
of O 0 0.004920841
NINCDS O 0 0.9296713
) O 0 0.012590994
. O 0 0.008258735

Acetaminophen B-Chemical 1 0.9998487
( O 0 0.01027277
up O 0 0.003866569
to O 0 0.0025899813
150 O 0 0.0032222879
micrograms O 0 0.15505995
/ O 0 0.0052701677
mL O 0 0.007134215
) O 0 0.0018592214
did O 0 0.0007587734
not O 0 0.00073767203
retard O 0 0.047752142
the O 0 0.0008338744
incorporation O 0 0.0019930198
of O 0 0.0011506649
radioactive O 0 0.079715066
adenosine B-Chemical 1 0.9990828
into O 0 0.0011551962
ATP B-Chemical 1 0.99693966
in O 0 0.0017502676
slices O 0 0.043589663
of O 0 0.0030987377
rat O 0 0.05127682
cerebral O 0 0.9756251
cortex O 0 0.5146266
. O 0 0.008671156

Thus O 0 0.008163924
the O 0 0.005681989
mechanism O 0 0.0047884383
by O 0 0.0042184694
which O 0 0.005578619
acetaminophen B-Chemical 1 0.99998045
antagonizes O 0 0.049362425
the O 0 0.00217549
actions O 0 0.030995717
of O 0 0.0036192052
caffeine B-Chemical 1 0.999793
in O 0 0.0029125826
the O 0 0.0036721497
CNS O 0 0.93226796
remains O 0 0.0052263145
unknown O 0 0.021296084
. O 0 0.009953847

A O 0 0.039989907
double O 0 0.0081888
- O 0 0.006868834
blind O 0 0.0067528267
study O 0 0.0024455728
of O 0 0.0018258004
the O 0 0.0013532676
efficacy O 0 0.002502406
and O 0 0.0013595736
safety O 0 0.0029314933
of O 0 0.0035145944
dothiepin B-Chemical 0 0.9999982
hydrochloride I-Chemical 0 0.99982625
in O 0 0.0016469094
the O 0 0.0015414497
treatment O 0 0.0026964238
of O 0 0.0035105576
major O 0 0.017141478
depressive B-Disease 2 0.9999502
disorder I-Disease 0 0.9972059
. O 0 0.013323913

In O 0 0.007816118
a O 0 0.006661143
6 O 0 0.0037441913
- O 0 0.0034976352
week O 0 0.0016242471
double O 0 0.0017134151
- O 0 0.0020834152
blind O 0 0.0032546625
parallel O 0 0.0010477045
treatment O 0 0.0013088699
study O 0 0.0013746212
, O 0 0.0025894481
dothiepin B-Chemical 0 0.9999957
and O 0 0.0025059232
amitriptyline B-Chemical 1 0.99999475
were O 0 0.00075155875
compared O 0 0.0003947905
to O 0 0.00057094335
placebo O 0 0.028737921
in O 0 0.00074784266
the O 0 0.0009815024
treatment O 0 0.001918738
of O 0 0.00264631
33 O 0 0.008291449
depressed B-Disease 2 0.87318367
outpatients O 0 0.20029022
. O 0 0.008192333

Dothiepin B-Chemical 0 0.9979874
and O 0 0.013309046
amitriptyline B-Chemical 1 0.99995387
were O 0 0.0040521612
equally O 0 0.0028052614
effective O 0 0.0019003347
in O 0 0.0013014543
alleviating O 0 0.15551399
the O 0 0.0014913952
symptoms O 0 0.8838883
of O 0 0.01050029
depressive B-Disease 2 0.99999523
illness I-Disease 0 0.9994843
, O 0 0.0035517998
and O 0 0.0014309501
both O 0 0.0012128765
were O 0 0.0015156548
significantly O 0 0.002268643
superior O 0 0.0042072632
to O 0 0.003611791
placebo O 0 0.23745482
. O 0 0.008065038

The O 0 0.0067026755
overall O 0 0.0052786195
incidence O 0 0.00722943
of O 0 0.00335788
side O 0 0.05224776
effects O 0 0.00319818
and O 0 0.0014991409
the O 0 0.0009423215
frequency O 0 0.0010755387
and O 0 0.0010469661
severity O 0 0.060646854
of O 0 0.0026418602
blurred B-Disease 0 0.9919546
vision I-Disease 0 0.9710636
, O 0 0.0036488809
dry B-Disease 2 0.3804568
mouth I-Disease 2 0.8597912
, O 0 0.0019796358
and O 0 0.0015118453
drowsiness O 0 0.9999331
were O 0 0.0010504294
significantly O 0 0.00125625
less O 0 0.0012417157
with O 0 0.0026946214
dothiepin B-Chemical 0 0.99998593
than O 0 0.0026596969
with O 0 0.009515517
amitriptyline B-Chemical 1 0.999964
. O 0 0.010641371

Dothiepin B-Chemical 0 0.9932161
also O 0 0.01503469
produced O 0 0.011875845
fewer O 0 0.013424749
CNS O 0 0.8756823
and O 0 0.018095763
cardiovascular O 0 0.99399936
effects O 0 0.071645185
. O 0 0.020513816

There O 0 0.015460359
were O 0 0.010746228
no O 0 0.0077529424
clinically O 0 0.015519472
important O 0 0.00726656
changes O 0 0.008597687
in O 0 0.008205091
laboratory O 0 0.013737602
parameters O 0 0.016103394
. O 0 0.0152972285

Dothiepin B-Chemical 0 0.9968004
thus O 0 0.008685153
was O 0 0.003934587
found O 0 0.002198448
to O 0 0.0017719378
be O 0 0.001537754
an O 0 0.0016774964
effective O 0 0.0017519656
antidepressant B-Chemical 1 0.99983525
drug O 0 0.6885919
associated O 0 0.0012152453
with O 0 0.00081566133
fewer O 0 0.00086624257
side O 0 0.04613624
effects O 0 0.0024898117
than O 0 0.0010505093
amitriptyline B-Chemical 1 0.9999908
in O 0 0.0012722724
the O 0 0.0014932666
treatment O 0 0.003127251
of O 0 0.005000614
depressed B-Disease 2 0.9623597
outpatients O 0 0.35333607
. O 0 0.008741601

Behavioral O 0 0.14923137
effects O 0 0.010327948
of O 0 0.00981559
diazepam B-Chemical 1 0.9999471
and O 0 0.019166093
propranolol B-Chemical 1 0.99996424
in O 0 0.004421591
patients O 0 0.018617764
with O 0 0.008111271
panic B-Disease 0 0.99991167
disorder I-Disease 0 0.99801195
and O 0 0.0993741
agoraphobia B-Disease 2 0.99994016
. O 0 0.016541328

The O 0 0.006655791
effects O 0 0.005518091
of O 0 0.0040845047
oral O 0 0.44394466
doses O 0 0.11132722
of O 0 0.0067206044
diazepam B-Chemical 1 0.9999918
( O 0 0.0029540872
single O 0 0.0008276007
dose O 0 0.0030424467
of O 0 0.00072130904
10 O 0 0.00058296614
mg O 0 0.089397125
and O 0 0.0004604431
a O 0 0.0004560646
median O 0 0.00031728545
dose O 0 0.0012839333
of O 0 0.00048170204
30 O 0 0.00034086418
mg O 0 0.083484165
/ O 0 0.0007838073
day O 0 0.00027582742
for O 0 0.00025139883
2 O 0 0.00034221477
weeks O 0 0.00026827966
) O 0 0.0007252106
and O 0 0.0006808978
propranolol B-Chemical 1 0.9999889
( O 0 0.00094574067
single O 0 0.0003967276
dose O 0 0.0015303574
of O 0 0.00045073152
80 O 0 0.00055542035
mg O 0 0.07225447
and O 0 0.00037366716
a O 0 0.00039022104
median O 0 0.0002820849
dose O 0 0.0012243988
of O 0 0.00049521937
240 O 0 0.0014163703
mg O 0 0.107238874
/ O 0 0.0007850541
day O 0 0.00026970843
for O 0 0.00024396283
2 O 0 0.00032441173
weeks O 0 0.00024384331
) O 0 0.00051696785
on O 0 0.00024406426
psychological O 0 0.06743433
performance O 0 0.0006554395
of O 0 0.00055943703
patients O 0 0.0038331007
with O 0 0.001354486
panic B-Disease 0 0.99998
disorders I-Disease 0 0.9870724
and O 0 0.007671517
agoraphobia B-Disease 2 0.9999944
were O 0 0.00080713123
investigated O 0 0.0005086957
in O 0 0.00062400557
a O 0 0.0010601869
double O 0 0.0011297631
- O 0 0.0021685865
blind O 0 0.0060021644
, O 0 0.001967623
randomized O 0 0.0022468122
and O 0 0.0029507533
crossover O 0 0.020351304
design O 0 0.011120445
. O 0 0.008497093

Both O 0 0.0111295525
drugs O 0 0.34718025
impaired B-Disease 0 0.0068147504
immediate I-Disease 0 0.0056451517
free I-Disease 0 0.00393295
recall I-Disease 0 0.005258472
but O 0 0.0019322406
the O 0 0.0016376778
decrease O 0 0.0016426702
was O 0 0.0016790751
greater O 0 0.0019017869
for O 0 0.0028701182
diazepam B-Chemical 1 0.9999546
than O 0 0.0074538602
propranolol B-Chemical 1 0.9999231
. O 0 0.01321509

Delayed B-Disease 0 0.115912825
free I-Disease 0 0.009613296
recall I-Disease 0 0.009464353
was I-Disease 0 0.004288579
also I-Disease 0 0.003485616
impaired I-Disease 0 0.0037549466
but O 0 0.002521898
the O 0 0.0023642401
two O 0 0.0025647983
drugs O 0 0.5395718
did O 0 0.004293338
not O 0 0.005314618
differ O 0 0.008653163
. O 0 0.010834472

Patients O 0 0.016222851
tapped O 0 0.012936952
faster O 0 0.004915254
after O 0 0.00325942
propranolol B-Chemical 1 0.99990296
than O 0 0.0032614372
diazepam B-Chemical 1 0.9999633
and O 0 0.0028071937
they O 0 0.0016795004
were O 0 0.0015963416
more O 0 0.0019310806
sedated O 0 0.047201533
after O 0 0.002158077
diazepam B-Chemical 1 0.9999372
than O 0 0.0067449254
propranolol B-Chemical 1 0.999913
. O 0 0.012939486

After O 0 0.0058667148
2 O 0 0.004341722
weeks O 0 0.0023674434
of O 0 0.0023804042
treatment O 0 0.0027090386
, O 0 0.0020210096
patients O 0 0.0022036259
tested O 0 0.00080763525
5 O 0 0.000855612
- O 0 0.0010271467
8 O 0 0.00047359103
h O 0 0.00034575982
after O 0 0.0002678896
the O 0 0.00037684926
last O 0 0.00034766019
dose O 0 0.0017449212
of O 0 0.0009004192
medication O 0 0.08727424
did O 0 0.0008153221
not O 0 0.00090471446
show O 0 0.001036343
any O 0 0.0017428999
decrement O 0 0.008390985
of O 0 0.0046731294
performance O 0 0.009709704
. O 0 0.008305246

These O 0 0.012687388
results O 0 0.008704494
are O 0 0.0067536687
similar O 0 0.004361699
to O 0 0.0042446316
those O 0 0.004821126
previously O 0 0.004137702
found O 0 0.0040205913
in O 0 0.00536539
healthy O 0 0.034225002
subjects O 0 0.015779413
. O 0 0.011941036

Accumulation O 0 0.023440752
of O 0 0.011065045
drugs O 0 0.50471246
was O 0 0.007188436
not O 0 0.0053815013
reflected O 0 0.0050262976
in O 0 0.0059241434
prolonged O 0 0.041307684
behavioral B-Disease 0 0.845718
impairment I-Disease 0 0.9595881
. O 0 0.015750201

Comparison O 0 0.0075687193
of O 0 0.0062851235
i O 0 0.0091599105
. O 0 0.0029060966
v O 0 0.032997023
. O 0 0.002039272
glycopyrrolate B-Chemical 1 0.99998367
and O 0 0.004732138
atropine B-Chemical 1 0.9999609
in O 0 0.00113034
the O 0 0.00090452086
prevention O 0 0.0042875158
of O 0 0.0018482287
bradycardia B-Disease 2 0.9998574
and O 0 0.0022167724
arrhythmias B-Disease 2 0.99994946
following O 0 0.0010906105
repeated O 0 0.0012083482
doses O 0 0.017135678
of O 0 0.0035105855
suxamethonium B-Chemical 1 0.99967635
in O 0 0.005135687
children O 0 0.022352893
. O 0 0.008616888

The O 0 0.0064037726
effectiveness O 0 0.004170599
of O 0 0.0036108028
administration O 0 0.041645
of O 0 0.0042287614
glycopyrrolate B-Chemical 1 0.99999
5 O 0 0.0014932518
and O 0 0.0010378532
10 O 0 0.00076112954
micrograms O 0 0.063564695
kg O 0 0.01464741
- O 0 0.0013393039
1 O 0 0.00059480977
and O 0 0.0007040355
atropine B-Chemical 1 0.99991703
10 O 0 0.0005764779
and O 0 0.00045894814
20 O 0 0.0004300103
micrograms O 0 0.03562399
kg O 0 0.008156265
- O 0 0.000957148
1 O 0 0.0004553786
i O 0 0.0011145248
. O 0 0.00033476428
v O 0 0.0053054118
. O 0 0.0002595856
immediately O 0 0.00026481392
before O 0 0.00018242955
the O 0 0.0002843463
induction O 0 0.0003776991
of O 0 0.00062014826
anaesthesia O 0 0.1877084
, O 0 0.0007867717
to O 0 0.00043459528
prevent O 0 0.00084718544
arrhythmia B-Disease 2 0.9999145
and O 0 0.0014526526
bradycardia B-Disease 2 0.9995938
following O 0 0.000563835
repeated O 0 0.0006332003
doses O 0 0.007860119
of O 0 0.0016214773
suxamethonium B-Chemical 1 0.9997745
in O 0 0.0019655547
children O 0 0.007837364
, O 0 0.003931579
was O 0 0.0036242397
studied O 0 0.006132937
. O 0 0.008183938

A O 0 0.028723417
control O 0 0.006294902
group O 0 0.004694046
was O 0 0.0030296592
included O 0 0.002028355
for O 0 0.0014148961
comparison O 0 0.0012848305
with O 0 0.0013774086
the O 0 0.0013322731
lower O 0 0.0015048877
dose O 0 0.0070264754
range O 0 0.003369915
of O 0 0.0067319204
glycopyrrolate B-Chemical 1 0.99998426
and O 0 0.058992658
atropine B-Chemical 1 0.99988735
. O 0 0.014039012

A O 0 0.027694138
frequency O 0 0.006284087
of O 0 0.005534663
bradycardia B-Disease 2 0.99869245
of O 0 0.0035635955
50 O 0 0.0027907994
% O 0 0.00154619
was O 0 0.0008411646
noted O 0 0.0005894781
in O 0 0.00055316393
the O 0 0.00054960203
control O 0 0.0005863614
group O 0 0.00086602883
, O 0 0.0008800337
but O 0 0.0005097728
this O 0 0.0004741186
was O 0 0.0005011566
not O 0 0.0004811702
significantly O 0 0.0007064551
different O 0 0.0006315372
from O 0 0.0008160578
the O 0 0.0009501454
frequency O 0 0.0015021818
with O 0 0.0019903698
the O 0 0.0027099869
active O 0 0.008426234
drugs O 0 0.89557695
. O 0 0.009430471

Bradycardia B-Disease 2 0.99753714
( O 0 0.008585672
defined O 0 0.003437099
as O 0 0.0025517181
a O 0 0.0023814815
decrease O 0 0.0014663801
in O 0 0.0011077689
heart O 0 0.20306048
rate O 0 0.0008633314
to O 0 0.0006202029
less O 0 0.0005863743
than O 0 0.0004256084
50 O 0 0.00082023727
beat O 0 0.012349434
min O 0 0.00087722123
- O 0 0.0011064818
1 O 0 0.00061519915
) O 0 0.00081100495
was O 0 0.00044695204
prevented O 0 0.00072141463
when O 0 0.00038132787
the O 0 0.0005136543
larger O 0 0.0006123649
dose O 0 0.002647234
of O 0 0.001265381
either O 0 0.0016156575
active O 0 0.0043358435
drug O 0 0.6753579
was O 0 0.004193264
used O 0 0.005548962
. O 0 0.007753508

It O 0 0.009904565
is O 0 0.005031349
recommended O 0 0.0032694547
that O 0 0.0021071336
either O 0 0.002427869
glycopyrrolate B-Chemical 1 0.9999801
10 O 0 0.0019303857
micrograms O 0 0.23142721
kg O 0 0.034274038
- O 0 0.0017867797
1 O 0 0.00070792966
or O 0 0.00067443534
atropine B-Chemical 1 0.9999125
20 O 0 0.00074096944
micrograms O 0 0.0972259
kg O 0 0.014438092
- O 0 0.00112991
1 O 0 0.00050791854
i O 0 0.0012368154
. O 0 0.00037051408
v O 0 0.006341243
. O 0 0.00029582682
should O 0 0.00021796298
immediately O 0 0.0003319523
precede O 0 0.0008484841
induction O 0 0.00048016125
of O 0 0.00073790015
anaesthesia O 0 0.18978219
, O 0 0.0008955346
in O 0 0.0005151414
children O 0 0.001501915
, O 0 0.00075808365
if O 0 0.00042731458
the O 0 0.00059730315
repeated O 0 0.0008688647
administration O 0 0.023714686
of O 0 0.0032983283
suxamethonium B-Chemical 1 0.9997116
is O 0 0.00499671
anticipated O 0 0.0067820265
. O 0 0.008075094

Veno B-Disease 0 0.2547867
- I-Disease 0 0.017928272
occlusive I-Disease 0 0.9727356
liver I-Disease 2 0.9914647
disease I-Disease 2 0.98237777
after O 0 0.0047750906
dacarbazine B-Chemical 0 0.99968004
therapy O 0 0.2878383
( O 0 0.035445325
DTIC B-Chemical 0 0.9998938
) O 0 0.0208939
for O 0 0.007225177
melanoma B-Disease 0 0.9976949
. O 0 0.014576249

A O 0 0.025250092
case O 0 0.006113877
of O 0 0.0050274855
veno B-Disease 0 0.19113968
- I-Disease 0 0.0067464653
occlusive I-Disease 0 0.98099387
disease I-Disease 0 0.76341194
of I-Disease 0 0.002326485
the I-Disease 0 0.0015228558
liver I-Disease 0 0.8896114
with O 0 0.001944957
fatal O 0 0.98956794
outcome O 0 0.011281046
after O 0 0.0009632573
dacarbazine B-Chemical 0 0.99986935
( O 0 0.016344858
DTIC B-Chemical 0 0.99996173
) O 0 0.0067710686
therapy O 0 0.015417227
for O 0 0.0024827358
melanoma B-Disease 0 0.9982722
is O 0 0.005827751
reported O 0 0.00866564
. O 0 0.009121292

There O 0 0.01242839
was O 0 0.008750399
a O 0 0.008848944
fulminant O 0 0.99594647
clinical O 0 0.020491024
course O 0 0.0054034386
from O 0 0.003920639
start O 0 0.0035635754
of O 0 0.005581079
symptoms O 0 0.8885937
until O 0 0.0068868846
death B-Disease 2 0.9958982
. O 0 0.014140132

At O 0 0.008971966
autopsy O 0 0.016276019
the O 0 0.0068613337
liver O 0 0.57505625
was O 0 0.0056479946
enlarged O 0 0.014867979
and O 0 0.004664985
firm O 0 0.039423548
with O 0 0.004929532
signs O 0 0.29828227
of O 0 0.009646974
venous B-Disease 0 0.99177164
congestion I-Disease 0 0.9984908
. O 0 0.015937189

Small O 0 0.057004172
- O 0 0.015418441
and O 0 0.009135672
medium O 0 0.013627852
- O 0 0.008204749
sized O 0 0.0060268464
hepatic O 0 0.8853197
veins O 0 0.48930812
were O 0 0.0070327027
blocked O 0 0.0104373265
by O 0 0.012478665
thrombosis B-Disease 2 0.9992205
. O 0 0.016788341

Eosinophilic O 0 0.8814351
infiltrations O 0 0.8380791
were O 0 0.02027836
found O 0 0.014322233
around O 0 0.015691414
the O 0 0.017547559
vessels O 0 0.18456493
. O 0 0.024815056

Published O 0 0.032111418
cases O 0 0.012551857
from O 0 0.007886014
the O 0 0.0065079923
literature O 0 0.007454361
are O 0 0.00593775
reviewed O 0 0.007829842
and O 0 0.0065028924
pertinent O 0 0.0070904363
features O 0 0.011887075
discussed O 0 0.009966119
. O 0 0.013543974

Maternal O 0 0.14911486
lithium B-Chemical 1 0.9979175
and O 0 0.007819506
neonatal O 0 0.015914215
Ebstein B-Disease 0 0.24261007
' I-Disease 0 0.004380735
s I-Disease 0 0.00347911
anomaly I-Disease 0 0.04357713
: O 0 0.0034279383
evaluation O 0 0.0027136775
with O 0 0.0031179774
cross O 0 0.0062429714
- O 0 0.008192434
sectional O 0 0.026947929
echocardiography O 0 0.13124073
. O 0 0.010154731

Cross O 0 0.1287358
- O 0 0.012436376
sectional O 0 0.011977779
echocardiography O 0 0.019239001
was O 0 0.0030386844
used O 0 0.0020538445
to O 0 0.0016261364
evaluate O 0 0.001115068
two O 0 0.0014864425
neonates O 0 0.0049837567
whose O 0 0.0030981752
mothers O 0 0.0071802526
ingested O 0 0.34653267
lithium B-Chemical 1 0.9996655
during O 0 0.0062227845
pregnancy O 0 0.76307327
. O 0 0.011820409

In O 0 0.010435614
one O 0 0.007474314
infant O 0 0.010463475
, O 0 0.0066014375
Ebstein B-Disease 0 0.077589296
' I-Disease 0 0.004523443
s I-Disease 0 0.0037491696
anomaly I-Disease 0 0.013192147
of O 0 0.0033160893
the O 0 0.0036141137
tricuspid O 0 0.24884546
valve O 0 0.036878314
was O 0 0.0058065164
identified O 0 0.007178703
. O 0 0.010266659

In O 0 0.0077904603
the O 0 0.005497288
other O 0 0.004167633
infant O 0 0.0068516023
cross O 0 0.0050372514
- O 0 0.003931374
sectional O 0 0.0056946534
echocardiography O 0 0.016659275
provided O 0 0.0012269393
reassurance O 0 0.00594512
that O 0 0.00096074864
the O 0 0.0011714313
infant O 0 0.0031173518
did O 0 0.0014504339
not O 0 0.0016694559
have O 0 0.0022227438
Ebstein B-Disease 0 0.2875207
' I-Disease 0 0.005601807
s I-Disease 0 0.0068045333
anomaly I-Disease 0 0.13676924
. O 0 0.009771023

Cross O 0 0.12547736
- O 0 0.010495397
sectional O 0 0.009155315
echocardiographic O 0 0.011532628
screening O 0 0.0026270347
of O 0 0.0019000337
newborns O 0 0.0047915797
exposed O 0 0.0012208151
to O 0 0.0011772413
lithium B-Chemical 1 0.9996412
during O 0 0.0006668088
gestation O 0 0.0026978834
can O 0 0.00043099932
provide O 0 0.00040451
highly O 0 0.00062093843
accurate O 0 0.0007314427
, O 0 0.0006874645
noninvasive O 0 0.0027432782
assessment O 0 0.00050487707
of O 0 0.0005908205
the O 0 0.00058334024
presence O 0 0.00065308163
or O 0 0.00083232723
absence O 0 0.0007654535
of O 0 0.0040194113
lithium B-Chemical 1 0.99991393
- O 0 0.02079837
induced O 0 0.0077516004
cardiac B-Disease 0 0.9964741
malformations I-Disease 0 0.9994862
. O 0 0.012959268

Effects O 0 0.014085164
of O 0 0.0071326373
training O 0 0.0045851977
on O 0 0.0027463445
the O 0 0.002648501
extent O 0 0.0020974006
of O 0 0.003171873
experimental O 0 0.006906506
myocardial B-Disease 0 0.999882
infarction I-Disease 2 0.9999771
in O 0 0.010078506
aging O 0 0.5978782
rats O 0 0.054088593
. O 0 0.011975165

The O 0 0.006839565
effects O 0 0.0055595413
of O 0 0.003983732
exercise O 0 0.01111319
on O 0 0.0013630461
the O 0 0.0014100114
severity O 0 0.05462088
of O 0 0.0046343133
isoproterenol B-Chemical 1 0.99997354
- O 0 0.02579633
induced O 0 0.003890585
myocardial B-Disease 0 0.99996793
infarction I-Disease 2 0.99999607
were O 0 0.0011263819
studied O 0 0.0007300054
in O 0 0.0005468172
female O 0 0.0029803608
albino O 0 0.009414404
rats O 0 0.0014371112
of O 0 0.00085091667
20 O 0 0.0008787944
, O 0 0.000944175
40 O 0 0.0008219821
, O 0 0.0009753867
60 O 0 0.0008890197
and O 0 0.0011657642
80 O 0 0.0017078373
weeks O 0 0.0015956956
of O 0 0.003502468
age O 0 0.010057324
. O 0 0.008171458

The O 0 0.008997879
rats O 0 0.009192726
were O 0 0.0048615453
trained O 0 0.0037885604
to O 0 0.0028031254
swim O 0 0.045205798
for O 0 0.0017763796
a O 0 0.0021574344
specific O 0 0.0015914282
duration O 0 0.00227886
and O 0 0.0025640063
for O 0 0.002257786
a O 0 0.0040516276
particular O 0 0.0037499103
period O 0 0.006018696
. O 0 0.008973641

The O 0 0.013990444
occurrence O 0 0.015578073
of O 0 0.014441464
infarcts B-Disease 0 0.99814904
were O 0 0.009910062
confirmed O 0 0.008216949
by O 0 0.010250366
histological O 0 0.40711883
methods O 0 0.016483018
. O 0 0.016624603

Elevations O 0 0.43226066
in O 0 0.0071627204
the O 0 0.005733556
serum O 0 0.37339804
GOT O 0 0.999808
and O 0 0.0066995304
GPT O 0 0.9984261
were O 0 0.0015961607
maximum O 0 0.0011087928
in O 0 0.0009399206
the O 0 0.0010957385
sedentary O 0 0.013585005
- O 0 0.002064467
isoproterenols B-Chemical 0 0.045274686
and O 0 0.001266799
minimum O 0 0.00097385363
in O 0 0.0014737409
the O 0 0.002312154
exercise O 0 0.05765249
- O 0 0.0069510625
controls O 0 0.00954797
. O 0 0.008318083

These O 0 0.010146826
changes O 0 0.0071144053
in O 0 0.0044411044
the O 0 0.0038877935
serum O 0 0.24607173
transaminases O 0 0.9995943
were O 0 0.0026869413
associated O 0 0.0020472158
with O 0 0.0017208304
corresponding O 0 0.0014976583
depletions O 0 0.0995093
in O 0 0.0018025073
the O 0 0.002826216
cardiac O 0 0.9414138
GOT O 0 0.9998472
and O 0 0.019658009
GPT O 0 0.9988373
. O 0 0.011995037

However O 0 0.010301876
, O 0 0.0077164704
age O 0 0.0065691173
was O 0 0.003287597
seen O 0 0.0022527485
to O 0 0.0018460347
interfere O 0 0.0017193386
with O 0 0.0015201039
the O 0 0.0014211972
responses O 0 0.0024913778
exhibited O 0 0.0014858978
by O 0 0.0020326432
the O 0 0.0021247065
young O 0 0.009080724
and O 0 0.004100128
old O 0 0.006534972
rats O 0 0.014555701
. O 0 0.0097129615

Studies O 0 0.024735926
dealing O 0 0.014323882
with O 0 0.011119124
myocardial B-Disease 0 0.9994715
infarction I-Disease 2 0.99994004
are O 0 0.007227486
more O 0 0.004998394
informative O 0 0.0052274596
when O 0 0.0036752368
dealt O 0 0.009949134
with O 0 0.007209238
age O 0 0.018827062
. O 0 0.01172776

Effect O 0 0.018381637
of O 0 0.015420874
polyethylene B-Chemical 1 0.97998595
glycol I-Chemical 1 0.9980988
400 I-Chemical 1 0.17846243
on O 0 0.0077723977
adriamycin B-Chemical 1 0.99969244
toxicity B-Disease 2 0.99866533
in O 0 0.011081097
mice O 0 0.010123247
. O 0 0.0136227375

The O 0 0.0071049808
effect O 0 0.0045844926
of O 0 0.0040134676
a O 0 0.0038203367
widely O 0 0.0032914977
used O 0 0.0020700337
organic O 0 0.96952033
solvent O 0 0.9574852
, O 0 0.012319518
polyethylene B-Chemical 1 0.99541795
glycol I-Chemical 1 0.9997811
400 I-Chemical 1 0.3692243
( O 0 0.002804787
PEG B-Chemical 0 0.94955134
400 I-Chemical 0 0.008766015
) O 0 0.0012144158
, O 0 0.00057312206
on O 0 0.00027812322
the O 0 0.0004374432
toxic O 0 0.49994937
action O 0 0.0045689256
of O 0 0.0007917488
an O 0 0.0014457811
acute O 0 0.9465157
or O 0 0.0014407618
chronic O 0 0.9680065
treatment O 0 0.00913095
with O 0 0.004494216
adriamycin B-Chemical 1 0.99996805
( O 0 0.043297376
ADR B-Chemical 1 0.999951
) O 0 0.0049056103
was O 0 0.0018734632
evaluated O 0 0.0021504078
in O 0 0.003385186
mice O 0 0.0046794056
. O 0 0.008061127

PEG B-Chemical 0 0.81565714
400 I-Chemical 0 0.018111208
impressively O 0 0.05856172
decreased O 0 0.0053089154
both O 0 0.003020836
acute O 0 0.86542135
high O 0 0.004504277
- O 0 0.0037459098
dose O 0 0.014574879
and O 0 0.0021742645
chronic O 0 0.93923485
low O 0 0.0055624475
- O 0 0.007421144
dose O 0 0.112105034
- O 0 0.033194687
ADR B-Chemical 1 0.99989295
- O 0 0.011760274
associated O 0 0.007874791
lethality O 0 0.7250786
. O 0 0.011193842

Light O 0 0.05564097
microscopic O 0 0.014041633
analysis O 0 0.007102472
showed O 0 0.004201117
a O 0 0.0044949986
significant O 0 0.0037487973
protection O 0 0.009429107
against O 0 0.005008951
ADR B-Chemical 1 0.9998896
- O 0 0.012512657
induced O 0 0.0060078655
cardiac B-Disease 0 0.9495609
morphological I-Disease 0 0.10612062
alterations I-Disease 0 0.29202318
. O 0 0.012513139

Such O 0 0.013043814
treatment O 0 0.007801303
did O 0 0.0044902256
not O 0 0.0033119232
diminish O 0 0.0035529851
the O 0 0.0034461168
ADR B-Chemical 1 0.9999043
antitumor O 0 0.9649751
activity O 0 0.005600566
in O 0 0.004194772
L1210 B-Disease 0 0.99987185
leukemia I-Disease 0 0.99996555
and O 0 0.013703271
in O 0 0.0069650062
Ehrlich B-Disease 0 0.99942327
ascites I-Disease 2 0.9997521
tumor I-Disease 0 0.997945
. O 0 0.015847577

Sublingual O 0 0.95384747
absorption O 0 0.22610295
of O 0 0.008828034
the O 0 0.007338479
quaternary B-Chemical 0 0.90878195
ammonium I-Chemical 0 0.99970776
antiarrhythmic O 0 0.9996018
agent O 0 0.906611
, O 0 0.038870897
UM B-Chemical 0 0.9826764
- I-Chemical 0 0.020785099
272 I-Chemical 0 0.16103052
. O 0 0.011625809

UM B-Chemical 0 0.8899249
- I-Chemical 0 0.016828323
272 I-Chemical 0 0.07500006
( O 0 0.008531651
N B-Chemical 0 0.9378994
, I-Chemical 0 0.006378455
N I-Chemical 0 0.9775734
- I-Chemical 0 0.005268883
dimethylpropranolol I-Chemical 0 0.28496554
) O 0 0.0032327613
, O 0 0.0012704142
a O 0 0.0011322729
quaternary O 0 0.18810037
antiarrhythmic O 0 0.9984452
agent O 0 0.4057275
, O 0 0.0016245942
was O 0 0.00072378176
administered O 0 0.0013293984
sublingually O 0 0.9876721
to O 0 0.0009465006
dogs O 0 0.004103554
with O 0 0.002992728
ouabain B-Chemical 1 0.99993277
- O 0 0.0175559
induced O 0 0.007518081
ventricular B-Disease 0 0.9995403
tachycardias I-Disease 0 0.99952996
. O 0 0.012236099

Both O 0 0.013957541
anti O 0 0.026634162
- O 0 0.014781622
arrhythmic O 0 0.996375
efficacy O 0 0.014680337
and O 0 0.0057346
bioavailability O 0 0.95704
were O 0 0.0037568447
compared O 0 0.0026101973
to O 0 0.00426258
oral O 0 0.71549946
drug O 0 0.8840212
. O 0 0.012932294

Sublingual O 0 0.98440915
UM B-Chemical 0 0.93745583
- I-Chemical 0 0.013041426
272 I-Chemical 0 0.028832309
converted O 0 0.0062832716
ventricular B-Disease 2 0.99664414
tachycardia I-Disease 2 0.99979883
to O 0 0.0035282178
sinus O 0 0.11427544
rhythm O 0 0.017291633
in O 0 0.0030168663
all O 0 0.003670358
5 O 0 0.004821993
dogs O 0 0.01058595
. O 0 0.009707485

The O 0 0.00719763
area O 0 0.0058402787
under O 0 0.002831638
the O 0 0.002500512
plasma O 0 0.0063757845
concentration O 0 0.0022077425
time O 0 0.00094510196
curve O 0 0.0013903109
at O 0 0.0005605836
90 O 0 0.0005334337
min O 0 0.00053401745
was O 0 0.00045726556
4 O 0 0.00043379152
- O 0 0.0005313503
12 O 0 0.00023823373
times O 0 0.0002053422
greater O 0 0.00026470056
than O 0 0.00023729159
for O 0 0.00028589249
oral O 0 0.23703738
drug O 0 0.60985404
, O 0 0.0007687437
suggesting O 0 0.00029143257
the O 0 0.0003388988
existence O 0 0.00040359292
of O 0 0.0005835437
an O 0 0.0011293961
absorption O 0 0.48665985
- O 0 0.0014035933
limiting O 0 0.000590252
process O 0 0.0004908489
in O 0 0.00043176912
the O 0 0.0005378467
intestine O 0 0.023276813
, O 0 0.00095613406
and O 0 0.00065285165
providing O 0 0.00064885383
an O 0 0.00088559394
alternate O 0 0.0012136935
form O 0 0.0009897334
of O 0 0.0017080096
administration O 0 0.09996729
for O 0 0.0027998616
quaternary O 0 0.5756581
drugs O 0 0.93973804
. O 0 0.009748405

Early O 0 0.07795636
adjuvant O 0 0.5921255
adriamycin B-Chemical 1 0.99866974
in O 0 0.02368001
superficial O 0 0.52405804
bladder B-Disease 0 0.9923906
carcinoma I-Disease 2 0.99913365
. O 0 0.03506151

A O 0 0.050078567
multicenter O 0 0.019931352
study O 0 0.005892314
was O 0 0.0036727637
performed O 0 0.002551233
in O 0 0.0022969577
110 O 0 0.0036301645
patients O 0 0.0031131934
with O 0 0.0021566194
superficial O 0 0.04950368
transitional O 0 0.28456274
cell O 0 0.15014073
carcinoma B-Disease 2 0.9996375
of I-Disease 0 0.008433037
the I-Disease 0 0.007824954
bladder I-Disease 0 0.96235985
. O 0 0.012364076

Adriamycin B-Chemical 1 0.9989273
( O 0 0.0112109305
50 O 0 0.0058413306
mg O 0 0.2534992
/ O 0 0.0049068606
50 O 0 0.0023527301
ml O 0 0.0035472936
) O 0 0.0018721946
was O 0 0.0007865098
administered O 0 0.00083965954
intravesically O 0 0.022196664
within O 0 0.0003836422
24 O 0 0.00040200396
h O 0 0.0003686738
after O 0 0.00033078503
transurethral O 0 0.0028911158
resection O 0 0.005609286
of O 0 0.0019132722
TA O 0 0.96845084
- O 0 0.009092625
T1 O 0 0.33020777
( O 0 0.006982057
O O 0 0.99583155
- O 0 0.009872773
A O 0 0.19731826
) O 0 0.013919155
bladder B-Disease 0 0.99463695
tumors I-Disease 2 0.99789846
. O 0 0.013503813

Instillation O 0 0.36532563
was O 0 0.005317421
repeated O 0 0.0031642457
twice O 0 0.0023814768
during O 0 0.0013878357
the O 0 0.0012116128
first O 0 0.0009292667
week O 0 0.0008351662
, O 0 0.0009809111
then O 0 0.00064791826
weekly O 0 0.00084189186
during O 0 0.00051633106
the O 0 0.0006443835
first O 0 0.0006652488
month O 0 0.00081050233
and O 0 0.0013740112
afterwards O 0 0.0022031802
monthly O 0 0.002059444
for O 0 0.0021276362
1 O 0 0.004044749
year O 0 0.005283807
. O 0 0.00753837

The O 0 0.00866592
tolerance O 0 0.025182376
was O 0 0.004170686
evaluated O 0 0.0025430345
in O 0 0.002032532
these O 0 0.0020882406
110 O 0 0.0034322941
patients O 0 0.0029493284
, O 0 0.0016855786
and O 0 0.0013136858
29 O 0 0.0018294837
patients O 0 0.0020256059
presented O 0 0.0016213421
with O 0 0.0020530235
local O 0 0.005637614
side O 0 0.24819003
- O 0 0.011089905
effects O 0 0.012323824
. O 0 0.009642668

In O 0 0.0072576907
24 O 0 0.004144862
of O 0 0.003537054
these O 0 0.0030083002
patients O 0 0.0050003105
chemical O 0 0.13439608
cystitis B-Disease 2 0.99996865
was O 0 0.0040739533
severe O 0 0.19510925
enough O 0 0.001451752
for O 0 0.0010573813
them O 0 0.002104368
to O 0 0.0013726184
drop O 0 0.0028252958
out O 0 0.0019350436
of O 0 0.0031583512
the O 0 0.004236831
study O 0 0.007792104
. O 0 0.008550946

No O 0 0.027154075
systemic O 0 0.7636626
side O 0 0.43036163
- O 0 0.02469761
effects O 0 0.019030191
were O 0 0.0157934
observed O 0 0.013731881
. O 0 0.019611329

Recurrence O 0 0.4517544
was O 0 0.0060070315
studied O 0 0.0038171732
in O 0 0.0025154266
82 O 0 0.0028702302
evaluable O 0 0.0036212003
patients O 0 0.0019496414
after O 0 0.0006490781
1 O 0 0.00074617437
year O 0 0.00057364337
of O 0 0.0006612337
follow O 0 0.000567884
- O 0 0.00092960463
up O 0 0.00045675196
and O 0 0.00052850915
in O 0 0.00043872022
72 O 0 0.0004912365
patients O 0 0.0008300303
followed O 0 0.00042288622
for O 0 0.0005169878
2 O 0 0.0008450562
- O 0 0.0011748613
3 O 0 0.0008221219
years O 0 0.0013496198
( O 0 0.0016220647
mean O 0 0.0015509187
32 O 0 0.0030073996
months O 0 0.0029466792
) O 0 0.00744537
. O 0 0.0072617875

Of O 0 0.011452466
the O 0 0.0063689575
82 O 0 0.0064193862
patients O 0 0.004775394
studied O 0 0.002790624
after O 0 0.0016969925
1 O 0 0.0020230473
year O 0 0.0017747992
, O 0 0.00208801
23 O 0 0.0020803716
had O 0 0.0015664562
primary O 0 0.002493864
and O 0 0.003477348
59 O 0 0.008067321
recurrent O 0 0.797239
disease O 0 0.92256105
. O 0 0.012943999

Of O 0 0.0101280315
the O 0 0.005435335
82 O 0 0.005316112
evaluable O 0 0.0065012663
patients O 0 0.0044672736
, O 0 0.0022163594
50 O 0 0.0015133979
did O 0 0.00081879535
not O 0 0.00066180713
show O 0 0.00051478605
any O 0 0.00060928497
recurrence O 0 0.4907062
after O 0 0.00046430598
1 O 0 0.0006740424
year O 0 0.0005778012
( O 0 0.0008181449
61 O 0 0.0010766714
% O 0 0.00073549047
) O 0 0.00092417066
, O 0 0.00060938596
while O 0 0.00042058702
32 O 0 0.0006200041
presented O 0 0.0005519589
with O 0 0.0006378748
one O 0 0.00067313603
or O 0 0.0009440819
more O 0 0.0016975122
recurrences O 0 0.5396121
( O 0 0.004454527
39 O 0 0.0052106157
% O 0 0.0051944638
) O 0 0.00848568
. O 0 0.007561376

Of O 0 0.012526057
these O 0 0.008360678
recurrences O 0 0.23739246
, O 0 0.006101491
27 O 0 0.004625617
were O 0 0.0031153683
T1 O 0 0.034740347
tumors B-Disease 2 0.7913154
while O 0 0.0020403846
five O 0 0.0016565999
progressed O 0 0.0044477656
to O 0 0.0022481682
more O 0 0.0033124222
highly O 0 0.0050638476
invasive O 0 0.08101619
lesions O 0 0.7614269
. O 0 0.012539795

In O 0 0.00738727
patients O 0 0.006881818
that O 0 0.0030682993
were O 0 0.0024352944
free O 0 0.0022317998
of O 0 0.0018798071
recurrence O 0 0.56427205
during O 0 0.0008371075
the O 0 0.00074756006
first O 0 0.00058132596
year O 0 0.00073242135
, O 0 0.0008358498
80 O 0 0.000701421
% O 0 0.00065072504
remained O 0 0.00066510524
tumor B-Disease 2 0.8417735
- O 0 0.0012390658
free O 0 0.00074054295
during O 0 0.00043701305
the O 0 0.0006464571
2 O 0 0.0008376094
- O 0 0.001089027
to O 0 0.00072913873
3 O 0 0.001029949
- O 0 0.0016081863
year O 0 0.001348461
follow O 0 0.0016594067
- O 0 0.003481723
up O 0 0.0032759067
period O 0 0.0045425566
. O 0 0.0072321

Of O 0 0.009857253
the O 0 0.0053560794
patients O 0 0.0057151336
developing O 0 0.0049218778
one O 0 0.0018148567
or O 0 0.0014211877
more O 0 0.0014061306
recurrences O 0 0.15676977
during O 0 0.00067588204
the O 0 0.0006538642
first O 0 0.0005413936
year O 0 0.00070463016
, O 0 0.0008085924
only O 0 0.0005493582
50 O 0 0.000855506
% O 0 0.0007102949
presented O 0 0.00067852886
with O 0 0.00077526696
further O 0 0.0011190248
recurrence O 0 0.5514381
once O 0 0.0016370963
the O 0 0.00199825
instillations O 0 0.11265524
were O 0 0.005170985
stopped O 0 0.011053516
. O 0 0.008330869

The O 0 0.0074769845
beneficial O 0 0.0072739427
effect O 0 0.0037025814
of O 0 0.004906949
Adriamycin B-Chemical 1 0.999864
appears O 0 0.0016932791
obvious O 0 0.0012933391
and O 0 0.001155204
might O 0 0.00060170406
be O 0 0.0006685503
related O 0 0.00044327843
to O 0 0.000500148
the O 0 0.00060046825
drug O 0 0.3494333
itself O 0 0.0014387319
, O 0 0.0009273655
the O 0 0.000575314
early O 0 0.0009876838
and O 0 0.00085016707
repeated O 0 0.00092875335
instillations O 0 0.047183245
after O 0 0.0013363536
TUR O 0 0.76297665
, O 0 0.0044268914
or O 0 0.0039693145
both O 0 0.0060323817
. O 0 0.0083566625

D B-Chemical 1 0.98042643
- I-Chemical 1 0.14565676
penicillamine I-Chemical 1 0.99984264
- O 0 0.122961305
induced O 0 0.036956847
angiopathy B-Disease 0 0.99985695
in O 0 0.025091222
rats O 0 0.07838564
. O 0 0.020328201

The O 0 0.007269901
effect O 0 0.0047427723
of O 0 0.0042367703
high O 0 0.0041990825
dose O 0 0.21427108
D B-Chemical 1 0.99739873
- I-Chemical 1 0.06293784
penicillamine I-Chemical 1 0.9999863
treatment O 0 0.007472167
on O 0 0.0009875876
aortic O 0 0.38624105
permeability O 0 0.6799917
to O 0 0.0013571576
albumin O 0 0.97662055
and O 0 0.0016121032
on O 0 0.0010047053
the O 0 0.001607221
ultrastructure O 0 0.01134071
of O 0 0.0038202133
the O 0 0.005077276
vessel O 0 0.26395115
. O 0 0.010264678

Male O 0 0.08729026
Sprague O 0 0.35740587
- O 0 0.011297801
Dawley O 0 0.03827445
rats O 0 0.0060046883
were O 0 0.00282417
treated O 0 0.0029196588
with O 0 0.0037964857
D B-Chemical 1 0.9963529
- I-Chemical 1 0.10201067
penicillamine I-Chemical 1 0.99999416
( O 0 0.10003185
D B-Chemical 1 0.9966683
- I-Chemical 1 0.0072264904
pen I-Chemical 1 0.05070942
) O 0 0.002033819
500 O 0 0.0022481915
mg O 0 0.136138
/ O 0 0.0019454467
kg O 0 0.003141544
/ O 0 0.001808153
day O 0 0.0009351211
for O 0 0.0010644544
10 O 0 0.0016689798
or O 0 0.0021590365
42 O 0 0.0042743403
days O 0 0.004041239
. O 0 0.006905584

Pair O 0 0.3490066
fed O 0 0.03524264
rats O 0 0.032860186
served O 0 0.029133946
as O 0 0.02603383
controls O 0 0.037369147
. O 0 0.031445514

Changes O 0 0.01166858
in O 0 0.006622447
aortic O 0 0.04016949
morphology O 0 0.006881848
were O 0 0.0029283199
examined O 0 0.001924209
by O 0 0.002526585
light O 0 0.00429698
- O 0 0.003650011
and O 0 0.002373631
transmission O 0 0.0062511656
- O 0 0.0041698227
electron O 0 0.014707068
microscopy O 0 0.004789327
( O 0 0.007372376
TEM O 0 0.066758014
) O 0 0.013146444
. O 0 0.010350685

In O 0 0.007243814
addition O 0 0.004209048
, O 0 0.0044622947
the O 0 0.0028353136
endothelial O 0 0.81204915
permeability O 0 0.7025115
and O 0 0.0018273984
the O 0 0.0010779852
penetration O 0 0.0066230865
through O 0 0.00065158796
the O 0 0.00063555606
aortic O 0 0.074224405
wall O 0 0.021558294
of O 0 0.0010381622
albumin O 0 0.9821332
were O 0 0.0005757616
studied O 0 0.00048347816
10 O 0 0.0003962011
minutes O 0 0.00028592706
, O 0 0.00041705844
24 O 0 0.00024141524
and O 0 0.000289776
48 O 0 0.0002490729
hours O 0 0.00020260738
after O 0 0.00021604475
i O 0 0.0011348666
. O 0 0.00038059356
v O 0 0.0071379375
. O 0 0.00036945488
injection O 0 0.0008851312
of O 0 0.00075859274
human O 0 0.0015827897
serum O 0 0.4849279
131I O 0 0.99768555
- O 0 0.01565377
albumin O 0 0.9949532
( O 0 0.012235418
131I O 0 0.9923741
- O 0 0.013553788
HSA O 0 0.9625664
) O 0 0.015241033
. O 0 0.008762908

TEM O 0 0.022420987
revealed O 0 0.006894658
extensive O 0 0.0055349227
elastolysis O 0 0.47826165
in O 0 0.0028776184
the O 0 0.0021862753
arterial O 0 0.4310014
wall O 0 0.09348768
of O 0 0.0049583763
D B-Chemical 1 0.99573225
- I-Chemical 1 0.011402843
pen I-Chemical 1 0.11005951
- O 0 0.002190982
treated O 0 0.0011857947
rats O 0 0.0030541585
, O 0 0.0012489406
consistent O 0 0.00078509975
with O 0 0.0011136375
an O 0 0.0018742067
inhibitory O 0 0.00978872
effect O 0 0.0023383088
on O 0 0.0023860896
crosslink O 0 0.040570818
formation O 0 0.034987967
. O 0 0.01025044

In O 0 0.006749374
experimental O 0 0.0050298865
animals O 0 0.0033213885
excess O 0 0.0040742042
deposition O 0 0.011389874
of O 0 0.0028556865
collagen O 0 0.63889176
and O 0 0.0026321707
glycoaminoglycans O 0 0.34654894
was O 0 0.0008982838
observed O 0 0.00044832582
in O 0 0.00051230646
the O 0 0.0005591874
subendothelial O 0 0.031252004
and O 0 0.00089911174
medial O 0 0.005926741
layer O 0 0.001357482
of O 0 0.0005914445
the O 0 0.0005711572
aortic O 0 0.11679394
wall O 0 0.04343758
, O 0 0.0009961067
together O 0 0.00060505205
with O 0 0.0007965428
prominent O 0 0.0036113637
basal O 0 0.0024585181
membrane O 0 0.014279423
substance O 0 0.94636846
around O 0 0.0024602765
aortic O 0 0.28693262
smooth O 0 0.060839355
muscle O 0 0.16001761
cells O 0 0.012665212
. O 0 0.009428871

The O 0 0.008812608
aorta O 0 0.07113502
/ O 0 0.011020669
serum O 0 0.11833876
- O 0 0.004118332
ratio O 0 0.0019810447
and O 0 0.0014064113
the O 0 0.0010322296
radioactive O 0 0.0062847356
build O 0 0.0016068063
- O 0 0.0012270754
up O 0 0.00047154035
24 O 0 0.00034466007
and O 0 0.00037129797
48 O 0 0.00028504085
hours O 0 0.00020837803
after O 0 0.0001938145
injection O 0 0.00068594975
of O 0 0.0007520778
131I O 0 0.9950789
- O 0 0.0037200295
HSA O 0 0.9297833
was O 0 0.000541148
reduced O 0 0.00046308868
in O 0 0.000392489
animals O 0 0.0004307911
treated O 0 0.00082383613
with O 0 0.001403451
D B-Chemical 1 0.9944073
- I-Chemical 1 0.0029086468
pen I-Chemical 1 0.0094065
for O 0 0.00032427383
42 O 0 0.00054120115
days O 0 0.00029730322
, O 0 0.000481866
indicating O 0 0.0003114847
an O 0 0.0006056954
impeded O 0 0.0007842006
transmural O 0 0.86287665
transport O 0 0.0020101664
of O 0 0.00067815254
tracer O 0 0.014895408
which O 0 0.0007581317
may O 0 0.00054979644
be O 0 0.0006425694
caused O 0 0.0008025526
by O 0 0.0010539418
a O 0 0.0016095159
steric O 0 0.070354275
exclusion O 0 0.0023940874
effect O 0 0.0021459928
of O 0 0.004102221
abundant O 0 0.007964176
hyaluronate B-Chemical 0 0.9995859
. O 0 0.013486166

The O 0 0.008639361
endothelial O 0 0.56038696
ultrastructure O 0 0.042032715
was O 0 0.004226668
unaffected O 0 0.0037048354
by O 0 0.004377099
D B-Chemical 1 0.99010545
- I-Chemical 1 0.0070201275
pen I-Chemical 1 0.046254084
, O 0 0.0012813237
and O 0 0.000689979
no O 0 0.00041149862
differences O 0 0.00038461442
in O 0 0.00055269693
aortic O 0 0.27907223
131I O 0 0.9937582
- O 0 0.0025892693
HSA O 0 0.8735401
radioactivity O 0 0.01842556
or O 0 0.000549303
aorta O 0 0.12350084
/ O 0 0.004126707
serum O 0 0.1402843
- O 0 0.0010586381
ratio O 0 0.00046985043
were O 0 0.00032198676
recorded O 0 0.0003248453
between O 0 0.00019310083
experimental O 0 0.00038373622
and O 0 0.00040453396
control O 0 0.00034117757
groups O 0 0.0004294958
10 O 0 0.0002862214
minutes O 0 0.00019524102
after O 0 0.00017136111
tracer O 0 0.0016389537
injection O 0 0.00090174103
, O 0 0.0005141858
indicating O 0 0.00028068988
that O 0 0.00029412282
the O 0 0.0004379994
permeability O 0 0.26724324
of O 0 0.00074552186
the O 0 0.0007649
endothelial O 0 0.9054635
barrier O 0 0.020292593
to O 0 0.0010517435
albumin O 0 0.9873962
remained O 0 0.0020671622
unaffected O 0 0.0024042295
by O 0 0.00414447
D B-Chemical 1 0.99068797
- I-Chemical 1 0.013857371
pen I-Chemical 1 0.09414734
treatment O 0 0.011412796
. O 0 0.009359979

These O 0 0.008056076
observations O 0 0.005527912
support O 0 0.0033509312
the O 0 0.0023583747
hypothesis O 0 0.0019938091
that O 0 0.0012383035
treatment O 0 0.0018494256
with O 0 0.0011695948
high O 0 0.0014269433
doses O 0 0.06807558
of O 0 0.005810663
D B-Chemical 1 0.9979231
- I-Chemical 1 0.010102315
pen I-Chemical 1 0.04295385
may O 0 0.0005925795
induce O 0 0.00046409134
a O 0 0.0011419218
fibroproliferative O 0 0.84199524
response O 0 0.0017112063
in O 0 0.000651348
rat O 0 0.009252911
aorta O 0 0.1640316
, O 0 0.00095897866
possibly O 0 0.0012434137
by O 0 0.0006184862
an O 0 0.0007586307
inhibitory O 0 0.002897395
effect O 0 0.0006246203
on O 0 0.0004922303
the O 0 0.0008529095
cross O 0 0.0020925119
- O 0 0.0023148595
linking O 0 0.0019978078
of O 0 0.0032188748
collagen O 0 0.68403834
and O 0 0.010364405
elastin O 0 0.87221843
. O 0 0.012233136

Effect O 0 0.010915678
of O 0 0.008412441
aspirin B-Chemical 1 0.99966085
on O 0 0.004757841
N B-Chemical 0 0.9922963
- I-Chemical 0 0.009621108
[ I-Chemical 0 0.0049563246
4 I-Chemical 0 0.0014586755
- I-Chemical 0 0.0019152309
( I-Chemical 0 0.0013076374
5 I-Chemical 0 0.00081889436
- I-Chemical 0 0.0016782035
nitro I-Chemical 0 0.9972255
- I-Chemical 0 0.003036993
2 I-Chemical 0 0.00095006084
- I-Chemical 0 0.0018992526
furyl I-Chemical 0 0.9697352
) I-Chemical 0 0.0059654326
- I-Chemical 0 0.0017751624
2 I-Chemical 0 0.0007925165
- I-Chemical 0 0.0017862472
thiazolyl I-Chemical 0 0.99869555
] I-Chemical 0 0.03930183
- I-Chemical 0 0.0074233855
formamide I-Chemical 0 0.9577563
- O 0 0.002477787
induced O 0 0.0009838354
epithelial O 0 0.17663124
proliferation O 0 0.647231
in O 0 0.0009118045
the O 0 0.0011224957
urinary O 0 0.90777993
bladder O 0 0.96761537
and O 0 0.004667001
forestomach O 0 0.9899159
of O 0 0.0052480265
the O 0 0.00533995
rat O 0 0.032889288
. O 0 0.008847493

The O 0 0.009221438
co O 0 0.3114977
- O 0 0.008325092
administration O 0 0.037894372
of O 0 0.0045452123
aspirin B-Chemical 1 0.9999279
with O 0 0.009394214
N B-Chemical 0 0.99758863
- I-Chemical 0 0.010477388
[ I-Chemical 0 0.0041060806
4 I-Chemical 0 0.000957262
- I-Chemical 0 0.001382715
( I-Chemical 0 0.00096347666
5 I-Chemical 0 0.0006256593
- I-Chemical 0 0.0013881861
nitro I-Chemical 0 0.99719846
- I-Chemical 0 0.0027214084
2 I-Chemical 0 0.0008395623
- I-Chemical 0 0.001745594
furyl I-Chemical 0 0.9700061
) I-Chemical 0 0.0058485684
- I-Chemical 0 0.0016850196
2 I-Chemical 0 0.00073395675
- I-Chemical 0 0.0016926563
thiazolyl I-Chemical 0 0.9987872
] I-Chemical 0 0.040540777
- I-Chemical 0 0.0075942706
formamide I-Chemical 0 0.9686919
( O 0 0.007872891
FANFT B-Chemical 1 0.9999136
) O 0 0.00199008
to O 0 0.00044505505
rats O 0 0.001202938
resulted O 0 0.00039041048
in O 0 0.00042301003
a O 0 0.00070678163
reduced O 0 0.0006281395
incidence O 0 0.015284362
of O 0 0.003891058
FANFT B-Chemical 1 0.9999628
- O 0 0.008513347
induced O 0 0.0017875578
bladder B-Disease 0 0.9982345
carcinomas I-Disease 0 0.9995993
but O 0 0.0018948752
a O 0 0.0021019953
concomitant O 0 0.005369219
induction O 0 0.0032806713
of O 0 0.010421288
forestomach B-Disease 0 0.99952924
tumors I-Disease 2 0.999158
. O 0 0.015121117

An O 0 0.012819742
autoradiographic O 0 0.010390942
study O 0 0.0048777014
was O 0 0.0029794814
performed O 0 0.0019678543
on O 0 0.0015029407
male O 0 0.011609743
F O 0 0.66107905
- O 0 0.0039433385
344 O 0 0.027860427
rats O 0 0.0023698818
fed O 0 0.0014491755
diet O 0 0.077455826
containing O 0 0.001192822
FANFT B-Chemical 1 0.9998265
at O 0 0.00051267404
a O 0 0.0006660339
level O 0 0.00033425627
of O 0 0.00058486813
0 O 0 0.00079909037
. O 0 0.0003290965
2 O 0 0.00039726516
% O 0 0.00046394736
and O 0 0.00047956526
/ O 0 0.0012596799
or O 0 0.00053039857
aspirin B-Chemical 1 0.99988735
at O 0 0.00035385278
a O 0 0.00049528515
level O 0 0.00025924944
of O 0 0.00047288192
0 O 0 0.0006573412
. O 0 0.00027415055
5 O 0 0.00028592165
% O 0 0.00033938457
to O 0 0.00023337583
evaluate O 0 0.00018187724
the O 0 0.000333813
effect O 0 0.00040984715
of O 0 0.00086778955
aspirin B-Chemical 1 0.9999418
on O 0 0.00046291214
the O 0 0.0006973326
increased O 0 0.0012920615
cell O 0 0.058466636
proliferation O 0 0.8639069
induced O 0 0.0025405004
by O 0 0.0044372166
FANFT B-Chemical 1 0.9998153
in O 0 0.0022717975
the O 0 0.0033314847
forestomach O 0 0.99104893
and O 0 0.010747982
bladder O 0 0.9754371
. O 0 0.011270612

FANFT B-Chemical 1 0.9990305
- O 0 0.01843662
induced O 0 0.006236769
cell O 0 0.03680308
proliferation O 0 0.60431665
in O 0 0.0018290527
the O 0 0.0015231719
bladder O 0 0.8833359
was O 0 0.0013436057
significantly O 0 0.0014986335
suppressed O 0 0.0013218352
by O 0 0.0018705088
aspirin B-Chemical 1 0.9999734
co O 0 0.90148276
- O 0 0.0036496783
administration O 0 0.019291664
after O 0 0.0004942938
4 O 0 0.00069204625
weeks O 0 0.00062244013
but O 0 0.0009730222
not O 0 0.0012503725
after O 0 0.0013916792
12 O 0 0.0023881544
weeks O 0 0.0033796963
. O 0 0.0062894546

In O 0 0.008321025
the O 0 0.0069865715
forestomach O 0 0.9649475
, O 0 0.0053635375
and O 0 0.0026444911
also O 0 0.0018066491
in O 0 0.0013860428
the O 0 0.0015084386
liver O 0 0.9350979
, O 0 0.0054068947
aspirin B-Chemical 1 0.9999219
did O 0 0.0011942378
not O 0 0.00096078904
affect O 0 0.00076896936
the O 0 0.001879597
FANFT B-Chemical 1 0.9998797
- O 0 0.0062348326
induced O 0 0.0022406315
increase O 0 0.0020556916
in O 0 0.0030865446
labeling O 0 0.007076643
index O 0 0.0086856205
. O 0 0.008975841

The O 0 0.006676241
present O 0 0.0037973153
results O 0 0.0034032918
are O 0 0.002543798
consistent O 0 0.0016604244
with O 0 0.0014543025
the O 0 0.0013165802
carcinogenicity O 0 0.963639
experiment O 0 0.00069934514
suggesting O 0 0.0005222515
that O 0 0.0004504457
different O 0 0.0005077917
mechanisms O 0 0.0010303304
are O 0 0.00067978783
involved O 0 0.00054739945
in O 0 0.0008989978
FANFT B-Chemical 1 0.99994874
carcinogenesis B-Disease 2 0.9986278
in O 0 0.0006983122
the O 0 0.00064296636
bladder O 0 0.9325612
and O 0 0.0016213654
forestomach O 0 0.99618113
, O 0 0.0013173518
and O 0 0.00058677857
that O 0 0.00046504036
aspirin B-Chemical 1 0.99993
' O 0 0.0010526527
s O 0 0.0005602396
effect O 0 0.00041952907
on O 0 0.00042355395
FANFT B-Chemical 1 0.99979
in O 0 0.00059562357
the O 0 0.00077302754
forestomach O 0 0.98912305
is O 0 0.0007516469
not O 0 0.0005504177
due O 0 0.0004694967
to O 0 0.0006480686
an O 0 0.0016102745
irritant O 0 0.9944924
effect O 0 0.002206177
associated O 0 0.002826353
with O 0 0.003416797
increased O 0 0.0069179167
cell O 0 0.2666043
proliferation O 0 0.9489032
. O 0 0.011393504

Also O 0 0.011981368
, O 0 0.0074200486
there O 0 0.0033886363
appears O 0 0.002753445
to O 0 0.0022196115
be O 0 0.0019989905
an O 0 0.0020804529
adaptation O 0 0.0021412726
by O 0 0.0016055079
the O 0 0.0014017011
rats O 0 0.0028301415
to O 0 0.0015694414
the O 0 0.002402303
chronic O 0 0.95780224
ingestion O 0 0.9526194
of O 0 0.06279883
aspirin B-Chemical 1 0.99990094
. O 0 0.016585112

A O 0 0.051001526
case O 0 0.016338503
of O 0 0.023601266
tardive B-Disease 0 0.99995446
dyskinesia I-Disease 2 0.99996364
caused O 0 0.13458212
by O 0 0.087912485
metoclopramide B-Chemical 1 0.99988437
. O 0 0.028544541

Abnormal B-Disease 0 0.12848288
involuntary I-Disease 0 0.9393625
movements I-Disease 0 0.10690303
appeared O 0 0.0029068233
in O 0 0.0018435005
the O 0 0.0016786683
mouth O 0 0.14054847
, O 0 0.0023036166
tongue O 0 0.2285263
, O 0 0.0018809447
neck O 0 0.2725726
and O 0 0.001027709
abdomen O 0 0.07845604
of O 0 0.000807166
a O 0 0.0009774695
64 O 0 0.0012871895
- O 0 0.0008651105
year O 0 0.00048964407
- O 0 0.0006514867
old O 0 0.00046391183
male O 0 0.0012465364
patient O 0 0.0005832412
after O 0 0.00026389924
he O 0 0.00059542974
took O 0 0.0005451254
metoclopramide B-Chemical 1 0.99998116
for O 0 0.0006559488
gastrointestinal B-Disease 0 0.99977475
disorder I-Disease 0 0.9990544
in O 0 0.00065745844
a O 0 0.0007708406
regimen O 0 0.0011032742
of O 0 0.0005579173
30 O 0 0.00040248444
mg O 0 0.019736676
per O 0 0.000364686
day O 0 0.00051850086
for O 0 0.000584898
a O 0 0.001135926
total O 0 0.0012420731
of O 0 0.0020638676
about O 0 0.0026111903
260 O 0 0.012649736
days O 0 0.0043549594
. O 0 0.0070578344

The O 0 0.015588374
symptoms O 0 0.5094076
exacerbated O 0 0.026845926
to O 0 0.008406533
a O 0 0.009019141
maximum O 0 0.007518608
in O 0 0.007976584
a O 0 0.011749626
month O 0 0.010827372
. O 0 0.014417845

When O 0 0.007826472
the O 0 0.0069816876
metoclopramide B-Chemical 1 0.9998822
administration O 0 0.3347731
was O 0 0.0031633405
discontinued O 0 0.03288941
, O 0 0.002170682
the O 0 0.0014715442
abnormal B-Disease 0 0.06845875
movements I-Disease 0 0.026378978
gradually O 0 0.0037906074
improved O 0 0.0028741087
to O 0 0.0021683315
a O 0 0.0038127769
considerable O 0 0.0046408367
extent O 0 0.005441556
. O 0 0.009057892

Attention O 0 0.043321066
to O 0 0.0050593377
the O 0 0.0035395992
possible O 0 0.002644818
induction O 0 0.0022893255
of O 0 0.0025264989
specific O 0 0.0029179829
tardive B-Disease 0 0.999997
dyskinesia I-Disease 2 0.9999969
is O 0 0.0030922457
called O 0 0.0020874694
for O 0 0.0011068829
in O 0 0.0013067774
the O 0 0.0015857653
use O 0 0.0022515752
of O 0 0.0033980964
this O 0 0.0048388657
drug O 0 0.7660947
. O 0 0.010202821

Intra O 0 0.42164806
- O 0 0.013553043
arterial O 0 0.61175793
BCNU B-Chemical 1 0.9996402
chemotherapy O 0 0.79109764
for O 0 0.0025655765
treatment O 0 0.003701871
of O 0 0.0044970815
malignant B-Disease 0 0.9994727
gliomas I-Disease 0 0.9998709
of O 0 0.0055885026
the O 0 0.0040116436
central O 0 0.019402856
nervous O 0 0.97837836
system O 0 0.01608855
. O 0 0.010536442

Because O 0 0.0062946333
of O 0 0.00502222
the O 0 0.003399207
rapid O 0 0.0046400484
systemic O 0 0.79919696
clearance O 0 0.21817267
of O 0 0.0058605857
BCNU B-Chemical 1 0.9999685
( O 0 0.0045371996
1 B-Chemical 0 0.0011723528
, I-Chemical 0 0.0010717941
3 I-Chemical 0 0.0007840972
- I-Chemical 0 0.0016552157
bis I-Chemical 0 0.95390886
- I-Chemical 0 0.0032207111
( I-Chemical 0 0.001200432
2 I-Chemical 0 0.0007753194
- I-Chemical 0 0.0017117115
chloroethyl I-Chemical 0 0.99437696
) I-Chemical 0 0.008379974
- I-Chemical 0 0.0018659871
1 I-Chemical 0 0.00075721316
- I-Chemical 0 0.0014858708
nitrosourea I-Chemical 0 0.99925226
) O 0 0.0040175715
, O 0 0.00082935044
intra O 0 0.019632598
- O 0 0.0010674115
arterial O 0 0.25374317
administration O 0 0.011786759
should O 0 0.00023686234
provide O 0 0.00027609788
a O 0 0.00045372342
substantial O 0 0.00044705006
advantage O 0 0.00041228588
over O 0 0.00033190075
intravenous O 0 0.15110837
administration O 0 0.031534944
for O 0 0.0008899715
the O 0 0.0014217226
treatment O 0 0.0036256849
of O 0 0.008301517
malignant B-Disease 0 0.99959844
gliomas I-Disease 0 0.99985886
. O 0 0.015362781

Thirty O 0 0.01520579
- O 0 0.007538877
six O 0 0.0029144108
patients O 0 0.0038536063
were O 0 0.0019965302
treated O 0 0.0018030718
with O 0 0.0017407408
BCNU B-Chemical 1 0.99978536
every O 0 0.00056187465
6 O 0 0.00047018463
to O 0 0.00041088302
8 O 0 0.00041496457
weeks O 0 0.00029704257
, O 0 0.00045362828
either O 0 0.00034228008
by O 0 0.0003943701
transfemoral O 0 0.0009644778
catheterization O 0 0.001520903
of O 0 0.00035250917
the O 0 0.00033647736
internal O 0 0.00052805594
carotid O 0 0.3173524
or O 0 0.00052242016
vertebral O 0 0.19193733
artery O 0 0.12206223
or O 0 0.00043974444
through O 0 0.00033646103
a O 0 0.00048353898
fully O 0 0.00032913164
implantable O 0 0.08741061
intracarotid O 0 0.97807765
drug O 0 0.4108035
delivery O 0 0.0010344776
system O 0 0.0009519513
, O 0 0.000665245
beginning O 0 0.00034217827
with O 0 0.0004834095
a O 0 0.00075011374
dose O 0 0.00263001
of O 0 0.0010868561
200 O 0 0.0029739777
mg O 0 0.30008456
/ O 0 0.0041685635
sq O 0 0.013048365
m O 0 0.007369201
body O 0 0.008434792
surface O 0 0.0076498906
area O 0 0.009545305
. O 0 0.008575332

Twelve O 0 0.015571911
patients O 0 0.010432949
with O 0 0.0062094196
Grade O 0 0.87068135
III O 0 0.07747182
or O 0 0.00313032
IV O 0 0.6419236
astrocytomas B-Disease 0 0.9994648
were O 0 0.0015930239
treated O 0 0.0012199816
after O 0 0.0006495536
partial O 0 0.0012505363
resection O 0 0.00361673
of O 0 0.0014102402
the O 0 0.0016127081
tumor B-Disease 2 0.8232989
without O 0 0.0024446782
prior O 0 0.0025671609
radiation O 0 0.3704612
therapy O 0 0.13351633
. O 0 0.009718705

After O 0 0.0054409597
two O 0 0.003776527
to O 0 0.0027198517
seven O 0 0.0019770453
cycles O 0 0.0016012372
of O 0 0.0017873631
chemotherapy O 0 0.57657456
, O 0 0.0016840412
nine O 0 0.0008910108
patients O 0 0.0016117287
showed O 0 0.00059103424
a O 0 0.00090327294
decrease O 0 0.0006641139
in O 0 0.0006776232
tumor B-Disease 2 0.8348325
size O 0 0.0013035228
and O 0 0.0010770096
surrounding O 0 0.0025746247
edema B-Disease 2 0.9997682
on O 0 0.0011023679
contrast O 0 0.0019491191
- O 0 0.0037273068
enhanced O 0 0.0026939309
computerized O 0 0.020987378
tomography O 0 0.29062042
scans O 0 0.015834777
. O 0 0.008706334

In O 0 0.0070304084
the O 0 0.0047518634
nine O 0 0.0035012164
responders O 0 0.0053157364
, O 0 0.0021442529
median O 0 0.0011628962
duration O 0 0.0011469639
of O 0 0.0012090857
chemotherapy O 0 0.45018163
response O 0 0.0012158204
from O 0 0.00065551203
the O 0 0.0005075069
time O 0 0.00038610815
of O 0 0.0005479572
operation O 0 0.00067785475
was O 0 0.00055032043
25 O 0 0.0007019502
weeks O 0 0.00043961575
( O 0 0.000802311
range O 0 0.0008397814
12 O 0 0.0006093224
to O 0 0.0007690214
more O 0 0.001259542
than O 0 0.0013304447
91 O 0 0.0038107669
weeks O 0 0.0026486923
) O 0 0.0071347347
. O 0 0.0070152692

The O 0 0.0062467894
median O 0 0.004255969
duration O 0 0.0033889702
of O 0 0.0028405234
survival O 0 0.016643003
in O 0 0.0014379559
the O 0 0.0010943188
12 O 0 0.0007088451
patients O 0 0.0012196836
was O 0 0.00063043204
54 O 0 0.00093427056
weeks O 0 0.00039527024
( O 0 0.0006183977
range O 0 0.0005753529
21 O 0 0.00049475295
to O 0 0.00033860476
more O 0 0.00044678588
than O 0 0.00034216783
156 O 0 0.0015316914
weeks O 0 0.00039931893
) O 0 0.0009481225
, O 0 0.00070431933
with O 0 0.0006025547
an O 0 0.0009700817
18 O 0 0.00091498677
- O 0 0.0012090723
month O 0 0.00084402127
survival O 0 0.0053926483
rate O 0 0.0019475123
of O 0 0.0034814202
42 O 0 0.006271041
% O 0 0.0071607884
. O 0 0.007675552

Twenty O 0 0.014496875
- O 0 0.007934908
four O 0 0.0033124113
patients O 0 0.0043808804
with O 0 0.002737007
recurrent O 0 0.7553235
Grade O 0 0.9751439
I O 0 0.030238062
to O 0 0.0014142483
IV O 0 0.6602755
astrocytomas B-Disease 0 0.999744
, O 0 0.0015110889
whose O 0 0.0010063149
resection O 0 0.0063048517
and O 0 0.00081860804
irradiation O 0 0.017695796
therapy O 0 0.007122035
had O 0 0.0005831595
failed O 0 0.0006652169
, O 0 0.0006952795
received O 0 0.00043558734
two O 0 0.00042795422
to O 0 0.00049962534
eight O 0 0.0005603598
courses O 0 0.001255503
of O 0 0.0015006498
intra O 0 0.06291191
- O 0 0.006966556
arterial O 0 0.901116
BCNU B-Chemical 1 0.9998565
therapy O 0 0.13771936
. O 0 0.00929194

Seventeen O 0 0.015967375
of O 0 0.006214633
these O 0 0.004310221
had O 0 0.0027674837
a O 0 0.0026408965
response O 0 0.0021513393
or O 0 0.0013372627
were O 0 0.0010389597
stable O 0 0.0008635066
for O 0 0.0005418794
a O 0 0.00073335756
median O 0 0.00053456804
of O 0 0.0006975692
20 O 0 0.0006841697
weeks O 0 0.00049679447
( O 0 0.0008814402
range O 0 0.000911818
6 O 0 0.0006640225
to O 0 0.0008103981
more O 0 0.0012977904
than O 0 0.0013480206
66 O 0 0.0037038499
weeks O 0 0.0027245507
) O 0 0.007333969
. O 0 0.007118533

The O 0 0.0082495
catheterization O 0 0.012801259
procedure O 0 0.005098195
is O 0 0.0037246803
safe O 0 0.004986011
, O 0 0.0030276405
with O 0 0.001956041
no O 0 0.0015965049
immediate O 0 0.0036628298
complication O 0 0.30200624
in O 0 0.0032000535
111 O 0 0.028148277
infusions O 0 0.09287147
of O 0 0.0109949345
BCNU B-Chemical 1 0.9997317
. O 0 0.01261397

A O 0 0.038823754
delayed O 0 0.015333769
complication O 0 0.17207293
in O 0 0.0036399968
nine O 0 0.0029295986
patients O 0 0.004401807
has O 0 0.0018263533
been O 0 0.001968467
unilateral O 0 0.09945635
loss B-Disease 0 0.005361391
of I-Disease 0 0.0027597775
vision I-Disease 0 0.6906487
secondary O 0 0.0069385534
to O 0 0.0029571152
a O 0 0.0071316045
retinal B-Disease 0 0.9760838
vasculitis I-Disease 2 0.9998037
. O 0 0.016849464

The O 0 0.007634215
frequency O 0 0.0060296147
of O 0 0.0054979157
visual B-Disease 2 0.3855846
loss I-Disease 2 0.012100363
decreased O 0 0.003086354
after O 0 0.0012409186
the O 0 0.0015416737
concentration O 0 0.0026577974
of O 0 0.0026193946
the O 0 0.0035751334
ethanol B-Chemical 1 0.9986473
diluent O 0 0.7130191
was O 0 0.0075669754
lowered O 0 0.03183051
. O 0 0.010246483

Provocation O 0 0.7655534
of O 0 0.018106772
postural O 0 0.9957684
hypotension B-Disease 2 0.99993324
by O 0 0.07638511
nitroglycerin B-Chemical 1 0.9999583
in O 0 0.031230977
diabetic B-Disease 2 0.99958163
autonomic I-Disease 0 0.9996474
neuropathy I-Disease 2 0.9999424
? O 0 0.30825666

The O 0 0.006729281
effect O 0 0.004508303
of O 0 0.004964655
nitroglycerin B-Chemical 1 0.99992836
on O 0 0.0018618992
heart O 0 0.43332443
rate O 0 0.0012894861
and O 0 0.0012429801
systolic O 0 0.6277516
blood O 0 0.009718568
pressure O 0 0.027604215
was O 0 0.00048369437
compared O 0 0.00028075813
in O 0 0.0003681968
5 O 0 0.00035596793
normal O 0 0.0006146755
subjects O 0 0.0008198582
, O 0 0.0006317394
12 O 0 0.00037590417
diabetic B-Disease 2 0.8884532
subjects O 0 0.0012548508
without O 0 0.0009705506
autonomic B-Disease 2 0.9994518
neuropathy I-Disease 2 0.9999877
, O 0 0.0031484654
and O 0 0.0014999334
5 O 0 0.0013670523
diabetic B-Disease 2 0.97007936
subjects O 0 0.0053861644
with O 0 0.005703657
autonomic B-Disease 2 0.9993729
neuropathy I-Disease 2 0.9999275
. O 0 0.013919843

The O 0 0.0066634337
magnitude O 0 0.0042929994
and O 0 0.0034208084
time O 0 0.001994375
course O 0 0.0018171394
of O 0 0.0014894549
the O 0 0.0010724693
increase O 0 0.0007301904
in O 0 0.00071514794
heart O 0 0.32827237
rate O 0 0.00066178635
and O 0 0.00063094246
the O 0 0.0004695652
decrease O 0 0.00044916745
in O 0 0.00042596678
systolic O 0 0.6003831
blood O 0 0.007474098
pressure O 0 0.03350276
after O 0 0.00033231676
nitroglycerin B-Chemical 1 0.99998426
were O 0 0.0004483286
similar O 0 0.00024619154
in O 0 0.00030254936
the O 0 0.00035718168
normal O 0 0.00091949984
and O 0 0.00067068596
diabetic B-Disease 2 0.9872773
subjects O 0 0.0020525693
without O 0 0.0008968513
autonomic B-Disease 2 0.99964416
neuropathy I-Disease 2 0.99999344
, O 0 0.0019934278
whereas O 0 0.00046518442
a O 0 0.0006849715
lesser O 0 0.0009718895
increase O 0 0.00033580567
in O 0 0.00039536445
heart O 0 0.32364637
rate O 0 0.0004673187
and O 0 0.0005143238
a O 0 0.00056506455
greater O 0 0.0003909203
decrease O 0 0.00043931033
in O 0 0.00047690124
systolic O 0 0.5673133
blood O 0 0.006120304
pressure O 0 0.022265302
occurred O 0 0.0007939602
in O 0 0.00079624983
the O 0 0.0012891429
diabetic B-Disease 2 0.9869495
subjects O 0 0.0070900475
with O 0 0.0064977286
autonomic B-Disease 2 0.9994491
neuropathy I-Disease 2 0.9999317
. O 0 0.014188363

It O 0 0.010081455
is O 0 0.005122232
therefore O 0 0.0035347657
suggested O 0 0.00219734
that O 0 0.0015065925
caution O 0 0.0015898645
should O 0 0.00081883895
be O 0 0.00093491276
exercised O 0 0.0017715659
when O 0 0.0005725771
prescribing O 0 0.024238637
vasodilator O 0 0.99859506
drugs O 0 0.8859149
in O 0 0.001439356
diabetic B-Disease 2 0.9957516
patients O 0 0.016225014
, O 0 0.0022015206
particularly O 0 0.002190738
those O 0 0.0032611722
with O 0 0.0056838477
autonomic B-Disease 2 0.99938846
neuropathy I-Disease 2 0.99992967
. O 0 0.014361057

Blood O 0 0.06900624
pressure O 0 0.026637938
response O 0 0.0068262815
to O 0 0.0045739724
chronic O 0 0.8421267
low O 0 0.0070486707
- O 0 0.0063903914
dose O 0 0.06499373
intrarenal O 0 0.996182
noradrenaline B-Chemical 1 0.9999374
infusion O 0 0.10226913
in O 0 0.0042365757
conscious O 0 0.07955469
rats O 0 0.017673275
. O 0 0.00972166

Sodium B-Chemical 0 0.9997831
chloride I-Chemical 0 0.9997105
solution O 0 0.21566935
( O 0 0.006015941
0 O 0 0.00297769
. O 0 0.0012879155
9 O 0 0.0012134964
% O 0 0.0012890962
) O 0 0.0014641407
or O 0 0.0009590696
noradrenaline B-Chemical 1 0.99986315
in O 0 0.00063920213
doses O 0 0.007604944
of O 0 0.0007471514
4 O 0 0.00051817455
, O 0 0.0005125905
12 O 0 0.00026464526
and O 0 0.00033606542
36 O 0 0.00038852033
micrograms O 0 0.025781993
h O 0 0.00040949218
- O 0 0.0007414087
1 O 0 0.00042606625
kg O 0 0.0023959843
- O 0 0.00073721743
1 O 0 0.0003585494
was O 0 0.0002778142
infused O 0 0.00046116277
for O 0 0.00020999038
five O 0 0.00020689951
consecutive O 0 0.0003386958
days O 0 0.00030902022
, O 0 0.00054232887
either O 0 0.0005150678
intrarenally O 0 0.87725097
( O 0 0.000892366
by O 0 0.00050894683
a O 0 0.0006185262
new O 0 0.0006955571
technique O 0 0.0010752386
) O 0 0.0012095562
or O 0 0.0006689853
intravenously O 0 0.001814158
into O 0 0.00074968114
rats O 0 0.0024567167
with O 0 0.0021256793
one O 0 0.002930345
kidney O 0 0.816956
removed O 0 0.007511693
. O 0 0.009390513

Intrarenal O 0 0.866441
infusion O 0 0.05211908
of O 0 0.010013982
noradrenaline B-Chemical 1 0.9998654
caused O 0 0.014197997
hypertension B-Disease 2 0.9998976
at O 0 0.0018496063
doses O 0 0.025476333
which O 0 0.001909476
did O 0 0.0012693257
not O 0 0.0012862349
do O 0 0.00140581
so O 0 0.0017851482
when O 0 0.0020332006
infused O 0 0.0075471476
intravenously O 0 0.017423265
. O 0 0.008295665

Intrarenal O 0 0.724131
compared O 0 0.003940068
with O 0 0.0032743688
intravenous O 0 0.33547786
infusion O 0 0.0511462
of O 0 0.005026675
noradrenaline B-Chemical 1 0.9999616
caused O 0 0.0027116034
higher O 0 0.001420004
plasma O 0 0.31474325
noradrenaline B-Chemical 1 0.99997604
concentrations O 0 0.0070827897
and O 0 0.00082542974
a O 0 0.0008276602
shift O 0 0.000763093
of O 0 0.0006005805
the O 0 0.00066527043
plasma O 0 0.13292874
noradrenaline B-Chemical 1 0.9999659
concentration O 0 0.0068307254
- O 0 0.0017929545
blood O 0 0.0060544107
pressure O 0 0.018588273
effect O 0 0.000841141
curve O 0 0.0018425867
towards O 0 0.0015302962
lower O 0 0.002438415
plasma O 0 0.29066
noradrenaline B-Chemical 1 0.99983525
levels O 0 0.0076012355
. O 0 0.008790519

These O 0 0.008102478
results O 0 0.0049662823
suggest O 0 0.0028648064
that O 0 0.0027637556
hypertension B-Disease 2 0.9997708
after O 0 0.0016846305
chronic O 0 0.976542
intrarenal O 0 0.9989863
noradrenaline B-Chemical 1 0.99998534
infusion O 0 0.10138898
is O 0 0.00074175565
produced O 0 0.0005613375
by O 0 0.00062714476
relatively O 0 0.00061768317
higher O 0 0.0004870013
levels O 0 0.0005316979
of O 0 0.0009857622
circulating O 0 0.077834435
noradrenaline B-Chemical 1 0.99996567
and O 0 0.0013787919
by O 0 0.0011125124
triggering O 0 0.002033818
of O 0 0.001463597
an O 0 0.0021037864
additional O 0 0.0017128387
intrarenal O 0 0.9838023
pressor O 0 0.99821496
mechanism O 0 0.011923777
. O 0 0.009800239

Characterization O 0 0.0174528
of O 0 0.017418679
estrogen B-Chemical 1 0.9994235
- O 0 0.028616646
induced O 0 0.01008773
adenohypophyseal B-Disease 0 0.99352175
tumors I-Disease 2 0.9976628
in O 0 0.006421811
the O 0 0.0067591853
Fischer O 0 0.6107525
344 O 0 0.13407019
rat O 0 0.022406286
. O 0 0.011814157

Pituitary B-Disease 0 0.9781172
tumors I-Disease 2 0.98892844
were O 0 0.005458884
induced O 0 0.0035973573
in O 0 0.0024920201
F344 O 0 0.45922816
female O 0 0.014699703
rats O 0 0.0053703235
by O 0 0.0018234295
chronic O 0 0.93343866
treatment O 0 0.008876733
with O 0 0.0052364
diethylstilbestrol B-Chemical 1 0.99998796
( O 0 0.027972583
DES B-Chemical 1 0.9997323
, O 0 0.0017916561
8 O 0 0.000922755
- O 0 0.0011434049
10 O 0 0.0008241805
mg O 0 0.081545316
) O 0 0.0018798799
implanted O 0 0.0023989892
subcutaneously O 0 0.0035483572
in O 0 0.0028203856
silastic O 0 0.078374
capsules O 0 0.22382623
. O 0 0.009770428

Over O 0 0.009936288
a O 0 0.0065773814
range O 0 0.0047068982
of O 0 0.0035793195
1 O 0 0.002767243
- O 0 0.0023355538
150 O 0 0.0015038463
days O 0 0.0007350137
of O 0 0.0011557939
DES B-Chemical 1 0.998575
treatment O 0 0.0018816986
, O 0 0.0009833346
pairs O 0 0.0005927504
of O 0 0.0006255506
control O 0 0.000650442
and O 0 0.0011800155
DES B-Chemical 1 0.99974066
- O 0 0.0018493693
treated O 0 0.00076719554
rats O 0 0.0014807688
were O 0 0.00054953626
sacrificed O 0 0.00052114925
, O 0 0.000809391
and O 0 0.0007468555
their O 0 0.00094299455
pituitaries O 0 0.05598929
dissociated O 0 0.0029272395
enzymatically O 0 0.023195824
into O 0 0.0012218731
single O 0 0.0026335556
- O 0 0.005131265
cell O 0 0.015483333
preparations O 0 0.024020465
. O 0 0.009490643

The O 0 0.0078078546
cell O 0 0.010492303
populations O 0 0.0048794816
were O 0 0.0023584731
examined O 0 0.0012960728
regarding O 0 0.0010720892
total O 0 0.0011964774
cell O 0 0.005041949
recovery O 0 0.0024247617
correlated O 0 0.00074008654
with O 0 0.000998258
gland O 0 0.5271913
weight O 0 0.049769953
, O 0 0.0019842705
intracellular O 0 0.04504111
prolactin O 0 0.99949634
( O 0 0.019008694
PRL O 0 0.99989283
) O 0 0.0022178243
content O 0 0.00050944975
and O 0 0.0005407896
subsequent O 0 0.00056644826
release O 0 0.014323808
in O 0 0.00040338677
primary O 0 0.00065352325
culture O 0 0.0017729931
, O 0 0.0009296188
immunocytochemical O 0 0.011142123
PRL O 0 0.99966896
staining O 0 0.0011250618
, O 0 0.00082033576
density O 0 0.00073464
and O 0 0.00066277484
/ O 0 0.001557043
or O 0 0.0004253776
size O 0 0.0006171153
alterations O 0 0.0017934596
via O 0 0.00040710115
separation O 0 0.0009406705
on O 0 0.00042111217
Ficoll O 0 0.9630467
- O 0 0.005051785
Hypaque O 0 0.9989219
and O 0 0.0006282057
by O 0 0.00050231256
unit O 0 0.00039600363
gravity O 0 0.006174713
sedimentation O 0 0.009892756
, O 0 0.0009622002
and O 0 0.0007102502
cell O 0 0.0062172785
cycle O 0 0.0029865424
analysis O 0 0.0009788509
, O 0 0.0010135057
after O 0 0.00058889604
acriflavine B-Chemical 0 0.99131244
DNA O 0 0.13107151
staining O 0 0.0025220814
, O 0 0.002620911
by O 0 0.0025527573
laser O 0 0.010645397
flow O 0 0.011509352
cytometry O 0 0.0068071703
. O 0 0.008390152

Total O 0 0.0131369205
cell O 0 0.013262668
yields O 0 0.006386692
from O 0 0.004709012
DES B-Chemical 1 0.99912184
- O 0 0.005439255
treated O 0 0.002080716
pituitaries O 0 0.0843196
increased O 0 0.0013746944
from O 0 0.0009265953
1 O 0 0.0008075975
. O 0 0.0004075927
3 O 0 0.0003653468
times O 0 0.00026614196
control O 0 0.00034430707
yields O 0 0.00047367686
at O 0 0.00029815707
8 O 0 0.00032290563
days O 0 0.00026186407
of O 0 0.00044836514
treatment O 0 0.00073039194
to O 0 0.00055427593
58 O 0 0.0011646487
. O 0 0.0005127571
9 O 0 0.0006766791
times O 0 0.0006011846
control O 0 0.0010102426
values O 0 0.0015768703
by O 0 0.0024719913
day O 0 0.0031858208
150 O 0 0.0074946526
. O 0 0.006814996

Intracellular O 0 0.1071783
PRL O 0 0.9964637
content O 0 0.0048800814
ranged O 0 0.003892411
from O 0 0.0023208938
1 O 0 0.0017593027
. O 0 0.00094656734
9 O 0 0.0008344721
to O 0 0.000609548
9 O 0 0.0006615685
. O 0 0.00039881974
4 O 0 0.00036642654
times O 0 0.0002830113
control O 0 0.0004036864
levels O 0 0.0005182897
, O 0 0.0009498702
and O 0 0.0011438216
PRL O 0 0.9998004
release O 0 0.05495379
in O 0 0.0005266134
vitro O 0 0.00086482405
was O 0 0.00048045247
significantly O 0 0.00059419044
and O 0 0.00053232163
consistently O 0 0.00044986253
higher O 0 0.0004212009
than O 0 0.00037115815
controls O 0 0.0010694268
, O 0 0.00075731997
after O 0 0.00038826338
at O 0 0.00051730796
least O 0 0.0005916554
8 O 0 0.0010300541
days O 0 0.0012688544
of O 0 0.003492762
DES B-Chemical 1 0.9983134
exposure O 0 0.024178265
. O 0 0.009923771

Beyond O 0 0.0146785015
8 O 0 0.0054693655
days O 0 0.0032685103
of O 0 0.0037861534
DES B-Chemical 1 0.9972262
exposure O 0 0.008408576
, O 0 0.0027170544
the O 0 0.0016670717
immunochemically O 0 0.717645
PRL O 0 0.99982786
- O 0 0.0020570925
positive O 0 0.0007647411
proportion O 0 0.0005858124
of O 0 0.00088983285
cells O 0 0.0015602211
increased O 0 0.0010206461
to O 0 0.00077489094
over O 0 0.00066975696
50 O 0 0.0015044379
% O 0 0.001511792
of O 0 0.0017523359
the O 0 0.0023186707
total O 0 0.0036662717
population O 0 0.009428564
. O 0 0.008148233

Increased O 0 0.011958687
density O 0 0.007569822
and O 0 0.005290661
/ O 0 0.006198751
or O 0 0.0024204624
size O 0 0.002830042
and O 0 0.002785949
PRL O 0 0.9994136
content O 0 0.001355623
were O 0 0.00085838017
indicated O 0 0.0005670538
for O 0 0.0004747766
the O 0 0.00054251915
majority O 0 0.0006943378
of O 0 0.0009925537
the O 0 0.0013902024
PRL O 0 0.99971646
cell O 0 0.019892538
population O 0 0.002639037
in O 0 0.0011117688
both O 0 0.0013440574
types O 0 0.0019726697
of O 0 0.0033379537
separation O 0 0.008003449
protocols O 0 0.007922366
. O 0 0.008762741

All O 0 0.010491343
these O 0 0.008380866
effects O 0 0.0076464238
of O 0 0.0075633163
DES B-Chemical 1 0.99768627
were O 0 0.004697411
more O 0 0.004046286
pronounced O 0 0.0044860374
among O 0 0.0049153734
previously O 0 0.00614642
ovariectomized O 0 0.7898632
animals O 0 0.009221822
. O 0 0.011604513

The O 0 0.007346519
data O 0 0.0059020785
extend O 0 0.0032515808
the O 0 0.002482775
findings O 0 0.0028564183
of O 0 0.0019526986
other O 0 0.0015001247
investigators O 0 0.0016471517
, O 0 0.0012017929
further O 0 0.0007438283
establishing O 0 0.0010146941
the O 0 0.0010907671
DES B-Chemical 1 0.9996896
- O 0 0.0027722374
induced O 0 0.0010818348
tumor B-Disease 2 0.9083514
as O 0 0.0010114782
a O 0 0.0011824736
model O 0 0.0010546965
for O 0 0.00087936653
study O 0 0.0017831662
of O 0 0.0034208097
PRL O 0 0.9995666
cellular O 0 0.05741988
control O 0 0.005458974
mechanisms O 0 0.01073735
. O 0 0.009365751

Age O 0 0.24368878
and O 0 0.03197571
renal O 0 0.9564096
clearance O 0 0.4149529
of O 0 0.060068913
cimetidine B-Chemical 1 0.99974126
. O 0 0.04266871

In O 0 0.007834371
35 O 0 0.0061004986
patients O 0 0.006377691
( O 0 0.0038208193
ages O 0 0.0026009823
20 O 0 0.0015282735
to O 0 0.0010695613
86 O 0 0.0016981419
yr O 0 0.0020041447
) O 0 0.0014950921
receiving O 0 0.0021363744
cimetidine B-Chemical 1 0.99998724
therapeutically O 0 0.15997855
two O 0 0.00064039
serum O 0 0.06586086
samples O 0 0.00070846285
and O 0 0.0005781058
all O 0 0.00043735196
urine O 0 0.08456872
formed O 0 0.0006276057
in O 0 0.00041521734
the O 0 0.00043734632
interim O 0 0.0022086431
were O 0 0.00040719277
collected O 0 0.0003351267
for O 0 0.0003416805
analysis O 0 0.0006742769
of O 0 0.0012212243
cimetidine B-Chemical 1 0.99998736
by O 0 0.001694742
high O 0 0.0019699512
- O 0 0.0027793106
pressure O 0 0.040075433
liquid O 0 0.007260708
chromatography O 0 0.015608693
and O 0 0.003563765
for O 0 0.004311033
creatinine B-Chemical 1 0.9955123
. O 0 0.009687548

Cimetidine B-Chemical 0 0.99846125
clearance O 0 0.4148402
decreased O 0 0.039946713
with O 0 0.032503262
age O 0 0.05052462
. O 0 0.033850912

The O 0 0.0075665205
extrapolated O 0 0.0059791165
6 O 0 0.0035987967
- O 0 0.003672087
hr O 0 0.0022169845
serum O 0 0.016636807
concentration O 0 0.0023000643
of O 0 0.0019058171
cimetidine B-Chemical 1 0.9999788
per O 0 0.0006958061
unit O 0 0.00069790904
dose O 0 0.0073367325
, O 0 0.0010048767
after O 0 0.0004708906
intravenous O 0 0.6936025
cimetidine B-Chemical 1 0.99999034
, O 0 0.002979875
increased O 0 0.0016814298
with O 0 0.0018159229
age O 0 0.0042111888
of O 0 0.0031984579
the O 0 0.0042818524
patients O 0 0.019048564
. O 0 0.008703325

The O 0 0.00739152
ratio O 0 0.006272473
of O 0 0.006328263
cimetidine B-Chemical 1 0.9999454
clearance O 0 0.40289068
to O 0 0.0028681047
creatinine B-Chemical 1 0.998743
clearance O 0 0.2941285
( O 0 0.0032662894
Rc O 0 0.5815347
) O 0 0.0013386543
averaged O 0 0.00054650306
4 O 0 0.0005060565
. O 0 0.00039911436
8 O 0 0.00051529246
+ O 0 0.0006786608
/ O 0 0.0016088777
- O 0 0.0010474629
2 O 0 0.00063078455
. O 0 0.00052164646
0 O 0 0.00090372877
, O 0 0.0009739083
indicating O 0 0.0008940281
net O 0 0.002211868
tubular O 0 0.5562191
secretion O 0 0.1831542
for O 0 0.007432934
cimetidine B-Chemical 1 0.9999428
. O 0 0.013766383

Rc O 0 0.3467756
seemed O 0 0.0071411254
to O 0 0.0038449792
be O 0 0.0026918238
independent O 0 0.0017641329
of O 0 0.0017898098
age O 0 0.0031332076
and O 0 0.0014874629
decreased O 0 0.0016479319
with O 0 0.0010260894
increasing O 0 0.0014406932
serum O 0 0.19226481
concentration O 0 0.004866609
of O 0 0.0042371647
cimetidine B-Chemical 1 0.999995
, O 0 0.002770037
suggesting O 0 0.0007402452
that O 0 0.00083981355
secretion O 0 0.026100146
of O 0 0.004738626
cimetidine B-Chemical 1 0.99998295
is O 0 0.0036580558
a O 0 0.005463424
saturable O 0 0.16171782
process O 0 0.0072467397
. O 0 0.008864218

There O 0 0.008433629
was O 0 0.0050646453
only O 0 0.0032015778
one O 0 0.0022104923
case O 0 0.001976135
of O 0 0.0027323281
dementia B-Disease 2 0.9995036
possibly O 0 0.008981676
due O 0 0.00093525386
to O 0 0.0012734071
cimetidine B-Chemical 1 0.9999938
( O 0 0.0026794358
with O 0 0.00067449774
a O 0 0.0008130826
drug O 0 0.19933414
level O 0 0.00033719538
of O 0 0.00058271334
1 O 0 0.0005449155
. O 0 0.0002844065
9 O 0 0.00037243453
microgram O 0 0.040516246
/ O 0 0.0010434986
ml O 0 0.0010189037
6 O 0 0.00026860164
hr O 0 0.00032022287
after O 0 0.00018793928
a O 0 0.0004379013
dose O 0 0.004459912
) O 0 0.00085055106
in O 0 0.00031156224
a O 0 0.00046136632
group O 0 0.00042639725
of O 0 0.00046568716
13 O 0 0.00052876107
patients O 0 0.00085916417
without O 0 0.00048767065
liver B-Disease 0 0.8191372
or I-Disease 0 0.00092533464
kidney I-Disease 0 0.94194394
disease I-Disease 0 0.86147255
who O 0 0.005293158
had O 0 0.0012458753
cimetidine B-Chemical 1 0.9999846
levels O 0 0.0011340171
above O 0 0.0009484744
1 O 0 0.0014012855
. O 0 0.0011579429
25 O 0 0.0025209324
microgram O 0 0.14034805
/ O 0 0.009880383
ml O 0 0.015626997
. O 0 0.008450197

Thus O 0 0.013029612
, O 0 0.01158235
high O 0 0.010337329
cimetidine B-Chemical 1 0.999866
levels O 0 0.0068423743
alone O 0 0.0056758663
do O 0 0.00442854
not O 0 0.0048303814
always O 0 0.006822513
induce O 0 0.008809519
dementia B-Disease 2 0.99917126
. O 0 0.015594887

Further O 0 0.011793705
observations O 0 0.008828684
on O 0 0.0055540237
the O 0 0.005683268
electrophysiologic O 0 0.27467492
effects O 0 0.008405104
of O 0 0.009119276
oral O 0 0.9741029
amiodarone B-Chemical 1 0.99994695
therapy O 0 0.5476295
. O 0 0.016130874

A O 0 0.02932494
case O 0 0.006156279
is O 0 0.0038135012
presented O 0 0.0028170764
of O 0 0.0024000702
a O 0 0.002649776
reversible O 0 0.2556036
intra B-Disease 0 0.15535769
- I-Disease 0 0.0042641205
Hisian I-Disease 0 0.202106
block I-Disease 0 0.0011532651
occurring O 0 0.001170559
under O 0 0.00066339975
amiodarone B-Chemical 1 0.99997556
treatment O 0 0.0021451612
for O 0 0.00087340013
atrial B-Disease 0 0.9990263
tachycardia I-Disease 2 0.99995136
in O 0 0.0010278712
a O 0 0.0013530382
patient O 0 0.0015774694
without O 0 0.0014374896
clear O 0 0.0025733672
intraventricular B-Disease 0 0.99244314
conduction I-Disease 0 0.60791284
abnormalities I-Disease 0 0.67083836
. O 0 0.009182315

His O 0 0.016501835
bundle O 0 0.011183208
recordings O 0 0.008203973
showed O 0 0.002926808
an O 0 0.0040163733
atrial B-Disease 0 0.9965354
tachycardia I-Disease 2 0.9999155
with O 0 0.00220649
intermittent O 0 0.12090869
exit O 0 0.0063314233
block O 0 0.0013480487
and O 0 0.0009842147
greatly O 0 0.002889611
prolonged O 0 0.012528445
BH O 0 0.5069122
and O 0 0.0013286594
HV O 0 0.235432
intervals O 0 0.0009432462
( O 0 0.0012925606
40 O 0 0.0010425722
and O 0 0.001332843
100 O 0 0.0028670453
msec O 0 0.06626762
, O 0 0.0040779505
respectively O 0 0.0064142332
) O 0 0.009354481
. O 0 0.0077333753

Thirty O 0 0.010989358
days O 0 0.004790061
after O 0 0.00340049
amiodarone B-Chemical 1 0.999826
discontinuation O 0 0.94511306
, O 0 0.0037228193
His O 0 0.0048276386
bundle O 0 0.003822531
electrograms O 0 0.25191697
showed O 0 0.001087373
atrial B-Disease 0 0.9353444
flutter I-Disease 0 0.9628649
without O 0 0.0015006593
intra O 0 0.050410073
- O 0 0.004081038
Hisian O 0 0.1871605
or O 0 0.0024804
infra O 0 0.008232947
- O 0 0.008593882
Hisian O 0 0.36560425
delay O 0 0.010858062
. O 0 0.009044471

Amiodarone B-Chemical 1 0.999374
should O 0 0.0050676498
be O 0 0.003693793
used O 0 0.0022079013
with O 0 0.0017248441
caution O 0 0.0016369901
during O 0 0.0009927166
long O 0 0.0013050745
- O 0 0.0015658232
term O 0 0.0008586256
oral O 0 0.3164609
therapy O 0 0.010937033
in O 0 0.0009084152
patients O 0 0.002507565
with O 0 0.0011271111
or O 0 0.0012298533
without O 0 0.001577523
clear O 0 0.0025939778
intraventricular O 0 0.974584
conduction O 0 0.42230186
defects O 0 0.009639104
. O 0 0.008610353

Development O 0 0.025572982
of O 0 0.010673326
clear B-Disease 0 0.009934185
cell I-Disease 0 0.04653847
adenocarcinoma I-Disease 0 0.99943143
in O 0 0.009798328
DES B-Chemical 1 0.9992268
- O 0 0.010164264
exposed O 0 0.004998043
offspring O 0 0.013303587
under O 0 0.005471365
observation O 0 0.008555697
. O 0 0.011407105

Two O 0 0.009109372
cases O 0 0.006949917
of O 0 0.004565663
clear B-Disease 0 0.0041738003
cell I-Disease 0 0.018794699
adenocarcinoma I-Disease 0 0.9995591
of I-Disease 0 0.0026076038
the I-Disease 0 0.0014545661
vagina I-Disease 0 0.07867763
detected O 0 0.00077667704
at O 0 0.0006725973
follow O 0 0.0006977018
- O 0 0.0011616322
up O 0 0.00066933065
in O 0 0.0007605307
young O 0 0.0045233252
women O 0 0.022273475
exposed O 0 0.0012414803
in O 0 0.0016168501
utero O 0 0.0638927
to O 0 0.003843471
diethylstilbestrol B-Chemical 1 0.99988484
are O 0 0.00782909
reported O 0 0.009842084
. O 0 0.0095125735

One O 0 0.011608156
patient O 0 0.008129344
, O 0 0.005237731
aged O 0 0.0044666133
23 O 0 0.0032359126
, O 0 0.0020393634
had O 0 0.0011587043
been O 0 0.0009864075
followed O 0 0.00063589134
for O 0 0.0005583636
2 O 0 0.0006246134
years O 0 0.00075032754
before O 0 0.00043335542
carcinoma B-Disease 2 0.9996326
was O 0 0.00092836533
diagnosed O 0 0.024806118
; O 0 0.001040964
the O 0 0.0004127119
second O 0 0.0004610702
patient O 0 0.00084366306
, O 0 0.00071612216
aged O 0 0.0009613897
22 O 0 0.00071627327
, O 0 0.00060108607
had O 0 0.00043246304
been O 0 0.0005034311
seen O 0 0.00042974154
on O 0 0.00039390323
a O 0 0.00078090496
regular O 0 0.0008429508
basis O 0 0.0009025055
for O 0 0.0009167294
5 O 0 0.0013437389
years O 0 0.0024166075
, O 0 0.0029930496
8 O 0 0.0031905642
months O 0 0.0039404985
. O 0 0.006600647

In O 0 0.0073319487
both O 0 0.0049326816
instances O 0 0.003358081
, O 0 0.0035745862
suspicion O 0 0.017704096
of O 0 0.0020758212
the O 0 0.0013927572
presence O 0 0.0012061347
of O 0 0.0023906
carcinoma B-Disease 2 0.9998579
was O 0 0.0017630785
aroused O 0 0.02603106
by O 0 0.001044384
the O 0 0.00091942796
palpation O 0 0.082819596
of O 0 0.0012142557
a O 0 0.0016404081
small O 0 0.0018945994
nodule O 0 0.29828182
in O 0 0.0024231432
the O 0 0.0034527357
vaginal O 0 0.23103511
fornix O 0 0.48797154
. O 0 0.009829633

Hysterosalpingography O 0 0.022418806
was O 0 0.0051703793
performed O 0 0.0029573415
on O 0 0.0019052221
both O 0 0.0017565632
patients O 0 0.0031247537
and O 0 0.0017559085
, O 0 0.0015473312
in O 0 0.00082005514
1 O 0 0.0007901385
instance O 0 0.00060541957
, O 0 0.00081499433
an O 0 0.0007941547
abnormal O 0 0.009566576
x O 0 0.004890875
- O 0 0.0020055843
ray O 0 0.057065956
film O 0 0.017909946
was O 0 0.0005748174
reflected O 0 0.00045347953
by O 0 0.00053728785
the O 0 0.000486611
gross O 0 0.0014735514
appearance O 0 0.0014852468
of O 0 0.0009192506
the O 0 0.0009986478
uterine O 0 0.5691239
cavity O 0 0.005256819
found O 0 0.0014858198
in O 0 0.001952323
the O 0 0.0027328788
surgical O 0 0.006190196
specimen O 0 0.008858602
. O 0 0.0092262365

Neurologic O 0 0.9487343
effects O 0 0.0089315465
of O 0 0.006425499
subarachnoid O 0 0.99905485
administration O 0 0.21567993
of O 0 0.0033625972
2 B-Chemical 0 0.0024774568
- I-Chemical 0 0.0052340357
chloroprocaine I-Chemical 0 0.9998971
- I-Chemical 0 0.013848043
CE I-Chemical 0 0.99550617
, O 0 0.003358292
bupivacaine B-Chemical 1 0.99993634
, O 0 0.0023321696
and O 0 0.0017124661
low O 0 0.00247994
pH O 0 0.3499908
normal O 0 0.0047828835
saline O 0 0.14512382
in O 0 0.0044143572
dogs O 0 0.014180423
. O 0 0.008800121

The O 0 0.006597037
purpose O 0 0.0048974752
of O 0 0.0036618763
this O 0 0.002470876
study O 0 0.0021427374
was O 0 0.0013101321
to O 0 0.00086691265
evaluate O 0 0.00054794416
the O 0 0.0009443599
neurologic O 0 0.9944037
consequences O 0 0.004301393
of O 0 0.0012060754
deliberate O 0 0.25026593
subarachnoid O 0 0.99956506
injection O 0 0.0026822812
of O 0 0.0007669744
large O 0 0.0008372343
volumes O 0 0.0018918234
of O 0 0.0010757089
2 B-Chemical 0 0.0013868118
- I-Chemical 0 0.0037549268
chloroprocaine I-Chemical 0 0.99981254
- I-Chemical 0 0.008777748
CE I-Chemical 0 0.9758507
in O 0 0.0026335795
experimental O 0 0.0043706163
animals O 0 0.005830003
. O 0 0.00829032

The O 0 0.007358954
possible O 0 0.0051317853
role O 0 0.0031648988
of O 0 0.003315059
low O 0 0.0036405863
pH O 0 0.22064494
as O 0 0.0015025537
well O 0 0.0010390468
as O 0 0.00096850033
total O 0 0.0009289963
volume O 0 0.001949007
as O 0 0.0010443729
potential O 0 0.0017124596
factors O 0 0.0067189913
in O 0 0.0022385684
causing O 0 0.07990841
neurotoxicity B-Disease 2 0.9998896
was O 0 0.0061812033
evaluated O 0 0.0065549356
. O 0 0.0090753315

The O 0 0.0073133423
65 O 0 0.005971329
dogs O 0 0.004928807
in O 0 0.002420742
the O 0 0.001817758
study O 0 0.0015312538
received O 0 0.001042386
injections O 0 0.0024106735
in O 0 0.0007388389
the O 0 0.0008612559
subarachnoid O 0 0.99886036
space O 0 0.0009232694
as O 0 0.0006273758
follows O 0 0.0013486377
: O 0 0.0007615486
6 O 0 0.00030208877
to O 0 0.00029155237
8 O 0 0.0003377182
ml O 0 0.00084981305
of O 0 0.0008072382
bupivacaine B-Chemical 1 0.9999784
( O 0 0.0033698669
N O 0 0.9717738
= O 0 0.0009519759
15 O 0 0.0004372465
) O 0 0.00080105435
, O 0 0.0006271991
2 B-Chemical 0 0.0005566096
- I-Chemical 0 0.0011958396
chloroprocaine I-Chemical 0 0.9998535
- I-Chemical 0 0.0049208337
CE I-Chemical 0 0.9946531
( O 0 0.0017360384
N O 0 0.9464292
= O 0 0.0009218762
20 O 0 0.00055410847
) O 0 0.0008445108
, O 0 0.0006126331
low O 0 0.0006679851
pH O 0 0.17184329
normal O 0 0.001374523
saline O 0 0.20840642
( O 0 0.0015148411
pH O 0 0.17856687
3 O 0 0.00051025837
. O 0 0.00036596906
0 O 0 0.0006757517
) O 0 0.00095518667
( O 0 0.0009925205
N O 0 0.85134995
= O 0 0.00096380577
20 O 0 0.00067297945
) O 0 0.0010509058
, O 0 0.0008458449
or O 0 0.00076735823
normal O 0 0.001989772
saline O 0 0.18056783
( O 0 0.0044062356
N O 0 0.94440556
= O 0 0.00450798
10 O 0 0.0039788196
) O 0 0.0076055597
. O 0 0.0071404856

Of O 0 0.009908181
the O 0 0.0051944414
20 O 0 0.0034629528
animals O 0 0.002155265
that O 0 0.0015393442
received O 0 0.0016970459
subarachnoid O 0 0.9980459
injection O 0 0.0044175033
of O 0 0.0016854111
2 B-Chemical 0 0.00156772
- I-Chemical 0 0.0033983223
chloroprocaine I-Chemical 0 0.9998771
- I-Chemical 0 0.005312991
CE I-Chemical 0 0.97475976
seven O 0 0.001045253
( O 0 0.0014994814
35 O 0 0.0011880611
% O 0 0.0015366012
) O 0 0.0023346373
developed O 0 0.0028816424
hind O 0 0.30006328
- O 0 0.009583837
limb O 0 0.71280277
paralysis B-Disease 2 0.9993063
. O 0 0.011767025

None O 0 0.012008427
of O 0 0.005746543
the O 0 0.0035061447
animals O 0 0.0023103291
that O 0 0.0016146624
received O 0 0.001988602
bupivacaine B-Chemical 1 0.99994683
, O 0 0.002630075
normal O 0 0.002264908
saline O 0 0.14843129
, O 0 0.0010861685
or O 0 0.00061749155
normal O 0 0.0012108128
saline O 0 0.047962558
titrated O 0 0.0012790681
to O 0 0.0006445531
a O 0 0.0012740823
pH O 0 0.16576284
3 O 0 0.0009350303
. O 0 0.0008076517
0 O 0 0.0014597968
developed O 0 0.002298101
hind O 0 0.2390787
- O 0 0.008620897
limb O 0 0.6937582
paralysis B-Disease 2 0.9993044
. O 0 0.011369837

Of O 0 0.010009477
the O 0 0.0053532557
15 O 0 0.0035362206
spinal O 0 0.013319495
cords O 0 0.008626445
of O 0 0.0017801581
the O 0 0.0011812599
animals O 0 0.00087913446
that O 0 0.0006890768
received O 0 0.000875652
2 B-Chemical 0 0.001091123
- I-Chemical 0 0.0025973532
chloroprocaine I-Chemical 0 0.9999026
- I-Chemical 0 0.007873002
CE I-Chemical 0 0.9917796
, O 0 0.0011329192
13 O 0 0.0008268514
showed O 0 0.0007084723
subpial B-Disease 0 0.9284581
necrosis I-Disease 2 0.9997521
; O 0 0.0047115176
the O 0 0.0013461788
nerve O 0 0.56195295
roots O 0 0.02936368
and O 0 0.0041191536
subarachnoid O 0 0.9994474
vessels O 0 0.313821
were O 0 0.0055284966
normal O 0 0.0096316915
. O 0 0.008416996

The O 0 0.0077375695
spinal O 0 0.028258635
cords O 0 0.014404861
of O 0 0.0030082862
the O 0 0.0018771369
animals O 0 0.0013164774
that O 0 0.0009906382
received O 0 0.0014248453
bupivacaine B-Chemical 1 0.99996424
, O 0 0.0024436552
low O 0 0.0015931968
pH O 0 0.39405277
normal O 0 0.0022599245
saline O 0 0.28620952
( O 0 0.001969143
pH O 0 0.20412973
3 O 0 0.00062306516
. O 0 0.00044621003
0 O 0 0.00078344066
) O 0 0.0009828522
, O 0 0.0007930763
or O 0 0.00068728044
normal O 0 0.0015726734
saline O 0 0.043389283
did O 0 0.0012910307
not O 0 0.001623886
show O 0 0.002274021
abnormal O 0 0.028730754
findings O 0 0.01411565
. O 0 0.00961725

Procainamide B-Chemical 0 0.9982974
- O 0 0.041500136
induced O 0 0.028555362
polymorphous O 0 0.9880476
ventricular B-Disease 2 0.9989483
tachycardia I-Disease 2 0.99962616
. O 0 0.039638266

Seven O 0 0.020581825
cases O 0 0.013015955
of O 0 0.012193272
procainamide B-Chemical 1 0.9998288
- O 0 0.016206468
induced O 0 0.008079396
polymorphous O 0 0.99312496
ventricular B-Disease 2 0.9996816
tachycardia I-Disease 2 0.9998869
are O 0 0.013192992
presented O 0 0.013317175
. O 0 0.01276591

In O 0 0.006934204
four O 0 0.004285037
patients O 0 0.0062976084
, O 0 0.004270647
polymorphous O 0 0.9450808
ventricular B-Disease 2 0.9996381
tachycardia I-Disease 2 0.99995744
appeared O 0 0.0014303937
after O 0 0.0005285222
intravenous O 0 0.16682042
administration O 0 0.030299766
of O 0 0.0009424589
200 O 0 0.0015727811
to O 0 0.00053808047
400 O 0 0.0018926034
mg O 0 0.12454131
of O 0 0.0012057631
procainamide B-Chemical 1 0.99993885
for O 0 0.00080608367
the O 0 0.0010641883
treatment O 0 0.0020159676
of O 0 0.0028372095
sustained O 0 0.13030833
ventricular B-Disease 2 0.99964
tachycardia I-Disease 2 0.9998915
. O 0 0.012223714

In O 0 0.0068628024
the O 0 0.004524064
remaining O 0 0.0031497558
three O 0 0.0021016463
patients O 0 0.00493234
, O 0 0.0035336607
procainamide B-Chemical 1 0.9999212
was O 0 0.0013954578
administered O 0 0.0014405175
orally O 0 0.0044373153
for O 0 0.0006776074
treatment O 0 0.0013605404
of O 0 0.001728365
chronic O 0 0.9726428
premature B-Disease 0 0.87643176
ventricular I-Disease 0 0.9984629
contractions I-Disease 0 0.9879483
or O 0 0.005546082
atrial B-Disease 0 0.9937949
flutter I-Disease 0 0.9906322
. O 0 0.010346001

These O 0 0.011842759
patients O 0 0.011610705
had O 0 0.0072583775
Q B-Disease 0 0.83778644
- I-Disease 0 0.010050432
T I-Disease 0 0.55618846
prolongation I-Disease 0 0.08638011
and O 0 0.004248091
recurrent O 0 0.9358694
syncope B-Disease 2 0.99994457
due O 0 0.003455099
to O 0 0.0043237847
polymorphous O 0 0.9939208
ventricular B-Disease 2 0.999716
tachycardia I-Disease 2 0.99988043
. O 0 0.016114067

In O 0 0.007327324
four O 0 0.004561662
patients O 0 0.0064235753
, O 0 0.0038884752
the O 0 0.0027107385
arrhythmia B-Disease 2 0.9995468
was O 0 0.0021114491
rapidly O 0 0.0028173204
diagnosed O 0 0.01672722
and O 0 0.0014197605
treated O 0 0.0014143485
with O 0 0.0012305563
disappearance O 0 0.003491687
of O 0 0.0016647665
further O 0 0.0020821602
episodes O 0 0.30375132
of O 0 0.004448815
the O 0 0.007137123
arrhythmia B-Disease 2 0.9996222
. O 0 0.011461949

In O 0 0.008318906
two O 0 0.0056693675
patients O 0 0.007603347
, O 0 0.0048285252
the O 0 0.0035612786
arrhythmia B-Disease 2 0.9994153
degenerated O 0 0.03605599
into O 0 0.0018632556
irreversible O 0 0.59192073
ventricular B-Disease 0 0.99841845
fibrillation I-Disease 0 0.99993944
and O 0 0.005129668
both O 0 0.0043433732
patients O 0 0.015614246
died O 0 0.06315223
. O 0 0.010179949

In O 0 0.007419662
the O 0 0.0053998763
seventh O 0 0.009810762
patient O 0 0.004472185
, O 0 0.0027839625
a O 0 0.0021336176
permanent O 0 0.010796003
ventricular O 0 0.9713684
pacemaker O 0 0.34950936
was O 0 0.0009369924
inserted O 0 0.00062654103
and O 0 0.00078966474
, O 0 0.00083511655
despite O 0 0.0005293017
continuation O 0 0.0025856611
of O 0 0.0013733885
procainamide B-Chemical 1 0.9999734
therapy O 0 0.054924693
, O 0 0.003233978
polymorphous O 0 0.98827773
ventricular B-Disease 2 0.9998023
tachycardia I-Disease 2 0.99993753
did O 0 0.0040918826
not O 0 0.004948528
reoccur O 0 0.0805522
. O 0 0.008945772

These O 0 0.008817358
seven O 0 0.005282494
cases O 0 0.0047951853
demonstrate O 0 0.002304962
that O 0 0.002469224
procainamide B-Chemical 1 0.999887
can O 0 0.0016559188
produce O 0 0.0012556345
an O 0 0.0019882869
acquired O 0 0.0047775367
prolonged B-Disease 0 0.041275617
Q I-Disease 0 0.97523016
- I-Disease 0 0.012081446
T I-Disease 0 0.8322417
syndrome I-Disease 0 0.8879963
with O 0 0.006068634
polymorphous O 0 0.9970546
ventricular B-Disease 2 0.99979466
tachycardia I-Disease 2 0.99990153
. O 0 0.015148778

Phenobarbitone B-Chemical 0 0.99971944
- O 0 0.015484265
induced O 0 0.005346333
enlargement B-Disease 0 0.11324942
of I-Disease 0 0.0029701425
the I-Disease 0 0.0021753947
liver I-Disease 0 0.7459078
in O 0 0.0015379795
the O 0 0.0013866588
rat O 0 0.005427514
: O 0 0.001929796
its O 0 0.0016433633
relationship O 0 0.0011797571
to O 0 0.0021760406
carbon B-Chemical 0 0.9900935
tetrachloride I-Chemical 0 0.9999807
- O 0 0.104900345
induced O 0 0.03491644
cirrhosis B-Disease 2 0.9999331
. O 0 0.019756021

The O 0 0.007663049
yield O 0 0.006863043
of O 0 0.005490256
severe O 0 0.46594095
cirrhosis B-Disease 2 0.99994445
of I-Disease 0 0.005247445
the I-Disease 0 0.002272921
liver I-Disease 0 0.9443453
( O 0 0.0022487578
defined O 0 0.00075091625
as O 0 0.0007386703
a O 0 0.001069274
shrunken O 0 0.04414757
finely O 0 0.0040132506
nodular O 0 0.9858704
liver O 0 0.9672927
with O 0 0.0021590393
micronodular O 0 0.99945885
histology O 0 0.8546487
, O 0 0.002009991
ascites B-Disease 2 0.9990139
greater O 0 0.0005594248
than O 0 0.00032395893
30 O 0 0.00031479425
ml O 0 0.0012107135
, O 0 0.0006434915
plasma O 0 0.00797992
albumin O 0 0.95506465
less O 0 0.00045609477
than O 0 0.00030458684
2 O 0 0.00040752513
. O 0 0.00026177394
2 O 0 0.00033696854
g O 0 0.00065977214
/ O 0 0.0012548777
dl O 0 0.019271102
, O 0 0.0010477059
splenomegaly B-Disease 0 0.99931777
2 O 0 0.0007917216
- O 0 0.00071218197
3 O 0 0.00029155487
times O 0 0.0002238934
normal O 0 0.0006147077
, O 0 0.00054283056
and O 0 0.0005370414
testicular O 0 0.96720713
atrophy B-Disease 2 0.99830735
approximately O 0 0.0004288126
half O 0 0.00027573563
normal O 0 0.00072986283
weight O 0 0.003902556
) O 0 0.0007623545
after O 0 0.0002032331
12 O 0 0.0002482166
doses O 0 0.0017876116
of O 0 0.00076721085
carbon B-Chemical 0 0.980714
tetrachloride I-Chemical 0 0.99999213
given O 0 0.00047473048
intragastrically O 0 0.20547013
in O 0 0.00054936367
the O 0 0.0008595571
phenobarbitone B-Chemical 1 0.99999356
- O 0 0.0023945773
primed O 0 0.0006946039
rat O 0 0.0032485966
was O 0 0.00042790893
increased O 0 0.00046958128
from O 0 0.00040951357
25 O 0 0.00055964355
% O 0 0.0004202023
to O 0 0.00029194675
56 O 0 0.00051437406
% O 0 0.00039828598
by O 0 0.00033375985
giving O 0 0.00040038468
the O 0 0.0003257394
initial O 0 0.00041063514
" O 0 0.00061933283
calibrating O 0 0.0007079047
" O 0 0.00064675376
dose O 0 0.0030560265
of O 0 0.0010542902
carbon B-Chemical 0 0.98392016
tetrachloride I-Chemical 0 0.9999895
at O 0 0.00058090175
the O 0 0.0005673075
peak O 0 0.0006922256
of O 0 0.0008909472
the O 0 0.0014976856
phenobarbitone B-Chemical 1 0.9999856
- O 0 0.0058917888
induced O 0 0.0024869377
enlargement B-Disease 0 0.34423336
of I-Disease 0 0.0041503645
the I-Disease 0 0.0055834716
liver I-Disease 0 0.9566232
. O 0 0.010962504

At O 0 0.0064002816
this O 0 0.004924606
point O 0 0.0035234818
it O 0 0.0030679111
was O 0 0.002121312
assumed O 0 0.0016722707
that O 0 0.0013676694
the O 0 0.0021107642
cytochrome O 0 0.9986156
P450 O 0 0.9998839
/ O 0 0.23041081
CCl4 B-Chemical 0 0.9999865
toxic O 0 0.9504204
state O 0 0.003505015
was O 0 0.001841729
both O 0 0.0019669451
maximal O 0 0.002931174
and O 0 0.004628736
stable O 0 0.0071008177
. O 0 0.008498236

The O 0 0.0068356637
optimal O 0 0.0040190755
rat O 0 0.0065161586
size O 0 0.0033088445
to O 0 0.0019451439
begin O 0 0.0025574407
phenobarbitone B-Chemical 1 0.9999591
was O 0 0.0012634792
determined O 0 0.0006408732
as O 0 0.00075652724
100 O 0 0.001339036
g O 0 0.0012141585
, O 0 0.00069712196
and O 0 0.00048308616
this O 0 0.00039683218
size O 0 0.0005321709
as O 0 0.0004109116
a O 0 0.00054723275
group O 0 0.00048118187
had O 0 0.0003388471
a O 0 0.0004385187
mean O 0 0.00031342186
maximum O 0 0.00036133884
relative O 0 0.0003644403
liver O 0 0.6536793
weight O 0 0.0055709155
increase O 0 0.00048170754
47 O 0 0.0011454428
% O 0 0.000630305
greater O 0 0.00048317914
than O 0 0.00050246937
normal O 0 0.0012863239
rats O 0 0.0018346554
of O 0 0.0015618728
the O 0 0.0018903303
same O 0 0.002198396
body O 0 0.016972648
weight O 0 0.03641916
. O 0 0.00908274

The O 0 0.007148137
optimal O 0 0.004023053
time O 0 0.0031243586
for O 0 0.0022084087
the O 0 0.0019819413
initial O 0 0.001799119
dose O 0 0.007529464
of O 0 0.0033411612
carbon B-Chemical 0 0.9898885
tetrachloride I-Chemical 0 0.9999795
was O 0 0.002616623
after O 0 0.0013116122
14 O 0 0.0021621326
days O 0 0.0021708214
on O 0 0.003718061
phenobarbitone B-Chemical 1 0.9998375
. O 0 0.011060929

Triamterene B-Chemical 0 0.9953127
nephrolithiasis B-Disease 2 0.99928975
complicating O 0 0.9363035
dyazide B-Chemical 0 0.9663695
therapy O 0 0.37950656
. O 0 0.03713671

A O 0 0.035973284
case O 0 0.007811231
of O 0 0.010488833
triamterene B-Chemical 0 0.9999877
nephrolithiasis B-Disease 2 0.99997485
is O 0 0.004749433
reported O 0 0.0023784132
in O 0 0.001261041
a O 0 0.0016218994
man O 0 0.04734422
after O 0 0.00073925435
4 O 0 0.00094989926
years O 0 0.00152601
of O 0 0.0030241017
hydrochlorothiazide B-Chemical 0 0.9999956
- I-Chemical 0 0.17335096
triamterene I-Chemical 0 0.9999956
therapy O 0 0.2819942
for O 0 0.0070582787
hypertension B-Disease 2 0.9998093
. O 0 0.012152459

The O 0 0.009579949
stone O 0 0.16257934
passed O 0 0.007273602
spontaneously O 0 0.01257944
and O 0 0.0037567378
was O 0 0.0025460094
found O 0 0.0017699745
to O 0 0.0017718887
contain O 0 0.0016202434
a O 0 0.0058296323
triamterene B-Chemical 0 0.9999931
metabolite O 0 0.98711026
admixed O 0 0.7228866
with O 0 0.06326669
uric B-Chemical 0 0.99997234
acid I-Chemical 0 0.9986738
salts I-Chemical 0 0.9993687
. O 0 0.020313764

Factors O 0 0.41890752
affecting O 0 0.0440914
triamterene B-Chemical 0 0.9999734
nephrolithiasis B-Disease 2 0.9999366
are O 0 0.0072535765
discussed O 0 0.0031591814
and O 0 0.0034506246
2 O 0 0.002872909
previously O 0 0.0027819644
reported O 0 0.004171193
cases O 0 0.007212631
are O 0 0.006978074
reviewed O 0 0.013693619
. O 0 0.011225248

Busulfan B-Chemical 0 0.9955486
- O 0 0.059859063
induced O 0 0.05093865
hemorrhagic B-Disease 2 0.9990276
cystitis I-Disease 0 0.99973387
. O 0 0.082480095

A O 0 0.033937756
case O 0 0.009967008
of O 0 0.00874409
a O 0 0.011373843
busulfan B-Chemical 1 0.9996644
- O 0 0.042163175
induced O 0 0.02076966
hemorrhage B-Disease 2 0.9999076
cystitis I-Disease 0 0.99995065
is O 0 0.02748187
reported O 0 0.01966355
. O 0 0.014620279

Spontaneous O 0 0.043091267
resolution O 0 0.023768917
occurred O 0 0.011361463
following O 0 0.00923109
cessation O 0 0.01621703
of O 0 0.010866511
the O 0 0.012268282
drug O 0 0.78524095
. O 0 0.018758312

The O 0 0.0069719474
similarity O 0 0.004806068
between O 0 0.0027930904
the O 0 0.0028092929
histologic O 0 0.195186
appearances O 0 0.051087823
of O 0 0.0038871213
busulfan B-Chemical 1 0.99994266
cystitis B-Disease 2 0.99998915
and O 0 0.005090676
both O 0 0.0014137948
radiation O 0 0.37131014
and O 0 0.0038159837
cyclophosphamide B-Chemical 1 0.9999682
- O 0 0.016737575
induced O 0 0.0031568096
cystitis B-Disease 2 0.99997985
is O 0 0.002506566
discussed O 0 0.0014750916
and O 0 0.0023367072
the O 0 0.002618002
world O 0 0.010788865
literature O 0 0.008152215
reviewed O 0 0.013588399
. O 0 0.009789791

In O 0 0.007336042
view O 0 0.006157271
of O 0 0.0038760724
the O 0 0.002662663
known O 0 0.0024836855
tendency O 0 0.0028617312
of O 0 0.0024349366
busulfan B-Chemical 1 0.99985135
to O 0 0.001479494
induce O 0 0.0009739501
cellular O 0 0.053345963
atypia O 0 0.9893169
and O 0 0.00393928
carcinoma B-Disease 2 0.9998801
in O 0 0.00086293736
other O 0 0.00075586216
sites O 0 0.00073628646
, O 0 0.0008596154
periodic O 0 0.0032228397
urinary O 0 0.825
cytology O 0 0.079229034
is O 0 0.00083810196
suggested O 0 0.0007232167
in O 0 0.00090370415
patients O 0 0.0024605878
on O 0 0.0011862912
long O 0 0.0024827605
- O 0 0.0044072107
term O 0 0.0040970426
therapy O 0 0.049779944
. O 0 0.009144232

Variant O 0 0.63714546
ventricular B-Disease 2 0.99620605
tachycardia I-Disease 2 0.99940383
in O 0 0.061614852
desipramine B-Chemical 1 0.9999018
toxicity B-Disease 2 0.99843436
. O 0 0.034552097

We O 0 0.01086068
report O 0 0.010050472
a O 0 0.006758922
case O 0 0.0047997995
of O 0 0.004967456
variant O 0 0.009295334
ventricular B-Disease 2 0.99944836
tachycardia I-Disease 2 0.9999337
induced O 0 0.021372057
by O 0 0.058953043
desipramine B-Chemical 1 0.999982
toxicity B-Disease 2 0.99927765
. O 0 0.016383043

Unusual O 0 0.045795105
features O 0 0.008142085
of O 0 0.004843802
the O 0 0.003817804
arrhythmia B-Disease 2 0.9995022
are O 0 0.0023490274
repetitive O 0 0.004240304
group O 0 0.0017174033
beating O 0 0.15096836
, O 0 0.0014514261
progressive O 0 0.07515727
shortening O 0 0.010045514
of O 0 0.0010210439
the O 0 0.0012803399
R O 0 0.9896902
- O 0 0.009964407
R O 0 0.9225737
interval O 0 0.0009850834
, O 0 0.00077309686
progressive O 0 0.040034935
widening O 0 0.0018149907
of O 0 0.0005563948
the O 0 0.0005560544
QRS O 0 0.93839544
complex O 0 0.00055907806
with O 0 0.00057904003
eventual O 0 0.022303095
failure O 0 0.4499603
of O 0 0.0012443418
intraventricular O 0 0.98319536
conduction O 0 0.28942877
, O 0 0.001182687
and O 0 0.0009099945
changes O 0 0.0011179822
in O 0 0.0010613534
direction O 0 0.0019828791
of O 0 0.0023210216
the O 0 0.0037263364
QRS O 0 0.9776153
axis O 0 0.027165975
. O 0 0.008639742

Recognition O 0 0.022368688
of O 0 0.007947657
variant O 0 0.009216117
ventricular B-Disease 2 0.9986778
tachycardia I-Disease 2 0.99989974
is O 0 0.002851958
important O 0 0.0014422133
because O 0 0.0012119383
therapy O 0 0.004051847
differs O 0 0.0014050049
from O 0 0.0015978492
that O 0 0.001568312
of O 0 0.0034505248
classic O 0 0.602771
ventricular B-Disease 2 0.99969363
tachycardia I-Disease 2 0.9998946
. O 0 0.014317549

Rebound O 0 0.96695733
hypertensive B-Disease 2 0.9975504
after O 0 0.013331895
sodium B-Chemical 1 0.999767
nitroprusside I-Chemical 1 0.99998426
prevented O 0 0.2792872
by O 0 0.028352136
saralasin B-Chemical 1 0.9998435
in O 0 0.0117847035
rats O 0 0.037347436
. O 0 0.0137458695

The O 0 0.007520487
role O 0 0.004489254
of O 0 0.0044171955
the O 0 0.004160902
renin O 0 0.996847
- O 0 0.035654843
- O 0 0.009697681
angiotensin B-Chemical 1 0.99983525
system O 0 0.0025210022
in O 0 0.0007335302
the O 0 0.00062947324
maintenance O 0 0.0008505105
of O 0 0.0007147237
blood O 0 0.013177963
pressure O 0 0.05928194
during O 0 0.0006322767
halothane B-Chemical 1 0.9997794
anesthesia O 0 0.4776932
and O 0 0.0067577865
sodium B-Chemical 1 0.99998355
nitroprusside I-Chemical 1 0.99999905
( O 0 0.10173258
SNP B-Chemical 1 0.97536296
) O 0 0.011745946
- O 0 0.0042038085
induced O 0 0.003979394
hypotension B-Disease 2 0.9999044
was O 0 0.0054012276
evaluated O 0 0.0061010597
. O 0 0.008721656

Control O 0 0.016236851
rats O 0 0.008796803
received O 0 0.0049090795
halothane B-Chemical 1 0.99913293
anesthesia O 0 0.5806825
( O 0 0.004033535
1 O 0 0.0017796939
MAC O 0 0.57039315
) O 0 0.0017310459
for O 0 0.00053965626
one O 0 0.0004914817
hour O 0 0.0004187428
, O 0 0.00066229585
followed O 0 0.0003981778
by O 0 0.00071657926
SNP B-Chemical 1 0.59669244
infusion O 0 0.0110019585
, O 0 0.00073582237
40 O 0 0.0005105299
microgram O 0 0.074535765
/ O 0 0.0015107464
kg O 0 0.0037998268
/ O 0 0.0013577588
min O 0 0.0005910517
, O 0 0.0005662387
for O 0 0.00033970375
30 O 0 0.0003864967
min O 0 0.0005631955
, O 0 0.000702577
followed O 0 0.0005381041
by O 0 0.0009146598
a O 0 0.0014060107
30 O 0 0.0012257063
- O 0 0.0023306988
min O 0 0.002545163
recovery O 0 0.00479435
period O 0 0.0046679243
. O 0 0.007409913

A O 0 0.02623742
second O 0 0.0055735237
group O 0 0.003933533
of O 0 0.0031043785
rats O 0 0.0046189306
was O 0 0.0016098139
treated O 0 0.0014780005
identically O 0 0.0014574116
and O 0 0.001214834
, O 0 0.001065049
in O 0 0.00053433824
addition O 0 0.00039518284
, O 0 0.0007338903
received O 0 0.00045727467
an O 0 0.00070770195
infusion O 0 0.006816396
of O 0 0.0017243285
saralasin B-Chemical 1 0.9999839
( O 0 0.0025588486
a O 0 0.0013122552
competitive O 0 0.022630809
inhibitor O 0 0.091140755
of O 0 0.006359209
angiotensin B-Chemical 1 0.99997735
II I-Chemical 1 0.85701436
) O 0 0.004209412
throughout O 0 0.001406355
the O 0 0.0021686505
experimental O 0 0.0037824176
period O 0 0.004928704
. O 0 0.007550717

In O 0 0.006966477
each O 0 0.0041717635
group O 0 0.004557792
, O 0 0.0045578917
SNP B-Chemical 1 0.50414264
infusion O 0 0.011585183
resulted O 0 0.0010675793
in O 0 0.00083292305
an O 0 0.0009890061
initial O 0 0.000705493
decrease O 0 0.0006416163
in O 0 0.00055283
blood O 0 0.004765859
pressure O 0 0.015582315
from O 0 0.00064235146
86 O 0 0.0011999295
torr O 0 0.047322404
and O 0 0.00083834166
83 O 0 0.0016556933
torr O 0 0.09351599
, O 0 0.0016877017
respectively O 0 0.0023027796
, O 0 0.0023152826
to O 0 0.0022200888
48 O 0 0.0035745096
torr O 0 0.12024069
. O 0 0.007267406

During O 0 0.0067050476
the O 0 0.0055848756
SNP B-Chemical 1 0.2607698
infusion O 0 0.007600088
the O 0 0.0017318437
control O 0 0.0012646506
animals O 0 0.00094437966
demonstrated O 0 0.00078349287
a O 0 0.0012094664
progressive O 0 0.082337454
increase B-Disease 0 0.00060854753
in I-Disease 0 0.000578323
blood I-Disease 0 0.00752358
pressure I-Disease 0 0.023117675
to O 0 0.0005506646
61 O 0 0.0014021938
torr O 0 0.14454344
, O 0 0.00086154364
whereas O 0 0.00064115506
the O 0 0.0011876385
saralasin B-Chemical 1 0.99995553
- O 0 0.0032916213
treated O 0 0.0017450084
animals O 0 0.001642037
showed O 0 0.00209077
no O 0 0.0029339152
change O 0 0.0060528005
. O 0 0.007969448

Following O 0 0.0086894315
discontinuation O 0 0.43853593
of O 0 0.006523775
SNP B-Chemical 1 0.7883064
, O 0 0.003087901
blood O 0 0.007935463
pressure O 0 0.024726959
in O 0 0.00088395627
the O 0 0.0007357933
control O 0 0.0006948847
animals O 0 0.0007048115
rebounded O 0 0.022473924
to O 0 0.0005505387
94 O 0 0.0009100886
torr O 0 0.08340336
, O 0 0.0007219005
as O 0 0.000501499
compared O 0 0.00040477928
with O 0 0.0007207714
78 O 0 0.0017464958
torr O 0 0.072119854
in O 0 0.001172101
the O 0 0.0022957297
saralasin B-Chemical 1 0.9999157
- O 0 0.008689062
treated O 0 0.006235347
rats O 0 0.017187532
. O 0 0.008910416

This O 0 0.010084202
study O 0 0.005414906
indicates O 0 0.002893329
that O 0 0.0019974692
with O 0 0.0019277601
stable O 0 0.002321914
halothane B-Chemical 1 0.99968576
anesthesia O 0 0.4130268
, O 0 0.0013466681
the O 0 0.00060905353
partial O 0 0.00079820614
recovery O 0 0.0009812624
of O 0 0.0006319249
blood O 0 0.011526514
pressure O 0 0.04803242
during O 0 0.00047932257
SNP B-Chemical 1 0.618465
infusion O 0 0.006238734
and O 0 0.0006164886
the O 0 0.00057903945
post O 0 0.0014165583
- O 0 0.0019842535
SNP B-Chemical 1 0.58144283
rebound O 0 0.14207222
of O 0 0.0011098962
blood O 0 0.023810387
pressure O 0 0.06538215
can O 0 0.0011933958
be O 0 0.0018111537
completely O 0 0.002512663
blocked O 0 0.006506609
by O 0 0.010275766
saralasin B-Chemical 1 0.9998399
. O 0 0.011331289

This O 0 0.009819009
demonstrates O 0 0.0044899364
the O 0 0.0037380918
participation O 0 0.003994023
of O 0 0.0027817027
the O 0 0.002814083
renin O 0 0.9977556
- O 0 0.03186895
- O 0 0.010415034
angiotensin B-Chemical 1 0.9998696
system O 0 0.0032049336
in O 0 0.0010681048
antagonizing O 0 0.023084192
the O 0 0.0011034533
combined O 0 0.0025469165
hypotensive B-Disease 2 0.9990607
effects O 0 0.009903164
of O 0 0.0091166645
halothane B-Chemical 1 0.99974495
and O 0 0.016820949
SNP B-Chemical 1 0.9433632
. O 0 0.010257616

Clinical O 0 0.47995505
nephrotoxicity B-Disease 2 0.99944144
of O 0 0.049707346
tobramycin B-Chemical 1 0.99812216
and O 0 0.052782208
gentamicin B-Chemical 1 0.99764013
. O 0 0.03129828

A O 0 0.14758645
prospective O 0 0.08770078
study O 0 0.07242625
. O 0 0.06709987

Nearly O 0 0.018295068
3 O 0 0.00802542
. O 0 0.0049696383
2 O 0 0.0041762386
million O 0 0.0050437553
people O 0 0.005218135
in O 0 0.002860269
this O 0 0.0029075241
country O 0 0.005601141
receive O 0 0.004077898
aminoglycoside B-Chemical 1 0.9921699
antibiotics O 0 0.8771862
annually O 0 0.06869314
. O 0 0.0121856015

Gentamicin B-Chemical 0 0.9992029
sulfate I-Chemical 0 0.99868065
and O 0 0.011821784
tobramycin B-Chemical 1 0.99969554
sulfate I-Chemical 0 0.9993655
continue O 0 0.002926839
to O 0 0.0016064155
demonstrate O 0 0.0013756244
ototoxicity B-Disease 2 0.99995434
and O 0 0.011082347
nephrotoxicity B-Disease 2 0.99998593
in O 0 0.00237392
both O 0 0.0021643837
animal O 0 0.0036218471
and O 0 0.0041174013
clinical O 0 0.02800929
studies O 0 0.008156214
. O 0 0.00879865

In O 0 0.007373559
this O 0 0.00509389
study O 0 0.00424419
, O 0 0.0032848038
62 O 0 0.0029395868
patients O 0 0.0022442378
with O 0 0.0010345526
confirmed O 0 0.0008057028
initial O 0 0.00082213053
normal O 0 0.0019051944
renal O 0 0.9698266
function O 0 0.0011033026
and O 0 0.0007494864
treated O 0 0.0007454114
with O 0 0.0005890002
2 O 0 0.000473666
to O 0 0.00033458753
5 O 0 0.0003640354
mg O 0 0.077873126
/ O 0 0.0010863614
kg O 0 0.0023068949
/ O 0 0.0008971401
day O 0 0.00034028912
of O 0 0.0007060459
gentamicin B-Chemical 1 0.99983275
sulfate I-Chemical 0 0.9997838
or O 0 0.001726357
tobramycin B-Chemical 1 0.999936
sulfate I-Chemical 0 0.9996099
for O 0 0.00043029408
a O 0 0.000500183
minimum O 0 0.00022079783
of O 0 0.00033588766
seven O 0 0.0002844553
days O 0 0.00024890056
were O 0 0.0002915865
followed O 0 0.00022757024
up O 0 0.00027527017
prospectively O 0 0.00046555488
for O 0 0.0002496806
the O 0 0.00035267408
development O 0 0.0007694385
of O 0 0.0008754156
aminoglycoside B-Chemical 1 0.9980343
- O 0 0.0027880643
related O 0 0.0004898942
renal B-Disease 0 0.99173754
failure I-Disease 0 0.83368456
, O 0 0.0010506801
defined O 0 0.00046841783
as O 0 0.0005143529
at O 0 0.00039317508
least O 0 0.00039235846
a O 0 0.0009001833
one O 0 0.00086354447
- O 0 0.0017514811
third O 0 0.0015857869
reduction O 0 0.002633752
in O 0 0.0029737868
renal O 0 0.9828015
function O 0 0.01001794
. O 0 0.008904909

In O 0 0.008606511
these O 0 0.0069929226
62 O 0 0.0072466503
patients O 0 0.0061087264
, O 0 0.0035625356
no O 0 0.0020559828
other O 0 0.0025027914
causes O 0 0.004658841
for O 0 0.0029289646
renal B-Disease 0 0.9924561
failure I-Disease 0 0.8733208
could O 0 0.0044008084
be O 0 0.00598249
identified O 0 0.006676077
. O 0 0.009683583

Five O 0 0.011252993
of O 0 0.0067566982
33 O 0 0.0062823095
( O 0 0.0039853333
15 O 0 0.002038505
% O 0 0.0020740083
) O 0 0.0018103627
of O 0 0.0011509083
the O 0 0.0011523131
tobramycin B-Chemical 1 0.99896574
- O 0 0.0021582288
treated O 0 0.0008621082
patients O 0 0.0016864166
and O 0 0.0006665987
16 O 0 0.00054920116
of O 0 0.0005711006
29 O 0 0.0011552558
( O 0 0.00073042844
55 O 0 0.0006565706
. O 0 0.00036896422
2 O 0 0.00048119537
% O 0 0.0006485252
) O 0 0.0008462293
of O 0 0.000723671
the O 0 0.0010598637
gentamicin B-Chemical 1 0.99843925
- O 0 0.0030409344
treated O 0 0.0020807995
patients O 0 0.0059621423
had O 0 0.003666878
renal B-Disease 0 0.9941209
failure I-Disease 0 0.9375955
. O 0 0.011064968

Thus O 0 0.0099504255
, O 0 0.009042117
gentamicin B-Chemical 1 0.98996687
was O 0 0.0036932495
associated O 0 0.00275733
with O 0 0.0024640874
renal B-Disease 0 0.9815761
failure I-Disease 0 0.6602762
more O 0 0.0017203538
than O 0 0.0008708896
three O 0 0.0008458312
times O 0 0.0009952028
as O 0 0.0016089305
often O 0 0.003046935
as O 0 0.0033864798
was O 0 0.0055454024
tobramycin B-Chemical 1 0.997546
. O 0 0.010380459

Metabolic O 0 0.49358305
involvement O 0 0.051885445
in O 0 0.041074328
adriamycin B-Chemical 1 0.99920744
cardiotoxicity B-Disease 2 0.9997861
. O 0 0.057460524

The O 0 0.009658725
cardiotoxic B-Disease 2 0.99693346
effects O 0 0.0101157045
of O 0 0.0068206363
adriamycin B-Chemical 1 0.9997942
were O 0 0.0028950735
studied O 0 0.0020254883
in O 0 0.0016146608
mammalian O 0 0.0043398263
myocardial O 0 0.99965215
cells O 0 0.0048360974
in O 0 0.0018444133
culture O 0 0.0035603244
as O 0 0.0027202659
a O 0 0.0042747613
model O 0 0.005464375
system O 0 0.010137557
. O 0 0.009220706

Adriamycin B-Chemical 1 0.998931
inhibited O 0 0.016765308
cell O 0 0.025264615
growth O 0 0.0118885655
and O 0 0.0036045823
the O 0 0.0026602587
rhythmic O 0 0.048776917
contractions O 0 0.742856
characteristic O 0 0.0040168124
of O 0 0.0059396443
myocardial O 0 0.99967885
cells O 0 0.016550181
in O 0 0.0063119894
culture O 0 0.016675537
. O 0 0.010645758

A O 0 0.028640475
possible O 0 0.005941007
involvement O 0 0.0060266973
of O 0 0.003816212
energy O 0 0.03690115
metabolism O 0 0.3538292
was O 0 0.0015832592
suggested O 0 0.000999844
previously O 0 0.0010402818
, O 0 0.0011891507
and O 0 0.0007515778
in O 0 0.00054868317
this O 0 0.0005554405
study O 0 0.00076094613
the O 0 0.0007265937
adenylate O 0 0.9109674
energy O 0 0.011599394
charge O 0 0.046045754
and O 0 0.001452033
phosphorylcreatine B-Chemical 0 0.9741693
mole O 0 0.13856779
fraction O 0 0.000806783
were O 0 0.00084702886
determined O 0 0.0007196999
in O 0 0.0011547194
the O 0 0.0022479105
adriamycin B-Chemical 1 0.9998166
- O 0 0.011516169
treated O 0 0.0069817267
cells O 0 0.015706982
. O 0 0.009698786

The O 0 0.010494249
adenylate O 0 0.7550225
energy O 0 0.020608101
charge O 0 0.039515592
was O 0 0.0031725275
found O 0 0.0018701525
to O 0 0.0016750529
be O 0 0.0016510653
significantly O 0 0.0019178366
decreased O 0 0.002451724
, O 0 0.0020401585
while O 0 0.0013370621
the O 0 0.0017716527
phophorylcreatine B-Chemical 0 0.20554638
mole O 0 0.23211662
fraction O 0 0.0034628313
was O 0 0.0046619996
unchanged O 0 0.006569712
. O 0 0.008507054

Such O 0 0.023470927
disparity O 0 0.015843386
suggests O 0 0.009532124
an O 0 0.013779704
inhibition O 0 0.02213215
of O 0 0.03223236
creatine B-Chemical 1 0.999803
phosphokinase O 0 0.99983144
. O 0 0.03140306

The O 0 0.0068779937
addition O 0 0.0039751367
of O 0 0.004828324
1 O 0 0.0045804256
mM O 0 0.6884352
adenosine B-Chemical 1 0.9958527
to O 0 0.001593844
the O 0 0.0015719547
myocardial O 0 0.99970585
cell O 0 0.037621476
cultures O 0 0.0019929837
markedly O 0 0.007829945
increases O 0 0.0008738296
the O 0 0.0010374464
ATP B-Chemical 1 0.9969901
concentration O 0 0.0022769328
through O 0 0.00077275507
a O 0 0.0013154102
pathway O 0 0.001629232
reportedly O 0 0.03536084
leading O 0 0.0026108413
to O 0 0.0016834915
a O 0 0.0033937548
compartmentalized O 0 0.014168595
ATP B-Chemical 1 0.9953128
pool O 0 0.0095650535
. O 0 0.008914223

In O 0 0.008126377
the O 0 0.007131671
adriamycin B-Chemical 1 0.9995396
- O 0 0.009632241
treated O 0 0.0030455363
cells O 0 0.0037381365
, O 0 0.001742656
the O 0 0.00081577705
addition O 0 0.00051978376
of O 0 0.0014436026
adenosine B-Chemical 1 0.9991742
increased O 0 0.0018738947
the O 0 0.0010390101
adenylate O 0 0.96892875
charge O 0 0.064754315
and O 0 0.0009419193
, O 0 0.00080798165
concomitant O 0 0.0012758292
with O 0 0.00054085
this O 0 0.0005222649
inrcease O 0 0.020643579
, O 0 0.00073140993
the O 0 0.00041291854
cells O 0 0.0009003651
' O 0 0.00067672966
functional O 0 0.0005652617
integrity O 0 0.00086318905
, O 0 0.0006004645
in O 0 0.00033939528
terms O 0 0.00030732644
of O 0 0.00047471782
percentage O 0 0.0003915861
of O 0 0.0008552631
beating O 0 0.10007499
cells O 0 0.0017805411
and O 0 0.0012073237
rate O 0 0.001206769
of O 0 0.002381921
contractions O 0 0.9160089
, O 0 0.0046445346
was O 0 0.003766641
maintained O 0 0.004823483
. O 0 0.007478347

Age O 0 0.38748097
- O 0 0.012524858
dependent O 0 0.0055793333
sensitivity O 0 0.0061591207
of O 0 0.0045833397
the O 0 0.004017526
rat O 0 0.010899453
to O 0 0.0047925776
neurotoxic B-Disease 2 0.99884063
effects O 0 0.037451956
of O 0 0.0326524
streptomycin B-Chemical 1 0.9994723
. O 0 0.014028225

Streptomycin B-Chemical 0 0.9956601
sulfate O 0 0.9963307
( O 0 0.007924682
300 O 0 0.006203611
mg O 0 0.22346824
/ O 0 0.0035458712
kg O 0 0.005168638
s O 0 0.0016023155
. O 0 0.0008567271
c O 0 0.004619838
. O 0 0.00065710297
) O 0 0.0009938087
was O 0 0.00046522927
injected O 0 0.00039607062
for O 0 0.0003587125
various O 0 0.00071468734
periods O 0 0.0006849983
into O 0 0.00046206565
preweanling O 0 0.43085253
rats O 0 0.002117075
and O 0 0.0011123441
for O 0 0.00090194074
3 O 0 0.0012483947
weeks O 0 0.0012437316
into O 0 0.0018203182
weanling O 0 0.07449911
rats O 0 0.014088576
. O 0 0.009194841

Beginning O 0 0.015063887
at O 0 0.0046674814
8 O 0 0.0032986042
days O 0 0.002031743
of O 0 0.0021413665
age O 0 0.0033236612
, O 0 0.0020141986
body O 0 0.0045151096
movement O 0 0.002603834
and O 0 0.00142723
hearing O 0 0.7658516
were O 0 0.00090396684
examined O 0 0.00059019885
for O 0 0.00065834034
6 O 0 0.00071529957
and O 0 0.0009697611
up O 0 0.0010669703
to O 0 0.0012924684
17 O 0 0.002428652
weeks O 0 0.0019425406
, O 0 0.004470882
respectively O 0 0.0079366835
. O 0 0.007880315

Abnormal B-Disease 0 0.12327352
movements I-Disease 0 0.031173268
and O 0 0.0060540466
deafness B-Disease 0 0.9968617
occurred O 0 0.0027254375
only O 0 0.0014062962
in O 0 0.0010627897
rats O 0 0.0019883157
treated O 0 0.00096191186
during O 0 0.00051971833
the O 0 0.0006729442
preweaning O 0 0.060624354
period O 0 0.00055820803
; O 0 0.0007926765
within O 0 0.00023411798
this O 0 0.00030584948
period O 0 0.00028063796
the O 0 0.00031365952
greatest O 0 0.00059437647
sensitivities O 0 0.0006294627
for O 0 0.00031448205
these O 0 0.00055105763
abnormalities O 0 0.048092082
occurred O 0 0.00049536314
from O 0 0.0004182704
2 O 0 0.0003919798
to O 0 0.00031871584
11 O 0 0.0005834767
- O 0 0.0005762387
17 O 0 0.00043848567
and O 0 0.00032735764
5 O 0 0.0002582003
to O 0 0.00023411262
11 O 0 0.0003193019
days O 0 0.00020564257
of O 0 0.00038083893
age O 0 0.0014927583
, O 0 0.0007915202
respectively O 0 0.0010520697
, O 0 0.00054670725
indicating O 0 0.0002739556
that O 0 0.00027110163
the O 0 0.00038193256
cochlea O 0 0.017076569
is O 0 0.0004305579
more O 0 0.00047527064
sensitive O 0 0.0003917426
to O 0 0.00052821956
streptomycin B-Chemical 1 0.9981194
than O 0 0.0003723326
the O 0 0.00051256263
site O 0 0.000678437
( O 0 0.0012615457
vestibular O 0 0.7482176
or O 0 0.0009913642
central O 0 0.0032243887
) O 0 0.0023449678
responsible O 0 0.0015862958
for O 0 0.0020763208
the O 0 0.0050938367
dyskinesias B-Disease 2 0.99985397
. O 0 0.010340647

Late O 0 0.33250913
, O 0 0.050578702
late O 0 0.08447254
doxorubicin B-Chemical 1 0.9987122
cardiotoxicity B-Disease 2 0.9997118
. O 0 0.05872906

Cardiac B-Disease 0 0.98152775
toxicity I-Disease 2 0.99733233
is O 0 0.0055748266
a O 0 0.004042617
major O 0 0.0032746864
complication O 0 0.22748485
which O 0 0.0025492907
limits O 0 0.0025935534
the O 0 0.0015246136
use O 0 0.0018065032
of O 0 0.0030590568
adriamycin B-Chemical 1 0.99975187
as O 0 0.0040669423
a O 0 0.007399042
chemotherapeutic O 0 0.97817594
agent O 0 0.8084356
. O 0 0.012835936

Cardiomyopathy B-Disease 0 0.9929396
is O 0 0.005954156
frequent O 0 0.005184639
when O 0 0.001866043
the O 0 0.0015010514
total O 0 0.0012457448
dose O 0 0.0036097874
exceeds O 0 0.00089504744
600 O 0 0.0030374208
mg O 0 0.25205487
/ O 0 0.0023684322
m2 O 0 0.008618766
and O 0 0.0007530524
occurs O 0 0.00053590816
within O 0 0.00041209295
one O 0 0.0005520062
to O 0 0.00063256896
six O 0 0.00066950003
months O 0 0.00089748815
after O 0 0.0010547619
cessation O 0 0.005703008
of O 0 0.004381251
therapy O 0 0.06324377
. O 0 0.008835671

A O 0 0.03349728
patient O 0 0.008422003
is O 0 0.0042962823
reported O 0 0.0032525472
who O 0 0.0035451604
developed O 0 0.0029128874
progressive O 0 0.43021172
cardiomyopathy B-Disease 2 0.9999509
two O 0 0.001174735
and O 0 0.0011564377
one O 0 0.0007529024
- O 0 0.0009788536
half O 0 0.00038712702
years O 0 0.0006412715
after O 0 0.00033609202
receiving O 0 0.0010222325
580 O 0 0.012852285
mg O 0 0.20082872
/ O 0 0.0023899297
m2 O 0 0.008497632
which O 0 0.0012952047
apparently O 0 0.0029120538
represents O 0 0.001968417
late O 0 0.007346682
, O 0 0.0059383833
late O 0 0.06452595
cardiotoxicity B-Disease 2 0.99993086
. O 0 0.012880767

Attenuation O 0 0.07525801
of O 0 0.0088118585
the O 0 0.0075566513
lithium B-Chemical 1 0.99970144
- O 0 0.021009263
induced O 0 0.0072615677
diabetes B-Disease 2 0.99952793
- I-Disease 0 0.08690691
insipidus I-Disease 0 0.99974877
- I-Disease 0 0.012765231
like I-Disease 0 0.0036852956
syndrome I-Disease 0 0.9594698
by O 0 0.014297367
amiloride B-Chemical 1 0.99985266
in O 0 0.0076943985
rats O 0 0.036234587
. O 0 0.010606667

The O 0 0.0074627874
effect O 0 0.0052703707
of O 0 0.0066281776
amiloride B-Chemical 1 0.9998265
on O 0 0.0034592191
lithium B-Chemical 1 0.99993646
- O 0 0.027322764
induced O 0 0.004729929
polydipsia B-Disease 2 0.99998677
and O 0 0.0077533983
polyuria B-Disease 2 0.9999161
and O 0 0.0011547523
on O 0 0.00044114128
the O 0 0.00075263996
lithium B-Chemical 1 0.99982077
concentration O 0 0.0020937824
in O 0 0.0005045355
the O 0 0.00056152215
plasma O 0 0.03715594
, O 0 0.0012429451
brain O 0 0.09834967
, O 0 0.00127622
kidney O 0 0.87862134
, O 0 0.0016594444
thyroid O 0 0.91140795
and O 0 0.0009363546
red O 0 0.0044728536
blood O 0 0.014619799
cells O 0 0.0015969361
was O 0 0.00074069336
investigated O 0 0.0006763886
in O 0 0.0010866749
rats O 0 0.0048039313
, O 0 0.0028849381
chronically O 0 0.032487005
treated O 0 0.0057450607
with O 0 0.011022019
LiCl B-Chemical 1 0.99908483
. O 0 0.011570451

Amiloride B-Chemical 0 0.9992418
reduced O 0 0.007873458
the O 0 0.0043208585
drinking O 0 0.4794764
and O 0 0.002845345
urine O 0 0.15297821
volume O 0 0.003119252
of O 0 0.0013503201
rats O 0 0.0025630468
in O 0 0.0008090074
an O 0 0.001521912
acute O 0 0.93721473
( O 0 0.0018386653
6 O 0 0.00051487196
or O 0 0.00050669553
12 O 0 0.00046094958
h O 0 0.00053509866
) O 0 0.0011250993
and O 0 0.0009331925
a O 0 0.0018127493
subacute O 0 0.99080944
( O 0 0.0032521095
3 O 0 0.0018640822
days O 0 0.0020269405
) O 0 0.004858593
experiment O 0 0.0041101146
. O 0 0.0072620455

6 O 0 0.006645471
h O 0 0.0039441367
after O 0 0.0022712648
the O 0 0.0022516833
administration O 0 0.03282145
of O 0 0.00453975
amiloride B-Chemical 1 0.9999535
, O 0 0.0033590132
a O 0 0.0014382559
reduction O 0 0.0012914336
was O 0 0.00058929506
observed O 0 0.00038371573
in O 0 0.0005290852
the O 0 0.0007442097
lithium B-Chemical 1 0.99965334
content O 0 0.00074650545
of O 0 0.00092654984
the O 0 0.0010472573
renal O 0 0.9930627
medulla O 0 0.8640486
but O 0 0.0011943596
not O 0 0.0010543535
in O 0 0.001238378
the O 0 0.0017525201
other O 0 0.0029380051
organs O 0 0.0683207
studied O 0 0.0085436525
. O 0 0.009562781

At O 0 0.0074226693
12 O 0 0.0051788357
h O 0 0.004022982
, O 0 0.00390847
all O 0 0.0025020856
the O 0 0.0023734616
tissues O 0 0.004187182
showed O 0 0.002200891
a O 0 0.003230064
slight O 0 0.003645325
increase O 0 0.0030278738
in O 0 0.005552207
lithium B-Chemical 1 0.9994655
levels O 0 0.010718418
. O 0 0.011623815

After O 0 0.005557904
3 O 0 0.003904121
days O 0 0.0023823017
of O 0 0.0023301975
combined O 0 0.00253933
treatment O 0 0.0030564794
, O 0 0.0020516396
a O 0 0.0016111918
marked O 0 0.002638717
elevation O 0 0.22919862
in O 0 0.0010033981
plasma O 0 0.028193492
and O 0 0.0015805801
tissue O 0 0.11606618
lithium B-Chemical 1 0.99985945
levels O 0 0.001771855
accompanied O 0 0.0036018863
a O 0 0.0030584228
reduction O 0 0.0038347542
in O 0 0.0035447981
water O 0 0.07835994
intake O 0 0.8278945
. O 0 0.011111209

In O 0 0.006907511
all O 0 0.0044456627
the O 0 0.0033226553
experiments O 0 0.0024913114
, O 0 0.0023796072
the O 0 0.0013879277
attenuation O 0 0.002056065
of O 0 0.001489862
the O 0 0.0017597617
lithium B-Chemical 1 0.9999496
- O 0 0.016603809
induced O 0 0.0033914512
diabetes B-Disease 2 0.9998319
- I-Disease 0 0.05987392
insipidus I-Disease 0 0.99990034
- I-Disease 0 0.008248407
like I-Disease 0 0.0009858947
syndrome I-Disease 0 0.95525044
by O 0 0.0039549186
amiloride B-Chemical 1 0.99997556
was O 0 0.00089690683
accompanied O 0 0.0015122981
by O 0 0.0005996659
a O 0 0.00064323307
reduction O 0 0.0006147619
of O 0 0.00044248352
the O 0 0.00037325243
ratio O 0 0.00050363434
between O 0 0.000273392
the O 0 0.00061675254
lithium B-Chemical 1 0.99982786
concentration O 0 0.0018746823
in O 0 0.00048267786
the O 0 0.0006209236
renal O 0 0.9911714
medulla O 0 0.85369605
and O 0 0.00079104555
its O 0 0.0009805635
levels O 0 0.0005040855
in O 0 0.00048618636
the O 0 0.0005953945
blood O 0 0.006169609
and O 0 0.001135182
an O 0 0.0017659559
elevation O 0 0.17766027
in O 0 0.0016613541
the O 0 0.0026004591
plasma O 0 0.21341653
potassium B-Chemical 1 0.9996037
level O 0 0.0065497067
. O 0 0.009232023

It O 0 0.010294897
is O 0 0.0053294543
concluded O 0 0.004099308
that O 0 0.003040054
acute O 0 0.9818361
amiloride B-Chemical 1 0.9999628
administration O 0 0.6797197
to O 0 0.0029670193
lithium B-Chemical 1 0.99995804
- O 0 0.0069116694
treated O 0 0.001240859
patients O 0 0.008420754
suffering O 0 0.95172364
from O 0 0.002570131
polydipsia B-Disease 2 0.9999896
and O 0 0.0044095353
polyuria B-Disease 2 0.9999167
might O 0 0.0005263153
relieve O 0 0.044703852
these O 0 0.00085590803
patients O 0 0.004928236
but O 0 0.00085467246
prolonged O 0 0.0690196
amiloride B-Chemical 1 0.9999794
supplementation O 0 0.95563334
would O 0 0.00085751934
result O 0 0.0010022264
in O 0 0.0011143427
elevated O 0 0.027191222
lithium B-Chemical 1 0.9998154
levels O 0 0.0022905488
and O 0 0.0030231618
might O 0 0.0025854558
be O 0 0.005151264
hazardous O 0 0.30030107
. O 0 0.009072394

Cardiovascular B-Disease 0 0.9910686
complications I-Disease 0 0.9325974
associated O 0 0.013793224
with O 0 0.012235245
terbutaline B-Chemical 1 0.9997738
treatment O 0 0.023797434
for O 0 0.009844291
preterm B-Disease 0 0.9736762
labor I-Disease 0 0.9605844
. O 0 0.018988905

Severe O 0 0.9287841
cardiovascular B-Disease 0 0.9971897
complications I-Disease 0 0.96308774
occurred O 0 0.0048207776
in O 0 0.0024643545
eight O 0 0.0017392896
of O 0 0.0021403385
160 O 0 0.0045823692
patients O 0 0.0033155929
treated O 0 0.0025994244
with O 0 0.003701519
terbutaline B-Chemical 1 0.999897
for O 0 0.0054462627
preterm B-Disease 0 0.9765389
labor I-Disease 0 0.94951135
. O 0 0.0130973905

Associated O 0 0.069757566
corticosteroid O 0 0.99538827
therapy O 0 0.053112358
and O 0 0.008656196
twin O 0 0.099235
gestations O 0 0.08736068
appear O 0 0.005155554
to O 0 0.004983362
be O 0 0.0067003937
predisposing O 0 0.092423536
factors O 0 0.045291964
. O 0 0.014094611

Potential O 0 0.034694824
mechanisms O 0 0.016758675
of O 0 0.013680847
the O 0 0.012344249
pathophysiology O 0 0.2536529
are O 0 0.013917115
briefly O 0 0.017170263
discussed O 0 0.0139864525
. O 0 0.017658984

Toxic B-Disease 0 0.99715495
hepatitis I-Disease 2 0.99987817
induced O 0 0.015377156
by O 0 0.006594924
antithyroid O 0 0.9917846
drugs O 0 0.92080337
: O 0 0.002880147
four O 0 0.00090900407
cases O 0 0.0015272049
including O 0 0.00094393705
one O 0 0.0008944114
with O 0 0.0011865494
cross O 0 0.0025674808
- O 0 0.0026187245
reactivity O 0 0.0037989642
between O 0 0.002298032
carbimazole B-Chemical 1 0.9997204
and O 0 0.0142633375
benzylthiouracil B-Chemical 0 0.9941759
. O 0 0.012041713

OBJECTIVE O 0 0.57764894
: O 0 0.010170483
This O 0 0.005808097
study O 0 0.0035417832
was O 0 0.002255144
conducted O 0 0.0014903204
to O 0 0.0011619647
assess O 0 0.0007135583
the O 0 0.0010429989
occurrence O 0 0.0023415547
of O 0 0.0022244938
hepatic B-Disease 0 0.9945957
adverse I-Disease 0 0.9851177
effects I-Disease 0 0.030991077
encountered O 0 0.0054056463
with O 0 0.0060748695
antithyroid O 0 0.99796885
drugs O 0 0.9723379
. O 0 0.011250595

METHODS O 0 0.012114838
: O 0 0.009323406
Retrospective O 0 0.027957467
review O 0 0.0046081594
of O 0 0.0028787774
medical O 0 0.0058332677
records O 0 0.0023836577
of O 0 0.0015621888
236 O 0 0.008671419
patients O 0 0.0025571075
with O 0 0.0014483333
hyperthyroidism B-Disease 2 0.9999341
admitted O 0 0.011562356
in O 0 0.0006907396
our O 0 0.00063778355
department O 0 0.001752773
( O 0 0.0013677431
in O 0 0.0008306526
- O 0 0.001436103
or O 0 0.0008263473
out O 0 0.0010564408
- O 0 0.0021014542
patients O 0 0.0034333675
) O 0 0.0032386342
from O 0 0.0025866197
1986 O 0 0.012665605
to O 0 0.0041474393
1992 O 0 0.018217236
. O 0 0.007887767

RESULTS O 0 0.02596608
: O 0 0.008613707
Four O 0 0.005712718
patients O 0 0.006336868
( O 0 0.003925957
1 O 0 0.0021474427
. O 0 0.0012519206
7 O 0 0.001147083
% O 0 0.0013161923
) O 0 0.0014008865
were O 0 0.00076022896
identified O 0 0.00066547457
with O 0 0.001290885
toxic B-Disease 0 0.9975083
hepatitis I-Disease 2 0.99999404
which O 0 0.0071861465
could O 0 0.00081191544
reasonably O 0 0.0014983146
be O 0 0.0009023284
attributed O 0 0.00079499895
to O 0 0.000945856
the O 0 0.0012907744
use O 0 0.0020893498
of O 0 0.004198835
antithyroid O 0 0.9966522
agent O 0 0.7634775
. O 0 0.011630905

Two O 0 0.0129367085
patients O 0 0.012033591
had O 0 0.007301934
a O 0 0.012356737
cholestatic B-Disease 0 0.9999573
hepatitis I-Disease 2 0.9999598
induced O 0 0.07334649
by O 0 0.035683997
carbimazole B-Chemical 1 0.99988365
( O 0 0.10664007
N B-Chemical 0 0.9973448
omercazole I-Chemical 0 0.65053606
) O 0 0.028761094
. O 0 0.012500119

Two O 0 0.01279912
others O 0 0.011134024
had O 0 0.006045278
a O 0 0.0063038776
mixed O 0 0.011507461
( O 0 0.012935015
cholestatic B-Disease 0 0.99993455
and O 0 0.024961516
cytolytic O 0 0.97456545
) O 0 0.17388642
hepatitis B-Disease 2 0.9998946
following O 0 0.0575147
carbimazole B-Chemical 1 0.999708
. O 0 0.017412191

One O 0 0.010011095
of O 0 0.0055964123
the O 0 0.0036674598
latter O 0 0.0040420643
two O 0 0.0018975991
patients O 0 0.003026835
further O 0 0.0015690163
experienced O 0 0.0027340152
a O 0 0.0028545896
cytolytic O 0 0.94528455
hepatitis B-Disease 2 0.9999732
which O 0 0.0054076645
appeared O 0 0.001622692
after O 0 0.0010446939
Benzylthiouracil B-Chemical 0 0.6090957
( O 0 0.0034617975
Basd B-Chemical 0 0.38291967
ne I-Chemical 0 0.6349055
) O 0 0.005740729
had O 0 0.0036441062
replaced O 0 0.006813208
carbimazole B-Chemical 1 0.99940705
. O 0 0.012213384

Biological O 0 0.053884786
features O 0 0.010988906
of O 0 0.009350689
hepatitis B-Disease 2 0.9998235
disappeared O 0 0.011694458
in O 0 0.0017497728
all O 0 0.0011789964
cases O 0 0.0015058244
after O 0 0.0005812961
cessation O 0 0.0023794747
of O 0 0.0008514779
the O 0 0.00082987896
incriminated O 0 0.11331697
drug O 0 0.73180604
, O 0 0.0016963789
while O 0 0.0010080256
biliary O 0 0.94702905
, O 0 0.0028026523
viral O 0 0.016807286
and O 0 0.0025318742
immunological O 0 0.065376796
searches O 0 0.0036994817
were O 0 0.0041960594
negative O 0 0.006868089
. O 0 0.008169158

Only O 0 0.011889467
2 O 0 0.006985043
patients O 0 0.0065265265
of O 0 0.0043919943
our O 0 0.0033945455
retrospective O 0 0.010592504
study O 0 0.0035927147
experienced O 0 0.0045596743
a O 0 0.0049706646
mild O 0 0.5420885
or O 0 0.007418861
severe O 0 0.8785383
neutropenia B-Disease 2 0.9996408
. O 0 0.017158195

CONCLUSION O 0 0.9173419
: O 0 0.02642601
Toxic B-Disease 0 0.99756324
hepatitis I-Disease 2 0.9999393
is O 0 0.005076052
a O 0 0.002845881
potential O 0 0.0022334175
adverse O 0 0.8735884
effect O 0 0.0012300125
of O 0 0.0015179912
antithyroid O 0 0.9952538
drugs O 0 0.90013546
which O 0 0.0014286694
warrants O 0 0.0012744815
, O 0 0.0008958085
as O 0 0.00049856777
for O 0 0.00044528654
haematological O 0 0.990031
disturbances O 0 0.8646944
, O 0 0.0011419826
a O 0 0.00087785296
pre O 0 0.006601394
- O 0 0.0010551775
therapeutic O 0 0.0024910385
determination O 0 0.0011214494
and O 0 0.0007676098
a O 0 0.0009263243
careful O 0 0.0010556243
follow O 0 0.00087007676
- O 0 0.001641289
up O 0 0.0011861937
of O 0 0.0018584135
relevant O 0 0.0025568677
biological O 0 0.0065260907
markers O 0 0.015211068
. O 0 0.009194476

Moreover O 0 0.015502536
, O 0 0.015623227
hepatotoxicity B-Disease 2 0.99981517
may O 0 0.0058561754
not O 0 0.003626641
be O 0 0.0029106583
restricted O 0 0.001975272
to O 0 0.0022063975
one O 0 0.0024298988
class O 0 0.0054621696
of O 0 0.0065963804
antithyroid O 0 0.9966863
agents O 0 0.8222962
. O 0 0.013981371

Interactive O 0 0.05409204
effects O 0 0.00830558
of O 0 0.005553864
variations O 0 0.0040330985
in O 0 0.003928546
[ O 0 0.035631854
Na B-Chemical 1 0.9997377
] O 0 0.008972534
o O 0 0.013728587
and O 0 0.003157854
[ O 0 0.029303577
Ca B-Chemical 1 0.9997049
] O 0 0.0052832034
o O 0 0.0049663316
on O 0 0.0015407065
rat O 0 0.011063752
atrial O 0 0.96288526
spontaneous O 0 0.06826277
frequency O 0 0.008625523
. O 0 0.009456055

The O 0 0.0072324486
effects O 0 0.005865928
of O 0 0.004003912
varying O 0 0.0034629034
the O 0 0.0024690116
extracellular O 0 0.053733706
concentrations O 0 0.010163463
of O 0 0.0074370615
Na B-Chemical 1 0.9999262
and O 0 0.012308128
Ca B-Chemical 1 0.9999428
( O 0 0.016168414
[ O 0 0.049006548
Na B-Chemical 1 0.999899
] O 0 0.004564651
o O 0 0.009137528
and O 0 0.0014345284
[ O 0 0.022545634
Ca B-Chemical 1 0.9998876
] O 0 0.004539996
o O 0 0.008740561
) O 0 0.0010405073
on O 0 0.00028546408
both O 0 0.0004151426
, O 0 0.00055924937
the O 0 0.00038402728
spontaneous O 0 0.007441276
beating O 0 0.043319613
and O 0 0.0005852317
the O 0 0.0004881539
negative O 0 0.00094122137
chronotropic O 0 0.99224454
action O 0 0.011110797
of O 0 0.0025153453
verapamil B-Chemical 1 0.9999882
, O 0 0.0023455815
were O 0 0.00107677
studied O 0 0.0012057705
in O 0 0.001334929
the O 0 0.0018724245
isolated O 0 0.0033231257
rat O 0 0.031795613
atria O 0 0.7472852
. O 0 0.009261898

Basal O 0 0.09197379
frequency O 0 0.008456427
( O 0 0.0073328894
BF O 0 0.1763367
) O 0 0.0037814102
evaluated O 0 0.0015406911
by O 0 0.0015463724
surface O 0 0.0023733252
electrogram O 0 0.7912055
was O 0 0.001281638
223 O 0 0.030746361
+ O 0 0.0011229642
/ O 0 0.0020995522
- O 0 0.0009731627
4 O 0 0.00047502833
beats O 0 0.16520831
/ O 0 0.0012711806
min O 0 0.0006193736
. O 0 0.00038630178
in O 0 0.00045451795
control O 0 0.0007692112
Krebs O 0 0.96303654
- O 0 0.0018558785
Ringer O 0 0.50563264
containing O 0 0.00078159804
137 O 0 0.051448494
mM O 0 0.825027
Na B-Chemical 1 0.9996234
and O 0 0.00154285
1 O 0 0.0014516492
. O 0 0.0011134661
35 O 0 0.002387559
mM O 0 0.73167264
Ca B-Chemical 1 0.99941635
( O 0 0.012458138
N O 0 0.9712821
) O 0 0.01421168
. O 0 0.00912816

It O 0 0.010795515
decreased O 0 0.007194735
by O 0 0.004785983
16 O 0 0.0036122254
+ O 0 0.0031434502
/ O 0 0.0047810175
- O 0 0.0023994753
3 O 0 0.0010495856
% O 0 0.0011403254
by O 0 0.0010659882
lowering O 0 0.05666453
[ O 0 0.031223489
Na B-Chemical 1 0.9998878
] O 0 0.0037245194
o O 0 0.0041844333
to O 0 0.0006968522
78 O 0 0.004236549
mM O 0 0.63294035
( O 0 0.0016824572
LNa O 0 0.784906
) O 0 0.001255976
, O 0 0.00069847726
23 O 0 0.0007719524
+ O 0 0.00061598246
/ O 0 0.001592684
- O 0 0.00082292996
2 O 0 0.0004174904
% O 0 0.00048021803
by O 0 0.00046555998
lowering O 0 0.007571828
simultaneously O 0 0.0009999356
[ O 0 0.022134997
Na B-Chemical 1 0.9998981
] O 0 0.002804192
o O 0 0.003439543
to O 0 0.0005746202
78 O 0 0.002937762
mM O 0 0.42313042
and O 0 0.0010329472
[ O 0 0.011439981
Ca B-Chemical 1 0.9998222
] O 0 0.0021728105
o O 0 0.0023710637
to O 0 0.0005038641
0 O 0 0.0008444927
. O 0 0.00045135687
675 O 0 0.055630263
mM O 0 0.46581727
( O 0 0.0014475617
LNa O 0 0.8100983
+ O 0 0.0012293239
LCa O 0 0.98046964
) O 0 0.0011339962
and O 0 0.0005853888
31 O 0 0.0009947987
+ O 0 0.00066527363
/ O 0 0.0017530333
- O 0 0.00083429297
5 O 0 0.00037427252
% O 0 0.0005125514
by O 0 0.0005567704
lowering O 0 0.04056044
[ O 0 0.023366116
Na B-Chemical 1 0.99989855
] O 0 0.0028774994
o O 0 0.0033663646
to O 0 0.00056648
78 O 0 0.0022823145
mM O 0 0.23621969
plus O 0 0.00057081354
increasing O 0 0.0013556548
[ O 0 0.021530114
Ca B-Chemical 1 0.999861
] O 0 0.003324002
o O 0 0.0033294822
to O 0 0.00074134866
3 O 0 0.00087054115
. O 0 0.0007645932
6 O 0 0.0011410519
mM O 0 0.34454206
( O 0 0.0043439697
LNa O 0 0.81986684
+ O 0 0.0063660825
HCa O 0 0.97743237
) O 0 0.01362773
. O 0 0.008768489

At O 0 0.008363997
normal O 0 0.011755995
[ O 0 0.019955112
Na B-Chemical 1 0.9992211
] O 0 0.009070621
o O 0 0.011383314
, O 0 0.0026035232
decrease O 0 0.0014888608
( O 0 0.0016756199
0 O 0 0.0012917762
. O 0 0.00068424403
675 O 0 0.041963924
mM O 0 0.3395451
) O 0 0.0011255534
or O 0 0.0005063267
increase O 0 0.00046115837
( O 0 0.0008019667
3 O 0 0.00045683034
. O 0 0.00034179812
6 O 0 0.00042438827
mM O 0 0.1973964
) O 0 0.0009792732
of O 0 0.0008614094
[ O 0 0.014498667
Ca B-Chemical 1 0.99987125
] O 0 0.002936597
o O 0 0.0032722824
did O 0 0.00044035685
not O 0 0.00043860273
modify O 0 0.0005938977
BF O 0 0.42626128
; O 0 0.000977552
a O 0 0.00052895816
reduction O 0 0.0005235967
of O 0 0.00041319377
ten O 0 0.00031759538
times O 0 0.00033704148
( O 0 0.0006784179
0 O 0 0.0006100371
. O 0 0.0003467653
135 O 0 0.0017113806
mM O 0 0.09934164
of O 0 0.0006583942
normal O 0 0.002718484
[ O 0 0.015162467
Ca B-Chemical 1 0.99986064
] O 0 0.003221832
o O 0 0.0041377
was O 0 0.0006294301
effective O 0 0.0007009419
to O 0 0.0006014474
reduce O 0 0.0007608058
BF O 0 0.19863136
by O 0 0.0013657886
40 O 0 0.0016834866
+ O 0 0.0021237198
/ O 0 0.004988992
- O 0 0.004189475
13 O 0 0.0043100794
% O 0 0.006217175
. O 0 0.0071251723

All O 0 0.01977743
negative O 0 0.019451194
chronotropic O 0 0.96002233
effects O 0 0.021654565
were O 0 0.015594402
BF O 0 0.5114935
- O 0 0.018772896
dependent O 0 0.013379561
. O 0 0.017436652

Dose O 0 0.47659066
- O 0 0.012398093
dependent O 0 0.006047322
bradycardia B-Disease 2 0.9991177
induced O 0 0.00656497
by O 0 0.0075985556
verapamil B-Chemical 1 0.9999697
was O 0 0.0057188207
potentiated O 0 0.39902577
by O 0 0.0067066234
LNa O 0 0.9636967
, O 0 0.0093063675
LCa O 0 0.9875158
, O 0 0.007754796
and O 0 0.0093313055
HCa O 0 0.98419005
. O 0 0.011886251

Independent O 0 0.027560549
but O 0 0.006310524
not O 0 0.003998109
additive O 0 0.007530441
effects O 0 0.005520611
of O 0 0.008443096
Na B-Chemical 1 0.99990654
and O 0 0.010216429
Ca B-Chemical 1 0.9998739
are O 0 0.0013424768
shown O 0 0.0005856131
by O 0 0.00068336364
decreases O 0 0.0005739464
in O 0 0.00041799937
the O 0 0.00043427842
values O 0 0.0005259076
of O 0 0.0009602563
[ O 0 0.02455433
verapamil B-Chemical 1 0.99999106
] O 0 0.0053836103
o O 0 0.0027092767
needed O 0 0.0003075395
to O 0 0.00036061028
reduce O 0 0.0004083757
BF O 0 0.19452307
by O 0 0.000564367
30 O 0 0.00039641059
% O 0 0.00066420797
( O 0 0.0010655137
IC30 O 0 0.9994394
) O 0 0.001023562
with O 0 0.00039869966
the O 0 0.00035179075
following O 0 0.00034012666
order O 0 0.00029727916
of O 0 0.0006356908
inhibitory O 0 0.02516778
potency O 0 0.27088216
: O 0 0.0057895044
LNa O 0 0.9317543
> O 0 0.0040001357
LCa O 0 0.9904544
> O 0 0.0037895415
HCa O 0 0.98542935
> O 0 0.0035749108
N O 0 0.9404236
, O 0 0.0019394645
resulting O 0 0.002239589
LNa O 0 0.8722646
+ O 0 0.0038248757
HCa O 0 0.9358581
similar O 0 0.0028813807
to O 0 0.0053793094
LNa O 0 0.8372134
. O 0 0.009187884

The O 0 0.010775597
[ O 0 0.021166656
verapamil B-Chemical 1 0.9998584
] O 0 0.012128474
o O 0 0.007815985
that O 0 0.0017644184
arrested O 0 0.0182053
atrial O 0 0.98237854
beating O 0 0.4873096
( O 0 0.004122813
AC O 0 0.9301071
) O 0 0.0022223864
was O 0 0.0006873407
also O 0 0.0007092214
potentiated O 0 0.02762324
with O 0 0.00073560403
the O 0 0.0006583664
order O 0 0.0006434709
LNa O 0 0.86455697
= O 0 0.0020208152
LNa O 0 0.76726806
+ O 0 0.0018211311
LCa O 0 0.98172325
= O 0 0.002807212
LNa O 0 0.76674825
+ O 0 0.002772232
HCa O 0 0.9823976
= O 0 0.0064930753
LCa O 0 0.9842897
> O 0 0.009822089
HCa O 0 0.9837235
= O 0 0.011900553
N O 0 0.9264318
. O 0 0.010106217

The O 0 0.006948058
results O 0 0.0048685996
indicate O 0 0.002969053
that O 0 0.0022540684
rat O 0 0.0067235143
atrial O 0 0.94956315
spontaneous O 0 0.06625102
beating O 0 0.12520319
is O 0 0.0010324223
more O 0 0.0008826324
dependent O 0 0.0006633521
on O 0 0.0006942823
[ O 0 0.021163305
Na B-Chemical 1 0.99988365
] O 0 0.0033091328
o O 0 0.0033300724
than O 0 0.00047144076
on O 0 0.000526314
[ O 0 0.011079581
Ca B-Chemical 1 0.9998307
] O 0 0.0027428914
o O 0 0.0027065007
in O 0 0.00054117176
a O 0 0.000790337
range O 0 0.00091576733
of O 0 0.0010613671
+ O 0 0.0014986093
/ O 0 0.0037000598
- O 0 0.001706849
50 O 0 0.0013970368
% O 0 0.0014260698
of O 0 0.0017171534
their O 0 0.0026754832
normal O 0 0.0056832926
concentration O 0 0.009945669
. O 0 0.008414793

Also O 0 0.009593913
the O 0 0.0055728834
enhancement O 0 0.0062133903
of O 0 0.0047856625
verapamil B-Chemical 1 0.99993277
effects O 0 0.006123492
on O 0 0.0012670548
atrial O 0 0.9732587
beating O 0 0.15689057
was O 0 0.0010100376
more O 0 0.0009603995
pronounced O 0 0.0011596495
at O 0 0.00078781345
LNa O 0 0.4506459
than O 0 0.0007846338
at O 0 0.0011215435
LCa O 0 0.95935637
. O 0 0.001497237
( O 0 0.0030258005
ABSTRACT O 0 0.010598063
TRUNCATED O 0 0.01566354
AT O 0 0.044468474
250 O 0 0.01101236
WORDS O 0 0.022825832
) O 0 0.03132712

Pseudo O 0 0.7005586
- O 0 0.026766438
allergic B-Disease 2 0.9985044
reactions I-Disease 2 0.6803926
to O 0 0.011148933
corticosteroids B-Chemical 1 0.999223
: O 0 0.021100702
diagnosis O 0 0.04800256
and O 0 0.01146102
alternatives O 0 0.017041322
. O 0 0.014635261

Two O 0 0.010379278
patients O 0 0.009418158
treated O 0 0.005717451
with O 0 0.004845766
parenteral O 0 0.9660889
paramethasone B-Chemical 1 0.99994195
( O 0 0.03404178
Triniol O 0 0.2243434
) O 0 0.0058598747
and O 0 0.003762242
dexamethasone B-Chemical 1 0.9996147
( O 0 0.010302124
Sedionbel O 0 0.113688245
) O 0 0.0067519727
are O 0 0.0049193213
described O 0 0.0057468805
. O 0 0.0091656335

A O 0 0.019955253
few O 0 0.0040243487
minutes O 0 0.0029462015
after O 0 0.0017900561
administration O 0 0.005927016
of O 0 0.0017985224
the O 0 0.0014441774
drugs O 0 0.70303404
, O 0 0.0016734995
they O 0 0.00085857
presented O 0 0.0015175599
urticaria B-Disease 2 0.99996066
( O 0 0.004833514
patients O 0 0.004658282
1 O 0 0.0009936402
and O 0 0.0009861806
2 O 0 0.0011152459
) O 0 0.0019286006
and O 0 0.0021264206
conjunctivitis B-Disease 0 0.999582
( O 0 0.006830227
patient O 0 0.0055834483
1 O 0 0.005437761
) O 0 0.009190384
. O 0 0.0079398425

The O 0 0.0064888904
purpose O 0 0.0047701667
of O 0 0.003491743
our O 0 0.0022618272
study O 0 0.0020919759
was O 0 0.0012847277
to O 0 0.0008422858
determine O 0 0.0004751696
the O 0 0.0007094273
cause O 0 0.0016068369
of O 0 0.0008213987
the O 0 0.00065713923
patients O 0 0.0027665982
' O 0 0.0009930052
reactions O 0 0.018702965
, O 0 0.00084416935
the O 0 0.0004581041
immunological O 0 0.020939847
mechanisms O 0 0.0010837638
involved O 0 0.0004807924
and O 0 0.0005399419
whether O 0 0.00028573629
these O 0 0.00068360404
patients O 0 0.0018165758
would O 0 0.00059505814
be O 0 0.0007560087
able O 0 0.00063374353
to O 0 0.0009592103
tolerate O 0 0.002170016
any O 0 0.0018574054
kind O 0 0.0055946684
of O 0 0.007780488
corticoid O 0 0.9978672
. O 0 0.012862591

Clinical O 0 0.038494337
examinations O 0 0.010786109
and O 0 0.0059253452
skin O 0 0.057264816
, O 0 0.0049786046
oral O 0 0.26469314
and O 0 0.0029328202
parenteral O 0 0.67093205
challenges O 0 0.0035976754
with O 0 0.0018747449
different O 0 0.002002039
corticosteroids B-Chemical 1 0.99928194
and O 0 0.0050699273
ELISA O 0 0.4115303
tests O 0 0.006999423
were O 0 0.004828911
performed O 0 0.005827983
. O 0 0.008423477

In O 0 0.007132232
the O 0 0.0048748646
two O 0 0.0033321716
patients O 0 0.0054759453
, O 0 0.0032737073
skin O 0 0.043721214
and O 0 0.0024175476
ELISA O 0 0.15705867
tests O 0 0.0031883991
with O 0 0.0016279047
paramethasone B-Chemical 1 0.99986887
were O 0 0.0012114599
negative O 0 0.0012905691
, O 0 0.0011379713
as O 0 0.0007272536
was O 0 0.0007094973
the O 0 0.0007799211
prick O 0 0.037764512
test O 0 0.0015003275
with O 0 0.0015030631
each O 0 0.0014573301
of O 0 0.003476542
its O 0 0.010565452
excipients O 0 0.9963786
. O 0 0.0118776085

A O 0 0.0407984
single O 0 0.008333626
- O 0 0.0068934397
blind O 0 0.008151756
parenteral O 0 0.4120495
challenge O 0 0.0025134985
with O 0 0.001725018
Triniol O 0 0.024178164
was O 0 0.000809482
positive O 0 0.0007071084
in O 0 0.0005376882
both O 0 0.00050978275
patients O 0 0.0010838959
after O 0 0.00029712674
the O 0 0.0004516999
administration O 0 0.01168951
of O 0 0.00076841156
1 O 0 0.0007020219
ml O 0 0.0013636006
of O 0 0.000822979
the O 0 0.00092738046
drug O 0 0.4203719
, O 0 0.0019312808
and O 0 0.0017193222
negative O 0 0.0025569764
with O 0 0.0035510273
its O 0 0.011479408
excipients O 0 0.9964018
. O 0 0.011446809

We O 0 0.008424259
also O 0 0.005543473
carried O 0 0.0034934694
out O 0 0.0029408294
oral O 0 0.10865349
and O 0 0.002743773
parenteral O 0 0.61047375
challenges O 0 0.0033201517
with O 0 0.0016302058
other O 0 0.001891917
corticosteroids B-Chemical 1 0.99935
and O 0 0.0028483693
found O 0 0.0018994758
intolerance O 0 0.88154835
to O 0 0.0025518925
some O 0 0.003647177
of O 0 0.0056752358
them O 0 0.01379698
. O 0 0.009528658

These O 0 0.011959397
results O 0 0.007973363
suggest O 0 0.0052608694
that O 0 0.005751694
paramethasone B-Chemical 1 0.99959975
caused O 0 0.015824918
pseudoallergic O 0 0.99623555
reactions O 0 0.33742428
in O 0 0.007166801
our O 0 0.007257499
patients O 0 0.022699343
. O 0 0.012262788

Corticosteroids O 0 0.9596563
different O 0 0.006661733
from O 0 0.005636793
paramethasone B-Chemical 1 0.9995245
also O 0 0.0035392123
produced O 0 0.002630504
hypersensitivity B-Disease 2 0.95612276
reactions O 0 0.102687106
in O 0 0.0013224568
these O 0 0.0015349567
patients O 0 0.0060057244
; O 0 0.0022551708
however O 0 0.0013666676
, O 0 0.0014735148
a O 0 0.0014072433
few O 0 0.0011050681
of O 0 0.0021882567
them O 0 0.0048399265
were O 0 0.004697955
tolerated O 0 0.061935194
. O 0 0.008715355

The O 0 0.011035797
basic O 0 0.00965308
mechanisms O 0 0.008062533
of O 0 0.006704946
those O 0 0.0068728356
reactions O 0 0.028515156
are O 0 0.0060323933
not O 0 0.005246966
yet O 0 0.0069537815
fully O 0 0.006850136
understood O 0 0.013770998
. O 0 0.011741203

To O 0 0.007132746
our O 0 0.005163222
knowledge O 0 0.005115275
, O 0 0.0036904328
this O 0 0.0021417814
is O 0 0.0016915445
the O 0 0.0013702841
first O 0 0.00116543
report O 0 0.0026302775
of O 0 0.0019459575
a O 0 0.0030684145
pseudo O 0 0.07569794
- O 0 0.013884832
allergy B-Disease 0 0.99707246
caused O 0 0.012785138
by O 0 0.027212732
paramethasone B-Chemical 1 0.99979407
. O 0 0.01573217

Study O 0 0.019843757
of O 0 0.007477456
the O 0 0.0051135668
role O 0 0.0036738843
of O 0 0.010141094
vitamin B-Chemical 1 0.99996424
B12 I-Chemical 1 0.9999931
and O 0 0.35339275
folinic B-Chemical 1 0.9999956
acid I-Chemical 1 0.9996406
supplementation O 0 0.9923798
in O 0 0.004097593
preventing O 0 0.066827744
hematologic O 0 0.99981827
toxicity B-Disease 2 0.99985576
of O 0 0.06632407
zidovudine B-Chemical 1 0.99579805
. O 0 0.012122671

A O 0 0.058628283
prospective O 0 0.011010741
, O 0 0.0052903546
randomized O 0 0.0030493464
study O 0 0.0022855133
was O 0 0.0014675312
conducted O 0 0.0009939407
to O 0 0.00079180393
evaluate O 0 0.0005278738
the O 0 0.00082115614
role O 0 0.00075502205
of O 0 0.006908462
vitamin B-Chemical 1 0.99999166
B12 I-Chemical 1 0.9999981
and O 0 0.23772973
folinic B-Chemical 1 0.9999981
acid I-Chemical 1 0.9996408
supplementation O 0 0.9890007
in O 0 0.0017544341
preventing O 0 0.020433946
zidovudine B-Chemical 1 0.99487704
( O 0 0.021493552
ZDV B-Chemical 0 0.9998128
) O 0 0.009493019
- O 0 0.0045837965
induced O 0 0.003991046
bone B-Disease 2 0.936068
marrow I-Disease 2 0.99385756
suppression I-Disease 2 0.7148942
. O 0 0.013022556

Seventy O 0 0.021591594
- O 0 0.009693396
five O 0 0.0042203427
human B-Disease 0 0.008610633
immunodeficiency I-Disease 0 0.9955942
virus I-Disease 0 0.7433538
( I-Disease 0 0.013494296
HIV I-Disease 0 0.93827343
) I-Disease 0 0.006988981
- I-Disease 0 0.0016766876
infected I-Disease 0 0.0007228691
patients O 0 0.001749372
with O 0 0.00080424343
CD4 O 0 0.44822544
+ O 0 0.00091628236
cell O 0 0.002255205
counts O 0 0.0006750813
< O 0 0.00054546323
500 O 0 0.0010565299
/ O 0 0.00088963954
mm3 O 0 0.0019810991
were O 0 0.00033460412
randomized O 0 0.00036399826
to O 0 0.00026696996
receive O 0 0.00031153965
either O 0 0.00050582836
ZDV B-Chemical 0 0.99934477
( O 0 0.00079524214
500 O 0 0.001280568
mg O 0 0.10091284
daily O 0 0.0011706515
) O 0 0.00080389326
alone O 0 0.0004933164
( O 0 0.0006599249
group O 0 0.00057824905
I O 0 0.0065900525
, O 0 0.0005455709
n O 0 0.00048434004
= O 0 0.0005917219
38 O 0 0.0006580095
) O 0 0.0006052038
or O 0 0.00033416197
in O 0 0.00037251017
combination O 0 0.0011681063
with O 0 0.0021580297
folinic B-Chemical 1 0.9999968
acid I-Chemical 1 0.9980282
( O 0 0.0027690316
15 O 0 0.0004660131
mg O 0 0.1204002
daily O 0 0.0015354062
) O 0 0.0011673176
and O 0 0.00089154573
intramascular O 0 0.9045836
vitamin B-Chemical 1 0.9999877
B12 I-Chemical 1 0.99999654
( O 0 0.0076757614
1000 O 0 0.002261435
micrograms O 0 0.08827655
monthly O 0 0.0011320766
) O 0 0.0016836405
( O 0 0.0012968582
group O 0 0.0013902328
II O 0 0.02415452
, O 0 0.0020907582
n O 0 0.0023656872
= O 0 0.0036419358
37 O 0 0.0046216827
) O 0 0.0076297577
. O 0 0.007222547

Finally O 0 0.009312933
, O 0 0.006552909
15 O 0 0.0033342845
patients O 0 0.003469401
were O 0 0.0018393357
excluded O 0 0.0016362999
from O 0 0.0011331043
the O 0 0.0009965901
study O 0 0.0012611853
( O 0 0.0014125643
noncompliance O 0 0.45273626
14 O 0 0.0010019582
, O 0 0.0012395555
death B-Disease 2 0.9950889
1 O 0 0.0010418562
) O 0 0.0013658985
; O 0 0.0008862464
thus O 0 0.0006407092
, O 0 0.000615811
60 O 0 0.00042450542
patients O 0 0.0009250226
( O 0 0.0006779445
31 O 0 0.0006624897
in O 0 0.00041374975
group O 0 0.0007669546
I O 0 0.004504468
and O 0 0.0008349112
29 O 0 0.0013009908
in O 0 0.00080111314
group O 0 0.001699105
II O 0 0.06426788
) O 0 0.0030028834
were O 0 0.002018714
eligible O 0 0.0029948258
for O 0 0.0028324458
analysis O 0 0.006532939
. O 0 0.007864392

No O 0 0.016522426
significant O 0 0.010298406
differences O 0 0.006597067
between O 0 0.0059163054
groups O 0 0.008015147
were O 0 0.0075772367
found O 0 0.006822103
at O 0 0.0081340475
enrollment O 0 0.016526379
. O 0 0.013204804

During O 0 0.007250153
the O 0 0.0059766346
study O 0 0.0063316957
, O 0 0.011091024
vitamin B-Chemical 1 0.9999294
B12 I-Chemical 1 0.9999894
and O 0 0.04473971
folate B-Chemical 0 0.999782
levels O 0 0.0016952899
were O 0 0.0009418955
significantly O 0 0.00090392155
higher O 0 0.0005727333
in O 0 0.00053106376
group O 0 0.0009835998
II O 0 0.07903402
patients O 0 0.005015303
; O 0 0.0011819315
however O 0 0.00058072124
, O 0 0.00049291854
no O 0 0.00024179603
differences O 0 0.0002593748
in O 0 0.00041921527
hemoglobin O 0 0.9135066
, O 0 0.0011375833
hematocrit O 0 0.7195899
, O 0 0.0006631668
mean O 0 0.00042509713
corpuscular O 0 0.9942979
volume O 0 0.008448783
, O 0 0.0008938219
and O 0 0.000619867
white O 0 0.011274596
- O 0 0.0015438845
cell O 0 0.0073560383
, O 0 0.0008939872
neutrophil O 0 0.13027297
and O 0 0.0007726737
platelet O 0 0.81049305
counts O 0 0.00070264743
were O 0 0.0004347225
observed O 0 0.0002914509
between O 0 0.00033335504
groups O 0 0.0007451699
at O 0 0.00050917594
3 O 0 0.0007032576
, O 0 0.0009838064
6 O 0 0.0007982422
, O 0 0.0013580626
9 O 0 0.0015081211
and O 0 0.0020794808
12 O 0 0.0025089337
months O 0 0.0036429046
. O 0 0.0063175815

Severe O 0 0.96453696
hematologic O 0 0.99887305
toxicity B-Disease 2 0.9996445
( O 0 0.00870284
neutrophil O 0 0.22976166
count O 0 0.0063321586
< O 0 0.001461853
1000 O 0 0.0016035663
/ O 0 0.0015353323
mm3 O 0 0.00325264
and O 0 0.0007739884
/ O 0 0.0013211833
or O 0 0.0005846321
hemoglobin O 0 0.79034
< O 0 0.0006682459
8 O 0 0.00045449266
g O 0 0.0008241227
/ O 0 0.001337078
dl O 0 0.010524392
) O 0 0.00092328794
occurred O 0 0.00048526446
in O 0 0.00042822474
4 O 0 0.00044952382
patients O 0 0.0008254455
assigned O 0 0.0004494467
to O 0 0.0006257283
group O 0 0.0012354513
I O 0 0.0072277877
and O 0 0.0014324575
7 O 0 0.0014370305
assigned O 0 0.001486369
to O 0 0.0025048316
group O 0 0.0059163054
II O 0 0.15931906
. O 0 0.009103526

There O 0 0.0105848415
was O 0 0.0066381465
no O 0 0.0042310134
correlation O 0 0.0037133745
between O 0 0.0042784703
vitamin B-Chemical 1 0.99992096
B12 I-Chemical 1 0.99998343
or O 0 0.03863907
folate B-Chemical 0 0.99967825
levels O 0 0.0049851066
and O 0 0.00533786
development O 0 0.010550941
of O 0 0.018604059
myelosuppression B-Disease 2 0.99988127
. O 0 0.0153848315

Vitamin B-Chemical 0 0.99989855
B12 I-Chemical 0 0.9999442
and O 0 0.22991477
folinic B-Chemical 1 0.99998486
acid I-Chemical 1 0.9993704
supplementation O 0 0.9871338
of O 0 0.015379908
ZDV B-Chemical 0 0.99984133
therapy O 0 0.03830145
does O 0 0.0007144157
not O 0 0.0006343445
seem O 0 0.00060964853
useful O 0 0.00056792866
in O 0 0.00045618668
preventing O 0 0.00122362
or O 0 0.00069570635
reducing O 0 0.0042134468
ZDV B-Chemical 0 0.9999329
- O 0 0.0048334356
induced O 0 0.0013185913
myelotoxicity B-Disease 0 0.999979
in O 0 0.0005346801
the O 0 0.00043743302
overall O 0 0.0005200618
treated O 0 0.0007196602
population O 0 0.0016990538
, O 0 0.00077762874
although O 0 0.00043318488
a O 0 0.0006911708
beneficial O 0 0.0011717684
effect O 0 0.0006621728
in O 0 0.0007005709
certain O 0 0.0012555862
subgroups O 0 0.0028265235
of O 0 0.0021488061
patients O 0 0.0090174535
cannot O 0 0.014759848
be O 0 0.004940842
excluded O 0 0.008266331
. O 0 0.008321289

Safety O 0 0.084523745
and O 0 0.02302599
side O 0 0.14277588
- O 0 0.02367557
effects O 0 0.022103801
of O 0 0.035455383
alprazolam B-Chemical 1 0.99985754
. O 0 0.030096827

Controlled O 0 0.031927835
study O 0 0.022631457
in O 0 0.023122927
agoraphobia B-Disease 2 0.9997075
with O 0 0.077378035
panic B-Disease 0 0.9996177
disorder I-Disease 0 0.9960704
. O 0 0.03126737

BACKGROUND O 0 0.5197249
: O 0 0.009101574
The O 0 0.004171506
widespread O 0 0.004788556
use O 0 0.0030415906
of O 0 0.0036953925
benzodiazepines B-Chemical 1 0.9998287
has O 0 0.0020283745
led O 0 0.0019649037
to O 0 0.0015254049
increasing O 0 0.0021651532
recognition O 0 0.0030382944
of O 0 0.0036041562
their O 0 0.0049836463
unwanted O 0 0.42575964
effects O 0 0.029781193
. O 0 0.010935575

The O 0 0.006909215
efficacy O 0 0.007044967
of O 0 0.0061221113
alprazolam B-Chemical 1 0.99996173
and O 0 0.004483083
placebo O 0 0.40711108
in O 0 0.0022850677
panic B-Disease 0 0.9999571
disorder I-Disease 0 0.99771
with O 0 0.011599604
agoraphobia B-Disease 2 0.99999607
, O 0 0.0022588242
and O 0 0.0008186041
the O 0 0.0006755556
side O 0 0.08184173
- O 0 0.0013975013
effect O 0 0.0005719341
and O 0 0.0007871951
adverse O 0 0.78370947
effect O 0 0.0008038579
profiles O 0 0.0007761554
of O 0 0.0013041947
both O 0 0.0015893967
drug O 0 0.50717473
groups O 0 0.0038620129
were O 0 0.0039199106
measured O 0 0.004134877
. O 0 0.007296551

METHOD O 0 0.029726839
: O 0 0.009262143
In O 0 0.004724358
London O 0 0.010443293
and O 0 0.0034958886
Toronto O 0 0.042090546
154 O 0 0.007221764
patients O 0 0.0025488774
who O 0 0.002113317
met O 0 0.0016690784
DSM O 0 0.27604818
- O 0 0.002535995
III O 0 0.02481533
criteria O 0 0.0011956184
for O 0 0.001043652
panic B-Disease 0 0.99995005
disorder I-Disease 0 0.9957775
with O 0 0.008607207
agoraphobia B-Disease 2 0.9999902
were O 0 0.0020571905
randomised O 0 0.0028505072
to O 0 0.002293683
alprazolam B-Chemical 1 0.9999497
or O 0 0.0052880743
placebo O 0 0.41593587
. O 0 0.008550966

Subjects O 0 0.0137983365
in O 0 0.007032783
each O 0 0.0047685057
drug O 0 0.074403524
group O 0 0.005066097
also O 0 0.0040645404
received O 0 0.0039306013
either O 0 0.004546979
exposure O 0 0.010106937
or O 0 0.008596647
relaxation O 0 0.4594395
. O 0 0.012923289

Treatment O 0 0.023722295
was O 0 0.006312612
from O 0 0.0040993197
weeks O 0 0.0024909915
0 O 0 0.0025649446
to O 0 0.0016955393
8 O 0 0.0015816793
and O 0 0.0015562071
was O 0 0.0014086692
then O 0 0.0014278506
tapered O 0 0.0032338488
from O 0 0.0018927337
weeks O 0 0.0018341509
8 O 0 0.0026736544
to O 0 0.0034672932
16 O 0 0.006128805
. O 0 0.007622443

RESULTS O 0 0.03966177
: O 0 0.016831543
Mean O 0 0.011911351
alprazolam B-Chemical 1 0.99958843
dose O 0 0.045810197
was O 0 0.009016078
5 O 0 0.008466144
mg O 0 0.30781543
daily O 0 0.018940998
. O 0 0.015151499

Compared O 0 0.0069317976
with O 0 0.005053962
placebo O 0 0.080693394
subjects O 0 0.0056755617
, O 0 0.0041884803
alprazolam B-Chemical 1 0.9999696
patients O 0 0.00684181
developed O 0 0.0015269411
more O 0 0.0011105388
adverse O 0 0.9021364
reactions O 0 0.09132054
( O 0 0.0014794848
21 O 0 0.0007649773
% O 0 0.0006453232
v O 0 0.0052440898
. O 0 0.0003674804
0 O 0 0.00056868186
% O 0 0.00055715634
) O 0 0.000747951
of O 0 0.000777563
depression B-Disease 2 0.99936134
, O 0 0.0027829648
enuresis B-Disease 0 0.9995396
, O 0 0.0023630823
disinhibition O 0 0.9906816
and O 0 0.0014586888
aggression B-Disease 2 0.9993948
; O 0 0.0017863103
and O 0 0.00055523566
more O 0 0.0006093067
side O 0 0.07271386
- O 0 0.0013709016
effects O 0 0.0011246138
, O 0 0.000867018
particularly O 0 0.0009835571
sedation O 0 0.8530186
, O 0 0.0033243578
irritability B-Disease 2 0.9999473
, O 0 0.0027980448
impaired B-Disease 0 0.009303036
memory I-Disease 0 0.65365475
, O 0 0.0032271284
weight B-Disease 0 0.014350487
loss I-Disease 0 0.0075378357
and O 0 0.011699486
ataxia B-Disease 2 0.99979895
. O 0 0.011520219

Side O 0 0.96918285
- O 0 0.014413997
effects O 0 0.007449043
tended O 0 0.0042156195
to O 0 0.0030032562
diminish O 0 0.0031966362
during O 0 0.0019654331
treatment O 0 0.0032183286
but O 0 0.0023756633
remained O 0 0.0025899322
significant O 0 0.002878898
at O 0 0.0028862732
week O 0 0.0037114609
8 O 0 0.0058095176
. O 0 0.007846755

Despite O 0 0.014621384
this O 0 0.010524314
, O 0 0.009797921
the O 0 0.0071425796
drop O 0 0.0107420515
- O 0 0.00853609
out O 0 0.00577895
rate O 0 0.0067251036
was O 0 0.008567962
low O 0 0.01272173
. O 0 0.014222986

CONCLUSIONS O 0 0.7665768
: O 0 0.020548671
Alprazolam B-Chemical 0 0.99986804
caused O 0 0.0070732157
side O 0 0.2953684
- O 0 0.004736863
effects O 0 0.0027218263
and O 0 0.0018196461
adverse O 0 0.8876511
effects O 0 0.0028728363
during O 0 0.0008639543
treatment O 0 0.0017556921
but O 0 0.0011725783
many O 0 0.001484719
patients O 0 0.003675347
were O 0 0.0020705983
willing O 0 0.0036474979
to O 0 0.0025851917
accept O 0 0.004895663
these O 0 0.006998686
. O 0 0.0084937485

Crescentic O 0 0.92807084
fibrillary O 0 0.8879665
glomerulonephritis B-Disease 2 0.9996772
associated O 0 0.010696685
with O 0 0.006464148
intermittent O 0 0.50097454
rifampin B-Chemical 1 0.99984705
therapy O 0 0.10929892
for O 0 0.0062534288
pulmonary B-Disease 0 0.99598277
tuberculosis I-Disease 2 0.99727327
. O 0 0.018035712

This O 0 0.009738771
case O 0 0.0051656035
study O 0 0.003744465
reveals O 0 0.0025752345
an O 0 0.0024907936
unusual O 0 0.003772735
finding O 0 0.0019373997
of O 0 0.001746899
rapidly O 0 0.0054662563
proliferative O 0 0.77742577
crescentic O 0 0.999476
glomerulonephritis B-Disease 2 0.9999914
in O 0 0.0016906778
a O 0 0.001341669
patient O 0 0.0011661184
treated O 0 0.0009198582
with O 0 0.0010730344
rifampin B-Chemical 1 0.99988806
who O 0 0.0016098084
had O 0 0.0005838141
no O 0 0.00053415186
other O 0 0.0010027881
identifiable O 0 0.008487394
causes O 0 0.003219248
for O 0 0.0019168914
developing O 0 0.010839651
this O 0 0.0052010203
disease O 0 0.8903607
. O 0 0.010970018

This O 0 0.009695319
patient O 0 0.006229957
underwent O 0 0.0038201984
a O 0 0.0033455305
10 O 0 0.0022900216
- O 0 0.0020474535
month O 0 0.00089668465
regimen O 0 0.001690021
of O 0 0.0014828206
rifampin B-Chemical 1 0.9999304
and O 0 0.0023710737
isoniazid B-Chemical 1 0.9999522
for O 0 0.00071166223
pulmonary B-Disease 0 0.9912509
tuberculosis I-Disease 2 0.9936395
and O 0 0.0013771959
was O 0 0.0006103954
discovered O 0 0.0006100051
to O 0 0.00042185752
have O 0 0.00042491418
developed O 0 0.00087719905
signs O 0 0.10448448
of O 0 0.0011629787
severe O 0 0.36590508
renal B-Disease 0 0.99280953
failure I-Disease 0 0.5750636
five O 0 0.000847962
weeks O 0 0.00086222973
after O 0 0.0009485183
completion O 0 0.0015862565
of O 0 0.0036918672
therapy O 0 0.041696552
. O 0 0.008423239

Renal O 0 0.53873855
biopsy O 0 0.01945687
revealed O 0 0.0069884574
severe O 0 0.39105144
glomerulonephritis B-Disease 2 0.999866
with O 0 0.009230361
crescents O 0 0.9774426
, O 0 0.005340555
electron O 0 0.02764297
dense O 0 0.00447383
fibrillar O 0 0.4383839
deposits O 0 0.37226266
and O 0 0.0054002674
moderate O 0 0.21659444
lymphocytic O 0 0.99956435
interstitial O 0 0.9925201
infiltrate O 0 0.9901462
. O 0 0.018953247

Other O 0 0.017237607
possible O 0 0.008008595
causes O 0 0.00818856
of O 0 0.0061151055
rapidly O 0 0.0101505425
progressive O 0 0.72582597
glomerulonephritis B-Disease 2 0.9999206
were O 0 0.0072801574
investigated O 0 0.004454284
and O 0 0.007217093
ruled O 0 0.017741041
out O 0 0.008876799
. O 0 0.011220385

This O 0 0.010345138
report O 0 0.007601203
documents O 0 0.005229407
the O 0 0.002660853
unusual O 0 0.0041961083
occurrence O 0 0.0036261033
of O 0 0.0023078946
rapidly O 0 0.005946972
progressive O 0 0.71148384
glomerulonephritis B-Disease 2 0.9999794
with O 0 0.007614573
crescents O 0 0.9862839
and O 0 0.0043258998
fibrillar O 0 0.88407093
glomerulonephritis B-Disease 2 0.9999695
in O 0 0.0025734857
a O 0 0.0030589493
patient O 0 0.0037107735
treated O 0 0.004735095
with O 0 0.009055949
rifampin B-Chemical 1 0.9997688
. O 0 0.011250432

Acute O 0 0.97364277
confusion B-Disease 2 0.91960204
induced O 0 0.006946275
by O 0 0.0045283437
a O 0 0.003833383
high O 0 0.0033016154
- O 0 0.0032344041
dose O 0 0.006381853
infusion O 0 0.010236559
of O 0 0.0024519898
5 B-Chemical 0 0.0024615522
- I-Chemical 0 0.0062992168
fluorouracil I-Chemical 0 0.99951553
and O 0 0.024721894
folinic B-Chemical 1 0.99996734
acid I-Chemical 1 0.99759763
. O 0 0.017476765

A O 0 0.045440733
61 O 0 0.012685746
- O 0 0.0071182866
year O 0 0.0036594048
- O 0 0.003378211
old O 0 0.0021807898
man O 0 0.03928192
was O 0 0.001332975
treated O 0 0.0012097129
with O 0 0.00095923775
combination O 0 0.0018307413
chemotherapy O 0 0.7835635
incorporating O 0 0.0030483436
cisplatinum B-Chemical 0 0.9999738
, O 0 0.01222263
etoposide B-Chemical 1 0.99986184
, O 0 0.001559907
high O 0 0.00094339176
- O 0 0.0011326192
dose O 0 0.0056337016
5 B-Chemical 0 0.0005724221
- I-Chemical 0 0.0013666839
fluorouracil I-Chemical 0 0.9994475
( O 0 0.0009970238
2 O 0 0.00050389004
, O 0 0.00057025213
250 O 0 0.0007753194
mg O 0 0.0915991
/ O 0 0.0014317728
m2 O 0 0.007656761
/ O 0 0.0011579682
24 O 0 0.00045124802
hours O 0 0.000489827
) O 0 0.0014154116
and O 0 0.0019572815
folinic B-Chemical 1 0.9999827
acid I-Chemical 1 0.98939663
for O 0 0.0024321424
an O 0 0.0064112316
inoperable O 0 0.99072015
gastric B-Disease 0 0.9987583
adenocarcinoma I-Disease 0 0.99985886
. O 0 0.01973356

He O 0 0.016337214
developed O 0 0.008643194
acute O 0 0.91290915
neurologic O 0 0.9987728
symptoms O 0 0.95842266
of O 0 0.0059395093
mental O 0 0.8339515
confusion B-Disease 2 0.9898044
, O 0 0.009748378
disorientation B-Disease 0 0.99979025
and O 0 0.0039504655
irritability B-Disease 2 0.99997175
, O 0 0.0015386862
and O 0 0.00066362036
then O 0 0.00049378566
lapsed O 0 0.016079072
into O 0 0.0002800259
a O 0 0.00061540323
deep O 0 0.0041290596
coma B-Disease 2 0.999918
, O 0 0.0008880308
lasting O 0 0.0007264972
for O 0 0.00027570728
approximately O 0 0.00031741947
40 O 0 0.00033166763
hours O 0 0.00020835854
during O 0 0.00021291476
the O 0 0.00029097998
first O 0 0.00030763046
dose O 0 0.0033907094
( O 0 0.00080185477
day O 0 0.0004813101
2 O 0 0.0006361609
) O 0 0.000996022
of O 0 0.0009141798
5 B-Chemical 0 0.001133825
- I-Chemical 0 0.0029772595
fluorouracil I-Chemical 0 0.9994326
and O 0 0.00971531
folinic B-Chemical 1 0.999979
acid I-Chemical 1 0.99774534
infusion O 0 0.46635193
. O 0 0.010465786

This O 0 0.0107621355
complication O 0 0.1000328
reappeared O 0 0.007179553
on O 0 0.0020936371
day O 0 0.001704157
25 O 0 0.0015841029
during O 0 0.0008111019
the O 0 0.0007915006
second O 0 0.0007722475
dose O 0 0.0030489315
of O 0 0.0011884578
5 B-Chemical 0 0.001031367
- I-Chemical 0 0.0026573502
fluorouracil I-Chemical 0 0.999699
and O 0 0.005579084
folinic B-Chemical 1 0.99999416
acid I-Chemical 1 0.99749655
, O 0 0.003194127
which O 0 0.0014390532
were O 0 0.0011505395
then O 0 0.0011396876
the O 0 0.00150906
only O 0 0.0022555357
drugs O 0 0.50291395
given O 0 0.004640859
. O 0 0.008025619

Because O 0 0.012821768
folinic B-Chemical 1 0.99990034
acid I-Chemical 1 0.9945064
was O 0 0.004453865
unlikely O 0 0.0021808147
to O 0 0.00148375
be O 0 0.0012927443
associated O 0 0.0011660029
with O 0 0.0009968295
this O 0 0.0009315409
condition O 0 0.0039975676
, O 0 0.0030525967
neurotoxicity B-Disease 2 0.9998777
due O 0 0.00072111934
to O 0 0.00074923073
high O 0 0.0013098837
- O 0 0.001923634
dose O 0 0.008466113
5 B-Chemical 0 0.001456239
- I-Chemical 0 0.003459979
fluorouracil I-Chemical 0 0.99871707
was O 0 0.0030251131
highly O 0 0.0050323685
suspected O 0 0.11462748
. O 0 0.009332658

The O 0 0.008065859
pathogenesis O 0 0.009709086
of O 0 0.0056038476
5 B-Chemical 0 0.00399032
- I-Chemical 0 0.0077524767
fluorouracil I-Chemical 0 0.9997638
neurotoxicity B-Disease 2 0.9999356
may O 0 0.001721427
be O 0 0.0010764488
due O 0 0.0006339807
to O 0 0.00071794796
a O 0 0.0016230914
Krebs O 0 0.9726246
cycle O 0 0.008041168
blockade O 0 0.35268348
by O 0 0.0030262552
fluoroacetate B-Chemical 0 0.9999813
and O 0 0.0276574
fluorocitrate B-Chemical 0 0.99999356
, O 0 0.07377671
thiamine B-Chemical 0 0.9999738
deficiency O 0 0.94425285
, O 0 0.00895893
or O 0 0.0052270987
dihydrouracil B-Chemical 0 0.9992248
dehydrogenase O 0 0.9992229
deficiency O 0 0.9472704
. O 0 0.011960681

High O 0 0.05736604
- O 0 0.01030739
dose O 0 0.013792218
5 B-Chemical 0 0.0041235415
- I-Chemical 0 0.006299455
fluorouracil I-Chemical 0 0.9995877
/ O 0 0.13475849
folinic B-Chemical 1 0.99998724
acid I-Chemical 1 0.99716216
infusion O 0 0.14582491
therapy O 0 0.023547312
has O 0 0.0010923981
recently O 0 0.0013725947
become O 0 0.0016838296
a O 0 0.0019516087
popular O 0 0.004310875
regimen O 0 0.005570876
for O 0 0.002733612
various O 0 0.012735172
cancers B-Disease 2 0.99743277
. O 0 0.012741936

It O 0 0.01115609
is O 0 0.0058143777
necessary O 0 0.0031964113
that O 0 0.0027329207
both O 0 0.0026397612
oncologists O 0 0.0058115865
and O 0 0.0029163032
neurologists O 0 0.008663612
be O 0 0.00208352
fully O 0 0.001720679
aware O 0 0.0023275234
of O 0 0.002991365
this O 0 0.0038372176
unusual O 0 0.033997074
complication O 0 0.8456221
. O 0 0.012997354

Effect O 0 0.012163356
of O 0 0.008523657
switching O 0 0.0125985015
carbamazepine B-Chemical 1 0.999951
to O 0 0.00769051
oxcarbazepine B-Chemical 0 0.99997723
on O 0 0.0029310668
the O 0 0.0033541676
plasma O 0 0.026186686
levels O 0 0.004686335
of O 0 0.010852429
neuroleptics O 0 0.999671
. O 0 0.013954595

A O 0 0.13084215
case O 0 0.07061052
report O 0 0.08946538
. O 0 0.068854846

Carbamazepine B-Chemical 1 0.9998387
was O 0 0.007008436
switched O 0 0.004927956
to O 0 0.0025207384
its O 0 0.0035442442
10 O 0 0.0023950168
- O 0 0.004407206
keto O 0 0.99884284
analogue O 0 0.68460923
oxcarbazepine B-Chemical 0 0.99999595
among O 0 0.0013406269
six O 0 0.00050277746
difficult O 0 0.000660614
- O 0 0.0011652047
to O 0 0.0006002808
- O 0 0.0014828362
treat O 0 0.0062562353
schizophrenic B-Disease 2 0.99987423
or O 0 0.0019493633
organic B-Disease 0 0.99943715
psychotic I-Disease 0 0.99999666
patients O 0 0.04723957
using O 0 0.0015441506
concomitantly O 0 0.26732793
haloperidol B-Chemical 1 0.99999535
, O 0 0.03323738
chlorpromazine B-Chemical 1 0.9999572
or O 0 0.021414217
clozapine B-Chemical 1 0.999938
. O 0 0.010947204

This O 0 0.010273584
change O 0 0.005351768
resulted O 0 0.0031141394
within O 0 0.0018772243
2 O 0 0.002035039
- O 0 0.0019246305
4 O 0 0.0008636316
weeks O 0 0.00054884795
in O 0 0.00058047
the O 0 0.000662269
50 O 0 0.0011813191
- O 0 0.0010860593
200 O 0 0.0009856833
% O 0 0.00058768917
increase O 0 0.000347612
in O 0 0.0004037694
the O 0 0.0004928448
plasma O 0 0.004396417
levels O 0 0.00056229765
of O 0 0.00081296137
these O 0 0.0013870614
neuroleptics O 0 0.9997763
and O 0 0.0017004083
the O 0 0.0016215892
appearance O 0 0.008159945
of O 0 0.016429933
extrapyramidal B-Disease 2 0.99999034
symptoms I-Disease 2 0.99780303
. O 0 0.013072802

None O 0 0.013722514
of O 0 0.0068567274
the O 0 0.0045117303
patients O 0 0.005039326
showed O 0 0.0023204905
any O 0 0.0021106962
clinical O 0 0.0065201265
deteriotation O 0 0.03592166
during O 0 0.0015264787
the O 0 0.001822156
following O 0 0.0021550541
3 O 0 0.0027849253
- O 0 0.0042082286
6 O 0 0.003331784
months O 0 0.0045657386
. O 0 0.0074252374

The O 0 0.006542121
results O 0 0.0046260282
of O 0 0.0036081034
this O 0 0.0023792644
case O 0 0.001908068
report O 0 0.002670015
support O 0 0.001092343
the O 0 0.0008834347
idea O 0 0.001033141
that O 0 0.00057885563
in O 0 0.0006131051
contrast O 0 0.00081654516
with O 0 0.0020683166
carbamazepine B-Chemical 1 0.999998
oxcarbazepine B-Chemical 0 0.99999833
does O 0 0.0006764447
not O 0 0.00056676037
induce O 0 0.00046881379
the O 0 0.000815994
hepatic O 0 0.9830676
microsomal O 0 0.9953408
enzyme O 0 0.24644615
systems O 0 0.0023730483
regulating O 0 0.0008478937
the O 0 0.0012619531
inactivation O 0 0.0029805633
of O 0 0.004281143
antipsychotic O 0 0.9997124
drugs O 0 0.95221084
. O 0 0.009905076

Time O 0 0.029127585
course O 0 0.012543201
of O 0 0.012491448
lipid O 0 0.9778389
peroxidation O 0 0.99989593
in O 0 0.023885842
puromycin B-Chemical 0 0.9950713
aminonucleoside I-Chemical 0 0.9999335
- O 0 0.254093
induced O 0 0.073152624
nephropathy B-Disease 2 0.99991226
. O 0 0.028292317

Reactive O 0 0.9636553
oxygen B-Chemical 1 0.9587145
species O 0 0.007056828
have O 0 0.0031963564
been O 0 0.002555849
implicated O 0 0.001673569
in O 0 0.0012364361
the O 0 0.0012062702
pathogenesis O 0 0.007910348
of O 0 0.0039736456
acute O 0 0.99777395
puromycin B-Chemical 0 0.99829596
aminonucleoside I-Chemical 0 0.99999213
( O 0 0.1758774
PAN B-Chemical 1 0.99993837
) O 0 0.049188472
- O 0 0.0055727726
induced O 0 0.0028828345
nephropathy B-Disease 2 0.99998534
, O 0 0.008950666
with O 0 0.0032486736
antioxidants O 0 0.9994821
significantly O 0 0.007539633
reducing O 0 0.008286891
the O 0 0.009793059
proteinuria B-Disease 2 0.9998753
. O 0 0.013119171

The O 0 0.008645309
temporal O 0 0.0105459
relationship O 0 0.003898843
between O 0 0.0032592895
lipid O 0 0.9462527
peroxidation O 0 0.99992347
in O 0 0.0032041173
the O 0 0.0026406215
kidney O 0 0.9193746
and O 0 0.006881059
proteinuria B-Disease 2 0.9999323
was O 0 0.0030578994
examined O 0 0.0021907852
in O 0 0.003284419
this O 0 0.004625615
study O 0 0.008496535
. O 0 0.009258688

Rats O 0 0.023722956
were O 0 0.0059028505
treated O 0 0.004169528
with O 0 0.00281257
a O 0 0.0026897076
single O 0 0.0021213212
IV O 0 0.19022185
injection O 0 0.004481478
of O 0 0.002953048
puromycin B-Chemical 0 0.98531854
aminonucleoside I-Chemical 0 0.99998474
, O 0 0.028227802
( O 0 0.008002608
PAN B-Chemical 1 0.999683
, O 0 0.0013899324
7 O 0 0.00052061427
. O 0 0.0003112211
5 O 0 0.0003373214
mg O 0 0.04573636
/ O 0 0.0011001026
kg O 0 0.003078434
) O 0 0.0007775064
and O 0 0.00039223596
24 O 0 0.00025751613
hour O 0 0.00021954898
urine O 0 0.012336286
samples O 0 0.00038032516
were O 0 0.00031150552
obtained O 0 0.00028585948
prior O 0 0.00021756372
to O 0 0.00027688715
sacrifice O 0 0.0005612969
on O 0 0.00021744946
days O 0 0.00028520857
3 O 0 0.0003735343
, O 0 0.0004895392
5 O 0 0.00034520577
, O 0 0.00047981628
7 O 0 0.00038037667
, O 0 0.0004911228
10 O 0 0.00041759433
, O 0 0.0005380687
17 O 0 0.0006264464
, O 0 0.00058810046
27 O 0 0.0007646777
, O 0 0.00070976006
41 O 0 0.001267939
( O 0 0.0012540215
N O 0 0.8168342
= O 0 0.0014571317
5 O 0 0.0009947318
- O 0 0.0015739114
10 O 0 0.0013734964
per O 0 0.0015901793
group O 0 0.004093204
) O 0 0.008737893
. O 0 0.0075683463

The O 0 0.0139954435
kidneys O 0 0.028303193
were O 0 0.009474761
removed O 0 0.007965521
, O 0 0.00889748
flushed O 0 0.010949037
with O 0 0.008279099
ice O 0 0.06696393
cold O 0 0.5628647
TRIS O 0 0.99877125
buffer O 0 0.4784636
. O 0 0.01886221

Kidney O 0 0.62066054
cortices O 0 0.29687077
from O 0 0.008653242
each O 0 0.0056582177
animal O 0 0.007454248
were O 0 0.0065251724
used O 0 0.006083084
to O 0 0.006982298
prepare O 0 0.011071044
homogenates O 0 0.054293696
. O 0 0.015665274

Tissue O 0 0.7167243
lipid O 0 0.95836663
peroxidation O 0 0.9997807
was O 0 0.0045598866
measured O 0 0.0018769884
in O 0 0.0015183802
whole O 0 0.0014590999
homogenates O 0 0.004183396
as O 0 0.001173509
well O 0 0.0009885799
as O 0 0.0011327184
in O 0 0.001193397
lipid O 0 0.7501079
extracts O 0 0.01253663
from O 0 0.0021720002
homogenates O 0 0.059960317
as O 0 0.006562719
thiobarbituric B-Chemical 1 0.9999399
acid I-Chemical 1 0.9988188
reactive O 0 0.9628471
substances O 0 0.99090517
. O 0 0.015200707

Proteinuria B-Disease 2 0.9985306
was O 0 0.0075561646
evident O 0 0.0042021144
at O 0 0.0025366114
day O 0 0.0022190413
5 O 0 0.0018872092
, O 0 0.0020055312
peaked O 0 0.0019564012
at O 0 0.0011782622
day O 0 0.00131245
7 O 0 0.0015121
and O 0 0.0019017381
persisted O 0 0.002261564
to O 0 0.0028696219
day O 0 0.00416609
27 O 0 0.008749201
. O 0 0.008190242

Lipid O 0 0.9969405
peroxidation O 0 0.99965656
in O 0 0.006100377
homogenates O 0 0.011791181
was O 0 0.0024014942
maximal O 0 0.0017012472
at O 0 0.0010694544
day O 0 0.0010450915
3 O 0 0.0010176306
and O 0 0.001171447
declined O 0 0.0017177287
rapidly O 0 0.0018563175
to O 0 0.0012851476
control O 0 0.0016348065
levels O 0 0.0020820135
by O 0 0.0032688272
day O 0 0.0038098404
17 O 0 0.0075730756
. O 0 0.0074028666

This O 0 0.011896113
study O 0 0.0068282546
supports O 0 0.0039533
the O 0 0.0033759195
role O 0 0.0024645706
of O 0 0.004270602
lipid O 0 0.9847585
peroxidation O 0 0.99995804
in O 0 0.0033664769
mediating O 0 0.0028588953
the O 0 0.0049702614
proteinuric B-Disease 0 0.9999541
injury I-Disease 0 0.99941623
in O 0 0.036047116
PAN B-Chemical 1 0.99982363
nephropathy B-Disease 2 0.99995065
. O 0 0.026648473

Composition O 0 0.021813443
of O 0 0.010501024
gall B-Disease 0 0.7914
bladder I-Disease 0 0.9608112
stones I-Disease 0 0.9906899
associated O 0 0.0070362557
with O 0 0.0060007134
octreotide B-Chemical 1 0.99964035
: O 0 0.007868416
response O 0 0.00486781
to O 0 0.0047094207
oral O 0 0.9673719
ursodeoxycholic B-Chemical 0 0.999936
acid I-Chemical 0 0.9959122
. O 0 0.018985558

Octreotide B-Chemical 0 0.9989623
, O 0 0.010644403
an O 0 0.0058651376
effective O 0 0.0037798837
treatment O 0 0.0038678546
for O 0 0.002342031
acromegaly B-Disease 0 0.9985903
, O 0 0.003507898
induces O 0 0.0016853838
gall B-Disease 0 0.93788064
bladder I-Disease 0 0.9880019
stones I-Disease 0 0.9918892
in O 0 0.0021630567
13 O 0 0.002658201
- O 0 0.002652961
60 O 0 0.0019769608
% O 0 0.0029045988
of O 0 0.0040155286
patients O 0 0.012146427
. O 0 0.00867091

Because O 0 0.0068367766
knowledge O 0 0.0057780026
of O 0 0.0042607384
stone O 0 0.47164014
composition O 0 0.0050342623
is O 0 0.0017276289
essential O 0 0.0011222301
for O 0 0.00071699044
studies O 0 0.0008270705
of O 0 0.00086629746
their O 0 0.0009836856
pathogenesis O 0 0.017033065
, O 0 0.0017598631
treatment O 0 0.0016592669
, O 0 0.0010462432
and O 0 0.0007019744
prevention O 0 0.006133791
, O 0 0.00078462256
this O 0 0.0004003152
was O 0 0.00038791154
investigated O 0 0.00033674823
by O 0 0.00051126815
direct O 0 0.0005038449
and O 0 0.0006493049
indirect O 0 0.0012393373
methods O 0 0.0007845769
in O 0 0.0007886351
14 O 0 0.0014068426
octreotide B-Chemical 1 0.9989586
treated O 0 0.0046863174
acromegalic B-Disease 0 0.9992022
patients O 0 0.027845262
with O 0 0.007017837
gall B-Disease 0 0.9910315
stones I-Disease 0 0.9976592
. O 0 0.015544655

Chemical O 0 0.8362334
analysis O 0 0.008360656
of O 0 0.006263491
gall B-Disease 0 0.8910388
stones I-Disease 0 0.9803175
retrieved O 0 0.0022496416
at O 0 0.0012911938
cholecystectomy O 0 0.03292563
from O 0 0.0009764518
two O 0 0.0007635647
patients O 0 0.0019970872
, O 0 0.0010296137
showed O 0 0.0005809698
that O 0 0.0005718239
they O 0 0.00071704783
contained O 0 0.00068104867
71 O 0 0.0022909618
% O 0 0.001422623
and O 0 0.0016195307
87 O 0 0.0034186416
% O 0 0.0034925414
cholesterol B-Chemical 1 0.9949673
by O 0 0.0067528337
weight O 0 0.03241199
. O 0 0.009321678

In O 0 0.0067148292
the O 0 0.004412182
remaining O 0 0.0030869527
12 O 0 0.0020289565
patients O 0 0.0028111674
, O 0 0.0017153837
localised O 0 0.0017117569
computed O 0 0.0014366857
tomography O 0 0.020950757
of O 0 0.00080710015
the O 0 0.000717084
gall O 0 0.4495371
bladder O 0 0.8989449
showed O 0 0.0005986072
that O 0 0.00041102796
eight O 0 0.00038822892
had O 0 0.0004830051
stones O 0 0.60760516
with O 0 0.00055851694
maximum O 0 0.00048995006
attenuation O 0 0.00096092664
scores O 0 0.0006958263
of O 0 0.0006177211
< O 0 0.0005958805
100 O 0 0.0008072455
Hounsfield O 0 0.002329923
units O 0 0.00052377593
( O 0 0.0006958959
values O 0 0.00051257736
of O 0 0.00074386154
< O 0 0.00092633977
100 O 0 0.0016950307
HU O 0 0.6665353
predict O 0 0.0013595392
cholesterol B-Chemical 1 0.99918455
rich O 0 0.02706875
, O 0 0.0076069995
dissolvable O 0 0.9423387
stones O 0 0.98449546
) O 0 0.0364797
. O 0 0.009831602

Gall O 0 0.3437885
bladder O 0 0.82755196
bile O 0 0.8645753
was O 0 0.005528004
obtained O 0 0.0038598566
by O 0 0.0036205945
ultrasound O 0 0.0128072025
guided O 0 0.0030793194
, O 0 0.0032724799
fine O 0 0.0054001724
needle O 0 0.0063312016
puncture O 0 0.009709568
from O 0 0.004134522
six O 0 0.004387085
patients O 0 0.013545834
. O 0 0.010414957

All O 0 0.0078096306
six O 0 0.004570309
patients O 0 0.0060120816
had O 0 0.0035955068
supersaturated O 0 0.93471456
bile O 0 0.9686857
( O 0 0.003689472
mean O 0 0.0015318313
( O 0 0.0020984483
SEM O 0 0.052267045
) O 0 0.0023399286
cholesterol B-Chemical 1 0.9961642
saturation O 0 0.004979992
index O 0 0.0009046458
of O 0 0.00077053916
1 O 0 0.00069971976
. O 0 0.00038591935
19 O 0 0.00076060946
( O 0 0.00064431166
0 O 0 0.0006174339
. O 0 0.00037696026
08 O 0 0.010388951
) O 0 0.0008296351
( O 0 0.000595566
range O 0 0.0006019116
1 O 0 0.00050469855
. O 0 0.00035477304
01 O 0 0.004435034
- O 0 0.00064988964
1 O 0 0.00040883565
. O 0 0.00029117372
53 O 0 0.0008249296
) O 0 0.0007678498
) O 0 0.00063568965
and O 0 0.00037765448
all O 0 0.00032230033
had O 0 0.00037110693
abnormally O 0 0.0050476524
rapid O 0 0.0054458054
cholesterol B-Chemical 1 0.99973994
microcrystal O 0 0.9801216
nucleation O 0 0.36053202
times O 0 0.00048689594
( O 0 0.00077147223
< O 0 0.0003969016
4 O 0 0.00027676707
days O 0 0.00026277392
( O 0 0.0004975586
range O 0 0.0005813869
1 O 0 0.00056188484
- O 0 0.00073167274
4 O 0 0.00044738853
) O 0 0.00089192094
) O 0 0.0008964352
, O 0 0.00061065075
whilst O 0 0.0006443546
in O 0 0.0004578747
four O 0 0.00049350056
, O 0 0.00097197667
the O 0 0.0009112035
bile O 0 0.8189657
contained O 0 0.0016511563
cholesterol B-Chemical 1 0.9994332
microcrystals O 0 0.9553973
immediately O 0 0.0035306262
after O 0 0.0026519569
sampling O 0 0.0052944063
. O 0 0.0076478757

Of O 0 0.009900887
the O 0 0.0052094692
12 O 0 0.003030263
patients O 0 0.0035837847
considered O 0 0.001736325
for O 0 0.0015592419
oral O 0 0.8644143
ursodeoxycholic B-Chemical 0 0.9999882
acid I-Chemical 0 0.9991555
( O 0 0.15025511
UDCA B-Chemical 0 0.99999785
) O 0 0.01592388
treatment O 0 0.0018208034
, O 0 0.00086717826
two O 0 0.0004120684
had O 0 0.00046357888
a O 0 0.0007716122
blocked O 0 0.0011305102
cystic O 0 0.46705583
duct O 0 0.6843116
and O 0 0.0010135421
were O 0 0.00067058206
not O 0 0.0005644294
started O 0 0.00079132494
on O 0 0.00077645876
UDCA B-Chemical 0 0.9999869
while O 0 0.001326985
one O 0 0.0012377353
was O 0 0.0015794626
lost O 0 0.0021277922
to O 0 0.0024141269
follow O 0 0.0032775886
up O 0 0.005502856
. O 0 0.007805963

After O 0 0.0056375363
one O 0 0.0041090865
year O 0 0.003009645
of O 0 0.0025234038
treatment O 0 0.0026798928
, O 0 0.001660075
five O 0 0.00069497107
of O 0 0.0007920073
the O 0 0.00059427315
remaining O 0 0.00051845174
nine O 0 0.0005681144
patients O 0 0.0011262939
showed O 0 0.00039864302
either O 0 0.00047610974
partial O 0 0.00082371687
( O 0 0.000734994
n O 0 0.00055502774
= O 0 0.0006447435
3 O 0 0.00038732233
) O 0 0.00056640175
or O 0 0.000332046
complete O 0 0.00037511982
( O 0 0.0006099251
n O 0 0.00055210723
= O 0 0.0007279019
2 O 0 0.0005613739
) O 0 0.0011016971
gall B-Disease 0 0.82659
stone I-Disease 0 0.97007644
dissolution O 0 0.9408947
, O 0 0.0018542927
suggesting O 0 0.0009137879
that O 0 0.0011614547
their O 0 0.0024173982
stones O 0 0.924623
were O 0 0.0067920964
cholesterol B-Chemical 1 0.99894863
rich O 0 0.06238231
. O 0 0.010847374

This O 0 0.011125532
corresponds O 0 0.005094537
, O 0 0.0049275374
by O 0 0.0035328113
actuarial O 0 0.31912887
( O 0 0.0036315373
life O 0 0.003414354
table O 0 0.0015031154
) O 0 0.0019598831
analysis O 0 0.0011768326
, O 0 0.0009810555
to O 0 0.00055863615
a O 0 0.0008214875
combined O 0 0.0011629842
gall B-Disease 0 0.94221586
stone I-Disease 0 0.9772726
dissolution O 0 0.88073206
rate O 0 0.00092612224
of O 0 0.0010981126
58 O 0 0.0018249819
. O 0 0.0006896375
3 O 0 0.0009079155
( O 0 0.001372336
15 O 0 0.0011488443
. O 0 0.0013743547
9 O 0 0.0024652903
% O 0 0.0042198137
) O 0 0.0076370905
. O 0 0.007389638

In O 0 0.0075954935
conclusion O 0 0.0053163487
, O 0 0.006706858
octreotide B-Chemical 1 0.9987011
induced O 0 0.005987262
gall B-Disease 0 0.9863977
stones I-Disease 0 0.9976665
are O 0 0.0021010493
generally O 0 0.0014799209
small O 0 0.0012666862
, O 0 0.001145503
multiple O 0 0.0016740876
, O 0 0.0011416896
and O 0 0.0010129967
cholesterol B-Chemical 1 0.9993067
rich O 0 0.005633843
although O 0 0.00068792654
, O 0 0.00076052017
in O 0 0.00039514288
common O 0 0.0006535109
with O 0 0.00063686364
spontaneous O 0 0.078653745
gall B-Disease 0 0.9960068
stone I-Disease 0 0.9950086
disease I-Disease 0 0.99168503
, O 0 0.0016938549
at O 0 0.0004019496
presentation O 0 0.0013542178
some O 0 0.00061586883
patients O 0 0.0014447027
will O 0 0.00048468664
have O 0 0.0005699179
a O 0 0.0011399151
blocked O 0 0.0019092017
cystic O 0 0.5482079
duct O 0 0.7174121
and O 0 0.0027651042
some O 0 0.0033844362
gall B-Disease 0 0.9818502
stones I-Disease 0 0.9977568
containing O 0 0.018033113
calcium B-Chemical 1 0.99909127
. O 0 0.013535733

Erythema B-Disease 0 0.99704653
multiforme I-Disease 0 0.99822325
and O 0 0.044739626
hypersensitivity B-Disease 2 0.9984914
myocarditis I-Disease 0 0.9999347
caused O 0 0.16019043
by O 0 0.057883456
ampicillin B-Chemical 1 0.9977272
. O 0 0.022486776

OBJECTIVE O 0 0.42036757
: O 0 0.009422759
To O 0 0.0043656393
report O 0 0.0054701306
a O 0 0.0036829575
case O 0 0.0028643871
of O 0 0.0048450786
erythema B-Disease 0 0.9998642
multiforme I-Disease 0 0.9995871
and O 0 0.03629824
hypersensitivity B-Disease 2 0.999634
myocarditis I-Disease 0 0.9999887
caused O 0 0.11801984
by O 0 0.051590554
ampicillin B-Chemical 1 0.9985481
. O 0 0.013297316

CASE O 0 0.3694673
SUMMARY O 0 0.0403959
: O 0 0.009006743
A O 0 0.016189743
13 O 0 0.00459882
- O 0 0.0038510144
year O 0 0.0022484388
- O 0 0.0024088556
old O 0 0.0017556995
boy O 0 0.0041595744
was O 0 0.0014111317
treated O 0 0.0017992697
with O 0 0.0022179543
ampicillin B-Chemical 1 0.9958508
and O 0 0.0034357666
gentamicin B-Chemical 1 0.9975986
because O 0 0.0024649035
of O 0 0.0050421143
suspected O 0 0.51230043
septicemia B-Disease 0 0.99941504
. O 0 0.016282259

Medications O 0 0.77358264
were O 0 0.007656638
discontinued O 0 0.014754342
when O 0 0.0042276834
erythema B-Disease 0 0.99955577
multiforme I-Disease 0 0.9987594
and O 0 0.009006468
congestive B-Disease 0 0.99993885
heart I-Disease 0 0.96696943
failure I-Disease 0 0.8994233
caused O 0 0.008276939
by O 0 0.013970895
myocarditis B-Disease 2 0.9999006
occurred O 0 0.024388041
. O 0 0.01266148

The O 0 0.012929367
patient O 0 0.012664647
was O 0 0.009032012
treated O 0 0.009046891
with O 0 0.010363989
methylprednisolone B-Chemical 1 0.9996444
and O 0 0.017442254
gradually O 0 0.029425742
improved O 0 0.021033712
. O 0 0.015659928

Macrophage O 0 0.9103847
- O 0 0.020540765
migration O 0 0.028963245
inhibition O 0 0.01807208
( O 0 0.010695736
MIF O 0 0.91757095
) O 0 0.0092627555
test O 0 0.005603911
with O 0 0.006467781
ampicillin B-Chemical 1 0.99259007
was O 0 0.0075512663
positive O 0 0.009827117
. O 0 0.011689649

DISCUSSION O 0 0.03233447
: O 0 0.0072632176
After O 0 0.0031036143
most O 0 0.0039098994
infections B-Disease 2 0.72920644
causing O 0 0.094396755
erythema B-Disease 0 0.9999207
multiforme I-Disease 0 0.9996933
and O 0 0.016238421
myocarditis B-Disease 2 0.99997556
were O 0 0.0026423563
ruled O 0 0.005289692
out O 0 0.0011094899
, O 0 0.001473181
a O 0 0.0016304804
drug B-Disease 0 0.6171333
- I-Disease 0 0.004543592
induced I-Disease 0 0.003668169
allergic I-Disease 2 0.9998511
reaction I-Disease 2 0.8043228
was O 0 0.0089743715
suspected O 0 0.2644875
. O 0 0.010695514

Positive O 0 0.043893117
MIF O 0 0.620324
test O 0 0.00696686
for O 0 0.0039314283
ampicillin B-Chemical 1 0.96995944
showed O 0 0.002551734
sensitization O 0 0.058668572
of O 0 0.002635103
the O 0 0.0021638123
patient O 0 0.0034794935
' O 0 0.0036938565
s O 0 0.0041590766
lymphocytes O 0 0.30185735
to O 0 0.0075457767
ampicillin B-Chemical 1 0.99589574
. O 0 0.011934798

CONCLUSIONS O 0 0.76283365
: O 0 0.02764261
Hypersensitivity B-Disease 0 0.9981306
myocarditis I-Disease 2 0.9999212
is O 0 0.0068725627
a O 0 0.005240457
rare O 0 0.015116963
and O 0 0.004383702
dangerous O 0 0.14442027
manifestation O 0 0.35136315
of O 0 0.010132659
allergy B-Disease 0 0.9986411
to O 0 0.014431288
penicillins B-Chemical 0 0.9982344
. O 0 0.0145840505

Clomipramine B-Chemical 0 0.9997937
- O 0 0.0226751
induced O 0 0.008997457
sleep B-Disease 0 0.9118861
disturbance I-Disease 0 0.7875626
does O 0 0.0034403198
not O 0 0.0032068093
impair O 0 0.0031886615
its O 0 0.01122446
prolactin O 0 0.9980806
- O 0 0.025976134
releasing O 0 0.20801365
action O 0 0.076422624
. O 0 0.01152665

The O 0 0.0068670837
present O 0 0.003992301
study O 0 0.0037296289
was O 0 0.002312104
undertaken O 0 0.0013864237
to O 0 0.001059682
examine O 0 0.0006414106
the O 0 0.0008259321
role O 0 0.0006054784
of O 0 0.0013180934
sleep B-Disease 0 0.9686211
disturbance I-Disease 0 0.9402861
, O 0 0.001835132
induced O 0 0.00096105534
by O 0 0.001691019
clomipramine B-Chemical 1 0.99999595
administration O 0 0.18130393
, O 0 0.0008626841
on O 0 0.00029663707
the O 0 0.00044868817
secretory O 0 0.002450504
rate O 0 0.00069011905
of O 0 0.0018776337
prolactin O 0 0.9992768
( O 0 0.01772806
PRL O 0 0.99979657
) O 0 0.0022826707
in O 0 0.00077967515
addition O 0 0.00067544787
to O 0 0.0011214205
the O 0 0.0015878205
direct O 0 0.0026999458
drug O 0 0.57050633
effect O 0 0.0068703988
. O 0 0.008651553

Two O 0 0.008112184
groups O 0 0.0050373515
of O 0 0.0035546313
supine O 0 0.0037653206
subjects O 0 0.0023587854
were O 0 0.0012917651
studied O 0 0.0010746199
under O 0 0.0007571064
placebo O 0 0.18468021
- O 0 0.0014678395
controlled O 0 0.0005921944
conditions O 0 0.00071670423
, O 0 0.00066110207
one O 0 0.00033158358
during O 0 0.00027624716
the O 0 0.00038777158
night O 0 0.00088273204
, O 0 0.00054622337
when O 0 0.00031515706
sleeping O 0 0.0859621
( O 0 0.00069296756
n O 0 0.0005458242
= O 0 0.00064130296
7 O 0 0.0004105995
) O 0 0.0006057035
and O 0 0.00041699206
the O 0 0.0004020887
other O 0 0.00049494393
at O 0 0.00047312854
daytime O 0 0.016338311
, O 0 0.00085155875
when O 0 0.00061835203
awake O 0 0.002849767
( O 0 0.0017175382
n O 0 0.0019469425
= O 0 0.0030468367
6 O 0 0.002805483
) O 0 0.006634711
. O 0 0.0067651

Each O 0 0.006860031
subject O 0 0.0042471336
received O 0 0.003167767
a O 0 0.0030597085
single O 0 0.0022926922
50 O 0 0.002333115
mg O 0 0.114479415
dose O 0 0.0066812895
of O 0 0.0024774699
clomipramine B-Chemical 1 0.99997985
given O 0 0.0012233095
orally O 0 0.010279332
2 O 0 0.0017282047
hours O 0 0.0014353482
before O 0 0.001797029
blood O 0 0.010566355
collection O 0 0.009010985
. O 0 0.008034408

Plasma O 0 0.64259213
PRL O 0 0.99778724
concentrations O 0 0.009953574
were O 0 0.0035519742
analysed O 0 0.002434229
at O 0 0.0015410586
10 O 0 0.0014177975
min O 0 0.001323502
intervals O 0 0.0010261383
and O 0 0.0012189733
underlying O 0 0.0019685717
secretory O 0 0.0045204167
rates O 0 0.001952782
calculated O 0 0.0017989333
by O 0 0.002843414
a O 0 0.004283113
deconvolution O 0 0.008276289
procedure O 0 0.006682075
. O 0 0.008886462

For O 0 0.006248083
both O 0 0.0043602553
experiments O 0 0.0031152766
the O 0 0.0026146723
drug O 0 0.42285556
intake O 0 0.6843114
led O 0 0.0017575967
to O 0 0.0009628875
significant O 0 0.0011080407
increases O 0 0.0010460758
in O 0 0.0013511813
PRL O 0 0.9998946
secretion O 0 0.12779215
, O 0 0.0014102457
acting O 0 0.002321364
preferentially O 0 0.0004980025
on O 0 0.0003871032
tonic O 0 0.6829486
secretion O 0 0.01629725
as O 0 0.0006609742
pulse O 0 0.006995321
amplitude O 0 0.0044862526
and O 0 0.00068862573
frequency O 0 0.00078179257
did O 0 0.00065603945
not O 0 0.0007585045
differ O 0 0.0010929205
significantly O 0 0.0016986278
from O 0 0.001824058
corresponding O 0 0.0020024793
control O 0 0.0033715344
values O 0 0.0055154795
. O 0 0.0073337634

During O 0 0.0065629035
the O 0 0.0052766413
night O 0 0.008459687
clomipramine B-Chemical 1 0.99994624
ingestion O 0 0.7913173
altered O 0 0.0026964906
the O 0 0.0012827617
complete O 0 0.0010114542
sleep O 0 0.22636028
architecture O 0 0.0019235554
in O 0 0.00068656553
that O 0 0.0006066753
it O 0 0.0009309447
suppressed O 0 0.0012936291
REM O 0 0.9913052
sleep O 0 0.30273312
and O 0 0.0011204542
the O 0 0.0010692588
sleep O 0 0.1529174
cycles O 0 0.0014269603
and O 0 0.0023083978
induced O 0 0.0035402505
increased O 0 0.007996891
wakefulness O 0 0.8767065
. O 0 0.0093742525

As O 0 0.0061150356
the O 0 0.0044607716
relative O 0 0.0029120771
increase O 0 0.0023340853
in O 0 0.0026865809
PRL O 0 0.99958163
secretion O 0 0.04541747
expressed O 0 0.00083293696
as O 0 0.0007320205
a O 0 0.0007141096
percentage O 0 0.00036705972
of O 0 0.00053744233
the O 0 0.00043893149
mean O 0 0.00041827242
did O 0 0.00038921833
not O 0 0.00039380978
significantly O 0 0.00055535213
differ O 0 0.00045408643
between O 0 0.0002645585
the O 0 0.00040115128
night O 0 0.00070649234
and O 0 0.00039533296
day O 0 0.00031822338
time O 0 0.00030057423
studies O 0 0.0005200261
( O 0 0.0007036139
46 O 0 0.0008575169
+ O 0 0.0006138994
/ O 0 0.0015148224
- O 0 0.00073827297
19 O 0 0.000571819
% O 0 0.00043576764
vs O 0 0.0006400653
34 O 0 0.0006512111
+ O 0 0.0005779601
/ O 0 0.0015270784
- O 0 0.0008077584
10 O 0 0.00043494217
% O 0 0.00058400165
) O 0 0.0008390561
, O 0 0.00055779924
it O 0 0.00042256346
can O 0 0.00029978546
be O 0 0.00036148285
concluded O 0 0.0003759629
that O 0 0.00030955038
the O 0 0.00043259477
observed O 0 0.0004597067
sleep B-Disease 0 0.88436323
disturbance I-Disease 0 0.68939334
did O 0 0.00074161077
not O 0 0.0007658595
interfere O 0 0.0008938202
with O 0 0.001137457
the O 0 0.0015054023
drug O 0 0.42204955
action O 0 0.009188475
per O 0 0.0028635457
se O 0 0.008763736
. O 0 0.008693511

The O 0 0.007069657
presence O 0 0.004839674
of O 0 0.005371669
REM O 0 0.9832078
sleep O 0 0.55033576
was O 0 0.0018626739
shown O 0 0.00093624624
not O 0 0.00081266934
to O 0 0.0006689442
be O 0 0.00065555575
a O 0 0.0006940898
determining O 0 0.0004350417
factor O 0 0.0026280493
either O 0 0.00052666507
for O 0 0.0003788484
secretory O 0 0.0032571773
pulse O 0 0.008608379
amplitude O 0 0.00615403
and O 0 0.00057603605
frequency O 0 0.00074063195
, O 0 0.00075179944
as O 0 0.00048770694
, O 0 0.00059226126
for O 0 0.00029542233
both O 0 0.0004078143
, O 0 0.00056749413
mean O 0 0.00041645794
nocturnal O 0 0.081099235
values O 0 0.00060128205
were O 0 0.0006065949
similar O 0 0.00053222856
with O 0 0.00095761317
and O 0 0.0014568277
without O 0 0.0018098422
prior O 0 0.0028661827
clomipramine B-Chemical 1 0.9999714
ingestion O 0 0.91843414
. O 0 0.011142905

Survey O 0 0.024070058
of O 0 0.014148874
complications O 0 0.2427629
of O 0 0.015597355
indocyanine B-Chemical 0 0.9966718
green I-Chemical 0 0.045363795
angiography O 0 0.5200503
in O 0 0.014758773
Japan O 0 0.26574388
. O 0 0.01799909

PURPOSE O 0 0.028650017
: O 0 0.009638585
We O 0 0.0049005104
evaluated O 0 0.0033824167
the O 0 0.0031125837
safety O 0 0.0042889165
of O 0 0.0040361066
indocyanine B-Chemical 0 0.997326
green I-Chemical 0 0.0075089536
for O 0 0.0028133912
use O 0 0.0041440413
in O 0 0.0051897247
fundus O 0 0.7516317
angiography O 0 0.502357
. O 0 0.01135764

METHODS O 0 0.011281583
: O 0 0.007683454
We O 0 0.0039017498
sent O 0 0.0031141364
a O 0 0.002506455
questionnaire O 0 0.0018571094
concerning O 0 0.0011614979
complications O 0 0.18165624
of O 0 0.0018405258
indocyanine B-Chemical 0 0.998934
green I-Chemical 0 0.00327393
to O 0 0.0007374535
32 O 0 0.0010404796
institutions O 0 0.0017374246
in O 0 0.0005890274
Japan O 0 0.05967357
, O 0 0.00066625
which O 0 0.0004648325
were O 0 0.00033752638
selected O 0 0.00027232643
on O 0 0.00022702105
the O 0 0.0003082493
basis O 0 0.00037503938
of O 0 0.0004923691
the O 0 0.0004875424
client O 0 0.0011801472
list O 0 0.0005414519
from O 0 0.0006425198
the O 0 0.00096280687
Topcon O 0 0.27780238
Company O 0 0.66905874
, O 0 0.00130522
which O 0 0.0013323469
manufactures O 0 0.013357907
the O 0 0.0022310696
indocyanine B-Chemical 0 0.9974795
green I-Chemical 0 0.014716918
fundus O 0 0.7658528
camera O 0 0.023694053
. O 0 0.009017791

RESULTS O 0 0.02869911
: O 0 0.009158794
Ophthalmologists O 0 0.007170664
at O 0 0.0026499724
15 O 0 0.0021188175
institutions O 0 0.0029763582
responded O 0 0.0020624853
, O 0 0.0013914753
reporting O 0 0.0012575628
a O 0 0.0008654983
total O 0 0.00064977776
of O 0 0.00083397137
3 O 0 0.0007336858
, O 0 0.0009104082
774 O 0 0.011277754
indocyanine B-Chemical 0 0.9897221
green I-Chemical 0 0.0017303965
angiograms O 0 0.07789973
performed O 0 0.0005740597
on O 0 0.0005238234
2 O 0 0.00085783075
, O 0 0.0011701265
820 O 0 0.0032693336
patients O 0 0.0017756678
between O 0 0.0011351552
June O 0 0.0026646925
1984 O 0 0.006249741
and O 0 0.0036082854
September O 0 0.00599165
1992 O 0 0.012720182
. O 0 0.007646909

Before O 0 0.011259117
angiography O 0 0.08611186
, O 0 0.0053903246
intradermal O 0 0.02314716
or O 0 0.0025741495
intravenous O 0 0.49348256
indocyanine B-Chemical 0 0.99905807
green I-Chemical 0 0.0067836284
testing O 0 0.0016340689
, O 0 0.001586932
or O 0 0.0009958261
both O 0 0.0010402135
was O 0 0.0011270914
performed O 0 0.0011370742
at O 0 0.001260882
13 O 0 0.0021231228
of O 0 0.002761286
15 O 0 0.003726064
institutions O 0 0.01020152
. O 0 0.007761013

For O 0 0.006966018
three O 0 0.0044905436
patients O 0 0.0062409993
, O 0 0.0037081775
the O 0 0.0022282964
decision O 0 0.0034629973
was O 0 0.0016686892
made O 0 0.0013910182
not O 0 0.0012558307
to O 0 0.0012428215
proceed O 0 0.0019400062
with O 0 0.0018458659
angiography O 0 0.064393476
after O 0 0.0015324214
positive O 0 0.003248899
preangiographic O 0 0.060663097
testing O 0 0.0069042174
. O 0 0.00894415

The O 0 0.007634312
dosage O 0 0.022442779
of O 0 0.0057908087
indocyanine B-Chemical 0 0.9958187
green I-Chemical 0 0.0063950676
used O 0 0.0018418633
for O 0 0.0013474205
angiography O 0 0.049599335
varied O 0 0.0014426109
from O 0 0.0010967124
25 O 0 0.0012822486
to O 0 0.0009410264
75 O 0 0.0017292472
mg O 0 0.11097856
, O 0 0.002122051
depending O 0 0.0022089942
upon O 0 0.0023079112
the O 0 0.0039653713
institution O 0 0.0080789095
. O 0 0.008711611

There O 0 0.008651985
were O 0 0.005367523
13 O 0 0.0039947666
cases O 0 0.00322106
of O 0 0.0024633352
adverse O 0 0.8618235
reactions O 0 0.1249802
( O 0 0.002747716
0 O 0 0.0013871276
. O 0 0.00057450304
34 O 0 0.00084043876
% O 0 0.00077259046
) O 0 0.00089869887
, O 0 0.00052535743
ten O 0 0.00029827876
of O 0 0.00045699932
which O 0 0.000589361
were O 0 0.00051678193
mild O 0 0.19546701
reactions O 0 0.017081035
such O 0 0.0006521795
as O 0 0.0015879612
nausea B-Disease 2 0.9999981
, O 0 0.011084076
exanthema B-Disease 0 0.99986243
, O 0 0.009632241
urtication B-Disease 0 0.9901058
, O 0 0.00411013
itchiness B-Disease 0 0.9992273
, O 0 0.0014686888
and O 0 0.0009783029
urgency O 0 0.37839016
to O 0 0.0010908922
defecate O 0 0.15912995
, O 0 0.0017400625
and O 0 0.0015906078
did O 0 0.0016638599
not O 0 0.0021987327
require O 0 0.0027111454
treatment O 0 0.007885326
. O 0 0.008518887

Also O 0 0.009426454
recorded O 0 0.0058040367
were O 0 0.0035613175
one O 0 0.002276084
case O 0 0.0019728031
of O 0 0.002301772
pain B-Disease 2 0.99234277
of O 0 0.0017804039
the O 0 0.0012097447
vein O 0 0.032012984
, O 0 0.0015087461
which O 0 0.001048603
required O 0 0.0006163298
treatment O 0 0.0016170988
, O 0 0.0017409837
and O 0 0.001599098
two O 0 0.0017236425
cases O 0 0.0048895827
of O 0 0.00912081
hypotension B-Disease 2 0.99985814
. O 0 0.01213104

The O 0 0.01370927
two O 0 0.011394438
hypotensive B-Disease 2 0.9878329
patients O 0 0.017549947
required O 0 0.0070620324
treatment O 0 0.012781237
for O 0 0.01188306
shock B-Disease 2 0.99399537
. O 0 0.022859644

CONCLUSIONS O 0 0.5183914
: O 0 0.009479747
A O 0 0.012194839
comparison O 0 0.002440931
of O 0 0.0021408724
frequency O 0 0.001773729
of O 0 0.0017140238
adverse O 0 0.9008098
reactions O 0 0.059940856
to O 0 0.0011841892
indocyanine B-Chemical 0 0.9989556
green I-Chemical 0 0.0027753476
with O 0 0.00066706206
the O 0 0.00051843096
previously O 0 0.0004751569
reported O 0 0.0005573098
frequency O 0 0.0005266339
of O 0 0.0005751923
such O 0 0.00055578334
reactions O 0 0.040414244
to O 0 0.0009590329
fluorescein B-Chemical 1 0.9973303
sodium I-Chemical 0 0.9998921
indicated O 0 0.0006482768
that O 0 0.0006550193
indocyanine B-Chemical 0 0.99872833
green I-Chemical 0 0.002866537
is O 0 0.0008405909
a O 0 0.0011767391
safe O 0 0.0021025415
as O 0 0.0015997568
fluorescein B-Chemical 1 0.80475634
for O 0 0.0017008812
use O 0 0.0030588403
in O 0 0.0043317387
angiography O 0 0.35037783
. O 0 0.008410268

Angioedema B-Disease 0 0.99771214
following O 0 0.015917128
the O 0 0.013028151
intravenous O 0 0.6001731
administration O 0 0.47540244
of O 0 0.06901506
metoprolol B-Chemical 1 0.9999405
. O 0 0.027248966

A O 0 0.040050443
72 O 0 0.007865413
- O 0 0.0065625645
year O 0 0.0035238687
- O 0 0.0032344228
old O 0 0.0020952239
woman O 0 0.00614184
was O 0 0.0013120957
admitted O 0 0.0022281415
to O 0 0.00081759307
the O 0 0.00081500213
hospital O 0 0.0021144536
with O 0 0.0009538097
" O 0 0.0013941453
flash O 0 0.018946195
" O 0 0.0017339884
pulmonary B-Disease 0 0.9531305
edema I-Disease 2 0.9999342
, O 0 0.0028495232
preceded O 0 0.002023997
by O 0 0.0022341902
chest B-Disease 0 0.86296576
pain I-Disease 2 0.99846137
, O 0 0.0055787824
requiring O 0 0.0050725807
intubation O 0 0.06450529
. O 0 0.009011052

Her O 0 0.016830944
medical O 0 0.014122134
history O 0 0.011800841
included O 0 0.0034276587
coronary B-Disease 0 0.4360333
artery I-Disease 0 0.302851
disease I-Disease 0 0.6486736
with O 0 0.002312281
previous O 0 0.0026208027
myocardial B-Disease 0 0.9998883
infarctions I-Disease 0 0.9998834
, O 0 0.02899194
hypertension B-Disease 2 0.99990475
, O 0 0.008041768
and O 0 0.0077697067
diabetes B-Disease 2 0.99912125
mellitus I-Disease 0 0.99939024
. O 0 0.015268675

A O 0 0.0537291
history O 0 0.039132725
of O 0 0.016963445
angioedema B-Disease 2 0.9998547
secondary O 0 0.12135825
to O 0 0.012648914
lisinopril B-Chemical 0 0.99992454
therapy O 0 0.2535108
was O 0 0.010058643
elicited O 0 0.014050331
. O 0 0.013929238

Current O 0 0.034119636
medications O 0 0.27194917
did O 0 0.0061622974
not O 0 0.004738489
include O 0 0.0065849666
angiotensin B-Chemical 1 0.9998596
- O 0 0.039956413
converting O 0 0.3317633
enzyme O 0 0.36511764
inhibitors O 0 0.27857834
or O 0 0.007050891
beta O 0 0.8989357
- O 0 0.07147313
blockers O 0 0.99837697
. O 0 0.012520778

She O 0 0.018853124
had O 0 0.010157655
no O 0 0.0077404254
previous O 0 0.008939898
beta O 0 0.48796603
- O 0 0.015679412
blocking O 0 0.021608256
drug O 0 0.82952744
exposure O 0 0.059064195
. O 0 0.017200498

During O 0 0.0061323093
the O 0 0.004258322
first O 0 0.0026919611
day O 0 0.0022235159
of O 0 0.00237575
hospitalization O 0 0.12317959
( O 0 0.0024109145
while O 0 0.0012188281
intubated O 0 0.009753244
) O 0 0.0023412907
, O 0 0.001498931
intravenous O 0 0.61716276
metoprolol B-Chemical 1 0.99999297
was O 0 0.0014947433
given O 0 0.0010906325
, O 0 0.0022327555
resulting O 0 0.0025472848
in O 0 0.003909556
severe O 0 0.8730894
angioedema B-Disease 2 0.9999429
. O 0 0.018462472

The O 0 0.01376758
angioedema B-Disease 2 0.99953926
resolved O 0 0.015566393
after O 0 0.00417128
therapy O 0 0.010142803
with O 0 0.005094967
intravenous O 0 0.9116019
steroids B-Chemical 1 0.9997508
and O 0 0.19287173
diphenhydramine B-Chemical 0 0.99998975
hydrochloride O 0 0.9996164
. O 0 0.019654294

Effect O 0 0.022853382
of O 0 0.018999204
coniine B-Chemical 1 0.96018225
on O 0 0.010630211
the O 0 0.011968189
developing O 0 0.032680333
chick O 0 0.3371502
embryo O 0 0.09377935
. O 0 0.021778215

Coniine B-Chemical 0 0.93543357
, O 0 0.012709297
an O 0 0.009886995
alkaloid O 0 0.98948133
from O 0 0.009549472
Conium O 0 0.99969256
maculatum O 0 0.98359954
( O 0 0.013690545
poison O 0 0.79995096
hemlock O 0 0.99756646
) O 0 0.014748902
, O 0 0.0028537484
has O 0 0.0014897613
been O 0 0.001767877
shown O 0 0.0014616728
to O 0 0.0021051404
be O 0 0.0039368114
teratogenic O 0 0.9980286
in O 0 0.0074176746
livestock O 0 0.50196594
. O 0 0.011547852

The O 0 0.009981572
major O 0 0.010049683
teratogenic O 0 0.99416476
outcome O 0 0.023461653
is O 0 0.0058064004
arthrogryposis B-Disease 0 0.9269767
, O 0 0.005387804
presumably O 0 0.0057598036
due O 0 0.0028678838
to O 0 0.004738514
nicotinic O 0 0.9995603
receptor O 0 0.7250653
blockade O 0 0.789627
. O 0 0.012159456

However O 0 0.011199862
, O 0 0.009955454
coniine B-Chemical 1 0.9527885
has O 0 0.0032103457
failed O 0 0.0025221198
to O 0 0.0017648485
produce O 0 0.0015840341
arthrogryposis B-Disease 0 0.7879031
in O 0 0.0013629125
rats O 0 0.0030908468
or O 0 0.0011254541
mice O 0 0.0009379212
and O 0 0.0015437787
is O 0 0.0014631482
only O 0 0.00175041
weakly O 0 0.004180894
teratogenic O 0 0.99851876
in O 0 0.0057555237
rabbits O 0 0.01773792
. O 0 0.009700439

The O 0 0.006896613
purpose O 0 0.0051721423
of O 0 0.003907842
this O 0 0.0026900426
study O 0 0.00237096
was O 0 0.0014994235
to O 0 0.0010270302
evaluate O 0 0.0006528124
and O 0 0.0009775573
compare O 0 0.00053218636
the O 0 0.0008623242
effects O 0 0.001823953
of O 0 0.0024541612
coniine B-Chemical 1 0.997299
and O 0 0.004622694
nicotine B-Chemical 1 0.99942076
in O 0 0.0028683625
the O 0 0.0037117505
developing O 0 0.034059424
chick O 0 0.27816987
. O 0 0.0102091115

Concentrations O 0 0.12597016
of O 0 0.009704874
coniine B-Chemical 1 0.9898775
and O 0 0.0077832616
nicotine B-Chemical 1 0.9996592
sulfate O 0 0.99890757
were O 0 0.0021450233
0 O 0 0.0017769597
. O 0 0.00077746337
015 O 0 0.084885724
% O 0 0.00088647776
, O 0 0.00077758566
0 O 0 0.00070119376
. O 0 0.00041324616
03 O 0 0.0077873683
% O 0 0.0005940455
, O 0 0.0005856131
0 O 0 0.00055930647
. O 0 0.00033464973
075 O 0 0.0049901
% O 0 0.000535264
, O 0 0.000519056
0 O 0 0.0004743514
. O 0 0.00026253826
15 O 0 0.0002898042
% O 0 0.0004234437
, O 0 0.00046352943
0 O 0 0.00045909645
. O 0 0.00026504326
75 O 0 0.00047690936
% O 0 0.0004625297
, O 0 0.00049805996
1 O 0 0.0003959551
. O 0 0.0002702178
5 O 0 0.00030768907
% O 0 0.0004475613
, O 0 0.00048310083
3 O 0 0.00035969258
% O 0 0.0004779001
, O 0 0.0004928955
and O 0 0.00044002238
6 O 0 0.00035723785
% O 0 0.0005177973
and O 0 0.00055168226
1 O 0 0.00063453475
% O 0 0.0007704598
, O 0 0.00085796975
5 O 0 0.00067999354
% O 0 0.0010695475
, O 0 0.0013156403
and O 0 0.0015150318
10 O 0 0.0019468024
% O 0 0.0031400898
, O 0 0.0046051373
respectively O 0 0.007746295
. O 0 0.007711737

Both O 0 0.014365487
compounds O 0 0.39428297
caused O 0 0.010147042
deformations B-Disease 0 0.5878517
and O 0 0.007839497
lethality O 0 0.43076894
in O 0 0.004215364
a O 0 0.0057544215
dose O 0 0.058994833
- O 0 0.0087452475
dependent O 0 0.00551331
manner O 0 0.009740988
. O 0 0.011084301

All O 0 0.0082720015
concentrations O 0 0.007721719
of O 0 0.006712337
nicotine B-Chemical 1 0.9995616
sulfate O 0 0.99911124
caused O 0 0.004363105
some O 0 0.0024920388
lethality O 0 0.5034641
but O 0 0.0012048015
a O 0 0.0010962606
no O 0 0.0005980429
effect O 0 0.0008333851
level O 0 0.00074036303
for O 0 0.0011113766
coniine B-Chemical 1 0.99539137
lethality O 0 0.61948204
was O 0 0.0024208284
0 O 0 0.0030199601
. O 0 0.002218624
75 O 0 0.0047065923
% O 0 0.006177546
. O 0 0.00712557

The O 0 0.008858551
deformations B-Disease 0 0.1603173
caused O 0 0.0057765814
by O 0 0.0042826184
both O 0 0.0033438855
coniine B-Chemical 1 0.9940593
and O 0 0.0053276774
nicotine B-Chemical 1 0.999801
sulfate O 0 0.99906546
were O 0 0.0021060067
excessive B-Disease 0 0.072091326
flexion I-Disease 0 0.5165131
or I-Disease 0 0.001412785
extension I-Disease 0 0.001826654
of I-Disease 0 0.0020189947
one I-Disease 0 0.0021455614
or I-Disease 0 0.0032713106
more I-Disease 0 0.006182976
toes I-Disease 0 0.36731634
. O 0 0.010406527

No O 0 0.0109136915
histopathological O 0 0.21530889
alterations O 0 0.011216598
or O 0 0.00280635
differences O 0 0.0015293361
in O 0 0.0015423784
bone O 0 0.14827713
formation O 0 0.004704845
were O 0 0.0009870821
seen O 0 0.00063599355
in O 0 0.00054765015
the O 0 0.0005933797
limbs O 0 0.07545827
or O 0 0.00065571134
toes O 0 0.08297576
of O 0 0.0007221093
any O 0 0.00052264385
chicks O 0 0.0020616741
from O 0 0.00047418955
any O 0 0.00046097464
group O 0 0.0008857618
; O 0 0.0011834466
however O 0 0.00070409046
, O 0 0.0007962453
extensive O 0 0.0008703827
cranial B-Disease 0 0.90616477
hemorrhage I-Disease 2 0.9999666
occurred O 0 0.0014266187
in O 0 0.0011049081
all O 0 0.0017934811
nicotine B-Chemical 1 0.99970907
sulfate O 0 0.9992065
- O 0 0.016758362
treated O 0 0.007882171
chicks O 0 0.04815136
. O 0 0.009461032

There O 0 0.009251136
was O 0 0.0057169064
a O 0 0.0045123817
statistically O 0 0.0027722733
significant O 0 0.0027030266
( O 0 0.0031236862
P O 0 0.04144992
< O 0 0.0013628696
or O 0 0.0009994208
= O 0 0.0013136987
0 O 0 0.0010097857
. O 0 0.0005793248
01 O 0 0.0035779981
) O 0 0.00089407654
decrease O 0 0.00048678598
in O 0 0.0004971902
movement O 0 0.0013077422
in O 0 0.00082107366
coniine B-Chemical 1 0.9921217
and O 0 0.0026781284
nicotine B-Chemical 1 0.99982566
sulfate O 0 0.99897194
treated O 0 0.0040750927
chicks O 0 0.01308436
as O 0 0.0024514366
determined O 0 0.0026229722
by O 0 0.00554017
ultrasound O 0 0.14053388
. O 0 0.009213984

Control O 0 0.017754892
chicks O 0 0.01129009
were O 0 0.00407141
in O 0 0.0026514817
motion O 0 0.0044478327
an O 0 0.0017975996
average O 0 0.0009677066
of O 0 0.0012291266
33 O 0 0.0016389661
. O 0 0.0005887019
67 O 0 0.0010025878
% O 0 0.0005705816
of O 0 0.00048712664
the O 0 0.00046157173
time O 0 0.00042725226
, O 0 0.00076542207
while O 0 0.000640018
coniine B-Chemical 1 0.9952224
- O 0 0.0017084895
treated O 0 0.0006939387
chicks O 0 0.002326826
were O 0 0.00043368913
only O 0 0.00037109948
moving O 0 0.0009807004
8 O 0 0.0004307726
. O 0 0.00028967715
95 O 0 0.0006027842
% O 0 0.00038593923
of O 0 0.00039273791
a O 0 0.00060524134
5 O 0 0.00046265847
- O 0 0.0006842825
min O 0 0.0004843832
interval O 0 0.0005633604
, O 0 0.000604161
and O 0 0.0005126437
no O 0 0.00044654682
movement O 0 0.001334924
was O 0 0.00081588083
observed O 0 0.0007965853
for O 0 0.0016590449
nicotine B-Chemical 1 0.9996209
sulfate O 0 0.99875796
treated O 0 0.020269645
chicks O 0 0.098273955
. O 0 0.009991972

In O 0 0.007623359
summary O 0 0.0046696723
, O 0 0.00483758
the O 0 0.003083091
chick O 0 0.021889092
embryo O 0 0.0057264008
provides O 0 0.0013034075
a O 0 0.00159212
reliable O 0 0.0013253115
and O 0 0.0011776777
simple O 0 0.0015339231
experimental O 0 0.0013620231
animal O 0 0.0019722483
model O 0 0.0022553524
of O 0 0.004915245
coniine B-Chemical 1 0.9982135
- O 0 0.019482967
induced O 0 0.009308553
arthrogryposis B-Disease 0 0.98029894
. O 0 0.011704873

Data O 0 0.013968235
from O 0 0.0060216035
this O 0 0.004040176
model O 0 0.0034038918
support O 0 0.0024667233
a O 0 0.0027615642
mechanism O 0 0.0025936817
involving O 0 0.0037762886
nicotinic O 0 0.9997614
receptor O 0 0.5470652
blockade O 0 0.46767768
with O 0 0.0029086438
subsequent O 0 0.0034149203
decreased O 0 0.0063337153
fetal O 0 0.5365483
movement O 0 0.021608192
. O 0 0.009547686

Immediate O 0 0.19909191
allergic B-Disease 2 0.99676114
reactions I-Disease 2 0.82003707
to O 0 0.046130154
amoxicillin B-Chemical 1 0.9967242
. O 0 0.04438857

A O 0 0.026070772
large O 0 0.0070895916
group O 0 0.004794546
of O 0 0.0038181646
patients O 0 0.0054003084
with O 0 0.0028457171
suspected O 0 0.151707
allergic B-Disease 2 0.99988544
reactions I-Disease 2 0.9035736
to O 0 0.0051506525
beta B-Chemical 0 0.9796774
- I-Chemical 0 0.034827966
lactam I-Chemical 0 0.99688053
antibiotics O 0 0.8443857
was O 0 0.0060865614
evaluated O 0 0.0068300385
. O 0 0.009612489

A O 0 0.024495522
detailed O 0 0.005333558
clinical O 0 0.008529091
history O 0 0.025843851
, O 0 0.003215975
together O 0 0.0016588349
with O 0 0.0015730087
skin O 0 0.08964371
tests O 0 0.008186118
, O 0 0.002460096
RAST O 0 0.97579354
( O 0 0.001651085
radioallergosorbent O 0 0.048838403
test O 0 0.0015371675
) O 0 0.0019466578
, O 0 0.00073651416
and O 0 0.00047588084
controlled O 0 0.00039578305
challenge O 0 0.0004980495
tests O 0 0.0013115946
, O 0 0.00063908205
was O 0 0.00034450812
used O 0 0.00028828386
to O 0 0.00026209635
establish O 0 0.00024022152
whether O 0 0.00021735801
patients O 0 0.003710759
allergic B-Disease 0 0.9993766
to O 0 0.0015400545
beta B-Chemical 0 0.982467
- I-Chemical 0 0.011989652
lactam I-Chemical 0 0.9948172
antibiotics O 0 0.5490138
had O 0 0.00058928045
selective O 0 0.0033186355
immediate O 0 0.0027010746
allergic B-Disease 0 0.9994093
responses O 0 0.012749257
to O 0 0.0011496866
amoxicillin B-Chemical 1 0.9996332
( O 0 0.007067863
AX B-Chemical 1 0.9965178
) O 0 0.0020815479
or O 0 0.00080301694
were O 0 0.0009599828
cross O 0 0.0018409411
- O 0 0.0022842404
reacting O 0 0.016307028
with O 0 0.0027722374
other O 0 0.006301324
penicillin B-Chemical 1 0.9998392
derivatives O 0 0.8395561
. O 0 0.011108821

Skin O 0 0.23939675
tests O 0 0.0103251785
were O 0 0.004929539
performed O 0 0.003268007
with O 0 0.0033218844
benzylpenicilloyl B-Chemical 0 0.73425066
- I-Chemical 0 0.012073926
poly I-Chemical 0 0.8626577
- I-Chemical 0 0.039509796
L I-Chemical 0 0.931471
- I-Chemical 0 0.012694003
lysine I-Chemical 0 0.6337976
( O 0 0.019444525
BPO B-Chemical 0 0.9999652
- I-Chemical 0 0.026084762
PLL I-Chemical 0 0.9930734
) O 0 0.008917754
, O 0 0.0022487277
benzylpenicilloate B-Chemical 0 0.974744
, O 0 0.002863419
benzylpenicillin B-Chemical 0 0.9979857
( O 0 0.01141802
PG B-Chemical 1 0.99973625
) O 0 0.011642147
, O 0 0.0038289477
ampicillin B-Chemical 1 0.99732447
( O 0 0.009541816
AMP B-Chemical 1 0.9995222
) O 0 0.009147054
, O 0 0.0056251497
and O 0 0.0073387227
AX B-Chemical 1 0.98714775
. O 0 0.010432132

RAST O 0 0.9161068
for O 0 0.020311173
BPO B-Chemical 0 0.9991003
- I-Chemical 0 0.049763028
PLL I-Chemical 0 0.9737892
and O 0 0.019602275
AX B-Chemical 1 0.9956357
- O 0 0.028568015
PLL O 0 0.88065374
was O 0 0.0116563495
done O 0 0.011554445
. O 0 0.014621693

When O 0 0.0071497983
both O 0 0.005216512
skin O 0 0.017498404
test O 0 0.004128781
and O 0 0.0033560707
RAST O 0 0.94305795
for O 0 0.0020583272
BPO B-Chemical 0 0.999514
were O 0 0.001343733
negative O 0 0.0013473955
, O 0 0.0012401474
single O 0 0.000967904
- O 0 0.001414133
blind O 0 0.006174768
, O 0 0.0009574694
placebo O 0 0.094900995
- O 0 0.0009275785
controlled O 0 0.00043793765
challenge O 0 0.00055452593
tests O 0 0.0010116898
were O 0 0.00055814866
done O 0 0.0004749627
to O 0 0.0005438109
ensure O 0 0.00047875088
tolerance O 0 0.03720993
of O 0 0.0030769345
PG B-Chemical 1 0.99934417
or O 0 0.003586844
sensitivity O 0 0.009064219
to O 0 0.0064841085
AX B-Chemical 1 0.99361897
. O 0 0.010663654

A O 0 0.025479555
total O 0 0.0077168397
of O 0 0.0065169614
177 O 0 0.014600953
patients O 0 0.006173355
were O 0 0.003422935
diagnosed O 0 0.011061025
as O 0 0.0039898446
allergic B-Disease 0 0.999008
to O 0 0.007942769
beta B-Chemical 0 0.97810763
- I-Chemical 0 0.06404913
lactam I-Chemical 0 0.99744886
antibiotics O 0 0.94156206
. O 0 0.014498809

We O 0 0.00793624
selected O 0 0.004935942
the O 0 0.0040723267
54 O 0 0.0050321324
( O 0 0.0031807278
30 O 0 0.0016017045
. O 0 0.0011999998
5 O 0 0.0011138321
% O 0 0.0014036362
) O 0 0.0015819249
cases O 0 0.0014677561
of O 0 0.0014964289
immediate O 0 0.005013775
AX B-Chemical 1 0.9967057
allergy B-Disease 0 0.99720544
with O 0 0.0042310692
good O 0 0.0059170625
tolerance O 0 0.36806062
of O 0 0.019857634
PG B-Chemical 1 0.9992741
. O 0 0.014292616

Anaphylaxis B-Disease 0 0.97883165
was O 0 0.006834848
seen O 0 0.0037895993
in O 0 0.0027343247
37 O 0 0.0026630482
patients O 0 0.0035983284
( O 0 0.0021774357
69 O 0 0.0019277765
% O 0 0.0014602779
) O 0 0.001557089
, O 0 0.0009601534
the O 0 0.0006709375
other O 0 0.00079439307
17 O 0 0.0013105865
( O 0 0.0011807032
31 O 0 0.0013286833
% O 0 0.0012480459
) O 0 0.0018852898
having O 0 0.0023026688
urticaria B-Disease 2 0.99988437
and O 0 0.007842732
/ O 0 0.041459035
or O 0 0.010449612
angioedema B-Disease 2 0.9999187
. O 0 0.016064232

All O 0 0.0075672287
the O 0 0.005310966
patients O 0 0.0055442248
were O 0 0.0029894402
skin O 0 0.0108463755
test O 0 0.0023054893
negative O 0 0.0020964504
to O 0 0.0018543121
BPO B-Chemical 0 0.99976975
; O 0 0.0026784444
49 O 0 0.0012518758
of O 0 0.0007663519
51 O 0 0.0014442605
( O 0 0.0008677775
96 O 0 0.000911362
% O 0 0.00065533834
) O 0 0.0007393678
were O 0 0.000412963
also O 0 0.00043926554
negative O 0 0.00069508003
to O 0 0.00069332623
MDM B-Disease 0 0.5309297
, O 0 0.0010911573
and O 0 0.0008009452
44 O 0 0.0010806688
of O 0 0.0009557082
46 O 0 0.0019090236
( O 0 0.0018416476
96 O 0 0.0025425616
% O 0 0.0025916733
) O 0 0.0043804767
to O 0 0.0046901535
PG B-Chemical 1 0.99718314
. O 0 0.010739002

Skin O 0 0.26260597
tests O 0 0.015410077
with O 0 0.009472604
AX B-Chemical 1 0.93112475
were O 0 0.0052437563
positive O 0 0.0042210417
in O 0 0.003790467
34 O 0 0.0051972517
( O 0 0.005138173
63 O 0 0.006473219
% O 0 0.0061033797
) O 0 0.008859599
patients O 0 0.013324371
. O 0 0.010949048

RAST O 0 0.7745412
was O 0 0.0070636314
positive O 0 0.0048469687
for O 0 0.0033933676
AX B-Chemical 1 0.9480722
in O 0 0.0022239706
22 O 0 0.0022409952
patients O 0 0.0030485142
( O 0 0.001895341
41 O 0 0.0021280262
% O 0 0.0014215885
) O 0 0.0016018181
and O 0 0.0011417379
to O 0 0.0013184876
BPO B-Chemical 0 0.9989575
in O 0 0.0014920272
just O 0 0.001607563
5 O 0 0.0018078525
( O 0 0.002985801
9 O 0 0.0031430405
% O 0 0.004954545
) O 0 0.008541193
. O 0 0.007983685

None O 0 0.017615965
of O 0 0.009308556
the O 0 0.006543634
sera O 0 0.010101704
with O 0 0.005194186
negative O 0 0.006648427
RAST O 0 0.96095526
for O 0 0.005096896
AX B-Chemical 1 0.98235303
were O 0 0.0054405206
positive O 0 0.006338633
to O 0 0.009247894
BPO B-Chemical 0 0.9986852
. O 0 0.015330398

Challenge O 0 0.030154891
tests O 0 0.009728499
with O 0 0.005655498
AX B-Chemical 1 0.9428007
were O 0 0.0025640028
performed O 0 0.0015110867
in O 0 0.0012098085
23 O 0 0.0014885914
subjects O 0 0.0015093108
( O 0 0.0011786855
43 O 0 0.0011835424
% O 0 0.0008282863
) O 0 0.0007958555
to O 0 0.0003603694
establish O 0 0.00032173455
the O 0 0.0004244812
diagnosis O 0 0.0019347242
of O 0 0.0007580363
immediate O 0 0.0051059574
allergic B-Disease 2 0.9999207
reaction I-Disease 2 0.64068866
to O 0 0.0015533972
AX B-Chemical 1 0.998279
, O 0 0.0011431234
and O 0 0.00059388217
in O 0 0.00044311408
15 O 0 0.00042398114
cases O 0 0.00084621523
( O 0 0.0008325109
28 O 0 0.0006615464
% O 0 0.0007508347
) O 0 0.00097048347
both O 0 0.00067394605
skin O 0 0.012678855
test O 0 0.0017685697
and O 0 0.0023645058
RAST O 0 0.95081973
for O 0 0.0030633442
AX B-Chemical 1 0.98518443
were O 0 0.005285529
negative O 0 0.007950268
. O 0 0.008889125

PG B-Chemical 1 0.9882216
was O 0 0.016775955
well O 0 0.0123007
tolerated O 0 0.025696957
by O 0 0.01237501
all O 0 0.010819418
54 O 0 0.017768435
patients O 0 0.021929856
. O 0 0.017347502

We O 0 0.0079327235
describe O 0 0.004917491
the O 0 0.0038963251
largest O 0 0.003804196
group O 0 0.0032394442
of O 0 0.0042559872
AX B-Chemical 1 0.9977939
- O 0 0.011483277
allergic B-Disease 0 0.99898535
patients O 0 0.028480714
who O 0 0.005046611
have O 0 0.002263973
tolerated O 0 0.20911407
PG B-Chemical 1 0.99902916
reported O 0 0.006106782
so O 0 0.005382675
far O 0 0.007553268
. O 0 0.009082251

Diagnosis O 0 0.05634477
of O 0 0.007320993
these O 0 0.0054625766
patients O 0 0.0063904272
can O 0 0.0026475124
be O 0 0.0022666308
achieved O 0 0.0018672406
only O 0 0.0016172566
if O 0 0.0014816447
specific O 0 0.0023094753
AX B-Chemical 1 0.9951342
- O 0 0.005743688
related O 0 0.0028519088
reagents O 0 0.2867923
are O 0 0.006491534
employed O 0 0.009003485
. O 0 0.009613828

Further O 0 0.0088185575
studies O 0 0.0056298245
are O 0 0.0035826503
necessary O 0 0.0018234825
to O 0 0.0015133173
determine O 0 0.00084595574
the O 0 0.0010538172
exact O 0 0.0015044835
extent O 0 0.0007398524
of O 0 0.001070851
this O 0 0.00095196906
problem O 0 0.0018387713
and O 0 0.0011303233
to O 0 0.0009138271
improve O 0 0.0008303563
the O 0 0.001265816
efficacy O 0 0.0034816584
of O 0 0.003203994
diagnostic O 0 0.0072747353
methods O 0 0.0072048753
. O 0 0.008768493

Reversal O 0 0.16920637
by O 0 0.009643201
phenylephrine B-Chemical 1 0.99924904
of O 0 0.004599065
the O 0 0.0025112173
beneficial O 0 0.0035605696
effects O 0 0.0027971363
of O 0 0.0025334575
intravenous O 0 0.93123233
nitroglycerin B-Chemical 1 0.9999877
in O 0 0.0026636256
patients O 0 0.017183183
with O 0 0.005964144
acute B-Disease 2 0.9991722
myocardial I-Disease 2 0.9999492
infarction I-Disease 2 0.99998224
. O 0 0.021988465

Nitroglycerin B-Chemical 0 0.9996112
has O 0 0.007304178
been O 0 0.004540082
shown O 0 0.0023368695
to O 0 0.001957219
reduce O 0 0.0019996928
ST O 0 0.9737099
- O 0 0.0038488717
segment O 0 0.0019670033
elevation O 0 0.17199317
during O 0 0.0008570203
acute B-Disease 2 0.9975551
myocardial I-Disease 2 0.9999839
infarction I-Disease 2 0.9999987
, O 0 0.0060371174
an O 0 0.0012364262
effect O 0 0.00079381996
potentiated O 0 0.058965586
in O 0 0.00065114314
the O 0 0.00069617596
dog O 0 0.0021247014
by O 0 0.0011536205
agents O 0 0.116766125
that O 0 0.0015265223
reverse O 0 0.35796288
nitroglycerin B-Chemical 1 0.9999882
- O 0 0.052470125
induced O 0 0.020717226
hypotension B-Disease 2 0.9998982
. O 0 0.013487543

Our O 0 0.0098235365
study O 0 0.007268814
was O 0 0.0047084866
designed O 0 0.003533936
to O 0 0.0023771352
determine O 0 0.0014388695
the O 0 0.0019274987
effects O 0 0.002908344
of O 0 0.003171522
combined O 0 0.015968777
nitroglycerin B-Chemical 1 0.9999771
and O 0 0.043063093
phenylephrine B-Chemical 1 0.999876
therapy O 0 0.3462178
. O 0 0.011741225

Ten O 0 0.011428031
patients O 0 0.008654603
with O 0 0.0047293967
acute O 0 0.91064876
transmural O 0 0.99355
myocardial B-Disease 0 0.9999064
infarctions I-Disease 0 0.9997905
received O 0 0.0020337591
intravenous O 0 0.87134296
nitroglycerin B-Chemical 1 0.99999404
, O 0 0.0016785413
sufficient O 0 0.00035443145
to O 0 0.0003669079
reduce O 0 0.00032673153
mean O 0 0.0003988304
arterial O 0 0.30729115
pressure O 0 0.023585433
from O 0 0.00048739323
107 O 0 0.0011924886
+ O 0 0.0006982081
/ O 0 0.0016352246
- O 0 0.0007069177
6 O 0 0.0002893459
to O 0 0.00031891157
85 O 0 0.0006842724
+ O 0 0.0006037761
/ O 0 0.0014299667
- O 0 0.00082221744
6 O 0 0.00040211817
mm O 0 0.0015659046
Hg O 0 0.7585203
( O 0 0.0009479657
P O 0 0.00819241
less O 0 0.0005798778
than O 0 0.0005556894
0 O 0 0.0011495047
. O 0 0.0009114862
001 O 0 0.14634803
) O 0 0.0022641346
, O 0 0.0020209872
for O 0 0.001797414
60 O 0 0.0030119338
minutes O 0 0.003882337
. O 0 0.006470809

Left O 0 0.08977451
ventricular O 0 0.9106119
filling O 0 0.016661525
pressure O 0 0.030241376
decreased O 0 0.0033977344
from O 0 0.0020104686
19 O 0 0.002703997
+ O 0 0.0017806734
/ O 0 0.0030751268
- O 0 0.0014888544
2 O 0 0.00071241986
to O 0 0.00060265104
11 O 0 0.00097276864
+ O 0 0.0009576077
/ O 0 0.002205641
- O 0 0.0013185166
2 O 0 0.0008236116
mm O 0 0.0026317844
Hg O 0 0.7815927
( O 0 0.0016514763
P O 0 0.011255917
less O 0 0.0012264083
than O 0 0.0013387002
0 O 0 0.0028908616
. O 0 0.00282633
001 O 0 0.23996304
) O 0 0.0086249085
. O 0 0.007818071

SigmaST O 0 0.19398205
, O 0 0.0076002744
the O 0 0.0039961347
sum O 0 0.003268381
of O 0 0.00359064
ST O 0 0.9572237
- O 0 0.0041061626
segment O 0 0.002170836
elevations O 0 0.064014755
in O 0 0.000909078
16 O 0 0.0011147811
precordial O 0 0.9755048
leads O 0 0.0009939357
, O 0 0.0011972272
decreased O 0 0.001272696
( O 0 0.0014106501
P O 0 0.023671469
less O 0 0.0007291606
than O 0 0.00067371555
0 O 0 0.0013616268
. O 0 0.0010368772
02 O 0 0.02398468
) O 0 0.0025943602
with O 0 0.002816609
intravenous O 0 0.870618
nitroglycerin B-Chemical 1 0.99993134
. O 0 0.01173284

Subsequent O 0 0.009479129
addition O 0 0.0040444145
of O 0 0.00517108
phenylephrine B-Chemical 1 0.9997466
infusion O 0 0.10882415
, O 0 0.002308949
sufficient O 0 0.00080636516
to O 0 0.0009160587
re O 0 0.03771317
- O 0 0.001535247
elevate O 0 0.0017540473
mean O 0 0.000520267
arterial O 0 0.27915367
pressure O 0 0.020684378
to O 0 0.0004554294
106 O 0 0.0008681588
+ O 0 0.0007826184
/ O 0 0.0020855612
- O 0 0.0008975548
4 O 0 0.0004259948
mm O 0 0.0015749219
Hg O 0 0.81455183
( O 0 0.0007388734
P O 0 0.008925841
less O 0 0.00036506203
than O 0 0.00030137625
0 O 0 0.000591177
. O 0 0.00035057357
001 O 0 0.102486126
) O 0 0.0005455522
for O 0 0.00023459997
30 O 0 0.00023408426
minutes O 0 0.00023865342
, O 0 0.00038844362
increased O 0 0.00037715404
left O 0 0.0009176286
ventricular O 0 0.9378265
filling O 0 0.0042115026
pressure O 0 0.01303901
to O 0 0.00041296103
17 O 0 0.00082647015
+ O 0 0.0006400165
/ O 0 0.0018665841
- O 0 0.00089156197
2 O 0 0.0004785465
mm O 0 0.0017471536
Hg O 0 0.82573575
( O 0 0.0007738607
P O 0 0.009319856
less O 0 0.00039527967
than O 0 0.00033660763
0 O 0 0.000677242
. O 0 0.00041626545
05 O 0 0.04243068
) O 0 0.000706942
and O 0 0.00048360674
also O 0 0.00054268516
significantly O 0 0.0009573181
increased O 0 0.0016576153
sigmaST O 0 0.68151283
( O 0 0.001971647
P O 0 0.029234169
less O 0 0.0011903022
than O 0 0.0012974289
0 O 0 0.0028657438
. O 0 0.0027156025
05 O 0 0.07702824
) O 0 0.0076695466
. O 0 0.007373336

Our O 0 0.0075410185
results O 0 0.0048427847
suggest O 0 0.0026795147
that O 0 0.0020775017
addition O 0 0.0014619671
of O 0 0.0030801452
phenylephrine B-Chemical 1 0.9999331
to O 0 0.0029520555
nitroglycerin B-Chemical 1 0.99998915
is O 0 0.0013983753
not O 0 0.00084259495
beneficial O 0 0.0016296733
in O 0 0.0007471438
the O 0 0.0008342153
treatment O 0 0.0014516154
of O 0 0.0016945048
patients O 0 0.011234811
with O 0 0.005229988
acute B-Disease 2 0.9992481
myocardial I-Disease 2 0.99995494
infarction I-Disease 2 0.9999839
. O 0 0.021205101

Acetazolamide B-Chemical 0 0.9996469
- O 0 0.02988578
induced O 0 0.014107013
nephrolithiasis B-Disease 2 0.9998275
: O 0 0.011902498
implications O 0 0.0054421285
for O 0 0.0034660096
treatment O 0 0.00662374
of O 0 0.010304346
neuromuscular B-Disease 0 0.99850804
disorders I-Disease 0 0.9980725
. O 0 0.017955402

Carbonic O 0 0.99075127
anhydrase O 0 0.9954484
inhibitors O 0 0.5092833
can O 0 0.030430986
cause O 0 0.26074028
nephrolithiasis B-Disease 2 0.9995604
. O 0 0.04373738

We O 0 0.0087350765
studied O 0 0.0060824663
20 O 0 0.0044569382
patients O 0 0.004724692
receiving O 0 0.0039973822
long O 0 0.0029904407
- O 0 0.0035543984
term O 0 0.0024057776
carbonic O 0 0.9984268
anhydrase O 0 0.9997532
inhibitor O 0 0.36275938
treatment O 0 0.0057682423
for O 0 0.002496737
periodic O 0 0.13603593
paralysis B-Disease 2 0.9997199
and O 0 0.033108164
myotonia B-Disease 0 0.99961686
. O 0 0.013024534

Three O 0 0.014752652
patients O 0 0.0134980865
on O 0 0.008190377
acetazolamide B-Chemical 0 0.999419
( O 0 0.010889846
15 O 0 0.005424746
% O 0 0.0069267773
) O 0 0.0089643495
developed O 0 0.01135826
renal B-Disease 0 0.9978911
calculi I-Disease 0 0.99882776
. O 0 0.020971876

Extracorporeal O 0 0.016707454
lithotripsy O 0 0.014614668
successfully O 0 0.0054929177
removed O 0 0.0033515077
a O 0 0.0042166444
renal B-Disease 0 0.99662894
calculus I-Disease 0 0.990802
in O 0 0.0016318084
one O 0 0.0010221272
patient O 0 0.0014039509
and O 0 0.0010579581
surgery O 0 0.0017643027
removed O 0 0.00088938395
a O 0 0.001669064
staghorn O 0 0.93140906
calculus B-Disease 0 0.9366445
in O 0 0.0019253496
another O 0 0.0025421
, O 0 0.0030981752
permitting O 0 0.0038123636
continued O 0 0.0042839264
treatment O 0 0.00831762
. O 0 0.008663089

Renal O 0 0.5368786
function O 0 0.017858898
remained O 0 0.014762412
normal O 0 0.015627826
in O 0 0.01231678
all O 0 0.013683594
patients O 0 0.02657983
. O 0 0.020371132

Nephrolithiasis B-Disease 0 0.99208903
is O 0 0.009058688
a O 0 0.007602936
complication O 0 0.27043894
of O 0 0.008490533
acetazolamide B-Chemical 0 0.99981827
but O 0 0.004843853
does O 0 0.0031478966
not O 0 0.00352742
preclude O 0 0.005343489
its O 0 0.008633209
use O 0 0.010079347
. O 0 0.011310121

Effects O 0 0.024718538
of O 0 0.016435638
calcium B-Chemical 1 0.99814224
channel O 0 0.8019636
blockers O 0 0.9990169
on O 0 0.008295057
bupivacaine B-Chemical 1 0.9999206
- O 0 0.050803933
induced O 0 0.017125923
toxicity B-Disease 2 0.9984705
. O 0 0.017287776

The O 0 0.006926688
purpose O 0 0.0052008615
of O 0 0.003935551
this O 0 0.0027133126
study O 0 0.0024015983
was O 0 0.0015206721
to O 0 0.001047206
investigate O 0 0.0006948705
the O 0 0.000978496
influence O 0 0.0009210238
of O 0 0.0025945823
calcium B-Chemical 1 0.99973875
channel O 0 0.80198836
blockers O 0 0.99959654
on O 0 0.0021893366
bupivacaine B-Chemical 1 0.99997437
- O 0 0.021352042
induced O 0 0.0073223384
acute O 0 0.996702
toxicity B-Disease 2 0.99941015
. O 0 0.01445325

For O 0 0.0059971027
each O 0 0.0035821402
of O 0 0.0033478083
the O 0 0.0023423657
three O 0 0.001510809
tested O 0 0.0016534132
calcium B-Chemical 1 0.99936527
channel O 0 0.8539369
blockers O 0 0.99989116
( O 0 0.05200394
diltiazem B-Chemical 1 0.9999976
, O 0 0.015608617
verapamil B-Chemical 1 0.99999034
and O 0 0.0040633646
bepridil B-Chemical 1 0.9999931
) O 0 0.0025527682
6 O 0 0.00033734058
groups O 0 0.00038503998
of O 0 0.0003975531
mice O 0 0.00027895015
were O 0 0.00036093584
treated O 0 0.00043254776
by O 0 0.00039441147
two O 0 0.00028856136
different O 0 0.00034978407
doses O 0 0.016945722
, O 0 0.0008427945
i O 0 0.0023240447
. O 0 0.00035083486
e O 0 0.0010052109
. O 0 0.00031554096
2 O 0 0.00034057442
and O 0 0.00035728182
10 O 0 0.00037834095
mg O 0 0.065577015
/ O 0 0.0010482226
kg O 0 0.002770046
/ O 0 0.0012833587
i O 0 0.0015703973
. O 0 0.00033579126
p O 0 0.0005573247
. O 0 0.00030860567
, O 0 0.0004397947
or O 0 0.00029059386
an O 0 0.00039543535
equal O 0 0.00027277728
volume O 0 0.00073720334
of O 0 0.0004409659
saline O 0 0.03990694
for O 0 0.00026208736
the O 0 0.0003084345
control O 0 0.0003370598
group O 0 0.000521301
( O 0 0.0005854361
n O 0 0.00046374375
= O 0 0.0005596339
20 O 0 0.00040860928
) O 0 0.0006585898
; O 0 0.0004931173
15 O 0 0.00022359643
minutes O 0 0.00020362357
later O 0 0.00023783087
, O 0 0.00036070796
all O 0 0.000255546
the O 0 0.00029144005
animals O 0 0.00030621942
were O 0 0.00034604798
injected O 0 0.00032129895
with O 0 0.00040946266
a O 0 0.0005880606
single O 0 0.0005243164
50 O 0 0.0008202626
mg O 0 0.13071814
/ O 0 0.0016943048
kg O 0 0.0037757955
/ O 0 0.0020576876
i O 0 0.0023743573
. O 0 0.00088618643
p O 0 0.0015425459
. O 0 0.0013417738
dose O 0 0.0068034353
of O 0 0.0066317506
bupivacaine B-Chemical 1 0.9998437
. O 0 0.010824645

The O 0 0.009341242
convulsant O 0 0.9980603
activity O 0 0.0066804797
, O 0 0.0035893759
the O 0 0.001820202
time O 0 0.0012561637
of O 0 0.0014415837
latency O 0 0.0032042025
to O 0 0.0012192084
convulse O 0 0.47865203
and O 0 0.0013062845
the O 0 0.001152262
mortality O 0 0.100180045
rate O 0 0.001467439
were O 0 0.0016435096
assessed O 0 0.0015777533
in O 0 0.0023292734
each O 0 0.0028232194
group O 0 0.0069371993
. O 0 0.008465836

The O 0 0.008076903
local O 0 0.008992353
anesthetic O 0 0.66936123
- O 0 0.00815854
induced O 0 0.0037929562
mortality O 0 0.37719837
was O 0 0.002461536
significantly O 0 0.0024248126
increased O 0 0.0022299911
by O 0 0.002011612
the O 0 0.0017446479
three O 0 0.0017145859
different O 0 0.003524135
calcium B-Chemical 1 0.999199
channel O 0 0.86324817
blockers O 0 0.99922705
. O 0 0.013101717

The O 0 0.00865442
convulsant O 0 0.99822944
activity O 0 0.0060660113
of O 0 0.0049509048
bupivacaine B-Chemical 1 0.99993885
was O 0 0.0021909445
not O 0 0.0011777316
significantly O 0 0.0014626399
modified O 0 0.0017592032
but O 0 0.0014524651
calcium B-Chemical 1 0.9996182
channel O 0 0.6738286
blockers O 0 0.9994766
decreased O 0 0.0013633285
the O 0 0.0004826562
time O 0 0.0003332883
of O 0 0.0005283953
latency O 0 0.0018962774
to O 0 0.00046854757
obtain O 0 0.0004754102
bupivacaine B-Chemical 1 0.99998236
- O 0 0.0066767503
induced O 0 0.0025269515
convulsions B-Disease 2 0.99998903
; O 0 0.0036768806
this O 0 0.0009000221
effect O 0 0.001077205
was O 0 0.0013431802
less O 0 0.0017324951
pronounced O 0 0.0037031975
with O 0 0.007585331
bepridil B-Chemical 1 0.9999114
. O 0 0.011049388

Epidural O 0 0.9065903
blood O 0 0.035609223
flow O 0 0.027193762
during O 0 0.010996025
prostaglandin B-Chemical 1 0.9999263
E1 I-Chemical 1 0.99895203
or O 0 0.047281705
trimethaphan B-Chemical 0 0.99991274
induced O 0 0.16589393
hypotension B-Disease 2 0.99986625
. O 0 0.024261773

To O 0 0.0063176863
evaluate O 0 0.0033868798
the O 0 0.0034524275
effect O 0 0.003110303
of O 0 0.011761503
prostaglandin B-Chemical 1 0.9999945
E1 I-Chemical 1 0.99990845
( O 0 0.23211388
PGE1 B-Chemical 1 0.999997
) O 0 0.040554143
or O 0 0.002370106
trimethaphan B-Chemical 0 0.9999893
( O 0 0.018045336
TMP B-Chemical 1 0.99992144
) O 0 0.0044996357
induced O 0 0.001145957
hypotension B-Disease 2 0.99995947
on O 0 0.00041936839
epidural O 0 0.74467564
blood O 0 0.020953007
flow O 0 0.016529601
( O 0 0.0014576659
EBF O 0 0.5626734
) O 0 0.0008828935
during O 0 0.0003218554
spinal O 0 0.04352305
surgery O 0 0.00252791
, O 0 0.00092724484
EBF O 0 0.28198683
was O 0 0.00036891355
measured O 0 0.00026578925
using O 0 0.00032793768
the O 0 0.0003795493
heat O 0 0.0033122054
clearance O 0 0.029966567
method O 0 0.0008217632
in O 0 0.00047295226
30 O 0 0.00041109064
patients O 0 0.0009002673
who O 0 0.0010411454
underwent O 0 0.00096217723
postero O 0 0.07059159
- O 0 0.0024756568
lateral O 0 0.0071899164
interbody O 0 0.27461693
fusion O 0 0.002713075
under O 0 0.0025183812
isoflurane B-Chemical 1 0.99522084
anaesthesia O 0 0.32426563
. O 0 0.009122382

An O 0 0.010313068
initial O 0 0.0051811277
dose O 0 0.0070388825
of O 0 0.0034559234
0 O 0 0.002970945
. O 0 0.0012992331
1 O 0 0.0012185699
microgram O 0 0.06855424
. O 0 0.0007877755
kg O 0 0.00688601
- O 0 0.0014317189
1 O 0 0.0006804814
. O 0 0.00042233977
min O 0 0.0006462091
- O 0 0.00082909677
1 O 0 0.0005006705
of O 0 0.000850954
PGE1 B-Chemical 1 0.99999464
( O 0 0.0017185268
15 O 0 0.00046462874
patients O 0 0.0013840765
) O 0 0.0009836559
, O 0 0.0005314603
or O 0 0.00035132206
10 O 0 0.0003973076
micrograms O 0 0.04031516
. O 0 0.00034231757
kg O 0 0.004194939
- O 0 0.0008707311
1 O 0 0.0004410767
. O 0 0.00028559417
min O 0 0.0004781416
- O 0 0.0006394964
1 O 0 0.00038265088
of O 0 0.00057598396
TMP B-Chemical 1 0.999728
( O 0 0.0009474985
15 O 0 0.00035408765
patients O 0 0.0010004119
) O 0 0.0006807308
was O 0 0.0002930933
administered O 0 0.00038899
intravenously O 0 0.0006264359
after O 0 0.00019043928
the O 0 0.0003533899
dural O 0 0.767032
opening O 0 0.004704466
and O 0 0.00046739128
the O 0 0.00038332667
dose O 0 0.0028329687
was O 0 0.0004079807
adjusted O 0 0.00047177167
to O 0 0.0003166306
maintain O 0 0.0002724771
the O 0 0.00036892833
mean O 0 0.00046121373
arterial O 0 0.2683775
blood O 0 0.0180848
pressure O 0 0.12364487
( O 0 0.00296098
MAP O 0 0.79126436
) O 0 0.0028277847
at O 0 0.0014429118
about O 0 0.0020813271
60 O 0 0.0036117136
mmHg O 0 0.012381219
. O 0 0.006637267

The O 0 0.011083858
hypotensive B-Disease 2 0.9928872
drug O 0 0.6519596
was O 0 0.005520614
discontinued O 0 0.01095068
at O 0 0.0024782629
the O 0 0.0025149637
completion O 0 0.0022637404
of O 0 0.0034062767
the O 0 0.0042697764
operative O 0 0.01002003
procedure O 0 0.008784006
. O 0 0.011018688

After O 0 0.007034158
starting O 0 0.007513582
PGE1 B-Chemical 1 0.99990237
or O 0 0.009311531
TMP B-Chemical 1 0.99975675
, O 0 0.007035503
MAP O 0 0.822918
and O 0 0.0015354297
rate O 0 0.00107547
pressure O 0 0.05240505
product O 0 0.004703361
( O 0 0.0022692399
RPP O 0 0.96165156
) O 0 0.0015003275
decreased O 0 0.0007442509
significantly O 0 0.0006074946
compared O 0 0.00030314733
with O 0 0.00052027544
preinfusion O 0 0.12078113
values O 0 0.0006347031
( O 0 0.0009041185
P O 0 0.03860861
< O 0 0.00051173085
0 O 0 0.0005682874
. O 0 0.0003419728
01 O 0 0.0032069844
) O 0 0.00069449306
, O 0 0.0004790202
and O 0 0.00038398174
the O 0 0.00036526463
degree O 0 0.00059047854
of O 0 0.0011622516
hypotension B-Disease 2 0.999969
due O 0 0.00073156715
to O 0 0.0011048685
PGE1 B-Chemical 1 0.999992
remained O 0 0.0012681788
constant O 0 0.00074587716
until O 0 0.0006321944
60 O 0 0.0010109879
min O 0 0.0013769179
after O 0 0.001406233
its O 0 0.004838971
discontinuation O 0 0.82806534
. O 0 0.008505865

Heart O 0 0.19574837
rate O 0 0.012934061
( O 0 0.013766163
HR O 0 0.27025196
) O 0 0.009591168
did O 0 0.0052231527
not O 0 0.004849454
change O 0 0.0052037397
in O 0 0.0055572595
either O 0 0.0075453804
group O 0 0.012176237
. O 0 0.012729543

EBFF O 0 0.14623696
did O 0 0.0064407014
not O 0 0.004117259
change O 0 0.0032776212
during O 0 0.0023151438
PGE1 B-Chemical 1 0.9999726
infusion O 0 0.09437112
whereas O 0 0.0012508992
in O 0 0.00090127887
the O 0 0.0011008359
TMP B-Chemical 1 0.99976796
group O 0 0.0022868814
, O 0 0.0017743632
EBF O 0 0.5621125
decreased O 0 0.0007995832
significantly O 0 0.00063527934
at O 0 0.00031477242
30 O 0 0.00028056843
and O 0 0.00033305452
60 O 0 0.00030471815
min O 0 0.00029242033
after O 0 0.00018458486
the O 0 0.00028930508
start O 0 0.00033666554
of O 0 0.00077250367
TMP B-Chemical 1 0.9998685
( O 0 0.0016544391
preinfusion O 0 0.19591428
: O 0 0.0007508103
45 O 0 0.0003851226
. O 0 0.0002757898
9 O 0 0.0004047669
+ O 0 0.0004803247
/ O 0 0.0011665663
- O 0 0.00066352775
13 O 0 0.00043158312
. O 0 0.00025075415
9 O 0 0.0003250808
ml O 0 0.0008543109
/ O 0 0.0011963961
100g O 0 0.085908614
/ O 0 0.0011679761
min O 0 0.00047430076
. O 0 0.00027657553
30 O 0 0.00025917232
min O 0 0.0003654227
: O 0 0.000490208
32 O 0 0.00047345605
. O 0 0.0002742496
3 O 0 0.00035978243
+ O 0 0.0004902005
/ O 0 0.0012084553
- O 0 0.00068609824
9 O 0 0.00037814316
. O 0 0.0002479578
9 O 0 0.00032148065
ml O 0 0.00078513945
/ O 0 0.0009089628
100 O 0 0.00067638926
g O 0 0.00073803484
/ O 0 0.0009846794
min O 0 0.00057206844
( O 0 0.000742884
P O 0 0.01767786
< O 0 0.0005144883
0 O 0 0.0005837289
. O 0 0.00037169748
05 O 0 0.025963021
) O 0 0.00062392984
. O 0 0.00027815453
60 O 0 0.00031977135
min O 0 0.00037567306
: O 0 0.00050927396
30 O 0 0.0003256034
+ O 0 0.00050549285
/ O 0 0.0011752985
- O 0 0.00072538684
7 O 0 0.0003841681
. O 0 0.00029398853
5 O 0 0.00034087233
ml O 0 0.00094824895
/ O 0 0.0011395704
100 O 0 0.0009374896
g O 0 0.0011042887
/ O 0 0.0015269497
min O 0 0.0010817442
( O 0 0.0016118322
P O 0 0.021778397
< O 0 0.001640957
0 O 0 0.0022061297
. O 0 0.002141836
05 O 0 0.051053956
) O 0 0.006050111
) O 0 0.008434538
. O 0 0.007846187

These O 0 0.009474224
results O 0 0.0060383026
suggest O 0 0.0037292466
that O 0 0.004067966
PGE1 B-Chemical 1 0.99996305
may O 0 0.0031669785
be O 0 0.001900778
preferable O 0 0.0013682513
to O 0 0.0013503894
TMP B-Chemical 1 0.9994512
for O 0 0.0013480027
hypotensive B-Disease 2 0.9991897
anaesthesia O 0 0.31871793
in O 0 0.0016765242
spinal O 0 0.17169173
surgery O 0 0.0067488626
because O 0 0.0031416486
TMP B-Chemical 1 0.99954826
decreased O 0 0.018980019
EBF O 0 0.87432647
. O 0 0.009979509

Dup B-Chemical 0 0.98368984
753 I-Chemical 0 0.6995499
prevents O 0 0.010144844
the O 0 0.006934999
development O 0 0.009378754
of O 0 0.011016726
puromycin B-Chemical 0 0.99120027
aminonucleoside I-Chemical 0 0.99992716
- O 0 0.24043421
induced O 0 0.06256068
nephrosis B-Disease 2 0.999824
. O 0 0.024970772

The O 0 0.007502545
appearance O 0 0.009598077
of O 0 0.0077480837
nephrotic B-Disease 2 0.99994624
syndromes I-Disease 0 0.9816949
such O 0 0.003393637
as O 0 0.0044838917
proteinuria B-Disease 2 0.99998593
, O 0 0.04165111
hypoalbuminemia B-Disease 0 0.999984
, O 0 0.030458057
hypercholesterolemia B-Disease 2 0.9999877
and O 0 0.0016010802
increase O 0 0.0005624043
in O 0 0.0006246698
blood B-Chemical 0 0.34653082
nitrogen I-Chemical 0 0.99370074
urea I-Chemical 1 0.99993765
, O 0 0.001942684
induced O 0 0.0006626542
in O 0 0.00048224145
rats O 0 0.001936619
by O 0 0.00054495526
injection O 0 0.0025341637
of O 0 0.0015794196
puromycin B-Chemical 0 0.9815092
aminonucleoside I-Chemical 0 0.99998295
was O 0 0.0020031533
markedly O 0 0.026010016
inhibited O 0 0.0013915859
by O 0 0.0008267396
oral O 0 0.5435882
administration O 0 0.14379239
of O 0 0.0039514867
Dup B-Chemical 0 0.99955875
753 I-Chemical 0 0.9858759
( O 0 0.0049263192
losartan B-Chemical 1 0.99997914
) O 0 0.0038897458
, O 0 0.0007677459
a O 0 0.0007188305
novel O 0 0.0023520084
angiotensin B-Chemical 1 0.9999865
II I-Chemical 1 0.9250017
receptor O 0 0.5566519
antagonist O 0 0.98511475
, O 0 0.0012837071
at O 0 0.00039063403
a O 0 0.00062841043
dose O 0 0.0018948591
of O 0 0.0008298382
1 O 0 0.000875511
or O 0 0.0008177497
2 O 0 0.001220908
mg O 0 0.117840625
/ O 0 0.003696739
kg O 0 0.0056809057
per O 0 0.00262083
day O 0 0.0047557056
. O 0 0.0073244874

The O 0 0.007107447
results O 0 0.0049977293
suggest O 0 0.002911043
a O 0 0.0032605103
possible O 0 0.002256798
involvement O 0 0.0034188544
of O 0 0.0022237697
the O 0 0.0023466218
renin O 0 0.9983815
- O 0 0.028759064
angiotensin B-Chemical 1 0.9998932
system O 0 0.0028874755
in O 0 0.0010219237
the O 0 0.0011308328
development O 0 0.0026202593
of O 0 0.0043087243
puromycin B-Chemical 0 0.99161494
aminonucleoside I-Chemical 0 0.9999633
- O 0 0.15439606
induced O 0 0.040273372
nephrosis B-Disease 2 0.999879
. O 0 0.018145287

Neuroplasticity O 0 0.18220301
of O 0 0.010283238
the O 0 0.007333889
adult O 0 0.008028094
primate O 0 0.008368206
auditory O 0 0.093489714
cortex O 0 0.14641367
following O 0 0.006222071
cochlear O 0 0.34622973
hearing B-Disease 0 0.95628047
loss I-Disease 0 0.0232033
. O 0 0.013129127

Tonotopic O 0 0.042546846
organization O 0 0.0084414035
is O 0 0.004724217
an O 0 0.0041008973
essential O 0 0.0026587811
feature O 0 0.0025328067
of O 0 0.0021019941
the O 0 0.0017425208
primary O 0 0.0024424873
auditory O 0 0.0987672
area O 0 0.004086891
( O 0 0.004715983
A1 O 0 0.5742778
) O 0 0.0055458443
of O 0 0.0045665274
primate O 0 0.010616639
cortex O 0 0.28677544
. O 0 0.009221051

In O 0 0.010253294
A1 O 0 0.07412907
of O 0 0.005169192
macaque O 0 0.0033516064
monkeys O 0 0.002812946
, O 0 0.0026490134
low O 0 0.0020537202
frequencies O 0 0.001779074
are O 0 0.0017128787
represented O 0 0.0018518039
rostrolaterally O 0 0.010174368
and O 0 0.0021696847
high O 0 0.002590797
frequencies O 0 0.0031303728
are O 0 0.0041901907
represented O 0 0.0061802897
caudomedially O 0 0.039923567
. O 0 0.009296564

The O 0 0.0070910715
purpose O 0 0.0053521004
of O 0 0.0040744226
this O 0 0.0028389127
study O 0 0.0025325383
was O 0 0.0016385823
to O 0 0.0011507367
determine O 0 0.00070280134
if O 0 0.0008528178
changes O 0 0.001328553
occur O 0 0.0011555156
in O 0 0.001111898
this O 0 0.0014490548
tonotopic O 0 0.09008072
organization O 0 0.002650512
following O 0 0.0026465189
cochlear O 0 0.35437268
hearing B-Disease 0 0.960785
loss I-Disease 0 0.017045869
. O 0 0.009309054

Under O 0 0.014352145
anesthesia O 0 0.11149
, O 0 0.005444297
the O 0 0.0029857955
superior O 0 0.0040673823
temporal O 0 0.01990394
gyrus O 0 0.33054888
of O 0 0.001374339
adult O 0 0.0013761643
macaque O 0 0.0006902756
monkeys O 0 0.0006715446
was O 0 0.00062542176
exposed O 0 0.00064518175
, O 0 0.0009083598
and O 0 0.00071586523
the O 0 0.00073252566
tonotopic O 0 0.056051783
organization O 0 0.0011466073
of O 0 0.0013450223
A1 O 0 0.51598716
was O 0 0.0011779964
mapped O 0 0.0011330335
using O 0 0.0013281197
conventional O 0 0.0021959196
microelectrode O 0 0.024598328
recording O 0 0.005889312
techniques O 0 0.0074117994
. O 0 0.008267479

Following O 0 0.00992274
recovery O 0 0.009757381
, O 0 0.0057314476
the O 0 0.0033507848
monkeys O 0 0.0027408807
were O 0 0.002392013
selectively O 0 0.0029678277
deafened O 0 0.02147329
for O 0 0.0016901441
high O 0 0.0024911147
frequencies O 0 0.0029806923
using O 0 0.0037637756
kanamycin B-Chemical 1 0.98001194
and O 0 0.012350191
furosemide B-Chemical 1 0.99985063
. O 0 0.012923557

The O 0 0.007408928
actual O 0 0.005415646
frequencies O 0 0.0043519107
deafened O 0 0.016887652
were O 0 0.0025680794
determined O 0 0.0016816445
by O 0 0.0018497558
the O 0 0.0015373931
loss O 0 0.0024287591
of O 0 0.0024279093
tone O 0 0.8297449
- O 0 0.004949486
burst O 0 0.014350917
elicited O 0 0.0053799828
auditory O 0 0.36828917
brainstem O 0 0.869248
responses O 0 0.01747595
. O 0 0.009960608

Three O 0 0.021341035
months O 0 0.013191959
after O 0 0.010804363
deafening O 0 0.23679541
, O 0 0.019958217
A1 O 0 0.44714537
was O 0 0.016308146
remapped O 0 0.019473657
. O 0 0.018719144

Postmortem O 0 0.59700596
cytoarchitectural O 0 0.09809864
features O 0 0.012736167
identifying O 0 0.009173917
A1 O 0 0.34414467
were O 0 0.0059902533
correlated O 0 0.004510868
with O 0 0.005377055
the O 0 0.0066251573
electrophysiologic O 0 0.72270554
data O 0 0.014413197
. O 0 0.013356222

The O 0 0.0074654436
results O 0 0.005303985
indicate O 0 0.0032745216
that O 0 0.0024235141
the O 0 0.0022307273
deprived O 0 0.003163736
area O 0 0.0021325294
of O 0 0.0020525125
A1 O 0 0.47078016
undergoes O 0 0.0013009865
extensive O 0 0.0015750622
reorganization O 0 0.0067835003
and O 0 0.0017060011
becomes O 0 0.0017992287
responsive O 0 0.0019182495
to O 0 0.0020111739
intact O 0 0.0033788339
cochlear O 0 0.13245988
frequencies O 0 0.007415811
. O 0 0.008795731

The O 0 0.007913679
region O 0 0.006117105
of O 0 0.0049274275
cortex O 0 0.034286357
that O 0 0.0018827486
represents O 0 0.0016317781
the O 0 0.0013792751
low O 0 0.0016015718
frequencies O 0 0.0014762896
was O 0 0.0012929554
not O 0 0.0012445303
obviously O 0 0.004067977
affected O 0 0.0017509692
by O 0 0.0024831896
the O 0 0.0030321532
cochlear O 0 0.40138918
hearing B-Disease 0 0.96629703
loss I-Disease 0 0.018929686
. O 0 0.009713144

Sodium B-Chemical 0 0.99969816
bicarbonate I-Chemical 0 0.99930155
alleviates O 0 0.86503255
penile B-Disease 2 0.9940294
pain I-Disease 2 0.9996997
induced O 0 0.009270811
by O 0 0.006804863
intracavernous O 0 0.9979208
injections O 0 0.0820985
for O 0 0.0062599187
erectile B-Disease 0 0.9996474
dysfunction I-Disease 0 0.9936619
. O 0 0.014765894

In O 0 0.0072937505
an O 0 0.005925542
attempt O 0 0.0036737185
to O 0 0.0021682386
determine O 0 0.0011156827
whether O 0 0.0009972588
penile B-Disease 2 0.95984876
pain I-Disease 2 0.9998234
associated O 0 0.0019157786
with O 0 0.0008847175
intracorporeal O 0 0.0022442462
injections O 0 0.00508415
could O 0 0.00041751948
be O 0 0.00044845638
due O 0 0.00029288515
to O 0 0.00033223725
the O 0 0.000408526
acidity O 0 0.75506765
of O 0 0.0006805565
the O 0 0.0005389259
medication O 0 0.12282256
, O 0 0.00052942906
we O 0 0.00021440821
performed O 0 0.0002673388
a O 0 0.0003959623
randomized O 0 0.00035876376
study O 0 0.00030768235
comparing O 0 0.00018732616
the O 0 0.00031439
incidence O 0 0.0022494742
of O 0 0.0008016607
penile B-Disease 2 0.9740035
pain I-Disease 2 0.9997714
following O 0 0.00059854495
intracorporeal O 0 0.0016040708
injections O 0 0.0029317634
with O 0 0.0005531249
or O 0 0.0005083472
without O 0 0.0005328738
the O 0 0.00058889965
addition O 0 0.0005287626
of O 0 0.0024055485
sodium B-Chemical 1 0.99984264
bicarbonate I-Chemical 0 0.999113
to O 0 0.0020903065
the O 0 0.0026962196
intracorporeal O 0 0.00902618
medications O 0 0.6853478
. O 0 0.0088341925

A O 0 0.020464944
total O 0 0.0052867173
of O 0 0.0038467147
38 O 0 0.0032367029
consecutive O 0 0.0018498464
patients O 0 0.0022834484
who O 0 0.0017059189
presented O 0 0.0009762545
to O 0 0.0006734375
our O 0 0.0005925518
clinic O 0 0.0009099368
with O 0 0.0007221602
impotence B-Disease 0 0.99534947
received O 0 0.0007612351
0 O 0 0.0008808755
. O 0 0.00032425742
2 O 0 0.00036648507
ml O 0 0.00089420396
. O 0 0.0002748849
of O 0 0.00036344383
a O 0 0.00047997068
combination O 0 0.0005727251
of O 0 0.00054761476
3 O 0 0.00046641042
drugs O 0 0.3799605
: O 0 0.0007944699
6 O 0 0.000329326
mg O 0 0.1681968
. O 0 0.0004272189
papaverine B-Chemical 1 0.99995315
, O 0 0.0009874601
100 O 0 0.0011004338
micrograms O 0 0.17652854
. O 0 0.00049619813
phentolamine B-Chemical 0 0.9999862
and O 0 0.0008293932
10 O 0 0.0006347988
micrograms O 0 0.30621812
. O 0 0.0007809824
prostaglandin B-Chemical 1 0.9999951
E1 I-Chemical 1 0.99940133
with O 0 0.002303715
( O 0 0.0030402187
pH O 0 0.3162762
7 O 0 0.000602134
. O 0 0.0004281264
05 O 0 0.041201886
) O 0 0.00063422724
or O 0 0.00037964236
without O 0 0.0005379641
( O 0 0.00112779
pH O 0 0.13457824
4 O 0 0.00048114816
. O 0 0.00034893275
17 O 0 0.00062792463
) O 0 0.0006430577
the O 0 0.00039984134
addition O 0 0.00038397664
of O 0 0.0015909978
sodium B-Chemical 1 0.999884
bicarbonate I-Chemical 0 0.9997365
( O 0 0.0043851356
0 O 0 0.0023878727
. O 0 0.0015786769
03 O 0 0.11610535
mEq O 0 0.8181629
. O 0 0.0033788113
) O 0 0.008169291
. O 0 0.007412179

Of O 0 0.010145015
the O 0 0.0055179964
19 O 0 0.0050467285
patients O 0 0.004896745
without O 0 0.0032435223
sodium B-Chemical 1 0.9996662
bicarbonate I-Chemical 0 0.9993305
added O 0 0.0014748796
to O 0 0.00078734435
the O 0 0.0007222638
medication O 0 0.0700503
11 O 0 0.0009148521
( O 0 0.0007505857
58 O 0 0.0008217479
% O 0 0.00062191865
) O 0 0.0007977567
complained O 0 0.05329241
of O 0 0.0007378894
penile B-Disease 2 0.9669903
pain I-Disease 2 0.9998128
due O 0 0.00049755606
to O 0 0.00042401854
the O 0 0.0004657981
medication O 0 0.08992156
, O 0 0.00060365355
while O 0 0.0003380832
only O 0 0.00035260475
1 O 0 0.0003959053
of O 0 0.00041436215
the O 0 0.00047726955
19 O 0 0.001042303
men O 0 0.06095992
( O 0 0.0009781241
5 O 0 0.0005722733
% O 0 0.0008491712
) O 0 0.0011789466
who O 0 0.001446111
received O 0 0.0015569333
sodium B-Chemical 1 0.99967396
bicarbonate I-Chemical 0 0.9994973
complained O 0 0.82961977
of O 0 0.009717777
penile B-Disease 2 0.9957567
pain I-Disease 2 0.99969864
. O 0 0.015145173

From O 0 0.008209786
these O 0 0.005069891
data O 0 0.0037893527
we O 0 0.0017835065
conclude O 0 0.001459009
that O 0 0.0011893808
the O 0 0.0013648401
penile B-Disease 2 0.9408965
pain I-Disease 2 0.9996586
following O 0 0.0009708122
intracorporeal O 0 0.002259614
injections O 0 0.0056600156
is O 0 0.00057695503
most O 0 0.00065670453
likely O 0 0.0004191901
due O 0 0.00031811357
to O 0 0.0003663628
the O 0 0.00045929936
acidity O 0 0.77198964
of O 0 0.00080208934
the O 0 0.0006904644
medication O 0 0.21120296
, O 0 0.000963039
which O 0 0.00075211504
can O 0 0.00052180706
be O 0 0.00068695267
overcome O 0 0.00073902967
by O 0 0.0012205791
elevating O 0 0.1175519
the O 0 0.0018062905
pH O 0 0.27142748
to O 0 0.0020916555
a O 0 0.003969164
neutral O 0 0.0083236005
level O 0 0.00495113
. O 0 0.008040361

The O 0 0.008292813
use O 0 0.006632568
and O 0 0.00608319
toxicity B-Disease 2 0.991869
of O 0 0.011202767
didanosine B-Chemical 1 0.9998685
( O 0 0.045590773
ddI B-Chemical 0 0.9966264
) O 0 0.0035121422
in O 0 0.001268789
HIV B-Disease 0 0.652537
antibody I-Disease 0 0.008794466
- I-Disease 0 0.0020792542
positive I-Disease 0 0.001313393
individuals O 0 0.0026450572
intolerant O 0 0.007764647
to O 0 0.0029407148
zidovudine B-Chemical 1 0.9836819
( O 0 0.034278214
AZT B-Chemical 1 0.99847084
) O 0 0.04767961

One O 0 0.011312266
hundred O 0 0.006725416
and O 0 0.0049525355
fifty O 0 0.0046212683
- O 0 0.0036127865
one O 0 0.0016301016
patients O 0 0.002660085
intolerant O 0 0.004425114
to O 0 0.0013459257
zidovudine B-Chemical 1 0.9831268
( O 0 0.008328221
AZT B-Chemical 1 0.9993185
) O 0 0.0030174644
received O 0 0.0011175805
didanosine B-Chemical 1 0.99977416
( O 0 0.006475722
ddI B-Chemical 0 0.985316
) O 0 0.00097249344
to O 0 0.00038560183
a O 0 0.00053287455
maximum O 0 0.00045249372
dose O 0 0.0016311636
of O 0 0.0007835856
12 O 0 0.0006390339
. O 0 0.0006543762
5 O 0 0.000983195
mg O 0 0.07855762
/ O 0 0.0042103473
kg O 0 0.008727616
/ O 0 0.0072755646
day O 0 0.005055698
. O 0 0.007522195

Patient O 0 0.018187461
response O 0 0.006623886
was O 0 0.0038372069
assessed O 0 0.0023219073
using O 0 0.001898188
changes O 0 0.0019693812
in O 0 0.0014381416
CD4 O 0 0.3801832
+ O 0 0.0018073595
lymphocyte O 0 0.39559832
subset O 0 0.001147892
count O 0 0.005137841
, O 0 0.002019914
HIV O 0 0.7471567
p24 O 0 0.34297428
antigen O 0 0.04101814
, O 0 0.0026467005
weight O 0 0.0058259275
, O 0 0.002485417
and O 0 0.0024320718
quality O 0 0.0030269339
of O 0 0.00521576
life O 0 0.016258277
. O 0 0.009318416

Seventy O 0 0.015769435
patients O 0 0.0095650535
developed O 0 0.005503287
major O 0 0.0044305166
opportunistic B-Disease 0 0.3102062
infections I-Disease 2 0.90574604
whilst O 0 0.004572214
on O 0 0.0013793217
therapy O 0 0.015650412
; O 0 0.0026464574
this O 0 0.0011976764
was O 0 0.0012999189
the O 0 0.0015076344
first O 0 0.0021430412
AIDS B-Disease 2 0.9981804
diagnosis O 0 0.04188844
in O 0 0.00575887
17 O 0 0.010505262
. O 0 0.008540413

Only O 0 0.00980754
minor O 0 0.008691749
changes O 0 0.0048671677
in O 0 0.0030286314
CD4 O 0 0.36536255
+ O 0 0.0027240224
lymphocyte O 0 0.33944106
subset O 0 0.0011464374
count O 0 0.0020883975
were O 0 0.00071944355
observed O 0 0.0004792591
in O 0 0.00080661767
AIDS B-Disease 2 0.99899894
patients O 0 0.007436653
, O 0 0.00096774445
although O 0 0.0004888166
a O 0 0.00068827963
more O 0 0.0006082106
significant O 0 0.00068770524
rise O 0 0.0010699303
occurred O 0 0.00088759226
in O 0 0.0008788785
those O 0 0.001502458
with O 0 0.0015837244
earlier O 0 0.0021941515
stages O 0 0.0040243506
of O 0 0.0063139154
disease O 0 0.92483985
. O 0 0.0113172

Of O 0 0.009950914
those O 0 0.0056704967
positive O 0 0.0037380492
for O 0 0.0023515497
p24 O 0 0.11566626
antigen O 0 0.009989208
at O 0 0.000996697
the O 0 0.0008083682
commencement O 0 0.00082210934
of O 0 0.00068984844
the O 0 0.00059855834
study O 0 0.00072402286
67 O 0 0.0011048912
% O 0 0.0005384479
showed O 0 0.00033380504
a O 0 0.00051880075
positive O 0 0.0005243754
response O 0 0.0009115791
, O 0 0.0008209336
and O 0 0.0005291329
this O 0 0.00043874347
was O 0 0.00045118865
most O 0 0.0006027323
likely O 0 0.00046183582
in O 0 0.00048261945
those O 0 0.0008491877
with O 0 0.0009010984
CD4 O 0 0.43860805
+ O 0 0.0015701551
lymphocyte O 0 0.3103877
subset O 0 0.0015183816
counts O 0 0.0019327116
above O 0 0.002144353
100 O 0 0.006236408
mm3 O 0 0.028536271
. O 0 0.007165584

A O 0 0.031285692
positive O 0 0.010327889
weight O 0 0.014200993
response O 0 0.0073051215
was O 0 0.0051889396
seen O 0 0.004164013
in O 0 0.0042179907
16 O 0 0.004881796
% O 0 0.0060315924
of O 0 0.007266811
patients O 0 0.018672818
. O 0 0.01241828

Most O 0 0.014078656
patients O 0 0.009843811
showed O 0 0.004608467
improvement O 0 0.003909526
in O 0 0.0026369384
individual O 0 0.0023463133
parameters O 0 0.0028904506
and O 0 0.0026627546
global O 0 0.0033729332
score O 0 0.003291094
of O 0 0.0036304095
quality O 0 0.0044908444
of O 0 0.0071742325
life O 0 0.023294717
. O 0 0.011136681

Adverse O 0 0.51561815
reactions O 0 0.04972726
possibly O 0 0.01982879
attributable O 0 0.010874437
to O 0 0.012213388
didanosine B-Chemical 1 0.99853015
were O 0 0.017054481
common O 0 0.020898856
. O 0 0.01856383

The O 0 0.0077470653
most O 0 0.0067601134
common O 0 0.0058065187
side O 0 0.18382086
- O 0 0.005523041
effect O 0 0.0023106446
was O 0 0.0026458458
diarrhoea B-Disease 0 0.9997763
, O 0 0.0032410857
which O 0 0.0016765798
resulted O 0 0.0010623125
in O 0 0.0011912662
cessation O 0 0.0050021233
of O 0 0.0021540434
therapy O 0 0.012067664
in O 0 0.0031655547
19 O 0 0.006537524
individuals O 0 0.008473436
. O 0 0.0080687525

Peripheral B-Disease 2 0.9676068
neuropathy I-Disease 2 0.9994123
occurred O 0 0.0113165695
in O 0 0.0066227578
12 O 0 0.005063377
patients O 0 0.00901596
and O 0 0.009965262
pancreatitis B-Disease 0 0.9998273
in O 0 0.011904147
six O 0 0.009967652
. O 0 0.01357946

Thirteen O 0 0.025006836
patients O 0 0.016198631
developed O 0 0.011009058
a O 0 0.009785433
raised O 0 0.010082744
serum O 0 0.21551082
amylase O 0 0.9778346
without O 0 0.014116757
abdominal B-Disease 0 0.9560387
pain I-Disease 2 0.99846053
. O 0 0.020604832

Seven O 0 0.015335901
patients O 0 0.011331406
developed O 0 0.0077037388
glucose B-Disease 1 0.9848311
tolerance I-Disease 0 0.11600499
curves I-Disease 0 0.004716045
characteristic O 0 0.0022677178
of O 0 0.0025228122
diabetes B-Disease 2 0.99816567
but O 0 0.0012020984
these O 0 0.0010763253
were O 0 0.00097618613
mild O 0 0.4072649
, O 0 0.0011597195
did O 0 0.00057702383
not O 0 0.00057996454
require O 0 0.0004985511
treatment O 0 0.0011325899
and O 0 0.0011642654
returned O 0 0.0012094687
to O 0 0.0012400976
normal O 0 0.002841638
on O 0 0.0023141387
ceasing O 0 0.23097073
didanosine B-Chemical 1 0.99911743
. O 0 0.010405289

Immunohistochemical O 0 0.023092631
studies O 0 0.0073539186
with O 0 0.0048293434
antibodies O 0 0.006158695
to O 0 0.003173696
neurofilament O 0 0.40585306
proteins O 0 0.0044065695
on O 0 0.0019626701
axonal B-Disease 0 0.87707716
damage I-Disease 0 0.9450181
in O 0 0.002376389
experimental O 0 0.0034658469
focal O 0 0.2502735
lesions O 0 0.6715066
in O 0 0.006519549
rat O 0 0.043908983
. O 0 0.010177897

Immunohistochemistry O 0 0.026891058
with O 0 0.006209858
monoclonal O 0 0.010104919
antibodies O 0 0.0070539988
against O 0 0.0027765853
neurofilament O 0 0.81496274
( O 0 0.006069025
NF O 0 0.9625541
) O 0 0.0023452467
proteins O 0 0.0011923568
of O 0 0.0009209325
middle O 0 0.0014393876
and O 0 0.0007086417
high O 0 0.00073306443
molecular O 0 0.00902532
weight O 0 0.01161144
class O 0 0.0051466716
, O 0 0.002538415
NF O 0 0.9871525
- O 0 0.0065567223
M O 0 0.92229575
and O 0 0.0018558113
NF O 0 0.99358165
- O 0 0.018976936
H O 1 0.99927205
, O 0 0.0013933489
was O 0 0.00061017607
used O 0 0.00051693973
to O 0 0.00057064847
study O 0 0.0011386458
axonal B-Disease 0 0.7356923
injury I-Disease 0 0.9899086
in O 0 0.0011281767
the O 0 0.00150536
borderzone O 0 0.98944443
of O 0 0.0025672168
focal O 0 0.2310201
lesions O 0 0.61362064
in O 0 0.0051914756
rats O 0 0.020003924
. O 0 0.0090416195

Focal O 0 0.4974034
injury B-Disease 0 0.8450282
in I-Disease 0 0.004591847
the I-Disease 0 0.0035804198
cortex I-Disease 0 0.099653974
was O 0 0.001760753
produced O 0 0.0013276271
by O 0 0.001463326
infusion O 0 0.009649733
of O 0 0.001998668
lactate B-Chemical 0 0.9832555
at O 0 0.0013003856
acid O 0 0.93892926
pH O 0 0.5848393
or O 0 0.0017431332
by O 0 0.002412227
stab O 0 0.52779055
caused O 0 0.0033085616
by O 0 0.0043864413
needle O 0 0.012443295
insertion O 0 0.007323919
. O 0 0.00876342

Infarcts B-Disease 0 0.8713043
in I-Disease 0 0.012030849
substantia I-Disease 0 0.93150824
nigra I-Disease 0 0.8746414
pars I-Disease 0 0.32155028
reticulata I-Disease 0 0.86426455
were O 0 0.0038704094
evoked O 0 0.13638377
by O 0 0.0037864642
prolonged O 0 0.11176945
pilocarpine B-Chemical 1 0.9999708
- O 0 0.024191845
induced O 0 0.0073559238
status B-Disease 0 0.078239046
epilepticus I-Disease 0 0.99987864
. O 0 0.01576205

Immunohistochemical O 0 0.023339756
staining O 0 0.009022692
for O 0 0.00512761
NFs O 0 0.03355182
showed O 0 0.0031683096
characteristic O 0 0.004011859
terminal O 0 0.0071692206
clubs O 0 0.031758577
of O 0 0.0035673107
axons O 0 0.023804853
in O 0 0.0028260923
the O 0 0.0041520144
borderzone O 0 0.9891431
of O 0 0.008925373
lesions O 0 0.7306028
. O 0 0.012774927

Differences O 0 0.0072320546
in O 0 0.004604436
the O 0 0.003396688
labelling O 0 0.0037766292
pattern O 0 0.0019219137
occurred O 0 0.0016953769
with O 0 0.001287384
different O 0 0.001007407
antibodies O 0 0.0024569246
which O 0 0.0012888238
apparently O 0 0.0020613726
depended O 0 0.0011242828
on O 0 0.00076508883
molecular O 0 0.010672369
weight O 0 0.009674295
class O 0 0.0040338356
of O 0 0.003255775
NFs O 0 0.423683
and O 0 0.0047854357
phosphorylation O 0 0.04811173
state O 0 0.010135893
. O 0 0.009091009

These O 0 0.009222449
immunohistochemical O 0 0.010367114
changes O 0 0.005239247
of O 0 0.004251021
NFs O 0 0.118797414
can O 0 0.0017343112
serve O 0 0.001856854
as O 0 0.0012963542
a O 0 0.001561107
marker O 0 0.0015267972
for O 0 0.0011816827
axonal B-Disease 0 0.8394652
damage I-Disease 0 0.93486863
in O 0 0.0015332629
various O 0 0.0030610906
experimental O 0 0.005129381
traumatic B-Disease 0 0.99930894
or O 0 0.026238503
ischemic O 0 0.99993384
lesions O 0 0.99258035
. O 0 0.014796484

Pharmacokinetic O 0 0.50088376
and O 0 0.010010461
clinical O 0 0.011669288
studies O 0 0.0055292565
in O 0 0.0042209676
patients O 0 0.008287843
with O 0 0.0077653253
cimetidine B-Chemical 1 0.9999671
- O 0 0.041698642
associated O 0 0.011103663
mental O 0 0.848125
confusion B-Disease 2 0.9776741
. O 0 0.014090608

15 O 0 0.012383271
cases O 0 0.012100237
of O 0 0.012448545
cimetidine B-Chemical 1 0.9999068
- O 0 0.025471432
associated O 0 0.009293877
mental O 0 0.67788327
confusion B-Disease 2 0.9425349
have O 0 0.0072849
been O 0 0.009025608
reported O 0 0.012010722
. O 0 0.012687335

In O 0 0.006845625
order O 0 0.003903325
that O 0 0.002945972
this O 0 0.0027065715
syndrome O 0 0.6041199
might O 0 0.0013874817
be O 0 0.0012511351
investigated O 0 0.00083621213
changes O 0 0.0013238505
in O 0 0.000998999
mental O 0 0.46470866
status O 0 0.004139905
( O 0 0.0044582477
M O 0 0.9711123
. O 0 0.0008376174
S O 0 0.845425
. O 0 0.00054703833
) O 0 0.00095816125
were O 0 0.00041066215
correlated O 0 0.00033380726
with O 0 0.00051517045
serum O 0 0.11074221
concentrations O 0 0.0038507169
and O 0 0.00091005303
renal O 0 0.98646265
and O 0 0.0010825513
hepatic O 0 0.9364849
function O 0 0.0006727903
in O 0 0.00038439082
36 O 0 0.00045549363
patients O 0 0.00094066246
, O 0 0.00051466096
30 O 0 0.0002739841
patients O 0 0.00060553325
had O 0 0.00036345315
no O 0 0.00045978843
M O 0 0.9212662
. O 0 0.00074681576
S O 0 0.6510359
. O 0 0.0005145099
change O 0 0.0006360308
on O 0 0.0006157582
cimetidine B-Chemical 1 0.9999708
and O 0 0.0015247457
6 O 0 0.0010112709
had O 0 0.0012585351
moderate O 0 0.0056061377
to O 0 0.0028889845
severe O 0 0.30694997
changes O 0 0.00974489
. O 0 0.00901578

These O 0 0.008559953
6 O 0 0.004568865
patients O 0 0.0047012563
had O 0 0.0024582269
both O 0 0.002139965
renal B-Disease 0 0.9654687
and I-Disease 0 0.0041651083
liver I-Disease 0 0.99782276
dysfunction I-Disease 0 0.9993531
( O 0 0.0063236044
P O 0 0.10942157
less O 0 0.0006262506
than O 0 0.00043674055
0 O 0 0.0008134805
. O 0 0.00044757585
05 O 0 0.0654103
) O 0 0.0007673758
, O 0 0.0004924942
as O 0 0.00035606755
well O 0 0.00038395796
as O 0 0.000698669
cimetidine B-Chemical 1 0.999992
trough O 0 0.41963243
- O 0 0.0014364696
concentrations O 0 0.00088981324
of O 0 0.0005282578
more O 0 0.0005390255
than O 0 0.00034899462
1 O 0 0.00052051456
. O 0 0.00034140502
25 O 0 0.00063154195
microgram O 0 0.054326367
/ O 0 0.0019880128
ml O 0 0.0030076066
( O 0 0.0016772283
P O 0 0.017284602
less O 0 0.0011523409
than O 0 0.0012759026
0 O 0 0.0028267172
. O 0 0.0027058467
05 O 0 0.07413332
) O 0 0.0076662623
. O 0 0.007384676

The O 0 0.0088728815
severity O 0 0.027018284
of O 0 0.008706938
M O 0 0.9528557
. O 0 0.0036750848
S O 0 0.7135435
. O 0 0.0015213478
changes O 0 0.001597879
increased O 0 0.0014389531
as O 0 0.0013812382
trough O 0 0.1691921
- O 0 0.0025378282
concentrations O 0 0.002904225
rose O 0 0.016328774
, O 0 0.0021347825
5 O 0 0.00152222
patients O 0 0.003381131
had O 0 0.0033306486
lumbar O 0 0.87534785
puncture O 0 0.07370222
. O 0 0.009695049

The O 0 0.008210489
cerebrospinal O 0 0.6648754
fluid O 0 0.058136348
: O 0 0.0054099415
serum O 0 0.039898753
ratio O 0 0.0026327816
of O 0 0.0031423084
cimetidine B-Chemical 1 0.99998856
concentrations O 0 0.021078886
was O 0 0.0010931764
0 O 0 0.00102718
. O 0 0.00040267213
24 O 0 0.00037830413
: O 0 0.0005719194
1 O 0 0.00039234094
and O 0 0.00038015918
indicates O 0 0.00032309128
that O 0 0.0004390303
cimetidine B-Chemical 1 0.9999864
passes O 0 0.008531745
the O 0 0.0005624187
blood O 0 0.03288021
- O 0 0.0017918813
brain O 0 0.060424373
barrier O 0 0.016464205
; O 0 0.0010707093
it O 0 0.00039924358
also O 0 0.00033380822
raises O 0 0.0002404736
the O 0 0.000350717
possibility O 0 0.00041323315
that O 0 0.00058128586
M O 0 0.9715807
. O 0 0.00072755094
S O 0 0.8041504
. O 0 0.00042890906
changes O 0 0.00059810135
are O 0 0.00048777342
due O 0 0.00037413125
to O 0 0.0005226573
blockade O 0 0.11591917
of O 0 0.002366153
histamine B-Chemical 1 0.99992967
H2 O 0 0.9983962
- O 0 0.009231377
receptors O 0 0.057661563
in O 0 0.0015933394
the O 0 0.002163414
central O 0 0.008536877
nervous O 0 0.9634371
system O 0 0.0123255495
. O 0 0.008872386

Patients O 0 0.014239168
likely O 0 0.0055335877
to O 0 0.0035759741
have O 0 0.0024525204
both O 0 0.0020021684
raised O 0 0.0025805284
trough O 0 0.15252303
- O 0 0.0027825017
concentrations O 0 0.0024451218
and O 0 0.0016228079
mental O 0 0.43697712
confusion B-Disease 2 0.88839495
are O 0 0.0011877574
those O 0 0.0013056713
with O 0 0.0011713086
both O 0 0.0015659431
severe O 0 0.42077965
renal B-Disease 0 0.9960905
and I-Disease 0 0.019246442
hepatic I-Disease 0 0.99917245
dysfunction I-Disease 0 0.9988186
. O 0 0.013149524

They O 0 0.0153340055
should O 0 0.0058088508
be O 0 0.0050595594
closely O 0 0.0035760384
observed O 0 0.0025905897
and O 0 0.003091377
should O 0 0.0019285005
be O 0 0.002385804
given O 0 0.0019929176
reduced O 0 0.0033727475
doses O 0 0.10296998
of O 0 0.026645679
cimetidine B-Chemical 1 0.9999423
. O 0 0.017729746

Prospective O 0 0.02563965
study O 0 0.0061892406
of O 0 0.00419277
the O 0 0.0029736932
long O 0 0.0027191278
- O 0 0.0026730478
term O 0 0.001291072
effects O 0 0.0021889617
of O 0 0.0026258219
somatostatin O 0 0.9980147
analog O 0 0.44615513
( O 0 0.0064911777
octreotide B-Chemical 1 0.9997105
) O 0 0.0023506102
on O 0 0.0006465341
gallbladder O 0 0.71595997
function O 0 0.001786606
and O 0 0.0026939295
gallstone B-Disease 0 0.999861
formation O 0 0.033363935
in O 0 0.0040756753
Chinese O 0 0.38233525
acromegalic B-Disease 0 0.99895716
patients O 0 0.059197236
. O 0 0.009796751

This O 0 0.009973909
article O 0 0.00577791
reports O 0 0.004029086
the O 0 0.0025377746
changes O 0 0.0022807557
in O 0 0.0014936982
gallbladder O 0 0.6045877
function O 0 0.0013347879
examined O 0 0.0006721731
by O 0 0.0010241723
ultrasonography O 0 0.16608424
in O 0 0.00061788486
20 O 0 0.00068210845
Chinese O 0 0.006806268
patients O 0 0.0013382514
with O 0 0.00059527706
active O 0 0.002276479
acromegaly B-Disease 0 0.99875236
treated O 0 0.001008405
with O 0 0.0006594867
sc O 0 0.14512321
injection O 0 0.0013641943
of O 0 0.0006129342
the O 0 0.0007092667
somatostatin O 0 0.9951448
analog O 0 0.22316743
octreotide B-Chemical 1 0.9997471
in O 0 0.0005427798
dosages O 0 0.09631717
of O 0 0.00080573576
300 O 0 0.0069884006
- O 0 0.00082374585
1500 O 0 0.0009197758
micrograms O 0 0.021401918
/ O 0 0.0007392125
day O 0 0.0002775074
for O 0 0.00025476655
a O 0 0.00042881054
mean O 0 0.00036160936
of O 0 0.0005733007
24 O 0 0.0005207945
. O 0 0.00049644266
2 O 0 0.00079554337
+ O 0 0.00113809
/ O 0 0.0026445363
- O 0 0.0021087844
13 O 0 0.0018953374
. O 0 0.0017376554
9 O 0 0.0030326697
months O 0 0.0036907378
. O 0 0.006300778

During O 0 0.0072739804
treatment O 0 0.0068595563
with O 0 0.00530059
octreotide B-Chemical 1 0.99907047
, O 0 0.004732435
17 O 0 0.0026142795
patients O 0 0.0027789567
developed O 0 0.0019751855
sludge O 0 0.36417574
, O 0 0.0020529835
10 O 0 0.0011150579
had O 0 0.0011824267
gallstones B-Disease 0 0.9997243
, O 0 0.0027070732
and O 0 0.0017282105
1 O 0 0.0018362857
developed O 0 0.0034433831
acute B-Disease 0 0.9981852
cholecystitis I-Disease 0 0.9999722
requiring O 0 0.023220906
surgery O 0 0.058005463
. O 0 0.010386908

In O 0 0.0072876285
all O 0 0.004722402
of O 0 0.0039836946
7 O 0 0.002756434
patients O 0 0.0031526526
examined O 0 0.0014923512
acutely O 0 0.05172207
, O 0 0.0026491683
gallbladder O 0 0.9147766
contractility O 0 0.9847904
was O 0 0.0015560833
inhibited O 0 0.0014649866
after O 0 0.00083355594
a O 0 0.0017636617
single O 0 0.0020144484
100 O 0 0.0044780476
- O 0 0.004860025
micrograms O 0 0.22866203
injection O 0 0.013768965
. O 0 0.00855963

In O 0 0.008699159
8 O 0 0.005987176
patients O 0 0.005578039
followed O 0 0.002906706
for O 0 0.0022488923
24 O 0 0.0019198989
weeks O 0 0.0016585316
, O 0 0.0027573365
gallbladder O 0 0.7500542
contractility O 0 0.9748964
remained O 0 0.005909478
depressed B-Disease 2 0.833867
throughout O 0 0.0043773125
therapy O 0 0.034706328
. O 0 0.009762511

After O 0 0.0064519704
withdrawal O 0 0.29064852
of O 0 0.0058069597
octreotide B-Chemical 1 0.9987489
in O 0 0.002468854
10 O 0 0.001633257
patients O 0 0.0024249258
without O 0 0.0015025807
gallstones B-Disease 0 0.9998294
, O 0 0.0022613187
8 O 0 0.0008255997
patients O 0 0.001159825
assessed O 0 0.00057997176
had O 0 0.0007099139
return O 0 0.0011784973
of O 0 0.0011572189
normal O 0 0.0028383404
gallbladder O 0 0.8981954
contractility O 0 0.95657414
within O 0 0.002164296
1 O 0 0.004198165
month O 0 0.004380115
. O 0 0.0071609644

In O 0 0.007094823
8 O 0 0.0044907182
of O 0 0.0032008642
the O 0 0.0021591985
remaining O 0 0.0016626266
10 O 0 0.0013820613
patients O 0 0.0019320394
who O 0 0.0018748117
developed O 0 0.0019528703
gallstones B-Disease 0 0.9998254
during O 0 0.0007796037
treatment O 0 0.0018693828
, O 0 0.0012599103
gallbladder O 0 0.87697685
contractility O 0 0.9536714
normalized O 0 0.00039687415
in O 0 0.00039864762
5 O 0 0.00037399007
patients O 0 0.0010191707
( O 0 0.0005741685
3 O 0 0.00029860967
of O 0 0.00033634846
whom O 0 0.0008198196
has O 0 0.00029927547
disappearance O 0 0.0010339491
of O 0 0.0004937951
their O 0 0.0005734095
stones O 0 0.72693706
within O 0 0.0002914187
3 O 0 0.0003967333
weeks O 0 0.00030644902
) O 0 0.00082098943
, O 0 0.0005661708
and O 0 0.00050946046
remained O 0 0.0006979719
depressed B-Disease 2 0.5856015
in O 0 0.00054650044
3 O 0 0.0006133263
( O 0 0.00074812135
2 O 0 0.0005168718
of O 0 0.00063313707
whom O 0 0.0016065722
had O 0 0.0010268934
stones O 0 0.5302127
present O 0 0.0012097694
at O 0 0.0015329695
6 O 0 0.0020559535
months O 0 0.0028837358
) O 0 0.0075630187
. O 0 0.0073150326

Our O 0 0.0073609883
results O 0 0.004727559
suggest O 0 0.0026127642
that O 0 0.0020688924
the O 0 0.0018485015
suppression O 0 0.002432835
of O 0 0.0019332984
gallbladder O 0 0.9587257
contractility O 0 0.9889959
is O 0 0.0009648408
the O 0 0.00066613953
cause O 0 0.0015110011
of O 0 0.0007022618
the O 0 0.00054262625
successive O 0 0.0007146076
formation O 0 0.0016855565
of O 0 0.0012803727
bile O 0 0.97704893
sludge O 0 0.9084821
, O 0 0.011106077
gallstones B-Disease 0 0.9999254
, O 0 0.0040131225
and O 0 0.0025142147
cholecystitis B-Disease 0 0.99995875
during O 0 0.0018683822
octreotide B-Chemical 1 0.99973685
therapy O 0 0.059667107
in O 0 0.003395368
Chinese O 0 0.34131053
acromegalic B-Disease 0 0.99894315
patients O 0 0.058396306
. O 0 0.009675835

It O 0 0.010494359
is O 0 0.0054668062
therefore O 0 0.0038842678
very O 0 0.0029509035
important O 0 0.0017590113
to O 0 0.0013772853
follow O 0 0.001011776
the O 0 0.0009500499
changes O 0 0.0010953039
of O 0 0.0011927998
gallbladder O 0 0.7767185
function O 0 0.0014190691
during O 0 0.0007952058
long O 0 0.0013313752
- O 0 0.00211241
term O 0 0.0016904715
octreotide B-Chemical 1 0.99946874
therapy O 0 0.054021206
of O 0 0.0079890825
acromegalic B-Disease 0 0.99933285
patients O 0 0.08557366
. O 0 0.009959572

Increase O 0 0.035370223
of O 0 0.025432793
Parkinson B-Disease 0 0.99929893
disability I-Disease 0 0.9931463
after O 0 0.014616843
fluoxetine B-Chemical 1 0.9998574
medication O 0 0.84345025
. O 0 0.020340474

Depression B-Disease 2 0.98985636
is O 0 0.010506595
a O 0 0.008635471
major O 0 0.0072933715
clinical O 0 0.011741082
feature O 0 0.00733659
of O 0 0.00915567
Parkinson B-Disease 0 0.99945694
' I-Disease 0 0.013718506
s I-Disease 0 0.011981007
disease I-Disease 0 0.78950113
. O 0 0.015231195

We O 0 0.0077870325
report O 0 0.0069754557
the O 0 0.003488821
increased O 0 0.002684734
amount O 0 0.0014857193
of O 0 0.0023672597
motor B-Disease 2 0.7645087
disability I-Disease 2 0.9712487
in O 0 0.0009341274
four O 0 0.0006266449
patients O 0 0.0020259665
with O 0 0.0010971952
idiopathic B-Disease 0 0.99143255
Parkinson I-Disease 0 0.99992085
' I-Disease 0 0.0024383643
s I-Disease 0 0.0013440786
disease I-Disease 0 0.28963554
after O 0 0.00080547243
exposure O 0 0.002615533
to O 0 0.0019414843
the O 0 0.004291746
antidepressant B-Chemical 1 0.9999068
fluoxetine B-Chemical 0 0.999944
. O 0 0.011733425

The O 0 0.006768555
possibility O 0 0.004608601
of O 0 0.003988272
a O 0 0.00379493
clinically O 0 0.02947288
relevant O 0 0.003026347
dopamine B-Chemical 1 0.99982125
- O 0 0.0039445134
antagonistic O 0 0.005191045
capacity O 0 0.0018537776
of O 0 0.0023421496
fluoxetine B-Chemical 1 0.9999846
in O 0 0.0018268364
Parkinson B-Disease 0 0.99981564
' I-Disease 0 0.0025983981
s I-Disease 0 0.0020341915
disease I-Disease 0 0.40627164
patients O 0 0.005960803
must O 0 0.002319615
be O 0 0.0039988593
considered O 0 0.00512301
. O 0 0.007983227

Sinus B-Disease 0 0.8836631
arrest I-Disease 0 0.6757062
associated O 0 0.014083251
with O 0 0.01115852
continuous O 0 0.012062787
- O 0 0.019391622
infusion O 0 0.34895766
cimetidine B-Chemical 1 0.9998473
. O 0 0.025336634

The O 0 0.007082519
administration O 0 0.012476193
of O 0 0.004154154
intermittent O 0 0.064042225
intravenous O 0 0.596971
infusions O 0 0.25543183
of O 0 0.006554918
cimetidine B-Chemical 1 0.99998796
is O 0 0.0029112261
infrequently O 0 0.005647671
associated O 0 0.0021204038
with O 0 0.002205539
the O 0 0.0025673732
development O 0 0.0061607067
of O 0 0.010599908
bradyarrhythmias B-Disease 0 0.99978036
. O 0 0.012139356

A O 0 0.037324063
40 O 0 0.008430929
- O 0 0.0066374964
year O 0 0.0035680705
- O 0 0.0033615557
old O 0 0.002279926
man O 0 0.07360767
with O 0 0.00272999
leukemia B-Disease 0 0.9998155
and O 0 0.0016178803
no O 0 0.0006575474
history O 0 0.015215084
of O 0 0.0013024061
cardiac B-Disease 0 0.8117951
disease I-Disease 0 0.8330066
developed O 0 0.0025064799
recurrent O 0 0.8350793
, O 0 0.0011287471
brief O 0 0.0006921952
episodes O 0 0.08901054
of O 0 0.0007147247
apparent O 0 0.0008073239
sinus B-Disease 0 0.68879133
arrest I-Disease 0 0.7828517
while O 0 0.00060296466
receiving O 0 0.0011447748
continuous O 0 0.0010712908
- O 0 0.002375321
infusion O 0 0.052682243
cimetidine B-Chemical 1 0.9999746
50 O 0 0.006917498
mg O 0 0.6043921
/ O 0 0.008928245
hour O 0 0.0044918596
. O 0 0.0072339484

The O 0 0.010005864
arrhythmias B-Disease 2 0.9992501
were O 0 0.0052001392
temporally O 0 0.005579063
related O 0 0.0019934487
to O 0 0.0022816805
cimetidine B-Chemical 1 0.9999808
administration O 0 0.50102943
, O 0 0.0024897617
disappeared O 0 0.0019800118
after O 0 0.0007506072
dechallenge O 0 0.99593616
, O 0 0.002055518
and O 0 0.0014556962
did O 0 0.0013104435
not O 0 0.0017697462
recur O 0 0.06227812
during O 0 0.0034629938
ranitidine B-Chemical 1 0.9999118
treatment O 0 0.02612773
. O 0 0.0106362505

This O 0 0.011511785
is O 0 0.005858153
the O 0 0.003977424
first O 0 0.002767768
reported O 0 0.0028039184
case O 0 0.002352333
of O 0 0.0031440358
sinus B-Disease 0 0.7974514
arrest I-Disease 0 0.8951247
associated O 0 0.0029541529
with O 0 0.0028001536
continuous O 0 0.00395536
- O 0 0.009751578
infusion O 0 0.28058982
cimetidine B-Chemical 1 0.9999237
. O 0 0.013881266

Phase O 0 0.03189592
II O 0 0.0273524
trial O 0 0.010630206
of O 0 0.009328502
vinorelbine B-Chemical 1 0.9978963
in O 0 0.008991664
metastatic O 0 0.99400216
squamous B-Disease 0 0.999456
cell I-Disease 0 0.74720234
esophageal I-Disease 0 0.99911374
carcinoma I-Disease 2 0.99981743
. O 0 0.027608495

European O 0 0.020979365
Organization O 0 0.014144844
for O 0 0.0074852873
Research O 0 0.014680611
and O 0 0.006868919
Treatment O 0 0.044202324
of O 0 0.0101501215
Cancer B-Disease 2 0.99501824
Gastrointestinal O 0 0.9965802
Treat O 0 0.9899227
Cancer B-Disease 2 0.99399334
Cooperative O 0 0.454821
Group O 0 0.15624814
. O 0 0.011504504

PURPOSE O 0 0.023419475
: O 0 0.0067381826
To O 0 0.002850076
evaluate O 0 0.0016483134
the O 0 0.0017733804
response O 0 0.0019076923
rate O 0 0.0013925451
and O 0 0.0015393823
toxic O 0 0.76448035
effects O 0 0.0040392363
of O 0 0.0031562243
vinorelbine B-Chemical 1 0.9999107
( O 0 0.010258735
VNB B-Chemical 1 0.9977671
) O 0 0.0015599938
administered O 0 0.00089298555
as O 0 0.0006714979
a O 0 0.0010062957
single O 0 0.001054363
agent O 0 0.06163258
in O 0 0.0021210276
metastatic O 0 0.99609286
squamous B-Disease 0 0.9997452
cell I-Disease 0 0.6852355
esophageal I-Disease 0 0.9994443
carcinoma I-Disease 2 0.9998878
. O 0 0.020118179

PATIENTS O 0 0.016650809
AND O 0 0.009196256
METHODS O 0 0.006970066
: O 0 0.0054659196
Forty O 0 0.0062120836
- O 0 0.003347118
six O 0 0.0014133211
eligible O 0 0.0016337485
patients O 0 0.0019134532
with O 0 0.0011529794
measurable O 0 0.0017555767
lesions O 0 0.1755506
were O 0 0.0012090488
included O 0 0.0009934234
and O 0 0.0012161573
were O 0 0.0012548233
stratified O 0 0.0018478833
according O 0 0.0017145544
to O 0 0.0022691814
previous O 0 0.004020784
chemotherapy O 0 0.8287582
. O 0 0.009527704

Thirty O 0 0.011795038
patients O 0 0.0074533946
without O 0 0.0036215547
prior O 0 0.0023309905
chemotherapy O 0 0.30832213
and O 0 0.0024174615
16 O 0 0.0017220957
pretreated O 0 0.0049564373
with O 0 0.0022631148
cisplatin B-Chemical 1 0.9998147
- O 0 0.003700951
based O 0 0.0014124479
chemotherapy O 0 0.52040356
were O 0 0.0016980593
assessable O 0 0.008316825
for O 0 0.0021203202
toxicity B-Disease 2 0.99436224
and O 0 0.0062740184
response O 0 0.01091397
. O 0 0.00948941

VNB B-Chemical 1 0.95461875
was O 0 0.0063779172
administered O 0 0.0042645717
weekly O 0 0.0034060325
as O 0 0.002162754
a O 0 0.0023724446
25 O 0 0.0024120135
- O 0 0.0022686827
mg O 0 0.18725382
/ O 0 0.0027847453
m2 O 0 0.00692297
short O 0 0.0009740986
intravenous O 0 0.28664178
( O 0 0.002489988
i O 0 0.004588259
. O 0 0.0016041014
v O 0 0.019074492
. O 0 0.0025455942
) O 0 0.0063096513
infusion O 0 0.019411415
. O 0 0.007903018

RESULTS O 0 0.023970269
: O 0 0.007704365
Six O 0 0.0046718656
of O 0 0.0031895086
30 O 0 0.001996124
patients O 0 0.0030935039
( O 0 0.0019795066
20 O 0 0.0011465854
% O 0 0.0011464603
) O 0 0.0010575762
without O 0 0.0005252113
prior O 0 0.00041940674
chemotherapy O 0 0.20113258
achieved O 0 0.0006520247
a O 0 0.0007678904
partial O 0 0.0009576369
response O 0 0.0014276303
( O 0 0.0024134482
PR O 0 0.8511689
) O 0 0.002125833
( O 0 0.0009985961
95 O 0 0.0010452888
% O 0 0.0007056073
confidence O 0 0.0015323684
interval O 0 0.0011334622
[ O 0 0.0040964475
CI O 0 0.35084397
] O 0 0.0023253872
, O 0 0.0015296451
8 O 0 0.0012198774
% O 0 0.0016853173
to O 0 0.0017956363
39 O 0 0.0042671585
% O 0 0.005009467
) O 0 0.008522403
. O 0 0.007820328

The O 0 0.0075015156
median O 0 0.005330256
duration O 0 0.0043996866
of O 0 0.003772995
response O 0 0.0036098459
was O 0 0.0025210155
21 O 0 0.00237405
weeks O 0 0.0015451476
( O 0 0.0024814275
range O 0 0.0027523597
, O 0 0.0030699186
17 O 0 0.003402357
to O 0 0.0030905101
28 O 0 0.0054980484
) O 0 0.009268215
. O 0 0.0086863935

One O 0 0.010032819
of O 0 0.005813386
16 O 0 0.0040245876
patients O 0 0.004965754
( O 0 0.00297719
6 O 0 0.0013615147
% O 0 0.0015451256
) O 0 0.001429684
with O 0 0.0007219585
prior O 0 0.00051812216
chemotherapy O 0 0.21468072
had O 0 0.00061502884
a O 0 0.00078807026
complete O 0 0.0005264889
response O 0 0.001078135
( O 0 0.001458123
CR O 0 0.28080696
) O 0 0.0009187449
of O 0 0.0005247464
31 O 0 0.0007014571
weeks O 0 0.00031788042
' O 0 0.0005760443
duration O 0 0.00068456435
( O 0 0.0010814139
95 O 0 0.0014535527
% O 0 0.0012428659
CI O 0 0.06762393
, O 0 0.0013591365
0 O 0 0.0014230561
% O 0 0.0015861872
to O 0 0.0016491298
30 O 0 0.002264738
% O 0 0.004546185
) O 0 0.008053118
. O 0 0.007643606

The O 0 0.007660486
overall O 0 0.006090766
response O 0 0.0050159213
rate O 0 0.003811379
( O 0 0.004216565
World O 0 0.0055814628
Health O 0 0.003102216
Organization O 0 0.0028321377
[ O 0 0.002907317
WHO O 0 0.0060948464
] O 0 0.0015985852
criteria O 0 0.0010108203
) O 0 0.0012084265
was O 0 0.00055352726
15 O 0 0.0004721986
% O 0 0.00070396945
( O 0 0.0008894585
CR O 0 0.12028162
, O 0 0.00083695515
2 O 0 0.0006000215
% O 0 0.00081142044
; O 0 0.0011848995
PR O 0 0.241396
13 O 0 0.0008851265
% O 0 0.0009340833
; O 0 0.0012090219
95 O 0 0.0013617266
% O 0 0.0012494744
CI O 0 0.047555044
, O 0 0.0013480796
6 O 0 0.0010194844
% O 0 0.0016766884
to O 0 0.0018432161
29 O 0 0.0043601897
% O 0 0.0050685317
) O 0 0.008699714
. O 0 0.008001927

The O 0 0.008412413
median O 0 0.0065342356
dose O 0 0.014877116
- O 0 0.0067903465
intensity O 0 0.003717178
( O 0 0.005590002
DI O 0 0.65281343
) O 0 0.004663438
was O 0 0.0024012693
20 O 0 0.0026398231
mg O 0 0.19469774
/ O 0 0.007918249
m2 O 0 0.03120441
/ O 0 0.009499369
wk O 0 0.006100276
. O 0 0.008933445

VNB B-Chemical 1 0.9553788
was O 0 0.007583304
well O 0 0.0048069735
tolerated O 0 0.0095971525
and O 0 0.0033421617
zero O 0 0.0021828846
instances O 0 0.0018062468
of O 0 0.0029515333
WHO O 0 0.018911576
grade O 0 0.52284235
4 O 0 0.0049621323
nonhematologic O 0 0.9996635
toxicity B-Disease 2 0.99815947
occurred O 0 0.01185407
. O 0 0.0105480105

At O 0 0.006160733
least O 0 0.004059812
one O 0 0.0034840945
episode O 0 0.0062573147
of O 0 0.0032551095
grade O 0 0.30612704
3 O 0 0.0019162637
or O 0 0.0015333303
4 O 0 0.001708308
granulocytopenia B-Disease 0 0.9996325
was O 0 0.0018613276
seen O 0 0.0015622452
in O 0 0.0018820382
59 O 0 0.0040283813
% O 0 0.0034799401
of O 0 0.004581778
patients O 0 0.014121066
. O 0 0.009185809

A O 0 0.06043992
grade O 0 0.1889939
2 O 0 0.0053125126
or O 0 0.0034188903
3 O 0 0.002536346
infection B-Disease 2 0.023298047
occurred O 0 0.0018574392
in O 0 0.0013104703
16 O 0 0.0013055507
% O 0 0.0013017202
of O 0 0.0013332264
patients O 0 0.0035015296
, O 0 0.0021796238
but O 0 0.0017404318
no O 0 0.0020978635
toxic O 0 0.9096334
deaths B-Disease 2 0.9574031
occurred O 0 0.010584242
. O 0 0.0102875

Other O 0 0.017005082
side O 0 0.041203644
effects O 0 0.007268972
were O 0 0.0040948913
rare O 0 0.017507114
, O 0 0.0039120317
and O 0 0.0030039528
peripheral B-Disease 0 0.8223095
neurotoxicity I-Disease 2 0.99997234
has O 0 0.0022069875
been O 0 0.002115161
minor O 0 0.004210115
( O 0 0.0031053277
26 O 0 0.0029078103
% O 0 0.0033233736
grade O 0 0.24692515
1 O 0 0.0058950717
) O 0 0.009623298
. O 0 0.008363198

CONCLUSION O 0 0.6229072
: O 0 0.009972491
These O 0 0.005590514
data O 0 0.0043805125
indicate O 0 0.0026211268
that O 0 0.0025348894
VNB B-Chemical 1 0.9817473
is O 0 0.0021746836
an O 0 0.0024786936
active O 0 0.0031308134
agent O 0 0.13564749
in O 0 0.003356416
metastatic O 0 0.9951308
esophageal B-Disease 0 0.99782026
squamous I-Disease 0 0.99985087
cell I-Disease 0 0.8627703
carcinoma I-Disease 2 0.9998153
. O 0 0.018941907

Given O 0 0.007580003
its O 0 0.0075174905
excellent O 0 0.006721855
tolerance O 0 0.05002762
profile O 0 0.0032277822
and O 0 0.0027784095
low O 0 0.003320521
toxicity B-Disease 2 0.9978629
, O 0 0.002431446
further O 0 0.0011911734
evaluation O 0 0.0013973681
of O 0 0.0020739194
VNB B-Chemical 1 0.9927735
in O 0 0.0017152253
combination O 0 0.0039793304
therapy O 0 0.025179978
is O 0 0.004352235
warranted O 0 0.0055287196
. O 0 0.008219546

Evaluation O 0 0.02076593
of O 0 0.013594267
adverse O 0 0.82757336
reactions O 0 0.10942227
of O 0 0.015651442
aponidine B-Chemical 0 0.7427444
hydrochloride I-Chemical 0 0.99955994
ophthalmic O 0 0.9766327
solution O 0 0.3519607
. O 0 0.018500045

We O 0 0.007196806
prospectively O 0 0.005331176
evaluated O 0 0.0029334673
the O 0 0.0025172052
adverse O 0 0.73777944
reactions O 0 0.053120304
of O 0 0.0032253389
apraclonidine B-Chemical 0 0.9999769
in O 0 0.0012351442
20 O 0 0.0008612111
normal O 0 0.0009730468
volunteers O 0 0.0017073439
by O 0 0.000737985
instilling O 0 0.0072478238
a O 0 0.0008306277
single O 0 0.0007022068
drop O 0 0.0013185793
of O 0 0.0010698043
1 O 0 0.0013217087
% O 0 0.0019314627
apraclonidine B-Chemical 0 0.99987483
in O 0 0.0023725235
their O 0 0.0035614257
right O 0 0.011067608
eyes O 0 0.17092228
. O 0 0.008784928

Examinations O 0 0.019743044
, O 0 0.007055449
including O 0 0.003694239
blood O 0 0.0089251995
pressure O 0 0.05346926
, O 0 0.0025275287
pulse O 0 0.0043582814
rate O 0 0.0012865253
, O 0 0.0016016711
conjunctiva O 0 0.5702264
and O 0 0.0013260158
cornea O 0 0.3352703
, O 0 0.0017745896
intraocular O 0 0.95386493
pressure O 0 0.31124225
( O 0 0.0028270357
IOP O 0 0.9974342
) O 0 0.0017137667
, O 0 0.000720746
pupil O 0 0.01894442
diameter O 0 0.0022561646
, O 0 0.0007046194
basal O 0 0.0009854011
tear O 0 0.1840763
secretion O 0 0.012839091
and O 0 0.0006903487
margin O 0 0.002825739
reflex O 0 0.6685974
distance O 0 0.0005356196
of O 0 0.00048028576
both O 0 0.00039972647
upper O 0 0.0011104589
and O 0 0.0005498294
lower O 0 0.0005744143
eyelids O 0 0.4843712
, O 0 0.0008117588
were O 0 0.00038757626
performed O 0 0.00030376876
prior O 0 0.00026294787
to O 0 0.0003755166
entry O 0 0.00069066713
and O 0 0.0005650145
at O 0 0.00043107307
1 O 0 0.000664995
, O 0 0.0007809064
3 O 0 0.00064389355
, O 0 0.0008819464
5 O 0 0.00075059646
and O 0 0.0010745666
7 O 0 0.0012998602
hours O 0 0.0014298637
after O 0 0.0020749024
instillation O 0 0.040666416
. O 0 0.008265397

The O 0 0.008429307
ocular B-Disease 0 0.9156017
hypotensive I-Disease 2 0.9995127
effects O 0 0.010926856
were O 0 0.002058763
statistically O 0 0.0012126766
significant O 0 0.0011699648
for O 0 0.0009479789
apraclonidine B-Chemical 0 0.9999871
- O 0 0.0042220643
treated O 0 0.0009640597
eyes O 0 0.036145125
throughout O 0 0.0003655266
the O 0 0.00042072096
study O 0 0.00052438915
and O 0 0.00045909995
also O 0 0.00040060037
statistically O 0 0.00037603782
significant O 0 0.0004268883
for O 0 0.00034029369
contralateral O 0 0.0041224924
eyes O 0 0.014185575
from O 0 0.00045818777
three O 0 0.00034591838
hours O 0 0.0003963471
after O 0 0.0004483105
topical O 0 0.69233006
administration O 0 0.08689029
of O 0 0.0029483975
1 O 0 0.003937372
% O 0 0.007013383
apraclonidine B-Chemical 0 0.9998399
. O 0 0.01066714

Decreases B-Disease 0 0.024339667
in I-Disease 0 0.0077463975
systolic I-Disease 0 0.33312178
blood I-Disease 0 0.01428141
pressure I-Disease 0 0.030285435
were O 0 0.00335856
statistically O 0 0.0027624692
, O 0 0.0033699658
but O 0 0.0027046169
not O 0 0.003127996
clinically O 0 0.033678625
, O 0 0.007505685
significant O 0 0.0082186395
. O 0 0.010236101

No O 0 0.010991451
significant O 0 0.006449404
changes O 0 0.0051975274
in O 0 0.0036557901
diastolic O 0 0.76217335
blood O 0 0.017315933
pressure O 0 0.065398276
, O 0 0.0027863597
pulse O 0 0.0047993585
rate O 0 0.0019099122
and O 0 0.00266111
basal O 0 0.0056657107
tear O 0 0.45731565
secretion O 0 0.061273802
were O 0 0.006124357
noted O 0 0.006662219
. O 0 0.009407104

Conjunctival B-Disease 0 0.94460213
blanching I-Disease 0 0.9839706
and O 0 0.036919508
mydriasis B-Disease 0 0.99900705
were O 0 0.02215372
commonly O 0 0.024747526
found O 0 0.019020015
. O 0 0.022860892

Upper O 0 0.185223
lid O 0 0.072149895
retraction O 0 0.15132095
was O 0 0.027754959
frequently O 0 0.030148584
noted O 0 0.027313335
. O 0 0.03148007

While O 0 0.007816621
the O 0 0.0052485247
elevations O 0 0.022968717
of O 0 0.0028254823
the O 0 0.0018708904
upper O 0 0.003093813
lid O 0 0.010463166
margin O 0 0.0031656031
in O 0 0.0008239162
most O 0 0.0009546134
subjects O 0 0.0010448995
were O 0 0.0005298099
not O 0 0.00043292812
more O 0 0.00050001784
than O 0 0.00034172364
2 O 0 0.00046784242
mm O 0 0.001050689
and O 0 0.00046330062
did O 0 0.00036677622
not O 0 0.00039806656
cause O 0 0.0013066324
noticeable O 0 0.0011774971
change O 0 0.0005123463
in O 0 0.00041497013
appearance O 0 0.0019617989
, O 0 0.000672571
one O 0 0.0003312044
subject O 0 0.00036395143
suffered O 0 0.053631496
from O 0 0.0005931374
mechanical O 0 0.10776811
entropion B-Disease 0 0.99569714
and O 0 0.0013468465
marked O 0 0.004208616
corneal B-Disease 0 0.9784454
abrasion I-Disease 0 0.95985657
3 O 0 0.0011231258
hours O 0 0.00069093646
after O 0 0.0007364737
instillation O 0 0.010129493
of O 0 0.0030412772
the O 0 0.0043244516
medication O 0 0.41642985
. O 0 0.008369262

This O 0 0.016119769
may O 0 0.0091937715
well O 0 0.0070193456
be O 0 0.0064091054
a O 0 0.006430665
particularly O 0 0.0063199024
notable O 0 0.010226922
finding O 0 0.008446418
in O 0 0.008230343
Asian O 0 0.37784776
people O 0 0.03033742
. O 0 0.013638476

Thiopentone B-Chemical 0 0.9969398
pretreatment O 0 0.27052137
for O 0 0.009192404
propofol B-Chemical 1 0.99860054
injection O 0 0.10881585
pain B-Disease 2 0.99769247
in O 0 0.008926304
ambulatory O 0 0.017479004
patients O 0 0.023541508
. O 0 0.013722926

This O 0 0.013494125
study O 0 0.00820922
investigated O 0 0.0057614916
propofol B-Chemical 1 0.9979607
injection O 0 0.056657597
pain B-Disease 2 0.9975526
in O 0 0.0048242654
patients O 0 0.008924681
undergoing O 0 0.0068162256
ambulatory O 0 0.013518553
anaesthesia O 0 0.2433316
. O 0 0.011834397

In O 0 0.007862276
a O 0 0.006589297
randomized O 0 0.0044825757
, O 0 0.0036391686
double O 0 0.0025822765
- O 0 0.0028559882
blind O 0 0.004211613
trial O 0 0.001710826
, O 0 0.0012017132
90 O 0 0.00072895817
women O 0 0.002839686
were O 0 0.00055315177
allocated O 0 0.0004222184
to O 0 0.0004144534
receive O 0 0.00042117498
one O 0 0.00040067107
of O 0 0.00056771195
three O 0 0.00046620303
treatments O 0 0.0013732682
prior O 0 0.00062410644
to O 0 0.0009234691
induction O 0 0.001470851
of O 0 0.002635578
anaesthesia O 0 0.28474045
with O 0 0.0072135874
propofol B-Chemical 1 0.9993729
. O 0 0.010544607

Patients O 0 0.01613157
in O 0 0.007071077
Group O 0 0.037448578
C O 0 0.616664
received O 0 0.002607842
2 O 0 0.0017603046
ml O 0 0.0030548554
normal O 0 0.0024157395
saline O 0 0.16600485
, O 0 0.002069631
Group O 0 0.059816223
L O 0 0.47491655
, O 0 0.0010856134
2 O 0 0.00059023546
ml O 0 0.0017141927
, O 0 0.0010931152
lidocaine B-Chemical 1 0.99980134
2 O 0 0.00068710814
% O 0 0.00069718575
( O 0 0.00066509284
40 O 0 0.00051913765
mg O 0 0.11381577
) O 0 0.0010605586
and O 0 0.00076077174
Group O 0 0.04856936
T O 0 0.5414233
, O 0 0.0009174319
2 O 0 0.0006243349
ml O 0 0.0026979423
thiopentone B-Chemical 1 0.9999298
2 O 0 0.0011022923
. O 0 0.0007860306
5 O 0 0.0010328725
% O 0 0.0017461177
( O 0 0.0025561128
50 O 0 0.0037082075
mg O 0 0.26517716
) O 0 0.009480428
. O 0 0.007847605

Venous O 0 0.11860904
discomfort O 0 0.6543615
was O 0 0.0042976695
assessed O 0 0.0024221682
with O 0 0.0021267678
a O 0 0.0025646763
visual O 0 0.1446564
analogue O 0 0.14658886
scale O 0 0.005654501
( O 0 0.002795182
VAS O 0 0.9437168
) O 0 0.0014984485
5 O 0 0.0005523014
- O 0 0.0006365357
15 O 0 0.0003024571
sec O 0 0.0003155855
after O 0 0.00021728095
commencing O 0 0.00075204344
propofol B-Chemical 1 0.9975102
administration O 0 0.027533589
using O 0 0.0004420503
an O 0 0.0006549331
infusion O 0 0.0058676237
pump O 0 0.018664824
( O 0 0.0007763148
rate O 0 0.0004853251
1000 O 0 0.0010933987
micrograms O 0 0.043927845
. O 0 0.0006083895
kg O 0 0.0043359213
- O 0 0.001659917
1 O 0 0.0012010832
. O 0 0.0011091526
min O 0 0.0022207648
- O 0 0.0037998562
1 O 0 0.004077004
) O 0 0.0076450566
. O 0 0.0073318095

Loss B-Disease 0 0.035520963
of I-Disease 0 0.015303192
consciousness I-Disease 0 0.91060954
occurred O 0 0.009723787
in O 0 0.007715426
60 O 0 0.0080726985
- O 0 0.009760234
90 O 0 0.008083469
sec O 0 0.0112582585
. O 0 0.013602044

Visual O 0 0.77960557
analogue O 0 0.08846074
scores O 0 0.0065594153
( O 0 0.0041684904
mean O 0 0.0024545158
+ O 0 0.0027380693
/ O 0 0.0055952105
- O 0 0.003181635
SD O 0 0.36713126
) O 0 0.0016760357
during O 0 0.0005216321
induction O 0 0.0006615505
were O 0 0.0005951579
lower O 0 0.0005857794
in O 0 0.00063983287
Groups O 0 0.087896675
L O 0 0.58703893
( O 0 0.0011307219
3 O 0 0.000496544
. O 0 0.0003305127
3 O 0 0.00041490127
+ O 0 0.0005534418
/ O 0 0.0015040338
- O 0 0.00081063295
2 O 0 0.00041534362
. O 0 0.0002912595
5 O 0 0.0003523477
) O 0 0.0006537112
and O 0 0.0005731438
T O 0 0.567614
( O 0 0.00082788424
4 O 0 0.00041349206
. O 0 0.000305911
1 O 0 0.00045415573
+ O 0 0.000535828
/ O 0 0.0014317156
- O 0 0.00078303466
2 O 0 0.0004048854
. O 0 0.00028496288
7 O 0 0.0003649766
) O 0 0.0005559108
than O 0 0.00027867398
in O 0 0.0004720753
Group O 0 0.069478154
C O 0 0.9129053
( O 0 0.0010793374
5 O 0 0.00045328072
. O 0 0.00034625325
6 O 0 0.0003899905
+ O 0 0.0006239179
/ O 0 0.0015641877
- O 0 0.0010405951
2 O 0 0.00064906944
. O 0 0.0005567152
3 O 0 0.0008439063
) O 0 0.0017931081
; O 0 0.0023104115
P O 0 0.030323073
= O 0 0.002852309
0 O 0 0.0031453543
. O 0 0.0032063078
0031 O 0 0.024141528
. O 0 0.0075698434

The O 0 0.0072245365
incidence O 0 0.008574254
of O 0 0.0044901855
venous O 0 0.59089005
discomfort O 0 0.9007338
was O 0 0.0020840375
lower O 0 0.0015154891
in O 0 0.001334589
Group O 0 0.07874238
L O 0 0.5922384
( O 0 0.0015836352
76 O 0 0.0014684302
. O 0 0.0004552736
6 O 0 0.0004264454
% O 0 0.00067398715
; O 0 0.0009362489
P O 0 0.013559953
< O 0 0.0005882305
0 O 0 0.0006635107
. O 0 0.0004271769
05 O 0 0.024509642
) O 0 0.0006759756
than O 0 0.00033183082
in O 0 0.0005320533
Group O 0 0.055871826
C O 0 0.9054866
( O 0 0.0013628885
100 O 0 0.0013203374
% O 0 0.0008875143
) O 0 0.0010211383
but O 0 0.0005727856
not O 0 0.00060719415
different O 0 0.0007744731
from O 0 0.0014088779
Group O 0 0.093351685
T O 0 0.5870459
( O 0 0.0036044251
90 O 0 0.0028144696
% O 0 0.004659624
) O 0 0.007944053
. O 0 0.0074890293

The O 0 0.009197821
VAS O 0 0.50198966
scores O 0 0.004728852
for O 0 0.002358984
recall O 0 0.0037528204
of O 0 0.002569868
pain B-Disease 2 0.9962457
in O 0 0.001216483
the O 0 0.00091802474
recovery O 0 0.0014386018
room O 0 0.00047824415
were O 0 0.00053482736
correlated O 0 0.00042479974
with O 0 0.0005796297
the O 0 0.0007303589
VAS O 0 0.86359423
scores O 0 0.0008391688
during O 0 0.00041680565
induction O 0 0.0007426236
( O 0 0.0010837348
r O 0 0.00093494524
= O 0 0.0010630084
0 O 0 0.00095389434
. O 0 0.000687289
7045 O 0 0.012271033
; O 0 0.0020549714
P O 0 0.019263525
< O 0 0.0018821143
0 O 0 0.0025702568
. O 0 0.002615553
0001 O 0 0.02345258
) O 0 0.008000125
. O 0 0.007718607

Recovery O 0 0.021266866
room O 0 0.004844671
discharge O 0 0.0069841864
times O 0 0.0024391518
were O 0 0.0022095891
similar O 0 0.0015918341
: O 0 0.003178536
C O 0 0.8739954
( O 0 0.0021165302
75 O 0 0.0013892085
. O 0 0.0005951806
9 O 0 0.000702804
+ O 0 0.0007461178
/ O 0 0.0015368852
- O 0 0.0008966957
19 O 0 0.0007177688
. O 0 0.00032524692
4 O 0 0.00036624828
min O 0 0.00052045006
) O 0 0.0009760709
; O 0 0.0009859528
L O 0 0.12313859
73 O 0 0.0012180349
. O 0 0.00033462385
6 O 0 0.00034516337
+ O 0 0.00051727745
/ O 0 0.001208704
- O 0 0.00072073913
21 O 0 0.0004916059
. O 0 0.0002885107
6 O 0 0.00031397722
min O 0 0.0005314431
) O 0 0.0011061123
; O 0 0.0012734405
T O 0 0.37803122
( O 0 0.0010574562
77 O 0 0.0014714956
. O 0 0.00052400166
1 O 0 0.00079973025
+ O 0 0.0010155558
/ O 0 0.002211322
- O 0 0.0017335989
18 O 0 0.001329798
. O 0 0.001330021
9 O 0 0.0023244373
min O 0 0.003702856
) O 0 0.0074541178
. O 0 0.007251221

Assessing O 0 0.012592606
their O 0 0.0075798375
overall O 0 0.006412757
satisfaction O 0 0.02121581
, O 0 0.0049205674
89 O 0 0.0049952194
. O 0 0.002147085
7 O 0 0.0021421085
% O 0 0.0025239799
would O 0 0.002142979
choose O 0 0.0036829892
propofol B-Chemical 1 0.9982009
anaesthesia O 0 0.30750975
again O 0 0.009624958
. O 0 0.010398811

We O 0 0.0069813626
conclude O 0 0.0043249964
that O 0 0.0034944287
lidocaine B-Chemical 1 0.9995915
reduces O 0 0.0027603933
the O 0 0.0017224859
incidence O 0 0.012360234
and O 0 0.0015664308
severity O 0 0.051071923
of O 0 0.0019292064
propofol B-Chemical 1 0.9998011
injection O 0 0.033880305
pain B-Disease 2 0.9986702
in O 0 0.00090766774
ambulatory O 0 0.0022721747
patients O 0 0.002654998
whereas O 0 0.0014928891
thiopentone B-Chemical 1 0.9999305
only O 0 0.0021575473
reduces O 0 0.0030426825
its O 0 0.0089239385
severity O 0 0.34997857
. O 0 0.010495368

Persistent O 0 0.5838482
paralysis B-Disease 2 0.9967456
after O 0 0.004888694
prolonged O 0 0.00764255
use O 0 0.003853939
of O 0 0.0044027097
atracurium B-Chemical 0 0.99902546
in O 0 0.0036216045
the O 0 0.0034641544
absence O 0 0.003284378
of O 0 0.009809966
corticosteroids O 1 0.9993044
. O 0 0.015638841

Neuromuscular O 0 0.35339755
blocking O 0 0.014885778
agents O 0 0.28970513
( O 0 0.008741222
NMBAs O 0 0.9806836
) O 0 0.0055612237
are O 0 0.0020781236
often O 0 0.0021954807
used O 0 0.0014302923
for O 0 0.0013246513
patients O 0 0.0032423106
requiring O 0 0.0026627125
prolonged O 0 0.009064614
mechanical O 0 0.191665
ventilation O 0 0.43674096
. O 0 0.01074716

Reports O 0 0.017980047
of O 0 0.0071311793
persistent O 0 0.10045397
paralysis B-Disease 2 0.9989955
after O 0 0.0015930283
the O 0 0.0014860703
discontinuance O 0 0.42349488
of O 0 0.001209614
these O 0 0.0011586568
drugs O 0 0.5542612
have O 0 0.00065439777
most O 0 0.0010151061
often O 0 0.0013694584
involved O 0 0.00076164614
aminosteroid O 0 0.9639937
- O 0 0.0016194708
based O 0 0.0006063106
NMBAs O 0 0.9032028
such O 0 0.00058086496
as O 0 0.000929067
vecuronium B-Chemical 0 0.99855095
bromide I-Chemical 0 0.99967945
, O 0 0.0017065485
especially O 0 0.0011091391
when O 0 0.0007936754
used O 0 0.0012173916
in O 0 0.001647424
conjunction O 0 0.0032054957
with O 0 0.005701186
corticosteroids O 1 0.9992086
. O 0 0.011220618

Atracurium B-Chemical 0 0.9970697
besylate I-Chemical 0 0.9999218
, O 0 0.00900502
a O 0 0.0041249143
short O 0 0.0023944878
- O 0 0.0032108708
acting O 0 0.00901428
benzylisoquinolinium B-Chemical 0 0.9959662
NMBA O 0 0.99899155
that O 0 0.00082023925
is O 0 0.0006928546
eliminated O 0 0.0007572572
independently O 0 0.000498248
of O 0 0.0008119827
renal O 0 0.9850118
or O 0 0.0010025235
hepatic O 0 0.971192
function O 0 0.0014040358
, O 0 0.0009689956
has O 0 0.00040161907
also O 0 0.00055587664
been O 0 0.00059803715
associated O 0 0.00072480354
with O 0 0.0009970494
persistent O 0 0.30247745
paralysis B-Disease 2 0.99989057
, O 0 0.002380691
but O 0 0.0011327399
only O 0 0.0011404766
when O 0 0.0012637887
used O 0 0.002367439
with O 0 0.005275132
corticosteroids O 1 0.9990797
. O 0 0.010952633

We O 0 0.007991086
report O 0 0.007149457
a O 0 0.004335378
case O 0 0.002800895
of O 0 0.0030858729
atracurium B-Chemical 0 0.99969137
- O 0 0.0059217927
related O 0 0.0012924253
paralysis B-Disease 2 0.9995757
persisting O 0 0.012991532
for O 0 0.00062040926
approximately O 0 0.00064152305
50 O 0 0.0008149916
hours O 0 0.00042203206
in O 0 0.00053997687
a O 0 0.0009163626
patient O 0 0.0012926905
who O 0 0.0019710325
was O 0 0.0013981169
not O 0 0.0016994276
treated O 0 0.0035599775
with O 0 0.0066165924
corticosteroids O 1 0.9992756
. O 0 0.012255537

A O 0 0.057371236
phase O 0 0.011927098
I O 0 0.020561997
/ O 0 0.009502017
II O 0 0.018232826
study O 0 0.0026565376
of O 0 0.0024871363
paclitaxel B-Chemical 1 0.99843246
plus O 0 0.0022534227
cisplatin B-Chemical 1 0.9996828
as O 0 0.0013699125
first O 0 0.0009515206
- O 0 0.0018669757
line O 0 0.0014595169
therapy O 0 0.003577833
for O 0 0.0009610105
head B-Disease 0 0.051174145
and I-Disease 0 0.0030153047
neck I-Disease 0 0.89282274
cancers I-Disease 2 0.9983342
: O 0 0.0092783775
preliminary O 0 0.0075144675
results O 0 0.0070442734
. O 0 0.009063641

Improved O 0 0.017063208
outcomes O 0 0.008995488
among O 0 0.00504432
patients O 0 0.0058363713
with O 0 0.0031345813
head B-Disease 0 0.047294915
and I-Disease 0 0.003270319
neck I-Disease 0 0.70952237
carcinomas I-Disease 0 0.9888087
require O 0 0.001299306
investigations O 0 0.0020672185
of O 0 0.0019191204
new O 0 0.0030032776
drugs O 0 0.6818587
for O 0 0.0030054771
induction O 0 0.0057935826
therapy O 0 0.088843524
. O 0 0.0099062165

Preliminary O 0 0.015415228
results O 0 0.006713545
of O 0 0.0056730835
an O 0 0.0063117626
Eastern O 0 0.18543905
Cooperative O 0 0.10188385
Oncology O 0 0.015395288
Group O 0 0.006897737
study O 0 0.0011991982
of O 0 0.0011195319
single O 0 0.0013976223
- O 0 0.002610217
agent O 0 0.3807174
paclitaxel B-Chemical 1 0.99987805
( O 0 0.032850195
Taxol B-Chemical 1 0.9999826
; O 0 0.019862168
Bristol O 0 0.39804143
- O 0 0.0025791726
Myers O 0 0.40295285
Squibb O 0 0.9856183
Company O 0 0.82677346
, O 0 0.0011328775
Princeton O 0 0.2692398
, O 0 0.0009748654
NJ O 0 0.5605984
) O 0 0.00082555483
reported O 0 0.000446125
a O 0 0.00052232115
37 O 0 0.0005005873
% O 0 0.00042222484
response O 0 0.00041895636
rate O 0 0.0003641895
in O 0 0.00035948138
patients O 0 0.0011306282
with O 0 0.0005458876
head B-Disease 0 0.049925286
and I-Disease 0 0.0011103469
neck I-Disease 0 0.85925674
cancer I-Disease 2 0.9993772
, O 0 0.001877378
and O 0 0.0006907541
the O 0 0.00066782214
paclitaxel B-Chemical 1 0.9994585
/ O 0 0.018810362
cisplatin B-Chemical 1 0.99966717
combination O 0 0.00197021
has O 0 0.00049044983
been O 0 0.0005202137
used O 0 0.00041407743
successfully O 0 0.0006561333
and O 0 0.00066947134
has O 0 0.0005031552
significantly O 0 0.00089646515
improved O 0 0.0011724639
median O 0 0.0008432194
response O 0 0.0015666061
duration O 0 0.0023158223
in O 0 0.0031901002
ovarian B-Disease 2 0.9993574
cancer I-Disease 2 0.99971753
patients O 0 0.2941079
. O 0 0.011286253

We O 0 0.008624562
initiated O 0 0.006108652
a O 0 0.005381425
phase O 0 0.005417781
I O 0 0.018184368
/ O 0 0.00635888
II O 0 0.019742941
trial O 0 0.0016177392
to O 0 0.00073800824
determine O 0 0.00041534423
the O 0 0.0006487818
response O 0 0.0010489709
and O 0 0.0011321272
toxicity B-Disease 2 0.9966708
of O 0 0.0015715933
escalating O 0 0.88916785
paclitaxel B-Chemical 1 0.9997118
doses O 0 0.057356026
combined O 0 0.0010453606
with O 0 0.00055912096
fixed O 0 0.0006535517
- O 0 0.0012157665
dose O 0 0.01454129
cisplatin B-Chemical 1 0.9996867
with O 0 0.0009894525
granulocyte O 0 0.9230858
colony O 0 0.35498896
- O 0 0.00347829
stimulating O 0 0.0014390846
factor O 0 0.0036151905
support O 0 0.0005578743
in O 0 0.0005766095
patients O 0 0.0017628141
with O 0 0.00094271655
untreated O 0 0.001885455
locally O 0 0.09205197
advanced O 0 0.24093124
inoperable O 0 0.98437065
head B-Disease 0 0.39300466
and I-Disease 0 0.010536809
neck I-Disease 0 0.9692434
carcinoma I-Disease 2 0.99970645
. O 0 0.015099439

To O 0 0.007971948
date O 0 0.006228236
, O 0 0.005257138
23 O 0 0.0040783067
men O 0 0.014123449
with O 0 0.0017933317
a O 0 0.0016597505
median O 0 0.0011541185
age O 0 0.0018745433
of O 0 0.001295758
50 O 0 0.0015879666
years O 0 0.0014108379
and O 0 0.0011760152
good O 0 0.001503867
performance O 0 0.0018991784
status O 0 0.0023628846
have O 0 0.0020730135
entered O 0 0.0040269876
the O 0 0.003976532
trial O 0 0.008740706
. O 0 0.008235514

Primary O 0 0.020207053
tumor B-Disease 2 0.63958454
sites O 0 0.0050122505
were O 0 0.0035779555
oropharynx O 0 0.80118906
, O 0 0.0027629829
10 O 0 0.0013891729
patients O 0 0.0025525193
; O 0 0.0021120359
hypopharynx O 0 0.9517701
, O 0 0.0011708413
four O 0 0.00056524767
; O 0 0.0012770856
larynx O 0 0.5521069
, O 0 0.0008761875
two O 0 0.00047601902
; O 0 0.0009784185
oral O 0 0.12867598
cavity O 0 0.0044450723
, O 0 0.0008447664
three O 0 0.00039342814
; O 0 0.00092351134
unknown O 0 0.0010803584
primary O 0 0.00082924974
, O 0 0.00086872565
two O 0 0.00055257947
; O 0 0.0011165023
and O 0 0.0007819155
nasal O 0 0.0067966525
cavity O 0 0.0042871204
and O 0 0.002357901
parotid O 0 0.7315982
gland O 0 0.41226393
, O 0 0.004436483
one O 0 0.003346334
each O 0 0.0041160504
. O 0 0.007589212

Of O 0 0.011619541
20 O 0 0.006336027
patients O 0 0.0058452757
evaluable O 0 0.008088751
for O 0 0.0027580631
toxicity B-Disease 2 0.98837835
, O 0 0.0029856283
four O 0 0.0013697578
had O 0 0.0015630592
stage O 0 0.0035115865
III O 0 0.043119866
and O 0 0.0023839455
16 O 0 0.002511559
had O 0 0.00268328
stage O 0 0.008320196
IV O 0 0.704957
disease O 0 0.8998063
. O 0 0.013264092

Treatment O 0 0.026302608
, O 0 0.0058184476
given O 0 0.0023272065
every O 0 0.001425568
21 O 0 0.0014734684
days O 0 0.00081495236
for O 0 0.00065165653
a O 0 0.0008047827
maximum O 0 0.0005831054
of O 0 0.0006063242
three O 0 0.00038723202
cycles O 0 0.0005054091
, O 0 0.00061159255
consisted O 0 0.00038615306
of O 0 0.0006933116
paclitaxel B-Chemical 1 0.99868983
by O 0 0.00078863965
3 O 0 0.00053087395
- O 0 0.0005458694
hour O 0 0.0002198716
infusion O 0 0.0008841462
followed O 0 0.00023534484
the O 0 0.00027633485
next O 0 0.000232093
day O 0 0.0003354406
by O 0 0.00045286265
a O 0 0.000586931
fixed O 0 0.00056062744
dose O 0 0.003580204
of O 0 0.0018438781
cisplatin B-Chemical 1 0.99974984
( O 0 0.0035618418
75 O 0 0.0031118798
mg O 0 0.36698508
/ O 0 0.008928039
m2 O 0 0.05856324
) O 0 0.009678065
. O 0 0.007725977

The O 0 0.0071220826
dose O 0 0.009916446
levels O 0 0.0034076725
incorporate O 0 0.0023363004
escalating O 0 0.60947424
paclitaxel B-Chemical 1 0.9995103
doses O 0 0.24112841
, O 0 0.0023082024
and O 0 0.0012085601
intrapatient O 0 0.047222007
escalations O 0 0.16497613
within O 0 0.0004322736
a O 0 0.0007734943
given O 0 0.00055616786
dose O 0 0.002884691
level O 0 0.00094393396
are O 0 0.001611372
permitted O 0 0.002578286
if O 0 0.0026418737
toxicity B-Disease 2 0.9938427
permits O 0 0.0073254723
. O 0 0.008694628

At O 0 0.0058731954
the O 0 0.0045083524
time O 0 0.002959312
of O 0 0.0027852128
this O 0 0.0021916379
writing O 0 0.007495674
, O 0 0.0018143816
dose O 0 0.0035744892
level O 0 0.0007522412
4 O 0 0.00082517683
( O 0 0.0010971789
260 O 0 0.0032003028
, O 0 0.0008633264
270 O 0 0.0025151141
, O 0 0.0006576737
and O 0 0.0005902118
280 O 0 0.0031546103
mg O 0 0.13533808
/ O 0 0.0018996521
m2 O 0 0.016777787
) O 0 0.0010952032
is O 0 0.00052977307
being O 0 0.0007519495
evaluated O 0 0.00063507527
; O 0 0.0011922545
three O 0 0.00061781384
patients O 0 0.001809403
from O 0 0.0013246324
this O 0 0.0016693773
level O 0 0.0020319636
are O 0 0.004126723
evaluable O 0 0.040236775
. O 0 0.007839547

With O 0 0.011124206
paclitaxel B-Chemical 1 0.9908586
doses O 0 0.041332364
of O 0 0.0037698739
200 O 0 0.0049045444
mg O 0 0.45657173
/ O 0 0.004182244
m2 O 0 0.016013218
and O 0 0.001025806
higher O 0 0.00080138416
, O 0 0.0011901321
granulocyte O 0 0.72214574
colony O 0 0.20731178
- O 0 0.00262351
stimulating O 0 0.0014480051
factor O 0 0.004116573
5 O 0 0.00055986224
micrograms O 0 0.054828152
/ O 0 0.0016626139
kg O 0 0.0034350255
/ O 0 0.001545186
d O 0 0.0008738921
is O 0 0.00068392424
given O 0 0.00064318336
( O 0 0.0013595419
days O 0 0.0010119183
4 O 0 0.0014917374
through O 0 0.001941498
12 O 0 0.0028968358
) O 0 0.006888757
. O 0 0.0069769514

Of O 0 0.010555264
18 O 0 0.0055616065
patients O 0 0.004906858
evaluable O 0 0.0059768218
for O 0 0.001824151
response O 0 0.0022499433
, O 0 0.0018331794
seven O 0 0.0011117307
( O 0 0.0014494288
39 O 0 0.0013981082
% O 0 0.0009932899
) O 0 0.0010021017
achieved O 0 0.00056872977
a O 0 0.00068874157
complete O 0 0.0005120002
response O 0 0.0008127917
and O 0 0.000831754
six O 0 0.0006363518
( O 0 0.0013864943
33 O 0 0.001591954
% O 0 0.0015193745
) O 0 0.0020920406
achieved O 0 0.0017646772
a O 0 0.003051407
partial O 0 0.0047369553
response O 0 0.007927494
. O 0 0.008679949

Three O 0 0.014891352
patients O 0 0.01255461
had O 0 0.0072106924
no O 0 0.0056407955
change O 0 0.0065746084
and O 0 0.0077118897
disease O 0 0.67935616
progressed O 0 0.037074346
in O 0 0.008822305
two O 0 0.010277028
. O 0 0.013555689

The O 0 0.018308954
overall O 0 0.016683256
response O 0 0.016283976
rate O 0 0.014460907
is O 0 0.014899581
72 O 0 0.01628726
% O 0 0.02058824
. O 0 0.01988818

Eleven O 0 0.022808883
responding O 0 0.01308877
patients O 0 0.010111513
had O 0 0.00572762
subsequent O 0 0.0056674597
surgery O 0 0.009565646
/ O 0 0.011279009
radiotherapy O 0 0.5324134
or O 0 0.0086775515
radical O 0 0.92312974
radiotherapy O 0 0.9586324
. O 0 0.016202858

Two O 0 0.011370018
pathologic O 0 0.049974173
complete O 0 0.0050793765
responses O 0 0.005202604
were O 0 0.002904867
observed O 0 0.0017866623
in O 0 0.0020084402
patients O 0 0.003787846
who O 0 0.0035171558
had O 0 0.0022684562
achieved O 0 0.0030283502
clinical O 0 0.010741149
complete O 0 0.004774658
responses O 0 0.011895042
. O 0 0.010024638

Alopecia B-Disease 0 0.99747187
, O 0 0.019742748
paresthesias B-Disease 0 0.99953604
, O 0 0.008062499
and O 0 0.005179885
arthralgias B-Disease 0 0.999858
/ O 0 0.13323978
myalgias B-Disease 0 0.99996054
have O 0 0.0013686137
occurred O 0 0.00127666
frequently O 0 0.001583679
, O 0 0.0011320141
but O 0 0.0006040455
with O 0 0.0005729104
one O 0 0.00048635877
exception O 0 0.00056982774
( O 0 0.0009629926
a O 0 0.001011242
grade O 0 0.37134752
3 O 0 0.0016325465
myalgia B-Disease 2 0.9999747
) O 0 0.0029637613
they O 0 0.0011654389
have O 0 0.0012422967
been O 0 0.0020863046
grade O 0 0.25467998
1 O 0 0.003423792
or O 0 0.0037760446
2 O 0 0.006080311
. O 0 0.0074048326

No O 0 0.019941762
dose O 0 0.036548164
- O 0 0.01648653
limiting O 0 0.01491336
hematologic O 0 0.9986848
toxicity B-Disease 2 0.99946314
has O 0 0.012073579
been O 0 0.012187345
seen O 0 0.011881465
. O 0 0.014748174

Paclitaxel B-Chemical 1 0.99896705
/ O 0 0.053518593
cisplatin B-Chemical 1 0.9987472
is O 0 0.0038323724
an O 0 0.0029204644
effective O 0 0.001965851
first O 0 0.0013409326
- O 0 0.002142406
line O 0 0.0015784815
regimen O 0 0.0022007844
for O 0 0.0008548676
locoregionally O 0 0.9912124
advanced O 0 0.16653319
head B-Disease 0 0.2102046
and I-Disease 0 0.0027898597
neck I-Disease 0 0.8794877
cancer I-Disease 2 0.99840957
and O 0 0.0034098527
continued O 0 0.0028699683
study O 0 0.0035972958
is O 0 0.0038122404
warranted O 0 0.005123476
. O 0 0.007916806

Results O 0 0.0121613685
thus O 0 0.0068847453
far O 0 0.003780758
suggest O 0 0.002152288
no O 0 0.0019520256
dose O 0 0.02143211
- O 0 0.0034508428
response O 0 0.0019425369
effect O 0 0.0014610535
for O 0 0.0013746223
paclitaxel B-Chemical 1 0.99870634
doses O 0 0.048960052
above O 0 0.0019925018
200 O 0 0.0066731083
mg O 0 0.5075388
/ O 0 0.013455351
m2 O 0 0.06766963
. O 0 0.008552433

Improvement O 0 0.032301508
of O 0 0.013130238
levodopa B-Chemical 1 0.99989474
- O 0 0.035303846
induced O 0 0.01148343
dyskinesia B-Disease 2 0.9999826
by O 0 0.030565556
propranolol B-Chemical 1 0.9999703
in O 0 0.008255298
Parkinson B-Disease 0 0.9997104
' I-Disease 0 0.010570552
s I-Disease 0 0.009033042
disease I-Disease 0 0.75642383
. O 0 0.012462729

Seven O 0 0.015072678
patients O 0 0.011222549
suffering O 0 0.6873186
from O 0 0.0052434034
Parkinson B-Disease 0 0.9994097
' I-Disease 0 0.0043311235
s I-Disease 0 0.0026279644
disease I-Disease 0 0.8101599
( O 0 0.0072633587
PD B-Disease 2 0.9991492
) O 0 0.003363093
with O 0 0.0010934164
severely O 0 0.06706989
disabling O 0 0.9957695
dyskinesia B-Disease 2 0.9999969
received O 0 0.0013257785
low O 0 0.0017239413
- O 0 0.002318757
dose O 0 0.04098703
propranolol B-Chemical 1 0.99998677
as O 0 0.0011120973
an O 0 0.0012790553
adjunct O 0 0.0013158519
to O 0 0.0010012725
the O 0 0.0013147733
currently O 0 0.0022703756
used O 0 0.0027038609
medical O 0 0.029892758
treatment O 0 0.009622094
. O 0 0.008705384

There O 0 0.009542574
was O 0 0.005975213
a O 0 0.004825491
significant O 0 0.0033515221
40 O 0 0.0027251495
% O 0 0.0023847779
improvement O 0 0.0017619997
in O 0 0.0013787603
the O 0 0.0019011796
dyskinesia B-Disease 2 0.9999777
score O 0 0.0031973016
without O 0 0.0018972667
increase O 0 0.0019446162
of O 0 0.006564143
parkinsonian B-Disease 2 0.9999496
motor B-Disease 0 0.9777014
disability I-Disease 0 0.99460596
. O 0 0.011496557

Ballistic O 0 0.121456176
and O 0 0.015512523
choreic O 0 0.9995478
dyskinesia B-Disease 2 0.9999684
were O 0 0.011238641
markedly O 0 0.06511869
ameliorated O 0 0.78994846
, O 0 0.010879126
whereas O 0 0.008100539
dystonia B-Disease 2 0.9999379
was O 0 0.009628658
not O 0 0.009046985
. O 0 0.011111734

This O 0 0.010030536
study O 0 0.0053040227
suggests O 0 0.0025209382
that O 0 0.002046684
administration O 0 0.01524736
of O 0 0.0020212913
low O 0 0.0019752777
doses O 0 0.046626814
of O 0 0.003150491
beta O 0 0.938169
- O 0 0.022611426
blockers O 0 0.99906677
may O 0 0.0011015733
improve O 0 0.0010209623
levodopa B-Chemical 1 0.9999856
- O 0 0.0050443104
induced O 0 0.0016813338
ballistic O 0 0.06688722
and O 0 0.0067877457
choreic O 0 0.9999417
dyskinesia B-Disease 2 0.9999902
in O 0 0.015597458
PD B-Disease 2 0.99879104
. O 0 0.011197791

Habitual O 0 0.38693026
use O 0 0.0073632454
of O 0 0.0072909137
acetaminophen B-Chemical 1 0.99994195
as O 0 0.004332275
a O 0 0.00400146
risk O 0 0.08348112
factor O 0 0.019157
for O 0 0.0018713865
chronic B-Disease 2 0.9927596
renal I-Disease 2 0.9989459
failure I-Disease 2 0.9879411
: O 0 0.006283024
a O 0 0.003553559
comparison O 0 0.0031944213
with O 0 0.008553723
phenacetin B-Chemical 1 0.99993885
. O 0 0.012925911

Six O 0 0.011129212
epidemiologic O 0 0.009513607
studies O 0 0.0046326085
in O 0 0.0030164304
the O 0 0.0026138118
United O 0 0.0044065616
States O 0 0.0050264243
and O 0 0.0014843456
Europe O 0 0.0040704003
indicate O 0 0.0005474242
that O 0 0.0005011755
habitual O 0 0.07071788
use O 0 0.0007393111
of O 0 0.0014444146
phenacetin B-Chemical 1 0.9999957
is O 0 0.0008359218
associated O 0 0.000692602
with O 0 0.00053088914
the O 0 0.0004867386
development O 0 0.0010827461
of O 0 0.0011450823
chronic B-Disease 2 0.9951395
renal I-Disease 2 0.99909127
failure I-Disease 2 0.9789394
and O 0 0.001213066
end B-Disease 2 0.0004677898
- I-Disease 2 0.0014880571
stage I-Disease 2 0.0027073373
renal I-Disease 2 0.99948007
disease I-Disease 2 0.9983151
( O 0 0.05865048
ESRD B-Disease 2 0.9999839
) O 0 0.0072645997
, O 0 0.00095425686
with O 0 0.0005766035
a O 0 0.0007652314
relative O 0 0.0005574293
risk O 0 0.011767923
in O 0 0.0008906029
the O 0 0.0011082396
range O 0 0.0019200343
of O 0 0.0022016503
4 O 0 0.0025509028
to O 0 0.003241528
19 O 0 0.0076250485
. O 0 0.006938204

As O 0 0.006877472
a O 0 0.005952745
result O 0 0.0035822662
of O 0 0.0029130036
these O 0 0.0024803448
and O 0 0.0021226802
other O 0 0.0017348356
studies O 0 0.0021544667
, O 0 0.003440869
phenacetin B-Chemical 1 0.99998236
has O 0 0.0013031755
now O 0 0.0015269832
been O 0 0.0012564756
withdrawn O 0 0.0028758335
from O 0 0.0013249939
the O 0 0.0016775697
market O 0 0.005966804
in O 0 0.0028503349
most O 0 0.006009241
countries O 0 0.045687187
. O 0 0.008711953

However O 0 0.00871299
, O 0 0.005888763
three O 0 0.0026165533
case O 0 0.0023842813
control O 0 0.0018158738
studies O 0 0.0017098547
, O 0 0.0014671065
one O 0 0.00077076786
each O 0 0.0005878438
in O 0 0.0008096479
North O 0 0.0029797943
Carolina O 0 0.012490916
, O 0 0.0010110562
northern O 0 0.0038884121
Maryland O 0 0.030034907
, O 0 0.00081715273
and O 0 0.0006979602
West O 0 0.0066269278
Berlin O 0 0.010998259
, O 0 0.00093472213
Germany O 0 0.008904843
, O 0 0.0005182842
showed O 0 0.00027711716
that O 0 0.00028607954
habitual O 0 0.04787032
use O 0 0.0005214198
of O 0 0.0011128421
acetaminophen B-Chemical 1 0.9999957
is O 0 0.0006841638
also O 0 0.00055097963
associated O 0 0.0007465296
with O 0 0.0010040799
chronic B-Disease 2 0.99528617
renal I-Disease 2 0.99929535
failure I-Disease 2 0.9914649
and O 0 0.00842212
ESRD B-Disease 2 0.9999796
, O 0 0.0014836242
with O 0 0.0006638229
a O 0 0.0008184388
relative O 0 0.00055944343
risk O 0 0.013738888
in O 0 0.00086969294
the O 0 0.0010798321
range O 0 0.0018890495
of O 0 0.0021680694
2 O 0 0.0026960417
to O 0 0.003038582
4 O 0 0.004950867
. O 0 0.006725298

These O 0 0.0087328805
studies O 0 0.0053161248
suggest O 0 0.0027733818
that O 0 0.0023497627
both O 0 0.0028931305
phenacetin B-Chemical 1 0.99998474
and O 0 0.013130981
acetaminophen B-Chemical 1 0.9999926
may O 0 0.0013664732
contribute O 0 0.00075492053
to O 0 0.00058506406
the O 0 0.000624209
burden O 0 0.0039061145
of O 0 0.0024017948
ESRD B-Disease 2 0.9999764
, O 0 0.0015905004
with O 0 0.00065254193
the O 0 0.0005972645
risk O 0 0.013799972
of O 0 0.00075297995
the O 0 0.00068255124
latter O 0 0.0016339195
being O 0 0.0012452049
somewhat O 0 0.0014929182
less O 0 0.0009824975
than O 0 0.0009417143
that O 0 0.001376231
of O 0 0.0028349196
the O 0 0.004221357
former O 0 0.05037325
. O 0 0.008600403

This O 0 0.010279977
apparent O 0 0.0055002784
difference O 0 0.0029875478
in O 0 0.0028742028
risk O 0 0.017390601
may O 0 0.0019319922
not O 0 0.0014944971
be O 0 0.0012871284
due O 0 0.0008756629
to O 0 0.00090550043
differences O 0 0.00080261886
in O 0 0.0013391236
nephrotoxic B-Disease 2 0.9991671
potential O 0 0.003500518
of O 0 0.0033172255
the O 0 0.0039181444
drugs O 0 0.87401825
themselves O 0 0.021830957
. O 0 0.009254485

A O 0 0.029094135
lower O 0 0.00621514
relative O 0 0.0036720538
risk O 0 0.018310279
would O 0 0.002004098
be O 0 0.0015605438
expected O 0 0.00096402806
for O 0 0.00096331694
acetaminophen B-Chemical 1 0.9999814
if O 0 0.00069154974
the O 0 0.00070338865
risk O 0 0.020799138
of O 0 0.0007740319
both O 0 0.00062956655
drugs O 0 0.55248356
in O 0 0.000532206
combination O 0 0.0009972174
with O 0 0.0006509077
other O 0 0.0008386548
analgesics O 0 0.9967002
was O 0 0.0007696446
higher O 0 0.0006649661
than O 0 0.0006252624
the O 0 0.0010570333
risk O 0 0.023527937
of O 0 0.0025062354
either O 0 0.0035722686
agent O 0 0.3949363
alone O 0 0.010096576
. O 0 0.009536987

Thus O 0 0.009952343
, O 0 0.010589461
acetaminophen B-Chemical 1 0.9999045
has O 0 0.003498978
been O 0 0.002162966
used O 0 0.0012309889
both O 0 0.000980963
as O 0 0.00091298454
a O 0 0.0010784791
single O 0 0.00087296375
agent O 0 0.05527711
and O 0 0.000933315
in O 0 0.00062780787
combination O 0 0.0011612533
with O 0 0.00083374884
other O 0 0.0011752464
analgesics O 0 0.9988387
, O 0 0.0023267514
whereas O 0 0.0016478631
phenacetin B-Chemical 1 0.999985
was O 0 0.0018470391
available O 0 0.001712449
only O 0 0.0020531144
in O 0 0.0030983167
combinations O 0 0.0061126156
. O 0 0.008111178

The O 0 0.006662578
possibility O 0 0.004498021
that O 0 0.0031244056
habitual O 0 0.06084117
use O 0 0.002546936
of O 0 0.0033194274
acetaminophen B-Chemical 1 0.9999865
alone O 0 0.0025465568
increases O 0 0.0011834669
the O 0 0.0010813118
risk O 0 0.07479068
of O 0 0.0031503728
ESRD B-Disease 2 0.9999558
has O 0 0.0011336694
not O 0 0.0010930403
been O 0 0.0011676957
clearly O 0 0.0011308823
demonstrated O 0 0.0015102164
, O 0 0.002987312
but O 0 0.002827653
cannot O 0 0.012099803
be O 0 0.0063622105
dismissed O 0 0.0413683
. O 0 0.009220123

Acetaminophen B-Chemical 1 0.99940324
- O 0 0.09360589
induced O 0 0.06376497
hypotension B-Disease 2 0.99886024
. O 0 0.057318803

Through O 0 0.011107962
30 O 0 0.004831427
years O 0 0.0041757626
of O 0 0.003018041
widespread O 0 0.0041893455
use O 0 0.002930803
, O 0 0.0045401854
acetaminophen B-Chemical 1 0.9999826
has O 0 0.0015857394
been O 0 0.0012928094
shown O 0 0.000763197
to O 0 0.0008326208
be O 0 0.0010117022
a O 0 0.001375179
remarkably O 0 0.0033589143
safe O 0 0.004274681
medication O 0 0.10951146
in O 0 0.0028038733
therapeutic O 0 0.06914211
dosages O 0 0.6349253
. O 0 0.010095656

The O 0 0.0101692015
potential O 0 0.009294448
for O 0 0.0071514645
acetaminophen B-Chemical 1 0.99987566
to O 0 0.006559872
produce O 0 0.0061228536
cardiovascular B-Disease 0 0.999501
toxicities I-Disease 2 0.999895
is O 0 0.0101868855
very O 0 0.009947726
low O 0 0.012714086
. O 0 0.012544

However O 0 0.01120301
, O 0 0.0112209525
acetaminophen B-Chemical 1 0.9998896
has O 0 0.0039136526
been O 0 0.0025378305
demonstrated O 0 0.001482697
to O 0 0.0012907216
produce O 0 0.0012258224
symptoms O 0 0.7217821
of O 0 0.0030279155
anaphylaxis B-Disease 2 0.9998343
, O 0 0.006934942
including O 0 0.0033854141
hypotension B-Disease 2 0.99995184
, O 0 0.0052899355
in O 0 0.00301323
sensitive O 0 0.00393086
individuals O 0 0.009594262
. O 0 0.008297968

This O 0 0.0106933545
article O 0 0.006453163
describes O 0 0.00478797
two O 0 0.0028280388
critically B-Disease 0 0.008399603
ill I-Disease 0 0.58823013
patients O 0 0.0047846045
in O 0 0.0012321202
whom O 0 0.002918249
transient O 0 0.033065148
episodes O 0 0.414784
of O 0 0.0037168178
hypotension B-Disease 2 0.99996316
reproducibly O 0 0.023739329
developed O 0 0.0028104684
after O 0 0.0014899259
administration O 0 0.1290327
of O 0 0.015240782
acetaminophen B-Chemical 1 0.99996126
. O 0 0.013153645

Other O 0 0.030992497
symptoms O 0 0.6493188
of O 0 0.017032173
allergic B-Disease 2 0.99934703
reactions I-Disease 2 0.8219138
were O 0 0.011063831
not O 0 0.008521925
clinically O 0 0.06633488
detectable O 0 0.010266659
. O 0 0.01439097

The O 0 0.013344972
hypotensive B-Disease 2 0.9921888
episodes O 0 0.5083945
were O 0 0.008596374
severe O 0 0.07663409
enough O 0 0.0058062854
to O 0 0.005277317
require O 0 0.005432832
vasopressor O 0 0.99030006
administration O 0 0.573589
. O 0 0.015076664

The O 0 0.0074273744
reports O 0 0.0057785828
illustrate O 0 0.003548703
the O 0 0.002786625
need O 0 0.0019689607
for O 0 0.0014332993
clinicians O 0 0.0023096919
to O 0 0.00123945
consider O 0 0.0012381697
acetaminophen B-Chemical 1 0.999977
in O 0 0.0019351045
patients O 0 0.007294918
with O 0 0.003783092
hypotension B-Disease 2 0.9999052
of O 0 0.0072685285
unknown O 0 0.044633448
origin O 0 0.025291126
. O 0 0.01051602

Reduction O 0 0.0253864
of O 0 0.011574847
heparan B-Chemical 0 0.9974515
sulphate I-Chemical 0 0.999666
- O 0 0.015172509
associated O 0 0.0031895272
anionic O 0 0.6900716
sites O 0 0.0015523178
in O 0 0.0010076584
the O 0 0.0010728197
glomerular O 0 0.8288306
basement O 0 0.45998275
membrane O 0 0.016576963
of O 0 0.0020452274
rats O 0 0.012694229
with O 0 0.005406546
streptozotocin B-Chemical 1 0.9999795
- O 0 0.068194784
induced O 0 0.030202454
diabetic B-Disease 2 0.99984944
nephropathy I-Disease 2 0.99997663
. O 0 0.038891125

Heparan B-Chemical 0 0.9924786
sulphate I-Chemical 0 0.9989391
- O 0 0.012051734
associated O 0 0.0041533653
anionic O 0 0.58535254
sites O 0 0.0018918168
in O 0 0.0011336645
the O 0 0.0010743686
glomerular O 0 0.8224653
basement O 0 0.46211606
membrane O 0 0.013715217
were O 0 0.0007180982
studied O 0 0.00061329996
in O 0 0.00048715586
rats O 0 0.0011676357
8 O 0 0.00040395436
months O 0 0.0002635643
after O 0 0.00022617565
induction O 0 0.00046286135
of O 0 0.0009979706
diabetes B-Disease 2 0.9990553
by O 0 0.0026109791
streptozotocin B-Chemical 1 0.9999856
and O 0 0.0012504845
in O 0 0.00069443655
age O 0 0.007041036
- O 0 0.002221433
adn O 0 0.22100386
sex O 0 0.11750272
- O 0 0.0012637273
matched O 0 0.0006371639
control O 0 0.0007513629
rats O 0 0.00209346
, O 0 0.0014124189
employing O 0 0.0014271593
the O 0 0.0019019987
cationic O 0 0.3091419
dye O 0 0.2502864
cuprolinic B-Chemical 0 0.87662804
blue I-Chemical 0 0.21869512
. O 0 0.011897822

Morphometric O 0 0.06425061
analysis O 0 0.009715888
at O 0 0.0052614165
the O 0 0.00469067
ultrastructural O 0 0.010489714
level O 0 0.003491093
was O 0 0.0035626695
performed O 0 0.0032206252
using O 0 0.0036261051
a O 0 0.005578246
computerized O 0 0.012871101
image O 0 0.010445667
processor O 0 0.02425283
. O 0 0.012768296

The O 0 0.010619013
heparan B-Chemical 0 0.98731613
sulphate I-Chemical 0 0.9979164
specificity O 0 0.006083908
of O 0 0.0027864764
the O 0 0.0019648075
cuprolinic B-Chemical 0 0.5647589
blue I-Chemical 0 0.03350481
staining O 0 0.0017905051
was O 0 0.0009338684
demonstrated O 0 0.0007381974
by O 0 0.0013774518
glycosaminoglycan B-Chemical 0 0.99943036
- O 0 0.015188748
degrading O 0 0.082470834
enzymes O 0 0.24507566
, O 0 0.001004245
showing O 0 0.0004857736
that O 0 0.00038599074
pretreatment O 0 0.036987387
of O 0 0.00072362303
the O 0 0.0006061696
sections O 0 0.0011580472
with O 0 0.0010568127
heparitinase O 0 0.97960746
abolished O 0 0.0019187168
all O 0 0.00079220725
staining O 0 0.0013574742
, O 0 0.0015635223
whereas O 0 0.0014244682
chondroitinase O 0 0.92945445
ABC O 0 0.33575663
had O 0 0.0024841207
no O 0 0.0028513
effect O 0 0.0058128373
. O 0 0.008248373

The O 0 0.007221986
majority O 0 0.005762246
of O 0 0.005224124
anionic O 0 0.5966084
sites O 0 0.0034607665
( O 0 0.0029876474
74 O 0 0.0025699597
% O 0 0.001431567
in O 0 0.0009946845
diabetic B-Disease 2 0.9566709
and O 0 0.0012209882
81 O 0 0.0017652527
% O 0 0.0007643477
in O 0 0.00049871363
control O 0 0.00061527017
rats O 0 0.0018947301
) O 0 0.0012698312
were O 0 0.0006036291
found O 0 0.00049562467
within O 0 0.00047338026
the O 0 0.0008835525
lamina O 0 0.0032913678
rara O 0 0.2240337
externa O 0 0.91587
of O 0 0.0039594127
the O 0 0.0040236856
glomerular O 0 0.96696264
basement O 0 0.85612196
membrane O 0 0.19418786
. O 0 0.011838258

A O 0 0.039547257
minority O 0 0.011864542
of O 0 0.00574163
anionic O 0 0.4954307
sites O 0 0.0027607766
were O 0 0.0017585525
scattered O 0 0.0019972117
throughout O 0 0.00081844826
the O 0 0.0009244975
lamina O 0 0.0026630939
densa O 0 0.09811872
and O 0 0.0012912379
lamina O 0 0.004113284
rara O 0 0.31855813
interna O 0 0.66326386
, O 0 0.0014769398
and O 0 0.0007497653
were O 0 0.0005348743
significantly O 0 0.0005830395
smaller O 0 0.00043027682
than O 0 0.00030476492
those O 0 0.0005197372
in O 0 0.00037550944
the O 0 0.000458364
lamina O 0 0.0017558844
rara O 0 0.16136877
externa O 0 0.8754761
of O 0 0.0010956362
the O 0 0.0007725802
glomerular O 0 0.9121763
basement O 0 0.5981968
membrane O 0 0.033820447
( O 0 0.0012562614
p O 0 0.00079056254
< O 0 0.0005645354
0 O 0 0.0006202251
. O 0 0.0003825438
001 O 0 0.030375922
and O 0 0.0004885077
p O 0 0.0006596794
< O 0 0.0005883011
0 O 0 0.00070180144
. O 0 0.00048506566
01 O 0 0.0023143254
for O 0 0.0006271651
diabetic B-Disease 2 0.9296122
and O 0 0.0015687407
control O 0 0.001749942
rats O 0 0.005751923
, O 0 0.0045057596
respectively O 0 0.0077676447
) O 0 0.010677159
. O 0 0.007914462

Diabetic B-Disease 0 0.9982027
rats O 0 0.018820876
progressively O 0 0.009385933
developed O 0 0.006155891
albuminuria B-Disease 2 0.9996414
reaching O 0 0.0045335223
40 O 0 0.001660154
. O 0 0.00079015695
3 O 0 0.00073481683
( O 0 0.00085176603
32 O 0 0.00075897656
. O 0 0.00041347035
2 O 0 0.0005159916
- O 0 0.0006802732
62 O 0 0.0007702755
. O 0 0.00032260315
0 O 0 0.00053186924
) O 0 0.00065359875
mg O 0 0.07653425
/ O 0 0.0008503181
24 O 0 0.0002499059
h O 0 0.00021382536
after O 0 0.00017693063
8 O 0 0.00025076853
months O 0 0.00019428114
in O 0 0.00023208305
contrast O 0 0.0002920036
to O 0 0.0002837029
the O 0 0.00032146805
control O 0 0.0003694749
animals O 0 0.0004196047
( O 0 0.0007275011
0 O 0 0.00057701697
. O 0 0.00028540115
8 O 0 0.0003700298
( O 0 0.0005043518
0 O 0 0.0004946379
. O 0 0.0002961948
2 O 0 0.0004318082
- O 0 0.0006250955
0 O 0 0.00051948405
. O 0 0.00032561147
9 O 0 0.00049225136
) O 0 0.00081557536
mg O 0 0.07280165
/ O 0 0.0012905691
24 O 0 0.0005395683
h O 0 0.0006337626
, O 0 0.0011191079
p O 0 0.0014322754
< O 0 0.0016646063
0 O 0 0.0024455555
. O 0 0.0025847072
002 O 0 0.12175555
) O 0 0.007820757
. O 0 0.0074826838

At O 0 0.005737445
the O 0 0.0043771216
same O 0 0.002675351
time O 0 0.0022743726
, O 0 0.0022419593
the O 0 0.0013536941
number O 0 0.001173146
of O 0 0.0022702678
heparan B-Chemical 0 0.9991358
sulphate I-Chemical 0 0.9998822
anionic O 0 0.956098
sites O 0 0.001100612
and O 0 0.00074042194
the O 0 0.00051142124
total O 0 0.0005861849
anionic O 0 0.5638847
site O 0 0.00065129617
surface O 0 0.0016051907
( O 0 0.00080936484
number O 0 0.00037690636
of O 0 0.0006345731
anionic O 0 0.60836524
sites O 0 0.0005874733
x O 0 0.0012397977
mean O 0 0.0005007908
anionic O 0 0.5154185
site O 0 0.0006176211
surface O 0 0.001767357
) O 0 0.0012466314
in O 0 0.00039703498
the O 0 0.00046294346
lamina O 0 0.0017734844
rara O 0 0.16573954
externa O 0 0.8805006
of O 0 0.001094875
the O 0 0.0007620161
glomerular O 0 0.91693497
basement O 0 0.5703004
membrane O 0 0.019712474
was O 0 0.00063408347
reduced O 0 0.0005534672
by O 0 0.0006162792
19 O 0 0.0009173921
% O 0 0.0006277254
( O 0 0.0006330044
p O 0 0.00058013655
< O 0 0.0005023387
0 O 0 0.00060221716
. O 0 0.00040078568
021 O 0 0.03190894
) O 0 0.0007955263
and O 0 0.0005437365
by O 0 0.0006222676
26 O 0 0.000853142
% O 0 0.00081616704
( O 0 0.0009736838
p O 0 0.0010407744
< O 0 0.0010820656
0 O 0 0.0014794532
. O 0 0.0013781177
02 O 0 0.022240555
) O 0 0.0040582023
, O 0 0.004740905
respectively O 0 0.007736003
. O 0 0.0077223

Number O 0 0.012788411
and O 0 0.0061836382
total O 0 0.004335378
anionic O 0 0.31350815
site O 0 0.0024524715
surface O 0 0.0027717573
in O 0 0.0012059726
the O 0 0.00093611603
remaining O 0 0.000791222
part O 0 0.00066603423
of O 0 0.0008057576
the O 0 0.0008544063
glomerular O 0 0.8678318
basement O 0 0.610468
membrane O 0 0.054120444
( O 0 0.002569025
lamina O 0 0.0039373795
densa O 0 0.12899415
and O 0 0.001857098
lamina O 0 0.0062471535
rara O 0 0.3894927
interna O 0 0.6805787
) O 0 0.005481692
were O 0 0.0026859755
not O 0 0.0028824098
significantly O 0 0.00542718
changed O 0 0.0077685746
. O 0 0.009197113

We O 0 0.0075322306
conclude O 0 0.004679203
that O 0 0.0036693541
in O 0 0.0044287336
streptozotocin B-Chemical 1 0.9999621
- O 0 0.0656395
diabetic B-Disease 2 0.9964729
rats O 0 0.01270236
with O 0 0.0012634612
an O 0 0.0015262461
increased O 0 0.0015428338
urinary O 0 0.9793224
albumin O 0 0.99921525
excretion O 0 0.99117774
, O 0 0.0018473704
a O 0 0.0011451243
reduced O 0 0.0011928532
heparan B-Chemical 0 0.9990094
sulphate I-Chemical 0 0.9998287
charge O 0 0.2529181
barrier O 0 0.055573948
/ O 0 0.0052505666
density O 0 0.0011347422
is O 0 0.00066439726
found O 0 0.0005312516
at O 0 0.0005646752
the O 0 0.0008644236
lamina O 0 0.0032283296
rara O 0 0.22363256
externa O 0 0.9146444
of O 0 0.0038580785
the O 0 0.003940683
glomerular O 0 0.9667642
basement O 0 0.8549441
membrane O 0 0.19272923
. O 0 0.011730877

Mediation O 0 0.47429255
of O 0 0.010624354
enhanced O 0 0.008802251
reflex O 0 0.95223093
vagal O 0 0.99840575
bradycardia B-Disease 2 0.9998354
by O 0 0.013246198
L B-Chemical 1 0.9902131
- I-Chemical 1 0.05326414
dopa I-Chemical 1 0.9998927
via O 0 0.0033449486
central O 0 0.027852762
dopamine B-Chemical 1 0.99948174
formation O 0 0.010271758
in O 0 0.0055457493
dogs O 0 0.017431658
. O 0 0.009946508

L B-Chemical 0 0.95693904
- I-Chemical 0 0.05646061
Dopa I-Chemical 0 0.9991021
( O 0 0.006486723
5 O 0 0.002459532
mg O 0 0.118162565
/ O 0 0.0031943668
kg O 0 0.005281577
i O 0 0.0035952798
. O 0 0.0008506463
v O 0 0.01710999
. O 0 0.0006394031
) O 0 0.0010404926
decreased O 0 0.00069940084
blood O 0 0.0055778325
pressure O 0 0.03231682
and O 0 0.00066257425
heart O 0 0.36083174
rate O 0 0.0005520999
after O 0 0.00040070424
extracerebral O 0 0.98956585
decarboxylase O 0 0.9908318
inhibition O 0 0.008245557
with O 0 0.0014570844
MK B-Chemical 0 0.99592626
- I-Chemical 0 0.0052270386
486 I-Chemical 0 0.59156996
( O 0 0.0008292154
25 O 0 0.0006861593
mg O 0 0.07809941
/ O 0 0.0012798291
kg O 0 0.0024925913
i O 0 0.002153872
. O 0 0.00067114504
v O 0 0.01293583
. O 0 0.00087274134
) O 0 0.0019756197
in O 0 0.0015603119
anesthetize O 0 0.392274
MAO B-Chemical 0 0.9999757
- O 0 0.014901372
inhibited O 0 0.0068484163
dogs O 0 0.023046972
. O 0 0.0094020935

In O 0 0.0075194226
addition O 0 0.0046428815
, O 0 0.006225748
reflex O 0 0.92563725
bradycardia B-Disease 2 0.99971
caused O 0 0.003723988
by O 0 0.0022141328
injected O 0 0.001989202
norepinephrine B-Chemical 1 0.9999497
was O 0 0.0011404607
significantly O 0 0.0012501058
enhanced O 0 0.0011241393
by O 0 0.0020829074
L B-Chemical 1 0.9900023
- I-Chemical 1 0.03912534
dopa I-Chemical 1 0.9999758
, O 0 0.00601268
DL B-Chemical 0 0.9078869
- I-Chemical 0 0.0027145387
Threo I-Chemical 0 0.13173841
- I-Chemical 0 0.0013370042
dihydroxyphenylserine I-Chemical 0 0.39787763
had O 0 0.00037986354
no O 0 0.00030469315
effect O 0 0.00042152984
on O 0 0.0003674667
blood O 0 0.0076542147
pressure O 0 0.059597805
, O 0 0.0014007051
heart O 0 0.25681457
rate O 0 0.001267772
or O 0 0.001911833
reflex O 0 0.86701775
responses O 0 0.009279891
to O 0 0.006528728
norepinephrine B-Chemical 1 0.9997539
. O 0 0.009644727

FLA B-Chemical 0 0.80980563
- I-Chemical 0 0.012816235
63 I-Chemical 0 0.008251473
, O 0 0.0048317937
a O 0 0.0049970658
dopamine B-Chemical 1 0.9996978
- O 0 0.016670369
beta O 0 0.8615671
- O 0 0.018717656
oxidase O 0 0.99636155
inhibitor O 0 0.25438365
, O 0 0.0015556078
did O 0 0.000533037
not O 0 0.00045176496
have O 0 0.0003701229
any O 0 0.00039114643
effect O 0 0.0004426784
on O 0 0.00036990314
the O 0 0.0009382519
hypotension B-Disease 2 0.9999784
, O 0 0.0068504247
bradycardia B-Disease 2 0.99979883
or O 0 0.0015967413
reflex O 0 0.96033335
- O 0 0.0032160578
enhancing O 0 0.0017455831
effect O 0 0.0020748652
of O 0 0.0060777958
L B-Chemical 1 0.99091434
- I-Chemical 1 0.14623323
dopa I-Chemical 1 0.99977416
. O 0 0.012255836

Pimozide B-Chemical 0 0.99960035
did O 0 0.0071442435
not O 0 0.0040021157
affect O 0 0.0022299702
the O 0 0.0021276525
actions O 0 0.019301252
of O 0 0.0042501832
L B-Chemical 1 0.9899108
- I-Chemical 1 0.029817892
dopa I-Chemical 1 0.999905
on O 0 0.0007487219
blood O 0 0.011915117
pressure O 0 0.041820563
and O 0 0.0011212924
heart O 0 0.37912408
rate O 0 0.0011110541
but O 0 0.0012278284
completely O 0 0.0015721762
blocked O 0 0.0026915052
the O 0 0.0023267304
enhancement O 0 0.006048176
of O 0 0.0073144683
reflexes O 0 0.99056834
. O 0 0.010505788

Removal O 0 0.019830069
of O 0 0.00645502
the O 0 0.0045437515
carotid O 0 0.5655271
sinuses O 0 0.48000163
caused O 0 0.0028440792
an O 0 0.0027789655
elevation O 0 0.16721648
blood O 0 0.019412221
pressure O 0 0.056723922
and O 0 0.0013908691
heart O 0 0.362453
rate O 0 0.0011209128
and O 0 0.0013468516
abolished O 0 0.0018005796
the O 0 0.0014199701
negative O 0 0.00292707
chronotropic O 0 0.9932546
effect O 0 0.004418401
of O 0 0.017720032
norepinephrine B-Chemical 1 0.99983716
. O 0 0.0107689975

However O 0 0.012687741
, O 0 0.013585325
L B-Chemical 1 0.940451
- I-Chemical 1 0.033145823
dopa I-Chemical 1 0.9998242
restored O 0 0.0039604544
the O 0 0.002488793
bradycardia B-Disease 2 0.99971765
caused O 0 0.0030394555
by O 0 0.0032939357
norepinephrine B-Chemical 1 0.9999138
in O 0 0.0009973021
addition O 0 0.0006661631
to O 0 0.0009784241
decreasing O 0 0.0017517119
blood O 0 0.017368648
pressure O 0 0.07679595
and O 0 0.004045147
heart O 0 0.6214641
rate O 0 0.006617097
. O 0 0.00872246

5 B-Chemical 0 0.011682994
- I-Chemical 0 0.011437262
HTP I-Chemical 0 0.21799581
( O 0 0.005062817
5 O 0 0.0024880003
mg O 0 0.084943175
/ O 0 0.0033428415
kg O 0 0.0054165185
i O 0 0.0037628245
. O 0 0.0009620907
v O 0 0.015924959
. O 0 0.0007479759
) O 0 0.0012161828
decreased O 0 0.0008604615
blood O 0 0.0050808373
pressure O 0 0.027753692
and O 0 0.0009788275
heart O 0 0.31311047
rate O 0 0.0009828607
and O 0 0.001328028
decreased O 0 0.0019580084
the O 0 0.0022322757
reflex O 0 0.9768683
bradycardia B-Disease 2 0.9997515
to O 0 0.008350943
norepinephrine B-Chemical 1 0.99977523
. O 0 0.010197776

It O 0 0.012472444
is O 0 0.006912579
concluded O 0 0.005686004
that O 0 0.0047782464
L B-Chemical 1 0.9633398
- I-Chemical 1 0.048010204
dopa I-Chemical 1 0.99989235
enhances O 0 0.0040443614
reflex O 0 0.98612183
bradycardia B-Disease 2 0.9997812
through O 0 0.0027823588
central O 0 0.0121639
alpha O 0 0.50601834
- O 0 0.011819485
receptor O 0 0.16928494
stimulation O 0 0.015500905
. O 0 0.010426885

Furthermore O 0 0.009817
, O 0 0.00688083
the O 0 0.0038515234
effects O 0 0.004088235
are O 0 0.0025439167
mediated O 0 0.0020168964
through O 0 0.0019665014
dopamine B-Chemical 1 0.99950325
rather O 0 0.0014438583
than O 0 0.001253757
norepinephrine B-Chemical 1 0.9998461
and O 0 0.0014697884
do O 0 0.0010799422
not O 0 0.0011918816
require O 0 0.0012131041
the O 0 0.0023181792
carotid O 0 0.6432194
sinus O 0 0.3862508
baroreceptors O 0 0.77450645
. O 0 0.009948293

Microangiopathic B-Disease 0 0.99242944
hemolytic I-Disease 2 0.99976224
anemia I-Disease 2 0.9999479
complicating O 0 0.99258244
FK506 B-Chemical 1 0.9999138
( O 0 0.42032397
tacrolimus B-Chemical 1 0.9998952
) O 0 0.12606668
therapy O 0 0.16291939
. O 0 0.016262455

We O 0 0.0076782284
describe O 0 0.0049772607
3 O 0 0.0039396244
episodes O 0 0.09856485
of O 0 0.006233935
microangiopathic B-Disease 0 0.9999336
hemolytic I-Disease 2 0.99999166
anemia I-Disease 2 0.999998
( O 0 0.5149472
MAHA B-Disease 2 0.9999597
) O 0 0.010629864
in O 0 0.0010872559
2 O 0 0.00106136
solid O 0 0.021965202
organ O 0 0.10601368
recipients O 0 0.008275851
under O 0 0.0017447426
FK506 B-Chemical 1 0.9999187
( O 0 0.050778426
tacrolimus B-Chemical 1 0.99993634
) O 0 0.040323287
therapy O 0 0.07996497
. O 0 0.009155809

In O 0 0.007147623
both O 0 0.0049972576
cases O 0 0.0057980474
, O 0 0.0040085455
discontinuation O 0 0.6160788
of O 0 0.003534376
FK506 B-Chemical 1 0.9999231
and O 0 0.0026731354
treatment O 0 0.0022601117
with O 0 0.001109492
plasma O 0 0.047680654
exchange O 0 0.0021223098
, O 0 0.00093046675
fresh O 0 0.0010367166
frozen O 0 0.0018973931
plasma O 0 0.019906951
replacement O 0 0.0047814357
, O 0 0.0020881807
corticosteroids B-Chemical 1 0.999571
, O 0 0.008171771
aspirin B-Chemical 1 0.999961
, O 0 0.0031609596
and O 0 0.0024771472
dipyridamole B-Chemical 1 0.99992394
led O 0 0.0027403985
to O 0 0.0026243574
resolution O 0 0.04495791
of O 0 0.01172739
MAHA B-Disease 2 0.99964356
. O 0 0.012694236

In O 0 0.009865117
one O 0 0.0069473763
patient O 0 0.00751307
, O 0 0.005967608
reintroduction O 0 0.00865501
of O 0 0.0057855737
FK506 B-Chemical 1 0.9997367
led O 0 0.0057152454
to O 0 0.0038753024
rapid O 0 0.010469915
recurrence O 0 0.9424573
of O 0 0.036715772
MAHA B-Disease 2 0.99963725
. O 0 0.017198374

FK506 B-Chemical 1 0.9993944
- O 0 0.02685158
associated O 0 0.010422883
MAHA B-Disease 2 0.9992828
is O 0 0.0046502007
probably O 0 0.0046879794
rare O 0 0.013066959
but O 0 0.0023718295
physicians O 0 0.0039715907
must O 0 0.0013510797
be O 0 0.0017434965
aware O 0 0.002196253
of O 0 0.002968456
this O 0 0.0041032345
severe O 0 0.57681334
complication O 0 0.90139896
. O 0 0.012998007

In O 0 0.007112985
our O 0 0.004741985
experience O 0 0.0050518885
and O 0 0.0029227172
according O 0 0.001780315
to O 0 0.0013422357
the O 0 0.0012800582
literature O 0 0.002453741
, O 0 0.00246659
FK506 B-Chemical 1 0.9998772
does O 0 0.00082476664
not O 0 0.00067117804
seem O 0 0.0006490091
to O 0 0.0005509266
cross O 0 0.0016284441
- O 0 0.0016512146
react O 0 0.0017539429
with O 0 0.0016371446
cyclosporin B-Chemical 1 0.9999949
A I-Chemical 1 0.9590599
( O 0 0.019223921
CyA B-Chemical 0 0.99997544
) O 0 0.00589788
, O 0 0.0011955228
an O 0 0.0011858525
immuno O 0 0.35774457
- O 0 0.0028509272
suppressive O 0 0.01125033
drug O 0 0.5386103
already O 0 0.0020126596
known O 0 0.0032304924
to O 0 0.003491317
induce O 0 0.0062169363
MAHA B-Disease 2 0.99966955
. O 0 0.012824154

Effect O 0 0.012985443
of O 0 0.008721919
some O 0 0.007415624
anticancer O 0 0.9237309
drugs O 0 0.8732528
and O 0 0.00635645
combined O 0 0.0076856143
chemotherapy O 0 0.8698153
on O 0 0.006744794
renal B-Disease 2 0.9993673
toxicity I-Disease 2 0.9996908
. O 0 0.020279353

The O 0 0.008968693
nephrotoxic B-Disease 2 0.996756
action O 0 0.028066464
of O 0 0.0045996984
anticancer O 0 0.97136813
drugs O 0 0.91439646
such O 0 0.0019663274
as O 0 0.0024014073
nitrogranulogen B-Chemical 0 0.99930906
( O 0 0.021582833
NG B-Chemical 0 0.9952674
) O 0 0.006647738
, O 0 0.002033193
methotrexate B-Chemical 1 0.99994147
( O 0 0.008987536
MTX B-Chemical 1 0.9999713
) O 0 0.003731318
, O 0 0.00091166544
5 B-Chemical 0 0.00052068004
- I-Chemical 0 0.0011080797
fluorouracil I-Chemical 0 0.9992638
( O 0 0.0010300452
5 B-Chemical 0 0.00051697623
- I-Chemical 0 0.0010247574
FU I-Chemical 0 0.7684102
) O 0 0.001156414
and O 0 0.00083682477
cyclophosphamide B-Chemical 1 0.9999479
( O 0 0.010593553
CY B-Chemical 1 0.99988365
) O 0 0.0020158982
administered O 0 0.0007499787
alone O 0 0.00048664675
or O 0 0.00043220585
in O 0 0.00045238135
combination O 0 0.0022175175
[ O 0 0.022087753
MTX B-Chemical 1 0.9999685
+ O 0 0.0013550513
5 B-Chemical 0 0.00067813
- I-Chemical 0 0.0015049836
FU I-Chemical 0 0.8854587
+ O 0 0.0018706974
CY B-Chemical 1 0.99976844
( O 0 0.0037172239
CMF O 0 0.9801838
) O 0 0.002952412
] O 0 0.0017629116
was O 0 0.0008485661
evaluated O 0 0.00090445665
in O 0 0.0012500314
experiments O 0 0.0017338712
on O 0 0.002274032
Wistar O 0 0.11494635
rats O 0 0.012282811
. O 0 0.008946471

After O 0 0.0063662003
drug O 0 0.22982036
administration O 0 0.21770981
, O 0 0.0068081087
creatinine B-Chemical 1 0.9969796
concentrations O 0 0.0043319236
in O 0 0.0011346611
the O 0 0.0009946276
plasma O 0 0.011346155
and O 0 0.0009399332
in O 0 0.0006312371
the O 0 0.00065939303
urine O 0 0.07529803
of O 0 0.0008362425
the O 0 0.0007654082
rats O 0 0.0018603728
were O 0 0.0008660779
determined O 0 0.0007910011
, O 0 0.0015185833
as O 0 0.0013840997
well O 0 0.0018837901
as O 0 0.0038913316
creatinine B-Chemical 1 0.99747616
clearance O 0 0.28040135
. O 0 0.009407363

Histopathologic O 0 0.4147105
evaluation O 0 0.016352013
of O 0 0.013153876
the O 0 0.0116075175
kidneys O 0 0.062445033
was O 0 0.011512386
also O 0 0.012001299
performed O 0 0.013850335
. O 0 0.017280115

After O 0 0.0077609625
MTX B-Chemical 1 0.9987941
administration O 0 0.10235714
a O 0 0.003709638
significant O 0 0.0022291597
increase O 0 0.0014463279
( O 0 0.0018631606
p O 0 0.001496456
= O 0 0.0013125363
0 O 0 0.0009646381
. O 0 0.0005114728
0228 O 0 0.004590856
) O 0 0.0008789937
in O 0 0.0004104539
the O 0 0.0004995367
plasma O 0 0.023920633
creatinine B-Chemical 1 0.9974842
concentration O 0 0.0013999303
and O 0 0.0006151224
a O 0 0.0006880445
significant O 0 0.0006447217
( O 0 0.00085531897
p O 0 0.00074563024
= O 0 0.00079064205
0 O 0 0.00068743166
. O 0 0.00044610671
0001 O 0 0.014342826
) O 0 0.0008931868
decrease O 0 0.0005690582
in O 0 0.00078556826
creatinine B-Chemical 1 0.9943768
clearance O 0 0.039267275
was O 0 0.0013210744
noted O 0 0.0013440523
compared O 0 0.0015918995
to O 0 0.0031168258
controls O 0 0.008931372
. O 0 0.007818777

After O 0 0.005938569
the O 0 0.004963745
administration O 0 0.016860873
of O 0 0.0049666874
NG B-Chemical 0 0.9789122
, O 0 0.0036000283
5 B-Chemical 0 0.0015633763
- I-Chemical 0 0.002257249
FU I-Chemical 0 0.7075839
and O 0 0.0015117913
CY B-Chemical 1 0.99940765
neither O 0 0.0008110378
a O 0 0.00084516726
statistically O 0 0.00051592226
significant O 0 0.00055767485
increase O 0 0.00042073702
in O 0 0.0005711654
creatinine B-Chemical 1 0.99698395
concentration O 0 0.0013086887
nor O 0 0.0005234116
an O 0 0.0007448064
increase O 0 0.00042250985
in O 0 0.000616642
creatinine B-Chemical 1 0.99745315
clearance O 0 0.04231644
was O 0 0.00058620726
observed O 0 0.00041074047
compared O 0 0.00047463007
to O 0 0.00074280537
the O 0 0.0010470325
group O 0 0.0018651958
receiving O 0 0.0036097362
no O 0 0.0033061537
cytostatics O 0 0.99203074
. O 0 0.011148286

Following O 0 0.009015849
polytherapy O 0 0.98485285
according O 0 0.0037264763
to O 0 0.002381008
the O 0 0.0022214593
CMF O 1 0.97922933
regimen O 1 0.045063566
, O 0 0.001692632
a O 0 0.0010463204
statistically O 0 0.0006482148
significant O 0 0.000708122
decrease O 0 0.00070397975
( O 0 0.0009173191
p O 0 0.0007959525
= O 0 0.0007973402
0 O 0 0.0006492157
. O 0 0.00037190874
0343 O 0 0.007751986
) O 0 0.00083561084
in O 0 0.00049296813
creatinine B-Chemical 1 0.9947396
clearance O 0 0.04159764
was O 0 0.0005915353
found O 0 0.0004888374
, O 0 0.0009553969
but O 0 0.0007868411
creatinine B-Chemical 1 0.9947641
concentration O 0 0.0016417993
did O 0 0.0007752167
not O 0 0.0008672531
increase O 0 0.00092713133
significantly O 0 0.0019407942
compared O 0 0.0017072585
to O 0 0.003282449
controls O 0 0.009992435
. O 0 0.007847694

CY B-Chemical 1 0.99789596
caused O 0 0.019720938
hemorrhagic B-Disease 2 0.9996704
cystitis I-Disease 0 0.9999559
in O 0 0.0045262696
40 O 0 0.002390232
% O 0 0.0016034679
of O 0 0.0012920941
rats O 0 0.0033178108
, O 0 0.0013298189
but O 0 0.00075699494
it O 0 0.00071916345
did O 0 0.00054009317
not O 0 0.00058248965
cause O 0 0.0015210587
this O 0 0.00077043014
complication O 0 0.21467742
when O 0 0.0007829974
combined O 0 0.0017073544
with O 0 0.0018237539
5 B-Chemical 0 0.0021432838
- I-Chemical 0 0.004705408
FU I-Chemical 0 0.8635112
and O 0 0.00828175
MTX B-Chemical 1 0.99971956
. O 0 0.010593093

Histologic O 0 0.2568209
changes O 0 0.0074602757
were O 0 0.003943713
found O 0 0.0022564759
in O 0 0.0018720237
rat O 0 0.00435264
kidneys O 0 0.03769321
after O 0 0.0007390843
administration O 0 0.038578324
of O 0 0.0026929278
MTX B-Chemical 1 0.9999807
, O 0 0.010869443
CY B-Chemical 1 0.99986565
and O 0 0.002127205
NG B-Chemical 0 0.98432225
, O 0 0.0008162533
while O 0 0.0003393283
no O 0 0.0002603192
such O 0 0.0003739658
change O 0 0.00045739286
was O 0 0.00035490617
observed O 0 0.00025705594
after O 0 0.00027536284
5 B-Chemical 0 0.0004771213
- I-Chemical 0 0.00094113935
FU I-Chemical 0 0.52948916
and O 0 0.0006291896
joint O 0 0.054647364
administration O 0 0.076798536
of O 0 0.0024014397
MTX B-Chemical 1 0.9999716
+ O 0 0.0020527225
5 B-Chemical 0 0.0011290427
- I-Chemical 0 0.0024806974
FU I-Chemical 0 0.8608347
+ O 0 0.0031140447
CY B-Chemical 1 0.99842525
compared O 0 0.0020522373
to O 0 0.0035779285
controls O 0 0.009848159
. O 0 0.0080803465

Our O 0 0.008935004
studies O 0 0.006109987
indicate O 0 0.0037766746
that O 0 0.0035538967
nephrotoxicity B-Disease 2 0.99994934
of O 0 0.022568787
MTX B-Chemical 1 0.99996376
+ O 0 0.004765725
5 B-Chemical 0 0.0015683561
- I-Chemical 0 0.002731899
FU I-Chemical 0 0.87844604
+ O 0 0.0024544017
CY B-Chemical 1 0.9992899
administered O 0 0.0029544227
jointly O 0 0.01425019
is O 0 0.0016000454
lower O 0 0.0018708842
than O 0 0.001980485
in O 0 0.0038984336
monotherapy O 0 0.66527915
. O 0 0.008859599

The O 0 0.011115758
interpeduncular O 0 0.36611614
nucleus O 0 0.0082035065
regulates O 0 0.0036152522
nicotine B-Chemical 1 0.9957838
' O 0 0.0052466453
s O 0 0.0036775684
effects O 0 0.0038179092
on O 0 0.002655593
free O 0 0.0059931306
- O 0 0.008304417
field O 0 0.0081951
activity O 0 0.009361575
. O 0 0.010317045

Partial O 0 0.02190702
lesions O 0 0.14988294
were O 0 0.0059748106
made O 0 0.0045458935
with O 0 0.0062953406
kainic B-Chemical 0 0.9999747
acid I-Chemical 0 0.97946817
in O 0 0.002281967
the O 0 0.0019783417
interpeduncular O 0 0.54208714
nucleus O 0 0.0019303398
of O 0 0.0015004661
the O 0 0.0017803987
ventral O 0 0.005519656
midbrain O 0 0.43675104
of O 0 0.0037133144
the O 0 0.004831549
rat O 0 0.01992205
. O 0 0.009057831

Compared O 0 0.0073766685
with O 0 0.0053827013
sham O 0 0.005045536
- O 0 0.0043340675
operated O 0 0.004161535
controls O 0 0.0033883806
, O 0 0.0022404366
lesions O 0 0.19367526
significantly O 0 0.0019872899
( O 0 0.0015067296
p O 0 0.0010238211
< O 0 0.00069340086
0 O 0 0.0006953269
. O 0 0.00037883647
25 O 0 0.00066139194
) O 0 0.0008320619
blunted O 0 0.0066970177
the O 0 0.00045344
early O 0 0.00096628553
( O 0 0.0008202845
< O 0 0.00043530058
60 O 0 0.000344774
min O 0 0.0004165979
) O 0 0.0006369162
free O 0 0.00070794683
- O 0 0.0010845818
field O 0 0.0011093878
locomotor B-Disease 0 0.9843896
hypoactivity I-Disease 0 0.99993813
caused O 0 0.0012297436
by O 0 0.0014774336
nicotine B-Chemical 1 0.9997867
( O 0 0.0016002343
0 O 0 0.000684008
. O 0 0.0002699976
5 O 0 0.00030433983
mg O 0 0.04138435
kg O 0 0.005116003
( O 0 0.0010746297
- O 0 0.0009877048
1 O 0 0.0005424864
) O 0 0.00079318136
, O 0 0.0005699347
i O 0 0.0012671018
. O 0 0.00036336
m O 0 0.0032647315
. O 0 0.0004093602
) O 0 0.000881347
, O 0 0.0005273885
enhanced O 0 0.00037466164
the O 0 0.00038221304
later O 0 0.00037854948
( O 0 0.000687838
60 O 0 0.0004856465
- O 0 0.00064012135
120 O 0 0.00049296784
min O 0 0.0005995139
) O 0 0.0014898238
nicotine B-Chemical 1 0.99923694
- O 0 0.0037443726
induced O 0 0.0023737699
hyperactivity B-Disease 2 0.9999331
, O 0 0.0030093002
and O 0 0.0019366144
raised O 0 0.0030420409
spontaneous O 0 0.08342921
nocturnal O 0 0.6424933
activity O 0 0.007825187
. O 0 0.008199288

Lesions O 0 0.31987253
reduced O 0 0.0061231502
the O 0 0.0035326434
extent O 0 0.0020934837
of O 0 0.0022744925
immunohistological O 0 0.04349233
staining O 0 0.0027648387
for O 0 0.001528502
choline B-Chemical 1 0.99968135
acetyltransferase O 0 0.975216
in O 0 0.00078625424
the O 0 0.0007850916
interpeduncular O 0 0.57249635
nucleus O 0 0.0010608314
( O 0 0.0007367145
p O 0 0.00063378015
< O 0 0.00052809727
0 O 0 0.00062448246
. O 0 0.00042070088
025 O 0 0.06331571
) O 0 0.00106126
, O 0 0.00072311715
but O 0 0.00052686594
not O 0 0.0005921992
for O 0 0.000780388
tyrosine B-Chemical 1 0.97485006
hydroxylase O 0 0.98897016
in O 0 0.0014021305
the O 0 0.0018197465
surrounding O 0 0.005933465
catecholaminergic O 0 0.99197936
A10 O 0 0.87503636
region O 0 0.008072706
. O 0 0.008384319

We O 0 0.007049969
conclude O 0 0.0042064344
that O 0 0.0030590289
the O 0 0.0029969306
interpeduncular O 0 0.62673646
nucleus O 0 0.003467079
mediates O 0 0.0016437327
nicotinic O 0 0.9997737
depression B-Disease 2 0.999549
of O 0 0.0030445145
locomotor O 0 0.8603097
activity O 0 0.0015107099
and O 0 0.0013821133
dampens O 0 0.008363329
nicotinic O 0 0.9998103
arousal O 0 0.9851981
mechanisms O 0 0.0034304708
located O 0 0.0020183797
elsewhere O 0 0.0022508877
in O 0 0.002504859
the O 0 0.0041256472
brain O 0 0.15751973
. O 0 0.00887037

Lithium B-Chemical 1 0.9996031
- O 0 0.016581744
associated O 0 0.006373115
cognitive B-Disease 0 0.64991623
and I-Disease 0 0.0034149638
functional I-Disease 0 0.0032895205
deficits I-Disease 0 0.385987
reduced O 0 0.0017882126
by O 0 0.0016293515
a O 0 0.0018288342
switch O 0 0.0021477307
to O 0 0.0022405111
divalproex B-Chemical 0 0.99995255
sodium I-Chemical 1 0.9996674
: O 0 0.0063362313
a O 0 0.0044400548
case O 0 0.005025373
series O 0 0.010285927
. O 0 0.009055829

BACKGROUND O 0 0.85387576
: O 0 0.021511948
Lithium B-Chemical 1 0.99952805
remains O 0 0.0037726364
a O 0 0.0031753017
first O 0 0.0019539273
- O 0 0.002780482
line O 0 0.002063922
treatment O 0 0.0016937639
for O 0 0.0009823532
the O 0 0.001420027
acute O 0 0.9012939
and O 0 0.002982114
maintenance O 0 0.00419795
treatment O 0 0.0057108873
of O 0 0.011021172
bipolar B-Disease 2 0.9991757
disorder I-Disease 0 0.9967571
. O 0 0.013066232

Although O 0 0.0068947724
much O 0 0.0043844925
has O 0 0.0031120174
been O 0 0.0024303915
written O 0 0.002089289
about O 0 0.0011138651
the O 0 0.000987013
management O 0 0.0014013782
of O 0 0.0009004509
the O 0 0.0006869559
more O 0 0.0007472207
common O 0 0.0009848482
adverse O 0 0.9283689
effects O 0 0.003471868
of O 0 0.0026296983
lithium B-Chemical 1 0.99995744
, O 0 0.0014759878
such O 0 0.0005619981
as O 0 0.0009777265
polyuria B-Disease 2 0.9999267
and O 0 0.002942337
tremor B-Disease 2 0.99997914
, O 0 0.0012881659
more O 0 0.0006147683
subtle O 0 0.00159097
lithium B-Chemical 1 0.9998078
side O 0 0.082861155
effects O 0 0.0016364526
such O 0 0.00069334736
as O 0 0.0012893719
cognitive B-Disease 2 0.9940573
deficits I-Disease 2 0.95868766
, O 0 0.0017352295
loss B-Disease 0 0.0032914006
of I-Disease 0 0.0017191422
creativity I-Disease 0 0.7744792
, O 0 0.00217383
and O 0 0.002053254
functional B-Disease 0 0.008349905
impairments I-Disease 0 0.8640631
remain O 0 0.0052636205
understudied O 0 0.075896315
. O 0 0.008404613

This O 0 0.010076242
report O 0 0.0072933678
summarizes O 0 0.0036404273
our O 0 0.0024346334
experience O 0 0.0031666127
in O 0 0.0016227043
switching O 0 0.0031676483
bipolar B-Disease 2 0.9943757
patients O 0 0.011670823
from O 0 0.0018382769
lithium B-Chemical 1 0.99987197
to O 0 0.0023969498
divalproex B-Chemical 0 0.9999757
sodium I-Chemical 1 0.9997557
to O 0 0.0015923156
alleviate O 0 0.019785678
such O 0 0.0027615642
cognitive B-Disease 0 0.89616114
and I-Disease 0 0.0051938775
functional I-Disease 0 0.042619225
impairments I-Disease 0 0.9553388
. O 0 0.009928344

METHOD O 0 0.06790468
: O 0 0.03174391
Open O 0 0.03231429
, O 0 0.021789685
case O 0 0.019059803
series O 0 0.025716696
design O 0 0.033626396
. O 0 0.026308639

RESULTS O 0 0.024118287
: O 0 0.007829887
We O 0 0.0038245232
report O 0 0.0038044685
seven O 0 0.001988726
cases O 0 0.0024273307
where O 0 0.0013884162
substitution O 0 0.024393374
of O 0 0.0024278143
lithium B-Chemical 1 0.9999198
, O 0 0.0019028317
either O 0 0.0006989907
fully O 0 0.00051482825
or O 0 0.0005532435
partially O 0 0.00080205157
, O 0 0.0010613919
with O 0 0.0010821563
divalproex B-Chemical 0 0.99998057
sodium I-Chemical 1 0.99984884
was O 0 0.0007353096
extremely O 0 0.0019740944
helpful O 0 0.0007490216
in O 0 0.0003906683
reducing O 0 0.0007036854
the O 0 0.00069836417
cognitive B-Disease 0 0.8238984
, I-Disease 0 0.0013008019
motivational I-Disease 0 0.09767793
, I-Disease 0 0.0010386816
or I-Disease 0 0.00078206474
creative I-Disease 0 0.0615869
deficits I-Disease 0 0.28817546
attributed O 0 0.0010177022
to O 0 0.0015418762
lithium B-Chemical 1 0.99963665
in O 0 0.0024109809
our O 0 0.0034990548
bipolar B-Disease 2 0.99461997
patients O 0 0.04378358
. O 0 0.009073119

CONCLUSION O 0 0.66611725
: O 0 0.0084811365
In O 0 0.003663966
this O 0 0.0027213732
preliminary O 0 0.003403442
report O 0 0.007366115
, O 0 0.0055048335
divalproex B-Chemical 0 0.9999554
sodium I-Chemical 1 0.9998084
was O 0 0.0011732068
a O 0 0.0010196142
superior O 0 0.0011158958
alternative O 0 0.00068834494
to O 0 0.0007229252
lithium B-Chemical 1 0.99980456
in O 0 0.00106231
bipolar B-Disease 2 0.9964999
patients O 0 0.014492658
experiencing O 0 0.38217402
cognitive B-Disease 2 0.9960955
deficits I-Disease 2 0.968568
, O 0 0.0023757853
loss B-Disease 0 0.004391248
of I-Disease 0 0.0024743008
creativity I-Disease 0 0.78900695
, O 0 0.0035028576
and O 0 0.0036531114
functional B-Disease 0 0.01879794
impairments I-Disease 0 0.9270475
. O 0 0.009309969

Effect O 0 0.014611371
of O 0 0.012434245
nifedipine B-Chemical 1 0.9998399
on O 0 0.005395731
renal O 0 0.9693943
function O 0 0.0052325167
in O 0 0.0038143487
liver O 0 0.89534986
transplant O 0 0.6991868
recipients O 0 0.059603043
receiving O 0 0.076243766
tacrolimus B-Chemical 1 0.99984
. O 0 0.015718294

The O 0 0.007379086
effect O 0 0.0050968695
of O 0 0.00595189
nifedipine B-Chemical 1 0.9999373
on O 0 0.0023958713
renal O 0 0.97855556
function O 0 0.00233074
in O 0 0.001268644
liver O 0 0.8541676
transplant O 0 0.45735464
recipients O 0 0.0064308783
who O 0 0.0018951757
were O 0 0.0008345644
receiving O 0 0.002239786
tacrolimus B-Chemical 1 0.99992967
was O 0 0.0012815747
evaluated O 0 0.0010554524
between O 0 0.00112256
January O 0 0.0023711186
1992 O 0 0.005585659
and O 0 0.0033396804
January O 0 0.0050060307
1996 O 0 0.010418078
. O 0 0.007374997

Two O 0 0.008133912
groups O 0 0.0051653613
of O 0 0.0037558223
patients O 0 0.00480299
receiving O 0 0.0049659777
tacrolimus B-Chemical 1 0.9999186
were O 0 0.0014332011
compared O 0 0.00054463145
over O 0 0.0004136456
a O 0 0.0006282715
period O 0 0.00040836475
of O 0 0.00057974353
1 O 0 0.0005682455
year O 0 0.00045323797
, O 0 0.00052822253
one O 0 0.0003156267
group O 0 0.00049414637
comprising O 0 0.0006045472
hypertensive B-Disease 2 0.9987828
patients O 0 0.0025545158
who O 0 0.0012993749
were O 0 0.000597156
receiving O 0 0.0029239387
nifedipine B-Chemical 1 0.9999902
, O 0 0.0014240611
and O 0 0.0007695987
the O 0 0.00066389213
other O 0 0.0008744002
comprising O 0 0.0014543424
nonhypertensive O 0 0.9950643
patients O 0 0.0061688367
not O 0 0.002968416
receiving O 0 0.039683186
nifedipine B-Chemical 1 0.99992895
. O 0 0.012148703

The O 0 0.010384718
time O 0 0.0072904965
from O 0 0.006488475
transplant O 0 0.030613182
to O 0 0.0046055107
baseline O 0 0.004582435
was O 0 0.0039247954
similar O 0 0.0034193338
in O 0 0.004710509
all O 0 0.0063179145
patients O 0 0.016572827
. O 0 0.012070177

Nifedipine B-Chemical 0 0.9996878
significantly O 0 0.010301476
improved O 0 0.007989024
kidney O 0 0.7027424
function O 0 0.0029602577
as O 0 0.0017210443
indicated O 0 0.0011507838
by O 0 0.0012619188
a O 0 0.0013198784
significant O 0 0.0011585652
lowering O 0 0.017325422
of O 0 0.001857433
serum O 0 0.45901668
creatinine B-Chemical 1 0.998539
levels O 0 0.0015382568
at O 0 0.0012604683
6 O 0 0.0014733486
and O 0 0.0023282918
12 O 0 0.0027155778
months O 0 0.003865309
. O 0 0.0065992926

The O 0 0.0066141267
observed O 0 0.0036688661
positive O 0 0.0033135877
impact O 0 0.002264861
of O 0 0.0035178126
nifedipine B-Chemical 1 0.9999759
on O 0 0.0012157473
reducing O 0 0.0024478748
the O 0 0.001945641
nephrotoxicity B-Disease 2 0.99999344
associated O 0 0.004322212
with O 0 0.0023947614
tacrolimus B-Chemical 1 0.99998474
in O 0 0.0011689945
liver O 0 0.94407886
transplant O 0 0.5422745
recipients O 0 0.005361305
should O 0 0.000332786
be O 0 0.00045992102
an O 0 0.0005742293
important O 0 0.00042547492
factor O 0 0.0022987144
in O 0 0.0005384971
selecting O 0 0.0006287289
an O 0 0.0011846945
agent O 0 0.07542407
to O 0 0.0014455615
treat O 0 0.036660384
hypertension B-Disease 2 0.9998994
in O 0 0.0036859487
this O 0 0.004501544
population O 0 0.012177315
. O 0 0.008518002

Alpha O 0 0.44793305
and O 0 0.014492932
beta O 0 0.7552498
coma B-Disease 2 0.9994803
in O 0 0.008467306
drug O 0 0.9075989
intoxication O 0 0.9995807
uncomplicated O 0 0.924859
by O 0 0.021332718
cerebral B-Disease 0 0.9981535
hypoxia I-Disease 2 0.9989549
. O 0 0.01730707

Four O 0 0.01078506
patients O 0 0.008850115
who O 0 0.00619294
were O 0 0.0034606927
rendered O 0 0.0047602346
comatose B-Disease 0 0.9637121
or O 0 0.0029666019
stuporous B-Disease 0 0.99954516
by O 0 0.0026290347
drug O 0 0.8725544
intoxication O 0 0.99978894
, O 0 0.0034355507
but O 0 0.0013051359
who O 0 0.002331485
were O 0 0.0015193152
not O 0 0.0018772179
hypoxic O 0 0.8736805
, O 0 0.0049838517
are O 0 0.0044304808
described O 0 0.0051987106
. O 0 0.00848643

Three O 0 0.008975078
patients O 0 0.007317585
received O 0 0.0036098459
high O 0 0.0031790624
doses O 0 0.022101393
of O 0 0.004385414
chlormethiazole B-Chemical 0 0.99998856
for O 0 0.0024568595
alcohol B-Chemical 1 0.9998957
withdrawal B-Disease 0 0.9989666
symptoms I-Disease 0 0.9973545
, O 0 0.0028370074
and O 0 0.0013664112
one O 0 0.00104399
took O 0 0.0013507734
a O 0 0.0033519587
suicidal O 0 0.99979085
overdose B-Disease 2 0.99989533
of O 0 0.05527475
nitrazepam B-Chemical 0 0.9999802
. O 0 0.0126583865

The O 0 0.007411137
patient O 0 0.0074001974
with O 0 0.0061151693
nitrazepam B-Chemical 0 0.99998736
overdose B-Disease 2 0.9999304
and O 0 0.0025623373
two O 0 0.0009834766
of O 0 0.0011396005
those O 0 0.0013569593
with O 0 0.001445828
chlormethiazole B-Chemical 0 0.99999535
intoxication O 0 0.99980384
conformed O 0 0.0012265407
to O 0 0.00045047866
the O 0 0.0004219627
criteria O 0 0.0005560597
of O 0 0.00068121555
' O 0 0.0013731295
alpha O 0 0.5158793
coma B-Disease 2 0.9999548
' O 0 0.0017597986
, O 0 0.00082168257
showing O 0 0.00058430067
non O 0 0.0024096016
- O 0 0.002043807
reactive O 0 0.15153795
generalized O 0 0.1562659
or O 0 0.0014759197
frontally O 0 0.5596311
predominant O 0 0.0021255033
alpha O 0 0.18854488
activity O 0 0.0029044787
in O 0 0.0029513708
the O 0 0.00510674
EEG O 0 0.95157665
. O 0 0.009100615

The O 0 0.0074198274
fourth O 0 0.0075066863
patient O 0 0.004944482
who O 0 0.004259201
was O 0 0.0023856405
unconscious O 0 0.091961056
after O 0 0.0013543196
chlormethiazole B-Chemical 0 0.9999825
administration O 0 0.4191438
exhibite O 0 0.48727074
generalized O 0 0.37739292
non O 0 0.024327282
- O 0 0.0059310663
reactive O 0 0.19969618
activity O 0 0.0021592295
in O 0 0.0017586832
the O 0 0.002454829
slow O 0 0.007427142
beta O 0 0.39768
range O 0 0.011124305
. O 0 0.009132715

All O 0 0.00834376
four O 0 0.0049286243
recovered O 0 0.004206588
completely O 0 0.0039022497
without O 0 0.0037101458
neurological B-Disease 0 0.99840623
sequelae I-Disease 0 0.97504854
following O 0 0.00281107
the O 0 0.002640266
withdrawal O 0 0.7286287
of O 0 0.0040071476
the O 0 0.0046013133
offending O 0 0.7268781
agents O 0 0.6573927
. O 0 0.012094197

The O 0 0.0068955617
similarities O 0 0.0048364694
between O 0 0.0028082374
the O 0 0.0026071316
effects O 0 0.002804856
of O 0 0.0023212435
structural O 0 0.0051098657
lesions O 0 0.5490921
and O 0 0.0027167546
pharmacological O 0 0.81299406
depression B-Disease 2 0.99928325
of O 0 0.0021952353
the O 0 0.0018288916
brain O 0 0.20088886
stem O 0 0.28811124
reticular O 0 0.72926927
formation O 0 0.011898103
are O 0 0.0056947996
discussed O 0 0.005976932
. O 0 0.0090521965

It O 0 0.010534115
is O 0 0.0054215975
suggested O 0 0.003386624
that O 0 0.0023691594
in O 0 0.0020160808
both O 0 0.0017812008
situations O 0 0.0028776005
disturbed O 0 0.015419014
reticulo O 0 0.68194383
- O 0 0.0052166255
thalamic O 0 0.5642983
interactions O 0 0.0019130671
are O 0 0.0011878024
important O 0 0.0009572775
in O 0 0.0012660727
the O 0 0.0018258855
pathogenesis O 0 0.012225671
of O 0 0.009396313
alpha O 0 0.9363597
coma B-Disease 2 0.99981123
. O 0 0.013789846

It O 0 0.00964199
is O 0 0.0047882935
concluded O 0 0.0032373322
that O 0 0.0019314317
when O 0 0.0013710139
this O 0 0.0013724125
electroencephalographic O 0 0.7919205
and O 0 0.0014727005
behavioural O 0 0.02755823
picture O 0 0.0016370042
is O 0 0.00072564854
seen O 0 0.00056522776
in O 0 0.00062130275
drug O 0 0.7375416
intoxication O 0 0.99978036
, O 0 0.0015817155
in O 0 0.0004979755
the O 0 0.00047169384
absence O 0 0.00035072234
of O 0 0.0008241977
significant O 0 0.0014961972
hypoxaemia B-Disease 0 0.99935955
, O 0 0.0019935805
a O 0 0.0017463587
favourable O 0 0.005056799
outcome O 0 0.005026062
may O 0 0.002866579
be O 0 0.0041834125
anticipated O 0 0.0058710994
. O 0 0.0077019124

Magnetic O 0 0.84749645
resonance O 0 0.14845389
volumetry O 0 0.03579897
of O 0 0.0069607166
the O 0 0.0057398714
cerebellum O 0 0.10144038
in O 0 0.0055988138
epileptic B-Disease 2 0.99945015
patients O 0 0.036464535
after O 0 0.006307095
phenytoin B-Chemical 1 0.99994993
overdosages B-Disease 0 0.9966426
. O 0 0.016014062

The O 0 0.006902665
aim O 0 0.0054962654
of O 0 0.0038996616
this O 0 0.0026131284
study O 0 0.0022575285
was O 0 0.001367135
to O 0 0.0008930647
evaluate O 0 0.0005377288
the O 0 0.00069961307
relationship O 0 0.0005846483
between O 0 0.0007014491
phenytoin B-Chemical 1 0.999992
medication O 0 0.582645
and O 0 0.0025967837
cerebellar B-Disease 0 0.99614185
atrophy I-Disease 2 0.99979025
in O 0 0.0013176572
patients O 0 0.0036961667
who O 0 0.0028269805
had O 0 0.0019780516
experienced O 0 0.00583998
clinical O 0 0.1552758
intoxication O 0 0.99927753
. O 0 0.012678475

Five O 0 0.012210163
females O 0 0.008813009
and O 0 0.0046586636
6 O 0 0.0026825494
males O 0 0.0035806766
, O 0 0.0022730236
21 O 0 0.0017767806
- O 0 0.0015056737
59 O 0 0.0012523928
years O 0 0.0008715828
of O 0 0.000762901
age O 0 0.001740474
, O 0 0.00088518055
were O 0 0.00051439
examined O 0 0.00037822954
with O 0 0.0005949878
a O 0 0.00092511764
1 O 0 0.00073532225
. O 0 0.00046293638
5 O 0 0.00059417234
- O 0 0.0011269368
T O 0 0.17048584
whole O 0 0.0009884018
- O 0 0.0014830006
body O 0 0.002834913
system O 0 0.001747918
using O 0 0.0013448385
a O 0 0.0023342294
circular O 0 0.004156889
polarized O 0 0.0061396076
head O 0 0.12902364
coil O 0 0.016507672
. O 0 0.00939027

Conventional O 0 0.031188928
spin O 0 0.06785875
echo O 0 0.040346526
images O 0 0.010581086
were O 0 0.0066128927
acquired O 0 0.008123118
in O 0 0.0050269803
the O 0 0.0056651784
sagittal O 0 0.024028357
and O 0 0.0076217838
transverse O 0 0.019355347
orientation O 0 0.0128931785
. O 0 0.012991152

In O 0 0.007655138
addition O 0 0.0043892595
, O 0 0.004304764
we O 0 0.0020282236
performed O 0 0.0018044697
a O 0 0.0021416713
high O 0 0.0022448164
- O 0 0.002772513
resolution O 0 0.006394613
3D O 0 0.01588856
gradient O 0 0.0038865139
echo O 0 0.09680156
, O 0 0.0021695825
T1 O 0 0.091391385
- O 0 0.0018159896
weighted O 0 0.0014129933
sequences O 0 0.0011864185
at O 0 0.001019816
a O 0 0.0019990965
1 O 0 0.0024029477
- O 0 0.0038625342
mm O 0 0.008104245
slice O 0 0.05210901
thickness O 0 0.057186846
. O 0 0.009712145

The O 0 0.010998586
images O 0 0.010900826
were O 0 0.006695882
subsequently O 0 0.005967017
processed O 0 0.0043799407
to O 0 0.0035971797
obtain O 0 0.0030477666
volumetric O 0 0.007821172
data O 0 0.0054308465
for O 0 0.0046950434
the O 0 0.0076159863
cerebellum O 0 0.20845304
. O 0 0.012174299

Cerebellar O 0 0.80418247
volume O 0 0.0090976665
for O 0 0.0032025443
the O 0 0.002494197
patient O 0 0.0024728654
group O 0 0.0016926997
ranged O 0 0.0016437864
between O 0 0.0008499378
67 O 0 0.0020076549
. O 0 0.00072058523
66 O 0 0.0012465988
and O 0 0.0009054552
131 O 0 0.0035399492
. O 0 0.00075183454
08 O 0 0.0047854036
ml O 0 0.0019219173
( O 0 0.0013965798
mean O 0 0.0011213694
108 O 0 0.0026044245
. O 0 0.0016493415
9 O 0 0.00279967
ml O 0 0.00743413
) O 0 0.009290444
. O 0 0.008021997

In O 0 0.0074716085
addition O 0 0.0043934397
3D O 0 0.010243022
gradient O 0 0.005834485
echo O 0 0.017858043
data O 0 0.0020584676
sets O 0 0.001293504
from O 0 0.0010465683
10 O 0 0.0008986073
healthy O 0 0.0022305897
male O 0 0.002525571
and O 0 0.0008595924
10 O 0 0.00071477453
healthy O 0 0.0023032266
female O 0 0.0026543527
age O 0 0.0022764648
- O 0 0.0012459892
matched O 0 0.00077959185
volunteers O 0 0.002107321
were O 0 0.001122807
used O 0 0.001219381
to O 0 0.0015735555
compare O 0 0.0019050301
cerebellar O 0 0.7795488
volumes O 0 0.017055297
. O 0 0.008165887

Using O 0 0.008593843
linear O 0 0.0069027
regression O 0 0.0071649193
we O 0 0.002122149
found O 0 0.0015367153
that O 0 0.0011145428
no O 0 0.000857383
correlation O 0 0.00078812585
exists O 0 0.0008415503
between O 0 0.0008002579
seizure B-Disease 2 0.99972326
duration O 0 0.0031533288
, O 0 0.0025818693
elevation O 0 0.28826055
of O 0 0.004055727
phenytoin B-Chemical 1 0.99998844
serum O 0 0.44141394
levels O 0 0.0032612977
and O 0 0.005406628
cerebellar O 0 0.9009621
volume O 0 0.019158682
. O 0 0.0085415775

However O 0 0.008637347
, O 0 0.0059961057
multiple O 0 0.0043144603
regression O 0 0.0056975805
for O 0 0.001552985
the O 0 0.0013540991
daily O 0 0.0023135848
dosage O 0 0.083506525
, O 0 0.0012684682
duration O 0 0.0010085126
of O 0 0.0016761281
phenytoin B-Chemical 1 0.99999046
treatment O 0 0.0030544007
and O 0 0.0015995571
cerebellar O 0 0.6903014
volume O 0 0.0024243214
revealed O 0 0.0011585548
a O 0 0.0016176638
correlation O 0 0.001431284
of O 0 0.0028306446
these O 0 0.004752576
parameters O 0 0.008742334
. O 0 0.008594349

We O 0 0.007467271
conclude O 0 0.004806296
that O 0 0.0044827717
phenytoin B-Chemical 1 0.9999703
overdosage B-Disease 0 0.9999467
does O 0 0.0020041123
not O 0 0.0012048003
necessarily O 0 0.0011183268
result O 0 0.0009080872
in O 0 0.0010379021
cerebellar B-Disease 0 0.9948496
atrophy I-Disease 2 0.9998858
and O 0 0.0013342972
it O 0 0.0007730615
is O 0 0.0004950414
unlikely O 0 0.00044368042
that O 0 0.000508258
phenytoin B-Chemical 1 0.9999901
medication O 0 0.20702684
was O 0 0.0005838113
the O 0 0.00053484295
only O 0 0.0006330829
cause O 0 0.0028296772
of O 0 0.0028667415
cerebellar B-Disease 0 0.99723864
atrophy I-Disease 2 0.9997253
in O 0 0.002205373
the O 0 0.0025609194
remaining O 0 0.0036871852
patients O 0 0.015106176
. O 0 0.008194169

Quantitative O 0 0.017291198
morphometric O 0 0.012480921
studies O 0 0.005856737
of O 0 0.004524908
the O 0 0.0036030007
cerebellum O 0 0.020531202
provide O 0 0.00199087
valuable O 0 0.0022567743
insights O 0 0.0020750063
into O 0 0.0015593406
the O 0 0.0023939256
pathogenesis O 0 0.01366461
of O 0 0.01311501
cerebellar B-Disease 0 0.9979054
disorders I-Disease 0 0.9974917
. O 0 0.014663606

Late O 0 0.08813113
recovery O 0 0.012394712
of O 0 0.007896317
renal O 0 0.92138594
function O 0 0.0054014404
in O 0 0.003522057
a O 0 0.0045036105
woman O 0 0.029087216
with O 0 0.0050326264
the O 0 0.008406786
hemolytic B-Disease 2 0.9998964
uremic I-Disease 2 0.99991846
syndrome I-Disease 2 0.9988599
. O 0 0.026019685

A O 0 0.033829775
case O 0 0.007242747
is O 0 0.0047622323
reported O 0 0.0037336904
of O 0 0.003491123
the O 0 0.004111856
hemolytic B-Disease 2 0.9999385
uremic I-Disease 2 0.9999732
syndrome I-Disease 2 0.99968183
( O 0 0.25921085
HUS B-Disease 2 0.9999845
) O 0 0.017569268
in O 0 0.0020777036
a O 0 0.003230692
woman O 0 0.044996064
taking O 0 0.018414551
oral B-Chemical 1 0.9854417
contraceptives I-Chemical 1 0.9998047
. O 0 0.016430913

She O 0 0.011556319
was O 0 0.0057564136
treated O 0 0.0044471463
with O 0 0.0038223967
heparin B-Chemical 1 0.9984158
, O 0 0.011055309
dipyridamole B-Chemical 1 0.9999496
and O 0 0.0029126583
hemodialysis O 0 0.8510137
; O 0 0.0021777495
and O 0 0.0006640409
after O 0 0.0003175233
more O 0 0.00045099645
than O 0 0.00027976013
three O 0 0.00026978814
months O 0 0.00031916922
, O 0 0.00051002495
her O 0 0.000629192
urinary O 0 0.56505203
output O 0 0.0010057484
rose O 0 0.003671082
above O 0 0.00038312355
500 O 0 0.0014295139
ml O 0 0.0016044887
; O 0 0.00076204917
and O 0 0.00038937642
six O 0 0.00026728702
months O 0 0.00029466677
after O 0 0.00027662245
the O 0 0.0005034018
onset O 0 0.0020362672
of O 0 0.0018640566
anuria B-Disease 2 0.9997521
, O 0 0.004262323
dialysis O 0 0.10984531
treatment O 0 0.0052436567
was O 0 0.0045006867
stopped O 0 0.01100351
. O 0 0.008143633

This O 0 0.009362694
case O 0 0.0048493794
emphasizes O 0 0.0037617416
the O 0 0.0024674723
possibility O 0 0.001978563
that O 0 0.002059647
HUS B-Disease 2 0.99995995
in O 0 0.0020797343
adults O 0 0.0068362686
is O 0 0.00090812094
not O 0 0.0007507335
invariably O 0 0.015164004
irreversible O 0 0.3808956
and O 0 0.0009908808
that O 0 0.00057791953
, O 0 0.0008917362
despite O 0 0.00060288253
prolonged O 0 0.019528188
oliguria B-Disease 0 0.9999442
, O 0 0.0019633626
recovery O 0 0.0021517775
of O 0 0.0018611504
renal O 0 0.9814336
function O 0 0.00323021
can O 0 0.0025527002
be O 0 0.0039800936
obtained O 0 0.0055279722
. O 0 0.007844562

Therefore O 0 0.007509372
, O 0 0.0062829764
in O 0 0.003383608
adult O 0 0.0037587797
patients O 0 0.004712195
affected O 0 0.002077052
by O 0 0.0034721585
HUS B-Disease 2 0.9999789
, O 0 0.0036225491
dialysis O 0 0.050978903
should O 0 0.00045909034
not O 0 0.000533701
be O 0 0.0005736237
discontinued O 0 0.010876602
prematurely O 0 0.027677199
; O 0 0.0011799763
moreover O 0 0.004329804
, O 0 0.0007806497
bilateral O 0 0.028624032
nephrectomy O 0 0.6040435
, O 0 0.0007616015
for O 0 0.00033491754
treatment O 0 0.00071749766
of O 0 0.0009985798
severe O 0 0.70965534
hypertension B-Disease 2 0.9999814
and O 0 0.019452743
microangiopathic B-Disease 0 0.9999838
hemolytic I-Disease 2 0.99999535
anemia I-Disease 2 0.99999714
, O 0 0.026376126
should O 0 0.0013733964
be O 0 0.002053092
performed O 0 0.00220109
with O 0 0.0037791042
caution O 0 0.0071043214
. O 0 0.007879241

Morphological O 0 0.03425831
features O 0 0.011811736
of O 0 0.009503606
encephalopathy B-Disease 2 0.9997522
after O 0 0.003290584
chronic O 0 0.9193411
administration O 0 0.24010374
of O 0 0.00358332
the O 0 0.0034892256
antiepileptic O 0 0.9998217
drug O 0 0.9850793
valproate B-Chemical 0 0.9999639
to O 0 0.0069908937
rats O 0 0.034343585
. O 0 0.009948871

A O 0 0.04235825
transmission O 0 0.014982504
electron O 0 0.019018838
microscopic O 0 0.013583638
study O 0 0.007204131
of O 0 0.0066461605
capillaries O 0 0.07457914
in O 0 0.00666072
the O 0 0.008928693
cerebellar O 0 0.9523274
cortex O 0 0.5607543
. O 0 0.013785499

Long O 0 0.037991136
- O 0 0.008555204
term O 0 0.004022222
intragastric O 0 0.44849074
application O 0 0.003652669
of O 0 0.0022322608
the O 0 0.0019714218
antiepileptic O 0 0.99983644
drug O 0 0.98605275
sodium B-Chemical 1 0.99997437
valproate I-Chemical 0 0.9999962
( O 0 0.017361047
Vupral O 1 0.6846405
" O 0 0.0021640027
Polfa O 0 0.99355
" O 0 0.0017277483
) O 0 0.0012601443
at O 0 0.0004651738
the O 0 0.00058060285
effective O 0 0.00085280515
dose O 0 0.0031987363
of O 0 0.0016966914
200 O 0 0.0049308795
mg O 0 0.40567896
/ O 0 0.007923319
kg O 0 0.016456833
b O 0 0.011135084
. O 0 0.008616326

w O 0 0.015440773
. O 0 0.004747254
once O 0 0.0032085243
daily O 0 0.0032194054
to O 0 0.0017021691
rats O 0 0.0026090306
for O 0 0.0010343904
1 O 0 0.001190461
, O 0 0.0010975134
3 O 0 0.0006737797
, O 0 0.00073081005
6 O 0 0.00043225382
, O 0 0.0005516002
9 O 0 0.0004260184
and O 0 0.00040995734
12 O 0 0.0003222647
months O 0 0.00032970952
revealed O 0 0.0006579769
neurological B-Disease 0 0.9991726
disorders I-Disease 0 0.99604696
indicating O 0 0.002211337
cerebellum B-Disease 0 0.9437561
damage I-Disease 0 0.9880205
( O 0 0.013841885
" O 0 0.017856797
valproate B-Chemical 0 0.9999808
encephalopathy B-Disease 2 0.9999485
" O 0 0.031763483
) O 0 0.01935894
. O 0 0.008867515

The O 0 0.0067708576
first O 0 0.0043233675
ultrastructural O 0 0.010073373
changes O 0 0.0036559084
in O 0 0.0020080884
structural O 0 0.0028172492
elements O 0 0.0021231116
of O 0 0.0013480919
the O 0 0.0011142826
blood O 0 0.057656486
- O 0 0.0040314477
brain O 0 0.19039191
- O 0 0.002848032
barrier O 0 0.020202959
( O 0 0.002543677
BBB O 0 0.99517584
) O 0 0.0013095776
in O 0 0.00050365884
the O 0 0.0006809433
cerebellar O 0 0.7262221
cortex O 0 0.061102208
were O 0 0.00065540895
detectable O 0 0.00052416977
after O 0 0.0005751441
3 O 0 0.000977093
months O 0 0.0010802931
of O 0 0.00207157
the O 0 0.0031167709
experiment O 0 0.00425486
. O 0 0.0074829534

They O 0 0.012979125
became O 0 0.0071616964
more O 0 0.0045082625
severe O 0 0.031135397
in O 0 0.0019368256
the O 0 0.0013704238
later O 0 0.00089966453
months O 0 0.00063412875
of O 0 0.0007308309
the O 0 0.00064596406
experiment O 0 0.00053469586
, O 0 0.00081895594
and O 0 0.0005920203
were O 0 0.0004998468
most O 0 0.00065135444
severe O 0 0.023039047
after O 0 0.00031945502
12 O 0 0.00036410918
months O 0 0.00036203914
, O 0 0.0006117681
located O 0 0.00050342386
mainly O 0 0.000789691
in O 0 0.00069460593
the O 0 0.0009515641
molecular O 0 0.010387289
layer O 0 0.005938093
of O 0 0.002882284
the O 0 0.004233822
cerebellar O 0 0.9575163
cortex O 0 0.49603173
. O 0 0.008648669

Lesions O 0 0.22706012
of O 0 0.014146008
the O 0 0.0111023905
capillary O 0 0.056047313
included O 0 0.011806704
necrosis B-Disease 2 0.99330246
of O 0 0.022525625
endothelial O 0 0.98078316
cells O 0 0.06380711
. O 0 0.019852502

Organelles O 0 0.0426398
of O 0 0.006579622
these O 0 0.0047703614
cells O 0 0.005227401
, O 0 0.002922856
in O 0 0.0013892653
particular O 0 0.0009618491
the O 0 0.0011809473
mitochondria O 0 0.17542274
( O 0 0.0014678205
increased O 0 0.00079030794
number O 0 0.0005882905
and O 0 0.000780269
size O 0 0.0010093123
, O 0 0.0009220844
distinct O 0 0.0007740013
degeneration O 0 0.8735161
of O 0 0.0010436922
their O 0 0.0011329806
matrix O 0 0.028342905
and O 0 0.0023467778
cristae O 0 0.62069255
) O 0 0.004102851
and O 0 0.002387943
Golgi O 0 0.0075901714
apparatus O 0 0.0040595555
were O 0 0.0044047697
altered O 0 0.0067504034
. O 0 0.008349198

Reduced O 0 0.014630545
size O 0 0.0068278853
of O 0 0.0047725923
capillary O 0 0.03624962
lumen O 0 0.00571226
and O 0 0.002686512
occlusion O 0 0.1377355
were O 0 0.0016036105
caused O 0 0.0015587007
by O 0 0.0017888917
swollen O 0 0.072107784
endothelial O 0 0.9373485
cells O 0 0.004396392
which O 0 0.002358341
had O 0 0.002065069
luminal B-Chemical 1 0.44295892
protrusions O 0 0.2124791
and O 0 0.006266677
swollen O 0 0.2098165
microvilli O 0 0.3466079
. O 0 0.011464203

Pressure O 0 0.09838554
on O 0 0.007307235
the O 0 0.0064869416
vessel O 0 0.021565327
wall O 0 0.03437126
was O 0 0.005196672
produced O 0 0.0047048903
by O 0 0.0064327302
enlarged O 0 0.08848099
perivascular O 0 0.90912145
astrocytic O 0 0.9864254
processes O 0 0.042568095
. O 0 0.014372348

Fragments O 0 0.02874868
of O 0 0.009296929
necrotic B-Disease 2 0.80861974
endothelial O 0 0.9095955
cells O 0 0.0063787457
were O 0 0.0021218895
in O 0 0.0013499631
the O 0 0.0012378778
vascular O 0 0.4026464
lumens O 0 0.014996635
and O 0 0.0012343903
in O 0 0.0008351976
these O 0 0.0010185903
there O 0 0.0007490252
was O 0 0.0012239763
loosening O 0 0.105264865
and O 0 0.002308992
breaking O 0 0.028068472
of O 0 0.0033565213
tight O 0 0.009673336
cellular O 0 0.064717025
junctions O 0 0.029883057
. O 0 0.0095492955

Damage O 0 0.15112731
to O 0 0.013543567
the O 0 0.012039025
vascular O 0 0.525319
basement O 0 0.46593013
lamina O 0 0.02739879
was O 0 0.011449174
also O 0 0.01163596
observed O 0 0.011624657
. O 0 0.017384972

Damage O 0 0.1570284
to O 0 0.0063350573
the O 0 0.0046420796
capillary O 0 0.03865612
was O 0 0.0031241612
accompanied O 0 0.0038224712
by O 0 0.0024805416
marked O 0 0.0045325453
damage O 0 0.6054604
to O 0 0.0019801136
neuroglial O 0 0.94164205
cells O 0 0.0058606747
, O 0 0.002477339
mainly O 0 0.0023258787
to O 0 0.0020944283
perivascular O 0 0.6396898
processes O 0 0.009971423
of O 0 0.008756258
astrocytes O 0 0.8090699
. O 0 0.010670411

The O 0 0.009987044
proliferation O 0 0.2538057
of O 0 0.007881101
astrocytes O 0 0.6186849
( O 0 0.0077972678
Bergmann O 0 0.65616894
' O 0 0.002768804
s O 0 0.0019058007
in O 0 0.0013701408
particular O 0 0.0013229551
) O 0 0.0028908507
and O 0 0.0021432675
occasionally O 0 0.0047046756
of O 0 0.00417956
oligodendrocytes O 0 0.655109
was O 0 0.0054566944
found O 0 0.006144562
. O 0 0.009349656

Alterations O 0 0.014191211
in O 0 0.0051667774
the O 0 0.0037165175
structural O 0 0.0041901907
elements O 0 0.0033076215
of O 0 0.002278567
the O 0 0.0021039394
BBB O 0 0.99439275
coexisted O 0 0.016382873
with O 0 0.0012672443
marked O 0 0.002584803
lesions O 0 0.24969274
of O 0 0.0015027525
neurons O 0 0.012520501
of O 0 0.0012882199
the O 0 0.0015208987
cerebellum O 0 0.2618821
( O 0 0.0036231105
Purkinje O 0 0.71739084
cells O 0 0.003519498
are O 0 0.0034805336
earliest O 0 0.0063919593
) O 0 0.011020076
. O 0 0.00826036

In O 0 0.008650035
electron O 0 0.0123579055
micrographs O 0 0.005156461
both O 0 0.0038120558
luminal B-Chemical 1 0.12953931
and O 0 0.0034632455
antiluminal O 0 0.037621282
sides O 0 0.0050057033
of O 0 0.0019565306
the O 0 0.0019266687
BBB O 0 0.9825638
of O 0 0.0021496098
the O 0 0.0024238452
cerebellar O 0 0.88303417
cortex O 0 0.17236604
had O 0 0.0031602955
similar O 0 0.0038525609
lesions O 0 0.44168803
. O 0 0.010576525

The O 0 0.007086383
possible O 0 0.0048504067
influence O 0 0.0031095287
of O 0 0.0032481365
the O 0 0.0031128535
hepatic B-Disease 2 0.99785787
damage I-Disease 2 0.99439126
, O 0 0.0069867005
mainly O 0 0.0098713795
hyperammonemia B-Disease 2 0.9999771
, O 0 0.0029223794
upon O 0 0.00093737035
the O 0 0.0012552171
development O 0 0.003063896
of O 0 0.007576897
valproate B-Chemical 0 0.99998724
encephalopathy B-Disease 2 0.99995685
is O 0 0.008052693
discussed O 0 0.006561109
. O 0 0.00925682

Fatal O 0 0.9379418
intracranial B-Disease 0 0.99574286
bleeding I-Disease 2 0.9992398
associated O 0 0.015055147
with O 0 0.010396415
prehospital O 0 0.093478374
use O 0 0.011216741
of O 0 0.018091537
epinephrine B-Chemical 1 0.9990972
. O 0 0.02010013

We O 0 0.007387916
present O 0 0.0039538345
a O 0 0.0040170695
case O 0 0.002651972
of O 0 0.0024742559
paramedic O 0 0.00852878
misjudgment O 0 0.13547184
in O 0 0.0010442276
the O 0 0.00089872297
execution O 0 0.0037711922
of O 0 0.0008221505
a O 0 0.00093423243
protocol O 0 0.0007946845
for O 0 0.0004282164
the O 0 0.0005390407
treatment O 0 0.0010062908
of O 0 0.0014718326
allergic B-Disease 2 0.99990034
reaction I-Disease 2 0.49096364
in O 0 0.0012503152
a O 0 0.0015738597
case O 0 0.0013936117
of O 0 0.0026080082
pulmonary B-Disease 0 0.9889904
edema I-Disease 2 0.9998969
with O 0 0.043955665
wheezing B-Disease 0 0.9994091
. O 0 0.013368602

The O 0 0.008307144
sudden O 0 0.91976005
onset O 0 0.011653758
of O 0 0.0049361065
respiratory B-Disease 0 0.98690957
distress I-Disease 0 0.99916315
, O 0 0.020212589
rash B-Disease 2 0.99989295
, O 0 0.0027542033
and O 0 0.0010551941
a O 0 0.0010466938
history O 0 0.0066133467
of O 0 0.00092923443
a O 0 0.0010880132
new O 0 0.0010967469
medicine O 0 0.008167003
led O 0 0.0007742654
the O 0 0.0006364902
two O 0 0.0006255291
paramedics O 0 0.0013697232
on O 0 0.00064470904
the O 0 0.0011006471
scene O 0 0.004451566
to O 0 0.0018012724
administer O 0 0.0053506866
subcutaneous O 0 0.57350856
epinephrine B-Chemical 1 0.9993106
. O 0 0.010457567

Subsequently O 0 0.02011692
, O 0 0.016490804
acute O 0 0.90038395
cardiac B-Disease 2 0.98312855
arrest I-Disease 2 0.9753397
and O 0 0.016641745
fatal O 0 0.9983968
subarachnoid B-Disease 0 0.9997925
hemorrhage I-Disease 2 0.99982136
occurred O 0 0.02473927
. O 0 0.015828043

Epinephrine B-Chemical 1 0.9988637
has O 0 0.0066199936
a O 0 0.0054504974
proven O 0 0.005378348
role O 0 0.0019244802
in O 0 0.001984521
cardiac B-Disease 2 0.94944686
arrest I-Disease 2 0.9453724
in O 0 0.001259176
prehospital O 0 0.08008864
care O 0 0.001820086
; O 0 0.0014053547
however O 0 0.00077213236
, O 0 0.0007292774
use O 0 0.0005272467
by O 0 0.0005590517
paramedics O 0 0.0010256721
in O 0 0.00041638888
patients O 0 0.0013231294
with O 0 0.0007118955
suspected O 0 0.1095432
allergic B-Disease 2 0.9999269
reaction I-Disease 2 0.72529995
and O 0 0.006079544
severe O 0 0.8315731
hypertension B-Disease 2 0.9999368
should O 0 0.0015171764
be O 0 0.0023517043
viewed O 0 0.003079277
with O 0 0.003933594
caution O 0 0.0074174004
. O 0 0.008066523

Role O 0 0.013630526
of O 0 0.007751307
activation O 0 0.008695139
of O 0 0.008632009
bradykinin B-Chemical 1 0.9999254
B2 O 0 0.99688476
receptors O 0 0.41395018
in O 0 0.0018152447
disruption O 0 0.0017147468
of O 0 0.0014915363
the O 0 0.0014599992
blood O 0 0.039733335
- O 0 0.0043596695
brain O 0 0.083198875
barrier O 0 0.022000797
during O 0 0.0032816178
acute O 0 0.9944154
hypertension B-Disease 2 0.9998785
. O 0 0.015070278

Cellular O 0 0.10403606
mechanisms O 0 0.0082689235
which O 0 0.004919555
account O 0 0.0031037813
for O 0 0.0018324886
disruption O 0 0.002065544
the O 0 0.001610246
blood O 0 0.02862781
- O 0 0.0036767512
brain O 0 0.059499934
barrier O 0 0.013537794
during O 0 0.0017308694
acute O 0 0.9881457
hypertension B-Disease 2 0.99991655
are O 0 0.005562949
not O 0 0.004666274
clear O 0 0.0066506797
. O 0 0.00874631

The O 0 0.0070700455
goal O 0 0.0057023806
of O 0 0.003631931
this O 0 0.0024298676
study O 0 0.002128513
was O 0 0.0013053082
to O 0 0.0008672799
determine O 0 0.0004953546
the O 0 0.0007168149
role O 0 0.0005457966
of O 0 0.0011523723
synthesis O 0 0.10568
/ O 0 0.012089651
release O 0 0.058339212
of O 0 0.002147124
bradykinin B-Chemical 1 0.999961
to O 0 0.0011713699
activate O 0 0.00090233574
B2 O 0 0.9742459
receptors O 0 0.1155435
in O 0 0.00069934106
disruption O 0 0.00083318545
of O 0 0.00084414677
the O 0 0.0009374209
blood O 0 0.03291856
- O 0 0.0034268
brain O 0 0.07383844
barrier O 0 0.01943939
during O 0 0.002827911
acute O 0 0.99439514
hypertension B-Disease 2 0.9998864
. O 0 0.014040128

Permeability O 0 0.13078581
of O 0 0.0062920484
the O 0 0.0041747564
blood O 0 0.03073785
- O 0 0.0050691916
brain O 0 0.04885811
barrier O 0 0.0101021575
was O 0 0.0011803332
quantitated O 0 0.0013540927
by O 0 0.0009199398
clearance O 0 0.014582476
of O 0 0.0009770143
fluorescent O 0 0.007509437
- O 0 0.0014859699
labeled O 0 0.0007171025
dextran B-Chemical 1 0.9813679
before O 0 0.0003638808
and O 0 0.0007005455
during O 0 0.00057893404
phenylephrine B-Chemical 1 0.9999776
- O 0 0.0075163483
induced O 0 0.0013596038
acute O 0 0.9934637
hypertension B-Disease 2 0.9999819
in O 0 0.00094402034
rats O 0 0.0035478836
treated O 0 0.00093457516
with O 0 0.0009137409
vehicle O 0 0.13743031
and O 0 0.003025645
Hoe B-Chemical 0 0.9997131
- I-Chemical 0 0.003125251
140 I-Chemical 0 0.0025344265
( O 0 0.0016444494
0 O 0 0.0016914803
. O 0 0.0014221274
1 O 0 0.003020121
microM O 0 0.43930337
) O 0 0.009753397
. O 0 0.007686909

Phenylephrine B-Chemical 0 0.9992705
infusion O 0 0.05050225
increased O 0 0.005299758
arterial O 0 0.5768797
pressure O 0 0.18542625
, O 0 0.0033294002
arteriolar O 0 0.9658867
diameter O 0 0.0066052815
and O 0 0.0013394996
clearance O 0 0.015000493
of O 0 0.0013969557
fluorescent O 0 0.0071246387
dextran B-Chemical 1 0.9925645
by O 0 0.0017689812
a O 0 0.0017477634
similar O 0 0.0011463402
magnitude O 0 0.0016577897
in O 0 0.0025193095
both O 0 0.0039251815
groups O 0 0.008096866
. O 0 0.008628965

These O 0 0.008566415
findings O 0 0.0066614076
suggest O 0 0.0028026975
that O 0 0.0021457206
disruption O 0 0.0021230287
of O 0 0.001687377
the O 0 0.0013606221
blood O 0 0.051167745
- O 0 0.0031199327
brain O 0 0.06295751
barrier O 0 0.012309786
during O 0 0.0006916552
acute O 0 0.98313624
hypertension B-Disease 2 0.9999739
is O 0 0.0010070571
not O 0 0.0005951673
related O 0 0.00046336505
to O 0 0.0005940761
the O 0 0.00085763296
synthesis O 0 0.047081105
/ O 0 0.008543147
release O 0 0.053081352
of O 0 0.0040530693
bradykinin B-Chemical 1 0.99989414
to O 0 0.004159488
activate O 0 0.0047366545
B2 O 0 0.9858958
receptors O 0 0.5195364
. O 0 0.011340422

Risk O 0 0.06946819
factors O 0 0.027118988
of O 0 0.022311011
sensorineural B-Disease 2 0.9995048
hearing I-Disease 2 0.9865194
loss I-Disease 2 0.052923188
in O 0 0.012196385
preterm O 0 0.93679255
infants O 0 0.14415151
. O 0 0.017943103

Among O 0 0.01513763
547 O 0 0.02781947
preterm O 0 0.3578426
infants O 0 0.007278809
of O 0 0.0027436672
< O 0 0.0018795308
or O 0 0.0012386668
= O 0 0.0012937135
34 O 0 0.00086468353
weeks O 0 0.00045314553
gestation O 0 0.0010997064
born O 0 0.0007581844
between O 0 0.00042720383
1987 O 0 0.0060793664
and O 0 0.00073845877
1991 O 0 0.0014301499
, O 0 0.00074520963
8 O 0 0.00050141726
children O 0 0.0010490698
( O 0 0.0008205637
1 O 0 0.00057444547
. O 0 0.0004011587
46 O 0 0.00081385457
% O 0 0.0008007479
) O 0 0.0011577676
developed O 0 0.0012261046
severe O 0 0.11128803
progressive O 0 0.2944134
and O 0 0.0045400043
bilateral O 0 0.7700381
sensorineural B-Disease 2 0.9999329
hearing I-Disease 2 0.99372166
loss I-Disease 2 0.09501225
. O 0 0.00984495

Perinatal O 0 0.13444267
risk O 0 0.02810628
factors O 0 0.008429191
of O 0 0.00362337
infants O 0 0.0041797427
with O 0 0.0022045549
hearing B-Disease 0 0.90717334
loss I-Disease 0 0.0027417904
were O 0 0.0008513068
compared O 0 0.00044287063
with O 0 0.0005781697
those O 0 0.00067297113
of O 0 0.0005636203
two O 0 0.00042745398
control O 0 0.00049783924
groups O 0 0.00063632824
matched O 0 0.00056098023
for O 0 0.00052573095
gestation O 0 0.0019673859
and O 0 0.0010616047
birth O 0 0.0030844281
weight O 0 0.0045911516
and O 0 0.0024931533
for O 0 0.0027691543
perinatal O 0 0.5370927
complications O 0 0.9062584
. O 0 0.01137323

Our O 0 0.008829293
observations O 0 0.006734468
demonstrated O 0 0.004158362
an O 0 0.004133387
association O 0 0.002429804
of O 0 0.003435278
hearing B-Disease 0 0.9062348
loss I-Disease 0 0.004705522
with O 0 0.002332085
a O 0 0.0028910802
higher O 0 0.0023480735
incidence O 0 0.017981226
of O 0 0.006740302
perinatal O 0 0.7952638
complications O 0 0.9489004
. O 0 0.013646613

Ototoxicity B-Disease 0 0.9976593
appeared O 0 0.006500585
closely O 0 0.0034920787
related O 0 0.002178391
to O 0 0.0017299782
a O 0 0.0019654545
prolonged O 0 0.0044075367
administration O 0 0.04389374
and O 0 0.001168295
higher O 0 0.00074449065
total O 0 0.00080552
dose O 0 0.008206502
of O 0 0.0020936572
ototoxic B-Disease 0 0.9997489
drugs O 0 0.96935713
, O 0 0.004472166
particularly O 0 0.0049504936
aminoglycosides B-Chemical 1 0.9913344
and O 0 0.015026904
furosemide B-Chemical 1 0.99989617
. O 0 0.011626575

Finally O 0 0.009026803
, O 0 0.006047634
we O 0 0.0026456984
strongly O 0 0.0024950681
recommend O 0 0.0014799006
to O 0 0.0012322982
prospectively O 0 0.0015932301
and O 0 0.0010179451
regularly O 0 0.00090922747
perform O 0 0.0005539073
audiologic O 0 0.019438416
assessment O 0 0.00059401407
in O 0 0.00051223545
sick O 0 0.0036341767
preterm O 0 0.23895167
children O 0 0.002004138
as O 0 0.00078448356
hearing B-Disease 0 0.89810437
loss I-Disease 0 0.0016288653
is O 0 0.0006253285
of O 0 0.0008438266
delayed O 0 0.0058454257
onset O 0 0.005355612
and O 0 0.0013232739
in O 0 0.0012047563
most O 0 0.002208826
cases O 0 0.0045323134
bilateral O 0 0.13083477
and O 0 0.006494998
severe O 0 0.514439
. O 0 0.010071329

Seizure B-Disease 2 0.9928582
resulting O 0 0.028545698
from O 0 0.023285415
a O 0 0.035320144
venlafaxine B-Chemical 1 0.99964356
overdose B-Disease 2 0.99948186
. O 0 0.0367143

OBJECTIVE O 0 0.44262967
: O 0 0.01619265
To O 0 0.00872783
report O 0 0.0118751805
a O 0 0.009548285
case O 0 0.008930194
of O 0 0.01729016
venlafaxine B-Chemical 1 0.9998857
overdose B-Disease 2 0.9997733
. O 0 0.022540098

CASE O 0 0.36888537
SUMMARY O 0 0.03982498
: O 0 0.008578435
A O 0 0.015121692
40 O 0 0.003991823
- O 0 0.0035709639
year O 0 0.0020584774
- O 0 0.0021765158
old O 0 0.0015374295
woman O 0 0.0062621823
with O 0 0.0014954851
major B-Disease 2 0.008381746
depression I-Disease 2 0.99977666
took O 0 0.0014624378
an O 0 0.0026584575
overdose B-Disease 2 0.99991417
of O 0 0.005050719
venlafaxine B-Chemical 1 0.99994206
in O 0 0.0021803903
an O 0 0.0035998125
apparent O 0 0.004174312
suicide O 0 0.96235245
attempt O 0 0.008677897
. O 0 0.009385761

After O 0 0.0065360754
the O 0 0.0055722315
ingestion O 0 0.09942897
of O 0 0.004460365
26 O 0 0.005437965
venlafaxine B-Chemical 1 0.9998692
50 O 0 0.0044607674
- O 0 0.002938585
mg O 0 0.3273945
tablets O 0 0.8677521
, O 0 0.0019695829
the O 0 0.0013177858
patient O 0 0.002207566
experienced O 0 0.0031225737
a O 0 0.003992377
witnessed O 0 0.07607305
generalized O 0 0.70844346
seizure B-Disease 2 0.9996431
. O 0 0.013582469

She O 0 0.011869042
was O 0 0.006004666
admitted O 0 0.006287578
to O 0 0.0028576127
the O 0 0.0023251837
medical O 0 0.0052763307
intensive O 0 0.0016090667
care O 0 0.0018977978
unit O 0 0.001285552
, O 0 0.0025529782
venlafaxine B-Chemical 1 0.9999144
was O 0 0.0013728119
discontinued O 0 0.016500156
, O 0 0.0015210726
and O 0 0.0013080138
no O 0 0.001240459
further O 0 0.002642359
sequelae O 0 0.6891473
were O 0 0.0053238557
seen O 0 0.0061996877
. O 0 0.00867346

DISCUSSION O 0 0.028669994
: O 0 0.006826266
To O 0 0.0031127334
our O 0 0.0024647452
knowledge O 0 0.0027653368
, O 0 0.0021001317
this O 0 0.0012080605
is O 0 0.0009835262
the O 0 0.000805927
first O 0 0.0006811256
reported O 0 0.001024017
case O 0 0.001057895
of O 0 0.0025758517
venlafaxine B-Chemical 1 0.9999802
overdose B-Disease 2 0.9999392
that O 0 0.0014652146
resulted O 0 0.0016025266
in O 0 0.002189918
a O 0 0.0051026763
generalized O 0 0.6587614
seizure B-Disease 2 0.99965453
. O 0 0.012205161

Based O 0 0.012860345
on O 0 0.004967607
nonoverdose O 0 0.06414035
pharmacokinetics O 0 0.71615696
and O 0 0.0031916862
pharmacodynamics O 0 0.67491364
of O 0 0.0034402723
venlafaxine B-Chemical 1 0.99994814
and O 0 0.0013873476
the O 0 0.00081640814
potential O 0 0.0011460541
risks O 0 0.0094070425
of O 0 0.001227599
available O 0 0.001047906
interventions O 0 0.0014289634
, O 0 0.0014468321
no O 0 0.0010854232
emergent O 0 0.004427098
therapy O 0 0.0205768
was O 0 0.0047688973
instituted O 0 0.011583935
. O 0 0.008563232

CONCLUSIONS O 0 0.5233276
: O 0 0.009686158
The O 0 0.0049615246
venlafaxine B-Chemical 1 0.99980575
overdose B-Disease 2 0.99982363
in O 0 0.0019923039
our O 0 0.0012126087
patient O 0 0.0015721779
resulted O 0 0.000816582
in O 0 0.0007687189
a O 0 0.0010477104
single O 0 0.0009278967
episode O 0 0.0059111193
of O 0 0.0016481243
generalized O 0 0.5037058
seizure B-Disease 2 0.9998505
but O 0 0.0023591397
elicited O 0 0.0028598488
no O 0 0.0024820545
further O 0 0.005648881
sequelae O 0 0.8945092
. O 0 0.01080234

Combined O 0 0.026031787
effects O 0 0.00983466
of O 0 0.00828015
prolonged O 0 0.36215732
prostaglandin B-Chemical 1 0.9999888
E1 I-Chemical 1 0.99979955
- O 0 0.06422671
induced O 0 0.0076982034
hypotension B-Disease 2 0.9999503
and O 0 0.0063123726
haemodilution B-Disease 2 0.9875157
on O 0 0.0025554372
human O 0 0.0065550637
hepatic O 0 0.97524184
function O 0 0.011976368
. O 0 0.010220552

Combined O 0 0.024848057
effects O 0 0.008861047
of O 0 0.007366456
prolonged O 0 0.37289926
prostaglandin B-Chemical 1 0.99999213
E1 I-Chemical 1 0.9998838
( O 0 0.280511
PGE1 B-Chemical 1 0.9999963
) O 0 0.10531464
- O 0 0.0052629393
induced O 0 0.0019488754
hypotension B-Disease 2 0.999969
and O 0 0.001983489
haemodilution B-Disease 2 0.98331314
on O 0 0.0006439151
hepatic O 0 0.9017155
function O 0 0.001177957
were O 0 0.0009050165
studied O 0 0.0010089297
in O 0 0.0010844262
30 O 0 0.0012159963
patients O 0 0.0031059757
undergoing O 0 0.0041368864
hip O 0 0.61922294
surgery O 0 0.021327317
. O 0 0.008952671

The O 0 0.0071286135
patients O 0 0.0067087137
were O 0 0.0032523335
randomly O 0 0.0016700862
allocated O 0 0.0013679032
to O 0 0.0010935726
one O 0 0.0008496228
of O 0 0.0009133631
three O 0 0.000607259
groups O 0 0.0011582336
; O 0 0.0012061938
those O 0 0.0006669165
in O 0 0.00045686515
group O 0 0.00075473066
A O 0 0.047377918
( O 0 0.00076882436
n O 0 0.0005694293
= O 0 0.0006497728
10 O 0 0.00041455336
) O 0 0.0005615804
were O 0 0.0002954975
subjected O 0 0.00022716852
to O 0 0.00031683597
controlled O 0 0.00053964194
hypotension B-Disease 2 0.9999502
alone O 0 0.00090955454
, O 0 0.00074217503
those O 0 0.00052472384
in O 0 0.0003656876
group O 0 0.000755726
B O 0 0.25016913
( O 0 0.0007883072
n O 0 0.00053995085
= O 0 0.00061495585
10 O 0 0.00039279487
) O 0 0.00055884867
to O 0 0.0003261928
haemodilution B-Disease 2 0.9033465
alone O 0 0.00054350874
and O 0 0.0005388747
those O 0 0.00063247135
in O 0 0.0004632856
group O 0 0.0011653845
C O 0 0.9345322
( O 0 0.0011574614
n O 0 0.00081213174
= O 0 0.0009674891
10 O 0 0.0006992352
) O 0 0.001073201
to O 0 0.00074268685
both O 0 0.0011475328
controlled O 0 0.002425349
hypotension B-Disease 2 0.9998518
and O 0 0.008837051
haemodilution B-Disease 2 0.9928437
. O 0 0.009669477

Haemodilution B-Disease 0 0.9674288
in O 0 0.0070536155
groups O 0 0.0064808135
B O 0 0.24477284
and O 0 0.0047749095
C O 0 0.89389914
was O 0 0.0017284751
produced O 0 0.0011503642
by O 0 0.001196225
withdrawing O 0 0.052621033
approximately O 0 0.0007370091
1000 O 0 0.0012409412
mL O 0 0.0013511941
of O 0 0.00055699755
blood O 0 0.0041959886
and O 0 0.0006506571
replacing O 0 0.00088839687
it O 0 0.0005021619
with O 0 0.00040882983
the O 0 0.0003708413
same O 0 0.0002710073
amount O 0 0.00030424987
of O 0 0.0009235541
dextran B-Chemical 1 0.9971769
solution O 0 0.09727
, O 0 0.001497719
and O 0 0.0009288529
final O 0 0.0011137787
haematocrit O 0 0.64735913
values O 0 0.0013058402
were O 0 0.0014764377
21 O 0 0.0020133913
or O 0 0.0022401894
22 O 0 0.0044336384
% O 0 0.005984294
. O 0 0.0069888975

Controlled O 0 0.017105589
hypotension B-Disease 2 0.9993129
in O 0 0.00546609
groups O 0 0.0049991338
A O 0 0.08438775
and O 0 0.0039654407
C O 0 0.93269277
was O 0 0.0019160669
induced O 0 0.0017840066
with O 0 0.002542615
PGE1 B-Chemical 1 0.9999896
to O 0 0.0011046701
maintain O 0 0.0006245268
mean O 0 0.0007481046
arterial O 0 0.25040564
blood O 0 0.008949075
pressure O 0 0.018814214
at O 0 0.0010312614
55 O 0 0.0018779751
mmHg O 0 0.0041304952
for O 0 0.0019176924
180 O 0 0.004546433
min O 0 0.0053656497
. O 0 0.0069851927

Measurements O 0 0.011216043
included O 0 0.0064410227
arterial O 0 0.4830672
ketone O 0 0.99131876
body O 0 0.04788719
ratio O 0 0.005667148
( O 0 0.00709787
AKBR O 0 0.9965888
, O 0 0.0061746775
aceto B-Chemical 0 0.993729
- I-Chemical 0 0.0302614
acetate I-Chemical 0 0.9994025
/ O 0 0.027042624
3 B-Chemical 0 0.0017058589
- I-Chemical 0 0.0036483074
hydroxybutyrate I-Chemical 0 0.9997317
) O 0 0.003593857
and O 0 0.0020522068
clinical O 0 0.016106931
hepatic O 0 0.9260458
function O 0 0.0056517185
parameters O 0 0.009359643
. O 0 0.00850502

AKBR O 0 0.91508967
and O 0 0.007950144
biological O 0 0.0072505963
hepatic O 0 0.7837497
function O 0 0.00323449
tests O 0 0.0031142093
showed O 0 0.0012522604
no O 0 0.0009952432
change O 0 0.0011832347
throughout O 0 0.0008358696
the O 0 0.001053336
time O 0 0.0010953607
course O 0 0.001776953
in O 0 0.0020294162
groups O 0 0.004252289
A O 0 0.14018683
and O 0 0.007876028
B O 0 0.5354205
. O 0 0.011393015

In O 0 0.009032799
group O 0 0.009660682
C O 0 0.9118136
, O 0 0.007430338
AKBR O 0 0.95228887
showed O 0 0.0016868092
a O 0 0.0016748729
significant O 0 0.0011724517
decrease O 0 0.00087488024
at O 0 0.0005731296
120 O 0 0.0007593167
min O 0 0.00073752727
( O 0 0.0009641011
- O 0 0.000841673
40 O 0 0.0005128759
% O 0 0.0005915062
) O 0 0.00067835307
and O 0 0.00041677742
at O 0 0.0003018533
180 O 0 0.0006026596
min O 0 0.0004974389
( O 0 0.0007085067
- O 0 0.0006788665
49 O 0 0.00065631745
% O 0 0.00048603254
) O 0 0.0005160455
after O 0 0.0001939663
the O 0 0.00028765213
start O 0 0.0003139991
of O 0 0.0006887395
hypotension B-Disease 2 0.9999629
and O 0 0.0007302162
at O 0 0.00033002748
60 O 0 0.00040700097
min O 0 0.0004854269
( O 0 0.00071790797
- O 0 0.0006887318
32 O 0 0.00053028075
% O 0 0.0004993582
) O 0 0.00056569016
after O 0 0.00022903517
recovery O 0 0.00070985977
of O 0 0.00078189233
normotension O 0 0.9834567
, O 0 0.0017352015
and O 0 0.003080614
SGOT O 0 0.9999938
, O 0 0.035723776
SGPT O 0 0.99999595
, O 0 0.00840567
LDH O 0 0.9996278
and O 0 0.0012085083
total O 0 0.0013236601
bilirubin B-Chemical 1 0.9993637
showed O 0 0.0014618906
significant O 0 0.0020894054
increases O 0 0.002305145
after O 0 0.002542078
operation O 0 0.0062990673
. O 0 0.0077848737

The O 0 0.0066562416
results O 0 0.004588054
suggest O 0 0.002543955
that O 0 0.0020202307
a O 0 0.0022629986
prolonged O 0 0.0037153773
combination O 0 0.0018541181
of O 0 0.0012361835
more O 0 0.0009924953
than O 0 0.00052972056
120 O 0 0.0007400604
min O 0 0.0006953709
of O 0 0.0013615178
PGE1 B-Chemical 1 0.9999963
- O 0 0.0131042395
induced O 0 0.002396423
hypotension B-Disease 2 0.9999758
and O 0 0.0020985783
moderate O 0 0.060811378
haemodilution B-Disease 2 0.9919233
would O 0 0.001397492
cause O 0 0.012454022
impairment B-Disease 0 0.42655668
of I-Disease 0 0.0051685544
hepatic I-Disease 0 0.98533833
function I-Disease 0 0.011623929
. O 0 0.009004062

Cardiovascular B-Disease 0 0.98994166
alterations I-Disease 0 0.090709314
in O 0 0.009520156
rat O 0 0.016051974
fetuses O 0 0.018307455
exposed O 0 0.0070011658
to O 0 0.009009281
calcium B-Chemical 1 0.99890196
channel O 0 0.9058714
blockers O 0 0.99904436
. O 0 0.018776879

Preclinical O 0 0.28411138
toxicologic O 0 0.112801656
investigation O 0 0.005258522
suggested O 0 0.0026620226
that O 0 0.0018391012
a O 0 0.002518261
new O 0 0.003292668
calcium B-Chemical 1 0.99946564
channel O 0 0.75561804
blocker O 0 0.9969003
, O 0 0.004047735
Ro B-Chemical 0 0.9630485
40 I-Chemical 0 0.0013813219
- I-Chemical 0 0.0013794991
5967 I-Chemical 0 0.0046604024
, O 0 0.0008203576
induced O 0 0.00088384334
cardiovascular B-Disease 0 0.9991541
alterations I-Disease 0 0.12327511
in O 0 0.000976697
rat O 0 0.0055395523
fetuses O 0 0.006302438
exposed O 0 0.0011592926
to O 0 0.001424924
this O 0 0.0021487696
agent O 0 0.18013726
during O 0 0.0043556234
organogenesis O 0 0.5251705
. O 0 0.010576051

The O 0 0.007130622
present O 0 0.0041909055
study O 0 0.0039863363
was O 0 0.002565096
designed O 0 0.0019037476
to O 0 0.0012185611
investigate O 0 0.0007564487
the O 0 0.0010201649
hypothesis O 0 0.0013551415
that O 0 0.001188443
calcium B-Chemical 1 0.9996711
channel O 0 0.7659702
blockers O 0 0.99954164
in O 0 0.0010718144
general O 0 0.0011727443
induce O 0 0.0011659984
cardiovascular B-Disease 0 0.9997758
malformations I-Disease 0 0.9997372
indicating O 0 0.0020893656
a O 0 0.0040217503
pharmacologic O 0 0.45642257
class O 0 0.016601935
effect O 0 0.007281229
. O 0 0.008774496

We O 0 0.008562451
studied O 0 0.006065764
three O 0 0.0040805326
calcium B-Chemical 1 0.9970504
channel O 0 0.55765396
blockers O 0 0.9986261
of O 0 0.002471534
different O 0 0.0013863128
structure O 0 0.002809592
, O 0 0.0055879112
nifedipine B-Chemical 1 0.9999924
, O 0 0.02285347
diltiazem B-Chemical 1 0.99999475
, O 0 0.003418471
and O 0 0.002511614
verapamil B-Chemical 1 0.9999707
, O 0 0.0026351016
along O 0 0.0015539207
with O 0 0.0020709883
the O 0 0.0027705084
new O 0 0.005862614
agent O 0 0.35495386
. O 0 0.010194667

Pregnant O 0 0.14696331
rats O 0 0.009774641
were O 0 0.0039679236
administered O 0 0.0029916936
one O 0 0.0016578062
of O 0 0.0017514217
these O 0 0.002321733
calcium B-Chemical 1 0.9994423
channel O 0 0.6398628
blockers O 0 0.9990013
during O 0 0.0005568781
the O 0 0.0005196668
period O 0 0.0004148269
of O 0 0.00067126396
cardiac O 0 0.5048993
morphogenesis O 0 0.0022736974
and O 0 0.0006839184
the O 0 0.00056441105
offspring O 0 0.0017079732
examined O 0 0.0004668049
on O 0 0.0005049108
day O 0 0.0007212077
20 O 0 0.0009756586
of O 0 0.0014542678
gestation O 0 0.005970604
for O 0 0.0030443377
cardiovascular B-Disease 0 0.999501
malformations I-Disease 0 0.9995189
. O 0 0.013830491

A O 0 0.037212525
low O 0 0.007563591
incidence O 0 0.012216566
of O 0 0.0058701895
cardiovascular B-Disease 0 0.9994898
malformations I-Disease 0 0.99975127
was O 0 0.0018864054
observed O 0 0.00068168057
after O 0 0.00047620255
exposure O 0 0.0010654448
to O 0 0.00047376083
each O 0 0.00032986578
of O 0 0.0005700885
the O 0 0.000558682
four O 0 0.00059945066
calcium B-Chemical 1 0.99945897
channel O 0 0.6720413
blockers O 0 0.9996855
, O 0 0.0016995206
but O 0 0.0006215376
this O 0 0.0005794573
incidence O 0 0.004874585
was O 0 0.0007774434
statistically O 0 0.0008158327
significant O 0 0.0011266855
only O 0 0.0014125165
for O 0 0.0023767937
verapamil B-Chemical 1 0.99994993
and O 0 0.04343917
nifedipine B-Chemical 1 0.99994636
. O 0 0.013419356

All O 0 0.007775885
four O 0 0.0047476776
agents O 0 0.020378299
were O 0 0.0033117929
associated O 0 0.0026176886
with O 0 0.0021829698
aortic O 0 0.3142896
arch O 0 0.4341009
branching O 0 0.044037525
variants O 0 0.0023776689
, O 0 0.0014883248
although O 0 0.00076792
significantly O 0 0.0010773651
increased O 0 0.0011079521
only O 0 0.0009739125
for O 0 0.0011335993
Ro B-Chemical 0 0.92692375
40 I-Chemical 0 0.0028469746
- I-Chemical 0 0.0038963864
5967 I-Chemical 0 0.011477606
and O 0 0.0062008156
verapamil B-Chemical 1 0.99983454
. O 0 0.011043872

The O 0 0.014798708
site O 0 0.0117989285
of O 0 0.011042497
common O 0 0.012055801
side O 0 0.13471334
effects O 0 0.022142148
of O 0 0.042830188
sumatriptan B-Chemical 1 0.9999095
. O 0 0.023810899

Atypical B-Disease 0 0.7835103
sensations I-Disease 0 0.9493728
following O 0 0.004753429
the O 0 0.003119826
use O 0 0.0025325057
of O 0 0.002693527
subcutaneous O 0 0.47079834
sumatriptan B-Chemical 1 0.9999789
are O 0 0.0031191842
common O 0 0.00343287
, O 0 0.003356832
but O 0 0.0025492702
of O 0 0.0039723516
uncertain O 0 0.010135353
origin O 0 0.015669817
. O 0 0.010225759

They O 0 0.01448425
are O 0 0.006967163
almost O 0 0.004600671
always O 0 0.0043340945
benign O 0 0.8610488
, O 0 0.0043161856
but O 0 0.0020775255
can O 0 0.0014307954
be O 0 0.0015601947
mistaken O 0 0.007708388
for O 0 0.001200811
a O 0 0.0022155535
serious O 0 0.2443235
adverse O 0 0.95996827
event O 0 0.044231
by O 0 0.004379046
the O 0 0.0047472673
patient O 0 0.009535128
. O 0 0.009154926

Two O 0 0.010174488
patients O 0 0.008904909
are O 0 0.004809285
presented O 0 0.0038339603
with O 0 0.0036405085
tingling B-Disease 0 0.9935743
or I-Disease 0 0.0034588906
burning I-Disease 0 0.92080164
sensations I-Disease 0 0.9506817
limited O 0 0.0020055508
to O 0 0.0017716155
areas O 0 0.0036507084
of O 0 0.0028643135
heat O 0 0.03535155
exposure O 0 0.029223548
or O 0 0.013226544
sunburn B-Disease 0 0.99941015
. O 0 0.017901646

In O 0 0.008907541
these O 0 0.0074159927
individuals O 0 0.0075539616
, O 0 0.0054490604
side O 0 0.02524429
effects O 0 0.0048862565
are O 0 0.0029604014
most O 0 0.003103495
likely O 0 0.0023275907
generated O 0 0.0023255975
superficially O 0 0.0074126422
in O 0 0.0039406684
the O 0 0.0057564634
skin O 0 0.1936109
. O 0 0.012469126

Macula O 0 0.8423082
toxicity B-Disease 2 0.9876232
after O 0 0.030757304
intravitreal O 0 0.99569607
amikacin B-Chemical 1 0.9986089
. O 0 0.044776976

BACKGROUND O 0 0.60236394
: O 0 0.009143375
Although O 0 0.00414292
intravitreal O 0 0.9820109
aminoglycosides B-Chemical 1 0.98156285
have O 0 0.0019933947
substantially O 0 0.002282927
improved O 0 0.0030707386
visual O 0 0.25947496
prognosis O 0 0.9007347
in O 0 0.0023737494
endophthalmitis B-Disease 0 0.9999192
, O 0 0.07599756
macular O 0 0.99997294
infarction B-Disease 2 0.9999877
may O 0 0.0031572478
impair O 0 0.002407229
full O 0 0.003075978
visual O 0 0.16517192
recovery O 0 0.012882908
. O 0 0.009008139

METHODS O 0 0.010892382
: O 0 0.007299733
We O 0 0.0035860906
present O 0 0.0021074563
a O 0 0.0023807092
case O 0 0.0017082056
of O 0 0.00190713
presumed O 0 0.025010904
amikacin B-Chemical 1 0.99988663
retinal B-Disease 0 0.9981359
toxicity I-Disease 2 0.9998369
following O 0 0.0015621857
treatment O 0 0.002573097
with O 0 0.0017215775
amikacin B-Chemical 1 0.9997534
and O 0 0.0024528191
vancomycin B-Chemical 1 0.99775404
for O 0 0.0017738752
alpha O 0 0.6139079
- O 0 0.023646511
haemolytic O 0 0.99876666
streptococcal B-Disease 0 0.99964094
endophthalmitis I-Disease 0 0.9999324
. O 0 0.03140053

RESULTS O 0 0.036372386
: O 0 0.013541744
Endophthalmitis B-Disease 0 0.9182042
resolved O 0 0.0070839874
with O 0 0.0034303912
improvement O 0 0.003076376
in O 0 0.0023632308
visual O 0 0.14435866
acuity O 0 0.9490655
to O 0 0.0018761166
6 O 0 0.0016333876
/ O 0 0.0030420737
24 O 0 0.0017628621
at O 0 0.0020015035
three O 0 0.0028488296
months O 0 0.0046811136
. O 0 0.007536009

Fundus O 0 0.8887122
fluorescein B-Chemical 1 0.9258184
angiography O 0 0.34704605
confirmed O 0 0.016521785
macular O 0 0.99896276
capillary O 0 0.5004978
closure O 0 0.045999806
and O 0 0.023387391
telangiectasis B-Disease 0 0.99667203
. O 0 0.027313583

CONCLUSIONS O 0 0.47280928
: O 0 0.011017233
Currently O 0 0.006715151
accepted O 0 0.0072398167
intravitreal O 0 0.9829564
antibiotic O 0 0.36219764
regimens O 0 0.06133779
may O 0 0.0037799953
cause O 0 0.06676481
retinal B-Disease 0 0.9984555
toxicity I-Disease 2 0.9998673
and O 0 0.1717353
macular O 0 0.99993956
ischaemia B-Disease 0 0.9999138
. O 0 0.0200265

Treatment O 0 0.03709968
strategies O 0 0.014459815
aimed O 0 0.010364395
at O 0 0.007952209
avoiding O 0 0.014918419
retinal B-Disease 0 0.9910296
toxicity I-Disease 2 0.9993001
are O 0 0.017455261
discussed O 0 0.012961129
. O 0 0.015835667

The O 0 0.011882495
role O 0 0.008173756
of O 0 0.009815492
nicotine B-Chemical 1 0.99818146
in O 0 0.0098613445
smoking O 1 0.98713547
- O 0 0.015008591
related O 0 0.0074076615
cardiovascular B-Disease 0 0.99740726
disease I-Disease 0 0.97766465
. O 0 0.018647386

Nicotine B-Chemical 1 0.9995121
activates O 0 0.008405221
the O 0 0.005477051
sympathetic O 0 0.93806285
nervous O 0 0.9665114
system O 0 0.0049320636
and O 0 0.0025959045
in O 0 0.0018516664
this O 0 0.0018240163
way O 0 0.0023616934
could O 0 0.0019018494
contribute O 0 0.0026662112
to O 0 0.0043184054
cardiovascular B-Disease 0 0.99743646
disease I-Disease 0 0.9720016
. O 0 0.014193307

Animal O 0 0.018319106
studies O 0 0.0063774586
and O 0 0.0042706933
mechanistic O 0 0.0041199536
studies O 0 0.0022609248
indicate O 0 0.0013144829
that O 0 0.001297419
nicotine B-Chemical 1 0.99923337
could O 0 0.0009445912
play O 0 0.0010008886
a O 0 0.0009932134
role O 0 0.0005064267
in O 0 0.00068765454
accelerating O 0 0.01497988
atherosclerosis B-Disease 2 0.9999336
, O 0 0.0025080852
but O 0 0.00063747977
evidence O 0 0.0005865856
among O 0 0.00086623797
humans O 0 0.0018045892
is O 0 0.0006815935
too O 0 0.0007656096
inadequate O 0 0.0011944694
to O 0 0.0007651538
be O 0 0.0010037163
definitive O 0 0.001602259
about O 0 0.001461899
such O 0 0.0024670523
an O 0 0.0051914263
effect O 0 0.0061951857
. O 0 0.008464896

Almost O 0 0.0133310035
certainly O 0 0.0076835016
, O 0 0.005837135
nicotine B-Chemical 1 0.9961015
via O 0 0.0022410771
its O 0 0.002655165
hemodynamic O 0 0.5054233
effects O 0 0.0031041794
contributes O 0 0.00076502614
to O 0 0.0008398095
acute O 0 0.97242314
cardiovascular O 0 0.9992242
events O 0 0.29276016
, O 0 0.0011319924
although O 0 0.00039293643
current O 0 0.0006349703
evidence O 0 0.00034642528
suggests O 0 0.00022320471
that O 0 0.00027000095
the O 0 0.0003485356
effects O 0 0.00082332763
of O 0 0.0009999365
nicotine B-Chemical 1 0.9996182
are O 0 0.0006047298
much O 0 0.000330657
less O 0 0.00034586826
important O 0 0.00030277474
than O 0 0.00029145507
are O 0 0.00043383014
the O 0 0.00047543788
prothrombotic O 0 0.82743037
effects O 0 0.0016037753
of O 0 0.0014014335
cigarette O 0 0.9627774
smoking O 1 0.9804977
or O 0 0.0016150214
the O 0 0.0017437198
effects O 0 0.004353821
of O 0 0.006448833
carbon B-Chemical 0 0.98923886
monoxide I-Chemical 0 0.99957055
. O 0 0.012411762

Nicotine B-Chemical 1 0.9990495
does O 0 0.012314646
not O 0 0.008896302
appear O 0 0.0075871265
to O 0 0.006937134
enhance O 0 0.007303355
thrombosis B-Disease 2 0.9990101
among O 0 0.019305566
humans O 0 0.043492585
. O 0 0.016899949

Clinical O 0 0.030845633
studies O 0 0.0062256395
of O 0 0.0047162604
pipe O 0 0.14480378
smokers O 0 0.17798778
and O 0 0.0025749574
people O 0 0.00446933
using O 0 0.001362786
transdermal O 0 0.9987501
nicotine B-Chemical 1 0.9995473
support O 0 0.00091604225
the O 0 0.00064140203
idea O 0 0.00079103385
that O 0 0.00050013367
toxins O 0 0.18709709
other O 0 0.00087493024
than O 0 0.00066548947
nicotine B-Chemical 1 0.999121
are O 0 0.0009177352
the O 0 0.00074370566
most O 0 0.0011178065
important O 0 0.0009361597
causes O 0 0.0031746754
of O 0 0.004337861
acute O 0 0.9943257
cardiovascular O 0 0.9993224
events O 0 0.5999642
. O 0 0.010910568

Finally O 0 0.008841845
, O 0 0.0060734944
the O 0 0.0032913194
dose O 0 0.006604916
response O 0 0.0026168234
for O 0 0.0013873734
cardiovascular O 0 0.9910239
events O 0 0.12096552
of O 0 0.0026324778
nicotine B-Chemical 1 0.99974996
appears O 0 0.00074651756
to O 0 0.0005590927
be O 0 0.00060365815
flat O 0 0.003236531
, O 0 0.0006951158
suggesting O 0 0.00032792645
that O 0 0.00034942443
if O 0 0.0004281219
nicotine B-Chemical 1 0.9992717
is O 0 0.0006983135
involved O 0 0.00055523304
, O 0 0.00094685017
adverse O 0 0.7997343
effects O 0 0.0014838509
might O 0 0.0005107577
be O 0 0.000726744
seen O 0 0.0006859737
with O 0 0.0010099717
relatively O 0 0.0015561144
low O 0 0.0024730982
- O 0 0.0037938247
level O 0 0.0024496382
cigarette O 0 0.8899176
exposures O 0 0.31087407
. O 0 0.010615652

Iatrogenically O 0 0.7615527
induced O 0 0.010396666
intractable O 0 0.9676359
atrioventricular B-Disease 0 0.98401695
reentrant I-Disease 0 0.98767686
tachycardia I-Disease 2 0.9999013
after O 0 0.0016966461
verapamil B-Chemical 1 0.9999559
and O 0 0.0015112925
catheter O 0 0.0031460722
ablation O 0 0.0015135084
in O 0 0.0006909809
a O 0 0.0010185995
patient O 0 0.0013694525
with O 0 0.0014810608
Wolff B-Disease 0 0.92317134
- I-Disease 0 0.009859334
Parkinson I-Disease 0 0.99986017
- I-Disease 0 0.009320191
White I-Disease 0 0.27018315
syndrome I-Disease 0 0.8839954
and O 0 0.008091116
idiopathic B-Disease 0 0.9993606
dilated I-Disease 2 0.99924123
cardiomyopathy I-Disease 2 0.99997556
. O 0 0.01928072

In O 0 0.008498158
a O 0 0.007430669
patient O 0 0.006767023
with O 0 0.0059276093
WPW B-Disease 0 0.9998815
syndrome I-Disease 0 0.9967765
and O 0 0.012550568
idiopathic B-Disease 0 0.9995233
dilated I-Disease 2 0.9995005
cardiomyopathy I-Disease 2 0.9999968
, O 0 0.033011977
intractable O 0 0.99238366
atrioventricular B-Disease 0 0.99025494
reentrant I-Disease 0 0.992432
tachycardia I-Disease 2 0.99995375
( O 0 0.023676593
AVRT B-Disease 0 0.99932885
) O 0 0.0064423135
was O 0 0.0038722055
iatrogenically O 0 0.58886427
induced O 0 0.009328991
. O 0 0.010614495

QRS O 0 0.8471216
without O 0 0.008298549
preexcitation O 0 0.98988265
, O 0 0.0047523254
caused O 0 0.0025168206
by O 0 0.0020897943
junctional O 0 0.017534887
escape O 0 0.0075820903
beats O 0 0.7407417
after O 0 0.0007922265
verapamil B-Chemical 1 0.9999614
or O 0 0.00089124433
unidirectional O 0 0.0021033129
antegrade O 0 0.0076718545
block O 0 0.00081158587
of O 0 0.0007266814
accessory O 0 0.0011632341
pathway O 0 0.00092688325
after O 0 0.0005041955
catheter O 0 0.002331114
ablation O 0 0.0024483884
, O 0 0.002246002
established O 0 0.0031209134
frequent O 0 0.04667189
AVRT B-Disease 0 0.9992692
attack O 0 0.80316186
. O 0 0.010699964

Epidemic O 0 0.19507572
of O 0 0.012120408
liver B-Disease 2 0.9829752
disease I-Disease 2 0.98082614
caused O 0 0.00812371
by O 0 0.0054894253
hydrochlorofluorocarbons B-Chemical 0 0.8563584
used O 0 0.0029026126
as O 0 0.0035736912
ozone B-Chemical 0 0.99349535
- O 0 0.009728936
sparing O 0 0.068802826
substitutes O 0 0.01608304
of O 0 0.009623753
chlorofluorocarbons B-Chemical 0 0.9531448
. O 0 0.01203658

BACKGROUND O 0 0.7677331
: O 0 0.01588742
Hydrochlorofluorocarbons B-Chemical 0 0.66524047
( O 0 0.008853496
HCFCs B-Chemical 0 0.84882396
) O 0 0.0048361565
are O 0 0.0019182457
used O 0 0.0013671466
increasingly O 0 0.0020148521
in O 0 0.0012505667
industry O 0 0.02261404
as O 0 0.0014575175
substitutes O 0 0.0051864795
for O 0 0.0016136987
ozone B-Chemical 0 0.9940103
- O 0 0.011006235
depleting O 0 0.101976775
chlorofluorocarbons B-Chemical 0 0.97427636
( O 0 0.016949179
CFCs B-Chemical 0 0.8946361
) O 0 0.014424405
. O 0 0.00892903

Limited O 0 0.055786796
studies O 0 0.009413248
in O 0 0.0060384683
animals O 0 0.0046480168
indicate O 0 0.0037696518
potential O 0 0.007409738
hepatotoxicity B-Disease 2 0.9999348
of O 0 0.0072342977
some O 0 0.0054168613
of O 0 0.006539912
these O 0 0.010252849
compounds O 0 0.8926303
. O 0 0.01377552

We O 0 0.00788332
investigated O 0 0.0047798133
an O 0 0.0052715978
epidemic O 0 0.0113190785
of O 0 0.004028307
liver B-Disease 2 0.9918357
disease I-Disease 2 0.98382735
in O 0 0.0016449052
nine O 0 0.001393844
industrial O 0 0.16070953
workers O 0 0.0024314818
who O 0 0.0011865777
had O 0 0.00046384963
had O 0 0.00040974532
repeated O 0 0.0005010859
accidental O 0 0.50638103
exposure O 0 0.0014084793
to O 0 0.00044790533
a O 0 0.0006751132
mixture O 0 0.0012378802
of O 0 0.0008611229
1 B-Chemical 0 0.0007946754
, I-Chemical 0 0.0007994796
1 I-Chemical 0 0.0006766278
- I-Chemical 0 0.0012609919
dichloro I-Chemical 0 0.95711786
- I-Chemical 0 0.0014896153
2 I-Chemical 0 0.0005148708
, I-Chemical 0 0.00058255286
2 I-Chemical 0 0.0004495236
, I-Chemical 0 0.0005713369
2 I-Chemical 0 0.00050827034
- I-Chemical 0 0.00083811546
trifluoroethane I-Chemical 0 0.04847598
( O 0 0.0014139693
HCFC B-Chemical 0 0.9936753
123 I-Chemical 0 0.19956565
) O 0 0.0011784979
and O 0 0.00066934753
1 B-Chemical 0 0.00080675835
- I-Chemical 0 0.0015962033
chloro I-Chemical 0 0.99441886
- I-Chemical 0 0.002158803
1 I-Chemical 0 0.000758686
, I-Chemical 0 0.0008065853
2 I-Chemical 0 0.0006567627
, I-Chemical 0 0.0008572653
2 I-Chemical 0 0.0007999479
, I-Chemical 0 0.0011581469
2 I-Chemical 0 0.0012680249
- I-Chemical 0 0.0025024463
tetrafluoroethane I-Chemical 0 0.59622884
( O 0 0.00732071
HCFC B-Chemical 0 0.9934202
124 I-Chemical 0 0.18753691
) O 0 0.011151267
. O 0 0.008186183

All O 0 0.016169682
nine O 0 0.012857173
exposed O 0 0.010375361
workers O 0 0.013723682
were O 0 0.009058902
affected O 0 0.007860684
to O 0 0.008389216
various O 0 0.014948559
degrees O 0 0.04868397
. O 0 0.018260773

Both O 0 0.011236293
compounds O 0 0.45273456
are O 0 0.006190737
metabolised O 0 0.6967258
in O 0 0.001939781
the O 0 0.001347008
same O 0 0.0008469054
way O 0 0.0011666408
as O 0 0.0010646448
1 B-Chemical 0 0.0013344288
- I-Chemical 0 0.002614538
bromo I-Chemical 0 0.99825746
- I-Chemical 0 0.004168029
1 I-Chemical 0 0.0010605996
- I-Chemical 0 0.0019727787
chloro I-Chemical 0 0.995799
- I-Chemical 0 0.0021612884
2 I-Chemical 0 0.0006152085
, I-Chemical 0 0.0006630891
2 I-Chemical 0 0.0004921842
, I-Chemical 0 0.0006128399
2 I-Chemical 0 0.0005368525
- I-Chemical 0 0.0008899248
trifluoroethane I-Chemical 0 0.059152722
( O 0 0.0016651516
halothane B-Chemical 1 0.9997003
) O 0 0.0015579173
to O 0 0.0004988135
form O 0 0.00074120384
reactive O 0 0.5684792
trifluoroacetyl B-Chemical 0 0.996214
halide O 0 0.9737318
intermediates O 0 0.19238757
, O 0 0.0016959631
which O 0 0.0010890379
have O 0 0.0008599176
been O 0 0.0011799785
implicated O 0 0.0012106155
in O 0 0.0016376075
the O 0 0.0033735102
hepatotoxicity B-Disease 2 0.9999696
of O 0 0.037083182
halothane B-Chemical 1 0.9996358
. O 0 0.012049362

We O 0 0.0096548665
aimed O 0 0.0064541567
to O 0 0.0044469945
test O 0 0.00407177
whether O 0 0.002352059
HCFCs B-Chemical 0 0.74857926
123 I-Chemical 0 0.03042161
and I-Chemical 0 0.0026516693
124 I-Chemical 0 0.0060809623
can O 0 0.0018411943
result O 0 0.0023631183
in O 0 0.0034118108
serious O 0 0.67250985
liver B-Disease 2 0.9977156
disease I-Disease 2 0.99638593
. O 0 0.01738642

METHODS O 0 0.011274872
: O 0 0.0077736555
For O 0 0.0036108473
one O 0 0.0030018531
severely O 0 0.0059060357
affected O 0 0.0020011456
worker O 0 0.0050792033
liver O 0 0.80391693
biopsy O 0 0.025722902
and O 0 0.0015226012
immunohistochemical O 0 0.0057420763
stainings O 0 0.004244083
for O 0 0.0008721402
the O 0 0.0010604379
presence O 0 0.001285571
of O 0 0.0030761668
trifluoroacetyl B-Chemical 0 0.98750263
protein O 0 0.01797055
adducts O 0 0.8700695
were O 0 0.006076405
done O 0 0.0058904346
. O 0 0.008175459

The O 0 0.0077040815
serum O 0 0.015375221
of O 0 0.004090044
six O 0 0.0020881272
affected O 0 0.0018404542
workers O 0 0.002730373
and O 0 0.0012084416
five O 0 0.0006644586
controls O 0 0.0012828001
was O 0 0.0006335944
tested O 0 0.00043981022
for O 0 0.0004550662
autoantibodies O 0 0.13546208
that O 0 0.00055827154
react O 0 0.0015176724
with O 0 0.00077535555
human O 0 0.0019971316
liver O 0 0.9910789
cytochrome O 0 0.9997222
- O 0 0.06993351
P450 O 0 0.99993074
2E1 O 0 0.99999
( O 0 0.03971882
P450 O 0 0.99990714
2E1 O 0 0.999982
) O 0 0.007984368
and O 0 0.0016940872
P58 O 0 0.5041451
protein O 0 0.0069752173
disulphide O 0 0.99353915
isomerase O 0 0.9951351
isoform O 0 0.032869443
( O 0 0.014448314
P58 O 0 0.66515976
) O 0 0.014499866
. O 0 0.008926364

FINDINGS O 0 0.07862911
: O 0 0.008394184
The O 0 0.0041142316
liver O 0 0.30936617
biopsy O 0 0.011117882
sample O 0 0.0028800126
showed O 0 0.0023518475
hepatocellular O 0 0.99997747
necrosis B-Disease 2 0.9999087
which O 0 0.0045647384
was O 0 0.0011081962
prominent O 0 0.0033512432
in O 0 0.00077952916
perivenular O 0 0.9196738
zone O 0 0.0018679084
three O 0 0.00040402595
and O 0 0.00060754665
extended O 0 0.00049878977
focally O 0 0.03272844
from O 0 0.00064292655
portal O 0 0.03149374
tracts O 0 0.0017403514
to O 0 0.00067290885
portal O 0 0.042762075
tracts O 0 0.0034189878
and O 0 0.0019244098
centrilobular O 0 0.9925356
areas O 0 0.011736014
( O 0 0.004912633
bridging O 0 0.055318266
necrosis B-Disease 2 0.9982651
) O 0 0.037003312
. O 0 0.009813412

Trifluoroacetyl B-Chemical 0 0.90559894
- O 0 0.025275486
adducted O 0 0.028118538
proteins O 0 0.012372796
were O 0 0.009103683
detected O 0 0.0070398524
in O 0 0.009074025
surviving O 0 0.026547736
hepatocytes O 0 0.5740799
. O 0 0.019123277

Autoantibodies O 0 0.2602828
against O 0 0.010088316
P450 O 0 0.9994079
2E1 O 0 0.99992263
or O 0 0.008441351
P58 O 0 0.7822763
, O 0 0.0027541625
previously O 0 0.0013809734
associated O 0 0.0016504279
with O 0 0.0026523
halothane B-Disease 1 0.9999558
hepatitis I-Disease 2 0.9999871
, O 0 0.009121478
were O 0 0.0012459565
detected O 0 0.00078025594
in O 0 0.0010419406
the O 0 0.0013914924
serum O 0 0.037721884
of O 0 0.0029221086
five O 0 0.002739812
affected O 0 0.0046303156
workers O 0 0.01736209
. O 0 0.008937228

INTERPRETATION O 0 0.06565258
: O 0 0.008525091
Repeated O 0 0.010646381
exposure O 0 0.0042761755
of O 0 0.00272701
human O 0 0.002700738
beings O 0 0.01611399
to O 0 0.0016187339
HCFCs B-Chemical 0 0.8892976
123 I-Chemical 0 0.030721586
and I-Chemical 0 0.0010035943
124 I-Chemical 0 0.002992416
can O 0 0.00051276595
result O 0 0.0006077439
in O 0 0.0007162491
serious O 0 0.35568008
liver B-Disease 2 0.99635893
injury I-Disease 2 0.9971522
in O 0 0.0012059566
a O 0 0.0014862756
large O 0 0.0012899694
proportion O 0 0.0011883671
of O 0 0.002136649
the O 0 0.0027167506
exposed O 0 0.004256072
population O 0 0.012535119
. O 0 0.008688167

Although O 0 0.0065344893
the O 0 0.0046109506
exact O 0 0.004596996
mechanism O 0 0.003256976
of O 0 0.0040895008
hepatotoxicity B-Disease 2 0.9999778
of O 0 0.003171653
these O 0 0.0019173584
agents O 0 0.22654764
is O 0 0.0010001966
not O 0 0.0007430844
known O 0 0.0010233505
, O 0 0.0009648536
the O 0 0.00058737444
results O 0 0.000694647
suggest O 0 0.0006112826
that O 0 0.0012110417
trifluoroacetyl B-Chemical 0 0.9914725
- O 0 0.0076687224
altered O 0 0.0031549255
liver O 0 0.9316354
proteins O 0 0.009705462
are O 0 0.005917713
involved O 0 0.0062311473
. O 0 0.008615031

In O 0 0.007687899
view O 0 0.0064556645
of O 0 0.0040513775
the O 0 0.002783989
potentially O 0 0.0034194102
widespread O 0 0.0033178078
use O 0 0.001627741
of O 0 0.0015284357
these O 0 0.00179283
compounds O 0 0.703308
, O 0 0.0018224637
there O 0 0.0007386414
is O 0 0.0009782662
an O 0 0.0014174018
urgent O 0 0.002242085
need O 0 0.0015288121
to O 0 0.0019491154
develop O 0 0.003533422
safer O 0 0.010828112
alternatives O 0 0.008740186
. O 0 0.008885311

Bile B-Disease 0 0.985023
duct I-Disease 0 0.836553
hamartoma I-Disease 0 0.98550075
occurring O 0 0.009175244
in O 0 0.004173597
association O 0 0.003018034
with O 0 0.0035183874
long O 0 0.003989649
- O 0 0.005173932
term O 0 0.0037340773
treatment O 0 0.0082282815
with O 0 0.013386676
danazol B-Chemical 1 0.99976605
. O 0 0.016827976

We O 0 0.008630141
report O 0 0.007832354
a O 0 0.0048710685
case O 0 0.003215041
of O 0 0.0034284077
bile B-Disease 0 0.94872004
duct I-Disease 0 0.94828427
hamartoma I-Disease 0 0.9976908
which O 0 0.0027668667
developed O 0 0.0018339438
in O 0 0.00094207056
a O 0 0.0012353854
patient O 0 0.0014009872
who O 0 0.0017411957
had O 0 0.0010419621
been O 0 0.0012439489
on O 0 0.001027429
long O 0 0.0021182983
- O 0 0.0040377784
term O 0 0.0042716055
danazol B-Chemical 1 0.9997943
treatment O 0 0.040574286
. O 0 0.011289223

Such O 0 0.012483545
patients O 0 0.008597004
should O 0 0.0033811084
be O 0 0.00294695
under O 0 0.0018164079
close O 0 0.0017056533
follow O 0 0.0015642131
- O 0 0.0022434136
up O 0 0.0013112675
, O 0 0.0015728364
preferably O 0 0.0014819609
with O 0 0.0013928396
periodic O 0 0.004802354
ultrasound O 0 0.021010397
examination O 0 0.0036862304
of O 0 0.0041362247
the O 0 0.0059732925
liver O 0 0.9463426
. O 0 0.012070507

If O 0 0.0067910254
the O 0 0.004925674
patient O 0 0.0048963875
develops O 0 0.0062664095
a O 0 0.0037327148
liver B-Disease 0 0.9742778
mass I-Disease 0 0.13504845
, O 0 0.0018018675
because O 0 0.0006777582
of O 0 0.000912842
non O 0 0.0026590961
- O 0 0.0013183382
specific O 0 0.00046840287
clinical O 0 0.00269094
features O 0 0.0013161435
and O 0 0.0009096373
imaging O 0 0.005888597
appearances O 0 0.022270339
, O 0 0.0010446934
biopsy O 0 0.0029897883
may O 0 0.00066868315
be O 0 0.00072056946
the O 0 0.0006964447
only O 0 0.0008194763
way O 0 0.0012536662
to O 0 0.0011922404
achieve O 0 0.0014151583
a O 0 0.0031811362
definitive O 0 0.005866918
diagnosis O 0 0.047088895
. O 0 0.009648423

Endocrine O 0 0.7193401
screening O 0 0.009391707
in O 0 0.0052166996
1 O 0 0.0044131437
, O 0 0.0044167866
022 O 0 0.3973233
men O 0 0.071493015
with O 0 0.0025516064
erectile B-Disease 0 0.99969053
dysfunction I-Disease 0 0.9837818
: O 0 0.0036219317
clinical O 0 0.0066359052
significance O 0 0.0025006935
and O 0 0.0026094548
cost O 0 0.004662725
- O 0 0.005205349
effective O 0 0.004760931
strategy O 0 0.007399735
. O 0 0.008861805

PURPOSE O 0 0.027156996
: O 0 0.008010773
We O 0 0.0039597545
reviewed O 0 0.0037409905
the O 0 0.0021040435
results O 0 0.0018318099
of O 0 0.0024967089
serum O 0 0.6097415
testosterone B-Chemical 1 0.99994814
and O 0 0.0055306624
prolactin O 0 0.9974178
determination O 0 0.0033286596
in O 0 0.0007602039
1 O 0 0.000835216
, O 0 0.00089504145
022 O 0 0.30578274
patients O 0 0.000890091
referred O 0 0.00043429458
because O 0 0.00031145418
of O 0 0.0007404548
erectile B-Disease 0 0.999879
dysfunction I-Disease 0 0.96851873
and O 0 0.0006479454
compared O 0 0.0002597626
the O 0 0.00036146838
data O 0 0.00050108496
with O 0 0.00046254115
history O 0 0.020932065
, O 0 0.00067792804
results O 0 0.00040462843
of O 0 0.00058380765
physical O 0 0.019069541
examination O 0 0.0010315949
, O 0 0.00065918255
other O 0 0.00042572565
etiological O 0 0.11578002
investigations O 0 0.0011551442
and O 0 0.0005847048
effects O 0 0.0010427991
of O 0 0.0009591549
endocrine O 0 0.96718293
therapy O 0 0.012865631
to O 0 0.00043983577
refine O 0 0.0008485095
the O 0 0.00041030138
rules O 0 0.00071275973
of O 0 0.00071298255
cost O 0 0.002015608
- O 0 0.0015214043
effective O 0 0.0009108104
endocrine O 0 0.8969989
screening O 0 0.0013967342
and O 0 0.0009766344
to O 0 0.00082635874
pinpoint O 0 0.0013716036
actual O 0 0.0014374821
responsibility O 0 0.005671868
for O 0 0.002556068
hormonal O 0 0.8921145
abnormalities O 0 0.607621
. O 0 0.009801039

MATERIALS O 0 0.047521375
AND O 0 0.018564297
METHODS O 0 0.016727721
: O 0 0.0191709
Testosterone B-Chemical 1 0.9987703
and O 0 0.013972741
prolactin O 0 0.97979236
were O 0 0.009508675
determined O 0 0.007845018
by O 0 0.012687466
radioimmunoassay O 0 0.6263356
. O 0 0.01648308

Every O 0 0.009440017
patient O 0 0.006929425
was O 0 0.0040000784
screened O 0 0.003122084
for O 0 0.0023607395
testosterone B-Chemical 1 0.9995932
and O 0 0.0029441854
451 O 0 0.047616307
were O 0 0.0009004218
screened O 0 0.00079799053
for O 0 0.0005924549
prolactin O 0 0.93831915
on O 0 0.00040718535
the O 0 0.00046641397
basis O 0 0.00052969885
of O 0 0.0007611299
low B-Disease 2 0.0022817205
sexual I-Disease 2 0.7769194
desire I-Disease 2 0.6743566
, O 0 0.0039099758
gynecomastia B-Disease 0 0.9998091
or O 0 0.0024958542
testosterone B-Chemical 1 0.999851
less O 0 0.0013009128
than O 0 0.00096938014
4 O 0 0.0014403117
ng O 0 0.0040453905
. O 0 0.0024287847
/ O 0 0.0075497697
ml O 0 0.013184822
. O 0 0.008186238

Determination O 0 0.019960329
was O 0 0.010421869
repeated O 0 0.007932856
in O 0 0.0070877117
case O 0 0.0071453047
of O 0 0.008318224
abnormal O 0 0.021913538
first O 0 0.00855118
results O 0 0.013068921
. O 0 0.015899258

Prolactin O 0 0.99402833
results O 0 0.006669171
were O 0 0.0038928736
compared O 0 0.0019460557
with O 0 0.0018230495
those O 0 0.0016765639
of O 0 0.0013338131
a O 0 0.0013236764
previous O 0 0.00089594425
personal O 0 0.0045052078
cohort O 0 0.0019933633
of O 0 0.0010809076
1 O 0 0.0010784977
, O 0 0.0011526594
340 O 0 0.004949345
patients O 0 0.0017044068
with O 0 0.0015562752
erectile B-Disease 0 0.9997689
dysfunction I-Disease 0 0.9793687
and O 0 0.0042683803
systematic O 0 0.0061723636
prolactin O 0 0.99273646
determination O 0 0.015430492
. O 0 0.009476596

Main O 0 0.03929506
clinical O 0 0.0112180365
criteria O 0 0.0048785396
tested O 0 0.002540589
regarding O 0 0.0020624541
efficiency O 0 0.0022979195
in O 0 0.0022260416
hormone O 0 0.955938
determination O 0 0.0042116866
were O 0 0.0019573392
low B-Disease 2 0.0036419427
sexual I-Disease 2 0.6652051
desire I-Disease 2 0.4221635
, O 0 0.0036692515
small O 0 0.0035848045
testes O 0 0.045275494
and O 0 0.0100469515
gynecomastia B-Disease 0 0.99937075
. O 0 0.014071589

Endocrine O 0 0.7414521
therapy O 0 0.0172131
consisted O 0 0.0053357193
of O 0 0.0069305208
testosterone B-Chemical 1 0.9998667
heptylate I-Chemical 0 0.89418226
or O 0 0.0030856968
human O 0 0.004792478
chorionic O 0 0.9972234
gonadotropin O 0 0.99972266
for O 0 0.0059512607
hypogonadism B-Disease 0 0.99994373
and O 0 0.07568427
bromocriptine B-Chemical 1 0.9999695
for O 0 0.019964514
hyperprolactinemia B-Disease 2 0.99994564
. O 0 0.017089026

RESULTS O 0 0.050412185
: O 0 0.01665141
Testosterone B-Chemical 1 0.9993444
was O 0 0.0038535988
less O 0 0.0022886598
than O 0 0.0013828354
3 O 0 0.0012819628
ng O 0 0.0026329912
. O 0 0.00092109654
/ O 0 0.0018355586
ml O 0 0.0021487367
. O 0 0.00062878215
in O 0 0.0006161025
107 O 0 0.0011744989
patients O 0 0.0014670442
but O 0 0.00088029454
normal O 0 0.0015320888
in O 0 0.0011627343
40 O 0 0.0016652532
% O 0 0.0021519605
at O 0 0.0020277894
repeat O 0 0.004714984
determination O 0 0.008599036
. O 0 0.008637809

The O 0 0.007586282
prevalence O 0 0.00642859
of O 0 0.004528384
repeatedly O 0 0.004490853
low O 0 0.0049449466
testosterone B-Chemical 1 0.9997687
increased O 0 0.0033234481
with O 0 0.0017330361
age O 0 0.005514128
( O 0 0.0015964152
4 O 0 0.00069247035
% O 0 0.0007076804
before O 0 0.00041361744
age O 0 0.0010777448
50 O 0 0.0009429461
years O 0 0.0010069386
and O 0 0.00097014196
9 O 0 0.001110157
% O 0 0.0014017653
50 O 0 0.0018170695
years O 0 0.0024514494
or O 0 0.0028350519
older O 0 0.013478652
) O 0 0.009956277
. O 0 0.008071798

Two O 0 0.029237695
pituitary B-Disease 0 0.9728214
tumors I-Disease 2 0.9878136
were O 0 0.015344844
discovered O 0 0.014414111
after O 0 0.011087667
testosterone B-Chemical 1 0.99869746
determination O 0 0.04816168
. O 0 0.020478766

Most O 0 0.010974198
of O 0 0.005951636
the O 0 0.00389091
other O 0 0.0032079846
low O 0 0.0049843695
testosterone B-Chemical 1 0.9998271
levels O 0 0.0020718125
seemed O 0 0.0013937796
to O 0 0.0008032367
result O 0 0.0008632877
from O 0 0.0011016022
nonorganic O 0 0.99966407
hypothalamic B-Disease 0 0.9943745
dysfunction I-Disease 0 0.9963781
because O 0 0.00056028494
of O 0 0.0009331124
normal O 0 0.0064121797
serum O 0 0.65220404
luteinizing O 0 0.9994822
hormone O 0 0.9976846
and O 0 0.0029680862
prolactin O 0 0.9968957
and O 0 0.0007379037
to O 0 0.0003909423
have O 0 0.00032107023
only O 0 0.0003378451
a O 0 0.00049416756
small O 0 0.00046555043
role O 0 0.00031789768
in O 0 0.0005616367
erectile B-Disease 0 0.99989474
dysfunction I-Disease 0 0.989129
( O 0 0.0015189716
definite O 0 0.013359076
improvement O 0 0.0005632387
in O 0 0.00030989383
only O 0 0.0003105323
16 O 0 0.00035240114
of O 0 0.00039791103
44 O 0 0.00082934654
[ O 0 0.0009620503
36 O 0 0.00046228638
% O 0 0.00054091646
] O 0 0.0007936206
after O 0 0.00030797257
androgen O 0 0.9988354
therapy O 0 0.017333347
, O 0 0.0008346603
normal O 0 0.00087372557
morning O 0 0.0018089941
or O 0 0.0004969669
nocturnal O 0 0.38871926
erections O 0 0.974326
in O 0 0.00061036483
30 O 0 0.0005243249
% O 0 0.00075802
and O 0 0.00087611435
definite O 0 0.018464252
vasculogenic O 0 0.97948074
contributions O 0 0.0035320136
in O 0 0.0024237286
42 O 0 0.004573506
% O 0 0.005250402
) O 0 0.008735199
. O 0 0.00770811

Determining O 0 0.014493095
testosterone B-Chemical 1 0.99794394
only O 0 0.004205853
in O 0 0.0025394724
cases O 0 0.0028402251
of O 0 0.0020267759
low B-Disease 2 0.003462693
sexual I-Disease 2 0.63821095
desire I-Disease 2 0.31104302
or O 0 0.0009899352
abnormal O 0 0.018295933
physical O 0 0.015655784
examination O 0 0.0009690768
would O 0 0.0004223575
have O 0 0.0004036789
missed O 0 0.0009186601
40 O 0 0.0004940201
% O 0 0.00044791258
of O 0 0.00041544865
the O 0 0.00043260958
cases O 0 0.0009484617
with O 0 0.0007076099
low O 0 0.0018403849
testosterone B-Chemical 1 0.9999193
, O 0 0.00147027
including O 0 0.00069335266
37 O 0 0.0009756734
% O 0 0.00085556635
of O 0 0.00091789704
those O 0 0.0015127626
subsequently O 0 0.0021811612
improved O 0 0.0037205187
by O 0 0.005138368
androgen O 0 0.999276
therapy O 0 0.21236385
. O 0 0.009889446

Prolactin O 0 0.9920106
exceeded O 0 0.0066049844
20 O 0 0.0045355135
ng O 0 0.006510565
. O 0 0.002330628
/ O 0 0.0034922557
ml O 0 0.003802781
. O 0 0.0012173279
in O 0 0.0011110192
5 O 0 0.0011037783
men O 0 0.014793113
and O 0 0.0013965565
was O 0 0.0013307222
normal O 0 0.0021626493
in O 0 0.0016969249
2 O 0 0.0022389358
at O 0 0.002280861
repeat O 0 0.0052424856
determination O 0 0.009360466
. O 0 0.009140353

Only O 0 0.046838902
1 O 0 0.041861616
prolactinoma B-Disease 2 0.9948201
was O 0 0.037996203
discovered O 0 0.04071715
. O 0 0.03740824

These O 0 0.009132755
data O 0 0.006659023
are O 0 0.0039810943
lower O 0 0.0027272396
than O 0 0.0014967417
those O 0 0.0015266954
we O 0 0.0007817019
found O 0 0.00068504526
during O 0 0.00054487423
the O 0 0.00058927253
last O 0 0.00046998213
2 O 0 0.0006107125
decades O 0 0.0010418528
( O 0 0.0008268964
overall O 0 0.0006912967
prolactin O 0 0.974738
greater O 0 0.0004702133
than O 0 0.0003191339
20 O 0 0.00043400202
ng O 0 0.0013000407
. O 0 0.000359145
/ O 0 0.0009931801
ml O 0 0.0013300888
. O 0 0.00032250723
in O 0 0.0003484298
1 O 0 0.00044125438
. O 0 0.00028453584
86 O 0 0.0005869033
% O 0 0.00043503378
of O 0 0.00048478527
1 O 0 0.00060509046
, O 0 0.0007460866
821 O 0 0.015149663
patients O 0 0.0016768664
, O 0 0.0013531283
prolactinomas B-Disease 0 0.9988851
in O 0 0.0010061364
7 O 0 0.001113348
, O 0 0.0014790249
0 O 0 0.0017032891
. O 0 0.0014594828
38 O 0 0.003492221
% O 0 0.0044755763
) O 0 0.0078284005
. O 0 0.0073875324

Bromocriptine B-Chemical 0 0.9992925
was O 0 0.008954087
definitely O 0 0.013445044
effective O 0 0.0040751123
in O 0 0.0027282098
cases O 0 0.0038962695
with O 0 0.003004884
prolactin O 0 0.983643
greater O 0 0.00215688
than O 0 0.0016816525
35 O 0 0.0026472178
ng O 0 0.0060190787
. O 0 0.0033277248
/ O 0 0.009238087
ml O 0 0.01547507
. O 0 0.009606

( O 0 0.011312458
8 O 0 0.0050774636
of O 0 0.003591438
12 O 0 0.0019921416
compared O 0 0.0012251799
to O 0 0.001185578
only O 0 0.0010405871
9 O 0 0.00096642325
of O 0 0.00090587576
22 O 0 0.0010787726
cases O 0 0.0012398142
with O 0 0.0010642031
prolactin O 0 0.975968
between O 0 0.000646878
20 O 0 0.00094208855
and O 0 0.000983241
35 O 0 0.0012002175
ng O 0 0.0029048258
. O 0 0.0014609429
/ O 0 0.0043137562
ml O 0 0.0070670233
. O 0 0.0037253809
) O 0 0.008797892
. O 0 0.0077519226

Testosterone B-Chemical 1 0.9992668
was O 0 0.0075764023
low O 0 0.0048490535
in O 0 0.0027916038
less O 0 0.002127298
than O 0 0.0013697996
50 O 0 0.001784124
% O 0 0.0013649052
of O 0 0.0012035994
cases O 0 0.001982264
with O 0 0.0016563004
prolactin O 0 0.9814392
greater O 0 0.0013918277
than O 0 0.0011850359
35 O 0 0.002037787
ng O 0 0.0049052727
. O 0 0.002773044
/ O 0 0.008206005
ml O 0 0.01406661
. O 0 0.008753671

CONCLUSIONS O 0 0.6016364
: O 0 0.012616903
Low O 0 0.035326324
prevalences O 0 0.009698643
and O 0 0.003375024
effects O 0 0.0033904857
of O 0 0.002839215
low O 0 0.0051265103
testosterone B-Chemical 1 0.9998944
and O 0 0.0033005206
high O 0 0.0035018723
prolactin O 0 0.9968836
in O 0 0.0023855064
erectile B-Disease 0 0.99982446
dysfunction I-Disease 0 0.98000836
cannot O 0 0.024152812
justify O 0 0.003739893
their O 0 0.0035574748
routine O 0 0.004736232
determination O 0 0.009614114
. O 0 0.008927748

However O 0 0.01002654
, O 0 0.0078083235
cost O 0 0.0072981506
- O 0 0.004800424
effective O 0 0.0023727291
screening O 0 0.002026818
strategies O 0 0.0016185751
recommended O 0 0.0010959103
so O 0 0.0007790141
far O 0 0.0007158509
missed O 0 0.0011756043
40 O 0 0.00065377005
to O 0 0.0004953803
50 O 0 0.000798902
% O 0 0.00066959223
of O 0 0.000698658
cases O 0 0.0014088819
improved O 0 0.0015819954
with O 0 0.0015374633
endocrine O 0 0.9591602
therapy O 0 0.044949867
and O 0 0.0037779952
the O 0 0.0053095575
pituitary B-Disease 0 0.9970018
tumors I-Disease 2 0.9985713
. O 0 0.013033328

We O 0 0.007992285
now O 0 0.0055552726
advocate O 0 0.0043579172
that O 0 0.0021976077
before O 0 0.00142363
age O 0 0.0027216764
50 O 0 0.002007582
years O 0 0.0022970263
testosterone B-Chemical 1 0.99960583
be O 0 0.0009134427
determined O 0 0.00046437702
only O 0 0.0004808593
in O 0 0.00045996511
cases O 0 0.00086967146
of O 0 0.00073623616
low B-Disease 2 0.0018626942
sexual I-Disease 2 0.6127155
desire I-Disease 2 0.27267554
and O 0 0.0008345898
abnormal O 0 0.0143092945
physical O 0 0.013453977
examination O 0 0.000993403
but O 0 0.00057086715
that O 0 0.00047664993
it O 0 0.00069388206
be O 0 0.0006467158
measured O 0 0.0005374003
in O 0 0.000820011
all O 0 0.0011985233
men O 0 0.06947726
older O 0 0.0049591567
than O 0 0.002098748
50 O 0 0.004907417
years O 0 0.0070028575
. O 0 0.0072585465

Prolactin O 0 0.9940156
should O 0 0.0048751845
be O 0 0.0035806259
determined O 0 0.0020233844
only O 0 0.0016777742
in O 0 0.0013618654
cases O 0 0.001883711
of O 0 0.0015264367
low B-Disease 2 0.0033873678
sexual I-Disease 2 0.7870532
desire I-Disease 2 0.69634783
, O 0 0.00409278
gynecomastia B-Disease 0 0.99977094
and O 0 0.0022389328
/ O 0 0.0074639637
or O 0 0.001420353
testosterone B-Chemical 1 0.9997012
less O 0 0.0012619412
than O 0 0.0009862507
4 O 0 0.0014734546
ng O 0 0.0040860297
. O 0 0.0024962693
/ O 0 0.0076422025
ml O 0 0.013322113
. O 0 0.008315637

Extrapyramidal O 0 0.9990569
side O 0 0.27501777
effects O 0 0.012790182
with O 0 0.009030583
risperidone B-Chemical 1 0.9999658
and O 0 0.021476114
haloperidol B-Chemical 1 0.9999838
at O 0 0.0029961958
comparable O 0 0.0029281361
D2 O 0 0.9793443
receptor O 0 0.18415298
occupancy O 0 0.0103937425
levels O 0 0.007710124
. O 0 0.009825054

Risperidone B-Chemical 1 0.999663
is O 0 0.007716281
an O 0 0.0065242914
antipsychotic O 0 0.9986682
drug O 0 0.71455824
with O 0 0.002825274
high O 0 0.0027765436
affinity O 0 0.005782439
at O 0 0.0019698255
dopamine B-Chemical 1 0.99983025
D2 O 0 0.99381447
and O 0 0.0051894835
serotonin B-Chemical 1 0.99963343
5 I-Chemical 0 0.004004977
- I-Chemical 0 0.008692414
HT2 I-Chemical 0 0.95246816
receptors O 0 0.30244917
. O 0 0.010663205

Previous O 0 0.008970487
clinical O 0 0.009228718
studies O 0 0.0038983761
have O 0 0.0022641756
proposed O 0 0.0022168318
that O 0 0.0016974985
risperidone B-Chemical 1 0.99997234
' O 0 0.002257999
s O 0 0.0011860133
pharmacologic O 0 0.08811813
profile O 0 0.0009061028
may O 0 0.0005726994
produce O 0 0.00045837843
improved O 0 0.00095115084
efficacy O 0 0.0015648328
for O 0 0.00042035736
negative O 0 0.003285079
psychotic B-Disease 2 0.9999974
symptoms I-Disease 2 0.9949077
and O 0 0.0011859139
decreased O 0 0.0011613761
propensity O 0 0.008324001
for O 0 0.00063361495
extrapyramidal O 0 0.9999932
side O 0 0.19661488
effects O 0 0.0048280903
; O 0 0.0018028215
features O 0 0.001281384
shared O 0 0.0011231493
by O 0 0.0011663741
so O 0 0.0012526815
- O 0 0.002322495
called O 0 0.002110737
' O 0 0.0033682336
atypical O 0 0.18956733
' O 0 0.012789749
neuroleptics O 0 0.9995454
. O 0 0.010197448

To O 0 0.0058458997
determine O 0 0.0028632772
if O 0 0.0025222565
routine O 0 0.0031889023
risperidone B-Chemical 1 0.9999509
treatment O 0 0.0040398994
is O 0 0.0012095873
associated O 0 0.0010527886
with O 0 0.00080618315
a O 0 0.0009343134
unique O 0 0.00075647025
degree O 0 0.0009045562
of O 0 0.0015369699
D2 O 0 0.99327576
receptor O 0 0.102976605
occupancy O 0 0.0012651181
and O 0 0.00049158576
pattern O 0 0.00034408507
of O 0 0.0005247817
clinical O 0 0.0061300774
effects O 0 0.0014609263
, O 0 0.00070951827
we O 0 0.00027953935
used O 0 0.00051275955
[ O 0 0.0062508485
123I O 0 0.9941912
] O 0 0.0067327903
IBZM O 0 0.99966395
SPECT O 0 0.9053645
to O 0 0.00034468263
determine O 0 0.0002435271
D2 O 0 0.918078
occupancy O 0 0.0007692523
in O 0 0.0003483551
subjects O 0 0.0006706167
treated O 0 0.00046575104
with O 0 0.00042410544
routine O 0 0.00046340327
clinical O 0 0.003140263
doses O 0 0.014877556
of O 0 0.0015475375
risperidone B-Chemical 1 0.9999913
( O 0 0.0011120451
n O 0 0.00072807324
= O 0 0.00082257326
12 O 0 0.0004896949
) O 0 0.001091123
or O 0 0.0012003849
haloperidol B-Chemical 1 0.9999845
( O 0 0.002767272
n O 0 0.00240162
= O 0 0.0034182533
7 O 0 0.0033939178
) O 0 0.0069248984
. O 0 0.006877518

Both O 0 0.014091661
risperidone B-Chemical 1 0.99983466
and O 0 0.016149538
haloperidol B-Chemical 1 0.9999784
produced O 0 0.005504694
D2 O 0 0.97596145
occupancy O 0 0.0027586217
levels O 0 0.0010523741
between O 0 0.0007181741
approximately O 0 0.00095002144
60 O 0 0.0009898777
and O 0 0.0010879867
90 O 0 0.0011182363
% O 0 0.0014927925
at O 0 0.0013406777
standard O 0 0.0023726185
clinical O 0 0.010811114
doses O 0 0.0761179
. O 0 0.009232608

There O 0 0.009829243
was O 0 0.0059594703
no O 0 0.0036475568
significant O 0 0.0034242056
difference O 0 0.002095226
between O 0 0.0018550537
occupancy O 0 0.0032293703
levels O 0 0.002310475
obtained O 0 0.0031056008
with O 0 0.0071287286
haloperidol B-Chemical 1 0.99998224
or O 0 0.032740198
risperidone B-Chemical 1 0.99993324
. O 0 0.013357982

Drug B-Disease 0 0.9769071
- I-Disease 0 0.017566668
induced I-Disease 0 0.008139009
parkinsonism I-Disease 2 0.99991024
was O 0 0.002804237
observed O 0 0.0011092162
in O 0 0.0010424104
subjects O 0 0.001641368
treated O 0 0.00125677
with O 0 0.0017862855
risperidone B-Chemical 1 0.9999913
( O 0 0.0018578105
42 O 0 0.0011083627
% O 0 0.0008602626
) O 0 0.0011668247
and O 0 0.0010953414
haloperidol B-Chemical 1 0.9999944
( O 0 0.0015568287
29 O 0 0.0012832632
% O 0 0.0008276859
) O 0 0.000990876
and O 0 0.00067469856
was O 0 0.0006320947
observed O 0 0.0005527707
at O 0 0.0007610713
occupancy O 0 0.0016052717
levels O 0 0.0014638624
above O 0 0.001967446
60 O 0 0.0034662553
% O 0 0.005817987
. O 0 0.006763405

Based O 0 0.011759486
on O 0 0.004349422
these O 0 0.0039856685
observations O 0 0.003896364
, O 0 0.0032645913
it O 0 0.0018962213
is O 0 0.0012062541
concluded O 0 0.0011077524
that O 0 0.00081689376
5 O 0 0.0010070984
- O 0 0.002281115
HT2 O 0 0.9205072
blockade O 0 0.15441288
obtained O 0 0.0007746658
with O 0 0.0011957295
risperidone B-Chemical 1 0.9999902
at O 0 0.00054295163
D2 O 0 0.9217176
occupancy O 0 0.0007485663
rates O 0 0.00044187126
of O 0 0.0005195381
60 O 0 0.00046784512
% O 0 0.0004745911
and O 0 0.00041021002
above O 0 0.00033609202
does O 0 0.00036531716
not O 0 0.0004556335
appear O 0 0.0005257347
to O 0 0.0005693565
protect O 0 0.0015791813
against O 0 0.00091788307
the O 0 0.0013786191
risk O 0 0.09336112
for O 0 0.002915529
extrapyramidal O 0 0.9999747
side O 0 0.5139551
effects O 0 0.03607453
. O 0 0.009887032

Treatment O 0 0.021754848
of O 0 0.006323302
previously O 0 0.0040352973
treated O 0 0.004595076
metastatic O 0 0.9936615
breast B-Disease 2 0.99954563
cancer I-Disease 2 0.99986935
by O 0 0.008562681
mitoxantrone B-Chemical 1 0.99982685
and O 0 0.001472983
48 O 0 0.0006547084
- O 0 0.00062830176
hour O 0 0.0002409257
continuous O 0 0.00034299804
infusion O 0 0.0014224118
of O 0 0.00053869985
high O 0 0.0008729097
- O 0 0.0012025016
dose O 0 0.0061088167
5 B-Chemical 0 0.0006030802
- I-Chemical 0 0.0011866015
FU I-Chemical 0 0.74130887
and O 0 0.0011788893
leucovorin B-Chemical 0 0.9999616
( O 0 0.0042896746
MFL B-Chemical 0 0.983296
) O 0 0.0019942627
: O 0 0.0010416524
low O 0 0.00082051754
palliative O 0 0.0014309692
benefit O 0 0.0017652265
and O 0 0.0014048263
high O 0 0.0020874825
treatment O 0 0.0049809366
- O 0 0.006586283
related O 0 0.0043717013
toxicity B-Disease 2 0.99786395
. O 0 0.010772365

For O 0 0.008180885
previously O 0 0.00633733
treated O 0 0.0063362704
advanced O 0 0.16430409
breast B-Disease 2 0.9987935
cancer I-Disease 2 0.9997093
, O 0 0.005496417
there O 0 0.0014459615
is O 0 0.0015408912
no O 0 0.0013595698
standard O 0 0.0022347453
second O 0 0.0031382304
- O 0 0.0060890485
line O 0 0.007484345
therapy O 0 0.04050735
. O 0 0.009787932

Combination O 0 0.3713189
chemotherapy O 0 0.6522139
with O 0 0.006882291
mitoxantrone B-Chemical 1 0.999476
, O 0 0.005155562
high O 0 0.0028018171
- O 0 0.0025679558
dose O 0 0.010427654
5 B-Chemical 0 0.001107464
- I-Chemical 0 0.0021531968
fluorouracil I-Chemical 0 0.9995109
( O 0 0.0015884354
5 B-Chemical 0 0.0007145396
- I-Chemical 0 0.0013175217
FU I-Chemical 0 0.772429
) O 0 0.0014361507
and O 0 0.001082624
leucovorin B-Chemical 0 0.99995565
( O 0 0.0034745862
MFL B-Chemical 0 0.99324304
regimen I-Chemical 0 0.027206361
) O 0 0.0016838216
had O 0 0.00062740064
been O 0 0.0007187678
reported O 0 0.0008441949
as O 0 0.00088255457
an O 0 0.0013996324
effective O 0 0.0015524182
and O 0 0.0020176223
well O 0 0.0025285422
tolerated O 0 0.078044936
regimen O 0 0.023132488
. O 0 0.008502538

From O 0 0.011067066
October O 0 0.007637026
1993 O 0 0.007700113
to O 0 0.002987556
November O 0 0.0031400537
1995 O 0 0.0046218536
, O 0 0.0015002168
we O 0 0.0006977102
treated O 0 0.00089873496
13 O 0 0.00089339877
patients O 0 0.0012394495
with O 0 0.0006616378
previously O 0 0.000755703
chemotherapy O 0 0.84623444
- O 0 0.0024964644
treated O 0 0.0012435644
metastatic O 0 0.99707174
breast B-Disease 2 0.99976796
cancer I-Disease 2 0.99993527
by O 0 0.0072264527
mitoxantrone B-Chemical 1 0.9999032
, O 0 0.0012405006
12 O 0 0.0003581987
mg O 0 0.13395575
/ O 0 0.0013887032
m2 O 0 0.008112782
, O 0 0.00043427804
on O 0 0.0002010354
day O 0 0.00026179562
1 O 0 0.00029442442
and O 0 0.00027482572
continuous O 0 0.00031615346
infusion O 0 0.0015448079
of O 0 0.00054409605
5 B-Chemical 0 0.0005357042
- I-Chemical 0 0.0011214312
FU I-Chemical 0 0.75670946
, O 0 0.00071555254
3000 O 0 0.0012385801
mg O 0 0.10222346
/ O 0 0.001354103
m2 O 0 0.009261724
, O 0 0.00055505894
together O 0 0.00039795385
with O 0 0.0007050641
leucovorin B-Chemical 0 0.99994695
, O 0 0.0011741873
300 O 0 0.002232866
mg O 0 0.22526598
/ O 0 0.0019591101
m2 O 0 0.010474258
, O 0 0.00079468987
for O 0 0.00048215452
48 O 0 0.0006195309
h O 0 0.00067979004
from O 0 0.0010016297
day O 0 0.0013454003
1 O 0 0.0022208167
to O 0 0.0027915584
2 O 0 0.0051679956
. O 0 0.006784519

Each O 0 0.011355021
course O 0 0.009600897
of O 0 0.008512808
chemotherapy O 0 0.30998304
was O 0 0.0063996813
given O 0 0.0045127696
every O 0 0.0043780594
4 O 0 0.006531005
weeks O 0 0.0073714787
. O 0 0.011355571

Most O 0 0.0124539165
of O 0 0.006872114
these O 0 0.0051670517
patients O 0 0.0055793384
had O 0 0.00271896
more O 0 0.0024754403
than O 0 0.001606475
two O 0 0.001891095
metastatic O 0 0.9340677
sites O 0 0.00335171
, O 0 0.003938369
with O 0 0.004180028
lung O 0 0.921975
metastasis O 0 0.9997435
predominant O 0 0.028972419
. O 0 0.013045687

Seven O 0 0.035170242
patients O 0 0.025053
had O 0 0.016487766
been O 0 0.015999008
treated O 0 0.017466083
with O 0 0.022807056
anthracycline B-Chemical 1 0.99907756
. O 0 0.030417306

Seven O 0 0.018042363
patients O 0 0.011264735
had O 0 0.0059471074
previously O 0 0.0046652644
received O 0 0.0042984164
radiotherapy O 0 0.27284774
and O 0 0.0044346075
seven O 0 0.0037720362
had O 0 0.0042845486
received O 0 0.006736057
hormone O 0 0.98485285
therapy O 0 0.18713836
. O 0 0.01320694

Median O 0 0.008239931
number O 0 0.004603114
of O 0 0.0039074305
courses O 0 0.0038101259
of O 0 0.0031586017
MFL B-Chemical 0 0.98279244
regimen I-Chemical 0 0.010592485
given O 0 0.00081074686
was O 0 0.0007550849
six O 0 0.00048062237
and O 0 0.00062393903
the O 0 0.0005050628
median O 0 0.00050572044
cumulative O 0 0.0015441565
dose O 0 0.00719578
of O 0 0.0017097129
mitoxantrone B-Chemical 1 0.9996507
was O 0 0.0015171655
68 O 0 0.0024339766
. O 0 0.0012375537
35 O 0 0.0022802784
mg O 0 0.19421732
/ O 0 0.009857696
m2 O 0 0.04600733
. O 0 0.008214867

One O 0 0.010914176
patient O 0 0.0069388687
had O 0 0.0037025358
complete O 0 0.002651398
response O 0 0.0028014744
, O 0 0.0021461751
seven O 0 0.0012179009
had O 0 0.00109741
stable O 0 0.0014049902
disease O 0 0.5281299
, O 0 0.001682976
none O 0 0.0011164646
had O 0 0.0009503581
partial O 0 0.0015350751
response O 0 0.0018288881
and O 0 0.0019587437
five O 0 0.0017520622
had O 0 0.0032130203
progressive O 0 0.45111972
disease O 0 0.93910235
. O 0 0.011985682

The O 0 0.011107369
overall O 0 0.00950327
objective O 0 0.009557797
response O 0 0.007424928
rate O 0 0.0060089193
was O 0 0.005866985
7 O 0 0.005592624
. O 0 0.005133831
6 O 0 0.0062220893
% O 0 0.010742154
. O 0 0.011814584

The O 0 0.013921381
median O 0 0.011355733
follow O 0 0.009402685
- O 0 0.010559721
up O 0 0.007428767
period O 0 0.006789475
was O 0 0.007949485
14 O 0 0.009601868
months O 0 0.009744273
. O 0 0.013532047

Median O 0 0.039885428
survival O 0 0.055169154
was O 0 0.03140661
16 O 0 0.030054653
months O 0 0.027336895
. O 0 0.032377433

Median O 0 0.024785647
progression O 0 0.16768536
- O 0 0.019253537
free O 0 0.0148803815
survival O 0 0.05148068
was O 0 0.01271202
5 O 0 0.011953741
months O 0 0.012312291
. O 0 0.016046913

A O 0 0.03284234
complete O 0 0.009292498
responder O 0 0.025055282
had O 0 0.0071936245
relapse O 0 0.96153617
- O 0 0.008666838
free O 0 0.0059145214
survival O 0 0.032899767
up O 0 0.004911417
to O 0 0.0050620846
17 O 0 0.008209554
months O 0 0.0068460302
. O 0 0.009906306

Major O 0 0.13340767
toxicities B-Disease 2 0.99650097
were O 0 0.046487063
cardiotoxicity B-Disease 2 0.9996644
and O 0 0.14333043
leukopenia B-Disease 2 0.9994709
. O 0 0.041623846

Eight O 0 0.012662625
patients O 0 0.008770292
were O 0 0.0044861054
dead O 0 0.0052574747
in O 0 0.0023440844
the O 0 0.001834948
last O 0 0.0012973208
follow O 0 0.0012771143
- O 0 0.0019327758
up O 0 0.0011204536
; O 0 0.0014712315
two O 0 0.00078338536
of O 0 0.0011741605
them O 0 0.0021962456
died O 0 0.006643227
of O 0 0.0025299941
treatment O 0 0.006615433
- O 0 0.007770456
related O 0 0.0048891925
toxicity B-Disease 2 0.9979
. O 0 0.01148298

The O 0 0.010478565
MFL B-Chemical 0 0.87517065
regimen I-Chemical 0 0.01244627
achieves O 0 0.0038692972
little O 0 0.002767921
palliative O 0 0.004039683
benefit O 0 0.0041373973
and O 0 0.002614523
induces O 0 0.0023091938
severe O 0 0.57183945
toxicity B-Disease 2 0.9982646
at O 0 0.002378067
a O 0 0.0037753957
fairly O 0 0.005488517
high O 0 0.00550842
rate O 0 0.006850188
. O 0 0.009499415

Administration O 0 0.06503543
of O 0 0.0064206724
this O 0 0.0038646979
regimen O 0 0.006044523
to O 0 0.0028731928
breast B-Disease 2 0.9975846
cancer I-Disease 2 0.9997069
patients O 0 0.03141834
who O 0 0.0033807773
have O 0 0.00086631364
been O 0 0.0008931562
treated O 0 0.0009990204
by O 0 0.0010632504
chemotherapy O 0 0.5707101
and O 0 0.0012237995
those O 0 0.0014239358
with O 0 0.0013145931
impaired B-Disease 0 0.0037248041
heart I-Disease 0 0.51011145
function I-Disease 0 0.0031763706
requires O 0 0.0019059386
careful O 0 0.005011185
attention O 0 0.010025931
. O 0 0.00821021

Ticlopidine B-Chemical 0 0.99965215
- O 0 0.037525974
induced O 0 0.015445539
aplastic B-Disease 2 0.9998698
anemia I-Disease 2 0.99996984
: O 0 0.018917143
report O 0 0.0060027763
of O 0 0.0024534608
three O 0 0.0016024497
Chinese O 0 0.018029263
patients O 0 0.004258067
and O 0 0.002769776
review O 0 0.0043951226
of O 0 0.004078589
the O 0 0.005208926
literature O 0 0.011114039
. O 0 0.009970956

In O 0 0.0077716913
this O 0 0.0054029725
study O 0 0.0044812146
, O 0 0.0033701053
three O 0 0.0016994817
Chinese O 0 0.010270458
patients O 0 0.0042141452
with O 0 0.0026747885
ticlopidine B-Chemical 1 0.9999913
- O 0 0.036044076
induced O 0 0.0077965776
aplastic B-Disease 2 0.9999852
anemia I-Disease 2 0.99999404
were O 0 0.0029377965
reported O 0 0.0015103826
and O 0 0.0010947802
another O 0 0.001091852
13 O 0 0.0012038597
patients O 0 0.00189903
in O 0 0.001263179
the O 0 0.0018245287
English O 0 0.0044257445
literature O 0 0.0041139424
were O 0 0.00459733
reviewed O 0 0.0097923335
. O 0 0.008910172

We O 0 0.008153318
attempted O 0 0.0059618205
to O 0 0.0035450093
find O 0 0.002550745
underlying O 0 0.0031584036
similarities O 0 0.002083174
, O 0 0.0019492481
evaluate O 0 0.0008153353
the O 0 0.0012917602
risk O 0 0.05178327
factors O 0 0.012369248
, O 0 0.0020389871
and O 0 0.0013472056
identify O 0 0.0010546853
appropriate O 0 0.0014447992
treatment O 0 0.0026919304
for O 0 0.0023631183
this O 0 0.0044173906
complication O 0 0.70101386
. O 0 0.010386315

All O 0 0.008004487
but O 0 0.005167508
one O 0 0.0030919209
of O 0 0.0026498893
the O 0 0.0019566724
patients O 0 0.0026226877
were O 0 0.0012086902
over O 0 0.0007145423
60 O 0 0.0008319466
years O 0 0.0009745344
old O 0 0.0009906547
, O 0 0.0010170859
and O 0 0.0008470505
the O 0 0.0008057304
6 O 0 0.00076583365
who O 0 0.0015391975
died O 0 0.0035698223
were O 0 0.0016434399
all O 0 0.0019518732
older O 0 0.005640079
than O 0 0.0030717696
65 O 0 0.006931223
. O 0 0.0072223004

Therefore O 0 0.010254727
, O 0 0.009224768
old O 0 0.0067582345
age O 0 0.006951079
may O 0 0.003951479
be O 0 0.00364277
a O 0 0.0043080803
risk O 0 0.04983424
factor O 0 0.01421462
for O 0 0.003687509
developing O 0 0.012059447
this O 0 0.007518049
complication O 0 0.7640336
. O 0 0.013833497

Agranulocytosis B-Disease 0 0.99925345
occurred O 0 0.008434469
3 O 0 0.0041789445
- O 0 0.0033608722
20 O 0 0.0015420114
weeks O 0 0.0008415786
after O 0 0.0006196361
initiation O 0 0.0009004347
of O 0 0.0014598038
ticlopidine B-Chemical 1 0.9999808
, O 0 0.0019220327
so O 0 0.00078323385
frequent O 0 0.0017597709
examination O 0 0.0011847035
of O 0 0.0011678817
white O 0 0.006956416
cell O 0 0.008917593
count O 0 0.004496386
during O 0 0.0015393955
treatment O 0 0.004045468
is O 0 0.0040481654
recommended O 0 0.006277248
. O 0 0.0080398815

There O 0 0.009475024
seemed O 0 0.006242099
to O 0 0.0035927165
be O 0 0.0025097656
no O 0 0.0014615905
direct O 0 0.0013781158
correlation O 0 0.0009454776
between O 0 0.0007415571
the O 0 0.0009295673
dose O 0 0.0038772046
or O 0 0.0009242763
duration O 0 0.0012086142
used O 0 0.001022245
and O 0 0.0014185753
the O 0 0.0015983256
severity O 0 0.078785606
of O 0 0.006720624
bone B-Disease 2 0.96561486
marrow I-Disease 2 0.9956476
suppression I-Disease 2 0.76795757
. O 0 0.013975192

Treatment O 0 0.054808512
for O 0 0.008546286
ticlopidine B-Chemical 1 0.99992967
- O 0 0.055292763
induced O 0 0.015019742
aplastic B-Disease 2 0.999954
anemia I-Disease 2 0.9999865
with O 0 0.024006696
colony O 0 0.5611187
- O 0 0.008762489
stimulating O 0 0.0039176135
factors O 0 0.006384575
seemed O 0 0.0025934398
to O 0 0.0022271562
have O 0 0.002792456
little O 0 0.0038338439
effect O 0 0.0066066366
. O 0 0.009241217

The O 0 0.0066512865
fact O 0 0.003955184
that O 0 0.0027904504
5 O 0 0.0020544152
of O 0 0.0017188967
the O 0 0.0012912969
6 O 0 0.0008827144
patients O 0 0.0013973926
who O 0 0.0012352801
received O 0 0.00075495936
concurrent O 0 0.0070334245
calcium B-Chemical 1 0.999729
channel O 0 0.7495209
blockers O 0 0.9996642
died O 0 0.072124
, O 0 0.0010214935
should O 0 0.00034678448
alert O 0 0.000875768
clinicians O 0 0.0009341728
to O 0 0.0005030545
be O 0 0.00062143017
more O 0 0.0007065156
cautious O 0 0.0012902975
when O 0 0.0006936805
using O 0 0.0010295514
these O 0 0.0016861494
two O 0 0.0021428105
drugs O 0 0.61784405
simultaneously O 0 0.0067586694
. O 0 0.008017771

Upregulation O 0 0.021903438
of O 0 0.006400518
the O 0 0.004067867
expression O 0 0.0036897475
of O 0 0.0041987533
vasopressin B-Chemical 1 0.99926096
gene O 0 0.00337344
in O 0 0.0014291259
the O 0 0.0015634054
paraventricular O 0 0.8418191
and O 0 0.0016779883
supraoptic O 0 0.69691676
nuclei O 0 0.0025454685
of O 0 0.001443096
the O 0 0.0020715916
lithium B-Chemical 1 0.99985707
- O 0 0.013590368
induced O 0 0.007475977
diabetes B-Disease 2 0.99963665
insipidus I-Disease 0 0.99973005
rat O 0 0.2565731
. O 0 0.012238928

The O 0 0.008003039
expression O 0 0.006813208
of O 0 0.0076541454
arginine B-Chemical 0 0.97451186
vasopressin I-Chemical 1 0.9998487
( O 0 0.088545874
AVP B-Chemical 1 0.99988174
) O 0 0.0049253004
gene O 0 0.0014453316
in O 0 0.0008501233
the O 0 0.0010880904
paraventricular O 0 0.92922
( O 0 0.0025617525
PVN O 0 0.8985333
) O 0 0.001530955
and O 0 0.0008985363
supraoptic O 0 0.74445325
nuclei O 0 0.0044832234
( O 0 0.0014858927
SON O 0 0.548619
) O 0 0.0009997684
was O 0 0.00042241786
investigated O 0 0.0003591575
in O 0 0.0005085701
rats O 0 0.00228048
with O 0 0.0014479456
lithium B-Chemical 1 0.9999567
( O 0 0.021485439
Li B-Chemical 1 0.9921598
) O 0 0.008399829
- O 0 0.0023561397
induced O 0 0.0016228312
polyuria B-Disease 2 0.9998703
, O 0 0.0020734803
using O 0 0.0010675975
in O 0 0.0012511552
situ O 0 0.004136521
hybridization O 0 0.00394328
histochemistry O 0 0.025880873
and O 0 0.0063117323
radioimmunoassay O 0 0.61864763
. O 0 0.009387778

The O 0 0.008586763
male O 0 0.013174187
Wistar O 0 0.036831193
rats O 0 0.0071745715
consuming O 0 0.0067500197
a O 0 0.0034102742
diet O 0 0.034615044
that O 0 0.001558389
contained O 0 0.0015916532
LiCl B-Chemical 1 0.9992261
( O 0 0.0026877297
60 O 0 0.0012657668
mmol O 0 0.3270834
/ O 0 0.0028599314
kg O 0 0.005140435
) O 0 0.0018786544
for O 0 0.00097592856
4 O 0 0.001308964
weeks O 0 0.0014008624
developed O 0 0.0034723333
marked O 0 0.0126963565
polyuria B-Disease 2 0.9993674
. O 0 0.011301147

The O 0 0.013330797
Li B-Chemical 1 0.89642674
- O 0 0.009131352
treated O 0 0.004579369
rats O 0 0.0051100575
produced O 0 0.0024131816
a O 0 0.0026146166
large O 0 0.0022311779
volume O 0 0.0036811766
of O 0 0.002816162
hypotonic O 0 0.85859174
urine O 0 0.5925764
with O 0 0.00426125
low O 0 0.0067376974
ionic O 0 0.8403654
concentrations O 0 0.072026394
. O 0 0.011610739

Plasma O 0 0.5842853
sodium B-Chemical 1 0.99835473
concentrations O 0 0.011115266
were O 0 0.0034086863
found O 0 0.00190278
to O 0 0.0016099188
be O 0 0.0014718601
slightly O 0 0.0013516381
increased O 0 0.0013769127
in O 0 0.001148454
the O 0 0.001721603
Li B-Chemical 1 0.9751658
- O 0 0.0026555334
treated O 0 0.0015557597
rats O 0 0.0027601635
compared O 0 0.0011368429
with O 0 0.002213458
those O 0 0.0036918495
in O 0 0.0038848126
controls O 0 0.0107315965
. O 0 0.008462891

Plasma O 0 0.17603168
concentration O 0 0.01007948
of O 0 0.008462278
AVP B-Chemical 1 0.99934417
and O 0 0.003930679
transcripts O 0 0.0031665359
of O 0 0.0036867526
AVP B-Chemical 1 0.9997795
gene O 0 0.0022125589
in O 0 0.0010267656
the O 0 0.0012146771
PVN O 0 0.8828961
and O 0 0.0013247876
SON O 0 0.5198569
were O 0 0.0007530607
significantly O 0 0.0009337185
increased O 0 0.0010148702
in O 0 0.00093564874
the O 0 0.0015525395
Li B-Chemical 1 0.9694307
- O 0 0.002830997
treated O 0 0.0019832172
rats O 0 0.0038657591
compared O 0 0.001899765
with O 0 0.004322057
controls O 0 0.011934051
. O 0 0.008452797

These O 0 0.008277569
results O 0 0.005103303
suggest O 0 0.002950393
that O 0 0.0027945521
dehydration B-Disease 2 0.98872924
and O 0 0.0032440508
/ O 0 0.004369585
or O 0 0.0010161559
the O 0 0.0008299695
activation O 0 0.0012884149
of O 0 0.0009147314
visceral O 0 0.40529737
afferent O 0 0.44501817
inputs O 0 0.018190652
may O 0 0.0005386842
contribute O 0 0.00045353922
to O 0 0.00042622755
the O 0 0.0005336623
elevation O 0 0.16771549
of O 0 0.0010960636
plasma O 0 0.24711342
AVP B-Chemical 1 0.99990475
and O 0 0.00083165057
the O 0 0.0005833813
upregulation O 0 0.0013169139
of O 0 0.0016485079
AVP B-Chemical 1 0.999881
gene O 0 0.001086113
expression O 0 0.00082793785
in O 0 0.00057914975
the O 0 0.00080284564
PVN O 0 0.7589634
and O 0 0.0008539797
the O 0 0.0009410304
SON O 0 0.34712222
of O 0 0.0013349539
the O 0 0.0020342332
Li B-Chemical 1 0.97855103
- O 0 0.006401228
induced O 0 0.0057756803
diabetes B-Disease 2 0.99959606
insipidus I-Disease 0 0.9997222
rat O 0 0.24096474
. O 0 0.011895742

Antinociceptive O 0 0.9959829
and O 0 0.015001122
antiamnesic O 0 0.97432363
properties O 0 0.008624166
of O 0 0.0062073776
the O 0 0.0056570107
presynaptic O 0 0.8483485
cholinergic O 0 0.9936063
amplifier O 0 0.6515499
PG B-Chemical 1 0.9993961
- I-Chemical 0 0.023439618
9 I-Chemical 0 0.010359504
. O 0 0.0103824735

The O 0 0.008611074
antinociceptive O 0 0.9852165
effect O 0 0.0041522803
of O 0 0.0035846615
3 B-Chemical 0 0.002493343
alpha I-Chemical 0 0.35208517
- I-Chemical 0 0.004520441
tropyl I-Chemical 0 0.3014269
2 I-Chemical 0 0.0015679946
- I-Chemical 0 0.0019495506
( I-Chemical 0 0.0012524275
p I-Chemical 0 0.0013973775
- I-Chemical 0 0.0026545753
bromophenyl I-Chemical 0 0.9550305
) I-Chemical 0 0.01383511
propionate I-Chemical 0 0.99977833
[ O 0 0.029881164
( O 0 0.0021249247
+ O 0 0.0011579468
/ O 0 0.0057721054
- O 0 0.0021946481
) O 0 0.0023475057
- O 0 0.0025300267
PG B-Chemical 1 0.99945647
- I-Chemical 0 0.002013518
9 I-Chemical 0 0.0006895596
] O 0 0.0010589997
( O 0 0.00067365996
10 O 0 0.00044781607
- O 0 0.00054163614
40 O 0 0.00036712427
mg O 0 0.036298268
kg O 0 0.0038143094
- O 0 0.0008159866
1 O 0 0.000425198
s O 0 0.00047923622
. O 0 0.0003334243
c O 0 0.002590006
. O 0 0.0003767013
; O 0 0.00068403507
30 O 0 0.0003147112
- O 0 0.000486185
60 O 0 0.00032176368
mg O 0 0.030121114
kg O 0 0.0037641937
- O 0 0.0008403679
1 O 0 0.00043496292
p O 0 0.000507526
. O 0 0.00032972303
o O 0 0.0016854993
. O 0 0.0003988658
; O 0 0.0007648928
10 O 0 0.00042623977
- O 0 0.00052941416
30 O 0 0.00026988
mg O 0 0.02894156
kg O 0 0.0037773382
- O 0 0.0008436466
1 O 0 0.00044665008
i O 0 0.001090926
. O 0 0.0003620257
v O 0 0.009651202
. O 0 0.00038500072
; O 0 0.00073025515
10 O 0 0.00040731076
- O 0 0.0005069405
30 O 0 0.0002528594
micrograms O 0 0.016944451
/ O 0 0.00091534725
mouse O 0 0.0005440747
i O 0 0.00174166
. O 0 0.00035808314
c O 0 0.005816322
. O 0 0.00036238373
v O 0 0.013463239
. O 0 0.00035586092
) O 0 0.0006742885
was O 0 0.0003046313
examined O 0 0.00024013771
in O 0 0.00034945676
mice O 0 0.00034382715
, O 0 0.00067680393
rats O 0 0.0010807778
and O 0 0.00056730397
guinea O 0 0.0112995
pigs O 0 0.0007541976
by O 0 0.0005257202
use O 0 0.00047836173
of O 0 0.0005589931
the O 0 0.0005817833
hot O 0 0.0071073123
- O 0 0.001683562
plate O 0 0.0018799216
, O 0 0.001146261
abdominal O 0 0.49585858
- O 0 0.0026060294
constriction O 0 0.68915987
, O 0 0.0015582845
tail O 0 0.0020027517
- O 0 0.0027009204
flick O 0 0.44378066
and O 0 0.003356457
paw O 0 0.9921759
- O 0 0.00807766
pressure O 0 0.07707605
tests O 0 0.010699218
. O 0 0.008182057

( O 0 0.018393429
+ O 0 0.011117587
/ O 0 0.014809196
- O 0 0.009426044
) O 0 0.008349357
- O 0 0.007788013
PG B-Chemical 1 0.99903464
- I-Chemical 0 0.0060971053
9 I-Chemical 0 0.0023948548
antinociception O 0 0.999772
peaked O 0 0.0025302784
15 O 0 0.001043615
min O 0 0.0011550302
after O 0 0.0008781642
injection O 0 0.002466088
and O 0 0.0025019348
then O 0 0.0031438593
slowly O 0 0.010094326
diminished O 0 0.008638083
. O 0 0.009283613

The O 0 0.010956982
antinociception O 0 0.99931085
produced O 0 0.0060893665
by O 0 0.005173304
( O 0 0.005153938
+ O 0 0.003200951
/ O 0 0.009515535
- O 0 0.004369083
) O 0 0.0042939736
- O 0 0.004270497
PG B-Chemical 1 0.99951315
- I-Chemical 0 0.002551007
9 I-Chemical 0 0.00068346394
was O 0 0.0004891668
prevented O 0 0.00094870984
by O 0 0.0006198472
the O 0 0.0006358917
unselective O 0 0.76793563
muscarinic O 0 0.99964404
antagonist O 0 0.99773896
atropine B-Chemical 1 0.9999932
, O 0 0.0025171223
the O 0 0.00071915047
M1 O 0 0.72345954
- O 0 0.0020127296
selective O 0 0.012125338
antagonists O 0 0.99291575
pirenzepine B-Chemical 0 0.9999963
and O 0 0.0052678115
dicyclomine B-Chemical 0 0.99999523
and O 0 0.0011099646
the O 0 0.0010379931
acetylcholine B-Chemical 1 0.9999565
depletor O 0 0.99997365
hemicholinium B-Chemical 0 0.9999902
- I-Chemical 0 0.0067361784
3 I-Chemical 0 0.0004912459
, O 0 0.00048704306
but O 0 0.00030621624
not O 0 0.00029752782
by O 0 0.0004069568
the O 0 0.00053583214
opioid O 0 0.9997464
antagonist O 0 0.99723923
naloxone B-Chemical 1 0.9999969
, O 0 0.0025292146
the O 0 0.000804693
gamma B-Chemical 0 0.8840264
- I-Chemical 0 0.035285756
aminobutyric I-Chemical 0 0.99989223
acidB I-Chemical 0 0.98678035
antagonist O 0 0.9825226
3 B-Chemical 0 0.0011876283
- I-Chemical 0 0.0025868763
aminopropyl I-Chemical 0 0.98382944
- I-Chemical 0 0.018963382
diethoxy I-Chemical 0 0.9983449
- I-Chemical 0 0.028514305
methyl I-Chemical 0 0.9966798
- I-Chemical 0 0.043306027
phosphinic I-Chemical 0 0.9987161
acid I-Chemical 0 0.98780966
, O 0 0.002218623
the O 0 0.0008321361
H3 O 0 0.72489023
agonist O 0 0.97847795
R B-Chemical 0 0.9956726
- I-Chemical 0 0.007880799
( I-Chemical 0 0.0015799437
alpha I-Chemical 0 0.39128777
) I-Chemical 0 0.0058488576
- I-Chemical 0 0.0024320232
methylhistamine I-Chemical 0 0.9915025
, O 0 0.00097472337
the O 0 0.00065178983
D2 O 0 0.99293447
antagonist O 0 0.9939837
quinpirole B-Chemical 0 0.9999927
, O 0 0.0012785656
the O 0 0.00047982906
5 B-Chemical 0 0.00047023973
- I-Chemical 0 0.0008429435
hydroxytryptamine4 I-Chemical 0 0.014757165
antagonist O 0 0.93670803
2 B-Chemical 0 0.0010625974
- I-Chemical 0 0.0024712472
methoxy I-Chemical 0 0.9968929
- I-Chemical 0 0.0026554426
4 I-Chemical 0 0.0006316184
- I-Chemical 0 0.0013252456
amino I-Chemical 0 0.6883243
- I-Chemical 0 0.0018036986
5 I-Chemical 0 0.00057249586
- I-Chemical 0 0.0013462764
chlorobenzoic I-Chemical 0 0.689122
acid I-Chemical 0 0.9489803
2 I-Chemical 0 0.0014819298
- I-Chemical 0 0.0027451406
( I-Chemical 0 0.0020300266
diethylamino I-Chemical 0 0.9960502
) I-Chemical 0 0.037079297
ethyl I-Chemical 0 0.9997787
ester I-Chemical 0 0.9990802
hydrochloride O 0 0.99988663
, O 0 0.0020898967
the O 0 0.0005936032
5 B-Chemical 0 0.0005570607
- I-Chemical 0 0.0010307922
hydroxytryptamin1A I-Chemical 0 0.031978305
antagonist O 0 0.9295392
1 B-Chemical 0 0.0011154849
- I-Chemical 0 0.0013132291
( I-Chemical 0 0.00082407007
2 I-Chemical 0 0.0006182209
- I-Chemical 0 0.0012732599
methoxyphenyl I-Chemical 0 0.8006848
) I-Chemical 0 0.002271772
- I-Chemical 0 0.0010995395
4 I-Chemical 0 0.0005249119
- I-Chemical 0 0.00091359677
[ I-Chemical 0 0.0011756087
4 I-Chemical 0 0.0005641991
- I-Chemical 0 0.0009999784
( I-Chemical 0 0.0008686661
2 I-Chemical 0 0.000756719
- I-Chemical 0 0.0016854769
phthalimido I-Chemical 0 0.9632637
) I-Chemical 0 0.012527466
butyl I-Chemical 0 0.99960214
] I-Chemical 0 0.122985736
piperazine I-Chemical 0 0.99993753
hydrobromide O 0 0.99988973
and O 0 0.004362024
the O 0 0.0045245984
polyamines O 0 0.99929893
depletor O 0 0.99991906
reserpine B-Chemical 1 0.9999634
. O 0 0.01630019

Based O 0 0.012405439
on O 0 0.004686144
these O 0 0.0044399975
data O 0 0.00424545
, O 0 0.003303917
it O 0 0.0020195118
can O 0 0.0012088167
be O 0 0.001150403
postulated O 0 0.0015949558
that O 0 0.00092796516
( O 0 0.0020971168
+ O 0 0.0015226624
/ O 0 0.0085850395
- O 0 0.0031432377
) O 0 0.0033096296
- O 0 0.0034717575
PG B-Chemical 1 0.9994991
- I-Chemical 0 0.0020230338
9 I-Chemical 0 0.00065426214
exerted O 0 0.0012867055
an O 0 0.0014504977
antinociceptive O 0 0.99859244
effect O 0 0.0012020625
mediated O 0 0.0010642532
by O 0 0.0014596204
a O 0 0.00218786
central O 0 0.008179858
potentiation O 0 0.7810933
of O 0 0.006315412
cholinergic O 0 0.989016
transmission O 0 0.04046191
. O 0 0.009181201

( O 0 0.017605098
+ O 0 0.010491882
/ O 0 0.014029604
- O 0 0.008717576
) O 0 0.0074951597
- O 0 0.0066039986
PG B-Chemical 1 0.99894387
- I-Chemical 0 0.004191134
9 I-Chemical 0 0.0013773311
( O 0 0.0012407989
10 O 0 0.0007684398
- O 0 0.00084449997
40 O 0 0.0005428386
mg O 0 0.04634665
kg O 0 0.0058026803
- O 0 0.0010580703
1 O 0 0.00052853074
i O 0 0.0011967552
. O 0 0.00037495143
p O 0 0.0006561968
. O 0 0.00039411176
) O 0 0.00077899033
was O 0 0.00036552415
able O 0 0.00027611526
to O 0 0.00041288705
prevent O 0 0.00094998017
amnesia B-Disease 2 0.9998858
induced O 0 0.0015570786
by O 0 0.0041188668
scopolamine B-Chemical 1 0.99999785
( O 0 0.0023741561
1 O 0 0.00060955965
mg O 0 0.13287407
kg O 0 0.008511915
- O 0 0.0009628343
1 O 0 0.000462808
i O 0 0.001089618
. O 0 0.000338946
p O 0 0.00061112875
. O 0 0.00038393526
) O 0 0.00091857597
and O 0 0.0008225807
dicyclomine B-Chemical 0 0.9999894
( O 0 0.0011233456
2 O 0 0.0005130931
mg O 0 0.078151956
kg O 0 0.005608196
- O 0 0.0010023725
1 O 0 0.0005474242
i O 0 0.001206638
. O 0 0.0004571797
p O 0 0.00081325846
. O 0 0.0005770516
) O 0 0.0011326201
in O 0 0.00072477845
the O 0 0.0009948366
mouse O 0 0.0018801552
passive O 0 0.0041446295
- O 0 0.005042463
avoidance O 0 0.01853793
test O 0 0.007555381
. O 0 0.008297678

Affinity O 0 0.028384883
profiles O 0 0.0060862643
of O 0 0.0060829828
( O 0 0.0064302804
+ O 0 0.0041980697
/ O 0 0.009595685
- O 0 0.005075886
) O 0 0.0047462606
- O 0 0.0044937953
PG B-Chemical 1 0.99941874
- I-Chemical 0 0.002627924
9 I-Chemical 0 0.0007464297
for O 0 0.0005116089
muscarinic O 0 0.9954822
receptor O 0 0.21081203
subtypes O 0 0.035967596
, O 0 0.00089624524
determined O 0 0.00034664597
by O 0 0.00050338183
functional O 0 0.0006093415
studies O 0 0.0006400469
( O 0 0.00072521507
rabbit O 0 0.0013665296
vas O 0 0.65863204
deferens O 0 0.37915868
for O 0 0.00049047905
M1 O 0 0.3612238
, O 0 0.00080161483
guinea O 0 0.006454662
pig O 0 0.0010835996
atrium O 0 0.40019345
for O 0 0.00049418025
M2 O 0 0.3650288
, O 0 0.0008765398
guinea O 0 0.007948057
pig O 0 0.001170549
ileum O 0 0.50304735
for O 0 0.00059092697
M3 O 0 0.95971984
and O 0 0.0007715568
immature O 0 0.0019326949
guinea O 0 0.018482624
pig O 0 0.0012443039
uterus O 0 0.12810063
for O 0 0.00046391046
putative O 0 0.0012396838
M4 O 0 0.9965153
) O 0 0.0025608768
, O 0 0.00068235194
have O 0 0.00035040118
shown O 0 0.0003452262
an O 0 0.0009461786
M4 O 0 0.9888508
/ O 0 0.004621198
M1 O 0 0.2307487
selectivity O 0 0.0022971753
ratio O 0 0.00050038286
of O 0 0.00051497924
10 O 0 0.0004780687
. O 0 0.0002677556
2 O 0 0.00029750515
that O 0 0.00022757263
might O 0 0.00023273165
be O 0 0.00034238514
responsible O 0 0.00033441372
for O 0 0.00031804226
the O 0 0.0006442327
antinociception O 0 0.9999515
and O 0 0.00080404687
the O 0 0.000612832
anti O 0 0.03582814
- O 0 0.008333737
amnesic B-Disease 0 0.9997813
effect O 0 0.00076549914
induced O 0 0.0009743738
by O 0 0.0013187916
( O 0 0.0021769542
+ O 0 0.0012169221
/ O 0 0.007587309
- O 0 0.0026051742
) O 0 0.002817827
- O 0 0.0031118544
PG B-Chemical 1 0.999265
- I-Chemical 0 0.001977165
9 I-Chemical 0 0.0008351985
through O 0 0.00070003903
an O 0 0.0013242905
increase O 0 0.0012049322
in O 0 0.0025762634
acetylcholine B-Chemical 1 0.99951553
extracellular O 0 0.21672514
levels O 0 0.008194728
. O 0 0.009148604

In O 0 0.007950662
the O 0 0.006411298
antinociceptive O 0 0.99569327
and O 0 0.005751525
antiamnesic O 0 0.9900799
dose O 0 0.07625183
range O 0 0.004242673
, O 0 0.0026862512
( O 0 0.0021481395
+ O 0 0.0014541098
/ O 0 0.0058040586
- O 0 0.0026253837
) O 0 0.0028160387
- O 0 0.0030189967
PG B-Chemical 1 0.99941385
- I-Chemical 0 0.0018230963
9 I-Chemical 0 0.00057813857
did O 0 0.00040269174
not O 0 0.00043766803
impair O 0 0.00040463536
mouse O 0 0.0007027666
performance O 0 0.00082004105
evaluated O 0 0.000580126
by O 0 0.00091569935
the O 0 0.0010750598
rota O 0 0.0767864
- O 0 0.0028072281
rod O 0 0.00707491
test O 0 0.0029500518
and O 0 0.0042715063
Animex O 0 0.2111255
apparatus O 0 0.008206452
. O 0 0.008211281

The O 0 0.008894121
effect O 0 0.0059276847
of O 0 0.0052327965
different O 0 0.004012408
anaesthetic O 0 0.31855708
agents O 0 0.3039683
in O 0 0.0049844733
hearing B-Disease 0 0.9450544
loss I-Disease 0 0.009734146
following O 0 0.006062264
spinal O 0 0.55378634
anaesthesia O 0 0.4988148
. O 0 0.011585857

The O 0 0.012802964
cause O 0 0.013816802
of O 0 0.010106031
hearing B-Disease 0 0.8337083
loss I-Disease 0 0.010631469
after O 0 0.0047273394
spinal O 0 0.2373181
anaesthesia O 0 0.30020496
is O 0 0.009154744
unknown O 0 0.0252346
. O 0 0.013882389

Up O 0 0.032183398
until O 0 0.0049848068
now O 0 0.004626507
, O 0 0.003479338
the O 0 0.0020320632
only O 0 0.0016362702
factor O 0 0.004449309
studied O 0 0.0014533332
has O 0 0.0009135202
been O 0 0.0008393575
the O 0 0.00061277935
effect O 0 0.0005722012
of O 0 0.0007234773
the O 0 0.0006483649
diameter O 0 0.0018285451
of O 0 0.000803498
the O 0 0.0008246499
spinal O 0 0.052709833
needle O 0 0.0026387572
on O 0 0.0009041047
post O 0 0.002509116
- O 0 0.0037432467
operative O 0 0.017418187
sensorineural B-Disease 2 0.9998615
hearing I-Disease 2 0.9889742
loss I-Disease 2 0.07442306
. O 0 0.010059982

The O 0 0.0070560165
aim O 0 0.005640475
of O 0 0.004023991
this O 0 0.0027193446
study O 0 0.0023689258
was O 0 0.0014859841
to O 0 0.0010404246
describe O 0 0.000974125
this O 0 0.0011395843
hearing B-Disease 0 0.859558
loss I-Disease 0 0.0021420778
and O 0 0.0009888026
to O 0 0.00067150267
investigate O 0 0.00051895995
other O 0 0.0010672366
factors O 0 0.0035978635
influencing O 0 0.0011701854
the O 0 0.0016602679
degree O 0 0.003081097
of O 0 0.005780926
hearing B-Disease 0 0.97845936
loss I-Disease 0 0.024096377
. O 0 0.00966734

Two O 0 0.008455856
groups O 0 0.005330104
of O 0 0.0037729407
22 O 0 0.0028811684
similar O 0 0.0014266784
patients O 0 0.0023763685
were O 0 0.0011716802
studied O 0 0.0010984401
: O 0 0.0011636872
one O 0 0.00054563483
group O 0 0.0006588873
received O 0 0.0005608338
6 O 0 0.0005031835
mL O 0 0.004307958
prilocaine B-Chemical 1 0.99996126
2 O 0 0.0008979466
% O 0 0.0008834775
; O 0 0.00087917375
and O 0 0.00053214305
the O 0 0.00049892906
other O 0 0.00060437055
received O 0 0.00075486954
3 O 0 0.0009756395
mL O 0 0.0067766067
bupivacaine B-Chemical 1 0.99982136
0 O 0 0.003078879
. O 0 0.0020707007
5 O 0 0.0031912012
% O 0 0.005869193
. O 0 0.0069699013

Patients O 0 0.013714409
given O 0 0.005506244
prilocaine B-Chemical 1 0.99976426
were O 0 0.0037306692
more O 0 0.0024223502
likely O 0 0.001450532
to O 0 0.0011282557
develop O 0 0.0014277166
hearing B-Disease 0 0.9167911
loss I-Disease 0 0.0034887944
( O 0 0.0012232757
10 O 0 0.0005130182
out O 0 0.00037066668
of O 0 0.00052898383
22 O 0 0.00073337334
) O 0 0.0006856263
than O 0 0.00028553072
those O 0 0.0005082982
given O 0 0.0004091125
bupivacaine B-Chemical 1 0.99994755
( O 0 0.0011494556
4 O 0 0.00049491966
out O 0 0.0004578073
of O 0 0.0007721599
22 O 0 0.0013325461
) O 0 0.0018529024
( O 0 0.0019406398
P O 0 0.03204968
< O 0 0.0020006048
0 O 0 0.0027390749
. O 0 0.00276051
05 O 0 0.05074258
) O 0 0.007728953
. O 0 0.0075754626

The O 0 0.007449395
average O 0 0.005194954
hearing B-Disease 0 0.48006055
loss I-Disease 0 0.004913312
for O 0 0.0019688958
speech O 0 0.045286305
frequencies O 0 0.001720868
was O 0 0.0012225138
about O 0 0.0009825303
10 O 0 0.0011169608
dB O 0 0.002479927
after O 0 0.00095612265
prilocaine B-Chemical 1 0.9998758
and O 0 0.0025407628
15 O 0 0.0021909957
dB O 0 0.0059087747
after O 0 0.003249648
bupivacaine B-Chemical 1 0.9995695
. O 0 0.010369508

None O 0 0.023428528
of O 0 0.01335399
the O 0 0.010533821
patients O 0 0.015354719
complained O 0 0.37702152
of O 0 0.0129959155
subjective O 0 0.1826647
hearing B-Disease 0 0.9696574
loss I-Disease 0 0.036429368
. O 0 0.017664071

Long O 0 0.037856918
- O 0 0.012771038
term O 0 0.006813008
follow O 0 0.0052789343
- O 0 0.005737951
up O 0 0.0035371953
of O 0 0.0037602338
the O 0 0.0037978676
patients O 0 0.007317924
was O 0 0.0049725594
not O 0 0.005680399
possible O 0 0.008599727
. O 0 0.011467936

A O 0 0.07749938
transient O 0 0.13653204
neurological B-Disease 0 0.9977284
deficit I-Disease 0 0.6038359
following O 0 0.002889581
intrathecal O 0 0.92232555
injection O 0 0.0066017257
of O 0 0.0021122391
1 O 0 0.0017667934
% O 0 0.002050812
hyperbaric O 0 0.9351896
bupivacaine B-Chemical 1 0.99990976
for O 0 0.0029865494
unilateral O 0 0.4498759
spinal O 0 0.5516543
anaesthesia O 0 0.42548755
. O 0 0.009574029

We O 0 0.0068439045
describe O 0 0.004182558
a O 0 0.0038060036
case O 0 0.002468361
of O 0 0.0025057788
transient O 0 0.14520964
neurological B-Disease 0 0.99951255
deficit I-Disease 0 0.68790185
that O 0 0.00072007795
occurred O 0 0.0007156479
after O 0 0.00036174277
unilateral O 0 0.083686866
spinal O 0 0.12820826
anaesthesia O 0 0.079107024
with O 0 0.00053258456
8 O 0 0.00047088432
mg O 0 0.0554923
of O 0 0.00055385765
1 O 0 0.0005513185
% O 0 0.0006256525
hyperbaric O 0 0.8449182
bupivacaine B-Chemical 1 0.9999536
slowly O 0 0.00275779
injected O 0 0.00059976993
through O 0 0.00060257857
a O 0 0.0010945336
25 O 0 0.0014257574
- O 0 0.001647758
gauge O 0 0.0020575966
pencil O 0 0.04528743
- O 0 0.0034878775
point O 0 0.0027289868
spinal O 0 0.13301618
needle O 0 0.015874589
. O 0 0.008839564

The O 0 0.0074523506
surgery O 0 0.007671543
and O 0 0.004256001
anaesthesia O 0 0.03125852
were O 0 0.0021318437
uneventful O 0 0.0023617337
, O 0 0.0016101121
but O 0 0.0008631767
3 O 0 0.00058335526
days O 0 0.00039455193
after O 0 0.0003236885
surgery O 0 0.0010140777
, O 0 0.000610478
the O 0 0.00040462552
patient O 0 0.00066303666
reported O 0 0.0005554733
an O 0 0.00062678114
area O 0 0.00066225225
of O 0 0.0007103786
hypoaesthesia O 0 0.97528154
over O 0 0.00045682443
L3 O 0 0.05161704
- O 0 0.0016895012
L4 O 0 0.028191386
dermatomes O 0 0.44864282
of O 0 0.00063280173
the O 0 0.0005480897
leg O 0 0.021335034
which O 0 0.0006900516
had O 0 0.00049808563
been O 0 0.0005428869
operated O 0 0.0012438785
on O 0 0.0004090846
( O 0 0.0009295647
loss B-Disease 0 0.001010591
of I-Disease 0 0.001231166
pinprick I-Disease 0 0.9759605
sensation I-Disease 0 0.9736608
) O 0 0.0036413406
without O 0 0.0016164068
reduction O 0 0.0030403982
in O 0 0.0029994939
muscular O 0 0.66163945
strength O 0 0.024089376
. O 0 0.009301142

Sensation O 0 0.568178
in O 0 0.008319017
this O 0 0.0058446657
area O 0 0.0056223283
returned O 0 0.003800071
to O 0 0.003024187
normal O 0 0.0038759927
over O 0 0.0023794996
the O 0 0.003302008
following O 0 0.0040549114
2 O 0 0.0056179343
weeks O 0 0.005848433
. O 0 0.009233715

Prospective O 0 0.047573958
multicentre O 0 0.014391274
studies O 0 0.004398728
with O 0 0.0028246182
a O 0 0.0025275575
large O 0 0.0019289072
population O 0 0.0021778117
and O 0 0.0013122446
a O 0 0.0012914605
long O 0 0.0009271235
follow O 0 0.0007235607
- O 0 0.0011118132
up O 0 0.0005214841
should O 0 0.00035216438
be O 0 0.0004676453
performed O 0 0.00040481208
in O 0 0.00042740873
order O 0 0.00039516512
to O 0 0.00048496787
evaluate O 0 0.00042401816
the O 0 0.00087410276
incidence O 0 0.0047497964
of O 0 0.001979095
this O 0 0.002293612
unusual O 0 0.017054044
side O 0 0.23004965
effect O 0 0.008510136
. O 0 0.009620871

However O 0 0.008739562
, O 0 0.0058321725
we O 0 0.0024910246
suggest O 0 0.0017080682
that O 0 0.0014795876
a O 0 0.0019142968
low O 0 0.0017465416
solution O 0 0.014103651
concentration O 0 0.0019407028
should O 0 0.00044206504
be O 0 0.0005107173
preferred O 0 0.00039653608
for O 0 0.00035419568
unilateral O 0 0.08226284
spinal O 0 0.13190591
anaesthesia O 0 0.08296062
with O 0 0.0004910099
a O 0 0.00073896
hyperbaric O 0 0.88034207
anaesthetic O 0 0.4461961
solution O 0 0.04044468
( O 0 0.0010535215
if O 0 0.0003718467
pencil O 0 0.0540069
- O 0 0.0007716564
point O 0 0.00029366947
needle O 0 0.0010132759
and O 0 0.00046838942
slow O 0 0.00090257433
injection O 0 0.0009841359
rate O 0 0.00043992425
are O 0 0.0004971237
employed O 0 0.00071951345
) O 0 0.0012724383
, O 0 0.00051337876
in O 0 0.00027716046
order O 0 0.00022842192
to O 0 0.00026544434
minimize O 0 0.00024303696
the O 0 0.0004122385
risk O 0 0.012878936
of O 0 0.0005831651
a O 0 0.0006965868
localized O 0 0.00043478672
high O 0 0.0005944921
peak O 0 0.0006713897
anaesthetic O 0 0.17669676
concentration O 0 0.0023113713
, O 0 0.0012789802
which O 0 0.0010287713
might O 0 0.00075203774
lead O 0 0.008453078
to O 0 0.0014159083
a O 0 0.003258588
transient O 0 0.2417061
neurological B-Disease 0 0.99947053
deficit I-Disease 0 0.91216165
. O 0 0.010625342

Transient B-Disease 0 0.8738017
neurologic I-Disease 0 0.99546474
symptoms I-Disease 0 0.95538443
after O 0 0.0028489192
spinal O 0 0.13440575
anesthesia O 0 0.20941228
: O 0 0.002663337
a O 0 0.0017889983
lower O 0 0.0014586352
incidence O 0 0.010481882
with O 0 0.0031856692
prilocaine B-Chemical 1 0.99997306
and O 0 0.009320622
bupivacaine B-Chemical 1 0.9999249
than O 0 0.0035100335
with O 0 0.00869617
lidocaine B-Chemical 1 0.99971575
. O 0 0.011611855

BACKGROUND O 0 0.62190574
: O 0 0.009385237
Recent O 0 0.0055441936
evidence O 0 0.0030089715
suggests O 0 0.001786619
that O 0 0.0017366267
transient B-Disease 0 0.26127172
neurologic I-Disease 0 0.99946696
symptoms I-Disease 0 0.99680007
( O 0 0.010660051
TNSs B-Disease 2 0.9694481
) O 0 0.002084975
frequently O 0 0.0011697409
follow O 0 0.00084894226
lidocaine B-Chemical 1 0.99983466
spinal O 0 0.28725538
anesthesia O 0 0.16840592
but O 0 0.0018156766
are O 0 0.0024370537
infrequent O 0 0.021477949
with O 0 0.00779622
bupivacaine B-Chemical 1 0.99984884
. O 0 0.011336825

However O 0 0.009054913
, O 0 0.0062713497
identification O 0 0.0037476756
of O 0 0.0029513987
a O 0 0.00281713
short O 0 0.0018308461
- O 0 0.002377991
acting O 0 0.0026814472
local O 0 0.0019674776
anesthetic O 0 0.33162344
to O 0 0.00083253183
substitute O 0 0.00091570534
for O 0 0.00078762096
lidocaine B-Chemical 1 0.9997695
for O 0 0.0008012154
brief O 0 0.0012275476
surgical O 0 0.0019285595
procedures O 0 0.0017979641
remains O 0 0.0018935023
an O 0 0.0034321505
important O 0 0.003544446
goal O 0 0.009291354
. O 0 0.008828867

Prilocaine B-Chemical 0 0.99219406
is O 0 0.008087696
an O 0 0.0073311296
amide O 0 0.4057533
local O 0 0.0056898664
anesthetic O 0 0.38925955
with O 0 0.0024300825
a O 0 0.0023035444
duration O 0 0.0019374248
of O 0 0.0020871607
action O 0 0.0050226343
similar O 0 0.0015578128
to O 0 0.0021559126
that O 0 0.0027743198
of O 0 0.008437645
lidocaine B-Chemical 1 0.9997584
. O 0 0.012280775

Accordingly O 0 0.00862583
, O 0 0.0062971152
the O 0 0.0034429738
present O 0 0.0022040722
, O 0 0.002656779
prospective O 0 0.002863931
double O 0 0.001589607
- O 0 0.0019025012
blind O 0 0.0033111572
study O 0 0.00093685125
compares O 0 0.0009219615
prilocaine B-Chemical 1 0.99997675
with O 0 0.002023862
lidocaine B-Chemical 1 0.999959
and O 0 0.002285101
bupivacaine B-Chemical 1 0.9999647
with O 0 0.0008724985
respect O 0 0.00054602866
to O 0 0.0005692724
duration O 0 0.00088516023
of O 0 0.0012128322
action O 0 0.004863479
and O 0 0.0018958278
relative O 0 0.0019427856
risk O 0 0.12149436
of O 0 0.009413368
TNSs B-Disease 2 0.98280805
. O 0 0.009749795

METHODS O 0 0.011259187
: O 0 0.0077632614
Ninety O 0 0.007455833
patients O 0 0.005114692
classified O 0 0.0029010824
as O 0 0.002226765
American O 0 0.0043459255
Society O 0 0.0024860837
of O 0 0.0013685392
Anesthesiologists O 0 0.030292956
physical O 0 0.010437717
status O 0 0.0017604722
I O 0 0.014199192
or O 0 0.00079843274
II O 0 0.030734437
who O 0 0.0010178467
were O 0 0.00041723385
scheduled O 0 0.0002948008
for O 0 0.00026230258
short O 0 0.00032640682
gynecologic O 0 0.030558053
procedures O 0 0.000530703
under O 0 0.00032221893
spinal O 0 0.052528247
anesthesia O 0 0.032922786
were O 0 0.00034372607
randomly O 0 0.0002043765
allocated O 0 0.00024516837
to O 0 0.00026928342
receive O 0 0.00031658387
2 O 0 0.00036810382
. O 0 0.00024554526
5 O 0 0.0002668834
ml O 0 0.00072526035
2 O 0 0.00039560196
% O 0 0.00053571316
lidocaine B-Chemical 1 0.9995123
in O 0 0.00042652307
7 O 0 0.00043869118
. O 0 0.00029041464
5 O 0 0.0003403855
% O 0 0.00056379434
glucose B-Chemical 1 0.8666671
, O 0 0.0006666674
2 O 0 0.00045031772
% O 0 0.00064359145
prilocaine B-Chemical 1 0.9999447
in O 0 0.00051215925
7 O 0 0.0004972919
. O 0 0.00032202792
5 O 0 0.00037539742
% O 0 0.00061517593
glucose B-Chemical 1 0.8219228
, O 0 0.00068841607
or O 0 0.0004904846
0 O 0 0.0007429612
. O 0 0.00040859682
5 O 0 0.00052364543
% O 0 0.0009839043
bupivacaine B-Chemical 1 0.9997067
in O 0 0.0011825869
7 O 0 0.001454098
. O 0 0.0014231673
5 O 0 0.0022954787
% O 0 0.0048347665
glucose B-Chemical 1 0.87809277
. O 0 0.008278294

All O 0 0.013367319
solutions O 0 0.017262852
were O 0 0.007915802
provided O 0 0.0058661946
in O 0 0.005046427
blinded O 0 0.0061730808
vials O 0 0.008106071
by O 0 0.0063025095
the O 0 0.006702305
hospital O 0 0.019027814
pharmacy O 0 0.10029199
. O 0 0.013748256

Details O 0 0.008435897
of O 0 0.0062556844
spinal O 0 0.059361037
puncture O 0 0.028658362
, O 0 0.003186496
extension O 0 0.002000145
and O 0 0.0014843597
regression O 0 0.0044522844
of O 0 0.0016974619
spinal O 0 0.17715485
block O 0 0.0020078332
, O 0 0.0013405832
and O 0 0.00092426926
the O 0 0.00081136945
times O 0 0.000729299
to O 0 0.0010043005
reach O 0 0.001504713
discharge O 0 0.0052680685
criteria O 0 0.0031226422
were O 0 0.0039273202
noted O 0 0.0050394624
. O 0 0.007842765

In O 0 0.0068655815
the O 0 0.0046717185
evening O 0 0.005475231
of O 0 0.002661148
postoperative O 0 0.012774578
day O 0 0.0015519467
1 O 0 0.0013522278
, O 0 0.0011839494
patients O 0 0.0013754816
were O 0 0.0006451706
evaluated O 0 0.0005305687
for O 0 0.0005668193
TNSs B-Disease 2 0.8062967
by O 0 0.0007027009
a O 0 0.0008007247
physician O 0 0.0023584308
unaware O 0 0.00089357665
of O 0 0.0006735412
the O 0 0.0006644305
drug O 0 0.28565902
administered O 0 0.0013631176
and O 0 0.00096470164
the O 0 0.00088101364
details O 0 0.0008308482
of O 0 0.0017802946
the O 0 0.0025750212
anesthetic O 0 0.4574978
procedure O 0 0.0069027464
. O 0 0.00872079

RESULTS O 0 0.024280056
: O 0 0.0078001665
Nine O 0 0.0062420815
of O 0 0.003237134
30 O 0 0.0018954346
patients O 0 0.0025251566
receiving O 0 0.002808502
lidocaine B-Chemical 1 0.9998747
experienced O 0 0.010787789
TNSs B-Disease 2 0.97037685
, O 0 0.0012635539
1 O 0 0.0005723223
of O 0 0.00050428114
30 O 0 0.00037067977
patients O 0 0.00089347153
receiving O 0 0.0016807384
prilocaine B-Chemical 1 0.99998796
( O 0 0.0030330129
P O 0 0.17036611
= O 0 0.00093603175
0 O 0 0.0006953994
. O 0 0.00040584104
03 O 0 0.014261414
) O 0 0.0007403235
had O 0 0.00043281214
them O 0 0.00092556485
, O 0 0.00076107925
and O 0 0.0006280049
none O 0 0.0007221492
of O 0 0.00092705275
30 O 0 0.0008733926
patients O 0 0.002475168
receiving O 0 0.0056062285
bupivacaine B-Chemical 1 0.9998826
had O 0 0.0074490355
TNSs B-Disease 2 0.9691316
. O 0 0.009216269

Times O 0 0.018196857
to O 0 0.0064144796
ambulate O 0 0.01033315
and O 0 0.0030990764
to O 0 0.001965071
void O 0 0.0034204894
were O 0 0.0012257905
similar O 0 0.0007486837
after O 0 0.0006718836
lidocaine B-Chemical 1 0.9998615
and O 0 0.0024650136
prilocaine B-Chemical 1 0.9999888
( O 0 0.0022850677
150 O 0 0.001215913
vs O 0 0.0009537907
. O 0 0.00034928258
165 O 0 0.0010320483
min O 0 0.0004040757
and O 0 0.00042926005
238 O 0 0.0017937977
vs O 0 0.0007533205
. O 0 0.00033127354
253 O 0 0.0040483354
min O 0 0.00048397426
, O 0 0.0005980079
respectively O 0 0.0008767893
) O 0 0.0008038967
but O 0 0.0003852465
prolonged O 0 0.0012905131
after O 0 0.00038582776
bupivacaine B-Chemical 1 0.9999639
( O 0 0.0013979385
200 O 0 0.0012527908
and O 0 0.0007322996
299 O 0 0.025889523
min O 0 0.0008831131
, O 0 0.0011730695
respectively O 0 0.0018586842
; O 0 0.0023757287
P O 0 0.03079366
< O 0 0.0019724483
0 O 0 0.0027056474
. O 0 0.00273369
05 O 0 0.04934413
) O 0 0.007669355
. O 0 0.0075350567

CONCLUSIONS O 0 0.717767
: O 0 0.01538481
Prilocaine B-Chemical 0 0.99165267
may O 0 0.0035814014
be O 0 0.0022871403
preferable O 0 0.0015724098
to O 0 0.0013375584
lidocaine B-Chemical 1 0.99966264
for O 0 0.00078012625
short O 0 0.00063527754
surgical O 0 0.0010734898
procedures O 0 0.0007409715
because O 0 0.0005111556
it O 0 0.00064390217
has O 0 0.00044941137
a O 0 0.00066810095
similar O 0 0.0004345708
duration O 0 0.00081148103
of O 0 0.001124503
action O 0 0.0050485292
but O 0 0.0013716395
a O 0 0.0021609159
lower O 0 0.0023827753
incidence O 0 0.028437573
of O 0 0.009691804
TNSs B-Disease 2 0.9824917
. O 0 0.010062223

Suxamethonium B-Chemical 1 0.99572927
- O 0 0.018306958
induced O 0 0.009402307
cardiac B-Disease 2 0.95384836
arrest I-Disease 2 0.9594224
and O 0 0.008001659
death B-Disease 2 0.9945081
following O 0 0.003963281
5 O 0 0.0034064874
days O 0 0.003327225
of O 0 0.006152363
immobilization O 0 0.060279135
. O 0 0.012119902

The O 0 0.0068172747
present O 0 0.004005797
report O 0 0.0052657104
describes O 0 0.0034940836
a O 0 0.0025337404
case O 0 0.0017129651
of O 0 0.0021594185
cardiac B-Disease 2 0.9731557
arrest I-Disease 2 0.9645248
and O 0 0.0015537551
subsequent O 0 0.0015590177
death B-Disease 2 0.99710244
as O 0 0.0008129838
a O 0 0.00086405315
result O 0 0.00057330454
of O 0 0.0010023257
hyperkalaemia B-Disease 0 0.99985576
following O 0 0.00061863556
the O 0 0.0005461234
use O 0 0.0006263153
of O 0 0.0010062648
suxamethonium B-Chemical 1 0.9997242
in O 0 0.0010198137
a O 0 0.0016972116
23 O 0 0.0022852547
- O 0 0.0022298181
year O 0 0.0018808981
- O 0 0.0035033468
old O 0 0.0041456553
Malawian O 0 0.028420849
woman O 0 0.053271558
. O 0 0.010001542

Five O 0 0.009360103
days O 0 0.004100679
after O 0 0.0024032474
the O 0 0.0022920675
onset O 0 0.0033425384
of O 0 0.0018973208
the O 0 0.00167081
symptoms O 0 0.75149
of O 0 0.0031783704
meningitis B-Disease 2 0.9992244
, O 0 0.0024296525
the O 0 0.0011021285
patient O 0 0.0017443716
aspirated O 0 0.003208349
stomach O 0 0.48968336
contents O 0 0.005268831
and O 0 0.0027566415
needed O 0 0.0023835646
endotracheal O 0 0.009841373
intubation O 0 0.063550346
. O 0 0.009373589

Forty O 0 0.016162727
seconds O 0 0.007890215
after O 0 0.0043031336
injection O 0 0.0061208983
of O 0 0.0060199797
suxamethonium B-Chemical 1 0.9996947
, O 0 0.021407243
bradycardia B-Disease 2 0.9995472
and O 0 0.010333944
cardiac B-Disease 2 0.985213
arrest I-Disease 2 0.9718042
occurred O 0 0.012494017
. O 0 0.011901061

Attempts O 0 0.025654584
to O 0 0.0153149525
resuscitate O 0 0.022318356
the O 0 0.011508186
patient O 0 0.013308244
were O 0 0.011807628
not O 0 0.01187486
successful O 0 0.016498942
. O 0 0.017965501

The O 0 0.009458351
serum O 0 0.022846485
level O 0 0.004511313
of O 0 0.0059462395
potassium B-Chemical 1 0.9995832
was O 0 0.00293722
observed O 0 0.001529302
to O 0 0.0016666664
be O 0 0.0018347551
8 O 0 0.0016909705
. O 0 0.0015338997
4 O 0 0.0023988525
mequiv O 0 0.7408986
L O 0 0.6451292
- O 0 0.009754299
1 O 0 0.007966885
. O 0 0.008865601

Apart O 0 0.016241865
from O 0 0.005633742
the O 0 0.003655224
reduction O 0 0.0031648402
in O 0 0.00164653
the O 0 0.0013257621
patient O 0 0.0016762463
' O 0 0.0012691425
s O 0 0.0008882733
level O 0 0.0004904548
of O 0 0.00089939457
consciousness O 0 0.93949234
, O 0 0.0008681112
there O 0 0.0003059361
were O 0 0.00036633696
no O 0 0.0002964598
signs O 0 0.03754211
of O 0 0.0007731046
motor O 0 0.1696875
neurone O 0 0.8830885
damage O 0 0.5414756
or O 0 0.0005037176
of O 0 0.0005160381
any O 0 0.0003708657
of O 0 0.00051602407
the O 0 0.00047117574
other O 0 0.000570256
known O 0 0.0009153277
predisposing O 0 0.049121942
conditions O 0 0.0013430095
for O 0 0.0010120961
hyperkalaemia B-Disease 0 0.9998012
following O 0 0.0014813761
the O 0 0.0019008323
administration O 0 0.12167549
of O 0 0.008678053
suxamethonium B-Chemical 1 0.99970764
. O 0 0.010818944

It O 0 0.010595404
is O 0 0.005625483
postulated O 0 0.0051492774
that O 0 0.0028732917
her O 0 0.005850476
death B-Disease 2 0.99622726
was O 0 0.002143292
caused O 0 0.0019191195
by O 0 0.0021010982
hypersensitivity B-Disease 2 0.9512289
to O 0 0.0019462672
suxamethonium B-Chemical 1 0.9999026
, O 0 0.0027921265
associated O 0 0.0016555744
with O 0 0.0017896472
her O 0 0.0031806098
5 O 0 0.0022417116
- O 0 0.0037442234
day O 0 0.0033503151
immobilization O 0 0.020135503
. O 0 0.008919584

Acute O 0 0.9956872
hepatitis B-Disease 2 0.99978906
, O 0 0.15664923
autoimmune B-Disease 2 0.9994529
hemolytic I-Disease 2 0.9999684
anemia I-Disease 2 0.9999882
, O 0 0.106053345
and O 0 0.009852498
erythroblastocytopenia B-Disease 0 0.5261786
induced O 0 0.0090959985
by O 0 0.015116936
ceftriaxone B-Chemical 1 0.99911505
. O 0 0.0143900495

An O 0 0.016348133
80 O 0 0.010786583
- O 0 0.0088469535
yr O 0 0.007998832
- O 0 0.005339992
old O 0 0.0040056906
man O 0 0.09585636
developed O 0 0.009524676
acute O 0 0.99906224
hepatitis B-Disease 2 0.9999813
shortly O 0 0.07925708
after O 0 0.0032078812
ingesting O 0 0.8624492
oral O 0 0.97182864
ceftriaxone B-Chemical 1 0.99952435
. O 0 0.014534992

Although O 0 0.007210549
the O 0 0.006015576
transaminases O 0 0.99773765
gradually O 0 0.0063422653
returned O 0 0.0017678417
to O 0 0.0010423631
baseline O 0 0.0009407713
after O 0 0.0004930158
withholding O 0 0.0039106836
the O 0 0.0008667301
beta B-Chemical 0 0.88373727
lactam I-Chemical 0 0.99764365
antibiotic O 0 0.48431754
, O 0 0.0012602487
there O 0 0.0003468225
was O 0 0.00043476783
a O 0 0.0005632551
gradual O 0 0.0005964993
increase O 0 0.00037876857
in O 0 0.0005291634
serum O 0 0.28323272
bilirubin B-Chemical 1 0.9999149
and O 0 0.0011029531
a O 0 0.0009927878
decrease O 0 0.0006028256
in O 0 0.0006182097
hemoglobin O 0 0.9016658
concentration O 0 0.0027298152
caused O 0 0.0015499317
by O 0 0.0020726111
an O 0 0.008576509
autoimmune B-Disease 2 0.9997975
hemolytic I-Disease 2 0.99998844
anemia I-Disease 2 0.9999918
and O 0 0.20734836
erythroblastocytopenia B-Disease 0 0.91993976
. O 0 0.012396691

These O 0 0.023445556
responded O 0 0.02091664
to O 0 0.016169447
systemic O 0 0.94636
steroids B-Chemical 1 0.9988996
and O 0 0.04259369
immunoglobulins O 0 0.9602031
. O 0 0.028581189

Despite O 0 0.008110397
the O 0 0.0050796997
widespread O 0 0.0050405115
use O 0 0.0027015295
of O 0 0.0021681902
these O 0 0.0019345509
agents O 0 0.08916456
this O 0 0.0013349734
triad O 0 0.03541982
of O 0 0.0016117656
side O 0 0.114428625
effects O 0 0.0028746882
has O 0 0.0007831242
not O 0 0.0008103279
previously O 0 0.00094105146
been O 0 0.0010777643
reported O 0 0.0012538192
in O 0 0.0012162501
connection O 0 0.0025635248
with O 0 0.0035713352
beta B-Chemical 0 0.9583433
lactam I-Chemical 0 0.99853814
antibiotics O 0 0.9591649
. O 0 0.0126047665

Thyroxine B-Chemical 0 0.99773175
abuse O 0 0.9954326
: O 0 0.014309475
an O 0 0.008784861
unusual O 0 0.011574029
case O 0 0.007238686
of O 0 0.01115923
thyrotoxicosis B-Disease 0 0.9995183
in O 0 0.015272297
pregnancy O 0 0.84927803
. O 0 0.016771395

Eating B-Disease 0 0.88545513
disorders I-Disease 0 0.94353116
and O 0 0.0067048124
the O 0 0.004116539
associated O 0 0.0040076086
behavioural O 0 0.05508087
problems O 0 0.055808313
and O 0 0.004618683
drug B-Disease 2 0.98666334
abuse I-Disease 2 0.99971694
are O 0 0.0077801757
uncommon O 0 0.114471346
in O 0 0.007369281
pregnancy O 0 0.753654
. O 0 0.011726383

When O 0 0.007473323
they O 0 0.0052511864
do O 0 0.003471906
occur O 0 0.0027167804
they O 0 0.0019736427
are O 0 0.0016251565
often O 0 0.0017964175
unrecognized O 0 0.002684775
because O 0 0.00077212276
of O 0 0.0012164008
denial O 0 0.38934088
but O 0 0.0007912291
when O 0 0.00048302213
significant O 0 0.00073663384
may O 0 0.00065228884
pose O 0 0.0011811462
a O 0 0.001295103
risk O 0 0.018778086
to O 0 0.0010348437
both O 0 0.0012989431
the O 0 0.0017860492
mother O 0 0.008861747
and O 0 0.004270442
her O 0 0.008432352
fetus O 0 0.111012176
. O 0 0.009703802

This O 0 0.009192209
case O 0 0.0047190525
illustrates O 0 0.0030960168
a O 0 0.002749427
number O 0 0.0016957524
of O 0 0.0018947688
problems O 0 0.012523491
that O 0 0.0009127367
may O 0 0.000828482
be O 0 0.000754351
encountered O 0 0.0009483511
in O 0 0.00071156357
women O 0 0.047739666
with O 0 0.0011560313
eating B-Disease 0 0.9850573
disorders I-Disease 0 0.9944325
in O 0 0.0010354558
pregnancy O 0 0.59383035
, O 0 0.0012430198
including O 0 0.0007475718
prolonged O 0 0.0057343524
and O 0 0.0018336114
recurrent O 0 0.91427475
metabolic O 0 0.9734794
disturbances O 0 0.99245185
and O 0 0.02958888
diuretic O 0 0.9999218
abuse O 0 0.9993624
. O 0 0.015094048

In O 0 0.0066832593
particular O 0 0.0039377273
it O 0 0.0034294815
illustrates O 0 0.0022891087
the O 0 0.002077072
derangements O 0 0.72439706
of O 0 0.0026049092
thyroid O 0 0.9603624
function O 0 0.0016208584
seen O 0 0.0007906585
in O 0 0.0007130003
pregnant O 0 0.04632322
women O 0 0.056039814
with O 0 0.0011297637
eating B-Disease 0 0.9847446
disorders I-Disease 0 0.99425536
and O 0 0.001262063
reminds O 0 0.005751378
us O 0 0.00078335224
that O 0 0.000380211
when O 0 0.00035570556
a O 0 0.00078158086
cause O 0 0.0026881287
for O 0 0.0007507796
thyrotoxicosis B-Disease 0 0.9999006
remains O 0 0.001286023
obscure O 0 0.13693795
, O 0 0.006944897
thyroxine B-Chemical 1 0.9998616
abuse O 0 0.99835277
should O 0 0.0014218944
be O 0 0.0021632966
considered O 0 0.0023112362
and O 0 0.0042725145
explored O 0 0.005669263
. O 0 0.008343105

Repeated O 0 0.19013032
trimipramine B-Chemical 0 0.9998909
induces O 0 0.01726202
dopamine B-Chemical 1 0.99976784
D2 O 0 0.997895
/ O 0 0.14209048
D3 O 0 0.9992107
and O 0 0.008201513
alpha1 O 0 0.97525465
- O 0 0.017477874
adrenergic O 0 0.99513763
up O 0 0.005801938
- O 0 0.008795833
regulation O 0 0.006754596
. O 0 0.009501343

Trimipramine B-Chemical 0 0.9987961
( O 0 0.021503415
TRI B-Chemical 1 0.9930875
) O 0 0.008104341
, O 0 0.0028697033
which O 0 0.0016569864
shows O 0 0.00084423565
a O 0 0.001352792
clinical O 0 0.01603005
antidepressant B-Chemical 1 0.9998826
activity O 0 0.0021734142
, O 0 0.0013109342
is O 0 0.000649147
chemically O 0 0.04436622
related O 0 0.0005138492
to O 0 0.00081974926
imipramine B-Chemical 0 0.9999933
but O 0 0.00072153076
does O 0 0.0003830392
not O 0 0.00041029826
inhibit O 0 0.00041220058
the O 0 0.00062666193
reuptake O 0 0.999469
of O 0 0.0013449878
noradrenaline B-Chemical 1 0.9999584
and O 0 0.001016864
5 B-Chemical 0 0.00069847994
- I-Chemical 0 0.0014630633
hydroxytryptamine I-Chemical 0 0.9160247
, O 0 0.0009277676
nor O 0 0.0006213528
does O 0 0.0006070778
it O 0 0.0009822831
induce O 0 0.001114392
beta O 0 0.7105993
- O 0 0.014431491
adrenergic O 0 0.99668056
down O 0 0.005551406
- O 0 0.0076185055
regulation O 0 0.0052200123
. O 0 0.0077101383

The O 0 0.012462042
mechanism O 0 0.010679813
of O 0 0.010041996
its O 0 0.015763745
antidepressant B-Chemical 1 0.999421
activity O 0 0.012476562
is O 0 0.008783417
still O 0 0.009501855
unknown O 0 0.026130263
. O 0 0.015384969

The O 0 0.006822339
aim O 0 0.005361676
of O 0 0.0037325644
the O 0 0.002485826
present O 0 0.0015181625
study O 0 0.0017697184
was O 0 0.001118078
to O 0 0.00077330717
find O 0 0.0006318472
out O 0 0.0005858459
whether O 0 0.00041590392
TRI B-Chemical 1 0.9783071
given O 0 0.00039477638
repeatedly O 0 0.0007361278
was O 0 0.00046039102
able O 0 0.00030919968
to O 0 0.00039564914
induce O 0 0.00037774775
adaptive O 0 0.001083785
changes O 0 0.00071841374
in O 0 0.00046125948
the O 0 0.00062523823
dopaminergic O 0 0.9644629
and O 0 0.0013708626
alpha1 O 0 0.97480154
- O 0 0.0056729093
adrenergic O 0 0.9951538
systems O 0 0.0019843867
, O 0 0.0011276143
demonstrated O 0 0.000737819
by O 0 0.0011457141
us O 0 0.001789332
previously O 0 0.0017479197
for O 0 0.0021920872
various O 0 0.014417093
antidepressants B-Chemical 1 0.999846
. O 0 0.01039154

TRI B-Chemical 1 0.9429339
was O 0 0.0069191945
given O 0 0.0035451385
to O 0 0.0031357836
male O 0 0.007507127
Wistar O 0 0.04759405
rats O 0 0.004096743
and O 0 0.002181951
male O 0 0.008877604
Albino O 0 0.3704052
Swiss O 0 0.0062316223
mice O 0 0.001287398
perorally O 0 0.079805434
twice O 0 0.0020959736
daily O 0 0.0030039744
for O 0 0.002232114
14 O 0 0.003870056
days O 0 0.0043724673
. O 0 0.007441682

In O 0 0.007560954
the O 0 0.005798341
acute O 0 0.6210341
experiment O 0 0.0037265136
TRI B-Chemical 1 0.99330807
( O 0 0.0028750652
given O 0 0.000984436
i O 0 0.0033469095
. O 0 0.0007671827
p O 0 0.0011666496
. O 0 0.00061240664
) O 0 0.001069968
does O 0 0.00042091034
not O 0 0.0004922368
antagonize O 0 0.004625613
the O 0 0.0011327356
reserpine B-Chemical 1 0.999995
hypothermia B-Disease 2 0.99984896
in O 0 0.0008045175
mice O 0 0.00049547176
and O 0 0.0007515397
does O 0 0.0004971599
not O 0 0.000625578
potentiate O 0 0.0025590565
the O 0 0.0010431916
5 B-Chemical 0 0.0013123727
- I-Chemical 0 0.0035354507
hydroxytryptophan I-Chemical 0 0.9823271
head O 0 0.7442943
twitches O 0 0.99661297
in O 0 0.0051334146
rats O 0 0.018491458
. O 0 0.008535502

TRI B-Chemical 1 0.92173296
given O 0 0.0047344994
repeatedly O 0 0.0043147635
to O 0 0.0025226718
rats O 0 0.0039986405
increases O 0 0.0017215932
the O 0 0.0019853804
locomotor O 2 0.9950418
hyperactivity B-Disease 2 0.99998474
induced O 0 0.0037139517
by O 0 0.0021465705
d B-Chemical 0 0.020932125
- I-Chemical 0 0.021923915
amphetamine I-Chemical 1 0.999997
, O 0 0.019599833
quinpirole B-Chemical 0 0.99998665
and O 0 0.0017651794
( O 0 0.0020291256
+ O 0 0.0011520435
) O 0 0.0018484337
- O 0 0.0012875672
7 O 0 0.0007859629
- O 0 0.002220281
hydroxy O 0 0.9990946
- O 0 0.0068114433
dipropyloaminotetralin O 0 0.09692182
( O 0 0.010819694
dopamine B-Chemical 1 0.9998357
D2 O 0 0.99315953
and O 0 0.007067924
D3 O 0 0.99918824
effects O 0 0.025123738
) O 0 0.020062994
. O 0 0.008850341

The O 0 0.01236936
stereotypies O 0 0.9984546
induced O 0 0.0084687155
by O 0 0.006533605
d B-Chemical 0 0.015459627
- I-Chemical 0 0.021436498
amphetamine I-Chemical 1 0.9999801
or O 0 0.012989115
apomorphine B-Chemical 1 0.999974
are O 0 0.0055323513
not O 0 0.004487085
potentiated O 0 0.29612908
by O 0 0.013083463
TRI B-Chemical 1 0.99618286
. O 0 0.011710408

It O 0 0.00911539
increases O 0 0.004605911
the O 0 0.0033443258
behaviour O 0 0.005921608
stimulation O 0 0.0039102337
evoked O 0 0.30990496
by O 0 0.0033137864
phenylephrine B-Chemical 1 0.99995553
( O 0 0.0025037976
given O 0 0.00060164975
intraventricularly O 0 0.872436
) O 0 0.0016352673
in O 0 0.00048109746
rats O 0 0.0015386833
, O 0 0.00058280944
evaluated O 0 0.00032012642
in O 0 0.00033322573
the O 0 0.0003523123
open O 0 0.0003807046
field O 0 0.00047391257
test O 0 0.0004108195
as O 0 0.0003529229
well O 0 0.00033837694
as O 0 0.0004339805
the O 0 0.0005768261
aggressiveness B-Disease 2 0.987895
evoked O 0 0.49067137
by O 0 0.001691581
clonidine B-Chemical 1 0.99998283
in O 0 0.0006261727
mice O 0 0.00046089818
, O 0 0.0007223902
both O 0 0.00045884796
these O 0 0.00068958354
effects O 0 0.0013569075
being O 0 0.0015023411
mediated O 0 0.0011083775
by O 0 0.0018575586
an O 0 0.004607965
alpha1 O 0 0.972693
- O 0 0.037350334
adrenergic O 0 0.9981798
receptor O 0 0.4080693
. O 0 0.010254

It O 0 0.010496513
may O 0 0.0053969594
be O 0 0.0036670328
concluded O 0 0.0027050364
that O 0 0.0017937928
, O 0 0.0020733138
like O 0 0.0012881585
other O 0 0.0015801475
tricyclic O 0 0.99992895
antidepressants B-Chemical 1 0.99997246
studied O 0 0.001472911
previously O 0 0.0009719866
, O 0 0.0014547178
TRI B-Chemical 1 0.9819229
given O 0 0.0003133791
repeatedly O 0 0.00056109764
increases O 0 0.00038288475
the O 0 0.00039455757
responsiveness O 0 0.00080603326
of O 0 0.0010390661
brain O 0 0.63389087
dopamine B-Chemical 1 0.9999651
D2 O 0 0.99775237
and O 0 0.004325429
D3 O 0 0.99986327
( O 0 0.0033244241
locomotor O 0 0.62527525
activity O 0 0.00072969723
but O 0 0.0005459293
not O 0 0.0006982204
stereotypy O 0 0.9997278
) O 0 0.0016536674
as O 0 0.0006266249
well O 0 0.00067512377
as O 0 0.0012444189
alpha1 O 0 0.9527599
- O 0 0.008728911
adrenergic O 0 0.99672085
receptors O 0 0.11951109
to O 0 0.0030215369
their O 0 0.005547638
agonists O 0 0.9063399
. O 0 0.009457618

A O 0 0.027043745
question O 0 0.0057852603
arises O 0 0.0044924906
whether O 0 0.0017366293
the O 0 0.0022911176
reuptake O 0 0.99909294
inhibition O 0 0.0042236424
is O 0 0.00085028197
of O 0 0.0007506594
any O 0 0.0005367056
importance O 0 0.00046050517
to O 0 0.00046190183
the O 0 0.00052393274
adaptive O 0 0.0011459526
changes O 0 0.0008482267
induced O 0 0.0007166461
by O 0 0.0008127515
repeated O 0 0.0010254474
antidepressants B-Chemical 1 0.99995124
, O 0 0.001317075
suggested O 0 0.00068521604
to O 0 0.00078395224
be O 0 0.001037485
responsible O 0 0.0011568257
for O 0 0.0014241236
the O 0 0.0031532797
antidepressant B-Chemical 1 0.99961287
activity O 0 0.009487456
. O 0 0.0086776195

Pethidine B-Chemical 0 0.99934155
- O 0 0.016889114
associated O 0 0.0075733126
seizure B-Disease 2 0.99875355
in O 0 0.0036854304
a O 0 0.003829039
healthy O 0 0.015184598
adolescent O 0 0.09487278
receiving O 0 0.011012422
pethidine B-Chemical 1 0.9999517
for O 0 0.004075221
postoperative B-Disease 0 0.87517506
pain I-Disease 2 0.99948454
control O 0 0.01171097
. O 0 0.011162778

A O 0 0.039217684
healthy O 0 0.016805789
17 O 0 0.007113908
- O 0 0.0047718924
year O 0 0.002459476
- O 0 0.0022571224
old O 0 0.0013638798
male O 0 0.0022671043
received O 0 0.00077322725
standard O 0 0.0007814484
intermittent O 0 0.025282215
doses O 0 0.016391397
of O 0 0.0016048638
pethidine B-Chemical 1 0.9999864
via O 0 0.00072500465
a O 0 0.0010134252
patient O 0 0.001545651
- O 0 0.001335683
controlled O 0 0.0007953213
analgesia O 0 0.9912356
( O 0 0.002327677
PCA O 0 0.90750736
) O 0 0.0021012144
pump O 0 0.0067451876
for O 0 0.000880513
management O 0 0.0023639763
of O 0 0.0030682436
postoperative B-Disease 0 0.8526664
pain I-Disease 2 0.9995517
control O 0 0.009667541
. O 0 0.00953325

Twenty O 0 0.018140078
- O 0 0.010364047
three O 0 0.0044940966
h O 0 0.0040281024
postoperatively O 0 0.0043461295
he O 0 0.004071998
developed O 0 0.0038147946
a O 0 0.004180479
brief O 0 0.004800671
self O 0 0.03302155
- O 0 0.009512183
limited O 0 0.007912973
seizure B-Disease 2 0.9990709
. O 0 0.014691211

Both O 0 0.011227978
plasma O 0 0.07212152
pethidine B-Chemical 1 0.99989915
and O 0 0.009854418
norpethidine B-Chemical 0 0.99900913
were O 0 0.0023881271
elevated O 0 0.0031268457
in O 0 0.001084148
the O 0 0.0010099038
range O 0 0.0014191428
associated O 0 0.0012311392
with O 0 0.001324529
clinical O 0 0.018258013
manifestations O 0 0.7424769
of O 0 0.0037735165
central O 0 0.026174692
nervous O 0 0.984769
system O 0 0.016137503
excitation O 0 0.5726891
. O 0 0.009526723

No O 0 0.01948107
other O 0 0.013395868
risk O 0 0.03877428
factors O 0 0.022068655
for O 0 0.010481789
CNS O 0 0.97694415
toxicity B-Disease 2 0.99752194
were O 0 0.014534262
identified O 0 0.012727423
. O 0 0.015558064

This O 0 0.010156078
method O 0 0.0062940367
allowed O 0 0.0038374471
frequent O 0 0.0057982644
self O 0 0.030702531
- O 0 0.003516265
dosing O 0 0.008877055
of O 0 0.0020795225
pethidine B-Chemical 1 0.99996316
at O 0 0.0008405139
short O 0 0.0007379963
time O 0 0.0006983797
intervals O 0 0.000819194
and O 0 0.0011706409
rapid O 0 0.0023812596
accumulation O 0 0.0030324215
of O 0 0.005811564
pethidine B-Chemical 1 0.9999641
and O 0 0.021985102
norpethidine B-Chemical 0 0.99911755
. O 0 0.010857473

The O 0 0.007937918
routine O 0 0.005937601
use O 0 0.0045223185
of O 0 0.00496624
pethidine B-Chemical 1 0.9999175
via O 0 0.003472939
PCA O 0 0.8279568
even O 0 0.0019876778
for O 0 0.0013258731
a O 0 0.0020220522
brief O 0 0.0023965905
postoperative O 0 0.104757786
analgesia O 0 0.98215723
should O 0 0.0030840249
be O 0 0.005299089
reconsidered O 0 0.007779469
. O 0 0.00897269

An O 0 0.01915003
unusual O 0 0.018805157
toxic O 0 0.61960435
reaction O 0 0.029687043
to O 0 0.007114575
axillary O 0 0.29213846
block O 0 0.010204911
by O 0 0.0109133
mepivacaine B-Chemical 0 0.99981195
with O 0 0.031710267
adrenaline B-Chemical 1 0.9996989
. O 0 0.017743163

An O 0 0.011671131
increase B-Disease 0 0.004879933
in I-Disease 0 0.0035950611
blood I-Disease 0 0.010137826
pressure I-Disease 0 0.083671056
, O 0 0.002768783
accompanied O 0 0.0026983721
by O 0 0.0019994264
atrial B-Disease 0 0.994645
fibrillation I-Disease 0 0.99998605
, O 0 0.0101902895
agitation B-Disease 2 0.9943786
, O 0 0.0022145028
incomprehensible B-Disease 0 0.052790556
shouts I-Disease 0 0.0968546
and O 0 0.00078922306
loss B-Disease 0 0.002354767
of I-Disease 0 0.0010267935
consciousness I-Disease 0 0.99421483
, O 0 0.0009643868
was O 0 0.00039126523
observed O 0 0.00025859723
in O 0 0.00038271124
an O 0 0.0008250095
elderly O 0 0.4240566
, O 0 0.0011618289
ASA O 1 0.9924763
classification O 0 0.0009450174
group O 0 0.0011223819
II O 0 0.1343161
, O 0 0.000996088
cardiovascularly O 0 0.44754264
medicated O 0 0.5557557
male O 0 0.0074846
, O 0 0.00059733225
12 O 0 0.00025626677
min O 0 0.00029782977
after O 0 0.00019210657
performance O 0 0.00042793344
of O 0 0.00047115237
axillary O 0 0.12623222
block O 0 0.0009866054
with O 0 0.000892869
mepivacaine B-Chemical 0 0.99996626
850 O 0 0.02651106
mg O 0 0.22511142
containing O 0 0.0006423943
adrenaline B-Chemical 1 0.9998952
0 O 0 0.001100685
. O 0 0.00048468847
225 O 0 0.002324424
mg O 0 0.08665247
, O 0 0.0010779286
for O 0 0.00078091014
correction O 0 0.0021948782
of O 0 0.0024437876
Dupuytren B-Disease 0 0.9981376
' I-Disease 0 0.0073260264
s I-Disease 0 0.007777931
contracture I-Disease 0 0.9949698
. O 0 0.010029181

After O 0 0.005715194
intravenous O 0 0.13852526
administration O 0 0.089863926
of O 0 0.007464818
labetalol B-Chemical 1 0.99999464
, O 0 0.037776962
metoprolol B-Chemical 1 0.99999475
and O 0 0.0034019933
midazolam B-Chemical 1 0.9999281
the O 0 0.0009851797
patient O 0 0.001319551
' O 0 0.0010651118
s O 0 0.000907637
condition O 0 0.0013633887
improved O 0 0.0016117885
, O 0 0.0014047167
and O 0 0.0012492583
15 O 0 0.0011801043
min O 0 0.0016873297
later O 0 0.0019068713
he O 0 0.0039588735
woke O 0 0.007441346
up O 0 0.0058372845
. O 0 0.008220349

The O 0 0.009180408
block O 0 0.007885456
was O 0 0.0048518656
successful O 0 0.0038974336
and O 0 0.0032869766
surgery O 0 0.0043086982
was O 0 0.0021802948
conducted O 0 0.0018061822
as O 0 0.0019432404
scheduled O 0 0.0019346799
despite O 0 0.00261207
persisting O 0 0.039647046
atrial B-Disease 0 0.9957612
fibrillation I-Disease 0 0.9998325
. O 0 0.014929916

Postoperatively O 0 0.03823978
, O 0 0.011409251
the O 0 0.0072723585
patient O 0 0.008138457
refused O 0 0.012329431
DC O 0 0.26380572
cardioversion O 0 0.6809434
and O 0 0.0077618873
was O 0 0.0073179966
treated O 0 0.012131821
medically O 0 0.80126345
. O 0 0.01496436

Both O 0 0.008070713
the O 0 0.004945711
temporal O 0 0.006050736
relationship O 0 0.0019190474
of O 0 0.0021753323
events O 0 0.019016523
and O 0 0.0014601736
the O 0 0.0009346713
response O 0 0.0010665557
to O 0 0.0006061424
treatment O 0 0.00080584944
suggest O 0 0.00033122147
that O 0 0.00038232526
a O 0 0.000725681
rapid O 0 0.001663989
systemic O 0 0.8943139
absorption O 0 0.60096264
of O 0 0.0025448892
mepivacaine B-Chemical 0 0.999985
with O 0 0.0021039916
adrenaline B-Chemical 1 0.99996924
and O 0 0.0010624743
/ O 0 0.0019766204
or O 0 0.00037175664
interaction O 0 0.00040308383
of O 0 0.0004595354
these O 0 0.0005693717
drugs O 0 0.37882587
with O 0 0.00051832077
the O 0 0.00048089758
patient O 0 0.00087139686
' O 0 0.00086694275
s O 0 0.0008947072
cardiovascular O 0 0.9809427
medications O 0 0.42848566
were O 0 0.0011662606
responsible O 0 0.001182063
for O 0 0.001337399
the O 0 0.0025106778
perioperative O 0 0.3865263
complications O 0 0.86661464
. O 0 0.010441657

Drug O 0 0.96223336
- O 0 0.015894677
associated O 0 0.008079399
acute O 0 0.9482409
- O 0 0.0106358295
onset O 0 0.017425241
vanishing B-Disease 0 0.36986887
bile I-Disease 0 0.9846373
duct I-Disease 0 0.9790578
and O 0 0.007007394
Stevens B-Disease 0 0.5414118
- I-Disease 0 0.008105625
Johnson I-Disease 0 0.30378214
syndromes I-Disease 0 0.7178066
in O 0 0.004215928
a O 0 0.007404251
child O 0 0.015333724
. O 0 0.009999032

Acute O 0 0.96275824
vanishing B-Disease 0 0.40805185
bile I-Disease 0 0.97623926
duct I-Disease 0 0.9837427
syndrome O 0 0.9607978
is O 0 0.002780453
a O 0 0.002405172
rare O 0 0.013493191
but O 0 0.0012085105
established O 0 0.0013484533
cause O 0 0.0034607714
of O 0 0.0015792969
progressive O 0 0.7788942
cholestasis B-Disease 2 0.999995
in O 0 0.001633655
adults O 0 0.016544532
, O 0 0.0010310536
is O 0 0.0005149721
most O 0 0.00070929853
often O 0 0.0010555071
drug O 0 0.3488141
or O 0 0.0009855161
toxin O 0 0.19227694
related O 0 0.0010870534
, O 0 0.0020491644
and O 0 0.0017846767
is O 0 0.0019421016
of O 0 0.0033347982
unknown O 0 0.021232631
pathogenesis O 0 0.095760494
. O 0 0.010938706

It O 0 0.022105291
has O 0 0.013220731
not O 0 0.011713387
been O 0 0.011352158
reported O 0 0.010877149
previously O 0 0.010699338
in O 0 0.012534577
children O 0 0.025866518
. O 0 0.017957538

Stevens B-Disease 0 0.27855036
- I-Disease 0 0.014991902
Johnson I-Disease 0 0.15528989
syndrome I-Disease 0 0.6594769
is O 0 0.0028911366
a O 0 0.0025426755
well O 0 0.0017192577
- O 0 0.0024639256
recognized O 0 0.001450106
immune O 0 0.33144102
complex O 0 0.0024055967
- O 0 0.0033011606
mediated O 0 0.00083098514
hypersensitivity B-Disease 2 0.93714416
reaction O 0 0.024108738
that O 0 0.00047317008
affects O 0 0.00031389552
all O 0 0.00042323224
age O 0 0.001479203
groups O 0 0.0008924186
, O 0 0.0008312652
is O 0 0.00047693483
drug O 0 0.27544633
or O 0 0.00068315066
infection B-Disease 2 0.2925862
induced O 0 0.0013577393
, O 0 0.0013903308
and O 0 0.0008272447
has O 0 0.0006649994
classic O 0 0.07971757
systemic O 0 0.9504922
, O 0 0.004368788
mucosal O 0 0.63216466
, O 0 0.004987482
and O 0 0.0045570955
dermatologic O 0 0.93163043
manifestations O 0 0.9728783
. O 0 0.012285519

A O 0 0.03145826
previously O 0 0.0061284453
healthy O 0 0.0102258455
child O 0 0.0052918405
who O 0 0.0040261284
developed O 0 0.0034219753
acute O 0 0.965624
, O 0 0.0049243392
severe O 0 0.38337743
, O 0 0.0019236177
rapidly O 0 0.002084067
progressive O 0 0.26235214
vanishing B-Disease 0 0.42802987
bile I-Disease 0 0.98823404
duct I-Disease 0 0.98748684
syndrome I-Disease 0 0.9601351
shortly O 0 0.004049933
after O 0 0.00053368823
Stevens B-Disease 0 0.27327067
- I-Disease 0 0.0025124697
Johnson I-Disease 0 0.19893554
syndrome I-Disease 0 0.74970794
is O 0 0.0009153233
described O 0 0.0007802994
; O 0 0.001621302
this O 0 0.00087581185
was O 0 0.0011648535
temporally O 0 0.0029467186
associated O 0 0.0026243252
with O 0 0.0055582947
ibuprofen B-Chemical 1 0.99992955
use O 0 0.012401806
. O 0 0.009852512

Despite O 0 0.010278188
therapy O 0 0.018567642
with O 0 0.0080290055
ursodeoxycholic B-Chemical 0 0.99993837
acid I-Chemical 0 0.99663585
, O 0 0.022553116
prednisone B-Chemical 1 0.9998759
, O 0 0.0029014798
and O 0 0.0012396808
then O 0 0.0010761131
tacrolimus B-Chemical 1 0.9999671
, O 0 0.0033954568
her O 0 0.008633159
cholestatic B-Disease 0 0.9999969
disease I-Disease 0 0.99791664
was O 0 0.0029658477
unrelenting O 0 0.89576966
, O 0 0.002334053
with O 0 0.0018188822
cirrhosis B-Disease 2 0.9999739
shown O 0 0.001283402
by O 0 0.001596235
biopsy O 0 0.0056749396
6 O 0 0.0015386987
months O 0 0.0017548901
after O 0 0.0023130476
presentation O 0 0.011177662
. O 0 0.008573184

This O 0 0.010057627
case O 0 0.0055726883
documents O 0 0.00708543
acute O 0 0.8703913
drug O 0 0.8924498
- O 0 0.0051646507
related O 0 0.0012392604
vanishing B-Disease 0 0.21078287
bile I-Disease 0 0.9821018
duct I-Disease 0 0.98627985
syndrome I-Disease 0 0.94985723
in O 0 0.00081963604
the O 0 0.00064299646
pediatric O 0 0.001581759
age O 0 0.0014395082
group O 0 0.0006934352
and O 0 0.0005916249
suggests O 0 0.00032803963
shared O 0 0.0008241707
immune O 0 0.21797408
mechanisms O 0 0.0014873904
in O 0 0.00062094734
the O 0 0.0006709904
pathogenesis O 0 0.0034497723
of O 0 0.0013382672
both O 0 0.0014367938
Stevens B-Disease 0 0.37192988
- I-Disease 0 0.00408238
Johnson I-Disease 0 0.23249009
syndrome I-Disease 0 0.77638113
and O 0 0.003822927
vanishing B-Disease 0 0.4858794
bile I-Disease 0 0.9894853
duct I-Disease 0 0.9920266
syndrome I-Disease 0 0.9906577
. O 0 0.013640761

High O 0 0.030478708
incidence O 0 0.016068077
of O 0 0.00829123
primary B-Disease 2 0.013087354
pulmonary I-Disease 2 0.9974481
hypertension I-Disease 2 0.9999733
associated O 0 0.025395954
with O 0 0.019224143
appetite B-Chemical 1 0.9996979
suppressants I-Chemical 1 0.99975294
in O 0 0.014895031
Belgium O 0 0.4356217
. O 0 0.012689385

Primary B-Disease 0 0.07246443
pulmonary I-Disease 2 0.9887473
hypertension I-Disease 2 0.9999399
is O 0 0.0050402577
a O 0 0.0037080965
rare O 0 0.022009179
, O 0 0.0028272402
progressive O 0 0.17582561
and O 0 0.002397075
incurable O 0 0.9073829
disease O 0 0.95267856
, O 0 0.0027682234
which O 0 0.0013371469
has O 0 0.00078741123
been O 0 0.0009523106
associated O 0 0.0010671086
with O 0 0.0012497094
the O 0 0.0016476089
intake O 0 0.67076826
of O 0 0.0095036775
appetite B-Chemical 0 0.9997571
suppressant I-Chemical 0 0.9996196
drugs O 0 0.9907742
. O 0 0.013348874

The O 0 0.0067346604
importance O 0 0.004201117
of O 0 0.0035118836
this O 0 0.0023035146
association O 0 0.0015175245
was O 0 0.0013911958
evaluated O 0 0.0010475691
in O 0 0.0010900487
Belgium O 0 0.01568764
while O 0 0.0007524069
this O 0 0.0007046882
country O 0 0.0014095353
still O 0 0.0006470857
had O 0 0.0006357565
no O 0 0.00065383484
restriction O 0 0.0018416011
on O 0 0.00087828044
the O 0 0.0016010015
prescription O 0 0.040977776
of O 0 0.007418145
appetite B-Chemical 1 0.99959856
suppressants I-Chemical 1 0.9997093
. O 0 0.015487361

Thirty O 0 0.015402684
- O 0 0.007734293
five O 0 0.0031318513
patients O 0 0.0040012677
with O 0 0.0022526914
primary B-Disease 2 0.0040990007
pulmonary I-Disease 2 0.99612916
hypertension I-Disease 2 0.9999888
and O 0 0.0022660873
85 O 0 0.0013762492
matched O 0 0.00066704804
controls O 0 0.0009860834
were O 0 0.00062943733
recruited O 0 0.000635167
over O 0 0.00049389957
32 O 0 0.0010417437
months O 0 0.0008498925
( O 0 0.0019179573
1992 O 0 0.0062836227
- O 0 0.0032897396
1994 O 0 0.007410256
) O 0 0.004730591
in O 0 0.004364584
Belgium O 0 0.07659736
. O 0 0.00827739

Exposure O 0 0.047532056
to O 0 0.010225102
appetite B-Chemical 0 0.9988391
- I-Chemical 0 0.025865696
suppressants I-Chemical 0 0.9990637
was O 0 0.0029642067
assessed O 0 0.0016220424
on O 0 0.0012358787
the O 0 0.0014390408
basis O 0 0.0017129113
of O 0 0.0023141443
hospital O 0 0.0061972057
records O 0 0.0046723196
and O 0 0.0041235653
standardized O 0 0.0053618513
interview O 0 0.008406433
. O 0 0.008622866

Twenty O 0 0.013716591
- O 0 0.0072023817
three O 0 0.0026841338
of O 0 0.0025782676
the O 0 0.001885217
patients O 0 0.0026772728
had O 0 0.0011299348
previously O 0 0.001019619
taken O 0 0.0009807766
appetite B-Chemical 1 0.99954283
suppressants I-Chemical 1 0.99991333
, O 0 0.0028992787
mainly O 0 0.002255598
fenfluramines B-Chemical 0 0.996669
, O 0 0.0010035349
as O 0 0.0004509554
compared O 0 0.00027332662
with O 0 0.00039960904
only O 0 0.00036671854
5 O 0 0.00032124107
of O 0 0.00039094788
the O 0 0.00042890743
controls O 0 0.0010524602
( O 0 0.0007901115
66 O 0 0.00083510735
versus O 0 0.0004896261
6 O 0 0.00052728044
% O 0 0.00088616065
, O 0 0.0011283025
p O 0 0.0014241142
< O 0 0.0016327687
0 O 0 0.0023673081
. O 0 0.0024502757
0001 O 0 0.025020262
) O 0 0.0077164597
. O 0 0.007445726

Five O 0 0.014001473
patients O 0 0.010379273
died O 0 0.009856691
before O 0 0.0032040088
the O 0 0.0033118874
interview O 0 0.0035931622
, O 0 0.0029816832
all O 0 0.0021743383
of O 0 0.0028143197
them O 0 0.0046679606
had O 0 0.0036386305
taken O 0 0.0051121823
appetite B-Chemical 1 0.9988619
suppressants I-Chemical 1 0.9995061
. O 0 0.01731651

In O 0 0.007659761
8 O 0 0.0051496318
patients O 0 0.0048050233
the O 0 0.002721342
diagnosis O 0 0.00464087
of O 0 0.0023231294
primary B-Disease 2 0.005442696
pulmonary I-Disease 2 0.99820364
hypertension I-Disease 2 0.9999919
was O 0 0.002612527
uncertain O 0 0.004596994
, O 0 0.0018102817
5 O 0 0.0010569155
of O 0 0.0014151157
them O 0 0.0027550561
had O 0 0.0023196
taken O 0 0.0035997545
appetite B-Chemical 1 0.99890244
suppressants I-Chemical 1 0.9995339
. O 0 0.0143501675

The O 0 0.007710605
patients O 0 0.007931628
who O 0 0.005681226
had O 0 0.0028879244
been O 0 0.0022390832
exposed O 0 0.0016338092
to O 0 0.0018357752
appetite B-Chemical 1 0.9996445
suppressants I-Chemical 1 0.99985766
tended O 0 0.0013247227
to O 0 0.0006967158
be O 0 0.00057912996
on O 0 0.00034017433
average O 0 0.0003821343
more O 0 0.0007022316
severely O 0 0.009947759
ill O 0 0.27814692
, O 0 0.0009948654
and O 0 0.0006169319
to O 0 0.00045170682
have O 0 0.0004378352
a O 0 0.00067374506
shorter O 0 0.00043881976
median O 0 0.00062287046
delay O 0 0.0012888383
between O 0 0.00078821933
onset O 0 0.0054030293
of O 0 0.003497909
symptoms O 0 0.9175301
and O 0 0.007288029
diagnosis O 0 0.115187205
. O 0 0.010191329

A O 0 0.031864792
policy O 0 0.009071135
of O 0 0.0047750073
unrestricted O 0 0.0053755813
prescription O 0 0.026729215
of O 0 0.0046208226
appetite B-Chemical 1 0.9997154
suppressants I-Chemical 1 0.9998801
may O 0 0.0026059216
lead O 0 0.024234038
to O 0 0.0011823875
a O 0 0.0016436183
high O 0 0.0016804505
incidence O 0 0.009044561
of O 0 0.0027002848
associated O 0 0.00400188
primary B-Disease 2 0.04130636
pulmonary I-Disease 2 0.999238
hypertension I-Disease 2 0.9999676
. O 0 0.018210793

Intake O 0 0.7872707
of O 0 0.01931952
appetite B-Chemical 1 0.9986761
suppressants I-Chemical 1 0.99938095
may O 0 0.008919633
accelerate O 0 0.0067237597
the O 0 0.0059234104
progression O 0 0.31072265
of O 0 0.009288422
the O 0 0.010203255
disease O 0 0.9159522
. O 0 0.016231295

Inappropriate O 0 0.03741047
use O 0 0.01084339
of O 0 0.012604162
carbamazepine B-Chemical 1 0.99994016
and O 0 0.028086508
vigabatrin B-Chemical 1 0.9999113
in O 0 0.0075237514
typical O 0 0.010177442
absence B-Disease 0 0.015289618
seizures I-Disease 2 0.9999211
. O 0 0.02006753

Carbamazepine B-Chemical 1 0.99978775
and O 0 0.03028767
vigabatrin B-Chemical 1 0.9997936
are O 0 0.011809298
contraindicated O 0 0.09424386
in O 0 0.0071836426
typical O 0 0.010601003
absence B-Disease 0 0.01589611
seizures I-Disease 2 0.9999062
. O 0 0.022037612

Of O 0 0.009748019
18 O 0 0.0049525965
consecutive O 0 0.0032876388
referrals O 0 0.0048063872
of O 0 0.0021786292
children O 0 0.002779201
with O 0 0.0012915226
resistant O 0 0.0013164066
typical O 0 0.001397774
absences O 0 0.71847516
only O 0 0.00084414275
, O 0 0.0008829592
eight O 0 0.00044081168
were O 0 0.000563457
erroneously O 0 0.005649077
treated O 0 0.00088895776
with O 0 0.0012482657
carbamazepine B-Chemical 1 0.9999913
either O 0 0.0010485167
as O 0 0.00108257
monotherapy O 0 0.32184097
or O 0 0.0012460983
as O 0 0.0016926167
an O 0 0.0029192634
add O 0 0.0035403902
- O 0 0.0058687953
on O 0 0.0042514857
. O 0 0.00781577

Vigabatrin B-Chemical 1 0.99914324
was O 0 0.011028408
also O 0 0.007116124
used O 0 0.0053354865
in O 0 0.004756997
the O 0 0.0048358375
treatment O 0 0.006490649
of O 0 0.0070454576
two O 0 0.0075479485
children O 0 0.020464666
. O 0 0.01295592

Frequency O 0 0.016637433
of O 0 0.007209416
absences O 0 0.55768317
increased O 0 0.0038492319
in O 0 0.0019140745
four O 0 0.0012499152
children O 0 0.0024075438
treated O 0 0.0014897953
with O 0 0.001718221
carbamazepine B-Chemical 1 0.99998987
and O 0 0.0011269121
two O 0 0.0005788546
of O 0 0.0008091423
these O 0 0.0011301845
developed O 0 0.0057980665
myoclonic B-Disease 2 0.9999933
jerks I-Disease 2 0.9999621
, O 0 0.0036566257
which O 0 0.0017414977
resolved O 0 0.0027270447
on O 0 0.00156157
withdrawal O 0 0.8161201
of O 0 0.016575042
carbamazepine B-Chemical 1 0.9999621
. O 0 0.01162331

Absences O 0 0.51035917
were O 0 0.009334802
aggravated O 0 0.26290163
in O 0 0.004165663
both O 0 0.0031909128
cases O 0 0.00454229
where O 0 0.0032563596
vigabatrin B-Chemical 1 0.99992585
was O 0 0.0027348758
added O 0 0.0023865234
on O 0 0.0019928832
to O 0 0.0030100269
concurrent O 0 0.009116976
treatment O 0 0.0135227125
. O 0 0.01054184

Optimal O 0 0.011498444
control O 0 0.0053763003
of O 0 0.004323569
the O 0 0.0034200784
absences O 0 0.666904
was O 0 0.0023801494
achieved O 0 0.0020712784
with O 0 0.0028569307
sodium B-Chemical 1 0.9999194
valproate I-Chemical 0 0.9999933
, O 0 0.034985475
lamotrigine B-Chemical 0 0.9999894
, O 0 0.003571042
or O 0 0.002490752
ethosuximide B-Chemical 0 0.9999751
alone O 0 0.0031086346
or O 0 0.0030115757
in O 0 0.0039155968
combination O 0 0.010612553
. O 0 0.008654342

Choreoathetoid B-Disease 0 0.45062006
movements I-Disease 0 0.035953242
associated O 0 0.012085665
with O 0 0.010115551
rapid O 0 0.014095119
adjustment O 0 0.012596211
to O 0 0.012922785
methadone B-Chemical 1 0.9987244
. O 0 0.01848156

Choreatiform B-Disease 0 0.26467288
hyperkinesias I-Disease 0 0.9971641
are O 0 0.006483587
known O 0 0.004424459
to O 0 0.0026609506
be O 0 0.0023747052
occasional O 0 0.009370694
movement B-Disease 0 0.027677666
abnormalities I-Disease 0 0.5851095
during O 0 0.0019940378
intoxications O 0 0.9996824
with O 0 0.009973442
cocaine B-Chemical 1 0.99990857
but O 0 0.005763011
not O 0 0.0068448726
opiates O 0 0.9994229
. O 0 0.01204695

This O 0 0.010182279
is O 0 0.0050313277
a O 0 0.0040153037
case O 0 0.0026471496
report O 0 0.0038057936
of O 0 0.003218783
euphoria O 0 0.9998752
and O 0 0.008450177
choreoathetoid B-Disease 0 0.99997556
movements I-Disease 0 0.18252066
both O 0 0.00090655877
transiently O 0 0.007970224
induced O 0 0.0008113285
by O 0 0.0007214991
rapid O 0 0.00122216
adjustment O 0 0.0006656658
to O 0 0.00035772895
the O 0 0.00045357746
selective O 0 0.0065227337
mu O 0 0.70596766
- O 0 0.0074371207
opioid O 0 0.99958557
receptor O 0 0.45565635
agonist O 0 0.97269934
methadone B-Chemical 1 0.99975544
in O 0 0.0010007179
an O 0 0.0016531062
inpatient O 0 0.0049788407
previously O 0 0.0022031288
abusing O 0 0.9652285
heroine B-Chemical 0 0.7292073
and O 0 0.014026424
cocaine B-Chemical 1 0.9997713
. O 0 0.011742415

In O 0 0.020767987
addition O 0 0.014998163
, O 0 0.020086292
minor O 0 0.027530653
EEG O 0 0.94881564
abnormalities O 0 0.37720335
occurred O 0 0.02368117
. O 0 0.022730175

Possible O 0 0.05645487
underlying O 0 0.033655804
neurobiological O 0 0.23509978
phenomena O 0 0.06258632
are O 0 0.025375377
discussed O 0 0.022481343
. O 0 0.026232779

Adverse O 0 0.37340817
effects O 0 0.023946792
of O 0 0.01967305
the O 0 0.019450575
atypical O 0 0.6955885
antipsychotics O 0 0.9990507
. O 0 0.031562883

Collaborative O 0 0.09374896
Working O 0 0.058112122
Group O 0 0.045925114
on O 0 0.020896457
Clinical O 0 0.16608788
Trial O 0 0.12879439
Evaluations O 0 0.03644388
. O 0 0.025342664

Adverse O 0 0.39705348
effects O 0 0.01779097
of O 0 0.015808048
antipsychotics O 0 0.9989674
often O 0 0.023526529
lead O 0 0.09674933
to O 0 0.012942688
noncompliance O 0 0.88454854
. O 0 0.017533384

Thus O 0 0.008404351
, O 0 0.0062798182
clinicians O 0 0.004490303
should O 0 0.0016716062
address O 0 0.0011575266
patients O 0 0.0022332957
' O 0 0.0013832938
concerns O 0 0.001598779
about O 0 0.00072674017
adverse O 0 0.79825974
effects O 0 0.0018171463
and O 0 0.00078569324
attempt O 0 0.00064346904
to O 0 0.000433348
choose O 0 0.0005797048
medications O 0 0.10526334
that O 0 0.00038247104
will O 0 0.00035799886
improve O 0 0.00032690383
their O 0 0.00055834453
patients O 0 0.0014724166
' O 0 0.0009149401
quality O 0 0.0006997505
of O 0 0.0010706747
life O 0 0.002516464
as O 0 0.0014896011
well O 0 0.001801094
as O 0 0.0028891962
overall O 0 0.004879195
health O 0 0.04689673
. O 0 0.008744661

The O 0 0.0076774107
side O 0 0.015817672
effect O 0 0.003535471
profiles O 0 0.0024129592
of O 0 0.002427772
the O 0 0.0020240431
atypical O 0 0.25641626
antipsychotics O 0 0.9997305
are O 0 0.0017639718
more O 0 0.001390352
advantageous O 0 0.0012271947
than O 0 0.0009207214
those O 0 0.001676893
of O 0 0.0020991666
the O 0 0.0028343
conventional O 0 0.006834223
neuroleptics O 0 0.9995789
. O 0 0.0106199905

Conventional O 0 0.021037798
agents O 0 0.07864363
are O 0 0.0046912865
associated O 0 0.003324756
with O 0 0.002393675
unwanted O 0 0.23764923
central O 0 0.010985451
nervous O 0 0.97688246
system O 0 0.002734239
effects O 0 0.0031632294
, O 0 0.0017033655
including O 0 0.0014845061
extrapyramidal B-Disease 2 0.9999987
symptoms I-Disease 2 0.99941075
( O 0 0.04283447
EPS B-Disease 2 0.9999434
) O 0 0.030582465
, O 0 0.0072397823
tardive B-Disease 0 0.99999845
dyskinesia I-Disease 2 0.9999987
, O 0 0.0053892094
sedation O 0 0.83966434
, O 0 0.00074837584
and O 0 0.00045909252
possible O 0 0.00045466985
impairment O 0 0.05569919
of O 0 0.0005178554
some O 0 0.00060647726
cognitive O 0 0.6552938
measures O 0 0.0005676664
, O 0 0.00057514734
as O 0 0.0003431791
well O 0 0.0003311965
as O 0 0.0004535768
cardiac O 0 0.5017075
effects O 0 0.0035789823
, O 0 0.00467269
orthostatic B-Disease 2 0.99996936
hypotension I-Disease 2 0.99999726
, O 0 0.006372595
hepatic O 0 0.9707544
changes O 0 0.0017534731
, O 0 0.0015242811
anticholinergic O 0 0.9997594
side O 0 0.15570231
effects O 0 0.008265831
, O 0 0.0044822763
sexual B-Disease 2 0.97278726
dysfunction I-Disease 2 0.9976648
, O 0 0.005008611
and O 0 0.0040178006
weight B-Disease 0 0.022339428
gain I-Disease 0 0.011536912
. O 0 0.008529071

The O 0 0.0074256733
newer O 0 0.01727589
atypical O 0 0.075581096
agents O 0 0.11670558
have O 0 0.0022304838
a O 0 0.0024246718
lower O 0 0.0017394446
risk O 0 0.06321251
of O 0 0.0035666989
EPS B-Disease 2 0.9998661
, O 0 0.0030114024
but O 0 0.00077485474
are O 0 0.00059657043
associated O 0 0.00059000397
in O 0 0.0004322493
varying O 0 0.00070985575
degrees O 0 0.0029626032
with O 0 0.0008060529
sedation O 0 0.8970291
, O 0 0.0012621285
cardiovascular O 0 0.9915481
effects O 0 0.004820812
, O 0 0.0015183709
anticholinergic O 0 0.9997985
effects O 0 0.003466287
, O 0 0.0010347437
weight B-Disease 0 0.0065284315
gain I-Disease 0 0.0027109522
, O 0 0.001713301
sexual B-Disease 2 0.9696526
dysfunction I-Disease 2 0.99874985
, O 0 0.002867742
hepatic O 0 0.96652925
effects O 0 0.0068002036
, O 0 0.0017314655
lowered O 0 0.014920941
seizure B-Disease 2 0.9998307
threshold O 0 0.0011431338
( O 0 0.0015638333
primarily O 0 0.0026240128
clozapine B-Chemical 1 0.9999889
) O 0 0.0058121094
, O 0 0.0019120385
and O 0 0.002655011
agranulocytosis B-Disease 0 0.9999751
( O 0 0.062313523
clozapine B-Chemical 1 0.99995494
only O 0 0.0055496325
) O 0 0.012954317
. O 0 0.007977694

Since O 0 0.0063948617
the O 0 0.004868651
incidence O 0 0.008206759
and O 0 0.0032187277
severity O 0 0.023302516
of O 0 0.0019713596
specific O 0 0.0011838953
adverse O 0 0.91362363
effects O 0 0.0030587078
differ O 0 0.0009641112
among O 0 0.0008267404
the O 0 0.00057144207
various O 0 0.0013121064
atypicals O 0 0.98910683
, O 0 0.000760857
the O 0 0.000375074
clinician O 0 0.0009951124
should O 0 0.00019956408
carefully O 0 0.00022724975
consider O 0 0.00022085238
which O 0 0.00048358503
side O 0 0.022192078
effects O 0 0.0011457964
are O 0 0.00050366845
most O 0 0.00058554666
likely O 0 0.00038275903
to O 0 0.00036796837
lead O 0 0.0034554568
to O 0 0.0003332721
the O 0 0.00035448174
individual O 0 0.00041280696
' O 0 0.0006792952
s O 0 0.00066072727
dissatisfaction O 0 0.07549152
and O 0 0.0007159034
noncompliance O 0 0.26780227
before O 0 0.00041420062
choosing O 0 0.000874746
an O 0 0.0015975548
antipsychotic O 0 0.99829406
for O 0 0.0015423357
a O 0 0.002975618
particular O 0 0.0028570218
patient O 0 0.00792469
. O 0 0.00803727

A O 0 0.03794575
randomized O 0 0.007423322
, O 0 0.0058244774
placebo O 0 0.12174149
- O 0 0.0035656656
controlled O 0 0.0016305456
dose O 0 0.010260613
- O 0 0.001916397
comparison O 0 0.0007543007
trial O 0 0.0013219133
of O 0 0.0018375629
haloperidol B-Chemical 1 0.99999475
for O 0 0.0016319405
psychosis B-Disease 0 0.9999242
and O 0 0.0032030176
disruptive B-Disease 0 0.78744495
behaviors I-Disease 0 0.7960101
in O 0 0.0037615628
Alzheimer B-Disease 0 0.9998989
' I-Disease 0 0.0076780072
s I-Disease 0 0.0066038766
disease I-Disease 0 0.7463041
. O 0 0.010064869

OBJECTIVE O 0 0.48495087
: O 0 0.007964157
The O 0 0.003426237
goal O 0 0.0030913139
of O 0 0.0020751809
this O 0 0.0014516029
study O 0 0.0013697951
was O 0 0.0008373229
to O 0 0.00056580285
compare O 0 0.0003377836
the O 0 0.0005046706
efficacy O 0 0.0013125938
and O 0 0.00067081634
side O 0 0.026086718
effects O 0 0.0010037686
of O 0 0.0006008753
two O 0 0.00041447
doses O 0 0.024162212
of O 0 0.0021951895
haloperidol B-Chemical 1 0.9999976
and O 0 0.0010290341
placebo O 0 0.115282655
in O 0 0.0004097674
the O 0 0.0004503366
treatment O 0 0.0008729634
of O 0 0.0014520874
psychosis B-Disease 0 0.9999459
and O 0 0.0020480694
disruptive B-Disease 0 0.7218786
behaviors I-Disease 0 0.6156434
in O 0 0.0012970966
patients O 0 0.0073584234
with O 0 0.003566221
Alzheimer B-Disease 0 0.9999006
' I-Disease 0 0.007407953
s I-Disease 0 0.006402168
disease I-Disease 0 0.7466286
. O 0 0.009891319

METHOD O 0 0.025699051
: O 0 0.007806354
In O 0 0.0036677662
a O 0 0.0034988683
6 O 0 0.0020777746
- O 0 0.0021225056
week O 0 0.0010284656
random O 0 0.0015554811
- O 0 0.0016334708
assignment O 0 0.0012229972
, O 0 0.0010161938
double O 0 0.0008275246
- O 0 0.0013290239
blind O 0 0.006323694
, O 0 0.00091799063
placebo O 0 0.11448399
- O 0 0.00094729994
controlled O 0 0.00044401007
trial O 0 0.0008307544
( O 0 0.0007761761
phase O 0 0.0010393126
A O 0 0.12294123
) O 0 0.0027449396
, O 0 0.0018926238
haloperidol B-Chemical 1 0.9999956
, O 0 0.0011780462
2 O 0 0.00055686117
- O 0 0.00063704647
3 O 0 0.00033101058
mg O 0 0.048104186
/ O 0 0.0008028161
day O 0 0.00032997713
( O 0 0.00048869423
standard O 0 0.00037581957
dose O 0 0.006815635
) O 0 0.001462215
, O 0 0.0007311311
and O 0 0.00088137726
haloperidol B-Chemical 1 0.9999958
, O 0 0.0010117268
0 O 0 0.00065484695
. O 0 0.00029268
50 O 0 0.00058091
- O 0 0.0005818692
0 O 0 0.00043256424
. O 0 0.00024599116
75 O 0 0.0004469768
mg O 0 0.032770928
/ O 0 0.00080994994
day O 0 0.0003736116
( O 0 0.00059301703
low O 0 0.00055926543
dose O 0 0.009154908
) O 0 0.0016430893
, O 0 0.00076847424
were O 0 0.0005195277
compared O 0 0.00041016252
in O 0 0.0007074151
71 O 0 0.0024609328
outpatients O 0 0.017151056
with O 0 0.0026384336
Alzheimer B-Disease 0 0.9998435
' I-Disease 0 0.0063763214
s I-Disease 0 0.0061937887
disease I-Disease 0 0.7153288
. O 0 0.009937104

For O 0 0.006354089
the O 0 0.0047466955
subsequent O 0 0.0037420096
6 O 0 0.0024193171
- O 0 0.002399083
week O 0 0.00110704
double O 0 0.0012539314
- O 0 0.001662552
blind O 0 0.0034540123
crossover O 0 0.008717654
phase O 0 0.0017474449
( O 0 0.0013454944
phase O 0 0.0017178897
B O 0 0.3959181
) O 0 0.001998501
, O 0 0.00070797926
patients O 0 0.00095487677
taking O 0 0.00080261694
standard O 0 0.00056575437
- O 0 0.0008766229
or O 0 0.00041730102
low O 0 0.00084736873
- O 0 0.0015103099
dose O 0 0.039605714
haloperidol B-Chemical 1 0.99999666
were O 0 0.0005567746
switched O 0 0.0007040268
to O 0 0.00037746676
placebo O 0 0.07028066
, O 0 0.0005803074
and O 0 0.00043219412
patients O 0 0.0009545061
taking O 0 0.00080517353
placebo O 0 0.01936553
were O 0 0.00042255965
randomly O 0 0.0002974501
assigned O 0 0.0003900098
to O 0 0.0005676838
standard O 0 0.0010015306
- O 0 0.0017813446
or O 0 0.0013432718
low O 0 0.0028025869
- O 0 0.0070578144
dose O 0 0.3004068
haloperidol B-Chemical 1 0.999967
. O 0 0.010968555

RESULTS O 0 0.023425909
: O 0 0.0074317106
For O 0 0.0031801716
the O 0 0.0026281145
60 O 0 0.002046274
patients O 0 0.0023660462
who O 0 0.0019857234
completed O 0 0.0010986216
phase O 0 0.0015374295
A O 0 0.049528472
, O 0 0.0011419567
standard O 0 0.0008673386
- O 0 0.0014540711
dose O 0 0.034727324
haloperidol B-Chemical 1 0.99999654
was O 0 0.0007671704
efficacious O 0 0.0046606525
and O 0 0.00053309137
superior O 0 0.0007623414
to O 0 0.00034461325
both O 0 0.00041462685
low O 0 0.00083766325
- O 0 0.0014661519
dose O 0 0.037927732
haloperidol B-Chemical 1 0.9999962
and O 0 0.000919853
placebo O 0 0.06800655
for O 0 0.0004061603
scores O 0 0.0007285974
on O 0 0.00043703473
the O 0 0.00091061293
Brief O 0 0.31577918
Psychiatric O 0 0.8882594
Rating O 0 0.91249514
Scale O 0 0.9927367
psychosis B-Disease 0 0.999821
factor O 0 0.021260986
and O 0 0.002980824
on O 0 0.0029249983
psychomotor B-Disease 0 0.9978484
agitation I-Disease 2 0.9933961
. O 0 0.010558661

Response O 0 0.02187272
rates O 0 0.0056769154
according O 0 0.0031443648
to O 0 0.0020368798
three O 0 0.0012271198
sets O 0 0.0011849705
of O 0 0.0011155184
criteria O 0 0.0010769896
were O 0 0.0006925001
greater O 0 0.0005292279
with O 0 0.0005270415
the O 0 0.00047892574
standard O 0 0.0005440047
dose O 0 0.006797744
( O 0 0.0009032807
55 O 0 0.00068071095
% O 0 0.00062424416
- O 0 0.00065833
60 O 0 0.00038224104
% O 0 0.0004775977
) O 0 0.0005509833
than O 0 0.00024570286
the O 0 0.000332551
low O 0 0.00051763747
dose O 0 0.0066680787
( O 0 0.00095771666
25 O 0 0.00075655006
% O 0 0.0007232929
- O 0 0.0007934407
35 O 0 0.00055285974
% O 0 0.00069701707
) O 0 0.00095402787
and O 0 0.0008106229
placebo O 0 0.057625588
( O 0 0.001602465
25 O 0 0.0016376504
% O 0 0.0019494067
- O 0 0.0026439575
30 O 0 0.0020940667
% O 0 0.004247397
) O 0 0.0075683827
. O 0 0.0073282127

The O 0 0.008374801
advantage O 0 0.006055148
of O 0 0.004863592
standard O 0 0.0038823918
dose O 0 0.0064619095
over O 0 0.0021961043
low O 0 0.0032157504
dose O 0 0.014415785
was O 0 0.003447226
replicated O 0 0.00323656
in O 0 0.0044837724
phase O 0 0.011175196
B O 0 0.5168643
. O 0 0.012575484

In O 0 0.008711607
phase O 0 0.0090815695
A O 0 0.105131865
, O 0 0.008948809
extrapyramidal B-Disease 0 0.99998164
signs I-Disease 0 0.93979496
tended O 0 0.0017792636
to O 0 0.0009749686
be O 0 0.00078740634
greater O 0 0.00055655977
with O 0 0.00053672097
the O 0 0.0004638096
standard O 0 0.00047635328
dose O 0 0.0021961485
than O 0 0.00030003567
in O 0 0.0003300942
the O 0 0.00034736222
other O 0 0.00037883723
two O 0 0.00036211094
conditions O 0 0.00063821225
, O 0 0.000639824
primarily O 0 0.0005339531
because O 0 0.00032643235
of O 0 0.0005602749
a O 0 0.00087423774
subgroup O 0 0.0035938758
( O 0 0.0011338891
20 O 0 0.0007572594
% O 0 0.0009790635
) O 0 0.0013604322
who O 0 0.0016276583
developed O 0 0.0019007092
moderate O 0 0.0080741
to O 0 0.003144206
severe O 0 0.5119499
signs O 0 0.7541726
. O 0 0.010568963

Low O 0 0.20723984
- O 0 0.012588612
dose O 0 0.08189517
haloperidol B-Chemical 1 0.9999671
did O 0 0.0030558186
not O 0 0.001820165
differ O 0 0.0015838578
from O 0 0.0013224505
placebo O 0 0.024758749
on O 0 0.0008012509
any O 0 0.00096597127
measure O 0 0.0008644303
of O 0 0.0018855528
efficacy O 0 0.0059423507
or O 0 0.0037527888
side O 0 0.20353614
effects O 0 0.022041226
. O 0 0.010047743

CONCLUSIONS O 0 0.41327947
: O 0 0.00792658
The O 0 0.0033725135
results O 0 0.0026114143
indicated O 0 0.0017782763
a O 0 0.0020086677
favorable O 0 0.0040798252
therapeutic O 0 0.009271666
profile O 0 0.0014152067
for O 0 0.0010697305
haloperidol B-Chemical 1 0.99999475
in O 0 0.00082632375
doses O 0 0.017955156
of O 0 0.0010002995
2 O 0 0.00083146506
- O 0 0.0009195721
3 O 0 0.00045059295
mg O 0 0.06815721
/ O 0 0.0010780308
day O 0 0.0004651665
, O 0 0.000680842
although O 0 0.0004992616
a O 0 0.00088220317
subgroup O 0 0.0020989997
developed O 0 0.0017069499
moderate O 0 0.013130629
to O 0 0.002694455
severe O 0 0.9077632
extrapyramidal B-Disease 0 0.99999034
signs I-Disease 0 0.9897195
. O 0 0.013047001

A O 0 0.024545787
starting O 0 0.005961592
dose O 0 0.008314937
of O 0 0.003990887
1 O 0 0.0029704913
mg O 0 0.19461758
/ O 0 0.0033844823
day O 0 0.0013687621
with O 0 0.0014553906
gradual O 0 0.0020745709
, O 0 0.002346414
upward O 0 0.0058909818
dose O 0 0.012423937
titration O 0 0.008832377
is O 0 0.0043007825
recommended O 0 0.0064872797
. O 0 0.008334982

The O 0 0.007403077
narrow O 0 0.007169204
therapeutic O 0 0.007616382
window O 0 0.0033709689
observed O 0 0.0016491823
with O 0 0.00274025
haloperidol B-Chemical 1 0.9999907
may O 0 0.0013107132
also O 0 0.0009247723
apply O 0 0.000591006
to O 0 0.0006133859
other O 0 0.0009004484
neuroleptics O 0 0.99980265
used O 0 0.00094759464
in O 0 0.0011496439
Alzheimer B-Disease 0 0.9999218
' I-Disease 0 0.0019311631
s I-Disease 0 0.0014089447
disease I-Disease 0 0.44995826
patients O 0 0.009123718
with O 0 0.0038862263
psychosis B-Disease 0 0.99987507
and O 0 0.008805363
disruptive B-Disease 0 0.88414747
behaviors I-Disease 0 0.8865705
. O 0 0.01050795

Effects O 0 0.022693569
of O 0 0.017652664
acetylsalicylic B-Chemical 1 0.9999789
acid I-Chemical 1 0.99910957
, O 0 0.0607933
dipyridamole B-Chemical 1 0.99995565
, O 0 0.006907206
and O 0 0.0033415821
hydrocortisone B-Chemical 1 0.99978083
on O 0 0.0023170323
epinephrine B-Chemical 1 0.9998481
- O 0 0.01510631
induced O 0 0.0069278404
myocardial B-Disease 2 0.9999356
injury I-Disease 2 0.9983638
in O 0 0.0075977934
dogs O 0 0.043599963
. O 0 0.010215329

A O 0 0.025640717
reproducible O 0 0.0070078024
model O 0 0.0041437834
for O 0 0.002414282
producing O 0 0.003206468
diffuse O 0 0.31101847
myocardial B-Disease 2 0.9999671
injury I-Disease 2 0.9996989
( O 0 0.03507451
epinephrine B-Chemical 1 0.9998721
infusion O 0 0.12839833
) O 0 0.0025555512
has O 0 0.0005079398
been O 0 0.00054899335
developed O 0 0.0006274087
to O 0 0.0004108002
study O 0 0.0005778113
the O 0 0.00050045556
cardioprotective O 0 0.825358
effects O 0 0.0014990054
of O 0 0.0009537552
agents O 0 0.1652752
or O 0 0.000795959
maneuvers O 0 0.03285077
which O 0 0.0009239919
might O 0 0.0005408139
alter O 0 0.00074420054
the O 0 0.0010368127
evolution O 0 0.00206132
of O 0 0.004922506
acute O 2 0.9992625
myocardial B-Disease 2 0.9999578
infarction I-Disease 2 0.99998486
. O 0 0.020913484

Infusions O 0 0.6662832
of O 0 0.009463904
epinephrine B-Chemical 1 0.9989747
( O 0 0.0045398795
4 O 0 0.0014460075
mug O 0 0.0012944931
per O 0 0.000599413
kilogram O 0 0.0010721178
per O 0 0.00045113364
minute O 0 0.00049332704
for O 0 0.00040133047
6 O 0 0.0003915051
hours O 0 0.000368141
) O 0 0.0008961637
increased O 0 0.0007630479
radiocalcium B-Chemical 0 0.9903335
uptakes O 0 0.24493696
into O 0 0.00029244905
intact O 0 0.00047251108
myocardium O 0 0.3135616
and O 0 0.00041483008
each O 0 0.00021761184
of O 0 0.0003915798
its O 0 0.00057964906
subcellular O 0 0.00041428747
components O 0 0.00047793996
with O 0 0.00044646024
the O 0 0.0004199082
mitochondrial O 0 0.079847306
fraction O 0 0.00032900617
showing O 0 0.00035161755
the O 0 0.00032134706
most O 0 0.0004441743
consistent O 0 0.00030071294
changes O 0 0.00040337097
when O 0 0.00022605578
compared O 0 0.00021797254
to O 0 0.00035837857
saline O 0 0.16604505
- O 0 0.00091931893
infused O 0 0.0007740912
control O 0 0.00036175863
animals O 0 0.00040949523
( O 0 0.00071172597
4 O 0 0.00041411023
, O 0 0.0005812978
957 O 0 0.01660244
vs O 0 0.00071619
. O 0 0.000328972
827 O 0 0.0020724684
counts O 0 0.00033446122
per O 0 0.00028306365
minute O 0 0.0004118752
per O 0 0.0004524515
gram O 0 0.0019544852
of O 0 0.0016633437
dried O 0 0.0065831514
tissue O 0 0.024496991
or O 0 0.0036761384
fraction O 0 0.0049330955
) O 0 0.012915839
. O 0 0.008515062

Myocardial O 0 0.9215648
concentrations O 0 0.011207098
of O 0 0.006734449
calcium B-Chemical 1 0.99749595
also O 0 0.0030146814
increased O 0 0.002576065
significantly O 0 0.002412966
( O 0 0.0017930673
12 O 0 0.00062267424
. O 0 0.0004643409
0 O 0 0.00063239905
vs O 0 0.0008129734
. O 0 0.00038689811
5 O 0 0.0003964015
. O 0 0.00033984726
0 O 0 0.0005371688
mg O 0 0.02110945
. O 0 0.0004014736
per O 0 0.00041880662
100 O 0 0.0012676283
Gm O 0 0.19222167
. O 0 0.0007661971
of O 0 0.0015510943
fat O 0 0.8512447
- O 0 0.00409362
free O 0 0.0038571183
dry O 0 0.06700613
weight O 0 0.05742644
) O 0 0.014746506
. O 0 0.008937593

Infusions O 0 0.7955896
of O 0 0.01430091
calcium B-Chemical 1 0.999166
chloride I-Chemical 0 0.9996934
sufficient O 0 0.002165385
to O 0 0.0017040141
raise O 0 0.0018519643
serum O 0 0.4012053
calcium B-Chemical 1 0.9996338
concentrations O 0 0.020214487
2 O 0 0.0015038535
mEq O 0 0.87492245
. O 0 0.00048478966
per O 0 0.00041993003
liter O 0 0.0016414234
failed O 0 0.0008571938
to O 0 0.0008730964
increase O 0 0.0012363254
calcium B-Chemical 1 0.9987777
influx O 0 0.6253342
into O 0 0.0018257084
the O 0 0.004215732
myocardial O 0 0.9995908
cell O 0 0.19157447
. O 0 0.011080695

Mitochondrial O 0 0.94980454
radiocalcium B-Chemical 0 0.9924833
uptakes O 0 0.45739108
were O 0 0.00336092
significantly O 0 0.002688337
decreased O 0 0.0024190522
in O 0 0.0012089773
animals O 0 0.0011446576
pretreated O 0 0.026203467
with O 0 0.006424157
acetylsalicylic B-Chemical 1 0.99999857
acid I-Chemical 1 0.9991954
or O 0 0.005693209
dipyridamole B-Chemical 1 0.9999865
or O 0 0.001021185
when O 0 0.00057893235
hydrocortisone B-Chemical 1 0.9998728
was O 0 0.0006387879
added O 0 0.00047847346
to O 0 0.000398084
the O 0 0.0005649606
epinephrine B-Chemical 1 0.99963033
infusion O 0 0.039055735
( O 0 0.0011435786
2 O 0 0.00056262437
, O 0 0.000702425
682 O 0 0.015887698
, O 0 0.0005945904
2 O 0 0.00045870757
, O 0 0.0006152789
803 O 0 0.04932793
, O 0 0.00055522134
and O 0 0.00046099
3 O 0 0.00041701627
, O 0 0.0004963798
424 O 0 0.00123424
counts O 0 0.0003339406
per O 0 0.00028349526
minute O 0 0.00041207683
per O 0 0.00045092727
gram O 0 0.0019460614
of O 0 0.00162395
dried O 0 0.0055799624
fraction O 0 0.0026249117
, O 0 0.005082682
respectively O 0 0.008292421
) O 0 0.011175438
. O 0 0.008167014

Myocardial O 0 0.97970474
calcium B-Chemical 1 0.9974589
concentrations O 0 0.00981154
also O 0 0.00320864
were O 0 0.0022893113
decreased O 0 0.002730725
( O 0 0.0020495923
11 O 0 0.0013115634
. O 0 0.0006184172
2 O 0 0.0006420956
, O 0 0.00069108134
8 O 0 0.00047993704
. O 0 0.00034125597
3 O 0 0.00038494458
, O 0 0.00046766715
and O 0 0.00041551594
8 O 0 0.00038125156
. O 0 0.00026474096
9 O 0 0.00035012353
mg O 0 0.022964558
. O 0 0.0002621948
per O 0 0.0002491465
100 O 0 0.00076951546
Gm O 0 0.22442915
. O 0 0.00032467223
of O 0 0.0005919019
fat O 0 0.89439696
- O 0 0.0013007299
free O 0 0.00080899737
dry O 0 0.019831885
weight O 0 0.017170722
, O 0 0.0010998049
respectively O 0 0.0013402118
) O 0 0.00086296705
in O 0 0.00034214012
the O 0 0.00036242558
three O 0 0.00031617243
treatment O 0 0.0007927849
groups O 0 0.0009916787
, O 0 0.0010401292
being O 0 0.0010521516
significantly O 0 0.0011695113
decreased O 0 0.001502458
only O 0 0.0012456593
in O 0 0.001582877
the O 0 0.0022250398
last O 0 0.0026238705
two O 0 0.004708312
. O 0 0.007748583

Evidence O 0 0.017086847
of O 0 0.008375913
microscopic O 0 0.015539751
damage O 0 0.47040796
was O 0 0.0041629807
graded O 0 0.011868887
as O 0 0.0027153443
less O 0 0.0025321566
severe O 0 0.06817882
in O 0 0.0024485912
the O 0 0.0026664978
three O 0 0.0027634571
treatment O 0 0.0066474127
groups O 0 0.009756846
. O 0 0.0100025805

Acetylsalicylic B-Chemical 0 0.99989045
acid I-Chemical 0 0.9970095
, O 0 0.03167099
dipyridamole B-Chemical 1 0.99989104
, O 0 0.007708683
and O 0 0.0036580039
hydrocortisone B-Chemical 1 0.99956924
all O 0 0.0017561568
appear O 0 0.0012718502
to O 0 0.001047177
have O 0 0.0011266742
cardioprotective O 0 0.82670957
effects O 0 0.0028992086
when O 0 0.0013250514
tested O 0 0.0017128323
in O 0 0.0026663798
this O 0 0.0039192145
model O 0 0.0073880223
. O 0 0.008993887

Clinical O 0 0.034552485
and O 0 0.0074356715
histopathologic O 0 0.116577424
examination O 0 0.0054294965
of O 0 0.004016732
renal O 0 0.97918403
allografts O 0 0.5904146
treated O 0 0.004072387
with O 0 0.0041797585
tacrolimus B-Chemical 1 0.99997866
( O 0 0.04833747
FK506 B-Chemical 1 0.9999281
) O 0 0.005956985
for O 0 0.0015224549
at O 0 0.0016474216
least O 0 0.0019267235
one O 0 0.0033540619
year O 0 0.0057100584
. O 0 0.008032394

BACKGROUND O 0 0.57762617
: O 0 0.008830156
We O 0 0.0041303127
clinically O 0 0.00765663
and O 0 0.0027873893
pathologically O 0 0.33515063
analyzed O 0 0.0016942692
renal O 0 0.95908827
allografts O 0 0.33287096
from O 0 0.0011630035
1 O 0 0.00089069933
9 O 0 0.00072388415
renal O 0 0.8050308
transplant O 0 0.22885425
patients O 0 0.0031609628
treated O 0 0.0011895768
with O 0 0.0018694708
tacrolimus B-Chemical 1 0.9999832
( O 0 0.02818966
FK506 B-Chemical 1 0.99993765
) O 0 0.004823323
for O 0 0.001273093
more O 0 0.0020333515
than O 0 0.0019263458
1 O 0 0.0037531562
year O 0 0.0048708552
. O 0 0.007031411

METHODS O 0 0.012019864
: O 0 0.008698678
Twenty O 0 0.0074052634
- O 0 0.004704524
six O 0 0.002179961
renal O 0 0.76935524
allograft O 0 0.7927086
biopsy O 0 0.014461464
specimens O 0 0.0018689515
from O 0 0.0011624353
1 O 0 0.0010122393
9 O 0 0.00088083156
renal O 0 0.7289643
transplant O 0 0.14416151
patients O 0 0.0023872324
who O 0 0.0016355461
underwent O 0 0.0011877216
transplantations O 0 0.028383806
between O 0 0.0012200855
1991 O 0 0.0037008142
and O 0 0.0028673194
1993 O 0 0.009942452
were O 0 0.003923882
evaluated O 0 0.005185264
. O 0 0.008199388

Thirteen O 0 0.0143050775
biopsies O 0 0.010055632
were O 0 0.0040720305
performed O 0 0.0024923827
from O 0 0.0020535344
stable O 0 0.0019209592
functioning O 0 0.006097366
renal O 0 0.9481713
allografts O 0 0.2548119
with O 0 0.0010965534
informed O 0 0.0019714264
consent O 0 0.002046793
( O 0 0.0010241449
nonepisode O 0 0.005739823
biopsy O 0 0.007854213
) O 0 0.0010751708
and O 0 0.00049745647
the O 0 0.00040224433
other O 0 0.00044194137
13 O 0 0.00055284187
were O 0 0.0003998518
from O 0 0.0004641723
dysfunctional O 0 0.013230657
renal O 0 0.96802694
allografts O 0 0.28768295
with O 0 0.00087277114
a O 0 0.0010426729
clinical O 0 0.0025632458
indication O 0 0.00086021103
for O 0 0.0010838701
biopsy O 0 0.013894706
( O 0 0.0041949567
episode O 0 0.036602564
biopsy O 0 0.05788776
) O 0 0.014820763
. O 0 0.008996721

RESULTS O 0 0.023218544
: O 0 0.007526842
The O 0 0.0035676074
main O 0 0.003521201
pathologic O 0 0.17112935
diagnoses O 0 0.06539324
( O 0 0.0026522293
some O 0 0.0013264038
overlap O 0 0.0011263416
) O 0 0.0018767759
were O 0 0.00094746245
acute O 0 0.9276746
rejection O 0 0.99846494
( O 0 0.011280679
AR O 0 0.9220328
; O 0 0.0013959018
n O 0 0.00065746537
= O 0 0.00073286396
4 O 0 0.00044146934
) O 0 0.0008388978
, O 0 0.0007401582
chronic O 0 0.8269168
rejection O 0 0.99754274
( O 0 0.004935066
CR O 0 0.5174175
; O 0 0.00095400977
n O 0 0.0005448802
= O 0 0.0006464521
5 O 0 0.00039552507
) O 0 0.00081730285
, O 0 0.0007413861
AR O 0 0.644055
+ O 0 0.00083393726
CR O 0 0.1967505
( O 0 0.0006457932
n O 0 0.0005088503
= O 0 0.00061579107
4 O 0 0.00039301245
) O 0 0.0007552055
, O 0 0.0006807084
recurrent O 0 0.7051048
IgA B-Disease 0 0.9991454
nephropathy I-Disease 2 0.99999726
( O 0 0.00461499
n O 0 0.0008555418
= O 0 0.0007584235
5 O 0 0.00037336844
) O 0 0.0006416891
, O 0 0.00044439686
normal O 0 0.0005422115
findings O 0 0.00081698137
( O 0 0.0006329978
n O 0 0.00051590457
= O 0 0.0006410421
2 O 0 0.00043056323
) O 0 0.0006901213
, O 0 0.00048017086
minimal O 0 0.00045109322
- O 0 0.0009469971
type O 0 0.0006529263
chronic O 0 0.9831676
FK506 B-Chemical 1 0.99999297
nephropathy B-Disease 2 0.9999963
( O 0 0.00699391
n O 0 0.0010081409
= O 0 0.00091983983
9 O 0 0.00058895926
) O 0 0.00088727375
, O 0 0.00069710764
and O 0 0.0007713061
mild O 0 0.48790333
- O 0 0.002532479
type O 0 0.0018906478
FK506 B-Chemical 1 0.9999652
nephropathy B-Disease 2 0.9999851
( O 0 0.011535096
n O 0 0.0035087978
= O 0 0.004300319
11 O 0 0.0046718074
) O 0 0.007532657
. O 0 0.007127142

Of O 0 0.010904616
the O 0 0.006142332
nonepisode O 0 0.011516364
biopsies O 0 0.008876946
, O 0 0.003440544
7 O 0 0.0017439182
and O 0 0.0013982794
4 O 0 0.0009813915
biopsies O 0 0.0018494512
showed O 0 0.00081902085
minimal O 0 0.001115468
- O 0 0.0017633237
type O 0 0.0010676668
and O 0 0.0016406969
mild O 0 0.75620484
- O 0 0.005019171
type O 0 0.002786948
chronic O 0 0.9962106
FK506 B-Chemical 1 0.99998116
nephropathy B-Disease 2 0.9999846
, O 0 0.10338649
respectively O 0 0.0328707
. O 0 0.009802288

Chronic O 0 0.99515533
FK506 B-Chemical 1 0.9998325
nephropathy B-Disease 2 0.99991167
consisted O 0 0.0047077867
of O 0 0.0029410447
rough O 0 0.003731029
and O 0 0.0022236195
foamy O 0 0.44874787
tubular O 0 0.8491242
vacuolization O 0 0.8965942
( O 0 0.002311789
5 O 0 0.0006571324
biopsies O 0 0.0039156736
) O 0 0.0019654976
, O 0 0.0011614476
arteriolopathy O 0 0.9916522
( O 0 0.0015199678
angiodegeneration O 0 0.005407767
of O 0 0.00060666486
the O 0 0.00057771226
arteriolar O 0 0.98191017
wall O 0 0.1156933
; O 0 0.0013736966
20 O 0 0.0004950251
biopsies O 0 0.0022217531
) O 0 0.0012475775
, O 0 0.0007485443
focal B-Disease 0 0.08632171
segmental I-Disease 0 0.083475605
glomerulosclerosis I-Disease 2 0.9999907
( O 0 0.004024536
4 O 0 0.00057882036
biopsies O 0 0.0024374109
) O 0 0.0011036468
and O 0 0.0006178975
the O 0 0.00060148636
striped O 0 0.002858341
form O 0 0.0009521232
of O 0 0.0018715345
interstitial B-Disease 0 0.9819879
fibrosis I-Disease 2 0.9998041
( O 0 0.017253188
11 O 0 0.005021729
biopsies O 0 0.01791565
) O 0 0.011931741
. O 0 0.008391255

The O 0 0.0083647445
serum O 0 0.082235515
creatinine B-Chemical 1 0.9915426
levels O 0 0.002787212
of O 0 0.002298921
patients O 0 0.0034071512
in O 0 0.001155252
the O 0 0.0012499272
mild O 0 0.74926716
- O 0 0.004083372
type O 0 0.0013526902
chronic O 0 0.9919029
FK506 B-Chemical 1 0.99999344
nephropathy B-Disease 2 0.99999607
group O 0 0.015703324
, O 0 0.0014237073
which O 0 0.00060553814
included O 0 0.0004045872
7 O 0 0.00038043575
episode O 0 0.0017232731
biopsies O 0 0.0030139233
, O 0 0.00067168806
were O 0 0.00036128747
statistically O 0 0.00031934876
higher O 0 0.00030029207
than O 0 0.0002506607
those O 0 0.0004393455
in O 0 0.0003204953
the O 0 0.00037108143
minimum O 0 0.00036997334
- O 0 0.0010845745
type O 0 0.00084660033
chronic O 0 0.98726803
FK506 B-Chemical 1 0.9999895
- O 0 0.14106426
nephropathy B-Disease 2 0.9999844
group O 0 0.011253901
( O 0 0.0049999636
P O 0 0.15217027
< O 0 0.0021245952
0 O 0 0.0027479592
. O 0 0.0026823333
001 O 0 0.19532241
) O 0 0.00819467
. O 0 0.0075645256

CONCLUSIONS O 0 0.5027096
: O 0 0.008977237
This O 0 0.0049757725
study O 0 0.0029121088
demonstrates O 0 0.0016897522
that O 0 0.0016814169
chronic O 0 0.9788396
FK506 B-Chemical 1 0.9999852
nephropathy B-Disease 2 0.99999225
consists O 0 0.0019182913
primarily O 0 0.0016987094
of O 0 0.0015173279
arteriolopathy O 0 0.99834645
manifesting O 0 0.85032594
as O 0 0.0010777499
insudative O 0 0.30873618
hyalinosis O 0 0.81109035
of O 0 0.0010473252
the O 0 0.0007202482
arteriolar O 0 0.9911226
wall O 0 0.15350124
, O 0 0.0010045068
and O 0 0.00050843926
suggests O 0 0.00027863946
that O 0 0.0004353819
mild O 0 0.6898843
- O 0 0.0029104617
type O 0 0.0010222577
chronic O 0 0.99264014
FK506 B-Chemical 1 0.9999939
nephropathy B-Disease 2 0.9999957
is O 0 0.0020199749
a O 0 0.0014221097
condition O 0 0.001911198
which O 0 0.0011914291
may O 0 0.00093578297
lead O 0 0.010627739
to O 0 0.0012789243
deterioration O 0 0.16779093
of O 0 0.0037127642
renal O 0 0.995806
allograft O 0 0.9880905
function O 0 0.015938526
. O 0 0.009570599

Different O 0 0.01661332
lobular O 0 0.9339232
distributions O 0 0.005448073
of O 0 0.004852727
altered O 0 0.00465555
hepatocyte O 0 0.85850763
tight O 0 0.007321361
junctions O 0 0.004381746
in O 0 0.0017801649
rat O 0 0.0044924687
models O 0 0.0027013316
of O 0 0.0037403905
intrahepatic B-Disease 0 0.9799574
and I-Disease 0 0.026136091
extrahepatic I-Disease 0 0.9997204
cholestasis I-Disease 2 0.9999795
. O 0 0.034045607

Hepatocyte O 0 0.9525858
tight O 0 0.015939081
junctions O 0 0.013149346
( O 0 0.0072500817
TJs O 0 0.52171564
) O 0 0.0043249037
, O 0 0.0018544482
the O 0 0.0010174457
only O 0 0.00088308624
intercellular O 0 0.013263069
barrier O 0 0.00388551
between O 0 0.0005369206
the O 0 0.0007458562
sinusoidal O 0 0.029973054
and O 0 0.0010778753
the O 0 0.0010189416
canalicular O 0 0.83396167
spaces O 0 0.0065320665
, O 0 0.0018091138
play O 0 0.001394563
a O 0 0.0017835558
key O 0 0.0019866715
role O 0 0.0019563371
in O 0 0.0037080927
bile O 0 0.94081116
formation O 0 0.05304789
. O 0 0.011203918

Although O 0 0.0094925305
hepatocyte O 0 0.8380012
TJs O 0 0.6533254
are O 0 0.004140394
impaired O 0 0.003832953
in O 0 0.0025119246
cholestasis B-Disease 2 0.9999753
, O 0 0.0037023085
attempts O 0 0.0016414531
to O 0 0.0006382458
localize O 0 0.00037558714
the O 0 0.00052337616
precise O 0 0.00062044803
site O 0 0.00066652225
of O 0 0.0012667422
hepatocyte O 0 0.98581773
TJ O 0 0.99935526
damage O 0 0.8802382
by O 0 0.0022894365
freeze O 0 0.042219248
- O 0 0.0043820203
fracture O 0 0.81476146
electron O 0 0.022546358
microscopy O 0 0.0022044585
have O 0 0.0019054534
produced O 0 0.0027306774
limited O 0 0.0038205797
information O 0 0.007059723
. O 0 0.0086923735

Recently O 0 0.014827253
, O 0 0.009465113
several O 0 0.0066160033
TJ O 0 0.98914415
- O 0 0.0071649454
associated O 0 0.0033097928
proteins O 0 0.004361711
like O 0 0.0041391877
ZO O 0 0.9941484
- O 0 0.005983803
1 O 0 0.002259553
and O 0 0.0024558064
7H6 O 0 0.43029082
have O 0 0.0023418632
been O 0 0.002962391
identified O 0 0.0031207977
and O 0 0.005787147
characterized O 0 0.012107375
. O 0 0.011472178

Immunolocalization O 0 0.021766348
of O 0 0.0143302195
7H6 O 0 0.4257801
appears O 0 0.007796374
to O 0 0.006535852
closely O 0 0.006505419
correlate O 0 0.007086211
with O 0 0.0102717625
paracellular O 0 0.76670545
permeability O 0 0.91316307
. O 0 0.017388778

We O 0 0.008088885
used O 0 0.005018121
rat O 0 0.006649252
models O 0 0.0037577066
of O 0 0.0043877093
intrahepatic B-Disease 0 0.9991431
cholestasis I-Disease 2 0.99999714
by O 0 0.19364882
ethinyl B-Chemical 0 0.9999968
estradiol I-Chemical 1 0.9999927
( O 0 0.07040318
EE B-Chemical 1 0.9970701
) O 0 0.0035685177
treatment O 0 0.0014613242
and O 0 0.0014268407
extrahepatic B-Disease 0 0.9997626
cholestasis I-Disease 2 0.9999982
by O 0 0.008225358
bile O 0 0.9891545
duct O 0 0.93127733
ligation O 0 0.039600775
( O 0 0.0062995097
BDL O 0 0.9984005
) O 0 0.0019683281
to O 0 0.0007656256
precisely O 0 0.00084189634
determine O 0 0.00068178907
the O 0 0.0015183694
site O 0 0.0023940485
of O 0 0.0060140765
TJ O 0 0.9978036
damage O 0 0.93668544
. O 0 0.012203947

Alterations O 0 0.018637003
in O 0 0.0072338944
hepatocyte O 0 0.8024737
TJs O 0 0.5031402
were O 0 0.0026840393
assessed O 0 0.0016140753
by O 0 0.0017479339
double O 0 0.0016887664
- O 0 0.0021108144
immunolabeling O 0 0.002604857
for O 0 0.0010173741
7H6 O 0 0.6780911
and O 0 0.0027881889
ZO O 0 0.9883178
- O 0 0.0031447415
1 O 0 0.001524602
using O 0 0.0013813757
a O 0 0.0022665854
confocal O 0 0.0033359826
laser O 0 0.00846801
scanning O 0 0.005536152
microscope O 0 0.008344333
. O 0 0.009218355

In O 0 0.008184964
control O 0 0.006050073
rats O 0 0.007606441
, O 0 0.0041192556
immunostaining O 0 0.0032576753
for O 0 0.0019993903
7H6 O 0 0.6911261
and O 0 0.004120144
ZO O 0 0.9910931
- O 0 0.0037561988
1 O 0 0.0013399618
colocalized O 0 0.0008676378
to O 0 0.0010738483
outline O 0 0.0020650045
bile O 0 0.88941354
canaliculi O 0 0.5494405
in O 0 0.0028209998
a O 0 0.004233818
continuous O 0 0.0047991285
fashion O 0 0.0128617
. O 0 0.008877328

In O 0 0.009063364
contrast O 0 0.0072019864
, O 0 0.0072563854
7H6 O 0 0.58913714
and O 0 0.0064673186
ZO O 0 0.9866376
- O 0 0.0050132666
1 O 0 0.0017506618
immunostaining O 0 0.0017047792
was O 0 0.0012431275
more O 0 0.0013801942
discontinuous O 0 0.0027461408
, O 0 0.0021539223
outlining O 0 0.002884635
the O 0 0.0025852406
bile O 0 0.92236847
canaliculi O 0 0.8005494
after O 0 0.005673379
BDL O 0 0.9969202
. O 0 0.011858735

Immunostaining O 0 0.015793476
for O 0 0.0064040124
7H6 O 0 0.4988054
, O 0 0.005676964
not O 0 0.0036081208
ZO O 0 0.9791047
- O 0 0.005103845
1 O 0 0.0016794138
, O 0 0.0013999108
decreased O 0 0.0011475488
and O 0 0.00087867054
predominantly O 0 0.0009090568
appeared O 0 0.00068207784
as O 0 0.00064563024
discrete O 0 0.0008703694
signals O 0 0.00097503694
in O 0 0.0007478743
the O 0 0.0009893426
submembranous O 0 0.10310214
cytoplasm O 0 0.001925565
of O 0 0.002912804
periportal O 0 0.97114336
hepatocytes O 0 0.6163388
after O 0 0.004594494
BDL O 0 0.9969777
. O 0 0.010560256

After O 0 0.0078121554
EE B-Chemical 1 0.7936143
treatment O 0 0.0072506205
, O 0 0.004038916
changes O 0 0.0024507255
in O 0 0.0014499422
immunostaining O 0 0.0018357359
for O 0 0.0010608607
7H6 O 0 0.75279903
and O 0 0.0026779782
ZO O 0 0.9934269
- O 0 0.0025444285
1 O 0 0.00068893883
were O 0 0.0004627286
similar O 0 0.0003338528
to O 0 0.00041042495
those O 0 0.000660253
seen O 0 0.0005079597
in O 0 0.0006509759
periportal O 0 0.89367735
hepatocytes O 0 0.29144546
after O 0 0.00074400124
BDL O 0 0.9980275
, O 0 0.0016454909
but O 0 0.0010166643
distributed O 0 0.0012221646
more O 0 0.0015553671
diffusely O 0 0.0035647808
throughout O 0 0.0021066645
the O 0 0.004486361
lobule O 0 0.7650991
. O 0 0.008534218

This O 0 0.010211262
study O 0 0.005622291
is O 0 0.0032721409
the O 0 0.0021738291
first O 0 0.0014345666
to O 0 0.0011697275
demonstrate O 0 0.000777253
that O 0 0.0009087615
impairment O 0 0.15481071
of O 0 0.0017262716
hepatocyte O 0 0.9826214
TJs O 0 0.87813836
occurs O 0 0.0007490837
heterogenously O 0 0.011426701
in O 0 0.0004706483
the O 0 0.0005849615
liver O 0 0.90746033
lobule O 0 0.890334
after O 0 0.00046812877
BDL O 0 0.99462354
and O 0 0.00071568653
suggests O 0 0.0003809789
that O 0 0.0006309494
BDL O 0 0.99746454
and O 0 0.0015286817
EE B-Chemical 1 0.9722322
treatments O 0 0.002441955
produce O 0 0.00083453144
different O 0 0.001252653
lobular O 0 0.99225205
distributions O 0 0.002189168
of O 0 0.0032739688
increased O 0 0.0060749534
paracellular O 0 0.77114546
permeability O 0 0.88966006
. O 0 0.010475346

Memory O 0 0.7017097
facilitation O 0 0.059163895
and O 0 0.0055284784
stimulation O 0 0.004798151
of O 0 0.0034887164
endogenous O 0 0.004509048
nerve O 0 0.8311014
growth O 0 0.04262616
factor O 0 0.055579796
synthesis O 0 0.0876773
by O 0 0.0029837196
the O 0 0.003997294
acetylcholine B-Chemical 1 0.99987674
releaser O 0 0.99949706
PG B-Chemical 1 0.99972624
- I-Chemical 0 0.027038971
9 I-Chemical 0 0.0083502885
. O 0 0.008372967

The O 0 0.008059238
effects O 0 0.0075802966
of O 0 0.008065806
PG B-Chemical 1 0.99935025
- I-Chemical 0 0.013434131
9 I-Chemical 0 0.003058388
( O 0 0.003726712
3alpha B-Chemical 0 0.98517805
- I-Chemical 0 0.004056362
tropyl I-Chemical 0 0.2599473
2 I-Chemical 0 0.0013120932
- I-Chemical 0 0.001674008
( I-Chemical 0 0.001110852
p I-Chemical 0 0.0012725954
- I-Chemical 0 0.0025631166
bromophenyl I-Chemical 0 0.957969
) I-Chemical 0 0.013862023
propionate I-Chemical 0 0.9997682
) O 0 0.007349583
, O 0 0.0010574805
the O 0 0.00078822044
acetylcholine B-Chemical 1 0.9998648
releaser O 0 0.99595344
, O 0 0.0011624718
on O 0 0.00044515557
memory O 0 0.06538858
processes O 0 0.0017670138
and O 0 0.0013633887
nerve O 0 0.714137
growth O 0 0.02754258
factor O 0 0.074858755
( O 0 0.0134859
NGF O 1 0.9997702
) O 0 0.008520241
synthesis O 0 0.034433708
were O 0 0.0044854283
evaluated O 0 0.005447841
. O 0 0.008327696

In O 0 0.007335316
the O 0 0.005198257
mouse O 0 0.0045718625
passive O 0 0.0061356407
- O 0 0.004105488
avoidance O 0 0.011716033
test O 0 0.0026970932
, O 0 0.0037586978
PG B-Chemical 1 0.99961865
- I-Chemical 0 0.003878995
9 I-Chemical 0 0.0009827319
( O 0 0.00091888587
10 O 0 0.00058968656
- O 0 0.0006870119
30 O 0 0.00033617776
mg O 0 0.03829876
/ O 0 0.0010733289
kg O 0 0.0026515052
, O 0 0.0006809264
i O 0 0.001448356
. O 0 0.00035611732
p O 0 0.0006152847
. O 0 0.00036751456
) O 0 0.00078924943
, O 0 0.00045658046
administered O 0 0.00041356852
20 O 0 0.00029865096
min O 0 0.00027115876
before O 0 0.00016805736
the O 0 0.00025712972
training O 0 0.00032889046
session O 0 0.00043245518
, O 0 0.00070530805
prevented O 0 0.003606917
amnesia B-Disease 2 0.99986076
induced O 0 0.0008136667
by O 0 0.0006014772
both O 0 0.00038255894
the O 0 0.00037708573
non O 0 0.0012430779
selective O 0 0.010978743
antimuscarinic O 0 0.99978215
drug O 0 0.9550438
scopolamine B-Chemical 1 0.9999976
and O 0 0.0013887732
the O 0 0.00097133865
M1 O 0 0.73566806
- O 0 0.0026269096
selective O 0 0.017459434
antagonist O 0 0.98990273
S B-Chemical 0 0.98135996
- I-Chemical 0 0.009197383
( I-Chemical 0 0.0036220264
- I-Chemical 0 0.004102085
) I-Chemical 0 0.004814107
- I-Chemical 0 0.005756916
ET I-Chemical 0 0.9129363
- I-Chemical 0 0.008551167
126 I-Chemical 0 0.019961426
. O 0 0.0076141045

In O 0 0.0070044547
the O 0 0.0047005825
same O 0 0.002830552
experimental O 0 0.003065847
conditions O 0 0.0034810116
, O 0 0.0051293666
PG B-Chemical 1 0.99952555
- I-Chemical 0 0.0049524843
9 I-Chemical 0 0.0012611
( O 0 0.00111434
5 O 0 0.00059218163
- O 0 0.00068514486
20 O 0 0.00037874226
microg O 0 0.00056164205
per O 0 0.00029861796
mouse O 0 0.00064742845
, O 0 0.0006894071
i O 0 0.0016452473
. O 0 0.0003974739
c O 0 0.0058665895
. O 0 0.0004003782
v O 0 0.014455506
. O 0 0.00039932958
) O 0 0.00077322026
was O 0 0.00036116698
also O 0 0.00037363905
able O 0 0.00030227433
to O 0 0.00043918344
prevent O 0 0.0008170371
antimuscarine O 0 0.63074386
- O 0 0.004225524
induced O 0 0.0019090653
amnesia B-Disease 2 0.99987185
, O 0 0.0015882114
demonstrating O 0 0.0008313135
a O 0 0.0014444531
central O 0 0.0023611072
localization O 0 0.0015838878
of O 0 0.0027792898
the O 0 0.003862446
activity O 0 0.0071933656
. O 0 0.008291135

At O 0 0.005870766
the O 0 0.0046307426
highest O 0 0.003573481
effective O 0 0.0033856167
doses O 0 0.09118566
, O 0 0.007885375
PG B-Chemical 1 0.9996575
- I-Chemical 0 0.004390276
9 I-Chemical 0 0.0009444756
did O 0 0.00054963893
not O 0 0.00047599062
produce O 0 0.00039986972
any O 0 0.0004925771
collateral O 0 0.19708592
symptoms O 0 0.67881894
as O 0 0.0005988183
revealed O 0 0.0005495661
by O 0 0.00059500907
the O 0 0.00057565485
Irwin O 0 0.12688957
test O 0 0.0007242899
, O 0 0.0007070113
and O 0 0.00051983277
it O 0 0.00048871303
did O 0 0.00036079393
not O 0 0.00038744626
modify O 0 0.0004992263
spontaneous O 0 0.030234937
motility O 0 0.3688617
and O 0 0.00092539546
inspection O 0 0.001349512
activity O 0 0.0010132163
, O 0 0.0010731099
as O 0 0.0008420411
revealed O 0 0.0010758205
by O 0 0.0015092324
the O 0 0.001906639
hole O 0 0.031192716
- O 0 0.0060668658
board O 0 0.00713157
test O 0 0.006940938
. O 0 0.008116075

PG B-Chemical 1 0.99689853
- I-Chemical 0 0.013837011
9 I-Chemical 0 0.0047719763
was O 0 0.0028493337
also O 0 0.0019945218
able O 0 0.0012576574
to O 0 0.001138629
increase O 0 0.00085290545
the O 0 0.00083930785
amount O 0 0.00065153424
of O 0 0.0020278206
NGF O 1 0.99986887
secreted O 0 0.002622037
in O 0 0.0010913381
vitro O 0 0.001963112
by O 0 0.0015917092
astrocytes O 0 0.27148798
in O 0 0.0013493501
a O 0 0.0024325158
dose O 0 0.02879408
- O 0 0.005055686
dependent O 0 0.0034014436
manner O 0 0.0069000334
. O 0 0.008395556

The O 0 0.008989609
maximal O 0 0.008328096
NGF O 1 0.99793303
contents O 0 0.009007577
obtained O 0 0.0036096175
by O 0 0.0044592367
PG B-Chemical 1 0.9993507
- I-Chemical 0 0.0047850106
9 I-Chemical 0 0.0015034145
were O 0 0.0011546375
17 O 0 0.0014276229
. O 0 0.0008645727
6 O 0 0.00096251786
- O 0 0.0015985417
fold O 0 0.0019827292
of O 0 0.0022381663
the O 0 0.0027979014
control O 0 0.003989498
value O 0 0.006224483
. O 0 0.008129187

During O 0 0.00803903
culture O 0 0.008218232
, O 0 0.0054706833
no O 0 0.0029783496
morphological O 0 0.0059480406
changes O 0 0.0035377836
were O 0 0.0024260161
found O 0 0.0017767076
at O 0 0.00169861
effective O 0 0.0026314987
concentrations O 0 0.006441742
of O 0 0.008261563
PG B-Chemical 1 0.9994703
- I-Chemical 0 0.021682667
9 I-Chemical 0 0.008872379
. O 0 0.008973455

The O 0 0.007483212
current O 0 0.0067018885
work O 0 0.0041265776
indicates O 0 0.0022029139
the O 0 0.0018127684
ability O 0 0.0016603176
of O 0 0.0030471613
PG B-Chemical 1 0.999767
- I-Chemical 0 0.0057740402
9 I-Chemical 0 0.0009843798
to O 0 0.0006032831
induce O 0 0.00053314934
beneficial O 0 0.0015878963
effects O 0 0.0014733179
on O 0 0.00062850385
cognitive O 0 0.8202427
processes O 0 0.0029383586
and O 0 0.0013211563
stimulate O 0 0.00087382004
activity O 0 0.0018294461
of O 0 0.0043459297
NGF O 1 0.9998696
synthesis O 0 0.22634244
in O 0 0.0050878567
astroglial O 0 0.9853795
cells O 0 0.027008623
. O 0 0.010319927

Therefore O 0 0.009698337
, O 0 0.0116162775
PG B-Chemical 1 0.9973647
- I-Chemical 0 0.007442319
9 I-Chemical 0 0.002541112
could O 0 0.0013978619
represent O 0 0.0013993745
a O 0 0.0013968686
potential O 0 0.0014073799
useful O 0 0.0012639385
drug O 0 0.13764055
able O 0 0.00078035414
to O 0 0.0008854682
improve O 0 0.0007945937
the O 0 0.0011607326
function O 0 0.0017707843
of O 0 0.00290603
impaired O 0 0.0071597984
cognitive O 0 0.8872878
processes O 0 0.020593038
. O 0 0.009783289

Mechanisms O 0 0.138941
of O 0 0.023703972
FK B-Chemical 1 0.99912196
506 I-Chemical 1 0.9927201
- O 0 0.023333695
induced O 0 0.0130547155
hypertension B-Disease 2 0.99958557
in O 0 0.01034962
the O 0 0.010886877
rat O 0 0.039021235
. O 0 0.014918944

- O 0 0.04226387
Tacrolimus B-Chemical 1 0.9994715
( O 0 0.052127607
FK B-Chemical 1 0.99944276
506 I-Chemical 1 0.9877407
) O 0 0.0102315275
is O 0 0.0039755027
a O 0 0.004605513
powerful O 0 0.008685428
, O 0 0.005672094
widely O 0 0.0064766053
used O 0 0.007218593
immunosuppressant O 0 0.9935499
. O 0 0.015745208

The O 0 0.009578434
clinical O 0 0.01118094
utility O 0 0.00681455
of O 0 0.008095143
FK B-Chemical 1 0.99955326
506 I-Chemical 1 0.9806676
is O 0 0.004411839
complicated O 0 0.012593627
by O 0 0.0046942956
substantial O 0 0.008220334
hypertension B-Disease 2 0.99985397
and O 0 0.08263723
nephrotoxicity B-Disease 2 0.9999511
. O 0 0.020100921

To O 0 0.006300521
clarify O 0 0.003438875
the O 0 0.0033592877
mechanisms O 0 0.0039325203
of O 0 0.0058071115
FK B-Chemical 1 0.9999051
506 I-Chemical 1 0.9980287
- O 0 0.01580014
induced O 0 0.002786423
hypertension B-Disease 2 0.99995255
, O 0 0.0015836172
we O 0 0.00039433947
studied O 0 0.0005751512
the O 0 0.00060556846
chronic O 0 0.830604
effects O 0 0.005121814
of O 0 0.0048837974
FK B-Chemical 1 0.99995875
506 I-Chemical 1 0.97348595
on O 0 0.0004057977
the O 0 0.0005849911
synthesis O 0 0.025105095
of O 0 0.00201594
endothelin O 0 0.99993384
- O 0 0.010871617
1 O 0 0.0009044631
( O 0 0.001167361
ET O 0 0.9444176
- O 0 0.0014725064
1 O 0 0.0005833085
) O 0 0.0007691284
, O 0 0.00046368368
the O 0 0.00030906353
expression O 0 0.0004341119
of O 0 0.00053392205
mRNA O 0 0.0007319161
of O 0 0.0009091235
ET O 0 0.9856852
- O 0 0.002259611
1 O 0 0.0006367523
and O 0 0.00085274415
endothelin O 0 0.9998246
- O 0 0.006156863
converting O 0 0.13468629
enzyme O 0 0.27436036
- O 0 0.0026400476
1 O 0 0.0007152611
( O 0 0.0009826968
ECE O 0 0.9193403
- O 0 0.0015587066
1 O 0 0.00062079163
) O 0 0.0008855255
, O 0 0.000602925
the O 0 0.0005411942
endothelial O 0 0.97094584
nitric B-Chemical 0 0.99993837
oxide I-Chemical 0 0.9997359
synthase O 0 0.98586535
( O 0 0.011680914
eNOS O 0 0.7081268
) O 0 0.0014311948
activity O 0 0.0006262464
, O 0 0.0005812317
and O 0 0.00042035413
the O 0 0.00037329705
expression O 0 0.0005324833
of O 0 0.000659234
mRNA O 0 0.0009225541
of O 0 0.0010942833
eNOS O 0 0.6478728
and O 0 0.0018197534
C O 0 0.9803844
- O 0 0.003260656
type O 0 0.0014638159
natriuretic O 0 0.9945117
peptide O 0 0.039898496
( O 0 0.008234867
CNP O 0 0.91631305
) O 0 0.0044693686
in O 0 0.0023352471
rat O 0 0.00995037
blood O 0 0.040511336
vessels O 0 0.26316866
. O 0 0.009630295

In O 0 0.0072195185
addition O 0 0.004135637
, O 0 0.0041280794
the O 0 0.0022841424
effect O 0 0.0015966105
of O 0 0.0016416883
the O 0 0.001315476
specific O 0 0.0013395017
endothelin O 0 0.9997497
type O 0 0.0031934346
A O 0 0.4984922
receptor O 0 0.56400764
antagonist O 0 0.9963805
FR B-Chemical 1 0.99580175
139317 I-Chemical 1 0.99992895
on O 0 0.0014382408
FK B-Chemical 1 0.9999113
506 I-Chemical 1 0.9936435
- O 0 0.0066517848
induced O 0 0.0031149832
hypertension B-Disease 2 0.99989045
in O 0 0.0031291842
rats O 0 0.009707304
was O 0 0.004433328
studied O 0 0.0071944483
. O 0 0.009092162

FK B-Chemical 1 0.99422365
506 I-Chemical 1 0.95865643
, O 0 0.04807659
5 O 0 0.03571832
mg O 0 0.45341492
. O 0 0.04208646

kg O 0 0.14732666
- O 0 0.0864134
1 O 0 0.069917284
. O 0 0.06788188

d O 0 0.013043103
- O 0 0.008285696
1 O 0 0.0035253994
given O 0 0.0018269417
for O 0 0.0014339308
4 O 0 0.0012213832
weeks O 0 0.0008269263
, O 0 0.0010901302
elevated O 0 0.0014685859
blood O 0 0.005185453
pressure O 0 0.02336658
from O 0 0.0007180711
102 O 0 0.003869527
+ O 0 0.00085388374
/ O 0 0.0018337851
- O 0 0.0008109459
13 O 0 0.0004819074
to O 0 0.00037078685
152 O 0 0.002246684
+ O 0 0.0006591241
/ O 0 0.0016275398
- O 0 0.0007892678
15 O 0 0.00036344523
mm O 0 0.0012432797
Hg O 0 0.6162916
and O 0 0.00045439412
increased O 0 0.0005033466
the O 0 0.00047620526
synthesis O 0 0.012197086
of O 0 0.0011730661
ET O 0 0.9867699
- O 0 0.0018113323
1 O 0 0.00048493064
and O 0 0.00040601363
the O 0 0.0003708696
levels O 0 0.00041156117
of O 0 0.00088095036
ET O 0 0.9811952
- O 0 0.0018442695
1 O 0 0.00057063263
mRNA O 0 0.00053101924
in O 0 0.0003937959
the O 0 0.0005227609
mesenteric O 0 0.13619487
artery O 0 0.13023834
( O 0 0.0015623041
240 O 0 0.0017918387
% O 0 0.0011462665
and O 0 0.0013501863
230 O 0 0.004313273
% O 0 0.0024927645
, O 0 0.0034944953
respectively O 0 0.0059635215
) O 0 0.009132884
. O 0 0.00769236

Little O 0 0.03632026
change O 0 0.0080743255
was O 0 0.0050446074
observed O 0 0.0029899946
in O 0 0.002898249
the O 0 0.0026792372
expression O 0 0.0032067774
of O 0 0.0044147866
ECE O 0 0.97854006
- O 0 0.008584174
1 O 0 0.003763468
mRNA O 0 0.00459772
and O 0 0.006101719
CNP O 0 0.8648077
mRNA O 0 0.012270923
. O 0 0.010672954

FK B-Chemical 1 0.9986646
506 I-Chemical 1 0.9783155
decreased O 0 0.018200375
eNOS O 0 0.4632753
activity O 0 0.0033227042
and O 0 0.002101652
the O 0 0.0014306026
levels O 0 0.0012188787
of O 0 0.0019235077
eNOS O 0 0.55510855
mRNA O 0 0.0013097579
in O 0 0.0007557253
the O 0 0.00088433403
aorta O 0 0.056127317
( O 0 0.001465431
48 O 0 0.0008600926
% O 0 0.0011563225
and O 0 0.0013213545
55 O 0 0.00207008
% O 0 0.0025672144
, O 0 0.0036621927
respectively O 0 0.006280669
) O 0 0.0095890425
. O 0 0.008026742

The O 0 0.007990694
administration O 0 0.025076518
of O 0 0.007462456
FR B-Chemical 1 0.97300017
139317 I-Chemical 1 0.999838
( O 0 0.004329699
10 O 0 0.0015863398
mg O 0 0.14946702
. O 0 0.0008983052
kg O 0 0.005365464
- O 0 0.0015728859
1 O 0 0.00084229425
. O 0 0.00058280665
d O 0 0.0010626712
- O 0 0.0014646496
1 O 0 0.001046493
) O 0 0.0018615465
prevented O 0 0.0061312164
FK B-Chemical 1 0.99988437
506 I-Chemical 1 0.9936619
- O 0 0.009650363
induced O 0 0.0051986226
hypertension B-Disease 2 0.9998573
in O 0 0.006280476
rats O 0 0.028823545
. O 0 0.009439393

These O 0 0.008983727
results O 0 0.0056924373
indicate O 0 0.0037085495
that O 0 0.0035891675
FK B-Chemical 1 0.99965143
506 I-Chemical 1 0.9778154
may O 0 0.001745137
increase O 0 0.0009770851
blood O 0 0.008167249
pressure O 0 0.030768536
not O 0 0.0006873223
only O 0 0.0006072248
by O 0 0.0007929357
increasing O 0 0.0014514979
ET O 0 0.98550004
- O 0 0.0027384951
1 O 0 0.00081681355
production O 0 0.0009883582
but O 0 0.000803735
also O 0 0.0009804874
by O 0 0.0014669193
decreasing O 0 0.003831737
NO B-Chemical 0 0.9991284
synthesis O 0 0.0983811
in O 0 0.003433752
the O 0 0.005050371
vasculature O 0 0.6351873
. O 0 0.009616443

